11058428
D008775_D013119 NONE high-dose_0\JJ\1740 <e1>methylprednisolone</e1>_1\NN\1740 may_2\MD\15209706 do_3\VB\1640855 more_4\JJR\1740 harm_5\NN\14052046 for_6\IN\1740 <e2>spinal_7\JJ\1740 cord_8\NN\3670849 injury</e2>_9\NN\14052046 ._10\.\1740
D008775_D013119 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 national_3\NNP\7846 acute_4\NNP\6822198 <e2>spinal_5\NNP\14027674 cord_6\NNP\3670849 injury</e2>_7\NNP\14052046 studies_8\NNPS\635850 (_9\-LRB-\1740 nascis_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 high-dose_13\FW\1740 <e1>methylprednisolone</e1>_14\NN\1740 became_15\VBD\146138 the_16\DT\1740 standard_17\NN\13577171 of_18\IN\1740 care_19\NN\575741 for_20\IN\1740 the_21\DT\1740 acute_22\JJ\1740 spinal_23\JJ\1740 cord_24\NN\3670849 injury_25\NN\14052046 ._26\.\1740
D008775_D013119 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 national_3\NNP\7846 acute_4\NNP\6822198 spinal_5\NNP\14027674 cord_6\NNP\3670849 injury_7\NNP\14052046 studies_8\NNPS\635850 (_9\-LRB-\1740 nascis_10\NN\1740 )_11\-RRB-\1740 ,_12\,\1740 high-dose_13\FW\1740 <e1>methylprednisolone</e1>_14\NN\1740 became_15\VBD\146138 the_16\DT\1740 standard_17\NN\13577171 of_18\IN\1740 care_19\NN\575741 for_20\IN\1740 the_21\DT\1740 acute_22\JJ\1740 <e2>spinal_23\JJ\1740 cord_24\NN\3670849 injury</e2>_25\NN\14052046 ._26\.\1740
D008775_D013119 NONE further_0\RB\1740 ,_1\,\1740 steroid_2\NN\14727670 myopathy_3\NN\14204950 recovers_4\NNS\1740 naturally_5\RB\1740 and_6\CC\1740 the_7\DT\1740 neurological_8\JJ\1740 improvement_9\NN\7359599 shown_10\VBN\2137132 in_11\IN\13603305 the_12\DT\1740 nascis_13\NN\1740 may_14\MD\15209706 be_15\VB\836236 just_16\RB\1740 a_17\DT\13649268 recording_18\NN\6791372 of_19\IN\1740 this_20\DT\1740 natural_21\JJ\1740 motor_22\NN\3699975 recovery_23\NN\7357388 from_24\IN\1740 the_25\DT\1740 steroid_26\NN\14727670 myopathy_27\NN\14204950 ,_28\,\1740 instead_29\RB\1740 of_30\IN\1740 any_31\DT\1740 protection_32\NN\407535 that_33\WDT\1740 <e1>methylprednisolone</e1>_34\NN\1740 offers_35\VBZ\2327200 to_36\TO\1740 the_37\DT\1740 <e2>spinal_38\JJ\1740 cord_39\NN\3670849 injury</e2>_40\NN\14052046 ._41\.\1740
D000305_D009135 NONE in_0\IN\13603305 the_1\DT\1740 nascis_2\NN\1740 ,_3\,\1740 there_4\EX\27167 was_5\VBD\836236 no_6\DT\7204911 mention_7\NN\6765044 regarding_8\VBG\689344 the_9\DT\1740 possibility_10\NN\5944958 of_11\IN\1740 acute_12\JJ\1740 <e1>corticosteroid</e1>_13\NN\14745635 <e2>myopathy</e2>_14\NN\14204950 that_15\IN\1740 high-dose_16\JJ\1740 methylprednisolone_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 ._20\.\1740
D000305_D009135 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 is_5\VBZ\836236 the_6\DT\1740 first_7\JJ\1740 discussion_8\NN\6252138 considering_9\VBG\689344 the_10\DT\1740 possibility_11\NN\5944958 that_12\IN\1740 the_13\DT\1740 methylprednisolone_14\NN\1740 recommended_15\VBN\875394 by_16\IN\1740 nascis_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 acute_20\JJ\1740 <e1>corticosteroid</e1>_21\NN\14745635 <e2>myopathy</e2>_22\NN\14204950 ._23\.\1740
D008775_D009135 CID in_0\IN\13603305 the_1\DT\1740 nascis_2\NN\1740 ,_3\,\1740 there_4\EX\27167 was_5\VBD\836236 no_6\DT\7204911 mention_7\NN\6765044 regarding_8\VBG\689344 the_9\DT\1740 possibility_10\NN\5944958 of_11\IN\1740 acute_12\JJ\1740 corticosteroid_13\NN\14745635 <e2>myopathy</e2>_14\NN\14204950 that_15\IN\1740 high-dose_16\JJ\1740 <e1>methylprednisolone</e1>_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 ._20\.\1740
D008775_D009135 CID further_0\RB\1740 ,_1\,\1740 steroid_2\NN\14727670 <e2>myopathy</e2>_3\NN\14204950 recovers_4\NNS\1740 naturally_5\RB\1740 and_6\CC\1740 the_7\DT\1740 neurological_8\JJ\1740 improvement_9\NN\7359599 shown_10\VBN\2137132 in_11\IN\13603305 the_12\DT\1740 nascis_13\NN\1740 may_14\MD\15209706 be_15\VB\836236 just_16\RB\1740 a_17\DT\13649268 recording_18\NN\6791372 of_19\IN\1740 this_20\DT\1740 natural_21\JJ\1740 motor_22\NN\3699975 recovery_23\NN\7357388 from_24\IN\1740 the_25\DT\1740 steroid_26\NN\14727670 myopathy_27\NN\14204950 ,_28\,\1740 instead_29\RB\1740 of_30\IN\1740 any_31\DT\1740 protection_32\NN\407535 that_33\WDT\1740 <e1>methylprednisolone</e1>_34\NN\1740 offers_35\VBZ\2327200 to_36\TO\1740 the_37\DT\1740 spinal_38\JJ\1740 cord_39\NN\3670849 injury_40\NN\14052046 ._41\.\1740
D008775_D009135 CID further_0\RB\1740 ,_1\,\1740 steroid_2\NN\14727670 myopathy_3\NN\14204950 recovers_4\NNS\1740 naturally_5\RB\1740 and_6\CC\1740 the_7\DT\1740 neurological_8\JJ\1740 improvement_9\NN\7359599 shown_10\VBN\2137132 in_11\IN\13603305 the_12\DT\1740 nascis_13\NN\1740 may_14\MD\15209706 be_15\VB\836236 just_16\RB\1740 a_17\DT\13649268 recording_18\NN\6791372 of_19\IN\1740 this_20\DT\1740 natural_21\JJ\1740 motor_22\NN\3699975 recovery_23\NN\7357388 from_24\IN\1740 the_25\DT\1740 steroid_26\NN\14727670 <e2>myopathy</e2>_27\NN\14204950 ,_28\,\1740 instead_29\RB\1740 of_30\IN\1740 any_31\DT\1740 protection_32\NN\407535 that_33\WDT\1740 <e1>methylprednisolone</e1>_34\NN\1740 offers_35\VBZ\2327200 to_36\TO\1740 the_37\DT\1740 spinal_38\JJ\1740 cord_39\NN\3670849 injury_40\NN\14052046 ._41\.\1740
D008775_D009135 CID to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 is_5\VBZ\836236 the_6\DT\1740 first_7\JJ\1740 discussion_8\NN\6252138 considering_9\VBG\689344 the_10\DT\1740 possibility_11\NN\5944958 that_12\IN\1740 the_13\DT\1740 <e1>methylprednisolone</e1>_14\NN\1740 recommended_15\VBN\875394 by_16\IN\1740 nascis_17\NN\1740 may_18\MD\15209706 cause_19\VB\1617192 acute_20\JJ\1740 corticosteroid_21\NN\14745635 <e2>myopathy</e2>_22\NN\14204950 ._23\.\1740
D013256_D009135 NONE further_0\RB\1740 ,_1\,\1740 <e1>steroid</e1>_2\NN\14727670 <e2>myopathy</e2>_3\NN\14204950 recovers_4\NNS\1740 naturally_5\RB\1740 and_6\CC\1740 the_7\DT\1740 neurological_8\JJ\1740 improvement_9\NN\7359599 shown_10\VBN\2137132 in_11\IN\13603305 the_12\DT\1740 nascis_13\NN\1740 may_14\MD\15209706 be_15\VB\836236 just_16\RB\1740 a_17\DT\13649268 recording_18\NN\6791372 of_19\IN\1740 this_20\DT\1740 natural_21\JJ\1740 motor_22\NN\3699975 recovery_23\NN\7357388 from_24\IN\1740 the_25\DT\1740 steroid_26\NN\14727670 myopathy_27\NN\14204950 ,_28\,\1740 instead_29\RB\1740 of_30\IN\1740 any_31\DT\1740 protection_32\NN\407535 that_33\WDT\1740 methylprednisolone_34\NN\1740 offers_35\VBZ\2327200 to_36\TO\1740 the_37\DT\1740 spinal_38\JJ\1740 cord_39\NN\3670849 injury_40\NN\14052046 ._41\.\1740
D013256_D009135 NONE further_0\RB\1740 ,_1\,\1740 <e1>steroid</e1>_2\NN\14727670 myopathy_3\NN\14204950 recovers_4\NNS\1740 naturally_5\RB\1740 and_6\CC\1740 the_7\DT\1740 neurological_8\JJ\1740 improvement_9\NN\7359599 shown_10\VBN\2137132 in_11\IN\13603305 the_12\DT\1740 nascis_13\NN\1740 may_14\MD\15209706 be_15\VB\836236 just_16\RB\1740 a_17\DT\13649268 recording_18\NN\6791372 of_19\IN\1740 this_20\DT\1740 natural_21\JJ\1740 motor_22\NN\3699975 recovery_23\NN\7357388 from_24\IN\1740 the_25\DT\1740 steroid_26\NN\14727670 <e2>myopathy</e2>_27\NN\14204950 ,_28\,\1740 instead_29\RB\1740 of_30\IN\1740 any_31\DT\1740 protection_32\NN\407535 that_33\WDT\1740 methylprednisolone_34\NN\1740 offers_35\VBZ\2327200 to_36\TO\1740 the_37\DT\1740 spinal_38\JJ\1740 cord_39\NN\3670849 injury_40\NN\14052046 ._41\.\1740
D013256_D009135 NONE further_0\RB\1740 ,_1\,\1740 steroid_2\NN\14727670 <e2>myopathy</e2>_3\NN\14204950 recovers_4\NNS\1740 naturally_5\RB\1740 and_6\CC\1740 the_7\DT\1740 neurological_8\JJ\1740 improvement_9\NN\7359599 shown_10\VBN\2137132 in_11\IN\13603305 the_12\DT\1740 nascis_13\NN\1740 may_14\MD\15209706 be_15\VB\836236 just_16\RB\1740 a_17\DT\13649268 recording_18\NN\6791372 of_19\IN\1740 this_20\DT\1740 natural_21\JJ\1740 motor_22\NN\3699975 recovery_23\NN\7357388 from_24\IN\1740 the_25\DT\1740 <e1>steroid</e1>_26\NN\14727670 myopathy_27\NN\14204950 ,_28\,\1740 instead_29\RB\1740 of_30\IN\1740 any_31\DT\1740 protection_32\NN\407535 that_33\WDT\1740 methylprednisolone_34\NN\1740 offers_35\VBZ\2327200 to_36\TO\1740 the_37\DT\1740 spinal_38\JJ\1740 cord_39\NN\3670849 injury_40\NN\14052046 ._41\.\1740
D013256_D009135 NONE further_0\RB\1740 ,_1\,\1740 steroid_2\NN\14727670 myopathy_3\NN\14204950 recovers_4\NNS\1740 naturally_5\RB\1740 and_6\CC\1740 the_7\DT\1740 neurological_8\JJ\1740 improvement_9\NN\7359599 shown_10\VBN\2137132 in_11\IN\13603305 the_12\DT\1740 nascis_13\NN\1740 may_14\MD\15209706 be_15\VB\836236 just_16\RB\1740 a_17\DT\13649268 recording_18\NN\6791372 of_19\IN\1740 this_20\DT\1740 natural_21\JJ\1740 motor_22\NN\3699975 recovery_23\NN\7357388 from_24\IN\1740 the_25\DT\1740 <e1>steroid</e1>_26\NN\14727670 <e2>myopathy</e2>_27\NN\14204950 ,_28\,\1740 instead_29\RB\1740 of_30\IN\1740 any_31\DT\1740 protection_32\NN\407535 that_33\WDT\1740 methylprednisolone_34\NN\1740 offers_35\VBZ\2327200 to_36\TO\1740 the_37\DT\1740 spinal_38\JJ\1740 cord_39\NN\3670849 injury_40\NN\14052046 ._41\.\1740
D013256_D013119 NONE further_0\RB\1740 ,_1\,\1740 <e1>steroid</e1>_2\NN\14727670 myopathy_3\NN\14204950 recovers_4\NNS\1740 naturally_5\RB\1740 and_6\CC\1740 the_7\DT\1740 neurological_8\JJ\1740 improvement_9\NN\7359599 shown_10\VBN\2137132 in_11\IN\13603305 the_12\DT\1740 nascis_13\NN\1740 may_14\MD\15209706 be_15\VB\836236 just_16\RB\1740 a_17\DT\13649268 recording_18\NN\6791372 of_19\IN\1740 this_20\DT\1740 natural_21\JJ\1740 motor_22\NN\3699975 recovery_23\NN\7357388 from_24\IN\1740 the_25\DT\1740 steroid_26\NN\14727670 myopathy_27\NN\14204950 ,_28\,\1740 instead_29\RB\1740 of_30\IN\1740 any_31\DT\1740 protection_32\NN\407535 that_33\WDT\1740 methylprednisolone_34\NN\1740 offers_35\VBZ\2327200 to_36\TO\1740 the_37\DT\1740 <e2>spinal_38\JJ\1740 cord_39\NN\3670849 injury</e2>_40\NN\14052046 ._41\.\1740
D013256_D013119 NONE further_0\RB\1740 ,_1\,\1740 steroid_2\NN\14727670 myopathy_3\NN\14204950 recovers_4\NNS\1740 naturally_5\RB\1740 and_6\CC\1740 the_7\DT\1740 neurological_8\JJ\1740 improvement_9\NN\7359599 shown_10\VBN\2137132 in_11\IN\13603305 the_12\DT\1740 nascis_13\NN\1740 may_14\MD\15209706 be_15\VB\836236 just_16\RB\1740 a_17\DT\13649268 recording_18\NN\6791372 of_19\IN\1740 this_20\DT\1740 natural_21\JJ\1740 motor_22\NN\3699975 recovery_23\NN\7357388 from_24\IN\1740 the_25\DT\1740 <e1>steroid</e1>_26\NN\14727670 myopathy_27\NN\14204950 ,_28\,\1740 instead_29\RB\1740 of_30\IN\1740 any_31\DT\1740 protection_32\NN\407535 that_33\WDT\1740 methylprednisolone_34\NN\1740 offers_35\VBZ\2327200 to_36\TO\1740 the_37\DT\1740 <e2>spinal_38\JJ\1740 cord_39\NN\3670849 injury</e2>_40\NN\14052046 ._41\.\1740
7785794
D014700_D012770 NONE refractory_0\JJ\1740 <e2>cardiogenic_1\JJ\1740 shock</e2>_2\NN\7510495 and_3\CC\1740 complete_4\VB\352826 heart_5\NN\5919034 block_6\NN\21939 after_7\IN\1740 <e1>verapamil</e1>_8\NN\2938514 sr_9\JJ\1740 and_10\CC\1740 metoprolol_11\NN\2832168 treatment_12\NN\654885 ._13\.\1740
D014700_D006327 CID refractory_0\JJ\1740 cardiogenic_1\JJ\1740 shock_2\NN\7510495 and_3\CC\1740 complete_4\VB\352826 <e2>heart_5\NN\5919034 block</e2>_6\NN\21939 after_7\IN\1740 <e1>verapamil</e1>_8\NN\2938514 sr_9\JJ\1740 and_10\CC\1740 metoprolol_11\NN\2832168 treatment_12\NN\654885 ._13\.\1740
D014700_D006327 CID a_0\DT\13649268 seventy-eight-year-old_1\JJ\1740 woman_2\NN\9605289 presented_3\VBN\2137132 with_4\IN\1740 complete_5\JJ\1740 <e2>heart_6\NN\5919034 block</e2>_7\NN\21939 and_8\CC\1740 refractory_9\JJ\1740 hypotension_10\NN\14057371 two_11\CD\13741022 days_12\NNS\15140892 after_13\IN\1740 a_14\DT\13649268 therapeutic_15\JJ\1740 dose_16\NN\3740161 of_17\IN\1740 sustained-release_18\NN\1740 <e1>verapamil</e1>_19\NNS\2938514 with_20\IN\1740 concomitant_21\JJ\1740 use_22\NN\407535 of_23\IN\1740 metoprolol_24\NN\2832168 ._25\.\1740
D008790_D012770 NONE refractory_0\JJ\1740 <e2>cardiogenic_1\JJ\1740 shock</e2>_2\NN\7510495 and_3\CC\1740 complete_4\VB\352826 heart_5\NN\5919034 block_6\NN\21939 after_7\IN\1740 verapamil_8\NN\2938514 sr_9\JJ\1740 and_10\CC\1740 <e1>metoprolol</e1>_11\NN\2832168 treatment_12\NN\654885 ._13\.\1740
D008790_D006327 CID refractory_0\JJ\1740 cardiogenic_1\JJ\1740 shock_2\NN\7510495 and_3\CC\1740 complete_4\VB\352826 <e2>heart_5\NN\5919034 block</e2>_6\NN\21939 after_7\IN\1740 verapamil_8\NN\2938514 sr_9\JJ\1740 and_10\CC\1740 <e1>metoprolol</e1>_11\NN\2832168 treatment_12\NN\654885 ._13\.\1740
D008790_D006327 CID a_0\DT\13649268 seventy-eight-year-old_1\JJ\1740 woman_2\NN\9605289 presented_3\VBN\2137132 with_4\IN\1740 complete_5\JJ\1740 <e2>heart_6\NN\5919034 block</e2>_7\NN\21939 and_8\CC\1740 refractory_9\JJ\1740 hypotension_10\NN\14057371 two_11\CD\13741022 days_12\NNS\15140892 after_13\IN\1740 a_14\DT\13649268 therapeutic_15\JJ\1740 dose_16\NN\3740161 of_17\IN\1740 sustained-release_18\NN\1740 verapamil_19\NNS\2938514 with_20\IN\1740 concomitant_21\JJ\1740 use_22\NN\407535 of_23\IN\1740 <e1>metoprolol</e1>_24\NN\2832168 ._25\.\1740
D014700_D007022 CID a_0\DT\13649268 seventy-eight-year-old_1\JJ\1740 woman_2\NN\9605289 presented_3\VBN\2137132 with_4\IN\1740 complete_5\JJ\1740 heart_6\NN\5919034 block_7\NN\21939 and_8\CC\1740 refractory_9\JJ\1740 <e2>hypotension</e2>_10\NN\14057371 two_11\CD\13741022 days_12\NNS\15140892 after_13\IN\1740 a_14\DT\13649268 therapeutic_15\JJ\1740 dose_16\NN\3740161 of_17\IN\1740 sustained-release_18\NN\1740 <e1>verapamil</e1>_19\NNS\2938514 with_20\IN\1740 concomitant_21\JJ\1740 use_22\NN\407535 of_23\IN\1740 metoprolol_24\NN\2832168 ._25\.\1740
D008790_D007022 CID a_0\DT\13649268 seventy-eight-year-old_1\JJ\1740 woman_2\NN\9605289 presented_3\VBN\2137132 with_4\IN\1740 complete_5\JJ\1740 heart_6\NN\5919034 block_7\NN\21939 and_8\CC\1740 refractory_9\JJ\1740 <e2>hypotension</e2>_10\NN\14057371 two_11\CD\13741022 days_12\NNS\15140892 after_13\IN\1740 a_14\DT\13649268 therapeutic_15\JJ\1740 dose_16\NN\3740161 of_17\IN\1740 sustained-release_18\NN\1740 verapamil_19\NNS\2938514 with_20\IN\1740 concomitant_21\JJ\1740 use_22\NN\407535 of_23\IN\1740 <e1>metoprolol</e1>_24\NN\2832168 ._25\.\1740
D001285_D007022 NONE the_0\DT\1740 patient_1\NN\9898892 continued_2\VBD\2367363 to_3\TO\1740 remain_4\VB\2604760 <e2>hypotensive</e2>_5\JJ\1740 with_6\IN\1740 complete_7\JJ\1740 heart_8\NN\5919034 block_9\NN\21939 ,_10\,\1740 even_11\RB\1740 with_12\IN\1740 multiple_13\JJ\1740 uses_14\NNS\407535 of_15\IN\1740 intravenous_16\JJ\1740 <e1>atropine</e1>_17\NN\14712692 as_18\RB\1740 well_19\RB\1740 as_20\IN\14622893 high_21\JJ\1740 doses_22\NNS\3740161 of_23\IN\1740 pressor_24\NN\9190918 agents_25\NNS\7347 such_26\JJ\1740 as_27\IN\14622893 dopamine_28\NN\14807737 and_29\CC\1740 dobutamine_30\NN\1740 ._31\.\1740
D001285_D006327 NONE the_0\DT\1740 patient_1\NN\9898892 continued_2\VBD\2367363 to_3\TO\1740 remain_4\VB\2604760 hypotensive_5\JJ\1740 with_6\IN\1740 complete_7\JJ\1740 <e2>heart_8\NN\5919034 block</e2>_9\NN\21939 ,_10\,\1740 even_11\RB\1740 with_12\IN\1740 multiple_13\JJ\1740 uses_14\NNS\407535 of_15\IN\1740 intravenous_16\JJ\1740 <e1>atropine</e1>_17\NN\14712692 as_18\RB\1740 well_19\RB\1740 as_20\IN\14622893 high_21\JJ\1740 doses_22\NNS\3740161 of_23\IN\1740 pressor_24\NN\9190918 agents_25\NNS\7347 such_26\JJ\1740 as_27\IN\14622893 dopamine_28\NN\14807737 and_29\CC\1740 dobutamine_30\NN\1740 ._31\.\1740
D004298_D007022 NONE the_0\DT\1740 patient_1\NN\9898892 continued_2\VBD\2367363 to_3\TO\1740 remain_4\VB\2604760 <e2>hypotensive</e2>_5\JJ\1740 with_6\IN\1740 complete_7\JJ\1740 heart_8\NN\5919034 block_9\NN\21939 ,_10\,\1740 even_11\RB\1740 with_12\IN\1740 multiple_13\JJ\1740 uses_14\NNS\407535 of_15\IN\1740 intravenous_16\JJ\1740 atropine_17\NN\14712692 as_18\RB\1740 well_19\RB\1740 as_20\IN\14622893 high_21\JJ\1740 doses_22\NNS\3740161 of_23\IN\1740 pressor_24\NN\9190918 agents_25\NNS\7347 such_26\JJ\1740 as_27\IN\14622893 <e1>dopamine</e1>_28\NN\14807737 and_29\CC\1740 dobutamine_30\NN\1740 ._31\.\1740
D004298_D006327 NONE the_0\DT\1740 patient_1\NN\9898892 continued_2\VBD\2367363 to_3\TO\1740 remain_4\VB\2604760 hypotensive_5\JJ\1740 with_6\IN\1740 complete_7\JJ\1740 <e2>heart_8\NN\5919034 block</e2>_9\NN\21939 ,_10\,\1740 even_11\RB\1740 with_12\IN\1740 multiple_13\JJ\1740 uses_14\NNS\407535 of_15\IN\1740 intravenous_16\JJ\1740 atropine_17\NN\14712692 as_18\RB\1740 well_19\RB\1740 as_20\IN\14622893 high_21\JJ\1740 doses_22\NNS\3740161 of_23\IN\1740 pressor_24\NN\9190918 agents_25\NNS\7347 such_26\JJ\1740 as_27\IN\14622893 <e1>dopamine</e1>_28\NN\14807737 and_29\CC\1740 dobutamine_30\NN\1740 ._31\.\1740
D004280_D007022 NONE the_0\DT\1740 patient_1\NN\9898892 continued_2\VBD\2367363 to_3\TO\1740 remain_4\VB\2604760 <e2>hypotensive</e2>_5\JJ\1740 with_6\IN\1740 complete_7\JJ\1740 heart_8\NN\5919034 block_9\NN\21939 ,_10\,\1740 even_11\RB\1740 with_12\IN\1740 multiple_13\JJ\1740 uses_14\NNS\407535 of_15\IN\1740 intravenous_16\JJ\1740 atropine_17\NN\14712692 as_18\RB\1740 well_19\RB\1740 as_20\IN\14622893 high_21\JJ\1740 doses_22\NNS\3740161 of_23\IN\1740 pressor_24\NN\9190918 agents_25\NNS\7347 such_26\JJ\1740 as_27\IN\14622893 dopamine_28\NN\14807737 and_29\CC\1740 <e1>dobutamine</e1>_30\NN\1740 ._31\.\1740
D004280_D006327 NONE the_0\DT\1740 patient_1\NN\9898892 continued_2\VBD\2367363 to_3\TO\1740 remain_4\VB\2604760 hypotensive_5\JJ\1740 with_6\IN\1740 complete_7\JJ\1740 <e2>heart_8\NN\5919034 block</e2>_9\NN\21939 ,_10\,\1740 even_11\RB\1740 with_12\IN\1740 multiple_13\JJ\1740 uses_14\NNS\407535 of_15\IN\1740 intravenous_16\JJ\1740 atropine_17\NN\14712692 as_18\RB\1740 well_19\RB\1740 as_20\IN\14622893 high_21\JJ\1740 doses_22\NNS\3740161 of_23\IN\1740 pressor_24\NN\9190918 agents_25\NNS\7347 such_26\JJ\1740 as_27\IN\14622893 dopamine_28\NN\14807737 and_29\CC\1740 <e1>dobutamine</e1>_30\NN\1740 ._31\.\1740
D002122_D007022 NONE however_0\RB\1740 ,_1\,\1740 shortly_2\RB\1740 after_3\IN\1740 the_4\DT\1740 use_5\NN\407535 of_6\IN\1740 intravenous_7\JJ\1740 <e1>calcium_8\NN\14625458 chloride</e1>_9\NN\14818238 ,_10\,\1740 the_11\DT\1740 refractory_12\JJ\1740 <e2>hypotension</e2>_13\NN\14057371 and_14\CC\1740 complete_15\VB\352826 heart_16\NN\5919034 block_17\NN\21939 resolved_18\VBN\352826 ._19\.\1740
D002122_D006327 NONE however_0\RB\1740 ,_1\,\1740 shortly_2\RB\1740 after_3\IN\1740 the_4\DT\1740 use_5\NN\407535 of_6\IN\1740 intravenous_7\JJ\1740 <e1>calcium_8\NN\14625458 chloride</e1>_9\NN\14818238 ,_10\,\1740 the_11\DT\1740 refractory_12\JJ\1740 hypotension_13\NN\14057371 and_14\CC\1740 complete_15\VB\352826 <e2>heart_16\NN\5919034 block</e2>_17\NN\21939 resolved_18\VBN\352826 ._19\.\1740
3057041
C020976_D006255 NONE multicenter_0\NN\1740 ,_1\,\1740 double-blind_2\NN\1740 ,_3\,\1740 multiple-dose_4\NN\1740 ,_5\,\1740 parallel-groups_6\JJ\1740 efficacy_7\NN\5199286 and_8\CC\1740 safety_9\NN\13920835 trial_10\NN\786195 of_11\IN\1740 <e1>azelastine</e1>_12\NN\1740 ,_13\,\1740 chlorpheniramine_14\NN\1740 ,_15\,\1740 and_16\CC\1740 placebo_17\VB\1740 in_18\IN\13603305 the_19\DT\1740 treatment_20\NN\654885 of_21\IN\1740 <e2>spring_22\NN\15236475 allergic_23\JJ\1740 rhinitis</e2>_24\NN\14336539 ._25\.\1740
C020976_D006255 NONE <e1>azelastine</e1>_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 novel_3\JJ\1740 antiallergic_4\JJ\1740 medication_5\NN\3247620 ,_6\,\1740 was_7\VBD\836236 compared_8\VBN\644583 with_9\IN\1740 chlorpheniramine_10\NN\1740 maleate_11\NN\2718811 and_12\CC\1740 placebo_13\NN\3740161 for_14\IN\1740 efficacy_15\NN\5199286 and_16\CC\1740 safety_17\NN\13920835 in_18\IN\13603305 the_19\DT\1740 treatment_20\NN\654885 of_21\IN\1740 <e2>spring_22\NN\15236475 allergic_23\JJ\1740 rhinitis</e2>_24\NN\14336539 in_25\IN\13603305 a_26\DT\13649268 multicenter_27\NN\1740 ,_28\,\1740 double-blind_29\NN\1740 ,_30\,\1740 multiple-dose_31\NN\1740 ,_32\,\1740 parallel-groups_33\NNS\1740 study_34\VBP\630380 ._35\.\1740
C020976_D006255 NONE <e1>azelastine</e1>_0\NN\1740 appears_1\VBZ\2604760 to_2\TO\1740 be_3\VB\836236 a_4\DT\13649268 safe_5\JJ\1740 ,_6\,\1740 efficacious_7\JJ\1740 medication_8\NN\3247620 for_9\IN\1740 <e2>seasonal_10\JJ\1740 allergic_11\JJ\1740 rhinitis</e2>_12\NN\14336539 ._13\.\1740
D002744_D006255 NONE multicenter_0\NN\1740 ,_1\,\1740 double-blind_2\NN\1740 ,_3\,\1740 multiple-dose_4\NN\1740 ,_5\,\1740 parallel-groups_6\JJ\1740 efficacy_7\NN\5199286 and_8\CC\1740 safety_9\NN\13920835 trial_10\NN\786195 of_11\IN\1740 azelastine_12\NN\1740 ,_13\,\1740 <e1>chlorpheniramine</e1>_14\NN\1740 ,_15\,\1740 and_16\CC\1740 placebo_17\VB\1740 in_18\IN\13603305 the_19\DT\1740 treatment_20\NN\654885 of_21\IN\1740 <e2>spring_22\NN\15236475 allergic_23\JJ\1740 rhinitis</e2>_24\NN\14336539 ._25\.\1740
D002744_D006255 NONE azelastine_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 novel_3\JJ\1740 antiallergic_4\JJ\1740 medication_5\NN\3247620 ,_6\,\1740 was_7\VBD\836236 compared_8\VBN\644583 with_9\IN\1740 <e1>chlorpheniramine_10\NN\1740 maleate</e1>_11\NN\2718811 and_12\CC\1740 placebo_13\NN\3740161 for_14\IN\1740 efficacy_15\NN\5199286 and_16\CC\1740 safety_17\NN\13920835 in_18\IN\13603305 the_19\DT\1740 treatment_20\NN\654885 of_21\IN\1740 <e2>spring_22\NN\15236475 allergic_23\JJ\1740 rhinitis</e2>_24\NN\14336539 in_25\IN\13603305 a_26\DT\13649268 multicenter_27\NN\1740 ,_28\,\1740 double-blind_29\NN\1740 ,_30\,\1740 multiple-dose_31\NN\1740 ,_32\,\1740 parallel-groups_33\NNS\1740 study_34\VBP\630380 ._35\.\1740
C020976_D006970 CID <e2>drowsiness</e2>_0\NN\14015731 and_1\CC\1740 altered_2\JJ\1740 taste_3\NN\5712076 perception_4\NN\5926676 were_5\VBD\836236 increased_6\VBN\169651 significantly_7\RB\1740 over_8\IN\5867413 placebo_9\NN\3740161 only_10\RB\1740 in_11\IN\13603305 the_12\DT\1740 high-dose_13\JJ\1740 <e1>azelastine</e1>_14\NN\1740 group_15\NN\2137 ._16\.\1740
C020976_D013651 CID drowsiness_0\NN\14015731 and_1\CC\1740 <e2>altered_2\JJ\1740 taste_3\NN\5712076 perception</e2>_4\NN\5926676 were_5\VBD\836236 increased_6\VBN\169651 significantly_7\RB\1740 over_8\IN\5867413 placebo_9\NN\3740161 only_10\RB\1740 in_11\IN\13603305 the_12\DT\1740 high-dose_13\JJ\1740 <e1>azelastine</e1>_14\NN\1740 group_15\NN\2137 ._16\.\1740
9214597
D004967_D010911 NONE over_0\IN\5867413 expression_1\NN\4679549 of_2\IN\1740 vascular_3\JJ\1740 endothelial_4\JJ\1740 growth_5\NN\13526110 factor_6\NN\7326557 and_7\CC\1740 its_8\PRP$\6125041 receptor_9\NN\5225602 during_10\IN\1740 the_11\DT\1740 development_12\NN\248977 of_13\IN\1740 <e1>estrogen-induced</e1>_14\JJ\1740 rat_15\NN\2329401 <e2>pituitary_16\JJ\1740 tumors</e2>_17\NNS\14234074 may_18\MD\15209706 mediate_19\VB\761713 estrogen-initiated_20\JJ\1740 tumor_21\NN\14234074 angiogenesis_22\NN\13489037 ._23\.\1740
D004967_D010911 NONE over_0\IN\5867413 expression_1\NN\4679549 of_2\IN\1740 vascular_3\JJ\1740 endothelial_4\JJ\1740 growth_5\NN\13526110 factor_6\NN\7326557 and_7\CC\1740 its_8\PRP$\6125041 receptor_9\NN\5225602 during_10\IN\1740 the_11\DT\1740 development_12\NN\248977 of_13\IN\1740 estrogen-induced_14\JJ\1740 rat_15\NN\2329401 <e2>pituitary_16\JJ\1740 tumors</e2>_17\NNS\14234074 may_18\MD\15209706 mediate_19\VB\761713 <e1>estrogen-initiated</e1>_20\JJ\1740 tumor_21\NN\14234074 angiogenesis_22\NN\13489037 ._23\.\1740
D004967_D009369 NONE over_0\IN\5867413 expression_1\NN\4679549 of_2\IN\1740 vascular_3\JJ\1740 endothelial_4\JJ\1740 growth_5\NN\13526110 factor_6\NN\7326557 and_7\CC\1740 its_8\PRP$\6125041 receptor_9\NN\5225602 during_10\IN\1740 the_11\DT\1740 development_12\NN\248977 of_13\IN\1740 <e1>estrogen-induced</e1>_14\JJ\1740 rat_15\NN\2329401 pituitary_16\JJ\1740 tumors_17\NNS\14234074 may_18\MD\15209706 mediate_19\VB\761713 estrogen-initiated_20\JJ\1740 <e2>tumor</e2>_21\NN\14234074 angiogenesis_22\NN\13489037 ._23\.\1740
D004967_D009369 NONE over_0\IN\5867413 expression_1\NN\4679549 of_2\IN\1740 vascular_3\JJ\1740 endothelial_4\JJ\1740 growth_5\NN\13526110 factor_6\NN\7326557 and_7\CC\1740 its_8\PRP$\6125041 receptor_9\NN\5225602 during_10\IN\1740 the_11\DT\1740 development_12\NN\248977 of_13\IN\1740 estrogen-induced_14\JJ\1740 rat_15\NN\2329401 pituitary_16\JJ\1740 tumors_17\NNS\14234074 may_18\MD\15209706 mediate_19\VB\761713 <e1>estrogen-initiated</e1>_20\JJ\1740 <e2>tumor</e2>_21\NN\14234074 angiogenesis_22\NN\13489037 ._23\.\1740
D004967_D009369 NONE <e1>estrogens</e1>_0\NNS\14745635 ,_1\,\1740 which_2\WDT\1740 have_3\VBP\2108377 been_4\VBN\836236 associated_5\VBN\628491 with_6\IN\1740 several_7\JJ\1740 types_8\NNS\5839024 of_9\IN\1740 human_10\JJ\1740 and_11\CC\1740 animal_12\JJ\1740 <e2>cancers</e2>_13\NNS\14239425 ,_14\,\1740 can_15\MD\3094503 induce_16\VB\1627355 tumor_17\NN\14234074 angiogenesis_18\NN\13489037 in_19\IN\13603305 the_20\DT\1740 pituitary_21\NN\5329735 of_22\IN\1740 fischer_23\NNP\1740 344_24\CD\1740 rats_25\NNS\2329401 ._26\.\1740
D004967_D009369 NONE <e1>estrogens</e1>_0\NNS\14745635 ,_1\,\1740 which_2\WDT\1740 have_3\VBP\2108377 been_4\VBN\836236 associated_5\VBN\628491 with_6\IN\1740 several_7\JJ\1740 types_8\NNS\5839024 of_9\IN\1740 human_10\JJ\1740 and_11\CC\1740 animal_12\JJ\1740 cancers_13\NNS\14239425 ,_14\,\1740 can_15\MD\3094503 induce_16\VB\1627355 <e2>tumor</e2>_17\NN\14234074 angiogenesis_18\NN\13489037 in_19\IN\13603305 the_20\DT\1740 pituitary_21\NN\5329735 of_22\IN\1740 fischer_23\NNP\1740 344_24\CD\1740 rats_25\NNS\2329401 ._26\.\1740
D004967_D009369 NONE the_0\DT\1740 mechanistic_1\JJ\1740 details_2\NNS\6634376 of_3\IN\1740 <e2>tumor</e2>_4\NN\14234074 angiogenesis_5\NN\13489037 induction_6\NN\7450842 ,_7\,\1740 during_8\IN\1740 <e1>estrogen</e1>_9\NN\14745635 carcinogenesis_10\NN\1740 ,_11\,\1740 are_12\VBP\836236 still_13\RB\1740 unknown_14\JJ\1740 ._15\.\1740
D004967_D009369 NONE to_0\TO\1740 elucidate_1\VB\939277 the_2\DT\1740 role_3\NN\719494 of_4\IN\1740 <e1>estrogen</e1>_5\NN\14745635 in_6\IN\13603305 the_7\DT\1740 regulation_8\NN\6652242 of_9\IN\1740 <e2>tumor</e2>_10\NN\14234074 angiogenesis_11\NN\13489037 in_12\IN\13603305 the_13\DT\1740 pituitary_14\NN\5329735 of_15\IN\1740 female_16\JJ\1740 rats_17\NNS\2329401 ,_18\,\1740 the_19\DT\1740 density_20\NN\4941325 of_21\IN\1740 blood_22\NN\5397468 vessels_23\NNS\5246511 was_24\VBD\836236 analysed_25\VBN\78760 using_26\VBG\1156834 factor_27\NN\7326557 viii_28\NN\13741022 related_29\JJ\1740 antigen_30\NN\20090 (_31\-LRB-\1740 fviiirag_32\NN\1740 )_33\-RRB-\1740 immunohistochemistry_34\NN\791527 and_35\CC\1740 the_36\DT\1740 expression_37\NN\4679549 of_38\IN\1740 vascular_39\JJ\1740 endothelial_40\JJ\1740 growth_41\NN\13526110 factor/vascular_42\JJ\1740 permeability_43\NN\4940146 factor_44\NN\7326557 (_45\-LRB-\1740 vegf/vpf_46\NN\1740 )_47\-RRB-\1740 was_48\VBD\836236 examined_49\VBN\789138 by_50\IN\1740 western_51\NN\6615026 blot_52\NN\4692157 and_53\CC\1740 immunohistochemical_54\JJ\1740 analysis_55\NN\633864 ._56\.\1740
D004967_D009369 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 over_4\IN\5867413 expression_5\NN\4679549 of_6\IN\1740 vegf_7\NN\1740 and_8\CC\1740 its_9\PRP$\6125041 receptor_10\NN\5225602 (_11\-LRB-\1740 vegfr-2_12\NN\1740 )_13\-RRB-\1740 may_14\MD\15209706 play_15\VB\1072262 an_16\DT\6697703 important_17\JJ\1740 role_18\NN\719494 in_19\IN\13603305 the_20\DT\1740 initial_21\JJ\1740 step_22\NN\168237 of_23\IN\1740 the_24\DT\1740 regulation_25\NN\6652242 of_26\IN\1740 <e1>estrogen</e1>_27\NN\14745635 induced_28\JJ\1740 <e2>tumor</e2>_29\NN\14234074 angiogenesis_30\NN\13489037 in_31\IN\13603305 the_32\DT\1740 rat_33\NN\2329401 pituitary_34\NN\5329735 ._35\.\1740
D004967_D063646 NONE the_0\DT\1740 mechanistic_1\JJ\1740 details_2\NNS\6634376 of_3\IN\1740 tumor_4\NN\14234074 angiogenesis_5\NN\13489037 induction_6\NN\7450842 ,_7\,\1740 during_8\IN\1740 <e1>estrogen</e1>_9\NN\14745635 <e2>carcinogenesis</e2>_10\NN\1740 ,_11\,\1740 are_12\VBP\836236 still_13\RB\1740 unknown_14\JJ\1740 ._15\.\1740
D004958_D009369 NONE the_0\DT\1740 high_1\JJ\1740 <e2>tumor</e2>_2\NN\14234074 angiogenic_3\JJ\1740 potential_4\NN\14481929 was_5\VBD\836236 associated_6\VBN\628491 with_7\IN\1740 an_8\DT\6697703 elevated_9\JJ\1740 vegf/vpf_10\NN\1740 protein_11\NN\14944888 expression_12\NN\4679549 in_13\IN\13603305 the_14\DT\1740 <e1>e2</e1>_15\NN\1740 exposed_16\JJ\1740 pituitary_17\NN\5329735 of_18\IN\1740 ovariectomized_19\JJ\1740 (_20\-LRB-\1740 ovex_21\JJ\1740 )_22\-RRB-\1740 rats_23\NNS\2329401 ._24\.\1740
15893386
D013390_D014313 CID <e1>succinylcholine-induced</e1>_0\JJ\1740 <e2>masseter_1\NN\5602132 muscle_2\NN\5289601 rigidity</e2>_3\NN\5023233 during_4\IN\1740 bronchoscopic_5\JJ\1740 removal_6\NN\383606 of_7\IN\1740 a_8\DT\13649268 tracheal_9\NN\1740 foreign_10\JJ\1740 body_11\NN\19128 ._12\.\1740
D013390_D014313 CID here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 describe_3\VBP\1001294 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 severe_7\JJ\1740 <e2>masseter_8\NN\5602132 muscle_9\NN\5289601 rigidity</e2>_10\NN\5023233 (_11\-LRB-\1740 jaw_12\NN\5269901 of_13\IN\1740 steel_14\NN\14586769 )_15\-RRB-\1740 after_16\IN\1740 <e1>succinylcholine</e1>_17\NN\3800001 (_18\-LRB-\1740 sch_19\NN\1740 )_20\-RRB-\1740 administration_21\NN\1133281 during_22\IN\1740 general_23\JJ\1740 anesthetic_24\JJ\1740 management_25\NN\1123598 for_26\IN\1740 rigid_27\JJ\1740 bronchoscopic_28\JJ\1740 removal_29\NN\383606 of_30\IN\1740 a_31\DT\13649268 tracheal_32\NN\1740 foreign_33\JJ\1740 body_34\NN\19128 ._35\.\1740
D013390_D014313 CID here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 describe_3\VBP\1001294 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 severe_7\JJ\1740 masseter_8\NN\5602132 muscle_9\NN\5289601 rigidity_10\NN\5023233 (_11\-LRB-\1740 <e2>jaw_12\NN\5269901 of_13\IN\1740 steel</e2>_14\NN\14586769 )_15\-RRB-\1740 after_16\IN\1740 <e1>succinylcholine</e1>_17\NN\3800001 (_18\-LRB-\1740 sch_19\NN\1740 )_20\-RRB-\1740 administration_21\NN\1133281 during_22\IN\1740 general_23\JJ\1740 anesthetic_24\JJ\1740 management_25\NN\1123598 for_26\IN\1740 rigid_27\JJ\1740 bronchoscopic_28\JJ\1740 removal_29\NN\383606 of_30\IN\1740 a_31\DT\13649268 tracheal_32\NN\1740 foreign_33\JJ\1740 body_34\NN\19128 ._35\.\1740
D013390_D014313 CID here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 describe_3\VBP\1001294 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 severe_7\JJ\1740 <e2>masseter_8\NN\5602132 muscle_9\NN\5289601 rigidity</e2>_10\NN\5023233 (_11\-LRB-\1740 jaw_12\NN\5269901 of_13\IN\1740 steel_14\NN\14586769 )_15\-RRB-\1740 after_16\IN\1740 succinylcholine_17\NN\3800001 (_18\-LRB-\1740 <e1>sch</e1>_19\NN\1740 )_20\-RRB-\1740 administration_21\NN\1133281 during_22\IN\1740 general_23\JJ\1740 anesthetic_24\JJ\1740 management_25\NN\1123598 for_26\IN\1740 rigid_27\JJ\1740 bronchoscopic_28\JJ\1740 removal_29\NN\383606 of_30\IN\1740 a_31\DT\13649268 tracheal_32\NN\1740 foreign_33\JJ\1740 body_34\NN\19128 ._35\.\1740
D013390_D014313 CID here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 describe_3\VBP\1001294 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 severe_7\JJ\1740 masseter_8\NN\5602132 muscle_9\NN\5289601 rigidity_10\NN\5023233 (_11\-LRB-\1740 <e2>jaw_12\NN\5269901 of_13\IN\1740 steel</e2>_14\NN\14586769 )_15\-RRB-\1740 after_16\IN\1740 succinylcholine_17\NN\3800001 (_18\-LRB-\1740 <e1>sch</e1>_19\NN\1740 )_20\-RRB-\1740 administration_21\NN\1133281 during_22\IN\1740 general_23\JJ\1740 anesthetic_24\JJ\1740 management_25\NN\1123598 for_26\IN\1740 rigid_27\JJ\1740 bronchoscopic_28\JJ\1740 removal_29\NN\383606 of_30\IN\1740 a_31\DT\13649268 tracheal_32\NN\1740 foreign_33\JJ\1740 body_34\NN\19128 ._35\.\1740
D015742_D008305 NONE anesthesia_0\NNP\14034177 was_1\VBD\836236 continued_2\VBN\2367363 uneventfully_3\RB\1740 with_4\IN\1740 <e1>propofol</e1>_5\NN\1740 infusion_6\NN\14589223 while_7\IN\15122231 all_8\DT\1740 facilities_9\NNS\21939 were_10\VBD\836236 available_11\JJ\1740 to_12\TO\1740 detect_13\VB\2163746 and_14\CC\1740 treat_15\JJ\1740 <e2>malignant_16\JJ\1740 hyperthermia</e2>_17\NN\14034177 ._18\.\1740
3461217
D008770_D011471 CID production_0\NN\30358 of_1\IN\1740 autochthonous_2\JJ\1740 <e2>prostate_3\NN\5329735 cancer</e2>_4\NN\14239425 in_5\IN\13603305 lobund-wistar_6\NN\1740 rats_7\NNS\2329401 by_8\IN\1740 treatments_9\NNS\654885 with_10\IN\1740 <e1>n-nitroso-n-methylurea</e1>_11\NN\1740 and_12\CC\1740 testosterone_13\NN\14747587 ._14\.\1740
D008770_D011471 CID more_0\JJR\1740 than_1\IN\1740 50_2\CD\13745420 %_3\NN\1740 of_4\IN\1740 lobund-wistar_5\NN\1740 (_6\-LRB-\1740 l-w_7\NN\1740 )_8\-RRB-\1740 strain_9\NN\7358060 rats_10\NNS\2329401 developed_11\VBD\1753788 large_12\JJ\1740 ,_13\,\1740 palpable_14\JJ\1740 <e2>prostate_15\NN\5329735 adenocarcinomas</e2>_16\NNS\14242337 (_17\-LRB-\1740 pas_18\NNS\285557 )_19\-RRB-\1740 following_20\VBG\1835496 treatments_21\NNS\654885 with_22\IN\1740 <e1>n-nitroso-n-methylurea</e1>_23\NN\1740 (_24\-LRB-\1740 cas_25\NN\14625458 :_26\:\1740 684_27\CD\1740 -_28\SYM\1740 93_29\CD\1740 -_30\SYM\1740 5_31\CD\13741022 )_32\-RRB-\1740 and_33\CC\1740 testosterone_34\NN\14747587 propionate_35\NN\1740 [_36\-LRB-\1740 (_37\-LRB-\1740 tp_38\NN\1740 )_39\-RRB-\1740 cas_40\NN\14625458 :_41\:\1740 57_42\CD\1740 -_43\SYM\1740 85_44\CD\1740 -_45\SYM\1740 2_46\CD\13741022 ]_47\-RRB-\1740 ,_48\,\1740 and_49\CC\1740 most_50\JJS\1740 of_51\IN\1740 the_52\DT\1740 tumor-bearing_53\JJ\1740 rats_54\NNS\2329401 manifested_55\VBD\1015244 metastatic_56\JJ\1740 lesions_57\NNS\14204950 ._58\.\1740
D008770_D011471 CID more_0\JJR\1740 than_1\IN\1740 50_2\CD\13745420 %_3\NN\1740 of_4\IN\1740 lobund-wistar_5\NN\1740 (_6\-LRB-\1740 l-w_7\NN\1740 )_8\-RRB-\1740 strain_9\NN\7358060 rats_10\NNS\2329401 developed_11\VBD\1753788 large_12\JJ\1740 ,_13\,\1740 palpable_14\JJ\1740 prostate_15\NN\5329735 adenocarcinomas_16\NNS\14242337 (_17\-LRB-\1740 <e2>pas</e2>_18\NNS\285557 )_19\-RRB-\1740 following_20\VBG\1835496 treatments_21\NNS\654885 with_22\IN\1740 <e1>n-nitroso-n-methylurea</e1>_23\NN\1740 (_24\-LRB-\1740 cas_25\NN\14625458 :_26\:\1740 684_27\CD\1740 -_28\SYM\1740 93_29\CD\1740 -_30\SYM\1740 5_31\CD\13741022 )_32\-RRB-\1740 and_33\CC\1740 testosterone_34\NN\14747587 propionate_35\NN\1740 [_36\-LRB-\1740 (_37\-LRB-\1740 tp_38\NN\1740 )_39\-RRB-\1740 cas_40\NN\14625458 :_41\:\1740 57_42\CD\1740 -_43\SYM\1740 85_44\CD\1740 -_45\SYM\1740 2_46\CD\13741022 ]_47\-RRB-\1740 ,_48\,\1740 and_49\CC\1740 most_50\JJS\1740 of_51\IN\1740 the_52\DT\1740 tumor-bearing_53\JJ\1740 rats_54\NNS\2329401 manifested_55\VBD\1015244 metastatic_56\JJ\1740 lesions_57\NNS\14204950 ._58\.\1740
D013739_D011471 NONE production_0\NN\30358 of_1\IN\1740 autochthonous_2\JJ\1740 <e2>prostate_3\NN\5329735 cancer</e2>_4\NN\14239425 in_5\IN\13603305 lobund-wistar_6\NN\1740 rats_7\NNS\2329401 by_8\IN\1740 treatments_9\NNS\654885 with_10\IN\1740 n-nitroso-n-methylurea_11\NN\1740 and_12\CC\1740 <e1>testosterone</e1>_13\NN\14747587 ._14\.\1740
D008770_D009369 NONE more_0\JJR\1740 than_1\IN\1740 50_2\CD\13745420 %_3\NN\1740 of_4\IN\1740 lobund-wistar_5\NN\1740 (_6\-LRB-\1740 l-w_7\NN\1740 )_8\-RRB-\1740 strain_9\NN\7358060 rats_10\NNS\2329401 developed_11\VBD\1753788 large_12\JJ\1740 ,_13\,\1740 palpable_14\JJ\1740 prostate_15\NN\5329735 adenocarcinomas_16\NNS\14242337 (_17\-LRB-\1740 pas_18\NNS\285557 )_19\-RRB-\1740 following_20\VBG\1835496 treatments_21\NNS\654885 with_22\IN\1740 <e1>n-nitroso-n-methylurea</e1>_23\NN\1740 (_24\-LRB-\1740 cas_25\NN\14625458 :_26\:\1740 684_27\CD\1740 -_28\SYM\1740 93_29\CD\1740 -_30\SYM\1740 5_31\CD\13741022 )_32\-RRB-\1740 and_33\CC\1740 testosterone_34\NN\14747587 propionate_35\NN\1740 [_36\-LRB-\1740 (_37\-LRB-\1740 tp_38\NN\1740 )_39\-RRB-\1740 cas_40\NN\14625458 :_41\:\1740 57_42\CD\1740 -_43\SYM\1740 85_44\CD\1740 -_45\SYM\1740 2_46\CD\13741022 ]_47\-RRB-\1740 ,_48\,\1740 and_49\CC\1740 most_50\JJS\1740 of_51\IN\1740 the_52\DT\1740 <e2>tumor-bearing</e2>_53\JJ\1740 rats_54\NNS\2329401 manifested_55\VBD\1015244 metastatic_56\JJ\1740 lesions_57\NNS\14204950 ._58\.\1740
D043343_D011471 CID more_0\JJR\1740 than_1\IN\1740 50_2\CD\13745420 %_3\NN\1740 of_4\IN\1740 lobund-wistar_5\NN\1740 (_6\-LRB-\1740 l-w_7\NN\1740 )_8\-RRB-\1740 strain_9\NN\7358060 rats_10\NNS\2329401 developed_11\VBD\1753788 large_12\JJ\1740 ,_13\,\1740 palpable_14\JJ\1740 <e2>prostate_15\NN\5329735 adenocarcinomas</e2>_16\NNS\14242337 (_17\-LRB-\1740 pas_18\NNS\285557 )_19\-RRB-\1740 following_20\VBG\1835496 treatments_21\NNS\654885 with_22\IN\1740 n-nitroso-n-methylurea_23\NN\1740 (_24\-LRB-\1740 cas_25\NN\14625458 :_26\:\1740 684_27\CD\1740 -_28\SYM\1740 93_29\CD\1740 -_30\SYM\1740 5_31\CD\13741022 )_32\-RRB-\1740 and_33\CC\1740 <e1>testosterone_34\NN\14747587 propionate</e1>_35\NN\1740 [_36\-LRB-\1740 (_37\-LRB-\1740 tp_38\NN\1740 )_39\-RRB-\1740 cas_40\NN\14625458 :_41\:\1740 57_42\CD\1740 -_43\SYM\1740 85_44\CD\1740 -_45\SYM\1740 2_46\CD\13741022 ]_47\-RRB-\1740 ,_48\,\1740 and_49\CC\1740 most_50\JJS\1740 of_51\IN\1740 the_52\DT\1740 tumor-bearing_53\JJ\1740 rats_54\NNS\2329401 manifested_55\VBD\1015244 metastatic_56\JJ\1740 lesions_57\NNS\14204950 ._58\.\1740
D043343_D011471 CID more_0\JJR\1740 than_1\IN\1740 50_2\CD\13745420 %_3\NN\1740 of_4\IN\1740 lobund-wistar_5\NN\1740 (_6\-LRB-\1740 l-w_7\NN\1740 )_8\-RRB-\1740 strain_9\NN\7358060 rats_10\NNS\2329401 developed_11\VBD\1753788 large_12\JJ\1740 ,_13\,\1740 palpable_14\JJ\1740 prostate_15\NN\5329735 adenocarcinomas_16\NNS\14242337 (_17\-LRB-\1740 <e2>pas</e2>_18\NNS\285557 )_19\-RRB-\1740 following_20\VBG\1835496 treatments_21\NNS\654885 with_22\IN\1740 n-nitroso-n-methylurea_23\NN\1740 (_24\-LRB-\1740 cas_25\NN\14625458 :_26\:\1740 684_27\CD\1740 -_28\SYM\1740 93_29\CD\1740 -_30\SYM\1740 5_31\CD\13741022 )_32\-RRB-\1740 and_33\CC\1740 <e1>testosterone_34\NN\14747587 propionate</e1>_35\NN\1740 [_36\-LRB-\1740 (_37\-LRB-\1740 tp_38\NN\1740 )_39\-RRB-\1740 cas_40\NN\14625458 :_41\:\1740 57_42\CD\1740 -_43\SYM\1740 85_44\CD\1740 -_45\SYM\1740 2_46\CD\13741022 ]_47\-RRB-\1740 ,_48\,\1740 and_49\CC\1740 most_50\JJS\1740 of_51\IN\1740 the_52\DT\1740 tumor-bearing_53\JJ\1740 rats_54\NNS\2329401 manifested_55\VBD\1015244 metastatic_56\JJ\1740 lesions_57\NNS\14204950 ._58\.\1740
D043343_D011471 CID more_0\JJR\1740 than_1\IN\1740 50_2\CD\13745420 %_3\NN\1740 of_4\IN\1740 lobund-wistar_5\NN\1740 (_6\-LRB-\1740 l-w_7\NN\1740 )_8\-RRB-\1740 strain_9\NN\7358060 rats_10\NNS\2329401 developed_11\VBD\1753788 large_12\JJ\1740 ,_13\,\1740 palpable_14\JJ\1740 <e2>prostate_15\NN\5329735 adenocarcinomas</e2>_16\NNS\14242337 (_17\-LRB-\1740 pas_18\NNS\285557 )_19\-RRB-\1740 following_20\VBG\1835496 treatments_21\NNS\654885 with_22\IN\1740 n-nitroso-n-methylurea_23\NN\1740 (_24\-LRB-\1740 cas_25\NN\14625458 :_26\:\1740 684_27\CD\1740 -_28\SYM\1740 93_29\CD\1740 -_30\SYM\1740 5_31\CD\13741022 )_32\-RRB-\1740 and_33\CC\1740 testosterone_34\NN\14747587 propionate_35\NN\1740 [_36\-LRB-\1740 (_37\-LRB-\1740 <e1>tp</e1>_38\NN\1740 )_39\-RRB-\1740 cas_40\NN\14625458 :_41\:\1740 57_42\CD\1740 -_43\SYM\1740 85_44\CD\1740 -_45\SYM\1740 2_46\CD\13741022 ]_47\-RRB-\1740 ,_48\,\1740 and_49\CC\1740 most_50\JJS\1740 of_51\IN\1740 the_52\DT\1740 tumor-bearing_53\JJ\1740 rats_54\NNS\2329401 manifested_55\VBD\1015244 metastatic_56\JJ\1740 lesions_57\NNS\14204950 ._58\.\1740
D043343_D011471 CID more_0\JJR\1740 than_1\IN\1740 50_2\CD\13745420 %_3\NN\1740 of_4\IN\1740 lobund-wistar_5\NN\1740 (_6\-LRB-\1740 l-w_7\NN\1740 )_8\-RRB-\1740 strain_9\NN\7358060 rats_10\NNS\2329401 developed_11\VBD\1753788 large_12\JJ\1740 ,_13\,\1740 palpable_14\JJ\1740 prostate_15\NN\5329735 adenocarcinomas_16\NNS\14242337 (_17\-LRB-\1740 <e2>pas</e2>_18\NNS\285557 )_19\-RRB-\1740 following_20\VBG\1835496 treatments_21\NNS\654885 with_22\IN\1740 n-nitroso-n-methylurea_23\NN\1740 (_24\-LRB-\1740 cas_25\NN\14625458 :_26\:\1740 684_27\CD\1740 -_28\SYM\1740 93_29\CD\1740 -_30\SYM\1740 5_31\CD\13741022 )_32\-RRB-\1740 and_33\CC\1740 testosterone_34\NN\14747587 propionate_35\NN\1740 [_36\-LRB-\1740 (_37\-LRB-\1740 <e1>tp</e1>_38\NN\1740 )_39\-RRB-\1740 cas_40\NN\14625458 :_41\:\1740 57_42\CD\1740 -_43\SYM\1740 85_44\CD\1740 -_45\SYM\1740 2_46\CD\13741022 ]_47\-RRB-\1740 ,_48\,\1740 and_49\CC\1740 most_50\JJS\1740 of_51\IN\1740 the_52\DT\1740 tumor-bearing_53\JJ\1740 rats_54\NNS\2329401 manifested_55\VBD\1015244 metastatic_56\JJ\1740 lesions_57\NNS\14204950 ._58\.\1740
D043343_D011471 CID within_0\IN\1740 the_1\DT\1740 same_2\JJ\1740 timeframe_3\NN\1740 ,_4\,\1740 no_5\DT\7204911 l-w_6\JJ\1740 rat_7\NN\2329401 developed_8\VBD\1753788 a_9\DT\13649268 similar_10\JJ\1740 palpable_11\JJ\1740 <e2>pa</e2>_12\NN\10080869 when_13\WRB\1740 treated_14\VBN\2376958 only_15\RB\1740 with_16\IN\1740 <e1>tp</e1>_17\NN\1740 ._18\.\1740
D043343_D011471 CID in_0\IN\13603305 l-w_1\JJ\1740 rats_2\NNS\2329401 ,_3\,\1740 <e1>tp</e1>_4\NN\1740 acted_5\VBD\1619354 as_6\IN\14622893 a_7\DT\13649268 tumor_8\NN\14234074 enhancement_9\NN\248977 agent_10\NN\7347 ,_11\,\1740 with_12\IN\1740 primary_13\JJ\1740 emphasis_14\NN\14434681 on_15\IN\1740 the_16\DT\1740 development_17\NN\248977 of_18\IN\1740 <e2>prostate_19\NN\5329735 cancer</e2>_20\NN\14239425 ._21\.\1740
D043343_D009369 NONE more_0\JJR\1740 than_1\IN\1740 50_2\CD\13745420 %_3\NN\1740 of_4\IN\1740 lobund-wistar_5\NN\1740 (_6\-LRB-\1740 l-w_7\NN\1740 )_8\-RRB-\1740 strain_9\NN\7358060 rats_10\NNS\2329401 developed_11\VBD\1753788 large_12\JJ\1740 ,_13\,\1740 palpable_14\JJ\1740 prostate_15\NN\5329735 adenocarcinomas_16\NNS\14242337 (_17\-LRB-\1740 pas_18\NNS\285557 )_19\-RRB-\1740 following_20\VBG\1835496 treatments_21\NNS\654885 with_22\IN\1740 n-nitroso-n-methylurea_23\NN\1740 (_24\-LRB-\1740 cas_25\NN\14625458 :_26\:\1740 684_27\CD\1740 -_28\SYM\1740 93_29\CD\1740 -_30\SYM\1740 5_31\CD\13741022 )_32\-RRB-\1740 and_33\CC\1740 <e1>testosterone_34\NN\14747587 propionate</e1>_35\NN\1740 [_36\-LRB-\1740 (_37\-LRB-\1740 tp_38\NN\1740 )_39\-RRB-\1740 cas_40\NN\14625458 :_41\:\1740 57_42\CD\1740 -_43\SYM\1740 85_44\CD\1740 -_45\SYM\1740 2_46\CD\13741022 ]_47\-RRB-\1740 ,_48\,\1740 and_49\CC\1740 most_50\JJS\1740 of_51\IN\1740 the_52\DT\1740 <e2>tumor-bearing</e2>_53\JJ\1740 rats_54\NNS\2329401 manifested_55\VBD\1015244 metastatic_56\JJ\1740 lesions_57\NNS\14204950 ._58\.\1740
D043343_D009369 NONE more_0\JJR\1740 than_1\IN\1740 50_2\CD\13745420 %_3\NN\1740 of_4\IN\1740 lobund-wistar_5\NN\1740 (_6\-LRB-\1740 l-w_7\NN\1740 )_8\-RRB-\1740 strain_9\NN\7358060 rats_10\NNS\2329401 developed_11\VBD\1753788 large_12\JJ\1740 ,_13\,\1740 palpable_14\JJ\1740 prostate_15\NN\5329735 adenocarcinomas_16\NNS\14242337 (_17\-LRB-\1740 pas_18\NNS\285557 )_19\-RRB-\1740 following_20\VBG\1835496 treatments_21\NNS\654885 with_22\IN\1740 n-nitroso-n-methylurea_23\NN\1740 (_24\-LRB-\1740 cas_25\NN\14625458 :_26\:\1740 684_27\CD\1740 -_28\SYM\1740 93_29\CD\1740 -_30\SYM\1740 5_31\CD\13741022 )_32\-RRB-\1740 and_33\CC\1740 testosterone_34\NN\14747587 propionate_35\NN\1740 [_36\-LRB-\1740 (_37\-LRB-\1740 <e1>tp</e1>_38\NN\1740 )_39\-RRB-\1740 cas_40\NN\14625458 :_41\:\1740 57_42\CD\1740 -_43\SYM\1740 85_44\CD\1740 -_45\SYM\1740 2_46\CD\13741022 ]_47\-RRB-\1740 ,_48\,\1740 and_49\CC\1740 most_50\JJS\1740 of_51\IN\1740 the_52\DT\1740 <e2>tumor-bearing</e2>_53\JJ\1740 rats_54\NNS\2329401 manifested_55\VBD\1015244 metastatic_56\JJ\1740 lesions_57\NNS\14204950 ._58\.\1740
D043343_D009369 NONE in_0\IN\13603305 l-w_1\JJ\1740 rats_2\NNS\2329401 ,_3\,\1740 <e1>tp</e1>_4\NN\1740 acted_5\VBD\1619354 as_6\IN\14622893 a_7\DT\13649268 <e2>tumor</e2>_8\NN\14234074 enhancement_9\NN\248977 agent_10\NN\7347 ,_11\,\1740 with_12\IN\1740 primary_13\JJ\1740 emphasis_14\NN\14434681 on_15\IN\1740 the_16\DT\1740 development_17\NN\248977 of_18\IN\1740 prostate_19\NN\5329735 cancer_20\NN\14239425 ._21\.\1740
8251368
D009543_D013684 CID photodistributed_0\JJ\1740 <e1>nifedipine-induced</e1>_1\JJ\1740 facial_2\JJ\1740 <e2>telangiectasia</e2>_3\NN\1740 ._4\.\1740
D009543_D013684 CID five_0\CD\13741022 months_1\NNS\15113229 after_2\IN\1740 starting_3\VBG\2009433 <e1>nifedipine</e1>_4\NN\2938514 (_5\-LRB-\1740 adalat_6\NN\1740 )_7\-RRB-\1740 ,_8\,\1740 two_9\CD\13741022 patients_10\NNS\9898892 developed_11\VBD\1753788 photodistributed_12\VBN\1740 facial_13\JJ\1740 <e2>telangiectasia</e2>_14\NN\1740 ,_15\,\1740 which_16\WDT\1740 became_17\VBD\146138 more_18\RBR\1740 noticeable_19\JJ\1740 with_20\IN\1740 time_21\NN\7308889 ._22\.\1740
D009543_D013684 CID five_0\CD\13741022 months_1\NNS\15113229 after_2\IN\1740 starting_3\VBG\2009433 nifedipine_4\NN\2938514 (_5\-LRB-\1740 <e1>adalat</e1>_6\NN\1740 )_7\-RRB-\1740 ,_8\,\1740 two_9\CD\13741022 patients_10\NNS\9898892 developed_11\VBD\1753788 photodistributed_12\VBN\1740 facial_13\JJ\1740 <e2>telangiectasia</e2>_14\NN\1740 ,_15\,\1740 which_16\WDT\1740 became_17\VBD\146138 more_18\RBR\1740 noticeable_19\JJ\1740 with_20\IN\1740 time_21\NN\7308889 ._22\.\1740
D017311_D013684 CID one_0\CD\13741022 commenced_1\VBD\348746 the_2\DT\1740 closely_3\RB\1740 related_4\JJ\1740 drug_5\NN\14778436 <e1>amlodipine</e1>_6\NN\1740 3_7\CD\13741022 years_8\NNS\15144371 later_9\RB\1740 ,_10\,\1740 with_11\IN\1740 recurrence_12\NN\7342049 of_13\IN\1740 <e2>telangiectasia</e2>_14\NN\1740 ._15\.\1740
17019386
D008353_D005910 NONE passage_0\NN\199130 of_1\IN\1740 <e1>mannitol</e1>_2\NN\3214670 into_3\IN\1740 the_4\DT\1740 brain_5\NN\5462674 around_6\IN\1740 <e2>gliomas</e2>_7\NNS\14236743 :_8\:\1740 a_9\DT\13649268 potential_10\JJ\1740 cause_11\NN\7323922 of_12\IN\1740 rebound_13\NN\7309781 phenomenon_14\NN\29677 ._15\.\1740
D008353_D005910 NONE methods_0\NNS\5616786 :_1\:\1740 <e1>mannitol</e1>_2\NNP\3214670 (_3\-LRB-\1740 18_4\CD\13745420 %_5\NN\1740 solution_6\NN\14586258 ;_7\:\1740 1_8\CD\13741022 g/kg_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 administered_12\VBN\2436349 as_13\IN\14622893 a_14\DT\13649268 bolus_15\NN\13899404 to_16\TO\1740 patients_17\NNS\9898892 (_18\-LRB-\1740 ten_19\CD\13745420 had_20\VBD\2108377 <e2>malignant_21\JJ\1740 glioma</e2>_22\NN\14236743 ,_23\,\1740 seven_24\CD\13741022 brain_25\NN\5462674 metastases_26\NNS\13533470 and_27\CC\1740 four_28\CD\13741022 meningioma_29\NN\14235200 )_30\-RRB-\1740 about_31\RB\1740 30_32\CD\13745420 minutes_33\NNS\6502378 before_34\IN\1740 craniotomy_35\NN\671351 ._36\.\1740
D008353_D005910 NONE <e1>mannitol</e1>_0\JJ\1740 concentrations_1\NNS\4916342 were_2\VBD\836236 measured_3\VBN\697589 in_4\IN\13603305 plasma_5\NN\5398023 and_6\CC\1740 white_7\JJ\1740 matter_8\NN\5670710 by_9\IN\1740 a_10\DT\13649268 modified_11\VBN\109660 version_12\NN\7170753 of_13\IN\1740 the_14\DT\1740 enzyme_15\NN\14723628 assay_16\NN\5733583 of_17\IN\1740 blonquist_18\NNP\1740 et_19\FW\1740 al._20\FW\1740 results_21\NNS\34213 :_22\:\1740 in_23\IN\13603305 most_24\JJS\1740 <e2>glioma</e2>_25\NN\14236743 patients_26\NNS\9898892 ,_27\,\1740 mannitol_28\NN\3214670 concentrations_29\NNS\4916342 in_30\IN\13603305 white_31\JJ\1740 matter_32\NN\5670710 were_33\VBD\836236 2_34\CD\13741022 to_35\TO\1740 6_36\CD\13741022 times_37\NNS\15113229 higher_38\JJR\1740 than_39\IN\1740 in_40\IN\13603305 plasma_41\NN\5398023 (_42\-LRB-\1740 mean_43\JJ\1740 3.5_44\CD\1740 times_45\NNS\15113229 )_46\-RRB-\1740 ._47\.\1740
D008353_D005910 NONE mannitol_0\JJ\1740 concentrations_1\NNS\4916342 were_2\VBD\836236 measured_3\VBN\697589 in_4\IN\13603305 plasma_5\NN\5398023 and_6\CC\1740 white_7\JJ\1740 matter_8\NN\5670710 by_9\IN\1740 a_10\DT\13649268 modified_11\VBN\109660 version_12\NN\7170753 of_13\IN\1740 the_14\DT\1740 enzyme_15\NN\14723628 assay_16\NN\5733583 of_17\IN\1740 blonquist_18\NNP\1740 et_19\FW\1740 al._20\FW\1740 results_21\NNS\34213 :_22\:\1740 in_23\IN\13603305 most_24\JJS\1740 <e2>glioma</e2>_25\NN\14236743 patients_26\NNS\9898892 ,_27\,\1740 <e1>mannitol</e1>_28\NN\3214670 concentrations_29\NNS\4916342 in_30\IN\13603305 white_31\JJ\1740 matter_32\NN\5670710 were_33\VBD\836236 2_34\CD\13741022 to_35\TO\1740 6_36\CD\13741022 times_37\NNS\15113229 higher_38\JJR\1740 than_39\IN\1740 in_40\IN\13603305 plasma_41\NN\5398023 (_42\-LRB-\1740 mean_43\JJ\1740 3.5_44\CD\1740 times_45\NNS\15113229 )_46\-RRB-\1740 ._47\.\1740
D008353_D005910 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 of_4\IN\1740 our_5\PRP$\1740 study_6\NN\635850 show_7\VBP\2137132 that_8\IN\1740 even_9\RB\1740 after_10\IN\1740 a_11\DT\13649268 single_12\JJ\1740 bolus_13\NN\13899404 ,_14\,\1740 <e1>mannitol</e1>_15\NN\3214670 may_16\MD\15209706 leak_17\VB\933821 through_18\IN\1740 the_19\DT\1740 altered_20\JJ\1740 bbb_21\NN\1740 near_22\IN\1740 <e2>gliomas</e2>_23\NNS\14236743 ,_24\,\1740 reversing_25\VBG\109660 the_26\DT\1740 initial_27\JJ\1740 plasma-to-blood_28\JJ\1740 osmotic_29\JJ\1740 gradient_30\NN\13859043 ,_31\,\1740 aggravating_32\VBG\126264 peritumoral_33\JJ\1740 edema_34\NN\14315192 and_35\CC\1740 promoting_36\VBG\2556126 rebound_37\NN\7309781 of_38\IN\1740 icp_39\NN\1740 ._40\.\1740
D008353_D001929 NONE aim_0\NN\5980875 :_1\:\1740 widespread_2\JJ\1740 use_3\NN\407535 of_4\IN\1740 <e1>mannitol</e1>_5\NN\3214670 to_6\TO\1740 reduce_7\VB\441445 <e2>brain_8\NN\5462674 edema</e2>_9\NN\14315192 and_10\CC\1740 lower_11\RBR\1740 elevated_12\JJ\1740 icp_13\NN\1740 in_14\IN\13603305 brain_15\NN\5462674 tumor_16\NN\14234074 patients_17\NNS\9898892 continues_18\VBZ\2367363 to_19\TO\1740 be_20\VB\836236 afflicted_21\VBN\1790020 by_22\IN\1740 the_23\DT\1740 so-called_24\JJ\1740 rebound_25\NN\7309781 phenomenon_26\NN\29677 ._27\.\1740
D008353_D019586 CID aim_0\NN\5980875 :_1\:\1740 widespread_2\JJ\1740 use_3\NN\407535 of_4\IN\1740 <e1>mannitol</e1>_5\NN\3214670 to_6\TO\1740 reduce_7\VB\441445 brain_8\NN\5462674 edema_9\NN\14315192 and_10\CC\1740 lower_11\RBR\1740 <e2>elevated_12\JJ\1740 icp</e2>_13\NN\1740 in_14\IN\13603305 brain_15\NN\5462674 tumor_16\NN\14234074 patients_17\NNS\9898892 continues_18\VBZ\2367363 to_19\TO\1740 be_20\VB\836236 afflicted_21\VBN\1790020 by_22\IN\1740 the_23\DT\1740 so-called_24\JJ\1740 rebound_25\NN\7309781 phenomenon_26\NN\29677 ._27\.\1740
D008353_D001932 NONE aim_0\NN\5980875 :_1\:\1740 widespread_2\JJ\1740 use_3\NN\407535 of_4\IN\1740 <e1>mannitol</e1>_5\NN\3214670 to_6\TO\1740 reduce_7\VB\441445 brain_8\NN\5462674 edema_9\NN\14315192 and_10\CC\1740 lower_11\RBR\1740 elevated_12\JJ\1740 icp_13\NN\1740 in_14\IN\13603305 <e2>brain_15\NN\5462674 tumor</e2>_16\NN\14234074 patients_17\NNS\9898892 continues_18\VBZ\2367363 to_19\TO\1740 be_20\VB\836236 afflicted_21\VBN\1790020 by_22\IN\1740 the_23\DT\1740 so-called_24\JJ\1740 rebound_25\NN\7309781 phenomenon_26\NN\29677 ._27\.\1740
D008353_D001932 NONE as_0\IN\14622893 a_1\DT\13649268 contribution_2\NN\786195 to_3\IN\1740 this_4\DT\1740 issue_5\NN\5809192 we_6\PRP\1740 decided_7\VBD\352826 to_8\TO\1740 research_9\VB\789138 the_10\DT\1740 possible_11\JJ\1740 passage_12\NN\199130 of_13\IN\1740 <e1>mannitol</e1>_14\NN\3214670 into_15\IN\1740 the_16\DT\1740 brain_17\NN\5462674 after_18\IN\1740 administration_19\NN\1133281 to_20\TO\1740 21_21\CD\13745420 <e2>brain_22\NN\5462674 tumor</e2>_23\NN\14234074 patients_24\NNS\9898892 ._25\.\1740
D008353_D009362 NONE methods_0\NNS\5616786 :_1\:\1740 <e1>mannitol</e1>_2\NNP\3214670 (_3\-LRB-\1740 18_4\CD\13745420 %_5\NN\1740 solution_6\NN\14586258 ;_7\:\1740 1_8\CD\13741022 g/kg_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 administered_12\VBN\2436349 as_13\IN\14622893 a_14\DT\13649268 bolus_15\NN\13899404 to_16\TO\1740 patients_17\NNS\9898892 (_18\-LRB-\1740 ten_19\CD\13745420 had_20\VBD\2108377 malignant_21\JJ\1740 glioma_22\NN\14236743 ,_23\,\1740 seven_24\CD\13741022 brain_25\NN\5462674 <e2>metastases</e2>_26\NNS\13533470 and_27\CC\1740 four_28\CD\13741022 meningioma_29\NN\14235200 )_30\-RRB-\1740 about_31\RB\1740 30_32\CD\13745420 minutes_33\NNS\6502378 before_34\IN\1740 craniotomy_35\NN\671351 ._36\.\1740
D008353_D009362 NONE in_0\IN\13603305 meningioma_1\NN\14235200 and_2\CC\1740 <e2>metastases</e2>_3\NNS\13533470 patients_4\NNS\9898892 plasma_5\NN\5398023 concentrations_6\NNS\4916342 of_7\IN\1740 <e1>mannitol</e1>_8\NN\3214670 were_9\VBD\836236 higher_10\JJR\1740 than_11\IN\1740 white_12\JJ\1740 matter_13\NN\5670710 concentrations_14\NNS\4916342 except_15\IN\1740 in_16\IN\13603305 three_17\CD\13741022 cases_18\NNS\7283608 with_19\IN\1740 infiltration_20\NN\975452 by_21\IN\1740 neoplastic_22\JJ\1740 cells_23\NNS\3080309 ._24\.\1740
D008353_D008579 NONE methods_0\NNS\5616786 :_1\:\1740 <e1>mannitol</e1>_2\NNP\3214670 (_3\-LRB-\1740 18_4\CD\13745420 %_5\NN\1740 solution_6\NN\14586258 ;_7\:\1740 1_8\CD\13741022 g/kg_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 administered_12\VBN\2436349 as_13\IN\14622893 a_14\DT\13649268 bolus_15\NN\13899404 to_16\TO\1740 patients_17\NNS\9898892 (_18\-LRB-\1740 ten_19\CD\13745420 had_20\VBD\2108377 malignant_21\JJ\1740 glioma_22\NN\14236743 ,_23\,\1740 seven_24\CD\13741022 brain_25\NN\5462674 metastases_26\NNS\13533470 and_27\CC\1740 four_28\CD\13741022 <e2>meningioma</e2>_29\NN\14235200 )_30\-RRB-\1740 about_31\RB\1740 30_32\CD\13745420 minutes_33\NNS\6502378 before_34\IN\1740 craniotomy_35\NN\671351 ._36\.\1740
D008353_D008579 NONE in_0\IN\13603305 <e2>meningioma</e2>_1\NN\14235200 and_2\CC\1740 metastases_3\NNS\13533470 patients_4\NNS\9898892 plasma_5\NN\5398023 concentrations_6\NNS\4916342 of_7\IN\1740 <e1>mannitol</e1>_8\NN\3214670 were_9\VBD\836236 higher_10\JJR\1740 than_11\IN\1740 white_12\JJ\1740 matter_13\NN\5670710 concentrations_14\NNS\4916342 except_15\IN\1740 in_16\IN\13603305 three_17\CD\13741022 cases_18\NNS\7283608 with_19\IN\1740 infiltration_20\NN\975452 by_21\IN\1740 neoplastic_22\JJ\1740 cells_23\NNS\3080309 ._24\.\1740
D008353_D004487 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 of_4\IN\1740 our_5\PRP$\1740 study_6\NN\635850 show_7\VBP\2137132 that_8\IN\1740 even_9\RB\1740 after_10\IN\1740 a_11\DT\13649268 single_12\JJ\1740 bolus_13\NN\13899404 ,_14\,\1740 <e1>mannitol</e1>_15\NN\3214670 may_16\MD\15209706 leak_17\VB\933821 through_18\IN\1740 the_19\DT\1740 altered_20\JJ\1740 bbb_21\NN\1740 near_22\IN\1740 gliomas_23\NNS\14236743 ,_24\,\1740 reversing_25\VBG\109660 the_26\DT\1740 initial_27\JJ\1740 plasma-to-blood_28\JJ\1740 osmotic_29\JJ\1740 gradient_30\NN\13859043 ,_31\,\1740 aggravating_32\VBG\126264 peritumoral_33\JJ\1740 <e2>edema</e2>_34\NN\14315192 and_35\CC\1740 promoting_36\VBG\2556126 rebound_37\NN\7309781 of_38\IN\1740 icp_39\NN\1740 ._40\.\1740
9209318
D015215_D009190 CID lifetime_0\NN\15113229 treatment_1\NN\654885 of_2\IN\1740 mice_3\NNS\2329401 with_4\IN\1740 <e1>azidothymidine</e1>_5\NN\1740 (_6\-LRB-\1740 azt_7\NN\3834836 )_8\-RRB-\1740 produces_9\VBZ\1617192 <e2>myelodysplasia</e2>_10\NN\1740 ._11\.\1740
D015215_D009190 CID lifetime_0\NN\15113229 treatment_1\NN\654885 of_2\IN\1740 mice_3\NNS\2329401 with_4\IN\1740 azidothymidine_5\NN\1740 (_6\-LRB-\1740 <e1>azt</e1>_7\NN\3834836 )_8\-RRB-\1740 produces_9\VBZ\1617192 <e2>myelodysplasia</e2>_10\NN\1740 ._11\.\1740
D015215_D009190 CID above_0\IN\6392001 mentioned_1\VBD\730052 <e1>azt</e1>_2\NN\3834836 incorporation_3\NN\1237415 may_4\MD\15209706 have_5\VB\2108377 induced_6\VBN\1627355 an_7\DT\6697703 ineffective_8\JJ\1740 hemopoiesis_9\NN\13526110 in_10\IN\13603305 the_11\DT\1740 primitive_12\JJ\1740 hemopoietic_13\JJ\1740 progenitor_14\NN\9792555 cells_15\NNS\3080309 ,_16\,\1740 which_17\WDT\1740 is_18\VBZ\836236 known_19\VBN\2110220 to_20\TO\1740 be_21\VB\836236 seen_22\VBN\2106506 commonly_23\RB\1740 in_24\IN\13603305 the_25\DT\1740 <e2>myelodysplastic_26\JJ\1740 syndrome</e2>_27\NN\5870365 ._28\.\1740
D015215_D000748 CID <e1>azt</e1>_0\NN\3834836 has_1\VBZ\2108377 induced_2\VBN\1627355 a_3\DT\13649268 <e2>macrocytic_4\JJ\1740 anemia</e2>_5\NN\14189204 in_6\IN\13603305 aids_7\NN\13974317 patients_8\NNS\9898892 on_9\IN\1740 long_10\JJ\1740 term_11\NN\6286395 azt_12\NN\3834836 therapy_13\NN\657604 ._14\.\1740
D015215_D000748 CID azt_0\NN\3834836 has_1\VBZ\2108377 induced_2\VBN\1627355 a_3\DT\13649268 <e2>macrocytic_4\JJ\1740 anemia</e2>_5\NN\14189204 in_6\IN\13603305 aids_7\NN\13974317 patients_8\NNS\9898892 on_9\IN\1740 long_10\JJ\1740 term_11\NN\6286395 <e1>azt</e1>_12\NN\3834836 therapy_13\NN\657604 ._14\.\1740
D015215_D000163 NONE <e1>azt</e1>_0\NN\3834836 has_1\VBZ\2108377 induced_2\VBN\1627355 a_3\DT\13649268 macrocytic_4\JJ\1740 anemia_5\NN\14189204 in_6\IN\13603305 <e2>aids</e2>_7\NN\13974317 patients_8\NNS\9898892 on_9\IN\1740 long_10\JJ\1740 term_11\NN\6286395 azt_12\NN\3834836 therapy_13\NN\657604 ._14\.\1740
D015215_D000163 NONE azt_0\NN\3834836 has_1\VBZ\2108377 induced_2\VBN\1627355 a_3\DT\13649268 macrocytic_4\JJ\1740 anemia_5\NN\14189204 in_6\IN\13603305 <e2>aids</e2>_7\NN\13974317 patients_8\NNS\9898892 on_9\IN\1740 long_10\JJ\1740 term_11\NN\6286395 <e1>azt</e1>_12\NN\3834836 therapy_13\NN\657604 ._14\.\1740
8514073
D008874_D014652 CID <e2>venous_0\JJ\1740 complications</e2>_1\NNS\1073995 of_2\IN\1740 <e1>midazolam</e1>_3\NN\2830852 versus_4\IN\1740 diazepam_5\NNS\2830852 ._6\.\1740
D008874_D014652 CID although_0\IN\1740 some_1\DT\1740 studies_2\NNS\635850 have_3\VBP\2108377 suggested_4\VBN\1010118 fewer_5\JJR\1740 <e2>venous_6\JJ\1740 complications</e2>_7\NNS\1073995 are_8\VBP\836236 associated_9\VBN\628491 with_10\IN\1740 <e1>midazolam</e1>_11\NN\2830852 than_12\IN\1740 with_13\IN\1740 diazepam_14\NNS\2830852 for_15\IN\1740 endoscopic_16\JJ\1740 procedures_17\NNS\407535 ,_18\,\1740 this_19\DT\1740 variable_20\NN\2452 has_21\VBZ\2108377 not_22\RB\1740 been_23\VBN\836236 well_24\RB\1740 documented_25\VBN\1000214 ._26\.\1740
D008874_D014652 CID we_0\PRP\1740 prospectively_1\RB\1740 evaluated_2\VBD\670261 the_3\DT\1740 incidence_4\NN\13821570 of_5\IN\1740 <e2>venous_6\JJ\1740 complications</e2>_7\NNS\1073995 after_8\IN\1740 intravenous_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 diazepam_12\NNS\2830852 or_13\CC\3541091 <e1>midazolam</e1>_14\NN\2830852 in_15\IN\13603305 122_16\CD\1740 consecutive_17\JJ\1740 patients_18\NNS\9898892 undergoing_19\VBG\109660 colonoscopy_20\NN\642045 and_21\CC\1740 esophagogastroduodenoscopy_22\VB\1740 ._23\.\1740
D008874_D014652 CID overall_0\RB\1740 ,_1\,\1740 <e2>venous_2\JJ\1740 complications</e2>_3\NNS\1073995 were_4\VBD\836236 more_5\RBR\1740 frequent_6\JJ\1740 with_7\IN\1740 diazepam_8\NN\2830852 (_9\-LRB-\1740 22_10\CD\13745420 of_11\IN\1740 62_12\CD\1740 patients_13\NNS\9898892 )_14\-RRB-\1740 than_15\IN\1740 with_16\IN\1740 <e1>midazolam</e1>_17\NNS\2830852 (_18\-LRB-\1740 4_19\CD\13741022 of_20\IN\1740 60_21\CD\13745420 patients_22\NNS\9898892 )_23\-RRB-\1740 (_24\-LRB-\1740 p_25\NN\14622893 <_26\XX\1740 0.001_27\CD\1740 )_28\-RRB-\1740 ._29\.\1740
D003975_D014652 CID <e2>venous_0\JJ\1740 complications</e2>_1\NNS\1073995 of_2\IN\1740 midazolam_3\NN\2830852 versus_4\IN\1740 <e1>diazepam</e1>_5\NNS\2830852 ._6\.\1740
D003975_D014652 CID although_0\IN\1740 some_1\DT\1740 studies_2\NNS\635850 have_3\VBP\2108377 suggested_4\VBN\1010118 fewer_5\JJR\1740 <e2>venous_6\JJ\1740 complications</e2>_7\NNS\1073995 are_8\VBP\836236 associated_9\VBN\628491 with_10\IN\1740 midazolam_11\NN\2830852 than_12\IN\1740 with_13\IN\1740 <e1>diazepam</e1>_14\NNS\2830852 for_15\IN\1740 endoscopic_16\JJ\1740 procedures_17\NNS\407535 ,_18\,\1740 this_19\DT\1740 variable_20\NN\2452 has_21\VBZ\2108377 not_22\RB\1740 been_23\VBN\836236 well_24\RB\1740 documented_25\VBN\1000214 ._26\.\1740
D003975_D014652 CID we_0\PRP\1740 prospectively_1\RB\1740 evaluated_2\VBD\670261 the_3\DT\1740 incidence_4\NN\13821570 of_5\IN\1740 <e2>venous_6\JJ\1740 complications</e2>_7\NNS\1073995 after_8\IN\1740 intravenous_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 <e1>diazepam</e1>_12\NNS\2830852 or_13\CC\3541091 midazolam_14\NN\2830852 in_15\IN\13603305 122_16\CD\1740 consecutive_17\JJ\1740 patients_18\NNS\9898892 undergoing_19\VBG\109660 colonoscopy_20\NN\642045 and_21\CC\1740 esophagogastroduodenoscopy_22\VB\1740 ._23\.\1740
D003975_D014652 CID overall_0\RB\1740 ,_1\,\1740 <e2>venous_2\JJ\1740 complications</e2>_3\NNS\1073995 were_4\VBD\836236 more_5\RBR\1740 frequent_6\JJ\1740 with_7\IN\1740 <e1>diazepam</e1>_8\NN\2830852 (_9\-LRB-\1740 22_10\CD\13745420 of_11\IN\1740 62_12\CD\1740 patients_13\NNS\9898892 )_14\-RRB-\1740 than_15\IN\1740 with_16\IN\1740 midazolam_17\NNS\2830852 (_18\-LRB-\1740 4_19\CD\13741022 of_20\IN\1740 60_21\CD\13745420 patients_22\NNS\9898892 )_23\-RRB-\1740 (_24\-LRB-\1740 p_25\NN\14622893 <_26\XX\1740 0.001_27\CD\1740 )_28\-RRB-\1740 ._29\.\1740
D003975_D010146 NONE <e2>pain</e2>_0\NN\14299637 at_1\IN\14622893 the_2\DT\1740 injection_3\NN\320852 site_4\NN\8673395 occurred_5\VBD\2623529 in_6\IN\13603305 35_7\CD\1740 %_8\NN\1740 (_9\-LRB-\1740 22_10\CD\13745420 of_11\IN\1740 62_12\CD\1740 )_13\-RRB-\1740 of_14\IN\1740 patients_15\NNS\9898892 in_16\IN\13603305 the_17\DT\1740 <e1>diazepam</e1>_18\NN\2830852 group_19\NN\2137 compared_20\VBN\644583 with_21\IN\1740 7_22\CD\13741022 %_23\NN\1740 (_24\-LRB-\1740 4_25\CD\13741022 of_26\IN\1740 60_27\CD\13745420 patients_28\NNS\9898892 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 midazolam_32\NN\2830852 group_33\NN\2137 (_34\-LRB-\1740 p_35\NN\14622893 <_36\XX\1740 0.001_37\CD\1740 )_38\-RRB-\1740 ._39\.\1740
D008874_D010146 NONE <e2>pain</e2>_0\NN\14299637 at_1\IN\14622893 the_2\DT\1740 injection_3\NN\320852 site_4\NN\8673395 occurred_5\VBD\2623529 in_6\IN\13603305 35_7\CD\1740 %_8\NN\1740 (_9\-LRB-\1740 22_10\CD\13745420 of_11\IN\1740 62_12\CD\1740 )_13\-RRB-\1740 of_14\IN\1740 patients_15\NNS\9898892 in_16\IN\13603305 the_17\DT\1740 diazepam_18\NN\2830852 group_19\NN\2137 compared_20\VBN\644583 with_21\IN\1740 7_22\CD\13741022 %_23\NN\1740 (_24\-LRB-\1740 4_25\CD\13741022 of_26\IN\1740 60_27\CD\13745420 patients_28\NNS\9898892 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 <e1>midazolam</e1>_32\NN\2830852 group_33\NN\2137 (_34\-LRB-\1740 p_35\NN\14622893 <_36\XX\1740 0.001_37\CD\1740 )_38\-RRB-\1740 ._39\.\1740
D000431_D010146 NONE smoking_0\NN\831191 ,_1\,\1740 nonsteroidal_2\JJ\1740 anti-inflammatory_3\JJ\1740 drug_4\NN\14778436 use_5\NN\407535 ,_6\,\1740 intravenous_7\JJ\1740 catheter_8\NN\4493505 site_9\NN\8673395 ,_10\,\1740 dwell_11\NN\1740 time_12\NN\7308889 of_13\IN\1740 the_14\DT\1740 needle_15\NN\13156083 ,_16\,\1740 <e1>alcohol</e1>_17\NN\7881800 use_18\NN\407535 ,_19\,\1740 and_20\CC\1740 <e2>pain</e2>_21\VB\64643 during_22\IN\1740 the_23\DT\1740 injection_24\NN\320852 had_25\VBD\2108377 no_26\DT\7204911 effect_27\NN\34213 on_28\IN\1740 the_29\DT\1740 incidence_30\NN\13821570 of_31\IN\1740 venous_32\JJ\1740 complications_33\NNS\1073995 ._34\.\1740
D000431_D014652 NONE smoking_0\NN\831191 ,_1\,\1740 nonsteroidal_2\JJ\1740 anti-inflammatory_3\JJ\1740 drug_4\NN\14778436 use_5\NN\407535 ,_6\,\1740 intravenous_7\JJ\1740 catheter_8\NN\4493505 site_9\NN\8673395 ,_10\,\1740 dwell_11\NN\1740 time_12\NN\7308889 of_13\IN\1740 the_14\DT\1740 needle_15\NN\13156083 ,_16\,\1740 <e1>alcohol</e1>_17\NN\7881800 use_18\NN\407535 ,_19\,\1740 and_20\CC\1740 pain_21\VB\64643 during_22\IN\1740 the_23\DT\1740 injection_24\NN\320852 had_25\VBD\2108377 no_26\DT\7204911 effect_27\NN\34213 on_28\IN\1740 the_29\DT\1740 incidence_30\NN\13821570 of_31\IN\1740 <e2>venous_32\JJ\1740 complications</e2>_33\NNS\1073995 ._34\.\1740
6892185
D002122_D015878 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>calcium_3\NN\14625458 chloride</e1>_4\NN\14818238 injected_5\VBN\81072 into_6\IN\1740 the_7\DT\1740 cerebral_8\JJ\1740 ventricles_9\NNS\5303402 of_10\IN\1740 group-housed_11\JJ\1740 unanaesthetized_12\JJ\1740 cats_13\NNS\2120997 upon_14\IN\1740 vocalization_15\NN\33020 (_16\-LRB-\1740 rage_17\NN\7516354 ,_18\,\1740 hissing_19\VBG\983824 and_20\CC\1740 snarling_21\VBG\941990 )_22\-RRB-\1740 ,_23\,\1740 fighting_24\VBG\1090335 (_25\-LRB-\1740 attack_26\NN\955060 with_27\IN\1740 paws_28\NNS\2153445 and_29\CC\1740 claws_30\NNS\5581514 ,_31\,\1740 defense_32\NN\952963 with_33\IN\1740 paws_34\NNS\2153445 and_35\CC\1740 claws_36\NNS\5581514 and_37\CC\1740 biting_38\VBG\1224001 )_39\-RRB-\1740 ,_40\,\1740 <e2>mydriasis</e2>_41\NN\365995 ,_42\,\1740 tremor_43\NN\345926 and_44\CC\1740 clonic-tonic_45\JJ\1740 convulsions_46\NNS\14081375 produced_47\VBN\1617192 by_48\IN\1740 carbachol_49\NN\1740 and_50\CC\1740 eserine_51\NN\1740 injected_52\VBN\81072 similarly_53\RB\1740 was_54\VBD\836236 investigated_55\VBN\644583 ._56\.\1740
D002122_D015878 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 <e2>mydriasis</e2>_5\NN\365995 ,_6\,\1740 tremor_7\NN\345926 and_8\CC\1740 clonic-tonic_9\JJ\1740 convulsions_10\NNS\14081375 evoked_11\VBN\1617192 by_12\IN\1740 carbachol_13\NN\1740 and_14\CC\1740 eserine_15\NN\1740 were_16\VBD\836236 not_17\RB\1740 significantly_18\RB\1740 changed_19\VBN\46534 by_20\IN\1740 <e1>calcium_21\NN\14625458 chloride</e1>_22\NN\14818238 ._23\.\1740
D002122_D015878 NONE it_0\PRP\6125041 is_1\VBZ\836236 apparent_2\JJ\1740 that_3\IN\1740 <e1>calcium_4\NN\14625458 chloride</e1>_5\NN\14818238 can_6\MD\3094503 "_7\``\1740 dissociate_8\VB\2431320 "_9\''\1740 vocalization_10\NN\33020 and_11\CC\1740 fighting_12\VBG\1090335 from_13\IN\1740 autonomic_14\JJ\1740 and_15\CC\1740 motor_16\NN\3699975 phenomena_17\NNS\29677 such_18\JJ\1740 as_19\IN\14622893 <e2>mydriasis</e2>_20\NN\365995 ,_21\,\1740 tremor_22\NN\345926 and_23\CC\1740 clonic-tonic_24\JJ\1740 convulsions_25\NNS\14081375 caused_26\VBN\1617192 by_27\IN\1740 carbachol_28\NN\1740 and_29\CC\1740 eserine_30\JJ\1740 ._31\.\1740
D002122_D014202 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>calcium_3\NN\14625458 chloride</e1>_4\NN\14818238 injected_5\VBN\81072 into_6\IN\1740 the_7\DT\1740 cerebral_8\JJ\1740 ventricles_9\NNS\5303402 of_10\IN\1740 group-housed_11\JJ\1740 unanaesthetized_12\JJ\1740 cats_13\NNS\2120997 upon_14\IN\1740 vocalization_15\NN\33020 (_16\-LRB-\1740 rage_17\NN\7516354 ,_18\,\1740 hissing_19\VBG\983824 and_20\CC\1740 snarling_21\VBG\941990 )_22\-RRB-\1740 ,_23\,\1740 fighting_24\VBG\1090335 (_25\-LRB-\1740 attack_26\NN\955060 with_27\IN\1740 paws_28\NNS\2153445 and_29\CC\1740 claws_30\NNS\5581514 ,_31\,\1740 defense_32\NN\952963 with_33\IN\1740 paws_34\NNS\2153445 and_35\CC\1740 claws_36\NNS\5581514 and_37\CC\1740 biting_38\VBG\1224001 )_39\-RRB-\1740 ,_40\,\1740 mydriasis_41\NN\365995 ,_42\,\1740 <e2>tremor</e2>_43\NN\345926 and_44\CC\1740 clonic-tonic_45\JJ\1740 convulsions_46\NNS\14081375 produced_47\VBN\1617192 by_48\IN\1740 carbachol_49\NN\1740 and_50\CC\1740 eserine_51\NN\1740 injected_52\VBN\81072 similarly_53\RB\1740 was_54\VBD\836236 investigated_55\VBN\644583 ._56\.\1740
D002122_D014202 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 mydriasis_5\NN\365995 ,_6\,\1740 <e2>tremor</e2>_7\NN\345926 and_8\CC\1740 clonic-tonic_9\JJ\1740 convulsions_10\NNS\14081375 evoked_11\VBN\1617192 by_12\IN\1740 carbachol_13\NN\1740 and_14\CC\1740 eserine_15\NN\1740 were_16\VBD\836236 not_17\RB\1740 significantly_18\RB\1740 changed_19\VBN\46534 by_20\IN\1740 <e1>calcium_21\NN\14625458 chloride</e1>_22\NN\14818238 ._23\.\1740
D002122_D014202 NONE it_0\PRP\6125041 is_1\VBZ\836236 apparent_2\JJ\1740 that_3\IN\1740 <e1>calcium_4\NN\14625458 chloride</e1>_5\NN\14818238 can_6\MD\3094503 "_7\``\1740 dissociate_8\VB\2431320 "_9\''\1740 vocalization_10\NN\33020 and_11\CC\1740 fighting_12\VBG\1090335 from_13\IN\1740 autonomic_14\JJ\1740 and_15\CC\1740 motor_16\NN\3699975 phenomena_17\NNS\29677 such_18\JJ\1740 as_19\IN\14622893 mydriasis_20\NN\365995 ,_21\,\1740 <e2>tremor</e2>_22\NN\345926 and_23\CC\1740 clonic-tonic_24\JJ\1740 convulsions_25\NNS\14081375 caused_26\VBN\1617192 by_27\IN\1740 carbachol_28\NN\1740 and_29\CC\1740 eserine_30\JJ\1740 ._31\.\1740
D002122_D004830 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>calcium_3\NN\14625458 chloride</e1>_4\NN\14818238 injected_5\VBN\81072 into_6\IN\1740 the_7\DT\1740 cerebral_8\JJ\1740 ventricles_9\NNS\5303402 of_10\IN\1740 group-housed_11\JJ\1740 unanaesthetized_12\JJ\1740 cats_13\NNS\2120997 upon_14\IN\1740 vocalization_15\NN\33020 (_16\-LRB-\1740 rage_17\NN\7516354 ,_18\,\1740 hissing_19\VBG\983824 and_20\CC\1740 snarling_21\VBG\941990 )_22\-RRB-\1740 ,_23\,\1740 fighting_24\VBG\1090335 (_25\-LRB-\1740 attack_26\NN\955060 with_27\IN\1740 paws_28\NNS\2153445 and_29\CC\1740 claws_30\NNS\5581514 ,_31\,\1740 defense_32\NN\952963 with_33\IN\1740 paws_34\NNS\2153445 and_35\CC\1740 claws_36\NNS\5581514 and_37\CC\1740 biting_38\VBG\1224001 )_39\-RRB-\1740 ,_40\,\1740 mydriasis_41\NN\365995 ,_42\,\1740 tremor_43\NN\345926 and_44\CC\1740 <e2>clonic-tonic_45\JJ\1740 convulsions</e2>_46\NNS\14081375 produced_47\VBN\1617192 by_48\IN\1740 carbachol_49\NN\1740 and_50\CC\1740 eserine_51\NN\1740 injected_52\VBN\81072 similarly_53\RB\1740 was_54\VBD\836236 investigated_55\VBN\644583 ._56\.\1740
D002122_D004830 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 mydriasis_5\NN\365995 ,_6\,\1740 tremor_7\NN\345926 and_8\CC\1740 <e2>clonic-tonic_9\JJ\1740 convulsions</e2>_10\NNS\14081375 evoked_11\VBN\1617192 by_12\IN\1740 carbachol_13\NN\1740 and_14\CC\1740 eserine_15\NN\1740 were_16\VBD\836236 not_17\RB\1740 significantly_18\RB\1740 changed_19\VBN\46534 by_20\IN\1740 <e1>calcium_21\NN\14625458 chloride</e1>_22\NN\14818238 ._23\.\1740
D002122_D004830 NONE it_0\PRP\6125041 is_1\VBZ\836236 apparent_2\JJ\1740 that_3\IN\1740 <e1>calcium_4\NN\14625458 chloride</e1>_5\NN\14818238 can_6\MD\3094503 "_7\``\1740 dissociate_8\VB\2431320 "_9\''\1740 vocalization_10\NN\33020 and_11\CC\1740 fighting_12\VBG\1090335 from_13\IN\1740 autonomic_14\JJ\1740 and_15\CC\1740 motor_16\NN\3699975 phenomena_17\NNS\29677 such_18\JJ\1740 as_19\IN\14622893 mydriasis_20\NN\365995 ,_21\,\1740 tremor_22\NN\345926 and_23\CC\1740 <e2>clonic-tonic_24\JJ\1740 convulsions</e2>_25\NNS\14081375 caused_26\VBN\1617192 by_27\IN\1740 carbachol_28\NN\1740 and_29\CC\1740 eserine_30\JJ\1740 ._31\.\1740
D002217_D015878 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 calcium_3\NN\14625458 chloride_4\NN\14818238 injected_5\VBN\81072 into_6\IN\1740 the_7\DT\1740 cerebral_8\JJ\1740 ventricles_9\NNS\5303402 of_10\IN\1740 group-housed_11\JJ\1740 unanaesthetized_12\JJ\1740 cats_13\NNS\2120997 upon_14\IN\1740 vocalization_15\NN\33020 (_16\-LRB-\1740 rage_17\NN\7516354 ,_18\,\1740 hissing_19\VBG\983824 and_20\CC\1740 snarling_21\VBG\941990 )_22\-RRB-\1740 ,_23\,\1740 fighting_24\VBG\1090335 (_25\-LRB-\1740 attack_26\NN\955060 with_27\IN\1740 paws_28\NNS\2153445 and_29\CC\1740 claws_30\NNS\5581514 ,_31\,\1740 defense_32\NN\952963 with_33\IN\1740 paws_34\NNS\2153445 and_35\CC\1740 claws_36\NNS\5581514 and_37\CC\1740 biting_38\VBG\1224001 )_39\-RRB-\1740 ,_40\,\1740 <e2>mydriasis</e2>_41\NN\365995 ,_42\,\1740 tremor_43\NN\345926 and_44\CC\1740 clonic-tonic_45\JJ\1740 convulsions_46\NNS\14081375 produced_47\VBN\1617192 by_48\IN\1740 <e1>carbachol</e1>_49\NN\1740 and_50\CC\1740 eserine_51\NN\1740 injected_52\VBN\81072 similarly_53\RB\1740 was_54\VBD\836236 investigated_55\VBN\644583 ._56\.\1740
D002217_D015878 CID on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 <e2>mydriasis</e2>_5\NN\365995 ,_6\,\1740 tremor_7\NN\345926 and_8\CC\1740 clonic-tonic_9\JJ\1740 convulsions_10\NNS\14081375 evoked_11\VBN\1617192 by_12\IN\1740 <e1>carbachol</e1>_13\NN\1740 and_14\CC\1740 eserine_15\NN\1740 were_16\VBD\836236 not_17\RB\1740 significantly_18\RB\1740 changed_19\VBN\46534 by_20\IN\1740 calcium_21\NN\14625458 chloride_22\NN\14818238 ._23\.\1740
D002217_D015878 CID it_0\PRP\6125041 is_1\VBZ\836236 apparent_2\JJ\1740 that_3\IN\1740 calcium_4\NN\14625458 chloride_5\NN\14818238 can_6\MD\3094503 "_7\``\1740 dissociate_8\VB\2431320 "_9\''\1740 vocalization_10\NN\33020 and_11\CC\1740 fighting_12\VBG\1090335 from_13\IN\1740 autonomic_14\JJ\1740 and_15\CC\1740 motor_16\NN\3699975 phenomena_17\NNS\29677 such_18\JJ\1740 as_19\IN\14622893 <e2>mydriasis</e2>_20\NN\365995 ,_21\,\1740 tremor_22\NN\345926 and_23\CC\1740 clonic-tonic_24\JJ\1740 convulsions_25\NNS\14081375 caused_26\VBN\1617192 by_27\IN\1740 <e1>carbachol</e1>_28\NN\1740 and_29\CC\1740 eserine_30\JJ\1740 ._31\.\1740
D002217_D014202 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 calcium_3\NN\14625458 chloride_4\NN\14818238 injected_5\VBN\81072 into_6\IN\1740 the_7\DT\1740 cerebral_8\JJ\1740 ventricles_9\NNS\5303402 of_10\IN\1740 group-housed_11\JJ\1740 unanaesthetized_12\JJ\1740 cats_13\NNS\2120997 upon_14\IN\1740 vocalization_15\NN\33020 (_16\-LRB-\1740 rage_17\NN\7516354 ,_18\,\1740 hissing_19\VBG\983824 and_20\CC\1740 snarling_21\VBG\941990 )_22\-RRB-\1740 ,_23\,\1740 fighting_24\VBG\1090335 (_25\-LRB-\1740 attack_26\NN\955060 with_27\IN\1740 paws_28\NNS\2153445 and_29\CC\1740 claws_30\NNS\5581514 ,_31\,\1740 defense_32\NN\952963 with_33\IN\1740 paws_34\NNS\2153445 and_35\CC\1740 claws_36\NNS\5581514 and_37\CC\1740 biting_38\VBG\1224001 )_39\-RRB-\1740 ,_40\,\1740 mydriasis_41\NN\365995 ,_42\,\1740 <e2>tremor</e2>_43\NN\345926 and_44\CC\1740 clonic-tonic_45\JJ\1740 convulsions_46\NNS\14081375 produced_47\VBN\1617192 by_48\IN\1740 <e1>carbachol</e1>_49\NN\1740 and_50\CC\1740 eserine_51\NN\1740 injected_52\VBN\81072 similarly_53\RB\1740 was_54\VBD\836236 investigated_55\VBN\644583 ._56\.\1740
D002217_D014202 CID on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 mydriasis_5\NN\365995 ,_6\,\1740 <e2>tremor</e2>_7\NN\345926 and_8\CC\1740 clonic-tonic_9\JJ\1740 convulsions_10\NNS\14081375 evoked_11\VBN\1617192 by_12\IN\1740 <e1>carbachol</e1>_13\NN\1740 and_14\CC\1740 eserine_15\NN\1740 were_16\VBD\836236 not_17\RB\1740 significantly_18\RB\1740 changed_19\VBN\46534 by_20\IN\1740 calcium_21\NN\14625458 chloride_22\NN\14818238 ._23\.\1740
D002217_D014202 CID it_0\PRP\6125041 is_1\VBZ\836236 apparent_2\JJ\1740 that_3\IN\1740 calcium_4\NN\14625458 chloride_5\NN\14818238 can_6\MD\3094503 "_7\``\1740 dissociate_8\VB\2431320 "_9\''\1740 vocalization_10\NN\33020 and_11\CC\1740 fighting_12\VBG\1090335 from_13\IN\1740 autonomic_14\JJ\1740 and_15\CC\1740 motor_16\NN\3699975 phenomena_17\NNS\29677 such_18\JJ\1740 as_19\IN\14622893 mydriasis_20\NN\365995 ,_21\,\1740 <e2>tremor</e2>_22\NN\345926 and_23\CC\1740 clonic-tonic_24\JJ\1740 convulsions_25\NNS\14081375 caused_26\VBN\1617192 by_27\IN\1740 <e1>carbachol</e1>_28\NN\1740 and_29\CC\1740 eserine_30\JJ\1740 ._31\.\1740
D002217_D004830 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 calcium_3\NN\14625458 chloride_4\NN\14818238 injected_5\VBN\81072 into_6\IN\1740 the_7\DT\1740 cerebral_8\JJ\1740 ventricles_9\NNS\5303402 of_10\IN\1740 group-housed_11\JJ\1740 unanaesthetized_12\JJ\1740 cats_13\NNS\2120997 upon_14\IN\1740 vocalization_15\NN\33020 (_16\-LRB-\1740 rage_17\NN\7516354 ,_18\,\1740 hissing_19\VBG\983824 and_20\CC\1740 snarling_21\VBG\941990 )_22\-RRB-\1740 ,_23\,\1740 fighting_24\VBG\1090335 (_25\-LRB-\1740 attack_26\NN\955060 with_27\IN\1740 paws_28\NNS\2153445 and_29\CC\1740 claws_30\NNS\5581514 ,_31\,\1740 defense_32\NN\952963 with_33\IN\1740 paws_34\NNS\2153445 and_35\CC\1740 claws_36\NNS\5581514 and_37\CC\1740 biting_38\VBG\1224001 )_39\-RRB-\1740 ,_40\,\1740 mydriasis_41\NN\365995 ,_42\,\1740 tremor_43\NN\345926 and_44\CC\1740 <e2>clonic-tonic_45\JJ\1740 convulsions</e2>_46\NNS\14081375 produced_47\VBN\1617192 by_48\IN\1740 <e1>carbachol</e1>_49\NN\1740 and_50\CC\1740 eserine_51\NN\1740 injected_52\VBN\81072 similarly_53\RB\1740 was_54\VBD\836236 investigated_55\VBN\644583 ._56\.\1740
D002217_D004830 CID on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 mydriasis_5\NN\365995 ,_6\,\1740 tremor_7\NN\345926 and_8\CC\1740 <e2>clonic-tonic_9\JJ\1740 convulsions</e2>_10\NNS\14081375 evoked_11\VBN\1617192 by_12\IN\1740 <e1>carbachol</e1>_13\NN\1740 and_14\CC\1740 eserine_15\NN\1740 were_16\VBD\836236 not_17\RB\1740 significantly_18\RB\1740 changed_19\VBN\46534 by_20\IN\1740 calcium_21\NN\14625458 chloride_22\NN\14818238 ._23\.\1740
D002217_D004830 CID it_0\PRP\6125041 is_1\VBZ\836236 apparent_2\JJ\1740 that_3\IN\1740 calcium_4\NN\14625458 chloride_5\NN\14818238 can_6\MD\3094503 "_7\``\1740 dissociate_8\VB\2431320 "_9\''\1740 vocalization_10\NN\33020 and_11\CC\1740 fighting_12\VBG\1090335 from_13\IN\1740 autonomic_14\JJ\1740 and_15\CC\1740 motor_16\NN\3699975 phenomena_17\NNS\29677 such_18\JJ\1740 as_19\IN\14622893 mydriasis_20\NN\365995 ,_21\,\1740 tremor_22\NN\345926 and_23\CC\1740 <e2>clonic-tonic_24\JJ\1740 convulsions</e2>_25\NNS\14081375 caused_26\VBN\1617192 by_27\IN\1740 <e1>carbachol</e1>_28\NN\1740 and_29\CC\1740 eserine_30\JJ\1740 ._31\.\1740
D010830_D015878 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 calcium_3\NN\14625458 chloride_4\NN\14818238 injected_5\VBN\81072 into_6\IN\1740 the_7\DT\1740 cerebral_8\JJ\1740 ventricles_9\NNS\5303402 of_10\IN\1740 group-housed_11\JJ\1740 unanaesthetized_12\JJ\1740 cats_13\NNS\2120997 upon_14\IN\1740 vocalization_15\NN\33020 (_16\-LRB-\1740 rage_17\NN\7516354 ,_18\,\1740 hissing_19\VBG\983824 and_20\CC\1740 snarling_21\VBG\941990 )_22\-RRB-\1740 ,_23\,\1740 fighting_24\VBG\1090335 (_25\-LRB-\1740 attack_26\NN\955060 with_27\IN\1740 paws_28\NNS\2153445 and_29\CC\1740 claws_30\NNS\5581514 ,_31\,\1740 defense_32\NN\952963 with_33\IN\1740 paws_34\NNS\2153445 and_35\CC\1740 claws_36\NNS\5581514 and_37\CC\1740 biting_38\VBG\1224001 )_39\-RRB-\1740 ,_40\,\1740 <e2>mydriasis</e2>_41\NN\365995 ,_42\,\1740 tremor_43\NN\345926 and_44\CC\1740 clonic-tonic_45\JJ\1740 convulsions_46\NNS\14081375 produced_47\VBN\1617192 by_48\IN\1740 carbachol_49\NN\1740 and_50\CC\1740 <e1>eserine</e1>_51\NN\1740 injected_52\VBN\81072 similarly_53\RB\1740 was_54\VBD\836236 investigated_55\VBN\644583 ._56\.\1740
D010830_D015878 CID on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 <e2>mydriasis</e2>_5\NN\365995 ,_6\,\1740 tremor_7\NN\345926 and_8\CC\1740 clonic-tonic_9\JJ\1740 convulsions_10\NNS\14081375 evoked_11\VBN\1617192 by_12\IN\1740 carbachol_13\NN\1740 and_14\CC\1740 <e1>eserine</e1>_15\NN\1740 were_16\VBD\836236 not_17\RB\1740 significantly_18\RB\1740 changed_19\VBN\46534 by_20\IN\1740 calcium_21\NN\14625458 chloride_22\NN\14818238 ._23\.\1740
D010830_D015878 CID it_0\PRP\6125041 is_1\VBZ\836236 apparent_2\JJ\1740 that_3\IN\1740 calcium_4\NN\14625458 chloride_5\NN\14818238 can_6\MD\3094503 "_7\``\1740 dissociate_8\VB\2431320 "_9\''\1740 vocalization_10\NN\33020 and_11\CC\1740 fighting_12\VBG\1090335 from_13\IN\1740 autonomic_14\JJ\1740 and_15\CC\1740 motor_16\NN\3699975 phenomena_17\NNS\29677 such_18\JJ\1740 as_19\IN\14622893 <e2>mydriasis</e2>_20\NN\365995 ,_21\,\1740 tremor_22\NN\345926 and_23\CC\1740 clonic-tonic_24\JJ\1740 convulsions_25\NNS\14081375 caused_26\VBN\1617192 by_27\IN\1740 carbachol_28\NN\1740 and_29\CC\1740 <e1>eserine</e1>_30\JJ\1740 ._31\.\1740
D010830_D014202 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 calcium_3\NN\14625458 chloride_4\NN\14818238 injected_5\VBN\81072 into_6\IN\1740 the_7\DT\1740 cerebral_8\JJ\1740 ventricles_9\NNS\5303402 of_10\IN\1740 group-housed_11\JJ\1740 unanaesthetized_12\JJ\1740 cats_13\NNS\2120997 upon_14\IN\1740 vocalization_15\NN\33020 (_16\-LRB-\1740 rage_17\NN\7516354 ,_18\,\1740 hissing_19\VBG\983824 and_20\CC\1740 snarling_21\VBG\941990 )_22\-RRB-\1740 ,_23\,\1740 fighting_24\VBG\1090335 (_25\-LRB-\1740 attack_26\NN\955060 with_27\IN\1740 paws_28\NNS\2153445 and_29\CC\1740 claws_30\NNS\5581514 ,_31\,\1740 defense_32\NN\952963 with_33\IN\1740 paws_34\NNS\2153445 and_35\CC\1740 claws_36\NNS\5581514 and_37\CC\1740 biting_38\VBG\1224001 )_39\-RRB-\1740 ,_40\,\1740 mydriasis_41\NN\365995 ,_42\,\1740 <e2>tremor</e2>_43\NN\345926 and_44\CC\1740 clonic-tonic_45\JJ\1740 convulsions_46\NNS\14081375 produced_47\VBN\1617192 by_48\IN\1740 carbachol_49\NN\1740 and_50\CC\1740 <e1>eserine</e1>_51\NN\1740 injected_52\VBN\81072 similarly_53\RB\1740 was_54\VBD\836236 investigated_55\VBN\644583 ._56\.\1740
D010830_D014202 CID on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 mydriasis_5\NN\365995 ,_6\,\1740 <e2>tremor</e2>_7\NN\345926 and_8\CC\1740 clonic-tonic_9\JJ\1740 convulsions_10\NNS\14081375 evoked_11\VBN\1617192 by_12\IN\1740 carbachol_13\NN\1740 and_14\CC\1740 <e1>eserine</e1>_15\NN\1740 were_16\VBD\836236 not_17\RB\1740 significantly_18\RB\1740 changed_19\VBN\46534 by_20\IN\1740 calcium_21\NN\14625458 chloride_22\NN\14818238 ._23\.\1740
D010830_D014202 CID it_0\PRP\6125041 is_1\VBZ\836236 apparent_2\JJ\1740 that_3\IN\1740 calcium_4\NN\14625458 chloride_5\NN\14818238 can_6\MD\3094503 "_7\``\1740 dissociate_8\VB\2431320 "_9\''\1740 vocalization_10\NN\33020 and_11\CC\1740 fighting_12\VBG\1090335 from_13\IN\1740 autonomic_14\JJ\1740 and_15\CC\1740 motor_16\NN\3699975 phenomena_17\NNS\29677 such_18\JJ\1740 as_19\IN\14622893 mydriasis_20\NN\365995 ,_21\,\1740 <e2>tremor</e2>_22\NN\345926 and_23\CC\1740 clonic-tonic_24\JJ\1740 convulsions_25\NNS\14081375 caused_26\VBN\1617192 by_27\IN\1740 carbachol_28\NN\1740 and_29\CC\1740 <e1>eserine</e1>_30\JJ\1740 ._31\.\1740
D010830_D004830 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 calcium_3\NN\14625458 chloride_4\NN\14818238 injected_5\VBN\81072 into_6\IN\1740 the_7\DT\1740 cerebral_8\JJ\1740 ventricles_9\NNS\5303402 of_10\IN\1740 group-housed_11\JJ\1740 unanaesthetized_12\JJ\1740 cats_13\NNS\2120997 upon_14\IN\1740 vocalization_15\NN\33020 (_16\-LRB-\1740 rage_17\NN\7516354 ,_18\,\1740 hissing_19\VBG\983824 and_20\CC\1740 snarling_21\VBG\941990 )_22\-RRB-\1740 ,_23\,\1740 fighting_24\VBG\1090335 (_25\-LRB-\1740 attack_26\NN\955060 with_27\IN\1740 paws_28\NNS\2153445 and_29\CC\1740 claws_30\NNS\5581514 ,_31\,\1740 defense_32\NN\952963 with_33\IN\1740 paws_34\NNS\2153445 and_35\CC\1740 claws_36\NNS\5581514 and_37\CC\1740 biting_38\VBG\1224001 )_39\-RRB-\1740 ,_40\,\1740 mydriasis_41\NN\365995 ,_42\,\1740 tremor_43\NN\345926 and_44\CC\1740 <e2>clonic-tonic_45\JJ\1740 convulsions</e2>_46\NNS\14081375 produced_47\VBN\1617192 by_48\IN\1740 carbachol_49\NN\1740 and_50\CC\1740 <e1>eserine</e1>_51\NN\1740 injected_52\VBN\81072 similarly_53\RB\1740 was_54\VBD\836236 investigated_55\VBN\644583 ._56\.\1740
D010830_D004830 CID on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 mydriasis_5\NN\365995 ,_6\,\1740 tremor_7\NN\345926 and_8\CC\1740 <e2>clonic-tonic_9\JJ\1740 convulsions</e2>_10\NNS\14081375 evoked_11\VBN\1617192 by_12\IN\1740 carbachol_13\NN\1740 and_14\CC\1740 <e1>eserine</e1>_15\NN\1740 were_16\VBD\836236 not_17\RB\1740 significantly_18\RB\1740 changed_19\VBN\46534 by_20\IN\1740 calcium_21\NN\14625458 chloride_22\NN\14818238 ._23\.\1740
D010830_D004830 CID it_0\PRP\6125041 is_1\VBZ\836236 apparent_2\JJ\1740 that_3\IN\1740 calcium_4\NN\14625458 chloride_5\NN\14818238 can_6\MD\3094503 "_7\``\1740 dissociate_8\VB\2431320 "_9\''\1740 vocalization_10\NN\33020 and_11\CC\1740 fighting_12\VBG\1090335 from_13\IN\1740 autonomic_14\JJ\1740 and_15\CC\1740 motor_16\NN\3699975 phenomena_17\NNS\29677 such_18\JJ\1740 as_19\IN\14622893 mydriasis_20\NN\365995 ,_21\,\1740 tremor_22\NN\345926 and_23\CC\1740 <e2>clonic-tonic_24\JJ\1740 convulsions</e2>_25\NNS\14081375 caused_26\VBN\1617192 by_27\IN\1740 carbachol_28\NN\1740 and_29\CC\1740 <e1>eserine</e1>_30\JJ\1740 ._31\.\1740
11337188
D010068_D018366 CID <e2>cutaneous_0\JJ\1740 leucocytoclastic_1\JJ\1740 vasculitis</e2>_2\NN\14336539 associated_3\VBN\628491 with_4\IN\1740 <e1>oxacillin</e1>_5\NN\3910417 ._6\.\1740
D010068_D018366 CID <e1>oxacillin</e1>_0\NNP\3910417 should_1\MD\1740 be_2\VB\836236 included_3\VBN\690614 among_4\IN\1740 the_5\DT\1740 drugs_6\NNS\14778436 that_7\WDT\1740 can_8\MD\3094503 cause_9\VB\1617192 <e2>leucocytoclastic_10\JJ\1740 vasculitis</e2>_11\NN\14336539 ._12\.\1740
D010068_D013203 NONE a_0\DT\13649268 67-year-old_1\JJ\1740 man_2\NN\9605289 who_3\WP\8299493 was_4\VBD\836236 treated_5\VBN\2376958 with_6\IN\1740 <e1>oxacillin</e1>_7\NN\3910417 for_8\IN\1740 one_9\CD\13741022 week_10\NN\15113229 because_11\IN\1740 of_12\IN\1740 <e2>staphylococcus_13\FW\1350855 aureus_14\FW\1740 bacteremia</e2>_15\NN\14204950 ,_16\,\1740 developed_17\VBD\1753788 renal_18\JJ\1740 failure_19\NN\66216 and_20\CC\1740 diffuse_21\JJ\1740 ,_22\,\1740 symmetric_23\JJ\1740 ,_24\,\1740 palpable_25\JJ\1740 purpuric_26\JJ\1740 lesions_27\NNS\14204950 on_28\IN\1740 his_29\PRP$\1740 feet_30\NNS\5563034 ._31\.\1740
D010068_D016470 NONE a_0\DT\13649268 67-year-old_1\JJ\1740 man_2\NN\9605289 who_3\WP\8299493 was_4\VBD\836236 treated_5\VBN\2376958 with_6\IN\1740 <e1>oxacillin</e1>_7\NN\3910417 for_8\IN\1740 one_9\CD\13741022 week_10\NN\15113229 because_11\IN\1740 of_12\IN\1740 <e2>staphylococcus_13\FW\1350855 aureus_14\FW\1740 bacteremia</e2>_15\NN\14204950 ,_16\,\1740 developed_17\VBD\1753788 renal_18\JJ\1740 failure_19\NN\66216 and_20\CC\1740 diffuse_21\JJ\1740 ,_22\,\1740 symmetric_23\JJ\1740 ,_24\,\1740 palpable_25\JJ\1740 purpuric_26\JJ\1740 lesions_27\NNS\14204950 on_28\IN\1740 his_29\PRP$\1740 feet_30\NNS\5563034 ._31\.\1740
D010068_D051437 CID a_0\DT\13649268 67-year-old_1\JJ\1740 man_2\NN\9605289 who_3\WP\8299493 was_4\VBD\836236 treated_5\VBN\2376958 with_6\IN\1740 <e1>oxacillin</e1>_7\NN\3910417 for_8\IN\1740 one_9\CD\13741022 week_10\NN\15113229 because_11\IN\1740 of_12\IN\1740 staphylococcus_13\FW\1350855 aureus_14\FW\1740 bacteremia_15\NN\14204950 ,_16\,\1740 developed_17\VBD\1753788 <e2>renal_18\JJ\1740 failure</e2>_19\NN\66216 and_20\CC\1740 diffuse_21\JJ\1740 ,_22\,\1740 symmetric_23\JJ\1740 ,_24\,\1740 palpable_25\JJ\1740 purpuric_26\JJ\1740 lesions_27\NNS\14204950 on_28\IN\1740 his_29\PRP$\1740 feet_30\NNS\5563034 ._31\.\1740
D010068_D011693 NONE a_0\DT\13649268 67-year-old_1\JJ\1740 man_2\NN\9605289 who_3\WP\8299493 was_4\VBD\836236 treated_5\VBN\2376958 with_6\IN\1740 <e1>oxacillin</e1>_7\NN\3910417 for_8\IN\1740 one_9\CD\13741022 week_10\NN\15113229 because_11\IN\1740 of_12\IN\1740 staphylococcus_13\FW\1350855 aureus_14\FW\1740 bacteremia_15\NN\14204950 ,_16\,\1740 developed_17\VBD\1753788 renal_18\JJ\1740 failure_19\NN\66216 and_20\CC\1740 diffuse_21\JJ\1740 ,_22\,\1740 symmetric_23\JJ\1740 ,_24\,\1740 palpable_25\JJ\1740 <e2>purpuric_26\JJ\1740 lesions</e2>_27\NNS\14204950 on_28\IN\1740 his_29\PRP$\1740 feet_30\NNS\5563034 ._31\.\1740
6111982
D011433_D001145 NONE its_0\PRP$\6125041 antiarrhythmic_1\JJ\1740 effectiveness_2\NN\5190804 surpasses_3\VBZ\1101913 that_4\DT\1740 of_5\IN\1740 <e1>propranolol</e1>_6\NN\1740 and_7\CC\1740 pindolol_8\NN\2832168 inhibiting_9\VBG\2510337 the_10\DT\1740 ouabain_11\NN\1740 <e2>arrhythmia</e2>_12\NN\14103288 in_13\IN\13603305 dogs_14\NNS\2083346 and_15\CC\1740 cats_16\NNS\2120997 ._17\.\1740
D010869_D001145 NONE its_0\PRP$\6125041 antiarrhythmic_1\JJ\1740 effectiveness_2\NN\5190804 surpasses_3\VBZ\1101913 that_4\DT\1740 of_5\IN\1740 propranolol_6\NN\1740 and_7\CC\1740 <e1>pindolol</e1>_8\NN\2832168 inhibiting_9\VBG\2510337 the_10\DT\1740 ouabain_11\NN\1740 <e2>arrhythmia</e2>_12\NN\14103288 in_13\IN\13603305 dogs_14\NNS\2083346 and_15\CC\1740 cats_16\NNS\2120997 ._17\.\1740
D010042_D001145 CID its_0\PRP$\6125041 antiarrhythmic_1\JJ\1740 effectiveness_2\NN\5190804 surpasses_3\VBZ\1101913 that_4\DT\1740 of_5\IN\1740 propranolol_6\NN\1740 and_7\CC\1740 pindolol_8\NN\2832168 inhibiting_9\VBG\2510337 the_10\DT\1740 <e1>ouabain</e1>_11\NN\1740 <e2>arrhythmia</e2>_12\NN\14103288 in_13\IN\13603305 dogs_14\NNS\2083346 and_15\CC\1740 cats_16\NNS\2120997 ._17\.\1740
10533019
D004110_D013746 CID rapid_0\JJ\1740 reversal_1\NN\199130 of_2\IN\1740 life-threatening_3\JJ\1740 <e1>diltiazem-induced</e1>_4\JJ\1740 <e2>tetany</e2>_5\NN\14304060 with_6\IN\1740 calcium_7\NN\14625458 chloride_8\NN\14818238 ._9\.\1740
D004110_D013746 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 who_4\WP\8299493 developed_5\VBD\1753788 <e2>tetany</e2>_6\NN\14304060 with_7\IN\1740 sudden_8\JJ\1740 respiratory_9\JJ\1740 arrest_10\NN\88481 after_11\IN\1740 the_12\DT\1740 infusion_13\NN\14589223 of_14\IN\1740 intravenous_15\JJ\1740 <e1>diltiazem</e1>_16\NN\2938514 ._17\.\1740
D004110_D013746 CID the_0\DT\1740 emergency_1\NN\7417644 physician_2\NN\10305802 should_3\MD\1740 be_4\VB\836236 aware_5\JJ\1740 that_6\IN\1740 life-threatening_7\JJ\1740 <e2>tetany</e2>_8\NN\14304060 may_9\MD\15209706 accompany_10\VB\1835496 the_11\DT\1740 administration_12\NN\1133281 of_13\IN\1740 intravenous_14\JJ\1740 <e1>diltiazem</e1>_15\NN\2938514 and_16\CC\1740 that_17\IN\1740 calcium_18\NN\14625458 chloride_19\NN\14818238 may_20\MD\15209706 be_21\VB\836236 a_22\DT\13649268 rapid_23\JJ\1740 and_24\CC\1740 effective_25\JJ\1740 remedy_26\NN\258854 ._27\.\1740
D002122_D013746 NONE rapid_0\JJ\1740 reversal_1\NN\199130 of_2\IN\1740 life-threatening_3\JJ\1740 diltiazem-induced_4\JJ\1740 <e2>tetany</e2>_5\NN\14304060 with_6\IN\1740 <e1>calcium_7\NN\14625458 chloride</e1>_8\NN\14818238 ._9\.\1740
D002122_D013746 NONE the_0\DT\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>calcium_3\NN\14625458 chloride</e1>_4\NN\14818238 rapidly_5\RB\1740 resolved_6\VBD\352826 the_7\DT\1740 patient_8\NN\9898892 's_9\POS\1740 <e2>tetany</e2>_10\NN\14304060 with_11\IN\1740 prompt_12\JJ\1740 recovery_13\NN\7357388 of_14\IN\1740 respiratory_15\JJ\1740 function_16\NN\13783581 ,_17\,\1740 averting_18\VBG\2452885 the_19\DT\1740 need_20\NN\13920835 for_21\IN\1740 more_22\RBR\1740 aggressive_23\JJ\1740 airway_24\NN\3253398 management_25\NN\1123598 and_26\CC\1740 ventilatory_27\JJ\1740 support_28\NN\407535 ._29\.\1740
D002122_D013746 NONE the_0\DT\1740 emergency_1\NN\7417644 physician_2\NN\10305802 should_3\MD\1740 be_4\VB\836236 aware_5\JJ\1740 that_6\IN\1740 life-threatening_7\JJ\1740 <e2>tetany</e2>_8\NN\14304060 may_9\MD\15209706 accompany_10\VB\1835496 the_11\DT\1740 administration_12\NN\1133281 of_13\IN\1740 intravenous_14\JJ\1740 diltiazem_15\NN\2938514 and_16\CC\1740 that_17\IN\1740 <e1>calcium_18\NN\14625458 chloride</e1>_19\NN\14818238 may_20\MD\15209706 be_21\VB\836236 a_22\DT\13649268 rapid_23\JJ\1740 and_24\CC\1740 effective_25\JJ\1740 remedy_26\NN\258854 ._27\.\1740
D004110_D012131 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 who_4\WP\8299493 developed_5\VBD\1753788 tetany_6\NN\14304060 with_7\IN\1740 sudden_8\JJ\1740 <e2>respiratory_9\JJ\1740 arrest</e2>_10\NN\88481 after_11\IN\1740 the_12\DT\1740 infusion_13\NN\14589223 of_14\IN\1740 intravenous_15\JJ\1740 <e1>diltiazem</e1>_16\NN\2938514 ._17\.\1740
14982270
D008713_D041781 CID <e1>methimazole-induced</e1>_0\JJ\1740 <e2>cholestatic_1\NN\1740 jaundice</e2>_2\NN\14299637 ._3\.\1740
D008713_D007565 NONE a_0\DT\13649268 43-year-old_1\JJ\1740 woman_2\NN\9605289 had_3\VBD\2108377 severe_4\JJ\1740 <e2>jaundice</e2>_5\NN\14299637 and_6\CC\1740 itching_7\VBG\63291 1_8\CD\13741022 month_9\NN\15113229 after_10\IN\1740 receiving_11\VBG\2210855 <e1>methimazole</e1>_12\NN\1740 (_13\-LRB-\1740 10_14\CD\13745420 mg_15\NN\13717155 tid_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 propranolol_19\NN\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg_22\NN\13717155 tid_23\NN\1740 )_24\-RRB-\1740 for_25\IN\1740 treatment_26\NN\654885 of_27\IN\1740 hyperthyroidism_28\NN\14059928 ._29\.\1740
D008713_D011537 CID a_0\DT\13649268 43-year-old_1\JJ\1740 woman_2\NN\9605289 had_3\VBD\2108377 severe_4\JJ\1740 jaundice_5\NN\14299637 and_6\CC\1740 <e2>itching</e2>_7\VBG\63291 1_8\CD\13741022 month_9\NN\15113229 after_10\IN\1740 receiving_11\VBG\2210855 <e1>methimazole</e1>_12\NN\1740 (_13\-LRB-\1740 10_14\CD\13745420 mg_15\NN\13717155 tid_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 propranolol_19\NN\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg_22\NN\13717155 tid_23\NN\1740 )_24\-RRB-\1740 for_25\IN\1740 treatment_26\NN\654885 of_27\IN\1740 hyperthyroidism_28\NN\14059928 ._29\.\1740
D008713_D006980 NONE a_0\DT\13649268 43-year-old_1\JJ\1740 woman_2\NN\9605289 had_3\VBD\2108377 severe_4\JJ\1740 jaundice_5\NN\14299637 and_6\CC\1740 itching_7\VBG\63291 1_8\CD\13741022 month_9\NN\15113229 after_10\IN\1740 receiving_11\VBG\2210855 <e1>methimazole</e1>_12\NN\1740 (_13\-LRB-\1740 10_14\CD\13745420 mg_15\NN\13717155 tid_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 propranolol_19\NN\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg_22\NN\13717155 tid_23\NN\1740 )_24\-RRB-\1740 for_25\IN\1740 treatment_26\NN\654885 of_27\IN\1740 <e2>hyperthyroidism</e2>_28\NN\14059928 ._29\.\1740
D011433_D007565 NONE a_0\DT\13649268 43-year-old_1\JJ\1740 woman_2\NN\9605289 had_3\VBD\2108377 severe_4\JJ\1740 <e2>jaundice</e2>_5\NN\14299637 and_6\CC\1740 itching_7\VBG\63291 1_8\CD\13741022 month_9\NN\15113229 after_10\IN\1740 receiving_11\VBG\2210855 methimazole_12\NN\1740 (_13\-LRB-\1740 10_14\CD\13745420 mg_15\NN\13717155 tid_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 <e1>propranolol</e1>_19\NN\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg_22\NN\13717155 tid_23\NN\1740 )_24\-RRB-\1740 for_25\IN\1740 treatment_26\NN\654885 of_27\IN\1740 hyperthyroidism_28\NN\14059928 ._29\.\1740
D011433_D011537 NONE a_0\DT\13649268 43-year-old_1\JJ\1740 woman_2\NN\9605289 had_3\VBD\2108377 severe_4\JJ\1740 jaundice_5\NN\14299637 and_6\CC\1740 <e2>itching</e2>_7\VBG\63291 1_8\CD\13741022 month_9\NN\15113229 after_10\IN\1740 receiving_11\VBG\2210855 methimazole_12\NN\1740 (_13\-LRB-\1740 10_14\CD\13745420 mg_15\NN\13717155 tid_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 <e1>propranolol</e1>_19\NN\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg_22\NN\13717155 tid_23\NN\1740 )_24\-RRB-\1740 for_25\IN\1740 treatment_26\NN\654885 of_27\IN\1740 hyperthyroidism_28\NN\14059928 ._29\.\1740
D011433_D006980 NONE a_0\DT\13649268 43-year-old_1\JJ\1740 woman_2\NN\9605289 had_3\VBD\2108377 severe_4\JJ\1740 jaundice_5\NN\14299637 and_6\CC\1740 itching_7\VBG\63291 1_8\CD\13741022 month_9\NN\15113229 after_10\IN\1740 receiving_11\VBG\2210855 methimazole_12\NN\1740 (_13\-LRB-\1740 10_14\CD\13745420 mg_15\NN\13717155 tid_16\NN\1740 )_17\-RRB-\1740 and_18\CC\1740 <e1>propranolol</e1>_19\NN\1740 (_20\-LRB-\1740 20_21\CD\13745420 mg_22\NN\13717155 tid_23\NN\1740 )_24\-RRB-\1740 for_25\IN\1740 treatment_26\NN\654885 of_27\IN\1740 <e2>hyperthyroidism</e2>_28\NN\14059928 ._29\.\1740
D008713_D002779 NONE <e1>methimazole-induced</e1>_0\JJ\1740 <e2>cholestasis</e2>_1\NN\14052403 was_2\VBD\836236 diagnosed_3\VBN\644583 ,_4\,\1740 and_5\CC\1740 propranolol_6\NN\1740 therapy_7\NN\657604 was_8\VBD\836236 resumed_9\VBN\2679899 ._10\.\1740
D011433_D002779 NONE methimazole-induced_0\JJ\1740 <e2>cholestasis</e2>_1\NN\14052403 was_2\VBD\836236 diagnosed_3\VBN\644583 ,_4\,\1740 and_5\CC\1740 <e1>propranolol</e1>_6\NN\1740 therapy_7\NN\657604 was_8\VBD\836236 resumed_9\VBN\2679899 ._10\.\1740
8638876
D011374_D006261 NONE a_0\DT\13649268 forty-six_1\NN\1740 year-old_2\NN\1740 premenopausal_3\JJ\1740 woman_4\NN\9605289 developed_5\VBD\1753788 <e2>headache</e2>_6\NN\5829480 ,_7\,\1740 nausea_8\NN\14299637 and_9\CC\1740 vomiting_10\NN\116687 ,_11\,\1740 left_12\VBD\120316 hemiparesis_13\NN\1740 and_14\CC\1740 seizure_15\VB\1740 two_16\CD\13741022 days_17\NNS\15140892 after_18\IN\1740 parenteral_19\JJ\1740 use_20\NN\407535 of_21\IN\1740 <e1>progesterone</e1>_22\NN\14747338 and_23\CC\1740 estradiol_24\NN\14749794 ._25\.\1740
D011374_D009325 NONE a_0\DT\13649268 forty-six_1\NN\1740 year-old_2\NN\1740 premenopausal_3\JJ\1740 woman_4\NN\9605289 developed_5\VBD\1753788 headache_6\NN\5829480 ,_7\,\1740 <e2>nausea</e2>_8\NN\14299637 and_9\CC\1740 vomiting_10\NN\116687 ,_11\,\1740 left_12\VBD\120316 hemiparesis_13\NN\1740 and_14\CC\1740 seizure_15\VB\1740 two_16\CD\13741022 days_17\NNS\15140892 after_18\IN\1740 parenteral_19\JJ\1740 use_20\NN\407535 of_21\IN\1740 <e1>progesterone</e1>_22\NN\14747338 and_23\CC\1740 estradiol_24\NN\14749794 ._25\.\1740
D011374_D014839 NONE a_0\DT\13649268 forty-six_1\NN\1740 year-old_2\NN\1740 premenopausal_3\JJ\1740 woman_4\NN\9605289 developed_5\VBD\1753788 headache_6\NN\5829480 ,_7\,\1740 nausea_8\NN\14299637 and_9\CC\1740 <e2>vomiting</e2>_10\NN\116687 ,_11\,\1740 left_12\VBD\120316 hemiparesis_13\NN\1740 and_14\CC\1740 seizure_15\VB\1740 two_16\CD\13741022 days_17\NNS\15140892 after_18\IN\1740 parenteral_19\JJ\1740 use_20\NN\407535 of_21\IN\1740 <e1>progesterone</e1>_22\NN\14747338 and_23\CC\1740 estradiol_24\NN\14749794 ._25\.\1740
D011374_D010291 NONE a_0\DT\13649268 forty-six_1\NN\1740 year-old_2\NN\1740 premenopausal_3\JJ\1740 woman_4\NN\9605289 developed_5\VBD\1753788 headache_6\NN\5829480 ,_7\,\1740 nausea_8\NN\14299637 and_9\CC\1740 vomiting_10\NN\116687 ,_11\,\1740 left_12\VBD\120316 <e2>hemiparesis</e2>_13\NN\1740 and_14\CC\1740 seizure_15\VB\1740 two_16\CD\13741022 days_17\NNS\15140892 after_18\IN\1740 parenteral_19\JJ\1740 use_20\NN\407535 of_21\IN\1740 <e1>progesterone</e1>_22\NN\14747338 and_23\CC\1740 estradiol_24\NN\14749794 ._25\.\1740
D011374_D012640 NONE a_0\DT\13649268 forty-six_1\NN\1740 year-old_2\NN\1740 premenopausal_3\JJ\1740 woman_4\NN\9605289 developed_5\VBD\1753788 headache_6\NN\5829480 ,_7\,\1740 nausea_8\NN\14299637 and_9\CC\1740 vomiting_10\NN\116687 ,_11\,\1740 left_12\VBD\120316 hemiparesis_13\NN\1740 and_14\CC\1740 <e2>seizure</e2>_15\VB\1740 two_16\CD\13741022 days_17\NNS\15140892 after_18\IN\1740 parenteral_19\JJ\1740 use_20\NN\407535 of_21\IN\1740 <e1>progesterone</e1>_22\NN\14747338 and_23\CC\1740 estradiol_24\NN\14749794 ._25\.\1740
D004958_D006261 NONE a_0\DT\13649268 forty-six_1\NN\1740 year-old_2\NN\1740 premenopausal_3\JJ\1740 woman_4\NN\9605289 developed_5\VBD\1753788 <e2>headache</e2>_6\NN\5829480 ,_7\,\1740 nausea_8\NN\14299637 and_9\CC\1740 vomiting_10\NN\116687 ,_11\,\1740 left_12\VBD\120316 hemiparesis_13\NN\1740 and_14\CC\1740 seizure_15\VB\1740 two_16\CD\13741022 days_17\NNS\15140892 after_18\IN\1740 parenteral_19\JJ\1740 use_20\NN\407535 of_21\IN\1740 progesterone_22\NN\14747338 and_23\CC\1740 <e1>estradiol</e1>_24\NN\14749794 ._25\.\1740
D004958_D009325 NONE a_0\DT\13649268 forty-six_1\NN\1740 year-old_2\NN\1740 premenopausal_3\JJ\1740 woman_4\NN\9605289 developed_5\VBD\1753788 headache_6\NN\5829480 ,_7\,\1740 <e2>nausea</e2>_8\NN\14299637 and_9\CC\1740 vomiting_10\NN\116687 ,_11\,\1740 left_12\VBD\120316 hemiparesis_13\NN\1740 and_14\CC\1740 seizure_15\VB\1740 two_16\CD\13741022 days_17\NNS\15140892 after_18\IN\1740 parenteral_19\JJ\1740 use_20\NN\407535 of_21\IN\1740 progesterone_22\NN\14747338 and_23\CC\1740 <e1>estradiol</e1>_24\NN\14749794 ._25\.\1740
D004958_D014839 NONE a_0\DT\13649268 forty-six_1\NN\1740 year-old_2\NN\1740 premenopausal_3\JJ\1740 woman_4\NN\9605289 developed_5\VBD\1753788 headache_6\NN\5829480 ,_7\,\1740 nausea_8\NN\14299637 and_9\CC\1740 <e2>vomiting</e2>_10\NN\116687 ,_11\,\1740 left_12\VBD\120316 hemiparesis_13\NN\1740 and_14\CC\1740 seizure_15\VB\1740 two_16\CD\13741022 days_17\NNS\15140892 after_18\IN\1740 parenteral_19\JJ\1740 use_20\NN\407535 of_21\IN\1740 progesterone_22\NN\14747338 and_23\CC\1740 <e1>estradiol</e1>_24\NN\14749794 ._25\.\1740
D004958_D010291 NONE a_0\DT\13649268 forty-six_1\NN\1740 year-old_2\NN\1740 premenopausal_3\JJ\1740 woman_4\NN\9605289 developed_5\VBD\1753788 headache_6\NN\5829480 ,_7\,\1740 nausea_8\NN\14299637 and_9\CC\1740 vomiting_10\NN\116687 ,_11\,\1740 left_12\VBD\120316 <e2>hemiparesis</e2>_13\NN\1740 and_14\CC\1740 seizure_15\VB\1740 two_16\CD\13741022 days_17\NNS\15140892 after_18\IN\1740 parenteral_19\JJ\1740 use_20\NN\407535 of_21\IN\1740 progesterone_22\NN\14747338 and_23\CC\1740 <e1>estradiol</e1>_24\NN\14749794 ._25\.\1740
D004958_D012640 NONE a_0\DT\13649268 forty-six_1\NN\1740 year-old_2\NN\1740 premenopausal_3\JJ\1740 woman_4\NN\9605289 developed_5\VBD\1753788 headache_6\NN\5829480 ,_7\,\1740 nausea_8\NN\14299637 and_9\CC\1740 vomiting_10\NN\116687 ,_11\,\1740 left_12\VBD\120316 hemiparesis_13\NN\1740 and_14\CC\1740 <e2>seizure</e2>_15\VB\1740 two_16\CD\13741022 days_17\NNS\15140892 after_18\IN\1740 parenteral_19\JJ\1740 use_20\NN\407535 of_21\IN\1740 progesterone_22\NN\14747338 and_23\CC\1740 <e1>estradiol</e1>_24\NN\14749794 ._25\.\1740
D004958_D003920 NONE in_0\IN\13603305 this_1\DT\1740 case_2\NN\7283608 ,_3\,\1740 the_4\DT\1740 authors_5\NNS\9610660 postulate_6\VBP\756338 that_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>estradiol</e1>_11\NN\14749794 and_12\CC\1740 progesterone_13\NN\14747338 and_14\CC\1740 the_15\DT\1740 underlying_16\VBG\2604760 <e2>dm</e2>_17\NN\14117805 increased_18\VBD\169651 vascular_19\JJ\1740 thrombogenicity_20\NN\1740 ,_21\,\1740 which_22\WDT\1740 provided_23\VBD\2199590 a_24\DT\13649268 common_25\JJ\1740 denominator_26\NN\13733167 for_27\IN\1740 thrombosis_28\NN\14100769 of_29\IN\1740 both_30\CC\1740 the_31\DT\1740 ica_32\NN\1740 and_33\CC\1740 the_34\DT\1740 venous_35\JJ\1740 sinus_36\NN\5248181 ._37\.\1740
D004958_D002341 CID in_0\IN\13603305 this_1\DT\1740 case_2\NN\7283608 ,_3\,\1740 the_4\DT\1740 authors_5\NNS\9610660 postulate_6\VBP\756338 that_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>estradiol</e1>_11\NN\14749794 and_12\CC\1740 progesterone_13\NN\14747338 and_14\CC\1740 the_15\DT\1740 underlying_16\VBG\2604760 dm_17\NN\14117805 increased_18\VBD\169651 vascular_19\JJ\1740 thrombogenicity_20\NN\1740 ,_21\,\1740 which_22\WDT\1740 provided_23\VBD\2199590 a_24\DT\13649268 common_25\JJ\1740 denominator_26\NN\13733167 for_27\IN\1740 <e2>thrombosis_28\NN\14100769 of_29\IN\1740 both_30\CC\1740 the_31\DT\1740 ica_32\NN\1740 and_33\CC\1740 the_34\DT\1740 venous_35\JJ\1740 sinus</e2>_36\NN\5248181 ._37\.\1740
D004958_D012851 CID in_0\IN\13603305 this_1\DT\1740 case_2\NN\7283608 ,_3\,\1740 the_4\DT\1740 authors_5\NNS\9610660 postulate_6\VBP\756338 that_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>estradiol</e1>_11\NN\14749794 and_12\CC\1740 progesterone_13\NN\14747338 and_14\CC\1740 the_15\DT\1740 underlying_16\VBG\2604760 dm_17\NN\14117805 increased_18\VBD\169651 vascular_19\JJ\1740 thrombogenicity_20\NN\1740 ,_21\,\1740 which_22\WDT\1740 provided_23\VBD\2199590 a_24\DT\13649268 common_25\JJ\1740 denominator_26\NN\13733167 for_27\IN\1740 <e2>thrombosis_28\NN\14100769 of_29\IN\1740 both_30\CC\1740 the_31\DT\1740 ica_32\NN\1740 and_33\CC\1740 the_34\DT\1740 venous_35\JJ\1740 sinus</e2>_36\NN\5248181 ._37\.\1740
D011374_D003920 NONE in_0\IN\13603305 this_1\DT\1740 case_2\NN\7283608 ,_3\,\1740 the_4\DT\1740 authors_5\NNS\9610660 postulate_6\VBP\756338 that_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 estradiol_11\NN\14749794 and_12\CC\1740 <e1>progesterone</e1>_13\NN\14747338 and_14\CC\1740 the_15\DT\1740 underlying_16\VBG\2604760 <e2>dm</e2>_17\NN\14117805 increased_18\VBD\169651 vascular_19\JJ\1740 thrombogenicity_20\NN\1740 ,_21\,\1740 which_22\WDT\1740 provided_23\VBD\2199590 a_24\DT\13649268 common_25\JJ\1740 denominator_26\NN\13733167 for_27\IN\1740 thrombosis_28\NN\14100769 of_29\IN\1740 both_30\CC\1740 the_31\DT\1740 ica_32\NN\1740 and_33\CC\1740 the_34\DT\1740 venous_35\JJ\1740 sinus_36\NN\5248181 ._37\.\1740
D011374_D002341 CID in_0\IN\13603305 this_1\DT\1740 case_2\NN\7283608 ,_3\,\1740 the_4\DT\1740 authors_5\NNS\9610660 postulate_6\VBP\756338 that_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 estradiol_11\NN\14749794 and_12\CC\1740 <e1>progesterone</e1>_13\NN\14747338 and_14\CC\1740 the_15\DT\1740 underlying_16\VBG\2604760 dm_17\NN\14117805 increased_18\VBD\169651 vascular_19\JJ\1740 thrombogenicity_20\NN\1740 ,_21\,\1740 which_22\WDT\1740 provided_23\VBD\2199590 a_24\DT\13649268 common_25\JJ\1740 denominator_26\NN\13733167 for_27\IN\1740 <e2>thrombosis_28\NN\14100769 of_29\IN\1740 both_30\CC\1740 the_31\DT\1740 ica_32\NN\1740 and_33\CC\1740 the_34\DT\1740 venous_35\JJ\1740 sinus</e2>_36\NN\5248181 ._37\.\1740
D011374_D012851 CID in_0\IN\13603305 this_1\DT\1740 case_2\NN\7283608 ,_3\,\1740 the_4\DT\1740 authors_5\NNS\9610660 postulate_6\VBP\756338 that_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 estradiol_11\NN\14749794 and_12\CC\1740 <e1>progesterone</e1>_13\NN\14747338 and_14\CC\1740 the_15\DT\1740 underlying_16\VBG\2604760 dm_17\NN\14117805 increased_18\VBD\169651 vascular_19\JJ\1740 thrombogenicity_20\NN\1740 ,_21\,\1740 which_22\WDT\1740 provided_23\VBD\2199590 a_24\DT\13649268 common_25\JJ\1740 denominator_26\NN\13733167 for_27\IN\1740 <e2>thrombosis_28\NN\14100769 of_29\IN\1740 both_30\CC\1740 the_31\DT\1740 ica_32\NN\1740 and_33\CC\1740 the_34\DT\1740 venous_35\JJ\1740 sinus</e2>_36\NN\5248181 ._37\.\1740
6732043
D000728_D020181 CID induction_0\NN\7450842 of_1\IN\1740 the_2\DT\1740 <e2>obstructive_3\JJ\1740 sleep_4\NN\14034177 apnea_5\NN\14299637 syndrome</e2>_6\NN\5870365 in_7\IN\13603305 a_8\DT\13649268 woman_9\NN\9605289 by_10\IN\1740 exogenous_11\JJ\1740 <e1>androgen</e1>_12\NN\14745635 administration_13\NN\1133281 ._14\.\1740
D000728_D020181 CID we_0\PRP\1740 documented_1\VBD\1000214 airway_2\NN\3253398 occlusion_3\NN\14081375 during_4\IN\1740 sleep_5\NN\14034177 and_6\CC\1740 an_7\DT\6697703 abnormally_8\RB\1740 high_9\JJ\1740 supraglottic_10\JJ\1740 resistance_11\NN\37396 while_12\IN\15122231 awake_13\JJ\1740 in_14\IN\13603305 a_15\DT\13649268 54-yr-old_16\JJ\1740 woman_17\NN\9605289 who_18\WP\8299493 had_19\VBD\2108377 developed_20\VBN\1753788 physical_21\JJ\1740 changes_22\NNS\7283608 and_23\CC\1740 the_24\DT\1740 <e2>syndrome_25\NN\5870365 of_26\IN\1740 obstructive_27\JJ\1740 sleep_28\NN\14034177 apnea</e2>_29\NN\14299637 while_30\IN\15122231 being_31\VBG\836236 administered_32\VBN\2436349 exogenous_33\JJ\1740 <e1>androgens</e1>_34\NNS\14745635 ._35\.\1740
D000728_D020181 CID a_0\DT\13649268 rechallenge_1\NN\1740 with_2\IN\1740 <e1>androgen</e1>_3\NN\14745635 produced_4\VBD\1617192 symptoms_5\NNS\5823932 of_6\IN\1740 <e2>obstructive_7\JJ\1740 sleep_8\NN\14034177 apnea</e2>_9\NN\14299637 that_10\WDT\1740 abated_11\VBN\441445 upon_12\IN\1740 withdrawal_13\NN\7206096 of_14\IN\1740 the_15\DT\1740 hormone_16\NN\5404728 ._17\.\1740
D000728_D020181 CID development_0\NN\248977 of_1\IN\1740 the_2\DT\1740 <e2>obstructive_3\JJ\1740 sleep_4\NN\14034177 apnea_5\NN\14299637 syndrome</e2>_6\NN\5870365 must_7\MD\9367203 be_8\VB\836236 considered_9\VBN\689344 a_10\DT\13649268 possible_11\JJ\1740 side_12\NN\8630039 effect_13\NN\34213 of_14\IN\1740 <e1>androgen</e1>_15\NN\14745635 therapy_16\NN\657604 ._17\.\1740
D000728_D012891 NONE previous_0\JJ\1740 reports_1\NNS\6470073 have_2\VBP\2108377 favored_3\VBN\2397637 a_4\DT\13649268 role_5\NN\719494 of_6\IN\1740 <e1>androgens</e1>_7\NNS\14745635 in_8\IN\13603305 the_9\DT\1740 pathogenesis_10\NN\13533470 of_11\IN\1740 <e2>sleep_12\NN\14034177 apnea</e2>_13\NN\14299637 ._14\.\1740
15814210
D003907_D009422 CID minor_0\JJ\1740 <e2>neurological_1\JJ\1740 dysfunction</e2>_2\NN\14204950 ,_3\,\1740 cognitive_4\JJ\1740 development_5\NN\248977 ,_6\,\1740 and_7\CC\1740 somatic_8\JJ\1740 development_9\NN\248977 at_10\IN\14622893 the_11\DT\1740 age_12\NN\4916342 of_13\IN\1740 3_14\CD\13741022 to_15\TO\1740 7_16\CD\13741022 years_17\NNS\15144371 after_18\IN\1740 <e1>dexamethasone</e1>_19\NN\2721538 treatment_20\NN\654885 in_21\IN\13603305 very-low_22\JJ\1740 birth-weight_23\JJ\1740 infants_24\NNS\9918248 ._25\.\1740
D003907_D009422 CID the_0\DT\1740 objective_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 assess_7\VB\670261 minor_8\JJ\1740 <e2>neurological_9\JJ\1740 dysfunction</e2>_10\NN\14204950 ,_11\,\1740 cognitive_12\JJ\1740 development_13\NN\248977 ,_14\,\1740 and_15\CC\1740 somatic_16\JJ\1740 development_17\NN\248977 after_18\IN\1740 <e1>dexamethasone</e1>_19\NN\2721538 therapy_20\NN\657604 in_21\IN\13603305 very-low-birthweight_22\JJ\1740 infants_23\NNS\9918248 ._24\.\1740
D003907_D009422 CID after_0\IN\1740 <e1>dexamethasone</e1>_1\NN\2721538 treatment_2\NN\654885 ,_3\,\1740 children_4\NNS\9622049 showed_5\VBD\2137132 a_6\DT\13649268 higher_7\JJR\1740 rate_8\NN\13815152 of_9\IN\1740 minor_10\JJ\1740 <e2>neurological_11\JJ\1740 dysfunctions</e2>_12\NNS\14204950 ._13\.\1740
6153967
D004737_D012640 CID in_0\IN\13603305 one_1\CD\13741022 patient_2\NN\9898892 ,_3\,\1740 <e1>enflurane</e1>_4\NN\3299929 administered_5\VBN\2436349 during_6\IN\1740 a_7\DT\13649268 donor_8\NN\9608709 nephrectomy_9\NN\393369 resulted_10\VBD\2633881 in_11\IN\13603305 unexpected_12\JJ\1740 partial_13\JJ\1740 motor_14\NN\3699975 <e2>seizures</e2>_15\NNS\14081375 ._16\.\1740
D004737_D012640 CID epileptic_0\JJ\1740 foci_1\NNS\5704266 delineated_2\VBD\2137132 and_3\CC\1740 activated_4\VBN\1641914 by_5\IN\1740 <e1>enflurane</e1>_6\NN\3299929 were_7\VBD\836236 surgically_8\RB\1740 ablated_9\VBN\469382 and_10\CC\1740 the_11\DT\1740 patients_12\NNS\9898892 are_13\VBP\836236 now_14\RB\1740 <e2>seizure-free</e2>_15\JJ\1740 ._16\.\1740
D004737_D004827 NONE <e2>epileptic</e2>_0\JJ\1740 foci_1\NNS\5704266 delineated_2\VBD\2137132 and_3\CC\1740 activated_4\VBN\1641914 by_5\IN\1740 <e1>enflurane</e1>_6\NN\3299929 were_7\VBD\836236 surgically_8\RB\1740 ablated_9\VBN\469382 and_10\CC\1740 the_11\DT\1740 patients_12\NNS\9898892 are_13\VBP\836236 now_14\RB\1740 seizure-free_15\JJ\1740 ._16\.\1740
D004737_D004827 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 <e1>enflurane</e1>_5\NN\3299929 may_6\MD\15209706 prove_7\VB\2604760 to_8\TO\1740 be_9\VB\836236 a_10\DT\13649268 safe_11\JJ\1740 fast_12\JJ\1740 acting_13\VBG\1619354 activator_14\NN\19613 of_15\IN\1740 <e2>epileptic</e2>_16\JJ\1740 foci_17\NNS\5704266 during_18\IN\1740 corticography_19\NN\1740 or_20\CC\3541091 depth_21\NN\5123416 electrode_22\VBP\1740 intraoperative_23\JJ\1740 recordings_24\NNS\6791372 ._25\.\1740
17574447
D010634_-1 NONE <e2>hepatonecrosis</e2>_0\NN\1740 and_1\CC\1740 cholangitis_2\NN\14336539 related_3\JJ\1740 to_4\TO\1740 long-term_5\JJ\1740 <e1>phenobarbital</e1>_6\JJ\1740 therapy_7\NN\657604 :_8\:\1740 an_9\DT\6697703 autopsy_10\JJ\1740 report_11\NN\6470073 of_12\IN\1740 two_13\CD\13741022 patients_14\NNS\9898892 ._15\.\1740
D010634_D002761 CID hepatonecrosis_0\NN\1740 and_1\CC\1740 <e2>cholangitis</e2>_2\NN\14336539 related_3\JJ\1740 to_4\TO\1740 long-term_5\JJ\1740 <e1>phenobarbital</e1>_6\JJ\1740 therapy_7\NN\657604 :_8\:\1740 an_9\DT\6697703 autopsy_10\JJ\1740 report_11\NN\6470073 of_12\IN\1740 two_13\CD\13741022 patients_14\NNS\9898892 ._15\.\1740
D010634_D008107 CID <e1>phenobarbital</e1>_0\JJ\1740 (_1\-LRB-\1740 pb_2\NN\14625458 )_3\-RRB-\1740 has_4\VBZ\2108377 a_5\DT\13649268 reputation_6\NN\14436875 for_7\IN\1740 safety_8\NN\13920835 ,_9\,\1740 and_10\CC\1740 it_11\PRP\6125041 is_12\VBZ\836236 commonly_13\RB\1740 believed_14\VBN\686447 that_15\IN\1740 pb-related_16\JJ\1740 increases_17\VBZ\169651 in_18\IN\13603305 serum_19\NN\5397468 aminotransferase_20\NN\15077571 levels_21\NNS\4916342 do_22\VBP\1640855 not_23\RB\1740 indicate_24\VB\952524 or_25\CC\3541091 predict_26\VB\916909 the_27\DT\1740 development_28\NN\248977 of_29\IN\1740 significant_30\JJ\1740 chronic_31\JJ\1740 <e2>liver_32\NN\5298729 disease</e2>_33\NN\14061805 ._34\.\1740
D010634_D008107 CID phenobarbital_0\JJ\1740 (_1\-LRB-\1740 <e1>pb</e1>_2\NN\14625458 )_3\-RRB-\1740 has_4\VBZ\2108377 a_5\DT\13649268 reputation_6\NN\14436875 for_7\IN\1740 safety_8\NN\13920835 ,_9\,\1740 and_10\CC\1740 it_11\PRP\6125041 is_12\VBZ\836236 commonly_13\RB\1740 believed_14\VBN\686447 that_15\IN\1740 pb-related_16\JJ\1740 increases_17\VBZ\169651 in_18\IN\13603305 serum_19\NN\5397468 aminotransferase_20\NN\15077571 levels_21\NNS\4916342 do_22\VBP\1640855 not_23\RB\1740 indicate_24\VB\952524 or_25\CC\3541091 predict_26\VB\916909 the_27\DT\1740 development_28\NN\248977 of_29\IN\1740 significant_30\JJ\1740 chronic_31\JJ\1740 <e2>liver_32\NN\5298729 disease</e2>_33\NN\14061805 ._34\.\1740
D010634_D008107 CID phenobarbital_0\JJ\1740 (_1\-LRB-\1740 pb_2\NN\14625458 )_3\-RRB-\1740 has_4\VBZ\2108377 a_5\DT\13649268 reputation_6\NN\14436875 for_7\IN\1740 safety_8\NN\13920835 ,_9\,\1740 and_10\CC\1740 it_11\PRP\6125041 is_12\VBZ\836236 commonly_13\RB\1740 believed_14\VBN\686447 that_15\IN\1740 <e1>pb-related</e1>_16\JJ\1740 increases_17\VBZ\169651 in_18\IN\13603305 serum_19\NN\5397468 aminotransferase_20\NN\15077571 levels_21\NNS\4916342 do_22\VBP\1640855 not_23\RB\1740 indicate_24\VB\952524 or_25\CC\3541091 predict_26\VB\916909 the_27\DT\1740 development_28\NN\248977 of_29\IN\1740 significant_30\JJ\1740 chronic_31\JJ\1740 <e2>liver_32\NN\5298729 disease</e2>_33\NN\14061805 ._34\.\1740
D010634_D008107 CID our_0\PRP$\1740 findings_1\NNS\7951464 illustrate_2\VBP\955601 that_3\IN\1740 <e1>pb</e1>_4\NN\14625458 may_5\MD\15209706 be_6\VB\836236 associated_7\VBN\628491 with_8\IN\1740 chronic_9\JJ\1740 <e2>liver_10\NN\5298729 damage</e2>_11\NN\7296428 ,_12\,\1740 which_13\WDT\1740 may_14\MD\15209706 lead_15\VB\1752884 to_16\IN\1740 more_17\RBR\1740 serious_18\JJ\1740 and_19\CC\1740 deleterious_20\JJ\1740 consequences_21\NNS\34213 ._22\.\1740
D010634_D004827 NONE here_0\RB\1740 we_1\PRP\1740 report_2\VBP\831651 of_3\IN\1740 two_4\CD\13741022 adult_5\JJ\1740 patients_6\NNS\9898892 with_7\IN\1740 a_8\DT\13649268 long_9\JJ\1740 history_10\NN\15120823 of_11\IN\1740 <e2>epilepsy</e2>_12\NN\14085708 treated_13\VBN\2376958 with_14\IN\1740 <e1>pb</e1>_15\NN\14625458 who_16\WP\8299493 died_17\VBD\146138 suddenly_18\RB\1740 :_19\:\1740 one_20\CD\13741022 as_21\IN\14622893 consequence_22\NN\34213 of_23\IN\1740 cardiac_24\JJ\1740 arrest_25\NN\88481 ,_26\,\1740 the_27\DT\1740 other_28\JJ\1740 of_29\IN\1740 acute_30\JJ\1740 bronchopneumonia_31\NN\14147627 ._32\.\1740
D010634_D006323 NONE here_0\RB\1740 we_1\PRP\1740 report_2\VBP\831651 of_3\IN\1740 two_4\CD\13741022 adult_5\JJ\1740 patients_6\NNS\9898892 with_7\IN\1740 a_8\DT\13649268 long_9\JJ\1740 history_10\NN\15120823 of_11\IN\1740 epilepsy_12\NN\14085708 treated_13\VBN\2376958 with_14\IN\1740 <e1>pb</e1>_15\NN\14625458 who_16\WP\8299493 died_17\VBD\146138 suddenly_18\RB\1740 :_19\:\1740 one_20\CD\13741022 as_21\IN\14622893 consequence_22\NN\34213 of_23\IN\1740 <e2>cardiac_24\JJ\1740 arrest</e2>_25\NN\88481 ,_26\,\1740 the_27\DT\1740 other_28\JJ\1740 of_29\IN\1740 acute_30\JJ\1740 bronchopneumonia_31\NN\14147627 ._32\.\1740
D010634_D001996 NONE here_0\RB\1740 we_1\PRP\1740 report_2\VBP\831651 of_3\IN\1740 two_4\CD\13741022 adult_5\JJ\1740 patients_6\NNS\9898892 with_7\IN\1740 a_8\DT\13649268 long_9\JJ\1740 history_10\NN\15120823 of_11\IN\1740 epilepsy_12\NN\14085708 treated_13\VBN\2376958 with_14\IN\1740 <e1>pb</e1>_15\NN\14625458 who_16\WP\8299493 died_17\VBD\146138 suddenly_18\RB\1740 :_19\:\1740 one_20\CD\13741022 as_21\IN\14622893 consequence_22\NN\34213 of_23\IN\1740 cardiac_24\JJ\1740 arrest_25\NN\88481 ,_26\,\1740 the_27\DT\1740 other_28\JJ\1740 of_29\IN\1740 acute_30\JJ\1740 <e2>bronchopneumonia</e2>_31\NN\14147627 ._32\.\1740
D010634_D056487 NONE for_0\IN\1740 this_1\DT\1740 reason_2\NN\9178821 ,_3\,\1740 each_4\DT\1740 clinician_5\NN\10462860 should_6\MD\1740 recognize_7\VB\686447 this_8\DT\1740 entity_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 differential_12\JJ\1740 diagnosis_13\NN\152018 of_14\IN\1740 <e1>pb-related</e1>_15\JJ\1740 asymptomatic_16\JJ\1740 <e2>chronic_17\JJ\1740 hepatic_18\JJ\1740 enzyme_19\NN\14723628 dysfunction</e2>_20\NN\14204950 ._21\.\1740
2220369
C015173_D020246 CID central_0\JJ\1740 <e2>vein_1\NN\5417975 thrombosis</e2>_2\NN\14100769 and_3\CC\1740 topical_4\JJ\1740 <e1>dipivalyl_5\JJ\1740 epinephrine</e1>_6\NN\14807929 ._7\.\1740
C015173_D020246 CID a_0\DT\13649268 report_1\NN\6470073 is_2\VBZ\836236 given_3\VBN\2327200 on_4\IN\1740 an_5\DT\6697703 83-year-old_6\JJ\1740 female_7\NN\15388 who_8\WP\8299493 acquired_9\VBD\109660 central_10\JJ\1740 <e2>vein_11\NN\5417975 thrombosis</e2>_12\NN\14100769 in_13\IN\13603305 her_14\PRP$\1740 seeing_15\NN\5708432 eye_16\NN\5299178 one_17\CD\13741022 day_18\NN\15154774 after_19\IN\1740 having_20\VBG\2108377 started_21\VBN\2009433 topical_22\JJ\1740 medication_23\NN\3247620 with_24\IN\1740 <e1>dipivalyl_25\JJ\1740 epinephrine</e1>_26\NN\14807929 for_27\IN\1740 advanced_28\JJ\1740 glaucoma_29\NN\14252864 discovered_30\VBN\2163746 in_31\IN\13603305 the_32\DT\1740 other_33\JJ\1740 eye_34\NN\5299178 ._35\.\1740
C015173_D005901 NONE a_0\DT\13649268 report_1\NN\6470073 is_2\VBZ\836236 given_3\VBN\2327200 on_4\IN\1740 an_5\DT\6697703 83-year-old_6\JJ\1740 female_7\NN\15388 who_8\WP\8299493 acquired_9\VBD\109660 central_10\JJ\1740 vein_11\NN\5417975 thrombosis_12\NN\14100769 in_13\IN\13603305 her_14\PRP$\1740 seeing_15\NN\5708432 eye_16\NN\5299178 one_17\CD\13741022 day_18\NN\15154774 after_19\IN\1740 having_20\VBG\2108377 started_21\VBN\2009433 topical_22\JJ\1740 medication_23\NN\3247620 with_24\IN\1740 <e1>dipivalyl_25\JJ\1740 epinephrine</e1>_26\NN\14807929 for_27\IN\1740 advanced_28\JJ\1740 <e2>glaucoma</e2>_29\NN\14252864 discovered_30\VBN\2163746 in_31\IN\13603305 the_32\DT\1740 other_33\JJ\1740 eye_34\NN\5299178 ._35\.\1740
17366349
C092292_D009459 CID <e2>neuroleptic_0\JJ\1740 malignant_1\JJ\1740 syndrome</e2>_2\NN\5870365 induced_3\VBN\1627355 by_4\IN\1740 <e1>ziprasidone</e1>_5\NN\1740 on_6\IN\1740 the_7\DT\1740 second_8\JJ\1740 day_9\NN\15154774 of_10\IN\1740 treatment_11\NN\654885 ._12\.\1740
C092292_D009459 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e2>neuroleptic_5\JJ\1740 malignant_6\JJ\1740 syndrome</e2>_7\NN\5870365 (_8\-LRB-\1740 nms_9\NN\13649268 )_10\-RRB-\1740 associated_11\VBN\628491 with_12\IN\1740 the_13\DT\1740 use_14\NN\407535 of_15\IN\1740 <e1>ziprasidone</e1>_16\NN\1740 ._17\.\1740
C092292_D009459 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 neuroleptic_5\JJ\1740 malignant_6\JJ\1740 syndrome_7\NN\5870365 (_8\-LRB-\1740 <e2>nms</e2>_9\NN\13649268 )_10\-RRB-\1740 associated_11\VBN\628491 with_12\IN\1740 the_13\DT\1740 use_14\NN\407535 of_15\IN\1740 <e1>ziprasidone</e1>_16\NN\1740 ._17\.\1740
C092292_D009459 CID although_0\IN\1740 conventional_1\JJ\1740 neuroleptics_2\NNS\4470232 are_3\VBP\836236 more_4\RBR\1740 frequently_5\RB\1740 associated_6\VBN\628491 with_7\IN\1740 <e2>nms</e2>_8\NN\13649268 ,_9\,\1740 atypical_10\JJ\1740 antipsychotic_11\JJ\1740 drugs_12\NNS\14778436 like_13\IN\5839024 <e1>ziprasidone</e1>_14\NN\1740 may_15\MD\15209706 also_16\RB\1740 be_17\VB\836236 a_18\DT\13649268 cause_19\NN\7323922 ._20\.\1740
C092292_D009459 CID the_0\DT\1740 patient_1\NN\9898892 is_2\VBZ\836236 a_3\DT\13649268 24-year-old_4\JJ\1740 male_5\JJ\1740 with_6\IN\1740 a_7\DT\13649268 history_8\NN\15120823 of_9\IN\1740 schizophrenia_10\NN\14398067 who_11\WP\8299493 developed_12\VBD\1753788 signs_13\NNS\6643763 and_14\CC\1740 symptoms_15\NNS\5823932 of_16\IN\1740 <e2>nms</e2>_17\NN\13649268 after_18\IN\1740 2_19\CD\13741022 days_20\NNS\15140892 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 an_24\DT\6697703 80-mg/day_25\NN\1740 dose_26\NN\3740161 of_27\IN\1740 orally_28\RB\1740 administrated_29\VBN\2436349 <e1>ziprasidone</e1>_30\NN\1740 ._31\.\1740
C092292_D009459 CID <e2>nms</e2>_0\NN\13649268 due_1\JJ\1740 to_2\TO\1740 <e1>ziprasidone</e1>_3\NN\1740 reported_4\VBN\831651 in_5\IN\13603305 the_6\DT\1740 literature_7\NN\6362953 ._8\.\1740
C092292_D012559 NONE the_0\DT\1740 patient_1\NN\9898892 is_2\VBZ\836236 a_3\DT\13649268 24-year-old_4\JJ\1740 male_5\JJ\1740 with_6\IN\1740 a_7\DT\13649268 history_8\NN\15120823 of_9\IN\1740 <e2>schizophrenia</e2>_10\NN\14398067 who_11\WP\8299493 developed_12\VBD\1753788 signs_13\NNS\6643763 and_14\CC\1740 symptoms_15\NNS\5823932 of_16\IN\1740 nms_17\NN\13649268 after_18\IN\1740 2_19\CD\13741022 days_20\NNS\15140892 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 an_24\DT\6697703 80-mg/day_25\NN\1740 dose_26\NN\3740161 of_27\IN\1740 orally_28\RB\1740 administrated_29\VBN\2436349 <e1>ziprasidone</e1>_30\NN\1740 ._31\.\1740
19370593
D004967_D054556 CID long-term_0\JJ\1740 <e1>oestrogen-only</e1>_1\JJ\1740 ht_2\NN\1740 significantly_3\RB\1740 increased_4\VBD\169651 the_5\DT\1740 risk_6\NN\14541044 of_7\IN\1740 <e2>venous_8\JJ\1740 thrombo-embolism</e2>_9\NN\1740 ,_10\,\1740 stroke_11\NN\556313 and_12\CC\1740 gallbladder_13\NN\5512139 disease_14\NN\14061805 (_15\-LRB-\1740 after_16\IN\1740 one_17\CD\13741022 to_18\TO\1740 two_19\CD\13741022 years_20\NNS\15144371 ,_21\,\1740 three_22\CD\13741022 years_23\NNS\15144371 and_24\CC\1740 seven_25\CD\13741022 years_26\NNS\15144371 '_27\POS\1740 use_28\NN\407535 respectively_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 but_32\CC\1740 did_33\VBD\1640855 not_34\RB\1740 significantly_35\RB\1740 increase_36\VB\169651 the_37\DT\1740 risk_38\NN\14541044 of_39\IN\1740 breast_40\NN\5225090 cancer_41\NN\14239425 ._42\.\1740
D004967_D020521 CID long-term_0\JJ\1740 <e1>oestrogen-only</e1>_1\JJ\1740 ht_2\NN\1740 significantly_3\RB\1740 increased_4\VBD\169651 the_5\DT\1740 risk_6\NN\14541044 of_7\IN\1740 venous_8\JJ\1740 thrombo-embolism_9\NN\1740 ,_10\,\1740 <e2>stroke</e2>_11\NN\556313 and_12\CC\1740 gallbladder_13\NN\5512139 disease_14\NN\14061805 (_15\-LRB-\1740 after_16\IN\1740 one_17\CD\13741022 to_18\TO\1740 two_19\CD\13741022 years_20\NNS\15144371 ,_21\,\1740 three_22\CD\13741022 years_23\NNS\15144371 and_24\CC\1740 seven_25\CD\13741022 years_26\NNS\15144371 '_27\POS\1740 use_28\NN\407535 respectively_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 but_32\CC\1740 did_33\VBD\1640855 not_34\RB\1740 significantly_35\RB\1740 increase_36\VB\169651 the_37\DT\1740 risk_38\NN\14541044 of_39\IN\1740 breast_40\NN\5225090 cancer_41\NN\14239425 ._42\.\1740
D004967_D005705 CID long-term_0\JJ\1740 <e1>oestrogen-only</e1>_1\JJ\1740 ht_2\NN\1740 significantly_3\RB\1740 increased_4\VBD\169651 the_5\DT\1740 risk_6\NN\14541044 of_7\IN\1740 venous_8\JJ\1740 thrombo-embolism_9\NN\1740 ,_10\,\1740 stroke_11\NN\556313 and_12\CC\1740 <e2>gallbladder_13\NN\5512139 disease</e2>_14\NN\14061805 (_15\-LRB-\1740 after_16\IN\1740 one_17\CD\13741022 to_18\TO\1740 two_19\CD\13741022 years_20\NNS\15144371 ,_21\,\1740 three_22\CD\13741022 years_23\NNS\15144371 and_24\CC\1740 seven_25\CD\13741022 years_26\NNS\15144371 '_27\POS\1740 use_28\NN\407535 respectively_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 but_32\CC\1740 did_33\VBD\1640855 not_34\RB\1740 significantly_35\RB\1740 increase_36\VB\169651 the_37\DT\1740 risk_38\NN\14541044 of_39\IN\1740 breast_40\NN\5225090 cancer_41\NN\14239425 ._42\.\1740
D004967_D001943 NONE long-term_0\JJ\1740 <e1>oestrogen-only</e1>_1\JJ\1740 ht_2\NN\1740 significantly_3\RB\1740 increased_4\VBD\169651 the_5\DT\1740 risk_6\NN\14541044 of_7\IN\1740 venous_8\JJ\1740 thrombo-embolism_9\NN\1740 ,_10\,\1740 stroke_11\NN\556313 and_12\CC\1740 gallbladder_13\NN\5512139 disease_14\NN\14061805 (_15\-LRB-\1740 after_16\IN\1740 one_17\CD\13741022 to_18\TO\1740 two_19\CD\13741022 years_20\NNS\15144371 ,_21\,\1740 three_22\CD\13741022 years_23\NNS\15144371 and_24\CC\1740 seven_25\CD\13741022 years_26\NNS\15144371 '_27\POS\1740 use_28\NN\407535 respectively_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 but_32\CC\1740 did_33\VBD\1640855 not_34\RB\1740 significantly_35\RB\1740 increase_36\VB\169651 the_37\DT\1740 risk_38\NN\14541044 of_39\IN\1740 <e2>breast_40\NN\5225090 cancer</e2>_41\NN\14239425 ._42\.\1740
2466960
D005472_D066126 NONE although_0\IN\1740 there_1\EX\27167 have_2\VBP\2108377 been_3\VBN\836236 anecdotal_4\JJ\1740 reports_5\NNS\6470073 of_6\IN\1740 <e2>cardiac_7\JJ\1740 toxicity</e2>_8\NN\13576101 associated_9\VBN\628491 with_10\IN\1740 <e1>fluorouracil</e1>_11\NN\2722166 (_12\-LRB-\1740 5-fu_13\NN\1740 )_14\-RRB-\1740 therapy_15\NN\657604 ,_16\,\1740 this_17\DT\1740 phenomenon_18\NN\29677 has_19\VBZ\2108377 not_20\RB\1740 been_21\VBN\836236 studied_22\VBN\630380 in_23\IN\13603305 a_24\DT\13649268 systematic_25\JJ\1740 fashion_26\NN\4916342 ._27\.\1740
D005472_D066126 NONE although_0\IN\1740 there_1\EX\27167 have_2\VBP\2108377 been_3\VBN\836236 anecdotal_4\JJ\1740 reports_5\NNS\6470073 of_6\IN\1740 <e2>cardiac_7\JJ\1740 toxicity</e2>_8\NN\13576101 associated_9\VBN\628491 with_10\IN\1740 fluorouracil_11\NN\2722166 (_12\-LRB-\1740 <e1>5-fu</e1>_13\NN\1740 )_14\-RRB-\1740 therapy_15\NN\657604 ,_16\,\1740 this_17\DT\1740 phenomenon_18\NN\29677 has_19\VBZ\2108377 not_20\RB\1740 been_21\VBN\836236 studied_22\VBN\630380 in_23\IN\13603305 a_24\DT\13649268 systematic_25\JJ\1740 fashion_26\NN\4916342 ._27\.\1740
D005472_D009369 NONE we_0\PRP\1740 prospectively_1\RB\1740 performed_2\VBD\2367363 continuous_3\JJ\1740 ambulatory_4\JJ\1740 ecg_5\NN\7000195 monitoring_6\NN\879759 on_7\IN\1740 25_8\CD\13745420 patients_9\NNS\9898892 undergoing_10\VBG\109660 <e1>5-fu</e1>_11\NN\1740 infusion_12\NN\14589223 for_13\IN\1740 treatment_14\NN\654885 of_15\IN\1740 solid_16\JJ\1740 <e2>tumors</e2>_17\NNS\14234074 in_18\IN\13603305 order_19\NN\7168131 to_20\TO\1740 assess_21\VB\670261 the_22\DT\1740 incidence_23\NN\13821570 of_24\IN\1740 ischemic_25\JJ\1740 st_26\JJ\1740 changes_27\NNS\7283608 ._28\.\1740
D005472_D007511 CID we_0\PRP\1740 prospectively_1\RB\1740 performed_2\VBD\2367363 continuous_3\JJ\1740 ambulatory_4\JJ\1740 ecg_5\NN\7000195 monitoring_6\NN\879759 on_7\IN\1740 25_8\CD\13745420 patients_9\NNS\9898892 undergoing_10\VBG\109660 <e1>5-fu</e1>_11\NN\1740 infusion_12\NN\14589223 for_13\IN\1740 treatment_14\NN\654885 of_15\IN\1740 solid_16\JJ\1740 tumors_17\NNS\14234074 in_18\IN\13603305 order_19\NN\7168131 to_20\TO\1740 assess_21\VB\670261 the_22\DT\1740 incidence_23\NN\13821570 of_24\IN\1740 <e2>ischemic</e2>_25\JJ\1740 st_26\JJ\1740 changes_27\NNS\7283608 ._28\.\1740
D005472_D007511 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>ischemic</e2>_3\JJ\1740 episodes_4\NNS\7283608 per_5\IN\1740 patient_6\NN\9898892 per_7\IN\1740 hour_8\NN\15154774 was_9\VBD\836236 0.05_10\CD\1740 +/-_11\CC\1740 0.02_12\CD\1740 prior_13\JJ\1740 to_14\TO\1740 <e1>5-fu</e1>_15\NN\1740 infusion_16\NN\14589223 v_17\IN\13634784 0.13_18\CD\1740 +/-_19\CC\1740 0.03_20\CD\1740 during_21\IN\1740 5-fu_22\NN\1740 infusion_23\NN\14589223 (_24\-LRB-\1740 p_25\NN\14622893 less_26\JJR\1740 than_27\IN\1740 .001_28\CD\1740 )_29\-RRB-\1740 ;_30\:\1740 the_31\DT\1740 duration_32\NN\15113229 of_33\IN\1740 ecg_34\NN\7000195 changes_35\NNS\7283608 was_36\VBD\836236 0.6_37\CD\1740 +/-_38\CC\1740 0.3_39\CD\1740 minutes_40\NNS\6502378 per_41\IN\1740 patient_42\NN\9898892 per_43\IN\1740 hour_44\NN\15154774 before_45\IN\1740 5-fu_46\NN\1740 v_47\IN\13634784 1.9_48\CD\1740 +/-_49\CC\1740 0.5_50\CD\1740 minutes_51\NNS\6502378 per_52\IN\1740 patient_53\NN\9898892 per_54\IN\1740 hour_55\NN\15154774 during_56\IN\1740 5-fu_57\NN\1740 (_58\-LRB-\1740 p_59\NN\14622893 less_60\JJR\1740 than_61\IN\1740 .01_62\CD\1740 )_63\-RRB-\1740 ._64\.\1740
D005472_D007511 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>ischemic</e2>_3\JJ\1740 episodes_4\NNS\7283608 per_5\IN\1740 patient_6\NN\9898892 per_7\IN\1740 hour_8\NN\15154774 was_9\VBD\836236 0.05_10\CD\1740 +/-_11\CC\1740 0.02_12\CD\1740 prior_13\JJ\1740 to_14\TO\1740 5-fu_15\NN\1740 infusion_16\NN\14589223 v_17\IN\13634784 0.13_18\CD\1740 +/-_19\CC\1740 0.03_20\CD\1740 during_21\IN\1740 <e1>5-fu</e1>_22\NN\1740 infusion_23\NN\14589223 (_24\-LRB-\1740 p_25\NN\14622893 less_26\JJR\1740 than_27\IN\1740 .001_28\CD\1740 )_29\-RRB-\1740 ;_30\:\1740 the_31\DT\1740 duration_32\NN\15113229 of_33\IN\1740 ecg_34\NN\7000195 changes_35\NNS\7283608 was_36\VBD\836236 0.6_37\CD\1740 +/-_38\CC\1740 0.3_39\CD\1740 minutes_40\NNS\6502378 per_41\IN\1740 patient_42\NN\9898892 per_43\IN\1740 hour_44\NN\15154774 before_45\IN\1740 5-fu_46\NN\1740 v_47\IN\13634784 1.9_48\CD\1740 +/-_49\CC\1740 0.5_50\CD\1740 minutes_51\NNS\6502378 per_52\IN\1740 patient_53\NN\9898892 per_54\IN\1740 hour_55\NN\15154774 during_56\IN\1740 5-fu_57\NN\1740 (_58\-LRB-\1740 p_59\NN\14622893 less_60\JJR\1740 than_61\IN\1740 .01_62\CD\1740 )_63\-RRB-\1740 ._64\.\1740
D005472_D007511 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>ischemic</e2>_3\JJ\1740 episodes_4\NNS\7283608 per_5\IN\1740 patient_6\NN\9898892 per_7\IN\1740 hour_8\NN\15154774 was_9\VBD\836236 0.05_10\CD\1740 +/-_11\CC\1740 0.02_12\CD\1740 prior_13\JJ\1740 to_14\TO\1740 5-fu_15\NN\1740 infusion_16\NN\14589223 v_17\IN\13634784 0.13_18\CD\1740 +/-_19\CC\1740 0.03_20\CD\1740 during_21\IN\1740 5-fu_22\NN\1740 infusion_23\NN\14589223 (_24\-LRB-\1740 p_25\NN\14622893 less_26\JJR\1740 than_27\IN\1740 .001_28\CD\1740 )_29\-RRB-\1740 ;_30\:\1740 the_31\DT\1740 duration_32\NN\15113229 of_33\IN\1740 ecg_34\NN\7000195 changes_35\NNS\7283608 was_36\VBD\836236 0.6_37\CD\1740 +/-_38\CC\1740 0.3_39\CD\1740 minutes_40\NNS\6502378 per_41\IN\1740 patient_42\NN\9898892 per_43\IN\1740 hour_44\NN\15154774 before_45\IN\1740 <e1>5-fu</e1>_46\NN\1740 v_47\IN\13634784 1.9_48\CD\1740 +/-_49\CC\1740 0.5_50\CD\1740 minutes_51\NNS\6502378 per_52\IN\1740 patient_53\NN\9898892 per_54\IN\1740 hour_55\NN\15154774 during_56\IN\1740 5-fu_57\NN\1740 (_58\-LRB-\1740 p_59\NN\14622893 less_60\JJR\1740 than_61\IN\1740 .01_62\CD\1740 )_63\-RRB-\1740 ._64\.\1740
D005472_D007511 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>ischemic</e2>_3\JJ\1740 episodes_4\NNS\7283608 per_5\IN\1740 patient_6\NN\9898892 per_7\IN\1740 hour_8\NN\15154774 was_9\VBD\836236 0.05_10\CD\1740 +/-_11\CC\1740 0.02_12\CD\1740 prior_13\JJ\1740 to_14\TO\1740 5-fu_15\NN\1740 infusion_16\NN\14589223 v_17\IN\13634784 0.13_18\CD\1740 +/-_19\CC\1740 0.03_20\CD\1740 during_21\IN\1740 5-fu_22\NN\1740 infusion_23\NN\14589223 (_24\-LRB-\1740 p_25\NN\14622893 less_26\JJR\1740 than_27\IN\1740 .001_28\CD\1740 )_29\-RRB-\1740 ;_30\:\1740 the_31\DT\1740 duration_32\NN\15113229 of_33\IN\1740 ecg_34\NN\7000195 changes_35\NNS\7283608 was_36\VBD\836236 0.6_37\CD\1740 +/-_38\CC\1740 0.3_39\CD\1740 minutes_40\NNS\6502378 per_41\IN\1740 patient_42\NN\9898892 per_43\IN\1740 hour_44\NN\15154774 before_45\IN\1740 5-fu_46\NN\1740 v_47\IN\13634784 1.9_48\CD\1740 +/-_49\CC\1740 0.5_50\CD\1740 minutes_51\NNS\6502378 per_52\IN\1740 patient_53\NN\9898892 per_54\IN\1740 hour_55\NN\15154774 during_56\IN\1740 <e1>5-fu</e1>_57\NN\1740 (_58\-LRB-\1740 p_59\NN\14622893 less_60\JJR\1740 than_61\IN\1740 .01_62\CD\1740 )_63\-RRB-\1740 ._64\.\1740
D005472_D007511 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>5-fu</e1>_3\NN\1740 infusion_4\NN\14589223 is_5\VBZ\836236 associated_6\VBN\628491 with_7\IN\1740 a_8\DT\13649268 significant_9\JJ\1740 increase_10\NN\13576355 in_11\IN\13603305 silent_12\JJ\1740 st_13\JJ\1740 segment_14\NN\3892891 deviation_15\NN\7337390 suggestive_16\JJ\1740 of_17\IN\1740 <e2>ischemia</e2>_18\NN\14195315 ,_19\,\1740 particularly_20\RB\1740 among_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 coronary_24\JJ\1740 artery_25\NN\5417975 disease_26\NN\14061805 ._27\.\1740
D005472_D000787 CID <e2>anginal</e2>_0\JJ\1740 episodes_1\NNS\7283608 were_2\VBD\836236 rare_3\JJ\1740 :_4\:\1740 only_5\RB\1740 one_6\CD\13741022 patient_7\NN\9898892 had_8\VBD\2108377 angina_9\NN\14171682 (_10\-LRB-\1740 during_11\IN\1740 <e1>5-fu</e1>_12\NN\1740 infusion_13\NN\14589223 )_14\-RRB-\1740 ._15\.\1740
D005472_D000787 CID anginal_0\JJ\1740 episodes_1\NNS\7283608 were_2\VBD\836236 rare_3\JJ\1740 :_4\:\1740 only_5\RB\1740 one_6\CD\13741022 patient_7\NN\9898892 had_8\VBD\2108377 <e2>angina</e2>_9\NN\14171682 (_10\-LRB-\1740 during_11\IN\1740 <e1>5-fu</e1>_12\NN\1740 infusion_13\NN\14589223 )_14\-RRB-\1740 ._15\.\1740
D005472_D003324 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>5-fu</e1>_3\NN\1740 infusion_4\NN\14589223 is_5\VBZ\836236 associated_6\VBN\628491 with_7\IN\1740 a_8\DT\13649268 significant_9\JJ\1740 increase_10\NN\13576355 in_11\IN\13603305 silent_12\JJ\1740 st_13\JJ\1740 segment_14\NN\3892891 deviation_15\NN\7337390 suggestive_16\JJ\1740 of_17\IN\1740 ischemia_18\NN\14195315 ,_19\,\1740 particularly_20\RB\1740 among_21\IN\1740 patients_22\NNS\9898892 with_23\IN\1740 <e2>coronary_24\JJ\1740 artery_25\NN\5417975 disease</e2>_26\NN\14061805 ._27\.\1740
12448656
D013792_D002292 NONE a_0\DT\13649268 phase_1\NN\15113229 ii_2\CD\13741022 study_3\NN\635850 of_4\IN\1740 <e1>thalidomide</e1>_5\NN\4166841 in_6\IN\13603305 advanced_7\JJ\1740 metastatic_8\JJ\1740 <e2>renal_9\JJ\1740 cell_10\NN\3080309 carcinoma</e2>_11\NN\14239918 ._12\.\1740
D013792_D002292 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 toxicity_5\NN\13576101 and_6\CC\1740 activity_7\NN\30358 of_8\IN\1740 <e1>thalidomide</e1>_9\NN\4166841 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 advanced_13\JJ\1740 metastatic_14\JJ\1740 <e2>renal_15\JJ\1740 cell_16\NN\3080309 cancer</e2>_17\NN\14239425 and_18\CC\1740 to_19\TO\1740 measure_20\VB\697589 changes_21\NNS\7283608 of_22\IN\1740 one_23\CD\13741022 angiogenic_24\JJ\1740 factor_25\NN\7326557 ,_26\,\1740 vascular_27\JJ\1740 endothelial_28\JJ\1740 growth_29\NN\13526110 factor_30\NN\7326557 (vegf)165_31\NN\1740 ,_32\,\1740 with_33\IN\1740 therapy_34\NN\657604 ._35\.\1740
D013792_D002292 NONE conclusion_0\NN\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 are_4\VBP\836236 consistent_5\JJ\1740 with_6\IN\1740 a_7\DT\13649268 low_8\JJ\1740 level_9\NN\4916342 of_10\IN\1740 activity_11\NN\30358 of_12\IN\1740 <e1>thalidomide</e1>_13\NN\4166841 in_14\IN\13603305 <e2>renal_15\JJ\1740 cell_16\NN\3080309 carcinoma</e2>_17\NN\14239918 ._18\.\1740
D013792_D002292 NONE the_0\DT\1740 dose-response_1\JJ\1740 relationship_2\NN\31921 ,_3\,\1740 if_4\IN\1740 any_5\DT\1740 ,_6\,\1740 of_7\IN\1740 <e1>thalidomide</e1>_8\NN\4166841 for_9\IN\1740 <e2>renal_10\JJ\1740 cell_11\NN\3080309 carcinoma</e2>_12\NN\14239918 is_13\VBZ\836236 unclear_14\JJ\1740 ._15\.\1740
D013792_D064420 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 <e2>toxicity</e2>_5\NN\13576101 and_6\CC\1740 activity_7\NN\30358 of_8\IN\1740 <e1>thalidomide</e1>_9\NN\4166841 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 advanced_13\JJ\1740 metastatic_14\JJ\1740 renal_15\JJ\1740 cell_16\NN\3080309 cancer_17\NN\14239425 and_18\CC\1740 to_19\TO\1740 measure_20\VB\697589 changes_21\NNS\7283608 of_22\IN\1740 one_23\CD\13741022 angiogenic_24\JJ\1740 factor_25\NN\7326557 ,_26\,\1740 vascular_27\JJ\1740 endothelial_28\JJ\1740 growth_29\NN\13526110 factor_30\NN\7326557 (vegf)165_31\NN\1740 ,_32\,\1740 with_33\IN\1740 therapy_34\NN\657604 ._35\.\1740
6942642
D049971_D007008 NONE <e1>thiazide</e1>_0\NN\3214670 diuretics_1\NNS\3247620 ,_2\,\1740 <e2>hypokalemia</e2>_3\NN\14299637 and_4\CC\1740 cardiac_5\FW\1740 arrhythmias_6\NNS\14103288 ._7\.\1740
D049971_D007008 NONE <e2>hypokalemia</e2>_0\NNP\14299637 is_1\VBZ\836236 a_2\DT\13649268 commonly_3\RB\1740 encountered_4\VBN\2604760 metabolic_5\JJ\1740 consequence_6\NN\34213 of_7\IN\1740 chronic_8\JJ\1740 <e1>thiazide</e1>_9\NN\3214670 therapy_10\NN\657604 ._11\.\1740
D049971_D007008 NONE in_0\IN\13603305 conclusion_1\NN\5837957 we_2\PRP\1740 found_3\VBD\2426171 that_4\IN\1740 <e1>thiazide</e1>_5\NN\3214670 diuretics_6\NNS\3247620 cause_7\VBP\1617192 <e2>hypokalemia</e2>_8\NN\14299637 and_9\CC\1740 depletion_10\NN\351638 of_11\IN\1740 body_12\NN\19128 potassium_13\NN\14625458 ._14\.\1740
D049971_D001145 NONE <e1>thiazide</e1>_0\NN\3214670 diuretics_1\NNS\3247620 ,_2\,\1740 hypokalemia_3\NN\14299637 and_4\CC\1740 <e2>cardiac_5\FW\1740 arrhythmias</e2>_6\NNS\14103288 ._7\.\1740
D006852_C563897 NONE we_0\PRP\1740 treated_1\VBD\2376958 38_2\CD\1740 patients_3\NNS\9898892 (_4\-LRB-\1740 22_5\CD\13745420 low_6\JJ\1740 renin_7\NN\14999106 ,_8\,\1740 16_9\CD\13745420 normal_10\JJ\1740 renin_11\NN\14999106 )_12\-RRB-\1740 with_13\IN\1740 moderate_14\JJ\1740 <e2>diastolic_15\JJ\1740 hypertension</e2>_16\NN\14057371 with_17\IN\1740 <e1>hydrochlorothiazide</e1>_18\NN\4423288 (_19\-LRB-\1740 hctc_20\NN\1740 )_21\-RRB-\1740 administered_22\VBN\2436349 on_23\IN\1740 a_24\DT\13649268 twice_25\JJ\1740 daily_26\JJ\1740 schedule_27\NN\5898568 ._28\.\1740
D006852_C563897 NONE we_0\PRP\1740 treated_1\VBD\2376958 38_2\CD\1740 patients_3\NNS\9898892 (_4\-LRB-\1740 22_5\CD\13745420 low_6\JJ\1740 renin_7\NN\14999106 ,_8\,\1740 16_9\CD\13745420 normal_10\JJ\1740 renin_11\NN\14999106 )_12\-RRB-\1740 with_13\IN\1740 moderate_14\JJ\1740 <e2>diastolic_15\JJ\1740 hypertension</e2>_16\NN\14057371 with_17\IN\1740 hydrochlorothiazide_18\NN\4423288 (_19\-LRB-\1740 <e1>hctc</e1>_20\NN\1740 )_21\-RRB-\1740 administered_22\VBN\2436349 on_23\IN\1740 a_24\DT\13649268 twice_25\JJ\1740 daily_26\JJ\1740 schedule_27\NN\5898568 ._28\.\1740
D011188_D007008 NONE in_0\IN\13603305 conclusion_1\NN\5837957 we_2\PRP\1740 found_3\VBD\2426171 that_4\IN\1740 thiazide_5\NN\3214670 diuretics_6\NNS\3247620 cause_7\VBP\1617192 <e2>hypokalemia</e2>_8\NN\14299637 and_9\CC\1740 depletion_10\NN\351638 of_11\IN\1740 body_12\NN\19128 <e1>potassium</e1>_13\NN\14625458 ._14\.\1740
2598570
D013496_D021501 CID the_0\DT\1740 epidemiology_1\NN\6043075 of_2\IN\1740 the_3\DT\1740 acute_4\JJ\1740 <e2>flank_5\NN\8426461 pain</e2>_6\NN\14299637 syndrome_7\NN\5870365 from_8\IN\1740 <e1>suprofen</e1>_9\NN\1740 ._10\.\1740
D000431_D006255 NONE case_0\NN\7283608 patients_1\NNS\9898892 were_2\VBD\836236 more_3\RBR\1740 likely_4\JJ\1740 to_5\TO\1740 be_6\VB\836236 men_7\NNS\8208016 (_8\-LRB-\1740 odds_9\NNS\4756635 ratio_10\NN\13815152 ,_11\,\1740 3.8_12\CD\1740 ;_13\:\1740 95_14\CD\1740 %_15\NN\1740 confidence_16\NN\5697135 interval_17\NN\33615 ,_18\,\1740 1.2_19\CD\1740 -_20\SYM\1740 12.1_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 suffer_24\VBP\2110220 from_25\IN\1740 <e2>hay_26\NN\7800740 fever</e2>_27\NN\14299637 and_28\CC\1740 asthma_29\NN\14145095 (_30\-LRB-\1740 odds_31\NNS\4756635 ratio_32\NN\13815152 ,_33\,\1740 3.4_34\CD\1740 ;_35\:\1740 95_36\CD\1740 %_37\NN\1740 confidence_38\NN\5697135 interval_39\NN\33615 ,_40\,\1740 1.0_41\CD\1740 -_42\SYM\1740 11.9_43\CD\1740 )_44\-RRB-\1740 ;_45\:\1740 to_46\TO\1740 participate_47\VB\2367363 in_48\IN\13603305 regular_49\JJ\1740 exercise_50\NN\621627 (_51\-LRB-\1740 odds_52\NNS\4756635 ratio_53\NN\13815152 ,_54\,\1740 5.9_55\CD\1740 ;_56\:\1740 95_57\CD\1740 %_58\NN\1740 confidence_59\NN\5697135 interval_60\NN\33615 ,_61\,\1740 1.1_62\CD\1740 -_63\SYM\1740 30.7_64\CD\1740 )_65\-RRB-\1740 ,_66\,\1740 especially_67\RB\1740 in_68\IN\13603305 the_69\DT\1740 use_70\NN\407535 of_71\IN\1740 nautilus_72\NN\4347754 equipment_73\NN\3575240 (_74\-LRB-\1740 p_75\NN\14622893 =_76\JJ\1740 0.02_77\CD\1740 )_78\-RRB-\1740 ;_79\:\1740 and_80\CC\1740 to_81\TO\1740 use_82\VB\1156834 <e1>alcohol</e1>_83\NN\7881800 (_84\-LRB-\1740 odds_85\NNS\4756635 ratio_86\NN\13815152 ,_87\,\1740 4.4_88\CD\1740 ;_89\:\1740 95_90\CD\1740 %_91\NN\1740 confidence_92\NN\5697135 interval_93\NN\33615 ,_94\,\1740 1.1_95\CD\1740 -_96\SYM\1740 17.5_97\CD\1740 )_98\-RRB-\1740 ._99\.\1740
D000431_D001249 NONE case_0\NN\7283608 patients_1\NNS\9898892 were_2\VBD\836236 more_3\RBR\1740 likely_4\JJ\1740 to_5\TO\1740 be_6\VB\836236 men_7\NNS\8208016 (_8\-LRB-\1740 odds_9\NNS\4756635 ratio_10\NN\13815152 ,_11\,\1740 3.8_12\CD\1740 ;_13\:\1740 95_14\CD\1740 %_15\NN\1740 confidence_16\NN\5697135 interval_17\NN\33615 ,_18\,\1740 1.2_19\CD\1740 -_20\SYM\1740 12.1_21\CD\1740 )_22\-RRB-\1740 ,_23\,\1740 suffer_24\VBP\2110220 from_25\IN\1740 hay_26\NN\7800740 fever_27\NN\14299637 and_28\CC\1740 <e2>asthma</e2>_29\NN\14145095 (_30\-LRB-\1740 odds_31\NNS\4756635 ratio_32\NN\13815152 ,_33\,\1740 3.4_34\CD\1740 ;_35\:\1740 95_36\CD\1740 %_37\NN\1740 confidence_38\NN\5697135 interval_39\NN\33615 ,_40\,\1740 1.0_41\CD\1740 -_42\SYM\1740 11.9_43\CD\1740 )_44\-RRB-\1740 ;_45\:\1740 to_46\TO\1740 participate_47\VB\2367363 in_48\IN\13603305 regular_49\JJ\1740 exercise_50\NN\621627 (_51\-LRB-\1740 odds_52\NNS\4756635 ratio_53\NN\13815152 ,_54\,\1740 5.9_55\CD\1740 ;_56\:\1740 95_57\CD\1740 %_58\NN\1740 confidence_59\NN\5697135 interval_60\NN\33615 ,_61\,\1740 1.1_62\CD\1740 -_63\SYM\1740 30.7_64\CD\1740 )_65\-RRB-\1740 ,_66\,\1740 especially_67\RB\1740 in_68\IN\13603305 the_69\DT\1740 use_70\NN\407535 of_71\IN\1740 nautilus_72\NN\4347754 equipment_73\NN\3575240 (_74\-LRB-\1740 p_75\NN\14622893 =_76\JJ\1740 0.02_77\CD\1740 )_78\-RRB-\1740 ;_79\:\1740 and_80\CC\1740 to_81\TO\1740 use_82\VB\1156834 <e1>alcohol</e1>_83\NN\7881800 (_84\-LRB-\1740 odds_85\NNS\4756635 ratio_86\NN\13815152 ,_87\,\1740 4.4_88\CD\1740 ;_89\:\1740 95_90\CD\1740 %_91\NN\1740 confidence_92\NN\5697135 interval_93\NN\33615 ,_94\,\1740 1.1_95\CD\1740 -_96\SYM\1740 17.5_97\CD\1740 )_98\-RRB-\1740 ._99\.\1740
D007052_D007674 NONE possible_0\JJ\1740 risk_1\NN\14541044 factors_2\NNS\7326557 included_3\VBD\690614 young_4\JJ\1740 age_5\NN\4916342 ,_6\,\1740 concurrent_7\JJ\1740 use_8\NN\407535 of_9\IN\1740 other_10\JJ\1740 analgesic_11\NN\3740161 agents_12\NNS\7347 (_13\-LRB-\1740 especially_14\RB\1740 <e1>ibuprofen</e1>_15\JJ\1740 )_16\-RRB-\1740 ,_17\,\1740 preexisting_18\VBG\2603699 <e2>renal_19\JJ\1740 disease</e2>_20\NN\14061805 ,_21\,\1740 a_22\DT\13649268 history_23\NN\15120823 of_24\IN\1740 kidney_25\NN\5333259 stones_26\NNS\19128 ,_27\,\1740 a_28\DT\13649268 history_29\NN\15120823 of_30\IN\1740 gout_31\NN\14186541 ,_32\,\1740 a_33\DT\13649268 recent_34\JJ\1740 increase_35\NN\13576355 in_36\IN\13603305 activity_37\NN\30358 ,_38\,\1740 a_39\DT\13649268 recent_40\JJ\1740 increase_41\NN\13576355 in_42\IN\13603305 sun_43\NN\11473954 exposure_44\NN\5042871 ,_45\,\1740 and_46\CC\1740 residence_47\NN\8491027 in_48\IN\13603305 the_49\DT\1740 sunbelt_50\NNP\1740 ._51\.\1740
D007052_D007669 NONE possible_0\JJ\1740 risk_1\NN\14541044 factors_2\NNS\7326557 included_3\VBD\690614 young_4\JJ\1740 age_5\NN\4916342 ,_6\,\1740 concurrent_7\JJ\1740 use_8\NN\407535 of_9\IN\1740 other_10\JJ\1740 analgesic_11\NN\3740161 agents_12\NNS\7347 (_13\-LRB-\1740 especially_14\RB\1740 <e1>ibuprofen</e1>_15\JJ\1740 )_16\-RRB-\1740 ,_17\,\1740 preexisting_18\VBG\2603699 renal_19\JJ\1740 disease_20\NN\14061805 ,_21\,\1740 a_22\DT\13649268 history_23\NN\15120823 of_24\IN\1740 <e2>kidney_25\NN\5333259 stones</e2>_26\NNS\19128 ,_27\,\1740 a_28\DT\13649268 history_29\NN\15120823 of_30\IN\1740 gout_31\NN\14186541 ,_32\,\1740 a_33\DT\13649268 recent_34\JJ\1740 increase_35\NN\13576355 in_36\IN\13603305 activity_37\NN\30358 ,_38\,\1740 a_39\DT\13649268 recent_40\JJ\1740 increase_41\NN\13576355 in_42\IN\13603305 sun_43\NN\11473954 exposure_44\NN\5042871 ,_45\,\1740 and_46\CC\1740 residence_47\NN\8491027 in_48\IN\13603305 the_49\DT\1740 sunbelt_50\NNP\1740 ._51\.\1740
D007052_D006073 NONE possible_0\JJ\1740 risk_1\NN\14541044 factors_2\NNS\7326557 included_3\VBD\690614 young_4\JJ\1740 age_5\NN\4916342 ,_6\,\1740 concurrent_7\JJ\1740 use_8\NN\407535 of_9\IN\1740 other_10\JJ\1740 analgesic_11\NN\3740161 agents_12\NNS\7347 (_13\-LRB-\1740 especially_14\RB\1740 <e1>ibuprofen</e1>_15\JJ\1740 )_16\-RRB-\1740 ,_17\,\1740 preexisting_18\VBG\2603699 renal_19\JJ\1740 disease_20\NN\14061805 ,_21\,\1740 a_22\DT\13649268 history_23\NN\15120823 of_24\IN\1740 kidney_25\NN\5333259 stones_26\NNS\19128 ,_27\,\1740 a_28\DT\13649268 history_29\NN\15120823 of_30\IN\1740 <e2>gout</e2>_31\NN\14186541 ,_32\,\1740 a_33\DT\13649268 recent_34\JJ\1740 increase_35\NN\13576355 in_36\IN\13603305 activity_37\NN\30358 ,_38\,\1740 a_39\DT\13649268 recent_40\JJ\1740 increase_41\NN\13576355 in_42\IN\13603305 sun_43\NN\11473954 exposure_44\NN\5042871 ,_45\,\1740 and_46\CC\1740 residence_47\NN\8491027 in_48\IN\13603305 the_49\DT\1740 sunbelt_50\NNP\1740 ._51\.\1740
458486
D063325_D004409 NONE <e1>tiapride</e1>_0\NN\1740 in_1\IN\13603305 levodopa-induced_2\JJ\1740 <e2>involuntary_3\JJ\1740 movements</e2>_4\NNS\191142 ._5\.\1740
D063325_D004409 NONE <e1>tiapride</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 substituted_3\VBN\126264 benzamide_4\NN\1740 derivative_5\JJ\1740 closely_6\RB\1740 related_7\JJ\1740 to_8\TO\1740 metoclopramide_9\NN\1740 ,_10\,\1740 reduced_11\VBN\441445 levodopa-induced_12\JJ\1740 peak_13\NN\13758296 dose_14\NN\3740161 <e2>involuntary_15\JJ\1740 movements</e2>_16\NNS\191142 in_17\IN\13603305 16_18\CD\13745420 patients_19\NNS\9898892 with_20\IN\1740 idiopathic_21\JJ\1740 parkinson_22\NNP\1740 's_23\POS\1740 disease_24\NN\14061805 ._25\.\1740
D007980_D004409 CID tiapride_0\NN\1740 in_1\IN\13603305 <e1>levodopa-induced</e1>_2\JJ\1740 <e2>involuntary_3\JJ\1740 movements</e2>_4\NNS\191142 ._5\.\1740
D007980_D004409 CID tiapride_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 substituted_3\VBN\126264 benzamide_4\NN\1740 derivative_5\JJ\1740 closely_6\RB\1740 related_7\JJ\1740 to_8\TO\1740 metoclopramide_9\NN\1740 ,_10\,\1740 reduced_11\VBN\441445 <e1>levodopa-induced</e1>_12\JJ\1740 peak_13\NN\13758296 dose_14\NN\3740161 <e2>involuntary_15\JJ\1740 movements</e2>_16\NNS\191142 in_17\IN\13603305 16_18\CD\13745420 patients_19\NNS\9898892 with_20\IN\1740 idiopathic_21\JJ\1740 parkinson_22\NNP\1740 's_23\POS\1740 disease_24\NN\14061805 ._25\.\1740
D007980_D004409 CID these_0\DT\1740 results_1\NNS\34213 fail_2\VBP\1798936 to_3\TO\1740 support_4\VB\2199590 the_5\DT\1740 notion_6\NN\5833840 that_7\IN\1740 <e1>levodopa-induced</e1>_8\JJ\1740 <e2>dyskinesias</e2>_9\NNS\14084880 are_10\VBP\836236 caused_11\VBN\1617192 by_12\IN\1740 overstimulation_13\NN\1740 of_14\IN\1740 a_15\DT\13649268 separate_16\JJ\1740 group_17\NN\2137 of_18\IN\1740 dopamine_19\NN\14807737 receptors_20\NNS\5225602 ._21\.\1740
D063325_D010300 NONE <e1>tiapride</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 substituted_3\VBN\126264 benzamide_4\NN\1740 derivative_5\JJ\1740 closely_6\RB\1740 related_7\JJ\1740 to_8\TO\1740 metoclopramide_9\NN\1740 ,_10\,\1740 reduced_11\VBN\441445 levodopa-induced_12\JJ\1740 peak_13\NN\13758296 dose_14\NN\3740161 involuntary_15\JJ\1740 movements_16\NNS\191142 in_17\IN\13603305 16_18\CD\13745420 patients_19\NNS\9898892 with_20\IN\1740 <e2>idiopathic_21\JJ\1740 parkinson_22\NNP\1740 's_23\POS\1740 disease</e2>_24\NN\14061805 ._25\.\1740
C037689_D004409 NONE tiapride_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 substituted_3\VBN\126264 <e1>benzamide</e1>_4\NN\1740 derivative_5\JJ\1740 closely_6\RB\1740 related_7\JJ\1740 to_8\TO\1740 metoclopramide_9\NN\1740 ,_10\,\1740 reduced_11\VBN\441445 levodopa-induced_12\JJ\1740 peak_13\NN\13758296 dose_14\NN\3740161 <e2>involuntary_15\JJ\1740 movements</e2>_16\NNS\191142 in_17\IN\13603305 16_18\CD\13745420 patients_19\NNS\9898892 with_20\IN\1740 idiopathic_21\JJ\1740 parkinson_22\NNP\1740 's_23\POS\1740 disease_24\NN\14061805 ._25\.\1740
C037689_D010300 NONE tiapride_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 substituted_3\VBN\126264 <e1>benzamide</e1>_4\NN\1740 derivative_5\JJ\1740 closely_6\RB\1740 related_7\JJ\1740 to_8\TO\1740 metoclopramide_9\NN\1740 ,_10\,\1740 reduced_11\VBN\441445 levodopa-induced_12\JJ\1740 peak_13\NN\13758296 dose_14\NN\3740161 involuntary_15\JJ\1740 movements_16\NNS\191142 in_17\IN\13603305 16_18\CD\13745420 patients_19\NNS\9898892 with_20\IN\1740 <e2>idiopathic_21\JJ\1740 parkinson_22\NNP\1740 's_23\POS\1740 disease</e2>_24\NN\14061805 ._25\.\1740
D008787_D004409 NONE tiapride_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 substituted_3\VBN\126264 benzamide_4\NN\1740 derivative_5\JJ\1740 closely_6\RB\1740 related_7\JJ\1740 to_8\TO\1740 <e1>metoclopramide</e1>_9\NN\1740 ,_10\,\1740 reduced_11\VBN\441445 levodopa-induced_12\JJ\1740 peak_13\NN\13758296 dose_14\NN\3740161 <e2>involuntary_15\JJ\1740 movements</e2>_16\NNS\191142 in_17\IN\13603305 16_18\CD\13745420 patients_19\NNS\9898892 with_20\IN\1740 idiopathic_21\JJ\1740 parkinson_22\NNP\1740 's_23\POS\1740 disease_24\NN\14061805 ._25\.\1740
D008787_D010300 NONE tiapride_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 substituted_3\VBN\126264 benzamide_4\NN\1740 derivative_5\JJ\1740 closely_6\RB\1740 related_7\JJ\1740 to_8\TO\1740 <e1>metoclopramide</e1>_9\NN\1740 ,_10\,\1740 reduced_11\VBN\441445 levodopa-induced_12\JJ\1740 peak_13\NN\13758296 dose_14\NN\3740161 involuntary_15\JJ\1740 movements_16\NNS\191142 in_17\IN\13603305 16_18\CD\13745420 patients_19\NNS\9898892 with_20\IN\1740 <e2>idiopathic_21\JJ\1740 parkinson_22\NNP\1740 's_23\POS\1740 disease</e2>_24\NN\14061805 ._25\.\1740
D007980_D010300 NONE tiapride_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 substituted_3\VBN\126264 benzamide_4\NN\1740 derivative_5\JJ\1740 closely_6\RB\1740 related_7\JJ\1740 to_8\TO\1740 metoclopramide_9\NN\1740 ,_10\,\1740 reduced_11\VBN\441445 <e1>levodopa-induced</e1>_12\JJ\1740 peak_13\NN\13758296 dose_14\NN\3740161 involuntary_15\JJ\1740 movements_16\NNS\191142 in_17\IN\13603305 16_18\CD\13745420 patients_19\NNS\9898892 with_20\IN\1740 <e2>idiopathic_21\JJ\1740 parkinson_22\NNP\1740 's_23\POS\1740 disease</e2>_24\NN\14061805 ._25\.\1740
D063325_D004421 NONE <e1>tiapride</e1>_0\NNP\1740 had_1\VBD\2108377 no_2\DT\7204911 effect_3\NN\34213 on_4\IN\1740 levodopa-induced_5\JJ\1740 early_6\JJ\1740 morning_7\NN\15113229 of_8\IN\1740 "_9\``\1740 off-period_10\JJ\1740 "_11\``\1740 segmental_12\JJ\1740 <e2>dystonia</e2>_13\NN\1740 ._14\.\1740
D007980_D004421 NONE tiapride_0\NNP\1740 had_1\VBD\2108377 no_2\DT\7204911 effect_3\NN\34213 on_4\IN\1740 <e1>levodopa-induced</e1>_5\JJ\1740 early_6\JJ\1740 morning_7\NN\15113229 of_8\IN\1740 "_9\``\1740 off-period_10\JJ\1740 "_11\``\1740 segmental_12\JJ\1740 <e2>dystonia</e2>_13\NN\1740 ._14\.\1740
D004298_D004409 NONE these_0\DT\1740 results_1\NNS\34213 fail_2\VBP\1798936 to_3\TO\1740 support_4\VB\2199590 the_5\DT\1740 notion_6\NN\5833840 that_7\IN\1740 levodopa-induced_8\JJ\1740 <e2>dyskinesias</e2>_9\NNS\14084880 are_10\VBP\836236 caused_11\VBN\1617192 by_12\IN\1740 overstimulation_13\NN\1740 of_14\IN\1740 a_15\DT\13649268 separate_16\JJ\1740 group_17\NN\2137 of_18\IN\1740 <e1>dopamine</e1>_19\NN\14807737 receptors_20\NNS\5225602 ._21\.\1740
17786501
D004221_D009901 NONE <e1>disulfiram-induced</e1>_0\JJ\1740 transient_1\JJ\1740 <e2>optic_2\NN\5299178 and_3\CC\1740 peripheral_4\JJ\1740 neuropathy</e2>_5\NN\14204950 :_6\:\1740 a_7\DT\13649268 case_8\NN\7283608 report_9\NN\6470073 ._10\.\1740
D004221_D009901 NONE aim_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e2>optic_7\JJ\1740 and_8\CC\1740 peripheral_9\JJ\1740 neuropathy</e2>_10\NN\14204950 after_11\IN\1740 chronic_12\JJ\1740 use_13\NN\407535 of_14\IN\1740 <e1>disulfiram</e1>_15\NN\3740161 for_16\IN\1740 alcohol_17\NN\7881800 dependence_18\NN\24720 management_19\NN\1123598 ._20\.\1740
D004221_D010523 NONE <e1>disulfiram-induced</e1>_0\JJ\1740 transient_1\JJ\1740 <e2>optic_2\NN\5299178 and_3\CC\1740 peripheral_4\JJ\1740 neuropathy</e2>_5\NN\14204950 :_6\:\1740 a_7\DT\13649268 case_8\NN\7283608 report_9\NN\6470073 ._10\.\1740
D004221_D010523 NONE aim_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e2>optic_7\JJ\1740 and_8\CC\1740 peripheral_9\JJ\1740 neuropathy</e2>_10\NN\14204950 after_11\IN\1740 chronic_12\JJ\1740 use_13\NN\407535 of_14\IN\1740 <e1>disulfiram</e1>_15\NN\3740161 for_16\IN\1740 alcohol_17\NN\7881800 dependence_18\NN\24720 management_19\NN\1123598 ._20\.\1740
D004221_D000437 NONE aim_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 optic_7\JJ\1740 and_8\CC\1740 peripheral_9\JJ\1740 neuropathy_10\NN\14204950 after_11\IN\1740 chronic_12\JJ\1740 use_13\NN\407535 of_14\IN\1740 <e1>disulfiram</e1>_15\NN\3740161 for_16\IN\1740 <e2>alcohol_17\NN\7881800 dependence</e2>_18\NN\24720 management_19\NN\1123598 ._20\.\1740
D004221_D000437 NONE he_0\PRP\14622893 had_1\VBD\2108377 been_2\VBN\836236 taking_3\VBG\2367363 <e1>disulfiram</e1>_4\NN\3740161 for_5\IN\1740 <e2>alcohol_6\NN\7881800 dependence</e2>_7\NN\24720 for_8\IN\1740 the_9\DT\1740 preceding_10\VBG\2690708 3_11\CD\13741022 years_12\NNS\15144371 ._13\.\1740
3961813
D003345_D009422 NONE dose-related_0\JJ\1740 beneficial_1\JJ\1740 and_2\CC\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 dietary_6\JJ\1740 <e1>corticosterone</e1>_7\NN\14752057 on_8\IN\1740 organophosphorus-induced_9\JJ\1740 delayed_10\VBN\439958 <e2>neuropathy</e2>_11\JJ\1740 in_12\IN\13603305 chickens_13\NNS\7644706 ._14\.\1740
D003345_D009422 NONE although_0\IN\1740 low_1\JJ\1740 concentrations_2\NNS\4916342 (_3\-LRB-\1740 less_4\JJR\1740 than_5\IN\1740 or_6\CC\3541091 equal_7\JJ\1740 to_8\TO\1740 50_9\CD\13745420 ppm_10\NN\1740 )_11\-RRB-\1740 of_12\IN\1740 <e1>corticosterone</e1>_13\NN\14752057 had_14\VBD\2108377 beneficial_15\JJ\1740 effects_16\NNS\13245626 on_17\IN\1740 totp-induced_18\JJ\1740 <e2>neuropathy</e2>_19\NN\14204950 ,_20\,\1740 greater_21\JJR\1740 than_22\IN\1740 or_23\CC\3541091 equal_24\JJ\1740 to_25\TO\1740 200_26\CD\1740 ppm_27\NN\1740 exacerbated_28\JJ\1740 clinical_29\JJ\1740 signs_30\NNS\6643763 in_31\IN\13603305 chickens_32\NNS\7644706 given_33\VBN\2327200 either_34\CC\1740 totp_35\NN\1740 or_36\CC\3541091 dfp_37\NN\1740 ._38\.\1740
D010755_D009422 NONE dose-related_0\JJ\1740 beneficial_1\JJ\1740 and_2\CC\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 dietary_6\JJ\1740 corticosterone_7\NN\14752057 on_8\IN\1740 <e1>organophosphorus-induced</e1>_9\JJ\1740 delayed_10\VBN\439958 <e2>neuropathy</e2>_11\JJ\1740 in_12\IN\13603305 chickens_13\NNS\7644706 ._14\.\1740
C025541_D009422 CID although_0\IN\1740 low_1\JJ\1740 concentrations_2\NNS\4916342 (_3\-LRB-\1740 less_4\JJR\1740 than_5\IN\1740 or_6\CC\3541091 equal_7\JJ\1740 to_8\TO\1740 50_9\CD\13745420 ppm_10\NN\1740 )_11\-RRB-\1740 of_12\IN\1740 corticosterone_13\NN\14752057 had_14\VBD\2108377 beneficial_15\JJ\1740 effects_16\NNS\13245626 on_17\IN\1740 <e1>totp-induced</e1>_18\JJ\1740 <e2>neuropathy</e2>_19\NN\14204950 ,_20\,\1740 greater_21\JJR\1740 than_22\IN\1740 or_23\CC\3541091 equal_24\JJ\1740 to_25\TO\1740 200_26\CD\1740 ppm_27\NN\1740 exacerbated_28\JJ\1740 clinical_29\JJ\1740 signs_30\NNS\6643763 in_31\IN\13603305 chickens_32\NNS\7644706 given_33\VBN\2327200 either_34\CC\1740 totp_35\NN\1740 or_36\CC\3541091 dfp_37\NN\1740 ._38\.\1740
C025541_D009422 CID although_0\IN\1740 low_1\JJ\1740 concentrations_2\NNS\4916342 (_3\-LRB-\1740 less_4\JJR\1740 than_5\IN\1740 or_6\CC\3541091 equal_7\JJ\1740 to_8\TO\1740 50_9\CD\13745420 ppm_10\NN\1740 )_11\-RRB-\1740 of_12\IN\1740 corticosterone_13\NN\14752057 had_14\VBD\2108377 beneficial_15\JJ\1740 effects_16\NNS\13245626 on_17\IN\1740 totp-induced_18\JJ\1740 <e2>neuropathy</e2>_19\NN\14204950 ,_20\,\1740 greater_21\JJR\1740 than_22\IN\1740 or_23\CC\3541091 equal_24\JJ\1740 to_25\TO\1740 200_26\CD\1740 ppm_27\NN\1740 exacerbated_28\JJ\1740 clinical_29\JJ\1740 signs_30\NNS\6643763 in_31\IN\13603305 chickens_32\NNS\7644706 given_33\VBN\2327200 either_34\CC\1740 <e1>totp</e1>_35\NN\1740 or_36\CC\3541091 dfp_37\NN\1740 ._38\.\1740
D007531_D009422 CID although_0\IN\1740 low_1\JJ\1740 concentrations_2\NNS\4916342 (_3\-LRB-\1740 less_4\JJR\1740 than_5\IN\1740 or_6\CC\3541091 equal_7\JJ\1740 to_8\TO\1740 50_9\CD\13745420 ppm_10\NN\1740 )_11\-RRB-\1740 of_12\IN\1740 corticosterone_13\NN\14752057 had_14\VBD\2108377 beneficial_15\JJ\1740 effects_16\NNS\13245626 on_17\IN\1740 totp-induced_18\JJ\1740 <e2>neuropathy</e2>_19\NN\14204950 ,_20\,\1740 greater_21\JJR\1740 than_22\IN\1740 or_23\CC\3541091 equal_24\JJ\1740 to_25\TO\1740 200_26\CD\1740 ppm_27\NN\1740 exacerbated_28\JJ\1740 clinical_29\JJ\1740 signs_30\NNS\6643763 in_31\IN\13603305 chickens_32\NNS\7644706 given_33\VBN\2327200 either_34\CC\1740 totp_35\NN\1740 or_36\CC\3541091 <e1>dfp</e1>_37\NN\1740 ._38\.\1740
C025541_D020258 NONE <e2>neurotoxic</e2>_0\JJ\1740 esterase_1\NN\1740 activities_2\VBZ\1740 24_3\CD\13745420 hr_4\NN\15154774 after_5\IN\1740 <e1>totp</e1>_6\NN\1740 or_7\CC\3541091 dfp_8\NN\1740 were_9\VBD\836236 less_10\JJR\1740 than_11\IN\1740 20_12\CD\13745420 %_13\NN\1740 of_14\IN\1740 values_15\NNS\5941423 measured_16\VBN\697589 in_17\IN\13603305 chickens_18\NNS\7644706 not_19\RB\1740 given_20\VBN\2327200 organophosphorous_21\JJ\1740 compounds_22\NNS\5869584 ._23\.\1740
D007531_D020258 NONE <e2>neurotoxic</e2>_0\JJ\1740 esterase_1\NN\1740 activities_2\VBZ\1740 24_3\CD\13745420 hr_4\NN\15154774 after_5\IN\1740 totp_6\NN\1740 or_7\CC\3541091 <e1>dfp</e1>_8\NN\1740 were_9\VBD\836236 less_10\JJR\1740 than_11\IN\1740 20_12\CD\13745420 %_13\NN\1740 of_14\IN\1740 values_15\NNS\5941423 measured_16\VBN\697589 in_17\IN\13603305 chickens_18\NNS\7644706 not_19\RB\1740 given_20\VBN\2327200 organophosphorous_21\JJ\1740 compounds_22\NNS\5869584 ._23\.\1740
D010755_D020258 NONE <e2>neurotoxic</e2>_0\JJ\1740 esterase_1\NN\1740 activities_2\VBZ\1740 24_3\CD\13745420 hr_4\NN\15154774 after_5\IN\1740 totp_6\NN\1740 or_7\CC\3541091 dfp_8\NN\1740 were_9\VBD\836236 less_10\JJR\1740 than_11\IN\1740 20_12\CD\13745420 %_13\NN\1740 of_14\IN\1740 values_15\NNS\5941423 measured_16\VBN\697589 in_17\IN\13603305 chickens_18\NNS\7644706 not_19\RB\1740 given_20\VBN\2327200 <e1>organophosphorous</e1>_21\JJ\1740 compounds_22\NNS\5869584 ._23\.\1740
C025541_D009410 CID <e2>degenerating_0\NN\1740 myelinated_1\VBD\1740 fibers</e2>_2\NNS\14580897 were_3\VBD\836236 also_4\RB\1740 evident_5\JJ\1740 in_6\IN\13603305 distal_7\JJ\1740 levels_8\NNS\4916342 of_9\IN\1740 the_10\DT\1740 peripheral_11\JJ\1740 nerves_12\NNS\14373582 of_13\IN\1740 chickens_14\NNS\7644706 given_15\VBN\2327200 <e1>totp</e1>_16\NN\1740 or_17\CC\3541091 dfp_18\NN\1740 ._19\.\1740
D007531_D009410 CID <e2>degenerating_0\NN\1740 myelinated_1\VBD\1740 fibers</e2>_2\NNS\14580897 were_3\VBD\836236 also_4\RB\1740 evident_5\JJ\1740 in_6\IN\13603305 distal_7\JJ\1740 levels_8\NNS\4916342 of_9\IN\1740 the_10\DT\1740 peripheral_11\JJ\1740 nerves_12\NNS\14373582 of_13\IN\1740 chickens_14\NNS\7644706 given_15\VBN\2327200 totp_16\NN\1740 or_17\CC\3541091 <e1>dfp</e1>_18\NN\1740 ._19\.\1740
1504402
D007741_D004342 CID <e2>hypersensitivity</e2>_0\NN\14531772 immune_1\JJ\1740 reaction_2\NN\13446390 as_3\IN\14622893 a_4\DT\13649268 mechanism_5\NN\13446390 for_6\IN\1740 <e1>dilevalol-associated</e1>_7\JJ\1740 hepatitis_8\NN\14127211 ._9\.\1740
D007741_D056486 CID hypersensitivity_0\NN\14531772 immune_1\JJ\1740 reaction_2\NN\13446390 as_3\IN\14622893 a_4\DT\13649268 mechanism_5\NN\13446390 for_6\IN\1740 <e1>dilevalol-associated</e1>_7\JJ\1740 <e2>hepatitis</e2>_8\NN\14127211 ._9\.\1740
D007741_D056486 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 lymphocyte_4\NN\5449959 reactivity_5\NN\5652926 to_6\TO\1740 <e1>dilevalol</e1>_7\NNS\1740 and_8\CC\1740 to_9\TO\1740 serum_10\NN\5397468 containing_11\VBG\2632940 putative_12\JJ\1740 ex_13\FW\10287213 vivo_14\FW\1740 dilevalol_15\JJ\1740 antigens_16\NNS\20090 or_17\CC\3541091 metabolites_18\NNS\20090 in_19\IN\13603305 a_20\DT\13649268 case_21\NN\7283608 of_22\IN\1740 dilevalol-induced_23\JJ\1740 <e2>liver_24\NN\5298729 injury</e2>_25\NN\14052046 ._26\.\1740
D007741_D056486 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 lymphocyte_4\NN\5449959 reactivity_5\NN\5652926 to_6\TO\1740 dilevalol_7\NNS\1740 and_8\CC\1740 to_9\TO\1740 serum_10\NN\5397468 containing_11\VBG\2632940 putative_12\JJ\1740 ex_13\FW\10287213 vivo_14\FW\1740 <e1>dilevalol</e1>_15\JJ\1740 antigens_16\NNS\20090 or_17\CC\3541091 metabolites_18\NNS\20090 in_19\IN\13603305 a_20\DT\13649268 case_21\NN\7283608 of_22\IN\1740 dilevalol-induced_23\JJ\1740 <e2>liver_24\NN\5298729 injury</e2>_25\NN\14052046 ._26\.\1740
D007741_D056486 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 assess_3\VB\670261 lymphocyte_4\NN\5449959 reactivity_5\NN\5652926 to_6\TO\1740 dilevalol_7\NNS\1740 and_8\CC\1740 to_9\TO\1740 serum_10\NN\5397468 containing_11\VBG\2632940 putative_12\JJ\1740 ex_13\FW\10287213 vivo_14\FW\1740 dilevalol_15\JJ\1740 antigens_16\NNS\20090 or_17\CC\3541091 metabolites_18\NNS\20090 in_19\IN\13603305 a_20\DT\13649268 case_21\NN\7283608 of_22\IN\1740 <e1>dilevalol-induced</e1>_23\JJ\1740 <e2>liver_24\NN\5298729 injury</e2>_25\NN\14052046 ._26\.\1740
D007741_D056486 CID patient_0\NN\9898892 :_1\:\1740 a_2\DT\13649268 58-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 a_6\DT\13649268 clinical_7\JJ\1740 diagnosis_8\NN\152018 of_9\IN\1740 <e1>dilevalol-induced</e1>_10\JJ\1740 <e2>liver_11\NN\5298729 injury</e2>_12\NN\14052046 ._13\.\1740
D007741_D056486 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 methodology_3\NN\6166748 used_4\VBD\1156834 allowed_5\VBD\797697 the_6\DT\1740 detection_7\NN\5708432 of_8\IN\1740 lymphocyte_9\NN\5449959 sensitization_10\NN\14531772 to_11\TO\1740 sera_12\NN\5397468 containing_13\VBG\2632940 ex_14\FW\10287213 vivo-prepared_15\JJ\1740 <e1>dilevalol</e1>_16\JJ\1740 antigens_17\NNS\20090 ,_18\,\1740 suggesting_19\VBG\1010118 the_20\DT\1740 involvement_21\NN\1080366 of_22\IN\1740 an_23\DT\6697703 immunologic_24\JJ\1740 mechanism_25\NN\13446390 in_26\IN\13603305 dilevalol-induced_27\JJ\1740 <e2>liver_28\NN\5298729 injury</e2>_29\NN\14052046 ._30\.\1740
D007741_D056486 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 methodology_3\NN\6166748 used_4\VBD\1156834 allowed_5\VBD\797697 the_6\DT\1740 detection_7\NN\5708432 of_8\IN\1740 lymphocyte_9\NN\5449959 sensitization_10\NN\14531772 to_11\TO\1740 sera_12\NN\5397468 containing_13\VBG\2632940 ex_14\FW\10287213 vivo-prepared_15\JJ\1740 dilevalol_16\JJ\1740 antigens_17\NNS\20090 ,_18\,\1740 suggesting_19\VBG\1010118 the_20\DT\1740 involvement_21\NN\1080366 of_22\IN\1740 an_23\DT\6697703 immunologic_24\JJ\1740 mechanism_25\NN\13446390 in_26\IN\13603305 <e1>dilevalol-induced</e1>_27\JJ\1740 <e2>liver_28\NN\5298729 injury</e2>_29\NN\14052046 ._30\.\1740
12760988
D013390_D010149 CID <e2>postoperative_0\JJ\1740 myalgia</e2>_1\NN\14322699 after_2\IN\1740 <e1>succinylcholine</e1>_3\NN\3800001 :_4\:\1740 no_5\DT\7204911 evidence_6\NN\5816287 for_7\IN\1740 an_8\DT\6697703 inflammatory_9\JJ\1740 origin_10\NN\8620061 ._11\.\1740
D013390_D010149 CID a_0\DT\13649268 common_1\JJ\1740 side_2\NN\8630039 effect_3\NN\34213 associated_4\VBN\628491 with_5\IN\1740 <e1>succinylcholine</e1>_6\NN\3800001 is_7\VBZ\836236 <e2>postoperative_8\JJ\1740 myalgia</e2>_9\NN\14322699 ._10\.\1740
D013390_D010149 CID implications_0\NN\5774614 :_1\:\1740 administration_2\NN\1133281 of_3\IN\1740 dexamethasone_4\NN\2721538 before_5\IN\1740 <e1>succinylcholine</e1>_6\NN\3800001 was_7\VBD\836236 not_8\RB\1740 effective_9\JJ\1740 in_10\IN\13603305 decreasing_11\VBG\169651 the_12\DT\1740 incidence_13\NN\13821570 or_14\CC\3541091 the_15\DT\1740 severity_16\NN\5036394 of_17\IN\1740 succinylcholine-induced_18\JJ\1740 <e2>postoperative_19\JJ\1740 myalgia</e2>_20\NN\14322699 ._21\.\1740
D013390_D010149 CID implications_0\NN\5774614 :_1\:\1740 administration_2\NN\1133281 of_3\IN\1740 dexamethasone_4\NN\2721538 before_5\IN\1740 succinylcholine_6\NN\3800001 was_7\VBD\836236 not_8\RB\1740 effective_9\JJ\1740 in_10\IN\13603305 decreasing_11\VBG\169651 the_12\DT\1740 incidence_13\NN\13821570 or_14\CC\3541091 the_15\DT\1740 severity_16\NN\5036394 of_17\IN\1740 <e1>succinylcholine-induced</e1>_18\JJ\1740 <e2>postoperative_19\JJ\1740 myalgia</e2>_20\NN\14322699 ._21\.\1740
D013390_D010149 CID pretreatment_0\NN\1740 with_1\IN\1740 dexamethasone_2\NN\2721538 is_3\VBZ\836236 not_4\RB\1740 justified_5\VBN\1012073 to_6\TO\1740 prevent_7\VB\1740 <e2>postoperative_8\JJ\1740 myalgia</e2>_9\NN\14322699 after_10\IN\1740 <e1>succinylcholine</e1>_11\NN\3800001 ._12\.\1740
D013390_D063806 CID the_0\DT\1740 incidence_1\NN\13821570 and_2\CC\1740 severity_3\NN\5036394 of_4\IN\1740 <e1>succinylcholine-associated</e1>_5\JJ\1740 <e2>myalgia</e2>_6\NN\14322699 was_7\VBD\836236 determined_8\VBN\1645601 in_9\IN\13603305 64_10\CD\1740 patients_11\NNS\9898892 pretreated_12\VBN\1740 with_13\IN\1740 saline_14\NN\14849367 or_15\CC\3541091 dexamethasone_16\NN\2721538 before_17\IN\1740 succinylcholine_18\NN\3800001 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 32_22\CD\1740 for_23\IN\1740 each_24\DT\1740 )_25\-RRB-\1740 ._26\.\1740
D013390_D063806 CID the_0\DT\1740 incidence_1\NN\13821570 and_2\CC\1740 severity_3\NN\5036394 of_4\IN\1740 succinylcholine-associated_5\JJ\1740 <e2>myalgia</e2>_6\NN\14322699 was_7\VBD\836236 determined_8\VBN\1645601 in_9\IN\13603305 64_10\CD\1740 patients_11\NNS\9898892 pretreated_12\VBN\1740 with_13\IN\1740 saline_14\NN\14849367 or_15\CC\3541091 dexamethasone_16\NN\2721538 before_17\IN\1740 <e1>succinylcholine</e1>_18\NN\3800001 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 32_22\CD\1740 for_23\IN\1740 each_24\DT\1740 )_25\-RRB-\1740 ._26\.\1740
D013390_D063806 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 there_3\EX\27167 is_4\VBZ\836236 no_5\DT\7204911 evidence_6\NN\5816287 for_7\IN\1740 an_8\DT\6697703 inflammatory_9\JJ\1740 origin_10\NN\8620061 of_11\IN\1740 <e1>succinylcholine-associated</e1>_12\JJ\1740 <e2>myalgia</e2>_13\NN\14322699 ._14\.\1740
D003907_D063806 NONE the_0\DT\1740 incidence_1\NN\13821570 and_2\CC\1740 severity_3\NN\5036394 of_4\IN\1740 succinylcholine-associated_5\JJ\1740 <e2>myalgia</e2>_6\NN\14322699 was_7\VBD\836236 determined_8\VBN\1645601 in_9\IN\13603305 64_10\CD\1740 patients_11\NNS\9898892 pretreated_12\VBN\1740 with_13\IN\1740 saline_14\NN\14849367 or_15\CC\3541091 <e1>dexamethasone</e1>_16\NN\2721538 before_17\IN\1740 succinylcholine_18\NN\3800001 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 32_22\CD\1740 for_23\IN\1740 each_24\DT\1740 )_25\-RRB-\1740 ._26\.\1740
D003907_D063806 NONE incidence_0\NN\13821570 and_1\CC\1740 severity_2\NN\5036394 of_3\IN\1740 <e2>myalgia</e2>_4\NN\14322699 did_5\VBD\1640855 not_6\RB\1740 differ_7\VB\1740 significantly_8\RB\1740 between_9\IN\1740 the_10\DT\1740 two_11\CD\13741022 groups_12\NNS\2137 :_13\:\1740 15_14\CD\13745420 patients_15\NNS\9898892 in_16\IN\13603305 the_17\DT\1740 <e1>dexamethasone</e1>_18\NN\2721538 group_19\NN\2137 complained_20\VBD\843959 of_21\IN\1740 myalgia_22\NN\14322699 compared_23\VBN\644583 with_24\IN\1740 18_25\CD\13745420 patients_26\NNS\9898892 in_27\IN\13603305 the_28\DT\1740 saline_29\NN\14849367 group_30\NN\2137 ,_31\,\1740 and_32\CC\1740 severe_33\JJ\1740 myalgia_34\NN\14322699 was_35\VBD\836236 reported_36\VBN\831651 by_37\IN\1740 five_38\CD\13741022 patients_39\NNS\9898892 and_40\CC\1740 three_41\CD\13741022 patients_42\NNS\9898892 ,_43\,\1740 respectively_44\RB\1740 (_45\-LRB-\1740 not_46\RB\1740 significant_47\JJ\1740 )_48\-RRB-\1740 ._49\.\1740
D003907_D063806 NONE incidence_0\NN\13821570 and_1\CC\1740 severity_2\NN\5036394 of_3\IN\1740 myalgia_4\NN\14322699 did_5\VBD\1640855 not_6\RB\1740 differ_7\VB\1740 significantly_8\RB\1740 between_9\IN\1740 the_10\DT\1740 two_11\CD\13741022 groups_12\NNS\2137 :_13\:\1740 15_14\CD\13745420 patients_15\NNS\9898892 in_16\IN\13603305 the_17\DT\1740 <e1>dexamethasone</e1>_18\NN\2721538 group_19\NN\2137 complained_20\VBD\843959 of_21\IN\1740 <e2>myalgia</e2>_22\NN\14322699 compared_23\VBN\644583 with_24\IN\1740 18_25\CD\13745420 patients_26\NNS\9898892 in_27\IN\13603305 the_28\DT\1740 saline_29\NN\14849367 group_30\NN\2137 ,_31\,\1740 and_32\CC\1740 severe_33\JJ\1740 myalgia_34\NN\14322699 was_35\VBD\836236 reported_36\VBN\831651 by_37\IN\1740 five_38\CD\13741022 patients_39\NNS\9898892 and_40\CC\1740 three_41\CD\13741022 patients_42\NNS\9898892 ,_43\,\1740 respectively_44\RB\1740 (_45\-LRB-\1740 not_46\RB\1740 significant_47\JJ\1740 )_48\-RRB-\1740 ._49\.\1740
D003907_D063806 NONE incidence_0\NN\13821570 and_1\CC\1740 severity_2\NN\5036394 of_3\IN\1740 myalgia_4\NN\14322699 did_5\VBD\1640855 not_6\RB\1740 differ_7\VB\1740 significantly_8\RB\1740 between_9\IN\1740 the_10\DT\1740 two_11\CD\13741022 groups_12\NNS\2137 :_13\:\1740 15_14\CD\13745420 patients_15\NNS\9898892 in_16\IN\13603305 the_17\DT\1740 <e1>dexamethasone</e1>_18\NN\2721538 group_19\NN\2137 complained_20\VBD\843959 of_21\IN\1740 myalgia_22\NN\14322699 compared_23\VBN\644583 with_24\IN\1740 18_25\CD\13745420 patients_26\NNS\9898892 in_27\IN\13603305 the_28\DT\1740 saline_29\NN\14849367 group_30\NN\2137 ,_31\,\1740 and_32\CC\1740 severe_33\JJ\1740 <e2>myalgia</e2>_34\NN\14322699 was_35\VBD\836236 reported_36\VBN\831651 by_37\IN\1740 five_38\CD\13741022 patients_39\NNS\9898892 and_40\CC\1740 three_41\CD\13741022 patients_42\NNS\9898892 ,_43\,\1740 respectively_44\RB\1740 (_45\-LRB-\1740 not_46\RB\1740 significant_47\JJ\1740 )_48\-RRB-\1740 ._49\.\1740
D003907_D010149 NONE implications_0\NN\5774614 :_1\:\1740 administration_2\NN\1133281 of_3\IN\1740 <e1>dexamethasone</e1>_4\NN\2721538 before_5\IN\1740 succinylcholine_6\NN\3800001 was_7\VBD\836236 not_8\RB\1740 effective_9\JJ\1740 in_10\IN\13603305 decreasing_11\VBG\169651 the_12\DT\1740 incidence_13\NN\13821570 or_14\CC\3541091 the_15\DT\1740 severity_16\NN\5036394 of_17\IN\1740 succinylcholine-induced_18\JJ\1740 <e2>postoperative_19\JJ\1740 myalgia</e2>_20\NN\14322699 ._21\.\1740
D003907_D010149 NONE pretreatment_0\NN\1740 with_1\IN\1740 <e1>dexamethasone</e1>_2\NN\2721538 is_3\VBZ\836236 not_4\RB\1740 justified_5\VBN\1012073 to_6\TO\1740 prevent_7\VB\1740 <e2>postoperative_8\JJ\1740 myalgia</e2>_9\NN\14322699 after_10\IN\1740 succinylcholine_11\NN\3800001 ._12\.\1740
11827497
D006493_D013921 CID delayed-onset_0\JJ\1740 <e1>heparin-induced</e1>_1\JJ\1740 <e2>thrombocytopenia</e2>_2\NN\14189204 ._3\.\1740
D006493_D013921 CID background_0\NN\4921011 :_1\:\1740 <e1>heparin-induced</e1>_2\JJ\1740 <e2>thrombocytopenia</e2>_3\NN\14189204 presents_4\VBZ\2137132 5_5\CD\13741022 to_6\TO\1740 12_7\CD\13745420 days_8\NNS\15140892 after_9\IN\1740 heparin_10\NN\2718259 exposure_11\NN\5042871 ,_12\,\1740 with_13\IN\1740 or_14\CC\3541091 without_15\IN\1740 arterial_16\JJ\1740 or_17\CC\3541091 venous_18\JJ\1740 thromboemboli_19\NN\1740 ._20\.\1740
D006493_D013921 CID background_0\NN\4921011 :_1\:\1740 heparin-induced_2\JJ\1740 <e2>thrombocytopenia</e2>_3\NN\14189204 presents_4\VBZ\2137132 5_5\CD\13741022 to_6\TO\1740 12_7\CD\13745420 days_8\NNS\15140892 after_9\IN\1740 <e1>heparin</e1>_10\NN\2718259 exposure_11\NN\5042871 ,_12\,\1740 with_13\IN\1740 or_14\CC\3541091 without_15\IN\1740 arterial_16\JJ\1740 or_17\CC\3541091 venous_18\JJ\1740 thromboemboli_19\NN\1740 ._20\.\1740
D006493_D013921 CID delayed_0\VBN\439958 recognition_1\NN\13932421 and_2\CC\1740 treatment_3\NN\654885 of_4\IN\1740 <e1>heparin-induced</e1>_5\JJ\1740 <e2>thrombocytopenia</e2>_6\NN\14189204 contribute_7\VBP\126264 to_8\TO\1740 poor_9\JJ\1740 patient_10\NN\9898892 outcomes_11\NNS\7291312 ._12\.\1740
D006493_D013921 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 and_4\CC\1740 increase_5\VB\169651 awareness_6\NN\5804793 of_7\IN\1740 a_8\DT\13649268 clinical_9\JJ\1740 scenario_10\NN\7009946 in_11\IN\13603305 which_12\WDT\1740 the_13\DT\1740 onset_14\NN\7325190 or_15\CC\3541091 manifestations_16\NNS\7321772 of_17\IN\1740 <e1>heparin-induced</e1>_18\JJ\1740 <e2>thrombocytopenia</e2>_19\NN\14189204 are_20\VBP\836236 delayed_21\VBN\439958 ._22\.\1740
D006493_D013921 CID patients_0\NNS\9898892 :_1\:\1740 14_2\CD\13745420 patients_3\NNS\9898892 seen_4\VBN\2106506 over_5\IN\5867413 a_6\DT\13649268 3-year_7\JJ\1740 period_8\NN\13575869 in_9\IN\13603305 whom_10\WP\1740 <e1>heparin-induced</e1>_11\JJ\1740 <e2>thrombocytopenia</e2>_12\NN\14189204 became_13\VBD\146138 apparent_14\JJ\1740 on_15\IN\1740 delayed_16\VBN\439958 presentation_17\NN\1027379 with_18\IN\1740 thromboembolic_19\JJ\1740 complications_20\NNS\1073995 ._21\.\1740
D006493_D013921 CID results_0\NNS\34213 :_1\:\1740 patients_2\NNS\9898892 went_3\VBD\2367363 home_4\RB\1740 after_5\IN\1740 hospitalizations_6\NNS\15113229 that_7\WDT\1740 had_8\VBD\2108377 included_9\VBN\690614 <e1>heparin</e1>_10\NN\2718259 exposure_11\NN\5042871 --_12\:\1740 in_13\IN\13603305 most_14\JJS\1740 cases_15\NNS\7283608 ,_16\,\1740 with_17\IN\1740 no_18\DT\7204911 <e2>thrombocytopenia</e2>_19\NN\14189204 recognized_20\VBD\686447 --_21\:\1740 only_22\RB\1740 to_23\TO\1740 return_24\VB\1835496 to_25\IN\1740 the_26\DT\1740 hospital_27\NN\3739518 (_28\-LRB-\1740 median_29\JJ\1740 ,_30\,\1740 day_31\NN\15154774 14_32\CD\13745420 )_33\-RRB-\1740 with_34\IN\1740 thromboembolic_35\NN\1740 complications_36\NNS\1073995 ._37\.\1740
D006493_D013921 CID conclusions_0\NNS\5837957 :_1\:\1740 delayed-onset_2\JJ\1740 <e1>heparin-induced</e1>_3\JJ\1740 <e2>thrombocytopenia</e2>_4\NN\14189204 is_5\VBZ\836236 increasingly_6\RB\1740 being_7\VBG\836236 recognized_8\VBN\686447 ._9\.\1740
D006493_D013921 CID to_0\TO\1740 avoid_1\VB\2452885 disastrous_2\JJ\1740 outcomes_3\NNS\7291312 ,_4\,\1740 physicians_5\NNS\10305802 must_6\MD\9367203 consider_7\VB\689344 <e1>heparin-induced</e1>_8\JJ\1740 <e2>thrombocytopenia</e2>_9\NN\14189204 whenever_10\WRB\1740 a_11\DT\13649268 recently_12\RB\1740 hospitalized_13\VBN\2348568 patient_14\NN\9898892 returns_15\NNS\6479665 with_16\IN\1740 thromboembolism_17\NN\14100769 ;_18\:\1740 therapy_19\NN\657604 with_20\IN\1740 alternative_21\JJ\1740 anticoagulants_22\NNS\3740161 ,_23\,\1740 not_24\RB\1740 heparin_25\NN\2718259 ,_26\,\1740 should_27\MD\1740 be_28\VB\836236 initiated_29\VBN\1617192 ._30\.\1740
D006493_D013921 CID to_0\TO\1740 avoid_1\VB\2452885 disastrous_2\JJ\1740 outcomes_3\NNS\7291312 ,_4\,\1740 physicians_5\NNS\10305802 must_6\MD\9367203 consider_7\VB\689344 heparin-induced_8\JJ\1740 <e2>thrombocytopenia</e2>_9\NN\14189204 whenever_10\WRB\1740 a_11\DT\13649268 recently_12\RB\1740 hospitalized_13\VBN\2348568 patient_14\NN\9898892 returns_15\NNS\6479665 with_16\IN\1740 thromboembolism_17\NN\14100769 ;_18\:\1740 therapy_19\NN\657604 with_20\IN\1740 alternative_21\JJ\1740 anticoagulants_22\NNS\3740161 ,_23\,\1740 not_24\RB\1740 <e1>heparin</e1>_25\NN\2718259 ,_26\,\1740 should_27\MD\1740 be_28\VB\836236 initiated_29\VBN\1617192 ._30\.\1740
D006493_D001157 CID background_0\NN\4921011 :_1\:\1740 <e1>heparin-induced</e1>_2\JJ\1740 thrombocytopenia_3\NN\14189204 presents_4\VBZ\2137132 5_5\CD\13741022 to_6\TO\1740 12_7\CD\13745420 days_8\NNS\15140892 after_9\IN\1740 heparin_10\NN\2718259 exposure_11\NN\5042871 ,_12\,\1740 with_13\IN\1740 or_14\CC\3541091 without_15\IN\1740 <e2>arterial_16\JJ\1740 or_17\CC\3541091 venous_18\JJ\1740 thromboemboli</e2>_19\NN\1740 ._20\.\1740
D006493_D001157 CID background_0\NN\4921011 :_1\:\1740 heparin-induced_2\JJ\1740 thrombocytopenia_3\NN\14189204 presents_4\VBZ\2137132 5_5\CD\13741022 to_6\TO\1740 12_7\CD\13745420 days_8\NNS\15140892 after_9\IN\1740 <e1>heparin</e1>_10\NN\2718259 exposure_11\NN\5042871 ,_12\,\1740 with_13\IN\1740 or_14\CC\3541091 without_15\IN\1740 <e2>arterial_16\JJ\1740 or_17\CC\3541091 venous_18\JJ\1740 thromboemboli</e2>_19\NN\1740 ._20\.\1740
D006493_D054556 CID background_0\NN\4921011 :_1\:\1740 <e1>heparin-induced</e1>_2\JJ\1740 thrombocytopenia_3\NN\14189204 presents_4\VBZ\2137132 5_5\CD\13741022 to_6\TO\1740 12_7\CD\13745420 days_8\NNS\15140892 after_9\IN\1740 heparin_10\NN\2718259 exposure_11\NN\5042871 ,_12\,\1740 with_13\IN\1740 or_14\CC\3541091 without_15\IN\1740 <e2>arterial_16\JJ\1740 or_17\CC\3541091 venous_18\JJ\1740 thromboemboli</e2>_19\NN\1740 ._20\.\1740
D006493_D054556 CID background_0\NN\4921011 :_1\:\1740 heparin-induced_2\JJ\1740 thrombocytopenia_3\NN\14189204 presents_4\VBZ\2137132 5_5\CD\13741022 to_6\TO\1740 12_7\CD\13745420 days_8\NNS\15140892 after_9\IN\1740 <e1>heparin</e1>_10\NN\2718259 exposure_11\NN\5042871 ,_12\,\1740 with_13\IN\1740 or_14\CC\3541091 without_15\IN\1740 <e2>arterial_16\JJ\1740 or_17\CC\3541091 venous_18\JJ\1740 thromboemboli</e2>_19\NN\1740 ._20\.\1740
D006493_D013923 NONE patients_0\NNS\9898892 :_1\:\1740 14_2\CD\13745420 patients_3\NNS\9898892 seen_4\VBN\2106506 over_5\IN\5867413 a_6\DT\13649268 3-year_7\JJ\1740 period_8\NN\13575869 in_9\IN\13603305 whom_10\WP\1740 <e1>heparin-induced</e1>_11\JJ\1740 thrombocytopenia_12\NN\14189204 became_13\VBD\146138 apparent_14\JJ\1740 on_15\IN\1740 delayed_16\VBN\439958 presentation_17\NN\1027379 with_18\IN\1740 <e2>thromboembolic</e2>_19\JJ\1740 complications_20\NNS\1073995 ._21\.\1740
D006493_D013923 NONE measurements_0\NNS\407535 :_1\:\1740 platelet_2\NN\5432736 counts_3\NNS\13582013 ,_4\,\1740 onset_5\NN\7325190 of_6\IN\1740 objectively_7\RB\1740 determined_8\JJ\1740 <e2>thromboembolism</e2>_9\NN\14100769 ,_10\,\1740 results_11\NNS\34213 of_12\IN\1740 <e1>heparin-induced</e1>_13\JJ\1740 platelet_14\NN\5432736 factor_15\NN\7326557 4_16\CD\13741022 antibody_17\NN\14728724 tests_18\NNS\5798043 ,_19\,\1740 and_20\CC\1740 outcomes_21\NNS\7291312 ._22\.\1740
D006493_D013923 NONE results_0\NNS\34213 :_1\:\1740 patients_2\NNS\9898892 went_3\VBD\2367363 home_4\RB\1740 after_5\IN\1740 hospitalizations_6\NNS\15113229 that_7\WDT\1740 had_8\VBD\2108377 included_9\VBN\690614 <e1>heparin</e1>_10\NN\2718259 exposure_11\NN\5042871 --_12\:\1740 in_13\IN\13603305 most_14\JJS\1740 cases_15\NNS\7283608 ,_16\,\1740 with_17\IN\1740 no_18\DT\7204911 thrombocytopenia_19\NN\14189204 recognized_20\VBD\686447 --_21\:\1740 only_22\RB\1740 to_23\TO\1740 return_24\VB\1835496 to_25\IN\1740 the_26\DT\1740 hospital_27\NN\3739518 (_28\-LRB-\1740 median_29\JJ\1740 ,_30\,\1740 day_31\NN\15154774 14_32\CD\13745420 )_33\-RRB-\1740 with_34\IN\1740 <e2>thromboembolic</e2>_35\NN\1740 complications_36\NNS\1073995 ._37\.\1740
D006493_D013923 NONE to_0\TO\1740 avoid_1\VB\2452885 disastrous_2\JJ\1740 outcomes_3\NNS\7291312 ,_4\,\1740 physicians_5\NNS\10305802 must_6\MD\9367203 consider_7\VB\689344 <e1>heparin-induced</e1>_8\JJ\1740 thrombocytopenia_9\NN\14189204 whenever_10\WRB\1740 a_11\DT\13649268 recently_12\RB\1740 hospitalized_13\VBN\2348568 patient_14\NN\9898892 returns_15\NNS\6479665 with_16\IN\1740 <e2>thromboembolism</e2>_17\NN\14100769 ;_18\:\1740 therapy_19\NN\657604 with_20\IN\1740 alternative_21\JJ\1740 anticoagulants_22\NNS\3740161 ,_23\,\1740 not_24\RB\1740 heparin_25\NN\2718259 ,_26\,\1740 should_27\MD\1740 be_28\VB\836236 initiated_29\VBN\1617192 ._30\.\1740
D006493_D013923 NONE to_0\TO\1740 avoid_1\VB\2452885 disastrous_2\JJ\1740 outcomes_3\NNS\7291312 ,_4\,\1740 physicians_5\NNS\10305802 must_6\MD\9367203 consider_7\VB\689344 heparin-induced_8\JJ\1740 thrombocytopenia_9\NN\14189204 whenever_10\WRB\1740 a_11\DT\13649268 recently_12\RB\1740 hospitalized_13\VBN\2348568 patient_14\NN\9898892 returns_15\NNS\6479665 with_16\IN\1740 <e2>thromboembolism</e2>_17\NN\14100769 ;_18\:\1740 therapy_19\NN\657604 with_20\IN\1740 alternative_21\JJ\1740 anticoagulants_22\NNS\3740161 ,_23\,\1740 not_24\RB\1740 <e1>heparin</e1>_25\NN\2718259 ,_26\,\1740 should_27\MD\1740 be_28\VB\836236 initiated_29\VBN\1617192 ._30\.\1740
1355091
D011224_D007024 CID <e2>orthostatic_0\JJ\1740 hypotension</e2>_1\NN\14057371 occurs_2\VBZ\2623529 following_3\VBG\1835496 alpha_4\NN\6828818 2-adrenoceptor_5\JJ\1740 blockade_6\NN\952963 in_7\IN\13603305 chronic_8\JJ\1740 <e1>prazosin-pretreated</e1>_9\JJ\1740 conscious_10\JJ\1740 spontaneously_11\JJ\1740 hypertensive_12\JJ\1740 rats_13\NNS\2329401 ._14\.\1740
D011224_D007024 CID however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 head-up_3\JJ\1740 tilt_4\NN\788973 induced_5\VBN\1627355 <e2>orthostatic_6\JJ\1740 hypotension</e2>_7\NN\14057371 in_8\IN\13603305 the_9\DT\1740 shr_10\NN\1740 treated_11\VBN\2376958 with_12\IN\1740 <e1>prazosin</e1>_13\NN\2698769 (_14\-LRB-\1740 -16_15\CD\1740 %_16\NN\1740 map_17\NN\4076846 ,_18\,\1740 n_19\NN\14622893 =_20\JJ\1740 6_21\CD\13741022 )_22\-RRB-\1740 ,_23\,\1740 but_24\CC\1740 not_25\RB\1740 in_26\IN\13603305 the_27\DT\1740 shr_28\NN\1740 treated_29\VBN\2376958 with_30\IN\1740 rauwolscine_31\NN\1740 (_32\-LRB-\1740 less_33\JJR\1740 than_34\IN\1740 +_35\CC\1740 2_36\CD\13741022 %_37\NN\1740 map_38\NN\4076846 ,_39\,\1740 n_40\NN\14622893 =_41\JJ\1740 6_42\CD\13741022 )_43\-RRB-\1740 ._44\.\1740
D011224_D007024 CID head-up_0\NN\1740 tilts_1\VBZ\2035919 in_2\IN\13603305 these_3\DT\1740 rats_4\NNS\2329401 did_5\VBD\1640855 not_6\RB\1740 produce_7\VB\1617192 <e2>orthostatic_8\JJ\1740 hypotension</e2>_9\NN\14057371 when_10\WRB\1740 performed_11\VBN\2367363 either_12\CC\1740 prior_13\RB\1740 to_14\TO\1740 or_15\CC\3541091 after_16\IN\1740 acute_17\JJ\1740 dosing_18\NN\1740 of_19\IN\1740 <e1>prazosin</e1>_20\NN\2698769 (_21\-LRB-\1740 0.1_22\CD\1740 mg_23\NN\13717155 kg-1_24\NN\1740 i.p._25\RB\1740 )_26\-RRB-\1740 ._27\.\1740
D011224_D006973 NONE orthostatic_0\JJ\1740 hypotension_1\NN\14057371 occurs_2\VBZ\2623529 following_3\VBG\1835496 alpha_4\NN\6828818 2-adrenoceptor_5\JJ\1740 blockade_6\NN\952963 in_7\IN\13603305 chronic_8\JJ\1740 <e1>prazosin-pretreated</e1>_9\JJ\1740 conscious_10\JJ\1740 spontaneously_11\JJ\1740 <e2>hypertensive</e2>_12\JJ\1740 rats_13\NNS\2329401 ._14\.\1740
D011224_D006973 NONE 1_0\LS\13741022 ._1\.\1740 studies_2\NNS\635850 were_3\VBD\836236 performed_4\VBN\2367363 to_5\TO\1740 evaluate_6\VB\670261 whether_7\IN\1740 chronic_8\JJ\1740 <e1>prazosin</e1>_9\NN\2698769 treatment_10\NN\654885 alters_11\VBZ\126264 the_12\DT\1740 alpha_13\NN\6828818 2-adrenoceptor_14\JJ\1740 function_15\NN\13783581 for_16\IN\1740 orthostatic_17\JJ\1740 control_18\NN\5190804 of_19\IN\1740 arterial_20\JJ\1740 blood_21\NN\5397468 pressure_22\NN\11419404 in_23\IN\13603305 conscious_24\JJ\1740 spontaneously_25\JJ\1740 <e2>hypertensive</e2>_26\JJ\1740 rats_27\NNS\2329401 (_28\-LRB-\1740 shr_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D015016_D007024 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 head-up_3\JJ\1740 tilt_4\NN\788973 induced_5\VBN\1627355 <e2>orthostatic_6\JJ\1740 hypotension</e2>_7\NN\14057371 in_8\IN\13603305 the_9\DT\1740 shr_10\NN\1740 treated_11\VBN\2376958 with_12\IN\1740 prazosin_13\NN\2698769 (_14\-LRB-\1740 -16_15\CD\1740 %_16\NN\1740 map_17\NN\4076846 ,_18\,\1740 n_19\NN\14622893 =_20\JJ\1740 6_21\CD\13741022 )_22\-RRB-\1740 ,_23\,\1740 but_24\CC\1740 not_25\RB\1740 in_26\IN\13603305 the_27\DT\1740 shr_28\NN\1740 treated_29\VBN\2376958 with_30\IN\1740 <e1>rauwolscine</e1>_31\NN\1740 (_32\-LRB-\1740 less_33\JJR\1740 than_34\IN\1740 +_35\CC\1740 2_36\CD\13741022 %_37\NN\1740 map_38\NN\4076846 ,_39\,\1740 n_40\NN\14622893 =_41\JJ\1740 6_42\CD\13741022 )_43\-RRB-\1740 ._44\.\1740
C014282_D001919 CID the_0\DT\1740 pressor_1\NN\9190918 responses_2\NNS\11410625 and_3\CC\1740 <e2>bradycardia</e2>_4\NN\14110674 to_5\TO\1740 the_6\DT\1740 alpha_7\NN\6828818 1-agonist_8\JJ\1740 <e1>cirazoline</e1>_9\NN\1740 (_10\-LRB-\1740 0.6_11\CD\1740 and_12\CC\1740 2_13\CD\13741022 micrograms_14\NNS\13717155 kg-1_15\NN\1740 i.v._16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 the_19\DT\1740 alpha_20\NN\6828818 2-agonist_21\JJ\1740 abbott-53693_22\NN\1740 (_23\-LRB-\1740 1_24\CD\13741022 and_25\CC\1740 3_26\CD\13741022 micrograms_27\NNS\13717155 kg-1_28\NN\1740 i.v._29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 and_32\CC\1740 noradrenaline_33\NN\14807929 (_34\-LRB-\1740 0.1_35\CD\1740 and_36\CC\1740 1.0_37\CD\1740 micrograms_38\NNS\13717155 kg-1_39\NN\1740 i.v._40\NN\1740 )_41\-RRB-\1740 were_42\VBD\836236 determined_43\VBN\1645601 in_44\IN\13603305 conscious_45\JJ\1740 shr_46\NN\1740 with_47\IN\1740 and_48\CC\1740 without_49\IN\1740 chronic_50\JJ\1740 prazosin_51\NN\2698769 pretreatment_52\NN\1740 ._53\.\1740
C014282_D001919 CID both_0\CC\1740 the_1\DT\1740 pressor_2\NN\9190918 and_3\CC\1740 <e2>bradycardia</e2>_4\NN\14110674 effects_5\NNS\13245626 of_6\IN\1740 <e1>cirazoline</e1>_7\NN\1740 were_8\VBD\836236 abolished_9\VBN\1740 in_10\IN\13603305 chronic_11\JJ\1740 prazosin_12\NN\2698769 treated_13\VBN\2376958 shr_14\NN\1740 (_15\-LRB-\1740 n_16\NN\14622893 =_17\JJ\1740 4_18\CD\13741022 )_19\-RRB-\1740 as_20\IN\14622893 compared_21\VBN\644583 to_22\TO\1740 the_23\DT\1740 untreated_24\JJ\1740 shr_25\NN\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 4_29\CD\13741022 )_30\-RRB-\1740 ._31\.\1740
C056299_D001919 CID the_0\DT\1740 pressor_1\NN\9190918 responses_2\NNS\11410625 and_3\CC\1740 <e2>bradycardia</e2>_4\NN\14110674 to_5\TO\1740 the_6\DT\1740 alpha_7\NN\6828818 1-agonist_8\JJ\1740 cirazoline_9\NN\1740 (_10\-LRB-\1740 0.6_11\CD\1740 and_12\CC\1740 2_13\CD\13741022 micrograms_14\NNS\13717155 kg-1_15\NN\1740 i.v._16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 the_19\DT\1740 alpha_20\NN\6828818 2-agonist_21\JJ\1740 <e1>abbott-53693</e1>_22\NN\1740 (_23\-LRB-\1740 1_24\CD\13741022 and_25\CC\1740 3_26\CD\13741022 micrograms_27\NNS\13717155 kg-1_28\NN\1740 i.v._29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 and_32\CC\1740 noradrenaline_33\NN\14807929 (_34\-LRB-\1740 0.1_35\CD\1740 and_36\CC\1740 1.0_37\CD\1740 micrograms_38\NNS\13717155 kg-1_39\NN\1740 i.v._40\NN\1740 )_41\-RRB-\1740 were_42\VBD\836236 determined_43\VBN\1645601 in_44\IN\13603305 conscious_45\JJ\1740 shr_46\NN\1740 with_47\IN\1740 and_48\CC\1740 without_49\IN\1740 chronic_50\JJ\1740 prazosin_51\NN\2698769 pretreatment_52\NN\1740 ._53\.\1740
C056299_D001919 CID on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 the_5\DT\1740 pressor_6\NN\9190918 effects_7\NNS\13245626 of_8\IN\1740 <e1>abbott-53693</e1>_9\NN\1740 were_10\VBD\836236 similar_11\JJ\1740 in_12\IN\13603305 both_13\DT\1740 groups_14\NNS\2137 of_15\IN\1740 shr_16\NN\1740 ,_17\,\1740 but_18\CC\1740 the_19\DT\1740 accompanying_20\VBG\1835496 <e2>bradycardia</e2>_21\NN\14110674 was_22\VBD\836236 greater_23\JJR\1740 in_24\IN\13603305 shr_25\NN\1740 with_26\IN\1740 chronic_27\JJ\1740 prazosin_28\NN\2698769 treatment_29\NN\654885 than_30\IN\1740 without_31\IN\1740 such_32\JJ\1740 treatment_33\NN\654885 ._34\.\1740
D009638_D001919 CID the_0\DT\1740 pressor_1\NN\9190918 responses_2\NNS\11410625 and_3\CC\1740 <e2>bradycardia</e2>_4\NN\14110674 to_5\TO\1740 the_6\DT\1740 alpha_7\NN\6828818 1-agonist_8\JJ\1740 cirazoline_9\NN\1740 (_10\-LRB-\1740 0.6_11\CD\1740 and_12\CC\1740 2_13\CD\13741022 micrograms_14\NNS\13717155 kg-1_15\NN\1740 i.v._16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 the_19\DT\1740 alpha_20\NN\6828818 2-agonist_21\JJ\1740 abbott-53693_22\NN\1740 (_23\-LRB-\1740 1_24\CD\13741022 and_25\CC\1740 3_26\CD\13741022 micrograms_27\NNS\13717155 kg-1_28\NN\1740 i.v._29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 and_32\CC\1740 <e1>noradrenaline</e1>_33\NN\14807929 (_34\-LRB-\1740 0.1_35\CD\1740 and_36\CC\1740 1.0_37\CD\1740 micrograms_38\NNS\13717155 kg-1_39\NN\1740 i.v._40\NN\1740 )_41\-RRB-\1740 were_42\VBD\836236 determined_43\VBN\1645601 in_44\IN\13603305 conscious_45\JJ\1740 shr_46\NN\1740 with_47\IN\1740 and_48\CC\1740 without_49\IN\1740 chronic_50\JJ\1740 prazosin_51\NN\2698769 pretreatment_52\NN\1740 ._53\.\1740
D009638_D001919 CID furthermore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 <e2>bradycardia</e2>_3\NN\14110674 that_4\WDT\1740 accompanied_5\VBD\1835496 the_6\DT\1740 <e1>noradrenaline-induced</e1>_7\JJ\1740 pressor_8\NN\9190918 effect_9\NN\34213 in_10\IN\13603305 shr_11\NN\1740 was_12\VBD\836236 similar_13\JJ\1740 with_14\IN\1740 and_15\CC\1740 without_16\IN\1740 chronic_17\JJ\1740 prazosin_18\NN\2698769 treatment_19\NN\654885 despite_20\IN\7501545 a_21\DT\13649268 47_22\CD\1740 -_23\SYM\1740 71_24\CD\1740 %_25\NN\1740 reduction_26\NN\351485 of_27\IN\1740 the_28\DT\1740 pressor_29\NN\9190918 effect_30\NN\34213 in_31\IN\13603305 chronic_32\JJ\1740 alpha_33\NN\6828818 1-receptor_34\NN\1740 blocked_35\VBD\1476483 shr.(abstract_36\NN\1740 truncated_37\VBN\2257767 at_38\IN\14622893 400_39\CD\1740 words_40\NNS\7109196 )_41\-RRB-\1740
D011224_D001919 NONE the_0\DT\1740 pressor_1\NN\9190918 responses_2\NNS\11410625 and_3\CC\1740 <e2>bradycardia</e2>_4\NN\14110674 to_5\TO\1740 the_6\DT\1740 alpha_7\NN\6828818 1-agonist_8\JJ\1740 cirazoline_9\NN\1740 (_10\-LRB-\1740 0.6_11\CD\1740 and_12\CC\1740 2_13\CD\13741022 micrograms_14\NNS\13717155 kg-1_15\NN\1740 i.v._16\NN\1740 )_17\-RRB-\1740 ,_18\,\1740 the_19\DT\1740 alpha_20\NN\6828818 2-agonist_21\JJ\1740 abbott-53693_22\NN\1740 (_23\-LRB-\1740 1_24\CD\13741022 and_25\CC\1740 3_26\CD\13741022 micrograms_27\NNS\13717155 kg-1_28\NN\1740 i.v._29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 and_32\CC\1740 noradrenaline_33\NN\14807929 (_34\-LRB-\1740 0.1_35\CD\1740 and_36\CC\1740 1.0_37\CD\1740 micrograms_38\NNS\13717155 kg-1_39\NN\1740 i.v._40\NN\1740 )_41\-RRB-\1740 were_42\VBD\836236 determined_43\VBN\1645601 in_44\IN\13603305 conscious_45\JJ\1740 shr_46\NN\1740 with_47\IN\1740 and_48\CC\1740 without_49\IN\1740 chronic_50\JJ\1740 <e1>prazosin</e1>_51\NN\2698769 pretreatment_52\NN\1740 ._53\.\1740
D011224_D001919 NONE both_0\CC\1740 the_1\DT\1740 pressor_2\NN\9190918 and_3\CC\1740 <e2>bradycardia</e2>_4\NN\14110674 effects_5\NNS\13245626 of_6\IN\1740 cirazoline_7\NN\1740 were_8\VBD\836236 abolished_9\VBN\1740 in_10\IN\13603305 chronic_11\JJ\1740 <e1>prazosin</e1>_12\NN\2698769 treated_13\VBN\2376958 shr_14\NN\1740 (_15\-LRB-\1740 n_16\NN\14622893 =_17\JJ\1740 4_18\CD\13741022 )_19\-RRB-\1740 as_20\IN\14622893 compared_21\VBN\644583 to_22\TO\1740 the_23\DT\1740 untreated_24\JJ\1740 shr_25\NN\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 4_29\CD\13741022 )_30\-RRB-\1740 ._31\.\1740
D011224_D001919 NONE on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 the_5\DT\1740 pressor_6\NN\9190918 effects_7\NNS\13245626 of_8\IN\1740 abbott-53693_9\NN\1740 were_10\VBD\836236 similar_11\JJ\1740 in_12\IN\13603305 both_13\DT\1740 groups_14\NNS\2137 of_15\IN\1740 shr_16\NN\1740 ,_17\,\1740 but_18\CC\1740 the_19\DT\1740 accompanying_20\VBG\1835496 <e2>bradycardia</e2>_21\NN\14110674 was_22\VBD\836236 greater_23\JJR\1740 in_24\IN\13603305 shr_25\NN\1740 with_26\IN\1740 chronic_27\JJ\1740 <e1>prazosin</e1>_28\NN\2698769 treatment_29\NN\654885 than_30\IN\1740 without_31\IN\1740 such_32\JJ\1740 treatment_33\NN\654885 ._34\.\1740
D011224_D001919 NONE furthermore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 <e2>bradycardia</e2>_3\NN\14110674 that_4\WDT\1740 accompanied_5\VBD\1835496 the_6\DT\1740 noradrenaline-induced_7\JJ\1740 pressor_8\NN\9190918 effect_9\NN\34213 in_10\IN\13603305 shr_11\NN\1740 was_12\VBD\836236 similar_13\JJ\1740 with_14\IN\1740 and_15\CC\1740 without_16\IN\1740 chronic_17\JJ\1740 <e1>prazosin</e1>_18\NN\2698769 treatment_19\NN\654885 despite_20\IN\7501545 a_21\DT\13649268 47_22\CD\1740 -_23\SYM\1740 71_24\CD\1740 %_25\NN\1740 reduction_26\NN\351485 of_27\IN\1740 the_28\DT\1740 pressor_29\NN\9190918 effect_30\NN\34213 in_31\IN\13603305 chronic_32\JJ\1740 alpha_33\NN\6828818 1-receptor_34\NN\1740 blocked_35\VBD\1476483 shr.(abstract_36\NN\1740 truncated_37\VBN\2257767 at_38\IN\14622893 400_39\CD\1740 words_40\NNS\7109196 )_41\-RRB-\1740
15579441
D011692_D000860 CID with_0\IN\1740 this_1\DT\1740 model_2\NN\5888929 ,_3\,\1740 we_4\PRP\1740 were_5\VBD\836236 able_6\JJ\1740 to_7\TO\1740 identify_8\VB\699815 diffuse_9\JJ\1740 cortical_10\JJ\1740 <e2>hypoxia</e2>_11\NN\14035298 in_12\IN\13603305 the_13\DT\1740 <e1>puromycin_14\NN\1740 aminonucleoside-induced</e1>_15\JJ\1740 nephrotic_16\JJ\1740 syndrome_17\NN\5870365 and_18\CC\1740 focal_19\JJ\1740 and_20\CC\1740 segmental_21\JJ\1740 hypoxia_22\NN\14035298 in_23\IN\13603305 the_24\DT\1740 remnant_25\JJ\1740 kidney_26\NN\5333259 model_27\NN\5888929 ._28\.\1740
D011692_D000860 CID with_0\IN\1740 this_1\DT\1740 model_2\NN\5888929 ,_3\,\1740 we_4\PRP\1740 were_5\VBD\836236 able_6\JJ\1740 to_7\TO\1740 identify_8\VB\699815 diffuse_9\JJ\1740 cortical_10\JJ\1740 hypoxia_11\NN\14035298 in_12\IN\13603305 the_13\DT\1740 <e1>puromycin_14\NN\1740 aminonucleoside-induced</e1>_15\JJ\1740 nephrotic_16\JJ\1740 syndrome_17\NN\5870365 and_18\CC\1740 focal_19\JJ\1740 and_20\CC\1740 segmental_21\JJ\1740 <e2>hypoxia</e2>_22\NN\14035298 in_23\IN\13603305 the_24\DT\1740 remnant_25\JJ\1740 kidney_26\NN\5333259 model_27\NN\5888929 ._28\.\1740
D011692_D000860 CID expression_0\NN\4679549 of_1\IN\1740 the_2\DT\1740 <e2>hypoxia-responsive</e2>_3\JJ\1740 transgene_4\NN\5436752 increased_5\VBD\169651 throughout_6\IN\1740 the_7\DT\1740 observation_8\NN\996969 period_9\NN\13575869 ,_10\,\1740 reaching_11\VBG\2005948 2.2-fold_12\RB\1740 at_13\IN\14622893 2_14\CD\13741022 weeks_15\NNS\15113229 in_16\IN\13603305 the_17\DT\1740 <e1>puromycin_18\NN\1740 aminonucleoside</e1>_19\NN\1740 model_20\NN\5888929 and_21\CC\1740 2.6-fold_22\JJ\1740 at_23\IN\14622893 4_24\CD\13741022 weeks_25\NNS\15113229 in_26\IN\13603305 the_27\DT\1740 remnant_28\JJ\1740 kidney_29\NN\5333259 model_30\NN\5888929 ,_31\,\1740 whereas_32\IN\1740 that_33\DT\1740 of_34\IN\1740 vascular_35\JJ\1740 endothelial_36\JJ\1740 growth_37\NN\13526110 factor_38\NN\7326557 showed_39\VBD\2137132 a_40\DT\13649268 mild_41\JJ\1740 decrease_42\NN\7296428 ,_43\,\1740 reflecting_44\VBG\923793 distinct_45\JJ\1740 behaviors_46\NNS\407535 of_47\IN\1740 the_48\DT\1740 two_49\CD\13741022 genes_50\NNS\8459252 ._51\.\1740
D011692_D009404 CID with_0\IN\1740 this_1\DT\1740 model_2\NN\5888929 ,_3\,\1740 we_4\PRP\1740 were_5\VBD\836236 able_6\JJ\1740 to_7\TO\1740 identify_8\VB\699815 diffuse_9\JJ\1740 cortical_10\JJ\1740 hypoxia_11\NN\14035298 in_12\IN\13603305 the_13\DT\1740 <e1>puromycin_14\NN\1740 aminonucleoside-induced</e1>_15\JJ\1740 <e2>nephrotic_16\JJ\1740 syndrome</e2>_17\NN\5870365 and_18\CC\1740 focal_19\JJ\1740 and_20\CC\1740 segmental_21\JJ\1740 hypoxia_22\NN\14035298 in_23\IN\13603305 the_24\DT\1740 remnant_25\JJ\1740 kidney_26\NN\5333259 model_27\NN\5888929 ._28\.\1740
8988571
D003042_D003693 CID fatal_0\JJ\1740 excited_1\JJ\1740 <e2>delirium</e2>_2\NN\14391660 following_3\VBG\1835496 <e1>cocaine</e1>_4\NN\3492717 use_5\NN\407535 :_6\:\1740 epidemiologic_7\JJ\1740 findings_8\NNS\7951464 provide_9\VBP\2199590 new_10\JJ\1740 evidence_11\NN\5816287 for_12\IN\1740 mechanisms_13\NNS\13446390 of_14\IN\1740 cocaine_15\NN\3492717 toxicity_16\NN\13576101 ._17\.\1740
D003042_D003693 CID fatal_0\JJ\1740 excited_1\JJ\1740 <e2>delirium</e2>_2\NN\14391660 following_3\VBG\1835496 cocaine_4\NN\3492717 use_5\NN\407535 :_6\:\1740 epidemiologic_7\JJ\1740 findings_8\NNS\7951464 provide_9\VBP\2199590 new_10\JJ\1740 evidence_11\NN\5816287 for_12\IN\1740 mechanisms_13\NNS\13446390 of_14\IN\1740 <e1>cocaine</e1>_15\NN\3492717 toxicity_16\NN\13576101 ._17\.\1740
D003042_D003693 CID we_0\PRP\1740 describe_1\VBP\1001294 an_2\DT\6697703 outbreak_3\NN\7283608 of_4\IN\1740 deaths_5\NNS\7296428 from_6\IN\1740 <e1>cocaine-induced</e1>_7\JJ\1740 excited_8\JJ\1740 <e2>delirium</e2>_9\NN\14391660 (_10\-LRB-\1740 edds_11\NNS\6702458 )_12\-RRB-\1740 in_13\IN\13603305 dade_14\NNP\1740 county_15\NNP\8630039 ,_16\,\1740 florida_17\NNP\1740 between_18\IN\1740 1979_19\CD\1740 and_20\CC\1740 1990_21\CD\1740 ._22\.\1740
D003042_D003693 CID we_0\PRP\1740 describe_1\VBP\1001294 an_2\DT\6697703 outbreak_3\NN\7283608 of_4\IN\1740 deaths_5\NNS\7296428 from_6\IN\1740 <e1>cocaine-induced</e1>_7\JJ\1740 excited_8\JJ\1740 delirium_9\NN\14391660 (_10\-LRB-\1740 <e2>edds</e2>_11\NNS\6702458 )_12\-RRB-\1740 in_13\IN\13603305 dade_14\NNP\1740 county_15\NNP\8630039 ,_16\,\1740 florida_17\NNP\1740 between_18\IN\1740 1979_19\CD\1740 and_20\CC\1740 1990_21\CD\1740 ._22\.\1740
D003042_D003693 CID from_0\IN\1740 a_1\DT\13649268 registry_2\NN\6502378 of_3\IN\1740 all_4\DT\1740 <e1>cocaine-related</e1>_5\JJ\1740 deaths_6\NNS\7296428 in_7\IN\13603305 dade_8\NNP\1740 county_9\NNP\8630039 ,_10\,\1740 florida_11\NNP\1740 ,_12\,\1740 from_13\IN\1740 1969_14\CD\1740 -_15\SYM\1740 1990_16\CD\1740 ,_17\,\1740 58_18\CD\1740 <e2>edds</e2>_19\NNS\6702458 were_20\VBD\836236 compared_21\VBN\644583 with_22\IN\1740 125_23\CD\1740 victims_24\NNS\9630641 of_25\IN\1740 accidental_26\JJ\1740 cocaine_27\NN\3492717 overdose_28\NN\1740 without_29\IN\1740 excited_30\JJ\1740 delirium_31\NN\14391660 ._32\.\1740
D003042_D003693 CID from_0\IN\1740 a_1\DT\13649268 registry_2\NN\6502378 of_3\IN\1740 all_4\DT\1740 <e1>cocaine-related</e1>_5\JJ\1740 deaths_6\NNS\7296428 in_7\IN\13603305 dade_8\NNP\1740 county_9\NNP\8630039 ,_10\,\1740 florida_11\NNP\1740 ,_12\,\1740 from_13\IN\1740 1969_14\CD\1740 -_15\SYM\1740 1990_16\CD\1740 ,_17\,\1740 58_18\CD\1740 edds_19\NNS\6702458 were_20\VBD\836236 compared_21\VBN\644583 with_22\IN\1740 125_23\CD\1740 victims_24\NNS\9630641 of_25\IN\1740 accidental_26\JJ\1740 cocaine_27\NN\3492717 overdose_28\NN\1740 without_29\IN\1740 excited_30\JJ\1740 <e2>delirium</e2>_31\NN\14391660 ._32\.\1740
D003042_D003693 CID from_0\IN\1740 a_1\DT\13649268 registry_2\NN\6502378 of_3\IN\1740 all_4\DT\1740 cocaine-related_5\JJ\1740 deaths_6\NNS\7296428 in_7\IN\13603305 dade_8\NNP\1740 county_9\NNP\8630039 ,_10\,\1740 florida_11\NNP\1740 ,_12\,\1740 from_13\IN\1740 1969_14\CD\1740 -_15\SYM\1740 1990_16\CD\1740 ,_17\,\1740 58_18\CD\1740 <e2>edds</e2>_19\NNS\6702458 were_20\VBD\836236 compared_21\VBN\644583 with_22\IN\1740 125_23\CD\1740 victims_24\NNS\9630641 of_25\IN\1740 accidental_26\JJ\1740 <e1>cocaine</e1>_27\NN\3492717 overdose_28\NN\1740 without_29\IN\1740 excited_30\JJ\1740 delirium_31\NN\14391660 ._32\.\1740
D003042_D003693 CID from_0\IN\1740 a_1\DT\13649268 registry_2\NN\6502378 of_3\IN\1740 all_4\DT\1740 cocaine-related_5\JJ\1740 deaths_6\NNS\7296428 in_7\IN\13603305 dade_8\NNP\1740 county_9\NNP\8630039 ,_10\,\1740 florida_11\NNP\1740 ,_12\,\1740 from_13\IN\1740 1969_14\CD\1740 -_15\SYM\1740 1990_16\CD\1740 ,_17\,\1740 58_18\CD\1740 edds_19\NNS\6702458 were_20\VBD\836236 compared_21\VBN\644583 with_22\IN\1740 125_23\CD\1740 victims_24\NNS\9630641 of_25\IN\1740 accidental_26\JJ\1740 <e1>cocaine</e1>_27\NN\3492717 overdose_28\NN\1740 without_29\IN\1740 excited_30\JJ\1740 <e2>delirium</e2>_31\NN\14391660 ._32\.\1740
D003042_D003693 CID <e2>edds</e2>_0\NNS\6702458 had_1\VBD\2108377 concentrations_2\NNS\4916342 of_3\IN\1740 <e1>cocaine</e1>_4\NN\3492717 and_5\CC\1740 benzoylecgonine_6\NN\1740 in_7\IN\13603305 autopsy_8\JJ\1740 blood_9\NN\5397468 that_10\WDT\1740 were_11\VBD\836236 similar_12\JJ\1740 to_13\TO\1740 those_14\DT\1740 for_15\IN\1740 controls_16\NNS\5190804 ._17\.\1740
D003042_D003693 CID the_0\DT\1740 epidemiologic_1\JJ\1740 findings_2\NNS\7951464 are_3\VBP\836236 most_4\RBS\1740 consistent_5\JJ\1740 with_6\IN\1740 the_7\DT\1740 hypothesis_8\NN\7162194 that_9\IN\1740 chronic_10\JJ\1740 <e1>cocaine</e1>_11\NN\3492717 use_12\VBP\1156834 disrupts_13\VBZ\362348 dopaminergic_14\JJ\1740 function_15\NN\13783581 and_16\CC\1740 ,_17\,\1740 when_18\WRB\1740 coupled_19\VBN\1295275 with_20\IN\1740 recent_21\JJ\1740 cocaine_22\NN\3492717 use_23\NN\407535 ,_24\,\1740 may_25\MD\15209706 precipitate_26\VB\1642924 agitation_27\NN\14373582 ,_28\,\1740 <e2>delirium</e2>_29\NN\14391660 ,_30\,\1740 aberrant_31\JJ\1740 thermoregulation_32\NN\1740 ,_33\,\1740 rhabdomyolysis_34\NN\1740 ,_35\,\1740 and_36\CC\1740 sudden_37\JJ\1740 death_38\NN\7296428 ._39\.\1740
D003042_D003693 CID the_0\DT\1740 epidemiologic_1\JJ\1740 findings_2\NNS\7951464 are_3\VBP\836236 most_4\RBS\1740 consistent_5\JJ\1740 with_6\IN\1740 the_7\DT\1740 hypothesis_8\NN\7162194 that_9\IN\1740 chronic_10\JJ\1740 cocaine_11\NN\3492717 use_12\VBP\1156834 disrupts_13\VBZ\362348 dopaminergic_14\JJ\1740 function_15\NN\13783581 and_16\CC\1740 ,_17\,\1740 when_18\WRB\1740 coupled_19\VBN\1295275 with_20\IN\1740 recent_21\JJ\1740 <e1>cocaine</e1>_22\NN\3492717 use_23\NN\407535 ,_24\,\1740 may_25\MD\15209706 precipitate_26\VB\1642924 agitation_27\NN\14373582 ,_28\,\1740 <e2>delirium</e2>_29\NN\14391660 ,_30\,\1740 aberrant_31\JJ\1740 thermoregulation_32\NN\1740 ,_33\,\1740 rhabdomyolysis_34\NN\1740 ,_35\,\1740 and_36\CC\1740 sudden_37\JJ\1740 death_38\NN\7296428 ._39\.\1740
D003042_D064420 NONE fatal_0\JJ\1740 excited_1\JJ\1740 delirium_2\NN\14391660 following_3\VBG\1835496 <e1>cocaine</e1>_4\NN\3492717 use_5\NN\407535 :_6\:\1740 epidemiologic_7\JJ\1740 findings_8\NNS\7951464 provide_9\VBP\2199590 new_10\JJ\1740 evidence_11\NN\5816287 for_12\IN\1740 mechanisms_13\NNS\13446390 of_14\IN\1740 cocaine_15\NN\3492717 <e2>toxicity</e2>_16\NN\13576101 ._17\.\1740
D003042_D064420 NONE fatal_0\JJ\1740 excited_1\JJ\1740 delirium_2\NN\14391660 following_3\VBG\1835496 cocaine_4\NN\3492717 use_5\NN\407535 :_6\:\1740 epidemiologic_7\JJ\1740 findings_8\NNS\7951464 provide_9\VBP\2199590 new_10\JJ\1740 evidence_11\NN\5816287 for_12\IN\1740 mechanisms_13\NNS\13446390 of_14\IN\1740 <e1>cocaine</e1>_15\NN\3492717 <e2>toxicity</e2>_16\NN\13576101 ._17\.\1740
D003042_D062787 NONE from_0\IN\1740 a_1\DT\13649268 registry_2\NN\6502378 of_3\IN\1740 all_4\DT\1740 <e1>cocaine-related</e1>_5\JJ\1740 deaths_6\NNS\7296428 in_7\IN\13603305 dade_8\NNP\1740 county_9\NNP\8630039 ,_10\,\1740 florida_11\NNP\1740 ,_12\,\1740 from_13\IN\1740 1969_14\CD\1740 -_15\SYM\1740 1990_16\CD\1740 ,_17\,\1740 58_18\CD\1740 edds_19\NNS\6702458 were_20\VBD\836236 compared_21\VBN\644583 with_22\IN\1740 125_23\CD\1740 victims_24\NNS\9630641 of_25\IN\1740 accidental_26\JJ\1740 cocaine_27\NN\3492717 <e2>overdose</e2>_28\NN\1740 without_29\IN\1740 excited_30\JJ\1740 delirium_31\NN\14391660 ._32\.\1740
D003042_D062787 NONE from_0\IN\1740 a_1\DT\13649268 registry_2\NN\6502378 of_3\IN\1740 all_4\DT\1740 cocaine-related_5\JJ\1740 deaths_6\NNS\7296428 in_7\IN\13603305 dade_8\NNP\1740 county_9\NNP\8630039 ,_10\,\1740 florida_11\NNP\1740 ,_12\,\1740 from_13\IN\1740 1969_14\CD\1740 -_15\SYM\1740 1990_16\CD\1740 ,_17\,\1740 58_18\CD\1740 edds_19\NNS\6702458 were_20\VBD\836236 compared_21\VBN\644583 with_22\IN\1740 125_23\CD\1740 victims_24\NNS\9630641 of_25\IN\1740 accidental_26\JJ\1740 <e1>cocaine</e1>_27\NN\3492717 <e2>overdose</e2>_28\NN\1740 without_29\IN\1740 excited_30\JJ\1740 delirium_31\NN\14391660 ._32\.\1740
C005618_D003693 NONE <e2>edds</e2>_0\NNS\6702458 had_1\VBD\2108377 concentrations_2\NNS\4916342 of_3\IN\1740 cocaine_4\NN\3492717 and_5\CC\1740 <e1>benzoylecgonine</e1>_6\NN\1740 in_7\IN\13603305 autopsy_8\JJ\1740 blood_9\NN\5397468 that_10\WDT\1740 were_11\VBD\836236 similar_12\JJ\1740 to_13\TO\1740 those_14\DT\1740 for_15\IN\1740 controls_16\NNS\5190804 ._17\.\1740
D003042_D011595 NONE the_0\DT\1740 epidemiologic_1\JJ\1740 findings_2\NNS\7951464 are_3\VBP\836236 most_4\RBS\1740 consistent_5\JJ\1740 with_6\IN\1740 the_7\DT\1740 hypothesis_8\NN\7162194 that_9\IN\1740 chronic_10\JJ\1740 <e1>cocaine</e1>_11\NN\3492717 use_12\VBP\1156834 disrupts_13\VBZ\362348 dopaminergic_14\JJ\1740 function_15\NN\13783581 and_16\CC\1740 ,_17\,\1740 when_18\WRB\1740 coupled_19\VBN\1295275 with_20\IN\1740 recent_21\JJ\1740 cocaine_22\NN\3492717 use_23\NN\407535 ,_24\,\1740 may_25\MD\15209706 precipitate_26\VB\1642924 <e2>agitation</e2>_27\NN\14373582 ,_28\,\1740 delirium_29\NN\14391660 ,_30\,\1740 aberrant_31\JJ\1740 thermoregulation_32\NN\1740 ,_33\,\1740 rhabdomyolysis_34\NN\1740 ,_35\,\1740 and_36\CC\1740 sudden_37\JJ\1740 death_38\NN\7296428 ._39\.\1740
D003042_D011595 NONE the_0\DT\1740 epidemiologic_1\JJ\1740 findings_2\NNS\7951464 are_3\VBP\836236 most_4\RBS\1740 consistent_5\JJ\1740 with_6\IN\1740 the_7\DT\1740 hypothesis_8\NN\7162194 that_9\IN\1740 chronic_10\JJ\1740 cocaine_11\NN\3492717 use_12\VBP\1156834 disrupts_13\VBZ\362348 dopaminergic_14\JJ\1740 function_15\NN\13783581 and_16\CC\1740 ,_17\,\1740 when_18\WRB\1740 coupled_19\VBN\1295275 with_20\IN\1740 recent_21\JJ\1740 <e1>cocaine</e1>_22\NN\3492717 use_23\NN\407535 ,_24\,\1740 may_25\MD\15209706 precipitate_26\VB\1642924 <e2>agitation</e2>_27\NN\14373582 ,_28\,\1740 delirium_29\NN\14391660 ,_30\,\1740 aberrant_31\JJ\1740 thermoregulation_32\NN\1740 ,_33\,\1740 rhabdomyolysis_34\NN\1740 ,_35\,\1740 and_36\CC\1740 sudden_37\JJ\1740 death_38\NN\7296428 ._39\.\1740
D003042_D012206 CID the_0\DT\1740 epidemiologic_1\JJ\1740 findings_2\NNS\7951464 are_3\VBP\836236 most_4\RBS\1740 consistent_5\JJ\1740 with_6\IN\1740 the_7\DT\1740 hypothesis_8\NN\7162194 that_9\IN\1740 chronic_10\JJ\1740 <e1>cocaine</e1>_11\NN\3492717 use_12\VBP\1156834 disrupts_13\VBZ\362348 dopaminergic_14\JJ\1740 function_15\NN\13783581 and_16\CC\1740 ,_17\,\1740 when_18\WRB\1740 coupled_19\VBN\1295275 with_20\IN\1740 recent_21\JJ\1740 cocaine_22\NN\3492717 use_23\NN\407535 ,_24\,\1740 may_25\MD\15209706 precipitate_26\VB\1642924 agitation_27\NN\14373582 ,_28\,\1740 delirium_29\NN\14391660 ,_30\,\1740 aberrant_31\JJ\1740 thermoregulation_32\NN\1740 ,_33\,\1740 <e2>rhabdomyolysis</e2>_34\NN\1740 ,_35\,\1740 and_36\CC\1740 sudden_37\JJ\1740 death_38\NN\7296428 ._39\.\1740
D003042_D012206 CID the_0\DT\1740 epidemiologic_1\JJ\1740 findings_2\NNS\7951464 are_3\VBP\836236 most_4\RBS\1740 consistent_5\JJ\1740 with_6\IN\1740 the_7\DT\1740 hypothesis_8\NN\7162194 that_9\IN\1740 chronic_10\JJ\1740 cocaine_11\NN\3492717 use_12\VBP\1156834 disrupts_13\VBZ\362348 dopaminergic_14\JJ\1740 function_15\NN\13783581 and_16\CC\1740 ,_17\,\1740 when_18\WRB\1740 coupled_19\VBN\1295275 with_20\IN\1740 recent_21\JJ\1740 <e1>cocaine</e1>_22\NN\3492717 use_23\NN\407535 ,_24\,\1740 may_25\MD\15209706 precipitate_26\VB\1642924 agitation_27\NN\14373582 ,_28\,\1740 delirium_29\NN\14391660 ,_30\,\1740 aberrant_31\JJ\1740 thermoregulation_32\NN\1740 ,_33\,\1740 <e2>rhabdomyolysis</e2>_34\NN\1740 ,_35\,\1740 and_36\CC\1740 sudden_37\JJ\1740 death_38\NN\7296428 ._39\.\1740
D003042_D003645 CID the_0\DT\1740 epidemiologic_1\JJ\1740 findings_2\NNS\7951464 are_3\VBP\836236 most_4\RBS\1740 consistent_5\JJ\1740 with_6\IN\1740 the_7\DT\1740 hypothesis_8\NN\7162194 that_9\IN\1740 chronic_10\JJ\1740 <e1>cocaine</e1>_11\NN\3492717 use_12\VBP\1156834 disrupts_13\VBZ\362348 dopaminergic_14\JJ\1740 function_15\NN\13783581 and_16\CC\1740 ,_17\,\1740 when_18\WRB\1740 coupled_19\VBN\1295275 with_20\IN\1740 recent_21\JJ\1740 cocaine_22\NN\3492717 use_23\NN\407535 ,_24\,\1740 may_25\MD\15209706 precipitate_26\VB\1642924 agitation_27\NN\14373582 ,_28\,\1740 delirium_29\NN\14391660 ,_30\,\1740 aberrant_31\JJ\1740 thermoregulation_32\NN\1740 ,_33\,\1740 rhabdomyolysis_34\NN\1740 ,_35\,\1740 and_36\CC\1740 <e2>sudden_37\JJ\1740 death</e2>_38\NN\7296428 ._39\.\1740
D003042_D003645 CID the_0\DT\1740 epidemiologic_1\JJ\1740 findings_2\NNS\7951464 are_3\VBP\836236 most_4\RBS\1740 consistent_5\JJ\1740 with_6\IN\1740 the_7\DT\1740 hypothesis_8\NN\7162194 that_9\IN\1740 chronic_10\JJ\1740 cocaine_11\NN\3492717 use_12\VBP\1156834 disrupts_13\VBZ\362348 dopaminergic_14\JJ\1740 function_15\NN\13783581 and_16\CC\1740 ,_17\,\1740 when_18\WRB\1740 coupled_19\VBN\1295275 with_20\IN\1740 recent_21\JJ\1740 <e1>cocaine</e1>_22\NN\3492717 use_23\NN\407535 ,_24\,\1740 may_25\MD\15209706 precipitate_26\VB\1642924 agitation_27\NN\14373582 ,_28\,\1740 delirium_29\NN\14391660 ,_30\,\1740 aberrant_31\JJ\1740 thermoregulation_32\NN\1740 ,_33\,\1740 rhabdomyolysis_34\NN\1740 ,_35\,\1740 and_36\CC\1740 <e2>sudden_37\JJ\1740 death</e2>_38\NN\7296428 ._39\.\1740
3934126
D014640_D007239 NONE <e1>vancomycin</e1>_0\NN\2716866 was_1\VBD\836236 curative_2\JJ\1740 in_3\IN\13603305 95_4\CD\1740 %_5\NN\1740 of_6\IN\1740 43_7\CD\1740 patients_8\NNS\9898892 with_9\IN\1740 proven_10\JJ\1740 <e2>infection</e2>_11\NN\14052046 ._12\.\1740
D014640_D007239 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>vancomycin</e1>_3\NN\2716866 ,_4\,\1740 administered_5\VBN\2436349 appropriately_6\RB\1740 ,_7\,\1740 constitutes_8\VBZ\1647229 safe_9\JJ\1740 ,_10\,\1740 effective_11\JJ\1740 therapy_12\NN\657604 for_13\IN\1740 <e2>infections</e2>_14\NNS\14052046 caused_15\VBN\1617192 by_16\IN\1740 susceptible_17\JJ\1740 bacteria_18\NNS\1326291 ._19\.\1740
D000617_D013924 NONE <e2>thrombophlebitis</e2>_0\NN\14352890 occurred_1\VBD\2623529 only_2\RB\1740 with_3\IN\1740 infusion_4\NN\14589223 through_5\IN\1740 peripheral_6\JJ\1740 cannulae_7\NN\1740 ;_8\:\1740 nephrotoxicity_9\NN\1740 and_10\CC\1740 ototoxicity_11\NN\1740 were_12\VBD\836236 confined_13\VBN\2510337 to_14\TO\1740 patients_15\NNS\9898892 receiving_16\VBG\2210855 an_17\DT\6697703 <e1>aminoglycoside</e1>_18\NN\1740 plus_19\CC\4723816 vancomycin_20\NN\2716866 ._21\.\1740
D000617_D007674 NONE thrombophlebitis_0\NN\14352890 occurred_1\VBD\2623529 only_2\RB\1740 with_3\IN\1740 infusion_4\NN\14589223 through_5\IN\1740 peripheral_6\JJ\1740 cannulae_7\NN\1740 ;_8\:\1740 <e2>nephrotoxicity</e2>_9\NN\1740 and_10\CC\1740 ototoxicity_11\NN\1740 were_12\VBD\836236 confined_13\VBN\2510337 to_14\TO\1740 patients_15\NNS\9898892 receiving_16\VBG\2210855 an_17\DT\6697703 <e1>aminoglycoside</e1>_18\NN\1740 plus_19\CC\4723816 vancomycin_20\NN\2716866 ._21\.\1740
D000617_D006311 NONE thrombophlebitis_0\NN\14352890 occurred_1\VBD\2623529 only_2\RB\1740 with_3\IN\1740 infusion_4\NN\14589223 through_5\IN\1740 peripheral_6\JJ\1740 cannulae_7\NN\1740 ;_8\:\1740 nephrotoxicity_9\NN\1740 and_10\CC\1740 <e2>ototoxicity</e2>_11\NN\1740 were_12\VBD\836236 confined_13\VBN\2510337 to_14\TO\1740 patients_15\NNS\9898892 receiving_16\VBG\2210855 an_17\DT\6697703 <e1>aminoglycoside</e1>_18\NN\1740 plus_19\CC\4723816 vancomycin_20\NN\2716866 ._21\.\1740
D014640_D013924 CID <e2>thrombophlebitis</e2>_0\NN\14352890 occurred_1\VBD\2623529 only_2\RB\1740 with_3\IN\1740 infusion_4\NN\14589223 through_5\IN\1740 peripheral_6\JJ\1740 cannulae_7\NN\1740 ;_8\:\1740 nephrotoxicity_9\NN\1740 and_10\CC\1740 ototoxicity_11\NN\1740 were_12\VBD\836236 confined_13\VBN\2510337 to_14\TO\1740 patients_15\NNS\9898892 receiving_16\VBG\2210855 an_17\DT\6697703 aminoglycoside_18\NN\1740 plus_19\CC\4723816 <e1>vancomycin</e1>_20\NN\2716866 ._21\.\1740
D014640_D007674 NONE thrombophlebitis_0\NN\14352890 occurred_1\VBD\2623529 only_2\RB\1740 with_3\IN\1740 infusion_4\NN\14589223 through_5\IN\1740 peripheral_6\JJ\1740 cannulae_7\NN\1740 ;_8\:\1740 <e2>nephrotoxicity</e2>_9\NN\1740 and_10\CC\1740 ototoxicity_11\NN\1740 were_12\VBD\836236 confined_13\VBN\2510337 to_14\TO\1740 patients_15\NNS\9898892 receiving_16\VBG\2210855 an_17\DT\6697703 aminoglycoside_18\NN\1740 plus_19\CC\4723816 <e1>vancomycin</e1>_20\NN\2716866 ._21\.\1740
D014640_D006311 CID thrombophlebitis_0\NN\14352890 occurred_1\VBD\2623529 only_2\RB\1740 with_3\IN\1740 infusion_4\NN\14589223 through_5\IN\1740 peripheral_6\JJ\1740 cannulae_7\NN\1740 ;_8\:\1740 nephrotoxicity_9\NN\1740 and_10\CC\1740 <e2>ototoxicity</e2>_11\NN\1740 were_12\VBD\836236 confined_13\VBN\2510337 to_14\TO\1740 patients_15\NNS\9898892 receiving_16\VBG\2210855 an_17\DT\6697703 aminoglycoside_18\NN\1740 plus_19\CC\4723816 <e1>vancomycin</e1>_20\NN\2716866 ._21\.\1740
16844102
D024502_D020258 NONE effect_0\NN\34213 of_1\IN\1740 <e1>alpha-tocopherol</e1>_2\NN\1740 and_3\CC\1740 deferoxamine_4\VB\1740 on_5\IN\1740 methamphetamine-induced_6\JJ\1740 <e2>neurotoxicity</e2>_7\NN\1740 ._8\.\1740
D024502_D020258 NONE this_0\DT\1740 study_1\NN\635850 examined_2\VBD\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 <e1>alpha-tocopherol</e1>_6\NN\1740 (_7\-LRB-\1740 alpha-tc_8\NNS\1740 )_9\-RRB-\1740 ,_10\,\1740 a_11\DT\13649268 scavenger_12\NN\14779550 of_13\IN\1740 reactive_14\JJ\1740 oxygen_15\NN\14622893 species_16\NNS\7992450 ,_17\,\1740 and_18\CC\1740 deferoxamine_19\VB\1740 (_20\-LRB-\1740 dfo_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 an_24\DT\6697703 iron_25\NN\14625458 chelator_26\NN\1740 ,_27\,\1740 on_28\IN\1740 the_29\DT\1740 ma-induced_30\JJ\1740 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D024502_D020258 NONE this_0\DT\1740 study_1\NN\635850 examined_2\VBD\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 alpha-tocopherol_6\NN\1740 (_7\-LRB-\1740 <e1>alpha-tc</e1>_8\NNS\1740 )_9\-RRB-\1740 ,_10\,\1740 a_11\DT\13649268 scavenger_12\NN\14779550 of_13\IN\1740 reactive_14\JJ\1740 oxygen_15\NN\14622893 species_16\NNS\7992450 ,_17\,\1740 and_18\CC\1740 deferoxamine_19\VB\1740 (_20\-LRB-\1740 dfo_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 an_24\DT\6697703 iron_25\NN\14625458 chelator_26\NN\1740 ,_27\,\1740 on_28\IN\1740 the_29\DT\1740 ma-induced_30\JJ\1740 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D003676_D020258 NONE effect_0\NN\34213 of_1\IN\1740 alpha-tocopherol_2\NN\1740 and_3\CC\1740 <e1>deferoxamine</e1>_4\VB\1740 on_5\IN\1740 methamphetamine-induced_6\JJ\1740 <e2>neurotoxicity</e2>_7\NN\1740 ._8\.\1740
D003676_D020258 NONE this_0\DT\1740 study_1\NN\635850 examined_2\VBD\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 alpha-tocopherol_6\NN\1740 (_7\-LRB-\1740 alpha-tc_8\NNS\1740 )_9\-RRB-\1740 ,_10\,\1740 a_11\DT\13649268 scavenger_12\NN\14779550 of_13\IN\1740 reactive_14\JJ\1740 oxygen_15\NN\14622893 species_16\NNS\7992450 ,_17\,\1740 and_18\CC\1740 <e1>deferoxamine</e1>_19\VB\1740 (_20\-LRB-\1740 dfo_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 an_24\DT\6697703 iron_25\NN\14625458 chelator_26\NN\1740 ,_27\,\1740 on_28\IN\1740 the_29\DT\1740 ma-induced_30\JJ\1740 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D003676_D020258 NONE this_0\DT\1740 study_1\NN\635850 examined_2\VBD\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 alpha-tocopherol_6\NN\1740 (_7\-LRB-\1740 alpha-tc_8\NNS\1740 )_9\-RRB-\1740 ,_10\,\1740 a_11\DT\13649268 scavenger_12\NN\14779550 of_13\IN\1740 reactive_14\JJ\1740 oxygen_15\NN\14622893 species_16\NNS\7992450 ,_17\,\1740 and_18\CC\1740 deferoxamine_19\VB\1740 (_20\-LRB-\1740 <e1>dfo</e1>_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 an_24\DT\6697703 iron_25\NN\14625458 chelator_26\NN\1740 ,_27\,\1740 on_28\IN\1740 the_29\DT\1740 ma-induced_30\JJ\1740 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D008694_D020258 NONE effect_0\NN\34213 of_1\IN\1740 alpha-tocopherol_2\NN\1740 and_3\CC\1740 deferoxamine_4\VB\1740 on_5\IN\1740 <e1>methamphetamine-induced</e1>_6\JJ\1740 <e2>neurotoxicity</e2>_7\NN\1740 ._8\.\1740
D008694_D020258 NONE <e1>methamphetamine</e1>_0\NNP\2704153 (ma)-induced_1\VBN\1740 dopaminergic_2\JJ\1740 <e2>neurotoxicity</e2>_3\NN\1740 is_4\VBZ\836236 believed_5\VBN\686447 to_6\TO\1740 be_7\VB\836236 associated_8\VBN\628491 with_9\IN\1740 the_10\DT\1740 increased_11\VBN\169651 formation_12\NN\7938773 of_13\IN\1740 free_14\JJ\1740 radicals_15\NNS\9465459 ._16\.\1740
D008694_D020258 NONE methamphetamine_0\NNP\2704153 <e1>(ma)-induced</e1>_1\VBN\1740 dopaminergic_2\JJ\1740 <e2>neurotoxicity</e2>_3\NN\1740 is_4\VBZ\836236 believed_5\VBN\686447 to_6\TO\1740 be_7\VB\836236 associated_8\VBN\628491 with_9\IN\1740 the_10\DT\1740 increased_11\VBN\169651 formation_12\NN\7938773 of_13\IN\1740 free_14\JJ\1740 radicals_15\NNS\9465459 ._16\.\1740
D008694_D020258 NONE this_0\DT\1740 study_1\NN\635850 examined_2\VBD\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 alpha-tocopherol_6\NN\1740 (_7\-LRB-\1740 alpha-tc_8\NNS\1740 )_9\-RRB-\1740 ,_10\,\1740 a_11\DT\13649268 scavenger_12\NN\14779550 of_13\IN\1740 reactive_14\JJ\1740 oxygen_15\NN\14622893 species_16\NNS\7992450 ,_17\,\1740 and_18\CC\1740 deferoxamine_19\VB\1740 (_20\-LRB-\1740 dfo_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 an_24\DT\6697703 iron_25\NN\14625458 chelator_26\NN\1740 ,_27\,\1740 on_28\IN\1740 the_29\DT\1740 <e1>ma-induced</e1>_30\JJ\1740 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D010100_D020258 NONE this_0\DT\1740 study_1\NN\635850 examined_2\VBD\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 alpha-tocopherol_6\NN\1740 (_7\-LRB-\1740 alpha-tc_8\NNS\1740 )_9\-RRB-\1740 ,_10\,\1740 a_11\DT\13649268 scavenger_12\NN\14779550 of_13\IN\1740 reactive_14\JJ\1740 <e1>oxygen</e1>_15\NN\14622893 species_16\NNS\7992450 ,_17\,\1740 and_18\CC\1740 deferoxamine_19\VB\1740 (_20\-LRB-\1740 dfo_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 an_24\DT\6697703 iron_25\NN\14625458 chelator_26\NN\1740 ,_27\,\1740 on_28\IN\1740 the_29\DT\1740 ma-induced_30\JJ\1740 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D007501_D020258 NONE this_0\DT\1740 study_1\NN\635850 examined_2\VBD\789138 the_3\DT\1740 effect_4\NN\34213 of_5\IN\1740 alpha-tocopherol_6\NN\1740 (_7\-LRB-\1740 alpha-tc_8\NNS\1740 )_9\-RRB-\1740 ,_10\,\1740 a_11\DT\13649268 scavenger_12\NN\14779550 of_13\IN\1740 reactive_14\JJ\1740 oxygen_15\NN\14622893 species_16\NNS\7992450 ,_17\,\1740 and_18\CC\1740 deferoxamine_19\VB\1740 (_20\-LRB-\1740 dfo_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 an_24\DT\6697703 <e1>iron</e1>_25\NN\14625458 chelator_26\NN\1740 ,_27\,\1740 on_28\IN\1740 the_29\DT\1740 ma-induced_30\JJ\1740 <e2>neurotoxicity</e2>_31\NN\1740 ._32\.\1740
D024502_D005334 NONE <e1>alpha-tc</e1>_0\NN\1740 and_1\CC\1740 dfo_2\NN\1740 attenuated_3\VBD\224901 the_4\DT\1740 ma-induced_5\JJ\1740 <e2>hyperthermia</e2>_6\NN\14034177 as_7\RB\1740 well_8\RB\1740 as_9\IN\14622893 the_10\DT\1740 alterations_11\NNS\7283608 in_12\IN\13603305 the_13\DT\1740 locomotor_14\NN\1740 activity_15\NN\30358 ._16\.\1740
D003676_D005334 NONE alpha-tc_0\NN\1740 and_1\CC\1740 <e1>dfo</e1>_2\NN\1740 attenuated_3\VBD\224901 the_4\DT\1740 ma-induced_5\JJ\1740 <e2>hyperthermia</e2>_6\NN\14034177 as_7\RB\1740 well_8\RB\1740 as_9\IN\14622893 the_10\DT\1740 alterations_11\NNS\7283608 in_12\IN\13603305 the_13\DT\1740 locomotor_14\NN\1740 activity_15\NN\30358 ._16\.\1740
D008694_D005334 CID alpha-tc_0\NN\1740 and_1\CC\1740 dfo_2\NN\1740 attenuated_3\VBD\224901 the_4\DT\1740 <e1>ma-induced</e1>_5\JJ\1740 <e2>hyperthermia</e2>_6\NN\14034177 as_7\RB\1740 well_8\RB\1740 as_9\IN\14622893 the_10\DT\1740 alterations_11\NNS\7283608 in_12\IN\13603305 the_13\DT\1740 locomotor_14\NN\1740 activity_15\NN\30358 ._16\.\1740
D024502_D009422 NONE this_0\DT\1740 suggests_1\VBZ\1010118 that_2\IN\1740 <e1>alpha-tc</e1>_3\NN\1740 and_4\CC\1740 dfo_5\NN\1740 ameliorate_6\VBP\126264 the_7\DT\1740 ma-induced_8\JJ\1740 <e2>neuronal_9\JJ\1740 damage</e2>_10\NN\7296428 by_11\IN\1740 decreasing_12\VBG\169651 the_13\DT\1740 level_14\NN\4916342 of_15\IN\1740 oxidative_16\JJ\1740 stress_17\NN\7083732 ._18\.\1740
D003676_D009422 NONE this_0\DT\1740 suggests_1\VBZ\1010118 that_2\IN\1740 alpha-tc_3\NN\1740 and_4\CC\1740 <e1>dfo</e1>_5\NN\1740 ameliorate_6\VBP\126264 the_7\DT\1740 ma-induced_8\JJ\1740 <e2>neuronal_9\JJ\1740 damage</e2>_10\NN\7296428 by_11\IN\1740 decreasing_12\VBG\169651 the_13\DT\1740 level_14\NN\4916342 of_15\IN\1740 oxidative_16\JJ\1740 stress_17\NN\7083732 ._18\.\1740
D008694_D009422 CID this_0\DT\1740 suggests_1\VBZ\1010118 that_2\IN\1740 alpha-tc_3\NN\1740 and_4\CC\1740 dfo_5\NN\1740 ameliorate_6\VBP\126264 the_7\DT\1740 <e1>ma-induced</e1>_8\JJ\1740 <e2>neuronal_9\JJ\1740 damage</e2>_10\NN\7296428 by_11\IN\1740 decreasing_12\VBG\169651 the_13\DT\1740 level_14\NN\4916342 of_15\IN\1740 oxidative_16\JJ\1740 stress_17\NN\7083732 ._18\.\1740
15867025
D006514_D006509 CID assessment_0\NN\5732756 was_1\VBD\836236 done_2\VBN\1640855 on_3\IN\1740 the_4\DT\1740 following_5\NN\8180190 :_6\:\1740 prenatal_7\JJ\1740 screening_8\NN\6887726 for_9\IN\1740 <e2>hepatitis_10\NN\14127211 b</e2>_11\NN\1355326 and_12\CC\1740 rubella_13\NN\14123044 ,_14\,\1740 administration_15\NN\1133281 of_16\IN\1740 the_17\DT\1740 hepatitis_18\NN\14127211 b_19\NN\1355326 vaccine_20\NN\3562739 birth_21\NN\15265518 dose_22\NN\3740161 to_23\IN\1740 all_24\DT\1740 infants_25\NNS\9918248 ,_26\,\1740 administration_27\NN\1133281 of_28\IN\1740 hepatitis_29\NN\14127211 b_30\NN\1355326 immune_31\JJ\1740 globulin_32\NN\14736972 to_33\TO\1740 infants_34\NNS\9918248 who_35\WP\8299493 were_36\VBD\836236 born_37\VBN\2630189 to_38\TO\1740 <e1>hepatitis_39\NN\14127211 b_40\NN\1355326 surface_41\NN\21939 antigen-positive</e1>_42\JJ\1740 mothers_43\NNS\10399491 ,_44\,\1740 rubella_45\NN\14123044 immunity_46\NN\13920835 ,_47\,\1740 and_48\CC\1740 administration_49\NN\1133281 of_50\IN\1740 in-hospital_51\JJ\1740 postpartum_52\NN\1740 rubella_53\NN\14123044 vaccine_54\NN\3562739 to_55\TO\1740 rubella_56\NN\14123044 nonimmune_57\JJ\1740 women_58\NNS\9605289 ._59\.\1740
D006514_D006509 CID assessment_0\NN\5732756 was_1\VBD\836236 done_2\VBN\1640855 on_3\IN\1740 the_4\DT\1740 following_5\NN\8180190 :_6\:\1740 prenatal_7\JJ\1740 screening_8\NN\6887726 for_9\IN\1740 hepatitis_10\NN\14127211 b_11\NN\1355326 and_12\CC\1740 rubella_13\NN\14123044 ,_14\,\1740 administration_15\NN\1133281 of_16\IN\1740 the_17\DT\1740 <e2>hepatitis_18\NN\14127211 b</e2>_19\NN\1355326 vaccine_20\NN\3562739 birth_21\NN\15265518 dose_22\NN\3740161 to_23\IN\1740 all_24\DT\1740 infants_25\NNS\9918248 ,_26\,\1740 administration_27\NN\1133281 of_28\IN\1740 hepatitis_29\NN\14127211 b_30\NN\1355326 immune_31\JJ\1740 globulin_32\NN\14736972 to_33\TO\1740 infants_34\NNS\9918248 who_35\WP\8299493 were_36\VBD\836236 born_37\VBN\2630189 to_38\TO\1740 <e1>hepatitis_39\NN\14127211 b_40\NN\1355326 surface_41\NN\21939 antigen-positive</e1>_42\JJ\1740 mothers_43\NNS\10399491 ,_44\,\1740 rubella_45\NN\14123044 immunity_46\NN\13920835 ,_47\,\1740 and_48\CC\1740 administration_49\NN\1133281 of_50\IN\1740 in-hospital_51\JJ\1740 postpartum_52\NN\1740 rubella_53\NN\14123044 vaccine_54\NN\3562739 to_55\TO\1740 rubella_56\NN\14123044 nonimmune_57\JJ\1740 women_58\NNS\9605289 ._59\.\1740
D006514_D006509 CID assessment_0\NN\5732756 was_1\VBD\836236 done_2\VBN\1640855 on_3\IN\1740 the_4\DT\1740 following_5\NN\8180190 :_6\:\1740 prenatal_7\JJ\1740 screening_8\NN\6887726 for_9\IN\1740 hepatitis_10\NN\14127211 b_11\NN\1355326 and_12\CC\1740 rubella_13\NN\14123044 ,_14\,\1740 administration_15\NN\1133281 of_16\IN\1740 the_17\DT\1740 hepatitis_18\NN\14127211 b_19\NN\1355326 vaccine_20\NN\3562739 birth_21\NN\15265518 dose_22\NN\3740161 to_23\IN\1740 all_24\DT\1740 infants_25\NNS\9918248 ,_26\,\1740 administration_27\NN\1133281 of_28\IN\1740 <e2>hepatitis_29\NN\14127211 b</e2>_30\NN\1355326 immune_31\JJ\1740 globulin_32\NN\14736972 to_33\TO\1740 infants_34\NNS\9918248 who_35\WP\8299493 were_36\VBD\836236 born_37\VBN\2630189 to_38\TO\1740 <e1>hepatitis_39\NN\14127211 b_40\NN\1355326 surface_41\NN\21939 antigen-positive</e1>_42\JJ\1740 mothers_43\NNS\10399491 ,_44\,\1740 rubella_45\NN\14123044 immunity_46\NN\13920835 ,_47\,\1740 and_48\CC\1740 administration_49\NN\1133281 of_50\IN\1740 in-hospital_51\JJ\1740 postpartum_52\NN\1740 rubella_53\NN\14123044 vaccine_54\NN\3562739 to_55\TO\1740 rubella_56\NN\14123044 nonimmune_57\JJ\1740 women_58\NNS\9605289 ._59\.\1740
D006514_D006509 CID all_0\DT\1740 infants_1\NNS\9918248 who_2\WP\8299493 were_3\VBD\836236 born_4\VBN\2630189 to_5\TO\1740 <e1>hepatitis_6\NN\14127211 b_7\NN\1355326 surface_8\NN\21939 antigen-positive</e1>_9\JJ\1740 mothers_10\NNS\10399491 also_11\RB\1740 received_12\VBD\2210855 <e2>hepatitis_13\NN\14127211 b</e2>_14\NN\1355326 immune_15\JJ\1740 globulin_16\NN\14736972 ._17\.\1740
D006514_D012409 NONE assessment_0\NN\5732756 was_1\VBD\836236 done_2\VBN\1640855 on_3\IN\1740 the_4\DT\1740 following_5\NN\8180190 :_6\:\1740 prenatal_7\JJ\1740 screening_8\NN\6887726 for_9\IN\1740 hepatitis_10\NN\14127211 b_11\NN\1355326 and_12\CC\1740 <e2>rubella</e2>_13\NN\14123044 ,_14\,\1740 administration_15\NN\1133281 of_16\IN\1740 the_17\DT\1740 hepatitis_18\NN\14127211 b_19\NN\1355326 vaccine_20\NN\3562739 birth_21\NN\15265518 dose_22\NN\3740161 to_23\IN\1740 all_24\DT\1740 infants_25\NNS\9918248 ,_26\,\1740 administration_27\NN\1133281 of_28\IN\1740 hepatitis_29\NN\14127211 b_30\NN\1355326 immune_31\JJ\1740 globulin_32\NN\14736972 to_33\TO\1740 infants_34\NNS\9918248 who_35\WP\8299493 were_36\VBD\836236 born_37\VBN\2630189 to_38\TO\1740 <e1>hepatitis_39\NN\14127211 b_40\NN\1355326 surface_41\NN\21939 antigen-positive</e1>_42\JJ\1740 mothers_43\NNS\10399491 ,_44\,\1740 rubella_45\NN\14123044 immunity_46\NN\13920835 ,_47\,\1740 and_48\CC\1740 administration_49\NN\1133281 of_50\IN\1740 in-hospital_51\JJ\1740 postpartum_52\NN\1740 rubella_53\NN\14123044 vaccine_54\NN\3562739 to_55\TO\1740 rubella_56\NN\14123044 nonimmune_57\JJ\1740 women_58\NNS\9605289 ._59\.\1740
D006514_D012409 NONE assessment_0\NN\5732756 was_1\VBD\836236 done_2\VBN\1640855 on_3\IN\1740 the_4\DT\1740 following_5\NN\8180190 :_6\:\1740 prenatal_7\JJ\1740 screening_8\NN\6887726 for_9\IN\1740 hepatitis_10\NN\14127211 b_11\NN\1355326 and_12\CC\1740 rubella_13\NN\14123044 ,_14\,\1740 administration_15\NN\1133281 of_16\IN\1740 the_17\DT\1740 hepatitis_18\NN\14127211 b_19\NN\1355326 vaccine_20\NN\3562739 birth_21\NN\15265518 dose_22\NN\3740161 to_23\IN\1740 all_24\DT\1740 infants_25\NNS\9918248 ,_26\,\1740 administration_27\NN\1133281 of_28\IN\1740 hepatitis_29\NN\14127211 b_30\NN\1355326 immune_31\JJ\1740 globulin_32\NN\14736972 to_33\TO\1740 infants_34\NNS\9918248 who_35\WP\8299493 were_36\VBD\836236 born_37\VBN\2630189 to_38\TO\1740 <e1>hepatitis_39\NN\14127211 b_40\NN\1355326 surface_41\NN\21939 antigen-positive</e1>_42\JJ\1740 mothers_43\NNS\10399491 ,_44\,\1740 <e2>rubella</e2>_45\NN\14123044 immunity_46\NN\13920835 ,_47\,\1740 and_48\CC\1740 administration_49\NN\1133281 of_50\IN\1740 in-hospital_51\JJ\1740 postpartum_52\NN\1740 rubella_53\NN\14123044 vaccine_54\NN\3562739 to_55\TO\1740 rubella_56\NN\14123044 nonimmune_57\JJ\1740 women_58\NNS\9605289 ._59\.\1740
D006514_D012409 NONE assessment_0\NN\5732756 was_1\VBD\836236 done_2\VBN\1640855 on_3\IN\1740 the_4\DT\1740 following_5\NN\8180190 :_6\:\1740 prenatal_7\JJ\1740 screening_8\NN\6887726 for_9\IN\1740 hepatitis_10\NN\14127211 b_11\NN\1355326 and_12\CC\1740 rubella_13\NN\14123044 ,_14\,\1740 administration_15\NN\1133281 of_16\IN\1740 the_17\DT\1740 hepatitis_18\NN\14127211 b_19\NN\1355326 vaccine_20\NN\3562739 birth_21\NN\15265518 dose_22\NN\3740161 to_23\IN\1740 all_24\DT\1740 infants_25\NNS\9918248 ,_26\,\1740 administration_27\NN\1133281 of_28\IN\1740 hepatitis_29\NN\14127211 b_30\NN\1355326 immune_31\JJ\1740 globulin_32\NN\14736972 to_33\TO\1740 infants_34\NNS\9918248 who_35\WP\8299493 were_36\VBD\836236 born_37\VBN\2630189 to_38\TO\1740 <e1>hepatitis_39\NN\14127211 b_40\NN\1355326 surface_41\NN\21939 antigen-positive</e1>_42\JJ\1740 mothers_43\NNS\10399491 ,_44\,\1740 rubella_45\NN\14123044 immunity_46\NN\13920835 ,_47\,\1740 and_48\CC\1740 administration_49\NN\1133281 of_50\IN\1740 in-hospital_51\JJ\1740 postpartum_52\NN\1740 <e2>rubella</e2>_53\NN\14123044 vaccine_54\NN\3562739 to_55\TO\1740 rubella_56\NN\14123044 nonimmune_57\JJ\1740 women_58\NNS\9605289 ._59\.\1740
D006514_D012409 NONE assessment_0\NN\5732756 was_1\VBD\836236 done_2\VBN\1640855 on_3\IN\1740 the_4\DT\1740 following_5\NN\8180190 :_6\:\1740 prenatal_7\JJ\1740 screening_8\NN\6887726 for_9\IN\1740 hepatitis_10\NN\14127211 b_11\NN\1355326 and_12\CC\1740 rubella_13\NN\14123044 ,_14\,\1740 administration_15\NN\1133281 of_16\IN\1740 the_17\DT\1740 hepatitis_18\NN\14127211 b_19\NN\1355326 vaccine_20\NN\3562739 birth_21\NN\15265518 dose_22\NN\3740161 to_23\IN\1740 all_24\DT\1740 infants_25\NNS\9918248 ,_26\,\1740 administration_27\NN\1133281 of_28\IN\1740 hepatitis_29\NN\14127211 b_30\NN\1355326 immune_31\JJ\1740 globulin_32\NN\14736972 to_33\TO\1740 infants_34\NNS\9918248 who_35\WP\8299493 were_36\VBD\836236 born_37\VBN\2630189 to_38\TO\1740 <e1>hepatitis_39\NN\14127211 b_40\NN\1355326 surface_41\NN\21939 antigen-positive</e1>_42\JJ\1740 mothers_43\NNS\10399491 ,_44\,\1740 rubella_45\NN\14123044 immunity_46\NN\13920835 ,_47\,\1740 and_48\CC\1740 administration_49\NN\1133281 of_50\IN\1740 in-hospital_51\JJ\1740 postpartum_52\NN\1740 rubella_53\NN\14123044 vaccine_54\NN\3562739 to_55\TO\1740 <e2>rubella</e2>_56\NN\14123044 nonimmune_57\JJ\1740 women_58\NNS\9605289 ._59\.\1740
16471092
C099041_D053201 NONE urinary_0\JJ\1740 symptoms_1\NNS\5823932 and_2\CC\1740 quality_3\NN\24264 of_4\IN\1740 life_5\NN\13954253 changes_6\NNS\7283608 in_7\IN\13603305 thai_8\JJ\1740 women_9\NNS\9605289 with_10\IN\1740 <e2>overactive_11\JJ\1740 bladder</e2>_12\NN\5515670 after_13\IN\1740 <e1>tolterodine</e1>_14\NN\1740 treatment_15\NN\654885 ._16\.\1740
C099041_D053201 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 study_3\VB\630380 the_4\DT\1740 urinary_5\JJ\1740 symptoms_6\NNS\5823932 and_7\CC\1740 quality_8\NN\24264 of_9\IN\1740 life_10\NN\13954253 changes_11\NNS\7283608 in_12\IN\13603305 thai_13\JJ\1740 women_14\NNS\9605289 with_15\IN\1740 <e2>overactive_16\JJ\1740 bladder</e2>_17\NN\5515670 (_18\-LRB-\1740 oab_19\NN\1740 )_20\-RRB-\1740 after_21\IN\1740 <e1>tolterodine</e1>_22\NN\1740 treatment_23\NN\654885 ._24\.\1740
C099041_D053201 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 study_3\VB\630380 the_4\DT\1740 urinary_5\JJ\1740 symptoms_6\NNS\5823932 and_7\CC\1740 quality_8\NN\24264 of_9\IN\1740 life_10\NN\13954253 changes_11\NNS\7283608 in_12\IN\13603305 thai_13\JJ\1740 women_14\NNS\9605289 with_15\IN\1740 overactive_16\JJ\1740 bladder_17\NN\5515670 (_18\-LRB-\1740 <e2>oab</e2>_19\NN\1740 )_20\-RRB-\1740 after_21\IN\1740 <e1>tolterodine</e1>_22\NN\1740 treatment_23\NN\654885 ._24\.\1740
C099041_D053201 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>tolterodine</e1>_2\NNP\1740 was_3\VBD\836236 well_4\RB\1740 tolerated_5\VBN\802318 and_6\CC\1740 its_7\PRP$\6125041 effects_8\NNS\13245626 improved_9\VBD\126264 the_10\DT\1740 quality_11\NN\24264 of_12\IN\1740 life_13\NN\13954253 in_14\IN\13603305 thai_15\JJ\1740 women_16\NNS\9605289 with_17\IN\1740 <e2>oab</e2>_18\NN\1740 ._19\.\1740
15974569
D007608_D010146 NONE two_0\CD\13741022 prodrugs_1\NNS\1740 of_2\IN\1740 potent_3\JJ\1740 and_4\CC\1740 selective_5\JJ\1740 glur5_6\NN\1740 <e1>kainate</e1>_7\NN\1740 receptor_8\NN\5225602 antagonists_9\NNS\7846 actives_10\VBZ\1740 in_11\IN\13603305 three_12\CD\13741022 animal_13\JJ\1740 models_14\NNS\5888929 of_15\IN\1740 <e2>pain</e2>_16\NN\14299637 ._17\.\1740
D005557_D010146 NONE their_0\PRP$\1740 ester_1\NN\14727670 prodrugs_2\NNS\1740 6_3\CD\13741022 and_4\CC\1740 8_5\CD\13741022 were_6\VBD\836236 orally_7\RB\1740 active_8\JJ\1740 in_9\IN\13603305 three_10\CD\13741022 models_11\NNS\5888929 of_12\IN\1740 <e2>pain</e2>_13\NN\14299637 :_14\:\1740 reversal_15\NN\199130 of_16\IN\1740 <e1>formalin-induced</e1>_17\JJ\1740 paw_18\NN\2153445 licking_19\NN\7291312 ,_20\,\1740 carrageenan-induced_21\JJ\1740 thermal_22\JJ\1740 hyperalgesia_23\NN\1740 ,_24\,\1740 and_25\CC\1740 capsaicin-induced_26\JJ\1740 mechanical_27\JJ\1740 hyperalgesia_28\NN\1740 ._29\.\1740
D005557_D006930 NONE their_0\PRP$\1740 ester_1\NN\14727670 prodrugs_2\NNS\1740 6_3\CD\13741022 and_4\CC\1740 8_5\CD\13741022 were_6\VBD\836236 orally_7\RB\1740 active_8\JJ\1740 in_9\IN\13603305 three_10\CD\13741022 models_11\NNS\5888929 of_12\IN\1740 pain_13\NN\14299637 :_14\:\1740 reversal_15\NN\199130 of_16\IN\1740 <e1>formalin-induced</e1>_17\JJ\1740 paw_18\NN\2153445 licking_19\NN\7291312 ,_20\,\1740 carrageenan-induced_21\JJ\1740 <e2>thermal_22\JJ\1740 hyperalgesia</e2>_23\NN\1740 ,_24\,\1740 and_25\CC\1740 capsaicin-induced_26\JJ\1740 mechanical_27\JJ\1740 hyperalgesia_28\NN\1740 ._29\.\1740
D005557_D006930 NONE their_0\PRP$\1740 ester_1\NN\14727670 prodrugs_2\NNS\1740 6_3\CD\13741022 and_4\CC\1740 8_5\CD\13741022 were_6\VBD\836236 orally_7\RB\1740 active_8\JJ\1740 in_9\IN\13603305 three_10\CD\13741022 models_11\NNS\5888929 of_12\IN\1740 pain_13\NN\14299637 :_14\:\1740 reversal_15\NN\199130 of_16\IN\1740 <e1>formalin-induced</e1>_17\JJ\1740 paw_18\NN\2153445 licking_19\NN\7291312 ,_20\,\1740 carrageenan-induced_21\JJ\1740 thermal_22\JJ\1740 hyperalgesia_23\NN\1740 ,_24\,\1740 and_25\CC\1740 capsaicin-induced_26\JJ\1740 <e2>mechanical_27\JJ\1740 hyperalgesia</e2>_28\NN\1740 ._29\.\1740
D002351_D010146 NONE their_0\PRP$\1740 ester_1\NN\14727670 prodrugs_2\NNS\1740 6_3\CD\13741022 and_4\CC\1740 8_5\CD\13741022 were_6\VBD\836236 orally_7\RB\1740 active_8\JJ\1740 in_9\IN\13603305 three_10\CD\13741022 models_11\NNS\5888929 of_12\IN\1740 <e2>pain</e2>_13\NN\14299637 :_14\:\1740 reversal_15\NN\199130 of_16\IN\1740 formalin-induced_17\JJ\1740 paw_18\NN\2153445 licking_19\NN\7291312 ,_20\,\1740 <e1>carrageenan-induced</e1>_21\JJ\1740 thermal_22\JJ\1740 hyperalgesia_23\NN\1740 ,_24\,\1740 and_25\CC\1740 capsaicin-induced_26\JJ\1740 mechanical_27\JJ\1740 hyperalgesia_28\NN\1740 ._29\.\1740
D002351_D006930 CID their_0\PRP$\1740 ester_1\NN\14727670 prodrugs_2\NNS\1740 6_3\CD\13741022 and_4\CC\1740 8_5\CD\13741022 were_6\VBD\836236 orally_7\RB\1740 active_8\JJ\1740 in_9\IN\13603305 three_10\CD\13741022 models_11\NNS\5888929 of_12\IN\1740 pain_13\NN\14299637 :_14\:\1740 reversal_15\NN\199130 of_16\IN\1740 formalin-induced_17\JJ\1740 paw_18\NN\2153445 licking_19\NN\7291312 ,_20\,\1740 <e1>carrageenan-induced</e1>_21\JJ\1740 <e2>thermal_22\JJ\1740 hyperalgesia</e2>_23\NN\1740 ,_24\,\1740 and_25\CC\1740 capsaicin-induced_26\JJ\1740 mechanical_27\JJ\1740 hyperalgesia_28\NN\1740 ._29\.\1740
D002351_D006930 CID their_0\PRP$\1740 ester_1\NN\14727670 prodrugs_2\NNS\1740 6_3\CD\13741022 and_4\CC\1740 8_5\CD\13741022 were_6\VBD\836236 orally_7\RB\1740 active_8\JJ\1740 in_9\IN\13603305 three_10\CD\13741022 models_11\NNS\5888929 of_12\IN\1740 pain_13\NN\14299637 :_14\:\1740 reversal_15\NN\199130 of_16\IN\1740 formalin-induced_17\JJ\1740 paw_18\NN\2153445 licking_19\NN\7291312 ,_20\,\1740 <e1>carrageenan-induced</e1>_21\JJ\1740 thermal_22\JJ\1740 hyperalgesia_23\NN\1740 ,_24\,\1740 and_25\CC\1740 capsaicin-induced_26\JJ\1740 <e2>mechanical_27\JJ\1740 hyperalgesia</e2>_28\NN\1740 ._29\.\1740
D002211_D010146 NONE their_0\PRP$\1740 ester_1\NN\14727670 prodrugs_2\NNS\1740 6_3\CD\13741022 and_4\CC\1740 8_5\CD\13741022 were_6\VBD\836236 orally_7\RB\1740 active_8\JJ\1740 in_9\IN\13603305 three_10\CD\13741022 models_11\NNS\5888929 of_12\IN\1740 <e2>pain</e2>_13\NN\14299637 :_14\:\1740 reversal_15\NN\199130 of_16\IN\1740 formalin-induced_17\JJ\1740 paw_18\NN\2153445 licking_19\NN\7291312 ,_20\,\1740 carrageenan-induced_21\JJ\1740 thermal_22\JJ\1740 hyperalgesia_23\NN\1740 ,_24\,\1740 and_25\CC\1740 <e1>capsaicin-induced</e1>_26\JJ\1740 mechanical_27\JJ\1740 hyperalgesia_28\NN\1740 ._29\.\1740
D002211_D006930 CID their_0\PRP$\1740 ester_1\NN\14727670 prodrugs_2\NNS\1740 6_3\CD\13741022 and_4\CC\1740 8_5\CD\13741022 were_6\VBD\836236 orally_7\RB\1740 active_8\JJ\1740 in_9\IN\13603305 three_10\CD\13741022 models_11\NNS\5888929 of_12\IN\1740 pain_13\NN\14299637 :_14\:\1740 reversal_15\NN\199130 of_16\IN\1740 formalin-induced_17\JJ\1740 paw_18\NN\2153445 licking_19\NN\7291312 ,_20\,\1740 carrageenan-induced_21\JJ\1740 <e2>thermal_22\JJ\1740 hyperalgesia</e2>_23\NN\1740 ,_24\,\1740 and_25\CC\1740 <e1>capsaicin-induced</e1>_26\JJ\1740 mechanical_27\JJ\1740 hyperalgesia_28\NN\1740 ._29\.\1740
D002211_D006930 CID their_0\PRP$\1740 ester_1\NN\14727670 prodrugs_2\NNS\1740 6_3\CD\13741022 and_4\CC\1740 8_5\CD\13741022 were_6\VBD\836236 orally_7\RB\1740 active_8\JJ\1740 in_9\IN\13603305 three_10\CD\13741022 models_11\NNS\5888929 of_12\IN\1740 pain_13\NN\14299637 :_14\:\1740 reversal_15\NN\199130 of_16\IN\1740 formalin-induced_17\JJ\1740 paw_18\NN\2153445 licking_19\NN\7291312 ,_20\,\1740 carrageenan-induced_21\JJ\1740 thermal_22\JJ\1740 hyperalgesia_23\NN\1740 ,_24\,\1740 and_25\CC\1740 <e1>capsaicin-induced</e1>_26\JJ\1740 <e2>mechanical_27\JJ\1740 hyperalgesia</e2>_28\NN\1740 ._29\.\1740
6504332
D010634_D004409 CID <e1>phenobarbital-induced</e1>_0\JJ\1740 <e2>dyskinesia</e2>_1\NN\14084880 in_2\IN\13603305 a_3\DT\13649268 neurologically-impaired_4\JJ\1740 child_5\NN\9622049 ._6\.\1740
D010634_D004409 CID a_0\DT\13649268 2-year-old_1\JJ\1740 child_2\NN\9622049 with_3\IN\1740 known_4\JJ\1740 neurologic_5\JJ\1740 impairment_6\NN\7296428 developed_7\VBD\1753788 a_8\DT\13649268 <e2>dyskinesia</e2>_9\NN\14084880 soon_10\RB\1740 after_11\IN\1740 starting_12\VBG\2009433 <e1>phenobarbital</e1>_13\JJ\1740 therapy_14\NN\657604 for_15\IN\1740 seizures_16\NNS\14081375 ._17\.\1740
D010634_D004409 CID on_0\IN\1740 repeat_1\NN\7296190 challenge_2\NN\13927383 with_3\IN\1740 <e1>phenobarbital</e1>_4\JJ\1740 ,_5\,\1740 the_6\DT\1740 <e2>dyskinesia</e2>_7\NN\14084880 recurred_8\VBD\339934 ._9\.\1740
D010634_D009422 NONE <e1>phenobarbital-induced</e1>_0\JJ\1740 dyskinesia_1\NN\14084880 in_2\IN\13603305 a_3\DT\13649268 <e2>neurologically-impaired</e2>_4\JJ\1740 child_5\NN\9622049 ._6\.\1740
D010634_D009422 NONE a_0\DT\13649268 2-year-old_1\JJ\1740 child_2\NN\9622049 with_3\IN\1740 known_4\JJ\1740 <e2>neurologic_5\JJ\1740 impairment</e2>_6\NN\7296428 developed_7\VBD\1753788 a_8\DT\13649268 dyskinesia_9\NN\14084880 soon_10\RB\1740 after_11\IN\1740 starting_12\VBG\2009433 <e1>phenobarbital</e1>_13\JJ\1740 therapy_14\NN\657604 for_15\IN\1740 seizures_16\NNS\14081375 ._17\.\1740
D010634_D012640 NONE a_0\DT\13649268 2-year-old_1\JJ\1740 child_2\NN\9622049 with_3\IN\1740 known_4\JJ\1740 neurologic_5\JJ\1740 impairment_6\NN\7296428 developed_7\VBD\1753788 a_8\DT\13649268 dyskinesia_9\NN\14084880 soon_10\RB\1740 after_11\IN\1740 starting_12\VBG\2009433 <e1>phenobarbital</e1>_13\JJ\1740 therapy_14\NN\657604 for_15\IN\1740 <e2>seizures</e2>_16\NNS\14081375 ._17\.\1740
D010634_D009069 NONE <e1>phenobarbital</e1>_0\NNP\2792049 should_1\MD\1740 be_2\VB\836236 added_3\VBN\156601 to_4\IN\1740 the_5\DT\1740 list_6\NN\6637824 of_7\IN\1740 anticonvulsant_8\JJ\1740 drugs_9\NNS\14778436 that_10\WDT\1740 can_11\MD\3094503 cause_12\VB\1617192 <e2>movement_13\NN\191142 disorders</e2>_14\NNS\14034177 ._15\.\1740
18356633
D000583_D007674 CID an_0\DT\6697703 evaluation_1\NN\874067 of_2\IN\1740 <e1>amikacin</e1>_3\NN\1740 <e2>nephrotoxicity</e2>_4\NN\1740 in_5\IN\13603305 the_6\DT\1740 hematology/oncology_7\JJ\1740 population_8\NN\7942152 ._9\.\1740
D000583_D007674 CID to_0\TO\1740 evaluate_1\VB\670261 <e1>amikacin-associated</e1>_2\JJ\1740 <e2>nephrotoxicity</e2>_3\NN\1740 in_4\IN\13603305 an_5\DT\6697703 adult_6\JJ\1740 hematology/oncology_7\JJ\1740 population_8\NN\7942152 ,_9\,\1740 a_10\DT\13649268 prospective_11\JJ\1740 ,_12\,\1740 randomized_13\JJ\1740 ,_14\,\1740 open-label_15\JJ\1740 trial_16\NN\786195 was_17\VBD\836236 conducted_18\VBN\2436349 at_19\IN\14622893 a_20\DT\13649268 university-affiliated_21\JJ\1740 medical_22\JJ\1740 center_23\NN\8497294 ._24\.\1740
D000583_D007674 CID the_0\DT\1740 occurrence_1\NN\29378 of_2\IN\1740 <e2>nephrotoxicity</e2>_3\NN\1740 by_4\IN\1740 means_5\NNS\44150 of_6\IN\1740 an_7\DT\6697703 increase_8\NN\13576355 in_9\IN\13603305 serum_10\NN\5397468 creatinine_11\NN\1740 and_12\CC\1740 evaluation_13\NN\874067 of_14\IN\1740 efficacy_15\NN\5199286 via_16\IN\1740 <e1>amikacin</e1>_17\NN\1740 serum_18\NN\5397468 concentrations_19\NNS\4916342 with_20\IN\1740 respective_21\JJ\1740 pathogens_22\NNS\9312843 were_23\VBD\836236 assessed_24\VBN\670261 ._25\.\1740
D000583_D009503 NONE <e1>amikacin</e1>_0\NNP\1740 is_1\VBZ\836236 an_2\DT\6697703 aminoglycoside_3\NN\1740 commonly_4\RB\1740 used_5\VBN\1156834 to_6\TO\1740 provide_7\VB\2199590 empirical_8\JJ\1740 double_9\JJ\1740 gram-negative_10\JJ\1740 treatment_11\NN\654885 for_12\IN\1740 <e2>febrile_13\JJ\1740 neutropenia</e2>_14\NN\14196405 and_15\CC\1740 other_16\JJ\1740 suspected_17\VBN\916909 infections_18\NNS\14052046 ._19\.\1740
D000583_D007239 NONE <e1>amikacin</e1>_0\NNP\1740 is_1\VBZ\836236 an_2\DT\6697703 aminoglycoside_3\NN\1740 commonly_4\RB\1740 used_5\VBN\1156834 to_6\TO\1740 provide_7\VB\2199590 empirical_8\JJ\1740 double_9\JJ\1740 gram-negative_10\JJ\1740 treatment_11\NN\654885 for_12\IN\1740 febrile_13\JJ\1740 neutropenia_14\NN\14196405 and_15\CC\1740 other_16\JJ\1740 suspected_17\VBN\916909 <e2>infections</e2>_18\NNS\14052046 ._19\.\1740
D000617_D009503 NONE amikacin_0\NNP\1740 is_1\VBZ\836236 an_2\DT\6697703 <e1>aminoglycoside</e1>_3\NN\1740 commonly_4\RB\1740 used_5\VBN\1156834 to_6\TO\1740 provide_7\VB\2199590 empirical_8\JJ\1740 double_9\JJ\1740 gram-negative_10\JJ\1740 treatment_11\NN\654885 for_12\IN\1740 <e2>febrile_13\JJ\1740 neutropenia</e2>_14\NN\14196405 and_15\CC\1740 other_16\JJ\1740 suspected_17\VBN\916909 infections_18\NNS\14052046 ._19\.\1740
D000617_D007239 NONE amikacin_0\NNP\1740 is_1\VBZ\836236 an_2\DT\6697703 <e1>aminoglycoside</e1>_3\NN\1740 commonly_4\RB\1740 used_5\VBN\1156834 to_6\TO\1740 provide_7\VB\2199590 empirical_8\JJ\1740 double_9\JJ\1740 gram-negative_10\JJ\1740 treatment_11\NN\654885 for_12\IN\1740 febrile_13\JJ\1740 neutropenia_14\NN\14196405 and_15\CC\1740 other_16\JJ\1740 suspected_17\VBN\916909 <e2>infections</e2>_18\NNS\14052046 ._19\.\1740
D000617_D006402 NONE forty_0\CD\13745420 patients_1\NNS\9898892 with_2\IN\1740 a_3\DT\13649268 diagnosis_4\NN\152018 consistent_5\JJ\1740 with_6\IN\1740 a_7\DT\13649268 <e2>hematologic/oncologic_8\JJ\1740 disorder</e2>_9\NN\14034177 that_10\WDT\1740 required_11\VBD\754942 treatment_12\NN\654885 with_13\IN\1740 an_14\DT\6697703 <e1>aminoglycoside</e1>_15\NN\1740 were_16\VBD\836236 randomized_17\VBN\278117 to_18\TO\1740 either_19\CC\1740 conventional_20\JJ\1740 or_21\CC\3541091 extended-interval_22\JJ\1740 amikacin_23\NN\1740 ._24\.\1740
D000617_D009369 NONE forty_0\CD\13745420 patients_1\NNS\9898892 with_2\IN\1740 a_3\DT\13649268 diagnosis_4\NN\152018 consistent_5\JJ\1740 with_6\IN\1740 a_7\DT\13649268 <e2>hematologic/oncologic_8\JJ\1740 disorder</e2>_9\NN\14034177 that_10\WDT\1740 required_11\VBD\754942 treatment_12\NN\654885 with_13\IN\1740 an_14\DT\6697703 <e1>aminoglycoside</e1>_15\NN\1740 were_16\VBD\836236 randomized_17\VBN\278117 to_18\TO\1740 either_19\CC\1740 conventional_20\JJ\1740 or_21\CC\3541091 extended-interval_22\JJ\1740 amikacin_23\NN\1740 ._24\.\1740
D000583_D006402 NONE forty_0\CD\13745420 patients_1\NNS\9898892 with_2\IN\1740 a_3\DT\13649268 diagnosis_4\NN\152018 consistent_5\JJ\1740 with_6\IN\1740 a_7\DT\13649268 <e2>hematologic/oncologic_8\JJ\1740 disorder</e2>_9\NN\14034177 that_10\WDT\1740 required_11\VBD\754942 treatment_12\NN\654885 with_13\IN\1740 an_14\DT\6697703 aminoglycoside_15\NN\1740 were_16\VBD\836236 randomized_17\VBN\278117 to_18\TO\1740 either_19\CC\1740 conventional_20\JJ\1740 or_21\CC\3541091 extended-interval_22\JJ\1740 <e1>amikacin</e1>_23\NN\1740 ._24\.\1740
D000583_D009369 NONE forty_0\CD\13745420 patients_1\NNS\9898892 with_2\IN\1740 a_3\DT\13649268 diagnosis_4\NN\152018 consistent_5\JJ\1740 with_6\IN\1740 a_7\DT\13649268 <e2>hematologic/oncologic_8\JJ\1740 disorder</e2>_9\NN\14034177 that_10\WDT\1740 required_11\VBD\754942 treatment_12\NN\654885 with_13\IN\1740 an_14\DT\6697703 aminoglycoside_15\NN\1740 were_16\VBD\836236 randomized_17\VBN\278117 to_18\TO\1740 either_19\CC\1740 conventional_20\JJ\1740 or_21\CC\3541091 extended-interval_22\JJ\1740 <e1>amikacin</e1>_23\NN\1740 ._24\.\1740
D003404_D007674 NONE the_0\DT\1740 occurrence_1\NN\29378 of_2\IN\1740 <e2>nephrotoxicity</e2>_3\NN\1740 by_4\IN\1740 means_5\NNS\44150 of_6\IN\1740 an_7\DT\6697703 increase_8\NN\13576355 in_9\IN\13603305 serum_10\NN\5397468 <e1>creatinine</e1>_11\NN\1740 and_12\CC\1740 evaluation_13\NN\874067 of_14\IN\1740 efficacy_15\NN\5199286 via_16\IN\1740 amikacin_17\NN\1740 serum_18\NN\5397468 concentrations_19\NNS\4916342 with_20\IN\1740 respective_21\JJ\1740 pathogens_22\NNS\9312843 were_23\VBD\836236 assessed_24\VBN\670261 ._25\.\1740
1564236
D013793_D023921 NONE relation_0\NN\2137 of_1\IN\1740 perfusion_2\NN\320852 defects_3\NNS\14462666 observed_4\VBN\2163746 with_5\IN\1740 myocardial_6\JJ\1740 contrast_7\NN\13854649 echocardiography_8\NN\177127 to_9\TO\1740 the_10\DT\1740 severity_11\NN\5036394 of_12\IN\1740 <e2>coronary_13\JJ\1740 stenosis</e2>_14\NN\14204950 :_15\:\1740 correlation_16\NN\13841213 with_17\IN\1740 <e1>thallium-201</e1>_18\JJ\1740 single-photon_19\NN\1740 emission_20\NN\44455 tomography_21\NN\900375 ._22\.\1740
D004176_D006940 CID during_0\IN\1740 <e1>dipyridamole-induced</e1>_1\JJ\1740 <e2>hyperemia</e2>_2\NN\14320394 ,_3\,\1740 12_4\CD\13745420 of_5\IN\1740 the_6\DT\1740 16_7\CD\13745420 dogs_8\NNS\2083346 with_9\IN\1740 a_10\DT\13649268 partial_11\JJ\1740 coronary_12\JJ\1740 stenosis_13\NN\14204950 had_14\VBD\2108377 a_15\DT\13649268 visible_16\JJ\1740 area_17\NN\8630985 of_18\IN\1740 hypoperfusion_19\NN\1740 by_20\IN\1740 contrast_21\NN\13854649 echocardiography_22\NN\177127 ._23\.\1740
D004176_D006940 CID the_0\DT\1740 four_1\CD\13741022 dogs_2\NNS\2083346 without_3\IN\1740 a_4\DT\13649268 perfusion_5\NN\320852 defect_6\NN\14462666 had_7\VBD\2108377 a_8\DT\13649268 stenosis_9\NN\14204950 that_10\WDT\1740 resulted_11\VBD\2633881 in_12\IN\13603305 a_13\DT\13649268 mild_14\NN\1740 (_15\-LRB-\1740 0_16\CD\13741022 %_17\NN\1740 to_18\TO\1740 50_19\CD\13745420 %_20\NN\1740 )_21\-RRB-\1740 reduction_22\NN\351485 in_23\IN\13603305 <e1>dipyridamole-induced</e1>_24\JJ\1740 <e2>hyperemia</e2>_25\NN\14320394 ._26\.\1740
D004176_D006940 CID thallium-201_0\VBG\1740 spect_1\NN\1740 demonstrated_2\VBD\2137132 a_3\DT\13649268 perfusion_4\NN\320852 defect_5\NN\14462666 in_6\IN\13603305 all_7\DT\1740 14_8\CD\13745420 dogs_9\NNS\2083346 analyzed_10\VBN\78760 during_11\IN\1740 <e1>dipyridamole-induced</e1>_12\JJ\1740 <e2>hyperemia</e2>_13\NN\14320394 ;_14\:\1740 the_15\DT\1740 size_16\NN\5090441 of_17\IN\1740 the_18\DT\1740 perfusion_19\NN\320852 defect_20\NN\14462666 correlated_21\VBD\2657219 with_22\IN\1740 the_23\DT\1740 anatomic_24\JJ\1740 area_25\NN\8630985 at_26\IN\14622893 risk_27\NN\14541044 (_28\-LRB-\1740 r_29\NN\13635336 =_30\JJ\1740 0.58_31\CD\1740 ;_32\:\1740 p_33\NN\14622893 less_34\JJR\1740 than_35\IN\1740 0.03_36\CD\1740 )_37\-RRB-\1740 and_38\CC\1740 with_39\IN\1740 the_40\DT\1740 perfusion_41\NN\320852 defect_42\NN\14462666 by_43\IN\1740 contrast_44\NN\13854649 echocardiography_45\NN\177127 (_46\-LRB-\1740 r_47\NN\13635336 =_48\JJ\1740 0.58_49\CD\1740 ;_50\:\1740 p_51\NN\14622893 less_52\JJR\1740 than_53\IN\1740 0.03_54\CD\1740 )_55\-RRB-\1740 ._56\.\1740
D004176_D023921 NONE during_0\IN\1740 <e1>dipyridamole-induced</e1>_1\JJ\1740 hyperemia_2\NN\14320394 ,_3\,\1740 12_4\CD\13745420 of_5\IN\1740 the_6\DT\1740 16_7\CD\13745420 dogs_8\NNS\2083346 with_9\IN\1740 a_10\DT\13649268 partial_11\JJ\1740 <e2>coronary_12\JJ\1740 stenosis</e2>_13\NN\14204950 had_14\VBD\2108377 a_15\DT\13649268 visible_16\JJ\1740 area_17\NN\8630985 of_18\IN\1740 hypoperfusion_19\NN\1740 by_20\IN\1740 contrast_21\NN\13854649 echocardiography_22\NN\177127 ._23\.\1740
D013793_D006940 NONE <e1>thallium-201</e1>_0\VBG\1740 spect_1\NN\1740 demonstrated_2\VBD\2137132 a_3\DT\13649268 perfusion_4\NN\320852 defect_5\NN\14462666 in_6\IN\13603305 all_7\DT\1740 14_8\CD\13745420 dogs_9\NNS\2083346 analyzed_10\VBN\78760 during_11\IN\1740 dipyridamole-induced_12\JJ\1740 <e2>hyperemia</e2>_13\NN\14320394 ;_14\:\1740 the_15\DT\1740 size_16\NN\5090441 of_17\IN\1740 the_18\DT\1740 perfusion_19\NN\320852 defect_20\NN\14462666 correlated_21\VBD\2657219 with_22\IN\1740 the_23\DT\1740 anatomic_24\JJ\1740 area_25\NN\8630985 at_26\IN\14622893 risk_27\NN\14541044 (_28\-LRB-\1740 r_29\NN\13635336 =_30\JJ\1740 0.58_31\CD\1740 ;_32\:\1740 p_33\NN\14622893 less_34\JJR\1740 than_35\IN\1740 0.03_36\CD\1740 )_37\-RRB-\1740 and_38\CC\1740 with_39\IN\1740 the_40\DT\1740 perfusion_41\NN\320852 defect_42\NN\14462666 by_43\IN\1740 contrast_44\NN\13854649 echocardiography_45\NN\177127 (_46\-LRB-\1740 r_47\NN\13635336 =_48\JJ\1740 0.58_49\CD\1740 ;_50\:\1740 p_51\NN\14622893 less_52\JJR\1740 than_53\IN\1740 0.03_54\CD\1740 )_55\-RRB-\1740 ._56\.\1740
9305828
D010862_D004833 CID neuropeptide-y_0\NN\1740 immunoreactivity_1\NN\1740 in_2\IN\13603305 the_3\DT\1740 <e1>pilocarpine</e1>_4\NN\14712692 model_5\NN\5888929 of_6\IN\1740 <e2>temporal_7\JJ\1740 lobe_8\JJ\1740 epilepsy</e2>_9\NN\14085708 ._10\.\1740
D010862_D004833 CID the_0\DT\1740 results_1\NNS\34213 demonstrate_2\VBP\2137132 that_3\IN\1740 changes_4\NNS\7283608 in_5\IN\13603305 npy_6\NN\1740 expression_7\NN\4679549 ,_8\,\1740 including_9\VBG\690614 expression_10\NN\4679549 in_11\IN\13603305 the_12\DT\1740 granule_13\NN\9290777 cells_14\NNS\3080309 and_15\CC\1740 mossy_16\NN\1740 fibres_17\NNS\14580897 and_18\CC\1740 the_19\DT\1740 loss_20\NN\13252973 of_21\IN\1740 vulnerable_22\JJ\1740 npy_23\NN\1740 neurons_24\NNS\5430628 ,_25\,\1740 are_26\VBP\836236 present_27\JJ\1740 in_28\IN\13603305 the_29\DT\1740 <e1>pilo</e1>_30\NN\1740 model_31\NN\5888929 of_32\IN\1740 <e2>tle</e2>_33\NN\1740 ._34\.\1740
D010862_D004827 NONE the_0\DT\1740 <e1>pilocarpine</e1>_1\NN\14712692 (_2\-LRB-\1740 pilo_3\NNS\1740 )_4\-RRB-\1740 model_5\NN\5888929 of_6\IN\1740 <e2>epilepsy</e2>_7\NN\14085708 is_8\VBZ\836236 characterized_9\VBN\609683 by_10\IN\1740 an_11\DT\6697703 acute_12\JJ\1740 period_13\NN\13575869 of_14\IN\1740 status_15\NN\24720 epilepticus_16\NN\1740 followed_17\VBN\1835496 by_18\IN\1740 spontaneous_19\JJ\1740 recurrent_20\JJ\1740 seizures_21\NNS\14081375 and_22\CC\1740 related_23\JJ\1740 brain_24\NN\5462674 damage_25\NN\7296428 ._26\.\1740
D010862_D004827 NONE the_0\DT\1740 pilocarpine_1\NN\14712692 (_2\-LRB-\1740 <e1>pilo</e1>_3\NNS\1740 )_4\-RRB-\1740 model_5\NN\5888929 of_6\IN\1740 <e2>epilepsy</e2>_7\NN\14085708 is_8\VBZ\836236 characterized_9\VBN\609683 by_10\IN\1740 an_11\DT\6697703 acute_12\JJ\1740 period_13\NN\13575869 of_14\IN\1740 status_15\NN\24720 epilepticus_16\NN\1740 followed_17\VBN\1835496 by_18\IN\1740 spontaneous_19\JJ\1740 recurrent_20\JJ\1740 seizures_21\NNS\14081375 and_22\CC\1740 related_23\JJ\1740 brain_24\NN\5462674 damage_25\NN\7296428 ._26\.\1740
D010862_D013226 NONE the_0\DT\1740 <e1>pilocarpine</e1>_1\NN\14712692 (_2\-LRB-\1740 pilo_3\NNS\1740 )_4\-RRB-\1740 model_5\NN\5888929 of_6\IN\1740 epilepsy_7\NN\14085708 is_8\VBZ\836236 characterized_9\VBN\609683 by_10\IN\1740 an_11\DT\6697703 acute_12\JJ\1740 period_13\NN\13575869 of_14\IN\1740 <e2>status_15\NN\24720 epilepticus</e2>_16\NN\1740 followed_17\VBN\1835496 by_18\IN\1740 spontaneous_19\JJ\1740 recurrent_20\JJ\1740 seizures_21\NNS\14081375 and_22\CC\1740 related_23\JJ\1740 brain_24\NN\5462674 damage_25\NN\7296428 ._26\.\1740
D010862_D013226 NONE the_0\DT\1740 pilocarpine_1\NN\14712692 (_2\-LRB-\1740 <e1>pilo</e1>_3\NNS\1740 )_4\-RRB-\1740 model_5\NN\5888929 of_6\IN\1740 epilepsy_7\NN\14085708 is_8\VBZ\836236 characterized_9\VBN\609683 by_10\IN\1740 an_11\DT\6697703 acute_12\JJ\1740 period_13\NN\13575869 of_14\IN\1740 <e2>status_15\NN\24720 epilepticus</e2>_16\NN\1740 followed_17\VBN\1835496 by_18\IN\1740 spontaneous_19\JJ\1740 recurrent_20\JJ\1740 seizures_21\NNS\14081375 and_22\CC\1740 related_23\JJ\1740 brain_24\NN\5462674 damage_25\NN\7296428 ._26\.\1740
D010862_D012640 NONE the_0\DT\1740 <e1>pilocarpine</e1>_1\NN\14712692 (_2\-LRB-\1740 pilo_3\NNS\1740 )_4\-RRB-\1740 model_5\NN\5888929 of_6\IN\1740 epilepsy_7\NN\14085708 is_8\VBZ\836236 characterized_9\VBN\609683 by_10\IN\1740 an_11\DT\6697703 acute_12\JJ\1740 period_13\NN\13575869 of_14\IN\1740 status_15\NN\24720 epilepticus_16\NN\1740 followed_17\VBN\1835496 by_18\IN\1740 spontaneous_19\JJ\1740 recurrent_20\JJ\1740 <e2>seizures</e2>_21\NNS\14081375 and_22\CC\1740 related_23\JJ\1740 brain_24\NN\5462674 damage_25\NN\7296428 ._26\.\1740
D010862_D012640 NONE the_0\DT\1740 pilocarpine_1\NN\14712692 (_2\-LRB-\1740 <e1>pilo</e1>_3\NNS\1740 )_4\-RRB-\1740 model_5\NN\5888929 of_6\IN\1740 epilepsy_7\NN\14085708 is_8\VBZ\836236 characterized_9\VBN\609683 by_10\IN\1740 an_11\DT\6697703 acute_12\JJ\1740 period_13\NN\13575869 of_14\IN\1740 status_15\NN\24720 epilepticus_16\NN\1740 followed_17\VBN\1835496 by_18\IN\1740 spontaneous_19\JJ\1740 recurrent_20\JJ\1740 <e2>seizures</e2>_21\NNS\14081375 and_22\CC\1740 related_23\JJ\1740 brain_24\NN\5462674 damage_25\NN\7296428 ._26\.\1740
D010862_D001930 NONE the_0\DT\1740 <e1>pilocarpine</e1>_1\NN\14712692 (_2\-LRB-\1740 pilo_3\NNS\1740 )_4\-RRB-\1740 model_5\NN\5888929 of_6\IN\1740 epilepsy_7\NN\14085708 is_8\VBZ\836236 characterized_9\VBN\609683 by_10\IN\1740 an_11\DT\6697703 acute_12\JJ\1740 period_13\NN\13575869 of_14\IN\1740 status_15\NN\24720 epilepticus_16\NN\1740 followed_17\VBN\1835496 by_18\IN\1740 spontaneous_19\JJ\1740 recurrent_20\JJ\1740 seizures_21\NNS\14081375 and_22\CC\1740 related_23\JJ\1740 <e2>brain_24\NN\5462674 damage</e2>_25\NN\7296428 ._26\.\1740
D010862_D001930 NONE the_0\DT\1740 pilocarpine_1\NN\14712692 (_2\-LRB-\1740 <e1>pilo</e1>_3\NNS\1740 )_4\-RRB-\1740 model_5\NN\5888929 of_6\IN\1740 epilepsy_7\NN\14085708 is_8\VBZ\836236 characterized_9\VBN\609683 by_10\IN\1740 an_11\DT\6697703 acute_12\JJ\1740 period_13\NN\13575869 of_14\IN\1740 status_15\NN\24720 epilepticus_16\NN\1740 followed_17\VBN\1835496 by_18\IN\1740 spontaneous_19\JJ\1740 recurrent_20\JJ\1740 seizures_21\NNS\14081375 and_22\CC\1740 related_23\JJ\1740 <e2>brain_24\NN\5462674 damage</e2>_25\NN\7296428 ._26\.\1740
7791169
D016595_D007674 NONE protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>misoprostol</e1>_3\NN\1740 on_4\IN\1740 indomethacin_5\NN\3828465 induced_6\JJ\1740 <e2>renal_7\JJ\1740 dysfunction</e2>_8\NN\14204950 in_9\IN\13603305 elderly_10\JJ\1740 patients_11\NNS\9898892 ._12\.\1740
D016595_D007674 NONE addition_0\NN\3081021 of_1\IN\1740 <e1>misoprostol</e1>_2\NN\1740 can_3\MD\3094503 minimize_4\VB\441445 this_5\DT\1740 <e2>renal_6\JJ\1740 impairment</e2>_7\NN\7296428 without_8\IN\1740 affecting_9\VBG\126264 pain_10\NN\14299637 control_11\NN\5190804 ._12\.\1740
D007213_D007674 CID protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 misoprostol_3\NN\1740 on_4\IN\1740 <e1>indomethacin</e1>_5\NN\3828465 induced_6\JJ\1740 <e2>renal_7\JJ\1740 dysfunction</e2>_8\NN\14204950 in_9\IN\13603305 elderly_10\JJ\1740 patients_11\NNS\9898892 ._12\.\1740
D007213_D007674 CID conclusion_0\NN\5837957 :_1\:\1740 hospitalized_2\VBN\2348568 elderly_3\JJ\1740 patients_4\NNS\9898892 are_5\VBP\836236 at_6\IN\14622893 risk_7\NN\14541044 for_8\IN\1740 developing_9\VBG\1753788 <e1>indomethacin</e1>_10\NN\3828465 related_11\JJ\1740 <e2>renal_12\JJ\1740 dysfunction</e2>_13\NN\14204950 ._14\.\1740
D016595_D010146 NONE addition_0\NN\3081021 of_1\IN\1740 <e1>misoprostol</e1>_2\NN\1740 can_3\MD\3094503 minimize_4\VB\441445 this_5\DT\1740 renal_6\JJ\1740 impairment_7\NN\7296428 without_8\IN\1740 affecting_9\VBG\126264 <e2>pain</e2>_10\NN\14299637 control_11\NN\5190804 ._12\.\1740
2021202
D007530_D007022 CID renal_0\JJ\1740 function_1\NN\13783581 and_2\CC\1740 hemodynamics_3\NNS\6080522 during_4\IN\1740 prolonged_5\JJ\1740 <e1>isoflurane-induced</e1>_6\JJ\1740 <e2>hypotension</e2>_7\NN\14057371 in_8\IN\13603305 humans_9\NNS\31264 ._10\.\1740
D007530_D007022 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>isoflurane-induced</e1>_3\JJ\1740 <e2>hypotension</e2>_4\NN\14057371 on_5\IN\1740 glomerular_6\JJ\1740 function_7\NN\13783581 and_8\CC\1740 renal_9\JJ\1740 blood_10\NN\5397468 flow_11\NN\7311115 was_12\VBD\836236 investigated_13\VBN\644583 in_14\IN\13603305 20_15\CD\13745420 human_16\JJ\1740 subjects_17\NNS\6598915 ._18\.\1740
D007530_D007022 CID <e2>hypotension</e2>_0\NN\14057371 was_1\VBD\836236 induced_2\VBN\1627355 for_3\IN\1740 236.9_4\CD\1740 +/-_5\CC\1740 15.1_6\CD\1740 min_7\NN\15154774 by_8\IN\1740 increasing_9\VBG\169651 the_10\DT\1740 <e1>isoflurane</e1>_11\NN\3570838 inspired_12\JJ\1740 concentration_13\NN\4916342 to_14\TO\1740 maintain_15\VB\2202928 a_16\DT\13649268 mean_17\NN\6021761 arterial_18\JJ\1740 pressure_19\NN\11419404 of_20\IN\1740 59.8_21\CD\1740 +/-_22\CC\1740 0.4_23\CD\1740 mmhg_24\NN\1740 ._25\.\1740
D007530_D007022 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 renal_3\JJ\1740 compensatory_4\JJ\1740 mechanisms_5\NNS\13446390 are_6\VBP\836236 preserved_7\VBN\2681795 during_8\IN\1740 <e1>isoflurane-induced</e1>_9\JJ\1740 <e2>hypotension</e2>_10\NN\14057371 and_11\CC\1740 that_12\IN\1740 renal_13\JJ\1740 function_14\NN\13783581 and_15\CC\1740 hemodynamics_16\VBZ\1740 quickly_17\RB\1740 return_18\VBP\1835496 to_19\IN\1740 normal_20\JJ\1740 when_21\WRB\1740 normotension_22\NN\1740 is_23\VBZ\836236 resumed_24\VBN\2679899 ._25\.\1740
17285209
D017311_D006973 NONE this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 on_5\IN\1740 a_6\DT\13649268 45-year_7\JJ\1740 old_8\JJ\1740 african-american_9\JJ\1740 female_10\NN\15388 with_11\IN\1740 newly_12\RB\1740 diagnosed_13\VBN\644583 <e2>hypertension</e2>_14\NN\14057371 ,_15\,\1740 who_16\WP\8299493 was_17\VBD\836236 started_18\VBN\2009433 on_19\IN\1740 a_20\DT\13649268 combination_21\NN\7951464 pill_22\NN\4424218 of_23\IN\1740 <e1>amlodipine/benazapril</e1>_24\JJ\1740 10/5_25\NN\1740 mg._26\NN\1740 the_27\DT\1740 very_28\RB\1740 next_29\JJ\1740 day_30\NN\15154774 ,_31\,\1740 she_32\PRP\1740 presented_33\VBD\2137132 at_34\IN\14622893 the_35\DT\1740 emergency_36\NN\7417644 room_37\NN\2735688 (_38\-LRB-\1740 er_39\NN\14625458 )_40\-RRB-\1740 with_41\IN\1740 abdominal_42\JJ\1740 pain_43\NN\14299637 ,_44\,\1740 nausea_45\NN\14299637 and_46\CC\1740 vomiting_47\NN\116687 ._48\.\1740
D017311_D015746 NONE this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 on_5\IN\1740 a_6\DT\13649268 45-year_7\JJ\1740 old_8\JJ\1740 african-american_9\JJ\1740 female_10\NN\15388 with_11\IN\1740 newly_12\RB\1740 diagnosed_13\VBN\644583 hypertension_14\NN\14057371 ,_15\,\1740 who_16\WP\8299493 was_17\VBD\836236 started_18\VBN\2009433 on_19\IN\1740 a_20\DT\13649268 combination_21\NN\7951464 pill_22\NN\4424218 of_23\IN\1740 <e1>amlodipine/benazapril</e1>_24\JJ\1740 10/5_25\NN\1740 mg._26\NN\1740 the_27\DT\1740 very_28\RB\1740 next_29\JJ\1740 day_30\NN\15154774 ,_31\,\1740 she_32\PRP\1740 presented_33\VBD\2137132 at_34\IN\14622893 the_35\DT\1740 emergency_36\NN\7417644 room_37\NN\2735688 (_38\-LRB-\1740 er_39\NN\14625458 )_40\-RRB-\1740 with_41\IN\1740 <e2>abdominal_42\JJ\1740 pain</e2>_43\NN\14299637 ,_44\,\1740 nausea_45\NN\14299637 and_46\CC\1740 vomiting_47\NN\116687 ._48\.\1740
D017311_D009325 NONE this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 on_5\IN\1740 a_6\DT\13649268 45-year_7\JJ\1740 old_8\JJ\1740 african-american_9\JJ\1740 female_10\NN\15388 with_11\IN\1740 newly_12\RB\1740 diagnosed_13\VBN\644583 hypertension_14\NN\14057371 ,_15\,\1740 who_16\WP\8299493 was_17\VBD\836236 started_18\VBN\2009433 on_19\IN\1740 a_20\DT\13649268 combination_21\NN\7951464 pill_22\NN\4424218 of_23\IN\1740 <e1>amlodipine/benazapril</e1>_24\JJ\1740 10/5_25\NN\1740 mg._26\NN\1740 the_27\DT\1740 very_28\RB\1740 next_29\JJ\1740 day_30\NN\15154774 ,_31\,\1740 she_32\PRP\1740 presented_33\VBD\2137132 at_34\IN\14622893 the_35\DT\1740 emergency_36\NN\7417644 room_37\NN\2735688 (_38\-LRB-\1740 er_39\NN\14625458 )_40\-RRB-\1740 with_41\IN\1740 abdominal_42\JJ\1740 pain_43\NN\14299637 ,_44\,\1740 <e2>nausea</e2>_45\NN\14299637 and_46\CC\1740 vomiting_47\NN\116687 ._48\.\1740
D017311_D014839 NONE this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 on_5\IN\1740 a_6\DT\13649268 45-year_7\JJ\1740 old_8\JJ\1740 african-american_9\JJ\1740 female_10\NN\15388 with_11\IN\1740 newly_12\RB\1740 diagnosed_13\VBN\644583 hypertension_14\NN\14057371 ,_15\,\1740 who_16\WP\8299493 was_17\VBD\836236 started_18\VBN\2009433 on_19\IN\1740 a_20\DT\13649268 combination_21\NN\7951464 pill_22\NN\4424218 of_23\IN\1740 <e1>amlodipine/benazapril</e1>_24\JJ\1740 10/5_25\NN\1740 mg._26\NN\1740 the_27\DT\1740 very_28\RB\1740 next_29\JJ\1740 day_30\NN\15154774 ,_31\,\1740 she_32\PRP\1740 presented_33\VBD\2137132 at_34\IN\14622893 the_35\DT\1740 emergency_36\NN\7417644 room_37\NN\2735688 (_38\-LRB-\1740 er_39\NN\14625458 )_40\-RRB-\1740 with_41\IN\1740 abdominal_42\JJ\1740 pain_43\NN\14299637 ,_44\,\1740 nausea_45\NN\14299637 and_46\CC\1740 <e2>vomiting</e2>_47\NN\116687 ._48\.\1740
C044946_D006973 NONE this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 on_5\IN\1740 a_6\DT\13649268 45-year_7\JJ\1740 old_8\JJ\1740 african-american_9\JJ\1740 female_10\NN\15388 with_11\IN\1740 newly_12\RB\1740 diagnosed_13\VBN\644583 <e2>hypertension</e2>_14\NN\14057371 ,_15\,\1740 who_16\WP\8299493 was_17\VBD\836236 started_18\VBN\2009433 on_19\IN\1740 a_20\DT\13649268 combination_21\NN\7951464 pill_22\NN\4424218 of_23\IN\1740 <e1>amlodipine/benazapril</e1>_24\JJ\1740 10/5_25\NN\1740 mg._26\NN\1740 the_27\DT\1740 very_28\RB\1740 next_29\JJ\1740 day_30\NN\15154774 ,_31\,\1740 she_32\PRP\1740 presented_33\VBD\2137132 at_34\IN\14622893 the_35\DT\1740 emergency_36\NN\7417644 room_37\NN\2735688 (_38\-LRB-\1740 er_39\NN\14625458 )_40\-RRB-\1740 with_41\IN\1740 abdominal_42\JJ\1740 pain_43\NN\14299637 ,_44\,\1740 nausea_45\NN\14299637 and_46\CC\1740 vomiting_47\NN\116687 ._48\.\1740
C044946_D015746 NONE this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 on_5\IN\1740 a_6\DT\13649268 45-year_7\JJ\1740 old_8\JJ\1740 african-american_9\JJ\1740 female_10\NN\15388 with_11\IN\1740 newly_12\RB\1740 diagnosed_13\VBN\644583 hypertension_14\NN\14057371 ,_15\,\1740 who_16\WP\8299493 was_17\VBD\836236 started_18\VBN\2009433 on_19\IN\1740 a_20\DT\13649268 combination_21\NN\7951464 pill_22\NN\4424218 of_23\IN\1740 <e1>amlodipine/benazapril</e1>_24\JJ\1740 10/5_25\NN\1740 mg._26\NN\1740 the_27\DT\1740 very_28\RB\1740 next_29\JJ\1740 day_30\NN\15154774 ,_31\,\1740 she_32\PRP\1740 presented_33\VBD\2137132 at_34\IN\14622893 the_35\DT\1740 emergency_36\NN\7417644 room_37\NN\2735688 (_38\-LRB-\1740 er_39\NN\14625458 )_40\-RRB-\1740 with_41\IN\1740 <e2>abdominal_42\JJ\1740 pain</e2>_43\NN\14299637 ,_44\,\1740 nausea_45\NN\14299637 and_46\CC\1740 vomiting_47\NN\116687 ._48\.\1740
C044946_D009325 NONE this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 on_5\IN\1740 a_6\DT\13649268 45-year_7\JJ\1740 old_8\JJ\1740 african-american_9\JJ\1740 female_10\NN\15388 with_11\IN\1740 newly_12\RB\1740 diagnosed_13\VBN\644583 hypertension_14\NN\14057371 ,_15\,\1740 who_16\WP\8299493 was_17\VBD\836236 started_18\VBN\2009433 on_19\IN\1740 a_20\DT\13649268 combination_21\NN\7951464 pill_22\NN\4424218 of_23\IN\1740 <e1>amlodipine/benazapril</e1>_24\JJ\1740 10/5_25\NN\1740 mg._26\NN\1740 the_27\DT\1740 very_28\RB\1740 next_29\JJ\1740 day_30\NN\15154774 ,_31\,\1740 she_32\PRP\1740 presented_33\VBD\2137132 at_34\IN\14622893 the_35\DT\1740 emergency_36\NN\7417644 room_37\NN\2735688 (_38\-LRB-\1740 er_39\NN\14625458 )_40\-RRB-\1740 with_41\IN\1740 abdominal_42\JJ\1740 pain_43\NN\14299637 ,_44\,\1740 <e2>nausea</e2>_45\NN\14299637 and_46\CC\1740 vomiting_47\NN\116687 ._48\.\1740
C044946_D014839 NONE this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 on_5\IN\1740 a_6\DT\13649268 45-year_7\JJ\1740 old_8\JJ\1740 african-american_9\JJ\1740 female_10\NN\15388 with_11\IN\1740 newly_12\RB\1740 diagnosed_13\VBN\644583 hypertension_14\NN\14057371 ,_15\,\1740 who_16\WP\8299493 was_17\VBD\836236 started_18\VBN\2009433 on_19\IN\1740 a_20\DT\13649268 combination_21\NN\7951464 pill_22\NN\4424218 of_23\IN\1740 <e1>amlodipine/benazapril</e1>_24\JJ\1740 10/5_25\NN\1740 mg._26\NN\1740 the_27\DT\1740 very_28\RB\1740 next_29\JJ\1740 day_30\NN\15154774 ,_31\,\1740 she_32\PRP\1740 presented_33\VBD\2137132 at_34\IN\14622893 the_35\DT\1740 emergency_36\NN\7417644 room_37\NN\2735688 (_38\-LRB-\1740 er_39\NN\14625458 )_40\-RRB-\1740 with_41\IN\1740 abdominal_42\JJ\1740 pain_43\NN\14299637 ,_44\,\1740 nausea_45\NN\14299637 and_46\CC\1740 <e2>vomiting</e2>_47\NN\116687 ._48\.\1740
D000809_D007410 NONE the_0\DT\1740 recognition_1\NN\13932421 of_2\IN\1740 <e1>angiotensin-converting</e1>_3\JJ\1740 enzyme_4\NN\14723628 (_5\-LRB-\1740 ace_6\NN\13741022 )_7\-RRB-\1740 and_8\CC\1740 angiotensin_9\NN\4522421 receptor_10\NN\5225602 blocker_11\NN\10101634 (_12\-LRB-\1740 arb_13\NN\9882007 )_14\-RRB-\1740 <e2>intestinal_15\JJ\1740 angioedema</e2>_16\NN\14316714 constitutes_17\VBZ\1647229 a_18\DT\13649268 challenge_19\NN\13927383 to_20\IN\1740 primary_21\JJ\1740 care_22\NN\575741 physicians_23\NNS\10305802 ,_24\,\1740 internists_25\NNS\10632576 ,_26\,\1740 emergency_27\NN\7417644 room_28\NN\2735688 personal_29\JJ\1740 and_30\CC\1740 surgeons_31\NNS\10020890 ._32\.\1740
D000809_D007410 NONE the_0\DT\1740 recognition_1\NN\13932421 of_2\IN\1740 angiotensin-converting_3\JJ\1740 enzyme_4\NN\14723628 (_5\-LRB-\1740 ace_6\NN\13741022 )_7\-RRB-\1740 and_8\CC\1740 <e1>angiotensin</e1>_9\NN\4522421 receptor_10\NN\5225602 blocker_11\NN\10101634 (_12\-LRB-\1740 arb_13\NN\9882007 )_14\-RRB-\1740 <e2>intestinal_15\JJ\1740 angioedema</e2>_16\NN\14316714 constitutes_17\VBZ\1647229 a_18\DT\13649268 challenge_19\NN\13927383 to_20\IN\1740 primary_21\JJ\1740 care_22\NN\575741 physicians_23\NNS\10305802 ,_24\,\1740 internists_25\NNS\10632576 ,_26\,\1740 emergency_27\NN\7417644 room_28\NN\2735688 personal_29\JJ\1740 and_30\CC\1740 surgeons_31\NNS\10020890 ._32\.\1740
D000809_D000799 NONE the_0\DT\1740 recognition_1\NN\13932421 of_2\IN\1740 <e1>angiotensin-converting</e1>_3\JJ\1740 enzyme_4\NN\14723628 (_5\-LRB-\1740 ace_6\NN\13741022 )_7\-RRB-\1740 and_8\CC\1740 angiotensin_9\NN\4522421 receptor_10\NN\5225602 blocker_11\NN\10101634 (_12\-LRB-\1740 arb_13\NN\9882007 )_14\-RRB-\1740 <e2>intestinal_15\JJ\1740 angioedema</e2>_16\NN\14316714 constitutes_17\VBZ\1647229 a_18\DT\13649268 challenge_19\NN\13927383 to_20\IN\1740 primary_21\JJ\1740 care_22\NN\575741 physicians_23\NNS\10305802 ,_24\,\1740 internists_25\NNS\10632576 ,_26\,\1740 emergency_27\NN\7417644 room_28\NN\2735688 personal_29\JJ\1740 and_30\CC\1740 surgeons_31\NNS\10020890 ._32\.\1740
D000809_D000799 NONE the_0\DT\1740 recognition_1\NN\13932421 of_2\IN\1740 angiotensin-converting_3\JJ\1740 enzyme_4\NN\14723628 (_5\-LRB-\1740 ace_6\NN\13741022 )_7\-RRB-\1740 and_8\CC\1740 <e1>angiotensin</e1>_9\NN\4522421 receptor_10\NN\5225602 blocker_11\NN\10101634 (_12\-LRB-\1740 arb_13\NN\9882007 )_14\-RRB-\1740 <e2>intestinal_15\JJ\1740 angioedema</e2>_16\NN\14316714 constitutes_17\VBZ\1647229 a_18\DT\13649268 challenge_19\NN\13927383 to_20\IN\1740 primary_21\JJ\1740 care_22\NN\575741 physicians_23\NNS\10305802 ,_24\,\1740 internists_25\NNS\10632576 ,_26\,\1740 emergency_27\NN\7417644 room_28\NN\2735688 personal_29\JJ\1740 and_30\CC\1740 surgeons_31\NNS\10020890 ._32\.\1740
7752389
D015232_D053201 CID <e1>prostaglandin_0\NN\5414534 e2-induced</e1>_1\JJ\1740 <e2>bladder_2\NN\5515670 hyperactivity</e2>_3\NN\14052403 in_4\IN\13603305 normal_5\JJ\1740 ,_6\,\1740 conscious_7\JJ\1740 rats_8\NNS\2329401 :_9\:\1740 involvement_10\NN\1080366 of_11\IN\1740 tachykinins_12\NNS\1740 ?_13\.\1740
D015320_D053201 NONE prostaglandin_0\NN\5414534 e2-induced_1\JJ\1740 <e2>bladder_2\NN\5515670 hyperactivity</e2>_3\NN\14052403 in_4\IN\13603305 normal_5\JJ\1740 ,_6\,\1740 conscious_7\JJ\1740 rats_8\NNS\2329401 :_9\:\1740 involvement_10\NN\1080366 of_11\IN\1740 <e1>tachykinins</e1>_12\NNS\1740 ?_13\.\1740
D015320_D053201 NONE prostanoids_0\NNS\1740 may_1\MD\15209706 ,_2\,\1740 via_3\IN\1740 release_4\NN\3748886 of_5\IN\1740 <e1>tachykinins</e1>_6\NNS\1740 ,_7\,\1740 contribute_8\VBP\126264 to_9\TO\1740 both_10\CC\1740 urge_11\JJ\1740 and_12\CC\1740 <e2>bladder_13\NN\5515670 hyperactivity</e2>_14\NN\14052403 seen_15\VBN\2106506 in_16\IN\13603305 inflammatory_17\JJ\1740 conditions_18\NNS\14512817 of_19\IN\1740 the_20\DT\1740 lower_21\JJR\1740 urinary_22\JJ\1740 tract_23\NN\8574314 ._24\.\1740
D011453_D053201 NONE <e1>prostanoids</e1>_0\NNS\1740 may_1\MD\15209706 ,_2\,\1740 via_3\IN\1740 release_4\NN\3748886 of_5\IN\1740 tachykinins_6\NNS\1740 ,_7\,\1740 contribute_8\VBP\126264 to_9\TO\1740 both_10\CC\1740 urge_11\JJ\1740 and_12\CC\1740 <e2>bladder_13\NN\5515670 hyperactivity</e2>_14\NN\14052403 seen_15\VBN\2106506 in_16\IN\13603305 inflammatory_17\JJ\1740 conditions_18\NNS\14512817 of_19\IN\1740 the_20\DT\1740 lower_21\JJR\1740 urinary_22\JJ\1740 tract_23\NN\8574314 ._24\.\1740
12907924
D008774_D009771 CID <e1>methylphenidate-induced</e1>_0\JJ\1740 <e2>obsessive-compulsive_1\JJ\1740 symptoms</e2>_2\NNS\5823932 in_3\IN\13603305 an_4\DT\6697703 elderly_5\JJ\1740 man_6\NN\9605289 ._7\.\1740
D008774_D009771 CID significant_0\JJ\1740 <e2>obsessive-compulsive_1\JJ\1740 behavior</e2>_2\NN\407535 ensued_3\VBN\2633881 but_4\CC\1740 diminished_5\VBD\169651 over_6\IN\5867413 several_7\JJ\1740 weeks_8\NNS\15113229 when_9\WRB\1740 <e1>methylphenidate</e1>_10\NN\4320126 was_11\VBD\836236 replaced_12\VBN\1631072 by_13\IN\1740 fluvoxamine_14\NN\1740 ._15\.\1740
D008774_D061218 NONE an_0\DT\6697703 82-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 <e2>treatment-resistant_4\JJ\1740 depression</e2>_5\NN\14373582 and_6\CC\1740 early_7\JJ\1740 alzheimer_8\NN\1740 's_9\POS\1740 disease_10\NN\14061805 was_11\VBD\836236 started_12\VBN\2009433 on_13\IN\1740 <e1>methylphenidate</e1>_14\NN\4320126 ._15\.\1740
D008774_D000544 NONE an_0\DT\6697703 82-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 treatment-resistant_4\JJ\1740 depression_5\NN\14373582 and_6\CC\1740 early_7\JJ\1740 <e2>alzheimer_8\NN\1740 's_9\POS\1740 disease</e2>_10\NN\14061805 was_11\VBD\836236 started_12\VBN\2009433 on_13\IN\1740 <e1>methylphenidate</e1>_14\NN\4320126 ._15\.\1740
D016666_D009771 NONE significant_0\JJ\1740 <e2>obsessive-compulsive_1\JJ\1740 behavior</e2>_2\NN\407535 ensued_3\VBN\2633881 but_4\CC\1740 diminished_5\VBD\169651 over_6\IN\5867413 several_7\JJ\1740 weeks_8\NNS\15113229 when_9\WRB\1740 methylphenidate_10\NN\4320126 was_11\VBD\836236 replaced_12\VBN\1631072 by_13\IN\1740 <e1>fluvoxamine</e1>_14\NN\1740 ._15\.\1740
8643973
D017239_D010051 NONE <e1>paclitaxel</e1>_0\NNP\1740 combined_1\VBN\2630189 with_2\IN\1740 carboplatin_3\NN\1740 in_4\IN\13603305 the_5\DT\1740 first-line_6\JJ\1740 treatment_7\NN\654885 of_8\IN\1740 advanced_9\JJ\1740 <e2>ovarian_10\JJ\1740 cancer</e2>_11\NN\14239425 ._12\.\1740
D017239_D010051 NONE in_0\IN\13603305 a_1\DT\13649268 phase_2\NN\15113229 i_3\PRP\14622893 study_4\VBP\630380 to_5\TO\1740 determine_6\VB\1645601 the_7\DT\1740 maximum_8\NN\13653902 tolerated_9\VBD\802318 dose_10\NN\3740161 of_11\IN\1740 <e1>paclitaxel</e1>_12\NN\1740 (_13\-LRB-\1740 taxol_14\NN\1740 ;_15\:\1740 bristol-myers_16\NNP\1740 squibb_17\NNP\1740 company_18\NNP\8053576 ,_19\,\1740 princeton_20\NNP\1740 ,_21\,\1740 nj_22\NNP\1740 )_23\-RRB-\1740 given_24\VBN\2327200 as_25\IN\14622893 a_26\DT\13649268 3-hour_27\CD\1740 infusion_28\NN\14589223 in_29\IN\13603305 combination_30\NN\7951464 with_31\IN\1740 carboplatin_32\NN\1740 administered_33\VBD\2436349 every_34\DT\1740 21_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 women_38\NNS\9605289 with_39\IN\1740 advanced_40\JJ\1740 <e2>ovarian_41\JJ\1740 cancer</e2>_42\NN\14239425 ,_43\,\1740 paclitaxel_44\NN\1740 doses_45\NNS\3740161 were_46\VBD\836236 escalated_47\VBN\153263 as_48\IN\14622893 follows_49\NNS\1740 :_50\:\1740 level_51\NN\4916342 1_52\CD\13741022 ,_53\,\1740 135_54\CD\1740 mg/m2_55\NN\1740 ;_56\:\1740 level_57\NN\4916342 2_58\CD\13741022 ,_59\,\1740 160_60\CD\1740 mg/m2_61\NN\1740 ;_62\:\1740 level_63\NN\4916342 3_64\CD\13741022 ,_65\,\1740 185_66\CD\1740 mg/m2_67\NN\1740 ;_68\:\1740 and_69\CC\1740 level_70\VB\1151110 4,210_71\CD\1740 mg/m2_72\NN\1740 ._73\.\1740
D017239_D010051 NONE in_0\IN\13603305 a_1\DT\13649268 phase_2\NN\15113229 i_3\PRP\14622893 study_4\VBP\630380 to_5\TO\1740 determine_6\VB\1645601 the_7\DT\1740 maximum_8\NN\13653902 tolerated_9\VBD\802318 dose_10\NN\3740161 of_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 <e1>taxol</e1>_14\NN\1740 ;_15\:\1740 bristol-myers_16\NNP\1740 squibb_17\NNP\1740 company_18\NNP\8053576 ,_19\,\1740 princeton_20\NNP\1740 ,_21\,\1740 nj_22\NNP\1740 )_23\-RRB-\1740 given_24\VBN\2327200 as_25\IN\14622893 a_26\DT\13649268 3-hour_27\CD\1740 infusion_28\NN\14589223 in_29\IN\13603305 combination_30\NN\7951464 with_31\IN\1740 carboplatin_32\NN\1740 administered_33\VBD\2436349 every_34\DT\1740 21_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 women_38\NNS\9605289 with_39\IN\1740 advanced_40\JJ\1740 <e2>ovarian_41\JJ\1740 cancer</e2>_42\NN\14239425 ,_43\,\1740 paclitaxel_44\NN\1740 doses_45\NNS\3740161 were_46\VBD\836236 escalated_47\VBN\153263 as_48\IN\14622893 follows_49\NNS\1740 :_50\:\1740 level_51\NN\4916342 1_52\CD\13741022 ,_53\,\1740 135_54\CD\1740 mg/m2_55\NN\1740 ;_56\:\1740 level_57\NN\4916342 2_58\CD\13741022 ,_59\,\1740 160_60\CD\1740 mg/m2_61\NN\1740 ;_62\:\1740 level_63\NN\4916342 3_64\CD\13741022 ,_65\,\1740 185_66\CD\1740 mg/m2_67\NN\1740 ;_68\:\1740 and_69\CC\1740 level_70\VB\1151110 4,210_71\CD\1740 mg/m2_72\NN\1740 ._73\.\1740
D017239_D010051 NONE in_0\IN\13603305 a_1\DT\13649268 phase_2\NN\15113229 i_3\PRP\14622893 study_4\VBP\630380 to_5\TO\1740 determine_6\VB\1645601 the_7\DT\1740 maximum_8\NN\13653902 tolerated_9\VBD\802318 dose_10\NN\3740161 of_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 taxol_14\NN\1740 ;_15\:\1740 bristol-myers_16\NNP\1740 squibb_17\NNP\1740 company_18\NNP\8053576 ,_19\,\1740 princeton_20\NNP\1740 ,_21\,\1740 nj_22\NNP\1740 )_23\-RRB-\1740 given_24\VBN\2327200 as_25\IN\14622893 a_26\DT\13649268 3-hour_27\CD\1740 infusion_28\NN\14589223 in_29\IN\13603305 combination_30\NN\7951464 with_31\IN\1740 carboplatin_32\NN\1740 administered_33\VBD\2436349 every_34\DT\1740 21_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 women_38\NNS\9605289 with_39\IN\1740 advanced_40\JJ\1740 <e2>ovarian_41\JJ\1740 cancer</e2>_42\NN\14239425 ,_43\,\1740 <e1>paclitaxel</e1>_44\NN\1740 doses_45\NNS\3740161 were_46\VBD\836236 escalated_47\VBN\153263 as_48\IN\14622893 follows_49\NNS\1740 :_50\:\1740 level_51\NN\4916342 1_52\CD\13741022 ,_53\,\1740 135_54\CD\1740 mg/m2_55\NN\1740 ;_56\:\1740 level_57\NN\4916342 2_58\CD\13741022 ,_59\,\1740 160_60\CD\1740 mg/m2_61\NN\1740 ;_62\:\1740 level_63\NN\4916342 3_64\CD\13741022 ,_65\,\1740 185_66\CD\1740 mg/m2_67\NN\1740 ;_68\:\1740 and_69\CC\1740 level_70\VB\1151110 4,210_71\CD\1740 mg/m2_72\NN\1740 ._73\.\1740
D016190_D010051 NONE paclitaxel_0\NNP\1740 combined_1\VBN\2630189 with_2\IN\1740 <e1>carboplatin</e1>_3\NN\1740 in_4\IN\13603305 the_5\DT\1740 first-line_6\JJ\1740 treatment_7\NN\654885 of_8\IN\1740 advanced_9\JJ\1740 <e2>ovarian_10\JJ\1740 cancer</e2>_11\NN\14239425 ._12\.\1740
D016190_D010051 NONE in_0\IN\13603305 a_1\DT\13649268 phase_2\NN\15113229 i_3\PRP\14622893 study_4\VBP\630380 to_5\TO\1740 determine_6\VB\1645601 the_7\DT\1740 maximum_8\NN\13653902 tolerated_9\VBD\802318 dose_10\NN\3740161 of_11\IN\1740 paclitaxel_12\NN\1740 (_13\-LRB-\1740 taxol_14\NN\1740 ;_15\:\1740 bristol-myers_16\NNP\1740 squibb_17\NNP\1740 company_18\NNP\8053576 ,_19\,\1740 princeton_20\NNP\1740 ,_21\,\1740 nj_22\NNP\1740 )_23\-RRB-\1740 given_24\VBN\2327200 as_25\IN\14622893 a_26\DT\13649268 3-hour_27\CD\1740 infusion_28\NN\14589223 in_29\IN\13603305 combination_30\NN\7951464 with_31\IN\1740 <e1>carboplatin</e1>_32\NN\1740 administered_33\VBD\2436349 every_34\DT\1740 21_35\CD\13745420 days_36\NNS\15140892 to_37\IN\1740 women_38\NNS\9605289 with_39\IN\1740 advanced_40\JJ\1740 <e2>ovarian_41\JJ\1740 cancer</e2>_42\NN\14239425 ,_43\,\1740 paclitaxel_44\NN\1740 doses_45\NNS\3740161 were_46\VBD\836236 escalated_47\VBN\153263 as_48\IN\14622893 follows_49\NNS\1740 :_50\:\1740 level_51\NN\4916342 1_52\CD\13741022 ,_53\,\1740 135_54\CD\1740 mg/m2_55\NN\1740 ;_56\:\1740 level_57\NN\4916342 2_58\CD\13741022 ,_59\,\1740 160_60\CD\1740 mg/m2_61\NN\1740 ;_62\:\1740 level_63\NN\4916342 3_64\CD\13741022 ,_65\,\1740 185_66\CD\1740 mg/m2_67\NN\1740 ;_68\:\1740 and_69\CC\1740 level_70\VB\1151110 4,210_71\CD\1740 mg/m2_72\NN\1740 ._73\.\1740
11912119
D007980_D004409 CID force_0\NN\5194151 overflow_1\NN\329227 and_2\CC\1740 <e1>levodopa-induced</e1>_3\JJ\1740 <e2>dyskinesias</e2>_4\NNS\14084880 in_5\IN\13603305 parkinson_6\NN\1740 's_7\POS\1740 disease_8\NN\14061805 ._9\.\1740
D007980_D004409 CID we_0\PRP\1740 assessed_1\VBD\670261 force_2\NN\5194151 coordination_3\NN\5640433 of_4\IN\1740 the_5\DT\1740 hand_6\NN\5566919 in_7\IN\13603305 parkinson_8\NNP\1740 's_9\POS\1740 disease_10\NN\14061805 and_11\CC\1740 its_12\PRP$\6125041 relationship_13\NN\31921 to_14\TO\1740 motor_15\NN\3699975 complications_16\NNS\1073995 of_17\IN\1740 <e1>levodopa</e1>_18\NN\14604959 therapy_19\NN\657604 ,_20\,\1740 particularly_21\RB\1740 to_22\TO\1740 levodopa-induced_23\JJ\1740 <e2>dyskinesias</e2>_24\NNS\14084880 (_25\-LRB-\1740 lid_26\NN\5313679 )_27\-RRB-\1740 ._28\.\1740
D007980_D004409 CID we_0\PRP\1740 assessed_1\VBD\670261 force_2\NN\5194151 coordination_3\NN\5640433 of_4\IN\1740 the_5\DT\1740 hand_6\NN\5566919 in_7\IN\13603305 parkinson_8\NNP\1740 's_9\POS\1740 disease_10\NN\14061805 and_11\CC\1740 its_12\PRP$\6125041 relationship_13\NN\31921 to_14\TO\1740 motor_15\NN\3699975 complications_16\NNS\1073995 of_17\IN\1740 <e1>levodopa</e1>_18\NN\14604959 therapy_19\NN\657604 ,_20\,\1740 particularly_21\RB\1740 to_22\TO\1740 levodopa-induced_23\JJ\1740 dyskinesias_24\NNS\14084880 (_25\-LRB-\1740 <e2>lid</e2>_26\NN\5313679 )_27\-RRB-\1740 ._28\.\1740
D007980_D004409 CID we_0\PRP\1740 assessed_1\VBD\670261 force_2\NN\5194151 coordination_3\NN\5640433 of_4\IN\1740 the_5\DT\1740 hand_6\NN\5566919 in_7\IN\13603305 parkinson_8\NNP\1740 's_9\POS\1740 disease_10\NN\14061805 and_11\CC\1740 its_12\PRP$\6125041 relationship_13\NN\31921 to_14\TO\1740 motor_15\NN\3699975 complications_16\NNS\1073995 of_17\IN\1740 levodopa_18\NN\14604959 therapy_19\NN\657604 ,_20\,\1740 particularly_21\RB\1740 to_22\TO\1740 <e1>levodopa-induced</e1>_23\JJ\1740 <e2>dyskinesias</e2>_24\NNS\14084880 (_25\-LRB-\1740 lid_26\NN\5313679 )_27\-RRB-\1740 ._28\.\1740
D007980_D004409 CID we_0\PRP\1740 assessed_1\VBD\670261 force_2\NN\5194151 coordination_3\NN\5640433 of_4\IN\1740 the_5\DT\1740 hand_6\NN\5566919 in_7\IN\13603305 parkinson_8\NNP\1740 's_9\POS\1740 disease_10\NN\14061805 and_11\CC\1740 its_12\PRP$\6125041 relationship_13\NN\31921 to_14\TO\1740 motor_15\NN\3699975 complications_16\NNS\1073995 of_17\IN\1740 levodopa_18\NN\14604959 therapy_19\NN\657604 ,_20\,\1740 particularly_21\RB\1740 to_22\TO\1740 <e1>levodopa-induced</e1>_23\JJ\1740 dyskinesias_24\NNS\14084880 (_25\-LRB-\1740 <e2>lid</e2>_26\NN\5313679 )_27\-RRB-\1740 ._28\.\1740
D007980_D004409 CID we_0\PRP\1740 studied_1\VBD\630380 two_2\CD\13741022 groups_3\NNS\2137 of_4\IN\1740 parkinson_5\NN\1740 's_6\POS\1740 disease_7\NN\14061805 patients_8\NNS\9898892 with_9\IN\1740 (_10\-LRB-\1740 parkinson_11\NN\1740 's_12\POS\1740 disease_13\NN\14061805 +_14\CC\1740 <e2>lid</e2>_15\NN\5313679 ,_16\,\1740 n_17\NN\14622893 =_18\JJ\1740 23_19\CD\13745420 )_20\-RRB-\1740 and_21\CC\1740 without_22\IN\1740 <e1>levodopa-induced</e1>_23\JJ\1740 dyskinesias_24\NNS\14084880 (_25\-LRB-\1740 parkinson_26\NN\1740 's_27\POS\1740 disease_28\NN\14061805 -_29\HYPH\1740 lid_30\NNP\5313679 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 10_34\CD\13745420 )_35\-RRB-\1740 ,_36\,\1740 and_37\CC\1740 age-matched_38\JJ\1740 healthy_39\JJ\1740 controls_40\NNS\5190804 ._41\.\1740
D007980_D004409 CID we_0\PRP\1740 studied_1\VBD\630380 two_2\CD\13741022 groups_3\NNS\2137 of_4\IN\1740 parkinson_5\NN\1740 's_6\POS\1740 disease_7\NN\14061805 patients_8\NNS\9898892 with_9\IN\1740 (_10\-LRB-\1740 parkinson_11\NN\1740 's_12\POS\1740 disease_13\NN\14061805 +_14\CC\1740 lid_15\NN\5313679 ,_16\,\1740 n_17\NN\14622893 =_18\JJ\1740 23_19\CD\13745420 )_20\-RRB-\1740 and_21\CC\1740 without_22\IN\1740 <e1>levodopa-induced</e1>_23\JJ\1740 <e2>dyskinesias</e2>_24\NNS\14084880 (_25\-LRB-\1740 parkinson_26\NN\1740 's_27\POS\1740 disease_28\NN\14061805 -_29\HYPH\1740 lid_30\NNP\5313679 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 10_34\CD\13745420 )_35\-RRB-\1740 ,_36\,\1740 and_37\CC\1740 age-matched_38\JJ\1740 healthy_39\JJ\1740 controls_40\NNS\5190804 ._41\.\1740
D007980_D004409 CID we_0\PRP\1740 studied_1\VBD\630380 two_2\CD\13741022 groups_3\NNS\2137 of_4\IN\1740 parkinson_5\NN\1740 's_6\POS\1740 disease_7\NN\14061805 patients_8\NNS\9898892 with_9\IN\1740 (_10\-LRB-\1740 parkinson_11\NN\1740 's_12\POS\1740 disease_13\NN\14061805 +_14\CC\1740 lid_15\NN\5313679 ,_16\,\1740 n_17\NN\14622893 =_18\JJ\1740 23_19\CD\13745420 )_20\-RRB-\1740 and_21\CC\1740 without_22\IN\1740 <e1>levodopa-induced</e1>_23\JJ\1740 dyskinesias_24\NNS\14084880 (_25\-LRB-\1740 parkinson_26\NN\1740 's_27\POS\1740 disease_28\NN\14061805 -_29\HYPH\1740 <e2>lid</e2>_30\NNP\5313679 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 10_34\CD\13745420 )_35\-RRB-\1740 ,_36\,\1740 and_37\CC\1740 age-matched_38\JJ\1740 healthy_39\JJ\1740 controls_40\NNS\5190804 ._41\.\1740
D007980_D004409 CID the_0\DT\1740 motor_1\NN\3699975 score_2\NN\5736149 of_3\IN\1740 the_4\DT\1740 unified_5\NNP\1740 parkinson_6\NNP\1740 's_7\POS\1740 disease_8\NNP\14061805 rating_9\NN\5733583 scale_10\NN\7260623 ,_11\,\1740 a_12\DT\13649268 <e2>dyskinesia</e2>_13\NN\14084880 score_14\NN\5736149 and_15\CC\1740 force_16\VBP\2506546 in_17\IN\13603305 a_18\DT\13649268 grip-lift_19\JJ\1740 paradigm_20\NN\13803782 were_21\VBD\836236 assessed_22\VBN\670261 on_23\NN\1740 and_24\CC\1740 off_25\NNP\1740 <e1>levodopa</e1>_26\NN\14604959 ._27\.\1740
D007980_D004409 CID in_0\IN\13603305 parkinson_1\NNP\1740 's_2\POS\1740 disease_3\NN\14061805 +_4\CC\1740 <e2>lid</e2>_5\NN\5313679 ,_6\,\1740 the_7\DT\1740 force_8\NN\5194151 involved_9\VBN\2676054 in_10\IN\13603305 pressing_11\VBG\1206218 down_12\RP\1740 the_13\DT\1740 object_14\NN\1930 before_15\IN\1740 lifting_16\NN\1740 was_17\VBD\836236 significantly_18\RB\1740 increased_19\VBN\169651 by_20\IN\1740 <e1>levodopa</e1>_21\NN\14604959 (_22\-LRB-\1740 by_23\IN\1740 61_24\CD\1740 %_25\NN\1740 ,_26\,\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D007980_D010300 NONE force_0\NN\5194151 overflow_1\NN\329227 and_2\CC\1740 <e1>levodopa-induced</e1>_3\JJ\1740 dyskinesias_4\NNS\14084880 in_5\IN\13603305 <e2>parkinson_6\NN\1740 's_7\POS\1740 disease</e2>_8\NN\14061805 ._9\.\1740
D007980_D010300 NONE we_0\PRP\1740 assessed_1\VBD\670261 force_2\NN\5194151 coordination_3\NN\5640433 of_4\IN\1740 the_5\DT\1740 hand_6\NN\5566919 in_7\IN\13603305 <e2>parkinson_8\NNP\1740 's_9\POS\1740 disease</e2>_10\NN\14061805 and_11\CC\1740 its_12\PRP$\6125041 relationship_13\NN\31921 to_14\TO\1740 motor_15\NN\3699975 complications_16\NNS\1073995 of_17\IN\1740 <e1>levodopa</e1>_18\NN\14604959 therapy_19\NN\657604 ,_20\,\1740 particularly_21\RB\1740 to_22\TO\1740 levodopa-induced_23\JJ\1740 dyskinesias_24\NNS\14084880 (_25\-LRB-\1740 lid_26\NN\5313679 )_27\-RRB-\1740 ._28\.\1740
D007980_D010300 NONE we_0\PRP\1740 assessed_1\VBD\670261 force_2\NN\5194151 coordination_3\NN\5640433 of_4\IN\1740 the_5\DT\1740 hand_6\NN\5566919 in_7\IN\13603305 <e2>parkinson_8\NNP\1740 's_9\POS\1740 disease</e2>_10\NN\14061805 and_11\CC\1740 its_12\PRP$\6125041 relationship_13\NN\31921 to_14\TO\1740 motor_15\NN\3699975 complications_16\NNS\1073995 of_17\IN\1740 levodopa_18\NN\14604959 therapy_19\NN\657604 ,_20\,\1740 particularly_21\RB\1740 to_22\TO\1740 <e1>levodopa-induced</e1>_23\JJ\1740 dyskinesias_24\NNS\14084880 (_25\-LRB-\1740 lid_26\NN\5313679 )_27\-RRB-\1740 ._28\.\1740
D007980_D010300 NONE we_0\PRP\1740 studied_1\VBD\630380 two_2\CD\13741022 groups_3\NNS\2137 of_4\IN\1740 <e2>parkinson_5\NN\1740 's_6\POS\1740 disease</e2>_7\NN\14061805 patients_8\NNS\9898892 with_9\IN\1740 (_10\-LRB-\1740 parkinson_11\NN\1740 's_12\POS\1740 disease_13\NN\14061805 +_14\CC\1740 lid_15\NN\5313679 ,_16\,\1740 n_17\NN\14622893 =_18\JJ\1740 23_19\CD\13745420 )_20\-RRB-\1740 and_21\CC\1740 without_22\IN\1740 <e1>levodopa-induced</e1>_23\JJ\1740 dyskinesias_24\NNS\14084880 (_25\-LRB-\1740 parkinson_26\NN\1740 's_27\POS\1740 disease_28\NN\14061805 -_29\HYPH\1740 lid_30\NNP\5313679 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 10_34\CD\13745420 )_35\-RRB-\1740 ,_36\,\1740 and_37\CC\1740 age-matched_38\JJ\1740 healthy_39\JJ\1740 controls_40\NNS\5190804 ._41\.\1740
D007980_D010300 NONE we_0\PRP\1740 studied_1\VBD\630380 two_2\CD\13741022 groups_3\NNS\2137 of_4\IN\1740 parkinson_5\NN\1740 's_6\POS\1740 disease_7\NN\14061805 patients_8\NNS\9898892 with_9\IN\1740 (_10\-LRB-\1740 <e2>parkinson_11\NN\1740 's_12\POS\1740 disease</e2>_13\NN\14061805 +_14\CC\1740 lid_15\NN\5313679 ,_16\,\1740 n_17\NN\14622893 =_18\JJ\1740 23_19\CD\13745420 )_20\-RRB-\1740 and_21\CC\1740 without_22\IN\1740 <e1>levodopa-induced</e1>_23\JJ\1740 dyskinesias_24\NNS\14084880 (_25\-LRB-\1740 parkinson_26\NN\1740 's_27\POS\1740 disease_28\NN\14061805 -_29\HYPH\1740 lid_30\NNP\5313679 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 10_34\CD\13745420 )_35\-RRB-\1740 ,_36\,\1740 and_37\CC\1740 age-matched_38\JJ\1740 healthy_39\JJ\1740 controls_40\NNS\5190804 ._41\.\1740
D007980_D010300 NONE we_0\PRP\1740 studied_1\VBD\630380 two_2\CD\13741022 groups_3\NNS\2137 of_4\IN\1740 parkinson_5\NN\1740 's_6\POS\1740 disease_7\NN\14061805 patients_8\NNS\9898892 with_9\IN\1740 (_10\-LRB-\1740 parkinson_11\NN\1740 's_12\POS\1740 disease_13\NN\14061805 +_14\CC\1740 lid_15\NN\5313679 ,_16\,\1740 n_17\NN\14622893 =_18\JJ\1740 23_19\CD\13745420 )_20\-RRB-\1740 and_21\CC\1740 without_22\IN\1740 <e1>levodopa-induced</e1>_23\JJ\1740 dyskinesias_24\NNS\14084880 (_25\-LRB-\1740 <e2>parkinson_26\NN\1740 's_27\POS\1740 disease</e2>_28\NN\14061805 -_29\HYPH\1740 lid_30\NNP\5313679 ,_31\,\1740 n_32\NN\14622893 =_33\JJ\1740 10_34\CD\13745420 )_35\-RRB-\1740 ,_36\,\1740 and_37\CC\1740 age-matched_38\JJ\1740 healthy_39\JJ\1740 controls_40\NNS\5190804 ._41\.\1740
D007980_D010300 NONE the_0\DT\1740 motor_1\NN\3699975 score_2\NN\5736149 of_3\IN\1740 the_4\DT\1740 unified_5\NNP\1740 <e2>parkinson_6\NNP\1740 's_7\POS\1740 disease</e2>_8\NNP\14061805 rating_9\NN\5733583 scale_10\NN\7260623 ,_11\,\1740 a_12\DT\13649268 dyskinesia_13\NN\14084880 score_14\NN\5736149 and_15\CC\1740 force_16\VBP\2506546 in_17\IN\13603305 a_18\DT\13649268 grip-lift_19\JJ\1740 paradigm_20\NN\13803782 were_21\VBD\836236 assessed_22\VBN\670261 on_23\NN\1740 and_24\CC\1740 off_25\NNP\1740 <e1>levodopa</e1>_26\NN\14604959 ._27\.\1740
D007980_D010300 NONE in_0\IN\13603305 <e2>parkinson_1\NNP\1740 's_2\POS\1740 disease</e2>_3\NN\14061805 +_4\CC\1740 lid_5\NN\5313679 ,_6\,\1740 the_7\DT\1740 force_8\NN\5194151 involved_9\VBN\2676054 in_10\IN\13603305 pressing_11\VBG\1206218 down_12\RP\1740 the_13\DT\1740 object_14\NN\1930 before_15\IN\1740 lifting_16\NN\1740 was_17\VBD\836236 significantly_18\RB\1740 increased_19\VBN\169651 by_20\IN\1740 <e1>levodopa</e1>_21\NN\14604959 (_22\-LRB-\1740 by_23\IN\1740 61_24\CD\1740 %_25\NN\1740 ,_26\,\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
3108839
D016685_D006463 CID <e1>mitomycin_0\NN\2716866 c</e1>_1\NN\13714184 associated_2\VBD\628491 <e2>hemolytic_3\JJ\1740 uremic_4\JJ\1740 syndrome</e2>_5\NN\5870365 ._6\.\1740
D016685_D006463 CID <e1>mitomycin_0\NN\2716866 c</e1>_1\NN\13714184 associated_2\VBD\628491 <e2>hemolytic_3\NNP\1740 uremic_4\JJ\1740 syndrome</e2>_5\NNP\5870365 (_6\-LRB-\1740 hus_7\NN\1740 )_8\-RRB-\1740 is_9\VBZ\836236 a_10\DT\13649268 potentially_11\RB\1740 fatal_12\JJ\1740 but_13\CC\1740 uncommon_14\JJ\1740 condition_15\NN\24720 that_16\WDT\1740 is_17\VBZ\836236 not_18\RB\1740 yet_19\RB\1740 widely_20\RB\1740 recognised_21\VBN\2256109 ._22\.\1740
D016685_D006463 CID <e1>mitomycin_0\NN\2716866 c</e1>_1\NN\13714184 associated_2\VBD\628491 hemolytic_3\NNP\1740 uremic_4\JJ\1740 syndrome_5\NNP\5870365 (_6\-LRB-\1740 <e2>hus</e2>_7\NN\1740 )_8\-RRB-\1740 is_9\VBZ\836236 a_10\DT\13649268 potentially_11\RB\1740 fatal_12\JJ\1740 but_13\CC\1740 uncommon_14\JJ\1740 condition_15\NN\24720 that_16\WDT\1740 is_17\VBZ\836236 not_18\RB\1740 yet_19\RB\1740 widely_20\RB\1740 recognised_21\VBN\2256109 ._22\.\1740
D016685_D000743 NONE it_0\PRP\6125041 consists_1\VBZ\2603699 of_2\IN\1740 microangiopathic_3\JJ\1740 <e2>hemolytic_4\JJ\1740 anemia</e2>_5\NN\14189204 ,_6\,\1740 thrombocytopenia_7\NN\14189204 and_8\CC\1740 progressive_9\JJ\1740 renal_10\JJ\1740 failure_11\NN\66216 associated_12\VBN\628491 with_13\IN\1740 <e1>mitomycin_14\NN\2716866 c</e1>_15\NN\13714184 treatment_16\NN\654885 and_17\CC\1740 affects_18\VBZ\126264 about_19\RB\1740 10_20\CD\13745420 %_21\NN\1740 of_22\IN\1740 patients_23\NNS\9898892 treated_24\VBN\2376958 with_25\IN\1740 this_26\DT\1740 agent_27\NN\7347 ._28\.\1740
D016685_D013921 NONE it_0\PRP\6125041 consists_1\VBZ\2603699 of_2\IN\1740 microangiopathic_3\JJ\1740 hemolytic_4\JJ\1740 anemia_5\NN\14189204 ,_6\,\1740 <e2>thrombocytopenia</e2>_7\NN\14189204 and_8\CC\1740 progressive_9\JJ\1740 renal_10\JJ\1740 failure_11\NN\66216 associated_12\VBN\628491 with_13\IN\1740 <e1>mitomycin_14\NN\2716866 c</e1>_15\NN\13714184 treatment_16\NN\654885 and_17\CC\1740 affects_18\VBZ\126264 about_19\RB\1740 10_20\CD\13745420 %_21\NN\1740 of_22\IN\1740 patients_23\NNS\9898892 treated_24\VBN\2376958 with_25\IN\1740 this_26\DT\1740 agent_27\NN\7347 ._28\.\1740
D016685_D013921 NONE we_0\PRP\1740 describe_1\VBP\1001294 the_2\DT\1740 clinical_3\JJ\1740 course_4\NN\883297 and_5\CC\1740 pathological_6\JJ\1740 findings_7\NNS\7951464 in_8\IN\13603305 a_9\DT\13649268 65_10\CD\1740 yr-old_11\NN\1740 man_12\NN\9605289 with_13\IN\1740 gastric_14\JJ\1740 adenocarcinoma_15\NN\14242337 who_16\WP\8299493 developed_17\VBD\1753788 renal_18\JJ\1740 failure_19\NN\66216 and_20\CC\1740 <e2>thrombocytopenia</e2>_21\NN\14189204 while_22\IN\15122231 on_23\IN\1740 treatment_24\NN\654885 with_25\IN\1740 <e1>mitomycin_26\NN\2716866 c</e1>_27\NN\13714184 and_28\CC\1740 died_29\VBD\146138 in_30\IN\13603305 pulmonary_31\JJ\1740 edema_32\NN\14315192 ._33\.\1740
D016685_D051437 CID it_0\PRP\6125041 consists_1\VBZ\2603699 of_2\IN\1740 microangiopathic_3\JJ\1740 hemolytic_4\JJ\1740 anemia_5\NN\14189204 ,_6\,\1740 thrombocytopenia_7\NN\14189204 and_8\CC\1740 progressive_9\JJ\1740 <e2>renal_10\JJ\1740 failure</e2>_11\NN\66216 associated_12\VBN\628491 with_13\IN\1740 <e1>mitomycin_14\NN\2716866 c</e1>_15\NN\13714184 treatment_16\NN\654885 and_17\CC\1740 affects_18\VBZ\126264 about_19\RB\1740 10_20\CD\13745420 %_21\NN\1740 of_22\IN\1740 patients_23\NNS\9898892 treated_24\VBN\2376958 with_25\IN\1740 this_26\DT\1740 agent_27\NN\7347 ._28\.\1740
D016685_D051437 CID the_0\DT\1740 <e2>renal_1\JJ\1740 failure</e2>_2\NN\66216 usually_3\RB\1740 develops_4\VBZ\1753788 about_5\RB\1740 8_6\CD\13741022 -_7\SYM\1740 10_8\CD\13745420 mth_9\NN\1740 after_10\IN\1740 start_11\NN\7290905 of_12\IN\1740 <e1>mitomycin_13\NN\2716866 c</e1>_14\NN\13714184 treatment_15\NN\654885 and_16\CC\1740 the_17\DT\1740 mortality_18\NN\5054863 is_19\VBZ\836236 approximately_20\RB\1740 60_21\CD\13745420 %_22\NN\1740 from_23\IN\1740 renal_24\JJ\1740 failure_25\NN\66216 or_26\CC\3541091 pulmonary_27\JJ\1740 edema_28\NN\14315192 ._29\.\1740
D016685_D051437 CID the_0\DT\1740 renal_1\JJ\1740 failure_2\NN\66216 usually_3\RB\1740 develops_4\VBZ\1753788 about_5\RB\1740 8_6\CD\13741022 -_7\SYM\1740 10_8\CD\13745420 mth_9\NN\1740 after_10\IN\1740 start_11\NN\7290905 of_12\IN\1740 <e1>mitomycin_13\NN\2716866 c</e1>_14\NN\13714184 treatment_15\NN\654885 and_16\CC\1740 the_17\DT\1740 mortality_18\NN\5054863 is_19\VBZ\836236 approximately_20\RB\1740 60_21\CD\13745420 %_22\NN\1740 from_23\IN\1740 <e2>renal_24\JJ\1740 failure</e2>_25\NN\66216 or_26\CC\3541091 pulmonary_27\JJ\1740 edema_28\NN\14315192 ._29\.\1740
D016685_D051437 CID we_0\PRP\1740 describe_1\VBP\1001294 the_2\DT\1740 clinical_3\JJ\1740 course_4\NN\883297 and_5\CC\1740 pathological_6\JJ\1740 findings_7\NNS\7951464 in_8\IN\13603305 a_9\DT\13649268 65_10\CD\1740 yr-old_11\NN\1740 man_12\NN\9605289 with_13\IN\1740 gastric_14\JJ\1740 adenocarcinoma_15\NN\14242337 who_16\WP\8299493 developed_17\VBD\1753788 <e2>renal_18\JJ\1740 failure</e2>_19\NN\66216 and_20\CC\1740 thrombocytopenia_21\NN\14189204 while_22\IN\15122231 on_23\IN\1740 treatment_24\NN\654885 with_25\IN\1740 <e1>mitomycin_26\NN\2716866 c</e1>_27\NN\13714184 and_28\CC\1740 died_29\VBD\146138 in_30\IN\13603305 pulmonary_31\JJ\1740 edema_32\NN\14315192 ._33\.\1740
D016685_D011654 NONE the_0\DT\1740 renal_1\JJ\1740 failure_2\NN\66216 usually_3\RB\1740 develops_4\VBZ\1753788 about_5\RB\1740 8_6\CD\13741022 -_7\SYM\1740 10_8\CD\13745420 mth_9\NN\1740 after_10\IN\1740 start_11\NN\7290905 of_12\IN\1740 <e1>mitomycin_13\NN\2716866 c</e1>_14\NN\13714184 treatment_15\NN\654885 and_16\CC\1740 the_17\DT\1740 mortality_18\NN\5054863 is_19\VBZ\836236 approximately_20\RB\1740 60_21\CD\13745420 %_22\NN\1740 from_23\IN\1740 renal_24\JJ\1740 failure_25\NN\66216 or_26\CC\3541091 <e2>pulmonary_27\JJ\1740 edema</e2>_28\NN\14315192 ._29\.\1740
D016685_D011654 NONE we_0\PRP\1740 describe_1\VBP\1001294 the_2\DT\1740 clinical_3\JJ\1740 course_4\NN\883297 and_5\CC\1740 pathological_6\JJ\1740 findings_7\NNS\7951464 in_8\IN\13603305 a_9\DT\13649268 65_10\CD\1740 yr-old_11\NN\1740 man_12\NN\9605289 with_13\IN\1740 gastric_14\JJ\1740 adenocarcinoma_15\NN\14242337 who_16\WP\8299493 developed_17\VBD\1753788 renal_18\JJ\1740 failure_19\NN\66216 and_20\CC\1740 thrombocytopenia_21\NN\14189204 while_22\IN\15122231 on_23\IN\1740 treatment_24\NN\654885 with_25\IN\1740 <e1>mitomycin_26\NN\2716866 c</e1>_27\NN\13714184 and_28\CC\1740 died_29\VBD\146138 in_30\IN\13603305 <e2>pulmonary_31\JJ\1740 edema</e2>_32\NN\14315192 ._33\.\1740
D016685_D013274 NONE we_0\PRP\1740 describe_1\VBP\1001294 the_2\DT\1740 clinical_3\JJ\1740 course_4\NN\883297 and_5\CC\1740 pathological_6\JJ\1740 findings_7\NNS\7951464 in_8\IN\13603305 a_9\DT\13649268 65_10\CD\1740 yr-old_11\NN\1740 man_12\NN\9605289 with_13\IN\1740 <e2>gastric_14\JJ\1740 adenocarcinoma</e2>_15\NN\14242337 who_16\WP\8299493 developed_17\VBD\1753788 renal_18\JJ\1740 failure_19\NN\66216 and_20\CC\1740 thrombocytopenia_21\NN\14189204 while_22\IN\15122231 on_23\IN\1740 treatment_24\NN\654885 with_25\IN\1740 <e1>mitomycin_26\NN\2716866 c</e1>_27\NN\13714184 and_28\CC\1740 died_29\VBD\146138 in_30\IN\13603305 pulmonary_31\JJ\1740 edema_32\NN\14315192 ._33\.\1740
17682013
D008727_D056784 CID background_0\NN\4921011 :_1\:\1740 a_2\DT\13649268 transient_3\JJ\1740 <e2>leukoencephalopathy</e2>_4\NN\1740 mimicking_5\VBG\1742886 cerebrovascular_6\NN\1740 accident_7\NN\7314427 has_8\VBZ\2108377 been_9\VBN\836236 described_10\VBN\1001294 as_11\IN\14622893 a_12\DT\13649268 complication_13\NN\1073995 of_14\IN\1740 chemotherapy_15\NN\661091 ,_16\,\1740 most_17\RBS\1740 commonly_18\RB\1740 in_19\IN\13603305 recipients_20\NNS\9764201 of_21\IN\1740 intrathecal_22\JJ\1740 <e1>methotrexate</e1>_23\NN\2722166 for_24\IN\1740 childhood_25\NN\15144371 leukaemia_26\NN\14239918 ._27\.\1740
D008727_D056784 CID results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 identified_3\VBD\699815 27_4\CD\13745420 reports_5\NNS\6470073 of_6\IN\1740 toxic_7\JJ\1740 <e2>leukoencephalopathy</e2>_8\NN\1740 in_9\IN\13603305 patients_10\NNS\9898892 treated_11\VBN\2376958 with_12\IN\1740 <e1>methotrexate</e1>_13\NN\2722166 (_14\-LRB-\1740 intrathecal_15\JJ\1740 ,_16\,\1740 systemic_17\JJ\1740 )_18\-RRB-\1740 ,_19\,\1740 5-fluorouracil_20\NN\1740 and_21\CC\1740 its_22\PRP$\6125041 derivative_23\JJ\1740 carmofur_24\NN\1740 ,_25\,\1740 and_26\CC\1740 capecitabine_27\NN\1740 ._28\.\1740
D008727_D002544 NONE background_0\NN\4921011 :_1\:\1740 a_2\DT\13649268 transient_3\JJ\1740 leukoencephalopathy_4\NN\1740 mimicking_5\VBG\1742886 <e2>cerebrovascular_6\NN\1740 accident</e2>_7\NN\7314427 has_8\VBZ\2108377 been_9\VBN\836236 described_10\VBN\1001294 as_11\IN\14622893 a_12\DT\13649268 complication_13\NN\1073995 of_14\IN\1740 chemotherapy_15\NN\661091 ,_16\,\1740 most_17\RBS\1740 commonly_18\RB\1740 in_19\IN\13603305 recipients_20\NNS\9764201 of_21\IN\1740 intrathecal_22\JJ\1740 <e1>methotrexate</e1>_23\NN\2722166 for_24\IN\1740 childhood_25\NN\15144371 leukaemia_26\NN\14239918 ._27\.\1740
D008727_D007938 NONE background_0\NN\4921011 :_1\:\1740 a_2\DT\13649268 transient_3\JJ\1740 leukoencephalopathy_4\NN\1740 mimicking_5\VBG\1742886 cerebrovascular_6\NN\1740 accident_7\NN\7314427 has_8\VBZ\2108377 been_9\VBN\836236 described_10\VBN\1001294 as_11\IN\14622893 a_12\DT\13649268 complication_13\NN\1073995 of_14\IN\1740 chemotherapy_15\NN\661091 ,_16\,\1740 most_17\RBS\1740 commonly_18\RB\1740 in_19\IN\13603305 recipients_20\NNS\9764201 of_21\IN\1740 intrathecal_22\JJ\1740 <e1>methotrexate</e1>_23\NN\2722166 for_24\IN\1740 childhood_25\NN\15144371 <e2>leukaemia</e2>_26\NN\14239918 ._27\.\1740
D005472_D056784 CID results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 identified_3\VBD\699815 27_4\CD\13745420 reports_5\NNS\6470073 of_6\IN\1740 toxic_7\JJ\1740 <e2>leukoencephalopathy</e2>_8\NN\1740 in_9\IN\13603305 patients_10\NNS\9898892 treated_11\VBN\2376958 with_12\IN\1740 methotrexate_13\NN\2722166 (_14\-LRB-\1740 intrathecal_15\JJ\1740 ,_16\,\1740 systemic_17\JJ\1740 )_18\-RRB-\1740 ,_19\,\1740 <e1>5-fluorouracil</e1>_20\NN\1740 and_21\CC\1740 its_22\PRP$\6125041 derivative_23\JJ\1740 carmofur_24\NN\1740 ,_25\,\1740 and_26\CC\1740 capecitabine_27\NN\1740 ._28\.\1740
C017367_D056784 CID results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 identified_3\VBD\699815 27_4\CD\13745420 reports_5\NNS\6470073 of_6\IN\1740 toxic_7\JJ\1740 <e2>leukoencephalopathy</e2>_8\NN\1740 in_9\IN\13603305 patients_10\NNS\9898892 treated_11\VBN\2376958 with_12\IN\1740 methotrexate_13\NN\2722166 (_14\-LRB-\1740 intrathecal_15\JJ\1740 ,_16\,\1740 systemic_17\JJ\1740 )_18\-RRB-\1740 ,_19\,\1740 5-fluorouracil_20\NN\1740 and_21\CC\1740 its_22\PRP$\6125041 derivative_23\JJ\1740 <e1>carmofur</e1>_24\NN\1740 ,_25\,\1740 and_26\CC\1740 capecitabine_27\NN\1740 ._28\.\1740
C110904_D056784 CID results_0\NNS\34213 :_1\:\1740 we_2\PRP\1740 identified_3\VBD\699815 27_4\CD\13745420 reports_5\NNS\6470073 of_6\IN\1740 toxic_7\JJ\1740 <e2>leukoencephalopathy</e2>_8\NN\1740 in_9\IN\13603305 patients_10\NNS\9898892 treated_11\VBN\2376958 with_12\IN\1740 methotrexate_13\NN\2722166 (_14\-LRB-\1740 intrathecal_15\JJ\1740 ,_16\,\1740 systemic_17\JJ\1740 )_18\-RRB-\1740 ,_19\,\1740 5-fluorouracil_20\NN\1740 and_21\CC\1740 its_22\PRP$\6125041 derivative_23\JJ\1740 carmofur_24\NN\1740 ,_25\,\1740 and_26\CC\1740 <e1>capecitabine</e1>_27\NN\1740 ._28\.\1740
6216862
D010396_D001172 NONE multiple_0\JJ\1740 side_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>penicillamine</e1>_4\NN\3740161 therapy_5\NN\657604 in_6\IN\13603305 one_7\CD\13741022 patient_8\NN\9898892 with_9\IN\1740 <e2>rheumatoid_10\JJ\1740 arthritis</e2>_11\NN\14171682 ._12\.\1740
D010396_D001172 NONE skin_0\NN\5237755 rashes_1\NNS\14321469 ,_2\,\1740 proteinuria_3\NN\14299637 ,_4\,\1740 systemic_5\JJ\1740 lupus_6\NN\14219661 erythematosus_7\NN\1740 ,_8\,\1740 polymyositis_9\NN\14350292 and_10\CC\1740 myasthenia_11\NN\14187378 gravis_12\NN\1740 have_13\VBP\2108377 all_14\DT\1740 been_15\VBN\836236 recorded_16\VBN\2225492 as_17\IN\14622893 complications_18\NNS\1073995 of_19\IN\1740 <e1>penicillamine</e1>_20\NN\3740161 therapy_21\NN\657604 in_22\IN\13603305 patients_23\NNS\9898892 with_24\IN\1740 <e2>rheumatoid_25\JJ\1740 arthritis</e2>_26\NN\14171682 ._27\.\1740
D010396_D001172 NONE the_0\DT\1740 skin_1\NN\5237755 lesion_2\NN\14204950 resembled_3\VBD\2657219 elastosis_4\NN\14034177 perforans_5\NNS\1740 serpiginosa_6\NN\1740 ,_7\,\1740 which_8\WDT\1740 has_9\VBZ\2108377 been_10\VBN\836236 reported_11\VBN\831651 as_12\IN\14622893 a_13\DT\13649268 rare_14\JJ\1740 side_15\NN\8630039 effect_16\NN\34213 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 wilson_20\NN\1740 's_21\POS\1740 disease_22\NN\14061805 but_23\CC\1740 not_24\RB\1740 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 <e2>rheumatoid_28\JJ\1740 arthritis</e2>_29\NN\14171682 treated_30\VBN\2376958 with_31\IN\1740 <e1>penicillamine</e1>_32\NN\3740161 ._33\.\1740
D010396_D005076 CID <e2>skin_0\NN\5237755 rashes</e2>_1\NNS\14321469 ,_2\,\1740 proteinuria_3\NN\14299637 ,_4\,\1740 systemic_5\JJ\1740 lupus_6\NN\14219661 erythematosus_7\NN\1740 ,_8\,\1740 polymyositis_9\NN\14350292 and_10\CC\1740 myasthenia_11\NN\14187378 gravis_12\NN\1740 have_13\VBP\2108377 all_14\DT\1740 been_15\VBN\836236 recorded_16\VBN\2225492 as_17\IN\14622893 complications_18\NNS\1073995 of_19\IN\1740 <e1>penicillamine</e1>_20\NN\3740161 therapy_21\NN\657604 in_22\IN\13603305 patients_23\NNS\9898892 with_24\IN\1740 rheumatoid_25\JJ\1740 arthritis_26\NN\14171682 ._27\.\1740
D010396_D011507 CID skin_0\NN\5237755 rashes_1\NNS\14321469 ,_2\,\1740 <e2>proteinuria</e2>_3\NN\14299637 ,_4\,\1740 systemic_5\JJ\1740 lupus_6\NN\14219661 erythematosus_7\NN\1740 ,_8\,\1740 polymyositis_9\NN\14350292 and_10\CC\1740 myasthenia_11\NN\14187378 gravis_12\NN\1740 have_13\VBP\2108377 all_14\DT\1740 been_15\VBN\836236 recorded_16\VBN\2225492 as_17\IN\14622893 complications_18\NNS\1073995 of_19\IN\1740 <e1>penicillamine</e1>_20\NN\3740161 therapy_21\NN\657604 in_22\IN\13603305 patients_23\NNS\9898892 with_24\IN\1740 rheumatoid_25\JJ\1740 arthritis_26\NN\14171682 ._27\.\1740
D010396_D008180 CID skin_0\NN\5237755 rashes_1\NNS\14321469 ,_2\,\1740 proteinuria_3\NN\14299637 ,_4\,\1740 <e2>systemic_5\JJ\1740 lupus_6\NN\14219661 erythematosus</e2>_7\NN\1740 ,_8\,\1740 polymyositis_9\NN\14350292 and_10\CC\1740 myasthenia_11\NN\14187378 gravis_12\NN\1740 have_13\VBP\2108377 all_14\DT\1740 been_15\VBN\836236 recorded_16\VBN\2225492 as_17\IN\14622893 complications_18\NNS\1073995 of_19\IN\1740 <e1>penicillamine</e1>_20\NN\3740161 therapy_21\NN\657604 in_22\IN\13603305 patients_23\NNS\9898892 with_24\IN\1740 rheumatoid_25\JJ\1740 arthritis_26\NN\14171682 ._27\.\1740
D010396_D017285 CID skin_0\NN\5237755 rashes_1\NNS\14321469 ,_2\,\1740 proteinuria_3\NN\14299637 ,_4\,\1740 systemic_5\JJ\1740 lupus_6\NN\14219661 erythematosus_7\NN\1740 ,_8\,\1740 <e2>polymyositis</e2>_9\NN\14350292 and_10\CC\1740 myasthenia_11\NN\14187378 gravis_12\NN\1740 have_13\VBP\2108377 all_14\DT\1740 been_15\VBN\836236 recorded_16\VBN\2225492 as_17\IN\14622893 complications_18\NNS\1073995 of_19\IN\1740 <e1>penicillamine</e1>_20\NN\3740161 therapy_21\NN\657604 in_22\IN\13603305 patients_23\NNS\9898892 with_24\IN\1740 rheumatoid_25\JJ\1740 arthritis_26\NN\14171682 ._27\.\1740
D010396_D009157 CID skin_0\NN\5237755 rashes_1\NNS\14321469 ,_2\,\1740 proteinuria_3\NN\14299637 ,_4\,\1740 systemic_5\JJ\1740 lupus_6\NN\14219661 erythematosus_7\NN\1740 ,_8\,\1740 polymyositis_9\NN\14350292 and_10\CC\1740 <e2>myasthenia_11\NN\14187378 gravis</e2>_12\NN\1740 have_13\VBP\2108377 all_14\DT\1740 been_15\VBN\836236 recorded_16\VBN\2225492 as_17\IN\14622893 complications_18\NNS\1073995 of_19\IN\1740 <e1>penicillamine</e1>_20\NN\3740161 therapy_21\NN\657604 in_22\IN\13603305 patients_23\NNS\9898892 with_24\IN\1740 rheumatoid_25\JJ\1740 arthritis_26\NN\14171682 ._27\.\1740
D010396_D012871 NONE the_0\DT\1740 <e2>skin_1\NN\5237755 lesion</e2>_2\NN\14204950 resembled_3\VBD\2657219 elastosis_4\NN\14034177 perforans_5\NNS\1740 serpiginosa_6\NN\1740 ,_7\,\1740 which_8\WDT\1740 has_9\VBZ\2108377 been_10\VBN\836236 reported_11\VBN\831651 as_12\IN\14622893 a_13\DT\13649268 rare_14\JJ\1740 side_15\NN\8630039 effect_16\NN\34213 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 wilson_20\NN\1740 's_21\POS\1740 disease_22\NN\14061805 but_23\CC\1740 not_24\RB\1740 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 rheumatoid_28\JJ\1740 arthritis_29\NN\14171682 treated_30\VBN\2376958 with_31\IN\1740 <e1>penicillamine</e1>_32\NN\3740161 ._33\.\1740
D010396_C536202 NONE the_0\DT\1740 skin_1\NN\5237755 lesion_2\NN\14204950 resembled_3\VBD\2657219 <e2>elastosis_4\NN\14034177 perforans_5\NNS\1740 serpiginosa</e2>_6\NN\1740 ,_7\,\1740 which_8\WDT\1740 has_9\VBZ\2108377 been_10\VBN\836236 reported_11\VBN\831651 as_12\IN\14622893 a_13\DT\13649268 rare_14\JJ\1740 side_15\NN\8630039 effect_16\NN\34213 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 wilson_20\NN\1740 's_21\POS\1740 disease_22\NN\14061805 but_23\CC\1740 not_24\RB\1740 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 rheumatoid_28\JJ\1740 arthritis_29\NN\14171682 treated_30\VBN\2376958 with_31\IN\1740 <e1>penicillamine</e1>_32\NN\3740161 ._33\.\1740
D010396_D006527 NONE the_0\DT\1740 skin_1\NN\5237755 lesion_2\NN\14204950 resembled_3\VBD\2657219 elastosis_4\NN\14034177 perforans_5\NNS\1740 serpiginosa_6\NN\1740 ,_7\,\1740 which_8\WDT\1740 has_9\VBZ\2108377 been_10\VBN\836236 reported_11\VBN\831651 as_12\IN\14622893 a_13\DT\13649268 rare_14\JJ\1740 side_15\NN\8630039 effect_16\NN\34213 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 <e2>wilson_20\NN\1740 's_21\POS\1740 disease</e2>_22\NN\14061805 but_23\CC\1740 not_24\RB\1740 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 rheumatoid_28\JJ\1740 arthritis_29\NN\14171682 treated_30\VBN\2376958 with_31\IN\1740 <e1>penicillamine</e1>_32\NN\3740161 ._33\.\1740
9636837
D016190_D020258 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 most_3\RBS\1740 striking_4\JJ\1740 of_5\IN\1740 <e1>carboplatin</e1>_6\NN\1740 's_7\POS\1740 advantages_8\NNS\5154517 (_9\-LRB-\1740 cbdca_10\NN\1740 )_11\-RRB-\1740 over_12\IN\5867413 cisplatin_13\NN\1740 (_14\-LRB-\1740 cddp_15\NN\1740 )_16\-RRB-\1740 is_17\VBZ\836236 its_18\PRP$\6125041 markedly_19\RB\1740 reduced_20\VBN\441445 rate_21\NN\13815152 of_22\IN\1740 <e2>neurotoxic</e2>_23\JJ\1740 effects_24\NNS\13245626 ._25\.\1740
D016190_D020258 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 most_3\RBS\1740 striking_4\JJ\1740 of_5\IN\1740 carboplatin_6\NN\1740 's_7\POS\1740 advantages_8\NNS\5154517 (_9\-LRB-\1740 <e1>cbdca</e1>_10\NN\1740 )_11\-RRB-\1740 over_12\IN\5867413 cisplatin_13\NN\1740 (_14\-LRB-\1740 cddp_15\NN\1740 )_16\-RRB-\1740 is_17\VBZ\836236 its_18\PRP$\6125041 markedly_19\RB\1740 reduced_20\VBN\441445 rate_21\NN\13815152 of_22\IN\1740 <e2>neurotoxic</e2>_23\JJ\1740 effects_24\NNS\13245626 ._25\.\1740
D016190_D020258 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 use_3\NN\407535 of_4\IN\1740 <e1>cbdca</e1>_5\NN\1740 higher-intensity_6\NN\1740 schedules_7\NNS\5898568 and_8\CC\1740 the_9\DT\1740 association_10\NN\8008335 with_11\IN\1740 other_12\JJ\1740 <e2>neurotoxic</e2>_13\JJ\1740 drugs_14\NNS\14778436 in_15\IN\13603305 polychemotherapy_16\NN\1740 may_17\MD\15209706 cause_18\VB\1617192 some_19\DT\1740 concern_20\NN\5682950 about_21\IN\1740 its_22\PRP$\6125041 safety_23\NN\13920835 with_24\IN\1740 respect_25\NN\5817845 to_26\TO\1740 peripheral_27\JJ\1740 nervous_28\JJ\1740 system_29\NN\3575240 damage_30\NN\7296428 ._31\.\1740
D016190_D020258 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>cbdca</e1>_2\NN\1740 is_3\VBZ\836236 <e2>neurotoxic</e2>_4\JJ\1740 in_5\IN\13603305 our_6\PRP$\1740 model_7\NN\5888929 ,_8\,\1740 and_9\CC\1740 the_10\DT\1740 type_11\NN\5839024 of_12\IN\1740 pathological_13\JJ\1740 changes_14\NNS\7283608 it_15\PRP\6125041 induces_16\VBZ\1627355 are_17\VBP\836236 so_18\RB\1740 closely_19\RB\1740 similar_20\JJ\1740 to_21\TO\1740 those_22\DT\1740 caused_23\VBN\1617192 by_24\IN\1740 cddp_25\NN\1740 that_26\IN\1740 it_27\PRP\6125041 is_28\VBZ\836236 probable_29\JJ\1740 that_30\IN\1740 neurotoxicity_31\NN\1740 is_32\VBZ\836236 induced_33\VBN\1627355 in_34\IN\13603305 the_35\DT\1740 two_36\CD\13741022 drugs_37\NNS\14778436 by_38\IN\1740 the_39\DT\1740 same_40\JJ\1740 mechanism_41\NN\13446390 ._42\.\1740
D016190_D020258 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>cbdca</e1>_2\NN\1740 is_3\VBZ\836236 neurotoxic_4\JJ\1740 in_5\IN\13603305 our_6\PRP$\1740 model_7\NN\5888929 ,_8\,\1740 and_9\CC\1740 the_10\DT\1740 type_11\NN\5839024 of_12\IN\1740 pathological_13\JJ\1740 changes_14\NNS\7283608 it_15\PRP\6125041 induces_16\VBZ\1627355 are_17\VBP\836236 so_18\RB\1740 closely_19\RB\1740 similar_20\JJ\1740 to_21\TO\1740 those_22\DT\1740 caused_23\VBN\1617192 by_24\IN\1740 cddp_25\NN\1740 that_26\IN\1740 it_27\PRP\6125041 is_28\VBZ\836236 probable_29\JJ\1740 that_30\IN\1740 <e2>neurotoxicity</e2>_31\NN\1740 is_32\VBZ\836236 induced_33\VBN\1627355 in_34\IN\13603305 the_35\DT\1740 two_36\CD\13741022 drugs_37\NNS\14778436 by_38\IN\1740 the_39\DT\1740 same_40\JJ\1740 mechanism_41\NN\13446390 ._42\.\1740
D002945_D020258 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 most_3\RBS\1740 striking_4\JJ\1740 of_5\IN\1740 carboplatin_6\NN\1740 's_7\POS\1740 advantages_8\NNS\5154517 (_9\-LRB-\1740 cbdca_10\NN\1740 )_11\-RRB-\1740 over_12\IN\5867413 <e1>cisplatin</e1>_13\NN\1740 (_14\-LRB-\1740 cddp_15\NN\1740 )_16\-RRB-\1740 is_17\VBZ\836236 its_18\PRP$\6125041 markedly_19\RB\1740 reduced_20\VBN\441445 rate_21\NN\13815152 of_22\IN\1740 <e2>neurotoxic</e2>_23\JJ\1740 effects_24\NNS\13245626 ._25\.\1740
D002945_D020258 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 most_3\RBS\1740 striking_4\JJ\1740 of_5\IN\1740 carboplatin_6\NN\1740 's_7\POS\1740 advantages_8\NNS\5154517 (_9\-LRB-\1740 cbdca_10\NN\1740 )_11\-RRB-\1740 over_12\IN\5867413 cisplatin_13\NN\1740 (_14\-LRB-\1740 <e1>cddp</e1>_15\NN\1740 )_16\-RRB-\1740 is_17\VBZ\836236 its_18\PRP$\6125041 markedly_19\RB\1740 reduced_20\VBN\441445 rate_21\NN\13815152 of_22\IN\1740 <e2>neurotoxic</e2>_23\JJ\1740 effects_24\NNS\13245626 ._25\.\1740
D002945_D020258 NONE conclusions_0\NNS\5837957 :_1\:\1740 cbdca_2\NN\1740 is_3\VBZ\836236 <e2>neurotoxic</e2>_4\JJ\1740 in_5\IN\13603305 our_6\PRP$\1740 model_7\NN\5888929 ,_8\,\1740 and_9\CC\1740 the_10\DT\1740 type_11\NN\5839024 of_12\IN\1740 pathological_13\JJ\1740 changes_14\NNS\7283608 it_15\PRP\6125041 induces_16\VBZ\1627355 are_17\VBP\836236 so_18\RB\1740 closely_19\RB\1740 similar_20\JJ\1740 to_21\TO\1740 those_22\DT\1740 caused_23\VBN\1617192 by_24\IN\1740 <e1>cddp</e1>_25\NN\1740 that_26\IN\1740 it_27\PRP\6125041 is_28\VBZ\836236 probable_29\JJ\1740 that_30\IN\1740 neurotoxicity_31\NN\1740 is_32\VBZ\836236 induced_33\VBN\1627355 in_34\IN\13603305 the_35\DT\1740 two_36\CD\13741022 drugs_37\NNS\14778436 by_38\IN\1740 the_39\DT\1740 same_40\JJ\1740 mechanism_41\NN\13446390 ._42\.\1740
D002945_D020258 NONE conclusions_0\NNS\5837957 :_1\:\1740 cbdca_2\NN\1740 is_3\VBZ\836236 neurotoxic_4\JJ\1740 in_5\IN\13603305 our_6\PRP$\1740 model_7\NN\5888929 ,_8\,\1740 and_9\CC\1740 the_10\DT\1740 type_11\NN\5839024 of_12\IN\1740 pathological_13\JJ\1740 changes_14\NNS\7283608 it_15\PRP\6125041 induces_16\VBZ\1627355 are_17\VBP\836236 so_18\RB\1740 closely_19\RB\1740 similar_20\JJ\1740 to_21\TO\1740 those_22\DT\1740 caused_23\VBN\1617192 by_24\IN\1740 <e1>cddp</e1>_25\NN\1740 that_26\IN\1740 it_27\PRP\6125041 is_28\VBZ\836236 probable_29\JJ\1740 that_30\IN\1740 <e2>neurotoxicity</e2>_31\NN\1740 is_32\VBZ\836236 induced_33\VBN\1627355 in_34\IN\13603305 the_35\DT\1740 two_36\CD\13741022 drugs_37\NNS\14778436 by_38\IN\1740 the_39\DT\1740 same_40\JJ\1740 mechanism_41\NN\13446390 ._42\.\1740
D016190_D010523 CID however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 use_3\NN\407535 of_4\IN\1740 <e1>cbdca</e1>_5\NN\1740 higher-intensity_6\NN\1740 schedules_7\NNS\5898568 and_8\CC\1740 the_9\DT\1740 association_10\NN\8008335 with_11\IN\1740 other_12\JJ\1740 neurotoxic_13\JJ\1740 drugs_14\NNS\14778436 in_15\IN\13603305 polychemotherapy_16\NN\1740 may_17\MD\15209706 cause_18\VB\1617192 some_19\DT\1740 concern_20\NN\5682950 about_21\IN\1740 its_22\PRP$\6125041 safety_23\NN\13920835 with_24\IN\1740 respect_25\NN\5817845 to_26\TO\1740 <e2>peripheral_27\JJ\1740 nervous_28\JJ\1740 system_29\NN\3575240 damage</e2>_30\NN\7296428 ._31\.\1740
D016190_D010523 CID results_0\NNS\34213 :_1\:\1740 <e1>cbdca</e1>_2\NN\1740 administration_3\NN\1133281 induced_4\VBD\1627355 dose-dependent_5\JJ\1740 <e2>peripheral_6\JJ\1740 neurotoxicity</e2>_7\NN\1740 ._8\.\1740
1728915
D002220_D006331 NONE <e1>carbamazepine-induced</e1>_0\JJ\1740 <e2>cardiac_1\JJ\1740 dysfunction</e2>_2\NN\14204950 ._3\.\1740
D002220_D006331 NONE from_0\IN\1740 the_1\DT\1740 analysis_2\NN\633864 of_3\IN\1740 these_4\DT\1740 cases_5\NNS\7283608 ,_6\,\1740 two_7\CD\13741022 distinct_8\JJ\1740 forms_9\NNS\6286395 of_10\IN\1740 <e1>carbamazepine-associated</e1>_11\JJ\1740 <e2>cardiac_12\JJ\1740 dysfunction</e2>_13\NN\14204950 emerged_14\VBD\422090 ._15\.\1740
D002220_D001919 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 sinus_3\NN\5248181 <e2>bradycardia</e2>_4\NN\14110674 and_5\CC\1740 atrioventricular_6\JJ\1740 block_7\NN\21939 ,_8\,\1740 induced_9\VBN\1627355 by_10\IN\1740 <e1>carbamazepine</e1>_11\NN\1740 ,_12\,\1740 prompted_13\VBD\1645601 an_14\DT\6697703 extensive_15\JJ\1740 literature_16\NN\6362953 review_17\NN\5733583 of_18\IN\1740 all_19\DT\1740 previously_20\RB\1740 reported_21\VBN\831651 cases_22\NNS\7283608 ._23\.\1740
D002220_D001919 CID the_0\DT\1740 second_1\JJ\1740 group_2\NN\2137 consisted_3\VBD\2603699 almost_4\RB\1740 exclusively_5\RB\1740 of_6\IN\1740 elderly_7\JJ\1740 women_8\NNS\9605289 who_9\WP\8299493 developed_10\VBD\1753788 potentially_11\RB\1740 life-threatening_12\JJ\1740 <e2>bradyarrhythmias</e2>_13\NNS\1740 or_14\CC\3541091 atrioventricular_15\JJ\1740 conduction_16\NN\11419404 delay_17\NN\15271008 ,_18\,\1740 associated_19\VBN\628491 with_20\IN\1740 either_21\CC\1740 therapeutic_22\JJ\1740 or_23\CC\3541091 modestly_24\RB\1740 elevated_25\JJ\1740 <e1>carbamazepine</e1>_26\NN\1740 serum_27\NN\5397468 levels_28\NNS\4916342 ._29\.\1740
D002220_D054537 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 sinus_3\NN\5248181 bradycardia_4\NN\14110674 and_5\CC\1740 <e2>atrioventricular_6\JJ\1740 block</e2>_7\NN\21939 ,_8\,\1740 induced_9\VBN\1627355 by_10\IN\1740 <e1>carbamazepine</e1>_11\NN\1740 ,_12\,\1740 prompted_13\VBD\1645601 an_14\DT\6697703 extensive_15\JJ\1740 literature_16\NN\6362953 review_17\NN\5733583 of_18\IN\1740 all_19\DT\1740 previously_20\RB\1740 reported_21\VBN\831651 cases_22\NNS\7283608 ._23\.\1740
D002220_D054537 CID the_0\DT\1740 second_1\JJ\1740 group_2\NN\2137 consisted_3\VBD\2603699 almost_4\RB\1740 exclusively_5\RB\1740 of_6\IN\1740 elderly_7\JJ\1740 women_8\NNS\9605289 who_9\WP\8299493 developed_10\VBD\1753788 potentially_11\RB\1740 life-threatening_12\JJ\1740 bradyarrhythmias_13\NNS\1740 or_14\CC\3541091 <e2>atrioventricular_15\JJ\1740 conduction_16\NN\11419404 delay</e2>_17\NN\15271008 ,_18\,\1740 associated_19\VBN\628491 with_20\IN\1740 either_21\CC\1740 therapeutic_22\JJ\1740 or_23\CC\3541091 modestly_24\RB\1740 elevated_25\JJ\1740 <e1>carbamazepine</e1>_26\NN\1740 serum_27\NN\5397468 levels_28\NNS\4916342 ._29\.\1740
D002220_D013616 CID one_0\CD\13741022 patient_1\NN\9898892 group_2\NN\2137 developed_3\VBD\1753788 <e2>sinus_4\NN\5248181 tachycardias</e2>_5\NNS\14110674 in_6\IN\13603305 the_7\DT\1740 setting_8\NN\8567235 of_9\IN\1740 a_10\DT\13649268 massive_11\JJ\1740 <e1>carbamazepine</e1>_12\NN\1740 overdose_13\NN\1740 ._14\.\1740
D002220_D062787 NONE one_0\CD\13741022 patient_1\NN\9898892 group_2\NN\2137 developed_3\VBD\1753788 sinus_4\NN\5248181 tachycardias_5\NNS\14110674 in_6\IN\13603305 the_7\DT\1740 setting_8\NN\8567235 of_9\IN\1740 a_10\DT\13649268 massive_11\JJ\1740 <e1>carbamazepine</e1>_12\NN\1740 <e2>overdose</e2>_13\NN\1740 ._14\.\1740
D002220_D001523 NONE because_0\IN\1740 <e1>carbamazepine</e1>_1\NN\1740 is_2\VBZ\836236 widely_3\RB\1740 used_4\VBN\1156834 in_5\IN\13603305 the_6\DT\1740 treatment_7\NN\654885 of_8\IN\1740 many_9\JJ\1740 neurologic_10\JJ\1740 and_11\CC\1740 <e2>psychiatric</e2>_12\JJ\1740 conditions_13\NNS\14512817 ,_14\,\1740 the_15\DT\1740 recognition_16\NN\13932421 of_17\IN\1740 the_18\DT\1740 latter_19\JJ\1740 syndrome_20\NN\5870365 has_21\VBZ\2108377 important_22\JJ\1740 implications_23\NNS\5774614 for_24\IN\1740 the_25\DT\1740 use_26\NN\407535 of_27\IN\1740 this_28\DT\1740 drug_29\NN\14778436 in_30\IN\13603305 elderly_31\JJ\1740 patients_32\NNS\9898892 ._33\.\1740
6323692
C018824_D001259 CID pretreatment_0\NN\1740 with_1\IN\1740 <e1>ammonium_2\NN\14743582 acetate</e1>_3\NN\15010703 (_4\-LRB-\1740 nh4ac_5\NN\1740 )_6\-RRB-\1740 (_7\-LRB-\1740 6_8\CD\13741022 mmol/kg_9\NNS\1740 s.c._10\FW\1740 )_11\-RRB-\1740 approximately_12\RB\1740 doubled_13\VBD\247390 the_14\DT\1740 time_15\NN\7308889 morphine-treated_16\JJ\1740 mice_17\NNS\2329401 remained_18\VBD\2604760 on_19\IN\1740 a_20\DT\13649268 hot_21\JJ\1740 surface_22\NN\21939 and_23\CC\1740 similarly_24\RB\1740 increased_25\VBD\169651 muscular_26\JJ\1740 <e2>incoordination</e2>_27\NN\5648247 by_28\IN\1740 diazepam_29\NN\2830852 ,_30\,\1740 but_31\CC\1740 nh4ac_32\NN\1740 treatment_33\NN\654885 alone_34\RB\1740 had_35\VBD\2108377 no_36\DT\7204911 effect_37\NN\34213 ._38\.\1740
C018824_D001259 CID pretreatment_0\NN\1740 with_1\IN\1740 ammonium_2\NN\14743582 acetate_3\NN\15010703 (_4\-LRB-\1740 <e1>nh4ac</e1>_5\NN\1740 )_6\-RRB-\1740 (_7\-LRB-\1740 6_8\CD\13741022 mmol/kg_9\NNS\1740 s.c._10\FW\1740 )_11\-RRB-\1740 approximately_12\RB\1740 doubled_13\VBD\247390 the_14\DT\1740 time_15\NN\7308889 morphine-treated_16\JJ\1740 mice_17\NNS\2329401 remained_18\VBD\2604760 on_19\IN\1740 a_20\DT\13649268 hot_21\JJ\1740 surface_22\NN\21939 and_23\CC\1740 similarly_24\RB\1740 increased_25\VBD\169651 muscular_26\JJ\1740 <e2>incoordination</e2>_27\NN\5648247 by_28\IN\1740 diazepam_29\NN\2830852 ,_30\,\1740 but_31\CC\1740 nh4ac_32\NN\1740 treatment_33\NN\654885 alone_34\RB\1740 had_35\VBD\2108377 no_36\DT\7204911 effect_37\NN\34213 ._38\.\1740
C018824_D001259 CID pretreatment_0\NN\1740 with_1\IN\1740 ammonium_2\NN\14743582 acetate_3\NN\15010703 (_4\-LRB-\1740 nh4ac_5\NN\1740 )_6\-RRB-\1740 (_7\-LRB-\1740 6_8\CD\13741022 mmol/kg_9\NNS\1740 s.c._10\FW\1740 )_11\-RRB-\1740 approximately_12\RB\1740 doubled_13\VBD\247390 the_14\DT\1740 time_15\NN\7308889 morphine-treated_16\JJ\1740 mice_17\NNS\2329401 remained_18\VBD\2604760 on_19\IN\1740 a_20\DT\13649268 hot_21\JJ\1740 surface_22\NN\21939 and_23\CC\1740 similarly_24\RB\1740 increased_25\VBD\169651 muscular_26\JJ\1740 <e2>incoordination</e2>_27\NN\5648247 by_28\IN\1740 diazepam_29\NN\2830852 ,_30\,\1740 but_31\CC\1740 <e1>nh4ac</e1>_32\NN\1740 treatment_33\NN\654885 alone_34\RB\1740 had_35\VBD\2108377 no_36\DT\7204911 effect_37\NN\34213 ._38\.\1740
C018824_D001259 CID both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 <e1>nh4ac</e1>_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 analgesia-_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 <e2>incoordination</e2>_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
C018824_D001259 CID both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 analgesia-_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 <e2>incoordination</e2>_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 <e1>nh4ac</e1>_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
D009020_D001259 NONE pretreatment_0\NN\1740 with_1\IN\1740 ammonium_2\NN\14743582 acetate_3\NN\15010703 (_4\-LRB-\1740 nh4ac_5\NN\1740 )_6\-RRB-\1740 (_7\-LRB-\1740 6_8\CD\13741022 mmol/kg_9\NNS\1740 s.c._10\FW\1740 )_11\-RRB-\1740 approximately_12\RB\1740 doubled_13\VBD\247390 the_14\DT\1740 time_15\NN\7308889 <e1>morphine-treated</e1>_16\JJ\1740 mice_17\NNS\2329401 remained_18\VBD\2604760 on_19\IN\1740 a_20\DT\13649268 hot_21\JJ\1740 surface_22\NN\21939 and_23\CC\1740 similarly_24\RB\1740 increased_25\VBD\169651 muscular_26\JJ\1740 <e2>incoordination</e2>_27\NN\5648247 by_28\IN\1740 diazepam_29\NN\2830852 ,_30\,\1740 but_31\CC\1740 nh4ac_32\NN\1740 treatment_33\NN\654885 alone_34\RB\1740 had_35\VBD\2108377 no_36\DT\7204911 effect_37\NN\34213 ._38\.\1740
D009020_D001259 NONE both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 <e1>morphine</e1>_11\NN\2707683 analgesia-_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 <e2>incoordination</e2>_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
D003975_D001259 CID pretreatment_0\NN\1740 with_1\IN\1740 ammonium_2\NN\14743582 acetate_3\NN\15010703 (_4\-LRB-\1740 nh4ac_5\NN\1740 )_6\-RRB-\1740 (_7\-LRB-\1740 6_8\CD\13741022 mmol/kg_9\NNS\1740 s.c._10\FW\1740 )_11\-RRB-\1740 approximately_12\RB\1740 doubled_13\VBD\247390 the_14\DT\1740 time_15\NN\7308889 morphine-treated_16\JJ\1740 mice_17\NNS\2329401 remained_18\VBD\2604760 on_19\IN\1740 a_20\DT\13649268 hot_21\JJ\1740 surface_22\NN\21939 and_23\CC\1740 similarly_24\RB\1740 increased_25\VBD\169651 muscular_26\JJ\1740 <e2>incoordination</e2>_27\NN\5648247 by_28\IN\1740 <e1>diazepam</e1>_29\NN\2830852 ,_30\,\1740 but_31\CC\1740 nh4ac_32\NN\1740 treatment_33\NN\654885 alone_34\RB\1740 had_35\VBD\2108377 no_36\DT\7204911 effect_37\NN\34213 ._38\.\1740
D003975_D001259 CID both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 analgesia-_12\JJ\1740 and_13\CC\1740 <e1>diazepam-induced</e1>_14\JJ\1740 muscular_15\JJ\1740 <e2>incoordination</e2>_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
D002118_D003866 NONE addition_0\NN\3081021 of_1\IN\1740 excess_2\JJ\1740 <e1>calcium</e1>_3\NN\14625458 reversed_4\VBD\109660 the_5\DT\1740 <e2>depression</e2>_6\NN\14373582 in_7\IN\13603305 both_8\DT\1740 tissues_9\NNS\5220461 ,_10\,\1740 but_11\CC\1740 calcium-independent_12\JJ\1740 catecholamine_13\NN\5407119 release_14\NN\3748886 by_15\IN\1740 acetaldehyde_16\NN\14584765 was_17\VBD\836236 not_18\RB\1740 blocked_19\VBN\1476483 by_20\IN\1740 nh4ac_21\NN\1740 ._22\.\1740
D002118_D003866 NONE addition_0\NN\3081021 of_1\IN\1740 excess_2\JJ\1740 calcium_3\NN\14625458 reversed_4\VBD\109660 the_5\DT\1740 <e2>depression</e2>_6\NN\14373582 in_7\IN\13603305 both_8\DT\1740 tissues_9\NNS\5220461 ,_10\,\1740 but_11\CC\1740 <e1>calcium-independent</e1>_12\JJ\1740 catecholamine_13\NN\5407119 release_14\NN\3748886 by_15\IN\1740 acetaldehyde_16\NN\14584765 was_17\VBD\836236 not_18\RB\1740 blocked_19\VBN\1476483 by_20\IN\1740 nh4ac_21\NN\1740 ._22\.\1740
D002395_D003866 NONE addition_0\NN\3081021 of_1\IN\1740 excess_2\JJ\1740 calcium_3\NN\14625458 reversed_4\VBD\109660 the_5\DT\1740 <e2>depression</e2>_6\NN\14373582 in_7\IN\13603305 both_8\DT\1740 tissues_9\NNS\5220461 ,_10\,\1740 but_11\CC\1740 calcium-independent_12\JJ\1740 <e1>catecholamine</e1>_13\NN\5407119 release_14\NN\3748886 by_15\IN\1740 acetaldehyde_16\NN\14584765 was_17\VBD\836236 not_18\RB\1740 blocked_19\VBN\1476483 by_20\IN\1740 nh4ac_21\NN\1740 ._22\.\1740
D000079_D003866 NONE addition_0\NN\3081021 of_1\IN\1740 excess_2\JJ\1740 calcium_3\NN\14625458 reversed_4\VBD\109660 the_5\DT\1740 <e2>depression</e2>_6\NN\14373582 in_7\IN\13603305 both_8\DT\1740 tissues_9\NNS\5220461 ,_10\,\1740 but_11\CC\1740 calcium-independent_12\JJ\1740 catecholamine_13\NN\5407119 release_14\NN\3748886 by_15\IN\1740 <e1>acetaldehyde</e1>_16\NN\14584765 was_17\VBD\836236 not_18\RB\1740 blocked_19\VBN\1476483 by_20\IN\1740 nh4ac_21\NN\1740 ._22\.\1740
C018824_D003866 NONE addition_0\NN\3081021 of_1\IN\1740 excess_2\JJ\1740 calcium_3\NN\14625458 reversed_4\VBD\109660 the_5\DT\1740 <e2>depression</e2>_6\NN\14373582 in_7\IN\13603305 both_8\DT\1740 tissues_9\NNS\5220461 ,_10\,\1740 but_11\CC\1740 calcium-independent_12\JJ\1740 catecholamine_13\NN\5407119 release_14\NN\3748886 by_15\IN\1740 acetaldehyde_16\NN\14584765 was_17\VBD\836236 not_18\RB\1740 blocked_19\VBN\1476483 by_20\IN\1740 <e1>nh4ac</e1>_21\NN\1740 ._22\.\1740
D014700_D000699 NONE both_0\CC\1740 <e1>verapamil</e1>_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 <e2>analgesia-</e2>_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 incoordination_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
D014700_D000699 NONE both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 <e2>analgesia-</e2>_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 incoordination_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 <e1>verapamil</e1>_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
D014700_D001259 NONE both_0\CC\1740 <e1>verapamil</e1>_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 analgesia-_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 <e2>incoordination</e2>_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
D014700_D001259 NONE both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 analgesia-_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 <e2>incoordination</e2>_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 <e1>verapamil</e1>_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
C018824_D000699 NONE both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 <e1>nh4ac</e1>_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 <e2>analgesia-</e2>_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 incoordination_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
C018824_D000699 NONE both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 <e2>analgesia-</e2>_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 incoordination_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 <e1>nh4ac</e1>_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
D009020_D000699 NONE both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 <e1>morphine</e1>_11\NN\2707683 <e2>analgesia-</e2>_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 incoordination_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
D003975_D000699 NONE both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 <e2>analgesia-</e2>_12\JJ\1740 and_13\CC\1740 <e1>diazepam-induced</e1>_14\JJ\1740 muscular_15\JJ\1740 incoordination_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
D000661_D000699 NONE both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 <e2>analgesia-</e2>_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 incoordination_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 <e1>amphetamine-induced</e1>_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
D000661_D001259 NONE both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 analgesia-_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 <e2>incoordination</e2>_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 <e1>amphetamine-induced</e1>_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 metrazol_33\NN\3740161 ._34\.\1740
D010433_D000699 NONE both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 <e2>analgesia-</e2>_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 incoordination_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 <e1>metrazol</e1>_33\NN\3740161 ._34\.\1740
D010433_D001259 NONE both_0\CC\1740 verapamil_1\NN\2938514 (_2\-LRB-\1740 10_3\CD\13745420 mg/kg_4\NN\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 nh4ac_8\NN\1740 pretreatment_9\NN\1740 enhanced_10\VBD\227165 morphine_11\NN\2707683 analgesia-_12\JJ\1740 and_13\CC\1740 diazepam-induced_14\JJ\1740 muscular_15\JJ\1740 <e2>incoordination</e2>_16\NN\5648247 and_17\CC\1740 antagonized_18\VBN\1787955 amphetamine-induced_19\JJ\1740 motor_20\NN\3699975 activity_21\NN\30358 ,_22\,\1740 and_23\CC\1740 neither_24\CC\1740 verapamil_25\NN\2938514 nor_26\CC\1740 nh4ac_27\NN\1740 affected_28\VBD\126264 the_29\DT\1740 convulsant_30\JJ\1740 action_31\NN\30358 of_32\IN\1740 <e1>metrazol</e1>_33\NN\3740161 ._34\.\1740
D002118_D022124 NONE the_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e2>hyperammonemia</e2>_4\NN\1740 exerts_5\VBZ\1158872 a_6\DT\13649268 <e1>calcium</e1>_7\NN\14625458 channel_8\NN\6251781 blocking_9\NN\562280 action_10\NN\30358 which_11\WDT\1740 enhances_12\VBZ\227165 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 central_16\JJ\1740 nervous_17\JJ\1740 system_18\NN\3575240 depressants_19\NNS\3248958 and_20\CC\1740 certain_21\JJ\1740 opioid_22\NN\1740 analgesics_23\NNS\3740161 ._24\.\1740
7072798
D002701_D000741 CID fatal_0\JJ\1740 <e2>aplastic_1\JJ\1740 anemia</e2>_2\NN\14189204 following_3\VBG\1835496 topical_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 ophthalmic_7\JJ\1740 <e1>chloramphenicol</e1>_8\NN\2716866 ._9\.\1740
D002701_D000741 CID a_0\DT\13649268 73-year-old_1\JJ\1740 woman_2\NN\9605289 died_3\VBD\146138 of_4\IN\1740 <e2>aplastic_5\JJ\1740 anemia</e2>_6\NN\14189204 less_7\JJR\1740 than_8\IN\1740 two_9\CD\13741022 months_10\NNS\15113229 after_11\IN\1740 undergoing_12\VBG\109660 cataract_13\JJ\1740 extraction_14\NN\13518963 and_15\CC\1740 beginning_16\VBG\941990 topical_17\JJ\1740 therapy_18\NN\657604 with_19\IN\1740 <e1>chloramphenicol</e1>_20\NN\2716866 ._21\.\1740
D002701_D000741 CID the_0\DT\1740 pattern_1\NN\5726345 of_2\IN\1740 the_3\DT\1740 <e2>aplastic_4\JJ\1740 anemia</e2>_5\NN\14189204 was_6\VBD\836236 associated_7\VBN\628491 with_8\IN\1740 an_9\DT\6697703 idiosyncratic_10\JJ\1740 response_11\NN\11410625 to_12\TO\1740 <e1>chloramphenicol</e1>_13\NN\2716866 ._14\.\1740
D002701_D000741 CID this_0\DT\1740 was_1\VBD\836236 the_2\DT\1740 second_3\JJ\1740 report_4\NN\6470073 of_5\IN\1740 fatal_6\JJ\1740 <e2>aplastic_7\JJ\1740 anemia</e2>_8\NN\14189204 after_9\IN\1740 topical_10\JJ\1740 treatment_11\NN\654885 with_12\IN\1740 <e1>chloramphenicol</e1>_13\NN\2716866 for_14\IN\1740 ocular_15\JJ\1740 conditions_16\NNS\14512817 ,_17\,\1740 although_18\IN\1740 two_19\CD\13741022 cases_20\NNS\7283608 of_21\IN\1740 reversible_22\JJ\1740 bone_23\NN\5286536 marrow_24\NN\5286536 hypoplasia_25\NN\14365950 have_26\VBP\2108377 also_27\RB\1740 been_28\VBN\836236 reported_29\VBN\831651 ._30\.\1740
D002701_D002386 NONE a_0\DT\13649268 73-year-old_1\JJ\1740 woman_2\NN\9605289 died_3\VBD\146138 of_4\IN\1740 aplastic_5\JJ\1740 anemia_6\NN\14189204 less_7\JJR\1740 than_8\IN\1740 two_9\CD\13741022 months_10\NNS\15113229 after_11\IN\1740 undergoing_12\VBG\109660 <e2>cataract</e2>_13\JJ\1740 extraction_14\NN\13518963 and_15\CC\1740 beginning_16\VBG\941990 topical_17\JJ\1740 therapy_18\NN\657604 with_19\IN\1740 <e1>chloramphenicol</e1>_20\NN\2716866 ._21\.\1740
D002701_D001855 NONE this_0\DT\1740 was_1\VBD\836236 the_2\DT\1740 second_3\JJ\1740 report_4\NN\6470073 of_5\IN\1740 fatal_6\JJ\1740 aplastic_7\JJ\1740 anemia_8\NN\14189204 after_9\IN\1740 topical_10\JJ\1740 treatment_11\NN\654885 with_12\IN\1740 <e1>chloramphenicol</e1>_13\NN\2716866 for_14\IN\1740 ocular_15\JJ\1740 conditions_16\NNS\14512817 ,_17\,\1740 although_18\IN\1740 two_19\CD\13741022 cases_20\NNS\7283608 of_21\IN\1740 reversible_22\JJ\1740 <e2>bone_23\NN\5286536 marrow_24\NN\5286536 hypoplasia</e2>_25\NN\14365950 have_26\VBP\2108377 also_27\RB\1740 been_28\VBN\836236 reported_29\VBN\831651 ._30\.\1740
D002701_D005128 NONE any_0\DT\1740 other_1\JJ\1740 suspected_2\VBN\916909 cases_3\NNS\7283608 of_4\IN\1740 <e2>ocular_5\JJ\1740 toxicity</e2>_6\NN\13576101 associated_7\VBN\628491 with_8\IN\1740 topically_9\RB\1740 applied_10\VBN\2676054 <e1>chloramphenicol</e1>_11\NN\2716866 should_12\MD\1740 be_13\VB\836236 reported_14\VBN\831651 to_15\IN\1740 the_16\DT\1740 national_17\NNP\7846 registry_18\NNP\6502378 of_19\IN\1740 drug-induced_20\JJ\1740 ocular_21\JJ\1740 side_22\NN\8630039 effects_23\NNS\13245626 ,_24\,\1740 oregon_25\NNP\1740 health_26\NNP\14447525 sciences_27\NNPS\5996646 university_28\NNP\7965085 ,_29\,\1740 portland_30\NNP\1740 ,_31\,\1740 or_32\NNP\3541091 97201_33\CD\1740 ._34\.\1740
8441146
D006046_D000741 CID bmt_0\NN\1740 was_1\VBD\836236 used_2\VBN\1156834 to_3\TO\1740 treat_4\VB\2376958 severe_5\JJ\1740 <e2>aplastic_6\JJ\1740 anemia</e2>_7\NN\14189204 which_8\WDT\1740 was_9\VBD\836236 caused_10\VBN\1617192 by_11\IN\1740 <e1>gold</e1>_12\NN\13371489 in_13\IN\13603305 one_14\CD\13741022 case_15\NN\7283608 and_16\CC\1740 d-penicillamine_17\NN\1740 in_18\IN\13603305 the_19\DT\1740 other_20\JJ\1740 ._21\.\1740
D010396_D000741 CID bmt_0\NN\1740 was_1\VBD\836236 used_2\VBN\1156834 to_3\TO\1740 treat_4\VB\2376958 severe_5\JJ\1740 <e2>aplastic_6\JJ\1740 anemia</e2>_7\NN\14189204 which_8\WDT\1740 was_9\VBD\836236 caused_10\VBN\1617192 by_11\IN\1740 gold_12\NN\13371489 in_13\IN\13603305 one_14\CD\13741022 case_15\NN\7283608 and_16\CC\1740 <e1>d-penicillamine</e1>_17\NN\1740 in_18\IN\13603305 the_19\DT\1740 other_20\JJ\1740 ._21\.\1740
8911359
D003520_D001749 CID <e1>cyclophosphamide</e1>_0\NN\1740 associated_1\VBD\628491 <e2>bladder_2\NN\5515670 cancer</e2>_3\NN\14239425 --_4\:\1740 a_5\DT\13649268 highly_6\RB\1740 aggressive_7\JJ\1740 disease_8\NN\14061805 :_9\:\1740 analysis_10\NN\633864 of_11\IN\1740 12_12\CD\13745420 cases_13\NNS\7283608 ._14\.\1740
D003520_D001749 CID materials_0\NNS\19613 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 the_4\DT\1740 medical_5\JJ\1740 records_6\NNS\6643408 of_7\IN\1740 6_8\CD\13741022 men_9\NNS\8208016 and_10\CC\1740 6_11\CD\13741022 women_12\NNS\9605289 (_13\-LRB-\1740 mean_14\NN\6021761 age_15\NN\4916342 55_16\CD\1740 years_17\NNS\15144371 )_18\-RRB-\1740 with_19\IN\1740 <e1>cyclophosphamide</e1>_20\NN\1740 associated_21\VBN\628491 <e2>bladder_22\NN\5515670 cancer</e2>_23\NN\14239425 were_24\VBD\836236 reviewed_25\VBN\644583 ._26\.\1740
D003520_D001749 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>cyclophosphamide</e1>_2\NN\1740 associated_3\VBD\628491 <e2>bladder_4\NN\5515670 tumor</e2>_5\NN\14234074 is_6\VBZ\836236 an_7\DT\6697703 aggressive_8\JJ\1740 disease_9\NN\14061805 ._10\.\1740
D003520_D014523 NONE purpose_0\NNP\5980875 :_1\:\1740 we_2\PRP\1740 gained_3\VBD\2238085 knowledge_4\NN\23100 of_5\IN\1740 the_6\DT\1740 etiology_7\NN\7326557 ,_8\,\1740 treatment_9\NN\654885 and_10\CC\1740 prevention_11\NN\1073995 of_12\IN\1740 <e1>cyclophosphamide</e1>_13\NN\1740 associated_14\VBN\628491 <e2>urothelial_15\JJ\1740 cancer</e2>_16\NN\14239425 ._17\.\1740
10193809
D011692_D011507 CID methods_0\NNS\5616786 :_1\:\1740 <e1>puromycin_2\NN\1740 aminonucleoside</e1>_3\NN\1740 (_4\-LRB-\1740 pan_5\NN\3101986 )_6\-RRB-\1740 was_7\VBD\836236 administered_8\VBN\2436349 to_9\IN\1740 sprague_10\NNP\1740 dawley_11\NNP\1740 rats_12\VBZ\2584097 to_13\TO\1740 induce_14\VB\1627355 <e2>proteinuria</e2>_15\NN\14299637 ._16\.\1740
D011692_D011507 CID methods_0\NNS\5616786 :_1\:\1740 puromycin_2\NN\1740 aminonucleoside_3\NN\1740 (_4\-LRB-\1740 <e1>pan</e1>_5\NN\3101986 )_6\-RRB-\1740 was_7\VBD\836236 administered_8\VBN\2436349 to_9\IN\1740 sprague_10\NNP\1740 dawley_11\NNP\1740 rats_12\VBZ\2584097 to_13\TO\1740 induce_14\VB\1627355 <e2>proteinuria</e2>_15\NN\14299637 ._16\.\1740
3780814
D010634_D063646 NONE <e2>anti-carcinogenic</e2>_0\JJ\1740 action_1\NN\30358 of_2\IN\1740 <e1>phenobarbital</e1>_3\JJ\1740 given_4\VBN\2327200 simultaneously_5\RB\1740 with_6\IN\1740 diethylnitrosamine_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 rat_10\NN\2329401 ._11\.\1740
D010634_D063646 NONE the_0\DT\1740 present_1\JJ\1740 work_2\NN\407535 has_3\VBZ\2108377 been_4\VBN\836236 planned_5\VBN\708538 in_6\IN\13603305 order_7\NN\7168131 to_8\TO\1740 elucidate_9\VB\939277 the_10\DT\1740 effect_11\NN\34213 of_12\IN\1740 <e1>phenobarbital</e1>_13\JJ\1740 (_14\-LRB-\1740 pb_15\NN\14625458 :_16\:\1740 15_17\CD\13745420 mg_18\NN\13717155 per_19\IN\1740 rat_20\NN\2329401 of_21\IN\1740 ingested_22\VBN\597915 dose_23\NN\3740161 )_24\-RRB-\1740 on_25\IN\1740 <e2>carcinogenesis</e2>_26\NN\1740 when_27\WRB\1740 it_28\PRP\6125041 is_29\VBZ\836236 administered_30\VBN\2436349 simultaneously_31\RB\1740 with_32\IN\1740 diethylnitrosamine_33\NN\1740 (_34\-LRB-\1740 den_35\NN\8580803 :_36\:\1740 10_37\CD\13745420 mg/kg/day_38\NN\1740 )_39\-RRB-\1740 ._40\.\1740
D010634_D063646 NONE the_0\DT\1740 present_1\JJ\1740 work_2\NN\407535 has_3\VBZ\2108377 been_4\VBN\836236 planned_5\VBN\708538 in_6\IN\13603305 order_7\NN\7168131 to_8\TO\1740 elucidate_9\VB\939277 the_10\DT\1740 effect_11\NN\34213 of_12\IN\1740 phenobarbital_13\JJ\1740 (_14\-LRB-\1740 <e1>pb</e1>_15\NN\14625458 :_16\:\1740 15_17\CD\13745420 mg_18\NN\13717155 per_19\IN\1740 rat_20\NN\2329401 of_21\IN\1740 ingested_22\VBN\597915 dose_23\NN\3740161 )_24\-RRB-\1740 on_25\IN\1740 <e2>carcinogenesis</e2>_26\NN\1740 when_27\WRB\1740 it_28\PRP\6125041 is_29\VBZ\836236 administered_30\VBN\2436349 simultaneously_31\RB\1740 with_32\IN\1740 diethylnitrosamine_33\NN\1740 (_34\-LRB-\1740 den_35\NN\8580803 :_36\:\1740 10_37\CD\13745420 mg/kg/day_38\NN\1740 )_39\-RRB-\1740 ._40\.\1740
D010634_D063646 NONE wistar_0\DT\1740 rats_1\NNS\2329401 (_2\-LRB-\1740 180_3\CD\1740 g_4\NN\13717155 )_5\-RRB-\1740 were_6\VBD\836236 treated_7\VBN\2376958 by_8\IN\1740 den_9\NN\8580803 alone_10\RB\1740 or_11\CC\3541091 by_12\IN\1740 den_13\NN\8580803 +_14\CC\1740 <e1>pb</e1>_15\NN\14625458 during_16\IN\1740 2_17\CD\13741022 ,_18\,\1740 4_19\CD\13741022 and_20\CC\1740 6_21\CD\13741022 weeks_22\NNS\15113229 according_23\VBG\2657219 to_24\IN\1740 our_25\PRP$\1740 schedule_26\NN\5898568 for_27\IN\1740 <e2>hepatocarcinogenesis</e2>_28\NN\1740 ._29\.\1740
D010634_D063646 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 <e1>pb</e1>_4\NNP\14625458 ,_5\,\1740 which_6\WDT\1740 promotes_7\VBZ\2556126 <e2>carcinogenesis</e2>_8\NN\1740 when_9\WRB\1740 administered_10\VBN\2436349 after_11\IN\1740 the_12\DT\1740 den_13\NN\8580803 treatment_14\NN\654885 ,_15\,\1740 reduces_16\VBZ\441445 the_17\DT\1740 carcinogen_18\NN\20090 effect_19\NN\34213 when_20\WRB\1740 given_21\VBN\2327200 simultaneously_22\RB\1740 with_23\IN\1740 den_24\NN\8580803 ._25\.\1740
D004052_D063646 NONE <e2>anti-carcinogenic</e2>_0\JJ\1740 action_1\NN\30358 of_2\IN\1740 phenobarbital_3\JJ\1740 given_4\VBN\2327200 simultaneously_5\RB\1740 with_6\IN\1740 <e1>diethylnitrosamine</e1>_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 rat_10\NN\2329401 ._11\.\1740
D004052_D063646 NONE the_0\DT\1740 present_1\JJ\1740 work_2\NN\407535 has_3\VBZ\2108377 been_4\VBN\836236 planned_5\VBN\708538 in_6\IN\13603305 order_7\NN\7168131 to_8\TO\1740 elucidate_9\VB\939277 the_10\DT\1740 effect_11\NN\34213 of_12\IN\1740 phenobarbital_13\JJ\1740 (_14\-LRB-\1740 pb_15\NN\14625458 :_16\:\1740 15_17\CD\13745420 mg_18\NN\13717155 per_19\IN\1740 rat_20\NN\2329401 of_21\IN\1740 ingested_22\VBN\597915 dose_23\NN\3740161 )_24\-RRB-\1740 on_25\IN\1740 <e2>carcinogenesis</e2>_26\NN\1740 when_27\WRB\1740 it_28\PRP\6125041 is_29\VBZ\836236 administered_30\VBN\2436349 simultaneously_31\RB\1740 with_32\IN\1740 <e1>diethylnitrosamine</e1>_33\NN\1740 (_34\-LRB-\1740 den_35\NN\8580803 :_36\:\1740 10_37\CD\13745420 mg/kg/day_38\NN\1740 )_39\-RRB-\1740 ._40\.\1740
D004052_D063646 NONE the_0\DT\1740 present_1\JJ\1740 work_2\NN\407535 has_3\VBZ\2108377 been_4\VBN\836236 planned_5\VBN\708538 in_6\IN\13603305 order_7\NN\7168131 to_8\TO\1740 elucidate_9\VB\939277 the_10\DT\1740 effect_11\NN\34213 of_12\IN\1740 phenobarbital_13\JJ\1740 (_14\-LRB-\1740 pb_15\NN\14625458 :_16\:\1740 15_17\CD\13745420 mg_18\NN\13717155 per_19\IN\1740 rat_20\NN\2329401 of_21\IN\1740 ingested_22\VBN\597915 dose_23\NN\3740161 )_24\-RRB-\1740 on_25\IN\1740 <e2>carcinogenesis</e2>_26\NN\1740 when_27\WRB\1740 it_28\PRP\6125041 is_29\VBZ\836236 administered_30\VBN\2436349 simultaneously_31\RB\1740 with_32\IN\1740 diethylnitrosamine_33\NN\1740 (_34\-LRB-\1740 <e1>den</e1>_35\NN\8580803 :_36\:\1740 10_37\CD\13745420 mg/kg/day_38\NN\1740 )_39\-RRB-\1740 ._40\.\1740
D004052_D063646 NONE wistar_0\DT\1740 rats_1\NNS\2329401 (_2\-LRB-\1740 180_3\CD\1740 g_4\NN\13717155 )_5\-RRB-\1740 were_6\VBD\836236 treated_7\VBN\2376958 by_8\IN\1740 <e1>den</e1>_9\NN\8580803 alone_10\RB\1740 or_11\CC\3541091 by_12\IN\1740 den_13\NN\8580803 +_14\CC\1740 pb_15\NN\14625458 during_16\IN\1740 2_17\CD\13741022 ,_18\,\1740 4_19\CD\13741022 and_20\CC\1740 6_21\CD\13741022 weeks_22\NNS\15113229 according_23\VBG\2657219 to_24\IN\1740 our_25\PRP$\1740 schedule_26\NN\5898568 for_27\IN\1740 <e2>hepatocarcinogenesis</e2>_28\NN\1740 ._29\.\1740
D004052_D063646 NONE wistar_0\DT\1740 rats_1\NNS\2329401 (_2\-LRB-\1740 180_3\CD\1740 g_4\NN\13717155 )_5\-RRB-\1740 were_6\VBD\836236 treated_7\VBN\2376958 by_8\IN\1740 den_9\NN\8580803 alone_10\RB\1740 or_11\CC\3541091 by_12\IN\1740 <e1>den</e1>_13\NN\8580803 +_14\CC\1740 pb_15\NN\14625458 during_16\IN\1740 2_17\CD\13741022 ,_18\,\1740 4_19\CD\13741022 and_20\CC\1740 6_21\CD\13741022 weeks_22\NNS\15113229 according_23\VBG\2657219 to_24\IN\1740 our_25\PRP$\1740 schedule_26\NN\5898568 for_27\IN\1740 <e2>hepatocarcinogenesis</e2>_28\NN\1740 ._29\.\1740
D004052_D063646 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 pb_4\NNP\14625458 ,_5\,\1740 which_6\WDT\1740 promotes_7\VBZ\2556126 <e2>carcinogenesis</e2>_8\NN\1740 when_9\WRB\1740 administered_10\VBN\2436349 after_11\IN\1740 the_12\DT\1740 <e1>den</e1>_13\NN\8580803 treatment_14\NN\654885 ,_15\,\1740 reduces_16\VBZ\441445 the_17\DT\1740 carcinogen_18\NN\20090 effect_19\NN\34213 when_20\WRB\1740 given_21\VBN\2327200 simultaneously_22\RB\1740 with_23\IN\1740 den_24\NN\8580803 ._25\.\1740
D004052_D063646 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 pb_4\NNP\14625458 ,_5\,\1740 which_6\WDT\1740 promotes_7\VBZ\2556126 <e2>carcinogenesis</e2>_8\NN\1740 when_9\WRB\1740 administered_10\VBN\2436349 after_11\IN\1740 the_12\DT\1740 den_13\NN\8580803 treatment_14\NN\654885 ,_15\,\1740 reduces_16\VBZ\441445 the_17\DT\1740 carcinogen_18\NN\20090 effect_19\NN\34213 when_20\WRB\1740 given_21\VBN\2327200 simultaneously_22\RB\1740 with_23\IN\1740 <e1>den</e1>_24\NN\8580803 ._25\.\1740
D010634_D011230 NONE after_0\IN\1740 the_1\DT\1740 end_2\NN\8568978 of_3\IN\1740 the_4\DT\1740 treatment_5\NN\654885 ,_6\,\1740 the_7\DT\1740 number_8\NN\5107765 and_9\CC\1740 the_10\DT\1740 size_11\NN\5090441 of_12\IN\1740 induced_13\VBN\1627355 pas_14\NN\285557 positive_15\JJ\1740 <e2>preneoplastic_16\JJ\1740 foci</e2>_17\NNS\5704266 was_18\VBD\836236 significantly_19\RB\1740 reduced_20\VBN\441445 when_21\WRB\1740 <e1>pb</e1>_22\NN\14625458 was_23\VBD\836236 given_24\VBN\2327200 simultaneously_25\RB\1740 with_26\IN\1740 den_27\NN\8580803 for_28\IN\1740 4_29\CD\13741022 and_30\CC\1740 6_31\CD\13741022 weeks_32\NNS\15113229 ._33\.\1740
D004052_D011230 CID after_0\IN\1740 the_1\DT\1740 end_2\NN\8568978 of_3\IN\1740 the_4\DT\1740 treatment_5\NN\654885 ,_6\,\1740 the_7\DT\1740 number_8\NN\5107765 and_9\CC\1740 the_10\DT\1740 size_11\NN\5090441 of_12\IN\1740 induced_13\VBN\1627355 pas_14\NN\285557 positive_15\JJ\1740 <e2>preneoplastic_16\JJ\1740 foci</e2>_17\NNS\5704266 was_18\VBD\836236 significantly_19\RB\1740 reduced_20\VBN\441445 when_21\WRB\1740 pb_22\NN\14625458 was_23\VBD\836236 given_24\VBN\2327200 simultaneously_25\RB\1740 with_26\IN\1740 <e1>den</e1>_27\NN\8580803 for_28\IN\1740 4_29\CD\13741022 and_30\CC\1740 6_31\CD\13741022 weeks_32\NNS\15113229 ._33\.\1740
D004052_D009369 NONE in_0\IN\13603305 <e1>den</e1>_1\NN\8580803 +_2\CC\1740 pb_3\NN\14625458 treated_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 the_7\DT\1740 survival_8\NN\13961642 was_9\VBD\836236 prolonged_10\JJ\1740 and_11\CC\1740 the_12\DT\1740 <e2>tumor</e2>_13\NN\14234074 incidence_14\NN\13821570 decreased_15\VBD\169651 as_16\IN\14622893 compared_17\VBN\644583 with_18\IN\1740 the_19\DT\1740 results_20\NNS\34213 obtained_21\VBN\2210855 by_22\IN\1740 den_23\NN\8580803 alone_24\RB\1740 ._25\.\1740
D004052_D009369 NONE in_0\IN\13603305 den_1\NN\8580803 +_2\CC\1740 pb_3\NN\14625458 treated_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 the_7\DT\1740 survival_8\NN\13961642 was_9\VBD\836236 prolonged_10\JJ\1740 and_11\CC\1740 the_12\DT\1740 <e2>tumor</e2>_13\NN\14234074 incidence_14\NN\13821570 decreased_15\VBD\169651 as_16\IN\14622893 compared_17\VBN\644583 with_18\IN\1740 the_19\DT\1740 results_20\NNS\34213 obtained_21\VBN\2210855 by_22\IN\1740 <e1>den</e1>_23\NN\8580803 alone_24\RB\1740 ._25\.\1740
D010634_D009369 NONE in_0\IN\13603305 den_1\NN\8580803 +_2\CC\1740 <e1>pb</e1>_3\NN\14625458 treated_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 the_7\DT\1740 survival_8\NN\13961642 was_9\VBD\836236 prolonged_10\JJ\1740 and_11\CC\1740 the_12\DT\1740 <e2>tumor</e2>_13\NN\14234074 incidence_14\NN\13821570 decreased_15\VBD\169651 as_16\IN\14622893 compared_17\VBN\644583 with_18\IN\1740 the_19\DT\1740 results_20\NNS\34213 obtained_21\VBN\2210855 by_22\IN\1740 den_23\NN\8580803 alone_24\RB\1740 ._25\.\1740
20683499
C029036_D000544 NONE effects_0\NNS\13245626 of_1\IN\1740 active_2\JJ\1740 constituents_3\NNS\3892891 of_4\IN\1740 crocus_5\NN\12411461 sativus_6\NN\1740 l._7\NNP\1740 ,_8\,\1740 <e1>crocin</e1>_9\NN\1740 on_10\IN\1740 streptozocin-induced_11\JJ\1740 model_12\NN\5888929 of_13\IN\1740 sporadic_14\JJ\1740 <e2>alzheimer_15\NN\1740 's_16\POS\1740 disease</e2>_17\NN\14061805 in_18\IN\13603305 male_19\JJ\1740 rats_20\NNS\2329401 ._21\.\1740
C029036_D000544 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 <e1>crocins</e1>_8\NNS\1740 on_9\IN\1740 sporadic_10\JJ\1740 <e2>alzheimer_11\NN\1740 's_12\POS\1740 disease</e2>_13\NN\14061805 induced_14\VBN\1627355 by_15\IN\1740 intracerebroventricular_16\JJ\1740 (_17\-LRB-\1740 icv_18\JJ\1740 )_19\-RRB-\1740 streptozocin_20\NN\1740 (_21\-LRB-\1740 stz_22\NN\1740 )_23\-RRB-\1740 in_24\IN\13603305 male_25\JJ\1740 rats_26\NNS\2329401 was_27\VBD\836236 investigated_28\VBN\644583 ._29\.\1740
C029036_D000544 NONE conclusion_0\NN\5837957 :_1\:\1740 therefore_2\RB\1740 ,_3\,\1740 these_4\DT\1740 results_5\NNS\34213 demonstrate_6\VBP\2137132 the_7\DT\1740 effectiveness_8\NN\5190804 of_9\IN\1740 <e1>crocin</e1>_10\NN\1740 (_11\-LRB-\1740 30_12\CD\13745420 mg/kg_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 antagonizing_16\VBG\1787955 the_17\DT\1740 cognitive_18\JJ\1740 deficits_19\NNS\5113133 caused_20\VBN\1617192 by_21\IN\1740 stz-icv_22\NN\1740 in_23\IN\13603305 rats_24\NNS\2329401 and_25\CC\1740 its_26\PRP$\6125041 potential_27\NN\14481929 in_28\IN\13603305 the_29\DT\1740 treatment_30\NN\654885 of_31\IN\1740 neurodegenerative_32\JJ\1740 diseases_33\NNS\14061805 such_34\JJ\1740 as_35\IN\14622893 <e2>alzheimer_36\NN\1740 's_37\POS\1740 disease</e2>_38\NN\14061805 ._39\.\1740
D013311_D000544 CID effects_0\NNS\13245626 of_1\IN\1740 active_2\JJ\1740 constituents_3\NNS\3892891 of_4\IN\1740 crocus_5\NN\12411461 sativus_6\NN\1740 l._7\NNP\1740 ,_8\,\1740 crocin_9\NN\1740 on_10\IN\1740 <e1>streptozocin-induced</e1>_11\JJ\1740 model_12\NN\5888929 of_13\IN\1740 sporadic_14\JJ\1740 <e2>alzheimer_15\NN\1740 's_16\POS\1740 disease</e2>_17\NN\14061805 in_18\IN\13603305 male_19\JJ\1740 rats_20\NNS\2329401 ._21\.\1740
D013311_D000544 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 crocins_8\NNS\1740 on_9\IN\1740 sporadic_10\JJ\1740 <e2>alzheimer_11\NN\1740 's_12\POS\1740 disease</e2>_13\NN\14061805 induced_14\VBN\1627355 by_15\IN\1740 intracerebroventricular_16\JJ\1740 (_17\-LRB-\1740 icv_18\JJ\1740 )_19\-RRB-\1740 <e1>streptozocin</e1>_20\NN\1740 (_21\-LRB-\1740 stz_22\NN\1740 )_23\-RRB-\1740 in_24\IN\13603305 male_25\JJ\1740 rats_26\NNS\2329401 was_27\VBD\836236 investigated_28\VBN\644583 ._29\.\1740
D013311_D000544 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 crocins_8\NNS\1740 on_9\IN\1740 sporadic_10\JJ\1740 <e2>alzheimer_11\NN\1740 's_12\POS\1740 disease</e2>_13\NN\14061805 induced_14\VBN\1627355 by_15\IN\1740 intracerebroventricular_16\JJ\1740 (_17\-LRB-\1740 icv_18\JJ\1740 )_19\-RRB-\1740 streptozocin_20\NN\1740 (_21\-LRB-\1740 <e1>stz</e1>_22\NN\1740 )_23\-RRB-\1740 in_24\IN\13603305 male_25\JJ\1740 rats_26\NNS\2329401 was_27\VBD\836236 investigated_28\VBN\644583 ._29\.\1740
D013311_D000544 CID in_0\IN\13603305 <e2>alzheimer_1\NN\1740 's_2\POS\1740 disease</e2>_3\NN\14061805 groups_4\NNS\2137 ,_5\,\1740 rats_6\NNS\2329401 were_7\VBD\836236 injected_8\VBN\81072 with_9\IN\1740 <e1>stz-icv</e1>_10\NN\1740 bilaterally_11\RB\1740 (_12\-LRB-\1740 3_13\CD\13741022 mg/kg_14\NN\1740 )_15\-RRB-\1740 in_16\IN\13603305 first_17\JJ\1740 day_18\NN\15154774 and_19\CC\1740 3_20\CD\13741022 days_21\NNS\15140892 later_22\RB\1740 ,_23\,\1740 a_24\DT\13649268 similar_25\JJ\1740 stz-icv_26\NN\1740 application_27\NN\947128 was_28\VBD\836236 repeated_29\VBN\952524 ._30\.\1740
D013311_D000544 CID in_0\IN\13603305 <e2>alzheimer_1\NN\1740 's_2\POS\1740 disease</e2>_3\NN\14061805 groups_4\NNS\2137 ,_5\,\1740 rats_6\NNS\2329401 were_7\VBD\836236 injected_8\VBN\81072 with_9\IN\1740 stz-icv_10\NN\1740 bilaterally_11\RB\1740 (_12\-LRB-\1740 3_13\CD\13741022 mg/kg_14\NN\1740 )_15\-RRB-\1740 in_16\IN\13603305 first_17\JJ\1740 day_18\NN\15154774 and_19\CC\1740 3_20\CD\13741022 days_21\NNS\15140892 later_22\RB\1740 ,_23\,\1740 a_24\DT\13649268 similar_25\JJ\1740 <e1>stz-icv</e1>_26\NN\1740 application_27\NN\947128 was_28\VBD\836236 repeated_29\VBN\952524 ._30\.\1740
D013311_D000544 CID conclusion_0\NN\5837957 :_1\:\1740 therefore_2\RB\1740 ,_3\,\1740 these_4\DT\1740 results_5\NNS\34213 demonstrate_6\VBP\2137132 the_7\DT\1740 effectiveness_8\NN\5190804 of_9\IN\1740 crocin_10\NN\1740 (_11\-LRB-\1740 30_12\CD\13745420 mg/kg_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 antagonizing_16\VBG\1787955 the_17\DT\1740 cognitive_18\JJ\1740 deficits_19\NNS\5113133 caused_20\VBN\1617192 by_21\IN\1740 <e1>stz-icv</e1>_22\NN\1740 in_23\IN\13603305 rats_24\NNS\2329401 and_25\CC\1740 its_26\PRP$\6125041 potential_27\NN\14481929 in_28\IN\13603305 the_29\DT\1740 treatment_30\NN\654885 of_31\IN\1740 neurodegenerative_32\JJ\1740 diseases_33\NNS\14061805 such_34\JJ\1740 as_35\IN\14622893 <e2>alzheimer_36\NN\1740 's_37\POS\1740 disease</e2>_38\NN\14061805 ._39\.\1740
C029036_D007859 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 <e1>crocin</e1>_3\NN\1740 in_4\IN\13603305 the_5\DT\1740 mentioned_6\VBN\730052 dose_7\NN\3740161 could_8\MD\1740 significantly_9\RB\1740 attenuated_10\VBN\224901 <e2>learning_11\NN\5701944 and_12\CC\1740 memory_13\NN\5926676 impairment</e2>_14\NN\7296428 in_15\IN\13603305 treated_16\VBN\2376958 stz-injected_17\JJ\1740 group_18\NN\2137 in_19\IN\13603305 passive_20\JJ\1740 avoidance_21\NN\203342 test_22\NN\5798043 ._23\.\1740
C029036_D008569 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 <e1>crocin</e1>_3\NN\1740 in_4\IN\13603305 the_5\DT\1740 mentioned_6\VBN\730052 dose_7\NN\3740161 could_8\MD\1740 significantly_9\RB\1740 attenuated_10\VBN\224901 <e2>learning_11\NN\5701944 and_12\CC\1740 memory_13\NN\5926676 impairment</e2>_14\NN\7296428 in_15\IN\13603305 treated_16\VBN\2376958 stz-injected_17\JJ\1740 group_18\NN\2137 in_19\IN\13603305 passive_20\JJ\1740 avoidance_21\NN\203342 test_22\NN\5798043 ._23\.\1740
D013311_D007859 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 crocin_3\NN\1740 in_4\IN\13603305 the_5\DT\1740 mentioned_6\VBN\730052 dose_7\NN\3740161 could_8\MD\1740 significantly_9\RB\1740 attenuated_10\VBN\224901 <e2>learning_11\NN\5701944 and_12\CC\1740 memory_13\NN\5926676 impairment</e2>_14\NN\7296428 in_15\IN\13603305 treated_16\VBN\2376958 <e1>stz-injected</e1>_17\JJ\1740 group_18\NN\2137 in_19\IN\13603305 passive_20\JJ\1740 avoidance_21\NN\203342 test_22\NN\5798043 ._23\.\1740
D013311_D008569 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 crocin_3\NN\1740 in_4\IN\13603305 the_5\DT\1740 mentioned_6\VBN\730052 dose_7\NN\3740161 could_8\MD\1740 significantly_9\RB\1740 attenuated_10\VBN\224901 <e2>learning_11\NN\5701944 and_12\CC\1740 memory_13\NN\5926676 impairment</e2>_14\NN\7296428 in_15\IN\13603305 treated_16\VBN\2376958 <e1>stz-injected</e1>_17\JJ\1740 group_18\NN\2137 in_19\IN\13603305 passive_20\JJ\1740 avoidance_21\NN\203342 test_22\NN\5798043 ._23\.\1740
C029036_D003072 NONE conclusion_0\NN\5837957 :_1\:\1740 therefore_2\RB\1740 ,_3\,\1740 these_4\DT\1740 results_5\NNS\34213 demonstrate_6\VBP\2137132 the_7\DT\1740 effectiveness_8\NN\5190804 of_9\IN\1740 <e1>crocin</e1>_10\NN\1740 (_11\-LRB-\1740 30_12\CD\13745420 mg/kg_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 antagonizing_16\VBG\1787955 the_17\DT\1740 <e2>cognitive_18\JJ\1740 deficits</e2>_19\NNS\5113133 caused_20\VBN\1617192 by_21\IN\1740 stz-icv_22\NN\1740 in_23\IN\13603305 rats_24\NNS\2329401 and_25\CC\1740 its_26\PRP$\6125041 potential_27\NN\14481929 in_28\IN\13603305 the_29\DT\1740 treatment_30\NN\654885 of_31\IN\1740 neurodegenerative_32\JJ\1740 diseases_33\NNS\14061805 such_34\JJ\1740 as_35\IN\14622893 alzheimer_36\NN\1740 's_37\POS\1740 disease_38\NN\14061805 ._39\.\1740
C029036_D019636 NONE conclusion_0\NN\5837957 :_1\:\1740 therefore_2\RB\1740 ,_3\,\1740 these_4\DT\1740 results_5\NNS\34213 demonstrate_6\VBP\2137132 the_7\DT\1740 effectiveness_8\NN\5190804 of_9\IN\1740 <e1>crocin</e1>_10\NN\1740 (_11\-LRB-\1740 30_12\CD\13745420 mg/kg_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 antagonizing_16\VBG\1787955 the_17\DT\1740 cognitive_18\JJ\1740 deficits_19\NNS\5113133 caused_20\VBN\1617192 by_21\IN\1740 stz-icv_22\NN\1740 in_23\IN\13603305 rats_24\NNS\2329401 and_25\CC\1740 its_26\PRP$\6125041 potential_27\NN\14481929 in_28\IN\13603305 the_29\DT\1740 treatment_30\NN\654885 of_31\IN\1740 <e2>neurodegenerative_32\JJ\1740 diseases</e2>_33\NNS\14061805 such_34\JJ\1740 as_35\IN\14622893 alzheimer_36\NN\1740 's_37\POS\1740 disease_38\NN\14061805 ._39\.\1740
D013311_D003072 CID conclusion_0\NN\5837957 :_1\:\1740 therefore_2\RB\1740 ,_3\,\1740 these_4\DT\1740 results_5\NNS\34213 demonstrate_6\VBP\2137132 the_7\DT\1740 effectiveness_8\NN\5190804 of_9\IN\1740 crocin_10\NN\1740 (_11\-LRB-\1740 30_12\CD\13745420 mg/kg_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 antagonizing_16\VBG\1787955 the_17\DT\1740 <e2>cognitive_18\JJ\1740 deficits</e2>_19\NNS\5113133 caused_20\VBN\1617192 by_21\IN\1740 <e1>stz-icv</e1>_22\NN\1740 in_23\IN\13603305 rats_24\NNS\2329401 and_25\CC\1740 its_26\PRP$\6125041 potential_27\NN\14481929 in_28\IN\13603305 the_29\DT\1740 treatment_30\NN\654885 of_31\IN\1740 neurodegenerative_32\JJ\1740 diseases_33\NNS\14061805 such_34\JJ\1740 as_35\IN\14622893 alzheimer_36\NN\1740 's_37\POS\1740 disease_38\NN\14061805 ._39\.\1740
D013311_D019636 NONE conclusion_0\NN\5837957 :_1\:\1740 therefore_2\RB\1740 ,_3\,\1740 these_4\DT\1740 results_5\NNS\34213 demonstrate_6\VBP\2137132 the_7\DT\1740 effectiveness_8\NN\5190804 of_9\IN\1740 crocin_10\NN\1740 (_11\-LRB-\1740 30_12\CD\13745420 mg/kg_13\NN\1740 )_14\-RRB-\1740 in_15\IN\13603305 antagonizing_16\VBG\1787955 the_17\DT\1740 cognitive_18\JJ\1740 deficits_19\NNS\5113133 caused_20\VBN\1617192 by_21\IN\1740 <e1>stz-icv</e1>_22\NN\1740 in_23\IN\13603305 rats_24\NNS\2329401 and_25\CC\1740 its_26\PRP$\6125041 potential_27\NN\14481929 in_28\IN\13603305 the_29\DT\1740 treatment_30\NN\654885 of_31\IN\1740 <e2>neurodegenerative_32\JJ\1740 diseases</e2>_33\NNS\14061805 such_34\JJ\1740 as_35\IN\14622893 alzheimer_36\NN\1740 's_37\POS\1740 disease_38\NN\14061805 ._39\.\1740
19674115
D011718_D000857 CID recurrent_0\JJ\1740 <e2>dysosmia</e2>_1\NN\14052403 induced_2\VBN\1627355 by_3\IN\1740 <e1>pyrazinamide</e1>_4\NN\1740 ._5\.\1740
D011718_D000857 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 reversible_5\JJ\1740 <e2>olfactory_6\JJ\1740 disorder</e2>_7\NN\14034177 related_8\JJ\1740 to_9\TO\1740 <e1>pyrazinamide</e1>_10\NN\1740 in_11\IN\13603305 a_12\DT\13649268 woman_13\NN\9605289 ,_14\,\1740 with_15\IN\1740 a_16\DT\13649268 positive_17\JJ\1740 rechallenge_18\NN\1740 ._19\.\1740
D011718_D000857 CID <e2>dysosmia</e2>_0\NNP\14052403 disappeared_1\VBD\2609764 completely_2\RB\1740 after_3\IN\1740 <e1>pyrazinamide</e1>_4\NN\1740 withdrawal_5\NN\7206096 and_6\CC\1740 recurred_7\VBN\339934 after_8\IN\1740 its_9\PRP$\6125041 rechallenge_10\NN\1740 ._11\.\1740
D011718_D056486 NONE <e1>pyrazinamide</e1>_0\NN\1740 can_1\MD\3094503 have_2\VB\2108377 adverse_3\JJ\1740 effects_4\NNS\13245626 such_5\JJ\1740 as_6\IN\14622893 <e2>hepatic_7\JJ\1740 toxicity</e2>_8\NN\13576101 ,_9\,\1740 hyperuricemia_10\NN\1740 or_11\CC\3541091 digestive_12\JJ\1740 disorders_13\NNS\14034177 ._14\.\1740
D011718_D033461 NONE <e1>pyrazinamide</e1>_0\NN\1740 can_1\MD\3094503 have_2\VB\2108377 adverse_3\JJ\1740 effects_4\NNS\13245626 such_5\JJ\1740 as_6\IN\14622893 hepatic_7\JJ\1740 toxicity_8\NN\13576101 ,_9\,\1740 <e2>hyperuricemia</e2>_10\NN\1740 or_11\CC\3541091 digestive_12\JJ\1740 disorders_13\NNS\14034177 ._14\.\1740
19944736
D013619_D012640 CID <e1>tacrine</e1>_0\NN\1740 ,_1\,\1740 administered_2\VBN\2436349 in_3\IN\13603305 licl_4\NN\1740 pre-treated_5\JJ\1740 rats_6\NNS\2329401 ,_7\,\1740 induces_8\VBZ\1627355 electrocorticographic_9\JJ\1740 <e2>seizures</e2>_10\NNS\14081375 and_11\CC\1740 delayed_12\VBD\439958 hippocampal_13\NN\1740 damage_14\NN\7296428 ._15\.\1740
D013619_D001930 CID <e1>tacrine</e1>_0\NN\1740 ,_1\,\1740 administered_2\VBN\2436349 in_3\IN\13603305 licl_4\NN\1740 pre-treated_5\JJ\1740 rats_6\NNS\2329401 ,_7\,\1740 induces_8\VBZ\1627355 electrocorticographic_9\JJ\1740 seizures_10\NNS\14081375 and_11\CC\1740 delayed_12\VBD\439958 <e2>hippocampal_13\NN\1740 damage</e2>_14\NN\7296428 ._15\.\1740
D013619_D001930 CID in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 <e1>tacrine-loaded</e1>_3\JJ\1740 nanoparticles_4\NNS\1740 administration_5\NN\1133281 induced_6\VBD\1627355 <e2>damage_7\NN\7296428 of_8\IN\1740 neuronal_9\JJ\1740 cells</e2>_10\NNS\3080309 in_11\IN\13603305 ca1_12\NN\1740 field_13\NN\8673395 of_14\IN\1740 the_15\DT\1740 hippocampus_16\NN\5462674 in_17\IN\13603305 all_18\DT\1740 treated_19\VBN\2376958 animals_20\NNS\4475 ,_21\,\1740 while_22\IN\15122231 the_23\DT\1740 saline_24\NN\14849367 solution_25\NN\14586258 of_26\IN\1740 tacrine_27\NN\1740 only_28\RB\1740 in_29\IN\13603305 60_30\CD\13745420 %_31\NN\1740 of_32\IN\1740 animals_33\NNS\4475 ._34\.\1740
D013619_D001930 CID in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 tacrine-loaded_3\JJ\1740 nanoparticles_4\NNS\1740 administration_5\NN\1133281 induced_6\VBD\1627355 <e2>damage_7\NN\7296428 of_8\IN\1740 neuronal_9\JJ\1740 cells</e2>_10\NNS\3080309 in_11\IN\13603305 ca1_12\NN\1740 field_13\NN\8673395 of_14\IN\1740 the_15\DT\1740 hippocampus_16\NN\5462674 in_17\IN\13603305 all_18\DT\1740 treated_19\VBN\2376958 animals_20\NNS\4475 ,_21\,\1740 while_22\IN\15122231 the_23\DT\1740 saline_24\NN\14849367 solution_25\NN\14586258 of_26\IN\1740 <e1>tacrine</e1>_27\NN\1740 only_28\RB\1740 in_29\IN\13603305 60_30\CD\13745420 %_31\NN\1740 of_32\IN\1740 animals_33\NNS\4475 ._34\.\1740
D018021_D012640 CID tacrine_0\NN\1740 ,_1\,\1740 administered_2\VBN\2436349 in_3\IN\13603305 <e1>licl</e1>_4\NN\1740 pre-treated_5\JJ\1740 rats_6\NNS\2329401 ,_7\,\1740 induces_8\VBZ\1627355 electrocorticographic_9\JJ\1740 <e2>seizures</e2>_10\NNS\14081375 and_11\CC\1740 delayed_12\VBD\439958 hippocampal_13\NN\1740 damage_14\NN\7296428 ._15\.\1740
D018021_D001930 CID tacrine_0\NN\1740 ,_1\,\1740 administered_2\VBN\2436349 in_3\IN\13603305 <e1>licl</e1>_4\NN\1740 pre-treated_5\JJ\1740 rats_6\NNS\2329401 ,_7\,\1740 induces_8\VBZ\1627355 electrocorticographic_9\JJ\1740 seizures_10\NNS\14081375 and_11\CC\1740 delayed_12\VBD\439958 <e2>hippocampal_13\NN\1740 damage</e2>_14\NN\7296428 ._15\.\1740
D013619_D004827 NONE all_0\PDT\1740 the_1\DT\1740 animals_2\NNS\4475 treated_3\VBN\2376958 with_4\IN\1740 <e1>tacrine-loaded</e1>_5\JJ\1740 nanoparticles_6\NNS\1740 showed_7\VBD\2137132 an_8\DT\6697703 earlier_9\JJR\1740 outcome_10\NN\7291312 of_11\IN\1740 cns_12\NN\5237227 adverse_13\JJ\1740 symptoms_14\NNS\5823932 ,_15\,\1740 i.e._16\FW\1740 <e2>epileptic</e2>_17\JJ\1740 onset_18\NN\7325190 ,_19\,\1740 with_20\IN\1740 respect_21\NN\5817845 to_22\IN\1740 those_23\DT\1740 animals_24\NNS\4475 treated_25\VBN\2376958 with_26\IN\1740 the_27\DT\1740 free_28\JJ\1740 compound_29\NN\5869584 (_30\-LRB-\1740 10_31\CD\13745420 min_32\NN\15154774 vs._33\CC\1740 22_34\CD\13745420 min_35\NN\15154774 respectively_36\RB\1740 )_37\-RRB-\1740 ._38\.\1740
D013619_D004827 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 the_3\DT\1740 evaluation_4\NN\874067 of_5\IN\1740 time-to-onset_6\NN\1740 of_7\IN\1740 symptoms_8\NNS\5823932 and_9\CC\1740 the_10\DT\1740 severity_11\NN\5036394 of_12\IN\1740 neurodegenerative_13\JJ\1740 processes_14\NNS\407535 induced_15\VBN\1627355 by_16\IN\1740 the_17\DT\1740 <e1>tacrine-lithium</e1>_18\NN\1740 model_19\NN\5888929 of_20\IN\1740 <e2>epilepsy</e2>_21\NN\14085708 in_22\IN\13603305 the_23\DT\1740 rat_24\NN\2329401 ,_25\,\1740 could_26\MD\1740 be_27\VB\836236 used_28\VBN\1156834 to_29\TO\1740 evaluate_30\VB\670261 preliminarily_31\RB\1740 the_32\DT\1740 capability_33\NN\5200169 of_34\IN\1740 a_35\DT\13649268 drug_36\NN\14778436 delivery_37\NN\315986 system_38\NN\3575240 to_39\TO\1740 trespass_40\NN\733883 (_41\-LRB-\1740 or_42\CC\3541091 not_43\RB\1740 )_44\-RRB-\1740 the_45\DT\1740 bbb_46\NN\1740 in_47\FW\13603305 vivo_48\FW\1740 ._49\.\1740
D008094_D004827 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 the_3\DT\1740 evaluation_4\NN\874067 of_5\IN\1740 time-to-onset_6\NN\1740 of_7\IN\1740 symptoms_8\NNS\5823932 and_9\CC\1740 the_10\DT\1740 severity_11\NN\5036394 of_12\IN\1740 neurodegenerative_13\JJ\1740 processes_14\NNS\407535 induced_15\VBN\1627355 by_16\IN\1740 the_17\DT\1740 <e1>tacrine-lithium</e1>_18\NN\1740 model_19\NN\5888929 of_20\IN\1740 <e2>epilepsy</e2>_21\NN\14085708 in_22\IN\13603305 the_23\DT\1740 rat_24\NN\2329401 ,_25\,\1740 could_26\MD\1740 be_27\VB\836236 used_28\VBN\1156834 to_29\TO\1740 evaluate_30\VB\670261 preliminarily_31\RB\1740 the_32\DT\1740 capability_33\NN\5200169 of_34\IN\1740 a_35\DT\13649268 drug_36\NN\14778436 delivery_37\NN\315986 system_38\NN\3575240 to_39\TO\1740 trespass_40\NN\733883 (_41\-LRB-\1740 or_42\CC\3541091 not_43\RB\1740 )_44\-RRB-\1740 the_45\DT\1740 bbb_46\NN\1740 in_47\FW\13603305 vivo_48\FW\1740 ._49\.\1740
1141447
D008094_D003919 CID the_0\DT\1740 renal_1\JJ\1740 pathology_2\NN\6045562 in_3\IN\13603305 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e1>lithium-induced</e1>_7\JJ\1740 <e2>diabetes_8\NNS\14075199 insipidus</e2>_9\NN\1740 ._10\.\1740
D008094_D003919 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e1>lithium-induced</e1>_3\JJ\1740 <e2>diabetes_4\NN\14075199 insipidus</e2>_5\NN\1740 is_6\VBZ\836236 reported_7\VBN\831651 ._8\.\1740
8686832
D008012_D001416 CID <e2>leg_0\NN\5560244 and_1\CC\1740 back_2\JJ\1740 pain</e2>_3\NN\14299637 after_4\IN\1740 spinal_5\JJ\1740 anaesthesia_6\NN\14034177 involving_7\VBG\2676054 hyperbaric_8\JJ\1740 5_9\CD\13741022 %_10\NN\1740 <e1>lignocaine</e1>_11\NN\1740 ._12\.\1740
D008012_D001416 CID <e2>leg_0\NNP\5560244 and/or_1\CC\1740 back_2\RB\1740 pain</e2>_3\NN\14299637 is_4\VBZ\836236 associated_5\VBN\628491 with_6\IN\1740 the_7\DT\1740 intrathecal_8\JJ\1740 use_9\NN\407535 of_10\IN\1740 hyperbaric_11\NN\1740 5_12\CD\13741022 %_13\NN\1740 <e1>lignocaine</e1>_14\NN\1740 ._15\.\1740
D000431_D010146 NONE five_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 13_3\CD\13745420 patients_4\NNS\9898892 (_5\-LRB-\1740 38_6\CD\1740 %_7\NN\1740 )_8\-RRB-\1740 with_9\IN\1740 <e2>pain</e2>_10\NN\14299637 and_11\CC\1740 seven_12\CD\13741022 of_13\IN\1740 the_14\DT\1740 41_15\CD\1740 patients_16\NNS\9898892 (_17\-LRB-\1740 17_18\CD\13745420 %_19\NN\1740 )_20\-RRB-\1740 without_21\IN\1740 pain_22\NN\14299637 admitted_23\VBN\822367 to_24\TO\1740 a_25\DT\13649268 high_26\JJ\1740 <e1>alcohol</e1>_27\NN\7881800 intake_28\NN\13440063 ,_29\,\1740 which_30\WDT\1740 might_31\MD\5029706 be_32\VB\836236 a_33\DT\13649268 contributing_34\VBG\126264 factor_35\NN\7326557 ._36\.\1740
D000431_D010146 NONE five_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 13_3\CD\13745420 patients_4\NNS\9898892 (_5\-LRB-\1740 38_6\CD\1740 %_7\NN\1740 )_8\-RRB-\1740 with_9\IN\1740 pain_10\NN\14299637 and_11\CC\1740 seven_12\CD\13741022 of_13\IN\1740 the_14\DT\1740 41_15\CD\1740 patients_16\NNS\9898892 (_17\-LRB-\1740 17_18\CD\13745420 %_19\NN\1740 )_20\-RRB-\1740 without_21\IN\1740 <e2>pain</e2>_22\NN\14299637 admitted_23\VBN\822367 to_24\TO\1740 a_25\DT\13649268 high_26\JJ\1740 <e1>alcohol</e1>_27\NN\7881800 intake_28\NN\13440063 ,_29\,\1740 which_30\WDT\1740 might_31\MD\5029706 be_32\VB\836236 a_33\DT\13649268 contributing_34\VBG\126264 factor_35\NN\7326557 ._36\.\1740
11185967
D003042_D012640 NONE objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 objective_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 the_10\DT\1740 prevalence_11\NN\4764412 of_12\IN\1740 positive_13\JJ\1740 plasma_14\NN\5398023 drug_15\NN\14778436 screening_16\NN\6887726 for_17\IN\1740 <e1>cocaine</e1>_18\NN\3492717 or_19\CC\3541091 amphetamine_20\NN\3248958 in_21\IN\13603305 adult_22\JJ\1740 emergency_23\NN\7417644 department_24\NN\8220714 <e2>seizure</e2>_25\NN\14081375 patients_26\NNS\9898892 ._27\.\1740
D003042_D012640 NONE conclusions_0\NNS\5837957 :_1\:\1740 during_2\IN\1740 this_3\DT\1740 study_4\NN\635850 period_5\NN\13575869 ,_6\,\1740 routine_7\JJ\1740 plasma_8\NN\5398023 screening_9\NN\6887726 for_10\IN\1740 <e1>cocaine</e1>_11\NN\3492717 and_12\CC\1740 amphetamines_13\NNS\3248958 in_14\IN\13603305 adult_15\JJ\1740 <e2>seizure</e2>_16\JJ\1740 patients_17\NNS\9898892 had_18\VBD\2108377 a_19\DT\13649268 low_20\JJ\1740 yield_21\NN\913705 ._22\.\1740
D000661_D012640 NONE objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 objective_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 determine_9\VB\1645601 the_10\DT\1740 prevalence_11\NN\4764412 of_12\IN\1740 positive_13\JJ\1740 plasma_14\NN\5398023 drug_15\NN\14778436 screening_16\NN\6887726 for_17\IN\1740 cocaine_18\NN\3492717 or_19\CC\3541091 <e1>amphetamine</e1>_20\NN\3248958 in_21\IN\13603305 adult_22\JJ\1740 emergency_23\NN\7417644 department_24\NN\8220714 <e2>seizure</e2>_25\NN\14081375 patients_26\NNS\9898892 ._27\.\1740
D000431_D012640 NONE patient_0\NN\9898892 demographics_1\NNS\6021499 ,_2\,\1740 history_3\NN\15120823 of_4\IN\1740 underlying_5\VBG\2604760 drug_6\NN\14778436 or_7\CC\3541091 <e1>alcohol-related</e1>_8\JJ\1740 <e2>seizure</e2>_9\JJ\1740 disorder_10\NN\14034177 ,_11\,\1740 estimated_12\VBN\637259 time_13\NN\7308889 from_14\IN\1740 seizure_15\NN\14081375 to_16\IN\1740 sample_17\NN\5820620 collection_18\NN\31264 ,_19\,\1740 history_20\NN\15120823 or_21\CC\3541091 suspicion_22\NN\5916739 of_23\IN\1740 cocaine_24\NN\3492717 or_25\CC\3541091 amphetamine_26\NN\3248958 abuse_27\NN\418025 ,_28\,\1740 results_29\NNS\34213 of_30\IN\1740 clinical_31\JJ\1740 urine_32\NN\14853947 testing_33\NN\639556 for_34\IN\1740 drugs_35\NNS\14778436 of_36\IN\1740 abuse_37\NN\418025 ,_38\,\1740 and_39\CC\1740 assay_40\NN\5733583 results_41\NNS\34213 were_42\VBD\836236 recorded_43\VBN\2225492 without_44\IN\1740 patient_45\NN\9898892 identifiers_46\NNS\6806469 ._47\.\1740
D000431_D012640 NONE patient_0\NN\9898892 demographics_1\NNS\6021499 ,_2\,\1740 history_3\NN\15120823 of_4\IN\1740 underlying_5\VBG\2604760 drug_6\NN\14778436 or_7\CC\3541091 <e1>alcohol-related</e1>_8\JJ\1740 seizure_9\JJ\1740 disorder_10\NN\14034177 ,_11\,\1740 estimated_12\VBN\637259 time_13\NN\7308889 from_14\IN\1740 <e2>seizure</e2>_15\NN\14081375 to_16\IN\1740 sample_17\NN\5820620 collection_18\NN\31264 ,_19\,\1740 history_20\NN\15120823 or_21\CC\3541091 suspicion_22\NN\5916739 of_23\IN\1740 cocaine_24\NN\3492717 or_25\CC\3541091 amphetamine_26\NN\3248958 abuse_27\NN\418025 ,_28\,\1740 results_29\NNS\34213 of_30\IN\1740 clinical_31\JJ\1740 urine_32\NN\14853947 testing_33\NN\639556 for_34\IN\1740 drugs_35\NNS\14778436 of_36\IN\1740 abuse_37\NN\418025 ,_38\,\1740 and_39\CC\1740 assay_40\NN\5733583 results_41\NNS\34213 were_42\VBD\836236 recorded_43\VBN\2225492 without_44\IN\1740 patient_45\NN\9898892 identifiers_46\NNS\6806469 ._47\.\1740
D000431_D019970 NONE patient_0\NN\9898892 demographics_1\NNS\6021499 ,_2\,\1740 history_3\NN\15120823 of_4\IN\1740 underlying_5\VBG\2604760 drug_6\NN\14778436 or_7\CC\3541091 <e1>alcohol-related</e1>_8\JJ\1740 seizure_9\JJ\1740 disorder_10\NN\14034177 ,_11\,\1740 estimated_12\VBN\637259 time_13\NN\7308889 from_14\IN\1740 seizure_15\NN\14081375 to_16\IN\1740 sample_17\NN\5820620 collection_18\NN\31264 ,_19\,\1740 history_20\NN\15120823 or_21\CC\3541091 suspicion_22\NN\5916739 of_23\IN\1740 <e2>cocaine_24\NN\3492717 or_25\CC\3541091 amphetamine_26\NN\3248958 abuse</e2>_27\NN\418025 ,_28\,\1740 results_29\NNS\34213 of_30\IN\1740 clinical_31\JJ\1740 urine_32\NN\14853947 testing_33\NN\639556 for_34\IN\1740 drugs_35\NNS\14778436 of_36\IN\1740 abuse_37\NN\418025 ,_38\,\1740 and_39\CC\1740 assay_40\NN\5733583 results_41\NNS\34213 were_42\VBD\836236 recorded_43\VBN\2225492 without_44\IN\1740 patient_45\NN\9898892 identifiers_46\NNS\6806469 ._47\.\1740
D000431_D019969 NONE patient_0\NN\9898892 demographics_1\NNS\6021499 ,_2\,\1740 history_3\NN\15120823 of_4\IN\1740 underlying_5\VBG\2604760 drug_6\NN\14778436 or_7\CC\3541091 <e1>alcohol-related</e1>_8\JJ\1740 seizure_9\JJ\1740 disorder_10\NN\14034177 ,_11\,\1740 estimated_12\VBN\637259 time_13\NN\7308889 from_14\IN\1740 seizure_15\NN\14081375 to_16\IN\1740 sample_17\NN\5820620 collection_18\NN\31264 ,_19\,\1740 history_20\NN\15120823 or_21\CC\3541091 suspicion_22\NN\5916739 of_23\IN\1740 <e2>cocaine_24\NN\3492717 or_25\CC\3541091 amphetamine_26\NN\3248958 abuse</e2>_27\NN\418025 ,_28\,\1740 results_29\NNS\34213 of_30\IN\1740 clinical_31\JJ\1740 urine_32\NN\14853947 testing_33\NN\639556 for_34\IN\1740 drugs_35\NNS\14778436 of_36\IN\1740 abuse_37\NN\418025 ,_38\,\1740 and_39\CC\1740 assay_40\NN\5733583 results_41\NNS\34213 were_42\VBD\836236 recorded_43\VBN\2225492 without_44\IN\1740 patient_45\NN\9898892 identifiers_46\NNS\6806469 ._47\.\1740
D000662_D012640 NONE conclusions_0\NNS\5837957 :_1\:\1740 during_2\IN\1740 this_3\DT\1740 study_4\NN\635850 period_5\NN\13575869 ,_6\,\1740 routine_7\JJ\1740 plasma_8\NN\5398023 screening_9\NN\6887726 for_10\IN\1740 cocaine_11\NN\3492717 and_12\CC\1740 <e1>amphetamines</e1>_13\NNS\3248958 in_14\IN\13603305 adult_15\JJ\1740 <e2>seizure</e2>_16\JJ\1740 patients_17\NNS\9898892 had_18\VBD\2108377 a_19\DT\13649268 low_20\JJ\1740 yield_21\NN\913705 ._22\.\1740
9564988
D064704_D012852 NONE open-label_0\JJ\1740 assessment_1\NN\5732756 of_2\IN\1740 <e1>levofloxacin</e1>_3\NN\1740 for_4\IN\1740 the_5\DT\1740 treatment_6\NN\654885 of_7\IN\1740 acute_8\JJ\1740 bacterial_9\JJ\1740 <e2>sinusitis</e2>_10\NN\14336539 in_11\IN\13603305 adults_12\NNS\7846 ._13\.\1740
D064704_D012852 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 efficacy_5\NN\5199286 and_6\CC\1740 safety_7\NN\13920835 of_8\IN\1740 <e1>levofloxacin</e1>_9\NN\1740 (_10\-LRB-\1740 500_11\CD\13745420 mg_12\NN\13717155 orally_13\RB\1740 once_14\RB\1740 daily_15\RB\1740 for_16\IN\1740 10_17\CD\13745420 to_18\TO\1740 14_19\CD\13745420 days_20\NNS\15140892 )_21\-RRB-\1740 in_22\IN\13603305 treating_23\VBG\2376958 adult_24\JJ\1740 outpatients_25\NNS\10405694 with_26\IN\1740 acute_27\JJ\1740 bacterial_28\JJ\1740 <e2>sinusitis</e2>_29\NN\14336539 ._30\.\1740
D064704_D012852 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 indicate_7\VBP\952524 that_8\IN\1740 <e1>levofloxacin</e1>_9\NN\1740 500_10\CD\13745420 mg_11\NN\13717155 once_12\RB\1740 daily_13\RB\1740 is_14\VBZ\836236 an_15\DT\6697703 effective_16\JJ\1740 and_17\CC\1740 safe_18\JJ\1740 treatment_19\NN\654885 for_20\IN\1740 acute_21\JJ\1740 bacterial_22\JJ\1740 <e2>sinusitis</e2>_23\NN\14336539 ._24\.\1740
10565806
C076029_D001714 CID <e2>hypomania-like</e2>_0\JJ\1740 syndrome_1\NN\5870365 induced_2\VBN\1627355 by_3\IN\1740 <e1>olanzapine</e1>_4\NN\1740 ._5\.\1740
C076029_D001714 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 female_3\JJ\1740 patient_4\NN\9898892 with_5\IN\1740 a_6\DT\13649268 diagnosis_7\NN\152018 of_8\IN\1740 a_9\DT\13649268 not_10\RB\1740 otherwise_11\RB\1740 specified_12\JJ\1740 psychotic_13\JJ\1740 disorder_14\NN\14034177 (_15\-LRB-\1740 dsm-iv_16\NN\1740 )_17\-RRB-\1740 who_18\WP\8299493 developed_19\VBD\1753788 <e2>hypomania</e2>_20\NN\1740 shortly_21\RB\1740 after_22\IN\1740 the_23\DT\1740 introduction_24\NN\235435 of_25\IN\1740 <e1>olanzapine</e1>_26\NN\1740 treatment_27\NN\654885 ._28\.\1740
C076029_D011618 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 female_3\JJ\1740 patient_4\NN\9898892 with_5\IN\1740 a_6\DT\13649268 diagnosis_7\NN\152018 of_8\IN\1740 a_9\DT\13649268 not_10\RB\1740 otherwise_11\RB\1740 specified_12\JJ\1740 <e2>psychotic_13\JJ\1740 disorder</e2>_14\NN\14034177 (_15\-LRB-\1740 dsm-iv_16\NN\1740 )_17\-RRB-\1740 who_18\WP\8299493 developed_19\VBD\1753788 hypomania_20\NN\1740 shortly_21\RB\1740 after_22\IN\1740 the_23\DT\1740 introduction_24\NN\235435 of_25\IN\1740 <e1>olanzapine</e1>_26\NN\1740 treatment_27\NN\654885 ._28\.\1740
9672273
D013629_D001943 NONE prevention_0\NN\1073995 of_1\IN\1740 <e2>breast_2\NN\5225090 cancer</e2>_3\NN\14239425 with_4\IN\1740 <e1>tamoxifen</e1>_5\NN\2714883 :_6\:\1740 preliminary_7\JJ\1740 findings_8\NNS\7951464 from_9\IN\1740 the_10\DT\1740 italian_11\JJ\1740 randomised_12\VBN\278117 trial_13\NN\786195 among_14\IN\1740 hysterectomised_15\JJ\1740 women_16\NNS\9605289 ._17\.\1740
D013629_D001943 NONE background_0\NN\4921011 :_1\:\1740 <e1>tamoxifen</e1>_2\NNP\2714883 is_3\VBZ\836236 a_4\DT\13649268 candidate_5\NN\10450303 chemopreventive_6\JJ\1740 agent_7\NN\7347 in_8\IN\13603305 <e2>breast_9\NN\5225090 cancer</e2>_10\NN\14239425 ,_11\,\1740 although_12\IN\1740 the_13\DT\1740 drug_14\NN\14778436 may_15\MD\15209706 be_16\VB\836236 associated_17\VBN\628491 with_18\IN\1740 the_19\DT\1740 development_20\NN\248977 of_21\IN\1740 endometrial_22\JJ\1740 cancer_23\NN\14239425 ._24\.\1740
D013629_D001943 NONE methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 october_3\NNP\15209706 ,_4\,\1740 1992_5\CD\1740 ,_6\,\1740 we_7\PRP\1740 started_8\VBD\2009433 a_9\DT\13649268 double-blind_10\JJ\1740 placebo-controlled_11\JJ\1740 ,_12\,\1740 randomised_13\VBD\278117 trial_14\NN\786195 of_15\IN\1740 <e1>tamoxifen</e1>_16\NN\2714883 in_17\IN\13603305 women_18\NNS\9605289 (_19\-LRB-\1740 mainly_20\RB\1740 in_21\IN\13603305 italy_22\NNP\1740 )_23\-RRB-\1740 who_24\WP\8299493 did_25\VBD\1640855 not_26\RB\1740 have_27\VB\2108377 <e2>breast_28\NN\5225090 cancer</e2>_29\NN\14239425 and_30\CC\1740 who_31\WP\8299493 had_32\VBD\2108377 had_33\VBN\2108377 a_34\DT\13649268 hysterectomy_35\NN\393369 ._36\.\1740
D013629_D001943 NONE there_0\EX\27167 is_1\VBZ\836236 no_2\DT\7204911 difference_3\NN\4723816 in_4\IN\13603305 <e2>breast-cancer</e2>_5\NN\1740 frequency_6\NN\15286249 between_7\IN\1740 the_8\DT\1740 placebo_9\NN\3740161 (_10\-LRB-\1740 22_11\CD\13745420 cases_12\NNS\7283608 )_13\-RRB-\1740 and_14\CC\1740 <e1>tamoxifen</e1>_15\NN\2714883 (_16\-LRB-\1740 19_17\CD\13745420 )_18\-RRB-\1740 arms_19\NNS\3575240 ._20\.\1740
D013629_D001943 NONE there_0\EX\27167 is_1\VBZ\836236 a_2\DT\13649268 statistically_3\RB\1740 significant_4\JJ\1740 reduction_5\NN\351485 of_6\IN\1740 <e2>breast_7\NN\5225090 cancer</e2>_8\NN\14239425 among_9\IN\1740 women_10\NNS\9605289 receiving_11\VBG\2210855 <e1>tamoxifen</e1>_12\NN\2714883 who_13\WP\8299493 also_14\RB\1740 used_15\VBD\1156834 hormone-replacement_16\JJ\1740 therapy_17\NN\657604 during_18\IN\1740 the_19\DT\1740 trial_20\NN\786195 :_21\:\1740 among_22\IN\1740 390_23\CD\1740 women_24\NNS\9605289 on_25\IN\1740 such_26\JJ\1740 therapy_27\NN\657604 and_28\CC\1740 allocated_29\VBN\2228698 to_30\TO\1740 placebo_31\VB\1740 ,_32\,\1740 we_33\PRP\1740 found_34\VBD\2426171 eight_35\CD\13741022 cases_36\NNS\7283608 of_37\IN\1740 breast_38\NN\5225090 cancer_39\NN\14239425 compared_40\VBN\644583 with_41\IN\1740 one_42\CD\13741022 case_43\NN\7283608 among_44\IN\1740 362_45\CD\1740 women_46\NNS\9605289 allocated_47\VBN\2228698 to_48\IN\1740 tamoxifen_49\NN\2714883 ._50\.\1740
D013629_D001943 NONE there_0\EX\27167 is_1\VBZ\836236 a_2\DT\13649268 statistically_3\RB\1740 significant_4\JJ\1740 reduction_5\NN\351485 of_6\IN\1740 breast_7\NN\5225090 cancer_8\NN\14239425 among_9\IN\1740 women_10\NNS\9605289 receiving_11\VBG\2210855 <e1>tamoxifen</e1>_12\NN\2714883 who_13\WP\8299493 also_14\RB\1740 used_15\VBD\1156834 hormone-replacement_16\JJ\1740 therapy_17\NN\657604 during_18\IN\1740 the_19\DT\1740 trial_20\NN\786195 :_21\:\1740 among_22\IN\1740 390_23\CD\1740 women_24\NNS\9605289 on_25\IN\1740 such_26\JJ\1740 therapy_27\NN\657604 and_28\CC\1740 allocated_29\VBN\2228698 to_30\TO\1740 placebo_31\VB\1740 ,_32\,\1740 we_33\PRP\1740 found_34\VBD\2426171 eight_35\CD\13741022 cases_36\NNS\7283608 of_37\IN\1740 <e2>breast_38\NN\5225090 cancer</e2>_39\NN\14239425 compared_40\VBN\644583 with_41\IN\1740 one_42\CD\13741022 case_43\NN\7283608 among_44\IN\1740 362_45\CD\1740 women_46\NNS\9605289 allocated_47\VBN\2228698 to_48\IN\1740 tamoxifen_49\NN\2714883 ._50\.\1740
D013629_D001943 NONE there_0\EX\27167 is_1\VBZ\836236 a_2\DT\13649268 statistically_3\RB\1740 significant_4\JJ\1740 reduction_5\NN\351485 of_6\IN\1740 <e2>breast_7\NN\5225090 cancer</e2>_8\NN\14239425 among_9\IN\1740 women_10\NNS\9605289 receiving_11\VBG\2210855 tamoxifen_12\NN\2714883 who_13\WP\8299493 also_14\RB\1740 used_15\VBD\1156834 hormone-replacement_16\JJ\1740 therapy_17\NN\657604 during_18\IN\1740 the_19\DT\1740 trial_20\NN\786195 :_21\:\1740 among_22\IN\1740 390_23\CD\1740 women_24\NNS\9605289 on_25\IN\1740 such_26\JJ\1740 therapy_27\NN\657604 and_28\CC\1740 allocated_29\VBN\2228698 to_30\TO\1740 placebo_31\VB\1740 ,_32\,\1740 we_33\PRP\1740 found_34\VBD\2426171 eight_35\CD\13741022 cases_36\NNS\7283608 of_37\IN\1740 breast_38\NN\5225090 cancer_39\NN\14239425 compared_40\VBN\644583 with_41\IN\1740 one_42\CD\13741022 case_43\NN\7283608 among_44\IN\1740 362_45\CD\1740 women_46\NNS\9605289 allocated_47\VBN\2228698 to_48\IN\1740 <e1>tamoxifen</e1>_49\NN\2714883 ._50\.\1740
D013629_D001943 NONE there_0\EX\27167 is_1\VBZ\836236 a_2\DT\13649268 statistically_3\RB\1740 significant_4\JJ\1740 reduction_5\NN\351485 of_6\IN\1740 breast_7\NN\5225090 cancer_8\NN\14239425 among_9\IN\1740 women_10\NNS\9605289 receiving_11\VBG\2210855 tamoxifen_12\NN\2714883 who_13\WP\8299493 also_14\RB\1740 used_15\VBD\1156834 hormone-replacement_16\JJ\1740 therapy_17\NN\657604 during_18\IN\1740 the_19\DT\1740 trial_20\NN\786195 :_21\:\1740 among_22\IN\1740 390_23\CD\1740 women_24\NNS\9605289 on_25\IN\1740 such_26\JJ\1740 therapy_27\NN\657604 and_28\CC\1740 allocated_29\VBN\2228698 to_30\TO\1740 placebo_31\VB\1740 ,_32\,\1740 we_33\PRP\1740 found_34\VBD\2426171 eight_35\CD\13741022 cases_36\NNS\7283608 of_37\IN\1740 <e2>breast_38\NN\5225090 cancer</e2>_39\NN\14239425 compared_40\VBN\644583 with_41\IN\1740 one_42\CD\13741022 case_43\NN\7283608 among_44\IN\1740 362_45\CD\1740 women_46\NNS\9605289 allocated_47\VBN\2228698 to_48\IN\1740 <e1>tamoxifen</e1>_49\NN\2714883 ._50\.\1740
D013629_D001943 NONE interpretation_0\NN\5926676 :_1\:\1740 although_2\IN\1740 this_3\DT\1740 preliminary_4\JJ\1740 analysis_5\NN\633864 has_6\VBZ\2108377 low_7\JJ\1740 power_8\NN\4723816 ,_9\,\1740 in_10\IN\13603305 this_11\DT\1740 cohort_12\NN\8184861 of_13\IN\1740 women_14\NNS\9605289 at_15\IN\14622893 low-to-normal_16\JJ\1740 risk_17\NN\14541044 of_18\IN\1740 <e2>breast_19\NN\5225090 cancer</e2>_20\NN\14239425 ,_21\,\1740 the_22\DT\1740 postulated_23\VBN\756338 protective_24\JJ\1740 effects_25\NNS\13245626 of_26\IN\1740 <e1>tamoxifen</e1>_27\NN\2714883 are_28\VBP\836236 not_29\RB\1740 yet_30\RB\1740 apparent_31\JJ\1740 ._32\.\1740
D013629_D016889 NONE background_0\NN\4921011 :_1\:\1740 <e1>tamoxifen</e1>_2\NNP\2714883 is_3\VBZ\836236 a_4\DT\13649268 candidate_5\NN\10450303 chemopreventive_6\JJ\1740 agent_7\NN\7347 in_8\IN\13603305 breast_9\NN\5225090 cancer_10\NN\14239425 ,_11\,\1740 although_12\IN\1740 the_13\DT\1740 drug_14\NN\14778436 may_15\MD\15209706 be_16\VB\836236 associated_17\VBN\628491 with_18\IN\1740 the_19\DT\1740 development_20\NN\248977 of_21\IN\1740 <e2>endometrial_22\JJ\1740 cancer</e2>_23\NN\14239425 ._24\.\1740
D013629_D014652 CID compared_0\VBN\644583 with_1\IN\1740 the_2\DT\1740 placebo_3\NN\3740161 group_4\NN\2137 ,_5\,\1740 there_6\EX\27167 was_7\VBD\836236 a_8\DT\13649268 significantly_9\RB\1740 increased_10\VBN\169651 risk_11\NN\14541044 of_12\IN\1740 <e2>vascular_13\JJ\1740 events</e2>_14\NNS\23100 and_15\CC\1740 hypertriglyceridaemia_16\NN\1740 among_17\IN\1740 women_18\NNS\9605289 on_19\IN\1740 <e1>tamoxifen</e1>_20\NN\2714883 ._21\.\1740
D013629_D015228 CID compared_0\VBN\644583 with_1\IN\1740 the_2\DT\1740 placebo_3\NN\3740161 group_4\NN\2137 ,_5\,\1740 there_6\EX\27167 was_7\VBD\836236 a_8\DT\13649268 significantly_9\RB\1740 increased_10\VBN\169651 risk_11\NN\14541044 of_12\IN\1740 vascular_13\JJ\1740 events_14\NNS\23100 and_15\CC\1740 <e2>hypertriglyceridaemia</e2>_16\NN\1740 among_17\IN\1740 women_18\NNS\9605289 on_19\IN\1740 <e1>tamoxifen</e1>_20\NN\2714883 ._21\.\1740
11077455
D020888_D014786 CID electro-oculography_0\NN\1740 ,_1\,\1740 electroretinography_2\NN\1740 ,_3\,\1740 visual_4\JJ\1740 evoked_5\VBN\1617192 potentials_6\NNS\14481929 ,_7\,\1740 and_8\CC\1740 multifocal_9\JJ\1740 electroretinography_10\NN\1740 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 <e1>vigabatrin-attributed</e1>_14\JJ\1740 <e2>visual_15\JJ\1740 field_16\NN\8673395 constriction</e2>_17\NN\5071027 ._18\.\1740
D020888_D014786 CID purpose_0\NNP\5980875 :_1\:\1740 symptomatic_2\JJ\1740 <e2>visual_3\JJ\1740 field_4\NN\8673395 constriction</e2>_5\NN\5071027 thought_6\VBD\670261 to_7\TO\1740 be_8\VB\836236 associated_9\VBN\628491 with_10\IN\1740 <e1>vigabatrin</e1>_11\NN\1740 has_12\VBZ\2108377 been_13\VBN\836236 reported_14\VBN\831651 ._15\.\1740
D020888_D014786 CID the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 investigated_3\VBD\644583 the_4\DT\1740 visual_5\JJ\1740 fields_6\NNS\8673395 and_7\CC\1740 visual_8\JJ\1740 electrophysiology_9\NN\1740 of_10\IN\1740 eight_11\CD\13741022 patients_12\NNS\9898892 with_13\IN\1740 known_14\JJ\1740 <e1>vigabatrin-attributed</e1>_15\JJ\1740 <e2>visual_16\JJ\1740 field_17\NN\8673395 loss</e2>_18\NN\13252973 ,_19\,\1740 three_20\CD\13741022 of_21\IN\1740 whom_22\WP\1740 were_23\VBD\836236 reported_24\VBN\831651 previously_25\RB\1740 ._26\.\1740
D020888_D014786 CID conclusion_0\NN\5837957 :_1\:\1740 marked_2\JJ\1740 <e2>visual_3\JJ\1740 field_4\NN\8673395 constriction</e2>_5\NN\5071027 appears_6\VBZ\2604760 to_7\TO\1740 be_8\VB\836236 associated_9\VBN\628491 with_10\IN\1740 <e1>vigabatrin</e1>_11\NN\1740 therapy_12\NN\657604 ._13\.\1740
1423339
D011433_D000647 CID <e2>amnestic_0\JJ\1740 syndrome</e2>_1\NN\5870365 associated_2\VBN\628491 with_3\IN\1740 <e1>propranolol</e1>_4\NN\1740 toxicity_5\NN\13576101 :_6\:\1740 a_7\DT\13649268 case_8\NN\7283608 report_9\NN\6470073 ._10\.\1740
D011433_D064420 NONE amnestic_0\JJ\1740 syndrome_1\NN\5870365 associated_2\VBN\628491 with_3\IN\1740 <e1>propranolol</e1>_4\NN\1740 <e2>toxicity</e2>_5\NN\13576101 :_6\:\1740 a_7\DT\13649268 case_8\NN\7283608 report_9\NN\6470073 ._10\.\1740
D011433_D064420 NONE an_0\DT\6697703 elderly_1\JJ\1740 woman_2\NN\9605289 developed_3\VBD\1753788 an_4\DT\6697703 alzheimer-like_5\JJ\1740 subacute_6\NN\1740 dementia_7\NN\14395018 as_8\IN\14622893 a_9\DT\13649268 result_10\NN\34213 of_11\IN\1740 <e1>propranolol</e1>_12\NN\1740 <e2>toxicity</e2>_13\NN\13576101 ._14\.\1740
D011433_D000544 NONE an_0\DT\6697703 elderly_1\JJ\1740 woman_2\NN\9605289 developed_3\VBD\1753788 an_4\DT\6697703 <e2>alzheimer-like</e2>_5\JJ\1740 subacute_6\NN\1740 dementia_7\NN\14395018 as_8\IN\14622893 a_9\DT\13649268 result_10\NN\34213 of_11\IN\1740 <e1>propranolol</e1>_12\NN\1740 toxicity_13\NN\13576101 ._14\.\1740
D011433_D003704 NONE an_0\DT\6697703 elderly_1\JJ\1740 woman_2\NN\9605289 developed_3\VBD\1753788 an_4\DT\6697703 alzheimer-like_5\JJ\1740 subacute_6\NN\1740 <e2>dementia</e2>_7\NN\14395018 as_8\IN\14622893 a_9\DT\13649268 result_10\NN\34213 of_11\IN\1740 <e1>propranolol</e1>_12\NN\1740 toxicity_13\NN\13576101 ._14\.\1740
7710775
D008315_D002545 CID time_0\NN\7308889 dependence_1\NN\24720 of_2\IN\1740 plasma_3\NN\5398023 <e1>malondialdehyde</e1>_4\NN\1740 ,_5\,\1740 oxypurines_6\NNS\1740 ,_7\,\1740 and_8\CC\1740 nucleosides_9\VBZ\1740 during_10\IN\1740 incomplete_11\JJ\1740 <e2>cerebral_12\JJ\1740 ischemia</e2>_13\NN\14195315 in_14\IN\13603305 the_15\DT\1740 rat_16\NN\2329401 ._17\.\1740
-1_D002545 NONE time_0\NN\7308889 dependence_1\NN\24720 of_2\IN\1740 plasma_3\NN\5398023 malondialdehyde_4\NN\1740 ,_5\,\1740 <e1>oxypurines</e1>_6\NNS\1740 ,_7\,\1740 and_8\CC\1740 nucleosides_9\VBZ\1740 during_10\IN\1740 incomplete_11\JJ\1740 <e2>cerebral_12\JJ\1740 ischemia</e2>_13\NN\14195315 in_14\IN\13603305 the_15\DT\1740 rat_16\NN\2329401 ._17\.\1740
D009705_D002545 NONE time_0\NN\7308889 dependence_1\NN\24720 of_2\IN\1740 plasma_3\NN\5398023 malondialdehyde_4\NN\1740 ,_5\,\1740 oxypurines_6\NNS\1740 ,_7\,\1740 and_8\CC\1740 <e1>nucleosides</e1>_9\VBZ\1740 during_10\IN\1740 incomplete_11\JJ\1740 <e2>cerebral_12\JJ\1740 ischemia</e2>_13\NN\14195315 in_14\IN\13603305 the_15\DT\1740 rat_16\NN\2329401 ._17\.\1740
-1_D007511 NONE during_0\IN\1740 <e2>ischemia</e2>_1\NN\14195315 ,_2\,\1740 a_3\DT\13649268 time-dependent_4\JJ\1740 increase_5\NN\13576355 of_6\IN\1740 plasma_7\NN\5398023 <e1>oxypurines</e1>_8\NNS\1740 and_9\CC\1740 nucleosides_10\NNS\14887305 was_11\VBD\836236 observed_12\VBN\2163746 ._13\.\1740
-1_D007511 NONE the_0\DT\1740 present_1\JJ\1740 data_2\NNS\7951464 indicate_3\VBP\952524 that_4\IN\1740 the_5\DT\1740 determination_6\NN\43195 of_7\IN\1740 malondialdehyde_8\NN\1740 ,_9\,\1740 <e1>oxypurines</e1>_10\NNS\1740 ,_11\,\1740 and_12\CC\1740 nucleosides_13\VBZ\1740 in_14\IN\13603305 peripheral_15\JJ\1740 blood_16\NN\5397468 ,_17\,\1740 may_18\MD\15209706 be_19\VB\836236 used_20\VBN\1156834 to_21\TO\1740 monitor_22\VB\2169352 the_23\DT\1740 metabolic_24\JJ\1740 alterations_25\NNS\7283608 of_26\IN\1740 tissues_27\NNS\5220461 occurring_28\VBG\2623529 during_29\IN\1740 <e2>ischemic</e2>_30\JJ\1740 phenomena_31\NNS\29677 ._32\.\1740
D009705_D007511 NONE during_0\IN\1740 <e2>ischemia</e2>_1\NN\14195315 ,_2\,\1740 a_3\DT\13649268 time-dependent_4\JJ\1740 increase_5\NN\13576355 of_6\IN\1740 plasma_7\NN\5398023 oxypurines_8\NNS\1740 and_9\CC\1740 <e1>nucleosides</e1>_10\NNS\14887305 was_11\VBD\836236 observed_12\VBN\2163746 ._13\.\1740
D009705_D007511 NONE the_0\DT\1740 present_1\JJ\1740 data_2\NNS\7951464 indicate_3\VBP\952524 that_4\IN\1740 the_5\DT\1740 determination_6\NN\43195 of_7\IN\1740 malondialdehyde_8\NN\1740 ,_9\,\1740 oxypurines_10\NNS\1740 ,_11\,\1740 and_12\CC\1740 <e1>nucleosides</e1>_13\VBZ\1740 in_14\IN\13603305 peripheral_15\JJ\1740 blood_16\NN\5397468 ,_17\,\1740 may_18\MD\15209706 be_19\VB\836236 used_20\VBN\1156834 to_21\TO\1740 monitor_22\VB\2169352 the_23\DT\1740 metabolic_24\JJ\1740 alterations_25\NNS\7283608 of_26\IN\1740 tissues_27\NNS\5220461 occurring_28\VBG\2623529 during_29\IN\1740 <e2>ischemic</e2>_30\JJ\1740 phenomena_31\NNS\29677 ._32\.\1740
D008315_D007511 NONE plasma_0\NN\5398023 <e1>malondialdehyde</e1>_1\NN\1740 ,_2\,\1740 which_3\WDT\1740 was_4\VBD\836236 present_5\JJ\1740 in_6\IN\13603305 minimal_7\JJ\1740 amount_8\NN\13329641 at_9\IN\14622893 zero_10\CD\13576982 time_11\NN\7308889 (_12\-LRB-\1740 0.058_13\CD\1740 mumol/liter_14\NN\1740 plasma_15\NN\5398023 ;_16\:\1740 sd_17\NN\1740 0.015_18\CD\1740 )_19\-RRB-\1740 ,_20\,\1740 increased_21\VBD\169651 after_22\IN\1740 5_23\CD\13741022 min_24\NN\15154774 of_25\IN\1740 <e2>ischemia</e2>_26\NN\14195315 ,_27\,\1740 resulting_28\VBG\2633881 in_29\IN\13603305 a_30\DT\13649268 fivefold_31\JJ\1740 increase_32\NN\13576355 after_33\IN\1740 30_34\CD\13745420 min_35\NN\15154774 of_36\IN\1740 carotid_37\NN\1740 occlusion_38\NN\14081375 (_39\-LRB-\1740 0.298_40\CD\1740 mumol/liter_41\JJ\1740 plasma_42\NN\5398023 ;_43\:\1740 sd_44\NN\1740 0.078_45\CD\1740 )_46\-RRB-\1740 ._47\.\1740
D008315_D007511 NONE increased_0\VBN\169651 plasma_1\NN\5398023 <e1>malondialdehyde</e1>_2\NN\1740 was_3\VBD\836236 also_4\RB\1740 recorded_5\VBN\2225492 in_6\IN\13603305 two_7\CD\13741022 other_8\JJ\1740 groups_9\NNS\2137 of_10\IN\1740 animals_11\NNS\4475 subjected_12\VBN\137313 to_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 experimental_16\JJ\1740 model_17\NN\5888929 ,_18\,\1740 one_19\CD\13741022 receiving_20\VBG\2210855 20_21\CD\13745420 mg/kg_22\NN\1740 b.w_23\NN\1740 ._24\.\1740 of_25\IN\1740 the_26\DT\1740 cyclooxygenase_27\NN\14732946 inhibitor_28\NN\20090 acetylsalicylate_29\NN\1740 intravenously_30\RB\1740 immediately_31\RB\1740 before_32\IN\1740 <e2>ischemia</e2>_33\NN\14195315 ,_34\,\1740 the_35\DT\1740 other_36\JJ\1740 receiving_37\VBG\2210855 650_38\CD\1740 micrograms/kg_39\NNS\1740 b.w_40\JJ\1740 ._41\.\1740 of_42\IN\1740 the_43\DT\1740 hypotensive_44\JJ\1740 drug_45\NN\14778436 nitroprusside_46\NN\1740 at_47\IN\14622893 a_48\DT\13649268 flow_49\NN\7311115 rate_50\NN\13815152 of_51\IN\1740 103_52\CD\1740 microliters/min_53\NN\1740 intravenously_54\RB\1740 during_55\IN\1740 ischemia_56\NN\14195315 ,_57\,\1740 although_58\IN\1740 in_59\IN\13603305 this_60\DT\1740 latter_61\JJ\1740 group_62\NN\2137 malondialdehyde_63\NN\1740 was_64\VBD\836236 significantly_65\RB\1740 higher_66\JJR\1740 ._67\.\1740
D008315_D007511 NONE increased_0\VBN\169651 plasma_1\NN\5398023 <e1>malondialdehyde</e1>_2\NN\1740 was_3\VBD\836236 also_4\RB\1740 recorded_5\VBN\2225492 in_6\IN\13603305 two_7\CD\13741022 other_8\JJ\1740 groups_9\NNS\2137 of_10\IN\1740 animals_11\NNS\4475 subjected_12\VBN\137313 to_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 experimental_16\JJ\1740 model_17\NN\5888929 ,_18\,\1740 one_19\CD\13741022 receiving_20\VBG\2210855 20_21\CD\13745420 mg/kg_22\NN\1740 b.w_23\NN\1740 ._24\.\1740 of_25\IN\1740 the_26\DT\1740 cyclooxygenase_27\NN\14732946 inhibitor_28\NN\20090 acetylsalicylate_29\NN\1740 intravenously_30\RB\1740 immediately_31\RB\1740 before_32\IN\1740 ischemia_33\NN\14195315 ,_34\,\1740 the_35\DT\1740 other_36\JJ\1740 receiving_37\VBG\2210855 650_38\CD\1740 micrograms/kg_39\NNS\1740 b.w_40\JJ\1740 ._41\.\1740 of_42\IN\1740 the_43\DT\1740 hypotensive_44\JJ\1740 drug_45\NN\14778436 nitroprusside_46\NN\1740 at_47\IN\14622893 a_48\DT\13649268 flow_49\NN\7311115 rate_50\NN\13815152 of_51\IN\1740 103_52\CD\1740 microliters/min_53\NN\1740 intravenously_54\RB\1740 during_55\IN\1740 <e2>ischemia</e2>_56\NN\14195315 ,_57\,\1740 although_58\IN\1740 in_59\IN\13603305 this_60\DT\1740 latter_61\JJ\1740 group_62\NN\2137 malondialdehyde_63\NN\1740 was_64\VBD\836236 significantly_65\RB\1740 higher_66\JJR\1740 ._67\.\1740
D008315_D007511 NONE increased_0\VBN\169651 plasma_1\NN\5398023 malondialdehyde_2\NN\1740 was_3\VBD\836236 also_4\RB\1740 recorded_5\VBN\2225492 in_6\IN\13603305 two_7\CD\13741022 other_8\JJ\1740 groups_9\NNS\2137 of_10\IN\1740 animals_11\NNS\4475 subjected_12\VBN\137313 to_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 experimental_16\JJ\1740 model_17\NN\5888929 ,_18\,\1740 one_19\CD\13741022 receiving_20\VBG\2210855 20_21\CD\13745420 mg/kg_22\NN\1740 b.w_23\NN\1740 ._24\.\1740 of_25\IN\1740 the_26\DT\1740 cyclooxygenase_27\NN\14732946 inhibitor_28\NN\20090 acetylsalicylate_29\NN\1740 intravenously_30\RB\1740 immediately_31\RB\1740 before_32\IN\1740 <e2>ischemia</e2>_33\NN\14195315 ,_34\,\1740 the_35\DT\1740 other_36\JJ\1740 receiving_37\VBG\2210855 650_38\CD\1740 micrograms/kg_39\NNS\1740 b.w_40\JJ\1740 ._41\.\1740 of_42\IN\1740 the_43\DT\1740 hypotensive_44\JJ\1740 drug_45\NN\14778436 nitroprusside_46\NN\1740 at_47\IN\14622893 a_48\DT\13649268 flow_49\NN\7311115 rate_50\NN\13815152 of_51\IN\1740 103_52\CD\1740 microliters/min_53\NN\1740 intravenously_54\RB\1740 during_55\IN\1740 ischemia_56\NN\14195315 ,_57\,\1740 although_58\IN\1740 in_59\IN\13603305 this_60\DT\1740 latter_61\JJ\1740 group_62\NN\2137 <e1>malondialdehyde</e1>_63\NN\1740 was_64\VBD\836236 significantly_65\RB\1740 higher_66\JJR\1740 ._67\.\1740
D008315_D007511 NONE increased_0\VBN\169651 plasma_1\NN\5398023 malondialdehyde_2\NN\1740 was_3\VBD\836236 also_4\RB\1740 recorded_5\VBN\2225492 in_6\IN\13603305 two_7\CD\13741022 other_8\JJ\1740 groups_9\NNS\2137 of_10\IN\1740 animals_11\NNS\4475 subjected_12\VBN\137313 to_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 experimental_16\JJ\1740 model_17\NN\5888929 ,_18\,\1740 one_19\CD\13741022 receiving_20\VBG\2210855 20_21\CD\13745420 mg/kg_22\NN\1740 b.w_23\NN\1740 ._24\.\1740 of_25\IN\1740 the_26\DT\1740 cyclooxygenase_27\NN\14732946 inhibitor_28\NN\20090 acetylsalicylate_29\NN\1740 intravenously_30\RB\1740 immediately_31\RB\1740 before_32\IN\1740 ischemia_33\NN\14195315 ,_34\,\1740 the_35\DT\1740 other_36\JJ\1740 receiving_37\VBG\2210855 650_38\CD\1740 micrograms/kg_39\NNS\1740 b.w_40\JJ\1740 ._41\.\1740 of_42\IN\1740 the_43\DT\1740 hypotensive_44\JJ\1740 drug_45\NN\14778436 nitroprusside_46\NN\1740 at_47\IN\14622893 a_48\DT\13649268 flow_49\NN\7311115 rate_50\NN\13815152 of_51\IN\1740 103_52\CD\1740 microliters/min_53\NN\1740 intravenously_54\RB\1740 during_55\IN\1740 <e2>ischemia</e2>_56\NN\14195315 ,_57\,\1740 although_58\IN\1740 in_59\IN\13603305 this_60\DT\1740 latter_61\JJ\1740 group_62\NN\2137 <e1>malondialdehyde</e1>_63\NN\1740 was_64\VBD\836236 significantly_65\RB\1740 higher_66\JJR\1740 ._67\.\1740
D008315_D007511 NONE the_0\DT\1740 present_1\JJ\1740 data_2\NNS\7951464 indicate_3\VBP\952524 that_4\IN\1740 the_5\DT\1740 determination_6\NN\43195 of_7\IN\1740 <e1>malondialdehyde</e1>_8\NN\1740 ,_9\,\1740 oxypurines_10\NNS\1740 ,_11\,\1740 and_12\CC\1740 nucleosides_13\VBZ\1740 in_14\IN\13603305 peripheral_15\JJ\1740 blood_16\NN\5397468 ,_17\,\1740 may_18\MD\15209706 be_19\VB\836236 used_20\VBN\1156834 to_21\TO\1740 monitor_22\VB\2169352 the_23\DT\1740 metabolic_24\JJ\1740 alterations_25\NNS\7283608 of_26\IN\1740 tissues_27\NNS\5220461 occurring_28\VBG\2623529 during_29\IN\1740 <e2>ischemic</e2>_30\JJ\1740 phenomena_31\NNS\29677 ._32\.\1740
D008315_D007022 NONE increased_0\VBN\169651 plasma_1\NN\5398023 <e1>malondialdehyde</e1>_2\NN\1740 was_3\VBD\836236 also_4\RB\1740 recorded_5\VBN\2225492 in_6\IN\13603305 two_7\CD\13741022 other_8\JJ\1740 groups_9\NNS\2137 of_10\IN\1740 animals_11\NNS\4475 subjected_12\VBN\137313 to_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 experimental_16\JJ\1740 model_17\NN\5888929 ,_18\,\1740 one_19\CD\13741022 receiving_20\VBG\2210855 20_21\CD\13745420 mg/kg_22\NN\1740 b.w_23\NN\1740 ._24\.\1740 of_25\IN\1740 the_26\DT\1740 cyclooxygenase_27\NN\14732946 inhibitor_28\NN\20090 acetylsalicylate_29\NN\1740 intravenously_30\RB\1740 immediately_31\RB\1740 before_32\IN\1740 ischemia_33\NN\14195315 ,_34\,\1740 the_35\DT\1740 other_36\JJ\1740 receiving_37\VBG\2210855 650_38\CD\1740 micrograms/kg_39\NNS\1740 b.w_40\JJ\1740 ._41\.\1740 of_42\IN\1740 the_43\DT\1740 <e2>hypotensive</e2>_44\JJ\1740 drug_45\NN\14778436 nitroprusside_46\NN\1740 at_47\IN\14622893 a_48\DT\13649268 flow_49\NN\7311115 rate_50\NN\13815152 of_51\IN\1740 103_52\CD\1740 microliters/min_53\NN\1740 intravenously_54\RB\1740 during_55\IN\1740 ischemia_56\NN\14195315 ,_57\,\1740 although_58\IN\1740 in_59\IN\13603305 this_60\DT\1740 latter_61\JJ\1740 group_62\NN\2137 malondialdehyde_63\NN\1740 was_64\VBD\836236 significantly_65\RB\1740 higher_66\JJR\1740 ._67\.\1740
D008315_D007022 NONE increased_0\VBN\169651 plasma_1\NN\5398023 malondialdehyde_2\NN\1740 was_3\VBD\836236 also_4\RB\1740 recorded_5\VBN\2225492 in_6\IN\13603305 two_7\CD\13741022 other_8\JJ\1740 groups_9\NNS\2137 of_10\IN\1740 animals_11\NNS\4475 subjected_12\VBN\137313 to_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 experimental_16\JJ\1740 model_17\NN\5888929 ,_18\,\1740 one_19\CD\13741022 receiving_20\VBG\2210855 20_21\CD\13745420 mg/kg_22\NN\1740 b.w_23\NN\1740 ._24\.\1740 of_25\IN\1740 the_26\DT\1740 cyclooxygenase_27\NN\14732946 inhibitor_28\NN\20090 acetylsalicylate_29\NN\1740 intravenously_30\RB\1740 immediately_31\RB\1740 before_32\IN\1740 ischemia_33\NN\14195315 ,_34\,\1740 the_35\DT\1740 other_36\JJ\1740 receiving_37\VBG\2210855 650_38\CD\1740 micrograms/kg_39\NNS\1740 b.w_40\JJ\1740 ._41\.\1740 of_42\IN\1740 the_43\DT\1740 <e2>hypotensive</e2>_44\JJ\1740 drug_45\NN\14778436 nitroprusside_46\NN\1740 at_47\IN\14622893 a_48\DT\13649268 flow_49\NN\7311115 rate_50\NN\13815152 of_51\IN\1740 103_52\CD\1740 microliters/min_53\NN\1740 intravenously_54\RB\1740 during_55\IN\1740 ischemia_56\NN\14195315 ,_57\,\1740 although_58\IN\1740 in_59\IN\13603305 this_60\DT\1740 latter_61\JJ\1740 group_62\NN\2137 <e1>malondialdehyde</e1>_63\NN\1740 was_64\VBD\836236 significantly_65\RB\1740 higher_66\JJR\1740 ._67\.\1740
D001241_D007511 NONE increased_0\VBN\169651 plasma_1\NN\5398023 malondialdehyde_2\NN\1740 was_3\VBD\836236 also_4\RB\1740 recorded_5\VBN\2225492 in_6\IN\13603305 two_7\CD\13741022 other_8\JJ\1740 groups_9\NNS\2137 of_10\IN\1740 animals_11\NNS\4475 subjected_12\VBN\137313 to_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 experimental_16\JJ\1740 model_17\NN\5888929 ,_18\,\1740 one_19\CD\13741022 receiving_20\VBG\2210855 20_21\CD\13745420 mg/kg_22\NN\1740 b.w_23\NN\1740 ._24\.\1740 of_25\IN\1740 the_26\DT\1740 cyclooxygenase_27\NN\14732946 inhibitor_28\NN\20090 <e1>acetylsalicylate</e1>_29\NN\1740 intravenously_30\RB\1740 immediately_31\RB\1740 before_32\IN\1740 <e2>ischemia</e2>_33\NN\14195315 ,_34\,\1740 the_35\DT\1740 other_36\JJ\1740 receiving_37\VBG\2210855 650_38\CD\1740 micrograms/kg_39\NNS\1740 b.w_40\JJ\1740 ._41\.\1740 of_42\IN\1740 the_43\DT\1740 hypotensive_44\JJ\1740 drug_45\NN\14778436 nitroprusside_46\NN\1740 at_47\IN\14622893 a_48\DT\13649268 flow_49\NN\7311115 rate_50\NN\13815152 of_51\IN\1740 103_52\CD\1740 microliters/min_53\NN\1740 intravenously_54\RB\1740 during_55\IN\1740 ischemia_56\NN\14195315 ,_57\,\1740 although_58\IN\1740 in_59\IN\13603305 this_60\DT\1740 latter_61\JJ\1740 group_62\NN\2137 malondialdehyde_63\NN\1740 was_64\VBD\836236 significantly_65\RB\1740 higher_66\JJR\1740 ._67\.\1740
D001241_D007511 NONE increased_0\VBN\169651 plasma_1\NN\5398023 malondialdehyde_2\NN\1740 was_3\VBD\836236 also_4\RB\1740 recorded_5\VBN\2225492 in_6\IN\13603305 two_7\CD\13741022 other_8\JJ\1740 groups_9\NNS\2137 of_10\IN\1740 animals_11\NNS\4475 subjected_12\VBN\137313 to_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 experimental_16\JJ\1740 model_17\NN\5888929 ,_18\,\1740 one_19\CD\13741022 receiving_20\VBG\2210855 20_21\CD\13745420 mg/kg_22\NN\1740 b.w_23\NN\1740 ._24\.\1740 of_25\IN\1740 the_26\DT\1740 cyclooxygenase_27\NN\14732946 inhibitor_28\NN\20090 <e1>acetylsalicylate</e1>_29\NN\1740 intravenously_30\RB\1740 immediately_31\RB\1740 before_32\IN\1740 ischemia_33\NN\14195315 ,_34\,\1740 the_35\DT\1740 other_36\JJ\1740 receiving_37\VBG\2210855 650_38\CD\1740 micrograms/kg_39\NNS\1740 b.w_40\JJ\1740 ._41\.\1740 of_42\IN\1740 the_43\DT\1740 hypotensive_44\JJ\1740 drug_45\NN\14778436 nitroprusside_46\NN\1740 at_47\IN\14622893 a_48\DT\13649268 flow_49\NN\7311115 rate_50\NN\13815152 of_51\IN\1740 103_52\CD\1740 microliters/min_53\NN\1740 intravenously_54\RB\1740 during_55\IN\1740 <e2>ischemia</e2>_56\NN\14195315 ,_57\,\1740 although_58\IN\1740 in_59\IN\13603305 this_60\DT\1740 latter_61\JJ\1740 group_62\NN\2137 malondialdehyde_63\NN\1740 was_64\VBD\836236 significantly_65\RB\1740 higher_66\JJR\1740 ._67\.\1740
D001241_D007022 NONE increased_0\VBN\169651 plasma_1\NN\5398023 malondialdehyde_2\NN\1740 was_3\VBD\836236 also_4\RB\1740 recorded_5\VBN\2225492 in_6\IN\13603305 two_7\CD\13741022 other_8\JJ\1740 groups_9\NNS\2137 of_10\IN\1740 animals_11\NNS\4475 subjected_12\VBN\137313 to_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 experimental_16\JJ\1740 model_17\NN\5888929 ,_18\,\1740 one_19\CD\13741022 receiving_20\VBG\2210855 20_21\CD\13745420 mg/kg_22\NN\1740 b.w_23\NN\1740 ._24\.\1740 of_25\IN\1740 the_26\DT\1740 cyclooxygenase_27\NN\14732946 inhibitor_28\NN\20090 <e1>acetylsalicylate</e1>_29\NN\1740 intravenously_30\RB\1740 immediately_31\RB\1740 before_32\IN\1740 ischemia_33\NN\14195315 ,_34\,\1740 the_35\DT\1740 other_36\JJ\1740 receiving_37\VBG\2210855 650_38\CD\1740 micrograms/kg_39\NNS\1740 b.w_40\JJ\1740 ._41\.\1740 of_42\IN\1740 the_43\DT\1740 <e2>hypotensive</e2>_44\JJ\1740 drug_45\NN\14778436 nitroprusside_46\NN\1740 at_47\IN\14622893 a_48\DT\13649268 flow_49\NN\7311115 rate_50\NN\13815152 of_51\IN\1740 103_52\CD\1740 microliters/min_53\NN\1740 intravenously_54\RB\1740 during_55\IN\1740 ischemia_56\NN\14195315 ,_57\,\1740 although_58\IN\1740 in_59\IN\13603305 this_60\DT\1740 latter_61\JJ\1740 group_62\NN\2137 malondialdehyde_63\NN\1740 was_64\VBD\836236 significantly_65\RB\1740 higher_66\JJR\1740 ._67\.\1740
D009599_D007511 NONE increased_0\VBN\169651 plasma_1\NN\5398023 malondialdehyde_2\NN\1740 was_3\VBD\836236 also_4\RB\1740 recorded_5\VBN\2225492 in_6\IN\13603305 two_7\CD\13741022 other_8\JJ\1740 groups_9\NNS\2137 of_10\IN\1740 animals_11\NNS\4475 subjected_12\VBN\137313 to_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 experimental_16\JJ\1740 model_17\NN\5888929 ,_18\,\1740 one_19\CD\13741022 receiving_20\VBG\2210855 20_21\CD\13745420 mg/kg_22\NN\1740 b.w_23\NN\1740 ._24\.\1740 of_25\IN\1740 the_26\DT\1740 cyclooxygenase_27\NN\14732946 inhibitor_28\NN\20090 acetylsalicylate_29\NN\1740 intravenously_30\RB\1740 immediately_31\RB\1740 before_32\IN\1740 <e2>ischemia</e2>_33\NN\14195315 ,_34\,\1740 the_35\DT\1740 other_36\JJ\1740 receiving_37\VBG\2210855 650_38\CD\1740 micrograms/kg_39\NNS\1740 b.w_40\JJ\1740 ._41\.\1740 of_42\IN\1740 the_43\DT\1740 hypotensive_44\JJ\1740 drug_45\NN\14778436 <e1>nitroprusside</e1>_46\NN\1740 at_47\IN\14622893 a_48\DT\13649268 flow_49\NN\7311115 rate_50\NN\13815152 of_51\IN\1740 103_52\CD\1740 microliters/min_53\NN\1740 intravenously_54\RB\1740 during_55\IN\1740 ischemia_56\NN\14195315 ,_57\,\1740 although_58\IN\1740 in_59\IN\13603305 this_60\DT\1740 latter_61\JJ\1740 group_62\NN\2137 malondialdehyde_63\NN\1740 was_64\VBD\836236 significantly_65\RB\1740 higher_66\JJR\1740 ._67\.\1740
D009599_D007511 NONE increased_0\VBN\169651 plasma_1\NN\5398023 malondialdehyde_2\NN\1740 was_3\VBD\836236 also_4\RB\1740 recorded_5\VBN\2225492 in_6\IN\13603305 two_7\CD\13741022 other_8\JJ\1740 groups_9\NNS\2137 of_10\IN\1740 animals_11\NNS\4475 subjected_12\VBN\137313 to_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 experimental_16\JJ\1740 model_17\NN\5888929 ,_18\,\1740 one_19\CD\13741022 receiving_20\VBG\2210855 20_21\CD\13745420 mg/kg_22\NN\1740 b.w_23\NN\1740 ._24\.\1740 of_25\IN\1740 the_26\DT\1740 cyclooxygenase_27\NN\14732946 inhibitor_28\NN\20090 acetylsalicylate_29\NN\1740 intravenously_30\RB\1740 immediately_31\RB\1740 before_32\IN\1740 ischemia_33\NN\14195315 ,_34\,\1740 the_35\DT\1740 other_36\JJ\1740 receiving_37\VBG\2210855 650_38\CD\1740 micrograms/kg_39\NNS\1740 b.w_40\JJ\1740 ._41\.\1740 of_42\IN\1740 the_43\DT\1740 hypotensive_44\JJ\1740 drug_45\NN\14778436 <e1>nitroprusside</e1>_46\NN\1740 at_47\IN\14622893 a_48\DT\13649268 flow_49\NN\7311115 rate_50\NN\13815152 of_51\IN\1740 103_52\CD\1740 microliters/min_53\NN\1740 intravenously_54\RB\1740 during_55\IN\1740 <e2>ischemia</e2>_56\NN\14195315 ,_57\,\1740 although_58\IN\1740 in_59\IN\13603305 this_60\DT\1740 latter_61\JJ\1740 group_62\NN\2137 malondialdehyde_63\NN\1740 was_64\VBD\836236 significantly_65\RB\1740 higher_66\JJR\1740 ._67\.\1740
D009599_D007022 NONE increased_0\VBN\169651 plasma_1\NN\5398023 malondialdehyde_2\NN\1740 was_3\VBD\836236 also_4\RB\1740 recorded_5\VBN\2225492 in_6\IN\13603305 two_7\CD\13741022 other_8\JJ\1740 groups_9\NNS\2137 of_10\IN\1740 animals_11\NNS\4475 subjected_12\VBN\137313 to_13\IN\1740 the_14\DT\1740 same_15\JJ\1740 experimental_16\JJ\1740 model_17\NN\5888929 ,_18\,\1740 one_19\CD\13741022 receiving_20\VBG\2210855 20_21\CD\13745420 mg/kg_22\NN\1740 b.w_23\NN\1740 ._24\.\1740 of_25\IN\1740 the_26\DT\1740 cyclooxygenase_27\NN\14732946 inhibitor_28\NN\20090 acetylsalicylate_29\NN\1740 intravenously_30\RB\1740 immediately_31\RB\1740 before_32\IN\1740 ischemia_33\NN\14195315 ,_34\,\1740 the_35\DT\1740 other_36\JJ\1740 receiving_37\VBG\2210855 650_38\CD\1740 micrograms/kg_39\NNS\1740 b.w_40\JJ\1740 ._41\.\1740 of_42\IN\1740 the_43\DT\1740 <e2>hypotensive</e2>_44\JJ\1740 drug_45\NN\14778436 <e1>nitroprusside</e1>_46\NN\1740 at_47\IN\14622893 a_48\DT\13649268 flow_49\NN\7311115 rate_50\NN\13815152 of_51\IN\1740 103_52\CD\1740 microliters/min_53\NN\1740 intravenously_54\RB\1740 during_55\IN\1740 ischemia_56\NN\14195315 ,_57\,\1740 although_58\IN\1740 in_59\IN\13603305 this_60\DT\1740 latter_61\JJ\1740 group_62\NN\2137 malondialdehyde_63\NN\1740 was_64\VBD\836236 significantly_65\RB\1740 higher_66\JJR\1740 ._67\.\1740
8888541
C047426_D020230 CID <e2>serotonin_0\NN\14807737 syndrome</e2>_1\NN\5870365 from_2\IN\1740 <e1>venlafaxine-tranylcypromine</e1>_3\NN\1740 interaction_4\NN\37396 ._5\.\1740
C047426_D020230 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 <e1>venlafaxine-maoi</e1>_3\JJ\1740 interaction_4\NN\37396 that_5\WDT\1740 resulted_6\VBD\2633881 in_7\IN\13603305 the_8\DT\1740 <e2>serotonin_9\NN\14807737 syndrome</e2>_10\NN\5870365 in_11\IN\13603305 a_12\DT\13649268 23-y-old_13\JJ\1740 male_14\NN\15388 who_15\WP\8299493 was_16\VBD\836236 taking_17\VBG\2367363 tranylcypromine_18\NN\3783017 for_19\IN\1740 depression_20\NN\14373582 ._21\.\1740
D014191_D020230 CID <e2>serotonin_0\NN\14807737 syndrome</e2>_1\NN\5870365 from_2\IN\1740 <e1>venlafaxine-tranylcypromine</e1>_3\NN\1740 interaction_4\NN\37396 ._5\.\1740
D014191_D020230 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 venlafaxine-maoi_3\JJ\1740 interaction_4\NN\37396 that_5\WDT\1740 resulted_6\VBD\2633881 in_7\IN\13603305 the_8\DT\1740 <e2>serotonin_9\NN\14807737 syndrome</e2>_10\NN\5870365 in_11\IN\13603305 a_12\DT\13649268 23-y-old_13\JJ\1740 male_14\NN\15388 who_15\WP\8299493 was_16\VBD\836236 taking_17\VBG\2367363 <e1>tranylcypromine</e1>_18\NN\3783017 for_19\IN\1740 depression_20\NN\14373582 ._21\.\1740
D012701_D009127 NONE excessive_0\JJ\1740 stimulation_1\NN\242808 of_2\IN\1740 <e1>serotonin</e1>_3\NN\14807737 5ht1a_4\NN\1740 receptors_5\NNS\5225602 causes_6\VBZ\1617192 a_7\DT\13649268 syndrome_8\NN\5870365 of_9\IN\1740 serotonin_10\NN\14807737 excess_11\NN\5119367 that_12\WDT\1740 consists_13\VBZ\2603699 of_14\IN\1740 shivering_15\NN\14299637 ,_16\,\1740 <e2>muscle_17\NN\5289601 rigidity</e2>_18\NN\5023233 ,_19\,\1740 salivation_20\NN\13553916 ,_21\,\1740 confusion_22\NN\13972797 ,_23\,\1740 agitation_24\NN\14373582 and_25\CC\1740 hyperthermia_26\NN\14034177 ._27\.\1740
D012701_D009127 NONE excessive_0\JJ\1740 stimulation_1\NN\242808 of_2\IN\1740 serotonin_3\NN\14807737 5ht1a_4\NN\1740 receptors_5\NNS\5225602 causes_6\VBZ\1617192 a_7\DT\13649268 syndrome_8\NN\5870365 of_9\IN\1740 <e1>serotonin</e1>_10\NN\14807737 excess_11\NN\5119367 that_12\WDT\1740 consists_13\VBZ\2603699 of_14\IN\1740 shivering_15\NN\14299637 ,_16\,\1740 <e2>muscle_17\NN\5289601 rigidity</e2>_18\NN\5023233 ,_19\,\1740 salivation_20\NN\13553916 ,_21\,\1740 confusion_22\NN\13972797 ,_23\,\1740 agitation_24\NN\14373582 and_25\CC\1740 hyperthermia_26\NN\14034177 ._27\.\1740
D012701_D012798 NONE excessive_0\JJ\1740 stimulation_1\NN\242808 of_2\IN\1740 <e1>serotonin</e1>_3\NN\14807737 5ht1a_4\NN\1740 receptors_5\NNS\5225602 causes_6\VBZ\1617192 a_7\DT\13649268 syndrome_8\NN\5870365 of_9\IN\1740 serotonin_10\NN\14807737 excess_11\NN\5119367 that_12\WDT\1740 consists_13\VBZ\2603699 of_14\IN\1740 shivering_15\NN\14299637 ,_16\,\1740 muscle_17\NN\5289601 rigidity_18\NN\5023233 ,_19\,\1740 <e2>salivation</e2>_20\NN\13553916 ,_21\,\1740 confusion_22\NN\13972797 ,_23\,\1740 agitation_24\NN\14373582 and_25\CC\1740 hyperthermia_26\NN\14034177 ._27\.\1740
D012701_D012798 NONE excessive_0\JJ\1740 stimulation_1\NN\242808 of_2\IN\1740 serotonin_3\NN\14807737 5ht1a_4\NN\1740 receptors_5\NNS\5225602 causes_6\VBZ\1617192 a_7\DT\13649268 syndrome_8\NN\5870365 of_9\IN\1740 <e1>serotonin</e1>_10\NN\14807737 excess_11\NN\5119367 that_12\WDT\1740 consists_13\VBZ\2603699 of_14\IN\1740 shivering_15\NN\14299637 ,_16\,\1740 muscle_17\NN\5289601 rigidity_18\NN\5023233 ,_19\,\1740 <e2>salivation</e2>_20\NN\13553916 ,_21\,\1740 confusion_22\NN\13972797 ,_23\,\1740 agitation_24\NN\14373582 and_25\CC\1740 hyperthermia_26\NN\14034177 ._27\.\1740
D012701_D003221 NONE excessive_0\JJ\1740 stimulation_1\NN\242808 of_2\IN\1740 <e1>serotonin</e1>_3\NN\14807737 5ht1a_4\NN\1740 receptors_5\NNS\5225602 causes_6\VBZ\1617192 a_7\DT\13649268 syndrome_8\NN\5870365 of_9\IN\1740 serotonin_10\NN\14807737 excess_11\NN\5119367 that_12\WDT\1740 consists_13\VBZ\2603699 of_14\IN\1740 shivering_15\NN\14299637 ,_16\,\1740 muscle_17\NN\5289601 rigidity_18\NN\5023233 ,_19\,\1740 salivation_20\NN\13553916 ,_21\,\1740 <e2>confusion</e2>_22\NN\13972797 ,_23\,\1740 agitation_24\NN\14373582 and_25\CC\1740 hyperthermia_26\NN\14034177 ._27\.\1740
D012701_D003221 NONE excessive_0\JJ\1740 stimulation_1\NN\242808 of_2\IN\1740 serotonin_3\NN\14807737 5ht1a_4\NN\1740 receptors_5\NNS\5225602 causes_6\VBZ\1617192 a_7\DT\13649268 syndrome_8\NN\5870365 of_9\IN\1740 <e1>serotonin</e1>_10\NN\14807737 excess_11\NN\5119367 that_12\WDT\1740 consists_13\VBZ\2603699 of_14\IN\1740 shivering_15\NN\14299637 ,_16\,\1740 muscle_17\NN\5289601 rigidity_18\NN\5023233 ,_19\,\1740 salivation_20\NN\13553916 ,_21\,\1740 <e2>confusion</e2>_22\NN\13972797 ,_23\,\1740 agitation_24\NN\14373582 and_25\CC\1740 hyperthermia_26\NN\14034177 ._27\.\1740
D012701_D011595 NONE excessive_0\JJ\1740 stimulation_1\NN\242808 of_2\IN\1740 <e1>serotonin</e1>_3\NN\14807737 5ht1a_4\NN\1740 receptors_5\NNS\5225602 causes_6\VBZ\1617192 a_7\DT\13649268 syndrome_8\NN\5870365 of_9\IN\1740 serotonin_10\NN\14807737 excess_11\NN\5119367 that_12\WDT\1740 consists_13\VBZ\2603699 of_14\IN\1740 shivering_15\NN\14299637 ,_16\,\1740 muscle_17\NN\5289601 rigidity_18\NN\5023233 ,_19\,\1740 salivation_20\NN\13553916 ,_21\,\1740 confusion_22\NN\13972797 ,_23\,\1740 <e2>agitation</e2>_24\NN\14373582 and_25\CC\1740 hyperthermia_26\NN\14034177 ._27\.\1740
D012701_D011595 NONE excessive_0\JJ\1740 stimulation_1\NN\242808 of_2\IN\1740 serotonin_3\NN\14807737 5ht1a_4\NN\1740 receptors_5\NNS\5225602 causes_6\VBZ\1617192 a_7\DT\13649268 syndrome_8\NN\5870365 of_9\IN\1740 <e1>serotonin</e1>_10\NN\14807737 excess_11\NN\5119367 that_12\WDT\1740 consists_13\VBZ\2603699 of_14\IN\1740 shivering_15\NN\14299637 ,_16\,\1740 muscle_17\NN\5289601 rigidity_18\NN\5023233 ,_19\,\1740 salivation_20\NN\13553916 ,_21\,\1740 confusion_22\NN\13972797 ,_23\,\1740 <e2>agitation</e2>_24\NN\14373582 and_25\CC\1740 hyperthermia_26\NN\14034177 ._27\.\1740
D012701_D005334 NONE excessive_0\JJ\1740 stimulation_1\NN\242808 of_2\IN\1740 <e1>serotonin</e1>_3\NN\14807737 5ht1a_4\NN\1740 receptors_5\NNS\5225602 causes_6\VBZ\1617192 a_7\DT\13649268 syndrome_8\NN\5870365 of_9\IN\1740 serotonin_10\NN\14807737 excess_11\NN\5119367 that_12\WDT\1740 consists_13\VBZ\2603699 of_14\IN\1740 shivering_15\NN\14299637 ,_16\,\1740 muscle_17\NN\5289601 rigidity_18\NN\5023233 ,_19\,\1740 salivation_20\NN\13553916 ,_21\,\1740 confusion_22\NN\13972797 ,_23\,\1740 agitation_24\NN\14373582 and_25\CC\1740 <e2>hyperthermia</e2>_26\NN\14034177 ._27\.\1740
D012701_D005334 NONE excessive_0\JJ\1740 stimulation_1\NN\242808 of_2\IN\1740 serotonin_3\NN\14807737 5ht1a_4\NN\1740 receptors_5\NNS\5225602 causes_6\VBZ\1617192 a_7\DT\13649268 syndrome_8\NN\5870365 of_9\IN\1740 <e1>serotonin</e1>_10\NN\14807737 excess_11\NN\5119367 that_12\WDT\1740 consists_13\VBZ\2603699 of_14\IN\1740 shivering_15\NN\14299637 ,_16\,\1740 muscle_17\NN\5289601 rigidity_18\NN\5023233 ,_19\,\1740 salivation_20\NN\13553916 ,_21\,\1740 confusion_22\NN\13972797 ,_23\,\1740 agitation_24\NN\14373582 and_25\CC\1740 <e2>hyperthermia</e2>_26\NN\14034177 ._27\.\1740
C047426_D003866 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 <e1>venlafaxine-maoi</e1>_3\JJ\1740 interaction_4\NN\37396 that_5\WDT\1740 resulted_6\VBD\2633881 in_7\IN\13603305 the_8\DT\1740 serotonin_9\NN\14807737 syndrome_10\NN\5870365 in_11\IN\13603305 a_12\DT\13649268 23-y-old_13\JJ\1740 male_14\NN\15388 who_15\WP\8299493 was_16\VBD\836236 taking_17\VBG\2367363 tranylcypromine_18\NN\3783017 for_19\IN\1740 <e2>depression</e2>_20\NN\14373582 ._21\.\1740
D014191_D003866 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 venlafaxine-maoi_3\JJ\1740 interaction_4\NN\37396 that_5\WDT\1740 resulted_6\VBD\2633881 in_7\IN\13603305 the_8\DT\1740 serotonin_9\NN\14807737 syndrome_10\NN\5870365 in_11\IN\13603305 a_12\DT\13649268 23-y-old_13\JJ\1740 male_14\NN\15388 who_15\WP\8299493 was_16\VBD\836236 taking_17\VBG\2367363 <e1>tranylcypromine</e1>_18\NN\3783017 for_19\IN\1740 <e2>depression</e2>_20\NN\14373582 ._21\.\1740
D003975_D009127 NONE vital_0\JJ\1740 signs_1\NNS\6643763 were_2\VBD\836236 :_3\:\1740 blood_4\NN\5397468 pressure_5\NN\11419404 120/67_6\VB\1740 mm_7\NN\13649268 hg_8\NNP\14625458 ,_9\,\1740 heart_10\NN\5919034 rate_11\NN\13815152 127/min_12\CD\1740 ,_13\,\1740 respiratory_14\JJ\1740 rate_15\NN\13815152 28/min_16\NN\1740 ,_17\,\1740 and_18\CC\1740 temperature_19\NN\13575869 97_20\CD\1740 f._21\NN\1740 after_22\IN\1740 180_23\CD\1740 mg_24\NN\13717155 of_25\IN\1740 <e1>diazepam</e1>_26\NNS\2830852 i.v._27\NN\1740 he_28\PRP\14622893 remained_29\VBD\2604760 tremulous_30\JJ\1740 with_31\IN\1740 <e2>muscle_32\NN\5289601 rigidity</e2>_33\NN\5023233 and_34\CC\1740 clenched_35\JJ\1740 jaws_36\NNS\5269901 ._37\.\1740
7282516
D004317_D009202 CID dose-effect_0\JJ\1740 and_1\CC\1740 structure-function_2\JJ\1740 relationships_3\NNS\31921 in_4\IN\13603305 <e1>doxorubicin</e1>_5\NN\2716866 <e2>cardiomyopathy</e2>_6\IN\14103288 ._7\.\1740
D004317_D009202 CID the_0\DT\1740 <e2>cardiomyopathy</e2>_1\JJ\1740 (_2\-LRB-\1740 cm_3\NN\13649268 )_4\-RRB-\1740 produced_5\VBN\1617192 by_6\IN\1740 the_7\DT\1740 anticancer_8\NN\1740 drug_9\NN\14778436 <e1>doxorubicin</e1>_10\NN\2716866 (_11\-LRB-\1740 dxr_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 adriamycin_15\NN\1740 )_16\-RRB-\1740 provides_17\VBZ\2199590 a_18\DT\13649268 unique_19\JJ\1740 opportunity_20\NN\14481929 to_21\TO\1740 analyze_22\VB\78760 dose-effect_23\JJ\1740 and_24\CC\1740 structure-function_25\JJ\1740 relationships_26\NNS\31921 during_27\IN\1740 development_28\NN\248977 of_29\IN\1740 myocardial_30\JJ\1740 disease_31\NN\14061805 ._32\.\1740
D004317_D009202 CID the_0\DT\1740 cardiomyopathy_1\JJ\1740 (_2\-LRB-\1740 <e2>cm</e2>_3\NN\13649268 )_4\-RRB-\1740 produced_5\VBN\1617192 by_6\IN\1740 the_7\DT\1740 anticancer_8\NN\1740 drug_9\NN\14778436 <e1>doxorubicin</e1>_10\NN\2716866 (_11\-LRB-\1740 dxr_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 adriamycin_15\NN\1740 )_16\-RRB-\1740 provides_17\VBZ\2199590 a_18\DT\13649268 unique_19\JJ\1740 opportunity_20\NN\14481929 to_21\TO\1740 analyze_22\VB\78760 dose-effect_23\JJ\1740 and_24\CC\1740 structure-function_25\JJ\1740 relationships_26\NNS\31921 during_27\IN\1740 development_28\NN\248977 of_29\IN\1740 myocardial_30\JJ\1740 disease_31\NN\14061805 ._32\.\1740
D004317_D009202 CID the_0\DT\1740 cardiomyopathy_1\JJ\1740 (_2\-LRB-\1740 cm_3\NN\13649268 )_4\-RRB-\1740 produced_5\VBN\1617192 by_6\IN\1740 the_7\DT\1740 anticancer_8\NN\1740 drug_9\NN\14778436 <e1>doxorubicin</e1>_10\NN\2716866 (_11\-LRB-\1740 dxr_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 adriamycin_15\NN\1740 )_16\-RRB-\1740 provides_17\VBZ\2199590 a_18\DT\13649268 unique_19\JJ\1740 opportunity_20\NN\14481929 to_21\TO\1740 analyze_22\VB\78760 dose-effect_23\JJ\1740 and_24\CC\1740 structure-function_25\JJ\1740 relationships_26\NNS\31921 during_27\IN\1740 development_28\NN\248977 of_29\IN\1740 <e2>myocardial_30\JJ\1740 disease</e2>_31\NN\14061805 ._32\.\1740
D004317_D009202 CID the_0\DT\1740 <e2>cardiomyopathy</e2>_1\JJ\1740 (_2\-LRB-\1740 cm_3\NN\13649268 )_4\-RRB-\1740 produced_5\VBN\1617192 by_6\IN\1740 the_7\DT\1740 anticancer_8\NN\1740 drug_9\NN\14778436 doxorubicin_10\NN\2716866 (_11\-LRB-\1740 <e1>dxr</e1>_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 adriamycin_15\NN\1740 )_16\-RRB-\1740 provides_17\VBZ\2199590 a_18\DT\13649268 unique_19\JJ\1740 opportunity_20\NN\14481929 to_21\TO\1740 analyze_22\VB\78760 dose-effect_23\JJ\1740 and_24\CC\1740 structure-function_25\JJ\1740 relationships_26\NNS\31921 during_27\IN\1740 development_28\NN\248977 of_29\IN\1740 myocardial_30\JJ\1740 disease_31\NN\14061805 ._32\.\1740
D004317_D009202 CID the_0\DT\1740 cardiomyopathy_1\JJ\1740 (_2\-LRB-\1740 <e2>cm</e2>_3\NN\13649268 )_4\-RRB-\1740 produced_5\VBN\1617192 by_6\IN\1740 the_7\DT\1740 anticancer_8\NN\1740 drug_9\NN\14778436 doxorubicin_10\NN\2716866 (_11\-LRB-\1740 <e1>dxr</e1>_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 adriamycin_15\NN\1740 )_16\-RRB-\1740 provides_17\VBZ\2199590 a_18\DT\13649268 unique_19\JJ\1740 opportunity_20\NN\14481929 to_21\TO\1740 analyze_22\VB\78760 dose-effect_23\JJ\1740 and_24\CC\1740 structure-function_25\JJ\1740 relationships_26\NNS\31921 during_27\IN\1740 development_28\NN\248977 of_29\IN\1740 myocardial_30\JJ\1740 disease_31\NN\14061805 ._32\.\1740
D004317_D009202 CID the_0\DT\1740 cardiomyopathy_1\JJ\1740 (_2\-LRB-\1740 cm_3\NN\13649268 )_4\-RRB-\1740 produced_5\VBN\1617192 by_6\IN\1740 the_7\DT\1740 anticancer_8\NN\1740 drug_9\NN\14778436 doxorubicin_10\NN\2716866 (_11\-LRB-\1740 <e1>dxr</e1>_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 adriamycin_15\NN\1740 )_16\-RRB-\1740 provides_17\VBZ\2199590 a_18\DT\13649268 unique_19\JJ\1740 opportunity_20\NN\14481929 to_21\TO\1740 analyze_22\VB\78760 dose-effect_23\JJ\1740 and_24\CC\1740 structure-function_25\JJ\1740 relationships_26\NNS\31921 during_27\IN\1740 development_28\NN\248977 of_29\IN\1740 <e2>myocardial_30\JJ\1740 disease</e2>_31\NN\14061805 ._32\.\1740
D004317_D009202 CID the_0\DT\1740 <e2>cardiomyopathy</e2>_1\JJ\1740 (_2\-LRB-\1740 cm_3\NN\13649268 )_4\-RRB-\1740 produced_5\VBN\1617192 by_6\IN\1740 the_7\DT\1740 anticancer_8\NN\1740 drug_9\NN\14778436 doxorubicin_10\NN\2716866 (_11\-LRB-\1740 dxr_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 <e1>adriamycin</e1>_15\NN\1740 )_16\-RRB-\1740 provides_17\VBZ\2199590 a_18\DT\13649268 unique_19\JJ\1740 opportunity_20\NN\14481929 to_21\TO\1740 analyze_22\VB\78760 dose-effect_23\JJ\1740 and_24\CC\1740 structure-function_25\JJ\1740 relationships_26\NNS\31921 during_27\IN\1740 development_28\NN\248977 of_29\IN\1740 myocardial_30\JJ\1740 disease_31\NN\14061805 ._32\.\1740
D004317_D009202 CID the_0\DT\1740 cardiomyopathy_1\JJ\1740 (_2\-LRB-\1740 <e2>cm</e2>_3\NN\13649268 )_4\-RRB-\1740 produced_5\VBN\1617192 by_6\IN\1740 the_7\DT\1740 anticancer_8\NN\1740 drug_9\NN\14778436 doxorubicin_10\NN\2716866 (_11\-LRB-\1740 dxr_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 <e1>adriamycin</e1>_15\NN\1740 )_16\-RRB-\1740 provides_17\VBZ\2199590 a_18\DT\13649268 unique_19\JJ\1740 opportunity_20\NN\14481929 to_21\TO\1740 analyze_22\VB\78760 dose-effect_23\JJ\1740 and_24\CC\1740 structure-function_25\JJ\1740 relationships_26\NNS\31921 during_27\IN\1740 development_28\NN\248977 of_29\IN\1740 myocardial_30\JJ\1740 disease_31\NN\14061805 ._32\.\1740
D004317_D009202 CID the_0\DT\1740 cardiomyopathy_1\JJ\1740 (_2\-LRB-\1740 cm_3\NN\13649268 )_4\-RRB-\1740 produced_5\VBN\1617192 by_6\IN\1740 the_7\DT\1740 anticancer_8\NN\1740 drug_9\NN\14778436 doxorubicin_10\NN\2716866 (_11\-LRB-\1740 dxr_12\NN\1740 )_13\-RRB-\1740 (_14\-LRB-\1740 <e1>adriamycin</e1>_15\NN\1740 )_16\-RRB-\1740 provides_17\VBZ\2199590 a_18\DT\13649268 unique_19\JJ\1740 opportunity_20\NN\14481929 to_21\TO\1740 analyze_22\VB\78760 dose-effect_23\JJ\1740 and_24\CC\1740 structure-function_25\JJ\1740 relationships_26\NNS\31921 during_27\IN\1740 development_28\NN\248977 of_29\IN\1740 <e2>myocardial_30\JJ\1740 disease</e2>_31\NN\14061805 ._32\.\1740
D004317_D009202 CID in_0\IN\13603305 <e2><e1>dxr-cm</e1></e2>_1\NN\1740 myocardial_2\JJ\1740 damage_3\NN\7296428 is_4\VBZ\836236 proportional_5\JJ\1740 to_6\TO\1740 the_7\DT\1740 degree_8\NN\4916342 of_9\IN\1740 cytotoxic_10\JJ\1740 insult_11\NN\6714976 (_12\-LRB-\1740 dxr_13\NN\1740 dose_14\NN\3740161 )_15\-RRB-\1740 while_16\IN\15122231 myocardial_17\JJ\1740 function_18\NN\13783581 is_19\VBZ\836236 preserved_20\VBN\2681795 until_21\IN\1740 a_22\DT\13649268 critical_23\JJ\1740 dose_24\NN\3740161 or_25\CC\3541091 degree_26\NN\4916342 of_27\IN\1740 damage_28\NN\7296428 is_29\VBZ\836236 reached_30\VBN\2005948 ,_31\,\1740 after_32\IN\1740 which_33\WDT\1740 myocardial_34\JJ\1740 performance_35\NN\6619065 deteriorates_36\NNS\1740 rapidly_37\RB\1740 ._38\.\1740
D004317_D009202 CID in_0\IN\13603305 <e1>dxr-cm</e1>_1\NN\1740 <e2>myocardial_2\JJ\1740 damage</e2>_3\NN\7296428 is_4\VBZ\836236 proportional_5\JJ\1740 to_6\TO\1740 the_7\DT\1740 degree_8\NN\4916342 of_9\IN\1740 cytotoxic_10\JJ\1740 insult_11\NN\6714976 (_12\-LRB-\1740 dxr_13\NN\1740 dose_14\NN\3740161 )_15\-RRB-\1740 while_16\IN\15122231 myocardial_17\JJ\1740 function_18\NN\13783581 is_19\VBZ\836236 preserved_20\VBN\2681795 until_21\IN\1740 a_22\DT\13649268 critical_23\JJ\1740 dose_24\NN\3740161 or_25\CC\3541091 degree_26\NN\4916342 of_27\IN\1740 damage_28\NN\7296428 is_29\VBZ\836236 reached_30\VBN\2005948 ,_31\,\1740 after_32\IN\1740 which_33\WDT\1740 myocardial_34\JJ\1740 performance_35\NN\6619065 deteriorates_36\NNS\1740 rapidly_37\RB\1740 ._38\.\1740
D004317_D009202 CID in_0\IN\13603305 <e2>dxr-cm</e2>_1\NN\1740 myocardial_2\JJ\1740 damage_3\NN\7296428 is_4\VBZ\836236 proportional_5\JJ\1740 to_6\TO\1740 the_7\DT\1740 degree_8\NN\4916342 of_9\IN\1740 cytotoxic_10\JJ\1740 insult_11\NN\6714976 (_12\-LRB-\1740 <e1>dxr</e1>_13\NN\1740 dose_14\NN\3740161 )_15\-RRB-\1740 while_16\IN\15122231 myocardial_17\JJ\1740 function_18\NN\13783581 is_19\VBZ\836236 preserved_20\VBN\2681795 until_21\IN\1740 a_22\DT\13649268 critical_23\JJ\1740 dose_24\NN\3740161 or_25\CC\3541091 degree_26\NN\4916342 of_27\IN\1740 damage_28\NN\7296428 is_29\VBZ\836236 reached_30\VBN\2005948 ,_31\,\1740 after_32\IN\1740 which_33\WDT\1740 myocardial_34\JJ\1740 performance_35\NN\6619065 deteriorates_36\NNS\1740 rapidly_37\RB\1740 ._38\.\1740
D004317_D009202 CID in_0\IN\13603305 dxr-cm_1\NN\1740 <e2>myocardial_2\JJ\1740 damage</e2>_3\NN\7296428 is_4\VBZ\836236 proportional_5\JJ\1740 to_6\TO\1740 the_7\DT\1740 degree_8\NN\4916342 of_9\IN\1740 cytotoxic_10\JJ\1740 insult_11\NN\6714976 (_12\-LRB-\1740 <e1>dxr</e1>_13\NN\1740 dose_14\NN\3740161 )_15\-RRB-\1740 while_16\IN\15122231 myocardial_17\JJ\1740 function_18\NN\13783581 is_19\VBZ\836236 preserved_20\VBN\2681795 until_21\IN\1740 a_22\DT\13649268 critical_23\JJ\1740 dose_24\NN\3740161 or_25\CC\3541091 degree_26\NN\4916342 of_27\IN\1740 damage_28\NN\7296428 is_29\VBZ\836236 reached_30\VBN\2005948 ,_31\,\1740 after_32\IN\1740 which_33\WDT\1740 myocardial_34\JJ\1740 performance_35\NN\6619065 deteriorates_36\NNS\1740 rapidly_37\RB\1740 ._38\.\1740
11838826
D018967_D006966 CID treatment_0\NN\654885 of_1\IN\1740 <e1>risperidone-induced</e1>_2\JJ\1740 <e2>hyperprolactinemia</e2>_3\NN\1740 with_4\IN\1740 a_5\DT\13649268 dopamine_6\NN\14807737 agonist_7\NN\9613191 in_8\IN\13603305 children_9\NNS\9622049 ._10\.\1740
D018967_D006966 CID background_0\NN\4921011 :_1\:\1740 <e1>risperidone</e1>_2\NN\1740 ,_3\,\1740 a_4\DT\13649268 potent_5\JJ\1740 antagonist_6\NN\7846 of_7\IN\1740 both_8\CC\1740 serotonergic_9\NN\1740 (_10\-LRB-\1740 5ht2a_11\NN\1740 )_12\-RRB-\1740 and_13\CC\1740 dopaminergic_14\JJ\1740 d2_15\NN\1740 receptors_16\NNS\5225602 is_17\VBZ\836236 associated_18\VBN\628491 with_19\IN\1740 <e2>hyperprolactinemia</e2>_20\NN\1740 in_21\IN\13603305 adults_22\NNS\7846 and_23\CC\1740 children_24\NNS\9622049 ._25\.\1740
D018967_D006966 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 successful_3\JJ\1740 treatment_4\NN\654885 of_5\IN\1740 <e1>risperidone-induced</e1>_6\JJ\1740 <e2>hyperprolactinemia</e2>_7\NN\1740 with_8\IN\1740 cabergoline_9\NN\1740 in_10\IN\13603305 youth_11\NN\9622049 ._12\.\1740
D018967_D006966 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 undertook_3\VBD\1641914 a_4\DT\13649268 retrospective_5\JJ\1740 case_6\NN\7283608 review_7\NN\5733583 of_8\IN\1740 four_9\CD\13741022 children_10\NNS\9622049 with_11\IN\1740 <e1>risperidone-induced</e1>_12\JJ\1740 <e2>hyperprolactinemia</e2>_13\NN\1740 treated_14\VBN\2376958 with_15\IN\1740 cabergoline_16\NN\1740 ._17\.\1740
D018967_D006966 CID conclusions_0\NNS\5837957 :_1\:\1740 cabergoline_2\NNP\1740 may_3\MD\15209706 be_4\VB\836236 useful_5\JJ\1740 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 <e1>risperidone-induced</e1>_10\JJ\1740 <e2>hyperprolactinemia</e2>_11\NN\1740 in_12\IN\13603305 youth_13\NN\9622049 ;_14\:\1740 however_15\RB\1740 ,_16\,\1740 further_17\JJ\1740 research_18\NN\633864 is_19\VBZ\836236 needed_20\VBN\2604760 ._21\.\1740
D004298_D006966 NONE treatment_0\NN\654885 of_1\IN\1740 risperidone-induced_2\JJ\1740 <e2>hyperprolactinemia</e2>_3\NN\1740 with_4\IN\1740 a_5\DT\13649268 <e1>dopamine</e1>_6\NN\14807737 agonist_7\NN\9613191 in_8\IN\13603305 children_9\NNS\9622049 ._10\.\1740
C047047_D006966 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 successful_3\JJ\1740 treatment_4\NN\654885 of_5\IN\1740 risperidone-induced_6\JJ\1740 <e2>hyperprolactinemia</e2>_7\NN\1740 with_8\IN\1740 <e1>cabergoline</e1>_9\NN\1740 in_10\IN\13603305 youth_11\NN\9622049 ._12\.\1740
C047047_D006966 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 undertook_3\VBD\1641914 a_4\DT\13649268 retrospective_5\JJ\1740 case_6\NN\7283608 review_7\NN\5733583 of_8\IN\1740 four_9\CD\13741022 children_10\NNS\9622049 with_11\IN\1740 risperidone-induced_12\JJ\1740 <e2>hyperprolactinemia</e2>_13\NN\1740 treated_14\VBN\2376958 with_15\IN\1740 <e1>cabergoline</e1>_16\NN\1740 ._17\.\1740
C047047_D006966 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>cabergoline</e1>_2\NNP\1740 may_3\MD\15209706 be_4\VB\836236 useful_5\JJ\1740 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 risperidone-induced_10\JJ\1740 <e2>hyperprolactinemia</e2>_11\NN\1740 in_12\IN\13603305 youth_13\NN\9622049 ;_14\:\1740 however_15\RB\1740 ,_16\,\1740 further_17\JJ\1740 research_18\NN\633864 is_19\VBZ\836236 needed_20\VBN\2604760 ._21\.\1740
D018967_D001523 NONE results_0\NNS\34213 :_1\:\1740 four_2\CD\13741022 males_3\NNS\15388 (_4\-LRB-\1740 age_5\NN\4916342 6_6\CD\13741022 -_7\SYM\1740 11_8\CD\13745420 years_9\NNS\15144371 )_10\-RRB-\1740 with_11\IN\1740 diagnostic_12\NNP\1740 and_13\CC\1740 statistical_14\NNP\1740 manual_15\NNP\6421301 of_16\IN\1740 <e2>mental_17\NNP\1740 disorders</e2>_18\NNPS\14034177 (_19\-LRB-\1740 fourth_20\JJ\1740 edition_21\NN\6590210 )_22\-RRB-\1740 bipolar_23\JJ\1740 disorder_24\NN\14034177 or_25\CC\3541091 psychoses_26\NNS\14380140 ,_27\,\1740 with_28\IN\1740 <e1>risperidone-induced</e1>_29\JJ\1740 elevations_30\NNS\7445480 in_31\IN\13603305 serum_32\NN\5397468 prolactin_33\NN\5410315 levels_34\NNS\4916342 (_35\-LRB-\1740 57.5_36\CD\1740 -_37\SYM\1740 129_38\CD\1740 ng/ml_39\NN\1740 ,_40\,\1740 normal_41\JJ\1740 5_42\CD\13741022 -_43\SYM\1740 15_44\CD\13745420 ng/ml_45\NN\1740 )_46\-RRB-\1740 ,_47\,\1740 were_48\VBD\836236 treated_49\VBN\2376958 with_50\IN\1740 cabergoline_51\NN\1740 (_52\-LRB-\1740 mean_53\NN\6021761 dose_54\NN\3740161 2.13_55\CD\1740 +/-_56\CC\1740 0.09_57\CD\1740 mg/week_58\NN\1740 )_59\-RRB-\1740 ._60\.\1740
D018967_D001714 NONE results_0\NNS\34213 :_1\:\1740 four_2\CD\13741022 males_3\NNS\15388 (_4\-LRB-\1740 age_5\NN\4916342 6_6\CD\13741022 -_7\SYM\1740 11_8\CD\13745420 years_9\NNS\15144371 )_10\-RRB-\1740 with_11\IN\1740 diagnostic_12\NNP\1740 and_13\CC\1740 statistical_14\NNP\1740 manual_15\NNP\6421301 of_16\IN\1740 mental_17\NNP\1740 disorders_18\NNPS\14034177 (_19\-LRB-\1740 fourth_20\JJ\1740 edition_21\NN\6590210 )_22\-RRB-\1740 <e2>bipolar_23\JJ\1740 disorder</e2>_24\NN\14034177 or_25\CC\3541091 psychoses_26\NNS\14380140 ,_27\,\1740 with_28\IN\1740 <e1>risperidone-induced</e1>_29\JJ\1740 elevations_30\NNS\7445480 in_31\IN\13603305 serum_32\NN\5397468 prolactin_33\NN\5410315 levels_34\NNS\4916342 (_35\-LRB-\1740 57.5_36\CD\1740 -_37\SYM\1740 129_38\CD\1740 ng/ml_39\NN\1740 ,_40\,\1740 normal_41\JJ\1740 5_42\CD\13741022 -_43\SYM\1740 15_44\CD\13745420 ng/ml_45\NN\1740 )_46\-RRB-\1740 ,_47\,\1740 were_48\VBD\836236 treated_49\VBN\2376958 with_50\IN\1740 cabergoline_51\NN\1740 (_52\-LRB-\1740 mean_53\NN\6021761 dose_54\NN\3740161 2.13_55\CD\1740 +/-_56\CC\1740 0.09_57\CD\1740 mg/week_58\NN\1740 )_59\-RRB-\1740 ._60\.\1740
D018967_D011605 NONE results_0\NNS\34213 :_1\:\1740 four_2\CD\13741022 males_3\NNS\15388 (_4\-LRB-\1740 age_5\NN\4916342 6_6\CD\13741022 -_7\SYM\1740 11_8\CD\13745420 years_9\NNS\15144371 )_10\-RRB-\1740 with_11\IN\1740 diagnostic_12\NNP\1740 and_13\CC\1740 statistical_14\NNP\1740 manual_15\NNP\6421301 of_16\IN\1740 mental_17\NNP\1740 disorders_18\NNPS\14034177 (_19\-LRB-\1740 fourth_20\JJ\1740 edition_21\NN\6590210 )_22\-RRB-\1740 bipolar_23\JJ\1740 disorder_24\NN\14034177 or_25\CC\3541091 <e2>psychoses</e2>_26\NNS\14380140 ,_27\,\1740 with_28\IN\1740 <e1>risperidone-induced</e1>_29\JJ\1740 elevations_30\NNS\7445480 in_31\IN\13603305 serum_32\NN\5397468 prolactin_33\NN\5410315 levels_34\NNS\4916342 (_35\-LRB-\1740 57.5_36\CD\1740 -_37\SYM\1740 129_38\CD\1740 ng/ml_39\NN\1740 ,_40\,\1740 normal_41\JJ\1740 5_42\CD\13741022 -_43\SYM\1740 15_44\CD\13745420 ng/ml_45\NN\1740 )_46\-RRB-\1740 ,_47\,\1740 were_48\VBD\836236 treated_49\VBN\2376958 with_50\IN\1740 cabergoline_51\NN\1740 (_52\-LRB-\1740 mean_53\NN\6021761 dose_54\NN\3740161 2.13_55\CD\1740 +/-_56\CC\1740 0.09_57\CD\1740 mg/week_58\NN\1740 )_59\-RRB-\1740 ._60\.\1740
C047047_D001523 NONE results_0\NNS\34213 :_1\:\1740 four_2\CD\13741022 males_3\NNS\15388 (_4\-LRB-\1740 age_5\NN\4916342 6_6\CD\13741022 -_7\SYM\1740 11_8\CD\13745420 years_9\NNS\15144371 )_10\-RRB-\1740 with_11\IN\1740 diagnostic_12\NNP\1740 and_13\CC\1740 statistical_14\NNP\1740 manual_15\NNP\6421301 of_16\IN\1740 <e2>mental_17\NNP\1740 disorders</e2>_18\NNPS\14034177 (_19\-LRB-\1740 fourth_20\JJ\1740 edition_21\NN\6590210 )_22\-RRB-\1740 bipolar_23\JJ\1740 disorder_24\NN\14034177 or_25\CC\3541091 psychoses_26\NNS\14380140 ,_27\,\1740 with_28\IN\1740 risperidone-induced_29\JJ\1740 elevations_30\NNS\7445480 in_31\IN\13603305 serum_32\NN\5397468 prolactin_33\NN\5410315 levels_34\NNS\4916342 (_35\-LRB-\1740 57.5_36\CD\1740 -_37\SYM\1740 129_38\CD\1740 ng/ml_39\NN\1740 ,_40\,\1740 normal_41\JJ\1740 5_42\CD\13741022 -_43\SYM\1740 15_44\CD\13745420 ng/ml_45\NN\1740 )_46\-RRB-\1740 ,_47\,\1740 were_48\VBD\836236 treated_49\VBN\2376958 with_50\IN\1740 <e1>cabergoline</e1>_51\NN\1740 (_52\-LRB-\1740 mean_53\NN\6021761 dose_54\NN\3740161 2.13_55\CD\1740 +/-_56\CC\1740 0.09_57\CD\1740 mg/week_58\NN\1740 )_59\-RRB-\1740 ._60\.\1740
C047047_D001714 NONE results_0\NNS\34213 :_1\:\1740 four_2\CD\13741022 males_3\NNS\15388 (_4\-LRB-\1740 age_5\NN\4916342 6_6\CD\13741022 -_7\SYM\1740 11_8\CD\13745420 years_9\NNS\15144371 )_10\-RRB-\1740 with_11\IN\1740 diagnostic_12\NNP\1740 and_13\CC\1740 statistical_14\NNP\1740 manual_15\NNP\6421301 of_16\IN\1740 mental_17\NNP\1740 disorders_18\NNPS\14034177 (_19\-LRB-\1740 fourth_20\JJ\1740 edition_21\NN\6590210 )_22\-RRB-\1740 <e2>bipolar_23\JJ\1740 disorder</e2>_24\NN\14034177 or_25\CC\3541091 psychoses_26\NNS\14380140 ,_27\,\1740 with_28\IN\1740 risperidone-induced_29\JJ\1740 elevations_30\NNS\7445480 in_31\IN\13603305 serum_32\NN\5397468 prolactin_33\NN\5410315 levels_34\NNS\4916342 (_35\-LRB-\1740 57.5_36\CD\1740 -_37\SYM\1740 129_38\CD\1740 ng/ml_39\NN\1740 ,_40\,\1740 normal_41\JJ\1740 5_42\CD\13741022 -_43\SYM\1740 15_44\CD\13745420 ng/ml_45\NN\1740 )_46\-RRB-\1740 ,_47\,\1740 were_48\VBD\836236 treated_49\VBN\2376958 with_50\IN\1740 <e1>cabergoline</e1>_51\NN\1740 (_52\-LRB-\1740 mean_53\NN\6021761 dose_54\NN\3740161 2.13_55\CD\1740 +/-_56\CC\1740 0.09_57\CD\1740 mg/week_58\NN\1740 )_59\-RRB-\1740 ._60\.\1740
C047047_D011605 NONE results_0\NNS\34213 :_1\:\1740 four_2\CD\13741022 males_3\NNS\15388 (_4\-LRB-\1740 age_5\NN\4916342 6_6\CD\13741022 -_7\SYM\1740 11_8\CD\13745420 years_9\NNS\15144371 )_10\-RRB-\1740 with_11\IN\1740 diagnostic_12\NNP\1740 and_13\CC\1740 statistical_14\NNP\1740 manual_15\NNP\6421301 of_16\IN\1740 mental_17\NNP\1740 disorders_18\NNPS\14034177 (_19\-LRB-\1740 fourth_20\JJ\1740 edition_21\NN\6590210 )_22\-RRB-\1740 bipolar_23\JJ\1740 disorder_24\NN\14034177 or_25\CC\3541091 <e2>psychoses</e2>_26\NNS\14380140 ,_27\,\1740 with_28\IN\1740 risperidone-induced_29\JJ\1740 elevations_30\NNS\7445480 in_31\IN\13603305 serum_32\NN\5397468 prolactin_33\NN\5410315 levels_34\NNS\4916342 (_35\-LRB-\1740 57.5_36\CD\1740 -_37\SYM\1740 129_38\CD\1740 ng/ml_39\NN\1740 ,_40\,\1740 normal_41\JJ\1740 5_42\CD\13741022 -_43\SYM\1740 15_44\CD\13745420 ng/ml_45\NN\1740 )_46\-RRB-\1740 ,_47\,\1740 were_48\VBD\836236 treated_49\VBN\2376958 with_50\IN\1740 <e1>cabergoline</e1>_51\NN\1740 (_52\-LRB-\1740 mean_53\NN\6021761 dose_54\NN\3740161 2.13_55\CD\1740 +/-_56\CC\1740 0.09_57\CD\1740 mg/week_58\NN\1740 )_59\-RRB-\1740 ._60\.\1740
16192988
D008694_D001523 CID <e1>methamphetamine</e1>_0\NNP\2704153 causes_1\VBZ\1617192 alterations_2\NNS\7283608 in_3\IN\13603305 the_4\DT\1740 map_5\NN\4076846 kinase-related_6\JJ\1740 pathways_7\NNS\5483677 in_8\IN\13603305 the_9\DT\1740 brains_10\NNS\5462674 of_11\IN\1740 mice_12\NNS\2329401 that_13\WDT\1740 display_14\VBP\2137132 increased_15\VBN\169651 <e2>aggressiveness</e2>_16\NN\4835724 ._17\.\1740
D008694_D001523 CID <e2>aggressive_0\JJ\1740 behaviors</e2>_1\NNS\407535 have_2\VBP\2108377 been_3\VBN\836236 reported_4\VBN\831651 in_5\IN\13603305 patients_6\NNS\9898892 who_7\WP\8299493 suffer_8\VBP\2110220 from_9\IN\1740 some_10\DT\1740 psychiatric_11\JJ\1740 disorders_12\NNS\14034177 ,_13\,\1740 and_14\CC\1740 are_15\VBP\836236 common_16\JJ\1740 in_17\IN\13603305 <e1>methamphetamine</e1>_18\NN\2704153 (_19\-LRB-\1740 meth_20\NN\2704153 )_21\-RRB-\1740 abusers_22\NNS\9633969 ._23\.\1740
D008694_D001523 CID aggressive_0\JJ\1740 behaviors_1\NNS\407535 have_2\VBP\2108377 been_3\VBN\836236 reported_4\VBN\831651 in_5\IN\13603305 patients_6\NNS\9898892 who_7\WP\8299493 suffer_8\VBP\2110220 from_9\IN\1740 some_10\DT\1740 <e2>psychiatric_11\JJ\1740 disorders</e2>_12\NNS\14034177 ,_13\,\1740 and_14\CC\1740 are_15\VBP\836236 common_16\JJ\1740 in_17\IN\13603305 <e1>methamphetamine</e1>_18\NN\2704153 (_19\-LRB-\1740 meth_20\NN\2704153 )_21\-RRB-\1740 abusers_22\NNS\9633969 ._23\.\1740
D008694_D001523 CID <e2>aggressive_0\JJ\1740 behaviors</e2>_1\NNS\407535 have_2\VBP\2108377 been_3\VBN\836236 reported_4\VBN\831651 in_5\IN\13603305 patients_6\NNS\9898892 who_7\WP\8299493 suffer_8\VBP\2110220 from_9\IN\1740 some_10\DT\1740 psychiatric_11\JJ\1740 disorders_12\NNS\14034177 ,_13\,\1740 and_14\CC\1740 are_15\VBP\836236 common_16\JJ\1740 in_17\IN\13603305 methamphetamine_18\NN\2704153 (_19\-LRB-\1740 <e1>meth</e1>_20\NN\2704153 )_21\-RRB-\1740 abusers_22\NNS\9633969 ._23\.\1740
D008694_D001523 CID aggressive_0\JJ\1740 behaviors_1\NNS\407535 have_2\VBP\2108377 been_3\VBN\836236 reported_4\VBN\831651 in_5\IN\13603305 patients_6\NNS\9898892 who_7\WP\8299493 suffer_8\VBP\2110220 from_9\IN\1740 some_10\DT\1740 <e2>psychiatric_11\JJ\1740 disorders</e2>_12\NNS\14034177 ,_13\,\1740 and_14\CC\1740 are_15\VBP\836236 common_16\JJ\1740 in_17\IN\13603305 methamphetamine_18\NN\2704153 (_19\-LRB-\1740 <e1>meth</e1>_20\NN\2704153 )_21\-RRB-\1740 abusers_22\NNS\9633969 ._23\.\1740
D008694_D001523 CID herein_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 report_3\VBP\831651 that_4\IN\1740 multiple_5\JJ\1740 (_6\-LRB-\1740 but_7\CC\1740 not_8\RB\1740 single_9\JJ\1740 )_10\-RRB-\1740 injections_11\NNS\320852 of_12\IN\1740 <e1>meth</e1>_13\NN\2704153 significantly_14\RB\1740 increased_15\VBD\169651 <e2>aggressiveness</e2>_16\NN\4835724 in_17\IN\13603305 male_18\JJ\1740 cd-1_19\NN\1740 mice_20\NNS\2329401 ._21\.\1740
D008694_D001523 CID this_0\DT\1740 increase_1\NN\13576355 in_2\IN\13603305 <e2>aggressiveness</e2>_3\NN\4835724 was_4\VBD\836236 not_5\RB\1740 secondary_6\JJ\1740 to_7\TO\1740 <e1>meth-induced</e1>_8\JJ\1740 hyperactivity_9\NN\14052403 ._10\.\1740
D008694_D006948 NONE this_0\DT\1740 increase_1\NN\13576355 in_2\IN\13603305 aggressiveness_3\NN\4835724 was_4\VBD\836236 not_5\RB\1740 secondary_6\JJ\1740 to_7\TO\1740 <e1>meth-induced</e1>_8\JJ\1740 <e2>hyperactivity</e2>_9\NN\14052403 ._10\.\1740
1732442
D004317_D009202 CID detection_0\NN\5708432 of_1\IN\1740 abnormal_2\JJ\1740 cardiac_3\JJ\1740 adrenergic_4\JJ\1740 neuron_5\NN\5430628 activity_6\NN\30358 in_7\IN\13603305 <e1>adriamycin-induced</e1>_8\JJ\1740 <e2>cardiomyopathy</e2>_9\NN\14103288 with_10\IN\1740 iodine-125-metaiodobenzylguanidine_11\NN\1740 ._12\.\1740
D004317_D009202 CID using_0\VBG\1156834 a_1\DT\13649268 rat_2\NN\2329401 model_3\NN\5888929 of_4\IN\1740 <e1>adriamycin-induced</e1>_5\JJ\1740 <e2>cardiomyopathy</e2>_6\NN\14103288 ,_7\,\1740 we_8\PRP\1740 tested_9\VBD\670261 the_10\DT\1740 hypothesis_11\NN\7162194 that_12\IN\1740 abnormal_13\JJ\1740 cardiac_14\JJ\1740 adrenergic_15\JJ\1740 neuron_16\NN\5430628 activity_17\NN\30358 may_18\MD\15209706 appear_19\VB\2604760 and_20\CC\1740 be_21\VB\836236 exacerbated_22\VBN\126264 dose-dependently_23\RB\1740 in_24\IN\13603305 adriamycin_25\NN\1740 cardiomyopathy_26\JJ\1740 ._27\.\1740
D004317_D009202 CID using_0\VBG\1156834 a_1\DT\13649268 rat_2\NN\2329401 model_3\NN\5888929 of_4\IN\1740 <e1>adriamycin-induced</e1>_5\JJ\1740 cardiomyopathy_6\NN\14103288 ,_7\,\1740 we_8\PRP\1740 tested_9\VBD\670261 the_10\DT\1740 hypothesis_11\NN\7162194 that_12\IN\1740 abnormal_13\JJ\1740 cardiac_14\JJ\1740 adrenergic_15\JJ\1740 neuron_16\NN\5430628 activity_17\NN\30358 may_18\MD\15209706 appear_19\VB\2604760 and_20\CC\1740 be_21\VB\836236 exacerbated_22\VBN\126264 dose-dependently_23\RB\1740 in_24\IN\13603305 adriamycin_25\NN\1740 <e2>cardiomyopathy</e2>_26\JJ\1740 ._27\.\1740
D004317_D009202 CID using_0\VBG\1156834 a_1\DT\13649268 rat_2\NN\2329401 model_3\NN\5888929 of_4\IN\1740 adriamycin-induced_5\JJ\1740 <e2>cardiomyopathy</e2>_6\NN\14103288 ,_7\,\1740 we_8\PRP\1740 tested_9\VBD\670261 the_10\DT\1740 hypothesis_11\NN\7162194 that_12\IN\1740 abnormal_13\JJ\1740 cardiac_14\JJ\1740 adrenergic_15\JJ\1740 neuron_16\NN\5430628 activity_17\NN\30358 may_18\MD\15209706 appear_19\VB\2604760 and_20\CC\1740 be_21\VB\836236 exacerbated_22\VBN\126264 dose-dependently_23\RB\1740 in_24\IN\13603305 <e1>adriamycin</e1>_25\NN\1740 cardiomyopathy_26\JJ\1740 ._27\.\1740
D004317_D009202 CID using_0\VBG\1156834 a_1\DT\13649268 rat_2\NN\2329401 model_3\NN\5888929 of_4\IN\1740 adriamycin-induced_5\JJ\1740 cardiomyopathy_6\NN\14103288 ,_7\,\1740 we_8\PRP\1740 tested_9\VBD\670261 the_10\DT\1740 hypothesis_11\NN\7162194 that_12\IN\1740 abnormal_13\JJ\1740 cardiac_14\JJ\1740 adrenergic_15\JJ\1740 neuron_16\NN\5430628 activity_17\NN\30358 may_18\MD\15209706 appear_19\VB\2604760 and_20\CC\1740 be_21\VB\836236 exacerbated_22\VBN\126264 dose-dependently_23\RB\1740 in_24\IN\13603305 <e1>adriamycin</e1>_25\NN\1740 <e2>cardiomyopathy</e2>_26\JJ\1740 ._27\.\1740
D004317_D009202 CID the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 impaired_3\JJ\1740 cardiac_4\JJ\1740 adrenergic_5\JJ\1740 neuron_6\NN\5430628 activity_7\NN\30358 in_8\IN\13603305 the_9\DT\1740 presence_10\NN\13954253 of_11\IN\1740 slight_12\JJ\1740 <e2>myocardial_13\JJ\1740 impairment</e2>_14\NN\7296428 (_15\-LRB-\1740 scattered_16\JJ\1740 or_17\CC\3541091 focal_18\JJ\1740 vacuolar_19\JJ\1740 degeneration_20\NN\29677 )_21\-RRB-\1740 indicates_22\VBZ\952524 that_23\IN\1740 mibg_24\NNP\1740 scintigraphy_25\NN\1740 may_26\MD\15209706 be_27\VB\836236 a_28\DT\13649268 useful_29\JJ\1740 method_30\NN\5616786 for_31\IN\1740 detection_32\NN\5708432 of_33\IN\1740 <e1>adriamycin-induced</e1>_34\JJ\1740 cardiomyopathy_35\NN\14103288 ._36\.\1740
D004317_D009202 CID the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 impaired_3\JJ\1740 cardiac_4\JJ\1740 adrenergic_5\JJ\1740 neuron_6\NN\5430628 activity_7\NN\30358 in_8\IN\13603305 the_9\DT\1740 presence_10\NN\13954253 of_11\IN\1740 slight_12\JJ\1740 myocardial_13\JJ\1740 impairment_14\NN\7296428 (_15\-LRB-\1740 scattered_16\JJ\1740 or_17\CC\3541091 focal_18\JJ\1740 vacuolar_19\JJ\1740 degeneration_20\NN\29677 )_21\-RRB-\1740 indicates_22\VBZ\952524 that_23\IN\1740 mibg_24\NNP\1740 scintigraphy_25\NN\1740 may_26\MD\15209706 be_27\VB\836236 a_28\DT\13649268 useful_29\JJ\1740 method_30\NN\5616786 for_31\IN\1740 detection_32\NN\5708432 of_33\IN\1740 <e1>adriamycin-induced</e1>_34\JJ\1740 <e2>cardiomyopathy</e2>_35\NN\14103288 ._36\.\1740
D019797_D009202 NONE detection_0\NN\5708432 of_1\IN\1740 abnormal_2\JJ\1740 cardiac_3\JJ\1740 adrenergic_4\JJ\1740 neuron_5\NN\5430628 activity_6\NN\30358 in_7\IN\13603305 adriamycin-induced_8\JJ\1740 <e2>cardiomyopathy</e2>_9\NN\14103288 with_10\IN\1740 <e1>iodine-125-metaiodobenzylguanidine</e1>_11\NN\1740 ._12\.\1740
D019797_D009202 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 impaired_3\JJ\1740 cardiac_4\JJ\1740 adrenergic_5\JJ\1740 neuron_6\NN\5430628 activity_7\NN\30358 in_8\IN\13603305 the_9\DT\1740 presence_10\NN\13954253 of_11\IN\1740 slight_12\JJ\1740 <e2>myocardial_13\JJ\1740 impairment</e2>_14\NN\7296428 (_15\-LRB-\1740 scattered_16\JJ\1740 or_17\CC\3541091 focal_18\JJ\1740 vacuolar_19\JJ\1740 degeneration_20\NN\29677 )_21\-RRB-\1740 indicates_22\VBZ\952524 that_23\IN\1740 <e1>mibg</e1>_24\NNP\1740 scintigraphy_25\NN\1740 may_26\MD\15209706 be_27\VB\836236 a_28\DT\13649268 useful_29\JJ\1740 method_30\NN\5616786 for_31\IN\1740 detection_32\NN\5708432 of_33\IN\1740 adriamycin-induced_34\JJ\1740 cardiomyopathy_35\NN\14103288 ._36\.\1740
D019797_D009202 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 impaired_3\JJ\1740 cardiac_4\JJ\1740 adrenergic_5\JJ\1740 neuron_6\NN\5430628 activity_7\NN\30358 in_8\IN\13603305 the_9\DT\1740 presence_10\NN\13954253 of_11\IN\1740 slight_12\JJ\1740 myocardial_13\JJ\1740 impairment_14\NN\7296428 (_15\-LRB-\1740 scattered_16\JJ\1740 or_17\CC\3541091 focal_18\JJ\1740 vacuolar_19\JJ\1740 degeneration_20\NN\29677 )_21\-RRB-\1740 indicates_22\VBZ\952524 that_23\IN\1740 <e1>mibg</e1>_24\NNP\1740 scintigraphy_25\NN\1740 may_26\MD\15209706 be_27\VB\836236 a_28\DT\13649268 useful_29\JJ\1740 method_30\NN\5616786 for_31\IN\1740 detection_32\NN\5708432 of_33\IN\1740 adriamycin-induced_34\JJ\1740 <e2>cardiomyopathy</e2>_35\NN\14103288 ._36\.\1740
D004317_C536522 NONE the_0\DT\1740 degree_1\NN\4916342 of_2\IN\1740 <e2>vacuolar_3\JJ\1740 degeneration_4\NN\29677 of_5\IN\1740 myocardial_6\JJ\1740 cells</e2>_7\NNS\3080309 was_8\VBD\836236 analyzed_9\VBN\78760 in_10\IN\13603305 relation_11\NN\2137 to_12\TO\1740 the_13\DT\1740 duration_14\NN\15113229 of_15\IN\1740 <e1>adriamycin</e1>_16\NN\1740 treatment_17\NN\654885 (_18\-LRB-\1740 2_19\CD\13741022 mg/kg_20\NN\1740 ,_21\,\1740 once_22\RB\1740 a_23\DT\13649268 week_24\NN\15113229 )_25\-RRB-\1740 ._26\.\1740
D004317_C536522 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 impaired_3\JJ\1740 cardiac_4\JJ\1740 adrenergic_5\JJ\1740 neuron_6\NN\5430628 activity_7\NN\30358 in_8\IN\13603305 the_9\DT\1740 presence_10\NN\13954253 of_11\IN\1740 slight_12\JJ\1740 myocardial_13\JJ\1740 impairment_14\NN\7296428 (_15\-LRB-\1740 scattered_16\JJ\1740 or_17\CC\3541091 focal_18\JJ\1740 <e2>vacuolar_19\JJ\1740 degeneration</e2>_20\NN\29677 )_21\-RRB-\1740 indicates_22\VBZ\952524 that_23\IN\1740 mibg_24\NNP\1740 scintigraphy_25\NN\1740 may_26\MD\15209706 be_27\VB\836236 a_28\DT\13649268 useful_29\JJ\1740 method_30\NN\5616786 for_31\IN\1740 detection_32\NN\5708432 of_33\IN\1740 <e1>adriamycin-induced</e1>_34\JJ\1740 cardiomyopathy_35\NN\14103288 ._36\.\1740
D019797_C536522 NONE the_0\DT\1740 appearance_1\NN\4723816 of_2\IN\1740 impaired_3\JJ\1740 cardiac_4\JJ\1740 adrenergic_5\JJ\1740 neuron_6\NN\5430628 activity_7\NN\30358 in_8\IN\13603305 the_9\DT\1740 presence_10\NN\13954253 of_11\IN\1740 slight_12\JJ\1740 myocardial_13\JJ\1740 impairment_14\NN\7296428 (_15\-LRB-\1740 scattered_16\JJ\1740 or_17\CC\3541091 focal_18\JJ\1740 <e2>vacuolar_19\JJ\1740 degeneration</e2>_20\NN\29677 )_21\-RRB-\1740 indicates_22\VBZ\952524 that_23\IN\1740 <e1>mibg</e1>_24\NNP\1740 scintigraphy_25\NN\1740 may_26\MD\15209706 be_27\VB\836236 a_28\DT\13649268 useful_29\JJ\1740 method_30\NN\5616786 for_31\IN\1740 detection_32\NN\5708432 of_33\IN\1740 adriamycin-induced_34\JJ\1740 cardiomyopathy_35\NN\14103288 ._36\.\1740
11890511
33969
C084820_D010302 NONE <e1>ethopropazine</e1>_0\NN\1740 and_1\CC\1740 benztropine_2\NN\1740 in_3\IN\13603305 neuroleptic-induced_4\JJ\1740 <e2>parkinsonism</e2>_5\NN\14085708 ._6\.\1740
C084820_D010302 NONE in_0\IN\13603305 a_1\DT\13649268 12-week_2\NN\1740 controlled_3\VBN\2422663 study_4\NN\635850 <e1>ethopropazine</e1>_5\NN\1740 was_6\VBD\836236 compared_7\VBN\644583 to_8\TO\1740 benztropine_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 treatment_12\NN\654885 of_13\IN\1740 <e2>parkinsonism</e2>_14\NN\14085708 induced_15\VBN\1627355 by_16\IN\1740 fluphenazine_17\NN\3713736 enanthate_18\NN\1740 in_19\IN\13603305 60_20\CD\13745420 schizophrenic_21\JJ\1740 outpatients_22\NNS\10405694 ._23\.\1740
C084820_D010302 NONE <e1>ethopropazine</e1>_0\NN\1740 and_1\CC\1740 benztropine_2\NN\1740 were_3\VBD\836236 found_4\VBN\2426171 to_5\TO\1740 be_6\VB\836236 equally_7\RB\1740 effective_8\JJ\1740 in_9\IN\13603305 controlling_10\VBG\2422663 <e2>parkinsonian_11\JJ\1740 symptoms</e2>_12\NNS\5823932 and_13\CC\1740 were_14\VBD\836236 as_15\RB\1740 efficacious_16\JJ\1740 as_17\IN\14622893 procyclidine_18\NN\3800001 ,_19\,\1740 their_20\PRP$\1740 previous_21\JJ\1740 antiparkinsonian_22\NN\1740 drug_23\NN\14778436 ._24\.\1740
D001590_D010302 NONE ethopropazine_0\NN\1740 and_1\CC\1740 <e1>benztropine</e1>_2\NN\1740 in_3\IN\13603305 neuroleptic-induced_4\JJ\1740 <e2>parkinsonism</e2>_5\NN\14085708 ._6\.\1740
D001590_D010302 NONE in_0\IN\13603305 a_1\DT\13649268 12-week_2\NN\1740 controlled_3\VBN\2422663 study_4\NN\635850 ethopropazine_5\NN\1740 was_6\VBD\836236 compared_7\VBN\644583 to_8\TO\1740 <e1>benztropine</e1>_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 treatment_12\NN\654885 of_13\IN\1740 <e2>parkinsonism</e2>_14\NN\14085708 induced_15\VBN\1627355 by_16\IN\1740 fluphenazine_17\NN\3713736 enanthate_18\NN\1740 in_19\IN\13603305 60_20\CD\13745420 schizophrenic_21\JJ\1740 outpatients_22\NNS\10405694 ._23\.\1740
D001590_D010302 NONE ethopropazine_0\NN\1740 and_1\CC\1740 <e1>benztropine</e1>_2\NN\1740 were_3\VBD\836236 found_4\VBN\2426171 to_5\TO\1740 be_6\VB\836236 equally_7\RB\1740 effective_8\JJ\1740 in_9\IN\13603305 controlling_10\VBG\2422663 <e2>parkinsonian_11\JJ\1740 symptoms</e2>_12\NNS\5823932 and_13\CC\1740 were_14\VBD\836236 as_15\RB\1740 efficacious_16\JJ\1740 as_17\IN\14622893 procyclidine_18\NN\3800001 ,_19\,\1740 their_20\PRP$\1740 previous_21\JJ\1740 antiparkinsonian_22\NN\1740 drug_23\NN\14778436 ._24\.\1740
D001590_D010302 NONE this_0\DT\1740 suggests_1\VBZ\1010118 that_2\IN\1740 <e1>benztropine</e1>_3\NN\1740 is_4\VBZ\836236 not_5\RB\1740 the_6\DT\1740 anticholinergic_7\JJ\1740 drug_8\NN\14778436 of_9\IN\1740 choice_10\NN\5788149 in_11\IN\13603305 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 neuroleptic-induced_15\JJ\1740 <e2>parkinsonian_16\JJ\1740 symptoms</e2>_17\NNS\5823932 ,_18\,\1740 because_19\IN\1740 of_20\IN\1740 its_21\PRP$\6125041 more_22\JJR\1740 toxic_23\JJ\1740 central_24\JJ\1740 and_25\CC\1740 peripheral_26\JJ\1740 atropinic_27\JJ\1740 effect_28\NN\34213 ._29\.\1740
C084820_D012559 NONE in_0\IN\13603305 a_1\DT\13649268 12-week_2\NN\1740 controlled_3\VBN\2422663 study_4\NN\635850 <e1>ethopropazine</e1>_5\NN\1740 was_6\VBD\836236 compared_7\VBN\644583 to_8\TO\1740 benztropine_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 treatment_12\NN\654885 of_13\IN\1740 parkinsonism_14\NN\14085708 induced_15\VBN\1627355 by_16\IN\1740 fluphenazine_17\NN\3713736 enanthate_18\NN\1740 in_19\IN\13603305 60_20\CD\13745420 <e2>schizophrenic</e2>_21\JJ\1740 outpatients_22\NNS\10405694 ._23\.\1740
D001590_D012559 NONE in_0\IN\13603305 a_1\DT\13649268 12-week_2\NN\1740 controlled_3\VBN\2422663 study_4\NN\635850 ethopropazine_5\NN\1740 was_6\VBD\836236 compared_7\VBN\644583 to_8\TO\1740 <e1>benztropine</e1>_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 treatment_12\NN\654885 of_13\IN\1740 parkinsonism_14\NN\14085708 induced_15\VBN\1627355 by_16\IN\1740 fluphenazine_17\NN\3713736 enanthate_18\NN\1740 in_19\IN\13603305 60_20\CD\13745420 <e2>schizophrenic</e2>_21\JJ\1740 outpatients_22\NNS\10405694 ._23\.\1740
C017610_D010302 CID in_0\IN\13603305 a_1\DT\13649268 12-week_2\NN\1740 controlled_3\VBN\2422663 study_4\NN\635850 ethopropazine_5\NN\1740 was_6\VBD\836236 compared_7\VBN\644583 to_8\TO\1740 benztropine_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 treatment_12\NN\654885 of_13\IN\1740 <e2>parkinsonism</e2>_14\NN\14085708 induced_15\VBN\1627355 by_16\IN\1740 <e1>fluphenazine_17\NN\3713736 enanthate</e1>_18\NN\1740 in_19\IN\13603305 60_20\CD\13745420 schizophrenic_21\JJ\1740 outpatients_22\NNS\10405694 ._23\.\1740
C017610_D012559 NONE in_0\IN\13603305 a_1\DT\13649268 12-week_2\NN\1740 controlled_3\VBN\2422663 study_4\NN\635850 ethopropazine_5\NN\1740 was_6\VBD\836236 compared_7\VBN\644583 to_8\TO\1740 benztropine_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 treatment_12\NN\654885 of_13\IN\1740 parkinsonism_14\NN\14085708 induced_15\VBN\1627355 by_16\IN\1740 <e1>fluphenazine_17\NN\3713736 enanthate</e1>_18\NN\1740 in_19\IN\13603305 60_20\CD\13745420 <e2>schizophrenic</e2>_21\JJ\1740 outpatients_22\NNS\10405694 ._23\.\1740
D011352_D010302 NONE ethopropazine_0\NN\1740 and_1\CC\1740 benztropine_2\NN\1740 were_3\VBD\836236 found_4\VBN\2426171 to_5\TO\1740 be_6\VB\836236 equally_7\RB\1740 effective_8\JJ\1740 in_9\IN\13603305 controlling_10\VBG\2422663 <e2>parkinsonian_11\JJ\1740 symptoms</e2>_12\NNS\5823932 and_13\CC\1740 were_14\VBD\836236 as_15\RB\1740 efficacious_16\JJ\1740 as_17\IN\14622893 <e1>procyclidine</e1>_18\NN\3800001 ,_19\,\1740 their_20\PRP$\1740 previous_21\JJ\1740 antiparkinsonian_22\NN\1740 drug_23\NN\14778436 ._24\.\1740
D001590_D004409 CID however_0\RB\1740 ,_1\,\1740 <e1>benztropine</e1>_2\NN\1740 treated_3\JJ\1740 patients_4\NNS\9898892 had_5\VBD\2108377 a_6\DT\13649268 significant_7\JJ\1740 increase_8\NN\13576355 in_9\IN\13603305 <e2>tardive_10\JJ\1740 dyskinesia</e2>_11\NN\14084880 compared_12\VBN\644583 to_13\TO\1740 their_14\PRP$\1740 condition_15\NN\24720 during_16\IN\1740 procyclindine_17\NN\1740 treatment_18\NN\654885 ,_19\,\1740 and_20\CC\1740 significantly_21\RB\1740 more_22\JJR\1740 anxiety_23\NN\14373582 and_24\CC\1740 depression_25\NN\14373582 than_26\IN\1740 ethopropazine_27\NN\1740 treated_28\JJ\1740 patients_29\NNS\9898892 ._30\.\1740
D001590_D001008 CID however_0\RB\1740 ,_1\,\1740 <e1>benztropine</e1>_2\NN\1740 treated_3\JJ\1740 patients_4\NNS\9898892 had_5\VBD\2108377 a_6\DT\13649268 significant_7\JJ\1740 increase_8\NN\13576355 in_9\IN\13603305 tardive_10\JJ\1740 dyskinesia_11\NN\14084880 compared_12\VBN\644583 to_13\TO\1740 their_14\PRP$\1740 condition_15\NN\24720 during_16\IN\1740 procyclindine_17\NN\1740 treatment_18\NN\654885 ,_19\,\1740 and_20\CC\1740 significantly_21\RB\1740 more_22\JJR\1740 <e2>anxiety</e2>_23\NN\14373582 and_24\CC\1740 depression_25\NN\14373582 than_26\IN\1740 ethopropazine_27\NN\1740 treated_28\JJ\1740 patients_29\NNS\9898892 ._30\.\1740
D001590_D003866 CID however_0\RB\1740 ,_1\,\1740 <e1>benztropine</e1>_2\NN\1740 treated_3\JJ\1740 patients_4\NNS\9898892 had_5\VBD\2108377 a_6\DT\13649268 significant_7\JJ\1740 increase_8\NN\13576355 in_9\IN\13603305 tardive_10\JJ\1740 dyskinesia_11\NN\14084880 compared_12\VBN\644583 to_13\TO\1740 their_14\PRP$\1740 condition_15\NN\24720 during_16\IN\1740 procyclindine_17\NN\1740 treatment_18\NN\654885 ,_19\,\1740 and_20\CC\1740 significantly_21\RB\1740 more_22\JJR\1740 anxiety_23\NN\14373582 and_24\CC\1740 <e2>depression</e2>_25\NN\14373582 than_26\IN\1740 ethopropazine_27\NN\1740 treated_28\JJ\1740 patients_29\NNS\9898892 ._30\.\1740
D011352_D004409 NONE however_0\RB\1740 ,_1\,\1740 benztropine_2\NN\1740 treated_3\JJ\1740 patients_4\NNS\9898892 had_5\VBD\2108377 a_6\DT\13649268 significant_7\JJ\1740 increase_8\NN\13576355 in_9\IN\13603305 <e2>tardive_10\JJ\1740 dyskinesia</e2>_11\NN\14084880 compared_12\VBN\644583 to_13\TO\1740 their_14\PRP$\1740 condition_15\NN\24720 during_16\IN\1740 <e1>procyclindine</e1>_17\NN\1740 treatment_18\NN\654885 ,_19\,\1740 and_20\CC\1740 significantly_21\RB\1740 more_22\JJR\1740 anxiety_23\NN\14373582 and_24\CC\1740 depression_25\NN\14373582 than_26\IN\1740 ethopropazine_27\NN\1740 treated_28\JJ\1740 patients_29\NNS\9898892 ._30\.\1740
D011352_D001008 NONE however_0\RB\1740 ,_1\,\1740 benztropine_2\NN\1740 treated_3\JJ\1740 patients_4\NNS\9898892 had_5\VBD\2108377 a_6\DT\13649268 significant_7\JJ\1740 increase_8\NN\13576355 in_9\IN\13603305 tardive_10\JJ\1740 dyskinesia_11\NN\14084880 compared_12\VBN\644583 to_13\TO\1740 their_14\PRP$\1740 condition_15\NN\24720 during_16\IN\1740 <e1>procyclindine</e1>_17\NN\1740 treatment_18\NN\654885 ,_19\,\1740 and_20\CC\1740 significantly_21\RB\1740 more_22\JJR\1740 <e2>anxiety</e2>_23\NN\14373582 and_24\CC\1740 depression_25\NN\14373582 than_26\IN\1740 ethopropazine_27\NN\1740 treated_28\JJ\1740 patients_29\NNS\9898892 ._30\.\1740
D011352_D003866 NONE however_0\RB\1740 ,_1\,\1740 benztropine_2\NN\1740 treated_3\JJ\1740 patients_4\NNS\9898892 had_5\VBD\2108377 a_6\DT\13649268 significant_7\JJ\1740 increase_8\NN\13576355 in_9\IN\13603305 tardive_10\JJ\1740 dyskinesia_11\NN\14084880 compared_12\VBN\644583 to_13\TO\1740 their_14\PRP$\1740 condition_15\NN\24720 during_16\IN\1740 <e1>procyclindine</e1>_17\NN\1740 treatment_18\NN\654885 ,_19\,\1740 and_20\CC\1740 significantly_21\RB\1740 more_22\JJR\1740 anxiety_23\NN\14373582 and_24\CC\1740 <e2>depression</e2>_25\NN\14373582 than_26\IN\1740 ethopropazine_27\NN\1740 treated_28\JJ\1740 patients_29\NNS\9898892 ._30\.\1740
C084820_D004409 NONE however_0\RB\1740 ,_1\,\1740 benztropine_2\NN\1740 treated_3\JJ\1740 patients_4\NNS\9898892 had_5\VBD\2108377 a_6\DT\13649268 significant_7\JJ\1740 increase_8\NN\13576355 in_9\IN\13603305 <e2>tardive_10\JJ\1740 dyskinesia</e2>_11\NN\14084880 compared_12\VBN\644583 to_13\TO\1740 their_14\PRP$\1740 condition_15\NN\24720 during_16\IN\1740 procyclindine_17\NN\1740 treatment_18\NN\654885 ,_19\,\1740 and_20\CC\1740 significantly_21\RB\1740 more_22\JJR\1740 anxiety_23\NN\14373582 and_24\CC\1740 depression_25\NN\14373582 than_26\IN\1740 <e1>ethopropazine</e1>_27\NN\1740 treated_28\JJ\1740 patients_29\NNS\9898892 ._30\.\1740
C084820_D001008 NONE however_0\RB\1740 ,_1\,\1740 benztropine_2\NN\1740 treated_3\JJ\1740 patients_4\NNS\9898892 had_5\VBD\2108377 a_6\DT\13649268 significant_7\JJ\1740 increase_8\NN\13576355 in_9\IN\13603305 tardive_10\JJ\1740 dyskinesia_11\NN\14084880 compared_12\VBN\644583 to_13\TO\1740 their_14\PRP$\1740 condition_15\NN\24720 during_16\IN\1740 procyclindine_17\NN\1740 treatment_18\NN\654885 ,_19\,\1740 and_20\CC\1740 significantly_21\RB\1740 more_22\JJR\1740 <e2>anxiety</e2>_23\NN\14373582 and_24\CC\1740 depression_25\NN\14373582 than_26\IN\1740 <e1>ethopropazine</e1>_27\NN\1740 treated_28\JJ\1740 patients_29\NNS\9898892 ._30\.\1740
C084820_D003866 NONE however_0\RB\1740 ,_1\,\1740 benztropine_2\NN\1740 treated_3\JJ\1740 patients_4\NNS\9898892 had_5\VBD\2108377 a_6\DT\13649268 significant_7\JJ\1740 increase_8\NN\13576355 in_9\IN\13603305 tardive_10\JJ\1740 dyskinesia_11\NN\14084880 compared_12\VBN\644583 to_13\TO\1740 their_14\PRP$\1740 condition_15\NN\24720 during_16\IN\1740 procyclindine_17\NN\1740 treatment_18\NN\654885 ,_19\,\1740 and_20\CC\1740 significantly_21\RB\1740 more_22\JJR\1740 anxiety_23\NN\14373582 and_24\CC\1740 <e2>depression</e2>_25\NN\14373582 than_26\IN\1740 <e1>ethopropazine</e1>_27\NN\1740 treated_28\JJ\1740 patients_29\NNS\9898892 ._30\.\1740
591536
D006493_D013923 NONE arterial_0\JJ\1740 <e2>thromboembolism</e2>_1\NN\14100769 in_2\IN\13603305 patients_3\NNS\9898892 receiving_4\VBG\2210855 systemic_5\JJ\1740 <e1>heparin</e1>_6\NN\2718259 therapy_7\NN\657604 :_8\:\1740 a_9\DT\13649268 complication_10\NN\1073995 associated_11\VBN\628491 with_12\IN\1740 heparin-induced_13\JJ\1740 thrombocytopenia_14\NN\14189204 ._15\.\1740
D006493_D013923 NONE arterial_0\JJ\1740 <e2>thromboembolism</e2>_1\NN\14100769 in_2\IN\13603305 patients_3\NNS\9898892 receiving_4\VBG\2210855 systemic_5\JJ\1740 heparin_6\NN\2718259 therapy_7\NN\657604 :_8\:\1740 a_9\DT\13649268 complication_10\NN\1073995 associated_11\VBN\628491 with_12\IN\1740 <e1>heparin-induced</e1>_13\JJ\1740 thrombocytopenia_14\NN\14189204 ._15\.\1740
D006493_D013923 NONE arterial_0\JJ\1740 <e2>thromboembolism</e2>_1\NN\14100769 is_2\VBZ\836236 a_3\DT\13649268 recognized_4\VBN\686447 complication_5\NN\1073995 of_6\IN\1740 systemic_7\JJ\1740 <e1>heparin</e1>_8\NN\2718259 therapy_9\NN\657604 ._10\.\1740
D006493_D013923 NONE the_0\DT\1740 common_1\JJ\1740 factor_2\NN\7326557 relating_3\NN\1740 <e2>thromboembolism</e2>_4\NN\14100769 and_5\CC\1740 thrombocytopenia_6\NN\14189204 is_7\VBZ\836236 <e1>heparin-induced</e1>_8\JJ\1740 platelet_9\NN\5432736 aggregation_10\NN\31264 ._11\.\1740
D006493_D013921 CID arterial_0\JJ\1740 thromboembolism_1\NN\14100769 in_2\IN\13603305 patients_3\NNS\9898892 receiving_4\VBG\2210855 systemic_5\JJ\1740 <e1>heparin</e1>_6\NN\2718259 therapy_7\NN\657604 :_8\:\1740 a_9\DT\13649268 complication_10\NN\1073995 associated_11\VBN\628491 with_12\IN\1740 heparin-induced_13\JJ\1740 <e2>thrombocytopenia</e2>_14\NN\14189204 ._15\.\1740
D006493_D013921 CID arterial_0\JJ\1740 thromboembolism_1\NN\14100769 in_2\IN\13603305 patients_3\NNS\9898892 receiving_4\VBG\2210855 systemic_5\JJ\1740 heparin_6\NN\2718259 therapy_7\NN\657604 :_8\:\1740 a_9\DT\13649268 complication_10\NN\1073995 associated_11\VBN\628491 with_12\IN\1740 <e1>heparin-induced</e1>_13\JJ\1740 <e2>thrombocytopenia</e2>_14\NN\14189204 ._15\.\1740
D006493_D013921 CID characteristic_0\JJ\1740 of_1\IN\1740 the_2\DT\1740 entity_3\NN\1740 is_4\VBZ\836236 arterial_5\JJ\1740 occlusion_6\NN\14081375 by_7\IN\1740 platelet-fibrin_8\NN\1740 thrombi_9\NN\5402091 with_10\IN\1740 distal_11\JJ\1740 ischemia_12\NN\14195315 occurring_13\VBG\2623529 four_14\CD\13741022 to_15\TO\1740 twenty_16\CD\13745420 days_17\NNS\15140892 after_18\IN\1740 the_19\DT\1740 initiation_20\NN\7450842 of_21\IN\1740 <e1>heparin</e1>_22\NN\2718259 therapy_23\NN\657604 ,_24\,\1740 preceded_25\VBN\2690708 by_26\IN\1740 profound_27\JJ\1740 <e2>thrombocytopenia</e2>_28\NN\14189204 with_29\IN\1740 platelet_30\NN\5432736 counts_31\NNS\13582013 in_32\IN\13603305 the_33\DT\1740 range_34\NN\5123416 of_35\IN\1740 30,000_36\CD\1740 to_37\TO\1740 40,000_38\CD\1740 per_39\IN\1740 cubic_40\JJ\1740 millimeter_41\NN\13649268 ._42\.\1740
D006493_D013921 CID the_0\DT\1740 common_1\JJ\1740 factor_2\NN\7326557 relating_3\NN\1740 thromboembolism_4\NN\14100769 and_5\CC\1740 <e2>thrombocytopenia</e2>_6\NN\14189204 is_7\VBZ\836236 <e1>heparin-induced</e1>_8\JJ\1740 platelet_9\NN\5432736 aggregation_10\NN\31264 ._11\.\1740
D006493_D001157 CID characteristic_0\JJ\1740 of_1\IN\1740 the_2\DT\1740 entity_3\NN\1740 is_4\VBZ\836236 <e2>arterial_5\JJ\1740 occlusion</e2>_6\NN\14081375 by_7\IN\1740 platelet-fibrin_8\NN\1740 thrombi_9\NN\5402091 with_10\IN\1740 distal_11\JJ\1740 ischemia_12\NN\14195315 occurring_13\VBG\2623529 four_14\CD\13741022 to_15\TO\1740 twenty_16\CD\13745420 days_17\NNS\15140892 after_18\IN\1740 the_19\DT\1740 initiation_20\NN\7450842 of_21\IN\1740 <e1>heparin</e1>_22\NN\2718259 therapy_23\NN\657604 ,_24\,\1740 preceded_25\VBN\2690708 by_26\IN\1740 profound_27\JJ\1740 thrombocytopenia_28\NN\14189204 with_29\IN\1740 platelet_30\NN\5432736 counts_31\NNS\13582013 in_32\IN\13603305 the_33\DT\1740 range_34\NN\5123416 of_35\IN\1740 30,000_36\CD\1740 to_37\TO\1740 40,000_38\CD\1740 per_39\IN\1740 cubic_40\JJ\1740 millimeter_41\NN\13649268 ._42\.\1740
D006493_D013927 NONE characteristic_0\JJ\1740 of_1\IN\1740 the_2\DT\1740 entity_3\NN\1740 is_4\VBZ\836236 arterial_5\JJ\1740 occlusion_6\NN\14081375 by_7\IN\1740 platelet-fibrin_8\NN\1740 <e2>thrombi</e2>_9\NN\5402091 with_10\IN\1740 distal_11\JJ\1740 ischemia_12\NN\14195315 occurring_13\VBG\2623529 four_14\CD\13741022 to_15\TO\1740 twenty_16\CD\13745420 days_17\NNS\15140892 after_18\IN\1740 the_19\DT\1740 initiation_20\NN\7450842 of_21\IN\1740 <e1>heparin</e1>_22\NN\2718259 therapy_23\NN\657604 ,_24\,\1740 preceded_25\VBN\2690708 by_26\IN\1740 profound_27\JJ\1740 thrombocytopenia_28\NN\14189204 with_29\IN\1740 platelet_30\NN\5432736 counts_31\NNS\13582013 in_32\IN\13603305 the_33\DT\1740 range_34\NN\5123416 of_35\IN\1740 30,000_36\CD\1740 to_37\TO\1740 40,000_38\CD\1740 per_39\IN\1740 cubic_40\JJ\1740 millimeter_41\NN\13649268 ._42\.\1740
D006493_D007511 NONE characteristic_0\JJ\1740 of_1\IN\1740 the_2\DT\1740 entity_3\NN\1740 is_4\VBZ\836236 arterial_5\JJ\1740 occlusion_6\NN\14081375 by_7\IN\1740 platelet-fibrin_8\NN\1740 thrombi_9\NN\5402091 with_10\IN\1740 distal_11\JJ\1740 <e2>ischemia</e2>_12\NN\14195315 occurring_13\VBG\2623529 four_14\CD\13741022 to_15\TO\1740 twenty_16\CD\13745420 days_17\NNS\15140892 after_18\IN\1740 the_19\DT\1740 initiation_20\NN\7450842 of_21\IN\1740 <e1>heparin</e1>_22\NN\2718259 therapy_23\NN\657604 ,_24\,\1740 preceded_25\VBN\2690708 by_26\IN\1740 profound_27\JJ\1740 thrombocytopenia_28\NN\14189204 with_29\IN\1740 platelet_30\NN\5432736 counts_31\NNS\13582013 in_32\IN\13603305 the_33\DT\1740 range_34\NN\5123416 of_35\IN\1740 30,000_36\CD\1740 to_37\TO\1740 40,000_38\CD\1740 per_39\IN\1740 cubic_40\JJ\1740 millimeter_41\NN\13649268 ._42\.\1740
D006493_D001791 NONE the_0\DT\1740 common_1\JJ\1740 factor_2\NN\7326557 relating_3\NN\1740 thromboembolism_4\NN\14100769 and_5\CC\1740 thrombocytopenia_6\NN\14189204 is_7\VBZ\836236 <e1>heparin-induced</e1>_8\JJ\1740 <e2>platelet_9\NN\5432736 aggregation</e2>_10\NN\31264 ._11\.\1740
133615
D003276_D013923 NONE <e2>thromboembolic</e2>_0\NN\1740 and_1\CC\1740 other_2\JJ\1740 complications_3\NNS\1073995 of_4\IN\1740 <e1>oral_5\JJ\1740 contraceptive</e1>_6\JJ\1740 therapy_7\NN\657604 in_8\IN\13603305 relationship_9\NN\31921 to_10\TO\1740 pretreatment_11\NN\1740 levels_12\NNS\4916342 of_13\IN\1740 blood_14\NN\5397468 coagulation_15\NN\13518963 factors_16\NNS\7326557 :_17\:\1740 summary_18\JJ\1740 report_19\NN\6470073 of_20\IN\1740 a_21\DT\13649268 ten-year_22\JJ\1740 study_23\NN\635850 ._24\.\1740
D003276_D001778 CID thromboembolic_0\NN\1740 and_1\CC\1740 other_2\JJ\1740 complications_3\NNS\1073995 of_4\IN\1740 <e1>oral_5\JJ\1740 contraceptive</e1>_6\JJ\1740 therapy_7\NN\657604 in_8\IN\13603305 relationship_9\NN\31921 to_10\TO\1740 pretreatment_11\NN\1740 levels_12\NNS\4916342 of_13\IN\1740 <e2>blood_14\NN\5397468 coagulation</e2>_15\NN\13518963 factors_16\NNS\7326557 :_17\:\1740 summary_18\JJ\1740 report_19\NN\6470073 of_20\IN\1740 a_21\DT\13649268 ten-year_22\JJ\1740 study_23\NN\635850 ._24\.\1740
19944333
C471405_D009203 NONE <e1>sorafenib-induced</e1>_0\JJ\1740 acute_1\JJ\1740 <e2>myocardial_2\JJ\1740 infarction</e2>_3\NN\14204950 due_4\JJ\1740 to_5\TO\1740 coronary_6\JJ\1740 artery_7\NN\5417975 spasm_8\NN\14299637 ._9\.\1740
C471405_D003329 CID <e1>sorafenib-induced</e1>_0\JJ\1740 acute_1\JJ\1740 myocardial_2\JJ\1740 infarction_3\NN\14204950 due_4\JJ\1740 to_5\TO\1740 <e2>coronary_6\JJ\1740 artery_7\NN\5417975 spasm</e2>_8\NN\14299637 ._9\.\1740
C471405_D003329 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 first_3\JJ\1740 case_4\NN\7283608 of_5\IN\1740 <e1>sorafenib-induced</e1>_6\JJ\1740 <e2>coronary_7\JJ\1740 artery_8\NN\5417975 spasm</e2>_9\NN\14299637 ._10\.\1740
D020108_D060050 NONE addition_0\NN\3081021 of_1\IN\1740 oral_2\JJ\1740 <e1>nicorandil</e1>_3\NN\1740 reduced_4\VBD\441445 his_5\PRP$\1740 symptoms_6\NNS\5823932 and_7\CC\1740 maintained_8\VBD\2202928 <e2>stable_9\JJ\1740 angina</e2>_10\JJ\1740 status_11\NN\24720 ._12\.\1740
16174948
D003042_D013345 CID absence_0\NN\14449405 of_1\IN\1740 acute_2\JJ\1740 cerebral_3\JJ\1740 vasoconstriction_4\NN\1149911 after_5\IN\1740 <e1>cocaine-associated</e1>_6\JJ\1740 <e2>subarachnoid_7\JJ\1740 hemorrhage</e2>_8\NN\14285662 ._9\.\1740
D003042_D013345 CID information_0\NN\6598915 on_1\IN\1740 these_2\DT\1740 effects_3\NNS\13245626 could_4\MD\1740 be_5\VB\836236 obtained_6\VBN\2210855 from_7\IN\1740 angiograms_8\NNS\4100620 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 <e1>cocaine-associated</e1>_12\JJ\1740 <e2>subarachnoid_13\JJ\1740 hemorrhage</e2>_14\NN\14285662 (_15\-LRB-\1740 sah_16\NN\1740 )_17\-RRB-\1740 who_18\WP\8299493 underwent_19\VBD\109660 angiography_20\NN\904623 shortly_21\RB\1740 after_22\IN\1740 cocaine_23\NN\3492717 use_24\NN\407535 ._25\.\1740
D003042_D013345 CID information_0\NN\6598915 on_1\IN\1740 these_2\DT\1740 effects_3\NNS\13245626 could_4\MD\1740 be_5\VB\836236 obtained_6\VBN\2210855 from_7\IN\1740 angiograms_8\NNS\4100620 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 <e1>cocaine-associated</e1>_12\JJ\1740 subarachnoid_13\JJ\1740 hemorrhage_14\NN\14285662 (_15\-LRB-\1740 <e2>sah</e2>_16\NN\1740 )_17\-RRB-\1740 who_18\WP\8299493 underwent_19\VBD\109660 angiography_20\NN\904623 shortly_21\RB\1740 after_22\IN\1740 cocaine_23\NN\3492717 use_24\NN\407535 ._25\.\1740
D003042_D013345 CID information_0\NN\6598915 on_1\IN\1740 these_2\DT\1740 effects_3\NNS\13245626 could_4\MD\1740 be_5\VB\836236 obtained_6\VBN\2210855 from_7\IN\1740 angiograms_8\NNS\4100620 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 cocaine-associated_12\JJ\1740 <e2>subarachnoid_13\JJ\1740 hemorrhage</e2>_14\NN\14285662 (_15\-LRB-\1740 sah_16\NN\1740 )_17\-RRB-\1740 who_18\WP\8299493 underwent_19\VBD\109660 angiography_20\NN\904623 shortly_21\RB\1740 after_22\IN\1740 <e1>cocaine</e1>_23\NN\3492717 use_24\NN\407535 ._25\.\1740
D003042_D013345 CID information_0\NN\6598915 on_1\IN\1740 these_2\DT\1740 effects_3\NNS\13245626 could_4\MD\1740 be_5\VB\836236 obtained_6\VBN\2210855 from_7\IN\1740 angiograms_8\NNS\4100620 of_9\IN\1740 patients_10\NNS\9898892 with_11\IN\1740 cocaine-associated_12\JJ\1740 subarachnoid_13\JJ\1740 hemorrhage_14\NN\14285662 (_15\-LRB-\1740 <e2>sah</e2>_16\NN\1740 )_17\-RRB-\1740 who_18\WP\8299493 underwent_19\VBD\109660 angiography_20\NN\904623 shortly_21\RB\1740 after_22\IN\1740 <e1>cocaine</e1>_23\NN\3492717 use_24\NN\407535 ._25\.\1740
D003042_D013345 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 screened_3\VBD\2533282 patients_4\NNS\9898892 with_5\IN\1740 <e2>sah</e2>_6\NN\1740 retrospectively_7\RB\1740 and_8\CC\1740 identified_9\VBD\699815 those_10\DT\1740 with_11\IN\1740 positive_12\JJ\1740 urine_13\NN\14853947 toxicology_14\NN\6054892 for_15\IN\1740 <e1>cocaine</e1>_16\NN\3492717 or_17\CC\3541091 its_18\PRP$\6125041 metabolites_19\NNS\20090 ._20\.\1740
D003042_D013345 CID conclusion_0\NN\5837957 :_1\:\1740 no_2\DT\7204911 quantitative_3\JJ\1740 evidence_4\NN\5816287 for_5\IN\1740 narrowing_6\NN\5064037 of_7\IN\1740 large_8\JJ\1740 cerebral_9\JJ\1740 arteries_10\NNS\5417975 or_11\CC\3541091 qualitative_12\JJ\1740 angiographic_13\JJ\1740 evidence_14\NN\5816287 for_15\IN\1740 distal_16\JJ\1740 narrowing_17\NN\5064037 or_18\CC\3541091 vasculitis_19\NN\14336539 could_20\MD\1740 be_21\VB\836236 found_22\VBN\2426171 in_23\IN\13603305 patients_24\NNS\9898892 who_25\WP\8299493 underwent_26\VBD\109660 angiography_27\NN\904623 after_28\IN\1740 aneurysmal_29\JJ\1740 <e2>sah</e2>_30\NN\1740 associated_31\VBN\628491 with_32\IN\1740 <e1>cocaine</e1>_33\NN\3492717 use_34\NN\407535 ._35\.\1740
D003042_D013901 NONE introduction_0\NNP\235435 :_1\:\1740 <e1>cocaine</e1>_2\NN\3492717 use_3\NN\407535 has_4\VBZ\2108377 been_5\VBN\836236 associated_6\VBN\628491 with_7\IN\1740 <e2>neurovascular_8\JJ\1740 complications</e2>_9\NNS\1073995 ,_10\,\1740 including_11\VBG\690614 arterial_12\JJ\1740 vasoconstriction_13\NN\1149911 and_14\CC\1740 vasculitis_15\NN\14336539 ._16\.\1740
D003042_D014657 NONE introduction_0\NNP\235435 :_1\:\1740 <e1>cocaine</e1>_2\NN\3492717 use_3\NN\407535 has_4\VBZ\2108377 been_5\VBN\836236 associated_6\VBN\628491 with_7\IN\1740 neurovascular_8\JJ\1740 complications_9\NNS\1073995 ,_10\,\1740 including_11\VBG\690614 arterial_12\JJ\1740 vasoconstriction_13\NN\1149911 and_14\CC\1740 <e2>vasculitis</e2>_15\NN\14336539 ._16\.\1740
D003042_D014657 NONE conclusion_0\NN\5837957 :_1\:\1740 no_2\DT\7204911 quantitative_3\JJ\1740 evidence_4\NN\5816287 for_5\IN\1740 narrowing_6\NN\5064037 of_7\IN\1740 large_8\JJ\1740 cerebral_9\JJ\1740 arteries_10\NNS\5417975 or_11\CC\3541091 qualitative_12\JJ\1740 angiographic_13\JJ\1740 evidence_14\NN\5816287 for_15\IN\1740 distal_16\JJ\1740 narrowing_17\NN\5064037 or_18\CC\3541091 <e2>vasculitis</e2>_19\NN\14336539 could_20\MD\1740 be_21\VB\836236 found_22\VBN\2426171 in_23\IN\13603305 patients_24\NNS\9898892 who_25\WP\8299493 underwent_26\VBD\109660 angiography_27\NN\904623 after_28\IN\1740 aneurysmal_29\JJ\1740 sah_30\NN\1740 associated_31\VBN\628491 with_32\IN\1740 <e1>cocaine</e1>_33\NN\3492717 use_34\NN\407535 ._35\.\1740
D003042_D017542 CID conclusion_0\NN\5837957 :_1\:\1740 no_2\DT\7204911 quantitative_3\JJ\1740 evidence_4\NN\5816287 for_5\IN\1740 narrowing_6\NN\5064037 of_7\IN\1740 large_8\JJ\1740 cerebral_9\JJ\1740 arteries_10\NNS\5417975 or_11\CC\3541091 qualitative_12\JJ\1740 angiographic_13\JJ\1740 evidence_14\NN\5816287 for_15\IN\1740 distal_16\JJ\1740 narrowing_17\NN\5064037 or_18\CC\3541091 vasculitis_19\NN\14336539 could_20\MD\1740 be_21\VB\836236 found_22\VBN\2426171 in_23\IN\13603305 patients_24\NNS\9898892 who_25\WP\8299493 underwent_26\VBD\109660 angiography_27\NN\904623 after_28\IN\1740 <e2>aneurysmal</e2>_29\JJ\1740 sah_30\NN\1740 associated_31\VBN\628491 with_32\IN\1740 <e1>cocaine</e1>_33\NN\3492717 use_34\NN\407535 ._35\.\1740
8267029
D010396_D005921 CID <e1>penicillamine-induced</e1>_0\JJ\1740 rapidly_1\RB\1740 progressive_2\JJ\1740 <e2>glomerulonephritis</e2>_3\NN\14113798 in_4\IN\13603305 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 rheumatoid_8\JJ\1740 arthritis_9\NN\14171682 ._10\.\1740
D010396_D005921 CID a_0\DT\13649268 67-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 presented_6\VBD\2137132 rapidly_7\RB\1740 progressive_8\JJ\1740 <e2>glomerulonephritis</e2>_9\NN\14113798 (_10\-LRB-\1740 rpgn_11\NN\1740 )_12\-RRB-\1740 after_13\IN\1740 5_14\CD\13741022 months_15\NNS\15113229 of_16\IN\1740 <e1>d-penicillamine</e1>_17\NN\1740 (_18\-LRB-\1740 250_19\CD\1740 mg/day_20\NN\1740 )_21\-RRB-\1740 treatment_22\NN\654885 ._23\.\1740
D010396_D005921 CID a_0\DT\13649268 67-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 presented_6\VBD\2137132 rapidly_7\RB\1740 progressive_8\JJ\1740 glomerulonephritis_9\NN\14113798 (_10\-LRB-\1740 <e2>rpgn</e2>_11\NN\1740 )_12\-RRB-\1740 after_13\IN\1740 5_14\CD\13741022 months_15\NNS\15113229 of_16\IN\1740 <e1>d-penicillamine</e1>_17\NN\1740 (_18\-LRB-\1740 250_19\CD\1740 mg/day_20\NN\1740 )_21\-RRB-\1740 treatment_22\NN\654885 ._23\.\1740
D010396_D005921 CID this_0\DT\1740 new_1\JJ\1740 case_2\NN\7283608 of_3\IN\1740 <e2>rpgn</e2>_4\NN\1740 in_5\IN\13603305 the_6\DT\1740 course_7\NN\883297 of_8\IN\1740 <e1>d-penicillamine</e1>_9\NN\1740 treatment_10\NN\654885 emphasizes_11\VBZ\943837 the_12\DT\1740 need_13\NN\13920835 for_14\IN\1740 frequent_15\JJ\1740 monitoring_16\NN\879759 of_17\IN\1740 renal_18\JJ\1740 function_19\NN\13783581 and_20\CC\1740 evaluation_21\NN\874067 of_22\IN\1740 urinary_23\JJ\1740 sediment_24\NN\20827 and_25\CC\1740 proteinuria_26\NN\14299637 in_27\IN\13603305 these_28\DT\1740 patients_29\NNS\9898892 ._30\.\1740
D010396_D001172 NONE <e1>penicillamine-induced</e1>_0\JJ\1740 rapidly_1\RB\1740 progressive_2\JJ\1740 glomerulonephritis_3\NN\14113798 in_4\IN\13603305 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 <e2>rheumatoid_8\JJ\1740 arthritis</e2>_9\NN\14171682 ._10\.\1740
D010396_D001172 NONE a_0\DT\13649268 67-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 <e2>rheumatoid_4\JJ\1740 arthritis</e2>_5\NN\14171682 presented_6\VBD\2137132 rapidly_7\RB\1740 progressive_8\JJ\1740 glomerulonephritis_9\NN\14113798 (_10\-LRB-\1740 rpgn_11\NN\1740 )_12\-RRB-\1740 after_13\IN\1740 5_14\CD\13741022 months_15\NNS\15113229 of_16\IN\1740 <e1>d-penicillamine</e1>_17\NN\1740 (_18\-LRB-\1740 250_19\CD\1740 mg/day_20\NN\1740 )_21\-RRB-\1740 treatment_22\NN\654885 ._23\.\1740
D010396_D011507 NONE this_0\DT\1740 new_1\JJ\1740 case_2\NN\7283608 of_3\IN\1740 rpgn_4\NN\1740 in_5\IN\13603305 the_6\DT\1740 course_7\NN\883297 of_8\IN\1740 <e1>d-penicillamine</e1>_9\NN\1740 treatment_10\NN\654885 emphasizes_11\VBZ\943837 the_12\DT\1740 need_13\NN\13920835 for_14\IN\1740 frequent_15\JJ\1740 monitoring_16\NN\879759 of_17\IN\1740 renal_18\JJ\1740 function_19\NN\13783581 and_20\CC\1740 evaluation_21\NN\874067 of_22\IN\1740 urinary_23\JJ\1740 sediment_24\NN\20827 and_25\CC\1740 <e2>proteinuria</e2>_26\NN\14299637 in_27\IN\13603305 these_28\DT\1740 patients_29\NNS\9898892 ._30\.\1740
2435991
C032151_D001145 NONE antiarrhythmic_0\JJ\1740 plasma_1\NN\5398023 concentrations_2\NNS\4916342 of_3\IN\1740 <e1>cibenzoline</e1>_4\NN\1740 on_5\IN\1740 canine_6\NN\5282746 <e2>ventricular_7\NN\1740 arrhythmias</e2>_8\VBZ\1740 ._9\.\1740
C032151_D001145 NONE using_0\VBG\1156834 two-stage_1\JJ\1740 coronary_2\JJ\1740 ligation-_3\NN\1740 ,_4\,\1740 digitalis-_5\NN\1740 ,_6\,\1740 and_7\CC\1740 adrenaline-induced_8\JJ\1740 canine_9\NN\5282746 <e2>ventricular_10\NN\1740 arrhythmias</e2>_11\VBZ\1740 ,_12\,\1740 antiarrhythmic_13\JJ\1740 effects_14\NNS\13245626 of_15\IN\1740 <e1>cibenzoline</e1>_16\NN\1740 were_17\VBD\836236 examined_18\VBN\789138 and_19\CC\1740 the_20\DT\1740 minimum_21\JJ\1740 effective_22\JJ\1740 plasma_23\NN\5398023 concentration_24\NN\4916342 for_25\IN\1740 each_26\DT\1740 arrhythmia_27\NN\14103288 model_28\NN\5888929 was_29\VBD\836236 determined_30\VBN\1645601 ._31\.\1740
C032151_D001145 NONE using_0\VBG\1156834 two-stage_1\JJ\1740 coronary_2\JJ\1740 ligation-_3\NN\1740 ,_4\,\1740 digitalis-_5\NN\1740 ,_6\,\1740 and_7\CC\1740 adrenaline-induced_8\JJ\1740 canine_9\NN\5282746 ventricular_10\NN\1740 arrhythmias_11\VBZ\1740 ,_12\,\1740 antiarrhythmic_13\JJ\1740 effects_14\NNS\13245626 of_15\IN\1740 <e1>cibenzoline</e1>_16\NN\1740 were_17\VBD\836236 examined_18\VBN\789138 and_19\CC\1740 the_20\DT\1740 minimum_21\JJ\1740 effective_22\JJ\1740 plasma_23\NN\5398023 concentration_24\NN\4916342 for_25\IN\1740 each_26\DT\1740 <e2>arrhythmia</e2>_27\NN\14103288 model_28\NN\5888929 was_29\VBD\836236 determined_30\VBN\1645601 ._31\.\1740
C032151_D001145 NONE <e1>cibenzoline</e1>_0\NNP\1740 suppressed_1\VBD\2510337 all_2\PDT\1740 the_3\DT\1740 <e2>arrhythmias</e2>_4\NNS\14103288 ,_5\,\1740 and_6\CC\1740 the_7\DT\1740 minimum_8\JJ\1740 effective_9\JJ\1740 plasma_10\NN\5398023 concentrations_11\NNS\4916342 for_12\IN\1740 arrhythmias_13\NNS\14103288 induced_14\VBN\1627355 by_15\IN\1740 24-h_16\JJ\1740 coronary_17\JJ\1740 ligation_18\NN\149084 ,_19\,\1740 48-h_20\JJ\1740 coronary_21\JJ\1740 ligation_22\NN\149084 ,_23\,\1740 digitalis_24\NN\15059939 ,_25\,\1740 and_26\CC\1740 adrenaline_27\NN\14807929 were_28\VBD\836236 1.9_29\CD\1740 +/-_30\CC\1740 0.9_31\CD\1740 (_32\-LRB-\1740 by_33\IN\1740 8_34\CD\13741022 mg/kg_35\NN\1740 i.v._36\NN\1740 )_37\-RRB-\1740 ,_38\,\1740 1.6_39\CD\1740 +/-_40\CC\1740 0.5_41\CD\1740 (_42\-LRB-\1740 by_43\IN\1740 8_44\CD\13741022 mg/kg_45\NN\1740 i.v._46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 0.6_49\CD\1740 +/-_50\CC\1740 0.2_51\CD\1740 (_52\-LRB-\1740 by_53\IN\1740 2_54\CD\13741022 mg/kg_55\NN\1740 i.v._56\NN\1740 )_57\-RRB-\1740 ,_58\,\1740 and_59\CC\1740 3.5_60\CD\1740 +/-_61\CC\1740 1.3_62\CD\1740 (_63\-LRB-\1740 by_64\IN\1740 5_65\CD\13741022 mg/kg_66\NN\1740 i.v._67\NN\1740 )_68\-RRB-\1740 micrograms/ml_69\NNS\1740 ,_70\,\1740 respectively_71\RB\1740 (_72\-LRB-\1740 mean_73\NN\6021761 +/-_74\CC\1740 sdm_75\NN\1740 ,_76\,\1740 n_77\NN\14622893 =_78\JJ\1740 6_79\CD\13741022 -_80\SYM\1740 7_81\CD\13741022 )_82\-RRB-\1740 ._83\.\1740
C032151_D001145 NONE <e1>cibenzoline</e1>_0\NNP\1740 suppressed_1\VBD\2510337 all_2\PDT\1740 the_3\DT\1740 arrhythmias_4\NNS\14103288 ,_5\,\1740 and_6\CC\1740 the_7\DT\1740 minimum_8\JJ\1740 effective_9\JJ\1740 plasma_10\NN\5398023 concentrations_11\NNS\4916342 for_12\IN\1740 <e2>arrhythmias</e2>_13\NNS\14103288 induced_14\VBN\1627355 by_15\IN\1740 24-h_16\JJ\1740 coronary_17\JJ\1740 ligation_18\NN\149084 ,_19\,\1740 48-h_20\JJ\1740 coronary_21\JJ\1740 ligation_22\NN\149084 ,_23\,\1740 digitalis_24\NN\15059939 ,_25\,\1740 and_26\CC\1740 adrenaline_27\NN\14807929 were_28\VBD\836236 1.9_29\CD\1740 +/-_30\CC\1740 0.9_31\CD\1740 (_32\-LRB-\1740 by_33\IN\1740 8_34\CD\13741022 mg/kg_35\NN\1740 i.v._36\NN\1740 )_37\-RRB-\1740 ,_38\,\1740 1.6_39\CD\1740 +/-_40\CC\1740 0.5_41\CD\1740 (_42\-LRB-\1740 by_43\IN\1740 8_44\CD\13741022 mg/kg_45\NN\1740 i.v._46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 0.6_49\CD\1740 +/-_50\CC\1740 0.2_51\CD\1740 (_52\-LRB-\1740 by_53\IN\1740 2_54\CD\13741022 mg/kg_55\NN\1740 i.v._56\NN\1740 )_57\-RRB-\1740 ,_58\,\1740 and_59\CC\1740 3.5_60\CD\1740 +/-_61\CC\1740 1.3_62\CD\1740 (_63\-LRB-\1740 by_64\IN\1740 5_65\CD\13741022 mg/kg_66\NN\1740 i.v._67\NN\1740 )_68\-RRB-\1740 micrograms/ml_69\NNS\1740 ,_70\,\1740 respectively_71\RB\1740 (_72\-LRB-\1740 mean_73\NN\6021761 +/-_74\CC\1740 sdm_75\NN\1740 ,_76\,\1740 n_77\NN\14622893 =_78\JJ\1740 6_79\CD\13741022 -_80\SYM\1740 7_81\CD\13741022 )_82\-RRB-\1740 ._83\.\1740
C032151_D001145 NONE because_0\IN\1740 <e1>cibenzoline</e1>_1\NN\1740 had_2\VBD\2108377 only_3\RB\1740 weak_4\JJ\1740 hypotensive_5\JJ\1740 and_6\CC\1740 sinus_7\NN\5248181 node_8\NN\13870805 depressive_9\JJ\1740 effects_10\NNS\13245626 and_11\CC\1740 was_12\VBD\836236 found_13\VBN\2426171 to_14\TO\1740 be_15\VB\836236 orally_16\RB\1740 active_17\JJ\1740 when_18\WRB\1740 given_19\VBN\2327200 to_20\TO\1740 coronary_21\JJ\1740 ligation_22\NN\149084 <e2>arrhythmia</e2>_23\NN\14103288 dogs_24\NNS\2083346 ,_25\,\1740 its_26\PRP$\6125041 clinical_27\JJ\1740 usefulness_28\NN\4723816 is_29\VBZ\836236 expected_30\VBN\670261 ._31\.\1740
D004071_D001145 CID using_0\VBG\1156834 two-stage_1\JJ\1740 coronary_2\JJ\1740 ligation-_3\NN\1740 ,_4\,\1740 <e1>digitalis-</e1>_5\NN\1740 ,_6\,\1740 and_7\CC\1740 adrenaline-induced_8\JJ\1740 canine_9\NN\5282746 <e2>ventricular_10\NN\1740 arrhythmias</e2>_11\VBZ\1740 ,_12\,\1740 antiarrhythmic_13\JJ\1740 effects_14\NNS\13245626 of_15\IN\1740 cibenzoline_16\NN\1740 were_17\VBD\836236 examined_18\VBN\789138 and_19\CC\1740 the_20\DT\1740 minimum_21\JJ\1740 effective_22\JJ\1740 plasma_23\NN\5398023 concentration_24\NN\4916342 for_25\IN\1740 each_26\DT\1740 arrhythmia_27\NN\14103288 model_28\NN\5888929 was_29\VBD\836236 determined_30\VBN\1645601 ._31\.\1740
D004071_D001145 CID using_0\VBG\1156834 two-stage_1\JJ\1740 coronary_2\JJ\1740 ligation-_3\NN\1740 ,_4\,\1740 <e1>digitalis-</e1>_5\NN\1740 ,_6\,\1740 and_7\CC\1740 adrenaline-induced_8\JJ\1740 canine_9\NN\5282746 ventricular_10\NN\1740 arrhythmias_11\VBZ\1740 ,_12\,\1740 antiarrhythmic_13\JJ\1740 effects_14\NNS\13245626 of_15\IN\1740 cibenzoline_16\NN\1740 were_17\VBD\836236 examined_18\VBN\789138 and_19\CC\1740 the_20\DT\1740 minimum_21\JJ\1740 effective_22\JJ\1740 plasma_23\NN\5398023 concentration_24\NN\4916342 for_25\IN\1740 each_26\DT\1740 <e2>arrhythmia</e2>_27\NN\14103288 model_28\NN\5888929 was_29\VBD\836236 determined_30\VBN\1645601 ._31\.\1740
D004071_D001145 CID cibenzoline_0\NNP\1740 suppressed_1\VBD\2510337 all_2\PDT\1740 the_3\DT\1740 <e2>arrhythmias</e2>_4\NNS\14103288 ,_5\,\1740 and_6\CC\1740 the_7\DT\1740 minimum_8\JJ\1740 effective_9\JJ\1740 plasma_10\NN\5398023 concentrations_11\NNS\4916342 for_12\IN\1740 arrhythmias_13\NNS\14103288 induced_14\VBN\1627355 by_15\IN\1740 24-h_16\JJ\1740 coronary_17\JJ\1740 ligation_18\NN\149084 ,_19\,\1740 48-h_20\JJ\1740 coronary_21\JJ\1740 ligation_22\NN\149084 ,_23\,\1740 <e1>digitalis</e1>_24\NN\15059939 ,_25\,\1740 and_26\CC\1740 adrenaline_27\NN\14807929 were_28\VBD\836236 1.9_29\CD\1740 +/-_30\CC\1740 0.9_31\CD\1740 (_32\-LRB-\1740 by_33\IN\1740 8_34\CD\13741022 mg/kg_35\NN\1740 i.v._36\NN\1740 )_37\-RRB-\1740 ,_38\,\1740 1.6_39\CD\1740 +/-_40\CC\1740 0.5_41\CD\1740 (_42\-LRB-\1740 by_43\IN\1740 8_44\CD\13741022 mg/kg_45\NN\1740 i.v._46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 0.6_49\CD\1740 +/-_50\CC\1740 0.2_51\CD\1740 (_52\-LRB-\1740 by_53\IN\1740 2_54\CD\13741022 mg/kg_55\NN\1740 i.v._56\NN\1740 )_57\-RRB-\1740 ,_58\,\1740 and_59\CC\1740 3.5_60\CD\1740 +/-_61\CC\1740 1.3_62\CD\1740 (_63\-LRB-\1740 by_64\IN\1740 5_65\CD\13741022 mg/kg_66\NN\1740 i.v._67\NN\1740 )_68\-RRB-\1740 micrograms/ml_69\NNS\1740 ,_70\,\1740 respectively_71\RB\1740 (_72\-LRB-\1740 mean_73\NN\6021761 +/-_74\CC\1740 sdm_75\NN\1740 ,_76\,\1740 n_77\NN\14622893 =_78\JJ\1740 6_79\CD\13741022 -_80\SYM\1740 7_81\CD\13741022 )_82\-RRB-\1740 ._83\.\1740
D004071_D001145 CID cibenzoline_0\NNP\1740 suppressed_1\VBD\2510337 all_2\PDT\1740 the_3\DT\1740 arrhythmias_4\NNS\14103288 ,_5\,\1740 and_6\CC\1740 the_7\DT\1740 minimum_8\JJ\1740 effective_9\JJ\1740 plasma_10\NN\5398023 concentrations_11\NNS\4916342 for_12\IN\1740 <e2>arrhythmias</e2>_13\NNS\14103288 induced_14\VBN\1627355 by_15\IN\1740 24-h_16\JJ\1740 coronary_17\JJ\1740 ligation_18\NN\149084 ,_19\,\1740 48-h_20\JJ\1740 coronary_21\JJ\1740 ligation_22\NN\149084 ,_23\,\1740 <e1>digitalis</e1>_24\NN\15059939 ,_25\,\1740 and_26\CC\1740 adrenaline_27\NN\14807929 were_28\VBD\836236 1.9_29\CD\1740 +/-_30\CC\1740 0.9_31\CD\1740 (_32\-LRB-\1740 by_33\IN\1740 8_34\CD\13741022 mg/kg_35\NN\1740 i.v._36\NN\1740 )_37\-RRB-\1740 ,_38\,\1740 1.6_39\CD\1740 +/-_40\CC\1740 0.5_41\CD\1740 (_42\-LRB-\1740 by_43\IN\1740 8_44\CD\13741022 mg/kg_45\NN\1740 i.v._46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 0.6_49\CD\1740 +/-_50\CC\1740 0.2_51\CD\1740 (_52\-LRB-\1740 by_53\IN\1740 2_54\CD\13741022 mg/kg_55\NN\1740 i.v._56\NN\1740 )_57\-RRB-\1740 ,_58\,\1740 and_59\CC\1740 3.5_60\CD\1740 +/-_61\CC\1740 1.3_62\CD\1740 (_63\-LRB-\1740 by_64\IN\1740 5_65\CD\13741022 mg/kg_66\NN\1740 i.v._67\NN\1740 )_68\-RRB-\1740 micrograms/ml_69\NNS\1740 ,_70\,\1740 respectively_71\RB\1740 (_72\-LRB-\1740 mean_73\NN\6021761 +/-_74\CC\1740 sdm_75\NN\1740 ,_76\,\1740 n_77\NN\14622893 =_78\JJ\1740 6_79\CD\13741022 -_80\SYM\1740 7_81\CD\13741022 )_82\-RRB-\1740 ._83\.\1740
D004837_D001145 CID using_0\VBG\1156834 two-stage_1\JJ\1740 coronary_2\JJ\1740 ligation-_3\NN\1740 ,_4\,\1740 digitalis-_5\NN\1740 ,_6\,\1740 and_7\CC\1740 <e1>adrenaline-induced</e1>_8\JJ\1740 canine_9\NN\5282746 <e2>ventricular_10\NN\1740 arrhythmias</e2>_11\VBZ\1740 ,_12\,\1740 antiarrhythmic_13\JJ\1740 effects_14\NNS\13245626 of_15\IN\1740 cibenzoline_16\NN\1740 were_17\VBD\836236 examined_18\VBN\789138 and_19\CC\1740 the_20\DT\1740 minimum_21\JJ\1740 effective_22\JJ\1740 plasma_23\NN\5398023 concentration_24\NN\4916342 for_25\IN\1740 each_26\DT\1740 arrhythmia_27\NN\14103288 model_28\NN\5888929 was_29\VBD\836236 determined_30\VBN\1645601 ._31\.\1740
D004837_D001145 CID using_0\VBG\1156834 two-stage_1\JJ\1740 coronary_2\JJ\1740 ligation-_3\NN\1740 ,_4\,\1740 digitalis-_5\NN\1740 ,_6\,\1740 and_7\CC\1740 <e1>adrenaline-induced</e1>_8\JJ\1740 canine_9\NN\5282746 ventricular_10\NN\1740 arrhythmias_11\VBZ\1740 ,_12\,\1740 antiarrhythmic_13\JJ\1740 effects_14\NNS\13245626 of_15\IN\1740 cibenzoline_16\NN\1740 were_17\VBD\836236 examined_18\VBN\789138 and_19\CC\1740 the_20\DT\1740 minimum_21\JJ\1740 effective_22\JJ\1740 plasma_23\NN\5398023 concentration_24\NN\4916342 for_25\IN\1740 each_26\DT\1740 <e2>arrhythmia</e2>_27\NN\14103288 model_28\NN\5888929 was_29\VBD\836236 determined_30\VBN\1645601 ._31\.\1740
D004837_D001145 CID cibenzoline_0\NNP\1740 suppressed_1\VBD\2510337 all_2\PDT\1740 the_3\DT\1740 <e2>arrhythmias</e2>_4\NNS\14103288 ,_5\,\1740 and_6\CC\1740 the_7\DT\1740 minimum_8\JJ\1740 effective_9\JJ\1740 plasma_10\NN\5398023 concentrations_11\NNS\4916342 for_12\IN\1740 arrhythmias_13\NNS\14103288 induced_14\VBN\1627355 by_15\IN\1740 24-h_16\JJ\1740 coronary_17\JJ\1740 ligation_18\NN\149084 ,_19\,\1740 48-h_20\JJ\1740 coronary_21\JJ\1740 ligation_22\NN\149084 ,_23\,\1740 digitalis_24\NN\15059939 ,_25\,\1740 and_26\CC\1740 <e1>adrenaline</e1>_27\NN\14807929 were_28\VBD\836236 1.9_29\CD\1740 +/-_30\CC\1740 0.9_31\CD\1740 (_32\-LRB-\1740 by_33\IN\1740 8_34\CD\13741022 mg/kg_35\NN\1740 i.v._36\NN\1740 )_37\-RRB-\1740 ,_38\,\1740 1.6_39\CD\1740 +/-_40\CC\1740 0.5_41\CD\1740 (_42\-LRB-\1740 by_43\IN\1740 8_44\CD\13741022 mg/kg_45\NN\1740 i.v._46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 0.6_49\CD\1740 +/-_50\CC\1740 0.2_51\CD\1740 (_52\-LRB-\1740 by_53\IN\1740 2_54\CD\13741022 mg/kg_55\NN\1740 i.v._56\NN\1740 )_57\-RRB-\1740 ,_58\,\1740 and_59\CC\1740 3.5_60\CD\1740 +/-_61\CC\1740 1.3_62\CD\1740 (_63\-LRB-\1740 by_64\IN\1740 5_65\CD\13741022 mg/kg_66\NN\1740 i.v._67\NN\1740 )_68\-RRB-\1740 micrograms/ml_69\NNS\1740 ,_70\,\1740 respectively_71\RB\1740 (_72\-LRB-\1740 mean_73\NN\6021761 +/-_74\CC\1740 sdm_75\NN\1740 ,_76\,\1740 n_77\NN\14622893 =_78\JJ\1740 6_79\CD\13741022 -_80\SYM\1740 7_81\CD\13741022 )_82\-RRB-\1740 ._83\.\1740
D004837_D001145 CID cibenzoline_0\NNP\1740 suppressed_1\VBD\2510337 all_2\PDT\1740 the_3\DT\1740 arrhythmias_4\NNS\14103288 ,_5\,\1740 and_6\CC\1740 the_7\DT\1740 minimum_8\JJ\1740 effective_9\JJ\1740 plasma_10\NN\5398023 concentrations_11\NNS\4916342 for_12\IN\1740 <e2>arrhythmias</e2>_13\NNS\14103288 induced_14\VBN\1627355 by_15\IN\1740 24-h_16\JJ\1740 coronary_17\JJ\1740 ligation_18\NN\149084 ,_19\,\1740 48-h_20\JJ\1740 coronary_21\JJ\1740 ligation_22\NN\149084 ,_23\,\1740 digitalis_24\NN\15059939 ,_25\,\1740 and_26\CC\1740 <e1>adrenaline</e1>_27\NN\14807929 were_28\VBD\836236 1.9_29\CD\1740 +/-_30\CC\1740 0.9_31\CD\1740 (_32\-LRB-\1740 by_33\IN\1740 8_34\CD\13741022 mg/kg_35\NN\1740 i.v._36\NN\1740 )_37\-RRB-\1740 ,_38\,\1740 1.6_39\CD\1740 +/-_40\CC\1740 0.5_41\CD\1740 (_42\-LRB-\1740 by_43\IN\1740 8_44\CD\13741022 mg/kg_45\NN\1740 i.v._46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 0.6_49\CD\1740 +/-_50\CC\1740 0.2_51\CD\1740 (_52\-LRB-\1740 by_53\IN\1740 2_54\CD\13741022 mg/kg_55\NN\1740 i.v._56\NN\1740 )_57\-RRB-\1740 ,_58\,\1740 and_59\CC\1740 3.5_60\CD\1740 +/-_61\CC\1740 1.3_62\CD\1740 (_63\-LRB-\1740 by_64\IN\1740 5_65\CD\13741022 mg/kg_66\NN\1740 i.v._67\NN\1740 )_68\-RRB-\1740 micrograms/ml_69\NNS\1740 ,_70\,\1740 respectively_71\RB\1740 (_72\-LRB-\1740 mean_73\NN\6021761 +/-_74\CC\1740 sdm_75\NN\1740 ,_76\,\1740 n_77\NN\14622893 =_78\JJ\1740 6_79\CD\13741022 -_80\SYM\1740 7_81\CD\13741022 )_82\-RRB-\1740 ._83\.\1740
D004837_D001145 CID the_0\DT\1740 concentration_1\NN\4916342 for_2\IN\1740 <e1>adrenaline-induced</e1>_3\JJ\1740 <e2>arrhythmia</e2>_4\NN\14103288 was_5\VBD\836236 significantly_6\RB\1740 higher_7\JJR\1740 than_8\IN\1740 those_9\DT\1740 for_10\IN\1740 the_11\DT\1740 other_12\JJ\1740 types_13\NNS\5839024 of_14\IN\1740 arrhythmias_15\NNS\14103288 ._16\.\1740
D004837_D001145 CID the_0\DT\1740 concentration_1\NN\4916342 for_2\IN\1740 <e1>adrenaline-induced</e1>_3\JJ\1740 arrhythmia_4\NN\14103288 was_5\VBD\836236 significantly_6\RB\1740 higher_7\JJR\1740 than_8\IN\1740 those_9\DT\1740 for_10\IN\1740 the_11\DT\1740 other_12\JJ\1740 types_13\NNS\5839024 of_14\IN\1740 <e2>arrhythmias</e2>_15\NNS\14103288 ._16\.\1740
C032151_D007022 NONE because_0\IN\1740 <e1>cibenzoline</e1>_1\NN\1740 had_2\VBD\2108377 only_3\RB\1740 weak_4\JJ\1740 <e2>hypotensive</e2>_5\JJ\1740 and_6\CC\1740 sinus_7\NN\5248181 node_8\NN\13870805 depressive_9\JJ\1740 effects_10\NNS\13245626 and_11\CC\1740 was_12\VBD\836236 found_13\VBN\2426171 to_14\TO\1740 be_15\VB\836236 orally_16\RB\1740 active_17\JJ\1740 when_18\WRB\1740 given_19\VBN\2327200 to_20\TO\1740 coronary_21\JJ\1740 ligation_22\NN\149084 arrhythmia_23\NN\14103288 dogs_24\NNS\2083346 ,_25\,\1740 its_26\PRP$\6125041 clinical_27\JJ\1740 usefulness_28\NN\4723816 is_29\VBZ\836236 expected_30\VBN\670261 ._31\.\1740
C032151_D003866 NONE because_0\IN\1740 <e1>cibenzoline</e1>_1\NN\1740 had_2\VBD\2108377 only_3\RB\1740 weak_4\JJ\1740 hypotensive_5\JJ\1740 and_6\CC\1740 sinus_7\NN\5248181 node_8\NN\13870805 <e2>depressive</e2>_9\JJ\1740 effects_10\NNS\13245626 and_11\CC\1740 was_12\VBD\836236 found_13\VBN\2426171 to_14\TO\1740 be_15\VB\836236 orally_16\RB\1740 active_17\JJ\1740 when_18\WRB\1740 given_19\VBN\2327200 to_20\TO\1740 coronary_21\JJ\1740 ligation_22\NN\149084 arrhythmia_23\NN\14103288 dogs_24\NNS\2083346 ,_25\,\1740 its_26\PRP$\6125041 clinical_27\JJ\1740 usefulness_28\NN\4723816 is_29\VBZ\836236 expected_30\VBN\670261 ._31\.\1740
7102237
D012601_D001049 NONE in_0\IN\13603305 patients_1\NNS\9898892 premedicated_2\VBN\1740 with_3\IN\1740 <e1>scopolamine</e1>_4\NN\14712692 +_5\CC\1740 morphine_6\NN\2707683 (_7\-LRB-\1740 +_8\CC\1740 5_9\CD\13741022 mg_10\NN\13717155 nitrazepam_11\IN\2830852 the_12\DT\1740 evening_13\NN\15164957 before_14\IN\1740 surgery_15\NN\6045562 )_16\-RRB-\1740 ,_17\,\1740 the_18\DT\1740 sleep-inducing_19\JJ\1740 effect_20\NN\34213 of_21\IN\1740 midazolam_22\NN\2830852 0.15_23\CD\1740 mg/kg_24\NN\1740 i.v._25\NN\1740 was_26\VBD\836236 clearly_27\RB\1740 slower_28\JJR\1740 in_29\IN\13603305 onset_30\NN\7325190 than_31\IN\1740 that_32\DT\1740 of_33\IN\1740 thiopentone_34\NN\1740 4.67_35\CD\1740 mg/kg_36\NN\1740 i.v._37\VBP\1740 somewhat_38\RB\1740 fewer_39\JJR\1740 cardiovascular_40\JJ\1740 and_41\CC\1740 local_42\JJ\1740 sequelae_43\NN\14501726 were_44\VBD\836236 found_45\VBN\2426171 in_46\IN\13603305 the_47\DT\1740 midazolam_48\NN\2830852 group_49\NN\2137 ,_50\,\1740 but_51\CC\1740 ,_52\,\1740 although_53\IN\1740 <e2>apnoea</e2>_54\NN\1740 occurred_55\VBD\2623529 less_56\RBR\1740 often_57\RB\1740 in_58\IN\13603305 the_59\DT\1740 midazolam_60\NN\2830852 group_61\NN\2137 it_62\PRP\6125041 lasted_63\VBD\2704349 longer_64\RBR\1740 ._65\.\1740
D009020_D001049 NONE in_0\IN\13603305 patients_1\NNS\9898892 premedicated_2\VBN\1740 with_3\IN\1740 scopolamine_4\NN\14712692 +_5\CC\1740 <e1>morphine</e1>_6\NN\2707683 (_7\-LRB-\1740 +_8\CC\1740 5_9\CD\13741022 mg_10\NN\13717155 nitrazepam_11\IN\2830852 the_12\DT\1740 evening_13\NN\15164957 before_14\IN\1740 surgery_15\NN\6045562 )_16\-RRB-\1740 ,_17\,\1740 the_18\DT\1740 sleep-inducing_19\JJ\1740 effect_20\NN\34213 of_21\IN\1740 midazolam_22\NN\2830852 0.15_23\CD\1740 mg/kg_24\NN\1740 i.v._25\NN\1740 was_26\VBD\836236 clearly_27\RB\1740 slower_28\JJR\1740 in_29\IN\13603305 onset_30\NN\7325190 than_31\IN\1740 that_32\DT\1740 of_33\IN\1740 thiopentone_34\NN\1740 4.67_35\CD\1740 mg/kg_36\NN\1740 i.v._37\VBP\1740 somewhat_38\RB\1740 fewer_39\JJR\1740 cardiovascular_40\JJ\1740 and_41\CC\1740 local_42\JJ\1740 sequelae_43\NN\14501726 were_44\VBD\836236 found_45\VBN\2426171 in_46\IN\13603305 the_47\DT\1740 midazolam_48\NN\2830852 group_49\NN\2137 ,_50\,\1740 but_51\CC\1740 ,_52\,\1740 although_53\IN\1740 <e2>apnoea</e2>_54\NN\1740 occurred_55\VBD\2623529 less_56\RBR\1740 often_57\RB\1740 in_58\IN\13603305 the_59\DT\1740 midazolam_60\NN\2830852 group_61\NN\2137 it_62\PRP\6125041 lasted_63\VBD\2704349 longer_64\RBR\1740 ._65\.\1740
D009567_D001049 NONE in_0\IN\13603305 patients_1\NNS\9898892 premedicated_2\VBN\1740 with_3\IN\1740 scopolamine_4\NN\14712692 +_5\CC\1740 morphine_6\NN\2707683 (_7\-LRB-\1740 +_8\CC\1740 5_9\CD\13741022 mg_10\NN\13717155 <e1>nitrazepam</e1>_11\IN\2830852 the_12\DT\1740 evening_13\NN\15164957 before_14\IN\1740 surgery_15\NN\6045562 )_16\-RRB-\1740 ,_17\,\1740 the_18\DT\1740 sleep-inducing_19\JJ\1740 effect_20\NN\34213 of_21\IN\1740 midazolam_22\NN\2830852 0.15_23\CD\1740 mg/kg_24\NN\1740 i.v._25\NN\1740 was_26\VBD\836236 clearly_27\RB\1740 slower_28\JJR\1740 in_29\IN\13603305 onset_30\NN\7325190 than_31\IN\1740 that_32\DT\1740 of_33\IN\1740 thiopentone_34\NN\1740 4.67_35\CD\1740 mg/kg_36\NN\1740 i.v._37\VBP\1740 somewhat_38\RB\1740 fewer_39\JJR\1740 cardiovascular_40\JJ\1740 and_41\CC\1740 local_42\JJ\1740 sequelae_43\NN\14501726 were_44\VBD\836236 found_45\VBN\2426171 in_46\IN\13603305 the_47\DT\1740 midazolam_48\NN\2830852 group_49\NN\2137 ,_50\,\1740 but_51\CC\1740 ,_52\,\1740 although_53\IN\1740 <e2>apnoea</e2>_54\NN\1740 occurred_55\VBD\2623529 less_56\RBR\1740 often_57\RB\1740 in_58\IN\13603305 the_59\DT\1740 midazolam_60\NN\2830852 group_61\NN\2137 it_62\PRP\6125041 lasted_63\VBD\2704349 longer_64\RBR\1740 ._65\.\1740
D008874_D001049 CID in_0\IN\13603305 patients_1\NNS\9898892 premedicated_2\VBN\1740 with_3\IN\1740 scopolamine_4\NN\14712692 +_5\CC\1740 morphine_6\NN\2707683 (_7\-LRB-\1740 +_8\CC\1740 5_9\CD\13741022 mg_10\NN\13717155 nitrazepam_11\IN\2830852 the_12\DT\1740 evening_13\NN\15164957 before_14\IN\1740 surgery_15\NN\6045562 )_16\-RRB-\1740 ,_17\,\1740 the_18\DT\1740 sleep-inducing_19\JJ\1740 effect_20\NN\34213 of_21\IN\1740 <e1>midazolam</e1>_22\NN\2830852 0.15_23\CD\1740 mg/kg_24\NN\1740 i.v._25\NN\1740 was_26\VBD\836236 clearly_27\RB\1740 slower_28\JJR\1740 in_29\IN\13603305 onset_30\NN\7325190 than_31\IN\1740 that_32\DT\1740 of_33\IN\1740 thiopentone_34\NN\1740 4.67_35\CD\1740 mg/kg_36\NN\1740 i.v._37\VBP\1740 somewhat_38\RB\1740 fewer_39\JJR\1740 cardiovascular_40\JJ\1740 and_41\CC\1740 local_42\JJ\1740 sequelae_43\NN\14501726 were_44\VBD\836236 found_45\VBN\2426171 in_46\IN\13603305 the_47\DT\1740 midazolam_48\NN\2830852 group_49\NN\2137 ,_50\,\1740 but_51\CC\1740 ,_52\,\1740 although_53\IN\1740 <e2>apnoea</e2>_54\NN\1740 occurred_55\VBD\2623529 less_56\RBR\1740 often_57\RB\1740 in_58\IN\13603305 the_59\DT\1740 midazolam_60\NN\2830852 group_61\NN\2137 it_62\PRP\6125041 lasted_63\VBD\2704349 longer_64\RBR\1740 ._65\.\1740
D008874_D001049 CID in_0\IN\13603305 patients_1\NNS\9898892 premedicated_2\VBN\1740 with_3\IN\1740 scopolamine_4\NN\14712692 +_5\CC\1740 morphine_6\NN\2707683 (_7\-LRB-\1740 +_8\CC\1740 5_9\CD\13741022 mg_10\NN\13717155 nitrazepam_11\IN\2830852 the_12\DT\1740 evening_13\NN\15164957 before_14\IN\1740 surgery_15\NN\6045562 )_16\-RRB-\1740 ,_17\,\1740 the_18\DT\1740 sleep-inducing_19\JJ\1740 effect_20\NN\34213 of_21\IN\1740 midazolam_22\NN\2830852 0.15_23\CD\1740 mg/kg_24\NN\1740 i.v._25\NN\1740 was_26\VBD\836236 clearly_27\RB\1740 slower_28\JJR\1740 in_29\IN\13603305 onset_30\NN\7325190 than_31\IN\1740 that_32\DT\1740 of_33\IN\1740 thiopentone_34\NN\1740 4.67_35\CD\1740 mg/kg_36\NN\1740 i.v._37\VBP\1740 somewhat_38\RB\1740 fewer_39\JJR\1740 cardiovascular_40\JJ\1740 and_41\CC\1740 local_42\JJ\1740 sequelae_43\NN\14501726 were_44\VBD\836236 found_45\VBN\2426171 in_46\IN\13603305 the_47\DT\1740 <e1>midazolam</e1>_48\NN\2830852 group_49\NN\2137 ,_50\,\1740 but_51\CC\1740 ,_52\,\1740 although_53\IN\1740 <e2>apnoea</e2>_54\NN\1740 occurred_55\VBD\2623529 less_56\RBR\1740 often_57\RB\1740 in_58\IN\13603305 the_59\DT\1740 midazolam_60\NN\2830852 group_61\NN\2137 it_62\PRP\6125041 lasted_63\VBD\2704349 longer_64\RBR\1740 ._65\.\1740
D008874_D001049 CID in_0\IN\13603305 patients_1\NNS\9898892 premedicated_2\VBN\1740 with_3\IN\1740 scopolamine_4\NN\14712692 +_5\CC\1740 morphine_6\NN\2707683 (_7\-LRB-\1740 +_8\CC\1740 5_9\CD\13741022 mg_10\NN\13717155 nitrazepam_11\IN\2830852 the_12\DT\1740 evening_13\NN\15164957 before_14\IN\1740 surgery_15\NN\6045562 )_16\-RRB-\1740 ,_17\,\1740 the_18\DT\1740 sleep-inducing_19\JJ\1740 effect_20\NN\34213 of_21\IN\1740 midazolam_22\NN\2830852 0.15_23\CD\1740 mg/kg_24\NN\1740 i.v._25\NN\1740 was_26\VBD\836236 clearly_27\RB\1740 slower_28\JJR\1740 in_29\IN\13603305 onset_30\NN\7325190 than_31\IN\1740 that_32\DT\1740 of_33\IN\1740 thiopentone_34\NN\1740 4.67_35\CD\1740 mg/kg_36\NN\1740 i.v._37\VBP\1740 somewhat_38\RB\1740 fewer_39\JJR\1740 cardiovascular_40\JJ\1740 and_41\CC\1740 local_42\JJ\1740 sequelae_43\NN\14501726 were_44\VBD\836236 found_45\VBN\2426171 in_46\IN\13603305 the_47\DT\1740 midazolam_48\NN\2830852 group_49\NN\2137 ,_50\,\1740 but_51\CC\1740 ,_52\,\1740 although_53\IN\1740 <e2>apnoea</e2>_54\NN\1740 occurred_55\VBD\2623529 less_56\RBR\1740 often_57\RB\1740 in_58\IN\13603305 the_59\DT\1740 <e1>midazolam</e1>_60\NN\2830852 group_61\NN\2137 it_62\PRP\6125041 lasted_63\VBD\2704349 longer_64\RBR\1740 ._65\.\1740
D013874_D001049 CID in_0\IN\13603305 patients_1\NNS\9898892 premedicated_2\VBN\1740 with_3\IN\1740 scopolamine_4\NN\14712692 +_5\CC\1740 morphine_6\NN\2707683 (_7\-LRB-\1740 +_8\CC\1740 5_9\CD\13741022 mg_10\NN\13717155 nitrazepam_11\IN\2830852 the_12\DT\1740 evening_13\NN\15164957 before_14\IN\1740 surgery_15\NN\6045562 )_16\-RRB-\1740 ,_17\,\1740 the_18\DT\1740 sleep-inducing_19\JJ\1740 effect_20\NN\34213 of_21\IN\1740 midazolam_22\NN\2830852 0.15_23\CD\1740 mg/kg_24\NN\1740 i.v._25\NN\1740 was_26\VBD\836236 clearly_27\RB\1740 slower_28\JJR\1740 in_29\IN\13603305 onset_30\NN\7325190 than_31\IN\1740 that_32\DT\1740 of_33\IN\1740 <e1>thiopentone</e1>_34\NN\1740 4.67_35\CD\1740 mg/kg_36\NN\1740 i.v._37\VBP\1740 somewhat_38\RB\1740 fewer_39\JJR\1740 cardiovascular_40\JJ\1740 and_41\CC\1740 local_42\JJ\1740 sequelae_43\NN\14501726 were_44\VBD\836236 found_45\VBN\2426171 in_46\IN\13603305 the_47\DT\1740 midazolam_48\NN\2830852 group_49\NN\2137 ,_50\,\1740 but_51\CC\1740 ,_52\,\1740 although_53\IN\1740 <e2>apnoea</e2>_54\NN\1740 occurred_55\VBD\2623529 less_56\RBR\1740 often_57\RB\1740 in_58\IN\13603305 the_59\DT\1740 midazolam_60\NN\2830852 group_61\NN\2137 it_62\PRP\6125041 lasted_63\VBD\2704349 longer_64\RBR\1740 ._65\.\1740
2051906
D001379_D002779 CID reversible_0\JJ\1740 <e2>cholestasis</e2>_1\NN\14052403 with_2\IN\1740 bile_3\NN\5405946 duct_4\NN\5248181 injury_5\NN\14052046 following_6\VBG\1835496 <e1>azathioprine</e1>_7\NN\3740161 therapy_8\NN\657604 ._9\.\1740
D001379_D002779 CID reversible_0\JJ\1740 cholestasis_1\NN\14052403 with_2\IN\1740 <e2>bile_3\NN\5405946 duct_4\NN\5248181 injury</e2>_5\NN\14052046 following_6\VBG\1835496 <e1>azathioprine</e1>_7\NN\3740161 therapy_8\NN\657604 ._9\.\1740
D001379_D002779 CID a_0\DT\13649268 67-year-old_1\JJ\1740 patient_2\NN\9898892 ,_3\,\1740 with_4\IN\1740 primary_5\JJ\1740 polymyositis_6\NN\14350292 and_7\CC\1740 without_8\IN\1740 previous_9\JJ\1740 evidence_10\NN\5816287 of_11\IN\1740 liver_12\NN\5298729 disease_13\NN\14061805 ,_14\,\1740 developed_15\VBD\1753788 clinical_16\JJ\1740 and_17\CC\1740 biochemical_18\JJ\1740 features_19\NNS\5849040 of_20\IN\1740 severe_21\JJ\1740 <e2>cholestasis</e2>_22\NN\14052403 3_23\CD\13741022 months_24\NNS\15113229 after_25\IN\1740 initiation_26\NN\7450842 of_27\IN\1740 <e1>azathioprine</e1>_28\NN\3740161 therapy_29\NN\657604 ._30\.\1740
D001379_D002779 CID it_0\PRP\6125041 is_1\VBZ\836236 believed_2\VBN\686447 that_3\IN\1740 this_4\DT\1740 is_5\VBZ\836236 the_6\DT\1740 first_7\JJ\1740 reported_8\VBN\831651 case_9\NN\7283608 of_10\IN\1740 reversible_11\JJ\1740 <e1>azathioprine-induced</e1>_12\JJ\1740 <e2>cholestasis</e2>_13\NN\14052403 associated_14\VBN\628491 with_15\IN\1740 histological_16\JJ\1740 evidence_17\NN\5816287 of_18\IN\1740 bile_19\NN\5405946 duct_20\NN\5248181 injury_21\NN\14052046 ._22\.\1740
D001379_D002779 CID it_0\PRP\6125041 is_1\VBZ\836236 believed_2\VBN\686447 that_3\IN\1740 this_4\DT\1740 is_5\VBZ\836236 the_6\DT\1740 first_7\JJ\1740 reported_8\VBN\831651 case_9\NN\7283608 of_10\IN\1740 reversible_11\JJ\1740 <e1>azathioprine-induced</e1>_12\JJ\1740 cholestasis_13\NN\14052403 associated_14\VBN\628491 with_15\IN\1740 histological_16\JJ\1740 evidence_17\NN\5816287 of_18\IN\1740 <e2>bile_19\NN\5405946 duct_20\NN\5248181 injury</e2>_21\NN\14052046 ._22\.\1740
D001379_D017285 NONE a_0\DT\13649268 67-year-old_1\JJ\1740 patient_2\NN\9898892 ,_3\,\1740 with_4\IN\1740 primary_5\JJ\1740 <e2>polymyositis</e2>_6\NN\14350292 and_7\CC\1740 without_8\IN\1740 previous_9\JJ\1740 evidence_10\NN\5816287 of_11\IN\1740 liver_12\NN\5298729 disease_13\NN\14061805 ,_14\,\1740 developed_15\VBD\1753788 clinical_16\JJ\1740 and_17\CC\1740 biochemical_18\JJ\1740 features_19\NNS\5849040 of_20\IN\1740 severe_21\JJ\1740 cholestasis_22\NN\14052403 3_23\CD\13741022 months_24\NNS\15113229 after_25\IN\1740 initiation_26\NN\7450842 of_27\IN\1740 <e1>azathioprine</e1>_28\NN\3740161 therapy_29\NN\657604 ._30\.\1740
D001379_D008107 NONE a_0\DT\13649268 67-year-old_1\JJ\1740 patient_2\NN\9898892 ,_3\,\1740 with_4\IN\1740 primary_5\JJ\1740 polymyositis_6\NN\14350292 and_7\CC\1740 without_8\IN\1740 previous_9\JJ\1740 evidence_10\NN\5816287 of_11\IN\1740 <e2>liver_12\NN\5298729 disease</e2>_13\NN\14061805 ,_14\,\1740 developed_15\VBD\1753788 clinical_16\JJ\1740 and_17\CC\1740 biochemical_18\JJ\1740 features_19\NNS\5849040 of_20\IN\1740 severe_21\JJ\1740 cholestasis_22\NN\14052403 3_23\CD\13741022 months_24\NNS\15113229 after_25\IN\1740 initiation_26\NN\7450842 of_27\IN\1740 <e1>azathioprine</e1>_28\NN\3740161 therapy_29\NN\657604 ._30\.\1740
803783
D010121_D014869 CID <e2>water_0\NN\14618834 intoxication</e2>_1\NN\14034177 associated_2\VBN\628491 with_3\IN\1740 <e1>oxytocin</e1>_4\NN\5407119 administration_5\NN\1133281 during_6\IN\1740 saline-induced_7\JJ\1740 abortion_8\NN\209943 ._9\.\1740
D010121_D014869 CID four_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 <e2>water_3\NN\14618834 intoxication</e2>_4\NN\14034177 in_5\IN\13603305 connection_6\NN\31921 with_7\IN\1740 <e1>oxytocin</e1>_8\NN\5407119 administration_9\NN\1133281 during_10\IN\1740 saline-induced_11\JJ\1740 abortions_12\NNS\209943 are_13\VBP\836236 described_14\VBN\1001294 ._15\.\1740
D010121_D014869 CID <e1>oxytocin</e1>_0\NN\5407119 administration_1\NN\1133281 during_2\IN\1740 midtrimester-induced_3\JJ\1740 abortions_4\NNS\209943 is_5\VBZ\836236 advocated_6\VBN\875394 only_7\RB\1740 if_8\IN\1740 it_9\PRP\6125041 can_10\MD\3094503 be_11\VB\836236 carried_12\VBN\1850315 out_13\RP\1740 under_14\IN\1740 careful_15\JJ\1740 observations_16\NNS\996969 of_17\IN\1740 an_18\DT\6697703 alert_19\JJ\1740 nursing_20\NN\654885 staff_21\NN\8208016 ,_22\,\1740 aware_23\JJ\1740 of_24\IN\1740 the_25\DT\1740 symptoms_26\NNS\5823932 of_27\IN\1740 <e2>water_28\NN\14618834 intoxication</e2>_29\NN\14034177 and_30\CC\1740 instructed_31\VBD\831651 to_32\TO\1740 watch_33\VB\661824 the_34\DT\1740 diuresis_35\NN\14299637 and_36\CC\1740 report_37\VB\831651 such_38\JJ\1740 early_39\JJ\1740 signs_40\NNS\6643763 of_41\IN\1740 the_42\DT\1740 syndrome_43\NN\5870365 as_44\IN\14622893 asthenia_45\NN\14547643 ,_46\,\1740 muscular_47\JJ\1740 irritability_48\NN\7552087 ,_49\,\1740 or_50\CC\3541091 headaches_51\NNS\5829480 ._52\.\1740
D010121_D000031 NONE water_0\NN\14618834 intoxication_1\NN\14034177 associated_2\VBN\628491 with_3\IN\1740 <e1>oxytocin</e1>_4\NN\5407119 administration_5\NN\1133281 during_6\IN\1740 saline-induced_7\JJ\1740 <e2>abortion</e2>_8\NN\209943 ._9\.\1740
D010121_D000031 NONE four_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 water_3\NN\14618834 intoxication_4\NN\14034177 in_5\IN\13603305 connection_6\NN\31921 with_7\IN\1740 <e1>oxytocin</e1>_8\NN\5407119 administration_9\NN\1133281 during_10\IN\1740 saline-induced_11\JJ\1740 <e2>abortions</e2>_12\NNS\209943 are_13\VBP\836236 described_14\VBN\1001294 ._15\.\1740
D010121_D000031 NONE <e1>oxytocin</e1>_0\NN\5407119 administration_1\NN\1133281 during_2\IN\1740 midtrimester-induced_3\JJ\1740 <e2>abortions</e2>_4\NNS\209943 is_5\VBZ\836236 advocated_6\VBN\875394 only_7\RB\1740 if_8\IN\1740 it_9\PRP\6125041 can_10\MD\3094503 be_11\VB\836236 carried_12\VBN\1850315 out_13\RP\1740 under_14\IN\1740 careful_15\JJ\1740 observations_16\NNS\996969 of_17\IN\1740 an_18\DT\6697703 alert_19\JJ\1740 nursing_20\NN\654885 staff_21\NN\8208016 ,_22\,\1740 aware_23\JJ\1740 of_24\IN\1740 the_25\DT\1740 symptoms_26\NNS\5823932 of_27\IN\1740 water_28\NN\14618834 intoxication_29\NN\14034177 and_30\CC\1740 instructed_31\VBD\831651 to_32\TO\1740 watch_33\VB\661824 the_34\DT\1740 diuresis_35\NN\14299637 and_36\CC\1740 report_37\VB\831651 such_38\JJ\1740 early_39\JJ\1740 signs_40\NNS\6643763 of_41\IN\1740 the_42\DT\1740 syndrome_43\NN\5870365 as_44\IN\14622893 asthenia_45\NN\14547643 ,_46\,\1740 muscular_47\JJ\1740 irritability_48\NN\7552087 ,_49\,\1740 or_50\CC\3541091 headaches_51\NNS\5829480 ._52\.\1740
D010121_D001247 NONE <e1>oxytocin</e1>_0\NN\5407119 administration_1\NN\1133281 during_2\IN\1740 midtrimester-induced_3\JJ\1740 abortions_4\NNS\209943 is_5\VBZ\836236 advocated_6\VBN\875394 only_7\RB\1740 if_8\IN\1740 it_9\PRP\6125041 can_10\MD\3094503 be_11\VB\836236 carried_12\VBN\1850315 out_13\RP\1740 under_14\IN\1740 careful_15\JJ\1740 observations_16\NNS\996969 of_17\IN\1740 an_18\DT\6697703 alert_19\JJ\1740 nursing_20\NN\654885 staff_21\NN\8208016 ,_22\,\1740 aware_23\JJ\1740 of_24\IN\1740 the_25\DT\1740 symptoms_26\NNS\5823932 of_27\IN\1740 water_28\NN\14618834 intoxication_29\NN\14034177 and_30\CC\1740 instructed_31\VBD\831651 to_32\TO\1740 watch_33\VB\661824 the_34\DT\1740 diuresis_35\NN\14299637 and_36\CC\1740 report_37\VB\831651 such_38\JJ\1740 early_39\JJ\1740 signs_40\NNS\6643763 of_41\IN\1740 the_42\DT\1740 syndrome_43\NN\5870365 as_44\IN\14622893 <e2>asthenia</e2>_45\NN\14547643 ,_46\,\1740 muscular_47\JJ\1740 irritability_48\NN\7552087 ,_49\,\1740 or_50\CC\3541091 headaches_51\NNS\5829480 ._52\.\1740
D010121_D001523 NONE <e1>oxytocin</e1>_0\NN\5407119 administration_1\NN\1133281 during_2\IN\1740 midtrimester-induced_3\JJ\1740 abortions_4\NNS\209943 is_5\VBZ\836236 advocated_6\VBN\875394 only_7\RB\1740 if_8\IN\1740 it_9\PRP\6125041 can_10\MD\3094503 be_11\VB\836236 carried_12\VBN\1850315 out_13\RP\1740 under_14\IN\1740 careful_15\JJ\1740 observations_16\NNS\996969 of_17\IN\1740 an_18\DT\6697703 alert_19\JJ\1740 nursing_20\NN\654885 staff_21\NN\8208016 ,_22\,\1740 aware_23\JJ\1740 of_24\IN\1740 the_25\DT\1740 symptoms_26\NNS\5823932 of_27\IN\1740 water_28\NN\14618834 intoxication_29\NN\14034177 and_30\CC\1740 instructed_31\VBD\831651 to_32\TO\1740 watch_33\VB\661824 the_34\DT\1740 diuresis_35\NN\14299637 and_36\CC\1740 report_37\VB\831651 such_38\JJ\1740 early_39\JJ\1740 signs_40\NNS\6643763 of_41\IN\1740 the_42\DT\1740 syndrome_43\NN\5870365 as_44\IN\14622893 asthenia_45\NN\14547643 ,_46\,\1740 muscular_47\JJ\1740 <e2>irritability</e2>_48\NN\7552087 ,_49\,\1740 or_50\CC\3541091 headaches_51\NNS\5829480 ._52\.\1740
D010121_D006261 NONE <e1>oxytocin</e1>_0\NN\5407119 administration_1\NN\1133281 during_2\IN\1740 midtrimester-induced_3\JJ\1740 abortions_4\NNS\209943 is_5\VBZ\836236 advocated_6\VBN\875394 only_7\RB\1740 if_8\IN\1740 it_9\PRP\6125041 can_10\MD\3094503 be_11\VB\836236 carried_12\VBN\1850315 out_13\RP\1740 under_14\IN\1740 careful_15\JJ\1740 observations_16\NNS\996969 of_17\IN\1740 an_18\DT\6697703 alert_19\JJ\1740 nursing_20\NN\654885 staff_21\NN\8208016 ,_22\,\1740 aware_23\JJ\1740 of_24\IN\1740 the_25\DT\1740 symptoms_26\NNS\5823932 of_27\IN\1740 water_28\NN\14618834 intoxication_29\NN\14034177 and_30\CC\1740 instructed_31\VBD\831651 to_32\TO\1740 watch_33\VB\661824 the_34\DT\1740 diuresis_35\NN\14299637 and_36\CC\1740 report_37\VB\831651 such_38\JJ\1740 early_39\JJ\1740 signs_40\NNS\6643763 of_41\IN\1740 the_42\DT\1740 syndrome_43\NN\5870365 as_44\IN\14622893 asthenia_45\NN\14547643 ,_46\,\1740 muscular_47\JJ\1740 irritability_48\NN\7552087 ,_49\,\1740 or_50\CC\3541091 <e2>headaches</e2>_51\NNS\5829480 ._52\.\1740
3001299
D008094_D018500 NONE it_0\PRP\6125041 has_1\VBZ\2108377 been_2\VBN\836236 suggested_3\VBN\1010118 that_4\IN\1740 adenylate_5\NN\1740 cyclase_6\NN\1740 inhibition_7\NN\1068773 may_8\MD\15209706 be_9\VB\836236 important_10\JJ\1740 in_11\IN\13603305 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 both_15\CC\1740 <e2>nephrogenic_16\JJ\1740 diabetes_17\NNS\14075199 insipidus</e2>_18\NN\1740 and_19\CC\1740 hypothyroidism_20\NN\14059928 during_21\IN\1740 <e1>lithium</e1>_22\NN\14625458 treatment_23\NN\654885 ._24\.\1740
D008094_D007037 CID it_0\PRP\6125041 has_1\VBZ\2108377 been_2\VBN\836236 suggested_3\VBN\1010118 that_4\IN\1740 adenylate_5\NN\1740 cyclase_6\NN\1740 inhibition_7\NN\1068773 may_8\MD\15209706 be_9\VB\836236 important_10\JJ\1740 in_11\IN\13603305 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 both_15\CC\1740 nephrogenic_16\JJ\1740 diabetes_17\NNS\14075199 insipidus_18\NN\1740 and_19\CC\1740 <e2>hypothyroidism</e2>_20\NN\14059928 during_21\IN\1740 <e1>lithium</e1>_22\NN\14625458 treatment_23\NN\654885 ._24\.\1740
D008094_D007037 CID <e2>hypothyroidism</e2>_0\NN\14059928 developed_1\VBD\1753788 in_2\IN\13603305 eight_3\CD\13741022 patients_4\NNS\9898892 while_5\IN\15122231 they_6\PRP\1740 were_7\VBD\836236 taking_8\VBG\2367363 <e1>lithium</e1>_9\NN\14625458 ._10\.\1740
1711760
D007530_D006973 NONE under_0\IN\1740 <e1>isoflurane</e1>_1\NN\3570838 anesthesia_2\NN\14034177 ,_3\,\1740 the_4\DT\1740 mca_5\NNP\1740 of_6\IN\1740 14_7\CD\13745420 spontaneously_8\JJ\1740 <e2>hypertensive</e2>_9\JJ\1740 rats_10\NNS\2329401 was_11\VBD\836236 occluded_12\VBN\2451370 ._13\.\1740
C009591_D009410 NONE the_0\DT\1740 extent_1\NN\13939892 of_2\IN\1740 <e2>neuronal_3\JJ\1740 injury</e2>_4\NN\14052046 was_5\VBD\836236 determined_6\VBN\1645601 by_7\IN\1740 <e1>2,3,5-triphenyltetrazolium</e1>_8\NN\1740 staining_9\NN\275424 ._10\.\1740
D010656_D006973 CID the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>phenylephrine-induced</e1>_4\JJ\1740 <e2>hypertension</e2>_5\NN\14057371 instituted_6\VBD\1641914 2_7\CD\13741022 h_8\NN\14622893 after_9\IN\1740 mcao_10\NN\1740 does_11\VBZ\1640855 not_12\RB\1740 aggravate_13\NN\1740 edema_14\NN\14315192 in_15\IN\13603305 the_16\DT\1740 ischemic_17\JJ\1740 core_18\NN\7996689 ,_19\,\1740 that_20\IN\1740 it_21\PRP\6125041 improves_22\VBZ\126264 edema_23\NN\14315192 in_24\IN\13603305 the_25\DT\1740 periphery_26\NN\13903079 of_27\IN\1740 the_28\DT\1740 ischemic_29\JJ\1740 territory_30\NN\8630985 ,_31\,\1740 and_32\CC\1740 that_33\IN\1740 it_34\PRP\6125041 reduces_35\VBZ\441445 the_36\DT\1740 area_37\NN\8630985 of_38\IN\1740 histochemical_39\JJ\1740 neuronal_40\JJ\1740 dysfunction_41\NN\14204950 ._42\.\1740
D010656_D020244 NONE the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>phenylephrine-induced</e1>_4\JJ\1740 hypertension_5\NN\14057371 instituted_6\VBD\1641914 2_7\CD\13741022 h_8\NN\14622893 after_9\IN\1740 <e2>mcao</e2>_10\NN\1740 does_11\VBZ\1640855 not_12\RB\1740 aggravate_13\NN\1740 edema_14\NN\14315192 in_15\IN\13603305 the_16\DT\1740 ischemic_17\JJ\1740 core_18\NN\7996689 ,_19\,\1740 that_20\IN\1740 it_21\PRP\6125041 improves_22\VBZ\126264 edema_23\NN\14315192 in_24\IN\13603305 the_25\DT\1740 periphery_26\NN\13903079 of_27\IN\1740 the_28\DT\1740 ischemic_29\JJ\1740 territory_30\NN\8630985 ,_31\,\1740 and_32\CC\1740 that_33\IN\1740 it_34\PRP\6125041 reduces_35\VBZ\441445 the_36\DT\1740 area_37\NN\8630985 of_38\IN\1740 histochemical_39\JJ\1740 neuronal_40\JJ\1740 dysfunction_41\NN\14204950 ._42\.\1740
D010656_D004487 NONE the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>phenylephrine-induced</e1>_4\JJ\1740 hypertension_5\NN\14057371 instituted_6\VBD\1641914 2_7\CD\13741022 h_8\NN\14622893 after_9\IN\1740 mcao_10\NN\1740 does_11\VBZ\1640855 not_12\RB\1740 aggravate_13\NN\1740 <e2>edema</e2>_14\NN\14315192 in_15\IN\13603305 the_16\DT\1740 ischemic_17\JJ\1740 core_18\NN\7996689 ,_19\,\1740 that_20\IN\1740 it_21\PRP\6125041 improves_22\VBZ\126264 edema_23\NN\14315192 in_24\IN\13603305 the_25\DT\1740 periphery_26\NN\13903079 of_27\IN\1740 the_28\DT\1740 ischemic_29\JJ\1740 territory_30\NN\8630985 ,_31\,\1740 and_32\CC\1740 that_33\IN\1740 it_34\PRP\6125041 reduces_35\VBZ\441445 the_36\DT\1740 area_37\NN\8630985 of_38\IN\1740 histochemical_39\JJ\1740 neuronal_40\JJ\1740 dysfunction_41\NN\14204950 ._42\.\1740
D010656_D004487 NONE the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>phenylephrine-induced</e1>_4\JJ\1740 hypertension_5\NN\14057371 instituted_6\VBD\1641914 2_7\CD\13741022 h_8\NN\14622893 after_9\IN\1740 mcao_10\NN\1740 does_11\VBZ\1640855 not_12\RB\1740 aggravate_13\NN\1740 edema_14\NN\14315192 in_15\IN\13603305 the_16\DT\1740 ischemic_17\JJ\1740 core_18\NN\7996689 ,_19\,\1740 that_20\IN\1740 it_21\PRP\6125041 improves_22\VBZ\126264 <e2>edema</e2>_23\NN\14315192 in_24\IN\13603305 the_25\DT\1740 periphery_26\NN\13903079 of_27\IN\1740 the_28\DT\1740 ischemic_29\JJ\1740 territory_30\NN\8630985 ,_31\,\1740 and_32\CC\1740 that_33\IN\1740 it_34\PRP\6125041 reduces_35\VBZ\441445 the_36\DT\1740 area_37\NN\8630985 of_38\IN\1740 histochemical_39\JJ\1740 neuronal_40\JJ\1740 dysfunction_41\NN\14204950 ._42\.\1740
D010656_D007511 NONE the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>phenylephrine-induced</e1>_4\JJ\1740 hypertension_5\NN\14057371 instituted_6\VBD\1641914 2_7\CD\13741022 h_8\NN\14622893 after_9\IN\1740 mcao_10\NN\1740 does_11\VBZ\1640855 not_12\RB\1740 aggravate_13\NN\1740 edema_14\NN\14315192 in_15\IN\13603305 the_16\DT\1740 <e2>ischemic</e2>_17\JJ\1740 core_18\NN\7996689 ,_19\,\1740 that_20\IN\1740 it_21\PRP\6125041 improves_22\VBZ\126264 edema_23\NN\14315192 in_24\IN\13603305 the_25\DT\1740 periphery_26\NN\13903079 of_27\IN\1740 the_28\DT\1740 ischemic_29\JJ\1740 territory_30\NN\8630985 ,_31\,\1740 and_32\CC\1740 that_33\IN\1740 it_34\PRP\6125041 reduces_35\VBZ\441445 the_36\DT\1740 area_37\NN\8630985 of_38\IN\1740 histochemical_39\JJ\1740 neuronal_40\JJ\1740 dysfunction_41\NN\14204950 ._42\.\1740
D010656_D007511 NONE the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>phenylephrine-induced</e1>_4\JJ\1740 hypertension_5\NN\14057371 instituted_6\VBD\1641914 2_7\CD\13741022 h_8\NN\14622893 after_9\IN\1740 mcao_10\NN\1740 does_11\VBZ\1640855 not_12\RB\1740 aggravate_13\NN\1740 edema_14\NN\14315192 in_15\IN\13603305 the_16\DT\1740 ischemic_17\JJ\1740 core_18\NN\7996689 ,_19\,\1740 that_20\IN\1740 it_21\PRP\6125041 improves_22\VBZ\126264 edema_23\NN\14315192 in_24\IN\13603305 the_25\DT\1740 periphery_26\NN\13903079 of_27\IN\1740 the_28\DT\1740 <e2>ischemic</e2>_29\JJ\1740 territory_30\NN\8630985 ,_31\,\1740 and_32\CC\1740 that_33\IN\1740 it_34\PRP\6125041 reduces_35\VBZ\441445 the_36\DT\1740 area_37\NN\8630985 of_38\IN\1740 histochemical_39\JJ\1740 neuronal_40\JJ\1740 dysfunction_41\NN\14204950 ._42\.\1740
D010656_D009410 NONE the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>phenylephrine-induced</e1>_4\JJ\1740 hypertension_5\NN\14057371 instituted_6\VBD\1641914 2_7\CD\13741022 h_8\NN\14622893 after_9\IN\1740 mcao_10\NN\1740 does_11\VBZ\1640855 not_12\RB\1740 aggravate_13\NN\1740 edema_14\NN\14315192 in_15\IN\13603305 the_16\DT\1740 ischemic_17\JJ\1740 core_18\NN\7996689 ,_19\,\1740 that_20\IN\1740 it_21\PRP\6125041 improves_22\VBZ\126264 edema_23\NN\14315192 in_24\IN\13603305 the_25\DT\1740 periphery_26\NN\13903079 of_27\IN\1740 the_28\DT\1740 ischemic_29\JJ\1740 territory_30\NN\8630985 ,_31\,\1740 and_32\CC\1740 that_33\IN\1740 it_34\PRP\6125041 reduces_35\VBZ\441445 the_36\DT\1740 area_37\NN\8630985 of_38\IN\1740 histochemical_39\JJ\1740 <e2>neuronal_40\JJ\1740 dysfunction</e2>_41\NN\14204950 ._42\.\1740
20735774
D000082_D017114 CID long-term_0\JJ\1740 prognosis_1\NN\6748969 for_2\IN\1740 transplant-free_3\JJ\1740 survivors_4\NNS\9630641 of_5\IN\1740 <e1>paracetamol-induced</e1>_6\JJ\1740 <e2>acute_7\JJ\1740 liver_8\NN\5298729 failure</e2>_9\NN\66216 ._10\.\1740
D000082_D017114 CID background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 prognosis_3\NN\6748969 for_4\IN\1740 transplant-free_5\JJ\1740 survivors_6\NNS\9630641 of_7\IN\1740 <e1>paracetamol-induced</e1>_8\JJ\1740 <e2>acute_9\JJ\1740 liver_10\NN\5298729 failure</e2>_11\NN\66216 remains_12\VBZ\2604760 unknown_13\JJ\1740 ._14\.\1740
D000082_D017114 CID aim_0\NN\5980875 :_1\:\1740 to_2\TO\1740 examine_3\VB\789138 whether_4\IN\1740 <e1>paracetamol-induced</e1>_5\JJ\1740 <e2>acute_6\JJ\1740 liver_7\NN\5298729 failure</e2>_8\NN\66216 increases_9\VBZ\169651 long-term_10\JJ\1740 mortality_11\NN\5054863 ._12\.\1740
D000082_D017114 CID on_0\IN\1740 average_1\JJ\1740 ,_2\,\1740 age-specific_3\JJ\1740 mortality_4\NN\5054863 rates_5\NNS\13308999 were_6\VBD\836236 slightly_7\RB\1740 higher_8\JJR\1740 for_9\IN\1740 the_10\DT\1740 101_11\CD\1740 patients_12\NNS\9898892 whose_13\WP$\1740 <e1>paracetamol-induced</e1>_14\JJ\1740 liver_15\NN\5298729 injury_16\NN\14052046 had_17\VBD\2108377 caused_18\VBN\1617192 an_19\DT\6697703 <e2>acute_20\JJ\1740 liver_21\NN\5298729 failure</e2>_22\NN\66216 (_23\-LRB-\1740 adjusted_24\VBN\126264 mortality_25\NN\5054863 rate_26\NN\13815152 ratio_27\NN\13815152 =_28\JJ\1740 1.70_29\CD\1740 ,_30\,\1740 95_31\CD\1740 %_32\NN\1740 ci_33\NN\13635336 1.02_34\CD\1740 -_35\SYM\1740 2.85_36\CD\1740 )_37\-RRB-\1740 ,_38\,\1740 but_39\CC\1740 the_40\DT\1740 association_41\NN\8008335 was_42\VBD\836236 age-dependent_43\JJ\1740 ,_44\,\1740 and_45\CC\1740 no_46\DT\7204911 survivors_47\NNS\9630641 of_48\IN\1740 acute_49\JJ\1740 liver_50\NN\5298729 failure_51\NN\66216 died_52\VBD\146138 of_53\IN\1740 liver_54\NN\5298729 disease_55\NN\14061805 ,_56\,\1740 whereas_57\IN\1740 suicides_58\NNS\219012 were_59\VBD\836236 frequent_60\JJ\1740 in_61\IN\13603305 both_62\DT\1740 groups_63\NNS\2137 ._64\.\1740
D000082_D017114 CID on_0\IN\1740 average_1\JJ\1740 ,_2\,\1740 age-specific_3\JJ\1740 mortality_4\NN\5054863 rates_5\NNS\13308999 were_6\VBD\836236 slightly_7\RB\1740 higher_8\JJR\1740 for_9\IN\1740 the_10\DT\1740 101_11\CD\1740 patients_12\NNS\9898892 whose_13\WP$\1740 <e1>paracetamol-induced</e1>_14\JJ\1740 liver_15\NN\5298729 injury_16\NN\14052046 had_17\VBD\2108377 caused_18\VBN\1617192 an_19\DT\6697703 acute_20\JJ\1740 liver_21\NN\5298729 failure_22\NN\66216 (_23\-LRB-\1740 adjusted_24\VBN\126264 mortality_25\NN\5054863 rate_26\NN\13815152 ratio_27\NN\13815152 =_28\JJ\1740 1.70_29\CD\1740 ,_30\,\1740 95_31\CD\1740 %_32\NN\1740 ci_33\NN\13635336 1.02_34\CD\1740 -_35\SYM\1740 2.85_36\CD\1740 )_37\-RRB-\1740 ,_38\,\1740 but_39\CC\1740 the_40\DT\1740 association_41\NN\8008335 was_42\VBD\836236 age-dependent_43\JJ\1740 ,_44\,\1740 and_45\CC\1740 no_46\DT\7204911 survivors_47\NNS\9630641 of_48\IN\1740 <e2>acute_49\JJ\1740 liver_50\NN\5298729 failure</e2>_51\NN\66216 died_52\VBD\146138 of_53\IN\1740 liver_54\NN\5298729 disease_55\NN\14061805 ,_56\,\1740 whereas_57\IN\1740 suicides_58\NNS\219012 were_59\VBD\836236 frequent_60\JJ\1740 in_61\IN\13603305 both_62\DT\1740 groups_63\NNS\2137 ._64\.\1740
D000082_D017114 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>paracetamol-induced</e1>_2\JJ\1740 <e2>acute_3\JJ\1740 liver_4\NN\5298729 failure</e2>_5\NN\66216 did_6\VBD\1640855 not_7\RB\1740 affect_8\VB\126264 long-term_9\JJ\1740 mortality_10\NN\5054863 ._11\.\1740
D000082_D056486 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 followed_3\VBD\1835496 up_4\RP\1740 all_5\DT\1740 transplant-free_6\JJ\1740 survivors_7\NNS\9630641 of_8\IN\1740 <e1>paracetamol-induced</e1>_9\JJ\1740 <e2>acute_10\JJ\1740 liver_11\NN\5298729 injury</e2>_12\NN\14052046 ,_13\,\1740 hospitalized_14\VBN\2348568 in_15\IN\13603305 a_16\DT\13649268 danish_17\JJ\1740 national_18\JJ\1740 referral_19\NN\9898892 centre_20\NN\8497294 during_21\IN\1740 1984_22\CD\1740 -_23\SYM\1740 2004_24\CD\1740 ._25\.\1740
D000082_D056486 NONE on_0\IN\1740 average_1\JJ\1740 ,_2\,\1740 age-specific_3\JJ\1740 mortality_4\NN\5054863 rates_5\NNS\13308999 were_6\VBD\836236 slightly_7\RB\1740 higher_8\JJR\1740 for_9\IN\1740 the_10\DT\1740 101_11\CD\1740 patients_12\NNS\9898892 whose_13\WP$\1740 <e1>paracetamol-induced</e1>_14\JJ\1740 <e2>liver_15\NN\5298729 injury</e2>_16\NN\14052046 had_17\VBD\2108377 caused_18\VBN\1617192 an_19\DT\6697703 acute_20\JJ\1740 liver_21\NN\5298729 failure_22\NN\66216 (_23\-LRB-\1740 adjusted_24\VBN\126264 mortality_25\NN\5054863 rate_26\NN\13815152 ratio_27\NN\13815152 =_28\JJ\1740 1.70_29\CD\1740 ,_30\,\1740 95_31\CD\1740 %_32\NN\1740 ci_33\NN\13635336 1.02_34\CD\1740 -_35\SYM\1740 2.85_36\CD\1740 )_37\-RRB-\1740 ,_38\,\1740 but_39\CC\1740 the_40\DT\1740 association_41\NN\8008335 was_42\VBD\836236 age-dependent_43\JJ\1740 ,_44\,\1740 and_45\CC\1740 no_46\DT\7204911 survivors_47\NNS\9630641 of_48\IN\1740 acute_49\JJ\1740 liver_50\NN\5298729 failure_51\NN\66216 died_52\VBD\146138 of_53\IN\1740 liver_54\NN\5298729 disease_55\NN\14061805 ,_56\,\1740 whereas_57\IN\1740 suicides_58\NNS\219012 were_59\VBD\836236 frequent_60\JJ\1740 in_61\IN\13603305 both_62\DT\1740 groups_63\NNS\2137 ._64\.\1740
D000082_D008107 NONE on_0\IN\1740 average_1\JJ\1740 ,_2\,\1740 age-specific_3\JJ\1740 mortality_4\NN\5054863 rates_5\NNS\13308999 were_6\VBD\836236 slightly_7\RB\1740 higher_8\JJR\1740 for_9\IN\1740 the_10\DT\1740 101_11\CD\1740 patients_12\NNS\9898892 whose_13\WP$\1740 <e1>paracetamol-induced</e1>_14\JJ\1740 liver_15\NN\5298729 injury_16\NN\14052046 had_17\VBD\2108377 caused_18\VBN\1617192 an_19\DT\6697703 acute_20\JJ\1740 liver_21\NN\5298729 failure_22\NN\66216 (_23\-LRB-\1740 adjusted_24\VBN\126264 mortality_25\NN\5054863 rate_26\NN\13815152 ratio_27\NN\13815152 =_28\JJ\1740 1.70_29\CD\1740 ,_30\,\1740 95_31\CD\1740 %_32\NN\1740 ci_33\NN\13635336 1.02_34\CD\1740 -_35\SYM\1740 2.85_36\CD\1740 )_37\-RRB-\1740 ,_38\,\1740 but_39\CC\1740 the_40\DT\1740 association_41\NN\8008335 was_42\VBD\836236 age-dependent_43\JJ\1740 ,_44\,\1740 and_45\CC\1740 no_46\DT\7204911 survivors_47\NNS\9630641 of_48\IN\1740 acute_49\JJ\1740 liver_50\NN\5298729 failure_51\NN\66216 died_52\VBD\146138 of_53\IN\1740 <e2>liver_54\NN\5298729 disease</e2>_55\NN\14061805 ,_56\,\1740 whereas_57\IN\1740 suicides_58\NNS\219012 were_59\VBD\836236 frequent_60\JJ\1740 in_61\IN\13603305 both_62\DT\1740 groups_63\NNS\2137 ._64\.\1740
20705401
D012701_D011605 NONE <e1>serotonin</e1>_0\NN\14807737 6_1\CD\13741022 receptor_2\NN\5225602 gene_3\NN\8459252 is_4\VBZ\836236 associated_5\VBN\628491 with_6\IN\1740 methamphetamine-induced_7\JJ\1740 <e2>psychosis</e2>_8\NN\14380140 in_9\IN\13603305 a_10\DT\13649268 japanese_11\JJ\1740 population_12\NN\7942152 ._13\.\1740
D012701_D011605 NONE these_0\DT\1740 animal_1\NN\4475 models_2\NNS\5888929 were_3\VBD\836236 considered_4\VBN\689344 to_5\TO\1740 reflect_6\VB\923793 the_7\DT\1740 positive_8\JJ\1740 symptoms_9\NNS\5823932 of_10\IN\1740 schizophrenia_11\NN\14398067 ,_12\,\1740 and_13\CC\1740 the_14\DT\1740 above_15\JJ\1740 evidence_16\NN\5816287 suggests_17\VBZ\1010118 that_18\IN\1740 altered_19\JJ\1740 <e1>5-ht6</e1>_20\JJ\1740 receptors_21\NNS\5225602 are_22\VBP\836236 involved_23\VBN\2676054 in_24\IN\13603305 the_25\DT\1740 pathophysiology_26\NN\1740 of_27\IN\1740 <e2>psychotic_28\JJ\1740 disorders</e2>_29\NNS\14034177 ._30\.\1740
D012701_D011605 NONE therefore_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 conducted_3\VBD\2436349 an_4\DT\6697703 analysis_5\NN\633864 of_6\IN\1740 the_7\DT\1740 association_8\NN\8008335 of_9\IN\1740 the_10\DT\1740 <e1>5-ht6</e1>_11\JJ\1740 gene_12\NN\8459252 (_13\-LRB-\1740 htr6_14\NN\1740 )_15\-RRB-\1740 with_16\IN\1740 meth-induced_17\JJ\1740 <e2>psychosis</e2>_18\NN\14380140 ._19\.\1740
D008694_D011605 CID serotonin_0\NN\14807737 6_1\CD\13741022 receptor_2\NN\5225602 gene_3\NN\8459252 is_4\VBZ\836236 associated_5\VBN\628491 with_6\IN\1740 <e1>methamphetamine-induced</e1>_7\JJ\1740 <e2>psychosis</e2>_8\NN\14380140 in_9\IN\13603305 a_10\DT\13649268 japanese_11\JJ\1740 population_12\NN\7942152 ._13\.\1740
D008694_D011605 CID the_0\DT\1740 symptoms_1\NNS\5823932 of_2\IN\1740 <e1>methamphetamine</e1>_3\NN\2704153 (meth)-induced_4\JJ\1740 <e2>psychosis</e2>_5\NN\14380140 are_6\VBP\836236 similar_7\JJ\1740 to_8\TO\1740 those_9\DT\1740 of_10\IN\1740 paranoid_11\NN\10490141 type_12\NN\5839024 schizophrenia_13\NN\14398067 ._14\.\1740
D008694_D011605 CID the_0\DT\1740 symptoms_1\NNS\5823932 of_2\IN\1740 methamphetamine_3\NN\2704153 <e1>(meth)-induced</e1>_4\JJ\1740 <e2>psychosis</e2>_5\NN\14380140 are_6\VBP\836236 similar_7\JJ\1740 to_8\TO\1740 those_9\DT\1740 of_10\IN\1740 paranoid_11\NN\10490141 type_12\NN\5839024 schizophrenia_13\NN\14398067 ._14\.\1740
D008694_D011605 CID therefore_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 conducted_3\VBD\2436349 an_4\DT\6697703 analysis_5\NN\633864 of_6\IN\1740 the_7\DT\1740 association_8\NN\8008335 of_9\IN\1740 the_10\DT\1740 5-ht6_11\JJ\1740 gene_12\NN\8459252 (_13\-LRB-\1740 htr6_14\NN\1740 )_15\-RRB-\1740 with_16\IN\1740 <e1>meth-induced</e1>_17\JJ\1740 <e2>psychosis</e2>_18\NN\14380140 ._19\.\1740
D008694_D011605 CID method_0\NNP\5616786 :_1\:\1740 using_2\VBG\1156834 five_3\CD\13741022 tagging_4\NN\1740 snps_5\NNS\11493266 (_6\-LRB-\1740 rs6693503_7\NN\1740 ,_8\,\1740 rs1805054_9\NN\1740 ,_10\,\1740 rs4912138_11\NN\1740 ,_12\,\1740 rs3790757_13\NN\1740 and_14\CC\1740 rs9659997_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 we_18\PRP\1740 conducted_19\VBD\2436349 a_20\DT\13649268 genetic_21\JJ\1740 association_22\NN\8008335 analysis_23\NN\633864 of_24\IN\1740 case-control_25\JJ\1740 samples_26\NNS\5820620 (_27\-LRB-\1740 197_28\CD\1740 <e1>meth-induced</e1>_29\JJ\1740 <e2>psychosis</e2>_30\NN\14380140 patients_31\NNS\9898892 and_32\CC\1740 337_33\CD\1740 controls_34\NNS\5190804 )_35\-RRB-\1740 in_36\IN\13603305 the_37\DT\1740 japanese_38\JJ\1740 population_39\NN\7942152 ._40\.\1740
D008694_D011605 CID results_0\NNS\34213 :_1\:\1740 rs6693503_2\NN\1740 was_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 <e1>meth-induced</e1>_6\JJ\1740 <e2>psychosis</e2>_7\NN\14380140 patients_8\NNS\9898892 in_9\IN\13603305 the_10\DT\1740 allele/genotype-wise_11\JJ\1740 analysis_12\NN\633864 ._13\.\1740
D008694_D011605 CID in_0\IN\13603305 the_1\DT\1740 haplotype-wise_2\JJ\1740 analysis_3\NN\633864 ,_4\,\1740 we_5\PRP\1740 detected_6\VBD\2163746 an_7\DT\6697703 association_8\NN\8008335 between_9\IN\1740 two_10\CD\13741022 markers_11\NNS\21939 (_12\-LRB-\1740 rs6693503_13\NN\1740 and_14\CC\1740 rs1805054_15\NN\1740 )_16\-RRB-\1740 and_17\CC\1740 three_18\CD\13741022 markers_19\NNS\21939 (_20\-LRB-\1740 rs6693503_21\NN\1740 ,_22\,\1740 rs1805054_23\NN\1740 and_24\CC\1740 rs4912138_25\NN\1740 )_26\-RRB-\1740 in_27\IN\13603305 htr6_28\NN\1740 and_29\CC\1740 <e1>meth-induced</e1>_30\JJ\1740 <e2>psychosis</e2>_31\NN\14380140 patients_32\NNS\9898892 ,_33\,\1740 respectively_34\RB\1740 ._35\.\1740
D008694_D011605 CID conclusion_0\NN\5837957 :_1\:\1740 htr6_2\NN\1740 may_3\MD\15209706 play_4\VB\1072262 an_5\DT\6697703 important_6\JJ\1740 role_7\NN\719494 in_8\IN\13603305 the_9\DT\1740 pathophysiology_10\NN\1740 of_11\IN\1740 <e1>meth-induced</e1>_12\JJ\1740 <e2>psychosis</e2>_13\NN\14380140 in_14\IN\13603305 the_15\DT\1740 japanese_16\JJ\1740 population_17\NN\7942152 ._18\.\1740
D012701_D006948 NONE the_0\DT\1740 <e1>serotonin</e1>_1\NN\14807737 6_2\CD\13741022 (_3\-LRB-\1740 5-ht6_4\JJ\1740 )_5\-RRB-\1740 receptor_6\NN\5225602 is_7\VBZ\836236 therapeutically_8\RB\1740 targeted_9\VBN\1151110 by_10\IN\1740 several_11\JJ\1740 second_12\JJ\1740 generation_13\NN\7942152 antipsychotics_14\NNS\4470232 ,_15\,\1740 such_16\JJ\1740 as_17\IN\14622893 clozapine_18\NN\3713736 and_19\CC\1740 olanzapine_20\NN\1740 ,_21\,\1740 and_22\CC\1740 d-amphetamine-induced_23\JJ\1740 <e2>hyperactivity</e2>_24\NN\14052403 in_25\IN\13603305 rats_26\NNS\2329401 is_27\VBZ\836236 corrected_28\VBN\138508 with_29\IN\1740 the_30\DT\1740 use_31\NN\407535 of_32\IN\1740 a_33\DT\13649268 selective_34\JJ\1740 5-ht6_35\NN\1740 receptor_36\NN\5225602 antagonist_37\NN\7846 ._38\.\1740
D012701_D006948 NONE the_0\DT\1740 serotonin_1\NN\14807737 6_2\CD\13741022 (_3\-LRB-\1740 <e1>5-ht6</e1>_4\JJ\1740 )_5\-RRB-\1740 receptor_6\NN\5225602 is_7\VBZ\836236 therapeutically_8\RB\1740 targeted_9\VBN\1151110 by_10\IN\1740 several_11\JJ\1740 second_12\JJ\1740 generation_13\NN\7942152 antipsychotics_14\NNS\4470232 ,_15\,\1740 such_16\JJ\1740 as_17\IN\14622893 clozapine_18\NN\3713736 and_19\CC\1740 olanzapine_20\NN\1740 ,_21\,\1740 and_22\CC\1740 d-amphetamine-induced_23\JJ\1740 <e2>hyperactivity</e2>_24\NN\14052403 in_25\IN\13603305 rats_26\NNS\2329401 is_27\VBZ\836236 corrected_28\VBN\138508 with_29\IN\1740 the_30\DT\1740 use_31\NN\407535 of_32\IN\1740 a_33\DT\13649268 selective_34\JJ\1740 5-ht6_35\NN\1740 receptor_36\NN\5225602 antagonist_37\NN\7846 ._38\.\1740
D012701_D006948 NONE the_0\DT\1740 serotonin_1\NN\14807737 6_2\CD\13741022 (_3\-LRB-\1740 5-ht6_4\JJ\1740 )_5\-RRB-\1740 receptor_6\NN\5225602 is_7\VBZ\836236 therapeutically_8\RB\1740 targeted_9\VBN\1151110 by_10\IN\1740 several_11\JJ\1740 second_12\JJ\1740 generation_13\NN\7942152 antipsychotics_14\NNS\4470232 ,_15\,\1740 such_16\JJ\1740 as_17\IN\14622893 clozapine_18\NN\3713736 and_19\CC\1740 olanzapine_20\NN\1740 ,_21\,\1740 and_22\CC\1740 d-amphetamine-induced_23\JJ\1740 <e2>hyperactivity</e2>_24\NN\14052403 in_25\IN\13603305 rats_26\NNS\2329401 is_27\VBZ\836236 corrected_28\VBN\138508 with_29\IN\1740 the_30\DT\1740 use_31\NN\407535 of_32\IN\1740 a_33\DT\13649268 selective_34\JJ\1740 <e1>5-ht6</e1>_35\NN\1740 receptor_36\NN\5225602 antagonist_37\NN\7846 ._38\.\1740
D003024_D006948 NONE the_0\DT\1740 serotonin_1\NN\14807737 6_2\CD\13741022 (_3\-LRB-\1740 5-ht6_4\JJ\1740 )_5\-RRB-\1740 receptor_6\NN\5225602 is_7\VBZ\836236 therapeutically_8\RB\1740 targeted_9\VBN\1151110 by_10\IN\1740 several_11\JJ\1740 second_12\JJ\1740 generation_13\NN\7942152 antipsychotics_14\NNS\4470232 ,_15\,\1740 such_16\JJ\1740 as_17\IN\14622893 <e1>clozapine</e1>_18\NN\3713736 and_19\CC\1740 olanzapine_20\NN\1740 ,_21\,\1740 and_22\CC\1740 d-amphetamine-induced_23\JJ\1740 <e2>hyperactivity</e2>_24\NN\14052403 in_25\IN\13603305 rats_26\NNS\2329401 is_27\VBZ\836236 corrected_28\VBN\138508 with_29\IN\1740 the_30\DT\1740 use_31\NN\407535 of_32\IN\1740 a_33\DT\13649268 selective_34\JJ\1740 5-ht6_35\NN\1740 receptor_36\NN\5225602 antagonist_37\NN\7846 ._38\.\1740
C076029_D006948 NONE the_0\DT\1740 serotonin_1\NN\14807737 6_2\CD\13741022 (_3\-LRB-\1740 5-ht6_4\JJ\1740 )_5\-RRB-\1740 receptor_6\NN\5225602 is_7\VBZ\836236 therapeutically_8\RB\1740 targeted_9\VBN\1151110 by_10\IN\1740 several_11\JJ\1740 second_12\JJ\1740 generation_13\NN\7942152 antipsychotics_14\NNS\4470232 ,_15\,\1740 such_16\JJ\1740 as_17\IN\14622893 clozapine_18\NN\3713736 and_19\CC\1740 <e1>olanzapine</e1>_20\NN\1740 ,_21\,\1740 and_22\CC\1740 d-amphetamine-induced_23\JJ\1740 <e2>hyperactivity</e2>_24\NN\14052403 in_25\IN\13603305 rats_26\NNS\2329401 is_27\VBZ\836236 corrected_28\VBN\138508 with_29\IN\1740 the_30\DT\1740 use_31\NN\407535 of_32\IN\1740 a_33\DT\13649268 selective_34\JJ\1740 5-ht6_35\NN\1740 receptor_36\NN\5225602 antagonist_37\NN\7846 ._38\.\1740
D003913_D006948 NONE the_0\DT\1740 serotonin_1\NN\14807737 6_2\CD\13741022 (_3\-LRB-\1740 5-ht6_4\JJ\1740 )_5\-RRB-\1740 receptor_6\NN\5225602 is_7\VBZ\836236 therapeutically_8\RB\1740 targeted_9\VBN\1151110 by_10\IN\1740 several_11\JJ\1740 second_12\JJ\1740 generation_13\NN\7942152 antipsychotics_14\NNS\4470232 ,_15\,\1740 such_16\JJ\1740 as_17\IN\14622893 clozapine_18\NN\3713736 and_19\CC\1740 olanzapine_20\NN\1740 ,_21\,\1740 and_22\CC\1740 <e1>d-amphetamine-induced</e1>_23\JJ\1740 <e2>hyperactivity</e2>_24\NN\14052403 in_25\IN\13603305 rats_26\NNS\2329401 is_27\VBZ\836236 corrected_28\VBN\138508 with_29\IN\1740 the_30\DT\1740 use_31\NN\407535 of_32\IN\1740 a_33\DT\13649268 selective_34\JJ\1740 5-ht6_35\NN\1740 receptor_36\NN\5225602 antagonist_37\NN\7846 ._38\.\1740
D012701_D012559 NONE these_0\DT\1740 animal_1\NN\4475 models_2\NNS\5888929 were_3\VBD\836236 considered_4\VBN\689344 to_5\TO\1740 reflect_6\VB\923793 the_7\DT\1740 positive_8\JJ\1740 symptoms_9\NNS\5823932 of_10\IN\1740 <e2>schizophrenia</e2>_11\NN\14398067 ,_12\,\1740 and_13\CC\1740 the_14\DT\1740 above_15\JJ\1740 evidence_16\NN\5816287 suggests_17\VBZ\1010118 that_18\IN\1740 altered_19\JJ\1740 <e1>5-ht6</e1>_20\JJ\1740 receptors_21\NNS\5225602 are_22\VBP\836236 involved_23\VBN\2676054 in_24\IN\13603305 the_25\DT\1740 pathophysiology_26\NN\1740 of_27\IN\1740 psychotic_28\JJ\1740 disorders_29\NNS\14034177 ._30\.\1740
D008694_D012563 NONE the_0\DT\1740 symptoms_1\NNS\5823932 of_2\IN\1740 <e1>methamphetamine</e1>_3\NN\2704153 (meth)-induced_4\JJ\1740 psychosis_5\NN\14380140 are_6\VBP\836236 similar_7\JJ\1740 to_8\TO\1740 those_9\DT\1740 of_10\IN\1740 <e2>paranoid_11\NN\10490141 type_12\NN\5839024 schizophrenia</e2>_13\NN\14398067 ._14\.\1740
D008694_D012563 NONE the_0\DT\1740 symptoms_1\NNS\5823932 of_2\IN\1740 methamphetamine_3\NN\2704153 <e1>(meth)-induced</e1>_4\JJ\1740 psychosis_5\NN\14380140 are_6\VBP\836236 similar_7\JJ\1740 to_8\TO\1740 those_9\DT\1740 of_10\IN\1740 <e2>paranoid_11\NN\10490141 type_12\NN\5839024 schizophrenia</e2>_13\NN\14398067 ._14\.\1740
14704468
C066440_D012640 NONE <e1>loreclezole</e1>_0\NNP\1740 (_1\-LRB-\1740 5_2\CD\13741022 mg/kg_3\NN\1740 )_4\-RRB-\1740 exerted_5\VBD\1158872 a_6\DT\13649268 significant_7\JJ\1740 protective_8\JJ\1740 action_9\NN\30358 in_10\IN\13603305 amygdala-kindled_11\JJ\1740 rats_12\NNS\2329401 ,_13\,\1740 reducing_14\VBG\441445 both_15\CC\1740 <e2>seizure</e2>_16\JJ\1740 and_17\CC\1740 afterdischarge_18\JJ\1740 durations_19\NNS\15113229 ._20\.\1740
18006530
D015742_D010146 CID reduction_0\NN\351485 of_1\IN\1740 <e2>pain</e2>_2\NN\14299637 during_3\IN\1740 induction_4\NN\7450842 with_5\IN\1740 target-controlled_6\JJ\1740 <e1>propofol</e1>_7\NN\1740 and_8\CC\1740 remifentanil_9\NN\1740 ._10\.\1740
D015742_D010146 CID background_0\NN\4921011 :_1\:\1740 <e2>pain</e2>_2\NN\14299637 on_3\IN\1740 injection_4\NN\320852 of_5\IN\1740 <e1>propofol</e1>_6\NN\1740 is_7\VBZ\836236 unpleasant_8\JJ\1740 ._9\.\1740
D015742_D010146 CID we_0\PRP\1740 hypothesized_1\VBD\719734 that_2\IN\1740 <e1>propofol</e1>_3\NN\1740 infusion_4\NN\14589223 <e2>pain</e2>_5\NN\14299637 might_6\MD\5029706 be_7\VB\836236 prevented_8\VBN\1740 by_9\IN\1740 infusing_10\VBG\606335 remifentanil_11\NN\1740 before_12\IN\1740 starting_13\VBG\2009433 the_14\DT\1740 propofol_15\NN\1740 infusion_16\NN\14589223 in_17\IN\13603305 a_18\DT\13649268 clinical_19\JJ\1740 setting_20\NN\8567235 where_21\WRB\1740 target-controlled_22\JJ\1740 infusions_23\NNS\14589223 (_24\-LRB-\1740 tci_25\NNP\1740 )_26\-RRB-\1740 of_27\IN\1740 both_28\DT\1740 drugs_29\NNS\14778436 were_30\VBD\836236 used_31\VBN\1156834 ._32\.\1740
D015742_D010146 CID we_0\PRP\1740 hypothesized_1\VBD\719734 that_2\IN\1740 propofol_3\NN\1740 infusion_4\NN\14589223 <e2>pain</e2>_5\NN\14299637 might_6\MD\5029706 be_7\VB\836236 prevented_8\VBN\1740 by_9\IN\1740 infusing_10\VBG\606335 remifentanil_11\NN\1740 before_12\IN\1740 starting_13\VBG\2009433 the_14\DT\1740 <e1>propofol</e1>_15\NN\1740 infusion_16\NN\14589223 in_17\IN\13603305 a_18\DT\13649268 clinical_19\JJ\1740 setting_20\NN\8567235 where_21\WRB\1740 target-controlled_22\JJ\1740 infusions_23\NNS\14589223 (_24\-LRB-\1740 tci_25\NNP\1740 )_26\-RRB-\1740 of_27\IN\1740 both_28\DT\1740 drugs_29\NNS\14778436 were_30\VBD\836236 used_31\VBN\1156834 ._32\.\1740
D015742_D010146 CID remifentanil-related_0\JJ\1740 complications_1\NNS\1073995 were_2\VBD\836236 assessed_3\VBN\670261 during_4\IN\1740 the_5\DT\1740 remifentanil_6\NN\1740 infusion_7\NN\14589223 ,_8\,\1740 and_9\CC\1740 <e2>pain</e2>_10\NN\14299637 caused_11\VBN\1617192 by_12\IN\1740 <e1>propofol</e1>_13\NN\1740 was_14\VBD\836236 evaluated_15\VBN\670261 using_16\VBG\1156834 a_17\DT\13649268 four-point_18\JJ\1740 scale_19\NN\7260623 during_20\IN\1740 the_21\DT\1740 propofol_22\NN\1740 infusion_23\NN\14589223 ._24\.\1740
D015742_D010146 CID remifentanil-related_0\JJ\1740 complications_1\NNS\1073995 were_2\VBD\836236 assessed_3\VBN\670261 during_4\IN\1740 the_5\DT\1740 remifentanil_6\NN\1740 infusion_7\NN\14589223 ,_8\,\1740 and_9\CC\1740 <e2>pain</e2>_10\NN\14299637 caused_11\VBN\1617192 by_12\IN\1740 propofol_13\NN\1740 was_14\VBD\836236 evaluated_15\VBN\670261 using_16\VBG\1156834 a_17\DT\13649268 four-point_18\JJ\1740 scale_19\NN\7260623 during_20\IN\1740 the_21\DT\1740 <e1>propofol</e1>_22\NN\1740 infusion_23\NN\14589223 ._24\.\1740
D015742_D010146 CID conclusions_0\NNS\5837957 :_1\:\1740 during_2\IN\1740 induction_3\NN\7450842 of_4\IN\1740 anaesthesia_5\NN\14034177 with_6\IN\1740 tci_7\NNP\1740 of_8\IN\1740 <e1>propofol</e1>_9\NN\1740 and_10\CC\1740 remifentanil_11\NN\1740 ,_12\,\1740 a_13\DT\13649268 significant_14\JJ\1740 reduction_15\NN\351485 in_16\IN\13603305 propofol_17\NN\1740 infusion_18\NN\14589223 <e2>pain</e2>_19\NN\14299637 was_20\VBD\836236 achieved_21\VBN\2524171 without_22\IN\1740 significant_23\JJ\1740 complications_24\NNS\1073995 by_25\IN\1740 prior_26\JJ\1740 administration_27\NN\1133281 of_28\IN\1740 remifentanil_29\NN\1740 at_30\IN\14622893 a_31\DT\13649268 target_32\NN\7258332 ce_33\NN\14625458 of_34\IN\1740 4_35\CD\13741022 ng_36\NN\13717155 ml(-1_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
D015742_D010146 CID conclusions_0\NNS\5837957 :_1\:\1740 during_2\IN\1740 induction_3\NN\7450842 of_4\IN\1740 anaesthesia_5\NN\14034177 with_6\IN\1740 tci_7\NNP\1740 of_8\IN\1740 propofol_9\NN\1740 and_10\CC\1740 remifentanil_11\NN\1740 ,_12\,\1740 a_13\DT\13649268 significant_14\JJ\1740 reduction_15\NN\351485 in_16\IN\13603305 <e1>propofol</e1>_17\NN\1740 infusion_18\NN\14589223 <e2>pain</e2>_19\NN\14299637 was_20\VBD\836236 achieved_21\VBN\2524171 without_22\IN\1740 significant_23\JJ\1740 complications_24\NNS\1073995 by_25\IN\1740 prior_26\JJ\1740 administration_27\NN\1133281 of_28\IN\1740 remifentanil_29\NN\1740 at_30\IN\14622893 a_31\DT\13649268 target_32\NN\7258332 ce_33\NN\14625458 of_34\IN\1740 4_35\CD\13741022 ng_36\NN\13717155 ml(-1_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
C071741_D010146 NONE reduction_0\NN\351485 of_1\IN\1740 <e2>pain</e2>_2\NN\14299637 during_3\IN\1740 induction_4\NN\7450842 with_5\IN\1740 target-controlled_6\JJ\1740 propofol_7\NN\1740 and_8\CC\1740 <e1>remifentanil</e1>_9\NN\1740 ._10\.\1740
C071741_D010146 NONE we_0\PRP\1740 hypothesized_1\VBD\719734 that_2\IN\1740 propofol_3\NN\1740 infusion_4\NN\14589223 <e2>pain</e2>_5\NN\14299637 might_6\MD\5029706 be_7\VB\836236 prevented_8\VBN\1740 by_9\IN\1740 infusing_10\VBG\606335 <e1>remifentanil</e1>_11\NN\1740 before_12\IN\1740 starting_13\VBG\2009433 the_14\DT\1740 propofol_15\NN\1740 infusion_16\NN\14589223 in_17\IN\13603305 a_18\DT\13649268 clinical_19\JJ\1740 setting_20\NN\8567235 where_21\WRB\1740 target-controlled_22\JJ\1740 infusions_23\NNS\14589223 (_24\-LRB-\1740 tci_25\NNP\1740 )_26\-RRB-\1740 of_27\IN\1740 both_28\DT\1740 drugs_29\NNS\14778436 were_30\VBD\836236 used_31\VBN\1156834 ._32\.\1740
C071741_D010146 NONE a_0\DT\13649268 prospective_1\JJ\1740 ,_2\,\1740 randomized_3\JJ\1740 ,_4\,\1740 double-blind_5\JJ\1740 ,_6\,\1740 placebo-controlled_7\JJ\1740 trial_8\NN\786195 was_9\VBD\836236 performed_10\VBN\2367363 to_11\TO\1740 determine_12\VB\1645601 the_13\DT\1740 effect-site_14\JJ\1740 concentration_15\NN\4916342 (_16\-LRB-\1740 ce_17\NN\14625458 )_18\-RRB-\1740 of_19\IN\1740 <e1>remifentanil</e1>_20\NN\1740 to_21\TO\1740 prevent_22\VB\1740 the_23\DT\1740 <e2>pain</e2>_24\NN\14299637 without_25\IN\1740 producing_26\VBG\1617192 complications_27\NNS\1073995 ._28\.\1740
C071741_D010146 NONE <e1>remifentanil-related</e1>_0\JJ\1740 complications_1\NNS\1073995 were_2\VBD\836236 assessed_3\VBN\670261 during_4\IN\1740 the_5\DT\1740 remifentanil_6\NN\1740 infusion_7\NN\14589223 ,_8\,\1740 and_9\CC\1740 <e2>pain</e2>_10\NN\14299637 caused_11\VBN\1617192 by_12\IN\1740 propofol_13\NN\1740 was_14\VBD\836236 evaluated_15\VBN\670261 using_16\VBG\1156834 a_17\DT\13649268 four-point_18\JJ\1740 scale_19\NN\7260623 during_20\IN\1740 the_21\DT\1740 propofol_22\NN\1740 infusion_23\NN\14589223 ._24\.\1740
C071741_D010146 NONE remifentanil-related_0\JJ\1740 complications_1\NNS\1073995 were_2\VBD\836236 assessed_3\VBN\670261 during_4\IN\1740 the_5\DT\1740 <e1>remifentanil</e1>_6\NN\1740 infusion_7\NN\14589223 ,_8\,\1740 and_9\CC\1740 <e2>pain</e2>_10\NN\14299637 caused_11\VBN\1617192 by_12\IN\1740 propofol_13\NN\1740 was_14\VBD\836236 evaluated_15\VBN\670261 using_16\VBG\1156834 a_17\DT\13649268 four-point_18\JJ\1740 scale_19\NN\7260623 during_20\IN\1740 the_21\DT\1740 propofol_22\NN\1740 infusion_23\NN\14589223 ._24\.\1740
C071741_D010146 NONE conclusions_0\NNS\5837957 :_1\:\1740 during_2\IN\1740 induction_3\NN\7450842 of_4\IN\1740 anaesthesia_5\NN\14034177 with_6\IN\1740 tci_7\NNP\1740 of_8\IN\1740 propofol_9\NN\1740 and_10\CC\1740 <e1>remifentanil</e1>_11\NN\1740 ,_12\,\1740 a_13\DT\13649268 significant_14\JJ\1740 reduction_15\NN\351485 in_16\IN\13603305 propofol_17\NN\1740 infusion_18\NN\14589223 <e2>pain</e2>_19\NN\14299637 was_20\VBD\836236 achieved_21\VBN\2524171 without_22\IN\1740 significant_23\JJ\1740 complications_24\NNS\1073995 by_25\IN\1740 prior_26\JJ\1740 administration_27\NN\1133281 of_28\IN\1740 remifentanil_29\NN\1740 at_30\IN\14622893 a_31\DT\13649268 target_32\NN\7258332 ce_33\NN\14625458 of_34\IN\1740 4_35\CD\13741022 ng_36\NN\13717155 ml(-1_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
C071741_D010146 NONE conclusions_0\NNS\5837957 :_1\:\1740 during_2\IN\1740 induction_3\NN\7450842 of_4\IN\1740 anaesthesia_5\NN\14034177 with_6\IN\1740 tci_7\NNP\1740 of_8\IN\1740 propofol_9\NN\1740 and_10\CC\1740 remifentanil_11\NN\1740 ,_12\,\1740 a_13\DT\13649268 significant_14\JJ\1740 reduction_15\NN\351485 in_16\IN\13603305 propofol_17\NN\1740 infusion_18\NN\14589223 <e2>pain</e2>_19\NN\14299637 was_20\VBD\836236 achieved_21\VBN\2524171 without_22\IN\1740 significant_23\JJ\1740 complications_24\NNS\1073995 by_25\IN\1740 prior_26\JJ\1740 administration_27\NN\1133281 of_28\IN\1740 <e1>remifentanil</e1>_29\NN\1740 at_30\IN\14622893 a_31\DT\13649268 target_32\NN\7258332 ce_33\NN\14625458 of_34\IN\1740 4_35\CD\13741022 ng_36\NN\13717155 ml(-1_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
8045270
C081198_D002375 NONE oral_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>kf17837</e1>_3\NN\1740 (_4\-LRB-\1740 2.5_5\CD\1740 ,_6\,\1740 10.0_7\CD\1740 and_8\CC\1740 30.0_9\CD\1740 mg/kg_10\NN\1740 )_11\-RRB-\1740 significantly_12\RB\1740 ameliorated_13\VBD\126264 the_14\DT\1740 <e2>cataleptic</e2>_15\JJ\1740 responses_16\NNS\11410625 induced_17\VBN\1627355 by_18\IN\1740 intracerebroventricular_19\JJ\1740 administration_20\NN\1133281 of_21\IN\1740 an_22\DT\6697703 adenosine_23\NN\14964367 a2a_24\NN\1740 receptor_25\NN\5225602 agonist_26\NN\9613191 ,_27\,\1740 cgs_28\NN\13577934 21680_29\CD\1740 (_30\-LRB-\1740 10_31\CD\13745420 micrograms_32\NNS\13717155 )_33\-RRB-\1740 ,_34\,\1740 in_35\IN\13603305 a_36\DT\13649268 dose-dependent_37\JJ\1740 manner_38\NN\4916342 ._39\.\1740
C081198_D002375 NONE <e1>kf17837</e1>_0\NN\1740 also_1\RB\1740 reduced_2\VBD\441445 the_3\DT\1740 <e2>catalepsy</e2>_4\NN\14023236 induced_5\VBN\1627355 by_6\IN\1740 haloperidol_7\NN\3713736 (_8\-LRB-\1740 1_9\CD\13741022 mg/kg_10\NN\1740 i.p._11\RB\1740 )_12\-RRB-\1740 and_13\CC\1740 by_14\IN\1740 reserpine_15\NN\2721160 (_16\-LRB-\1740 5_17\CD\13741022 mg/kg_18\NN\1740 i.p._19\RB\1740 )_20\-RRB-\1740 ._21\.\1740
D000241_D002375 NONE oral_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 kf17837_3\NN\1740 (_4\-LRB-\1740 2.5_5\CD\1740 ,_6\,\1740 10.0_7\CD\1740 and_8\CC\1740 30.0_9\CD\1740 mg/kg_10\NN\1740 )_11\-RRB-\1740 significantly_12\RB\1740 ameliorated_13\VBD\126264 the_14\DT\1740 <e2>cataleptic</e2>_15\JJ\1740 responses_16\NNS\11410625 induced_17\VBN\1627355 by_18\IN\1740 intracerebroventricular_19\JJ\1740 administration_20\NN\1133281 of_21\IN\1740 an_22\DT\6697703 <e1>adenosine</e1>_23\NN\14964367 a2a_24\NN\1740 receptor_25\NN\5225602 agonist_26\NN\9613191 ,_27\,\1740 cgs_28\NN\13577934 21680_29\CD\1740 (_30\-LRB-\1740 10_31\CD\13745420 micrograms_32\NNS\13717155 )_33\-RRB-\1740 ,_34\,\1740 in_35\IN\13603305 a_36\DT\13649268 dose-dependent_37\JJ\1740 manner_38\NN\4916342 ._39\.\1740
C061282_D002375 CID oral_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 kf17837_3\NN\1740 (_4\-LRB-\1740 2.5_5\CD\1740 ,_6\,\1740 10.0_7\CD\1740 and_8\CC\1740 30.0_9\CD\1740 mg/kg_10\NN\1740 )_11\-RRB-\1740 significantly_12\RB\1740 ameliorated_13\VBD\126264 the_14\DT\1740 <e2>cataleptic</e2>_15\JJ\1740 responses_16\NNS\11410625 induced_17\VBN\1627355 by_18\IN\1740 intracerebroventricular_19\JJ\1740 administration_20\NN\1133281 of_21\IN\1740 an_22\DT\6697703 adenosine_23\NN\14964367 a2a_24\NN\1740 receptor_25\NN\5225602 agonist_26\NN\9613191 ,_27\,\1740 <e1>cgs_28\NN\13577934 21680</e1>_29\CD\1740 (_30\-LRB-\1740 10_31\CD\13745420 micrograms_32\NNS\13717155 )_33\-RRB-\1740 ,_34\,\1740 in_35\IN\13603305 a_36\DT\13649268 dose-dependent_37\JJ\1740 manner_38\NN\4916342 ._39\.\1740
D006220_D002375 CID kf17837_0\NN\1740 also_1\RB\1740 reduced_2\VBD\441445 the_3\DT\1740 <e2>catalepsy</e2>_4\NN\14023236 induced_5\VBN\1627355 by_6\IN\1740 <e1>haloperidol</e1>_7\NN\3713736 (_8\-LRB-\1740 1_9\CD\13741022 mg/kg_10\NN\1740 i.p._11\RB\1740 )_12\-RRB-\1740 and_13\CC\1740 by_14\IN\1740 reserpine_15\NN\2721160 (_16\-LRB-\1740 5_17\CD\13741022 mg/kg_18\NN\1740 i.p._19\RB\1740 )_20\-RRB-\1740 ._21\.\1740
D012110_D002375 CID kf17837_0\NN\1740 also_1\RB\1740 reduced_2\VBD\441445 the_3\DT\1740 <e2>catalepsy</e2>_4\NN\14023236 induced_5\VBN\1627355 by_6\IN\1740 haloperidol_7\NN\3713736 (_8\-LRB-\1740 1_9\CD\13741022 mg/kg_10\NN\1740 i.p._11\RB\1740 )_12\-RRB-\1740 and_13\CC\1740 by_14\IN\1740 <e1>reserpine</e1>_15\NN\2721160 (_16\-LRB-\1740 5_17\CD\13741022 mg/kg_18\NN\1740 i.p._19\RB\1740 )_20\-RRB-\1740 ._21\.\1740
C081198_D010302 NONE furthermore_0\RB\1740 ,_1\,\1740 <e1>kf17837</e1>_2\NN\1740 may_3\MD\15209706 be_4\VB\836236 a_5\DT\13649268 useful_6\JJ\1740 drug_7\NN\14778436 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 <e2>parkinsonism</e2>_12\NN\14085708 ._13\.\1740
17344330
D008691_D013575 CID <e2>syncope</e2>_0\NN\7478169 and_1\CC\1740 qt_2\NNP\1740 prolongation_3\NN\1017987 among_4\IN\1740 patients_5\NNS\9898892 treated_6\VBN\2376958 with_7\IN\1740 <e1>methadone</e1>_8\NN\3808564 for_9\IN\1740 heroin_10\JJ\1740 dependence_11\NN\24720 in_12\IN\13603305 the_13\DT\1740 city_14\NN\8626283 of_15\IN\1740 copenhagen_16\NNP\1740 ._17\.\1740
D008691_D013575 CID as_0\IN\14622893 heroin_1\NN\3492717 addicts_2\NNS\10059582 sometimes_3\RB\1740 faint_4\VBP\23868 while_5\IN\15122231 using_6\VBG\1156834 illicit_7\NN\1740 drugs_8\NNS\14778436 ,_9\,\1740 doctors_10\NNS\10305802 might_11\MD\5029706 attribute_12\VB\670261 too_13\RB\1740 many_14\JJ\1740 episodes_15\NNS\7283608 of_16\IN\1740 <e2>syncope</e2>_17\NN\7478169 to_18\TO\1740 illicit_19\VB\1740 drug_20\NN\14778436 use_21\NN\407535 and_22\CC\1740 thereby_23\RB\1740 underestimate_24\VB\695226 the_25\DT\1740 incidence_26\NN\13821570 of_27\IN\1740 tdp_28\NN\1740 in_29\IN\13603305 this_30\DT\1740 special_31\JJ\1740 population_32\NN\7942152 ,_33\,\1740 and_34\CC\1740 the_35\DT\1740 high_36\JJ\1740 mortality_37\NN\5054863 in_38\IN\13603305 this_39\DT\1740 population_40\NN\7942152 may_41\MD\15209706 ,_42\,\1740 in_43\IN\13603305 part_44\NN\31921 ,_45\,\1740 be_46\VB\836236 caused_47\VBN\1617192 by_48\IN\1740 the_49\DT\1740 proarrhythmic_50\JJ\1740 effect_51\NN\34213 of_52\IN\1740 <e1>methadone</e1>_53\NN\3808564 ._54\.\1740
D008691_D013575 CID the_0\DT\1740 association_1\NN\8008335 between_2\IN\1740 opioid_3\NN\1740 dose_4\NN\3740161 and_5\CC\1740 qt_6\CD\1740 ,_7\,\1740 and_8\CC\1740 <e1>methadone</e1>_9\NN\3808564 dose_10\NN\3740161 and_11\CC\1740 reporting_12\NN\6681177 of_13\IN\1740 <e2>syncope</e2>_14\NN\7478169 was_15\VBD\836236 assessed_16\VBN\670261 using_17\VBG\1156834 multivariate_18\JJ\1740 linear_19\JJ\1740 regression_20\NN\14501726 and_21\CC\1740 logistic_22\JJ\1740 regression_23\NN\14501726 ,_24\,\1740 respectively_25\RB\1740 ._26\.\1740
D008691_D013575 CID a_0\DT\13649268 50_1\CD\13745420 mg_2\NN\13717155 higher_3\JJR\1740 <e1>methadone</e1>_4\NN\3808564 dose_5\NN\3740161 was_6\VBD\836236 associated_7\VBN\628491 with_8\IN\1740 a_9\DT\13649268 1.2_10\CD\1740 (_11\-LRB-\1740 95_12\CD\1740 %_13\NN\1740 ci_14\NN\13635336 1.1_15\CD\1740 to_16\TO\1740 1.4_17\CD\1740 )_18\-RRB-\1740 times_19\NNS\15113229 higher_20\JJR\1740 odds_21\NNS\4756635 for_22\IN\1740 <e2>syncope</e2>_23\NN\7478169 ._24\.\1740
D008691_D013575 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>methadone</e1>_2\NN\3808564 is_3\VBZ\836236 associated_4\VBN\628491 with_5\IN\1740 qt_6\NN\1740 prolongation_7\NN\1017987 and_8\CC\1740 higher_9\JJR\1740 reporting_10\NN\6681177 of_11\IN\1740 <e2>syncope</e2>_12\NN\7478169 in_13\IN\13603305 a_14\DT\13649268 population_15\NN\7942152 of_16\IN\1740 heroin_17\NN\3492717 addicts_18\NNS\10059582 ._19\.\1740
D008691_D008133 CID syncope_0\NN\7478169 and_1\CC\1740 <e2>qt_2\NNP\1740 prolongation</e2>_3\NN\1017987 among_4\IN\1740 patients_5\NNS\9898892 treated_6\VBN\2376958 with_7\IN\1740 <e1>methadone</e1>_8\NN\3808564 for_9\IN\1740 heroin_10\JJ\1740 dependence_11\NN\24720 in_12\IN\13603305 the_13\DT\1740 city_14\NN\8626283 of_15\IN\1740 copenhagen_16\NNP\1740 ._17\.\1740
D008691_D008133 CID among_0\IN\1740 the_1\DT\1740 subjects_2\NNS\6598915 treated_3\VBN\2376958 with_4\IN\1740 <e1>methadone</e1>_5\NN\3808564 ,_6\,\1740 28_7\CD\13745420 %_8\NN\1740 men_9\NNS\8208016 and_10\CC\1740 32_11\CD\1740 %_12\NN\1740 women_13\NNS\9605289 had_14\VBD\2108377 <e2>prolonged_15\VBN\317700 qtc_16\NN\1740 interval</e2>_17\NN\33615 ._18\.\1740
D008691_D008133 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>methadone</e1>_2\NN\3808564 is_3\VBZ\836236 associated_4\VBN\628491 with_5\IN\1740 <e2>qt_6\NN\1740 prolongation</e2>_7\NN\1017987 and_8\CC\1740 higher_9\JJR\1740 reporting_10\NN\6681177 of_11\IN\1740 syncope_12\NN\7478169 in_13\IN\13603305 a_14\DT\13649268 population_15\NN\7942152 of_16\IN\1740 heroin_17\NN\3492717 addicts_18\NNS\10059582 ._19\.\1740
D003932_D013575 NONE <e2>syncope</e2>_0\NN\7478169 and_1\CC\1740 qt_2\NNP\1740 prolongation_3\NN\1017987 among_4\IN\1740 patients_5\NNS\9898892 treated_6\VBN\2376958 with_7\IN\1740 methadone_8\NN\3808564 for_9\IN\1740 <e1>heroin</e1>_10\JJ\1740 dependence_11\NN\24720 in_12\IN\13603305 the_13\DT\1740 city_14\NN\8626283 of_15\IN\1740 copenhagen_16\NNP\1740 ._17\.\1740
D003932_D013575 NONE as_0\IN\14622893 <e1>heroin</e1>_1\NN\3492717 addicts_2\NNS\10059582 sometimes_3\RB\1740 faint_4\VBP\23868 while_5\IN\15122231 using_6\VBG\1156834 illicit_7\NN\1740 drugs_8\NNS\14778436 ,_9\,\1740 doctors_10\NNS\10305802 might_11\MD\5029706 attribute_12\VB\670261 too_13\RB\1740 many_14\JJ\1740 episodes_15\NNS\7283608 of_16\IN\1740 <e2>syncope</e2>_17\NN\7478169 to_18\TO\1740 illicit_19\VB\1740 drug_20\NN\14778436 use_21\NN\407535 and_22\CC\1740 thereby_23\RB\1740 underestimate_24\VB\695226 the_25\DT\1740 incidence_26\NN\13821570 of_27\IN\1740 tdp_28\NN\1740 in_29\IN\13603305 this_30\DT\1740 special_31\JJ\1740 population_32\NN\7942152 ,_33\,\1740 and_34\CC\1740 the_35\DT\1740 high_36\JJ\1740 mortality_37\NN\5054863 in_38\IN\13603305 this_39\DT\1740 population_40\NN\7942152 may_41\MD\15209706 ,_42\,\1740 in_43\IN\13603305 part_44\NN\31921 ,_45\,\1740 be_46\VB\836236 caused_47\VBN\1617192 by_48\IN\1740 the_49\DT\1740 proarrhythmic_50\JJ\1740 effect_51\NN\34213 of_52\IN\1740 methadone_53\NN\3808564 ._54\.\1740
D003932_D013575 NONE conclusions_0\NNS\5837957 :_1\:\1740 methadone_2\NN\3808564 is_3\VBZ\836236 associated_4\VBN\628491 with_5\IN\1740 qt_6\NN\1740 prolongation_7\NN\1017987 and_8\CC\1740 higher_9\JJR\1740 reporting_10\NN\6681177 of_11\IN\1740 <e2>syncope</e2>_12\NN\7478169 in_13\IN\13603305 a_14\DT\13649268 population_15\NN\7942152 of_16\IN\1740 <e1>heroin</e1>_17\NN\3492717 addicts_18\NNS\10059582 ._19\.\1740
D003932_D008133 NONE syncope_0\NN\7478169 and_1\CC\1740 <e2>qt_2\NNP\1740 prolongation</e2>_3\NN\1017987 among_4\IN\1740 patients_5\NNS\9898892 treated_6\VBN\2376958 with_7\IN\1740 methadone_8\NN\3808564 for_9\IN\1740 <e1>heroin</e1>_10\JJ\1740 dependence_11\NN\24720 in_12\IN\13603305 the_13\DT\1740 city_14\NN\8626283 of_15\IN\1740 copenhagen_16\NNP\1740 ._17\.\1740
D003932_D008133 NONE conclusions_0\NNS\5837957 :_1\:\1740 methadone_2\NN\3808564 is_3\VBZ\836236 associated_4\VBN\628491 with_5\IN\1740 <e2>qt_6\NN\1740 prolongation</e2>_7\NN\1017987 and_8\CC\1740 higher_9\JJR\1740 reporting_10\NN\6681177 of_11\IN\1740 syncope_12\NN\7478169 in_13\IN\13603305 a_14\DT\13649268 population_15\NN\7942152 of_16\IN\1740 <e1>heroin</e1>_17\NN\3492717 addicts_18\NNS\10059582 ._19\.\1740
D008691_D016171 NONE prolongation_0\NN\1017987 of_1\IN\1740 the_2\DT\1740 qt_3\NNP\1740 interval_4\NN\33615 in_5\IN\13603305 the_6\DT\1740 ecg_7\NN\7000195 of_8\IN\1740 patients_9\NNS\9898892 with_10\IN\1740 <e2>torsade_11\NN\1740 de_12\IN\1740 pointes</e2>_13\NNS\1740 (_14\-LRB-\1740 tdp_15\NN\1740 )_16\-RRB-\1740 has_17\VBZ\2108377 been_18\VBN\836236 reported_19\VBN\831651 in_20\IN\13603305 <e1>methadone</e1>_21\NN\3808564 users_22\NNS\7846 ._23\.\1740
D008691_D016171 NONE prolongation_0\NN\1017987 of_1\IN\1740 the_2\DT\1740 qt_3\NNP\1740 interval_4\NN\33615 in_5\IN\13603305 the_6\DT\1740 ecg_7\NN\7000195 of_8\IN\1740 patients_9\NNS\9898892 with_10\IN\1740 torsade_11\NN\1740 de_12\IN\1740 pointes_13\NNS\1740 (_14\-LRB-\1740 <e2>tdp</e2>_15\NN\1740 )_16\-RRB-\1740 has_17\VBZ\2108377 been_18\VBN\836236 reported_19\VBN\831651 in_20\IN\13603305 <e1>methadone</e1>_21\NN\3808564 users_22\NNS\7846 ._23\.\1740
D008691_D016171 NONE as_0\IN\14622893 heroin_1\NN\3492717 addicts_2\NNS\10059582 sometimes_3\RB\1740 faint_4\VBP\23868 while_5\IN\15122231 using_6\VBG\1156834 illicit_7\NN\1740 drugs_8\NNS\14778436 ,_9\,\1740 doctors_10\NNS\10305802 might_11\MD\5029706 attribute_12\VB\670261 too_13\RB\1740 many_14\JJ\1740 episodes_15\NNS\7283608 of_16\IN\1740 syncope_17\NN\7478169 to_18\TO\1740 illicit_19\VB\1740 drug_20\NN\14778436 use_21\NN\407535 and_22\CC\1740 thereby_23\RB\1740 underestimate_24\VB\695226 the_25\DT\1740 incidence_26\NN\13821570 of_27\IN\1740 <e2>tdp</e2>_28\NN\1740 in_29\IN\13603305 this_30\DT\1740 special_31\JJ\1740 population_32\NN\7942152 ,_33\,\1740 and_34\CC\1740 the_35\DT\1740 high_36\JJ\1740 mortality_37\NN\5054863 in_38\IN\13603305 this_39\DT\1740 population_40\NN\7942152 may_41\MD\15209706 ,_42\,\1740 in_43\IN\13603305 part_44\NN\31921 ,_45\,\1740 be_46\VB\836236 caused_47\VBN\1617192 by_48\IN\1740 the_49\DT\1740 proarrhythmic_50\JJ\1740 effect_51\NN\34213 of_52\IN\1740 <e1>methadone</e1>_53\NN\3808564 ._54\.\1740
D003932_D016171 NONE as_0\IN\14622893 <e1>heroin</e1>_1\NN\3492717 addicts_2\NNS\10059582 sometimes_3\RB\1740 faint_4\VBP\23868 while_5\IN\15122231 using_6\VBG\1156834 illicit_7\NN\1740 drugs_8\NNS\14778436 ,_9\,\1740 doctors_10\NNS\10305802 might_11\MD\5029706 attribute_12\VB\670261 too_13\RB\1740 many_14\JJ\1740 episodes_15\NNS\7283608 of_16\IN\1740 syncope_17\NN\7478169 to_18\TO\1740 illicit_19\VB\1740 drug_20\NN\14778436 use_21\NN\407535 and_22\CC\1740 thereby_23\RB\1740 underestimate_24\VB\695226 the_25\DT\1740 incidence_26\NN\13821570 of_27\IN\1740 <e2>tdp</e2>_28\NN\1740 in_29\IN\13603305 this_30\DT\1740 special_31\JJ\1740 population_32\NN\7942152 ,_33\,\1740 and_34\CC\1740 the_35\DT\1740 high_36\JJ\1740 mortality_37\NN\5054863 in_38\IN\13603305 this_39\DT\1740 population_40\NN\7942152 may_41\MD\15209706 ,_42\,\1740 in_43\IN\13603305 part_44\NN\31921 ,_45\,\1740 be_46\VB\836236 caused_47\VBN\1617192 by_48\IN\1740 the_49\DT\1740 proarrhythmic_50\JJ\1740 effect_51\NN\34213 of_52\IN\1740 methadone_53\NN\3808564 ._54\.\1740
9799166
D003042_D020521 CID <e2>stroke</e2>_0\NN\556313 and_1\CC\1740 <e1>cocaine</e1>_2\NN\3492717 or_3\CC\3541091 amphetamine_4\NN\3248958 use_5\NN\407535 ._6\.\1740
D003042_D020521 CID the_0\DT\1740 association_1\NN\8008335 of_2\IN\1740 <e1>cocaine</e1>_3\NN\3492717 and_4\CC\1740 amphetamine_5\NN\3248958 use_6\NN\407535 with_7\IN\1740 hemorrhagic_8\JJ\1740 and_9\CC\1740 ischemic_10\JJ\1740 <e2>stroke</e2>_11\NN\556313 is_12\VBZ\836236 based_13\VBN\2694933 almost_14\RB\1740 solely_15\RB\1740 on_16\IN\1740 data_17\NNS\7951464 from_18\IN\1740 case_19\NN\7283608 series_20\NN\8456993 ._21\.\1740
D003042_D020521 CID the_0\DT\1740 limited_1\JJ\1740 number_2\NN\5107765 of_3\IN\1740 epidemiologic_4\JJ\1740 studies_5\NNS\635850 of_6\IN\1740 <e2>stroke</e2>_7\NN\556313 and_8\CC\1740 use_9\NN\407535 of_10\IN\1740 <e1>cocaine</e1>_11\NN\3492717 and/or_12\CC\1740 amphetamine_13\NN\3248958 have_14\VBP\2108377 been_15\VBN\836236 done_16\VBN\1640855 in_17\IN\13603305 settings_18\NNS\8567235 that_19\WDT\1740 serve_20\VBP\2669789 mostly_21\RB\1740 the_22\DT\1740 poor_23\JJ\1740 and/or_24\CC\1740 minorities_25\NNS\7950920 ._26\.\1740
D003042_D020521 CID the_0\DT\1740 univariate_1\NN\1740 matched_2\VBN\2664769 odds_3\NNS\4756635 ratio_4\NN\13815152 for_5\IN\1740 <e2>stroke</e2>_6\NN\556313 in_7\IN\13603305 women_8\NNS\9605289 who_9\WP\8299493 admitted_10\VBD\822367 to_11\TO\1740 using_12\VBG\1156834 <e1>cocaine</e1>_13\NN\3492717 and/or_14\CC\1740 amphetamine_15\NN\3248958 was_16\VBD\836236 8.5_17\CD\1740 (_18\-LRB-\1740 95_19\CD\1740 %_20\NN\1740 confidence_21\NN\5697135 interval_22\NN\33615 =_23\JJ\1740 3.6_24\CD\1740 -_25\SYM\1740 20.0_26\CD\1740 )_27\-RRB-\1740 ._28\.\1740
D003042_D020521 CID the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 <e1>cocaine</e1>_3\NN\3492717 and/or_4\CC\1740 amphetamine_5\NN\3248958 is_6\VBZ\836236 a_7\DT\13649268 strong_8\JJ\1740 risk_9\NN\14541044 factor_10\NN\7326557 for_11\IN\1740 <e2>stroke</e2>_12\NN\556313 in_13\IN\13603305 this_14\DT\1740 socioeconomically_15\RB\1740 heterogeneous_16\JJ\1740 ,_17\,\1740 insured_18\VBN\664483 urban_19\JJ\1740 population_20\NN\7942152 ._21\.\1740
D000661_D020521 CID <e2>stroke</e2>_0\NN\556313 and_1\CC\1740 cocaine_2\NN\3492717 or_3\CC\3541091 <e1>amphetamine</e1>_4\NN\3248958 use_5\NN\407535 ._6\.\1740
D000661_D020521 CID the_0\DT\1740 association_1\NN\8008335 of_2\IN\1740 cocaine_3\NN\3492717 and_4\CC\1740 <e1>amphetamine</e1>_5\NN\3248958 use_6\NN\407535 with_7\IN\1740 hemorrhagic_8\JJ\1740 and_9\CC\1740 ischemic_10\JJ\1740 <e2>stroke</e2>_11\NN\556313 is_12\VBZ\836236 based_13\VBN\2694933 almost_14\RB\1740 solely_15\RB\1740 on_16\IN\1740 data_17\NNS\7951464 from_18\IN\1740 case_19\NN\7283608 series_20\NN\8456993 ._21\.\1740
D000661_D020521 CID the_0\DT\1740 limited_1\JJ\1740 number_2\NN\5107765 of_3\IN\1740 epidemiologic_4\JJ\1740 studies_5\NNS\635850 of_6\IN\1740 <e2>stroke</e2>_7\NN\556313 and_8\CC\1740 use_9\NN\407535 of_10\IN\1740 cocaine_11\NN\3492717 and/or_12\CC\1740 <e1>amphetamine</e1>_13\NN\3248958 have_14\VBP\2108377 been_15\VBN\836236 done_16\VBN\1640855 in_17\IN\13603305 settings_18\NNS\8567235 that_19\WDT\1740 serve_20\VBP\2669789 mostly_21\RB\1740 the_22\DT\1740 poor_23\JJ\1740 and/or_24\CC\1740 minorities_25\NNS\7950920 ._26\.\1740
D000661_D020521 CID the_0\DT\1740 univariate_1\NN\1740 matched_2\VBN\2664769 odds_3\NNS\4756635 ratio_4\NN\13815152 for_5\IN\1740 <e2>stroke</e2>_6\NN\556313 in_7\IN\13603305 women_8\NNS\9605289 who_9\WP\8299493 admitted_10\VBD\822367 to_11\TO\1740 using_12\VBG\1156834 cocaine_13\NN\3492717 and/or_14\CC\1740 <e1>amphetamine</e1>_15\NN\3248958 was_16\VBD\836236 8.5_17\CD\1740 (_18\-LRB-\1740 95_19\CD\1740 %_20\NN\1740 confidence_21\NN\5697135 interval_22\NN\33615 =_23\JJ\1740 3.6_24\CD\1740 -_25\SYM\1740 20.0_26\CD\1740 )_27\-RRB-\1740 ._28\.\1740
D000661_D020521 CID the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 cocaine_3\NN\3492717 and/or_4\CC\1740 <e1>amphetamine</e1>_5\NN\3248958 is_6\VBZ\836236 a_7\DT\13649268 strong_8\JJ\1740 risk_9\NN\14541044 factor_10\NN\7326557 for_11\IN\1740 <e2>stroke</e2>_12\NN\556313 in_13\IN\13603305 this_14\DT\1740 socioeconomically_15\RB\1740 heterogeneous_16\JJ\1740 ,_17\,\1740 insured_18\VBN\664483 urban_19\JJ\1740 population_20\NN\7942152 ._21\.\1740
D003042_D007511 NONE the_0\DT\1740 association_1\NN\8008335 of_2\IN\1740 <e1>cocaine</e1>_3\NN\3492717 and_4\CC\1740 amphetamine_5\NN\3248958 use_6\NN\407535 with_7\IN\1740 hemorrhagic_8\JJ\1740 and_9\CC\1740 <e2>ischemic</e2>_10\JJ\1740 stroke_11\NN\556313 is_12\VBZ\836236 based_13\VBN\2694933 almost_14\RB\1740 solely_15\RB\1740 on_16\IN\1740 data_17\NNS\7951464 from_18\IN\1740 case_19\NN\7283608 series_20\NN\8456993 ._21\.\1740
D000661_D007511 NONE the_0\DT\1740 association_1\NN\8008335 of_2\IN\1740 cocaine_3\NN\3492717 and_4\CC\1740 <e1>amphetamine</e1>_5\NN\3248958 use_6\NN\407535 with_7\IN\1740 hemorrhagic_8\JJ\1740 and_9\CC\1740 <e2>ischemic</e2>_10\JJ\1740 stroke_11\NN\556313 is_12\VBZ\836236 based_13\VBN\2694933 almost_14\RB\1740 solely_15\RB\1740 on_16\IN\1740 data_17\NNS\7951464 from_18\IN\1740 case_19\NN\7283608 series_20\NN\8456993 ._21\.\1740
11226639
D008550_D053608 CID dual_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>melatonin</e1>_3\NN\5407119 on_4\IN\1740 barbiturate-induced_5\JJ\1740 <e2>narcosis</e2>_6\NN\5678932 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D008550_D053608 CID <e1>melatonin</e1>_0\NNP\5407119 affects_1\VBZ\126264 the_2\DT\1740 circadian_3\JJ\1740 sleep/wake_4\NN\1740 cycle_5\NN\15269513 ,_6\,\1740 but_7\CC\1740 it_8\PRP\6125041 is_9\VBZ\836236 not_10\RB\1740 clear_11\JJ\1740 whether_12\IN\1740 it_13\PRP\6125041 may_14\MD\15209706 influence_15\VB\137313 drug-induced_16\JJ\1740 <e2>narcosis</e2>_17\NN\5678932 ._18\.\1740
D008550_D053608 CID <e1>melatonin</e1>_0\NN\5407119 pre-treatment_1\NN\1740 affected_2\VBD\126264 in_3\IN\13603305 a_4\DT\13649268 dual_5\JJ\1740 manner_6\NN\4916342 barbiturate_7\NN\4166841 <e2>narcosis</e2>_8\NN\5678932 ,_9\,\1740 however_10\RB\1740 ,_11\,\1740 no_12\DT\7204911 dose-effect_13\JJ\1740 correlation_14\NN\13841213 was_15\VBD\836236 found_16\VBN\2426171 ._17\.\1740
D008550_D053608 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 the_3\DT\1740 highest_4\JJS\1740 dose_5\NN\3740161 of_6\IN\1740 <e1>melatonin</e1>_7\NN\5407119 (_8\-LRB-\1740 50_9\CD\13745420 mg/kg_10\NN\1740 )_11\-RRB-\1740 caused_12\VBD\1617192 a_13\DT\13649268 paradoxical_14\JJ\1740 increase_15\NN\13576355 in_16\IN\13603305 the_17\DT\1740 latency_18\NN\15269513 and_19\CC\1740 produced_20\VBD\1617192 a_21\DT\13649268 sustained_22\JJ\1740 reduction_23\NN\351485 of_24\IN\1740 the_25\DT\1740 duration_26\NN\15113229 of_27\IN\1740 <e2>narcosis</e2>_28\NN\5678932 ,_29\,\1740 and_30\CC\1740 a_31\DT\13649268 reduction_32\NN\351485 in_33\IN\13603305 mortality_34\NN\5054863 rate_35\NN\13815152 ._36\.\1740
D008550_D053608 CID <e1>melatonin</e1>_0\NN\5407119 0.5_1\CD\1740 and_2\CC\1740 5_3\CD\13741022 mg/kg_4\NN\1740 influenced_5\VBD\137313 the_6\DT\1740 duration_7\NN\15113229 but_8\CC\1740 not_9\RB\1740 the_10\DT\1740 latency_11\NN\15269513 of_12\IN\1740 ketamine-_13\NN\1740 or_14\CC\3541091 diazepam-induced_15\JJ\1740 <e2>narcosis</e2>_16\NN\5678932 ._17\.\1740
D008550_D053608 CID thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 dual_3\JJ\1740 action_4\NN\30358 of_5\IN\1740 <e1>melatonin</e1>_6\NN\5407119 on_7\IN\1740 pharmacological_8\JJ\1740 <e2>narcosis</e2>_9\NN\5678932 seems_10\VBZ\2604760 to_11\TO\1740 be_12\VB\836236 specific_13\JJ\1740 for_14\IN\1740 the_15\DT\1740 barbiturate_16\NN\4166841 mechanism_17\NN\13446390 of_18\IN\1740 action_19\NN\30358 ._20\.\1740
C032232_D053608 NONE dual_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 melatonin_3\NN\5407119 on_4\IN\1740 <e1>barbiturate-induced</e1>_5\JJ\1740 <e2>narcosis</e2>_6\NN\5678932 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
C032232_D053608 NONE melatonin_0\NN\5407119 pre-treatment_1\NN\1740 affected_2\VBD\126264 in_3\IN\13603305 a_4\DT\13649268 dual_5\JJ\1740 manner_6\NN\4916342 <e1>barbiturate</e1>_7\NN\4166841 <e2>narcosis</e2>_8\NN\5678932 ,_9\,\1740 however_10\RB\1740 ,_11\,\1740 no_12\DT\7204911 dose-effect_13\JJ\1740 correlation_14\NN\13841213 was_15\VBD\836236 found_16\VBN\2426171 ._17\.\1740
C032232_D053608 NONE in_0\IN\13603305 particular_1\JJ\1740 ,_2\,\1740 low_3\JJ\1740 doses_4\NNS\3740161 reduced_5\VBD\441445 the_6\DT\1740 latency_7\NN\15269513 to_8\TO\1740 and_9\CC\1740 prolonged_10\VBD\317700 the_11\DT\1740 duration_12\NN\15113229 of_13\IN\1740 <e1>barbiturate</e1>_14\NN\4166841 <e2>narcosis</e2>_15\NN\5678932 ._16\.\1740
C032232_D053608 NONE thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 dual_3\JJ\1740 action_4\NN\30358 of_5\IN\1740 melatonin_6\NN\5407119 on_7\IN\1740 pharmacological_8\JJ\1740 <e2>narcosis</e2>_9\NN\5678932 seems_10\VBZ\2604760 to_11\TO\1740 be_12\VB\836236 specific_13\JJ\1740 for_14\IN\1740 the_15\DT\1740 <e1>barbiturate</e1>_16\NN\4166841 mechanism_17\NN\13446390 of_18\IN\1740 action_19\NN\30358 ._20\.\1740
D007649_D053608 CID melatonin_0\NN\5407119 0.5_1\CD\1740 and_2\CC\1740 5_3\CD\13741022 mg/kg_4\NN\1740 influenced_5\VBD\137313 the_6\DT\1740 duration_7\NN\15113229 but_8\CC\1740 not_9\RB\1740 the_10\DT\1740 latency_11\NN\15269513 of_12\IN\1740 <e1>ketamine-</e1>_13\NN\1740 or_14\CC\3541091 diazepam-induced_15\JJ\1740 <e2>narcosis</e2>_16\NN\5678932 ._17\.\1740
D003975_D053608 CID melatonin_0\NN\5407119 0.5_1\CD\1740 and_2\CC\1740 5_3\CD\13741022 mg/kg_4\NN\1740 influenced_5\VBD\137313 the_6\DT\1740 duration_7\NN\15113229 but_8\CC\1740 not_9\RB\1740 the_10\DT\1740 latency_11\NN\15269513 of_12\IN\1740 ketamine-_13\NN\1740 or_14\CC\3541091 <e1>diazepam-induced</e1>_15\JJ\1740 <e2>narcosis</e2>_16\NN\5678932 ._17\.\1740
2894433
D003975_D001919 CID <e1>diazepam</e1>_0\NNS\2830852 facilitates_1\VBZ\2547586 reflex_2\JJ\1740 <e2>bradycardia</e2>_3\NN\14110674 in_4\IN\13603305 conscious_5\JJ\1740 rats_6\NNS\2329401 ._7\.\1740
D003975_D001919 CID intravenous_0\JJ\1740 pretreatment_1\NN\1740 of_2\IN\1740 the_3\DT\1740 rats_4\NNS\2329401 with_5\IN\1740 <e1>diazepam</e1>_6\NNS\2830852 ,_7\,\1740 although_8\IN\1740 causing_9\VBG\1617192 no_10\DT\7204911 change_11\NN\7283608 in_12\IN\13603305 the_13\DT\1740 adrenaline-induced_14\JJ\1740 pressor_15\NN\9190918 effect_16\NN\34213 ,_17\,\1740 did_18\VBD\1640855 enhance_19\VB\227165 the_20\DT\1740 adrenaline-induced_21\JJ\1740 reflex_22\JJ\1740 <e2>bradycardia</e2>_23\NN\14110674 ._24\.\1740
D003975_D001919 CID however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 <e1>diazepam</e1>_3\NN\2830852 enhancement_4\NN\248977 of_5\IN\1740 adrenaline-induced_6\JJ\1740 reflex_7\JJ\1740 <e2>bradycardia</e2>_8\NN\14110674 was_9\VBD\836236 antagonized_10\VBN\1787955 by_11\IN\1740 pretreatment_12\NN\1740 of_13\IN\1740 rats_14\NNS\2329401 with_15\IN\1740 an_16\DT\6697703 intravenous_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 picrotoxin_20\NN\1740 (_21\-LRB-\1740 an_22\DT\6697703 agent_23\NN\7347 blocks_24\VBZ\1476483 chloride_25\NN\14818238 channels_26\NNS\6251781 by_27\IN\1740 binding_28\VBG\1290422 to_29\TO\1740 sites_30\NNS\8673395 associated_31\VBN\628491 with_32\IN\1740 the_33\DT\1740 benzodiazepine-gaba-chloride_34\NN\1740 channel_35\NN\6251781 macromolecular_36\JJ\1740 complex_37\NN\5869584 )_38\-RRB-\1740 ._39\.\1740
D003975_D001919 CID the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>diazepam</e1>_4\NN\2830852 acts_5\VBZ\1619354 through_6\IN\1740 the_7\DT\1740 benzodiazepine-gaba-chloride_8\NN\1740 channel_9\NN\6251781 macromolecular_10\JJ\1740 complex_11\NN\5869584 within_12\IN\1740 the_13\DT\1740 central_14\JJ\1740 nervous_15\JJ\1740 system_16\NN\3575240 to_17\TO\1740 facilitate_18\VB\2547586 reflex_19\JJ\1740 <e2>bradycardia</e2>_20\NN\14110674 mediated_21\VBN\761713 through_22\IN\1740 baroreceptor_23\NN\5299178 reflexes_24\NNS\859001 in_25\IN\13603305 response_26\NN\11410625 to_27\TO\1740 an_28\DT\6697703 acute_29\JJ\1740 increase_30\NN\13576355 in_31\IN\13603305 arterial_32\JJ\1740 pressure_33\NN\11419404 ._34\.\1740
D004837_D001919 CID also_0\RB\1740 ,_1\,\1740 reflex_2\JJ\1740 <e2>bradycardia</e2>_3\NN\14110674 was_4\VBD\836236 produced_5\VBN\1617192 in_6\IN\13603305 rats_7\NNS\2329401 by_8\IN\1740 intravenous_9\JJ\1740 infusion_10\NN\14589223 of_11\IN\1740 <e1>adrenaline</e1>_12\NN\14807929 (_13\-LRB-\1740 1.25_14\CD\1740 -_15\SYM\1740 2.5_16\CD\1740 micrograms_17\NNS\13717155 kg-1_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D004837_D001919 CID intravenous_0\JJ\1740 pretreatment_1\NN\1740 of_2\IN\1740 the_3\DT\1740 rats_4\NNS\2329401 with_5\IN\1740 diazepam_6\NNS\2830852 ,_7\,\1740 although_8\IN\1740 causing_9\VBG\1617192 no_10\DT\7204911 change_11\NN\7283608 in_12\IN\13603305 the_13\DT\1740 <e1>adrenaline-induced</e1>_14\JJ\1740 pressor_15\NN\9190918 effect_16\NN\34213 ,_17\,\1740 did_18\VBD\1640855 enhance_19\VB\227165 the_20\DT\1740 adrenaline-induced_21\JJ\1740 reflex_22\JJ\1740 <e2>bradycardia</e2>_23\NN\14110674 ._24\.\1740
D004837_D001919 CID intravenous_0\JJ\1740 pretreatment_1\NN\1740 of_2\IN\1740 the_3\DT\1740 rats_4\NNS\2329401 with_5\IN\1740 diazepam_6\NNS\2830852 ,_7\,\1740 although_8\IN\1740 causing_9\VBG\1617192 no_10\DT\7204911 change_11\NN\7283608 in_12\IN\13603305 the_13\DT\1740 adrenaline-induced_14\JJ\1740 pressor_15\NN\9190918 effect_16\NN\34213 ,_17\,\1740 did_18\VBD\1640855 enhance_19\VB\227165 the_20\DT\1740 <e1>adrenaline-induced</e1>_21\JJ\1740 reflex_22\JJ\1740 <e2>bradycardia</e2>_23\NN\14110674 ._24\.\1740
D004837_D001919 CID however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 diazepam_3\NN\2830852 enhancement_4\NN\248977 of_5\IN\1740 <e1>adrenaline-induced</e1>_6\JJ\1740 reflex_7\JJ\1740 <e2>bradycardia</e2>_8\NN\14110674 was_9\VBD\836236 antagonized_10\VBN\1787955 by_11\IN\1740 pretreatment_12\NN\1740 of_13\IN\1740 rats_14\NNS\2329401 with_15\IN\1740 an_16\DT\6697703 intravenous_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 picrotoxin_20\NN\1740 (_21\-LRB-\1740 an_22\DT\6697703 agent_23\NN\7347 blocks_24\VBZ\1476483 chloride_25\NN\14818238 channels_26\NNS\6251781 by_27\IN\1740 binding_28\VBG\1290422 to_29\TO\1740 sites_30\NNS\8673395 associated_31\VBN\628491 with_32\IN\1740 the_33\DT\1740 benzodiazepine-gaba-chloride_34\NN\1740 channel_35\NN\6251781 macromolecular_36\JJ\1740 complex_37\NN\5869584 )_38\-RRB-\1740 ._39\.\1740
D010852_D001919 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 diazepam_3\NN\2830852 enhancement_4\NN\248977 of_5\IN\1740 adrenaline-induced_6\JJ\1740 reflex_7\JJ\1740 <e2>bradycardia</e2>_8\NN\14110674 was_9\VBD\836236 antagonized_10\VBN\1787955 by_11\IN\1740 pretreatment_12\NN\1740 of_13\IN\1740 rats_14\NNS\2329401 with_15\IN\1740 an_16\DT\6697703 intravenous_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 <e1>picrotoxin</e1>_20\NN\1740 (_21\-LRB-\1740 an_22\DT\6697703 agent_23\NN\7347 blocks_24\VBZ\1476483 chloride_25\NN\14818238 channels_26\NNS\6251781 by_27\IN\1740 binding_28\VBG\1290422 to_29\TO\1740 sites_30\NNS\8673395 associated_31\VBN\628491 with_32\IN\1740 the_33\DT\1740 benzodiazepine-gaba-chloride_34\NN\1740 channel_35\NN\6251781 macromolecular_36\JJ\1740 complex_37\NN\5869584 )_38\-RRB-\1740 ._39\.\1740
D002712_D001919 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 diazepam_3\NN\2830852 enhancement_4\NN\248977 of_5\IN\1740 adrenaline-induced_6\JJ\1740 reflex_7\JJ\1740 <e2>bradycardia</e2>_8\NN\14110674 was_9\VBD\836236 antagonized_10\VBN\1787955 by_11\IN\1740 pretreatment_12\NN\1740 of_13\IN\1740 rats_14\NNS\2329401 with_15\IN\1740 an_16\DT\6697703 intravenous_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 picrotoxin_20\NN\1740 (_21\-LRB-\1740 an_22\DT\6697703 agent_23\NN\7347 blocks_24\VBZ\1476483 <e1>chloride</e1>_25\NN\14818238 channels_26\NNS\6251781 by_27\IN\1740 binding_28\VBG\1290422 to_29\TO\1740 sites_30\NNS\8673395 associated_31\VBN\628491 with_32\IN\1740 the_33\DT\1740 benzodiazepine-gaba-chloride_34\NN\1740 channel_35\NN\6251781 macromolecular_36\JJ\1740 complex_37\NN\5869584 )_38\-RRB-\1740 ._39\.\1740
D002712_D001919 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 diazepam_3\NN\2830852 enhancement_4\NN\248977 of_5\IN\1740 adrenaline-induced_6\JJ\1740 reflex_7\JJ\1740 <e2>bradycardia</e2>_8\NN\14110674 was_9\VBD\836236 antagonized_10\VBN\1787955 by_11\IN\1740 pretreatment_12\NN\1740 of_13\IN\1740 rats_14\NNS\2329401 with_15\IN\1740 an_16\DT\6697703 intravenous_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 picrotoxin_20\NN\1740 (_21\-LRB-\1740 an_22\DT\6697703 agent_23\NN\7347 blocks_24\VBZ\1476483 chloride_25\NN\14818238 channels_26\NNS\6251781 by_27\IN\1740 binding_28\VBG\1290422 to_29\TO\1740 sites_30\NNS\8673395 associated_31\VBN\628491 with_32\IN\1740 the_33\DT\1740 <e1>benzodiazepine-gaba-chloride</e1>_34\NN\1740 channel_35\NN\6251781 macromolecular_36\JJ\1740 complex_37\NN\5869584 )_38\-RRB-\1740 ._39\.\1740
D002712_D001919 NONE the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 diazepam_4\NN\2830852 acts_5\VBZ\1619354 through_6\IN\1740 the_7\DT\1740 <e1>benzodiazepine-gaba-chloride</e1>_8\NN\1740 channel_9\NN\6251781 macromolecular_10\JJ\1740 complex_11\NN\5869584 within_12\IN\1740 the_13\DT\1740 central_14\JJ\1740 nervous_15\JJ\1740 system_16\NN\3575240 to_17\TO\1740 facilitate_18\VB\2547586 reflex_19\JJ\1740 <e2>bradycardia</e2>_20\NN\14110674 mediated_21\VBN\761713 through_22\IN\1740 baroreceptor_23\NN\5299178 reflexes_24\NNS\859001 in_25\IN\13603305 response_26\NN\11410625 to_27\TO\1740 an_28\DT\6697703 acute_29\JJ\1740 increase_30\NN\13576355 in_31\IN\13603305 arterial_32\JJ\1740 pressure_33\NN\11419404 ._34\.\1740
D001569_D001919 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 diazepam_3\NN\2830852 enhancement_4\NN\248977 of_5\IN\1740 adrenaline-induced_6\JJ\1740 reflex_7\JJ\1740 <e2>bradycardia</e2>_8\NN\14110674 was_9\VBD\836236 antagonized_10\VBN\1787955 by_11\IN\1740 pretreatment_12\NN\1740 of_13\IN\1740 rats_14\NNS\2329401 with_15\IN\1740 an_16\DT\6697703 intravenous_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 picrotoxin_20\NN\1740 (_21\-LRB-\1740 an_22\DT\6697703 agent_23\NN\7347 blocks_24\VBZ\1476483 chloride_25\NN\14818238 channels_26\NNS\6251781 by_27\IN\1740 binding_28\VBG\1290422 to_29\TO\1740 sites_30\NNS\8673395 associated_31\VBN\628491 with_32\IN\1740 the_33\DT\1740 <e1>benzodiazepine-gaba-chloride</e1>_34\NN\1740 channel_35\NN\6251781 macromolecular_36\JJ\1740 complex_37\NN\5869584 )_38\-RRB-\1740 ._39\.\1740
D001569_D001919 NONE the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 diazepam_4\NN\2830852 acts_5\VBZ\1619354 through_6\IN\1740 the_7\DT\1740 <e1>benzodiazepine-gaba-chloride</e1>_8\NN\1740 channel_9\NN\6251781 macromolecular_10\JJ\1740 complex_11\NN\5869584 within_12\IN\1740 the_13\DT\1740 central_14\JJ\1740 nervous_15\JJ\1740 system_16\NN\3575240 to_17\TO\1740 facilitate_18\VB\2547586 reflex_19\JJ\1740 <e2>bradycardia</e2>_20\NN\14110674 mediated_21\VBN\761713 through_22\IN\1740 baroreceptor_23\NN\5299178 reflexes_24\NNS\859001 in_25\IN\13603305 response_26\NN\11410625 to_27\TO\1740 an_28\DT\6697703 acute_29\JJ\1740 increase_30\NN\13576355 in_31\IN\13603305 arterial_32\JJ\1740 pressure_33\NN\11419404 ._34\.\1740
D005680_D001919 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 diazepam_3\NN\2830852 enhancement_4\NN\248977 of_5\IN\1740 adrenaline-induced_6\JJ\1740 reflex_7\JJ\1740 <e2>bradycardia</e2>_8\NN\14110674 was_9\VBD\836236 antagonized_10\VBN\1787955 by_11\IN\1740 pretreatment_12\NN\1740 of_13\IN\1740 rats_14\NNS\2329401 with_15\IN\1740 an_16\DT\6697703 intravenous_17\JJ\1740 dose_18\NN\3740161 of_19\IN\1740 picrotoxin_20\NN\1740 (_21\-LRB-\1740 an_22\DT\6697703 agent_23\NN\7347 blocks_24\VBZ\1476483 chloride_25\NN\14818238 channels_26\NNS\6251781 by_27\IN\1740 binding_28\VBG\1290422 to_29\TO\1740 sites_30\NNS\8673395 associated_31\VBN\628491 with_32\IN\1740 the_33\DT\1740 <e1>benzodiazepine-gaba-chloride</e1>_34\NN\1740 channel_35\NN\6251781 macromolecular_36\JJ\1740 complex_37\NN\5869584 )_38\-RRB-\1740 ._39\.\1740
D005680_D001919 NONE the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 diazepam_4\NN\2830852 acts_5\VBZ\1619354 through_6\IN\1740 the_7\DT\1740 <e1>benzodiazepine-gaba-chloride</e1>_8\NN\1740 channel_9\NN\6251781 macromolecular_10\JJ\1740 complex_11\NN\5869584 within_12\IN\1740 the_13\DT\1740 central_14\JJ\1740 nervous_15\JJ\1740 system_16\NN\3575240 to_17\TO\1740 facilitate_18\VB\2547586 reflex_19\JJ\1740 <e2>bradycardia</e2>_20\NN\14110674 mediated_21\VBN\761713 through_22\IN\1740 baroreceptor_23\NN\5299178 reflexes_24\NNS\859001 in_25\IN\13603305 response_26\NN\11410625 to_27\TO\1740 an_28\DT\6697703 acute_29\JJ\1740 increase_30\NN\13576355 in_31\IN\13603305 arterial_32\JJ\1740 pressure_33\NN\11419404 ._34\.\1740
7905523
C059896_D015658 NONE the_0\DT\1740 safety_1\NN\13920835 and_2\CC\1740 efficacy_3\NN\5199286 of_4\IN\1740 combination_5\NN\7951464 <e1>n-butyl-deoxynojirimycin</e1>_6\NN\1740 (_7\-LRB-\1740 sc-48334_8\NNS\1740 )_9\-RRB-\1740 and_10\CC\1740 zidovudine_11\NN\3834836 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>hiv-1_15\NN\1740 infection</e2>_16\NN\14052046 and_17\CC\1740 200_18\CD\1740 -_19\SYM\1740 500_20\CD\13745420 cd4_21\NN\14888310 cells/mm3_22\NNS\1740 ._23\.\1740
C059896_D015658 NONE the_0\DT\1740 safety_1\NN\13920835 and_2\CC\1740 efficacy_3\NN\5199286 of_4\IN\1740 combination_5\NN\7951464 n-butyl-deoxynojirimycin_6\NN\1740 (_7\-LRB-\1740 <e1>sc-48334</e1>_8\NNS\1740 )_9\-RRB-\1740 and_10\CC\1740 zidovudine_11\NN\3834836 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>hiv-1_15\NN\1740 infection</e2>_16\NN\14052046 and_17\CC\1740 200_18\CD\1740 -_19\SYM\1740 500_20\CD\13745420 cd4_21\NN\14888310 cells/mm3_22\NNS\1740 ._23\.\1740
D015215_D015658 NONE the_0\DT\1740 safety_1\NN\13920835 and_2\CC\1740 efficacy_3\NN\5199286 of_4\IN\1740 combination_5\NN\7951464 n-butyl-deoxynojirimycin_6\NN\1740 (_7\-LRB-\1740 sc-48334_8\NNS\1740 )_9\-RRB-\1740 and_10\CC\1740 <e1>zidovudine</e1>_11\NN\3834836 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>hiv-1_15\NN\1740 infection</e2>_16\NN\14052046 and_17\CC\1740 200_18\CD\1740 -_19\SYM\1740 500_20\CD\13745420 cd4_21\NN\14888310 cells/mm3_22\NNS\1740 ._23\.\1740
C059896_D007153 NONE the_0\DT\1740 mean_1\NN\6021761 <e1>sc-48334</e1>_2\NN\1740 steady-state_3\JJ\1740 trough_4\NN\9366017 level_5\NN\4916342 (_6\-LRB-\1740 4.04_7\CD\1740 +/-_8\CC\1740 0.99_9\CD\1740 micrograms/ml_10\NNS\1740 )_11\-RRB-\1740 was_12\VBD\836236 below_13\IN\1740 the_14\DT\1740 in_15\FW\13603305 vitro_16\FW\1740 inhibitory_17\JJ\1740 concentration_18\NN\4916342 for_19\IN\1740 human_20\JJ\1740 <e2>immunodeficiency</e2>_21\NN\13973990 virus_22\NN\9312843 (_23\-LRB-\1740 hiv_24\NN\14186340 )_25\-RRB-\1740 ._26\.\1740
19289093
D006493_D007022 NONE recently_0\RB\1740 ,_1\,\1740 a_2\DT\13649268 number_3\NN\5107765 of_4\IN\1740 commercial_5\JJ\1740 lots_6\NNS\13757724 of_7\IN\1740 <e1>heparin</e1>_8\NN\2718259 products_9\NNS\3076708 were_10\VBD\836236 found_11\VBN\2426171 to_12\TO\1740 be_13\VB\836236 contaminated_14\VBN\1534147 with_15\IN\1740 an_16\DT\6697703 oversulfated_17\JJ\1740 chondroitin_18\NN\1740 sulfate_19\NN\15010703 (_20\-LRB-\1740 oscs_21\JJ\1740 )_22\-RRB-\1740 derivative_23\NN\5802185 that_24\WDT\1740 could_25\MD\1740 elicit_26\VB\1617192 a_27\DT\13649268 <e2>hypotensive</e2>_28\JJ\1740 response_29\NN\11410625 in_30\IN\13603305 pigs_31\NNS\2395003 following_32\VBG\1835496 a_33\DT\13649268 single_34\JJ\1740 high-dose_35\JJ\1740 infusion_36\NN\14589223 ._37\.\1740
D006493_D007022 NONE using_0\VBG\1156834 both_1\DT\1740 contaminated_2\VBN\1534147 <e1>heparin</e1>_3\NN\2718259 products_4\NNS\3076708 and_5\CC\1740 the_6\DT\1740 synthetically_7\RB\1740 produced_8\VBN\1617192 derivative_9\JJ\1740 ,_10\,\1740 we_11\PRP\1740 showed_12\VBD\2137132 that_13\IN\1740 the_14\DT\1740 oscs_15\NN\1740 produces_16\VBZ\1617192 dose-dependent_17\JJ\1740 <e2>hypotension</e2>_18\NN\14057371 in_19\IN\13603305 pigs_20\NNS\2395003 ._21\.\1740
D002809_D007022 CID recently_0\RB\1740 ,_1\,\1740 a_2\DT\13649268 number_3\NN\5107765 of_4\IN\1740 commercial_5\JJ\1740 lots_6\NNS\13757724 of_7\IN\1740 heparin_8\NN\2718259 products_9\NNS\3076708 were_10\VBD\836236 found_11\VBN\2426171 to_12\TO\1740 be_13\VB\836236 contaminated_14\VBN\1534147 with_15\IN\1740 an_16\DT\6697703 oversulfated_17\JJ\1740 <e1>chondroitin_18\NN\1740 sulfate</e1>_19\NN\15010703 (_20\-LRB-\1740 oscs_21\JJ\1740 )_22\-RRB-\1740 derivative_23\NN\5802185 that_24\WDT\1740 could_25\MD\1740 elicit_26\VB\1617192 a_27\DT\13649268 <e2>hypotensive</e2>_28\JJ\1740 response_29\NN\11410625 in_30\IN\13603305 pigs_31\NNS\2395003 following_32\VBG\1835496 a_33\DT\13649268 single_34\JJ\1740 high-dose_35\JJ\1740 infusion_36\NN\14589223 ._37\.\1740
12231232
D006220_D010300 NONE <e1>haloperidol</e1>_0\NNP\3713736 (_1\-LRB-\1740 1_2\CD\13741022 mg/kg_3\NN\1740 ip_4\NN\5999797 )_5\-RRB-\1740 induced_6\JJ\1740 <e2>parkinsonian-like</e2>_7\JJ\1740 muscle_8\NN\5289601 rigidity_9\NN\5023233 ,_10\,\1740 measured_11\VBN\697589 as_12\IN\14622893 an_13\DT\6697703 increased_14\VBN\169651 resistance_15\NN\37396 of_16\IN\1740 a_17\DT\13649268 rat_18\NN\2329401 's_19\POS\1740 hind_20\NN\2568959 foot_21\NN\5563034 to_22\TO\1740 passive_23\JJ\1740 flexion_24\NN\14034177 and_25\CC\1740 extension_26\NN\15272029 at_27\IN\14622893 the_28\DT\1740 ankle_29\NN\5578251 joint_30\NN\5220461 ._31\.\1740
D006220_D009127 CID <e1>haloperidol</e1>_0\NNP\3713736 (_1\-LRB-\1740 1_2\CD\13741022 mg/kg_3\NN\1740 ip_4\NN\5999797 )_5\-RRB-\1740 induced_6\JJ\1740 parkinsonian-like_7\JJ\1740 <e2>muscle_8\NN\5289601 rigidity</e2>_9\NN\5023233 ,_10\,\1740 measured_11\VBN\697589 as_12\IN\14622893 an_13\DT\6697703 increased_14\VBN\169651 resistance_15\NN\37396 of_16\IN\1740 a_17\DT\13649268 rat_18\NN\2329401 's_19\POS\1740 hind_20\NN\2568959 foot_21\NN\5563034 to_22\TO\1740 passive_23\JJ\1740 flexion_24\NN\14034177 and_25\CC\1740 extension_26\NN\15272029 at_27\IN\14622893 the_28\DT\1740 ankle_29\NN\5578251 joint_30\NN\5220461 ._31\.\1740
D006220_D009127 CID aida_0\NN\1740 in_1\IN\13603305 doses_2\NNS\3740161 of_3\IN\1740 7.5_4\CD\1740 -_5\SYM\1740 15_6\CD\13745420 microg/0.5_7\CD\1740 microl_8\NN\1740 diminished_9\VBD\169651 the_10\DT\1740 <e1>haloperidol-induced</e1>_11\JJ\1740 <e2>muscle_12\NN\5289601 rigidity</e2>_13\NN\5023233 ._14\.\1740
C095756_D009127 NONE <e1>aida</e1>_0\NN\1740 in_1\IN\13603305 doses_2\NNS\3740161 of_3\IN\1740 7.5_4\CD\1740 -_5\SYM\1740 15_6\CD\13745420 microg/0.5_7\CD\1740 microl_8\NN\1740 diminished_9\VBD\169651 the_10\DT\1740 haloperidol-induced_11\JJ\1740 <e2>muscle_12\NN\5289601 rigidity</e2>_13\NN\5023233 ._14\.\1740
871943
D013390_D001049 CID the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 serum_3\NN\5397468 cholinesterase_4\NN\14732946 in_5\IN\13603305 <e1>succinylcholine</e1>_6\NN\3800001 <e2>apnoea</e2>_7\NN\1740 ._8\.\1740
D013390_D001049 CID fifteen_0\CD\13745420 patients_1\NNS\9898892 demonstrating_2\VBG\2137132 unexpected_3\JJ\1740 prolonged_4\JJ\1740 <e2>apnoea</e2>_5\NN\1740 lasting_6\VBG\2704349 several_7\JJ\1740 hours_8\NNS\15118228 after_9\IN\1740 <e1>succinylcholine</e1>_10\NN\3800001 have_11\VBP\2108377 been_12\VBN\836236 treated_13\VBN\2376958 by_14\IN\1740 a_15\DT\13649268 new_16\JJ\1740 preparation_17\NN\407535 of_18\IN\1740 human_19\JJ\1740 serum_20\NN\5397468 cholinesterase_21\NN\14732946 ._22\.\1740
D013390_D001049 CID the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 serum_3\NN\5397468 cholinesterase_4\NN\14732946 in_5\IN\13603305 <e1>succinylcholine</e1>_6\NN\3800001 <e2>apnoea</e2>_7\NN\1740 provided_8\VBD\2199590 considerable_9\JJ\1740 relief_10\NN\7492516 to_11\IN\1740 both_12\CC\1740 patient_13\NN\9898892 and_14\CC\1740 anaesthetist_15\VBP\1740 ._16\.\1740
19692487
D008094_D011141 NONE mice_0\NNS\2329401 lacking_1\VBG\1740 mpges-1_2\NN\1740 are_3\VBP\836236 resistant_4\JJ\1740 to_5\TO\1740 <e1>lithium-induced</e1>_6\JJ\1740 <e2>polyuria</e2>_7\NN\14113228 ._8\.\1740
D008094_D011141 NONE cyclooxygenase-2_0\NN\14737847 activity_1\NN\30358 is_2\VBZ\836236 required_3\VBN\754942 for_4\IN\1740 the_5\DT\1740 development_6\NN\248977 of_7\IN\1740 <e1>lithium-induced</e1>_8\JJ\1740 <e2>polyuria</e2>_9\NN\14113228 ._10\.\1740
D008094_D011141 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 assess_6\VB\670261 <e1>lithium-induced</e1>_7\JJ\1740 <e2>polyuria</e2>_8\NN\14113228 in_9\IN\13603305 mice_10\NNS\2329401 deficient_11\JJ\1740 in_12\IN\13603305 microsomal_13\JJ\1740 prostaglandin_14\NN\5414534 e_15\NN\14724645 synthase-1_16\NN\1740 (_17\-LRB-\1740 mpges-1_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D008094_D011141 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 mpges-1_3\NN\1740 -/-_4\JJ\1740 mice_5\NNS\2329401 were_6\VBD\836236 largely_7\RB\1740 resistant_8\JJ\1740 to_9\TO\1740 <e1>lithium-induced</e1>_10\JJ\1740 <e2>polyuria</e2>_11\NN\14113228 and_12\CC\1740 a_13\DT\13649268 urine_14\NN\14853947 concentrating_15\NN\1740 defect_16\NN\14462666 ,_17\,\1740 accompanied_18\VBN\1835496 by_19\IN\1740 nearly_20\RB\1740 complete_21\JJ\1740 blockade_22\NN\952963 of_23\IN\1740 high_24\JJ\1740 urine_25\NN\14853947 pge(2_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 camp_29\NN\3763727 output_30\NN\4007894 ._31\.\1740
D008094_D011141 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 mpges-1-derived_3\VBD\1740 pge(2_4\NN\1740 )_5\-RRB-\1740 mediates_6\VBZ\761713 <e1>lithium-induced</e1>_7\JJ\1740 <e2>polyuria</e2>_8\NN\14113228 likely_9\JJ\1740 via_10\IN\1740 inhibition_11\NN\1068773 of_12\IN\1740 aqp2_13\NN\1740 and_14\CC\1740 nkcc2_15\NN\1740 expression_16\NN\4679549 ._17\.\1740
D011458_D011141 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 was_3\VBD\836236 undertaken_4\VBN\1641914 to_5\TO\1740 assess_6\VB\670261 lithium-induced_7\JJ\1740 <e2>polyuria</e2>_8\NN\14113228 in_9\IN\13603305 mice_10\NNS\2329401 deficient_11\JJ\1740 in_12\IN\13603305 microsomal_13\JJ\1740 <e1>prostaglandin_14\NN\5414534 e</e1>_15\NN\14724645 synthase-1_16\NN\1740 (_17\-LRB-\1740 mpges-1_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D018021_D011141 CID a_0\DT\13649268 2-wk_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 <e1>licl</e1>_4\NN\1740 (_5\-LRB-\1740 4_6\CD\13741022 mmol.kg(-1).day(-1_7\NN\1740 )_8\-RRB-\1740 ip_9\NN\5999797 )_10\-RRB-\1740 in_11\IN\13603305 mpges-1_12\NN\1740 +_13\CC\1740 /+_14\JJ\1740 mice_15\NNS\2329401 led_16\VBD\1752884 to_17\TO\1740 a_18\DT\13649268 marked_19\JJ\1740 <e2>polyuria</e2>_20\NN\14113228 with_21\IN\1740 hyposmotic_22\JJ\1740 urine_23\NN\14853947 ._24\.\1740
D015232_D011141 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 mpges-1_3\NN\1740 -/-_4\JJ\1740 mice_5\NNS\2329401 were_6\VBD\836236 largely_7\RB\1740 resistant_8\JJ\1740 to_9\TO\1740 lithium-induced_10\JJ\1740 <e2>polyuria</e2>_11\NN\14113228 and_12\CC\1740 a_13\DT\13649268 urine_14\NN\14853947 concentrating_15\NN\1740 defect_16\NN\14462666 ,_17\,\1740 accompanied_18\VBN\1835496 by_19\IN\1740 nearly_20\RB\1740 complete_21\JJ\1740 blockade_22\NN\952963 of_23\IN\1740 high_24\JJ\1740 urine_25\NN\14853947 <e1>pge(2_26\NN\1740 )</e1>_27\-RRB-\1740 and_28\CC\1740 camp_29\NN\3763727 output_30\NN\4007894 ._31\.\1740
D015232_D011141 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 mpges-1-derived_3\VBD\1740 <e1>pge(2_4\NN\1740 )</e1>_5\-RRB-\1740 mediates_6\VBZ\761713 lithium-induced_7\JJ\1740 <e2>polyuria</e2>_8\NN\14113228 likely_9\JJ\1740 via_10\IN\1740 inhibition_11\NN\1068773 of_12\IN\1740 aqp2_13\NN\1740 and_14\CC\1740 nkcc2_15\NN\1740 expression_16\NN\4679549 ._17\.\1740
2907585
-1_D002375 NONE reversal_0\NN\199130 of_1\IN\1740 neuroleptic-induced_2\JJ\1740 <e2>catalepsy</e2>_3\NN\14023236 by_4\IN\1740 novel_5\JJ\1740 <e1>aryl-piperazine</e1>_6\JJ\1740 anxiolytic_7\JJ\1740 drugs_8\NNS\14778436 ._9\.\1740
-1_D002375 NONE a_0\DT\13649268 series_1\NN\8456993 of_2\IN\1740 <e1>aryl-piperazine</e1>_3\JJ\1740 analogues_4\NNS\4743605 of_5\IN\1740 buspirone_6\NN\3771443 and_7\CC\1740 other_8\JJ\1740 5-hydroxytryptaminergic_9\JJ\1740 agonists_10\NNS\9613191 were_11\VBD\836236 tested_12\VBN\670261 for_13\IN\1740 their_14\PRP$\1740 ability_15\NN\4723816 to_16\TO\1740 reverse_17\VB\109660 haloperidol_18\NN\3713736 induced_19\JJ\1740 <e2>catalepsy</e2>_20\NN\14023236 ._21\.\1740
D002065_D002375 NONE the_0\DT\1740 novel_1\JJ\1740 anxiolytic_2\JJ\1740 drug_3\NN\14778436 ,_4\,\1740 <e1>buspirone</e1>_5\NN\3771443 ,_6\,\1740 reverses_7\VBZ\109660 <e2>catalepsy</e2>_8\NN\14023236 induced_9\VBN\1627355 by_10\IN\1740 haloperidol_11\NN\3713736 ._12\.\1740
D002065_D002375 NONE a_0\DT\13649268 series_1\NN\8456993 of_2\IN\1740 aryl-piperazine_3\JJ\1740 analogues_4\NNS\4743605 of_5\IN\1740 <e1>buspirone</e1>_6\NN\3771443 and_7\CC\1740 other_8\JJ\1740 5-hydroxytryptaminergic_9\JJ\1740 agonists_10\NNS\9613191 were_11\VBD\836236 tested_12\VBN\670261 for_13\IN\1740 their_14\PRP$\1740 ability_15\NN\4723816 to_16\TO\1740 reverse_17\VB\109660 haloperidol_18\NN\3713736 induced_19\JJ\1740 <e2>catalepsy</e2>_20\NN\14023236 ._21\.\1740
D006220_D002375 CID the_0\DT\1740 novel_1\JJ\1740 anxiolytic_2\JJ\1740 drug_3\NN\14778436 ,_4\,\1740 buspirone_5\NN\3771443 ,_6\,\1740 reverses_7\VBZ\109660 <e2>catalepsy</e2>_8\NN\14023236 induced_9\VBN\1627355 by_10\IN\1740 <e1>haloperidol</e1>_11\NN\3713736 ._12\.\1740
D006220_D002375 CID a_0\DT\13649268 series_1\NN\8456993 of_2\IN\1740 aryl-piperazine_3\JJ\1740 analogues_4\NNS\4743605 of_5\IN\1740 buspirone_6\NN\3771443 and_7\CC\1740 other_8\JJ\1740 5-hydroxytryptaminergic_9\JJ\1740 agonists_10\NNS\9613191 were_11\VBD\836236 tested_12\VBN\670261 for_13\IN\1740 their_14\PRP$\1740 ability_15\NN\4723816 to_16\TO\1740 reverse_17\VB\109660 <e1>haloperidol</e1>_18\NN\3713736 induced_19\JJ\1740 <e2>catalepsy</e2>_20\NN\14023236 ._21\.\1740
D058825_D002375 NONE a_0\DT\13649268 series_1\NN\8456993 of_2\IN\1740 aryl-piperazine_3\JJ\1740 analogues_4\NNS\4743605 of_5\IN\1740 buspirone_6\NN\3771443 and_7\CC\1740 other_8\JJ\1740 <e1>5-hydroxytryptaminergic_9\JJ\1740 agonists</e1>_10\NNS\9613191 were_11\VBD\836236 tested_12\VBN\670261 for_13\IN\1740 their_14\PRP$\1740 ability_15\NN\4723816 to_16\TO\1740 reverse_17\VB\109660 haloperidol_18\NN\3713736 induced_19\JJ\1740 <e2>catalepsy</e2>_20\NN\14023236 ._21\.\1740
D012701_D002375 NONE those_0\DT\1740 drugs_1\NNS\14778436 with_2\IN\1740 strong_3\JJ\1740 affinity_4\NN\11426530 for_5\IN\1740 <e1>5-hydroxytryptamine1a</e1>_6\NN\1740 receptors_7\NNS\5225602 were_8\VBD\836236 able_9\JJ\1740 to_10\TO\1740 reverse_11\VB\109660 <e2>catalepsy</e2>_12\NN\14023236 ._13\.\1740
D012701_D002375 NONE however_0\RB\1740 ,_1\,\1740 inhibition_2\NN\1068773 of_3\IN\1740 postsynaptic_4\JJ\1740 <e1>5-ht</e1>_5\NN\1740 receptors_6\NNS\5225602 neither_7\CC\1740 inhibited_8\VBD\2510337 nor_9\CC\1740 potentiated_10\VBD\229605 reversal_11\NN\199130 of_12\IN\1740 <e2>catalepsy</e2>_13\NN\14023236 and_14\CC\1740 leaves_15\NNS\13087625 open_16\VBP\146138 the_17\DT\1740 question_18\NN\7193184 as_19\IN\14622893 to_20\IN\1740 the_21\DT\1740 site_22\NN\8673395 or_23\CC\3541091 mechanism_24\NN\13446390 for_25\IN\1740 this_26\DT\1740 effect_27\NN\34213 ._28\.\1740
9098464
D005473_D062788 CID a_0\DT\13649268 murine_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 <e2>adenomyosis</e2>_4\NN\14204950 :_5\:\1740 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 hyperprolactinemia_9\NN\1740 induced_10\VBN\1627355 by_11\IN\1740 <e1>fluoxetine_12\NN\4169152 hydrochloride</e1>_13\NN\14817592 ,_14\,\1740 a_15\DT\13649268 selective_16\JJ\1740 serotonin_17\NN\14807737 reuptake_18\NN\13571580 inhibitor_19\NN\20090 ,_20\,\1740 on_21\IN\1740 adenomyosis_22\NN\14204950 induction_23\NN\7450842 in_24\IN\13603305 wistar_25\NNP\1740 albino_26\NN\9606527 rats_27\NNS\2329401 ._28\.\1740
D005473_D062788 CID a_0\DT\13649268 murine_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 adenomyosis_4\NN\14204950 :_5\:\1740 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 hyperprolactinemia_9\NN\1740 induced_10\VBN\1627355 by_11\IN\1740 <e1>fluoxetine_12\NN\4169152 hydrochloride</e1>_13\NN\14817592 ,_14\,\1740 a_15\DT\13649268 selective_16\JJ\1740 serotonin_17\NN\14807737 reuptake_18\NN\13571580 inhibitor_19\NN\20090 ,_20\,\1740 on_21\IN\1740 <e2>adenomyosis</e2>_22\NN\14204950 induction_23\NN\7450842 in_24\IN\13603305 wistar_25\NNP\1740 albino_26\NN\9606527 rats_27\NNS\2329401 ._28\.\1740
D005473_D062788 CID objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 whether_10\IN\1740 <e1>fluoxetine</e1>_11\NN\4169152 given_12\VBN\2327200 to_13\TO\1740 castrated_14\VBN\224901 and_15\CC\1740 noncastrated_16\JJ\1740 rats_17\NNS\2329401 caused_18\VBD\1617192 hyperprolactinemia_19\NN\1740 and_20\CC\1740 its_21\PRP$\6125041 effects_22\NNS\13245626 with_23\IN\1740 respect_24\NN\5817845 to_25\TO\1740 <e2>adenomyosis</e2>_26\NN\14204950 ._27\.\1740
D005473_D062788 CID histological_0\JJ\1740 studies_1\NNS\635850 revealed_2\VBD\2137132 11_3\CD\13745420 cases_4\NNS\7283608 of_5\IN\1740 <e2>adenomyosis</e2>_6\NN\14204950 ,_7\,\1740 all_8\RB\1740 within_9\IN\1740 the_10\DT\1740 noncastrated_11\JJ\1740 group_12\NN\2137 receiving_13\VBG\2210855 <e1>fluoxetine</e1>_14\NN\4169152 ._15\.\1740
D005473_D006966 CID a_0\DT\13649268 murine_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 adenomyosis_4\NN\14204950 :_5\:\1740 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 <e2>hyperprolactinemia</e2>_9\NN\1740 induced_10\VBN\1627355 by_11\IN\1740 <e1>fluoxetine_12\NN\4169152 hydrochloride</e1>_13\NN\14817592 ,_14\,\1740 a_15\DT\13649268 selective_16\JJ\1740 serotonin_17\NN\14807737 reuptake_18\NN\13571580 inhibitor_19\NN\20090 ,_20\,\1740 on_21\IN\1740 adenomyosis_22\NN\14204950 induction_23\NN\7450842 in_24\IN\13603305 wistar_25\NNP\1740 albino_26\NN\9606527 rats_27\NNS\2329401 ._28\.\1740
D005473_D006966 CID objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 investigate_9\VB\644583 whether_10\IN\1740 <e1>fluoxetine</e1>_11\NN\4169152 given_12\VBN\2327200 to_13\TO\1740 castrated_14\VBN\224901 and_15\CC\1740 noncastrated_16\JJ\1740 rats_17\NNS\2329401 caused_18\VBD\1617192 <e2>hyperprolactinemia</e2>_19\NN\1740 and_20\CC\1740 its_21\PRP$\6125041 effects_22\NNS\13245626 with_23\IN\1740 respect_24\NN\5817845 to_25\TO\1740 adenomyosis_26\NN\14204950 ._27\.\1740
D005473_D006966 CID design_0\NN\927261 :_1\:\1740 <e1>fluoxetine</e1>_2\NN\4169152 ,_3\,\1740 a_4\DT\13649268 serotonin_5\NN\14807737 reuptake_6\NN\13571580 inhibitor_7\NN\20090 ,_8\,\1740 was_9\VBD\836236 given_10\VBN\2327200 to_11\IN\1740 wistar_12\NNP\1740 albino_13\NNPS\9606527 rats_14\NNS\2329401 for_15\IN\1740 98_16\CD\1740 days_17\NNS\15140892 to_18\TO\1740 produce_19\VB\1617192 <e2>hyperprolactinemia</e2>_20\NN\1740 ._21\.\1740
D012701_D062788 NONE a_0\DT\13649268 murine_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 <e2>adenomyosis</e2>_4\NN\14204950 :_5\:\1740 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 hyperprolactinemia_9\NN\1740 induced_10\VBN\1627355 by_11\IN\1740 fluoxetine_12\NN\4169152 hydrochloride_13\NN\14817592 ,_14\,\1740 a_15\DT\13649268 selective_16\JJ\1740 <e1>serotonin</e1>_17\NN\14807737 reuptake_18\NN\13571580 inhibitor_19\NN\20090 ,_20\,\1740 on_21\IN\1740 adenomyosis_22\NN\14204950 induction_23\NN\7450842 in_24\IN\13603305 wistar_25\NNP\1740 albino_26\NN\9606527 rats_27\NNS\2329401 ._28\.\1740
D012701_D062788 NONE a_0\DT\13649268 murine_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 adenomyosis_4\NN\14204950 :_5\:\1740 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 hyperprolactinemia_9\NN\1740 induced_10\VBN\1627355 by_11\IN\1740 fluoxetine_12\NN\4169152 hydrochloride_13\NN\14817592 ,_14\,\1740 a_15\DT\13649268 selective_16\JJ\1740 <e1>serotonin</e1>_17\NN\14807737 reuptake_18\NN\13571580 inhibitor_19\NN\20090 ,_20\,\1740 on_21\IN\1740 <e2>adenomyosis</e2>_22\NN\14204950 induction_23\NN\7450842 in_24\IN\13603305 wistar_25\NNP\1740 albino_26\NN\9606527 rats_27\NNS\2329401 ._28\.\1740
D012701_D006966 NONE a_0\DT\13649268 murine_1\JJ\1740 model_2\NN\5888929 of_3\IN\1740 adenomyosis_4\NN\14204950 :_5\:\1740 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 <e2>hyperprolactinemia</e2>_9\NN\1740 induced_10\VBN\1627355 by_11\IN\1740 fluoxetine_12\NN\4169152 hydrochloride_13\NN\14817592 ,_14\,\1740 a_15\DT\13649268 selective_16\JJ\1740 <e1>serotonin</e1>_17\NN\14807737 reuptake_18\NN\13571580 inhibitor_19\NN\20090 ,_20\,\1740 on_21\IN\1740 adenomyosis_22\NN\14204950 induction_23\NN\7450842 in_24\IN\13603305 wistar_25\NNP\1740 albino_26\NN\9606527 rats_27\NNS\2329401 ._28\.\1740
D012701_D006966 NONE design_0\NN\927261 :_1\:\1740 fluoxetine_2\NN\4169152 ,_3\,\1740 a_4\DT\13649268 <e1>serotonin</e1>_5\NN\14807737 reuptake_6\NN\13571580 inhibitor_7\NN\20090 ,_8\,\1740 was_9\VBD\836236 given_10\VBN\2327200 to_11\IN\1740 wistar_12\NNP\1740 albino_13\NNPS\9606527 rats_14\NNS\2329401 for_15\IN\1740 98_16\CD\1740 days_17\NNS\15140892 to_18\TO\1740 produce_19\VB\1617192 <e2>hyperprolactinemia</e2>_20\NN\1740 ._21\.\1740
28952
D011188_D007008 NONE initial_0\JJ\1740 <e1>potassium</e1>_1\NN\14625458 loss_2\NN\13252973 and_3\CC\1740 <e2>hypokalaemia</e2>_4\NN\1740 during_5\IN\1740 chlorthalidone_6\NN\3214670 administration_7\NN\1133281 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 essential_11\JJ\1740 hypertension_12\NN\14057371 :_13\:\1740 the_14\DT\1740 influence_15\NN\5190804 of_16\IN\1740 dietary_17\JJ\1740 sodium_18\NN\14625458 restriction_19\NN\5846054 ._20\.\1740
D011188_D007008 NONE to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 initial_3\JJ\1740 <e1>potassium</e1>_4\NN\14625458 loss_5\NN\13252973 and_6\CC\1740 development_7\NN\248977 of_8\IN\1740 <e2>hypokalaemia</e2>_9\NN\1740 during_10\IN\1740 the_11\DT\1740 administration_12\NN\1133281 of_13\IN\1740 an_14\DT\6697703 oral_15\JJ\1740 diuretic_16\NN\3247620 ,_17\,\1740 metabolic_18\JJ\1740 balance_19\NN\13934900 studies_20\NNS\635850 were_21\VBD\836236 performed_22\VBN\2367363 in_23\IN\13603305 ten_24\CD\13745420 patients_25\NNS\9898892 with_26\IN\1740 essential_27\JJ\1740 hypertension_28\NN\14057371 who_29\WP\8299493 had_30\VBD\2108377 shown_31\VBN\2137132 hypokalaemia_32\NN\1740 under_33\IN\1740 prior_34\JJ\1740 oral_35\JJ\1740 diuretic_36\NN\3247620 treatment_37\NN\654885 ._38\.\1740
D011188_D007008 NONE to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 initial_3\JJ\1740 <e1>potassium</e1>_4\NN\14625458 loss_5\NN\13252973 and_6\CC\1740 development_7\NN\248977 of_8\IN\1740 hypokalaemia_9\NN\1740 during_10\IN\1740 the_11\DT\1740 administration_12\NN\1133281 of_13\IN\1740 an_14\DT\6697703 oral_15\JJ\1740 diuretic_16\NN\3247620 ,_17\,\1740 metabolic_18\JJ\1740 balance_19\NN\13934900 studies_20\NNS\635850 were_21\VBD\836236 performed_22\VBN\2367363 in_23\IN\13603305 ten_24\CD\13745420 patients_25\NNS\9898892 with_26\IN\1740 essential_27\JJ\1740 hypertension_28\NN\14057371 who_29\WP\8299493 had_30\VBD\2108377 shown_31\VBN\2137132 <e2>hypokalaemia</e2>_32\NN\1740 under_33\IN\1740 prior_34\JJ\1740 oral_35\JJ\1740 diuretic_36\NN\3247620 treatment_37\NN\654885 ._38\.\1740
D011188_D006973 NONE initial_0\JJ\1740 <e1>potassium</e1>_1\NN\14625458 loss_2\NN\13252973 and_3\CC\1740 hypokalaemia_4\NN\1740 during_5\IN\1740 chlorthalidone_6\NN\3214670 administration_7\NN\1133281 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 essential_11\JJ\1740 <e2>hypertension</e2>_12\NN\14057371 :_13\:\1740 the_14\DT\1740 influence_15\NN\5190804 of_16\IN\1740 dietary_17\JJ\1740 sodium_18\NN\14625458 restriction_19\NN\5846054 ._20\.\1740
D011188_D006973 NONE to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 initial_3\JJ\1740 <e1>potassium</e1>_4\NN\14625458 loss_5\NN\13252973 and_6\CC\1740 development_7\NN\248977 of_8\IN\1740 hypokalaemia_9\NN\1740 during_10\IN\1740 the_11\DT\1740 administration_12\NN\1133281 of_13\IN\1740 an_14\DT\6697703 oral_15\JJ\1740 diuretic_16\NN\3247620 ,_17\,\1740 metabolic_18\JJ\1740 balance_19\NN\13934900 studies_20\NNS\635850 were_21\VBD\836236 performed_22\VBN\2367363 in_23\IN\13603305 ten_24\CD\13745420 patients_25\NNS\9898892 with_26\IN\1740 essential_27\JJ\1740 <e2>hypertension</e2>_28\NN\14057371 who_29\WP\8299493 had_30\VBD\2108377 shown_31\VBN\2137132 hypokalaemia_32\NN\1740 under_33\IN\1740 prior_34\JJ\1740 oral_35\JJ\1740 diuretic_36\NN\3247620 treatment_37\NN\654885 ._38\.\1740
D002752_D007008 CID initial_0\JJ\1740 potassium_1\NN\14625458 loss_2\NN\13252973 and_3\CC\1740 <e2>hypokalaemia</e2>_4\NN\1740 during_5\IN\1740 <e1>chlorthalidone</e1>_6\NN\3214670 administration_7\NN\1133281 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 essential_11\JJ\1740 hypertension_12\NN\14057371 :_13\:\1740 the_14\DT\1740 influence_15\NN\5190804 of_16\IN\1740 dietary_17\JJ\1740 sodium_18\NN\14625458 restriction_19\NN\5846054 ._20\.\1740
D002752_D006973 NONE initial_0\JJ\1740 potassium_1\NN\14625458 loss_2\NN\13252973 and_3\CC\1740 hypokalaemia_4\NN\1740 during_5\IN\1740 <e1>chlorthalidone</e1>_6\NN\3214670 administration_7\NN\1133281 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 essential_11\JJ\1740 <e2>hypertension</e2>_12\NN\14057371 :_13\:\1740 the_14\DT\1740 influence_15\NN\5190804 of_16\IN\1740 dietary_17\JJ\1740 sodium_18\NN\14625458 restriction_19\NN\5846054 ._20\.\1740
D012964_D007008 NONE initial_0\JJ\1740 potassium_1\NN\14625458 loss_2\NN\13252973 and_3\CC\1740 <e2>hypokalaemia</e2>_4\NN\1740 during_5\IN\1740 chlorthalidone_6\NN\3214670 administration_7\NN\1133281 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 essential_11\JJ\1740 hypertension_12\NN\14057371 :_13\:\1740 the_14\DT\1740 influence_15\NN\5190804 of_16\IN\1740 dietary_17\JJ\1740 <e1>sodium</e1>_18\NN\14625458 restriction_19\NN\5846054 ._20\.\1740
D012964_D006973 NONE initial_0\JJ\1740 potassium_1\NN\14625458 loss_2\NN\13252973 and_3\CC\1740 hypokalaemia_4\NN\1740 during_5\IN\1740 chlorthalidone_6\NN\3214670 administration_7\NN\1133281 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 essential_11\JJ\1740 <e2>hypertension</e2>_12\NN\14057371 :_13\:\1740 the_14\DT\1740 influence_15\NN\5190804 of_16\IN\1740 dietary_17\JJ\1740 <e1>sodium</e1>_18\NN\14625458 restriction_19\NN\5846054 ._20\.\1740
12042105
C052342_D053040 CID <e1>topiramate-induced</e1>_0\JJ\1740 <e2>nephrolithiasis</e2>_1\NN\14115914 ._2\.\1740
C052342_D053040 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 first_3\JJ\1740 two_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 <e1>topiramate-induced</e1>_7\JJ\1740 <e2>nephrolithiasis</e2>_8\NN\14115914 in_9\IN\13603305 the_10\DT\1740 urologic_11\JJ\1740 literature_12\NN\6362953 ._13\.\1740
C052342_D004827 NONE <e1>topiramate</e1>_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 recently_3\RB\1740 developed_4\VBN\1753788 antiepileptic_5\JJ\1740 medication_6\NN\3247620 that_7\WDT\1740 is_8\VBZ\836236 becoming_9\VBG\146138 more_10\RBR\1740 widely_11\RB\1740 prescribed_12\VBN\748282 because_13\IN\1740 of_14\IN\1740 its_15\PRP$\6125041 efficacy_16\NN\5199286 in_17\IN\13603305 treating_18\VBG\2376958 <e2>refractory_19\JJ\1740 seizures</e2>_20\NNS\14081375 ._21\.\1740
C020243_D053040 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 a_3\DT\13649268 distal_4\JJ\1740 tubular_5\JJ\1740 acidification_6\NN\13518963 defect_7\NN\14462666 may_8\MD\15209706 result_9\VB\2633881 ,_10\,\1740 thus_11\RB\1740 impairing_12\VBG\258857 the_13\DT\1740 normal_14\JJ\1740 compensatory_15\JJ\1740 drop_16\NN\13899200 in_17\IN\13603305 urine_18\NN\14853947 ph._19\NN\1740 these_20\DT\1740 factors_21\NNS\7326557 can_22\MD\3094503 lead_23\VB\1752884 to_24\TO\1740 the_25\DT\1740 development_26\NN\248977 of_27\IN\1740 <e1>calcium_28\NN\14625458 phosphate</e1>_29\NN\15010703 <e2>nephrolithiasis</e2>_30\NN\14115914 ._31\.\1740
15858223
D014635_D056486 CID <e1>valproic_0\JJ\1740 acid</e1>_1\NN\14818238 i_2\CD\14622893 :_3\:\1740 time_4\NN\7308889 course_5\NN\883297 of_6\IN\1740 lipid_7\NN\14944888 peroxidation_8\NN\1740 biomarkers_9\NNS\1740 ,_10\,\1740 <e2>liver_11\NN\5298729 toxicity</e2>_12\NN\13576101 ,_13\,\1740 and_14\CC\1740 valproic_15\JJ\1740 acid_16\NN\14818238 metabolite_17\NN\20090 levels_18\NNS\4916342 in_19\IN\13603305 rats_20\NNS\2329401 ._21\.\1740
D014635_D056486 CID valproic_0\JJ\1740 acid_1\NN\14818238 i_2\CD\14622893 :_3\:\1740 time_4\NN\7308889 course_5\NN\883297 of_6\IN\1740 lipid_7\NN\14944888 peroxidation_8\NN\1740 biomarkers_9\NNS\1740 ,_10\,\1740 <e2>liver_11\NN\5298729 toxicity</e2>_12\NN\13576101 ,_13\,\1740 and_14\CC\1740 <e1>valproic_15\JJ\1740 acid</e1>_16\NN\14818238 metabolite_17\NN\20090 levels_18\NNS\4916342 in_19\IN\13603305 rats_20\NNS\2329401 ._21\.\1740
D014635_D056486 CID to_0\TO\1740 determine_1\VB\1645601 whether_2\IN\1740 there_3\EX\27167 was_4\VBD\836236 a_5\DT\13649268 temporal_6\JJ\1740 relationship_7\NN\31921 between_8\IN\1740 <e1>vpa-associated</e1>_9\JJ\1740 oxidative_10\JJ\1740 stress_11\NN\7083732 and_12\CC\1740 <e2>hepatotoxicity</e2>_13\NN\1740 ,_14\,\1740 adult_15\JJ\1740 male_16\JJ\1740 sprague-dawley_17\NN\1740 rats_18\NNS\2329401 were_19\VBD\836236 treated_20\VBN\2376958 ip_21\NN\5999797 with_22\IN\1740 vpa_23\NN\1740 (_24\-LRB-\1740 500_25\CD\13745420 mg/kg_26\NN\1740 )_27\-RRB-\1740 or_28\CC\3541091 0.9_29\CD\1740 %_30\NN\1740 saline_31\NN\14849367 (_32\-LRB-\1740 vehicle_33\NN\3100490 )_34\-RRB-\1740 once_35\RB\1740 daily_36\RB\1740 for_37\IN\1740 2_38\CD\13741022 ,_39\,\1740 4_40\CD\13741022 ,_41\,\1740 7_42\CD\13741022 ,_43\,\1740 10_44\CD\13745420 ,_45\,\1740 or_46\CC\3541091 14_47\CD\13745420 days_48\NNS\15140892 ._49\.\1740
D014635_D056486 CID to_0\TO\1740 determine_1\VB\1645601 whether_2\IN\1740 there_3\EX\27167 was_4\VBD\836236 a_5\DT\13649268 temporal_6\JJ\1740 relationship_7\NN\31921 between_8\IN\1740 vpa-associated_9\JJ\1740 oxidative_10\JJ\1740 stress_11\NN\7083732 and_12\CC\1740 <e2>hepatotoxicity</e2>_13\NN\1740 ,_14\,\1740 adult_15\JJ\1740 male_16\JJ\1740 sprague-dawley_17\NN\1740 rats_18\NNS\2329401 were_19\VBD\836236 treated_20\VBN\2376958 ip_21\NN\5999797 with_22\IN\1740 <e1>vpa</e1>_23\NN\1740 (_24\-LRB-\1740 500_25\CD\13745420 mg/kg_26\NN\1740 )_27\-RRB-\1740 or_28\CC\3541091 0.9_29\CD\1740 %_30\NN\1740 saline_31\NN\14849367 (_32\-LRB-\1740 vehicle_33\NN\3100490 )_34\-RRB-\1740 once_35\RB\1740 daily_36\RB\1740 for_37\IN\1740 2_38\CD\13741022 ,_39\,\1740 4_40\CD\13741022 ,_41\,\1740 7_42\CD\13741022 ,_43\,\1740 10_44\CD\13745420 ,_45\,\1740 or_46\CC\3541091 14_47\CD\13745420 days_48\NNS\15140892 ._49\.\1740
D005978_D056486 NONE <e2>liver_0\NN\5298729 toxicity</e2>_1\NN\13576101 was_2\VBD\836236 evaluated_3\VBN\670261 based_4\VBN\2694933 on_5\IN\1740 serum_6\NN\5397468 levels_7\NNS\4916342 of_8\IN\1740 <e1>alpha-glutathione</e1>_9\JJ\1740 s-transferase_10\NN\1740 (_11\-LRB-\1740 alpha-gst_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 by_15\IN\1740 histology_16\NN\6060049 ._17\.\1740
D014635_D009336 CID overall_0\RB\1740 ,_1\,\1740 these_2\DT\1740 findings_3\NNS\7951464 indicate_4\VBP\952524 that_5\IN\1740 <e1>vpa</e1>_6\NN\1740 treatment_7\NN\654885 results_8\VBZ\2633881 in_9\IN\13603305 oxidative_10\JJ\1740 stress_11\NN\7083732 ,_12\,\1740 as_13\IN\14622893 measured_14\VBN\697589 by_15\IN\1740 levels_16\NNS\4916342 of_17\IN\1740 15-f(2t)-isop_18\NN\1740 ,_19\,\1740 which_20\WDT\1740 precedes_21\VBZ\2690708 the_22\DT\1740 onset_23\NN\7325190 of_24\IN\1740 <e2>necrosis</e2>_25\NN\11444117 ,_26\,\1740 steatosis_27\NN\1740 ,_28\,\1740 and_29\CC\1740 elevated_30\JJ\1740 levels_31\NNS\4916342 of_32\IN\1740 serum_33\NN\5397468 alpha-gst_34\NN\1740 ._35\.\1740
D014635_D005234 CID overall_0\RB\1740 ,_1\,\1740 these_2\DT\1740 findings_3\NNS\7951464 indicate_4\VBP\952524 that_5\IN\1740 <e1>vpa</e1>_6\NN\1740 treatment_7\NN\654885 results_8\VBZ\2633881 in_9\IN\13603305 oxidative_10\JJ\1740 stress_11\NN\7083732 ,_12\,\1740 as_13\IN\14622893 measured_14\VBN\697589 by_15\IN\1740 levels_16\NNS\4916342 of_17\IN\1740 15-f(2t)-isop_18\NN\1740 ,_19\,\1740 which_20\WDT\1740 precedes_21\VBZ\2690708 the_22\DT\1740 onset_23\NN\7325190 of_24\IN\1740 necrosis_25\NN\11444117 ,_26\,\1740 <e2>steatosis</e2>_27\NN\1740 ,_28\,\1740 and_29\CC\1740 elevated_30\JJ\1740 levels_31\NNS\4916342 of_32\IN\1740 serum_33\NN\5397468 alpha-gst_34\NN\1740 ._35\.\1740
C075750_D009336 NONE overall_0\RB\1740 ,_1\,\1740 these_2\DT\1740 findings_3\NNS\7951464 indicate_4\VBP\952524 that_5\IN\1740 vpa_6\NN\1740 treatment_7\NN\654885 results_8\VBZ\2633881 in_9\IN\13603305 oxidative_10\JJ\1740 stress_11\NN\7083732 ,_12\,\1740 as_13\IN\14622893 measured_14\VBN\697589 by_15\IN\1740 levels_16\NNS\4916342 of_17\IN\1740 <e1>15-f(2t)-isop</e1>_18\NN\1740 ,_19\,\1740 which_20\WDT\1740 precedes_21\VBZ\2690708 the_22\DT\1740 onset_23\NN\7325190 of_24\IN\1740 <e2>necrosis</e2>_25\NN\11444117 ,_26\,\1740 steatosis_27\NN\1740 ,_28\,\1740 and_29\CC\1740 elevated_30\JJ\1740 levels_31\NNS\4916342 of_32\IN\1740 serum_33\NN\5397468 alpha-gst_34\NN\1740 ._35\.\1740
C075750_D005234 NONE overall_0\RB\1740 ,_1\,\1740 these_2\DT\1740 findings_3\NNS\7951464 indicate_4\VBP\952524 that_5\IN\1740 vpa_6\NN\1740 treatment_7\NN\654885 results_8\VBZ\2633881 in_9\IN\13603305 oxidative_10\JJ\1740 stress_11\NN\7083732 ,_12\,\1740 as_13\IN\14622893 measured_14\VBN\697589 by_15\IN\1740 levels_16\NNS\4916342 of_17\IN\1740 <e1>15-f(2t)-isop</e1>_18\NN\1740 ,_19\,\1740 which_20\WDT\1740 precedes_21\VBZ\2690708 the_22\DT\1740 onset_23\NN\7325190 of_24\IN\1740 necrosis_25\NN\11444117 ,_26\,\1740 <e2>steatosis</e2>_27\NN\1740 ,_28\,\1740 and_29\CC\1740 elevated_30\JJ\1740 levels_31\NNS\4916342 of_32\IN\1740 serum_33\NN\5397468 alpha-gst_34\NN\1740 ._35\.\1740
16820346
C065179_D006973 NONE <e1>atorvastatin</e1>_0\NN\3676175 prevented_1\VBD\1740 and_2\CC\1740 reversed_3\VBN\109660 dexamethasone-induced_4\JJ\1740 <e2>hypertension</e2>_5\NN\14057371 in_6\IN\13603305 the_7\DT\1740 rat_8\NN\2329401 ._9\.\1740
C065179_D006973 NONE to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 antioxidant_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>atorvastatin</e1>_6\NN\3676175 (_7\-LRB-\1740 atorva_8\NN\1740 )_9\-RRB-\1740 on_10\IN\1740 dexamethasone_11\NN\2721538 (dex)-induced_12\VBD\1740 <e2>hypertension</e2>_13\NN\14057371 ,_14\,\1740 60_15\CD\13745420 male_16\JJ\1740 sprague-dawley_17\NN\1740 rats_18\NNS\2329401 were_19\VBD\836236 treated_20\VBN\2376958 with_21\IN\1740 atorva_22\NN\1740 30_23\CD\13745420 mg/kg/day_24\NN\1740 or_25\CC\3541091 tap_26\NN\7371293 water_27\NN\14618834 for_28\IN\1740 15_29\CD\13745420 days_30\NNS\15140892 ._31\.\1740
C065179_D006973 NONE to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 antioxidant_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 atorvastatin_6\NN\3676175 (_7\-LRB-\1740 <e1>atorva</e1>_8\NN\1740 )_9\-RRB-\1740 on_10\IN\1740 dexamethasone_11\NN\2721538 (dex)-induced_12\VBD\1740 <e2>hypertension</e2>_13\NN\14057371 ,_14\,\1740 60_15\CD\13745420 male_16\JJ\1740 sprague-dawley_17\NN\1740 rats_18\NNS\2329401 were_19\VBD\836236 treated_20\VBN\2376958 with_21\IN\1740 atorva_22\NN\1740 30_23\CD\13745420 mg/kg/day_24\NN\1740 or_25\CC\3541091 tap_26\NN\7371293 water_27\NN\14618834 for_28\IN\1740 15_29\CD\13745420 days_30\NNS\15140892 ._31\.\1740
C065179_D006973 NONE to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 antioxidant_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 atorvastatin_6\NN\3676175 (_7\-LRB-\1740 atorva_8\NN\1740 )_9\-RRB-\1740 on_10\IN\1740 dexamethasone_11\NN\2721538 (dex)-induced_12\VBD\1740 <e2>hypertension</e2>_13\NN\14057371 ,_14\,\1740 60_15\CD\13745420 male_16\JJ\1740 sprague-dawley_17\NN\1740 rats_18\NNS\2329401 were_19\VBD\836236 treated_20\VBN\2376958 with_21\IN\1740 <e1>atorva</e1>_22\NN\1740 30_23\CD\13745420 mg/kg/day_24\NN\1740 or_25\CC\3541091 tap_26\NN\7371293 water_27\NN\14618834 for_28\IN\1740 15_29\CD\13745420 days_30\NNS\15140892 ._31\.\1740
C065179_D006973 NONE <e1>atorva</e1>_0\NNP\1740 reversed_1\VBD\109660 dex-induced_2\JJ\1740 <e2>hypertension</e2>_3\NN\14057371 (_4\-LRB-\1740 129_5\CD\1740 +/-_6\CC\1740 0.6_7\CD\1740 mmhg_8\NN\1740 ,_9\,\1740 vs._10\CC\1740 135_11\CD\1740 +/-_12\CC\1740 0.6_13\CD\1740 mmhg_14\NN\1740 p_15\NN\14622893 '_16\''\1740 <_17\XX\1740 0.05_18\CD\1740 )_19\-RRB-\1740 and_20\CC\1740 decreased_21\VBD\169651 plasma_22\NN\5398023 superoxide_23\NN\14971519 (_24\-LRB-\1740 7931_25\CD\1740 +/-_26\CC\1740 392.8_27\CD\1740 dex_28\NN\1740 ,_29\,\1740 1187_30\CD\1740 +/-_31\CC\1740 441.2_32\CD\1740 atorva_33\NN\1740 +_34\CC\1740 dex_35\NN\1740 ,_36\,\1740 p_37\NN\14622893 <_38\XX\1740 0.0001_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
C065179_D006973 NONE atorva_0\NNP\1740 reversed_1\VBD\109660 dex-induced_2\JJ\1740 <e2>hypertension</e2>_3\NN\14057371 (_4\-LRB-\1740 129_5\CD\1740 +/-_6\CC\1740 0.6_7\CD\1740 mmhg_8\NN\1740 ,_9\,\1740 vs._10\CC\1740 135_11\CD\1740 +/-_12\CC\1740 0.6_13\CD\1740 mmhg_14\NN\1740 p_15\NN\14622893 '_16\''\1740 <_17\XX\1740 0.05_18\CD\1740 )_19\-RRB-\1740 and_20\CC\1740 decreased_21\VBD\169651 plasma_22\NN\5398023 superoxide_23\NN\14971519 (_24\-LRB-\1740 7931_25\CD\1740 +/-_26\CC\1740 392.8_27\CD\1740 dex_28\NN\1740 ,_29\,\1740 1187_30\CD\1740 +/-_31\CC\1740 441.2_32\CD\1740 <e1>atorva</e1>_33\NN\1740 +_34\CC\1740 dex_35\NN\1740 ,_36\,\1740 p_37\NN\14622893 <_38\XX\1740 0.0001_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
C065179_D006973 NONE thus_0\RB\1740 ,_1\,\1740 <e1>atorvastatin</e1>_2\NN\3676175 prevented_3\VBD\1740 and_4\CC\1740 reversed_5\VBN\109660 dexamethasone-induced_6\JJ\1740 <e2>hypertension</e2>_7\NN\14057371 in_8\IN\13603305 the_9\DT\1740 rat_10\NN\2329401 ._11\.\1740
D003907_D006973 CID atorvastatin_0\NN\3676175 prevented_1\VBD\1740 and_2\CC\1740 reversed_3\VBN\109660 <e1>dexamethasone-induced</e1>_4\JJ\1740 <e2>hypertension</e2>_5\NN\14057371 in_6\IN\13603305 the_7\DT\1740 rat_8\NN\2329401 ._9\.\1740
D003907_D006973 CID to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 antioxidant_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 atorvastatin_6\NN\3676175 (_7\-LRB-\1740 atorva_8\NN\1740 )_9\-RRB-\1740 on_10\IN\1740 <e1>dexamethasone</e1>_11\NN\2721538 (dex)-induced_12\VBD\1740 <e2>hypertension</e2>_13\NN\14057371 ,_14\,\1740 60_15\CD\13745420 male_16\JJ\1740 sprague-dawley_17\NN\1740 rats_18\NNS\2329401 were_19\VBD\836236 treated_20\VBN\2376958 with_21\IN\1740 atorva_22\NN\1740 30_23\CD\13745420 mg/kg/day_24\NN\1740 or_25\CC\3541091 tap_26\NN\7371293 water_27\NN\14618834 for_28\IN\1740 15_29\CD\13745420 days_30\NNS\15140892 ._31\.\1740
D003907_D006973 CID to_0\TO\1740 assess_1\VB\670261 the_2\DT\1740 antioxidant_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 atorvastatin_6\NN\3676175 (_7\-LRB-\1740 atorva_8\NN\1740 )_9\-RRB-\1740 on_10\IN\1740 dexamethasone_11\NN\2721538 <e1>(dex)-induced</e1>_12\VBD\1740 <e2>hypertension</e2>_13\NN\14057371 ,_14\,\1740 60_15\CD\13745420 male_16\JJ\1740 sprague-dawley_17\NN\1740 rats_18\NNS\2329401 were_19\VBD\836236 treated_20\VBN\2376958 with_21\IN\1740 atorva_22\NN\1740 30_23\CD\13745420 mg/kg/day_24\NN\1740 or_25\CC\3541091 tap_26\NN\7371293 water_27\NN\14618834 for_28\IN\1740 15_29\CD\13745420 days_30\NNS\15140892 ._31\.\1740
D003907_D006973 CID atorva_0\NNP\1740 reversed_1\VBD\109660 <e1>dex-induced</e1>_2\JJ\1740 <e2>hypertension</e2>_3\NN\14057371 (_4\-LRB-\1740 129_5\CD\1740 +/-_6\CC\1740 0.6_7\CD\1740 mmhg_8\NN\1740 ,_9\,\1740 vs._10\CC\1740 135_11\CD\1740 +/-_12\CC\1740 0.6_13\CD\1740 mmhg_14\NN\1740 p_15\NN\14622893 '_16\''\1740 <_17\XX\1740 0.05_18\CD\1740 )_19\-RRB-\1740 and_20\CC\1740 decreased_21\VBD\169651 plasma_22\NN\5398023 superoxide_23\NN\14971519 (_24\-LRB-\1740 7931_25\CD\1740 +/-_26\CC\1740 392.8_27\CD\1740 dex_28\NN\1740 ,_29\,\1740 1187_30\CD\1740 +/-_31\CC\1740 441.2_32\CD\1740 atorva_33\NN\1740 +_34\CC\1740 dex_35\NN\1740 ,_36\,\1740 p_37\NN\14622893 <_38\XX\1740 0.0001_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
D003907_D006973 CID atorva_0\NNP\1740 reversed_1\VBD\109660 dex-induced_2\JJ\1740 <e2>hypertension</e2>_3\NN\14057371 (_4\-LRB-\1740 129_5\CD\1740 +/-_6\CC\1740 0.6_7\CD\1740 mmhg_8\NN\1740 ,_9\,\1740 vs._10\CC\1740 135_11\CD\1740 +/-_12\CC\1740 0.6_13\CD\1740 mmhg_14\NN\1740 p_15\NN\14622893 '_16\''\1740 <_17\XX\1740 0.05_18\CD\1740 )_19\-RRB-\1740 and_20\CC\1740 decreased_21\VBD\169651 plasma_22\NN\5398023 superoxide_23\NN\14971519 (_24\-LRB-\1740 7931_25\CD\1740 +/-_26\CC\1740 392.8_27\CD\1740 <e1>dex</e1>_28\NN\1740 ,_29\,\1740 1187_30\CD\1740 +/-_31\CC\1740 441.2_32\CD\1740 atorva_33\NN\1740 +_34\CC\1740 dex_35\NN\1740 ,_36\,\1740 p_37\NN\14622893 <_38\XX\1740 0.0001_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
D003907_D006973 CID atorva_0\NNP\1740 reversed_1\VBD\109660 dex-induced_2\JJ\1740 <e2>hypertension</e2>_3\NN\14057371 (_4\-LRB-\1740 129_5\CD\1740 +/-_6\CC\1740 0.6_7\CD\1740 mmhg_8\NN\1740 ,_9\,\1740 vs._10\CC\1740 135_11\CD\1740 +/-_12\CC\1740 0.6_13\CD\1740 mmhg_14\NN\1740 p_15\NN\14622893 '_16\''\1740 <_17\XX\1740 0.05_18\CD\1740 )_19\-RRB-\1740 and_20\CC\1740 decreased_21\VBD\169651 plasma_22\NN\5398023 superoxide_23\NN\14971519 (_24\-LRB-\1740 7931_25\CD\1740 +/-_26\CC\1740 392.8_27\CD\1740 dex_28\NN\1740 ,_29\,\1740 1187_30\CD\1740 +/-_31\CC\1740 441.2_32\CD\1740 atorva_33\NN\1740 +_34\CC\1740 <e1>dex</e1>_35\NN\1740 ,_36\,\1740 p_37\NN\14622893 <_38\XX\1740 0.0001_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
D003907_D006973 CID thus_0\RB\1740 ,_1\,\1740 atorvastatin_2\NN\3676175 prevented_3\VBD\1740 and_4\CC\1740 reversed_5\VBN\109660 <e1>dexamethasone-induced</e1>_6\JJ\1740 <e2>hypertension</e2>_7\NN\14057371 in_8\IN\13603305 the_9\DT\1740 rat_10\NN\2329401 ._11\.\1740
D013481_D006973 NONE atorva_0\NNP\1740 reversed_1\VBD\109660 dex-induced_2\JJ\1740 <e2>hypertension</e2>_3\NN\14057371 (_4\-LRB-\1740 129_5\CD\1740 +/-_6\CC\1740 0.6_7\CD\1740 mmhg_8\NN\1740 ,_9\,\1740 vs._10\CC\1740 135_11\CD\1740 +/-_12\CC\1740 0.6_13\CD\1740 mmhg_14\NN\1740 p_15\NN\14622893 '_16\''\1740 <_17\XX\1740 0.05_18\CD\1740 )_19\-RRB-\1740 and_20\CC\1740 decreased_21\VBD\169651 plasma_22\NN\5398023 <e1>superoxide</e1>_23\NN\14971519 (_24\-LRB-\1740 7931_25\CD\1740 +/-_26\CC\1740 392.8_27\CD\1740 dex_28\NN\1740 ,_29\,\1740 1187_30\CD\1740 +/-_31\CC\1740 441.2_32\CD\1740 atorva_33\NN\1740 +_34\CC\1740 dex_35\NN\1740 ,_36\,\1740 p_37\NN\14622893 <_38\XX\1740 0.0001_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
18674790
D004041_D009765 CID high_0\JJ\1740 <e1>fat</e1>_1\JJ\1740 diet-fed_2\JJ\1740 <e2>obese</e2>_3\JJ\1740 rats_4\NNS\2329401 are_5\VBP\836236 highly_6\RB\1740 sensitive_7\JJ\1740 to_8\TO\1740 doxorubicin-induced_9\JJ\1740 cardiotoxicity_10\NN\1740 ._11\.\1740
D004041_D009765 CID in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 investigated_6\VBD\644583 whether_7\IN\1740 a_8\DT\13649268 physiological_9\JJ\1740 intervention_10\NN\1239064 by_11\IN\1740 feeding_12\VBG\1182709 40_13\CD\13745420 %_14\NN\1740 high_15\JJ\1740 <e1>fat</e1>_16\JJ\1740 diet_17\NN\7560652 (_18\-LRB-\1740 hfd_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 which_22\WDT\1740 induces_23\VBZ\1627355 <e2>obesity</e2>_24\NN\4999401 in_25\IN\13603305 male_26\JJ\1740 sprague-dawley_27\NN\1740 rats_28\NNS\2329401 (_29\-LRB-\1740 250_30\CD\1740 -_31\SYM\1740 275_32\CD\1740 g_33\NN\13717155 )_34\-RRB-\1740 ,_35\,\1740 sensitizes_36\VBZ\126264 to_37\TO\1740 doxorubicin-induced_38\JJ\1740 cardiotoxicity_39\NN\1740 ._40\.\1740
D004041_D066126 NONE high_0\JJ\1740 <e1>fat</e1>_1\JJ\1740 diet-fed_2\JJ\1740 obese_3\JJ\1740 rats_4\NNS\2329401 are_5\VBP\836236 highly_6\RB\1740 sensitive_7\JJ\1740 to_8\TO\1740 doxorubicin-induced_9\JJ\1740 <e2>cardiotoxicity</e2>_10\NN\1740 ._11\.\1740
D004041_D066126 NONE in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 investigated_6\VBD\644583 whether_7\IN\1740 a_8\DT\13649268 physiological_9\JJ\1740 intervention_10\NN\1239064 by_11\IN\1740 feeding_12\VBG\1182709 40_13\CD\13745420 %_14\NN\1740 high_15\JJ\1740 <e1>fat</e1>_16\JJ\1740 diet_17\NN\7560652 (_18\-LRB-\1740 hfd_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 which_22\WDT\1740 induces_23\VBZ\1627355 obesity_24\NN\4999401 in_25\IN\13603305 male_26\JJ\1740 sprague-dawley_27\NN\1740 rats_28\NNS\2329401 (_29\-LRB-\1740 250_30\CD\1740 -_31\SYM\1740 275_32\CD\1740 g_33\NN\13717155 )_34\-RRB-\1740 ,_35\,\1740 sensitizes_36\VBZ\126264 to_37\TO\1740 doxorubicin-induced_38\JJ\1740 <e2>cardiotoxicity</e2>_39\NN\1740 ._40\.\1740
D004317_D009765 NONE high_0\JJ\1740 fat_1\JJ\1740 diet-fed_2\JJ\1740 <e2>obese</e2>_3\JJ\1740 rats_4\NNS\2329401 are_5\VBP\836236 highly_6\RB\1740 sensitive_7\JJ\1740 to_8\TO\1740 <e1>doxorubicin-induced</e1>_9\JJ\1740 cardiotoxicity_10\NN\1740 ._11\.\1740
D004317_D009765 NONE in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 investigated_6\VBD\644583 whether_7\IN\1740 a_8\DT\13649268 physiological_9\JJ\1740 intervention_10\NN\1239064 by_11\IN\1740 feeding_12\VBG\1182709 40_13\CD\13745420 %_14\NN\1740 high_15\JJ\1740 fat_16\JJ\1740 diet_17\NN\7560652 (_18\-LRB-\1740 hfd_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 which_22\WDT\1740 induces_23\VBZ\1627355 <e2>obesity</e2>_24\NN\4999401 in_25\IN\13603305 male_26\JJ\1740 sprague-dawley_27\NN\1740 rats_28\NNS\2329401 (_29\-LRB-\1740 250_30\CD\1740 -_31\SYM\1740 275_32\CD\1740 g_33\NN\13717155 )_34\-RRB-\1740 ,_35\,\1740 sensitizes_36\VBZ\126264 to_37\TO\1740 <e1>doxorubicin-induced</e1>_38\JJ\1740 cardiotoxicity_39\NN\1740 ._40\.\1740
D004317_D009765 NONE a_0\DT\13649268 ld(10_1\NN\1740 )_2\-RRB-\1740 dose_3\NN\3740161 (_4\-LRB-\1740 8_5\CD\13741022 mg_6\NN\13717155 <e1>doxorubicin/kg</e1>_7\NN\1740 ,_8\,\1740 ip_9\FW\5999797 )_10\-RRB-\1740 administered_11\VBN\2436349 on_12\IN\1740 day_13\NN\15154774 43_14\CD\1740 of_15\IN\1740 the_16\DT\1740 hfd_17\NN\1740 feeding_18\NN\838098 regimen_19\NNS\5898568 led_20\VBD\1752884 to_21\IN\1740 higher_22\JJR\1740 cardiotoxicity_23\NN\1740 ,_24\,\1740 cardiac_25\JJ\1740 dysfunction_26\NN\14204950 ,_27\,\1740 lipid_28\NN\14944888 peroxidation_29\NN\1740 ,_30\,\1740 and_31\CC\1740 80_32\CD\13745420 %_33\NN\1740 mortality_34\NN\5054863 in_35\IN\13603305 the_36\DT\1740 <e2>obese</e2>_37\JJ\1740 (_38\-LRB-\1740 ob_39\NN\6043075 )_40\-RRB-\1740 rats_41\NNS\2329401 in_42\IN\13603305 the_43\DT\1740 absence_44\NN\14449405 of_45\IN\1740 any_46\DT\1740 significant_47\JJ\1740 renal_48\JJ\1740 or_49\CC\3541091 hepatic_50\JJ\1740 toxicity_51\NN\13576101 ._52\.\1740
D004317_D009765 NONE a_0\DT\13649268 ld(10_1\NN\1740 )_2\-RRB-\1740 dose_3\NN\3740161 (_4\-LRB-\1740 8_5\CD\13741022 mg_6\NN\13717155 <e1>doxorubicin/kg</e1>_7\NN\1740 ,_8\,\1740 ip_9\FW\5999797 )_10\-RRB-\1740 administered_11\VBN\2436349 on_12\IN\1740 day_13\NN\15154774 43_14\CD\1740 of_15\IN\1740 the_16\DT\1740 hfd_17\NN\1740 feeding_18\NN\838098 regimen_19\NNS\5898568 led_20\VBD\1752884 to_21\IN\1740 higher_22\JJR\1740 cardiotoxicity_23\NN\1740 ,_24\,\1740 cardiac_25\JJ\1740 dysfunction_26\NN\14204950 ,_27\,\1740 lipid_28\NN\14944888 peroxidation_29\NN\1740 ,_30\,\1740 and_31\CC\1740 80_32\CD\13745420 %_33\NN\1740 mortality_34\NN\5054863 in_35\IN\13603305 the_36\DT\1740 obese_37\JJ\1740 (_38\-LRB-\1740 <e2>ob</e2>_39\NN\6043075 )_40\-RRB-\1740 rats_41\NNS\2329401 in_42\IN\13603305 the_43\DT\1740 absence_44\NN\14449405 of_45\IN\1740 any_46\DT\1740 significant_47\JJ\1740 renal_48\JJ\1740 or_49\CC\3541091 hepatic_50\JJ\1740 toxicity_51\NN\13576101 ._52\.\1740
D004317_D009765 NONE <e1>doxorubicin</e1>_0\NN\2716866 toxicokinetics_1\NNS\1740 studies_2\NNS\635850 revealed_3\VBD\2137132 no_4\DT\7204911 change_5\NN\7283608 in_6\IN\13603305 accumulation_7\NN\13497135 of_8\IN\1740 doxorubicin_9\NN\2716866 and_10\CC\1740 doxorubicinol_11\NN\1740 (_12\-LRB-\1740 toxic_13\JJ\1740 metabolite_14\NN\20090 )_15\-RRB-\1740 in_16\IN\13603305 the_17\DT\1740 normal_18\JJ\1740 diet-fed_19\NN\1740 (_20\-LRB-\1740 nd_21\NN\14625458 )_22\-RRB-\1740 and_23\CC\1740 <e2>ob</e2>_24\NN\6043075 hearts_25\NNS\496167 ._26\.\1740
D004317_D009765 NONE doxorubicin_0\NN\2716866 toxicokinetics_1\NNS\1740 studies_2\NNS\635850 revealed_3\VBD\2137132 no_4\DT\7204911 change_5\NN\7283608 in_6\IN\13603305 accumulation_7\NN\13497135 of_8\IN\1740 <e1>doxorubicin</e1>_9\NN\2716866 and_10\CC\1740 doxorubicinol_11\NN\1740 (_12\-LRB-\1740 toxic_13\JJ\1740 metabolite_14\NN\20090 )_15\-RRB-\1740 in_16\IN\13603305 the_17\DT\1740 normal_18\JJ\1740 diet-fed_19\NN\1740 (_20\-LRB-\1740 nd_21\NN\14625458 )_22\-RRB-\1740 and_23\CC\1740 <e2>ob</e2>_24\NN\6043075 hearts_25\NNS\496167 ._26\.\1740
D004317_D009765 NONE mechanistic_0\JJ\1740 studies_1\NNS\635850 revealed_2\VBD\2137132 that_3\IN\1740 <e2>ob</e2>_4\NN\6043075 rats_5\NNS\2329401 are_6\VBP\836236 sensitized_7\VBN\126264 due_8\IN\5174653 to_9\IN\1740 :_10\:\1740 (_11\-LRB-\1740 1_12\LS\13741022 )_13\-RRB-\1740 higher_14\JJR\1740 oxyradical_15\JJ\1740 stress_16\NN\7083732 leading_17\VBG\1752884 to_18\TO\1740 upregulation_19\NN\1740 of_20\IN\1740 uncoupling_21\VBG\1356038 proteins_22\NNS\14944888 2_23\CD\13741022 and_24\CC\1740 3_25\CD\13741022 ,_26\,\1740 (_27\-LRB-\1740 2_28\LS\13741022 )_29\-RRB-\1740 downregulation_30\NN\1740 of_31\IN\1740 cardiac_32\JJ\1740 peroxisome_33\NN\1740 proliferators_34\NNS\1740 activated_35\VBD\1641914 receptor-alpha_36\NN\1740 ,_37\,\1740 (_38\-LRB-\1740 3_39\CD\13741022 )_40\-RRB-\1740 decreased_41\VBD\169651 plasma_42\NN\5398023 adiponectin_43\NN\1740 levels_44\NNS\4916342 ,_45\,\1740 (_46\-LRB-\1740 4_47\CD\13741022 )_48\-RRB-\1740 decreased_49\VBD\169651 cardiac_50\JJ\1740 fatty-acid_51\JJ\1740 oxidation_52\NN\13447361 (_53\-LRB-\1740 666.9+/-14.0_54\CD\1740 nmol/min/g_55\NN\1740 heart_56\NN\5919034 in_57\IN\13603305 nd_58\NN\14625458 versus_59\CC\1740 400.2+/-11.8_60\CD\1740 nmol/min/g_61\NN\1740 heart_62\NN\5919034 in_63\IN\13603305 ob_64\NN\6043075 )_65\-RRB-\1740 ,_66\,\1740 (_67\-LRB-\1740 5_68\CD\13741022 )_69\-RRB-\1740 decreased_70\VBD\169651 mitochondrial_71\JJ\1740 amp-alpha2_72\NN\1740 protein_73\NN\14944888 kinase_74\NN\14732946 ,_75\,\1740 and_76\CC\1740 (_77\-LRB-\1740 6_78\CD\13741022 )_79\-RRB-\1740 86_80\CD\1740 %_81\NN\1740 drop_82\NN\13899200 in_83\IN\13603305 cardiac_84\JJ\1740 atp_85\NN\14964590 levels_86\NNS\4916342 accompanied_87\VBN\1835496 by_88\IN\1740 decreased_89\VBN\169651 atp/adp_90\NN\1740 ratio_91\NN\13815152 after_92\IN\1740 <e1>doxorubicin</e1>_93\NN\2716866 administration_94\NN\1133281 ._95\.\1740
D004317_D009765 NONE mechanistic_0\JJ\1740 studies_1\NNS\635850 revealed_2\VBD\2137132 that_3\IN\1740 ob_4\NN\6043075 rats_5\NNS\2329401 are_6\VBP\836236 sensitized_7\VBN\126264 due_8\IN\5174653 to_9\IN\1740 :_10\:\1740 (_11\-LRB-\1740 1_12\LS\13741022 )_13\-RRB-\1740 higher_14\JJR\1740 oxyradical_15\JJ\1740 stress_16\NN\7083732 leading_17\VBG\1752884 to_18\TO\1740 upregulation_19\NN\1740 of_20\IN\1740 uncoupling_21\VBG\1356038 proteins_22\NNS\14944888 2_23\CD\13741022 and_24\CC\1740 3_25\CD\13741022 ,_26\,\1740 (_27\-LRB-\1740 2_28\LS\13741022 )_29\-RRB-\1740 downregulation_30\NN\1740 of_31\IN\1740 cardiac_32\JJ\1740 peroxisome_33\NN\1740 proliferators_34\NNS\1740 activated_35\VBD\1641914 receptor-alpha_36\NN\1740 ,_37\,\1740 (_38\-LRB-\1740 3_39\CD\13741022 )_40\-RRB-\1740 decreased_41\VBD\169651 plasma_42\NN\5398023 adiponectin_43\NN\1740 levels_44\NNS\4916342 ,_45\,\1740 (_46\-LRB-\1740 4_47\CD\13741022 )_48\-RRB-\1740 decreased_49\VBD\169651 cardiac_50\JJ\1740 fatty-acid_51\JJ\1740 oxidation_52\NN\13447361 (_53\-LRB-\1740 666.9+/-14.0_54\CD\1740 nmol/min/g_55\NN\1740 heart_56\NN\5919034 in_57\IN\13603305 nd_58\NN\14625458 versus_59\CC\1740 400.2+/-11.8_60\CD\1740 nmol/min/g_61\NN\1740 heart_62\NN\5919034 in_63\IN\13603305 <e2>ob</e2>_64\NN\6043075 )_65\-RRB-\1740 ,_66\,\1740 (_67\-LRB-\1740 5_68\CD\13741022 )_69\-RRB-\1740 decreased_70\VBD\169651 mitochondrial_71\JJ\1740 amp-alpha2_72\NN\1740 protein_73\NN\14944888 kinase_74\NN\14732946 ,_75\,\1740 and_76\CC\1740 (_77\-LRB-\1740 6_78\CD\13741022 )_79\-RRB-\1740 86_80\CD\1740 %_81\NN\1740 drop_82\NN\13899200 in_83\IN\13603305 cardiac_84\JJ\1740 atp_85\NN\14964590 levels_86\NNS\4916342 accompanied_87\VBN\1835496 by_88\IN\1740 decreased_89\VBN\169651 atp/adp_90\NN\1740 ratio_91\NN\13815152 after_92\IN\1740 <e1>doxorubicin</e1>_93\NN\2716866 administration_94\NN\1133281 ._95\.\1740
D004317_D009765 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 hfd-induced_3\JJ\1740 <e2>obese</e2>_4\JJ\1740 rats_5\NNS\2329401 are_6\VBP\836236 highly_7\RB\1740 sensitized_8\VBN\126264 to_9\TO\1740 <e1>doxorubicin-induced</e1>_10\JJ\1740 cardiotoxicity_11\NN\1740 by_12\IN\1740 substantially_13\RB\1740 downregulating_14\VBG\1740 cardiac_15\JJ\1740 mitochondrial_16\JJ\1740 atp_17\NN\14964590 generation_18\NN\7942152 ,_19\,\1740 increasing_20\VBG\169651 oxidative_21\JJ\1740 stress_22\NN\7083732 and_23\CC\1740 downregulating_24\VBG\1740 the_25\DT\1740 jak/stat3_26\JJ\1740 pathway_27\NN\5483677 ._28\.\1740
D004317_D066126 NONE high_0\JJ\1740 fat_1\JJ\1740 diet-fed_2\JJ\1740 obese_3\JJ\1740 rats_4\NNS\2329401 are_5\VBP\836236 highly_6\RB\1740 sensitive_7\JJ\1740 to_8\TO\1740 <e1>doxorubicin-induced</e1>_9\JJ\1740 <e2>cardiotoxicity</e2>_10\NN\1740 ._11\.\1740
D004317_D066126 NONE often_0\RB\1740 ,_1\,\1740 chemotherapy_2\NN\661091 by_3\IN\1740 <e1>doxorubicin</e1>_4\NN\2716866 (_5\-LRB-\1740 adriamycin_6\NN\1740 )_7\-RRB-\1740 is_8\VBZ\836236 limited_9\VBN\2510337 due_10\IN\5174653 to_11\IN\1740 life_12\NN\13954253 threatening_13\VBG\2603699 <e2>cardiotoxicity</e2>_14\NN\1740 in_15\IN\13603305 patients_16\NNS\9898892 during_17\IN\1740 and_18\CC\1740 posttherapy_19\NN\1740 ._20\.\1740
D004317_D066126 NONE often_0\RB\1740 ,_1\,\1740 chemotherapy_2\NN\661091 by_3\IN\1740 doxorubicin_4\NN\2716866 (_5\-LRB-\1740 <e1>adriamycin</e1>_6\NN\1740 )_7\-RRB-\1740 is_8\VBZ\836236 limited_9\VBN\2510337 due_10\IN\5174653 to_11\IN\1740 life_12\NN\13954253 threatening_13\VBG\2603699 <e2>cardiotoxicity</e2>_14\NN\1740 in_15\IN\13603305 patients_16\NNS\9898892 during_17\IN\1740 and_18\CC\1740 posttherapy_19\NN\1740 ._20\.\1740
D004317_D066126 NONE recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 have_3\VBP\2108377 shown_4\VBN\2137132 that_5\IN\1740 moderate_6\JJ\1740 diet_7\JJ\1740 restriction_8\NN\5846054 remarkably_9\RB\1740 protects_10\VBZ\1127795 against_11\IN\1740 <e1>doxorubicin-induced</e1>_12\JJ\1740 <e2>cardiotoxicity</e2>_13\NN\1740 ._14\.\1740
D004317_D066126 NONE in_0\IN\13603305 the_1\DT\1740 current_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 we_5\PRP\1740 investigated_6\VBD\644583 whether_7\IN\1740 a_8\DT\13649268 physiological_9\JJ\1740 intervention_10\NN\1239064 by_11\IN\1740 feeding_12\VBG\1182709 40_13\CD\13745420 %_14\NN\1740 high_15\JJ\1740 fat_16\JJ\1740 diet_17\NN\7560652 (_18\-LRB-\1740 hfd_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 which_22\WDT\1740 induces_23\VBZ\1627355 obesity_24\NN\4999401 in_25\IN\13603305 male_26\JJ\1740 sprague-dawley_27\NN\1740 rats_28\NNS\2329401 (_29\-LRB-\1740 250_30\CD\1740 -_31\SYM\1740 275_32\CD\1740 g_33\NN\13717155 )_34\-RRB-\1740 ,_35\,\1740 sensitizes_36\VBZ\126264 to_37\TO\1740 <e1>doxorubicin-induced</e1>_38\JJ\1740 <e2>cardiotoxicity</e2>_39\NN\1740 ._40\.\1740
D004317_D066126 NONE a_0\DT\13649268 ld(10_1\NN\1740 )_2\-RRB-\1740 dose_3\NN\3740161 (_4\-LRB-\1740 8_5\CD\13741022 mg_6\NN\13717155 <e1>doxorubicin/kg</e1>_7\NN\1740 ,_8\,\1740 ip_9\FW\5999797 )_10\-RRB-\1740 administered_11\VBN\2436349 on_12\IN\1740 day_13\NN\15154774 43_14\CD\1740 of_15\IN\1740 the_16\DT\1740 hfd_17\NN\1740 feeding_18\NN\838098 regimen_19\NNS\5898568 led_20\VBD\1752884 to_21\IN\1740 higher_22\JJR\1740 <e2>cardiotoxicity</e2>_23\NN\1740 ,_24\,\1740 cardiac_25\JJ\1740 dysfunction_26\NN\14204950 ,_27\,\1740 lipid_28\NN\14944888 peroxidation_29\NN\1740 ,_30\,\1740 and_31\CC\1740 80_32\CD\13745420 %_33\NN\1740 mortality_34\NN\5054863 in_35\IN\13603305 the_36\DT\1740 obese_37\JJ\1740 (_38\-LRB-\1740 ob_39\NN\6043075 )_40\-RRB-\1740 rats_41\NNS\2329401 in_42\IN\13603305 the_43\DT\1740 absence_44\NN\14449405 of_45\IN\1740 any_46\DT\1740 significant_47\JJ\1740 renal_48\JJ\1740 or_49\CC\3541091 hepatic_50\JJ\1740 toxicity_51\NN\13576101 ._52\.\1740
D004317_D066126 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 hfd-induced_3\JJ\1740 obese_4\JJ\1740 rats_5\NNS\2329401 are_6\VBP\836236 highly_7\RB\1740 sensitized_8\VBN\126264 to_9\TO\1740 <e1>doxorubicin-induced</e1>_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 by_12\IN\1740 substantially_13\RB\1740 downregulating_14\VBG\1740 cardiac_15\JJ\1740 mitochondrial_16\JJ\1740 atp_17\NN\14964590 generation_18\NN\7942152 ,_19\,\1740 increasing_20\VBG\169651 oxidative_21\JJ\1740 stress_22\NN\7083732 and_23\CC\1740 downregulating_24\VBG\1740 the_25\DT\1740 jak/stat3_26\JJ\1740 pathway_27\NN\5483677 ._28\.\1740
D004317_D006331 CID a_0\DT\13649268 ld(10_1\NN\1740 )_2\-RRB-\1740 dose_3\NN\3740161 (_4\-LRB-\1740 8_5\CD\13741022 mg_6\NN\13717155 <e1>doxorubicin/kg</e1>_7\NN\1740 ,_8\,\1740 ip_9\FW\5999797 )_10\-RRB-\1740 administered_11\VBN\2436349 on_12\IN\1740 day_13\NN\15154774 43_14\CD\1740 of_15\IN\1740 the_16\DT\1740 hfd_17\NN\1740 feeding_18\NN\838098 regimen_19\NNS\5898568 led_20\VBD\1752884 to_21\IN\1740 higher_22\JJR\1740 cardiotoxicity_23\NN\1740 ,_24\,\1740 <e2>cardiac_25\JJ\1740 dysfunction</e2>_26\NN\14204950 ,_27\,\1740 lipid_28\NN\14944888 peroxidation_29\NN\1740 ,_30\,\1740 and_31\CC\1740 80_32\CD\13745420 %_33\NN\1740 mortality_34\NN\5054863 in_35\IN\13603305 the_36\DT\1740 obese_37\JJ\1740 (_38\-LRB-\1740 ob_39\NN\6043075 )_40\-RRB-\1740 rats_41\NNS\2329401 in_42\IN\13603305 the_43\DT\1740 absence_44\NN\14449405 of_45\IN\1740 any_46\DT\1740 significant_47\JJ\1740 renal_48\JJ\1740 or_49\CC\3541091 hepatic_50\JJ\1740 toxicity_51\NN\13576101 ._52\.\1740
D004317_D007674 NONE a_0\DT\13649268 ld(10_1\NN\1740 )_2\-RRB-\1740 dose_3\NN\3740161 (_4\-LRB-\1740 8_5\CD\13741022 mg_6\NN\13717155 <e1>doxorubicin/kg</e1>_7\NN\1740 ,_8\,\1740 ip_9\FW\5999797 )_10\-RRB-\1740 administered_11\VBN\2436349 on_12\IN\1740 day_13\NN\15154774 43_14\CD\1740 of_15\IN\1740 the_16\DT\1740 hfd_17\NN\1740 feeding_18\NN\838098 regimen_19\NNS\5898568 led_20\VBD\1752884 to_21\IN\1740 higher_22\JJR\1740 cardiotoxicity_23\NN\1740 ,_24\,\1740 cardiac_25\JJ\1740 dysfunction_26\NN\14204950 ,_27\,\1740 lipid_28\NN\14944888 peroxidation_29\NN\1740 ,_30\,\1740 and_31\CC\1740 80_32\CD\13745420 %_33\NN\1740 mortality_34\NN\5054863 in_35\IN\13603305 the_36\DT\1740 obese_37\JJ\1740 (_38\-LRB-\1740 ob_39\NN\6043075 )_40\-RRB-\1740 rats_41\NNS\2329401 in_42\IN\13603305 the_43\DT\1740 absence_44\NN\14449405 of_45\IN\1740 any_46\DT\1740 significant_47\JJ\1740 <e2>renal_48\JJ\1740 or_49\CC\3541091 hepatic_50\JJ\1740 toxicity</e2>_51\NN\13576101 ._52\.\1740
D004317_D056486 NONE a_0\DT\13649268 ld(10_1\NN\1740 )_2\-RRB-\1740 dose_3\NN\3740161 (_4\-LRB-\1740 8_5\CD\13741022 mg_6\NN\13717155 <e1>doxorubicin/kg</e1>_7\NN\1740 ,_8\,\1740 ip_9\FW\5999797 )_10\-RRB-\1740 administered_11\VBN\2436349 on_12\IN\1740 day_13\NN\15154774 43_14\CD\1740 of_15\IN\1740 the_16\DT\1740 hfd_17\NN\1740 feeding_18\NN\838098 regimen_19\NNS\5898568 led_20\VBD\1752884 to_21\IN\1740 higher_22\JJR\1740 cardiotoxicity_23\NN\1740 ,_24\,\1740 cardiac_25\JJ\1740 dysfunction_26\NN\14204950 ,_27\,\1740 lipid_28\NN\14944888 peroxidation_29\NN\1740 ,_30\,\1740 and_31\CC\1740 80_32\CD\13745420 %_33\NN\1740 mortality_34\NN\5054863 in_35\IN\13603305 the_36\DT\1740 obese_37\JJ\1740 (_38\-LRB-\1740 ob_39\NN\6043075 )_40\-RRB-\1740 rats_41\NNS\2329401 in_42\IN\13603305 the_43\DT\1740 absence_44\NN\14449405 of_45\IN\1740 any_46\DT\1740 significant_47\JJ\1740 <e2>renal_48\JJ\1740 or_49\CC\3541091 hepatic_50\JJ\1740 toxicity</e2>_51\NN\13576101 ._52\.\1740
C010013_D009765 NONE doxorubicin_0\NN\2716866 toxicokinetics_1\NNS\1740 studies_2\NNS\635850 revealed_3\VBD\2137132 no_4\DT\7204911 change_5\NN\7283608 in_6\IN\13603305 accumulation_7\NN\13497135 of_8\IN\1740 doxorubicin_9\NN\2716866 and_10\CC\1740 <e1>doxorubicinol</e1>_11\NN\1740 (_12\-LRB-\1740 toxic_13\JJ\1740 metabolite_14\NN\20090 )_15\-RRB-\1740 in_16\IN\13603305 the_17\DT\1740 normal_18\JJ\1740 diet-fed_19\NN\1740 (_20\-LRB-\1740 nd_21\NN\14625458 )_22\-RRB-\1740 and_23\CC\1740 <e2>ob</e2>_24\NN\6043075 hearts_25\NNS\496167 ._26\.\1740
D000249_D009765 NONE mechanistic_0\JJ\1740 studies_1\NNS\635850 revealed_2\VBD\2137132 that_3\IN\1740 <e2>ob</e2>_4\NN\6043075 rats_5\NNS\2329401 are_6\VBP\836236 sensitized_7\VBN\126264 due_8\IN\5174653 to_9\IN\1740 :_10\:\1740 (_11\-LRB-\1740 1_12\LS\13741022 )_13\-RRB-\1740 higher_14\JJR\1740 oxyradical_15\JJ\1740 stress_16\NN\7083732 leading_17\VBG\1752884 to_18\TO\1740 upregulation_19\NN\1740 of_20\IN\1740 uncoupling_21\VBG\1356038 proteins_22\NNS\14944888 2_23\CD\13741022 and_24\CC\1740 3_25\CD\13741022 ,_26\,\1740 (_27\-LRB-\1740 2_28\LS\13741022 )_29\-RRB-\1740 downregulation_30\NN\1740 of_31\IN\1740 cardiac_32\JJ\1740 peroxisome_33\NN\1740 proliferators_34\NNS\1740 activated_35\VBD\1641914 receptor-alpha_36\NN\1740 ,_37\,\1740 (_38\-LRB-\1740 3_39\CD\13741022 )_40\-RRB-\1740 decreased_41\VBD\169651 plasma_42\NN\5398023 adiponectin_43\NN\1740 levels_44\NNS\4916342 ,_45\,\1740 (_46\-LRB-\1740 4_47\CD\13741022 )_48\-RRB-\1740 decreased_49\VBD\169651 cardiac_50\JJ\1740 fatty-acid_51\JJ\1740 oxidation_52\NN\13447361 (_53\-LRB-\1740 666.9+/-14.0_54\CD\1740 nmol/min/g_55\NN\1740 heart_56\NN\5919034 in_57\IN\13603305 nd_58\NN\14625458 versus_59\CC\1740 400.2+/-11.8_60\CD\1740 nmol/min/g_61\NN\1740 heart_62\NN\5919034 in_63\IN\13603305 ob_64\NN\6043075 )_65\-RRB-\1740 ,_66\,\1740 (_67\-LRB-\1740 5_68\CD\13741022 )_69\-RRB-\1740 decreased_70\VBD\169651 mitochondrial_71\JJ\1740 <e1>amp-alpha2</e1>_72\NN\1740 protein_73\NN\14944888 kinase_74\NN\14732946 ,_75\,\1740 and_76\CC\1740 (_77\-LRB-\1740 6_78\CD\13741022 )_79\-RRB-\1740 86_80\CD\1740 %_81\NN\1740 drop_82\NN\13899200 in_83\IN\13603305 cardiac_84\JJ\1740 atp_85\NN\14964590 levels_86\NNS\4916342 accompanied_87\VBN\1835496 by_88\IN\1740 decreased_89\VBN\169651 atp/adp_90\NN\1740 ratio_91\NN\13815152 after_92\IN\1740 doxorubicin_93\NN\2716866 administration_94\NN\1133281 ._95\.\1740
D000249_D009765 NONE mechanistic_0\JJ\1740 studies_1\NNS\635850 revealed_2\VBD\2137132 that_3\IN\1740 ob_4\NN\6043075 rats_5\NNS\2329401 are_6\VBP\836236 sensitized_7\VBN\126264 due_8\IN\5174653 to_9\IN\1740 :_10\:\1740 (_11\-LRB-\1740 1_12\LS\13741022 )_13\-RRB-\1740 higher_14\JJR\1740 oxyradical_15\JJ\1740 stress_16\NN\7083732 leading_17\VBG\1752884 to_18\TO\1740 upregulation_19\NN\1740 of_20\IN\1740 uncoupling_21\VBG\1356038 proteins_22\NNS\14944888 2_23\CD\13741022 and_24\CC\1740 3_25\CD\13741022 ,_26\,\1740 (_27\-LRB-\1740 2_28\LS\13741022 )_29\-RRB-\1740 downregulation_30\NN\1740 of_31\IN\1740 cardiac_32\JJ\1740 peroxisome_33\NN\1740 proliferators_34\NNS\1740 activated_35\VBD\1641914 receptor-alpha_36\NN\1740 ,_37\,\1740 (_38\-LRB-\1740 3_39\CD\13741022 )_40\-RRB-\1740 decreased_41\VBD\169651 plasma_42\NN\5398023 adiponectin_43\NN\1740 levels_44\NNS\4916342 ,_45\,\1740 (_46\-LRB-\1740 4_47\CD\13741022 )_48\-RRB-\1740 decreased_49\VBD\169651 cardiac_50\JJ\1740 fatty-acid_51\JJ\1740 oxidation_52\NN\13447361 (_53\-LRB-\1740 666.9+/-14.0_54\CD\1740 nmol/min/g_55\NN\1740 heart_56\NN\5919034 in_57\IN\13603305 nd_58\NN\14625458 versus_59\CC\1740 400.2+/-11.8_60\CD\1740 nmol/min/g_61\NN\1740 heart_62\NN\5919034 in_63\IN\13603305 <e2>ob</e2>_64\NN\6043075 )_65\-RRB-\1740 ,_66\,\1740 (_67\-LRB-\1740 5_68\CD\13741022 )_69\-RRB-\1740 decreased_70\VBD\169651 mitochondrial_71\JJ\1740 <e1>amp-alpha2</e1>_72\NN\1740 protein_73\NN\14944888 kinase_74\NN\14732946 ,_75\,\1740 and_76\CC\1740 (_77\-LRB-\1740 6_78\CD\13741022 )_79\-RRB-\1740 86_80\CD\1740 %_81\NN\1740 drop_82\NN\13899200 in_83\IN\13603305 cardiac_84\JJ\1740 atp_85\NN\14964590 levels_86\NNS\4916342 accompanied_87\VBN\1835496 by_88\IN\1740 decreased_89\VBN\169651 atp/adp_90\NN\1740 ratio_91\NN\13815152 after_92\IN\1740 doxorubicin_93\NN\2716866 administration_94\NN\1133281 ._95\.\1740
D000255_D009765 NONE mechanistic_0\JJ\1740 studies_1\NNS\635850 revealed_2\VBD\2137132 that_3\IN\1740 <e2>ob</e2>_4\NN\6043075 rats_5\NNS\2329401 are_6\VBP\836236 sensitized_7\VBN\126264 due_8\IN\5174653 to_9\IN\1740 :_10\:\1740 (_11\-LRB-\1740 1_12\LS\13741022 )_13\-RRB-\1740 higher_14\JJR\1740 oxyradical_15\JJ\1740 stress_16\NN\7083732 leading_17\VBG\1752884 to_18\TO\1740 upregulation_19\NN\1740 of_20\IN\1740 uncoupling_21\VBG\1356038 proteins_22\NNS\14944888 2_23\CD\13741022 and_24\CC\1740 3_25\CD\13741022 ,_26\,\1740 (_27\-LRB-\1740 2_28\LS\13741022 )_29\-RRB-\1740 downregulation_30\NN\1740 of_31\IN\1740 cardiac_32\JJ\1740 peroxisome_33\NN\1740 proliferators_34\NNS\1740 activated_35\VBD\1641914 receptor-alpha_36\NN\1740 ,_37\,\1740 (_38\-LRB-\1740 3_39\CD\13741022 )_40\-RRB-\1740 decreased_41\VBD\169651 plasma_42\NN\5398023 adiponectin_43\NN\1740 levels_44\NNS\4916342 ,_45\,\1740 (_46\-LRB-\1740 4_47\CD\13741022 )_48\-RRB-\1740 decreased_49\VBD\169651 cardiac_50\JJ\1740 fatty-acid_51\JJ\1740 oxidation_52\NN\13447361 (_53\-LRB-\1740 666.9+/-14.0_54\CD\1740 nmol/min/g_55\NN\1740 heart_56\NN\5919034 in_57\IN\13603305 nd_58\NN\14625458 versus_59\CC\1740 400.2+/-11.8_60\CD\1740 nmol/min/g_61\NN\1740 heart_62\NN\5919034 in_63\IN\13603305 ob_64\NN\6043075 )_65\-RRB-\1740 ,_66\,\1740 (_67\-LRB-\1740 5_68\CD\13741022 )_69\-RRB-\1740 decreased_70\VBD\169651 mitochondrial_71\JJ\1740 amp-alpha2_72\NN\1740 protein_73\NN\14944888 kinase_74\NN\14732946 ,_75\,\1740 and_76\CC\1740 (_77\-LRB-\1740 6_78\CD\13741022 )_79\-RRB-\1740 86_80\CD\1740 %_81\NN\1740 drop_82\NN\13899200 in_83\IN\13603305 cardiac_84\JJ\1740 <e1>atp</e1>_85\NN\14964590 levels_86\NNS\4916342 accompanied_87\VBN\1835496 by_88\IN\1740 decreased_89\VBN\169651 atp/adp_90\NN\1740 ratio_91\NN\13815152 after_92\IN\1740 doxorubicin_93\NN\2716866 administration_94\NN\1133281 ._95\.\1740
D000255_D009765 NONE mechanistic_0\JJ\1740 studies_1\NNS\635850 revealed_2\VBD\2137132 that_3\IN\1740 ob_4\NN\6043075 rats_5\NNS\2329401 are_6\VBP\836236 sensitized_7\VBN\126264 due_8\IN\5174653 to_9\IN\1740 :_10\:\1740 (_11\-LRB-\1740 1_12\LS\13741022 )_13\-RRB-\1740 higher_14\JJR\1740 oxyradical_15\JJ\1740 stress_16\NN\7083732 leading_17\VBG\1752884 to_18\TO\1740 upregulation_19\NN\1740 of_20\IN\1740 uncoupling_21\VBG\1356038 proteins_22\NNS\14944888 2_23\CD\13741022 and_24\CC\1740 3_25\CD\13741022 ,_26\,\1740 (_27\-LRB-\1740 2_28\LS\13741022 )_29\-RRB-\1740 downregulation_30\NN\1740 of_31\IN\1740 cardiac_32\JJ\1740 peroxisome_33\NN\1740 proliferators_34\NNS\1740 activated_35\VBD\1641914 receptor-alpha_36\NN\1740 ,_37\,\1740 (_38\-LRB-\1740 3_39\CD\13741022 )_40\-RRB-\1740 decreased_41\VBD\169651 plasma_42\NN\5398023 adiponectin_43\NN\1740 levels_44\NNS\4916342 ,_45\,\1740 (_46\-LRB-\1740 4_47\CD\13741022 )_48\-RRB-\1740 decreased_49\VBD\169651 cardiac_50\JJ\1740 fatty-acid_51\JJ\1740 oxidation_52\NN\13447361 (_53\-LRB-\1740 666.9+/-14.0_54\CD\1740 nmol/min/g_55\NN\1740 heart_56\NN\5919034 in_57\IN\13603305 nd_58\NN\14625458 versus_59\CC\1740 400.2+/-11.8_60\CD\1740 nmol/min/g_61\NN\1740 heart_62\NN\5919034 in_63\IN\13603305 <e2>ob</e2>_64\NN\6043075 )_65\-RRB-\1740 ,_66\,\1740 (_67\-LRB-\1740 5_68\CD\13741022 )_69\-RRB-\1740 decreased_70\VBD\169651 mitochondrial_71\JJ\1740 amp-alpha2_72\NN\1740 protein_73\NN\14944888 kinase_74\NN\14732946 ,_75\,\1740 and_76\CC\1740 (_77\-LRB-\1740 6_78\CD\13741022 )_79\-RRB-\1740 86_80\CD\1740 %_81\NN\1740 drop_82\NN\13899200 in_83\IN\13603305 cardiac_84\JJ\1740 <e1>atp</e1>_85\NN\14964590 levels_86\NNS\4916342 accompanied_87\VBN\1835496 by_88\IN\1740 decreased_89\VBN\169651 atp/adp_90\NN\1740 ratio_91\NN\13815152 after_92\IN\1740 doxorubicin_93\NN\2716866 administration_94\NN\1133281 ._95\.\1740
D000255_D009765 NONE mechanistic_0\JJ\1740 studies_1\NNS\635850 revealed_2\VBD\2137132 that_3\IN\1740 <e2>ob</e2>_4\NN\6043075 rats_5\NNS\2329401 are_6\VBP\836236 sensitized_7\VBN\126264 due_8\IN\5174653 to_9\IN\1740 :_10\:\1740 (_11\-LRB-\1740 1_12\LS\13741022 )_13\-RRB-\1740 higher_14\JJR\1740 oxyradical_15\JJ\1740 stress_16\NN\7083732 leading_17\VBG\1752884 to_18\TO\1740 upregulation_19\NN\1740 of_20\IN\1740 uncoupling_21\VBG\1356038 proteins_22\NNS\14944888 2_23\CD\13741022 and_24\CC\1740 3_25\CD\13741022 ,_26\,\1740 (_27\-LRB-\1740 2_28\LS\13741022 )_29\-RRB-\1740 downregulation_30\NN\1740 of_31\IN\1740 cardiac_32\JJ\1740 peroxisome_33\NN\1740 proliferators_34\NNS\1740 activated_35\VBD\1641914 receptor-alpha_36\NN\1740 ,_37\,\1740 (_38\-LRB-\1740 3_39\CD\13741022 )_40\-RRB-\1740 decreased_41\VBD\169651 plasma_42\NN\5398023 adiponectin_43\NN\1740 levels_44\NNS\4916342 ,_45\,\1740 (_46\-LRB-\1740 4_47\CD\13741022 )_48\-RRB-\1740 decreased_49\VBD\169651 cardiac_50\JJ\1740 fatty-acid_51\JJ\1740 oxidation_52\NN\13447361 (_53\-LRB-\1740 666.9+/-14.0_54\CD\1740 nmol/min/g_55\NN\1740 heart_56\NN\5919034 in_57\IN\13603305 nd_58\NN\14625458 versus_59\CC\1740 400.2+/-11.8_60\CD\1740 nmol/min/g_61\NN\1740 heart_62\NN\5919034 in_63\IN\13603305 ob_64\NN\6043075 )_65\-RRB-\1740 ,_66\,\1740 (_67\-LRB-\1740 5_68\CD\13741022 )_69\-RRB-\1740 decreased_70\VBD\169651 mitochondrial_71\JJ\1740 amp-alpha2_72\NN\1740 protein_73\NN\14944888 kinase_74\NN\14732946 ,_75\,\1740 and_76\CC\1740 (_77\-LRB-\1740 6_78\CD\13741022 )_79\-RRB-\1740 86_80\CD\1740 %_81\NN\1740 drop_82\NN\13899200 in_83\IN\13603305 cardiac_84\JJ\1740 atp_85\NN\14964590 levels_86\NNS\4916342 accompanied_87\VBN\1835496 by_88\IN\1740 decreased_89\VBN\169651 <e1>atp/adp</e1>_90\NN\1740 ratio_91\NN\13815152 after_92\IN\1740 doxorubicin_93\NN\2716866 administration_94\NN\1133281 ._95\.\1740
D000255_D009765 NONE mechanistic_0\JJ\1740 studies_1\NNS\635850 revealed_2\VBD\2137132 that_3\IN\1740 ob_4\NN\6043075 rats_5\NNS\2329401 are_6\VBP\836236 sensitized_7\VBN\126264 due_8\IN\5174653 to_9\IN\1740 :_10\:\1740 (_11\-LRB-\1740 1_12\LS\13741022 )_13\-RRB-\1740 higher_14\JJR\1740 oxyradical_15\JJ\1740 stress_16\NN\7083732 leading_17\VBG\1752884 to_18\TO\1740 upregulation_19\NN\1740 of_20\IN\1740 uncoupling_21\VBG\1356038 proteins_22\NNS\14944888 2_23\CD\13741022 and_24\CC\1740 3_25\CD\13741022 ,_26\,\1740 (_27\-LRB-\1740 2_28\LS\13741022 )_29\-RRB-\1740 downregulation_30\NN\1740 of_31\IN\1740 cardiac_32\JJ\1740 peroxisome_33\NN\1740 proliferators_34\NNS\1740 activated_35\VBD\1641914 receptor-alpha_36\NN\1740 ,_37\,\1740 (_38\-LRB-\1740 3_39\CD\13741022 )_40\-RRB-\1740 decreased_41\VBD\169651 plasma_42\NN\5398023 adiponectin_43\NN\1740 levels_44\NNS\4916342 ,_45\,\1740 (_46\-LRB-\1740 4_47\CD\13741022 )_48\-RRB-\1740 decreased_49\VBD\169651 cardiac_50\JJ\1740 fatty-acid_51\JJ\1740 oxidation_52\NN\13447361 (_53\-LRB-\1740 666.9+/-14.0_54\CD\1740 nmol/min/g_55\NN\1740 heart_56\NN\5919034 in_57\IN\13603305 nd_58\NN\14625458 versus_59\CC\1740 400.2+/-11.8_60\CD\1740 nmol/min/g_61\NN\1740 heart_62\NN\5919034 in_63\IN\13603305 <e2>ob</e2>_64\NN\6043075 )_65\-RRB-\1740 ,_66\,\1740 (_67\-LRB-\1740 5_68\CD\13741022 )_69\-RRB-\1740 decreased_70\VBD\169651 mitochondrial_71\JJ\1740 amp-alpha2_72\NN\1740 protein_73\NN\14944888 kinase_74\NN\14732946 ,_75\,\1740 and_76\CC\1740 (_77\-LRB-\1740 6_78\CD\13741022 )_79\-RRB-\1740 86_80\CD\1740 %_81\NN\1740 drop_82\NN\13899200 in_83\IN\13603305 cardiac_84\JJ\1740 atp_85\NN\14964590 levels_86\NNS\4916342 accompanied_87\VBN\1835496 by_88\IN\1740 decreased_89\VBN\169651 <e1>atp/adp</e1>_90\NN\1740 ratio_91\NN\13815152 after_92\IN\1740 doxorubicin_93\NN\2716866 administration_94\NN\1133281 ._95\.\1740
D000255_D009765 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 hfd-induced_3\JJ\1740 <e2>obese</e2>_4\JJ\1740 rats_5\NNS\2329401 are_6\VBP\836236 highly_7\RB\1740 sensitized_8\VBN\126264 to_9\TO\1740 doxorubicin-induced_10\JJ\1740 cardiotoxicity_11\NN\1740 by_12\IN\1740 substantially_13\RB\1740 downregulating_14\VBG\1740 cardiac_15\JJ\1740 mitochondrial_16\JJ\1740 <e1>atp</e1>_17\NN\14964590 generation_18\NN\7942152 ,_19\,\1740 increasing_20\VBG\169651 oxidative_21\JJ\1740 stress_22\NN\7083732 and_23\CC\1740 downregulating_24\VBG\1740 the_25\DT\1740 jak/stat3_26\JJ\1740 pathway_27\NN\5483677 ._28\.\1740
D000244_D009765 NONE mechanistic_0\JJ\1740 studies_1\NNS\635850 revealed_2\VBD\2137132 that_3\IN\1740 <e2>ob</e2>_4\NN\6043075 rats_5\NNS\2329401 are_6\VBP\836236 sensitized_7\VBN\126264 due_8\IN\5174653 to_9\IN\1740 :_10\:\1740 (_11\-LRB-\1740 1_12\LS\13741022 )_13\-RRB-\1740 higher_14\JJR\1740 oxyradical_15\JJ\1740 stress_16\NN\7083732 leading_17\VBG\1752884 to_18\TO\1740 upregulation_19\NN\1740 of_20\IN\1740 uncoupling_21\VBG\1356038 proteins_22\NNS\14944888 2_23\CD\13741022 and_24\CC\1740 3_25\CD\13741022 ,_26\,\1740 (_27\-LRB-\1740 2_28\LS\13741022 )_29\-RRB-\1740 downregulation_30\NN\1740 of_31\IN\1740 cardiac_32\JJ\1740 peroxisome_33\NN\1740 proliferators_34\NNS\1740 activated_35\VBD\1641914 receptor-alpha_36\NN\1740 ,_37\,\1740 (_38\-LRB-\1740 3_39\CD\13741022 )_40\-RRB-\1740 decreased_41\VBD\169651 plasma_42\NN\5398023 adiponectin_43\NN\1740 levels_44\NNS\4916342 ,_45\,\1740 (_46\-LRB-\1740 4_47\CD\13741022 )_48\-RRB-\1740 decreased_49\VBD\169651 cardiac_50\JJ\1740 fatty-acid_51\JJ\1740 oxidation_52\NN\13447361 (_53\-LRB-\1740 666.9+/-14.0_54\CD\1740 nmol/min/g_55\NN\1740 heart_56\NN\5919034 in_57\IN\13603305 nd_58\NN\14625458 versus_59\CC\1740 400.2+/-11.8_60\CD\1740 nmol/min/g_61\NN\1740 heart_62\NN\5919034 in_63\IN\13603305 ob_64\NN\6043075 )_65\-RRB-\1740 ,_66\,\1740 (_67\-LRB-\1740 5_68\CD\13741022 )_69\-RRB-\1740 decreased_70\VBD\169651 mitochondrial_71\JJ\1740 amp-alpha2_72\NN\1740 protein_73\NN\14944888 kinase_74\NN\14732946 ,_75\,\1740 and_76\CC\1740 (_77\-LRB-\1740 6_78\CD\13741022 )_79\-RRB-\1740 86_80\CD\1740 %_81\NN\1740 drop_82\NN\13899200 in_83\IN\13603305 cardiac_84\JJ\1740 atp_85\NN\14964590 levels_86\NNS\4916342 accompanied_87\VBN\1835496 by_88\IN\1740 decreased_89\VBN\169651 <e1>atp/adp</e1>_90\NN\1740 ratio_91\NN\13815152 after_92\IN\1740 doxorubicin_93\NN\2716866 administration_94\NN\1133281 ._95\.\1740
D000244_D009765 NONE mechanistic_0\JJ\1740 studies_1\NNS\635850 revealed_2\VBD\2137132 that_3\IN\1740 ob_4\NN\6043075 rats_5\NNS\2329401 are_6\VBP\836236 sensitized_7\VBN\126264 due_8\IN\5174653 to_9\IN\1740 :_10\:\1740 (_11\-LRB-\1740 1_12\LS\13741022 )_13\-RRB-\1740 higher_14\JJR\1740 oxyradical_15\JJ\1740 stress_16\NN\7083732 leading_17\VBG\1752884 to_18\TO\1740 upregulation_19\NN\1740 of_20\IN\1740 uncoupling_21\VBG\1356038 proteins_22\NNS\14944888 2_23\CD\13741022 and_24\CC\1740 3_25\CD\13741022 ,_26\,\1740 (_27\-LRB-\1740 2_28\LS\13741022 )_29\-RRB-\1740 downregulation_30\NN\1740 of_31\IN\1740 cardiac_32\JJ\1740 peroxisome_33\NN\1740 proliferators_34\NNS\1740 activated_35\VBD\1641914 receptor-alpha_36\NN\1740 ,_37\,\1740 (_38\-LRB-\1740 3_39\CD\13741022 )_40\-RRB-\1740 decreased_41\VBD\169651 plasma_42\NN\5398023 adiponectin_43\NN\1740 levels_44\NNS\4916342 ,_45\,\1740 (_46\-LRB-\1740 4_47\CD\13741022 )_48\-RRB-\1740 decreased_49\VBD\169651 cardiac_50\JJ\1740 fatty-acid_51\JJ\1740 oxidation_52\NN\13447361 (_53\-LRB-\1740 666.9+/-14.0_54\CD\1740 nmol/min/g_55\NN\1740 heart_56\NN\5919034 in_57\IN\13603305 nd_58\NN\14625458 versus_59\CC\1740 400.2+/-11.8_60\CD\1740 nmol/min/g_61\NN\1740 heart_62\NN\5919034 in_63\IN\13603305 <e2>ob</e2>_64\NN\6043075 )_65\-RRB-\1740 ,_66\,\1740 (_67\-LRB-\1740 5_68\CD\13741022 )_69\-RRB-\1740 decreased_70\VBD\169651 mitochondrial_71\JJ\1740 amp-alpha2_72\NN\1740 protein_73\NN\14944888 kinase_74\NN\14732946 ,_75\,\1740 and_76\CC\1740 (_77\-LRB-\1740 6_78\CD\13741022 )_79\-RRB-\1740 86_80\CD\1740 %_81\NN\1740 drop_82\NN\13899200 in_83\IN\13603305 cardiac_84\JJ\1740 atp_85\NN\14964590 levels_86\NNS\4916342 accompanied_87\VBN\1835496 by_88\IN\1740 decreased_89\VBN\169651 <e1>atp/adp</e1>_90\NN\1740 ratio_91\NN\13815152 after_92\IN\1740 doxorubicin_93\NN\2716866 administration_94\NN\1133281 ._95\.\1740
D000255_D066126 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 hfd-induced_3\JJ\1740 obese_4\JJ\1740 rats_5\NNS\2329401 are_6\VBP\836236 highly_7\RB\1740 sensitized_8\VBN\126264 to_9\TO\1740 doxorubicin-induced_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 by_12\IN\1740 substantially_13\RB\1740 downregulating_14\VBG\1740 cardiac_15\JJ\1740 mitochondrial_16\JJ\1740 <e1>atp</e1>_17\NN\14964590 generation_18\NN\7942152 ,_19\,\1740 increasing_20\VBG\169651 oxidative_21\JJ\1740 stress_22\NN\7083732 and_23\CC\1740 downregulating_24\VBG\1740 the_25\DT\1740 jak/stat3_26\JJ\1740 pathway_27\NN\5483677 ._28\.\1740
8424298
D007741_D007022 CID effects_0\NNS\13245626 of_1\IN\1740 deliberate_2\JJ\1740 <e2>hypotension</e2>_3\NN\14057371 induced_4\VBN\1627355 by_5\IN\1740 <e1>labetalol</e1>_6\NNS\2721160 with_7\IN\1740 isoflurane_8\NN\3570838 on_9\IN\1740 neuropsychological_10\JJ\1740 function_11\NN\13783581 ._12\.\1740
D007741_D007022 CID twenty-four_0\CD\13745420 patients_1\NNS\9898892 were_2\VBD\836236 anaesthetized_3\VBN\84738 for_4\IN\1740 middle-ear_5\JJ\1740 surgery_6\NN\6045562 with_7\IN\1740 deliberate_8\JJ\1740 <e2>hypotension</e2>_9\NN\14057371 induced_10\VBN\1627355 by_11\IN\1740 <e1>labetalol</e1>_12\NNS\2721160 with_13\IN\1740 isoflurane_14\NN\3570838 (_15\-LRB-\1740 hypotensive_16\JJ\1740 group_17\NN\2137 )_18\-RRB-\1740 ._19\.\1740
D007741_D007022 CID twenty-four_0\CD\13745420 patients_1\NNS\9898892 were_2\VBD\836236 anaesthetized_3\VBN\84738 for_4\IN\1740 middle-ear_5\JJ\1740 surgery_6\NN\6045562 with_7\IN\1740 deliberate_8\JJ\1740 hypotension_9\NN\14057371 induced_10\VBN\1627355 by_11\IN\1740 <e1>labetalol</e1>_12\NNS\2721160 with_13\IN\1740 isoflurane_14\NN\3570838 (_15\-LRB-\1740 <e2>hypotensive</e2>_16\JJ\1740 group_17\NN\2137 )_18\-RRB-\1740 ._19\.\1740
D007741_D007022 CID the_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e2>hypotension</e2>_4\NN\14057371 induced_5\VBN\1627355 by_6\IN\1740 <e1>labetalol</e1>_7\NNS\2721160 with_8\IN\1740 isoflurane_9\NN\3570838 has_10\VBZ\2108377 no_11\DT\7204911 significant_12\JJ\1740 harmful_13\JJ\1740 effects_14\NNS\13245626 on_15\IN\1740 mental_16\JJ\1740 functions_17\NNS\13783581 compared_18\VBN\644583 to_19\TO\1740 normotensive_20\JJ\1740 anaesthesia_21\NN\14034177 ._22\.\1740
D007530_D007022 CID effects_0\NNS\13245626 of_1\IN\1740 deliberate_2\JJ\1740 <e2>hypotension</e2>_3\NN\14057371 induced_4\VBN\1627355 by_5\IN\1740 labetalol_6\NNS\2721160 with_7\IN\1740 <e1>isoflurane</e1>_8\NN\3570838 on_9\IN\1740 neuropsychological_10\JJ\1740 function_11\NN\13783581 ._12\.\1740
D007530_D007022 CID twenty-four_0\CD\13745420 patients_1\NNS\9898892 were_2\VBD\836236 anaesthetized_3\VBN\84738 for_4\IN\1740 middle-ear_5\JJ\1740 surgery_6\NN\6045562 with_7\IN\1740 deliberate_8\JJ\1740 <e2>hypotension</e2>_9\NN\14057371 induced_10\VBN\1627355 by_11\IN\1740 labetalol_12\NNS\2721160 with_13\IN\1740 <e1>isoflurane</e1>_14\NN\3570838 (_15\-LRB-\1740 hypotensive_16\JJ\1740 group_17\NN\2137 )_18\-RRB-\1740 ._19\.\1740
D007530_D007022 CID twenty-four_0\CD\13745420 patients_1\NNS\9898892 were_2\VBD\836236 anaesthetized_3\VBN\84738 for_4\IN\1740 middle-ear_5\JJ\1740 surgery_6\NN\6045562 with_7\IN\1740 deliberate_8\JJ\1740 hypotension_9\NN\14057371 induced_10\VBN\1627355 by_11\IN\1740 labetalol_12\NNS\2721160 with_13\IN\1740 <e1>isoflurane</e1>_14\NN\3570838 (_15\-LRB-\1740 <e2>hypotensive</e2>_16\JJ\1740 group_17\NN\2137 )_18\-RRB-\1740 ._19\.\1740
D007530_D007022 CID the_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e2>hypotension</e2>_4\NN\14057371 induced_5\VBN\1627355 by_6\IN\1740 labetalol_7\NNS\2721160 with_8\IN\1740 <e1>isoflurane</e1>_9\NN\3570838 has_10\VBZ\2108377 no_11\DT\7204911 significant_12\JJ\1740 harmful_13\JJ\1740 effects_14\NNS\13245626 on_15\IN\1740 mental_16\JJ\1740 functions_17\NNS\13783581 compared_18\VBN\644583 to_19\TO\1740 normotensive_20\JJ\1740 anaesthesia_21\NN\14034177 ._22\.\1740
9758264
D005492_D008180 CID epileptogenic_0\JJ\1740 activity_1\NN\30358 of_2\IN\1740 <e1>folic_3\JJ\1740 acid</e1>_4\NN\14818238 after_5\IN\1740 drug_6\NN\14778436 induces_7\VBZ\1627355 <e2>sle</e2>_8\NN\14229912 (_9\-LRB-\1740 folic_10\JJ\1740 acid_11\NN\14818238 and_12\CC\1740 epilepsy_13\NN\14085708 )_14\-RRB-\1740
D005492_D008180 CID epileptogenic_0\JJ\1740 activity_1\NN\30358 of_2\IN\1740 folic_3\JJ\1740 acid_4\NN\14818238 after_5\IN\1740 drug_6\NN\14778436 induces_7\VBZ\1627355 <e2>sle</e2>_8\NN\14229912 (_9\-LRB-\1740 <e1>folic_10\JJ\1740 acid</e1>_11\NN\14818238 and_12\CC\1740 epilepsy_13\NN\14085708 )_14\-RRB-\1740
D005492_D008180 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 epileptic_3\JJ\1740 pregnant_4\JJ\1740 patient_5\NN\9898892 's_6\POS\1740 autoimmune_7\JJ\1740 disease_8\NN\14061805 (_9\-LRB-\1740 probably_10\RB\1740 drug-induced_11\JJ\1740 <e2>lupus</e2>_12\NN\14219661 )_13\-RRB-\1740 could_14\MD\1740 damage_15\VB\126264 the_16\DT\1740 blood-brain_17\JJ\1740 barrier_18\NN\3839993 ,_19\,\1740 therefore_20\RB\1740 the_21\DT\1740 therapeutic_22\JJ\1740 dose_23\NN\3740161 (_24\-LRB-\1740 >_25\CD\1740 or_26\CC\3541091 =_27\JJ\1740 1_28\CD\13741022 mg_29\NN\13717155 )_30\-RRB-\1740 of_31\IN\1740 <e1>folic_32\JJ\1740 acid</e1>_33\NN\14818238 triggered_34\VBD\1641914 a_35\DT\13649268 cluster_36\NN\7959269 of_37\IN\1740 seizures_38\NNS\14081375 ._39\.\1740
D005492_D004827 NONE epileptogenic_0\JJ\1740 activity_1\NN\30358 of_2\IN\1740 <e1>folic_3\JJ\1740 acid</e1>_4\NN\14818238 after_5\IN\1740 drug_6\NN\14778436 induces_7\VBZ\1627355 sle_8\NN\14229912 (_9\-LRB-\1740 folic_10\JJ\1740 acid_11\NN\14818238 and_12\CC\1740 <e2>epilepsy</e2>_13\NN\14085708 )_14\-RRB-\1740
D005492_D004827 NONE epileptogenic_0\JJ\1740 activity_1\NN\30358 of_2\IN\1740 folic_3\JJ\1740 acid_4\NN\14818238 after_5\IN\1740 drug_6\NN\14778436 induces_7\VBZ\1627355 sle_8\NN\14229912 (_9\-LRB-\1740 <e1>folic_10\JJ\1740 acid</e1>_11\NN\14818238 and_12\CC\1740 <e2>epilepsy</e2>_13\NN\14085708 )_14\-RRB-\1740
D005492_D004827 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 study_3\VB\630380 the_4\DT\1740 effect_5\NN\34213 of_6\IN\1740 <e1>folic_7\JJ\1740 acid-containing</e1>_8\JJ\1740 multivitamin_9\NN\7938149 supplementation_10\NN\5108947 in_11\IN\13603305 <e2>epileptic</e2>_12\JJ\1740 women_13\NNS\9605289 before_14\IN\1740 and_15\CC\1740 during_16\IN\1740 pregnancy_17\NN\14034177 in_18\IN\13603305 order_19\NN\7168131 to_20\TO\1740 determine_21\VB\1645601 the_22\DT\1740 rate_23\NN\13815152 of_24\IN\1740 structural_25\JJ\1740 birth_26\NN\15265518 defects_27\NNS\14462666 and_28\CC\1740 epilepsy-related_29\JJ\1740 side_30\NN\8630039 effects_31\NNS\13245626 ._32\.\1740
D005492_D004827 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 study_3\VB\630380 the_4\DT\1740 effect_5\NN\34213 of_6\IN\1740 <e1>folic_7\JJ\1740 acid-containing</e1>_8\JJ\1740 multivitamin_9\NN\7938149 supplementation_10\NN\5108947 in_11\IN\13603305 epileptic_12\JJ\1740 women_13\NNS\9605289 before_14\IN\1740 and_15\CC\1740 during_16\IN\1740 pregnancy_17\NN\14034177 in_18\IN\13603305 order_19\NN\7168131 to_20\TO\1740 determine_21\VB\1645601 the_22\DT\1740 rate_23\NN\13815152 of_24\IN\1740 structural_25\JJ\1740 birth_26\NN\15265518 defects_27\NNS\14462666 and_28\CC\1740 <e2>epilepsy-related</e2>_29\JJ\1740 side_30\NN\8630039 effects_31\NNS\13245626 ._32\.\1740
D005492_D004827 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 60_3\CD\13745420 <e2>epileptic</e2>_4\JJ\1740 women_5\NNS\9605289 with_6\IN\1740 periconceptional_7\JJ\1740 <e1>folic_8\JJ\1740 acid</e1>_9\NN\14818238 (_10\-LRB-\1740 0.8_11\CD\1740 mg)-containing_12\NN\1740 multivitamin_13\NN\7938149 supplementation_14\NN\5108947 ,_15\,\1740 no_16\DT\7204911 one_17\NN\13741022 developed_18\VBD\1753788 epilepsy-related_19\JJ\1740 side_20\NN\8630039 effects_21\NNS\13245626 during_22\IN\1740 the_23\DT\1740 periconception_24\NN\1740 period_25\NN\13575869 ._26\.\1740
D005492_D004827 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 60_3\CD\13745420 epileptic_4\JJ\1740 women_5\NNS\9605289 with_6\IN\1740 periconceptional_7\JJ\1740 <e1>folic_8\JJ\1740 acid</e1>_9\NN\14818238 (_10\-LRB-\1740 0.8_11\CD\1740 mg)-containing_12\NN\1740 multivitamin_13\NN\7938149 supplementation_14\NN\5108947 ,_15\,\1740 no_16\DT\7204911 one_17\NN\13741022 developed_18\VBD\1753788 <e2>epilepsy-related</e2>_19\JJ\1740 side_20\NN\8630039 effects_21\NNS\13245626 during_22\IN\1740 the_23\DT\1740 periconception_24\NN\1740 period_25\NN\13575869 ._26\.\1740
D005492_D004827 NONE this_0\DT\1740 22-year-old_1\JJ\1740 <e2>epileptic</e2>_2\JJ\1740 woman_3\NN\9605289 was_4\VBD\836236 treated_5\VBN\2376958 continuously_6\RB\1740 by_7\IN\1740 carbamazepine_8\NN\1740 and_9\CC\1740 a_10\DT\13649268 <e1>folic_11\JJ\1740 acid</e1>_12\NN\14818238 (_13\-LRB-\1740 1_14\CD\13741022 mg)-containing_15\NN\1740 multivitamin_16\NN\7938149 from_17\IN\1740 the_18\DT\1740 20th_19\JJ\1740 week_20\NN\15113229 of_21\IN\1740 gestation_22\NN\15116532 ._23\.\1740
D005492_D004827 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 <e2>epileptic</e2>_3\JJ\1740 pregnant_4\JJ\1740 patient_5\NN\9898892 's_6\POS\1740 autoimmune_7\JJ\1740 disease_8\NN\14061805 (_9\-LRB-\1740 probably_10\RB\1740 drug-induced_11\JJ\1740 lupus_12\NN\14219661 )_13\-RRB-\1740 could_14\MD\1740 damage_15\VB\126264 the_16\DT\1740 blood-brain_17\JJ\1740 barrier_18\NN\3839993 ,_19\,\1740 therefore_20\RB\1740 the_21\DT\1740 therapeutic_22\JJ\1740 dose_23\NN\3740161 (_24\-LRB-\1740 >_25\CD\1740 or_26\CC\3541091 =_27\JJ\1740 1_28\CD\13741022 mg_29\NN\13717155 )_30\-RRB-\1740 of_31\IN\1740 <e1>folic_32\JJ\1740 acid</e1>_33\NN\14818238 triggered_34\VBD\1641914 a_35\DT\13649268 cluster_36\NN\7959269 of_37\IN\1740 seizures_38\NNS\14081375 ._39\.\1740
D005492_D004827 NONE physiological_0\JJ\1740 dose_1\NN\3740161 (_2\-LRB-\1740 <_3\XX\1740 1_4\CD\13741022 mg_5\NN\13717155 )_6\-RRB-\1740 of_7\IN\1740 <e1>folic_8\JJ\1740 acid</e1>_9\NN\14818238 both_10\CC\1740 in_11\IN\13603305 healthy_12\JJ\1740 and_13\CC\1740 60_14\CD\13745420 <e2>epileptic</e2>_15\JJ\1740 women_16\NNS\9605289 ,_17\,\1740 all_18\DT\1740 without_19\IN\1740 any_20\DT\1740 autoimmune_21\JJ\1740 disease_22\NN\14061805 ,_23\,\1740 did_24\VBD\1640855 not_25\RB\1740 increase_26\VB\169651 the_27\DT\1740 risk_28\NN\14541044 for_29\IN\1740 epileptic_30\JJ\1740 seizures_31\NNS\14081375 ._32\.\1740
D005492_D004827 NONE physiological_0\JJ\1740 dose_1\NN\3740161 (_2\-LRB-\1740 <_3\XX\1740 1_4\CD\13741022 mg_5\NN\13717155 )_6\-RRB-\1740 of_7\IN\1740 <e1>folic_8\JJ\1740 acid</e1>_9\NN\14818238 both_10\CC\1740 in_11\IN\13603305 healthy_12\JJ\1740 and_13\CC\1740 60_14\CD\13745420 epileptic_15\JJ\1740 women_16\NNS\9605289 ,_17\,\1740 all_18\DT\1740 without_19\IN\1740 any_20\DT\1740 autoimmune_21\JJ\1740 disease_22\NN\14061805 ,_23\,\1740 did_24\VBD\1640855 not_25\RB\1740 increase_26\VB\169651 the_27\DT\1740 risk_28\NN\14541044 for_29\IN\1740 <e2>epileptic_30\JJ\1740 seizures</e2>_31\NNS\14081375 ._32\.\1740
D005492_D000014 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 study_3\VB\630380 the_4\DT\1740 effect_5\NN\34213 of_6\IN\1740 <e1>folic_7\JJ\1740 acid-containing</e1>_8\JJ\1740 multivitamin_9\NN\7938149 supplementation_10\NN\5108947 in_11\IN\13603305 epileptic_12\JJ\1740 women_13\NNS\9605289 before_14\IN\1740 and_15\CC\1740 during_16\IN\1740 pregnancy_17\NN\14034177 in_18\IN\13603305 order_19\NN\7168131 to_20\TO\1740 determine_21\VB\1645601 the_22\DT\1740 rate_23\NN\13815152 of_24\IN\1740 structural_25\JJ\1740 <e2>birth_26\NN\15265518 defects</e2>_27\NNS\14462666 and_28\CC\1740 epilepsy-related_29\JJ\1740 side_30\NN\8630039 effects_31\NNS\13245626 ._32\.\1740
D002220_D004827 NONE this_0\DT\1740 22-year-old_1\JJ\1740 <e2>epileptic</e2>_2\JJ\1740 woman_3\NN\9605289 was_4\VBD\836236 treated_5\VBN\2376958 continuously_6\RB\1740 by_7\IN\1740 <e1>carbamazepine</e1>_8\NN\1740 and_9\CC\1740 a_10\DT\13649268 folic_11\JJ\1740 acid_12\NN\14818238 (_13\-LRB-\1740 1_14\CD\13741022 mg)-containing_15\NN\1740 multivitamin_16\NN\7938149 from_17\IN\1740 the_18\DT\1740 20th_19\JJ\1740 week_20\NN\15113229 of_21\IN\1740 gestation_22\NN\15116532 ._23\.\1740
D005492_D001327 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 epileptic_3\JJ\1740 pregnant_4\JJ\1740 patient_5\NN\9898892 's_6\POS\1740 <e2>autoimmune_7\JJ\1740 disease</e2>_8\NN\14061805 (_9\-LRB-\1740 probably_10\RB\1740 drug-induced_11\JJ\1740 lupus_12\NN\14219661 )_13\-RRB-\1740 could_14\MD\1740 damage_15\VB\126264 the_16\DT\1740 blood-brain_17\JJ\1740 barrier_18\NN\3839993 ,_19\,\1740 therefore_20\RB\1740 the_21\DT\1740 therapeutic_22\JJ\1740 dose_23\NN\3740161 (_24\-LRB-\1740 >_25\CD\1740 or_26\CC\3541091 =_27\JJ\1740 1_28\CD\13741022 mg_29\NN\13717155 )_30\-RRB-\1740 of_31\IN\1740 <e1>folic_32\JJ\1740 acid</e1>_33\NN\14818238 triggered_34\VBD\1641914 a_35\DT\13649268 cluster_36\NN\7959269 of_37\IN\1740 seizures_38\NNS\14081375 ._39\.\1740
D005492_D001327 NONE physiological_0\JJ\1740 dose_1\NN\3740161 (_2\-LRB-\1740 <_3\XX\1740 1_4\CD\13741022 mg_5\NN\13717155 )_6\-RRB-\1740 of_7\IN\1740 <e1>folic_8\JJ\1740 acid</e1>_9\NN\14818238 both_10\CC\1740 in_11\IN\13603305 healthy_12\JJ\1740 and_13\CC\1740 60_14\CD\13745420 epileptic_15\JJ\1740 women_16\NNS\9605289 ,_17\,\1740 all_18\DT\1740 without_19\IN\1740 any_20\DT\1740 <e2>autoimmune_21\JJ\1740 disease</e2>_22\NN\14061805 ,_23\,\1740 did_24\VBD\1640855 not_25\RB\1740 increase_26\VB\169651 the_27\DT\1740 risk_28\NN\14541044 for_29\IN\1740 epileptic_30\JJ\1740 seizures_31\NNS\14081375 ._32\.\1740
D005492_D012640 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 epileptic_3\JJ\1740 pregnant_4\JJ\1740 patient_5\NN\9898892 's_6\POS\1740 autoimmune_7\JJ\1740 disease_8\NN\14061805 (_9\-LRB-\1740 probably_10\RB\1740 drug-induced_11\JJ\1740 lupus_12\NN\14219661 )_13\-RRB-\1740 could_14\MD\1740 damage_15\VB\126264 the_16\DT\1740 blood-brain_17\JJ\1740 barrier_18\NN\3839993 ,_19\,\1740 therefore_20\RB\1740 the_21\DT\1740 therapeutic_22\JJ\1740 dose_23\NN\3740161 (_24\-LRB-\1740 >_25\CD\1740 or_26\CC\3541091 =_27\JJ\1740 1_28\CD\13741022 mg_29\NN\13717155 )_30\-RRB-\1740 of_31\IN\1740 <e1>folic_32\JJ\1740 acid</e1>_33\NN\14818238 triggered_34\VBD\1641914 a_35\DT\13649268 cluster_36\NN\7959269 of_37\IN\1740 <e2>seizures</e2>_38\NNS\14081375 ._39\.\1740
9875685
D014031_D064420 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 effect_5\NN\34213 of_6\IN\1740 dosage_7\NN\13576355 regimen_8\NN\5898568 (_9\-LRB-\1740 once-daily_10\JJ\1740 vs._11\CC\1740 twice-daily_12\RB\1740 )_13\-RRB-\1740 of_14\IN\1740 <e1>tobramicyn</e1>_15\NN\1740 on_16\IN\1740 steady-state_17\JJ\1740 serum_18\NN\5397468 concentrations_19\NNS\4916342 and_20\CC\1740 <e2>toxicity</e2>_21\NN\13576101 ._22\.\1740
D003404_D007674 NONE increased_0\VBN\169651 serum_1\NN\5397468 <e1>creatinine</e1>_2\NN\1740 was_3\VBD\836236 observed_4\VBN\2163746 in_5\IN\13603305 73_6\CD\1740 %_7\NN\1740 of_8\IN\1740 patients_9\NNS\9898892 in_10\IN\13603305 od_11\NN\6702458 versus_12\CC\1740 57_13\CD\1740 %_14\NN\1740 of_15\IN\1740 patients_16\NNS\9898892 in_17\IN\13603305 td_18\NN\1740 ,_19\,\1740 without_20\IN\1740 evidence_21\NN\5816287 of_22\IN\1740 <e2>nephrotoxicity</e2>_23\NN\1740 ._24\.\1740
20331935
D018967_D006966 CID objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 the_5\DT\1740 present_6\JJ\1740 study_7\NN\635850 was_8\VBD\836236 to_9\TO\1740 investigate_10\VB\644583 the_11\DT\1740 effect_12\NN\34213 of_13\IN\1740 <e1>risperidone-induced</e1>_14\JJ\1740 <e2>hyperprolactinemia</e2>_15\NN\1740 on_16\IN\1740 trabecular_17\JJ\1740 bone_18\NN\5286536 mineral_19\JJ\1740 density_20\NN\4941325 (_21\-LRB-\1740 bmd_22\NN\1740 )_23\-RRB-\1740 in_24\IN\13603305 children_25\NNS\9622049 and_26\CC\1740 adolescents_27\NNS\9622049 ._28\.\1740
D018967_D006966 CID results_0\NNS\34213 :_1\:\1740 <e2>hyperprolactinemia</e2>_2\NNP\1740 was_3\VBD\836236 present_4\JJ\1740 in_5\IN\13603305 49_6\CD\1740 %_7\NN\1740 of_8\IN\1740 83_9\CD\1740 boys_10\NNS\9624168 (_11\-LRB-\1740 n_12\NN\14622893 =_13\JJ\1740 41_14\CD\1740 )_15\-RRB-\1740 treated_16\VBN\2376958 with_17\IN\1740 <e1>risperidone</e1>_18\NN\1740 for_19\IN\1740 a_20\DT\13649268 mean_21\NN\6021761 of_22\IN\1740 2.9_23\CD\1740 years_24\NNS\15144371 ._25\.\1740
D018967_D006966 CID of_0\IN\1740 13_1\CD\13745420 documented_2\VBN\1000214 fractures_3\NNS\14285662 ,_4\,\1740 3_5\CD\13741022 occurred_6\VBD\2623529 after_7\IN\1740 <e1>risperidone</e1>_8\NN\1740 and_9\CC\1740 ssris_10\NN\2718811 were_11\VBD\836236 started_12\VBN\2009433 ,_13\,\1740 and_14\CC\1740 none_15\NN\15228378 occurred_16\VBD\2623529 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 <e2>hyperprolactinemia</e2>_20\NN\1740 ._21\.\1740
D018967_D006966 CID conclusions_0\NNS\5837957 :_1\:\1740 this_2\DT\1740 is_3\VBZ\836236 the_4\DT\1740 first_5\JJ\1740 study_6\NN\635850 to_7\TO\1740 link_8\VB\628491 <e1>risperidone-induced</e1>_9\JJ\1740 <e2>hyperprolactinemia</e2>_10\NN\1740 and_11\CC\1740 ssri_12\NN\2718811 treatment_13\NN\654885 to_14\TO\1740 lower_15\JJR\1740 bmd_16\NN\1740 in_17\IN\13603305 children_18\NNS\9622049 and_19\CC\1740 adolescents_20\NNS\9622049 ._21\.\1740
D013739_D006966 NONE serum_0\NN\5397468 <e1>testosterone</e1>_1\NN\14747587 concentration_2\NN\4916342 increased_3\VBN\169651 with_4\IN\1740 pubertal_5\JJ\1740 status_6\NN\24720 but_7\CC\1740 was_8\VBD\836236 not_9\RB\1740 affected_10\VBN\126264 by_11\IN\1740 <e2>hyperprolactinemia</e2>_12\NN\1740 ._13\.\1740
D018967_D050723 NONE of_0\IN\1740 13_1\CD\13745420 documented_2\VBN\1000214 <e2>fractures</e2>_3\NNS\14285662 ,_4\,\1740 3_5\CD\13741022 occurred_6\VBD\2623529 after_7\IN\1740 <e1>risperidone</e1>_8\NN\1740 and_9\CC\1740 ssris_10\NN\2718811 were_11\VBD\836236 started_12\VBN\2009433 ,_13\,\1740 and_14\CC\1740 none_15\NN\15228378 occurred_16\VBD\2623529 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 hyperprolactinemia_20\NN\1740 ._21\.\1740
16225977
C012052_D013981 CID <e1>amisulpride</e1>_0\RB\1740 related_1\JJ\1740 <e2>tic-like_2\JJ\1740 symptoms</e2>_3\NNS\5823932 in_4\IN\13603305 an_5\DT\6697703 adolescent_6\JJ\1740 schizophrenic_7\JJ\1740 ._8\.\1740
C012052_D013981 CID the_0\DT\1740 <e2>tic-like_1\JJ\1740 symptoms</e2>_2\NNS\5823932 resolved_3\VBN\352826 completely_4\RB\1740 after_5\IN\1740 we_6\PRP\1740 reduced_7\VBD\441445 the_8\DT\1740 dose_9\NN\3740161 of_10\IN\1740 <e1>amisulpride</e1>_11\NN\1740 down_12\IN\1896031 to_13\IN\1740 800_14\CD\1740 mg_15\NN\13717155 per_16\IN\1740 day_17\NN\15154774 ._18\.\1740
C012052_D013981 CID together_0\RB\1740 with_1\IN\1740 previously_2\RB\1740 reported_3\VBN\831651 cases_4\NNS\7283608 ,_5\,\1740 our_6\PRP$\1740 patient_7\NN\9898892 suggests_8\VBZ\1010118 that_9\IN\1740 <e2>tic-like_10\JJ\1740 symptoms</e2>_11\NNS\5823932 might_12\MD\5029706 occur_13\VB\2623529 in_14\IN\13603305 certain_15\JJ\1740 vulnerable_16\JJ\1740 individuals_17\NNS\7347 during_18\IN\1740 treatment_19\NN\654885 with_20\IN\1740 atypical_21\JJ\1740 antipsychotics_22\NNS\4470232 such_23\JJ\1740 as_24\IN\14622893 quetiapine_25\NN\1740 ,_26\,\1740 clozapine_27\NN\3713736 ,_28\,\1740 or_29\CC\3541091 <e1>amisulpride</e1>_30\RB\1740 ._31\.\1740
C012052_D012559 NONE <e1>amisulpride</e1>_0\RB\1740 related_1\JJ\1740 tic-like_2\JJ\1740 symptoms_3\NNS\5823932 in_4\IN\13603305 an_5\DT\6697703 adolescent_6\JJ\1740 <e2>schizophrenic</e2>_7\JJ\1740 ._8\.\1740
C012052_D012559 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 15-year-old_3\JJ\1740 girl_4\NN\10787470 <e2>schizophrenic</e2>_5\JJ\1740 who_6\WP\8299493 developed_7\VBD\1753788 frequent_8\JJ\1740 involuntary_9\JJ\1740 eye-blinking_10\JJ\1740 movements_11\NNS\191142 after_12\IN\1740 5_13\CD\13741022 months_14\NNS\15113229 of_15\IN\1740 <e1>amisulpride</e1>_16\JJ\1740 treatment_17\NN\654885 (_18\-LRB-\1740 1000_19\CD\13745420 mg_20\NN\13717155 per_21\IN\1740 day_22\NN\15154774 )_23\-RRB-\1740 ._24\.\1740
D018967_D013981 NONE <e2>tic_0\NN\14361664 disorders</e2>_1\NNS\14034177 can_2\MD\3094503 be_3\VB\836236 effectively_4\RB\1740 treated_5\VBN\2376958 by_6\IN\1740 atypical_7\JJ\1740 antipsychotics_8\NNS\4470232 such_9\JJ\1740 as_10\IN\14622893 <e1>risperidone</e1>_11\NN\1740 ,_12\,\1740 olanzapine_13\NN\1740 and_14\CC\1740 ziprasidone_15\NN\1740 ._16\.\1740
C076029_D013981 NONE <e2>tic_0\NN\14361664 disorders</e2>_1\NNS\14034177 can_2\MD\3094503 be_3\VB\836236 effectively_4\RB\1740 treated_5\VBN\2376958 by_6\IN\1740 atypical_7\JJ\1740 antipsychotics_8\NNS\4470232 such_9\JJ\1740 as_10\IN\14622893 risperidone_11\NN\1740 ,_12\,\1740 <e1>olanzapine</e1>_13\NN\1740 and_14\CC\1740 ziprasidone_15\NN\1740 ._16\.\1740
C092292_D013981 NONE <e2>tic_0\NN\14361664 disorders</e2>_1\NNS\14034177 can_2\MD\3094503 be_3\VB\836236 effectively_4\RB\1740 treated_5\VBN\2376958 by_6\IN\1740 atypical_7\JJ\1740 antipsychotics_8\NNS\4470232 such_9\JJ\1740 as_10\IN\14622893 risperidone_11\NN\1740 ,_12\,\1740 olanzapine_13\NN\1740 and_14\CC\1740 <e1>ziprasidone</e1>_15\NN\1740 ._16\.\1740
C069541_D013981 NONE however_0\RB\1740 ,_1\,\1740 there_2\EX\27167 are_3\VBP\836236 two_4\CD\13741022 case_5\NN\7283608 reports_6\NNS\6470073 that_7\WDT\1740 show_8\VBP\2137132 <e2>tic-like_9\JJ\1740 symptoms</e2>_10\NNS\5823932 ,_11\,\1740 including_12\VBG\690614 motor_13\NN\3699975 and_14\CC\1740 phonic_15\JJ\1740 variants_16\NNS\7366289 ,_17\,\1740 occurring_18\VBG\2623529 during_19\IN\1740 treatment_20\NN\654885 with_21\IN\1740 <e1>quetiapine</e1>_22\NN\1740 or_23\CC\3541091 clozapine_24\NN\3713736 ._25\.\1740
C069541_D013981 NONE together_0\RB\1740 with_1\IN\1740 previously_2\RB\1740 reported_3\VBN\831651 cases_4\NNS\7283608 ,_5\,\1740 our_6\PRP$\1740 patient_7\NN\9898892 suggests_8\VBZ\1010118 that_9\IN\1740 <e2>tic-like_10\JJ\1740 symptoms</e2>_11\NNS\5823932 might_12\MD\5029706 occur_13\VB\2623529 in_14\IN\13603305 certain_15\JJ\1740 vulnerable_16\JJ\1740 individuals_17\NNS\7347 during_18\IN\1740 treatment_19\NN\654885 with_20\IN\1740 atypical_21\JJ\1740 antipsychotics_22\NNS\4470232 such_23\JJ\1740 as_24\IN\14622893 <e1>quetiapine</e1>_25\NN\1740 ,_26\,\1740 clozapine_27\NN\3713736 ,_28\,\1740 or_29\CC\3541091 amisulpride_30\RB\1740 ._31\.\1740
D003024_D013981 NONE however_0\RB\1740 ,_1\,\1740 there_2\EX\27167 are_3\VBP\836236 two_4\CD\13741022 case_5\NN\7283608 reports_6\NNS\6470073 that_7\WDT\1740 show_8\VBP\2137132 <e2>tic-like_9\JJ\1740 symptoms</e2>_10\NNS\5823932 ,_11\,\1740 including_12\VBG\690614 motor_13\NN\3699975 and_14\CC\1740 phonic_15\JJ\1740 variants_16\NNS\7366289 ,_17\,\1740 occurring_18\VBG\2623529 during_19\IN\1740 treatment_20\NN\654885 with_21\IN\1740 quetiapine_22\NN\1740 or_23\CC\3541091 <e1>clozapine</e1>_24\NN\3713736 ._25\.\1740
D003024_D013981 NONE together_0\RB\1740 with_1\IN\1740 previously_2\RB\1740 reported_3\VBN\831651 cases_4\NNS\7283608 ,_5\,\1740 our_6\PRP$\1740 patient_7\NN\9898892 suggests_8\VBZ\1010118 that_9\IN\1740 <e2>tic-like_10\JJ\1740 symptoms</e2>_11\NNS\5823932 might_12\MD\5029706 occur_13\VB\2623529 in_14\IN\13603305 certain_15\JJ\1740 vulnerable_16\JJ\1740 individuals_17\NNS\7347 during_18\IN\1740 treatment_19\NN\654885 with_20\IN\1740 atypical_21\JJ\1740 antipsychotics_22\NNS\4470232 such_23\JJ\1740 as_24\IN\14622893 quetiapine_25\NN\1740 ,_26\,\1740 <e1>clozapine</e1>_27\NN\3713736 ,_28\,\1740 or_29\CC\3541091 amisulpride_30\RB\1740 ._31\.\1740
C012052_D020820 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 15-year-old_3\JJ\1740 girl_4\NN\10787470 schizophrenic_5\JJ\1740 who_6\WP\8299493 developed_7\VBD\1753788 frequent_8\JJ\1740 <e2>involuntary_9\JJ\1740 eye-blinking_10\JJ\1740 movements</e2>_11\NNS\191142 after_12\IN\1740 5_13\CD\13741022 months_14\NNS\15113229 of_15\IN\1740 <e1>amisulpride</e1>_16\JJ\1740 treatment_17\NN\654885 (_18\-LRB-\1740 1000_19\CD\13745420 mg_20\NN\13717155 per_21\IN\1740 day_22\NN\15154774 )_23\-RRB-\1740 ._24\.\1740
6540303
D000588_D002389 NONE effects_0\NNS\13245626 of_1\IN\1740 <e1>amine</e1>_2\JJ\1740 pretreatment_3\NN\1740 on_4\IN\1740 ketamine_5\NN\3054098 <e2>catatonia</e2>_6\NN\14544672 in_7\IN\13603305 pinealectomized_8\JJ\1740 or_9\CC\3541091 hypophysectomized_10\VBN\173338 animals_11\NNS\4475 ._12\.\1740
D007649_D002389 CID effects_0\NNS\13245626 of_1\IN\1740 amine_2\JJ\1740 pretreatment_3\NN\1740 on_4\IN\1740 <e1>ketamine</e1>_5\NN\3054098 <e2>catatonia</e2>_6\NN\14544672 in_7\IN\13603305 pinealectomized_8\JJ\1740 or_9\CC\3541091 hypophysectomized_10\VBN\173338 animals_11\NNS\4475 ._12\.\1740
D007649_D002389 CID the_0\DT\1740 present_1\JJ\1740 studies_2\NNS\635850 were_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 clarify_6\VB\939277 the_7\DT\1740 role_8\NN\719494 of_9\IN\1740 catecholamines_10\NNS\5407119 and_11\CC\1740 pineal_12\VB\1740 idolamines_13\NNS\1740 on_14\IN\1740 <e1>ketamine-induced</e1>_15\JJ\1740 <e2>catatonia</e2>_16\NN\14544672 in_17\IN\13603305 the_18\DT\1740 intact_19\JJ\1740 ,_20\,\1740 pinealectomized_21\JJ\1740 or_22\CC\3541091 hypophysectomized_23\JJ\1740 chick_24\NN\1791625 and_25\CC\1740 rat_26\NN\2329401 ._27\.\1740
D007649_D002389 CID in_0\IN\13603305 the_1\DT\1740 pinealectomized_2\JJ\1740 chick_3\NN\1791625 ,_4\,\1740 pretreatment_5\NN\1740 with_6\IN\1740 dopamine_7\NN\14807737 increased_8\VBD\169651 the_9\DT\1740 duration_10\NN\15113229 of_11\IN\1740 <e2>catatonia</e2>_12\NN\14544672 (_13\-LRB-\1740 doc_14\NN\10305802 )_15\-RRB-\1740 after_16\IN\1740 <e1>ketamine</e1>_17\NN\3054098 ,_18\,\1740 but_19\CC\1740 pretreatment_20\NN\1740 with_21\IN\1740 norepinephrine_22\NN\14807929 did_23\VBD\1640855 not_24\RB\1740 ._25\.\1740
D007649_D002389 CID furthermore_0\RB\1740 ,_1\,\1740 dopamine_2\NN\14807737 appeared_3\VBD\2604760 to_4\TO\1740 act_5\VB\1619354 on_6\IN\1740 systems_7\NNS\3575240 more_8\RBR\1740 closely_9\RB\1740 involved_10\VBN\2676054 with_11\IN\1740 the_12\DT\1740 induction_13\NN\7450842 of_14\IN\1740 <e1>ketamine</e1>_15\NN\3054098 <e2>catatonia</e2>_16\NN\14544672 rather_17\RB\1740 than_18\IN\1740 directly_19\RB\1740 on_20\IN\1740 the_21\DT\1740 pituitary_22\NN\5329735 ._23\.\1740
D002395_D002389 NONE the_0\DT\1740 present_1\JJ\1740 studies_2\NNS\635850 were_3\VBD\836236 designed_4\VBN\1631534 to_5\TO\1740 clarify_6\VB\939277 the_7\DT\1740 role_8\NN\719494 of_9\IN\1740 <e1>catecholamines</e1>_10\NNS\5407119 and_11\CC\1740 pineal_12\VB\1740 idolamines_13\NNS\1740 on_14\IN\1740 ketamine-induced_15\JJ\1740 <e2>catatonia</e2>_16\NN\14544672 in_17\IN\13603305 the_18\DT\1740 intact_19\JJ\1740 ,_20\,\1740 pinealectomized_21\JJ\1740 or_22\CC\3541091 hypophysectomized_23\JJ\1740 chick_24\NN\1791625 and_25\CC\1740 rat_26\NN\2329401 ._27\.\1740
D004298_D002389 CID in_0\IN\13603305 the_1\DT\1740 pinealectomized_2\JJ\1740 chick_3\NN\1791625 ,_4\,\1740 pretreatment_5\NN\1740 with_6\IN\1740 <e1>dopamine</e1>_7\NN\14807737 increased_8\VBD\169651 the_9\DT\1740 duration_10\NN\15113229 of_11\IN\1740 <e2>catatonia</e2>_12\NN\14544672 (_13\-LRB-\1740 doc_14\NN\10305802 )_15\-RRB-\1740 after_16\IN\1740 ketamine_17\NN\3054098 ,_18\,\1740 but_19\CC\1740 pretreatment_20\NN\1740 with_21\IN\1740 norepinephrine_22\NN\14807929 did_23\VBD\1640855 not_24\RB\1740 ._25\.\1740
D004298_D002389 CID furthermore_0\RB\1740 ,_1\,\1740 <e1>dopamine</e1>_2\NN\14807737 appeared_3\VBD\2604760 to_4\TO\1740 act_5\VB\1619354 on_6\IN\1740 systems_7\NNS\3575240 more_8\RBR\1740 closely_9\RB\1740 involved_10\VBN\2676054 with_11\IN\1740 the_12\DT\1740 induction_13\NN\7450842 of_14\IN\1740 ketamine_15\NN\3054098 <e2>catatonia</e2>_16\NN\14544672 rather_17\RB\1740 than_18\IN\1740 directly_19\RB\1740 on_20\IN\1740 the_21\DT\1740 pituitary_22\NN\5329735 ._23\.\1740
D009638_D002389 NONE in_0\IN\13603305 the_1\DT\1740 pinealectomized_2\JJ\1740 chick_3\NN\1791625 ,_4\,\1740 pretreatment_5\NN\1740 with_6\IN\1740 dopamine_7\NN\14807737 increased_8\VBD\169651 the_9\DT\1740 duration_10\NN\15113229 of_11\IN\1740 <e2>catatonia</e2>_12\NN\14544672 (_13\-LRB-\1740 doc_14\NN\10305802 )_15\-RRB-\1740 after_16\IN\1740 ketamine_17\NN\3054098 ,_18\,\1740 but_19\CC\1740 pretreatment_20\NN\1740 with_21\IN\1740 <e1>norepinephrine</e1>_22\NN\14807929 did_23\VBD\1640855 not_24\RB\1740 ._25\.\1740
6292680
D004317_D009202 CID <e1>doxorubicin</e1>_0\NN\2716866 <e2>cardiomyopathy</e2>_1\JJ\1740 in_2\IN\13603305 children_3\NNS\9622049 with_4\IN\1740 left-sided_5\JJ\1740 wilms_6\NN\1740 tumor_7\NN\14234074 ._8\.\1740
D004317_D009202 CID two_0\CD\13741022 children_1\NNS\9622049 with_2\IN\1740 wilms_3\JJ\1740 tumor_4\NN\14234074 of_5\IN\1740 the_6\DT\1740 left_7\JJ\1740 kidney_8\NN\5333259 experienced_9\VBD\2108377 severe_10\JJ\1740 anthracycline_11\NN\1740 <e2>cardiomyopathy</e2>_12\NN\14103288 after_13\IN\1740 irradiation_14\NN\13920835 to_15\TO\1740 the_16\DT\1740 tumor_17\NN\14234074 bed_18\NN\2821943 and_19\CC\1740 conventional_20\JJ\1740 dosage_21\NN\13576355 of_22\IN\1740 <e1>doxorubicin</e1>_23\NN\2716866 ._24\.\1740
D004317_D009202 CID the_0\DT\1740 <e2>cardiomyopathy</e2>_1\JJ\1740 is_2\VBZ\836236 attributed_3\VBN\670261 1_4\CD\13741022 )_5\-RRB-\1740 to_6\TO\1740 the_7\DT\1740 fact_8\NN\5816287 that_9\IN\1740 radiation_10\NN\11452218 fields_11\NNS\8673395 for_12\IN\1740 left_13\JJ\1740 wilms_14\NN\1740 tumor_15\NN\14234074 include_16\VBP\690614 the_17\DT\1740 lower_18\JJR\1740 portion_19\NN\31921 of_20\IN\1740 the_21\DT\1740 heart_22\NN\5919034 and_23\CC\1740 2_24\CD\13741022 )_25\-RRB-\1740 to_26\TO\1740 the_27\DT\1740 interaction_28\NN\37396 of_29\IN\1740 <e1>doxorubicin</e1>_30\NN\2716866 and_31\CC\1740 irradiation_32\NN\13920835 on_33\IN\1740 cardiac_34\JJ\1740 muscle_35\NN\5289601 ._36\.\1740
D004317_D009396 NONE <e1>doxorubicin</e1>_0\NN\2716866 cardiomyopathy_1\JJ\1740 in_2\IN\13603305 children_3\NNS\9622049 with_4\IN\1740 left-sided_5\JJ\1740 <e2>wilms_6\NN\1740 tumor</e2>_7\NN\14234074 ._8\.\1740
D004317_D009396 NONE two_0\CD\13741022 children_1\NNS\9622049 with_2\IN\1740 <e2>wilms_3\JJ\1740 tumor</e2>_4\NN\14234074 of_5\IN\1740 the_6\DT\1740 left_7\JJ\1740 kidney_8\NN\5333259 experienced_9\VBD\2108377 severe_10\JJ\1740 anthracycline_11\NN\1740 cardiomyopathy_12\NN\14103288 after_13\IN\1740 irradiation_14\NN\13920835 to_15\TO\1740 the_16\DT\1740 tumor_17\NN\14234074 bed_18\NN\2821943 and_19\CC\1740 conventional_20\JJ\1740 dosage_21\NN\13576355 of_22\IN\1740 <e1>doxorubicin</e1>_23\NN\2716866 ._24\.\1740
D004317_D009396 NONE the_0\DT\1740 cardiomyopathy_1\JJ\1740 is_2\VBZ\836236 attributed_3\VBN\670261 1_4\CD\13741022 )_5\-RRB-\1740 to_6\TO\1740 the_7\DT\1740 fact_8\NN\5816287 that_9\IN\1740 radiation_10\NN\11452218 fields_11\NNS\8673395 for_12\IN\1740 left_13\JJ\1740 <e2>wilms_14\NN\1740 tumor</e2>_15\NN\14234074 include_16\VBP\690614 the_17\DT\1740 lower_18\JJR\1740 portion_19\NN\31921 of_20\IN\1740 the_21\DT\1740 heart_22\NN\5919034 and_23\CC\1740 2_24\CD\13741022 )_25\-RRB-\1740 to_26\TO\1740 the_27\DT\1740 interaction_28\NN\37396 of_29\IN\1740 <e1>doxorubicin</e1>_30\NN\2716866 and_31\CC\1740 irradiation_32\NN\13920835 on_33\IN\1740 cardiac_34\JJ\1740 muscle_35\NN\5289601 ._36\.\1740
D004317_D009396 NONE it_0\PRP\6125041 is_1\VBZ\836236 recommended_2\VBN\875394 that_3\IN\1740 <e1>doxorubicin</e1>_4\NN\2716866 dosage_5\NN\13576355 be_6\VBP\836236 sharply_7\RB\1740 restricted_8\JJ\1740 in_9\IN\13603305 children_10\NNS\9622049 with_11\IN\1740 <e2>wilms_12\NN\1740 tumor</e2>_13\NN\14234074 of_14\IN\1740 the_15\DT\1740 left_16\JJ\1740 kidney_17\NN\5333259 who_18\WP\8299493 receive_19\VBP\2210855 postoperative_20\JJ\1740 irradiation_21\NN\13920835 ._22\.\1740
D018943_D009396 NONE two_0\CD\13741022 children_1\NNS\9622049 with_2\IN\1740 <e2>wilms_3\JJ\1740 tumor</e2>_4\NN\14234074 of_5\IN\1740 the_6\DT\1740 left_7\JJ\1740 kidney_8\NN\5333259 experienced_9\VBD\2108377 severe_10\JJ\1740 <e1>anthracycline</e1>_11\NN\1740 cardiomyopathy_12\NN\14103288 after_13\IN\1740 irradiation_14\NN\13920835 to_15\TO\1740 the_16\DT\1740 tumor_17\NN\14234074 bed_18\NN\2821943 and_19\CC\1740 conventional_20\JJ\1740 dosage_21\NN\13576355 of_22\IN\1740 doxorubicin_23\NN\2716866 ._24\.\1740
D018943_D009202 NONE two_0\CD\13741022 children_1\NNS\9622049 with_2\IN\1740 wilms_3\JJ\1740 tumor_4\NN\14234074 of_5\IN\1740 the_6\DT\1740 left_7\JJ\1740 kidney_8\NN\5333259 experienced_9\VBD\2108377 severe_10\JJ\1740 <e1>anthracycline</e1>_11\NN\1740 <e2>cardiomyopathy</e2>_12\NN\14103288 after_13\IN\1740 irradiation_14\NN\13920835 to_15\TO\1740 the_16\DT\1740 tumor_17\NN\14234074 bed_18\NN\2821943 and_19\CC\1740 conventional_20\JJ\1740 dosage_21\NN\13576355 of_22\IN\1740 doxorubicin_23\NN\2716866 ._24\.\1740
D018943_D009369 NONE two_0\CD\13741022 children_1\NNS\9622049 with_2\IN\1740 wilms_3\JJ\1740 tumor_4\NN\14234074 of_5\IN\1740 the_6\DT\1740 left_7\JJ\1740 kidney_8\NN\5333259 experienced_9\VBD\2108377 severe_10\JJ\1740 <e1>anthracycline</e1>_11\NN\1740 cardiomyopathy_12\NN\14103288 after_13\IN\1740 irradiation_14\NN\13920835 to_15\TO\1740 the_16\DT\1740 <e2>tumor</e2>_17\NN\14234074 bed_18\NN\2821943 and_19\CC\1740 conventional_20\JJ\1740 dosage_21\NN\13576355 of_22\IN\1740 doxorubicin_23\NN\2716866 ._24\.\1740
D004317_D009369 NONE two_0\CD\13741022 children_1\NNS\9622049 with_2\IN\1740 wilms_3\JJ\1740 tumor_4\NN\14234074 of_5\IN\1740 the_6\DT\1740 left_7\JJ\1740 kidney_8\NN\5333259 experienced_9\VBD\2108377 severe_10\JJ\1740 anthracycline_11\NN\1740 cardiomyopathy_12\NN\14103288 after_13\IN\1740 irradiation_14\NN\13920835 to_15\TO\1740 the_16\DT\1740 <e2>tumor</e2>_17\NN\14234074 bed_18\NN\2821943 and_19\CC\1740 conventional_20\JJ\1740 dosage_21\NN\13576355 of_22\IN\1740 <e1>doxorubicin</e1>_23\NN\2716866 ._24\.\1740
2826064
D010096_D007008 NONE beta-2-adrenoceptor-mediated_0\JJ\1740 <e2>hypokalemia</e2>_1\NN\14299637 and_2\CC\1740 its_3\PRP$\6125041 abolishment_4\NN\209943 by_5\IN\1740 <e1>oxprenolol</e1>_6\NN\1740 ._7\.\1740
D010096_D007008 NONE subsequently_0\RB\1740 we_1\PRP\1740 investigated_2\VBD\644583 the_3\DT\1740 efficacy_4\NN\5199286 of_5\IN\1740 <e1>oxprenolol</e1>_6\NN\1740 in_7\IN\13603305 antagonizing_8\VBG\1787955 such_9\JJ\1740 <e2>hypokalemia</e2>_10\NN\14299637 ,_11\,\1740 together_12\RB\1740 with_13\IN\1740 the_14\DT\1740 pharmacokinetic_15\JJ\1740 interaction_16\NN\37396 between_17\IN\1740 both_18\DT\1740 drugs_19\NNS\14778436 ._20\.\1740
D010096_D007008 NONE in_0\IN\13603305 spite_1\NN\7550369 of_2\IN\1740 higher_3\JJR\1740 terbutaline_4\NN\1740 concentrations_5\NNS\4916342 after_6\IN\1740 <e1>oxprenolol</e1>_7\JJ\1740 pretreatment_8\NN\1740 ,_9\,\1740 the_10\DT\1740 <e2>hypokalemia</e2>_11\NN\14299637 was_12\VBD\836236 almost_13\RB\1740 completely_14\RB\1740 antagonized_15\VBN\1787955 by_16\IN\1740 the_17\DT\1740 beta_18\NN\6828818 2-blocking_19\JJ\1740 action_20\NN\30358 ._21\.\1740
D013726_D007008 CID the_0\DT\1740 time_1\NN\7308889 course_2\NN\883297 and_3\CC\1740 concentration-effect_4\JJ\1740 relationship_5\NN\31921 of_6\IN\1740 <e1>terbutaline-induced</e1>_7\JJ\1740 <e2>hypokalemia</e2>_8\NN\14299637 was_9\VBD\836236 studied_10\VBN\630380 ,_11\,\1740 using_12\VBG\1156834 computer-aided_13\JJ\1740 pharmacokinetic-dynamic_14\JJ\1740 modeling_15\NN\4157320 ._16\.\1740
D013726_D007008 CID in_0\IN\13603305 spite_1\NN\7550369 of_2\IN\1740 higher_3\JJR\1740 <e1>terbutaline</e1>_4\NN\1740 concentrations_5\NNS\4916342 after_6\IN\1740 oxprenolol_7\JJ\1740 pretreatment_8\NN\1740 ,_9\,\1740 the_10\DT\1740 <e2>hypokalemia</e2>_11\NN\14299637 was_12\VBD\836236 almost_13\RB\1740 completely_14\RB\1740 antagonized_15\VBN\1787955 by_16\IN\1740 the_17\DT\1740 beta_18\NN\6828818 2-blocking_19\JJ\1740 action_20\NN\30358 ._21\.\1740
9915601
D007538_D001919 CID enhanced_0\VBN\227165 <e2>bradycardia</e2>_1\NN\14110674 induced_2\VBN\1627355 by_3\IN\1740 beta-adrenoceptor_4\JJ\1740 antagonists_5\NNS\7846 in_6\IN\13603305 rats_7\NNS\2329401 pretreated_8\VBN\1740 with_9\IN\1740 <e1>isoniazid</e1>_10\NN\2716205 ._11\.\1740
D007538_D001919 CID high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 <e1>isoniazid</e1>_3\NNS\2716205 increase_4\VBP\169651 hypotension_5\NN\14057371 induced_6\VBN\1627355 by_7\IN\1740 vasodilators_8\NNS\3198383 and_9\CC\1740 change_10\VBP\46534 the_11\DT\1740 accompanying_12\VBG\1835496 reflex_13\JJ\1740 tachycardia_14\NN\14110674 to_15\TO\1740 <e2>bradycardia</e2>_16\NN\14110674 ,_17\,\1740 an_18\DT\6697703 interaction_19\NN\37396 attributed_20\VBN\670261 to_21\TO\1740 decreased_22\VBN\169651 synthesis_23\NN\13446390 of_24\IN\1740 brain_25\NN\5462674 gamma-aminobutyric_26\JJ\1740 acid_27\NN\14818238 (_28\-LRB-\1740 gaba_29\NN\14601829 )_30\-RRB-\1740 ._31\.\1740
D007538_D001919 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 possible_6\JJ\1740 enhancement_7\NN\248977 by_8\IN\1740 <e1>isoniazid</e1>_9\NN\2716205 of_10\IN\1740 <e2>bradycardia</e2>_11\NN\14110674 induced_12\VBN\1627355 by_13\IN\1740 beta-adrenoceptor_14\JJ\1740 antagonists_15\NNS\7846 was_16\VBD\836236 determined_17\VBN\1645601 in_18\IN\13603305 rats_19\NNS\2329401 anaesthetised_20\VBN\84738 with_21\IN\1740 chloralose-urethane_22\NN\1740 ._23\.\1740
D007538_D001919 CID <e1>isoniazid</e1>_0\NNS\2716205 significantly_1\RB\1740 increased_2\VBD\169651 <e2>bradycardia</e2>_3\NN\14110674 after_4\IN\1740 propranolol_5\NN\1740 ,_6\,\1740 pindolol_7\NN\2832168 ,_8\,\1740 labetalol_9\NN\2721160 and_10\CC\1740 atenolol_11\NNS\2832168 ,_12\,\1740 as_13\RB\1740 well_14\RB\1740 as_15\IN\14622893 after_16\IN\1740 clonidine_17\NN\2721160 ,_18\,\1740 but_19\CC\1740 not_20\RB\1740 after_21\IN\1740 hexamethonium_22\NN\1740 or_23\CC\3541091 carbachol_24\NN\1740 ._25\.\1740
D007538_D007022 CID high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 <e1>isoniazid</e1>_3\NNS\2716205 increase_4\VBP\169651 <e2>hypotension</e2>_5\NN\14057371 induced_6\VBN\1627355 by_7\IN\1740 vasodilators_8\NNS\3198383 and_9\CC\1740 change_10\VBP\46534 the_11\DT\1740 accompanying_12\VBG\1835496 reflex_13\JJ\1740 tachycardia_14\NN\14110674 to_15\TO\1740 bradycardia_16\NN\14110674 ,_17\,\1740 an_18\DT\6697703 interaction_19\NN\37396 attributed_20\VBN\670261 to_21\TO\1740 decreased_22\VBN\169651 synthesis_23\NN\13446390 of_24\IN\1740 brain_25\NN\5462674 gamma-aminobutyric_26\JJ\1740 acid_27\NN\14818238 (_28\-LRB-\1740 gaba_29\NN\14601829 )_30\-RRB-\1740 ._31\.\1740
D007538_D013610 NONE high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 <e1>isoniazid</e1>_3\NNS\2716205 increase_4\VBP\169651 hypotension_5\NN\14057371 induced_6\VBN\1627355 by_7\IN\1740 vasodilators_8\NNS\3198383 and_9\CC\1740 change_10\VBP\46534 the_11\DT\1740 accompanying_12\VBG\1835496 reflex_13\JJ\1740 <e2>tachycardia</e2>_14\NN\14110674 to_15\TO\1740 bradycardia_16\NN\14110674 ,_17\,\1740 an_18\DT\6697703 interaction_19\NN\37396 attributed_20\VBN\670261 to_21\TO\1740 decreased_22\VBN\169651 synthesis_23\NN\13446390 of_24\IN\1740 brain_25\NN\5462674 gamma-aminobutyric_26\JJ\1740 acid_27\NN\14818238 (_28\-LRB-\1740 gaba_29\NN\14601829 )_30\-RRB-\1740 ._31\.\1740
D005680_D007022 NONE high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 isoniazid_3\NNS\2716205 increase_4\VBP\169651 <e2>hypotension</e2>_5\NN\14057371 induced_6\VBN\1627355 by_7\IN\1740 vasodilators_8\NNS\3198383 and_9\CC\1740 change_10\VBP\46534 the_11\DT\1740 accompanying_12\VBG\1835496 reflex_13\JJ\1740 tachycardia_14\NN\14110674 to_15\TO\1740 bradycardia_16\NN\14110674 ,_17\,\1740 an_18\DT\6697703 interaction_19\NN\37396 attributed_20\VBN\670261 to_21\TO\1740 decreased_22\VBN\169651 synthesis_23\NN\13446390 of_24\IN\1740 brain_25\NN\5462674 <e1>gamma-aminobutyric_26\JJ\1740 acid</e1>_27\NN\14818238 (_28\-LRB-\1740 gaba_29\NN\14601829 )_30\-RRB-\1740 ._31\.\1740
D005680_D007022 NONE high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 isoniazid_3\NNS\2716205 increase_4\VBP\169651 <e2>hypotension</e2>_5\NN\14057371 induced_6\VBN\1627355 by_7\IN\1740 vasodilators_8\NNS\3198383 and_9\CC\1740 change_10\VBP\46534 the_11\DT\1740 accompanying_12\VBG\1835496 reflex_13\JJ\1740 tachycardia_14\NN\14110674 to_15\TO\1740 bradycardia_16\NN\14110674 ,_17\,\1740 an_18\DT\6697703 interaction_19\NN\37396 attributed_20\VBN\670261 to_21\TO\1740 decreased_22\VBN\169651 synthesis_23\NN\13446390 of_24\IN\1740 brain_25\NN\5462674 gamma-aminobutyric_26\JJ\1740 acid_27\NN\14818238 (_28\-LRB-\1740 <e1>gaba</e1>_29\NN\14601829 )_30\-RRB-\1740 ._31\.\1740
D005680_D013610 NONE high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 isoniazid_3\NNS\2716205 increase_4\VBP\169651 hypotension_5\NN\14057371 induced_6\VBN\1627355 by_7\IN\1740 vasodilators_8\NNS\3198383 and_9\CC\1740 change_10\VBP\46534 the_11\DT\1740 accompanying_12\VBG\1835496 reflex_13\JJ\1740 <e2>tachycardia</e2>_14\NN\14110674 to_15\TO\1740 bradycardia_16\NN\14110674 ,_17\,\1740 an_18\DT\6697703 interaction_19\NN\37396 attributed_20\VBN\670261 to_21\TO\1740 decreased_22\VBN\169651 synthesis_23\NN\13446390 of_24\IN\1740 brain_25\NN\5462674 <e1>gamma-aminobutyric_26\JJ\1740 acid</e1>_27\NN\14818238 (_28\-LRB-\1740 gaba_29\NN\14601829 )_30\-RRB-\1740 ._31\.\1740
D005680_D013610 NONE high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 isoniazid_3\NNS\2716205 increase_4\VBP\169651 hypotension_5\NN\14057371 induced_6\VBN\1627355 by_7\IN\1740 vasodilators_8\NNS\3198383 and_9\CC\1740 change_10\VBP\46534 the_11\DT\1740 accompanying_12\VBG\1835496 reflex_13\JJ\1740 <e2>tachycardia</e2>_14\NN\14110674 to_15\TO\1740 bradycardia_16\NN\14110674 ,_17\,\1740 an_18\DT\6697703 interaction_19\NN\37396 attributed_20\VBN\670261 to_21\TO\1740 decreased_22\VBN\169651 synthesis_23\NN\13446390 of_24\IN\1740 brain_25\NN\5462674 gamma-aminobutyric_26\JJ\1740 acid_27\NN\14818238 (_28\-LRB-\1740 <e1>gaba</e1>_29\NN\14601829 )_30\-RRB-\1740 ._31\.\1740
D005680_D001919 NONE high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 isoniazid_3\NNS\2716205 increase_4\VBP\169651 hypotension_5\NN\14057371 induced_6\VBN\1627355 by_7\IN\1740 vasodilators_8\NNS\3198383 and_9\CC\1740 change_10\VBP\46534 the_11\DT\1740 accompanying_12\VBG\1835496 reflex_13\JJ\1740 tachycardia_14\NN\14110674 to_15\TO\1740 <e2>bradycardia</e2>_16\NN\14110674 ,_17\,\1740 an_18\DT\6697703 interaction_19\NN\37396 attributed_20\VBN\670261 to_21\TO\1740 decreased_22\VBN\169651 synthesis_23\NN\13446390 of_24\IN\1740 brain_25\NN\5462674 <e1>gamma-aminobutyric_26\JJ\1740 acid</e1>_27\NN\14818238 (_28\-LRB-\1740 gaba_29\NN\14601829 )_30\-RRB-\1740 ._31\.\1740
D005680_D001919 NONE high_0\JJ\1740 doses_1\NNS\3740161 of_2\IN\1740 isoniazid_3\NNS\2716205 increase_4\VBP\169651 hypotension_5\NN\14057371 induced_6\VBN\1627355 by_7\IN\1740 vasodilators_8\NNS\3198383 and_9\CC\1740 change_10\VBP\46534 the_11\DT\1740 accompanying_12\VBG\1835496 reflex_13\JJ\1740 tachycardia_14\NN\14110674 to_15\TO\1740 <e2>bradycardia</e2>_16\NN\14110674 ,_17\,\1740 an_18\DT\6697703 interaction_19\NN\37396 attributed_20\VBN\670261 to_21\TO\1740 decreased_22\VBN\169651 synthesis_23\NN\13446390 of_24\IN\1740 brain_25\NN\5462674 gamma-aminobutyric_26\JJ\1740 acid_27\NN\14818238 (_28\-LRB-\1740 <e1>gaba</e1>_29\NN\14601829 )_30\-RRB-\1740 ._31\.\1740
D002698_D001919 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 possible_6\JJ\1740 enhancement_7\NN\248977 by_8\IN\1740 isoniazid_9\NN\2716205 of_10\IN\1740 <e2>bradycardia</e2>_11\NN\14110674 induced_12\VBN\1627355 by_13\IN\1740 beta-adrenoceptor_14\JJ\1740 antagonists_15\NNS\7846 was_16\VBD\836236 determined_17\VBN\1645601 in_18\IN\13603305 rats_19\NNS\2329401 anaesthetised_20\VBN\84738 with_21\IN\1740 <e1>chloralose-urethane</e1>_22\NN\1740 ._23\.\1740
D014520_D001919 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 possible_6\JJ\1740 enhancement_7\NN\248977 by_8\IN\1740 isoniazid_9\NN\2716205 of_10\IN\1740 <e2>bradycardia</e2>_11\NN\14110674 induced_12\VBN\1627355 by_13\IN\1740 beta-adrenoceptor_14\JJ\1740 antagonists_15\NNS\7846 was_16\VBD\836236 determined_17\VBN\1645601 in_18\IN\13603305 rats_19\NNS\2329401 anaesthetised_20\VBN\84738 with_21\IN\1740 <e1>chloralose-urethane</e1>_22\NN\1740 ._23\.\1740
D011433_D001919 NONE isoniazid_0\NNS\2716205 significantly_1\RB\1740 increased_2\VBD\169651 <e2>bradycardia</e2>_3\NN\14110674 after_4\IN\1740 <e1>propranolol</e1>_5\NN\1740 ,_6\,\1740 pindolol_7\NN\2832168 ,_8\,\1740 labetalol_9\NN\2721160 and_10\CC\1740 atenolol_11\NNS\2832168 ,_12\,\1740 as_13\RB\1740 well_14\RB\1740 as_15\IN\14622893 after_16\IN\1740 clonidine_17\NN\2721160 ,_18\,\1740 but_19\CC\1740 not_20\RB\1740 after_21\IN\1740 hexamethonium_22\NN\1740 or_23\CC\3541091 carbachol_24\NN\1740 ._25\.\1740
D010869_D001919 NONE isoniazid_0\NNS\2716205 significantly_1\RB\1740 increased_2\VBD\169651 <e2>bradycardia</e2>_3\NN\14110674 after_4\IN\1740 propranolol_5\NN\1740 ,_6\,\1740 <e1>pindolol</e1>_7\NN\2832168 ,_8\,\1740 labetalol_9\NN\2721160 and_10\CC\1740 atenolol_11\NNS\2832168 ,_12\,\1740 as_13\RB\1740 well_14\RB\1740 as_15\IN\14622893 after_16\IN\1740 clonidine_17\NN\2721160 ,_18\,\1740 but_19\CC\1740 not_20\RB\1740 after_21\IN\1740 hexamethonium_22\NN\1740 or_23\CC\3541091 carbachol_24\NN\1740 ._25\.\1740
D007741_D001919 NONE isoniazid_0\NNS\2716205 significantly_1\RB\1740 increased_2\VBD\169651 <e2>bradycardia</e2>_3\NN\14110674 after_4\IN\1740 propranolol_5\NN\1740 ,_6\,\1740 pindolol_7\NN\2832168 ,_8\,\1740 <e1>labetalol</e1>_9\NN\2721160 and_10\CC\1740 atenolol_11\NNS\2832168 ,_12\,\1740 as_13\RB\1740 well_14\RB\1740 as_15\IN\14622893 after_16\IN\1740 clonidine_17\NN\2721160 ,_18\,\1740 but_19\CC\1740 not_20\RB\1740 after_21\IN\1740 hexamethonium_22\NN\1740 or_23\CC\3541091 carbachol_24\NN\1740 ._25\.\1740
D001262_D001919 NONE isoniazid_0\NNS\2716205 significantly_1\RB\1740 increased_2\VBD\169651 <e2>bradycardia</e2>_3\NN\14110674 after_4\IN\1740 propranolol_5\NN\1740 ,_6\,\1740 pindolol_7\NN\2832168 ,_8\,\1740 labetalol_9\NN\2721160 and_10\CC\1740 <e1>atenolol</e1>_11\NNS\2832168 ,_12\,\1740 as_13\RB\1740 well_14\RB\1740 as_15\IN\14622893 after_16\IN\1740 clonidine_17\NN\2721160 ,_18\,\1740 but_19\CC\1740 not_20\RB\1740 after_21\IN\1740 hexamethonium_22\NN\1740 or_23\CC\3541091 carbachol_24\NN\1740 ._25\.\1740
D003000_D001919 NONE isoniazid_0\NNS\2716205 significantly_1\RB\1740 increased_2\VBD\169651 <e2>bradycardia</e2>_3\NN\14110674 after_4\IN\1740 propranolol_5\NN\1740 ,_6\,\1740 pindolol_7\NN\2832168 ,_8\,\1740 labetalol_9\NN\2721160 and_10\CC\1740 atenolol_11\NNS\2832168 ,_12\,\1740 as_13\RB\1740 well_14\RB\1740 as_15\IN\14622893 after_16\IN\1740 <e1>clonidine</e1>_17\NN\2721160 ,_18\,\1740 but_19\CC\1740 not_20\RB\1740 after_21\IN\1740 hexamethonium_22\NN\1740 or_23\CC\3541091 carbachol_24\NN\1740 ._25\.\1740
D018738_D001919 NONE isoniazid_0\NNS\2716205 significantly_1\RB\1740 increased_2\VBD\169651 <e2>bradycardia</e2>_3\NN\14110674 after_4\IN\1740 propranolol_5\NN\1740 ,_6\,\1740 pindolol_7\NN\2832168 ,_8\,\1740 labetalol_9\NN\2721160 and_10\CC\1740 atenolol_11\NNS\2832168 ,_12\,\1740 as_13\RB\1740 well_14\RB\1740 as_15\IN\14622893 after_16\IN\1740 clonidine_17\NN\2721160 ,_18\,\1740 but_19\CC\1740 not_20\RB\1740 after_21\IN\1740 <e1>hexamethonium</e1>_22\NN\1740 or_23\CC\3541091 carbachol_24\NN\1740 ._25\.\1740
D002217_D001919 NONE isoniazid_0\NNS\2716205 significantly_1\RB\1740 increased_2\VBD\169651 <e2>bradycardia</e2>_3\NN\14110674 after_4\IN\1740 propranolol_5\NN\1740 ,_6\,\1740 pindolol_7\NN\2832168 ,_8\,\1740 labetalol_9\NN\2721160 and_10\CC\1740 atenolol_11\NNS\2832168 ,_12\,\1740 as_13\RB\1740 well_14\RB\1740 as_15\IN\14622893 after_16\IN\1740 clonidine_17\NN\2721160 ,_18\,\1740 but_19\CC\1740 not_20\RB\1740 after_21\IN\1740 hexamethonium_22\NN\1740 or_23\CC\3541091 <e1>carbachol</e1>_24\NN\1740 ._25\.\1740
6496797
D014196_D006327 CID complete_0\JJ\1740 <e2>heart_1\NN\5919034 block</e2>_2\NN\21939 following_3\VBG\1835496 a_4\DT\13649268 single_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 <e1>trazodone</e1>_8\NN\3829085 ._9\.\1740
D014196_D006327 CID forty_0\CD\13745420 minutes_1\NNS\6502378 after_2\IN\1740 receiving_3\VBG\2210855 a_4\DT\13649268 single_5\JJ\1740 starting_6\VBG\2009433 dose_7\NN\3740161 of_8\IN\1740 <e1>trazodone</e1>_9\NN\3829085 ,_10\,\1740 a_11\DT\13649268 patient_12\NN\9898892 developed_13\VBD\1753788 complete_14\JJ\1740 <e2>heart_15\NN\5919034 block</e2>_16\NN\21939 ._17\.\1740
7604176
D017035_D009135 NONE <e1>pravastatin-associated</e1>_0\JJ\1740 <e2>myopathy</e2>_1\NN\14204950 ._2\.\1740
D017035_D009135 NONE he_0\PRP\14622893 was_1\VBD\836236 admitted_2\VBN\822367 with_3\IN\1740 acute_4\JJ\1740 <e2>myopathy</e2>_5\NN\14204950 of_6\IN\1740 the_7\DT\1740 lower_8\JJR\1740 limbs_9\NNS\5559908 which_10\WDT\1740 resolved_11\VBD\352826 in_12\IN\13603305 a_13\DT\13649268 few_14\JJ\1740 days_15\NNS\15140892 after_16\IN\1740 <e1>pravastatin</e1>_17\NN\3676175 discontinuation_18\NN\209943 ._19\.\1740
D017035_D009135 NONE while_0\IN\15122231 lovastatin_1\NN\3676175 and_2\CC\1740 simvastatin_3\NN\3676175 have_4\VBP\2108377 been_5\VBN\836236 associated_6\VBN\628491 with_7\IN\1740 toxic_8\JJ\1740 <e2>myopathy</e2>_9\NN\14204950 ,_10\,\1740 <e1>pravastatin-associated</e1>_11\JJ\1740 myopathy_12\NN\14204950 could_13\MD\1740 represent_14\VB\2664769 a_15\DT\13649268 distinct_16\JJ\1740 ,_17\,\1740 inflammatory_18\JJ\1740 entity_19\NN\1740 ._20\.\1740
D017035_D009135 NONE while_0\IN\15122231 lovastatin_1\NN\3676175 and_2\CC\1740 simvastatin_3\NN\3676175 have_4\VBP\2108377 been_5\VBN\836236 associated_6\VBN\628491 with_7\IN\1740 toxic_8\JJ\1740 myopathy_9\NN\14204950 ,_10\,\1740 <e1>pravastatin-associated</e1>_11\JJ\1740 <e2>myopathy</e2>_12\NN\14204950 could_13\MD\1740 represent_14\VB\2664769 a_15\DT\13649268 distinct_16\JJ\1740 ,_17\,\1740 inflammatory_18\JJ\1740 entity_19\NN\1740 ._20\.\1740
D017035_D009220 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 <e2>inflammatory_4\JJ\1740 myopathy</e2>_5\NN\14204950 associated_6\VBN\628491 with_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>pravastatin</e1>_11\NN\3676175 ,_12\,\1740 a_13\DT\13649268 new_14\JJ\1740 hydrophilic_15\JJ\1740 3-hydroxy-3_16\NN\1740 methylglutaril_17\NN\1740 coenzyme_18\NN\14682133 a_19\NN\13649268 reductase_20\NN\14732946 inhibitor_21\NN\20090 ,_22\,\1740 is_23\VBZ\836236 reported_24\VBN\831651 ._25\.\1740
D017035_D006937 NONE he_0\PRP\14622893 assumed_1\VBD\719734 <e1>pravastatin</e1>_2\NN\3676175 (_3\-LRB-\1740 20_4\CD\13745420 mg/day_5\NN\1740 )_6\-RRB-\1740 because_7\IN\1740 of_8\IN\1740 <e2>hypercholesterolemia</e2>_9\NN\14299637 ._10\.\1740
D008148_D009135 NONE while_0\IN\15122231 <e1>lovastatin</e1>_1\NN\3676175 and_2\CC\1740 simvastatin_3\NN\3676175 have_4\VBP\2108377 been_5\VBN\836236 associated_6\VBN\628491 with_7\IN\1740 toxic_8\JJ\1740 <e2>myopathy</e2>_9\NN\14204950 ,_10\,\1740 pravastatin-associated_11\JJ\1740 myopathy_12\NN\14204950 could_13\MD\1740 represent_14\VB\2664769 a_15\DT\13649268 distinct_16\JJ\1740 ,_17\,\1740 inflammatory_18\JJ\1740 entity_19\NN\1740 ._20\.\1740
D008148_D009135 NONE while_0\IN\15122231 <e1>lovastatin</e1>_1\NN\3676175 and_2\CC\1740 simvastatin_3\NN\3676175 have_4\VBP\2108377 been_5\VBN\836236 associated_6\VBN\628491 with_7\IN\1740 toxic_8\JJ\1740 myopathy_9\NN\14204950 ,_10\,\1740 pravastatin-associated_11\JJ\1740 <e2>myopathy</e2>_12\NN\14204950 could_13\MD\1740 represent_14\VB\2664769 a_15\DT\13649268 distinct_16\JJ\1740 ,_17\,\1740 inflammatory_18\JJ\1740 entity_19\NN\1740 ._20\.\1740
D019821_D009135 NONE while_0\IN\15122231 lovastatin_1\NN\3676175 and_2\CC\1740 <e1>simvastatin</e1>_3\NN\3676175 have_4\VBP\2108377 been_5\VBN\836236 associated_6\VBN\628491 with_7\IN\1740 toxic_8\JJ\1740 <e2>myopathy</e2>_9\NN\14204950 ,_10\,\1740 pravastatin-associated_11\JJ\1740 myopathy_12\NN\14204950 could_13\MD\1740 represent_14\VB\2664769 a_15\DT\13649268 distinct_16\JJ\1740 ,_17\,\1740 inflammatory_18\JJ\1740 entity_19\NN\1740 ._20\.\1740
D019821_D009135 NONE while_0\IN\15122231 lovastatin_1\NN\3676175 and_2\CC\1740 <e1>simvastatin</e1>_3\NN\3676175 have_4\VBP\2108377 been_5\VBN\836236 associated_6\VBN\628491 with_7\IN\1740 toxic_8\JJ\1740 myopathy_9\NN\14204950 ,_10\,\1740 pravastatin-associated_11\JJ\1740 <e2>myopathy</e2>_12\NN\14204950 could_13\MD\1740 represent_14\VB\2664769 a_15\DT\13649268 distinct_16\JJ\1740 ,_17\,\1740 inflammatory_18\JJ\1740 entity_19\NN\1740 ._20\.\1740
20466178
D016559_D003872 NONE rosaceiform_0\NN\1740 <e2>dermatitis</e2>_1\NN\14226056 associated_2\VBN\628491 with_3\IN\1740 topical_4\JJ\1740 <e1>tacrolimus</e1>_5\NN\1740 treatment_6\NN\654885 ._7\.\1740
D016559_D003872 NONE we_0\PRP\1740 describe_1\VBP\1001294 herein_2\RB\1740 3_3\CD\13741022 patients_4\NNS\9898892 who_5\WP\8299493 developed_6\VBD\1753788 rosacea-like_7\JJ\1740 <e2>dermatitis</e2>_8\NN\14226056 eruptions_9\NNS\7307754 while_10\IN\15122231 using_11\VBG\1156834 0.03_12\CD\1740 %_13\NN\1740 or_14\CC\3541091 0.1_15\CD\1740 %_16\NN\1740 <e1>tacrolimus</e1>_17\NN\1740 ointment_18\JJ\1740 for_19\IN\1740 facial_20\JJ\1740 dermatitis_21\NN\14226056 ._22\.\1740
D016559_D003872 NONE continuous_0\JJ\1740 topical_1\JJ\1740 use_2\NN\407535 of_3\IN\1740 immunomodulators_4\NNS\1740 such_5\JJ\1740 as_6\IN\14622893 <e1>tacrolimus</e1>_7\NN\1740 or_8\CC\3541091 pimecrolimus_9\NN\1740 should_10\MD\1740 be_11\VB\836236 regarded_12\VBN\689344 as_13\IN\14622893 a_14\DT\13649268 potential_15\JJ\1740 cause_16\NN\7323922 of_17\IN\1740 rosaceiform_18\NN\1740 <e2>dermatitis</e2>_19\NN\14226056 ,_20\,\1740 although_21\IN\1740 many_22\JJ\1740 cases_23\NNS\7283608 have_24\VBP\2108377 not_25\RB\1740 been_26\VBN\836236 reported_27\VBN\831651 ._28\.\1740
D016559_D012393 NONE we_0\PRP\1740 describe_1\VBP\1001294 herein_2\RB\1740 3_3\CD\13741022 patients_4\NNS\9898892 who_5\WP\8299493 developed_6\VBD\1753788 <e2>rosacea-like</e2>_7\JJ\1740 dermatitis_8\NN\14226056 eruptions_9\NNS\7307754 while_10\IN\15122231 using_11\VBG\1156834 0.03_12\CD\1740 %_13\NN\1740 or_14\CC\3541091 0.1_15\CD\1740 %_16\NN\1740 <e1>tacrolimus</e1>_17\NN\1740 ointment_18\JJ\1740 for_19\IN\1740 facial_20\JJ\1740 dermatitis_21\NN\14226056 ._22\.\1740
D016559_D003875 NONE we_0\PRP\1740 describe_1\VBP\1001294 herein_2\RB\1740 3_3\CD\13741022 patients_4\NNS\9898892 who_5\WP\8299493 developed_6\VBD\1753788 rosacea-like_7\JJ\1740 dermatitis_8\NN\14226056 <e2>eruptions</e2>_9\NNS\7307754 while_10\IN\15122231 using_11\VBG\1156834 0.03_12\CD\1740 %_13\NN\1740 or_14\CC\3541091 0.1_15\CD\1740 %_16\NN\1740 <e1>tacrolimus</e1>_17\NN\1740 ointment_18\JJ\1740 for_19\IN\1740 facial_20\JJ\1740 dermatitis_21\NN\14226056 ._22\.\1740
D016559_D005148 NONE we_0\PRP\1740 describe_1\VBP\1001294 herein_2\RB\1740 3_3\CD\13741022 patients_4\NNS\9898892 who_5\WP\8299493 developed_6\VBD\1753788 rosacea-like_7\JJ\1740 dermatitis_8\NN\14226056 eruptions_9\NNS\7307754 while_10\IN\15122231 using_11\VBG\1156834 0.03_12\CD\1740 %_13\NN\1740 or_14\CC\3541091 0.1_15\CD\1740 %_16\NN\1740 <e1>tacrolimus</e1>_17\NN\1740 ointment_18\JJ\1740 for_19\IN\1740 <e2>facial_20\JJ\1740 dermatitis</e2>_21\NN\14226056 ._22\.\1740
C117268_D003872 CID continuous_0\JJ\1740 topical_1\JJ\1740 use_2\NN\407535 of_3\IN\1740 immunomodulators_4\NNS\1740 such_5\JJ\1740 as_6\IN\14622893 tacrolimus_7\NN\1740 or_8\CC\3541091 <e1>pimecrolimus</e1>_9\NN\1740 should_10\MD\1740 be_11\VB\836236 regarded_12\VBN\689344 as_13\IN\14622893 a_14\DT\13649268 potential_15\JJ\1740 cause_16\NN\7323922 of_17\IN\1740 rosaceiform_18\NN\1740 <e2>dermatitis</e2>_19\NN\14226056 ,_20\,\1740 although_21\IN\1740 many_22\JJ\1740 cases_23\NNS\7283608 have_24\VBP\2108377 not_25\RB\1740 been_26\VBN\836236 reported_27\VBN\831651 ._28\.\1740
663266
D003973_D014693 NONE <e2>ventricular_0\JJ\1740 fibrillation</e2>_1\NN\14361664 from_2\IN\1740 <e1>diatrizoate</e1>_3\NN\1740 with_4\IN\1740 and_5\CC\1740 without_6\IN\1740 chelating_7\VBG\2621395 agents_8\NNS\7347 ._9\.\1740
C027278_D064420 NONE the_0\DT\1740 <e2>toxicity</e2>_1\NN\13576101 of_2\IN\1740 <e1>renografin_3\NNP\1740 76_4\CD\1740 %</e1>_5\NN\1740 was_6\VBD\836236 compared_7\VBN\644583 with_8\IN\1740 that_9\DT\1740 of_10\IN\1740 hypaque_11\NN\1740 76_12\CD\1740 %_13\NN\1740 by_14\IN\1740 selective_15\JJ\1740 injection_16\NN\320852 of_17\IN\1740 each_18\DT\1740 into_19\IN\1740 the_20\DT\1740 right_21\JJ\1740 coronary_22\JJ\1740 artery_23\NN\5417975 of_24\IN\1740 dogs_25\NNS\2083346 ._26\.\1740
C027278_D064420 NONE the_0\DT\1740 <e2>toxicity</e2>_1\NN\13576101 of_2\IN\1740 renografin_3\NNP\1740 76_4\CD\1740 %_5\NN\1740 was_6\VBD\836236 compared_7\VBN\644583 with_8\IN\1740 that_9\DT\1740 of_10\IN\1740 <e1>hypaque_11\NN\1740 76_12\CD\1740 %</e1>_13\NN\1740 by_14\IN\1740 selective_15\JJ\1740 injection_16\NN\320852 of_17\IN\1740 each_18\DT\1740 into_19\IN\1740 the_20\DT\1740 right_21\JJ\1740 coronary_22\JJ\1740 artery_23\NN\5417975 of_24\IN\1740 dogs_25\NNS\2083346 ._26\.\1740
D003974_D014693 NONE <e2>ventricular_0\JJ\1740 fibrillation</e2>_1\NN\14361664 occurred_2\VBD\2623529 significantly_3\RB\1740 more_4\RBR\1740 often_5\RB\1740 with_6\IN\1740 <e1>renografin</e1>_7\NNP\1740 ,_8\,\1740 suggesting_9\VBG\1010118 that_10\IN\1740 chelating_11\NN\1740 agents_12\NNS\7347 contribute_13\VBP\126264 to_14\TO\1740 toxicity_15\NN\13576101 in_16\IN\13603305 coronary_17\JJ\1740 angiography_18\NN\904623 ._19\.\1740
D003974_D064420 NONE ventricular_0\JJ\1740 fibrillation_1\NN\14361664 occurred_2\VBD\2623529 significantly_3\RB\1740 more_4\RBR\1740 often_5\RB\1740 with_6\IN\1740 <e1>renografin</e1>_7\NNP\1740 ,_8\,\1740 suggesting_9\VBG\1010118 that_10\IN\1740 chelating_11\NN\1740 agents_12\NNS\7347 contribute_13\VBP\126264 to_14\TO\1740 <e2>toxicity</e2>_15\NN\13576101 in_16\IN\13603305 coronary_17\JJ\1740 angiography_18\NN\904623 ._19\.\1740
15638391
D006220_D006966 CID aging_0\NN\13526110 process_1\NN\407535 of_2\IN\1740 epithelial_3\JJ\1740 cells_4\NNS\3080309 of_5\IN\1740 the_6\DT\1740 rat_7\NN\2329401 prostate_8\NN\5329735 lateral_9\NN\560529 lobe_10\VBD\1740 in_11\IN\13603305 experimental_12\JJ\1740 <e2>hyperprolactinemia</e2>_13\NN\1740 induced_14\VBN\1627355 by_15\IN\1740 <e1>haloperidol</e1>_16\NN\3713736 ._17\.\1740
D006220_D006966 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 influence_9\NN\5190804 of_10\IN\1740 <e2>hyperprolactinemia</e2>_11\NN\1740 ,_12\,\1740 induced_13\VBN\1627355 by_14\IN\1740 <e1>haloperidol</e1>_15\NN\3713736 (_16\-LRB-\1740 hal_17\NN\1740 )_18\-RRB-\1740 on_19\IN\1740 age_20\NN\4916342 related_21\JJ\1740 morphology_22\NN\6037666 and_23\CC\1740 function_24\NN\13783581 changes_25\NNS\7283608 of_26\IN\1740 epithelial_27\JJ\1740 cells_28\NNS\3080309 in_29\IN\13603305 rat_30\NN\2329401 prostate_31\NN\5329735 lateral_32\NN\560529 lobe_33\VBD\1740 ._34\.\1740
D006220_D006966 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 influence_9\NN\5190804 of_10\IN\1740 <e2>hyperprolactinemia</e2>_11\NN\1740 ,_12\,\1740 induced_13\VBN\1627355 by_14\IN\1740 haloperidol_15\NN\3713736 (_16\-LRB-\1740 <e1>hal</e1>_17\NN\1740 )_18\-RRB-\1740 on_19\IN\1740 age_20\NN\4916342 related_21\JJ\1740 morphology_22\NN\6037666 and_23\CC\1740 function_24\NN\13783581 changes_25\NNS\7283608 of_26\IN\1740 epithelial_27\JJ\1740 cells_28\NNS\3080309 in_29\IN\13603305 rat_30\NN\2329401 prostate_31\NN\5329735 lateral_32\NN\560529 lobe_33\VBD\1740 ._34\.\1740
15266362
D004280_D002312 NONE the_0\DT\1740 47-year-old_1\JJ\1740 female_2\JJ\1740 patient_3\NN\9898892 ,_4\,\1740 known_5\VBN\2110220 to_6\TO\1740 have_7\VB\2108377 <e2>hypertrophic_8\JJ\1740 cardiomyopathy</e2>_9\JJ\1740 ,_10\,\1740 was_11\VBD\836236 admitted_12\VBN\822367 with_13\IN\1740 biventricular_14\JJ\1740 failure_15\NN\66216 and_16\CC\1740 managed_17\VBD\2524171 aggressively_18\RB\1740 with_19\IN\1740 <e1>dobutamine</e1>_20\NN\1740 infusion_21\NN\14589223 and_22\CC\1740 other_23\JJ\1740 drugs_24\NNS\14778436 while_25\IN\15122231 being_26\VBG\836236 assessed_27\VBN\670261 for_28\IN\1740 heart_29\NN\5919034 transplantation_30\NN\671351 ._31\.\1740
D004280_D018754 NONE the_0\DT\1740 47-year-old_1\JJ\1740 female_2\JJ\1740 patient_3\NN\9898892 ,_4\,\1740 known_5\VBN\2110220 to_6\TO\1740 have_7\VB\2108377 hypertrophic_8\JJ\1740 cardiomyopathy_9\JJ\1740 ,_10\,\1740 was_11\VBD\836236 admitted_12\VBN\822367 with_13\IN\1740 <e2>biventricular_14\JJ\1740 failure</e2>_15\NN\66216 and_16\CC\1740 managed_17\VBD\2524171 aggressively_18\RB\1740 with_19\IN\1740 <e1>dobutamine</e1>_20\NN\1740 infusion_21\NN\14589223 and_22\CC\1740 other_23\JJ\1740 drugs_24\NNS\14778436 while_25\IN\15122231 being_26\VBG\836236 assessed_27\VBN\670261 for_28\IN\1740 heart_29\NN\5919034 transplantation_30\NN\671351 ._31\.\1740
D004280_D004342 CID it_0\PRP\6125041 is_1\VBZ\836236 likely_2\JJ\1740 that_3\IN\1740 the_4\DT\1740 <e2>hypersensitivity</e2>_5\NN\14531772 (_6\-LRB-\1740 eosinophilic_7\JJ\1740 )_8\-RRB-\1740 myocarditis_9\NN\14338942 was_10\VBD\836236 related_11\JJ\1740 to_12\TO\1740 <e1>dobutamine</e1>_13\NN\1740 infusion_14\NN\14589223 therapy_15\NN\657604 ._16\.\1740
D004280_D004802 CID it_0\PRP\6125041 is_1\VBZ\836236 likely_2\JJ\1740 that_3\IN\1740 the_4\DT\1740 hypersensitivity_5\NN\14531772 (_6\-LRB-\1740 <e2>eosinophilic</e2>_7\JJ\1740 )_8\-RRB-\1740 myocarditis_9\NN\14338942 was_10\VBD\836236 related_11\JJ\1740 to_12\TO\1740 <e1>dobutamine</e1>_13\NN\1740 infusion_14\NN\14589223 therapy_15\NN\657604 ._16\.\1740
D004280_D009205 CID it_0\PRP\6125041 is_1\VBZ\836236 likely_2\JJ\1740 that_3\IN\1740 the_4\DT\1740 hypersensitivity_5\NN\14531772 (_6\-LRB-\1740 eosinophilic_7\JJ\1740 )_8\-RRB-\1740 <e2>myocarditis</e2>_9\NN\14338942 was_10\VBD\836236 related_11\JJ\1740 to_12\TO\1740 <e1>dobutamine</e1>_13\NN\1740 infusion_14\NN\14589223 therapy_15\NN\657604 ._16\.\1740
2004015
D015215_C565469 NONE sensitivity_0\NN\5651971 of_1\IN\1740 erythroid_2\JJ\1740 progenitor_3\NN\9792555 colonies_4\NNS\7965085 to_5\TO\1740 erythropoietin_6\NN\14888310 in_7\IN\13603305 <e1>azidothymidine</e1>_8\NN\1740 treated_9\JJ\1740 <e2>immunodeficient</e2>_10\JJ\1740 mice_11\NNS\2329401 ._12\.\1740
D015215_D000740 CID the_0\DT\1740 <e2>anaemia</e2>_1\NN\14299637 induced_2\VBN\1627355 by_3\IN\1740 <e1>3'-azido-3'dideoxythymidine</e1>_4\NN\1740 (_5\-LRB-\1740 azt_6\NN\3834836 )_7\-RRB-\1740 is_8\VBZ\836236 poorly_9\RB\1740 understood_10\VBN\588888 ._11\.\1740
D015215_D000740 CID the_0\DT\1740 <e2>anaemia</e2>_1\NN\14299637 induced_2\VBN\1627355 by_3\IN\1740 3'-azido-3'dideoxythymidine_4\NN\1740 (_5\-LRB-\1740 <e1>azt</e1>_6\NN\3834836 )_7\-RRB-\1740 is_8\VBZ\836236 poorly_9\RB\1740 understood_10\VBN\588888 ._11\.\1740
D015215_D000740 CID we_0\PRP\1740 have_1\VBP\2108377 used_2\VBN\1156834 a_3\DT\13649268 murine_4\JJ\1740 model_5\NN\5888929 of_6\IN\1740 aids_7\NN\13974317 ,_8\,\1740 infection_9\NN\14052046 of_10\IN\1740 female_11\JJ\1740 c57bl/6_12\NN\1740 mice_13\NNS\2329401 with_14\IN\1740 lp-bm5_15\NN\1740 murine_16\NN\2329401 leukaemia_17\NN\14239918 (_18\-LRB-\1740 mulv_19\JJ\1740 )_20\-RRB-\1740 virus_21\NN\9312843 ,_22\,\1740 to_23\TO\1740 determine_24\VB\1645601 if_25\IN\1740 <e1>azt-induced</e1>_26\JJ\1740 <e2>anaemia</e2>_27\NN\14299637 is_28\VBZ\836236 due_29\JJ\1740 ,_30\,\1740 in_31\IN\13603305 part_32\NN\31921 ,_33\,\1740 to_34\TO\1740 decreased_35\VBN\169651 responsiveness_36\NN\5652926 of_37\IN\1740 erythropoietic_38\JJ\1740 precursors_39\NNS\14580897 (_40\-LRB-\1740 bfu-e_41\NN\1740 )_42\-RRB-\1740 to_43\TO\1740 erythropoietin_44\NN\14888310 (_45\-LRB-\1740 epo_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D015215_D000740 CID <e1>azt</e1>_0\NN\3834836 produced_1\VBD\1617192 <e2>anaemia</e2>_2\NN\14299637 in_3\IN\13603305 both_4\DT\1740 groups_5\NNS\2137 ,_6\,\1740 in_7\IN\13603305 a_8\DT\13649268 dose-dependent_9\JJ\1740 fashion_10\NN\4916342 ._11\.\1740
D015215_D000740 CID despite_0\IN\7501545 the_1\DT\1740 <e2>anaemia</e2>_2\NN\14299637 ,_3\,\1740 the_4\DT\1740 number_5\NN\5107765 of_6\IN\1740 splenic_7\JJ\1740 and_8\CC\1740 bone_9\NN\5286536 marrow_10\NN\5286536 bfu-e_11\NN\1740 in_12\IN\13603305 <e1>azt</e1>_13\NN\3834836 treated_14\JJ\1740 mice_15\NNS\2329401 increased_16\VBD\169651 up_17\RB\1740 to_18\TO\1740 five-fold_19\RB\1740 over_20\IN\5867413 levels_21\NNS\4916342 observed_22\VBN\2163746 in_23\IN\13603305 infected_24\JJ\1740 untreated_25\JJ\1740 animals_26\NNS\4475 after_27\IN\1740 15_28\CD\13745420 d_29\NN\15089472 of_30\IN\1740 treatment_31\NN\654885 ._32\.\1740
D015215_D000740 CID the_0\DT\1740 mean_1\NN\6021761 plasma_2\NN\5398023 levels_3\NNS\4916342 of_4\IN\1740 epo_5\NN\1740 observed_6\VBN\2163746 in_7\IN\13603305 <e1>azt</e1>_8\NN\3834836 treated_9\JJ\1740 mice_10\NNS\2329401 were_11\VBD\836236 appropriate_12\JJ\1740 for_13\IN\1740 the_14\DT\1740 degree_15\NN\4916342 of_16\IN\1740 <e2>anaemia</e2>_17\NN\14299637 observed_18\VBN\2163746 when_19\WRB\1740 compared_20\VBN\644583 with_21\IN\1740 phenylhydrazine_22\NN\1740 (_23\-LRB-\1740 phz_24\NN\1740 )_25\-RRB-\1740 treated_26\VBN\2376958 mice_27\NNS\2329401 ._28\.\1740
D015215_D000740 CID the_0\DT\1740 numbers_1\NNS\508091 of_2\IN\1740 bfu-e_3\NN\1740 and_4\CC\1740 the_5\DT\1740 percentage_6\NN\13815742 of_7\IN\1740 bone_8\NN\5286536 marrow_9\NN\5286536 erythroblasts_10\NNS\5447757 observed_11\VBN\2163746 were_12\VBD\836236 comparable_13\JJ\1740 in_14\IN\13603305 <e1>azt</e1>_15\NN\3834836 and_16\CC\1740 phz_17\NN\1740 treated_18\JJ\1740 mice_19\NNS\2329401 with_20\IN\1740 similar_21\JJ\1740 degrees_22\NNS\4916342 of_23\IN\1740 <e2>anaemia</e2>_24\NN\14299637 ._25\.\1740
D015215_D000740 CID however_0\RB\1740 ,_1\,\1740 reticulocytosis_2\NN\1740 was_3\VBD\836236 inappropriate_4\JJ\1740 for_5\IN\1740 the_6\DT\1740 degree_7\NN\4916342 of_8\IN\1740 <e2>anaemia</e2>_9\NN\14299637 observed_10\VBN\2163746 in_11\IN\13603305 <e1>azt</e1>_12\NN\3834836 treated_13\VBN\2376958 infected_14\JJ\1740 mice_15\NNS\2329401 ._16\.\1740
D015215_D000740 CID <e1>azt-induced</e1>_0\JJ\1740 peripheral_1\JJ\1740 <e2>anaemia</e2>_2\NN\14299637 in_3\IN\13603305 the_4\DT\1740 face_5\NN\5225090 of_6\IN\1740 increased_7\VBN\169651 numbers_8\NNS\508091 of_9\IN\1740 bfu-e_10\NN\1740 and_11\CC\1740 increased_12\VBN\169651 levels_13\NNS\4916342 of_14\IN\1740 plasma_15\NN\5398023 epo_16\NN\1740 suggest_17\VBP\1010118 a_18\DT\13649268 lesion_19\NN\14204950 in_20\IN\13603305 terminal_21\JJ\1740 differentiation_22\NN\5748054 ._23\.\1740
D015215_D000163 NONE we_0\PRP\1740 have_1\VBP\2108377 used_2\VBN\1156834 a_3\DT\13649268 murine_4\JJ\1740 model_5\NN\5888929 of_6\IN\1740 <e2>aids</e2>_7\NN\13974317 ,_8\,\1740 infection_9\NN\14052046 of_10\IN\1740 female_11\JJ\1740 c57bl/6_12\NN\1740 mice_13\NNS\2329401 with_14\IN\1740 lp-bm5_15\NN\1740 murine_16\NN\2329401 leukaemia_17\NN\14239918 (_18\-LRB-\1740 mulv_19\JJ\1740 )_20\-RRB-\1740 virus_21\NN\9312843 ,_22\,\1740 to_23\TO\1740 determine_24\VB\1645601 if_25\IN\1740 <e1>azt-induced</e1>_26\JJ\1740 anaemia_27\NN\14299637 is_28\VBZ\836236 due_29\JJ\1740 ,_30\,\1740 in_31\IN\13603305 part_32\NN\31921 ,_33\,\1740 to_34\TO\1740 decreased_35\VBN\169651 responsiveness_36\NN\5652926 of_37\IN\1740 erythropoietic_38\JJ\1740 precursors_39\NNS\14580897 (_40\-LRB-\1740 bfu-e_41\NN\1740 )_42\-RRB-\1740 to_43\TO\1740 erythropoietin_44\NN\14888310 (_45\-LRB-\1740 epo_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D015215_D007239 NONE we_0\PRP\1740 have_1\VBP\2108377 used_2\VBN\1156834 a_3\DT\13649268 murine_4\JJ\1740 model_5\NN\5888929 of_6\IN\1740 aids_7\NN\13974317 ,_8\,\1740 <e2>infection</e2>_9\NN\14052046 of_10\IN\1740 female_11\JJ\1740 c57bl/6_12\NN\1740 mice_13\NNS\2329401 with_14\IN\1740 lp-bm5_15\NN\1740 murine_16\NN\2329401 leukaemia_17\NN\14239918 (_18\-LRB-\1740 mulv_19\JJ\1740 )_20\-RRB-\1740 virus_21\NN\9312843 ,_22\,\1740 to_23\TO\1740 determine_24\VB\1645601 if_25\IN\1740 <e1>azt-induced</e1>_26\JJ\1740 anaemia_27\NN\14299637 is_28\VBZ\836236 due_29\JJ\1740 ,_30\,\1740 in_31\IN\13603305 part_32\NN\31921 ,_33\,\1740 to_34\TO\1740 decreased_35\VBN\169651 responsiveness_36\NN\5652926 of_37\IN\1740 erythropoietic_38\JJ\1740 precursors_39\NNS\14580897 (_40\-LRB-\1740 bfu-e_41\NN\1740 )_42\-RRB-\1740 to_43\TO\1740 erythropoietin_44\NN\14888310 (_45\-LRB-\1740 epo_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
D015215_D007938 NONE we_0\PRP\1740 have_1\VBP\2108377 used_2\VBN\1156834 a_3\DT\13649268 murine_4\JJ\1740 model_5\NN\5888929 of_6\IN\1740 aids_7\NN\13974317 ,_8\,\1740 infection_9\NN\14052046 of_10\IN\1740 female_11\JJ\1740 c57bl/6_12\NN\1740 mice_13\NNS\2329401 with_14\IN\1740 lp-bm5_15\NN\1740 murine_16\NN\2329401 <e2>leukaemia</e2>_17\NN\14239918 (_18\-LRB-\1740 mulv_19\JJ\1740 )_20\-RRB-\1740 virus_21\NN\9312843 ,_22\,\1740 to_23\TO\1740 determine_24\VB\1645601 if_25\IN\1740 <e1>azt-induced</e1>_26\JJ\1740 anaemia_27\NN\14299637 is_28\VBZ\836236 due_29\JJ\1740 ,_30\,\1740 in_31\IN\13603305 part_32\NN\31921 ,_33\,\1740 to_34\TO\1740 decreased_35\VBN\169651 responsiveness_36\NN\5652926 of_37\IN\1740 erythropoietic_38\JJ\1740 precursors_39\NNS\14580897 (_40\-LRB-\1740 bfu-e_41\NN\1740 )_42\-RRB-\1740 to_43\TO\1740 erythropoietin_44\NN\14888310 (_45\-LRB-\1740 epo_46\NN\1740 )_47\-RRB-\1740 ._48\.\1740
C030299_D000740 NONE the_0\DT\1740 mean_1\NN\6021761 plasma_2\NN\5398023 levels_3\NNS\4916342 of_4\IN\1740 epo_5\NN\1740 observed_6\VBN\2163746 in_7\IN\13603305 azt_8\NN\3834836 treated_9\JJ\1740 mice_10\NNS\2329401 were_11\VBD\836236 appropriate_12\JJ\1740 for_13\IN\1740 the_14\DT\1740 degree_15\NN\4916342 of_16\IN\1740 <e2>anaemia</e2>_17\NN\14299637 observed_18\VBN\2163746 when_19\WRB\1740 compared_20\VBN\644583 with_21\IN\1740 <e1>phenylhydrazine</e1>_22\NN\1740 (_23\-LRB-\1740 phz_24\NN\1740 )_25\-RRB-\1740 treated_26\VBN\2376958 mice_27\NNS\2329401 ._28\.\1740
C030299_D000740 NONE the_0\DT\1740 mean_1\NN\6021761 plasma_2\NN\5398023 levels_3\NNS\4916342 of_4\IN\1740 epo_5\NN\1740 observed_6\VBN\2163746 in_7\IN\13603305 azt_8\NN\3834836 treated_9\JJ\1740 mice_10\NNS\2329401 were_11\VBD\836236 appropriate_12\JJ\1740 for_13\IN\1740 the_14\DT\1740 degree_15\NN\4916342 of_16\IN\1740 <e2>anaemia</e2>_17\NN\14299637 observed_18\VBN\2163746 when_19\WRB\1740 compared_20\VBN\644583 with_21\IN\1740 phenylhydrazine_22\NN\1740 (_23\-LRB-\1740 <e1>phz</e1>_24\NN\1740 )_25\-RRB-\1740 treated_26\VBN\2376958 mice_27\NNS\2329401 ._28\.\1740
C030299_D000740 NONE the_0\DT\1740 numbers_1\NNS\508091 of_2\IN\1740 bfu-e_3\NN\1740 and_4\CC\1740 the_5\DT\1740 percentage_6\NN\13815742 of_7\IN\1740 bone_8\NN\5286536 marrow_9\NN\5286536 erythroblasts_10\NNS\5447757 observed_11\VBN\2163746 were_12\VBD\836236 comparable_13\JJ\1740 in_14\IN\13603305 azt_15\NN\3834836 and_16\CC\1740 <e1>phz</e1>_17\NN\1740 treated_18\JJ\1740 mice_19\NNS\2329401 with_20\IN\1740 similar_21\JJ\1740 degrees_22\NNS\4916342 of_23\IN\1740 <e2>anaemia</e2>_24\NN\14299637 ._25\.\1740
D015215_D045262 NONE however_0\RB\1740 ,_1\,\1740 <e2>reticulocytosis</e2>_2\NN\1740 was_3\VBD\836236 inappropriate_4\JJ\1740 for_5\IN\1740 the_6\DT\1740 degree_7\NN\4916342 of_8\IN\1740 anaemia_9\NN\14299637 observed_10\VBN\2163746 in_11\IN\13603305 <e1>azt</e1>_12\NN\3834836 treated_13\VBN\2376958 infected_14\JJ\1740 mice_15\NNS\2329401 ._16\.\1740
188339
D003276_D008113 CID etiologic_0\JJ\1740 factors_1\NNS\7326557 in_2\IN\13603305 the_3\DT\1740 pathogenesis_4\NN\13533470 of_5\IN\1740 <e2>liver_6\NN\5298729 tumors</e2>_7\NNS\14234074 associated_8\VBN\628491 with_9\IN\1740 <e1>oral_10\JJ\1740 contraceptives</e1>_11\NNS\3183080 ._12\.\1740
D003276_D008113 CID within_0\IN\1740 the_1\DT\1740 last_2\JJ\1740 several_3\JJ\1740 years_4\NNS\15144371 ,_5\,\1740 previously_6\RB\1740 rare_7\JJ\1740 <e2>liver_8\NN\5298729 tumors</e2>_9\NNS\14234074 have_10\VBP\2108377 been_11\VBN\836236 seen_12\VBN\2106506 in_13\IN\13603305 young_14\JJ\1740 women_15\NNS\9605289 using_16\VBG\1156834 <e1>oral_17\JJ\1740 contraceptive</e1>_18\JJ\1740 steroids_19\NNS\14727670 ._20\.\1740
D003276_D008113 CID the_0\DT\1740 registry_1\NNP\6502378 for_2\IN\1740 <e2>liver_3\NNP\5298729 tumors</e2>_4\NNS\14234074 associated_5\VBN\628491 with_6\IN\1740 <e1>oral_7\JJ\1740 contraceptives</e1>_8\NNPS\3183080 at_9\IN\14622893 the_10\DT\1740 university_11\NNP\7965085 of_12\IN\1740 california_13\NNP\1740 ,_14\,\1740 irvine_15\NNP\1740 ,_16\,\1740 has_17\VBZ\2108377 clearly_18\RB\1740 identified_19\VBN\699815 27_20\CD\13745420 cases_21\NNS\7283608 ._22\.\1740
D013256_D008113 NONE within_0\IN\1740 the_1\DT\1740 last_2\JJ\1740 several_3\JJ\1740 years_4\NNS\15144371 ,_5\,\1740 previously_6\RB\1740 rare_7\JJ\1740 <e2>liver_8\NN\5298729 tumors</e2>_9\NNS\14234074 have_10\VBP\2108377 been_11\VBN\836236 seen_12\VBN\2106506 in_13\IN\13603305 young_14\JJ\1740 women_15\NNS\9605289 using_16\VBG\1156834 oral_17\JJ\1740 contraceptive_18\JJ\1740 <e1>steroids</e1>_19\NNS\14727670 ._20\.\1740
6293644
D006220_D002375 CID calcitonin_0\NN\5413241 injection_1\NN\320852 resulted_2\VBD\2633881 in_3\IN\13603305 a_4\DT\13649268 potentiation_5\NN\13564910 of_6\IN\1740 <e1>haloperidol-induced</e1>_7\JJ\1740 <e2>catalepsy</e2>_8\NN\14023236 and_9\CC\1740 a_10\DT\13649268 partial_11\JJ\1740 prevention_12\NN\1073995 of_13\IN\1740 apomorphine-induced_14\JJ\1740 hyperactivity_15\NN\14052403 ._16\.\1740
D006220_D006948 NONE calcitonin_0\NN\5413241 injection_1\NN\320852 resulted_2\VBD\2633881 in_3\IN\13603305 a_4\DT\13649268 potentiation_5\NN\13564910 of_6\IN\1740 <e1>haloperidol-induced</e1>_7\JJ\1740 catalepsy_8\NN\14023236 and_9\CC\1740 a_10\DT\13649268 partial_11\JJ\1740 prevention_12\NN\1073995 of_13\IN\1740 apomorphine-induced_14\JJ\1740 <e2>hyperactivity</e2>_15\NN\14052403 ._16\.\1740
D001058_D002375 NONE calcitonin_0\NN\5413241 injection_1\NN\320852 resulted_2\VBD\2633881 in_3\IN\13603305 a_4\DT\13649268 potentiation_5\NN\13564910 of_6\IN\1740 haloperidol-induced_7\JJ\1740 <e2>catalepsy</e2>_8\NN\14023236 and_9\CC\1740 a_10\DT\13649268 partial_11\JJ\1740 prevention_12\NN\1073995 of_13\IN\1740 <e1>apomorphine-induced</e1>_14\JJ\1740 hyperactivity_15\NN\14052403 ._16\.\1740
D001058_D006948 CID calcitonin_0\NN\5413241 injection_1\NN\320852 resulted_2\VBD\2633881 in_3\IN\13603305 a_4\DT\13649268 potentiation_5\NN\13564910 of_6\IN\1740 haloperidol-induced_7\JJ\1740 catalepsy_8\NN\14023236 and_9\CC\1740 a_10\DT\13649268 partial_11\JJ\1740 prevention_12\NN\1073995 of_13\IN\1740 <e1>apomorphine-induced</e1>_14\JJ\1740 <e2>hyperactivity</e2>_15\NN\14052403 ._16\.\1740
11243580
D008012_D012640 CID the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 nitrergic_3\JJ\1740 system_4\NN\3575240 in_5\IN\13603305 <e1>lidocaine-induced</e1>_6\JJ\1740 <e2>convulsion</e2>_7\NN\14081375 in_8\IN\13603305 the_9\DT\1740 mouse_10\NN\2329401 ._11\.\1740
D008012_D012640 CID the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 n-nitro-l-arginine-methyl_3\NN\1740 ester_4\NN\14727670 (_5\-LRB-\1740 l-name_6\NN\1740 )_7\-RRB-\1740 a_8\DT\13649268 nitric_9\JJ\1740 oxide_10\NN\14818238 (_11\-LRB-\1740 no_12\NN\7204911 )_13\-RRB-\1740 synthase_14\NN\1740 inhibitor_15\NN\20090 and_16\CC\1740 l-arginine_17\NN\1740 ,_18\,\1740 a_19\DT\13649268 no_20\NN\7204911 precursor_21\NN\14580897 ,_22\,\1740 were_23\VBD\836236 investigated_24\VBN\644583 on_25\IN\1740 <e1>lidocaine-induced</e1>_26\JJ\1740 <e2>convulsions</e2>_27\NNS\14081375 ._28\.\1740
D008012_D012640 CID l-name_0\NN\1740 (_1\-LRB-\1740 100_2\CD\13745420 mg/kg_3\NN\1740 ,_4\,\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 diazepam_8\NN\2830852 (_9\-LRB-\1740 2_10\CD\13741022 mg/kg_11\NN\1740 )_12\-RRB-\1740 significantly_13\RB\1740 decreased_14\VBD\169651 the_15\DT\1740 incidence_16\NN\13821570 of_17\IN\1740 <e1>lidocaine</e1>_18\NN\3681148 (_19\-LRB-\1740 50_20\CD\13745420 mg/kg)-induced_21\JJ\1740 <e2>convulsions</e2>_22\NNS\14081375 ._23\.\1740
D008012_D012640 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 the_3\DT\1740 l-arginine_4\NN\1740 treatment_5\NN\654885 increased_6\VBD\169651 the_7\DT\1740 incidence_8\NN\13821570 of_9\IN\1740 <e1>lidocaine</e1>_10\NN\3681148 (_11\-LRB-\1740 80_12\CD\13745420 mg/kg_13\NN\1740 ,_14\,\1740 i.p.)-induced_15\JJ\1740 <e2>convulsions</e2>_16\NNS\14081375 significantly_17\RB\1740 ._18\.\1740
D008012_D012640 CID these_0\DT\1740 results_1\NNS\34213 may_2\MD\15209706 suggest_3\VB\1010118 that_4\IN\1740 no_5\NN\7204911 is_6\VBZ\836236 a_7\DT\13649268 proconvulsant_8\JJ\1740 mediator_9\NN\10351874 in_10\IN\13603305 <e1>lidocaine-induced</e1>_11\JJ\1740 <e2>convulsions</e2>_12\NNS\14081375 ._13\.\1740
D019331_D012640 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>n-nitro-l-arginine-methyl_3\NN\1740 ester</e1>_4\NN\14727670 (_5\-LRB-\1740 l-name_6\NN\1740 )_7\-RRB-\1740 a_8\DT\13649268 nitric_9\JJ\1740 oxide_10\NN\14818238 (_11\-LRB-\1740 no_12\NN\7204911 )_13\-RRB-\1740 synthase_14\NN\1740 inhibitor_15\NN\20090 and_16\CC\1740 l-arginine_17\NN\1740 ,_18\,\1740 a_19\DT\13649268 no_20\NN\7204911 precursor_21\NN\14580897 ,_22\,\1740 were_23\VBD\836236 investigated_24\VBN\644583 on_25\IN\1740 lidocaine-induced_26\JJ\1740 <e2>convulsions</e2>_27\NNS\14081375 ._28\.\1740
D019331_D012640 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 n-nitro-l-arginine-methyl_3\NN\1740 ester_4\NN\14727670 (_5\-LRB-\1740 <e1>l-name</e1>_6\NN\1740 )_7\-RRB-\1740 a_8\DT\13649268 nitric_9\JJ\1740 oxide_10\NN\14818238 (_11\-LRB-\1740 no_12\NN\7204911 )_13\-RRB-\1740 synthase_14\NN\1740 inhibitor_15\NN\20090 and_16\CC\1740 l-arginine_17\NN\1740 ,_18\,\1740 a_19\DT\13649268 no_20\NN\7204911 precursor_21\NN\14580897 ,_22\,\1740 were_23\VBD\836236 investigated_24\VBN\644583 on_25\IN\1740 lidocaine-induced_26\JJ\1740 <e2>convulsions</e2>_27\NNS\14081375 ._28\.\1740
D019331_D012640 NONE <e1>l-name</e1>_0\NN\1740 (_1\-LRB-\1740 100_2\CD\13745420 mg/kg_3\NN\1740 ,_4\,\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 diazepam_8\NN\2830852 (_9\-LRB-\1740 2_10\CD\13741022 mg/kg_11\NN\1740 )_12\-RRB-\1740 significantly_13\RB\1740 decreased_14\VBD\169651 the_15\DT\1740 incidence_16\NN\13821570 of_17\IN\1740 lidocaine_18\NN\3681148 (_19\-LRB-\1740 50_20\CD\13745420 mg/kg)-induced_21\JJ\1740 <e2>convulsions</e2>_22\NNS\14081375 ._23\.\1740
D009569_D012640 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 n-nitro-l-arginine-methyl_3\NN\1740 ester_4\NN\14727670 (_5\-LRB-\1740 l-name_6\NN\1740 )_7\-RRB-\1740 a_8\DT\13649268 <e1>nitric_9\JJ\1740 oxide</e1>_10\NN\14818238 (_11\-LRB-\1740 no_12\NN\7204911 )_13\-RRB-\1740 synthase_14\NN\1740 inhibitor_15\NN\20090 and_16\CC\1740 l-arginine_17\NN\1740 ,_18\,\1740 a_19\DT\13649268 no_20\NN\7204911 precursor_21\NN\14580897 ,_22\,\1740 were_23\VBD\836236 investigated_24\VBN\644583 on_25\IN\1740 lidocaine-induced_26\JJ\1740 <e2>convulsions</e2>_27\NNS\14081375 ._28\.\1740
D009569_D012640 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 n-nitro-l-arginine-methyl_3\NN\1740 ester_4\NN\14727670 (_5\-LRB-\1740 l-name_6\NN\1740 )_7\-RRB-\1740 a_8\DT\13649268 nitric_9\JJ\1740 oxide_10\NN\14818238 (_11\-LRB-\1740 <e1>no</e1>_12\NN\7204911 )_13\-RRB-\1740 synthase_14\NN\1740 inhibitor_15\NN\20090 and_16\CC\1740 l-arginine_17\NN\1740 ,_18\,\1740 a_19\DT\13649268 no_20\NN\7204911 precursor_21\NN\14580897 ,_22\,\1740 were_23\VBD\836236 investigated_24\VBN\644583 on_25\IN\1740 lidocaine-induced_26\JJ\1740 <e2>convulsions</e2>_27\NNS\14081375 ._28\.\1740
D009569_D012640 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 n-nitro-l-arginine-methyl_3\NN\1740 ester_4\NN\14727670 (_5\-LRB-\1740 l-name_6\NN\1740 )_7\-RRB-\1740 a_8\DT\13649268 nitric_9\JJ\1740 oxide_10\NN\14818238 (_11\-LRB-\1740 no_12\NN\7204911 )_13\-RRB-\1740 synthase_14\NN\1740 inhibitor_15\NN\20090 and_16\CC\1740 l-arginine_17\NN\1740 ,_18\,\1740 a_19\DT\13649268 <e1>no</e1>_20\NN\7204911 precursor_21\NN\14580897 ,_22\,\1740 were_23\VBD\836236 investigated_24\VBN\644583 on_25\IN\1740 lidocaine-induced_26\JJ\1740 <e2>convulsions</e2>_27\NNS\14081375 ._28\.\1740
D009569_D012640 NONE these_0\DT\1740 results_1\NNS\34213 may_2\MD\15209706 suggest_3\VB\1010118 that_4\IN\1740 <e1>no</e1>_5\NN\7204911 is_6\VBZ\836236 a_7\DT\13649268 proconvulsant_8\JJ\1740 mediator_9\NN\10351874 in_10\IN\13603305 lidocaine-induced_11\JJ\1740 <e2>convulsions</e2>_12\NNS\14081375 ._13\.\1740
D001120_D012640 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 n-nitro-l-arginine-methyl_3\NN\1740 ester_4\NN\14727670 (_5\-LRB-\1740 l-name_6\NN\1740 )_7\-RRB-\1740 a_8\DT\13649268 nitric_9\JJ\1740 oxide_10\NN\14818238 (_11\-LRB-\1740 no_12\NN\7204911 )_13\-RRB-\1740 synthase_14\NN\1740 inhibitor_15\NN\20090 and_16\CC\1740 <e1>l-arginine</e1>_17\NN\1740 ,_18\,\1740 a_19\DT\13649268 no_20\NN\7204911 precursor_21\NN\14580897 ,_22\,\1740 were_23\VBD\836236 investigated_24\VBN\644583 on_25\IN\1740 lidocaine-induced_26\JJ\1740 <e2>convulsions</e2>_27\NNS\14081375 ._28\.\1740
D001120_D012640 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 the_3\DT\1740 <e1>l-arginine</e1>_4\NN\1740 treatment_5\NN\654885 increased_6\VBD\169651 the_7\DT\1740 incidence_8\NN\13821570 of_9\IN\1740 lidocaine_10\NN\3681148 (_11\-LRB-\1740 80_12\CD\13745420 mg/kg_13\NN\1740 ,_14\,\1740 i.p.)-induced_15\JJ\1740 <e2>convulsions</e2>_16\NNS\14081375 significantly_17\RB\1740 ._18\.\1740
D003975_D012640 NONE l-name_0\NN\1740 (_1\-LRB-\1740 100_2\CD\13745420 mg/kg_3\NN\1740 ,_4\,\1740 i.p._5\RB\1740 )_6\-RRB-\1740 and_7\CC\1740 <e1>diazepam</e1>_8\NN\2830852 (_9\-LRB-\1740 2_10\CD\13741022 mg/kg_11\NN\1740 )_12\-RRB-\1740 significantly_13\RB\1740 decreased_14\VBD\169651 the_15\DT\1740 incidence_16\NN\13821570 of_17\IN\1740 lidocaine_18\NN\3681148 (_19\-LRB-\1740 50_20\CD\13745420 mg/kg)-induced_21\JJ\1740 <e2>convulsions</e2>_22\NNS\14081375 ._23\.\1740
326460
D001539_D007008 CID amelioration_0\NN\248977 of_1\IN\1740 <e1>bendrofluazide-induced</e1>_2\JJ\1740 <e2>hypokalemia</e2>_3\NN\14299637 by_4\IN\1740 timolol_5\CD\2832168 ._6\.\1740
D001539_D007008 CID the_0\DT\1740 beta_1\NN\6828818 adrenergic_2\JJ\1740 blocking_3\NN\562280 drug_4\NN\14778436 ,_5\,\1740 timolol_6\CD\2832168 ,_7\,\1740 tended_8\VBD\2604760 to_9\TO\1740 correct_10\VB\138508 the_11\DT\1740 <e2>hypokalemia</e2>_12\NN\14299637 of_13\IN\1740 short-term_14\JJ\1740 <e1>bendrofluazide</e1>_15\NN\1740 treatment_16\NN\654885 in_17\IN\13603305 6_18\CD\13741022 healthy_19\JJ\1740 male_20\JJ\1740 subjects_21\NNS\6598915 and_22\CC\1740 although_23\IN\1740 the_24\DT\1740 effect_25\NN\34213 was_26\VBD\836236 small_27\JJ\1740 it_28\PRP\6125041 was_29\VBD\836236 significant_30\JJ\1740 ._31\.\1740
D013999_D007008 NONE amelioration_0\NN\248977 of_1\IN\1740 bendrofluazide-induced_2\JJ\1740 <e2>hypokalemia</e2>_3\NN\14299637 by_4\IN\1740 <e1>timolol</e1>_5\CD\2832168 ._6\.\1740
D013999_D007008 NONE the_0\DT\1740 beta_1\NN\6828818 adrenergic_2\JJ\1740 blocking_3\NN\562280 drug_4\NN\14778436 ,_5\,\1740 <e1>timolol</e1>_6\CD\2832168 ,_7\,\1740 tended_8\VBD\2604760 to_9\TO\1740 correct_10\VB\138508 the_11\DT\1740 <e2>hypokalemia</e2>_12\NN\14299637 of_13\IN\1740 short-term_14\JJ\1740 bendrofluazide_15\NN\1740 treatment_16\NN\654885 in_17\IN\13603305 6_18\CD\13741022 healthy_19\JJ\1740 male_20\JJ\1740 subjects_21\NNS\6598915 and_22\CC\1740 although_23\IN\1740 the_24\DT\1740 effect_25\NN\34213 was_26\VBD\836236 small_27\JJ\1740 it_28\PRP\6125041 was_29\VBD\836236 significant_30\JJ\1740 ._31\.\1740
17923537
D005446_D014605 NONE intraocular_0\JJ\1740 pressure_1\NN\11419404 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 <e2>uveitis</e2>_5\NN\14336539 treated_6\VBN\2376958 with_7\IN\1740 <e1>fluocinolone_8\NN\1740 acetonide</e1>_9\NN\1740 implants_10\NNS\4013729 ._11\.\1740
D005446_D014605 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 the_4\DT\1740 incidence_5\NN\13821570 and_6\CC\1740 management_7\NN\1123598 of_8\IN\1740 elevated_9\JJ\1740 intraocular_10\JJ\1740 pressure_11\NN\11419404 (_12\-LRB-\1740 iop_13\NNS\11495041 )_14\-RRB-\1740 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 <e2>uveitis</e2>_18\NN\14336539 treated_19\VBN\2376958 with_20\IN\1740 the_21\DT\1740 <e1>fluocinolone_22\NN\1740 acetonide</e1>_23\NN\1740 (_24\-LRB-\1740 fa_25\NN\6868043 )_26\-RRB-\1740 intravitreal_27\VBP\1740 implant_28\NN\4013729 ._29\.\1740
D005446_D014605 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 the_4\DT\1740 incidence_5\NN\13821570 and_6\CC\1740 management_7\NN\1123598 of_8\IN\1740 elevated_9\JJ\1740 intraocular_10\JJ\1740 pressure_11\NN\11419404 (_12\-LRB-\1740 iop_13\NNS\11495041 )_14\-RRB-\1740 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 <e2>uveitis</e2>_18\NN\14336539 treated_19\VBN\2376958 with_20\IN\1740 the_21\DT\1740 fluocinolone_22\NN\1740 acetonide_23\NN\1740 (_24\-LRB-\1740 <e1>fa</e1>_25\NN\6868043 )_26\-RRB-\1740 intravitreal_27\VBP\1740 implant_28\NN\4013729 ._29\.\1740
D005446_D009798 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 the_4\DT\1740 incidence_5\NN\13821570 and_6\CC\1740 management_7\NN\1123598 of_8\IN\1740 <e2>elevated_9\JJ\1740 intraocular_10\JJ\1740 pressure</e2>_11\NN\11419404 (_12\-LRB-\1740 iop_13\NNS\11495041 )_14\-RRB-\1740 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 uveitis_18\NN\14336539 treated_19\VBN\2376958 with_20\IN\1740 the_21\DT\1740 <e1>fluocinolone_22\NN\1740 acetonide</e1>_23\NN\1740 (_24\-LRB-\1740 fa_25\NN\6868043 )_26\-RRB-\1740 intravitreal_27\VBP\1740 implant_28\NN\4013729 ._29\.\1740
D005446_D009798 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 the_4\DT\1740 incidence_5\NN\13821570 and_6\CC\1740 management_7\NN\1123598 of_8\IN\1740 <e2>elevated_9\JJ\1740 intraocular_10\JJ\1740 pressure</e2>_11\NN\11419404 (_12\-LRB-\1740 iop_13\NNS\11495041 )_14\-RRB-\1740 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 uveitis_18\NN\14336539 treated_19\VBN\2376958 with_20\IN\1740 the_21\DT\1740 fluocinolone_22\NN\1740 acetonide_23\NN\1740 (_24\-LRB-\1740 <e1>fa</e1>_25\NN\6868043 )_26\-RRB-\1740 intravitreal_27\VBP\1740 implant_28\NN\4013729 ._29\.\1740
14736955
D004317_D009401 CID mitochondrial_0\JJ\1740 dna_1\NN\14994328 and_2\CC\1740 its_3\PRP$\6125041 respiratory_4\JJ\1740 chain_5\NN\8457976 products_6\NNS\3076708 are_7\VBP\836236 defective_8\JJ\1740 in_9\IN\13603305 <e1>doxorubicin</e1>_10\NN\2716866 <e2>nephrosis</e2>_11\NN\14304060 ._12\.\1740
D004317_D007674 NONE background_0\NN\4921011 :_1\:\1740 <e1>doxorubicin</e1>_2\NN\2716866 induces_3\VBZ\1627355 a_4\DT\13649268 self-perpetuating_5\JJ\1740 <e2>nephropathy</e2>_6\JJ\1740 characterized_7\VBN\609683 by_8\IN\1740 early_9\JJ\1740 glomerular_10\JJ\1740 and_11\CC\1740 late-onset_12\JJ\1740 tubular_13\JJ\1740 lesions_14\NNS\14204950 in_15\IN\13603305 rats_16\NNS\2329401 ._17\.\1740
D004317_D007674 NONE background_0\NN\4921011 :_1\:\1740 <e1>doxorubicin</e1>_2\NN\2716866 induces_3\VBZ\1627355 a_4\DT\13649268 self-perpetuating_5\JJ\1740 nephropathy_6\JJ\1740 characterized_7\VBN\609683 by_8\IN\1740 early_9\JJ\1740 <e2>glomerular_10\JJ\1740 and_11\CC\1740 late-onset_12\JJ\1740 tubular_13\JJ\1740 lesions</e2>_14\NNS\14204950 in_15\IN\13603305 rats_16\NNS\2329401 ._17\.\1740
D004317_D007674 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 suggest_4\VBP\1010118 an_5\DT\6697703 important_6\JJ\1740 role_7\NN\719494 for_8\IN\1740 quantitative_9\JJ\1740 and_10\CC\1740 qualitative_11\JJ\1740 mtdna_12\NN\1740 alterations_13\NNS\7283608 through_14\IN\1740 the_15\DT\1740 reduction_16\NN\351485 of_17\IN\1740 mtdna-encoded_18\JJ\1740 respiratory_19\JJ\1740 chain_20\NN\8457976 function_21\NN\13783581 and_22\CC\1740 induction_23\NN\7450842 of_24\IN\1740 superoxide_25\NN\14971519 in_26\IN\13603305 <e1>doxorubicin-induced</e1>_27\JJ\1740 <e2>renal_28\JJ\1740 lesions</e2>_29\NNS\14204950 ._30\.\1740
C102006_D007674 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 '_3\``\1740 long-term_4\JJ\1740 '_5\''\1740 group_6\NN\2137 had_7\VBD\2108377 significant_8\JJ\1740 <e2>glomerular_9\JJ\1740 and_10\CC\1740 tubular_11\JJ\1740 lesions</e2>_12\NNS\14204950 ,_13\,\1740 depressed_14\JJ\1740 activities_15\NNS\30358 of_16\IN\1740 mtdna-encoded_17\JJ\1740 nadh_18\NN\1740 dehydrogenase_19\NN\1740 and_20\CC\1740 cytochrome-c_21\NN\1740 oxidase_22\NN\14732946 (_23\-LRB-\1740 cox_24\NN\14732946 )_25\-RRB-\1740 and_26\CC\1740 increased_27\VBN\169651 <e1>citrate</e1>_28\NN\14850483 synthase_29\NN\1740 activity_30\NN\30358 ._31\.\1740
D013481_D007674 NONE among_0\IN\1740 all_1\DT\1740 animals_2\NNS\4475 ,_3\,\1740 <e2>glomerular_4\JJ\1740 and_5\CC\1740 tubular_6\JJ\1740 injury</e2>_7\NN\14052046 were_8\VBD\836236 inversely_9\RB\1740 correlated_10\VBN\2657219 with_11\IN\1740 mtdna_12\NN\1740 levels_13\NNS\4916342 ,_14\,\1740 mtdna-encoded_15\JJ\1740 respiratory_16\JJ\1740 chain_17\NN\8457976 activities_18\NNS\30358 and_19\CC\1740 with_20\IN\1740 the_21\DT\1740 expression_22\NN\4679549 of_23\IN\1740 the_24\DT\1740 mtdna-encoded_25\JJ\1740 respiratory_26\JJ\1740 chain_27\NN\8457976 subunit_28\NN\13604718 cox-i._29\NN\1740 injury_30\NN\14052046 was_31\VBD\836236 positively_32\RB\1740 correlated_33\VBN\2657219 with_34\IN\1740 <e1>superoxide</e1>_35\NN\14971519 production_36\NN\30358 and_37\CC\1740 the_38\DT\1740 activities_39\NNS\30358 of_40\IN\1740 nucleus-encoded_41\JJ\1740 mitochondrial_42\JJ\1740 or_43\CC\3541091 cytoplasmic_44\JJ\1740 enzymes_45\NNS\14723628 ._46\.\1740
D013481_D007674 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 suggest_4\VBP\1010118 an_5\DT\6697703 important_6\JJ\1740 role_7\NN\719494 for_8\IN\1740 quantitative_9\JJ\1740 and_10\CC\1740 qualitative_11\JJ\1740 mtdna_12\NN\1740 alterations_13\NNS\7283608 through_14\IN\1740 the_15\DT\1740 reduction_16\NN\351485 of_17\IN\1740 mtdna-encoded_18\JJ\1740 respiratory_19\JJ\1740 chain_20\NN\8457976 function_21\NN\13783581 and_22\CC\1740 induction_23\NN\7450842 of_24\IN\1740 <e1>superoxide</e1>_25\NN\14971519 in_26\IN\13603305 doxorubicin-induced_27\JJ\1740 <e2>renal_28\JJ\1740 lesions</e2>_29\NNS\14204950 ._30\.\1740
20727411
-1_D011605 NONE neural_0\NNP\1740 correlates_1\VBZ\2657219 of_2\IN\1740 <e1>s-ketamine</e1>_3\NN\1740 induced_4\JJ\1740 <e2>psychosis</e2>_5\NN\14380140 during_6\IN\1740 overt_7\JJ\1740 continuous_8\JJ\1740 verbal_9\JJ\1740 fluency_10\NN\7066659 ._11\.\1740
D016202_D012559 NONE the_0\DT\1740 glutamatergic_1\JJ\1740 <e1>n-methyl-d-aspartate</e1>_2\NN\1740 (_3\-LRB-\1740 nmda_4\NN\1740 )_5\-RRB-\1740 receptor_6\NN\5225602 has_7\VBZ\2108377 been_8\VBN\836236 implicated_9\VBN\2677097 in_10\IN\13603305 the_11\DT\1740 pathophysiology_12\NN\1740 of_13\IN\1740 <e2>schizophrenia</e2>_14\NN\14398067 ._15\.\1740
D016202_D012559 NONE the_0\DT\1740 glutamatergic_1\JJ\1740 n-methyl-d-aspartate_2\NN\1740 (_3\-LRB-\1740 <e1>nmda</e1>_4\NN\1740 )_5\-RRB-\1740 receptor_6\NN\5225602 has_7\VBZ\2108377 been_8\VBN\836236 implicated_9\VBN\2677097 in_10\IN\13603305 the_11\DT\1740 pathophysiology_12\NN\1740 of_13\IN\1740 <e2>schizophrenia</e2>_14\NN\14398067 ._15\.\1740
D016202_D012559 NONE administered_0\VBN\2436349 to_1\TO\1740 healthy_2\JJ\1740 volunteers_3\NNS\10582746 ,_4\,\1740 a_5\DT\13649268 subanesthetic_6\JJ\1740 dose_7\NN\3740161 of_8\IN\1740 the_9\DT\1740 non-competitive_10\JJ\1740 <e1>nmda</e1>_11\NN\1740 receptor_12\NN\5225602 antagonist_13\NN\7846 ketamine_14\NN\3054098 leads_15\VBZ\1752884 to_16\TO\1740 psychopathological_17\JJ\1740 symptoms_18\NNS\5823932 similar_19\JJ\1740 to_20\TO\1740 those_21\DT\1740 observed_22\VBN\2163746 in_23\IN\13603305 <e2>schizophrenia</e2>_24\NN\14398067 ._25\.\1740
D016202_D012559 NONE our_0\PRP$\1740 results_1\NNS\34213 provide_2\VBP\2199590 further_3\JJ\1740 support_4\NN\407535 for_5\IN\1740 the_6\DT\1740 hypothesis_7\NN\7162194 of_8\IN\1740 an_9\DT\6697703 <e1>nmda</e1>_10\NN\1740 receptor_11\NN\5225602 dysfunction_12\NN\14204950 in_13\IN\13603305 the_14\DT\1740 pathophysiology_15\NN\1740 of_16\IN\1740 <e2>schizophrenia</e2>_17\NN\14398067 ._18\.\1740
D007649_D012559 NONE administered_0\VBN\2436349 to_1\TO\1740 healthy_2\JJ\1740 volunteers_3\NNS\10582746 ,_4\,\1740 a_5\DT\13649268 subanesthetic_6\JJ\1740 dose_7\NN\3740161 of_8\IN\1740 the_9\DT\1740 non-competitive_10\JJ\1740 nmda_11\NN\1740 receptor_12\NN\5225602 antagonist_13\NN\7846 <e1>ketamine</e1>_14\NN\3054098 leads_15\VBZ\1752884 to_16\TO\1740 psychopathological_17\JJ\1740 symptoms_18\NNS\5823932 similar_19\JJ\1740 to_20\TO\1740 those_21\DT\1740 observed_22\VBN\2163746 in_23\IN\13603305 <e2>schizophrenia</e2>_24\NN\14398067 ._25\.\1740
D007649_D012559 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 <e2>schizophrenia</e2>_3\NN\14398067 ,_4\,\1740 <e1>ketamine</e1>_5\NN\3054098 exacerbates_6\VBZ\126264 the_7\DT\1740 core_8\NN\7996689 symptoms_9\NNS\5823932 of_10\IN\1740 illness_11\NN\14052046 ,_12\,\1740 supporting_13\VBG\2199590 the_14\DT\1740 hypothesis_15\NN\7162194 of_16\IN\1740 a_17\DT\13649268 glutamatergic_18\JJ\1740 dysfunction_19\NN\14204950 ._20\.\1740
D007649_D012559 NONE <e1>ketamine</e1>_0\NN\3054098 induces_1\VBZ\1627355 activation_2\NN\13561719 changes_3\NNS\7283608 in_4\IN\13603305 healthy_5\JJ\1740 subjects_6\NNS\6598915 similar_7\JJ\1740 to_8\TO\1740 those_9\DT\1740 observed_10\VBN\2163746 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 <e2>schizophrenia</e2>_14\NN\14398067 ,_15\,\1740 particularly_16\RB\1740 in_17\IN\13603305 frontal_18\JJ\1740 and_19\CC\1740 temporal_20\JJ\1740 brain_21\NN\5462674 regions_22\NNS\27167 ._23\.\1740
D007649_D018754 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 schizophrenia_3\NN\14398067 ,_4\,\1740 <e1>ketamine</e1>_5\NN\3054098 exacerbates_6\VBZ\126264 the_7\DT\1740 core_8\NN\7996689 symptoms_9\NNS\5823932 of_10\IN\1740 illness_11\NN\14052046 ,_12\,\1740 supporting_13\VBG\2199590 the_14\DT\1740 hypothesis_15\NN\7162194 of_16\IN\1740 a_17\DT\13649268 <e2>glutamatergic_18\JJ\1740 dysfunction</e2>_19\NN\14204950 ._20\.\1740
D007649_D011605 CID <e1>ketamine</e1>_0\NNP\3054098 elicited_1\VBD\1617192 <e2>psychosis</e2>_2\NN\14380140 like_3\IN\5839024 psychopathology_4\NN\6136258 ._5\.\1740
3969369
D013739_D063646 NONE promotional_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>testosterone</e1>_3\NN\14747587 and_4\CC\1740 dietary_5\JJ\1740 fat_6\NN\14938907 on_7\IN\1740 prostate_8\NN\5329735 <e2>carcinogenesis</e2>_9\NN\1740 in_10\IN\13603305 genetically_11\RB\1740 susceptible_12\JJ\1740 rats_13\NNS\2329401 ._14\.\1740
D013739_D011471 CID conventional_0\JJ\1740 lw_1\NNP\1740 rats_2\NNS\2329401 ,_3\,\1740 implanted_4\VBN\1421622 with_5\IN\1740 <e1>testosterone</e1>_6\NN\14747587 at_7\IN\14622893 age_8\NN\4916342 4_9\CD\13741022 months_10\NNS\15113229 ,_11\,\1740 developed_12\VBD\1753788 a_13\DT\13649268 higher_14\JJR\1740 incidence_15\NN\13821570 of_16\IN\1740 <e2>prostate_17\NN\5329735 cancer</e2>_18\NN\14239425 after_19\IN\1740 an_20\DT\6697703 average_21\JJ\1740 interval_22\NN\33615 of_23\IN\1740 14_24\CD\13745420 months_25\NNS\15113229 :_26\:\1740 24_27\CD\13745420 %_28\NN\1740 had_29\VBD\2108377 developed_30\VBN\1753788 gross_31\JJ\1740 tumors_32\NNS\14234074 ,_33\,\1740 and_34\CC\1740 40_35\CD\13745420 %_36\NN\1740 when_37\WRB\1740 it_38\PRP\6125041 included_39\VBD\690614 microscopic_40\JJ\1740 tumors_41\NNS\14234074 ._42\.\1740
D013739_D011471 CID preliminary_0\JJ\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e1>testosterone-treated</e1>_4\JJ\1740 lw_5\NN\1740 rats_6\NNS\2329401 that_7\WDT\1740 were_8\VBD\836236 fed_9\VBN\1182709 the_10\DT\1740 same_11\JJ\1740 diet_12\NN\7560652 ,_13\,\1740 which_14\WDT\1740 was_15\VBD\836236 supplemented_16\VBN\182406 with_17\IN\1740 corn_18\NN\12141495 oil_19\NN\14938907 up_20\RB\1740 to_21\TO\1740 20_22\CD\13745420 %_23\NN\1740 fat_24\JJ\1740 ,_25\,\1740 developed_26\VBD\1753788 <e2>prostate_27\NN\5329735 cancer</e2>_28\NN\14239425 after_29\IN\1740 intervals_30\NNS\33615 of_31\IN\1740 6_32\CD\13741022 -_33\SYM\1740 12_34\CD\13745420 months_35\NNS\15113229 ._36\.\1740
D013739_D009369 NONE conventional_0\JJ\1740 lw_1\NNP\1740 rats_2\NNS\2329401 ,_3\,\1740 implanted_4\VBN\1421622 with_5\IN\1740 <e1>testosterone</e1>_6\NN\14747587 at_7\IN\14622893 age_8\NN\4916342 4_9\CD\13741022 months_10\NNS\15113229 ,_11\,\1740 developed_12\VBD\1753788 a_13\DT\13649268 higher_14\JJR\1740 incidence_15\NN\13821570 of_16\IN\1740 prostate_17\NN\5329735 cancer_18\NN\14239425 after_19\IN\1740 an_20\DT\6697703 average_21\JJ\1740 interval_22\NN\33615 of_23\IN\1740 14_24\CD\13745420 months_25\NNS\15113229 :_26\:\1740 24_27\CD\13745420 %_28\NN\1740 had_29\VBD\2108377 developed_30\VBN\1753788 gross_31\JJ\1740 <e2>tumors</e2>_32\NNS\14234074 ,_33\,\1740 and_34\CC\1740 40_35\CD\13745420 %_36\NN\1740 when_37\WRB\1740 it_38\PRP\6125041 included_39\VBD\690614 microscopic_40\JJ\1740 tumors_41\NNS\14234074 ._42\.\1740
D013739_D009369 NONE conventional_0\JJ\1740 lw_1\NNP\1740 rats_2\NNS\2329401 ,_3\,\1740 implanted_4\VBN\1421622 with_5\IN\1740 <e1>testosterone</e1>_6\NN\14747587 at_7\IN\14622893 age_8\NN\4916342 4_9\CD\13741022 months_10\NNS\15113229 ,_11\,\1740 developed_12\VBD\1753788 a_13\DT\13649268 higher_14\JJR\1740 incidence_15\NN\13821570 of_16\IN\1740 prostate_17\NN\5329735 cancer_18\NN\14239425 after_19\IN\1740 an_20\DT\6697703 average_21\JJ\1740 interval_22\NN\33615 of_23\IN\1740 14_24\CD\13745420 months_25\NNS\15113229 :_26\:\1740 24_27\CD\13745420 %_28\NN\1740 had_29\VBD\2108377 developed_30\VBN\1753788 gross_31\JJ\1740 tumors_32\NNS\14234074 ,_33\,\1740 and_34\CC\1740 40_35\CD\13745420 %_36\NN\1740 when_37\WRB\1740 it_38\PRP\6125041 included_39\VBD\690614 microscopic_40\JJ\1740 <e2>tumors</e2>_41\NNS\14234074 ._42\.\1740
D013739_D011472 CID conventional_0\JJ\1740 sd_1\NN\1740 rats_2\NNS\2329401 fed_3\VBD\1182709 diet_4\JJ\1740 l-485_5\NN\1740 and_6\CC\1740 treated_7\VBN\2376958 with_8\IN\1740 <e1>testosterone</e1>_9\NN\14747587 developed_10\VBD\1753788 only_11\RB\1740 <e2>prostatitis</e2>_12\NN\14336539 ._13\.\1740
2339463
D015119_D020225 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 42-year-old_3\JJ\1740 woman_4\NN\9605289 who_5\WP\8299493 developed_6\VBD\1753788 superior_7\JJ\1740 <e2>sagittal_8\JJ\1740 and_9\CC\1740 left_10\VBD\120316 transverse_11\JJ\1740 sinus_12\NN\5248181 thrombosis</e2>_13\NN\14100769 associated_14\VBN\628491 with_15\IN\1740 prolonged_16\JJ\1740 <e1>epsilon-aminocaproic_17\JJ\1740 acid</e1>_18\NN\14818238 therapy_19\NN\657604 for_20\IN\1740 menorrhagia_21\NN\13513747 ._22\.\1740
D015119_D020227 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 42-year-old_3\JJ\1740 woman_4\NN\9605289 who_5\WP\8299493 developed_6\VBD\1753788 superior_7\JJ\1740 <e2>sagittal_8\JJ\1740 and_9\CC\1740 left_10\VBD\120316 transverse_11\JJ\1740 sinus_12\NN\5248181 thrombosis</e2>_13\NN\14100769 associated_14\VBN\628491 with_15\IN\1740 prolonged_16\JJ\1740 <e1>epsilon-aminocaproic_17\JJ\1740 acid</e1>_18\NN\14818238 therapy_19\NN\657604 for_20\IN\1740 menorrhagia_21\NN\13513747 ._22\.\1740
D015119_D008595 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 42-year-old_3\JJ\1740 woman_4\NN\9605289 who_5\WP\8299493 developed_6\VBD\1753788 superior_7\JJ\1740 sagittal_8\JJ\1740 and_9\CC\1740 left_10\VBD\120316 transverse_11\JJ\1740 sinus_12\NN\5248181 thrombosis_13\NN\14100769 associated_14\VBN\628491 with_15\IN\1740 prolonged_16\JJ\1740 <e1>epsilon-aminocaproic_17\JJ\1740 acid</e1>_18\NN\14818238 therapy_19\NN\657604 for_20\IN\1740 <e2>menorrhagia</e2>_21\NN\13513747 ._22\.\1740
D015119_D013923 NONE although_0\IN\1740 increased_1\VBN\169651 risk_2\NN\14541044 of_3\IN\1740 <e2>thromboembolic_4\NN\1740 disease</e2>_5\NN\14061805 has_6\VBZ\2108377 been_7\VBN\836236 reported_8\VBN\831651 during_9\IN\1740 treatment_10\NN\654885 with_11\IN\1740 <e1>epsilon-aminocaproic_12\JJ\1740 acid</e1>_13\NN\14818238 ,_14\,\1740 cerebral_15\JJ\1740 sinus_16\NN\5248181 thrombosis_17\NN\14100769 has_18\VBZ\2108377 not_19\RB\1740 been_20\VBN\836236 previously_21\RB\1740 described_22\VBN\1001294 ._23\.\1740
D015119_D012851 NONE although_0\IN\1740 increased_1\VBN\169651 risk_2\NN\14541044 of_3\IN\1740 thromboembolic_4\NN\1740 disease_5\NN\14061805 has_6\VBZ\2108377 been_7\VBN\836236 reported_8\VBN\831651 during_9\IN\1740 treatment_10\NN\654885 with_11\IN\1740 <e1>epsilon-aminocaproic_12\JJ\1740 acid</e1>_13\NN\14818238 ,_14\,\1740 <e2>cerebral_15\JJ\1740 sinus_16\NN\5248181 thrombosis</e2>_17\NN\14100769 has_18\VBZ\2108377 not_19\RB\1740 been_20\VBN\836236 previously_21\RB\1740 described_22\VBN\1001294 ._23\.\1740
8268147
D010396_D017285 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>polymyositis</e2>_3\NN\14350292 in_4\IN\13603305 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 primary_8\JJ\1740 biliary_9\JJ\1740 cirrhosis_10\NN\14116321 treated_11\VBN\2376958 with_12\IN\1740 <e1>d-penicillamine</e1>_13\NN\1740 ._14\.\1740
D010396_D017285 CID <e2>polymyositis/dermatomyositis</e2>_0\NN\1740 can_1\MD\3094503 develop_2\VB\1753788 as_3\IN\14622893 one_4\CD\13741022 of_5\IN\1740 the_6\DT\1740 autoimmune_7\JJ\1740 complications_8\NNS\1073995 of_9\IN\1740 <e1>d-penicillamine</e1>_10\NN\1740 treatment_11\NN\654885 ,_12\,\1740 but_13\CC\1740 its_14\PRP$\6125041 exact_15\JJ\1740 pathogenesis_16\NN\13533470 remains_17\VBZ\2604760 unclear_18\JJ\1740 ._19\.\1740
D010396_D017285 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 primary_5\JJ\1740 biliary_6\JJ\1740 cirrhosis_7\NN\14116321 ,_8\,\1740 who_9\WP\8299493 developed_10\VBD\1753788 <e2>polymyositis</e2>_11\NN\14350292 while_12\IN\15122231 receiving_13\VBG\2210855 <e1>d-penicillamine</e1>_14\NN\1740 therapy_15\NN\657604 ._16\.\1740
D010396_D017285 CID patients_0\NNS\9898892 receiving_1\VBG\2210855 <e1>d-penicillamine</e1>_2\NN\1740 therapy_3\NN\657604 should_4\MD\1740 be_5\VB\836236 followed_6\VBN\1835496 carefully_7\RB\1740 for_8\IN\1740 the_9\DT\1740 development_10\NN\248977 of_11\IN\1740 autoimmune_12\JJ\1740 complications_13\NNS\1073995 like_14\IN\5839024 <e2>polymyositis/dermatomyositis</e2>_15\NN\1740 ._16\.\1740
D010396_D008105 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 polymyositis_3\NN\14350292 in_4\IN\13603305 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 <e2>primary_8\JJ\1740 biliary_9\JJ\1740 cirrhosis</e2>_10\NN\14116321 treated_11\VBN\2376958 with_12\IN\1740 <e1>d-penicillamine</e1>_13\NN\1740 ._14\.\1740
D010396_D008105 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 <e2>primary_5\JJ\1740 biliary_6\JJ\1740 cirrhosis</e2>_7\NN\14116321 ,_8\,\1740 who_9\WP\8299493 developed_10\VBD\1753788 polymyositis_11\NN\14350292 while_12\IN\15122231 receiving_13\VBG\2210855 <e1>d-penicillamine</e1>_14\NN\1740 therapy_15\NN\657604 ._16\.\1740
D010396_D012216 NONE although_0\IN\1740 <e1>d-penicillamine</e1>_1\NN\1740 has_2\VBZ\2108377 been_3\VBN\836236 used_4\VBN\1156834 for_5\IN\1740 many_6\JJ\1740 <e2>rheumatologic_7\JJ\1740 diseases</e2>_8\NNS\14061805 ,_9\,\1740 toxicity_10\NN\13576101 limits_11\VBZ\2510337 its_12\PRP$\6125041 usefulness_13\NN\4723816 in_14\IN\13603305 many_15\JJ\1740 patients_16\NNS\9898892 ._17\.\1740
D010396_D064420 NONE although_0\IN\1740 <e1>d-penicillamine</e1>_1\NN\1740 has_2\VBZ\2108377 been_3\VBN\836236 used_4\VBN\1156834 for_5\IN\1740 many_6\JJ\1740 rheumatologic_7\JJ\1740 diseases_8\NNS\14061805 ,_9\,\1740 <e2>toxicity</e2>_10\NN\13576101 limits_11\VBZ\2510337 its_12\PRP$\6125041 usefulness_13\NN\4723816 in_14\IN\13603305 many_15\JJ\1740 patients_16\NNS\9898892 ._17\.\1740
D010396_D003882 NONE <e2>polymyositis/dermatomyositis</e2>_0\NN\1740 can_1\MD\3094503 develop_2\VB\1753788 as_3\IN\14622893 one_4\CD\13741022 of_5\IN\1740 the_6\DT\1740 autoimmune_7\JJ\1740 complications_8\NNS\1073995 of_9\IN\1740 <e1>d-penicillamine</e1>_10\NN\1740 treatment_11\NN\654885 ,_12\,\1740 but_13\CC\1740 its_14\PRP$\6125041 exact_15\JJ\1740 pathogenesis_16\NN\13533470 remains_17\VBZ\2604760 unclear_18\JJ\1740 ._19\.\1740
D010396_D003882 NONE patients_0\NNS\9898892 receiving_1\VBG\2210855 <e1>d-penicillamine</e1>_2\NN\1740 therapy_3\NN\657604 should_4\MD\1740 be_5\VB\836236 followed_6\VBN\1835496 carefully_7\RB\1740 for_8\IN\1740 the_9\DT\1740 development_10\NN\248977 of_11\IN\1740 autoimmune_12\JJ\1740 complications_13\NNS\1073995 like_14\IN\5839024 <e2>polymyositis/dermatomyositis</e2>_15\NN\1740 ._16\.\1740
9165568
D018967_D009459 CID <e2>neuroleptic_0\JJ\1740 malignant_1\JJ\1740 syndrome</e2>_2\NN\5870365 with_3\IN\1740 <e1>risperidone</e1>_4\NN\1740 ._5\.\1740
D018967_D009459 CID a_0\DT\13649268 73-year-old_1\JJ\1740 woman_2\NN\9605289 developed_3\VBD\1753788 <e2>neuroleptic_4\JJ\1740 malignant_5\JJ\1740 syndrome</e2>_6\NN\5870365 after_7\IN\1740 monotherapy_8\NN\1740 with_9\IN\1740 <e1>risperidone</e1>_10\NN\1740 ._11\.\1740
D018967_D009459 CID it_0\PRP\6125041 appears_1\VBZ\2604760 that_2\IN\1740 the_3\DT\1740 protection_4\NN\407535 from_5\IN\1740 extrapyramidal_6\JJ\1740 side_7\NN\8630039 effects_8\NNS\13245626 observed_9\VBN\2163746 with_10\IN\1740 <e1>risperidone</e1>_11\NN\1740 does_12\VBZ\1640855 not_13\RB\1740 ensure_14\VB\664483 protection_15\NN\407535 from_16\IN\1740 <e2>neuroleptic_17\JJ\1740 malignant_18\JJ\1740 syndrome</e2>_19\NN\5870365 ._20\.\1740
D004298_D009459 NONE <e2>neuroleptic_0\JJ\1740 malignant_1\JJ\1740 syndrome</e2>_2\NN\5870365 is_3\VBZ\836236 thought_4\VBN\670261 to_5\TO\1740 be_6\VB\836236 a_7\DT\13649268 result_8\NN\34213 of_9\IN\1740 <e1>dopamine</e1>_10\NN\14807737 d2_11\NN\1740 receptor_12\NN\5225602 blockade_13\NN\952963 in_14\IN\13603305 the_15\DT\1740 striatum_16\NN\5497363 of_17\IN\1740 the_18\DT\1740 basal_19\JJ\1740 ganglia_20\NN\5462674 ._21\.\1740
D018967_D001480 NONE the_0\DT\1740 high_1\JJ\1740 ratio_2\NN\13815152 is_3\VBZ\836236 believed_4\VBN\686447 to_5\TO\1740 impart_6\VB\952524 the_7\DT\1740 low_8\JJ\1740 frequency_9\NN\15286249 of_10\IN\1740 <e2>extrapyramidal_11\JJ\1740 symptoms</e2>_12\NNS\5823932 with_13\IN\1740 <e1>risperidone</e1>_14\NN\1740 at_15\IN\14622893 low_16\JJ\1740 dosages_17\NNS\13576355 ._18\.\1740
20164825
D008687_D007674 NONE <e1>metformin</e1>_0\NN\2719105 prevents_1\VBZ\1740 experimental_2\JJ\1740 gentamicin-induced_3\JJ\1740 <e2>nephropathy</e2>_4\NN\14573196 by_5\IN\1740 a_6\DT\13649268 mitochondria-dependent_7\JJ\1740 pathway_8\NN\5483677 ._9\.\1740
D008687_D007674 NONE these_0\DT\1740 in_1\FW\13603305 vivo_2\FW\1740 markers_3\NNS\21939 of_4\IN\1740 <e2>kidney_5\NN\5333259 dysfunction</e2>_6\NN\14204950 and_7\CC\1740 their_8\PRP$\1740 correction_9\NN\248977 by_10\IN\1740 <e1>metformin</e1>_11\NN\2719105 were_12\VBD\836236 complemented_13\VBN\2673134 by_14\IN\1740 in_15\FW\13603305 vitro_16\FW\1740 studies_17\NNS\635850 of_18\IN\1740 mitochondrial_19\JJ\1740 function_20\NN\13783581 ._21\.\1740
D008687_D007674 NONE thus_0\RB\1740 ,_1\,\1740 our_2\PRP$\1740 study_3\NN\635850 suggests_4\VBZ\1010118 that_5\IN\1740 pleiotropic_6\JJ\1740 effects_7\NNS\13245626 of_8\IN\1740 <e1>metformin</e1>_9\NN\2719105 can_10\MD\3094503 lessen_11\NN\1740 gentamicin_12\NN\2716866 <e2>nephrotoxicity</e2>_13\NN\1740 and_14\CC\1740 improve_15\VBP\126264 mitochondrial_16\JJ\1740 homeostasis_17\NN\13934900 ._18\.\1740
D005839_D007674 NONE metformin_0\NN\2719105 prevents_1\VBZ\1740 experimental_2\JJ\1740 <e1>gentamicin-induced</e1>_3\JJ\1740 <e2>nephropathy</e2>_4\NN\14573196 by_5\IN\1740 a_6\DT\13649268 mitochondria-dependent_7\JJ\1740 pathway_8\NN\5483677 ._9\.\1740
D005839_D007674 NONE thus_0\RB\1740 ,_1\,\1740 our_2\PRP$\1740 study_3\NN\635850 suggests_4\VBZ\1010118 that_5\IN\1740 pleiotropic_6\JJ\1740 effects_7\NNS\13245626 of_8\IN\1740 metformin_9\NN\2719105 can_10\MD\3094503 lessen_11\NN\1740 <e1>gentamicin</e1>_12\NN\2716866 <e2>nephrotoxicity</e2>_13\NN\1740 and_14\CC\1740 improve_15\VBP\126264 mitochondrial_16\JJ\1740 homeostasis_17\NN\13934900 ._18\.\1740
D008687_D014652 NONE the_0\DT\1740 antidiabetic_1\JJ\1740 drug_2\NN\14778436 <e1>metformin</e1>_3\NN\2719105 can_4\MD\3094503 diminish_5\VB\169651 apoptosis_6\NN\11486178 induced_7\VBN\1627355 by_8\IN\1740 oxidative_9\JJ\1740 stress_10\NN\7083732 in_11\IN\13603305 endothelial_12\JJ\1740 cells_13\NNS\3080309 and_14\CC\1740 prevent_15\VBP\1740 <e2>vascular_16\JJ\1740 dysfunction</e2>_17\NN\14204950 even_18\RB\1740 in_19\IN\13603305 nondiabetic_20\JJ\1740 patients_21\NNS\9898892 ._22\.\1740
D005839_D064420 NONE here_0\RB\1740 we_1\PRP\1740 tested_2\VBD\670261 whether_3\IN\1740 it_4\PRP\6125041 has_5\VBZ\2108377 a_6\DT\13649268 beneficial_7\JJ\1740 effect_8\NN\34213 in_9\IN\13603305 a_10\DT\13649268 rat_11\NN\2329401 model_12\NN\5888929 of_13\IN\1740 <e1>gentamicin</e1>_14\NN\2716866 <e2>toxicity</e2>_15\NN\13576101 ._16\.\1740
D008687_D058186 NONE <e1>metformin</e1>_0\NN\2719105 treatment_1\NN\654885 fully_2\RB\1740 blocked_3\VBD\1476483 gentamicin-mediated_4\JJ\1740 <e2>acute_5\JJ\1740 renal_6\JJ\1740 failure</e2>_7\NN\66216 ._8\.\1740
D005839_D058186 CID metformin_0\NN\2719105 treatment_1\NN\654885 fully_2\RB\1740 blocked_3\VBD\1476483 <e1>gentamicin-mediated</e1>_4\JJ\1740 <e2>acute_5\JJ\1740 renal_6\JJ\1740 failure</e2>_7\NN\66216 ._8\.\1740
6728084
D000617_D007674 NONE <e2>nephrotoxic</e2>_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>aminoglycoside</e1>_3\NN\1740 treatment_4\NN\654885 on_5\IN\1740 renal_6\JJ\1740 protein_7\NN\14944888 reabsorption_8\NN\13526110 and_9\CC\1740 accumulation_10\NN\13497135 ._11\.\1740
D000617_D007674 NONE thus_0\RB\1740 ,_1\,\1740 <e1>aminoglycosides</e1>_2\NNS\1740 may_3\MD\15209706 act_4\VB\1619354 as_5\IN\14622893 nephrotoxicants_6\NNS\1740 at_7\IN\14622893 glomerular_8\JJ\1740 and/or_9\CC\1740 tubular_10\JJ\1740 level_11\NN\4916342 inducing_12\VBG\1627355 <e2>impairment_13\NN\7296428 of_14\IN\1740 renal_15\JJ\1740 reabsorption</e2>_16\NN\13526110 and_17\CC\1740 accumulation_18\NN\13497135 of_19\IN\1740 proteins_20\NNS\14944888 ._21\.\1740
625456
D002119_D006934 CID one_0\CD\13741022 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 <e2>hypercalcaemia</e2>_4\NN\14299637 and_5\CC\1740 two_6\CD\13741022 of_7\IN\1740 recurrent_8\JJ\1740 nephrolithiasis_9\NN\14115914 are_10\VBP\836236 reported_11\VBN\831651 in_12\IN\13603305 patients_13\NNS\9898892 who_14\WP\8299493 had_15\VBD\2108377 regularly_16\RB\1740 consumed_17\VBN\1168468 large_18\JJ\1740 amounts_19\NNS\13329641 of_20\IN\1740 <e1>calcium_21\NN\14625458 carbon-ate-sodium</e1>_22\NN\1740 bicarbonate_23\VBP\1740 powders_24\NNS\15046900 for_25\IN\1740 more_26\JJR\1740 than_27\IN\1740 20_28\CD\13745420 years_29\NNS\15144371 ._30\.\1740
D002119_D053040 CID one_0\CD\13741022 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 hypercalcaemia_4\NN\14299637 and_5\CC\1740 two_6\CD\13741022 of_7\IN\1740 recurrent_8\JJ\1740 <e2>nephrolithiasis</e2>_9\NN\14115914 are_10\VBP\836236 reported_11\VBN\831651 in_12\IN\13603305 patients_13\NNS\9898892 who_14\WP\8299493 had_15\VBD\2108377 regularly_16\RB\1740 consumed_17\VBN\1168468 large_18\JJ\1740 amounts_19\NNS\13329641 of_20\IN\1740 <e1>calcium_21\NN\14625458 carbon-ate-sodium</e1>_22\NN\1740 bicarbonate_23\VBP\1740 powders_24\NNS\15046900 for_25\IN\1740 more_26\JJR\1740 than_27\IN\1740 20_28\CD\13745420 years_29\NNS\15144371 ._30\.\1740
D017693_D006934 CID one_0\CD\13741022 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 <e2>hypercalcaemia</e2>_4\NN\14299637 and_5\CC\1740 two_6\CD\13741022 of_7\IN\1740 recurrent_8\JJ\1740 nephrolithiasis_9\NN\14115914 are_10\VBP\836236 reported_11\VBN\831651 in_12\IN\13603305 patients_13\NNS\9898892 who_14\WP\8299493 had_15\VBD\2108377 regularly_16\RB\1740 consumed_17\VBN\1168468 large_18\JJ\1740 amounts_19\NNS\13329641 of_20\IN\1740 calcium_21\NN\14625458 <e1>carbon-ate-sodium_22\NN\1740 bicarbonate</e1>_23\VBP\1740 powders_24\NNS\15046900 for_25\IN\1740 more_26\JJR\1740 than_27\IN\1740 20_28\CD\13745420 years_29\NNS\15144371 ._30\.\1740
D017693_D053040 CID one_0\CD\13741022 case_1\NN\7283608 of_2\IN\1740 acute_3\JJ\1740 hypercalcaemia_4\NN\14299637 and_5\CC\1740 two_6\CD\13741022 of_7\IN\1740 recurrent_8\JJ\1740 <e2>nephrolithiasis</e2>_9\NN\14115914 are_10\VBP\836236 reported_11\VBN\831651 in_12\IN\13603305 patients_13\NNS\9898892 who_14\WP\8299493 had_15\VBD\2108377 regularly_16\RB\1740 consumed_17\VBN\1168468 large_18\JJ\1740 amounts_19\NNS\13329641 of_20\IN\1740 calcium_21\NN\14625458 <e1>carbon-ate-sodium_22\NN\1740 bicarbonate</e1>_23\VBP\1740 powders_24\NNS\15046900 for_25\IN\1740 more_26\JJR\1740 than_27\IN\1740 20_28\CD\13745420 years_29\NNS\15144371 ._30\.\1740
18363626
D020927_D001919 CID although_0\IN\1740 <e1>dexmedetomidine</e1>_1\NN\1740 sedation_2\NN\14034177 was_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 a_6\DT\13649268 16_7\CD\13745420 %_8\NN\1740 incidence_9\NN\13821570 of_10\IN\1740 <e2>bradycardia</e2>_11\NN\14110674 ,_12\,\1740 all_13\DT\1740 concomitant_14\JJ\1740 mean_15\VBP\928630 arterial_16\JJ\1740 blood_17\NN\5397468 pressures_18\NNS\11419404 were_19\VBD\836236 within_20\IN\1740 20_21\CD\13745420 %_22\NN\1740 of_23\IN\1740 age-adjusted_24\JJ\1740 normal_25\JJ\1740 range_26\NN\5123416 and_27\CC\1740 oxygen_28\NN\14622893 saturations_29\NNS\13534954 were_30\VBD\836236 95_31\CD\1740 %_32\NN\1740 or_33\CC\3541091 higher_34\JJR\1740 ._35\.\1740
D010100_D001919 NONE although_0\IN\1740 dexmedetomidine_1\NN\1740 sedation_2\NN\14034177 was_3\VBD\836236 associated_4\VBN\628491 with_5\IN\1740 a_6\DT\13649268 16_7\CD\13745420 %_8\NN\1740 incidence_9\NN\13821570 of_10\IN\1740 <e2>bradycardia</e2>_11\NN\14110674 ,_12\,\1740 all_13\DT\1740 concomitant_14\JJ\1740 mean_15\VBP\928630 arterial_16\JJ\1740 blood_17\NN\5397468 pressures_18\NNS\11419404 were_19\VBD\836236 within_20\IN\1740 20_21\CD\13745420 %_22\NN\1740 of_23\IN\1740 age-adjusted_24\JJ\1740 normal_25\JJ\1740 range_26\NN\5123416 and_27\CC\1740 <e1>oxygen</e1>_28\NN\14622893 saturations_29\NNS\13534954 were_30\VBD\836236 95_31\CD\1740 %_32\NN\1740 or_33\CC\3541091 higher_34\JJR\1740 ._35\.\1740
1286498
D005442_D009325 CID the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 were_5\VBD\836236 <e2>nausea</e2>_6\JJ\1740 and_7\CC\1740 vomiting_8\NN\116687 in_9\IN\13603305 the_10\DT\1740 <e1>flumazenil</e1>_11\NN\1740 group_12\NN\2137 and_13\CC\1740 nausea_14\NN\14299637 and_15\CC\1740 injection-site_16\JJ\1740 pain_17\NN\14299637 in_18\IN\13603305 the_19\DT\1740 placebo_20\NN\3740161 group_21\NN\2137 ._22\.\1740
D005442_D009325 CID the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 were_5\VBD\836236 nausea_6\JJ\1740 and_7\CC\1740 vomiting_8\NN\116687 in_9\IN\13603305 the_10\DT\1740 <e1>flumazenil</e1>_11\NN\1740 group_12\NN\2137 and_13\CC\1740 <e2>nausea</e2>_14\NN\14299637 and_15\CC\1740 injection-site_16\JJ\1740 pain_17\NN\14299637 in_18\IN\13603305 the_19\DT\1740 placebo_20\NN\3740161 group_21\NN\2137 ._22\.\1740
D005442_D014839 CID the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 were_5\VBD\836236 nausea_6\JJ\1740 and_7\CC\1740 <e2>vomiting</e2>_8\NN\116687 in_9\IN\13603305 the_10\DT\1740 <e1>flumazenil</e1>_11\NN\1740 group_12\NN\2137 and_13\CC\1740 nausea_14\NN\14299637 and_15\CC\1740 injection-site_16\JJ\1740 pain_17\NN\14299637 in_18\IN\13603305 the_19\DT\1740 placebo_20\NN\3740161 group_21\NN\2137 ._22\.\1740
D005442_D010146 NONE the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 were_5\VBD\836236 nausea_6\JJ\1740 and_7\CC\1740 vomiting_8\NN\116687 in_9\IN\13603305 the_10\DT\1740 <e1>flumazenil</e1>_11\NN\1740 group_12\NN\2137 and_13\CC\1740 nausea_14\NN\14299637 and_15\CC\1740 injection-site_16\JJ\1740 <e2>pain</e2>_17\NN\14299637 in_18\IN\13603305 the_19\DT\1740 placebo_20\NN\3740161 group_21\NN\2137 ._22\.\1740
8599504
D004329_D000799 CID <e2>angioedema</e2>_0\NNP\14316714 associated_1\VBN\628491 with_2\IN\1740 <e1>droperidol</e1>_3\NN\1740 administration_4\NN\1133281 ._5\.\1740
D004329_D000799 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 previously_6\RB\1740 healthy_7\JJ\1740 19-year-old_8\JJ\1740 man_9\NN\9605289 with_10\IN\1740 no_11\DT\7204911 known_12\JJ\1740 drug_13\NN\14778436 allergies_14\NNS\14533203 in_15\IN\13603305 whom_16\WP\1740 <e2>angioedema</e2>_17\VBP\1740 with_18\IN\1740 significant_19\JJ\1740 tongue_20\NN\5301392 swelling_21\NN\14315071 and_22\CC\1740 protrusion_23\NN\13919685 developed_24\VBD\1753788 within_25\IN\1740 10_26\CD\13745420 minutes_27\NNS\6502378 of_28\IN\1740 the_29\DT\1740 administration_30\NN\1133281 of_31\IN\1740 a_32\DT\13649268 single_33\JJ\1740 iv_34\CD\13741022 dose_35\NN\3740161 of_36\IN\1740 <e1>droperidol</e1>_37\NN\1740 ._38\.\1740
D004329_D004342 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 previously_6\RB\1740 healthy_7\JJ\1740 19-year-old_8\JJ\1740 man_9\NN\9605289 with_10\IN\1740 no_11\DT\7204911 known_12\JJ\1740 <e2>drug_13\NN\14778436 allergies</e2>_14\NNS\14533203 in_15\IN\13603305 whom_16\WP\1740 angioedema_17\VBP\1740 with_18\IN\1740 significant_19\JJ\1740 tongue_20\NN\5301392 swelling_21\NN\14315071 and_22\CC\1740 protrusion_23\NN\13919685 developed_24\VBD\1753788 within_25\IN\1740 10_26\CD\13745420 minutes_27\NNS\6502378 of_28\IN\1740 the_29\DT\1740 administration_30\NN\1133281 of_31\IN\1740 a_32\DT\13649268 single_33\JJ\1740 iv_34\CD\13741022 dose_35\NN\3740161 of_36\IN\1740 <e1>droperidol</e1>_37\NN\1740 ._38\.\1740
D004329_D014060 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 previously_6\RB\1740 healthy_7\JJ\1740 19-year-old_8\JJ\1740 man_9\NN\9605289 with_10\IN\1740 no_11\DT\7204911 known_12\JJ\1740 drug_13\NN\14778436 allergies_14\NNS\14533203 in_15\IN\13603305 whom_16\WP\1740 angioedema_17\VBP\1740 with_18\IN\1740 significant_19\JJ\1740 <e2>tongue_20\NN\5301392 swelling</e2>_21\NN\14315071 and_22\CC\1740 protrusion_23\NN\13919685 developed_24\VBD\1753788 within_25\IN\1740 10_26\CD\13745420 minutes_27\NNS\6502378 of_28\IN\1740 the_29\DT\1740 administration_30\NN\1133281 of_31\IN\1740 a_32\DT\13649268 single_33\JJ\1740 iv_34\CD\13741022 dose_35\NN\3740161 of_36\IN\1740 <e1>droperidol</e1>_37\NN\1740 ._38\.\1740
D004329_D004487 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 previously_6\RB\1740 healthy_7\JJ\1740 19-year-old_8\JJ\1740 man_9\NN\9605289 with_10\IN\1740 no_11\DT\7204911 known_12\JJ\1740 drug_13\NN\14778436 allergies_14\NNS\14533203 in_15\IN\13603305 whom_16\WP\1740 angioedema_17\VBP\1740 with_18\IN\1740 significant_19\JJ\1740 <e2>tongue_20\NN\5301392 swelling</e2>_21\NN\14315071 and_22\CC\1740 protrusion_23\NN\13919685 developed_24\VBD\1753788 within_25\IN\1740 10_26\CD\13745420 minutes_27\NNS\6502378 of_28\IN\1740 the_29\DT\1740 administration_30\NN\1133281 of_31\IN\1740 a_32\DT\13649268 single_33\JJ\1740 iv_34\CD\13741022 dose_35\NN\3740161 of_36\IN\1740 <e1>droperidol</e1>_37\NN\1740 ._38\.\1740
9514561
D002211_D010146 CID experimental_0\JJ\1740 cranial_1\JJ\1740 <e2>pain</e2>_2\NN\14299637 elicited_3\VBN\1617192 by_4\IN\1740 <e1>capsaicin</e1>_5\NN\15032661 :_6\:\1740 a_7\DT\13649268 pet_8\NN\15388 study_9\NN\635850 ._10\.\1740
D002211_D010146 CID a_0\DT\13649268 small_1\JJ\1740 amount_2\NN\13329641 of_3\IN\1740 <e1>capsaicin</e1>_4\NN\15032661 was_5\VBD\836236 administered_6\VBN\2436349 subcutaneously_7\RB\1740 in_8\IN\13603305 the_9\DT\1740 right_10\JJ\1740 forehead_11\NN\5601758 to_12\TO\1740 evoke_13\VB\1617192 a_14\DT\13649268 burning_15\VBG\1564144 <e2>painful</e2>_16\JJ\1740 sensation_17\NN\5708432 in_18\IN\13603305 the_19\DT\1740 first_20\JJ\1740 division_21\NN\8190754 of_22\IN\1740 the_23\DT\1740 trigeminal_24\JJ\1740 nerve_25\NN\5475681 ._26\.\1740
9848575
D018943_D009202 NONE chronic_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 a_3\DT\13649268 novel_4\JJ\1740 synthetic_5\JJ\1740 <e1>anthracycline</e1>_6\NN\1740 derivative_7\NN\5802185 (_8\-LRB-\1740 sm-5887_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 normal_12\JJ\1740 heart_13\NN\5919034 and_14\CC\1740 doxorubicin-induced_15\JJ\1740 <e2>cardiomyopathy</e2>_16\JJ\1740 in_17\IN\13603305 beagle_18\JJ\1740 dogs_19\NNS\2083346 ._20\.\1740
C055866_D009202 NONE chronic_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 a_3\DT\13649268 novel_4\JJ\1740 synthetic_5\JJ\1740 anthracycline_6\NN\1740 derivative_7\NN\5802185 (_8\-LRB-\1740 <e1>sm-5887</e1>_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 normal_12\JJ\1740 heart_13\NN\5919034 and_14\CC\1740 doxorubicin-induced_15\JJ\1740 <e2>cardiomyopathy</e2>_16\JJ\1740 in_17\IN\13603305 beagle_18\JJ\1740 dogs_19\NNS\2083346 ._20\.\1740
C055866_D009202 NONE animals_0\NNS\4475 which_1\WDT\1740 received_2\VBD\2210855 over_3\RB\1740 six_4\CD\13741022 courses_5\NNS\883297 of_6\IN\1740 doxorubicin_7\NN\2716866 demonstrated_8\VBD\2137132 the_9\DT\1740 electrocardiogram_10\NN\7000195 (_11\-LRB-\1740 ecg_12\NN\7000195 )_13\-RRB-\1740 changes_14\NNS\7283608 ,_15\,\1740 decrease_16\NN\7296428 of_17\IN\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 high-grade_21\JJ\1740 histopathological_22\JJ\1740 <e2>cardiomyopathy</e2>_23\NN\14103288 ,_24\,\1740 while_25\IN\15122231 animals_26\NNS\4475 which_27\WDT\1740 were_28\VBD\836236 terminally_29\RB\1740 sacrificed_30\VBN\2316304 after_31\IN\1740 the_32\DT\1740 <e1>sm-5887</e1>_33\JJ\1740 administration_34\NN\1133281 did_35\VBD\1640855 not_36\RB\1740 show_37\VB\2137132 any_38\DT\1740 changes_39\NNS\7283608 in_40\IN\13603305 ecg_41\NNP\7000195 ,_42\,\1740 blood_43\NN\5397468 pressure_44\NN\11419404 and_45\CC\1740 histopathological_46\JJ\1740 examinations_47\NNS\633864 ._48\.\1740
C055866_D009202 NONE to_0\TO\1740 examine_1\VB\789138 a_2\DT\13649268 possibly_3\RB\1740 deteriorating_4\VBG\208836 cardiotoxic_5\JJ\1740 effect_6\NN\34213 of_7\IN\1740 <e1>sm-5887</e1>_8\NN\1740 ,_9\,\1740 low-grade_10\JJ\1740 <e2>cardiomyopathy</e2>_11\NN\14103288 was_12\VBD\836236 induced_13\VBN\1627355 in_14\IN\13603305 dogs_15\NNS\2083346 by_16\IN\1740 four_17\CD\13741022 courses_18\NNS\883297 of_19\IN\1740 doxorubicin_20\NN\2716866 (_21\-LRB-\1740 1.5_22\CD\1740 mg/kg_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
C055866_D009202 NONE on_0\IN\1740 the_1\DT\1740 contrary_2\NN\13854649 ,_3\,\1740 the_4\DT\1740 <e1>sm-5887</e1>_5\NN\1740 treatment_6\NN\654885 did_7\VBD\1640855 not_8\RB\1740 progress_9\VB\252019 the_10\DT\1740 grade_11\NN\7975026 of_12\IN\1740 <e2>cardiomyopathy</e2>_13\JJ\1740 ._14\.\1740
D004317_D009202 CID chronic_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 a_3\DT\13649268 novel_4\JJ\1740 synthetic_5\JJ\1740 anthracycline_6\NN\1740 derivative_7\NN\5802185 (_8\-LRB-\1740 sm-5887_9\NN\1740 )_10\-RRB-\1740 on_11\IN\1740 normal_12\JJ\1740 heart_13\NN\5919034 and_14\CC\1740 <e1>doxorubicin-induced</e1>_15\JJ\1740 <e2>cardiomyopathy</e2>_16\JJ\1740 in_17\IN\13603305 beagle_18\JJ\1740 dogs_19\NNS\2083346 ._20\.\1740
D004317_D009202 CID animals_0\NNS\4475 which_1\WDT\1740 received_2\VBD\2210855 over_3\RB\1740 six_4\CD\13741022 courses_5\NNS\883297 of_6\IN\1740 <e1>doxorubicin</e1>_7\NN\2716866 demonstrated_8\VBD\2137132 the_9\DT\1740 electrocardiogram_10\NN\7000195 (_11\-LRB-\1740 ecg_12\NN\7000195 )_13\-RRB-\1740 changes_14\NNS\7283608 ,_15\,\1740 decrease_16\NN\7296428 of_17\IN\1740 blood_18\NN\5397468 pressure_19\NN\11419404 and_20\CC\1740 high-grade_21\JJ\1740 histopathological_22\JJ\1740 <e2>cardiomyopathy</e2>_23\NN\14103288 ,_24\,\1740 while_25\IN\15122231 animals_26\NNS\4475 which_27\WDT\1740 were_28\VBD\836236 terminally_29\RB\1740 sacrificed_30\VBN\2316304 after_31\IN\1740 the_32\DT\1740 sm-5887_33\JJ\1740 administration_34\NN\1133281 did_35\VBD\1640855 not_36\RB\1740 show_37\VB\2137132 any_38\DT\1740 changes_39\NNS\7283608 in_40\IN\13603305 ecg_41\NNP\7000195 ,_42\,\1740 blood_43\NN\5397468 pressure_44\NN\11419404 and_45\CC\1740 histopathological_46\JJ\1740 examinations_47\NNS\633864 ._48\.\1740
D004317_D009202 CID to_0\TO\1740 examine_1\VB\789138 a_2\DT\13649268 possibly_3\RB\1740 deteriorating_4\VBG\208836 cardiotoxic_5\JJ\1740 effect_6\NN\34213 of_7\IN\1740 sm-5887_8\NN\1740 ,_9\,\1740 low-grade_10\JJ\1740 <e2>cardiomyopathy</e2>_11\NN\14103288 was_12\VBD\836236 induced_13\VBN\1627355 in_14\IN\13603305 dogs_15\NNS\2083346 by_16\IN\1740 four_17\CD\13741022 courses_18\NNS\883297 of_19\IN\1740 <e1>doxorubicin</e1>_20\NN\2716866 (_21\-LRB-\1740 1.5_22\CD\1740 mg/kg_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
C055866_D066126 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 investigate_5\VB\644583 the_6\DT\1740 chronic_7\JJ\1740 <e2>cardiotoxic</e2>_8\JJ\1740 potential_9\NN\14481929 of_10\IN\1740 <e1>sm-5887</e1>_11\NN\1740 and_12\CC\1740 a_13\DT\13649268 possible_14\JJ\1740 deteriorating_15\VBG\208836 effect_16\NN\34213 of_17\IN\1740 sm-5887_18\NN\1740 on_19\IN\1740 low-grade_20\JJ\1740 cardiotoxicity_21\NN\1740 pre-induced_22\VBN\1740 by_23\IN\1740 doxorubicin_24\NN\2716866 in_25\IN\13603305 beagle_26\JJ\1740 dogs_27\NNS\2083346 ._28\.\1740
C055866_D066126 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 investigate_5\VB\644583 the_6\DT\1740 chronic_7\JJ\1740 cardiotoxic_8\JJ\1740 potential_9\NN\14481929 of_10\IN\1740 <e1>sm-5887</e1>_11\NN\1740 and_12\CC\1740 a_13\DT\13649268 possible_14\JJ\1740 deteriorating_15\VBG\208836 effect_16\NN\34213 of_17\IN\1740 sm-5887_18\NN\1740 on_19\IN\1740 low-grade_20\JJ\1740 <e2>cardiotoxicity</e2>_21\NN\1740 pre-induced_22\VBN\1740 by_23\IN\1740 doxorubicin_24\NN\2716866 in_25\IN\13603305 beagle_26\JJ\1740 dogs_27\NNS\2083346 ._28\.\1740
C055866_D066126 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 investigate_5\VB\644583 the_6\DT\1740 chronic_7\JJ\1740 <e2>cardiotoxic</e2>_8\JJ\1740 potential_9\NN\14481929 of_10\IN\1740 sm-5887_11\NN\1740 and_12\CC\1740 a_13\DT\13649268 possible_14\JJ\1740 deteriorating_15\VBG\208836 effect_16\NN\34213 of_17\IN\1740 <e1>sm-5887</e1>_18\NN\1740 on_19\IN\1740 low-grade_20\JJ\1740 cardiotoxicity_21\NN\1740 pre-induced_22\VBN\1740 by_23\IN\1740 doxorubicin_24\NN\2716866 in_25\IN\13603305 beagle_26\JJ\1740 dogs_27\NNS\2083346 ._28\.\1740
C055866_D066126 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 investigate_5\VB\644583 the_6\DT\1740 chronic_7\JJ\1740 cardiotoxic_8\JJ\1740 potential_9\NN\14481929 of_10\IN\1740 sm-5887_11\NN\1740 and_12\CC\1740 a_13\DT\13649268 possible_14\JJ\1740 deteriorating_15\VBG\208836 effect_16\NN\34213 of_17\IN\1740 <e1>sm-5887</e1>_18\NN\1740 on_19\IN\1740 low-grade_20\JJ\1740 <e2>cardiotoxicity</e2>_21\NN\1740 pre-induced_22\VBN\1740 by_23\IN\1740 doxorubicin_24\NN\2716866 in_25\IN\13603305 beagle_26\JJ\1740 dogs_27\NNS\2083346 ._28\.\1740
C055866_D066126 NONE to_0\TO\1740 examine_1\VB\789138 a_2\DT\13649268 possibly_3\RB\1740 deteriorating_4\VBG\208836 <e2>cardiotoxic</e2>_5\JJ\1740 effect_6\NN\34213 of_7\IN\1740 <e1>sm-5887</e1>_8\NN\1740 ,_9\,\1740 low-grade_10\JJ\1740 cardiomyopathy_11\NN\14103288 was_12\VBD\836236 induced_13\VBN\1627355 in_14\IN\13603305 dogs_15\NNS\2083346 by_16\IN\1740 four_17\CD\13741022 courses_18\NNS\883297 of_19\IN\1740 doxorubicin_20\NN\2716866 (_21\-LRB-\1740 1.5_22\CD\1740 mg/kg_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
C055866_D066126 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>sm-5887</e1>_3\NN\1740 does_4\VBZ\1640855 not_5\RB\1740 have_6\VB\2108377 any_7\DT\1740 potential_8\NN\14481929 of_9\IN\1740 chronic_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 and_12\CC\1740 deteriorating_13\VBG\208836 effect_14\NN\34213 on_15\IN\1740 doxorubicin-induced_16\JJ\1740 cardiotoxicity_17\NN\1740 in_18\IN\13603305 dogs_19\NNS\2083346 ._20\.\1740
C055866_D066126 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>sm-5887</e1>_3\NN\1740 does_4\VBZ\1640855 not_5\RB\1740 have_6\VB\2108377 any_7\DT\1740 potential_8\NN\14481929 of_9\IN\1740 chronic_10\JJ\1740 cardiotoxicity_11\NN\1740 and_12\CC\1740 deteriorating_13\VBG\208836 effect_14\NN\34213 on_15\IN\1740 doxorubicin-induced_16\JJ\1740 <e2>cardiotoxicity</e2>_17\NN\1740 in_18\IN\13603305 dogs_19\NNS\2083346 ._20\.\1740
D004317_D066126 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 investigate_5\VB\644583 the_6\DT\1740 chronic_7\JJ\1740 <e2>cardiotoxic</e2>_8\JJ\1740 potential_9\NN\14481929 of_10\IN\1740 sm-5887_11\NN\1740 and_12\CC\1740 a_13\DT\13649268 possible_14\JJ\1740 deteriorating_15\VBG\208836 effect_16\NN\34213 of_17\IN\1740 sm-5887_18\NN\1740 on_19\IN\1740 low-grade_20\JJ\1740 cardiotoxicity_21\NN\1740 pre-induced_22\VBN\1740 by_23\IN\1740 <e1>doxorubicin</e1>_24\NN\2716866 in_25\IN\13603305 beagle_26\JJ\1740 dogs_27\NNS\2083346 ._28\.\1740
D004317_D066126 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 investigate_5\VB\644583 the_6\DT\1740 chronic_7\JJ\1740 cardiotoxic_8\JJ\1740 potential_9\NN\14481929 of_10\IN\1740 sm-5887_11\NN\1740 and_12\CC\1740 a_13\DT\13649268 possible_14\JJ\1740 deteriorating_15\VBG\208836 effect_16\NN\34213 of_17\IN\1740 sm-5887_18\NN\1740 on_19\IN\1740 low-grade_20\JJ\1740 <e2>cardiotoxicity</e2>_21\NN\1740 pre-induced_22\VBN\1740 by_23\IN\1740 <e1>doxorubicin</e1>_24\NN\2716866 in_25\IN\13603305 beagle_26\JJ\1740 dogs_27\NNS\2083346 ._28\.\1740
D004317_D066126 NONE to_0\TO\1740 examine_1\VB\789138 a_2\DT\13649268 possibly_3\RB\1740 deteriorating_4\VBG\208836 <e2>cardiotoxic</e2>_5\JJ\1740 effect_6\NN\34213 of_7\IN\1740 sm-5887_8\NN\1740 ,_9\,\1740 low-grade_10\JJ\1740 cardiomyopathy_11\NN\14103288 was_12\VBD\836236 induced_13\VBN\1627355 in_14\IN\13603305 dogs_15\NNS\2083346 by_16\IN\1740 four_17\CD\13741022 courses_18\NNS\883297 of_19\IN\1740 <e1>doxorubicin</e1>_20\NN\2716866 (_21\-LRB-\1740 1.5_22\CD\1740 mg/kg_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D004317_D066126 NONE the_0\DT\1740 low-grade_1\JJ\1740 <e2>cardiotoxic</e2>_2\JJ\1740 changes_3\NNS\7283608 were_4\VBD\836236 enhanced_5\VBN\227165 by_6\IN\1740 the_7\DT\1740 additional_8\JJ\1740 <e1>doxorubicin</e1>_9\NN\2716866 treatment_10\NN\654885 ._11\.\1740
D004317_D066126 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 sm-5887_3\NN\1740 does_4\VBZ\1640855 not_5\RB\1740 have_6\VB\2108377 any_7\DT\1740 potential_8\NN\14481929 of_9\IN\1740 chronic_10\JJ\1740 <e2>cardiotoxicity</e2>_11\NN\1740 and_12\CC\1740 deteriorating_13\VBG\208836 effect_14\NN\34213 on_15\IN\1740 <e1>doxorubicin-induced</e1>_16\JJ\1740 cardiotoxicity_17\NN\1740 in_18\IN\13603305 dogs_19\NNS\2083346 ._20\.\1740
D004317_D066126 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 sm-5887_3\NN\1740 does_4\VBZ\1640855 not_5\RB\1740 have_6\VB\2108377 any_7\DT\1740 potential_8\NN\14481929 of_9\IN\1740 chronic_10\JJ\1740 cardiotoxicity_11\NN\1740 and_12\CC\1740 deteriorating_13\VBG\208836 effect_14\NN\34213 on_15\IN\1740 <e1>doxorubicin-induced</e1>_16\JJ\1740 <e2>cardiotoxicity</e2>_17\NN\1740 in_18\IN\13603305 dogs_19\NNS\2083346 ._20\.\1740
11573852
D000666_D012640 CID <e1>amphotericin_0\NN\2716866 b-induced</e1>_1\JJ\1740 <e2>seizures</e2>_2\NNS\14081375 in_3\IN\13603305 a_4\DT\13649268 patient_5\NN\9898892 with_6\IN\1740 aids_7\NN\13974317 ._8\.\1740
D000666_D012640 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 multiple_7\JJ\1740 episodes_8\NNS\7283608 of_9\IN\1740 <e2>seizure</e2>_10\JJ\1740 activity_11\NN\30358 in_12\IN\13603305 an_13\DT\6697703 aids_14\NN\13974317 patent_15\NN\6470073 following_16\VBG\1835496 <e1>amphotericin_17\NN\2716866 b</e1>_18\NN\1355326 infusion_19\NN\14589223 ._20\.\1740
D000666_D012640 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 46-year-old_4\JJ\1740 african-american_5\JJ\1740 man_6\NN\9605289 experienced_7\VBD\2108377 recurrent_8\JJ\1740 grand_9\JJ\1740 mal_10\JJ\1740 seizures_11\NNS\14081375 during_12\IN\1740 intravenous_13\JJ\1740 infusion_14\NN\14589223 of_15\IN\1740 <e1>amphotericin_16\NN\2716866 b</e1>_17\NN\1355326 ,_18\,\1740 then_19\RB\1740 petit_20\JJ\1740 mal_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 as_23\IN\14622893 the_24\DT\1740 infusion_25\NN\14589223 was_26\VBD\836236 stopped_27\VBN\2452885 and_28\CC\1740 the_29\DT\1740 drug_30\NN\14778436 concentrations_31\NNS\4916342 decreased_32\VBD\169651 with_33\IN\1740 time_34\NN\7308889 ._35\.\1740
D000666_D012640 CID despite_0\IN\7501545 administration_1\NN\1133281 of_2\IN\1740 phenytoin_3\NN\3550533 and_4\CC\1740 lorazepam_5\NN\2830852 ,_6\,\1740 the_7\DT\1740 <e2>seizures</e2>_8\NNS\14081375 persisted_9\VBD\118523 and_10\CC\1740 occurred_11\VBD\2623529 only_12\RB\1740 during_13\IN\1740 <e1>amphotercin_14\NN\1740 b</e1>_15\NN\1355326 administration_16\NN\1133281 ._17\.\1740
D000666_D012640 CID the_0\DT\1740 time_1\NN\7308889 course_2\NN\883297 of_3\IN\1740 events_4\NNS\23100 suggested_5\VBD\1010118 that_6\IN\1740 <e1>amphotericin_7\NN\2716866 b</e1>_8\NN\1355326 was_9\VBD\836236 the_10\DT\1740 cause_11\NN\7323922 of_12\IN\1740 the_13\DT\1740 <e2>seizures</e2>_14\NNS\14081375 in_15\IN\13603305 this_16\DT\1740 aids_17\NN\13974317 patient_18\NN\9898892 ._19\.\1740
D000666_D012640 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>amphotericin_2\NN\2716866 b</e1>_3\NN\1355326 seems_4\VBZ\2604760 to_5\TO\1740 be_6\VB\836236 the_7\DT\1740 probable_8\JJ\1740 cause_9\NN\7323922 of_10\IN\1740 the_11\DT\1740 <e2>seizures</e2>_12\NNS\14081375 ._13\.\1740
D000666_D012640 CID to_0\IN\1740 date_1\NN\15155220 ,_2\,\1740 only_3\RB\1740 three_4\CD\13741022 cases_5\NNS\7283608 of_6\IN\1740 <e2>seizures</e2>_7\NNS\14081375 associated_8\VBN\628491 with_9\IN\1740 <e1>amphotericin_10\NN\2716866 b</e1>_11\NN\1355326 have_12\VBP\2108377 been_13\VBN\836236 reported_14\VBN\831651 in_15\IN\13603305 the_16\DT\1740 literature_17\NN\6362953 ,_18\,\1740 but_19\CC\1740 healthcare_20\NN\654885 providers_21\NNS\9882716 should_22\MD\1740 be_23\VB\836236 aware_24\JJ\1740 of_25\IN\1740 the_26\DT\1740 potential_27\NN\14481929 for_28\IN\1740 this_29\DT\1740 rare_30\JJ\1740 adverse_31\JJ\1740 effect_32\NN\34213 ._33\.\1740
D000666_D000163 NONE <e1>amphotericin_0\NN\2716866 b-induced</e1>_1\JJ\1740 seizures_2\NNS\14081375 in_3\IN\13603305 a_4\DT\13649268 patient_5\NN\9898892 with_6\IN\1740 <e2>aids</e2>_7\NN\13974317 ._8\.\1740
D000666_D000163 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 multiple_7\JJ\1740 episodes_8\NNS\7283608 of_9\IN\1740 seizure_10\JJ\1740 activity_11\NN\30358 in_12\IN\13603305 an_13\DT\6697703 <e2>aids</e2>_14\NN\13974317 patent_15\NN\6470073 following_16\VBG\1835496 <e1>amphotericin_17\NN\2716866 b</e1>_18\NN\1355326 infusion_19\NN\14589223 ._20\.\1740
D000666_D000163 NONE the_0\DT\1740 time_1\NN\7308889 course_2\NN\883297 of_3\IN\1740 events_4\NNS\23100 suggested_5\VBD\1010118 that_6\IN\1740 <e1>amphotericin_7\NN\2716866 b</e1>_8\NN\1355326 was_9\VBD\836236 the_10\DT\1740 cause_11\NN\7323922 of_12\IN\1740 the_13\DT\1740 seizures_14\NNS\14081375 in_15\IN\13603305 this_16\DT\1740 <e2>aids</e2>_17\NN\13974317 patient_18\NN\9898892 ._19\.\1740
D000666_D004830 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 46-year-old_4\JJ\1740 african-american_5\JJ\1740 man_6\NN\9605289 experienced_7\VBD\2108377 recurrent_8\JJ\1740 <e2>grand_9\JJ\1740 mal_10\JJ\1740 seizures</e2>_11\NNS\14081375 during_12\IN\1740 intravenous_13\JJ\1740 infusion_14\NN\14589223 of_15\IN\1740 <e1>amphotericin_16\NN\2716866 b</e1>_17\NN\1355326 ,_18\,\1740 then_19\RB\1740 petit_20\JJ\1740 mal_21\JJ\1740 seizures_22\NNS\14081375 as_23\IN\14622893 the_24\DT\1740 infusion_25\NN\14589223 was_26\VBD\836236 stopped_27\VBN\2452885 and_28\CC\1740 the_29\DT\1740 drug_30\NN\14778436 concentrations_31\NNS\4916342 decreased_32\VBD\169651 with_33\IN\1740 time_34\NN\7308889 ._35\.\1740
D010672_D012640 NONE despite_0\IN\7501545 administration_1\NN\1133281 of_2\IN\1740 <e1>phenytoin</e1>_3\NN\3550533 and_4\CC\1740 lorazepam_5\NN\2830852 ,_6\,\1740 the_7\DT\1740 <e2>seizures</e2>_8\NNS\14081375 persisted_9\VBD\118523 and_10\CC\1740 occurred_11\VBD\2623529 only_12\RB\1740 during_13\IN\1740 amphotercin_14\NN\1740 b_15\NN\1355326 administration_16\NN\1133281 ._17\.\1740
D008140_D012640 NONE despite_0\IN\7501545 administration_1\NN\1133281 of_2\IN\1740 phenytoin_3\NN\3550533 and_4\CC\1740 <e1>lorazepam</e1>_5\NN\2830852 ,_6\,\1740 the_7\DT\1740 <e2>seizures</e2>_8\NNS\14081375 persisted_9\VBD\118523 and_10\CC\1740 occurred_11\VBD\2623529 only_12\RB\1740 during_13\IN\1740 amphotercin_14\NN\1740 b_15\NN\1355326 administration_16\NN\1133281 ._17\.\1740
D000431_D000437 NONE the_0\DT\1740 patient_1\NN\9898892 had_2\VBD\2108377 a_3\DT\13649268 history_4\NN\15120823 of_5\IN\1740 <e2>alcohol_6\NN\7881800 abuse</e2>_7\NN\418025 ;_8\:\1740 <e1>alcohol</e1>_9\NN\7881800 intake_10\VBP\1740 as_11\RB\1740 well_12\RB\1740 as_13\IN\14622893 withdrawal_14\NN\7206096 can_15\MD\3094503 also_16\RB\1740 cause_17\VB\1617192 seizures_18\NNS\14081375 ._19\.\1740
D000431_D012640 NONE the_0\DT\1740 patient_1\NN\9898892 had_2\VBD\2108377 a_3\DT\13649268 history_4\NN\15120823 of_5\IN\1740 alcohol_6\NN\7881800 abuse_7\NN\418025 ;_8\:\1740 <e1>alcohol</e1>_9\NN\7881800 intake_10\VBP\1740 as_11\RB\1740 well_12\RB\1740 as_13\IN\14622893 withdrawal_14\NN\7206096 can_15\MD\3094503 also_16\RB\1740 cause_17\VB\1617192 <e2>seizures</e2>_18\NNS\14081375 ._19\.\1740
D016049_D012640 NONE <e1>didanosine</e1>_0\NNP\2725367 also_1\RB\1740 has_2\VBZ\2108377 a_3\DT\13649268 potential_4\NN\14481929 for_5\IN\1740 inducing_6\VBG\1627355 <e2>seizures</e2>_7\NNS\14081375 ._8\.\1740
8012887
D006493_D013927 CID failure_0\NN\66216 of_1\IN\1740 ancrod_2\JJ\1740 in_3\IN\13603305 the_4\DT\1740 treatment_5\NN\654885 of_6\IN\1740 <e1>heparin-induced</e1>_7\JJ\1740 arterial_8\JJ\1740 <e2>thrombosis</e2>_9\NN\14100769 ._10\.\1740
D006493_D013927 CID the_0\DT\1740 morbidity_1\NN\13826959 and_2\CC\1740 mortality_3\NN\5054863 associated_4\VBN\628491 with_5\IN\1740 <e1>heparin-induced</e1>_6\JJ\1740 <e2>thrombosis</e2>_7\NN\14100769 remain_8\VBP\2604760 high_9\JJ\1740 despite_10\IN\7501545 numerous_11\JJ\1740 empirical_12\JJ\1740 therapies_13\NNS\657604 ._14\.\1740
D006493_D013927 CID ancrod_0\JJ\1740 has_1\VBZ\2108377 been_2\VBN\836236 used_3\VBN\1156834 successfully_4\RB\1740 for_5\IN\1740 prophylaxis_6\NN\1077350 against_7\IN\1740 development_8\NN\248977 of_9\IN\1740 <e2>thrombosis</e2>_10\NN\14100769 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 <e1>heparin</e1>_14\NN\2718259 induced_15\VBD\1627355 platelet_16\NN\5432736 aggregation_17\NN\31264 who_18\WP\8299493 require_19\VBP\754942 brief_20\JJ\1740 reexposure_21\NN\1740 to_22\TO\1740 heparin_23\NN\2718259 ,_24\,\1740 but_25\CC\1740 its_26\PRP$\6125041 success_27\NN\7283608 in_28\IN\13603305 patients_29\NNS\9898892 who_30\WP\8299493 have_31\VBP\2108377 developed_32\VBN\1753788 the_33\DT\1740 thrombosis_34\NN\14100769 syndrome_35\NN\5870365 is_36\VBZ\836236 not_37\RB\1740 well_38\RB\1740 defined_39\VBN\2604760 ._40\.\1740
D006493_D013927 CID ancrod_0\JJ\1740 has_1\VBZ\2108377 been_2\VBN\836236 used_3\VBN\1156834 successfully_4\RB\1740 for_5\IN\1740 prophylaxis_6\NN\1077350 against_7\IN\1740 development_8\NN\248977 of_9\IN\1740 thrombosis_10\NN\14100769 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 <e1>heparin</e1>_14\NN\2718259 induced_15\VBD\1627355 platelet_16\NN\5432736 aggregation_17\NN\31264 who_18\WP\8299493 require_19\VBP\754942 brief_20\JJ\1740 reexposure_21\NN\1740 to_22\TO\1740 heparin_23\NN\2718259 ,_24\,\1740 but_25\CC\1740 its_26\PRP$\6125041 success_27\NN\7283608 in_28\IN\13603305 patients_29\NNS\9898892 who_30\WP\8299493 have_31\VBP\2108377 developed_32\VBN\1753788 the_33\DT\1740 <e2>thrombosis</e2>_34\NN\14100769 syndrome_35\NN\5870365 is_36\VBZ\836236 not_37\RB\1740 well_38\RB\1740 defined_39\VBN\2604760 ._40\.\1740
D006493_D013927 CID ancrod_0\JJ\1740 has_1\VBZ\2108377 been_2\VBN\836236 used_3\VBN\1156834 successfully_4\RB\1740 for_5\IN\1740 prophylaxis_6\NN\1077350 against_7\IN\1740 development_8\NN\248977 of_9\IN\1740 <e2>thrombosis</e2>_10\NN\14100769 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 heparin_14\NN\2718259 induced_15\VBD\1627355 platelet_16\NN\5432736 aggregation_17\NN\31264 who_18\WP\8299493 require_19\VBP\754942 brief_20\JJ\1740 reexposure_21\NN\1740 to_22\TO\1740 <e1>heparin</e1>_23\NN\2718259 ,_24\,\1740 but_25\CC\1740 its_26\PRP$\6125041 success_27\NN\7283608 in_28\IN\13603305 patients_29\NNS\9898892 who_30\WP\8299493 have_31\VBP\2108377 developed_32\VBN\1753788 the_33\DT\1740 thrombosis_34\NN\14100769 syndrome_35\NN\5870365 is_36\VBZ\836236 not_37\RB\1740 well_38\RB\1740 defined_39\VBN\2604760 ._40\.\1740
D006493_D013927 CID ancrod_0\JJ\1740 has_1\VBZ\2108377 been_2\VBN\836236 used_3\VBN\1156834 successfully_4\RB\1740 for_5\IN\1740 prophylaxis_6\NN\1077350 against_7\IN\1740 development_8\NN\248977 of_9\IN\1740 thrombosis_10\NN\14100769 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 heparin_14\NN\2718259 induced_15\VBD\1627355 platelet_16\NN\5432736 aggregation_17\NN\31264 who_18\WP\8299493 require_19\VBP\754942 brief_20\JJ\1740 reexposure_21\NN\1740 to_22\TO\1740 <e1>heparin</e1>_23\NN\2718259 ,_24\,\1740 but_25\CC\1740 its_26\PRP$\6125041 success_27\NN\7283608 in_28\IN\13603305 patients_29\NNS\9898892 who_30\WP\8299493 have_31\VBP\2108377 developed_32\VBN\1753788 the_33\DT\1740 <e2>thrombosis</e2>_34\NN\14100769 syndrome_35\NN\5870365 is_36\VBZ\836236 not_37\RB\1740 well_38\RB\1740 defined_39\VBN\2604760 ._40\.\1740
D006493_D013927 CID the_0\DT\1740 authors_1\NNS\9610660 present_2\VBP\2137132 a_3\DT\13649268 case_4\NN\7283608 of_5\IN\1740 failure_6\NN\66216 of_7\IN\1740 ancrod_8\JJ\1740 treatment_9\NN\654885 in_10\IN\13603305 a_11\DT\13649268 patient_12\NN\9898892 with_13\IN\1740 <e1>heparin-induced</e1>_14\JJ\1740 <e2>thrombosis</e2>_15\NN\14100769 ._16\.\1740
D006493_D001791 NONE ancrod_0\JJ\1740 has_1\VBZ\2108377 been_2\VBN\836236 used_3\VBN\1156834 successfully_4\RB\1740 for_5\IN\1740 prophylaxis_6\NN\1077350 against_7\IN\1740 development_8\NN\248977 of_9\IN\1740 thrombosis_10\NN\14100769 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 <e1>heparin</e1>_14\NN\2718259 induced_15\VBD\1627355 <e2>platelet_16\NN\5432736 aggregation</e2>_17\NN\31264 who_18\WP\8299493 require_19\VBP\754942 brief_20\JJ\1740 reexposure_21\NN\1740 to_22\TO\1740 heparin_23\NN\2718259 ,_24\,\1740 but_25\CC\1740 its_26\PRP$\6125041 success_27\NN\7283608 in_28\IN\13603305 patients_29\NNS\9898892 who_30\WP\8299493 have_31\VBP\2108377 developed_32\VBN\1753788 the_33\DT\1740 thrombosis_34\NN\14100769 syndrome_35\NN\5870365 is_36\VBZ\836236 not_37\RB\1740 well_38\RB\1740 defined_39\VBN\2604760 ._40\.\1740
D006493_D001791 NONE ancrod_0\JJ\1740 has_1\VBZ\2108377 been_2\VBN\836236 used_3\VBN\1156834 successfully_4\RB\1740 for_5\IN\1740 prophylaxis_6\NN\1077350 against_7\IN\1740 development_8\NN\248977 of_9\IN\1740 thrombosis_10\NN\14100769 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 heparin_14\NN\2718259 induced_15\VBD\1627355 <e2>platelet_16\NN\5432736 aggregation</e2>_17\NN\31264 who_18\WP\8299493 require_19\VBP\754942 brief_20\JJ\1740 reexposure_21\NN\1740 to_22\TO\1740 <e1>heparin</e1>_23\NN\2718259 ,_24\,\1740 but_25\CC\1740 its_26\PRP$\6125041 success_27\NN\7283608 in_28\IN\13603305 patients_29\NNS\9898892 who_30\WP\8299493 have_31\VBP\2108377 developed_32\VBN\1753788 the_33\DT\1740 thrombosis_34\NN\14100769 syndrome_35\NN\5870365 is_36\VBZ\836236 not_37\RB\1740 well_38\RB\1740 defined_39\VBN\2604760 ._40\.\1740
8766220
D014147_D006212 CID nightmares_0\NNS\14411243 and_1\CC\1740 <e2>hallucinations</e2>_2\NNS\14376855 after_3\IN\1740 long-term_4\JJ\1740 intake_5\NN\13440063 of_6\IN\1740 <e1>tramadol</e1>_7\NN\1740 combined_8\VBN\2630189 with_9\IN\1740 antidepressants_10\NNS\3740161 ._11\.\1740
D014147_D006212 CID fifty-six_0\CD\1740 days_1\NNS\15140892 after_2\IN\1740 initiation_3\NN\7450842 of_4\IN\1740 the_5\DT\1740 treatment_6\NN\654885 the_7\DT\1740 patient_8\NN\9898892 presented_9\VBD\2137132 <e2>hallucinations</e2>_10\NNS\14376855 that_11\WDT\1740 only_12\RB\1740 stopped_13\VBD\2452885 after_14\IN\1740 the_15\DT\1740 withdrawal_16\NN\7206096 of_17\IN\1740 psycho-active_18\JJ\1740 drugs_19\NNS\14778436 and_20\CC\1740 <e1>tramadol</e1>_21\NN\1740 ._22\.\1740
D014147_D009369 NONE <e1>tramadol</e1>_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 weak_3\JJ\1740 opioid_4\NN\1740 with_5\IN\1740 effects_6\NNS\13245626 on_7\IN\1740 adrenergic_8\JJ\1740 and_9\CC\1740 serotonergic_10\JJ\1740 neurotransmission_11\NN\1740 that_12\WDT\1740 is_13\VBZ\836236 used_14\VBN\1156834 to_15\TO\1740 treat_16\VB\2376958 <e2>cancer</e2>_17\NN\14239425 pain_18\NN\14299637 and_19\CC\1740 chronic_20\JJ\1740 non_21\JJ\1740 malignant_22\JJ\1740 pain_23\NN\14299637 ._24\.\1740
D014147_D010146 NONE <e1>tramadol</e1>_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 weak_3\JJ\1740 opioid_4\NN\1740 with_5\IN\1740 effects_6\NNS\13245626 on_7\IN\1740 adrenergic_8\JJ\1740 and_9\CC\1740 serotonergic_10\JJ\1740 neurotransmission_11\NN\1740 that_12\WDT\1740 is_13\VBZ\836236 used_14\VBN\1156834 to_15\TO\1740 treat_16\VB\2376958 cancer_17\NN\14239425 <e2>pain</e2>_18\NN\14299637 and_19\CC\1740 chronic_20\JJ\1740 non_21\JJ\1740 malignant_22\JJ\1740 pain_23\NN\14299637 ._24\.\1740
D014147_D010146 NONE <e1>tramadol</e1>_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 weak_3\JJ\1740 opioid_4\NN\1740 with_5\IN\1740 effects_6\NNS\13245626 on_7\IN\1740 adrenergic_8\JJ\1740 and_9\CC\1740 serotonergic_10\JJ\1740 neurotransmission_11\NN\1740 that_12\WDT\1740 is_13\VBZ\836236 used_14\VBN\1156834 to_15\TO\1740 treat_16\VB\2376958 cancer_17\NN\14239425 pain_18\NN\14299637 and_19\CC\1740 chronic_20\JJ\1740 non_21\JJ\1740 malignant_22\JJ\1740 <e2>pain</e2>_23\NN\14299637 ._24\.\1740
D017374_-1 NONE this_0\DT\1740 drug_1\NN\14778436 was_2\VBD\836236 initiated_3\VBN\1617192 in_4\IN\13603305 association_5\NN\8008335 with_6\IN\1740 <e1>paroxetine</e1>_7\NN\1740 and_8\CC\1740 dosulepine_9\NN\1740 hydrochloride_10\NN\14817592 in_11\IN\13603305 a_12\DT\13649268 <e2>tetraparetic</e2>_13\JJ\1740 patient_14\NN\9898892 with_15\IN\1740 chronic_16\JJ\1740 pain_17\NN\14299637 ._18\.\1740
D017374_D059350 NONE this_0\DT\1740 drug_1\NN\14778436 was_2\VBD\836236 initiated_3\VBN\1617192 in_4\IN\13603305 association_5\NN\8008335 with_6\IN\1740 <e1>paroxetine</e1>_7\NN\1740 and_8\CC\1740 dosulepine_9\NN\1740 hydrochloride_10\NN\14817592 in_11\IN\13603305 a_12\DT\13649268 tetraparetic_13\JJ\1740 patient_14\NN\9898892 with_15\IN\1740 <e2>chronic_16\JJ\1740 pain</e2>_17\NN\14299637 ._18\.\1740
D004308_-1 NONE this_0\DT\1740 drug_1\NN\14778436 was_2\VBD\836236 initiated_3\VBN\1617192 in_4\IN\13603305 association_5\NN\8008335 with_6\IN\1740 paroxetine_7\NN\1740 and_8\CC\1740 <e1>dosulepine_9\NN\1740 hydrochloride</e1>_10\NN\14817592 in_11\IN\13603305 a_12\DT\13649268 <e2>tetraparetic</e2>_13\JJ\1740 patient_14\NN\9898892 with_15\IN\1740 chronic_16\JJ\1740 pain_17\NN\14299637 ._18\.\1740
D004308_D059350 NONE this_0\DT\1740 drug_1\NN\14778436 was_2\VBD\836236 initiated_3\VBN\1617192 in_4\IN\13603305 association_5\NN\8008335 with_6\IN\1740 paroxetine_7\NN\1740 and_8\CC\1740 <e1>dosulepine_9\NN\1740 hydrochloride</e1>_10\NN\14817592 in_11\IN\13603305 a_12\DT\13649268 tetraparetic_13\JJ\1740 patient_14\NN\9898892 with_15\IN\1740 <e2>chronic_16\JJ\1740 pain</e2>_17\NN\14299637 ._18\.\1740
3088349
D000661_D009069 CID transient_0\JJ\1740 <e2>contralateral_1\JJ\1740 rotation</e2>_2\NN\331950 following_3\VBG\1835496 unilateral_4\JJ\1740 substantia_5\RB\1740 nigra_6\JJ\1740 lesion_7\NN\14204950 reflects_8\VBZ\923793 susceptibility_9\NN\13920835 of_10\IN\1740 the_11\DT\1740 nigrostriatal_12\JJ\1740 system_13\NN\3575240 to_14\TO\1740 exhaustion_15\NN\14016361 by_16\IN\1740 <e1>amphetamine</e1>_17\NN\3248958 ._18\.\1740
D000661_D009069 CID in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 clarify_3\VB\939277 the_4\DT\1740 nature_5\NN\4723816 of_6\IN\1740 this_7\DT\1740 initial_8\JJ\1740 <e2>contralateral_9\JJ\1740 rotation</e2>_10\NN\331950 we_11\PRP\1740 examined_12\VBD\789138 the_13\DT\1740 effect_14\NN\34213 of_15\IN\1740 the_16\DT\1740 duration_17\NN\15113229 of_18\IN\1740 recovery_19\NN\7357388 period_20\NN\13575869 after_21\IN\1740 the_22\DT\1740 lesion_23\NN\14204950 ,_24\,\1740 on_25\IN\1740 <e1>amphetamine-induced</e1>_26\JJ\1740 rotational_27\JJ\1740 behavior_28\NN\407535 ._29\.\1740
D000661_D009069 CID in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 clarify_3\VB\939277 the_4\DT\1740 nature_5\NN\4723816 of_6\IN\1740 this_7\DT\1740 initial_8\JJ\1740 contralateral_9\JJ\1740 rotation_10\NN\331950 we_11\PRP\1740 examined_12\VBD\789138 the_13\DT\1740 effect_14\NN\34213 of_15\IN\1740 the_16\DT\1740 duration_17\NN\15113229 of_18\IN\1740 recovery_19\NN\7357388 period_20\NN\13575869 after_21\IN\1740 the_22\DT\1740 lesion_23\NN\14204950 ,_24\,\1740 on_25\IN\1740 <e1>amphetamine-induced</e1>_26\JJ\1740 <e2>rotational_27\JJ\1740 behavior</e2>_28\NN\407535 ._29\.\1740
D000661_D009069 CID a_0\DT\13649268 substantial_1\JJ\1740 degree_2\NN\4916342 of_3\IN\1740 contralateral_4\JJ\1740 preference_5\NN\7497473 was_6\VBD\836236 still_7\RB\1740 evident_8\JJ\1740 when_9\WRB\1740 <e1>amphetamine</e1>_10\NN\3248958 was_11\VBD\836236 administered_12\VBN\2436349 for_13\IN\1740 the_14\DT\1740 first_15\JJ\1740 time_16\NN\7308889 24_17\CD\13745420 days_18\NNS\15140892 after_19\IN\1740 lesioning_20\NN\1740 ,_21\,\1740 indicating_22\VBG\952524 involvement_23\NN\1080366 of_24\IN\1740 spared_25\VBN\2725714 cells_26\NNS\3080309 in_27\IN\13603305 the_28\DT\1740 <e2>contralateral_29\JJ\1740 rotation</e2>_30\NN\331950 ._31\.\1740
D000661_D009069 CID however_0\RB\1740 ,_1\,\1740 regardless_2\RB\1740 of_3\IN\1740 the_4\DT\1740 duration_5\NN\15113229 of_6\IN\1740 recovery_7\NN\7357388 (_8\-LRB-\1740 and_9\CC\1740 irrespective_10\RB\1740 of_11\IN\1740 either_12\DT\1740 lesion_13\NN\14204950 volume_14\NN\33615 ,_15\,\1740 <e1>amphetamine</e1>_16\NN\3248958 dose_17\NN\3740161 ,_18\,\1740 or_19\CC\3541091 post-lesion_20\JJ\1740 motor_21\NN\3699975 exercise_22\NN\621627 )_23\-RRB-\1740 ,_24\,\1740 amphetamine-induced_25\JJ\1740 <e2>rotation</e2>_26\NN\331950 tended_27\VBD\2604760 to_28\TO\1740 become_29\VB\146138 gradually_30\RB\1740 more_31\RBR\1740 ipsilateral_32\JJ\1740 as_33\IN\14622893 the_34\DT\1740 observation_35\NN\996969 session_36\NN\7142566 progressed_37\VBD\252019 ,_38\,\1740 and_39\CC\1740 all_40\DT\1740 rats_41\NNS\2329401 circled_42\VBD\1835496 ipsilaterally_43\RB\1740 to_44\TO\1740 the_45\DT\1740 lesion_46\NN\14204950 in_47\IN\13603305 response_48\NN\11410625 to_49\TO\1740 further_50\JJ\1740 amphetamine_51\VB\1740 injections_52\NNS\320852 ._53\.\1740
D000661_D009069 CID however_0\RB\1740 ,_1\,\1740 regardless_2\RB\1740 of_3\IN\1740 the_4\DT\1740 duration_5\NN\15113229 of_6\IN\1740 recovery_7\NN\7357388 (_8\-LRB-\1740 and_9\CC\1740 irrespective_10\RB\1740 of_11\IN\1740 either_12\DT\1740 lesion_13\NN\14204950 volume_14\NN\33615 ,_15\,\1740 amphetamine_16\NN\3248958 dose_17\NN\3740161 ,_18\,\1740 or_19\CC\3541091 post-lesion_20\JJ\1740 motor_21\NN\3699975 exercise_22\NN\621627 )_23\-RRB-\1740 ,_24\,\1740 <e1>amphetamine-induced</e1>_25\JJ\1740 <e2>rotation</e2>_26\NN\331950 tended_27\VBD\2604760 to_28\TO\1740 become_29\VB\146138 gradually_30\RB\1740 more_31\RBR\1740 ipsilateral_32\JJ\1740 as_33\IN\14622893 the_34\DT\1740 observation_35\NN\996969 session_36\NN\7142566 progressed_37\VBD\252019 ,_38\,\1740 and_39\CC\1740 all_40\DT\1740 rats_41\NNS\2329401 circled_42\VBD\1835496 ipsilaterally_43\RB\1740 to_44\TO\1740 the_45\DT\1740 lesion_46\NN\14204950 in_47\IN\13603305 response_48\NN\11410625 to_49\TO\1740 further_50\JJ\1740 amphetamine_51\VB\1740 injections_52\NNS\320852 ._53\.\1740
D000661_D009069 CID however_0\RB\1740 ,_1\,\1740 regardless_2\RB\1740 of_3\IN\1740 the_4\DT\1740 duration_5\NN\15113229 of_6\IN\1740 recovery_7\NN\7357388 (_8\-LRB-\1740 and_9\CC\1740 irrespective_10\RB\1740 of_11\IN\1740 either_12\DT\1740 lesion_13\NN\14204950 volume_14\NN\33615 ,_15\,\1740 amphetamine_16\NN\3248958 dose_17\NN\3740161 ,_18\,\1740 or_19\CC\3541091 post-lesion_20\JJ\1740 motor_21\NN\3699975 exercise_22\NN\621627 )_23\-RRB-\1740 ,_24\,\1740 amphetamine-induced_25\JJ\1740 <e2>rotation</e2>_26\NN\331950 tended_27\VBD\2604760 to_28\TO\1740 become_29\VB\146138 gradually_30\RB\1740 more_31\RBR\1740 ipsilateral_32\JJ\1740 as_33\IN\14622893 the_34\DT\1740 observation_35\NN\996969 session_36\NN\7142566 progressed_37\VBD\252019 ,_38\,\1740 and_39\CC\1740 all_40\DT\1740 rats_41\NNS\2329401 circled_42\VBD\1835496 ipsilaterally_43\RB\1740 to_44\TO\1740 the_45\DT\1740 lesion_46\NN\14204950 in_47\IN\13603305 response_48\NN\11410625 to_49\TO\1740 further_50\JJ\1740 <e1>amphetamine</e1>_51\VB\1740 injections_52\NNS\320852 ._53\.\1740
D000661_D009069 CID these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>amphetamine</e1>_4\NN\3248958 has_5\VBZ\2108377 an_6\DT\6697703 irreversible_7\JJ\1740 effect_8\NN\34213 on_9\IN\1740 the_10\DT\1740 post-lesion_11\JJ\1740 da_12\NN\10484858 pool_13\NN\3302121 contributing_14\VBG\126264 to_15\TO\1740 <e2>contralateral_16\JJ\1740 rotation</e2>_17\NN\331950 ._18\.\1740
D000661_-1 NONE transient_0\JJ\1740 contralateral_1\JJ\1740 rotation_2\NN\331950 following_3\VBG\1835496 unilateral_4\JJ\1740 <e2>substantia_5\RB\1740 nigra_6\JJ\1740 lesion</e2>_7\NN\14204950 reflects_8\VBZ\923793 susceptibility_9\NN\13920835 of_10\IN\1740 the_11\DT\1740 nigrostriatal_12\JJ\1740 system_13\NN\3575240 to_14\TO\1740 exhaustion_15\NN\14016361 by_16\IN\1740 <e1>amphetamine</e1>_17\NN\3248958 ._18\.\1740
D016627_-1 NONE following_0\VBG\1835496 unilateral_1\JJ\1740 <e1>6-ohda</e1>_2\NN\1740 induced_3\VBN\1627355 <e2>sn_4\NN\14625458 lesion</e2>_5\NN\14204950 ,_6\,\1740 a_7\DT\13649268 transient_8\JJ\1740 period_9\NN\13575869 of_10\IN\1740 contralateral_11\JJ\1740 rotation_12\NN\331950 has_13\VBZ\2108377 been_14\VBN\836236 reported_15\VBN\831651 to_16\TO\1740 precede_17\VB\2690708 the_18\DT\1740 predominant_19\JJ\1740 ipsilateral_20\JJ\1740 circling_21\NN\1740 ._22\.\1740
D016627_D009069 NONE following_0\VBG\1835496 unilateral_1\JJ\1740 <e1>6-ohda</e1>_2\NN\1740 induced_3\VBN\1627355 sn_4\NN\14625458 lesion_5\NN\14204950 ,_6\,\1740 a_7\DT\13649268 transient_8\JJ\1740 period_9\NN\13575869 of_10\IN\1740 <e2>contralateral_11\JJ\1740 rotation</e2>_12\NN\331950 has_13\VBZ\2108377 been_14\VBN\836236 reported_15\VBN\831651 to_16\TO\1740 precede_17\VB\2690708 the_18\DT\1740 predominant_19\JJ\1740 ipsilateral_20\JJ\1740 circling_21\NN\1740 ._22\.\1740
D016627_D009069 NONE following_0\VBG\1835496 unilateral_1\JJ\1740 <e1>6-ohda</e1>_2\NN\1740 induced_3\VBN\1627355 sn_4\NN\14625458 lesion_5\NN\14204950 ,_6\,\1740 a_7\DT\13649268 transient_8\JJ\1740 period_9\NN\13575869 of_10\IN\1740 contralateral_11\JJ\1740 rotation_12\NN\331950 has_13\VBZ\2108377 been_14\VBN\836236 reported_15\VBN\831651 to_16\TO\1740 precede_17\VB\2690708 the_18\DT\1740 predominant_19\JJ\1740 <e2>ipsilateral_20\JJ\1740 circling</e2>_21\NN\1740 ._22\.\1740
12739036
D003401_D008180 NONE differential_0\JJ\1740 diagnosis_1\NN\152018 of_2\IN\1740 high_3\JJ\1740 serum_4\NN\5397468 <e1>creatine</e1>_5\NN\14601829 kinase_6\NN\14732946 levels_7\NNS\4916342 in_8\IN\13603305 <e2>systemic_9\JJ\1740 lupus_10\NN\14219661 erythematosus</e2>_11\NN\1740 ._12\.\1740
D002738_D009135 NONE we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 clinical_3\JJ\1740 and_4\CC\1740 bioptic_5\JJ\1740 findings_6\NNS\7951464 for_7\IN\1740 a_8\DT\13649268 57-year-old_9\JJ\1740 woman_10\NN\9605289 with_11\IN\1740 severe_12\JJ\1740 <e1>chloroquine-induced</e1>_13\JJ\1740 <e2>myopathy</e2>_14\NN\14204950 ._15\.\1740
D002738_D009135 NONE as_0\IN\14622893 it_1\PRP\6125041 revealed_2\VBD\2137132 <e1>chloroquine-induced</e1>_3\JJ\1740 <e2>myopathy</e2>_4\NN\14204950 ,_5\,\1740 medication_6\NN\3247620 was_7\VBD\836236 stopped_8\VBN\2452885 ._9\.\1740
D001379_D008180 NONE since_0\IN\1740 1989_1\CD\1740 ,_2\,\1740 she_3\PRP\1740 had_4\VBD\2108377 been_5\VBN\836236 suffering_6\VBG\2110220 from_7\IN\1740 <e2>systemic_8\JJ\1740 lupus_9\NN\14219661 erythematosus</e2>_10\NN\1740 (_11\-LRB-\1740 sle_12\NN\14229912 )_13\-RRB-\1740 with_14\IN\1740 renal_15\JJ\1740 involvement_16\NN\1080366 and_17\CC\1740 undergone_18\JJ\1740 periods_19\NNS\13575869 of_20\IN\1740 treatment_21\NN\654885 with_22\IN\1740 <e1>azathioprine</e1>_23\NN\3740161 and_24\CC\1740 cyclophosphamide_25\NN\1740 ._26\.\1740
D001379_D008180 NONE since_0\IN\1740 1989_1\CD\1740 ,_2\,\1740 she_3\PRP\1740 had_4\VBD\2108377 been_5\VBN\836236 suffering_6\VBG\2110220 from_7\IN\1740 systemic_8\JJ\1740 lupus_9\NN\14219661 erythematosus_10\NN\1740 (_11\-LRB-\1740 <e2>sle</e2>_12\NN\14229912 )_13\-RRB-\1740 with_14\IN\1740 renal_15\JJ\1740 involvement_16\NN\1080366 and_17\CC\1740 undergone_18\JJ\1740 periods_19\NNS\13575869 of_20\IN\1740 treatment_21\NN\654885 with_22\IN\1740 <e1>azathioprine</e1>_23\NN\3740161 and_24\CC\1740 cyclophosphamide_25\NN\1740 ._26\.\1740
D001379_D007674 NONE since_0\IN\1740 1989_1\CD\1740 ,_2\,\1740 she_3\PRP\1740 had_4\VBD\2108377 been_5\VBN\836236 suffering_6\VBG\2110220 from_7\IN\1740 systemic_8\JJ\1740 lupus_9\NN\14219661 erythematosus_10\NN\1740 (_11\-LRB-\1740 sle_12\NN\14229912 )_13\-RRB-\1740 with_14\IN\1740 <e2>renal_15\JJ\1740 involvement</e2>_16\NN\1080366 and_17\CC\1740 undergone_18\JJ\1740 periods_19\NNS\13575869 of_20\IN\1740 treatment_21\NN\654885 with_22\IN\1740 <e1>azathioprine</e1>_23\NN\3740161 and_24\CC\1740 cyclophosphamide_25\NN\1740 ._26\.\1740
D003520_D008180 NONE since_0\IN\1740 1989_1\CD\1740 ,_2\,\1740 she_3\PRP\1740 had_4\VBD\2108377 been_5\VBN\836236 suffering_6\VBG\2110220 from_7\IN\1740 <e2>systemic_8\JJ\1740 lupus_9\NN\14219661 erythematosus</e2>_10\NN\1740 (_11\-LRB-\1740 sle_12\NN\14229912 )_13\-RRB-\1740 with_14\IN\1740 renal_15\JJ\1740 involvement_16\NN\1080366 and_17\CC\1740 undergone_18\JJ\1740 periods_19\NNS\13575869 of_20\IN\1740 treatment_21\NN\654885 with_22\IN\1740 azathioprine_23\NN\3740161 and_24\CC\1740 <e1>cyclophosphamide</e1>_25\NN\1740 ._26\.\1740
D003520_D008180 NONE since_0\IN\1740 1989_1\CD\1740 ,_2\,\1740 she_3\PRP\1740 had_4\VBD\2108377 been_5\VBN\836236 suffering_6\VBG\2110220 from_7\IN\1740 systemic_8\JJ\1740 lupus_9\NN\14219661 erythematosus_10\NN\1740 (_11\-LRB-\1740 <e2>sle</e2>_12\NN\14229912 )_13\-RRB-\1740 with_14\IN\1740 renal_15\JJ\1740 involvement_16\NN\1080366 and_17\CC\1740 undergone_18\JJ\1740 periods_19\NNS\13575869 of_20\IN\1740 treatment_21\NN\654885 with_22\IN\1740 azathioprine_23\NN\3740161 and_24\CC\1740 <e1>cyclophosphamide</e1>_25\NN\1740 ._26\.\1740
D003520_D007674 NONE since_0\IN\1740 1989_1\CD\1740 ,_2\,\1740 she_3\PRP\1740 had_4\VBD\2108377 been_5\VBN\836236 suffering_6\VBG\2110220 from_7\IN\1740 systemic_8\JJ\1740 lupus_9\NN\14219661 erythematosus_10\NN\1740 (_11\-LRB-\1740 sle_12\NN\14229912 )_13\-RRB-\1740 with_14\IN\1740 <e2>renal_15\JJ\1740 involvement</e2>_16\NN\1080366 and_17\CC\1740 undergone_18\JJ\1740 periods_19\NNS\13575869 of_20\IN\1740 treatment_21\NN\654885 with_22\IN\1740 azathioprine_23\NN\3740161 and_24\CC\1740 <e1>cyclophosphamide</e1>_25\NN\1740 ._26\.\1740
D002738_D018771 NONE additional_0\JJ\1740 therapy_1\NN\657604 with_2\IN\1740 <e1>chloroquine</e1>_3\NN\2721948 (_4\-LRB-\1740 cq_5\NN\1740 )_6\-RRB-\1740 was_7\VBD\836236 started_8\VBN\2009433 because_9\IN\1740 of_10\IN\1740 <e2>arthralgia</e2>_11\NN\14322699 ._12\.\1740
D002738_D018771 NONE additional_0\JJ\1740 therapy_1\NN\657604 with_2\IN\1740 chloroquine_3\NN\2721948 (_4\-LRB-\1740 <e1>cq</e1>_5\NN\1740 )_6\-RRB-\1740 was_7\VBD\836236 started_8\VBN\2009433 because_9\IN\1740 of_10\IN\1740 <e2>arthralgia</e2>_11\NN\14322699 ._12\.\1740
D013256_D009220 NONE <e2>myositis</e2>_0\NNP\14336539 was_1\VBD\836236 suspected_2\VBN\916909 ,_3\,\1740 and_4\CC\1740 the_5\DT\1740 patient_6\NN\9898892 was_7\VBD\836236 treated_8\VBN\2376958 with_9\IN\1740 <e1>steroids</e1>_10\NNS\14727670 ._11\.\1740
3220106
D009538_D006948 CID receptor_0\NN\5225602 mechanisms_1\NNS\13446390 of_2\IN\1740 <e1>nicotine-induced</e1>_3\JJ\1740 <e2>locomotor_4\NN\1740 hyperactivity</e2>_5\NN\14052403 in_6\IN\13603305 chronic_7\JJ\1740 nicotine-treated_8\JJ\1740 rats_9\NNS\2329401 ._10\.\1740
D009538_D006948 CID receptor_0\NN\5225602 mechanisms_1\NNS\13446390 of_2\IN\1740 nicotine-induced_3\JJ\1740 <e2>locomotor_4\NN\1740 hyperactivity</e2>_5\NN\14052403 in_6\IN\13603305 chronic_7\JJ\1740 <e1>nicotine-treated</e1>_8\JJ\1740 rats_9\NNS\2329401 ._10\.\1740
D009538_D006948 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chronic_4\JJ\1740 <e1>nicotine-treated</e1>_5\JJ\1740 rats_6\NNS\2329401 develop_7\VBP\1753788 <e2>locomotor_8\NN\1740 hyperactivity</e2>_9\NN\14052403 in_10\IN\13603305 response_11\NN\11410625 to_12\TO\1740 nicotine_13\NN\14712692 initially_14\RB\1740 due_15\JJ\1740 to_16\IN\1740 increases_17\NNS\13576355 of_18\IN\1740 both_19\CC\1740 the_20\DT\1740 density_21\NN\4941325 of_22\IN\1740 nicotinic_23\JJ\1740 receptors_24\NNS\5225602 and_25\CC\1740 da_26\NN\10484858 concentration_27\NN\4916342 ,_28\,\1740 followed_29\VBN\1835496 by_30\IN\1740 inducing_31\VBG\1627355 da_32\NN\10484858 receptor_33\NN\5225602 supersensitivity_34\NN\1740 in_35\IN\13603305 the_36\DT\1740 striatum_37\NN\5497363 ._38\.\1740
D009538_D006948 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chronic_4\JJ\1740 nicotine-treated_5\JJ\1740 rats_6\NNS\2329401 develop_7\VBP\1753788 <e2>locomotor_8\NN\1740 hyperactivity</e2>_9\NN\14052403 in_10\IN\13603305 response_11\NN\11410625 to_12\TO\1740 <e1>nicotine</e1>_13\NN\14712692 initially_14\RB\1740 due_15\JJ\1740 to_16\IN\1740 increases_17\NNS\13576355 of_18\IN\1740 both_19\CC\1740 the_20\DT\1740 density_21\NN\4941325 of_22\IN\1740 nicotinic_23\JJ\1740 receptors_24\NNS\5225602 and_25\CC\1740 da_26\NN\10484858 concentration_27\NN\4916342 ,_28\,\1740 followed_29\VBN\1835496 by_30\IN\1740 inducing_31\VBG\1627355 da_32\NN\10484858 receptor_33\NN\5225602 supersensitivity_34\NN\1740 in_35\IN\13603305 the_36\DT\1740 striatum_37\NN\5497363 ._38\.\1740
D004298_D006948 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chronic_4\JJ\1740 nicotine-treated_5\JJ\1740 rats_6\NNS\2329401 develop_7\VBP\1753788 <e2>locomotor_8\NN\1740 hyperactivity</e2>_9\NN\14052403 in_10\IN\13603305 response_11\NN\11410625 to_12\TO\1740 nicotine_13\NN\14712692 initially_14\RB\1740 due_15\JJ\1740 to_16\IN\1740 increases_17\NNS\13576355 of_18\IN\1740 both_19\CC\1740 the_20\DT\1740 density_21\NN\4941325 of_22\IN\1740 nicotinic_23\JJ\1740 receptors_24\NNS\5225602 and_25\CC\1740 <e1>da</e1>_26\NN\10484858 concentration_27\NN\4916342 ,_28\,\1740 followed_29\VBN\1835496 by_30\IN\1740 inducing_31\VBG\1627355 da_32\NN\10484858 receptor_33\NN\5225602 supersensitivity_34\NN\1740 in_35\IN\13603305 the_36\DT\1740 striatum_37\NN\5497363 ._38\.\1740
D004298_D006948 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chronic_4\JJ\1740 nicotine-treated_5\JJ\1740 rats_6\NNS\2329401 develop_7\VBP\1753788 <e2>locomotor_8\NN\1740 hyperactivity</e2>_9\NN\14052403 in_10\IN\13603305 response_11\NN\11410625 to_12\TO\1740 nicotine_13\NN\14712692 initially_14\RB\1740 due_15\JJ\1740 to_16\IN\1740 increases_17\NNS\13576355 of_18\IN\1740 both_19\CC\1740 the_20\DT\1740 density_21\NN\4941325 of_22\IN\1740 nicotinic_23\JJ\1740 receptors_24\NNS\5225602 and_25\CC\1740 da_26\NN\10484858 concentration_27\NN\4916342 ,_28\,\1740 followed_29\VBN\1835496 by_30\IN\1740 inducing_31\VBG\1627355 <e1>da</e1>_32\NN\10484858 receptor_33\NN\5225602 supersensitivity_34\NN\1740 in_35\IN\13603305 the_36\DT\1740 striatum_37\NN\5497363 ._38\.\1740
2790457
D002220_D012640 NONE chronic_0\JJ\1740 <e1>carbamazepine</e1>_1\NN\1740 inhibits_2\VBZ\2510337 the_3\DT\1740 development_4\NN\248977 of_5\IN\1740 local_6\JJ\1740 anesthetic_7\JJ\1740 <e2>seizures</e2>_8\NNS\14081375 kindled_9\VBN\2764245 by_10\IN\1740 cocaine_11\NN\3492717 and_12\CC\1740 lidocaine_13\NN\3681148 ._14\.\1740
D002220_D012640 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>carbamazepine</e1>_3\NN\1740 (_4\-LRB-\1740 cbz_5\NN\1740 )_6\-RRB-\1740 treatment_7\NN\654885 on_8\IN\1740 local_9\JJ\1740 anesthetic-kindled_10\JJ\1740 <e2>seizures</e2>_11\NNS\14081375 and_12\CC\1740 lethality_13\NN\4790449 were_14\VBD\836236 evaluated_15\VBN\670261 in_16\IN\13603305 different_17\JJ\1740 stages_18\NNS\15113229 of_19\IN\1740 the_20\DT\1740 kindling_21\NN\15101361 process_22\NN\407535 and_23\CC\1740 under_24\IN\1740 different_25\JJ\1740 methods_26\NNS\5616786 of_27\IN\1740 cbz_28\NN\1740 administration_29\NN\1133281 ._30\.\1740
D002220_D012640 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 carbamazepine_3\NN\1740 (_4\-LRB-\1740 <e1>cbz</e1>_5\NN\1740 )_6\-RRB-\1740 treatment_7\NN\654885 on_8\IN\1740 local_9\JJ\1740 anesthetic-kindled_10\JJ\1740 <e2>seizures</e2>_11\NNS\14081375 and_12\CC\1740 lethality_13\NN\4790449 were_14\VBD\836236 evaluated_15\VBN\670261 in_16\IN\13603305 different_17\JJ\1740 stages_18\NNS\15113229 of_19\IN\1740 the_20\DT\1740 kindling_21\NN\15101361 process_22\NN\407535 and_23\CC\1740 under_24\IN\1740 different_25\JJ\1740 methods_26\NNS\5616786 of_27\IN\1740 cbz_28\NN\1740 administration_29\NN\1133281 ._30\.\1740
D002220_D012640 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 carbamazepine_3\NN\1740 (_4\-LRB-\1740 cbz_5\NN\1740 )_6\-RRB-\1740 treatment_7\NN\654885 on_8\IN\1740 local_9\JJ\1740 anesthetic-kindled_10\JJ\1740 <e2>seizures</e2>_11\NNS\14081375 and_12\CC\1740 lethality_13\NN\4790449 were_14\VBD\836236 evaluated_15\VBN\670261 in_16\IN\13603305 different_17\JJ\1740 stages_18\NNS\15113229 of_19\IN\1740 the_20\DT\1740 kindling_21\NN\15101361 process_22\NN\407535 and_23\CC\1740 under_24\IN\1740 different_25\JJ\1740 methods_26\NNS\5616786 of_27\IN\1740 <e1>cbz</e1>_28\NN\1740 administration_29\NN\1133281 ._30\.\1740
D002220_D012640 NONE chronic_0\JJ\1740 oral_1\JJ\1740 <e1>cbz</e1>_2\NN\1740 inhibited_3\VBD\2510337 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 both_7\CC\1740 lidocaine-_8\NN\1740 and_9\CC\1740 cocaine-induced_10\JJ\1740 <e2>seizures</e2>_11\NNS\14081375 ,_12\,\1740 but_13\CC\1740 had_14\VBD\2108377 little_15\JJ\1740 effect_16\NN\34213 on_17\IN\1740 the_18\DT\1740 fully_19\RB\1740 developed_20\VBN\1753788 local_21\JJ\1740 anesthetic_22\JJ\1740 seizures_23\NNS\14081375 ._24\.\1740
D002220_D012640 NONE chronic_0\JJ\1740 oral_1\JJ\1740 <e1>cbz</e1>_2\NN\1740 inhibited_3\VBD\2510337 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 both_7\CC\1740 lidocaine-_8\NN\1740 and_9\CC\1740 cocaine-induced_10\JJ\1740 seizures_11\NNS\14081375 ,_12\,\1740 but_13\CC\1740 had_14\VBD\2108377 little_15\JJ\1740 effect_16\NN\34213 on_17\IN\1740 the_18\DT\1740 fully_19\RB\1740 developed_20\VBN\1753788 local_21\JJ\1740 anesthetic_22\JJ\1740 <e2>seizures</e2>_23\NNS\14081375 ._24\.\1740
D002220_D012640 NONE chronic_0\JJ\1740 <e1>cbz</e1>_1\NN\1740 also_2\RB\1740 decreased_3\VBD\169651 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>seizure-related</e2>_7\JJ\1740 mortality_8\NN\5054863 in_9\IN\13603305 the_10\DT\1740 cocaine-injected_11\JJ\1740 rats_12\NNS\2329401 ._13\.\1740
D002220_D012640 NONE acute_0\JJ\1740 <e1>cbz</e1>_1\NN\1740 over_2\IN\5867413 a_3\DT\13649268 range_4\NN\5123416 of_5\IN\1740 doses_6\NNS\3740161 (_7\-LRB-\1740 15_8\CD\13745420 -_9\SYM\1740 50_10\CD\13745420 mg/kg_11\NN\1740 )_12\-RRB-\1740 had_13\VBD\2108377 no_14\DT\7204911 effect_15\NN\34213 on_16\IN\1740 completed_17\VBN\352826 lidocaine-kindled_18\JJ\1740 or_19\CC\3541091 acute_20\JJ\1740 cocaine-induced_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 ._23\.\1740
D002220_D012640 NONE repeated_0\VBN\952524 i.p._1\RB\1740 injection_2\NN\320852 of_3\IN\1740 <e1>cbz</e1>_4\NN\1740 (_5\-LRB-\1740 15_6\CD\13745420 mg/kg_7\NN\1740 )_8\-RRB-\1740 also_9\RB\1740 was_10\VBD\836236 without_11\IN\1740 effect_12\NN\34213 on_13\IN\1740 the_14\DT\1740 development_15\NN\248977 of_16\IN\1740 lidocaine-_17\NN\1740 or_18\CC\3541091 cocaine-kindled_19\JJ\1740 <e2>seizures</e2>_20\NNS\14081375 ._21\.\1740
D002220_D012640 NONE the_0\DT\1740 differential_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>cbz</e1>_4\NN\1740 depending_5\VBG\2604760 upon_6\IN\1740 stage_7\NN\15113229 of_8\IN\1740 <e2>seizure</e2>_9\JJ\1740 development_10\NN\248977 suggest_11\VBP\1010118 that_12\IN\1740 distinct_13\JJ\1740 mechanisms_14\NNS\13446390 underlie_15\VBP\2604760 the_16\DT\1740 development_17\NN\248977 versus_18\CC\1740 maintenance_19\NN\266806 of_20\IN\1740 local_21\JJ\1740 anesthetic-kindled_22\JJ\1740 seizures_23\NNS\14081375 ._24\.\1740
D002220_D012640 NONE the_0\DT\1740 differential_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>cbz</e1>_4\NN\1740 depending_5\VBG\2604760 upon_6\IN\1740 stage_7\NN\15113229 of_8\IN\1740 seizure_9\JJ\1740 development_10\NN\248977 suggest_11\VBP\1010118 that_12\IN\1740 distinct_13\JJ\1740 mechanisms_14\NNS\13446390 underlie_15\VBP\2604760 the_16\DT\1740 development_17\NN\248977 versus_18\CC\1740 maintenance_19\NN\266806 of_20\IN\1740 local_21\JJ\1740 anesthetic-kindled_22\JJ\1740 <e2>seizures</e2>_23\NNS\14081375 ._24\.\1740
D003042_D012640 CID chronic_0\JJ\1740 carbamazepine_1\NN\1740 inhibits_2\VBZ\2510337 the_3\DT\1740 development_4\NN\248977 of_5\IN\1740 local_6\JJ\1740 anesthetic_7\JJ\1740 <e2>seizures</e2>_8\NNS\14081375 kindled_9\VBN\2764245 by_10\IN\1740 <e1>cocaine</e1>_11\NN\3492717 and_12\CC\1740 lidocaine_13\NN\3681148 ._14\.\1740
D003042_D012640 CID chronic_0\JJ\1740 oral_1\JJ\1740 cbz_2\NN\1740 inhibited_3\VBD\2510337 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 both_7\CC\1740 lidocaine-_8\NN\1740 and_9\CC\1740 <e1>cocaine-induced</e1>_10\JJ\1740 <e2>seizures</e2>_11\NNS\14081375 ,_12\,\1740 but_13\CC\1740 had_14\VBD\2108377 little_15\JJ\1740 effect_16\NN\34213 on_17\IN\1740 the_18\DT\1740 fully_19\RB\1740 developed_20\VBN\1753788 local_21\JJ\1740 anesthetic_22\JJ\1740 seizures_23\NNS\14081375 ._24\.\1740
D003042_D012640 CID chronic_0\JJ\1740 oral_1\JJ\1740 cbz_2\NN\1740 inhibited_3\VBD\2510337 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 both_7\CC\1740 lidocaine-_8\NN\1740 and_9\CC\1740 <e1>cocaine-induced</e1>_10\JJ\1740 seizures_11\NNS\14081375 ,_12\,\1740 but_13\CC\1740 had_14\VBD\2108377 little_15\JJ\1740 effect_16\NN\34213 on_17\IN\1740 the_18\DT\1740 fully_19\RB\1740 developed_20\VBN\1753788 local_21\JJ\1740 anesthetic_22\JJ\1740 <e2>seizures</e2>_23\NNS\14081375 ._24\.\1740
D003042_D012640 CID chronic_0\JJ\1740 cbz_1\NN\1740 also_2\RB\1740 decreased_3\VBD\169651 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>seizure-related</e2>_7\JJ\1740 mortality_8\NN\5054863 in_9\IN\13603305 the_10\DT\1740 <e1>cocaine-injected</e1>_11\JJ\1740 rats_12\NNS\2329401 ._13\.\1740
D003042_D012640 CID acute_0\JJ\1740 cbz_1\NN\1740 over_2\IN\5867413 a_3\DT\13649268 range_4\NN\5123416 of_5\IN\1740 doses_6\NNS\3740161 (_7\-LRB-\1740 15_8\CD\13745420 -_9\SYM\1740 50_10\CD\13745420 mg/kg_11\NN\1740 )_12\-RRB-\1740 had_13\VBD\2108377 no_14\DT\7204911 effect_15\NN\34213 on_16\IN\1740 completed_17\VBN\352826 lidocaine-kindled_18\JJ\1740 or_19\CC\3541091 acute_20\JJ\1740 <e1>cocaine-induced</e1>_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 ._23\.\1740
D003042_D012640 CID repeated_0\VBN\952524 i.p._1\RB\1740 injection_2\NN\320852 of_3\IN\1740 cbz_4\NN\1740 (_5\-LRB-\1740 15_6\CD\13745420 mg/kg_7\NN\1740 )_8\-RRB-\1740 also_9\RB\1740 was_10\VBD\836236 without_11\IN\1740 effect_12\NN\34213 on_13\IN\1740 the_14\DT\1740 development_15\NN\248977 of_16\IN\1740 lidocaine-_17\NN\1740 or_18\CC\3541091 <e1>cocaine-kindled</e1>_19\JJ\1740 <e2>seizures</e2>_20\NNS\14081375 ._21\.\1740
D008012_D012640 CID chronic_0\JJ\1740 carbamazepine_1\NN\1740 inhibits_2\VBZ\2510337 the_3\DT\1740 development_4\NN\248977 of_5\IN\1740 local_6\JJ\1740 anesthetic_7\JJ\1740 <e2>seizures</e2>_8\NNS\14081375 kindled_9\VBN\2764245 by_10\IN\1740 cocaine_11\NN\3492717 and_12\CC\1740 <e1>lidocaine</e1>_13\NN\3681148 ._14\.\1740
D008012_D012640 CID chronic_0\JJ\1740 oral_1\JJ\1740 cbz_2\NN\1740 inhibited_3\VBD\2510337 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 both_7\CC\1740 <e1>lidocaine-</e1>_8\NN\1740 and_9\CC\1740 cocaine-induced_10\JJ\1740 <e2>seizures</e2>_11\NNS\14081375 ,_12\,\1740 but_13\CC\1740 had_14\VBD\2108377 little_15\JJ\1740 effect_16\NN\34213 on_17\IN\1740 the_18\DT\1740 fully_19\RB\1740 developed_20\VBN\1753788 local_21\JJ\1740 anesthetic_22\JJ\1740 seizures_23\NNS\14081375 ._24\.\1740
D008012_D012640 CID chronic_0\JJ\1740 oral_1\JJ\1740 cbz_2\NN\1740 inhibited_3\VBD\2510337 the_4\DT\1740 development_5\NN\248977 of_6\IN\1740 both_7\CC\1740 <e1>lidocaine-</e1>_8\NN\1740 and_9\CC\1740 cocaine-induced_10\JJ\1740 seizures_11\NNS\14081375 ,_12\,\1740 but_13\CC\1740 had_14\VBD\2108377 little_15\JJ\1740 effect_16\NN\34213 on_17\IN\1740 the_18\DT\1740 fully_19\RB\1740 developed_20\VBN\1753788 local_21\JJ\1740 anesthetic_22\JJ\1740 <e2>seizures</e2>_23\NNS\14081375 ._24\.\1740
D008012_D012640 CID acute_0\JJ\1740 cbz_1\NN\1740 over_2\IN\5867413 a_3\DT\13649268 range_4\NN\5123416 of_5\IN\1740 doses_6\NNS\3740161 (_7\-LRB-\1740 15_8\CD\13745420 -_9\SYM\1740 50_10\CD\13745420 mg/kg_11\NN\1740 )_12\-RRB-\1740 had_13\VBD\2108377 no_14\DT\7204911 effect_15\NN\34213 on_16\IN\1740 completed_17\VBN\352826 <e1>lidocaine-kindled</e1>_18\JJ\1740 or_19\CC\3541091 acute_20\JJ\1740 cocaine-induced_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 ._23\.\1740
D008012_D012640 CID repeated_0\VBN\952524 i.p._1\RB\1740 injection_2\NN\320852 of_3\IN\1740 cbz_4\NN\1740 (_5\-LRB-\1740 15_6\CD\13745420 mg/kg_7\NN\1740 )_8\-RRB-\1740 also_9\RB\1740 was_10\VBD\836236 without_11\IN\1740 effect_12\NN\34213 on_13\IN\1740 the_14\DT\1740 development_15\NN\248977 of_16\IN\1740 <e1>lidocaine-</e1>_17\NN\1740 or_18\CC\3541091 cocaine-kindled_19\JJ\1740 <e2>seizures</e2>_20\NNS\14081375 ._21\.\1740
16116131
D007980_D004409 CID the_0\DT\1740 neural_1\JJ\1740 mechanisms_2\NNS\13446390 and_3\CC\1740 circuitry_4\NN\3278248 involved_5\VBN\2676054 in_6\IN\13603305 <e1>levodopa-induced</e1>_7\JJ\1740 <e2>dyskinesia</e2>_8\NN\14084880 are_9\VBP\836236 unclear_10\JJ\1740 ._11\.\1740
D001058_D010300 NONE using_0\VBG\1156834 repetitive_1\JJ\1740 transcranial_2\JJ\1740 magnetic_3\JJ\1740 stimulation_4\NN\242808 (_5\-LRB-\1740 rtms_6\NNS\1740 )_7\-RRB-\1740 over_8\IN\5867413 the_9\DT\1740 supplementary_10\NN\1740 motor_11\NN\3699975 area_12\NN\8630985 (_13\-LRB-\1740 sma_14\NN\1740 )_15\-RRB-\1740 in_16\IN\13603305 a_17\DT\13649268 group_18\NN\2137 of_19\IN\1740 patients_20\NNS\9898892 with_21\IN\1740 advanced_22\JJ\1740 <e2>parkinson_23\NN\1740 disease</e2>_24\NN\14061805 ,_25\,\1740 the_26\DT\1740 authors_27\NNS\9610660 investigated_28\VBD\644583 whether_29\IN\1740 modulation_30\NN\7044917 of_31\IN\1740 sma_32\NN\1740 excitability_33\NN\5653575 may_34\MD\15209706 result_35\VB\2633881 in_36\IN\13603305 a_37\DT\13649268 modification_38\NN\191142 of_39\IN\1740 a_40\DT\13649268 dyskinetic_41\JJ\1740 state_42\NN\8491826 induced_43\VBN\1627355 by_44\IN\1740 continuous_45\JJ\1740 <e1>apomorphine</e1>_46\NN\3786417 infusion_47\NN\14589223 ._48\.\1740
D001058_D004409 NONE using_0\VBG\1156834 repetitive_1\JJ\1740 transcranial_2\JJ\1740 magnetic_3\JJ\1740 stimulation_4\NN\242808 (_5\-LRB-\1740 rtms_6\NNS\1740 )_7\-RRB-\1740 over_8\IN\5867413 the_9\DT\1740 supplementary_10\NN\1740 motor_11\NN\3699975 area_12\NN\8630985 (_13\-LRB-\1740 sma_14\NN\1740 )_15\-RRB-\1740 in_16\IN\13603305 a_17\DT\13649268 group_18\NN\2137 of_19\IN\1740 patients_20\NNS\9898892 with_21\IN\1740 advanced_22\JJ\1740 parkinson_23\NN\1740 disease_24\NN\14061805 ,_25\,\1740 the_26\DT\1740 authors_27\NNS\9610660 investigated_28\VBD\644583 whether_29\IN\1740 modulation_30\NN\7044917 of_31\IN\1740 sma_32\NN\1740 excitability_33\NN\5653575 may_34\MD\15209706 result_35\VB\2633881 in_36\IN\13603305 a_37\DT\13649268 modification_38\NN\191142 of_39\IN\1740 a_40\DT\13649268 <e2>dyskinetic</e2>_41\JJ\1740 state_42\NN\8491826 induced_43\VBN\1627355 by_44\IN\1740 continuous_45\JJ\1740 <e1>apomorphine</e1>_46\NN\3786417 infusion_47\NN\14589223 ._48\.\1740
9867728
D005277_D006349 NONE risk_0\NN\14541044 for_1\IN\1740 <e2>valvular_2\JJ\1740 heart_3\NN\5919034 disease</e2>_4\NN\14061805 among_5\IN\1740 users_6\NNS\7846 of_7\IN\1740 <e1>fenfluramine</e1>_8\NN\1740 and_9\CC\1740 dexfenfluramine_10\NN\1740 who_11\WP\8299493 underwent_12\VBD\109660 echocardiography_13\NN\177127 before_14\IN\1740 use_15\NN\407535 of_16\IN\1740 medication_17\NN\3247620 ._18\.\1740
D005277_D006349 NONE background_0\NN\4921011 :_1\:\1740 because_2\IN\1740 uncontrolled_3\JJ\1740 echocardiographic_4\JJ\1740 surveys_5\NNS\635850 suggested_6\VBD\1010118 that_7\IN\1740 up_8\IN\1740 to_9\TO\1740 30_10\CD\13745420 %_11\NN\1740 to_12\IN\1740 38_13\CD\1740 %_14\NN\1740 of_15\IN\1740 users_16\NNS\7846 of_17\IN\1740 <e1>fenfluramine</e1>_18\NN\1740 and_19\CC\1740 dexfenfluramine_20\NN\1740 had_21\VBD\2108377 <e2>valvular_22\JJ\1740 disease</e2>_23\NN\14061805 ,_24\,\1740 these_25\DT\1740 drugs_26\NNS\14778436 were_27\VBD\836236 withdrawn_28\VBN\1835496 from_29\IN\1740 the_30\DT\1740 market_31\NN\407535 ._32\.\1740
D005277_D006349 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 risk_5\NN\14541044 for_6\IN\1740 new_7\JJ\1740 or_8\CC\3541091 worsening_9\VBG\146138 <e2>valvular_10\JJ\1740 abnormalities</e2>_11\NNS\14034177 among_12\IN\1740 users_13\NNS\7846 of_14\IN\1740 <e1>fenfluramine</e1>_15\NN\1740 or_16\CC\3541091 dexfenfluramine_17\NN\1740 who_18\WP\8299493 underwent_19\VBD\109660 echocardiography_20\NN\177127 before_21\IN\1740 they_22\PRP\1740 began_23\VBD\941990 to_24\TO\1740 take_25\VB\2367363 these_26\DT\1740 medications._27\NN\1740 design_28\NN\927261 :_29\:\1740 cohort_30\NN\8184861 study_31\NN\635850 ._32\.\1740
D005277_D006349 NONE results_0\NNS\34213 :_1\:\1740 two_2\CD\13741022 patients_3\NNS\9898892 (_4\-LRB-\1740 4.3_5\CD\1740 %_6\NN\1740 [_7\-LRB-\1740 95_8\CD\1740 %_9\NN\1740 ci_10\NN\13635336 ,_11\,\1740 0.6_12\CD\1740 %_13\NN\1740 to_14\IN\1740 14.8_15\CD\1740 %_16\NN\1740 ]_17\-RRB-\1740 )_18\-RRB-\1740 receiving_19\VBG\2210855 <e1>fenfluramine-phentermine</e1>_20\NN\1740 developed_21\VBD\1753788 <e2>valvular_22\JJ\1740 heart_23\NN\5919034 disease</e2>_24\NN\14061805 ._25\.\1740
D020372_D006349 NONE risk_0\NN\14541044 for_1\IN\1740 <e2>valvular_2\JJ\1740 heart_3\NN\5919034 disease</e2>_4\NN\14061805 among_5\IN\1740 users_6\NNS\7846 of_7\IN\1740 fenfluramine_8\NN\1740 and_9\CC\1740 <e1>dexfenfluramine</e1>_10\NN\1740 who_11\WP\8299493 underwent_12\VBD\109660 echocardiography_13\NN\177127 before_14\IN\1740 use_15\NN\407535 of_16\IN\1740 medication_17\NN\3247620 ._18\.\1740
D020372_D006349 NONE background_0\NN\4921011 :_1\:\1740 because_2\IN\1740 uncontrolled_3\JJ\1740 echocardiographic_4\JJ\1740 surveys_5\NNS\635850 suggested_6\VBD\1010118 that_7\IN\1740 up_8\IN\1740 to_9\TO\1740 30_10\CD\13745420 %_11\NN\1740 to_12\IN\1740 38_13\CD\1740 %_14\NN\1740 of_15\IN\1740 users_16\NNS\7846 of_17\IN\1740 fenfluramine_18\NN\1740 and_19\CC\1740 <e1>dexfenfluramine</e1>_20\NN\1740 had_21\VBD\2108377 <e2>valvular_22\JJ\1740 disease</e2>_23\NN\14061805 ,_24\,\1740 these_25\DT\1740 drugs_26\NNS\14778436 were_27\VBD\836236 withdrawn_28\VBN\1835496 from_29\IN\1740 the_30\DT\1740 market_31\NN\407535 ._32\.\1740
D020372_D006349 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 the_4\DT\1740 risk_5\NN\14541044 for_6\IN\1740 new_7\JJ\1740 or_8\CC\3541091 worsening_9\VBG\146138 <e2>valvular_10\JJ\1740 abnormalities</e2>_11\NNS\14034177 among_12\IN\1740 users_13\NNS\7846 of_14\IN\1740 fenfluramine_15\NN\1740 or_16\CC\3541091 <e1>dexfenfluramine</e1>_17\NN\1740 who_18\WP\8299493 underwent_19\VBD\109660 echocardiography_20\NN\177127 before_21\IN\1740 they_22\PRP\1740 began_23\VBD\941990 to_24\TO\1740 take_25\VB\2367363 these_26\DT\1740 medications._27\NN\1740 design_28\NN\927261 :_29\:\1740 cohort_30\NN\8184861 study_31\NN\635850 ._32\.\1740
D010645_D006349 NONE results_0\NNS\34213 :_1\:\1740 two_2\CD\13741022 patients_3\NNS\9898892 (_4\-LRB-\1740 4.3_5\CD\1740 %_6\NN\1740 [_7\-LRB-\1740 95_8\CD\1740 %_9\NN\1740 ci_10\NN\13635336 ,_11\,\1740 0.6_12\CD\1740 %_13\NN\1740 to_14\IN\1740 14.8_15\CD\1740 %_16\NN\1740 ]_17\-RRB-\1740 )_18\-RRB-\1740 receiving_19\VBG\2210855 <e1>fenfluramine-phentermine</e1>_20\NN\1740 developed_21\VBD\1753788 <e2>valvular_22\JJ\1740 heart_23\NN\5919034 disease</e2>_24\NN\14061805 ._25\.\1740
804391
D012293_D011507 CID light_0\JJ\1740 chain_1\NN\8457976 <e2>proteinuria</e2>_2\NN\14299637 and_3\CC\1740 cellular_4\JJ\1740 mediated_5\JJ\1740 immunity_6\NN\13920835 in_7\IN\13603305 <e1>rifampin</e1>_8\JJ\1740 treated_9\JJ\1740 patients_10\NNS\9898892 with_11\IN\1740 tuberculosis_12\NN\14127211 ._13\.\1740
D012293_D011507 CID light_0\JJ\1740 chain_1\NN\8457976 <e2>proteinuria</e2>_2\NN\14299637 was_3\VBD\836236 found_4\VBN\2426171 in_5\IN\13603305 9_6\CD\13741022 of_7\IN\1740 17_8\CD\13745420 tuberculosis_9\NN\14127211 patients_10\NNS\9898892 treated_11\VBN\2376958 with_12\IN\1740 <e1>rifampin</e1>_13\NN\2716205 ._14\.\1740
D012293_D014376 NONE light_0\JJ\1740 chain_1\NN\8457976 proteinuria_2\NN\14299637 and_3\CC\1740 cellular_4\JJ\1740 mediated_5\JJ\1740 immunity_6\NN\13920835 in_7\IN\13603305 <e1>rifampin</e1>_8\JJ\1740 treated_9\JJ\1740 patients_10\NNS\9898892 with_11\IN\1740 <e2>tuberculosis</e2>_12\NN\14127211 ._13\.\1740
D012293_D014376 NONE light_0\JJ\1740 chain_1\NN\8457976 proteinuria_2\NN\14299637 was_3\VBD\836236 found_4\VBN\2426171 in_5\IN\13603305 9_6\CD\13741022 of_7\IN\1740 17_8\CD\13745420 <e2>tuberculosis</e2>_9\NN\14127211 patients_10\NNS\9898892 treated_11\VBN\2376958 with_12\IN\1740 <e1>rifampin</e1>_13\NN\2716205 ._14\.\1740
9523850
D008775_D018771 NONE value_0\NN\5856066 of_1\IN\1740 <e1>methylprednisolone</e1>_2\NN\1740 in_3\IN\13603305 prevention_4\NN\1073995 of_5\IN\1740 the_6\DT\1740 <e2>arthralgia-myalgia</e2>_7\JJ\1740 syndrome_8\NN\5870365 associated_9\VBN\628491 with_10\IN\1740 the_11\DT\1740 total_12\JJ\1740 dose_13\NN\3740161 infusion_14\NN\14589223 of_15\IN\1740 iron_16\NN\14625458 dextran_17\NN\1740 :_18\:\1740 a_19\DT\13649268 double_20\JJ\1740 blind_21\JJ\1740 randomized_22\JJ\1740 trial_23\NN\786195 ._24\.\1740
D008775_D018771 NONE these_0\DT\1740 data_1\NNS\7951464 demonstrate_2\VBP\2137132 that_3\IN\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>mp</e1>_6\NN\10249459 before_7\IN\1740 and_8\CC\1740 after_9\IN\1740 tdi_10\NN\1740 reduces_11\VBZ\441445 the_12\DT\1740 frequency_13\NN\15286249 and_14\CC\1740 severity_15\NN\5036394 of_16\IN\1740 the_17\DT\1740 <e2>arthralgia-myalgia</e2>_18\JJ\1740 syndrome_19\NN\5870365 ._20\.\1740
D008775_D063806 NONE value_0\NN\5856066 of_1\IN\1740 <e1>methylprednisolone</e1>_2\NN\1740 in_3\IN\13603305 prevention_4\NN\1073995 of_5\IN\1740 the_6\DT\1740 <e2>arthralgia-myalgia</e2>_7\JJ\1740 syndrome_8\NN\5870365 associated_9\VBN\628491 with_10\IN\1740 the_11\DT\1740 total_12\JJ\1740 dose_13\NN\3740161 infusion_14\NN\14589223 of_15\IN\1740 iron_16\NN\14625458 dextran_17\NN\1740 :_18\:\1740 a_19\DT\13649268 double_20\JJ\1740 blind_21\JJ\1740 randomized_22\JJ\1740 trial_23\NN\786195 ._24\.\1740
D008775_D063806 NONE these_0\DT\1740 data_1\NNS\7951464 demonstrate_2\VBP\2137132 that_3\IN\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>mp</e1>_6\NN\10249459 before_7\IN\1740 and_8\CC\1740 after_9\IN\1740 tdi_10\NN\1740 reduces_11\VBZ\441445 the_12\DT\1740 frequency_13\NN\15286249 and_14\CC\1740 severity_15\NN\5036394 of_16\IN\1740 the_17\DT\1740 <e2>arthralgia-myalgia</e2>_18\JJ\1740 syndrome_19\NN\5870365 ._20\.\1740
D007505_D018771 CID value_0\NN\5856066 of_1\IN\1740 methylprednisolone_2\NN\1740 in_3\IN\13603305 prevention_4\NN\1073995 of_5\IN\1740 the_6\DT\1740 <e2>arthralgia-myalgia</e2>_7\JJ\1740 syndrome_8\NN\5870365 associated_9\VBN\628491 with_10\IN\1740 the_11\DT\1740 total_12\JJ\1740 dose_13\NN\3740161 infusion_14\NN\14589223 of_15\IN\1740 <e1>iron_16\NN\14625458 dextran</e1>_17\NN\1740 :_18\:\1740 a_19\DT\13649268 double_20\JJ\1740 blind_21\JJ\1740 randomized_22\JJ\1740 trial_23\NN\786195 ._24\.\1740
D007505_D063806 NONE value_0\NN\5856066 of_1\IN\1740 methylprednisolone_2\NN\1740 in_3\IN\13603305 prevention_4\NN\1073995 of_5\IN\1740 the_6\DT\1740 <e2>arthralgia-myalgia</e2>_7\JJ\1740 syndrome_8\NN\5870365 associated_9\VBN\628491 with_10\IN\1740 the_11\DT\1740 total_12\JJ\1740 dose_13\NN\3740161 infusion_14\NN\14589223 of_15\IN\1740 <e1>iron_16\NN\14625458 dextran</e1>_17\NN\1740 :_18\:\1740 a_19\DT\13649268 double_20\JJ\1740 blind_21\JJ\1740 randomized_22\JJ\1740 trial_23\NN\786195 ._24\.\1740
2569282
D020927_D009127 NONE <e1>dexmedetomidine</e1>_0\NNP\1740 ,_1\,\1740 acting_2\VBG\1619354 through_3\IN\1740 central_4\JJ\1740 alpha-2_5\NN\1740 adrenoceptors_6\NNS\1740 ,_7\,\1740 prevents_8\VBZ\1740 opiate-induced_9\JJ\1740 <e2>muscle_10\NN\5289601 rigidity</e2>_11\NN\5023233 in_12\IN\13603305 the_13\DT\1740 rat_14\NN\2329401 ._15\.\1740
D020927_D009127 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 authors_6\NNS\9610660 determined_7\VBD\1645601 if_8\IN\1740 treatment_9\NN\654885 with_10\IN\1740 <e1>d-med</e1>_11\NN\1740 prevents_12\VBZ\1740 the_13\DT\1740 <e2>muscle_14\NN\5289601 rigidity</e2>_15\NN\5023233 caused_16\VBN\1617192 by_17\IN\1740 high-dose_18\JJ\1740 alfentanil_19\JJ\1740 anesthesia_20\NN\14034177 in_21\IN\13603305 the_22\DT\1740 rat_23\NN\2329401 ._24\.\1740
D020927_D009127 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 <e1>d-med</e1>_3\NN\1740 prevented_4\VBD\1740 alfentanil-induced_5\JJ\1740 <e2>muscle_6\NN\5289601 rigidity</e2>_7\NN\5023233 in_8\IN\13603305 a_9\DT\13649268 dose-dependent_10\JJ\1740 fashion_11\NN\4916342 ._12\.\1740
D020927_D009123 NONE the_0\DT\1740 highly-selective_1\JJ\1740 alpha-2_2\NN\1740 adrenergic_3\JJ\1740 agonist_4\NN\9613191 <e1>dexmedetomidine</e1>_5\NN\1740 (_6\-LRB-\1740 d-med_7\NN\1740 )_8\-RRB-\1740 is_9\VBZ\836236 capable_10\JJ\1740 of_11\IN\1740 inducing_12\VBG\1627355 <e2>muscle_13\NN\5289601 flaccidity</e2>_14\NN\4938228 and_15\CC\1740 anesthesia_16\NN\14034177 in_17\IN\13603305 rats_18\NNS\2329401 and_19\CC\1740 dogs_20\NNS\2083346 ._21\.\1740
D020927_D009123 NONE the_0\DT\1740 highly-selective_1\JJ\1740 alpha-2_2\NN\1740 adrenergic_3\JJ\1740 agonist_4\NN\9613191 dexmedetomidine_5\NN\1740 (_6\-LRB-\1740 <e1>d-med</e1>_7\NN\1740 )_8\-RRB-\1740 is_9\VBZ\836236 capable_10\JJ\1740 of_11\IN\1740 inducing_12\VBG\1627355 <e2>muscle_13\NN\5289601 flaccidity</e2>_14\NN\4938228 and_15\CC\1740 anesthesia_16\NN\14034177 in_17\IN\13603305 rats_18\NNS\2329401 and_19\CC\1740 dogs_20\NNS\2083346 ._21\.\1740
D015760_D009127 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 the_5\DT\1740 authors_6\NNS\9610660 determined_7\VBD\1645601 if_8\IN\1740 treatment_9\NN\654885 with_10\IN\1740 d-med_11\NN\1740 prevents_12\VBZ\1740 the_13\DT\1740 <e2>muscle_14\NN\5289601 rigidity</e2>_15\NN\5023233 caused_16\VBN\1617192 by_17\IN\1740 high-dose_18\JJ\1740 <e1>alfentanil</e1>_19\JJ\1740 anesthesia_20\NN\14034177 in_21\IN\13603305 the_22\DT\1740 rat_23\NN\2329401 ._24\.\1740
D015760_D009127 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 d-med_3\NN\1740 prevented_4\VBD\1740 <e1>alfentanil-induced</e1>_5\JJ\1740 <e2>muscle_6\NN\5289601 rigidity</e2>_7\NN\5023233 in_8\IN\13603305 a_9\DT\13649268 dose-dependent_10\JJ\1740 fashion_11\NN\4916342 ._12\.\1740
D020927_D018476 NONE the_0\DT\1740 high-dose_1\JJ\1740 <e1>d-med</e1>_2\NN\1740 animals_3\NNS\4475 were_4\VBD\836236 flaccid_5\JJ\1740 ,_6\,\1740 <e2>akinetic</e2>_7\JJ\1740 ,_8\,\1740 and_9\CC\1740 lacked_10\VBD\1740 a_11\DT\13649268 startle_12\JJ\1740 response_13\NN\11410625 during_14\IN\1740 the_15\DT\1740 entire_16\JJ\1740 experimental_17\JJ\1740 period_18\NN\13575869 ._19\.\1740
D020927_D012021 NONE the_0\DT\1740 high-dose_1\JJ\1740 <e1>d-med</e1>_2\NN\1740 animals_3\NNS\4475 were_4\VBD\836236 flaccid_5\JJ\1740 ,_6\,\1740 akinetic_7\JJ\1740 ,_8\,\1740 and_9\CC\1740 lacked_10\VBD\1740 a_11\DT\13649268 <e2>startle</e2>_12\JJ\1740 response_13\NN\11410625 during_14\IN\1740 the_15\DT\1740 entire_16\JJ\1740 experimental_17\JJ\1740 period_18\NN\13575869 ._19\.\1740
12481039
D012964_D012640 NONE reduced_0\VBN\441445 <e1>sodium</e1>_1\NN\14625458 channel_2\NN\6251781 density_3\NN\4941325 ,_4\,\1740 altered_5\JJ\1740 voltage_6\NN\11449002 dependence_7\NN\24720 of_8\IN\1740 inactivation_9\NN\13518963 ,_10\,\1740 and_11\CC\1740 increased_12\VBD\169651 susceptibility_13\NN\13920835 to_14\TO\1740 <e2>seizures</e2>_15\NNS\14081375 in_16\IN\13603305 mice_17\NNS\2329401 lacking_18\VBG\1740 sodium_19\NN\14625458 channel_20\NN\6251781 beta_21\NN\6828818 2-subunits_22\NNS\1740 ._23\.\1740
D012964_D012640 NONE reduced_0\VBN\441445 sodium_1\NN\14625458 channel_2\NN\6251781 density_3\NN\4941325 ,_4\,\1740 altered_5\JJ\1740 voltage_6\NN\11449002 dependence_7\NN\24720 of_8\IN\1740 inactivation_9\NN\13518963 ,_10\,\1740 and_11\CC\1740 increased_12\VBD\169651 susceptibility_13\NN\13920835 to_14\TO\1740 <e2>seizures</e2>_15\NNS\14081375 in_16\IN\13603305 mice_17\NNS\2329401 lacking_18\VBG\1740 <e1>sodium</e1>_19\NN\14625458 channel_20\NN\6251781 beta_21\NN\6828818 2-subunits_22\NNS\1740 ._23\.\1740
D010862_D012640 CID beta2(-/-_0\VBN\1740 )_1\-RRB-\1740 mice_2\NNS\2329401 displayed_3\VBD\2137132 increased_4\VBN\169651 susceptibility_5\NN\13920835 to_6\IN\1740 <e2>seizures</e2>_7\NNS\14081375 ,_8\,\1740 as_9\IN\14622893 indicated_10\VBN\952524 by_11\IN\1740 reduced_12\VBN\441445 latency_13\NN\15269513 and_14\CC\1740 threshold_15\NN\15265518 for_16\IN\1740 <e1>pilocarpine-induced</e1>_17\JJ\1740 seizures_18\NNS\14081375 ,_19\,\1740 but_20\CC\1740 seemed_21\VBD\2604760 normal_22\JJ\1740 in_23\IN\13603305 other_24\JJ\1740 neurological_25\JJ\1740 tests_26\NNS\5798043 ._27\.\1740
D010862_D012640 CID beta2(-/-_0\VBN\1740 )_1\-RRB-\1740 mice_2\NNS\2329401 displayed_3\VBD\2137132 increased_4\VBN\169651 susceptibility_5\NN\13920835 to_6\IN\1740 seizures_7\NNS\14081375 ,_8\,\1740 as_9\IN\14622893 indicated_10\VBN\952524 by_11\IN\1740 reduced_12\VBN\441445 latency_13\NN\15269513 and_14\CC\1740 threshold_15\NN\15265518 for_16\IN\1740 <e1>pilocarpine-induced</e1>_17\JJ\1740 <e2>seizures</e2>_18\NNS\14081375 ,_19\,\1740 but_20\CC\1740 seemed_21\VBD\2604760 normal_22\JJ\1740 in_23\IN\13603305 other_24\JJ\1740 neurological_25\JJ\1740 tests_26\NNS\5798043 ._27\.\1740
20195852
D003287_D007674 CID risk_0\NN\14541044 of_1\IN\1740 <e2>nephropathy</e2>_2\NN\14573196 after_3\IN\1740 consumption_4\NN\13440063 of_5\IN\1740 nonionic_6\JJ\1740 <e1>contrast_7\NN\13854649 media</e1>_8\NNS\3575240 by_9\IN\1740 children_10\NNS\9622049 undergoing_11\VBG\109660 cardiac_12\JJ\1740 angiography_13\NN\904623 :_14\:\1740 a_15\DT\13649268 prospective_16\JJ\1740 study_17\NN\635850 ._18\.\1740
D003287_D007674 CID despite_0\IN\7501545 increasing_1\VBG\169651 reports_2\NNS\6470073 on_3\IN\1740 nonionic_4\JJ\1740 <e1>contrast_5\NN\13854649 media-induced</e1>_6\JJ\1740 <e2>nephropathy</e2>_7\NN\14573196 (_8\-LRB-\1740 cin_9\NN\1740 )_10\-RRB-\1740 in_11\IN\13603305 hospitalized_12\VBN\2348568 adult_13\JJ\1740 patients_14\NNS\9898892 during_15\IN\1740 cardiac_16\JJ\1740 procedures_17\NNS\407535 ,_18\,\1740 the_19\DT\1740 studies_20\NNS\635850 in_21\IN\13603305 pediatrics_22\NNS\6043075 are_23\VBP\836236 limited_24\VBN\2510337 ,_25\,\1740 with_26\IN\1740 even_27\RB\1740 less_28\RBR\1740 focus_29\NN\5704266 on_30\IN\1740 possible_31\JJ\1740 predisposing_32\VBG\680841 factors_33\NNS\7326557 and_34\CC\1740 preventive_35\JJ\1740 measures_36\NNS\168237 for_37\IN\1740 patients_38\NNS\9898892 undergoing_39\VBG\109660 cardiac_40\JJ\1740 angiography_41\NN\904623 ._42\.\1740
D003287_D007674 CID despite_0\IN\7501545 increasing_1\VBG\169651 reports_2\NNS\6470073 on_3\IN\1740 nonionic_4\JJ\1740 <e1>contrast_5\NN\13854649 media-induced</e1>_6\JJ\1740 nephropathy_7\NN\14573196 (_8\-LRB-\1740 <e2>cin</e2>_9\NN\1740 )_10\-RRB-\1740 in_11\IN\13603305 hospitalized_12\VBN\2348568 adult_13\JJ\1740 patients_14\NNS\9898892 during_15\IN\1740 cardiac_16\JJ\1740 procedures_17\NNS\407535 ,_18\,\1740 the_19\DT\1740 studies_20\NNS\635850 in_21\IN\13603305 pediatrics_22\NNS\6043075 are_23\VBP\836236 limited_24\VBN\2510337 ,_25\,\1740 with_26\IN\1740 even_27\RB\1740 less_28\RBR\1740 focus_29\NN\5704266 on_30\IN\1740 possible_31\JJ\1740 predisposing_32\VBG\680841 factors_33\NNS\7326557 and_34\CC\1740 preventive_35\JJ\1740 measures_36\NNS\168237 for_37\IN\1740 patients_38\NNS\9898892 undergoing_39\VBG\109660 cardiac_40\JJ\1740 angiography_41\NN\904623 ._42\.\1740
D003287_D007674 CID this_0\DT\1740 prospective_1\JJ\1740 study_2\NN\635850 determined_3\VBD\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>cin</e2>_7\NN\1740 for_8\IN\1740 two_9\CD\13741022 nonionic_10\JJ\1740 <e1>contrast_11\NN\13854649 media</e1>_12\NNS\3575240 (_13\-LRB-\1740 cm_14\NN\13649268 )_15\-RRB-\1740 ,_16\,\1740 iopromide_17\NN\1740 and_18\CC\1740 iohexol_19\NN\1740 ,_20\,\1740 among_21\IN\1740 80_22\CD\13745420 patients_23\NNS\9898892 younger_24\JJR\1740 than_25\IN\1740 18_26\CD\13745420 years_27\NNS\15144371 and_28\CC\1740 compared_29\VBD\644583 the_30\DT\1740 rates_31\NNS\13308999 for_32\IN\1740 this_33\DT\1740 complication_34\NN\1073995 in_35\IN\13603305 relation_36\NN\2137 to_37\TO\1740 the_38\DT\1740 type_39\NN\5839024 and_40\CC\1740 dosage_41\NN\13576355 of_42\IN\1740 cm_43\NN\13649268 and_44\CC\1740 the_45\DT\1740 presence_46\NN\13954253 of_47\IN\1740 cyanosis_48\NN\14299637 ._49\.\1740
D003287_D007674 CID this_0\DT\1740 prospective_1\JJ\1740 study_2\NN\635850 determined_3\VBD\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>cin</e2>_7\NN\1740 for_8\IN\1740 two_9\CD\13741022 nonionic_10\JJ\1740 contrast_11\NN\13854649 media_12\NNS\3575240 (_13\-LRB-\1740 <e1>cm</e1>_14\NN\13649268 )_15\-RRB-\1740 ,_16\,\1740 iopromide_17\NN\1740 and_18\CC\1740 iohexol_19\NN\1740 ,_20\,\1740 among_21\IN\1740 80_22\CD\13745420 patients_23\NNS\9898892 younger_24\JJR\1740 than_25\IN\1740 18_26\CD\13745420 years_27\NNS\15144371 and_28\CC\1740 compared_29\VBD\644583 the_30\DT\1740 rates_31\NNS\13308999 for_32\IN\1740 this_33\DT\1740 complication_34\NN\1073995 in_35\IN\13603305 relation_36\NN\2137 to_37\TO\1740 the_38\DT\1740 type_39\NN\5839024 and_40\CC\1740 dosage_41\NN\13576355 of_42\IN\1740 cm_43\NN\13649268 and_44\CC\1740 the_45\DT\1740 presence_46\NN\13954253 of_47\IN\1740 cyanosis_48\NN\14299637 ._49\.\1740
D003287_D007674 CID this_0\DT\1740 prospective_1\JJ\1740 study_2\NN\635850 determined_3\VBD\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>cin</e2>_7\NN\1740 for_8\IN\1740 two_9\CD\13741022 nonionic_10\JJ\1740 contrast_11\NN\13854649 media_12\NNS\3575240 (_13\-LRB-\1740 cm_14\NN\13649268 )_15\-RRB-\1740 ,_16\,\1740 iopromide_17\NN\1740 and_18\CC\1740 iohexol_19\NN\1740 ,_20\,\1740 among_21\IN\1740 80_22\CD\13745420 patients_23\NNS\9898892 younger_24\JJR\1740 than_25\IN\1740 18_26\CD\13745420 years_27\NNS\15144371 and_28\CC\1740 compared_29\VBD\644583 the_30\DT\1740 rates_31\NNS\13308999 for_32\IN\1740 this_33\DT\1740 complication_34\NN\1073995 in_35\IN\13603305 relation_36\NN\2137 to_37\TO\1740 the_38\DT\1740 type_39\NN\5839024 and_40\CC\1740 dosage_41\NN\13576355 of_42\IN\1740 <e1>cm</e1>_43\NN\13649268 and_44\CC\1740 the_45\DT\1740 presence_46\NN\13954253 of_47\IN\1740 cyanosis_48\NN\14299637 ._49\.\1740
D003287_D007674 CID whereas_0\IN\1740 33.3_1\CD\1740 %_2\NN\1740 of_3\IN\1740 the_4\DT\1740 patients_5\NNS\9898892 with_6\IN\1740 <e2>cin</e2>_7\NN\1740 were_8\VBD\836236 among_9\IN\1740 those_10\DT\1740 who_11\WP\8299493 received_12\VBD\2210855 the_13\DT\1740 proper_14\JJ\1740 dosage_15\NN\13576355 of_16\IN\1740 <e1>cm</e1>_17\NN\13649268 ,_18\,\1740 the_19\DT\1740 percentage_20\NN\13815742 increased_21\VBD\169651 to_22\IN\1740 66.6_23\CD\1740 %_24\NN\1740 among_25\IN\1740 those_26\DT\1740 who_27\WP\8299493 received_28\VBD\2210855 larger_29\JJR\1740 doses_30\NNS\3740161 ,_31\,\1740 with_32\IN\1740 a_33\DT\13649268 significant_34\JJ\1740 difference_35\NN\4723816 in_36\IN\13603305 the_37\DT\1740 incidence_38\NN\13821570 of_39\IN\1740 cin_40\NN\1740 related_41\JJ\1740 to_42\TO\1740 the_43\DT\1740 different_44\JJ\1740 dosages_45\NNS\13576355 of_46\IN\1740 cm_47\NN\13649268 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.014_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D003287_D007674 CID whereas_0\IN\1740 33.3_1\CD\1740 %_2\NN\1740 of_3\IN\1740 the_4\DT\1740 patients_5\NNS\9898892 with_6\IN\1740 cin_7\NN\1740 were_8\VBD\836236 among_9\IN\1740 those_10\DT\1740 who_11\WP\8299493 received_12\VBD\2210855 the_13\DT\1740 proper_14\JJ\1740 dosage_15\NN\13576355 of_16\IN\1740 <e1>cm</e1>_17\NN\13649268 ,_18\,\1740 the_19\DT\1740 percentage_20\NN\13815742 increased_21\VBD\169651 to_22\IN\1740 66.6_23\CD\1740 %_24\NN\1740 among_25\IN\1740 those_26\DT\1740 who_27\WP\8299493 received_28\VBD\2210855 larger_29\JJR\1740 doses_30\NNS\3740161 ,_31\,\1740 with_32\IN\1740 a_33\DT\13649268 significant_34\JJ\1740 difference_35\NN\4723816 in_36\IN\13603305 the_37\DT\1740 incidence_38\NN\13821570 of_39\IN\1740 <e2>cin</e2>_40\NN\1740 related_41\JJ\1740 to_42\TO\1740 the_43\DT\1740 different_44\JJ\1740 dosages_45\NNS\13576355 of_46\IN\1740 cm_47\NN\13649268 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.014_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D003287_D007674 CID whereas_0\IN\1740 33.3_1\CD\1740 %_2\NN\1740 of_3\IN\1740 the_4\DT\1740 patients_5\NNS\9898892 with_6\IN\1740 <e2>cin</e2>_7\NN\1740 were_8\VBD\836236 among_9\IN\1740 those_10\DT\1740 who_11\WP\8299493 received_12\VBD\2210855 the_13\DT\1740 proper_14\JJ\1740 dosage_15\NN\13576355 of_16\IN\1740 cm_17\NN\13649268 ,_18\,\1740 the_19\DT\1740 percentage_20\NN\13815742 increased_21\VBD\169651 to_22\IN\1740 66.6_23\CD\1740 %_24\NN\1740 among_25\IN\1740 those_26\DT\1740 who_27\WP\8299493 received_28\VBD\2210855 larger_29\JJR\1740 doses_30\NNS\3740161 ,_31\,\1740 with_32\IN\1740 a_33\DT\13649268 significant_34\JJ\1740 difference_35\NN\4723816 in_36\IN\13603305 the_37\DT\1740 incidence_38\NN\13821570 of_39\IN\1740 cin_40\NN\1740 related_41\JJ\1740 to_42\TO\1740 the_43\DT\1740 different_44\JJ\1740 dosages_45\NNS\13576355 of_46\IN\1740 <e1>cm</e1>_47\NN\13649268 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.014_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D003287_D007674 CID whereas_0\IN\1740 33.3_1\CD\1740 %_2\NN\1740 of_3\IN\1740 the_4\DT\1740 patients_5\NNS\9898892 with_6\IN\1740 cin_7\NN\1740 were_8\VBD\836236 among_9\IN\1740 those_10\DT\1740 who_11\WP\8299493 received_12\VBD\2210855 the_13\DT\1740 proper_14\JJ\1740 dosage_15\NN\13576355 of_16\IN\1740 cm_17\NN\13649268 ,_18\,\1740 the_19\DT\1740 percentage_20\NN\13815742 increased_21\VBD\169651 to_22\IN\1740 66.6_23\CD\1740 %_24\NN\1740 among_25\IN\1740 those_26\DT\1740 who_27\WP\8299493 received_28\VBD\2210855 larger_29\JJR\1740 doses_30\NNS\3740161 ,_31\,\1740 with_32\IN\1740 a_33\DT\13649268 significant_34\JJ\1740 difference_35\NN\4723816 in_36\IN\13603305 the_37\DT\1740 incidence_38\NN\13821570 of_39\IN\1740 <e2>cin</e2>_40\NN\1740 related_41\JJ\1740 to_42\TO\1740 the_43\DT\1740 different_44\JJ\1740 dosages_45\NNS\13576355 of_46\IN\1740 <e1>cm</e1>_47\NN\13649268 (_48\-LRB-\1740 p_49\NN\14622893 =_50\JJ\1740 0.014_51\CD\1740 )_52\-RRB-\1740 ._53\.\1740
D003287_D007674 CID the_0\DT\1740 incidence_1\NN\13821570 depends_2\VBZ\2604760 on_3\IN\1740 dosage_4\NN\13576355 but_5\CC\1740 not_6\RB\1740 on_7\IN\1740 the_8\DT\1740 type_9\NN\5839024 of_10\IN\1740 consumed_11\VBN\1168468 nonionic_12\JJ\1740 <e1>cm</e1>_13\NN\13649268 ,_14\,\1740 nor_15\CC\1740 on_16\IN\1740 the_17\DT\1740 presence_18\NN\13954253 of_19\IN\1740 cyanosis_20\NN\14299637 ,_21\,\1740 and_22\CC\1740 although_23\IN\1740 <e2>cin</e2>_24\NN\1740 usually_25\RB\1740 is_26\VBZ\836236 reversible_27\JJ\1740 ,_28\,\1740 more_29\JJR\1740 concern_30\NN\5682950 is_31\VBZ\836236 needed_32\VBN\2604760 for_33\IN\1740 the_34\DT\1740 prevention_35\NN\1073995 of_36\IN\1740 such_37\PDT\1740 a_38\DT\13649268 complication_39\NN\1073995 in_40\IN\13603305 children_41\NNS\9622049 ._42\.\1740
D003287_D003490 NONE this_0\DT\1740 prospective_1\JJ\1740 study_2\NN\635850 determined_3\VBD\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 cin_7\NN\1740 for_8\IN\1740 two_9\CD\13741022 nonionic_10\JJ\1740 <e1>contrast_11\NN\13854649 media</e1>_12\NNS\3575240 (_13\-LRB-\1740 cm_14\NN\13649268 )_15\-RRB-\1740 ,_16\,\1740 iopromide_17\NN\1740 and_18\CC\1740 iohexol_19\NN\1740 ,_20\,\1740 among_21\IN\1740 80_22\CD\13745420 patients_23\NNS\9898892 younger_24\JJR\1740 than_25\IN\1740 18_26\CD\13745420 years_27\NNS\15144371 and_28\CC\1740 compared_29\VBD\644583 the_30\DT\1740 rates_31\NNS\13308999 for_32\IN\1740 this_33\DT\1740 complication_34\NN\1073995 in_35\IN\13603305 relation_36\NN\2137 to_37\TO\1740 the_38\DT\1740 type_39\NN\5839024 and_40\CC\1740 dosage_41\NN\13576355 of_42\IN\1740 cm_43\NN\13649268 and_44\CC\1740 the_45\DT\1740 presence_46\NN\13954253 of_47\IN\1740 <e2>cyanosis</e2>_48\NN\14299637 ._49\.\1740
D003287_D003490 NONE this_0\DT\1740 prospective_1\JJ\1740 study_2\NN\635850 determined_3\VBD\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 cin_7\NN\1740 for_8\IN\1740 two_9\CD\13741022 nonionic_10\JJ\1740 contrast_11\NN\13854649 media_12\NNS\3575240 (_13\-LRB-\1740 <e1>cm</e1>_14\NN\13649268 )_15\-RRB-\1740 ,_16\,\1740 iopromide_17\NN\1740 and_18\CC\1740 iohexol_19\NN\1740 ,_20\,\1740 among_21\IN\1740 80_22\CD\13745420 patients_23\NNS\9898892 younger_24\JJR\1740 than_25\IN\1740 18_26\CD\13745420 years_27\NNS\15144371 and_28\CC\1740 compared_29\VBD\644583 the_30\DT\1740 rates_31\NNS\13308999 for_32\IN\1740 this_33\DT\1740 complication_34\NN\1073995 in_35\IN\13603305 relation_36\NN\2137 to_37\TO\1740 the_38\DT\1740 type_39\NN\5839024 and_40\CC\1740 dosage_41\NN\13576355 of_42\IN\1740 cm_43\NN\13649268 and_44\CC\1740 the_45\DT\1740 presence_46\NN\13954253 of_47\IN\1740 <e2>cyanosis</e2>_48\NN\14299637 ._49\.\1740
D003287_D003490 NONE this_0\DT\1740 prospective_1\JJ\1740 study_2\NN\635850 determined_3\VBD\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 cin_7\NN\1740 for_8\IN\1740 two_9\CD\13741022 nonionic_10\JJ\1740 contrast_11\NN\13854649 media_12\NNS\3575240 (_13\-LRB-\1740 cm_14\NN\13649268 )_15\-RRB-\1740 ,_16\,\1740 iopromide_17\NN\1740 and_18\CC\1740 iohexol_19\NN\1740 ,_20\,\1740 among_21\IN\1740 80_22\CD\13745420 patients_23\NNS\9898892 younger_24\JJR\1740 than_25\IN\1740 18_26\CD\13745420 years_27\NNS\15144371 and_28\CC\1740 compared_29\VBD\644583 the_30\DT\1740 rates_31\NNS\13308999 for_32\IN\1740 this_33\DT\1740 complication_34\NN\1073995 in_35\IN\13603305 relation_36\NN\2137 to_37\TO\1740 the_38\DT\1740 type_39\NN\5839024 and_40\CC\1740 dosage_41\NN\13576355 of_42\IN\1740 <e1>cm</e1>_43\NN\13649268 and_44\CC\1740 the_45\DT\1740 presence_46\NN\13954253 of_47\IN\1740 <e2>cyanosis</e2>_48\NN\14299637 ._49\.\1740
D003287_D003490 NONE the_0\DT\1740 incidence_1\NN\13821570 depends_2\VBZ\2604760 on_3\IN\1740 dosage_4\NN\13576355 but_5\CC\1740 not_6\RB\1740 on_7\IN\1740 the_8\DT\1740 type_9\NN\5839024 of_10\IN\1740 consumed_11\VBN\1168468 nonionic_12\JJ\1740 <e1>cm</e1>_13\NN\13649268 ,_14\,\1740 nor_15\CC\1740 on_16\IN\1740 the_17\DT\1740 presence_18\NN\13954253 of_19\IN\1740 <e2>cyanosis</e2>_20\NN\14299637 ,_21\,\1740 and_22\CC\1740 although_23\IN\1740 cin_24\NN\1740 usually_25\RB\1740 is_26\VBZ\836236 reversible_27\JJ\1740 ,_28\,\1740 more_29\JJR\1740 concern_30\NN\5682950 is_31\VBZ\836236 needed_32\VBN\2604760 for_33\IN\1740 the_34\DT\1740 prevention_35\NN\1073995 of_36\IN\1740 such_37\PDT\1740 a_38\DT\13649268 complication_39\NN\1073995 in_40\IN\13603305 children_41\NNS\9622049 ._42\.\1740
C038192_D007674 CID this_0\DT\1740 prospective_1\JJ\1740 study_2\NN\635850 determined_3\VBD\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>cin</e2>_7\NN\1740 for_8\IN\1740 two_9\CD\13741022 nonionic_10\JJ\1740 contrast_11\NN\13854649 media_12\NNS\3575240 (_13\-LRB-\1740 cm_14\NN\13649268 )_15\-RRB-\1740 ,_16\,\1740 <e1>iopromide</e1>_17\NN\1740 and_18\CC\1740 iohexol_19\NN\1740 ,_20\,\1740 among_21\IN\1740 80_22\CD\13745420 patients_23\NNS\9898892 younger_24\JJR\1740 than_25\IN\1740 18_26\CD\13745420 years_27\NNS\15144371 and_28\CC\1740 compared_29\VBD\644583 the_30\DT\1740 rates_31\NNS\13308999 for_32\IN\1740 this_33\DT\1740 complication_34\NN\1073995 in_35\IN\13603305 relation_36\NN\2137 to_37\TO\1740 the_38\DT\1740 type_39\NN\5839024 and_40\CC\1740 dosage_41\NN\13576355 of_42\IN\1740 cm_43\NN\13649268 and_44\CC\1740 the_45\DT\1740 presence_46\NN\13954253 of_47\IN\1740 cyanosis_48\NN\14299637 ._49\.\1740
C038192_D003490 NONE this_0\DT\1740 prospective_1\JJ\1740 study_2\NN\635850 determined_3\VBD\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 cin_7\NN\1740 for_8\IN\1740 two_9\CD\13741022 nonionic_10\JJ\1740 contrast_11\NN\13854649 media_12\NNS\3575240 (_13\-LRB-\1740 cm_14\NN\13649268 )_15\-RRB-\1740 ,_16\,\1740 <e1>iopromide</e1>_17\NN\1740 and_18\CC\1740 iohexol_19\NN\1740 ,_20\,\1740 among_21\IN\1740 80_22\CD\13745420 patients_23\NNS\9898892 younger_24\JJR\1740 than_25\IN\1740 18_26\CD\13745420 years_27\NNS\15144371 and_28\CC\1740 compared_29\VBD\644583 the_30\DT\1740 rates_31\NNS\13308999 for_32\IN\1740 this_33\DT\1740 complication_34\NN\1073995 in_35\IN\13603305 relation_36\NN\2137 to_37\TO\1740 the_38\DT\1740 type_39\NN\5839024 and_40\CC\1740 dosage_41\NN\13576355 of_42\IN\1740 cm_43\NN\13649268 and_44\CC\1740 the_45\DT\1740 presence_46\NN\13954253 of_47\IN\1740 <e2>cyanosis</e2>_48\NN\14299637 ._49\.\1740
D007472_D007674 CID this_0\DT\1740 prospective_1\JJ\1740 study_2\NN\635850 determined_3\VBD\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>cin</e2>_7\NN\1740 for_8\IN\1740 two_9\CD\13741022 nonionic_10\JJ\1740 contrast_11\NN\13854649 media_12\NNS\3575240 (_13\-LRB-\1740 cm_14\NN\13649268 )_15\-RRB-\1740 ,_16\,\1740 iopromide_17\NN\1740 and_18\CC\1740 <e1>iohexol</e1>_19\NN\1740 ,_20\,\1740 among_21\IN\1740 80_22\CD\13745420 patients_23\NNS\9898892 younger_24\JJR\1740 than_25\IN\1740 18_26\CD\13745420 years_27\NNS\15144371 and_28\CC\1740 compared_29\VBD\644583 the_30\DT\1740 rates_31\NNS\13308999 for_32\IN\1740 this_33\DT\1740 complication_34\NN\1073995 in_35\IN\13603305 relation_36\NN\2137 to_37\TO\1740 the_38\DT\1740 type_39\NN\5839024 and_40\CC\1740 dosage_41\NN\13576355 of_42\IN\1740 cm_43\NN\13649268 and_44\CC\1740 the_45\DT\1740 presence_46\NN\13954253 of_47\IN\1740 cyanosis_48\NN\14299637 ._49\.\1740
D007472_D003490 NONE this_0\DT\1740 prospective_1\JJ\1740 study_2\NN\635850 determined_3\VBD\1645601 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 cin_7\NN\1740 for_8\IN\1740 two_9\CD\13741022 nonionic_10\JJ\1740 contrast_11\NN\13854649 media_12\NNS\3575240 (_13\-LRB-\1740 cm_14\NN\13649268 )_15\-RRB-\1740 ,_16\,\1740 iopromide_17\NN\1740 and_18\CC\1740 <e1>iohexol</e1>_19\NN\1740 ,_20\,\1740 among_21\IN\1740 80_22\CD\13745420 patients_23\NNS\9898892 younger_24\JJR\1740 than_25\IN\1740 18_26\CD\13745420 years_27\NNS\15144371 and_28\CC\1740 compared_29\VBD\644583 the_30\DT\1740 rates_31\NNS\13308999 for_32\IN\1740 this_33\DT\1740 complication_34\NN\1073995 in_35\IN\13603305 relation_36\NN\2137 to_37\TO\1740 the_38\DT\1740 type_39\NN\5839024 and_40\CC\1740 dosage_41\NN\13576355 of_42\IN\1740 cm_43\NN\13649268 and_44\CC\1740 the_45\DT\1740 presence_46\NN\13954253 of_47\IN\1740 <e2>cyanosis</e2>_48\NN\14299637 ._49\.\1740
15673851
D016202_D020760 NONE the_0\DT\1740 activation_1\NN\13561719 of_2\IN\1740 spinal_3\JJ\1740 <e1>n-methyl-d-aspartate</e1>_4\NN\1740 receptors_5\NNS\5225602 may_6\MD\15209706 contribute_7\VB\126264 to_8\TO\1740 degeneration_9\NN\29677 of_10\IN\1740 spinal_11\JJ\1740 motor_12\NN\3699975 neurons_13\NNS\5430628 induced_14\VBN\1627355 by_15\IN\1740 neuraxial_16\JJ\1740 morphine_17\NN\2707683 after_18\IN\1740 a_19\DT\13649268 noninjurious_20\JJ\1740 interval_21\NN\33615 of_22\IN\1740 <e2>spinal_23\JJ\1740 cord_24\NN\3670849 ischemia</e2>_25\NN\14195315 ._26\.\1740
D016202_D020760 NONE we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 opioids_3\NNS\1740 may_4\MD\15209706 be_5\VB\836236 neurotoxic_6\JJ\1740 in_7\IN\13603305 the_8\DT\1740 setting_9\NN\8567235 of_10\IN\1740 <e2>spinal_11\JJ\1740 cord_12\NN\3670849 ischemia</e2>_13\NN\14195315 via_14\IN\1740 <e1>nmda</e1>_15\NN\1740 receptor_16\NN\5225602 activation_17\NN\13561719 ._18\.\1740
D009020_D020760 NONE the_0\DT\1740 activation_1\NN\13561719 of_2\IN\1740 spinal_3\JJ\1740 n-methyl-d-aspartate_4\NN\1740 receptors_5\NNS\5225602 may_6\MD\15209706 contribute_7\VB\126264 to_8\TO\1740 degeneration_9\NN\29677 of_10\IN\1740 spinal_11\JJ\1740 motor_12\NN\3699975 neurons_13\NNS\5430628 induced_14\VBN\1627355 by_15\IN\1740 neuraxial_16\JJ\1740 <e1>morphine</e1>_17\NN\2707683 after_18\IN\1740 a_19\DT\13649268 noninjurious_20\JJ\1740 interval_21\NN\33615 of_22\IN\1740 <e2>spinal_23\JJ\1740 cord_24\NN\3670849 ischemia</e2>_25\NN\14195315 ._26\.\1740
D016202_D001157 NONE we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 the_5\DT\1740 degeneration_6\NN\29677 of_7\IN\1740 spinal_8\JJ\1740 motor_9\NN\3699975 neurons_10\NNS\5430628 and_11\CC\1740 activation_12\NN\13561719 of_13\IN\1740 <e1>n-methyl-d-aspartate</e1>_14\NN\1740 (_15\-LRB-\1740 nmda_16\NN\1740 )_17\-RRB-\1740 receptors_18\NNS\5225602 after_19\IN\1740 neuraxial_20\JJ\1740 morphine_21\NN\2707683 following_22\VBG\1835496 a_23\DT\13649268 noninjurious_24\JJ\1740 interval_25\NN\33615 of_26\IN\1740 <e2>aortic_27\JJ\1740 occlusion</e2>_28\NN\14081375 in_29\IN\13603305 rats_30\NNS\2329401 ._31\.\1740
D016202_D001157 NONE we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 the_5\DT\1740 degeneration_6\NN\29677 of_7\IN\1740 spinal_8\JJ\1740 motor_9\NN\3699975 neurons_10\NNS\5430628 and_11\CC\1740 activation_12\NN\13561719 of_13\IN\1740 n-methyl-d-aspartate_14\NN\1740 (_15\-LRB-\1740 <e1>nmda</e1>_16\NN\1740 )_17\-RRB-\1740 receptors_18\NNS\5225602 after_19\IN\1740 neuraxial_20\JJ\1740 morphine_21\NN\2707683 following_22\VBG\1835496 a_23\DT\13649268 noninjurious_24\JJ\1740 interval_25\NN\33615 of_26\IN\1740 <e2>aortic_27\JJ\1740 occlusion</e2>_28\NN\14081375 in_29\IN\13603305 rats_30\NNS\2329401 ._31\.\1740
D009020_D001157 NONE we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 the_5\DT\1740 degeneration_6\NN\29677 of_7\IN\1740 spinal_8\JJ\1740 motor_9\NN\3699975 neurons_10\NNS\5430628 and_11\CC\1740 activation_12\NN\13561719 of_13\IN\1740 n-methyl-d-aspartate_14\NN\1740 (_15\-LRB-\1740 nmda_16\NN\1740 )_17\-RRB-\1740 receptors_18\NNS\5225602 after_19\IN\1740 neuraxial_20\JJ\1740 <e1>morphine</e1>_21\NN\2707683 following_22\VBG\1835496 a_23\DT\13649268 noninjurious_24\JJ\1740 interval_25\NN\33615 of_26\IN\1740 <e2>aortic_27\JJ\1740 occlusion</e2>_28\NN\14081375 in_29\IN\13603305 rats_30\NNS\2329401 ._31\.\1740
D016291_D020336 NONE second_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 investigated_3\VBD\644583 the_4\DT\1740 effect_5\NN\34213 of_6\IN\1740 it_7\NN\6125041 <e1>mk-801</e1>_8\NN\1740 (_9\-LRB-\1740 30_10\CD\13745420 mug_11\NN\13756125 )_12\-RRB-\1740 on_13\IN\1740 the_14\DT\1740 histopathologic_15\JJ\1740 changes_16\NNS\7283608 in_17\IN\13603305 the_18\DT\1740 spinal_19\JJ\1740 cord_20\NN\3670849 after_21\IN\1740 morphine-induced_22\JJ\1740 <e2>spastic_23\JJ\1740 paraparesis</e2>_24\NN\14558599 ._25\.\1740
D016291_D020336 NONE it_0\NNP\6125041 <e1>mk-801</e1>_1\NN\1740 significantly_2\RB\1740 reduced_3\VBD\441445 the_4\DT\1740 number_5\NN\5107765 of_6\IN\1740 dark-stained_7\JJ\1740 alpha-motoneurons_8\NNS\1740 after_9\IN\1740 morphine-induced_10\JJ\1740 <e2>spastic_11\JJ\1740 paraparesis</e2>_12\NN\14558599 compared_13\VBN\644583 with_14\IN\1740 the_15\DT\1740 saline_16\NN\14849367 group_17\NN\2137 ._18\.\1740
D009020_D020336 CID second_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 investigated_3\VBD\644583 the_4\DT\1740 effect_5\NN\34213 of_6\IN\1740 it_7\NN\6125041 mk-801_8\NN\1740 (_9\-LRB-\1740 30_10\CD\13745420 mug_11\NN\13756125 )_12\-RRB-\1740 on_13\IN\1740 the_14\DT\1740 histopathologic_15\JJ\1740 changes_16\NNS\7283608 in_17\IN\13603305 the_18\DT\1740 spinal_19\JJ\1740 cord_20\NN\3670849 after_21\IN\1740 <e1>morphine-induced</e1>_22\JJ\1740 <e2>spastic_23\JJ\1740 paraparesis</e2>_24\NN\14558599 ._25\.\1740
D009020_D020336 CID it_0\NNP\6125041 mk-801_1\NN\1740 significantly_2\RB\1740 reduced_3\VBD\441445 the_4\DT\1740 number_5\NN\5107765 of_6\IN\1740 dark-stained_7\JJ\1740 alpha-motoneurons_8\NNS\1740 after_9\IN\1740 <e1>morphine-induced</e1>_10\JJ\1740 <e2>spastic_11\JJ\1740 paraparesis</e2>_12\NN\14558599 compared_13\VBN\644583 with_14\IN\1740 the_15\DT\1740 saline_16\NN\14849367 group_17\NN\2137 ._18\.\1740
D009020_D020336 CID these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 it_4\NN\6125041 <e1>morphine</e1>_5\NN\2707683 induces_6\VBZ\1627355 <e2>spastic_7\JJ\1740 paraparesis</e2>_8\NN\14558599 with_9\IN\1740 a_10\DT\13649268 concomitant_11\JJ\1740 increase_12\NN\13576355 in_13\IN\13603305 csf_14\NN\1740 glutamate_15\NN\15010703 ,_16\,\1740 which_17\WDT\1740 is_18\VBZ\836236 involved_19\VBN\2676054 in_20\IN\13603305 nmda_21\NN\1740 receptor_22\NN\5225602 activation_23\NN\13561719 ._24\.\1740
D018698_D020336 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 it_4\NN\6125041 morphine_5\NN\2707683 induces_6\VBZ\1627355 <e2>spastic_7\JJ\1740 paraparesis</e2>_8\NN\14558599 with_9\IN\1740 a_10\DT\13649268 concomitant_11\JJ\1740 increase_12\NN\13576355 in_13\IN\13603305 csf_14\NN\1740 <e1>glutamate</e1>_15\NN\15010703 ,_16\,\1740 which_17\WDT\1740 is_18\VBZ\836236 involved_19\VBN\2676054 in_20\IN\13603305 nmda_21\NN\1740 receptor_22\NN\5225602 activation_23\NN\13561719 ._24\.\1740
D016202_D020336 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 it_4\NN\6125041 morphine_5\NN\2707683 induces_6\VBZ\1627355 <e2>spastic_7\JJ\1740 paraparesis</e2>_8\NN\14558599 with_9\IN\1740 a_10\DT\13649268 concomitant_11\JJ\1740 increase_12\NN\13576355 in_13\IN\13603305 csf_14\NN\1740 glutamate_15\NN\15010703 ,_16\,\1740 which_17\WDT\1740 is_18\VBZ\836236 involved_19\VBN\2676054 in_20\IN\13603305 <e1>nmda</e1>_21\NN\1740 receptor_22\NN\5225602 activation_23\NN\13561719 ._24\.\1740
D016202_D020258 NONE we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 opioids_3\NNS\1740 may_4\MD\15209706 be_5\VB\836236 <e2>neurotoxic</e2>_6\JJ\1740 in_7\IN\13603305 the_8\DT\1740 setting_9\NN\8567235 of_10\IN\1740 spinal_11\JJ\1740 cord_12\NN\3670849 ischemia_13\NN\14195315 via_14\IN\1740 <e1>nmda</e1>_15\NN\1740 receptor_16\NN\5225602 activation_17\NN\13561719 ._18\.\1740
7647582
D004737_D056486 CID two_0\CD\13741022 halogenated_1\VBN\1740 anesthetics_2\NNS\3247620 ,_3\,\1740 <e1>enflurane</e1>_4\NN\3299929 and_5\CC\1740 isoflurane_6\NN\3570838 ,_7\,\1740 have_8\VBP\2108377 been_9\VBN\836236 associated_10\VBN\628491 with_11\IN\1740 an_12\DT\6697703 allergic-type_13\JJ\1740 <e2>hepatic_14\JJ\1740 injury</e2>_15\NN\14052046 both_16\CC\1740 alone_17\RB\1740 and_18\CC\1740 following_19\VBG\1835496 previous_20\JJ\1740 exposure_21\NN\5042871 to_22\TO\1740 halothane_23\NN\3570838 ._24\.\1740
D004737_D056486 CID this_0\DT\1740 supports_1\NNS\407535 and_2\CC\1740 extends_3\VBZ\153263 previous_4\JJ\1740 evidence_5\NN\5816287 for_6\IN\1740 a_7\DT\13649268 mechanism_8\NN\13446390 by_9\IN\1740 which_10\WDT\1740 <e1>enflurane</e1>_11\NN\3299929 and/or_12\CC\1740 isoflurane_13\NN\3570838 could_14\MD\1740 produce_15\VB\1617192 a_16\DT\13649268 hypersensitivity_17\NN\14531772 condition_18\NN\24720 similar_19\JJ\1740 to_20\TO\1740 that_21\DT\1740 of_22\IN\1740 halothane_23\NN\3570838 <e2>hepatitis</e2>_24\NN\14127211 either_25\CC\1740 alone_26\RB\1740 or_27\CC\3541091 subsequent_28\JJ\1740 to_29\TO\1740 halothane_30\NN\3570838 administration_31\NN\1133281 ._32\.\1740
D007530_D056486 CID two_0\CD\13741022 halogenated_1\VBN\1740 anesthetics_2\NNS\3247620 ,_3\,\1740 enflurane_4\NN\3299929 and_5\CC\1740 <e1>isoflurane</e1>_6\NN\3570838 ,_7\,\1740 have_8\VBP\2108377 been_9\VBN\836236 associated_10\VBN\628491 with_11\IN\1740 an_12\DT\6697703 allergic-type_13\JJ\1740 <e2>hepatic_14\JJ\1740 injury</e2>_15\NN\14052046 both_16\CC\1740 alone_17\RB\1740 and_18\CC\1740 following_19\VBG\1835496 previous_20\JJ\1740 exposure_21\NN\5042871 to_22\TO\1740 halothane_23\NN\3570838 ._24\.\1740
D007530_D056486 CID this_0\DT\1740 supports_1\NNS\407535 and_2\CC\1740 extends_3\VBZ\153263 previous_4\JJ\1740 evidence_5\NN\5816287 for_6\IN\1740 a_7\DT\13649268 mechanism_8\NN\13446390 by_9\IN\1740 which_10\WDT\1740 enflurane_11\NN\3299929 and/or_12\CC\1740 <e1>isoflurane</e1>_13\NN\3570838 could_14\MD\1740 produce_15\VB\1617192 a_16\DT\13649268 hypersensitivity_17\NN\14531772 condition_18\NN\24720 similar_19\JJ\1740 to_20\TO\1740 that_21\DT\1740 of_22\IN\1740 halothane_23\NN\3570838 <e2>hepatitis</e2>_24\NN\14127211 either_25\CC\1740 alone_26\RB\1740 or_27\CC\3541091 subsequent_28\JJ\1740 to_29\TO\1740 halothane_30\NN\3570838 administration_31\NN\1133281 ._32\.\1740
D006221_D056486 CID two_0\CD\13741022 halogenated_1\VBN\1740 anesthetics_2\NNS\3247620 ,_3\,\1740 enflurane_4\NN\3299929 and_5\CC\1740 isoflurane_6\NN\3570838 ,_7\,\1740 have_8\VBP\2108377 been_9\VBN\836236 associated_10\VBN\628491 with_11\IN\1740 an_12\DT\6697703 allergic-type_13\JJ\1740 <e2>hepatic_14\JJ\1740 injury</e2>_15\NN\14052046 both_16\CC\1740 alone_17\RB\1740 and_18\CC\1740 following_19\VBG\1835496 previous_20\JJ\1740 exposure_21\NN\5042871 to_22\TO\1740 <e1>halothane</e1>_23\NN\3570838 ._24\.\1740
D006221_D056486 CID <e1>halothane</e1>_0\NN\3570838 <e2>hepatitis</e2>_1\NN\14127211 appears_2\VBZ\2604760 to_3\TO\1740 involve_4\VB\2676054 an_5\DT\6697703 aberrant_6\JJ\1740 immune_7\JJ\1740 response_8\NN\11410625 ._9\.\1740
D006221_D056486 CID an_0\DT\6697703 antibody_1\NN\14728724 response_2\NN\11410625 to_3\TO\1740 a_4\DT\13649268 protein-bound_5\JJ\1740 biotransformation_6\NN\1740 product_7\NN\3076708 (_8\-LRB-\1740 trifluoroacetyl_9\NN\1740 adduct_10\NN\14818238 )_11\-RRB-\1740 has_12\VBZ\2108377 been_13\VBN\836236 detected_14\VBN\2163746 on_15\IN\1740 <e1>halothane</e1>_16\NN\3570838 <e2>hepatitis</e2>_17\NN\14127211 patients_18\NNS\9898892 ._19\.\1740
D006221_D056486 CID this_0\DT\1740 supports_1\NNS\407535 and_2\CC\1740 extends_3\VBZ\153263 previous_4\JJ\1740 evidence_5\NN\5816287 for_6\IN\1740 a_7\DT\13649268 mechanism_8\NN\13446390 by_9\IN\1740 which_10\WDT\1740 enflurane_11\NN\3299929 and/or_12\CC\1740 isoflurane_13\NN\3570838 could_14\MD\1740 produce_15\VB\1617192 a_16\DT\13649268 hypersensitivity_17\NN\14531772 condition_18\NN\24720 similar_19\JJ\1740 to_20\TO\1740 that_21\DT\1740 of_22\IN\1740 <e1>halothane</e1>_23\NN\3570838 <e2>hepatitis</e2>_24\NN\14127211 either_25\CC\1740 alone_26\RB\1740 or_27\CC\3541091 subsequent_28\JJ\1740 to_29\TO\1740 halothane_30\NN\3570838 administration_31\NN\1133281 ._32\.\1740
D006221_D056486 CID this_0\DT\1740 supports_1\NNS\407535 and_2\CC\1740 extends_3\VBZ\153263 previous_4\JJ\1740 evidence_5\NN\5816287 for_6\IN\1740 a_7\DT\13649268 mechanism_8\NN\13446390 by_9\IN\1740 which_10\WDT\1740 enflurane_11\NN\3299929 and/or_12\CC\1740 isoflurane_13\NN\3570838 could_14\MD\1740 produce_15\VB\1617192 a_16\DT\13649268 hypersensitivity_17\NN\14531772 condition_18\NN\24720 similar_19\JJ\1740 to_20\TO\1740 that_21\DT\1740 of_22\IN\1740 halothane_23\NN\3570838 <e2>hepatitis</e2>_24\NN\14127211 either_25\CC\1740 alone_26\RB\1740 or_27\CC\3541091 subsequent_28\JJ\1740 to_29\TO\1740 <e1>halothane</e1>_30\NN\3570838 administration_31\NN\1133281 ._32\.\1740
D014269_D056486 NONE an_0\DT\6697703 antibody_1\NN\14728724 response_2\NN\11410625 to_3\TO\1740 a_4\DT\13649268 protein-bound_5\JJ\1740 biotransformation_6\NN\1740 product_7\NN\3076708 (_8\-LRB-\1740 <e1>trifluoroacetyl</e1>_9\NN\1740 adduct_10\NN\14818238 )_11\-RRB-\1740 has_12\VBZ\2108377 been_13\VBN\836236 detected_14\VBN\2163746 on_15\IN\1740 halothane_16\NN\3570838 <e2>hepatitis</e2>_17\NN\14127211 patients_18\NNS\9898892 ._19\.\1740
D004737_D004342 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 performed_3\VBN\2367363 to_4\TO\1740 determine_5\VB\1645601 cross-reactivity_6\NN\1740 between_7\IN\1740 <e1>enflurane</e1>_8\NN\3299929 and_9\CC\1740 isoflurane_10\NN\3570838 with_11\IN\1740 the_12\DT\1740 <e2>hypersensitivity</e2>_13\NN\14531772 induced_14\VBN\1627355 by_15\IN\1740 halothane_16\NN\3570838 ._17\.\1740
D004737_D004342 NONE this_0\DT\1740 supports_1\NNS\407535 and_2\CC\1740 extends_3\VBZ\153263 previous_4\JJ\1740 evidence_5\NN\5816287 for_6\IN\1740 a_7\DT\13649268 mechanism_8\NN\13446390 by_9\IN\1740 which_10\WDT\1740 <e1>enflurane</e1>_11\NN\3299929 and/or_12\CC\1740 isoflurane_13\NN\3570838 could_14\MD\1740 produce_15\VB\1617192 a_16\DT\13649268 <e2>hypersensitivity</e2>_17\NN\14531772 condition_18\NN\24720 similar_19\JJ\1740 to_20\TO\1740 that_21\DT\1740 of_22\IN\1740 halothane_23\NN\3570838 hepatitis_24\NN\14127211 either_25\CC\1740 alone_26\RB\1740 or_27\CC\3541091 subsequent_28\JJ\1740 to_29\TO\1740 halothane_30\NN\3570838 administration_31\NN\1133281 ._32\.\1740
D007530_D004342 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 performed_3\VBN\2367363 to_4\TO\1740 determine_5\VB\1645601 cross-reactivity_6\NN\1740 between_7\IN\1740 enflurane_8\NN\3299929 and_9\CC\1740 <e1>isoflurane</e1>_10\NN\3570838 with_11\IN\1740 the_12\DT\1740 <e2>hypersensitivity</e2>_13\NN\14531772 induced_14\VBN\1627355 by_15\IN\1740 halothane_16\NN\3570838 ._17\.\1740
D007530_D004342 NONE this_0\DT\1740 supports_1\NNS\407535 and_2\CC\1740 extends_3\VBZ\153263 previous_4\JJ\1740 evidence_5\NN\5816287 for_6\IN\1740 a_7\DT\13649268 mechanism_8\NN\13446390 by_9\IN\1740 which_10\WDT\1740 enflurane_11\NN\3299929 and/or_12\CC\1740 <e1>isoflurane</e1>_13\NN\3570838 could_14\MD\1740 produce_15\VB\1617192 a_16\DT\13649268 <e2>hypersensitivity</e2>_17\NN\14531772 condition_18\NN\24720 similar_19\JJ\1740 to_20\TO\1740 that_21\DT\1740 of_22\IN\1740 halothane_23\NN\3570838 hepatitis_24\NN\14127211 either_25\CC\1740 alone_26\RB\1740 or_27\CC\3541091 subsequent_28\JJ\1740 to_29\TO\1740 halothane_30\NN\3570838 administration_31\NN\1133281 ._32\.\1740
D006221_D004342 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 performed_3\VBN\2367363 to_4\TO\1740 determine_5\VB\1645601 cross-reactivity_6\NN\1740 between_7\IN\1740 enflurane_8\NN\3299929 and_9\CC\1740 isoflurane_10\NN\3570838 with_11\IN\1740 the_12\DT\1740 <e2>hypersensitivity</e2>_13\NN\14531772 induced_14\VBN\1627355 by_15\IN\1740 <e1>halothane</e1>_16\NN\3570838 ._17\.\1740
D006221_D004342 NONE this_0\DT\1740 supports_1\NNS\407535 and_2\CC\1740 extends_3\VBZ\153263 previous_4\JJ\1740 evidence_5\NN\5816287 for_6\IN\1740 a_7\DT\13649268 mechanism_8\NN\13446390 by_9\IN\1740 which_10\WDT\1740 enflurane_11\NN\3299929 and/or_12\CC\1740 isoflurane_13\NN\3570838 could_14\MD\1740 produce_15\VB\1617192 a_16\DT\13649268 <e2>hypersensitivity</e2>_17\NN\14531772 condition_18\NN\24720 similar_19\JJ\1740 to_20\TO\1740 that_21\DT\1740 of_22\IN\1740 <e1>halothane</e1>_23\NN\3570838 hepatitis_24\NN\14127211 either_25\CC\1740 alone_26\RB\1740 or_27\CC\3541091 subsequent_28\JJ\1740 to_29\TO\1740 halothane_30\NN\3570838 administration_31\NN\1133281 ._32\.\1740
D006221_D004342 NONE this_0\DT\1740 supports_1\NNS\407535 and_2\CC\1740 extends_3\VBZ\153263 previous_4\JJ\1740 evidence_5\NN\5816287 for_6\IN\1740 a_7\DT\13649268 mechanism_8\NN\13446390 by_9\IN\1740 which_10\WDT\1740 enflurane_11\NN\3299929 and/or_12\CC\1740 isoflurane_13\NN\3570838 could_14\MD\1740 produce_15\VB\1617192 a_16\DT\13649268 <e2>hypersensitivity</e2>_17\NN\14531772 condition_18\NN\24720 similar_19\JJ\1740 to_20\TO\1740 that_21\DT\1740 of_22\IN\1740 halothane_23\NN\3570838 hepatitis_24\NN\14127211 either_25\CC\1740 alone_26\RB\1740 or_27\CC\3541091 subsequent_28\JJ\1740 to_29\TO\1740 <e1>halothane</e1>_30\NN\3570838 administration_31\NN\1133281 ._32\.\1740
7059267
D002747_D009901 CID <e1>chlorpropamide-induced</e1>_0\JJ\1740 <e2>optic_1\NN\5299178 neuropathy</e2>_2\JJ\1740 ._3\.\1740
D002747_D009901 CID a_0\DT\13649268 65-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 adult-onset_4\JJ\1740 diabetes_5\NNS\14075199 treated_6\VBN\2376958 with_7\IN\1740 <e1>chlorpropamide</e1>_8\NN\1740 (_9\-LRB-\1740 diabenese_10\NN\1740 )_11\-RRB-\1740 had_12\VBD\2108377 a_13\DT\13649268 <e2>toxic_14\JJ\1740 optic_15\NN\5299178 neuropathy</e2>_16\JJ\1740 that_17\WDT\1740 resolved_18\VBD\352826 with_19\IN\1740 discontinuation_20\NN\209943 of_21\IN\1740 chlorpropamide_22\NN\1740 therapy_23\NN\657604 ._24\.\1740
D002747_D009901 CID a_0\DT\13649268 65-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 adult-onset_4\JJ\1740 diabetes_5\NNS\14075199 treated_6\VBN\2376958 with_7\IN\1740 chlorpropamide_8\NN\1740 (_9\-LRB-\1740 <e1>diabenese</e1>_10\NN\1740 )_11\-RRB-\1740 had_12\VBD\2108377 a_13\DT\13649268 <e2>toxic_14\JJ\1740 optic_15\NN\5299178 neuropathy</e2>_16\JJ\1740 that_17\WDT\1740 resolved_18\VBD\352826 with_19\IN\1740 discontinuation_20\NN\209943 of_21\IN\1740 chlorpropamide_22\NN\1740 therapy_23\NN\657604 ._24\.\1740
D002747_D009901 CID a_0\DT\13649268 65-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 adult-onset_4\JJ\1740 diabetes_5\NNS\14075199 treated_6\VBN\2376958 with_7\IN\1740 chlorpropamide_8\NN\1740 (_9\-LRB-\1740 diabenese_10\NN\1740 )_11\-RRB-\1740 had_12\VBD\2108377 a_13\DT\13649268 <e2>toxic_14\JJ\1740 optic_15\NN\5299178 neuropathy</e2>_16\JJ\1740 that_17\WDT\1740 resolved_18\VBD\352826 with_19\IN\1740 discontinuation_20\NN\209943 of_21\IN\1740 <e1>chlorpropamide</e1>_22\NN\1740 therapy_23\NN\657604 ._24\.\1740
D002747_D003924 NONE a_0\DT\13649268 65-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 <e2>adult-onset_4\JJ\1740 diabetes</e2>_5\NNS\14075199 treated_6\VBN\2376958 with_7\IN\1740 <e1>chlorpropamide</e1>_8\NN\1740 (_9\-LRB-\1740 diabenese_10\NN\1740 )_11\-RRB-\1740 had_12\VBD\2108377 a_13\DT\13649268 toxic_14\JJ\1740 optic_15\NN\5299178 neuropathy_16\JJ\1740 that_17\WDT\1740 resolved_18\VBD\352826 with_19\IN\1740 discontinuation_20\NN\209943 of_21\IN\1740 chlorpropamide_22\NN\1740 therapy_23\NN\657604 ._24\.\1740
D002747_D003924 NONE a_0\DT\13649268 65-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 <e2>adult-onset_4\JJ\1740 diabetes</e2>_5\NNS\14075199 treated_6\VBN\2376958 with_7\IN\1740 chlorpropamide_8\NN\1740 (_9\-LRB-\1740 <e1>diabenese</e1>_10\NN\1740 )_11\-RRB-\1740 had_12\VBD\2108377 a_13\DT\13649268 toxic_14\JJ\1740 optic_15\NN\5299178 neuropathy_16\JJ\1740 that_17\WDT\1740 resolved_18\VBD\352826 with_19\IN\1740 discontinuation_20\NN\209943 of_21\IN\1740 chlorpropamide_22\NN\1740 therapy_23\NN\657604 ._24\.\1740
D002747_D003924 NONE a_0\DT\13649268 65-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 <e2>adult-onset_4\JJ\1740 diabetes</e2>_5\NNS\14075199 treated_6\VBN\2376958 with_7\IN\1740 chlorpropamide_8\NN\1740 (_9\-LRB-\1740 diabenese_10\NN\1740 )_11\-RRB-\1740 had_12\VBD\2108377 a_13\DT\13649268 toxic_14\JJ\1740 optic_15\NN\5299178 neuropathy_16\JJ\1740 that_17\WDT\1740 resolved_18\VBD\352826 with_19\IN\1740 discontinuation_20\NN\209943 of_21\IN\1740 <e1>chlorpropamide</e1>_22\NN\1740 therapy_23\NN\657604 ._24\.\1740
2528969
11208990
D009569_D007674 NONE association_0\NN\8008335 of_1\IN\1740 <e1>nitric_2\JJ\1740 oxide</e1>_3\NN\14818238 production_4\NN\30358 and_5\CC\1740 apoptosis_6\NN\11486178 in_7\IN\13603305 a_8\DT\13649268 model_9\NN\5888929 of_10\IN\1740 experimental_11\JJ\1740 <e2>nephropathy</e2>_12\NN\14573196 ._13\.\1740
D009569_D009404 NONE we_0\PRP\1740 have_1\VBP\2108377 studied_2\VBN\630380 the_3\DT\1740 role_4\NN\719494 of_5\IN\1740 <e1>no</e1>_6\NN\7204911 and_7\CC\1740 its_8\PRP$\6125041 association_9\NN\8008335 with_10\IN\1740 apoptosis_11\NN\11486178 in_12\IN\13603305 an_13\DT\6697703 experimental_14\JJ\1740 model_15\NN\5888929 of_16\IN\1740 <e2>nephrotic_17\JJ\1740 syndrome</e2>_18\NN\5870365 induced_19\VBN\1627355 by_20\IN\1740 a_21\DT\13649268 single_22\JJ\1740 injection_23\NN\320852 of_24\IN\1740 adriamycin_25\NN\1740 (_26\-LRB-\1740 adr_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D004317_D009404 CID we_0\PRP\1740 have_1\VBP\2108377 studied_2\VBN\630380 the_3\DT\1740 role_4\NN\719494 of_5\IN\1740 no_6\NN\7204911 and_7\CC\1740 its_8\PRP$\6125041 association_9\NN\8008335 with_10\IN\1740 apoptosis_11\NN\11486178 in_12\IN\13603305 an_13\DT\6697703 experimental_14\JJ\1740 model_15\NN\5888929 of_16\IN\1740 <e2>nephrotic_17\JJ\1740 syndrome</e2>_18\NN\5870365 induced_19\VBN\1627355 by_20\IN\1740 a_21\DT\13649268 single_22\JJ\1740 injection_23\NN\320852 of_24\IN\1740 <e1>adriamycin</e1>_25\NN\1740 (_26\-LRB-\1740 adr_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D004317_D009404 CID we_0\PRP\1740 have_1\VBP\2108377 studied_2\VBN\630380 the_3\DT\1740 role_4\NN\719494 of_5\IN\1740 no_6\NN\7204911 and_7\CC\1740 its_8\PRP$\6125041 association_9\NN\8008335 with_10\IN\1740 apoptosis_11\NN\11486178 in_12\IN\13603305 an_13\DT\6697703 experimental_14\JJ\1740 model_15\NN\5888929 of_16\IN\1740 <e2>nephrotic_17\JJ\1740 syndrome</e2>_18\NN\5870365 induced_19\VBN\1627355 by_20\IN\1740 a_21\DT\13649268 single_22\JJ\1740 injection_23\NN\320852 of_24\IN\1740 adriamycin_25\NN\1740 (_26\-LRB-\1740 <e1>adr</e1>_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
D004317_D007674 NONE rats_0\NNS\2329401 were_1\VBD\836236 stratified_2\VBN\650353 into_3\IN\1740 control_4\NN\5190804 groups_5\NNS\2137 and_6\CC\1740 <e1>adr-induced</e1>_7\JJ\1740 <e2>nephropathy</e2>_8\JJ\1740 groups_9\NNS\2137 ._10\.\1740
D004317_D007674 NONE urine_0\NN\14853947 nitrite_1\JJ\1740 levels_2\NNS\4916342 were_3\VBD\836236 significantly_4\RB\1740 increased_5\VBN\169651 in_6\IN\13603305 the_7\DT\1740 <e2><e1>adr-nephropathy</e1></e2>_8\JJ\1740 group_9\NN\2137 (_10\-LRB-\1740 p_11\NN\14622893 <_12\XX\1740 0.05_13\CD\1740 )_14\-RRB-\1740 ._15\.\1740
D004317_D007674 NONE in_0\IN\13603305 the_1\DT\1740 iprk_2\NN\1740 phenylephrine_3\NN\2682038 and_4\CC\1740 acetylcholine_5\NN\14807558 related_6\JJ\1740 responses_7\NNS\11410625 were_8\VBD\836236 significantly_9\RB\1740 impaired_10\JJ\1740 in_11\IN\13603305 the_12\DT\1740 <e2><e1>adr-nephropathy</e1></e2>_13\JJ\1740 group_14\NN\2137 ._15\.\1740
D004317_D007674 NONE however_0\RB\1740 ,_1\,\1740 in_2\IN\13603305 the_3\DT\1740 <e2><e1>adr-nephropathy</e1></e2>_4\JJ\1740 group_5\NN\2137 ,_6\,\1740 numerous_7\JJ\1740 apoptotic_8\JJ\1740 cells_9\NNS\3080309 were_10\VBD\836236 identified_11\VBN\699815 in_12\IN\13603305 the_13\DT\1740 tubulointerstitial_14\JJ\1740 areas_15\NNS\8630985 ._16\.\1740
D004317_C537346 NONE results_0\NNS\34213 :_1\:\1740 histopathological_2\JJ\1740 examination_3\NN\633864 of_4\IN\1740 the_5\DT\1740 kidneys_6\NNS\5333259 of_7\IN\1740 rats_8\NNS\2329401 treated_9\VBN\2376958 with_10\IN\1740 <e1>adr</e1>_11\NN\1740 revealed_12\VBD\2137132 focal_13\JJ\1740 areas_14\NNS\8630985 of_15\IN\1740 <e2>mesangial_16\JJ\1740 proliferation</e2>_17\NN\13489037 and_18\CC\1740 mild_19\JJ\1740 tubulointerstitial_20\JJ\1740 inflammation_21\NN\14299637 ._22\.\1740
D004317_D009395 NONE results_0\NNS\34213 :_1\:\1740 histopathological_2\JJ\1740 examination_3\NN\633864 of_4\IN\1740 the_5\DT\1740 kidneys_6\NNS\5333259 of_7\IN\1740 rats_8\NNS\2329401 treated_9\VBN\2376958 with_10\IN\1740 <e1>adr</e1>_11\NN\1740 revealed_12\VBD\2137132 focal_13\JJ\1740 areas_14\NNS\8630985 of_15\IN\1740 mesangial_16\JJ\1740 proliferation_17\NN\13489037 and_18\CC\1740 mild_19\JJ\1740 <e2>tubulointerstitial_20\JJ\1740 inflammation</e2>_21\NN\14299637 ._22\.\1740
D009573_D007674 NONE urine_0\NN\14853947 <e1>nitrite</e1>_1\JJ\1740 levels_2\NNS\4916342 were_3\VBD\836236 significantly_4\RB\1740 increased_5\VBN\169651 in_6\IN\13603305 the_7\DT\1740 <e2>adr-nephropathy</e2>_8\JJ\1740 group_9\NN\2137 (_10\-LRB-\1740 p_11\NN\14622893 <_12\XX\1740 0.05_13\CD\1740 )_14\-RRB-\1740 ._15\.\1740
D010656_D007674 NONE in_0\IN\13603305 the_1\DT\1740 iprk_2\NN\1740 <e1>phenylephrine</e1>_3\NN\2682038 and_4\CC\1740 acetylcholine_5\NN\14807558 related_6\JJ\1740 responses_7\NNS\11410625 were_8\VBD\836236 significantly_9\RB\1740 impaired_10\JJ\1740 in_11\IN\13603305 the_12\DT\1740 <e2>adr-nephropathy</e2>_13\JJ\1740 group_14\NN\2137 ._15\.\1740
D000109_D007674 NONE in_0\IN\13603305 the_1\DT\1740 iprk_2\NN\1740 phenylephrine_3\NN\2682038 and_4\CC\1740 <e1>acetylcholine</e1>_5\NN\14807558 related_6\JJ\1740 responses_7\NNS\11410625 were_8\VBD\836236 significantly_9\RB\1740 impaired_10\JJ\1740 in_11\IN\13603305 the_12\DT\1740 <e2>adr-nephropathy</e2>_13\JJ\1740 group_14\NN\2137 ._15\.\1740
D009569_D009401 NONE conclusion_0\NN\5837957 :_1\:\1740 we_2\PRP\1740 suggest_3\VBP\1010118 that_4\IN\1740 interactions_5\NNS\37396 between_6\IN\1740 <e1>no</e1>_7\NN\7204911 and_8\CC\1740 apoptosis_9\NN\11486178 are_10\VBP\836236 important_11\JJ\1740 in_12\IN\13603305 the_13\DT\1740 pathogenesis_14\NN\13533470 of_15\IN\1740 the_16\DT\1740 adr-induced_17\JJ\1740 <e2>nephrosis</e2>_18\NN\14304060 ._19\.\1740
D004317_D009401 NONE conclusion_0\NN\5837957 :_1\:\1740 we_2\PRP\1740 suggest_3\VBP\1010118 that_4\IN\1740 interactions_5\NNS\37396 between_6\IN\1740 no_7\NN\7204911 and_8\CC\1740 apoptosis_9\NN\11486178 are_10\VBP\836236 important_11\JJ\1740 in_12\IN\13603305 the_13\DT\1740 pathogenesis_14\NN\13533470 of_15\IN\1740 the_16\DT\1740 <e1>adr-induced</e1>_17\JJ\1740 <e2>nephrosis</e2>_18\NN\14304060 ._19\.\1740
16634859
D000431_D006130 CID this_0\DT\1740 study_1\NN\635850 examined_2\VBD\789138 the_3\DT\1740 utility_4\NN\8186047 of_5\IN\1740 biometry_6\NN\6037298 for_7\IN\1740 detecting_8\VBG\2163746 <e1>alcohol-related</e1>_9\JJ\1740 fetal_10\JJ\1740 <e2>growth_11\NN\13526110 impairment</e2>_12\NN\7296428 ._13\.\1740
D000431_D006130 CID any_0\DT\1740 <e1>alcohol</e1>_1\NN\7881800 consumption_2\NN\13440063 postpregnancy_3\NN\1740 recognition_4\NN\13932421 among_5\IN\1740 the_6\DT\1740 heavy_7\JJ\1740 drinkers_8\NNS\9612848 resulted_9\VBD\2633881 in_10\IN\13603305 <e2>reduced_11\VBN\441445 cerebellar_12\NN\1740 growth</e2>_13\NN\13526110 as_14\RB\1740 well_15\RB\1740 as_16\IN\14622893 decreased_17\VBN\169651 cranial_18\JJ\1740 to_19\TO\1740 body_20\NN\19128 growth_21\NN\13526110 in_22\IN\13603305 comparison_23\NN\635850 with_24\IN\1740 women_25\NNS\9605289 who_26\WP\8299493 either_27\DT\1740 quit_28\VBD\2383440 drinking_29\NN\838098 or_30\CC\3541091 who_31\WP\8299493 were_32\VBD\836236 nondrinkers_33\NNS\7846 ._34\.\1740
D000431_D006130 CID any_0\DT\1740 <e1>alcohol</e1>_1\NN\7881800 consumption_2\NN\13440063 postpregnancy_3\NN\1740 recognition_4\NN\13932421 among_5\IN\1740 the_6\DT\1740 heavy_7\JJ\1740 drinkers_8\NNS\9612848 resulted_9\VBD\2633881 in_10\IN\13603305 reduced_11\VBN\441445 cerebellar_12\NN\1740 growth_13\NN\13526110 as_14\RB\1740 well_15\RB\1740 as_16\IN\14622893 <e2>decreased_17\VBN\169651 cranial_18\JJ\1740 to_19\TO\1740 body_20\NN\19128 growth</e2>_21\NN\13526110 in_22\IN\13603305 comparison_23\NN\635850 with_24\IN\1740 women_25\NNS\9605289 who_26\WP\8299493 either_27\DT\1740 quit_28\VBD\2383440 drinking_29\NN\838098 or_30\CC\3541091 who_31\WP\8299493 were_32\VBD\836236 nondrinkers_33\NNS\7846 ._34\.\1740
16428827
C004742_D000647 NONE <e1>daidzein</e1>_0\NN\1740 activates_1\VBZ\1641914 choline_2\NN\15090742 acetyltransferase_3\NN\1740 from_4\IN\1740 mc-ixc_5\NN\1740 cells_6\NNS\3080309 and_7\CC\1740 improves_8\VBZ\126264 drug-induced_9\JJ\1740 <e2>amnesia</e2>_10\NN\5669934 ._11\.\1740
C004742_D000647 NONE administration_0\NN\1133281 of_1\IN\1740 <e1>daidzein</e1>_2\NN\1740 (_3\-LRB-\1740 4.5_4\CD\1740 mg/kg_5\NN\1740 body_6\NN\19128 weight_7\NN\5009170 )_8\-RRB-\1740 to_9\TO\1740 mice_10\NNS\2329401 was_11\VBD\836236 shown_12\VBN\2137132 significantly_13\RB\1740 to_14\TO\1740 reverse_15\VB\109660 scopolamine-induced_16\JJ\1740 <e2>amnesia</e2>_17\NN\5669934 ,_18\,\1740 according_19\VBG\2657219 to_20\IN\1740 the_21\DT\1740 results_22\NNS\34213 of_23\IN\1740 a_24\DT\13649268 y-maze_25\JJ\1740 test_26\NN\5798043 ._27\.\1740
C004742_D000647 NONE these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 <e1>daidzein</e1>_4\NN\1740 might_5\MD\5029706 play_6\VB\1072262 a_7\DT\13649268 role_8\NN\719494 in_9\IN\13603305 acetylcholine_10\NN\14807558 biosynthesis_11\NN\13565379 as_12\IN\14622893 a_13\DT\13649268 chat_14\NN\7133701 activator_15\NN\19613 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 it_19\PRP\6125041 also_20\RB\1740 ameliorates_21\VBZ\126264 scopolamine-induced_22\JJ\1740 <e2>amnesia</e2>_23\NN\5669934 ._24\.\1740
D002794_D000647 NONE daidzein_0\NN\1740 activates_1\VBZ\1641914 <e1>choline</e1>_2\NN\15090742 acetyltransferase_3\NN\1740 from_4\IN\1740 mc-ixc_5\NN\1740 cells_6\NNS\3080309 and_7\CC\1740 improves_8\VBZ\126264 drug-induced_9\JJ\1740 <e2>amnesia</e2>_10\NN\5669934 ._11\.\1740
D002794_D000544 NONE the_0\DT\1740 <e1>choline</e1>_1\NN\15090742 acetyltransferase_2\NN\1740 (_3\-LRB-\1740 chat_4\NN\7133701 )_5\-RRB-\1740 activator_6\NN\19613 ,_7\,\1740 which_8\WDT\1740 enhances_9\VBZ\227165 cholinergic_10\JJ\1740 transmission_11\NN\121166 via_12\IN\1740 an_13\DT\6697703 augmentation_14\NN\7356676 of_15\IN\1740 the_16\DT\1740 enzymatic_17\JJ\1740 production_18\NN\30358 of_19\IN\1740 acetylcholine_20\NN\14807558 (_21\-LRB-\1740 ach_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 is_25\VBZ\836236 an_26\DT\6697703 important_27\JJ\1740 factor_28\NN\7326557 in_29\IN\13603305 the_30\DT\1740 treatment_31\NN\654885 of_32\IN\1740 <e2>alzheimer_33\NN\1740 's_34\POS\1740 disease</e2>_35\NN\14061805 (_36\-LRB-\1740 ad_37\NN\7247071 )_38\-RRB-\1740 ._39\.\1740
D002794_D000544 NONE the_0\DT\1740 <e1>choline</e1>_1\NN\15090742 acetyltransferase_2\NN\1740 (_3\-LRB-\1740 chat_4\NN\7133701 )_5\-RRB-\1740 activator_6\NN\19613 ,_7\,\1740 which_8\WDT\1740 enhances_9\VBZ\227165 cholinergic_10\JJ\1740 transmission_11\NN\121166 via_12\IN\1740 an_13\DT\6697703 augmentation_14\NN\7356676 of_15\IN\1740 the_16\DT\1740 enzymatic_17\JJ\1740 production_18\NN\30358 of_19\IN\1740 acetylcholine_20\NN\14807558 (_21\-LRB-\1740 ach_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 is_25\VBZ\836236 an_26\DT\6697703 important_27\JJ\1740 factor_28\NN\7326557 in_29\IN\13603305 the_30\DT\1740 treatment_31\NN\654885 of_32\IN\1740 alzheimer_33\NN\1740 's_34\POS\1740 disease_35\NN\14061805 (_36\-LRB-\1740 <e2>ad</e2>_37\NN\7247071 )_38\-RRB-\1740 ._39\.\1740
D000109_D000544 NONE the_0\DT\1740 choline_1\NN\15090742 acetyltransferase_2\NN\1740 (_3\-LRB-\1740 chat_4\NN\7133701 )_5\-RRB-\1740 activator_6\NN\19613 ,_7\,\1740 which_8\WDT\1740 enhances_9\VBZ\227165 cholinergic_10\JJ\1740 transmission_11\NN\121166 via_12\IN\1740 an_13\DT\6697703 augmentation_14\NN\7356676 of_15\IN\1740 the_16\DT\1740 enzymatic_17\JJ\1740 production_18\NN\30358 of_19\IN\1740 <e1>acetylcholine</e1>_20\NN\14807558 (_21\-LRB-\1740 ach_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 is_25\VBZ\836236 an_26\DT\6697703 important_27\JJ\1740 factor_28\NN\7326557 in_29\IN\13603305 the_30\DT\1740 treatment_31\NN\654885 of_32\IN\1740 <e2>alzheimer_33\NN\1740 's_34\POS\1740 disease</e2>_35\NN\14061805 (_36\-LRB-\1740 ad_37\NN\7247071 )_38\-RRB-\1740 ._39\.\1740
D000109_D000544 NONE the_0\DT\1740 choline_1\NN\15090742 acetyltransferase_2\NN\1740 (_3\-LRB-\1740 chat_4\NN\7133701 )_5\-RRB-\1740 activator_6\NN\19613 ,_7\,\1740 which_8\WDT\1740 enhances_9\VBZ\227165 cholinergic_10\JJ\1740 transmission_11\NN\121166 via_12\IN\1740 an_13\DT\6697703 augmentation_14\NN\7356676 of_15\IN\1740 the_16\DT\1740 enzymatic_17\JJ\1740 production_18\NN\30358 of_19\IN\1740 <e1>acetylcholine</e1>_20\NN\14807558 (_21\-LRB-\1740 ach_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 is_25\VBZ\836236 an_26\DT\6697703 important_27\JJ\1740 factor_28\NN\7326557 in_29\IN\13603305 the_30\DT\1740 treatment_31\NN\654885 of_32\IN\1740 alzheimer_33\NN\1740 's_34\POS\1740 disease_35\NN\14061805 (_36\-LRB-\1740 <e2>ad</e2>_37\NN\7247071 )_38\-RRB-\1740 ._39\.\1740
D000109_D000544 NONE the_0\DT\1740 choline_1\NN\15090742 acetyltransferase_2\NN\1740 (_3\-LRB-\1740 chat_4\NN\7133701 )_5\-RRB-\1740 activator_6\NN\19613 ,_7\,\1740 which_8\WDT\1740 enhances_9\VBZ\227165 cholinergic_10\JJ\1740 transmission_11\NN\121166 via_12\IN\1740 an_13\DT\6697703 augmentation_14\NN\7356676 of_15\IN\1740 the_16\DT\1740 enzymatic_17\JJ\1740 production_18\NN\30358 of_19\IN\1740 acetylcholine_20\NN\14807558 (_21\-LRB-\1740 <e1>ach</e1>_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 is_25\VBZ\836236 an_26\DT\6697703 important_27\JJ\1740 factor_28\NN\7326557 in_29\IN\13603305 the_30\DT\1740 treatment_31\NN\654885 of_32\IN\1740 <e2>alzheimer_33\NN\1740 's_34\POS\1740 disease</e2>_35\NN\14061805 (_36\-LRB-\1740 ad_37\NN\7247071 )_38\-RRB-\1740 ._39\.\1740
D000109_D000544 NONE the_0\DT\1740 choline_1\NN\15090742 acetyltransferase_2\NN\1740 (_3\-LRB-\1740 chat_4\NN\7133701 )_5\-RRB-\1740 activator_6\NN\19613 ,_7\,\1740 which_8\WDT\1740 enhances_9\VBZ\227165 cholinergic_10\JJ\1740 transmission_11\NN\121166 via_12\IN\1740 an_13\DT\6697703 augmentation_14\NN\7356676 of_15\IN\1740 the_16\DT\1740 enzymatic_17\JJ\1740 production_18\NN\30358 of_19\IN\1740 acetylcholine_20\NN\14807558 (_21\-LRB-\1740 <e1>ach</e1>_22\NN\1740 )_23\-RRB-\1740 ,_24\,\1740 is_25\VBZ\836236 an_26\DT\6697703 important_27\JJ\1740 factor_28\NN\7326557 in_29\IN\13603305 the_30\DT\1740 treatment_31\NN\654885 of_32\IN\1740 alzheimer_33\NN\1740 's_34\POS\1740 disease_35\NN\14061805 (_36\-LRB-\1740 <e2>ad</e2>_37\NN\7247071 )_38\-RRB-\1740 ._39\.\1740
C004742_D007859 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 investigate_3\VB\644583 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>daidzein</e1>_7\NN\1740 from_8\IN\1740 pueraria_9\NNP\11585340 thunbergiana_10\NN\1740 on_11\IN\1740 scopolamine-induced_12\JJ\1740 <e2>impairments_13\NNS\7296428 of_14\IN\1740 learning_15\NN\5701944 and_16\CC\1740 memory</e2>_17\NN\5926676 ,_18\,\1740 we_19\PRP\1740 conducted_20\VBD\2436349 a_21\DT\13649268 series_22\NN\8456993 of_23\IN\1740 in_24\FW\13603305 vivo_25\FW\1740 tests_26\NNS\5798043 ._27\.\1740
C004742_D008569 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 investigate_3\VB\644583 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>daidzein</e1>_7\NN\1740 from_8\IN\1740 pueraria_9\NNP\11585340 thunbergiana_10\NN\1740 on_11\IN\1740 scopolamine-induced_12\JJ\1740 <e2>impairments_13\NNS\7296428 of_14\IN\1740 learning_15\NN\5701944 and_16\CC\1740 memory</e2>_17\NN\5926676 ,_18\,\1740 we_19\PRP\1740 conducted_20\VBD\2436349 a_21\DT\13649268 series_22\NN\8456993 of_23\IN\1740 in_24\FW\13603305 vivo_25\FW\1740 tests_26\NNS\5798043 ._27\.\1740
D012601_D007859 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 investigate_3\VB\644583 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 daidzein_7\NN\1740 from_8\IN\1740 pueraria_9\NNP\11585340 thunbergiana_10\NN\1740 on_11\IN\1740 <e1>scopolamine-induced</e1>_12\JJ\1740 <e2>impairments_13\NNS\7296428 of_14\IN\1740 learning_15\NN\5701944 and_16\CC\1740 memory</e2>_17\NN\5926676 ,_18\,\1740 we_19\PRP\1740 conducted_20\VBD\2436349 a_21\DT\13649268 series_22\NN\8456993 of_23\IN\1740 in_24\FW\13603305 vivo_25\FW\1740 tests_26\NNS\5798043 ._27\.\1740
D012601_D008569 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 investigate_3\VB\644583 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 daidzein_7\NN\1740 from_8\IN\1740 pueraria_9\NNP\11585340 thunbergiana_10\NN\1740 on_11\IN\1740 <e1>scopolamine-induced</e1>_12\JJ\1740 <e2>impairments_13\NNS\7296428 of_14\IN\1740 learning_15\NN\5701944 and_16\CC\1740 memory</e2>_17\NN\5926676 ,_18\,\1740 we_19\PRP\1740 conducted_20\VBD\2436349 a_21\DT\13649268 series_22\NN\8456993 of_23\IN\1740 in_24\FW\13603305 vivo_25\FW\1740 tests_26\NNS\5798043 ._27\.\1740
D012601_D000647 CID administration_0\NN\1133281 of_1\IN\1740 daidzein_2\NN\1740 (_3\-LRB-\1740 4.5_4\CD\1740 mg/kg_5\NN\1740 body_6\NN\19128 weight_7\NN\5009170 )_8\-RRB-\1740 to_9\TO\1740 mice_10\NNS\2329401 was_11\VBD\836236 shown_12\VBN\2137132 significantly_13\RB\1740 to_14\TO\1740 reverse_15\VB\109660 <e1>scopolamine-induced</e1>_16\JJ\1740 <e2>amnesia</e2>_17\NN\5669934 ,_18\,\1740 according_19\VBG\2657219 to_20\IN\1740 the_21\DT\1740 results_22\NNS\34213 of_23\IN\1740 a_24\DT\13649268 y-maze_25\JJ\1740 test_26\NN\5798043 ._27\.\1740
D012601_D000647 CID these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 daidzein_4\NN\1740 might_5\MD\5029706 play_6\VB\1072262 a_7\DT\13649268 role_8\NN\719494 in_9\IN\13603305 acetylcholine_10\NN\14807558 biosynthesis_11\NN\13565379 as_12\IN\14622893 a_13\DT\13649268 chat_14\NN\7133701 activator_15\NN\19613 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 it_19\PRP\6125041 also_20\RB\1740 ameliorates_21\VBZ\126264 <e1>scopolamine-induced</e1>_22\JJ\1740 <e2>amnesia</e2>_23\NN\5669934 ._24\.\1740
D000109_D000647 NONE these_0\DT\1740 results_1\NNS\34213 indicate_2\VBP\952524 that_3\IN\1740 daidzein_4\NN\1740 might_5\MD\5029706 play_6\VB\1072262 a_7\DT\13649268 role_8\NN\719494 in_9\IN\13603305 <e1>acetylcholine</e1>_10\NN\14807558 biosynthesis_11\NN\13565379 as_12\IN\14622893 a_13\DT\13649268 chat_14\NN\7133701 activator_15\NN\19613 ,_16\,\1740 and_17\CC\1740 that_18\IN\1740 it_19\PRP\6125041 also_20\RB\1740 ameliorates_21\VBZ\126264 scopolamine-induced_22\JJ\1740 <e2>amnesia</e2>_23\NN\5669934 ._24\.\1740
7910951
D003473_D010243 NONE prolonged_0\JJ\1740 <e2>paralysis</e2>_1\NN\14557898 due_2\IN\5174653 to_3\IN\1740 <e1>nondepolarizing_4\VBG\1740 neuromuscular_5\JJ\1740 blocking_6\NN\562280 agents</e1>_7\NNS\7347 and_8\CC\1740 corticosteroids_9\NNS\14745635 ._10\.\1740
D000305_D010243 NONE prolonged_0\JJ\1740 <e2>paralysis</e2>_1\NN\14557898 due_2\IN\5174653 to_3\IN\1740 nondepolarizing_4\VBG\1740 neuromuscular_5\JJ\1740 blocking_6\NN\562280 agents_7\NNS\7347 and_8\CC\1740 <e1>corticosteroids</e1>_9\NNS\14745635 ._10\.\1740
D003473_D018908 CID the_0\DT\1740 long-term_1\JJ\1740 use_2\NN\407535 of_3\IN\1740 <e1>nondepolarizing_4\VBG\1740 neuromuscular_5\JJ\1740 blocking_6\NN\562280 agents</e1>_7\NNS\7347 (_8\-LRB-\1740 nd-nmba_9\NN\1740 )_10\-RRB-\1740 has_11\VBZ\2108377 recently_12\RB\1740 been_13\VBN\836236 implicated_14\VBN\2677097 as_15\IN\14622893 a_16\DT\13649268 cause_17\NN\7323922 of_18\IN\1740 prolonged_19\JJ\1740 <e2>muscle_20\NN\5289601 weakness</e2>_21\NN\14462666 ,_22\,\1740 although_23\IN\1740 the_24\DT\1740 site_25\NN\8673395 of_26\IN\1740 the_27\DT\1740 lesion_28\NN\14204950 and_29\CC\1740 the_30\DT\1740 predisposing_31\VBG\680841 factors_32\NNS\7326557 have_33\VBP\2108377 been_34\VBN\836236 unclear_35\JJ\1740 ._36\.\1740
D003473_D018908 CID the_0\DT\1740 long-term_1\JJ\1740 use_2\NN\407535 of_3\IN\1740 nondepolarizing_4\VBG\1740 neuromuscular_5\JJ\1740 blocking_6\NN\562280 agents_7\NNS\7347 (_8\-LRB-\1740 <e1>nd-nmba</e1>_9\NN\1740 )_10\-RRB-\1740 has_11\VBZ\2108377 recently_12\RB\1740 been_13\VBN\836236 implicated_14\VBN\2677097 as_15\IN\14622893 a_16\DT\13649268 cause_17\NN\7323922 of_18\IN\1740 prolonged_19\JJ\1740 <e2>muscle_20\NN\5289601 weakness</e2>_21\NN\14462666 ,_22\,\1740 although_23\IN\1740 the_24\DT\1740 site_25\NN\8673395 of_26\IN\1740 the_27\DT\1740 lesion_28\NN\14204950 and_29\CC\1740 the_30\DT\1740 predisposing_31\VBG\680841 factors_32\NNS\7326557 have_33\VBP\2108377 been_34\VBN\836236 unclear_35\JJ\1740 ._36\.\1740
D003473_D018908 CID we_0\PRP\1740 report_1\VBP\831651 3_2\CD\13741022 patients_3\NNS\9898892 (_4\-LRB-\1740 age_5\NN\4916342 37_6\CD\1740 -_7\SYM\1740 52_8\CD\1740 years_9\NNS\15144371 )_10\-RRB-\1740 with_11\IN\1740 acute_12\JJ\1740 respiratory_13\JJ\1740 insufficiency_14\NN\14462946 who_15\WP\8299493 developed_16\VBD\1753788 prolonged_17\JJ\1740 <e2>weakness</e2>_18\NN\14462666 following_19\VBG\1835496 the_20\DT\1740 discontinuation_21\NN\209943 of_22\IN\1740 <e1>nd-nmbas</e1>_23\NN\1740 ._24\.\1740
D003473_D018908 CID the_0\DT\1740 <e2>weakness</e2>_1\NN\14462666 in_2\IN\13603305 these_3\DT\1740 patients_4\NNS\9898892 is_5\VBZ\836236 due_6\JJ\1740 to_7\TO\1740 pathology_8\NN\6045562 at_9\IN\14622893 both_10\CC\1740 the_11\DT\1740 neuromuscular_12\JJ\1740 junction_13\NN\8664443 (_14\-LRB-\1740 most_15\RBS\1740 likely_16\RB\1740 due_17\JJ\1740 to_18\TO\1740 <e1>nd-nmba</e1>_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 muscle_22\NN\5289601 (_23\-LRB-\1740 most_24\RBS\1740 likely_25\RB\1740 due_26\JJ\1740 to_27\TO\1740 corticosteroids_28\NNS\14745635 )_29\-RRB-\1740 ._30\.\1740
D003473_D012131 NONE we_0\PRP\1740 report_1\VBP\831651 3_2\CD\13741022 patients_3\NNS\9898892 (_4\-LRB-\1740 age_5\NN\4916342 37_6\CD\1740 -_7\SYM\1740 52_8\CD\1740 years_9\NNS\15144371 )_10\-RRB-\1740 with_11\IN\1740 acute_12\JJ\1740 <e2>respiratory_13\JJ\1740 insufficiency</e2>_14\NN\14462946 who_15\WP\8299493 developed_16\VBD\1753788 prolonged_17\JJ\1740 weakness_18\NN\14462666 following_19\VBG\1835496 the_20\DT\1740 discontinuation_21\NN\209943 of_22\IN\1740 <e1>nd-nmbas</e1>_23\NN\1740 ._24\.\1740
D014673_D009135 NONE the_0\DT\1740 serum_1\NN\5397468 <e1>vecuronium</e1>_2\NN\1740 level_3\NN\4916342 measured_4\VBN\697589 in_5\IN\13603305 1_6\CD\13741022 patient_7\NN\9898892 14_8\CD\13745420 days_9\NNS\15140892 after_10\IN\1740 the_11\DT\1740 drug_12\NN\14778436 had_13\VBD\2108377 been_14\VBN\836236 discontinued_15\VBN\2609764 was_16\VBD\836236 172_17\CD\1740 ng/ml._18\NN\1740 a_19\NN\13649268 muscle_20\NN\5289601 biopsy_21\NN\5739043 in_22\IN\13603305 this_23\DT\1740 patient_24\NN\9898892 showed_25\VBD\2137132 <e2>loss_26\NN\13252973 of_27\IN\1740 thick_28\JJ\1740 ,_29\,\1740 myosin_30\NN\15022171 filaments</e2>_31\NNS\14866889 ._32\.\1740
D003473_D009468 CID the_0\DT\1740 weakness_1\NN\14462666 in_2\IN\13603305 these_3\DT\1740 patients_4\NNS\9898892 is_5\VBZ\836236 due_6\JJ\1740 to_7\TO\1740 <e2>pathology_8\NN\6045562 at_9\IN\14622893 both_10\CC\1740 the_11\DT\1740 neuromuscular_12\JJ\1740 junction</e2>_13\NN\8664443 (_14\-LRB-\1740 most_15\RBS\1740 likely_16\RB\1740 due_17\JJ\1740 to_18\TO\1740 <e1>nd-nmba</e1>_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 muscle_22\NN\5289601 (_23\-LRB-\1740 most_24\RBS\1740 likely_25\RB\1740 due_26\JJ\1740 to_27\TO\1740 corticosteroids_28\NNS\14745635 )_29\-RRB-\1740 ._30\.\1740
D000305_D018908 NONE the_0\DT\1740 <e2>weakness</e2>_1\NN\14462666 in_2\IN\13603305 these_3\DT\1740 patients_4\NNS\9898892 is_5\VBZ\836236 due_6\JJ\1740 to_7\TO\1740 pathology_8\NN\6045562 at_9\IN\14622893 both_10\CC\1740 the_11\DT\1740 neuromuscular_12\JJ\1740 junction_13\NN\8664443 (_14\-LRB-\1740 most_15\RBS\1740 likely_16\RB\1740 due_17\JJ\1740 to_18\TO\1740 nd-nmba_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 muscle_22\NN\5289601 (_23\-LRB-\1740 most_24\RBS\1740 likely_25\RB\1740 due_26\JJ\1740 to_27\TO\1740 <e1>corticosteroids</e1>_28\NNS\14745635 )_29\-RRB-\1740 ._30\.\1740
D000305_D009468 NONE the_0\DT\1740 weakness_1\NN\14462666 in_2\IN\13603305 these_3\DT\1740 patients_4\NNS\9898892 is_5\VBZ\836236 due_6\JJ\1740 to_7\TO\1740 <e2>pathology_8\NN\6045562 at_9\IN\14622893 both_10\CC\1740 the_11\DT\1740 neuromuscular_12\JJ\1740 junction</e2>_13\NN\8664443 (_14\-LRB-\1740 most_15\RBS\1740 likely_16\RB\1740 due_17\JJ\1740 to_18\TO\1740 nd-nmba_19\NN\1740 )_20\-RRB-\1740 and_21\CC\1740 muscle_22\NN\5289601 (_23\-LRB-\1740 most_24\RBS\1740 likely_25\RB\1740 due_26\JJ\1740 to_27\TO\1740 <e1>corticosteroids</e1>_28\NNS\14745635 )_29\-RRB-\1740 ._30\.\1740
7437994
6127992
D014700_D017202 NONE three_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 <e2>ischaemic_3\JJ\1740 heart_4\NN\5919034 disease</e2>_5\NN\14061805 developed_6\VBD\1753788 profound_7\JJ\1740 cardiac_8\JJ\1740 failure_9\NN\66216 ,_10\,\1740 hypotension_11\NN\14057371 and_12\CC\1740 bradycardia_13\NN\14110674 during_14\IN\1740 combined_15\JJ\1740 therapy_16\NN\657604 with_17\IN\1740 <e1>verapamil</e1>_18\NN\2938514 and_19\CC\1740 beta-adrenergic_20\JJ\1740 blocking_21\NN\562280 drugs_22\NNS\14778436 ._23\.\1740
D014700_D006333 CID three_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 ischaemic_3\JJ\1740 heart_4\NN\5919034 disease_5\NN\14061805 developed_6\VBD\1753788 profound_7\JJ\1740 <e2>cardiac_8\JJ\1740 failure</e2>_9\NN\66216 ,_10\,\1740 hypotension_11\NN\14057371 and_12\CC\1740 bradycardia_13\NN\14110674 during_14\IN\1740 combined_15\JJ\1740 therapy_16\NN\657604 with_17\IN\1740 <e1>verapamil</e1>_18\NN\2938514 and_19\CC\1740 beta-adrenergic_20\JJ\1740 blocking_21\NN\562280 drugs_22\NNS\14778436 ._23\.\1740
D014700_D007022 CID three_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 ischaemic_3\JJ\1740 heart_4\NN\5919034 disease_5\NN\14061805 developed_6\VBD\1753788 profound_7\JJ\1740 cardiac_8\JJ\1740 failure_9\NN\66216 ,_10\,\1740 <e2>hypotension</e2>_11\NN\14057371 and_12\CC\1740 bradycardia_13\NN\14110674 during_14\IN\1740 combined_15\JJ\1740 therapy_16\NN\657604 with_17\IN\1740 <e1>verapamil</e1>_18\NN\2938514 and_19\CC\1740 beta-adrenergic_20\JJ\1740 blocking_21\NN\562280 drugs_22\NNS\14778436 ._23\.\1740
D014700_D001919 CID three_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 ischaemic_3\JJ\1740 heart_4\NN\5919034 disease_5\NN\14061805 developed_6\VBD\1753788 profound_7\JJ\1740 cardiac_8\JJ\1740 failure_9\NN\66216 ,_10\,\1740 hypotension_11\NN\14057371 and_12\CC\1740 <e2>bradycardia</e2>_13\NN\14110674 during_14\IN\1740 combined_15\JJ\1740 therapy_16\NN\657604 with_17\IN\1740 <e1>verapamil</e1>_18\NN\2938514 and_19\CC\1740 beta-adrenergic_20\JJ\1740 blocking_21\NN\562280 drugs_22\NNS\14778436 ._23\.\1740
D000319_D017202 NONE three_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 <e2>ischaemic_3\JJ\1740 heart_4\NN\5919034 disease</e2>_5\NN\14061805 developed_6\VBD\1753788 profound_7\JJ\1740 cardiac_8\JJ\1740 failure_9\NN\66216 ,_10\,\1740 hypotension_11\NN\14057371 and_12\CC\1740 bradycardia_13\NN\14110674 during_14\IN\1740 combined_15\JJ\1740 therapy_16\NN\657604 with_17\IN\1740 verapamil_18\NN\2938514 and_19\CC\1740 <e1>beta-adrenergic_20\JJ\1740 blocking_21\NN\562280 drugs</e1>_22\NNS\14778436 ._23\.\1740
D000319_D006333 CID three_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 ischaemic_3\JJ\1740 heart_4\NN\5919034 disease_5\NN\14061805 developed_6\VBD\1753788 profound_7\JJ\1740 <e2>cardiac_8\JJ\1740 failure</e2>_9\NN\66216 ,_10\,\1740 hypotension_11\NN\14057371 and_12\CC\1740 bradycardia_13\NN\14110674 during_14\IN\1740 combined_15\JJ\1740 therapy_16\NN\657604 with_17\IN\1740 verapamil_18\NN\2938514 and_19\CC\1740 <e1>beta-adrenergic_20\JJ\1740 blocking_21\NN\562280 drugs</e1>_22\NNS\14778436 ._23\.\1740
D000319_D007022 CID three_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 ischaemic_3\JJ\1740 heart_4\NN\5919034 disease_5\NN\14061805 developed_6\VBD\1753788 profound_7\JJ\1740 cardiac_8\JJ\1740 failure_9\NN\66216 ,_10\,\1740 <e2>hypotension</e2>_11\NN\14057371 and_12\CC\1740 bradycardia_13\NN\14110674 during_14\IN\1740 combined_15\JJ\1740 therapy_16\NN\657604 with_17\IN\1740 verapamil_18\NN\2938514 and_19\CC\1740 <e1>beta-adrenergic_20\JJ\1740 blocking_21\NN\562280 drugs</e1>_22\NNS\14778436 ._23\.\1740
D000319_D001919 CID three_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 ischaemic_3\JJ\1740 heart_4\NN\5919034 disease_5\NN\14061805 developed_6\VBD\1753788 profound_7\JJ\1740 cardiac_8\JJ\1740 failure_9\NN\66216 ,_10\,\1740 hypotension_11\NN\14057371 and_12\CC\1740 <e2>bradycardia</e2>_13\NN\14110674 during_14\IN\1740 combined_15\JJ\1740 therapy_16\NN\657604 with_17\IN\1740 verapamil_18\NN\2938514 and_19\CC\1740 <e1>beta-adrenergic_20\JJ\1740 blocking_21\NN\562280 drugs</e1>_22\NNS\14778436 ._23\.\1740
15764424
D002395_D011605 NONE quantitative_0\JJ\1740 drug_1\NN\14778436 levels_2\NNS\4916342 in_3\IN\13603305 stimulant_4\JJ\1740 <e2>psychosis</e2>_5\NN\14380140 :_6\:\1740 relationship_7\NN\31921 to_8\TO\1740 symptom_9\NN\5823932 severity_10\NN\5036394 ,_11\,\1740 <e1>catecholamines</e1>_12\NNS\5407119 and_13\CC\1740 hyperkinesia_14\NN\1740 ._15\.\1740
D002395_D011605 NONE to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 quantitative_5\JJ\1740 stimulant_6\JJ\1740 drug_7\NN\14778436 levels_8\NNS\4916342 ,_9\,\1740 <e1>catecholamines</e1>_10\NNS\5407119 ,_11\,\1740 and_12\CC\1740 <e2>psychotic_13\JJ\1740 symptoms</e2>_14\NNS\5823932 ,_15\,\1740 nineteen_16\CD\13745420 patients_17\NNS\9898892 in_18\IN\13603305 a_19\DT\13649268 psychiatric_20\JJ\1740 emergency_21\NN\7417644 service_22\NN\575741 with_23\IN\1740 a_24\DT\13649268 diagnosis_25\NN\152018 of_26\IN\1740 amphetamine-_27\NN\1740 or_28\CC\3541091 cocaine-induced_29\JJ\1740 psychosis_30\NN\14380140 were_31\VBD\836236 interviewed_32\VBN\964694 ,_33\,\1740 and_34\CC\1740 plasma_35\NN\5398023 and_36\CC\1740 urine_37\NN\14853947 were_38\VBD\836236 collected_39\VBN\2281093 for_40\IN\1740 quantitative_41\JJ\1740 assays_42\NNS\5733583 of_43\IN\1740 stimulant_44\JJ\1740 drug_45\NN\14778436 and_46\CC\1740 catecholamine_47\NN\5407119 metabolite_48\NN\20090 levels_49\NNS\4916342 ._50\.\1740
D002395_D011605 NONE to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 quantitative_5\JJ\1740 stimulant_6\JJ\1740 drug_7\NN\14778436 levels_8\NNS\4916342 ,_9\,\1740 <e1>catecholamines</e1>_10\NNS\5407119 ,_11\,\1740 and_12\CC\1740 psychotic_13\JJ\1740 symptoms_14\NNS\5823932 ,_15\,\1740 nineteen_16\CD\13745420 patients_17\NNS\9898892 in_18\IN\13603305 a_19\DT\13649268 psychiatric_20\JJ\1740 emergency_21\NN\7417644 service_22\NN\575741 with_23\IN\1740 a_24\DT\13649268 diagnosis_25\NN\152018 of_26\IN\1740 amphetamine-_27\NN\1740 or_28\CC\3541091 cocaine-induced_29\JJ\1740 <e2>psychosis</e2>_30\NN\14380140 were_31\VBD\836236 interviewed_32\VBN\964694 ,_33\,\1740 and_34\CC\1740 plasma_35\NN\5398023 and_36\CC\1740 urine_37\NN\14853947 were_38\VBD\836236 collected_39\VBN\2281093 for_40\IN\1740 quantitative_41\JJ\1740 assays_42\NNS\5733583 of_43\IN\1740 stimulant_44\JJ\1740 drug_45\NN\14778436 and_46\CC\1740 catecholamine_47\NN\5407119 metabolite_48\NN\20090 levels_49\NNS\4916342 ._50\.\1740
D002395_D011605 NONE to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 quantitative_5\JJ\1740 stimulant_6\JJ\1740 drug_7\NN\14778436 levels_8\NNS\4916342 ,_9\,\1740 catecholamines_10\NNS\5407119 ,_11\,\1740 and_12\CC\1740 <e2>psychotic_13\JJ\1740 symptoms</e2>_14\NNS\5823932 ,_15\,\1740 nineteen_16\CD\13745420 patients_17\NNS\9898892 in_18\IN\13603305 a_19\DT\13649268 psychiatric_20\JJ\1740 emergency_21\NN\7417644 service_22\NN\575741 with_23\IN\1740 a_24\DT\13649268 diagnosis_25\NN\152018 of_26\IN\1740 amphetamine-_27\NN\1740 or_28\CC\3541091 cocaine-induced_29\JJ\1740 psychosis_30\NN\14380140 were_31\VBD\836236 interviewed_32\VBN\964694 ,_33\,\1740 and_34\CC\1740 plasma_35\NN\5398023 and_36\CC\1740 urine_37\NN\14853947 were_38\VBD\836236 collected_39\VBN\2281093 for_40\IN\1740 quantitative_41\JJ\1740 assays_42\NNS\5733583 of_43\IN\1740 stimulant_44\JJ\1740 drug_45\NN\14778436 and_46\CC\1740 <e1>catecholamine</e1>_47\NN\5407119 metabolite_48\NN\20090 levels_49\NNS\4916342 ._50\.\1740
D002395_D011605 NONE to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 quantitative_5\JJ\1740 stimulant_6\JJ\1740 drug_7\NN\14778436 levels_8\NNS\4916342 ,_9\,\1740 catecholamines_10\NNS\5407119 ,_11\,\1740 and_12\CC\1740 psychotic_13\JJ\1740 symptoms_14\NNS\5823932 ,_15\,\1740 nineteen_16\CD\13745420 patients_17\NNS\9898892 in_18\IN\13603305 a_19\DT\13649268 psychiatric_20\JJ\1740 emergency_21\NN\7417644 service_22\NN\575741 with_23\IN\1740 a_24\DT\13649268 diagnosis_25\NN\152018 of_26\IN\1740 amphetamine-_27\NN\1740 or_28\CC\3541091 cocaine-induced_29\JJ\1740 <e2>psychosis</e2>_30\NN\14380140 were_31\VBD\836236 interviewed_32\VBN\964694 ,_33\,\1740 and_34\CC\1740 plasma_35\NN\5398023 and_36\CC\1740 urine_37\NN\14853947 were_38\VBD\836236 collected_39\VBN\2281093 for_40\IN\1740 quantitative_41\JJ\1740 assays_42\NNS\5733583 of_43\IN\1740 stimulant_44\JJ\1740 drug_45\NN\14778436 and_46\CC\1740 <e1>catecholamine</e1>_47\NN\5407119 metabolite_48\NN\20090 levels_49\NNS\4916342 ._50\.\1740
D002395_D006948 NONE quantitative_0\JJ\1740 drug_1\NN\14778436 levels_2\NNS\4916342 in_3\IN\13603305 stimulant_4\JJ\1740 psychosis_5\NN\14380140 :_6\:\1740 relationship_7\NN\31921 to_8\TO\1740 symptom_9\NN\5823932 severity_10\NN\5036394 ,_11\,\1740 <e1>catecholamines</e1>_12\NNS\5407119 and_13\CC\1740 <e2>hyperkinesia</e2>_14\NN\1740 ._15\.\1740
D002395_D001523 NONE to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 quantitative_5\JJ\1740 stimulant_6\JJ\1740 drug_7\NN\14778436 levels_8\NNS\4916342 ,_9\,\1740 <e1>catecholamines</e1>_10\NNS\5407119 ,_11\,\1740 and_12\CC\1740 psychotic_13\JJ\1740 symptoms_14\NNS\5823932 ,_15\,\1740 nineteen_16\CD\13745420 patients_17\NNS\9898892 in_18\IN\13603305 a_19\DT\13649268 <e2>psychiatric</e2>_20\JJ\1740 emergency_21\NN\7417644 service_22\NN\575741 with_23\IN\1740 a_24\DT\13649268 diagnosis_25\NN\152018 of_26\IN\1740 amphetamine-_27\NN\1740 or_28\CC\3541091 cocaine-induced_29\JJ\1740 psychosis_30\NN\14380140 were_31\VBD\836236 interviewed_32\VBN\964694 ,_33\,\1740 and_34\CC\1740 plasma_35\NN\5398023 and_36\CC\1740 urine_37\NN\14853947 were_38\VBD\836236 collected_39\VBN\2281093 for_40\IN\1740 quantitative_41\JJ\1740 assays_42\NNS\5733583 of_43\IN\1740 stimulant_44\JJ\1740 drug_45\NN\14778436 and_46\CC\1740 catecholamine_47\NN\5407119 metabolite_48\NN\20090 levels_49\NNS\4916342 ._50\.\1740
D002395_D001523 NONE to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 quantitative_5\JJ\1740 stimulant_6\JJ\1740 drug_7\NN\14778436 levels_8\NNS\4916342 ,_9\,\1740 catecholamines_10\NNS\5407119 ,_11\,\1740 and_12\CC\1740 psychotic_13\JJ\1740 symptoms_14\NNS\5823932 ,_15\,\1740 nineteen_16\CD\13745420 patients_17\NNS\9898892 in_18\IN\13603305 a_19\DT\13649268 <e2>psychiatric</e2>_20\JJ\1740 emergency_21\NN\7417644 service_22\NN\575741 with_23\IN\1740 a_24\DT\13649268 diagnosis_25\NN\152018 of_26\IN\1740 amphetamine-_27\NN\1740 or_28\CC\3541091 cocaine-induced_29\JJ\1740 psychosis_30\NN\14380140 were_31\VBD\836236 interviewed_32\VBN\964694 ,_33\,\1740 and_34\CC\1740 plasma_35\NN\5398023 and_36\CC\1740 urine_37\NN\14853947 were_38\VBD\836236 collected_39\VBN\2281093 for_40\IN\1740 quantitative_41\JJ\1740 assays_42\NNS\5733583 of_43\IN\1740 stimulant_44\JJ\1740 drug_45\NN\14778436 and_46\CC\1740 <e1>catecholamine</e1>_47\NN\5407119 metabolite_48\NN\20090 levels_49\NNS\4916342 ._50\.\1740
D000661_D011605 CID to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 quantitative_5\JJ\1740 stimulant_6\JJ\1740 drug_7\NN\14778436 levels_8\NNS\4916342 ,_9\,\1740 catecholamines_10\NNS\5407119 ,_11\,\1740 and_12\CC\1740 <e2>psychotic_13\JJ\1740 symptoms</e2>_14\NNS\5823932 ,_15\,\1740 nineteen_16\CD\13745420 patients_17\NNS\9898892 in_18\IN\13603305 a_19\DT\13649268 psychiatric_20\JJ\1740 emergency_21\NN\7417644 service_22\NN\575741 with_23\IN\1740 a_24\DT\13649268 diagnosis_25\NN\152018 of_26\IN\1740 <e1>amphetamine-</e1>_27\NN\1740 or_28\CC\3541091 cocaine-induced_29\JJ\1740 psychosis_30\NN\14380140 were_31\VBD\836236 interviewed_32\VBN\964694 ,_33\,\1740 and_34\CC\1740 plasma_35\NN\5398023 and_36\CC\1740 urine_37\NN\14853947 were_38\VBD\836236 collected_39\VBN\2281093 for_40\IN\1740 quantitative_41\JJ\1740 assays_42\NNS\5733583 of_43\IN\1740 stimulant_44\JJ\1740 drug_45\NN\14778436 and_46\CC\1740 catecholamine_47\NN\5407119 metabolite_48\NN\20090 levels_49\NNS\4916342 ._50\.\1740
D000661_D011605 CID to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 quantitative_5\JJ\1740 stimulant_6\JJ\1740 drug_7\NN\14778436 levels_8\NNS\4916342 ,_9\,\1740 catecholamines_10\NNS\5407119 ,_11\,\1740 and_12\CC\1740 psychotic_13\JJ\1740 symptoms_14\NNS\5823932 ,_15\,\1740 nineteen_16\CD\13745420 patients_17\NNS\9898892 in_18\IN\13603305 a_19\DT\13649268 psychiatric_20\JJ\1740 emergency_21\NN\7417644 service_22\NN\575741 with_23\IN\1740 a_24\DT\13649268 diagnosis_25\NN\152018 of_26\IN\1740 <e1>amphetamine-</e1>_27\NN\1740 or_28\CC\3541091 cocaine-induced_29\JJ\1740 <e2>psychosis</e2>_30\NN\14380140 were_31\VBD\836236 interviewed_32\VBN\964694 ,_33\,\1740 and_34\CC\1740 plasma_35\NN\5398023 and_36\CC\1740 urine_37\NN\14853947 were_38\VBD\836236 collected_39\VBN\2281093 for_40\IN\1740 quantitative_41\JJ\1740 assays_42\NNS\5733583 of_43\IN\1740 stimulant_44\JJ\1740 drug_45\NN\14778436 and_46\CC\1740 catecholamine_47\NN\5407119 metabolite_48\NN\20090 levels_49\NNS\4916342 ._50\.\1740
D000661_D001523 NONE to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 quantitative_5\JJ\1740 stimulant_6\JJ\1740 drug_7\NN\14778436 levels_8\NNS\4916342 ,_9\,\1740 catecholamines_10\NNS\5407119 ,_11\,\1740 and_12\CC\1740 psychotic_13\JJ\1740 symptoms_14\NNS\5823932 ,_15\,\1740 nineteen_16\CD\13745420 patients_17\NNS\9898892 in_18\IN\13603305 a_19\DT\13649268 <e2>psychiatric</e2>_20\JJ\1740 emergency_21\NN\7417644 service_22\NN\575741 with_23\IN\1740 a_24\DT\13649268 diagnosis_25\NN\152018 of_26\IN\1740 <e1>amphetamine-</e1>_27\NN\1740 or_28\CC\3541091 cocaine-induced_29\JJ\1740 psychosis_30\NN\14380140 were_31\VBD\836236 interviewed_32\VBN\964694 ,_33\,\1740 and_34\CC\1740 plasma_35\NN\5398023 and_36\CC\1740 urine_37\NN\14853947 were_38\VBD\836236 collected_39\VBN\2281093 for_40\IN\1740 quantitative_41\JJ\1740 assays_42\NNS\5733583 of_43\IN\1740 stimulant_44\JJ\1740 drug_45\NN\14778436 and_46\CC\1740 catecholamine_47\NN\5407119 metabolite_48\NN\20090 levels_49\NNS\4916342 ._50\.\1740
D003042_D011605 CID to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 quantitative_5\JJ\1740 stimulant_6\JJ\1740 drug_7\NN\14778436 levels_8\NNS\4916342 ,_9\,\1740 catecholamines_10\NNS\5407119 ,_11\,\1740 and_12\CC\1740 <e2>psychotic_13\JJ\1740 symptoms</e2>_14\NNS\5823932 ,_15\,\1740 nineteen_16\CD\13745420 patients_17\NNS\9898892 in_18\IN\13603305 a_19\DT\13649268 psychiatric_20\JJ\1740 emergency_21\NN\7417644 service_22\NN\575741 with_23\IN\1740 a_24\DT\13649268 diagnosis_25\NN\152018 of_26\IN\1740 amphetamine-_27\NN\1740 or_28\CC\3541091 <e1>cocaine-induced</e1>_29\JJ\1740 psychosis_30\NN\14380140 were_31\VBD\836236 interviewed_32\VBN\964694 ,_33\,\1740 and_34\CC\1740 plasma_35\NN\5398023 and_36\CC\1740 urine_37\NN\14853947 were_38\VBD\836236 collected_39\VBN\2281093 for_40\IN\1740 quantitative_41\JJ\1740 assays_42\NNS\5733583 of_43\IN\1740 stimulant_44\JJ\1740 drug_45\NN\14778436 and_46\CC\1740 catecholamine_47\NN\5407119 metabolite_48\NN\20090 levels_49\NNS\4916342 ._50\.\1740
D003042_D011605 CID to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 quantitative_5\JJ\1740 stimulant_6\JJ\1740 drug_7\NN\14778436 levels_8\NNS\4916342 ,_9\,\1740 catecholamines_10\NNS\5407119 ,_11\,\1740 and_12\CC\1740 psychotic_13\JJ\1740 symptoms_14\NNS\5823932 ,_15\,\1740 nineteen_16\CD\13745420 patients_17\NNS\9898892 in_18\IN\13603305 a_19\DT\13649268 psychiatric_20\JJ\1740 emergency_21\NN\7417644 service_22\NN\575741 with_23\IN\1740 a_24\DT\13649268 diagnosis_25\NN\152018 of_26\IN\1740 amphetamine-_27\NN\1740 or_28\CC\3541091 <e1>cocaine-induced</e1>_29\JJ\1740 <e2>psychosis</e2>_30\NN\14380140 were_31\VBD\836236 interviewed_32\VBN\964694 ,_33\,\1740 and_34\CC\1740 plasma_35\NN\5398023 and_36\CC\1740 urine_37\NN\14853947 were_38\VBD\836236 collected_39\VBN\2281093 for_40\IN\1740 quantitative_41\JJ\1740 assays_42\NNS\5733583 of_43\IN\1740 stimulant_44\JJ\1740 drug_45\NN\14778436 and_46\CC\1740 catecholamine_47\NN\5407119 metabolite_48\NN\20090 levels_49\NNS\4916342 ._50\.\1740
D003042_D001523 NONE to_0\TO\1740 examine_1\VB\789138 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 quantitative_5\JJ\1740 stimulant_6\JJ\1740 drug_7\NN\14778436 levels_8\NNS\4916342 ,_9\,\1740 catecholamines_10\NNS\5407119 ,_11\,\1740 and_12\CC\1740 psychotic_13\JJ\1740 symptoms_14\NNS\5823932 ,_15\,\1740 nineteen_16\CD\13745420 patients_17\NNS\9898892 in_18\IN\13603305 a_19\DT\13649268 <e2>psychiatric</e2>_20\JJ\1740 emergency_21\NN\7417644 service_22\NN\575741 with_23\IN\1740 a_24\DT\13649268 diagnosis_25\NN\152018 of_26\IN\1740 amphetamine-_27\NN\1740 or_28\CC\3541091 <e1>cocaine-induced</e1>_29\JJ\1740 psychosis_30\NN\14380140 were_31\VBD\836236 interviewed_32\VBN\964694 ,_33\,\1740 and_34\CC\1740 plasma_35\NN\5398023 and_36\CC\1740 urine_37\NN\14853947 were_38\VBD\836236 collected_39\VBN\2281093 for_40\IN\1740 quantitative_41\JJ\1740 assays_42\NNS\5733583 of_43\IN\1740 stimulant_44\JJ\1740 drug_45\NN\14778436 and_46\CC\1740 catecholamine_47\NN\5407119 metabolite_48\NN\20090 levels_49\NNS\4916342 ._50\.\1740
D008694_D006948 CID <e1>methamphetamine</e1>_0\NNP\2704153 or_1\CC\3541091 amphetamine_2\NN\3248958 levels_3\NNS\4916342 were_4\VBD\836236 related_5\JJ\1740 to_6\TO\1740 several_7\JJ\1740 psychopathology_8\NN\6136258 scores_9\NNS\13757724 and_10\CC\1740 the_11\DT\1740 global_12\JJ\1740 <e2>hyperkinesia</e2>_13\NN\1740 rating_14\NN\5733583 ._15\.\1740
D000661_D006948 CID methamphetamine_0\NNP\2704153 or_1\CC\3541091 <e1>amphetamine</e1>_2\NN\3248958 levels_3\NNS\4916342 were_4\VBD\836236 related_5\JJ\1740 to_6\TO\1740 several_7\JJ\1740 psychopathology_8\NN\6136258 scores_9\NNS\13757724 and_10\CC\1740 the_11\DT\1740 global_12\JJ\1740 <e2>hyperkinesia</e2>_13\NN\1740 rating_14\NN\5733583 ._15\.\1740
2343592
D015378_D012640 NONE <e2>seizure</e2>_0\NN\14081375 activity_1\NN\30358 with_2\IN\1740 <e1>imipenem</e1>_3\NN\1740 therapy_4\NN\657604 :_5\:\1740 incidence_6\NN\13821570 and_7\CC\1740 risk_8\NN\14541044 factors_9\NNS\7326557 ._10\.\1740
C044650_D020521 NONE two_0\CD\13741022 elderly_1\JJ\1740 patients_2\NNS\9898892 with_3\IN\1740 a_4\DT\13649268 history_5\NN\15120823 of_6\IN\1740 either_7\CC\1740 <e2>cerebral_8\JJ\1740 vascular_9\JJ\1740 accident</e2>_10\NN\7314427 (_11\-LRB-\1740 cva_12\NN\14081375 )_13\-RRB-\1740 or_14\CC\3541091 head_15\NN\5225090 trauma_16\NN\14052046 and_17\CC\1740 no_18\DT\7204911 evidence_19\NN\5816287 of_20\IN\1740 renal_21\JJ\1740 disease_22\NN\14061805 developed_23\VBD\1753788 seizures_24\NNS\14081375 while_25\IN\15122231 receiving_26\VBG\2210855 maximum_27\NN\13653902 doses_28\NNS\3740161 of_29\IN\1740 <e1>imipenem/cilastatin</e1>_30\NN\1740 ._31\.\1740
C044650_D020521 NONE two_0\CD\13741022 elderly_1\JJ\1740 patients_2\NNS\9898892 with_3\IN\1740 a_4\DT\13649268 history_5\NN\15120823 of_6\IN\1740 either_7\CC\1740 cerebral_8\JJ\1740 vascular_9\JJ\1740 accident_10\NN\7314427 (_11\-LRB-\1740 <e2>cva</e2>_12\NN\14081375 )_13\-RRB-\1740 or_14\CC\3541091 head_15\NN\5225090 trauma_16\NN\14052046 and_17\CC\1740 no_18\DT\7204911 evidence_19\NN\5816287 of_20\IN\1740 renal_21\JJ\1740 disease_22\NN\14061805 developed_23\VBD\1753788 seizures_24\NNS\14081375 while_25\IN\15122231 receiving_26\VBG\2210855 maximum_27\NN\13653902 doses_28\NNS\3740161 of_29\IN\1740 <e1>imipenem/cilastatin</e1>_30\NN\1740 ._31\.\1740
C044650_D006259 NONE two_0\CD\13741022 elderly_1\JJ\1740 patients_2\NNS\9898892 with_3\IN\1740 a_4\DT\13649268 history_5\NN\15120823 of_6\IN\1740 either_7\CC\1740 cerebral_8\JJ\1740 vascular_9\JJ\1740 accident_10\NN\7314427 (_11\-LRB-\1740 cva_12\NN\14081375 )_13\-RRB-\1740 or_14\CC\3541091 <e2>head_15\NN\5225090 trauma</e2>_16\NN\14052046 and_17\CC\1740 no_18\DT\7204911 evidence_19\NN\5816287 of_20\IN\1740 renal_21\JJ\1740 disease_22\NN\14061805 developed_23\VBD\1753788 seizures_24\NNS\14081375 while_25\IN\15122231 receiving_26\VBG\2210855 maximum_27\NN\13653902 doses_28\NNS\3740161 of_29\IN\1740 <e1>imipenem/cilastatin</e1>_30\NN\1740 ._31\.\1740
C044650_D007674 NONE two_0\CD\13741022 elderly_1\JJ\1740 patients_2\NNS\9898892 with_3\IN\1740 a_4\DT\13649268 history_5\NN\15120823 of_6\IN\1740 either_7\CC\1740 cerebral_8\JJ\1740 vascular_9\JJ\1740 accident_10\NN\7314427 (_11\-LRB-\1740 cva_12\NN\14081375 )_13\-RRB-\1740 or_14\CC\3541091 head_15\NN\5225090 trauma_16\NN\14052046 and_17\CC\1740 no_18\DT\7204911 evidence_19\NN\5816287 of_20\IN\1740 <e2>renal_21\JJ\1740 disease</e2>_22\NN\14061805 developed_23\VBD\1753788 seizures_24\NNS\14081375 while_25\IN\15122231 receiving_26\VBG\2210855 maximum_27\NN\13653902 doses_28\NNS\3740161 of_29\IN\1740 <e1>imipenem/cilastatin</e1>_30\NN\1740 ._31\.\1740
C044650_D012640 CID two_0\CD\13741022 elderly_1\JJ\1740 patients_2\NNS\9898892 with_3\IN\1740 a_4\DT\13649268 history_5\NN\15120823 of_6\IN\1740 either_7\CC\1740 cerebral_8\JJ\1740 vascular_9\JJ\1740 accident_10\NN\7314427 (_11\-LRB-\1740 cva_12\NN\14081375 )_13\-RRB-\1740 or_14\CC\3541091 head_15\NN\5225090 trauma_16\NN\14052046 and_17\CC\1740 no_18\DT\7204911 evidence_19\NN\5816287 of_20\IN\1740 renal_21\JJ\1740 disease_22\NN\14061805 developed_23\VBD\1753788 <e2>seizures</e2>_24\NNS\14081375 while_25\IN\15122231 receiving_26\VBG\2210855 maximum_27\NN\13653902 doses_28\NNS\3740161 of_29\IN\1740 <e1>imipenem/cilastatin</e1>_30\NN\1740 ._31\.\1740
D010672_D012640 NONE all_0\DT\1740 <e2>seizures</e2>_1\NNS\14081375 were_2\VBD\836236 controlled_3\VBN\2422663 with_4\IN\1740 therapeutic_5\JJ\1740 doses_6\NNS\3740161 of_7\IN\1740 <e1>phenytoin</e1>_8\NN\3550533 ._9\.\1740
D047090_D012640 NONE both_0\DT\1740 patients_1\NNS\9898892 had_2\VBD\2108377 received_3\VBN\2210855 maximum_4\NN\13653902 doses_5\NNS\3740161 of_6\IN\1740 other_7\JJ\1740 <e1>beta-lactam</e1>_8\JJ\1740 antibiotics_9\NNS\2716205 without_10\IN\1740 evidence_11\NN\5816287 of_12\IN\1740 <e2>seizure</e2>_13\JJ\1740 activity_14\NN\30358 ._15\.\1740
18161408
D002996_D009203 CID <e2>myocardial_0\JJ\1740 infarction</e2>_1\NN\14204950 in_2\IN\13603305 pregnancy_3\NN\14034177 associated_4\VBN\628491 with_5\IN\1740 <e1>clomiphene_6\NN\3329880 citrate</e1>_7\NN\14850483 for_8\IN\1740 ovulation_9\NN\13526110 induction_10\NN\7450842 :_11\:\1740 a_12\DT\13649268 case_13\NN\7283608 report_14\NN\6470073 ._15\.\1740
D002996_D009203 CID conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 appears_3\VBZ\2604760 to_4\TO\1740 be_5\VB\836236 the_6\DT\1740 first_7\JJ\1740 reported_8\VBN\831651 case_9\NN\7283608 documenting_10\VBG\1000214 a_11\DT\13649268 possible_12\JJ\1740 association_13\NN\8008335 between_14\IN\1740 <e1>cc</e1>_15\NN\13616054 and_16\CC\1740 <e2>myocardial_17\JJ\1740 infarction</e2>_18\NN\14204950 ._19\.\1740
D002996_D013923 CID <e2>thromboembolism</e2>_0\NN\14100769 is_1\VBZ\836236 a_2\DT\13649268 rare_3\JJ\1740 but_4\CC\1740 life-threatening_5\JJ\1740 complication_6\NN\1073995 that_7\WDT\1740 has_8\VBZ\2108377 been_9\VBN\836236 reported_10\VBN\831651 after_11\IN\1740 ovulation_12\NN\13526110 induction_13\NN\7450842 with_14\IN\1740 <e1>cc</e1>_15\NN\13616054 ._16\.\1740
D002996_D002637 NONE case_0\NN\7283608 :_1\:\1740 a_2\DT\13649268 33-year-old_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 a_6\DT\13649268 5-week_7\JJ\1740 gestation_8\NN\15116532 had_9\VBD\2108377 recently_10\RB\1740 received_11\VBN\2210855 <e1>cc</e1>_12\NN\13616054 for_13\IN\1740 ovulation_14\NN\13526110 induction_15\NN\7450842 and_16\CC\1740 presented_17\VBN\2137132 with_18\IN\1740 <e2>chest_19\JJ\1740 pain</e2>_20\NN\14299637 ._21\.\1740
D002996_D013927 NONE <e2>thrombosis</e2>_0\NN\14100769 might_1\MD\5029706 be_2\VB\836236 a_3\DT\13649268 rare_4\JJ\1740 but_5\CC\1740 hazardous_6\JJ\1740 complication_7\NN\1073995 of_8\IN\1740 <e1>cc</e1>_9\NN\13616054 ._10\.\1740
16960342
D019259_D006509 NONE sustained_0\JJ\1740 clinical_1\JJ\1740 improvement_2\NN\7359599 of_3\IN\1740 a_4\DT\13649268 patient_5\NN\9898892 with_6\IN\1740 decompensated_7\JJ\1740 <e2>hepatitis_8\NN\14127211 b</e2>_9\NN\1355326 virus-related_10\JJ\1740 cirrhosis_11\NN\14116321 after_12\IN\1740 treatment_13\NN\654885 with_14\IN\1740 <e1>lamivudine</e1>_15\NN\3834836 monotherapy_16\NN\1740 ._17\.\1740
D019259_D005355 NONE sustained_0\JJ\1740 clinical_1\JJ\1740 improvement_2\NN\7359599 of_3\IN\1740 a_4\DT\13649268 patient_5\NN\9898892 with_6\IN\1740 decompensated_7\JJ\1740 hepatitis_8\NN\14127211 b_9\NN\1355326 virus-related_10\JJ\1740 <e2>cirrhosis</e2>_11\NN\14116321 after_12\IN\1740 treatment_13\NN\654885 with_14\IN\1740 <e1>lamivudine</e1>_15\NN\3834836 monotherapy_16\NN\1740 ._17\.\1740
D019259_D005355 NONE the_0\DT\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>lamivudine</e1>_3\NN\3834836 to_4\TO\1740 patients_5\NNS\9898892 with_6\IN\1740 hbv-related_7\JJ\1740 <e2>cirrhosis</e2>_8\NN\14116321 ,_9\,\1740 like_10\IN\5839024 our_11\PRP$\1740 present_12\JJ\1740 case_13\NN\7283608 ,_14\,\1740 should_15\MD\1740 be_16\VB\836236 considered_17\VBN\689344 as_18\IN\14622893 an_19\DT\6697703 initial_20\JJ\1740 medical_21\JJ\1740 therapeutic_22\JJ\1740 option_23\NN\6480506 ,_24\,\1740 especially_25\RB\1740 in_26\IN\13603305 countries_27\NNS\8359949 where_28\WRB\1740 liver_29\NN\5298729 transplantation_30\NN\671351 is_31\VBZ\836236 not_32\RB\1740 reliably_33\RB\1740 available_34\JJ\1740 ._35\.\1740
3300918
D008784_D014652 CID a_0\DT\13649268 rare_1\JJ\1740 case_2\NN\7283608 of_3\IN\1740 morbid_4\JJ\1740 <e2>vasospasm</e2>_5\NN\1740 ,_6\,\1740 together_7\RB\1740 with_8\IN\1740 striking_9\JJ\1740 angiographic_10\JJ\1740 findings_11\NNS\7951464 ,_12\,\1740 is_13\VBZ\836236 described_14\VBN\1001294 secondary_15\JJ\1740 to_16\TO\1740 the_17\DT\1740 ingestion_18\NN\13440063 of_19\IN\1740 <e1>methysergide</e1>_20\NN\1740 by_21\IN\1740 a_22\DT\13649268 48-year-old_23\JJ\1740 woman_24\NN\9605289 ._25\.\1740
D004876_D005734 NONE a_0\DT\13649268 discussion_1\NN\6252138 of_2\IN\1740 the_3\DT\1740 history_4\NN\15120823 of_5\IN\1740 <e1>ergot</e1>_6\NN\14276936 includes_7\VBZ\690614 its_8\PRP$\6125041 original_9\JJ\1740 discovery_10\NN\30358 ,_11\,\1740 the_12\DT\1740 epidemics_13\NNS\7435273 of_14\IN\1740 <e2>gangrene</e2>_15\NN\14204950 that_16\IN\1740 it_17\PRP\6125041 has_18\VBZ\2108377 caused_19\VBN\1617192 through_20\IN\1740 the_21\DT\1740 ages_22\NNS\4916342 and_23\CC\1740 its_24\PRP$\6125041 past_25\NN\28270 and_26\CC\1740 present_27\JJ\1740 role_28\NN\719494 in_29\IN\13603305 the_30\DT\1740 management_31\NN\1123598 of_32\IN\1740 migraine_33\NN\14326607 headache_34\NN\5829480 ._35\.\1740
D004876_D008881 CID a_0\DT\13649268 discussion_1\NN\6252138 of_2\IN\1740 the_3\DT\1740 history_4\NN\15120823 of_5\IN\1740 <e1>ergot</e1>_6\NN\14276936 includes_7\VBZ\690614 its_8\PRP$\6125041 original_9\JJ\1740 discovery_10\NN\30358 ,_11\,\1740 the_12\DT\1740 epidemics_13\NNS\7435273 of_14\IN\1740 gangrene_15\NN\14204950 that_16\IN\1740 it_17\PRP\6125041 has_18\VBZ\2108377 caused_19\VBN\1617192 through_20\IN\1740 the_21\DT\1740 ages_22\NNS\4916342 and_23\CC\1740 its_24\PRP$\6125041 past_25\NN\28270 and_26\CC\1740 present_27\JJ\1740 role_28\NN\719494 in_29\IN\13603305 the_30\DT\1740 management_31\NN\1123598 of_32\IN\1740 <e2>migraine_33\NN\14326607 headache</e2>_34\NN\5829480 ._35\.\1740
D004876_D008881 CID despite_0\IN\7501545 the_1\DT\1740 advent_2\NN\48225 of_3\IN\1740 calcium_4\NN\14625458 channel_5\NN\6251781 blockers_6\NNS\10101634 and_7\CC\1740 beta-adrenergic_8\JJ\1740 antagonists_9\NNS\7846 ,_10\,\1740 <e1>ergot</e1>_11\NN\14276936 preparations_12\NNS\407535 continue_13\VBP\2367363 to_14\TO\1740 play_15\VB\1072262 a_16\DT\13649268 major_17\JJ\1740 role_18\NN\719494 in_19\IN\13603305 <e2>migraine</e2>_20\NN\14326607 therapy_21\NN\657604 ,_22\,\1740 so_23\IN\6868043 that_24\IN\1740 the_25\DT\1740 danger_26\NN\13920835 of_27\IN\1740 st._28\NNP\1740 anthony_29\NNP\1740 's_30\POS\1740 fire_31\JJ\1740 persists_32\NNS\1740 ._33\.\1740
D002118_D008881 NONE despite_0\IN\7501545 the_1\DT\1740 advent_2\NN\48225 of_3\IN\1740 <e1>calcium</e1>_4\NN\14625458 channel_5\NN\6251781 blockers_6\NNS\10101634 and_7\CC\1740 beta-adrenergic_8\JJ\1740 antagonists_9\NNS\7846 ,_10\,\1740 ergot_11\NN\14276936 preparations_12\NNS\407535 continue_13\VBP\2367363 to_14\TO\1740 play_15\VB\1072262 a_16\DT\13649268 major_17\JJ\1740 role_18\NN\719494 in_19\IN\13603305 <e2>migraine</e2>_20\NN\14326607 therapy_21\NN\657604 ,_22\,\1740 so_23\IN\6868043 that_24\IN\1740 the_25\DT\1740 danger_26\NN\13920835 of_27\IN\1740 st._28\NNP\1740 anthony_29\NNP\1740 's_30\POS\1740 fire_31\JJ\1740 persists_32\NNS\1740 ._33\.\1740
D002118_D004881 NONE despite_0\IN\7501545 the_1\DT\1740 advent_2\NN\48225 of_3\IN\1740 <e1>calcium</e1>_4\NN\14625458 channel_5\NN\6251781 blockers_6\NNS\10101634 and_7\CC\1740 beta-adrenergic_8\JJ\1740 antagonists_9\NNS\7846 ,_10\,\1740 ergot_11\NN\14276936 preparations_12\NNS\407535 continue_13\VBP\2367363 to_14\TO\1740 play_15\VB\1072262 a_16\DT\13649268 major_17\JJ\1740 role_18\NN\719494 in_19\IN\13603305 migraine_20\NN\14326607 therapy_21\NN\657604 ,_22\,\1740 so_23\IN\6868043 that_24\IN\1740 the_25\DT\1740 danger_26\NN\13920835 of_27\IN\1740 <e2>st._28\NNP\1740 anthony_29\NNP\1740 's_30\POS\1740 fire</e2>_31\JJ\1740 persists_32\NNS\1740 ._33\.\1740
D004876_D004881 NONE despite_0\IN\7501545 the_1\DT\1740 advent_2\NN\48225 of_3\IN\1740 calcium_4\NN\14625458 channel_5\NN\6251781 blockers_6\NNS\10101634 and_7\CC\1740 beta-adrenergic_8\JJ\1740 antagonists_9\NNS\7846 ,_10\,\1740 <e1>ergot</e1>_11\NN\14276936 preparations_12\NNS\407535 continue_13\VBP\2367363 to_14\TO\1740 play_15\VB\1072262 a_16\DT\13649268 major_17\JJ\1740 role_18\NN\719494 in_19\IN\13603305 migraine_20\NN\14326607 therapy_21\NN\657604 ,_22\,\1740 so_23\IN\6868043 that_24\IN\1740 the_25\DT\1740 danger_26\NN\13920835 of_27\IN\1740 <e2>st._28\NNP\1740 anthony_29\NNP\1740 's_30\POS\1740 fire</e2>_31\JJ\1740 persists_32\NNS\1740 ._33\.\1740
19642243
C096918_D058186 NONE <e2>acute_0\JJ\1740 renal_1\JJ\1740 failure</e2>_2\NN\66216 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 aids_6\NN\13974317 on_7\IN\1740 <e1>tenofovir</e1>_8\NN\1740 while_9\IN\15122231 receiving_10\VBG\2210855 prolonged_11\JJ\1740 vancomycin_12\NN\2716866 course_13\NN\883297 for_14\IN\1740 osteomyelitis_15\NN\14351321 ._16\.\1740
C096918_D000163 NONE acute_0\JJ\1740 renal_1\JJ\1740 failure_2\NN\66216 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 <e2>aids</e2>_6\NN\13974317 on_7\IN\1740 <e1>tenofovir</e1>_8\NN\1740 while_9\IN\15122231 receiving_10\VBG\2210855 prolonged_11\JJ\1740 vancomycin_12\NN\2716866 course_13\NN\883297 for_14\IN\1740 osteomyelitis_15\NN\14351321 ._16\.\1740
C096918_D010019 NONE acute_0\JJ\1740 renal_1\JJ\1740 failure_2\NN\66216 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 aids_6\NN\13974317 on_7\IN\1740 <e1>tenofovir</e1>_8\NN\1740 while_9\IN\15122231 receiving_10\VBG\2210855 prolonged_11\JJ\1740 vancomycin_12\NN\2716866 course_13\NN\883297 for_14\IN\1740 <e2>osteomyelitis</e2>_15\NN\14351321 ._16\.\1740
D014640_D058186 CID <e2>acute_0\JJ\1740 renal_1\JJ\1740 failure</e2>_2\NN\66216 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 aids_6\NN\13974317 on_7\IN\1740 tenofovir_8\NN\1740 while_9\IN\15122231 receiving_10\VBG\2210855 prolonged_11\JJ\1740 <e1>vancomycin</e1>_12\NN\2716866 course_13\NN\883297 for_14\IN\1740 osteomyelitis_15\NN\14351321 ._16\.\1740
D014640_D000163 NONE acute_0\JJ\1740 renal_1\JJ\1740 failure_2\NN\66216 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 <e2>aids</e2>_6\NN\13974317 on_7\IN\1740 tenofovir_8\NN\1740 while_9\IN\15122231 receiving_10\VBG\2210855 prolonged_11\JJ\1740 <e1>vancomycin</e1>_12\NN\2716866 course_13\NN\883297 for_14\IN\1740 osteomyelitis_15\NN\14351321 ._16\.\1740
D014640_D010019 NONE acute_0\JJ\1740 renal_1\JJ\1740 failure_2\NN\66216 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 aids_6\NN\13974317 on_7\IN\1740 tenofovir_8\NN\1740 while_9\IN\15122231 receiving_10\VBG\2210855 prolonged_11\JJ\1740 <e1>vancomycin</e1>_12\NN\2716866 course_13\NN\883297 for_14\IN\1740 <e2>osteomyelitis</e2>_15\NN\14351321 ._16\.\1740
D014640_D051437 NONE <e2>renal_0\JJ\1740 failure</e2>_1\NN\66216 developed_2\VBD\1753788 after_3\IN\1740 a_4\DT\13649268 prolonged_5\JJ\1740 course_6\NN\883297 of_7\IN\1740 <e1>vancomycin</e1>_8\NN\2716866 therapy_9\NN\657604 in_10\IN\13603305 2_11\CD\13741022 patients_12\NNS\9898892 who_13\WP\8299493 were_14\VBD\836236 receiving_15\VBG\2210855 tenofovir_16\NN\1740 disoproxil_17\NN\1740 fumarate_18\VBP\1740 as_19\IN\14622893 part_20\NN\31921 of_21\IN\1740 an_22\DT\6697703 antiretroviral_23\JJ\1740 regimen_24\NN\5898568 ._25\.\1740
D014640_D051437 NONE clinicians_0\NNS\10462860 should_1\MD\1740 be_2\VB\836236 aware_3\JJ\1740 that_4\IN\1740 tenofovir_5\NN\1740 may_6\MD\15209706 raise_7\VB\153263 the_8\DT\1740 risk_9\NN\14541044 of_10\IN\1740 <e2>renal_11\JJ\1740 failure</e2>_12\NN\66216 during_13\IN\1740 prolonged_14\JJ\1740 administration_15\NN\1133281 of_16\IN\1740 <e1>vancomycin</e1>_17\NN\2716866 ._18\.\1740
C418563_D051437 NONE <e2>renal_0\JJ\1740 failure</e2>_1\NN\66216 developed_2\VBD\1753788 after_3\IN\1740 a_4\DT\13649268 prolonged_5\JJ\1740 course_6\NN\883297 of_7\IN\1740 vancomycin_8\NN\2716866 therapy_9\NN\657604 in_10\IN\13603305 2_11\CD\13741022 patients_12\NNS\9898892 who_13\WP\8299493 were_14\VBD\836236 receiving_15\VBG\2210855 <e1>tenofovir_16\NN\1740 disoproxil_17\NN\1740 fumarate</e1>_18\VBP\1740 as_19\IN\14622893 part_20\NN\31921 of_21\IN\1740 an_22\DT\6697703 antiretroviral_23\JJ\1740 regimen_24\NN\5898568 ._25\.\1740
C096918_D005198 NONE <e1>tenofovir</e1>_0\NNP\1740 has_1\VBZ\2108377 been_2\VBN\836236 implicated_3\VBN\2677097 in_4\IN\13603305 the_5\DT\1740 development_6\NN\248977 of_7\IN\1740 <e2>fanconi_8\NN\1740 syndrome</e2>_9\NN\5870365 and_10\CC\1740 renal_11\JJ\1740 insufficiency_12\NN\14462946 because_13\IN\1740 of_14\IN\1740 its_15\PRP$\6125041 effects_16\NNS\13245626 on_17\IN\1740 the_18\DT\1740 proximal_19\JJ\1740 renal_20\JJ\1740 tubule_21\NN\5246511 ._22\.\1740
C096918_D051437 NONE <e1>tenofovir</e1>_0\NNP\1740 has_1\VBZ\2108377 been_2\VBN\836236 implicated_3\VBN\2677097 in_4\IN\13603305 the_5\DT\1740 development_6\NN\248977 of_7\IN\1740 fanconi_8\NN\1740 syndrome_9\NN\5870365 and_10\CC\1740 <e2>renal_11\JJ\1740 insufficiency</e2>_12\NN\14462946 because_13\IN\1740 of_14\IN\1740 its_15\PRP$\6125041 effects_16\NNS\13245626 on_17\IN\1740 the_18\DT\1740 proximal_19\JJ\1740 renal_20\JJ\1740 tubule_21\NN\5246511 ._22\.\1740
C096918_D051437 NONE clinicians_0\NNS\10462860 should_1\MD\1740 be_2\VB\836236 aware_3\JJ\1740 that_4\IN\1740 <e1>tenofovir</e1>_5\NN\1740 may_6\MD\15209706 raise_7\VB\153263 the_8\DT\1740 risk_9\NN\14541044 of_10\IN\1740 <e2>renal_11\JJ\1740 failure</e2>_12\NN\66216 during_13\IN\1740 prolonged_14\JJ\1740 administration_15\NN\1133281 of_16\IN\1740 vancomycin_17\NN\2716866 ._18\.\1740
D014640_D007674 NONE <e1>vancomycin</e1>_0\NN\2716866 <e2>nephrotoxicity</e2>_1\NN\1740 is_2\VBZ\836236 infrequent_3\JJ\1740 but_4\CC\1740 may_5\MD\15209706 result_6\VB\2633881 from_7\IN\1740 coadministration_8\NN\1740 with_9\IN\1740 a_10\DT\13649268 nephrotoxic_11\JJ\1740 agent_12\NN\7347 ._13\.\1740
D014640_D007674 NONE <e1>vancomycin</e1>_0\NN\2716866 nephrotoxicity_1\NN\1740 is_2\VBZ\836236 infrequent_3\JJ\1740 but_4\CC\1740 may_5\MD\15209706 result_6\VB\2633881 from_7\IN\1740 coadministration_8\NN\1740 with_9\IN\1740 a_10\DT\13649268 <e2>nephrotoxic</e2>_11\JJ\1740 agent_12\NN\7347 ._13\.\1740
6454943
D002216_D011507 NONE effect_0\NN\34213 of_1\IN\1740 <e1>captopril</e1>_2\NN\2673637 on_3\IN\1740 pre-existing_4\JJ\1740 and_5\CC\1740 aminonucleoside-induced_6\JJ\1740 <e2>proteinuria</e2>_7\NN\14299637 in_8\IN\13603305 spontaneously_9\JJ\1740 hypertensive_10\JJ\1740 rats_11\NNS\2329401 ._12\.\1740
D002216_D011507 NONE <e2>proteinuria</e2>_0\NN\14299637 is_1\VBZ\836236 a_2\DT\13649268 side_3\JJ\1740 effect_4\NN\34213 of_5\IN\1740 <e1>captopril</e1>_6\NN\2673637 treatment_7\NN\654885 in_8\IN\13603305 hypertensive_9\JJ\1740 patients_10\NNS\9898892 ._11\.\1740
D002216_D011507 NONE oral_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>captopril</e1>_3\NN\2673637 at_4\IN\14622893 100_5\CD\13745420 mg/kg_6\NN\1740 for_7\IN\1740 14_8\CD\13745420 days_9\NNS\15140892 failed_10\VBD\1798936 to_11\TO\1740 aggravate_12\NN\1740 <e2>proteinuria</e2>_13\NN\14299637 pre-existing_14\NN\1740 in_15\IN\13603305 shr_16\NN\1740 ._17\.\1740
D002216_D011507 NONE also_0\RB\1740 ,_1\,\1740 <e1>captopril</e1>_2\NN\2673637 treatment_3\NN\654885 failed_4\VBD\1798936 to_5\TO\1740 potentiate_6\VB\229605 or_7\CC\3541091 facilitate_8\VB\2547586 development_9\NN\248977 of_10\IN\1740 massive_11\JJ\1740 <e2>proteinuria</e2>_12\NN\14299637 invoked_13\VBN\1617192 by_14\IN\1740 puromycin_15\NN\1740 aminonucleoside_16\NN\1740 in_17\IN\13603305 shr_18\NN\1740 ._19\.\1740
D002216_D006973 NONE effect_0\NN\34213 of_1\IN\1740 <e1>captopril</e1>_2\NN\2673637 on_3\IN\1740 pre-existing_4\JJ\1740 and_5\CC\1740 aminonucleoside-induced_6\JJ\1740 proteinuria_7\NN\14299637 in_8\IN\13603305 spontaneously_9\JJ\1740 <e2>hypertensive</e2>_10\JJ\1740 rats_11\NNS\2329401 ._12\.\1740
D002216_D006973 NONE proteinuria_0\NN\14299637 is_1\VBZ\836236 a_2\DT\13649268 side_3\JJ\1740 effect_4\NN\34213 of_5\IN\1740 <e1>captopril</e1>_6\NN\2673637 treatment_7\NN\654885 in_8\IN\13603305 <e2>hypertensive</e2>_9\JJ\1740 patients_10\NNS\9898892 ._11\.\1740
D011692_D011507 CID effect_0\NN\34213 of_1\IN\1740 captopril_2\NN\2673637 on_3\IN\1740 pre-existing_4\JJ\1740 and_5\CC\1740 <e1>aminonucleoside-induced</e1>_6\JJ\1740 <e2>proteinuria</e2>_7\NN\14299637 in_8\IN\13603305 spontaneously_9\JJ\1740 hypertensive_10\JJ\1740 rats_11\NNS\2329401 ._12\.\1740
D011692_D011507 CID also_0\RB\1740 ,_1\,\1740 captopril_2\NN\2673637 treatment_3\NN\654885 failed_4\VBD\1798936 to_5\TO\1740 potentiate_6\VB\229605 or_7\CC\3541091 facilitate_8\VB\2547586 development_9\NN\248977 of_10\IN\1740 massive_11\JJ\1740 <e2>proteinuria</e2>_12\NN\14299637 invoked_13\VBN\1617192 by_14\IN\1740 <e1>puromycin_15\NN\1740 aminonucleoside</e1>_16\NN\1740 in_17\IN\13603305 shr_18\NN\1740 ._19\.\1740
D011692_D006973 NONE effect_0\NN\34213 of_1\IN\1740 captopril_2\NN\2673637 on_3\IN\1740 pre-existing_4\JJ\1740 and_5\CC\1740 <e1>aminonucleoside-induced</e1>_6\JJ\1740 proteinuria_7\NN\14299637 in_8\IN\13603305 spontaneously_9\JJ\1740 <e2>hypertensive</e2>_10\JJ\1740 rats_11\NNS\2329401 ._12\.\1740
D002216_D007674 NONE the_0\DT\1740 possibility_1\NN\5944958 of_2\IN\1740 reproducing_3\VBG\1621555 the_4\DT\1740 same_5\JJ\1740 <e2>renal_6\JJ\1740 abnormality</e2>_7\NN\14034177 with_8\IN\1740 <e1>captopril</e1>_9\NN\2673637 was_10\VBD\836236 examined_11\VBN\789138 in_12\IN\13603305 shr_13\NN\1740 ._14\.\1740
10328196
D020123_D064420 NONE systemic_0\JJ\1740 <e2>toxicity</e2>_1\NN\13576101 following_2\VBG\1835496 administration_3\NN\1133281 of_4\IN\1740 <e1>sirolimus</e1>_5\NN\1740 (_6\-LRB-\1740 formerly_7\RB\1740 rapamycin_8\NN\1740 )_9\-RRB-\1740 for_10\IN\1740 psoriasis_11\NN\14219661 :_12\:\1740 association_13\NN\8008335 of_14\IN\1740 capillary_15\JJ\1740 leak_16\NN\9304465 syndrome_17\NN\5870365 with_18\IN\1740 apoptosis_19\NN\11486178 of_20\IN\1740 lesional_21\JJ\1740 lymphocytes_22\NNS\5449959 ._23\.\1740
D020123_D064420 NONE systemic_0\JJ\1740 <e2>toxicity</e2>_1\NN\13576101 following_2\VBG\1835496 administration_3\NN\1133281 of_4\IN\1740 sirolimus_5\NN\1740 (_6\-LRB-\1740 formerly_7\RB\1740 <e1>rapamycin</e1>_8\NN\1740 )_9\-RRB-\1740 for_10\IN\1740 psoriasis_11\NN\14219661 :_12\:\1740 association_13\NN\8008335 of_14\IN\1740 capillary_15\JJ\1740 leak_16\NN\9304465 syndrome_17\NN\5870365 with_18\IN\1740 apoptosis_19\NN\11486178 of_20\IN\1740 lesional_21\JJ\1740 lymphocytes_22\NNS\5449959 ._23\.\1740
D020123_D011565 NONE systemic_0\JJ\1740 toxicity_1\NN\13576101 following_2\VBG\1835496 administration_3\NN\1133281 of_4\IN\1740 <e1>sirolimus</e1>_5\NN\1740 (_6\-LRB-\1740 formerly_7\RB\1740 rapamycin_8\NN\1740 )_9\-RRB-\1740 for_10\IN\1740 <e2>psoriasis</e2>_11\NN\14219661 :_12\:\1740 association_13\NN\8008335 of_14\IN\1740 capillary_15\JJ\1740 leak_16\NN\9304465 syndrome_17\NN\5870365 with_18\IN\1740 apoptosis_19\NN\11486178 of_20\IN\1740 lesional_21\JJ\1740 lymphocytes_22\NNS\5449959 ._23\.\1740
D020123_D011565 NONE systemic_0\JJ\1740 toxicity_1\NN\13576101 following_2\VBG\1835496 administration_3\NN\1133281 of_4\IN\1740 sirolimus_5\NN\1740 (_6\-LRB-\1740 formerly_7\RB\1740 <e1>rapamycin</e1>_8\NN\1740 )_9\-RRB-\1740 for_10\IN\1740 <e2>psoriasis</e2>_11\NN\14219661 :_12\:\1740 association_13\NN\8008335 of_14\IN\1740 capillary_15\JJ\1740 leak_16\NN\9304465 syndrome_17\NN\5870365 with_18\IN\1740 apoptosis_19\NN\11486178 of_20\IN\1740 lesional_21\JJ\1740 lymphocytes_22\NNS\5449959 ._23\.\1740
D020123_D011565 NONE after_0\IN\1740 2_1\CD\13741022 individuals_2\NNS\7347 with_3\IN\1740 <e2>psoriasis</e2>_4\NN\14219661 developed_5\VBD\1753788 a_6\DT\13649268 capillary_7\JJ\1740 leak_8\NN\9304465 syndrome_9\NN\5870365 following_10\VBG\1835496 treatment_11\NN\654885 with_12\IN\1740 oral_13\JJ\1740 <e1>sirolimus</e1>_14\NN\1740 lesional_15\JJ\1740 skin_16\NN\5237755 cells_17\NNS\3080309 and_18\CC\1740 activated_19\VBN\1641914 peripheral_20\JJ\1740 blood_21\NN\5397468 cells_22\NNS\3080309 were_23\VBD\836236 analyzed_24\VBN\78760 for_25\IN\1740 induction_26\NN\7450842 of_27\IN\1740 apoptosis_28\NN\11486178 ._29\.\1740
D020123_D011565 NONE observations_0\NN\996969 :_1\:\1740 a_2\DT\13649268 keratome_3\NN\1740 skin_4\NN\5237755 specimen_5\NN\5820620 from_6\IN\1740 1_7\CD\13741022 patient_8\NN\9898892 with_9\IN\1740 <e1>sirolimus-induced</e1>_10\JJ\1740 capillary_11\JJ\1740 leak_12\NN\9304465 syndrome_13\NN\5870365 had_14\VBD\2108377 a_15\DT\13649268 2.3-fold_16\JJ\1740 increase_17\NN\13576355 in_18\IN\13603305 percentage_19\NN\13815742 of_20\IN\1740 apoptotic_21\JJ\1740 cells_22\NNS\3080309 (_23\-LRB-\1740 to_24\TO\1740 48_25\CD\1740 %_26\NN\1740 )_27\-RRB-\1740 compared_28\VBN\644583 with_29\IN\1740 an_30\DT\6697703 unaffected_31\JJ\1740 sirolimus-treated_32\JJ\1740 patient_33\NN\9898892 with_34\IN\1740 <e2>psoriasis</e2>_35\NN\14219661 (_36\-LRB-\1740 21_37\CD\13745420 %_38\NN\1740 )_39\-RRB-\1740 ._40\.\1740
D020123_D011565 NONE observations_0\NN\996969 :_1\:\1740 a_2\DT\13649268 keratome_3\NN\1740 skin_4\NN\5237755 specimen_5\NN\5820620 from_6\IN\1740 1_7\CD\13741022 patient_8\NN\9898892 with_9\IN\1740 sirolimus-induced_10\JJ\1740 capillary_11\JJ\1740 leak_12\NN\9304465 syndrome_13\NN\5870365 had_14\VBD\2108377 a_15\DT\13649268 2.3-fold_16\JJ\1740 increase_17\NN\13576355 in_18\IN\13603305 percentage_19\NN\13815742 of_20\IN\1740 apoptotic_21\JJ\1740 cells_22\NNS\3080309 (_23\-LRB-\1740 to_24\TO\1740 48_25\CD\1740 %_26\NN\1740 )_27\-RRB-\1740 compared_28\VBN\644583 with_29\IN\1740 an_30\DT\6697703 unaffected_31\JJ\1740 <e1>sirolimus-treated</e1>_32\JJ\1740 patient_33\NN\9898892 with_34\IN\1740 <e2>psoriasis</e2>_35\NN\14219661 (_36\-LRB-\1740 21_37\CD\13745420 %_38\NN\1740 )_39\-RRB-\1740 ._40\.\1740
D020123_D011565 NONE activated_0\VBN\1641914 peripheral_1\JJ\1740 blood_2\NN\5397468 t_3\NN\14999913 cells_4\NNS\3080309 from_5\IN\1740 patients_6\NNS\9898892 with_7\IN\1740 <e2>psoriasis</e2>_8\NN\14219661 tended_9\VBD\2604760 to_10\TO\1740 exhibit_11\VB\2632167 greater_12\JJR\1740 spontaneous_13\JJ\1740 or_14\CC\3541091 dexamethasone-induced_15\JJ\1740 apoptosis_16\NN\11486178 than_17\IN\1740 did_18\VBD\1640855 normal_19\JJ\1740 t_20\NN\14999913 cells_21\NNS\3080309 ,_22\,\1740 particularly_23\RB\1740 in_24\IN\13603305 the_25\DT\1740 presence_26\NN\13954253 of_27\IN\1740 <e1>sirolimus</e1>_28\NN\1740 ._29\.\1740
D020123_D019559 CID systemic_0\JJ\1740 toxicity_1\NN\13576101 following_2\VBG\1835496 administration_3\NN\1133281 of_4\IN\1740 <e1>sirolimus</e1>_5\NN\1740 (_6\-LRB-\1740 formerly_7\RB\1740 rapamycin_8\NN\1740 )_9\-RRB-\1740 for_10\IN\1740 psoriasis_11\NN\14219661 :_12\:\1740 association_13\NN\8008335 of_14\IN\1740 <e2>capillary_15\JJ\1740 leak_16\NN\9304465 syndrome</e2>_17\NN\5870365 with_18\IN\1740 apoptosis_19\NN\11486178 of_20\IN\1740 lesional_21\JJ\1740 lymphocytes_22\NNS\5449959 ._23\.\1740
D020123_D019559 CID systemic_0\JJ\1740 toxicity_1\NN\13576101 following_2\VBG\1835496 administration_3\NN\1133281 of_4\IN\1740 sirolimus_5\NN\1740 (_6\-LRB-\1740 formerly_7\RB\1740 <e1>rapamycin</e1>_8\NN\1740 )_9\-RRB-\1740 for_10\IN\1740 psoriasis_11\NN\14219661 :_12\:\1740 association_13\NN\8008335 of_14\IN\1740 <e2>capillary_15\JJ\1740 leak_16\NN\9304465 syndrome</e2>_17\NN\5870365 with_18\IN\1740 apoptosis_19\NN\11486178 of_20\IN\1740 lesional_21\JJ\1740 lymphocytes_22\NNS\5449959 ._23\.\1740
D020123_D019559 CID after_0\IN\1740 2_1\CD\13741022 individuals_2\NNS\7347 with_3\IN\1740 psoriasis_4\NN\14219661 developed_5\VBD\1753788 a_6\DT\13649268 <e2>capillary_7\JJ\1740 leak_8\NN\9304465 syndrome</e2>_9\NN\5870365 following_10\VBG\1835496 treatment_11\NN\654885 with_12\IN\1740 oral_13\JJ\1740 <e1>sirolimus</e1>_14\NN\1740 lesional_15\JJ\1740 skin_16\NN\5237755 cells_17\NNS\3080309 and_18\CC\1740 activated_19\VBN\1641914 peripheral_20\JJ\1740 blood_21\NN\5397468 cells_22\NNS\3080309 were_23\VBD\836236 analyzed_24\VBN\78760 for_25\IN\1740 induction_26\NN\7450842 of_27\IN\1740 apoptosis_28\NN\11486178 ._29\.\1740
D020123_D019559 CID observations_0\NN\996969 :_1\:\1740 a_2\DT\13649268 keratome_3\NN\1740 skin_4\NN\5237755 specimen_5\NN\5820620 from_6\IN\1740 1_7\CD\13741022 patient_8\NN\9898892 with_9\IN\1740 <e1>sirolimus-induced</e1>_10\JJ\1740 <e2>capillary_11\JJ\1740 leak_12\NN\9304465 syndrome</e2>_13\NN\5870365 had_14\VBD\2108377 a_15\DT\13649268 2.3-fold_16\JJ\1740 increase_17\NN\13576355 in_18\IN\13603305 percentage_19\NN\13815742 of_20\IN\1740 apoptotic_21\JJ\1740 cells_22\NNS\3080309 (_23\-LRB-\1740 to_24\TO\1740 48_25\CD\1740 %_26\NN\1740 )_27\-RRB-\1740 compared_28\VBN\644583 with_29\IN\1740 an_30\DT\6697703 unaffected_31\JJ\1740 sirolimus-treated_32\JJ\1740 patient_33\NN\9898892 with_34\IN\1740 psoriasis_35\NN\14219661 (_36\-LRB-\1740 21_37\CD\13745420 %_38\NN\1740 )_39\-RRB-\1740 ._40\.\1740
D020123_D019559 CID observations_0\NN\996969 :_1\:\1740 a_2\DT\13649268 keratome_3\NN\1740 skin_4\NN\5237755 specimen_5\NN\5820620 from_6\IN\1740 1_7\CD\13741022 patient_8\NN\9898892 with_9\IN\1740 sirolimus-induced_10\JJ\1740 <e2>capillary_11\JJ\1740 leak_12\NN\9304465 syndrome</e2>_13\NN\5870365 had_14\VBD\2108377 a_15\DT\13649268 2.3-fold_16\JJ\1740 increase_17\NN\13576355 in_18\IN\13603305 percentage_19\NN\13815742 of_20\IN\1740 apoptotic_21\JJ\1740 cells_22\NNS\3080309 (_23\-LRB-\1740 to_24\TO\1740 48_25\CD\1740 %_26\NN\1740 )_27\-RRB-\1740 compared_28\VBN\644583 with_29\IN\1740 an_30\DT\6697703 unaffected_31\JJ\1740 <e1>sirolimus-treated</e1>_32\JJ\1740 patient_33\NN\9898892 with_34\IN\1740 psoriasis_35\NN\14219661 (_36\-LRB-\1740 21_37\CD\13745420 %_38\NN\1740 )_39\-RRB-\1740 ._40\.\1740
D020123_D019559 CID conclusions_0\NNS\5837957 :_1\:\1740 severe_2\JJ\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>sirolimus</e1>_6\NN\1740 include_7\VBP\690614 fever_8\NN\14299637 ,_9\,\1740 anemia_10\NN\14189204 ,_11\,\1740 and_12\CC\1740 <e2>capillary_13\JJ\1740 leak_14\NN\9304465 syndrome</e2>_15\NN\5870365 ._16\.\1740
D003907_D011565 NONE activated_0\VBN\1641914 peripheral_1\JJ\1740 blood_2\NN\5397468 t_3\NN\14999913 cells_4\NNS\3080309 from_5\IN\1740 patients_6\NNS\9898892 with_7\IN\1740 <e2>psoriasis</e2>_8\NN\14219661 tended_9\VBD\2604760 to_10\TO\1740 exhibit_11\VB\2632167 greater_12\JJR\1740 spontaneous_13\JJ\1740 or_14\CC\3541091 <e1>dexamethasone-induced</e1>_15\JJ\1740 apoptosis_16\NN\11486178 than_17\IN\1740 did_18\VBD\1640855 normal_19\JJ\1740 t_20\NN\14999913 cells_21\NNS\3080309 ,_22\,\1740 particularly_23\RB\1740 in_24\IN\13603305 the_25\DT\1740 presence_26\NN\13954253 of_27\IN\1740 sirolimus_28\NN\1740 ._29\.\1740
D020123_D005334 NONE conclusions_0\NNS\5837957 :_1\:\1740 severe_2\JJ\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>sirolimus</e1>_6\NN\1740 include_7\VBP\690614 <e2>fever</e2>_8\NN\14299637 ,_9\,\1740 anemia_10\NN\14189204 ,_11\,\1740 and_12\CC\1740 capillary_13\JJ\1740 leak_14\NN\9304465 syndrome_15\NN\5870365 ._16\.\1740
D020123_D000740 NONE conclusions_0\NNS\5837957 :_1\:\1740 severe_2\JJ\1740 adverse_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>sirolimus</e1>_6\NN\1740 include_7\VBP\690614 fever_8\NN\14299637 ,_9\,\1740 <e2>anemia</e2>_10\NN\14189204 ,_11\,\1740 and_12\CC\1740 capillary_13\JJ\1740 leak_14\NN\9304465 syndrome_15\NN\5870365 ._16\.\1740
2716967
D007649_D002375 CID <e2>catalepsy</e2>_0\NNP\14023236 induced_1\VBN\1627355 by_2\IN\1740 combinations_3\NNS\7951464 of_4\IN\1740 <e1>ketamine</e1>_5\NN\3054098 and_6\CC\1740 morphine_7\NN\2707683 :_8\:\1740 potentiation_9\NN\13564910 ,_10\,\1740 antagonism_11\NN\24720 ,_12\,\1740 tolerance_13\NN\5032565 and_14\CC\1740 cross-tolerance_15\NN\1740 in_16\IN\13603305 the_17\DT\1740 rat_18\NN\2329401 ._19\.\1740
D007649_D002375 CID previous_0\JJ\1740 studies_1\NNS\635850 demonstrated_2\VBD\2137132 that_3\IN\1740 both_4\CC\1740 <e1>ketamine</e1>_5\NN\3054098 and_6\CC\1740 morphine_7\NN\2707683 induced_8\JJ\1740 analgesia_9\NN\14034177 and_10\CC\1740 <e2>catalepsy</e2>_11\NN\14023236 in_12\IN\13603305 the_13\DT\1740 rat_14\NN\2329401 ._15\.\1740
D007649_D002375 CID pre-treatment_0\JJ\1740 with_1\IN\1740 <e1>ketamine</e1>_2\NN\3054098 produced_3\VBD\1617192 cross-tolerance_4\NN\1740 to_5\TO\1740 morphine_6\NN\2707683 ,_7\,\1740 whereas_8\IN\1740 pretreatment_9\NN\1740 with_10\IN\1740 morphine_11\NN\2707683 did_12\VBD\1640855 not_13\RB\1740 induce_14\VB\1627355 cross-tolerance_15\NN\1740 to_16\TO\1740 ketamine_17\VB\1740 but_18\CC\1740 rather_19\RB\1740 augmented_20\VBD\153263 the_21\DT\1740 <e2>cataleptic</e2>_22\JJ\1740 response_23\NN\11410625 ;_24\:\1740 this_25\DT\1740 augmentation_26\NN\7356676 was_27\VBD\836236 attributed_28\VBN\670261 to_29\TO\1740 residual_30\JJ\1740 morphine_31\NN\2707683 in_32\IN\13603305 the_33\DT\1740 brain_34\NN\5462674 ._35\.\1740
D007649_D002375 CID pre-treatment_0\JJ\1740 with_1\IN\1740 ketamine_2\NN\3054098 produced_3\VBD\1617192 cross-tolerance_4\NN\1740 to_5\TO\1740 morphine_6\NN\2707683 ,_7\,\1740 whereas_8\IN\1740 pretreatment_9\NN\1740 with_10\IN\1740 morphine_11\NN\2707683 did_12\VBD\1640855 not_13\RB\1740 induce_14\VB\1627355 cross-tolerance_15\NN\1740 to_16\TO\1740 <e1>ketamine</e1>_17\VB\1740 but_18\CC\1740 rather_19\RB\1740 augmented_20\VBD\153263 the_21\DT\1740 <e2>cataleptic</e2>_22\JJ\1740 response_23\NN\11410625 ;_24\:\1740 this_25\DT\1740 augmentation_26\NN\7356676 was_27\VBD\836236 attributed_28\VBN\670261 to_29\TO\1740 residual_30\JJ\1740 morphine_31\NN\2707683 in_32\IN\13603305 the_33\DT\1740 brain_34\NN\5462674 ._35\.\1740
D009020_D002375 CID <e2>catalepsy</e2>_0\NNP\14023236 induced_1\VBN\1627355 by_2\IN\1740 combinations_3\NNS\7951464 of_4\IN\1740 ketamine_5\NN\3054098 and_6\CC\1740 <e1>morphine</e1>_7\NN\2707683 :_8\:\1740 potentiation_9\NN\13564910 ,_10\,\1740 antagonism_11\NN\24720 ,_12\,\1740 tolerance_13\NN\5032565 and_14\CC\1740 cross-tolerance_15\NN\1740 in_16\IN\13603305 the_17\DT\1740 rat_18\NN\2329401 ._19\.\1740
D009020_D002375 CID previous_0\JJ\1740 studies_1\NNS\635850 demonstrated_2\VBD\2137132 that_3\IN\1740 both_4\CC\1740 ketamine_5\NN\3054098 and_6\CC\1740 <e1>morphine</e1>_7\NN\2707683 induced_8\JJ\1740 analgesia_9\NN\14034177 and_10\CC\1740 <e2>catalepsy</e2>_11\NN\14023236 in_12\IN\13603305 the_13\DT\1740 rat_14\NN\2329401 ._15\.\1740
D009020_D002375 CID pre-treatment_0\JJ\1740 with_1\IN\1740 ketamine_2\NN\3054098 produced_3\VBD\1617192 cross-tolerance_4\NN\1740 to_5\TO\1740 <e1>morphine</e1>_6\NN\2707683 ,_7\,\1740 whereas_8\IN\1740 pretreatment_9\NN\1740 with_10\IN\1740 morphine_11\NN\2707683 did_12\VBD\1640855 not_13\RB\1740 induce_14\VB\1627355 cross-tolerance_15\NN\1740 to_16\TO\1740 ketamine_17\VB\1740 but_18\CC\1740 rather_19\RB\1740 augmented_20\VBD\153263 the_21\DT\1740 <e2>cataleptic</e2>_22\JJ\1740 response_23\NN\11410625 ;_24\:\1740 this_25\DT\1740 augmentation_26\NN\7356676 was_27\VBD\836236 attributed_28\VBN\670261 to_29\TO\1740 residual_30\JJ\1740 morphine_31\NN\2707683 in_32\IN\13603305 the_33\DT\1740 brain_34\NN\5462674 ._35\.\1740
D009020_D002375 CID pre-treatment_0\JJ\1740 with_1\IN\1740 ketamine_2\NN\3054098 produced_3\VBD\1617192 cross-tolerance_4\NN\1740 to_5\TO\1740 morphine_6\NN\2707683 ,_7\,\1740 whereas_8\IN\1740 pretreatment_9\NN\1740 with_10\IN\1740 <e1>morphine</e1>_11\NN\2707683 did_12\VBD\1640855 not_13\RB\1740 induce_14\VB\1627355 cross-tolerance_15\NN\1740 to_16\TO\1740 ketamine_17\VB\1740 but_18\CC\1740 rather_19\RB\1740 augmented_20\VBD\153263 the_21\DT\1740 <e2>cataleptic</e2>_22\JJ\1740 response_23\NN\11410625 ;_24\:\1740 this_25\DT\1740 augmentation_26\NN\7356676 was_27\VBD\836236 attributed_28\VBN\670261 to_29\TO\1740 residual_30\JJ\1740 morphine_31\NN\2707683 in_32\IN\13603305 the_33\DT\1740 brain_34\NN\5462674 ._35\.\1740
D009020_D002375 CID pre-treatment_0\JJ\1740 with_1\IN\1740 ketamine_2\NN\3054098 produced_3\VBD\1617192 cross-tolerance_4\NN\1740 to_5\TO\1740 morphine_6\NN\2707683 ,_7\,\1740 whereas_8\IN\1740 pretreatment_9\NN\1740 with_10\IN\1740 morphine_11\NN\2707683 did_12\VBD\1640855 not_13\RB\1740 induce_14\VB\1627355 cross-tolerance_15\NN\1740 to_16\TO\1740 ketamine_17\VB\1740 but_18\CC\1740 rather_19\RB\1740 augmented_20\VBD\153263 the_21\DT\1740 <e2>cataleptic</e2>_22\JJ\1740 response_23\NN\11410625 ;_24\:\1740 this_25\DT\1740 augmentation_26\NN\7356676 was_27\VBD\836236 attributed_28\VBN\670261 to_29\TO\1740 residual_30\JJ\1740 <e1>morphine</e1>_31\NN\2707683 in_32\IN\13603305 the_33\DT\1740 brain_34\NN\5462674 ._35\.\1740
D007649_D000699 NONE previous_0\JJ\1740 studies_1\NNS\635850 demonstrated_2\VBD\2137132 that_3\IN\1740 both_4\CC\1740 <e1>ketamine</e1>_5\NN\3054098 and_6\CC\1740 morphine_7\NN\2707683 induced_8\JJ\1740 <e2>analgesia</e2>_9\NN\14034177 and_10\CC\1740 catalepsy_11\NN\14023236 in_12\IN\13603305 the_13\DT\1740 rat_14\NN\2329401 ._15\.\1740
D009020_D000699 NONE previous_0\JJ\1740 studies_1\NNS\635850 demonstrated_2\VBD\2137132 that_3\IN\1740 both_4\CC\1740 ketamine_5\NN\3054098 and_6\CC\1740 <e1>morphine</e1>_7\NN\2707683 induced_8\JJ\1740 <e2>analgesia</e2>_9\NN\14034177 and_10\CC\1740 catalepsy_11\NN\14023236 in_12\IN\13603305 the_13\DT\1740 rat_14\NN\2329401 ._15\.\1740
D007649_D009127 NONE latency_0\NN\15269513 to_1\TO\1740 the_2\DT\1740 loss_3\NN\13252973 of_4\IN\1740 righting_5\VBG\126264 reflex_6\JJ\1740 ,_7\,\1740 <e2>rigidity</e2>_8\NN\5023233 and_9\CC\1740 behavior_10\NN\407535 on_11\IN\1740 recovery_12\NN\7357388 ,_13\,\1740 reflected_14\VBD\923793 the_15\DT\1740 relative_16\JJ\1740 predominance_17\NN\14441825 of_18\IN\1740 <e1>ketamine</e1>_19\NN\3054098 or_20\CC\3541091 morphine_21\NN\2707683 in_22\IN\13603305 each_23\DT\1740 combination_24\NN\7951464 ._25\.\1740
D009020_D009127 NONE latency_0\NN\15269513 to_1\TO\1740 the_2\DT\1740 loss_3\NN\13252973 of_4\IN\1740 righting_5\VBG\126264 reflex_6\JJ\1740 ,_7\,\1740 <e2>rigidity</e2>_8\NN\5023233 and_9\CC\1740 behavior_10\NN\407535 on_11\IN\1740 recovery_12\NN\7357388 ,_13\,\1740 reflected_14\VBD\923793 the_15\DT\1740 relative_16\JJ\1740 predominance_17\NN\14441825 of_18\IN\1740 ketamine_19\NN\3054098 or_20\CC\3541091 <e1>morphine</e1>_21\NN\2707683 in_22\IN\13603305 each_23\DT\1740 combination_24\NN\7951464 ._25\.\1740
D009270_D002375 NONE <e1>naloxone</e1>_0\NN\3808977 inhibited_1\VBD\2510337 the_2\DT\1740 induced_3\VBN\1627355 <e2>cataleptic</e2>_4\JJ\1740 effects_5\NNS\13245626 ._6\.\1740
D009270_D002375 NONE while_0\IN\15122231 the_1\DT\1740 mutual_2\JJ\1740 potentiation_3\NN\13564910 ,_4\,\1740 antagonism_5\NN\24720 and_6\CC\1740 tolerance_7\NN\5032565 suggest_8\VBP\1010118 common_9\JJ\1740 mechanisms_10\NNS\13446390 for_11\IN\1740 the_12\DT\1740 induced_13\VBN\1627355 <e2>catalepsy</e2>_14\NN\14023236 ,_15\,\1740 differences_16\NNS\4723816 in_17\IN\13603305 latency_18\NN\15269513 ,_19\,\1740 rigidity_20\NN\5023233 and_21\CC\1740 behavior_22\NN\407535 ,_23\,\1740 asymmetry_24\NN\5062748 of_25\IN\1740 cross-tolerance_26\NN\1740 and_27\CC\1740 a_28\DT\13649268 widely-different_29\JJ\1740 id50_30\NN\1740 for_31\IN\1740 <e1>naloxone</e1>_32\NN\3808977 would_33\MD\1740 argue_34\VB\772967 against_35\IN\1740 an_36\DT\6697703 action_37\NN\30358 at_38\IN\14622893 a_39\DT\13649268 single_40\JJ\1740 opioid_41\JJ\1740 site_42\NN\8673395 ._43\.\1740
D009270_D009127 NONE while_0\IN\15122231 the_1\DT\1740 mutual_2\JJ\1740 potentiation_3\NN\13564910 ,_4\,\1740 antagonism_5\NN\24720 and_6\CC\1740 tolerance_7\NN\5032565 suggest_8\VBP\1010118 common_9\JJ\1740 mechanisms_10\NNS\13446390 for_11\IN\1740 the_12\DT\1740 induced_13\VBN\1627355 catalepsy_14\NN\14023236 ,_15\,\1740 differences_16\NNS\4723816 in_17\IN\13603305 latency_18\NN\15269513 ,_19\,\1740 <e2>rigidity</e2>_20\NN\5023233 and_21\CC\1740 behavior_22\NN\407535 ,_23\,\1740 asymmetry_24\NN\5062748 of_25\IN\1740 cross-tolerance_26\NN\1740 and_27\CC\1740 a_28\DT\13649268 widely-different_29\JJ\1740 id50_30\NN\1740 for_31\IN\1740 <e1>naloxone</e1>_32\NN\3808977 would_33\MD\1740 argue_34\VB\772967 against_35\IN\1740 an_36\DT\6697703 action_37\NN\30358 at_38\IN\14622893 a_39\DT\13649268 single_40\JJ\1740 opioid_41\JJ\1740 site_42\NN\8673395 ._43\.\1740
11861791
D011064_D006333 NONE activation_0\NN\13561719 of_1\IN\1740 <e1>poly(adp-ribose_2\NN\1740 )</e1>_3\-RRB-\1740 polymerase_4\NN\14732946 contributes_5\VBZ\126264 to_6\TO\1740 development_7\NN\248977 of_8\IN\1740 doxorubicin-induced_9\JJ\1740 <e2>heart_10\NN\5919034 failure</e2>_11\NN\66216 ._12\.\1740
D004317_D006333 CID activation_0\NN\13561719 of_1\IN\1740 poly(adp-ribose_2\NN\1740 )_3\-RRB-\1740 polymerase_4\NN\14732946 contributes_5\VBZ\126264 to_6\TO\1740 development_7\NN\248977 of_8\IN\1740 <e1>doxorubicin-induced</e1>_9\JJ\1740 <e2>heart_10\NN\5919034 failure</e2>_11\NN\66216 ._12\.\1740
D004317_D066126 NONE increased_0\VBN\169651 oxidative_1\JJ\1740 stress_2\NN\7083732 is_3\VBZ\836236 a_4\DT\13649268 major_5\JJ\1740 factor_6\NN\7326557 implicated_7\VBN\2677097 in_8\IN\13603305 the_9\DT\1740 <e2>cardiotoxicity</e2>_10\NN\1740 of_11\IN\1740 <e1>doxorubicin</e1>_12\NN\2716866 (_13\-LRB-\1740 dox_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 a_17\DT\13649268 widely_18\RB\1740 used_19\VBN\1156834 antitumor_20\NN\1740 anthracycline_21\NN\1740 antibiotic_22\NN\2716205 ._23\.\1740
D004317_D066126 NONE increased_0\VBN\169651 oxidative_1\JJ\1740 stress_2\NN\7083732 is_3\VBZ\836236 a_4\DT\13649268 major_5\JJ\1740 factor_6\NN\7326557 implicated_7\VBN\2677097 in_8\IN\13603305 the_9\DT\1740 <e2>cardiotoxicity</e2>_10\NN\1740 of_11\IN\1740 doxorubicin_12\NN\2716866 (_13\-LRB-\1740 <e1>dox</e1>_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 a_17\DT\13649268 widely_18\RB\1740 used_19\VBN\1156834 antitumor_20\NN\1740 anthracycline_21\NN\1740 antibiotic_22\NN\2716205 ._23\.\1740
D004317_D066126 NONE thus_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 hypothesized_3\VBD\719734 that_4\IN\1740 the_5\DT\1740 activation_6\NN\13561719 of_7\IN\1740 parp_8\NN\1740 may_9\MD\15209706 contribute_10\VB\126264 to_11\TO\1740 the_12\DT\1740 <e1>dox-induced</e1>_13\JJ\1740 <e2>cardiotoxicity</e2>_14\NN\1740 ._15\.\1740
D004317_D066126 NONE thus_0\RB\1740 ,_1\,\1740 parp_2\NN\1740 activation_3\NN\13561719 contributes_4\VBZ\126264 to_5\TO\1740 the_6\DT\1740 <e2>cardiotoxicity</e2>_7\NN\1740 of_8\IN\1740 <e1>dox</e1>_9\NN\1740 ._10\.\1740
D018943_D066126 NONE increased_0\VBN\169651 oxidative_1\JJ\1740 stress_2\NN\7083732 is_3\VBZ\836236 a_4\DT\13649268 major_5\JJ\1740 factor_6\NN\7326557 implicated_7\VBN\2677097 in_8\IN\13603305 the_9\DT\1740 <e2>cardiotoxicity</e2>_10\NN\1740 of_11\IN\1740 doxorubicin_12\NN\2716866 (_13\-LRB-\1740 dox_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 a_17\DT\13649268 widely_18\RB\1740 used_19\VBN\1156834 antitumor_20\NN\1740 <e1>anthracycline</e1>_21\NN\1740 antibiotic_22\NN\2716205 ._23\.\1740
C434926_D006331 NONE using_0\VBG\1156834 a_1\DT\13649268 dual_2\JJ\1740 approach_3\NN\940842 of_4\IN\1740 parp-1_5\NN\1740 suppression_6\NN\13489037 ,_7\,\1740 by_8\IN\1740 genetic_9\JJ\1740 deletion_10\NN\13508333 or_11\CC\3541091 pharmacological_12\JJ\1740 inhibition_13\NN\1068773 with_14\IN\1740 the_15\DT\1740 phenanthridinone_16\NN\1740 parp_17\NN\1740 inhibitor_18\NN\20090 <e1>pj34</e1>_19\NN\1740 ,_20\,\1740 we_21\PRP\1740 now_22\RB\1740 demonstrate_23\VBP\2137132 the_24\DT\1740 role_25\NN\719494 of_26\IN\1740 parp_27\NN\1740 in_28\IN\13603305 the_29\DT\1740 development_30\NN\248977 of_31\IN\1740 <e2>cardiac_32\JJ\1740 dysfunction</e2>_33\NN\14204950 induced_34\VBN\1627355 by_35\IN\1740 dox_36\NN\1740 ._37\.\1740
C434926_D006331 NONE treatment_0\NN\654885 with_1\IN\1740 a_2\DT\13649268 <e1>pj34</e1>_3\NN\1740 significantly_4\RB\1740 improved_5\VBD\126264 <e2>cardiac_6\JJ\1740 dysfunction</e2>_7\NN\14204950 and_8\CC\1740 increased_9\VBD\169651 the_10\DT\1740 survival_11\NN\13961642 of_12\IN\1740 the_13\DT\1740 animals_14\NNS\4475 ._15\.\1740
D004317_D006331 NONE using_0\VBG\1156834 a_1\DT\13649268 dual_2\JJ\1740 approach_3\NN\940842 of_4\IN\1740 parp-1_5\NN\1740 suppression_6\NN\13489037 ,_7\,\1740 by_8\IN\1740 genetic_9\JJ\1740 deletion_10\NN\13508333 or_11\CC\3541091 pharmacological_12\JJ\1740 inhibition_13\NN\1068773 with_14\IN\1740 the_15\DT\1740 phenanthridinone_16\NN\1740 parp_17\NN\1740 inhibitor_18\NN\20090 pj34_19\NN\1740 ,_20\,\1740 we_21\PRP\1740 now_22\RB\1740 demonstrate_23\VBP\2137132 the_24\DT\1740 role_25\NN\719494 of_26\IN\1740 parp_27\NN\1740 in_28\IN\13603305 the_29\DT\1740 development_30\NN\248977 of_31\IN\1740 <e2>cardiac_32\JJ\1740 dysfunction</e2>_33\NN\14204950 induced_34\VBN\1627355 by_35\IN\1740 <e1>dox</e1>_36\NN\1740 ._37\.\1740
D004317_D005117 NONE parp_0\NN\1740 inhibitors_1\NNS\20090 may_2\MD\15209706 exert_3\VB\1158872 protective_4\JJ\1740 effects_5\NNS\13245626 against_6\IN\1740 the_7\DT\1740 development_8\NN\248977 of_9\IN\1740 severe_10\JJ\1740 <e2>cardiac_11\JJ\1740 complications</e2>_12\NNS\1073995 associated_13\VBN\628491 with_14\IN\1740 the_15\DT\1740 <e1>dox</e1>_16\NN\1740 treatment_17\NN\654885 ._18\.\1740
12109865
3131282
C009166_D063646 NONE <e2>co-carcinogenic</e2>_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>retinyl_3\NN\1740 acetate</e1>_4\NN\15010703 on_5\IN\1740 forestomach_6\NN\1740 carcinogenesis_7\NN\1740 of_8\IN\1740 male_9\JJ\1740 f344_10\NN\1740 rats_11\NNS\2329401 induced_12\VBN\1627355 with_13\IN\1740 butylated_14\VBN\182406 hydroxyanisole_15\NN\1740 ._16\.\1740
C009166_D013274 NONE co-carcinogenic_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>retinyl_3\NN\1740 acetate</e1>_4\NN\15010703 on_5\IN\1740 <e2>forestomach_6\NN\1740 carcinogenesis</e2>_7\NN\1740 of_8\IN\1740 male_9\JJ\1740 f344_10\NN\1740 rats_11\NNS\2329401 induced_12\VBN\1627355 with_13\IN\1740 butylated_14\VBN\182406 hydroxyanisole_15\NN\1740 ._16\.\1740
C009166_D013274 NONE the_0\DT\1740 potential_1\JJ\1740 modifying_2\NN\1740 effect_3\NN\34213 of_4\IN\1740 <e1>retinyl_5\NN\1740 acetate</e1>_6\NN\15010703 (_7\-LRB-\1740 ra_8\NN\14625458 )_9\-RRB-\1740 on_10\IN\1740 butylated_11\VBN\182406 hydroxyanisole_12\NN\1740 (bha)-induced_13\CD\1740 rat_14\NN\2329401 <e2>forestomach_15\NN\1740 tumorigenesis</e2>_16\NN\1740 was_17\VBD\836236 examined_18\VBN\789138 ._19\.\1740
C009166_D013274 NONE the_0\DT\1740 potential_1\JJ\1740 modifying_2\NN\1740 effect_3\NN\34213 of_4\IN\1740 retinyl_5\NN\1740 acetate_6\NN\15010703 (_7\-LRB-\1740 <e1>ra</e1>_8\NN\14625458 )_9\-RRB-\1740 on_10\IN\1740 butylated_11\VBN\182406 hydroxyanisole_12\NN\1740 (bha)-induced_13\CD\1740 rat_14\NN\2329401 <e2>forestomach_15\NN\1740 tumorigenesis</e2>_16\NN\1740 was_17\VBD\836236 examined_18\VBN\789138 ._19\.\1740
C009166_D013274 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 bha_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 <e1>ra</e1>_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 <e2>forestomach_37\NN\1740 tumors</e2>_38\NNS\14234074 (_39\-LRB-\1740 squamous_40\JJ\1740 cell_41\NN\3080309 papilloma_42\NN\14236226 and_43\CC\1740 carcinoma_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 carcinoma_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 carcinoma_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 ra-free_72\NN\1740 water_73\NN\14618834 ._74\.\1740
C009166_D013274 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 bha_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 ra_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 <e2>forestomach_37\NN\1740 tumors</e2>_38\NNS\14234074 (_39\-LRB-\1740 squamous_40\JJ\1740 cell_41\NN\3080309 papilloma_42\NN\14236226 and_43\CC\1740 carcinoma_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 carcinoma_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 carcinoma_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 <e1>ra-free</e1>_72\NN\1740 water_73\NN\14618834 ._74\.\1740
C009166_D013274 NONE these_0\DT\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>ra</e1>_4\NN\14625458 acted_5\VBD\1619354 as_6\IN\14622893 a_7\DT\13649268 co-carcinogen_8\NN\1740 in_9\IN\13603305 the_10\DT\1740 bha_11\NN\1740 <e2>forestomach_12\NN\1740 carcinogenesis</e2>_13\NN\1740 of_14\IN\1740 the_15\DT\1740 rat_16\NN\2329401 ._17\.\1740
D002083_D063646 NONE <e2>co-carcinogenic</e2>_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 retinyl_3\NN\1740 acetate_4\NN\15010703 on_5\IN\1740 forestomach_6\NN\1740 carcinogenesis_7\NN\1740 of_8\IN\1740 male_9\JJ\1740 f344_10\NN\1740 rats_11\NNS\2329401 induced_12\VBN\1627355 with_13\IN\1740 <e1>butylated_14\VBN\182406 hydroxyanisole</e1>_15\NN\1740 ._16\.\1740
D002083_D013274 CID co-carcinogenic_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 retinyl_3\NN\1740 acetate_4\NN\15010703 on_5\IN\1740 <e2>forestomach_6\NN\1740 carcinogenesis</e2>_7\NN\1740 of_8\IN\1740 male_9\JJ\1740 f344_10\NN\1740 rats_11\NNS\2329401 induced_12\VBN\1627355 with_13\IN\1740 <e1>butylated_14\VBN\182406 hydroxyanisole</e1>_15\NN\1740 ._16\.\1740
D002083_D013274 CID the_0\DT\1740 potential_1\JJ\1740 modifying_2\NN\1740 effect_3\NN\34213 of_4\IN\1740 retinyl_5\NN\1740 acetate_6\NN\15010703 (_7\-LRB-\1740 ra_8\NN\14625458 )_9\-RRB-\1740 on_10\IN\1740 <e1>butylated_11\VBN\182406 hydroxyanisole</e1>_12\NN\1740 (bha)-induced_13\CD\1740 rat_14\NN\2329401 <e2>forestomach_15\NN\1740 tumorigenesis</e2>_16\NN\1740 was_17\VBD\836236 examined_18\VBN\789138 ._19\.\1740
D002083_D013274 CID the_0\DT\1740 potential_1\JJ\1740 modifying_2\NN\1740 effect_3\NN\34213 of_4\IN\1740 retinyl_5\NN\1740 acetate_6\NN\15010703 (_7\-LRB-\1740 ra_8\NN\14625458 )_9\-RRB-\1740 on_10\IN\1740 butylated_11\VBN\182406 hydroxyanisole_12\NN\1740 <e1>(bha)-induced</e1>_13\CD\1740 rat_14\NN\2329401 <e2>forestomach_15\NN\1740 tumorigenesis</e2>_16\NN\1740 was_17\VBD\836236 examined_18\VBN\789138 ._19\.\1740
D002083_D013274 CID in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 <e1>bha</e1>_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 ra_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 <e2>forestomach_37\NN\1740 tumors</e2>_38\NNS\14234074 (_39\-LRB-\1740 squamous_40\JJ\1740 cell_41\NN\3080309 papilloma_42\NN\14236226 and_43\CC\1740 carcinoma_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 carcinoma_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 carcinoma_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 ra-free_72\NN\1740 water_73\NN\14618834 ._74\.\1740
D002083_D013274 CID these_0\DT\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 ra_4\NN\14625458 acted_5\VBD\1619354 as_6\IN\14622893 a_7\DT\13649268 co-carcinogen_8\NN\1740 in_9\IN\13603305 the_10\DT\1740 <e1>bha</e1>_11\NN\1740 <e2>forestomach_12\NN\1740 carcinogenesis</e2>_13\NN\1740 of_14\IN\1740 the_15\DT\1740 rat_16\NN\2329401 ._17\.\1740
D002083_D010212 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 <e1>bha</e1>_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 ra_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 forestomach_37\NN\1740 tumors_38\NNS\14234074 (_39\-LRB-\1740 <e2>squamous_40\JJ\1740 cell_41\NN\3080309 papilloma</e2>_42\NN\14236226 and_43\CC\1740 carcinoma_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 carcinoma_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 carcinoma_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 ra-free_72\NN\1740 water_73\NN\14618834 ._74\.\1740
D002083_D002277 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 <e1>bha</e1>_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 ra_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 forestomach_37\NN\1740 tumors_38\NNS\14234074 (_39\-LRB-\1740 squamous_40\JJ\1740 cell_41\NN\3080309 papilloma_42\NN\14236226 and_43\CC\1740 <e2>carcinoma</e2>_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 carcinoma_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 carcinoma_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 ra-free_72\NN\1740 water_73\NN\14618834 ._74\.\1740
D002083_D002277 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 <e1>bha</e1>_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 ra_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 forestomach_37\NN\1740 tumors_38\NNS\14234074 (_39\-LRB-\1740 squamous_40\JJ\1740 cell_41\NN\3080309 papilloma_42\NN\14236226 and_43\CC\1740 carcinoma_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 <e2>carcinoma</e2>_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 carcinoma_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 ra-free_72\NN\1740 water_73\NN\14618834 ._74\.\1740
D002083_D002277 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 <e1>bha</e1>_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 ra_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 forestomach_37\NN\1740 tumors_38\NNS\14234074 (_39\-LRB-\1740 squamous_40\JJ\1740 cell_41\NN\3080309 papilloma_42\NN\14236226 and_43\CC\1740 carcinoma_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 carcinoma_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 <e2>carcinoma</e2>_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 ra-free_72\NN\1740 water_73\NN\14618834 ._74\.\1740
C009166_D010212 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 bha_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 <e1>ra</e1>_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 forestomach_37\NN\1740 tumors_38\NNS\14234074 (_39\-LRB-\1740 <e2>squamous_40\JJ\1740 cell_41\NN\3080309 papilloma</e2>_42\NN\14236226 and_43\CC\1740 carcinoma_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 carcinoma_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 carcinoma_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 ra-free_72\NN\1740 water_73\NN\14618834 ._74\.\1740
C009166_D010212 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 bha_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 ra_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 forestomach_37\NN\1740 tumors_38\NNS\14234074 (_39\-LRB-\1740 <e2>squamous_40\JJ\1740 cell_41\NN\3080309 papilloma</e2>_42\NN\14236226 and_43\CC\1740 carcinoma_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 carcinoma_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 carcinoma_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 <e1>ra-free</e1>_72\NN\1740 water_73\NN\14618834 ._74\.\1740
C009166_D010212 NONE tumors_0\NNS\14234074 ,_1\,\1740 all_2\DT\1740 <e2>papillomas</e2>_3\NNS\14236226 ,_4\,\1740 were_5\VBD\836236 induced_6\VBN\1627355 in_7\IN\13603305 3_8\CD\13741022 rats_9\NNS\2329401 (_10\-LRB-\1740 17_11\CD\13745420 %_12\NN\1740 )_13\-RRB-\1740 with_14\IN\1740 0.25_15\CD\1740 %_16\NN\1740 <e1>ra</e1>_17\NN\14625458 and_18\CC\1740 in_19\IN\13603305 one_20\CD\13741022 rat_21\NN\2329401 (_22\-LRB-\1740 10_23\CD\13745420 %_24\NN\1740 )_25\-RRB-\1740 with_26\IN\1740 0.05_27\CD\1740 %_28\NN\1740 ra_29\NN\14625458 co-administration_30\NN\1740 ._31\.\1740
C009166_D010212 NONE tumors_0\NNS\14234074 ,_1\,\1740 all_2\DT\1740 <e2>papillomas</e2>_3\NNS\14236226 ,_4\,\1740 were_5\VBD\836236 induced_6\VBN\1627355 in_7\IN\13603305 3_8\CD\13741022 rats_9\NNS\2329401 (_10\-LRB-\1740 17_11\CD\13745420 %_12\NN\1740 )_13\-RRB-\1740 with_14\IN\1740 0.25_15\CD\1740 %_16\NN\1740 ra_17\NN\14625458 and_18\CC\1740 in_19\IN\13603305 one_20\CD\13741022 rat_21\NN\2329401 (_22\-LRB-\1740 10_23\CD\13745420 %_24\NN\1740 )_25\-RRB-\1740 with_26\IN\1740 0.05_27\CD\1740 %_28\NN\1740 <e1>ra</e1>_29\NN\14625458 co-administration_30\NN\1740 ._31\.\1740
C009166_D002277 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 bha_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 <e1>ra</e1>_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 forestomach_37\NN\1740 tumors_38\NNS\14234074 (_39\-LRB-\1740 squamous_40\JJ\1740 cell_41\NN\3080309 papilloma_42\NN\14236226 and_43\CC\1740 <e2>carcinoma</e2>_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 carcinoma_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 carcinoma_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 ra-free_72\NN\1740 water_73\NN\14618834 ._74\.\1740
C009166_D002277 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 bha_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 <e1>ra</e1>_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 forestomach_37\NN\1740 tumors_38\NNS\14234074 (_39\-LRB-\1740 squamous_40\JJ\1740 cell_41\NN\3080309 papilloma_42\NN\14236226 and_43\CC\1740 carcinoma_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 <e2>carcinoma</e2>_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 carcinoma_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 ra-free_72\NN\1740 water_73\NN\14618834 ._74\.\1740
C009166_D002277 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 bha_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 <e1>ra</e1>_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 forestomach_37\NN\1740 tumors_38\NNS\14234074 (_39\-LRB-\1740 squamous_40\JJ\1740 cell_41\NN\3080309 papilloma_42\NN\14236226 and_43\CC\1740 carcinoma_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 carcinoma_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 <e2>carcinoma</e2>_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 ra-free_72\NN\1740 water_73\NN\14618834 ._74\.\1740
C009166_D002277 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 bha_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 ra_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 forestomach_37\NN\1740 tumors_38\NNS\14234074 (_39\-LRB-\1740 squamous_40\JJ\1740 cell_41\NN\3080309 papilloma_42\NN\14236226 and_43\CC\1740 <e2>carcinoma</e2>_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 carcinoma_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 carcinoma_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 <e1>ra-free</e1>_72\NN\1740 water_73\NN\14618834 ._74\.\1740
C009166_D002277 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 bha_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 ra_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 forestomach_37\NN\1740 tumors_38\NNS\14234074 (_39\-LRB-\1740 squamous_40\JJ\1740 cell_41\NN\3080309 papilloma_42\NN\14236226 and_43\CC\1740 carcinoma_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 <e2>carcinoma</e2>_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 carcinoma_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 <e1>ra-free</e1>_72\NN\1740 water_73\NN\14618834 ._74\.\1740
C009166_D002277 NONE in_0\IN\13603305 groups_1\NNS\2137 given_2\VBN\2327200 2_3\CD\13741022 %_4\NN\1740 bha_5\NN\1740 ,_6\,\1740 although_7\IN\1740 marked_8\JJ\1740 hyperplastic_9\JJ\1740 changes_10\NNS\7283608 of_11\IN\1740 the_12\DT\1740 forestomach_13\NN\1740 epithelium_14\NN\5267548 were_15\VBD\836236 observed_16\VBN\2163746 in_17\IN\13603305 all_18\DT\1740 animals_19\NNS\4475 ,_20\,\1740 co-administration_21\NN\1740 of_22\IN\1740 0.25_23\CD\1740 %_24\NN\1740 ra_25\NN\14625458 significantly_26\RB\1740 (_27\-LRB-\1740 p_28\NN\14622893 less_29\JJR\1740 than_30\IN\1740 0.05_31\CD\1740 )_32\-RRB-\1740 increased_33\VBD\169651 the_34\DT\1740 incidence_35\NN\13821570 of_36\IN\1740 forestomach_37\NN\1740 tumors_38\NNS\14234074 (_39\-LRB-\1740 squamous_40\JJ\1740 cell_41\NN\3080309 papilloma_42\NN\14236226 and_43\CC\1740 carcinoma_44\NN\14239918 )_45\-RRB-\1740 to_46\TO\1740 60_47\CD\13745420 %_48\NN\1740 (_49\-LRB-\1740 9/15_50\CD\1740 ,_51\,\1740 2_52\CD\13741022 rats_53\NNS\2329401 with_54\IN\1740 carcinoma_55\NN\14239918 )_56\-RRB-\1740 from_57\IN\1740 15_58\CD\13745420 %_59\NN\1740 (_60\-LRB-\1740 3/20_61\CD\1740 ,_62\,\1740 one_63\CD\13741022 rat_64\NN\2329401 with_65\IN\1740 <e2>carcinoma</e2>_66\NN\14239918 )_67\-RRB-\1740 in_68\IN\13603305 the_69\DT\1740 group_70\NN\2137 given_71\VBN\2327200 <e1>ra-free</e1>_72\NN\1740 water_73\NN\14618834 ._74\.\1740
D002083_D017573 NONE in_0\IN\13603305 rats_1\NNS\2329401 given_2\IN\5892096 1_3\CD\13741022 %_4\NN\1740 <e1>bha</e1>_5\NN\1740 ,_6\,\1740 ra_7\NN\14625458 co-administered_8\VBN\1740 at_9\IN\14622893 a_10\DT\13649268 dose_11\NN\3740161 of_12\IN\1740 0.05_13\CD\1740 ,_14\,\1740 0.1_15\CD\1740 ,_16\,\1740 0.2_17\CD\1740 or_18\CC\3541091 0.25_19\CD\1740 %_20\NN\1740 showed_21\VBD\2137132 a_22\DT\13649268 dose-dependent_23\JJ\1740 enhancing_24\NN\1740 effect_25\NN\34213 on_26\IN\1740 the_27\DT\1740 development_28\NN\248977 of_29\IN\1740 the_30\DT\1740 bha-induced_31\JJ\1740 <e2>epithelial_32\JJ\1740 hyperplasia</e2>_33\NN\14365950 ._34\.\1740
D002083_D017573 NONE in_0\IN\13603305 rats_1\NNS\2329401 given_2\IN\5892096 1_3\CD\13741022 %_4\NN\1740 bha_5\NN\1740 ,_6\,\1740 ra_7\NN\14625458 co-administered_8\VBN\1740 at_9\IN\14622893 a_10\DT\13649268 dose_11\NN\3740161 of_12\IN\1740 0.05_13\CD\1740 ,_14\,\1740 0.1_15\CD\1740 ,_16\,\1740 0.2_17\CD\1740 or_18\CC\3541091 0.25_19\CD\1740 %_20\NN\1740 showed_21\VBD\2137132 a_22\DT\13649268 dose-dependent_23\JJ\1740 enhancing_24\NN\1740 effect_25\NN\34213 on_26\IN\1740 the_27\DT\1740 development_28\NN\248977 of_29\IN\1740 the_30\DT\1740 <e1>bha-induced</e1>_31\JJ\1740 <e2>epithelial_32\JJ\1740 hyperplasia</e2>_33\NN\14365950 ._34\.\1740
C009166_D017573 NONE in_0\IN\13603305 rats_1\NNS\2329401 given_2\IN\5892096 1_3\CD\13741022 %_4\NN\1740 bha_5\NN\1740 ,_6\,\1740 <e1>ra</e1>_7\NN\14625458 co-administered_8\VBN\1740 at_9\IN\14622893 a_10\DT\13649268 dose_11\NN\3740161 of_12\IN\1740 0.05_13\CD\1740 ,_14\,\1740 0.1_15\CD\1740 ,_16\,\1740 0.2_17\CD\1740 or_18\CC\3541091 0.25_19\CD\1740 %_20\NN\1740 showed_21\VBD\2137132 a_22\DT\13649268 dose-dependent_23\JJ\1740 enhancing_24\NN\1740 effect_25\NN\34213 on_26\IN\1740 the_27\DT\1740 development_28\NN\248977 of_29\IN\1740 the_30\DT\1740 bha-induced_31\JJ\1740 <e2>epithelial_32\JJ\1740 hyperplasia</e2>_33\NN\14365950 ._34\.\1740
C009166_D009369 NONE <e2>tumors</e2>_0\NNS\14234074 ,_1\,\1740 all_2\DT\1740 papillomas_3\NNS\14236226 ,_4\,\1740 were_5\VBD\836236 induced_6\VBN\1627355 in_7\IN\13603305 3_8\CD\13741022 rats_9\NNS\2329401 (_10\-LRB-\1740 17_11\CD\13745420 %_12\NN\1740 )_13\-RRB-\1740 with_14\IN\1740 0.25_15\CD\1740 %_16\NN\1740 <e1>ra</e1>_17\NN\14625458 and_18\CC\1740 in_19\IN\13603305 one_20\CD\13741022 rat_21\NN\2329401 (_22\-LRB-\1740 10_23\CD\13745420 %_24\NN\1740 )_25\-RRB-\1740 with_26\IN\1740 0.05_27\CD\1740 %_28\NN\1740 ra_29\NN\14625458 co-administration_30\NN\1740 ._31\.\1740
C009166_D009369 NONE <e2>tumors</e2>_0\NNS\14234074 ,_1\,\1740 all_2\DT\1740 papillomas_3\NNS\14236226 ,_4\,\1740 were_5\VBD\836236 induced_6\VBN\1627355 in_7\IN\13603305 3_8\CD\13741022 rats_9\NNS\2329401 (_10\-LRB-\1740 17_11\CD\13745420 %_12\NN\1740 )_13\-RRB-\1740 with_14\IN\1740 0.25_15\CD\1740 %_16\NN\1740 ra_17\NN\14625458 and_18\CC\1740 in_19\IN\13603305 one_20\CD\13741022 rat_21\NN\2329401 (_22\-LRB-\1740 10_23\CD\13745420 %_24\NN\1740 )_25\-RRB-\1740 with_26\IN\1740 0.05_27\CD\1740 %_28\NN\1740 <e1>ra</e1>_29\NN\14625458 co-administration_30\NN\1740 ._31\.\1740
19234905
D007980_D004409 CID ten_0\CD\13745420 consecutive_1\JJ\1740 patients_2\NNS\9898892 (_3\-LRB-\1740 mean_4\NN\6021761 age_5\NN\4916342 ,_6\,\1740 58.4_7\CD\1740 +/-_8\CC\1740 6.8_9\CD\1740 years_10\NNS\15144371 ;_11\:\1740 7_12\CD\13741022 men_13\NNS\8208016 ,_14\,\1740 3_15\CD\13741022 women_16\NNS\9605289 )_17\-RRB-\1740 with_18\IN\1740 similar_19\JJ\1740 characteristics_20\NNS\5849040 at_21\IN\14622893 the_22\DT\1740 duration_23\NN\15113229 of_24\IN\1740 disease_25\NN\14061805 (_26\-LRB-\1740 mean_27\NN\6021761 disease_28\NN\14061805 time_29\NN\7308889 ,_30\,\1740 8.4_31\CD\1740 +/-_32\CC\1740 3.5_33\CD\1740 years_34\NNS\15144371 )_35\-RRB-\1740 ,_36\,\1740 disabling_37\VBG\126264 motor_38\NN\3699975 fluctuations_39\NNS\7345593 (_40\-LRB-\1740 hoehn_41\NN\1740 __42\NNP\1740 yahr_43\NNP\1740 stage_44\NN\15113229 3_45\CD\13741022 -_46\SYM\1740 5_47\CD\13741022 in_48\IN\13603305 off-drug_49\JJ\1740 phases_50\NNS\15113229 )_51\-RRB-\1740 and_52\CC\1740 <e1>levodopa-induced</e1>_53\JJ\1740 <e2>dyskinesias</e2>_54\NNS\14084880 were_55\VBD\836236 selected_56\VBN\697589 ._57\.\1740
D014635_D006423 NONE complications_0\NNS\1073995 were_1\VBD\836236 observed_2\VBN\2163746 in_3\IN\13603305 two_4\CD\13741022 patients_5\NNS\9898892 :_6\:\1740 one_7\CD\13741022 had_8\VBD\2108377 a_9\DT\13649268 left_10\JJ\1740 <e2>homonymous_11\JJ\1740 hemianopsia</e2>_12\NN\14552802 after_13\IN\1740 pallidotomy_14\NN\1740 and_15\CC\1740 another_16\DT\1740 one_17\CD\13741022 developed_18\VBD\1753788 left_19\VBN\120316 hemiballistic_20\JJ\1740 movements_21\NNS\191142 3_22\CD\13741022 days_23\NNS\15140892 after_24\IN\1740 subthalamotomy_25\NN\1740 which_26\WDT\1740 partly_27\RB\1740 improved_28\VBD\126264 within_29\IN\1740 1_30\CD\13741022 month_31\NN\15113229 with_32\IN\1740 <e1>valproate</e1>_33\NNP\1740 1000_34\CD\13745420 mg/day_35\NN\1740 ._36\.\1740
8600333
C053519_D001859 NONE cardiac_0\JJ\1740 function_1\NN\13783581 was_2\VBD\836236 assessed_3\VBN\670261 in_4\IN\13603305 long-term_5\JJ\1740 survivors_6\NNS\9630641 of_7\IN\1740 malignant_8\JJ\1740 <e2>bone_9\NN\5286536 tumors</e2>_10\NNS\14234074 who_11\WP\8299493 were_12\VBD\836236 treated_13\VBN\2376958 according_14\VBG\2657219 to_15\IN\1740 <e1>rosen_16\NNP\1740 's_17\POS\1740 t5_18\NN\1740 or_19\CC\3541091 t10_20\NN\1740 protocol</e1>_21\NN\6652242 ,_22\,\1740 both_23\DT\1740 including_24\VBG\690614 doxorubicin_25\NN\2716866 ._26\.\1740
D004317_D001859 NONE cardiac_0\JJ\1740 function_1\NN\13783581 was_2\VBD\836236 assessed_3\VBN\670261 in_4\IN\13603305 long-term_5\JJ\1740 survivors_6\NNS\9630641 of_7\IN\1740 malignant_8\JJ\1740 <e2>bone_9\NN\5286536 tumors</e2>_10\NNS\14234074 who_11\WP\8299493 were_12\VBD\836236 treated_13\VBN\2376958 according_14\VBG\2657219 to_15\IN\1740 rosen_16\NNP\1740 's_17\POS\1740 t5_18\NN\1740 or_19\CC\3541091 t10_20\NN\1740 protocol_21\NN\6652242 ,_22\,\1740 both_23\DT\1740 including_24\VBG\690614 <e1>doxorubicin</e1>_25\NN\2716866 ._26\.\1740
D004317_D066126 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e1>doxorubicin-induced</e1>_3\JJ\1740 <e2>cardiotoxicity</e2>_4\NN\1740 is_5\VBZ\836236 high_6\JJ\1740 and_7\CC\1740 increases_8\VBZ\169651 with_9\IN\1740 follow-up_10\NN\4599396 ,_11\,\1740 irrespective_12\RB\1740 of_13\IN\1740 cumulative_14\JJ\1740 dose_15\NN\3740161 ._16\.\1740
6308526
C024224_D000699 NONE pretreatment_0\NN\1740 with_1\IN\1740 <e1>naloxazone</e1>_2\NN\1740 significantly_3\RB\1740 blocked_4\VBD\1476483 morphine_5\JJ\1740 <e2>analgesia</e2>_6\NN\14034177 ,_7\,\1740 catalepsy_8\NN\14023236 and_9\CC\1740 hypothermia_10\NN\14034177 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 which_14\WDT\1740 completely_15\RB\1740 eliminated_16\VBD\1619929 high-affinity_17\JJ\1740 binding_18\NN\4688246 in_19\IN\13603305 brain_20\NN\5462674 membranes_21\NNS\4188643 ._22\.\1740
C024224_D002375 NONE pretreatment_0\NN\1740 with_1\IN\1740 <e1>naloxazone</e1>_2\NN\1740 significantly_3\RB\1740 blocked_4\VBD\1476483 morphine_5\JJ\1740 analgesia_6\NN\14034177 ,_7\,\1740 <e2>catalepsy</e2>_8\NN\14023236 and_9\CC\1740 hypothermia_10\NN\14034177 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 which_14\WDT\1740 completely_15\RB\1740 eliminated_16\VBD\1619929 high-affinity_17\JJ\1740 binding_18\NN\4688246 in_19\IN\13603305 brain_20\NN\5462674 membranes_21\NNS\4188643 ._22\.\1740
C024224_D007035 NONE pretreatment_0\NN\1740 with_1\IN\1740 <e1>naloxazone</e1>_2\NN\1740 significantly_3\RB\1740 blocked_4\VBD\1476483 morphine_5\JJ\1740 analgesia_6\NN\14034177 ,_7\,\1740 catalepsy_8\NN\14023236 and_9\CC\1740 <e2>hypothermia</e2>_10\NN\14034177 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 which_14\WDT\1740 completely_15\RB\1740 eliminated_16\VBD\1619929 high-affinity_17\JJ\1740 binding_18\NN\4688246 in_19\IN\13603305 brain_20\NN\5462674 membranes_21\NNS\4188643 ._22\.\1740
D009020_D000699 NONE pretreatment_0\NN\1740 with_1\IN\1740 naloxazone_2\NN\1740 significantly_3\RB\1740 blocked_4\VBD\1476483 <e1>morphine</e1>_5\JJ\1740 <e2>analgesia</e2>_6\NN\14034177 ,_7\,\1740 catalepsy_8\NN\14023236 and_9\CC\1740 hypothermia_10\NN\14034177 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 which_14\WDT\1740 completely_15\RB\1740 eliminated_16\VBD\1619929 high-affinity_17\JJ\1740 binding_18\NN\4688246 in_19\IN\13603305 brain_20\NN\5462674 membranes_21\NNS\4188643 ._22\.\1740
D009020_D002375 CID pretreatment_0\NN\1740 with_1\IN\1740 naloxazone_2\NN\1740 significantly_3\RB\1740 blocked_4\VBD\1476483 <e1>morphine</e1>_5\JJ\1740 analgesia_6\NN\14034177 ,_7\,\1740 <e2>catalepsy</e2>_8\NN\14023236 and_9\CC\1740 hypothermia_10\NN\14034177 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 which_14\WDT\1740 completely_15\RB\1740 eliminated_16\VBD\1619929 high-affinity_17\JJ\1740 binding_18\NN\4688246 in_19\IN\13603305 brain_20\NN\5462674 membranes_21\NNS\4188643 ._22\.\1740
D009020_D007035 CID pretreatment_0\NN\1740 with_1\IN\1740 naloxazone_2\NN\1740 significantly_3\RB\1740 blocked_4\VBD\1476483 <e1>morphine</e1>_5\JJ\1740 analgesia_6\NN\14034177 ,_7\,\1740 catalepsy_8\NN\14023236 and_9\CC\1740 <e2>hypothermia</e2>_10\NN\14034177 at_11\IN\14622893 a_12\DT\13649268 dose_13\NN\3740161 which_14\WDT\1740 completely_15\RB\1740 eliminated_16\VBD\1619929 high-affinity_17\JJ\1740 binding_18\NN\4688246 in_19\IN\13603305 brain_20\NN\5462674 membranes_21\NNS\4188643 ._22\.\1740
C024224_D007022 NONE moreover_0\RB\1740 ,_1\,\1740 <e1>naloxazone</e1>_2\NN\1740 significantly_3\RB\1740 attenuated_4\VBD\224901 the_5\DT\1740 morphine-induced_6\JJ\1740 <e2>hypotension</e2>_7\NN\14057371 and_8\CC\1740 respiratory_9\JJ\1740 depression_10\NN\14373582 ,_11\,\1740 whereas_12\IN\1740 morphine-induced_13\JJ\1740 bradycardia_14\NN\14110674 was_15\VBD\836236 less_16\RBR\1740 affected_17\VBN\126264 ._18\.\1740
C024224_D012131 NONE moreover_0\RB\1740 ,_1\,\1740 <e1>naloxazone</e1>_2\NN\1740 significantly_3\RB\1740 attenuated_4\VBD\224901 the_5\DT\1740 morphine-induced_6\JJ\1740 hypotension_7\NN\14057371 and_8\CC\1740 <e2>respiratory_9\JJ\1740 depression</e2>_10\NN\14373582 ,_11\,\1740 whereas_12\IN\1740 morphine-induced_13\JJ\1740 bradycardia_14\NN\14110674 was_15\VBD\836236 less_16\RBR\1740 affected_17\VBN\126264 ._18\.\1740
C024224_D001919 NONE moreover_0\RB\1740 ,_1\,\1740 <e1>naloxazone</e1>_2\NN\1740 significantly_3\RB\1740 attenuated_4\VBD\224901 the_5\DT\1740 morphine-induced_6\JJ\1740 hypotension_7\NN\14057371 and_8\CC\1740 respiratory_9\JJ\1740 depression_10\NN\14373582 ,_11\,\1740 whereas_12\IN\1740 morphine-induced_13\JJ\1740 <e2>bradycardia</e2>_14\NN\14110674 was_15\VBD\836236 less_16\RBR\1740 affected_17\VBN\126264 ._18\.\1740
D009020_D007022 CID moreover_0\RB\1740 ,_1\,\1740 naloxazone_2\NN\1740 significantly_3\RB\1740 attenuated_4\VBD\224901 the_5\DT\1740 <e1>morphine-induced</e1>_6\JJ\1740 <e2>hypotension</e2>_7\NN\14057371 and_8\CC\1740 respiratory_9\JJ\1740 depression_10\NN\14373582 ,_11\,\1740 whereas_12\IN\1740 morphine-induced_13\JJ\1740 bradycardia_14\NN\14110674 was_15\VBD\836236 less_16\RBR\1740 affected_17\VBN\126264 ._18\.\1740
D009020_D007022 CID moreover_0\RB\1740 ,_1\,\1740 naloxazone_2\NN\1740 significantly_3\RB\1740 attenuated_4\VBD\224901 the_5\DT\1740 morphine-induced_6\JJ\1740 <e2>hypotension</e2>_7\NN\14057371 and_8\CC\1740 respiratory_9\JJ\1740 depression_10\NN\14373582 ,_11\,\1740 whereas_12\IN\1740 <e1>morphine-induced</e1>_13\JJ\1740 bradycardia_14\NN\14110674 was_15\VBD\836236 less_16\RBR\1740 affected_17\VBN\126264 ._18\.\1740
D009020_D012131 NONE moreover_0\RB\1740 ,_1\,\1740 naloxazone_2\NN\1740 significantly_3\RB\1740 attenuated_4\VBD\224901 the_5\DT\1740 <e1>morphine-induced</e1>_6\JJ\1740 hypotension_7\NN\14057371 and_8\CC\1740 <e2>respiratory_9\JJ\1740 depression</e2>_10\NN\14373582 ,_11\,\1740 whereas_12\IN\1740 morphine-induced_13\JJ\1740 bradycardia_14\NN\14110674 was_15\VBD\836236 less_16\RBR\1740 affected_17\VBN\126264 ._18\.\1740
D009020_D012131 NONE moreover_0\RB\1740 ,_1\,\1740 naloxazone_2\NN\1740 significantly_3\RB\1740 attenuated_4\VBD\224901 the_5\DT\1740 morphine-induced_6\JJ\1740 hypotension_7\NN\14057371 and_8\CC\1740 <e2>respiratory_9\JJ\1740 depression</e2>_10\NN\14373582 ,_11\,\1740 whereas_12\IN\1740 <e1>morphine-induced</e1>_13\JJ\1740 bradycardia_14\NN\14110674 was_15\VBD\836236 less_16\RBR\1740 affected_17\VBN\126264 ._18\.\1740
D009020_D001919 CID moreover_0\RB\1740 ,_1\,\1740 naloxazone_2\NN\1740 significantly_3\RB\1740 attenuated_4\VBD\224901 the_5\DT\1740 <e1>morphine-induced</e1>_6\JJ\1740 hypotension_7\NN\14057371 and_8\CC\1740 respiratory_9\JJ\1740 depression_10\NN\14373582 ,_11\,\1740 whereas_12\IN\1740 morphine-induced_13\JJ\1740 <e2>bradycardia</e2>_14\NN\14110674 was_15\VBD\836236 less_16\RBR\1740 affected_17\VBN\126264 ._18\.\1740
D009020_D001919 CID moreover_0\RB\1740 ,_1\,\1740 naloxazone_2\NN\1740 significantly_3\RB\1740 attenuated_4\VBD\224901 the_5\DT\1740 morphine-induced_6\JJ\1740 hypotension_7\NN\14057371 and_8\CC\1740 respiratory_9\JJ\1740 depression_10\NN\14373582 ,_11\,\1740 whereas_12\IN\1740 <e1>morphine-induced</e1>_13\JJ\1740 <e2>bradycardia</e2>_14\NN\14110674 was_15\VBD\836236 less_16\RBR\1740 affected_17\VBN\126264 ._18\.\1740
9326871
D017291_D017180 CID <e1>clarithromycin-induced</e1>_0\JJ\1740 <e2>ventricular_1\JJ\1740 tachycardia</e2>_2\NN\14110674 ._3\.\1740
D004917_D005759 CID although_0\IN\1740 the_1\DT\1740 side-effect_2\JJ\1740 profile_3\NN\6999802 of_4\IN\1740 <e1>erythromycin</e1>_5\NN\2716866 is_6\VBZ\836236 established_7\VBN\2426171 ,_8\,\1740 including_9\VBG\690614 <e2>gastroenteritis</e2>_10\NN\14171682 and_11\CC\1740 interactions_12\NNS\37396 with_13\IN\1740 other_14\JJ\1740 drugs_15\NNS\14778436 subject_16\JJ\1740 to_17\TO\1740 hepatic_18\JJ\1740 mixed-function_19\NN\1740 oxidase_20\NN\14732946 metabolism_21\NN\13526110 ,_22\,\1740 experience_23\NN\5984287 with_24\IN\1740 the_25\DT\1740 newer_26\JJR\1740 macrolides_27\NNS\1740 is_28\VBZ\836236 still_29\RB\1740 being_30\VBG\836236 recorded_31\VBN\2225492 ._32\.\1740
D018942_D005759 NONE although_0\IN\1740 the_1\DT\1740 side-effect_2\JJ\1740 profile_3\NN\6999802 of_4\IN\1740 erythromycin_5\NN\2716866 is_6\VBZ\836236 established_7\VBN\2426171 ,_8\,\1740 including_9\VBG\690614 <e2>gastroenteritis</e2>_10\NN\14171682 and_11\CC\1740 interactions_12\NNS\37396 with_13\IN\1740 other_14\JJ\1740 drugs_15\NNS\14778436 subject_16\JJ\1740 to_17\TO\1740 hepatic_18\JJ\1740 mixed-function_19\NN\1740 oxidase_20\NN\14732946 metabolism_21\NN\13526110 ,_22\,\1740 experience_23\NN\5984287 with_24\IN\1740 the_25\DT\1740 newer_26\JJR\1740 <e1>macrolides</e1>_27\NNS\1740 is_28\VBZ\836236 still_29\RB\1740 being_30\VBG\836236 recorded_31\VBN\2225492 ._32\.\1740
D004917_D066126 NONE <e2>cardiotoxicity</e2>_0\NN\1740 has_1\VBZ\2108377 been_2\VBN\836236 demonstrated_3\VBN\2137132 after_4\IN\1740 both_5\CC\1740 intravenous_6\JJ\1740 and_7\CC\1740 oral_8\JJ\1740 administration_9\NN\1133281 of_10\IN\1740 <e1>erythromycin</e1>_11\NN\2716866 but_12\CC\1740 has_13\VBZ\2108377 never_14\RB\1740 been_15\VBN\836236 reported_16\VBN\831651 with_17\IN\1740 the_18\DT\1740 newer_19\JJR\1740 macrolides_20\NNS\1740 ._21\.\1740
D018942_D066126 NONE <e2>cardiotoxicity</e2>_0\NN\1740 has_1\VBZ\2108377 been_2\VBN\836236 demonstrated_3\VBN\2137132 after_4\IN\1740 both_5\CC\1740 intravenous_6\JJ\1740 and_7\CC\1740 oral_8\JJ\1740 administration_9\NN\1133281 of_10\IN\1740 erythromycin_11\NN\2716866 but_12\CC\1740 has_13\VBZ\2108377 never_14\RB\1740 been_15\VBN\836236 reported_16\VBN\831651 with_17\IN\1740 the_18\DT\1740 newer_19\JJR\1740 <e1>macrolides</e1>_20\NNS\1740 ._21\.\1740
D017291_D001145 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e2>ventricular_5\JJ\1740 dysrhythmias</e2>_6\NNS\1740 that_7\WDT\1740 occurred_8\VBD\2623529 after_9\IN\1740 six_10\CD\13741022 therapeutic_11\JJ\1740 doses_12\NNS\3740161 of_13\IN\1740 <e1>clarithromycin</e1>_14\NN\1740 ._15\.\1740
2594614
C045856_D002318 NONE protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 a_3\DT\13649268 specific_4\JJ\1740 platelet-activating_5\JJ\1740 factor_6\NN\7326557 antagonist_7\NN\7846 ,_8\,\1740 <e1>bn_9\NN\1740 52021</e1>_10\CD\1740 ,_11\,\1740 on_12\IN\1740 bupivacaine-induced_13\JJ\1740 <e2>cardiovascular_14\JJ\1740 impairments</e2>_15\NNS\7296428 in_16\IN\13603305 rats_17\NNS\2329401 ._18\.\1740
C045856_D002318 NONE since_0\IN\1740 the_1\DT\1740 administration_2\NN\1133281 of_3\IN\1740 <e1>bn_4\NN\1740 52021</e1>_5\CD\1740 ,_6\,\1740 at_7\IN\14622893 all_8\DT\1740 doses_9\NNS\3740161 studied_10\VBN\630380 ,_11\,\1740 did_12\VBD\1640855 not_13\RB\1740 alter_14\VB\126264 mbp_15\NN\1740 and_16\CC\1740 hr_17\NN\15154774 at_18\IN\14622893 the_19\DT\1740 doses_20\NNS\3740161 used_21\VBN\1156834 ,_22\,\1740 the_23\DT\1740 bulk_24\NN\5121418 of_25\IN\1740 these_26\DT\1740 results_27\NNS\34213 clearly_28\RB\1740 demonstrate_29\VBP\2137132 a_30\DT\13649268 protective_31\JJ\1740 action_32\NN\30358 of_33\IN\1740 bn_34\NN\1740 52021_35\CD\1740 ,_36\,\1740 a_37\DT\13649268 specific_38\JJ\1740 antagonist_39\NN\7846 of_40\IN\1740 paf_41\NN\1740 ,_42\,\1740 against_43\IN\1740 bupivacaine-induced_44\JJ\1740 <e2>cardiovascular_45\JJ\1740 toxicity</e2>_46\NN\13576101 ._47\.\1740
C045856_D002318 NONE since_0\IN\1740 the_1\DT\1740 administration_2\NN\1133281 of_3\IN\1740 bn_4\NN\1740 52021_5\CD\1740 ,_6\,\1740 at_7\IN\14622893 all_8\DT\1740 doses_9\NNS\3740161 studied_10\VBN\630380 ,_11\,\1740 did_12\VBD\1640855 not_13\RB\1740 alter_14\VB\126264 mbp_15\NN\1740 and_16\CC\1740 hr_17\NN\15154774 at_18\IN\14622893 the_19\DT\1740 doses_20\NNS\3740161 used_21\VBN\1156834 ,_22\,\1740 the_23\DT\1740 bulk_24\NN\5121418 of_25\IN\1740 these_26\DT\1740 results_27\NNS\34213 clearly_28\RB\1740 demonstrate_29\VBP\2137132 a_30\DT\13649268 protective_31\JJ\1740 action_32\NN\30358 of_33\IN\1740 <e1>bn_34\NN\1740 52021</e1>_35\CD\1740 ,_36\,\1740 a_37\DT\13649268 specific_38\JJ\1740 antagonist_39\NN\7846 of_40\IN\1740 paf_41\NN\1740 ,_42\,\1740 against_43\IN\1740 bupivacaine-induced_44\JJ\1740 <e2>cardiovascular_45\JJ\1740 toxicity</e2>_46\NN\13576101 ._47\.\1740
D002045_D002318 NONE protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 a_3\DT\13649268 specific_4\JJ\1740 platelet-activating_5\JJ\1740 factor_6\NN\7326557 antagonist_7\NN\7846 ,_8\,\1740 bn_9\NN\1740 52021_10\CD\1740 ,_11\,\1740 on_12\IN\1740 <e1>bupivacaine-induced</e1>_13\JJ\1740 <e2>cardiovascular_14\JJ\1740 impairments</e2>_15\NNS\7296428 in_16\IN\13603305 rats_17\NNS\2329401 ._18\.\1740
D002045_D002318 NONE since_0\IN\1740 the_1\DT\1740 administration_2\NN\1133281 of_3\IN\1740 bn_4\NN\1740 52021_5\CD\1740 ,_6\,\1740 at_7\IN\14622893 all_8\DT\1740 doses_9\NNS\3740161 studied_10\VBN\630380 ,_11\,\1740 did_12\VBD\1640855 not_13\RB\1740 alter_14\VB\126264 mbp_15\NN\1740 and_16\CC\1740 hr_17\NN\15154774 at_18\IN\14622893 the_19\DT\1740 doses_20\NNS\3740161 used_21\VBN\1156834 ,_22\,\1740 the_23\DT\1740 bulk_24\NN\5121418 of_25\IN\1740 these_26\DT\1740 results_27\NNS\34213 clearly_28\RB\1740 demonstrate_29\VBP\2137132 a_30\DT\13649268 protective_31\JJ\1740 action_32\NN\30358 of_33\IN\1740 bn_34\NN\1740 52021_35\CD\1740 ,_36\,\1740 a_37\DT\13649268 specific_38\JJ\1740 antagonist_39\NN\7846 of_40\IN\1740 paf_41\NN\1740 ,_42\,\1740 against_43\IN\1740 <e1>bupivacaine-induced</e1>_44\JJ\1740 <e2>cardiovascular_45\JJ\1740 toxicity</e2>_46\NN\13576101 ._47\.\1740
D002045_D007022 CID administration_0\NN\1133281 of_1\IN\1740 the_2\DT\1740 local_3\JJ\1740 anaesthetic_4\JJ\1740 <e1>bupivacaine</e1>_5\NN\1740 (_6\-LRB-\1740 1.5_7\CD\1740 or_8\CC\3541091 2_9\CD\13741022 mg/kg_10\NN\1740 ,_11\,\1740 i.v._12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 rats_15\NNS\2329401 elicited_16\VBD\1617192 a_17\DT\13649268 marked_18\JJ\1740 <e2>decrease_19\NN\7296428 of_20\IN\1740 mean_21\NN\6021761 arterial_22\JJ\1740 blood_23\NN\5397468 pressure_24\NN\11419404 (_25\-LRB-\1740 mbp_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 heart_29\NN\5919034 rate_30\NN\13815152 (_31\-LRB-\1740 hr_32\NN\15154774 )</e2>_33\-RRB-\1740 leading_34\VBG\1752884 to_35\TO\1740 death_36\NN\7296428 (_37\-LRB-\1740 in_38\IN\13603305 67_39\CD\1740 %_40\NN\1740 or_41\CC\3541091 90_42\CD\13745420 %_43\NN\1740 of_44\IN\1740 animals_45\NNS\4475 respectively_46\RB\1740 )_47\-RRB-\1740 ._48\.\1740
D002045_D007022 CID intravenous_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 the_3\DT\1740 specific_4\JJ\1740 platelet-activating_5\JJ\1740 factor_6\NN\7326557 (_7\-LRB-\1740 paf_8\NN\1740 )_9\-RRB-\1740 antagonist_10\NN\7846 bn_11\NN\1740 52021_12\CD\1740 (_13\-LRB-\1740 10_14\CD\13745420 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 30_18\CD\13745420 min_19\NN\15154774 before_20\IN\1740 <e1>bupivacaine</e1>_21\NN\1740 administration_22\NN\1133281 (_23\-LRB-\1740 2_24\CD\13741022 mg/kg_25\NN\1740 i.v._26\NN\1740 )_27\-RRB-\1740 suppressed_28\VBD\2510337 both_29\CC\1740 the_30\DT\1740 <e2>decrease_31\NN\7296428 of_32\IN\1740 mbp_33\NN\1740 and_34\CC\1740 hr</e2>_35\NN\15154774 ._36\.\1740
D002045_D007022 CID when_0\WRB\1740 bn_1\NN\1740 52021_2\CD\1740 (_3\-LRB-\1740 20_4\CD\13745420 mg/kg_5\NN\1740 i.v._6\NN\1740 )_7\-RRB-\1740 was_8\VBD\836236 injected_9\VBN\81072 immediately_10\RB\1740 after_11\IN\1740 <e1>bupivacaine</e1>_12\NN\1740 (_13\-LRB-\1740 2_14\CD\13741022 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 a_18\DT\13649268 partial_19\JJ\1740 reversion_20\NN\13286801 of_21\IN\1740 the_22\DT\1740 <e2>decrease_23\NN\7296428 of_24\IN\1740 mbp_25\NN\1740 and_26\CC\1740 hr</e2>_27\NN\15154774 was_28\VBD\836236 observed_29\VBN\2163746 ,_30\,\1740 whereas_31\IN\1740 the_32\DT\1740 dose_33\NN\3740161 of_34\IN\1740 10_35\CD\13745420 mg/kg_36\NN\1740 was_37\VBD\836236 ineffective_38\JJ\1740 ._39\.\1740
D002045_D001919 CID administration_0\NN\1133281 of_1\IN\1740 the_2\DT\1740 local_3\JJ\1740 anaesthetic_4\JJ\1740 <e1>bupivacaine</e1>_5\NN\1740 (_6\-LRB-\1740 1.5_7\CD\1740 or_8\CC\3541091 2_9\CD\13741022 mg/kg_10\NN\1740 ,_11\,\1740 i.v._12\NN\1740 )_13\-RRB-\1740 to_14\TO\1740 rats_15\NNS\2329401 elicited_16\VBD\1617192 a_17\DT\13649268 marked_18\JJ\1740 <e2>decrease_19\NN\7296428 of_20\IN\1740 mean_21\NN\6021761 arterial_22\JJ\1740 blood_23\NN\5397468 pressure_24\NN\11419404 (_25\-LRB-\1740 mbp_26\NN\1740 )_27\-RRB-\1740 and_28\CC\1740 heart_29\NN\5919034 rate_30\NN\13815152 (_31\-LRB-\1740 hr_32\NN\15154774 )</e2>_33\-RRB-\1740 leading_34\VBG\1752884 to_35\TO\1740 death_36\NN\7296428 (_37\-LRB-\1740 in_38\IN\13603305 67_39\CD\1740 %_40\NN\1740 or_41\CC\3541091 90_42\CD\13745420 %_43\NN\1740 of_44\IN\1740 animals_45\NNS\4475 respectively_46\RB\1740 )_47\-RRB-\1740 ._48\.\1740
D002045_D001919 CID intravenous_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 the_3\DT\1740 specific_4\JJ\1740 platelet-activating_5\JJ\1740 factor_6\NN\7326557 (_7\-LRB-\1740 paf_8\NN\1740 )_9\-RRB-\1740 antagonist_10\NN\7846 bn_11\NN\1740 52021_12\CD\1740 (_13\-LRB-\1740 10_14\CD\13745420 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 30_18\CD\13745420 min_19\NN\15154774 before_20\IN\1740 <e1>bupivacaine</e1>_21\NN\1740 administration_22\NN\1133281 (_23\-LRB-\1740 2_24\CD\13741022 mg/kg_25\NN\1740 i.v._26\NN\1740 )_27\-RRB-\1740 suppressed_28\VBD\2510337 both_29\CC\1740 the_30\DT\1740 <e2>decrease_31\NN\7296428 of_32\IN\1740 mbp_33\NN\1740 and_34\CC\1740 hr</e2>_35\NN\15154774 ._36\.\1740
D002045_D001919 CID when_0\WRB\1740 bn_1\NN\1740 52021_2\CD\1740 (_3\-LRB-\1740 20_4\CD\13745420 mg/kg_5\NN\1740 i.v._6\NN\1740 )_7\-RRB-\1740 was_8\VBD\836236 injected_9\VBN\81072 immediately_10\RB\1740 after_11\IN\1740 <e1>bupivacaine</e1>_12\NN\1740 (_13\-LRB-\1740 2_14\CD\13741022 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 a_18\DT\13649268 partial_19\JJ\1740 reversion_20\NN\13286801 of_21\IN\1740 the_22\DT\1740 <e2>decrease_23\NN\7296428 of_24\IN\1740 mbp_25\NN\1740 and_26\CC\1740 hr</e2>_27\NN\15154774 was_28\VBD\836236 observed_29\VBN\2163746 ,_30\,\1740 whereas_31\IN\1740 the_32\DT\1740 dose_33\NN\3740161 of_34\IN\1740 10_35\CD\13745420 mg/kg_36\NN\1740 was_37\VBD\836236 ineffective_38\JJ\1740 ._39\.\1740
C045856_D007022 NONE intravenous_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 the_3\DT\1740 specific_4\JJ\1740 platelet-activating_5\JJ\1740 factor_6\NN\7326557 (_7\-LRB-\1740 paf_8\NN\1740 )_9\-RRB-\1740 antagonist_10\NN\7846 <e1>bn_11\NN\1740 52021</e1>_12\CD\1740 (_13\-LRB-\1740 10_14\CD\13745420 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 30_18\CD\13745420 min_19\NN\15154774 before_20\IN\1740 bupivacaine_21\NN\1740 administration_22\NN\1133281 (_23\-LRB-\1740 2_24\CD\13741022 mg/kg_25\NN\1740 i.v._26\NN\1740 )_27\-RRB-\1740 suppressed_28\VBD\2510337 both_29\CC\1740 the_30\DT\1740 <e2>decrease_31\NN\7296428 of_32\IN\1740 mbp_33\NN\1740 and_34\CC\1740 hr</e2>_35\NN\15154774 ._36\.\1740
C045856_D007022 NONE when_0\WRB\1740 <e1>bn_1\NN\1740 52021</e1>_2\CD\1740 (_3\-LRB-\1740 20_4\CD\13745420 mg/kg_5\NN\1740 i.v._6\NN\1740 )_7\-RRB-\1740 was_8\VBD\836236 injected_9\VBN\81072 immediately_10\RB\1740 after_11\IN\1740 bupivacaine_12\NN\1740 (_13\-LRB-\1740 2_14\CD\13741022 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 a_18\DT\13649268 partial_19\JJ\1740 reversion_20\NN\13286801 of_21\IN\1740 the_22\DT\1740 <e2>decrease_23\NN\7296428 of_24\IN\1740 mbp_25\NN\1740 and_26\CC\1740 hr</e2>_27\NN\15154774 was_28\VBD\836236 observed_29\VBN\2163746 ,_30\,\1740 whereas_31\IN\1740 the_32\DT\1740 dose_33\NN\3740161 of_34\IN\1740 10_35\CD\13745420 mg/kg_36\NN\1740 was_37\VBD\836236 ineffective_38\JJ\1740 ._39\.\1740
C045856_D001919 NONE intravenous_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 the_3\DT\1740 specific_4\JJ\1740 platelet-activating_5\JJ\1740 factor_6\NN\7326557 (_7\-LRB-\1740 paf_8\NN\1740 )_9\-RRB-\1740 antagonist_10\NN\7846 <e1>bn_11\NN\1740 52021</e1>_12\CD\1740 (_13\-LRB-\1740 10_14\CD\13745420 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 30_18\CD\13745420 min_19\NN\15154774 before_20\IN\1740 bupivacaine_21\NN\1740 administration_22\NN\1133281 (_23\-LRB-\1740 2_24\CD\13741022 mg/kg_25\NN\1740 i.v._26\NN\1740 )_27\-RRB-\1740 suppressed_28\VBD\2510337 both_29\CC\1740 the_30\DT\1740 <e2>decrease_31\NN\7296428 of_32\IN\1740 mbp_33\NN\1740 and_34\CC\1740 hr</e2>_35\NN\15154774 ._36\.\1740
C045856_D001919 NONE when_0\WRB\1740 <e1>bn_1\NN\1740 52021</e1>_2\CD\1740 (_3\-LRB-\1740 20_4\CD\13745420 mg/kg_5\NN\1740 i.v._6\NN\1740 )_7\-RRB-\1740 was_8\VBD\836236 injected_9\VBN\81072 immediately_10\RB\1740 after_11\IN\1740 bupivacaine_12\NN\1740 (_13\-LRB-\1740 2_14\CD\13741022 mg/kg_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 a_18\DT\13649268 partial_19\JJ\1740 reversion_20\NN\13286801 of_21\IN\1740 the_22\DT\1740 <e2>decrease_23\NN\7296428 of_24\IN\1740 mbp_25\NN\1740 and_26\CC\1740 hr</e2>_27\NN\15154774 was_28\VBD\836236 observed_29\VBN\2163746 ,_30\,\1740 whereas_31\IN\1740 the_32\DT\1740 dose_33\NN\3740161 of_34\IN\1740 10_35\CD\13745420 mg/kg_36\NN\1740 was_37\VBD\836236 ineffective_38\JJ\1740 ._39\.\1740
D002045_D018376 NONE thus_0\RB\1740 ,_1\,\1740 consistent_2\JJ\1740 with_3\IN\1740 its_4\PRP$\6125041 direct_5\JJ\1740 effect_6\NN\34213 on_7\IN\1740 heart_8\NN\5919034 ,_9\,\1740 paf_10\NN\1740 appears_11\VBZ\2604760 to_12\TO\1740 be_13\VB\836236 implicated_14\VBN\2677097 in_15\IN\13603305 <e1>bupivacaine-induced</e1>_16\JJ\1740 <e2>cardiovascular_17\JJ\1740 alterations</e2>_18\NNS\7283608 ._19\.\1740
9061311
D013481_D017114 NONE neutrophil_0\NN\5449959 <e1>superoxide</e1>_1\NN\14971519 and_2\CC\1740 hydrogen_3\NN\14622893 peroxide_4\NN\14780040 production_5\NN\30358 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 <e2>acute_9\JJ\1740 liver_10\NN\5298729 failure</e2>_11\NN\66216 ._12\.\1740
D013481_D017114 NONE defects_0\NNS\14462666 in_1\IN\13603305 <e1>superoxide</e1>_2\NN\14971519 and_3\CC\1740 hydrogen_4\NN\14622893 peroxide_5\NN\14780040 production_6\NN\30358 may_7\MD\15209706 be_8\VB\836236 implicated_9\VBN\2677097 in_10\IN\13603305 the_11\DT\1740 high_12\JJ\1740 incidence_13\NN\13821570 of_14\IN\1740 bacterial_15\JJ\1740 infections_16\NNS\14052046 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 <e2>acute_20\JJ\1740 liver_21\NN\5298729 failure</e2>_22\NN\66216 (_23\-LRB-\1740 alf_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
D013481_D017114 NONE defects_0\NNS\14462666 in_1\IN\13603305 <e1>superoxide</e1>_2\NN\14971519 and_3\CC\1740 hydrogen_4\NN\14622893 peroxide_5\NN\14780040 production_6\NN\30358 may_7\MD\15209706 be_8\VB\836236 implicated_9\VBN\2677097 in_10\IN\13603305 the_11\DT\1740 high_12\JJ\1740 incidence_13\NN\13821570 of_14\IN\1740 bacterial_15\JJ\1740 infections_16\NNS\14052046 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 acute_20\JJ\1740 liver_21\NN\5298729 failure_22\NN\66216 (_23\-LRB-\1740 <e2>alf</e2>_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
D013481_D017114 NONE <e1>superoxide</e1>_0\NN\14971519 and_1\CC\1740 hydrogen_2\NN\14622893 peroxide_3\NN\14780040 production_4\NN\30358 by_5\IN\1740 <e2>alf</e2>_6\NN\1740 neutrophils_7\NNS\5449959 stimulated_8\VBN\137313 with_9\IN\1740 zymosan_10\NN\1740 opsonized_11\VBN\126264 with_12\IN\1740 alf_13\NN\1740 serum_14\NN\5397468 was_15\VBD\836236 significantly_16\RB\1740 reduced_17\VBN\441445 compared_18\VBN\644583 with_19\IN\1740 the_20\DT\1740 control_21\JJ\1740 subjects_22\NNS\6598915 (_23\-LRB-\1740 p_24\NN\14622893 <_25\XX\1740 0.01_26\CD\1740 )_27\-RRB-\1740 ._28\.\1740
D013481_D017114 NONE <e1>superoxide</e1>_0\NN\14971519 and_1\CC\1740 hydrogen_2\NN\14622893 peroxide_3\NN\14780040 production_4\NN\30358 by_5\IN\1740 alf_6\NN\1740 neutrophils_7\NNS\5449959 stimulated_8\VBN\137313 with_9\IN\1740 zymosan_10\NN\1740 opsonized_11\VBN\126264 with_12\IN\1740 <e2>alf</e2>_13\NN\1740 serum_14\NN\5397468 was_15\VBD\836236 significantly_16\RB\1740 reduced_17\VBN\441445 compared_18\VBN\644583 with_19\IN\1740 the_20\DT\1740 control_21\JJ\1740 subjects_22\NNS\6598915 (_23\-LRB-\1740 p_24\NN\14622893 <_25\XX\1740 0.01_26\CD\1740 )_27\-RRB-\1740 ._28\.\1740
D013481_D017114 NONE <e1>superoxide</e1>_0\NN\14971519 and_1\CC\1740 hydrogen_2\NN\14622893 peroxide_3\NN\14780040 production_4\NN\30358 in_5\IN\13603305 neutrophils_6\NNS\5449959 stimulated_7\VBN\137313 with_8\IN\1740 formyl-methionyl-leucyl-phenylalanine_9\NN\1740 (_10\-LRB-\1740 fmlp_11\NN\1740 )_12\-RRB-\1740 from_13\IN\1740 a_14\DT\13649268 further_15\JJ\1740 18_16\CD\13745420 <e2>alf</e2>_17\NN\1740 patients_18\NNS\9898892 was_19\VBD\836236 unaffected_20\JJ\1740 compared_21\VBN\644583 with_22\IN\1740 control_23\NN\5190804 neutrophils_24\NNS\5449959 ._25\.\1740
D006861_D017114 NONE neutrophil_0\NN\5449959 superoxide_1\NN\14971519 and_2\CC\1740 <e1>hydrogen_3\NN\14622893 peroxide</e1>_4\NN\14780040 production_5\NN\30358 in_6\IN\13603305 patients_7\NNS\9898892 with_8\IN\1740 <e2>acute_9\JJ\1740 liver_10\NN\5298729 failure</e2>_11\NN\66216 ._12\.\1740
D006861_D017114 NONE defects_0\NNS\14462666 in_1\IN\13603305 superoxide_2\NN\14971519 and_3\CC\1740 <e1>hydrogen_4\NN\14622893 peroxide</e1>_5\NN\14780040 production_6\NN\30358 may_7\MD\15209706 be_8\VB\836236 implicated_9\VBN\2677097 in_10\IN\13603305 the_11\DT\1740 high_12\JJ\1740 incidence_13\NN\13821570 of_14\IN\1740 bacterial_15\JJ\1740 infections_16\NNS\14052046 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 <e2>acute_20\JJ\1740 liver_21\NN\5298729 failure</e2>_22\NN\66216 (_23\-LRB-\1740 alf_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
D006861_D017114 NONE defects_0\NNS\14462666 in_1\IN\13603305 superoxide_2\NN\14971519 and_3\CC\1740 <e1>hydrogen_4\NN\14622893 peroxide</e1>_5\NN\14780040 production_6\NN\30358 may_7\MD\15209706 be_8\VB\836236 implicated_9\VBN\2677097 in_10\IN\13603305 the_11\DT\1740 high_12\JJ\1740 incidence_13\NN\13821570 of_14\IN\1740 bacterial_15\JJ\1740 infections_16\NNS\14052046 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 acute_20\JJ\1740 liver_21\NN\5298729 failure_22\NN\66216 (_23\-LRB-\1740 <e2>alf</e2>_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
D006861_D017114 NONE superoxide_0\NN\14971519 and_1\CC\1740 <e1>hydrogen_2\NN\14622893 peroxide</e1>_3\NN\14780040 production_4\NN\30358 by_5\IN\1740 <e2>alf</e2>_6\NN\1740 neutrophils_7\NNS\5449959 stimulated_8\VBN\137313 with_9\IN\1740 zymosan_10\NN\1740 opsonized_11\VBN\126264 with_12\IN\1740 alf_13\NN\1740 serum_14\NN\5397468 was_15\VBD\836236 significantly_16\RB\1740 reduced_17\VBN\441445 compared_18\VBN\644583 with_19\IN\1740 the_20\DT\1740 control_21\JJ\1740 subjects_22\NNS\6598915 (_23\-LRB-\1740 p_24\NN\14622893 <_25\XX\1740 0.01_26\CD\1740 )_27\-RRB-\1740 ._28\.\1740
D006861_D017114 NONE superoxide_0\NN\14971519 and_1\CC\1740 <e1>hydrogen_2\NN\14622893 peroxide</e1>_3\NN\14780040 production_4\NN\30358 by_5\IN\1740 alf_6\NN\1740 neutrophils_7\NNS\5449959 stimulated_8\VBN\137313 with_9\IN\1740 zymosan_10\NN\1740 opsonized_11\VBN\126264 with_12\IN\1740 <e2>alf</e2>_13\NN\1740 serum_14\NN\5397468 was_15\VBD\836236 significantly_16\RB\1740 reduced_17\VBN\441445 compared_18\VBN\644583 with_19\IN\1740 the_20\DT\1740 control_21\JJ\1740 subjects_22\NNS\6598915 (_23\-LRB-\1740 p_24\NN\14622893 <_25\XX\1740 0.01_26\CD\1740 )_27\-RRB-\1740 ._28\.\1740
D006861_D017114 NONE superoxide_0\NN\14971519 and_1\CC\1740 <e1>hydrogen_2\NN\14622893 peroxide</e1>_3\NN\14780040 production_4\NN\30358 in_5\IN\13603305 neutrophils_6\NNS\5449959 stimulated_7\VBN\137313 with_8\IN\1740 formyl-methionyl-leucyl-phenylalanine_9\NN\1740 (_10\-LRB-\1740 fmlp_11\NN\1740 )_12\-RRB-\1740 from_13\IN\1740 a_14\DT\13649268 further_15\JJ\1740 18_16\CD\13745420 <e2>alf</e2>_17\NN\1740 patients_18\NNS\9898892 was_19\VBD\836236 unaffected_20\JJ\1740 compared_21\VBN\644583 with_22\IN\1740 control_23\NN\5190804 neutrophils_24\NNS\5449959 ._25\.\1740
D013481_D001424 NONE defects_0\NNS\14462666 in_1\IN\13603305 <e1>superoxide</e1>_2\NN\14971519 and_3\CC\1740 hydrogen_4\NN\14622893 peroxide_5\NN\14780040 production_6\NN\30358 may_7\MD\15209706 be_8\VB\836236 implicated_9\VBN\2677097 in_10\IN\13603305 the_11\DT\1740 high_12\JJ\1740 incidence_13\NN\13821570 of_14\IN\1740 <e2>bacterial_15\JJ\1740 infections</e2>_16\NNS\14052046 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 acute_20\JJ\1740 liver_21\NN\5298729 failure_22\NN\66216 (_23\-LRB-\1740 alf_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
D006861_D001424 NONE defects_0\NNS\14462666 in_1\IN\13603305 superoxide_2\NN\14971519 and_3\CC\1740 <e1>hydrogen_4\NN\14622893 peroxide</e1>_5\NN\14780040 production_6\NN\30358 may_7\MD\15209706 be_8\VB\836236 implicated_9\VBN\2677097 in_10\IN\13603305 the_11\DT\1740 high_12\JJ\1740 incidence_13\NN\13821570 of_14\IN\1740 <e2>bacterial_15\JJ\1740 infections</e2>_16\NNS\14052046 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 acute_20\JJ\1740 liver_21\NN\5298729 failure_22\NN\66216 (_23\-LRB-\1740 alf_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
D010100_D017114 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 <e1>oxygen</e1>_5\NN\14622893 radical_6\JJ\1740 production_7\NN\30358 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 <e2>alf</e2>_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 paracetamol_14\NN\1740 overdose_15\NN\1740 was_16\VBD\836236 compared_17\VBN\644583 with_18\IN\1740 that_19\DT\1740 of_20\IN\1740 healthy_21\JJ\1740 volunteers_22\NNS\10582746 ._23\.\1740
D010100_D062787 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 <e1>oxygen</e1>_5\NN\14622893 radical_6\JJ\1740 production_7\NN\30358 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 alf_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 paracetamol_14\NN\1740 <e2>overdose</e2>_15\NN\1740 was_16\VBD\836236 compared_17\VBN\644583 with_18\IN\1740 that_19\DT\1740 of_20\IN\1740 healthy_21\JJ\1740 volunteers_22\NNS\10582746 ._23\.\1740
D000082_D017114 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 oxygen_5\NN\14622893 radical_6\JJ\1740 production_7\NN\30358 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 <e2>alf</e2>_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 <e1>paracetamol</e1>_14\NN\1740 overdose_15\NN\1740 was_16\VBD\836236 compared_17\VBN\644583 with_18\IN\1740 that_19\DT\1740 of_20\IN\1740 healthy_21\JJ\1740 volunteers_22\NNS\10582746 ._23\.\1740
D000082_D017114 CID these_0\DT\1740 results_1\NNS\34213 demonstrate_2\VBP\2137132 a_3\DT\13649268 neutrophil_4\NN\5449959 defect_5\NN\14462666 in_6\IN\13603305 <e2>alf</e2>_7\NN\1740 due_8\IN\5174653 to_9\TO\1740 <e1>paracetamol</e1>_10\NN\1740 overdose_11\RB\1740 ,_12\,\1740 that_13\RB\1740 is_14\VBZ\836236 complement_15\NN\6313651 dependent_16\JJ\1740 but_17\CC\1740 independent_18\JJ\1740 of_19\IN\1740 serum_20\NN\5397468 complement_21\NN\6313651 ,_22\,\1740 possibly_23\RB\1740 connected_24\VBN\628491 to_25\TO\1740 the_26\DT\1740 complement_27\NN\6313651 receptor_28\NN\5225602 ._29\.\1740
D000082_D062787 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 oxygen_5\NN\14622893 radical_6\JJ\1740 production_7\NN\30358 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 alf_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 <e1>paracetamol</e1>_14\NN\1740 <e2>overdose</e2>_15\NN\1740 was_16\VBD\836236 compared_17\VBN\644583 with_18\IN\1740 that_19\DT\1740 of_20\IN\1740 healthy_21\JJ\1740 volunteers_22\NNS\10582746 ._23\.\1740
D000082_D062787 NONE these_0\DT\1740 results_1\NNS\34213 demonstrate_2\VBP\2137132 a_3\DT\13649268 neutrophil_4\NN\5449959 defect_5\NN\14462666 in_6\IN\13603305 alf_7\NN\1740 due_8\IN\5174653 to_9\TO\1740 <e1>paracetamol</e1>_10\NN\1740 <e2>overdose</e2>_11\RB\1740 ,_12\,\1740 that_13\RB\1740 is_14\VBZ\836236 complement_15\NN\6313651 dependent_16\JJ\1740 but_17\CC\1740 independent_18\JJ\1740 of_19\IN\1740 serum_20\NN\5397468 complement_21\NN\6313651 ,_22\,\1740 possibly_23\RB\1740 connected_24\VBN\628491 to_25\TO\1740 the_26\DT\1740 complement_27\NN\6313651 receptor_28\NN\5225602 ._29\.\1740
D009240_D017114 NONE superoxide_0\NN\14971519 and_1\CC\1740 hydrogen_2\NN\14622893 peroxide_3\NN\14780040 production_4\NN\30358 in_5\IN\13603305 neutrophils_6\NNS\5449959 stimulated_7\VBN\137313 with_8\IN\1740 <e1>formyl-methionyl-leucyl-phenylalanine</e1>_9\NN\1740 (_10\-LRB-\1740 fmlp_11\NN\1740 )_12\-RRB-\1740 from_13\IN\1740 a_14\DT\13649268 further_15\JJ\1740 18_16\CD\13745420 <e2>alf</e2>_17\NN\1740 patients_18\NNS\9898892 was_19\VBD\836236 unaffected_20\JJ\1740 compared_21\VBN\644583 with_22\IN\1740 control_23\NN\5190804 neutrophils_24\NNS\5449959 ._25\.\1740
D009240_D017114 NONE superoxide_0\NN\14971519 and_1\CC\1740 hydrogen_2\NN\14622893 peroxide_3\NN\14780040 production_4\NN\30358 in_5\IN\13603305 neutrophils_6\NNS\5449959 stimulated_7\VBN\137313 with_8\IN\1740 formyl-methionyl-leucyl-phenylalanine_9\NN\1740 (_10\-LRB-\1740 <e1>fmlp</e1>_11\NN\1740 )_12\-RRB-\1740 from_13\IN\1740 a_14\DT\13649268 further_15\JJ\1740 18_16\CD\13745420 <e2>alf</e2>_17\NN\1740 patients_18\NNS\9898892 was_19\VBD\836236 unaffected_20\JJ\1740 compared_21\VBN\644583 with_22\IN\1740 control_23\NN\5190804 neutrophils_24\NNS\5449959 ._25\.\1740
18483878
D003520_D003556 CID exaggerated_0\JJ\1740 expression_1\NN\4679549 of_2\IN\1740 inflammatory_3\JJ\1740 mediators_4\NNS\10351874 in_5\IN\13603305 vasoactive_6\JJ\1740 intestinal_7\JJ\1740 polypeptide_8\NN\14743046 knockout_9\NN\10787470 (_10\-LRB-\1740 vip-/-_11\NN\1740 )_12\-RRB-\1740 mice_13\NNS\2329401 with_14\IN\1740 <e1>cyclophosphamide</e1>_15\NN\1740 (cyp)-induced_16\JJ\1740 <e2>cystitis</e2>_17\NN\14566129 ._18\.\1740
D003520_D003556 CID exaggerated_0\JJ\1740 expression_1\NN\4679549 of_2\IN\1740 inflammatory_3\JJ\1740 mediators_4\NNS\10351874 in_5\IN\13603305 vasoactive_6\JJ\1740 intestinal_7\JJ\1740 polypeptide_8\NN\14743046 knockout_9\NN\10787470 (_10\-LRB-\1740 vip-/-_11\NN\1740 )_12\-RRB-\1740 mice_13\NNS\2329401 with_14\IN\1740 cyclophosphamide_15\NN\1740 <e1>(cyp)-induced</e1>_16\JJ\1740 <e2>cystitis</e2>_17\NN\14566129 ._18\.\1740
D003520_D003556 CID vip(-/-_0\NN\1740 )_1\-RRB-\1740 mice_2\NNS\2329401 exhibit_3\VBP\2632167 altered_4\JJ\1740 bladder_5\NN\5515670 function_6\NN\13783581 and_7\CC\1740 neurochemical_8\JJ\1740 properties_9\NNS\32613 in_10\IN\13603305 micturition_11\NN\13473097 pathways_12\NNS\5483677 after_13\IN\1740 <e1>cyclophosphamide</e1>_14\NN\1740 (cyp)-induced_15\JJ\1740 <e2>cystitis</e2>_16\NN\14566129 ._17\.\1740
D003520_D003556 CID vip(-/-_0\NN\1740 )_1\-RRB-\1740 mice_2\NNS\2329401 exhibit_3\VBP\2632167 altered_4\JJ\1740 bladder_5\NN\5515670 function_6\NN\13783581 and_7\CC\1740 neurochemical_8\JJ\1740 properties_9\NNS\32613 in_10\IN\13603305 micturition_11\NN\13473097 pathways_12\NNS\5483677 after_13\IN\1740 cyclophosphamide_14\NN\1740 <e1>(cyp)-induced</e1>_15\JJ\1740 <e2>cystitis</e2>_16\NN\14566129 ._17\.\1740
D003520_D003556 CID a_0\DT\13649268 mouse_1\NN\2329401 inflammatory_2\JJ\1740 cytokine_3\NN\14728724 and_4\CC\1740 receptor_5\NN\5225602 rt2_6\NN\1740 profiler_7\NN\1740 array_8\NN\7938773 was_9\VBD\836236 used_10\VBN\1156834 to_11\TO\1740 determine_12\VB\1645601 regulated_13\JJ\1740 transcripts_14\NNS\6362953 in_15\IN\13603305 the_16\DT\1740 urinary_17\JJ\1740 bladder_18\NN\5515670 of_19\IN\1740 wild_20\JJ\1740 type_21\NN\5839024 (_22\-LRB-\1740 wt_23\NN\1740 )_24\-RRB-\1740 and_25\CC\1740 vip(-/-_26\NN\1740 )_27\-RRB-\1740 mice_28\NNS\2329401 with_29\IN\1740 or_30\CC\3541091 without_31\IN\1740 <e1>cyp-induced</e1>_32\JJ\1740 <e2>cystitis</e2>_33\NN\14566129 (_34\-LRB-\1740 150_35\CD\1740 mg/kg_36\NN\1740 ;_37\:\1740 i.p._38\RB\1740 ;_39\:\1740 48_40\CD\1740 h_41\NN\14622893 )_42\-RRB-\1740 ._43\.\1740
D003520_D001745 NONE the_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 in_4\IN\13603305 vip(-/-_5\NN\1740 )_6\-RRB-\1740 mice_7\NNS\2329401 with_8\IN\1740 <e2>bladder_9\NN\5515670 inflammation</e2>_10\NN\14299637 ,_11\,\1740 inflammatory_12\JJ\1740 mediators_13\NNS\10351874 are_14\VBP\836236 increased_15\VBN\169651 above_16\IN\6392001 that_17\DT\1740 observed_18\VBN\2163746 in_19\IN\13603305 wt_20\NNP\1740 with_21\IN\1740 <e1>cyp</e1>_22\NNP\1740 ._23\.\1740
19300240
D005472_D054549 CID <e1>5_0\CD\13741022 flourouracil-induced</e1>_1\JJ\1740 <e2>apical_2\JJ\1740 ballooning_3\NN\302394 syndrome</e2>_4\NN\5870365 :_5\:\1740 a_6\DT\13649268 case_7\NN\7283608 report_8\NN\6470073 ._9\.\1740
D005472_D015179 NONE she_0\PRP\1740 underwent_1\VBD\109660 recent_2\JJ\1740 chemotherapy_3\NN\661091 with_4\IN\1740 <e1>fluorouracil</e1>_5\NN\2722166 for_6\IN\1740 metastatic_7\JJ\1740 <e2>colorectal_8\JJ\1740 cancer</e2>_9\NN\14239425 ._10\.\1740
D002395_D009369 NONE in_0\IN\13603305 our_1\PRP$\1740 patient_2\NN\9898892 ,_3\,\1740 both_4\CC\1740 supraphysiologic_5\JJ\1740 levels_6\NNS\4916342 of_7\IN\1740 plasma_8\NN\5398023 <e1>catecholamines</e1>_9\NNS\5407119 and_10\CC\1740 stress_11\NN\7083732 related_12\JJ\1740 neuropeptides_13\NNS\1740 caused_14\VBN\1617192 by_15\IN\1740 <e2>cancer</e2>_16\NN\14239425 diagnosis_17\NN\152018 as_18\RB\1740 well_19\RB\1740 as_20\IN\14622893 chemotherapy_21\NN\661091 may_22\MD\15209706 have_23\VB\2108377 contributed_24\VBN\126264 the_25\DT\1740 development_26\NN\248977 of_27\IN\1740 abs_28\NN\14592610 ._29\.\1740
D002395_D054549 NONE in_0\IN\13603305 our_1\PRP$\1740 patient_2\NN\9898892 ,_3\,\1740 both_4\CC\1740 supraphysiologic_5\JJ\1740 levels_6\NNS\4916342 of_7\IN\1740 plasma_8\NN\5398023 <e1>catecholamines</e1>_9\NNS\5407119 and_10\CC\1740 stress_11\NN\7083732 related_12\JJ\1740 neuropeptides_13\NNS\1740 caused_14\VBN\1617192 by_15\IN\1740 cancer_16\NN\14239425 diagnosis_17\NN\152018 as_18\RB\1740 well_19\RB\1740 as_20\IN\14622893 chemotherapy_21\NN\661091 may_22\MD\15209706 have_23\VB\2108377 contributed_24\VBN\126264 the_25\DT\1740 development_26\NN\248977 of_27\IN\1740 <e2>abs</e2>_28\NN\14592610 ._29\.\1740
11078231
D004280_D017202 NONE <e2>myocardial_0\JJ\1740 ischemia</e2>_1\NN\14195315 due_2\JJ\1740 to_3\TO\1740 coronary_4\JJ\1740 artery_5\NN\5417975 spasm_6\NN\14299637 during_7\IN\1740 <e1>dobutamine</e1>_8\NN\1740 stress_9\NN\7083732 echocardiography_10\NN\177127 ._11\.\1740
D004280_D017202 NONE <e1>dobutamine</e1>_0\JJ\1740 stress_1\NN\7083732 echocardiography_2\NN\177127 (_3\-LRB-\1740 dse_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 useful_8\JJ\1740 and_9\CC\1740 safe_10\JJ\1740 provocation_11\NN\1221611 test_12\NN\5798043 for_13\IN\1740 <e2>myocardial_14\JJ\1740 ischemia</e2>_15\NN\14195315 ._16\.\1740
D004280_D017202 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 is_6\VBZ\836236 to_7\TO\1740 examine_8\VB\789138 whether_9\IN\1740 <e2>myocardial_10\JJ\1740 ischemia</e2>_11\NN\14195315 due_12\JJ\1740 to_13\TO\1740 coronary_14\JJ\1740 spasm_15\NN\14299637 is_16\VBZ\836236 induced_17\VBN\1627355 by_18\IN\1740 <e1>dobutamine</e1>_19\NN\1740 ._20\.\1740
D004280_D003329 CID myocardial_0\JJ\1740 ischemia_1\NN\14195315 due_2\JJ\1740 to_3\TO\1740 <e2>coronary_4\JJ\1740 artery_5\NN\5417975 spasm</e2>_6\NN\14299637 during_7\IN\1740 <e1>dobutamine</e1>_8\NN\1740 stress_9\NN\7083732 echocardiography_10\NN\177127 ._11\.\1740
D004280_D003329 CID the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 is_6\VBZ\836236 to_7\TO\1740 examine_8\VB\789138 whether_9\IN\1740 myocardial_10\JJ\1740 ischemia_11\NN\14195315 due_12\JJ\1740 to_13\TO\1740 <e2>coronary_14\JJ\1740 spasm</e2>_15\NN\14299637 is_16\VBZ\836236 induced_17\VBN\1627355 by_18\IN\1740 <e1>dobutamine</e1>_19\NN\1740 ._20\.\1740
D004280_D003329 CID these_0\DT\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>dobutamine</e1>_4\NN\1740 can_5\MD\3094503 provoke_6\VB\1617192 <e2>coronary_7\JJ\1740 spasm</e2>_8\NN\14299637 in_9\IN\13603305 some_10\DT\1740 patients_11\NNS\9898892 with_12\IN\1740 coronary_13\JJ\1740 spastic_14\JJ\1740 angina_15\NN\14171682 ._16\.\1740
D000109_D023921 NONE coronary_0\JJ\1740 spasm_1\NN\14299637 was_2\VBD\836236 induced_3\VBN\1627355 by_4\IN\1740 intracoronary_5\JJ\1740 injection_6\NN\320852 of_7\IN\1740 <e1>acetylcholine</e1>_8\NN\14807558 ,_9\,\1740 and_10\CC\1740 no_11\DT\7204911 fixed_12\VBN\205885 <e2>coronary_13\JJ\1740 artery_14\NN\5417975 stenosis</e2>_15\NN\14204950 was_16\VBD\836236 documented_17\VBN\1000214 on_18\IN\1740 angiograms_19\NNS\4100620 in_20\IN\13603305 all_21\DT\1740 patients_22\NNS\9898892 ._23\.\1740
D004280_D000788 CID these_0\DT\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e1>dobutamine</e1>_4\NN\1740 can_5\MD\3094503 provoke_6\VB\1617192 coronary_7\JJ\1740 spasm_8\NN\14299637 in_9\IN\13603305 some_10\DT\1740 patients_11\NNS\9898892 with_12\IN\1740 <e2>coronary_13\JJ\1740 spastic_14\JJ\1740 angina</e2>_15\NN\14171682 ._16\.\1740
9630698
D006220_D009127 CID <e2>muscle_0\NN\5289601 rigidity</e2>_1\NN\5023233 was_2\VBD\836236 induced_3\VBN\1627355 by_4\IN\1740 <e1>haloperidol</e1>_5\NN\3713736 (_6\-LRB-\1740 2.5_7\CD\1740 mg/kg_8\NN\1740 i.p._9\RB\1740 )_10\-RRB-\1740 ._11\.\1740
D006220_D009127 CID 5,7-dichlorokynurenic_0\JJ\1740 acid_1\NN\14818238 (_2\-LRB-\1740 5,7-dcka_3\NN\1740 )_4\-RRB-\1740 ,_5\,\1740 a_6\DT\13649268 selective_7\JJ\1740 glycine_8\NN\14601829 site_9\NN\8673395 antagonist_10\NN\7846 ,_11\,\1740 injected_12\VBN\81072 in_13\IN\13603305 doses_14\NNS\3740161 of_15\IN\1740 2.5_16\CD\1740 and_17\CC\1740 4.5_18\CD\1740 microg/0.5_19\CD\1740 microl_20\NN\1740 bilaterally_21\RB\1740 ,_22\,\1740 into_23\IN\1740 the_24\DT\1740 rostral_25\JJ\1740 region_26\NN\27167 of_27\IN\1740 the_28\DT\1740 striatum_29\NN\5497363 ,_30\,\1740 decreased_31\VBD\169651 both_32\CC\1740 the_33\DT\1740 <e1>haloperidol-induced</e1>_34\JJ\1740 <e2>muscle_35\NN\5289601 rigidity</e2>_36\NN\5023233 (_37\-LRB-\1740 mmg_38\NN\1740 )_39\-RRB-\1740 and_40\CC\1740 the_41\DT\1740 enhanced_42\VBN\227165 electromyographic_43\JJ\1740 activity_44\NN\30358 (_45\-LRB-\1740 emg_46\NN\7005158 )_47\-RRB-\1740 ._48\.\1740
C066192_D009127 NONE <e1>5,7-dichlorokynurenic_0\JJ\1740 acid</e1>_1\NN\14818238 (_2\-LRB-\1740 5,7-dcka_3\NN\1740 )_4\-RRB-\1740 ,_5\,\1740 a_6\DT\13649268 selective_7\JJ\1740 glycine_8\NN\14601829 site_9\NN\8673395 antagonist_10\NN\7846 ,_11\,\1740 injected_12\VBN\81072 in_13\IN\13603305 doses_14\NNS\3740161 of_15\IN\1740 2.5_16\CD\1740 and_17\CC\1740 4.5_18\CD\1740 microg/0.5_19\CD\1740 microl_20\NN\1740 bilaterally_21\RB\1740 ,_22\,\1740 into_23\IN\1740 the_24\DT\1740 rostral_25\JJ\1740 region_26\NN\27167 of_27\IN\1740 the_28\DT\1740 striatum_29\NN\5497363 ,_30\,\1740 decreased_31\VBD\169651 both_32\CC\1740 the_33\DT\1740 haloperidol-induced_34\JJ\1740 <e2>muscle_35\NN\5289601 rigidity</e2>_36\NN\5023233 (_37\-LRB-\1740 mmg_38\NN\1740 )_39\-RRB-\1740 and_40\CC\1740 the_41\DT\1740 enhanced_42\VBN\227165 electromyographic_43\JJ\1740 activity_44\NN\30358 (_45\-LRB-\1740 emg_46\NN\7005158 )_47\-RRB-\1740 ._48\.\1740
C066192_D009127 NONE 5,7-dichlorokynurenic_0\JJ\1740 acid_1\NN\14818238 (_2\-LRB-\1740 <e1>5,7-dcka</e1>_3\NN\1740 )_4\-RRB-\1740 ,_5\,\1740 a_6\DT\13649268 selective_7\JJ\1740 glycine_8\NN\14601829 site_9\NN\8673395 antagonist_10\NN\7846 ,_11\,\1740 injected_12\VBN\81072 in_13\IN\13603305 doses_14\NNS\3740161 of_15\IN\1740 2.5_16\CD\1740 and_17\CC\1740 4.5_18\CD\1740 microg/0.5_19\CD\1740 microl_20\NN\1740 bilaterally_21\RB\1740 ,_22\,\1740 into_23\IN\1740 the_24\DT\1740 rostral_25\JJ\1740 region_26\NN\27167 of_27\IN\1740 the_28\DT\1740 striatum_29\NN\5497363 ,_30\,\1740 decreased_31\VBD\169651 both_32\CC\1740 the_33\DT\1740 haloperidol-induced_34\JJ\1740 <e2>muscle_35\NN\5289601 rigidity</e2>_36\NN\5023233 (_37\-LRB-\1740 mmg_38\NN\1740 )_39\-RRB-\1740 and_40\CC\1740 the_41\DT\1740 enhanced_42\VBN\227165 electromyographic_43\JJ\1740 activity_44\NN\30358 (_45\-LRB-\1740 emg_46\NN\7005158 )_47\-RRB-\1740 ._48\.\1740
D005998_D009127 NONE 5,7-dichlorokynurenic_0\JJ\1740 acid_1\NN\14818238 (_2\-LRB-\1740 5,7-dcka_3\NN\1740 )_4\-RRB-\1740 ,_5\,\1740 a_6\DT\13649268 selective_7\JJ\1740 <e1>glycine</e1>_8\NN\14601829 site_9\NN\8673395 antagonist_10\NN\7846 ,_11\,\1740 injected_12\VBN\81072 in_13\IN\13603305 doses_14\NNS\3740161 of_15\IN\1740 2.5_16\CD\1740 and_17\CC\1740 4.5_18\CD\1740 microg/0.5_19\CD\1740 microl_20\NN\1740 bilaterally_21\RB\1740 ,_22\,\1740 into_23\IN\1740 the_24\DT\1740 rostral_25\JJ\1740 region_26\NN\27167 of_27\IN\1740 the_28\DT\1740 striatum_29\NN\5497363 ,_30\,\1740 decreased_31\VBD\169651 both_32\CC\1740 the_33\DT\1740 haloperidol-induced_34\JJ\1740 <e2>muscle_35\NN\5289601 rigidity</e2>_36\NN\5023233 (_37\-LRB-\1740 mmg_38\NN\1740 )_39\-RRB-\1740 and_40\CC\1740 the_41\DT\1740 enhanced_42\VBN\227165 electromyographic_43\JJ\1740 activity_44\NN\30358 (_45\-LRB-\1740 emg_46\NN\7005158 )_47\-RRB-\1740 ._48\.\1740
12139551
D008787_D006323 CID <e2>cardiac_0\JJ\1740 arrest</e2>_1\NN\88481 after_2\IN\1740 intravenous_3\JJ\1740 <e1>metoclopramide</e1>_4\NN\1740 -_5\:\1740 a_6\DT\13649268 case_7\NN\7283608 of_8\IN\1740 five_9\CD\13741022 repeated_10\VBN\952524 injections_11\NNS\320852 of_12\IN\1740 metoclopramide_13\NN\1740 causing_14\VBG\1617192 five_15\CD\13741022 episodes_16\NNS\7283608 of_17\IN\1740 cardiac_18\JJ\1740 arrest_19\NN\88481 ._20\.\1740
D008787_D006323 CID cardiac_0\JJ\1740 arrest_1\NN\88481 after_2\IN\1740 intravenous_3\JJ\1740 <e1>metoclopramide</e1>_4\NN\1740 -_5\:\1740 a_6\DT\13649268 case_7\NN\7283608 of_8\IN\1740 five_9\CD\13741022 repeated_10\VBN\952524 injections_11\NNS\320852 of_12\IN\1740 metoclopramide_13\NN\1740 causing_14\VBG\1617192 five_15\CD\13741022 episodes_16\NNS\7283608 of_17\IN\1740 <e2>cardiac_18\JJ\1740 arrest</e2>_19\NN\88481 ._20\.\1740
D008787_D006323 CID <e2>cardiac_0\JJ\1740 arrest</e2>_1\NN\88481 after_2\IN\1740 intravenous_3\JJ\1740 metoclopramide_4\NN\1740 -_5\:\1740 a_6\DT\13649268 case_7\NN\7283608 of_8\IN\1740 five_9\CD\13741022 repeated_10\VBN\952524 injections_11\NNS\320852 of_12\IN\1740 <e1>metoclopramide</e1>_13\NN\1740 causing_14\VBG\1617192 five_15\CD\13741022 episodes_16\NNS\7283608 of_17\IN\1740 cardiac_18\JJ\1740 arrest_19\NN\88481 ._20\.\1740
D008787_D006323 CID cardiac_0\JJ\1740 arrest_1\NN\88481 after_2\IN\1740 intravenous_3\JJ\1740 metoclopramide_4\NN\1740 -_5\:\1740 a_6\DT\13649268 case_7\NN\7283608 of_8\IN\1740 five_9\CD\13741022 repeated_10\VBN\952524 injections_11\NNS\320852 of_12\IN\1740 <e1>metoclopramide</e1>_13\NN\1740 causing_14\VBG\1617192 five_15\CD\13741022 episodes_16\NNS\7283608 of_17\IN\1740 <e2>cardiac_18\JJ\1740 arrest</e2>_19\NN\88481 ._20\.\1740
D008787_D006323 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 where_4\WRB\1740 intravenous_5\JJ\1740 injection_6\NN\320852 of_7\IN\1740 <e1>metoclopramide</e1>_8\NN\1740 was_9\VBD\836236 immediately_10\RB\1740 followed_11\VBN\1835496 by_12\IN\1740 <e2>asystole</e2>_13\NN\14204950 repeatedly_14\RB\1740 ._15\.\1740
D008787_D006323 CID the_0\DT\1740 patient_1\NN\9898892 received_2\VBD\2210855 <e1>metoclopramide</e1>_3\NN\1740 10_4\CD\13745420 mg_5\NN\13717155 i.v._6\NN\1740 five_7\CD\13741022 times_8\NNS\15113229 during_9\IN\1740 48_10\CD\1740 h._11\NN\1740 after_12\IN\1740 interviewing_13\VBG\964694 the_14\DT\1740 attending_15\VBG\2655135 nurses_16\NNS\10165109 and_17\CC\1740 reviewing_18\VBG\644583 the_19\DT\1740 written_20\VBN\1697816 documentation_21\NN\6650070 ,_22\,\1740 it_23\PRP\6125041 is_24\VBZ\836236 clear_25\JJ\1740 that_26\IN\1740 every_27\DT\1740 administration_28\NN\1133281 of_29\IN\1740 metoclopramide_30\NN\1740 was_31\VBD\836236 immediately_32\RB\1740 (_33\-LRB-\1740 within_34\IN\1740 s_35\NNS\15154774 )_36\-RRB-\1740 followed_37\VBN\1835496 by_38\IN\1740 <e2>asystole</e2>_39\NN\14204950 ._40\.\1740
D008787_D006323 CID the_0\DT\1740 patient_1\NN\9898892 received_2\VBD\2210855 metoclopramide_3\NN\1740 10_4\CD\13745420 mg_5\NN\13717155 i.v._6\NN\1740 five_7\CD\13741022 times_8\NNS\15113229 during_9\IN\1740 48_10\CD\1740 h._11\NN\1740 after_12\IN\1740 interviewing_13\VBG\964694 the_14\DT\1740 attending_15\VBG\2655135 nurses_16\NNS\10165109 and_17\CC\1740 reviewing_18\VBG\644583 the_19\DT\1740 written_20\VBN\1697816 documentation_21\NN\6650070 ,_22\,\1740 it_23\PRP\6125041 is_24\VBZ\836236 clear_25\JJ\1740 that_26\IN\1740 every_27\DT\1740 administration_28\NN\1133281 of_29\IN\1740 <e1>metoclopramide</e1>_30\NN\1740 was_31\VBD\836236 immediately_32\RB\1740 (_33\-LRB-\1740 within_34\IN\1740 s_35\NNS\15154774 )_36\-RRB-\1740 followed_37\VBN\1835496 by_38\IN\1740 <e2>asystole</e2>_39\NN\14204950 ._40\.\1740
D008787_D006323 CID we_0\PRP\1740 interpret_1\VBP\588888 this_2\DT\1740 as_3\IN\14622893 episodes_4\NNS\7283608 of_5\IN\1740 <e2>cardiac_6\JJ\1740 arrest</e2>_7\NN\88481 caused_8\VBN\1617192 by_9\IN\1740 <e1>metoclopramide</e1>_10\NN\1740 ._11\.\1740
11022397
D014331_D008569 NONE outcome_0\NN\7291312 measures_1\NN\168237 :_2\:\1740 pupil_3\NNP\10059162 size_4\NN\5090441 at_5\IN\14622893 time_6\NN\7308889 points_7\NNS\5868954 after_8\IN\1740 administration_9\NN\1133281 of_10\IN\1740 <e1>tropicamide</e1>_11\NN\1740 and_12\CC\1740 pilocarpine_13\NN\14712692 ;_14\:\1740 scopolamine-induced_15\JJ\1740 <e2>impairment_16\NN\7296428 in_17\IN\13603305 word_18\NN\6284225 recall</e2>_19\NN\7185325 ._20\.\1740
D010862_D008569 NONE outcome_0\NN\7291312 measures_1\NN\168237 :_2\:\1740 pupil_3\NNP\10059162 size_4\NN\5090441 at_5\IN\14622893 time_6\NN\7308889 points_7\NNS\5868954 after_8\IN\1740 administration_9\NN\1133281 of_10\IN\1740 tropicamide_11\NN\1740 and_12\CC\1740 <e1>pilocarpine</e1>_13\NN\14712692 ;_14\:\1740 scopolamine-induced_15\JJ\1740 <e2>impairment_16\NN\7296428 in_17\IN\13603305 word_18\NN\6284225 recall</e2>_19\NN\7185325 ._20\.\1740
D012601_D008569 CID outcome_0\NN\7291312 measures_1\NN\168237 :_2\:\1740 pupil_3\NNP\10059162 size_4\NN\5090441 at_5\IN\14622893 time_6\NN\7308889 points_7\NNS\5868954 after_8\IN\1740 administration_9\NN\1133281 of_10\IN\1740 tropicamide_11\NN\1740 and_12\CC\1740 pilocarpine_13\NN\14712692 ;_14\:\1740 <e1>scopolamine-induced</e1>_15\JJ\1740 <e2>impairment_16\NN\7296428 in_17\IN\13603305 word_18\NN\6284225 recall</e2>_19\NN\7185325 ._20\.\1740
D012601_D008569 CID compared_0\VBN\644583 with_1\IN\1740 the_2\DT\1740 young_3\JJ\1740 group_4\NN\2137 ,_5\,\1740 the_6\DT\1740 elderly_7\JJ\1740 group_8\NN\2137 had_9\VBD\2108377 greater_10\JJR\1740 <e1>scopolamine-induced</e1>_11\JJ\1740 <e2>impairment_12\NN\7296428 in_13\IN\13603305 word_14\NN\6284225 recall</e2>_15\NN\7185325 60_16\CD\13745420 ,_17\,\1740 90_18\CD\13745420 and_19\CC\1740 120_20\CD\13745420 minutes_21\NNS\6502378 after_22\IN\1740 administration_23\NN\1133281 (_24\-LRB-\1740 p_25\NN\14622893 <_26\XX\1740 0.05_27\CD\1740 )_28\-RRB-\1740 ._29\.\1740
16047871
D014859_C535509 NONE <e1>warfarin-induced</e1>_0\JJ\1740 <e2>leukocytoclastic_1\JJ\1740 vasculitis</e2>_2\NN\14336539 ._3\.\1740
D014859_C535509 NONE we_0\PRP\1740 report_1\VBP\831651 4_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 late-onset_5\JJ\1740 <e2>lv</e2>_6\NN\1740 probably_7\RB\1740 due_8\IN\5174653 to_9\IN\1740 <e1>warfarin</e1>_10\NN\2718259 ._11\.\1740
D014859_C535509 NONE <e2>lv</e2>_0\NNP\1740 may_1\MD\15209706 be_2\VB\836236 a_3\DT\13649268 late-onset_4\JJ\1740 adverse_5\JJ\1740 reaction_6\NN\13446390 associated_7\VBN\628491 with_8\IN\1740 <e1>warfarin</e1>_9\NN\2718259 therapy_10\NN\657604 ._11\.\1740
D014859_D012871 NONE all_0\DT\1740 4_1\CD\13741022 patients_2\NNS\9898892 presented_3\VBN\2137132 with_4\IN\1740 <e2>skin_5\NN\5237755 eruptions</e2>_6\NNS\7307754 that_7\WDT\1740 developed_8\VBD\1753788 after_9\IN\1740 receiving_10\VBG\2210855 <e1>warfarin</e1>_11\NN\2718259 for_12\IN\1740 several_13\JJ\1740 years_14\NNS\15144371 ._15\.\1740
D014859_D012871 NONE the_0\DT\1740 results_1\NNS\34213 of_2\IN\1740 <e2>skin_3\NN\5237755 lesion</e2>_4\NN\14204950 biopsies_5\NNS\5739043 were_6\VBD\836236 available_7\JJ\1740 in_8\IN\13603305 3_9\CD\13741022 patients_10\NNS\9898892 ,_11\,\1740 confirming_12\VBG\1011725 lv_13\NNP\1740 cutaneous_14\JJ\1740 lesions_15\NNS\14204950 resolved_16\VBN\352826 in_17\IN\13603305 all_18\DT\1740 patients_19\NNS\9898892 after_20\IN\1740 <e1>warfarin</e1>_21\NN\2718259 was_22\VBD\836236 discontinued_23\VBN\2609764 ._24\.\1740
D014859_D018366 CID the_0\DT\1740 results_1\NNS\34213 of_2\IN\1740 skin_3\NN\5237755 lesion_4\NN\14204950 biopsies_5\NNS\5739043 were_6\VBD\836236 available_7\JJ\1740 in_8\IN\13603305 3_9\CD\13741022 patients_10\NNS\9898892 ,_11\,\1740 confirming_12\VBG\1011725 <e2>lv_13\NNP\1740 cutaneous_14\JJ\1740 lesions</e2>_15\NNS\14204950 resolved_16\VBN\352826 in_17\IN\13603305 all_18\DT\1740 patients_19\NNS\9898892 after_20\IN\1740 <e1>warfarin</e1>_21\NN\2718259 was_22\VBD\836236 discontinued_23\VBN\2609764 ._24\.\1740
16364460
D016713_D000647 NONE microinjection_0\NN\1740 of_1\IN\1740 <e1>ritanserin</e1>_2\NN\1740 into_3\IN\1740 the_4\DT\1740 ca1_5\NN\1740 region_6\NN\27167 of_7\IN\1740 hippocampus_8\NN\5462674 improves_9\NNS\1740 scopolamine-induced_10\JJ\1740 <e2>amnesia</e2>_11\NN\5669934 in_12\IN\13603305 adult_13\JJ\1740 male_14\JJ\1740 rats_15\NNS\2329401 ._16\.\1740
D016713_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>ritanserin</e1>_3\NN\1740 (_4\-LRB-\1740 5-ht2_5\NN\1740 antagonist_6\NN\7846 )_7\-RRB-\1740 on_8\IN\1740 scopolamine_9\NN\14712692 (_10\-LRB-\1740 muscarinic_11\JJ\1740 cholinergic_12\NN\1740 antagonist)-induced_13\JJ\1740 <e2>amnesia</e2>_14\NN\5669934 in_15\IN\13603305 morris_16\NNP\1740 water_17\NN\14618834 maze_18\NN\4377057 (_19\-LRB-\1740 mwm_20\NN\1740 )_21\-RRB-\1740 was_22\VBD\836236 investigated_23\VBN\644583 ._24\.\1740
D016713_D000647 NONE our_0\PRP$\1740 findings_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 microinjection_4\NN\1740 of_5\IN\1740 <e1>ritanserin</e1>_6\NN\1740 into_7\IN\1740 the_8\DT\1740 ca1_9\NN\1740 region_10\NN\27167 of_11\IN\1740 the_12\DT\1740 hippocampus_13\NN\5462674 improves_14\VBZ\126264 the_15\DT\1740 scopolamine-induced_16\JJ\1740 <e2>amnesia</e2>_17\NN\5669934 ._18\.\1740
D012601_D000647 CID microinjection_0\NN\1740 of_1\IN\1740 ritanserin_2\NN\1740 into_3\IN\1740 the_4\DT\1740 ca1_5\NN\1740 region_6\NN\27167 of_7\IN\1740 hippocampus_8\NN\5462674 improves_9\NNS\1740 <e1>scopolamine-induced</e1>_10\JJ\1740 <e2>amnesia</e2>_11\NN\5669934 in_12\IN\13603305 adult_13\JJ\1740 male_14\JJ\1740 rats_15\NNS\2329401 ._16\.\1740
D012601_D000647 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 ritanserin_3\NN\1740 (_4\-LRB-\1740 5-ht2_5\NN\1740 antagonist_6\NN\7846 )_7\-RRB-\1740 on_8\IN\1740 <e1>scopolamine</e1>_9\NN\14712692 (_10\-LRB-\1740 muscarinic_11\JJ\1740 cholinergic_12\NN\1740 antagonist)-induced_13\JJ\1740 <e2>amnesia</e2>_14\NN\5669934 in_15\IN\13603305 morris_16\NNP\1740 water_17\NN\14618834 maze_18\NN\4377057 (_19\-LRB-\1740 mwm_20\NN\1740 )_21\-RRB-\1740 was_22\VBD\836236 investigated_23\VBN\644583 ._24\.\1740
D012601_D000647 CID our_0\PRP$\1740 findings_1\NNS\7951464 show_2\VBP\2137132 that_3\IN\1740 microinjection_4\NN\1740 of_5\IN\1740 ritanserin_6\NN\1740 into_7\IN\1740 the_8\DT\1740 ca1_9\NN\1740 region_10\NN\27167 of_11\IN\1740 the_12\DT\1740 hippocampus_13\NN\5462674 improves_14\VBZ\126264 the_15\DT\1740 <e1>scopolamine-induced</e1>_16\JJ\1740 <e2>amnesia</e2>_17\NN\5669934 ._18\.\1740
16418614
D011441_D014657 CID <e1>ptu-associated</e1>_0\JJ\1740 <e2>vasculitis</e2>_1\NN\14336539 in_2\IN\13603305 a_3\DT\13649268 girl_4\NN\10787470 with_5\IN\1740 turner_6\NNP\10732967 syndrome_7\NNP\5870365 and_8\CC\1740 graves_9\NN\15143477 '_10\POS\1740 disease_11\NN\14061805 ._12\.\1740
D011441_D014657 CID the_0\DT\1740 diagnosis_1\NN\152018 of_2\IN\1740 <e1>propylthiouracil</e1>_3\NN\14727670 (ptu)-associated_4\NN\1740 <e2>vasculitis</e2>_5\NN\14336539 was_6\VBD\836236 made_7\VBN\126264 by_8\IN\1740 observation_9\NN\996969 of_10\IN\1740 consistent_11\JJ\1740 clinical_12\JJ\1740 features_13\NNS\5849040 ,_14\,\1740 the_15\DT\1740 detection_16\NN\5708432 of_17\IN\1740 elevated_18\JJ\1740 ana_19\NN\7951464 and_20\CC\1740 anca_21\NN\1740 in_22\IN\13603305 the_23\DT\1740 blood_24\NN\5397468 ,_25\,\1740 and_26\CC\1740 the_27\DT\1740 observed_28\VBN\2163746 clinical_29\JJ\1740 resolution_30\NN\6470073 of_31\IN\1740 symptoms_32\NNS\5823932 following_33\VBG\1835496 withdrawal_34\NN\7206096 of_35\IN\1740 ptu_36\NN\1740 ._37\.\1740
D011441_D014657 CID the_0\DT\1740 diagnosis_1\NN\152018 of_2\IN\1740 propylthiouracil_3\NN\14727670 <e1>(ptu)-associated</e1>_4\NN\1740 <e2>vasculitis</e2>_5\NN\14336539 was_6\VBD\836236 made_7\VBN\126264 by_8\IN\1740 observation_9\NN\996969 of_10\IN\1740 consistent_11\JJ\1740 clinical_12\JJ\1740 features_13\NNS\5849040 ,_14\,\1740 the_15\DT\1740 detection_16\NN\5708432 of_17\IN\1740 elevated_18\JJ\1740 ana_19\NN\7951464 and_20\CC\1740 anca_21\NN\1740 in_22\IN\13603305 the_23\DT\1740 blood_24\NN\5397468 ,_25\,\1740 and_26\CC\1740 the_27\DT\1740 observed_28\VBN\2163746 clinical_29\JJ\1740 resolution_30\NN\6470073 of_31\IN\1740 symptoms_32\NNS\5823932 following_33\VBG\1835496 withdrawal_34\NN\7206096 of_35\IN\1740 ptu_36\NN\1740 ._37\.\1740
D011441_D014657 CID the_0\DT\1740 diagnosis_1\NN\152018 of_2\IN\1740 propylthiouracil_3\NN\14727670 (ptu)-associated_4\NN\1740 <e2>vasculitis</e2>_5\NN\14336539 was_6\VBD\836236 made_7\VBN\126264 by_8\IN\1740 observation_9\NN\996969 of_10\IN\1740 consistent_11\JJ\1740 clinical_12\JJ\1740 features_13\NNS\5849040 ,_14\,\1740 the_15\DT\1740 detection_16\NN\5708432 of_17\IN\1740 elevated_18\JJ\1740 ana_19\NN\7951464 and_20\CC\1740 anca_21\NN\1740 in_22\IN\13603305 the_23\DT\1740 blood_24\NN\5397468 ,_25\,\1740 and_26\CC\1740 the_27\DT\1740 observed_28\VBN\2163746 clinical_29\JJ\1740 resolution_30\NN\6470073 of_31\IN\1740 symptoms_32\NNS\5823932 following_33\VBG\1835496 withdrawal_34\NN\7206096 of_35\IN\1740 <e1>ptu</e1>_36\NN\1740 ._37\.\1740
D011441_D014424 NONE <e1>ptu-associated</e1>_0\JJ\1740 vasculitis_1\NN\14336539 in_2\IN\13603305 a_3\DT\13649268 girl_4\NN\10787470 with_5\IN\1740 <e2>turner_6\NNP\10732967 syndrome</e2>_7\NNP\5870365 and_8\CC\1740 graves_9\NN\15143477 '_10\POS\1740 disease_11\NN\14061805 ._12\.\1740
D011441_D006111 NONE <e1>ptu-associated</e1>_0\JJ\1740 vasculitis_1\NN\14336539 in_2\IN\13603305 a_3\DT\13649268 girl_4\NN\10787470 with_5\IN\1740 turner_6\NNP\10732967 syndrome_7\NNP\5870365 and_8\CC\1740 <e2>graves_9\NN\15143477 '_10\POS\1740 disease</e2>_11\NN\14061805 ._12\.\1740
7263204
D007213_D000741 CID fatal_0\JJ\1740 <e2>aplastic_1\JJ\1740 anemia</e2>_2\NN\14189204 due_3\IN\5174653 to_4\TO\1740 <e1>indomethacin</e1>_5\NN\3828465 --_6\:\1740 lymphocyte_7\NN\5449959 transformation_8\NN\7296428 tests_9\NNS\5798043 in_10\FW\13603305 vitro_11\FW\1740 ._12\.\1740
D007213_D000741 CID although_0\IN\1740 <e1>indomethacin</e1>_1\NN\3828465 has_2\VBZ\2108377 been_3\VBN\836236 implicated_4\VBN\2677097 as_5\IN\14622893 a_6\DT\13649268 possible_7\JJ\1740 cause_8\NN\7323922 of_9\IN\1740 <e2>aplastic_10\JJ\1740 anemia</e2>_11\NN\14189204 on_12\IN\1740 the_13\DT\1740 basis_14\NN\13790712 of_15\IN\1740 a_16\DT\13649268 few_17\JJ\1740 clinical_18\JJ\1740 observations_19\NNS\996969 ,_20\,\1740 its_21\PRP$\6125041 role_22\NN\719494 has_23\VBZ\2108377 not_24\RB\1740 been_25\VBN\836236 definitely_26\RB\1740 established_27\VBN\2426171 ._28\.\1740
D007213_D000741 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 fatal_3\JJ\1740 <e2>aplastic_4\JJ\1740 anemia</e2>_5\NN\14189204 is_6\VBZ\836236 described_7\VBN\1001294 in_8\IN\13603305 which_9\WDT\1740 no_10\DT\7204911 drugs_11\NNS\14778436 other_12\JJ\1740 than_13\IN\1740 allopurinol_14\NN\3740161 and_15\CC\1740 <e1>indomethacin</e1>_16\NN\3828465 were_17\VBD\836236 given_18\VBN\2327200 ._19\.\1740
D007213_D000741 CID a_0\DT\13649268 positive_1\JJ\1740 lymphocyte_2\NN\5449959 transformation_3\NN\7296428 test_4\VBP\670261 with_5\IN\1740 <e1>indomethacin</e1>_6\NN\3828465 in_7\FW\13603305 vitro_8\FW\1740 further_9\RB\1740 substantiates_10\VBZ\2604760 the_11\DT\1740 potential_12\JJ\1740 role_13\NN\719494 of_14\IN\1740 this_15\DT\1740 drug_16\NN\14778436 in_17\IN\13603305 causing_18\VBG\1617192 <e2>aplastic_19\JJ\1740 anemia</e2>_20\NN\14189204 in_21\IN\13603305 a_22\DT\13649268 susceptible_23\JJ\1740 patient_24\NN\9898892 ._25\.\1740
D000493_D000741 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 fatal_3\JJ\1740 <e2>aplastic_4\JJ\1740 anemia</e2>_5\NN\14189204 is_6\VBZ\836236 described_7\VBN\1001294 in_8\IN\13603305 which_9\WDT\1740 no_10\DT\7204911 drugs_11\NNS\14778436 other_12\JJ\1740 than_13\IN\1740 <e1>allopurinol</e1>_14\NN\3740161 and_15\CC\1740 indomethacin_16\NN\3828465 were_17\VBD\836236 given_18\VBN\2327200 ._19\.\1740
9545159
D020117_D008133 CID <e2>prolongation_0\NN\1017987 of_1\IN\1740 the_2\DT\1740 qt_3\NNP\1740 interval</e2>_4\NN\33615 related_5\JJ\1740 to_6\TO\1740 <e1>cisapride-diltiazem</e1>_7\JJ\1740 interaction_8\NN\37396 ._9\.\1740
D004110_D008133 CID <e2>prolongation_0\NN\1017987 of_1\IN\1740 the_2\DT\1740 qt_3\NNP\1740 interval</e2>_4\NN\33615 related_5\JJ\1740 to_6\TO\1740 <e1>cisapride-diltiazem</e1>_7\JJ\1740 interaction_8\NN\37396 ._9\.\1740
D020117_D015835 NONE <e1>cisapride</e1>_0\RB\1740 ,_1\,\1740 a_2\DT\13649268 cytochrome_3\NN\14888884 p450_4\NN\1740 3a4_5\NN\1740 (_6\-LRB-\1740 cyp3a4_7\NN\1740 )_8\-RRB-\1740 substrate_9\NN\19613 ,_10\,\1740 is_11\VBZ\836236 widely_12\RB\1740 prescribed_13\VBN\748282 for_14\IN\1740 the_15\DT\1740 treatment_16\NN\654885 of_17\IN\1740 <e2>gastrointestinal_18\JJ\1740 motility_19\NN\4773351 disorders</e2>_20\NNS\14034177 ._21\.\1740
D004917_D008133 CID <e2>prolongation_0\NN\1017987 of_1\IN\1740 qt_2\NNP\1740 interval</e2>_3\NN\33615 ,_4\,\1740 torsades_5\NNS\1740 de_6\IN\1740 pointes_7\NNS\1740 ,_8\,\1740 and_9\CC\1740 sudden_10\JJ\1740 cardiac_11\JJ\1740 death_12\NN\7296428 have_13\VBP\2108377 been_14\VBN\836236 reported_15\VBN\831651 after_16\IN\1740 concomitant_17\JJ\1740 administration_18\NN\1133281 with_19\IN\1740 <e1>erythromycin</e1>_20\NN\2716866 or_21\CC\3541091 azole_22\NN\1740 antifungal_23\NN\14778436 agents_24\NNS\7347 ,_25\,\1740 but_26\CC\1740 not_27\RB\1740 with_28\IN\1740 other_29\JJ\1740 cyp3a4_30\NN\1740 inhibitors_31\NNS\20090 ._32\.\1740
D004917_D016171 CID prolongation_0\NN\1017987 of_1\IN\1740 qt_2\NNP\1740 interval_3\NN\33615 ,_4\,\1740 <e2>torsades_5\NNS\1740 de_6\IN\1740 pointes</e2>_7\NNS\1740 ,_8\,\1740 and_9\CC\1740 sudden_10\JJ\1740 cardiac_11\JJ\1740 death_12\NN\7296428 have_13\VBP\2108377 been_14\VBN\836236 reported_15\VBN\831651 after_16\IN\1740 concomitant_17\JJ\1740 administration_18\NN\1133281 with_19\IN\1740 <e1>erythromycin</e1>_20\NN\2716866 or_21\CC\3541091 azole_22\NN\1740 antifungal_23\NN\14778436 agents_24\NNS\7347 ,_25\,\1740 but_26\CC\1740 not_27\RB\1740 with_28\IN\1740 other_29\JJ\1740 cyp3a4_30\NN\1740 inhibitors_31\NNS\20090 ._32\.\1740
D004917_D016757 CID prolongation_0\NN\1017987 of_1\IN\1740 qt_2\NNP\1740 interval_3\NN\33615 ,_4\,\1740 torsades_5\NNS\1740 de_6\IN\1740 pointes_7\NNS\1740 ,_8\,\1740 and_9\CC\1740 <e2>sudden_10\JJ\1740 cardiac_11\JJ\1740 death</e2>_12\NN\7296428 have_13\VBP\2108377 been_14\VBN\836236 reported_15\VBN\831651 after_16\IN\1740 concomitant_17\JJ\1740 administration_18\NN\1133281 with_19\IN\1740 <e1>erythromycin</e1>_20\NN\2716866 or_21\CC\3541091 azole_22\NN\1740 antifungal_23\NN\14778436 agents_24\NNS\7347 ,_25\,\1740 but_26\CC\1740 not_27\RB\1740 with_28\IN\1740 other_29\JJ\1740 cyp3a4_30\NN\1740 inhibitors_31\NNS\20090 ._32\.\1740
D001393_D008133 CID <e2>prolongation_0\NN\1017987 of_1\IN\1740 qt_2\NNP\1740 interval</e2>_3\NN\33615 ,_4\,\1740 torsades_5\NNS\1740 de_6\IN\1740 pointes_7\NNS\1740 ,_8\,\1740 and_9\CC\1740 sudden_10\JJ\1740 cardiac_11\JJ\1740 death_12\NN\7296428 have_13\VBP\2108377 been_14\VBN\836236 reported_15\VBN\831651 after_16\IN\1740 concomitant_17\JJ\1740 administration_18\NN\1133281 with_19\IN\1740 erythromycin_20\NN\2716866 or_21\CC\3541091 <e1>azole</e1>_22\NN\1740 antifungal_23\NN\14778436 agents_24\NNS\7347 ,_25\,\1740 but_26\CC\1740 not_27\RB\1740 with_28\IN\1740 other_29\JJ\1740 cyp3a4_30\NN\1740 inhibitors_31\NNS\20090 ._32\.\1740
D001393_D016171 CID prolongation_0\NN\1017987 of_1\IN\1740 qt_2\NNP\1740 interval_3\NN\33615 ,_4\,\1740 <e2>torsades_5\NNS\1740 de_6\IN\1740 pointes</e2>_7\NNS\1740 ,_8\,\1740 and_9\CC\1740 sudden_10\JJ\1740 cardiac_11\JJ\1740 death_12\NN\7296428 have_13\VBP\2108377 been_14\VBN\836236 reported_15\VBN\831651 after_16\IN\1740 concomitant_17\JJ\1740 administration_18\NN\1133281 with_19\IN\1740 erythromycin_20\NN\2716866 or_21\CC\3541091 <e1>azole</e1>_22\NN\1740 antifungal_23\NN\14778436 agents_24\NNS\7347 ,_25\,\1740 but_26\CC\1740 not_27\RB\1740 with_28\IN\1740 other_29\JJ\1740 cyp3a4_30\NN\1740 inhibitors_31\NNS\20090 ._32\.\1740
D001393_D016757 CID prolongation_0\NN\1017987 of_1\IN\1740 qt_2\NNP\1740 interval_3\NN\33615 ,_4\,\1740 torsades_5\NNS\1740 de_6\IN\1740 pointes_7\NNS\1740 ,_8\,\1740 and_9\CC\1740 <e2>sudden_10\JJ\1740 cardiac_11\JJ\1740 death</e2>_12\NN\7296428 have_13\VBP\2108377 been_14\VBN\836236 reported_15\VBN\831651 after_16\IN\1740 concomitant_17\JJ\1740 administration_18\NN\1133281 with_19\IN\1740 erythromycin_20\NN\2716866 or_21\CC\3541091 <e1>azole</e1>_22\NN\1740 antifungal_23\NN\14778436 agents_24\NNS\7347 ,_25\,\1740 but_26\CC\1740 not_27\RB\1740 with_28\IN\1740 other_29\JJ\1740 cyp3a4_30\NN\1740 inhibitors_31\NNS\20090 ._32\.\1740
D020117_D005764 NONE a_0\DT\13649268 possible_1\JJ\1740 drug_2\NN\14778436 interaction_3\NN\37396 occurred_4\VBD\2623529 in_5\IN\13603305 a_6\DT\13649268 45-year-old_7\JJ\1740 woman_8\NN\9605289 who_9\WP\8299493 was_10\VBD\836236 taking_11\VBG\2367363 <e1>cisapride</e1>_12\NN\1740 for_13\IN\1740 <e2>gastroesophageal_14\JJ\1740 reflux_15\NN\14204950 disorder</e2>_16\NN\14034177 and_17\CC\1740 diltiazem_18\NN\2938514 ,_19\,\1740 an_20\DT\6697703 agent_21\NN\7347 that_22\WDT\1740 has_23\VBZ\2108377 inhibitory_24\JJ\1740 effect_25\NN\34213 on_26\IN\1740 cyp3a4_27\NN\1740 ,_28\,\1740 for_29\IN\1740 hypertension_30\NN\14057371 ._31\.\1740
D020117_D006973 NONE a_0\DT\13649268 possible_1\JJ\1740 drug_2\NN\14778436 interaction_3\NN\37396 occurred_4\VBD\2623529 in_5\IN\13603305 a_6\DT\13649268 45-year-old_7\JJ\1740 woman_8\NN\9605289 who_9\WP\8299493 was_10\VBD\836236 taking_11\VBG\2367363 <e1>cisapride</e1>_12\NN\1740 for_13\IN\1740 gastroesophageal_14\JJ\1740 reflux_15\NN\14204950 disorder_16\NN\14034177 and_17\CC\1740 diltiazem_18\NN\2938514 ,_19\,\1740 an_20\DT\6697703 agent_21\NN\7347 that_22\WDT\1740 has_23\VBZ\2108377 inhibitory_24\JJ\1740 effect_25\NN\34213 on_26\IN\1740 cyp3a4_27\NN\1740 ,_28\,\1740 for_29\IN\1740 <e2>hypertension</e2>_30\NN\14057371 ._31\.\1740
D004110_D005764 NONE a_0\DT\13649268 possible_1\JJ\1740 drug_2\NN\14778436 interaction_3\NN\37396 occurred_4\VBD\2623529 in_5\IN\13603305 a_6\DT\13649268 45-year-old_7\JJ\1740 woman_8\NN\9605289 who_9\WP\8299493 was_10\VBD\836236 taking_11\VBG\2367363 cisapride_12\NN\1740 for_13\IN\1740 <e2>gastroesophageal_14\JJ\1740 reflux_15\NN\14204950 disorder</e2>_16\NN\14034177 and_17\CC\1740 <e1>diltiazem</e1>_18\NN\2938514 ,_19\,\1740 an_20\DT\6697703 agent_21\NN\7347 that_22\WDT\1740 has_23\VBZ\2108377 inhibitory_24\JJ\1740 effect_25\NN\34213 on_26\IN\1740 cyp3a4_27\NN\1740 ,_28\,\1740 for_29\IN\1740 hypertension_30\NN\14057371 ._31\.\1740
D004110_D006973 NONE a_0\DT\13649268 possible_1\JJ\1740 drug_2\NN\14778436 interaction_3\NN\37396 occurred_4\VBD\2623529 in_5\IN\13603305 a_6\DT\13649268 45-year-old_7\JJ\1740 woman_8\NN\9605289 who_9\WP\8299493 was_10\VBD\836236 taking_11\VBG\2367363 cisapride_12\NN\1740 for_13\IN\1740 gastroesophageal_14\JJ\1740 reflux_15\NN\14204950 disorder_16\NN\14034177 and_17\CC\1740 <e1>diltiazem</e1>_18\NN\2938514 ,_19\,\1740 an_20\DT\6697703 agent_21\NN\7347 that_22\WDT\1740 has_23\VBZ\2108377 inhibitory_24\JJ\1740 effect_25\NN\34213 on_26\IN\1740 cyp3a4_27\NN\1740 ,_28\,\1740 for_29\IN\1740 <e2>hypertension</e2>_30\NN\14057371 ._31\.\1740
2320800
D007069_D001002 CID lethal_0\JJ\1740 <e2>anuria</e2>_1\NNS\14061805 complicating_2\VBG\126264 high_3\JJ\1740 dose_4\NN\3740161 <e1>ifosfamide</e1>_5\NN\1740 chemotherapy_6\NN\661091 in_7\IN\13603305 a_8\DT\13649268 breast_9\NN\5225090 cancer_10\NN\14239425 patient_11\NN\9898892 with_12\IN\1740 an_13\DT\6697703 impaired_14\JJ\1740 renal_15\JJ\1740 function_16\NN\13783581 ._17\.\1740
D007069_D001002 CID a_0\DT\13649268 sixty-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 advanced_4\JJ\1740 breast_5\NN\5225090 cancer_6\NN\14239425 ,_7\,\1740 previously_8\RB\1740 treated_9\VBN\2376958 with_10\IN\1740 cisplatin_11\NN\1740 ,_12\,\1740 developed_13\VBD\1753788 an_14\DT\6697703 irreversible_15\JJ\1740 lethal_16\JJ\1740 renal_17\JJ\1740 failure_18\NN\66216 with_19\IN\1740 <e2>anuria</e2>_20\NN\14061805 ,_21\,\1740 the_22\DT\1740 day_23\NN\15154774 after_24\IN\1740 5_25\CD\13741022 g/m2_26\NN\1740 bolus_27\NN\13899404 <e1>ifosfamide</e1>_28\NN\1740 ._29\.\1740
D007069_D001002 CID we_0\PRP\1740 strongly_1\RB\1740 suspect_2\VBP\916909 that_3\IN\1740 this_4\DT\1740 lethal_5\JJ\1740 <e2>anuria</e2>_6\NN\14061805 was_7\VBD\836236 mainly_8\RB\1740 due_9\JJ\1740 to_10\TO\1740 <e1>ifosfamide</e1>_11\NN\1740 ,_12\,\1740 occurring_13\VBG\2623529 in_14\IN\13603305 a_15\DT\13649268 patient_16\NN\9898892 having_17\VBG\2108377 received_18\VBN\2210855 previous_19\JJ\1740 cisplatin_20\NN\1740 chemotherapy_21\NN\661091 and_22\CC\1740 with_23\IN\1740 poor_24\JJ\1740 kidney_25\NN\5333259 perfusion_26\NN\320852 due_27\JJ\1740 to_28\TO\1740 transient_29\JJ\1740 hypotension_30\NN\14057371 ._31\.\1740
D007069_D001943 NONE lethal_0\JJ\1740 anuria_1\NNS\14061805 complicating_2\VBG\126264 high_3\JJ\1740 dose_4\NN\3740161 <e1>ifosfamide</e1>_5\NN\1740 chemotherapy_6\NN\661091 in_7\IN\13603305 a_8\DT\13649268 <e2>breast_9\NN\5225090 cancer</e2>_10\NN\14239425 patient_11\NN\9898892 with_12\IN\1740 an_13\DT\6697703 impaired_14\JJ\1740 renal_15\JJ\1740 function_16\NN\13783581 ._17\.\1740
D007069_D001943 NONE a_0\DT\13649268 sixty-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 advanced_4\JJ\1740 <e2>breast_5\NN\5225090 cancer</e2>_6\NN\14239425 ,_7\,\1740 previously_8\RB\1740 treated_9\VBN\2376958 with_10\IN\1740 cisplatin_11\NN\1740 ,_12\,\1740 developed_13\VBD\1753788 an_14\DT\6697703 irreversible_15\JJ\1740 lethal_16\JJ\1740 renal_17\JJ\1740 failure_18\NN\66216 with_19\IN\1740 anuria_20\NN\14061805 ,_21\,\1740 the_22\DT\1740 day_23\NN\15154774 after_24\IN\1740 5_25\CD\13741022 g/m2_26\NN\1740 bolus_27\NN\13899404 <e1>ifosfamide</e1>_28\NN\1740 ._29\.\1740
D007069_D007674 CID lethal_0\JJ\1740 anuria_1\NNS\14061805 complicating_2\VBG\126264 high_3\JJ\1740 dose_4\NN\3740161 <e1>ifosfamide</e1>_5\NN\1740 chemotherapy_6\NN\661091 in_7\IN\13603305 a_8\DT\13649268 breast_9\NN\5225090 cancer_10\NN\14239425 patient_11\NN\9898892 with_12\IN\1740 an_13\DT\6697703 <e2>impaired_14\JJ\1740 renal_15\JJ\1740 function</e2>_16\NN\13783581 ._17\.\1740
D007069_D007674 CID <e1>ifosfamide</e1>_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 known_3\JJ\1740 <e2>nephrotoxic</e2>_4\JJ\1740 drug_5\NN\14778436 with_6\IN\1740 demonstrated_7\VBN\2137132 tubulopathies_8\NNS\1740 ._9\.\1740
D007069_D007674 CID <e1>ifosfamide</e1>_0\NNP\1740 is_1\VBZ\836236 a_2\DT\13649268 known_3\JJ\1740 nephrotoxic_4\JJ\1740 drug_5\NN\14778436 with_6\IN\1740 demonstrated_7\VBN\2137132 <e2>tubulopathies</e2>_8\NNS\1740 ._9\.\1740
D007069_D007674 CID we_0\PRP\1740 recommend_1\VBP\875394 careful_2\JJ\1740 use_3\NN\407535 of_4\IN\1740 <e1>ifosfamide</e1>_5\NN\1740 in_6\IN\13603305 patients_7\NNS\9898892 pretreated_8\VBN\1740 with_9\IN\1740 <e2>nephrotoxic</e2>_10\JJ\1740 chemotherapy_11\NN\661091 and_12\CC\1740 inadequate_13\JJ\1740 renal_14\JJ\1740 perfusion_15\NN\320852 ._16\.\1740
D002945_D001943 NONE a_0\DT\13649268 sixty-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 advanced_4\JJ\1740 <e2>breast_5\NN\5225090 cancer</e2>_6\NN\14239425 ,_7\,\1740 previously_8\RB\1740 treated_9\VBN\2376958 with_10\IN\1740 <e1>cisplatin</e1>_11\NN\1740 ,_12\,\1740 developed_13\VBD\1753788 an_14\DT\6697703 irreversible_15\JJ\1740 lethal_16\JJ\1740 renal_17\JJ\1740 failure_18\NN\66216 with_19\IN\1740 anuria_20\NN\14061805 ,_21\,\1740 the_22\DT\1740 day_23\NN\15154774 after_24\IN\1740 5_25\CD\13741022 g/m2_26\NN\1740 bolus_27\NN\13899404 ifosfamide_28\NN\1740 ._29\.\1740
D002945_D051437 NONE a_0\DT\13649268 sixty-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 advanced_4\JJ\1740 breast_5\NN\5225090 cancer_6\NN\14239425 ,_7\,\1740 previously_8\RB\1740 treated_9\VBN\2376958 with_10\IN\1740 <e1>cisplatin</e1>_11\NN\1740 ,_12\,\1740 developed_13\VBD\1753788 an_14\DT\6697703 irreversible_15\JJ\1740 lethal_16\JJ\1740 <e2>renal_17\JJ\1740 failure</e2>_18\NN\66216 with_19\IN\1740 anuria_20\NN\14061805 ,_21\,\1740 the_22\DT\1740 day_23\NN\15154774 after_24\IN\1740 5_25\CD\13741022 g/m2_26\NN\1740 bolus_27\NN\13899404 ifosfamide_28\NN\1740 ._29\.\1740
D002945_D001002 NONE a_0\DT\13649268 sixty-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 advanced_4\JJ\1740 breast_5\NN\5225090 cancer_6\NN\14239425 ,_7\,\1740 previously_8\RB\1740 treated_9\VBN\2376958 with_10\IN\1740 <e1>cisplatin</e1>_11\NN\1740 ,_12\,\1740 developed_13\VBD\1753788 an_14\DT\6697703 irreversible_15\JJ\1740 lethal_16\JJ\1740 renal_17\JJ\1740 failure_18\NN\66216 with_19\IN\1740 <e2>anuria</e2>_20\NN\14061805 ,_21\,\1740 the_22\DT\1740 day_23\NN\15154774 after_24\IN\1740 5_25\CD\13741022 g/m2_26\NN\1740 bolus_27\NN\13899404 ifosfamide_28\NN\1740 ._29\.\1740
D002945_D001002 NONE we_0\PRP\1740 strongly_1\RB\1740 suspect_2\VBP\916909 that_3\IN\1740 this_4\DT\1740 lethal_5\JJ\1740 <e2>anuria</e2>_6\NN\14061805 was_7\VBD\836236 mainly_8\RB\1740 due_9\JJ\1740 to_10\TO\1740 ifosfamide_11\NN\1740 ,_12\,\1740 occurring_13\VBG\2623529 in_14\IN\13603305 a_15\DT\13649268 patient_16\NN\9898892 having_17\VBG\2108377 received_18\VBN\2210855 previous_19\JJ\1740 <e1>cisplatin</e1>_20\NN\1740 chemotherapy_21\NN\661091 and_22\CC\1740 with_23\IN\1740 poor_24\JJ\1740 kidney_25\NN\5333259 perfusion_26\NN\320852 due_27\JJ\1740 to_28\TO\1740 transient_29\JJ\1740 hypotension_30\NN\14057371 ._31\.\1740
D007069_D051437 NONE a_0\DT\13649268 sixty-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 advanced_4\JJ\1740 breast_5\NN\5225090 cancer_6\NN\14239425 ,_7\,\1740 previously_8\RB\1740 treated_9\VBN\2376958 with_10\IN\1740 cisplatin_11\NN\1740 ,_12\,\1740 developed_13\VBD\1753788 an_14\DT\6697703 irreversible_15\JJ\1740 lethal_16\JJ\1740 <e2>renal_17\JJ\1740 failure</e2>_18\NN\66216 with_19\IN\1740 anuria_20\NN\14061805 ,_21\,\1740 the_22\DT\1740 day_23\NN\15154774 after_24\IN\1740 5_25\CD\13741022 g/m2_26\NN\1740 bolus_27\NN\13899404 <e1>ifosfamide</e1>_28\NN\1740 ._29\.\1740
D007069_D007022 NONE we_0\PRP\1740 strongly_1\RB\1740 suspect_2\VBP\916909 that_3\IN\1740 this_4\DT\1740 lethal_5\JJ\1740 anuria_6\NN\14061805 was_7\VBD\836236 mainly_8\RB\1740 due_9\JJ\1740 to_10\TO\1740 <e1>ifosfamide</e1>_11\NN\1740 ,_12\,\1740 occurring_13\VBG\2623529 in_14\IN\13603305 a_15\DT\13649268 patient_16\NN\9898892 having_17\VBG\2108377 received_18\VBN\2210855 previous_19\JJ\1740 cisplatin_20\NN\1740 chemotherapy_21\NN\661091 and_22\CC\1740 with_23\IN\1740 poor_24\JJ\1740 kidney_25\NN\5333259 perfusion_26\NN\320852 due_27\JJ\1740 to_28\TO\1740 transient_29\JJ\1740 <e2>hypotension</e2>_30\NN\14057371 ._31\.\1740
D002945_D007022 NONE we_0\PRP\1740 strongly_1\RB\1740 suspect_2\VBP\916909 that_3\IN\1740 this_4\DT\1740 lethal_5\JJ\1740 anuria_6\NN\14061805 was_7\VBD\836236 mainly_8\RB\1740 due_9\JJ\1740 to_10\TO\1740 ifosfamide_11\NN\1740 ,_12\,\1740 occurring_13\VBG\2623529 in_14\IN\13603305 a_15\DT\13649268 patient_16\NN\9898892 having_17\VBG\2108377 received_18\VBN\2210855 previous_19\JJ\1740 <e1>cisplatin</e1>_20\NN\1740 chemotherapy_21\NN\661091 and_22\CC\1740 with_23\IN\1740 poor_24\JJ\1740 kidney_25\NN\5333259 perfusion_26\NN\320852 due_27\JJ\1740 to_28\TO\1740 transient_29\JJ\1740 <e2>hypotension</e2>_30\NN\14057371 ._31\.\1740
16586083
D016861_D009203 CID randomised_0\VBN\278117 clinical_1\JJ\1740 trials_2\NNS\786195 and_3\CC\1740 observational_4\JJ\1740 studies_5\NNS\635850 have_6\VBP\2108377 shown_7\VBN\2137132 an_8\DT\6697703 increased_9\VBN\169651 risk_10\NN\14541044 of_11\IN\1740 <e2>myocardial_12\JJ\1740 infarction</e2>_13\NN\14204950 ,_14\,\1740 stroke_15\NN\556313 ,_16\,\1740 hypertension_17\NN\14057371 and_18\CC\1740 heart_19\NN\5919034 failure_20\NN\66216 during_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>cyclooxygenase_24\NN\14732946 inhibitors</e1>_25\NNS\20090 ._26\.\1740
D016861_D020521 CID randomised_0\VBN\278117 clinical_1\JJ\1740 trials_2\NNS\786195 and_3\CC\1740 observational_4\JJ\1740 studies_5\NNS\635850 have_6\VBP\2108377 shown_7\VBN\2137132 an_8\DT\6697703 increased_9\VBN\169651 risk_10\NN\14541044 of_11\IN\1740 myocardial_12\JJ\1740 infarction_13\NN\14204950 ,_14\,\1740 <e2>stroke</e2>_15\NN\556313 ,_16\,\1740 hypertension_17\NN\14057371 and_18\CC\1740 heart_19\NN\5919034 failure_20\NN\66216 during_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>cyclooxygenase_24\NN\14732946 inhibitors</e1>_25\NNS\20090 ._26\.\1740
D016861_D006973 CID randomised_0\VBN\278117 clinical_1\JJ\1740 trials_2\NNS\786195 and_3\CC\1740 observational_4\JJ\1740 studies_5\NNS\635850 have_6\VBP\2108377 shown_7\VBN\2137132 an_8\DT\6697703 increased_9\VBN\169651 risk_10\NN\14541044 of_11\IN\1740 myocardial_12\JJ\1740 infarction_13\NN\14204950 ,_14\,\1740 stroke_15\NN\556313 ,_16\,\1740 <e2>hypertension</e2>_17\NN\14057371 and_18\CC\1740 heart_19\NN\5919034 failure_20\NN\66216 during_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>cyclooxygenase_24\NN\14732946 inhibitors</e1>_25\NNS\20090 ._26\.\1740
D016861_D006333 CID randomised_0\VBN\278117 clinical_1\JJ\1740 trials_2\NNS\786195 and_3\CC\1740 observational_4\JJ\1740 studies_5\NNS\635850 have_6\VBP\2108377 shown_7\VBN\2137132 an_8\DT\6697703 increased_9\VBN\169651 risk_10\NN\14541044 of_11\IN\1740 myocardial_12\JJ\1740 infarction_13\NN\14204950 ,_14\,\1740 stroke_15\NN\556313 ,_16\,\1740 hypertension_17\NN\14057371 and_18\CC\1740 <e2>heart_19\NN\5919034 failure</e2>_20\NN\66216 during_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>cyclooxygenase_24\NN\14732946 inhibitors</e1>_25\NNS\20090 ._26\.\1740
C109794_D002318 NONE diagnostic_0\JJ\1740 markers_1\NNS\21939 such_2\JJ\1740 as_3\IN\14622893 <e1>n-terminal_4\JJ\1740 pro_5\JJ\1740 brain_6\NN\5462674 natriuretic_7\JJ\1740 peptide</e1>_8\NN\14724264 (_9\-LRB-\1740 nt-probnp_10\NN\1740 )_11\-RRB-\1740 or_12\CC\3541091 high-sensitive_13\JJ\1740 c-reactive_14\JJ\1740 protein_15\NN\14944888 might_16\MD\5029706 help_17\VB\2556126 in_18\IN\13603305 the_19\DT\1740 early_20\JJ\1740 identification_21\NN\151497 of_22\IN\1740 patients_23\NNS\9898892 at_24\IN\14622893 risk_25\NN\14541044 ,_26\,\1740 thus_27\RB\1740 avoiding_28\VBG\2452885 the_29\DT\1740 occurrence_30\NN\29378 of_31\IN\1740 serious_32\JJ\1740 <e2>cardiovascular_33\JJ\1740 toxicity</e2>_34\NN\13576101 ._35\.\1740
C109794_D002318 NONE diagnostic_0\JJ\1740 markers_1\NNS\21939 such_2\JJ\1740 as_3\IN\14622893 n-terminal_4\JJ\1740 pro_5\JJ\1740 brain_6\NN\5462674 natriuretic_7\JJ\1740 peptide_8\NN\14724264 (_9\-LRB-\1740 <e1>nt-probnp</e1>_10\NN\1740 )_11\-RRB-\1740 or_12\CC\3541091 high-sensitive_13\JJ\1740 c-reactive_14\JJ\1740 protein_15\NN\14944888 might_16\MD\5029706 help_17\VB\2556126 in_18\IN\13603305 the_19\DT\1740 early_20\JJ\1740 identification_21\NN\151497 of_22\IN\1740 patients_23\NNS\9898892 at_24\IN\14622893 risk_25\NN\14541044 ,_26\,\1740 thus_27\RB\1740 avoiding_28\VBG\2452885 the_29\DT\1740 occurrence_30\NN\29378 of_31\IN\1740 serious_32\JJ\1740 <e2>cardiovascular_33\JJ\1740 toxicity</e2>_34\NN\13576101 ._35\.\1740
6615052
D006493_D013921 CID <e1>heparin-induced</e1>_0\JJ\1740 <e2>thrombocytopenia</e2>_1\NN\14189204 ,_2\,\1740 thrombosis_3\NN\14100769 ,_4\,\1740 and_5\CC\1740 hemorrhage_6\NN\14285662 ._7\.\1740
D006493_D013921 CID sixty-two_0\CD\1740 patients_1\NNS\9898892 with_2\IN\1740 a_3\DT\13649268 <e1>heparin-induced</e1>_4\JJ\1740 <e2>thrombocytopenia</e2>_5\NN\14189204 are_6\VBP\836236 reported_7\VBN\831651 ._8\.\1740
D006493_D013927 NONE <e1>heparin-induced</e1>_0\JJ\1740 thrombocytopenia_1\NN\14189204 ,_2\,\1740 <e2>thrombosis</e2>_3\NN\14100769 ,_4\,\1740 and_5\CC\1740 hemorrhage_6\NN\14285662 ._7\.\1740
D006493_D006470 CID <e1>heparin-induced</e1>_0\JJ\1740 thrombocytopenia_1\NN\14189204 ,_2\,\1740 thrombosis_3\NN\14100769 ,_4\,\1740 and_5\CC\1740 <e2>hemorrhage</e2>_6\NN\14285662 ._7\.\1740
D006493_D006470 CID clinical_0\JJ\1740 manifestations_1\NNS\7321772 of_2\IN\1740 this_3\DT\1740 disorder_4\NN\14034177 include_5\VBP\690614 <e2>hemorrhage</e2>_6\NN\14285662 or_7\CC\3541091 ,_8\,\1740 more_9\RBR\1740 frequently_10\RB\1740 ,_11\,\1740 thromboembolic_12\NN\1740 events_13\NNS\23100 in_14\IN\13603305 patients_15\NNS\9898892 receiving_16\VBG\2210855 <e1>heparin</e1>_17\NN\2718259 ._18\.\1740
D006493_D013923 CID clinical_0\JJ\1740 manifestations_1\NNS\7321772 of_2\IN\1740 this_3\DT\1740 disorder_4\NN\14034177 include_5\VBP\690614 hemorrhage_6\NN\14285662 or_7\CC\3541091 ,_8\,\1740 more_9\RBR\1740 frequently_10\RB\1740 ,_11\,\1740 <e2>thromboembolic</e2>_12\NN\1740 events_13\NNS\23100 in_14\IN\13603305 patients_15\NNS\9898892 receiving_16\VBG\2210855 <e1>heparin</e1>_17\NN\2718259 ._18\.\1740
D006493_D001791 NONE laboratory_0\JJ\1740 testing_1\NN\639556 has_2\VBZ\2108377 revealed_3\VBN\2137132 <e2>a_4\DT\13649268 falling_5\VBG\1835496 platelet_6\NN\5432736 count</e2>_7\NN\13582013 ,_8\,\1740 increased_9\VBD\169651 resistance_10\NN\37396 to_11\TO\1740 <e1>heparin</e1>_12\NN\2718259 ,_13\,\1740 and_14\CC\1740 aggregation_15\NN\31264 of_16\IN\1740 platelets_17\NNS\5432736 by_18\IN\1740 the_19\DT\1740 patient_20\NN\9898892 's_21\POS\1740 plasma_22\NN\5398023 when_23\WRB\1740 heparin_24\NN\2718259 is_25\VBZ\836236 added_26\VBN\156601 ._27\.\1740
D006493_D001791 NONE laboratory_0\JJ\1740 testing_1\NN\639556 has_2\VBZ\2108377 revealed_3\VBN\2137132 <e2>a_4\DT\13649268 falling_5\VBG\1835496 platelet_6\NN\5432736 count</e2>_7\NN\13582013 ,_8\,\1740 increased_9\VBD\169651 resistance_10\NN\37396 to_11\TO\1740 heparin_12\NN\2718259 ,_13\,\1740 and_14\CC\1740 aggregation_15\NN\31264 of_16\IN\1740 platelets_17\NNS\5432736 by_18\IN\1740 the_19\DT\1740 patient_20\NN\9898892 's_21\POS\1740 plasma_22\NN\5398023 when_23\WRB\1740 <e1>heparin</e1>_24\NN\2718259 is_25\VBZ\836236 added_26\VBN\156601 ._27\.\1740
D006493_D001791 NONE if_0\IN\1740 the_1\DT\1740 platelet_2\NN\5432736 count_3\NN\13582013 falls_4\VBZ\1835496 to_5\IN\1740 less_6\JJR\1740 than_7\IN\1740 100,000/mm3_8\NN\1740 ,_9\,\1740 while_10\IN\15122231 the_11\DT\1740 patient_12\NN\9898892 is_13\VBZ\836236 receiving_14\VBG\2210855 <e1>heparin</e1>_15\NN\2718259 ,_16\,\1740 <e2>platelet_17\NN\5432736 aggregation</e2>_18\NN\31264 testing_19\NN\639556 ,_20\,\1740 using_21\VBG\1156834 the_22\DT\1740 patient_23\NN\9898892 's_24\POS\1740 plasma_25\NN\5398023 ,_26\,\1740 is_27\VBZ\836236 indicated_28\VBN\952524 ._29\.\1740
14648024
D014212_D004893 CID <e1>all-_0\JJ\1740 trans-retinoic_1\JJ\1740 acid-induced</e1>_2\JJ\1740 <e2>erythema_3\NN\14227218 nodosum</e2>_4\NN\1740 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 acute_8\JJ\1740 promyelocytic_9\JJ\1740 leukemia_10\NN\14239918 ._11\.\1740
D014212_D004893 CID <e2>erythema_0\NN\14227218 nodosum</e2>_1\NN\1740 associated_2\VBN\628491 with_3\IN\1740 <e1>all-_4\JJ\1740 trans-retinoic_5\JJ\1740 acid</e1>_6\NN\14818238 (_7\-LRB-\1740 atra_8\NN\1740 )_9\-RRB-\1740 for_10\IN\1740 acute_11\JJ\1740 promyelocytic_12\JJ\1740 leukemia_13\NN\14239918 (_14\-LRB-\1740 apl_15\NN\1740 )_16\-RRB-\1740 is_17\VBZ\836236 very_18\RB\1740 rare_19\JJ\1740 ._20\.\1740
D014212_D004893 CID <e2>erythema_0\NN\14227218 nodosum</e2>_1\NN\1740 associated_2\VBN\628491 with_3\IN\1740 all-_4\JJ\1740 trans-retinoic_5\JJ\1740 acid_6\NN\14818238 (_7\-LRB-\1740 <e1>atra</e1>_8\NN\1740 )_9\-RRB-\1740 for_10\IN\1740 acute_11\JJ\1740 promyelocytic_12\JJ\1740 leukemia_13\NN\14239918 (_14\-LRB-\1740 apl_15\NN\1740 )_16\-RRB-\1740 is_17\VBZ\836236 very_18\RB\1740 rare_19\JJ\1740 ._20\.\1740
D014212_D004893 CID we_0\PRP\1740 describe_1\VBP\1001294 four_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 classic_5\JJ\1740 apl_6\NN\1740 who_7\WP\8299493 developed_8\VBD\1753788 <e2>erythema_9\NN\14227218 nodosum</e2>_10\NN\1740 during_11\IN\1740 <e1>atra</e1>_12\NN\1740 therapy_13\NN\657604 ._14\.\1740
D014212_D004893 CID fever_0\NNS\14299637 and_1\CC\1740 subsequent_2\JJ\1740 multiple_3\JJ\1740 painful_4\JJ\1740 <e2>erythematous_5\JJ\1740 nodules</e2>_6\NNS\5264913 over_7\IN\5867413 extremities_8\NNS\5225090 developed_9\VBN\1753788 on_10\IN\1740 d11_11\NN\1740 ,_12\,\1740 d16_13\NN\1740 ,_14\,\1740 d17_15\NN\1740 ,_16\,\1740 and_17\CC\1740 d19_18\NN\1740 ,_19\,\1740 respectively_20\RB\1740 ,_21\,\1740 after_22\IN\1740 <e1>atra</e1>_23\NN\1740 therapy_24\NN\657604 ._25\.\1740
D014212_D004893 CID <e1>atra</e1>_0\NN\1740 seemed_1\VBD\2604760 to_2\TO\1740 be_3\VB\836236 the_4\DT\1740 most_5\RBS\1740 possible_6\JJ\1740 etiology_7\NN\7326557 of_8\IN\1740 <e2>erythema_9\NN\14227218 nodosum</e2>_10\NN\1740 in_11\IN\13603305 our_12\PRP$\1740 patients_13\NNS\9898892 ._14\.\1740
D014212_D004893 CID short-term_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 steroid_3\NN\14727670 is_4\VBZ\836236 very_5\RB\1740 effective_6\JJ\1740 in_7\IN\13603305 <e1>atra-induced</e1>_8\JJ\1740 <e2>erythema_9\NN\14227218 nodosum</e2>_10\NN\1740 ._11\.\1740
D014212_D015473 NONE <e1>all-_0\JJ\1740 trans-retinoic_1\JJ\1740 acid-induced</e1>_2\JJ\1740 erythema_3\NN\14227218 nodosum_4\NN\1740 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 <e2>acute_8\JJ\1740 promyelocytic_9\JJ\1740 leukemia</e2>_10\NN\14239918 ._11\.\1740
D014212_D015473 NONE erythema_0\NN\14227218 nodosum_1\NN\1740 associated_2\VBN\628491 with_3\IN\1740 <e1>all-_4\JJ\1740 trans-retinoic_5\JJ\1740 acid</e1>_6\NN\14818238 (_7\-LRB-\1740 atra_8\NN\1740 )_9\-RRB-\1740 for_10\IN\1740 <e2>acute_11\JJ\1740 promyelocytic_12\JJ\1740 leukemia</e2>_13\NN\14239918 (_14\-LRB-\1740 apl_15\NN\1740 )_16\-RRB-\1740 is_17\VBZ\836236 very_18\RB\1740 rare_19\JJ\1740 ._20\.\1740
D014212_D015473 NONE erythema_0\NN\14227218 nodosum_1\NN\1740 associated_2\VBN\628491 with_3\IN\1740 <e1>all-_4\JJ\1740 trans-retinoic_5\JJ\1740 acid</e1>_6\NN\14818238 (_7\-LRB-\1740 atra_8\NN\1740 )_9\-RRB-\1740 for_10\IN\1740 acute_11\JJ\1740 promyelocytic_12\JJ\1740 leukemia_13\NN\14239918 (_14\-LRB-\1740 <e2>apl</e2>_15\NN\1740 )_16\-RRB-\1740 is_17\VBZ\836236 very_18\RB\1740 rare_19\JJ\1740 ._20\.\1740
D014212_D015473 NONE erythema_0\NN\14227218 nodosum_1\NN\1740 associated_2\VBN\628491 with_3\IN\1740 all-_4\JJ\1740 trans-retinoic_5\JJ\1740 acid_6\NN\14818238 (_7\-LRB-\1740 <e1>atra</e1>_8\NN\1740 )_9\-RRB-\1740 for_10\IN\1740 <e2>acute_11\JJ\1740 promyelocytic_12\JJ\1740 leukemia</e2>_13\NN\14239918 (_14\-LRB-\1740 apl_15\NN\1740 )_16\-RRB-\1740 is_17\VBZ\836236 very_18\RB\1740 rare_19\JJ\1740 ._20\.\1740
D014212_D015473 NONE erythema_0\NN\14227218 nodosum_1\NN\1740 associated_2\VBN\628491 with_3\IN\1740 all-_4\JJ\1740 trans-retinoic_5\JJ\1740 acid_6\NN\14818238 (_7\-LRB-\1740 <e1>atra</e1>_8\NN\1740 )_9\-RRB-\1740 for_10\IN\1740 acute_11\JJ\1740 promyelocytic_12\JJ\1740 leukemia_13\NN\14239918 (_14\-LRB-\1740 <e2>apl</e2>_15\NN\1740 )_16\-RRB-\1740 is_17\VBZ\836236 very_18\RB\1740 rare_19\JJ\1740 ._20\.\1740
D014212_D015473 NONE we_0\PRP\1740 describe_1\VBP\1001294 four_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 classic_5\JJ\1740 <e2>apl</e2>_6\NN\1740 who_7\WP\8299493 developed_8\VBD\1753788 erythema_9\NN\14227218 nodosum_10\NN\1740 during_11\IN\1740 <e1>atra</e1>_12\NN\1740 therapy_13\NN\657604 ._14\.\1740
D014212_D005334 CID <e2>fever</e2>_0\NNS\14299637 and_1\CC\1740 subsequent_2\JJ\1740 multiple_3\JJ\1740 painful_4\JJ\1740 erythematous_5\JJ\1740 nodules_6\NNS\5264913 over_7\IN\5867413 extremities_8\NNS\5225090 developed_9\VBN\1753788 on_10\IN\1740 d11_11\NN\1740 ,_12\,\1740 d16_13\NN\1740 ,_14\,\1740 d17_15\NN\1740 ,_16\,\1740 and_17\CC\1740 d19_18\NN\1740 ,_19\,\1740 respectively_20\RB\1740 ,_21\,\1740 after_22\IN\1740 <e1>atra</e1>_23\NN\1740 therapy_24\NN\657604 ._25\.\1740
D014212_D010146 NONE fever_0\NNS\14299637 and_1\CC\1740 subsequent_2\JJ\1740 multiple_3\JJ\1740 <e2>painful</e2>_4\JJ\1740 erythematous_5\JJ\1740 nodules_6\NNS\5264913 over_7\IN\5867413 extremities_8\NNS\5225090 developed_9\VBN\1753788 on_10\IN\1740 d11_11\NN\1740 ,_12\,\1740 d16_13\NN\1740 ,_14\,\1740 d17_15\NN\1740 ,_16\,\1740 and_17\CC\1740 d19_18\NN\1740 ,_19\,\1740 respectively_20\RB\1740 ,_21\,\1740 after_22\IN\1740 <e1>atra</e1>_23\NN\1740 therapy_24\NN\657604 ._25\.\1740
D013256_D004893 NONE short-term_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 <e1>steroid</e1>_3\NN\14727670 is_4\VBZ\836236 very_5\RB\1740 effective_6\JJ\1740 in_7\IN\13603305 atra-induced_8\JJ\1740 <e2>erythema_9\NN\14227218 nodosum</e2>_10\NN\1740 ._11\.\1740
17490864
D000661_D006948 CID <e1>amphetamine-induced</e1>_0\JJ\1740 <e2>locomotor_1\NN\1740 hyperactivity</e2>_2\NN\14052403 was_3\VBD\836236 similar_4\JJ\1740 in_5\IN\13603305 all_6\DT\1740 groups_7\NNS\2137 ._8\.\1740
21418164
D008130_D064420 NONE <e1>ccnu</e1>_0\NN\1740 (_1\-LRB-\1740 lomustine_2\NN\2722458 )_3\-RRB-\1740 <e2>toxicity</e2>_4\NN\13576101 in_5\IN\13603305 dogs_6\NNS\2083346 :_7\:\1740 a_8\DT\13649268 retrospective_9\JJ\1740 study_10\NN\635850 (_11\-LRB-\1740 2002_12\CD\1740 -_13\SYM\1740 07_14\CD\1740 )_15\-RRB-\1740 ._16\.\1740
D008130_D064420 NONE ccnu_0\NN\1740 (_1\-LRB-\1740 <e1>lomustine</e1>_2\NN\2722458 )_3\-RRB-\1740 <e2>toxicity</e2>_4\NN\13576101 in_5\IN\13603305 dogs_6\NNS\2083346 :_7\:\1740 a_8\DT\13649268 retrospective_9\JJ\1740 study_10\NN\635850 (_11\-LRB-\1740 2002_12\CD\1740 -_13\SYM\1740 07_14\CD\1740 )_15\-RRB-\1740 ._16\.\1740
D008130_D064420 NONE results_0\NNS\34213 :_1\:\1740 of_2\IN\1740 the_3\DT\1740 206_4\CD\1740 dogs_5\NNS\2083346 treated_6\VBN\2376958 with_7\IN\1740 <e1>ccnu</e1>_8\NNS\1740 ,_9\,\1740 185_10\CD\1740 met_11\VBD\1182709 the_12\DT\1740 inclusion_13\NN\13927383 criteria_14\NNS\13577171 for_15\IN\1740 at_16\IN\14622893 least_17\JJS\1740 one_18\CD\13741022 class_19\NN\7951464 of_20\IN\1740 <e2>toxicity</e2>_21\NN\13576101 ._22\.\1740
D008130_D064420 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>ccnu-associated</e1>_2\JJ\1740 <e2>toxicity</e2>_3\NN\13576101 in_4\IN\13603305 dogs_5\NNS\2083346 is_6\VBZ\836236 common_7\JJ\1740 ,_8\,\1740 but_9\CC\1740 is_10\VBZ\836236 usually_11\RB\1740 not_12\RB\1740 life_13\NN\13954253 threatening_14\VBG\2603699 ._15\.\1740
D008130_D006402 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>haematological_7\JJ\1740 ,_8\,\1740 renal_9\JJ\1740 ,_10\,\1740 hepatic_11\JJ\1740 and_12\CC\1740 gastrointestinal_13\JJ\1740 toxicities</e2>_14\NNS\13576101 in_15\IN\13603305 tumour-bearing_16\JJ\1740 dogs_17\NNS\2083346 receiving_18\VBG\2210855 <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea</e1>_19\CD\1740 (_20\-LRB-\1740 ccnu_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D008130_D006402 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>haematological_7\JJ\1740 ,_8\,\1740 renal_9\JJ\1740 ,_10\,\1740 hepatic_11\JJ\1740 and_12\CC\1740 gastrointestinal_13\JJ\1740 toxicities</e2>_14\NNS\13576101 in_15\IN\13603305 tumour-bearing_16\JJ\1740 dogs_17\NNS\2083346 receiving_18\VBG\2210855 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\CD\1740 (_20\-LRB-\1740 <e1>ccnu</e1>_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D008130_D007674 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>haematological_7\JJ\1740 ,_8\,\1740 renal_9\JJ\1740 ,_10\,\1740 hepatic_11\JJ\1740 and_12\CC\1740 gastrointestinal_13\JJ\1740 toxicities</e2>_14\NNS\13576101 in_15\IN\13603305 tumour-bearing_16\JJ\1740 dogs_17\NNS\2083346 receiving_18\VBG\2210855 <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea</e1>_19\CD\1740 (_20\-LRB-\1740 ccnu_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D008130_D007674 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>haematological_7\JJ\1740 ,_8\,\1740 renal_9\JJ\1740 ,_10\,\1740 hepatic_11\JJ\1740 and_12\CC\1740 gastrointestinal_13\JJ\1740 toxicities</e2>_14\NNS\13576101 in_15\IN\13603305 tumour-bearing_16\JJ\1740 dogs_17\NNS\2083346 receiving_18\VBG\2210855 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\CD\1740 (_20\-LRB-\1740 <e1>ccnu</e1>_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D008130_D056486 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>haematological_7\JJ\1740 ,_8\,\1740 renal_9\JJ\1740 ,_10\,\1740 hepatic_11\JJ\1740 and_12\CC\1740 gastrointestinal_13\JJ\1740 toxicities</e2>_14\NNS\13576101 in_15\IN\13603305 tumour-bearing_16\JJ\1740 dogs_17\NNS\2083346 receiving_18\VBG\2210855 <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea</e1>_19\CD\1740 (_20\-LRB-\1740 ccnu_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D008130_D056486 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>haematological_7\JJ\1740 ,_8\,\1740 renal_9\JJ\1740 ,_10\,\1740 hepatic_11\JJ\1740 and_12\CC\1740 gastrointestinal_13\JJ\1740 toxicities</e2>_14\NNS\13576101 in_15\IN\13603305 tumour-bearing_16\JJ\1740 dogs_17\NNS\2083346 receiving_18\VBG\2210855 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\CD\1740 (_20\-LRB-\1740 <e1>ccnu</e1>_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D008130_D005767 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>haematological_7\JJ\1740 ,_8\,\1740 renal_9\JJ\1740 ,_10\,\1740 hepatic_11\JJ\1740 and_12\CC\1740 gastrointestinal_13\JJ\1740 toxicities</e2>_14\NNS\13576101 in_15\IN\13603305 tumour-bearing_16\JJ\1740 dogs_17\NNS\2083346 receiving_18\VBG\2210855 <e1>1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea</e1>_19\CD\1740 (_20\-LRB-\1740 ccnu_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D008130_D005767 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 the_4\DT\1740 incidence_5\NN\13821570 of_6\IN\1740 <e2>haematological_7\JJ\1740 ,_8\,\1740 renal_9\JJ\1740 ,_10\,\1740 hepatic_11\JJ\1740 and_12\CC\1740 gastrointestinal_13\JJ\1740 toxicities</e2>_14\NNS\13576101 in_15\IN\13603305 tumour-bearing_16\JJ\1740 dogs_17\NNS\2083346 receiving_18\VBG\2210855 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea_19\CD\1740 (_20\-LRB-\1740 <e1>ccnu</e1>_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D008130_D008223 NONE <e1>ccnu</e1>_0\NNS\1740 was_1\VBD\836236 used_2\VBN\1156834 most_3\RBS\1740 commonly_4\RB\1740 in_5\IN\13603305 the_6\DT\1740 treatment_7\NN\654885 of_8\IN\1740 <e2>lymphoma</e2>_9\NN\14239918 ,_10\,\1740 mast_11\NN\4267577 cell_12\NN\3080309 tumour_13\NN\14234074 ,_14\,\1740 brain_15\NN\5462674 tumour_16\NN\14234074 ,_17\,\1740 histiocytic_18\JJ\1740 tumours_19\NNS\14234074 and_20\CC\1740 epitheliotropic_21\JJ\1740 lymphoma_22\NN\14239918 ._23\.\1740
D008130_D008223 NONE <e1>ccnu</e1>_0\NNS\1740 was_1\VBD\836236 used_2\VBN\1156834 most_3\RBS\1740 commonly_4\RB\1740 in_5\IN\13603305 the_6\DT\1740 treatment_7\NN\654885 of_8\IN\1740 lymphoma_9\NN\14239918 ,_10\,\1740 mast_11\NN\4267577 cell_12\NN\3080309 tumour_13\NN\14234074 ,_14\,\1740 brain_15\NN\5462674 tumour_16\NN\14234074 ,_17\,\1740 histiocytic_18\JJ\1740 tumours_19\NNS\14234074 and_20\CC\1740 <e2>epitheliotropic_21\JJ\1740 lymphoma</e2>_22\NN\14239918 ._23\.\1740
D008130_D034801 NONE <e1>ccnu</e1>_0\NNS\1740 was_1\VBD\836236 used_2\VBN\1156834 most_3\RBS\1740 commonly_4\RB\1740 in_5\IN\13603305 the_6\DT\1740 treatment_7\NN\654885 of_8\IN\1740 lymphoma_9\NN\14239918 ,_10\,\1740 <e2>mast_11\NN\4267577 cell_12\NN\3080309 tumour</e2>_13\NN\14234074 ,_14\,\1740 brain_15\NN\5462674 tumour_16\NN\14234074 ,_17\,\1740 histiocytic_18\JJ\1740 tumours_19\NNS\14234074 and_20\CC\1740 epitheliotropic_21\JJ\1740 lymphoma_22\NN\14239918 ._23\.\1740
D008130_D001932 NONE <e1>ccnu</e1>_0\NNS\1740 was_1\VBD\836236 used_2\VBN\1156834 most_3\RBS\1740 commonly_4\RB\1740 in_5\IN\13603305 the_6\DT\1740 treatment_7\NN\654885 of_8\IN\1740 lymphoma_9\NN\14239918 ,_10\,\1740 mast_11\NN\4267577 cell_12\NN\3080309 tumour_13\NN\14234074 ,_14\,\1740 <e2>brain_15\NN\5462674 tumour</e2>_16\NN\14234074 ,_17\,\1740 histiocytic_18\JJ\1740 tumours_19\NNS\14234074 and_20\CC\1740 epitheliotropic_21\JJ\1740 lymphoma_22\NN\14239918 ._23\.\1740
D008130_D015620 NONE <e1>ccnu</e1>_0\NNS\1740 was_1\VBD\836236 used_2\VBN\1156834 most_3\RBS\1740 commonly_4\RB\1740 in_5\IN\13603305 the_6\DT\1740 treatment_7\NN\654885 of_8\IN\1740 lymphoma_9\NN\14239918 ,_10\,\1740 mast_11\NN\4267577 cell_12\NN\3080309 tumour_13\NN\14234074 ,_14\,\1740 brain_15\NN\5462674 tumour_16\NN\14234074 ,_17\,\1740 <e2>histiocytic_18\JJ\1740 tumours</e2>_19\NNS\14234074 and_20\CC\1740 epitheliotropic_21\JJ\1740 lymphoma_22\NN\14239918 ._23\.\1740
D000409_D064420 NONE potential_0\JJ\1740 renal_1\JJ\1740 <e2>toxicity</e2>_2\NN\13576101 and_3\CC\1740 elevated_4\JJ\1740 <e1>alanine</e1>_5\NN\14601829 transaminase_6\NN\15077571 (_7\-LRB-\1740 alt_8\NN\13836371 )_9\-RRB-\1740 concentration_10\NN\4916342 were_11\VBD\836236 reported_12\VBN\831651 in_13\IN\13603305 12.2_14\CD\1740 %_15\NN\1740 and_16\CC\1740 48.8_17\CD\1740 %_18\NN\1740 of_19\IN\1740 dogs_20\NNS\2083346 ,_21\,\1740 respectively_22\RB\1740 ._23\.\1740
9022662
D010389_D002819 CID <e1>pemoline</e1>_0\NN\1740 induced_1\VBD\1627355 acute_2\JJ\1740 <e2>choreoathetosis</e2>_3\NN\1740 :_4\:\1740 case_5\NN\7283608 report_6\NN\6470073 and_7\CC\1740 review_8\NN\5733583 of_9\IN\1740 the_10\DT\1740 literature_11\NN\6362953 ._12\.\1740
D010389_D002819 CID the_0\DT\1740 following_1\VBG\1835496 case_2\NN\7283608 describes_3\VBZ\1001294 two_4\CD\13741022 children_5\NNS\9622049 acutely_6\RB\1740 poisoned_7\VBN\2579447 with_8\IN\1740 <e1>pemoline</e1>_9\NN\1740 who_10\WP\8299493 experienced_11\VBD\2108377 profound_12\JJ\1740 <e2>choreoathetosis</e2>_13\NN\1740 ._14\.\1740
D010389_D002819 CID the_0\DT\1740 possibility_1\NN\5944958 of_2\IN\1740 <e2>choreoathetoid</e2>_3\NN\1740 movements_4\NNS\191142 should_5\MD\1740 be_6\VB\836236 considered_7\VBN\689344 in_8\IN\13603305 patients_9\NNS\9898892 presenting_10\VBG\2137132 after_11\IN\1740 <e1>pemoline</e1>_12\NN\1740 overdose_13\NN\1740 ._14\.\1740
D010389_D001264 CID <e1>pemoline</e1>_0\NN\1740 induced_1\VBD\1627355 acute_2\JJ\1740 <e2>choreoathetosis</e2>_3\NN\1740 :_4\:\1740 case_5\NN\7283608 report_6\NN\6470073 and_7\CC\1740 review_8\NN\5733583 of_9\IN\1740 the_10\DT\1740 literature_11\NN\6362953 ._12\.\1740
D010389_D001264 CID the_0\DT\1740 following_1\VBG\1835496 case_2\NN\7283608 describes_3\VBZ\1001294 two_4\CD\13741022 children_5\NNS\9622049 acutely_6\RB\1740 poisoned_7\VBN\2579447 with_8\IN\1740 <e1>pemoline</e1>_9\NN\1740 who_10\WP\8299493 experienced_11\VBD\2108377 profound_12\JJ\1740 <e2>choreoathetosis</e2>_13\NN\1740 ._14\.\1740
D010389_D001264 CID the_0\DT\1740 possibility_1\NN\5944958 of_2\IN\1740 <e2>choreoathetoid</e2>_3\NN\1740 movements_4\NNS\191142 should_5\MD\1740 be_6\VB\836236 considered_7\VBN\689344 in_8\IN\13603305 patients_9\NNS\9898892 presenting_10\VBG\2137132 after_11\IN\1740 <e1>pemoline</e1>_12\NN\1740 overdose_13\NN\1740 ._14\.\1740
D010389_D001289 NONE background_0\NN\4921011 :_1\:\1740 <e1>pemoline</e1>_2\NN\1740 is_3\VBZ\836236 an_4\DT\6697703 oxazolidine_5\NN\1740 derivative_6\NN\5802185 that_7\WDT\1740 is_8\VBZ\836236 structurally_9\RB\1740 different_10\JJ\1740 from_11\IN\1740 amphetamines_12\NNS\3248958 and_13\CC\1740 used_14\VBN\1156834 in_15\IN\13603305 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 <e2>attention_19\NN\5701944 deficit_20\NN\5113133 disorder</e2>_21\NN\14034177 ._22\.\1740
C064210_D001289 NONE background_0\NN\4921011 :_1\:\1740 pemoline_2\NN\1740 is_3\VBZ\836236 an_4\DT\6697703 <e1>oxazolidine</e1>_5\NN\1740 derivative_6\NN\5802185 that_7\WDT\1740 is_8\VBZ\836236 structurally_9\RB\1740 different_10\JJ\1740 from_11\IN\1740 amphetamines_12\NNS\3248958 and_13\CC\1740 used_14\VBN\1156834 in_15\IN\13603305 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 <e2>attention_19\NN\5701944 deficit_20\NN\5113133 disorder</e2>_21\NN\14034177 ._22\.\1740
D000662_D001289 NONE background_0\NN\4921011 :_1\:\1740 pemoline_2\NN\1740 is_3\VBZ\836236 an_4\DT\6697703 oxazolidine_5\NN\1740 derivative_6\NN\5802185 that_7\WDT\1740 is_8\VBZ\836236 structurally_9\RB\1740 different_10\JJ\1740 from_11\IN\1740 <e1>amphetamines</e1>_12\NNS\3248958 and_13\CC\1740 used_14\VBN\1156834 in_15\IN\13603305 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 <e2>attention_19\NN\5701944 deficit_20\NN\5113133 disorder</e2>_21\NN\14034177 ._22\.\1740
D010389_D009069 NONE <e1>pemoline</e1>_0\NN\1740 has_1\VBZ\2108377 not_2\RB\1740 been_3\VBN\836236 commonly_4\RB\1740 associated_5\VBN\628491 in_6\IN\13603305 the_7\DT\1740 literature_8\NN\6362953 as_9\IN\14622893 a_10\DT\13649268 cause_11\NN\7323922 of_12\IN\1740 acute_13\JJ\1740 <e2>movement_14\NN\191142 disorders</e2>_15\NNS\14034177 ._16\.\1740
D010389_D009069 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>pemoline</e1>_2\NN\1740 associated_3\VBN\628491 <e2>movement_4\NN\191142 disorder</e2>_5\NN\14034177 has_6\VBZ\2108377 been_7\VBN\836236 rarely_8\RB\1740 reported_9\VBN\831651 in_10\IN\13603305 the_11\DT\1740 acute_12\JJ\1740 toxicology_13\NN\6054892 literature_14\NN\6362953 ._15\.\1740
D008774_D001289 NONE the_0\DT\1740 children_1\NNS\9622049 had_2\VBD\2108377 a_3\DT\13649268 medical_4\JJ\1740 history_5\NN\15120823 significant_6\JJ\1740 for_7\IN\1740 <e2>attention_8\NN\5701944 deficit_9\NN\5113133 disorder</e2>_10\NN\14034177 previously_11\RB\1740 treated_12\VBN\2376958 with_13\IN\1740 <e1>methylphenidate</e1>_14\NN\4320126 without_15\IN\1740 success_16\NN\7283608 ._17\.\1740
D001569_D002819 NONE the_0\DT\1740 children_1\NNS\9622049 received_2\VBD\2210855 gastrointestinal_3\JJ\1740 decontamination_4\NN\391599 and_5\CC\1740 high_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 intravenous_9\JJ\1740 <e1>benzodiazepines</e1>_10\NNS\3771443 in_11\IN\13603305 an_12\DT\6697703 attempt_13\NN\407535 to_14\TO\1740 control_15\VB\2422663 the_16\DT\1740 <e2>choreoathetoid</e2>_17\NN\1740 movements_18\NNS\191142 ._19\.\1740
D001569_D001264 NONE the_0\DT\1740 children_1\NNS\9622049 received_2\VBD\2210855 gastrointestinal_3\JJ\1740 decontamination_4\NN\391599 and_5\CC\1740 high_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 intravenous_9\JJ\1740 <e1>benzodiazepines</e1>_10\NNS\3771443 in_11\IN\13603305 an_12\DT\6697703 attempt_13\NN\407535 to_14\TO\1740 control_15\VB\2422663 the_16\DT\1740 <e2>choreoathetoid</e2>_17\NN\1740 movements_18\NNS\191142 ._19\.\1740
D010389_D062787 CID the_0\DT\1740 possibility_1\NN\5944958 of_2\IN\1740 choreoathetoid_3\NN\1740 movements_4\NNS\191142 should_5\MD\1740 be_6\VB\836236 considered_7\VBN\689344 in_8\IN\13603305 patients_9\NNS\9898892 presenting_10\VBG\2137132 after_11\IN\1740 <e1>pemoline</e1>_12\NN\1740 <e2>overdose</e2>_13\NN\1740 ._14\.\1740
839274
D003276_D000236 CID hepatic_0\JJ\1740 <e2>adenomas</e2>_1\NNS\14236226 and_2\CC\1740 focal_3\JJ\1740 nodular_4\JJ\1740 hyperplasia_5\NN\14365950 of_6\IN\1740 the_7\DT\1740 liver_8\NN\5298729 in_9\IN\13603305 young_10\JJ\1740 women_11\NNS\9605289 on_12\IN\1740 <e1>oral_13\JJ\1740 contraceptives</e1>_14\NNS\3183080 :_15\:\1740 case_16\NN\7283608 reports_17\NNS\6470073 ._18\.\1740
D003276_D000236 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 hepatic_3\JJ\1740 <e2>adenoma</e2>_4\NN\14236226 and_5\CC\1740 one_6\CD\13741022 of_7\IN\1740 focal_8\JJ\1740 nodular_9\JJ\1740 hyperplasia_10\NN\14365950 presumably_11\RB\1740 associated_12\VBN\628491 with_13\IN\1740 the_14\DT\1740 use_15\NN\407535 of_16\IN\1740 <e1>oral_17\JJ\1740 contraceptives</e1>_18\NNS\3183080 ,_19\,\1740 are_20\VBP\836236 reported_21\VBN\831651 ._22\.\1740
D003276_D020518 CID hepatic_0\JJ\1740 adenomas_1\NNS\14236226 and_2\CC\1740 <e2>focal_3\JJ\1740 nodular_4\JJ\1740 hyperplasia</e2>_5\NN\14365950 of_6\IN\1740 the_7\DT\1740 liver_8\NN\5298729 in_9\IN\13603305 young_10\JJ\1740 women_11\NNS\9605289 on_12\IN\1740 <e1>oral_13\JJ\1740 contraceptives</e1>_14\NNS\3183080 :_15\:\1740 case_16\NN\7283608 reports_17\NNS\6470073 ._18\.\1740
D003276_D020518 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 hepatic_3\JJ\1740 adenoma_4\NN\14236226 and_5\CC\1740 one_6\CD\13741022 of_7\IN\1740 <e2>focal_8\JJ\1740 nodular_9\JJ\1740 hyperplasia</e2>_10\NN\14365950 presumably_11\RB\1740 associated_12\VBN\628491 with_13\IN\1740 the_14\DT\1740 use_15\NN\407535 of_16\IN\1740 <e1>oral_17\JJ\1740 contraceptives</e1>_18\NNS\3183080 ,_19\,\1740 are_20\VBP\836236 reported_21\VBN\831651 ._22\.\1740
18177388
D000661_D054549 CID reverse_0\NN\13854649 or_1\CC\3541091 inverted_2\JJ\1740 <e2>left_3\JJ\1740 ventricular_4\JJ\1740 apical_5\JJ\1740 ballooning_6\NN\302394 syndrome</e2>_7\NN\5870365 (_8\-LRB-\1740 reverse_9\NN\13854649 takotsubo_10\NNP\1740 cardiomyopathy_11\NN\14103288 )_12\-RRB-\1740 in_13\IN\13603305 a_14\DT\13649268 young_15\JJ\1740 woman_16\NN\9605289 in_17\IN\13603305 the_18\DT\1740 setting_19\NN\8567235 of_20\IN\1740 <e1>amphetamine</e1>_21\NN\3248958 use_22\NN\407535 ._23\.\1740
D000661_D054549 CID reverse_0\NN\13854649 or_1\CC\3541091 inverted_2\JJ\1740 left_3\JJ\1740 ventricular_4\JJ\1740 apical_5\JJ\1740 ballooning_6\NN\302394 syndrome_7\NN\5870365 (_8\-LRB-\1740 reverse_9\NN\13854649 <e2>takotsubo_10\NNP\1740 cardiomyopathy</e2>_11\NN\14103288 )_12\-RRB-\1740 in_13\IN\13603305 a_14\DT\13649268 young_15\JJ\1740 woman_16\NN\9605289 in_17\IN\13603305 the_18\DT\1740 setting_19\NN\8567235 of_20\IN\1740 <e1>amphetamine</e1>_21\NN\3248958 use_22\NN\407535 ._23\.\1740
D000661_D054549 CID in_0\IN\13603305 this_1\DT\1740 article_2\NN\6367571 ,_3\,\1740 we_4\PRP\1740 report_5\VBP\831651 an_6\DT\6697703 interesting_7\JJ\1740 case_8\NN\7283608 of_9\IN\1740 a_10\DT\13649268 young_11\JJ\1740 woman_12\NN\9605289 who_13\WP\8299493 presented_14\VBD\2137132 with_15\IN\1740 this_16\DT\1740 rare_17\JJ\1740 type_18\NN\5839024 of_19\IN\1740 reverse_20\JJ\1740 <e2>apical_21\JJ\1740 ballooning_22\NN\302394 syndrome</e2>_23\NN\5870365 occurring_24\VBG\2623529 after_25\IN\1740 <e1>amphetamine</e1>_26\NN\3248958 use_27\NN\407535 ._28\.\1740
12851669
D017373_D054556 NONE absolute_0\JJ\1740 and_1\CC\1740 attributable_2\JJ\1740 risk_3\NN\14541044 of_4\IN\1740 <e2>venous_5\JJ\1740 thromboembolism</e2>_6\NN\14100769 in_7\IN\13603305 women_8\NNS\9605289 on_9\IN\1740 combined_10\JJ\1740 <e1>cyproterone_11\NN\1740 acetate</e1>_12\NN\15010703 and_13\CC\1740 ethinylestradiol_14\NN\1740 ._15\.\1740
D017373_D054556 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 achieve_3\VB\2524171 absolute_4\JJ\1740 risk_5\NN\14541044 estimates_6\NNS\5802185 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 among_13\IN\1740 women_14\NNS\9605289 on_15\IN\1740 <e1>cyproterone_16\NN\1740 acetate</e1>_17\NN\15010703 plus_18\CC\4723816 ethinylestradiol_19\NN\1740 (_20\-LRB-\1740 cpa/ee_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 and_24\CC\1740 among_25\IN\1740 women_26\NNS\9605289 on_27\IN\1740 combined_28\JJ\1740 oral_29\JJ\1740 contraceptives_30\NNS\3183080 (_31\-LRB-\1740 cocs_32\NNS\1740 )_33\-RRB-\1740 ._34\.\1740
D017373_D054556 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 achieve_3\VB\2524171 absolute_4\JJ\1740 risk_5\NN\14541044 estimates_6\NNS\5802185 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 among_13\IN\1740 women_14\NNS\9605289 on_15\IN\1740 <e1>cyproterone_16\NN\1740 acetate</e1>_17\NN\15010703 plus_18\CC\4723816 ethinylestradiol_19\NN\1740 (_20\-LRB-\1740 cpa/ee_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 and_24\CC\1740 among_25\IN\1740 women_26\NNS\9605289 on_27\IN\1740 combined_28\JJ\1740 oral_29\JJ\1740 contraceptives_30\NNS\3183080 (_31\-LRB-\1740 cocs_32\NNS\1740 )_33\-RRB-\1740 ._34\.\1740
D017373_D054556 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 achieve_3\VB\2524171 absolute_4\JJ\1740 risk_5\NN\14541044 estimates_6\NNS\5802185 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 among_13\IN\1740 women_14\NNS\9605289 on_15\IN\1740 cyproterone_16\NN\1740 acetate_17\NN\15010703 plus_18\CC\4723816 ethinylestradiol_19\NN\1740 (_20\-LRB-\1740 <e1>cpa/ee</e1>_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 and_24\CC\1740 among_25\IN\1740 women_26\NNS\9605289 on_27\IN\1740 combined_28\JJ\1740 oral_29\JJ\1740 contraceptives_30\NNS\3183080 (_31\-LRB-\1740 cocs_32\NNS\1740 )_33\-RRB-\1740 ._34\.\1740
D017373_D054556 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 achieve_3\VB\2524171 absolute_4\JJ\1740 risk_5\NN\14541044 estimates_6\NNS\5802185 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 among_13\IN\1740 women_14\NNS\9605289 on_15\IN\1740 cyproterone_16\NN\1740 acetate_17\NN\15010703 plus_18\CC\4723816 ethinylestradiol_19\NN\1740 (_20\-LRB-\1740 <e1>cpa/ee</e1>_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 and_24\CC\1740 among_25\IN\1740 women_26\NNS\9605289 on_27\IN\1740 combined_28\JJ\1740 oral_29\JJ\1740 contraceptives_30\NNS\3183080 (_31\-LRB-\1740 cocs_32\NNS\1740 )_33\-RRB-\1740 ._34\.\1740
D017373_D054556 NONE the_0\DT\1740 corresponding_1\JJ\1740 absolute_2\JJ\1740 risk_3\NN\14541044 of_4\IN\1740 <e2>vte</e2>_5\NN\1740 was_6\VBD\836236 3.4_7\CD\1740 (_8\-LRB-\1740 range_9\NN\5123416 ,_10\,\1740 3.1_11\CD\1740 -_12\SYM\1740 3.8_13\CD\1740 )_14\-RRB-\1740 per_15\IN\1740 10_16\CD\13745420 000_17\CD\1740 women_18\NNS\9605289 years_19\NNS\15144371 among_20\IN\1740 the_21\DT\1740 women_22\NNS\9605289 on_23\IN\1740 cocs_24\NN\1740 ,_25\,\1740 4.2_26\CD\1740 (_27\-LRB-\1740 range_28\NN\5123416 ,_29\,\1740 3.2_30\CD\1740 -_31\SYM\1740 5.2_32\CD\1740 )_33\-RRB-\1740 per_34\IN\1740 10_35\CD\13745420 000_36\CD\1740 women_37\NNS\9605289 years_38\NNS\15144371 among_39\IN\1740 women_40\NNS\9605289 on_41\IN\1740 levonorgestrel-containing_42\JJ\1740 cocs_43\NN\1740 ,_44\,\1740 and_45\CC\1740 3.1_46\CD\1740 (_47\-LRB-\1740 range_48\NN\5123416 ,_49\,\1740 1.3_50\CD\1740 -_51\SYM\1740 4.9_52\CD\1740 )_53\-RRB-\1740 per_54\IN\1740 10_55\CD\13745420 000_56\CD\1740 women_57\NNS\9605289 years_58\NNS\15144371 among_59\IN\1740 the_60\DT\1740 women_61\NNS\9605289 on_62\IN\1740 <e1>cpa/ee</e1>_63\NN\1740 ._64\.\1740
D017373_D054556 NONE conclusion_0\NN\5837957 :_1\:\1740 our_2\PRP$\1740 results_3\NNS\34213 suggest_4\VBP\1010118 the_5\DT\1740 absolute_6\JJ\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>vte</e2>_9\NN\1740 among_10\IN\1740 danish_11\JJ\1740 women_12\NNS\9605289 on_13\IN\1740 cocs_14\NN\1740 is_15\VBZ\836236 similar_16\JJ\1740 to_17\TO\1740 that_18\DT\1740 among_19\IN\1740 women_20\NNS\9605289 taking_21\VBG\2367363 <e1>cpa/ee</e1>_22\NN\1740 ._23\.\1740
D004997_D054556 NONE absolute_0\JJ\1740 and_1\CC\1740 attributable_2\JJ\1740 risk_3\NN\14541044 of_4\IN\1740 <e2>venous_5\JJ\1740 thromboembolism</e2>_6\NN\14100769 in_7\IN\13603305 women_8\NNS\9605289 on_9\IN\1740 combined_10\JJ\1740 cyproterone_11\NN\1740 acetate_12\NN\15010703 and_13\CC\1740 <e1>ethinylestradiol</e1>_14\NN\1740 ._15\.\1740
D004997_D054556 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 achieve_3\VB\2524171 absolute_4\JJ\1740 risk_5\NN\14541044 estimates_6\NNS\5802185 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 among_13\IN\1740 women_14\NNS\9605289 on_15\IN\1740 cyproterone_16\NN\1740 acetate_17\NN\15010703 plus_18\CC\4723816 <e1>ethinylestradiol</e1>_19\NN\1740 (_20\-LRB-\1740 cpa/ee_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 and_24\CC\1740 among_25\IN\1740 women_26\NNS\9605289 on_27\IN\1740 combined_28\JJ\1740 oral_29\JJ\1740 contraceptives_30\NNS\3183080 (_31\-LRB-\1740 cocs_32\NNS\1740 )_33\-RRB-\1740 ._34\.\1740
D004997_D054556 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 achieve_3\VB\2524171 absolute_4\JJ\1740 risk_5\NN\14541044 estimates_6\NNS\5802185 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 among_13\IN\1740 women_14\NNS\9605289 on_15\IN\1740 cyproterone_16\NN\1740 acetate_17\NN\15010703 plus_18\CC\4723816 <e1>ethinylestradiol</e1>_19\NN\1740 (_20\-LRB-\1740 cpa/ee_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 and_24\CC\1740 among_25\IN\1740 women_26\NNS\9605289 on_27\IN\1740 combined_28\JJ\1740 oral_29\JJ\1740 contraceptives_30\NNS\3183080 (_31\-LRB-\1740 cocs_32\NNS\1740 )_33\-RRB-\1740 ._34\.\1740
D004997_D054556 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 achieve_3\VB\2524171 absolute_4\JJ\1740 risk_5\NN\14541044 estimates_6\NNS\5802185 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 among_13\IN\1740 women_14\NNS\9605289 on_15\IN\1740 cyproterone_16\NN\1740 acetate_17\NN\15010703 plus_18\CC\4723816 ethinylestradiol_19\NN\1740 (_20\-LRB-\1740 <e1>cpa/ee</e1>_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 and_24\CC\1740 among_25\IN\1740 women_26\NNS\9605289 on_27\IN\1740 combined_28\JJ\1740 oral_29\JJ\1740 contraceptives_30\NNS\3183080 (_31\-LRB-\1740 cocs_32\NNS\1740 )_33\-RRB-\1740 ._34\.\1740
D004997_D054556 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 achieve_3\VB\2524171 absolute_4\JJ\1740 risk_5\NN\14541044 estimates_6\NNS\5802185 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 among_13\IN\1740 women_14\NNS\9605289 on_15\IN\1740 cyproterone_16\NN\1740 acetate_17\NN\15010703 plus_18\CC\4723816 ethinylestradiol_19\NN\1740 (_20\-LRB-\1740 <e1>cpa/ee</e1>_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 and_24\CC\1740 among_25\IN\1740 women_26\NNS\9605289 on_27\IN\1740 combined_28\JJ\1740 oral_29\JJ\1740 contraceptives_30\NNS\3183080 (_31\-LRB-\1740 cocs_32\NNS\1740 )_33\-RRB-\1740 ._34\.\1740
D004997_D054556 NONE the_0\DT\1740 corresponding_1\JJ\1740 absolute_2\JJ\1740 risk_3\NN\14541044 of_4\IN\1740 <e2>vte</e2>_5\NN\1740 was_6\VBD\836236 3.4_7\CD\1740 (_8\-LRB-\1740 range_9\NN\5123416 ,_10\,\1740 3.1_11\CD\1740 -_12\SYM\1740 3.8_13\CD\1740 )_14\-RRB-\1740 per_15\IN\1740 10_16\CD\13745420 000_17\CD\1740 women_18\NNS\9605289 years_19\NNS\15144371 among_20\IN\1740 the_21\DT\1740 women_22\NNS\9605289 on_23\IN\1740 cocs_24\NN\1740 ,_25\,\1740 4.2_26\CD\1740 (_27\-LRB-\1740 range_28\NN\5123416 ,_29\,\1740 3.2_30\CD\1740 -_31\SYM\1740 5.2_32\CD\1740 )_33\-RRB-\1740 per_34\IN\1740 10_35\CD\13745420 000_36\CD\1740 women_37\NNS\9605289 years_38\NNS\15144371 among_39\IN\1740 women_40\NNS\9605289 on_41\IN\1740 levonorgestrel-containing_42\JJ\1740 cocs_43\NN\1740 ,_44\,\1740 and_45\CC\1740 3.1_46\CD\1740 (_47\-LRB-\1740 range_48\NN\5123416 ,_49\,\1740 1.3_50\CD\1740 -_51\SYM\1740 4.9_52\CD\1740 )_53\-RRB-\1740 per_54\IN\1740 10_55\CD\13745420 000_56\CD\1740 women_57\NNS\9605289 years_58\NNS\15144371 among_59\IN\1740 the_60\DT\1740 women_61\NNS\9605289 on_62\IN\1740 <e1>cpa/ee</e1>_63\NN\1740 ._64\.\1740
D004997_D054556 NONE conclusion_0\NN\5837957 :_1\:\1740 our_2\PRP$\1740 results_3\NNS\34213 suggest_4\VBP\1010118 the_5\DT\1740 absolute_6\JJ\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>vte</e2>_9\NN\1740 among_10\IN\1740 danish_11\JJ\1740 women_12\NNS\9605289 on_13\IN\1740 cocs_14\NN\1740 is_15\VBZ\836236 similar_16\JJ\1740 to_17\TO\1740 that_18\DT\1740 among_19\IN\1740 women_20\NNS\9605289 taking_21\VBG\2367363 <e1>cpa/ee</e1>_22\NN\1740 ._23\.\1740
D003277_D054556 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 achieve_3\VB\2524171 absolute_4\JJ\1740 risk_5\NN\14541044 estimates_6\NNS\5802185 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 among_13\IN\1740 women_14\NNS\9605289 on_15\IN\1740 cyproterone_16\NN\1740 acetate_17\NN\15010703 plus_18\CC\4723816 ethinylestradiol_19\NN\1740 (_20\-LRB-\1740 cpa/ee_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 and_24\CC\1740 among_25\IN\1740 women_26\NNS\9605289 on_27\IN\1740 <e1>combined_28\JJ\1740 oral_29\JJ\1740 contraceptives</e1>_30\NNS\3183080 (_31\-LRB-\1740 cocs_32\NNS\1740 )_33\-RRB-\1740 ._34\.\1740
D003277_D054556 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 achieve_3\VB\2524171 absolute_4\JJ\1740 risk_5\NN\14541044 estimates_6\NNS\5802185 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 among_13\IN\1740 women_14\NNS\9605289 on_15\IN\1740 cyproterone_16\NN\1740 acetate_17\NN\15010703 plus_18\CC\4723816 ethinylestradiol_19\NN\1740 (_20\-LRB-\1740 cpa/ee_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 and_24\CC\1740 among_25\IN\1740 women_26\NNS\9605289 on_27\IN\1740 <e1>combined_28\JJ\1740 oral_29\JJ\1740 contraceptives</e1>_30\NNS\3183080 (_31\-LRB-\1740 cocs_32\NNS\1740 )_33\-RRB-\1740 ._34\.\1740
D003277_D054556 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 achieve_3\VB\2524171 absolute_4\JJ\1740 risk_5\NN\14541044 estimates_6\NNS\5802185 of_7\IN\1740 <e2>venous_8\JJ\1740 thromboembolism</e2>_9\NN\14100769 (_10\-LRB-\1740 vte_11\NN\1740 )_12\-RRB-\1740 among_13\IN\1740 women_14\NNS\9605289 on_15\IN\1740 cyproterone_16\NN\1740 acetate_17\NN\15010703 plus_18\CC\4723816 ethinylestradiol_19\NN\1740 (_20\-LRB-\1740 cpa/ee_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 and_24\CC\1740 among_25\IN\1740 women_26\NNS\9605289 on_27\IN\1740 combined_28\JJ\1740 oral_29\JJ\1740 contraceptives_30\NNS\3183080 (_31\-LRB-\1740 <e1>cocs</e1>_32\NNS\1740 )_33\-RRB-\1740 ._34\.\1740
D003277_D054556 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 achieve_3\VB\2524171 absolute_4\JJ\1740 risk_5\NN\14541044 estimates_6\NNS\5802185 of_7\IN\1740 venous_8\JJ\1740 thromboembolism_9\NN\14100769 (_10\-LRB-\1740 <e2>vte</e2>_11\NN\1740 )_12\-RRB-\1740 among_13\IN\1740 women_14\NNS\9605289 on_15\IN\1740 cyproterone_16\NN\1740 acetate_17\NN\15010703 plus_18\CC\4723816 ethinylestradiol_19\NN\1740 (_20\-LRB-\1740 cpa/ee_21\NN\1740 )_22\-RRB-\1740 ,_23\,\1740 and_24\CC\1740 among_25\IN\1740 women_26\NNS\9605289 on_27\IN\1740 combined_28\JJ\1740 oral_29\JJ\1740 contraceptives_30\NNS\3183080 (_31\-LRB-\1740 <e1>cocs</e1>_32\NNS\1740 )_33\-RRB-\1740 ._34\.\1740
D003277_D054556 CID results_0\NNS\34213 :_1\:\1740 during_2\IN\1740 the_3\DT\1740 time_4\NN\7308889 frame_5\NN\3391770 of_6\IN\1740 the_7\DT\1740 study_8\NN\635850 ,_9\,\1740 330_10\CD\1740 women_11\NNS\9605289 were_12\VBD\836236 found_13\VBN\2426171 to_14\TO\1740 have_15\VB\2108377 had_16\VBN\2108377 <e2>vte</e2>_17\NN\1740 while_18\IN\15122231 on_19\IN\1740 <e1>cocs</e1>_20\NN\1740 ._21\.\1740
D003277_D054556 CID the_0\DT\1740 corresponding_1\JJ\1740 absolute_2\JJ\1740 risk_3\NN\14541044 of_4\IN\1740 <e2>vte</e2>_5\NN\1740 was_6\VBD\836236 3.4_7\CD\1740 (_8\-LRB-\1740 range_9\NN\5123416 ,_10\,\1740 3.1_11\CD\1740 -_12\SYM\1740 3.8_13\CD\1740 )_14\-RRB-\1740 per_15\IN\1740 10_16\CD\13745420 000_17\CD\1740 women_18\NNS\9605289 years_19\NNS\15144371 among_20\IN\1740 the_21\DT\1740 women_22\NNS\9605289 on_23\IN\1740 <e1>cocs</e1>_24\NN\1740 ,_25\,\1740 4.2_26\CD\1740 (_27\-LRB-\1740 range_28\NN\5123416 ,_29\,\1740 3.2_30\CD\1740 -_31\SYM\1740 5.2_32\CD\1740 )_33\-RRB-\1740 per_34\IN\1740 10_35\CD\13745420 000_36\CD\1740 women_37\NNS\9605289 years_38\NNS\15144371 among_39\IN\1740 women_40\NNS\9605289 on_41\IN\1740 levonorgestrel-containing_42\JJ\1740 cocs_43\NN\1740 ,_44\,\1740 and_45\CC\1740 3.1_46\CD\1740 (_47\-LRB-\1740 range_48\NN\5123416 ,_49\,\1740 1.3_50\CD\1740 -_51\SYM\1740 4.9_52\CD\1740 )_53\-RRB-\1740 per_54\IN\1740 10_55\CD\13745420 000_56\CD\1740 women_57\NNS\9605289 years_58\NNS\15144371 among_59\IN\1740 the_60\DT\1740 women_61\NNS\9605289 on_62\IN\1740 cpa/ee_63\NN\1740 ._64\.\1740
D003277_D054556 CID the_0\DT\1740 corresponding_1\JJ\1740 absolute_2\JJ\1740 risk_3\NN\14541044 of_4\IN\1740 <e2>vte</e2>_5\NN\1740 was_6\VBD\836236 3.4_7\CD\1740 (_8\-LRB-\1740 range_9\NN\5123416 ,_10\,\1740 3.1_11\CD\1740 -_12\SYM\1740 3.8_13\CD\1740 )_14\-RRB-\1740 per_15\IN\1740 10_16\CD\13745420 000_17\CD\1740 women_18\NNS\9605289 years_19\NNS\15144371 among_20\IN\1740 the_21\DT\1740 women_22\NNS\9605289 on_23\IN\1740 cocs_24\NN\1740 ,_25\,\1740 4.2_26\CD\1740 (_27\-LRB-\1740 range_28\NN\5123416 ,_29\,\1740 3.2_30\CD\1740 -_31\SYM\1740 5.2_32\CD\1740 )_33\-RRB-\1740 per_34\IN\1740 10_35\CD\13745420 000_36\CD\1740 women_37\NNS\9605289 years_38\NNS\15144371 among_39\IN\1740 women_40\NNS\9605289 on_41\IN\1740 levonorgestrel-containing_42\JJ\1740 <e1>cocs</e1>_43\NN\1740 ,_44\,\1740 and_45\CC\1740 3.1_46\CD\1740 (_47\-LRB-\1740 range_48\NN\5123416 ,_49\,\1740 1.3_50\CD\1740 -_51\SYM\1740 4.9_52\CD\1740 )_53\-RRB-\1740 per_54\IN\1740 10_55\CD\13745420 000_56\CD\1740 women_57\NNS\9605289 years_58\NNS\15144371 among_59\IN\1740 the_60\DT\1740 women_61\NNS\9605289 on_62\IN\1740 cpa/ee_63\NN\1740 ._64\.\1740
D003277_D054556 CID conclusion_0\NN\5837957 :_1\:\1740 our_2\PRP$\1740 results_3\NNS\34213 suggest_4\VBP\1010118 the_5\DT\1740 absolute_6\JJ\1740 risk_7\NN\14541044 of_8\IN\1740 <e2>vte</e2>_9\NN\1740 among_10\IN\1740 danish_11\JJ\1740 women_12\NNS\9605289 on_13\IN\1740 <e1>cocs</e1>_14\NN\1740 is_15\VBZ\836236 similar_16\JJ\1740 to_17\TO\1740 that_18\DT\1740 among_19\IN\1740 women_20\NNS\9605289 taking_21\VBG\2367363 cpa/ee_22\NN\1740 ._23\.\1740
D016912_D054556 NONE the_0\DT\1740 corresponding_1\JJ\1740 absolute_2\JJ\1740 risk_3\NN\14541044 of_4\IN\1740 <e2>vte</e2>_5\NN\1740 was_6\VBD\836236 3.4_7\CD\1740 (_8\-LRB-\1740 range_9\NN\5123416 ,_10\,\1740 3.1_11\CD\1740 -_12\SYM\1740 3.8_13\CD\1740 )_14\-RRB-\1740 per_15\IN\1740 10_16\CD\13745420 000_17\CD\1740 women_18\NNS\9605289 years_19\NNS\15144371 among_20\IN\1740 the_21\DT\1740 women_22\NNS\9605289 on_23\IN\1740 cocs_24\NN\1740 ,_25\,\1740 4.2_26\CD\1740 (_27\-LRB-\1740 range_28\NN\5123416 ,_29\,\1740 3.2_30\CD\1740 -_31\SYM\1740 5.2_32\CD\1740 )_33\-RRB-\1740 per_34\IN\1740 10_35\CD\13745420 000_36\CD\1740 women_37\NNS\9605289 years_38\NNS\15144371 among_39\IN\1740 women_40\NNS\9605289 on_41\IN\1740 <e1>levonorgestrel-containing</e1>_42\JJ\1740 cocs_43\NN\1740 ,_44\,\1740 and_45\CC\1740 3.1_46\CD\1740 (_47\-LRB-\1740 range_48\NN\5123416 ,_49\,\1740 1.3_50\CD\1740 -_51\SYM\1740 4.9_52\CD\1740 )_53\-RRB-\1740 per_54\IN\1740 10_55\CD\13745420 000_56\CD\1740 women_57\NNS\9605289 years_58\NNS\15144371 among_59\IN\1740 the_60\DT\1740 women_61\NNS\9605289 on_62\IN\1740 cpa/ee_63\NN\1740 ._64\.\1740
3670965
D012459_D012202 NONE <e2>reye_0\NN\1740 syndrome</e2>_1\NN\5870365 may_2\MD\15209706 be_3\VB\836236 disappearing_4\VBG\2609764 from_5\IN\1740 australia_6\NNP\1740 despite_7\IN\7501545 a_8\DT\13649268 total_9\JJ\1740 lack_10\NN\14449126 of_11\IN\1740 association_12\NN\8008335 with_13\IN\1740 <e1>salicylates</e1>_14\NNS\3828465 or_15\CC\3541091 aspirin_16\NN\2707683 ingestion_17\NN\13440063 ,_18\,\1740 since_19\IN\1740 there_20\EX\27167 were_21\VBD\836236 no_22\DT\7204911 cases_23\NNS\7283608 found_24\VBN\2426171 at_25\IN\14622893 the_26\DT\1740 children_27\NNP\9622049 's_28\POS\1740 hospital_29\NNP\3739518 in_30\IN\13603305 1983_31\CD\1740 ,_32\,\1740 1984_33\CD\1740 ,_34\,\1740 or_35\CC\3541091 1985_36\CD\1740 ._37\.\1740
D001241_D012202 CID <e2>reye_0\NN\1740 syndrome</e2>_1\NN\5870365 may_2\MD\15209706 be_3\VB\836236 disappearing_4\VBG\2609764 from_5\IN\1740 australia_6\NNP\1740 despite_7\IN\7501545 a_8\DT\13649268 total_9\JJ\1740 lack_10\NN\14449126 of_11\IN\1740 association_12\NN\8008335 with_13\IN\1740 salicylates_14\NNS\3828465 or_15\CC\3541091 <e1>aspirin</e1>_16\NN\2707683 ingestion_17\NN\13440063 ,_18\,\1740 since_19\IN\1740 there_20\EX\27167 were_21\VBD\836236 no_22\DT\7204911 cases_23\NNS\7283608 found_24\VBN\2426171 at_25\IN\14622893 the_26\DT\1740 children_27\NNP\9622049 's_28\POS\1740 hospital_29\NNP\3739518 in_30\IN\13603305 1983_31\CD\1740 ,_32\,\1740 1984_33\CD\1740 ,_34\,\1740 or_35\CC\3541091 1985_36\CD\1740 ._37\.\1740
10692744
D000086_D005862 CID <e1>acetazolamide-induced</e1>_0\JJ\1740 <e2>gerstmann_1\NN\1740 syndrome</e2>_2\NN\5870365 ._3\.\1740
D000086_D005862 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e1>acetazolamide-induced</e1>_5\JJ\1740 <e2>gerstmann_6\NN\1740 syndrome</e2>_7\NN\5870365 in_8\IN\13603305 a_9\DT\13649268 patient_10\NN\9898892 with_11\IN\1740 normal_12\JJ\1740 renal_13\JJ\1740 function_14\NN\13783581 ,_15\,\1740 to_16\TO\1740 highlight_17\VB\514463 predisposing_18\VBG\680841 factors_19\NNS\7326557 that_20\WDT\1740 are_21\VBP\836236 frequently_22\RB\1740 overlooked_23\VBN\2127853 ._24\.\1740
D000086_D003221 NONE acute_0\JJ\1740 <e2>confusion</e2>_1\NN\13972797 induced_2\VBN\1627355 by_3\IN\1740 <e1>acetazolamide</e1>_4\NN\1740 is_5\VBZ\836236 a_6\DT\13649268 well_7\RB\1740 known_8\JJ\1740 adverse_9\JJ\1740 drug_10\NN\14778436 reaction_11\NN\13446390 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 renal_15\JJ\1740 impairment_16\NN\7296428 ._17\.\1740
D000086_D007674 NONE acute_0\JJ\1740 confusion_1\NN\13972797 induced_2\VBN\1627355 by_3\IN\1740 <e1>acetazolamide</e1>_4\NN\1740 is_5\VBZ\836236 a_6\DT\13649268 well_7\RB\1740 known_8\JJ\1740 adverse_9\JJ\1740 drug_10\NN\14778436 reaction_11\NN\13446390 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>renal_15\JJ\1740 impairment</e2>_16\NN\7296428 ._17\.\1740
19940105
D018698_D010300 NONE metabotropic_0\NN\1740 <e1>glutamate</e1>_1\NN\15010703 7_2\CD\13741022 receptor_3\NN\5225602 subtype_4\NN\1740 modulates_5\VBZ\1724459 motor_6\NN\3699975 symptoms_7\NNS\5823932 in_8\IN\13603305 rodent_9\JJ\1740 models_10\NNS\5888929 of_11\IN\1740 <e2>parkinson_12\NN\1740 's_13\POS\1740 disease</e2>_14\NN\14061805 ._15\.\1740
D018698_D010300 NONE metabotropic_0\NN\1740 <e1>glutamate</e1>_1\NN\15010703 (_2\-LRB-\1740 mglu_3\NNS\1740 )_4\-RRB-\1740 receptors_5\NNS\5225602 modulate_6\VBP\1724459 synaptic_7\JJ\1740 transmission_8\NN\121166 in_9\IN\13603305 the_10\DT\1740 central_11\JJ\1740 nervous_12\JJ\1740 system_13\NN\3575240 and_14\CC\1740 represent_15\VB\2664769 promising_16\VBG\1010118 therapeutic_17\JJ\1740 targets_18\NNS\7258332 for_19\IN\1740 symptomatic_20\JJ\1740 treatment_21\NN\654885 of_22\IN\1740 <e2>parkinson_23\NN\1740 's_24\POS\1740 disease</e2>_25\NN\14061805 (_26\-LRB-\1740 pd_27\NN\14625458 )_28\-RRB-\1740 ._29\.\1740
D018698_D010300 NONE metabotropic_0\NN\1740 <e1>glutamate</e1>_1\NN\15010703 (_2\-LRB-\1740 mglu_3\NNS\1740 )_4\-RRB-\1740 receptors_5\NNS\5225602 modulate_6\VBP\1724459 synaptic_7\JJ\1740 transmission_8\NN\121166 in_9\IN\13603305 the_10\DT\1740 central_11\JJ\1740 nervous_12\JJ\1740 system_13\NN\3575240 and_14\CC\1740 represent_15\VB\2664769 promising_16\VBG\1010118 therapeutic_17\JJ\1740 targets_18\NNS\7258332 for_19\IN\1740 symptomatic_20\JJ\1740 treatment_21\NN\654885 of_22\IN\1740 parkinson_23\NN\1740 's_24\POS\1740 disease_25\NN\14061805 (_26\-LRB-\1740 <e2>pd</e2>_27\NN\14625458 )_28\-RRB-\1740 ._29\.\1740
C507346_D010300 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>n_3\NN\14622893 ,_4\,\1740 n'-dibenzhydrylethane-1,2-diamine_5\NN\1740 dihydrochloride</e1>_6\NN\1740 (_7\-LRB-\1740 amn082_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 the_11\DT\1740 first_12\JJ\1740 selective_13\JJ\1740 allosteric_14\JJ\1740 activator_15\NN\19613 of_16\IN\1740 mglu7_17\NN\1740 receptors_18\NNS\5225602 ,_19\,\1740 were_20\VBD\836236 thus_21\RB\1740 tested_22\VBN\670261 in_23\IN\13603305 different_24\JJ\1740 rodent_25\JJ\1740 models_26\NNS\5888929 of_27\IN\1740 <e2>pd</e2>_28\NN\14625458 ._29\.\1740
C507346_D010300 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 n_3\NN\14622893 ,_4\,\1740 n'-dibenzhydrylethane-1,2-diamine_5\NN\1740 dihydrochloride_6\NN\1740 (_7\-LRB-\1740 <e1>amn082</e1>_8\NN\1740 )_9\-RRB-\1740 ,_10\,\1740 the_11\DT\1740 first_12\JJ\1740 selective_13\JJ\1740 allosteric_14\JJ\1740 activator_15\NN\19613 of_16\IN\1740 mglu7_17\NN\1740 receptors_18\NNS\5225602 ,_19\,\1740 were_20\VBD\836236 thus_21\RB\1740 tested_22\VBN\670261 in_23\IN\13603305 different_24\JJ\1740 rodent_25\JJ\1740 models_26\NNS\5888929 of_27\IN\1740 <e2>pd</e2>_28\NN\14625458 ._29\.\1740
C507346_D010300 NONE in_0\IN\13603305 a_1\DT\13649268 more_2\RBR\1740 complex_3\JJ\1740 task_4\NN\575741 commonly_5\RB\1740 used_6\VBN\1156834 to_7\TO\1740 evaluate_8\VB\670261 major_9\JJ\1740 akinetic_10\JJ\1740 symptoms_11\NNS\5823932 of_12\IN\1740 <e2>pd</e2>_13\NN\14625458 patients_14\NNS\9898892 ,_15\,\1740 5_16\CD\13741022 mg/kg_17\NN\1740 <e1>amn082</e1>_18\NN\1740 reverses_19\VBZ\109660 the_20\DT\1740 increased_21\VBN\169651 reaction_22\NN\13446390 time_23\NN\7308889 to_24\TO\1740 respond_25\VB\2367363 to_26\TO\1740 a_27\DT\13649268 cue_28\NN\7010821 of_29\IN\1740 bilateral_30\JJ\1740 6-ohda-lesioned_31\NNP\1740 rats_32\NNS\2329401 ._33\.\1740
C507346_D010300 NONE higher_0\JJR\1740 doses_1\NNS\3740161 of_2\IN\1740 <e1>amn082</e1>_3\NN\1740 (_4\-LRB-\1740 10_5\CD\13745420 and_6\CC\1740 20_7\CD\13745420 mg/kg_8\NN\1740 p.o._9\NN\10360747 )_10\-RRB-\1740 have_11\VBP\2108377 no_12\DT\7204911 effect_13\NN\34213 on_14\IN\1740 the_15\DT\1740 same_16\JJ\1740 models_17\NNS\5888929 of_18\IN\1740 <e2>pd</e2>_19\NN\14625458 ._20\.\1740
C507346_D002375 NONE here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 show_3\VBP\2137132 that_4\IN\1740 oral_5\JJ\1740 (_6\-LRB-\1740 5_7\CD\13741022 mg/kg_8\NN\1740 )_9\-RRB-\1740 or_10\CC\3541091 intrastriatal_11\JJ\1740 administration_12\NN\1133281 (_13\-LRB-\1740 0.1_14\CD\1740 and_15\CC\1740 0.5_16\CD\1740 nmol_17\NNS\1740 )_18\-RRB-\1740 of_19\IN\1740 <e1>amn082</e1>_20\NN\1740 reverses_21\VBZ\109660 haloperidol-induced_22\JJ\1740 <e2>catalepsy</e2>_23\NN\14023236 in_24\IN\13603305 rats_25\NNS\2329401 ._26\.\1740
C507346_D002375 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 <e1>amn082</e1>_3\NN\1740 reduces_4\VBZ\441445 the_5\DT\1740 duration_6\NN\15113229 of_7\IN\1740 haloperidol-induced_8\JJ\1740 <e2>catalepsy</e2>_9\NN\14023236 in_10\IN\13603305 a_11\DT\13649268 mglu7_12\NN\1740 receptor-dependent_13\JJ\1740 manner_14\NN\4916342 in_15\IN\13603305 wild-type_16\JJ\1740 but_17\CC\1740 not_18\RB\1740 mglu7_19\NN\1740 receptor_20\NN\5225602 knockout_21\JJ\1740 mice_22\NNS\2329401 ._23\.\1740
D006220_D002375 CID here_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 show_3\VBP\2137132 that_4\IN\1740 oral_5\JJ\1740 (_6\-LRB-\1740 5_7\CD\13741022 mg/kg_8\NN\1740 )_9\-RRB-\1740 or_10\CC\3541091 intrastriatal_11\JJ\1740 administration_12\NN\1133281 (_13\-LRB-\1740 0.1_14\CD\1740 and_15\CC\1740 0.5_16\CD\1740 nmol_17\NNS\1740 )_18\-RRB-\1740 of_19\IN\1740 amn082_20\NN\1740 reverses_21\VBZ\109660 <e1>haloperidol-induced</e1>_22\JJ\1740 <e2>catalepsy</e2>_23\NN\14023236 in_24\IN\13603305 rats_25\NNS\2329401 ._26\.\1740
D006220_D002375 CID in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 amn082_3\NN\1740 reduces_4\VBZ\441445 the_5\DT\1740 duration_6\NN\15113229 of_7\IN\1740 <e1>haloperidol-induced</e1>_8\JJ\1740 <e2>catalepsy</e2>_9\NN\14023236 in_10\IN\13603305 a_11\DT\13649268 mglu7_12\NN\1740 receptor-dependent_13\JJ\1740 manner_14\NN\4916342 in_15\IN\13603305 wild-type_16\JJ\1740 but_17\CC\1740 not_18\RB\1740 mglu7_19\NN\1740 receptor_20\NN\5225602 knockout_21\JJ\1740 mice_22\NNS\2329401 ._23\.\1740
C507346_D018476 NONE in_0\IN\13603305 a_1\DT\13649268 more_2\RBR\1740 complex_3\JJ\1740 task_4\NN\575741 commonly_5\RB\1740 used_6\VBN\1156834 to_7\TO\1740 evaluate_8\VB\670261 major_9\JJ\1740 <e2>akinetic</e2>_10\JJ\1740 symptoms_11\NNS\5823932 of_12\IN\1740 pd_13\NN\14625458 patients_14\NNS\9898892 ,_15\,\1740 5_16\CD\13741022 mg/kg_17\NN\1740 <e1>amn082</e1>_18\NN\1740 reverses_19\VBZ\109660 the_20\DT\1740 increased_21\VBN\169651 reaction_22\NN\13446390 time_23\NN\7308889 to_24\TO\1740 respond_25\VB\2367363 to_26\TO\1740 a_27\DT\13649268 cue_28\NN\7010821 of_29\IN\1740 bilateral_30\JJ\1740 6-ohda-lesioned_31\NNP\1740 rats_32\NNS\2329401 ._33\.\1740
D016627_D018476 NONE in_0\IN\13603305 a_1\DT\13649268 more_2\RBR\1740 complex_3\JJ\1740 task_4\NN\575741 commonly_5\RB\1740 used_6\VBN\1156834 to_7\TO\1740 evaluate_8\VB\670261 major_9\JJ\1740 <e2>akinetic</e2>_10\JJ\1740 symptoms_11\NNS\5823932 of_12\IN\1740 pd_13\NN\14625458 patients_14\NNS\9898892 ,_15\,\1740 5_16\CD\13741022 mg/kg_17\NN\1740 amn082_18\NN\1740 reverses_19\VBZ\109660 the_20\DT\1740 increased_21\VBN\169651 reaction_22\NN\13446390 time_23\NN\7308889 to_24\TO\1740 respond_25\VB\2367363 to_26\TO\1740 a_27\DT\13649268 cue_28\NN\7010821 of_29\IN\1740 bilateral_30\JJ\1740 <e1>6-ohda-lesioned</e1>_31\NNP\1740 rats_32\NNS\2329401 ._33\.\1740
D016627_D010300 NONE in_0\IN\13603305 a_1\DT\13649268 more_2\RBR\1740 complex_3\JJ\1740 task_4\NN\575741 commonly_5\RB\1740 used_6\VBN\1156834 to_7\TO\1740 evaluate_8\VB\670261 major_9\JJ\1740 akinetic_10\JJ\1740 symptoms_11\NNS\5823932 of_12\IN\1740 <e2>pd</e2>_13\NN\14625458 patients_14\NNS\9898892 ,_15\,\1740 5_16\CD\13741022 mg/kg_17\NN\1740 amn082_18\NN\1740 reverses_19\VBZ\109660 the_20\DT\1740 increased_21\VBN\169651 reaction_22\NN\13446390 time_23\NN\7308889 to_24\TO\1740 respond_25\VB\2367363 to_26\TO\1740 a_27\DT\13649268 cue_28\NN\7010821 of_29\IN\1740 bilateral_30\JJ\1740 <e1>6-ohda-lesioned</e1>_31\NNP\1740 rats_32\NNS\2329401 ._33\.\1740
2980315
C053571_D014693 NONE frequencies_0\NNS\15286249 of_1\IN\1740 <e2>ventricular_2\JJ\1740 fibrillation</e2>_3\NN\14361664 were_4\VBD\836236 significantly_5\RB\1740 lower_6\JJR\1740 (_7\-LRB-\1740 p_8\NN\14622893 less_9\JJR\1740 than_10\IN\1740 0.05_11\CD\1740 )_12\-RRB-\1740 after_13\IN\1740 <e1>iopentol</e1>_14\NN\1740 (_15\-LRB-\1740 0_16\CD\13741022 %_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 iohexol_20\NN\1740 (_21\-LRB-\1740 3_22\CD\13741022 %_23\NN\1740 )_24\-RRB-\1740 than_25\IN\1740 after_26\IN\1740 metrizoate_27\NN\1740 (_28\-LRB-\1740 22_29\CD\13745420 %_30\NN\1740 )_31\-RRB-\1740 ._32\.\1740
D007472_D014693 NONE frequencies_0\NNS\15286249 of_1\IN\1740 <e2>ventricular_2\JJ\1740 fibrillation</e2>_3\NN\14361664 were_4\VBD\836236 significantly_5\RB\1740 lower_6\JJR\1740 (_7\-LRB-\1740 p_8\NN\14622893 less_9\JJR\1740 than_10\IN\1740 0.05_11\CD\1740 )_12\-RRB-\1740 after_13\IN\1740 iopentol_14\NN\1740 (_15\-LRB-\1740 0_16\CD\13741022 %_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 <e1>iohexol</e1>_20\NN\1740 (_21\-LRB-\1740 3_22\CD\13741022 %_23\NN\1740 )_24\-RRB-\1740 than_25\IN\1740 after_26\IN\1740 metrizoate_27\NN\1740 (_28\-LRB-\1740 22_29\CD\13745420 %_30\NN\1740 )_31\-RRB-\1740 ._32\.\1740
D008794_D014693 CID frequencies_0\NNS\15286249 of_1\IN\1740 <e2>ventricular_2\JJ\1740 fibrillation</e2>_3\NN\14361664 were_4\VBD\836236 significantly_5\RB\1740 lower_6\JJR\1740 (_7\-LRB-\1740 p_8\NN\14622893 less_9\JJR\1740 than_10\IN\1740 0.05_11\CD\1740 )_12\-RRB-\1740 after_13\IN\1740 iopentol_14\NN\1740 (_15\-LRB-\1740 0_16\CD\13741022 %_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 iohexol_20\NN\1740 (_21\-LRB-\1740 3_22\CD\13741022 %_23\NN\1740 )_24\-RRB-\1740 than_25\IN\1740 after_26\IN\1740 <e1>metrizoate</e1>_27\NN\1740 (_28\-LRB-\1740 22_29\CD\13745420 %_30\NN\1740 )_31\-RRB-\1740 ._32\.\1740
6433367
D011453_D012640 NONE effect_0\NN\34213 of_1\IN\1740 <e1>prostaglandin</e1>_2\NN\5414534 synthetase_3\NN\1740 inhibitors_4\NNS\20090 on_5\IN\1740 experimentally_6\RB\1740 induced_7\VBN\1627355 <e2>convulsions</e2>_8\NNS\14081375 in_9\IN\13603305 rats_10\NNS\2329401 ._11\.\1740
D011453_D012640 NONE to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 <e1>prostaglandins</e1>_5\NNS\5414534 (_6\-LRB-\1740 pgs_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 <e2>seizure</e2>_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 convulsions_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 flurothyl_24\NN\1740 ,_25\,\1740 picrotoxin_26\NN\1740 ,_27\,\1740 pentetrazol_28\NN\1740 (_29\-LRB-\1740 ptz_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 bicuculline_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D011453_D012640 NONE to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 <e1>prostaglandins</e1>_5\NNS\5414534 (_6\-LRB-\1740 pgs_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 seizure_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 <e2>convulsions</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 flurothyl_24\NN\1740 ,_25\,\1740 picrotoxin_26\NN\1740 ,_27\,\1740 pentetrazol_28\NN\1740 (_29\-LRB-\1740 ptz_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 bicuculline_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D011453_D012640 NONE to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 prostaglandins_5\NNS\5414534 (_6\-LRB-\1740 <e1>pgs</e1>_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 <e2>seizure</e2>_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 convulsions_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 flurothyl_24\NN\1740 ,_25\,\1740 picrotoxin_26\NN\1740 ,_27\,\1740 pentetrazol_28\NN\1740 (_29\-LRB-\1740 ptz_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 bicuculline_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D011453_D012640 NONE to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 prostaglandins_5\NNS\5414534 (_6\-LRB-\1740 <e1>pgs</e1>_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 seizure_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 <e2>convulsions</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 flurothyl_24\NN\1740 ,_25\,\1740 picrotoxin_26\NN\1740 ,_27\,\1740 pentetrazol_28\NN\1740 (_29\-LRB-\1740 ptz_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 bicuculline_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D011453_D012640 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e1>pgs</e1>_4\NNS\1740 are_5\VBP\836236 involved_6\VBN\2676054 in_7\IN\13603305 the_8\DT\1740 mechanism(s_9\NN\1740 )_10\-RRB-\1740 underlying_11\VBG\2604760 fluorthyl-_12\NN\1740 and_13\CC\1740 ptz-induced_14\JJ\1740 <e2>convulsions</e2>_15\NNS\14081375 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 picrotoxin-_19\NN\1740 ,_20\,\1740 electroshock-_21\NN\1740 ,_22\,\1740 or_23\CC\3541091 bicuculline-induced_24\JJ\1740 convulsions_25\NNS\14081375 ._26\.\1740
D011453_D012640 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e1>pgs</e1>_4\NNS\1740 are_5\VBP\836236 involved_6\VBN\2676054 in_7\IN\13603305 the_8\DT\1740 mechanism(s_9\NN\1740 )_10\-RRB-\1740 underlying_11\VBG\2604760 fluorthyl-_12\NN\1740 and_13\CC\1740 ptz-induced_14\JJ\1740 convulsions_15\NNS\14081375 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 picrotoxin-_19\NN\1740 ,_20\,\1740 electroshock-_21\NN\1740 ,_22\,\1740 or_23\CC\3541091 bicuculline-induced_24\JJ\1740 <e2>convulsions</e2>_25\NNS\14081375 ._26\.\1740
D005481_D012640 CID to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 prostaglandins_5\NNS\5414534 (_6\-LRB-\1740 pgs_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 <e2>seizure</e2>_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 convulsions_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 <e1>flurothyl</e1>_24\NN\1740 ,_25\,\1740 picrotoxin_26\NN\1740 ,_27\,\1740 pentetrazol_28\NN\1740 (_29\-LRB-\1740 ptz_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 bicuculline_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D005481_D012640 CID to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 prostaglandins_5\NNS\5414534 (_6\-LRB-\1740 pgs_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 seizure_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 <e2>convulsions</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 <e1>flurothyl</e1>_24\NN\1740 ,_25\,\1740 picrotoxin_26\NN\1740 ,_27\,\1740 pentetrazol_28\NN\1740 (_29\-LRB-\1740 ptz_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 bicuculline_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D005481_D012640 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 pgs_4\NNS\1740 are_5\VBP\836236 involved_6\VBN\2676054 in_7\IN\13603305 the_8\DT\1740 mechanism(s_9\NN\1740 )_10\-RRB-\1740 underlying_11\VBG\2604760 <e1>fluorthyl-</e1>_12\NN\1740 and_13\CC\1740 ptz-induced_14\JJ\1740 <e2>convulsions</e2>_15\NNS\14081375 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 picrotoxin-_19\NN\1740 ,_20\,\1740 electroshock-_21\NN\1740 ,_22\,\1740 or_23\CC\3541091 bicuculline-induced_24\JJ\1740 convulsions_25\NNS\14081375 ._26\.\1740
D005481_D012640 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 pgs_4\NNS\1740 are_5\VBP\836236 involved_6\VBN\2676054 in_7\IN\13603305 the_8\DT\1740 mechanism(s_9\NN\1740 )_10\-RRB-\1740 underlying_11\VBG\2604760 <e1>fluorthyl-</e1>_12\NN\1740 and_13\CC\1740 ptz-induced_14\JJ\1740 convulsions_15\NNS\14081375 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 picrotoxin-_19\NN\1740 ,_20\,\1740 electroshock-_21\NN\1740 ,_22\,\1740 or_23\CC\3541091 bicuculline-induced_24\JJ\1740 <e2>convulsions</e2>_25\NNS\14081375 ._26\.\1740
D010852_D012640 CID to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 prostaglandins_5\NNS\5414534 (_6\-LRB-\1740 pgs_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 <e2>seizure</e2>_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 convulsions_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 flurothyl_24\NN\1740 ,_25\,\1740 <e1>picrotoxin</e1>_26\NN\1740 ,_27\,\1740 pentetrazol_28\NN\1740 (_29\-LRB-\1740 ptz_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 bicuculline_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D010852_D012640 CID to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 prostaglandins_5\NNS\5414534 (_6\-LRB-\1740 pgs_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 seizure_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 <e2>convulsions</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 flurothyl_24\NN\1740 ,_25\,\1740 <e1>picrotoxin</e1>_26\NN\1740 ,_27\,\1740 pentetrazol_28\NN\1740 (_29\-LRB-\1740 ptz_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 bicuculline_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D010852_D012640 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 pgs_4\NNS\1740 are_5\VBP\836236 involved_6\VBN\2676054 in_7\IN\13603305 the_8\DT\1740 mechanism(s_9\NN\1740 )_10\-RRB-\1740 underlying_11\VBG\2604760 fluorthyl-_12\NN\1740 and_13\CC\1740 ptz-induced_14\JJ\1740 <e2>convulsions</e2>_15\NNS\14081375 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 <e1>picrotoxin-</e1>_19\NN\1740 ,_20\,\1740 electroshock-_21\NN\1740 ,_22\,\1740 or_23\CC\3541091 bicuculline-induced_24\JJ\1740 convulsions_25\NNS\14081375 ._26\.\1740
D010852_D012640 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 pgs_4\NNS\1740 are_5\VBP\836236 involved_6\VBN\2676054 in_7\IN\13603305 the_8\DT\1740 mechanism(s_9\NN\1740 )_10\-RRB-\1740 underlying_11\VBG\2604760 fluorthyl-_12\NN\1740 and_13\CC\1740 ptz-induced_14\JJ\1740 convulsions_15\NNS\14081375 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 <e1>picrotoxin-</e1>_19\NN\1740 ,_20\,\1740 electroshock-_21\NN\1740 ,_22\,\1740 or_23\CC\3541091 bicuculline-induced_24\JJ\1740 <e2>convulsions</e2>_25\NNS\14081375 ._26\.\1740
D010433_D012640 CID to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 prostaglandins_5\NNS\5414534 (_6\-LRB-\1740 pgs_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 <e2>seizure</e2>_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 convulsions_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 flurothyl_24\NN\1740 ,_25\,\1740 picrotoxin_26\NN\1740 ,_27\,\1740 <e1>pentetrazol</e1>_28\NN\1740 (_29\-LRB-\1740 ptz_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 bicuculline_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D010433_D012640 CID to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 prostaglandins_5\NNS\5414534 (_6\-LRB-\1740 pgs_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 seizure_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 <e2>convulsions</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 flurothyl_24\NN\1740 ,_25\,\1740 picrotoxin_26\NN\1740 ,_27\,\1740 <e1>pentetrazol</e1>_28\NN\1740 (_29\-LRB-\1740 ptz_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 bicuculline_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D010433_D012640 CID to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 prostaglandins_5\NNS\5414534 (_6\-LRB-\1740 pgs_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 <e2>seizure</e2>_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 convulsions_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 flurothyl_24\NN\1740 ,_25\,\1740 picrotoxin_26\NN\1740 ,_27\,\1740 pentetrazol_28\NN\1740 (_29\-LRB-\1740 <e1>ptz</e1>_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 bicuculline_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D010433_D012640 CID to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 prostaglandins_5\NNS\5414534 (_6\-LRB-\1740 pgs_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 seizure_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 <e2>convulsions</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 flurothyl_24\NN\1740 ,_25\,\1740 picrotoxin_26\NN\1740 ,_27\,\1740 pentetrazol_28\NN\1740 (_29\-LRB-\1740 <e1>ptz</e1>_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 bicuculline_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D010433_D012640 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 pgs_4\NNS\1740 are_5\VBP\836236 involved_6\VBN\2676054 in_7\IN\13603305 the_8\DT\1740 mechanism(s_9\NN\1740 )_10\-RRB-\1740 underlying_11\VBG\2604760 fluorthyl-_12\NN\1740 and_13\CC\1740 <e1>ptz-induced</e1>_14\JJ\1740 <e2>convulsions</e2>_15\NNS\14081375 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 picrotoxin-_19\NN\1740 ,_20\,\1740 electroshock-_21\NN\1740 ,_22\,\1740 or_23\CC\3541091 bicuculline-induced_24\JJ\1740 convulsions_25\NNS\14081375 ._26\.\1740
D010433_D012640 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 pgs_4\NNS\1740 are_5\VBP\836236 involved_6\VBN\2676054 in_7\IN\13603305 the_8\DT\1740 mechanism(s_9\NN\1740 )_10\-RRB-\1740 underlying_11\VBG\2604760 fluorthyl-_12\NN\1740 and_13\CC\1740 <e1>ptz-induced</e1>_14\JJ\1740 convulsions_15\NNS\14081375 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 picrotoxin-_19\NN\1740 ,_20\,\1740 electroshock-_21\NN\1740 ,_22\,\1740 or_23\CC\3541091 bicuculline-induced_24\JJ\1740 <e2>convulsions</e2>_25\NNS\14081375 ._26\.\1740
D001640_D012640 CID to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 prostaglandins_5\NNS\5414534 (_6\-LRB-\1740 pgs_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 <e2>seizure</e2>_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 convulsions_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 flurothyl_24\NN\1740 ,_25\,\1740 picrotoxin_26\NN\1740 ,_27\,\1740 pentetrazol_28\NN\1740 (_29\-LRB-\1740 ptz_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 <e1>bicuculline</e1>_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D001640_D012640 CID to_0\TO\1740 investigate_1\VB\644583 the_2\DT\1740 relationship_3\NN\31921 of_4\IN\1740 prostaglandins_5\NNS\5414534 (_6\-LRB-\1740 pgs_7\NNS\1740 )_8\-RRB-\1740 to_9\TO\1740 seizure_10\VB\1740 induction_11\NN\7450842 ,_12\,\1740 the_13\DT\1740 effects_14\NNS\13245626 of_15\IN\1740 six_16\CD\13741022 pg_17\NN\1740 synthetase_18\NN\1740 inhibitors_19\NNS\20090 on_20\IN\1740 <e2>convulsions</e2>_21\NNS\14081375 induced_22\VBN\1627355 by_23\IN\1740 flurothyl_24\NN\1740 ,_25\,\1740 picrotoxin_26\NN\1740 ,_27\,\1740 pentetrazol_28\NN\1740 (_29\-LRB-\1740 ptz_30\NN\1740 )_31\-RRB-\1740 ,_32\,\1740 electroshock_33\NN\662681 or_34\CC\3541091 <e1>bicuculline</e1>_35\NN\1740 were_36\VBD\836236 evaluated_37\VBN\670261 ._38\.\1740
D001640_D012640 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 pgs_4\NNS\1740 are_5\VBP\836236 involved_6\VBN\2676054 in_7\IN\13603305 the_8\DT\1740 mechanism(s_9\NN\1740 )_10\-RRB-\1740 underlying_11\VBG\2604760 fluorthyl-_12\NN\1740 and_13\CC\1740 ptz-induced_14\JJ\1740 <e2>convulsions</e2>_15\NNS\14081375 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 picrotoxin-_19\NN\1740 ,_20\,\1740 electroshock-_21\NN\1740 ,_22\,\1740 or_23\CC\3541091 <e1>bicuculline-induced</e1>_24\JJ\1740 convulsions_25\NNS\14081375 ._26\.\1740
D001640_D012640 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 pgs_4\NNS\1740 are_5\VBP\836236 involved_6\VBN\2676054 in_7\IN\13603305 the_8\DT\1740 mechanism(s_9\NN\1740 )_10\-RRB-\1740 underlying_11\VBG\2604760 fluorthyl-_12\NN\1740 and_13\CC\1740 ptz-induced_14\JJ\1740 convulsions_15\NNS\14081375 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 picrotoxin-_19\NN\1740 ,_20\,\1740 electroshock-_21\NN\1740 ,_22\,\1740 or_23\CC\3541091 <e1>bicuculline-induced</e1>_24\JJ\1740 <e2>convulsions</e2>_25\NNS\14081375 ._26\.\1740
16600756
D011453_D053201 NONE nerve_0\NN\5475681 growth_1\NN\13526110 factor_2\NN\7326557 and_3\CC\1740 <e1>prostaglandins</e1>_4\NNS\5414534 in_5\IN\13603305 the_6\DT\1740 urine_7\NN\14853947 of_8\IN\1740 female_9\JJ\1740 patients_10\NNS\9898892 with_11\IN\1740 <e2>overactive_12\JJ\1740 bladder</e2>_13\NN\5515670 ._14\.\1740
D011453_D053201 NONE we_0\PRP\1740 investigated_1\VBD\644583 changes_2\NNS\7283608 in_3\IN\13603305 urinary_4\JJ\1740 ngf_5\NN\14734348 and_6\CC\1740 <e1>pgs</e1>_7\NNS\1740 in_8\IN\13603305 women_9\NNS\9605289 with_10\IN\1740 <e2>oab</e2>_11\NN\1740 ._12\.\1740
D011453_D053201 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 correlations_3\NNS\13841213 between_4\IN\1740 urinary_5\JJ\1740 ngf_6\NN\14734348 and_7\CC\1740 <e1>pg</e1>_8\NN\1740 ,_9\,\1740 and_10\CC\1740 urodynamic_11\JJ\1740 parameters_12\NNS\5858936 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 <e2>oab</e2>_16\NN\1740 were_17\VBD\836236 examined_18\VBN\789138 ._19\.\1740
D011453_D053201 NONE conclusions_0\NNS\5837957 :_1\:\1740 ngf_2\NN\14734348 and_3\CC\1740 <e1>pgs</e1>_4\NNS\1740 have_5\VBP\2108377 important_6\JJ\1740 roles_7\NNS\719494 in_8\IN\13603305 the_9\DT\1740 development_10\NN\248977 of_11\IN\1740 <e2>oab</e2>_12\NN\1740 symptoms_13\NNS\5823932 in_14\IN\13603305 female_15\JJ\1740 patients_16\NNS\9898892 ._17\.\1740
D015232_D053201 CID results_0\NNS\34213 :_1\:\1740 urinary_2\JJ\1740 ngf_3\NN\14734348 ,_4\,\1740 <e1>pge2</e1>_5\NN\1740 and_6\CC\1740 pgf2alpha_7\NN\1740 were_8\VBD\836236 significantly_9\RB\1740 increased_10\VBN\169651 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 <e2>oab</e2>_14\NN\1740 compared_15\VBN\644583 with_16\IN\1740 controls_17\NNS\5190804 (_18\-LRB-\1740 p_19\NN\14622893 <_20\XX\1740 0.05_21\CD\1740 )_22\-RRB-\1740 ._23\.\1740
D015232_D053201 CID in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 <e2>oab</e2>_3\NN\1740 urinary_4\JJ\1740 <e1>pge2</e1>_5\NN\1740 positively_6\RB\1740 correlated_7\VBD\2657219 with_8\IN\1740 volume_9\NN\33615 at_10\IN\14622893 first_11\JJ\1740 desire_12\NN\26192 to_13\TO\1740 void_14\JJ\1740 and_15\CC\1740 maximum_16\JJ\1740 cystometric_17\JJ\1740 capacity_18\NN\5202497 (_19\-LRB-\1740 p_20\NN\14622893 <_21\XX\1740 0.05_22\CD\1740 )_23\-RRB-\1740 ._24\.\1740
D015237_D053201 CID results_0\NNS\34213 :_1\:\1740 urinary_2\JJ\1740 ngf_3\NN\14734348 ,_4\,\1740 pge2_5\NN\1740 and_6\CC\1740 <e1>pgf2alpha</e1>_7\NN\1740 were_8\VBD\836236 significantly_9\RB\1740 increased_10\VBN\169651 in_11\IN\13603305 patients_12\NNS\9898892 with_13\IN\1740 <e2>oab</e2>_14\NN\1740 compared_15\VBN\644583 with_16\IN\1740 controls_17\NNS\5190804 (_18\-LRB-\1740 p_19\NN\14622893 <_20\XX\1740 0.05_21\CD\1740 )_22\-RRB-\1740 ._23\.\1740
D015237_D053201 CID urinary_0\JJ\1740 ngf_1\NN\14734348 ,_2\,\1740 <e1>pgf2alpha</e1>_3\NN\1740 and_4\CC\1740 pgi2_5\NN\1740 did_6\VBD\1640855 not_7\RB\1740 correlate_8\VB\2657219 with_9\IN\1740 urodynamic_10\JJ\1740 parameters_11\NNS\5858936 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>oab</e2>_15\NN\1740 ._16\.\1740
D011464_D053201 NONE however_0\RB\1740 ,_1\,\1740 urinary_2\JJ\1740 <e1>pgi2</e1>_3\NN\1740 was_4\VBD\836236 not_5\RB\1740 different_6\JJ\1740 between_7\IN\1740 controls_8\NNS\5190804 and_9\CC\1740 patients_10\NNS\9898892 with_11\IN\1740 <e2>oab</e2>_12\NN\1740 ._13\.\1740
D011464_D053201 NONE urinary_0\JJ\1740 ngf_1\NN\14734348 ,_2\,\1740 pgf2alpha_3\NN\1740 and_4\CC\1740 <e1>pgi2</e1>_5\NN\1740 did_6\VBD\1640855 not_7\RB\1740 correlate_8\VB\2657219 with_9\IN\1740 urodynamic_10\JJ\1740 parameters_11\NNS\5858936 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>oab</e2>_15\NN\1740 ._16\.\1740
8410199
D018698_D012640 NONE loss_0\NN\13252973 of_1\IN\1740 <e1>glutamate</e1>_2\JJ\1740 decarboxylase_3\NN\14732946 mrna-containing_4\JJ\1740 neurons_5\NNS\5430628 in_6\IN\13603305 the_7\DT\1740 rat_8\NN\2329401 dentate_9\NN\1740 gyrus_10\NN\5225602 following_11\VBG\1835496 pilocarpine-induced_12\JJ\1740 <e2>seizures</e2>_13\NNS\14081375 ._14\.\1740
D018698_D012640 NONE in_0\FW\13603305 situ_1\FW\1740 hybridization_2\NN\847340 methods_3\NNS\5616786 were_4\VBD\836236 used_5\VBN\1156834 to_6\TO\1740 determine_7\VB\1645601 if_8\IN\1740 <e1>glutamic_9\JJ\1740 acid</e1>_10\NN\14818238 decarboxylase_11\NN\14732946 (_12\-LRB-\1740 gad_13\NN\14380473 )_14\-RRB-\1740 mrna-containing_15\JJ\1740 neurons_16\NNS\5430628 within_17\IN\1740 the_18\DT\1740 hilus_19\NN\5223370 of_20\IN\1740 the_21\DT\1740 dentate_22\NN\1740 gyrus_23\NN\5225602 are_24\VBP\836236 vulnerable_25\JJ\1740 to_26\TO\1740 <e2>seizure-induced</e2>_27\JJ\1740 damage_28\NN\7296428 in_29\IN\13603305 a_30\DT\13649268 model_31\NN\5888929 of_32\IN\1740 chronic_33\JJ\1740 seizures_34\NNS\14081375 ._35\.\1740
D018698_D012640 NONE in_0\FW\13603305 situ_1\FW\1740 hybridization_2\NN\847340 methods_3\NNS\5616786 were_4\VBD\836236 used_5\VBN\1156834 to_6\TO\1740 determine_7\VB\1645601 if_8\IN\1740 <e1>glutamic_9\JJ\1740 acid</e1>_10\NN\14818238 decarboxylase_11\NN\14732946 (_12\-LRB-\1740 gad_13\NN\14380473 )_14\-RRB-\1740 mrna-containing_15\JJ\1740 neurons_16\NNS\5430628 within_17\IN\1740 the_18\DT\1740 hilus_19\NN\5223370 of_20\IN\1740 the_21\DT\1740 dentate_22\NN\1740 gyrus_23\NN\5225602 are_24\VBP\836236 vulnerable_25\JJ\1740 to_26\TO\1740 seizure-induced_27\JJ\1740 damage_28\NN\7296428 in_29\IN\13603305 a_30\DT\13649268 model_31\NN\5888929 of_32\IN\1740 chronic_33\JJ\1740 <e2>seizures</e2>_34\NNS\14081375 ._35\.\1740
D010862_D012640 CID loss_0\NN\13252973 of_1\IN\1740 glutamate_2\JJ\1740 decarboxylase_3\NN\14732946 mrna-containing_4\JJ\1740 neurons_5\NNS\5430628 in_6\IN\13603305 the_7\DT\1740 rat_8\NN\2329401 dentate_9\NN\1740 gyrus_10\NN\5225602 following_11\VBG\1835496 <e1>pilocarpine-induced</e1>_12\JJ\1740 <e2>seizures</e2>_13\NNS\14081375 ._14\.\1740
D010862_D012640 CID sprague-dawley_0\JJ\1740 rats_1\NNS\2329401 were_2\VBD\836236 injected_3\VBN\81072 intraperitoneally_4\RB\1740 with_5\IN\1740 <e1>pilocarpine</e1>_6\NN\14712692 ,_7\,\1740 and_8\CC\1740 the_9\DT\1740 hippocampal_10\NN\1740 formation_11\NN\7938773 was_12\VBD\836236 studied_13\VBN\630380 histologically_14\RB\1740 at_15\IN\14622893 1_16\CD\13741022 ,_17\,\1740 2_18\CD\13741022 ,_19\,\1740 4_20\CD\13741022 ,_21\,\1740 and_22\CC\1740 8_23\CD\13741022 week_24\NN\15113229 intervals_25\NNS\33615 after_26\IN\1740 pilocarpine-induced_27\JJ\1740 <e2>seizures</e2>_28\NNS\14081375 ._29\.\1740
D010862_D012640 CID sprague-dawley_0\JJ\1740 rats_1\NNS\2329401 were_2\VBD\836236 injected_3\VBN\81072 intraperitoneally_4\RB\1740 with_5\IN\1740 pilocarpine_6\NN\14712692 ,_7\,\1740 and_8\CC\1740 the_9\DT\1740 hippocampal_10\NN\1740 formation_11\NN\7938773 was_12\VBD\836236 studied_13\VBN\630380 histologically_14\RB\1740 at_15\IN\14622893 1_16\CD\13741022 ,_17\,\1740 2_18\CD\13741022 ,_19\,\1740 4_20\CD\13741022 ,_21\,\1740 and_22\CC\1740 8_23\CD\13741022 week_24\NN\15113229 intervals_25\NNS\33615 after_26\IN\1740 <e1>pilocarpine-induced</e1>_27\JJ\1740 <e2>seizures</e2>_28\NNS\14081375 ._29\.\1740
C028911_D009410 NONE additional_0\JJ\1740 neuronanatomical_1\JJ\1740 studies_2\NNS\635850 ,_3\,\1740 including_4\VBG\690614 <e1>cresyl_5\NN\1740 violet</e1>_6\JJ\1740 staining_7\NN\275424 ,_8\,\1740 <e2>neuronal_9\JJ\1740 degeneration</e2>_10\NN\29677 methods_11\NNS\5616786 ,_12\,\1740 and_13\CC\1740 histochemical_14\JJ\1740 localization_15\NN\151497 of_16\IN\1740 glial_17\JJ\1740 fibrillary_18\JJ\1740 acidic_19\JJ\1740 protein_20\NN\14944888 ,_21\,\1740 suggested_22\VBD\1010118 that_23\IN\1740 the_24\DT\1740 decrease_25\NN\7296428 in_26\IN\13603305 the_27\DT\1740 number_28\NN\5107765 of_29\IN\1740 gad_30\NN\14380473 mrna-containing_31\JJ\1740 neurons_32\NNS\5430628 was_33\VBD\836236 related_34\JJ\1740 to_35\TO\1740 neuronal_36\JJ\1740 loss_37\NN\13252973 rather_38\RB\1740 than_39\IN\1740 to_40\TO\1740 a_41\DT\13649268 decrease_42\NN\7296428 in_43\IN\13603305 gad_44\NN\14380473 mrna_45\NN\14832193 levels_46\NNS\4916342 ._47\.\1740
C028911_D009410 NONE additional_0\JJ\1740 neuronanatomical_1\JJ\1740 studies_2\NNS\635850 ,_3\,\1740 including_4\VBG\690614 <e1>cresyl_5\NN\1740 violet</e1>_6\JJ\1740 staining_7\NN\275424 ,_8\,\1740 neuronal_9\JJ\1740 degeneration_10\NN\29677 methods_11\NNS\5616786 ,_12\,\1740 and_13\CC\1740 histochemical_14\JJ\1740 localization_15\NN\151497 of_16\IN\1740 glial_17\JJ\1740 fibrillary_18\JJ\1740 acidic_19\JJ\1740 protein_20\NN\14944888 ,_21\,\1740 suggested_22\VBD\1010118 that_23\IN\1740 the_24\DT\1740 decrease_25\NN\7296428 in_26\IN\13603305 the_27\DT\1740 number_28\NN\5107765 of_29\IN\1740 gad_30\NN\14380473 mrna-containing_31\JJ\1740 neurons_32\NNS\5430628 was_33\VBD\836236 related_34\JJ\1740 to_35\TO\1740 <e2>neuronal_36\JJ\1740 loss</e2>_37\NN\13252973 rather_38\RB\1740 than_39\IN\1740 to_40\TO\1740 a_41\DT\13649268 decrease_42\NN\7296428 in_43\IN\13603305 gad_44\NN\14380473 mrna_45\NN\14832193 levels_46\NNS\4916342 ._47\.\1740
1636026
D013496_D058186 CID although_0\IN\1740 <e1>suprofen</e1>_1\NN\1740 has_2\VBZ\2108377 been_3\VBN\836236 associated_4\VBN\628491 with_5\IN\1740 the_6\DT\1740 development_7\NN\248977 of_8\IN\1740 <e2>acute_9\JJ\1740 renal_10\JJ\1740 failure</e2>_11\NN\66216 in_12\IN\13603305 greater_13\JJR\1740 than_14\IN\1740 100_15\CD\13745420 subjects_16\NNS\6598915 ,_17\,\1740 the_18\DT\1740 mechanism_19\NN\13446390 of_20\IN\1740 damage_21\NN\7296428 remains_22\VBZ\2604760 unclear_23\JJ\1740 ._24\.\1740
D013496_D058186 CID in_0\IN\13603305 summary_1\NN\6722453 ,_2\,\1740 <e1>suprofen</e1>_3\NN\1740 causes_4\VBZ\1617192 <e2>acute_5\JJ\1740 declines_6\NNS\13458571 in_7\IN\13603305 renal_8\JJ\1740 function</e2>_9\NN\13783581 ,_10\,\1740 most_11\RBS\1740 likely_12\RB\1740 by_13\IN\1740 directly_14\RB\1740 altering_15\VBG\126264 the_16\DT\1740 intrarenal_17\JJ\1740 distribution_18\NN\5726596 of_19\IN\1740 uric_20\JJ\1740 acid_21\NN\14818238 ._22\.\1740
D013496_D007674 NONE the_0\DT\1740 direct_1\JJ\1740 <e2>nephrotoxic</e2>_2\JJ\1740 effects_3\NNS\13245626 of_4\IN\1740 a_5\DT\13649268 single_6\JJ\1740 dose_7\NN\3740161 of_8\IN\1740 15_9\CD\13745420 mg_10\NN\13717155 of_11\IN\1740 <e1>suprofen</e1>_12\NN\1740 were_13\VBD\836236 compared_14\VBN\644583 in_15\IN\13603305 the_16\DT\1740 recirculating_17\NN\1740 isolated_18\VBN\2512305 rat_19\NN\2329401 kidney_20\NN\5333259 perfused_21\VBN\454868 with_22\IN\1740 cell-free_23\JJ\1740 buffer_24\NN\14818238 with_25\IN\1740 or_26\CC\3541091 without_27\IN\1740 the_28\DT\1740 addition_29\NN\3081021 of_30\IN\1740 5_31\CD\13741022 mg/dl_32\NN\1740 of_33\IN\1740 uric_34\JJ\1740 acid_35\NN\14818238 ._36\.\1740
D014527_D007674 NONE the_0\DT\1740 direct_1\JJ\1740 <e2>nephrotoxic</e2>_2\JJ\1740 effects_3\NNS\13245626 of_4\IN\1740 a_5\DT\13649268 single_6\JJ\1740 dose_7\NN\3740161 of_8\IN\1740 15_9\CD\13745420 mg_10\NN\13717155 of_11\IN\1740 suprofen_12\NN\1740 were_13\VBD\836236 compared_14\VBN\644583 in_15\IN\13603305 the_16\DT\1740 recirculating_17\NN\1740 isolated_18\VBN\2512305 rat_19\NN\2329401 kidney_20\NN\5333259 perfused_21\VBN\454868 with_22\IN\1740 cell-free_23\JJ\1740 buffer_24\NN\14818238 with_25\IN\1740 or_26\CC\3541091 without_27\IN\1740 the_28\DT\1740 addition_29\NN\3081021 of_30\IN\1740 5_31\CD\13741022 mg/dl_32\NN\1740 of_33\IN\1740 <e1>uric_34\JJ\1740 acid</e1>_35\NN\14818238 ._36\.\1740
D014527_D058186 NONE in_0\IN\13603305 summary_1\NN\6722453 ,_2\,\1740 suprofen_3\NN\1740 causes_4\VBZ\1617192 <e2>acute_5\JJ\1740 declines_6\NNS\13458571 in_7\IN\13603305 renal_8\JJ\1740 function</e2>_9\NN\13783581 ,_10\,\1740 most_11\RBS\1740 likely_12\RB\1740 by_13\IN\1740 directly_14\RB\1740 altering_15\VBG\126264 the_16\DT\1740 intrarenal_17\JJ\1740 distribution_18\NN\5726596 of_19\IN\1740 <e1>uric_20\JJ\1740 acid</e1>_21\NN\14818238 ._22\.\1740
6637851
D000638_D064420 NONE long-term_0\JJ\1740 efficacy_1\NN\5199286 and_2\CC\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 high-dose_5\JJ\1740 <e1>amiodarone</e1>_6\NN\2715941 therapy_7\NN\657604 for_8\IN\1740 ventricular_9\JJ\1740 tachycardia_10\NN\14110674 or_11\CC\3541091 ventricular_12\JJ\1740 fibrillation_13\NN\14361664 ._14\.\1740
D000638_D064420 NONE although_0\IN\1740 large-dose_1\JJ\1740 <e1>amiodarone</e1>_2\NN\2715941 is_3\VBZ\836236 highly_4\RB\1740 effective_5\JJ\1740 in_6\IN\13603305 the_7\DT\1740 long-term_8\JJ\1740 treatment_9\NN\654885 of_10\IN\1740 vt_11\NN\1740 or_12\CC\3541091 vf_13\NN\1740 refractory_14\JJ\1740 to_15\TO\1740 conventional_16\JJ\1740 antiarrhythmic_17\JJ\1740 drugs_18\NNS\14778436 ,_19\,\1740 it_20\PRP\6125041 causes_21\VBZ\1617192 significant_22\JJ\1740 <e2>toxicity</e2>_23\NN\13576101 in_24\IN\13603305 approximately_25\RB\1740 50_26\CD\13745420 %_27\NN\1740 of_28\IN\1740 patients_29\NNS\9898892 ._30\.\1740
D000638_D017180 NONE long-term_0\JJ\1740 efficacy_1\NN\5199286 and_2\CC\1740 toxicity_3\NN\13576101 of_4\IN\1740 high-dose_5\JJ\1740 <e1>amiodarone</e1>_6\NN\2715941 therapy_7\NN\657604 for_8\IN\1740 <e2>ventricular_9\JJ\1740 tachycardia</e2>_10\NN\14110674 or_11\CC\3541091 ventricular_12\JJ\1740 fibrillation_13\NN\14361664 ._14\.\1740
D000638_D017180 NONE <e1>amiodarone</e1>_0\NN\2715941 was_1\VBD\836236 administered_2\VBN\2436349 to_3\TO\1740 154_4\CD\1740 patients_5\NNS\9898892 who_6\WP\8299493 had_7\VBD\2108377 sustained_8\JJ\1740 ,_9\,\1740 symptomatic_10\JJ\1740 <e2>ventricular_11\JJ\1740 tachycardia</e2>_12\NN\14110674 (_13\-LRB-\1740 vt_14\NN\1740 )_15\-RRB-\1740 (_16\-LRB-\1740 n_17\NN\14622893 =_18\JJ\1740 118_19\CD\1740 )_20\-RRB-\1740 or_21\CC\3541091 a_22\DT\13649268 cardiac_23\JJ\1740 arrest_24\NN\88481 (_25\-LRB-\1740 n_26\NN\14622893 =_27\JJ\1740 36_28\CD\1740 )_29\-RRB-\1740 and_30\CC\1740 who_31\WP\8299493 were_32\VBD\836236 refractory_33\JJ\1740 to_34\TO\1740 conventional_35\JJ\1740 antiarrhythmic_36\JJ\1740 drugs_37\NNS\14778436 ._38\.\1740
D000638_D017180 NONE <e1>amiodarone</e1>_0\NN\2715941 was_1\VBD\836236 administered_2\VBN\2436349 to_3\TO\1740 154_4\CD\1740 patients_5\NNS\9898892 who_6\WP\8299493 had_7\VBD\2108377 sustained_8\JJ\1740 ,_9\,\1740 symptomatic_10\JJ\1740 ventricular_11\JJ\1740 tachycardia_12\NN\14110674 (_13\-LRB-\1740 <e2>vt</e2>_14\NN\1740 )_15\-RRB-\1740 (_16\-LRB-\1740 n_17\NN\14622893 =_18\JJ\1740 118_19\CD\1740 )_20\-RRB-\1740 or_21\CC\3541091 a_22\DT\13649268 cardiac_23\JJ\1740 arrest_24\NN\88481 (_25\-LRB-\1740 n_26\NN\14622893 =_27\JJ\1740 36_28\CD\1740 )_29\-RRB-\1740 and_30\CC\1740 who_31\WP\8299493 were_32\VBD\836236 refractory_33\JJ\1740 to_34\TO\1740 conventional_35\JJ\1740 antiarrhythmic_36\JJ\1740 drugs_37\NNS\14778436 ._38\.\1740
D000638_D017180 NONE sixty-nine_0\JJ\1740 percent_1\NN\13815742 of_2\IN\1740 patients_3\NNS\9898892 continued_4\VBD\2367363 treatment_5\NN\654885 with_6\IN\1740 <e1>amiodarone</e1>_7\NN\2715941 and_8\CC\1740 had_9\VBD\2108377 no_10\DT\7204911 recurrence_11\NN\7342049 of_12\IN\1740 symptomatic_13\JJ\1740 <e2>vt</e2>_14\NN\1740 or_15\CC\3541091 ventricular_16\JJ\1740 fibrillation_17\NN\14361664 (_18\-LRB-\1740 vf_19\NN\1740 )_20\-RRB-\1740 over_21\IN\5867413 a_22\DT\13649268 follow-up_23\NN\4599396 of_24\IN\1740 6_25\CD\13741022 to_26\TO\1740 52_27\CD\1740 months_28\NNS\15113229 (_29\-LRB-\1740 mean_30\NN\6021761 +/-_31\CC\1740 standard_32\JJ\1740 deviation_33\NN\7337390 14.2_34\CD\1740 +/-_35\CC\1740 8.2_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
D000638_D017180 NONE six_0\CD\13741022 percent_1\NN\13815742 of_2\IN\1740 the_3\DT\1740 patients_4\NNS\9898892 had_5\VBD\2108377 a_6\DT\13649268 nonfatal_7\JJ\1740 recurrence_8\NN\7342049 of_9\IN\1740 <e2>vt</e2>_10\NN\1740 and_11\CC\1740 were_12\VBD\836236 successfully_13\RB\1740 managed_14\VBN\2524171 by_15\IN\1740 continuing_16\VBG\2367363 <e1>amiodarone</e1>_17\NN\2715941 at_18\IN\14622893 a_19\DT\13649268 higher_20\JJR\1740 dose_21\NN\3740161 or_22\CC\3541091 by_23\IN\1740 the_24\DT\1740 addition_25\NN\3081021 of_26\IN\1740 a_27\DT\13649268 conventional_28\JJ\1740 antiarrhythmic_29\JJ\1740 drug_30\NN\14778436 ._31\.\1740
D000638_D017180 NONE although_0\IN\1740 large-dose_1\JJ\1740 <e1>amiodarone</e1>_2\NN\2715941 is_3\VBZ\836236 highly_4\RB\1740 effective_5\JJ\1740 in_6\IN\13603305 the_7\DT\1740 long-term_8\JJ\1740 treatment_9\NN\654885 of_10\IN\1740 <e2>vt</e2>_11\NN\1740 or_12\CC\3541091 vf_13\NN\1740 refractory_14\JJ\1740 to_15\TO\1740 conventional_16\JJ\1740 antiarrhythmic_17\JJ\1740 drugs_18\NNS\14778436 ,_19\,\1740 it_20\PRP\6125041 causes_21\VBZ\1617192 significant_22\JJ\1740 toxicity_23\NN\13576101 in_24\IN\13603305 approximately_25\RB\1740 50_26\CD\13745420 %_27\NN\1740 of_28\IN\1740 patients_29\NNS\9898892 ._30\.\1740
D000638_D017180 NONE however_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 the_3\DT\1740 dose_4\NN\3740161 is_5\VBZ\836236 adjusted_6\VBN\126264 based_7\VBN\2694933 on_8\IN\1740 clinical_9\JJ\1740 response_10\NN\11410625 or_11\CC\3541091 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 adverse_15\JJ\1740 effects_16\NNS\13245626 ,_17\,\1740 75_18\CD\1740 %_19\NN\1740 of_20\IN\1740 patients_21\NNS\9898892 with_22\IN\1740 <e2>vt</e2>_23\NN\1740 or_24\CC\3541091 vf_25\NN\1740 can_26\MD\3094503 be_27\VB\836236 successfully_28\RB\1740 managed_29\VBN\2524171 with_30\IN\1740 <e1>amiodarone</e1>_31\NN\2715941 ._32\.\1740
D000638_D014693 NONE long-term_0\JJ\1740 efficacy_1\NN\5199286 and_2\CC\1740 toxicity_3\NN\13576101 of_4\IN\1740 high-dose_5\JJ\1740 <e1>amiodarone</e1>_6\NN\2715941 therapy_7\NN\657604 for_8\IN\1740 ventricular_9\JJ\1740 tachycardia_10\NN\14110674 or_11\CC\3541091 <e2>ventricular_12\JJ\1740 fibrillation</e2>_13\NN\14361664 ._14\.\1740
D000638_D014693 NONE sixty-nine_0\JJ\1740 percent_1\NN\13815742 of_2\IN\1740 patients_3\NNS\9898892 continued_4\VBD\2367363 treatment_5\NN\654885 with_6\IN\1740 <e1>amiodarone</e1>_7\NN\2715941 and_8\CC\1740 had_9\VBD\2108377 no_10\DT\7204911 recurrence_11\NN\7342049 of_12\IN\1740 symptomatic_13\JJ\1740 vt_14\NN\1740 or_15\CC\3541091 <e2>ventricular_16\JJ\1740 fibrillation</e2>_17\NN\14361664 (_18\-LRB-\1740 vf_19\NN\1740 )_20\-RRB-\1740 over_21\IN\5867413 a_22\DT\13649268 follow-up_23\NN\4599396 of_24\IN\1740 6_25\CD\13741022 to_26\TO\1740 52_27\CD\1740 months_28\NNS\15113229 (_29\-LRB-\1740 mean_30\NN\6021761 +/-_31\CC\1740 standard_32\JJ\1740 deviation_33\NN\7337390 14.2_34\CD\1740 +/-_35\CC\1740 8.2_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
D000638_D014693 NONE sixty-nine_0\JJ\1740 percent_1\NN\13815742 of_2\IN\1740 patients_3\NNS\9898892 continued_4\VBD\2367363 treatment_5\NN\654885 with_6\IN\1740 <e1>amiodarone</e1>_7\NN\2715941 and_8\CC\1740 had_9\VBD\2108377 no_10\DT\7204911 recurrence_11\NN\7342049 of_12\IN\1740 symptomatic_13\JJ\1740 vt_14\NN\1740 or_15\CC\3541091 ventricular_16\JJ\1740 fibrillation_17\NN\14361664 (_18\-LRB-\1740 <e2>vf</e2>_19\NN\1740 )_20\-RRB-\1740 over_21\IN\5867413 a_22\DT\13649268 follow-up_23\NN\4599396 of_24\IN\1740 6_25\CD\13741022 to_26\TO\1740 52_27\CD\1740 months_28\NNS\15113229 (_29\-LRB-\1740 mean_30\NN\6021761 +/-_31\CC\1740 standard_32\JJ\1740 deviation_33\NN\7337390 14.2_34\CD\1740 +/-_35\CC\1740 8.2_36\CD\1740 )_37\-RRB-\1740 ._38\.\1740
D000638_D014693 NONE although_0\IN\1740 large-dose_1\JJ\1740 <e1>amiodarone</e1>_2\NN\2715941 is_3\VBZ\836236 highly_4\RB\1740 effective_5\JJ\1740 in_6\IN\13603305 the_7\DT\1740 long-term_8\JJ\1740 treatment_9\NN\654885 of_10\IN\1740 vt_11\NN\1740 or_12\CC\3541091 <e2>vf</e2>_13\NN\1740 refractory_14\JJ\1740 to_15\TO\1740 conventional_16\JJ\1740 antiarrhythmic_17\JJ\1740 drugs_18\NNS\14778436 ,_19\,\1740 it_20\PRP\6125041 causes_21\VBZ\1617192 significant_22\JJ\1740 toxicity_23\NN\13576101 in_24\IN\13603305 approximately_25\RB\1740 50_26\CD\13745420 %_27\NN\1740 of_28\IN\1740 patients_29\NNS\9898892 ._30\.\1740
D000638_D014693 NONE however_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 the_3\DT\1740 dose_4\NN\3740161 is_5\VBZ\836236 adjusted_6\VBN\126264 based_7\VBN\2694933 on_8\IN\1740 clinical_9\JJ\1740 response_10\NN\11410625 or_11\CC\3541091 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 adverse_15\JJ\1740 effects_16\NNS\13245626 ,_17\,\1740 75_18\CD\1740 %_19\NN\1740 of_20\IN\1740 patients_21\NNS\9898892 with_22\IN\1740 vt_23\NN\1740 or_24\CC\3541091 <e2>vf</e2>_25\NN\1740 can_26\MD\3094503 be_27\VB\836236 successfully_28\RB\1740 managed_29\VBN\2524171 with_30\IN\1740 <e1>amiodarone</e1>_31\NN\2715941 ._32\.\1740
D000638_D006323 NONE <e1>amiodarone</e1>_0\NN\2715941 was_1\VBD\836236 administered_2\VBN\2436349 to_3\TO\1740 154_4\CD\1740 patients_5\NNS\9898892 who_6\WP\8299493 had_7\VBD\2108377 sustained_8\JJ\1740 ,_9\,\1740 symptomatic_10\JJ\1740 ventricular_11\JJ\1740 tachycardia_12\NN\14110674 (_13\-LRB-\1740 vt_14\NN\1740 )_15\-RRB-\1740 (_16\-LRB-\1740 n_17\NN\14622893 =_18\JJ\1740 118_19\CD\1740 )_20\-RRB-\1740 or_21\CC\3541091 a_22\DT\13649268 <e2>cardiac_23\JJ\1740 arrest</e2>_24\NN\88481 (_25\-LRB-\1740 n_26\NN\14622893 =_27\JJ\1740 36_28\CD\1740 )_29\-RRB-\1740 and_30\CC\1740 who_31\WP\8299493 were_32\VBD\836236 refractory_33\JJ\1740 to_34\TO\1740 conventional_35\JJ\1740 antiarrhythmic_36\JJ\1740 drugs_37\NNS\14778436 ._38\.\1740
12734532
D010665_D009203 CID case_0\NN\7283608 report_1\NN\6470073 :_2\:\1740 <e1>dexatrim</e1>_3\NN\1740 (_4\-LRB-\1740 phenylpropanolamine_5\NN\2682038 )_6\-RRB-\1740 as_7\IN\14622893 a_8\DT\13649268 cause_9\NN\7323922 of_10\IN\1740 <e2>myocardial_11\JJ\1740 infarction</e2>_12\NN\14204950 ._13\.\1740
D010665_D009203 CID case_0\NN\7283608 report_1\NN\6470073 :_2\:\1740 dexatrim_3\NN\1740 (_4\-LRB-\1740 <e1>phenylpropanolamine</e1>_5\NN\2682038 )_6\-RRB-\1740 as_7\IN\14622893 a_8\DT\13649268 cause_9\NN\7323922 of_10\IN\1740 <e2>myocardial_11\JJ\1740 infarction</e2>_12\NN\14204950 ._13\.\1740
D010665_D009202 NONE several_0\JJ\1740 reports_1\NNS\6470073 have_2\VBP\2108377 linked_3\VBN\628491 the_4\DT\1740 abuse_5\NN\418025 of_6\IN\1740 <e1>ppa</e1>_7\NN\1740 with_8\IN\1740 <e2>myocardial_9\JJ\1740 injury</e2>_10\NN\14052046 ,_11\,\1740 especially_12\RB\1740 when_13\WRB\1740 overdose_14\NN\1740 is_15\VBZ\836236 involved_16\VBN\2676054 ._17\.\1740
D010665_D009202 NONE we_0\PRP\1740 report_1\VBP\831651 here_2\RB\1740 the_3\DT\1740 first_4\JJ\1740 case_5\NN\7283608 of_6\IN\1740 <e1>dexatrim</e1>_7\NN\1740 (ppa)-induced_8\VBN\1740 <e2>myocardial_9\JJ\1740 injury</e2>_10\NN\14052046 in_11\IN\13603305 a_12\DT\13649268 young_13\JJ\1740 woman_14\NN\9605289 who_15\WP\8299493 was_16\VBD\836236 using_17\VBG\1156834 it_18\PRP\6125041 at_19\IN\14622893 recommended_20\VBN\875394 doses_21\NNS\3740161 for_22\IN\1740 weight_23\NN\5009170 control_24\NN\5190804 ._25\.\1740
D010665_D009202 NONE we_0\PRP\1740 report_1\VBP\831651 here_2\RB\1740 the_3\DT\1740 first_4\JJ\1740 case_5\NN\7283608 of_6\IN\1740 dexatrim_7\NN\1740 <e1>(ppa)-induced</e1>_8\VBN\1740 <e2>myocardial_9\JJ\1740 injury</e2>_10\NN\14052046 in_11\IN\13603305 a_12\DT\13649268 young_13\JJ\1740 woman_14\NN\9605289 who_15\WP\8299493 was_16\VBD\836236 using_17\VBG\1156834 it_18\PRP\6125041 at_19\IN\14622893 recommended_20\VBN\875394 doses_21\NNS\3740161 for_22\IN\1740 weight_23\NN\5009170 control_24\NN\5190804 ._25\.\1740
D010665_D009202 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 we_3\PRP\1740 review_4\VBP\644583 the_5\DT\1740 7_6\CD\13741022 other_7\JJ\1740 cases_8\NNS\7283608 of_9\IN\1740 <e1>ppa</e1>_10\NN\1740 related_11\JJ\1740 <e2>myocardial_12\JJ\1740 injury</e2>_13\NN\14052046 that_14\WDT\1740 have_15\VBP\2108377 been_16\VBN\836236 reported_17\VBN\831651 so_18\RB\1740 far_19\RB\1740 ._20\.\1740
D010665_D062787 NONE several_0\JJ\1740 reports_1\NNS\6470073 have_2\VBP\2108377 linked_3\VBN\628491 the_4\DT\1740 abuse_5\NN\418025 of_6\IN\1740 <e1>ppa</e1>_7\NN\1740 with_8\IN\1740 myocardial_9\JJ\1740 injury_10\NN\14052046 ,_11\,\1740 especially_12\RB\1740 when_13\WRB\1740 <e2>overdose</e2>_14\NN\1740 is_15\VBZ\836236 involved_16\VBN\2676054 ._17\.\1740
3535719
D009428_D064420 NONE relative_0\JJ\1740 efficacy_1\NN\5199286 and_2\CC\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 <e1>netilmicin</e1>_5\NN\1740 and_6\CC\1740 tobramycin_7\NN\2716866 in_8\IN\13603305 oncology_9\NN\6043075 patients_10\NNS\9898892 ._11\.\1740
D014031_D064420 NONE relative_0\JJ\1740 efficacy_1\NN\5199286 and_2\CC\1740 <e2>toxicity</e2>_3\NN\13576101 of_4\IN\1740 netilmicin_5\NN\1740 and_6\CC\1740 <e1>tobramycin</e1>_7\NN\2716866 in_8\IN\13603305 oncology_9\NN\6043075 patients_10\NNS\9898892 ._11\.\1740
D009428_D007239 NONE we_0\PRP\1740 prospectively_1\RB\1740 compared_2\VBD\644583 the_3\DT\1740 efficacy_4\NN\5199286 and_5\CC\1740 safety_6\NN\13920835 of_7\IN\1740 <e1>netilmicin_8\NN\1740 sulfate</e1>_9\NN\15010703 or_10\CC\3541091 tobramycin_11\NN\2716866 sulfate_12\NN\15010703 in_13\IN\13603305 conjunction_14\NN\5048123 with_15\IN\1740 piperacillin_16\NN\3910033 sodium_17\NN\14625458 in_18\IN\13603305 118_19\CD\1740 immunocompromised_20\VBN\1740 patients_21\NNS\9898892 with_22\IN\1740 presumed_23\VBN\719734 severe_24\JJ\1740 <e2>infections</e2>_25\NNS\14052046 ._26\.\1740
D014031_D007239 NONE we_0\PRP\1740 prospectively_1\RB\1740 compared_2\VBD\644583 the_3\DT\1740 efficacy_4\NN\5199286 and_5\CC\1740 safety_6\NN\13920835 of_7\IN\1740 netilmicin_8\NN\1740 sulfate_9\NN\15010703 or_10\CC\3541091 <e1>tobramycin_11\NN\2716866 sulfate</e1>_12\NN\15010703 in_13\IN\13603305 conjunction_14\NN\5048123 with_15\IN\1740 piperacillin_16\NN\3910033 sodium_17\NN\14625458 in_18\IN\13603305 118_19\CD\1740 immunocompromised_20\VBN\1740 patients_21\NNS\9898892 with_22\IN\1740 presumed_23\VBN\719734 severe_24\JJ\1740 <e2>infections</e2>_25\NNS\14052046 ._26\.\1740
D010878_D007239 NONE we_0\PRP\1740 prospectively_1\RB\1740 compared_2\VBD\644583 the_3\DT\1740 efficacy_4\NN\5199286 and_5\CC\1740 safety_6\NN\13920835 of_7\IN\1740 netilmicin_8\NN\1740 sulfate_9\NN\15010703 or_10\CC\3541091 tobramycin_11\NN\2716866 sulfate_12\NN\15010703 in_13\IN\13603305 conjunction_14\NN\5048123 with_15\IN\1740 <e1>piperacillin_16\NN\3910033 sodium</e1>_17\NN\14625458 in_18\IN\13603305 118_19\CD\1740 immunocompromised_20\VBN\1740 patients_21\NNS\9898892 with_22\IN\1740 presumed_23\VBN\719734 severe_24\JJ\1740 <e2>infections</e2>_25\NNS\14052046 ._26\.\1740
D009428_D007674 CID <e2>nephrotoxicity</e2>_0\NN\1740 occurred_1\VBD\2623529 in_2\IN\13603305 a_3\DT\13649268 similar_4\JJ\1740 proportion_5\NN\13824815 in_6\IN\13603305 patients_7\NNS\9898892 treated_8\VBN\2376958 with_9\IN\1740 <e1>netilmicin</e1>_10\NN\1740 and_11\CC\1740 tobramycin_12\NN\2716866 (_13\-LRB-\1740 17_14\CD\13745420 %_15\NN\1740 vs_16\CC\13634784 11_17\CD\13745420 %_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D014031_D007674 CID <e2>nephrotoxicity</e2>_0\NN\1740 occurred_1\VBD\2623529 in_2\IN\13603305 a_3\DT\13649268 similar_4\JJ\1740 proportion_5\NN\13824815 in_6\IN\13603305 patients_7\NNS\9898892 treated_8\VBN\2376958 with_9\IN\1740 netilmicin_10\NN\1740 and_11\CC\1740 <e1>tobramycin</e1>_12\NN\2716866 (_13\-LRB-\1740 17_14\CD\13745420 %_15\NN\1740 vs_16\CC\13634784 11_17\CD\13745420 %_18\NN\1740 )_19\-RRB-\1740 ._20\.\1740
D009428_D006311 CID <e2>ototoxicity</e2>_0\NN\1740 occurred_1\VBD\2623529 in_2\IN\13603305 four_3\CD\13741022 (_4\-LRB-\1740 9.5_5\CD\1740 %_6\NN\1740 )_7\-RRB-\1740 of_8\IN\1740 42_9\CD\1740 <e1>netilmicin</e1>_10\NN\1740 and_11\CC\1740 piperacillin_12\NN\3910033 and_13\CC\1740 in_14\IN\13603305 12_15\CD\13745420 (_16\-LRB-\1740 22_17\CD\13745420 %_18\NN\1740 )_19\-RRB-\1740 of_20\IN\1740 54_21\CD\1740 tobramycin_22\NN\2716866 and_23\CC\1740 piperacillin-treated_24\JJ\1740 patients_25\NNS\9898892 ._26\.\1740
D009428_D006311 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 aminoglycoside-associated_3\JJ\1740 <e2>ototoxicity</e2>_4\NN\1740 was_5\VBD\836236 less_6\RBR\1740 severe_7\JJ\1740 and_8\CC\1740 more_9\RBR\1740 often_10\RB\1740 reversible_11\JJ\1740 with_12\IN\1740 <e1>netilmicin</e1>_13\NN\1740 than_14\IN\1740 with_15\IN\1740 tobramycin_16\NN\2716866 ._17\.\1740
D010878_D006311 CID <e2>ototoxicity</e2>_0\NN\1740 occurred_1\VBD\2623529 in_2\IN\13603305 four_3\CD\13741022 (_4\-LRB-\1740 9.5_5\CD\1740 %_6\NN\1740 )_7\-RRB-\1740 of_8\IN\1740 42_9\CD\1740 netilmicin_10\NN\1740 and_11\CC\1740 <e1>piperacillin</e1>_12\NN\3910033 and_13\CC\1740 in_14\IN\13603305 12_15\CD\13745420 (_16\-LRB-\1740 22_17\CD\13745420 %_18\NN\1740 )_19\-RRB-\1740 of_20\IN\1740 54_21\CD\1740 tobramycin_22\NN\2716866 and_23\CC\1740 piperacillin-treated_24\JJ\1740 patients_25\NNS\9898892 ._26\.\1740
D010878_D006311 CID <e2>ototoxicity</e2>_0\NN\1740 occurred_1\VBD\2623529 in_2\IN\13603305 four_3\CD\13741022 (_4\-LRB-\1740 9.5_5\CD\1740 %_6\NN\1740 )_7\-RRB-\1740 of_8\IN\1740 42_9\CD\1740 netilmicin_10\NN\1740 and_11\CC\1740 piperacillin_12\NN\3910033 and_13\CC\1740 in_14\IN\13603305 12_15\CD\13745420 (_16\-LRB-\1740 22_17\CD\13745420 %_18\NN\1740 )_19\-RRB-\1740 of_20\IN\1740 54_21\CD\1740 tobramycin_22\NN\2716866 and_23\CC\1740 <e1>piperacillin-treated</e1>_24\JJ\1740 patients_25\NNS\9898892 ._26\.\1740
D014031_D006311 CID <e2>ototoxicity</e2>_0\NN\1740 occurred_1\VBD\2623529 in_2\IN\13603305 four_3\CD\13741022 (_4\-LRB-\1740 9.5_5\CD\1740 %_6\NN\1740 )_7\-RRB-\1740 of_8\IN\1740 42_9\CD\1740 netilmicin_10\NN\1740 and_11\CC\1740 piperacillin_12\NN\3910033 and_13\CC\1740 in_14\IN\13603305 12_15\CD\13745420 (_16\-LRB-\1740 22_17\CD\13745420 %_18\NN\1740 )_19\-RRB-\1740 of_20\IN\1740 54_21\CD\1740 <e1>tobramycin</e1>_22\NN\2716866 and_23\CC\1740 piperacillin-treated_24\JJ\1740 patients_25\NNS\9898892 ._26\.\1740
D014031_D006311 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 aminoglycoside-associated_3\JJ\1740 <e2>ototoxicity</e2>_4\NN\1740 was_5\VBD\836236 less_6\RBR\1740 severe_7\JJ\1740 and_8\CC\1740 more_9\RBR\1740 often_10\RB\1740 reversible_11\JJ\1740 with_12\IN\1740 netilmicin_13\NN\1740 than_14\IN\1740 with_15\IN\1740 <e1>tobramycin</e1>_16\NN\2716866 ._17\.\1740
D000617_D006311 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 <e1>aminoglycoside-associated</e1>_3\JJ\1740 <e2>ototoxicity</e2>_4\NN\1740 was_5\VBD\836236 less_6\RBR\1740 severe_7\JJ\1740 and_8\CC\1740 more_9\RBR\1740 often_10\RB\1740 reversible_11\JJ\1740 with_12\IN\1740 netilmicin_13\NN\1740 than_14\IN\1740 with_15\IN\1740 tobramycin_16\NN\2716866 ._17\.\1740
6115999
D001539_D006973 NONE adverse_0\JJ\1740 reactions_1\NNS\13446390 to_2\TO\1740 <e1>bendrofluazide</e1>_3\VB\1740 and_4\CC\1740 propranolol_5\NN\1740 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 mild_10\JJ\1740 <e2>hypertension</e2>_11\NN\14057371 ._12\.\1740
D001539_D006973 NONE participants_0\NNS\9816771 in_1\IN\13603305 the_2\DT\1740 medical_3\NNP\635850 research_4\NNP\633864 council_5\NNP\8077292 treatment_6\NN\654885 trial_7\NN\786195 for_8\IN\1740 mild_9\JJ\1740 <e2>hypertension</e2>_10\NN\14057371 are_11\VBP\836236 randomly_12\RB\1740 allocated_13\VBN\2228698 to_14\IN\1740 one_15\CD\13741022 of_16\IN\1740 four_17\CD\13741022 treatment_18\NN\654885 groups_19\NNS\2137 :_20\:\1740 <e1>bendrofluazide</e1>_21\NN\1740 ,_22\,\1740 propranolol_23\NN\1740 ,_24\,\1740 or_25\CC\3541091 a_26\DT\13649268 placebo_27\NN\3740161 for_28\IN\1740 either_29\DT\1740 of_30\IN\1740 these_31\DT\1740 drugs_32\NNS\14778436 ._33\.\1740
D011433_D006973 NONE adverse_0\JJ\1740 reactions_1\NNS\13446390 to_2\TO\1740 bendrofluazide_3\VB\1740 and_4\CC\1740 <e1>propranolol</e1>_5\NN\1740 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 mild_10\JJ\1740 <e2>hypertension</e2>_11\NN\14057371 ._12\.\1740
D011433_D006973 NONE participants_0\NNS\9816771 in_1\IN\13603305 the_2\DT\1740 medical_3\NNP\635850 research_4\NNP\633864 council_5\NNP\8077292 treatment_6\NN\654885 trial_7\NN\786195 for_8\IN\1740 mild_9\JJ\1740 <e2>hypertension</e2>_10\NN\14057371 are_11\VBP\836236 randomly_12\RB\1740 allocated_13\VBN\2228698 to_14\IN\1740 one_15\CD\13741022 of_16\IN\1740 four_17\CD\13741022 treatment_18\NN\654885 groups_19\NNS\2137 :_20\:\1740 bendrofluazide_21\NN\1740 ,_22\,\1740 <e1>propranolol</e1>_23\NN\1740 ,_24\,\1740 or_25\CC\3541091 a_26\DT\13649268 placebo_27\NN\3740161 for_28\IN\1740 either_29\DT\1740 of_30\IN\1740 these_31\DT\1740 drugs_32\NNS\14778436 ._33\.\1740
D001539_D007172 CID the_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 an_3\DT\6697703 association_4\NN\8008335 between_5\IN\1740 <e1>bendrofluazide</e1>_6\NN\1740 treatment_7\NN\654885 and_8\CC\1740 <e2>impotence</e2>_9\NN\4723816 ,_10\,\1740 and_11\CC\1740 impotence_12\NN\4723816 also_13\RB\1740 occurred_14\VBD\2623529 more_15\RBR\1740 frequently_16\RB\1740 in_17\IN\13603305 patients_18\NNS\9898892 taking_19\VBG\2367363 propranolol_20\NN\1740 than_21\IN\1740 in_22\IN\13603305 those_23\DT\1740 taking_24\VBG\2367363 placebos_25\NNS\3740161 ._26\.\1740
D001539_D007172 CID the_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 an_3\DT\6697703 association_4\NN\8008335 between_5\IN\1740 <e1>bendrofluazide</e1>_6\NN\1740 treatment_7\NN\654885 and_8\CC\1740 impotence_9\NN\4723816 ,_10\,\1740 and_11\CC\1740 <e2>impotence</e2>_12\NN\4723816 also_13\RB\1740 occurred_14\VBD\2623529 more_15\RBR\1740 frequently_16\RB\1740 in_17\IN\13603305 patients_18\NNS\9898892 taking_19\VBG\2367363 propranolol_20\NN\1740 than_21\IN\1740 in_22\IN\13603305 those_23\DT\1740 taking_24\VBG\2367363 placebos_25\NNS\3740161 ._26\.\1740
D011433_D007172 CID the_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 an_3\DT\6697703 association_4\NN\8008335 between_5\IN\1740 bendrofluazide_6\NN\1740 treatment_7\NN\654885 and_8\CC\1740 <e2>impotence</e2>_9\NN\4723816 ,_10\,\1740 and_11\CC\1740 impotence_12\NN\4723816 also_13\RB\1740 occurred_14\VBD\2623529 more_15\RBR\1740 frequently_16\RB\1740 in_17\IN\13603305 patients_18\NNS\9898892 taking_19\VBG\2367363 <e1>propranolol</e1>_20\NN\1740 than_21\IN\1740 in_22\IN\13603305 those_23\DT\1740 taking_24\VBG\2367363 placebos_25\NNS\3740161 ._26\.\1740
D011433_D007172 CID the_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 an_3\DT\6697703 association_4\NN\8008335 between_5\IN\1740 bendrofluazide_6\NN\1740 treatment_7\NN\654885 and_8\CC\1740 impotence_9\NN\4723816 ,_10\,\1740 and_11\CC\1740 <e2>impotence</e2>_12\NN\4723816 also_13\RB\1740 occurred_14\VBD\2623529 more_15\RBR\1740 frequently_16\RB\1740 in_17\IN\13603305 patients_18\NNS\9898892 taking_19\VBG\2367363 <e1>propranolol</e1>_20\NN\1740 than_21\IN\1740 in_22\IN\13603305 those_23\DT\1740 taking_24\VBG\2367363 placebos_25\NNS\3740161 ._26\.\1740
D001539_D018149 CID other_0\JJ\1740 adverse_1\JJ\1740 reactions_2\NNS\13446390 significantly_3\RB\1740 linked_4\VBN\628491 with_5\IN\1740 active_6\JJ\1740 drugs_7\NNS\14778436 include_8\VBP\690614 <e2>impaired_9\JJ\1740 glucose_10\NN\14710501 tolerance</e2>_11\NN\5032565 in_12\IN\13603305 men_13\NNS\8208016 and_14\CC\1740 women_15\NNS\9605289 and_16\CC\1740 gout_17\NN\14186541 in_18\IN\13603305 men_19\NNS\8208016 ,_20\,\1740 associated_21\VBN\628491 with_22\IN\1740 <e1>bendrofluazide</e1>_23\NN\1740 treatment_24\NN\654885 ,_25\,\1740 and_26\CC\1740 raynaud_27\NNP\1740 's_28\POS\1740 phenomenon_29\NN\29677 and_30\CC\1740 dyspnoea_31\NN\14299637 in_32\IN\13603305 men_33\NNS\8208016 and_34\CC\1740 women_35\NNS\9605289 taking_36\VBG\2367363 propranolol_37\NN\1740 ._38\.\1740
D001539_D006073 CID other_0\JJ\1740 adverse_1\JJ\1740 reactions_2\NNS\13446390 significantly_3\RB\1740 linked_4\VBN\628491 with_5\IN\1740 active_6\JJ\1740 drugs_7\NNS\14778436 include_8\VBP\690614 impaired_9\JJ\1740 glucose_10\NN\14710501 tolerance_11\NN\5032565 in_12\IN\13603305 men_13\NNS\8208016 and_14\CC\1740 women_15\NNS\9605289 and_16\CC\1740 <e2>gout</e2>_17\NN\14186541 in_18\IN\13603305 men_19\NNS\8208016 ,_20\,\1740 associated_21\VBN\628491 with_22\IN\1740 <e1>bendrofluazide</e1>_23\NN\1740 treatment_24\NN\654885 ,_25\,\1740 and_26\CC\1740 raynaud_27\NNP\1740 's_28\POS\1740 phenomenon_29\NN\29677 and_30\CC\1740 dyspnoea_31\NN\14299637 in_32\IN\13603305 men_33\NNS\8208016 and_34\CC\1740 women_35\NNS\9605289 taking_36\VBG\2367363 propranolol_37\NN\1740 ._38\.\1740
D001539_D011928 NONE other_0\JJ\1740 adverse_1\JJ\1740 reactions_2\NNS\13446390 significantly_3\RB\1740 linked_4\VBN\628491 with_5\IN\1740 active_6\JJ\1740 drugs_7\NNS\14778436 include_8\VBP\690614 impaired_9\JJ\1740 glucose_10\NN\14710501 tolerance_11\NN\5032565 in_12\IN\13603305 men_13\NNS\8208016 and_14\CC\1740 women_15\NNS\9605289 and_16\CC\1740 gout_17\NN\14186541 in_18\IN\13603305 men_19\NNS\8208016 ,_20\,\1740 associated_21\VBN\628491 with_22\IN\1740 <e1>bendrofluazide</e1>_23\NN\1740 treatment_24\NN\654885 ,_25\,\1740 and_26\CC\1740 <e2>raynaud_27\NNP\1740 's_28\POS\1740 phenomenon</e2>_29\NN\29677 and_30\CC\1740 dyspnoea_31\NN\14299637 in_32\IN\13603305 men_33\NNS\8208016 and_34\CC\1740 women_35\NNS\9605289 taking_36\VBG\2367363 propranolol_37\NN\1740 ._38\.\1740
D001539_D004417 NONE other_0\JJ\1740 adverse_1\JJ\1740 reactions_2\NNS\13446390 significantly_3\RB\1740 linked_4\VBN\628491 with_5\IN\1740 active_6\JJ\1740 drugs_7\NNS\14778436 include_8\VBP\690614 impaired_9\JJ\1740 glucose_10\NN\14710501 tolerance_11\NN\5032565 in_12\IN\13603305 men_13\NNS\8208016 and_14\CC\1740 women_15\NNS\9605289 and_16\CC\1740 gout_17\NN\14186541 in_18\IN\13603305 men_19\NNS\8208016 ,_20\,\1740 associated_21\VBN\628491 with_22\IN\1740 <e1>bendrofluazide</e1>_23\NN\1740 treatment_24\NN\654885 ,_25\,\1740 and_26\CC\1740 raynaud_27\NNP\1740 's_28\POS\1740 phenomenon_29\NN\29677 and_30\CC\1740 <e2>dyspnoea</e2>_31\NN\14299637 in_32\IN\13603305 men_33\NNS\8208016 and_34\CC\1740 women_35\NNS\9605289 taking_36\VBG\2367363 propranolol_37\NN\1740 ._38\.\1740
D011433_D018149 NONE other_0\JJ\1740 adverse_1\JJ\1740 reactions_2\NNS\13446390 significantly_3\RB\1740 linked_4\VBN\628491 with_5\IN\1740 active_6\JJ\1740 drugs_7\NNS\14778436 include_8\VBP\690614 <e2>impaired_9\JJ\1740 glucose_10\NN\14710501 tolerance</e2>_11\NN\5032565 in_12\IN\13603305 men_13\NNS\8208016 and_14\CC\1740 women_15\NNS\9605289 and_16\CC\1740 gout_17\NN\14186541 in_18\IN\13603305 men_19\NNS\8208016 ,_20\,\1740 associated_21\VBN\628491 with_22\IN\1740 bendrofluazide_23\NN\1740 treatment_24\NN\654885 ,_25\,\1740 and_26\CC\1740 raynaud_27\NNP\1740 's_28\POS\1740 phenomenon_29\NN\29677 and_30\CC\1740 dyspnoea_31\NN\14299637 in_32\IN\13603305 men_33\NNS\8208016 and_34\CC\1740 women_35\NNS\9605289 taking_36\VBG\2367363 <e1>propranolol</e1>_37\NN\1740 ._38\.\1740
D011433_D006073 NONE other_0\JJ\1740 adverse_1\JJ\1740 reactions_2\NNS\13446390 significantly_3\RB\1740 linked_4\VBN\628491 with_5\IN\1740 active_6\JJ\1740 drugs_7\NNS\14778436 include_8\VBP\690614 impaired_9\JJ\1740 glucose_10\NN\14710501 tolerance_11\NN\5032565 in_12\IN\13603305 men_13\NNS\8208016 and_14\CC\1740 women_15\NNS\9605289 and_16\CC\1740 <e2>gout</e2>_17\NN\14186541 in_18\IN\13603305 men_19\NNS\8208016 ,_20\,\1740 associated_21\VBN\628491 with_22\IN\1740 bendrofluazide_23\NN\1740 treatment_24\NN\654885 ,_25\,\1740 and_26\CC\1740 raynaud_27\NNP\1740 's_28\POS\1740 phenomenon_29\NN\29677 and_30\CC\1740 dyspnoea_31\NN\14299637 in_32\IN\13603305 men_33\NNS\8208016 and_34\CC\1740 women_35\NNS\9605289 taking_36\VBG\2367363 <e1>propranolol</e1>_37\NN\1740 ._38\.\1740
D011433_D011928 CID other_0\JJ\1740 adverse_1\JJ\1740 reactions_2\NNS\13446390 significantly_3\RB\1740 linked_4\VBN\628491 with_5\IN\1740 active_6\JJ\1740 drugs_7\NNS\14778436 include_8\VBP\690614 impaired_9\JJ\1740 glucose_10\NN\14710501 tolerance_11\NN\5032565 in_12\IN\13603305 men_13\NNS\8208016 and_14\CC\1740 women_15\NNS\9605289 and_16\CC\1740 gout_17\NN\14186541 in_18\IN\13603305 men_19\NNS\8208016 ,_20\,\1740 associated_21\VBN\628491 with_22\IN\1740 bendrofluazide_23\NN\1740 treatment_24\NN\654885 ,_25\,\1740 and_26\CC\1740 <e2>raynaud_27\NNP\1740 's_28\POS\1740 phenomenon</e2>_29\NN\29677 and_30\CC\1740 dyspnoea_31\NN\14299637 in_32\IN\13603305 men_33\NNS\8208016 and_34\CC\1740 women_35\NNS\9605289 taking_36\VBG\2367363 <e1>propranolol</e1>_37\NN\1740 ._38\.\1740
D011433_D004417 CID other_0\JJ\1740 adverse_1\JJ\1740 reactions_2\NNS\13446390 significantly_3\RB\1740 linked_4\VBN\628491 with_5\IN\1740 active_6\JJ\1740 drugs_7\NNS\14778436 include_8\VBP\690614 impaired_9\JJ\1740 glucose_10\NN\14710501 tolerance_11\NN\5032565 in_12\IN\13603305 men_13\NNS\8208016 and_14\CC\1740 women_15\NNS\9605289 and_16\CC\1740 gout_17\NN\14186541 in_18\IN\13603305 men_19\NNS\8208016 ,_20\,\1740 associated_21\VBN\628491 with_22\IN\1740 bendrofluazide_23\NN\1740 treatment_24\NN\654885 ,_25\,\1740 and_26\CC\1740 raynaud_27\NNP\1740 's_28\POS\1740 phenomenon_29\NN\29677 and_30\CC\1740 <e2>dyspnoea</e2>_31\NN\14299637 in_32\IN\13603305 men_33\NNS\8208016 and_34\CC\1740 women_35\NNS\9605289 taking_36\VBG\2367363 <e1>propranolol</e1>_37\NN\1740 ._38\.\1740
D011433_D003316 NONE no_0\DT\7204911 <e2>corneal_1\NN\1740 disease</e2>_2\NN\14061805 is_3\VBZ\836236 known_4\VBN\2110220 to_5\TO\1740 have_6\VB\2108377 occurred_7\VBN\2623529 in_8\IN\13603305 the_9\DT\1740 <e1>propranolol</e1>_10\NN\1740 group_11\NN\2137 ._12\.\1740
11847945
D007530_D002779 CID acute_0\JJ\1740 <e2>cholestatic_1\JJ\1740 hepatitis</e2>_2\NN\14127211 after_3\IN\1740 exposure_4\NN\5042871 to_5\TO\1740 <e1>isoflurane</e1>_6\NN\3570838 ._7\.\1740
D007530_D002779 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 acute_7\JJ\1740 <e2>cholestatic_8\JJ\1740 hepatitis</e2>_9\NN\14127211 following_10\VBG\1835496 exposure_11\NN\5042871 to_12\TO\1740 the_13\DT\1740 inhalational_14\JJ\1740 anesthetic_15\JJ\1740 <e1>isoflurane</e1>_16\NN\3570838 ._17\.\1740
D007530_D002779 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>isoflurane</e1>_2\NNP\3570838 ,_3\,\1740 a_4\DT\13649268 common_5\JJ\1740 anesthetic_6\JJ\1740 agent_7\NN\7347 ,_8\,\1740 can_9\MD\3094503 cause_10\VB\1617192 severe_11\JJ\1740 <e2>cholestatic_12\JJ\1740 hepatitis</e2>_13\NN\14127211 ._14\.\1740
D007530_D056486 CID acute_0\JJ\1740 <e2>cholestatic_1\JJ\1740 hepatitis</e2>_2\NN\14127211 after_3\IN\1740 exposure_4\NN\5042871 to_5\TO\1740 <e1>isoflurane</e1>_6\NN\3570838 ._7\.\1740
D007530_D056486 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 acute_7\JJ\1740 <e2>cholestatic_8\JJ\1740 hepatitis</e2>_9\NN\14127211 following_10\VBG\1835496 exposure_11\NN\5042871 to_12\TO\1740 the_13\DT\1740 inhalational_14\JJ\1740 anesthetic_15\JJ\1740 <e1>isoflurane</e1>_16\NN\3570838 ._17\.\1740
D007530_D056486 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>isoflurane</e1>_2\NNP\3570838 ,_3\,\1740 a_4\DT\13649268 common_5\JJ\1740 anesthetic_6\JJ\1740 agent_7\NN\7347 ,_8\,\1740 can_9\MD\3094503 cause_10\VB\1617192 severe_11\JJ\1740 <e2>cholestatic_12\JJ\1740 hepatitis</e2>_13\NN\14127211 ._14\.\1740
D004177_D000699 NONE no_0\DT\7204911 other_1\JJ\1740 medications_2\NNS\3247620 were_3\VBD\836236 involved_4\VBN\2676054 except_5\IN\1740 for_6\IN\1740 <e1>dipyrone</e1>_7\NN\1740 for_8\IN\1740 <e2>analgesia</e2>_9\NN\14034177 ._10\.\1740
12013711
D018967_D010468 CID <e1>risperidone-associated</e1>_0\JJ\1740 ,_1\,\1740 benign_2\JJ\1740 transient_3\JJ\1740 <e2>visual_4\JJ\1740 disturbances</e2>_5\NNS\407535 in_6\IN\13603305 schizophrenic_7\JJ\1740 patients_8\NNS\9898892 with_9\IN\1740 a_10\DT\13649268 past_11\JJ\1740 history_12\NN\15120823 of_13\IN\1740 lsd_14\NN\3097890 abuse_15\NN\418025 ._16\.\1740
D018967_D010468 CID they_0\PRP\1740 both_1\DT\1740 reported_2\VBD\831651 short_3\JJ\1740 episodes_4\NNS\7283608 of_5\IN\1740 transient_6\JJ\1740 <e2>visual_7\JJ\1740 disturbances</e2>_8\NNS\407535 ,_9\,\1740 which_10\WDT\1740 appeared_11\VBD\2604760 immediately_12\RB\1740 after_13\IN\1740 starting_14\VBG\2009433 treatment_15\NN\654885 with_16\IN\1740 <e1>risperidone</e1>_17\NN\1740 ._18\.\1740
D018967_D010468 CID <e1>risperidone</e1>_0\NN\1740 administration_1\NN\1133281 was_2\VBD\836236 continued_3\VBN\2367363 and_4\CC\1740 the_5\DT\1740 <e2>visual_6\JJ\1740 disturbances</e2>_7\NNS\407535 gradually_8\RB\1740 wore_9\VBD\2630189 off_10\RP\1740 ._11\.\1740
D018967_D012559 NONE <e1>risperidone-associated</e1>_0\JJ\1740 ,_1\,\1740 benign_2\JJ\1740 transient_3\JJ\1740 visual_4\JJ\1740 disturbances_5\NNS\407535 in_6\IN\13603305 <e2>schizophrenic</e2>_7\JJ\1740 patients_8\NNS\9898892 with_9\IN\1740 a_10\DT\13649268 past_11\JJ\1740 history_12\NN\15120823 of_13\IN\1740 lsd_14\NN\3097890 abuse_15\NN\418025 ._16\.\1740
D018967_D012559 NONE two_0\CD\13741022 <e2>schizophrenic</e2>_1\JJ\1740 patients_2\NNS\9898892 ,_3\,\1740 who_4\WP\8299493 had_5\VBD\2108377 a_6\DT\13649268 prior_7\JJ\1740 history_8\NN\15120823 of_9\IN\1740 lsd_10\NN\3097890 abuse_11\NN\418025 and_12\CC\1740 who_13\WP\8299493 had_14\VBD\2108377 previously_15\RB\1740 developed_16\VBN\1753788 eps_17\NN\1740 with_18\IN\1740 classic_19\JJ\1740 antipsychotics_20\NNS\4470232 ,_21\,\1740 were_22\VBD\836236 successfully_23\RB\1740 treated_24\VBN\2376958 with_25\IN\1740 <e1>risperidone</e1>_26\NN\1740 ._27\.\1740
D008238_D010468 NONE risperidone-associated_0\JJ\1740 ,_1\,\1740 benign_2\JJ\1740 transient_3\JJ\1740 <e2>visual_4\JJ\1740 disturbances</e2>_5\NNS\407535 in_6\IN\13603305 schizophrenic_7\JJ\1740 patients_8\NNS\9898892 with_9\IN\1740 a_10\DT\13649268 past_11\JJ\1740 history_12\NN\15120823 of_13\IN\1740 <e1>lsd</e1>_14\NN\3097890 abuse_15\NN\418025 ._16\.\1740
D008238_D010468 NONE this_0\DT\1740 imagery_1\NN\5765159 resembled_2\VBD\2657219 <e2>visual_3\JJ\1740 disturbances</e2>_4\NNS\407535 previously_5\RB\1740 experienced_6\VBN\2108377 as_7\IN\14622893 "_8\``\1740 flashbacks_9\NNS\6401328 "_10\''\1740 related_11\JJ\1740 to_12\TO\1740 prior_13\JJ\1740 <e1>lsd</e1>_14\NN\3097890 consumption_15\NN\13440063 ._16\.\1740
D008238_D012559 NONE risperidone-associated_0\JJ\1740 ,_1\,\1740 benign_2\JJ\1740 transient_3\JJ\1740 visual_4\JJ\1740 disturbances_5\NNS\407535 in_6\IN\13603305 <e2>schizophrenic</e2>_7\JJ\1740 patients_8\NNS\9898892 with_9\IN\1740 a_10\DT\13649268 past_11\JJ\1740 history_12\NN\15120823 of_13\IN\1740 <e1>lsd</e1>_14\NN\3097890 abuse_15\NN\418025 ._16\.\1740
D008238_D012559 NONE two_0\CD\13741022 <e2>schizophrenic</e2>_1\JJ\1740 patients_2\NNS\9898892 ,_3\,\1740 who_4\WP\8299493 had_5\VBD\2108377 a_6\DT\13649268 prior_7\JJ\1740 history_8\NN\15120823 of_9\IN\1740 <e1>lsd</e1>_10\NN\3097890 abuse_11\NN\418025 and_12\CC\1740 who_13\WP\8299493 had_14\VBD\2108377 previously_15\RB\1740 developed_16\VBN\1753788 eps_17\NN\1740 with_18\IN\1740 classic_19\JJ\1740 antipsychotics_20\NNS\4470232 ,_21\,\1740 were_22\VBD\836236 successfully_23\RB\1740 treated_24\VBN\2376958 with_25\IN\1740 risperidone_26\NN\1740 ._27\.\1740
D008238_D001480 NONE two_0\CD\13741022 schizophrenic_1\JJ\1740 patients_2\NNS\9898892 ,_3\,\1740 who_4\WP\8299493 had_5\VBD\2108377 a_6\DT\13649268 prior_7\JJ\1740 history_8\NN\15120823 of_9\IN\1740 <e1>lsd</e1>_10\NN\3097890 abuse_11\NN\418025 and_12\CC\1740 who_13\WP\8299493 had_14\VBD\2108377 previously_15\RB\1740 developed_16\VBN\1753788 <e2>eps</e2>_17\NN\1740 with_18\IN\1740 classic_19\JJ\1740 antipsychotics_20\NNS\4470232 ,_21\,\1740 were_22\VBD\836236 successfully_23\RB\1740 treated_24\VBN\2376958 with_25\IN\1740 risperidone_26\NN\1740 ._27\.\1740
D018967_D001480 NONE two_0\CD\13741022 schizophrenic_1\JJ\1740 patients_2\NNS\9898892 ,_3\,\1740 who_4\WP\8299493 had_5\VBD\2108377 a_6\DT\13649268 prior_7\JJ\1740 history_8\NN\15120823 of_9\IN\1740 lsd_10\NN\3097890 abuse_11\NN\418025 and_12\CC\1740 who_13\WP\8299493 had_14\VBD\2108377 previously_15\RB\1740 developed_16\VBN\1753788 <e2>eps</e2>_17\NN\1740 with_18\IN\1740 classic_19\JJ\1740 antipsychotics_20\NNS\4470232 ,_21\,\1740 were_22\VBD\836236 successfully_23\RB\1740 treated_24\VBN\2376958 with_25\IN\1740 <e1>risperidone</e1>_26\NN\1740 ._27\.\1740
19923525
D009553_D008569 NONE <e1>nimodipine</e1>_0\NN\1740 prevents_1\VBZ\1740 <e2>memory_2\NN\5926676 impairment</e2>_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 nitroglycerin-induced_6\JJ\1740 hypotension_7\NN\14057371 in_8\IN\13603305 adult_9\JJ\1740 mice_10\NNS\2329401 ._11\.\1740
D009553_D007022 NONE <e1>nimodipine</e1>_0\NN\1740 prevents_1\VBZ\1740 memory_2\NN\5926676 impairment_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 nitroglycerin-induced_6\JJ\1740 <e2>hypotension</e2>_7\NN\14057371 in_8\IN\13603305 adult_9\JJ\1740 mice_10\NNS\2329401 ._11\.\1740
D009553_D007022 NONE we_0\PRP\1740 tested_1\VBD\670261 the_2\DT\1740 hypothesis_3\NN\7162194 that_4\IN\1740 <e1>nimodipine</e1>_5\NN\1740 (_6\-LRB-\1740 nimo_7\NN\1740 )_8\-RRB-\1740 administered_9\VBN\2436349 at_10\IN\14622893 the_11\DT\1740 onset_12\NN\7325190 of_13\IN\1740 nitroglycerin_14\NN\15015501 (ntg)-induced_15\JJ\1740 <e2>hypotension</e2>_16\NN\14057371 would_17\MD\1740 preserve_18\VB\2681795 long-term_19\JJ\1740 associative_20\JJ\1740 memory_21\NN\5926676 ._22\.\1740
D009553_D007022 NONE we_0\PRP\1740 tested_1\VBD\670261 the_2\DT\1740 hypothesis_3\NN\7162194 that_4\IN\1740 nimodipine_5\NN\1740 (_6\-LRB-\1740 <e1>nimo</e1>_7\NN\1740 )_8\-RRB-\1740 administered_9\VBN\2436349 at_10\IN\14622893 the_11\DT\1740 onset_12\NN\7325190 of_13\IN\1740 nitroglycerin_14\NN\15015501 (ntg)-induced_15\JJ\1740 <e2>hypotension</e2>_16\NN\14057371 would_17\MD\1740 preserve_18\VB\2681795 long-term_19\JJ\1740 associative_20\JJ\1740 memory_21\NN\5926676 ._22\.\1740
D009553_D007022 NONE mice_0\NNS\2329401 subjected_1\VBD\137313 to_2\TO\1740 <e2>hypotensive</e2>_3\JJ\1740 episodes_4\NNS\7283608 showed_5\VBD\2137132 a_6\DT\13649268 significant_7\JJ\1740 decrease_8\NN\7296428 in_9\IN\13603305 latency_10\NN\15269513 time_11\NN\7308889 (_12\-LRB-\1740 178_13\CD\1740 +/-_14\CC\1740 156_15\CD\1740 s_16\NNS\15154774 )_17\-RRB-\1740 compared_18\VBN\644583 with_19\IN\1740 those_20\DT\1740 injected_21\VBN\81072 with_22\IN\1740 saline_23\NN\14849367 ,_24\,\1740 ntg_25\NN\1740 +_26\CC\1740 <e1>nimo</e1>_27\NN\1740 ,_28\,\1740 or_29\CC\3541091 delayed_30\VBN\439958 ntg_31\NN\1740 (_32\-LRB-\1740 580_33\CD\1740 +/-_34\CC\1740 81_35\CD\1740 s_36\NNS\15154774 ,_37\,\1740 557_38\CD\1740 +/-_39\CC\1740 67_40\CD\1740 s_41\NNS\15154774 ,_42\,\1740 and_43\CC\1740 493_44\CD\1740 +/-_45\CC\1740 146_46\CD\1740 s_47\NNS\15154774 ,_48\,\1740 respectively_49\RB\1740 )_50\-RRB-\1740 ._51\.\1740
D009553_D007022 NONE <e1>nimo</e1>_0\NN\1740 attenuated_1\VBD\224901 the_2\DT\1740 disruption_3\NN\1066163 in_4\IN\13603305 consolidation_5\NN\7373803 of_6\IN\1740 long-term_7\JJ\1740 memory_8\NN\5926676 caused_9\VBN\1617192 by_10\IN\1740 ntg_11\NN\1740 but_12\CC\1740 did_13\VBD\1640855 not_14\RB\1740 improve_15\VB\126264 latency_16\NN\15269513 in_17\IN\13603305 the_18\DT\1740 absence_19\NN\14449405 of_20\IN\1740 <e2>hypotension</e2>_21\NN\14057371 ._22\.\1740
D009553_D007022 NONE the_0\DT\1740 observed_1\VBN\2163746 effect_2\NN\34213 of_3\IN\1740 <e1>nimo</e1>_4\NN\1740 may_5\MD\15209706 have_6\VB\2108377 been_7\VBN\836236 attributable_8\JJ\1740 to_9\TO\1740 the_10\DT\1740 preservation_11\NN\817680 of_12\IN\1740 calcium_13\NN\14625458 homeostasis_14\NN\13934900 during_15\IN\1740 <e2>hypotension</e2>_16\NN\14057371 ,_17\,\1740 because_18\IN\1740 there_19\EX\27167 were_20\VBD\836236 no_21\DT\7204911 differences_22\NNS\4723816 in_23\IN\13603305 the_24\DT\1740 pbto(2_25\NN\1740 )_26\-RRB-\1740 indices_27\NNS\13850304 among_28\IN\1740 groups_29\NNS\2137 ._30\.\1740
D005996_D008569 CID nimodipine_0\NN\1740 prevents_1\VBZ\1740 <e2>memory_2\NN\5926676 impairment</e2>_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 <e1>nitroglycerin-induced</e1>_6\JJ\1740 hypotension_7\NN\14057371 in_8\IN\13603305 adult_9\JJ\1740 mice_10\NNS\2329401 ._11\.\1740
D005996_D007022 CID nimodipine_0\NN\1740 prevents_1\VBZ\1740 memory_2\NN\5926676 impairment_3\NN\7296428 caused_4\VBN\1617192 by_5\IN\1740 <e1>nitroglycerin-induced</e1>_6\JJ\1740 <e2>hypotension</e2>_7\NN\14057371 in_8\IN\13603305 adult_9\JJ\1740 mice_10\NNS\2329401 ._11\.\1740
D005996_D007022 CID we_0\PRP\1740 tested_1\VBD\670261 the_2\DT\1740 hypothesis_3\NN\7162194 that_4\IN\1740 nimodipine_5\NN\1740 (_6\-LRB-\1740 nimo_7\NN\1740 )_8\-RRB-\1740 administered_9\VBN\2436349 at_10\IN\14622893 the_11\DT\1740 onset_12\NN\7325190 of_13\IN\1740 <e1>nitroglycerin</e1>_14\NN\15015501 (ntg)-induced_15\JJ\1740 <e2>hypotension</e2>_16\NN\14057371 would_17\MD\1740 preserve_18\VB\2681795 long-term_19\JJ\1740 associative_20\JJ\1740 memory_21\NN\5926676 ._22\.\1740
D005996_D007022 CID we_0\PRP\1740 tested_1\VBD\670261 the_2\DT\1740 hypothesis_3\NN\7162194 that_4\IN\1740 nimodipine_5\NN\1740 (_6\-LRB-\1740 nimo_7\NN\1740 )_8\-RRB-\1740 administered_9\VBN\2436349 at_10\IN\14622893 the_11\DT\1740 onset_12\NN\7325190 of_13\IN\1740 nitroglycerin_14\NN\15015501 <e1>(ntg)-induced</e1>_15\JJ\1740 <e2>hypotension</e2>_16\NN\14057371 would_17\MD\1740 preserve_18\VB\2681795 long-term_19\JJ\1740 associative_20\JJ\1740 memory_21\NN\5926676 ._22\.\1740
D005996_D007022 CID mice_0\NNS\2329401 subjected_1\VBD\137313 to_2\TO\1740 <e2>hypotensive</e2>_3\JJ\1740 episodes_4\NNS\7283608 showed_5\VBD\2137132 a_6\DT\13649268 significant_7\JJ\1740 decrease_8\NN\7296428 in_9\IN\13603305 latency_10\NN\15269513 time_11\NN\7308889 (_12\-LRB-\1740 178_13\CD\1740 +/-_14\CC\1740 156_15\CD\1740 s_16\NNS\15154774 )_17\-RRB-\1740 compared_18\VBN\644583 with_19\IN\1740 those_20\DT\1740 injected_21\VBN\81072 with_22\IN\1740 saline_23\NN\14849367 ,_24\,\1740 <e1>ntg</e1>_25\NN\1740 +_26\CC\1740 nimo_27\NN\1740 ,_28\,\1740 or_29\CC\3541091 delayed_30\VBN\439958 ntg_31\NN\1740 (_32\-LRB-\1740 580_33\CD\1740 +/-_34\CC\1740 81_35\CD\1740 s_36\NNS\15154774 ,_37\,\1740 557_38\CD\1740 +/-_39\CC\1740 67_40\CD\1740 s_41\NNS\15154774 ,_42\,\1740 and_43\CC\1740 493_44\CD\1740 +/-_45\CC\1740 146_46\CD\1740 s_47\NNS\15154774 ,_48\,\1740 respectively_49\RB\1740 )_50\-RRB-\1740 ._51\.\1740
D005996_D007022 CID mice_0\NNS\2329401 subjected_1\VBD\137313 to_2\TO\1740 <e2>hypotensive</e2>_3\JJ\1740 episodes_4\NNS\7283608 showed_5\VBD\2137132 a_6\DT\13649268 significant_7\JJ\1740 decrease_8\NN\7296428 in_9\IN\13603305 latency_10\NN\15269513 time_11\NN\7308889 (_12\-LRB-\1740 178_13\CD\1740 +/-_14\CC\1740 156_15\CD\1740 s_16\NNS\15154774 )_17\-RRB-\1740 compared_18\VBN\644583 with_19\IN\1740 those_20\DT\1740 injected_21\VBN\81072 with_22\IN\1740 saline_23\NN\14849367 ,_24\,\1740 ntg_25\NN\1740 +_26\CC\1740 nimo_27\NN\1740 ,_28\,\1740 or_29\CC\3541091 delayed_30\VBN\439958 <e1>ntg</e1>_31\NN\1740 (_32\-LRB-\1740 580_33\CD\1740 +/-_34\CC\1740 81_35\CD\1740 s_36\NNS\15154774 ,_37\,\1740 557_38\CD\1740 +/-_39\CC\1740 67_40\CD\1740 s_41\NNS\15154774 ,_42\,\1740 and_43\CC\1740 493_44\CD\1740 +/-_45\CC\1740 146_46\CD\1740 s_47\NNS\15154774 ,_48\,\1740 respectively_49\RB\1740 )_50\-RRB-\1740 ._51\.\1740
D005996_D007022 CID conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 a_3\DT\13649268 pa_4\NN\10080869 retention_5\NN\809465 paradigm_6\NN\13803782 ,_7\,\1740 the_8\DT\1740 injection_9\NN\320852 of_10\IN\1740 <e1>ntg</e1>_11\NN\1740 immediately_12\RB\1740 after_13\IN\1740 learning_14\NN\5701944 produced_15\VBD\1617192 a_16\DT\13649268 significant_17\JJ\1740 impairment_18\NN\7296428 of_19\IN\1740 long-term_20\JJ\1740 associative_21\JJ\1740 memory_22\NN\5926676 in_23\IN\13603305 mice_24\NNS\2329401 ,_25\,\1740 whereas_26\IN\1740 delayed_27\VBD\439958 induced_28\JJ\1740 <e2>hypotension</e2>_29\NN\14057371 had_30\VBD\2108377 no_31\DT\7204911 effect_32\NN\34213 ._33\.\1740
D005996_D007022 CID nimo_0\NN\1740 attenuated_1\VBD\224901 the_2\DT\1740 disruption_3\NN\1066163 in_4\IN\13603305 consolidation_5\NN\7373803 of_6\IN\1740 long-term_7\JJ\1740 memory_8\NN\5926676 caused_9\VBN\1617192 by_10\IN\1740 <e1>ntg</e1>_11\NN\1740 but_12\CC\1740 did_13\VBD\1640855 not_14\RB\1740 improve_15\VB\126264 latency_16\NN\15269513 in_17\IN\13603305 the_18\DT\1740 absence_19\NN\14449405 of_20\IN\1740 <e2>hypotension</e2>_21\NN\14057371 ._22\.\1740
D002118_D007022 NONE the_0\DT\1740 observed_1\VBN\2163746 effect_2\NN\34213 of_3\IN\1740 nimo_4\NN\1740 may_5\MD\15209706 have_6\VB\2108377 been_7\VBN\836236 attributable_8\JJ\1740 to_9\TO\1740 the_10\DT\1740 preservation_11\NN\817680 of_12\IN\1740 <e1>calcium</e1>_13\NN\14625458 homeostasis_14\NN\13934900 during_15\IN\1740 <e2>hypotension</e2>_16\NN\14057371 ,_17\,\1740 because_18\IN\1740 there_19\EX\27167 were_20\VBD\836236 no_21\DT\7204911 differences_22\NNS\4723816 in_23\IN\13603305 the_24\DT\1740 pbto(2_25\NN\1740 )_26\-RRB-\1740 indices_27\NNS\13850304 among_28\IN\1740 groups_29\NNS\2137 ._30\.\1740
6436733
D014635_D004827 NONE <e1>valproic_0\JJ\1740 acid</e1>_1\NN\14818238 (_2\-LRB-\1740 vpa_3\NN\1740 )_4\-RRB-\1740 was_5\VBD\836236 given_6\VBN\2327200 to_7\TO\1740 24_8\CD\13745420 <e2>epileptic</e2>_9\JJ\1740 patients_10\NNS\9898892 who_11\WP\8299493 were_12\VBD\836236 already_13\RB\1740 being_14\VBG\836236 treated_15\VBN\2376958 with_16\IN\1740 other_17\JJ\1740 antiepileptic_18\JJ\1740 drugs_19\NNS\14778436 ._20\.\1740
D014635_D004827 NONE valproic_0\JJ\1740 acid_1\NN\14818238 (_2\-LRB-\1740 <e1>vpa</e1>_3\NN\1740 )_4\-RRB-\1740 was_5\VBD\836236 given_6\VBN\2327200 to_7\TO\1740 24_8\CD\13745420 <e2>epileptic</e2>_9\JJ\1740 patients_10\NNS\9898892 who_11\WP\8299493 were_12\VBD\836236 already_13\RB\1740 being_14\VBG\836236 treated_15\VBN\2376958 with_16\IN\1740 other_17\JJ\1740 antiepileptic_18\JJ\1740 drugs_19\NNS\14778436 ._20\.\1740
D000641_D006970 CID <e1>ammonia</e1>_0\NN\14940386 (_1\-LRB-\1740 nh3_2\NN\1740 )_3\-RRB-\1740 was_4\VBD\836236 higher_5\JJR\1740 in_6\IN\13603305 patients_7\NNS\9898892 who_8\WP\8299493 ,_9\,\1740 during_10\IN\1740 continuous_11\JJ\1740 therapy_12\NN\657604 ,_13\,\1740 complained_14\VBD\843959 of_15\IN\1740 <e2>drowsiness</e2>_16\NN\14015731 (_17\-LRB-\1740 7_18\CD\13741022 patients_19\NNS\9898892 )_20\-RRB-\1740 than_21\IN\1740 in_22\IN\13603305 those_23\DT\1740 who_24\WP\8299493 were_25\VBD\836236 symptom-free_26\JJ\1740 (_27\-LRB-\1740 17_28\CD\13745420 patients_29\NNS\9898892 )_30\-RRB-\1740 ,_31\,\1740 although_32\IN\1740 vpa_33\NN\1740 plasma_34\NN\5398023 levels_35\NNS\4916342 were_36\VBD\836236 similar_37\JJ\1740 in_38\IN\13603305 both_39\DT\1740 groups_40\NNS\2137 ._41\.\1740
D000641_D006970 CID ammonia_0\NN\14940386 (_1\-LRB-\1740 <e1>nh3</e1>_2\NN\1740 )_3\-RRB-\1740 was_4\VBD\836236 higher_5\JJR\1740 in_6\IN\13603305 patients_7\NNS\9898892 who_8\WP\8299493 ,_9\,\1740 during_10\IN\1740 continuous_11\JJ\1740 therapy_12\NN\657604 ,_13\,\1740 complained_14\VBD\843959 of_15\IN\1740 <e2>drowsiness</e2>_16\NN\14015731 (_17\-LRB-\1740 7_18\CD\13741022 patients_19\NNS\9898892 )_20\-RRB-\1740 than_21\IN\1740 in_22\IN\13603305 those_23\DT\1740 who_24\WP\8299493 were_25\VBD\836236 symptom-free_26\JJ\1740 (_27\-LRB-\1740 17_28\CD\13745420 patients_29\NNS\9898892 )_30\-RRB-\1740 ,_31\,\1740 although_32\IN\1740 vpa_33\NN\1740 plasma_34\NN\5398023 levels_35\NNS\4916342 were_36\VBD\836236 similar_37\JJ\1740 in_38\IN\13603305 both_39\DT\1740 groups_40\NNS\2137 ._41\.\1740
D014635_D006970 CID ammonia_0\NN\14940386 (_1\-LRB-\1740 nh3_2\NN\1740 )_3\-RRB-\1740 was_4\VBD\836236 higher_5\JJR\1740 in_6\IN\13603305 patients_7\NNS\9898892 who_8\WP\8299493 ,_9\,\1740 during_10\IN\1740 continuous_11\JJ\1740 therapy_12\NN\657604 ,_13\,\1740 complained_14\VBD\843959 of_15\IN\1740 <e2>drowsiness</e2>_16\NN\14015731 (_17\-LRB-\1740 7_18\CD\13741022 patients_19\NNS\9898892 )_20\-RRB-\1740 than_21\IN\1740 in_22\IN\13603305 those_23\DT\1740 who_24\WP\8299493 were_25\VBD\836236 symptom-free_26\JJ\1740 (_27\-LRB-\1740 17_28\CD\13745420 patients_29\NNS\9898892 )_30\-RRB-\1740 ,_31\,\1740 although_32\IN\1740 <e1>vpa</e1>_33\NN\1740 plasma_34\NN\5398023 levels_35\NNS\4916342 were_36\VBD\836236 similar_37\JJ\1740 in_38\IN\13603305 both_39\DT\1740 groups_40\NNS\2137 ._41\.\1740
20533999
D004298_D020258 NONE <e1>dopamine</e1>_0\NNP\14807737 is_1\VBZ\836236 not_2\RB\1740 essential_3\JJ\1740 for_4\IN\1740 the_5\DT\1740 development_6\NN\248977 of_7\IN\1740 methamphetamine-induced_8\JJ\1740 <e2>neurotoxicity</e2>_9\NN\1740 ._10\.\1740
D004298_D020258 NONE here_0\RB\1740 we_1\PRP\1740 show_2\VBP\2137132 that_3\IN\1740 the_4\DT\1740 recently_5\RB\1740 reported_6\VBN\831651 ability_7\NN\4723816 of_8\IN\1740 l-dihydroxyphenylalanine_9\NN\1740 to_10\TO\1740 reverse_11\VB\109660 the_12\DT\1740 protective_13\JJ\1740 effect_14\NN\34213 of_15\IN\1740 alpha-methyl-para-tyrosine_16\NN\1740 on_17\IN\1740 meth-induced_18\JJ\1740 <e1>da</e1>_19\NN\10484858 <e2>neurotoxicity</e2>_20\NN\1740 is_21\VBZ\836236 also_22\RB\1740 confounded_23\VBN\2604760 by_24\IN\1740 drug_25\NN\14778436 effects_26\NNS\13245626 on_27\IN\1740 body_28\NN\19128 temperature_29\NN\13575869 ._30\.\1740
D004298_D020258 NONE further_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 show_3\VBP\2137132 that_4\IN\1740 mice_5\NNS\2329401 genetically_6\RB\1740 engineered_7\VBD\1639714 to_8\TO\1740 be_9\VB\836236 deficient_10\JJ\1740 in_11\IN\13603305 brain_12\NN\5462674 <e1>da</e1>_13\NN\10484858 develop_14\VBP\1753788 meth_15\NN\2704153 <e2>neurotoxicity</e2>_16\NN\1740 ,_17\,\1740 as_18\RB\1740 long_19\RB\1740 as_20\IN\14622893 the_21\DT\1740 thermic_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 meth_25\NN\2704153 are_26\VBP\836236 preserved_27\VBN\2681795 ._28\.\1740
D004298_D020258 NONE taken_0\VBN\2367363 together_1\RB\1740 ,_2\,\1740 these_3\DT\1740 findings_4\NNS\7951464 demonstrate_5\VBP\2137132 that_6\IN\1740 <e1>da</e1>_7\NN\10484858 is_8\VBZ\836236 not_9\RB\1740 essential_10\JJ\1740 for_11\IN\1740 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 meth-induced_15\JJ\1740 dopaminergic_16\JJ\1740 <e2>neurotoxicity</e2>_17\NN\1740 and_18\CC\1740 suggest_19\VBP\1010118 that_20\IN\1740 mechanisms_21\NNS\13446390 independent_22\JJ\1740 of_23\IN\1740 da_24\NN\10484858 warrant_25\VBP\1012073 more_26\RBR\1740 intense_27\JJ\1740 investigation_28\NN\5797597 ._29\.\1740
D004298_D020258 NONE taken_0\VBN\2367363 together_1\RB\1740 ,_2\,\1740 these_3\DT\1740 findings_4\NNS\7951464 demonstrate_5\VBP\2137132 that_6\IN\1740 da_7\NN\10484858 is_8\VBZ\836236 not_9\RB\1740 essential_10\JJ\1740 for_11\IN\1740 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 meth-induced_15\JJ\1740 dopaminergic_16\JJ\1740 <e2>neurotoxicity</e2>_17\NN\1740 and_18\CC\1740 suggest_19\VBP\1010118 that_20\IN\1740 mechanisms_21\NNS\13446390 independent_22\JJ\1740 of_23\IN\1740 <e1>da</e1>_24\NN\10484858 warrant_25\VBP\1012073 more_26\RBR\1740 intense_27\JJ\1740 investigation_28\NN\5797597 ._29\.\1740
D008694_D020258 CID dopamine_0\NNP\14807737 is_1\VBZ\836236 not_2\RB\1740 essential_3\JJ\1740 for_4\IN\1740 the_5\DT\1740 development_6\NN\248977 of_7\IN\1740 <e1>methamphetamine-induced</e1>_8\JJ\1740 <e2>neurotoxicity</e2>_9\NN\1740 ._10\.\1740
D008694_D020258 CID here_0\RB\1740 we_1\PRP\1740 show_2\VBP\2137132 that_3\IN\1740 the_4\DT\1740 recently_5\RB\1740 reported_6\VBN\831651 ability_7\NN\4723816 of_8\IN\1740 l-dihydroxyphenylalanine_9\NN\1740 to_10\TO\1740 reverse_11\VB\109660 the_12\DT\1740 protective_13\JJ\1740 effect_14\NN\34213 of_15\IN\1740 alpha-methyl-para-tyrosine_16\NN\1740 on_17\IN\1740 <e1>meth-induced</e1>_18\JJ\1740 da_19\NN\10484858 <e2>neurotoxicity</e2>_20\NN\1740 is_21\VBZ\836236 also_22\RB\1740 confounded_23\VBN\2604760 by_24\IN\1740 drug_25\NN\14778436 effects_26\NNS\13245626 on_27\IN\1740 body_28\NN\19128 temperature_29\NN\13575869 ._30\.\1740
D008694_D020258 CID further_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 show_3\VBP\2137132 that_4\IN\1740 mice_5\NNS\2329401 genetically_6\RB\1740 engineered_7\VBD\1639714 to_8\TO\1740 be_9\VB\836236 deficient_10\JJ\1740 in_11\IN\13603305 brain_12\NN\5462674 da_13\NN\10484858 develop_14\VBP\1753788 <e1>meth</e1>_15\NN\2704153 <e2>neurotoxicity</e2>_16\NN\1740 ,_17\,\1740 as_18\RB\1740 long_19\RB\1740 as_20\IN\14622893 the_21\DT\1740 thermic_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 meth_25\NN\2704153 are_26\VBP\836236 preserved_27\VBN\2681795 ._28\.\1740
D008694_D020258 CID further_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 show_3\VBP\2137132 that_4\IN\1740 mice_5\NNS\2329401 genetically_6\RB\1740 engineered_7\VBD\1639714 to_8\TO\1740 be_9\VB\836236 deficient_10\JJ\1740 in_11\IN\13603305 brain_12\NN\5462674 da_13\NN\10484858 develop_14\VBP\1753788 meth_15\NN\2704153 <e2>neurotoxicity</e2>_16\NN\1740 ,_17\,\1740 as_18\RB\1740 long_19\RB\1740 as_20\IN\14622893 the_21\DT\1740 thermic_22\JJ\1740 effects_23\NNS\13245626 of_24\IN\1740 <e1>meth</e1>_25\NN\2704153 are_26\VBP\836236 preserved_27\VBN\2681795 ._28\.\1740
D008694_D020258 CID taken_0\VBN\2367363 together_1\RB\1740 ,_2\,\1740 these_3\DT\1740 findings_4\NNS\7951464 demonstrate_5\VBP\2137132 that_6\IN\1740 da_7\NN\10484858 is_8\VBZ\836236 not_9\RB\1740 essential_10\JJ\1740 for_11\IN\1740 the_12\DT\1740 development_13\NN\248977 of_14\IN\1740 <e1>meth-induced</e1>_15\JJ\1740 dopaminergic_16\JJ\1740 <e2>neurotoxicity</e2>_17\NN\1740 and_18\CC\1740 suggest_19\VBP\1010118 that_20\IN\1740 mechanisms_21\NNS\13446390 independent_22\JJ\1740 of_23\IN\1740 da_24\NN\10484858 warrant_25\VBP\1012073 more_26\RBR\1740 intense_27\JJ\1740 investigation_28\NN\5797597 ._29\.\1740
D004298_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 <e1>dopamine</e1>_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 (meth)-induced_11\JJ\1740 <e2>toxicity</e2>_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 toxicity_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 toxicity_35\NN\13576101 ._36\.\1740
D004298_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 <e1>dopamine</e1>_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 (meth)-induced_11\JJ\1740 toxicity_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 <e2>toxicity</e2>_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 toxicity_35\NN\13576101 ._36\.\1740
D004298_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 <e1>dopamine</e1>_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 (meth)-induced_11\JJ\1740 toxicity_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 toxicity_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 <e2>toxicity</e2>_35\NN\13576101 ._36\.\1740
D004298_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 <e1>da</e1>_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 (meth)-induced_11\JJ\1740 <e2>toxicity</e2>_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 toxicity_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 toxicity_35\NN\13576101 ._36\.\1740
D004298_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 <e1>da</e1>_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 (meth)-induced_11\JJ\1740 toxicity_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 <e2>toxicity</e2>_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 toxicity_35\NN\13576101 ._36\.\1740
D004298_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 <e1>da</e1>_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 (meth)-induced_11\JJ\1740 toxicity_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 toxicity_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 <e2>toxicity</e2>_35\NN\13576101 ._36\.\1740
D004298_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 (meth)-induced_11\JJ\1740 <e2>toxicity</e2>_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 <e1>da</e1>_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 toxicity_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 toxicity_35\NN\13576101 ._36\.\1740
D004298_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 (meth)-induced_11\JJ\1740 toxicity_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 <e1>da</e1>_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 <e2>toxicity</e2>_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 toxicity_35\NN\13576101 ._36\.\1740
D004298_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 (meth)-induced_11\JJ\1740 toxicity_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 <e1>da</e1>_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 toxicity_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 <e2>toxicity</e2>_35\NN\13576101 ._36\.\1740
D004298_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 (meth)-induced_11\JJ\1740 <e2>toxicity</e2>_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 toxicity_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 <e1>da</e1>_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 toxicity_35\NN\13576101 ._36\.\1740
D004298_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 (meth)-induced_11\JJ\1740 toxicity_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 <e2>toxicity</e2>_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 <e1>da</e1>_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 toxicity_35\NN\13576101 ._36\.\1740
D004298_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 (meth)-induced_11\JJ\1740 toxicity_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 toxicity_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 <e1>da</e1>_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 <e2>toxicity</e2>_35\NN\13576101 ._36\.\1740
D008694_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 <e1>methamphetamine</e1>_10\NN\2704153 (meth)-induced_11\JJ\1740 <e2>toxicity</e2>_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 toxicity_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 toxicity_35\NN\13576101 ._36\.\1740
D008694_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 <e1>methamphetamine</e1>_10\NN\2704153 (meth)-induced_11\JJ\1740 toxicity_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 <e2>toxicity</e2>_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 toxicity_35\NN\13576101 ._36\.\1740
D008694_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 <e1>methamphetamine</e1>_10\NN\2704153 (meth)-induced_11\JJ\1740 toxicity_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 toxicity_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 <e2>toxicity</e2>_35\NN\13576101 ._36\.\1740
D008694_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 <e1>(meth)-induced</e1>_11\JJ\1740 <e2>toxicity</e2>_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 toxicity_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 toxicity_35\NN\13576101 ._36\.\1740
D008694_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 <e1>(meth)-induced</e1>_11\JJ\1740 toxicity_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 <e2>toxicity</e2>_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 toxicity_35\NN\13576101 ._36\.\1740
D008694_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 widely_2\RB\1740 believed_3\VBN\686447 that_4\IN\1740 dopamine_5\NN\14807737 (_6\-LRB-\1740 da_7\NN\10484858 )_8\-RRB-\1740 mediates_9\VBZ\761713 methamphetamine_10\NN\2704153 <e1>(meth)-induced</e1>_11\JJ\1740 toxicity_12\NN\13576101 to_13\TO\1740 brain_14\VB\1400044 dopaminergic_15\JJ\1740 neurons_16\NNS\5430628 ,_17\,\1740 because_18\IN\1740 drugs_19\NNS\14778436 that_20\WDT\1740 interfere_21\VBP\2451370 with_22\IN\1740 da_23\NN\10484858 neurotransmission_24\NN\1740 decrease_25\NN\7296428 toxicity_26\NN\13576101 ,_27\,\1740 whereas_28\IN\1740 drugs_29\NNS\14778436 that_30\WDT\1740 increase_31\VBP\169651 da_32\NN\10484858 neurotransmission_33\NN\1740 enhance_34\VBP\227165 <e2>toxicity</e2>_35\NN\13576101 ._36\.\1740
D007980_D020258 NONE here_0\RB\1740 we_1\PRP\1740 show_2\VBP\2137132 that_3\IN\1740 the_4\DT\1740 recently_5\RB\1740 reported_6\VBN\831651 ability_7\NN\4723816 of_8\IN\1740 <e1>l-dihydroxyphenylalanine</e1>_9\NN\1740 to_10\TO\1740 reverse_11\VB\109660 the_12\DT\1740 protective_13\JJ\1740 effect_14\NN\34213 of_15\IN\1740 alpha-methyl-para-tyrosine_16\NN\1740 on_17\IN\1740 meth-induced_18\JJ\1740 da_19\NN\10484858 <e2>neurotoxicity</e2>_20\NN\1740 is_21\VBZ\836236 also_22\RB\1740 confounded_23\VBN\2604760 by_24\IN\1740 drug_25\NN\14778436 effects_26\NNS\13245626 on_27\IN\1740 body_28\NN\19128 temperature_29\NN\13575869 ._30\.\1740
D019805_D020258 NONE here_0\RB\1740 we_1\PRP\1740 show_2\VBP\2137132 that_3\IN\1740 the_4\DT\1740 recently_5\RB\1740 reported_6\VBN\831651 ability_7\NN\4723816 of_8\IN\1740 l-dihydroxyphenylalanine_9\NN\1740 to_10\TO\1740 reverse_11\VB\109660 the_12\DT\1740 protective_13\JJ\1740 effect_14\NN\34213 of_15\IN\1740 <e1>alpha-methyl-para-tyrosine</e1>_16\NN\1740 on_17\IN\1740 meth-induced_18\JJ\1740 da_19\NN\10484858 <e2>neurotoxicity</e2>_20\NN\1740 is_21\VBZ\836236 also_22\RB\1740 confounded_23\VBN\2604760 by_24\IN\1740 drug_25\NN\14778436 effects_26\NNS\13245626 on_27\IN\1740 body_28\NN\19128 temperature_29\NN\13575869 ._30\.\1740
D004298_D009461 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 we_3\PRP\1740 demonstrate_4\VBP\2137132 that_5\IN\1740 mice_6\NNS\2329401 genetically_7\RB\1740 engineered_8\VBD\1639714 to_9\TO\1740 have_10\VB\2108377 unilateral_11\JJ\1740 brain_12\NN\5462674 <e1>da</e1>_13\NN\10484858 deficits_14\NNS\5113133 develop_15\VBP\1753788 meth-induced_16\JJ\1740 <e2>dopaminergic_17\JJ\1740 deficits</e2>_18\NNS\5113133 that_19\WDT\1740 are_20\VBP\836236 of_21\IN\1740 comparable_22\JJ\1740 magnitude_23\NN\4916342 on_24\IN\1740 both_25\DT\1740 sides_26\NNS\8630039 of_27\IN\1740 the_28\DT\1740 brain_29\NN\5462674 ._30\.\1740
D008694_D009461 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 we_3\PRP\1740 demonstrate_4\VBP\2137132 that_5\IN\1740 mice_6\NNS\2329401 genetically_7\RB\1740 engineered_8\VBD\1639714 to_9\TO\1740 have_10\VB\2108377 unilateral_11\JJ\1740 brain_12\NN\5462674 da_13\NN\10484858 deficits_14\NNS\5113133 develop_15\VBP\1753788 <e1>meth-induced</e1>_16\JJ\1740 <e2>dopaminergic_17\JJ\1740 deficits</e2>_18\NNS\5113133 that_19\WDT\1740 are_20\VBP\836236 of_21\IN\1740 comparable_22\JJ\1740 magnitude_23\NN\4916342 on_24\IN\1740 both_25\DT\1740 sides_26\NNS\8630039 of_27\IN\1740 the_28\DT\1740 brain_29\NN\5462674 ._30\.\1740
15517007
D003520_D006331 CID however_0\RB\1740 ,_1\,\1740 caution_2\NN\4662951 is_3\VBZ\836236 required_4\VBN\754942 when_5\WRB\1740 <e1>cyclophosphamide</e1>_6\NN\1740 or_7\CC\3541091 anthracyclines_8\NNS\1740 such_9\JJ\1740 as_10\IN\14622893 mitoxantrone_11\NN\1740 are_12\VBP\836236 used_13\VBN\1156834 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 a_17\DT\13649268 possible_18\JJ\1740 underlying_19\VBG\2604760 <e2>heart_20\NN\5919034 damage</e2>_21\NN\7296428 ,_22\,\1740 for_23\IN\1740 example_24\NN\5816287 ,_25\,\1740 systemic_26\JJ\1740 sclerosis_27\NN\14204950 patients_28\NNS\9898892 ._29\.\1740
D003520_D012595 NONE however_0\RB\1740 ,_1\,\1740 caution_2\NN\4662951 is_3\VBZ\836236 required_4\VBN\754942 when_5\WRB\1740 <e1>cyclophosphamide</e1>_6\NN\1740 or_7\CC\3541091 anthracyclines_8\NNS\1740 such_9\JJ\1740 as_10\IN\14622893 mitoxantrone_11\NN\1740 are_12\VBP\836236 used_13\VBN\1156834 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 a_17\DT\13649268 possible_18\JJ\1740 underlying_19\VBG\2604760 heart_20\NN\5919034 damage_21\NN\7296428 ,_22\,\1740 for_23\IN\1740 example_24\NN\5816287 ,_25\,\1740 <e2>systemic_26\JJ\1740 sclerosis</e2>_27\NN\14204950 patients_28\NNS\9898892 ._29\.\1740
D018943_D006331 NONE however_0\RB\1740 ,_1\,\1740 caution_2\NN\4662951 is_3\VBZ\836236 required_4\VBN\754942 when_5\WRB\1740 cyclophosphamide_6\NN\1740 or_7\CC\3541091 <e1>anthracyclines</e1>_8\NNS\1740 such_9\JJ\1740 as_10\IN\14622893 mitoxantrone_11\NN\1740 are_12\VBP\836236 used_13\VBN\1156834 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 a_17\DT\13649268 possible_18\JJ\1740 underlying_19\VBG\2604760 <e2>heart_20\NN\5919034 damage</e2>_21\NN\7296428 ,_22\,\1740 for_23\IN\1740 example_24\NN\5816287 ,_25\,\1740 systemic_26\JJ\1740 sclerosis_27\NN\14204950 patients_28\NNS\9898892 ._29\.\1740
D018943_D012595 NONE however_0\RB\1740 ,_1\,\1740 caution_2\NN\4662951 is_3\VBZ\836236 required_4\VBN\754942 when_5\WRB\1740 cyclophosphamide_6\NN\1740 or_7\CC\3541091 <e1>anthracyclines</e1>_8\NNS\1740 such_9\JJ\1740 as_10\IN\14622893 mitoxantrone_11\NN\1740 are_12\VBP\836236 used_13\VBN\1156834 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 a_17\DT\13649268 possible_18\JJ\1740 underlying_19\VBG\2604760 heart_20\NN\5919034 damage_21\NN\7296428 ,_22\,\1740 for_23\IN\1740 example_24\NN\5816287 ,_25\,\1740 <e2>systemic_26\JJ\1740 sclerosis</e2>_27\NN\14204950 patients_28\NNS\9898892 ._29\.\1740
D008942_D006331 CID however_0\RB\1740 ,_1\,\1740 caution_2\NN\4662951 is_3\VBZ\836236 required_4\VBN\754942 when_5\WRB\1740 cyclophosphamide_6\NN\1740 or_7\CC\3541091 anthracyclines_8\NNS\1740 such_9\JJ\1740 as_10\IN\14622893 <e1>mitoxantrone</e1>_11\NN\1740 are_12\VBP\836236 used_13\VBN\1156834 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 a_17\DT\13649268 possible_18\JJ\1740 underlying_19\VBG\2604760 <e2>heart_20\NN\5919034 damage</e2>_21\NN\7296428 ,_22\,\1740 for_23\IN\1740 example_24\NN\5816287 ,_25\,\1740 systemic_26\JJ\1740 sclerosis_27\NN\14204950 patients_28\NNS\9898892 ._29\.\1740
D008942_D012595 NONE however_0\RB\1740 ,_1\,\1740 caution_2\NN\4662951 is_3\VBZ\836236 required_4\VBN\754942 when_5\WRB\1740 cyclophosphamide_6\NN\1740 or_7\CC\3541091 anthracyclines_8\NNS\1740 such_9\JJ\1740 as_10\IN\14622893 <e1>mitoxantrone</e1>_11\NN\1740 are_12\VBP\836236 used_13\VBN\1156834 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 a_17\DT\13649268 possible_18\JJ\1740 underlying_19\VBG\2604760 heart_20\NN\5919034 damage_21\NN\7296428 ,_22\,\1740 for_23\IN\1740 example_24\NN\5816287 ,_25\,\1740 <e2>systemic_26\JJ\1740 sclerosis</e2>_27\NN\14204950 patients_28\NNS\9898892 ._29\.\1740
16157917
C047781_D009207 CID <e1>lamotrigine</e1>_0\NNP\1740 associated_1\VBD\628491 with_2\IN\1740 exacerbation_3\NN\374224 or_4\CC\3541091 de_5\FW\1740 novo_6\FW\1740 <e2>myoclonus</e2>_7\NN\14360459 in_8\IN\13603305 idiopathic_9\JJ\1740 generalized_10\JJ\1740 epilepsies_11\NNS\14085708 ._12\.\1740
C047781_D009207 CID five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 idiopathic_3\JJ\1740 generalized_4\JJ\1740 epilepsies_5\NNS\14085708 (_6\-LRB-\1740 ige_7\NN\15030481 )_8\-RRB-\1740 treated_9\VBN\2376958 with_10\IN\1740 <e1>lamotrigine</e1>_11\NN\1740 (_12\-LRB-\1740 ltg_13\NN\1740 )_14\-RRB-\1740 experienced_15\VBD\2108377 exacerbation_16\NN\374224 or_17\CC\3541091 de_18\FW\1740 novo_19\FW\1740 appearance_20\NN\4723816 of_21\IN\1740 <e2>myoclonic_22\JJ\1740 jerks</e2>_23\NNS\10322238 (_24\-LRB-\1740 mj_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
C047781_D009207 CID five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 idiopathic_3\JJ\1740 generalized_4\JJ\1740 epilepsies_5\NNS\14085708 (_6\-LRB-\1740 ige_7\NN\15030481 )_8\-RRB-\1740 treated_9\VBN\2376958 with_10\IN\1740 <e1>lamotrigine</e1>_11\NN\1740 (_12\-LRB-\1740 ltg_13\NN\1740 )_14\-RRB-\1740 experienced_15\VBD\2108377 exacerbation_16\NN\374224 or_17\CC\3541091 de_18\FW\1740 novo_19\FW\1740 appearance_20\NN\4723816 of_21\IN\1740 myoclonic_22\JJ\1740 jerks_23\NNS\10322238 (_24\-LRB-\1740 <e2>mj</e2>_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
C047781_D009207 CID five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 idiopathic_3\JJ\1740 generalized_4\JJ\1740 epilepsies_5\NNS\14085708 (_6\-LRB-\1740 ige_7\NN\15030481 )_8\-RRB-\1740 treated_9\VBN\2376958 with_10\IN\1740 lamotrigine_11\NN\1740 (_12\-LRB-\1740 <e1>ltg</e1>_13\NN\1740 )_14\-RRB-\1740 experienced_15\VBD\2108377 exacerbation_16\NN\374224 or_17\CC\3541091 de_18\FW\1740 novo_19\FW\1740 appearance_20\NN\4723816 of_21\IN\1740 <e2>myoclonic_22\JJ\1740 jerks</e2>_23\NNS\10322238 (_24\-LRB-\1740 mj_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
C047781_D009207 CID five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 idiopathic_3\JJ\1740 generalized_4\JJ\1740 epilepsies_5\NNS\14085708 (_6\-LRB-\1740 ige_7\NN\15030481 )_8\-RRB-\1740 treated_9\VBN\2376958 with_10\IN\1740 lamotrigine_11\NN\1740 (_12\-LRB-\1740 <e1>ltg</e1>_13\NN\1740 )_14\-RRB-\1740 experienced_15\VBD\2108377 exacerbation_16\NN\374224 or_17\CC\3541091 de_18\FW\1740 novo_19\FW\1740 appearance_20\NN\4723816 of_21\IN\1740 myoclonic_22\JJ\1740 jerks_23\NNS\10322238 (_24\-LRB-\1740 <e2>mj</e2>_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
C047781_D009207 CID in_0\IN\13603305 three_1\CD\13741022 patients_2\NNS\9898892 ,_3\,\1740 <e1>ltg</e1>_4\NN\1740 exacerbated_5\VBD\126264 <e2>mj</e2>_6\NN\1740 in_7\IN\13603305 a_8\DT\13649268 dose-dependent_9\JJ\1740 manner_10\NN\4916342 with_11\IN\1740 early_12\JJ\1740 aggravation_13\NN\7518261 during_14\IN\1740 titration_15\NN\647713 ._16\.\1740
C047781_D009207 CID <e2>mj</e2>_0\NNP\1740 disappeared_1\VBD\2609764 when_2\WRB\1740 <e1>ltg</e1>_3\NN\1740 dose_4\NN\3740161 was_5\VBD\836236 decreased_6\VBN\169651 by_7\IN\1740 25_8\CD\13745420 to_9\TO\1740 50_10\CD\13745420 %_11\NN\1740 ._12\.\1740
C047781_D009207 CID in_0\IN\13603305 two_1\CD\13741022 patients_2\NNS\9898892 ,_3\,\1740 <e1>ltg</e1>_4\NN\1740 exacerbated_5\VBD\126264 <e2>mj</e2>_6\NN\1740 in_7\IN\13603305 a_8\DT\13649268 delayed_9\VBN\439958 but_10\CC\1740 more_11\RBR\1740 severe_12\JJ\1740 manner_13\NN\4916342 ,_14\,\1740 with_15\IN\1740 myoclonic_16\JJ\1740 status_17\NN\24720 that_18\WDT\1740 only_19\RB\1740 ceased_20\VBD\1740 after_21\IN\1740 ltg_22\NNP\1740 withdrawal_23\NN\7206096 ._24\.\1740
C047781_D009207 CID in_0\IN\13603305 two_1\CD\13741022 patients_2\NNS\9898892 ,_3\,\1740 <e1>ltg</e1>_4\NN\1740 exacerbated_5\VBD\126264 mj_6\NN\1740 in_7\IN\13603305 a_8\DT\13649268 delayed_9\VBN\439958 but_10\CC\1740 more_11\RBR\1740 severe_12\JJ\1740 manner_13\NN\4916342 ,_14\,\1740 with_15\IN\1740 <e2>myoclonic_16\JJ\1740 status</e2>_17\NN\24720 that_18\WDT\1740 only_19\RB\1740 ceased_20\VBD\1740 after_21\IN\1740 ltg_22\NNP\1740 withdrawal_23\NN\7206096 ._24\.\1740
C047781_D009207 CID in_0\IN\13603305 two_1\CD\13741022 patients_2\NNS\9898892 ,_3\,\1740 ltg_4\NN\1740 exacerbated_5\VBD\126264 <e2>mj</e2>_6\NN\1740 in_7\IN\13603305 a_8\DT\13649268 delayed_9\VBN\439958 but_10\CC\1740 more_11\RBR\1740 severe_12\JJ\1740 manner_13\NN\4916342 ,_14\,\1740 with_15\IN\1740 myoclonic_16\JJ\1740 status_17\NN\24720 that_18\WDT\1740 only_19\RB\1740 ceased_20\VBD\1740 after_21\IN\1740 <e1>ltg</e1>_22\NNP\1740 withdrawal_23\NN\7206096 ._24\.\1740
C047781_D009207 CID in_0\IN\13603305 two_1\CD\13741022 patients_2\NNS\9898892 ,_3\,\1740 ltg_4\NN\1740 exacerbated_5\VBD\126264 mj_6\NN\1740 in_7\IN\13603305 a_8\DT\13649268 delayed_9\VBN\439958 but_10\CC\1740 more_11\RBR\1740 severe_12\JJ\1740 manner_13\NN\4916342 ,_14\,\1740 with_15\IN\1740 <e2>myoclonic_16\JJ\1740 status</e2>_17\NN\24720 that_18\WDT\1740 only_19\RB\1740 ceased_20\VBD\1740 after_21\IN\1740 <e1>ltg</e1>_22\NNP\1740 withdrawal_23\NN\7206096 ._24\.\1740
C047781_C562694 NONE <e1>lamotrigine</e1>_0\NNP\1740 associated_1\VBD\628491 with_2\IN\1740 exacerbation_3\NN\374224 or_4\CC\3541091 de_5\FW\1740 novo_6\FW\1740 myoclonus_7\NN\14360459 in_8\IN\13603305 <e2>idiopathic_9\JJ\1740 generalized_10\JJ\1740 epilepsies</e2>_11\NNS\14085708 ._12\.\1740
C047781_C562694 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 <e2>idiopathic_3\JJ\1740 generalized_4\JJ\1740 epilepsies</e2>_5\NNS\14085708 (_6\-LRB-\1740 ige_7\NN\15030481 )_8\-RRB-\1740 treated_9\VBN\2376958 with_10\IN\1740 <e1>lamotrigine</e1>_11\NN\1740 (_12\-LRB-\1740 ltg_13\NN\1740 )_14\-RRB-\1740 experienced_15\VBD\2108377 exacerbation_16\NN\374224 or_17\CC\3541091 de_18\FW\1740 novo_19\FW\1740 appearance_20\NN\4723816 of_21\IN\1740 myoclonic_22\JJ\1740 jerks_23\NNS\10322238 (_24\-LRB-\1740 mj_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
C047781_C562694 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 idiopathic_3\JJ\1740 generalized_4\JJ\1740 epilepsies_5\NNS\14085708 (_6\-LRB-\1740 <e2>ige</e2>_7\NN\15030481 )_8\-RRB-\1740 treated_9\VBN\2376958 with_10\IN\1740 <e1>lamotrigine</e1>_11\NN\1740 (_12\-LRB-\1740 ltg_13\NN\1740 )_14\-RRB-\1740 experienced_15\VBD\2108377 exacerbation_16\NN\374224 or_17\CC\3541091 de_18\FW\1740 novo_19\FW\1740 appearance_20\NN\4723816 of_21\IN\1740 myoclonic_22\JJ\1740 jerks_23\NNS\10322238 (_24\-LRB-\1740 mj_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
C047781_C562694 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 <e2>idiopathic_3\JJ\1740 generalized_4\JJ\1740 epilepsies</e2>_5\NNS\14085708 (_6\-LRB-\1740 ige_7\NN\15030481 )_8\-RRB-\1740 treated_9\VBN\2376958 with_10\IN\1740 lamotrigine_11\NN\1740 (_12\-LRB-\1740 <e1>ltg</e1>_13\NN\1740 )_14\-RRB-\1740 experienced_15\VBD\2108377 exacerbation_16\NN\374224 or_17\CC\3541091 de_18\FW\1740 novo_19\FW\1740 appearance_20\NN\4723816 of_21\IN\1740 myoclonic_22\JJ\1740 jerks_23\NNS\10322238 (_24\-LRB-\1740 mj_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
C047781_C562694 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 idiopathic_3\JJ\1740 generalized_4\JJ\1740 epilepsies_5\NNS\14085708 (_6\-LRB-\1740 <e2>ige</e2>_7\NN\15030481 )_8\-RRB-\1740 treated_9\VBN\2376958 with_10\IN\1740 lamotrigine_11\NN\1740 (_12\-LRB-\1740 <e1>ltg</e1>_13\NN\1740 )_14\-RRB-\1740 experienced_15\VBD\2108377 exacerbation_16\NN\374224 or_17\CC\3541091 de_18\FW\1740 novo_19\FW\1740 appearance_20\NN\4723816 of_21\IN\1740 myoclonic_22\JJ\1740 jerks_23\NNS\10322238 (_24\-LRB-\1740 mj_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
12911170
D002939_D009395 CID <e1>ciprofloxacin-induced</e1>_0\JJ\1740 acute_1\JJ\1740 <e2>interstitial_2\JJ\1740 nephritis</e2>_3\NN\14113228 and_4\CC\1740 autoimmune_5\JJ\1740 hemolytic_6\JJ\1740 anemia_7\NN\14189204 ._8\.\1740
D002939_D009395 CID <e1>ciprofloxacin</e1>_0\NN\2716866 has_1\VBZ\2108377 been_2\VBN\836236 associated_3\VBN\628491 with_4\IN\1740 several_5\JJ\1740 side_6\NN\8630039 effects_7\NNS\13245626 including_8\VBG\690614 <e2>interstitial_9\JJ\1740 nephritis</e2>_10\NN\14113228 and_11\CC\1740 hemolytic_12\JJ\1740 anemia_13\NN\14189204 ._14\.\1740
D002939_D009395 CID in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 ,_3\,\1740 we_4\PRP\1740 describe_5\VBP\1001294 a_6\DT\13649268 case_7\NN\7283608 of_8\IN\1740 <e1>ciprofloxacin-induced</e1>_9\JJ\1740 <e2>interstitial_10\JJ\1740 nephritis</e2>_11\NN\14113228 and_12\CC\1740 autoimmune_13\JJ\1740 hemolytic_14\JJ\1740 anemia_15\NN\14189204 ._16\.\1740
D002939_D000744 NONE <e1>ciprofloxacin-induced</e1>_0\JJ\1740 acute_1\JJ\1740 interstitial_2\JJ\1740 nephritis_3\NN\14113228 and_4\CC\1740 <e2>autoimmune_5\JJ\1740 hemolytic_6\JJ\1740 anemia</e2>_7\NN\14189204 ._8\.\1740
D002939_D000744 NONE in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 ,_3\,\1740 we_4\PRP\1740 describe_5\VBP\1001294 a_6\DT\13649268 case_7\NN\7283608 of_8\IN\1740 <e1>ciprofloxacin-induced</e1>_9\JJ\1740 interstitial_10\JJ\1740 nephritis_11\NN\14113228 and_12\CC\1740 <e2>autoimmune_13\JJ\1740 hemolytic_14\JJ\1740 anemia</e2>_15\NN\14189204 ._16\.\1740
D002939_D000743 CID <e1>ciprofloxacin</e1>_0\NN\2716866 has_1\VBZ\2108377 been_2\VBN\836236 associated_3\VBN\628491 with_4\IN\1740 several_5\JJ\1740 side_6\NN\8630039 effects_7\NNS\13245626 including_8\VBG\690614 interstitial_9\JJ\1740 nephritis_10\NN\14113228 and_11\CC\1740 <e2>hemolytic_12\JJ\1740 anemia</e2>_13\NN\14189204 ._14\.\1740
D013256_D000743 NONE <e2>hemolytic_0\JJ\1740 anemia</e2>_1\NN\14189204 improved_2\VBD\126264 after_3\IN\1740 stopping_4\VBG\2452885 the_5\DT\1740 drug_6\NN\14778436 and_7\CC\1740 initiation_8\NN\7450842 of_9\IN\1740 <e1>steroid</e1>_10\NN\14727670 therapy_11\NN\657604 ._12\.\1740
2886572
D004837_D006973 CID enhanced_0\VBN\227165 stimulus-induced_1\JJ\1740 neurotransmitter_2\NN\14807410 overflow_3\NN\329227 in_4\IN\13603305 <e1>epinephrine-induced</e1>_5\JJ\1740 <e2>hypertensive</e2>_6\JJ\1740 rats_7\NNS\2329401 is_8\VBZ\836236 not_9\RB\1740 mediated_10\VBN\761713 by_11\IN\1740 prejunctional_12\JJ\1740 beta-adrenoceptor_13\NN\5608868 activation_14\NN\13561719 ._15\.\1740
2322844
D011453_D010146 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 intrathecal_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>prostaglandins</e1>_6\NNS\5414534 on_7\IN\1740 <e2>pain</e2>_8\NN\14299637 responses_9\NNS\11410625 in_10\IN\13603305 conscious_11\JJ\1740 mice_12\NNS\2329401 were_13\VBD\836236 evaluated_14\VBN\670261 by_15\IN\1740 using_16\VBG\1156834 hot_17\JJ\1740 plate_18\NN\2797881 and_19\CC\1740 acetic_20\JJ\1740 acid_21\NN\14818238 writhing_22\NN\1740 tests_23\NNS\5798043 ._24\.\1740
D019342_D010146 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 intrathecal_3\JJ\1740 administration_4\NN\1133281 of_5\IN\1740 prostaglandins_6\NNS\5414534 on_7\IN\1740 <e2>pain</e2>_8\NN\14299637 responses_9\NNS\11410625 in_10\IN\13603305 conscious_11\JJ\1740 mice_12\NNS\2329401 were_13\VBD\836236 evaluated_14\VBN\670261 by_15\IN\1740 using_16\VBG\1156834 hot_17\JJ\1740 plate_18\NN\2797881 and_19\CC\1740 <e1>acetic_20\JJ\1740 acid</e1>_21\NN\14818238 writhing_22\NN\1740 tests_23\NNS\5798043 ._24\.\1740
D015230_D006930 CID <e1>prostaglandin_0\NN\5414534 d2</e1>_1\NN\1740 (_2\-LRB-\1740 0.5_3\CD\1740 -_4\SYM\1740 3_5\CD\13741022 ng/mouse_6\NN\1740 )_7\-RRB-\1740 had_8\VBD\2108377 a_9\DT\13649268 <e2>hyperalgesic</e2>_10\JJ\1740 action_11\NN\30358 on_12\IN\1740 the_13\DT\1740 response_14\NN\11410625 to_15\TO\1740 a_16\DT\13649268 hot_17\JJ\1740 plate_18\NN\2797881 during_19\IN\1740 a_20\DT\13649268 3_21\CD\13741022 -_22\SYM\1740 60_23\CD\13745420 min_24\NN\15154774 period_25\NN\13575869 after_26\IN\1740 injection_27\NN\320852 ._28\.\1740
D015230_D006930 CID prostaglandin_0\NN\5414534 e2_1\NN\1740 showed_2\VBD\2137132 a_3\DT\13649268 <e2>hyperalgesic</e2>_4\JJ\1740 effect_5\NN\34213 at_6\IN\14622893 doses_7\NNS\3740161 of_8\IN\1740 1_9\CD\13741022 pg_10\NN\1740 to_11\TO\1740 10_12\CD\13745420 ng/mouse_13\NN\1740 ,_14\,\1740 but_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 lasted_18\VBD\2704349 shorter_19\JJR\1740 (_20\-LRB-\1740 3_21\CD\13741022 -_22\SYM\1740 30_23\CD\13745420 min_24\NN\15154774 )_25\-RRB-\1740 than_26\IN\1740 that_27\DT\1740 of_28\IN\1740 <e1>prostaglandin_29\NN\5414534 d2</e1>_30\NN\1740 ._31\.\1740
D015230_D006930 CID the_0\DT\1740 <e2>hyperalgesic</e2>_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 <e1>prostaglandin_4\NN\5414534 d2</e1>_5\NN\1740 was_6\VBD\836236 blocked_7\VBN\1476483 by_8\IN\1740 simultaneous_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 a_12\DT\13649268 substance_13\NN\20827 p_14\NN\14622893 antagonist_15\NN\7846 (_16\-LRB-\1740 greater_17\JJR\1740 than_18\IN\1740 or_19\CC\3541091 equal_20\JJ\1740 to_21\TO\1740 100_22\CD\13745420 ng_23\NN\13717155 )_24\-RRB-\1740 but_25\CC\1740 not_26\RB\1740 by_27\IN\1740 ah6809_28\NN\1740 ,_29\,\1740 a_30\DT\13649268 prostanoid_31\JJ\1740 ep1-receptor_32\NN\1740 antagonist_33\NN\7846 ._34\.\1740
D015230_D006930 CID these_0\DT\1740 results_1\NNS\34213 demonstrate_2\VBP\2137132 that_3\IN\1740 both_4\CC\1740 <e1>prostaglandin_5\NN\5414534 d2</e1>_6\NN\1740 and_7\CC\1740 prostaglandin_8\NN\5414534 e2_9\NN\1740 exert_10\VBP\1158872 <e2>hyperalgesia</e2>_11\NN\1740 in_12\IN\13603305 the_13\DT\1740 spinal_14\JJ\1740 cord_15\NN\3670849 ,_16\,\1740 but_17\CC\1740 in_18\IN\13603305 different_19\JJ\1740 ways_20\NNS\4341686 ._21\.\1740
D015232_D006930 CID <e1>prostaglandin_0\NN\5414534 e2</e1>_1\NN\1740 showed_2\VBD\2137132 a_3\DT\13649268 <e2>hyperalgesic</e2>_4\JJ\1740 effect_5\NN\34213 at_6\IN\14622893 doses_7\NNS\3740161 of_8\IN\1740 1_9\CD\13741022 pg_10\NN\1740 to_11\TO\1740 10_12\CD\13745420 ng/mouse_13\NN\1740 ,_14\,\1740 but_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 lasted_18\VBD\2704349 shorter_19\JJR\1740 (_20\-LRB-\1740 3_21\CD\13741022 -_22\SYM\1740 30_23\CD\13745420 min_24\NN\15154774 )_25\-RRB-\1740 than_26\IN\1740 that_27\DT\1740 of_28\IN\1740 prostaglandin_29\NN\5414534 d2_30\NN\1740 ._31\.\1740
D015232_D006930 CID conversely_0\RB\1740 ,_1\,\1740 <e1>prostaglandin_2\NN\5414534 e2-induced</e1>_3\JJ\1740 <e2>hyperalgesia</e2>_4\NN\1740 was_5\VBD\836236 blocked_6\VBN\1476483 by_7\IN\1740 ah6809_8\NN\1740 (_9\-LRB-\1740 greater_10\JJR\1740 than_11\IN\1740 or_12\CC\3541091 equal_13\JJ\1740 to_14\TO\1740 500_15\CD\13745420 ng_16\NN\13717155 )_17\-RRB-\1740 but_18\CC\1740 not_19\RB\1740 by_20\IN\1740 the_21\DT\1740 substance_22\NN\20827 p_23\NN\14622893 antagonist_24\NN\7846 ._25\.\1740
D015232_D006930 CID these_0\DT\1740 results_1\NNS\34213 demonstrate_2\VBP\2137132 that_3\IN\1740 both_4\CC\1740 prostaglandin_5\NN\5414534 d2_6\NN\1740 and_7\CC\1740 <e1>prostaglandin_8\NN\5414534 e2</e1>_9\NN\1740 exert_10\VBP\1158872 <e2>hyperalgesia</e2>_11\NN\1740 in_12\IN\13603305 the_13\DT\1740 spinal_14\JJ\1740 cord_15\NN\3670849 ,_16\,\1740 but_17\CC\1740 in_18\IN\13603305 different_19\JJ\1740 ways_20\NNS\4341686 ._21\.\1740
D011453_D006930 NONE prostaglandin_0\NN\5414534 e2_1\NN\1740 showed_2\VBD\2137132 a_3\DT\13649268 <e2>hyperalgesic</e2>_4\JJ\1740 effect_5\NN\34213 at_6\IN\14622893 doses_7\NNS\3740161 of_8\IN\1740 1_9\CD\13741022 <e1>pg</e1>_10\NN\1740 to_11\TO\1740 10_12\CD\13745420 ng/mouse_13\NN\1740 ,_14\,\1740 but_15\CC\1740 the_16\DT\1740 effect_17\NN\34213 lasted_18\VBD\2704349 shorter_19\JJR\1740 (_20\-LRB-\1740 3_21\CD\13741022 -_22\SYM\1740 30_23\CD\13745420 min_24\NN\15154774 )_25\-RRB-\1740 than_26\IN\1740 that_27\DT\1740 of_28\IN\1740 prostaglandin_29\NN\5414534 d2_30\NN\1740 ._31\.\1740
C053876_D006930 NONE the_0\DT\1740 <e2>hyperalgesic</e2>_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 prostaglandin_4\NN\5414534 d2_5\NN\1740 was_6\VBD\836236 blocked_7\VBN\1476483 by_8\IN\1740 simultaneous_9\JJ\1740 injection_10\NN\320852 of_11\IN\1740 a_12\DT\13649268 substance_13\NN\20827 p_14\NN\14622893 antagonist_15\NN\7846 (_16\-LRB-\1740 greater_17\JJR\1740 than_18\IN\1740 or_19\CC\3541091 equal_20\JJ\1740 to_21\TO\1740 100_22\CD\13745420 ng_23\NN\13717155 )_24\-RRB-\1740 but_25\CC\1740 not_26\RB\1740 by_27\IN\1740 <e1>ah6809</e1>_28\NN\1740 ,_29\,\1740 a_30\DT\13649268 prostanoid_31\JJ\1740 ep1-receptor_32\NN\1740 antagonist_33\NN\7846 ._34\.\1740
C053876_D006930 NONE conversely_0\RB\1740 ,_1\,\1740 prostaglandin_2\NN\5414534 e2-induced_3\JJ\1740 <e2>hyperalgesia</e2>_4\NN\1740 was_5\VBD\836236 blocked_6\VBN\1476483 by_7\IN\1740 <e1>ah6809</e1>_8\NN\1740 (_9\-LRB-\1740 greater_10\JJR\1740 than_11\IN\1740 or_12\CC\3541091 equal_13\JJ\1740 to_14\TO\1740 500_15\CD\13745420 ng_16\NN\13717155 )_17\-RRB-\1740 but_18\CC\1740 not_19\RB\1740 by_20\IN\1740 the_21\DT\1740 substance_22\NN\20827 p_23\NN\14622893 antagonist_24\NN\7846 ._25\.\1740
D015237_D010146 NONE <e1>prostaglandin_0\NN\5414534 f2_1\NNP\1740 alpha</e1>_2\NN\6828818 had_3\VBD\2108377 little_4\JJ\1740 effect_5\NN\34213 on_6\IN\1740 <e2>pain</e2>_7\NN\14299637 responses_8\NNS\11410625 ._9\.\1740
6150641
D002927_D007172 CID sixty_0\CD\13745420 percent_1\NN\13815742 of_2\IN\1740 the_3\DT\1740 males_4\NNS\15388 developed_5\VBD\1753788 breast_6\NN\5225090 changes_7\NNS\7283608 or_8\CC\3541091 <e2>impotence</e2>_9\NN\4723816 while_10\IN\15122231 taking_11\VBG\2367363 <e1>cimetidine</e1>_12\NN\14778019 and_13\CC\1740 in_14\IN\13603305 all_15\DT\1740 cases_16\NNS\7283608 these_17\DT\1740 changes_18\NNS\7283608 disappeared_19\VBD\2609764 when_20\WRB\1740 cimetidine_21\NN\14778019 was_22\VBD\836236 replaced_23\VBN\1631072 by_24\IN\1740 ranitidine_25\NN\14778019 ._26\.\1740
D002927_D007172 CID sixty_0\CD\13745420 percent_1\NN\13815742 of_2\IN\1740 the_3\DT\1740 males_4\NNS\15388 developed_5\VBD\1753788 breast_6\NN\5225090 changes_7\NNS\7283608 or_8\CC\3541091 <e2>impotence</e2>_9\NN\4723816 while_10\IN\15122231 taking_11\VBG\2367363 cimetidine_12\NN\14778019 and_13\CC\1740 in_14\IN\13603305 all_15\DT\1740 cases_16\NNS\7283608 these_17\DT\1740 changes_18\NNS\7283608 disappeared_19\VBD\2609764 when_20\WRB\1740 <e1>cimetidine</e1>_21\NN\14778019 was_22\VBD\836236 replaced_23\VBN\1631072 by_24\IN\1740 ranitidine_25\NN\14778019 ._26\.\1740
D011899_D007172 NONE sixty_0\CD\13745420 percent_1\NN\13815742 of_2\IN\1740 the_3\DT\1740 males_4\NNS\15388 developed_5\VBD\1753788 breast_6\NN\5225090 changes_7\NNS\7283608 or_8\CC\3541091 <e2>impotence</e2>_9\NN\4723816 while_10\IN\15122231 taking_11\VBG\2367363 cimetidine_12\NN\14778019 and_13\CC\1740 in_14\IN\13603305 all_15\DT\1740 cases_16\NNS\7283608 these_17\DT\1740 changes_18\NNS\7283608 disappeared_19\VBD\2609764 when_20\WRB\1740 cimetidine_21\NN\14778019 was_22\VBD\836236 replaced_23\VBN\1631072 by_24\IN\1740 <e1>ranitidine</e1>_25\NN\14778019 ._26\.\1740
D002927_D056486 NONE treatment_0\NN\654885 with_1\IN\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 <e1>cimetidine</e1>_5\NN\14778019 (_6\-LRB-\1740 one_7\CD\13741022 to_8\TO\1740 60_9\CD\13745420 months_10\NNS\15113229 ;_11\:\1740 median_12\NN\6021761 ,_13\,\1740 11_14\CD\13745420 months_15\NNS\15113229 )_16\-RRB-\1740 or_17\CC\3541091 ranitidine_18\NN\14778019 (_19\-LRB-\1740 two_20\CD\13741022 to_21\TO\1740 31_22\CD\1740 months_23\NNS\15113229 ;_24\:\1740 median_25\NN\6021761 ,_26\,\1740 14_27\CD\13745420 months_28\NNS\15113229 )_29\-RRB-\1740 was_30\VBD\836236 not_31\RB\1740 associated_32\VBN\628491 with_33\IN\1740 <e2>hepatic_34\JJ\1740 or_35\CC\3541091 hematologic_36\JJ\1740 toxicity</e2>_37\NN\13576101 or_38\CC\3541091 alterations_39\NNS\7283608 of_40\IN\1740 serum_41\NN\5397468 gastrin_42\NN\5408684 concentrations_43\NNS\4916342 ,_44\,\1740 but_45\CC\1740 ranitidine_46\NN\14778019 therapy_47\NN\657604 was_48\VBD\836236 associated_49\VBN\628491 with_50\IN\1740 a_51\DT\13649268 significantly_52\RB\1740 lower_53\JJR\1740 serum_54\NN\5397468 creatinine_55\NN\1740 level_56\NN\4916342 than_57\IN\1740 seen_58\VBN\2106506 with_59\IN\1740 cimetidine_60\NN\14778019 therapy_61\NN\657604 ._62\.\1740
D002927_D056486 NONE treatment_0\NN\654885 with_1\IN\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 cimetidine_5\NN\14778019 (_6\-LRB-\1740 one_7\CD\13741022 to_8\TO\1740 60_9\CD\13745420 months_10\NNS\15113229 ;_11\:\1740 median_12\NN\6021761 ,_13\,\1740 11_14\CD\13745420 months_15\NNS\15113229 )_16\-RRB-\1740 or_17\CC\3541091 ranitidine_18\NN\14778019 (_19\-LRB-\1740 two_20\CD\13741022 to_21\TO\1740 31_22\CD\1740 months_23\NNS\15113229 ;_24\:\1740 median_25\NN\6021761 ,_26\,\1740 14_27\CD\13745420 months_28\NNS\15113229 )_29\-RRB-\1740 was_30\VBD\836236 not_31\RB\1740 associated_32\VBN\628491 with_33\IN\1740 <e2>hepatic_34\JJ\1740 or_35\CC\3541091 hematologic_36\JJ\1740 toxicity</e2>_37\NN\13576101 or_38\CC\3541091 alterations_39\NNS\7283608 of_40\IN\1740 serum_41\NN\5397468 gastrin_42\NN\5408684 concentrations_43\NNS\4916342 ,_44\,\1740 but_45\CC\1740 ranitidine_46\NN\14778019 therapy_47\NN\657604 was_48\VBD\836236 associated_49\VBN\628491 with_50\IN\1740 a_51\DT\13649268 significantly_52\RB\1740 lower_53\JJR\1740 serum_54\NN\5397468 creatinine_55\NN\1740 level_56\NN\4916342 than_57\IN\1740 seen_58\VBN\2106506 with_59\IN\1740 <e1>cimetidine</e1>_60\NN\14778019 therapy_61\NN\657604 ._62\.\1740
D002927_D006402 NONE treatment_0\NN\654885 with_1\IN\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 <e1>cimetidine</e1>_5\NN\14778019 (_6\-LRB-\1740 one_7\CD\13741022 to_8\TO\1740 60_9\CD\13745420 months_10\NNS\15113229 ;_11\:\1740 median_12\NN\6021761 ,_13\,\1740 11_14\CD\13745420 months_15\NNS\15113229 )_16\-RRB-\1740 or_17\CC\3541091 ranitidine_18\NN\14778019 (_19\-LRB-\1740 two_20\CD\13741022 to_21\TO\1740 31_22\CD\1740 months_23\NNS\15113229 ;_24\:\1740 median_25\NN\6021761 ,_26\,\1740 14_27\CD\13745420 months_28\NNS\15113229 )_29\-RRB-\1740 was_30\VBD\836236 not_31\RB\1740 associated_32\VBN\628491 with_33\IN\1740 <e2>hepatic_34\JJ\1740 or_35\CC\3541091 hematologic_36\JJ\1740 toxicity</e2>_37\NN\13576101 or_38\CC\3541091 alterations_39\NNS\7283608 of_40\IN\1740 serum_41\NN\5397468 gastrin_42\NN\5408684 concentrations_43\NNS\4916342 ,_44\,\1740 but_45\CC\1740 ranitidine_46\NN\14778019 therapy_47\NN\657604 was_48\VBD\836236 associated_49\VBN\628491 with_50\IN\1740 a_51\DT\13649268 significantly_52\RB\1740 lower_53\JJR\1740 serum_54\NN\5397468 creatinine_55\NN\1740 level_56\NN\4916342 than_57\IN\1740 seen_58\VBN\2106506 with_59\IN\1740 cimetidine_60\NN\14778019 therapy_61\NN\657604 ._62\.\1740
D002927_D006402 NONE treatment_0\NN\654885 with_1\IN\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 cimetidine_5\NN\14778019 (_6\-LRB-\1740 one_7\CD\13741022 to_8\TO\1740 60_9\CD\13745420 months_10\NNS\15113229 ;_11\:\1740 median_12\NN\6021761 ,_13\,\1740 11_14\CD\13745420 months_15\NNS\15113229 )_16\-RRB-\1740 or_17\CC\3541091 ranitidine_18\NN\14778019 (_19\-LRB-\1740 two_20\CD\13741022 to_21\TO\1740 31_22\CD\1740 months_23\NNS\15113229 ;_24\:\1740 median_25\NN\6021761 ,_26\,\1740 14_27\CD\13745420 months_28\NNS\15113229 )_29\-RRB-\1740 was_30\VBD\836236 not_31\RB\1740 associated_32\VBN\628491 with_33\IN\1740 <e2>hepatic_34\JJ\1740 or_35\CC\3541091 hematologic_36\JJ\1740 toxicity</e2>_37\NN\13576101 or_38\CC\3541091 alterations_39\NNS\7283608 of_40\IN\1740 serum_41\NN\5397468 gastrin_42\NN\5408684 concentrations_43\NNS\4916342 ,_44\,\1740 but_45\CC\1740 ranitidine_46\NN\14778019 therapy_47\NN\657604 was_48\VBD\836236 associated_49\VBN\628491 with_50\IN\1740 a_51\DT\13649268 significantly_52\RB\1740 lower_53\JJR\1740 serum_54\NN\5397468 creatinine_55\NN\1740 level_56\NN\4916342 than_57\IN\1740 seen_58\VBN\2106506 with_59\IN\1740 <e1>cimetidine</e1>_60\NN\14778019 therapy_61\NN\657604 ._62\.\1740
D011899_D056486 NONE treatment_0\NN\654885 with_1\IN\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 cimetidine_5\NN\14778019 (_6\-LRB-\1740 one_7\CD\13741022 to_8\TO\1740 60_9\CD\13745420 months_10\NNS\15113229 ;_11\:\1740 median_12\NN\6021761 ,_13\,\1740 11_14\CD\13745420 months_15\NNS\15113229 )_16\-RRB-\1740 or_17\CC\3541091 <e1>ranitidine</e1>_18\NN\14778019 (_19\-LRB-\1740 two_20\CD\13741022 to_21\TO\1740 31_22\CD\1740 months_23\NNS\15113229 ;_24\:\1740 median_25\NN\6021761 ,_26\,\1740 14_27\CD\13745420 months_28\NNS\15113229 )_29\-RRB-\1740 was_30\VBD\836236 not_31\RB\1740 associated_32\VBN\628491 with_33\IN\1740 <e2>hepatic_34\JJ\1740 or_35\CC\3541091 hematologic_36\JJ\1740 toxicity</e2>_37\NN\13576101 or_38\CC\3541091 alterations_39\NNS\7283608 of_40\IN\1740 serum_41\NN\5397468 gastrin_42\NN\5408684 concentrations_43\NNS\4916342 ,_44\,\1740 but_45\CC\1740 ranitidine_46\NN\14778019 therapy_47\NN\657604 was_48\VBD\836236 associated_49\VBN\628491 with_50\IN\1740 a_51\DT\13649268 significantly_52\RB\1740 lower_53\JJR\1740 serum_54\NN\5397468 creatinine_55\NN\1740 level_56\NN\4916342 than_57\IN\1740 seen_58\VBN\2106506 with_59\IN\1740 cimetidine_60\NN\14778019 therapy_61\NN\657604 ._62\.\1740
D011899_D056486 NONE treatment_0\NN\654885 with_1\IN\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 cimetidine_5\NN\14778019 (_6\-LRB-\1740 one_7\CD\13741022 to_8\TO\1740 60_9\CD\13745420 months_10\NNS\15113229 ;_11\:\1740 median_12\NN\6021761 ,_13\,\1740 11_14\CD\13745420 months_15\NNS\15113229 )_16\-RRB-\1740 or_17\CC\3541091 ranitidine_18\NN\14778019 (_19\-LRB-\1740 two_20\CD\13741022 to_21\TO\1740 31_22\CD\1740 months_23\NNS\15113229 ;_24\:\1740 median_25\NN\6021761 ,_26\,\1740 14_27\CD\13745420 months_28\NNS\15113229 )_29\-RRB-\1740 was_30\VBD\836236 not_31\RB\1740 associated_32\VBN\628491 with_33\IN\1740 <e2>hepatic_34\JJ\1740 or_35\CC\3541091 hematologic_36\JJ\1740 toxicity</e2>_37\NN\13576101 or_38\CC\3541091 alterations_39\NNS\7283608 of_40\IN\1740 serum_41\NN\5397468 gastrin_42\NN\5408684 concentrations_43\NNS\4916342 ,_44\,\1740 but_45\CC\1740 <e1>ranitidine</e1>_46\NN\14778019 therapy_47\NN\657604 was_48\VBD\836236 associated_49\VBN\628491 with_50\IN\1740 a_51\DT\13649268 significantly_52\RB\1740 lower_53\JJR\1740 serum_54\NN\5397468 creatinine_55\NN\1740 level_56\NN\4916342 than_57\IN\1740 seen_58\VBN\2106506 with_59\IN\1740 cimetidine_60\NN\14778019 therapy_61\NN\657604 ._62\.\1740
D011899_D006402 NONE treatment_0\NN\654885 with_1\IN\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 cimetidine_5\NN\14778019 (_6\-LRB-\1740 one_7\CD\13741022 to_8\TO\1740 60_9\CD\13745420 months_10\NNS\15113229 ;_11\:\1740 median_12\NN\6021761 ,_13\,\1740 11_14\CD\13745420 months_15\NNS\15113229 )_16\-RRB-\1740 or_17\CC\3541091 <e1>ranitidine</e1>_18\NN\14778019 (_19\-LRB-\1740 two_20\CD\13741022 to_21\TO\1740 31_22\CD\1740 months_23\NNS\15113229 ;_24\:\1740 median_25\NN\6021761 ,_26\,\1740 14_27\CD\13745420 months_28\NNS\15113229 )_29\-RRB-\1740 was_30\VBD\836236 not_31\RB\1740 associated_32\VBN\628491 with_33\IN\1740 <e2>hepatic_34\JJ\1740 or_35\CC\3541091 hematologic_36\JJ\1740 toxicity</e2>_37\NN\13576101 or_38\CC\3541091 alterations_39\NNS\7283608 of_40\IN\1740 serum_41\NN\5397468 gastrin_42\NN\5408684 concentrations_43\NNS\4916342 ,_44\,\1740 but_45\CC\1740 ranitidine_46\NN\14778019 therapy_47\NN\657604 was_48\VBD\836236 associated_49\VBN\628491 with_50\IN\1740 a_51\DT\13649268 significantly_52\RB\1740 lower_53\JJR\1740 serum_54\NN\5397468 creatinine_55\NN\1740 level_56\NN\4916342 than_57\IN\1740 seen_58\VBN\2106506 with_59\IN\1740 cimetidine_60\NN\14778019 therapy_61\NN\657604 ._62\.\1740
D011899_D006402 NONE treatment_0\NN\654885 with_1\IN\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 cimetidine_5\NN\14778019 (_6\-LRB-\1740 one_7\CD\13741022 to_8\TO\1740 60_9\CD\13745420 months_10\NNS\15113229 ;_11\:\1740 median_12\NN\6021761 ,_13\,\1740 11_14\CD\13745420 months_15\NNS\15113229 )_16\-RRB-\1740 or_17\CC\3541091 ranitidine_18\NN\14778019 (_19\-LRB-\1740 two_20\CD\13741022 to_21\TO\1740 31_22\CD\1740 months_23\NNS\15113229 ;_24\:\1740 median_25\NN\6021761 ,_26\,\1740 14_27\CD\13745420 months_28\NNS\15113229 )_29\-RRB-\1740 was_30\VBD\836236 not_31\RB\1740 associated_32\VBN\628491 with_33\IN\1740 <e2>hepatic_34\JJ\1740 or_35\CC\3541091 hematologic_36\JJ\1740 toxicity</e2>_37\NN\13576101 or_38\CC\3541091 alterations_39\NNS\7283608 of_40\IN\1740 serum_41\NN\5397468 gastrin_42\NN\5408684 concentrations_43\NNS\4916342 ,_44\,\1740 but_45\CC\1740 <e1>ranitidine</e1>_46\NN\14778019 therapy_47\NN\657604 was_48\VBD\836236 associated_49\VBN\628491 with_50\IN\1740 a_51\DT\13649268 significantly_52\RB\1740 lower_53\JJR\1740 serum_54\NN\5397468 creatinine_55\NN\1740 level_56\NN\4916342 than_57\IN\1740 seen_58\VBN\2106506 with_59\IN\1740 cimetidine_60\NN\14778019 therapy_61\NN\657604 ._62\.\1740
D003404_D056486 NONE treatment_0\NN\654885 with_1\IN\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 cimetidine_5\NN\14778019 (_6\-LRB-\1740 one_7\CD\13741022 to_8\TO\1740 60_9\CD\13745420 months_10\NNS\15113229 ;_11\:\1740 median_12\NN\6021761 ,_13\,\1740 11_14\CD\13745420 months_15\NNS\15113229 )_16\-RRB-\1740 or_17\CC\3541091 ranitidine_18\NN\14778019 (_19\-LRB-\1740 two_20\CD\13741022 to_21\TO\1740 31_22\CD\1740 months_23\NNS\15113229 ;_24\:\1740 median_25\NN\6021761 ,_26\,\1740 14_27\CD\13745420 months_28\NNS\15113229 )_29\-RRB-\1740 was_30\VBD\836236 not_31\RB\1740 associated_32\VBN\628491 with_33\IN\1740 <e2>hepatic_34\JJ\1740 or_35\CC\3541091 hematologic_36\JJ\1740 toxicity</e2>_37\NN\13576101 or_38\CC\3541091 alterations_39\NNS\7283608 of_40\IN\1740 serum_41\NN\5397468 gastrin_42\NN\5408684 concentrations_43\NNS\4916342 ,_44\,\1740 but_45\CC\1740 ranitidine_46\NN\14778019 therapy_47\NN\657604 was_48\VBD\836236 associated_49\VBN\628491 with_50\IN\1740 a_51\DT\13649268 significantly_52\RB\1740 lower_53\JJR\1740 serum_54\NN\5397468 <e1>creatinine</e1>_55\NN\1740 level_56\NN\4916342 than_57\IN\1740 seen_58\VBN\2106506 with_59\IN\1740 cimetidine_60\NN\14778019 therapy_61\NN\657604 ._62\.\1740
D003404_D006402 NONE treatment_0\NN\654885 with_1\IN\1740 high_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 cimetidine_5\NN\14778019 (_6\-LRB-\1740 one_7\CD\13741022 to_8\TO\1740 60_9\CD\13745420 months_10\NNS\15113229 ;_11\:\1740 median_12\NN\6021761 ,_13\,\1740 11_14\CD\13745420 months_15\NNS\15113229 )_16\-RRB-\1740 or_17\CC\3541091 ranitidine_18\NN\14778019 (_19\-LRB-\1740 two_20\CD\13741022 to_21\TO\1740 31_22\CD\1740 months_23\NNS\15113229 ;_24\:\1740 median_25\NN\6021761 ,_26\,\1740 14_27\CD\13745420 months_28\NNS\15113229 )_29\-RRB-\1740 was_30\VBD\836236 not_31\RB\1740 associated_32\VBN\628491 with_33\IN\1740 <e2>hepatic_34\JJ\1740 or_35\CC\3541091 hematologic_36\JJ\1740 toxicity</e2>_37\NN\13576101 or_38\CC\3541091 alterations_39\NNS\7283608 of_40\IN\1740 serum_41\NN\5397468 gastrin_42\NN\5408684 concentrations_43\NNS\4916342 ,_44\,\1740 but_45\CC\1740 ranitidine_46\NN\14778019 therapy_47\NN\657604 was_48\VBD\836236 associated_49\VBN\628491 with_50\IN\1740 a_51\DT\13649268 significantly_52\RB\1740 lower_53\JJR\1740 serum_54\NN\5397468 <e1>creatinine</e1>_55\NN\1740 level_56\NN\4916342 than_57\IN\1740 seen_58\VBN\2106506 with_59\IN\1740 cimetidine_60\NN\14778019 therapy_61\NN\657604 ._62\.\1740
15075188
D011692_D009404 CID increased_0\VBN\169651 expression_1\NN\4679549 and_2\CC\1740 apical_3\JJ\1740 targeting_4\NN\1740 of_5\IN\1740 renal_6\JJ\1740 enac_7\NN\1740 subunits_8\NNS\13604718 in_9\IN\13603305 <e1>puromycin_10\NN\1740 aminonucleoside-induced</e1>_11\JJ\1740 <e2>nephrotic_12\JJ\1740 syndrome</e2>_13\NN\5870365 in_14\IN\13603305 rats_15\NNS\2329401 ._16\.\1740
D011692_D009404 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 the_3\DT\1740 increased_4\VBN\169651 or_5\CC\3541091 sustained_6\JJ\1740 expression_7\NN\4679549 of_8\IN\1740 enac_9\NN\1740 subunits_10\NNS\13604718 combined_11\VBN\2630189 with_12\IN\1740 increased_13\VBN\169651 apical_14\JJ\1740 targeting_15\NN\1740 in_16\IN\13603305 the_17\DT\1740 dct2_18\NN\1740 ,_19\,\1740 connecting_20\VBG\628491 tubule_21\NN\5246511 ,_22\,\1740 and_23\CC\1740 collecting_24\VBG\2281093 duct_25\NN\5248181 are_26\VBP\836236 likely_27\JJ\1740 to_28\TO\1740 play_29\VB\1072262 a_30\DT\13649268 role_31\NN\719494 in_32\IN\13603305 the_33\DT\1740 sodium_34\NN\14625458 retention_35\NN\809465 associated_36\VBN\628491 with_37\IN\1740 <e1>pan-induced</e1>_38\JJ\1740 <e2>nephrotic_39\JJ\1740 syndrome</e2>_40\NN\5870365 ._41\.\1740
D012964_D009404 NONE <e2>nephrotic_0\JJ\1740 syndrome</e2>_1\NN\5870365 is_2\VBZ\836236 often_3\RB\1740 accompanied_4\VBN\1835496 by_5\IN\1740 <e1>sodium</e1>_6\NN\14625458 retention_7\NN\809465 and_8\CC\1740 generalized_9\JJ\1740 edema_10\NN\14315192 ._11\.\1740
D012964_D009404 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 the_3\DT\1740 increased_4\VBN\169651 or_5\CC\3541091 sustained_6\JJ\1740 expression_7\NN\4679549 of_8\IN\1740 enac_9\NN\1740 subunits_10\NNS\13604718 combined_11\VBN\2630189 with_12\IN\1740 increased_13\VBN\169651 apical_14\JJ\1740 targeting_15\NN\1740 in_16\IN\13603305 the_17\DT\1740 dct2_18\NN\1740 ,_19\,\1740 connecting_20\VBG\628491 tubule_21\NN\5246511 ,_22\,\1740 and_23\CC\1740 collecting_24\VBG\2281093 duct_25\NN\5248181 are_26\VBP\836236 likely_27\JJ\1740 to_28\TO\1740 play_29\VB\1072262 a_30\DT\13649268 role_31\NN\719494 in_32\IN\13603305 the_33\DT\1740 <e1>sodium</e1>_34\NN\14625458 retention_35\NN\809465 associated_36\VBN\628491 with_37\IN\1740 pan-induced_38\JJ\1740 <e2>nephrotic_39\JJ\1740 syndrome</e2>_40\NN\5870365 ._41\.\1740
D012964_D004487 NONE nephrotic_0\JJ\1740 syndrome_1\NN\5870365 is_2\VBZ\836236 often_3\RB\1740 accompanied_4\VBN\1835496 by_5\IN\1740 <e1>sodium</e1>_6\NN\14625458 retention_7\NN\809465 and_8\CC\1740 generalized_9\JJ\1740 <e2>edema</e2>_10\NN\14315192 ._11\.\1740
D011692_D011507 CID after_0\IN\1740 7_1\CD\13741022 days_2\NNS\15140892 ,_3\,\1740 <e1>pan</e1>_4\NN\3101986 treatment_5\NN\654885 induced_6\VBD\1627355 significant_7\JJ\1740 <e2>proteinuria</e2>_8\NN\14299637 ,_9\,\1740 hypoalbuminemia_10\NN\1740 ,_11\,\1740 decreased_12\VBD\169651 urinary_13\JJ\1740 sodium_14\NN\14625458 excretion_15\NN\13466586 ,_16\,\1740 and_17\CC\1740 extensive_18\JJ\1740 ascites_19\NNS\14204950 ._20\.\1740
D011692_D034141 CID after_0\IN\1740 7_1\CD\13741022 days_2\NNS\15140892 ,_3\,\1740 <e1>pan</e1>_4\NN\3101986 treatment_5\NN\654885 induced_6\VBD\1627355 significant_7\JJ\1740 proteinuria_8\NN\14299637 ,_9\,\1740 <e2>hypoalbuminemia</e2>_10\NN\1740 ,_11\,\1740 decreased_12\VBD\169651 urinary_13\JJ\1740 sodium_14\NN\14625458 excretion_15\NN\13466586 ,_16\,\1740 and_17\CC\1740 extensive_18\JJ\1740 ascites_19\NNS\14204950 ._20\.\1740
D011692_D001201 CID after_0\IN\1740 7_1\CD\13741022 days_2\NNS\15140892 ,_3\,\1740 <e1>pan</e1>_4\NN\3101986 treatment_5\NN\654885 induced_6\VBD\1627355 significant_7\JJ\1740 proteinuria_8\NN\14299637 ,_9\,\1740 hypoalbuminemia_10\NN\1740 ,_11\,\1740 decreased_12\VBD\169651 urinary_13\JJ\1740 sodium_14\NN\14625458 excretion_15\NN\13466586 ,_16\,\1740 and_17\CC\1740 extensive_18\JJ\1740 <e2>ascites</e2>_19\NNS\14204950 ._20\.\1740
D012964_D011507 NONE after_0\IN\1740 7_1\CD\13741022 days_2\NNS\15140892 ,_3\,\1740 pan_4\NN\3101986 treatment_5\NN\654885 induced_6\VBD\1627355 significant_7\JJ\1740 <e2>proteinuria</e2>_8\NN\14299637 ,_9\,\1740 hypoalbuminemia_10\NN\1740 ,_11\,\1740 decreased_12\VBD\169651 urinary_13\JJ\1740 <e1>sodium</e1>_14\NN\14625458 excretion_15\NN\13466586 ,_16\,\1740 and_17\CC\1740 extensive_18\JJ\1740 ascites_19\NNS\14204950 ._20\.\1740
D012964_D034141 NONE after_0\IN\1740 7_1\CD\13741022 days_2\NNS\15140892 ,_3\,\1740 pan_4\NN\3101986 treatment_5\NN\654885 induced_6\VBD\1627355 significant_7\JJ\1740 proteinuria_8\NN\14299637 ,_9\,\1740 <e2>hypoalbuminemia</e2>_10\NN\1740 ,_11\,\1740 decreased_12\VBD\169651 urinary_13\JJ\1740 <e1>sodium</e1>_14\NN\14625458 excretion_15\NN\13466586 ,_16\,\1740 and_17\CC\1740 extensive_18\JJ\1740 ascites_19\NNS\14204950 ._20\.\1740
D012964_D001201 NONE after_0\IN\1740 7_1\CD\13741022 days_2\NNS\15140892 ,_3\,\1740 pan_4\NN\3101986 treatment_5\NN\654885 induced_6\VBD\1627355 significant_7\JJ\1740 proteinuria_8\NN\14299637 ,_9\,\1740 hypoalbuminemia_10\NN\1740 ,_11\,\1740 decreased_12\VBD\169651 urinary_13\JJ\1740 <e1>sodium</e1>_14\NN\14625458 excretion_15\NN\13466586 ,_16\,\1740 and_17\CC\1740 extensive_18\JJ\1740 <e2>ascites</e2>_19\NNS\14204950 ._20\.\1740
16006300
D002119_D064420 NONE <e1>calcium_0\NN\14625458 carbonate</e1>_1\NN\15010703 <e2>toxicity</e2>_2\NN\13576101 :_3\:\1740 the_4\DT\1740 updated_5\JJ\1740 milk-alkali_6\JJ\1740 syndrome_7\NN\5870365 ;_8\:\1740 report_9\NN\6470073 of_10\IN\1740 3_11\CD\13741022 cases_12\NNS\7283608 and_13\CC\1740 review_14\NN\5733583 of_15\IN\1740 the_16\DT\1740 literature_17\NN\6362953 ._18\.\1740
D002119_D006934 CID <e1>calcium_0\NN\14625458 carbonate</e1>_1\NN\15010703 toxicity_2\NN\13576101 :_3\:\1740 the_4\DT\1740 updated_5\JJ\1740 <e2>milk-alkali_6\JJ\1740 syndrome</e2>_7\NN\5870365 ;_8\:\1740 report_9\NN\6470073 of_10\IN\1740 3_11\CD\13741022 cases_12\NNS\7283608 and_13\CC\1740 review_14\NN\5733583 of_15\IN\1740 the_16\DT\1740 literature_17\NN\6362953 ._18\.\1740
D002119_D006934 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 3_4\CD\13741022 patients_5\NNS\9898892 with_6\IN\1740 <e1>calcium_7\NN\14625458 carbonate-induced</e1>_8\JJ\1740 <e2>hypercalcemia</e2>_9\NN\14299637 and_10\CC\1740 gain_11\VB\2238085 insights_12\NNS\5710020 into_13\IN\1740 the_14\DT\1740 cause_15\NN\7323922 and_16\CC\1740 management_17\NN\1123598 of_18\IN\1740 the_19\DT\1740 milk-alkali_20\JJ\1740 syndrome_21\NN\5870365 ._22\.\1740
D002119_D006934 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 3_4\CD\13741022 patients_5\NNS\9898892 with_6\IN\1740 <e1>calcium_7\NN\14625458 carbonate-induced</e1>_8\JJ\1740 hypercalcemia_9\NN\14299637 and_10\CC\1740 gain_11\VB\2238085 insights_12\NNS\5710020 into_13\IN\1740 the_14\DT\1740 cause_15\NN\7323922 and_16\CC\1740 management_17\NN\1123598 of_18\IN\1740 the_19\DT\1740 <e2>milk-alkali_20\JJ\1740 syndrome</e2>_21\NN\5870365 ._22\.\1740
D002119_D006934 CID conclusion_0\NN\5837957 :_1\:\1740 <e2>milk-alkali_2\JJ\1740 syndrome</e2>_3\NN\5870365 may_4\MD\15209706 be_5\VB\836236 a_6\DT\13649268 common_7\JJ\1740 cause_8\NN\7323922 of_9\IN\1740 unexplained_10\JJ\1740 hypercalcemia_11\NN\14299637 and_12\CC\1740 can_13\MD\3094503 be_14\VB\836236 precipitated_15\VBN\1642924 by_16\IN\1740 small_17\JJ\1740 amounts_18\NNS\13329641 of_19\IN\1740 orally_20\RB\1740 ingested_21\VBN\597915 <e1>calcium_22\NN\14625458 carbonate</e1>_23\NN\15010703 in_24\IN\13603305 susceptible_25\JJ\1740 persons_26\NNS\7347 ._27\.\1740
D002119_D006934 CID conclusion_0\NN\5837957 :_1\:\1740 milk-alkali_2\JJ\1740 syndrome_3\NN\5870365 may_4\MD\15209706 be_5\VB\836236 a_6\DT\13649268 common_7\JJ\1740 cause_8\NN\7323922 of_9\IN\1740 unexplained_10\JJ\1740 <e2>hypercalcemia</e2>_11\NN\14299637 and_12\CC\1740 can_13\MD\3094503 be_14\VB\836236 precipitated_15\VBN\1642924 by_16\IN\1740 small_17\JJ\1740 amounts_18\NNS\13329641 of_19\IN\1740 orally_20\RB\1740 ingested_21\VBN\597915 <e1>calcium_22\NN\14625458 carbonate</e1>_23\NN\15010703 in_24\IN\13603305 susceptible_25\JJ\1740 persons_26\NNS\7347 ._27\.\1740
D002118_D006934 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 report_3\VBP\831651 the_4\DT\1740 clinical_5\JJ\1740 and_6\CC\1740 laboratory_7\JJ\1740 data_8\NNS\7951464 in_9\IN\13603305 3_10\CD\13741022 patients_11\NNS\9898892 who_12\WP\8299493 presented_13\VBD\2137132 with_14\IN\1740 severe_15\JJ\1740 <e2>hypercalcemia</e2>_16\NN\14299637 (_17\-LRB-\1740 corrected_18\VBN\138508 serum_19\NN\5397468 <e1>calcium</e1>_20\NN\14625458 >_21\NN\1740 or_22\CC\3541091 =_23\JJ\1740 14_24\CD\13745420 mg/dl_25\NN\1740 )_26\-RRB-\1740 and_27\CC\1740 review_28\VB\644583 the_29\DT\1740 pertinent_30\JJ\1740 literature_31\NN\6362953 on_32\IN\1740 milk-alkali_33\JJ\1740 syndrome_34\NN\5870365 ._35\.\1740
D002118_D006934 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 report_3\VBP\831651 the_4\DT\1740 clinical_5\JJ\1740 and_6\CC\1740 laboratory_7\JJ\1740 data_8\NNS\7951464 in_9\IN\13603305 3_10\CD\13741022 patients_11\NNS\9898892 who_12\WP\8299493 presented_13\VBD\2137132 with_14\IN\1740 severe_15\JJ\1740 hypercalcemia_16\NN\14299637 (_17\-LRB-\1740 corrected_18\VBN\138508 serum_19\NN\5397468 <e1>calcium</e1>_20\NN\14625458 >_21\NN\1740 or_22\CC\3541091 =_23\JJ\1740 14_24\CD\13745420 mg/dl_25\NN\1740 )_26\-RRB-\1740 and_27\CC\1740 review_28\VB\644583 the_29\DT\1740 pertinent_30\JJ\1740 literature_31\NN\6362953 on_32\IN\1740 <e2>milk-alkali_33\JJ\1740 syndrome</e2>_34\NN\5870365 ._35\.\1740
C097949_D058186 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 3_3\CD\13741022 patients_4\NNS\9898892 had_5\VBD\2108377 <e2>acute_6\JJ\1740 renal_7\JJ\1740 insufficiency</e2>_8\NN\14462946 ,_9\,\1740 relative_10\JJ\1740 metabolic_11\JJ\1740 alkalosis_12\NN\14204950 ,_13\,\1740 and_14\CC\1740 low_15\JJ\1740 parathyroid_16\JJ\1740 hormone_17\NN\5404728 (_18\-LRB-\1740 pth_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 pth-related_22\JJ\1740 peptide_23\NN\14724264 ,_24\,\1740 and_25\CC\1740 <e1>1,25-dihydroxyvitamin_26\NN\1740 d</e1>_27\NN\15089472 concentrations_28\NNS\4916342 ._29\.\1740
C097949_D000471 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 3_3\CD\13741022 patients_4\NNS\9898892 had_5\VBD\2108377 acute_6\JJ\1740 renal_7\JJ\1740 insufficiency_8\NN\14462946 ,_9\,\1740 relative_10\JJ\1740 <e2>metabolic_11\JJ\1740 alkalosis</e2>_12\NN\14204950 ,_13\,\1740 and_14\CC\1740 low_15\JJ\1740 parathyroid_16\JJ\1740 hormone_17\NN\5404728 (_18\-LRB-\1740 pth_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 pth-related_22\JJ\1740 peptide_23\NN\14724264 ,_24\,\1740 and_25\CC\1740 <e1>1,25-dihydroxyvitamin_26\NN\1740 d</e1>_27\NN\15089472 concentrations_28\NNS\4916342 ._29\.\1740
D002118_D006996 NONE the_0\DT\1740 2_1\CD\13741022 patients_2\NNS\9898892 with_3\IN\1740 the_4\DT\1740 higher_5\JJR\1740 serum_6\NN\5397468 <e1>calcium</e1>_7\NN\14625458 concentrations_8\NNS\4916342 received_9\VBD\2210855 pamidronate_10\NN\1740 intravenously_11\RB\1740 (_12\-LRB-\1740 60_13\CD\13745420 and_14\CC\1740 30_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 respectively_18\RB\1740 )_19\-RRB-\1740 ,_20\,\1740 which_21\WDT\1740 caused_22\VBD\1617192 severe_23\JJ\1740 <e2>hypocalcemia</e2>_24\NN\14299637 ._25\.\1740
C019248_D006996 CID the_0\DT\1740 2_1\CD\13741022 patients_2\NNS\9898892 with_3\IN\1740 the_4\DT\1740 higher_5\JJR\1740 serum_6\NN\5397468 calcium_7\NN\14625458 concentrations_8\NNS\4916342 received_9\VBD\2210855 <e1>pamidronate</e1>_10\NN\1740 intravenously_11\RB\1740 (_12\-LRB-\1740 60_13\CD\13745420 and_14\CC\1740 30_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 respectively_18\RB\1740 )_19\-RRB-\1740 ,_20\,\1740 which_21\WDT\1740 caused_22\VBD\1617192 severe_23\JJ\1740 <e2>hypocalcemia</e2>_24\NN\14299637 ._25\.\1740
C019248_D006996 CID <e1>pamidronate</e1>_0\NN\1740 treatment_1\NN\654885 is_2\VBZ\836236 associated_3\VBN\628491 with_4\IN\1740 considerable_5\JJ\1740 risk_6\NN\14541044 for_7\IN\1740 <e2>hypocalcemia</e2>_8\NN\14299637 ,_9\,\1740 even_10\RB\1740 in_11\IN\13603305 cases_12\NNS\7283608 of_13\IN\1740 initially_14\RB\1740 severe_15\JJ\1740 hypercalcemia_16\NN\14299637 ._17\.\1740
C019248_D006934 NONE <e1>pamidronate</e1>_0\NN\1740 treatment_1\NN\654885 is_2\VBZ\836236 associated_3\VBN\628491 with_4\IN\1740 considerable_5\JJ\1740 risk_6\NN\14541044 for_7\IN\1740 hypocalcemia_8\NN\14299637 ,_9\,\1740 even_10\RB\1740 in_11\IN\13603305 cases_12\NNS\7283608 of_13\IN\1740 initially_14\RB\1740 severe_15\JJ\1740 <e2>hypercalcemia</e2>_16\NN\14299637 ._17\.\1740
3115150
D007650_D009127 NONE <e1>ketanserin</e1>_0\NN\1740 pretreatment_1\NN\1740 reverses_2\VBZ\109660 alfentanil-induced_3\JJ\1740 <e2>muscle_4\NN\5289601 rigidity</e2>_5\NN\5023233 ._6\.\1740
D007650_D009127 NONE systemic_0\JJ\1740 pretreatment_1\NN\1740 with_2\IN\1740 <e1>ketanserin</e1>_3\NN\1740 ,_4\,\1740 a_5\DT\13649268 relatively_6\RB\1740 specific_7\JJ\1740 type-2_8\JJ\1740 serotonin_9\NN\14807737 receptor_10\NN\5225602 antagonist_11\NN\7846 ,_12\,\1740 significantly_13\RB\1740 attenuated_14\VBD\224901 the_15\DT\1740 <e2>muscle_16\NN\5289601 rigidity</e2>_17\NN\5023233 produced_18\VBN\1617192 in_19\IN\13603305 rats_20\NNS\2329401 by_21\IN\1740 the_22\DT\1740 potent_23\JJ\1740 short-acting_24\JJ\1740 opiate_25\JJ\1740 agonist_26\NN\9613191 alfentanil_27\NN\1740 ._28\.\1740
D007650_D009127 NONE despite_0\IN\7501545 the_1\DT\1740 absence_2\NN\14449405 of_3\IN\1740 <e2>rigidity</e2>_4\NN\5023233 ,_5\,\1740 animals_6\NNS\4475 that_7\WDT\1740 received_8\VBD\2210855 <e1>ketanserin</e1>_9\NN\1740 (_10\-LRB-\1740 greater_11\JJR\1740 than_12\IN\1740 0.31_13\CD\1740 mg/kg_14\NN\1740 i.p._15\RB\1740 )_16\-RRB-\1740 followed_17\VBN\1835496 by_18\IN\1740 alfentanil_19\NN\1740 were_20\VBD\836236 motionless_21\JJ\1740 ,_22\,\1740 flaccid_23\NN\1740 ,_24\,\1740 and_25\CC\1740 less_26\RBR\1740 responsive_27\JJ\1740 to_28\TO\1740 external_29\JJ\1740 stimuli_30\NNS\5816287 than_31\IN\1740 were_32\VBD\836236 animals_33\NNS\4475 receiving_34\VBG\2210855 alfentanil_35\NN\1740 alone_36\RB\1740 ._37\.\1740
D015760_D009127 CID ketanserin_0\NN\1740 pretreatment_1\NN\1740 reverses_2\VBZ\109660 <e1>alfentanil-induced</e1>_3\JJ\1740 <e2>muscle_4\NN\5289601 rigidity</e2>_5\NN\5023233 ._6\.\1740
D015760_D009127 CID systemic_0\JJ\1740 pretreatment_1\NN\1740 with_2\IN\1740 ketanserin_3\NN\1740 ,_4\,\1740 a_5\DT\13649268 relatively_6\RB\1740 specific_7\JJ\1740 type-2_8\JJ\1740 serotonin_9\NN\14807737 receptor_10\NN\5225602 antagonist_11\NN\7846 ,_12\,\1740 significantly_13\RB\1740 attenuated_14\VBD\224901 the_15\DT\1740 <e2>muscle_16\NN\5289601 rigidity</e2>_17\NN\5023233 produced_18\VBN\1617192 in_19\IN\13603305 rats_20\NNS\2329401 by_21\IN\1740 the_22\DT\1740 potent_23\JJ\1740 short-acting_24\JJ\1740 opiate_25\JJ\1740 agonist_26\NN\9613191 <e1>alfentanil</e1>_27\NN\1740 ._28\.\1740
D015760_D009127 CID chlordiazepoxide_0\NN\2830852 at_1\IN\14622893 doses_2\NNS\3740161 up_3\IN\1740 to_4\TO\1740 10_5\CD\13745420 mg/kg_6\NN\1740 failed_7\VBD\1798936 to_8\TO\1740 significantly_9\RB\1740 influence_10\VB\137313 the_11\DT\1740 <e2>rigidity</e2>_12\NN\5023233 produced_13\VBN\1617192 by_14\IN\1740 <e1>alfentanil</e1>_15\JJ\1740 ._16\.\1740
D015760_D009127 CID despite_0\IN\7501545 the_1\DT\1740 absence_2\NN\14449405 of_3\IN\1740 <e2>rigidity</e2>_4\NN\5023233 ,_5\,\1740 animals_6\NNS\4475 that_7\WDT\1740 received_8\VBD\2210855 ketanserin_9\NN\1740 (_10\-LRB-\1740 greater_11\JJR\1740 than_12\IN\1740 0.31_13\CD\1740 mg/kg_14\NN\1740 i.p._15\RB\1740 )_16\-RRB-\1740 followed_17\VBN\1835496 by_18\IN\1740 <e1>alfentanil</e1>_19\NN\1740 were_20\VBD\836236 motionless_21\JJ\1740 ,_22\,\1740 flaccid_23\NN\1740 ,_24\,\1740 and_25\CC\1740 less_26\RBR\1740 responsive_27\JJ\1740 to_28\TO\1740 external_29\JJ\1740 stimuli_30\NNS\5816287 than_31\IN\1740 were_32\VBD\836236 animals_33\NNS\4475 receiving_34\VBG\2210855 alfentanil_35\NN\1740 alone_36\RB\1740 ._37\.\1740
D015760_D009127 CID despite_0\IN\7501545 the_1\DT\1740 absence_2\NN\14449405 of_3\IN\1740 <e2>rigidity</e2>_4\NN\5023233 ,_5\,\1740 animals_6\NNS\4475 that_7\WDT\1740 received_8\VBD\2210855 ketanserin_9\NN\1740 (_10\-LRB-\1740 greater_11\JJR\1740 than_12\IN\1740 0.31_13\CD\1740 mg/kg_14\NN\1740 i.p._15\RB\1740 )_16\-RRB-\1740 followed_17\VBN\1835496 by_18\IN\1740 alfentanil_19\NN\1740 were_20\VBD\836236 motionless_21\JJ\1740 ,_22\,\1740 flaccid_23\NN\1740 ,_24\,\1740 and_25\CC\1740 less_26\RBR\1740 responsive_27\JJ\1740 to_28\TO\1740 external_29\JJ\1740 stimuli_30\NNS\5816287 than_31\IN\1740 were_32\VBD\836236 animals_33\NNS\4475 receiving_34\VBG\2210855 <e1>alfentanil</e1>_35\NN\1740 alone_36\RB\1740 ._37\.\1740
D012701_D009127 NONE systemic_0\JJ\1740 pretreatment_1\NN\1740 with_2\IN\1740 ketanserin_3\NN\1740 ,_4\,\1740 a_5\DT\13649268 relatively_6\RB\1740 specific_7\JJ\1740 type-2_8\JJ\1740 <e1>serotonin</e1>_9\NN\14807737 receptor_10\NN\5225602 antagonist_11\NN\7846 ,_12\,\1740 significantly_13\RB\1740 attenuated_14\VBD\224901 the_15\DT\1740 <e2>muscle_16\NN\5289601 rigidity</e2>_17\NN\5023233 produced_18\VBN\1617192 in_19\IN\13603305 rats_20\NNS\2329401 by_21\IN\1740 the_22\DT\1740 potent_23\JJ\1740 short-acting_24\JJ\1740 opiate_25\JJ\1740 agonist_26\NN\9613191 alfentanil_27\NN\1740 ._28\.\1740
D012701_D009127 NONE pretreatment_0\NN\1740 with_1\IN\1740 type-2_2\JJ\1740 <e1>serotonin</e1>_3\NN\14807737 antagonists_4\NNS\7846 may_5\MD\15209706 be_6\VB\836236 clinically_7\RB\1740 useful_8\JJ\1740 in_9\IN\13603305 attenuating_10\VBG\224901 opiate-induced_11\JJ\1740 <e2>rigidity</e2>_12\NN\5023233 ,_13\,\1740 although_14\IN\1740 further_15\JJ\1740 studies_16\NNS\635850 will_17\MD\5650329 be_18\VB\836236 necessary_19\JJ\1740 to_20\TO\1740 assess_21\VB\670261 the_22\DT\1740 interaction_23\NN\37396 of_24\IN\1740 possibly_25\RB\1740 enhanced_26\VBN\227165 cns_27\NN\5237227 ,_28\,\1740 cardiovascular_29\JJ\1740 ,_30\,\1740 and_31\CC\1740 respiratory_32\JJ\1740 depression_33\NN\14373582 ._34\.\1740
D002707_D009127 NONE <e1>chlordiazepoxide</e1>_0\NN\2830852 at_1\IN\14622893 doses_2\NNS\3740161 up_3\IN\1740 to_4\TO\1740 10_5\CD\13745420 mg/kg_6\NN\1740 failed_7\VBD\1798936 to_8\TO\1740 significantly_9\RB\1740 influence_10\VB\137313 the_11\DT\1740 <e2>rigidity</e2>_12\NN\5023233 produced_13\VBN\1617192 by_14\IN\1740 alfentanil_15\JJ\1740 ._16\.\1740
D012701_D002318 NONE pretreatment_0\NN\1740 with_1\IN\1740 type-2_2\JJ\1740 <e1>serotonin</e1>_3\NN\14807737 antagonists_4\NNS\7846 may_5\MD\15209706 be_6\VB\836236 clinically_7\RB\1740 useful_8\JJ\1740 in_9\IN\13603305 attenuating_10\VBG\224901 opiate-induced_11\JJ\1740 rigidity_12\NN\5023233 ,_13\,\1740 although_14\IN\1740 further_15\JJ\1740 studies_16\NNS\635850 will_17\MD\5650329 be_18\VB\836236 necessary_19\JJ\1740 to_20\TO\1740 assess_21\VB\670261 the_22\DT\1740 interaction_23\NN\37396 of_24\IN\1740 possibly_25\RB\1740 enhanced_26\VBN\227165 cns_27\NN\5237227 ,_28\,\1740 <e2>cardiovascular_29\JJ\1740 ,_30\,\1740 and_31\CC\1740 respiratory_32\JJ\1740 depression</e2>_33\NN\14373582 ._34\.\1740
D012701_D012131 NONE pretreatment_0\NN\1740 with_1\IN\1740 type-2_2\JJ\1740 <e1>serotonin</e1>_3\NN\14807737 antagonists_4\NNS\7846 may_5\MD\15209706 be_6\VB\836236 clinically_7\RB\1740 useful_8\JJ\1740 in_9\IN\13603305 attenuating_10\VBG\224901 opiate-induced_11\JJ\1740 rigidity_12\NN\5023233 ,_13\,\1740 although_14\IN\1740 further_15\JJ\1740 studies_16\NNS\635850 will_17\MD\5650329 be_18\VB\836236 necessary_19\JJ\1740 to_20\TO\1740 assess_21\VB\670261 the_22\DT\1740 interaction_23\NN\37396 of_24\IN\1740 possibly_25\RB\1740 enhanced_26\VBN\227165 cns_27\NN\5237227 ,_28\,\1740 <e2>cardiovascular_29\JJ\1740 ,_30\,\1740 and_31\CC\1740 respiratory_32\JJ\1740 depression</e2>_33\NN\14373582 ._34\.\1740
18513945
D010121_D007022 CID <e1>oxytocin</e1>_0\NN\5407119 is_1\VBZ\836236 a_2\DT\13649268 commonly_3\RB\1740 used_4\VBN\1156834 uterotonic_5\JJ\1740 that_6\WDT\1740 can_7\MD\3094503 cause_8\VB\1617192 significant_9\JJ\1740 and_10\CC\1740 even_11\RB\1740 fatal_12\JJ\1740 <e2>hypotension</e2>_13\NN\14057371 ,_14\,\1740 particularly_15\RB\1740 when_16\WRB\1740 given_17\VBN\2327200 as_18\IN\14622893 a_19\DT\13649268 bolus_20\NN\13899404 ._21\.\1740
D010121_D007022 CID <e1>oxytocin-induced</e1>_0\JJ\1740 <e2>hypotension</e2>_1\NN\14057371 at_2\IN\14622893 cesarean_3\NN\42541 delivery_4\NN\315986 may_5\MD\15209706 be_6\VB\836236 incorrectly_7\RB\1740 attributed_8\VBN\670261 to_9\TO\1740 blood_10\NN\5397468 loss_11\NN\13252973 ._12\.\1740
D010121_D007022 CID <e2>hypotension</e2>_0\NN\14057371 in_1\IN\13603305 response_2\NN\11410625 to_3\TO\1740 <e1>oxytocin</e1>_4\NN\5407119 was_5\VBD\836236 associated_6\VBN\628491 with_7\IN\1740 a_8\DT\13649268 decrease_9\NN\7296428 in_10\IN\13603305 systemic_11\JJ\1740 vascular_12\JJ\1740 resistance_13\NN\37396 and_14\CC\1740 a_15\DT\13649268 compensatory_16\JJ\1740 increase_17\NN\13576355 in_18\IN\13603305 stroke_19\NN\556313 volume_20\NN\33615 ,_21\,\1740 heart_22\NN\5919034 rate_23\NN\13815152 and_24\CC\1740 cardiac_25\JJ\1740 output_26\NN\4007894 ._27\.\1740
D010121_D006473 NONE <e1>oxytocin-induced</e1>_0\JJ\1740 hypotension_1\NN\14057371 at_2\IN\14622893 cesarean_3\NN\42541 delivery_4\NN\315986 may_5\MD\15209706 be_6\VB\836236 incorrectly_7\RB\1740 attributed_8\VBN\670261 to_9\TO\1740 <e2>blood_10\NN\5397468 loss</e2>_11\NN\13252973 ._12\.\1740
D010121_D020521 NONE hypotension_0\NN\14057371 in_1\IN\13603305 response_2\NN\11410625 to_3\TO\1740 <e1>oxytocin</e1>_4\NN\5407119 was_5\VBD\836236 associated_6\VBN\628491 with_7\IN\1740 a_8\DT\13649268 decrease_9\NN\7296428 in_10\IN\13603305 systemic_11\JJ\1740 vascular_12\JJ\1740 resistance_13\NN\37396 and_14\CC\1740 a_15\DT\13649268 compensatory_16\JJ\1740 increase_17\NN\13576355 in_18\IN\13603305 <e2>stroke</e2>_19\NN\556313 volume_20\NN\33615 ,_21\,\1740 heart_22\NN\5919034 rate_23\NN\13815152 and_24\CC\1740 cardiac_25\JJ\1740 output_26\NN\4007894 ._27\.\1740
2722224
D006854_D006973 CID <e1>hydrocortisone-induced</e1>_0\JJ\1740 <e2>hypertension</e2>_1\NN\14057371 in_2\IN\13603305 humans_3\NNS\31264 :_4\:\1740 pressor_5\NN\9190918 responsiveness_6\NN\5652926 and_7\CC\1740 sympathetic_8\JJ\1740 function_9\NN\13783581 ._10\.\1740
D006854_D006973 CID the_0\DT\1740 <e2>rise_1\NN\7324673 in_2\IN\13603305 resting_3\VBG\2604760 blood_4\NN\5397468 pressure</e2>_5\NN\11419404 with_6\IN\1740 <e1>hydrocortisone</e1>_7\NN\14751417 is_8\VBZ\836236 associated_9\VBN\628491 with_10\IN\1740 an_11\DT\6697703 increased_12\VBN\169651 cardiac_13\JJ\1740 output_14\NN\4007894 (_15\-LRB-\1740 presumably_16\RB\1740 due_17\JJ\1740 to_18\TO\1740 increased_19\VBN\169651 blood_20\NN\5397468 volume_21\NN\33615 )_22\-RRB-\1740 ._23\.\1740
D006854_D016534 NONE the_0\DT\1740 rise_1\NN\7324673 in_2\IN\13603305 resting_3\VBG\2604760 blood_4\NN\5397468 pressure_5\NN\11419404 with_6\IN\1740 <e1>hydrocortisone</e1>_7\NN\14751417 is_8\VBZ\836236 associated_9\VBN\628491 with_10\IN\1740 an_11\DT\6697703 <e2>increased_12\VBN\169651 cardiac_13\JJ\1740 output</e2>_14\NN\4007894 (_15\-LRB-\1740 presumably_16\RB\1740 due_17\JJ\1740 to_18\TO\1740 increased_19\VBN\169651 blood_20\NN\5397468 volume_21\NN\33615 )_22\-RRB-\1740 ._23\.\1740
16720068
D017374_D009459 CID possible_0\JJ\1740 <e2>neuroleptic_1\JJ\1740 malignant_2\JJ\1740 syndrome</e2>_3\NN\5870365 related_4\JJ\1740 to_5\TO\1740 concomitant_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 <e1>paroxetine</e1>_9\NN\1740 and_10\CC\1740 alprazolam_11\NNS\2830852 ._12\.\1740
D017374_D009459 CID this_0\DT\1740 patient_1\NN\9898892 presented_2\VBN\2137132 with_3\IN\1740 symptoms_4\NNS\5823932 of_5\IN\1740 <e2>neuroleptic_6\JJ\1740 malignant_7\JJ\1740 syndrome</e2>_8\NN\5870365 (_9\-LRB-\1740 nms_10\NN\13649268 )_11\-RRB-\1740 ,_12\,\1740 thus_13\RB\1740 demonstrating_14\VBG\2137132 that_15\IN\1740 nms-like_16\JJ\1740 symptoms_17\NNS\5823932 can_18\MD\3094503 occur_19\VB\2623529 after_20\IN\1740 combined_21\JJ\1740 <e1>paroxetine</e1>_22\NN\1740 and_23\CC\1740 alprazolam_24\NN\2830852 treatment_25\NN\654885 ._26\.\1740
D017374_D009459 CID this_0\DT\1740 patient_1\NN\9898892 presented_2\VBN\2137132 with_3\IN\1740 symptoms_4\NNS\5823932 of_5\IN\1740 neuroleptic_6\JJ\1740 malignant_7\JJ\1740 syndrome_8\NN\5870365 (_9\-LRB-\1740 <e2>nms</e2>_10\NN\13649268 )_11\-RRB-\1740 ,_12\,\1740 thus_13\RB\1740 demonstrating_14\VBG\2137132 that_15\IN\1740 nms-like_16\JJ\1740 symptoms_17\NNS\5823932 can_18\MD\3094503 occur_19\VB\2623529 after_20\IN\1740 combined_21\JJ\1740 <e1>paroxetine</e1>_22\NN\1740 and_23\CC\1740 alprazolam_24\NN\2830852 treatment_25\NN\654885 ._26\.\1740
D017374_D009459 CID this_0\DT\1740 patient_1\NN\9898892 presented_2\VBN\2137132 with_3\IN\1740 symptoms_4\NNS\5823932 of_5\IN\1740 neuroleptic_6\JJ\1740 malignant_7\JJ\1740 syndrome_8\NN\5870365 (_9\-LRB-\1740 nms_10\NN\13649268 )_11\-RRB-\1740 ,_12\,\1740 thus_13\RB\1740 demonstrating_14\VBG\2137132 that_15\IN\1740 <e2>nms-like</e2>_16\JJ\1740 symptoms_17\NNS\5823932 can_18\MD\3094503 occur_19\VB\2623529 after_20\IN\1740 combined_21\JJ\1740 <e1>paroxetine</e1>_22\NN\1740 and_23\CC\1740 alprazolam_24\NN\2830852 treatment_25\NN\654885 ._26\.\1740
D000525_D009459 CID possible_0\JJ\1740 <e2>neuroleptic_1\JJ\1740 malignant_2\JJ\1740 syndrome</e2>_3\NN\5870365 related_4\JJ\1740 to_5\TO\1740 concomitant_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 paroxetine_9\NN\1740 and_10\CC\1740 <e1>alprazolam</e1>_11\NNS\2830852 ._12\.\1740
D000525_D009459 CID this_0\DT\1740 patient_1\NN\9898892 presented_2\VBN\2137132 with_3\IN\1740 symptoms_4\NNS\5823932 of_5\IN\1740 <e2>neuroleptic_6\JJ\1740 malignant_7\JJ\1740 syndrome</e2>_8\NN\5870365 (_9\-LRB-\1740 nms_10\NN\13649268 )_11\-RRB-\1740 ,_12\,\1740 thus_13\RB\1740 demonstrating_14\VBG\2137132 that_15\IN\1740 nms-like_16\JJ\1740 symptoms_17\NNS\5823932 can_18\MD\3094503 occur_19\VB\2623529 after_20\IN\1740 combined_21\JJ\1740 paroxetine_22\NN\1740 and_23\CC\1740 <e1>alprazolam</e1>_24\NN\2830852 treatment_25\NN\654885 ._26\.\1740
D000525_D009459 CID this_0\DT\1740 patient_1\NN\9898892 presented_2\VBN\2137132 with_3\IN\1740 symptoms_4\NNS\5823932 of_5\IN\1740 neuroleptic_6\JJ\1740 malignant_7\JJ\1740 syndrome_8\NN\5870365 (_9\-LRB-\1740 <e2>nms</e2>_10\NN\13649268 )_11\-RRB-\1740 ,_12\,\1740 thus_13\RB\1740 demonstrating_14\VBG\2137132 that_15\IN\1740 nms-like_16\JJ\1740 symptoms_17\NNS\5823932 can_18\MD\3094503 occur_19\VB\2623529 after_20\IN\1740 combined_21\JJ\1740 paroxetine_22\NN\1740 and_23\CC\1740 <e1>alprazolam</e1>_24\NN\2830852 treatment_25\NN\654885 ._26\.\1740
D000525_D009459 CID this_0\DT\1740 patient_1\NN\9898892 presented_2\VBN\2137132 with_3\IN\1740 symptoms_4\NNS\5823932 of_5\IN\1740 neuroleptic_6\JJ\1740 malignant_7\JJ\1740 syndrome_8\NN\5870365 (_9\-LRB-\1740 nms_10\NN\13649268 )_11\-RRB-\1740 ,_12\,\1740 thus_13\RB\1740 demonstrating_14\VBG\2137132 that_15\IN\1740 <e2>nms-like</e2>_16\JJ\1740 symptoms_17\NNS\5823932 can_18\MD\3094503 occur_19\VB\2623529 after_20\IN\1740 combined_21\JJ\1740 paroxetine_22\NN\1740 and_23\CC\1740 <e1>alprazolam</e1>_24\NN\2830852 treatment_25\NN\654885 ._26\.\1740
D017374_D011596 NONE on_0\IN\1740 the_1\DT\1740 10th_2\JJ\1740 day_3\NN\15154774 of_4\IN\1740 <e1>paroxetine</e1>_5\NN\1740 and_6\CC\1740 alprazolam_7\NN\2830852 treatment_8\NN\654885 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 exhibited_12\VBD\2632167 marked_13\JJ\1740 <e2>psychomotor_14\NN\1740 retardation</e2>_15\NN\7296428 ,_16\,\1740 disorientation_17\NN\5896733 ,_18\,\1740 and_19\CC\1740 severe_20\JJ\1740 muscle_21\NN\5289601 rigidity_22\NN\5023233 with_23\IN\1740 tremors_24\NNS\345926 ._25\.\1740
D017374_D009127 NONE on_0\IN\1740 the_1\DT\1740 10th_2\JJ\1740 day_3\NN\15154774 of_4\IN\1740 <e1>paroxetine</e1>_5\NN\1740 and_6\CC\1740 alprazolam_7\NN\2830852 treatment_8\NN\654885 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 exhibited_12\VBD\2632167 marked_13\JJ\1740 psychomotor_14\NN\1740 retardation_15\NN\7296428 ,_16\,\1740 disorientation_17\NN\5896733 ,_18\,\1740 and_19\CC\1740 severe_20\JJ\1740 <e2>muscle_21\NN\5289601 rigidity</e2>_22\NN\5023233 with_23\IN\1740 tremors_24\NNS\345926 ._25\.\1740
D017374_D014202 NONE on_0\IN\1740 the_1\DT\1740 10th_2\JJ\1740 day_3\NN\15154774 of_4\IN\1740 <e1>paroxetine</e1>_5\NN\1740 and_6\CC\1740 alprazolam_7\NN\2830852 treatment_8\NN\654885 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 exhibited_12\VBD\2632167 marked_13\JJ\1740 psychomotor_14\NN\1740 retardation_15\NN\7296428 ,_16\,\1740 disorientation_17\NN\5896733 ,_18\,\1740 and_19\CC\1740 severe_20\JJ\1740 muscle_21\NN\5289601 rigidity_22\NN\5023233 with_23\IN\1740 <e2>tremors</e2>_24\NNS\345926 ._25\.\1740
D000525_D011596 NONE on_0\IN\1740 the_1\DT\1740 10th_2\JJ\1740 day_3\NN\15154774 of_4\IN\1740 paroxetine_5\NN\1740 and_6\CC\1740 <e1>alprazolam</e1>_7\NN\2830852 treatment_8\NN\654885 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 exhibited_12\VBD\2632167 marked_13\JJ\1740 <e2>psychomotor_14\NN\1740 retardation</e2>_15\NN\7296428 ,_16\,\1740 disorientation_17\NN\5896733 ,_18\,\1740 and_19\CC\1740 severe_20\JJ\1740 muscle_21\NN\5289601 rigidity_22\NN\5023233 with_23\IN\1740 tremors_24\NNS\345926 ._25\.\1740
D000525_D009127 NONE on_0\IN\1740 the_1\DT\1740 10th_2\JJ\1740 day_3\NN\15154774 of_4\IN\1740 paroxetine_5\NN\1740 and_6\CC\1740 <e1>alprazolam</e1>_7\NN\2830852 treatment_8\NN\654885 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 exhibited_12\VBD\2632167 marked_13\JJ\1740 psychomotor_14\NN\1740 retardation_15\NN\7296428 ,_16\,\1740 disorientation_17\NN\5896733 ,_18\,\1740 and_19\CC\1740 severe_20\JJ\1740 <e2>muscle_21\NN\5289601 rigidity</e2>_22\NN\5023233 with_23\IN\1740 tremors_24\NNS\345926 ._25\.\1740
D000525_D014202 NONE on_0\IN\1740 the_1\DT\1740 10th_2\JJ\1740 day_3\NN\15154774 of_4\IN\1740 paroxetine_5\NN\1740 and_6\CC\1740 <e1>alprazolam</e1>_7\NN\2830852 treatment_8\NN\654885 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 exhibited_12\VBD\2632167 marked_13\JJ\1740 psychomotor_14\NN\1740 retardation_15\NN\7296428 ,_16\,\1740 disorientation_17\NN\5896733 ,_18\,\1740 and_19\CC\1740 severe_20\JJ\1740 muscle_21\NN\5289601 rigidity_22\NN\5023233 with_23\IN\1740 <e2>tremors</e2>_24\NNS\345926 ._25\.\1740
19721134
D010862_D001145 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 <e1>pilocarpine</e1>_9\NN\14712692 and_10\CC\1740 explore_11\VB\789138 the_12\DT\1740 underlying_13\VBG\2604760 ionic_14\JJ\1740 mechanism_15\NN\13446390 ,_16\,\1740 using_17\VBG\1156834 both_18\CC\1740 aconitine-induced_19\JJ\1740 rat_20\NN\2329401 and_21\CC\1740 ouabain-induced_22\JJ\1740 guinea_23\NN\13388245 pig_24\NN\2395003 <e2>arrhythmia</e2>_25\NN\14103288 models_26\NNS\5888929 ._27\.\1740
D010862_D001145 NONE the_0\DT\1740 current_1\JJ\1740 data_2\NNS\7951464 showed_3\VBD\2137132 that_4\IN\1740 <e1>pilocarpine</e1>_5\NN\14712692 significantly_6\RB\1740 delayed_7\VBD\439958 onset_8\NN\7325190 of_9\IN\1740 <e2>arrhythmias</e2>_10\NNS\14103288 ,_11\,\1740 decreased_12\VBD\169651 the_13\DT\1740 time_14\NN\7308889 course_15\NN\883297 of_16\IN\1740 ventricular_17\JJ\1740 tachycardia_18\NN\14110674 and_19\CC\1740 fibrillation_20\NN\14361664 ,_21\,\1740 reduced_22\VBN\441445 arrhythmia_23\NN\14103288 score_24\NN\5736149 ,_25\,\1740 and_26\CC\1740 increased_27\VBD\169651 the_28\DT\1740 survival_29\NN\13961642 time_30\NN\7308889 of_31\IN\1740 arrhythmic_32\JJ\1740 rats_33\NNS\2329401 and_34\CC\1740 guinea_35\NN\13388245 pigs_36\NNS\2395003 ._37\.\1740
D010862_D001145 NONE the_0\DT\1740 current_1\JJ\1740 data_2\NNS\7951464 showed_3\VBD\2137132 that_4\IN\1740 <e1>pilocarpine</e1>_5\NN\14712692 significantly_6\RB\1740 delayed_7\VBD\439958 onset_8\NN\7325190 of_9\IN\1740 arrhythmias_10\NNS\14103288 ,_11\,\1740 decreased_12\VBD\169651 the_13\DT\1740 time_14\NN\7308889 course_15\NN\883297 of_16\IN\1740 ventricular_17\JJ\1740 tachycardia_18\NN\14110674 and_19\CC\1740 fibrillation_20\NN\14361664 ,_21\,\1740 reduced_22\VBN\441445 <e2>arrhythmia</e2>_23\NN\14103288 score_24\NN\5736149 ,_25\,\1740 and_26\CC\1740 increased_27\VBD\169651 the_28\DT\1740 survival_29\NN\13961642 time_30\NN\7308889 of_31\IN\1740 arrhythmic_32\JJ\1740 rats_33\NNS\2329401 and_34\CC\1740 guinea_35\NN\13388245 pigs_36\NNS\2395003 ._37\.\1740
D010862_D001145 NONE the_0\DT\1740 current_1\JJ\1740 data_2\NNS\7951464 showed_3\VBD\2137132 that_4\IN\1740 <e1>pilocarpine</e1>_5\NN\14712692 significantly_6\RB\1740 delayed_7\VBD\439958 onset_8\NN\7325190 of_9\IN\1740 arrhythmias_10\NNS\14103288 ,_11\,\1740 decreased_12\VBD\169651 the_13\DT\1740 time_14\NN\7308889 course_15\NN\883297 of_16\IN\1740 ventricular_17\JJ\1740 tachycardia_18\NN\14110674 and_19\CC\1740 fibrillation_20\NN\14361664 ,_21\,\1740 reduced_22\VBN\441445 arrhythmia_23\NN\14103288 score_24\NN\5736149 ,_25\,\1740 and_26\CC\1740 increased_27\VBD\169651 the_28\DT\1740 survival_29\NN\13961642 time_30\NN\7308889 of_31\IN\1740 <e2>arrhythmic</e2>_32\JJ\1740 rats_33\NNS\2329401 and_34\CC\1740 guinea_35\NN\13388245 pigs_36\NNS\2395003 ._37\.\1740
D010862_D001145 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>pilocarpine</e1>_4\NN\14712692 produced_5\VBD\1617192 antiarrhythmic_6\JJ\1740 actions_7\NNS\30358 on_8\IN\1740 <e2>arrhythmic</e2>_9\JJ\1740 rat_10\NN\2329401 and_11\CC\1740 guinea_12\NN\13388245 pig_13\NN\2395003 models_14\NNS\5888929 induced_15\VBN\1627355 by_16\IN\1740 aconitine_17\NN\1740 or_18\CC\3541091 ouabain_19\NN\1740 via_20\IN\1740 stimulating_21\VBG\137313 the_22\DT\1740 cardiac_23\JJ\1740 m(3)-machr._24\NN\1740 the_25\DT\1740 mechanism_26\NN\13446390 may_27\MD\15209706 be_28\VB\836236 related_29\JJ\1740 to_30\TO\1740 the_31\DT\1740 improvement_32\NN\7359599 of_33\IN\1740 ca(2_34\NN\1740 +_35\CC\1740 )_36\-RRB-\1740 handling_37\NN\623162 ._38\.\1740
D000157_D001145 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 pilocarpine_9\NN\14712692 and_10\CC\1740 explore_11\VB\789138 the_12\DT\1740 underlying_13\VBG\2604760 ionic_14\JJ\1740 mechanism_15\NN\13446390 ,_16\,\1740 using_17\VBG\1156834 both_18\CC\1740 <e1>aconitine-induced</e1>_19\JJ\1740 rat_20\NN\2329401 and_21\CC\1740 ouabain-induced_22\JJ\1740 guinea_23\NN\13388245 pig_24\NN\2395003 <e2>arrhythmia</e2>_25\NN\14103288 models_26\NNS\5888929 ._27\.\1740
D000157_D001145 CID these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 pilocarpine_4\NN\14712692 produced_5\VBD\1617192 antiarrhythmic_6\JJ\1740 actions_7\NNS\30358 on_8\IN\1740 <e2>arrhythmic</e2>_9\JJ\1740 rat_10\NN\2329401 and_11\CC\1740 guinea_12\NN\13388245 pig_13\NN\2395003 models_14\NNS\5888929 induced_15\VBN\1627355 by_16\IN\1740 <e1>aconitine</e1>_17\NN\1740 or_18\CC\3541091 ouabain_19\NN\1740 via_20\IN\1740 stimulating_21\VBG\137313 the_22\DT\1740 cardiac_23\JJ\1740 m(3)-machr._24\NN\1740 the_25\DT\1740 mechanism_26\NN\13446390 may_27\MD\15209706 be_28\VB\836236 related_29\JJ\1740 to_30\TO\1740 the_31\DT\1740 improvement_32\NN\7359599 of_33\IN\1740 ca(2_34\NN\1740 +_35\CC\1740 )_36\-RRB-\1740 handling_37\NN\623162 ._38\.\1740
D010042_D001145 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 evaluate_5\VB\670261 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 pilocarpine_9\NN\14712692 and_10\CC\1740 explore_11\VB\789138 the_12\DT\1740 underlying_13\VBG\2604760 ionic_14\JJ\1740 mechanism_15\NN\13446390 ,_16\,\1740 using_17\VBG\1156834 both_18\CC\1740 aconitine-induced_19\JJ\1740 rat_20\NN\2329401 and_21\CC\1740 <e1>ouabain-induced</e1>_22\JJ\1740 guinea_23\NN\13388245 pig_24\NN\2395003 <e2>arrhythmia</e2>_25\NN\14103288 models_26\NNS\5888929 ._27\.\1740
D010042_D001145 CID these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 pilocarpine_4\NN\14712692 produced_5\VBD\1617192 antiarrhythmic_6\JJ\1740 actions_7\NNS\30358 on_8\IN\1740 <e2>arrhythmic</e2>_9\JJ\1740 rat_10\NN\2329401 and_11\CC\1740 guinea_12\NN\13388245 pig_13\NN\2395003 models_14\NNS\5888929 induced_15\VBN\1627355 by_16\IN\1740 aconitine_17\NN\1740 or_18\CC\3541091 <e1>ouabain</e1>_19\NN\1740 via_20\IN\1740 stimulating_21\VBG\137313 the_22\DT\1740 cardiac_23\JJ\1740 m(3)-machr._24\NN\1740 the_25\DT\1740 mechanism_26\NN\13446390 may_27\MD\15209706 be_28\VB\836236 related_29\JJ\1740 to_30\TO\1740 the_31\DT\1740 improvement_32\NN\7359599 of_33\IN\1740 ca(2_34\NN\1740 +_35\CC\1740 )_36\-RRB-\1740 handling_37\NN\623162 ._38\.\1740
D010862_D017180 NONE the_0\DT\1740 current_1\JJ\1740 data_2\NNS\7951464 showed_3\VBD\2137132 that_4\IN\1740 <e1>pilocarpine</e1>_5\NN\14712692 significantly_6\RB\1740 delayed_7\VBD\439958 onset_8\NN\7325190 of_9\IN\1740 arrhythmias_10\NNS\14103288 ,_11\,\1740 decreased_12\VBD\169651 the_13\DT\1740 time_14\NN\7308889 course_15\NN\883297 of_16\IN\1740 <e2>ventricular_17\JJ\1740 tachycardia_18\NN\14110674 and_19\CC\1740 fibrillation</e2>_20\NN\14361664 ,_21\,\1740 reduced_22\VBN\441445 arrhythmia_23\NN\14103288 score_24\NN\5736149 ,_25\,\1740 and_26\CC\1740 increased_27\VBD\169651 the_28\DT\1740 survival_29\NN\13961642 time_30\NN\7308889 of_31\IN\1740 arrhythmic_32\JJ\1740 rats_33\NNS\2329401 and_34\CC\1740 guinea_35\NN\13388245 pigs_36\NNS\2395003 ._37\.\1740
D010862_D014693 NONE the_0\DT\1740 current_1\JJ\1740 data_2\NNS\7951464 showed_3\VBD\2137132 that_4\IN\1740 <e1>pilocarpine</e1>_5\NN\14712692 significantly_6\RB\1740 delayed_7\VBD\439958 onset_8\NN\7325190 of_9\IN\1740 arrhythmias_10\NNS\14103288 ,_11\,\1740 decreased_12\VBD\169651 the_13\DT\1740 time_14\NN\7308889 course_15\NN\883297 of_16\IN\1740 <e2>ventricular_17\JJ\1740 tachycardia_18\NN\14110674 and_19\CC\1740 fibrillation</e2>_20\NN\14361664 ,_21\,\1740 reduced_22\VBN\441445 arrhythmia_23\NN\14103288 score_24\NN\5736149 ,_25\,\1740 and_26\CC\1740 increased_27\VBD\169651 the_28\DT\1740 survival_29\NN\13961642 time_30\NN\7308889 of_31\IN\1740 arrhythmic_32\JJ\1740 rats_33\NNS\2329401 and_34\CC\1740 guinea_35\NN\13388245 pigs_36\NNS\2395003 ._37\.\1740
D002118_D001145 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 pilocarpine_4\NN\14712692 produced_5\VBD\1617192 antiarrhythmic_6\JJ\1740 actions_7\NNS\30358 on_8\IN\1740 <e2>arrhythmic</e2>_9\JJ\1740 rat_10\NN\2329401 and_11\CC\1740 guinea_12\NN\13388245 pig_13\NN\2395003 models_14\NNS\5888929 induced_15\VBN\1627355 by_16\IN\1740 aconitine_17\NN\1740 or_18\CC\3541091 ouabain_19\NN\1740 via_20\IN\1740 stimulating_21\VBG\137313 the_22\DT\1740 cardiac_23\JJ\1740 m(3)-machr._24\NN\1740 the_25\DT\1740 mechanism_26\NN\13446390 may_27\MD\15209706 be_28\VB\836236 related_29\JJ\1740 to_30\TO\1740 the_31\DT\1740 improvement_32\NN\7359599 of_33\IN\1740 <e1>ca(2</e1>_34\NN\1740 +_35\CC\1740 )_36\-RRB-\1740 handling_37\NN\623162 ._38\.\1740
21294084
D010406_D004827 NONE effects_0\NNS\13245626 of_1\IN\1740 the_2\DT\1740 hippocampal_3\NN\1740 deep_4\JJ\1740 brain_5\NN\5462674 stimulation_6\NN\242808 on_7\IN\1740 cortical_8\JJ\1740 <e2>epileptic</e2>_9\JJ\1740 discharges_10\NNS\7283608 in_11\IN\13603305 <e1>penicillin</e1>_12\NN\2716866 -_13\HYPH\1740 induced_14\VBN\1627355 epilepsy_15\NN\14085708 model_16\NN\5888929 in_17\IN\13603305 rats_18\NNS\2329401 ._19\.\1740
D010406_D004827 NONE effects_0\NNS\13245626 of_1\IN\1740 the_2\DT\1740 hippocampal_3\NN\1740 deep_4\JJ\1740 brain_5\NN\5462674 stimulation_6\NN\242808 on_7\IN\1740 cortical_8\JJ\1740 epileptic_9\JJ\1740 discharges_10\NNS\7283608 in_11\IN\13603305 <e1>penicillin</e1>_12\NN\2716866 -_13\HYPH\1740 induced_14\VBN\1627355 <e2>epilepsy</e2>_15\NN\14085708 model_16\NN\5888929 in_17\IN\13603305 rats_18\NNS\2329401 ._19\.\1740
D010406_D004827 NONE the_0\DT\1740 aim_1\NN\5980875 was_2\VBD\836236 to_3\TO\1740 evaluate_4\VB\670261 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 high_8\JJ\1740 frequency_9\NN\15286249 hippocampal_10\NN\1740 stimulation_11\NN\242808 on_12\IN\1740 cortical_13\JJ\1740 <e2>epileptic</e2>_14\JJ\1740 activity_15\NN\30358 in_16\IN\13603305 <e1>penicillin-induced</e1>_17\JJ\1740 epilepsy_18\NN\14085708 model_19\NN\5888929 ._20\.\1740
D010406_D004827 NONE the_0\DT\1740 aim_1\NN\5980875 was_2\VBD\836236 to_3\TO\1740 evaluate_4\VB\670261 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 high_8\JJ\1740 frequency_9\NN\15286249 hippocampal_10\NN\1740 stimulation_11\NN\242808 on_12\IN\1740 cortical_13\JJ\1740 epileptic_14\JJ\1740 activity_15\NN\30358 in_16\IN\13603305 <e1>penicillin-induced</e1>_17\JJ\1740 <e2>epilepsy</e2>_18\NN\14085708 model_19\NN\5888929 ._20\.\1740
D010406_D004827 NONE results_0\NNS\34213 :_1\:\1740 high_2\JJ\1740 frequency_3\NN\15286249 hippocampal_4\NN\1740 dbs_5\NN\14622893 suppressed_6\VBD\2510337 the_7\DT\1740 acute_8\JJ\1740 <e1>penicillin-induced</e1>_9\JJ\1740 cortical_10\JJ\1740 <e2>epileptic</e2>_11\JJ\1740 activity_12\NN\30358 independent_13\JJ\1740 from_14\IN\1740 stimulus_15\NN\5816287 intensity_16\NN\5090441 ._17\.\1740
14742097
D004809_D020018 NONE a_0\DT\13649268 randomized_1\JJ\1740 ,_2\,\1740 placebo-controlled_3\JJ\1740 ,_4\,\1740 crossover_5\NN\13526110 study_6\NN\635850 of_7\IN\1740 <e1>ephedrine</e1>_8\NN\14712692 for_9\IN\1740 ssri-induced_10\JJ\1740 female_11\JJ\1740 <e2>sexual_12\JJ\1740 dysfunction</e2>_13\NN\14204950 ._14\.\1740
D004809_D020018 NONE the_0\DT\1740 objective_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 determine_7\VB\1645601 whether_8\IN\1740 <e1>ephedrine</e1>_9\NN\14712692 ,_10\,\1740 an_11\DT\6697703 alpha-_12\NN\1740 and_13\CC\1740 beta-adrenergic_14\JJ\1740 agonist_15\NN\9613191 previously_16\RB\1740 shown_17\VBN\2137132 to_18\TO\1740 enhance_19\VB\227165 genital_20\JJ\1740 blood_21\NN\5397468 flow_22\NN\7311115 in_23\IN\13603305 women_24\NNS\9605289 ,_25\,\1740 has_26\VBZ\2108377 beneficial_27\JJ\1740 effects_28\NNS\13245626 in_29\IN\13603305 reversing_30\VBG\109660 antidepressant-induced_31\JJ\1740 <e2>sexual_32\JJ\1740 dysfunction</e2>_33\NN\14204950 ._34\.\1740
D004809_D020018 NONE nineteen_0\CD\13745420 <e2>sexually_1\RB\1740 dysfunctional</e2>_2\JJ\1740 women_3\NNS\9605289 receiving_4\VBG\2210855 either_5\DT\1740 fluoxetine_6\NN\4169152 ,_7\,\1740 sertraline_8\NN\4169152 ,_9\,\1740 or_10\CC\3541091 paroxetine_11\NN\1740 participated_12\VBN\2367363 in_13\IN\13603305 an_14\DT\6697703 eight-week_15\NN\1740 ,_16\,\1740 double-blind_17\JJ\1740 ,_18\,\1740 placebo-controlled_19\JJ\1740 ,_20\,\1740 cross-over_21\JJ\1740 study_22\NN\635850 of_23\IN\1740 the_24\DT\1740 effects_25\NNS\13245626 of_26\IN\1740 <e1>ephedrine</e1>_27\NN\14712692 (_28\-LRB-\1740 50_29\CD\13745420 mg_30\NN\13717155 )_31\-RRB-\1740 on_32\IN\1740 self-report_33\JJ\1740 measures_34\NNS\168237 of_35\IN\1740 sexual_36\JJ\1740 desire_37\NN\26192 ,_38\,\1740 arousal_39\NN\199130 ,_40\,\1740 orgasm_41\NN\61598 ,_42\,\1740 and_43\CC\1740 sexual_44\JJ\1740 satisfaction_45\NN\7531105 ._46\.\1740
D005473_D020018 CID nineteen_0\CD\13745420 <e2>sexually_1\RB\1740 dysfunctional</e2>_2\JJ\1740 women_3\NNS\9605289 receiving_4\VBG\2210855 either_5\DT\1740 <e1>fluoxetine</e1>_6\NN\4169152 ,_7\,\1740 sertraline_8\NN\4169152 ,_9\,\1740 or_10\CC\3541091 paroxetine_11\NN\1740 participated_12\VBN\2367363 in_13\IN\13603305 an_14\DT\6697703 eight-week_15\NN\1740 ,_16\,\1740 double-blind_17\JJ\1740 ,_18\,\1740 placebo-controlled_19\JJ\1740 ,_20\,\1740 cross-over_21\JJ\1740 study_22\NN\635850 of_23\IN\1740 the_24\DT\1740 effects_25\NNS\13245626 of_26\IN\1740 ephedrine_27\NN\14712692 (_28\-LRB-\1740 50_29\CD\13745420 mg_30\NN\13717155 )_31\-RRB-\1740 on_32\IN\1740 self-report_33\JJ\1740 measures_34\NNS\168237 of_35\IN\1740 sexual_36\JJ\1740 desire_37\NN\26192 ,_38\,\1740 arousal_39\NN\199130 ,_40\,\1740 orgasm_41\NN\61598 ,_42\,\1740 and_43\CC\1740 sexual_44\JJ\1740 satisfaction_45\NN\7531105 ._46\.\1740
D020280_D020018 CID nineteen_0\CD\13745420 <e2>sexually_1\RB\1740 dysfunctional</e2>_2\JJ\1740 women_3\NNS\9605289 receiving_4\VBG\2210855 either_5\DT\1740 fluoxetine_6\NN\4169152 ,_7\,\1740 <e1>sertraline</e1>_8\NN\4169152 ,_9\,\1740 or_10\CC\3541091 paroxetine_11\NN\1740 participated_12\VBN\2367363 in_13\IN\13603305 an_14\DT\6697703 eight-week_15\NN\1740 ,_16\,\1740 double-blind_17\JJ\1740 ,_18\,\1740 placebo-controlled_19\JJ\1740 ,_20\,\1740 cross-over_21\JJ\1740 study_22\NN\635850 of_23\IN\1740 the_24\DT\1740 effects_25\NNS\13245626 of_26\IN\1740 ephedrine_27\NN\14712692 (_28\-LRB-\1740 50_29\CD\13745420 mg_30\NN\13717155 )_31\-RRB-\1740 on_32\IN\1740 self-report_33\JJ\1740 measures_34\NNS\168237 of_35\IN\1740 sexual_36\JJ\1740 desire_37\NN\26192 ,_38\,\1740 arousal_39\NN\199130 ,_40\,\1740 orgasm_41\NN\61598 ,_42\,\1740 and_43\CC\1740 sexual_44\JJ\1740 satisfaction_45\NN\7531105 ._46\.\1740
D017374_D020018 CID nineteen_0\CD\13745420 <e2>sexually_1\RB\1740 dysfunctional</e2>_2\JJ\1740 women_3\NNS\9605289 receiving_4\VBG\2210855 either_5\DT\1740 fluoxetine_6\NN\4169152 ,_7\,\1740 sertraline_8\NN\4169152 ,_9\,\1740 or_10\CC\3541091 <e1>paroxetine</e1>_11\NN\1740 participated_12\VBN\2367363 in_13\IN\13603305 an_14\DT\6697703 eight-week_15\NN\1740 ,_16\,\1740 double-blind_17\JJ\1740 ,_18\,\1740 placebo-controlled_19\JJ\1740 ,_20\,\1740 cross-over_21\JJ\1740 study_22\NN\635850 of_23\IN\1740 the_24\DT\1740 effects_25\NNS\13245626 of_26\IN\1740 ephedrine_27\NN\14712692 (_28\-LRB-\1740 50_29\CD\13745420 mg_30\NN\13717155 )_31\-RRB-\1740 on_32\IN\1740 self-report_33\JJ\1740 measures_34\NNS\168237 of_35\IN\1740 sexual_36\JJ\1740 desire_37\NN\26192 ,_38\,\1740 arousal_39\NN\199130 ,_40\,\1740 orgasm_41\NN\61598 ,_42\,\1740 and_43\CC\1740 sexual_44\JJ\1740 satisfaction_45\NN\7531105 ._46\.\1740
11868798
D013148_D007008 NONE <e1>spironolactone</e1>_0\NN\2721160 :_1\:\1740 is_2\VBZ\836236 it_3\PRP\6125041 a_4\DT\13649268 novel_5\JJ\1740 drug_6\NN\14778436 for_7\IN\1740 the_8\DT\1740 prevention_9\NN\1073995 of_10\IN\1740 amphotericin_11\NN\2716866 b-related_12\JJ\1740 <e2>hypokalemia</e2>_13\NN\14299637 in_14\IN\13603305 cancer_15\NN\14239425 patients_16\NNS\9898892 ?_17\.\1740
D013148_D007008 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 <e1>spironolactone</e1>_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 <e2>hypokalemia</e2>_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D013148_D007008 NONE conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 showed_4\VBD\2137132 that_5\IN\1740 <e1>spironolactone</e1>_6\NN\2721160 can_7\MD\3094503 reduce_8\VB\441445 potassium_9\NN\14625458 requirements_10\NNS\1129920 and_11\CC\1740 prevent_12\VBP\1740 <e2>hypokalemia</e2>_13\NN\14299637 by_14\IN\1740 reducing_15\VBG\441445 urinary_16\JJ\1740 potassium_17\NN\14625458 loss_18\NN\13252973 in_19\IN\13603305 neutropenic_20\JJ\1740 patients_21\NNS\9898892 on_22\IN\1740 amb_23\NN\1740 treatment_24\NN\654885 ._25\.\1740
D013148_D009369 NONE <e1>spironolactone</e1>_0\NN\2721160 :_1\:\1740 is_2\VBZ\836236 it_3\PRP\6125041 a_4\DT\13649268 novel_5\JJ\1740 drug_6\NN\14778436 for_7\IN\1740 the_8\DT\1740 prevention_9\NN\1073995 of_10\IN\1740 amphotericin_11\NN\2716866 b-related_12\JJ\1740 hypokalemia_13\NN\14299637 in_14\IN\13603305 <e2>cancer</e2>_15\NN\14239425 patients_16\NNS\9898892 ?_17\.\1740
D000666_D007008 CID spironolactone_0\NN\2721160 :_1\:\1740 is_2\VBZ\836236 it_3\PRP\6125041 a_4\DT\13649268 novel_5\JJ\1740 drug_6\NN\14778436 for_7\IN\1740 the_8\DT\1740 prevention_9\NN\1073995 of_10\IN\1740 <e1>amphotericin_11\NN\2716866 b-related</e1>_12\JJ\1740 <e2>hypokalemia</e2>_13\NN\14299637 in_14\IN\13603305 cancer_15\NN\14239425 patients_16\NNS\9898892 ?_17\.\1740
D000666_D007008 CID selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>amb.</e1>_24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 <e2>hypokalemia</e2>_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D000666_D007008 CID selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 <e1>amb.</e1>_33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 <e2>hypokalemia</e2>_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D000666_D007008 CID selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 <e2>hypokalemia</e2>_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 <e1>amb</e1>_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D000666_D007008 CID conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 showed_4\VBD\2137132 that_5\IN\1740 spironolactone_6\NN\2721160 can_7\MD\3094503 reduce_8\VB\441445 potassium_9\NN\14625458 requirements_10\NNS\1129920 and_11\CC\1740 prevent_12\VBP\1740 <e2>hypokalemia</e2>_13\NN\14299637 by_14\IN\1740 reducing_15\VBG\441445 urinary_16\JJ\1740 potassium_17\NN\14625458 loss_18\NN\13252973 in_19\IN\13603305 neutropenic_20\JJ\1740 patients_21\NNS\9898892 on_22\IN\1740 <e1>amb</e1>_23\NN\1740 treatment_24\NN\654885 ._25\.\1740
D000666_D009369 NONE spironolactone_0\NN\2721160 :_1\:\1740 is_2\VBZ\836236 it_3\PRP\6125041 a_4\DT\13649268 novel_5\JJ\1740 drug_6\NN\14778436 for_7\IN\1740 the_8\DT\1740 prevention_9\NN\1073995 of_10\IN\1740 <e1>amphotericin_11\NN\2716866 b-related</e1>_12\JJ\1740 hypokalemia_13\NN\14299637 in_14\IN\13603305 <e2>cancer</e2>_15\NN\14239425 patients_16\NNS\9898892 ?_17\.\1740
D000666_D007674 NONE objective_0\NN\5980875 :_1\:\1740 <e2>nephrotoxicity</e2>_2\NN\1740 is_3\VBZ\836236 the_4\DT\1740 major_5\JJ\1740 adverse_6\JJ\1740 effect_7\NN\34213 of_8\IN\1740 <e1>amphotericin_9\NN\2716866 b</e1>_10\NN\1355326 (_11\-LRB-\1740 amb_12\NN\1740 )_13\-RRB-\1740 ,_14\,\1740 often_15\RB\1740 limiting_16\VBG\2510337 administration_17\NN\1133281 of_18\IN\1740 full_19\JJ\1740 dosage_20\NN\13576355 ._21\.\1740
D000666_D007674 NONE objective_0\NN\5980875 :_1\:\1740 <e2>nephrotoxicity</e2>_2\NN\1740 is_3\VBZ\836236 the_4\DT\1740 major_5\JJ\1740 adverse_6\JJ\1740 effect_7\NN\34213 of_8\IN\1740 amphotericin_9\NN\2716866 b_10\NN\1355326 (_11\-LRB-\1740 <e1>amb</e1>_12\NN\1740 )_13\-RRB-\1740 ,_14\,\1740 often_15\RB\1740 limiting_16\VBG\2510337 administration_17\NN\1133281 of_18\IN\1740 full_19\JJ\1740 dosage_20\NN\13576355 ._21\.\1740
D011188_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 <e1>potassium</e1>_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D011188_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 <e1>potassium</e1>_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 <e2>toxicity</e2>_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D011188_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 <e1>potassium</e1>_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D011188_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 <e1>potassium</e1>_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 <e2>toxicity</e2>_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D011188_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 <e1>potassium</e1>_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D011188_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 <e2>toxicity</e2>_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 <e1>potassium</e1>_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D011188_D007008 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 <e1>potassium</e1>_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 <e2>hypokalemia</e2>_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D011188_D007008 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 <e1>potassium</e1>_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 <e2>hypokalemia</e2>_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D011188_D007008 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 <e1>potassium</e1>_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 <e2>hypokalemia</e2>_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D011188_D007008 NONE conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 showed_4\VBD\2137132 that_5\IN\1740 spironolactone_6\NN\2721160 can_7\MD\3094503 reduce_8\VB\441445 <e1>potassium</e1>_9\NN\14625458 requirements_10\NNS\1129920 and_11\CC\1740 prevent_12\VBP\1740 <e2>hypokalemia</e2>_13\NN\14299637 by_14\IN\1740 reducing_15\VBG\441445 urinary_16\JJ\1740 potassium_17\NN\14625458 loss_18\NN\13252973 in_19\IN\13603305 neutropenic_20\JJ\1740 patients_21\NNS\9898892 on_22\IN\1740 amb_23\NN\1740 treatment_24\NN\654885 ._25\.\1740
D011188_D007008 NONE conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 showed_4\VBD\2137132 that_5\IN\1740 spironolactone_6\NN\2721160 can_7\MD\3094503 reduce_8\VB\441445 potassium_9\NN\14625458 requirements_10\NNS\1129920 and_11\CC\1740 prevent_12\VBP\1740 <e2>hypokalemia</e2>_13\NN\14299637 by_14\IN\1740 reducing_15\VBG\441445 urinary_16\JJ\1740 <e1>potassium</e1>_17\NN\14625458 loss_18\NN\13252973 in_19\IN\13603305 neutropenic_20\JJ\1740 patients_21\NNS\9898892 on_22\IN\1740 amb_23\NN\1740 treatment_24\NN\654885 ._25\.\1740
D011188_D009503 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 <e1>potassium</e1>_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 <e2>neutropenic</e2>_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D011188_D009503 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 <e1>potassium</e1>_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 <e2>neutropenic</e2>_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D011188_D009503 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 <e1>potassium</e1>_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 <e2>neutropenic</e2>_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D011188_D009503 NONE conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 showed_4\VBD\2137132 that_5\IN\1740 spironolactone_6\NN\2721160 can_7\MD\3094503 reduce_8\VB\441445 <e1>potassium</e1>_9\NN\14625458 requirements_10\NNS\1129920 and_11\CC\1740 prevent_12\VBP\1740 hypokalemia_13\NN\14299637 by_14\IN\1740 reducing_15\VBG\441445 urinary_16\JJ\1740 potassium_17\NN\14625458 loss_18\NN\13252973 in_19\IN\13603305 <e2>neutropenic</e2>_20\JJ\1740 patients_21\NNS\9898892 on_22\IN\1740 amb_23\NN\1740 treatment_24\NN\654885 ._25\.\1740
D011188_D009503 NONE conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 showed_4\VBD\2137132 that_5\IN\1740 spironolactone_6\NN\2721160 can_7\MD\3094503 reduce_8\VB\441445 potassium_9\NN\14625458 requirements_10\NNS\1129920 and_11\CC\1740 prevent_12\VBP\1740 hypokalemia_13\NN\14299637 by_14\IN\1740 reducing_15\VBG\441445 urinary_16\JJ\1740 <e1>potassium</e1>_17\NN\14625458 loss_18\NN\13252973 in_19\IN\13603305 <e2>neutropenic</e2>_20\JJ\1740 patients_21\NNS\9898892 on_22\IN\1740 amb_23\NN\1740 treatment_24\NN\654885 ._25\.\1740
D000666_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>amb.</e1>_24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D000666_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>amb.</e1>_24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 <e2>toxicity</e2>_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D000666_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 <e1>amb.</e1>_33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D000666_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 <e2>toxicity</e2>_31\NN\13576101 of_32\IN\1740 <e1>amb.</e1>_33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D000666_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 <e1>amb</e1>_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D000666_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 <e2>toxicity</e2>_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 <e1>amb</e1>_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D000666_D009503 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 <e1>amb.</e1>_24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 <e2>neutropenic</e2>_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D000666_D009503 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 <e1>amb.</e1>_33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 <e2>neutropenic</e2>_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D000666_D009503 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 spironolactone_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 <e2>neutropenic</e2>_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 <e1>amb</e1>_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D000666_D009503 NONE conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 showed_4\VBD\2137132 that_5\IN\1740 spironolactone_6\NN\2721160 can_7\MD\3094503 reduce_8\VB\441445 potassium_9\NN\14625458 requirements_10\NNS\1129920 and_11\CC\1740 prevent_12\VBP\1740 hypokalemia_13\NN\14299637 by_14\IN\1740 reducing_15\VBG\441445 urinary_16\JJ\1740 potassium_17\NN\14625458 loss_18\NN\13252973 in_19\IN\13603305 <e2>neutropenic</e2>_20\JJ\1740 patients_21\NNS\9898892 on_22\IN\1740 <e1>amb</e1>_23\NN\1740 treatment_24\NN\654885 ._25\.\1740
D013148_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 <e1>spironolactone</e1>_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D013148_D064420 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 <e2>toxicity</e2>_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 <e1>spironolactone</e1>_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 neutropenic_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D013148_D009503 NONE selective_0\JJ\1740 distal_1\JJ\1740 tubular_2\JJ\1740 epithelial_3\JJ\1740 toxicity_4\NN\13576101 seems_5\VBZ\2604760 to_6\TO\1740 be_7\VB\836236 responsible_8\JJ\1740 for_9\IN\1740 the_10\DT\1740 profound_11\JJ\1740 potassium_12\NN\14625458 wasting_13\VBG\1158572 that_14\WDT\1740 is_15\VBZ\836236 a_16\DT\13649268 major_17\JJ\1740 clinical_18\JJ\1740 side_19\NN\8630039 effect_20\NN\34213 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 amb._24\NN\1740 potassium_25\NN\14625458 depletion_26\NN\351638 also_27\RB\1740 potentiates_28\VBZ\229605 the_29\DT\1740 tubular_30\JJ\1740 toxicity_31\NN\13576101 of_32\IN\1740 amb._33\NN\1740 this_34\DT\1740 study_35\NN\635850 was_36\VBD\836236 designed_37\VBN\1631534 to_38\TO\1740 assess_39\VB\670261 the_40\DT\1740 ability_41\NN\4723816 of_42\IN\1740 <e1>spironolactone</e1>_43\NN\2721160 to_44\TO\1740 reduce_45\VB\441445 potassium_46\NN\14625458 requirements_47\NNS\1129920 and_48\CC\1740 to_49\TO\1740 prevent_50\VB\1740 hypokalemia_51\NN\14299637 in_52\IN\13603305 <e2>neutropenic</e2>_53\JJ\1740 patients_54\NNS\9898892 on_55\IN\1740 amb_56\NN\1740 treatment_57\NN\654885 ._58\.\1740
D013148_D009503 NONE conclusion_0\NN\5837957 :_1\:\1740 this_2\DT\1740 study_3\NN\635850 showed_4\VBD\2137132 that_5\IN\1740 <e1>spironolactone</e1>_6\NN\2721160 can_7\MD\3094503 reduce_8\VB\441445 potassium_9\NN\14625458 requirements_10\NNS\1129920 and_11\CC\1740 prevent_12\VBP\1740 hypokalemia_13\NN\14299637 by_14\IN\1740 reducing_15\VBG\441445 urinary_16\JJ\1740 potassium_17\NN\14625458 loss_18\NN\13252973 in_19\IN\13603305 <e2>neutropenic</e2>_20\JJ\1740 patients_21\NNS\9898892 on_22\IN\1740 amb_23\NN\1740 treatment_24\NN\654885 ._25\.\1740
D000666_D006402 NONE methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 26_5\CD\13745420 patients_6\NNS\9898892 with_7\IN\1740 various_8\JJ\1740 <e2>hematological_9\JJ\1740 disorders</e2>_10\NNS\14034177 were_11\VBD\836236 randomized_12\VBN\278117 to_13\TO\1740 receive_14\VB\2210855 either_15\CC\1740 intravenous_16\JJ\1740 <e1>amb</e1>_17\NN\1740 alone_18\RB\1740 or_19\CC\3541091 amb_20\NN\1740 and_21\CC\1740 oral_22\JJ\1740 spironolactone_23\NN\2721160 100_24\CD\13745420 mg_25\NN\13717155 twice_26\RB\1740 daily_27\RB\1740 when_28\WRB\1740 developing_29\VBG\1753788 a_30\DT\13649268 proven_31\VBN\2604760 or_32\CC\3541091 suspected_33\VBN\916909 fungal_34\JJ\1740 infection_35\NN\14052046 ._36\.\1740
D000666_D006402 NONE methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 26_5\CD\13745420 patients_6\NNS\9898892 with_7\IN\1740 various_8\JJ\1740 <e2>hematological_9\JJ\1740 disorders</e2>_10\NNS\14034177 were_11\VBD\836236 randomized_12\VBN\278117 to_13\TO\1740 receive_14\VB\2210855 either_15\CC\1740 intravenous_16\JJ\1740 amb_17\NN\1740 alone_18\RB\1740 or_19\CC\3541091 <e1>amb</e1>_20\NN\1740 and_21\CC\1740 oral_22\JJ\1740 spironolactone_23\NN\2721160 100_24\CD\13745420 mg_25\NN\13717155 twice_26\RB\1740 daily_27\RB\1740 when_28\WRB\1740 developing_29\VBG\1753788 a_30\DT\13649268 proven_31\VBN\2604760 or_32\CC\3541091 suspected_33\VBN\916909 fungal_34\JJ\1740 infection_35\NN\14052046 ._36\.\1740
D000666_D009181 NONE methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 26_5\CD\13745420 patients_6\NNS\9898892 with_7\IN\1740 various_8\JJ\1740 hematological_9\JJ\1740 disorders_10\NNS\14034177 were_11\VBD\836236 randomized_12\VBN\278117 to_13\TO\1740 receive_14\VB\2210855 either_15\CC\1740 intravenous_16\JJ\1740 <e1>amb</e1>_17\NN\1740 alone_18\RB\1740 or_19\CC\3541091 amb_20\NN\1740 and_21\CC\1740 oral_22\JJ\1740 spironolactone_23\NN\2721160 100_24\CD\13745420 mg_25\NN\13717155 twice_26\RB\1740 daily_27\RB\1740 when_28\WRB\1740 developing_29\VBG\1753788 a_30\DT\13649268 proven_31\VBN\2604760 or_32\CC\3541091 suspected_33\VBN\916909 <e2>fungal_34\JJ\1740 infection</e2>_35\NN\14052046 ._36\.\1740
D000666_D009181 NONE methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 26_5\CD\13745420 patients_6\NNS\9898892 with_7\IN\1740 various_8\JJ\1740 hematological_9\JJ\1740 disorders_10\NNS\14034177 were_11\VBD\836236 randomized_12\VBN\278117 to_13\TO\1740 receive_14\VB\2210855 either_15\CC\1740 intravenous_16\JJ\1740 amb_17\NN\1740 alone_18\RB\1740 or_19\CC\3541091 <e1>amb</e1>_20\NN\1740 and_21\CC\1740 oral_22\JJ\1740 spironolactone_23\NN\2721160 100_24\CD\13745420 mg_25\NN\13717155 twice_26\RB\1740 daily_27\RB\1740 when_28\WRB\1740 developing_29\VBG\1753788 a_30\DT\13649268 proven_31\VBN\2604760 or_32\CC\3541091 suspected_33\VBN\916909 <e2>fungal_34\JJ\1740 infection</e2>_35\NN\14052046 ._36\.\1740
D013148_D006402 NONE methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 26_5\CD\13745420 patients_6\NNS\9898892 with_7\IN\1740 various_8\JJ\1740 <e2>hematological_9\JJ\1740 disorders</e2>_10\NNS\14034177 were_11\VBD\836236 randomized_12\VBN\278117 to_13\TO\1740 receive_14\VB\2210855 either_15\CC\1740 intravenous_16\JJ\1740 amb_17\NN\1740 alone_18\RB\1740 or_19\CC\3541091 amb_20\NN\1740 and_21\CC\1740 oral_22\JJ\1740 <e1>spironolactone</e1>_23\NN\2721160 100_24\CD\13745420 mg_25\NN\13717155 twice_26\RB\1740 daily_27\RB\1740 when_28\WRB\1740 developing_29\VBG\1753788 a_30\DT\13649268 proven_31\VBN\2604760 or_32\CC\3541091 suspected_33\VBN\916909 fungal_34\JJ\1740 infection_35\NN\14052046 ._36\.\1740
D013148_D009181 NONE methods_0\NNS\5616786 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 26_5\CD\13745420 patients_6\NNS\9898892 with_7\IN\1740 various_8\JJ\1740 hematological_9\JJ\1740 disorders_10\NNS\14034177 were_11\VBD\836236 randomized_12\VBN\278117 to_13\TO\1740 receive_14\VB\2210855 either_15\CC\1740 intravenous_16\JJ\1740 amb_17\NN\1740 alone_18\RB\1740 or_19\CC\3541091 amb_20\NN\1740 and_21\CC\1740 oral_22\JJ\1740 <e1>spironolactone</e1>_23\NN\2721160 100_24\CD\13745420 mg_25\NN\13717155 twice_26\RB\1740 daily_27\RB\1740 when_28\WRB\1740 developing_29\VBG\1753788 a_30\DT\13649268 proven_31\VBN\2604760 or_32\CC\3541091 suspected_33\VBN\916909 <e2>fungal_34\JJ\1740 infection</e2>_35\NN\14052046 ._36\.\1740
12549952
D016642_D017114 CID <e2>acute_0\JJ\1740 liver_1\NN\5298729 failure</e2>_2\NN\66216 with_3\IN\1740 concurrent_4\JJ\1740 <e1>bupropion</e1>_5\NN\1740 and_6\CC\1740 carbimazole_7\NN\1740 therapy_8\NN\657604 ._9\.\1740
D016642_D017114 CID discussion_0\NN\6252138 :_1\:\1740 although_2\IN\1740 there_3\EX\27167 is_4\VBZ\836236 increasing_5\VBG\169651 evidence_6\NN\5816287 of_7\IN\1740 hepatotoxicity_8\NN\1740 induced_9\VBN\1627355 by_10\IN\1740 <e1>bupropion</e1>_11\NN\1740 ,_12\,\1740 this_13\DT\1740 is_14\VBZ\836236 the_15\DT\1740 first_16\JJ\1740 case_17\NN\7283608 of_18\IN\1740 fatality_19\NN\7355491 that_20\WDT\1740 could_21\MD\1740 have_22\VB\2108377 resulted_23\VBN\2633881 from_24\IN\1740 <e2>acute_25\JJ\1740 liver_26\NN\5298729 failure</e2>_27\NN\66216 in_28\IN\13603305 a_29\DT\13649268 patient_30\NN\9898892 receiving_31\VBG\2210855 bupropion_32\NN\1740 while_33\IN\15122231 on_34\IN\1740 concomitant_35\JJ\1740 treatment_36\NN\654885 with_37\IN\1740 carbimazole_38\NN\1740 ._39\.\1740
D016642_D017114 CID discussion_0\NN\6252138 :_1\:\1740 although_2\IN\1740 there_3\EX\27167 is_4\VBZ\836236 increasing_5\VBG\169651 evidence_6\NN\5816287 of_7\IN\1740 hepatotoxicity_8\NN\1740 induced_9\VBN\1627355 by_10\IN\1740 bupropion_11\NN\1740 ,_12\,\1740 this_13\DT\1740 is_14\VBZ\836236 the_15\DT\1740 first_16\JJ\1740 case_17\NN\7283608 of_18\IN\1740 fatality_19\NN\7355491 that_20\WDT\1740 could_21\MD\1740 have_22\VB\2108377 resulted_23\VBN\2633881 from_24\IN\1740 <e2>acute_25\JJ\1740 liver_26\NN\5298729 failure</e2>_27\NN\66216 in_28\IN\13603305 a_29\DT\13649268 patient_30\NN\9898892 receiving_31\VBG\2210855 <e1>bupropion</e1>_32\NN\1740 while_33\IN\15122231 on_34\IN\1740 concomitant_35\JJ\1740 treatment_36\NN\654885 with_37\IN\1740 carbimazole_38\NN\1740 ._39\.\1740
D016642_D017114 CID conclusions_0\NNS\5837957 :_1\:\1740 clinicians_2\NNS\10462860 should_3\MD\1740 be_4\VB\836236 aware_5\JJ\1740 of_6\IN\1740 the_7\DT\1740 possibility_8\NN\5944958 of_9\IN\1740 <e2>acute_10\JJ\1740 liver_11\NN\5298729 insult</e2>_12\NN\6714976 induced_13\VBN\1627355 by_14\IN\1740 <e1>bupropion</e1>_15\NN\1740 given_16\VBN\2327200 concurrently_17\RB\1740 with_18\IN\1740 other_19\JJ\1740 hepatotoxic_20\JJ\1740 drugs_21\NNS\14778436 ._22\.\1740
D002231_D017114 CID <e2>acute_0\JJ\1740 liver_1\NN\5298729 failure</e2>_2\NN\66216 with_3\IN\1740 concurrent_4\JJ\1740 bupropion_5\NN\1740 and_6\CC\1740 <e1>carbimazole</e1>_7\NN\1740 therapy_8\NN\657604 ._9\.\1740
D002231_D017114 CID discussion_0\NN\6252138 :_1\:\1740 although_2\IN\1740 there_3\EX\27167 is_4\VBZ\836236 increasing_5\VBG\169651 evidence_6\NN\5816287 of_7\IN\1740 hepatotoxicity_8\NN\1740 induced_9\VBN\1627355 by_10\IN\1740 bupropion_11\NN\1740 ,_12\,\1740 this_13\DT\1740 is_14\VBZ\836236 the_15\DT\1740 first_16\JJ\1740 case_17\NN\7283608 of_18\IN\1740 fatality_19\NN\7355491 that_20\WDT\1740 could_21\MD\1740 have_22\VB\2108377 resulted_23\VBN\2633881 from_24\IN\1740 <e2>acute_25\JJ\1740 liver_26\NN\5298729 failure</e2>_27\NN\66216 in_28\IN\13603305 a_29\DT\13649268 patient_30\NN\9898892 receiving_31\VBG\2210855 bupropion_32\NN\1740 while_33\IN\15122231 on_34\IN\1740 concomitant_35\JJ\1740 treatment_36\NN\654885 with_37\IN\1740 <e1>carbimazole</e1>_38\NN\1740 ._39\.\1740
D016642_D017093 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 fatal_7\JJ\1740 <e2>liver_8\NN\5298729 failure</e2>_9\NN\66216 possibly_10\RB\1740 associated_11\VBN\628491 with_12\IN\1740 concurrent_13\JJ\1740 use_14\NN\407535 of_15\IN\1740 <e1>bupropion</e1>_16\NN\1740 and_17\CC\1740 carbimazole_18\NN\1740 ._19\.\1740
D002231_D017093 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 fatal_7\JJ\1740 <e2>liver_8\NN\5298729 failure</e2>_9\NN\66216 possibly_10\RB\1740 associated_11\VBN\628491 with_12\IN\1740 concurrent_13\JJ\1740 use_14\NN\407535 of_15\IN\1740 bupropion_16\NN\1740 and_17\CC\1740 <e1>carbimazole</e1>_18\NN\1740 ._19\.\1740
D002231_D006980 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 41-year-old_4\JJ\1740 chinese_5\JJ\1740 man_6\NN\9605289 with_7\IN\1740 a_8\DT\13649268 history_9\NN\15120823 of_10\IN\1740 <e2>hyperthyroidism</e2>_11\NN\14059928 had_12\VBD\2108377 been_13\VBN\836236 treated_14\VBN\2376958 with_15\IN\1740 <e1>carbimazole</e1>_16\NN\1740 and_17\CC\1740 propranolol_18\NN\1740 for_19\IN\1740 the_20\DT\1740 past_21\JJ\1740 5_22\CD\13741022 years_23\NNS\15144371 ._24\.\1740
D011433_D006980 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 41-year-old_4\JJ\1740 chinese_5\JJ\1740 man_6\NN\9605289 with_7\IN\1740 a_8\DT\13649268 history_9\NN\15120823 of_10\IN\1740 <e2>hyperthyroidism</e2>_11\NN\14059928 had_12\VBD\2108377 been_13\VBN\836236 treated_14\VBN\2376958 with_15\IN\1740 carbimazole_16\NN\1740 and_17\CC\1740 <e1>propranolol</e1>_18\NN\1740 for_19\IN\1740 the_20\DT\1740 past_21\JJ\1740 5_22\CD\13741022 years_23\NNS\15144371 ._24\.\1740
D016642_D056486 CID the_0\DT\1740 likelihood_1\NN\4756172 that_2\IN\1740 <e1>bupropion</e1>_3\NN\1740 induced_4\VBD\1627355 <e2>hepatotoxicity</e2>_5\NN\1740 in_6\IN\13603305 our_7\PRP$\1740 patient_8\NN\9898892 was_9\VBD\836236 possible_10\JJ\1740 ,_11\,\1740 based_12\VBN\2694933 on_13\IN\1740 the_14\DT\1740 naranjo_15\NNP\1740 probability_16\NN\33615 scale_17\NN\7260623 ._18\.\1740
D016642_D056486 CID discussion_0\NN\6252138 :_1\:\1740 although_2\IN\1740 there_3\EX\27167 is_4\VBZ\836236 increasing_5\VBG\169651 evidence_6\NN\5816287 of_7\IN\1740 <e2>hepatotoxicity</e2>_8\NN\1740 induced_9\VBN\1627355 by_10\IN\1740 <e1>bupropion</e1>_11\NN\1740 ,_12\,\1740 this_13\DT\1740 is_14\VBZ\836236 the_15\DT\1740 first_16\JJ\1740 case_17\NN\7283608 of_18\IN\1740 fatality_19\NN\7355491 that_20\WDT\1740 could_21\MD\1740 have_22\VB\2108377 resulted_23\VBN\2633881 from_24\IN\1740 acute_25\JJ\1740 liver_26\NN\5298729 failure_27\NN\66216 in_28\IN\13603305 a_29\DT\13649268 patient_30\NN\9898892 receiving_31\VBG\2210855 bupropion_32\NN\1740 while_33\IN\15122231 on_34\IN\1740 concomitant_35\JJ\1740 treatment_36\NN\654885 with_37\IN\1740 carbimazole_38\NN\1740 ._39\.\1740
D016642_D056486 CID discussion_0\NN\6252138 :_1\:\1740 although_2\IN\1740 there_3\EX\27167 is_4\VBZ\836236 increasing_5\VBG\169651 evidence_6\NN\5816287 of_7\IN\1740 <e2>hepatotoxicity</e2>_8\NN\1740 induced_9\VBN\1627355 by_10\IN\1740 bupropion_11\NN\1740 ,_12\,\1740 this_13\DT\1740 is_14\VBZ\836236 the_15\DT\1740 first_16\JJ\1740 case_17\NN\7283608 of_18\IN\1740 fatality_19\NN\7355491 that_20\WDT\1740 could_21\MD\1740 have_22\VB\2108377 resulted_23\VBN\2633881 from_24\IN\1740 acute_25\JJ\1740 liver_26\NN\5298729 failure_27\NN\66216 in_28\IN\13603305 a_29\DT\13649268 patient_30\NN\9898892 receiving_31\VBG\2210855 <e1>bupropion</e1>_32\NN\1740 while_33\IN\15122231 on_34\IN\1740 concomitant_35\JJ\1740 treatment_36\NN\654885 with_37\IN\1740 carbimazole_38\NN\1740 ._39\.\1740
D016642_D056486 CID conclusions_0\NNS\5837957 :_1\:\1740 clinicians_2\NNS\10462860 should_3\MD\1740 be_4\VB\836236 aware_5\JJ\1740 of_6\IN\1740 the_7\DT\1740 possibility_8\NN\5944958 of_9\IN\1740 acute_10\JJ\1740 liver_11\NN\5298729 insult_12\NN\6714976 induced_13\VBN\1627355 by_14\IN\1740 <e1>bupropion</e1>_15\NN\1740 given_16\VBN\2327200 concurrently_17\RB\1740 with_18\IN\1740 other_19\JJ\1740 <e2>hepatotoxic</e2>_20\JJ\1740 drugs_21\NNS\14778436 ._22\.\1740
D002231_D056486 CID discussion_0\NN\6252138 :_1\:\1740 although_2\IN\1740 there_3\EX\27167 is_4\VBZ\836236 increasing_5\VBG\169651 evidence_6\NN\5816287 of_7\IN\1740 <e2>hepatotoxicity</e2>_8\NN\1740 induced_9\VBN\1627355 by_10\IN\1740 bupropion_11\NN\1740 ,_12\,\1740 this_13\DT\1740 is_14\VBZ\836236 the_15\DT\1740 first_16\JJ\1740 case_17\NN\7283608 of_18\IN\1740 fatality_19\NN\7355491 that_20\WDT\1740 could_21\MD\1740 have_22\VB\2108377 resulted_23\VBN\2633881 from_24\IN\1740 acute_25\JJ\1740 liver_26\NN\5298729 failure_27\NN\66216 in_28\IN\13603305 a_29\DT\13649268 patient_30\NN\9898892 receiving_31\VBG\2210855 bupropion_32\NN\1740 while_33\IN\15122231 on_34\IN\1740 concomitant_35\JJ\1740 treatment_36\NN\654885 with_37\IN\1740 <e1>carbimazole</e1>_38\NN\1740 ._39\.\1740
7197363
D001058_D012892 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 <e2>rem_3\NN\14024882 sleep_4\NN\14034177 deprivation</e2>_5\NN\14493145 (_6\-LRB-\1740 remd_7\NN\1740 )_8\-RRB-\1740 on_9\IN\1740 <e1>apomorphine-induced</e1>_10\JJ\1740 aggressiveness_11\NN\4835724 and_12\CC\1740 quipazine-induced_13\JJ\1740 head_14\NN\5225090 twitches_15\VBZ\10054 in_16\IN\13603305 rats_17\NNS\2329401 were_18\VBD\836236 determined_19\VBN\1645601 ._20\.\1740
D001058_D012892 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 rem_3\NN\14024882 sleep_4\NN\14034177 deprivation_5\NN\14493145 (_6\-LRB-\1740 <e2>remd</e2>_7\NN\1740 )_8\-RRB-\1740 on_9\IN\1740 <e1>apomorphine-induced</e1>_10\JJ\1740 aggressiveness_11\NN\4835724 and_12\CC\1740 quipazine-induced_13\JJ\1740 head_14\NN\5225090 twitches_15\VBZ\10054 in_16\IN\13603305 rats_17\NNS\2329401 were_18\VBD\836236 determined_19\VBN\1645601 ._20\.\1740
D001058_D012892 NONE forty-eight_0\CD\1740 hr_1\NN\15154774 of_2\IN\1740 <e2>remd</e2>_3\NN\1740 increased_4\VBD\169651 <e1>apomorphine-induced</e1>_5\JJ\1740 aggressiveness_6\NN\4835724 ,_7\,\1740 and_8\CC\1740 reduced_9\VBN\441445 (_10\-LRB-\1740 immediately_11\RB\1740 after_12\IN\1740 completing_13\VBG\352826 of_14\IN\1740 remd_15\NN\1740 )_16\-RRB-\1740 or_17\CC\3541091 increased_18\VBN\169651 (_19\-LRB-\1740 96_20\CD\1740 hr_21\NN\15154774 after_22\IN\1740 completing_23\VBG\352826 of_24\IN\1740 remd_25\NN\1740 )_26\-RRB-\1740 quipazine-induced_27\JJ\1740 head_28\NN\5225090 twitches_29\VBZ\10054 ._30\.\1740
D001058_D012892 NONE forty-eight_0\CD\1740 hr_1\NN\15154774 of_2\IN\1740 remd_3\NN\1740 increased_4\VBD\169651 <e1>apomorphine-induced</e1>_5\JJ\1740 aggressiveness_6\NN\4835724 ,_7\,\1740 and_8\CC\1740 reduced_9\VBN\441445 (_10\-LRB-\1740 immediately_11\RB\1740 after_12\IN\1740 completing_13\VBG\352826 of_14\IN\1740 <e2>remd</e2>_15\NN\1740 )_16\-RRB-\1740 or_17\CC\3541091 increased_18\VBN\169651 (_19\-LRB-\1740 96_20\CD\1740 hr_21\NN\15154774 after_22\IN\1740 completing_23\VBG\352826 of_24\IN\1740 remd_25\NN\1740 )_26\-RRB-\1740 quipazine-induced_27\JJ\1740 head_28\NN\5225090 twitches_29\VBZ\10054 ._30\.\1740
D001058_D012892 NONE forty-eight_0\CD\1740 hr_1\NN\15154774 of_2\IN\1740 remd_3\NN\1740 increased_4\VBD\169651 <e1>apomorphine-induced</e1>_5\JJ\1740 aggressiveness_6\NN\4835724 ,_7\,\1740 and_8\CC\1740 reduced_9\VBN\441445 (_10\-LRB-\1740 immediately_11\RB\1740 after_12\IN\1740 completing_13\VBG\352826 of_14\IN\1740 remd_15\NN\1740 )_16\-RRB-\1740 or_17\CC\3541091 increased_18\VBN\169651 (_19\-LRB-\1740 96_20\CD\1740 hr_21\NN\15154774 after_22\IN\1740 completing_23\VBG\352826 of_24\IN\1740 <e2>remd</e2>_25\NN\1740 )_26\-RRB-\1740 quipazine-induced_27\JJ\1740 head_28\NN\5225090 twitches_29\VBZ\10054 ._30\.\1740
D001058_D001523 CID the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 rem_3\NN\14024882 sleep_4\NN\14034177 deprivation_5\NN\14493145 (_6\-LRB-\1740 remd_7\NN\1740 )_8\-RRB-\1740 on_9\IN\1740 <e1>apomorphine-induced</e1>_10\JJ\1740 <e2>aggressiveness</e2>_11\NN\4835724 and_12\CC\1740 quipazine-induced_13\JJ\1740 head_14\NN\5225090 twitches_15\VBZ\10054 in_16\IN\13603305 rats_17\NNS\2329401 were_18\VBD\836236 determined_19\VBN\1645601 ._20\.\1740
D001058_D001523 CID forty-eight_0\CD\1740 hr_1\NN\15154774 of_2\IN\1740 remd_3\NN\1740 increased_4\VBD\169651 <e1>apomorphine-induced</e1>_5\JJ\1740 <e2>aggressiveness</e2>_6\NN\4835724 ,_7\,\1740 and_8\CC\1740 reduced_9\VBN\441445 (_10\-LRB-\1740 immediately_11\RB\1740 after_12\IN\1740 completing_13\VBG\352826 of_14\IN\1740 remd_15\NN\1740 )_16\-RRB-\1740 or_17\CC\3541091 increased_18\VBN\169651 (_19\-LRB-\1740 96_20\CD\1740 hr_21\NN\15154774 after_22\IN\1740 completing_23\VBG\352826 of_24\IN\1740 remd_25\NN\1740 )_26\-RRB-\1740 quipazine-induced_27\JJ\1740 head_28\NN\5225090 twitches_29\VBZ\10054 ._30\.\1740
D001058_D009069 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 rem_3\NN\14024882 sleep_4\NN\14034177 deprivation_5\NN\14493145 (_6\-LRB-\1740 remd_7\NN\1740 )_8\-RRB-\1740 on_9\IN\1740 <e1>apomorphine-induced</e1>_10\JJ\1740 aggressiveness_11\NN\4835724 and_12\CC\1740 quipazine-induced_13\JJ\1740 <e2>head_14\NN\5225090 twitches</e2>_15\VBZ\10054 in_16\IN\13603305 rats_17\NNS\2329401 were_18\VBD\836236 determined_19\VBN\1645601 ._20\.\1740
D001058_D009069 NONE forty-eight_0\CD\1740 hr_1\NN\15154774 of_2\IN\1740 remd_3\NN\1740 increased_4\VBD\169651 <e1>apomorphine-induced</e1>_5\JJ\1740 aggressiveness_6\NN\4835724 ,_7\,\1740 and_8\CC\1740 reduced_9\VBN\441445 (_10\-LRB-\1740 immediately_11\RB\1740 after_12\IN\1740 completing_13\VBG\352826 of_14\IN\1740 remd_15\NN\1740 )_16\-RRB-\1740 or_17\CC\3541091 increased_18\VBN\169651 (_19\-LRB-\1740 96_20\CD\1740 hr_21\NN\15154774 after_22\IN\1740 completing_23\VBG\352826 of_24\IN\1740 remd_25\NN\1740 )_26\-RRB-\1740 quipazine-induced_27\JJ\1740 <e2>head_28\NN\5225090 twitches</e2>_29\VBZ\10054 ._30\.\1740
D011814_D012892 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 <e2>rem_3\NN\14024882 sleep_4\NN\14034177 deprivation</e2>_5\NN\14493145 (_6\-LRB-\1740 remd_7\NN\1740 )_8\-RRB-\1740 on_9\IN\1740 apomorphine-induced_10\JJ\1740 aggressiveness_11\NN\4835724 and_12\CC\1740 <e1>quipazine-induced</e1>_13\JJ\1740 head_14\NN\5225090 twitches_15\VBZ\10054 in_16\IN\13603305 rats_17\NNS\2329401 were_18\VBD\836236 determined_19\VBN\1645601 ._20\.\1740
D011814_D012892 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 rem_3\NN\14024882 sleep_4\NN\14034177 deprivation_5\NN\14493145 (_6\-LRB-\1740 <e2>remd</e2>_7\NN\1740 )_8\-RRB-\1740 on_9\IN\1740 apomorphine-induced_10\JJ\1740 aggressiveness_11\NN\4835724 and_12\CC\1740 <e1>quipazine-induced</e1>_13\JJ\1740 head_14\NN\5225090 twitches_15\VBZ\10054 in_16\IN\13603305 rats_17\NNS\2329401 were_18\VBD\836236 determined_19\VBN\1645601 ._20\.\1740
D011814_D012892 NONE forty-eight_0\CD\1740 hr_1\NN\15154774 of_2\IN\1740 <e2>remd</e2>_3\NN\1740 increased_4\VBD\169651 apomorphine-induced_5\JJ\1740 aggressiveness_6\NN\4835724 ,_7\,\1740 and_8\CC\1740 reduced_9\VBN\441445 (_10\-LRB-\1740 immediately_11\RB\1740 after_12\IN\1740 completing_13\VBG\352826 of_14\IN\1740 remd_15\NN\1740 )_16\-RRB-\1740 or_17\CC\3541091 increased_18\VBN\169651 (_19\-LRB-\1740 96_20\CD\1740 hr_21\NN\15154774 after_22\IN\1740 completing_23\VBG\352826 of_24\IN\1740 remd_25\NN\1740 )_26\-RRB-\1740 <e1>quipazine-induced</e1>_27\JJ\1740 head_28\NN\5225090 twitches_29\VBZ\10054 ._30\.\1740
D011814_D012892 NONE forty-eight_0\CD\1740 hr_1\NN\15154774 of_2\IN\1740 remd_3\NN\1740 increased_4\VBD\169651 apomorphine-induced_5\JJ\1740 aggressiveness_6\NN\4835724 ,_7\,\1740 and_8\CC\1740 reduced_9\VBN\441445 (_10\-LRB-\1740 immediately_11\RB\1740 after_12\IN\1740 completing_13\VBG\352826 of_14\IN\1740 <e2>remd</e2>_15\NN\1740 )_16\-RRB-\1740 or_17\CC\3541091 increased_18\VBN\169651 (_19\-LRB-\1740 96_20\CD\1740 hr_21\NN\15154774 after_22\IN\1740 completing_23\VBG\352826 of_24\IN\1740 remd_25\NN\1740 )_26\-RRB-\1740 <e1>quipazine-induced</e1>_27\JJ\1740 head_28\NN\5225090 twitches_29\VBZ\10054 ._30\.\1740
D011814_D012892 NONE forty-eight_0\CD\1740 hr_1\NN\15154774 of_2\IN\1740 remd_3\NN\1740 increased_4\VBD\169651 apomorphine-induced_5\JJ\1740 aggressiveness_6\NN\4835724 ,_7\,\1740 and_8\CC\1740 reduced_9\VBN\441445 (_10\-LRB-\1740 immediately_11\RB\1740 after_12\IN\1740 completing_13\VBG\352826 of_14\IN\1740 remd_15\NN\1740 )_16\-RRB-\1740 or_17\CC\3541091 increased_18\VBN\169651 (_19\-LRB-\1740 96_20\CD\1740 hr_21\NN\15154774 after_22\IN\1740 completing_23\VBG\352826 of_24\IN\1740 <e2>remd</e2>_25\NN\1740 )_26\-RRB-\1740 <e1>quipazine-induced</e1>_27\JJ\1740 head_28\NN\5225090 twitches_29\VBZ\10054 ._30\.\1740
D011814_D001523 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 rem_3\NN\14024882 sleep_4\NN\14034177 deprivation_5\NN\14493145 (_6\-LRB-\1740 remd_7\NN\1740 )_8\-RRB-\1740 on_9\IN\1740 apomorphine-induced_10\JJ\1740 <e2>aggressiveness</e2>_11\NN\4835724 and_12\CC\1740 <e1>quipazine-induced</e1>_13\JJ\1740 head_14\NN\5225090 twitches_15\VBZ\10054 in_16\IN\13603305 rats_17\NNS\2329401 were_18\VBD\836236 determined_19\VBN\1645601 ._20\.\1740
D011814_D001523 NONE forty-eight_0\CD\1740 hr_1\NN\15154774 of_2\IN\1740 remd_3\NN\1740 increased_4\VBD\169651 apomorphine-induced_5\JJ\1740 <e2>aggressiveness</e2>_6\NN\4835724 ,_7\,\1740 and_8\CC\1740 reduced_9\VBN\441445 (_10\-LRB-\1740 immediately_11\RB\1740 after_12\IN\1740 completing_13\VBG\352826 of_14\IN\1740 remd_15\NN\1740 )_16\-RRB-\1740 or_17\CC\3541091 increased_18\VBN\169651 (_19\-LRB-\1740 96_20\CD\1740 hr_21\NN\15154774 after_22\IN\1740 completing_23\VBG\352826 of_24\IN\1740 remd_25\NN\1740 )_26\-RRB-\1740 <e1>quipazine-induced</e1>_27\JJ\1740 head_28\NN\5225090 twitches_29\VBZ\10054 ._30\.\1740
D011814_D009069 CID the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 rem_3\NN\14024882 sleep_4\NN\14034177 deprivation_5\NN\14493145 (_6\-LRB-\1740 remd_7\NN\1740 )_8\-RRB-\1740 on_9\IN\1740 apomorphine-induced_10\JJ\1740 aggressiveness_11\NN\4835724 and_12\CC\1740 <e1>quipazine-induced</e1>_13\JJ\1740 <e2>head_14\NN\5225090 twitches</e2>_15\VBZ\10054 in_16\IN\13603305 rats_17\NNS\2329401 were_18\VBD\836236 determined_19\VBN\1645601 ._20\.\1740
D011814_D009069 CID forty-eight_0\CD\1740 hr_1\NN\15154774 of_2\IN\1740 remd_3\NN\1740 increased_4\VBD\169651 apomorphine-induced_5\JJ\1740 aggressiveness_6\NN\4835724 ,_7\,\1740 and_8\CC\1740 reduced_9\VBN\441445 (_10\-LRB-\1740 immediately_11\RB\1740 after_12\IN\1740 completing_13\VBG\352826 of_14\IN\1740 remd_15\NN\1740 )_16\-RRB-\1740 or_17\CC\3541091 increased_18\VBN\169651 (_19\-LRB-\1740 96_20\CD\1740 hr_21\NN\15154774 after_22\IN\1740 completing_23\VBG\352826 of_24\IN\1740 remd_25\NN\1740 )_26\-RRB-\1740 <e1>quipazine-induced</e1>_27\JJ\1740 <e2>head_28\NN\5225090 twitches</e2>_29\VBZ\10054 ._30\.\1740
8665051
D000305_D009135 NONE occasional_0\JJ\1740 case_1\NN\7283608 reports_2\NNS\6470073 have_3\VBP\2108377 shown_4\VBN\2137132 that_5\IN\1740 acute_6\JJ\1740 <e2>myopathy</e2>_7\NN\14204950 may_8\MD\15209706 occur_9\VB\2623529 in_10\IN\13603305 patients_11\NNS\9898892 treated_12\VBN\2376958 with_13\IN\1740 massive_14\JJ\1740 doses_15\NNS\3740161 of_16\IN\1740 <e1>corticosteroids</e1>_17\NNS\14745635 ._18\.\1740
D008775_D000855 CID therefore_0\RB\1740 ,_1\,\1740 60_2\CD\13745420 male_3\JJ\1740 rats_4\NNS\2329401 were_5\VBD\836236 randomly_6\RB\1740 assigned_7\VBN\2475922 to_8\TO\1740 receive_9\VB\2210855 daily_10\JJ\1740 injection_11\NN\320852 of_12\IN\1740 saline_13\NN\14849367 (_14\-LRB-\1740 c_15\NN\13714184 )_16\-RRB-\1740 ,_17\,\1740 <e1>methylprednisolone</e1>_18\NN\1740 (_19\-LRB-\1740 m_20\NN\13649268 )_21\-RRB-\1740 ,_22\,\1740 or_23\CC\3541091 triamcinolone_24\NN\14751417 (_25\-LRB-\1740 t_26\NN\14999913 )_27\-RRB-\1740 80_28\CD\13745420 mg/kg/d_29\NN\1740 for_30\IN\1740 5_31\CD\13741022 d._32\NN\1740 nutritional_33\NNP\1740 intake_34\NN\13440063 ,_35\,\1740 measured_36\VBN\697589 daily_37\RB\1740 in_38\IN\13603305 15_39\CD\13745420 animals_40\NNS\4475 ,_41\,\1740 showed_42\VBD\2137132 a_43\DT\13649268 significant_44\JJ\1740 <e2>reduction_45\NN\351485 of_46\IN\1740 food_47\NN\20090 intake</e2>_48\NN\13440063 in_49\IN\13603305 the_50\DT\1740 steroid-treated_51\JJ\1740 groups_52\NNS\2137 (_53\-LRB-\1740 -50_54\CD\1740 and_55\CC\1740 -79_56\CD\1740 %_57\NN\1740 in_58\IN\13603305 m_59\NN\13649268 and_60\CC\1740 t_61\NN\14999913 ,_62\,\1740 respectively_63\RB\1740 )_64\-RRB-\1740 ._65\.\1740
D008775_D000855 CID therefore_0\RB\1740 ,_1\,\1740 60_2\CD\13745420 male_3\JJ\1740 rats_4\NNS\2329401 were_5\VBD\836236 randomly_6\RB\1740 assigned_7\VBN\2475922 to_8\TO\1740 receive_9\VB\2210855 daily_10\JJ\1740 injection_11\NN\320852 of_12\IN\1740 saline_13\NN\14849367 (_14\-LRB-\1740 c_15\NN\13714184 )_16\-RRB-\1740 ,_17\,\1740 methylprednisolone_18\NN\1740 (_19\-LRB-\1740 <e1>m</e1>_20\NN\13649268 )_21\-RRB-\1740 ,_22\,\1740 or_23\CC\3541091 triamcinolone_24\NN\14751417 (_25\-LRB-\1740 t_26\NN\14999913 )_27\-RRB-\1740 80_28\CD\13745420 mg/kg/d_29\NN\1740 for_30\IN\1740 5_31\CD\13741022 d._32\NN\1740 nutritional_33\NNP\1740 intake_34\NN\13440063 ,_35\,\1740 measured_36\VBN\697589 daily_37\RB\1740 in_38\IN\13603305 15_39\CD\13745420 animals_40\NNS\4475 ,_41\,\1740 showed_42\VBD\2137132 a_43\DT\13649268 significant_44\JJ\1740 <e2>reduction_45\NN\351485 of_46\IN\1740 food_47\NN\20090 intake</e2>_48\NN\13440063 in_49\IN\13603305 the_50\DT\1740 steroid-treated_51\JJ\1740 groups_52\NNS\2137 (_53\-LRB-\1740 -50_54\CD\1740 and_55\CC\1740 -79_56\CD\1740 %_57\NN\1740 in_58\IN\13603305 m_59\NN\13649268 and_60\CC\1740 t_61\NN\14999913 ,_62\,\1740 respectively_63\RB\1740 )_64\-RRB-\1740 ._65\.\1740
D008775_D000855 CID therefore_0\RB\1740 ,_1\,\1740 60_2\CD\13745420 male_3\JJ\1740 rats_4\NNS\2329401 were_5\VBD\836236 randomly_6\RB\1740 assigned_7\VBN\2475922 to_8\TO\1740 receive_9\VB\2210855 daily_10\JJ\1740 injection_11\NN\320852 of_12\IN\1740 saline_13\NN\14849367 (_14\-LRB-\1740 c_15\NN\13714184 )_16\-RRB-\1740 ,_17\,\1740 methylprednisolone_18\NN\1740 (_19\-LRB-\1740 m_20\NN\13649268 )_21\-RRB-\1740 ,_22\,\1740 or_23\CC\3541091 triamcinolone_24\NN\14751417 (_25\-LRB-\1740 t_26\NN\14999913 )_27\-RRB-\1740 80_28\CD\13745420 mg/kg/d_29\NN\1740 for_30\IN\1740 5_31\CD\13741022 d._32\NN\1740 nutritional_33\NNP\1740 intake_34\NN\13440063 ,_35\,\1740 measured_36\VBN\697589 daily_37\RB\1740 in_38\IN\13603305 15_39\CD\13745420 animals_40\NNS\4475 ,_41\,\1740 showed_42\VBD\2137132 a_43\DT\13649268 significant_44\JJ\1740 <e2>reduction_45\NN\351485 of_46\IN\1740 food_47\NN\20090 intake</e2>_48\NN\13440063 in_49\IN\13603305 the_50\DT\1740 steroid-treated_51\JJ\1740 groups_52\NNS\2137 (_53\-LRB-\1740 -50_54\CD\1740 and_55\CC\1740 -79_56\CD\1740 %_57\NN\1740 in_58\IN\13603305 <e1>m</e1>_59\NN\13649268 and_60\CC\1740 t_61\NN\14999913 ,_62\,\1740 respectively_63\RB\1740 )_64\-RRB-\1740 ._65\.\1740
D014221_D000855 CID therefore_0\RB\1740 ,_1\,\1740 60_2\CD\13745420 male_3\JJ\1740 rats_4\NNS\2329401 were_5\VBD\836236 randomly_6\RB\1740 assigned_7\VBN\2475922 to_8\TO\1740 receive_9\VB\2210855 daily_10\JJ\1740 injection_11\NN\320852 of_12\IN\1740 saline_13\NN\14849367 (_14\-LRB-\1740 c_15\NN\13714184 )_16\-RRB-\1740 ,_17\,\1740 methylprednisolone_18\NN\1740 (_19\-LRB-\1740 m_20\NN\13649268 )_21\-RRB-\1740 ,_22\,\1740 or_23\CC\3541091 <e1>triamcinolone</e1>_24\NN\14751417 (_25\-LRB-\1740 t_26\NN\14999913 )_27\-RRB-\1740 80_28\CD\13745420 mg/kg/d_29\NN\1740 for_30\IN\1740 5_31\CD\13741022 d._32\NN\1740 nutritional_33\NNP\1740 intake_34\NN\13440063 ,_35\,\1740 measured_36\VBN\697589 daily_37\RB\1740 in_38\IN\13603305 15_39\CD\13745420 animals_40\NNS\4475 ,_41\,\1740 showed_42\VBD\2137132 a_43\DT\13649268 significant_44\JJ\1740 <e2>reduction_45\NN\351485 of_46\IN\1740 food_47\NN\20090 intake</e2>_48\NN\13440063 in_49\IN\13603305 the_50\DT\1740 steroid-treated_51\JJ\1740 groups_52\NNS\2137 (_53\-LRB-\1740 -50_54\CD\1740 and_55\CC\1740 -79_56\CD\1740 %_57\NN\1740 in_58\IN\13603305 m_59\NN\13649268 and_60\CC\1740 t_61\NN\14999913 ,_62\,\1740 respectively_63\RB\1740 )_64\-RRB-\1740 ._65\.\1740
D014221_D000855 CID therefore_0\RB\1740 ,_1\,\1740 60_2\CD\13745420 male_3\JJ\1740 rats_4\NNS\2329401 were_5\VBD\836236 randomly_6\RB\1740 assigned_7\VBN\2475922 to_8\TO\1740 receive_9\VB\2210855 daily_10\JJ\1740 injection_11\NN\320852 of_12\IN\1740 saline_13\NN\14849367 (_14\-LRB-\1740 c_15\NN\13714184 )_16\-RRB-\1740 ,_17\,\1740 methylprednisolone_18\NN\1740 (_19\-LRB-\1740 m_20\NN\13649268 )_21\-RRB-\1740 ,_22\,\1740 or_23\CC\3541091 triamcinolone_24\NN\14751417 (_25\-LRB-\1740 <e1>t</e1>_26\NN\14999913 )_27\-RRB-\1740 80_28\CD\13745420 mg/kg/d_29\NN\1740 for_30\IN\1740 5_31\CD\13741022 d._32\NN\1740 nutritional_33\NNP\1740 intake_34\NN\13440063 ,_35\,\1740 measured_36\VBN\697589 daily_37\RB\1740 in_38\IN\13603305 15_39\CD\13745420 animals_40\NNS\4475 ,_41\,\1740 showed_42\VBD\2137132 a_43\DT\13649268 significant_44\JJ\1740 <e2>reduction_45\NN\351485 of_46\IN\1740 food_47\NN\20090 intake</e2>_48\NN\13440063 in_49\IN\13603305 the_50\DT\1740 steroid-treated_51\JJ\1740 groups_52\NNS\2137 (_53\-LRB-\1740 -50_54\CD\1740 and_55\CC\1740 -79_56\CD\1740 %_57\NN\1740 in_58\IN\13603305 m_59\NN\13649268 and_60\CC\1740 t_61\NN\14999913 ,_62\,\1740 respectively_63\RB\1740 )_64\-RRB-\1740 ._65\.\1740
D014221_D000855 CID therefore_0\RB\1740 ,_1\,\1740 60_2\CD\13745420 male_3\JJ\1740 rats_4\NNS\2329401 were_5\VBD\836236 randomly_6\RB\1740 assigned_7\VBN\2475922 to_8\TO\1740 receive_9\VB\2210855 daily_10\JJ\1740 injection_11\NN\320852 of_12\IN\1740 saline_13\NN\14849367 (_14\-LRB-\1740 c_15\NN\13714184 )_16\-RRB-\1740 ,_17\,\1740 methylprednisolone_18\NN\1740 (_19\-LRB-\1740 m_20\NN\13649268 )_21\-RRB-\1740 ,_22\,\1740 or_23\CC\3541091 triamcinolone_24\NN\14751417 (_25\-LRB-\1740 t_26\NN\14999913 )_27\-RRB-\1740 80_28\CD\13745420 mg/kg/d_29\NN\1740 for_30\IN\1740 5_31\CD\13741022 d._32\NN\1740 nutritional_33\NNP\1740 intake_34\NN\13440063 ,_35\,\1740 measured_36\VBN\697589 daily_37\RB\1740 in_38\IN\13603305 15_39\CD\13745420 animals_40\NNS\4475 ,_41\,\1740 showed_42\VBD\2137132 a_43\DT\13649268 significant_44\JJ\1740 <e2>reduction_45\NN\351485 of_46\IN\1740 food_47\NN\20090 intake</e2>_48\NN\13440063 in_49\IN\13603305 the_50\DT\1740 steroid-treated_51\JJ\1740 groups_52\NNS\2137 (_53\-LRB-\1740 -50_54\CD\1740 and_55\CC\1740 -79_56\CD\1740 %_57\NN\1740 in_58\IN\13603305 m_59\NN\13649268 and_60\CC\1740 <e1>t</e1>_61\NN\14999913 ,_62\,\1740 respectively_63\RB\1740 )_64\-RRB-\1740 ._65\.\1740
D013256_D000855 NONE therefore_0\RB\1740 ,_1\,\1740 60_2\CD\13745420 male_3\JJ\1740 rats_4\NNS\2329401 were_5\VBD\836236 randomly_6\RB\1740 assigned_7\VBN\2475922 to_8\TO\1740 receive_9\VB\2210855 daily_10\JJ\1740 injection_11\NN\320852 of_12\IN\1740 saline_13\NN\14849367 (_14\-LRB-\1740 c_15\NN\13714184 )_16\-RRB-\1740 ,_17\,\1740 methylprednisolone_18\NN\1740 (_19\-LRB-\1740 m_20\NN\13649268 )_21\-RRB-\1740 ,_22\,\1740 or_23\CC\3541091 triamcinolone_24\NN\14751417 (_25\-LRB-\1740 t_26\NN\14999913 )_27\-RRB-\1740 80_28\CD\13745420 mg/kg/d_29\NN\1740 for_30\IN\1740 5_31\CD\13741022 d._32\NN\1740 nutritional_33\NNP\1740 intake_34\NN\13440063 ,_35\,\1740 measured_36\VBN\697589 daily_37\RB\1740 in_38\IN\13603305 15_39\CD\13745420 animals_40\NNS\4475 ,_41\,\1740 showed_42\VBD\2137132 a_43\DT\13649268 significant_44\JJ\1740 <e2>reduction_45\NN\351485 of_46\IN\1740 food_47\NN\20090 intake</e2>_48\NN\13440063 in_49\IN\13603305 the_50\DT\1740 <e1>steroid-treated</e1>_51\JJ\1740 groups_52\NNS\2137 (_53\-LRB-\1740 -50_54\CD\1740 and_55\CC\1740 -79_56\CD\1740 %_57\NN\1740 in_58\IN\13603305 m_59\NN\13649268 and_60\CC\1740 t_61\NN\14999913 ,_62\,\1740 respectively_63\RB\1740 )_64\-RRB-\1740 ._65\.\1740
D013256_D013746 NONE half-relaxation_0\JJ\1740 time_1\NN\7308889 was_2\VBD\836236 prolonged_3\VBN\317700 in_4\IN\13603305 both_5\CC\1740 <e1>steroid</e1>_6\NN\14727670 groups_7\NNS\2137 ,_8\,\1740 and_9\CC\1740 time_10\NN\7308889 to_11\TO\1740 peak_12\JJ\1740 tension_13\NN\14375890 was_14\VBD\836236 longer_15\JJR\1740 with_16\IN\1740 m_17\NN\13649268 ,_18\,\1740 whereas_19\IN\1740 <e2>tetanic</e2>_20\JJ\1740 tensions_21\NNS\14375890 were_22\VBD\836236 similar_23\JJ\1740 ._24\.\1740
D008775_D013746 NONE half-relaxation_0\JJ\1740 time_1\NN\7308889 was_2\VBD\836236 prolonged_3\VBN\317700 in_4\IN\13603305 both_5\CC\1740 steroid_6\NN\14727670 groups_7\NNS\2137 ,_8\,\1740 and_9\CC\1740 time_10\NN\7308889 to_11\TO\1740 peak_12\JJ\1740 tension_13\NN\14375890 was_14\VBD\836236 longer_15\JJR\1740 with_16\IN\1740 <e1>m</e1>_17\NN\13649268 ,_18\,\1740 whereas_19\IN\1740 <e2>tetanic</e2>_20\JJ\1740 tensions_21\NNS\14375890 were_22\VBD\836236 similar_23\JJ\1740 ._24\.\1740
D013256_D009133 NONE atpase_0\NN\1740 staining_1\NN\275424 of_2\IN\1740 the_3\DT\1740 diaphragm_4\NN\3736970 ,_5\,\1740 scalenus_6\JJ\1740 medius_7\NN\1740 ,_8\,\1740 and_9\CC\1740 gastrocnemius_10\NN\5289861 showed_11\VBD\2137132 type_12\NN\5839024 iib_13\NN\1740 fiber_14\NN\14580897 <e2>atrophy</e2>_15\NN\14299637 in_16\IN\13603305 the_17\DT\1740 <e1>steroid</e1>_18\NN\14727670 groups_19\NNS\2137 and_20\CC\1740 also_21\RB\1740 diaphragmatic_22\JJ\1740 type_23\NN\5839024 iia_24\NN\1740 atrophy_25\NN\14299637 with_26\IN\1740 t_27\NN\14999913 ,_28\,\1740 whereas_29\IN\1740 histologic_30\JJ\1740 examinations_31\NNS\633864 revealed_32\VBD\2137132 a_33\DT\13649268 normal_34\JJ\1740 muscular_35\JJ\1740 pattern_36\NN\5726345 with_37\IN\1740 absence_38\NN\14449405 of_39\IN\1740 necrosis_40\NN\11444117 ._41\.\1740
D013256_D009133 NONE atpase_0\NN\1740 staining_1\NN\275424 of_2\IN\1740 the_3\DT\1740 diaphragm_4\NN\3736970 ,_5\,\1740 scalenus_6\JJ\1740 medius_7\NN\1740 ,_8\,\1740 and_9\CC\1740 gastrocnemius_10\NN\5289861 showed_11\VBD\2137132 type_12\NN\5839024 iib_13\NN\1740 fiber_14\NN\14580897 atrophy_15\NN\14299637 in_16\IN\13603305 the_17\DT\1740 <e1>steroid</e1>_18\NN\14727670 groups_19\NNS\2137 and_20\CC\1740 also_21\RB\1740 diaphragmatic_22\JJ\1740 type_23\NN\5839024 iia_24\NN\1740 <e2>atrophy</e2>_25\NN\14299637 with_26\IN\1740 t_27\NN\14999913 ,_28\,\1740 whereas_29\IN\1740 histologic_30\JJ\1740 examinations_31\NNS\633864 revealed_32\VBD\2137132 a_33\DT\13649268 normal_34\JJ\1740 muscular_35\JJ\1740 pattern_36\NN\5726345 with_37\IN\1740 absence_38\NN\14449405 of_39\IN\1740 necrosis_40\NN\11444117 ._41\.\1740
D013256_D009133 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 (_3\-LRB-\1740 1_4\LS\13741022 )_5\-RRB-\1740 short-term_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 massive_9\JJ\1740 doses_10\NNS\3740161 of_11\IN\1740 <e1>steroids</e1>_12\NNS\14727670 induced_13\VBD\1627355 severe_14\JJ\1740 respiratory_15\NN\1740 and_16\CC\1740 limb_17\JJ\1740 muscle_18\NN\5289601 wasting_19\VBG\1158572 ;_20\:\1740 (_21\-LRB-\1740 2_22\LS\13741022 )_23\-RRB-\1740 both_24\DT\1740 types_25\NNS\5839024 of_26\IN\1740 steroids_27\NNS\14727670 induced_28\VBN\1627355 predominantly_29\RB\1740 type_30\NN\5839024 iib_31\NN\1740 atrophy_32\NN\14299637 ,_33\,\1740 resulting_34\VBG\2633881 in_35\IN\13603305 the_36\DT\1740 expected_37\VBN\670261 alterations_38\NNS\7283608 in_39\IN\13603305 diaphragm_40\NN\3736970 contractile_41\NN\1740 properties_42\NNS\32613 ;_43\:\1740 (_44\-LRB-\1740 3_45\LS\13741022 )_46\-RRB-\1740 neither_47\CC\1740 steroid_48\NN\14727670 caused_49\VBD\1617192 muscle_50\NN\5289601 necrosis_51\NN\11444117 ;_52\:\1740 (_53\-LRB-\1740 4_54\LS\13741022 )_55\-RRB-\1740 type_56\NN\5839024 iib_57\NN\1740 <e2>atrophy</e2>_58\NN\14299637 was_59\VBD\836236 not_60\RB\1740 caused_61\VBN\1617192 by_62\IN\1740 acute_63\JJ\1740 nutritional_64\JJ\1740 deprivation_65\NN\14493145 alone_66\RB\1740 ._67\.\1740
D013256_D009133 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 (_3\-LRB-\1740 1_4\LS\13741022 )_5\-RRB-\1740 short-term_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 massive_9\JJ\1740 doses_10\NNS\3740161 of_11\IN\1740 steroids_12\NNS\14727670 induced_13\VBD\1627355 severe_14\JJ\1740 respiratory_15\NN\1740 and_16\CC\1740 limb_17\JJ\1740 muscle_18\NN\5289601 wasting_19\VBG\1158572 ;_20\:\1740 (_21\-LRB-\1740 2_22\LS\13741022 )_23\-RRB-\1740 both_24\DT\1740 types_25\NNS\5839024 of_26\IN\1740 <e1>steroids</e1>_27\NNS\14727670 induced_28\VBN\1627355 predominantly_29\RB\1740 type_30\NN\5839024 iib_31\NN\1740 atrophy_32\NN\14299637 ,_33\,\1740 resulting_34\VBG\2633881 in_35\IN\13603305 the_36\DT\1740 expected_37\VBN\670261 alterations_38\NNS\7283608 in_39\IN\13603305 diaphragm_40\NN\3736970 contractile_41\NN\1740 properties_42\NNS\32613 ;_43\:\1740 (_44\-LRB-\1740 3_45\LS\13741022 )_46\-RRB-\1740 neither_47\CC\1740 steroid_48\NN\14727670 caused_49\VBD\1617192 muscle_50\NN\5289601 necrosis_51\NN\11444117 ;_52\:\1740 (_53\-LRB-\1740 4_54\LS\13741022 )_55\-RRB-\1740 type_56\NN\5839024 iib_57\NN\1740 <e2>atrophy</e2>_58\NN\14299637 was_59\VBD\836236 not_60\RB\1740 caused_61\VBN\1617192 by_62\IN\1740 acute_63\JJ\1740 nutritional_64\JJ\1740 deprivation_65\NN\14493145 alone_66\RB\1740 ._67\.\1740
D013256_D009133 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 (_3\-LRB-\1740 1_4\LS\13741022 )_5\-RRB-\1740 short-term_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 massive_9\JJ\1740 doses_10\NNS\3740161 of_11\IN\1740 steroids_12\NNS\14727670 induced_13\VBD\1627355 severe_14\JJ\1740 respiratory_15\NN\1740 and_16\CC\1740 limb_17\JJ\1740 muscle_18\NN\5289601 wasting_19\VBG\1158572 ;_20\:\1740 (_21\-LRB-\1740 2_22\LS\13741022 )_23\-RRB-\1740 both_24\DT\1740 types_25\NNS\5839024 of_26\IN\1740 steroids_27\NNS\14727670 induced_28\VBN\1627355 predominantly_29\RB\1740 type_30\NN\5839024 iib_31\NN\1740 atrophy_32\NN\14299637 ,_33\,\1740 resulting_34\VBG\2633881 in_35\IN\13603305 the_36\DT\1740 expected_37\VBN\670261 alterations_38\NNS\7283608 in_39\IN\13603305 diaphragm_40\NN\3736970 contractile_41\NN\1740 properties_42\NNS\32613 ;_43\:\1740 (_44\-LRB-\1740 3_45\LS\13741022 )_46\-RRB-\1740 neither_47\CC\1740 <e1>steroid</e1>_48\NN\14727670 caused_49\VBD\1617192 muscle_50\NN\5289601 necrosis_51\NN\11444117 ;_52\:\1740 (_53\-LRB-\1740 4_54\LS\13741022 )_55\-RRB-\1740 type_56\NN\5839024 iib_57\NN\1740 <e2>atrophy</e2>_58\NN\14299637 was_59\VBD\836236 not_60\RB\1740 caused_61\VBN\1617192 by_62\IN\1740 acute_63\JJ\1740 nutritional_64\JJ\1740 deprivation_65\NN\14493145 alone_66\RB\1740 ._67\.\1740
D013256_D009336 NONE atpase_0\NN\1740 staining_1\NN\275424 of_2\IN\1740 the_3\DT\1740 diaphragm_4\NN\3736970 ,_5\,\1740 scalenus_6\JJ\1740 medius_7\NN\1740 ,_8\,\1740 and_9\CC\1740 gastrocnemius_10\NN\5289861 showed_11\VBD\2137132 type_12\NN\5839024 iib_13\NN\1740 fiber_14\NN\14580897 atrophy_15\NN\14299637 in_16\IN\13603305 the_17\DT\1740 <e1>steroid</e1>_18\NN\14727670 groups_19\NNS\2137 and_20\CC\1740 also_21\RB\1740 diaphragmatic_22\JJ\1740 type_23\NN\5839024 iia_24\NN\1740 atrophy_25\NN\14299637 with_26\IN\1740 t_27\NN\14999913 ,_28\,\1740 whereas_29\IN\1740 histologic_30\JJ\1740 examinations_31\NNS\633864 revealed_32\VBD\2137132 a_33\DT\13649268 normal_34\JJ\1740 muscular_35\JJ\1740 pattern_36\NN\5726345 with_37\IN\1740 absence_38\NN\14449405 of_39\IN\1740 <e2>necrosis</e2>_40\NN\11444117 ._41\.\1740
D013256_D009336 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 (_3\-LRB-\1740 1_4\LS\13741022 )_5\-RRB-\1740 short-term_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 massive_9\JJ\1740 doses_10\NNS\3740161 of_11\IN\1740 <e1>steroids</e1>_12\NNS\14727670 induced_13\VBD\1627355 severe_14\JJ\1740 respiratory_15\NN\1740 and_16\CC\1740 limb_17\JJ\1740 muscle_18\NN\5289601 wasting_19\VBG\1158572 ;_20\:\1740 (_21\-LRB-\1740 2_22\LS\13741022 )_23\-RRB-\1740 both_24\DT\1740 types_25\NNS\5839024 of_26\IN\1740 steroids_27\NNS\14727670 induced_28\VBN\1627355 predominantly_29\RB\1740 type_30\NN\5839024 iib_31\NN\1740 atrophy_32\NN\14299637 ,_33\,\1740 resulting_34\VBG\2633881 in_35\IN\13603305 the_36\DT\1740 expected_37\VBN\670261 alterations_38\NNS\7283608 in_39\IN\13603305 diaphragm_40\NN\3736970 contractile_41\NN\1740 properties_42\NNS\32613 ;_43\:\1740 (_44\-LRB-\1740 3_45\LS\13741022 )_46\-RRB-\1740 neither_47\CC\1740 steroid_48\NN\14727670 caused_49\VBD\1617192 muscle_50\NN\5289601 <e2>necrosis</e2>_51\NN\11444117 ;_52\:\1740 (_53\-LRB-\1740 4_54\LS\13741022 )_55\-RRB-\1740 type_56\NN\5839024 iib_57\NN\1740 atrophy_58\NN\14299637 was_59\VBD\836236 not_60\RB\1740 caused_61\VBN\1617192 by_62\IN\1740 acute_63\JJ\1740 nutritional_64\JJ\1740 deprivation_65\NN\14493145 alone_66\RB\1740 ._67\.\1740
D013256_D009336 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 (_3\-LRB-\1740 1_4\LS\13741022 )_5\-RRB-\1740 short-term_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 massive_9\JJ\1740 doses_10\NNS\3740161 of_11\IN\1740 steroids_12\NNS\14727670 induced_13\VBD\1627355 severe_14\JJ\1740 respiratory_15\NN\1740 and_16\CC\1740 limb_17\JJ\1740 muscle_18\NN\5289601 wasting_19\VBG\1158572 ;_20\:\1740 (_21\-LRB-\1740 2_22\LS\13741022 )_23\-RRB-\1740 both_24\DT\1740 types_25\NNS\5839024 of_26\IN\1740 <e1>steroids</e1>_27\NNS\14727670 induced_28\VBN\1627355 predominantly_29\RB\1740 type_30\NN\5839024 iib_31\NN\1740 atrophy_32\NN\14299637 ,_33\,\1740 resulting_34\VBG\2633881 in_35\IN\13603305 the_36\DT\1740 expected_37\VBN\670261 alterations_38\NNS\7283608 in_39\IN\13603305 diaphragm_40\NN\3736970 contractile_41\NN\1740 properties_42\NNS\32613 ;_43\:\1740 (_44\-LRB-\1740 3_45\LS\13741022 )_46\-RRB-\1740 neither_47\CC\1740 steroid_48\NN\14727670 caused_49\VBD\1617192 muscle_50\NN\5289601 <e2>necrosis</e2>_51\NN\11444117 ;_52\:\1740 (_53\-LRB-\1740 4_54\LS\13741022 )_55\-RRB-\1740 type_56\NN\5839024 iib_57\NN\1740 atrophy_58\NN\14299637 was_59\VBD\836236 not_60\RB\1740 caused_61\VBN\1617192 by_62\IN\1740 acute_63\JJ\1740 nutritional_64\JJ\1740 deprivation_65\NN\14493145 alone_66\RB\1740 ._67\.\1740
D013256_D009336 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 (_3\-LRB-\1740 1_4\LS\13741022 )_5\-RRB-\1740 short-term_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 massive_9\JJ\1740 doses_10\NNS\3740161 of_11\IN\1740 steroids_12\NNS\14727670 induced_13\VBD\1627355 severe_14\JJ\1740 respiratory_15\NN\1740 and_16\CC\1740 limb_17\JJ\1740 muscle_18\NN\5289601 wasting_19\VBG\1158572 ;_20\:\1740 (_21\-LRB-\1740 2_22\LS\13741022 )_23\-RRB-\1740 both_24\DT\1740 types_25\NNS\5839024 of_26\IN\1740 steroids_27\NNS\14727670 induced_28\VBN\1627355 predominantly_29\RB\1740 type_30\NN\5839024 iib_31\NN\1740 atrophy_32\NN\14299637 ,_33\,\1740 resulting_34\VBG\2633881 in_35\IN\13603305 the_36\DT\1740 expected_37\VBN\670261 alterations_38\NNS\7283608 in_39\IN\13603305 diaphragm_40\NN\3736970 contractile_41\NN\1740 properties_42\NNS\32613 ;_43\:\1740 (_44\-LRB-\1740 3_45\LS\13741022 )_46\-RRB-\1740 neither_47\CC\1740 <e1>steroid</e1>_48\NN\14727670 caused_49\VBD\1617192 muscle_50\NN\5289601 <e2>necrosis</e2>_51\NN\11444117 ;_52\:\1740 (_53\-LRB-\1740 4_54\LS\13741022 )_55\-RRB-\1740 type_56\NN\5839024 iib_57\NN\1740 atrophy_58\NN\14299637 was_59\VBD\836236 not_60\RB\1740 caused_61\VBN\1617192 by_62\IN\1740 acute_63\JJ\1740 nutritional_64\JJ\1740 deprivation_65\NN\14493145 alone_66\RB\1740 ._67\.\1740
D014221_D009133 CID atpase_0\NN\1740 staining_1\NN\275424 of_2\IN\1740 the_3\DT\1740 diaphragm_4\NN\3736970 ,_5\,\1740 scalenus_6\JJ\1740 medius_7\NN\1740 ,_8\,\1740 and_9\CC\1740 gastrocnemius_10\NN\5289861 showed_11\VBD\2137132 type_12\NN\5839024 iib_13\NN\1740 fiber_14\NN\14580897 <e2>atrophy</e2>_15\NN\14299637 in_16\IN\13603305 the_17\DT\1740 steroid_18\NN\14727670 groups_19\NNS\2137 and_20\CC\1740 also_21\RB\1740 diaphragmatic_22\JJ\1740 type_23\NN\5839024 iia_24\NN\1740 atrophy_25\NN\14299637 with_26\IN\1740 <e1>t</e1>_27\NN\14999913 ,_28\,\1740 whereas_29\IN\1740 histologic_30\JJ\1740 examinations_31\NNS\633864 revealed_32\VBD\2137132 a_33\DT\13649268 normal_34\JJ\1740 muscular_35\JJ\1740 pattern_36\NN\5726345 with_37\IN\1740 absence_38\NN\14449405 of_39\IN\1740 necrosis_40\NN\11444117 ._41\.\1740
D014221_D009133 CID atpase_0\NN\1740 staining_1\NN\275424 of_2\IN\1740 the_3\DT\1740 diaphragm_4\NN\3736970 ,_5\,\1740 scalenus_6\JJ\1740 medius_7\NN\1740 ,_8\,\1740 and_9\CC\1740 gastrocnemius_10\NN\5289861 showed_11\VBD\2137132 type_12\NN\5839024 iib_13\NN\1740 fiber_14\NN\14580897 atrophy_15\NN\14299637 in_16\IN\13603305 the_17\DT\1740 steroid_18\NN\14727670 groups_19\NNS\2137 and_20\CC\1740 also_21\RB\1740 diaphragmatic_22\JJ\1740 type_23\NN\5839024 iia_24\NN\1740 <e2>atrophy</e2>_25\NN\14299637 with_26\IN\1740 <e1>t</e1>_27\NN\14999913 ,_28\,\1740 whereas_29\IN\1740 histologic_30\JJ\1740 examinations_31\NNS\633864 revealed_32\VBD\2137132 a_33\DT\13649268 normal_34\JJ\1740 muscular_35\JJ\1740 pattern_36\NN\5726345 with_37\IN\1740 absence_38\NN\14449405 of_39\IN\1740 necrosis_40\NN\11444117 ._41\.\1740
D014221_D009133 CID finally_0\RB\1740 ,_1\,\1740 a_2\DT\13649268 pair-fed_3\JJ\1740 (_4\-LRB-\1740 pf_5\NN\1740 )_6\-RRB-\1740 study_7\NN\635850 ,_8\,\1740 performed_9\VBN\2367363 in_10\IN\13603305 18_11\CD\13745420 rats_12\NNS\2329401 (_13\-LRB-\1740 c_14\NN\13714184 ,_15\,\1740 <e1>t</e1>_16\NN\14999913 ,_17\,\1740 and_18\CC\1740 pf_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 showed_22\VBD\2137132 that_23\IN\1740 <e2>muscle_24\NN\5289601 atrophy</e2>_25\NN\14299637 was_26\VBD\836236 considerably_27\RB\1740 less_28\RBR\1740 pronounced_29\JJ\1740 in_30\IN\13603305 pf_31\NN\1740 animals_32\NNS\4475 than_33\IN\1740 in_34\IN\13603305 t-treated_35\JJ\1740 animals_36\NNS\4475 ._37\.\1740
D014221_D009133 CID finally_0\RB\1740 ,_1\,\1740 a_2\DT\13649268 pair-fed_3\JJ\1740 (_4\-LRB-\1740 pf_5\NN\1740 )_6\-RRB-\1740 study_7\NN\635850 ,_8\,\1740 performed_9\VBN\2367363 in_10\IN\13603305 18_11\CD\13745420 rats_12\NNS\2329401 (_13\-LRB-\1740 c_14\NN\13714184 ,_15\,\1740 t_16\NN\14999913 ,_17\,\1740 and_18\CC\1740 pf_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 showed_22\VBD\2137132 that_23\IN\1740 <e2>muscle_24\NN\5289601 atrophy</e2>_25\NN\14299637 was_26\VBD\836236 considerably_27\RB\1740 less_28\RBR\1740 pronounced_29\JJ\1740 in_30\IN\13603305 pf_31\NN\1740 animals_32\NNS\4475 than_33\IN\1740 in_34\IN\13603305 <e1>t-treated</e1>_35\JJ\1740 animals_36\NNS\4475 ._37\.\1740
D014221_D009336 NONE atpase_0\NN\1740 staining_1\NN\275424 of_2\IN\1740 the_3\DT\1740 diaphragm_4\NN\3736970 ,_5\,\1740 scalenus_6\JJ\1740 medius_7\NN\1740 ,_8\,\1740 and_9\CC\1740 gastrocnemius_10\NN\5289861 showed_11\VBD\2137132 type_12\NN\5839024 iib_13\NN\1740 fiber_14\NN\14580897 atrophy_15\NN\14299637 in_16\IN\13603305 the_17\DT\1740 steroid_18\NN\14727670 groups_19\NNS\2137 and_20\CC\1740 also_21\RB\1740 diaphragmatic_22\JJ\1740 type_23\NN\5839024 iia_24\NN\1740 atrophy_25\NN\14299637 with_26\IN\1740 <e1>t</e1>_27\NN\14999913 ,_28\,\1740 whereas_29\IN\1740 histologic_30\JJ\1740 examinations_31\NNS\633864 revealed_32\VBD\2137132 a_33\DT\13649268 normal_34\JJ\1740 muscular_35\JJ\1740 pattern_36\NN\5726345 with_37\IN\1740 absence_38\NN\14449405 of_39\IN\1740 <e2>necrosis</e2>_40\NN\11444117 ._41\.\1740
D013256_D001284 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 (_3\-LRB-\1740 1_4\LS\13741022 )_5\-RRB-\1740 short-term_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 massive_9\JJ\1740 doses_10\NNS\3740161 of_11\IN\1740 <e1>steroids</e1>_12\NNS\14727670 induced_13\VBD\1627355 severe_14\JJ\1740 respiratory_15\NN\1740 and_16\CC\1740 limb_17\JJ\1740 muscle_18\NN\5289601 wasting_19\VBG\1158572 ;_20\:\1740 (_21\-LRB-\1740 2_22\LS\13741022 )_23\-RRB-\1740 both_24\DT\1740 types_25\NNS\5839024 of_26\IN\1740 steroids_27\NNS\14727670 induced_28\VBN\1627355 predominantly_29\RB\1740 type_30\NN\5839024 iib_31\NN\1740 <e2>atrophy</e2>_32\NN\14299637 ,_33\,\1740 resulting_34\VBG\2633881 in_35\IN\13603305 the_36\DT\1740 expected_37\VBN\670261 alterations_38\NNS\7283608 in_39\IN\13603305 diaphragm_40\NN\3736970 contractile_41\NN\1740 properties_42\NNS\32613 ;_43\:\1740 (_44\-LRB-\1740 3_45\LS\13741022 )_46\-RRB-\1740 neither_47\CC\1740 steroid_48\NN\14727670 caused_49\VBD\1617192 muscle_50\NN\5289601 necrosis_51\NN\11444117 ;_52\:\1740 (_53\-LRB-\1740 4_54\LS\13741022 )_55\-RRB-\1740 type_56\NN\5839024 iib_57\NN\1740 atrophy_58\NN\14299637 was_59\VBD\836236 not_60\RB\1740 caused_61\VBN\1617192 by_62\IN\1740 acute_63\JJ\1740 nutritional_64\JJ\1740 deprivation_65\NN\14493145 alone_66\RB\1740 ._67\.\1740
D013256_D001284 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 (_3\-LRB-\1740 1_4\LS\13741022 )_5\-RRB-\1740 short-term_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 massive_9\JJ\1740 doses_10\NNS\3740161 of_11\IN\1740 steroids_12\NNS\14727670 induced_13\VBD\1627355 severe_14\JJ\1740 respiratory_15\NN\1740 and_16\CC\1740 limb_17\JJ\1740 muscle_18\NN\5289601 wasting_19\VBG\1158572 ;_20\:\1740 (_21\-LRB-\1740 2_22\LS\13741022 )_23\-RRB-\1740 both_24\DT\1740 types_25\NNS\5839024 of_26\IN\1740 <e1>steroids</e1>_27\NNS\14727670 induced_28\VBN\1627355 predominantly_29\RB\1740 type_30\NN\5839024 iib_31\NN\1740 <e2>atrophy</e2>_32\NN\14299637 ,_33\,\1740 resulting_34\VBG\2633881 in_35\IN\13603305 the_36\DT\1740 expected_37\VBN\670261 alterations_38\NNS\7283608 in_39\IN\13603305 diaphragm_40\NN\3736970 contractile_41\NN\1740 properties_42\NNS\32613 ;_43\:\1740 (_44\-LRB-\1740 3_45\LS\13741022 )_46\-RRB-\1740 neither_47\CC\1740 steroid_48\NN\14727670 caused_49\VBD\1617192 muscle_50\NN\5289601 necrosis_51\NN\11444117 ;_52\:\1740 (_53\-LRB-\1740 4_54\LS\13741022 )_55\-RRB-\1740 type_56\NN\5839024 iib_57\NN\1740 atrophy_58\NN\14299637 was_59\VBD\836236 not_60\RB\1740 caused_61\VBN\1617192 by_62\IN\1740 acute_63\JJ\1740 nutritional_64\JJ\1740 deprivation_65\NN\14493145 alone_66\RB\1740 ._67\.\1740
D013256_D001284 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 (_3\-LRB-\1740 1_4\LS\13741022 )_5\-RRB-\1740 short-term_6\JJ\1740 treatment_7\NN\654885 with_8\IN\1740 massive_9\JJ\1740 doses_10\NNS\3740161 of_11\IN\1740 steroids_12\NNS\14727670 induced_13\VBD\1627355 severe_14\JJ\1740 respiratory_15\NN\1740 and_16\CC\1740 limb_17\JJ\1740 muscle_18\NN\5289601 wasting_19\VBG\1158572 ;_20\:\1740 (_21\-LRB-\1740 2_22\LS\13741022 )_23\-RRB-\1740 both_24\DT\1740 types_25\NNS\5839024 of_26\IN\1740 steroids_27\NNS\14727670 induced_28\VBN\1627355 predominantly_29\RB\1740 type_30\NN\5839024 iib_31\NN\1740 <e2>atrophy</e2>_32\NN\14299637 ,_33\,\1740 resulting_34\VBG\2633881 in_35\IN\13603305 the_36\DT\1740 expected_37\VBN\670261 alterations_38\NNS\7283608 in_39\IN\13603305 diaphragm_40\NN\3736970 contractile_41\NN\1740 properties_42\NNS\32613 ;_43\:\1740 (_44\-LRB-\1740 3_45\LS\13741022 )_46\-RRB-\1740 neither_47\CC\1740 <e1>steroid</e1>_48\NN\14727670 caused_49\VBD\1617192 muscle_50\NN\5289601 necrosis_51\NN\11444117 ;_52\:\1740 (_53\-LRB-\1740 4_54\LS\13741022 )_55\-RRB-\1740 type_56\NN\5839024 iib_57\NN\1740 atrophy_58\NN\14299637 was_59\VBD\836236 not_60\RB\1740 caused_61\VBN\1617192 by_62\IN\1740 acute_63\JJ\1740 nutritional_64\JJ\1740 deprivation_65\NN\14493145 alone_66\RB\1740 ._67\.\1740
2709684
D010695_D006029 NONE <e1>phlorizin-induced</e1>_0\JJ\1740 <e2>glycosuria</e2>_1\NN\14299637 does_2\VBZ\1640855 not_3\RB\1740 prevent_4\VB\1740 gentamicin_5\NN\2716866 nephrotoxicity_6\NN\1740 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D010695_D006029 NONE dm_0\NN\14117805 rats_1\NNS\2329401 with_2\IN\1740 mild_3\JJ\1740 <e2>glycosuria</e2>_4\NN\14299637 (_5\-LRB-\1740 similar_6\JJ\1740 in_7\IN\13603305 degree_8\NN\4916342 to_9\TO\1740 that_10\DT\1740 of_11\IN\1740 the_12\DT\1740 <e1>p</e1>_13\NN\14622893 treated_14\JJ\1740 animals_15\NNS\4475 )_16\-RRB-\1740 were_17\VBD\836236 also_18\RB\1740 studied_19\VBN\630380 ._20\.\1740
D010695_D006029 NONE in_0\IN\13603305 group_1\NNP\2137 i_2\CD\14622893 ,_3\,\1740 <e1>p</e1>_4\NN\14622893 induced_5\VBD\1627355 a_6\DT\13649268 moderate_7\JJ\1740 and_8\CC\1740 stable_9\JJ\1740 <e2>glycosuria</e2>_10\NN\14299637 (_11\-LRB-\1740 3.9_12\CD\1740 +/-_13\CC\1740 0.1_14\CD\1740 g/day_15\NN\1740 ,_16\,\1740 se_17\NN\14724645 )_18\-RRB-\1740 ,_19\,\1740 and_20\CC\1740 no_21\DT\7204911 functional_22\JJ\1740 or_23\CC\3541091 morphologic_24\JJ\1740 evidence_25\NN\5816287 of_26\IN\1740 renal_27\JJ\1740 dysfunction_28\NN\14204950 (_29\-LRB-\1740 baseline_30\NN\7260623 ccr_31\NNS\1740 2.1_32\CD\1740 +/-_33\CC\1740 0.1_34\CD\1740 ml/min_35\NN\1740 ,_36\,\1740 undetectable_37\JJ\1740 lysozymuria_38\NNS\1740 )_39\-RRB-\1740 or_40\CC\3541091 damage_41\NN\7296428 (_42\-LRB-\1740 tubular_43\JJ\1740 necrosis_44\NN\11444117 score_45\NN\5736149 [_46\-LRB-\1740 maximum_47\NN\13653902 4_48\CD\13741022 ]_49\-RRB-\1740 ,_50\,\1740 zero_51\CD\13576982 )_52\-RRB-\1740 ._53\.\1740
D010695_D007674 NONE <e1>phlorizin-induced</e1>_0\JJ\1740 glycosuria_1\NN\14299637 does_2\VBZ\1640855 not_3\RB\1740 prevent_4\VB\1740 gentamicin_5\NN\2716866 <e2>nephrotoxicity</e2>_6\NN\1740 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D010695_D007674 NONE the_0\DT\1740 protection_1\NN\407535 from_2\IN\1740 gentamicin_3\NN\2716866 <e2>nephrotoxicity</e2>_4\NN\1740 was_5\VBD\836236 studied_6\VBN\630380 in_7\IN\13603305 non-diabetic_8\JJ\1740 rats_9\NNS\2329401 with_10\IN\1740 chronic_11\JJ\1740 solute_12\JJ\1740 diuresis_13\NN\14299637 induced_14\VBN\1627355 by_15\IN\1740 blockage_16\NN\14034177 of_17\IN\1740 tubular_18\JJ\1740 glucose_19\NN\14710501 reabsorption_20\NN\13526110 with_21\IN\1740 <e1>phlorizin</e1>_22\NN\1740 (_23\-LRB-\1740 p_24\NN\14622893 )_25\-RRB-\1740 ._26\.\1740
D010695_D007674 NONE the_0\DT\1740 protection_1\NN\407535 from_2\IN\1740 gentamicin_3\NN\2716866 <e2>nephrotoxicity</e2>_4\NN\1740 was_5\VBD\836236 studied_6\VBN\630380 in_7\IN\13603305 non-diabetic_8\JJ\1740 rats_9\NNS\2329401 with_10\IN\1740 chronic_11\JJ\1740 solute_12\JJ\1740 diuresis_13\NN\14299637 induced_14\VBN\1627355 by_15\IN\1740 blockage_16\NN\14034177 of_17\IN\1740 tubular_18\JJ\1740 glucose_19\NN\14710501 reabsorption_20\NN\13526110 with_21\IN\1740 phlorizin_22\NN\1740 (_23\-LRB-\1740 <e1>p</e1>_24\NN\14622893 )_25\-RRB-\1740 ._26\.\1740
D010695_D007674 NONE in_0\IN\13603305 group_1\NNP\2137 i_2\CD\14622893 ,_3\,\1740 <e1>p</e1>_4\NN\14622893 induced_5\VBD\1627355 a_6\DT\13649268 moderate_7\JJ\1740 and_8\CC\1740 stable_9\JJ\1740 glycosuria_10\NN\14299637 (_11\-LRB-\1740 3.9_12\CD\1740 +/-_13\CC\1740 0.1_14\CD\1740 g/day_15\NN\1740 ,_16\,\1740 se_17\NN\14724645 )_18\-RRB-\1740 ,_19\,\1740 and_20\CC\1740 no_21\DT\7204911 functional_22\JJ\1740 or_23\CC\3541091 morphologic_24\JJ\1740 evidence_25\NN\5816287 of_26\IN\1740 <e2>renal_27\JJ\1740 dysfunction</e2>_28\NN\14204950 (_29\-LRB-\1740 baseline_30\NN\7260623 ccr_31\NNS\1740 2.1_32\CD\1740 +/-_33\CC\1740 0.1_34\CD\1740 ml/min_35\NN\1740 ,_36\,\1740 undetectable_37\JJ\1740 lysozymuria_38\NNS\1740 )_39\-RRB-\1740 or_40\CC\3541091 damage_41\NN\7296428 (_42\-LRB-\1740 tubular_43\JJ\1740 necrosis_44\NN\11444117 score_45\NN\5736149 [_46\-LRB-\1740 maximum_47\NN\13653902 4_48\CD\13741022 ]_49\-RRB-\1740 ,_50\,\1740 zero_51\CD\13576982 )_52\-RRB-\1740 ._53\.\1740
D005839_D006029 NONE phlorizin-induced_0\JJ\1740 <e2>glycosuria</e2>_1\NN\14299637 does_2\VBZ\1640855 not_3\RB\1740 prevent_4\VB\1740 <e1>gentamicin</e1>_5\NN\2716866 nephrotoxicity_6\NN\1740 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D005839_D006029 NONE because_0\IN\1740 rats_1\NNS\2329401 with_2\IN\1740 streptozotocin-induced_3\JJ\1740 diabetes_4\NN\14075199 mellitus_5\NN\1740 (_6\-LRB-\1740 dm_7\NN\14117805 )_8\-RRB-\1740 have_9\VBP\2108377 a_10\DT\13649268 high_11\JJ\1740 solute_12\NN\20827 diuresis_13\NN\14299637 (_14\-LRB-\1740 <e2>glycosuria</e2>_15\NN\14299637 of_16\IN\1740 10_17\CD\13745420 to_18\TO\1740 12_19\CD\13745420 g/day_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 we_23\PRP\1740 have_24\VBP\2108377 suggested_25\VBN\1010118 that_26\IN\1740 this_27\DT\1740 may_28\MD\15209706 in_29\IN\13603305 part_30\NN\31921 be_31\VB\836236 responsible_32\JJ\1740 for_33\IN\1740 their_34\PRP$\1740 resistance_35\NN\37396 to_36\TO\1740 <e1>gentamicin-induced</e1>_37\JJ\1740 acute_38\JJ\1740 renal_39\JJ\1740 failure_40\NN\66216 (_41\-LRB-\1740 arf_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D005839_D007674 NONE phlorizin-induced_0\JJ\1740 glycosuria_1\NN\14299637 does_2\VBZ\1640855 not_3\RB\1740 prevent_4\VB\1740 <e1>gentamicin</e1>_5\NN\2716866 <e2>nephrotoxicity</e2>_6\NN\1740 in_7\IN\13603305 rats_8\NNS\2329401 ._9\.\1740
D005839_D007674 NONE the_0\DT\1740 protection_1\NN\407535 from_2\IN\1740 <e1>gentamicin</e1>_3\NN\2716866 <e2>nephrotoxicity</e2>_4\NN\1740 was_5\VBD\836236 studied_6\VBN\630380 in_7\IN\13603305 non-diabetic_8\JJ\1740 rats_9\NNS\2329401 with_10\IN\1740 chronic_11\JJ\1740 solute_12\JJ\1740 diuresis_13\NN\14299637 induced_14\VBN\1627355 by_15\IN\1740 blockage_16\NN\14034177 of_17\IN\1740 tubular_18\JJ\1740 glucose_19\NN\14710501 reabsorption_20\NN\13526110 with_21\IN\1740 phlorizin_22\NN\1740 (_23\-LRB-\1740 p_24\NN\14622893 )_25\-RRB-\1740 ._26\.\1740
D005839_D007674 NONE <e2>nephrotoxic</e2>_0\JJ\1740 doses_1\NNS\3740161 (_2\-LRB-\1740 40_3\CD\13745420 mg/kg_4\NN\1740 body_5\NN\19128 wt/day_6\NN\1740 )_7\-RRB-\1740 of_8\IN\1740 <e1>gentamicin</e1>_9\NN\2716866 were_10\VBD\836236 injected_11\VBN\81072 during_12\IN\1740 the_13\DT\1740 last_14\JJ\1740 nine_15\CD\13741022 days_16\NNS\15140892 of_17\IN\1740 study_18\NN\635850 to_19\IN\1740 the_20\DT\1740 animals_21\NNS\4475 of_22\IN\1740 groups_23\NNS\2137 ii_24\CD\13741022 to_25\TO\1740 iv_26\CD\13741022 ._27\.\1740
D013311_D003920 CID because_0\IN\1740 rats_1\NNS\2329401 with_2\IN\1740 <e1>streptozotocin-induced</e1>_3\JJ\1740 <e2>diabetes_4\NN\14075199 mellitus</e2>_5\NN\1740 (_6\-LRB-\1740 dm_7\NN\14117805 )_8\-RRB-\1740 have_9\VBP\2108377 a_10\DT\13649268 high_11\JJ\1740 solute_12\NN\20827 diuresis_13\NN\14299637 (_14\-LRB-\1740 glycosuria_15\NN\14299637 of_16\IN\1740 10_17\CD\13745420 to_18\TO\1740 12_19\CD\13745420 g/day_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 we_23\PRP\1740 have_24\VBP\2108377 suggested_25\VBN\1010118 that_26\IN\1740 this_27\DT\1740 may_28\MD\15209706 in_29\IN\13603305 part_30\NN\31921 be_31\VB\836236 responsible_32\JJ\1740 for_33\IN\1740 their_34\PRP$\1740 resistance_35\NN\37396 to_36\TO\1740 gentamicin-induced_37\JJ\1740 acute_38\JJ\1740 renal_39\JJ\1740 failure_40\NN\66216 (_41\-LRB-\1740 arf_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D013311_D003920 CID because_0\IN\1740 rats_1\NNS\2329401 with_2\IN\1740 <e1>streptozotocin-induced</e1>_3\JJ\1740 diabetes_4\NN\14075199 mellitus_5\NN\1740 (_6\-LRB-\1740 <e2>dm</e2>_7\NN\14117805 )_8\-RRB-\1740 have_9\VBP\2108377 a_10\DT\13649268 high_11\JJ\1740 solute_12\NN\20827 diuresis_13\NN\14299637 (_14\-LRB-\1740 glycosuria_15\NN\14299637 of_16\IN\1740 10_17\CD\13745420 to_18\TO\1740 12_19\CD\13745420 g/day_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 we_23\PRP\1740 have_24\VBP\2108377 suggested_25\VBN\1010118 that_26\IN\1740 this_27\DT\1740 may_28\MD\15209706 in_29\IN\13603305 part_30\NN\31921 be_31\VB\836236 responsible_32\JJ\1740 for_33\IN\1740 their_34\PRP$\1740 resistance_35\NN\37396 to_36\TO\1740 gentamicin-induced_37\JJ\1740 acute_38\JJ\1740 renal_39\JJ\1740 failure_40\NN\66216 (_41\-LRB-\1740 arf_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D013311_D006029 NONE because_0\IN\1740 rats_1\NNS\2329401 with_2\IN\1740 <e1>streptozotocin-induced</e1>_3\JJ\1740 diabetes_4\NN\14075199 mellitus_5\NN\1740 (_6\-LRB-\1740 dm_7\NN\14117805 )_8\-RRB-\1740 have_9\VBP\2108377 a_10\DT\13649268 high_11\JJ\1740 solute_12\NN\20827 diuresis_13\NN\14299637 (_14\-LRB-\1740 <e2>glycosuria</e2>_15\NN\14299637 of_16\IN\1740 10_17\CD\13745420 to_18\TO\1740 12_19\CD\13745420 g/day_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 we_23\PRP\1740 have_24\VBP\2108377 suggested_25\VBN\1010118 that_26\IN\1740 this_27\DT\1740 may_28\MD\15209706 in_29\IN\13603305 part_30\NN\31921 be_31\VB\836236 responsible_32\JJ\1740 for_33\IN\1740 their_34\PRP$\1740 resistance_35\NN\37396 to_36\TO\1740 gentamicin-induced_37\JJ\1740 acute_38\JJ\1740 renal_39\JJ\1740 failure_40\NN\66216 (_41\-LRB-\1740 arf_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D013311_D058186 NONE because_0\IN\1740 rats_1\NNS\2329401 with_2\IN\1740 <e1>streptozotocin-induced</e1>_3\JJ\1740 diabetes_4\NN\14075199 mellitus_5\NN\1740 (_6\-LRB-\1740 dm_7\NN\14117805 )_8\-RRB-\1740 have_9\VBP\2108377 a_10\DT\13649268 high_11\JJ\1740 solute_12\NN\20827 diuresis_13\NN\14299637 (_14\-LRB-\1740 glycosuria_15\NN\14299637 of_16\IN\1740 10_17\CD\13745420 to_18\TO\1740 12_19\CD\13745420 g/day_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 we_23\PRP\1740 have_24\VBP\2108377 suggested_25\VBN\1010118 that_26\IN\1740 this_27\DT\1740 may_28\MD\15209706 in_29\IN\13603305 part_30\NN\31921 be_31\VB\836236 responsible_32\JJ\1740 for_33\IN\1740 their_34\PRP$\1740 resistance_35\NN\37396 to_36\TO\1740 gentamicin-induced_37\JJ\1740 <e2>acute_38\JJ\1740 renal_39\JJ\1740 failure</e2>_40\NN\66216 (_41\-LRB-\1740 arf_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D013311_D058186 NONE because_0\IN\1740 rats_1\NNS\2329401 with_2\IN\1740 <e1>streptozotocin-induced</e1>_3\JJ\1740 diabetes_4\NN\14075199 mellitus_5\NN\1740 (_6\-LRB-\1740 dm_7\NN\14117805 )_8\-RRB-\1740 have_9\VBP\2108377 a_10\DT\13649268 high_11\JJ\1740 solute_12\NN\20827 diuresis_13\NN\14299637 (_14\-LRB-\1740 glycosuria_15\NN\14299637 of_16\IN\1740 10_17\CD\13745420 to_18\TO\1740 12_19\CD\13745420 g/day_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 we_23\PRP\1740 have_24\VBP\2108377 suggested_25\VBN\1010118 that_26\IN\1740 this_27\DT\1740 may_28\MD\15209706 in_29\IN\13603305 part_30\NN\31921 be_31\VB\836236 responsible_32\JJ\1740 for_33\IN\1740 their_34\PRP$\1740 resistance_35\NN\37396 to_36\TO\1740 gentamicin-induced_37\JJ\1740 acute_38\JJ\1740 renal_39\JJ\1740 failure_40\NN\66216 (_41\-LRB-\1740 <e2>arf</e2>_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D005839_D003920 NONE because_0\IN\1740 rats_1\NNS\2329401 with_2\IN\1740 streptozotocin-induced_3\JJ\1740 <e2>diabetes_4\NN\14075199 mellitus</e2>_5\NN\1740 (_6\-LRB-\1740 dm_7\NN\14117805 )_8\-RRB-\1740 have_9\VBP\2108377 a_10\DT\13649268 high_11\JJ\1740 solute_12\NN\20827 diuresis_13\NN\14299637 (_14\-LRB-\1740 glycosuria_15\NN\14299637 of_16\IN\1740 10_17\CD\13745420 to_18\TO\1740 12_19\CD\13745420 g/day_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 we_23\PRP\1740 have_24\VBP\2108377 suggested_25\VBN\1010118 that_26\IN\1740 this_27\DT\1740 may_28\MD\15209706 in_29\IN\13603305 part_30\NN\31921 be_31\VB\836236 responsible_32\JJ\1740 for_33\IN\1740 their_34\PRP$\1740 resistance_35\NN\37396 to_36\TO\1740 <e1>gentamicin-induced</e1>_37\JJ\1740 acute_38\JJ\1740 renal_39\JJ\1740 failure_40\NN\66216 (_41\-LRB-\1740 arf_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D005839_D003920 NONE because_0\IN\1740 rats_1\NNS\2329401 with_2\IN\1740 streptozotocin-induced_3\JJ\1740 diabetes_4\NN\14075199 mellitus_5\NN\1740 (_6\-LRB-\1740 <e2>dm</e2>_7\NN\14117805 )_8\-RRB-\1740 have_9\VBP\2108377 a_10\DT\13649268 high_11\JJ\1740 solute_12\NN\20827 diuresis_13\NN\14299637 (_14\-LRB-\1740 glycosuria_15\NN\14299637 of_16\IN\1740 10_17\CD\13745420 to_18\TO\1740 12_19\CD\13745420 g/day_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 we_23\PRP\1740 have_24\VBP\2108377 suggested_25\VBN\1010118 that_26\IN\1740 this_27\DT\1740 may_28\MD\15209706 in_29\IN\13603305 part_30\NN\31921 be_31\VB\836236 responsible_32\JJ\1740 for_33\IN\1740 their_34\PRP$\1740 resistance_35\NN\37396 to_36\TO\1740 <e1>gentamicin-induced</e1>_37\JJ\1740 acute_38\JJ\1740 renal_39\JJ\1740 failure_40\NN\66216 (_41\-LRB-\1740 arf_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D005839_D003920 NONE the_0\DT\1740 protection_1\NN\407535 from_2\IN\1740 <e1>gentamicin</e1>_3\NN\2716866 nephrotoxicity_4\NN\1740 was_5\VBD\836236 studied_6\VBN\630380 in_7\IN\13603305 <e2>non-diabetic</e2>_8\JJ\1740 rats_9\NNS\2329401 with_10\IN\1740 chronic_11\JJ\1740 solute_12\JJ\1740 diuresis_13\NN\14299637 induced_14\VBN\1627355 by_15\IN\1740 blockage_16\NN\14034177 of_17\IN\1740 tubular_18\JJ\1740 glucose_19\NN\14710501 reabsorption_20\NN\13526110 with_21\IN\1740 phlorizin_22\NN\1740 (_23\-LRB-\1740 p_24\NN\14622893 )_25\-RRB-\1740 ._26\.\1740
D005839_D003920 NONE group_0\NN\2137 1_1\CD\13741022 (_2\-LRB-\1740 p_3\NN\14622893 alone_4\RB\1740 )_5\-RRB-\1740 received_6\VBD\2210855 p_7\NN\14622893 ,_8\,\1740 360_9\CD\1740 mg/day_10\NN\1740 ,_11\,\1740 for_12\IN\1740 15_13\CD\13745420 days_14\NNS\15140892 ;_15\:\1740 group_16\NN\2137 ii_17\CD\13741022 (_18\-LRB-\1740 p_19\NN\14622893 +_20\CC\1740 <e1>gentamicin</e1>_21\NN\2716866 )_22\-RRB-\1740 ;_23\:\1740 group_24\NN\2137 iii_25\CD\13741022 (_26\-LRB-\1740 gentamicin_27\NN\2716866 alone_28\RB\1740 )_29\-RRB-\1740 and_30\CC\1740 group_31\NN\2137 iv_32\CD\13741022 (_33\-LRB-\1740 mild_34\JJ\1740 <e2>dm</e2>_35\NN\14117805 +_36\CC\1740 gentamicin_37\NN\2716866 )_38\-RRB-\1740 ._39\.\1740
D005839_D003920 NONE group_0\NN\2137 1_1\CD\13741022 (_2\-LRB-\1740 p_3\NN\14622893 alone_4\RB\1740 )_5\-RRB-\1740 received_6\VBD\2210855 p_7\NN\14622893 ,_8\,\1740 360_9\CD\1740 mg/day_10\NN\1740 ,_11\,\1740 for_12\IN\1740 15_13\CD\13745420 days_14\NNS\15140892 ;_15\:\1740 group_16\NN\2137 ii_17\CD\13741022 (_18\-LRB-\1740 p_19\NN\14622893 +_20\CC\1740 gentamicin_21\NN\2716866 )_22\-RRB-\1740 ;_23\:\1740 group_24\NN\2137 iii_25\CD\13741022 (_26\-LRB-\1740 <e1>gentamicin</e1>_27\NN\2716866 alone_28\RB\1740 )_29\-RRB-\1740 and_30\CC\1740 group_31\NN\2137 iv_32\CD\13741022 (_33\-LRB-\1740 mild_34\JJ\1740 <e2>dm</e2>_35\NN\14117805 +_36\CC\1740 gentamicin_37\NN\2716866 )_38\-RRB-\1740 ._39\.\1740
D005839_D003920 NONE group_0\NN\2137 1_1\CD\13741022 (_2\-LRB-\1740 p_3\NN\14622893 alone_4\RB\1740 )_5\-RRB-\1740 received_6\VBD\2210855 p_7\NN\14622893 ,_8\,\1740 360_9\CD\1740 mg/day_10\NN\1740 ,_11\,\1740 for_12\IN\1740 15_13\CD\13745420 days_14\NNS\15140892 ;_15\:\1740 group_16\NN\2137 ii_17\CD\13741022 (_18\-LRB-\1740 p_19\NN\14622893 +_20\CC\1740 gentamicin_21\NN\2716866 )_22\-RRB-\1740 ;_23\:\1740 group_24\NN\2137 iii_25\CD\13741022 (_26\-LRB-\1740 gentamicin_27\NN\2716866 alone_28\RB\1740 )_29\-RRB-\1740 and_30\CC\1740 group_31\NN\2137 iv_32\CD\13741022 (_33\-LRB-\1740 mild_34\JJ\1740 <e2>dm</e2>_35\NN\14117805 +_36\CC\1740 <e1>gentamicin</e1>_37\NN\2716866 )_38\-RRB-\1740 ._39\.\1740
D005839_D058186 CID because_0\IN\1740 rats_1\NNS\2329401 with_2\IN\1740 streptozotocin-induced_3\JJ\1740 diabetes_4\NN\14075199 mellitus_5\NN\1740 (_6\-LRB-\1740 dm_7\NN\14117805 )_8\-RRB-\1740 have_9\VBP\2108377 a_10\DT\13649268 high_11\JJ\1740 solute_12\NN\20827 diuresis_13\NN\14299637 (_14\-LRB-\1740 glycosuria_15\NN\14299637 of_16\IN\1740 10_17\CD\13745420 to_18\TO\1740 12_19\CD\13745420 g/day_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 we_23\PRP\1740 have_24\VBP\2108377 suggested_25\VBN\1010118 that_26\IN\1740 this_27\DT\1740 may_28\MD\15209706 in_29\IN\13603305 part_30\NN\31921 be_31\VB\836236 responsible_32\JJ\1740 for_33\IN\1740 their_34\PRP$\1740 resistance_35\NN\37396 to_36\TO\1740 <e1>gentamicin-induced</e1>_37\JJ\1740 <e2>acute_38\JJ\1740 renal_39\JJ\1740 failure</e2>_40\NN\66216 (_41\-LRB-\1740 arf_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D005839_D058186 CID because_0\IN\1740 rats_1\NNS\2329401 with_2\IN\1740 streptozotocin-induced_3\JJ\1740 diabetes_4\NN\14075199 mellitus_5\NN\1740 (_6\-LRB-\1740 dm_7\NN\14117805 )_8\-RRB-\1740 have_9\VBP\2108377 a_10\DT\13649268 high_11\JJ\1740 solute_12\NN\20827 diuresis_13\NN\14299637 (_14\-LRB-\1740 glycosuria_15\NN\14299637 of_16\IN\1740 10_17\CD\13745420 to_18\TO\1740 12_19\CD\13745420 g/day_20\NN\1740 )_21\-RRB-\1740 ,_22\,\1740 we_23\PRP\1740 have_24\VBP\2108377 suggested_25\VBN\1010118 that_26\IN\1740 this_27\DT\1740 may_28\MD\15209706 in_29\IN\13603305 part_30\NN\31921 be_31\VB\836236 responsible_32\JJ\1740 for_33\IN\1740 their_34\PRP$\1740 resistance_35\NN\37396 to_36\TO\1740 <e1>gentamicin-induced</e1>_37\JJ\1740 acute_38\JJ\1740 renal_39\JJ\1740 failure_40\NN\66216 (_41\-LRB-\1740 <e2>arf</e2>_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D005839_D058186 CID in_0\IN\13603305 group_1\NNP\2137 ii_2\CD\13741022 ,_3\,\1740 p_4\NN\14622893 did_5\VBD\1640855 not_6\RB\1740 prevent_7\VB\1740 <e2><e1>gentamicin-arf</e1></e2>_8\NN\1740 (_9\-LRB-\1740 maximal_10\JJ\1740 decrease_11\NN\7296428 in_12\IN\13603305 ccr_13\NNS\1740 at_14\IN\14622893 day_15\NN\15154774 9.89_16\CD\1740 %_17\NN\1740 ,_18\,\1740 p_19\NN\14622893 less_20\JJR\1740 than_21\IN\1740 0.001_22\CD\1740 ;_23\:\1740 peak_24\NN\13758296 lysozymuria_25\NNS\1740 ,_26\,\1740 1863_27\CD\1740 +/-_28\CC\1740 321_29\CD\1740 micrograms/day_30\NN\1740 ;_31\:\1740 and_32\CC\1740 tubular_33\JJ\1740 necrosis_34\NN\11444117 score_35\NN\5736149 ,_36\,\1740 3.9_37\CD\1740 +/-_38\CC\1740 0.1_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
D005947_D007674 NONE the_0\DT\1740 protection_1\NN\407535 from_2\IN\1740 gentamicin_3\NN\2716866 <e2>nephrotoxicity</e2>_4\NN\1740 was_5\VBD\836236 studied_6\VBN\630380 in_7\IN\13603305 non-diabetic_8\JJ\1740 rats_9\NNS\2329401 with_10\IN\1740 chronic_11\JJ\1740 solute_12\JJ\1740 diuresis_13\NN\14299637 induced_14\VBN\1627355 by_15\IN\1740 blockage_16\NN\14034177 of_17\IN\1740 tubular_18\JJ\1740 <e1>glucose</e1>_19\NN\14710501 reabsorption_20\NN\13526110 with_21\IN\1740 phlorizin_22\NN\1740 (_23\-LRB-\1740 p_24\NN\14622893 )_25\-RRB-\1740 ._26\.\1740
D005947_D003920 NONE the_0\DT\1740 protection_1\NN\407535 from_2\IN\1740 gentamicin_3\NN\2716866 nephrotoxicity_4\NN\1740 was_5\VBD\836236 studied_6\VBN\630380 in_7\IN\13603305 <e2>non-diabetic</e2>_8\JJ\1740 rats_9\NNS\2329401 with_10\IN\1740 chronic_11\JJ\1740 solute_12\JJ\1740 diuresis_13\NN\14299637 induced_14\VBN\1627355 by_15\IN\1740 blockage_16\NN\14034177 of_17\IN\1740 tubular_18\JJ\1740 <e1>glucose</e1>_19\NN\14710501 reabsorption_20\NN\13526110 with_21\IN\1740 phlorizin_22\NN\1740 (_23\-LRB-\1740 p_24\NN\14622893 )_25\-RRB-\1740 ._26\.\1740
D010695_D003920 NONE the_0\DT\1740 protection_1\NN\407535 from_2\IN\1740 gentamicin_3\NN\2716866 nephrotoxicity_4\NN\1740 was_5\VBD\836236 studied_6\VBN\630380 in_7\IN\13603305 <e2>non-diabetic</e2>_8\JJ\1740 rats_9\NNS\2329401 with_10\IN\1740 chronic_11\JJ\1740 solute_12\JJ\1740 diuresis_13\NN\14299637 induced_14\VBN\1627355 by_15\IN\1740 blockage_16\NN\14034177 of_17\IN\1740 tubular_18\JJ\1740 glucose_19\NN\14710501 reabsorption_20\NN\13526110 with_21\IN\1740 <e1>phlorizin</e1>_22\NN\1740 (_23\-LRB-\1740 p_24\NN\14622893 )_25\-RRB-\1740 ._26\.\1740
D010695_D003920 NONE the_0\DT\1740 protection_1\NN\407535 from_2\IN\1740 gentamicin_3\NN\2716866 nephrotoxicity_4\NN\1740 was_5\VBD\836236 studied_6\VBN\630380 in_7\IN\13603305 <e2>non-diabetic</e2>_8\JJ\1740 rats_9\NNS\2329401 with_10\IN\1740 chronic_11\JJ\1740 solute_12\JJ\1740 diuresis_13\NN\14299637 induced_14\VBN\1627355 by_15\IN\1740 blockage_16\NN\14034177 of_17\IN\1740 tubular_18\JJ\1740 glucose_19\NN\14710501 reabsorption_20\NN\13526110 with_21\IN\1740 phlorizin_22\NN\1740 (_23\-LRB-\1740 <e1>p</e1>_24\NN\14622893 )_25\-RRB-\1740 ._26\.\1740
D010695_D003920 NONE <e2>dm</e2>_0\NN\14117805 rats_1\NNS\2329401 with_2\IN\1740 mild_3\JJ\1740 glycosuria_4\NN\14299637 (_5\-LRB-\1740 similar_6\JJ\1740 in_7\IN\13603305 degree_8\NN\4916342 to_9\TO\1740 that_10\DT\1740 of_11\IN\1740 the_12\DT\1740 <e1>p</e1>_13\NN\14622893 treated_14\JJ\1740 animals_15\NNS\4475 )_16\-RRB-\1740 were_17\VBD\836236 also_18\RB\1740 studied_19\VBN\630380 ._20\.\1740
D010695_D003920 NONE group_0\NN\2137 1_1\CD\13741022 (_2\-LRB-\1740 <e1>p</e1>_3\NN\14622893 alone_4\RB\1740 )_5\-RRB-\1740 received_6\VBD\2210855 p_7\NN\14622893 ,_8\,\1740 360_9\CD\1740 mg/day_10\NN\1740 ,_11\,\1740 for_12\IN\1740 15_13\CD\13745420 days_14\NNS\15140892 ;_15\:\1740 group_16\NN\2137 ii_17\CD\13741022 (_18\-LRB-\1740 p_19\NN\14622893 +_20\CC\1740 gentamicin_21\NN\2716866 )_22\-RRB-\1740 ;_23\:\1740 group_24\NN\2137 iii_25\CD\13741022 (_26\-LRB-\1740 gentamicin_27\NN\2716866 alone_28\RB\1740 )_29\-RRB-\1740 and_30\CC\1740 group_31\NN\2137 iv_32\CD\13741022 (_33\-LRB-\1740 mild_34\JJ\1740 <e2>dm</e2>_35\NN\14117805 +_36\CC\1740 gentamicin_37\NN\2716866 )_38\-RRB-\1740 ._39\.\1740
D010695_D003920 NONE group_0\NN\2137 1_1\CD\13741022 (_2\-LRB-\1740 p_3\NN\14622893 alone_4\RB\1740 )_5\-RRB-\1740 received_6\VBD\2210855 <e1>p</e1>_7\NN\14622893 ,_8\,\1740 360_9\CD\1740 mg/day_10\NN\1740 ,_11\,\1740 for_12\IN\1740 15_13\CD\13745420 days_14\NNS\15140892 ;_15\:\1740 group_16\NN\2137 ii_17\CD\13741022 (_18\-LRB-\1740 p_19\NN\14622893 +_20\CC\1740 gentamicin_21\NN\2716866 )_22\-RRB-\1740 ;_23\:\1740 group_24\NN\2137 iii_25\CD\13741022 (_26\-LRB-\1740 gentamicin_27\NN\2716866 alone_28\RB\1740 )_29\-RRB-\1740 and_30\CC\1740 group_31\NN\2137 iv_32\CD\13741022 (_33\-LRB-\1740 mild_34\JJ\1740 <e2>dm</e2>_35\NN\14117805 +_36\CC\1740 gentamicin_37\NN\2716866 )_38\-RRB-\1740 ._39\.\1740
D010695_D003920 NONE group_0\NN\2137 1_1\CD\13741022 (_2\-LRB-\1740 p_3\NN\14622893 alone_4\RB\1740 )_5\-RRB-\1740 received_6\VBD\2210855 p_7\NN\14622893 ,_8\,\1740 360_9\CD\1740 mg/day_10\NN\1740 ,_11\,\1740 for_12\IN\1740 15_13\CD\13745420 days_14\NNS\15140892 ;_15\:\1740 group_16\NN\2137 ii_17\CD\13741022 (_18\-LRB-\1740 <e1>p</e1>_19\NN\14622893 +_20\CC\1740 gentamicin_21\NN\2716866 )_22\-RRB-\1740 ;_23\:\1740 group_24\NN\2137 iii_25\CD\13741022 (_26\-LRB-\1740 gentamicin_27\NN\2716866 alone_28\RB\1740 )_29\-RRB-\1740 and_30\CC\1740 group_31\NN\2137 iv_32\CD\13741022 (_33\-LRB-\1740 mild_34\JJ\1740 <e2>dm</e2>_35\NN\14117805 +_36\CC\1740 gentamicin_37\NN\2716866 )_38\-RRB-\1740 ._39\.\1740
D010695_D009956 NONE in_0\IN\13603305 group_1\NNP\2137 i_2\CD\14622893 ,_3\,\1740 <e1>p</e1>_4\NN\14622893 induced_5\VBD\1627355 a_6\DT\13649268 moderate_7\JJ\1740 and_8\CC\1740 stable_9\JJ\1740 glycosuria_10\NN\14299637 (_11\-LRB-\1740 3.9_12\CD\1740 +/-_13\CC\1740 0.1_14\CD\1740 g/day_15\NN\1740 ,_16\,\1740 se_17\NN\14724645 )_18\-RRB-\1740 ,_19\,\1740 and_20\CC\1740 no_21\DT\7204911 functional_22\JJ\1740 or_23\CC\3541091 morphologic_24\JJ\1740 evidence_25\NN\5816287 of_26\IN\1740 renal_27\JJ\1740 dysfunction_28\NN\14204950 (_29\-LRB-\1740 baseline_30\NN\7260623 ccr_31\NNS\1740 2.1_32\CD\1740 +/-_33\CC\1740 0.1_34\CD\1740 ml/min_35\NN\1740 ,_36\,\1740 undetectable_37\JJ\1740 lysozymuria_38\NNS\1740 )_39\-RRB-\1740 or_40\CC\3541091 damage_41\NN\7296428 (_42\-LRB-\1740 <e2>tubular_43\JJ\1740 necrosis</e2>_44\NN\11444117 score_45\NN\5736149 [_46\-LRB-\1740 maximum_47\NN\13653902 4_48\CD\13741022 ]_49\-RRB-\1740 ,_50\,\1740 zero_51\CD\13576982 )_52\-RRB-\1740 ._53\.\1740
D010695_D009956 NONE in_0\IN\13603305 group_1\NNP\2137 ii_2\CD\13741022 ,_3\,\1740 <e1>p</e1>_4\NN\14622893 did_5\VBD\1640855 not_6\RB\1740 prevent_7\VB\1740 gentamicin-arf_8\NN\1740 (_9\-LRB-\1740 maximal_10\JJ\1740 decrease_11\NN\7296428 in_12\IN\13603305 ccr_13\NNS\1740 at_14\IN\14622893 day_15\NN\15154774 9.89_16\CD\1740 %_17\NN\1740 ,_18\,\1740 p_19\NN\14622893 less_20\JJR\1740 than_21\IN\1740 0.001_22\CD\1740 ;_23\:\1740 peak_24\NN\13758296 lysozymuria_25\NNS\1740 ,_26\,\1740 1863_27\CD\1740 +/-_28\CC\1740 321_29\CD\1740 micrograms/day_30\NN\1740 ;_31\:\1740 and_32\CC\1740 <e2>tubular_33\JJ\1740 necrosis</e2>_34\NN\11444117 score_35\NN\5736149 ,_36\,\1740 3.9_37\CD\1740 +/-_38\CC\1740 0.1_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
D010695_D009956 NONE in_0\IN\13603305 group_1\NNP\2137 ii_2\CD\13741022 ,_3\,\1740 p_4\NN\14622893 did_5\VBD\1640855 not_6\RB\1740 prevent_7\VB\1740 gentamicin-arf_8\NN\1740 (_9\-LRB-\1740 maximal_10\JJ\1740 decrease_11\NN\7296428 in_12\IN\13603305 ccr_13\NNS\1740 at_14\IN\14622893 day_15\NN\15154774 9.89_16\CD\1740 %_17\NN\1740 ,_18\,\1740 <e1>p</e1>_19\NN\14622893 less_20\JJR\1740 than_21\IN\1740 0.001_22\CD\1740 ;_23\:\1740 peak_24\NN\13758296 lysozymuria_25\NNS\1740 ,_26\,\1740 1863_27\CD\1740 +/-_28\CC\1740 321_29\CD\1740 micrograms/day_30\NN\1740 ;_31\:\1740 and_32\CC\1740 <e2>tubular_33\JJ\1740 necrosis</e2>_34\NN\11444117 score_35\NN\5736149 ,_36\,\1740 3.9_37\CD\1740 +/-_38\CC\1740 0.1_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
D010695_D009956 NONE these_0\DT\1740 values_1\NNS\5941423 were_2\VBD\836236 not_3\RB\1740 different_4\JJ\1740 from_5\IN\1740 those_6\DT\1740 of_7\IN\1740 group_8\NNP\2137 iii_9\CD\13741022 :_10\:\1740 maximal_11\JJ\1740 decrease_12\NN\7296428 in_13\IN\13603305 ccr_14\NN\1740 73_15\CD\1740 %_16\NN\1740 (_17\-LRB-\1740 <e1>p</e1>_18\NN\14622893 less_19\JJR\1740 than_20\IN\1740 0.001_21\CD\1740 )_22\-RRB-\1740 ;_23\:\1740 lysozymuria_24\NNS\1740 ,_25\,\1740 2147_26\CD\1740 +/-_27\CC\1740 701_28\CD\1740 micrograms/day_29\NN\1740 ;_30\:\1740 <e2>tubular_31\JJ\1740 necrosis</e2>_32\NN\11444117 score_33\NN\5736149 ,_34\,\1740 3.8_35\CD\1740 +/-_36\CC\1740 0.1_37\CD\1740 ._38\.\1740
D010695_D058186 NONE in_0\IN\13603305 group_1\NNP\2137 ii_2\CD\13741022 ,_3\,\1740 <e1>p</e1>_4\NN\14622893 did_5\VBD\1640855 not_6\RB\1740 prevent_7\VB\1740 <e2>gentamicin-arf</e2>_8\NN\1740 (_9\-LRB-\1740 maximal_10\JJ\1740 decrease_11\NN\7296428 in_12\IN\13603305 ccr_13\NNS\1740 at_14\IN\14622893 day_15\NN\15154774 9.89_16\CD\1740 %_17\NN\1740 ,_18\,\1740 p_19\NN\14622893 less_20\JJR\1740 than_21\IN\1740 0.001_22\CD\1740 ;_23\:\1740 peak_24\NN\13758296 lysozymuria_25\NNS\1740 ,_26\,\1740 1863_27\CD\1740 +/-_28\CC\1740 321_29\CD\1740 micrograms/day_30\NN\1740 ;_31\:\1740 and_32\CC\1740 tubular_33\JJ\1740 necrosis_34\NN\11444117 score_35\NN\5736149 ,_36\,\1740 3.9_37\CD\1740 +/-_38\CC\1740 0.1_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
D010695_D058186 NONE in_0\IN\13603305 group_1\NNP\2137 ii_2\CD\13741022 ,_3\,\1740 p_4\NN\14622893 did_5\VBD\1640855 not_6\RB\1740 prevent_7\VB\1740 <e2>gentamicin-arf</e2>_8\NN\1740 (_9\-LRB-\1740 maximal_10\JJ\1740 decrease_11\NN\7296428 in_12\IN\13603305 ccr_13\NNS\1740 at_14\IN\14622893 day_15\NN\15154774 9.89_16\CD\1740 %_17\NN\1740 ,_18\,\1740 <e1>p</e1>_19\NN\14622893 less_20\JJR\1740 than_21\IN\1740 0.001_22\CD\1740 ;_23\:\1740 peak_24\NN\13758296 lysozymuria_25\NNS\1740 ,_26\,\1740 1863_27\CD\1740 +/-_28\CC\1740 321_29\CD\1740 micrograms/day_30\NN\1740 ;_31\:\1740 and_32\CC\1740 tubular_33\JJ\1740 necrosis_34\NN\11444117 score_35\NN\5736149 ,_36\,\1740 3.9_37\CD\1740 +/-_38\CC\1740 0.1_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
D005839_D009956 NONE in_0\IN\13603305 group_1\NNP\2137 ii_2\CD\13741022 ,_3\,\1740 p_4\NN\14622893 did_5\VBD\1640855 not_6\RB\1740 prevent_7\VB\1740 <e1>gentamicin-arf</e1>_8\NN\1740 (_9\-LRB-\1740 maximal_10\JJ\1740 decrease_11\NN\7296428 in_12\IN\13603305 ccr_13\NNS\1740 at_14\IN\14622893 day_15\NN\15154774 9.89_16\CD\1740 %_17\NN\1740 ,_18\,\1740 p_19\NN\14622893 less_20\JJR\1740 than_21\IN\1740 0.001_22\CD\1740 ;_23\:\1740 peak_24\NN\13758296 lysozymuria_25\NNS\1740 ,_26\,\1740 1863_27\CD\1740 +/-_28\CC\1740 321_29\CD\1740 micrograms/day_30\NN\1740 ;_31\:\1740 and_32\CC\1740 <e2>tubular_33\JJ\1740 necrosis</e2>_34\NN\11444117 score_35\NN\5736149 ,_36\,\1740 3.9_37\CD\1740 +/-_38\CC\1740 0.1_39\CD\1740 )_40\-RRB-\1740 ._41\.\1740
15531665
D001205_D002318 CID does_0\VBZ\1640855 supplemental_1\JJ\1740 <e1>vitamin_2\NN\7570720 c</e1>_3\NN\13714184 increase_4\VBP\169651 <e2>cardiovascular_5\JJ\1740 disease</e2>_6\NN\14061805 risk_7\NN\14541044 in_8\IN\13603305 women_9\NNS\9605289 with_10\IN\1740 diabetes_11\NNS\14075199 ?_12\.\1740
D001205_D002318 CID objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 objective_3\NN\5980875 was_4\VBD\836236 to_5\TO\1740 examine_6\VB\789138 the_7\DT\1740 relation_8\NN\2137 between_9\IN\1740 <e1>vitamin_10\NN\7570720 c</e1>_11\NN\13714184 intake_12\NN\13440063 and_13\CC\1740 mortality_14\NN\5054863 from_15\IN\1740 <e2>cardiovascular_16\JJ\1740 disease</e2>_17\NN\14061805 ._18\.\1740
D001205_D002318 CID design_0\NN\927261 :_1\:\1740 we_2\PRP\1740 studied_3\VBD\630380 the_4\DT\1740 relation_5\NN\2137 between_6\IN\1740 <e1>vitamin_7\NN\7570720 c</e1>_8\NN\13714184 intake_9\NN\13440063 and_10\CC\1740 mortality_11\NN\5054863 from_12\IN\1740 total_13\JJ\1740 <e2>cardiovascular_14\JJ\1740 disease</e2>_15\NN\14061805 (_16\-LRB-\1740 n_17\NN\14622893 =_18\JJ\1740 281_19\CD\1740 )_20\-RRB-\1740 ,_21\,\1740 coronary_22\JJ\1740 artery_23\NN\5417975 disease_24\NN\14061805 (_25\-LRB-\1740 n_26\NN\14622893 =_27\JJ\1740 175_28\CD\1740 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 stroke_32\NN\556313 (_33\-LRB-\1740 n_34\NN\14622893 =_35\JJ\1740 57_36\CD\1740 )_37\-RRB-\1740 in_38\IN\13603305 1923_39\CD\1740 postmenopausal_40\JJ\1740 women_41\NNS\9605289 who_42\WP\8299493 reported_43\VBD\831651 being_44\VBG\836236 diabetic_45\JJ\1740 at_46\IN\14622893 baseline_47\NN\7260623 ._48\.\1740
D001205_D002318 CID diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 <e2>cardiovascular_29\JJ\1740 disease</e2>_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 <e1>vitamin_86\NN\7570720 c</e1>_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D001205_D002318 CID diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 <e2>cardiovascular_61\JJ\1740 disease</e2>_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 <e1>vitamin_86\NN\7570720 c</e1>_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D001205_D002318 CID <e1>vitamin_0\NN\7570720 c</e1>_1\NN\13714184 intake_2\NN\13440063 was_3\VBD\836236 unrelated_4\JJ\1740 to_5\TO\1740 mortality_6\NN\5054863 from_7\IN\1740 <e2>cardiovascular_8\JJ\1740 disease</e2>_9\NN\14061805 in_10\IN\13603305 the_11\DT\1740 nondiabetic_12\JJ\1740 subjects_13\NNS\6598915 at_14\IN\14622893 baseline_15\NN\7260623 ._16\.\1740
D001205_D002318 CID conclusion_0\NN\5837957 :_1\:\1740 a_2\DT\13649268 high_3\JJ\1740 <e1>vitamin_4\NN\7570720 c</e1>_5\NN\13714184 intake_6\NN\13440063 from_7\IN\1740 supplements_8\NNS\6365467 is_9\VBZ\836236 associated_10\VBN\628491 with_11\IN\1740 an_12\DT\6697703 increased_13\VBN\169651 risk_14\NN\14541044 of_15\IN\1740 <e2>cardiovascular_16\JJ\1740 disease</e2>_17\NN\14061805 mortality_18\NN\5054863 in_19\IN\13603305 postmenopausal_20\JJ\1740 women_21\NNS\9605289 with_22\IN\1740 diabetes_23\NNS\14075199 ._24\.\1740
D001205_D003920 NONE does_0\VBZ\1640855 supplemental_1\JJ\1740 <e1>vitamin_2\NN\7570720 c</e1>_3\NN\13714184 increase_4\VBP\169651 cardiovascular_5\JJ\1740 disease_6\NN\14061805 risk_7\NN\14541044 in_8\IN\13603305 women_9\NNS\9605289 with_10\IN\1740 <e2>diabetes</e2>_11\NNS\14075199 ?_12\.\1740
D001205_D003920 NONE these_0\DT\1740 observations_1\NNS\996969 led_2\VBD\1752884 us_3\PRP\14964590 to_4\TO\1740 hypothesize_5\VB\719734 that_6\IN\1740 a_7\DT\13649268 high_8\JJ\1740 intake_9\NN\13440063 of_10\IN\1740 <e1>vitamin_11\NN\7570720 c</e1>_12\NN\13714184 in_13\IN\13603305 <e2>diabetic</e2>_14\JJ\1740 persons_15\NNS\7347 might_16\MD\5029706 promote_17\VB\2556126 atherosclerosis_18\NN\14108324 ._19\.\1740
D001205_D003920 NONE design_0\NN\927261 :_1\:\1740 we_2\PRP\1740 studied_3\VBD\630380 the_4\DT\1740 relation_5\NN\2137 between_6\IN\1740 <e1>vitamin_7\NN\7570720 c</e1>_8\NN\13714184 intake_9\NN\13440063 and_10\CC\1740 mortality_11\NN\5054863 from_12\IN\1740 total_13\JJ\1740 cardiovascular_14\JJ\1740 disease_15\NN\14061805 (_16\-LRB-\1740 n_17\NN\14622893 =_18\JJ\1740 281_19\CD\1740 )_20\-RRB-\1740 ,_21\,\1740 coronary_22\JJ\1740 artery_23\NN\5417975 disease_24\NN\14061805 (_25\-LRB-\1740 n_26\NN\14622893 =_27\JJ\1740 175_28\CD\1740 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 stroke_32\NN\556313 (_33\-LRB-\1740 n_34\NN\14622893 =_35\JJ\1740 57_36\CD\1740 )_37\-RRB-\1740 in_38\IN\13603305 1923_39\CD\1740 postmenopausal_40\JJ\1740 women_41\NNS\9605289 who_42\WP\8299493 reported_43\VBD\831651 being_44\VBG\836236 <e2>diabetic</e2>_45\JJ\1740 at_46\IN\14622893 baseline_47\NN\7260623 ._48\.\1740
D001205_D003920 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 <e2>diabetes</e2>_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 <e1>vitamin_86\NN\7570720 c</e1>_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D001205_D003920 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 <e2>diabetes</e2>_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 <e1>vitamin_86\NN\7570720 c</e1>_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D001205_D003920 NONE conclusion_0\NN\5837957 :_1\:\1740 a_2\DT\13649268 high_3\JJ\1740 <e1>vitamin_4\NN\7570720 c</e1>_5\NN\13714184 intake_6\NN\13440063 from_7\IN\1740 supplements_8\NNS\6365467 is_9\VBZ\836236 associated_10\VBN\628491 with_11\IN\1740 an_12\DT\6697703 increased_13\VBN\169651 risk_14\NN\14541044 of_15\IN\1740 cardiovascular_16\JJ\1740 disease_17\NN\14061805 mortality_18\NN\5054863 in_19\IN\13603305 postmenopausal_20\JJ\1740 women_21\NNS\9605289 with_22\IN\1740 <e2>diabetes</e2>_23\NNS\14075199 ._24\.\1740
D001205_D050197 NONE these_0\DT\1740 observations_1\NNS\996969 led_2\VBD\1752884 us_3\PRP\14964590 to_4\TO\1740 hypothesize_5\VB\719734 that_6\IN\1740 a_7\DT\13649268 high_8\JJ\1740 intake_9\NN\13440063 of_10\IN\1740 <e1>vitamin_11\NN\7570720 c</e1>_12\NN\13714184 in_13\IN\13603305 diabetic_14\JJ\1740 persons_15\NNS\7347 might_16\MD\5029706 promote_17\VB\2556126 <e2>atherosclerosis</e2>_18\NN\14108324 ._19\.\1740
D001205_D003324 NONE design_0\NN\927261 :_1\:\1740 we_2\PRP\1740 studied_3\VBD\630380 the_4\DT\1740 relation_5\NN\2137 between_6\IN\1740 <e1>vitamin_7\NN\7570720 c</e1>_8\NN\13714184 intake_9\NN\13440063 and_10\CC\1740 mortality_11\NN\5054863 from_12\IN\1740 total_13\JJ\1740 cardiovascular_14\JJ\1740 disease_15\NN\14061805 (_16\-LRB-\1740 n_17\NN\14622893 =_18\JJ\1740 281_19\CD\1740 )_20\-RRB-\1740 ,_21\,\1740 <e2>coronary_22\JJ\1740 artery_23\NN\5417975 disease</e2>_24\NN\14061805 (_25\-LRB-\1740 n_26\NN\14622893 =_27\JJ\1740 175_28\CD\1740 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 stroke_32\NN\556313 (_33\-LRB-\1740 n_34\NN\14622893 =_35\JJ\1740 57_36\CD\1740 )_37\-RRB-\1740 in_38\IN\13603305 1923_39\CD\1740 postmenopausal_40\JJ\1740 women_41\NNS\9605289 who_42\WP\8299493 reported_43\VBD\831651 being_44\VBG\836236 diabetic_45\JJ\1740 at_46\IN\14622893 baseline_47\NN\7260623 ._48\.\1740
D001205_D003324 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 <e2>coronary_15\JJ\1740 artery_16\NN\5417975 disease</e2>_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 <e1>vitamin_86\NN\7570720 c</e1>_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D001205_D020521 NONE design_0\NN\927261 :_1\:\1740 we_2\PRP\1740 studied_3\VBD\630380 the_4\DT\1740 relation_5\NN\2137 between_6\IN\1740 <e1>vitamin_7\NN\7570720 c</e1>_8\NN\13714184 intake_9\NN\13440063 and_10\CC\1740 mortality_11\NN\5054863 from_12\IN\1740 total_13\JJ\1740 cardiovascular_14\JJ\1740 disease_15\NN\14061805 (_16\-LRB-\1740 n_17\NN\14622893 =_18\JJ\1740 281_19\CD\1740 )_20\-RRB-\1740 ,_21\,\1740 coronary_22\JJ\1740 artery_23\NN\5417975 disease_24\NN\14061805 (_25\-LRB-\1740 n_26\NN\14622893 =_27\JJ\1740 175_28\CD\1740 )_29\-RRB-\1740 ,_30\,\1740 and_31\CC\1740 <e2>stroke</e2>_32\NN\556313 (_33\-LRB-\1740 n_34\NN\14622893 =_35\JJ\1740 57_36\CD\1740 )_37\-RRB-\1740 in_38\IN\13603305 1923_39\CD\1740 postmenopausal_40\JJ\1740 women_41\NNS\9605289 who_42\WP\8299493 reported_43\VBD\831651 being_44\VBG\836236 diabetic_45\JJ\1740 at_46\IN\14622893 baseline_47\NN\7260623 ._48\.\1740
D005492_D003324 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 <e2>coronary_15\JJ\1740 artery_16\NN\5417975 disease</e2>_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 <e1>folate</e1>_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D005492_D002318 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 <e2>cardiovascular_29\JJ\1740 disease</e2>_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 <e1>folate</e1>_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D005492_D002318 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 <e1>folate</e1>_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 <e2>cardiovascular_61\JJ\1740 disease</e2>_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D005492_D003920 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 <e2>diabetes</e2>_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 <e1>folate</e1>_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D005492_D003920 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 <e2>diabetes</e2>_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 <e1>folate</e1>_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D014810_D003324 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 <e2>coronary_15\JJ\1740 artery_16\NN\5417975 disease</e2>_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 <e1>vitamin_49\NN\7570720 e</e1>_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D014810_D002318 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 <e2>cardiovascular_29\JJ\1740 disease</e2>_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 <e1>vitamin_49\NN\7570720 e</e1>_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D014810_D002318 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 <e1>vitamin_49\NN\7570720 e</e1>_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 <e2>cardiovascular_61\JJ\1740 disease</e2>_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D014810_D003920 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 <e2>diabetes</e2>_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 <e1>vitamin_49\NN\7570720 e</e1>_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D014810_D003920 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 <e2>diabetes</e2>_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 <e1>vitamin_49\NN\7570720 e</e1>_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 beta-carotene_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D019207_D003324 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 <e2>coronary_15\JJ\1740 artery_16\NN\5417975 disease</e2>_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 <e1>beta-carotene</e1>_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D019207_D002318 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 <e2>cardiovascular_29\JJ\1740 disease</e2>_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 <e1>beta-carotene</e1>_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D019207_D002318 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 <e1>beta-carotene</e1>_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 <e2>cardiovascular_61\JJ\1740 disease</e2>_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D019207_D003920 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 <e2>diabetes</e2>_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 diabetes_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 <e1>beta-carotene</e1>_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
D019207_D003920 NONE diet_0\NNP\7560652 was_1\VBD\836236 assessed_2\VBN\670261 with_3\IN\1740 a_4\DT\13649268 food-frequency_5\JJ\1740 questionnaire_6\NN\6473563 at_7\IN\14622893 baseline_8\NN\7260623 ,_9\,\1740 and_10\CC\1740 subjects_11\NNS\6598915 initially_12\RB\1740 free_13\JJ\1740 of_14\IN\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 were_18\VBD\836236 prospectively_19\RB\1740 followed_20\VBN\1835496 for_21\IN\1740 15_22\CD\13745420 y._23\NN\1740 results_24\NNS\34213 :_25\:\1740 after_26\IN\1740 adjustment_27\NN\7357388 for_28\IN\1740 cardiovascular_29\JJ\1740 disease_30\NN\14061805 risk_31\NN\14541044 factors_32\NNS\7326557 ,_33\,\1740 type_34\NN\5839024 of_35\IN\1740 diabetes_36\NN\14075199 medication_37\NN\3247620 used_38\VBN\1156834 ,_39\,\1740 duration_40\NN\15113229 of_41\IN\1740 <e2>diabetes</e2>_42\NNS\14075199 ,_43\,\1740 and_44\CC\1740 intakes_45\NNS\13440063 of_46\IN\1740 folate_47\NN\15090742 ,_48\,\1740 vitamin_49\NN\7570720 e_50\NN\14724645 ,_51\,\1740 and_52\CC\1740 <e1>beta-carotene</e1>_53\NN\14720962 ,_54\,\1740 the_55\DT\1740 adjusted_56\VBN\126264 relative_57\JJ\1740 risks_58\NNS\14541044 of_59\IN\1740 total_60\JJ\1740 cardiovascular_61\JJ\1740 disease_62\NN\14061805 mortality_63\NN\5054863 were_64\VBD\836236 1.0_65\CD\1740 ,_66\,\1740 0.97_67\CD\1740 ,_68\,\1740 1.11_69\CD\1740 ,_70\,\1740 1.47_71\CD\1740 ,_72\,\1740 and_73\CC\1740 1.84_74\CD\1740 (_75\-LRB-\1740 p_76\NN\14622893 for_77\IN\1740 trend_78\NN\8679972 <_79\XX\1740 0.01_80\CD\1740 )_81\-RRB-\1740 across_82\IN\1740 quintiles_83\NNS\1740 of_84\IN\1740 total_85\JJ\1740 vitamin_86\NN\7570720 c_87\NN\13714184 intake_88\NN\13440063 from_89\IN\1740 food_90\NN\20090 and_91\CC\1740 supplements_92\NNS\6365467 ._93\.\1740
16563323
C071741_D009207 NONE <e1>remifentanil</e1>_0\NN\1740 pretreatment_1\NN\1740 reduces_2\VBZ\441445 <e2>myoclonus</e2>_3\NN\14360459 after_4\IN\1740 etomidate_5\NN\1740 ._6\.\1740
C071741_D009207 NONE study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 the_3\DT\1740 aim_4\NN\5980875 of_5\IN\1740 the_6\DT\1740 study_7\NN\635850 was_8\VBD\836236 to_9\TO\1740 compare_10\VB\644583 the_11\DT\1740 effect_12\NN\34213 of_13\IN\1740 pretreatment_14\NN\1740 with_15\IN\1740 <e1>remifentanil</e1>_16\NN\1740 1_17\CD\13741022 microg/kg_18\NN\1740 and_19\CC\1740 the_20\DT\1740 effect_21\NN\34213 of_22\IN\1740 gender_23\NN\6309383 on_24\IN\1740 the_25\DT\1740 incidence_26\NN\13821570 of_27\IN\1740 <e2>myoclonus</e2>_28\NN\14360459 after_29\IN\1740 anesthesia_30\NN\14034177 induction_31\NN\7450842 with_32\IN\1740 etomidate_33\NN\1740 ._34\.\1740
C071741_D009207 NONE main_0\JJ\1740 results_1\NNS\34213 :_2\:\1740 the_3\DT\1740 incidence_4\NN\13821570 of_5\IN\1740 <e2>myoclonus</e2>_6\NN\14360459 was_7\VBD\836236 significantly_8\RB\1740 lower_9\JJR\1740 in_10\IN\13603305 the_11\DT\1740 <e1>remifentanil</e1>_12\NN\1740 group_13\NN\2137 (_14\-LRB-\1740 6.7_15\CD\1740 %_16\NN\1740 )_17\-RRB-\1740 than_18\IN\1740 in_19\IN\13603305 the_20\DT\1740 placebo_21\NN\3740161 group_22\NN\2137 (_23\-LRB-\1740 70_24\CD\13745420 %_25\NN\1740 )_26\-RRB-\1740 (_27\-LRB-\1740 p_28\NN\14622893 <_29\XX\1740 0.001_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
C071741_D009207 NONE conclusion_0\NN\5837957 :_1\:\1740 pretreatment_2\NN\1740 with_3\IN\1740 <e1>remifentanil</e1>_4\NN\1740 1_5\CD\13741022 microg/kg_6\NN\1740 reduced_7\VBD\441445 <e2>myoclonus</e2>_8\NN\14360459 after_9\IN\1740 etomidate_10\NN\1740 induction_11\NN\7450842 without_12\IN\1740 side_13\NN\8630039 effects_14\NNS\13245626 such_15\JJ\1740 as_16\IN\14622893 sedation_17\NN\14034177 ,_18\,\1740 apnea_19\NN\14299637 ,_20\,\1740 nausea_21\NN\14299637 ,_22\,\1740 or_23\CC\3541091 pruritus_24\NN\5723563 ._25\.\1740
D005045_D009207 CID remifentanil_0\NN\1740 pretreatment_1\NN\1740 reduces_2\VBZ\441445 <e2>myoclonus</e2>_3\NN\14360459 after_4\IN\1740 <e1>etomidate</e1>_5\NN\1740 ._6\.\1740
D005045_D009207 CID study_0\VB\630380 objective_1\NN\5980875 :_2\:\1740 the_3\DT\1740 aim_4\NN\5980875 of_5\IN\1740 the_6\DT\1740 study_7\NN\635850 was_8\VBD\836236 to_9\TO\1740 compare_10\VB\644583 the_11\DT\1740 effect_12\NN\34213 of_13\IN\1740 pretreatment_14\NN\1740 with_15\IN\1740 remifentanil_16\NN\1740 1_17\CD\13741022 microg/kg_18\NN\1740 and_19\CC\1740 the_20\DT\1740 effect_21\NN\34213 of_22\IN\1740 gender_23\NN\6309383 on_24\IN\1740 the_25\DT\1740 incidence_26\NN\13821570 of_27\IN\1740 <e2>myoclonus</e2>_28\NN\14360459 after_29\IN\1740 anesthesia_30\NN\14034177 induction_31\NN\7450842 with_32\IN\1740 <e1>etomidate</e1>_33\NN\1740 ._34\.\1740
D005045_D009207 CID in_0\IN\13603305 the_1\DT\1740 placebo_2\NN\3740161 group_3\NN\2137 ,_4\,\1740 male_5\JJ\1740 patients_6\NNS\9898892 were_7\VBD\836236 associated_8\VBN\628491 with_9\IN\1740 significantly_10\RB\1740 increased_11\VBD\169651 incidence_12\NN\13821570 of_13\IN\1740 <e2>myoclonus</e2>_14\NN\14360459 after_15\IN\1740 <e1>etomidate</e1>_16\JJ\1740 administration_17\NN\1133281 ._18\.\1740
D005045_D009207 CID conclusion_0\NN\5837957 :_1\:\1740 pretreatment_2\NN\1740 with_3\IN\1740 remifentanil_4\NN\1740 1_5\CD\13741022 microg/kg_6\NN\1740 reduced_7\VBD\441445 <e2>myoclonus</e2>_8\NN\14360459 after_9\IN\1740 <e1>etomidate</e1>_10\NN\1740 induction_11\NN\7450842 without_12\IN\1740 side_13\NN\8630039 effects_14\NNS\13245626 such_15\JJ\1740 as_16\IN\14622893 sedation_17\NN\14034177 ,_18\,\1740 apnea_19\NN\14299637 ,_20\,\1740 nausea_21\NN\14299637 ,_22\,\1740 or_23\CC\3541091 pruritus_24\NN\5723563 ._25\.\1740
D005045_D009207 CID men_0\NN\8208016 experience_1\NN\5984287 increased_2\VBD\169651 incidence_3\NN\13821570 of_4\IN\1740 <e2>myoclonus</e2>_5\NN\14360459 than_6\IN\1740 women_7\NNS\9605289 after_8\IN\1740 <e1>etomidate</e1>_9\JJ\1740 administration_10\NN\1133281 ._11\.\1740
C071741_D001049 NONE conclusion_0\NN\5837957 :_1\:\1740 pretreatment_2\NN\1740 with_3\IN\1740 <e1>remifentanil</e1>_4\NN\1740 1_5\CD\13741022 microg/kg_6\NN\1740 reduced_7\VBD\441445 myoclonus_8\NN\14360459 after_9\IN\1740 etomidate_10\NN\1740 induction_11\NN\7450842 without_12\IN\1740 side_13\NN\8630039 effects_14\NNS\13245626 such_15\JJ\1740 as_16\IN\14622893 sedation_17\NN\14034177 ,_18\,\1740 <e2>apnea</e2>_19\NN\14299637 ,_20\,\1740 nausea_21\NN\14299637 ,_22\,\1740 or_23\CC\3541091 pruritus_24\NN\5723563 ._25\.\1740
C071741_D009325 NONE conclusion_0\NN\5837957 :_1\:\1740 pretreatment_2\NN\1740 with_3\IN\1740 <e1>remifentanil</e1>_4\NN\1740 1_5\CD\13741022 microg/kg_6\NN\1740 reduced_7\VBD\441445 myoclonus_8\NN\14360459 after_9\IN\1740 etomidate_10\NN\1740 induction_11\NN\7450842 without_12\IN\1740 side_13\NN\8630039 effects_14\NNS\13245626 such_15\JJ\1740 as_16\IN\14622893 sedation_17\NN\14034177 ,_18\,\1740 apnea_19\NN\14299637 ,_20\,\1740 <e2>nausea</e2>_21\NN\14299637 ,_22\,\1740 or_23\CC\3541091 pruritus_24\NN\5723563 ._25\.\1740
C071741_D011537 NONE conclusion_0\NN\5837957 :_1\:\1740 pretreatment_2\NN\1740 with_3\IN\1740 <e1>remifentanil</e1>_4\NN\1740 1_5\CD\13741022 microg/kg_6\NN\1740 reduced_7\VBD\441445 myoclonus_8\NN\14360459 after_9\IN\1740 etomidate_10\NN\1740 induction_11\NN\7450842 without_12\IN\1740 side_13\NN\8630039 effects_14\NNS\13245626 such_15\JJ\1740 as_16\IN\14622893 sedation_17\NN\14034177 ,_18\,\1740 apnea_19\NN\14299637 ,_20\,\1740 nausea_21\NN\14299637 ,_22\,\1740 or_23\CC\3541091 <e2>pruritus</e2>_24\NN\5723563 ._25\.\1740
D005045_D001049 NONE conclusion_0\NN\5837957 :_1\:\1740 pretreatment_2\NN\1740 with_3\IN\1740 remifentanil_4\NN\1740 1_5\CD\13741022 microg/kg_6\NN\1740 reduced_7\VBD\441445 myoclonus_8\NN\14360459 after_9\IN\1740 <e1>etomidate</e1>_10\NN\1740 induction_11\NN\7450842 without_12\IN\1740 side_13\NN\8630039 effects_14\NNS\13245626 such_15\JJ\1740 as_16\IN\14622893 sedation_17\NN\14034177 ,_18\,\1740 <e2>apnea</e2>_19\NN\14299637 ,_20\,\1740 nausea_21\NN\14299637 ,_22\,\1740 or_23\CC\3541091 pruritus_24\NN\5723563 ._25\.\1740
D005045_D009325 NONE conclusion_0\NN\5837957 :_1\:\1740 pretreatment_2\NN\1740 with_3\IN\1740 remifentanil_4\NN\1740 1_5\CD\13741022 microg/kg_6\NN\1740 reduced_7\VBD\441445 myoclonus_8\NN\14360459 after_9\IN\1740 <e1>etomidate</e1>_10\NN\1740 induction_11\NN\7450842 without_12\IN\1740 side_13\NN\8630039 effects_14\NNS\13245626 such_15\JJ\1740 as_16\IN\14622893 sedation_17\NN\14034177 ,_18\,\1740 apnea_19\NN\14299637 ,_20\,\1740 <e2>nausea</e2>_21\NN\14299637 ,_22\,\1740 or_23\CC\3541091 pruritus_24\NN\5723563 ._25\.\1740
D005045_D011537 NONE conclusion_0\NN\5837957 :_1\:\1740 pretreatment_2\NN\1740 with_3\IN\1740 remifentanil_4\NN\1740 1_5\CD\13741022 microg/kg_6\NN\1740 reduced_7\VBD\441445 myoclonus_8\NN\14360459 after_9\IN\1740 <e1>etomidate</e1>_10\NN\1740 induction_11\NN\7450842 without_12\IN\1740 side_13\NN\8630039 effects_14\NNS\13245626 such_15\JJ\1740 as_16\IN\14622893 sedation_17\NN\14034177 ,_18\,\1740 apnea_19\NN\14299637 ,_20\,\1740 nausea_21\NN\14299637 ,_22\,\1740 or_23\CC\3541091 <e2>pruritus</e2>_24\NN\5723563 ._25\.\1740
16584858
C013592_D009203 NONE role_0\NN\719494 of_1\IN\1740 <e1>mangiferin</e1>_2\NN\1740 on_3\IN\1740 biochemical_4\JJ\1740 alterations_5\NNS\7283608 and_6\CC\1740 antioxidant_7\JJ\1740 status_8\NN\24720 in_9\IN\13603305 isoproterenol-induced_10\JJ\1740 <e2>myocardial_11\JJ\1740 infarction</e2>_12\NN\14204950 in_13\IN\13603305 rats_14\NNS\2329401 ._15\.\1740
C013592_D009203 NONE the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 dealt_3\VBD\964911 with_4\IN\1740 the_5\DT\1740 protective_6\JJ\1740 role_7\NN\719494 of_8\IN\1740 <e1>mangiferin</e1>_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 polyphenol_12\NN\1740 from_13\IN\1740 mangifera_14\NNP\11567411 indica_15\NNP\1740 linn_16\NNP\1740 ._17\.\1740 (_18\-LRB-\1740 anacardiaceae_19\NN\11562747 )_20\-RRB-\1740 ,_21\,\1740 on_22\IN\1740 isoproterenol_23\NN\3740161 (isph)-induced_24\JJ\1740 <e2>myocardial_25\JJ\1740 infarction</e2>_26\NN\14204950 (_27\-LRB-\1740 mi_28\NN\14207561 )_29\-RRB-\1740 in_30\IN\13603305 rats_31\NNS\2329401 through_32\IN\1740 its_33\PRP$\6125041 antioxidative_34\JJ\1740 mechanism_35\NN\13446390 ._36\.\1740
C013592_D009203 NONE the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 dealt_3\VBD\964911 with_4\IN\1740 the_5\DT\1740 protective_6\JJ\1740 role_7\NN\719494 of_8\IN\1740 <e1>mangiferin</e1>_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 polyphenol_12\NN\1740 from_13\IN\1740 mangifera_14\NNP\11567411 indica_15\NNP\1740 linn_16\NNP\1740 ._17\.\1740 (_18\-LRB-\1740 anacardiaceae_19\NN\11562747 )_20\-RRB-\1740 ,_21\,\1740 on_22\IN\1740 isoproterenol_23\NN\3740161 (isph)-induced_24\JJ\1740 myocardial_25\JJ\1740 infarction_26\NN\14204950 (_27\-LRB-\1740 <e2>mi</e2>_28\NN\14207561 )_29\-RRB-\1740 in_30\IN\13603305 rats_31\NNS\2329401 through_32\IN\1740 its_33\PRP$\6125041 antioxidative_34\JJ\1740 mechanism_35\NN\13446390 ._36\.\1740
C013592_D009203 NONE upon_0\IN\1740 pretreatment_1\NN\1740 with_2\IN\1740 <e1>mangiferin</e1>_3\NN\1740 (_4\-LRB-\1740 100_5\CD\13745420 mg/kg_6\NN\1740 body_7\NN\19128 weight_8\NN\5009170 suspended_9\VBN\1481360 in_10\IN\13603305 2_11\CD\13741022 ml_12\NN\13616054 of_13\IN\1740 dimethyl_14\JJ\1740 sulphoxide_15\NN\1740 )_16\-RRB-\1740 given_17\VBN\2327200 intraperitoneally_18\RB\1740 for_19\IN\1740 28_20\CD\13745420 days_21\NNS\15140892 to_22\TO\1740 <e2>mi</e2>_23\NN\14207561 rats_24\NNS\2329401 protected_25\VBD\1127795 the_26\DT\1740 above-mentioned_27\JJ\1740 parameters_28\NNS\5858936 to_29\TO\1740 fall_30\VB\1835496 from_31\IN\1740 the_32\DT\1740 normal_33\JJ\1740 levels_34\NNS\4916342 ._35\.\1740
C013592_D009203 NONE activities_0\NNS\30358 of_1\IN\1740 heart_2\NN\5919034 tissue_3\NN\5220461 enzymic_4\JJ\1740 antioxidants_5\NNS\14724436 and_6\CC\1740 serum_7\NN\5397468 non-enzymic_8\JJ\1740 antioxidants_9\NNS\14724436 levels_10\NNS\4916342 rose_11\VBD\1835496 significantly_12\RB\1740 upon_13\IN\1740 <e1>mangiferin</e1>_14\NN\1740 administration_15\NN\1133281 as_16\IN\14622893 compared_17\VBN\644583 to_18\TO\1740 isph-induced_19\JJ\1740 <e2>mi</e2>_20\NN\14207561 rats_21\NNS\2329401 ._22\.\1740
C013592_D009203 NONE from_0\IN\1740 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 it_4\PRP\6125041 is_5\VBZ\836236 concluded_6\VBN\628491 that_7\IN\1740 <e1>mangiferin</e1>_8\NN\1740 exerts_9\VBZ\1158872 a_10\DT\13649268 beneficial_11\JJ\1740 effect_12\NN\34213 against_13\IN\1740 isph-induced_14\JJ\1740 <e2>mi</e2>_15\NN\14207561 due_16\JJ\1740 to_17\TO\1740 its_18\PRP$\6125041 antioxidant_19\JJ\1740 potential_20\NN\14481929 ,_21\,\1740 which_22\WDT\1740 regulated_23\VBD\296178 the_24\DT\1740 tissues_25\NNS\5220461 defense_26\NN\952963 system_27\NN\3575240 against_28\IN\1740 cardiac_29\JJ\1740 damage_30\NN\7296428 ._31\.\1740
D007545_D009203 CID role_0\NN\719494 of_1\IN\1740 mangiferin_2\NN\1740 on_3\IN\1740 biochemical_4\JJ\1740 alterations_5\NNS\7283608 and_6\CC\1740 antioxidant_7\JJ\1740 status_8\NN\24720 in_9\IN\13603305 <e1>isoproterenol-induced</e1>_10\JJ\1740 <e2>myocardial_11\JJ\1740 infarction</e2>_12\NN\14204950 in_13\IN\13603305 rats_14\NNS\2329401 ._15\.\1740
D007545_D009203 CID the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 dealt_3\VBD\964911 with_4\IN\1740 the_5\DT\1740 protective_6\JJ\1740 role_7\NN\719494 of_8\IN\1740 mangiferin_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 polyphenol_12\NN\1740 from_13\IN\1740 mangifera_14\NNP\11567411 indica_15\NNP\1740 linn_16\NNP\1740 ._17\.\1740 (_18\-LRB-\1740 anacardiaceae_19\NN\11562747 )_20\-RRB-\1740 ,_21\,\1740 on_22\IN\1740 <e1>isoproterenol</e1>_23\NN\3740161 (isph)-induced_24\JJ\1740 <e2>myocardial_25\JJ\1740 infarction</e2>_26\NN\14204950 (_27\-LRB-\1740 mi_28\NN\14207561 )_29\-RRB-\1740 in_30\IN\13603305 rats_31\NNS\2329401 through_32\IN\1740 its_33\PRP$\6125041 antioxidative_34\JJ\1740 mechanism_35\NN\13446390 ._36\.\1740
D007545_D009203 CID the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 dealt_3\VBD\964911 with_4\IN\1740 the_5\DT\1740 protective_6\JJ\1740 role_7\NN\719494 of_8\IN\1740 mangiferin_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 polyphenol_12\NN\1740 from_13\IN\1740 mangifera_14\NNP\11567411 indica_15\NNP\1740 linn_16\NNP\1740 ._17\.\1740 (_18\-LRB-\1740 anacardiaceae_19\NN\11562747 )_20\-RRB-\1740 ,_21\,\1740 on_22\IN\1740 <e1>isoproterenol</e1>_23\NN\3740161 (isph)-induced_24\JJ\1740 myocardial_25\JJ\1740 infarction_26\NN\14204950 (_27\-LRB-\1740 <e2>mi</e2>_28\NN\14207561 )_29\-RRB-\1740 in_30\IN\13603305 rats_31\NNS\2329401 through_32\IN\1740 its_33\PRP$\6125041 antioxidative_34\JJ\1740 mechanism_35\NN\13446390 ._36\.\1740
D007545_D009203 CID the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 dealt_3\VBD\964911 with_4\IN\1740 the_5\DT\1740 protective_6\JJ\1740 role_7\NN\719494 of_8\IN\1740 mangiferin_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 polyphenol_12\NN\1740 from_13\IN\1740 mangifera_14\NNP\11567411 indica_15\NNP\1740 linn_16\NNP\1740 ._17\.\1740 (_18\-LRB-\1740 anacardiaceae_19\NN\11562747 )_20\-RRB-\1740 ,_21\,\1740 on_22\IN\1740 isoproterenol_23\NN\3740161 <e1>(isph)-induced</e1>_24\JJ\1740 <e2>myocardial_25\JJ\1740 infarction</e2>_26\NN\14204950 (_27\-LRB-\1740 mi_28\NN\14207561 )_29\-RRB-\1740 in_30\IN\13603305 rats_31\NNS\2329401 through_32\IN\1740 its_33\PRP$\6125041 antioxidative_34\JJ\1740 mechanism_35\NN\13446390 ._36\.\1740
D007545_D009203 CID the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 dealt_3\VBD\964911 with_4\IN\1740 the_5\DT\1740 protective_6\JJ\1740 role_7\NN\719494 of_8\IN\1740 mangiferin_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 polyphenol_12\NN\1740 from_13\IN\1740 mangifera_14\NNP\11567411 indica_15\NNP\1740 linn_16\NNP\1740 ._17\.\1740 (_18\-LRB-\1740 anacardiaceae_19\NN\11562747 )_20\-RRB-\1740 ,_21\,\1740 on_22\IN\1740 isoproterenol_23\NN\3740161 <e1>(isph)-induced</e1>_24\JJ\1740 myocardial_25\JJ\1740 infarction_26\NN\14204950 (_27\-LRB-\1740 <e2>mi</e2>_28\NN\14207561 )_29\-RRB-\1740 in_30\IN\13603305 rats_31\NNS\2329401 through_32\IN\1740 its_33\PRP$\6125041 antioxidative_34\JJ\1740 mechanism_35\NN\13446390 ._36\.\1740
D007545_D009203 CID activities_0\NNS\30358 of_1\IN\1740 heart_2\NN\5919034 tissue_3\NN\5220461 enzymic_4\JJ\1740 antioxidants_5\NNS\14724436 and_6\CC\1740 serum_7\NN\5397468 non-enzymic_8\JJ\1740 antioxidants_9\NNS\14724436 levels_10\NNS\4916342 rose_11\VBD\1835496 significantly_12\RB\1740 upon_13\IN\1740 mangiferin_14\NN\1740 administration_15\NN\1133281 as_16\IN\14622893 compared_17\VBN\644583 to_18\TO\1740 <e1>isph-induced</e1>_19\JJ\1740 <e2>mi</e2>_20\NN\14207561 rats_21\NNS\2329401 ._22\.\1740
D007545_D009203 CID from_0\IN\1740 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 it_4\PRP\6125041 is_5\VBZ\836236 concluded_6\VBN\628491 that_7\IN\1740 mangiferin_8\NN\1740 exerts_9\VBZ\1158872 a_10\DT\13649268 beneficial_11\JJ\1740 effect_12\NN\34213 against_13\IN\1740 <e1>isph-induced</e1>_14\JJ\1740 <e2>mi</e2>_15\NN\14207561 due_16\JJ\1740 to_17\TO\1740 its_18\PRP$\6125041 antioxidant_19\JJ\1740 potential_20\NN\14481929 ,_21\,\1740 which_22\WDT\1740 regulated_23\VBD\296178 the_24\DT\1740 tissues_25\NNS\5220461 defense_26\NN\952963 system_27\NN\3575240 against_28\IN\1740 cardiac_29\JJ\1740 damage_30\NN\7296428 ._31\.\1740
D059808_D009203 NONE the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 dealt_3\VBD\964911 with_4\IN\1740 the_5\DT\1740 protective_6\JJ\1740 role_7\NN\719494 of_8\IN\1740 mangiferin_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 <e1>polyphenol</e1>_12\NN\1740 from_13\IN\1740 mangifera_14\NNP\11567411 indica_15\NNP\1740 linn_16\NNP\1740 ._17\.\1740 (_18\-LRB-\1740 anacardiaceae_19\NN\11562747 )_20\-RRB-\1740 ,_21\,\1740 on_22\IN\1740 isoproterenol_23\NN\3740161 (isph)-induced_24\JJ\1740 <e2>myocardial_25\JJ\1740 infarction</e2>_26\NN\14204950 (_27\-LRB-\1740 mi_28\NN\14207561 )_29\-RRB-\1740 in_30\IN\13603305 rats_31\NNS\2329401 through_32\IN\1740 its_33\PRP$\6125041 antioxidative_34\JJ\1740 mechanism_35\NN\13446390 ._36\.\1740
D059808_D009203 NONE the_0\DT\1740 current_1\JJ\1740 study_2\NN\635850 dealt_3\VBD\964911 with_4\IN\1740 the_5\DT\1740 protective_6\JJ\1740 role_7\NN\719494 of_8\IN\1740 mangiferin_9\NN\1740 ,_10\,\1740 a_11\DT\13649268 <e1>polyphenol</e1>_12\NN\1740 from_13\IN\1740 mangifera_14\NNP\11567411 indica_15\NNP\1740 linn_16\NNP\1740 ._17\.\1740 (_18\-LRB-\1740 anacardiaceae_19\NN\11562747 )_20\-RRB-\1740 ,_21\,\1740 on_22\IN\1740 isoproterenol_23\NN\3740161 (isph)-induced_24\JJ\1740 myocardial_25\JJ\1740 infarction_26\NN\14204950 (_27\-LRB-\1740 <e2>mi</e2>_28\NN\14207561 )_29\-RRB-\1740 in_30\IN\13603305 rats_31\NNS\2329401 through_32\IN\1740 its_33\PRP$\6125041 antioxidative_34\JJ\1740 mechanism_35\NN\13446390 ._36\.\1740
D007545_D009202 NONE subcutaneous_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 <e1>isph</e1>_3\NN\1740 (_4\-LRB-\1740 200_5\CD\1740 mg/kg_6\NN\1740 body_7\NN\19128 weight_8\NN\5009170 in_9\IN\13603305 1_10\CD\13741022 ml_11\NN\13616054 saline_12\NN\14849367 )_13\-RRB-\1740 to_14\TO\1740 rats_15\NNS\2329401 for_16\IN\1740 2_17\CD\13741022 consecutive_18\JJ\1740 days_19\NNS\15140892 caused_20\VBD\1617192 <e2>myocardial_21\JJ\1740 damage</e2>_22\NN\7296428 in_23\IN\13603305 rat_24\NN\2329401 heart_25\NN\5919034 ,_26\,\1740 which_27\WDT\1740 was_28\VBD\836236 determined_29\VBN\1645601 by_30\IN\1740 the_31\DT\1740 increased_32\VBN\169651 activity_33\NN\30358 of_34\IN\1740 serum_35\NN\5397468 lactate_36\NN\14850483 dehydrogenase_37\NN\1740 (_38\-LRB-\1740 ldh_39\NN\1740 )_40\-RRB-\1740 and_41\CC\1740 creatine_42\NN\14601829 phosphokinase_43\NN\1740 isoenzymes_44\NNS\1740 (_45\-LRB-\1740 ck-mb_46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 uric_50\JJ\1740 acid_51\NN\14818238 level_52\NN\4916342 and_53\CC\1740 reduced_54\VBN\441445 plasma_55\NN\5398023 iron_56\NN\14625458 binding_57\NN\4688246 capacity_58\NN\5202497 ._59\.\1740
D019344_D009202 NONE subcutaneous_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 isph_3\NN\1740 (_4\-LRB-\1740 200_5\CD\1740 mg/kg_6\NN\1740 body_7\NN\19128 weight_8\NN\5009170 in_9\IN\13603305 1_10\CD\13741022 ml_11\NN\13616054 saline_12\NN\14849367 )_13\-RRB-\1740 to_14\TO\1740 rats_15\NNS\2329401 for_16\IN\1740 2_17\CD\13741022 consecutive_18\JJ\1740 days_19\NNS\15140892 caused_20\VBD\1617192 <e2>myocardial_21\JJ\1740 damage</e2>_22\NN\7296428 in_23\IN\13603305 rat_24\NN\2329401 heart_25\NN\5919034 ,_26\,\1740 which_27\WDT\1740 was_28\VBD\836236 determined_29\VBN\1645601 by_30\IN\1740 the_31\DT\1740 increased_32\VBN\169651 activity_33\NN\30358 of_34\IN\1740 serum_35\NN\5397468 <e1>lactate</e1>_36\NN\14850483 dehydrogenase_37\NN\1740 (_38\-LRB-\1740 ldh_39\NN\1740 )_40\-RRB-\1740 and_41\CC\1740 creatine_42\NN\14601829 phosphokinase_43\NN\1740 isoenzymes_44\NNS\1740 (_45\-LRB-\1740 ck-mb_46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 uric_50\JJ\1740 acid_51\NN\14818238 level_52\NN\4916342 and_53\CC\1740 reduced_54\VBN\441445 plasma_55\NN\5398023 iron_56\NN\14625458 binding_57\NN\4688246 capacity_58\NN\5202497 ._59\.\1740
D003401_D009202 NONE subcutaneous_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 isph_3\NN\1740 (_4\-LRB-\1740 200_5\CD\1740 mg/kg_6\NN\1740 body_7\NN\19128 weight_8\NN\5009170 in_9\IN\13603305 1_10\CD\13741022 ml_11\NN\13616054 saline_12\NN\14849367 )_13\-RRB-\1740 to_14\TO\1740 rats_15\NNS\2329401 for_16\IN\1740 2_17\CD\13741022 consecutive_18\JJ\1740 days_19\NNS\15140892 caused_20\VBD\1617192 <e2>myocardial_21\JJ\1740 damage</e2>_22\NN\7296428 in_23\IN\13603305 rat_24\NN\2329401 heart_25\NN\5919034 ,_26\,\1740 which_27\WDT\1740 was_28\VBD\836236 determined_29\VBN\1645601 by_30\IN\1740 the_31\DT\1740 increased_32\VBN\169651 activity_33\NN\30358 of_34\IN\1740 serum_35\NN\5397468 lactate_36\NN\14850483 dehydrogenase_37\NN\1740 (_38\-LRB-\1740 ldh_39\NN\1740 )_40\-RRB-\1740 and_41\CC\1740 <e1>creatine</e1>_42\NN\14601829 phosphokinase_43\NN\1740 isoenzymes_44\NNS\1740 (_45\-LRB-\1740 ck-mb_46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 uric_50\JJ\1740 acid_51\NN\14818238 level_52\NN\4916342 and_53\CC\1740 reduced_54\VBN\441445 plasma_55\NN\5398023 iron_56\NN\14625458 binding_57\NN\4688246 capacity_58\NN\5202497 ._59\.\1740
D014527_D009202 NONE subcutaneous_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 isph_3\NN\1740 (_4\-LRB-\1740 200_5\CD\1740 mg/kg_6\NN\1740 body_7\NN\19128 weight_8\NN\5009170 in_9\IN\13603305 1_10\CD\13741022 ml_11\NN\13616054 saline_12\NN\14849367 )_13\-RRB-\1740 to_14\TO\1740 rats_15\NNS\2329401 for_16\IN\1740 2_17\CD\13741022 consecutive_18\JJ\1740 days_19\NNS\15140892 caused_20\VBD\1617192 <e2>myocardial_21\JJ\1740 damage</e2>_22\NN\7296428 in_23\IN\13603305 rat_24\NN\2329401 heart_25\NN\5919034 ,_26\,\1740 which_27\WDT\1740 was_28\VBD\836236 determined_29\VBN\1645601 by_30\IN\1740 the_31\DT\1740 increased_32\VBN\169651 activity_33\NN\30358 of_34\IN\1740 serum_35\NN\5397468 lactate_36\NN\14850483 dehydrogenase_37\NN\1740 (_38\-LRB-\1740 ldh_39\NN\1740 )_40\-RRB-\1740 and_41\CC\1740 creatine_42\NN\14601829 phosphokinase_43\NN\1740 isoenzymes_44\NNS\1740 (_45\-LRB-\1740 ck-mb_46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 <e1>uric_50\JJ\1740 acid</e1>_51\NN\14818238 level_52\NN\4916342 and_53\CC\1740 reduced_54\VBN\441445 plasma_55\NN\5398023 iron_56\NN\14625458 binding_57\NN\4688246 capacity_58\NN\5202497 ._59\.\1740
D007501_D009202 NONE subcutaneous_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 isph_3\NN\1740 (_4\-LRB-\1740 200_5\CD\1740 mg/kg_6\NN\1740 body_7\NN\19128 weight_8\NN\5009170 in_9\IN\13603305 1_10\CD\13741022 ml_11\NN\13616054 saline_12\NN\14849367 )_13\-RRB-\1740 to_14\TO\1740 rats_15\NNS\2329401 for_16\IN\1740 2_17\CD\13741022 consecutive_18\JJ\1740 days_19\NNS\15140892 caused_20\VBD\1617192 <e2>myocardial_21\JJ\1740 damage</e2>_22\NN\7296428 in_23\IN\13603305 rat_24\NN\2329401 heart_25\NN\5919034 ,_26\,\1740 which_27\WDT\1740 was_28\VBD\836236 determined_29\VBN\1645601 by_30\IN\1740 the_31\DT\1740 increased_32\VBN\169651 activity_33\NN\30358 of_34\IN\1740 serum_35\NN\5397468 lactate_36\NN\14850483 dehydrogenase_37\NN\1740 (_38\-LRB-\1740 ldh_39\NN\1740 )_40\-RRB-\1740 and_41\CC\1740 creatine_42\NN\14601829 phosphokinase_43\NN\1740 isoenzymes_44\NNS\1740 (_45\-LRB-\1740 ck-mb_46\NN\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 uric_50\JJ\1740 acid_51\NN\14818238 level_52\NN\4916342 and_53\CC\1740 reduced_54\VBN\441445 plasma_55\NN\5398023 <e1>iron</e1>_56\NN\14625458 binding_57\NN\4688246 capacity_58\NN\5202497 ._59\.\1740
C013592_D017202 NONE the_0\DT\1740 protective_1\JJ\1740 role_2\NN\719494 of_3\IN\1740 <e1>mangiferin</e1>_4\NN\1740 was_5\VBD\836236 analyzed_6\VBN\78760 by_7\IN\1740 triphenyl_8\NN\1740 tetrazolium_9\NN\1740 chloride_10\NN\14818238 (_11\-LRB-\1740 ttc_12\NN\1740 )_13\-RRB-\1740 test_14\VBP\670261 used_15\VBN\1156834 for_16\IN\1740 macroscopic_17\JJ\1740 enzyme_18\NN\14723628 mapping_19\NN\13783581 assay_20\NN\5733583 of_21\IN\1740 the_22\DT\1740 <e2>ischemic_23\JJ\1740 myocardium</e2>_24\NN\5389939 ._25\.\1740
C009591_D017202 NONE the_0\DT\1740 protective_1\JJ\1740 role_2\NN\719494 of_3\IN\1740 mangiferin_4\NN\1740 was_5\VBD\836236 analyzed_6\VBN\78760 by_7\IN\1740 <e1>triphenyl_8\NN\1740 tetrazolium_9\NN\1740 chloride</e1>_10\NN\14818238 (_11\-LRB-\1740 ttc_12\NN\1740 )_13\-RRB-\1740 test_14\VBP\670261 used_15\VBN\1156834 for_16\IN\1740 macroscopic_17\JJ\1740 enzyme_18\NN\14723628 mapping_19\NN\13783581 assay_20\NN\5733583 of_21\IN\1740 the_22\DT\1740 <e2>ischemic_23\JJ\1740 myocardium</e2>_24\NN\5389939 ._25\.\1740
C009591_D017202 NONE the_0\DT\1740 protective_1\JJ\1740 role_2\NN\719494 of_3\IN\1740 mangiferin_4\NN\1740 was_5\VBD\836236 analyzed_6\VBN\78760 by_7\IN\1740 triphenyl_8\NN\1740 tetrazolium_9\NN\1740 chloride_10\NN\14818238 (_11\-LRB-\1740 <e1>ttc</e1>_12\NN\1740 )_13\-RRB-\1740 test_14\VBP\670261 used_15\VBN\1156834 for_16\IN\1740 macroscopic_17\JJ\1740 enzyme_18\NN\14723628 mapping_19\NN\13783581 assay_20\NN\5733583 of_21\IN\1740 the_22\DT\1740 <e2>ischemic_23\JJ\1740 myocardium</e2>_24\NN\5389939 ._25\.\1740
D013481_D009203 NONE the_0\DT\1740 heart_1\NN\5919034 tissue_2\NN\5220461 antioxidant_3\JJ\1740 enzymes_4\NNS\14723628 such_5\JJ\1740 as_6\IN\14622893 <e1>superoxide</e1>_7\NN\14971519 dismutase_8\NN\1740 ,_9\,\1740 catalase_10\NN\14732946 ,_11\,\1740 glutathione_12\NN\1740 peroxidase_13\NN\14971234 ,_14\,\1740 glutathione_15\NN\1740 transferase_16\NN\14732946 and_17\CC\1740 glutathione_18\NN\1740 reductase_19\NN\14732946 activities_20\NNS\30358 ,_21\,\1740 non-enzymic_22\JJ\1740 antioxidants_23\NNS\14724436 such_24\JJ\1740 as_25\IN\14622893 cerruloplasmin_26\NN\1740 ,_27\,\1740 vitamin_28\NN\7570720 c_29\NN\13714184 ,_30\,\1740 vitamin_31\NN\7570720 e_32\NN\14724645 and_33\CC\1740 glutathione_34\NN\1740 levels_35\NNS\4916342 were_36\VBD\836236 altered_37\VBN\126264 in_38\IN\13603305 <e2>mi</e2>_39\NN\14207561 rats_40\NNS\2329401 ._41\.\1740
D005978_D009203 NONE the_0\DT\1740 heart_1\NN\5919034 tissue_2\NN\5220461 antioxidant_3\JJ\1740 enzymes_4\NNS\14723628 such_5\JJ\1740 as_6\IN\14622893 superoxide_7\NN\14971519 dismutase_8\NN\1740 ,_9\,\1740 catalase_10\NN\14732946 ,_11\,\1740 <e1>glutathione</e1>_12\NN\1740 peroxidase_13\NN\14971234 ,_14\,\1740 glutathione_15\NN\1740 transferase_16\NN\14732946 and_17\CC\1740 glutathione_18\NN\1740 reductase_19\NN\14732946 activities_20\NNS\30358 ,_21\,\1740 non-enzymic_22\JJ\1740 antioxidants_23\NNS\14724436 such_24\JJ\1740 as_25\IN\14622893 cerruloplasmin_26\NN\1740 ,_27\,\1740 vitamin_28\NN\7570720 c_29\NN\13714184 ,_30\,\1740 vitamin_31\NN\7570720 e_32\NN\14724645 and_33\CC\1740 glutathione_34\NN\1740 levels_35\NNS\4916342 were_36\VBD\836236 altered_37\VBN\126264 in_38\IN\13603305 <e2>mi</e2>_39\NN\14207561 rats_40\NNS\2329401 ._41\.\1740
D005978_D009203 NONE the_0\DT\1740 heart_1\NN\5919034 tissue_2\NN\5220461 antioxidant_3\JJ\1740 enzymes_4\NNS\14723628 such_5\JJ\1740 as_6\IN\14622893 superoxide_7\NN\14971519 dismutase_8\NN\1740 ,_9\,\1740 catalase_10\NN\14732946 ,_11\,\1740 glutathione_12\NN\1740 peroxidase_13\NN\14971234 ,_14\,\1740 <e1>glutathione</e1>_15\NN\1740 transferase_16\NN\14732946 and_17\CC\1740 glutathione_18\NN\1740 reductase_19\NN\14732946 activities_20\NNS\30358 ,_21\,\1740 non-enzymic_22\JJ\1740 antioxidants_23\NNS\14724436 such_24\JJ\1740 as_25\IN\14622893 cerruloplasmin_26\NN\1740 ,_27\,\1740 vitamin_28\NN\7570720 c_29\NN\13714184 ,_30\,\1740 vitamin_31\NN\7570720 e_32\NN\14724645 and_33\CC\1740 glutathione_34\NN\1740 levels_35\NNS\4916342 were_36\VBD\836236 altered_37\VBN\126264 in_38\IN\13603305 <e2>mi</e2>_39\NN\14207561 rats_40\NNS\2329401 ._41\.\1740
D005978_D009203 NONE the_0\DT\1740 heart_1\NN\5919034 tissue_2\NN\5220461 antioxidant_3\JJ\1740 enzymes_4\NNS\14723628 such_5\JJ\1740 as_6\IN\14622893 superoxide_7\NN\14971519 dismutase_8\NN\1740 ,_9\,\1740 catalase_10\NN\14732946 ,_11\,\1740 glutathione_12\NN\1740 peroxidase_13\NN\14971234 ,_14\,\1740 glutathione_15\NN\1740 transferase_16\NN\14732946 and_17\CC\1740 <e1>glutathione</e1>_18\NN\1740 reductase_19\NN\14732946 activities_20\NNS\30358 ,_21\,\1740 non-enzymic_22\JJ\1740 antioxidants_23\NNS\14724436 such_24\JJ\1740 as_25\IN\14622893 cerruloplasmin_26\NN\1740 ,_27\,\1740 vitamin_28\NN\7570720 c_29\NN\13714184 ,_30\,\1740 vitamin_31\NN\7570720 e_32\NN\14724645 and_33\CC\1740 glutathione_34\NN\1740 levels_35\NNS\4916342 were_36\VBD\836236 altered_37\VBN\126264 in_38\IN\13603305 <e2>mi</e2>_39\NN\14207561 rats_40\NNS\2329401 ._41\.\1740
D005978_D009203 NONE the_0\DT\1740 heart_1\NN\5919034 tissue_2\NN\5220461 antioxidant_3\JJ\1740 enzymes_4\NNS\14723628 such_5\JJ\1740 as_6\IN\14622893 superoxide_7\NN\14971519 dismutase_8\NN\1740 ,_9\,\1740 catalase_10\NN\14732946 ,_11\,\1740 glutathione_12\NN\1740 peroxidase_13\NN\14971234 ,_14\,\1740 glutathione_15\NN\1740 transferase_16\NN\14732946 and_17\CC\1740 glutathione_18\NN\1740 reductase_19\NN\14732946 activities_20\NNS\30358 ,_21\,\1740 non-enzymic_22\JJ\1740 antioxidants_23\NNS\14724436 such_24\JJ\1740 as_25\IN\14622893 cerruloplasmin_26\NN\1740 ,_27\,\1740 vitamin_28\NN\7570720 c_29\NN\13714184 ,_30\,\1740 vitamin_31\NN\7570720 e_32\NN\14724645 and_33\CC\1740 <e1>glutathione</e1>_34\NN\1740 levels_35\NNS\4916342 were_36\VBD\836236 altered_37\VBN\126264 in_38\IN\13603305 <e2>mi</e2>_39\NN\14207561 rats_40\NNS\2329401 ._41\.\1740
D001205_D009203 NONE the_0\DT\1740 heart_1\NN\5919034 tissue_2\NN\5220461 antioxidant_3\JJ\1740 enzymes_4\NNS\14723628 such_5\JJ\1740 as_6\IN\14622893 superoxide_7\NN\14971519 dismutase_8\NN\1740 ,_9\,\1740 catalase_10\NN\14732946 ,_11\,\1740 glutathione_12\NN\1740 peroxidase_13\NN\14971234 ,_14\,\1740 glutathione_15\NN\1740 transferase_16\NN\14732946 and_17\CC\1740 glutathione_18\NN\1740 reductase_19\NN\14732946 activities_20\NNS\30358 ,_21\,\1740 non-enzymic_22\JJ\1740 antioxidants_23\NNS\14724436 such_24\JJ\1740 as_25\IN\14622893 cerruloplasmin_26\NN\1740 ,_27\,\1740 <e1>vitamin_28\NN\7570720 c</e1>_29\NN\13714184 ,_30\,\1740 vitamin_31\NN\7570720 e_32\NN\14724645 and_33\CC\1740 glutathione_34\NN\1740 levels_35\NNS\4916342 were_36\VBD\836236 altered_37\VBN\126264 in_38\IN\13603305 <e2>mi</e2>_39\NN\14207561 rats_40\NNS\2329401 ._41\.\1740
D014810_D009203 NONE the_0\DT\1740 heart_1\NN\5919034 tissue_2\NN\5220461 antioxidant_3\JJ\1740 enzymes_4\NNS\14723628 such_5\JJ\1740 as_6\IN\14622893 superoxide_7\NN\14971519 dismutase_8\NN\1740 ,_9\,\1740 catalase_10\NN\14732946 ,_11\,\1740 glutathione_12\NN\1740 peroxidase_13\NN\14971234 ,_14\,\1740 glutathione_15\NN\1740 transferase_16\NN\14732946 and_17\CC\1740 glutathione_18\NN\1740 reductase_19\NN\14732946 activities_20\NNS\30358 ,_21\,\1740 non-enzymic_22\JJ\1740 antioxidants_23\NNS\14724436 such_24\JJ\1740 as_25\IN\14622893 cerruloplasmin_26\NN\1740 ,_27\,\1740 vitamin_28\NN\7570720 c_29\NN\13714184 ,_30\,\1740 <e1>vitamin_31\NN\7570720 e</e1>_32\NN\14724645 and_33\CC\1740 glutathione_34\NN\1740 levels_35\NNS\4916342 were_36\VBD\836236 altered_37\VBN\126264 in_38\IN\13603305 <e2>mi</e2>_39\NN\14207561 rats_40\NNS\2329401 ._41\.\1740
D004121_D009203 NONE upon_0\IN\1740 pretreatment_1\NN\1740 with_2\IN\1740 mangiferin_3\NN\1740 (_4\-LRB-\1740 100_5\CD\13745420 mg/kg_6\NN\1740 body_7\NN\19128 weight_8\NN\5009170 suspended_9\VBN\1481360 in_10\IN\13603305 2_11\CD\13741022 ml_12\NN\13616054 of_13\IN\1740 <e1>dimethyl_14\JJ\1740 sulphoxide</e1>_15\NN\1740 )_16\-RRB-\1740 given_17\VBN\2327200 intraperitoneally_18\RB\1740 for_19\IN\1740 28_20\CD\13745420 days_21\NNS\15140892 to_22\TO\1740 <e2>mi</e2>_23\NN\14207561 rats_24\NNS\2329401 protected_25\VBD\1127795 the_26\DT\1740 above-mentioned_27\JJ\1740 parameters_28\NNS\5858936 to_29\TO\1740 fall_30\VB\1835496 from_31\IN\1740 the_32\DT\1740 normal_33\JJ\1740 levels_34\NNS\4916342 ._35\.\1740
C013592_D006331 NONE from_0\IN\1740 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 it_4\PRP\6125041 is_5\VBZ\836236 concluded_6\VBN\628491 that_7\IN\1740 <e1>mangiferin</e1>_8\NN\1740 exerts_9\VBZ\1158872 a_10\DT\13649268 beneficial_11\JJ\1740 effect_12\NN\34213 against_13\IN\1740 isph-induced_14\JJ\1740 mi_15\NN\14207561 due_16\JJ\1740 to_17\TO\1740 its_18\PRP$\6125041 antioxidant_19\JJ\1740 potential_20\NN\14481929 ,_21\,\1740 which_22\WDT\1740 regulated_23\VBD\296178 the_24\DT\1740 tissues_25\NNS\5220461 defense_26\NN\952963 system_27\NN\3575240 against_28\IN\1740 <e2>cardiac_29\JJ\1740 damage</e2>_30\NN\7296428 ._31\.\1740
D007545_D006331 NONE from_0\IN\1740 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 it_4\PRP\6125041 is_5\VBZ\836236 concluded_6\VBN\628491 that_7\IN\1740 mangiferin_8\NN\1740 exerts_9\VBZ\1158872 a_10\DT\13649268 beneficial_11\JJ\1740 effect_12\NN\34213 against_13\IN\1740 <e1>isph-induced</e1>_14\JJ\1740 mi_15\NN\14207561 due_16\JJ\1740 to_17\TO\1740 its_18\PRP$\6125041 antioxidant_19\JJ\1740 potential_20\NN\14481929 ,_21\,\1740 which_22\WDT\1740 regulated_23\VBD\296178 the_24\DT\1740 tissues_25\NNS\5220461 defense_26\NN\952963 system_27\NN\3575240 against_28\IN\1740 <e2>cardiac_29\JJ\1740 damage</e2>_30\NN\7296428 ._31\.\1740
2004
D013881_D017180 CID although_0\IN\1740 most_1\JJS\1740 patients_2\NNS\9898892 were_3\VBD\836236 receiving_4\VBG\2210855 several_5\JJ\1740 drugs_6\NNS\14778436 ,_7\,\1740 <e1>mellaril</e1>_8\NNP\3713736 (_9\-LRB-\1740 thioridazine_10\NN\3713736 )_11\-RRB-\1740 appeared_12\VBD\2604760 to_13\TO\1740 be_14\VB\836236 responsible_15\JJ\1740 for_16\IN\1740 five_17\CD\13741022 cases_18\NNS\7283608 of_19\IN\1740 <e2>ventricular_20\JJ\1740 tachycardia</e2>_21\NN\14110674 ,_22\,\1740 one_23\CD\13741022 of_24\IN\1740 which_25\WDT\1740 was_26\VBD\836236 fatal_27\JJ\1740 in_28\IN\13603305 a_29\DT\13649268 35_30\CD\1740 year_31\NN\15113229 old_32\JJ\1740 woman_33\NN\9605289 ._34\.\1740
D013881_D017180 CID although_0\IN\1740 most_1\JJS\1740 patients_2\NNS\9898892 were_3\VBD\836236 receiving_4\VBG\2210855 several_5\JJ\1740 drugs_6\NNS\14778436 ,_7\,\1740 mellaril_8\NNP\3713736 (_9\-LRB-\1740 <e1>thioridazine</e1>_10\NN\3713736 )_11\-RRB-\1740 appeared_12\VBD\2604760 to_13\TO\1740 be_14\VB\836236 responsible_15\JJ\1740 for_16\IN\1740 five_17\CD\13741022 cases_18\NNS\7283608 of_19\IN\1740 <e2>ventricular_20\JJ\1740 tachycardia</e2>_21\NN\14110674 ,_22\,\1740 one_23\CD\13741022 of_24\IN\1740 which_25\WDT\1740 was_26\VBD\836236 fatal_27\JJ\1740 in_28\IN\13603305 a_29\DT\13649268 35_30\CD\1740 year_31\NN\15113229 old_32\JJ\1740 woman_33\NN\9605289 ._34\.\1740
D002746_D013617 NONE <e2>supraventricular_0\JJ\1740 tachycardia</e2>_1\NN\14110674 developed_2\VBD\1753788 in_3\IN\13603305 one_4\CD\13741022 patient_5\NN\9898892 receiving_6\VBG\2210855 <e1>thorazine</e1>_7\NN\3713736 (_8\-LRB-\1740 chlorpromazine_9\NN\3713736 )_10\-RRB-\1740 ._11\.\1740
D002746_D013617 NONE <e2>supraventricular_0\JJ\1740 tachycardia</e2>_1\NN\14110674 developed_2\VBD\1753788 in_3\IN\13603305 one_4\CD\13741022 patient_5\NN\9898892 receiving_6\VBG\2210855 thorazine_7\NN\3713736 (_8\-LRB-\1740 <e1>chlorpromazine</e1>_9\NN\3713736 )_10\-RRB-\1740 ._11\.\1740
D009661_D002037 CID <e1>aventyl</e1>_0\NN\1740 (_1\-LRB-\1740 nortriptyline_2\NN\4482543 )_3\-RRB-\1740 and_4\CC\1740 elavil_5\NN\4482543 (_6\-LRB-\1740 amitriptyline_7\NN\4482543 )_8\-RRB-\1740 each_9\DT\1740 produced_10\VBD\1617192 <e2>left_11\JJ\1740 bundle_12\NN\7951464 branch_13\NN\8220714 block</e2>_14\NN\21939 in_15\IN\13603305 a_16\DT\13649268 73_17\CD\1740 year_18\NN\15113229 old_19\JJ\1740 woman_20\NN\9605289 ._21\.\1740
D009661_D002037 CID aventyl_0\NN\1740 (_1\-LRB-\1740 <e1>nortriptyline</e1>_2\NN\4482543 )_3\-RRB-\1740 and_4\CC\1740 elavil_5\NN\4482543 (_6\-LRB-\1740 amitriptyline_7\NN\4482543 )_8\-RRB-\1740 each_9\DT\1740 produced_10\VBD\1617192 <e2>left_11\JJ\1740 bundle_12\NN\7951464 branch_13\NN\8220714 block</e2>_14\NN\21939 in_15\IN\13603305 a_16\DT\13649268 73_17\CD\1740 year_18\NN\15113229 old_19\JJ\1740 woman_20\NN\9605289 ._21\.\1740
D000639_D002037 CID aventyl_0\NN\1740 (_1\-LRB-\1740 nortriptyline_2\NN\4482543 )_3\-RRB-\1740 and_4\CC\1740 <e1>elavil</e1>_5\NN\4482543 (_6\-LRB-\1740 amitriptyline_7\NN\4482543 )_8\-RRB-\1740 each_9\DT\1740 produced_10\VBD\1617192 <e2>left_11\JJ\1740 bundle_12\NN\7951464 branch_13\NN\8220714 block</e2>_14\NN\21939 in_15\IN\13603305 a_16\DT\13649268 73_17\CD\1740 year_18\NN\15113229 old_19\JJ\1740 woman_20\NN\9605289 ._21\.\1740
D000639_D002037 CID aventyl_0\NN\1740 (_1\-LRB-\1740 nortriptyline_2\NN\4482543 )_3\-RRB-\1740 and_4\CC\1740 elavil_5\NN\4482543 (_6\-LRB-\1740 <e1>amitriptyline</e1>_7\NN\4482543 )_8\-RRB-\1740 each_9\DT\1740 produced_10\VBD\1617192 <e2>left_11\JJ\1740 bundle_12\NN\7951464 branch_13\NN\8220714 block</e2>_14\NN\21939 in_15\IN\13603305 a_16\DT\13649268 73_17\CD\1740 year_18\NN\15113229 old_19\JJ\1740 woman_20\NN\9605289 ._21\.\1740
D008012_D001145 NONE the_0\DT\1740 <e2>ventricular_1\NN\1740 arrhythmias</e2>_2\NNS\14103288 responded_3\VBD\2367363 to_4\TO\1740 intravenous_5\JJ\1740 administration_6\NN\1133281 of_7\IN\1740 <e1>lidocaine</e1>_8\NN\3681148 and_9\CC\1740 to_10\TO\1740 direct_11\JJ\1740 current_12\JJ\1740 electric_13\JJ\1740 shock_14\NN\7510495 ;_15\:\1740 ventricular_16\JJ\1740 pacing_17\NN\15122011 was_18\VBD\836236 required_19\VBN\754942 in_20\IN\13603305 some_21\DT\1740 instances_22\NNS\7283608 and_23\CC\1740 intravenous_24\JJ\1740 administration_25\NN\1133281 of_26\IN\1740 propranolol_27\NN\1740 combined_28\VBN\2630189 with_29\IN\1740 ventricular_30\JJ\1740 pacing_31\NN\15122011 in_32\IN\13603305 one_33\CD\13741022 ._34\.\1740
D011433_D001145 NONE the_0\DT\1740 <e2>ventricular_1\NN\1740 arrhythmias</e2>_2\NNS\14103288 responded_3\VBD\2367363 to_4\TO\1740 intravenous_5\JJ\1740 administration_6\NN\1133281 of_7\IN\1740 lidocaine_8\NN\3681148 and_9\CC\1740 to_10\TO\1740 direct_11\JJ\1740 current_12\JJ\1740 electric_13\JJ\1740 shock_14\NN\7510495 ;_15\:\1740 ventricular_16\JJ\1740 pacing_17\NN\15122011 was_18\VBD\836236 required_19\VBN\754942 in_20\IN\13603305 some_21\DT\1740 instances_22\NNS\7283608 and_23\CC\1740 intravenous_24\JJ\1740 administration_25\NN\1133281 of_26\IN\1740 <e1>propranolol</e1>_27\NN\1740 combined_28\VBN\2630189 with_29\IN\1740 ventricular_30\JJ\1740 pacing_31\NN\15122011 in_32\IN\13603305 one_33\CD\13741022 ._34\.\1740
D010640_D005117 NONE a_0\DT\13649268 prospective_1\JJ\1740 clinical_2\JJ\1740 trial_3\NN\786195 is_4\VBZ\836236 suggested_5\VBN\1010118 to_6\TO\1740 quantify_7\VB\947077 the_8\DT\1740 risk_9\NN\14541044 of_10\IN\1740 <e2>cardiac_11\JJ\1740 complications</e2>_12\NNS\1073995 to_13\TO\1740 patients_14\NNS\9898892 receiving_15\VBG\2210855 <e1>phenothiazines</e1>_16\NNS\14771088 or_17\CC\3541091 tricyclic_18\JJ\1740 antidepressant_19\JJ\1740 drugs_20\NNS\14778436 ._21\.\1740
12745515
D016642_D012640 CID <e2>seizure</e2>_0\NNP\14081375 associated_1\VBN\628491 with_2\IN\1740 sleep_3\NN\14034177 deprivation_4\NN\14493145 and_5\CC\1740 sustained-release_6\JJ\1740 <e1>bupropion</e1>_7\NN\1740 ._8\.\1740
D016642_D012640 CID this_0\DT\1740 case_1\NN\7283608 report_2\NN\6470073 describes_3\VBZ\1001294 a_4\DT\13649268 generalized_5\VBN\634472 <e2>seizure</e2>_6\NN\14081375 associated_7\VBN\628491 with_8\IN\1740 sustained-release_9\JJ\1740 <e1>bupropion</e1>_10\NN\1740 use_11\NN\407535 and_12\CC\1740 sleep_13\NN\14034177 deprivation_14\NN\14493145 ._15\.\1740
D016642_D012640 CID after_0\IN\1740 5_1\CD\13741022 weeks_2\NNS\15113229 of_3\IN\1740 <e1>bupropion</e1>_4\NN\1740 use_5\NN\407535 ,_6\,\1740 the_7\DT\1740 subject_8\NN\6598915 experienced_9\VBD\2108377 a_10\DT\13649268 generalized_11\JJ\1740 tonic_12\JJ\1740 clonic_13\NN\1740 <e2>seizure</e2>_14\NN\14081375 after_15\IN\1740 staying_16\VBG\2604760 up_17\RP\1740 nearly_18\RB\1740 all_19\DT\1740 night_20\NN\15113229 packing_21\VBG\1486312 and_22\CC\1740 moving_23\VBG\2367363 to_24\IN\1740 a_25\DT\13649268 new_26\JJ\1740 residence_27\NN\8491027 ._28\.\1740
D016642_D012640 CID we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 sleep_3\NN\14034177 deprivation_4\NN\14493145 may_5\MD\15209706 add_6\VB\156601 to_7\IN\1740 the_8\DT\1740 risk_9\NN\14541044 of_10\IN\1740 <e1>bupropion-associated</e1>_11\JJ\1740 <e2>seizures</e2>_12\NNS\14081375 ._13\.\1740
D016642_D012892 NONE seizure_0\NNP\14081375 associated_1\VBN\628491 with_2\IN\1740 <e2>sleep_3\NN\14034177 deprivation</e2>_4\NN\14493145 and_5\CC\1740 sustained-release_6\JJ\1740 <e1>bupropion</e1>_7\NN\1740 ._8\.\1740
D016642_D012892 NONE this_0\DT\1740 case_1\NN\7283608 report_2\NN\6470073 describes_3\VBZ\1001294 a_4\DT\13649268 generalized_5\VBN\634472 seizure_6\NN\14081375 associated_7\VBN\628491 with_8\IN\1740 sustained-release_9\JJ\1740 <e1>bupropion</e1>_10\NN\1740 use_11\NN\407535 and_12\CC\1740 <e2>sleep_13\NN\14034177 deprivation</e2>_14\NN\14493145 ._15\.\1740
D016642_D012892 NONE we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 <e2>sleep_3\NN\14034177 deprivation</e2>_4\NN\14493145 may_5\MD\15209706 add_6\VB\156601 to_7\IN\1740 the_8\DT\1740 risk_9\NN\14541044 of_10\IN\1740 <e1>bupropion-associated</e1>_11\JJ\1740 seizures_12\NNS\14081375 ._13\.\1740
3708922
D016572_D007674 CID experimental_0\JJ\1740 <e1>cyclosporine</e1>_1\NN\1740 <e2>nephrotoxicity</e2>_2\NN\1740 :_3\:\1740 risk_4\NN\14541044 of_5\IN\1740 concomitant_6\JJ\1740 chemotherapy_7\NN\661091 ._8\.\1740
D016572_D007674 CID the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 <e1>cyclosporine</e1>_3\NN\1740 (_4\-LRB-\1740 csa_5\NN\1740 )_6\-RRB-\1740 alone_7\RB\1740 or_8\CC\3541091 in_9\IN\13603305 combination_10\NN\7951464 with_11\IN\1740 various_12\JJ\1740 chemotherapeutics_13\NNS\1740 in_14\IN\13603305 the_15\DT\1740 development_16\NN\248977 of_17\IN\1740 <e2>renal_18\JJ\1740 toxicity</e2>_19\NN\13576101 was_20\VBD\836236 evaluated_21\VBN\670261 in_22\IN\13603305 rats_23\NNS\2329401 ._24\.\1740
D016572_D007674 CID the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 cyclosporine_3\NN\1740 (_4\-LRB-\1740 <e1>csa</e1>_5\NN\1740 )_6\-RRB-\1740 alone_7\RB\1740 or_8\CC\3541091 in_9\IN\13603305 combination_10\NN\7951464 with_11\IN\1740 various_12\JJ\1740 chemotherapeutics_13\NNS\1740 in_14\IN\13603305 the_15\DT\1740 development_16\NN\248977 of_17\IN\1740 <e2>renal_18\JJ\1740 toxicity</e2>_19\NN\13576101 was_20\VBD\836236 evaluated_21\VBN\670261 in_22\IN\13603305 rats_23\NNS\2329401 ._24\.\1740
D016572_D007674 CID the_0\DT\1740 combined_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 <e1>csa</e1>_4\NN\1740 and_5\CC\1740 various_6\JJ\1740 chemotherapeutic_7\JJ\1740 drugs_8\NNS\14778436 with_9\IN\1740 a_10\DT\13649268 <e2>nephrotoxic</e2>_11\JJ\1740 potential_12\NN\14481929 ,_13\,\1740 such_14\JJ\1740 as_15\IN\14622893 gentamicin_16\NN\2716866 (_17\-LRB-\1740 at_18\IN\14622893 therapeutic_19\JJ\1740 doses_20\NNS\3740161 )_21\-RRB-\1740 ,_22\,\1740 amphothericin_23\NN\1740 b_24\NN\1355326 and_25\CC\1740 ketoconazole_26\NN\1740 ,_27\,\1740 which_28\WDT\1740 are_29\VBP\836236 frequently_30\RB\1740 used_31\VBN\1156834 in_32\IN\13603305 immunosuppressed_33\JJ\1740 patients_34\NNS\9898892 ,_35\,\1740 did_36\VBD\1640855 not_37\RB\1740 aggravate_38\VB\126264 the_39\DT\1740 csa_40\NN\1740 induced_41\JJ\1740 toxicity_42\NN\13576101 in_43\IN\13603305 the_44\DT\1740 rat_45\NN\2329401 model_46\NN\5888929 ._47\.\1740
D016572_D007674 CID the_0\DT\1740 combined_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 csa_4\NN\1740 and_5\CC\1740 various_6\JJ\1740 chemotherapeutic_7\JJ\1740 drugs_8\NNS\14778436 with_9\IN\1740 a_10\DT\13649268 <e2>nephrotoxic</e2>_11\JJ\1740 potential_12\NN\14481929 ,_13\,\1740 such_14\JJ\1740 as_15\IN\14622893 gentamicin_16\NN\2716866 (_17\-LRB-\1740 at_18\IN\14622893 therapeutic_19\JJ\1740 doses_20\NNS\3740161 )_21\-RRB-\1740 ,_22\,\1740 amphothericin_23\NN\1740 b_24\NN\1355326 and_25\CC\1740 ketoconazole_26\NN\1740 ,_27\,\1740 which_28\WDT\1740 are_29\VBP\836236 frequently_30\RB\1740 used_31\VBN\1156834 in_32\IN\13603305 immunosuppressed_33\JJ\1740 patients_34\NNS\9898892 ,_35\,\1740 did_36\VBD\1640855 not_37\RB\1740 aggravate_38\VB\126264 the_39\DT\1740 <e1>csa</e1>_40\NN\1740 induced_41\JJ\1740 toxicity_42\NN\13576101 in_43\IN\13603305 the_44\DT\1740 rat_45\NN\2329401 model_46\NN\5888929 ._47\.\1740
D016572_D007674 CID gentamicin_0\NN\2716866 at_1\IN\14622893 toxic_2\JJ\1740 doses_3\NNS\3740161 ,_4\,\1740 however_5\RB\1740 ,_6\,\1740 increased_7\VBN\169651 <e1>csa</e1>_8\NN\1740 <e2>nephrotoxicity</e2>_9\NN\1740 ._10\.\1740
D016572_D007674 CID thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 <e2>nephrotoxicity</e2>_3\NN\1740 induced_4\VBN\1627355 by_5\IN\1740 <e1>csa</e1>_6\NN\1740 has_7\VBZ\2108377 a_8\DT\13649268 different_9\JJ\1740 pathogenetic_10\JJ\1740 mechanism_11\NN\13446390 ._12\.\1740
D016572_D064420 NONE the_0\DT\1740 combined_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 <e1>csa</e1>_4\NN\1740 and_5\CC\1740 various_6\JJ\1740 chemotherapeutic_7\JJ\1740 drugs_8\NNS\14778436 with_9\IN\1740 a_10\DT\13649268 nephrotoxic_11\JJ\1740 potential_12\NN\14481929 ,_13\,\1740 such_14\JJ\1740 as_15\IN\14622893 gentamicin_16\NN\2716866 (_17\-LRB-\1740 at_18\IN\14622893 therapeutic_19\JJ\1740 doses_20\NNS\3740161 )_21\-RRB-\1740 ,_22\,\1740 amphothericin_23\NN\1740 b_24\NN\1355326 and_25\CC\1740 ketoconazole_26\NN\1740 ,_27\,\1740 which_28\WDT\1740 are_29\VBP\836236 frequently_30\RB\1740 used_31\VBN\1156834 in_32\IN\13603305 immunosuppressed_33\JJ\1740 patients_34\NNS\9898892 ,_35\,\1740 did_36\VBD\1640855 not_37\RB\1740 aggravate_38\VB\126264 the_39\DT\1740 csa_40\NN\1740 induced_41\JJ\1740 <e2>toxicity</e2>_42\NN\13576101 in_43\IN\13603305 the_44\DT\1740 rat_45\NN\2329401 model_46\NN\5888929 ._47\.\1740
D016572_D064420 NONE the_0\DT\1740 combined_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 csa_4\NN\1740 and_5\CC\1740 various_6\JJ\1740 chemotherapeutic_7\JJ\1740 drugs_8\NNS\14778436 with_9\IN\1740 a_10\DT\13649268 nephrotoxic_11\JJ\1740 potential_12\NN\14481929 ,_13\,\1740 such_14\JJ\1740 as_15\IN\14622893 gentamicin_16\NN\2716866 (_17\-LRB-\1740 at_18\IN\14622893 therapeutic_19\JJ\1740 doses_20\NNS\3740161 )_21\-RRB-\1740 ,_22\,\1740 amphothericin_23\NN\1740 b_24\NN\1355326 and_25\CC\1740 ketoconazole_26\NN\1740 ,_27\,\1740 which_28\WDT\1740 are_29\VBP\836236 frequently_30\RB\1740 used_31\VBN\1156834 in_32\IN\13603305 immunosuppressed_33\JJ\1740 patients_34\NNS\9898892 ,_35\,\1740 did_36\VBD\1640855 not_37\RB\1740 aggravate_38\VB\126264 the_39\DT\1740 <e1>csa</e1>_40\NN\1740 induced_41\JJ\1740 <e2>toxicity</e2>_42\NN\13576101 in_43\IN\13603305 the_44\DT\1740 rat_45\NN\2329401 model_46\NN\5888929 ._47\.\1740
D005839_D007674 NONE the_0\DT\1740 combined_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 csa_4\NN\1740 and_5\CC\1740 various_6\JJ\1740 chemotherapeutic_7\JJ\1740 drugs_8\NNS\14778436 with_9\IN\1740 a_10\DT\13649268 <e2>nephrotoxic</e2>_11\JJ\1740 potential_12\NN\14481929 ,_13\,\1740 such_14\JJ\1740 as_15\IN\14622893 <e1>gentamicin</e1>_16\NN\2716866 (_17\-LRB-\1740 at_18\IN\14622893 therapeutic_19\JJ\1740 doses_20\NNS\3740161 )_21\-RRB-\1740 ,_22\,\1740 amphothericin_23\NN\1740 b_24\NN\1355326 and_25\CC\1740 ketoconazole_26\NN\1740 ,_27\,\1740 which_28\WDT\1740 are_29\VBP\836236 frequently_30\RB\1740 used_31\VBN\1156834 in_32\IN\13603305 immunosuppressed_33\JJ\1740 patients_34\NNS\9898892 ,_35\,\1740 did_36\VBD\1640855 not_37\RB\1740 aggravate_38\VB\126264 the_39\DT\1740 csa_40\NN\1740 induced_41\JJ\1740 toxicity_42\NN\13576101 in_43\IN\13603305 the_44\DT\1740 rat_45\NN\2329401 model_46\NN\5888929 ._47\.\1740
D005839_D007674 NONE <e1>gentamicin</e1>_0\NN\2716866 at_1\IN\14622893 toxic_2\JJ\1740 doses_3\NNS\3740161 ,_4\,\1740 however_5\RB\1740 ,_6\,\1740 increased_7\VBN\169651 csa_8\NN\1740 <e2>nephrotoxicity</e2>_9\NN\1740 ._10\.\1740
D005839_D064420 NONE the_0\DT\1740 combined_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 csa_4\NN\1740 and_5\CC\1740 various_6\JJ\1740 chemotherapeutic_7\JJ\1740 drugs_8\NNS\14778436 with_9\IN\1740 a_10\DT\13649268 nephrotoxic_11\JJ\1740 potential_12\NN\14481929 ,_13\,\1740 such_14\JJ\1740 as_15\IN\14622893 <e1>gentamicin</e1>_16\NN\2716866 (_17\-LRB-\1740 at_18\IN\14622893 therapeutic_19\JJ\1740 doses_20\NNS\3740161 )_21\-RRB-\1740 ,_22\,\1740 amphothericin_23\NN\1740 b_24\NN\1355326 and_25\CC\1740 ketoconazole_26\NN\1740 ,_27\,\1740 which_28\WDT\1740 are_29\VBP\836236 frequently_30\RB\1740 used_31\VBN\1156834 in_32\IN\13603305 immunosuppressed_33\JJ\1740 patients_34\NNS\9898892 ,_35\,\1740 did_36\VBD\1640855 not_37\RB\1740 aggravate_38\VB\126264 the_39\DT\1740 csa_40\NN\1740 induced_41\JJ\1740 <e2>toxicity</e2>_42\NN\13576101 in_43\IN\13603305 the_44\DT\1740 rat_45\NN\2329401 model_46\NN\5888929 ._47\.\1740
D000666_D007674 NONE the_0\DT\1740 combined_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 csa_4\NN\1740 and_5\CC\1740 various_6\JJ\1740 chemotherapeutic_7\JJ\1740 drugs_8\NNS\14778436 with_9\IN\1740 a_10\DT\13649268 <e2>nephrotoxic</e2>_11\JJ\1740 potential_12\NN\14481929 ,_13\,\1740 such_14\JJ\1740 as_15\IN\14622893 gentamicin_16\NN\2716866 (_17\-LRB-\1740 at_18\IN\14622893 therapeutic_19\JJ\1740 doses_20\NNS\3740161 )_21\-RRB-\1740 ,_22\,\1740 <e1>amphothericin_23\NN\1740 b</e1>_24\NN\1355326 and_25\CC\1740 ketoconazole_26\NN\1740 ,_27\,\1740 which_28\WDT\1740 are_29\VBP\836236 frequently_30\RB\1740 used_31\VBN\1156834 in_32\IN\13603305 immunosuppressed_33\JJ\1740 patients_34\NNS\9898892 ,_35\,\1740 did_36\VBD\1640855 not_37\RB\1740 aggravate_38\VB\126264 the_39\DT\1740 csa_40\NN\1740 induced_41\JJ\1740 toxicity_42\NN\13576101 in_43\IN\13603305 the_44\DT\1740 rat_45\NN\2329401 model_46\NN\5888929 ._47\.\1740
D000666_D064420 NONE the_0\DT\1740 combined_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 csa_4\NN\1740 and_5\CC\1740 various_6\JJ\1740 chemotherapeutic_7\JJ\1740 drugs_8\NNS\14778436 with_9\IN\1740 a_10\DT\13649268 nephrotoxic_11\JJ\1740 potential_12\NN\14481929 ,_13\,\1740 such_14\JJ\1740 as_15\IN\14622893 gentamicin_16\NN\2716866 (_17\-LRB-\1740 at_18\IN\14622893 therapeutic_19\JJ\1740 doses_20\NNS\3740161 )_21\-RRB-\1740 ,_22\,\1740 <e1>amphothericin_23\NN\1740 b</e1>_24\NN\1355326 and_25\CC\1740 ketoconazole_26\NN\1740 ,_27\,\1740 which_28\WDT\1740 are_29\VBP\836236 frequently_30\RB\1740 used_31\VBN\1156834 in_32\IN\13603305 immunosuppressed_33\JJ\1740 patients_34\NNS\9898892 ,_35\,\1740 did_36\VBD\1640855 not_37\RB\1740 aggravate_38\VB\126264 the_39\DT\1740 csa_40\NN\1740 induced_41\JJ\1740 <e2>toxicity</e2>_42\NN\13576101 in_43\IN\13603305 the_44\DT\1740 rat_45\NN\2329401 model_46\NN\5888929 ._47\.\1740
D007654_D007674 NONE the_0\DT\1740 combined_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 csa_4\NN\1740 and_5\CC\1740 various_6\JJ\1740 chemotherapeutic_7\JJ\1740 drugs_8\NNS\14778436 with_9\IN\1740 a_10\DT\13649268 <e2>nephrotoxic</e2>_11\JJ\1740 potential_12\NN\14481929 ,_13\,\1740 such_14\JJ\1740 as_15\IN\14622893 gentamicin_16\NN\2716866 (_17\-LRB-\1740 at_18\IN\14622893 therapeutic_19\JJ\1740 doses_20\NNS\3740161 )_21\-RRB-\1740 ,_22\,\1740 amphothericin_23\NN\1740 b_24\NN\1355326 and_25\CC\1740 <e1>ketoconazole</e1>_26\NN\1740 ,_27\,\1740 which_28\WDT\1740 are_29\VBP\836236 frequently_30\RB\1740 used_31\VBN\1156834 in_32\IN\13603305 immunosuppressed_33\JJ\1740 patients_34\NNS\9898892 ,_35\,\1740 did_36\VBD\1640855 not_37\RB\1740 aggravate_38\VB\126264 the_39\DT\1740 csa_40\NN\1740 induced_41\JJ\1740 toxicity_42\NN\13576101 in_43\IN\13603305 the_44\DT\1740 rat_45\NN\2329401 model_46\NN\5888929 ._47\.\1740
D007654_D064420 NONE the_0\DT\1740 combined_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 csa_4\NN\1740 and_5\CC\1740 various_6\JJ\1740 chemotherapeutic_7\JJ\1740 drugs_8\NNS\14778436 with_9\IN\1740 a_10\DT\13649268 nephrotoxic_11\JJ\1740 potential_12\NN\14481929 ,_13\,\1740 such_14\JJ\1740 as_15\IN\14622893 gentamicin_16\NN\2716866 (_17\-LRB-\1740 at_18\IN\14622893 therapeutic_19\JJ\1740 doses_20\NNS\3740161 )_21\-RRB-\1740 ,_22\,\1740 amphothericin_23\NN\1740 b_24\NN\1355326 and_25\CC\1740 <e1>ketoconazole</e1>_26\NN\1740 ,_27\,\1740 which_28\WDT\1740 are_29\VBP\836236 frequently_30\RB\1740 used_31\VBN\1156834 in_32\IN\13603305 immunosuppressed_33\JJ\1740 patients_34\NNS\9898892 ,_35\,\1740 did_36\VBD\1640855 not_37\RB\1740 aggravate_38\VB\126264 the_39\DT\1740 csa_40\NN\1740 induced_41\JJ\1740 <e2>toxicity</e2>_42\NN\13576101 in_43\IN\13603305 the_44\DT\1740 rat_45\NN\2329401 model_46\NN\5888929 ._47\.\1740
15266215
C406224_D013927 NONE effects_0\NNS\13245626 of_1\IN\1740 the_2\DT\1740 cyclooxygenase-2_3\NN\14737847 specific_4\JJ\1740 inhibitor_5\NN\20090 <e1>valdecoxib</e1>_6\NN\3124700 versus_7\CC\1740 nonsteroidal_8\JJ\1740 antiinflammatory_9\JJ\1740 agents_10\NNS\7347 and_11\CC\1740 placebo_12\VB\1740 on_13\IN\1740 cardiovascular_14\JJ\1740 <e2>thrombotic</e2>_15\JJ\1740 events_16\NNS\23100 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 arthritis_20\NN\14171682 ._21\.\1740
C406224_D013927 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 <e2>thrombotic</e2>_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 thrombotic_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 <e1>valdecoxib</e1>_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 diclofenac_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 ibuprofen_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 naproxen_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 osteoarthritis_57\NN\14186541 and_58\CC\1740 rheumatoid_59\JJ\1740 arthritis_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
C406224_D013927 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 thrombotic_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 <e2>thrombotic</e2>_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 <e1>valdecoxib</e1>_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 diclofenac_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 ibuprofen_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 naproxen_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 osteoarthritis_57\NN\14186541 and_58\CC\1740 rheumatoid_59\JJ\1740 arthritis_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
C406224_D013927 NONE crude_0\NN\14686352 and_1\CC\1740 exposure-adjusted_2\JJ\1740 incidences_3\NNS\13821570 of_4\IN\1740 <e2>thrombotic</e2>_5\JJ\1740 events_6\NNS\23100 were_7\VBD\836236 similar_8\JJ\1740 for_9\IN\1740 <e1>valdecoxib</e1>_10\NN\3124700 ,_11\,\1740 nsaids_12\NNS\2721538 ,_13\,\1740 and_14\CC\1740 placebo_15\NN\3740161 ._16\.\1740
C406224_D013927 NONE the_0\DT\1740 risk_1\NN\14541044 of_2\IN\1740 serious_3\JJ\1740 <e2>thrombotic</e2>_4\JJ\1740 events_5\NNS\23100 was_6\VBD\836236 also_7\RB\1740 similar_8\JJ\1740 for_9\IN\1740 each_10\DT\1740 <e1>valdecoxib</e1>_11\NN\3124700 dose_12\NN\3740161 ._13\.\1740
C406224_D013927 NONE <e2>thrombotic</e2>_0\JJ\1740 risk_1\NN\14541044 was_2\VBD\836236 consistently_3\RB\1740 higher_4\JJR\1740 for_5\IN\1740 users_6\NNS\7846 of_7\IN\1740 aspirin_8\NN\2707683 users_9\NNS\7846 than_10\IN\1740 nonusers_11\NNS\1740 of_12\IN\1740 aspirin_13\NN\2707683 (_14\-LRB-\1740 placebo_15\NN\3740161 ,_16\,\1740 1.4_17\CD\1740 %_18\NN\1740 vs._19\CC\1740 0_20\CD\13741022 %_21\NN\1740 ;_22\:\1740 <e1>valdecoxib</e1>_23\NN\3124700 ,_24\,\1740 1.7_25\CD\1740 %_26\NN\1740 vs._27\CC\1740 0.2_28\CD\1740 %_29\NN\1740 ;_30\:\1740 nsaids_31\NNS\2721538 ,_32\,\1740 1.9_33\CD\1740 %_34\NN\1740 vs._35\CC\1740 0.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
C406224_D013927 NONE short-_0\NN\1740 and_1\CC\1740 intermediate-term_2\JJ\1740 treatment_3\NN\654885 with_4\IN\1740 therapeutic_5\JJ\1740 (_6\-LRB-\1740 10_7\CD\13745420 or_8\CC\3541091 20_9\CD\13745420 mg_10\NN\13717155 daily_11\RB\1740 )_12\-RRB-\1740 and_13\CC\1740 supratherapeutic_14\JJ\1740 (_15\-LRB-\1740 40_16\CD\13745420 or_17\CC\3541091 80_18\CD\13745420 mg_19\NN\13717155 daily_20\RB\1740 )_21\-RRB-\1740 <e1>valdecoxib</e1>_22\NN\3124700 doses_23\NNS\3740161 was_24\VBD\836236 not_25\RB\1740 associated_26\VBN\628491 with_27\IN\1740 an_28\DT\6697703 increased_29\VBN\169651 incidence_30\NN\13821570 of_31\IN\1740 <e2>thrombotic</e2>_32\JJ\1740 events_33\NNS\23100 relative_34\JJ\1740 to_35\TO\1740 nonselective_36\JJ\1740 nsaids_37\NNS\2721538 or_38\CC\3541091 placebo_39\NN\3740161 in_40\IN\13603305 osteoarthritis_41\NN\14186541 and_42\CC\1740 rheumatoid_43\JJ\1740 arthritis_44\NN\14171682 patients_45\NNS\9898892 in_46\IN\13603305 controlled_47\VBN\2422663 clinical_48\JJ\1740 trials_49\NNS\786195 ._50\.\1740
C406224_D001168 NONE effects_0\NNS\13245626 of_1\IN\1740 the_2\DT\1740 cyclooxygenase-2_3\NN\14737847 specific_4\JJ\1740 inhibitor_5\NN\20090 <e1>valdecoxib</e1>_6\NN\3124700 versus_7\CC\1740 nonsteroidal_8\JJ\1740 antiinflammatory_9\JJ\1740 agents_10\NNS\7347 and_11\CC\1740 placebo_12\VB\1740 on_13\IN\1740 cardiovascular_14\JJ\1740 thrombotic_15\JJ\1740 events_16\NNS\23100 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 <e2>arthritis</e2>_20\NN\14171682 ._21\.\1740
C406224_D010003 NONE we_0\PRP\1740 evaluated_1\VBD\670261 cardiovascular_2\JJ\1740 event_3\NN\23100 data_4\NNS\7951464 for_5\IN\1740 <e1>valdecoxib</e1>_6\NN\3124700 ,_7\,\1740 a_8\DT\13649268 new_9\JJ\1740 cox-2-specific_10\JJ\1740 inhibitor_11\NN\20090 in_12\IN\13603305 approximately_13\RB\1740 8000_14\CD\1740 patients_15\NNS\9898892 with_16\IN\1740 <e2>osteoarthritis</e2>_17\NN\14186541 and_18\CC\1740 rheumatoid_19\JJ\1740 arthritis_20\NN\14171682 treated_21\VBN\2376958 with_22\IN\1740 this_23\DT\1740 agent_24\NN\7347 in_25\IN\13603305 randomized_26\VBN\278117 clinical_27\JJ\1740 trials_28\NNS\786195 ._29\.\1740
C406224_D010003 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 thrombotic_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 thrombotic_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 <e1>valdecoxib</e1>_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 diclofenac_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 ibuprofen_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 naproxen_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 <e2>osteoarthritis</e2>_57\NN\14186541 and_58\CC\1740 rheumatoid_59\JJ\1740 arthritis_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
C406224_D010003 NONE short-_0\NN\1740 and_1\CC\1740 intermediate-term_2\JJ\1740 treatment_3\NN\654885 with_4\IN\1740 therapeutic_5\JJ\1740 (_6\-LRB-\1740 10_7\CD\13745420 or_8\CC\3541091 20_9\CD\13745420 mg_10\NN\13717155 daily_11\RB\1740 )_12\-RRB-\1740 and_13\CC\1740 supratherapeutic_14\JJ\1740 (_15\-LRB-\1740 40_16\CD\13745420 or_17\CC\3541091 80_18\CD\13745420 mg_19\NN\13717155 daily_20\RB\1740 )_21\-RRB-\1740 <e1>valdecoxib</e1>_22\NN\3124700 doses_23\NNS\3740161 was_24\VBD\836236 not_25\RB\1740 associated_26\VBN\628491 with_27\IN\1740 an_28\DT\6697703 increased_29\VBN\169651 incidence_30\NN\13821570 of_31\IN\1740 thrombotic_32\JJ\1740 events_33\NNS\23100 relative_34\JJ\1740 to_35\TO\1740 nonselective_36\JJ\1740 nsaids_37\NNS\2721538 or_38\CC\3541091 placebo_39\NN\3740161 in_40\IN\13603305 <e2>osteoarthritis</e2>_41\NN\14186541 and_42\CC\1740 rheumatoid_43\JJ\1740 arthritis_44\NN\14171682 patients_45\NNS\9898892 in_46\IN\13603305 controlled_47\VBN\2422663 clinical_48\JJ\1740 trials_49\NNS\786195 ._50\.\1740
C406224_D001172 NONE we_0\PRP\1740 evaluated_1\VBD\670261 cardiovascular_2\JJ\1740 event_3\NN\23100 data_4\NNS\7951464 for_5\IN\1740 <e1>valdecoxib</e1>_6\NN\3124700 ,_7\,\1740 a_8\DT\13649268 new_9\JJ\1740 cox-2-specific_10\JJ\1740 inhibitor_11\NN\20090 in_12\IN\13603305 approximately_13\RB\1740 8000_14\CD\1740 patients_15\NNS\9898892 with_16\IN\1740 osteoarthritis_17\NN\14186541 and_18\CC\1740 <e2>rheumatoid_19\JJ\1740 arthritis</e2>_20\NN\14171682 treated_21\VBN\2376958 with_22\IN\1740 this_23\DT\1740 agent_24\NN\7347 in_25\IN\13603305 randomized_26\VBN\278117 clinical_27\JJ\1740 trials_28\NNS\786195 ._29\.\1740
C406224_D001172 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 thrombotic_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 thrombotic_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 <e1>valdecoxib</e1>_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 diclofenac_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 ibuprofen_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 naproxen_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 osteoarthritis_57\NN\14186541 and_58\CC\1740 <e2>rheumatoid_59\JJ\1740 arthritis</e2>_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
C406224_D001172 NONE short-_0\NN\1740 and_1\CC\1740 intermediate-term_2\JJ\1740 treatment_3\NN\654885 with_4\IN\1740 therapeutic_5\JJ\1740 (_6\-LRB-\1740 10_7\CD\13745420 or_8\CC\3541091 20_9\CD\13745420 mg_10\NN\13717155 daily_11\RB\1740 )_12\-RRB-\1740 and_13\CC\1740 supratherapeutic_14\JJ\1740 (_15\-LRB-\1740 40_16\CD\13745420 or_17\CC\3541091 80_18\CD\13745420 mg_19\NN\13717155 daily_20\RB\1740 )_21\-RRB-\1740 <e1>valdecoxib</e1>_22\NN\3124700 doses_23\NNS\3740161 was_24\VBD\836236 not_25\RB\1740 associated_26\VBN\628491 with_27\IN\1740 an_28\DT\6697703 increased_29\VBN\169651 incidence_30\NN\13821570 of_31\IN\1740 thrombotic_32\JJ\1740 events_33\NNS\23100 relative_34\JJ\1740 to_35\TO\1740 nonselective_36\JJ\1740 nsaids_37\NNS\2721538 or_38\CC\3541091 placebo_39\NN\3740161 in_40\IN\13603305 osteoarthritis_41\NN\14186541 and_42\CC\1740 <e2>rheumatoid_43\JJ\1740 arthritis</e2>_44\NN\14171682 patients_45\NNS\9898892 in_46\IN\13603305 controlled_47\VBN\2422663 clinical_48\JJ\1740 trials_49\NNS\786195 ._50\.\1740
D004008_D013927 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 <e2>thrombotic</e2>_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 thrombotic_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 valdecoxib_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 <e1>diclofenac</e1>_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 ibuprofen_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 naproxen_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 osteoarthritis_57\NN\14186541 and_58\CC\1740 rheumatoid_59\JJ\1740 arthritis_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
D004008_D013927 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 thrombotic_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 <e2>thrombotic</e2>_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 valdecoxib_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 <e1>diclofenac</e1>_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 ibuprofen_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 naproxen_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 osteoarthritis_57\NN\14186541 and_58\CC\1740 rheumatoid_59\JJ\1740 arthritis_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
D004008_D010003 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 thrombotic_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 thrombotic_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 valdecoxib_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 <e1>diclofenac</e1>_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 ibuprofen_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 naproxen_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 <e2>osteoarthritis</e2>_57\NN\14186541 and_58\CC\1740 rheumatoid_59\JJ\1740 arthritis_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
D004008_D001172 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 thrombotic_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 thrombotic_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 valdecoxib_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 <e1>diclofenac</e1>_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 ibuprofen_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 naproxen_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 osteoarthritis_57\NN\14186541 and_58\CC\1740 <e2>rheumatoid_59\JJ\1740 arthritis</e2>_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
D007052_D013927 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 <e2>thrombotic</e2>_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 thrombotic_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 valdecoxib_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 diclofenac_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 <e1>ibuprofen</e1>_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 naproxen_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 osteoarthritis_57\NN\14186541 and_58\CC\1740 rheumatoid_59\JJ\1740 arthritis_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
D007052_D013927 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 thrombotic_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 <e2>thrombotic</e2>_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 valdecoxib_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 diclofenac_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 <e1>ibuprofen</e1>_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 naproxen_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 osteoarthritis_57\NN\14186541 and_58\CC\1740 rheumatoid_59\JJ\1740 arthritis_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
D007052_D010003 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 thrombotic_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 thrombotic_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 valdecoxib_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 diclofenac_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 <e1>ibuprofen</e1>_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 naproxen_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 <e2>osteoarthritis</e2>_57\NN\14186541 and_58\CC\1740 rheumatoid_59\JJ\1740 arthritis_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
D007052_D001172 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 thrombotic_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 thrombotic_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 valdecoxib_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 diclofenac_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 <e1>ibuprofen</e1>_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 naproxen_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 osteoarthritis_57\NN\14186541 and_58\CC\1740 <e2>rheumatoid_59\JJ\1740 arthritis</e2>_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
D009288_D013927 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 <e2>thrombotic</e2>_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 thrombotic_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 valdecoxib_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 diclofenac_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 ibuprofen_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 <e1>naproxen</e1>_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 osteoarthritis_57\NN\14186541 and_58\CC\1740 rheumatoid_59\JJ\1740 arthritis_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
D009288_D013927 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 thrombotic_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 <e2>thrombotic</e2>_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 valdecoxib_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 diclofenac_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 ibuprofen_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 <e1>naproxen</e1>_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 osteoarthritis_57\NN\14186541 and_58\CC\1740 rheumatoid_59\JJ\1740 arthritis_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
D009288_D010003 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 thrombotic_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 thrombotic_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 valdecoxib_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 diclofenac_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 ibuprofen_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 <e1>naproxen</e1>_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 <e2>osteoarthritis</e2>_57\NN\14186541 and_58\CC\1740 rheumatoid_59\JJ\1740 arthritis_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
D009288_D001172 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 cardiovascular_3\JJ\1740 thrombotic_4\JJ\1740 events_5\NNS\23100 (_6\-LRB-\1740 cardiac_7\FW\1740 ,_8\,\1740 cerebrovascular_9\JJ\1740 and_10\CC\1740 peripheral_11\JJ\1740 vascular_12\JJ\1740 ,_13\,\1740 or_14\CC\3541091 arterial_15\JJ\1740 thrombotic_16\NN\1740 )_17\-RRB-\1740 was_18\VBD\836236 determined_19\VBN\1645601 by_20\IN\1740 analyzing_21\VBG\78760 pooled_22\JJ\1740 valdecoxib_23\NN\3124700 (_24\-LRB-\1740 10_25\CD\13745420 -_26\SYM\1740 80_27\CD\13745420 mg_28\NN\13717155 daily_29\RB\1740 )_30\-RRB-\1740 ,_31\,\1740 nonselective_32\JJ\1740 nsaid_33\NN\2721538 (_34\-LRB-\1740 diclofenac_35\JJ\1740 75_36\CD\1740 mg_37\NN\13717155 bid_38\NN\7160883 ,_39\,\1740 ibuprofen_40\NN\3828465 800_41\CD\1740 mg_42\NN\13717155 tid_43\NN\1740 ,_44\,\1740 or_45\CC\3541091 <e1>naproxen</e1>_46\NN\3828465 500_47\CD\13745420 mg_48\NN\13717155 bid_49\VBN\897241 )_50\-RRB-\1740 and_51\CC\1740 placebo_52\NN\3740161 data_53\NNS\7951464 from_54\IN\1740 10_55\CD\13745420 randomized_56\JJ\1740 osteoarthritis_57\NN\14186541 and_58\CC\1740 <e2>rheumatoid_59\JJ\1740 arthritis</e2>_60\NN\14171682 trials_61\NNS\786195 that_62\WDT\1740 were_63\VBD\836236 6_64\CD\13741022 -_65\SYM\1740 52_66\CD\1740 weeks_67\NNS\15113229 in_68\IN\13603305 duration_69\NN\15113229 ._70\.\1740
D001241_D013927 CID <e2>thrombotic</e2>_0\JJ\1740 risk_1\NN\14541044 was_2\VBD\836236 consistently_3\RB\1740 higher_4\JJR\1740 for_5\IN\1740 users_6\NNS\7846 of_7\IN\1740 <e1>aspirin</e1>_8\NN\2707683 users_9\NNS\7846 than_10\IN\1740 nonusers_11\NNS\1740 of_12\IN\1740 aspirin_13\NN\2707683 (_14\-LRB-\1740 placebo_15\NN\3740161 ,_16\,\1740 1.4_17\CD\1740 %_18\NN\1740 vs._19\CC\1740 0_20\CD\13741022 %_21\NN\1740 ;_22\:\1740 valdecoxib_23\NN\3124700 ,_24\,\1740 1.7_25\CD\1740 %_26\NN\1740 vs._27\CC\1740 0.2_28\CD\1740 %_29\NN\1740 ;_30\:\1740 nsaids_31\NNS\2721538 ,_32\,\1740 1.9_33\CD\1740 %_34\NN\1740 vs._35\CC\1740 0.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
D001241_D013927 CID <e2>thrombotic</e2>_0\JJ\1740 risk_1\NN\14541044 was_2\VBD\836236 consistently_3\RB\1740 higher_4\JJR\1740 for_5\IN\1740 users_6\NNS\7846 of_7\IN\1740 aspirin_8\NN\2707683 users_9\NNS\7846 than_10\IN\1740 nonusers_11\NNS\1740 of_12\IN\1740 <e1>aspirin</e1>_13\NN\2707683 (_14\-LRB-\1740 placebo_15\NN\3740161 ,_16\,\1740 1.4_17\CD\1740 %_18\NN\1740 vs._19\CC\1740 0_20\CD\13741022 %_21\NN\1740 ;_22\:\1740 valdecoxib_23\NN\3124700 ,_24\,\1740 1.7_25\CD\1740 %_26\NN\1740 vs._27\CC\1740 0.2_28\CD\1740 %_29\NN\1740 ;_30\:\1740 nsaids_31\NNS\2721538 ,_32\,\1740 1.9_33\CD\1740 %_34\NN\1740 vs._35\CC\1740 0.5_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
3311455
D016572_D007674 CID group_0\NN\2137 ii_1\CD\13741022 also_2\RB\1740 showed_3\VBD\2137132 a_4\DT\13649268 significant_5\JJ\1740 decrease_6\NN\7296428 of_7\IN\1740 chronic_8\JJ\1740 <e2>nephrotoxicity</e2>_9\NN\1740 secondary_10\JJ\1740 to_11\TO\1740 long-term_12\JJ\1740 therapy_13\NN\657604 with_14\IN\1740 <e1>cyclosporine</e1>_15\NN\1740 ._16\.\1740
D016572_D007674 CID we_0\PRP\1740 think_1\VBP\670261 that_2\IN\1740 even_3\RB\1740 these_4\DT\1740 lower_5\JJR\1740 dosages_6\NNS\13576355 of_7\IN\1740 <e1>cyclosporine</e1>_8\NN\1740 can_9\MD\3094503 cause_10\VB\1617192 chronic_11\JJ\1740 <e2>nephrotoxicity</e2>_12\NN\1740 and_13\CC\1740 that_14\IN\1740 further_15\JJ\1740 modification_16\NN\191142 of_17\IN\1740 the_18\DT\1740 immunosuppressive_19\JJ\1740 regimen_20\NN\5898568 is_21\VBZ\836236 required_22\VBN\754942 to_23\TO\1740 completely_24\RB\1740 abolish_25\VB\1740 this_26\DT\1740 toxic_27\JJ\1740 side_28\NN\8630039 effect_29\NN\34213 ._30\.\1740
20635749
D000638_D006333 NONE severe_0\JJ\1740 <e2>congestive_1\JJ\1740 heart_2\NN\5919034 failure</e2>_3\NN\66216 patient_4\NN\9898892 on_5\IN\1740 <e1>amiodarone</e1>_6\JJ\1740 presenting_7\NN\1740 with_8\IN\1740 myxedemic_9\JJ\1740 coma_10\NN\5678932 :_11\:\1740 a_12\DT\13649268 case_13\NN\7283608 report_14\NN\6470073 ._15\.\1740
D000638_D006333 NONE this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 of_5\IN\1740 myxedema_6\JJ\1740 coma_7\NN\5678932 secondary_8\JJ\1740 to_9\TO\1740 <e1>amiodarone-induced</e1>_10\JJ\1740 hypothyroidism_11\NN\14059928 in_12\IN\13603305 a_13\DT\13649268 patient_14\NN\9898892 with_15\IN\1740 severe_16\JJ\1740 <e2>congestive_17\JJ\1740 heart_18\NN\5919034 failure</e2>_19\NN\66216 (_20\-LRB-\1740 chf_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D000638_D006333 NONE this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 of_5\IN\1740 myxedema_6\JJ\1740 coma_7\NN\5678932 secondary_8\JJ\1740 to_9\TO\1740 <e1>amiodarone-induced</e1>_10\JJ\1740 hypothyroidism_11\NN\14059928 in_12\IN\13603305 a_13\DT\13649268 patient_14\NN\9898892 with_15\IN\1740 severe_16\JJ\1740 congestive_17\JJ\1740 heart_18\NN\5919034 failure_19\NN\66216 (_20\-LRB-\1740 <e2>chf</e2>_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D000638_D006333 NONE patients_0\NNS\9898892 with_1\IN\1740 <e2>chf</e2>_2\NN\1740 on_3\IN\1740 <e1>amiodarone</e1>_4\NN\2715941 may_5\MD\15209706 suffer_6\VB\2110220 serious_7\JJ\1740 morbidity_8\NN\13826959 and_9\CC\1740 mortality_10\NN\5054863 from_11\IN\1740 hypothyroidism_12\NN\14059928 ,_13\,\1740 and_14\CC\1740 thus_15\RB\1740 may_16\MD\15209706 deserve_17\VB\2604760 closer_18\JJR\1740 follow_19\VB\1835496 up_20\RP\1740 for_21\IN\1740 thyroid_22\NN\5329735 stimulating_23\NN\1740 hormone_24\NN\5404728 (_25\-LRB-\1740 tsh_26\NN\5407119 )_27\-RRB-\1740 levels_28\NNS\4916342 ._29\.\1740
D000638_D006333 NONE this_0\DT\1740 case_1\NN\7283608 report_2\NN\6470073 carries_3\VBZ\1850315 an_4\DT\6697703 important_5\JJ\1740 clinical_6\JJ\1740 application_7\NN\947128 given_8\VBN\2327200 the_9\DT\1740 frequent_10\JJ\1740 usage_11\NN\407535 of_12\IN\1740 <e1>amiodarone</e1>_13\NN\2715941 among_14\IN\1740 <e2>chf</e2>_15\NN\1740 patients_16\NNS\9898892 ._17\.\1740
D000638_D009230 CID severe_0\JJ\1740 congestive_1\JJ\1740 heart_2\NN\5919034 failure_3\NN\66216 patient_4\NN\9898892 on_5\IN\1740 <e1>amiodarone</e1>_6\JJ\1740 presenting_7\NN\1740 with_8\IN\1740 <e2>myxedemic_9\JJ\1740 coma</e2>_10\NN\5678932 :_11\:\1740 a_12\DT\13649268 case_13\NN\7283608 report_14\NN\6470073 ._15\.\1740
D000638_D009230 CID this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 of_5\IN\1740 <e2>myxedema_6\JJ\1740 coma</e2>_7\NN\5678932 secondary_8\JJ\1740 to_9\TO\1740 <e1>amiodarone-induced</e1>_10\JJ\1740 hypothyroidism_11\NN\14059928 in_12\IN\13603305 a_13\DT\13649268 patient_14\NN\9898892 with_15\IN\1740 severe_16\JJ\1740 congestive_17\JJ\1740 heart_18\NN\5919034 failure_19\NN\66216 (_20\-LRB-\1740 chf_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D000638_D009230 CID to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 and_3\CC\1740 after_4\IN\1740 reviewing_5\VBG\644583 the_6\DT\1740 literature_7\NN\6362953 there_8\EX\27167 is_9\VBZ\836236 one_10\CD\13741022 case_11\NN\7283608 report_12\NN\6470073 of_13\IN\1740 <e2>myxedema_14\JJ\1740 coma</e2>_15\NN\5678932 during_16\IN\1740 long_17\JJ\1740 term_18\NN\6286395 <e1>amiodarone</e1>_19\NN\2715941 therapy_20\NN\657604 ._21\.\1740
D000638_D003128 CID severe_0\JJ\1740 congestive_1\JJ\1740 heart_2\NN\5919034 failure_3\NN\66216 patient_4\NN\9898892 on_5\IN\1740 <e1>amiodarone</e1>_6\JJ\1740 presenting_7\NN\1740 with_8\IN\1740 <e2>myxedemic_9\JJ\1740 coma</e2>_10\NN\5678932 :_11\:\1740 a_12\DT\13649268 case_13\NN\7283608 report_14\NN\6470073 ._15\.\1740
D000638_D003128 CID this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 of_5\IN\1740 <e2>myxedema_6\JJ\1740 coma</e2>_7\NN\5678932 secondary_8\JJ\1740 to_9\TO\1740 <e1>amiodarone-induced</e1>_10\JJ\1740 hypothyroidism_11\NN\14059928 in_12\IN\13603305 a_13\DT\13649268 patient_14\NN\9898892 with_15\IN\1740 severe_16\JJ\1740 congestive_17\JJ\1740 heart_18\NN\5919034 failure_19\NN\66216 (_20\-LRB-\1740 chf_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D000638_D003128 CID to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 and_3\CC\1740 after_4\IN\1740 reviewing_5\VBG\644583 the_6\DT\1740 literature_7\NN\6362953 there_8\EX\27167 is_9\VBZ\836236 one_10\CD\13741022 case_11\NN\7283608 report_12\NN\6470073 of_13\IN\1740 <e2>myxedema_14\JJ\1740 coma</e2>_15\NN\5678932 during_16\IN\1740 long_17\JJ\1740 term_18\NN\6286395 <e1>amiodarone</e1>_19\NN\2715941 therapy_20\NN\657604 ._21\.\1740
D000638_D007037 CID this_0\DT\1740 is_1\VBZ\836236 a_2\DT\13649268 case_3\NN\7283608 report_4\NN\6470073 of_5\IN\1740 myxedema_6\JJ\1740 coma_7\NN\5678932 secondary_8\JJ\1740 to_9\TO\1740 <e1>amiodarone-induced</e1>_10\JJ\1740 <e2>hypothyroidism</e2>_11\NN\14059928 in_12\IN\13603305 a_13\DT\13649268 patient_14\NN\9898892 with_15\IN\1740 severe_16\JJ\1740 congestive_17\JJ\1740 heart_18\NN\5919034 failure_19\NN\66216 (_20\-LRB-\1740 chf_21\NN\1740 )_22\-RRB-\1740 ._23\.\1740
D000638_D007037 CID patients_0\NNS\9898892 with_1\IN\1740 chf_2\NN\1740 on_3\IN\1740 <e1>amiodarone</e1>_4\NN\2715941 may_5\MD\15209706 suffer_6\VB\2110220 serious_7\JJ\1740 morbidity_8\NN\13826959 and_9\CC\1740 mortality_10\NN\5054863 from_11\IN\1740 <e2>hypothyroidism</e2>_12\NN\14059928 ,_13\,\1740 and_14\CC\1740 thus_15\RB\1740 may_16\MD\15209706 deserve_17\VB\2604760 closer_18\JJR\1740 follow_19\VB\1835496 up_20\RP\1740 for_21\IN\1740 thyroid_22\NN\5329735 stimulating_23\NN\1740 hormone_24\NN\5404728 (_25\-LRB-\1740 tsh_26\NN\5407119 )_27\-RRB-\1740 levels_28\NNS\4916342 ._29\.\1740
17042884
C069541_D001480 NONE placebo-level_0\JJ\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>extrapyramidal_3\JJ\1740 symptoms</e2>_4\NNS\5823932 (_5\-LRB-\1740 eps_6\NN\1740 )_7\-RRB-\1740 with_8\IN\1740 <e1>quetiapine</e1>_9\NN\1740 in_10\IN\13603305 controlled_11\VBN\2422663 studies_12\NNS\635850 of_13\IN\1740 patients_14\NNS\9898892 with_15\IN\1740 bipolar_16\JJ\1740 mania_17\NN\9180259 ._18\.\1740
C069541_D001480 NONE placebo-level_0\JJ\1740 incidence_1\NN\13821570 of_2\IN\1740 extrapyramidal_3\JJ\1740 symptoms_4\NNS\5823932 (_5\-LRB-\1740 <e2>eps</e2>_6\NN\1740 )_7\-RRB-\1740 with_8\IN\1740 <e1>quetiapine</e1>_9\NN\1740 in_10\IN\13603305 controlled_11\VBN\2422663 studies_12\NNS\635850 of_13\IN\1740 patients_14\NNS\9898892 with_15\IN\1740 bipolar_16\JJ\1740 mania_17\NN\9180259 ._18\.\1740
C069541_D001480 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 <e2>extrapyramidal_4\JJ\1740 symptoms</e2>_5\NNS\5823932 (_6\-LRB-\1740 eps_7\NN\1740 )_8\-RRB-\1740 ,_9\,\1740 including_10\VBG\690614 akathisia_11\NN\1740 ,_12\,\1740 with_13\IN\1740 <e1>quetiapine</e1>_14\NN\1740 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 bipolar_18\JJ\1740 mania_19\NN\9180259 ._20\.\1740
C069541_D001480 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 extrapyramidal_4\JJ\1740 symptoms_5\NNS\5823932 (_6\-LRB-\1740 <e2>eps</e2>_7\NN\1740 )_8\-RRB-\1740 ,_9\,\1740 including_10\VBG\690614 akathisia_11\NN\1740 ,_12\,\1740 with_13\IN\1740 <e1>quetiapine</e1>_14\NN\1740 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 bipolar_18\JJ\1740 mania_19\NN\9180259 ._20\.\1740
C069541_D001480 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 incidence_3\NN\13821570 of_4\IN\1740 <e2>eps-related</e2>_5\JJ\1740 adverse_6\JJ\1740 events_7\NNS\23100 ,_8\,\1740 including_9\VBG\690614 akathisia_10\NN\1740 ,_11\,\1740 was_12\VBD\836236 no_13\RB\1740 different_14\JJ\1740 with_15\IN\1740 <e1>quetiapine</e1>_16\NN\1740 monotherapy_17\NN\1740 (_18\-LRB-\1740 12.9_19\CD\1740 %_20\NN\1740 )_21\-RRB-\1740 than_22\IN\1740 with_23\IN\1740 placebo_24\NN\3740161 (_25\-LRB-\1740 13.1_26\CD\1740 %_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
C069541_D001480 NONE similarly_0\RB\1740 ,_1\,\1740 <e2>eps-related</e2>_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 with_5\IN\1740 <e1>qtp</e1>_6\NN\1740 +_7\CC\1740 li/dvp_8\NN\1740 (_9\-LRB-\1740 21.4_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 no_14\RB\1740 different_15\JJ\1740 than_16\IN\1740 with_17\IN\1740 pbo_18\NN\1740 +_19\CC\1740 li/dvp_20\NN\1740 (_21\-LRB-\1740 19.2_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
C069541_D001480 NONE haloperidol_0\NNP\3713736 induced_1\VBD\1627355 a_2\DT\13649268 significantly_3\RB\1740 higher_4\JJR\1740 incidence_5\NN\13821570 (_6\-LRB-\1740 p_7\NN\14622893 <_8\XX\1740 0.001_9\CD\1740 )_10\-RRB-\1740 of_11\IN\1740 akathisia_12\NN\1740 (_13\-LRB-\1740 33.3_14\CD\1740 %_15\NN\1740 versus_16\CC\1740 5.9_17\CD\1740 %_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 tremor_21\NN\345926 (_22\-LRB-\1740 30.3_23\CD\1740 %_24\NN\1740 versus_25\CC\1740 7.8_26\CD\1740 %_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 <e2>extrapyramidal_31\JJ\1740 syndrome</e2>_32\NN\5870365 (_33\-LRB-\1740 35.4_34\CD\1740 %_35\NN\1740 versus_36\CC\1740 5.9_37\CD\1740 %_38\NN\1740 )_39\-RRB-\1740 than_40\IN\1740 <e1>quetiapine</e1>_41\NN\1740 ._42\.\1740
C069541_D001480 NONE conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 bipolar_3\JJ\1740 mania_4\NN\9180259 ,_5\,\1740 the_6\DT\1740 incidence_7\NN\13821570 of_8\IN\1740 <e2>eps</e2>_9\NN\1740 ,_10\,\1740 including_11\VBG\690614 akathisia_12\NN\1740 ,_13\,\1740 with_14\IN\1740 <e1>quetiapine</e1>_15\NN\1740 therapy_16\NN\657604 is_17\VBZ\836236 similar_18\JJ\1740 to_19\TO\1740 that_20\DT\1740 with_21\IN\1740 placebo_22\NN\3740161 ._23\.\1740
C069541_D001714 NONE placebo-level_0\JJ\1740 incidence_1\NN\13821570 of_2\IN\1740 extrapyramidal_3\JJ\1740 symptoms_4\NNS\5823932 (_5\-LRB-\1740 eps_6\NN\1740 )_7\-RRB-\1740 with_8\IN\1740 <e1>quetiapine</e1>_9\NN\1740 in_10\IN\13603305 controlled_11\VBN\2422663 studies_12\NNS\635850 of_13\IN\1740 patients_14\NNS\9898892 with_15\IN\1740 <e2>bipolar_16\JJ\1740 mania</e2>_17\NN\9180259 ._18\.\1740
C069541_D001714 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 extrapyramidal_4\JJ\1740 symptoms_5\NNS\5823932 (_6\-LRB-\1740 eps_7\NN\1740 )_8\-RRB-\1740 ,_9\,\1740 including_10\VBG\690614 akathisia_11\NN\1740 ,_12\,\1740 with_13\IN\1740 <e1>quetiapine</e1>_14\NN\1740 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 <e2>bipolar_18\JJ\1740 mania</e2>_19\NN\9180259 ._20\.\1740
C069541_D001714 NONE conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 <e2>bipolar_3\JJ\1740 mania</e2>_4\NN\9180259 ,_5\,\1740 the_6\DT\1740 incidence_7\NN\13821570 of_8\IN\1740 eps_9\NN\1740 ,_10\,\1740 including_11\VBG\690614 akathisia_12\NN\1740 ,_13\,\1740 with_14\IN\1740 <e1>quetiapine</e1>_15\NN\1740 therapy_16\NN\657604 is_17\VBZ\836236 similar_18\JJ\1740 to_19\TO\1740 that_20\DT\1740 with_21\IN\1740 placebo_22\NN\3740161 ._23\.\1740
C069541_D017109 NONE objectives_0\NNS\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 extrapyramidal_4\JJ\1740 symptoms_5\NNS\5823932 (_6\-LRB-\1740 eps_7\NN\1740 )_8\-RRB-\1740 ,_9\,\1740 including_10\VBG\690614 <e2>akathisia</e2>_11\NN\1740 ,_12\,\1740 with_13\IN\1740 <e1>quetiapine</e1>_14\NN\1740 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 bipolar_18\JJ\1740 mania_19\NN\9180259 ._20\.\1740
C069541_D017109 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 incidence_3\NN\13821570 of_4\IN\1740 eps-related_5\JJ\1740 adverse_6\JJ\1740 events_7\NNS\23100 ,_8\,\1740 including_9\VBG\690614 <e2>akathisia</e2>_10\NN\1740 ,_11\,\1740 was_12\VBD\836236 no_13\RB\1740 different_14\JJ\1740 with_15\IN\1740 <e1>quetiapine</e1>_16\NN\1740 monotherapy_17\NN\1740 (_18\-LRB-\1740 12.9_19\CD\1740 %_20\NN\1740 )_21\-RRB-\1740 than_22\IN\1740 with_23\IN\1740 placebo_24\NN\3740161 (_25\-LRB-\1740 13.1_26\CD\1740 %_27\NN\1740 )_28\-RRB-\1740 ._29\.\1740
C069541_D017109 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>akathisia</e2>_3\NN\1740 was_4\VBD\836236 low_5\JJ\1740 and_6\CC\1740 similar_7\JJ\1740 with_8\IN\1740 <e1>quetiapine</e1>_9\NN\1740 monotherapy_10\NN\1740 (_11\-LRB-\1740 3.3_12\CD\1740 %_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 placebo_16\NN\3740161 (_17\-LRB-\1740 6.1_18\CD\1740 %_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 with_23\IN\1740 qtp_24\NN\1740 +_25\CC\1740 li/dvp_26\NN\1740 (_27\-LRB-\1740 3.6_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 and_31\CC\1740 pbo_32\NN\1740 +_33\CC\1740 li/dvp_34\NN\1740 (_35\-LRB-\1740 4.9_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
C069541_D017109 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>akathisia</e2>_3\NN\1740 was_4\VBD\836236 low_5\JJ\1740 and_6\CC\1740 similar_7\JJ\1740 with_8\IN\1740 quetiapine_9\NN\1740 monotherapy_10\NN\1740 (_11\-LRB-\1740 3.3_12\CD\1740 %_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 placebo_16\NN\3740161 (_17\-LRB-\1740 6.1_18\CD\1740 %_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 with_23\IN\1740 <e1>qtp</e1>_24\NN\1740 +_25\CC\1740 li/dvp_26\NN\1740 (_27\-LRB-\1740 3.6_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 and_31\CC\1740 pbo_32\NN\1740 +_33\CC\1740 li/dvp_34\NN\1740 (_35\-LRB-\1740 4.9_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
C069541_D017109 NONE haloperidol_0\NNP\3713736 induced_1\VBD\1627355 a_2\DT\13649268 significantly_3\RB\1740 higher_4\JJR\1740 incidence_5\NN\13821570 (_6\-LRB-\1740 p_7\NN\14622893 <_8\XX\1740 0.001_9\CD\1740 )_10\-RRB-\1740 of_11\IN\1740 <e2>akathisia</e2>_12\NN\1740 (_13\-LRB-\1740 33.3_14\CD\1740 %_15\NN\1740 versus_16\CC\1740 5.9_17\CD\1740 %_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 tremor_21\NN\345926 (_22\-LRB-\1740 30.3_23\CD\1740 %_24\NN\1740 versus_25\CC\1740 7.8_26\CD\1740 %_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 extrapyramidal_31\JJ\1740 syndrome_32\NN\5870365 (_33\-LRB-\1740 35.4_34\CD\1740 %_35\NN\1740 versus_36\CC\1740 5.9_37\CD\1740 %_38\NN\1740 )_39\-RRB-\1740 than_40\IN\1740 <e1>quetiapine</e1>_41\NN\1740 ._42\.\1740
C069541_D017109 NONE conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 bipolar_3\JJ\1740 mania_4\NN\9180259 ,_5\,\1740 the_6\DT\1740 incidence_7\NN\13821570 of_8\IN\1740 eps_9\NN\1740 ,_10\,\1740 including_11\VBG\690614 <e2>akathisia</e2>_12\NN\1740 ,_13\,\1740 with_14\IN\1740 <e1>quetiapine</e1>_15\NN\1740 therapy_16\NN\657604 is_17\VBZ\836236 similar_18\JJ\1740 to_19\TO\1740 that_20\DT\1740 with_21\IN\1740 placebo_22\NN\3740161 ._23\.\1740
D008094_D001480 CID similarly_0\RB\1740 ,_1\,\1740 <e2>eps-related</e2>_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 with_5\IN\1740 qtp_6\NN\1740 +_7\CC\1740 <e1>li/dvp</e1>_8\NN\1740 (_9\-LRB-\1740 21.4_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 no_14\RB\1740 different_15\JJ\1740 than_16\IN\1740 with_17\IN\1740 pbo_18\NN\1740 +_19\CC\1740 li/dvp_20\NN\1740 (_21\-LRB-\1740 19.2_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D008094_D001480 CID similarly_0\RB\1740 ,_1\,\1740 <e2>eps-related</e2>_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 with_5\IN\1740 qtp_6\NN\1740 +_7\CC\1740 li/dvp_8\NN\1740 (_9\-LRB-\1740 21.4_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 no_14\RB\1740 different_15\JJ\1740 than_16\IN\1740 with_17\IN\1740 pbo_18\NN\1740 +_19\CC\1740 <e1>li/dvp</e1>_20\NN\1740 (_21\-LRB-\1740 19.2_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D008094_D001480 CID adverse_0\JJ\1740 events_1\NNS\23100 related_2\JJ\1740 to_3\TO\1740 <e2>eps</e2>_4\NN\1740 occurred_5\VBD\2623529 in_6\IN\13603305 59.6_7\CD\1740 %_8\NN\1740 of_9\IN\1740 patients_10\NNS\9898892 treated_11\VBN\2376958 with_12\IN\1740 haloperidol_13\NN\3713736 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 99_17\CD\1740 )_18\-RRB-\1740 monotherapy_19\NN\1740 ,_20\,\1740 whereas_21\IN\1740 26.5_22\CD\1740 %_23\NN\1740 of_24\IN\1740 patients_25\NNS\9898892 treated_26\VBN\2376958 with_27\IN\1740 <e1>lithium</e1>_28\NN\14625458 (_29\-LRB-\1740 n_30\NN\14622893 =_31\JJ\1740 98_32\CD\1740 )_33\-RRB-\1740 monotherapy_34\NN\1740 experienced_35\JJ\1740 adverse_36\JJ\1740 events_37\NNS\23100 related_38\JJ\1740 to_39\TO\1740 eps_40\NN\1740 ._41\.\1740
D008094_D001480 CID adverse_0\JJ\1740 events_1\NNS\23100 related_2\JJ\1740 to_3\TO\1740 eps_4\NN\1740 occurred_5\VBD\2623529 in_6\IN\13603305 59.6_7\CD\1740 %_8\NN\1740 of_9\IN\1740 patients_10\NNS\9898892 treated_11\VBN\2376958 with_12\IN\1740 haloperidol_13\NN\3713736 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 99_17\CD\1740 )_18\-RRB-\1740 monotherapy_19\NN\1740 ,_20\,\1740 whereas_21\IN\1740 26.5_22\CD\1740 %_23\NN\1740 of_24\IN\1740 patients_25\NNS\9898892 treated_26\VBN\2376958 with_27\IN\1740 <e1>lithium</e1>_28\NN\14625458 (_29\-LRB-\1740 n_30\NN\14622893 =_31\JJ\1740 98_32\CD\1740 )_33\-RRB-\1740 monotherapy_34\NN\1740 experienced_35\JJ\1740 adverse_36\JJ\1740 events_37\NNS\23100 related_38\JJ\1740 to_39\TO\1740 <e2>eps</e2>_40\NN\1740 ._41\.\1740
D014635_D001480 NONE similarly_0\RB\1740 ,_1\,\1740 <e2>eps-related</e2>_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 with_5\IN\1740 qtp_6\NN\1740 +_7\CC\1740 <e1>li/dvp</e1>_8\NN\1740 (_9\-LRB-\1740 21.4_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 no_14\RB\1740 different_15\JJ\1740 than_16\IN\1740 with_17\IN\1740 pbo_18\NN\1740 +_19\CC\1740 li/dvp_20\NN\1740 (_21\-LRB-\1740 19.2_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D014635_D001480 NONE similarly_0\RB\1740 ,_1\,\1740 <e2>eps-related</e2>_2\JJ\1740 adverse_3\JJ\1740 events_4\NNS\23100 with_5\IN\1740 qtp_6\NN\1740 +_7\CC\1740 li/dvp_8\NN\1740 (_9\-LRB-\1740 21.4_10\CD\1740 %_11\NN\1740 )_12\-RRB-\1740 were_13\VBD\836236 no_14\RB\1740 different_15\JJ\1740 than_16\IN\1740 with_17\IN\1740 pbo_18\NN\1740 +_19\CC\1740 <e1>li/dvp</e1>_20\NN\1740 (_21\-LRB-\1740 19.2_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ._25\.\1740
D006220_D001480 CID adverse_0\JJ\1740 events_1\NNS\23100 related_2\JJ\1740 to_3\TO\1740 <e2>eps</e2>_4\NN\1740 occurred_5\VBD\2623529 in_6\IN\13603305 59.6_7\CD\1740 %_8\NN\1740 of_9\IN\1740 patients_10\NNS\9898892 treated_11\VBN\2376958 with_12\IN\1740 <e1>haloperidol</e1>_13\NN\3713736 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 99_17\CD\1740 )_18\-RRB-\1740 monotherapy_19\NN\1740 ,_20\,\1740 whereas_21\IN\1740 26.5_22\CD\1740 %_23\NN\1740 of_24\IN\1740 patients_25\NNS\9898892 treated_26\VBN\2376958 with_27\IN\1740 lithium_28\NN\14625458 (_29\-LRB-\1740 n_30\NN\14622893 =_31\JJ\1740 98_32\CD\1740 )_33\-RRB-\1740 monotherapy_34\NN\1740 experienced_35\JJ\1740 adverse_36\JJ\1740 events_37\NNS\23100 related_38\JJ\1740 to_39\TO\1740 eps_40\NN\1740 ._41\.\1740
D006220_D001480 CID adverse_0\JJ\1740 events_1\NNS\23100 related_2\JJ\1740 to_3\TO\1740 eps_4\NN\1740 occurred_5\VBD\2623529 in_6\IN\13603305 59.6_7\CD\1740 %_8\NN\1740 of_9\IN\1740 patients_10\NNS\9898892 treated_11\VBN\2376958 with_12\IN\1740 <e1>haloperidol</e1>_13\NN\3713736 (_14\-LRB-\1740 n_15\NN\14622893 =_16\JJ\1740 99_17\CD\1740 )_18\-RRB-\1740 monotherapy_19\NN\1740 ,_20\,\1740 whereas_21\IN\1740 26.5_22\CD\1740 %_23\NN\1740 of_24\IN\1740 patients_25\NNS\9898892 treated_26\VBN\2376958 with_27\IN\1740 lithium_28\NN\14625458 (_29\-LRB-\1740 n_30\NN\14622893 =_31\JJ\1740 98_32\CD\1740 )_33\-RRB-\1740 monotherapy_34\NN\1740 experienced_35\JJ\1740 adverse_36\JJ\1740 events_37\NNS\23100 related_38\JJ\1740 to_39\TO\1740 <e2>eps</e2>_40\NN\1740 ._41\.\1740
D006220_D001480 CID <e1>haloperidol</e1>_0\NNP\3713736 induced_1\VBD\1627355 a_2\DT\13649268 significantly_3\RB\1740 higher_4\JJR\1740 incidence_5\NN\13821570 (_6\-LRB-\1740 p_7\NN\14622893 <_8\XX\1740 0.001_9\CD\1740 )_10\-RRB-\1740 of_11\IN\1740 akathisia_12\NN\1740 (_13\-LRB-\1740 33.3_14\CD\1740 %_15\NN\1740 versus_16\CC\1740 5.9_17\CD\1740 %_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 tremor_21\NN\345926 (_22\-LRB-\1740 30.3_23\CD\1740 %_24\NN\1740 versus_25\CC\1740 7.8_26\CD\1740 %_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 <e2>extrapyramidal_31\JJ\1740 syndrome</e2>_32\NN\5870365 (_33\-LRB-\1740 35.4_34\CD\1740 %_35\NN\1740 versus_36\CC\1740 5.9_37\CD\1740 %_38\NN\1740 )_39\-RRB-\1740 than_40\IN\1740 quetiapine_41\NN\1740 ._42\.\1740
D008094_D017109 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>akathisia</e2>_3\NN\1740 was_4\VBD\836236 low_5\JJ\1740 and_6\CC\1740 similar_7\JJ\1740 with_8\IN\1740 quetiapine_9\NN\1740 monotherapy_10\NN\1740 (_11\-LRB-\1740 3.3_12\CD\1740 %_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 placebo_16\NN\3740161 (_17\-LRB-\1740 6.1_18\CD\1740 %_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 with_23\IN\1740 qtp_24\NN\1740 +_25\CC\1740 <e1>li/dvp</e1>_26\NN\1740 (_27\-LRB-\1740 3.6_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 and_31\CC\1740 pbo_32\NN\1740 +_33\CC\1740 li/dvp_34\NN\1740 (_35\-LRB-\1740 4.9_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
D008094_D017109 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>akathisia</e2>_3\NN\1740 was_4\VBD\836236 low_5\JJ\1740 and_6\CC\1740 similar_7\JJ\1740 with_8\IN\1740 quetiapine_9\NN\1740 monotherapy_10\NN\1740 (_11\-LRB-\1740 3.3_12\CD\1740 %_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 placebo_16\NN\3740161 (_17\-LRB-\1740 6.1_18\CD\1740 %_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 with_23\IN\1740 qtp_24\NN\1740 +_25\CC\1740 li/dvp_26\NN\1740 (_27\-LRB-\1740 3.6_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 and_31\CC\1740 pbo_32\NN\1740 +_33\CC\1740 <e1>li/dvp</e1>_34\NN\1740 (_35\-LRB-\1740 4.9_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
D014635_D017109 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>akathisia</e2>_3\NN\1740 was_4\VBD\836236 low_5\JJ\1740 and_6\CC\1740 similar_7\JJ\1740 with_8\IN\1740 quetiapine_9\NN\1740 monotherapy_10\NN\1740 (_11\-LRB-\1740 3.3_12\CD\1740 %_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 placebo_16\NN\3740161 (_17\-LRB-\1740 6.1_18\CD\1740 %_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 with_23\IN\1740 qtp_24\NN\1740 +_25\CC\1740 <e1>li/dvp</e1>_26\NN\1740 (_27\-LRB-\1740 3.6_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 and_31\CC\1740 pbo_32\NN\1740 +_33\CC\1740 li/dvp_34\NN\1740 (_35\-LRB-\1740 4.9_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
D014635_D017109 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>akathisia</e2>_3\NN\1740 was_4\VBD\836236 low_5\JJ\1740 and_6\CC\1740 similar_7\JJ\1740 with_8\IN\1740 quetiapine_9\NN\1740 monotherapy_10\NN\1740 (_11\-LRB-\1740 3.3_12\CD\1740 %_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 placebo_16\NN\3740161 (_17\-LRB-\1740 6.1_18\CD\1740 %_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 and_22\CC\1740 with_23\IN\1740 qtp_24\NN\1740 +_25\CC\1740 li/dvp_26\NN\1740 (_27\-LRB-\1740 3.6_28\CD\1740 %_29\NN\1740 )_30\-RRB-\1740 and_31\CC\1740 pbo_32\NN\1740 +_33\CC\1740 <e1>li/dvp</e1>_34\NN\1740 (_35\-LRB-\1740 4.9_36\CD\1740 %_37\NN\1740 )_38\-RRB-\1740 ._39\.\1740
D008094_D014202 CID <e1>lithium</e1>_0\NNP\14625458 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 significantly_5\RB\1740 higher_6\JJR\1740 incidence_7\NN\13821570 (_8\-LRB-\1740 p_9\NN\14622893 <_10\XX\1740 0.05_11\CD\1740 )_12\-RRB-\1740 of_13\IN\1740 <e2>tremor</e2>_14\NN\345926 (_15\-LRB-\1740 18.4_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 than_19\IN\1740 quetiapine_20\NN\1740 (_21\-LRB-\1740 5.6_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ;_25\:\1740 cerebellar_26\JJ\1740 tremor_27\NN\345926 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 a_31\DT\13649268 known_32\JJ\1740 adverse_33\JJ\1740 effect_34\NN\34213 of_35\IN\1740 lithium_36\NN\14625458 ,_37\,\1740 may_38\MD\15209706 have_39\VB\2108377 contributed_40\VBN\126264 to_41\IN\1740 the_42\DT\1740 elevated_43\JJ\1740 rate_44\NN\13815152 of_45\IN\1740 tremor_46\NN\345926 in_47\IN\13603305 patients_48\NNS\9898892 receiving_49\VBG\2210855 lithium_50\NN\14625458 therapy_51\NN\657604 ._52\.\1740
D008094_D014202 CID <e1>lithium</e1>_0\NNP\14625458 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 significantly_5\RB\1740 higher_6\JJR\1740 incidence_7\NN\13821570 (_8\-LRB-\1740 p_9\NN\14622893 <_10\XX\1740 0.05_11\CD\1740 )_12\-RRB-\1740 of_13\IN\1740 tremor_14\NN\345926 (_15\-LRB-\1740 18.4_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 than_19\IN\1740 quetiapine_20\NN\1740 (_21\-LRB-\1740 5.6_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ;_25\:\1740 cerebellar_26\JJ\1740 <e2>tremor</e2>_27\NN\345926 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 a_31\DT\13649268 known_32\JJ\1740 adverse_33\JJ\1740 effect_34\NN\34213 of_35\IN\1740 lithium_36\NN\14625458 ,_37\,\1740 may_38\MD\15209706 have_39\VB\2108377 contributed_40\VBN\126264 to_41\IN\1740 the_42\DT\1740 elevated_43\JJ\1740 rate_44\NN\13815152 of_45\IN\1740 tremor_46\NN\345926 in_47\IN\13603305 patients_48\NNS\9898892 receiving_49\VBG\2210855 lithium_50\NN\14625458 therapy_51\NN\657604 ._52\.\1740
D008094_D014202 CID <e1>lithium</e1>_0\NNP\14625458 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 significantly_5\RB\1740 higher_6\JJR\1740 incidence_7\NN\13821570 (_8\-LRB-\1740 p_9\NN\14622893 <_10\XX\1740 0.05_11\CD\1740 )_12\-RRB-\1740 of_13\IN\1740 tremor_14\NN\345926 (_15\-LRB-\1740 18.4_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 than_19\IN\1740 quetiapine_20\NN\1740 (_21\-LRB-\1740 5.6_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ;_25\:\1740 cerebellar_26\JJ\1740 tremor_27\NN\345926 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 a_31\DT\13649268 known_32\JJ\1740 adverse_33\JJ\1740 effect_34\NN\34213 of_35\IN\1740 lithium_36\NN\14625458 ,_37\,\1740 may_38\MD\15209706 have_39\VB\2108377 contributed_40\VBN\126264 to_41\IN\1740 the_42\DT\1740 elevated_43\JJ\1740 rate_44\NN\13815152 of_45\IN\1740 <e2>tremor</e2>_46\NN\345926 in_47\IN\13603305 patients_48\NNS\9898892 receiving_49\VBG\2210855 lithium_50\NN\14625458 therapy_51\NN\657604 ._52\.\1740
D008094_D014202 CID lithium_0\NNP\14625458 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 significantly_5\RB\1740 higher_6\JJR\1740 incidence_7\NN\13821570 (_8\-LRB-\1740 p_9\NN\14622893 <_10\XX\1740 0.05_11\CD\1740 )_12\-RRB-\1740 of_13\IN\1740 <e2>tremor</e2>_14\NN\345926 (_15\-LRB-\1740 18.4_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 than_19\IN\1740 quetiapine_20\NN\1740 (_21\-LRB-\1740 5.6_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ;_25\:\1740 cerebellar_26\JJ\1740 tremor_27\NN\345926 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 a_31\DT\13649268 known_32\JJ\1740 adverse_33\JJ\1740 effect_34\NN\34213 of_35\IN\1740 <e1>lithium</e1>_36\NN\14625458 ,_37\,\1740 may_38\MD\15209706 have_39\VB\2108377 contributed_40\VBN\126264 to_41\IN\1740 the_42\DT\1740 elevated_43\JJ\1740 rate_44\NN\13815152 of_45\IN\1740 tremor_46\NN\345926 in_47\IN\13603305 patients_48\NNS\9898892 receiving_49\VBG\2210855 lithium_50\NN\14625458 therapy_51\NN\657604 ._52\.\1740
D008094_D014202 CID lithium_0\NNP\14625458 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 significantly_5\RB\1740 higher_6\JJR\1740 incidence_7\NN\13821570 (_8\-LRB-\1740 p_9\NN\14622893 <_10\XX\1740 0.05_11\CD\1740 )_12\-RRB-\1740 of_13\IN\1740 tremor_14\NN\345926 (_15\-LRB-\1740 18.4_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 than_19\IN\1740 quetiapine_20\NN\1740 (_21\-LRB-\1740 5.6_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ;_25\:\1740 cerebellar_26\JJ\1740 <e2>tremor</e2>_27\NN\345926 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 a_31\DT\13649268 known_32\JJ\1740 adverse_33\JJ\1740 effect_34\NN\34213 of_35\IN\1740 <e1>lithium</e1>_36\NN\14625458 ,_37\,\1740 may_38\MD\15209706 have_39\VB\2108377 contributed_40\VBN\126264 to_41\IN\1740 the_42\DT\1740 elevated_43\JJ\1740 rate_44\NN\13815152 of_45\IN\1740 tremor_46\NN\345926 in_47\IN\13603305 patients_48\NNS\9898892 receiving_49\VBG\2210855 lithium_50\NN\14625458 therapy_51\NN\657604 ._52\.\1740
D008094_D014202 CID lithium_0\NNP\14625458 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 significantly_5\RB\1740 higher_6\JJR\1740 incidence_7\NN\13821570 (_8\-LRB-\1740 p_9\NN\14622893 <_10\XX\1740 0.05_11\CD\1740 )_12\-RRB-\1740 of_13\IN\1740 tremor_14\NN\345926 (_15\-LRB-\1740 18.4_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 than_19\IN\1740 quetiapine_20\NN\1740 (_21\-LRB-\1740 5.6_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ;_25\:\1740 cerebellar_26\JJ\1740 tremor_27\NN\345926 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 a_31\DT\13649268 known_32\JJ\1740 adverse_33\JJ\1740 effect_34\NN\34213 of_35\IN\1740 <e1>lithium</e1>_36\NN\14625458 ,_37\,\1740 may_38\MD\15209706 have_39\VB\2108377 contributed_40\VBN\126264 to_41\IN\1740 the_42\DT\1740 elevated_43\JJ\1740 rate_44\NN\13815152 of_45\IN\1740 <e2>tremor</e2>_46\NN\345926 in_47\IN\13603305 patients_48\NNS\9898892 receiving_49\VBG\2210855 lithium_50\NN\14625458 therapy_51\NN\657604 ._52\.\1740
D008094_D014202 CID lithium_0\NNP\14625458 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 significantly_5\RB\1740 higher_6\JJR\1740 incidence_7\NN\13821570 (_8\-LRB-\1740 p_9\NN\14622893 <_10\XX\1740 0.05_11\CD\1740 )_12\-RRB-\1740 of_13\IN\1740 <e2>tremor</e2>_14\NN\345926 (_15\-LRB-\1740 18.4_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 than_19\IN\1740 quetiapine_20\NN\1740 (_21\-LRB-\1740 5.6_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ;_25\:\1740 cerebellar_26\JJ\1740 tremor_27\NN\345926 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 a_31\DT\13649268 known_32\JJ\1740 adverse_33\JJ\1740 effect_34\NN\34213 of_35\IN\1740 lithium_36\NN\14625458 ,_37\,\1740 may_38\MD\15209706 have_39\VB\2108377 contributed_40\VBN\126264 to_41\IN\1740 the_42\DT\1740 elevated_43\JJ\1740 rate_44\NN\13815152 of_45\IN\1740 tremor_46\NN\345926 in_47\IN\13603305 patients_48\NNS\9898892 receiving_49\VBG\2210855 <e1>lithium</e1>_50\NN\14625458 therapy_51\NN\657604 ._52\.\1740
D008094_D014202 CID lithium_0\NNP\14625458 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 significantly_5\RB\1740 higher_6\JJR\1740 incidence_7\NN\13821570 (_8\-LRB-\1740 p_9\NN\14622893 <_10\XX\1740 0.05_11\CD\1740 )_12\-RRB-\1740 of_13\IN\1740 tremor_14\NN\345926 (_15\-LRB-\1740 18.4_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 than_19\IN\1740 quetiapine_20\NN\1740 (_21\-LRB-\1740 5.6_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ;_25\:\1740 cerebellar_26\JJ\1740 <e2>tremor</e2>_27\NN\345926 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 a_31\DT\13649268 known_32\JJ\1740 adverse_33\JJ\1740 effect_34\NN\34213 of_35\IN\1740 lithium_36\NN\14625458 ,_37\,\1740 may_38\MD\15209706 have_39\VB\2108377 contributed_40\VBN\126264 to_41\IN\1740 the_42\DT\1740 elevated_43\JJ\1740 rate_44\NN\13815152 of_45\IN\1740 tremor_46\NN\345926 in_47\IN\13603305 patients_48\NNS\9898892 receiving_49\VBG\2210855 <e1>lithium</e1>_50\NN\14625458 therapy_51\NN\657604 ._52\.\1740
D008094_D014202 CID lithium_0\NNP\14625458 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 significantly_5\RB\1740 higher_6\JJR\1740 incidence_7\NN\13821570 (_8\-LRB-\1740 p_9\NN\14622893 <_10\XX\1740 0.05_11\CD\1740 )_12\-RRB-\1740 of_13\IN\1740 tremor_14\NN\345926 (_15\-LRB-\1740 18.4_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 than_19\IN\1740 quetiapine_20\NN\1740 (_21\-LRB-\1740 5.6_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ;_25\:\1740 cerebellar_26\JJ\1740 tremor_27\NN\345926 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 a_31\DT\13649268 known_32\JJ\1740 adverse_33\JJ\1740 effect_34\NN\34213 of_35\IN\1740 lithium_36\NN\14625458 ,_37\,\1740 may_38\MD\15209706 have_39\VB\2108377 contributed_40\VBN\126264 to_41\IN\1740 the_42\DT\1740 elevated_43\JJ\1740 rate_44\NN\13815152 of_45\IN\1740 <e2>tremor</e2>_46\NN\345926 in_47\IN\13603305 patients_48\NNS\9898892 receiving_49\VBG\2210855 <e1>lithium</e1>_50\NN\14625458 therapy_51\NN\657604 ._52\.\1740
C069541_D014202 NONE lithium_0\NNP\14625458 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 significantly_5\RB\1740 higher_6\JJR\1740 incidence_7\NN\13821570 (_8\-LRB-\1740 p_9\NN\14622893 <_10\XX\1740 0.05_11\CD\1740 )_12\-RRB-\1740 of_13\IN\1740 <e2>tremor</e2>_14\NN\345926 (_15\-LRB-\1740 18.4_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 than_19\IN\1740 <e1>quetiapine</e1>_20\NN\1740 (_21\-LRB-\1740 5.6_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ;_25\:\1740 cerebellar_26\JJ\1740 tremor_27\NN\345926 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 a_31\DT\13649268 known_32\JJ\1740 adverse_33\JJ\1740 effect_34\NN\34213 of_35\IN\1740 lithium_36\NN\14625458 ,_37\,\1740 may_38\MD\15209706 have_39\VB\2108377 contributed_40\VBN\126264 to_41\IN\1740 the_42\DT\1740 elevated_43\JJ\1740 rate_44\NN\13815152 of_45\IN\1740 tremor_46\NN\345926 in_47\IN\13603305 patients_48\NNS\9898892 receiving_49\VBG\2210855 lithium_50\NN\14625458 therapy_51\NN\657604 ._52\.\1740
C069541_D014202 NONE lithium_0\NNP\14625458 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 significantly_5\RB\1740 higher_6\JJR\1740 incidence_7\NN\13821570 (_8\-LRB-\1740 p_9\NN\14622893 <_10\XX\1740 0.05_11\CD\1740 )_12\-RRB-\1740 of_13\IN\1740 tremor_14\NN\345926 (_15\-LRB-\1740 18.4_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 than_19\IN\1740 <e1>quetiapine</e1>_20\NN\1740 (_21\-LRB-\1740 5.6_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ;_25\:\1740 cerebellar_26\JJ\1740 <e2>tremor</e2>_27\NN\345926 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 a_31\DT\13649268 known_32\JJ\1740 adverse_33\JJ\1740 effect_34\NN\34213 of_35\IN\1740 lithium_36\NN\14625458 ,_37\,\1740 may_38\MD\15209706 have_39\VB\2108377 contributed_40\VBN\126264 to_41\IN\1740 the_42\DT\1740 elevated_43\JJ\1740 rate_44\NN\13815152 of_45\IN\1740 tremor_46\NN\345926 in_47\IN\13603305 patients_48\NNS\9898892 receiving_49\VBG\2210855 lithium_50\NN\14625458 therapy_51\NN\657604 ._52\.\1740
C069541_D014202 NONE lithium_0\NNP\14625458 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 significantly_5\RB\1740 higher_6\JJR\1740 incidence_7\NN\13821570 (_8\-LRB-\1740 p_9\NN\14622893 <_10\XX\1740 0.05_11\CD\1740 )_12\-RRB-\1740 of_13\IN\1740 tremor_14\NN\345926 (_15\-LRB-\1740 18.4_16\CD\1740 %_17\NN\1740 )_18\-RRB-\1740 than_19\IN\1740 <e1>quetiapine</e1>_20\NN\1740 (_21\-LRB-\1740 5.6_22\CD\1740 %_23\NN\1740 )_24\-RRB-\1740 ;_25\:\1740 cerebellar_26\JJ\1740 tremor_27\NN\345926 ,_28\,\1740 which_29\WDT\1740 is_30\VBZ\836236 a_31\DT\13649268 known_32\JJ\1740 adverse_33\JJ\1740 effect_34\NN\34213 of_35\IN\1740 lithium_36\NN\14625458 ,_37\,\1740 may_38\MD\15209706 have_39\VB\2108377 contributed_40\VBN\126264 to_41\IN\1740 the_42\DT\1740 elevated_43\JJ\1740 rate_44\NN\13815152 of_45\IN\1740 <e2>tremor</e2>_46\NN\345926 in_47\IN\13603305 patients_48\NNS\9898892 receiving_49\VBG\2210855 lithium_50\NN\14625458 therapy_51\NN\657604 ._52\.\1740
C069541_D014202 NONE haloperidol_0\NNP\3713736 induced_1\VBD\1627355 a_2\DT\13649268 significantly_3\RB\1740 higher_4\JJR\1740 incidence_5\NN\13821570 (_6\-LRB-\1740 p_7\NN\14622893 <_8\XX\1740 0.001_9\CD\1740 )_10\-RRB-\1740 of_11\IN\1740 akathisia_12\NN\1740 (_13\-LRB-\1740 33.3_14\CD\1740 %_15\NN\1740 versus_16\CC\1740 5.9_17\CD\1740 %_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 <e2>tremor</e2>_21\NN\345926 (_22\-LRB-\1740 30.3_23\CD\1740 %_24\NN\1740 versus_25\CC\1740 7.8_26\CD\1740 %_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 extrapyramidal_31\JJ\1740 syndrome_32\NN\5870365 (_33\-LRB-\1740 35.4_34\CD\1740 %_35\NN\1740 versus_36\CC\1740 5.9_37\CD\1740 %_38\NN\1740 )_39\-RRB-\1740 than_40\IN\1740 <e1>quetiapine</e1>_41\NN\1740 ._42\.\1740
D006220_D017109 CID <e1>haloperidol</e1>_0\NNP\3713736 induced_1\VBD\1627355 a_2\DT\13649268 significantly_3\RB\1740 higher_4\JJR\1740 incidence_5\NN\13821570 (_6\-LRB-\1740 p_7\NN\14622893 <_8\XX\1740 0.001_9\CD\1740 )_10\-RRB-\1740 of_11\IN\1740 <e2>akathisia</e2>_12\NN\1740 (_13\-LRB-\1740 33.3_14\CD\1740 %_15\NN\1740 versus_16\CC\1740 5.9_17\CD\1740 %_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 tremor_21\NN\345926 (_22\-LRB-\1740 30.3_23\CD\1740 %_24\NN\1740 versus_25\CC\1740 7.8_26\CD\1740 %_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 extrapyramidal_31\JJ\1740 syndrome_32\NN\5870365 (_33\-LRB-\1740 35.4_34\CD\1740 %_35\NN\1740 versus_36\CC\1740 5.9_37\CD\1740 %_38\NN\1740 )_39\-RRB-\1740 than_40\IN\1740 quetiapine_41\NN\1740 ._42\.\1740
D006220_D014202 CID <e1>haloperidol</e1>_0\NNP\3713736 induced_1\VBD\1627355 a_2\DT\13649268 significantly_3\RB\1740 higher_4\JJR\1740 incidence_5\NN\13821570 (_6\-LRB-\1740 p_7\NN\14622893 <_8\XX\1740 0.001_9\CD\1740 )_10\-RRB-\1740 of_11\IN\1740 akathisia_12\NN\1740 (_13\-LRB-\1740 33.3_14\CD\1740 %_15\NN\1740 versus_16\CC\1740 5.9_17\CD\1740 %_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 <e2>tremor</e2>_21\NN\345926 (_22\-LRB-\1740 30.3_23\CD\1740 %_24\NN\1740 versus_25\CC\1740 7.8_26\CD\1740 %_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 and_30\CC\1740 extrapyramidal_31\JJ\1740 syndrome_32\NN\5870365 (_33\-LRB-\1740 35.4_34\CD\1740 %_35\NN\1740 versus_36\CC\1740 5.9_37\CD\1740 %_38\NN\1740 )_39\-RRB-\1740 than_40\IN\1740 quetiapine_41\NN\1740 ._42\.\1740
85485
D001556_D006528 CID changes_0\NNS\7283608 in_1\IN\13603305 peroxisomes_2\NNS\1740 in_3\IN\13603305 preneoplastic_4\JJ\1740 liver_5\NN\5298729 and_6\CC\1740 <e2>hepatoma</e2>_7\NN\14242337 of_8\IN\1740 mice_9\NNS\2329401 induced_10\VBN\1627355 by_11\IN\1740 <e1>alpha-benzene_12\JJ\1740 hexachloride</e1>_13\NN\1740 ._14\.\1740
D001556_D006528 CID peroxisomes_0\NNS\1740 in_1\IN\13603305 <e2>hepatomas</e2>_2\NNS\14242337 and_3\CC\1740 hyperplastic_4\JJ\1740 preneoplastic_5\JJ\1740 liver_6\NN\5298729 lesions_7\NNS\14204950 induced_8\VBN\1627355 in_9\IN\13603305 mice_10\NNS\2329401 by_11\IN\1740 500_12\CD\13745420 ppm_13\NN\1740 <e1>alpha-benzene_14\JJ\1740 hexachloride</e1>_15\NN\1740 were_16\VBD\836236 examined_17\VBN\789138 histochemically_18\RB\1740 and_19\CC\1740 electron_20\NN\9338013 microscopically_21\RB\1740 ._22\.\1740
D001556_D017093 NONE peroxisomes_0\NNS\1740 in_1\IN\13603305 hepatomas_2\NNS\14242337 and_3\CC\1740 hyperplastic_4\JJ\1740 preneoplastic_5\JJ\1740 <e2>liver_6\NN\5298729 lesions</e2>_7\NNS\14204950 induced_8\VBN\1627355 in_9\IN\13603305 mice_10\NNS\2329401 by_11\IN\1740 500_12\CD\13745420 ppm_13\NN\1740 <e1>alpha-benzene_14\JJ\1740 hexachloride</e1>_15\NN\1740 were_16\VBD\836236 examined_17\VBN\789138 histochemically_18\RB\1740 and_19\CC\1740 electron_20\NN\9338013 microscopically_21\RB\1740 ._22\.\1740
C012282_D006528 NONE although_0\IN\1740 most_1\JJS\1740 of_2\IN\1740 the_3\DT\1740 <e2>hepatomas</e2>_4\NNS\14242337 were_5\VBD\836236 well-differentiated_6\JJ\1740 tumors_7\NNS\14234074 and_8\CC\1740 contained_9\VBD\2632940 a_10\DT\13649268 considerable_11\JJ\1740 number_12\NN\5107765 of_13\IN\1740 peroxisomes_14\NNS\1740 ,_15\,\1740 the_16\DT\1740 tumor_17\NN\14234074 cells_18\NNS\3080309 did_19\VBD\1640855 not_20\RB\1740 respond_21\VB\2367363 to_22\IN\1740 <e1>ethyl-alpha-p-chlorophenoxyisobutyrate</e1>_23\CD\1740 with_24\IN\1740 proliferation_25\NN\13489037 of_26\IN\1740 peroxisomes_27\NNS\1740 ._28\.\1740
C012282_D009369 NONE although_0\IN\1740 most_1\JJS\1740 of_2\IN\1740 the_3\DT\1740 hepatomas_4\NNS\14242337 were_5\VBD\836236 well-differentiated_6\JJ\1740 <e2>tumors</e2>_7\NNS\14234074 and_8\CC\1740 contained_9\VBD\2632940 a_10\DT\13649268 considerable_11\JJ\1740 number_12\NN\5107765 of_13\IN\1740 peroxisomes_14\NNS\1740 ,_15\,\1740 the_16\DT\1740 tumor_17\NN\14234074 cells_18\NNS\3080309 did_19\VBD\1640855 not_20\RB\1740 respond_21\VB\2367363 to_22\IN\1740 <e1>ethyl-alpha-p-chlorophenoxyisobutyrate</e1>_23\CD\1740 with_24\IN\1740 proliferation_25\NN\13489037 of_26\IN\1740 peroxisomes_27\NNS\1740 ._28\.\1740
C012282_D009369 NONE although_0\IN\1740 most_1\JJS\1740 of_2\IN\1740 the_3\DT\1740 hepatomas_4\NNS\14242337 were_5\VBD\836236 well-differentiated_6\JJ\1740 tumors_7\NNS\14234074 and_8\CC\1740 contained_9\VBD\2632940 a_10\DT\13649268 considerable_11\JJ\1740 number_12\NN\5107765 of_13\IN\1740 peroxisomes_14\NNS\1740 ,_15\,\1740 the_16\DT\1740 <e2>tumor</e2>_17\NN\14234074 cells_18\NNS\3080309 did_19\VBD\1640855 not_20\RB\1740 respond_21\VB\2367363 to_22\IN\1740 <e1>ethyl-alpha-p-chlorophenoxyisobutyrate</e1>_23\CD\1740 with_24\IN\1740 proliferation_25\NN\13489037 of_26\IN\1740 peroxisomes_27\NNS\1740 ._28\.\1740
14975762
D004317_D009369 NONE <e1>doxorubicin</e1>_0\NNP\2716866 is_1\VBZ\836236 an_2\DT\6697703 <e2>anti-tumor</e2>_3\JJ\1740 agent_4\NN\7347 that_5\WDT\1740 represses_6\VBZ\2424652 cardiac-specific_7\JJ\1740 gene_8\NN\8459252 expression_9\NN\4679549 and_10\CC\1740 induces_11\VBZ\1627355 myocardial_12\JJ\1740 cell_13\NN\3080309 apoptosis_14\NN\11486178 ._15\.\1740
D004317_D006333 CID these_0\DT\1740 findings_1\NNS\7951464 demonstrate_2\VBP\2137132 that_3\IN\1740 overexpression_4\NN\1740 of_5\IN\1740 p300_6\NN\1740 protects_7\VBZ\1127795 cardiac_8\JJ\1740 myocytes_9\NNS\1740 from_10\IN\1740 <e1>doxorubicin-induced</e1>_11\JJ\1740 apoptosis_12\NN\11486178 and_13\CC\1740 reduces_14\VBZ\441445 the_15\DT\1740 extent_16\NN\13939892 of_17\IN\1740 acute_18\JJ\1740 <e2>heart_19\NN\5919034 failure</e2>_20\NN\66216 in_21\IN\13603305 adult_22\JJ\1740 mice_23\NNS\2329401 in_24\FW\13603305 vivo_25\FW\1740 ._26\.\1740
15930398
D015742_D000647 CID assessment_0\NN\5732756 of_1\IN\1740 the_2\DT\1740 onset_3\NN\7325190 and_4\CC\1740 persistence_5\NN\5053688 of_6\IN\1740 <e2>amnesia</e2>_7\NN\5669934 during_8\IN\1740 procedural_9\JJ\1740 sedation_10\NN\14034177 with_11\IN\1740 <e1>propofol</e1>_12\NN\1740 ._13\.\1740
18201582
C084178_D006973 NONE results_0\NNS\34213 of_1\IN\1740 a_2\DT\13649268 comparative_3\JJ\1740 ,_4\,\1740 phase_5\NN\15113229 iii_6\CD\13741022 ,_7\,\1740 12-week_8\NN\1740 ,_9\,\1740 multicenter_10\NN\1740 ,_11\,\1740 prospective_12\JJ\1740 ,_13\,\1740 randomized_14\JJ\1740 ,_15\,\1740 double-blind_16\JJ\1740 assessment_17\NN\5732756 of_18\IN\1740 the_19\DT\1740 efficacy_20\NN\5199286 and_21\CC\1740 tolerability_22\NN\1740 of_23\IN\1740 a_24\DT\13649268 fixed-dose_25\JJ\1740 combination_26\NN\7951464 of_27\IN\1740 <e1>telmisartan</e1>_28\JJ\1740 and_29\CC\1740 amlodipine_30\NN\1740 versus_31\CC\1740 amlodipine_32\NN\1740 monotherapy_33\NN\1740 in_34\IN\13603305 indian_35\JJ\1740 adults_36\NNS\7846 with_37\IN\1740 stage_38\NN\15113229 ii_39\CD\13741022 <e2>hypertension</e2>_40\NN\14057371 ._41\.\1740
C084178_D006973 NONE objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 evaluate_9\VB\670261 the_10\DT\1740 efficacy_11\NN\5199286 and_12\CC\1740 tolerability_13\NN\1740 of_14\IN\1740 a_15\DT\13649268 new_16\JJ\1740 fixed-dose_17\JJ\1740 combination_18\NN\7951464 (_19\-LRB-\1740 fdc_20\NN\1740 )_21\-RRB-\1740 of_22\IN\1740 <e1>telmisartan</e1>_23\NN\1740 40_24\CD\13745420 mg_25\NN\13717155 +_26\CC\1740 amlodipine_27\NN\1740 5_28\CD\13741022 mg_29\NN\13717155 (_30\-LRB-\1740 t+a_31\NN\1740 )_32\-RRB-\1740 compared_33\VBN\644583 with_34\IN\1740 amlodipine_35\JJ\1740 5-mg_36\JJ\1740 monotherapy_37\NN\1740 (_38\-LRB-\1740 a_39\NN\13649268 )_40\-RRB-\1740 in_41\IN\13603305 adult_42\JJ\1740 indian_43\JJ\1740 patients_44\NNS\9898892 with_45\IN\1740 stage_46\NN\15113229 ii_47\CD\13741022 <e2>hypertension</e2>_48\NN\14057371 ._49\.\1740
D017311_D006973 NONE results_0\NNS\34213 of_1\IN\1740 a_2\DT\13649268 comparative_3\JJ\1740 ,_4\,\1740 phase_5\NN\15113229 iii_6\CD\13741022 ,_7\,\1740 12-week_8\NN\1740 ,_9\,\1740 multicenter_10\NN\1740 ,_11\,\1740 prospective_12\JJ\1740 ,_13\,\1740 randomized_14\JJ\1740 ,_15\,\1740 double-blind_16\JJ\1740 assessment_17\NN\5732756 of_18\IN\1740 the_19\DT\1740 efficacy_20\NN\5199286 and_21\CC\1740 tolerability_22\NN\1740 of_23\IN\1740 a_24\DT\13649268 fixed-dose_25\JJ\1740 combination_26\NN\7951464 of_27\IN\1740 telmisartan_28\JJ\1740 and_29\CC\1740 <e1>amlodipine</e1>_30\NN\1740 versus_31\CC\1740 amlodipine_32\NN\1740 monotherapy_33\NN\1740 in_34\IN\13603305 indian_35\JJ\1740 adults_36\NNS\7846 with_37\IN\1740 stage_38\NN\15113229 ii_39\CD\13741022 <e2>hypertension</e2>_40\NN\14057371 ._41\.\1740
D017311_D006973 NONE results_0\NNS\34213 of_1\IN\1740 a_2\DT\13649268 comparative_3\JJ\1740 ,_4\,\1740 phase_5\NN\15113229 iii_6\CD\13741022 ,_7\,\1740 12-week_8\NN\1740 ,_9\,\1740 multicenter_10\NN\1740 ,_11\,\1740 prospective_12\JJ\1740 ,_13\,\1740 randomized_14\JJ\1740 ,_15\,\1740 double-blind_16\JJ\1740 assessment_17\NN\5732756 of_18\IN\1740 the_19\DT\1740 efficacy_20\NN\5199286 and_21\CC\1740 tolerability_22\NN\1740 of_23\IN\1740 a_24\DT\13649268 fixed-dose_25\JJ\1740 combination_26\NN\7951464 of_27\IN\1740 telmisartan_28\JJ\1740 and_29\CC\1740 amlodipine_30\NN\1740 versus_31\CC\1740 <e1>amlodipine</e1>_32\NN\1740 monotherapy_33\NN\1740 in_34\IN\13603305 indian_35\JJ\1740 adults_36\NNS\7846 with_37\IN\1740 stage_38\NN\15113229 ii_39\CD\13741022 <e2>hypertension</e2>_40\NN\14057371 ._41\.\1740
D017311_D006973 NONE objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 evaluate_9\VB\670261 the_10\DT\1740 efficacy_11\NN\5199286 and_12\CC\1740 tolerability_13\NN\1740 of_14\IN\1740 a_15\DT\13649268 new_16\JJ\1740 fixed-dose_17\JJ\1740 combination_18\NN\7951464 (_19\-LRB-\1740 fdc_20\NN\1740 )_21\-RRB-\1740 of_22\IN\1740 telmisartan_23\NN\1740 40_24\CD\13745420 mg_25\NN\13717155 +_26\CC\1740 <e1>amlodipine</e1>_27\NN\1740 5_28\CD\13741022 mg_29\NN\13717155 (_30\-LRB-\1740 t+a_31\NN\1740 )_32\-RRB-\1740 compared_33\VBN\644583 with_34\IN\1740 amlodipine_35\JJ\1740 5-mg_36\JJ\1740 monotherapy_37\NN\1740 (_38\-LRB-\1740 a_39\NN\13649268 )_40\-RRB-\1740 in_41\IN\13603305 adult_42\JJ\1740 indian_43\JJ\1740 patients_44\NNS\9898892 with_45\IN\1740 stage_46\NN\15113229 ii_47\CD\13741022 <e2>hypertension</e2>_48\NN\14057371 ._49\.\1740
D017311_D006973 NONE objective_0\NN\5980875 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 was_7\VBD\836236 to_8\TO\1740 evaluate_9\VB\670261 the_10\DT\1740 efficacy_11\NN\5199286 and_12\CC\1740 tolerability_13\NN\1740 of_14\IN\1740 a_15\DT\13649268 new_16\JJ\1740 fixed-dose_17\JJ\1740 combination_18\NN\7951464 (_19\-LRB-\1740 fdc_20\NN\1740 )_21\-RRB-\1740 of_22\IN\1740 telmisartan_23\NN\1740 40_24\CD\13745420 mg_25\NN\13717155 +_26\CC\1740 amlodipine_27\NN\1740 5_28\CD\13741022 mg_29\NN\13717155 (_30\-LRB-\1740 t+a_31\NN\1740 )_32\-RRB-\1740 compared_33\VBN\644583 with_34\IN\1740 <e1>amlodipine</e1>_35\JJ\1740 5-mg_36\JJ\1740 monotherapy_37\NN\1740 (_38\-LRB-\1740 a_39\NN\13649268 )_40\-RRB-\1740 in_41\IN\13603305 adult_42\JJ\1740 indian_43\JJ\1740 patients_44\NNS\9898892 with_45\IN\1740 stage_46\NN\15113229 ii_47\CD\13741022 <e2>hypertension</e2>_48\NN\14057371 ._49\.\1740
19917396
D016559_D006332 CID reversible_0\JJ\1740 <e2>myocardial_1\JJ\1740 hypertrophy</e2>_2\NN\14365950 induced_3\VBN\1627355 by_4\IN\1740 <e1>tacrolimus</e1>_5\NN\1740 in_6\IN\13603305 a_7\DT\13649268 pediatric_8\JJ\1740 heart_9\NN\5919034 transplant_10\NN\5267548 recipient_11\NN\9764201 :_12\:\1740 case_13\NN\7283608 report_14\NN\6470073 ._15\.\1740
D016559_D006332 CID herein_0\RB\1740 we_1\PRP\1740 describe_2\VBP\1001294 transient_3\JJ\1740 <e2>myocardial_4\JJ\1740 hypertrophy</e2>_5\NN\14365950 induced_6\VBN\1627355 by_7\IN\1740 <e1>tacrolimus</e1>_8\NN\1740 after_9\IN\1740 heart_10\NN\5919034 transplantation_11\NN\671351 ._12\.\1740
D016559_D006332 CID <e2>myocardial_0\JJ\1740 hypertrophy</e2>_1\NN\14365950 completely_2\RB\1740 resolved_3\VBN\352826 upon_4\IN\1740 reducing_5\VBG\441445 the_6\DT\1740 target_7\NN\7258332 concentration_8\NN\4916342 of_9\IN\1740 <e1>tacrolimus</e1>_10\NN\1740 and_11\CC\1740 did_12\VBD\1640855 not_13\RB\1740 recur_14\VB\339934 ,_15\,\1740 as_16\IN\14622893 confirmed_17\VBN\1011725 at_18\IN\14622893 echocardiography_19\NN\177127 and_20\CC\1740 myocardial_21\JJ\1740 biopsy_22\NN\5739043 ._23\.\1740
D016559_D006332 CID thus_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 conclude_3\VBP\628491 that_4\IN\1740 <e1>tacrolimus</e1>_5\NN\1740 induces_6\VBZ\1627355 reversible_7\JJ\1740 <e2>myocardial_8\JJ\1740 hypertrophy</e2>_9\NN\14365950 ._10\.\1740
10074612
D008775_D007022 CID <e2>hypotension</e2>_0\NN\14057371 ,_1\,\1740 bradycardia_2\NN\14110674 ,_3\,\1740 and_4\CC\1740 asystole_5\NN\14204950 after_6\IN\1740 high-dose_7\JJ\1740 intravenous_8\JJ\1740 <e1>methylprednisolone</e1>_9\NN\1740 in_10\IN\13603305 a_11\DT\13649268 monitored_12\VBN\2169352 patient_13\NN\9898892 ._14\.\1740
D008775_D007022 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 <e2>hypotension</e2>_5\NN\14057371 ,_6\,\1740 bradycardia_7\NN\14110674 ,_8\,\1740 and_9\CC\1740 asystole_10\NN\14204950 after_11\IN\1740 intravenous_12\JJ\1740 administration_13\NN\1133281 of_14\IN\1740 high-dose_15\JJ\1740 <e1>methylprednisolone</e1>_16\NN\1740 in_17\IN\13603305 a_18\DT\13649268 73-year-old_19\JJ\1740 patient_20\NN\9898892 who_21\WP\8299493 underwent_22\VBD\109660 electrocardiographic_23\JJ\1740 (_24\-LRB-\1740 ecg_25\NN\7000195 )_26\-RRB-\1740 monitoring_27\VBG\2169352 throughout_28\IN\1740 the_29\DT\1740 episode_30\NN\7283608 ._31\.\1740
D008775_D001919 CID hypotension_0\NN\14057371 ,_1\,\1740 <e2>bradycardia</e2>_2\NN\14110674 ,_3\,\1740 and_4\CC\1740 asystole_5\NN\14204950 after_6\IN\1740 high-dose_7\JJ\1740 intravenous_8\JJ\1740 <e1>methylprednisolone</e1>_9\NN\1740 in_10\IN\13603305 a_11\DT\13649268 monitored_12\VBN\2169352 patient_13\NN\9898892 ._14\.\1740
D008775_D001919 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 hypotension_5\NN\14057371 ,_6\,\1740 <e2>bradycardia</e2>_7\NN\14110674 ,_8\,\1740 and_9\CC\1740 asystole_10\NN\14204950 after_11\IN\1740 intravenous_12\JJ\1740 administration_13\NN\1133281 of_14\IN\1740 high-dose_15\JJ\1740 <e1>methylprednisolone</e1>_16\NN\1740 in_17\IN\13603305 a_18\DT\13649268 73-year-old_19\JJ\1740 patient_20\NN\9898892 who_21\WP\8299493 underwent_22\VBD\109660 electrocardiographic_23\JJ\1740 (_24\-LRB-\1740 ecg_25\NN\7000195 )_26\-RRB-\1740 monitoring_27\VBG\2169352 throughout_28\IN\1740 the_29\DT\1740 episode_30\NN\7283608 ._31\.\1740
D008775_D006323 CID hypotension_0\NN\14057371 ,_1\,\1740 bradycardia_2\NN\14110674 ,_3\,\1740 and_4\CC\1740 <e2>asystole</e2>_5\NN\14204950 after_6\IN\1740 high-dose_7\JJ\1740 intravenous_8\JJ\1740 <e1>methylprednisolone</e1>_9\NN\1740 in_10\IN\13603305 a_11\DT\13649268 monitored_12\VBN\2169352 patient_13\NN\9898892 ._14\.\1740
D008775_D006323 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 hypotension_5\NN\14057371 ,_6\,\1740 bradycardia_7\NN\14110674 ,_8\,\1740 and_9\CC\1740 <e2>asystole</e2>_10\NN\14204950 after_11\IN\1740 intravenous_12\JJ\1740 administration_13\NN\1133281 of_14\IN\1740 high-dose_15\JJ\1740 <e1>methylprednisolone</e1>_16\NN\1740 in_17\IN\13603305 a_18\DT\13649268 73-year-old_19\JJ\1740 patient_20\NN\9898892 who_21\WP\8299493 underwent_22\VBD\109660 electrocardiographic_23\JJ\1740 (_24\-LRB-\1740 ecg_25\NN\7000195 )_26\-RRB-\1740 monitoring_27\VBG\2169352 throughout_28\IN\1740 the_29\DT\1740 episode_30\NN\7283608 ._31\.\1740
D008775_D003645 NONE this_0\DT\1740 study_1\NN\635850 reviews_2\VBZ\644583 the_3\DT\1740 current_4\JJ\1740 proposed_5\VBN\1010118 mechanisms_6\NNS\13446390 of_7\IN\1740 <e2>sudden_8\JJ\1740 death</e2>_9\NN\7296428 after_10\IN\1740 a_11\DT\13649268 high_12\JJ\1740 dose_13\NN\3740161 of_14\IN\1740 intravenous_15\JJ\1740 <e1>methylprednisolone</e1>_16\NN\1740 (_17\-LRB-\1740 ivmp_18\NNP\1740 )_19\-RRB-\1740 ._20\.\1740
D008775_D003645 NONE this_0\DT\1740 study_1\NN\635850 reviews_2\VBZ\644583 the_3\DT\1740 current_4\JJ\1740 proposed_5\VBN\1010118 mechanisms_6\NNS\13446390 of_7\IN\1740 <e2>sudden_8\JJ\1740 death</e2>_9\NN\7296428 after_10\IN\1740 a_11\DT\13649268 high_12\JJ\1740 dose_13\NN\3740161 of_14\IN\1740 intravenous_15\JJ\1740 methylprednisolone_16\NN\1740 (_17\-LRB-\1740 <e1>ivmp</e1>_18\NNP\1740 )_19\-RRB-\1740 ._20\.\1740
11704023
D013999_D005901 NONE comparison_0\NN\635850 of_1\IN\1740 aqueous_2\JJ\1740 and_3\CC\1740 gellan_4\VB\1740 ophthalmic_5\JJ\1740 <e1>timolol</e1>_6\NNS\2832168 with_7\IN\1740 placebo_8\NN\3740161 on_9\IN\1740 the_10\DT\1740 24-hour_11\JJ\1740 heart_12\NN\5919034 rate_13\NN\13815152 response_14\NN\11410625 in_15\IN\13603305 patients_16\NNS\9898892 on_17\IN\1740 treatment_18\NN\654885 for_19\IN\1740 <e2>glaucoma</e2>_20\NN\14252864 ._21\.\1740
D013999_D005901 NONE design_0\NN\927261 :_1\:\1740 this_2\DT\1740 trial_3\NN\786195 evaluated_4\VBD\670261 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 placebo_8\NN\3740161 ,_9\,\1740 0.5_10\CD\1740 %_11\NN\1740 aqueous_12\JJ\1740 <e1>timolol</e1>_13\NNS\2832168 (_14\-LRB-\1740 timolol_15\CD\2832168 solution_16\NN\14586258 )_17\-RRB-\1740 and_18\CC\1740 a_19\DT\13649268 0.5_20\CD\1740 %_21\NN\1740 timolol_22\JJ\1740 suspension_23\NN\14586258 that_24\WDT\1740 forms_25\VBZ\1617192 a_26\DT\13649268 gel_27\NN\14588219 on_28\IN\1740 application_29\NN\947128 to_30\IN\1740 the_31\DT\1740 conjunctiva_32\NN\5327134 (_33\-LRB-\1740 timolol_34\CD\2832168 gellan_35\NN\1740 )_36\-RRB-\1740 on_37\IN\1740 the_38\DT\1740 24-hour_39\JJ\1740 heart_40\NN\5919034 rate_41\NN\13815152 in_42\IN\13603305 patients_43\NNS\9898892 currently_44\RB\1740 being_45\VBG\836236 treated_46\VBN\2376958 for_47\IN\1740 <e2>glaucoma</e2>_48\NN\14252864 to_49\TO\1740 quantify_50\VB\947077 the_51\DT\1740 reduction_52\NN\351485 in_53\IN\13603305 mean_54\JJ\1740 heart_55\NN\5919034 rate_56\NN\13815152 ._57\.\1740
D013999_D005901 NONE design_0\NN\927261 :_1\:\1740 this_2\DT\1740 trial_3\NN\786195 evaluated_4\VBD\670261 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 placebo_8\NN\3740161 ,_9\,\1740 0.5_10\CD\1740 %_11\NN\1740 aqueous_12\JJ\1740 timolol_13\NNS\2832168 (_14\-LRB-\1740 <e1>timolol</e1>_15\CD\2832168 solution_16\NN\14586258 )_17\-RRB-\1740 and_18\CC\1740 a_19\DT\13649268 0.5_20\CD\1740 %_21\NN\1740 timolol_22\JJ\1740 suspension_23\NN\14586258 that_24\WDT\1740 forms_25\VBZ\1617192 a_26\DT\13649268 gel_27\NN\14588219 on_28\IN\1740 application_29\NN\947128 to_30\IN\1740 the_31\DT\1740 conjunctiva_32\NN\5327134 (_33\-LRB-\1740 timolol_34\CD\2832168 gellan_35\NN\1740 )_36\-RRB-\1740 on_37\IN\1740 the_38\DT\1740 24-hour_39\JJ\1740 heart_40\NN\5919034 rate_41\NN\13815152 in_42\IN\13603305 patients_43\NNS\9898892 currently_44\RB\1740 being_45\VBG\836236 treated_46\VBN\2376958 for_47\IN\1740 <e2>glaucoma</e2>_48\NN\14252864 to_49\TO\1740 quantify_50\VB\947077 the_51\DT\1740 reduction_52\NN\351485 in_53\IN\13603305 mean_54\JJ\1740 heart_55\NN\5919034 rate_56\NN\13815152 ._57\.\1740
D013999_D005901 NONE design_0\NN\927261 :_1\:\1740 this_2\DT\1740 trial_3\NN\786195 evaluated_4\VBD\670261 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 placebo_8\NN\3740161 ,_9\,\1740 0.5_10\CD\1740 %_11\NN\1740 aqueous_12\JJ\1740 timolol_13\NNS\2832168 (_14\-LRB-\1740 timolol_15\CD\2832168 solution_16\NN\14586258 )_17\-RRB-\1740 and_18\CC\1740 a_19\DT\13649268 0.5_20\CD\1740 %_21\NN\1740 <e1>timolol</e1>_22\JJ\1740 suspension_23\NN\14586258 that_24\WDT\1740 forms_25\VBZ\1617192 a_26\DT\13649268 gel_27\NN\14588219 on_28\IN\1740 application_29\NN\947128 to_30\IN\1740 the_31\DT\1740 conjunctiva_32\NN\5327134 (_33\-LRB-\1740 timolol_34\CD\2832168 gellan_35\NN\1740 )_36\-RRB-\1740 on_37\IN\1740 the_38\DT\1740 24-hour_39\JJ\1740 heart_40\NN\5919034 rate_41\NN\13815152 in_42\IN\13603305 patients_43\NNS\9898892 currently_44\RB\1740 being_45\VBG\836236 treated_46\VBN\2376958 for_47\IN\1740 <e2>glaucoma</e2>_48\NN\14252864 to_49\TO\1740 quantify_50\VB\947077 the_51\DT\1740 reduction_52\NN\351485 in_53\IN\13603305 mean_54\JJ\1740 heart_55\NN\5919034 rate_56\NN\13815152 ._57\.\1740
D013999_D005901 NONE design_0\NN\927261 :_1\:\1740 this_2\DT\1740 trial_3\NN\786195 evaluated_4\VBD\670261 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 placebo_8\NN\3740161 ,_9\,\1740 0.5_10\CD\1740 %_11\NN\1740 aqueous_12\JJ\1740 timolol_13\NNS\2832168 (_14\-LRB-\1740 timolol_15\CD\2832168 solution_16\NN\14586258 )_17\-RRB-\1740 and_18\CC\1740 a_19\DT\13649268 0.5_20\CD\1740 %_21\NN\1740 timolol_22\JJ\1740 suspension_23\NN\14586258 that_24\WDT\1740 forms_25\VBZ\1617192 a_26\DT\13649268 gel_27\NN\14588219 on_28\IN\1740 application_29\NN\947128 to_30\IN\1740 the_31\DT\1740 conjunctiva_32\NN\5327134 (_33\-LRB-\1740 <e1>timolol</e1>_34\CD\2832168 gellan_35\NN\1740 )_36\-RRB-\1740 on_37\IN\1740 the_38\DT\1740 24-hour_39\JJ\1740 heart_40\NN\5919034 rate_41\NN\13815152 in_42\IN\13603305 patients_43\NNS\9898892 currently_44\RB\1740 being_45\VBG\836236 treated_46\VBN\2376958 for_47\IN\1740 <e2>glaucoma</e2>_48\NN\14252864 to_49\TO\1740 quantify_50\VB\947077 the_51\DT\1740 reduction_52\NN\351485 in_53\IN\13603305 mean_54\JJ\1740 heart_55\NN\5919034 rate_56\NN\13815152 ._57\.\1740
D013999_D005902 NONE methods_0\NNS\5616786 :_1\:\1740 forty-three_2\JJ\1740 caucasian_3\JJ\1740 patients_4\NNS\9898892 with_5\IN\1740 primary_6\JJ\1740 <e2>open-angle_7\JJ\1740 glaucoma</e2>_8\NN\14252864 or_9\CC\3541091 ocular_10\JJ\1740 hypertension_11\NN\14057371 with_12\IN\1740 a_13\DT\13649268 mean_14\NN\6021761 (_15\-LRB-\1740 +_16\CC\1740 /-sd_17\NN\1740 )_18\-RRB-\1740 age_19\NN\4916342 of_20\IN\1740 63_21\CD\1740 (_22\-LRB-\1740 +_23\CC\1740 /-8_24\LS\1740 )_25\-RRB-\1740 years_26\NNS\15144371 were_27\VBD\836236 randomized_28\VBN\278117 and_29\CC\1740 crossed_30\VBN\2050132 over_31\RP\1740 in_32\IN\13603305 a_33\DT\13649268 double-masked_34\JJ\1740 manner_35\NN\4916342 to_36\TO\1740 14_37\CD\13745420 days_38\NNS\15140892 of_39\IN\1740 treatment_40\NN\654885 with_41\IN\1740 placebo_42\NN\3740161 (_43\-LRB-\1740 morning_44\NN\15113229 and_45\CC\1740 evening_46\NN\15164957 in_47\IN\13603305 both_48\DT\1740 eyes_49\NNS\5945642 )_50\-RRB-\1740 ,_51\,\1740 <e1>timolol</e1>_52\VB\1740 solution_53\NN\14586258 (_54\-LRB-\1740 morning_55\NN\15113229 and_56\CC\1740 evening_57\NN\15164957 in_58\IN\13603305 both_59\DT\1740 eyes_60\NNS\5945642 )_61\-RRB-\1740 ,_62\,\1740 or_63\CC\3541091 timolol_64\CD\2832168 gellan_65\NN\1740 (_66\-LRB-\1740 morning_67\NN\15113229 in_68\IN\13603305 both_69\DT\1740 eyes_70\NNS\5945642 with_71\IN\1740 placebo_72\NN\3740161 in_73\IN\13603305 the_74\DT\1740 evening_75\NN\15164957 )_76\-RRB-\1740 ._77\.\1740
D013999_D005902 NONE methods_0\NNS\5616786 :_1\:\1740 forty-three_2\JJ\1740 caucasian_3\JJ\1740 patients_4\NNS\9898892 with_5\IN\1740 primary_6\JJ\1740 <e2>open-angle_7\JJ\1740 glaucoma</e2>_8\NN\14252864 or_9\CC\3541091 ocular_10\JJ\1740 hypertension_11\NN\14057371 with_12\IN\1740 a_13\DT\13649268 mean_14\NN\6021761 (_15\-LRB-\1740 +_16\CC\1740 /-sd_17\NN\1740 )_18\-RRB-\1740 age_19\NN\4916342 of_20\IN\1740 63_21\CD\1740 (_22\-LRB-\1740 +_23\CC\1740 /-8_24\LS\1740 )_25\-RRB-\1740 years_26\NNS\15144371 were_27\VBD\836236 randomized_28\VBN\278117 and_29\CC\1740 crossed_30\VBN\2050132 over_31\RP\1740 in_32\IN\13603305 a_33\DT\13649268 double-masked_34\JJ\1740 manner_35\NN\4916342 to_36\TO\1740 14_37\CD\13745420 days_38\NNS\15140892 of_39\IN\1740 treatment_40\NN\654885 with_41\IN\1740 placebo_42\NN\3740161 (_43\-LRB-\1740 morning_44\NN\15113229 and_45\CC\1740 evening_46\NN\15164957 in_47\IN\13603305 both_48\DT\1740 eyes_49\NNS\5945642 )_50\-RRB-\1740 ,_51\,\1740 timolol_52\VB\1740 solution_53\NN\14586258 (_54\-LRB-\1740 morning_55\NN\15113229 and_56\CC\1740 evening_57\NN\15164957 in_58\IN\13603305 both_59\DT\1740 eyes_60\NNS\5945642 )_61\-RRB-\1740 ,_62\,\1740 or_63\CC\3541091 <e1>timolol</e1>_64\CD\2832168 gellan_65\NN\1740 (_66\-LRB-\1740 morning_67\NN\15113229 in_68\IN\13603305 both_69\DT\1740 eyes_70\NNS\5945642 with_71\IN\1740 placebo_72\NN\3740161 in_73\IN\13603305 the_74\DT\1740 evening_75\NN\15164957 )_76\-RRB-\1740 ._77\.\1740
D013999_D009798 NONE methods_0\NNS\5616786 :_1\:\1740 forty-three_2\JJ\1740 caucasian_3\JJ\1740 patients_4\NNS\9898892 with_5\IN\1740 primary_6\JJ\1740 open-angle_7\JJ\1740 glaucoma_8\NN\14252864 or_9\CC\3541091 <e2>ocular_10\JJ\1740 hypertension</e2>_11\NN\14057371 with_12\IN\1740 a_13\DT\13649268 mean_14\NN\6021761 (_15\-LRB-\1740 +_16\CC\1740 /-sd_17\NN\1740 )_18\-RRB-\1740 age_19\NN\4916342 of_20\IN\1740 63_21\CD\1740 (_22\-LRB-\1740 +_23\CC\1740 /-8_24\LS\1740 )_25\-RRB-\1740 years_26\NNS\15144371 were_27\VBD\836236 randomized_28\VBN\278117 and_29\CC\1740 crossed_30\VBN\2050132 over_31\RP\1740 in_32\IN\13603305 a_33\DT\13649268 double-masked_34\JJ\1740 manner_35\NN\4916342 to_36\TO\1740 14_37\CD\13745420 days_38\NNS\15140892 of_39\IN\1740 treatment_40\NN\654885 with_41\IN\1740 placebo_42\NN\3740161 (_43\-LRB-\1740 morning_44\NN\15113229 and_45\CC\1740 evening_46\NN\15164957 in_47\IN\13603305 both_48\DT\1740 eyes_49\NNS\5945642 )_50\-RRB-\1740 ,_51\,\1740 <e1>timolol</e1>_52\VB\1740 solution_53\NN\14586258 (_54\-LRB-\1740 morning_55\NN\15113229 and_56\CC\1740 evening_57\NN\15164957 in_58\IN\13603305 both_59\DT\1740 eyes_60\NNS\5945642 )_61\-RRB-\1740 ,_62\,\1740 or_63\CC\3541091 timolol_64\CD\2832168 gellan_65\NN\1740 (_66\-LRB-\1740 morning_67\NN\15113229 in_68\IN\13603305 both_69\DT\1740 eyes_70\NNS\5945642 with_71\IN\1740 placebo_72\NN\3740161 in_73\IN\13603305 the_74\DT\1740 evening_75\NN\15164957 )_76\-RRB-\1740 ._77\.\1740
D013999_D009798 NONE methods_0\NNS\5616786 :_1\:\1740 forty-three_2\JJ\1740 caucasian_3\JJ\1740 patients_4\NNS\9898892 with_5\IN\1740 primary_6\JJ\1740 open-angle_7\JJ\1740 glaucoma_8\NN\14252864 or_9\CC\3541091 <e2>ocular_10\JJ\1740 hypertension</e2>_11\NN\14057371 with_12\IN\1740 a_13\DT\13649268 mean_14\NN\6021761 (_15\-LRB-\1740 +_16\CC\1740 /-sd_17\NN\1740 )_18\-RRB-\1740 age_19\NN\4916342 of_20\IN\1740 63_21\CD\1740 (_22\-LRB-\1740 +_23\CC\1740 /-8_24\LS\1740 )_25\-RRB-\1740 years_26\NNS\15144371 were_27\VBD\836236 randomized_28\VBN\278117 and_29\CC\1740 crossed_30\VBN\2050132 over_31\RP\1740 in_32\IN\13603305 a_33\DT\13649268 double-masked_34\JJ\1740 manner_35\NN\4916342 to_36\TO\1740 14_37\CD\13745420 days_38\NNS\15140892 of_39\IN\1740 treatment_40\NN\654885 with_41\IN\1740 placebo_42\NN\3740161 (_43\-LRB-\1740 morning_44\NN\15113229 and_45\CC\1740 evening_46\NN\15164957 in_47\IN\13603305 both_48\DT\1740 eyes_49\NNS\5945642 )_50\-RRB-\1740 ,_51\,\1740 timolol_52\VB\1740 solution_53\NN\14586258 (_54\-LRB-\1740 morning_55\NN\15113229 and_56\CC\1740 evening_57\NN\15164957 in_58\IN\13603305 both_59\DT\1740 eyes_60\NNS\5945642 )_61\-RRB-\1740 ,_62\,\1740 or_63\CC\3541091 <e1>timolol</e1>_64\CD\2832168 gellan_65\NN\1740 (_66\-LRB-\1740 morning_67\NN\15113229 in_68\IN\13603305 both_69\DT\1740 eyes_70\NNS\5945642 with_71\IN\1740 placebo_72\NN\3740161 in_73\IN\13603305 the_74\DT\1740 evening_75\NN\15164957 )_76\-RRB-\1740 ._77\.\1740
19135948
C107135_D006086 NONE <e2>graft-versus-host_0\NN\1740 disease</e2>_1\NN\14061805 prophylaxis_2\NN\1077350 with_3\IN\1740 <e1>everolimus</e1>_4\NN\1740 and_5\CC\1740 tacrolimus_6\NN\1740 is_7\VBZ\836236 associated_8\VBN\628491 with_9\IN\1740 a_10\DT\13649268 high_11\JJ\1740 incidence_12\NN\13821570 of_13\IN\1740 sinusoidal_14\JJ\1740 obstruction_15\NN\4341686 syndrome_16\NN\5870365 and_17\CC\1740 microangiopathy_18\VBN\1740 :_19\:\1740 results_20\NNS\34213 of_21\IN\1740 the_22\DT\1740 evtac_23\NNP\1740 trial_24\NN\786195 ._25\.\1740
C107135_D006504 CID graft-versus-host_0\NN\1740 disease_1\NN\14061805 prophylaxis_2\NN\1077350 with_3\IN\1740 <e1>everolimus</e1>_4\NN\1740 and_5\CC\1740 tacrolimus_6\NN\1740 is_7\VBZ\836236 associated_8\VBN\628491 with_9\IN\1740 a_10\DT\13649268 high_11\JJ\1740 incidence_12\NN\13821570 of_13\IN\1740 <e2>sinusoidal_14\JJ\1740 obstruction_15\NN\4341686 syndrome</e2>_16\NN\5870365 and_17\CC\1740 microangiopathy_18\VBN\1740 :_19\:\1740 results_20\NNS\34213 of_21\IN\1740 the_22\DT\1740 evtac_23\NNP\1740 trial_24\NN\786195 ._25\.\1740
C107135_D014652 CID graft-versus-host_0\NN\1740 disease_1\NN\14061805 prophylaxis_2\NN\1077350 with_3\IN\1740 <e1>everolimus</e1>_4\NN\1740 and_5\CC\1740 tacrolimus_6\NN\1740 is_7\VBZ\836236 associated_8\VBN\628491 with_9\IN\1740 a_10\DT\13649268 high_11\JJ\1740 incidence_12\NN\13821570 of_13\IN\1740 sinusoidal_14\JJ\1740 obstruction_15\NN\4341686 syndrome_16\NN\5870365 and_17\CC\1740 <e2>microangiopathy</e2>_18\VBN\1740 :_19\:\1740 results_20\NNS\34213 of_21\IN\1740 the_22\DT\1740 evtac_23\NNP\1740 trial_24\NN\786195 ._25\.\1740
D016559_D006086 NONE <e2>graft-versus-host_0\NN\1740 disease</e2>_1\NN\14061805 prophylaxis_2\NN\1077350 with_3\IN\1740 everolimus_4\NN\1740 and_5\CC\1740 <e1>tacrolimus</e1>_6\NN\1740 is_7\VBZ\836236 associated_8\VBN\628491 with_9\IN\1740 a_10\DT\13649268 high_11\JJ\1740 incidence_12\NN\13821570 of_13\IN\1740 sinusoidal_14\JJ\1740 obstruction_15\NN\4341686 syndrome_16\NN\5870365 and_17\CC\1740 microangiopathy_18\VBN\1740 :_19\:\1740 results_20\NNS\34213 of_21\IN\1740 the_22\DT\1740 evtac_23\NNP\1740 trial_24\NN\786195 ._25\.\1740
D016559_D006504 CID graft-versus-host_0\NN\1740 disease_1\NN\14061805 prophylaxis_2\NN\1077350 with_3\IN\1740 everolimus_4\NN\1740 and_5\CC\1740 <e1>tacrolimus</e1>_6\NN\1740 is_7\VBZ\836236 associated_8\VBN\628491 with_9\IN\1740 a_10\DT\13649268 high_11\JJ\1740 incidence_12\NN\13821570 of_13\IN\1740 <e2>sinusoidal_14\JJ\1740 obstruction_15\NN\4341686 syndrome</e2>_16\NN\5870365 and_17\CC\1740 microangiopathy_18\VBN\1740 :_19\:\1740 results_20\NNS\34213 of_21\IN\1740 the_22\DT\1740 evtac_23\NNP\1740 trial_24\NN\786195 ._25\.\1740
D016559_D014652 CID graft-versus-host_0\NN\1740 disease_1\NN\14061805 prophylaxis_2\NN\1077350 with_3\IN\1740 everolimus_4\NN\1740 and_5\CC\1740 <e1>tacrolimus</e1>_6\NN\1740 is_7\VBZ\836236 associated_8\VBN\628491 with_9\IN\1740 a_10\DT\13649268 high_11\JJ\1740 incidence_12\NN\13821570 of_13\IN\1740 sinusoidal_14\JJ\1740 obstruction_15\NN\4341686 syndrome_16\NN\5870365 and_17\CC\1740 <e2>microangiopathy</e2>_18\VBN\1740 :_19\:\1740 results_20\NNS\34213 of_21\IN\1740 the_22\DT\1740 evtac_23\NNP\1740 trial_24\NN\786195 ._25\.\1740
D008727_D006086 NONE a_0\DT\13649268 calcineurin_1\NN\1740 inhibitor_2\NN\20090 combined_3\VBN\2630189 with_4\IN\1740 <e1>methotrexate</e1>_5\NN\2722166 is_6\VBZ\836236 the_7\DT\1740 standard_8\JJ\1740 prophylaxis_9\NN\1077350 for_10\IN\1740 <e2>graft-versus-host_11\JJ\1740 disease</e2>_12\NN\14061805 (_13\-LRB-\1740 gvhd_14\NN\1740 )_15\-RRB-\1740 after_16\IN\1740 allogeneic_17\JJ\1740 hematopoietic_18\JJ\1740 stem_19\NN\6290637 cell_20\NN\3080309 transplantation_21\NN\671351 (_22\-LRB-\1740 hsct_23\NNS\1740 )_24\-RRB-\1740 ._25\.\1740
D008727_D006086 NONE a_0\DT\13649268 calcineurin_1\NN\1740 inhibitor_2\NN\20090 combined_3\VBN\2630189 with_4\IN\1740 <e1>methotrexate</e1>_5\NN\2722166 is_6\VBZ\836236 the_7\DT\1740 standard_8\JJ\1740 prophylaxis_9\NN\1077350 for_10\IN\1740 graft-versus-host_11\JJ\1740 disease_12\NN\14061805 (_13\-LRB-\1740 <e2>gvhd</e2>_14\NN\1740 )_15\-RRB-\1740 after_16\IN\1740 allogeneic_17\JJ\1740 hematopoietic_18\JJ\1740 stem_19\NN\6290637 cell_20\NN\3080309 transplantation_21\NN\671351 (_22\-LRB-\1740 hsct_23\NNS\1740 )_24\-RRB-\1740 ._25\.\1740
C107135_D009190 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 a_3\DT\13649268 combination_4\NN\7951464 of_5\IN\1740 <e1>everolimus</e1>_6\NN\1740 and_7\CC\1740 tacrolimus_8\NN\1740 in_9\IN\13603305 24_10\CD\13745420 patients_11\NNS\9898892 (_12\-LRB-\1740 median_13\JJ\1740 age_14\NN\4916342 ,_15\,\1740 62_16\CD\1740 years_17\NNS\15144371 )_18\-RRB-\1740 with_19\IN\1740 either_20\CC\1740 <e2>myelodysplastic_21\JJ\1740 syndrome</e2>_22\NN\5870365 (_23\-LRB-\1740 mds_24\NN\14622893 ;_25\:\1740 n_26\NN\14622893 =_27\JJ\1740 17_28\CD\13745420 )_29\-RRB-\1740 or_30\CC\3541091 acute_31\JJ\1740 myeloid_32\JJ\1740 leukemia_33\NN\14239918 (_34\-LRB-\1740 aml_35\NN\1740 ;_36\:\1740 n_37\NN\14622893 =_38\JJ\1740 7_39\CD\13741022 )_40\-RRB-\1740 undergoing_41\VBG\109660 intensive_42\JJ\1740 conditioning_43\NN\5752544 followed_44\VBN\1835496 by_45\IN\1740 hsct_46\NNS\1740 from_47\IN\1740 related_48\JJ\1740 (_49\-LRB-\1740 n_50\NN\14622893 =_51\JJ\1740 4_52\CD\13741022 )_53\-RRB-\1740 or_54\CC\3541091 unrelated_55\JJ\1740 (_56\-LRB-\1740 n_57\NN\14622893 =_58\JJ\1740 20_59\CD\13745420 )_60\-RRB-\1740 donors_61\NNS\9608709 ._62\.\1740
C107135_D009190 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 a_3\DT\13649268 combination_4\NN\7951464 of_5\IN\1740 <e1>everolimus</e1>_6\NN\1740 and_7\CC\1740 tacrolimus_8\NN\1740 in_9\IN\13603305 24_10\CD\13745420 patients_11\NNS\9898892 (_12\-LRB-\1740 median_13\JJ\1740 age_14\NN\4916342 ,_15\,\1740 62_16\CD\1740 years_17\NNS\15144371 )_18\-RRB-\1740 with_19\IN\1740 either_20\CC\1740 myelodysplastic_21\JJ\1740 syndrome_22\NN\5870365 (_23\-LRB-\1740 <e2>mds</e2>_24\NN\14622893 ;_25\:\1740 n_26\NN\14622893 =_27\JJ\1740 17_28\CD\13745420 )_29\-RRB-\1740 or_30\CC\3541091 acute_31\JJ\1740 myeloid_32\JJ\1740 leukemia_33\NN\14239918 (_34\-LRB-\1740 aml_35\NN\1740 ;_36\:\1740 n_37\NN\14622893 =_38\JJ\1740 7_39\CD\13741022 )_40\-RRB-\1740 undergoing_41\VBG\109660 intensive_42\JJ\1740 conditioning_43\NN\5752544 followed_44\VBN\1835496 by_45\IN\1740 hsct_46\NNS\1740 from_47\IN\1740 related_48\JJ\1740 (_49\-LRB-\1740 n_50\NN\14622893 =_51\JJ\1740 4_52\CD\13741022 )_53\-RRB-\1740 or_54\CC\3541091 unrelated_55\JJ\1740 (_56\-LRB-\1740 n_57\NN\14622893 =_58\JJ\1740 20_59\CD\13745420 )_60\-RRB-\1740 donors_61\NNS\9608709 ._62\.\1740
C107135_D015470 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 a_3\DT\13649268 combination_4\NN\7951464 of_5\IN\1740 <e1>everolimus</e1>_6\NN\1740 and_7\CC\1740 tacrolimus_8\NN\1740 in_9\IN\13603305 24_10\CD\13745420 patients_11\NNS\9898892 (_12\-LRB-\1740 median_13\JJ\1740 age_14\NN\4916342 ,_15\,\1740 62_16\CD\1740 years_17\NNS\15144371 )_18\-RRB-\1740 with_19\IN\1740 either_20\CC\1740 myelodysplastic_21\JJ\1740 syndrome_22\NN\5870365 (_23\-LRB-\1740 mds_24\NN\14622893 ;_25\:\1740 n_26\NN\14622893 =_27\JJ\1740 17_28\CD\13745420 )_29\-RRB-\1740 or_30\CC\3541091 <e2>acute_31\JJ\1740 myeloid_32\JJ\1740 leukemia</e2>_33\NN\14239918 (_34\-LRB-\1740 aml_35\NN\1740 ;_36\:\1740 n_37\NN\14622893 =_38\JJ\1740 7_39\CD\13741022 )_40\-RRB-\1740 undergoing_41\VBG\109660 intensive_42\JJ\1740 conditioning_43\NN\5752544 followed_44\VBN\1835496 by_45\IN\1740 hsct_46\NNS\1740 from_47\IN\1740 related_48\JJ\1740 (_49\-LRB-\1740 n_50\NN\14622893 =_51\JJ\1740 4_52\CD\13741022 )_53\-RRB-\1740 or_54\CC\3541091 unrelated_55\JJ\1740 (_56\-LRB-\1740 n_57\NN\14622893 =_58\JJ\1740 20_59\CD\13745420 )_60\-RRB-\1740 donors_61\NNS\9608709 ._62\.\1740
C107135_D015470 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 a_3\DT\13649268 combination_4\NN\7951464 of_5\IN\1740 <e1>everolimus</e1>_6\NN\1740 and_7\CC\1740 tacrolimus_8\NN\1740 in_9\IN\13603305 24_10\CD\13745420 patients_11\NNS\9898892 (_12\-LRB-\1740 median_13\JJ\1740 age_14\NN\4916342 ,_15\,\1740 62_16\CD\1740 years_17\NNS\15144371 )_18\-RRB-\1740 with_19\IN\1740 either_20\CC\1740 myelodysplastic_21\JJ\1740 syndrome_22\NN\5870365 (_23\-LRB-\1740 mds_24\NN\14622893 ;_25\:\1740 n_26\NN\14622893 =_27\JJ\1740 17_28\CD\13745420 )_29\-RRB-\1740 or_30\CC\3541091 acute_31\JJ\1740 myeloid_32\JJ\1740 leukemia_33\NN\14239918 (_34\-LRB-\1740 <e2>aml</e2>_35\NN\1740 ;_36\:\1740 n_37\NN\14622893 =_38\JJ\1740 7_39\CD\13741022 )_40\-RRB-\1740 undergoing_41\VBG\109660 intensive_42\JJ\1740 conditioning_43\NN\5752544 followed_44\VBN\1835496 by_45\IN\1740 hsct_46\NNS\1740 from_47\IN\1740 related_48\JJ\1740 (_49\-LRB-\1740 n_50\NN\14622893 =_51\JJ\1740 4_52\CD\13741022 )_53\-RRB-\1740 or_54\CC\3541091 unrelated_55\JJ\1740 (_56\-LRB-\1740 n_57\NN\14622893 =_58\JJ\1740 20_59\CD\13745420 )_60\-RRB-\1740 donors_61\NNS\9608709 ._62\.\1740
D016559_D009190 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 a_3\DT\13649268 combination_4\NN\7951464 of_5\IN\1740 everolimus_6\NN\1740 and_7\CC\1740 <e1>tacrolimus</e1>_8\NN\1740 in_9\IN\13603305 24_10\CD\13745420 patients_11\NNS\9898892 (_12\-LRB-\1740 median_13\JJ\1740 age_14\NN\4916342 ,_15\,\1740 62_16\CD\1740 years_17\NNS\15144371 )_18\-RRB-\1740 with_19\IN\1740 either_20\CC\1740 <e2>myelodysplastic_21\JJ\1740 syndrome</e2>_22\NN\5870365 (_23\-LRB-\1740 mds_24\NN\14622893 ;_25\:\1740 n_26\NN\14622893 =_27\JJ\1740 17_28\CD\13745420 )_29\-RRB-\1740 or_30\CC\3541091 acute_31\JJ\1740 myeloid_32\JJ\1740 leukemia_33\NN\14239918 (_34\-LRB-\1740 aml_35\NN\1740 ;_36\:\1740 n_37\NN\14622893 =_38\JJ\1740 7_39\CD\13741022 )_40\-RRB-\1740 undergoing_41\VBG\109660 intensive_42\JJ\1740 conditioning_43\NN\5752544 followed_44\VBN\1835496 by_45\IN\1740 hsct_46\NNS\1740 from_47\IN\1740 related_48\JJ\1740 (_49\-LRB-\1740 n_50\NN\14622893 =_51\JJ\1740 4_52\CD\13741022 )_53\-RRB-\1740 or_54\CC\3541091 unrelated_55\JJ\1740 (_56\-LRB-\1740 n_57\NN\14622893 =_58\JJ\1740 20_59\CD\13745420 )_60\-RRB-\1740 donors_61\NNS\9608709 ._62\.\1740
D016559_D009190 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 a_3\DT\13649268 combination_4\NN\7951464 of_5\IN\1740 everolimus_6\NN\1740 and_7\CC\1740 <e1>tacrolimus</e1>_8\NN\1740 in_9\IN\13603305 24_10\CD\13745420 patients_11\NNS\9898892 (_12\-LRB-\1740 median_13\JJ\1740 age_14\NN\4916342 ,_15\,\1740 62_16\CD\1740 years_17\NNS\15144371 )_18\-RRB-\1740 with_19\IN\1740 either_20\CC\1740 myelodysplastic_21\JJ\1740 syndrome_22\NN\5870365 (_23\-LRB-\1740 <e2>mds</e2>_24\NN\14622893 ;_25\:\1740 n_26\NN\14622893 =_27\JJ\1740 17_28\CD\13745420 )_29\-RRB-\1740 or_30\CC\3541091 acute_31\JJ\1740 myeloid_32\JJ\1740 leukemia_33\NN\14239918 (_34\-LRB-\1740 aml_35\NN\1740 ;_36\:\1740 n_37\NN\14622893 =_38\JJ\1740 7_39\CD\13741022 )_40\-RRB-\1740 undergoing_41\VBG\109660 intensive_42\JJ\1740 conditioning_43\NN\5752544 followed_44\VBN\1835496 by_45\IN\1740 hsct_46\NNS\1740 from_47\IN\1740 related_48\JJ\1740 (_49\-LRB-\1740 n_50\NN\14622893 =_51\JJ\1740 4_52\CD\13741022 )_53\-RRB-\1740 or_54\CC\3541091 unrelated_55\JJ\1740 (_56\-LRB-\1740 n_57\NN\14622893 =_58\JJ\1740 20_59\CD\13745420 )_60\-RRB-\1740 donors_61\NNS\9608709 ._62\.\1740
D016559_D015470 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 a_3\DT\13649268 combination_4\NN\7951464 of_5\IN\1740 everolimus_6\NN\1740 and_7\CC\1740 <e1>tacrolimus</e1>_8\NN\1740 in_9\IN\13603305 24_10\CD\13745420 patients_11\NNS\9898892 (_12\-LRB-\1740 median_13\JJ\1740 age_14\NN\4916342 ,_15\,\1740 62_16\CD\1740 years_17\NNS\15144371 )_18\-RRB-\1740 with_19\IN\1740 either_20\CC\1740 myelodysplastic_21\JJ\1740 syndrome_22\NN\5870365 (_23\-LRB-\1740 mds_24\NN\14622893 ;_25\:\1740 n_26\NN\14622893 =_27\JJ\1740 17_28\CD\13745420 )_29\-RRB-\1740 or_30\CC\3541091 <e2>acute_31\JJ\1740 myeloid_32\JJ\1740 leukemia</e2>_33\NN\14239918 (_34\-LRB-\1740 aml_35\NN\1740 ;_36\:\1740 n_37\NN\14622893 =_38\JJ\1740 7_39\CD\13741022 )_40\-RRB-\1740 undergoing_41\VBG\109660 intensive_42\JJ\1740 conditioning_43\NN\5752544 followed_44\VBN\1835496 by_45\IN\1740 hsct_46\NNS\1740 from_47\IN\1740 related_48\JJ\1740 (_49\-LRB-\1740 n_50\NN\14622893 =_51\JJ\1740 4_52\CD\13741022 )_53\-RRB-\1740 or_54\CC\3541091 unrelated_55\JJ\1740 (_56\-LRB-\1740 n_57\NN\14622893 =_58\JJ\1740 20_59\CD\13745420 )_60\-RRB-\1740 donors_61\NNS\9608709 ._62\.\1740
D016559_D015470 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 a_3\DT\13649268 combination_4\NN\7951464 of_5\IN\1740 everolimus_6\NN\1740 and_7\CC\1740 <e1>tacrolimus</e1>_8\NN\1740 in_9\IN\13603305 24_10\CD\13745420 patients_11\NNS\9898892 (_12\-LRB-\1740 median_13\JJ\1740 age_14\NN\4916342 ,_15\,\1740 62_16\CD\1740 years_17\NNS\15144371 )_18\-RRB-\1740 with_19\IN\1740 either_20\CC\1740 myelodysplastic_21\JJ\1740 syndrome_22\NN\5870365 (_23\-LRB-\1740 mds_24\NN\14622893 ;_25\:\1740 n_26\NN\14622893 =_27\JJ\1740 17_28\CD\13745420 )_29\-RRB-\1740 or_30\CC\3541091 acute_31\JJ\1740 myeloid_32\JJ\1740 leukemia_33\NN\14239918 (_34\-LRB-\1740 <e2>aml</e2>_35\NN\1740 ;_36\:\1740 n_37\NN\14622893 =_38\JJ\1740 7_39\CD\13741022 )_40\-RRB-\1740 undergoing_41\VBG\109660 intensive_42\JJ\1740 conditioning_43\NN\5752544 followed_44\VBN\1835496 by_45\IN\1740 hsct_46\NNS\1740 from_47\IN\1740 related_48\JJ\1740 (_49\-LRB-\1740 n_50\NN\14622893 =_51\JJ\1740 4_52\CD\13741022 )_53\-RRB-\1740 or_54\CC\3541091 unrelated_55\JJ\1740 (_56\-LRB-\1740 n_57\NN\14622893 =_58\JJ\1740 20_59\CD\13745420 )_60\-RRB-\1740 donors_61\NNS\9608709 ._62\.\1740
10091616
D007980_D004409 CID worsening_0\NN\13457378 of_1\IN\1740 <e1>levodopa-induced</e1>_2\JJ\1740 <e2>dyskinesias</e2>_3\NNS\14084880 by_4\IN\1740 motor_5\NN\3699975 and_6\CC\1740 mental_7\JJ\1740 tasks_8\NNS\575741 ._9\.\1740
D001058_D010300 NONE ten_0\CD\13745420 patients_1\NNS\9898892 who_2\WP\8299493 had_3\VBD\2108377 <e2>parkinson_4\NNP\1740 's_5\POS\1740 disease</e2>_6\NN\14061805 with_7\IN\1740 disabling_8\VBG\126264 dyskinesia_9\NN\14084880 were_10\VBD\836236 included_11\VBN\690614 in_12\IN\13603305 this_13\DT\1740 study_14\NN\635850 to_15\TO\1740 evaluate_16\VB\670261 the_17\DT\1740 role_18\NN\719494 of_19\IN\1740 mental_20\JJ\1740 (_21\-LRB-\1740 mental_22\JJ\1740 calculation_23\NN\1023820 )_24\-RRB-\1740 and_25\CC\1740 motor_26\NN\3699975 (_27\-LRB-\1740 flexion/extension_28\NN\1740 of_29\IN\1740 right_30\JJ\1740 fingers_31\NNS\5566097 ,_32\,\1740 flexion/extension_33\NN\1740 of_34\IN\1740 left_35\JJ\1740 fingers_36\NNS\5566097 ,_37\,\1740 flexion/extension_38\NN\1740 of_39\IN\1740 the_40\DT\1740 neck_41\NN\5225090 ,_42\,\1740 speaking_43\VBG\740577 aloud_44\RB\1740 )_45\-RRB-\1740 tasks_46\NNS\575741 on_47\IN\1740 the_48\DT\1740 worsening_49\NN\13457378 of_50\IN\1740 peak-dose_51\JJ\1740 dyskinesia_52\NN\14084880 following_53\VBG\1835496 administration_54\NN\1133281 of_55\IN\1740 an_56\DT\6697703 effective_57\JJ\1740 single_58\JJ\1740 dose_59\NN\3740161 of_60\IN\1740 <e1>apomorphine</e1>_61\NN\3786417 ._62\.\1740
D001058_D004409 CID ten_0\CD\13745420 patients_1\NNS\9898892 who_2\WP\8299493 had_3\VBD\2108377 parkinson_4\NNP\1740 's_5\POS\1740 disease_6\NN\14061805 with_7\IN\1740 disabling_8\VBG\126264 <e2>dyskinesia</e2>_9\NN\14084880 were_10\VBD\836236 included_11\VBN\690614 in_12\IN\13603305 this_13\DT\1740 study_14\NN\635850 to_15\TO\1740 evaluate_16\VB\670261 the_17\DT\1740 role_18\NN\719494 of_19\IN\1740 mental_20\JJ\1740 (_21\-LRB-\1740 mental_22\JJ\1740 calculation_23\NN\1023820 )_24\-RRB-\1740 and_25\CC\1740 motor_26\NN\3699975 (_27\-LRB-\1740 flexion/extension_28\NN\1740 of_29\IN\1740 right_30\JJ\1740 fingers_31\NNS\5566097 ,_32\,\1740 flexion/extension_33\NN\1740 of_34\IN\1740 left_35\JJ\1740 fingers_36\NNS\5566097 ,_37\,\1740 flexion/extension_38\NN\1740 of_39\IN\1740 the_40\DT\1740 neck_41\NN\5225090 ,_42\,\1740 speaking_43\VBG\740577 aloud_44\RB\1740 )_45\-RRB-\1740 tasks_46\NNS\575741 on_47\IN\1740 the_48\DT\1740 worsening_49\NN\13457378 of_50\IN\1740 peak-dose_51\JJ\1740 dyskinesia_52\NN\14084880 following_53\VBG\1835496 administration_54\NN\1133281 of_55\IN\1740 an_56\DT\6697703 effective_57\JJ\1740 single_58\JJ\1740 dose_59\NN\3740161 of_60\IN\1740 <e1>apomorphine</e1>_61\NN\3786417 ._62\.\1740
D001058_D004409 CID ten_0\CD\13745420 patients_1\NNS\9898892 who_2\WP\8299493 had_3\VBD\2108377 parkinson_4\NNP\1740 's_5\POS\1740 disease_6\NN\14061805 with_7\IN\1740 disabling_8\VBG\126264 dyskinesia_9\NN\14084880 were_10\VBD\836236 included_11\VBN\690614 in_12\IN\13603305 this_13\DT\1740 study_14\NN\635850 to_15\TO\1740 evaluate_16\VB\670261 the_17\DT\1740 role_18\NN\719494 of_19\IN\1740 mental_20\JJ\1740 (_21\-LRB-\1740 mental_22\JJ\1740 calculation_23\NN\1023820 )_24\-RRB-\1740 and_25\CC\1740 motor_26\NN\3699975 (_27\-LRB-\1740 flexion/extension_28\NN\1740 of_29\IN\1740 right_30\JJ\1740 fingers_31\NNS\5566097 ,_32\,\1740 flexion/extension_33\NN\1740 of_34\IN\1740 left_35\JJ\1740 fingers_36\NNS\5566097 ,_37\,\1740 flexion/extension_38\NN\1740 of_39\IN\1740 the_40\DT\1740 neck_41\NN\5225090 ,_42\,\1740 speaking_43\VBG\740577 aloud_44\RB\1740 )_45\-RRB-\1740 tasks_46\NNS\575741 on_47\IN\1740 the_48\DT\1740 worsening_49\NN\13457378 of_50\IN\1740 peak-dose_51\JJ\1740 <e2>dyskinesia</e2>_52\NN\14084880 following_53\VBG\1835496 administration_54\NN\1133281 of_55\IN\1740 an_56\DT\6697703 effective_57\JJ\1740 single_58\JJ\1740 dose_59\NN\3740161 of_60\IN\1740 <e1>apomorphine</e1>_61\NN\3786417 ._62\.\1740
950631
D010396_D007674 CID immunopathology_0\NN\6051542 of_1\IN\1740 <e1>penicillamine-induced</e1>_2\JJ\1740 <e2>glomerular_3\JJ\1740 disease</e2>_4\NN\14061805 ._5\.\1740
D010396_D001172 NONE four_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 <e2>rheumatoid_3\JJ\1740 arthritis</e2>_4\NN\14171682 developed_5\VBD\1753788 heavy_6\JJ\1740 proteinuria_7\NN\14299637 after_8\IN\1740 five_9\CD\13741022 to_10\TO\1740 12_11\CD\13745420 months_12\NNS\15113229 of_13\IN\1740 treatment_14\NN\654885 with_15\IN\1740 <e1>d-penicillamine</e1>_16\NN\1740 ._17\.\1740
D010396_D011507 CID four_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 rheumatoid_3\JJ\1740 arthritis_4\NN\14171682 developed_5\VBD\1753788 heavy_6\JJ\1740 <e2>proteinuria</e2>_7\NN\14299637 after_8\IN\1740 five_9\CD\13741022 to_10\TO\1740 12_11\CD\13745420 months_12\NNS\15113229 of_13\IN\1740 treatment_14\NN\654885 with_15\IN\1740 <e1>d-penicillamine</e1>_16\NN\1740 ._17\.\1740
7803371
D003915_D003072 CID <e2>cognitive_0\JJ\1740 deterioration</e2>_1\NN\14560612 from_2\IN\1740 long-term_3\JJ\1740 abuse_4\NN\418025 of_5\IN\1740 <e1>dextromethorphan</e1>_6\NN\1740 :_7\:\1740 a_8\DT\13649268 case_9\NN\7283608 report_10\NN\6470073 ._11\.\1740
D003915_D003072 CID this_0\DT\1740 report_1\NN\6470073 describes_2\VBZ\1001294 a_3\DT\13649268 case_4\NN\7283608 of_5\IN\1740 <e2>cognitive_6\JJ\1740 deterioration</e2>_7\NN\14560612 resulting_8\VBG\2633881 from_9\IN\1740 prolonged_10\JJ\1740 use_11\NN\407535 of_12\IN\1740 <e1>dm</e1>_13\NN\14117805 ._14\.\1740
9105126
D013256_D018658 CID postinfarction_0\NN\1740 <e2>ventricular_1\NN\1740 septal_2\JJ\1740 defect</e2>_3\NN\14462666 associated_4\VBN\628491 with_5\IN\1740 long-term_6\JJ\1740 <e1>steroid</e1>_7\NN\14727670 therapy_8\NN\657604 ._9\.\1740
D013256_D018658 CID two_0\CD\13741022 cases_1\NNS\7283608 of_2\IN\1740 postinfarction_3\NN\1740 <e2>ventricular_4\NN\1740 septal_5\JJ\1740 rupture</e2>_6\NN\14285662 in_7\IN\13603305 patients_8\NNS\9898892 on_9\IN\1740 long-term_10\JJ\1740 <e1>steroid</e1>_11\NN\14727670 therapy_12\NN\657604 are_13\VBP\836236 presented_14\VBN\2137132 and_15\CC\1740 the_16\DT\1740 favourable_17\JJ\1740 outcome_18\NN\7291312 in_19\IN\13603305 both_20\DT\1740 cases_21\NNS\7283608 described_22\VBN\1001294 ._23\.\1740
D013256_D018658 CID a_0\DT\13649268 possible_1\JJ\1740 association_2\NN\8008335 between_3\IN\1740 <e1>steroid</e1>_4\NN\14727670 therapy_5\NN\657604 and_6\CC\1740 subsequent_7\JJ\1740 postinfarction_8\NN\1740 <e2>septal_9\JJ\1740 rupture</e2>_10\NN\14285662 is_11\VBZ\836236 discussed_12\VBN\1033527 ._13\.\1740
15276120
D014859_D006470 CID time_0\NN\7308889 trends_1\NNS\8679972 in_2\IN\13603305 <e1>warfarin-associated</e1>_3\JJ\1740 <e2>hemorrhage</e2>_4\NN\14285662 ._5\.\1740
D014859_D006470 CID the_0\DT\1740 annual_1\JJ\1740 incidence_2\NN\13821570 of_3\IN\1740 <e1>warfarin-related</e1>_4\JJ\1740 <e2>bleeding</e2>_5\NN\14285662 at_6\IN\14622893 brigham_7\NNP\1740 and_8\CC\1740 women_9\NNP\9605289 's_10\POS\1740 hospital_11\NNP\3739518 increased_12\VBD\169651 from_13\IN\1740 0.97/1,000_14\CD\1740 patient_15\NN\9898892 admissions_16\NNS\49003 in_17\IN\13603305 the_18\DT\1740 first_19\JJ\1740 time_20\NN\7308889 period_21\NN\13575869 (_22\-LRB-\1740 january_23\NNP\15209706 1995_24\CD\1740 to_25\IN\1740 october_26\NNP\15209706 1998_27\CD\1740 )_28\-RRB-\1740 to_29\TO\1740 1.19/1,000_30\NN\1740 patient_31\NN\9898892 admissions_32\NNS\49003 in_33\IN\13603305 the_34\DT\1740 second_35\JJ\1740 time_36\NN\7308889 period_37\NN\13575869 (_38\-LRB-\1740 november_39\NNP\15209706 1998_40\CD\1740 to_41\IN\1740 august_42\NNP\15209706 2002_43\CD\1740 )_44\-RRB-\1740 of_45\IN\1740 this_46\DT\1740 study_47\NN\635850 ._48\.\1740
11694026
C012655_D014581 NONE tolerability_0\NN\1740 of_1\IN\1740 <e1>nimesulide</e1>_2\NN\1740 and_3\CC\1740 paracetamol_4\NN\1740 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 nsaid-induced_8\JJ\1740 <e2>urticaria/angioedema</e2>_9\NN\1740 ._10\.\1740
C012655_D014581 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 we_3\PRP\1740 investigated_4\VBD\644583 tolerability_5\NN\1740 and_6\CC\1740 reliability_7\NN\4669247 of_8\IN\1740 <e1>nimesulide</e1>_9\NN\1740 and_10\CC\1740 paracetamol_11\NN\1740 in_12\IN\13603305 a_13\DT\13649268 very_14\RB\1740 large_15\JJ\1740 number_16\NN\5107765 of_17\IN\1740 patients_18\NNS\9898892 with_19\IN\1740 an_20\DT\6697703 exclusive_21\JJ\1740 well-documented_22\JJ\1740 history_23\NN\15120823 of_24\IN\1740 nsaid-induced_25\JJ\1740 <e2>urticaria/angioedema</e2>_26\NN\1740 ._27\.\1740
C012655_D014581 NONE a_0\DT\13649268 single-placebo-controlled_1\JJ\1740 oral_2\JJ\1740 challenge_3\NN\13927383 procedure_4\NN\407535 with_5\IN\1740 <e1>nimesulide</e1>_6\NN\1740 or_7\CC\3541091 paracetamol_8\NN\1740 was_9\VBD\836236 applied_10\VBN\2676054 to_11\TO\1740 829_12\CD\1740 patients_13\NNS\9898892 with_14\IN\1740 a_15\DT\13649268 history_16\NN\15120823 of_17\IN\1740 nsaid-induced_18\JJ\1740 <e2>urticaria/angioedema</e2>_19\NN\1740 ._20\.\1740
C012655_D014581 NONE taken_0\VBN\2367363 together_1\RB\1740 ,_2\,\1740 our_3\PRP$\1740 results_4\NNS\34213 confirm_5\VBP\1011725 the_6\DT\1740 good_7\JJ\1740 tolerability_8\NN\1740 of_9\IN\1740 <e1>nimesulide</e1>_10\NN\1740 and_11\CC\1740 paracetamol_12\NN\1740 in_13\IN\13603305 patients_14\NNS\9898892 who_15\WP\8299493 experienced_16\VBD\2108377 <e2>urticaria/angioedema</e2>_17\NN\1740 caused_18\VBN\1617192 by_19\IN\1740 nsaids_20\NNS\2721538 ._21\.\1740
C012655_D000799 CID tolerability_0\NN\1740 of_1\IN\1740 <e1>nimesulide</e1>_2\NN\1740 and_3\CC\1740 paracetamol_4\NN\1740 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 nsaid-induced_8\JJ\1740 <e2>urticaria/angioedema</e2>_9\NN\1740 ._10\.\1740
C012655_D000799 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 we_3\PRP\1740 investigated_4\VBD\644583 tolerability_5\NN\1740 and_6\CC\1740 reliability_7\NN\4669247 of_8\IN\1740 <e1>nimesulide</e1>_9\NN\1740 and_10\CC\1740 paracetamol_11\NN\1740 in_12\IN\13603305 a_13\DT\13649268 very_14\RB\1740 large_15\JJ\1740 number_16\NN\5107765 of_17\IN\1740 patients_18\NNS\9898892 with_19\IN\1740 an_20\DT\6697703 exclusive_21\JJ\1740 well-documented_22\JJ\1740 history_23\NN\15120823 of_24\IN\1740 nsaid-induced_25\JJ\1740 <e2>urticaria/angioedema</e2>_26\NN\1740 ._27\.\1740
C012655_D000799 CID a_0\DT\13649268 single-placebo-controlled_1\JJ\1740 oral_2\JJ\1740 challenge_3\NN\13927383 procedure_4\NN\407535 with_5\IN\1740 <e1>nimesulide</e1>_6\NN\1740 or_7\CC\3541091 paracetamol_8\NN\1740 was_9\VBD\836236 applied_10\VBN\2676054 to_11\TO\1740 829_12\CD\1740 patients_13\NNS\9898892 with_14\IN\1740 a_15\DT\13649268 history_16\NN\15120823 of_17\IN\1740 nsaid-induced_18\JJ\1740 <e2>urticaria/angioedema</e2>_19\NN\1740 ._20\.\1740
C012655_D000799 CID taken_0\VBN\2367363 together_1\RB\1740 ,_2\,\1740 our_3\PRP$\1740 results_4\NNS\34213 confirm_5\VBP\1011725 the_6\DT\1740 good_7\JJ\1740 tolerability_8\NN\1740 of_9\IN\1740 <e1>nimesulide</e1>_10\NN\1740 and_11\CC\1740 paracetamol_12\NN\1740 in_13\IN\13603305 patients_14\NNS\9898892 who_15\WP\8299493 experienced_16\VBD\2108377 <e2>urticaria/angioedema</e2>_17\NN\1740 caused_18\VBN\1617192 by_19\IN\1740 nsaids_20\NNS\2721538 ._21\.\1740
D000082_D014581 NONE tolerability_0\NN\1740 of_1\IN\1740 nimesulide_2\NN\1740 and_3\CC\1740 <e1>paracetamol</e1>_4\NN\1740 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 nsaid-induced_8\JJ\1740 <e2>urticaria/angioedema</e2>_9\NN\1740 ._10\.\1740
D000082_D014581 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 we_3\PRP\1740 investigated_4\VBD\644583 tolerability_5\NN\1740 and_6\CC\1740 reliability_7\NN\4669247 of_8\IN\1740 nimesulide_9\NN\1740 and_10\CC\1740 <e1>paracetamol</e1>_11\NN\1740 in_12\IN\13603305 a_13\DT\13649268 very_14\RB\1740 large_15\JJ\1740 number_16\NN\5107765 of_17\IN\1740 patients_18\NNS\9898892 with_19\IN\1740 an_20\DT\6697703 exclusive_21\JJ\1740 well-documented_22\JJ\1740 history_23\NN\15120823 of_24\IN\1740 nsaid-induced_25\JJ\1740 <e2>urticaria/angioedema</e2>_26\NN\1740 ._27\.\1740
D000082_D014581 NONE a_0\DT\13649268 single-placebo-controlled_1\JJ\1740 oral_2\JJ\1740 challenge_3\NN\13927383 procedure_4\NN\407535 with_5\IN\1740 nimesulide_6\NN\1740 or_7\CC\3541091 <e1>paracetamol</e1>_8\NN\1740 was_9\VBD\836236 applied_10\VBN\2676054 to_11\TO\1740 829_12\CD\1740 patients_13\NNS\9898892 with_14\IN\1740 a_15\DT\13649268 history_16\NN\15120823 of_17\IN\1740 nsaid-induced_18\JJ\1740 <e2>urticaria/angioedema</e2>_19\NN\1740 ._20\.\1740
D000082_D014581 NONE taken_0\VBN\2367363 together_1\RB\1740 ,_2\,\1740 our_3\PRP$\1740 results_4\NNS\34213 confirm_5\VBP\1011725 the_6\DT\1740 good_7\JJ\1740 tolerability_8\NN\1740 of_9\IN\1740 nimesulide_10\NN\1740 and_11\CC\1740 <e1>paracetamol</e1>_12\NN\1740 in_13\IN\13603305 patients_14\NNS\9898892 who_15\WP\8299493 experienced_16\VBD\2108377 <e2>urticaria/angioedema</e2>_17\NN\1740 caused_18\VBN\1617192 by_19\IN\1740 nsaids_20\NNS\2721538 ._21\.\1740
D000082_D000799 CID tolerability_0\NN\1740 of_1\IN\1740 nimesulide_2\NN\1740 and_3\CC\1740 <e1>paracetamol</e1>_4\NN\1740 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 nsaid-induced_8\JJ\1740 <e2>urticaria/angioedema</e2>_9\NN\1740 ._10\.\1740
D000082_D000799 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 we_3\PRP\1740 investigated_4\VBD\644583 tolerability_5\NN\1740 and_6\CC\1740 reliability_7\NN\4669247 of_8\IN\1740 nimesulide_9\NN\1740 and_10\CC\1740 <e1>paracetamol</e1>_11\NN\1740 in_12\IN\13603305 a_13\DT\13649268 very_14\RB\1740 large_15\JJ\1740 number_16\NN\5107765 of_17\IN\1740 patients_18\NNS\9898892 with_19\IN\1740 an_20\DT\6697703 exclusive_21\JJ\1740 well-documented_22\JJ\1740 history_23\NN\15120823 of_24\IN\1740 nsaid-induced_25\JJ\1740 <e2>urticaria/angioedema</e2>_26\NN\1740 ._27\.\1740
D000082_D000799 CID a_0\DT\13649268 single-placebo-controlled_1\JJ\1740 oral_2\JJ\1740 challenge_3\NN\13927383 procedure_4\NN\407535 with_5\IN\1740 nimesulide_6\NN\1740 or_7\CC\3541091 <e1>paracetamol</e1>_8\NN\1740 was_9\VBD\836236 applied_10\VBN\2676054 to_11\TO\1740 829_12\CD\1740 patients_13\NNS\9898892 with_14\IN\1740 a_15\DT\13649268 history_16\NN\15120823 of_17\IN\1740 nsaid-induced_18\JJ\1740 <e2>urticaria/angioedema</e2>_19\NN\1740 ._20\.\1740
D000082_D000799 CID taken_0\VBN\2367363 together_1\RB\1740 ,_2\,\1740 our_3\PRP$\1740 results_4\NNS\34213 confirm_5\VBP\1011725 the_6\DT\1740 good_7\JJ\1740 tolerability_8\NN\1740 of_9\IN\1740 nimesulide_10\NN\1740 and_11\CC\1740 <e1>paracetamol</e1>_12\NN\1740 in_13\IN\13603305 patients_14\NNS\9898892 who_15\WP\8299493 experienced_16\VBD\2108377 <e2>urticaria/angioedema</e2>_17\NN\1740 caused_18\VBN\1617192 by_19\IN\1740 nsaids_20\NNS\2721538 ._21\.\1740
D000894_D014581 NONE tolerability_0\NN\1740 of_1\IN\1740 nimesulide_2\NN\1740 and_3\CC\1740 paracetamol_4\NN\1740 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 <e1>nsaid-induced</e1>_8\JJ\1740 <e2>urticaria/angioedema</e2>_9\NN\1740 ._10\.\1740
D000894_D014581 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 we_3\PRP\1740 investigated_4\VBD\644583 tolerability_5\NN\1740 and_6\CC\1740 reliability_7\NN\4669247 of_8\IN\1740 nimesulide_9\NN\1740 and_10\CC\1740 paracetamol_11\NN\1740 in_12\IN\13603305 a_13\DT\13649268 very_14\RB\1740 large_15\JJ\1740 number_16\NN\5107765 of_17\IN\1740 patients_18\NNS\9898892 with_19\IN\1740 an_20\DT\6697703 exclusive_21\JJ\1740 well-documented_22\JJ\1740 history_23\NN\15120823 of_24\IN\1740 <e1>nsaid-induced</e1>_25\JJ\1740 <e2>urticaria/angioedema</e2>_26\NN\1740 ._27\.\1740
D000894_D014581 NONE a_0\DT\13649268 single-placebo-controlled_1\JJ\1740 oral_2\JJ\1740 challenge_3\NN\13927383 procedure_4\NN\407535 with_5\IN\1740 nimesulide_6\NN\1740 or_7\CC\3541091 paracetamol_8\NN\1740 was_9\VBD\836236 applied_10\VBN\2676054 to_11\TO\1740 829_12\CD\1740 patients_13\NNS\9898892 with_14\IN\1740 a_15\DT\13649268 history_16\NN\15120823 of_17\IN\1740 <e1>nsaid-induced</e1>_18\JJ\1740 <e2>urticaria/angioedema</e2>_19\NN\1740 ._20\.\1740
D000894_D014581 NONE furthermore_0\RB\1740 ,_1\,\1740 18.28_2\CD\1740 %_3\NN\1740 of_4\IN\1740 patients_5\NNS\9898892 with_6\IN\1740 a_7\DT\13649268 history_8\NN\15120823 of_9\IN\1740 chronic_10\JJ\1740 <e2>urticaria</e2>_11\NNS\14533203 and_12\CC\1740 11.8_13\CD\1740 %_14\NN\1740 of_15\IN\1740 subjects_16\NNS\6598915 with_17\IN\1740 an_18\DT\6697703 history_19\NN\15120823 of_20\IN\1740 <e1>nsaid-induced</e1>_21\JJ\1740 urticaria/angioedema_22\NN\1740 or_23\CC\3541091 angioedema_24\NN\14316714 alone_25\RB\1740 (_26\-LRB-\1740 with_27\IN\1740 or_28\CC\3541091 without_29\IN\1740 chronic_30\JJ\1740 urticaria_31\NNS\14533203 )_32\-RRB-\1740 resulted_33\VBD\2633881 to_34\TO\1740 be_35\VB\836236 intolerant_36\JJ\1740 to_37\TO\1740 alternative_38\JJ\1740 drugs_39\NNS\14778436 ._40\.\1740
D000894_D014581 NONE furthermore_0\RB\1740 ,_1\,\1740 18.28_2\CD\1740 %_3\NN\1740 of_4\IN\1740 patients_5\NNS\9898892 with_6\IN\1740 a_7\DT\13649268 history_8\NN\15120823 of_9\IN\1740 chronic_10\JJ\1740 urticaria_11\NNS\14533203 and_12\CC\1740 11.8_13\CD\1740 %_14\NN\1740 of_15\IN\1740 subjects_16\NNS\6598915 with_17\IN\1740 an_18\DT\6697703 history_19\NN\15120823 of_20\IN\1740 <e1>nsaid-induced</e1>_21\JJ\1740 <e2>urticaria/angioedema</e2>_22\NN\1740 or_23\CC\3541091 angioedema_24\NN\14316714 alone_25\RB\1740 (_26\-LRB-\1740 with_27\IN\1740 or_28\CC\3541091 without_29\IN\1740 chronic_30\JJ\1740 urticaria_31\NNS\14533203 )_32\-RRB-\1740 resulted_33\VBD\2633881 to_34\TO\1740 be_35\VB\836236 intolerant_36\JJ\1740 to_37\TO\1740 alternative_38\JJ\1740 drugs_39\NNS\14778436 ._40\.\1740
D000894_D014581 NONE furthermore_0\RB\1740 ,_1\,\1740 18.28_2\CD\1740 %_3\NN\1740 of_4\IN\1740 patients_5\NNS\9898892 with_6\IN\1740 a_7\DT\13649268 history_8\NN\15120823 of_9\IN\1740 chronic_10\JJ\1740 urticaria_11\NNS\14533203 and_12\CC\1740 11.8_13\CD\1740 %_14\NN\1740 of_15\IN\1740 subjects_16\NNS\6598915 with_17\IN\1740 an_18\DT\6697703 history_19\NN\15120823 of_20\IN\1740 <e1>nsaid-induced</e1>_21\JJ\1740 urticaria/angioedema_22\NN\1740 or_23\CC\3541091 angioedema_24\NN\14316714 alone_25\RB\1740 (_26\-LRB-\1740 with_27\IN\1740 or_28\CC\3541091 without_29\IN\1740 chronic_30\JJ\1740 <e2>urticaria</e2>_31\NNS\14533203 )_32\-RRB-\1740 resulted_33\VBD\2633881 to_34\TO\1740 be_35\VB\836236 intolerant_36\JJ\1740 to_37\TO\1740 alternative_38\JJ\1740 drugs_39\NNS\14778436 ._40\.\1740
D000894_D014581 NONE taken_0\VBN\2367363 together_1\RB\1740 ,_2\,\1740 our_3\PRP$\1740 results_4\NNS\34213 confirm_5\VBP\1011725 the_6\DT\1740 good_7\JJ\1740 tolerability_8\NN\1740 of_9\IN\1740 nimesulide_10\NN\1740 and_11\CC\1740 paracetamol_12\NN\1740 in_13\IN\13603305 patients_14\NNS\9898892 who_15\WP\8299493 experienced_16\VBD\2108377 <e2>urticaria/angioedema</e2>_17\NN\1740 caused_18\VBN\1617192 by_19\IN\1740 <e1>nsaids</e1>_20\NNS\2721538 ._21\.\1740
D000894_D014581 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 reaction_5\NN\13446390 to_6\TO\1740 these_7\DT\1740 alternative_8\JJ\1740 study_9\NN\635850 drugs_10\NNS\14778436 is_11\VBZ\836236 statistically_12\RB\1740 increased_13\VBN\169651 by_14\IN\1740 a_15\DT\13649268 history_16\NN\15120823 of_17\IN\1740 chronic_18\JJ\1740 <e2>urticaria</e2>_19\NNS\14533203 and_20\CC\1740 ,_21\,\1740 above_22\RB\1740 all_23\RB\1740 ,_24\,\1740 by_25\IN\1740 a_26\DT\13649268 history_27\NN\15120823 of_28\IN\1740 <e1>nsaid-induced</e1>_29\JJ\1740 angioedema_30\NN\14316714 ._31\.\1740
D000894_D000799 CID tolerability_0\NN\1740 of_1\IN\1740 nimesulide_2\NN\1740 and_3\CC\1740 paracetamol_4\NN\1740 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 <e1>nsaid-induced</e1>_8\JJ\1740 <e2>urticaria/angioedema</e2>_9\NN\1740 ._10\.\1740
D000894_D000799 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 we_3\PRP\1740 investigated_4\VBD\644583 tolerability_5\NN\1740 and_6\CC\1740 reliability_7\NN\4669247 of_8\IN\1740 nimesulide_9\NN\1740 and_10\CC\1740 paracetamol_11\NN\1740 in_12\IN\13603305 a_13\DT\13649268 very_14\RB\1740 large_15\JJ\1740 number_16\NN\5107765 of_17\IN\1740 patients_18\NNS\9898892 with_19\IN\1740 an_20\DT\6697703 exclusive_21\JJ\1740 well-documented_22\JJ\1740 history_23\NN\15120823 of_24\IN\1740 <e1>nsaid-induced</e1>_25\JJ\1740 <e2>urticaria/angioedema</e2>_26\NN\1740 ._27\.\1740
D000894_D000799 CID a_0\DT\13649268 single-placebo-controlled_1\JJ\1740 oral_2\JJ\1740 challenge_3\NN\13927383 procedure_4\NN\407535 with_5\IN\1740 nimesulide_6\NN\1740 or_7\CC\3541091 paracetamol_8\NN\1740 was_9\VBD\836236 applied_10\VBN\2676054 to_11\TO\1740 829_12\CD\1740 patients_13\NNS\9898892 with_14\IN\1740 a_15\DT\13649268 history_16\NN\15120823 of_17\IN\1740 <e1>nsaid-induced</e1>_18\JJ\1740 <e2>urticaria/angioedema</e2>_19\NN\1740 ._20\.\1740
D000894_D000799 CID furthermore_0\RB\1740 ,_1\,\1740 18.28_2\CD\1740 %_3\NN\1740 of_4\IN\1740 patients_5\NNS\9898892 with_6\IN\1740 a_7\DT\13649268 history_8\NN\15120823 of_9\IN\1740 chronic_10\JJ\1740 urticaria_11\NNS\14533203 and_12\CC\1740 11.8_13\CD\1740 %_14\NN\1740 of_15\IN\1740 subjects_16\NNS\6598915 with_17\IN\1740 an_18\DT\6697703 history_19\NN\15120823 of_20\IN\1740 <e1>nsaid-induced</e1>_21\JJ\1740 <e2>urticaria/angioedema</e2>_22\NN\1740 or_23\CC\3541091 angioedema_24\NN\14316714 alone_25\RB\1740 (_26\-LRB-\1740 with_27\IN\1740 or_28\CC\3541091 without_29\IN\1740 chronic_30\JJ\1740 urticaria_31\NNS\14533203 )_32\-RRB-\1740 resulted_33\VBD\2633881 to_34\TO\1740 be_35\VB\836236 intolerant_36\JJ\1740 to_37\TO\1740 alternative_38\JJ\1740 drugs_39\NNS\14778436 ._40\.\1740
D000894_D000799 CID furthermore_0\RB\1740 ,_1\,\1740 18.28_2\CD\1740 %_3\NN\1740 of_4\IN\1740 patients_5\NNS\9898892 with_6\IN\1740 a_7\DT\13649268 history_8\NN\15120823 of_9\IN\1740 chronic_10\JJ\1740 urticaria_11\NNS\14533203 and_12\CC\1740 11.8_13\CD\1740 %_14\NN\1740 of_15\IN\1740 subjects_16\NNS\6598915 with_17\IN\1740 an_18\DT\6697703 history_19\NN\15120823 of_20\IN\1740 <e1>nsaid-induced</e1>_21\JJ\1740 urticaria/angioedema_22\NN\1740 or_23\CC\3541091 <e2>angioedema</e2>_24\NN\14316714 alone_25\RB\1740 (_26\-LRB-\1740 with_27\IN\1740 or_28\CC\3541091 without_29\IN\1740 chronic_30\JJ\1740 urticaria_31\NNS\14533203 )_32\-RRB-\1740 resulted_33\VBD\2633881 to_34\TO\1740 be_35\VB\836236 intolerant_36\JJ\1740 to_37\TO\1740 alternative_38\JJ\1740 drugs_39\NNS\14778436 ._40\.\1740
D000894_D000799 CID taken_0\VBN\2367363 together_1\RB\1740 ,_2\,\1740 our_3\PRP$\1740 results_4\NNS\34213 confirm_5\VBP\1011725 the_6\DT\1740 good_7\JJ\1740 tolerability_8\NN\1740 of_9\IN\1740 nimesulide_10\NN\1740 and_11\CC\1740 paracetamol_12\NN\1740 in_13\IN\13603305 patients_14\NNS\9898892 who_15\WP\8299493 experienced_16\VBD\2108377 <e2>urticaria/angioedema</e2>_17\NN\1740 caused_18\VBN\1617192 by_19\IN\1740 <e1>nsaids</e1>_20\NNS\2721538 ._21\.\1740
D000894_D000799 CID however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 risk_3\NN\14541044 of_4\IN\1740 reaction_5\NN\13446390 to_6\TO\1740 these_7\DT\1740 alternative_8\JJ\1740 study_9\NN\635850 drugs_10\NNS\14778436 is_11\VBZ\836236 statistically_12\RB\1740 increased_13\VBN\169651 by_14\IN\1740 a_15\DT\13649268 history_16\NN\15120823 of_17\IN\1740 chronic_18\JJ\1740 urticaria_19\NNS\14533203 and_20\CC\1740 ,_21\,\1740 above_22\RB\1740 all_23\RB\1740 ,_24\,\1740 by_25\IN\1740 a_26\DT\13649268 history_27\NN\15120823 of_28\IN\1740 <e1>nsaid-induced</e1>_29\JJ\1740 <e2>angioedema</e2>_30\NN\14316714 ._31\.\1740
19707748
D064704_D012640 CID <e2>seizures</e2>_0\NNS\14081375 associated_1\VBN\628491 with_2\IN\1740 <e1>levofloxacin</e1>_3\NN\1740 :_4\:\1740 case_5\NN\7283608 presentation_6\NN\1027379 and_7\CC\1740 literature_8\NN\6362953 review_9\NN\5733583 ._10\.\1740
D064704_D012640 CID purpose_0\NNP\5980875 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 patient_8\NN\9898892 who_9\WP\8299493 developed_10\VBD\1753788 <e2>seizures</e2>_11\NNS\14081375 shortly_12\RB\1740 after_13\IN\1740 initiating_14\VBG\1617192 treatment_15\NN\654885 with_16\IN\1740 <e1>levofloxacin</e1>_17\NN\1740 and_18\CC\1740 to_19\TO\1740 discuss_20\VB\1033527 the_21\DT\1740 potential_22\JJ\1740 drug-drug_23\JJ\1740 interactions_24\NNS\37396 related_25\JJ\1740 to_26\TO\1740 the_27\DT\1740 inhibition_28\NN\1068773 of_29\IN\1740 cytochrome_30\NN\14888884 p450_31\NN\1740 (_32\-LRB-\1740 cyp_33\NN\1740 )_34\-RRB-\1740 1a2_35\NN\1740 in_36\IN\13603305 this_37\DT\1740 case_38\NN\7283608 ,_39\,\1740 as_40\RB\1740 well_41\RB\1740 as_42\IN\14622893 in_43\IN\13603305 other_44\JJ\1740 cases_45\NNS\7283608 ,_46\,\1740 of_47\IN\1740 levofloxacin-induced_48\JJ\1740 seizures_49\NNS\14081375 ._50\.\1740
D064704_D012640 CID purpose_0\NNP\5980875 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 patient_8\NN\9898892 who_9\WP\8299493 developed_10\VBD\1753788 seizures_11\NNS\14081375 shortly_12\RB\1740 after_13\IN\1740 initiating_14\VBG\1617192 treatment_15\NN\654885 with_16\IN\1740 <e1>levofloxacin</e1>_17\NN\1740 and_18\CC\1740 to_19\TO\1740 discuss_20\VB\1033527 the_21\DT\1740 potential_22\JJ\1740 drug-drug_23\JJ\1740 interactions_24\NNS\37396 related_25\JJ\1740 to_26\TO\1740 the_27\DT\1740 inhibition_28\NN\1068773 of_29\IN\1740 cytochrome_30\NN\14888884 p450_31\NN\1740 (_32\-LRB-\1740 cyp_33\NN\1740 )_34\-RRB-\1740 1a2_35\NN\1740 in_36\IN\13603305 this_37\DT\1740 case_38\NN\7283608 ,_39\,\1740 as_40\RB\1740 well_41\RB\1740 as_42\IN\14622893 in_43\IN\13603305 other_44\JJ\1740 cases_45\NNS\7283608 ,_46\,\1740 of_47\IN\1740 levofloxacin-induced_48\JJ\1740 <e2>seizures</e2>_49\NNS\14081375 ._50\.\1740
D064704_D012640 CID purpose_0\NNP\5980875 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 patient_8\NN\9898892 who_9\WP\8299493 developed_10\VBD\1753788 <e2>seizures</e2>_11\NNS\14081375 shortly_12\RB\1740 after_13\IN\1740 initiating_14\VBG\1617192 treatment_15\NN\654885 with_16\IN\1740 levofloxacin_17\NN\1740 and_18\CC\1740 to_19\TO\1740 discuss_20\VB\1033527 the_21\DT\1740 potential_22\JJ\1740 drug-drug_23\JJ\1740 interactions_24\NNS\37396 related_25\JJ\1740 to_26\TO\1740 the_27\DT\1740 inhibition_28\NN\1068773 of_29\IN\1740 cytochrome_30\NN\14888884 p450_31\NN\1740 (_32\-LRB-\1740 cyp_33\NN\1740 )_34\-RRB-\1740 1a2_35\NN\1740 in_36\IN\13603305 this_37\DT\1740 case_38\NN\7283608 ,_39\,\1740 as_40\RB\1740 well_41\RB\1740 as_42\IN\14622893 in_43\IN\13603305 other_44\JJ\1740 cases_45\NNS\7283608 ,_46\,\1740 of_47\IN\1740 <e1>levofloxacin-induced</e1>_48\JJ\1740 seizures_49\NNS\14081375 ._50\.\1740
D064704_D012640 CID purpose_0\NNP\5980875 :_1\:\1740 we_2\PRP\1740 present_3\VBP\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 a_7\DT\13649268 patient_8\NN\9898892 who_9\WP\8299493 developed_10\VBD\1753788 seizures_11\NNS\14081375 shortly_12\RB\1740 after_13\IN\1740 initiating_14\VBG\1617192 treatment_15\NN\654885 with_16\IN\1740 levofloxacin_17\NN\1740 and_18\CC\1740 to_19\TO\1740 discuss_20\VB\1033527 the_21\DT\1740 potential_22\JJ\1740 drug-drug_23\JJ\1740 interactions_24\NNS\37396 related_25\JJ\1740 to_26\TO\1740 the_27\DT\1740 inhibition_28\NN\1068773 of_29\IN\1740 cytochrome_30\NN\14888884 p450_31\NN\1740 (_32\-LRB-\1740 cyp_33\NN\1740 )_34\-RRB-\1740 1a2_35\NN\1740 in_36\IN\13603305 this_37\DT\1740 case_38\NN\7283608 ,_39\,\1740 as_40\RB\1740 well_41\RB\1740 as_42\IN\14622893 in_43\IN\13603305 other_44\JJ\1740 cases_45\NNS\7283608 ,_46\,\1740 of_47\IN\1740 <e1>levofloxacin-induced</e1>_48\JJ\1740 <e2>seizures</e2>_49\NNS\14081375 ._50\.\1740
D064704_D012640 CID results_0\NNS\34213 :_1\:\1740 six_2\CD\13741022 cases_3\NNS\7283608 of_4\IN\1740 <e1>levofloxacin-induced</e1>_5\JJ\1740 <e2>seizures</e2>_6\NNS\14081375 have_7\VBP\2108377 been_8\VBN\836236 reported_9\VBN\831651 in_10\IN\13603305 the_11\DT\1740 literature_12\NN\6362953 ._13\.\1740
15811908
C012052_D010673 NONE <e2>pheochromocytoma</e2>_0\NNS\14235200 unmasked_1\VBN\853195 by_2\IN\1740 <e1>amisulpride</e1>_3\RB\1740 and_4\CC\1740 tiapride_5\NN\1740 ._6\.\1740
C012052_D010673 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 the_4\DT\1740 unmasking_5\NN\7215377 of_6\IN\1740 <e2>pheochromocytoma</e2>_7\NN\14235200 in_8\IN\13603305 a_9\DT\13649268 patient_10\NN\9898892 treated_11\VBN\2376958 with_12\IN\1740 <e1>amisulpride</e1>_13\NN\1740 and_14\CC\1740 tiapride_15\NN\1740 ._16\.\1740
C012052_D010673 NONE conclusions_0\NNS\5837957 :_1\:\1740 as_2\IN\14622893 of_3\IN\1740 march_4\NNP\15209706 24_5\CD\13745420 ,_6\,\1740 2005_7\CD\1740 ,_8\,\1740 this_9\DT\1740 is_10\VBZ\836236 the_11\DT\1740 first_12\JJ\1740 reported_13\VBN\831651 case_14\NN\7283608 of_15\IN\1740 <e1>amisulpride-</e1>_16\NN\1740 and_17\CC\1740 tiapride-induced_18\JJ\1740 hypertensive_19\JJ\1740 crisis_20\NN\14411243 in_21\IN\13603305 a_22\DT\13649268 patient_23\NN\9898892 with_24\IN\1740 <e2>pheochromocytoma</e2>_25\NN\14235200 ._26\.\1740
D063325_D010673 NONE <e2>pheochromocytoma</e2>_0\NNS\14235200 unmasked_1\VBN\853195 by_2\IN\1740 amisulpride_3\RB\1740 and_4\CC\1740 <e1>tiapride</e1>_5\NN\1740 ._6\.\1740
D063325_D010673 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 describe_3\VB\1001294 the_4\DT\1740 unmasking_5\NN\7215377 of_6\IN\1740 <e2>pheochromocytoma</e2>_7\NN\14235200 in_8\IN\13603305 a_9\DT\13649268 patient_10\NN\9898892 treated_11\VBN\2376958 with_12\IN\1740 amisulpride_13\NN\1740 and_14\CC\1740 <e1>tiapride</e1>_15\NN\1740 ._16\.\1740
D063325_D010673 NONE conclusions_0\NNS\5837957 :_1\:\1740 as_2\IN\14622893 of_3\IN\1740 march_4\NNP\15209706 24_5\CD\13745420 ,_6\,\1740 2005_7\CD\1740 ,_8\,\1740 this_9\DT\1740 is_10\VBZ\836236 the_11\DT\1740 first_12\JJ\1740 reported_13\VBN\831651 case_14\NN\7283608 of_15\IN\1740 amisulpride-_16\NN\1740 and_17\CC\1740 <e1>tiapride-induced</e1>_18\JJ\1740 hypertensive_19\JJ\1740 crisis_20\NN\14411243 in_21\IN\13603305 a_22\DT\13649268 patient_23\NN\9898892 with_24\IN\1740 <e2>pheochromocytoma</e2>_25\NN\14235200 ._26\.\1740
C012052_D006973 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 42-year-old_4\JJ\1740 white_5\JJ\1740 man_6\NN\9605289 developed_7\VBD\1753788 acute_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 with_10\IN\1740 severe_11\JJ\1740 headache_12\NN\5829480 and_13\CC\1740 vomiting_14\NN\116687 2_15\CD\13741022 hours_16\NNS\15118228 after_17\IN\1740 the_18\DT\1740 first_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 <e1>amisulpride</e1>_22\RB\1740 100_23\CD\13745420 mg_24\NN\13717155 and_25\CC\1740 tiapride_26\NN\1740 100_27\CD\13745420 mg._28\NN\1740 both_29\DT\1740 drugs_30\NNS\14778436 were_31\VBD\836236 immediately_32\RB\1740 discontinued_33\VBN\2609764 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 patient_37\NN\9898892 recovered_38\VBN\2210855 after_39\IN\1740 subsequent_40\JJ\1740 nicardipine_41\NN\1740 and_42\CC\1740 verapamil_43\NN\2938514 treatment_44\NN\654885 ._45\.\1740
C012052_D006973 CID in_0\IN\13603305 our_1\PRP$\1740 case_2\NN\7283608 ,_3\,\1740 use_4\NN\407535 of_5\IN\1740 the_6\DT\1740 naranjo_7\NNP\1740 probability_8\NN\33615 scale_9\NN\7260623 indicated_10\VBD\952524 a_11\DT\13649268 possible_12\JJ\1740 relationship_13\NN\31921 between_14\IN\1740 the_15\DT\1740 <e2>hypertensive</e2>_16\JJ\1740 crisis_17\NN\14411243 and_18\CC\1740 <e1>amisulpride</e1>_19\RB\1740 and_20\CC\1740 tiapride_21\NN\1740 therapy_22\NN\657604 ._23\.\1740
C012052_D006973 CID conclusions_0\NNS\5837957 :_1\:\1740 as_2\IN\14622893 of_3\IN\1740 march_4\NNP\15209706 24_5\CD\13745420 ,_6\,\1740 2005_7\CD\1740 ,_8\,\1740 this_9\DT\1740 is_10\VBZ\836236 the_11\DT\1740 first_12\JJ\1740 reported_13\VBN\831651 case_14\NN\7283608 of_15\IN\1740 <e1>amisulpride-</e1>_16\NN\1740 and_17\CC\1740 tiapride-induced_18\JJ\1740 <e2>hypertensive</e2>_19\JJ\1740 crisis_20\NN\14411243 in_21\IN\13603305 a_22\DT\13649268 patient_23\NN\9898892 with_24\IN\1740 pheochromocytoma_25\NN\14235200 ._26\.\1740
C012052_D006261 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 42-year-old_4\JJ\1740 white_5\JJ\1740 man_6\NN\9605289 developed_7\VBD\1753788 acute_8\JJ\1740 hypertension_9\NN\14057371 with_10\IN\1740 severe_11\JJ\1740 <e2>headache</e2>_12\NN\5829480 and_13\CC\1740 vomiting_14\NN\116687 2_15\CD\13741022 hours_16\NNS\15118228 after_17\IN\1740 the_18\DT\1740 first_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 <e1>amisulpride</e1>_22\RB\1740 100_23\CD\13745420 mg_24\NN\13717155 and_25\CC\1740 tiapride_26\NN\1740 100_27\CD\13745420 mg._28\NN\1740 both_29\DT\1740 drugs_30\NNS\14778436 were_31\VBD\836236 immediately_32\RB\1740 discontinued_33\VBN\2609764 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 patient_37\NN\9898892 recovered_38\VBN\2210855 after_39\IN\1740 subsequent_40\JJ\1740 nicardipine_41\NN\1740 and_42\CC\1740 verapamil_43\NN\2938514 treatment_44\NN\654885 ._45\.\1740
C012052_D014839 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 42-year-old_4\JJ\1740 white_5\JJ\1740 man_6\NN\9605289 developed_7\VBD\1753788 acute_8\JJ\1740 hypertension_9\NN\14057371 with_10\IN\1740 severe_11\JJ\1740 headache_12\NN\5829480 and_13\CC\1740 <e2>vomiting</e2>_14\NN\116687 2_15\CD\13741022 hours_16\NNS\15118228 after_17\IN\1740 the_18\DT\1740 first_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 <e1>amisulpride</e1>_22\RB\1740 100_23\CD\13745420 mg_24\NN\13717155 and_25\CC\1740 tiapride_26\NN\1740 100_27\CD\13745420 mg._28\NN\1740 both_29\DT\1740 drugs_30\NNS\14778436 were_31\VBD\836236 immediately_32\RB\1740 discontinued_33\VBN\2609764 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 patient_37\NN\9898892 recovered_38\VBN\2210855 after_39\IN\1740 subsequent_40\JJ\1740 nicardipine_41\NN\1740 and_42\CC\1740 verapamil_43\NN\2938514 treatment_44\NN\654885 ._45\.\1740
D063325_D006973 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 42-year-old_4\JJ\1740 white_5\JJ\1740 man_6\NN\9605289 developed_7\VBD\1753788 acute_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 with_10\IN\1740 severe_11\JJ\1740 headache_12\NN\5829480 and_13\CC\1740 vomiting_14\NN\116687 2_15\CD\13741022 hours_16\NNS\15118228 after_17\IN\1740 the_18\DT\1740 first_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 amisulpride_22\RB\1740 100_23\CD\13745420 mg_24\NN\13717155 and_25\CC\1740 <e1>tiapride</e1>_26\NN\1740 100_27\CD\13745420 mg._28\NN\1740 both_29\DT\1740 drugs_30\NNS\14778436 were_31\VBD\836236 immediately_32\RB\1740 discontinued_33\VBN\2609764 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 patient_37\NN\9898892 recovered_38\VBN\2210855 after_39\IN\1740 subsequent_40\JJ\1740 nicardipine_41\NN\1740 and_42\CC\1740 verapamil_43\NN\2938514 treatment_44\NN\654885 ._45\.\1740
D063325_D006973 CID in_0\IN\13603305 our_1\PRP$\1740 case_2\NN\7283608 ,_3\,\1740 use_4\NN\407535 of_5\IN\1740 the_6\DT\1740 naranjo_7\NNP\1740 probability_8\NN\33615 scale_9\NN\7260623 indicated_10\VBD\952524 a_11\DT\13649268 possible_12\JJ\1740 relationship_13\NN\31921 between_14\IN\1740 the_15\DT\1740 <e2>hypertensive</e2>_16\JJ\1740 crisis_17\NN\14411243 and_18\CC\1740 amisulpride_19\RB\1740 and_20\CC\1740 <e1>tiapride</e1>_21\NN\1740 therapy_22\NN\657604 ._23\.\1740
D063325_D006973 CID conclusions_0\NNS\5837957 :_1\:\1740 as_2\IN\14622893 of_3\IN\1740 march_4\NNP\15209706 24_5\CD\13745420 ,_6\,\1740 2005_7\CD\1740 ,_8\,\1740 this_9\DT\1740 is_10\VBZ\836236 the_11\DT\1740 first_12\JJ\1740 reported_13\VBN\831651 case_14\NN\7283608 of_15\IN\1740 amisulpride-_16\NN\1740 and_17\CC\1740 <e1>tiapride-induced</e1>_18\JJ\1740 <e2>hypertensive</e2>_19\JJ\1740 crisis_20\NN\14411243 in_21\IN\13603305 a_22\DT\13649268 patient_23\NN\9898892 with_24\IN\1740 pheochromocytoma_25\NN\14235200 ._26\.\1740
D063325_D006261 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 42-year-old_4\JJ\1740 white_5\JJ\1740 man_6\NN\9605289 developed_7\VBD\1753788 acute_8\JJ\1740 hypertension_9\NN\14057371 with_10\IN\1740 severe_11\JJ\1740 <e2>headache</e2>_12\NN\5829480 and_13\CC\1740 vomiting_14\NN\116687 2_15\CD\13741022 hours_16\NNS\15118228 after_17\IN\1740 the_18\DT\1740 first_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 amisulpride_22\RB\1740 100_23\CD\13745420 mg_24\NN\13717155 and_25\CC\1740 <e1>tiapride</e1>_26\NN\1740 100_27\CD\13745420 mg._28\NN\1740 both_29\DT\1740 drugs_30\NNS\14778436 were_31\VBD\836236 immediately_32\RB\1740 discontinued_33\VBN\2609764 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 patient_37\NN\9898892 recovered_38\VBN\2210855 after_39\IN\1740 subsequent_40\JJ\1740 nicardipine_41\NN\1740 and_42\CC\1740 verapamil_43\NN\2938514 treatment_44\NN\654885 ._45\.\1740
D063325_D014839 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 42-year-old_4\JJ\1740 white_5\JJ\1740 man_6\NN\9605289 developed_7\VBD\1753788 acute_8\JJ\1740 hypertension_9\NN\14057371 with_10\IN\1740 severe_11\JJ\1740 headache_12\NN\5829480 and_13\CC\1740 <e2>vomiting</e2>_14\NN\116687 2_15\CD\13741022 hours_16\NNS\15118228 after_17\IN\1740 the_18\DT\1740 first_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 amisulpride_22\RB\1740 100_23\CD\13745420 mg_24\NN\13717155 and_25\CC\1740 <e1>tiapride</e1>_26\NN\1740 100_27\CD\13745420 mg._28\NN\1740 both_29\DT\1740 drugs_30\NNS\14778436 were_31\VBD\836236 immediately_32\RB\1740 discontinued_33\VBN\2609764 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 patient_37\NN\9898892 recovered_38\VBN\2210855 after_39\IN\1740 subsequent_40\JJ\1740 nicardipine_41\NN\1740 and_42\CC\1740 verapamil_43\NN\2938514 treatment_44\NN\654885 ._45\.\1740
D009529_D006973 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 42-year-old_4\JJ\1740 white_5\JJ\1740 man_6\NN\9605289 developed_7\VBD\1753788 acute_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 with_10\IN\1740 severe_11\JJ\1740 headache_12\NN\5829480 and_13\CC\1740 vomiting_14\NN\116687 2_15\CD\13741022 hours_16\NNS\15118228 after_17\IN\1740 the_18\DT\1740 first_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 amisulpride_22\RB\1740 100_23\CD\13745420 mg_24\NN\13717155 and_25\CC\1740 tiapride_26\NN\1740 100_27\CD\13745420 mg._28\NN\1740 both_29\DT\1740 drugs_30\NNS\14778436 were_31\VBD\836236 immediately_32\RB\1740 discontinued_33\VBN\2609764 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 patient_37\NN\9898892 recovered_38\VBN\2210855 after_39\IN\1740 subsequent_40\JJ\1740 <e1>nicardipine</e1>_41\NN\1740 and_42\CC\1740 verapamil_43\NN\2938514 treatment_44\NN\654885 ._45\.\1740
D009529_D006261 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 42-year-old_4\JJ\1740 white_5\JJ\1740 man_6\NN\9605289 developed_7\VBD\1753788 acute_8\JJ\1740 hypertension_9\NN\14057371 with_10\IN\1740 severe_11\JJ\1740 <e2>headache</e2>_12\NN\5829480 and_13\CC\1740 vomiting_14\NN\116687 2_15\CD\13741022 hours_16\NNS\15118228 after_17\IN\1740 the_18\DT\1740 first_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 amisulpride_22\RB\1740 100_23\CD\13745420 mg_24\NN\13717155 and_25\CC\1740 tiapride_26\NN\1740 100_27\CD\13745420 mg._28\NN\1740 both_29\DT\1740 drugs_30\NNS\14778436 were_31\VBD\836236 immediately_32\RB\1740 discontinued_33\VBN\2609764 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 patient_37\NN\9898892 recovered_38\VBN\2210855 after_39\IN\1740 subsequent_40\JJ\1740 <e1>nicardipine</e1>_41\NN\1740 and_42\CC\1740 verapamil_43\NN\2938514 treatment_44\NN\654885 ._45\.\1740
D009529_D014839 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 42-year-old_4\JJ\1740 white_5\JJ\1740 man_6\NN\9605289 developed_7\VBD\1753788 acute_8\JJ\1740 hypertension_9\NN\14057371 with_10\IN\1740 severe_11\JJ\1740 headache_12\NN\5829480 and_13\CC\1740 <e2>vomiting</e2>_14\NN\116687 2_15\CD\13741022 hours_16\NNS\15118228 after_17\IN\1740 the_18\DT\1740 first_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 amisulpride_22\RB\1740 100_23\CD\13745420 mg_24\NN\13717155 and_25\CC\1740 tiapride_26\NN\1740 100_27\CD\13745420 mg._28\NN\1740 both_29\DT\1740 drugs_30\NNS\14778436 were_31\VBD\836236 immediately_32\RB\1740 discontinued_33\VBN\2609764 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 patient_37\NN\9898892 recovered_38\VBN\2210855 after_39\IN\1740 subsequent_40\JJ\1740 <e1>nicardipine</e1>_41\NN\1740 and_42\CC\1740 verapamil_43\NN\2938514 treatment_44\NN\654885 ._45\.\1740
D014700_D006973 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 42-year-old_4\JJ\1740 white_5\JJ\1740 man_6\NN\9605289 developed_7\VBD\1753788 acute_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 with_10\IN\1740 severe_11\JJ\1740 headache_12\NN\5829480 and_13\CC\1740 vomiting_14\NN\116687 2_15\CD\13741022 hours_16\NNS\15118228 after_17\IN\1740 the_18\DT\1740 first_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 amisulpride_22\RB\1740 100_23\CD\13745420 mg_24\NN\13717155 and_25\CC\1740 tiapride_26\NN\1740 100_27\CD\13745420 mg._28\NN\1740 both_29\DT\1740 drugs_30\NNS\14778436 were_31\VBD\836236 immediately_32\RB\1740 discontinued_33\VBN\2609764 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 patient_37\NN\9898892 recovered_38\VBN\2210855 after_39\IN\1740 subsequent_40\JJ\1740 nicardipine_41\NN\1740 and_42\CC\1740 <e1>verapamil</e1>_43\NN\2938514 treatment_44\NN\654885 ._45\.\1740
D014700_D006261 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 42-year-old_4\JJ\1740 white_5\JJ\1740 man_6\NN\9605289 developed_7\VBD\1753788 acute_8\JJ\1740 hypertension_9\NN\14057371 with_10\IN\1740 severe_11\JJ\1740 <e2>headache</e2>_12\NN\5829480 and_13\CC\1740 vomiting_14\NN\116687 2_15\CD\13741022 hours_16\NNS\15118228 after_17\IN\1740 the_18\DT\1740 first_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 amisulpride_22\RB\1740 100_23\CD\13745420 mg_24\NN\13717155 and_25\CC\1740 tiapride_26\NN\1740 100_27\CD\13745420 mg._28\NN\1740 both_29\DT\1740 drugs_30\NNS\14778436 were_31\VBD\836236 immediately_32\RB\1740 discontinued_33\VBN\2609764 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 patient_37\NN\9898892 recovered_38\VBN\2210855 after_39\IN\1740 subsequent_40\JJ\1740 nicardipine_41\NN\1740 and_42\CC\1740 <e1>verapamil</e1>_43\NN\2938514 treatment_44\NN\654885 ._45\.\1740
D014700_D014839 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 42-year-old_4\JJ\1740 white_5\JJ\1740 man_6\NN\9605289 developed_7\VBD\1753788 acute_8\JJ\1740 hypertension_9\NN\14057371 with_10\IN\1740 severe_11\JJ\1740 headache_12\NN\5829480 and_13\CC\1740 <e2>vomiting</e2>_14\NN\116687 2_15\CD\13741022 hours_16\NNS\15118228 after_17\IN\1740 the_18\DT\1740 first_19\JJ\1740 doses_20\NNS\3740161 of_21\IN\1740 amisulpride_22\RB\1740 100_23\CD\13745420 mg_24\NN\13717155 and_25\CC\1740 tiapride_26\NN\1740 100_27\CD\13745420 mg._28\NN\1740 both_29\DT\1740 drugs_30\NNS\14778436 were_31\VBD\836236 immediately_32\RB\1740 discontinued_33\VBN\2609764 ,_34\,\1740 and_35\CC\1740 the_36\DT\1740 patient_37\NN\9898892 recovered_38\VBN\2210855 after_39\IN\1740 subsequent_40\JJ\1740 nicardipine_41\NN\1740 and_42\CC\1740 <e1>verapamil</e1>_43\NN\2938514 treatment_44\NN\654885 ._45\.\1740
C037689_D010673 NONE discussion_0\NN\6252138 :_1\:\1740 drug-induced_2\JJ\1740 symptoms_3\NNS\5823932 of_4\IN\1740 <e2>pheochromocytoma</e2>_5\NN\14235200 are_6\VBP\836236 often_7\RB\1740 associated_8\VBN\628491 with_9\IN\1740 the_10\DT\1740 use_11\NN\407535 of_12\IN\1740 substituted_13\VBN\126264 <e1>benzamide</e1>_14\NN\1740 drugs_15\NNS\14778436 ,_16\,\1740 but_17\CC\1740 the_18\DT\1740 underlying_19\VBG\2604760 mechanism_20\NN\13446390 is_21\VBZ\836236 unknown_22\JJ\1740 ._23\.\1740
19719056
D019342_D010146 NONE acute_0\JJ\1740 analgesic_1\NN\3740161 and_2\CC\1740 antiinflammatory_3\JJ\1740 activities_4\NNS\30358 were_5\VBD\836236 ascertained_6\VBN\664483 using_7\VBG\1156834 <e1>acetic_8\JJ\1740 acid</e1>_9\NN\14818238 induced_10\JJ\1740 <e2>writhing</e2>_11\NN\1740 model_12\NN\5888929 (_13\-LRB-\1740 mice_14\NNS\2329401 )_15\-RRB-\1740 and_16\CC\1740 carrageenan-induced_17\JJ\1740 rat_18\NN\2329401 paw_19\NN\2153445 edema_20\NN\14315192 model_21\NN\5888929 ,_22\,\1740 respectively_23\RB\1740 ._24\.\1740
D019342_D004487 NONE acute_0\JJ\1740 analgesic_1\NN\3740161 and_2\CC\1740 antiinflammatory_3\JJ\1740 activities_4\NNS\30358 were_5\VBD\836236 ascertained_6\VBN\664483 using_7\VBG\1156834 <e1>acetic_8\JJ\1740 acid</e1>_9\NN\14818238 induced_10\JJ\1740 writhing_11\NN\1740 model_12\NN\5888929 (_13\-LRB-\1740 mice_14\NNS\2329401 )_15\-RRB-\1740 and_16\CC\1740 carrageenan-induced_17\JJ\1740 rat_18\NN\2329401 paw_19\NN\2153445 <e2>edema</e2>_20\NN\14315192 model_21\NN\5888929 ,_22\,\1740 respectively_23\RB\1740 ._24\.\1740
D002351_D010146 CID acute_0\JJ\1740 analgesic_1\NN\3740161 and_2\CC\1740 antiinflammatory_3\JJ\1740 activities_4\NNS\30358 were_5\VBD\836236 ascertained_6\VBN\664483 using_7\VBG\1156834 acetic_8\JJ\1740 acid_9\NN\14818238 induced_10\JJ\1740 <e2>writhing</e2>_11\NN\1740 model_12\NN\5888929 (_13\-LRB-\1740 mice_14\NNS\2329401 )_15\-RRB-\1740 and_16\CC\1740 <e1>carrageenan-induced</e1>_17\JJ\1740 rat_18\NN\2329401 paw_19\NN\2153445 edema_20\NN\14315192 model_21\NN\5888929 ,_22\,\1740 respectively_23\RB\1740 ._24\.\1740
D002351_D004487 CID acute_0\JJ\1740 analgesic_1\NN\3740161 and_2\CC\1740 antiinflammatory_3\JJ\1740 activities_4\NNS\30358 were_5\VBD\836236 ascertained_6\VBN\664483 using_7\VBG\1156834 acetic_8\JJ\1740 acid_9\NN\14818238 induced_10\JJ\1740 writhing_11\NN\1740 model_12\NN\5888929 (_13\-LRB-\1740 mice_14\NNS\2329401 )_15\-RRB-\1740 and_16\CC\1740 <e1>carrageenan-induced</e1>_17\JJ\1740 rat_18\NN\2329401 paw_19\NN\2153445 <e2>edema</e2>_20\NN\14315192 model_21\NN\5888929 ,_22\,\1740 respectively_23\RB\1740 ._24\.\1740
7707116
D015474_D009447 NONE phase_0\NN\15113229 i_1\CD\14622893 trial_2\NN\786195 of_3\IN\1740 <e1>13-cis-retinoic_4\JJ\1740 acid</e1>_5\NN\14818238 in_6\IN\13603305 children_7\NNS\9622049 with_8\IN\1740 <e2>neuroblastoma</e2>_9\NN\14239425 following_10\VBG\1835496 bone_11\NN\5286536 marrow_12\NN\5286536 transplantation_13\NN\671351 ._14\.\1740
D015474_D009447 NONE purpose_0\NNP\5980875 :_1\:\1740 treatment_2\NN\654885 of_3\IN\1740 <e2>neuroblastoma</e2>_4\NN\14239425 cell_5\NN\3080309 lines_6\NNS\8426461 with_7\IN\1740 <e1>13-cis-retinoic_8\JJ\1740 acid</e1>_9\NN\14818238 (_10\-LRB-\1740 cis-ra_11\NN\1740 )_12\-RRB-\1740 can_13\MD\3094503 cause_14\VB\1617192 sustained_15\JJ\1740 inhibition_16\NN\1068773 of_17\IN\1740 proliferation_18\NN\13489037 ._19\.\1740
D015474_D009447 NONE purpose_0\NNP\5980875 :_1\:\1740 treatment_2\NN\654885 of_3\IN\1740 <e2>neuroblastoma</e2>_4\NN\14239425 cell_5\NN\3080309 lines_6\NNS\8426461 with_7\IN\1740 13-cis-retinoic_8\JJ\1740 acid_9\NN\14818238 (_10\-LRB-\1740 <e1>cis-ra</e1>_11\NN\1740 )_12\-RRB-\1740 can_13\MD\3094503 cause_14\VB\1617192 sustained_15\JJ\1740 inhibition_16\NN\1068773 of_17\IN\1740 proliferation_18\NN\13489037 ._19\.\1740
D015474_D009447 NONE since_0\IN\1740 <e1>cis-ra</e1>_1\NN\1740 has_2\VBZ\2108377 demonstrated_3\VBN\2137132 clinical_4\JJ\1740 responses_5\NNS\11410625 in_6\IN\13603305 <e2>neuroblastoma</e2>_7\NN\14239425 patients_8\NNS\9898892 ,_9\,\1740 it_10\PRP\6125041 may_11\MD\15209706 be_12\VB\836236 effective_13\JJ\1740 in_14\IN\13603305 preventing_15\VBG\1740 relapse_16\NN\66636 after_17\IN\1740 cytotoxic_18\JJ\1740 therapy_19\NN\657604 ._20\.\1740
D015474_D009447 NONE this_0\DT\1740 phase_1\NN\15113229 i_2\CD\14622893 trial_3\NN\786195 was_4\VBD\836236 designed_5\VBN\1631534 to_6\TO\1740 determine_7\VB\1645601 the_8\DT\1740 maximal-tolerated_9\JJ\1740 dosage_10\NN\13576355 (_11\-LRB-\1740 mtd_12\NN\1740 )_13\-RRB-\1740 ,_14\,\1740 toxicities_15\NNS\13576101 ,_16\,\1740 and_17\CC\1740 pharmacokinetics_18\NNS\6054892 of_19\IN\1740 <e1>cis-ra</e1>_20\NN\1740 administered_21\VBN\2436349 on_22\IN\1740 an_23\DT\6697703 intermittent_24\JJ\1740 schedule_25\NN\5898568 in_26\IN\13603305 children_27\NNS\9622049 with_28\IN\1740 <e2>neuroblastoma</e2>_29\NN\14239425 following_30\VBG\1835496 bone_31\NN\5286536 marrow_32\NN\5286536 transplantation_33\NN\671351 (_34\-LRB-\1740 bmt_35\NN\1740 )_36\-RRB-\1740 ._37\.\1740
D015474_D064420 NONE this_0\DT\1740 phase_1\NN\15113229 i_2\CD\14622893 trial_3\NN\786195 was_4\VBD\836236 designed_5\VBN\1631534 to_6\TO\1740 determine_7\VB\1645601 the_8\DT\1740 maximal-tolerated_9\JJ\1740 dosage_10\NN\13576355 (_11\-LRB-\1740 mtd_12\NN\1740 )_13\-RRB-\1740 ,_14\,\1740 <e2>toxicities</e2>_15\NNS\13576101 ,_16\,\1740 and_17\CC\1740 pharmacokinetics_18\NNS\6054892 of_19\IN\1740 <e1>cis-ra</e1>_20\NN\1740 administered_21\VBN\2436349 on_22\IN\1740 an_23\DT\6697703 intermittent_24\JJ\1740 schedule_25\NN\5898568 in_26\IN\13603305 children_27\NNS\9622049 with_28\IN\1740 neuroblastoma_29\NN\14239425 following_30\VBG\1835496 bone_31\NN\5286536 marrow_32\NN\5286536 transplantation_33\NN\671351 (_34\-LRB-\1740 bmt_35\NN\1740 )_36\-RRB-\1740 ._37\.\1740
D015474_D064420 NONE all_0\DT\1740 <e2>toxicities</e2>_1\NNS\13576101 resolved_2\VBN\352826 after_3\IN\1740 <e1>cis-ra</e1>_4\NN\1740 was_5\VBD\836236 discontinued_6\VBN\2609764 ._7\.\1740
D015474_D006934 CID the_0\DT\1740 dlt_1\NN\1740 included_2\VBD\690614 <e2>hypercalcemia</e2>_3\NN\14299637 ,_4\,\1740 and_5\CC\1740 may_6\MD\15209706 be_7\VB\836236 predicted_8\VBN\916909 by_9\IN\1740 serum_10\NN\5397468 <e1>cis-ra</e1>_11\NN\1740 levels_12\NNS\4916342 ._13\.\1740
11858397
D008787_D016171 CID <e2>torsade_0\NNP\1740 de_1\NNP\1740 pointes</e2>_2\NNS\1740 induced_3\VBN\1627355 by_4\IN\1740 <e1>metoclopramide</e1>_5\NN\1740 in_6\IN\13603305 an_7\DT\6697703 elderly_8\JJ\1740 woman_9\NN\9605289 with_10\IN\1740 preexisting_11\VBG\2603699 complete_12\JJ\1740 left_13\JJ\1740 bundle_14\NN\7951464 branch_15\NN\8220714 block_16\NN\21939 ._17\.\1740
D008787_D016171 CID we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 a_3\DT\13649268 92-year-old_4\JJ\1740 woman_5\NN\9605289 with_6\IN\1740 preexisting_7\VBG\2603699 complete_8\JJ\1740 left_9\JJ\1740 bundle_10\NN\7951464 branch_11\NN\8220714 block_12\NN\21939 who_13\WP\8299493 developed_14\VBD\1753788 <e2>torsade_15\NN\1740 de_16\IN\1740 pointes</e2>_17\NNS\1740 after_18\IN\1740 intravenous_19\JJ\1740 and_20\CC\1740 oral_21\JJ\1740 administration_22\NN\1133281 of_23\IN\1740 <e1>metoclopramide</e1>_24\NN\1740 ._25\.\1740
D008787_D016171 CID this_0\DT\1740 is_1\VBZ\836236 the_2\DT\1740 first_3\JJ\1740 documentation_4\NN\6650070 that_5\WDT\1740 <e1>metoclopramide</e1>_6\NN\1740 provokes_7\VBZ\1617192 <e2>torsade_8\VB\1740 de_9\IN\1740 pointes</e2>_10\NNS\1740 clinically_11\RB\1740 ._12\.\1740
D008787_D016171 CID <e1>metoclopramide</e1>_0\NN\1740 should_1\MD\1740 be_2\VB\836236 used_3\VBN\1156834 cautiously_4\RB\1740 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 a_8\DT\13649268 risk_9\NN\14541044 of_10\IN\1740 <e2>torsade_11\NN\1740 de_12\NNP\1740 pointes</e2>_13\NNS\1740 ._14\.\1740
D008787_D002037 NONE torsade_0\NNP\1740 de_1\NNP\1740 pointes_2\NNS\1740 induced_3\VBN\1627355 by_4\IN\1740 <e1>metoclopramide</e1>_5\NN\1740 in_6\IN\13603305 an_7\DT\6697703 elderly_8\JJ\1740 woman_9\NN\9605289 with_10\IN\1740 preexisting_11\VBG\2603699 complete_12\JJ\1740 <e2>left_13\JJ\1740 bundle_14\NN\7951464 branch_15\NN\8220714 block</e2>_16\NN\21939 ._17\.\1740
D008787_D002037 NONE we_0\PRP\1740 report_1\VBP\831651 on_2\IN\1740 a_3\DT\13649268 92-year-old_4\JJ\1740 woman_5\NN\9605289 with_6\IN\1740 preexisting_7\VBG\2603699 complete_8\JJ\1740 <e2>left_9\JJ\1740 bundle_10\NN\7951464 branch_11\NN\8220714 block</e2>_12\NN\21939 who_13\WP\8299493 developed_14\VBD\1753788 torsade_15\NN\1740 de_16\IN\1740 pointes_17\NNS\1740 after_18\IN\1740 intravenous_19\JJ\1740 and_20\CC\1740 oral_21\JJ\1740 administration_22\NN\1133281 of_23\IN\1740 <e1>metoclopramide</e1>_24\NN\1740 ._25\.\1740
D020117_D016171 CID this_0\DT\1740 patient_1\NN\9898892 also_2\RB\1740 developed_3\VBD\1753788 <e2>torsade_4\NN\1740 de_5\IN\1740 pointes</e2>_6\NNS\1740 when_7\WRB\1740 <e1>cisapride</e1>_8\NN\1740 and_9\CC\1740 erythromycin_10\NN\2716866 were_11\VBD\836236 given_12\VBN\2327200 simultaneously_13\RB\1740 ._14\.\1740
D004917_D016171 CID this_0\DT\1740 patient_1\NN\9898892 also_2\RB\1740 developed_3\VBD\1753788 <e2>torsade_4\NN\1740 de_5\IN\1740 pointes</e2>_6\NNS\1740 when_7\WRB\1740 cisapride_8\NN\1740 and_9\CC\1740 <e1>erythromycin</e1>_10\NN\2716866 were_11\VBD\836236 given_12\VBN\2327200 simultaneously_13\RB\1740 ._14\.\1740
7007443
D000082_D017114 CID acid_0\NN\14818238 protease_1\NN\14732946 (_2\-LRB-\1740 cathepsin_3\NN\1740 d_4\NN\15089472 )_5\-RRB-\1740 activity_6\NN\30358 was_7\VBD\836236 increased_8\VBN\169651 about_9\RB\1740 tenfold_10\NN\1740 in_11\IN\13603305 patients_12\NNS\9898892 who_13\WP\8299493 died_14\VBD\146138 and_15\CC\1740 nearly_16\RB\1740 fourfold_17\RB\1740 in_18\IN\13603305 those_19\DT\1740 who_20\WP\8299493 survived_21\VBD\1108148 <e2>fulminant_22\JJ\1740 hepatic_23\JJ\1740 failure</e2>_24\NN\66216 after_25\IN\1740 <e1>paracetamol</e1>_26\NN\1740 overdose_27\NN\1740 ,_28\,\1740 whereas_29\IN\1740 activities_30\NNS\30358 were_31\VBD\836236 increased_32\VBN\169651 equally_33\RB\1740 in_34\IN\13603305 patients_35\NNS\9898892 with_36\IN\1740 fulminant_37\JJ\1740 hepatic_38\JJ\1740 failure_39\NN\66216 due_40\JJ\1740 to_41\TO\1740 viral_42\JJ\1740 hepatitis_43\NN\14127211 whether_44\IN\1740 or_45\CC\3541091 not_46\RB\1740 they_47\PRP\1740 survived_48\VBD\1108148 ._49\.\1740
D000082_D017114 CID acid_0\NN\14818238 protease_1\NN\14732946 (_2\-LRB-\1740 cathepsin_3\NN\1740 d_4\NN\15089472 )_5\-RRB-\1740 activity_6\NN\30358 was_7\VBD\836236 increased_8\VBN\169651 about_9\RB\1740 tenfold_10\NN\1740 in_11\IN\13603305 patients_12\NNS\9898892 who_13\WP\8299493 died_14\VBD\146138 and_15\CC\1740 nearly_16\RB\1740 fourfold_17\RB\1740 in_18\IN\13603305 those_19\DT\1740 who_20\WP\8299493 survived_21\VBD\1108148 fulminant_22\JJ\1740 hepatic_23\JJ\1740 failure_24\NN\66216 after_25\IN\1740 <e1>paracetamol</e1>_26\NN\1740 overdose_27\NN\1740 ,_28\,\1740 whereas_29\IN\1740 activities_30\NNS\30358 were_31\VBD\836236 increased_32\VBN\169651 equally_33\RB\1740 in_34\IN\13603305 patients_35\NNS\9898892 with_36\IN\1740 <e2>fulminant_37\JJ\1740 hepatic_38\JJ\1740 failure</e2>_39\NN\66216 due_40\JJ\1740 to_41\TO\1740 viral_42\JJ\1740 hepatitis_43\NN\14127211 whether_44\IN\1740 or_45\CC\3541091 not_46\RB\1740 they_47\PRP\1740 survived_48\VBD\1108148 ._49\.\1740
D000082_D062787 NONE acid_0\NN\14818238 protease_1\NN\14732946 (_2\-LRB-\1740 cathepsin_3\NN\1740 d_4\NN\15089472 )_5\-RRB-\1740 activity_6\NN\30358 was_7\VBD\836236 increased_8\VBN\169651 about_9\RB\1740 tenfold_10\NN\1740 in_11\IN\13603305 patients_12\NNS\9898892 who_13\WP\8299493 died_14\VBD\146138 and_15\CC\1740 nearly_16\RB\1740 fourfold_17\RB\1740 in_18\IN\13603305 those_19\DT\1740 who_20\WP\8299493 survived_21\VBD\1108148 fulminant_22\JJ\1740 hepatic_23\JJ\1740 failure_24\NN\66216 after_25\IN\1740 <e1>paracetamol</e1>_26\NN\1740 <e2>overdose</e2>_27\NN\1740 ,_28\,\1740 whereas_29\IN\1740 activities_30\NNS\30358 were_31\VBD\836236 increased_32\VBN\169651 equally_33\RB\1740 in_34\IN\13603305 patients_35\NNS\9898892 with_36\IN\1740 fulminant_37\JJ\1740 hepatic_38\JJ\1740 failure_39\NN\66216 due_40\JJ\1740 to_41\TO\1740 viral_42\JJ\1740 hepatitis_43\NN\14127211 whether_44\IN\1740 or_45\CC\3541091 not_46\RB\1740 they_47\PRP\1740 survived_48\VBD\1108148 ._49\.\1740
D000082_D006525 NONE acid_0\NN\14818238 protease_1\NN\14732946 (_2\-LRB-\1740 cathepsin_3\NN\1740 d_4\NN\15089472 )_5\-RRB-\1740 activity_6\NN\30358 was_7\VBD\836236 increased_8\VBN\169651 about_9\RB\1740 tenfold_10\NN\1740 in_11\IN\13603305 patients_12\NNS\9898892 who_13\WP\8299493 died_14\VBD\146138 and_15\CC\1740 nearly_16\RB\1740 fourfold_17\RB\1740 in_18\IN\13603305 those_19\DT\1740 who_20\WP\8299493 survived_21\VBD\1108148 fulminant_22\JJ\1740 hepatic_23\JJ\1740 failure_24\NN\66216 after_25\IN\1740 <e1>paracetamol</e1>_26\NN\1740 overdose_27\NN\1740 ,_28\,\1740 whereas_29\IN\1740 activities_30\NNS\30358 were_31\VBD\836236 increased_32\VBN\169651 equally_33\RB\1740 in_34\IN\13603305 patients_35\NNS\9898892 with_36\IN\1740 fulminant_37\JJ\1740 hepatic_38\JJ\1740 failure_39\NN\66216 due_40\JJ\1740 to_41\TO\1740 <e2>viral_42\JJ\1740 hepatitis</e2>_43\NN\14127211 whether_44\IN\1740 or_45\CC\3541091 not_46\RB\1740 they_47\PRP\1740 survived_48\VBD\1108148 ._49\.\1740
3653576
C001335_D058186 CID <e2>acute_0\JJ\1740 experimental_1\JJ\1740 models_2\NNS\5888929 of_3\IN\1740 renal_4\JJ\1740 damage</e2>_5\NN\7296428 to_6\TO\1740 the_7\DT\1740 proximal_8\JJ\1740 tubular_9\JJ\1740 ,_10\,\1740 glomerular_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 papillary_14\JJ\1740 regions_15\NNS\27167 of_16\IN\1740 the_17\DT\1740 rat_18\NN\2329401 were_19\VBD\836236 produced_20\VBN\1617192 by_21\IN\1740 administration_22\NN\1133281 of_23\IN\1740 <e1>hexachloro-1:3-butadiene</e1>_24\NN\1740 (_25\-LRB-\1740 hcbd_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 puromycin_29\NN\1740 aminonucleoside_30\NN\1740 (_31\-LRB-\1740 pan_32\NN\3101986 )_33\-RRB-\1740 ,_34\,\1740 and_35\CC\1740 2-bromoethylamine_36\NN\1740 (_37\-LRB-\1740 bea_38\NN\1740 )_39\-RRB-\1740 ,_40\,\1740 respectively_41\RB\1740 ._42\.\1740
C001335_D058186 CID <e2>acute_0\JJ\1740 experimental_1\JJ\1740 models_2\NNS\5888929 of_3\IN\1740 renal_4\JJ\1740 damage</e2>_5\NN\7296428 to_6\TO\1740 the_7\DT\1740 proximal_8\JJ\1740 tubular_9\JJ\1740 ,_10\,\1740 glomerular_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 papillary_14\JJ\1740 regions_15\NNS\27167 of_16\IN\1740 the_17\DT\1740 rat_18\NN\2329401 were_19\VBD\836236 produced_20\VBN\1617192 by_21\IN\1740 administration_22\NN\1133281 of_23\IN\1740 hexachloro-1:3-butadiene_24\NN\1740 (_25\-LRB-\1740 <e1>hcbd</e1>_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 puromycin_29\NN\1740 aminonucleoside_30\NN\1740 (_31\-LRB-\1740 pan_32\NN\3101986 )_33\-RRB-\1740 ,_34\,\1740 and_35\CC\1740 2-bromoethylamine_36\NN\1740 (_37\-LRB-\1740 bea_38\NN\1740 )_39\-RRB-\1740 ,_40\,\1740 respectively_41\RB\1740 ._42\.\1740
D011692_D058186 CID <e2>acute_0\JJ\1740 experimental_1\JJ\1740 models_2\NNS\5888929 of_3\IN\1740 renal_4\JJ\1740 damage</e2>_5\NN\7296428 to_6\TO\1740 the_7\DT\1740 proximal_8\JJ\1740 tubular_9\JJ\1740 ,_10\,\1740 glomerular_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 papillary_14\JJ\1740 regions_15\NNS\27167 of_16\IN\1740 the_17\DT\1740 rat_18\NN\2329401 were_19\VBD\836236 produced_20\VBN\1617192 by_21\IN\1740 administration_22\NN\1133281 of_23\IN\1740 hexachloro-1:3-butadiene_24\NN\1740 (_25\-LRB-\1740 hcbd_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 <e1>puromycin_29\NN\1740 aminonucleoside</e1>_30\NN\1740 (_31\-LRB-\1740 pan_32\NN\3101986 )_33\-RRB-\1740 ,_34\,\1740 and_35\CC\1740 2-bromoethylamine_36\NN\1740 (_37\-LRB-\1740 bea_38\NN\1740 )_39\-RRB-\1740 ,_40\,\1740 respectively_41\RB\1740 ._42\.\1740
D011692_D058186 CID <e2>acute_0\JJ\1740 experimental_1\JJ\1740 models_2\NNS\5888929 of_3\IN\1740 renal_4\JJ\1740 damage</e2>_5\NN\7296428 to_6\TO\1740 the_7\DT\1740 proximal_8\JJ\1740 tubular_9\JJ\1740 ,_10\,\1740 glomerular_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 papillary_14\JJ\1740 regions_15\NNS\27167 of_16\IN\1740 the_17\DT\1740 rat_18\NN\2329401 were_19\VBD\836236 produced_20\VBN\1617192 by_21\IN\1740 administration_22\NN\1133281 of_23\IN\1740 hexachloro-1:3-butadiene_24\NN\1740 (_25\-LRB-\1740 hcbd_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 puromycin_29\NN\1740 aminonucleoside_30\NN\1740 (_31\-LRB-\1740 <e1>pan</e1>_32\NN\3101986 )_33\-RRB-\1740 ,_34\,\1740 and_35\CC\1740 2-bromoethylamine_36\NN\1740 (_37\-LRB-\1740 bea_38\NN\1740 )_39\-RRB-\1740 ,_40\,\1740 respectively_41\RB\1740 ._42\.\1740
C004504_D058186 CID <e2>acute_0\JJ\1740 experimental_1\JJ\1740 models_2\NNS\5888929 of_3\IN\1740 renal_4\JJ\1740 damage</e2>_5\NN\7296428 to_6\TO\1740 the_7\DT\1740 proximal_8\JJ\1740 tubular_9\JJ\1740 ,_10\,\1740 glomerular_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 papillary_14\JJ\1740 regions_15\NNS\27167 of_16\IN\1740 the_17\DT\1740 rat_18\NN\2329401 were_19\VBD\836236 produced_20\VBN\1617192 by_21\IN\1740 administration_22\NN\1133281 of_23\IN\1740 hexachloro-1:3-butadiene_24\NN\1740 (_25\-LRB-\1740 hcbd_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 puromycin_29\NN\1740 aminonucleoside_30\NN\1740 (_31\-LRB-\1740 pan_32\NN\3101986 )_33\-RRB-\1740 ,_34\,\1740 and_35\CC\1740 <e1>2-bromoethylamine</e1>_36\NN\1740 (_37\-LRB-\1740 bea_38\NN\1740 )_39\-RRB-\1740 ,_40\,\1740 respectively_41\RB\1740 ._42\.\1740
C004504_D058186 CID <e2>acute_0\JJ\1740 experimental_1\JJ\1740 models_2\NNS\5888929 of_3\IN\1740 renal_4\JJ\1740 damage</e2>_5\NN\7296428 to_6\TO\1740 the_7\DT\1740 proximal_8\JJ\1740 tubular_9\JJ\1740 ,_10\,\1740 glomerular_11\JJ\1740 ,_12\,\1740 and_13\CC\1740 papillary_14\JJ\1740 regions_15\NNS\27167 of_16\IN\1740 the_17\DT\1740 rat_18\NN\2329401 were_19\VBD\836236 produced_20\VBN\1617192 by_21\IN\1740 administration_22\NN\1133281 of_23\IN\1740 hexachloro-1:3-butadiene_24\NN\1740 (_25\-LRB-\1740 hcbd_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 puromycin_29\NN\1740 aminonucleoside_30\NN\1740 (_31\-LRB-\1740 pan_32\NN\3101986 )_33\-RRB-\1740 ,_34\,\1740 and_35\CC\1740 2-bromoethylamine_36\NN\1740 (_37\-LRB-\1740 <e1>bea</e1>_38\NN\1740 )_39\-RRB-\1740 ,_40\,\1740 respectively_41\RB\1740 ._42\.\1740
C001335_D007674 NONE tubular_0\JJ\1740 damage_1\NN\7296428 produced_2\VBN\1617192 by_3\IN\1740 <e1>hcbd</e1>_4\NN\1740 or_5\CC\3541091 bea_6\NN\1740 was_7\VBD\836236 discriminated_8\VBN\650353 both_9\CC\1740 quantitatively_10\RB\1740 and_11\CC\1740 qualitatively_12\RB\1740 from_13\IN\1740 <e2>glomerular_14\JJ\1740 damage</e2>_15\NN\7296428 produced_16\VBN\1617192 by_17\IN\1740 pan_18\NN\3101986 ._19\.\1740
C004504_D007674 NONE tubular_0\JJ\1740 damage_1\NN\7296428 produced_2\VBN\1617192 by_3\IN\1740 hcbd_4\NN\1740 or_5\CC\3541091 <e1>bea</e1>_6\NN\1740 was_7\VBD\836236 discriminated_8\VBN\650353 both_9\CC\1740 quantitatively_10\RB\1740 and_11\CC\1740 qualitatively_12\RB\1740 from_13\IN\1740 <e2>glomerular_14\JJ\1740 damage</e2>_15\NN\7296428 produced_16\VBN\1617192 by_17\IN\1740 pan_18\NN\3101986 ._19\.\1740
D011692_D007674 NONE tubular_0\JJ\1740 damage_1\NN\7296428 produced_2\VBN\1617192 by_3\IN\1740 hcbd_4\NN\1740 or_5\CC\3541091 bea_6\NN\1740 was_7\VBD\836236 discriminated_8\VBN\650353 both_9\CC\1740 quantitatively_10\RB\1740 and_11\CC\1740 qualitatively_12\RB\1740 from_13\IN\1740 <e2>glomerular_14\JJ\1740 damage</e2>_15\NN\7296428 produced_16\VBN\1617192 by_17\IN\1740 <e1>pan</e1>_18\NN\3101986 ._19\.\1740
3084782
D008625_D009393 CID a_0\DT\13649268 strong_1\JJ\1740 association_2\NN\8008335 has_3\VBZ\2108377 been_4\VBN\836236 found_5\VBN\2426171 between_6\IN\1740 <e2>nephritis</e2>_7\NN\14113228 and_8\CC\1740 dermatitis_9\NN\14226056 due_10\IN\5174653 to_11\TO\1740 <e1>tiopronin</e1>_12\NNP\1740 (_13\-LRB-\1740 a_14\DT\13649268 d-penicillamine_15\NN\1740 like_16\JJ\1740 compound_17\NN\5869584 )_18\-RRB-\1740 and_19\CC\1740 class_20\NN\7951464 i_21\CD\14622893 antigens_22\NNS\20090 b35-cw4_23\JJ\1740 ,_24\,\1740 and_25\CC\1740 between_26\IN\1740 dermatitis_27\NN\14226056 due_28\IN\5174653 to_29\TO\1740 gold_30\NN\13371489 thiosulphate_31\NN\1740 and_32\CC\1740 b35_33\NN\1740 ._34\.\1740
D008625_D009393 CID compared_0\VBN\644583 to_1\TO\1740 healthy_2\JJ\1740 controls_3\NNS\5190804 a_4\DT\13649268 lower_5\JJR\1740 dr5_6\NN\1740 frequency_7\NN\15286249 was_8\VBD\836236 observed_9\VBN\2163746 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 ra_13\NN\14625458 except_14\IN\1740 for_15\IN\1740 the_16\DT\1740 <e1>tiopronin</e1>_17\NN\1740 related_18\JJ\1740 <e2>nephritis</e2>_19\NN\14113228 group_20\NN\2137 ._21\.\1740
D008625_D003872 CID a_0\DT\13649268 strong_1\JJ\1740 association_2\NN\8008335 has_3\VBZ\2108377 been_4\VBN\836236 found_5\VBN\2426171 between_6\IN\1740 nephritis_7\NN\14113228 and_8\CC\1740 <e2>dermatitis</e2>_9\NN\14226056 due_10\IN\5174653 to_11\TO\1740 <e1>tiopronin</e1>_12\NNP\1740 (_13\-LRB-\1740 a_14\DT\13649268 d-penicillamine_15\NN\1740 like_16\JJ\1740 compound_17\NN\5869584 )_18\-RRB-\1740 and_19\CC\1740 class_20\NN\7951464 i_21\CD\14622893 antigens_22\NNS\20090 b35-cw4_23\JJ\1740 ,_24\,\1740 and_25\CC\1740 between_26\IN\1740 dermatitis_27\NN\14226056 due_28\IN\5174653 to_29\TO\1740 gold_30\NN\13371489 thiosulphate_31\NN\1740 and_32\CC\1740 b35_33\NN\1740 ._34\.\1740
D008625_D003872 CID a_0\DT\13649268 strong_1\JJ\1740 association_2\NN\8008335 has_3\VBZ\2108377 been_4\VBN\836236 found_5\VBN\2426171 between_6\IN\1740 nephritis_7\NN\14113228 and_8\CC\1740 dermatitis_9\NN\14226056 due_10\IN\5174653 to_11\TO\1740 <e1>tiopronin</e1>_12\NNP\1740 (_13\-LRB-\1740 a_14\DT\13649268 d-penicillamine_15\NN\1740 like_16\JJ\1740 compound_17\NN\5869584 )_18\-RRB-\1740 and_19\CC\1740 class_20\NN\7951464 i_21\CD\14622893 antigens_22\NNS\20090 b35-cw4_23\JJ\1740 ,_24\,\1740 and_25\CC\1740 between_26\IN\1740 <e2>dermatitis</e2>_27\NN\14226056 due_28\IN\5174653 to_29\TO\1740 gold_30\NN\13371489 thiosulphate_31\NN\1740 and_32\CC\1740 b35_33\NN\1740 ._34\.\1740
D010396_D009393 NONE a_0\DT\13649268 strong_1\JJ\1740 association_2\NN\8008335 has_3\VBZ\2108377 been_4\VBN\836236 found_5\VBN\2426171 between_6\IN\1740 <e2>nephritis</e2>_7\NN\14113228 and_8\CC\1740 dermatitis_9\NN\14226056 due_10\IN\5174653 to_11\TO\1740 tiopronin_12\NNP\1740 (_13\-LRB-\1740 a_14\DT\13649268 <e1>d-penicillamine</e1>_15\NN\1740 like_16\JJ\1740 compound_17\NN\5869584 )_18\-RRB-\1740 and_19\CC\1740 class_20\NN\7951464 i_21\CD\14622893 antigens_22\NNS\20090 b35-cw4_23\JJ\1740 ,_24\,\1740 and_25\CC\1740 between_26\IN\1740 dermatitis_27\NN\14226056 due_28\IN\5174653 to_29\TO\1740 gold_30\NN\13371489 thiosulphate_31\NN\1740 and_32\CC\1740 b35_33\NN\1740 ._34\.\1740
D010396_D003872 NONE a_0\DT\13649268 strong_1\JJ\1740 association_2\NN\8008335 has_3\VBZ\2108377 been_4\VBN\836236 found_5\VBN\2426171 between_6\IN\1740 nephritis_7\NN\14113228 and_8\CC\1740 <e2>dermatitis</e2>_9\NN\14226056 due_10\IN\5174653 to_11\TO\1740 tiopronin_12\NNP\1740 (_13\-LRB-\1740 a_14\DT\13649268 <e1>d-penicillamine</e1>_15\NN\1740 like_16\JJ\1740 compound_17\NN\5869584 )_18\-RRB-\1740 and_19\CC\1740 class_20\NN\7951464 i_21\CD\14622893 antigens_22\NNS\20090 b35-cw4_23\JJ\1740 ,_24\,\1740 and_25\CC\1740 between_26\IN\1740 dermatitis_27\NN\14226056 due_28\IN\5174653 to_29\TO\1740 gold_30\NN\13371489 thiosulphate_31\NN\1740 and_32\CC\1740 b35_33\NN\1740 ._34\.\1740
D010396_D003872 NONE a_0\DT\13649268 strong_1\JJ\1740 association_2\NN\8008335 has_3\VBZ\2108377 been_4\VBN\836236 found_5\VBN\2426171 between_6\IN\1740 nephritis_7\NN\14113228 and_8\CC\1740 dermatitis_9\NN\14226056 due_10\IN\5174653 to_11\TO\1740 tiopronin_12\NNP\1740 (_13\-LRB-\1740 a_14\DT\13649268 <e1>d-penicillamine</e1>_15\NN\1740 like_16\JJ\1740 compound_17\NN\5869584 )_18\-RRB-\1740 and_19\CC\1740 class_20\NN\7951464 i_21\CD\14622893 antigens_22\NNS\20090 b35-cw4_23\JJ\1740 ,_24\,\1740 and_25\CC\1740 between_26\IN\1740 <e2>dermatitis</e2>_27\NN\14226056 due_28\IN\5174653 to_29\TO\1740 gold_30\NN\13371489 thiosulphate_31\NN\1740 and_32\CC\1740 b35_33\NN\1740 ._34\.\1740
D006046_D009393 NONE a_0\DT\13649268 strong_1\JJ\1740 association_2\NN\8008335 has_3\VBZ\2108377 been_4\VBN\836236 found_5\VBN\2426171 between_6\IN\1740 <e2>nephritis</e2>_7\NN\14113228 and_8\CC\1740 dermatitis_9\NN\14226056 due_10\IN\5174653 to_11\TO\1740 tiopronin_12\NNP\1740 (_13\-LRB-\1740 a_14\DT\13649268 d-penicillamine_15\NN\1740 like_16\JJ\1740 compound_17\NN\5869584 )_18\-RRB-\1740 and_19\CC\1740 class_20\NN\7951464 i_21\CD\14622893 antigens_22\NNS\20090 b35-cw4_23\JJ\1740 ,_24\,\1740 and_25\CC\1740 between_26\IN\1740 dermatitis_27\NN\14226056 due_28\IN\5174653 to_29\TO\1740 <e1>gold</e1>_30\NN\13371489 thiosulphate_31\NN\1740 and_32\CC\1740 b35_33\NN\1740 ._34\.\1740
D006046_D003872 CID a_0\DT\13649268 strong_1\JJ\1740 association_2\NN\8008335 has_3\VBZ\2108377 been_4\VBN\836236 found_5\VBN\2426171 between_6\IN\1740 nephritis_7\NN\14113228 and_8\CC\1740 <e2>dermatitis</e2>_9\NN\14226056 due_10\IN\5174653 to_11\TO\1740 tiopronin_12\NNP\1740 (_13\-LRB-\1740 a_14\DT\13649268 d-penicillamine_15\NN\1740 like_16\JJ\1740 compound_17\NN\5869584 )_18\-RRB-\1740 and_19\CC\1740 class_20\NN\7951464 i_21\CD\14622893 antigens_22\NNS\20090 b35-cw4_23\JJ\1740 ,_24\,\1740 and_25\CC\1740 between_26\IN\1740 dermatitis_27\NN\14226056 due_28\IN\5174653 to_29\TO\1740 <e1>gold</e1>_30\NN\13371489 thiosulphate_31\NN\1740 and_32\CC\1740 b35_33\NN\1740 ._34\.\1740
D006046_D003872 CID a_0\DT\13649268 strong_1\JJ\1740 association_2\NN\8008335 has_3\VBZ\2108377 been_4\VBN\836236 found_5\VBN\2426171 between_6\IN\1740 nephritis_7\NN\14113228 and_8\CC\1740 dermatitis_9\NN\14226056 due_10\IN\5174653 to_11\TO\1740 tiopronin_12\NNP\1740 (_13\-LRB-\1740 a_14\DT\13649268 d-penicillamine_15\NN\1740 like_16\JJ\1740 compound_17\NN\5869584 )_18\-RRB-\1740 and_19\CC\1740 class_20\NN\7951464 i_21\CD\14622893 antigens_22\NNS\20090 b35-cw4_23\JJ\1740 ,_24\,\1740 and_25\CC\1740 between_26\IN\1740 <e2>dermatitis</e2>_27\NN\14226056 due_28\IN\5174653 to_29\TO\1740 <e1>gold</e1>_30\NN\13371489 thiosulphate_31\NN\1740 and_32\CC\1740 b35_33\NN\1740 ._34\.\1740
-1_D009393 NONE a_0\DT\13649268 strong_1\JJ\1740 association_2\NN\8008335 has_3\VBZ\2108377 been_4\VBN\836236 found_5\VBN\2426171 between_6\IN\1740 <e2>nephritis</e2>_7\NN\14113228 and_8\CC\1740 dermatitis_9\NN\14226056 due_10\IN\5174653 to_11\TO\1740 tiopronin_12\NNP\1740 (_13\-LRB-\1740 a_14\DT\13649268 d-penicillamine_15\NN\1740 like_16\JJ\1740 compound_17\NN\5869584 )_18\-RRB-\1740 and_19\CC\1740 class_20\NN\7951464 i_21\CD\14622893 antigens_22\NNS\20090 b35-cw4_23\JJ\1740 ,_24\,\1740 and_25\CC\1740 between_26\IN\1740 dermatitis_27\NN\14226056 due_28\IN\5174653 to_29\TO\1740 gold_30\NN\13371489 <e1>thiosulphate</e1>_31\NN\1740 and_32\CC\1740 b35_33\NN\1740 ._34\.\1740
-1_D003872 NONE a_0\DT\13649268 strong_1\JJ\1740 association_2\NN\8008335 has_3\VBZ\2108377 been_4\VBN\836236 found_5\VBN\2426171 between_6\IN\1740 nephritis_7\NN\14113228 and_8\CC\1740 <e2>dermatitis</e2>_9\NN\14226056 due_10\IN\5174653 to_11\TO\1740 tiopronin_12\NNP\1740 (_13\-LRB-\1740 a_14\DT\13649268 d-penicillamine_15\NN\1740 like_16\JJ\1740 compound_17\NN\5869584 )_18\-RRB-\1740 and_19\CC\1740 class_20\NN\7951464 i_21\CD\14622893 antigens_22\NNS\20090 b35-cw4_23\JJ\1740 ,_24\,\1740 and_25\CC\1740 between_26\IN\1740 dermatitis_27\NN\14226056 due_28\IN\5174653 to_29\TO\1740 gold_30\NN\13371489 <e1>thiosulphate</e1>_31\NN\1740 and_32\CC\1740 b35_33\NN\1740 ._34\.\1740
-1_D003872 NONE a_0\DT\13649268 strong_1\JJ\1740 association_2\NN\8008335 has_3\VBZ\2108377 been_4\VBN\836236 found_5\VBN\2426171 between_6\IN\1740 nephritis_7\NN\14113228 and_8\CC\1740 dermatitis_9\NN\14226056 due_10\IN\5174653 to_11\TO\1740 tiopronin_12\NNP\1740 (_13\-LRB-\1740 a_14\DT\13649268 d-penicillamine_15\NN\1740 like_16\JJ\1740 compound_17\NN\5869584 )_18\-RRB-\1740 and_19\CC\1740 class_20\NN\7951464 i_21\CD\14622893 antigens_22\NNS\20090 b35-cw4_23\JJ\1740 ,_24\,\1740 and_25\CC\1740 between_26\IN\1740 <e2>dermatitis</e2>_27\NN\14226056 due_28\IN\5174653 to_29\TO\1740 gold_30\NN\13371489 <e1>thiosulphate</e1>_31\NN\1740 and_32\CC\1740 b35_33\NN\1740 ._34\.\1740
D008625_D001172 NONE compared_0\VBN\644583 to_1\TO\1740 healthy_2\JJ\1740 controls_3\NNS\5190804 a_4\DT\13649268 lower_5\JJR\1740 dr5_6\NN\1740 frequency_7\NN\15286249 was_8\VBD\836236 observed_9\VBN\2163746 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 <e2>ra</e2>_13\NN\14625458 except_14\IN\1740 for_15\IN\1740 the_16\DT\1740 <e1>tiopronin</e1>_17\NN\1740 related_18\JJ\1740 nephritis_19\NN\14113228 group_20\NN\2137 ._21\.\1740
3703509
D011241_D053609 NONE following_0\VBG\1835496 short_1\JJ\1740 exposure_2\NN\5042871 to_3\TO\1740 oral_4\JJ\1740 <e1>prednisone</e1>_5\NN\2721538 ,_6\,\1740 both_7\DT\1740 boys_8\NNS\9624168 developed_9\VBD\1753788 <e2>lethargy</e2>_10\NN\14014621 ,_11\,\1740 increasing_12\VBG\169651 somnolence_13\NN\14015731 ,_14\,\1740 polydipsia_15\NNP\14040660 ,_16\,\1740 polyphagia_17\NN\1740 ,_18\,\1740 and_19\CC\1740 polyuria_20\VBP\1740 ._21\.\1740
D011241_D006970 NONE following_0\VBG\1835496 short_1\JJ\1740 exposure_2\NN\5042871 to_3\TO\1740 oral_4\JJ\1740 <e1>prednisone</e1>_5\NN\2721538 ,_6\,\1740 both_7\DT\1740 boys_8\NNS\9624168 developed_9\VBD\1753788 lethargy_10\NN\14014621 ,_11\,\1740 increasing_12\VBG\169651 <e2>somnolence</e2>_13\NN\14015731 ,_14\,\1740 polydipsia_15\NNP\14040660 ,_16\,\1740 polyphagia_17\NN\1740 ,_18\,\1740 and_19\CC\1740 polyuria_20\VBP\1740 ._21\.\1740
D011241_D059606 NONE following_0\VBG\1835496 short_1\JJ\1740 exposure_2\NN\5042871 to_3\TO\1740 oral_4\JJ\1740 <e1>prednisone</e1>_5\NN\2721538 ,_6\,\1740 both_7\DT\1740 boys_8\NNS\9624168 developed_9\VBD\1753788 lethargy_10\NN\14014621 ,_11\,\1740 increasing_12\VBG\169651 somnolence_13\NN\14015731 ,_14\,\1740 <e2>polydipsia</e2>_15\NNP\14040660 ,_16\,\1740 polyphagia_17\NN\1740 ,_18\,\1740 and_19\CC\1740 polyuria_20\VBP\1740 ._21\.\1740
D011241_D006963 NONE following_0\VBG\1835496 short_1\JJ\1740 exposure_2\NN\5042871 to_3\TO\1740 oral_4\JJ\1740 <e1>prednisone</e1>_5\NN\2721538 ,_6\,\1740 both_7\DT\1740 boys_8\NNS\9624168 developed_9\VBD\1753788 lethargy_10\NN\14014621 ,_11\,\1740 increasing_12\VBG\169651 somnolence_13\NN\14015731 ,_14\,\1740 polydipsia_15\NNP\14040660 ,_16\,\1740 <e2>polyphagia</e2>_17\NN\1740 ,_18\,\1740 and_19\CC\1740 polyuria_20\VBP\1740 ._21\.\1740
D011241_D011141 NONE following_0\VBG\1835496 short_1\JJ\1740 exposure_2\NN\5042871 to_3\TO\1740 oral_4\JJ\1740 <e1>prednisone</e1>_5\NN\2721538 ,_6\,\1740 both_7\DT\1740 boys_8\NNS\9624168 developed_9\VBD\1753788 lethargy_10\NN\14014621 ,_11\,\1740 increasing_12\VBG\169651 somnolence_13\NN\14015731 ,_14\,\1740 polydipsia_15\NNP\14040660 ,_16\,\1740 polyphagia_17\NN\1740 ,_18\,\1740 and_19\CC\1740 <e2>polyuria</e2>_20\VBP\1740 ._21\.\1740
D019344_D000140 NONE nonketotic_0\JJ\1740 <e2>lactic_1\JJ\1740 acidosis</e2>_2\NN\14204950 was_3\VBD\836236 present_4\JJ\1740 in_5\IN\13603305 one_6\CD\13741022 and_7\CC\1740 ketosis_8\NN\14299637 without_9\IN\1740 a_10\DT\13649268 known_11\JJ\1740 serum_12\NN\5397468 <e1>lactate</e1>_13\NN\14850483 level_14\NN\4916342 was_15\VBD\836236 present_16\JJ\1740 in_17\IN\13603305 the_18\DT\1740 other_19\JJ\1740 ._20\.\1740
D019344_D007662 NONE nonketotic_0\JJ\1740 lactic_1\JJ\1740 acidosis_2\NN\14204950 was_3\VBD\836236 present_4\JJ\1740 in_5\IN\13603305 one_6\CD\13741022 and_7\CC\1740 <e2>ketosis</e2>_8\NN\14299637 without_9\IN\1740 a_10\DT\13649268 known_11\JJ\1740 serum_12\NN\5397468 <e1>lactate</e1>_13\NN\14850483 level_14\NN\4916342 was_15\VBD\836236 present_16\JJ\1740 in_17\IN\13603305 the_18\DT\1740 other_19\JJ\1740 ._20\.\1740
1687392
D004298_D002375 NONE blockade_0\NN\952963 of_1\IN\1740 both_2\CC\1740 d-1_3\NN\1740 and_4\CC\1740 d-2_5\JJ\1740 <e1>dopamine</e1>_6\NN\14807737 receptors_7\NNS\5225602 may_8\MD\15209706 induce_9\VB\1627355 <e2>catalepsy</e2>_10\NN\14023236 in_11\IN\13603305 mice_12\NNS\2329401 ._13\.\1740
D004298_D002375 NONE the_0\DT\1740 <e2>catalepsy</e2>_1\NN\14023236 induced_2\VBN\1627355 by_3\IN\1740 <e1>dopamine</e1>_4\NN\14807737 antagonists_5\NNS\7846 has_6\VBZ\2108377 been_7\VBN\836236 tested_8\VBN\670261 and_9\CC\1740 the_10\DT\1740 possible_11\JJ\1740 dopamine_12\NN\14807737 subtypes_13\NNS\1740 involved_14\VBN\2676054 in_15\IN\13603305 catalepsy_16\NN\14023236 was_17\VBD\836236 determined_18\VBN\1645601 ._19\.\1740
D004298_D002375 NONE the_0\DT\1740 catalepsy_1\NN\14023236 induced_2\VBN\1627355 by_3\IN\1740 <e1>dopamine</e1>_4\NN\14807737 antagonists_5\NNS\7846 has_6\VBZ\2108377 been_7\VBN\836236 tested_8\VBN\670261 and_9\CC\1740 the_10\DT\1740 possible_11\JJ\1740 dopamine_12\NN\14807737 subtypes_13\NNS\1740 involved_14\VBN\2676054 in_15\IN\13603305 <e2>catalepsy</e2>_16\NN\14023236 was_17\VBD\836236 determined_18\VBN\1645601 ._19\.\1740
D004298_D002375 NONE the_0\DT\1740 <e2>catalepsy</e2>_1\NN\14023236 induced_2\VBN\1627355 by_3\IN\1740 dopamine_4\NN\14807737 antagonists_5\NNS\7846 has_6\VBZ\2108377 been_7\VBN\836236 tested_8\VBN\670261 and_9\CC\1740 the_10\DT\1740 possible_11\JJ\1740 <e1>dopamine</e1>_12\NN\14807737 subtypes_13\NNS\1740 involved_14\VBN\2676054 in_15\IN\13603305 catalepsy_16\NN\14023236 was_17\VBD\836236 determined_18\VBN\1645601 ._19\.\1740
D004298_D002375 NONE the_0\DT\1740 catalepsy_1\NN\14023236 induced_2\VBN\1627355 by_3\IN\1740 dopamine_4\NN\14807737 antagonists_5\NNS\7846 has_6\VBZ\2108377 been_7\VBN\836236 tested_8\VBN\670261 and_9\CC\1740 the_10\DT\1740 possible_11\JJ\1740 <e1>dopamine</e1>_12\NN\14807737 subtypes_13\NNS\1740 involved_14\VBN\2676054 in_15\IN\13603305 <e2>catalepsy</e2>_16\NN\14023236 was_17\VBD\836236 determined_18\VBN\1645601 ._19\.\1740
D004298_D002375 NONE <e1>dopamine</e1>_0\NN\14807737 antagonist_1\NN\7846 fluphenazine_2\NN\3713736 ,_3\,\1740 d-1_4\NN\1740 antagonist_5\NN\7846 sch_6\NN\1740 23390_7\CD\1740 or_8\CC\3541091 d-2_9\JJ\1740 antagonist_10\NN\7846 sulpiride_11\NN\1740 induced_12\VBD\1627355 <e2>catalepsy</e2>_13\NN\14023236 ._14\.\1740
D004298_D002375 NONE combination_0\NN\7951464 of_1\IN\1740 skf_2\NN\1740 38393_3\CD\1740 with_4\IN\1740 quinpirole_5\NN\1740 did_6\VBD\1640855 not_7\RB\1740 cause_8\VB\1617192 potentiated_9\JJ\1740 inhibitory_10\JJ\1740 effect_11\NN\34213 on_12\IN\1740 <e2>catalepsy</e2>_13\NN\14023236 induced_14\VBN\1627355 by_15\IN\1740 <e1>dopamine</e1>_16\NN\14807737 antagonists_17\NNS\7846 ._18\.\1740
D005476_D002375 CID dopamine_0\NN\14807737 antagonist_1\NN\7846 <e1>fluphenazine</e1>_2\NN\3713736 ,_3\,\1740 d-1_4\NN\1740 antagonist_5\NN\7846 sch_6\NN\1740 23390_7\CD\1740 or_8\CC\3541091 d-2_9\JJ\1740 antagonist_10\NN\7846 sulpiride_11\NN\1740 induced_12\VBD\1627355 <e2>catalepsy</e2>_13\NN\14023236 ._14\.\1740
D005476_D002375 CID d-1_0\JJ\1740 agonist_1\NN\9613191 skf_2\NN\1740 38393_3\CD\1740 or_4\CC\3541091 d-2_5\JJ\1740 agonist_6\NN\9613191 quinpirole_7\NN\1740 decreased_8\VBD\169651 the_9\DT\1740 <e2>catalepsy</e2>_10\NN\14023236 induced_11\VBN\1627355 by_12\IN\1740 <e1>fluphenazine</e1>_13\NN\3713736 ,_14\,\1740 sch_15\NN\1740 23390_16\CD\1740 or_17\CC\3541091 sulpiride_18\NN\1740 ._19\.\1740
C534628_D002375 CID dopamine_0\NN\14807737 antagonist_1\NN\7846 fluphenazine_2\NN\3713736 ,_3\,\1740 d-1_4\NN\1740 antagonist_5\NN\7846 <e1>sch_6\NN\1740 23390</e1>_7\CD\1740 or_8\CC\3541091 d-2_9\JJ\1740 antagonist_10\NN\7846 sulpiride_11\NN\1740 induced_12\VBD\1627355 <e2>catalepsy</e2>_13\NN\14023236 ._14\.\1740
C534628_D002375 CID combination_0\NN\7951464 of_1\IN\1740 <e1>sch_2\NN\1740 23390</e1>_3\CD\1740 with_4\IN\1740 sulpiride_5\NN\1740 did_6\VBD\1640855 not_7\RB\1740 induce_8\VB\1627355 <e2>catalepsy</e2>_9\NN\14023236 potentiation_10\NN\13564910 ._11\.\1740
C534628_D002375 CID d-1_0\JJ\1740 agonist_1\NN\9613191 skf_2\NN\1740 38393_3\CD\1740 or_4\CC\3541091 d-2_5\JJ\1740 agonist_6\NN\9613191 quinpirole_7\NN\1740 decreased_8\VBD\169651 the_9\DT\1740 <e2>catalepsy</e2>_10\NN\14023236 induced_11\VBN\1627355 by_12\IN\1740 fluphenazine_13\NN\3713736 ,_14\,\1740 <e1>sch_15\NN\1740 23390</e1>_16\CD\1740 or_17\CC\3541091 sulpiride_18\NN\1740 ._19\.\1740
D013469_D002375 CID dopamine_0\NN\14807737 antagonist_1\NN\7846 fluphenazine_2\NN\3713736 ,_3\,\1740 d-1_4\NN\1740 antagonist_5\NN\7846 sch_6\NN\1740 23390_7\CD\1740 or_8\CC\3541091 d-2_9\JJ\1740 antagonist_10\NN\7846 <e1>sulpiride</e1>_11\NN\1740 induced_12\VBD\1627355 <e2>catalepsy</e2>_13\NN\14023236 ._14\.\1740
D013469_D002375 CID combination_0\NN\7951464 of_1\IN\1740 sch_2\NN\1740 23390_3\CD\1740 with_4\IN\1740 <e1>sulpiride</e1>_5\NN\1740 did_6\VBD\1640855 not_7\RB\1740 induce_8\VB\1627355 <e2>catalepsy</e2>_9\NN\14023236 potentiation_10\NN\13564910 ._11\.\1740
D013469_D002375 CID d-1_0\JJ\1740 agonist_1\NN\9613191 skf_2\NN\1740 38393_3\CD\1740 or_4\CC\3541091 d-2_5\JJ\1740 agonist_6\NN\9613191 quinpirole_7\NN\1740 decreased_8\VBD\169651 the_9\DT\1740 <e2>catalepsy</e2>_10\NN\14023236 induced_11\VBN\1627355 by_12\IN\1740 fluphenazine_13\NN\3713736 ,_14\,\1740 sch_15\NN\1740 23390_16\CD\1740 or_17\CC\3541091 <e1>sulpiride</e1>_18\NN\1740 ._19\.\1740
D015647_D002375 NONE d-1_0\JJ\1740 agonist_1\NN\9613191 <e1>skf_2\NN\1740 38393</e1>_3\CD\1740 or_4\CC\3541091 d-2_5\JJ\1740 agonist_6\NN\9613191 quinpirole_7\NN\1740 decreased_8\VBD\169651 the_9\DT\1740 <e2>catalepsy</e2>_10\NN\14023236 induced_11\VBN\1627355 by_12\IN\1740 fluphenazine_13\NN\3713736 ,_14\,\1740 sch_15\NN\1740 23390_16\CD\1740 or_17\CC\3541091 sulpiride_18\NN\1740 ._19\.\1740
D015647_D002375 NONE combination_0\NN\7951464 of_1\IN\1740 <e1>skf_2\NN\1740 38393</e1>_3\CD\1740 with_4\IN\1740 quinpirole_5\NN\1740 did_6\VBD\1640855 not_7\RB\1740 cause_8\VB\1617192 potentiated_9\JJ\1740 inhibitory_10\JJ\1740 effect_11\NN\34213 on_12\IN\1740 <e2>catalepsy</e2>_13\NN\14023236 induced_14\VBN\1627355 by_15\IN\1740 dopamine_16\NN\14807737 antagonists_17\NNS\7846 ._18\.\1740
D019257_D002375 NONE d-1_0\JJ\1740 agonist_1\NN\9613191 skf_2\NN\1740 38393_3\CD\1740 or_4\CC\3541091 d-2_5\JJ\1740 agonist_6\NN\9613191 <e1>quinpirole</e1>_7\NN\1740 decreased_8\VBD\169651 the_9\DT\1740 <e2>catalepsy</e2>_10\NN\14023236 induced_11\VBN\1627355 by_12\IN\1740 fluphenazine_13\NN\3713736 ,_14\,\1740 sch_15\NN\1740 23390_16\CD\1740 or_17\CC\3541091 sulpiride_18\NN\1740 ._19\.\1740
D019257_D002375 NONE combination_0\NN\7951464 of_1\IN\1740 skf_2\NN\1740 38393_3\CD\1740 with_4\IN\1740 <e1>quinpirole</e1>_5\NN\1740 did_6\VBD\1640855 not_7\RB\1740 cause_8\VB\1617192 potentiated_9\JJ\1740 inhibitory_10\JJ\1740 effect_11\NN\34213 on_12\IN\1740 <e2>catalepsy</e2>_13\NN\14023236 induced_14\VBN\1627355 by_15\IN\1740 dopamine_16\NN\14807737 antagonists_17\NNS\7846 ._18\.\1740
4090988
D000082_D001749 CID induction_0\NN\7450842 by_1\IN\1740 <e1>paracetamol</e1>_2\NN\1740 of_3\IN\1740 <e2>bladder_4\NN\5515670 and_5\CC\1740 liver_6\NN\5298729 tumours</e2>_7\NNS\14234074 in_8\IN\13603305 the_9\DT\1740 rat_10\NN\2329401 ._11\.\1740
D000082_D001749 CID papillomas_0\NNS\14236226 of_1\IN\1740 the_2\DT\1740 transitional_3\JJ\1740 epithelium_4\NN\5267548 of_5\IN\1740 the_6\DT\1740 bladder_7\NN\5515670 developed_8\VBD\1753788 in_9\IN\13603305 all_10\DT\1740 <e1>paracetamol-treated</e1>_11\JJ\1740 groups_12\NNS\2137 ,_13\,\1740 and_14\CC\1740 three_15\CD\13741022 rats_16\NNS\2329401 bore_17\VBD\1552519 <e2>bladder_18\NN\5515670 carcinomas</e2>_19\NNS\14239918 ._20\.\1740
D000082_D008113 CID induction_0\NN\7450842 by_1\IN\1740 <e1>paracetamol</e1>_2\NN\1740 of_3\IN\1740 <e2>bladder_4\NN\5515670 and_5\CC\1740 liver_6\NN\5298729 tumours</e2>_7\NNS\14234074 in_8\IN\13603305 the_9\DT\1740 rat_10\NN\2329401 ._11\.\1740
D000082_D008113 CID an_0\DT\6697703 electron_1\NN\9338013 microscope_2\NN\3709206 study_3\NN\635850 of_4\IN\1740 the_5\DT\1740 livers_6\NNS\5298729 of_7\IN\1740 <e1>paracetamol-treated</e1>_8\JJ\1740 rats_9\NNS\2329401 revealed_10\VBD\2137132 ultrastructural_11\JJ\1740 changes_12\NNS\7283608 in_13\IN\13603305 the_14\DT\1740 hepatocytes_15\NNS\1740 that_16\WDT\1740 resemble_17\VBP\2657219 those_18\DT\1740 that_19\WDT\1740 result_20\VBP\2633881 from_21\IN\1740 exposure_22\NN\5042871 to_23\TO\1740 a_24\DT\13649268 variety_25\NN\7951464 of_26\IN\1740 known_27\VBN\2110220 <e2>hepatocarcinogens</e2>_28\NNS\1740 ._29\.\1740
D000082_D010212 NONE <e2>papillomas</e2>_0\NNS\14236226 of_1\IN\1740 the_2\DT\1740 transitional_3\JJ\1740 epithelium_4\NN\5267548 of_5\IN\1740 the_6\DT\1740 bladder_7\NN\5515670 developed_8\VBD\1753788 in_9\IN\13603305 all_10\DT\1740 <e1>paracetamol-treated</e1>_11\JJ\1740 groups_12\NNS\2137 ,_13\,\1740 and_14\CC\1740 three_15\CD\13741022 rats_16\NNS\2329401 bore_17\VBD\1552519 bladder_18\NN\5515670 carcinomas_19\NNS\14239918 ._20\.\1740
D000082_D006965 CID additionally_0\RB\1740 ,_1\,\1740 20_2\CD\13745420 to_3\TO\1740 25_4\CD\13745420 %_5\NN\1740 of_6\IN\1740 <e1>paracetamol-treated</e1>_7\JJ\1740 rats_8\NNS\2329401 developed_9\VBD\1753788 <e2>hyperplasia</e2>_10\NN\14365950 of_11\IN\1740 the_12\DT\1740 bladder_13\NN\5515670 epithelium_14\NN\5267548 ,_15\,\1740 which_16\WDT\1740 was_17\VBD\836236 not_18\RB\1740 coincident_19\JJ\1740 with_20\IN\1740 the_21\DT\1740 presence_22\NN\13954253 of_23\IN\1740 bladder_24\NN\5515670 calculi_25\NNS\9416076 ._26\.\1740
D000082_D001744 NONE additionally_0\RB\1740 ,_1\,\1740 20_2\CD\13745420 to_3\TO\1740 25_4\CD\13745420 %_5\NN\1740 of_6\IN\1740 <e1>paracetamol-treated</e1>_7\JJ\1740 rats_8\NNS\2329401 developed_9\VBD\1753788 hyperplasia_10\NN\14365950 of_11\IN\1740 the_12\DT\1740 bladder_13\NN\5515670 epithelium_14\NN\5267548 ,_15\,\1740 which_16\WDT\1740 was_17\VBD\836236 not_18\RB\1740 coincident_19\JJ\1740 with_20\IN\1740 the_21\DT\1740 presence_22\NN\13954253 of_23\IN\1740 <e2>bladder_24\NN\5515670 calculi</e2>_25\NNS\9416076 ._26\.\1740
D000082_D009369 NONE a_0\DT\13649268 low_1\JJ\1740 yield_2\NN\913705 of_3\IN\1740 <e2>tumours</e2>_4\NNS\14234074 at_5\IN\14622893 various_6\JJ\1740 other_7\JJ\1740 sites_8\NNS\8673395 also_9\RB\1740 arose_10\VBD\2623529 following_11\VBG\1835496 <e1>paracetamol</e1>_12\NN\1740 feeding_13\NN\838098 ._14\.\1740
11524350
D002045_D064420 NONE systemic_0\JJ\1740 <e2>toxicity</e2>_1\NN\13576101 and_2\CC\1740 resuscitation_3\NN\1047338 in_4\IN\13603305 <e1>bupivacaine-</e1>_5\NN\1740 ,_6\,\1740 levobupivacaine-_7\NN\1740 ,_8\,\1740 or_9\CC\3541091 ropivacaine-infused_10\JJ\1740 rats_11\NNS\2329401 ._12\.\1740
D002045_D064420 NONE we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 systemic_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 of_5\IN\1740 <e1>bupivacaine</e1>_6\NN\1740 ,_7\,\1740 levobupivacaine_8\NN\1740 ,_9\,\1740 and_10\CC\1740 ropivacaine_11\VB\1740 in_12\IN\13603305 anesthetized_13\JJ\1740 rats_14\NNS\2329401 ._15\.\1740
D002045_D064420 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 systemic_4\JJ\1740 <e2>toxicity</e2>_5\NN\13576101 of_6\IN\1740 levobupivacaine_7\NN\1740 is_8\VBZ\836236 intermediate_9\JJ\1740 between_10\IN\1740 that_11\DT\1740 of_12\IN\1740 ropivacaine_13\NN\1740 and_14\CC\1740 <e1>bupivacaine</e1>_15\NN\1740 when_16\WRB\1740 administered_17\VBN\2436349 at_18\IN\14622893 the_19\DT\1740 same_20\JJ\1740 rate_21\NN\13815152 and_22\CC\1740 that_23\IN\1740 ropivacaine-induced_24\JJ\1740 cardiac_25\JJ\1740 arrest_26\NN\88481 appears_27\VBZ\2604760 to_28\TO\1740 be_29\VB\836236 more_30\RBR\1740 susceptible_31\JJ\1740 to_32\TO\1740 treatment_33\NN\654885 than_34\IN\1740 that_35\DT\1740 induced_36\VBN\1627355 by_37\IN\1740 bupivacaine_38\NN\1740 or_39\CC\3541091 levobupivacaine_40\NN\1740 ._41\.\1740
D002045_D064420 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 systemic_4\JJ\1740 <e2>toxicity</e2>_5\NN\13576101 of_6\IN\1740 levobupivacaine_7\NN\1740 is_8\VBZ\836236 intermediate_9\JJ\1740 between_10\IN\1740 that_11\DT\1740 of_12\IN\1740 ropivacaine_13\NN\1740 and_14\CC\1740 bupivacaine_15\NN\1740 when_16\WRB\1740 administered_17\VBN\2436349 at_18\IN\14622893 the_19\DT\1740 same_20\JJ\1740 rate_21\NN\13815152 and_22\CC\1740 that_23\IN\1740 ropivacaine-induced_24\JJ\1740 cardiac_25\JJ\1740 arrest_26\NN\88481 appears_27\VBZ\2604760 to_28\TO\1740 be_29\VB\836236 more_30\RBR\1740 susceptible_31\JJ\1740 to_32\TO\1740 treatment_33\NN\654885 than_34\IN\1740 that_35\DT\1740 induced_36\VBN\1627355 by_37\IN\1740 <e1>bupivacaine</e1>_38\NN\1740 or_39\CC\3541091 levobupivacaine_40\NN\1740 ._41\.\1740
C476513_D064420 NONE systemic_0\JJ\1740 <e2>toxicity</e2>_1\NN\13576101 and_2\CC\1740 resuscitation_3\NN\1047338 in_4\IN\13603305 bupivacaine-_5\NN\1740 ,_6\,\1740 <e1>levobupivacaine-</e1>_7\NN\1740 ,_8\,\1740 or_9\CC\3541091 ropivacaine-infused_10\JJ\1740 rats_11\NNS\2329401 ._12\.\1740
C476513_D064420 NONE we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 systemic_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 of_5\IN\1740 bupivacaine_6\NN\1740 ,_7\,\1740 <e1>levobupivacaine</e1>_8\NN\1740 ,_9\,\1740 and_10\CC\1740 ropivacaine_11\VB\1740 in_12\IN\13603305 anesthetized_13\JJ\1740 rats_14\NNS\2329401 ._15\.\1740
C476513_D064420 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 systemic_4\JJ\1740 <e2>toxicity</e2>_5\NN\13576101 of_6\IN\1740 <e1>levobupivacaine</e1>_7\NN\1740 is_8\VBZ\836236 intermediate_9\JJ\1740 between_10\IN\1740 that_11\DT\1740 of_12\IN\1740 ropivacaine_13\NN\1740 and_14\CC\1740 bupivacaine_15\NN\1740 when_16\WRB\1740 administered_17\VBN\2436349 at_18\IN\14622893 the_19\DT\1740 same_20\JJ\1740 rate_21\NN\13815152 and_22\CC\1740 that_23\IN\1740 ropivacaine-induced_24\JJ\1740 cardiac_25\JJ\1740 arrest_26\NN\88481 appears_27\VBZ\2604760 to_28\TO\1740 be_29\VB\836236 more_30\RBR\1740 susceptible_31\JJ\1740 to_32\TO\1740 treatment_33\NN\654885 than_34\IN\1740 that_35\DT\1740 induced_36\VBN\1627355 by_37\IN\1740 bupivacaine_38\NN\1740 or_39\CC\3541091 levobupivacaine_40\NN\1740 ._41\.\1740
C476513_D064420 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 systemic_4\JJ\1740 <e2>toxicity</e2>_5\NN\13576101 of_6\IN\1740 levobupivacaine_7\NN\1740 is_8\VBZ\836236 intermediate_9\JJ\1740 between_10\IN\1740 that_11\DT\1740 of_12\IN\1740 ropivacaine_13\NN\1740 and_14\CC\1740 bupivacaine_15\NN\1740 when_16\WRB\1740 administered_17\VBN\2436349 at_18\IN\14622893 the_19\DT\1740 same_20\JJ\1740 rate_21\NN\13815152 and_22\CC\1740 that_23\IN\1740 ropivacaine-induced_24\JJ\1740 cardiac_25\JJ\1740 arrest_26\NN\88481 appears_27\VBZ\2604760 to_28\TO\1740 be_29\VB\836236 more_30\RBR\1740 susceptible_31\JJ\1740 to_32\TO\1740 treatment_33\NN\654885 than_34\IN\1740 that_35\DT\1740 induced_36\VBN\1627355 by_37\IN\1740 bupivacaine_38\NN\1740 or_39\CC\3541091 <e1>levobupivacaine</e1>_40\NN\1740 ._41\.\1740
C037663_D064420 NONE systemic_0\JJ\1740 <e2>toxicity</e2>_1\NN\13576101 and_2\CC\1740 resuscitation_3\NN\1047338 in_4\IN\13603305 bupivacaine-_5\NN\1740 ,_6\,\1740 levobupivacaine-_7\NN\1740 ,_8\,\1740 or_9\CC\3541091 <e1>ropivacaine-infused</e1>_10\JJ\1740 rats_11\NNS\2329401 ._12\.\1740
C037663_D064420 NONE we_0\PRP\1740 compared_1\VBD\644583 the_2\DT\1740 systemic_3\JJ\1740 <e2>toxicity</e2>_4\NN\13576101 of_5\IN\1740 bupivacaine_6\NN\1740 ,_7\,\1740 levobupivacaine_8\NN\1740 ,_9\,\1740 and_10\CC\1740 <e1>ropivacaine</e1>_11\VB\1740 in_12\IN\13603305 anesthetized_13\JJ\1740 rats_14\NNS\2329401 ._15\.\1740
C037663_D064420 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 systemic_4\JJ\1740 <e2>toxicity</e2>_5\NN\13576101 of_6\IN\1740 levobupivacaine_7\NN\1740 is_8\VBZ\836236 intermediate_9\JJ\1740 between_10\IN\1740 that_11\DT\1740 of_12\IN\1740 <e1>ropivacaine</e1>_13\NN\1740 and_14\CC\1740 bupivacaine_15\NN\1740 when_16\WRB\1740 administered_17\VBN\2436349 at_18\IN\14622893 the_19\DT\1740 same_20\JJ\1740 rate_21\NN\13815152 and_22\CC\1740 that_23\IN\1740 ropivacaine-induced_24\JJ\1740 cardiac_25\JJ\1740 arrest_26\NN\88481 appears_27\VBZ\2604760 to_28\TO\1740 be_29\VB\836236 more_30\RBR\1740 susceptible_31\JJ\1740 to_32\TO\1740 treatment_33\NN\654885 than_34\IN\1740 that_35\DT\1740 induced_36\VBN\1627355 by_37\IN\1740 bupivacaine_38\NN\1740 or_39\CC\3541091 levobupivacaine_40\NN\1740 ._41\.\1740
C037663_D064420 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 systemic_4\JJ\1740 <e2>toxicity</e2>_5\NN\13576101 of_6\IN\1740 levobupivacaine_7\NN\1740 is_8\VBZ\836236 intermediate_9\JJ\1740 between_10\IN\1740 that_11\DT\1740 of_12\IN\1740 ropivacaine_13\NN\1740 and_14\CC\1740 bupivacaine_15\NN\1740 when_16\WRB\1740 administered_17\VBN\2436349 at_18\IN\14622893 the_19\DT\1740 same_20\JJ\1740 rate_21\NN\13815152 and_22\CC\1740 that_23\IN\1740 <e1>ropivacaine-induced</e1>_24\JJ\1740 cardiac_25\JJ\1740 arrest_26\NN\88481 appears_27\VBZ\2604760 to_28\TO\1740 be_29\VB\836236 more_30\RBR\1740 susceptible_31\JJ\1740 to_32\TO\1740 treatment_33\NN\654885 than_34\IN\1740 that_35\DT\1740 induced_36\VBN\1627355 by_37\IN\1740 bupivacaine_38\NN\1740 or_39\CC\3541091 levobupivacaine_40\NN\1740 ._41\.\1740
C476513_D012640 CID the_0\DT\1740 cumulative_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 <e1>levobupivacaine</e1>_4\NN\1740 and_5\CC\1740 ropivacaine_6\NN\1740 that_7\WDT\1740 produced_8\VBD\1617192 <e2>seizures</e2>_9\NNS\14081375 were_10\VBD\836236 similar_11\JJ\1740 and_12\CC\1740 were_13\VBD\836236 larger_14\JJR\1740 than_15\IN\1740 those_16\DT\1740 of_17\IN\1740 bupivacaine_18\NN\1740 ._19\.\1740
C037663_D012640 CID the_0\DT\1740 cumulative_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 levobupivacaine_4\NN\1740 and_5\CC\1740 <e1>ropivacaine</e1>_6\NN\1740 that_7\WDT\1740 produced_8\VBD\1617192 <e2>seizures</e2>_9\NNS\14081375 were_10\VBD\836236 similar_11\JJ\1740 and_12\CC\1740 were_13\VBD\836236 larger_14\JJR\1740 than_15\IN\1740 those_16\DT\1740 of_17\IN\1740 bupivacaine_18\NN\1740 ._19\.\1740
D002045_D012640 NONE the_0\DT\1740 cumulative_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 levobupivacaine_4\NN\1740 and_5\CC\1740 ropivacaine_6\NN\1740 that_7\WDT\1740 produced_8\VBD\1617192 <e2>seizures</e2>_9\NNS\14081375 were_10\VBD\836236 similar_11\JJ\1740 and_12\CC\1740 were_13\VBD\836236 larger_14\JJR\1740 than_15\IN\1740 those_16\DT\1740 of_17\IN\1740 <e1>bupivacaine</e1>_18\NN\1740 ._19\.\1740
C476513_D001145 CID the_0\DT\1740 cumulative_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 <e1>levobupivacaine</e1>_4\NN\1740 that_5\WDT\1740 produced_6\VBD\1617192 <e2>dysrhythmias</e2>_7\NNS\1740 and_8\CC\1740 asystole_9\NN\14204950 were_10\VBD\836236 smaller_11\JJR\1740 than_12\IN\1740 the_13\DT\1740 corresponding_14\JJ\1740 doses_15\NNS\3740161 of_16\IN\1740 ropivacaine_17\NN\1740 ,_18\,\1740 but_19\CC\1740 they_20\PRP\1740 were_21\VBD\836236 larger_22\JJR\1740 than_23\IN\1740 those_24\DT\1740 of_25\IN\1740 bupivacaine_26\NN\1740 ._27\.\1740
C476513_D006323 CID the_0\DT\1740 cumulative_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 <e1>levobupivacaine</e1>_4\NN\1740 that_5\WDT\1740 produced_6\VBD\1617192 dysrhythmias_7\NNS\1740 and_8\CC\1740 <e2>asystole</e2>_9\NN\14204950 were_10\VBD\836236 smaller_11\JJR\1740 than_12\IN\1740 the_13\DT\1740 corresponding_14\JJ\1740 doses_15\NNS\3740161 of_16\IN\1740 ropivacaine_17\NN\1740 ,_18\,\1740 but_19\CC\1740 they_20\PRP\1740 were_21\VBD\836236 larger_22\JJR\1740 than_23\IN\1740 those_24\DT\1740 of_25\IN\1740 bupivacaine_26\NN\1740 ._27\.\1740
C476513_D006323 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 systemic_4\JJ\1740 toxicity_5\NN\13576101 of_6\IN\1740 <e1>levobupivacaine</e1>_7\NN\1740 is_8\VBZ\836236 intermediate_9\JJ\1740 between_10\IN\1740 that_11\DT\1740 of_12\IN\1740 ropivacaine_13\NN\1740 and_14\CC\1740 bupivacaine_15\NN\1740 when_16\WRB\1740 administered_17\VBN\2436349 at_18\IN\14622893 the_19\DT\1740 same_20\JJ\1740 rate_21\NN\13815152 and_22\CC\1740 that_23\IN\1740 ropivacaine-induced_24\JJ\1740 <e2>cardiac_25\JJ\1740 arrest</e2>_26\NN\88481 appears_27\VBZ\2604760 to_28\TO\1740 be_29\VB\836236 more_30\RBR\1740 susceptible_31\JJ\1740 to_32\TO\1740 treatment_33\NN\654885 than_34\IN\1740 that_35\DT\1740 induced_36\VBN\1627355 by_37\IN\1740 bupivacaine_38\NN\1740 or_39\CC\3541091 levobupivacaine_40\NN\1740 ._41\.\1740
C476513_D006323 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 systemic_4\JJ\1740 toxicity_5\NN\13576101 of_6\IN\1740 levobupivacaine_7\NN\1740 is_8\VBZ\836236 intermediate_9\JJ\1740 between_10\IN\1740 that_11\DT\1740 of_12\IN\1740 ropivacaine_13\NN\1740 and_14\CC\1740 bupivacaine_15\NN\1740 when_16\WRB\1740 administered_17\VBN\2436349 at_18\IN\14622893 the_19\DT\1740 same_20\JJ\1740 rate_21\NN\13815152 and_22\CC\1740 that_23\IN\1740 ropivacaine-induced_24\JJ\1740 <e2>cardiac_25\JJ\1740 arrest</e2>_26\NN\88481 appears_27\VBZ\2604760 to_28\TO\1740 be_29\VB\836236 more_30\RBR\1740 susceptible_31\JJ\1740 to_32\TO\1740 treatment_33\NN\654885 than_34\IN\1740 that_35\DT\1740 induced_36\VBN\1627355 by_37\IN\1740 bupivacaine_38\NN\1740 or_39\CC\3541091 <e1>levobupivacaine</e1>_40\NN\1740 ._41\.\1740
C037663_D001145 CID the_0\DT\1740 cumulative_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 levobupivacaine_4\NN\1740 that_5\WDT\1740 produced_6\VBD\1617192 <e2>dysrhythmias</e2>_7\NNS\1740 and_8\CC\1740 asystole_9\NN\14204950 were_10\VBD\836236 smaller_11\JJR\1740 than_12\IN\1740 the_13\DT\1740 corresponding_14\JJ\1740 doses_15\NNS\3740161 of_16\IN\1740 <e1>ropivacaine</e1>_17\NN\1740 ,_18\,\1740 but_19\CC\1740 they_20\PRP\1740 were_21\VBD\836236 larger_22\JJR\1740 than_23\IN\1740 those_24\DT\1740 of_25\IN\1740 bupivacaine_26\NN\1740 ._27\.\1740
C037663_D006323 CID the_0\DT\1740 cumulative_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 levobupivacaine_4\NN\1740 that_5\WDT\1740 produced_6\VBD\1617192 dysrhythmias_7\NNS\1740 and_8\CC\1740 <e2>asystole</e2>_9\NN\14204950 were_10\VBD\836236 smaller_11\JJR\1740 than_12\IN\1740 the_13\DT\1740 corresponding_14\JJ\1740 doses_15\NNS\3740161 of_16\IN\1740 <e1>ropivacaine</e1>_17\NN\1740 ,_18\,\1740 but_19\CC\1740 they_20\PRP\1740 were_21\VBD\836236 larger_22\JJR\1740 than_23\IN\1740 those_24\DT\1740 of_25\IN\1740 bupivacaine_26\NN\1740 ._27\.\1740
C037663_D006323 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 systemic_4\JJ\1740 toxicity_5\NN\13576101 of_6\IN\1740 levobupivacaine_7\NN\1740 is_8\VBZ\836236 intermediate_9\JJ\1740 between_10\IN\1740 that_11\DT\1740 of_12\IN\1740 <e1>ropivacaine</e1>_13\NN\1740 and_14\CC\1740 bupivacaine_15\NN\1740 when_16\WRB\1740 administered_17\VBN\2436349 at_18\IN\14622893 the_19\DT\1740 same_20\JJ\1740 rate_21\NN\13815152 and_22\CC\1740 that_23\IN\1740 ropivacaine-induced_24\JJ\1740 <e2>cardiac_25\JJ\1740 arrest</e2>_26\NN\88481 appears_27\VBZ\2604760 to_28\TO\1740 be_29\VB\836236 more_30\RBR\1740 susceptible_31\JJ\1740 to_32\TO\1740 treatment_33\NN\654885 than_34\IN\1740 that_35\DT\1740 induced_36\VBN\1627355 by_37\IN\1740 bupivacaine_38\NN\1740 or_39\CC\3541091 levobupivacaine_40\NN\1740 ._41\.\1740
C037663_D006323 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 systemic_4\JJ\1740 toxicity_5\NN\13576101 of_6\IN\1740 levobupivacaine_7\NN\1740 is_8\VBZ\836236 intermediate_9\JJ\1740 between_10\IN\1740 that_11\DT\1740 of_12\IN\1740 ropivacaine_13\NN\1740 and_14\CC\1740 bupivacaine_15\NN\1740 when_16\WRB\1740 administered_17\VBN\2436349 at_18\IN\14622893 the_19\DT\1740 same_20\JJ\1740 rate_21\NN\13815152 and_22\CC\1740 that_23\IN\1740 <e1>ropivacaine-induced</e1>_24\JJ\1740 <e2>cardiac_25\JJ\1740 arrest</e2>_26\NN\88481 appears_27\VBZ\2604760 to_28\TO\1740 be_29\VB\836236 more_30\RBR\1740 susceptible_31\JJ\1740 to_32\TO\1740 treatment_33\NN\654885 than_34\IN\1740 that_35\DT\1740 induced_36\VBN\1627355 by_37\IN\1740 bupivacaine_38\NN\1740 or_39\CC\3541091 levobupivacaine_40\NN\1740 ._41\.\1740
D002045_D001145 NONE the_0\DT\1740 cumulative_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 levobupivacaine_4\NN\1740 that_5\WDT\1740 produced_6\VBD\1617192 <e2>dysrhythmias</e2>_7\NNS\1740 and_8\CC\1740 asystole_9\NN\14204950 were_10\VBD\836236 smaller_11\JJR\1740 than_12\IN\1740 the_13\DT\1740 corresponding_14\JJ\1740 doses_15\NNS\3740161 of_16\IN\1740 ropivacaine_17\NN\1740 ,_18\,\1740 but_19\CC\1740 they_20\PRP\1740 were_21\VBD\836236 larger_22\JJR\1740 than_23\IN\1740 those_24\DT\1740 of_25\IN\1740 <e1>bupivacaine</e1>_26\NN\1740 ._27\.\1740
D002045_D006323 NONE the_0\DT\1740 cumulative_1\JJ\1740 doses_2\NNS\3740161 of_3\IN\1740 levobupivacaine_4\NN\1740 that_5\WDT\1740 produced_6\VBD\1617192 dysrhythmias_7\NNS\1740 and_8\CC\1740 <e2>asystole</e2>_9\NN\14204950 were_10\VBD\836236 smaller_11\JJR\1740 than_12\IN\1740 the_13\DT\1740 corresponding_14\JJ\1740 doses_15\NNS\3740161 of_16\IN\1740 ropivacaine_17\NN\1740 ,_18\,\1740 but_19\CC\1740 they_20\PRP\1740 were_21\VBD\836236 larger_22\JJR\1740 than_23\IN\1740 those_24\DT\1740 of_25\IN\1740 <e1>bupivacaine</e1>_26\NN\1740 ._27\.\1740
D002045_D006323 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 systemic_4\JJ\1740 toxicity_5\NN\13576101 of_6\IN\1740 levobupivacaine_7\NN\1740 is_8\VBZ\836236 intermediate_9\JJ\1740 between_10\IN\1740 that_11\DT\1740 of_12\IN\1740 ropivacaine_13\NN\1740 and_14\CC\1740 <e1>bupivacaine</e1>_15\NN\1740 when_16\WRB\1740 administered_17\VBN\2436349 at_18\IN\14622893 the_19\DT\1740 same_20\JJ\1740 rate_21\NN\13815152 and_22\CC\1740 that_23\IN\1740 ropivacaine-induced_24\JJ\1740 <e2>cardiac_25\JJ\1740 arrest</e2>_26\NN\88481 appears_27\VBZ\2604760 to_28\TO\1740 be_29\VB\836236 more_30\RBR\1740 susceptible_31\JJ\1740 to_32\TO\1740 treatment_33\NN\654885 than_34\IN\1740 that_35\DT\1740 induced_36\VBN\1627355 by_37\IN\1740 bupivacaine_38\NN\1740 or_39\CC\3541091 levobupivacaine_40\NN\1740 ._41\.\1740
D002045_D006323 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 the_3\DT\1740 systemic_4\JJ\1740 toxicity_5\NN\13576101 of_6\IN\1740 levobupivacaine_7\NN\1740 is_8\VBZ\836236 intermediate_9\JJ\1740 between_10\IN\1740 that_11\DT\1740 of_12\IN\1740 ropivacaine_13\NN\1740 and_14\CC\1740 bupivacaine_15\NN\1740 when_16\WRB\1740 administered_17\VBN\2436349 at_18\IN\14622893 the_19\DT\1740 same_20\JJ\1740 rate_21\NN\13815152 and_22\CC\1740 that_23\IN\1740 ropivacaine-induced_24\JJ\1740 <e2>cardiac_25\JJ\1740 arrest</e2>_26\NN\88481 appears_27\VBZ\2604760 to_28\TO\1740 be_29\VB\836236 more_30\RBR\1740 susceptible_31\JJ\1740 to_32\TO\1740 treatment_33\NN\654885 than_34\IN\1740 that_35\DT\1740 induced_36\VBN\1627355 by_37\IN\1740 <e1>bupivacaine</e1>_38\NN\1740 or_39\CC\3541091 levobupivacaine_40\NN\1740 ._41\.\1740
8106150
D007980_D004409 NONE effect_0\NN\34213 of_1\IN\1740 nondopaminergic_2\JJ\1740 drugs_3\NNS\14778436 on_4\IN\1740 <e1>l-dopa-induced</e1>_5\JJ\1740 <e2>dyskinesias</e2>_6\NNS\14084880 in_7\IN\13603305 mptp-treated_8\JJ\1740 monkeys_9\NNS\2469914 ._10\.\1740
D007980_D004409 NONE a_0\DT\13649268 series_1\NN\8456993 of_2\IN\1740 agents_3\NNS\7347 acting_4\VBG\1619354 primarily_5\RB\1740 on_6\IN\1740 neurotransmitters_7\NNS\14807410 other_8\JJ\1740 than_9\IN\1740 dopamine_10\NN\14807737 were_11\VBD\836236 then_12\RB\1740 tested_13\VBN\670261 in_14\IN\13603305 combination_15\NN\7951464 with_16\IN\1740 <e1>l-dopa</e1>_17\NN\14604959 to_18\TO\1740 see_19\VB\2106506 if_20\IN\1740 the_21\DT\1740 <e2>dyskinetic</e2>_22\JJ\1740 movements_23\NNS\191142 would_24\MD\1740 be_25\VB\836236 modified_26\VBN\109660 ._27\.\1740
D015632_D004409 NONE effect_0\NN\34213 of_1\IN\1740 nondopaminergic_2\JJ\1740 drugs_3\NNS\14778436 on_4\IN\1740 l-dopa-induced_5\JJ\1740 <e2>dyskinesias</e2>_6\NNS\14084880 in_7\IN\13603305 <e1>mptp-treated</e1>_8\JJ\1740 monkeys_9\NNS\2469914 ._10\.\1740
D015632_D020734 CID a_0\DT\13649268 group_1\NN\2137 of_2\IN\1740 four_3\CD\13741022 monkeys_4\NNS\2469914 was_5\VBD\836236 rendered_6\VBN\120316 <e2>parkinsonian</e2>_7\JJ\1740 with_8\IN\1740 the_9\DT\1740 toxin_10\NN\15032376 <e1>mptp</e1>_11\NNP\1740 ._12\.\1740
D004298_D004409 NONE a_0\DT\13649268 series_1\NN\8456993 of_2\IN\1740 agents_3\NNS\7347 acting_4\VBG\1619354 primarily_5\RB\1740 on_6\IN\1740 neurotransmitters_7\NNS\14807410 other_8\JJ\1740 than_9\IN\1740 <e1>dopamine</e1>_10\NN\14807737 were_11\VBD\836236 then_12\RB\1740 tested_13\VBN\670261 in_14\IN\13603305 combination_15\NN\7951464 with_16\IN\1740 l-dopa_17\NN\14604959 to_18\TO\1740 see_19\VB\2106506 if_20\IN\1740 the_21\DT\1740 <e2>dyskinetic</e2>_22\JJ\1740 movements_23\NNS\191142 would_24\MD\1740 be_25\VB\836236 modified_26\VBN\109660 ._27\.\1740
D003000_D004409 NONE several_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 including_3\VBG\690614 <e1>clonidine</e1>_4\NN\2721160 ,_5\,\1740 physostigmine_6\NN\14712692 ,_7\,\1740 methysergide_8\NN\1740 ,_9\,\1740 5-mdot_10\FW\1740 ,_11\,\1740 propranolol_12\NN\1740 ,_13\,\1740 and_14\CC\1740 mk-801_15\NN\1740 ,_16\,\1740 markedly_17\RB\1740 reduced_18\VBD\441445 the_19\DT\1740 <e2>dyskinetic</e2>_20\JJ\1740 movements_21\NNS\191142 but_22\CC\1740 at_23\IN\14622893 the_24\DT\1740 cost_25\NN\13275288 of_26\IN\1740 a_27\DT\13649268 return_28\NN\6479665 of_29\IN\1740 parkinsonian_30\JJ\1740 symptomatology_31\NN\1740 ._32\.\1740
D003000_D020734 NONE several_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 including_3\VBG\690614 <e1>clonidine</e1>_4\NN\2721160 ,_5\,\1740 physostigmine_6\NN\14712692 ,_7\,\1740 methysergide_8\NN\1740 ,_9\,\1740 5-mdot_10\FW\1740 ,_11\,\1740 propranolol_12\NN\1740 ,_13\,\1740 and_14\CC\1740 mk-801_15\NN\1740 ,_16\,\1740 markedly_17\RB\1740 reduced_18\VBD\441445 the_19\DT\1740 dyskinetic_20\JJ\1740 movements_21\NNS\191142 but_22\CC\1740 at_23\IN\14622893 the_24\DT\1740 cost_25\NN\13275288 of_26\IN\1740 a_27\DT\13649268 return_28\NN\6479665 of_29\IN\1740 <e2>parkinsonian</e2>_30\JJ\1740 symptomatology_31\NN\1740 ._32\.\1740
D010830_D004409 NONE several_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 including_3\VBG\690614 clonidine_4\NN\2721160 ,_5\,\1740 <e1>physostigmine</e1>_6\NN\14712692 ,_7\,\1740 methysergide_8\NN\1740 ,_9\,\1740 5-mdot_10\FW\1740 ,_11\,\1740 propranolol_12\NN\1740 ,_13\,\1740 and_14\CC\1740 mk-801_15\NN\1740 ,_16\,\1740 markedly_17\RB\1740 reduced_18\VBD\441445 the_19\DT\1740 <e2>dyskinetic</e2>_20\JJ\1740 movements_21\NNS\191142 but_22\CC\1740 at_23\IN\14622893 the_24\DT\1740 cost_25\NN\13275288 of_26\IN\1740 a_27\DT\13649268 return_28\NN\6479665 of_29\IN\1740 parkinsonian_30\JJ\1740 symptomatology_31\NN\1740 ._32\.\1740
D010830_D020734 NONE several_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 including_3\VBG\690614 clonidine_4\NN\2721160 ,_5\,\1740 <e1>physostigmine</e1>_6\NN\14712692 ,_7\,\1740 methysergide_8\NN\1740 ,_9\,\1740 5-mdot_10\FW\1740 ,_11\,\1740 propranolol_12\NN\1740 ,_13\,\1740 and_14\CC\1740 mk-801_15\NN\1740 ,_16\,\1740 markedly_17\RB\1740 reduced_18\VBD\441445 the_19\DT\1740 dyskinetic_20\JJ\1740 movements_21\NNS\191142 but_22\CC\1740 at_23\IN\14622893 the_24\DT\1740 cost_25\NN\13275288 of_26\IN\1740 a_27\DT\13649268 return_28\NN\6479665 of_29\IN\1740 <e2>parkinsonian</e2>_30\JJ\1740 symptomatology_31\NN\1740 ._32\.\1740
D008784_D004409 NONE several_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 including_3\VBG\690614 clonidine_4\NN\2721160 ,_5\,\1740 physostigmine_6\NN\14712692 ,_7\,\1740 <e1>methysergide</e1>_8\NN\1740 ,_9\,\1740 5-mdot_10\FW\1740 ,_11\,\1740 propranolol_12\NN\1740 ,_13\,\1740 and_14\CC\1740 mk-801_15\NN\1740 ,_16\,\1740 markedly_17\RB\1740 reduced_18\VBD\441445 the_19\DT\1740 <e2>dyskinetic</e2>_20\JJ\1740 movements_21\NNS\191142 but_22\CC\1740 at_23\IN\14622893 the_24\DT\1740 cost_25\NN\13275288 of_26\IN\1740 a_27\DT\13649268 return_28\NN\6479665 of_29\IN\1740 parkinsonian_30\JJ\1740 symptomatology_31\NN\1740 ._32\.\1740
D008784_D020734 NONE several_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 including_3\VBG\690614 clonidine_4\NN\2721160 ,_5\,\1740 physostigmine_6\NN\14712692 ,_7\,\1740 <e1>methysergide</e1>_8\NN\1740 ,_9\,\1740 5-mdot_10\FW\1740 ,_11\,\1740 propranolol_12\NN\1740 ,_13\,\1740 and_14\CC\1740 mk-801_15\NN\1740 ,_16\,\1740 markedly_17\RB\1740 reduced_18\VBD\441445 the_19\DT\1740 dyskinetic_20\JJ\1740 movements_21\NNS\191142 but_22\CC\1740 at_23\IN\14622893 the_24\DT\1740 cost_25\NN\13275288 of_26\IN\1740 a_27\DT\13649268 return_28\NN\6479665 of_29\IN\1740 <e2>parkinsonian</e2>_30\JJ\1740 symptomatology_31\NN\1740 ._32\.\1740
-1_D004409 NONE several_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 including_3\VBG\690614 clonidine_4\NN\2721160 ,_5\,\1740 physostigmine_6\NN\14712692 ,_7\,\1740 methysergide_8\NN\1740 ,_9\,\1740 <e1>5-mdot</e1>_10\FW\1740 ,_11\,\1740 propranolol_12\NN\1740 ,_13\,\1740 and_14\CC\1740 mk-801_15\NN\1740 ,_16\,\1740 markedly_17\RB\1740 reduced_18\VBD\441445 the_19\DT\1740 <e2>dyskinetic</e2>_20\JJ\1740 movements_21\NNS\191142 but_22\CC\1740 at_23\IN\14622893 the_24\DT\1740 cost_25\NN\13275288 of_26\IN\1740 a_27\DT\13649268 return_28\NN\6479665 of_29\IN\1740 parkinsonian_30\JJ\1740 symptomatology_31\NN\1740 ._32\.\1740
-1_D020734 NONE several_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 including_3\VBG\690614 clonidine_4\NN\2721160 ,_5\,\1740 physostigmine_6\NN\14712692 ,_7\,\1740 methysergide_8\NN\1740 ,_9\,\1740 <e1>5-mdot</e1>_10\FW\1740 ,_11\,\1740 propranolol_12\NN\1740 ,_13\,\1740 and_14\CC\1740 mk-801_15\NN\1740 ,_16\,\1740 markedly_17\RB\1740 reduced_18\VBD\441445 the_19\DT\1740 dyskinetic_20\JJ\1740 movements_21\NNS\191142 but_22\CC\1740 at_23\IN\14622893 the_24\DT\1740 cost_25\NN\13275288 of_26\IN\1740 a_27\DT\13649268 return_28\NN\6479665 of_29\IN\1740 <e2>parkinsonian</e2>_30\JJ\1740 symptomatology_31\NN\1740 ._32\.\1740
D011433_D004409 NONE several_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 including_3\VBG\690614 clonidine_4\NN\2721160 ,_5\,\1740 physostigmine_6\NN\14712692 ,_7\,\1740 methysergide_8\NN\1740 ,_9\,\1740 5-mdot_10\FW\1740 ,_11\,\1740 <e1>propranolol</e1>_12\NN\1740 ,_13\,\1740 and_14\CC\1740 mk-801_15\NN\1740 ,_16\,\1740 markedly_17\RB\1740 reduced_18\VBD\441445 the_19\DT\1740 <e2>dyskinetic</e2>_20\JJ\1740 movements_21\NNS\191142 but_22\CC\1740 at_23\IN\14622893 the_24\DT\1740 cost_25\NN\13275288 of_26\IN\1740 a_27\DT\13649268 return_28\NN\6479665 of_29\IN\1740 parkinsonian_30\JJ\1740 symptomatology_31\NN\1740 ._32\.\1740
D011433_D020734 NONE several_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 including_3\VBG\690614 clonidine_4\NN\2721160 ,_5\,\1740 physostigmine_6\NN\14712692 ,_7\,\1740 methysergide_8\NN\1740 ,_9\,\1740 5-mdot_10\FW\1740 ,_11\,\1740 <e1>propranolol</e1>_12\NN\1740 ,_13\,\1740 and_14\CC\1740 mk-801_15\NN\1740 ,_16\,\1740 markedly_17\RB\1740 reduced_18\VBD\441445 the_19\DT\1740 dyskinetic_20\JJ\1740 movements_21\NNS\191142 but_22\CC\1740 at_23\IN\14622893 the_24\DT\1740 cost_25\NN\13275288 of_26\IN\1740 a_27\DT\13649268 return_28\NN\6479665 of_29\IN\1740 <e2>parkinsonian</e2>_30\JJ\1740 symptomatology_31\NN\1740 ._32\.\1740
D016291_D004409 NONE several_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 including_3\VBG\690614 clonidine_4\NN\2721160 ,_5\,\1740 physostigmine_6\NN\14712692 ,_7\,\1740 methysergide_8\NN\1740 ,_9\,\1740 5-mdot_10\FW\1740 ,_11\,\1740 propranolol_12\NN\1740 ,_13\,\1740 and_14\CC\1740 <e1>mk-801</e1>_15\NN\1740 ,_16\,\1740 markedly_17\RB\1740 reduced_18\VBD\441445 the_19\DT\1740 <e2>dyskinetic</e2>_20\JJ\1740 movements_21\NNS\191142 but_22\CC\1740 at_23\IN\14622893 the_24\DT\1740 cost_25\NN\13275288 of_26\IN\1740 a_27\DT\13649268 return_28\NN\6479665 of_29\IN\1740 parkinsonian_30\JJ\1740 symptomatology_31\NN\1740 ._32\.\1740
D016291_D020734 NONE several_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 including_3\VBG\690614 clonidine_4\NN\2721160 ,_5\,\1740 physostigmine_6\NN\14712692 ,_7\,\1740 methysergide_8\NN\1740 ,_9\,\1740 5-mdot_10\FW\1740 ,_11\,\1740 propranolol_12\NN\1740 ,_13\,\1740 and_14\CC\1740 <e1>mk-801</e1>_15\NN\1740 ,_16\,\1740 markedly_17\RB\1740 reduced_18\VBD\441445 the_19\DT\1740 dyskinetic_20\JJ\1740 movements_21\NNS\191142 but_22\CC\1740 at_23\IN\14622893 the_24\DT\1740 cost_25\NN\13275288 of_26\IN\1740 a_27\DT\13649268 return_28\NN\6479665 of_29\IN\1740 <e2>parkinsonian</e2>_30\JJ\1740 symptomatology_31\NN\1740 ._32\.\1740
D015016_D004409 NONE however_0\RB\1740 ,_1\,\1740 <e1>yohimbine</e1>_2\NN\1740 and_3\CC\1740 meperidine_4\NN\3808564 reduced_5\VBD\441445 predominantly_6\RB\1740 the_7\DT\1740 <e2>dyskinetic</e2>_8\JJ\1740 movements_9\NNS\191142 ._10\.\1740
D008614_D004409 NONE however_0\RB\1740 ,_1\,\1740 yohimbine_2\NN\1740 and_3\CC\1740 <e1>meperidine</e1>_4\NN\3808564 reduced_5\VBD\441445 predominantly_6\RB\1740 the_7\DT\1740 <e2>dyskinetic</e2>_8\JJ\1740 movements_9\NNS\191142 ._10\.\1740
D001418_D020821 NONE <e1>baclofen</e1>_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 useful_3\JJ\1740 in_4\IN\13603305 one_5\CD\13741022 monkey_6\NN\2469914 against_7\IN\1740 a_8\DT\13649268 more_9\RBR\1740 <e2>dystonic</e2>_10\JJ\1740 form_11\NN\6286395 of_12\IN\1740 dyskinesia_13\NN\14084880 ._14\.\1740
D001418_D004409 NONE <e1>baclofen</e1>_0\NNP\1740 was_1\VBD\836236 also_2\RB\1740 useful_3\JJ\1740 in_4\IN\13603305 one_5\CD\13741022 monkey_6\NN\2469914 against_7\IN\1740 a_8\DT\13649268 more_9\RBR\1740 dystonic_10\JJ\1740 form_11\NN\6286395 of_12\IN\1740 <e2>dyskinesia</e2>_13\NN\14084880 ._14\.\1740
D001285_D020821 NONE <e1>atropine</e1>_0\NN\14712692 converted_1\VBD\126264 the_2\DT\1740 <e2>dystonic</e2>_3\JJ\1740 movements_4\NNS\191142 into_5\IN\1740 chorea_6\NN\14253124 ._7\.\1740
D001285_D002819 NONE <e1>atropine</e1>_0\NN\14712692 converted_1\VBD\126264 the_2\DT\1740 dystonic_3\JJ\1740 movements_4\NNS\191142 into_5\IN\1740 <e2>chorea</e2>_6\NN\14253124 ._7\.\1740
3431591
C031662_D064420 NONE <e1>cb_0\NN\1740 3717</e1>_1\CD\1740 ,_2\,\1740 n10-propargyl-5,8-dideazafolic_3\JJ\1740 acid_4\NN\14818238 ,_5\,\1740 is_6\VBZ\836236 a_7\DT\13649268 tight-binding_8\JJ\1740 inhibitor_9\NN\20090 of_10\IN\1740 thymidylate_11\JJ\1740 synthase_12\NN\1740 (_13\-LRB-\1740 ts_14\NN\14999913 )_15\-RRB-\1740 whose_16\WP$\1740 <e2>cytotoxicity</e2>_17\NN\13583478 is_18\VBZ\836236 mediated_19\VBN\761713 solely_20\RB\1740 through_21\IN\1740 the_22\DT\1740 inhibition_23\NN\1068773 of_24\IN\1740 this_25\DT\1740 enzyme_26\NN\14723628 ._27\.\1740
C031662_D064420 NONE cb_0\NN\1740 3717_1\CD\1740 ,_2\,\1740 <e1>n10-propargyl-5,8-dideazafolic_3\JJ\1740 acid</e1>_4\NN\14818238 ,_5\,\1740 is_6\VBZ\836236 a_7\DT\13649268 tight-binding_8\JJ\1740 inhibitor_9\NN\20090 of_10\IN\1740 thymidylate_11\JJ\1740 synthase_12\NN\1740 (_13\-LRB-\1740 ts_14\NN\14999913 )_15\-RRB-\1740 whose_16\WP$\1740 <e2>cytotoxicity</e2>_17\NN\13583478 is_18\VBZ\836236 mediated_19\VBN\761713 solely_20\RB\1740 through_21\IN\1740 the_22\DT\1740 inhibition_23\NN\1068773 of_24\IN\1740 this_25\DT\1740 enzyme_26\NN\14723628 ._27\.\1740
C031662_D064420 NONE as_0\IN\14622893 inhibitors_1\NNS\20090 of_2\IN\1740 isolated_3\VBN\2512305 l1210_4\NN\1740 ts_5\NN\14999913 ,_6\,\1740 cb_7\NN\1740 3717_8\CD\1740 di-_9\VBD\1740 ,_10\,\1740 tri-_11\NN\1740 ,_12\,\1740 tetra-_13\NN\1740 and_14\CC\1740 pentaglutamate_15\NN\1740 are_16\VBP\836236 26-_17\CD\1740 ,_18\,\1740 87-_19\CD\1740 ,_20\,\1740 119-_21\NN\1740 and_22\CC\1740 114-fold_23\RB\1740 more_24\JJR\1740 potent_25\JJ\1740 than_26\IN\1740 <e1>cb_27\NN\1740 3717</e1>_28\CD\1740 ,_29\,\1740 respectively_30\RB\1740 ,_31\,\1740 and_32\CC\1740 their_33\PRP$\1740 formation_34\NN\7938773 may_35\MD\15209706 ,_36\,\1740 therefore_37\RB\1740 ,_38\,\1740 be_39\VB\836236 an_40\DT\6697703 important_41\JJ\1740 determinant_42\NN\5686481 of_43\IN\1740 cb_44\NN\1740 3717_45\CD\1740 <e2>cytotoxicity</e2>_46\NN\13583478 ._47\.\1740
C031662_D064420 NONE as_0\IN\14622893 inhibitors_1\NNS\20090 of_2\IN\1740 isolated_3\VBN\2512305 l1210_4\NN\1740 ts_5\NN\14999913 ,_6\,\1740 cb_7\NN\1740 3717_8\CD\1740 di-_9\VBD\1740 ,_10\,\1740 tri-_11\NN\1740 ,_12\,\1740 tetra-_13\NN\1740 and_14\CC\1740 pentaglutamate_15\NN\1740 are_16\VBP\836236 26-_17\CD\1740 ,_18\,\1740 87-_19\CD\1740 ,_20\,\1740 119-_21\NN\1740 and_22\CC\1740 114-fold_23\RB\1740 more_24\JJR\1740 potent_25\JJ\1740 than_26\IN\1740 cb_27\NN\1740 3717_28\CD\1740 ,_29\,\1740 respectively_30\RB\1740 ,_31\,\1740 and_32\CC\1740 their_33\PRP$\1740 formation_34\NN\7938773 may_35\MD\15209706 ,_36\,\1740 therefore_37\RB\1740 ,_38\,\1740 be_39\VB\836236 an_40\DT\6697703 important_41\JJ\1740 determinant_42\NN\5686481 of_43\IN\1740 <e1>cb_44\NN\1740 3717</e1>_45\CD\1740 <e2>cytotoxicity</e2>_46\NN\13583478 ._47\.\1740
C031662_D001943 NONE in_0\IN\13603305 early_1\JJ\1740 clinical_2\JJ\1740 studies_3\NNS\635850 with_4\IN\1740 <e1>cb_5\NN\1740 3717</e1>_6\CD\1740 ,_7\,\1740 activity_8\NN\30358 has_9\VBZ\2108377 been_10\VBN\836236 seen_11\VBN\2106506 in_12\IN\13603305 <e2>breast_13\NN\5225090 cancer</e2>_14\NN\14239425 ,_15\,\1740 ovarian_16\JJ\1740 cancer_17\NN\14239425 ,_18\,\1740 hepatoma_19\NN\14242337 ,_20\,\1740 and_21\CC\1740 mesothelioma_22\NN\14242337 ._23\.\1740
C031662_D010051 NONE in_0\IN\13603305 early_1\JJ\1740 clinical_2\JJ\1740 studies_3\NNS\635850 with_4\IN\1740 <e1>cb_5\NN\1740 3717</e1>_6\CD\1740 ,_7\,\1740 activity_8\NN\30358 has_9\VBZ\2108377 been_10\VBN\836236 seen_11\VBN\2106506 in_12\IN\13603305 breast_13\NN\5225090 cancer_14\NN\14239425 ,_15\,\1740 <e2>ovarian_16\JJ\1740 cancer</e2>_17\NN\14239425 ,_18\,\1740 hepatoma_19\NN\14242337 ,_20\,\1740 and_21\CC\1740 mesothelioma_22\NN\14242337 ._23\.\1740
C031662_D006528 NONE in_0\IN\13603305 early_1\JJ\1740 clinical_2\JJ\1740 studies_3\NNS\635850 with_4\IN\1740 <e1>cb_5\NN\1740 3717</e1>_6\CD\1740 ,_7\,\1740 activity_8\NN\30358 has_9\VBZ\2108377 been_10\VBN\836236 seen_11\VBN\2106506 in_12\IN\13603305 breast_13\NN\5225090 cancer_14\NN\14239425 ,_15\,\1740 ovarian_16\JJ\1740 cancer_17\NN\14239425 ,_18\,\1740 <e2>hepatoma</e2>_19\NN\14242337 ,_20\,\1740 and_21\CC\1740 mesothelioma_22\NN\14242337 ._23\.\1740
C031662_D008654 NONE in_0\IN\13603305 early_1\JJ\1740 clinical_2\JJ\1740 studies_3\NNS\635850 with_4\IN\1740 <e1>cb_5\NN\1740 3717</e1>_6\CD\1740 ,_7\,\1740 activity_8\NN\30358 has_9\VBZ\2108377 been_10\VBN\836236 seen_11\VBN\2106506 in_12\IN\13603305 breast_13\NN\5225090 cancer_14\NN\14239425 ,_15\,\1740 ovarian_16\JJ\1740 cancer_17\NN\14239425 ,_18\,\1740 hepatoma_19\NN\14242337 ,_20\,\1740 and_21\CC\1740 <e2>mesothelioma</e2>_22\NN\14242337 ._23\.\1740
18589141
D006493_D013921 CID <e1>heparin-induced</e1>_0\JJ\1740 <e2>thrombocytopenia</e2>_1\NN\14189204 after_2\IN\1740 liver_3\NN\5298729 transplantation_4\NN\671351 ._5\.\1740
D006493_D013921 CID <e1>heparin-induced</e1>_0\JJ\1740 <e2>thrombocytopenia</e2>_1\NN\14189204 (_2\-LRB-\1740 hit_3\NN\36762 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 adverse_7\JJ\1740 immune-mediated_8\JJ\1740 reaction_9\NN\13446390 to_10\TO\1740 heparin_11\NN\2718259 ,_12\,\1740 resulting_13\VBG\2633881 in_14\IN\13603305 platelet_15\NN\5432736 count_16\NN\13582013 decreases_17\VBZ\169651 of_18\IN\1740 more_19\JJR\1740 than_20\IN\1740 50_21\CD\13745420 %_22\NN\1740 ._23\.\1740
D006493_D013921 CID <e1>heparin-induced</e1>_0\JJ\1740 thrombocytopenia_1\NN\14189204 (_2\-LRB-\1740 <e2>hit</e2>_3\NN\36762 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 adverse_7\JJ\1740 immune-mediated_8\JJ\1740 reaction_9\NN\13446390 to_10\TO\1740 heparin_11\NN\2718259 ,_12\,\1740 resulting_13\VBG\2633881 in_14\IN\13603305 platelet_15\NN\5432736 count_16\NN\13582013 decreases_17\VBZ\169651 of_18\IN\1740 more_19\JJR\1740 than_20\IN\1740 50_21\CD\13745420 %_22\NN\1740 ._23\.\1740
D006493_D013921 CID heparin-induced_0\JJ\1740 <e2>thrombocytopenia</e2>_1\NN\14189204 (_2\-LRB-\1740 hit_3\NN\36762 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 adverse_7\JJ\1740 immune-mediated_8\JJ\1740 reaction_9\NN\13446390 to_10\TO\1740 <e1>heparin</e1>_11\NN\2718259 ,_12\,\1740 resulting_13\VBG\2633881 in_14\IN\13603305 platelet_15\NN\5432736 count_16\NN\13582013 decreases_17\VBZ\169651 of_18\IN\1740 more_19\JJR\1740 than_20\IN\1740 50_21\CD\13745420 %_22\NN\1740 ._23\.\1740
D006493_D013921 CID heparin-induced_0\JJ\1740 thrombocytopenia_1\NN\14189204 (_2\-LRB-\1740 <e2>hit</e2>_3\NN\36762 )_4\-RRB-\1740 is_5\VBZ\836236 an_6\DT\6697703 adverse_7\JJ\1740 immune-mediated_8\JJ\1740 reaction_9\NN\13446390 to_10\TO\1740 <e1>heparin</e1>_11\NN\2718259 ,_12\,\1740 resulting_13\VBG\2633881 in_14\IN\13603305 platelet_15\NN\5432736 count_16\NN\13582013 decreases_17\VBZ\169651 of_18\IN\1740 more_19\JJR\1740 than_20\IN\1740 50_21\CD\13745420 %_22\NN\1740 ._23\.\1740
D006493_D013921 CID the_0\DT\1740 frequencies_1\NNS\15286249 of_2\IN\1740 <e2>hit</e2>_3\NN\36762 after_4\IN\1740 liver_5\NN\5298729 transplantation_6\NN\671351 and_7\CC\1740 platelet_8\NN\5432736 factor_9\NN\7326557 <e1>4/heparin-reactive</e1>_10\JJ\1740 antibody_11\NN\14728724 (_12\-LRB-\1740 hit_13\NN\36762 antibody_14\NN\14728724 )_15\-RRB-\1740 positivity_16\NN\13856574 in_17\IN\13603305 liver_18\NN\5298729 transplantation_19\NN\671351 patients_20\NNS\9898892 ,_21\,\1740 however_22\RB\1740 ,_23\,\1740 are_24\VBP\836236 unknown_25\JJ\1740 ._26\.\1740
D006493_D013921 CID the_0\DT\1740 frequencies_1\NNS\15286249 of_2\IN\1740 hit_3\NN\36762 after_4\IN\1740 liver_5\NN\5298729 transplantation_6\NN\671351 and_7\CC\1740 platelet_8\NN\5432736 factor_9\NN\7326557 <e1>4/heparin-reactive</e1>_10\JJ\1740 antibody_11\NN\14728724 (_12\-LRB-\1740 <e2>hit</e2>_13\NN\36762 antibody_14\NN\14728724 )_15\-RRB-\1740 positivity_16\NN\13856574 in_17\IN\13603305 liver_18\NN\5298729 transplantation_19\NN\671351 patients_20\NNS\9898892 ,_21\,\1740 however_22\RB\1740 ,_23\,\1740 are_24\VBP\836236 unknown_25\JJ\1740 ._26\.\1740
D006493_D013921 CID none_0\NN\15228378 of_1\IN\1740 the_2\DT\1740 subjects/patients_3\NNS\1740 developed_4\VBD\1753788 <e1>ufh-related</e1>_5\JJ\1740 <e2>hit</e2>_6\NN\36762 ._7\.\1740
D006493_D013927 NONE background_0\NN\4921011 :_1\:\1740 <e1>unfractionated_2\VBN\1740 heparin_3\NN\2718259 sodium</e1>_4\NN\14625458 (_5\-LRB-\1740 ufh_6\NN\1740 )_7\-RRB-\1740 or_8\CC\3541091 low-molecular_9\JJ\1740 weight_10\NN\5009170 heparin_11\NN\2718259 (_12\-LRB-\1740 lmwh_13\NN\1740 )_14\-RRB-\1740 is_15\VBZ\836236 used_16\VBN\1156834 in_17\IN\13603305 anticoagulant_18\JJ\1740 protocols_19\NNS\6652242 at_20\IN\14622893 several_21\JJ\1740 institutions_22\NNS\8008335 to_23\TO\1740 prevent_24\VB\1740 <e2>thrombosis</e2>_25\NN\14100769 after_26\IN\1740 liver_27\NN\5298729 transplantation_28\NN\671351 ._29\.\1740
D006493_D013927 NONE background_0\NN\4921011 :_1\:\1740 unfractionated_2\VBN\1740 heparin_3\NN\2718259 sodium_4\NN\14625458 (_5\-LRB-\1740 <e1>ufh</e1>_6\NN\1740 )_7\-RRB-\1740 or_8\CC\3541091 low-molecular_9\JJ\1740 weight_10\NN\5009170 heparin_11\NN\2718259 (_12\-LRB-\1740 lmwh_13\NN\1740 )_14\-RRB-\1740 is_15\VBZ\836236 used_16\VBN\1156834 in_17\IN\13603305 anticoagulant_18\JJ\1740 protocols_19\NNS\6652242 at_20\IN\14622893 several_21\JJ\1740 institutions_22\NNS\8008335 to_23\TO\1740 prevent_24\VB\1740 <e2>thrombosis</e2>_25\NN\14100769 after_26\IN\1740 liver_27\NN\5298729 transplantation_28\NN\671351 ._29\.\1740
D006495_D013927 NONE background_0\NN\4921011 :_1\:\1740 unfractionated_2\VBN\1740 heparin_3\NN\2718259 sodium_4\NN\14625458 (_5\-LRB-\1740 ufh_6\NN\1740 )_7\-RRB-\1740 or_8\CC\3541091 <e1>low-molecular_9\JJ\1740 weight_10\NN\5009170 heparin</e1>_11\NN\2718259 (_12\-LRB-\1740 lmwh_13\NN\1740 )_14\-RRB-\1740 is_15\VBZ\836236 used_16\VBN\1156834 in_17\IN\13603305 anticoagulant_18\JJ\1740 protocols_19\NNS\6652242 at_20\IN\14622893 several_21\JJ\1740 institutions_22\NNS\8008335 to_23\TO\1740 prevent_24\VB\1740 <e2>thrombosis</e2>_25\NN\14100769 after_26\IN\1740 liver_27\NN\5298729 transplantation_28\NN\671351 ._29\.\1740
D006493_D001791 NONE the_0\DT\1740 <e1>heparin-induced</e1>_1\JJ\1740 <e2>platelet_2\NN\5432736 aggregation</e2>_3\NN\31264 test_4\NN\5798043 was_5\VBD\836236 negative_6\JJ\1740 in_7\IN\13603305 these_8\DT\1740 patients_9\NNS\9898892 ._10\.\1740
7337133
D000082_D001929 CID massive_0\JJ\1740 <e2>cerebral_1\JJ\1740 edema</e2>_2\NN\14315192 associated_3\VBN\628491 with_4\IN\1740 fulminant_5\JJ\1740 hepatic_6\JJ\1740 failure_7\NN\66216 in_8\IN\13603305 <e1>acetaminophen</e1>_9\JJ\1740 overdose_10\NN\1740 :_11\:\1740 possible_12\JJ\1740 role_13\NN\719494 of_14\IN\1740 cranial_15\JJ\1740 decompression_16\NN\617059 ._17\.\1740
D000082_D001929 CID we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 fatal_5\JJ\1740 <e1>acetaminophen-induced</e1>_6\JJ\1740 fulminant_7\JJ\1740 hepatic_8\JJ\1740 failure_9\NN\66216 ,_10\,\1740 with_11\IN\1740 signs_12\NNS\6643763 and_13\CC\1740 symptoms_14\NNS\5823932 of_15\IN\1740 <e2>cerebral_16\JJ\1740 edema</e2>_17\NN\14315192 ,_18\,\1740 unresponsive_19\JJ\1740 to_20\TO\1740 conventional_21\JJ\1740 medical_22\JJ\1740 therapy_23\NN\657604 ._24\.\1740
D000082_D017093 CID massive_0\JJ\1740 cerebral_1\JJ\1740 edema_2\NN\14315192 associated_3\VBN\628491 with_4\IN\1740 fulminant_5\JJ\1740 <e2>hepatic_6\JJ\1740 failure</e2>_7\NN\66216 in_8\IN\13603305 <e1>acetaminophen</e1>_9\JJ\1740 overdose_10\NN\1740 :_11\:\1740 possible_12\JJ\1740 role_13\NN\719494 of_14\IN\1740 cranial_15\JJ\1740 decompression_16\NN\617059 ._17\.\1740
D000082_D017093 CID we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 fatal_5\JJ\1740 <e1>acetaminophen-induced</e1>_6\JJ\1740 <e2>fulminant_7\JJ\1740 hepatic_8\JJ\1740 failure</e2>_9\NN\66216 ,_10\,\1740 with_11\IN\1740 signs_12\NNS\6643763 and_13\CC\1740 symptoms_14\NNS\5823932 of_15\IN\1740 cerebral_16\JJ\1740 edema_17\NN\14315192 ,_18\,\1740 unresponsive_19\JJ\1740 to_20\TO\1740 conventional_21\JJ\1740 medical_22\JJ\1740 therapy_23\NN\657604 ._24\.\1740
D000082_D062787 NONE massive_0\JJ\1740 cerebral_1\JJ\1740 edema_2\NN\14315192 associated_3\VBN\628491 with_4\IN\1740 fulminant_5\JJ\1740 hepatic_6\JJ\1740 failure_7\NN\66216 in_8\IN\13603305 <e1>acetaminophen</e1>_9\JJ\1740 <e2>overdose</e2>_10\NN\1740 :_11\:\1740 possible_12\JJ\1740 role_13\NN\719494 of_14\IN\1740 cranial_15\JJ\1740 decompression_16\NN\617059 ._17\.\1740
10539815
D000809_D051437 NONE predictors_0\NNS\10756433 of_1\IN\1740 <e2>decreased_2\VBN\169651 renal_3\JJ\1740 function</e2>_4\NN\13783581 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 heart_8\NN\5919034 failure_9\NN\66216 during_10\IN\1740 <e1>angiotensin-converting</e1>_11\JJ\1740 enzyme_12\NN\14723628 inhibitor_13\NN\20090 therapy_14\NN\657604 :_15\:\1740 results_16\NNS\34213 from_17\IN\1740 the_18\DT\1740 studies_19\NNS\635850 of_20\IN\1740 left_21\JJ\1740 ventricular_22\NN\1740 dysfunction_23\NN\14204950 (_24\-LRB-\1740 solvd_25\NN\1740 )_26\-RRB-\1740
D000809_D051437 NONE background_0\NN\4921011 :_1\:\1740 although_2\IN\1740 <e1>angiotensin-converting</e1>_3\JJ\1740 enzyme_4\NN\14723628 inhibitor_5\NN\20090 therapy_6\NN\657604 reduces_7\VBZ\441445 mortality_8\NN\5054863 rates_9\NNS\13308999 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 congestive_13\JJ\1740 heart_14\NN\5919034 failure_15\NN\66216 (_16\-LRB-\1740 chf_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 it_20\PRP\6125041 may_21\MD\15209706 also_22\RB\1740 cause_23\VB\1617192 <e2>decreased_24\VBN\169651 renal_25\JJ\1740 function</e2>_26\NN\13783581 ._27\.\1740
D000809_D051437 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 quantify_3\VB\947077 specific_4\JJ\1740 clinical_5\JJ\1740 predictors_6\NNS\10756433 of_7\IN\1740 <e2>reduction_8\NN\351485 in_9\IN\13603305 renal_10\JJ\1740 function</e2>_11\NN\13783581 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 chf_15\NN\1740 who_16\WP\8299493 are_17\VBP\836236 prescribed_18\VBN\748282 <e1>angiotensin-converting</e1>_19\JJ\1740 enzyme_20\NN\14723628 inhibitor_21\NN\20090 therapy_22\NN\657604 ._23\.\1740
D000809_D006333 NONE predictors_0\NNS\10756433 of_1\IN\1740 decreased_2\VBN\169651 renal_3\JJ\1740 function_4\NN\13783581 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 <e2>heart_8\NN\5919034 failure</e2>_9\NN\66216 during_10\IN\1740 <e1>angiotensin-converting</e1>_11\JJ\1740 enzyme_12\NN\14723628 inhibitor_13\NN\20090 therapy_14\NN\657604 :_15\:\1740 results_16\NNS\34213 from_17\IN\1740 the_18\DT\1740 studies_19\NNS\635850 of_20\IN\1740 left_21\JJ\1740 ventricular_22\NN\1740 dysfunction_23\NN\14204950 (_24\-LRB-\1740 solvd_25\NN\1740 )_26\-RRB-\1740
D000809_D006333 NONE background_0\NN\4921011 :_1\:\1740 although_2\IN\1740 <e1>angiotensin-converting</e1>_3\JJ\1740 enzyme_4\NN\14723628 inhibitor_5\NN\20090 therapy_6\NN\657604 reduces_7\VBZ\441445 mortality_8\NN\5054863 rates_9\NNS\13308999 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 <e2>congestive_13\JJ\1740 heart_14\NN\5919034 failure</e2>_15\NN\66216 (_16\-LRB-\1740 chf_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 it_20\PRP\6125041 may_21\MD\15209706 also_22\RB\1740 cause_23\VB\1617192 decreased_24\VBN\169651 renal_25\JJ\1740 function_26\NN\13783581 ._27\.\1740
D000809_D006333 NONE background_0\NN\4921011 :_1\:\1740 although_2\IN\1740 <e1>angiotensin-converting</e1>_3\JJ\1740 enzyme_4\NN\14723628 inhibitor_5\NN\20090 therapy_6\NN\657604 reduces_7\VBZ\441445 mortality_8\NN\5054863 rates_9\NNS\13308999 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 congestive_13\JJ\1740 heart_14\NN\5919034 failure_15\NN\66216 (_16\-LRB-\1740 <e2>chf</e2>_17\NN\1740 )_18\-RRB-\1740 ,_19\,\1740 it_20\PRP\6125041 may_21\MD\15209706 also_22\RB\1740 cause_23\VB\1617192 decreased_24\VBN\169651 renal_25\JJ\1740 function_26\NN\13783581 ._27\.\1740
D000809_D006333 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 quantify_3\VB\947077 specific_4\JJ\1740 clinical_5\JJ\1740 predictors_6\NNS\10756433 of_7\IN\1740 reduction_8\NN\351485 in_9\IN\13603305 renal_10\JJ\1740 function_11\NN\13783581 in_12\IN\13603305 patients_13\NNS\9898892 with_14\IN\1740 <e2>chf</e2>_15\NN\1740 who_16\WP\8299493 are_17\VBP\836236 prescribed_18\VBN\748282 <e1>angiotensin-converting</e1>_19\JJ\1740 enzyme_20\NN\14723628 inhibitor_21\NN\20090 therapy_22\NN\657604 ._23\.\1740
D000809_D018487 NONE predictors_0\NNS\10756433 of_1\IN\1740 decreased_2\VBN\169651 renal_3\JJ\1740 function_4\NN\13783581 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 heart_8\NN\5919034 failure_9\NN\66216 during_10\IN\1740 <e1>angiotensin-converting</e1>_11\JJ\1740 enzyme_12\NN\14723628 inhibitor_13\NN\20090 therapy_14\NN\657604 :_15\:\1740 results_16\NNS\34213 from_17\IN\1740 the_18\DT\1740 studies_19\NNS\635850 of_20\IN\1740 <e2>left_21\JJ\1740 ventricular_22\NN\1740 dysfunction</e2>_23\NN\14204950 (_24\-LRB-\1740 solvd_25\NN\1740 )_26\-RRB-\1740
D004656_D018487 NONE method_0\NNP\5616786 :_1\:\1740 we_2\PRP\1740 analyzed_3\VBD\78760 data_4\NNS\7951464 from_5\IN\1740 the_6\DT\1740 studies_7\NNPS\635850 of_8\IN\1740 <e2>left_9\NNP\8621598 ventricular_10\NNP\1740 dysfunction</e2>_11\NNP\14204950 (_12\-LRB-\1740 solvd_13\NN\1740 )_14\-RRB-\1740 ,_15\,\1740 a_16\DT\13649268 randomized_17\JJ\1740 ,_18\,\1740 double-blind_19\JJ\1740 ,_20\,\1740 placebo-controlled_21\JJ\1740 trial_22\NN\786195 of_23\IN\1740 <e1>enalapril</e1>_24\NN\2673637 for_25\IN\1740 the_26\DT\1740 treatment_27\NN\654885 of_28\IN\1740 chf_29\NN\1740 ._30\.\1740
D004656_D006333 NONE method_0\NNP\5616786 :_1\:\1740 we_2\PRP\1740 analyzed_3\VBD\78760 data_4\NNS\7951464 from_5\IN\1740 the_6\DT\1740 studies_7\NNPS\635850 of_8\IN\1740 left_9\NNP\8621598 ventricular_10\NNP\1740 dysfunction_11\NNP\14204950 (_12\-LRB-\1740 solvd_13\NN\1740 )_14\-RRB-\1740 ,_15\,\1740 a_16\DT\13649268 randomized_17\JJ\1740 ,_18\,\1740 double-blind_19\JJ\1740 ,_20\,\1740 placebo-controlled_21\JJ\1740 trial_22\NN\786195 of_23\IN\1740 <e1>enalapril</e1>_24\NN\2673637 for_25\IN\1740 the_26\DT\1740 treatment_27\NN\654885 of_28\IN\1740 <e2>chf</e2>_29\NN\1740 ._30\.\1740
D004656_D006333 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>enalapril</e1>_2\NNP\2673637 use_3\NN\407535 caused_4\VBD\1617192 a_5\DT\13649268 33_6\CD\1740 %_7\NN\1740 increase_8\NN\13576355 in_9\IN\13603305 the_10\DT\1740 risk_11\NN\14541044 of_12\IN\1740 decreased_13\VBN\169651 renal_14\JJ\1740 function_15\NN\13783581 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 <e2>chf</e2>_19\NN\1740 ._20\.\1740
D004656_D006333 NONE diabetes_0\NNS\14075199 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 an_4\DT\6697703 increased_5\VBN\169651 risk_6\NN\14541044 of_7\IN\1740 renal_8\JJ\1740 impairment_9\NN\7296428 in_10\IN\13603305 all_11\DT\1740 patients_12\NNS\9898892 with_13\IN\1740 <e2>chf</e2>_14\NN\1740 ,_15\,\1740 but_16\CC\1740 this_17\DT\1740 risk_18\NN\14541044 was_19\VBD\836236 reduced_20\VBN\441445 in_21\IN\13603305 the_22\DT\1740 <e1>enalapril</e1>_23\NN\2673637 group_24\NN\2137 compared_25\VBN\644583 with_26\IN\1740 the_27\DT\1740 placebo_28\NN\3740161 group_29\NN\2137 ._30\.\1740
D003404_D051437 NONE <e2>decreased_0\VBN\169651 renal_1\JJ\1740 function</e2>_2\NN\13783581 was_3\VBD\836236 defined_4\VBN\2604760 as_5\IN\14622893 a_6\DT\13649268 rise_7\NN\7324673 in_8\IN\13603305 serum_9\NN\5397468 <e1>creatinine</e1>_10\NN\1740 >_11\NN\1740 /=0.5_12\:\1740 mg/dl_13\NN\1740 (_14\-LRB-\1740 44_15\CD\1740 micromol/l_16\NN\1740 )_17\-RRB-\1740 from_18\IN\1740 baseline_19\NN\7260623 ._20\.\1740
D003404_D006973 NONE we_0\PRP\1740 used_1\VBD\1156834 time-to-event_2\JJ\1740 analysis_3\NN\633864 to_4\TO\1740 identify_5\VB\699815 potential_6\JJ\1740 predictors_7\NNS\10756433 of_8\IN\1740 decrease_9\NN\7296428 in_10\IN\13603305 renal_11\JJ\1740 function_12\NN\13783581 including_13\VBG\690614 age_14\NN\4916342 ,_15\,\1740 baseline_16\NN\7260623 ejection_17\NN\45250 fraction_18\NN\14806838 ,_19\,\1740 baseline_20\NN\7260623 <e1>creatinine</e1>_21\NN\1740 ,_22\,\1740 low_23\JJ\1740 systolic_24\JJ\1740 blood_25\NN\5397468 pressure_26\NN\11419404 (_27\-LRB-\1740 <_28\XX\1740 100_29\CD\13745420 mm_30\NN\13649268 hg_31\FW\14625458 )_32\-RRB-\1740 ,_33\,\1740 history_34\NN\15120823 of_35\IN\1740 <e2>hypertension</e2>_36\NN\14057371 ,_37\,\1740 diabetes_38\NNS\14075199 ,_39\,\1740 and_40\CC\1740 use_41\NN\407535 of_42\IN\1740 antiplatelet_43\NN\1740 ,_44\,\1740 diuretic_45\NN\3247620 ,_46\,\1740 and_47\CC\1740 beta-blocker_48\NN\1740 therapy_49\NN\657604 ._50\.\1740
D003404_D003920 NONE we_0\PRP\1740 used_1\VBD\1156834 time-to-event_2\JJ\1740 analysis_3\NN\633864 to_4\TO\1740 identify_5\VB\699815 potential_6\JJ\1740 predictors_7\NNS\10756433 of_8\IN\1740 decrease_9\NN\7296428 in_10\IN\13603305 renal_11\JJ\1740 function_12\NN\13783581 including_13\VBG\690614 age_14\NN\4916342 ,_15\,\1740 baseline_16\NN\7260623 ejection_17\NN\45250 fraction_18\NN\14806838 ,_19\,\1740 baseline_20\NN\7260623 <e1>creatinine</e1>_21\NN\1740 ,_22\,\1740 low_23\JJ\1740 systolic_24\JJ\1740 blood_25\NN\5397468 pressure_26\NN\11419404 (_27\-LRB-\1740 <_28\XX\1740 100_29\CD\13745420 mm_30\NN\13649268 hg_31\FW\14625458 )_32\-RRB-\1740 ,_33\,\1740 history_34\NN\15120823 of_35\IN\1740 hypertension_36\NN\14057371 ,_37\,\1740 <e2>diabetes</e2>_38\NNS\14075199 ,_39\,\1740 and_40\CC\1740 use_41\NN\407535 of_42\IN\1740 antiplatelet_43\NN\1740 ,_44\,\1740 diuretic_45\NN\3247620 ,_46\,\1740 and_47\CC\1740 beta-blocker_48\NN\1740 therapy_49\NN\657604 ._50\.\1740
D004232_D006973 NONE we_0\PRP\1740 used_1\VBD\1156834 time-to-event_2\JJ\1740 analysis_3\NN\633864 to_4\TO\1740 identify_5\VB\699815 potential_6\JJ\1740 predictors_7\NNS\10756433 of_8\IN\1740 decrease_9\NN\7296428 in_10\IN\13603305 renal_11\JJ\1740 function_12\NN\13783581 including_13\VBG\690614 age_14\NN\4916342 ,_15\,\1740 baseline_16\NN\7260623 ejection_17\NN\45250 fraction_18\NN\14806838 ,_19\,\1740 baseline_20\NN\7260623 creatinine_21\NN\1740 ,_22\,\1740 low_23\JJ\1740 systolic_24\JJ\1740 blood_25\NN\5397468 pressure_26\NN\11419404 (_27\-LRB-\1740 <_28\XX\1740 100_29\CD\13745420 mm_30\NN\13649268 hg_31\FW\14625458 )_32\-RRB-\1740 ,_33\,\1740 history_34\NN\15120823 of_35\IN\1740 <e2>hypertension</e2>_36\NN\14057371 ,_37\,\1740 diabetes_38\NNS\14075199 ,_39\,\1740 and_40\CC\1740 use_41\NN\407535 of_42\IN\1740 antiplatelet_43\NN\1740 ,_44\,\1740 <e1>diuretic</e1>_45\NN\3247620 ,_46\,\1740 and_47\CC\1740 beta-blocker_48\NN\1740 therapy_49\NN\657604 ._50\.\1740
D004232_D003920 NONE we_0\PRP\1740 used_1\VBD\1156834 time-to-event_2\JJ\1740 analysis_3\NN\633864 to_4\TO\1740 identify_5\VB\699815 potential_6\JJ\1740 predictors_7\NNS\10756433 of_8\IN\1740 decrease_9\NN\7296428 in_10\IN\13603305 renal_11\JJ\1740 function_12\NN\13783581 including_13\VBG\690614 age_14\NN\4916342 ,_15\,\1740 baseline_16\NN\7260623 ejection_17\NN\45250 fraction_18\NN\14806838 ,_19\,\1740 baseline_20\NN\7260623 creatinine_21\NN\1740 ,_22\,\1740 low_23\JJ\1740 systolic_24\JJ\1740 blood_25\NN\5397468 pressure_26\NN\11419404 (_27\-LRB-\1740 <_28\XX\1740 100_29\CD\13745420 mm_30\NN\13649268 hg_31\FW\14625458 )_32\-RRB-\1740 ,_33\,\1740 history_34\NN\15120823 of_35\IN\1740 hypertension_36\NN\14057371 ,_37\,\1740 <e2>diabetes</e2>_38\NNS\14075199 ,_39\,\1740 and_40\CC\1740 use_41\NN\407535 of_42\IN\1740 antiplatelet_43\NN\1740 ,_44\,\1740 <e1>diuretic</e1>_45\NN\3247620 ,_46\,\1740 and_47\CC\1740 beta-blocker_48\NN\1740 therapy_49\NN\657604 ._50\.\1740
D004232_D003920 NONE by_0\IN\1740 multivariate_1\JJ\1740 analysis_2\NN\633864 ,_3\,\1740 in_4\IN\13603305 both_5\CC\1740 the_6\DT\1740 placebo_7\NN\3740161 and_8\CC\1740 enalapril_9\JJ\1740 groups_10\NNS\2137 older_11\JJR\1740 age_12\NN\4916342 ,_13\,\1740 <e1>diuretic</e1>_14\NN\3247620 therapy_15\NN\657604 ,_16\,\1740 and_17\CC\1740 <e2>diabetes</e2>_18\NNS\14075199 were_19\VBD\836236 associated_20\VBN\628491 with_21\IN\1740 decreased_22\VBN\169651 renal_23\JJ\1740 function_24\NN\13783581 ,_25\,\1740 whereas_26\IN\1740 beta-blocker_27\NN\1740 therapy_28\NN\657604 and_29\CC\1740 higher_30\JJR\1740 ejection_31\NN\45250 fraction_32\NN\14806838 were_33\VBD\836236 renoprotective_34\JJ\1740 ._35\.\1740
D004656_D051437 CID results_0\NNS\34213 :_1\:\1740 patients_2\NNS\9898892 randomly_3\RB\1740 assigned_4\VBD\2475922 to_5\TO\1740 <e1>enalapril</e1>_6\NN\2673637 had_7\VBD\2108377 a_8\DT\13649268 33_9\CD\1740 %_10\NN\1740 greater_11\JJR\1740 likelihood_12\NN\4756172 of_13\IN\1740 <e2>decreased_14\VBN\169651 renal_15\JJ\1740 function</e2>_16\NN\13783581 than_17\IN\1740 controls_18\NNS\5190804 (_19\-LRB-\1740 p_20\NN\14622893 =_21\JJ\1740 .003_22\CD\1740 )_23\-RRB-\1740 ._24\.\1740
D004656_D051437 CID by_0\IN\1740 multivariate_1\JJ\1740 analysis_2\NN\633864 ,_3\,\1740 in_4\IN\13603305 both_5\CC\1740 the_6\DT\1740 placebo_7\NN\3740161 and_8\CC\1740 <e1>enalapril</e1>_9\JJ\1740 groups_10\NNS\2137 older_11\JJR\1740 age_12\NN\4916342 ,_13\,\1740 diuretic_14\NN\3247620 therapy_15\NN\657604 ,_16\,\1740 and_17\CC\1740 diabetes_18\NNS\14075199 were_19\VBD\836236 associated_20\VBN\628491 with_21\IN\1740 <e2>decreased_22\VBN\169651 renal_23\JJ\1740 function</e2>_24\NN\13783581 ,_25\,\1740 whereas_26\IN\1740 beta-blocker_27\NN\1740 therapy_28\NN\657604 and_29\CC\1740 higher_30\JJR\1740 ejection_31\NN\45250 fraction_32\NN\14806838 were_33\VBD\836236 renoprotective_34\JJ\1740 ._35\.\1740
D004656_D051437 CID older_0\JJR\1740 age_1\NN\4916342 was_2\VBD\836236 associated_3\VBN\628491 with_4\IN\1740 a_5\DT\13649268 greater_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 developing_9\VBG\1753788 <e2>decreased_10\VBN\169651 renal_11\JJ\1740 function</e2>_12\NN\13783581 in_13\IN\13603305 both_14\DT\1740 groups_15\NNS\2137 ,_16\,\1740 but_17\CC\1740 significantly_18\RB\1740 more_19\RBR\1740 so_20\RB\1740 in_21\IN\13603305 the_22\DT\1740 <e1>enalapril</e1>_23\JJ\1740 group_24\NN\2137 (_25\-LRB-\1740 enalapril_26\NN\2673637 :_27\:\1740 risk_28\NN\14541044 ratio_29\NN\13815152 [_30\-LRB-\1740 rr_31\NN\1740 ]_32\-RRB-\1740 1.42_33\CD\1740 per_34\IN\1740 10_35\CD\13745420 years_36\NNS\15144371 ,_37\,\1740 95_38\CD\1740 %_39\NN\1740 confidence_40\NN\5697135 interval_41\NN\33615 [_42\-LRB-\1740 ci_43\NNP\13635336 ]_44\-RRB-\1740 1.32_45\CD\1740 -_46\SYM\1740 1.52_47\CD\1740 with_48\IN\1740 enalapril_49\NN\2673637 ;_50\:\1740 placebo_51\NN\3740161 :_52\:\1740 rr_53\NN\1740 1.18_54\CD\1740 ,_55\,\1740 95_56\CD\1740 %_57\NN\1740 ci_58\NN\13635336 1.12_59\CD\1740 -_60\SYM\1740 1.25_61\CD\1740 )_62\-RRB-\1740 ._63\.\1740
D004656_D051437 CID older_0\JJR\1740 age_1\NN\4916342 was_2\VBD\836236 associated_3\VBN\628491 with_4\IN\1740 a_5\DT\13649268 greater_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 developing_9\VBG\1753788 <e2>decreased_10\VBN\169651 renal_11\JJ\1740 function</e2>_12\NN\13783581 in_13\IN\13603305 both_14\DT\1740 groups_15\NNS\2137 ,_16\,\1740 but_17\CC\1740 significantly_18\RB\1740 more_19\RBR\1740 so_20\RB\1740 in_21\IN\13603305 the_22\DT\1740 enalapril_23\JJ\1740 group_24\NN\2137 (_25\-LRB-\1740 <e1>enalapril</e1>_26\NN\2673637 :_27\:\1740 risk_28\NN\14541044 ratio_29\NN\13815152 [_30\-LRB-\1740 rr_31\NN\1740 ]_32\-RRB-\1740 1.42_33\CD\1740 per_34\IN\1740 10_35\CD\13745420 years_36\NNS\15144371 ,_37\,\1740 95_38\CD\1740 %_39\NN\1740 confidence_40\NN\5697135 interval_41\NN\33615 [_42\-LRB-\1740 ci_43\NNP\13635336 ]_44\-RRB-\1740 1.32_45\CD\1740 -_46\SYM\1740 1.52_47\CD\1740 with_48\IN\1740 enalapril_49\NN\2673637 ;_50\:\1740 placebo_51\NN\3740161 :_52\:\1740 rr_53\NN\1740 1.18_54\CD\1740 ,_55\,\1740 95_56\CD\1740 %_57\NN\1740 ci_58\NN\13635336 1.12_59\CD\1740 -_60\SYM\1740 1.25_61\CD\1740 )_62\-RRB-\1740 ._63\.\1740
D004656_D051437 CID older_0\JJR\1740 age_1\NN\4916342 was_2\VBD\836236 associated_3\VBN\628491 with_4\IN\1740 a_5\DT\13649268 greater_6\JJR\1740 risk_7\NN\14541044 of_8\IN\1740 developing_9\VBG\1753788 <e2>decreased_10\VBN\169651 renal_11\JJ\1740 function</e2>_12\NN\13783581 in_13\IN\13603305 both_14\DT\1740 groups_15\NNS\2137 ,_16\,\1740 but_17\CC\1740 significantly_18\RB\1740 more_19\RBR\1740 so_20\RB\1740 in_21\IN\13603305 the_22\DT\1740 enalapril_23\JJ\1740 group_24\NN\2137 (_25\-LRB-\1740 enalapril_26\NN\2673637 :_27\:\1740 risk_28\NN\14541044 ratio_29\NN\13815152 [_30\-LRB-\1740 rr_31\NN\1740 ]_32\-RRB-\1740 1.42_33\CD\1740 per_34\IN\1740 10_35\CD\13745420 years_36\NNS\15144371 ,_37\,\1740 95_38\CD\1740 %_39\NN\1740 confidence_40\NN\5697135 interval_41\NN\33615 [_42\-LRB-\1740 ci_43\NNP\13635336 ]_44\-RRB-\1740 1.32_45\CD\1740 -_46\SYM\1740 1.52_47\CD\1740 with_48\IN\1740 <e1>enalapril</e1>_49\NN\2673637 ;_50\:\1740 placebo_51\NN\3740161 :_52\:\1740 rr_53\NN\1740 1.18_54\CD\1740 ,_55\,\1740 95_56\CD\1740 %_57\NN\1740 ci_58\NN\13635336 1.12_59\CD\1740 -_60\SYM\1740 1.25_61\CD\1740 )_62\-RRB-\1740 ._63\.\1740
D004656_D051437 CID diuretic_0\NN\3247620 therapy_1\NN\657604 was_2\VBD\836236 likewise_3\RB\1740 associated_4\VBN\628491 with_5\IN\1740 a_6\DT\13649268 greater_7\JJR\1740 risk_8\NN\14541044 of_9\IN\1740 <e2>decreased_10\VBN\169651 renal_11\JJ\1740 function</e2>_12\NN\13783581 in_13\IN\13603305 the_14\DT\1740 <e1>enalapril</e1>_15\JJ\1740 group_16\NN\2137 (_17\-LRB-\1740 rr_18\NN\1740 1.89_19\CD\1740 ,_20\,\1740 95_21\CD\1740 %_22\NN\1740 ci_23\NN\13635336 1.70_24\CD\1740 -_25\SYM\1740 2.08_26\CD\1740 )_27\-RRB-\1740 than_28\IN\1740 in_29\IN\13603305 the_30\DT\1740 placebo_31\NN\3740161 group_32\NN\2137 (_33\-LRB-\1740 rr_34\NN\1740 1.35_35\CD\1740 ,_36\,\1740 95_37\CD\1740 %_38\NN\1740 ci_39\NN\13635336 1.09_40\CD\1740 -_41\SYM\1740 1.66_42\CD\1740 )_43\-RRB-\1740 ._44\.\1740
D004656_D051437 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>enalapril</e1>_2\NNP\2673637 use_3\NN\407535 caused_4\VBD\1617192 a_5\DT\13649268 33_6\CD\1740 %_7\NN\1740 increase_8\NN\13576355 in_9\IN\13603305 the_10\DT\1740 risk_11\NN\14541044 of_12\IN\1740 <e2>decreased_13\VBN\169651 renal_14\JJ\1740 function</e2>_15\NN\13783581 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 chf_19\NN\1740 ._20\.\1740
D004656_D051437 CID diabetes_0\NNS\14075199 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 an_4\DT\6697703 increased_5\VBN\169651 risk_6\NN\14541044 of_7\IN\1740 <e2>renal_8\JJ\1740 impairment</e2>_9\NN\7296428 in_10\IN\13603305 all_11\DT\1740 patients_12\NNS\9898892 with_13\IN\1740 chf_14\NN\1740 ,_15\,\1740 but_16\CC\1740 this_17\DT\1740 risk_18\NN\14541044 was_19\VBD\836236 reduced_20\VBN\441445 in_21\IN\13603305 the_22\DT\1740 <e1>enalapril</e1>_23\NN\2673637 group_24\NN\2137 compared_25\VBN\644583 with_26\IN\1740 the_27\DT\1740 placebo_28\NN\3740161 group_29\NN\2137 ._30\.\1740
D004656_D003920 NONE by_0\IN\1740 multivariate_1\JJ\1740 analysis_2\NN\633864 ,_3\,\1740 in_4\IN\13603305 both_5\CC\1740 the_6\DT\1740 placebo_7\NN\3740161 and_8\CC\1740 <e1>enalapril</e1>_9\JJ\1740 groups_10\NNS\2137 older_11\JJR\1740 age_12\NN\4916342 ,_13\,\1740 diuretic_14\NN\3247620 therapy_15\NN\657604 ,_16\,\1740 and_17\CC\1740 <e2>diabetes</e2>_18\NNS\14075199 were_19\VBD\836236 associated_20\VBN\628491 with_21\IN\1740 decreased_22\VBN\169651 renal_23\JJ\1740 function_24\NN\13783581 ,_25\,\1740 whereas_26\IN\1740 beta-blocker_27\NN\1740 therapy_28\NN\657604 and_29\CC\1740 higher_30\JJR\1740 ejection_31\NN\45250 fraction_32\NN\14806838 were_33\VBD\836236 renoprotective_34\JJ\1740 ._35\.\1740
D004656_D003920 NONE conversely_0\RB\1740 ,_1\,\1740 <e1>enalapril</e1>_2\NN\2673637 had_3\VBD\2108377 a_4\DT\13649268 relative_5\JJ\1740 renoprotective_6\JJ\1740 effect_7\NN\34213 (_8\-LRB-\1740 rr_9\NN\1740 1.33_10\CD\1740 ,_11\,\1740 95_12\CD\1740 %_13\NN\1740 ci_14\NN\13635336 1.13_15\CD\1740 -_16\SYM\1740 1.53_17\CD\1740 )_18\-RRB-\1740 compared_19\VBN\644583 with_20\IN\1740 placebo_21\NN\3740161 (_22\-LRB-\1740 rr_23\NN\1740 1.96_24\CD\1740 ,_25\,\1740 95_26\CD\1740 %_27\NN\1740 ci_28\NN\13635336 1.57_29\CD\1740 -_30\SYM\1740 2.44_31\CD\1740 )_32\-RRB-\1740 in_33\IN\13603305 patients_34\NNS\9898892 with_35\IN\1740 <e2>diabetes</e2>_36\NNS\14075199 ._37\.\1740
D004656_D003920 NONE <e2>diabetes</e2>_0\NNS\14075199 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 an_4\DT\6697703 increased_5\VBN\169651 risk_6\NN\14541044 of_7\IN\1740 renal_8\JJ\1740 impairment_9\NN\7296428 in_10\IN\13603305 all_11\DT\1740 patients_12\NNS\9898892 with_13\IN\1740 chf_14\NN\1740 ,_15\,\1740 but_16\CC\1740 this_17\DT\1740 risk_18\NN\14541044 was_19\VBD\836236 reduced_20\VBN\441445 in_21\IN\13603305 the_22\DT\1740 <e1>enalapril</e1>_23\NN\2673637 group_24\NN\2137 compared_25\VBN\644583 with_26\IN\1740 the_27\DT\1740 placebo_28\NN\3740161 group_29\NN\2137 ._30\.\1740
D004232_D051437 CID by_0\IN\1740 multivariate_1\JJ\1740 analysis_2\NN\633864 ,_3\,\1740 in_4\IN\13603305 both_5\CC\1740 the_6\DT\1740 placebo_7\NN\3740161 and_8\CC\1740 enalapril_9\JJ\1740 groups_10\NNS\2137 older_11\JJR\1740 age_12\NN\4916342 ,_13\,\1740 <e1>diuretic</e1>_14\NN\3247620 therapy_15\NN\657604 ,_16\,\1740 and_17\CC\1740 diabetes_18\NNS\14075199 were_19\VBD\836236 associated_20\VBN\628491 with_21\IN\1740 <e2>decreased_22\VBN\169651 renal_23\JJ\1740 function</e2>_24\NN\13783581 ,_25\,\1740 whereas_26\IN\1740 beta-blocker_27\NN\1740 therapy_28\NN\657604 and_29\CC\1740 higher_30\JJR\1740 ejection_31\NN\45250 fraction_32\NN\14806838 were_33\VBD\836236 renoprotective_34\JJ\1740 ._35\.\1740
D004232_D051437 CID <e1>diuretic</e1>_0\NN\3247620 therapy_1\NN\657604 was_2\VBD\836236 likewise_3\RB\1740 associated_4\VBN\628491 with_5\IN\1740 a_6\DT\13649268 greater_7\JJR\1740 risk_8\NN\14541044 of_9\IN\1740 <e2>decreased_10\VBN\169651 renal_11\JJ\1740 function</e2>_12\NN\13783581 in_13\IN\13603305 the_14\DT\1740 enalapril_15\JJ\1740 group_16\NN\2137 (_17\-LRB-\1740 rr_18\NN\1740 1.89_19\CD\1740 ,_20\,\1740 95_21\CD\1740 %_22\NN\1740 ci_23\NN\13635336 1.70_24\CD\1740 -_25\SYM\1740 2.08_26\CD\1740 )_27\-RRB-\1740 than_28\IN\1740 in_29\IN\13603305 the_30\DT\1740 placebo_31\NN\3740161 group_32\NN\2137 (_33\-LRB-\1740 rr_34\NN\1740 1.35_35\CD\1740 ,_36\,\1740 95_37\CD\1740 %_38\NN\1740 ci_39\NN\13635336 1.09_40\CD\1740 -_41\SYM\1740 1.66_42\CD\1740 )_43\-RRB-\1740 ._44\.\1740
18441470
D008094_D054537 CID complete_0\JJ\1740 <e2>atrioventricular_1\JJ\1740 block</e2>_2\NN\21939 secondary_3\JJ\1740 to_4\TO\1740 <e1>lithium</e1>_5\NN\14625458 therapy_6\NN\657604 ._7\.\1740
D008094_D054537 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 case_3\NN\7283608 ,_4\,\1740 complete_5\VBP\352826 <e2>atrioventricular_6\JJ\1740 (_7\-LRB-\1740 av_8\NN\15214068 )_9\-RRB-\1740 block</e2>_10\NN\21939 with_11\IN\1740 syncopal_12\NN\1740 attacks_13\NNS\955060 developed_14\VBD\1753788 secondary_15\JJ\1740 to_16\TO\1740 <e1>lithium</e1>_17\NN\14625458 therapy_18\NN\657604 ,_19\,\1740 necessitating_20\VBG\2635956 permanent_21\JJ\1740 pacemaker_22\NN\5925366 implantation_23\NN\13526110 ._24\.\1740
D008094_D012804 CID <e2>sinus_0\NN\5248181 node_1\NN\13870805 dysfunction</e2>_2\NN\14204950 has_3\VBZ\2108377 been_4\VBN\836236 reported_5\VBN\831651 most_6\RBS\1740 frequently_7\RB\1740 among_8\IN\1740 the_9\DT\1740 adverse_10\JJ\1740 cardiovascular_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 <e1>lithium</e1>_14\NN\14625458 ._15\.\1740
D008094_D013575 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 case_3\NN\7283608 ,_4\,\1740 complete_5\VBP\352826 atrioventricular_6\JJ\1740 (_7\-LRB-\1740 av_8\NN\15214068 )_9\-RRB-\1740 block_10\NN\21939 with_11\IN\1740 <e2>syncopal_12\NN\1740 attacks</e2>_13\NNS\955060 developed_14\VBD\1753788 secondary_15\JJ\1740 to_16\TO\1740 <e1>lithium</e1>_17\NN\14625458 therapy_18\NN\657604 ,_19\,\1740 necessitating_20\VBG\2635956 permanent_21\JJ\1740 pacemaker_22\NN\5925366 implantation_23\NN\13526110 ._24\.\1740
D008094_D013575 NONE serum_0\NN\5397468 <e1>lithium</e1>_1\NN\14625458 levels_2\NNS\4916342 remained_3\VBD\2604760 under_4\IN\1740 or_5\CC\3541091 within_6\IN\1740 the_7\DT\1740 therapeutic_8\JJ\1740 range_9\NN\5123416 during_10\IN\1740 the_11\DT\1740 <e2>syncopal_12\NN\1740 attacks</e2>_13\NNS\955060 ._14\.\1740
3973521
11230490
D004317_D066126 NONE reduced_0\VBN\441445 <e2>cardiotoxicity</e2>_1\NN\1740 and_2\CC\1740 preserved_3\VBD\2681795 antitumor_4\NN\1740 efficacy_5\NN\5199286 of_6\IN\1740 liposome-encapsulated_7\JJ\1740 <e1>doxorubicin</e1>_8\NN\2716866 and_9\CC\1740 cyclophosphamide_10\NN\1740 compared_11\VBN\644583 with_12\IN\1740 conventional_13\JJ\1740 doxorubicin_14\NN\2716866 and_15\CC\1740 cyclophosphamide_16\NN\1740 in_17\IN\13603305 a_18\DT\13649268 randomized_19\JJ\1740 ,_20\,\1740 multicenter_21\NN\1740 trial_22\NN\786195 of_23\IN\1740 metastatic_24\JJ\1740 breast_25\NN\5225090 cancer_26\NN\14239425 ._27\.\1740
D004317_D066126 NONE reduced_0\VBN\441445 <e2>cardiotoxicity</e2>_1\NN\1740 and_2\CC\1740 preserved_3\VBD\2681795 antitumor_4\NN\1740 efficacy_5\NN\5199286 of_6\IN\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 and_9\CC\1740 cyclophosphamide_10\NN\1740 compared_11\VBN\644583 with_12\IN\1740 conventional_13\JJ\1740 <e1>doxorubicin</e1>_14\NN\2716866 and_15\CC\1740 cyclophosphamide_16\NN\1740 in_17\IN\13603305 a_18\DT\13649268 randomized_19\JJ\1740 ,_20\,\1740 multicenter_21\NN\1740 trial_22\NN\786195 of_23\IN\1740 metastatic_24\JJ\1740 breast_25\NN\5225090 cancer_26\NN\14239425 ._27\.\1740
D004317_D066126 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 whether_4\IN\1740 <e1>myocet</e1>_5\NNP\1740 (_6\-LRB-\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 ;_9\:\1740 the_10\DT\1740 liposome_11\NNP\5517578 company_12\NNP\8053576 ,_13\,\1740 elan_14\NNP\7555184 corporation_15\NNP\8059870 ,_16\,\1740 princeton_17\NNP\1740 ,_18\,\1740 nj_19\NNP\1740 )_20\-RRB-\1740 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 cyclophosphamide_24\NN\1740 significantly_25\RB\1740 reduces_26\VBZ\441445 doxorubicin_27\NN\2716866 <e2>cardiotoxicity</e2>_28\NN\1740 while_29\IN\15122231 providing_30\VBG\2199590 comparable_31\JJ\1740 antitumor_32\NN\1740 efficacy_33\NN\5199286 in_34\IN\13603305 first-line_35\JJ\1740 treatment_36\NN\654885 of_37\IN\1740 metastatic_38\JJ\1740 breast_39\NN\5225090 cancer_40\NN\14239425 (_41\-LRB-\1740 mbc_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D004317_D066126 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 whether_4\IN\1740 myocet_5\NNP\1740 (_6\-LRB-\1740 liposome-encapsulated_7\JJ\1740 <e1>doxorubicin</e1>_8\NN\2716866 ;_9\:\1740 the_10\DT\1740 liposome_11\NNP\5517578 company_12\NNP\8053576 ,_13\,\1740 elan_14\NNP\7555184 corporation_15\NNP\8059870 ,_16\,\1740 princeton_17\NNP\1740 ,_18\,\1740 nj_19\NNP\1740 )_20\-RRB-\1740 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 cyclophosphamide_24\NN\1740 significantly_25\RB\1740 reduces_26\VBZ\441445 doxorubicin_27\NN\2716866 <e2>cardiotoxicity</e2>_28\NN\1740 while_29\IN\15122231 providing_30\VBG\2199590 comparable_31\JJ\1740 antitumor_32\NN\1740 efficacy_33\NN\5199286 in_34\IN\13603305 first-line_35\JJ\1740 treatment_36\NN\654885 of_37\IN\1740 metastatic_38\JJ\1740 breast_39\NN\5225090 cancer_40\NN\14239425 (_41\-LRB-\1740 mbc_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D004317_D066126 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 whether_4\IN\1740 myocet_5\NNP\1740 (_6\-LRB-\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 ;_9\:\1740 the_10\DT\1740 liposome_11\NNP\5517578 company_12\NNP\8053576 ,_13\,\1740 elan_14\NNP\7555184 corporation_15\NNP\8059870 ,_16\,\1740 princeton_17\NNP\1740 ,_18\,\1740 nj_19\NNP\1740 )_20\-RRB-\1740 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 cyclophosphamide_24\NN\1740 significantly_25\RB\1740 reduces_26\VBZ\441445 <e1>doxorubicin</e1>_27\NN\2716866 <e2>cardiotoxicity</e2>_28\NN\1740 while_29\IN\15122231 providing_30\VBG\2199590 comparable_31\JJ\1740 antitumor_32\NN\1740 efficacy_33\NN\5199286 in_34\IN\13603305 first-line_35\JJ\1740 treatment_36\NN\654885 of_37\IN\1740 metastatic_38\JJ\1740 breast_39\NN\5225090 cancer_40\NN\14239425 (_41\-LRB-\1740 mbc_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D004317_D066126 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>myocet</e1>_2\NNP\1740 improves_3\VBZ\126264 the_4\DT\1740 therapeutic_5\JJ\1740 index_6\NN\13850304 of_7\IN\1740 doxorubicin_8\NN\2716866 by_9\IN\1740 significantly_10\RB\1740 reducing_11\VBG\441445 <e2>cardiotoxicity</e2>_12\NN\1740 and_13\CC\1740 grade_14\NN\7975026 4_15\CD\13741022 neutropenia_16\NN\14196405 and_17\CC\1740 provides_18\VBZ\2199590 comparable_19\JJ\1740 antitumor_20\NN\1740 efficacy_21\NN\5199286 ,_22\,\1740 when_23\WRB\1740 used_24\VBN\1156834 in_25\IN\13603305 combination_26\NN\7951464 with_27\IN\1740 cyclophosphamide_28\NN\1740 as_29\IN\14622893 first-line_30\JJ\1740 therapy_31\NN\657604 for_32\IN\1740 mbc_33\NN\1740 ._34\.\1740
D004317_D066126 NONE conclusion_0\NN\5837957 :_1\:\1740 myocet_2\NNP\1740 improves_3\VBZ\126264 the_4\DT\1740 therapeutic_5\JJ\1740 index_6\NN\13850304 of_7\IN\1740 <e1>doxorubicin</e1>_8\NN\2716866 by_9\IN\1740 significantly_10\RB\1740 reducing_11\VBG\441445 <e2>cardiotoxicity</e2>_12\NN\1740 and_13\CC\1740 grade_14\NN\7975026 4_15\CD\13741022 neutropenia_16\NN\14196405 and_17\CC\1740 provides_18\VBZ\2199590 comparable_19\JJ\1740 antitumor_20\NN\1740 efficacy_21\NN\5199286 ,_22\,\1740 when_23\WRB\1740 used_24\VBN\1156834 in_25\IN\13603305 combination_26\NN\7951464 with_27\IN\1740 cyclophosphamide_28\NN\1740 as_29\IN\14622893 first-line_30\JJ\1740 therapy_31\NN\657604 for_32\IN\1740 mbc_33\NN\1740 ._34\.\1740
D004317_D001943 NONE reduced_0\VBN\441445 cardiotoxicity_1\NN\1740 and_2\CC\1740 preserved_3\VBD\2681795 antitumor_4\NN\1740 efficacy_5\NN\5199286 of_6\IN\1740 liposome-encapsulated_7\JJ\1740 <e1>doxorubicin</e1>_8\NN\2716866 and_9\CC\1740 cyclophosphamide_10\NN\1740 compared_11\VBN\644583 with_12\IN\1740 conventional_13\JJ\1740 doxorubicin_14\NN\2716866 and_15\CC\1740 cyclophosphamide_16\NN\1740 in_17\IN\13603305 a_18\DT\13649268 randomized_19\JJ\1740 ,_20\,\1740 multicenter_21\NN\1740 trial_22\NN\786195 of_23\IN\1740 metastatic_24\JJ\1740 <e2>breast_25\NN\5225090 cancer</e2>_26\NN\14239425 ._27\.\1740
D004317_D001943 NONE reduced_0\VBN\441445 cardiotoxicity_1\NN\1740 and_2\CC\1740 preserved_3\VBD\2681795 antitumor_4\NN\1740 efficacy_5\NN\5199286 of_6\IN\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 and_9\CC\1740 cyclophosphamide_10\NN\1740 compared_11\VBN\644583 with_12\IN\1740 conventional_13\JJ\1740 <e1>doxorubicin</e1>_14\NN\2716866 and_15\CC\1740 cyclophosphamide_16\NN\1740 in_17\IN\13603305 a_18\DT\13649268 randomized_19\JJ\1740 ,_20\,\1740 multicenter_21\NN\1740 trial_22\NN\786195 of_23\IN\1740 metastatic_24\JJ\1740 <e2>breast_25\NN\5225090 cancer</e2>_26\NN\14239425 ._27\.\1740
D004317_D001943 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 whether_4\IN\1740 <e1>myocet</e1>_5\NNP\1740 (_6\-LRB-\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 ;_9\:\1740 the_10\DT\1740 liposome_11\NNP\5517578 company_12\NNP\8053576 ,_13\,\1740 elan_14\NNP\7555184 corporation_15\NNP\8059870 ,_16\,\1740 princeton_17\NNP\1740 ,_18\,\1740 nj_19\NNP\1740 )_20\-RRB-\1740 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 cyclophosphamide_24\NN\1740 significantly_25\RB\1740 reduces_26\VBZ\441445 doxorubicin_27\NN\2716866 cardiotoxicity_28\NN\1740 while_29\IN\15122231 providing_30\VBG\2199590 comparable_31\JJ\1740 antitumor_32\NN\1740 efficacy_33\NN\5199286 in_34\IN\13603305 first-line_35\JJ\1740 treatment_36\NN\654885 of_37\IN\1740 metastatic_38\JJ\1740 <e2>breast_39\NN\5225090 cancer</e2>_40\NN\14239425 (_41\-LRB-\1740 mbc_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D004317_D001943 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 whether_4\IN\1740 <e1>myocet</e1>_5\NNP\1740 (_6\-LRB-\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 ;_9\:\1740 the_10\DT\1740 liposome_11\NNP\5517578 company_12\NNP\8053576 ,_13\,\1740 elan_14\NNP\7555184 corporation_15\NNP\8059870 ,_16\,\1740 princeton_17\NNP\1740 ,_18\,\1740 nj_19\NNP\1740 )_20\-RRB-\1740 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 cyclophosphamide_24\NN\1740 significantly_25\RB\1740 reduces_26\VBZ\441445 doxorubicin_27\NN\2716866 cardiotoxicity_28\NN\1740 while_29\IN\15122231 providing_30\VBG\2199590 comparable_31\JJ\1740 antitumor_32\NN\1740 efficacy_33\NN\5199286 in_34\IN\13603305 first-line_35\JJ\1740 treatment_36\NN\654885 of_37\IN\1740 metastatic_38\JJ\1740 breast_39\NN\5225090 cancer_40\NN\14239425 (_41\-LRB-\1740 <e2>mbc</e2>_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D004317_D001943 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 whether_4\IN\1740 myocet_5\NNP\1740 (_6\-LRB-\1740 liposome-encapsulated_7\JJ\1740 <e1>doxorubicin</e1>_8\NN\2716866 ;_9\:\1740 the_10\DT\1740 liposome_11\NNP\5517578 company_12\NNP\8053576 ,_13\,\1740 elan_14\NNP\7555184 corporation_15\NNP\8059870 ,_16\,\1740 princeton_17\NNP\1740 ,_18\,\1740 nj_19\NNP\1740 )_20\-RRB-\1740 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 cyclophosphamide_24\NN\1740 significantly_25\RB\1740 reduces_26\VBZ\441445 doxorubicin_27\NN\2716866 cardiotoxicity_28\NN\1740 while_29\IN\15122231 providing_30\VBG\2199590 comparable_31\JJ\1740 antitumor_32\NN\1740 efficacy_33\NN\5199286 in_34\IN\13603305 first-line_35\JJ\1740 treatment_36\NN\654885 of_37\IN\1740 metastatic_38\JJ\1740 <e2>breast_39\NN\5225090 cancer</e2>_40\NN\14239425 (_41\-LRB-\1740 mbc_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D004317_D001943 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 whether_4\IN\1740 myocet_5\NNP\1740 (_6\-LRB-\1740 liposome-encapsulated_7\JJ\1740 <e1>doxorubicin</e1>_8\NN\2716866 ;_9\:\1740 the_10\DT\1740 liposome_11\NNP\5517578 company_12\NNP\8053576 ,_13\,\1740 elan_14\NNP\7555184 corporation_15\NNP\8059870 ,_16\,\1740 princeton_17\NNP\1740 ,_18\,\1740 nj_19\NNP\1740 )_20\-RRB-\1740 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 cyclophosphamide_24\NN\1740 significantly_25\RB\1740 reduces_26\VBZ\441445 doxorubicin_27\NN\2716866 cardiotoxicity_28\NN\1740 while_29\IN\15122231 providing_30\VBG\2199590 comparable_31\JJ\1740 antitumor_32\NN\1740 efficacy_33\NN\5199286 in_34\IN\13603305 first-line_35\JJ\1740 treatment_36\NN\654885 of_37\IN\1740 metastatic_38\JJ\1740 breast_39\NN\5225090 cancer_40\NN\14239425 (_41\-LRB-\1740 <e2>mbc</e2>_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D004317_D001943 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 whether_4\IN\1740 myocet_5\NNP\1740 (_6\-LRB-\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 ;_9\:\1740 the_10\DT\1740 liposome_11\NNP\5517578 company_12\NNP\8053576 ,_13\,\1740 elan_14\NNP\7555184 corporation_15\NNP\8059870 ,_16\,\1740 princeton_17\NNP\1740 ,_18\,\1740 nj_19\NNP\1740 )_20\-RRB-\1740 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 cyclophosphamide_24\NN\1740 significantly_25\RB\1740 reduces_26\VBZ\441445 <e1>doxorubicin</e1>_27\NN\2716866 cardiotoxicity_28\NN\1740 while_29\IN\15122231 providing_30\VBG\2199590 comparable_31\JJ\1740 antitumor_32\NN\1740 efficacy_33\NN\5199286 in_34\IN\13603305 first-line_35\JJ\1740 treatment_36\NN\654885 of_37\IN\1740 metastatic_38\JJ\1740 <e2>breast_39\NN\5225090 cancer</e2>_40\NN\14239425 (_41\-LRB-\1740 mbc_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D004317_D001943 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 whether_4\IN\1740 myocet_5\NNP\1740 (_6\-LRB-\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 ;_9\:\1740 the_10\DT\1740 liposome_11\NNP\5517578 company_12\NNP\8053576 ,_13\,\1740 elan_14\NNP\7555184 corporation_15\NNP\8059870 ,_16\,\1740 princeton_17\NNP\1740 ,_18\,\1740 nj_19\NNP\1740 )_20\-RRB-\1740 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 cyclophosphamide_24\NN\1740 significantly_25\RB\1740 reduces_26\VBZ\441445 <e1>doxorubicin</e1>_27\NN\2716866 cardiotoxicity_28\NN\1740 while_29\IN\15122231 providing_30\VBG\2199590 comparable_31\JJ\1740 antitumor_32\NN\1740 efficacy_33\NN\5199286 in_34\IN\13603305 first-line_35\JJ\1740 treatment_36\NN\654885 of_37\IN\1740 metastatic_38\JJ\1740 breast_39\NN\5225090 cancer_40\NN\14239425 (_41\-LRB-\1740 <e2>mbc</e2>_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D004317_D001943 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 two_4\CD\13741022 hundred_5\CD\13745420 ninety-seven_6\JJ\1740 patients_7\NNS\9898892 with_8\IN\1740 <e2>mbc</e2>_9\NN\1740 and_10\CC\1740 no_11\DT\7204911 prior_12\JJ\1740 chemotherapy_13\NN\661091 for_14\IN\1740 metastatic_15\JJ\1740 disease_16\NN\14061805 were_17\VBD\836236 randomized_18\VBN\278117 to_19\TO\1740 receive_20\VB\2210855 either_21\CC\1740 60_22\CD\13745420 mg/m(2_23\NN\1740 )_24\-RRB-\1740 of_25\IN\1740 <e1>myocet</e1>_26\NNP\1740 (_27\-LRB-\1740 m_28\NN\13649268 )_29\-RRB-\1740 or_30\CC\3541091 conventional_31\JJ\1740 doxorubicin_32\NN\2716866 (_33\-LRB-\1740 a_34\NN\13649268 )_35\-RRB-\1740 ,_36\,\1740 in_37\IN\13603305 combination_38\NN\7951464 with_39\IN\1740 600_40\CD\1740 mg/m(2_41\NN\1740 )_42\-RRB-\1740 of_43\IN\1740 cyclophosphamide_44\NN\1740 (_45\-LRB-\1740 c_46\NN\13714184 )_47\-RRB-\1740 ,_48\,\1740 every_49\DT\1740 3_50\CD\13741022 weeks_51\NNS\15113229 until_52\IN\1740 disease_53\NN\14061805 progression_54\NN\8457976 or_55\CC\3541091 unacceptable_56\JJ\1740 toxicity_57\NN\13576101 ._58\.\1740
D004317_D001943 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 two_4\CD\13741022 hundred_5\CD\13745420 ninety-seven_6\JJ\1740 patients_7\NNS\9898892 with_8\IN\1740 <e2>mbc</e2>_9\NN\1740 and_10\CC\1740 no_11\DT\7204911 prior_12\JJ\1740 chemotherapy_13\NN\661091 for_14\IN\1740 metastatic_15\JJ\1740 disease_16\NN\14061805 were_17\VBD\836236 randomized_18\VBN\278117 to_19\TO\1740 receive_20\VB\2210855 either_21\CC\1740 60_22\CD\13745420 mg/m(2_23\NN\1740 )_24\-RRB-\1740 of_25\IN\1740 myocet_26\NNP\1740 (_27\-LRB-\1740 m_28\NN\13649268 )_29\-RRB-\1740 or_30\CC\3541091 conventional_31\JJ\1740 <e1>doxorubicin</e1>_32\NN\2716866 (_33\-LRB-\1740 a_34\NN\13649268 )_35\-RRB-\1740 ,_36\,\1740 in_37\IN\13603305 combination_38\NN\7951464 with_39\IN\1740 600_40\CD\1740 mg/m(2_41\NN\1740 )_42\-RRB-\1740 of_43\IN\1740 cyclophosphamide_44\NN\1740 (_45\-LRB-\1740 c_46\NN\13714184 )_47\-RRB-\1740 ,_48\,\1740 every_49\DT\1740 3_50\CD\13741022 weeks_51\NNS\15113229 until_52\IN\1740 disease_53\NN\14061805 progression_54\NN\8457976 or_55\CC\3541091 unacceptable_56\JJ\1740 toxicity_57\NN\13576101 ._58\.\1740
D004317_D001943 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>myocet</e1>_2\NNP\1740 improves_3\VBZ\126264 the_4\DT\1740 therapeutic_5\JJ\1740 index_6\NN\13850304 of_7\IN\1740 doxorubicin_8\NN\2716866 by_9\IN\1740 significantly_10\RB\1740 reducing_11\VBG\441445 cardiotoxicity_12\NN\1740 and_13\CC\1740 grade_14\NN\7975026 4_15\CD\13741022 neutropenia_16\NN\14196405 and_17\CC\1740 provides_18\VBZ\2199590 comparable_19\JJ\1740 antitumor_20\NN\1740 efficacy_21\NN\5199286 ,_22\,\1740 when_23\WRB\1740 used_24\VBN\1156834 in_25\IN\13603305 combination_26\NN\7951464 with_27\IN\1740 cyclophosphamide_28\NN\1740 as_29\IN\14622893 first-line_30\JJ\1740 therapy_31\NN\657604 for_32\IN\1740 <e2>mbc</e2>_33\NN\1740 ._34\.\1740
D004317_D001943 NONE conclusion_0\NN\5837957 :_1\:\1740 myocet_2\NNP\1740 improves_3\VBZ\126264 the_4\DT\1740 therapeutic_5\JJ\1740 index_6\NN\13850304 of_7\IN\1740 <e1>doxorubicin</e1>_8\NN\2716866 by_9\IN\1740 significantly_10\RB\1740 reducing_11\VBG\441445 cardiotoxicity_12\NN\1740 and_13\CC\1740 grade_14\NN\7975026 4_15\CD\13741022 neutropenia_16\NN\14196405 and_17\CC\1740 provides_18\VBZ\2199590 comparable_19\JJ\1740 antitumor_20\NN\1740 efficacy_21\NN\5199286 ,_22\,\1740 when_23\WRB\1740 used_24\VBN\1156834 in_25\IN\13603305 combination_26\NN\7951464 with_27\IN\1740 cyclophosphamide_28\NN\1740 as_29\IN\14622893 first-line_30\JJ\1740 therapy_31\NN\657604 for_32\IN\1740 <e2>mbc</e2>_33\NN\1740 ._34\.\1740
D003520_D066126 NONE reduced_0\VBN\441445 <e2>cardiotoxicity</e2>_1\NN\1740 and_2\CC\1740 preserved_3\VBD\2681795 antitumor_4\NN\1740 efficacy_5\NN\5199286 of_6\IN\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 and_9\CC\1740 <e1>cyclophosphamide</e1>_10\NN\1740 compared_11\VBN\644583 with_12\IN\1740 conventional_13\JJ\1740 doxorubicin_14\NN\2716866 and_15\CC\1740 cyclophosphamide_16\NN\1740 in_17\IN\13603305 a_18\DT\13649268 randomized_19\JJ\1740 ,_20\,\1740 multicenter_21\NN\1740 trial_22\NN\786195 of_23\IN\1740 metastatic_24\JJ\1740 breast_25\NN\5225090 cancer_26\NN\14239425 ._27\.\1740
D003520_D066126 NONE reduced_0\VBN\441445 <e2>cardiotoxicity</e2>_1\NN\1740 and_2\CC\1740 preserved_3\VBD\2681795 antitumor_4\NN\1740 efficacy_5\NN\5199286 of_6\IN\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 and_9\CC\1740 cyclophosphamide_10\NN\1740 compared_11\VBN\644583 with_12\IN\1740 conventional_13\JJ\1740 doxorubicin_14\NN\2716866 and_15\CC\1740 <e1>cyclophosphamide</e1>_16\NN\1740 in_17\IN\13603305 a_18\DT\13649268 randomized_19\JJ\1740 ,_20\,\1740 multicenter_21\NN\1740 trial_22\NN\786195 of_23\IN\1740 metastatic_24\JJ\1740 breast_25\NN\5225090 cancer_26\NN\14239425 ._27\.\1740
D003520_D066126 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 whether_4\IN\1740 myocet_5\NNP\1740 (_6\-LRB-\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 ;_9\:\1740 the_10\DT\1740 liposome_11\NNP\5517578 company_12\NNP\8053576 ,_13\,\1740 elan_14\NNP\7555184 corporation_15\NNP\8059870 ,_16\,\1740 princeton_17\NNP\1740 ,_18\,\1740 nj_19\NNP\1740 )_20\-RRB-\1740 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 <e1>cyclophosphamide</e1>_24\NN\1740 significantly_25\RB\1740 reduces_26\VBZ\441445 doxorubicin_27\NN\2716866 <e2>cardiotoxicity</e2>_28\NN\1740 while_29\IN\15122231 providing_30\VBG\2199590 comparable_31\JJ\1740 antitumor_32\NN\1740 efficacy_33\NN\5199286 in_34\IN\13603305 first-line_35\JJ\1740 treatment_36\NN\654885 of_37\IN\1740 metastatic_38\JJ\1740 breast_39\NN\5225090 cancer_40\NN\14239425 (_41\-LRB-\1740 mbc_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D003520_D066126 NONE conclusion_0\NN\5837957 :_1\:\1740 myocet_2\NNP\1740 improves_3\VBZ\126264 the_4\DT\1740 therapeutic_5\JJ\1740 index_6\NN\13850304 of_7\IN\1740 doxorubicin_8\NN\2716866 by_9\IN\1740 significantly_10\RB\1740 reducing_11\VBG\441445 <e2>cardiotoxicity</e2>_12\NN\1740 and_13\CC\1740 grade_14\NN\7975026 4_15\CD\13741022 neutropenia_16\NN\14196405 and_17\CC\1740 provides_18\VBZ\2199590 comparable_19\JJ\1740 antitumor_20\NN\1740 efficacy_21\NN\5199286 ,_22\,\1740 when_23\WRB\1740 used_24\VBN\1156834 in_25\IN\13603305 combination_26\NN\7951464 with_27\IN\1740 <e1>cyclophosphamide</e1>_28\NN\1740 as_29\IN\14622893 first-line_30\JJ\1740 therapy_31\NN\657604 for_32\IN\1740 mbc_33\NN\1740 ._34\.\1740
D003520_D001943 NONE reduced_0\VBN\441445 cardiotoxicity_1\NN\1740 and_2\CC\1740 preserved_3\VBD\2681795 antitumor_4\NN\1740 efficacy_5\NN\5199286 of_6\IN\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 and_9\CC\1740 <e1>cyclophosphamide</e1>_10\NN\1740 compared_11\VBN\644583 with_12\IN\1740 conventional_13\JJ\1740 doxorubicin_14\NN\2716866 and_15\CC\1740 cyclophosphamide_16\NN\1740 in_17\IN\13603305 a_18\DT\13649268 randomized_19\JJ\1740 ,_20\,\1740 multicenter_21\NN\1740 trial_22\NN\786195 of_23\IN\1740 metastatic_24\JJ\1740 <e2>breast_25\NN\5225090 cancer</e2>_26\NN\14239425 ._27\.\1740
D003520_D001943 NONE reduced_0\VBN\441445 cardiotoxicity_1\NN\1740 and_2\CC\1740 preserved_3\VBD\2681795 antitumor_4\NN\1740 efficacy_5\NN\5199286 of_6\IN\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 and_9\CC\1740 cyclophosphamide_10\NN\1740 compared_11\VBN\644583 with_12\IN\1740 conventional_13\JJ\1740 doxorubicin_14\NN\2716866 and_15\CC\1740 <e1>cyclophosphamide</e1>_16\NN\1740 in_17\IN\13603305 a_18\DT\13649268 randomized_19\JJ\1740 ,_20\,\1740 multicenter_21\NN\1740 trial_22\NN\786195 of_23\IN\1740 metastatic_24\JJ\1740 <e2>breast_25\NN\5225090 cancer</e2>_26\NN\14239425 ._27\.\1740
D003520_D001943 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 whether_4\IN\1740 myocet_5\NNP\1740 (_6\-LRB-\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 ;_9\:\1740 the_10\DT\1740 liposome_11\NNP\5517578 company_12\NNP\8053576 ,_13\,\1740 elan_14\NNP\7555184 corporation_15\NNP\8059870 ,_16\,\1740 princeton_17\NNP\1740 ,_18\,\1740 nj_19\NNP\1740 )_20\-RRB-\1740 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 <e1>cyclophosphamide</e1>_24\NN\1740 significantly_25\RB\1740 reduces_26\VBZ\441445 doxorubicin_27\NN\2716866 cardiotoxicity_28\NN\1740 while_29\IN\15122231 providing_30\VBG\2199590 comparable_31\JJ\1740 antitumor_32\NN\1740 efficacy_33\NN\5199286 in_34\IN\13603305 first-line_35\JJ\1740 treatment_36\NN\654885 of_37\IN\1740 metastatic_38\JJ\1740 <e2>breast_39\NN\5225090 cancer</e2>_40\NN\14239425 (_41\-LRB-\1740 mbc_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D003520_D001943 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 determine_3\VB\1645601 whether_4\IN\1740 myocet_5\NNP\1740 (_6\-LRB-\1740 liposome-encapsulated_7\JJ\1740 doxorubicin_8\NN\2716866 ;_9\:\1740 the_10\DT\1740 liposome_11\NNP\5517578 company_12\NNP\8053576 ,_13\,\1740 elan_14\NNP\7555184 corporation_15\NNP\8059870 ,_16\,\1740 princeton_17\NNP\1740 ,_18\,\1740 nj_19\NNP\1740 )_20\-RRB-\1740 in_21\IN\13603305 combination_22\NN\7951464 with_23\IN\1740 <e1>cyclophosphamide</e1>_24\NN\1740 significantly_25\RB\1740 reduces_26\VBZ\441445 doxorubicin_27\NN\2716866 cardiotoxicity_28\NN\1740 while_29\IN\15122231 providing_30\VBG\2199590 comparable_31\JJ\1740 antitumor_32\NN\1740 efficacy_33\NN\5199286 in_34\IN\13603305 first-line_35\JJ\1740 treatment_36\NN\654885 of_37\IN\1740 metastatic_38\JJ\1740 breast_39\NN\5225090 cancer_40\NN\14239425 (_41\-LRB-\1740 <e2>mbc</e2>_42\NN\1740 )_43\-RRB-\1740 ._44\.\1740
D003520_D001943 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 two_4\CD\13741022 hundred_5\CD\13745420 ninety-seven_6\JJ\1740 patients_7\NNS\9898892 with_8\IN\1740 <e2>mbc</e2>_9\NN\1740 and_10\CC\1740 no_11\DT\7204911 prior_12\JJ\1740 chemotherapy_13\NN\661091 for_14\IN\1740 metastatic_15\JJ\1740 disease_16\NN\14061805 were_17\VBD\836236 randomized_18\VBN\278117 to_19\TO\1740 receive_20\VB\2210855 either_21\CC\1740 60_22\CD\13745420 mg/m(2_23\NN\1740 )_24\-RRB-\1740 of_25\IN\1740 myocet_26\NNP\1740 (_27\-LRB-\1740 m_28\NN\13649268 )_29\-RRB-\1740 or_30\CC\3541091 conventional_31\JJ\1740 doxorubicin_32\NN\2716866 (_33\-LRB-\1740 a_34\NN\13649268 )_35\-RRB-\1740 ,_36\,\1740 in_37\IN\13603305 combination_38\NN\7951464 with_39\IN\1740 600_40\CD\1740 mg/m(2_41\NN\1740 )_42\-RRB-\1740 of_43\IN\1740 <e1>cyclophosphamide</e1>_44\NN\1740 (_45\-LRB-\1740 c_46\NN\13714184 )_47\-RRB-\1740 ,_48\,\1740 every_49\DT\1740 3_50\CD\13741022 weeks_51\NNS\15113229 until_52\IN\1740 disease_53\NN\14061805 progression_54\NN\8457976 or_55\CC\3541091 unacceptable_56\JJ\1740 toxicity_57\NN\13576101 ._58\.\1740
D003520_D001943 NONE conclusion_0\NN\5837957 :_1\:\1740 myocet_2\NNP\1740 improves_3\VBZ\126264 the_4\DT\1740 therapeutic_5\JJ\1740 index_6\NN\13850304 of_7\IN\1740 doxorubicin_8\NN\2716866 by_9\IN\1740 significantly_10\RB\1740 reducing_11\VBG\441445 cardiotoxicity_12\NN\1740 and_13\CC\1740 grade_14\NN\7975026 4_15\CD\13741022 neutropenia_16\NN\14196405 and_17\CC\1740 provides_18\VBZ\2199590 comparable_19\JJ\1740 antitumor_20\NN\1740 efficacy_21\NN\5199286 ,_22\,\1740 when_23\WRB\1740 used_24\VBN\1156834 in_25\IN\13603305 combination_26\NN\7951464 with_27\IN\1740 <e1>cyclophosphamide</e1>_28\NN\1740 as_29\IN\14622893 first-line_30\JJ\1740 therapy_31\NN\657604 for_32\IN\1740 <e2>mbc</e2>_33\NN\1740 ._34\.\1740
D004317_D064420 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 two_4\CD\13741022 hundred_5\CD\13745420 ninety-seven_6\JJ\1740 patients_7\NNS\9898892 with_8\IN\1740 mbc_9\NN\1740 and_10\CC\1740 no_11\DT\7204911 prior_12\JJ\1740 chemotherapy_13\NN\661091 for_14\IN\1740 metastatic_15\JJ\1740 disease_16\NN\14061805 were_17\VBD\836236 randomized_18\VBN\278117 to_19\TO\1740 receive_20\VB\2210855 either_21\CC\1740 60_22\CD\13745420 mg/m(2_23\NN\1740 )_24\-RRB-\1740 of_25\IN\1740 <e1>myocet</e1>_26\NNP\1740 (_27\-LRB-\1740 m_28\NN\13649268 )_29\-RRB-\1740 or_30\CC\3541091 conventional_31\JJ\1740 doxorubicin_32\NN\2716866 (_33\-LRB-\1740 a_34\NN\13649268 )_35\-RRB-\1740 ,_36\,\1740 in_37\IN\13603305 combination_38\NN\7951464 with_39\IN\1740 600_40\CD\1740 mg/m(2_41\NN\1740 )_42\-RRB-\1740 of_43\IN\1740 cyclophosphamide_44\NN\1740 (_45\-LRB-\1740 c_46\NN\13714184 )_47\-RRB-\1740 ,_48\,\1740 every_49\DT\1740 3_50\CD\13741022 weeks_51\NNS\15113229 until_52\IN\1740 disease_53\NN\14061805 progression_54\NN\8457976 or_55\CC\3541091 unacceptable_56\JJ\1740 <e2>toxicity</e2>_57\NN\13576101 ._58\.\1740
D004317_D064420 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 two_4\CD\13741022 hundred_5\CD\13745420 ninety-seven_6\JJ\1740 patients_7\NNS\9898892 with_8\IN\1740 mbc_9\NN\1740 and_10\CC\1740 no_11\DT\7204911 prior_12\JJ\1740 chemotherapy_13\NN\661091 for_14\IN\1740 metastatic_15\JJ\1740 disease_16\NN\14061805 were_17\VBD\836236 randomized_18\VBN\278117 to_19\TO\1740 receive_20\VB\2210855 either_21\CC\1740 60_22\CD\13745420 mg/m(2_23\NN\1740 )_24\-RRB-\1740 of_25\IN\1740 myocet_26\NNP\1740 (_27\-LRB-\1740 m_28\NN\13649268 )_29\-RRB-\1740 or_30\CC\3541091 conventional_31\JJ\1740 <e1>doxorubicin</e1>_32\NN\2716866 (_33\-LRB-\1740 a_34\NN\13649268 )_35\-RRB-\1740 ,_36\,\1740 in_37\IN\13603305 combination_38\NN\7951464 with_39\IN\1740 600_40\CD\1740 mg/m(2_41\NN\1740 )_42\-RRB-\1740 of_43\IN\1740 cyclophosphamide_44\NN\1740 (_45\-LRB-\1740 c_46\NN\13714184 )_47\-RRB-\1740 ,_48\,\1740 every_49\DT\1740 3_50\CD\13741022 weeks_51\NNS\15113229 until_52\IN\1740 disease_53\NN\14061805 progression_54\NN\8457976 or_55\CC\3541091 unacceptable_56\JJ\1740 <e2>toxicity</e2>_57\NN\13576101 ._58\.\1740
D003520_D064420 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 two_4\CD\13741022 hundred_5\CD\13745420 ninety-seven_6\JJ\1740 patients_7\NNS\9898892 with_8\IN\1740 mbc_9\NN\1740 and_10\CC\1740 no_11\DT\7204911 prior_12\JJ\1740 chemotherapy_13\NN\661091 for_14\IN\1740 metastatic_15\JJ\1740 disease_16\NN\14061805 were_17\VBD\836236 randomized_18\VBN\278117 to_19\TO\1740 receive_20\VB\2210855 either_21\CC\1740 60_22\CD\13745420 mg/m(2_23\NN\1740 )_24\-RRB-\1740 of_25\IN\1740 myocet_26\NNP\1740 (_27\-LRB-\1740 m_28\NN\13649268 )_29\-RRB-\1740 or_30\CC\3541091 conventional_31\JJ\1740 doxorubicin_32\NN\2716866 (_33\-LRB-\1740 a_34\NN\13649268 )_35\-RRB-\1740 ,_36\,\1740 in_37\IN\13603305 combination_38\NN\7951464 with_39\IN\1740 600_40\CD\1740 mg/m(2_41\NN\1740 )_42\-RRB-\1740 of_43\IN\1740 <e1>cyclophosphamide</e1>_44\NN\1740 (_45\-LRB-\1740 c_46\NN\13714184 )_47\-RRB-\1740 ,_48\,\1740 every_49\DT\1740 3_50\CD\13741022 weeks_51\NNS\15113229 until_52\IN\1740 disease_53\NN\14061805 progression_54\NN\8457976 or_55\CC\3541091 unacceptable_56\JJ\1740 <e2>toxicity</e2>_57\NN\13576101 ._58\.\1740
D004317_D009503 CID conclusion_0\NN\5837957 :_1\:\1740 <e1>myocet</e1>_2\NNP\1740 improves_3\VBZ\126264 the_4\DT\1740 therapeutic_5\JJ\1740 index_6\NN\13850304 of_7\IN\1740 doxorubicin_8\NN\2716866 by_9\IN\1740 significantly_10\RB\1740 reducing_11\VBG\441445 cardiotoxicity_12\NN\1740 and_13\CC\1740 grade_14\NN\7975026 4_15\CD\13741022 <e2>neutropenia</e2>_16\NN\14196405 and_17\CC\1740 provides_18\VBZ\2199590 comparable_19\JJ\1740 antitumor_20\NN\1740 efficacy_21\NN\5199286 ,_22\,\1740 when_23\WRB\1740 used_24\VBN\1156834 in_25\IN\13603305 combination_26\NN\7951464 with_27\IN\1740 cyclophosphamide_28\NN\1740 as_29\IN\14622893 first-line_30\JJ\1740 therapy_31\NN\657604 for_32\IN\1740 mbc_33\NN\1740 ._34\.\1740
D004317_D009503 CID conclusion_0\NN\5837957 :_1\:\1740 myocet_2\NNP\1740 improves_3\VBZ\126264 the_4\DT\1740 therapeutic_5\JJ\1740 index_6\NN\13850304 of_7\IN\1740 <e1>doxorubicin</e1>_8\NN\2716866 by_9\IN\1740 significantly_10\RB\1740 reducing_11\VBG\441445 cardiotoxicity_12\NN\1740 and_13\CC\1740 grade_14\NN\7975026 4_15\CD\13741022 <e2>neutropenia</e2>_16\NN\14196405 and_17\CC\1740 provides_18\VBZ\2199590 comparable_19\JJ\1740 antitumor_20\NN\1740 efficacy_21\NN\5199286 ,_22\,\1740 when_23\WRB\1740 used_24\VBN\1156834 in_25\IN\13603305 combination_26\NN\7951464 with_27\IN\1740 cyclophosphamide_28\NN\1740 as_29\IN\14622893 first-line_30\JJ\1740 therapy_31\NN\657604 for_32\IN\1740 mbc_33\NN\1740 ._34\.\1740
D003520_D009503 CID conclusion_0\NN\5837957 :_1\:\1740 myocet_2\NNP\1740 improves_3\VBZ\126264 the_4\DT\1740 therapeutic_5\JJ\1740 index_6\NN\13850304 of_7\IN\1740 doxorubicin_8\NN\2716866 by_9\IN\1740 significantly_10\RB\1740 reducing_11\VBG\441445 cardiotoxicity_12\NN\1740 and_13\CC\1740 grade_14\NN\7975026 4_15\CD\13741022 <e2>neutropenia</e2>_16\NN\14196405 and_17\CC\1740 provides_18\VBZ\2199590 comparable_19\JJ\1740 antitumor_20\NN\1740 efficacy_21\NN\5199286 ,_22\,\1740 when_23\WRB\1740 used_24\VBN\1156834 in_25\IN\13603305 combination_26\NN\7951464 with_27\IN\1740 <e1>cyclophosphamide</e1>_28\NN\1740 as_29\IN\14622893 first-line_30\JJ\1740 therapy_31\NN\657604 for_32\IN\1740 mbc_33\NN\1740 ._34\.\1740
11467664
D008687_D041781 CID <e2>cholestatic_0\JJ\1740 jaundice</e2>_1\NN\14299637 associated_2\VBN\628491 with_3\IN\1740 the_4\DT\1740 use_5\NN\407535 of_6\IN\1740 <e1>metformin</e1>_7\NN\2719105 ._8\.\1740
D008687_D041781 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 patient_3\NN\9898892 who_4\WP\8299493 developed_5\VBD\1753788 <e2>cholestatic_6\NN\1740 jaundice</e2>_7\NN\14299637 shortly_8\RB\1740 after_9\IN\1740 initiation_10\NN\7450842 of_11\IN\1740 treatment_12\NN\654885 with_13\IN\1740 <e1>metformin_14\NN\2719105 hydrochloride</e1>_15\NN\14817592 ._16\.\1740
D008687_D007565 NONE <e1>metformin_0\NN\2719105 hydrochloride</e1>_1\NN\14817592 was_2\VBD\836236 discontinued_3\VBN\2609764 ,_4\,\1740 and_5\CC\1740 the_6\DT\1740 patient_7\NN\9898892 's_8\POS\1740 <e2>jaundice</e2>_9\NN\14299637 resolved_10\VBN\352826 slowly_11\RB\1740 over_12\IN\5867413 a_13\DT\13649268 period_14\NN\13575869 of_15\IN\1740 several_16\JJ\1740 months_17\NNS\15113229 ._18\.\1740
D008687_D007565 NONE given_0\VBN\2327200 the_1\DT\1740 onset_2\NN\7325190 of_3\IN\1740 his_4\PRP$\1740 <e2>jaundice</e2>_5\NN\14299637 2_6\CD\13741022 wk_7\NN\1740 after_8\IN\1740 the_9\DT\1740 initiation_10\NN\7450842 of_11\IN\1740 <e1>metformin</e1>_12\NN\2719105 ,_13\,\1740 we_14\PRP\1740 believe_15\VBP\686447 that_16\IN\1740 this_17\DT\1740 case_18\NN\7283608 represents_19\VBZ\2664769 an_20\DT\6697703 example_21\NN\5816287 of_22\IN\1740 metformin-associated_23\JJ\1740 hepatotoxicity_24\NN\1740 ,_25\,\1740 the_26\DT\1740 first_27\JJ\1740 such_28\JJ\1740 case_29\NN\7283608 reported_30\VBN\831651 ._31\.\1740
D008687_D007565 NONE given_0\VBN\2327200 the_1\DT\1740 onset_2\NN\7325190 of_3\IN\1740 his_4\PRP$\1740 <e2>jaundice</e2>_5\NN\14299637 2_6\CD\13741022 wk_7\NN\1740 after_8\IN\1740 the_9\DT\1740 initiation_10\NN\7450842 of_11\IN\1740 metformin_12\NN\2719105 ,_13\,\1740 we_14\PRP\1740 believe_15\VBP\686447 that_16\IN\1740 this_17\DT\1740 case_18\NN\7283608 represents_19\VBZ\2664769 an_20\DT\6697703 example_21\NN\5816287 of_22\IN\1740 <e1>metformin-associated</e1>_23\JJ\1740 hepatotoxicity_24\NN\1740 ,_25\,\1740 the_26\DT\1740 first_27\JJ\1740 such_28\JJ\1740 case_29\NN\7283608 reported_30\VBN\831651 ._31\.\1740
D008687_D056486 NONE given_0\VBN\2327200 the_1\DT\1740 onset_2\NN\7325190 of_3\IN\1740 his_4\PRP$\1740 jaundice_5\NN\14299637 2_6\CD\13741022 wk_7\NN\1740 after_8\IN\1740 the_9\DT\1740 initiation_10\NN\7450842 of_11\IN\1740 <e1>metformin</e1>_12\NN\2719105 ,_13\,\1740 we_14\PRP\1740 believe_15\VBP\686447 that_16\IN\1740 this_17\DT\1740 case_18\NN\7283608 represents_19\VBZ\2664769 an_20\DT\6697703 example_21\NN\5816287 of_22\IN\1740 metformin-associated_23\JJ\1740 <e2>hepatotoxicity</e2>_24\NN\1740 ,_25\,\1740 the_26\DT\1740 first_27\JJ\1740 such_28\JJ\1740 case_29\NN\7283608 reported_30\VBN\831651 ._31\.\1740
D008687_D056486 NONE given_0\VBN\2327200 the_1\DT\1740 onset_2\NN\7325190 of_3\IN\1740 his_4\PRP$\1740 jaundice_5\NN\14299637 2_6\CD\13741022 wk_7\NN\1740 after_8\IN\1740 the_9\DT\1740 initiation_10\NN\7450842 of_11\IN\1740 metformin_12\NN\2719105 ,_13\,\1740 we_14\PRP\1740 believe_15\VBP\686447 that_16\IN\1740 this_17\DT\1740 case_18\NN\7283608 represents_19\VBZ\2664769 an_20\DT\6697703 example_21\NN\5816287 of_22\IN\1740 <e1>metformin-associated</e1>_23\JJ\1740 <e2>hepatotoxicity</e2>_24\NN\1740 ,_25\,\1740 the_26\DT\1740 first_27\JJ\1740 such_28\JJ\1740 case_29\NN\7283608 reported_30\VBN\831651 ._31\.\1740
19319147
D014859_D006470 NONE rapid_0\JJ\1740 reversal_1\NN\199130 of_2\IN\1740 anticoagulation_3\NN\657604 reduces_4\VBZ\441445 <e2>hemorrhage</e2>_5\NN\14285662 volume_6\NN\33615 in_7\IN\13603305 a_8\DT\13649268 mouse_9\NN\2329401 model_10\NN\5888929 of_11\IN\1740 <e1>warfarin-associated</e1>_12\JJ\1740 intracerebral_13\JJ\1740 hemorrhage_14\NN\14285662 ._15\.\1740
D014859_D002543 CID rapid_0\JJ\1740 reversal_1\NN\199130 of_2\IN\1740 anticoagulation_3\NN\657604 reduces_4\VBZ\441445 hemorrhage_5\NN\14285662 volume_6\NN\33615 in_7\IN\13603305 a_8\DT\13649268 mouse_9\NN\2329401 model_10\NN\5888929 of_11\IN\1740 <e1>warfarin-associated</e1>_12\JJ\1740 <e2>intracerebral_13\JJ\1740 hemorrhage</e2>_14\NN\14285662 ._15\.\1740
D014859_D002543 CID <e1>warfarin-associated</e1>_0\JJ\1740 <e2>intracerebral_1\JJ\1740 hemorrhage</e2>_2\NN\14285662 (_3\-LRB-\1740 w-ich_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 severe_8\JJ\1740 type_9\NN\5839024 of_10\IN\1740 stroke_11\NN\556313 ._12\.\1740
D014859_D002543 CID <e1>warfarin-associated</e1>_0\JJ\1740 intracerebral_1\JJ\1740 hemorrhage_2\NN\14285662 (_3\-LRB-\1740 <e2>w-ich</e2>_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 severe_8\JJ\1740 type_9\NN\5839024 of_10\IN\1740 stroke_11\NN\556313 ._12\.\1740
D014859_D020521 NONE <e1>warfarin-associated</e1>_0\JJ\1740 intracerebral_1\JJ\1740 hemorrhage_2\NN\14285662 (_3\-LRB-\1740 w-ich_4\NN\1740 )_5\-RRB-\1740 is_6\VBZ\836236 a_7\DT\13649268 severe_8\JJ\1740 type_9\NN\5839024 of_10\IN\1740 <e2>stroke</e2>_11\NN\556313 ._12\.\1740
C025667_D002543 NONE we_0\PRP\1740 provide_1\VBP\2199590 experimental_2\JJ\1740 data_3\NNS\7951464 suggesting_4\VBG\1010118 <e1>pcc</e1>_5\NN\1740 to_6\TO\1740 be_7\VB\836236 an_8\DT\6697703 effective_9\JJ\1740 acute_10\JJ\1740 treatment_11\NN\654885 for_12\IN\1740 <e2>w-ich</e2>_13\NN\1740 in_14\IN\13603305 terms_15\NNS\13945919 of_16\IN\1740 reducing_17\VBG\441445 hemorrhagic_18\JJ\1740 blood_19\NN\5397468 volume_20\NN\33615 ._21\.\1740
2557556
D015232_D006930 CID intradermal_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 mu_3\NN\6828818 ,_4\,\1740 but_5\CC\1740 not_6\RB\1740 delta_7\NN\9193282 or_8\CC\3541091 kappa_9\NN\6828818 opioid-agonists_10\NNS\1740 ,_11\,\1740 however_12\RB\1740 ,_13\,\1740 produced_14\VBD\1617192 dose-dependent_15\JJ\1740 inhibition_16\NN\1068773 of_17\IN\1740 <e1>prostaglandin_18\NN\5414534 e2-induced</e1>_19\JJ\1740 <e2>hyperalgesia</e2>_20\NN\1740 ._21\.\1740
D009020_D006930 NONE <e1>morphine</e1>_0\NN\2707683 did_1\VBD\1640855 not_2\RB\1740 ,_3\,\1740 however_4\RB\1740 ,_5\,\1740 alter_6\VBP\126264 the_7\DT\1740 <e2>hyperalgesia</e2>_8\NN\1740 induced_9\VBN\1627355 by_10\IN\1740 8-bromo_11\JJ\1740 cyclic_12\JJ\1740 adenosine_13\NN\14964367 monophosphate_14\NN\1740 ._15\.\1740
D015124_D006930 CID morphine_0\NN\2707683 did_1\VBD\1640855 not_2\RB\1740 ,_3\,\1740 however_4\RB\1740 ,_5\,\1740 alter_6\VBP\126264 the_7\DT\1740 <e2>hyperalgesia</e2>_8\NN\1740 induced_9\VBN\1627355 by_10\IN\1740 <e1>8-bromo_11\JJ\1740 cyclic_12\JJ\1740 adenosine_13\NN\14964367 monophosphate</e1>_14\NN\1740 ._15\.\1740
4069770
D005839_D007674 NONE <e1>gentamicin</e1>_0\NN\2716866 <e2>nephropathy</e2>_1\NN\14573196 in_2\IN\13603305 a_3\DT\13649268 neonate_4\NN\9827683 ._5\.\1740
D005839_D058186 CID the_0\DT\1740 clinical_1\JJ\1740 and_2\CC\1740 autopsy_3\JJ\1740 findings_4\NNS\7951464 in_5\IN\13603305 a_6\DT\13649268 premature_7\JJ\1740 baby_8\NN\9918248 who_9\WP\8299493 died_10\VBD\146138 of_11\IN\1740 <e2>acute_12\JJ\1740 renal_13\JJ\1740 failure</e2>_14\NN\66216 after_15\IN\1740 therapy_16\NN\657604 with_17\IN\1740 <e1>gentamicin</e1>_18\NN\2716866 (_19\-LRB-\1740 5_20\CD\13741022 mg/kg/day_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 penicillin_24\NN\2716866 are_25\VBP\836236 presented_26\VBN\2137132 ._27\.\1740
D010406_D058186 NONE the_0\DT\1740 clinical_1\JJ\1740 and_2\CC\1740 autopsy_3\JJ\1740 findings_4\NNS\7951464 in_5\IN\13603305 a_6\DT\13649268 premature_7\JJ\1740 baby_8\NN\9918248 who_9\WP\8299493 died_10\VBD\146138 of_11\IN\1740 <e2>acute_12\JJ\1740 renal_13\JJ\1740 failure</e2>_14\NN\66216 after_15\IN\1740 therapy_16\NN\657604 with_17\IN\1740 gentamicin_18\NN\2716866 (_19\-LRB-\1740 5_20\CD\13741022 mg/kg/day_21\NN\1740 )_22\-RRB-\1740 and_23\CC\1740 <e1>penicillin</e1>_24\NN\2716866 are_25\VBP\836236 presented_26\VBN\2137132 ._27\.\1740
D005839_D001002 NONE the_0\DT\1740 serum_1\NN\5397468 <e1>gentamicin</e1>_2\NN\2716866 concentration_3\NN\4916342 had_4\VBD\2108377 reached_5\VBN\2005948 toxic_6\JJ\1740 levels_7\NNS\4916342 when_8\WRB\1740 <e2>anuria</e2>_9\NNS\14061805 developed_10\VBD\1753788 ._11\.\1740
2840807
D009074_D004421 CID a_0\DT\13649268 <e2>dystonia-like</e2>_1\JJ\1740 syndrome_2\NN\5870365 after_3\IN\1740 neuropeptide_4\NN\1740 (_5\-LRB-\1740 <e1>msh/acth</e1>_6\JJ\1740 )_7\-RRB-\1740 stimulation_8\NN\242808 of_9\IN\1740 the_10\DT\1740 rat_11\NN\2329401 locus_12\NN\8645963 ceruleus_13\FW\1740 ._14\.\1740
D000324_D004421 CID a_0\DT\13649268 <e2>dystonia-like</e2>_1\JJ\1740 syndrome_2\NN\5870365 after_3\IN\1740 neuropeptide_4\NN\1740 (_5\-LRB-\1740 <e1>msh/acth</e1>_6\JJ\1740 )_7\-RRB-\1740 stimulation_8\NN\242808 of_9\IN\1740 the_10\DT\1740 rat_11\NN\2329401 locus_12\NN\8645963 ceruleus_13\FW\1740 ._14\.\1740
D000324_D003866 NONE however_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 is_3\VBZ\836236 not_4\RB\1740 certain_5\JJ\1740 as_6\IN\14622893 to_7\IN\1740 the_8\DT\1740 following_9\NN\8180190 :_10\:\1740 (_11\-LRB-\1740 a_12\LS\13649268 )_13\-RRB-\1740 what_14\WDT\1740 receptors_15\NNS\5225602 were_16\VBD\836236 stimulated_17\VBN\137313 by_18\IN\1740 the_19\DT\1740 <e1>acth</e1>_20\NN\5407119 n-terminal_21\JJ\1740 fragments_22\NNS\9385911 at_23\IN\14622893 the_24\DT\1740 lc_25\NN\1740 that_26\WDT\1740 resulted_27\VBD\2633881 in_28\IN\13603305 this_29\DT\1740 disorder_30\NN\14034177 ;_31\:\1740 (_32\-LRB-\1740 b_33\LS\1355326 )_34\-RRB-\1740 whether_35\IN\1740 ne_36\NN\14622893 ,_37\,\1740 released_38\VBN\1435380 onto_39\IN\1740 purkinje_40\NN\1740 cell_41\NN\3080309 synapses_42\NNS\13526110 located_43\JJ\1740 at_44\IN\14622893 terminals_45\NNS\4306080 of_46\IN\1740 the_47\DT\1740 ceruleo-cerebellar_48\JJ\1740 pathway_49\NN\5483677 ,_50\,\1740 did_51\VBD\1640855 indeed_52\RB\1740 cause_53\VB\1617192 the_54\DT\1740 long-term_55\JJ\1740 <e2>depression</e2>_56\NN\14373582 at_57\IN\14622893 purkinje_58\NN\1740 cell_59\NN\3080309 synapses_60\NNS\13526110 (_61\-LRB-\1740 previously_62\RB\1740 described_63\VBN\1001294 by_64\IN\1740 others_65\NNS\1740 )_66\-RRB-\1740 that_67\WDT\1740 resulted_68\VBD\2633881 in_69\IN\13603305 the_70\DT\1740 long_71\JJ\1740 duration_72\NN\15113229 of_73\IN\1740 the_74\DT\1740 movement_75\NN\191142 disorder_76\NN\14034177 ;_77\:\1740 (_78\-LRB-\1740 c_79\LS\13714184 )_80\-RRB-\1740 whether_81\IN\1740 the_82\DT\1740 inhibition_83\NN\1068773 of_84\IN\1740 inhibitory_85\JJ\1740 purkinje_86\NN\1740 cells_87\NNS\3080309 resulted_88\VBD\2633881 in_89\IN\13603305 disinhibition_90\NN\1740 or_91\CC\3541091 increased_92\VBD\169651 excitability_93\NN\5653575 of_94\IN\1740 the_95\DT\1740 unilateral_96\JJ\1740 cerebellar_97\NN\1740 fastigial_98\JJ\1740 or_99\CC\3541091 interpositus_100\NN\1740 nuclei_101\NNS\5445668 ,_102\,\1740 the_103\DT\1740 output_104\NN\4007894 targets_105\NNS\7258332 of_106\IN\1740 the_107\DT\1740 purkinje_108\NNP\1740 cell_109\NN\3080309 axons_110\NNS\5464104 ,_111\,\1740 that_112\WDT\1740 may_113\MD\15209706 have_114\VB\2108377 been_115\VBN\836236 an_116\DT\6697703 important_117\JJ\1740 contributing_118\VBG\126264 factor_119\NN\7326557 to_120\TO\1740 this_121\DT\1740 disorder_122\NN\14034177 ._123\.\1740
D000324_D009069 NONE however_0\RB\1740 ,_1\,\1740 it_2\PRP\6125041 is_3\VBZ\836236 not_4\RB\1740 certain_5\JJ\1740 as_6\IN\14622893 to_7\IN\1740 the_8\DT\1740 following_9\NN\8180190 :_10\:\1740 (_11\-LRB-\1740 a_12\LS\13649268 )_13\-RRB-\1740 what_14\WDT\1740 receptors_15\NNS\5225602 were_16\VBD\836236 stimulated_17\VBN\137313 by_18\IN\1740 the_19\DT\1740 <e1>acth</e1>_20\NN\5407119 n-terminal_21\JJ\1740 fragments_22\NNS\9385911 at_23\IN\14622893 the_24\DT\1740 lc_25\NN\1740 that_26\WDT\1740 resulted_27\VBD\2633881 in_28\IN\13603305 this_29\DT\1740 disorder_30\NN\14034177 ;_31\:\1740 (_32\-LRB-\1740 b_33\LS\1355326 )_34\-RRB-\1740 whether_35\IN\1740 ne_36\NN\14622893 ,_37\,\1740 released_38\VBN\1435380 onto_39\IN\1740 purkinje_40\NN\1740 cell_41\NN\3080309 synapses_42\NNS\13526110 located_43\JJ\1740 at_44\IN\14622893 terminals_45\NNS\4306080 of_46\IN\1740 the_47\DT\1740 ceruleo-cerebellar_48\JJ\1740 pathway_49\NN\5483677 ,_50\,\1740 did_51\VBD\1640855 indeed_52\RB\1740 cause_53\VB\1617192 the_54\DT\1740 long-term_55\JJ\1740 depression_56\NN\14373582 at_57\IN\14622893 purkinje_58\NN\1740 cell_59\NN\3080309 synapses_60\NNS\13526110 (_61\-LRB-\1740 previously_62\RB\1740 described_63\VBN\1001294 by_64\IN\1740 others_65\NNS\1740 )_66\-RRB-\1740 that_67\WDT\1740 resulted_68\VBD\2633881 in_69\IN\13603305 the_70\DT\1740 long_71\JJ\1740 duration_72\NN\15113229 of_73\IN\1740 the_74\DT\1740 <e2>movement_75\NN\191142 disorder</e2>_76\NN\14034177 ;_77\:\1740 (_78\-LRB-\1740 c_79\LS\13714184 )_80\-RRB-\1740 whether_81\IN\1740 the_82\DT\1740 inhibition_83\NN\1068773 of_84\IN\1740 inhibitory_85\JJ\1740 purkinje_86\NN\1740 cells_87\NNS\3080309 resulted_88\VBD\2633881 in_89\IN\13603305 disinhibition_90\NN\1740 or_91\CC\3541091 increased_92\VBD\169651 excitability_93\NN\5653575 of_94\IN\1740 the_95\DT\1740 unilateral_96\JJ\1740 cerebellar_97\NN\1740 fastigial_98\JJ\1740 or_99\CC\3541091 interpositus_100\NN\1740 nuclei_101\NNS\5445668 ,_102\,\1740 the_103\DT\1740 output_104\NN\4007894 targets_105\NNS\7258332 of_106\IN\1740 the_107\DT\1740 purkinje_108\NNP\1740 cell_109\NN\3080309 axons_110\NNS\5464104 ,_111\,\1740 that_112\WDT\1740 may_113\MD\15209706 have_114\VB\2108377 been_115\VBN\836236 an_116\DT\6697703 important_117\JJ\1740 contributing_118\VBG\126264 factor_119\NN\7326557 to_120\TO\1740 this_121\DT\1740 disorder_122\NN\14034177 ._123\.\1740
2533791
D017325_D006509 NONE these_0\DT\1740 infants_1\NNS\9918248 are_2\VBP\836236 treated_3\VBN\2376958 with_4\IN\1740 two_5\CD\13741022 injections_6\NNS\320852 of_7\IN\1740 <e2>hepatitis_8\NN\14127211 b</e2>_9\NN\1355326 immune_10\JJ\1740 globulin_11\NN\14736972 (_12\-LRB-\1740 hbig_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 at_16\IN\14622893 least_17\JJS\1740 three_18\CD\13741022 injections_19\NNS\320852 of_20\IN\1740 plasma_21\NN\5398023 derived_22\VBN\634472 <e1>hepatitis_23\NN\14127211 b_24\NN\1355326 vaccine</e1>_25\NN\3562739 ._26\.\1740
18808529
D007545_D009202 CID <e1>isoproterenol</e1>_0\NN\3740161 induces_1\VBZ\1627355 primary_2\JJ\1740 loss_3\NN\13252973 of_4\IN\1740 dystrophin_5\NN\1740 in_6\IN\13603305 rat_7\NN\2329401 hearts_8\NNS\496167 :_9\:\1740 correlation_10\NN\13841213 with_11\IN\1740 <e2>myocardial_12\JJ\1740 injury</e2>_13\NN\14052046 ._14\.\1740
D007545_D009202 CID the_0\DT\1740 mechanism_1\NN\13446390 of_2\IN\1740 <e1>isoproterenol-induced</e1>_3\JJ\1740 <e2>myocardial_4\JJ\1740 damage</e2>_5\NN\7296428 is_6\VBZ\836236 unknown_7\JJ\1740 ,_8\,\1740 but_9\CC\1740 a_10\DT\13649268 mismatch_11\NN\5695806 of_12\IN\1740 oxygen_13\NN\14622893 supply_14\NN\13576355 vs._15\CC\1740 demand_16\NN\6513366 following_17\VBG\1835496 coronary_18\JJ\1740 hypotension_19\NN\14057371 and_20\CC\1740 myocardial_21\JJ\1740 hyperactivity_22\NN\14052403 is_23\VBZ\836236 the_24\DT\1740 best_25\JJS\1740 explanation_26\NN\6722453 for_27\IN\1740 the_28\DT\1740 complex_29\JJ\1740 morphological_30\JJ\1740 alterations_31\NNS\7283608 observed_32\VBN\2163746 ._33\.\1740
D007545_D009202 CID the_0\DT\1740 mechanism_1\NN\13446390 of_2\IN\1740 <e1>isoproterenol-induced</e1>_3\JJ\1740 myocardial_4\JJ\1740 damage_5\NN\7296428 is_6\VBZ\836236 unknown_7\JJ\1740 ,_8\,\1740 but_9\CC\1740 a_10\DT\13649268 mismatch_11\NN\5695806 of_12\IN\1740 oxygen_13\NN\14622893 supply_14\NN\13576355 vs._15\CC\1740 demand_16\NN\6513366 following_17\VBG\1835496 coronary_18\JJ\1740 hypotension_19\NN\14057371 and_20\CC\1740 <e2>myocardial_21\JJ\1740 hyperactivity</e2>_22\NN\14052403 is_23\VBZ\836236 the_24\DT\1740 best_25\JJS\1740 explanation_26\NN\6722453 for_27\IN\1740 the_28\DT\1740 complex_29\JJ\1740 morphological_30\JJ\1740 alterations_31\NNS\7283608 observed_32\VBN\2163746 ._33\.\1740
D007545_D007022 NONE the_0\DT\1740 mechanism_1\NN\13446390 of_2\IN\1740 <e1>isoproterenol-induced</e1>_3\JJ\1740 myocardial_4\JJ\1740 damage_5\NN\7296428 is_6\VBZ\836236 unknown_7\JJ\1740 ,_8\,\1740 but_9\CC\1740 a_10\DT\13649268 mismatch_11\NN\5695806 of_12\IN\1740 oxygen_13\NN\14622893 supply_14\NN\13576355 vs._15\CC\1740 demand_16\NN\6513366 following_17\VBG\1835496 coronary_18\JJ\1740 <e2>hypotension</e2>_19\NN\14057371 and_20\CC\1740 myocardial_21\JJ\1740 hyperactivity_22\NN\14052403 is_23\VBZ\836236 the_24\DT\1740 best_25\JJS\1740 explanation_26\NN\6722453 for_27\IN\1740 the_28\DT\1740 complex_29\JJ\1740 morphological_30\JJ\1740 alterations_31\NNS\7283608 observed_32\VBN\2163746 ._33\.\1740
D010100_D009202 NONE the_0\DT\1740 mechanism_1\NN\13446390 of_2\IN\1740 isoproterenol-induced_3\JJ\1740 <e2>myocardial_4\JJ\1740 damage</e2>_5\NN\7296428 is_6\VBZ\836236 unknown_7\JJ\1740 ,_8\,\1740 but_9\CC\1740 a_10\DT\13649268 mismatch_11\NN\5695806 of_12\IN\1740 <e1>oxygen</e1>_13\NN\14622893 supply_14\NN\13576355 vs._15\CC\1740 demand_16\NN\6513366 following_17\VBG\1835496 coronary_18\JJ\1740 hypotension_19\NN\14057371 and_20\CC\1740 myocardial_21\JJ\1740 hyperactivity_22\NN\14052403 is_23\VBZ\836236 the_24\DT\1740 best_25\JJS\1740 explanation_26\NN\6722453 for_27\IN\1740 the_28\DT\1740 complex_29\JJ\1740 morphological_30\JJ\1740 alterations_31\NNS\7283608 observed_32\VBN\2163746 ._33\.\1740
D010100_D009202 NONE the_0\DT\1740 mechanism_1\NN\13446390 of_2\IN\1740 isoproterenol-induced_3\JJ\1740 myocardial_4\JJ\1740 damage_5\NN\7296428 is_6\VBZ\836236 unknown_7\JJ\1740 ,_8\,\1740 but_9\CC\1740 a_10\DT\13649268 mismatch_11\NN\5695806 of_12\IN\1740 <e1>oxygen</e1>_13\NN\14622893 supply_14\NN\13576355 vs._15\CC\1740 demand_16\NN\6513366 following_17\VBG\1835496 coronary_18\JJ\1740 hypotension_19\NN\14057371 and_20\CC\1740 <e2>myocardial_21\JJ\1740 hyperactivity</e2>_22\NN\14052403 is_23\VBZ\836236 the_24\DT\1740 best_25\JJS\1740 explanation_26\NN\6722453 for_27\IN\1740 the_28\DT\1740 complex_29\JJ\1740 morphological_30\JJ\1740 alterations_31\NNS\7283608 observed_32\VBN\2163746 ._33\.\1740
D010100_D007022 NONE the_0\DT\1740 mechanism_1\NN\13446390 of_2\IN\1740 isoproterenol-induced_3\JJ\1740 myocardial_4\JJ\1740 damage_5\NN\7296428 is_6\VBZ\836236 unknown_7\JJ\1740 ,_8\,\1740 but_9\CC\1740 a_10\DT\13649268 mismatch_11\NN\5695806 of_12\IN\1740 <e1>oxygen</e1>_13\NN\14622893 supply_14\NN\13576355 vs._15\CC\1740 demand_16\NN\6513366 following_17\VBG\1835496 coronary_18\JJ\1740 <e2>hypotension</e2>_19\NN\14057371 and_20\CC\1740 myocardial_21\JJ\1740 hyperactivity_22\NN\14052403 is_23\VBZ\836236 the_24\DT\1740 best_25\JJS\1740 explanation_26\NN\6722453 for_27\IN\1740 the_28\DT\1740 complex_29\JJ\1740 morphological_30\JJ\1740 alterations_31\NNS\7283608 observed_32\VBN\2163746 ._33\.\1740
D007545_D007511 CID these_0\DT\1740 changes_1\NNS\7283608 ,_2\,\1740 related_3\JJ\1740 to_4\TO\1740 <e2>ischaemic_5\JJ\1740 injury</e2>_6\NN\14052046 ,_7\,\1740 explain_8\VB\831651 the_9\DT\1740 severe_10\JJ\1740 alterations_11\NNS\7283608 in_12\IN\13603305 the_13\DT\1740 structural_14\JJ\1740 integrity_15\NN\24720 of_16\IN\1740 the_17\DT\1740 sarcolemma_18\NN\5426243 of_19\IN\1740 cardiomyocytes_20\NNS\1740 and_21\CC\1740 hence_22\RB\1740 severe_23\JJ\1740 and_24\CC\1740 irreversible_25\JJ\1740 injury_26\NN\14052046 induced_27\VBN\1627355 by_28\IN\1740 <e1>isoproterenol</e1>_29\NN\3740161 ._30\.\1740
9952311
D004317_D028361 CID <e2>structural_0\JJ\1740 and_1\CC\1740 functional_2\JJ\1740 impairment_3\NN\7296428 of_4\IN\1740 mitochondria</e2>_5\NN\5445668 in_6\IN\13603305 <e1>adriamycin-induced</e1>_7\JJ\1740 cardiomyopathy_8\JJ\1740 in_9\IN\13603305 mice_10\NNS\2329401 :_11\:\1740 suppression_12\NN\13489037 of_13\IN\1740 cytochrome_14\NN\14888884 c_15\NN\13714184 oxidase_16\NN\14732946 ii_17\CD\13741022 gene_18\NN\8459252 expression_19\NN\4679549 ._20\.\1740
D004317_D028361 CID knowing_0\VBG\2110220 that_1\IN\1740 heart_2\NN\5919034 mitochondria_3\NN\5445668 represent_4\VB\2664769 almost_5\RB\1740 40_6\CD\13745420 %_7\NN\1740 of_8\IN\1740 heart_9\NN\5919034 muscle_10\NN\5289601 by_11\IN\1740 weight_12\NN\5009170 ,_13\,\1740 we_14\PRP\1740 conclude_15\VBP\628491 that_16\IN\1740 the_17\DT\1740 deteriorating_18\VBG\208836 effects_19\NNS\13245626 of_20\IN\1740 <e1>adr</e1>_21\NN\1740 on_22\IN\1740 cardiovascular_23\JJ\1740 function_24\NN\13783581 involve_25\VBP\2676054 <e2>mitochondrial_26\JJ\1740 structural_27\JJ\1740 and_28\CC\1740 functional_29\JJ\1740 impairment</e2>_30\NN\7296428 ._31\.\1740
D004317_D009202 NONE structural_0\JJ\1740 and_1\CC\1740 functional_2\JJ\1740 impairment_3\NN\7296428 of_4\IN\1740 mitochondria_5\NN\5445668 in_6\IN\13603305 <e1>adriamycin-induced</e1>_7\JJ\1740 <e2>cardiomyopathy</e2>_8\JJ\1740 in_9\IN\13603305 mice_10\NNS\2329401 :_11\:\1740 suppression_12\NN\13489037 of_13\IN\1740 cytochrome_14\NN\14888884 c_15\NN\13714184 oxidase_16\NN\14732946 ii_17\CD\13741022 gene_18\NN\8459252 expression_19\NN\4679549 ._20\.\1740
D004317_D009369 NONE the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 <e1>adriamycin</e1>_3\NN\1740 (_4\-LRB-\1740 adr_5\NN\1740 )_6\-RRB-\1740 in_7\IN\13603305 <e2>cancer</e2>_8\NN\14239425 chemotherapy_9\NN\661091 has_10\VBZ\2108377 been_11\VBN\836236 limited_12\VBN\2510337 due_13\IN\5174653 to_14\TO\1740 its_15\PRP$\6125041 cumulative_16\JJ\1740 cardiovascular_17\JJ\1740 toxicity_18\NN\13576101 ._19\.\1740
D004317_D009369 NONE the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 adriamycin_3\NN\1740 (_4\-LRB-\1740 <e1>adr</e1>_5\NN\1740 )_6\-RRB-\1740 in_7\IN\13603305 <e2>cancer</e2>_8\NN\14239425 chemotherapy_9\NN\661091 has_10\VBZ\2108377 been_11\VBN\836236 limited_12\VBN\2510337 due_13\IN\5174653 to_14\TO\1740 its_15\PRP$\6125041 cumulative_16\JJ\1740 cardiovascular_17\JJ\1740 toxicity_18\NN\13576101 ._19\.\1740
D004317_D002318 NONE the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 <e1>adriamycin</e1>_3\NN\1740 (_4\-LRB-\1740 adr_5\NN\1740 )_6\-RRB-\1740 in_7\IN\13603305 cancer_8\NN\14239425 chemotherapy_9\NN\661091 has_10\VBZ\2108377 been_11\VBN\836236 limited_12\VBN\2510337 due_13\IN\5174653 to_14\TO\1740 its_15\PRP$\6125041 cumulative_16\JJ\1740 <e2>cardiovascular_17\JJ\1740 toxicity</e2>_18\NN\13576101 ._19\.\1740
D004317_D002318 NONE the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 adriamycin_3\NN\1740 (_4\-LRB-\1740 <e1>adr</e1>_5\NN\1740 )_6\-RRB-\1740 in_7\IN\13603305 cancer_8\NN\14239425 chemotherapy_9\NN\661091 has_10\VBZ\2108377 been_11\VBN\836236 limited_12\VBN\2510337 due_13\IN\5174653 to_14\TO\1740 its_15\PRP$\6125041 cumulative_16\JJ\1740 <e2>cardiovascular_17\JJ\1740 toxicity</e2>_18\NN\13576101 ._19\.\1740
D004317_D001145 NONE our_0\PRP$\1740 results_1\NNS\34213 indicated_2\VBD\952524 that_3\IN\1740 1_4\LS\13741022 )_5\-RRB-\1740 treatment_6\NN\654885 of_7\IN\1740 mice_8\NNS\2329401 with_9\IN\1740 <e1>adr</e1>_10\NN\1740 caused_11\VBD\1617192 <e2>cardiovascular_12\JJ\1740 arrhythmias</e2>_13\NNS\14103288 characterized_14\VBN\609683 by_15\IN\1740 bradycardia_16\NN\14110674 ,_17\,\1740 extension_18\NN\15272029 of_19\IN\1740 ventricular_20\JJ\1740 depolarization_21\NN\11412727 time_22\NN\7308889 (_23\-LRB-\1740 tqrs_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 failure_28\NN\66216 of_29\IN\1740 qrs_30\NN\1740 at_31\IN\14622893 high_32\JJ\1740 concentrations_33\NNS\4916342 (_34\-LRB-\1740 10_35\CD\13745420 -_36\SYM\1740 14_37\CD\13745420 mg/kg_38\NN\1740 body_39\NN\19128 weight_40\NN\5009170 cumulative_41\JJ\1740 dose_42\NN\3740161 )_43\-RRB-\1740 ;_44\:\1740 2_45\LS\13741022 )_46\-RRB-\1740 the_47\DT\1740 heart_48\NN\5919034 mitochondria_49\NN\5445668 underwent_50\VBD\109660 swelling_51\NN\14315071 ,_52\,\1740 fusion_53\NN\7373277 ,_54\,\1740 dissolution_55\NN\13518963 ,_56\,\1740 and/or_57\CC\1740 disruption_58\NN\1066163 of_59\IN\1740 mitochondrial_60\JJ\1740 cristae_61\NN\1740 after_62\IN\1740 several_63\JJ\1740 weeks_64\NNS\15113229 of_65\IN\1740 treatment_66\NN\654885 ._67\.\1740
D004317_D001919 CID our_0\PRP$\1740 results_1\NNS\34213 indicated_2\VBD\952524 that_3\IN\1740 1_4\LS\13741022 )_5\-RRB-\1740 treatment_6\NN\654885 of_7\IN\1740 mice_8\NNS\2329401 with_9\IN\1740 <e1>adr</e1>_10\NN\1740 caused_11\VBD\1617192 cardiovascular_12\JJ\1740 arrhythmias_13\NNS\14103288 characterized_14\VBN\609683 by_15\IN\1740 <e2>bradycardia</e2>_16\NN\14110674 ,_17\,\1740 extension_18\NN\15272029 of_19\IN\1740 ventricular_20\JJ\1740 depolarization_21\NN\11412727 time_22\NN\7308889 (_23\-LRB-\1740 tqrs_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 failure_28\NN\66216 of_29\IN\1740 qrs_30\NN\1740 at_31\IN\14622893 high_32\JJ\1740 concentrations_33\NNS\4916342 (_34\-LRB-\1740 10_35\CD\13745420 -_36\SYM\1740 14_37\CD\13745420 mg/kg_38\NN\1740 body_39\NN\19128 weight_40\NN\5009170 cumulative_41\JJ\1740 dose_42\NN\3740161 )_43\-RRB-\1740 ;_44\:\1740 2_45\LS\13741022 )_46\-RRB-\1740 the_47\DT\1740 heart_48\NN\5919034 mitochondria_49\NN\5445668 underwent_50\VBD\109660 swelling_51\NN\14315071 ,_52\,\1740 fusion_53\NN\7373277 ,_54\,\1740 dissolution_55\NN\13518963 ,_56\,\1740 and/or_57\CC\1740 disruption_58\NN\1066163 of_59\IN\1740 mitochondrial_60\JJ\1740 cristae_61\NN\1740 after_62\IN\1740 several_63\JJ\1740 weeks_64\NNS\15113229 of_65\IN\1740 treatment_66\NN\654885 ._67\.\1740
D004317_D004487 NONE our_0\PRP$\1740 results_1\NNS\34213 indicated_2\VBD\952524 that_3\IN\1740 1_4\LS\13741022 )_5\-RRB-\1740 treatment_6\NN\654885 of_7\IN\1740 mice_8\NNS\2329401 with_9\IN\1740 <e1>adr</e1>_10\NN\1740 caused_11\VBD\1617192 cardiovascular_12\JJ\1740 arrhythmias_13\NNS\14103288 characterized_14\VBN\609683 by_15\IN\1740 bradycardia_16\NN\14110674 ,_17\,\1740 extension_18\NN\15272029 of_19\IN\1740 ventricular_20\JJ\1740 depolarization_21\NN\11412727 time_22\NN\7308889 (_23\-LRB-\1740 tqrs_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 and_27\CC\1740 failure_28\NN\66216 of_29\IN\1740 qrs_30\NN\1740 at_31\IN\14622893 high_32\JJ\1740 concentrations_33\NNS\4916342 (_34\-LRB-\1740 10_35\CD\13745420 -_36\SYM\1740 14_37\CD\13745420 mg/kg_38\NN\1740 body_39\NN\19128 weight_40\NN\5009170 cumulative_41\JJ\1740 dose_42\NN\3740161 )_43\-RRB-\1740 ;_44\:\1740 2_45\LS\13741022 )_46\-RRB-\1740 the_47\DT\1740 heart_48\NN\5919034 mitochondria_49\NN\5445668 underwent_50\VBD\109660 <e2>swelling</e2>_51\NN\14315071 ,_52\,\1740 fusion_53\NN\7373277 ,_54\,\1740 dissolution_55\NN\13518963 ,_56\,\1740 and/or_57\CC\1740 disruption_58\NN\1066163 of_59\IN\1740 mitochondrial_60\JJ\1740 cristae_61\NN\1740 after_62\IN\1740 several_63\JJ\1740 weeks_64\NNS\15113229 of_65\IN\1740 treatment_66\NN\654885 ._67\.\1740
10523326
D009569_D006973 NONE <e1>nitric_0\JJ\1740 oxide</e1>_1\NN\14818238 synthase_2\NN\1740 expression_3\NN\4679549 in_4\IN\13603305 the_5\DT\1740 course_6\NN\883297 of_7\IN\1740 lead-induced_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 ._10\.\1740
D009569_D006973 NONE we_0\PRP\1740 recently_1\RB\1740 showed_2\VBD\2137132 elevated_3\JJ\1740 reactive_4\JJ\1740 oxygen_5\NN\14622893 species_6\NNS\7992450 (_7\-LRB-\1740 ros_8\NN\6894544 )_9\-RRB-\1740 ,_10\,\1740 reduced_11\VBD\441445 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 <e1>no</e1>_15\DT\7204911 metabolites_16\NNS\20090 (_17\-LRB-\1740 nox_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 and_21\CC\1740 increased_22\VBD\169651 no_23\NN\7204911 sequestration_24\NN\1201021 as_25\IN\14622893 nitrotyrosine_26\NN\1740 in_27\IN\13603305 various_28\JJ\1740 tissues_29\NNS\5220461 in_30\IN\13603305 rats_31\NNS\2329401 with_32\IN\1740 lead-induced_33\JJ\1740 <e2>hypertension</e2>_34\NN\14057371 ._35\.\1740
D009569_D006973 NONE we_0\PRP\1740 recently_1\RB\1740 showed_2\VBD\2137132 elevated_3\JJ\1740 reactive_4\JJ\1740 oxygen_5\NN\14622893 species_6\NNS\7992450 (_7\-LRB-\1740 ros_8\NN\6894544 )_9\-RRB-\1740 ,_10\,\1740 reduced_11\VBD\441445 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 no_15\DT\7204911 metabolites_16\NNS\20090 (_17\-LRB-\1740 nox_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 and_21\CC\1740 increased_22\VBD\169651 <e1>no</e1>_23\NN\7204911 sequestration_24\NN\1201021 as_25\IN\14622893 nitrotyrosine_26\NN\1740 in_27\IN\13603305 various_28\JJ\1740 tissues_29\NNS\5220461 in_30\IN\13603305 rats_31\NNS\2329401 with_32\IN\1740 lead-induced_33\JJ\1740 <e2>hypertension</e2>_34\NN\14057371 ._35\.\1740
D009569_D006973 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 discern_5\VB\1740 whether_6\IN\1740 the_7\DT\1740 reduction_8\NN\351485 in_9\IN\13603305 urinary_10\JJ\1740 nox_11\NN\1740 in_12\IN\13603305 lead-induced_13\JJ\1740 <e2>hypertension</e2>_14\NN\14057371 is_15\VBZ\836236 ,_16\,\1740 in_17\IN\13603305 part_18\NN\31921 ,_19\,\1740 due_20\JJ\1740 to_21\TO\1740 depressed_22\JJ\1740 <e1>no</e1>_23\NN\7204911 synthase_24\NN\1740 (_25\-LRB-\1740 nos_26\NN\7204911 )_27\-RRB-\1740 expression_28\NN\4679549 ._29\.\1740
D009569_D006973 NONE this_0\DT\1740 is_1\VBZ\836236 ,_2\,\1740 in_3\IN\13603305 part_4\NN\31921 ,_5\,\1740 due_6\JJ\1740 to_7\TO\1740 ros-mediated_8\JJ\1740 <e1>no</e1>_9\NN\7204911 inactivation_10\NN\13518963 ,_11\,\1740 lead-associated_12\JJ\1740 inhibition_13\NN\1068773 of_14\IN\1740 nos_15\NN\7204911 activity_16\NN\30358 ,_17\,\1740 and_18\CC\1740 perhaps_19\RB\1740 stimulatory_20\JJ\1740 actions_21\NNS\30358 of_22\IN\1740 increased_23\VBN\169651 shear_24\NN\7358060 stress_25\NN\7083732 associated_26\VBN\628491 with_27\IN\1740 <e2>hypertension</e2>_28\NN\14057371 ._29\.\1740
D007854_D006973 CID nitric_0\JJ\1740 oxide_1\NN\14818238 synthase_2\NN\1740 expression_3\NN\4679549 in_4\IN\13603305 the_5\DT\1740 course_6\NN\883297 of_7\IN\1740 <e1>lead-induced</e1>_8\JJ\1740 <e2>hypertension</e2>_9\NN\14057371 ._10\.\1740
D007854_D006973 CID we_0\PRP\1740 recently_1\RB\1740 showed_2\VBD\2137132 elevated_3\JJ\1740 reactive_4\JJ\1740 oxygen_5\NN\14622893 species_6\NNS\7992450 (_7\-LRB-\1740 ros_8\NN\6894544 )_9\-RRB-\1740 ,_10\,\1740 reduced_11\VBD\441445 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 no_15\DT\7204911 metabolites_16\NNS\20090 (_17\-LRB-\1740 nox_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 and_21\CC\1740 increased_22\VBD\169651 no_23\NN\7204911 sequestration_24\NN\1201021 as_25\IN\14622893 nitrotyrosine_26\NN\1740 in_27\IN\13603305 various_28\JJ\1740 tissues_29\NNS\5220461 in_30\IN\13603305 rats_31\NNS\2329401 with_32\IN\1740 <e1>lead-induced</e1>_33\JJ\1740 <e2>hypertension</e2>_34\NN\14057371 ._35\.\1740
D007854_D006973 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 discern_5\VB\1740 whether_6\IN\1740 the_7\DT\1740 reduction_8\NN\351485 in_9\IN\13603305 urinary_10\JJ\1740 nox_11\NN\1740 in_12\IN\13603305 <e1>lead-induced</e1>_13\JJ\1740 <e2>hypertension</e2>_14\NN\14057371 is_15\VBZ\836236 ,_16\,\1740 in_17\IN\13603305 part_18\NN\31921 ,_19\,\1740 due_20\JJ\1740 to_21\TO\1740 depressed_22\JJ\1740 no_23\NN\7204911 synthase_24\NN\1740 (_25\-LRB-\1740 nos_26\NN\7204911 )_27\-RRB-\1740 expression_28\NN\4679549 ._29\.\1740
D007854_D006973 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 <e1>lead-induced</e1>_3\JJ\1740 <e2>hypertension</e2>_4\NN\14057371 in_5\IN\13603305 this_6\DT\1740 model_7\NN\5888929 was_8\VBD\836236 associated_9\VBN\628491 with_10\IN\1740 a_11\DT\13649268 compensatory_12\JJ\1740 upregulation_13\NN\1740 of_14\IN\1740 renal_15\JJ\1740 and_16\CC\1740 vascular_17\JJ\1740 enos_18\NN\1740 and_19\CC\1740 inos_20\NN\1740 expression_21\NN\4679549 ._22\.\1740
D007854_D006973 CID this_0\DT\1740 is_1\VBZ\836236 ,_2\,\1740 in_3\IN\13603305 part_4\NN\31921 ,_5\,\1740 due_6\JJ\1740 to_7\TO\1740 ros-mediated_8\JJ\1740 no_9\NN\7204911 inactivation_10\NN\13518963 ,_11\,\1740 <e1>lead-associated</e1>_12\JJ\1740 inhibition_13\NN\1068773 of_14\IN\1740 nos_15\NN\7204911 activity_16\NN\30358 ,_17\,\1740 and_18\CC\1740 perhaps_19\RB\1740 stimulatory_20\JJ\1740 actions_21\NNS\30358 of_22\IN\1740 increased_23\VBN\169651 shear_24\NN\7358060 stress_25\NN\7083732 associated_26\VBN\628491 with_27\IN\1740 <e2>hypertension</e2>_28\NN\14057371 ._29\.\1740
D010100_D006973 NONE we_0\PRP\1740 recently_1\RB\1740 showed_2\VBD\2137132 elevated_3\JJ\1740 reactive_4\JJ\1740 <e1>oxygen</e1>_5\NN\14622893 species_6\NNS\7992450 (_7\-LRB-\1740 ros_8\NN\6894544 )_9\-RRB-\1740 ,_10\,\1740 reduced_11\VBD\441445 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 no_15\DT\7204911 metabolites_16\NNS\20090 (_17\-LRB-\1740 nox_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 and_21\CC\1740 increased_22\VBD\169651 no_23\NN\7204911 sequestration_24\NN\1201021 as_25\IN\14622893 nitrotyrosine_26\NN\1740 in_27\IN\13603305 various_28\JJ\1740 tissues_29\NNS\5220461 in_30\IN\13603305 rats_31\NNS\2329401 with_32\IN\1740 lead-induced_33\JJ\1740 <e2>hypertension</e2>_34\NN\14057371 ._35\.\1740
C002744_D006973 NONE we_0\PRP\1740 recently_1\RB\1740 showed_2\VBD\2137132 elevated_3\JJ\1740 reactive_4\JJ\1740 oxygen_5\NN\14622893 species_6\NNS\7992450 (_7\-LRB-\1740 ros_8\NN\6894544 )_9\-RRB-\1740 ,_10\,\1740 reduced_11\VBD\441445 urinary_12\JJ\1740 excretion_13\NN\13466586 of_14\IN\1740 no_15\DT\7204911 metabolites_16\NNS\20090 (_17\-LRB-\1740 nox_18\NN\1740 )_19\-RRB-\1740 ,_20\,\1740 and_21\CC\1740 increased_22\VBD\169651 no_23\NN\7204911 sequestration_24\NN\1201021 as_25\IN\14622893 <e1>nitrotyrosine</e1>_26\NN\1740 in_27\IN\13603305 various_28\JJ\1740 tissues_29\NNS\5220461 in_30\IN\13603305 rats_31\NNS\2329401 with_32\IN\1740 lead-induced_33\JJ\1740 <e2>hypertension</e2>_34\NN\14057371 ._35\.\1740
D014810_D006973 NONE <e1>vitamin_0\NN\7570720 e</e1>_1\NN\14724645 supplementation_2\NN\5108947 ameliorated_3\VBD\126264 <e2>hypertension</e2>_4\NN\14057371 ,_5\,\1740 lowered_6\JJ\1740 plasma_7\NN\5398023 mda_8\NN\1740 concentration_9\NN\4916342 ,_10\,\1740 and_11\CC\1740 raised_12\VBD\153263 urinary_13\JJ\1740 nox_14\NN\1740 excretion_15\NN\13466586 while_16\IN\15122231 significantly_17\RB\1740 lowering_18\VBG\1850315 vascular_19\JJ\1740 ,_20\,\1740 but_21\CC\1740 not_22\RB\1740 renal_23\JJ\1740 ,_24\,\1740 tissue_25\NN\5220461 enos_26\NN\1740 and_27\CC\1740 inos_28\NN\1740 expression_29\NN\4679549 ._30\.\1740
D008315_D006973 NONE vitamin_0\NN\7570720 e_1\NN\14724645 supplementation_2\NN\5108947 ameliorated_3\VBD\126264 <e2>hypertension</e2>_4\NN\14057371 ,_5\,\1740 lowered_6\JJ\1740 plasma_7\NN\5398023 <e1>mda</e1>_8\NN\1740 concentration_9\NN\4916342 ,_10\,\1740 and_11\CC\1740 raised_12\VBD\153263 urinary_13\JJ\1740 nox_14\NN\1740 excretion_15\NN\13466586 while_16\IN\15122231 significantly_17\RB\1740 lowering_18\VBG\1850315 vascular_19\JJ\1740 ,_20\,\1740 but_21\CC\1740 not_22\RB\1740 renal_23\JJ\1740 ,_24\,\1740 tissue_25\NN\5220461 enos_26\NN\1740 and_27\CC\1740 inos_28\NN\1740 expression_29\NN\4679549 ._30\.\1740
1610717
D003042_D012640 CID <e1>cocaine-induced</e1>_0\JJ\1740 brainstem_1\NN\5462674 <e2>seizures</e2>_2\NNS\14081375 and_3\CC\1740 behavior_4\NN\407535 ._5\.\1740
783197
D010042_D003324 NONE effects_0\NNS\13245626 of_1\IN\1740 <e1>ouabain</e1>_2\NN\1740 on_3\IN\1740 myocardial_4\JJ\1740 oxygen_5\NN\14622893 supply_6\NN\13576355 and_7\CC\1740 demand_8\NN\6513366 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 chronic_12\JJ\1740 <e2>coronary_13\JJ\1740 artery_14\NN\5417975 disease</e2>_15\NN\14061805 ._16\.\1740
D010042_D003324 NONE we_0\PRP\1740 assessed_1\VBD\670261 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>ouabain</e1>_5\NN\1740 (_6\-LRB-\1740 0.015_7\CD\1740 mg/kg_8\NN\1740 body_9\NN\19128 weight_10\NN\5009170 )_11\-RRB-\1740 on_12\IN\1740 hemodynamic_13\JJ\1740 ,_14\,\1740 volumetric_15\JJ\1740 ,_16\,\1740 and_17\CC\1740 metabolic_18\JJ\1740 parameters_19\NNS\5858936 in_20\IN\13603305 11_21\CD\13745420 patients_22\NNS\9898892 with_23\IN\1740 severe_24\JJ\1740 chronic_25\JJ\1740 <e2>coronary_26\JJ\1740 artery_27\NN\5417975 disease</e2>_28\NN\14061805 without_29\IN\1740 clinical_30\JJ\1740 congestive_31\JJ\1740 heart_32\NN\5919034 failure_33\NN\66216 ._34\.\1740
D010042_D003324 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 chronic_6\JJ\1740 <e2>coronary_7\JJ\1740 artery_8\NN\5417975 disease</e2>_9\NN\14061805 who_10\WP\8299493 are_11\VBP\836236 not_12\RB\1740 in_13\IN\13603305 clinical_14\JJ\1740 congestive_15\JJ\1740 heart_16\NN\5919034 failure_17\NN\66216 left_18\VBD\120316 ventricular_19\JJ\1740 end-diastolic_20\JJ\1740 volume_21\NN\33615 falls_22\VBZ\1835496 after_23\IN\1740 <e1>ouabain</e1>_24\NN\1740 administration_25\NN\1133281 even_26\RB\1740 when_27\WRB\1740 it_28\PRP\6125041 is_29\VBZ\836236 initially_30\RB\1740 normal_31\JJ\1740 ._32\.\1740
D010100_D003324 NONE effects_0\NNS\13245626 of_1\IN\1740 ouabain_2\NN\1740 on_3\IN\1740 myocardial_4\JJ\1740 <e1>oxygen</e1>_5\NN\14622893 supply_6\NN\13576355 and_7\CC\1740 demand_8\NN\6513366 in_9\IN\13603305 patients_10\NNS\9898892 with_11\IN\1740 chronic_12\JJ\1740 <e2>coronary_13\JJ\1740 artery_14\NN\5417975 disease</e2>_15\NN\14061805 ._16\.\1740
D010100_D003324 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 digitalis_3\NN\15059939 glycosides_4\NNS\14727670 on_5\IN\1740 myocardial_6\JJ\1740 <e1>oxygen</e1>_7\NN\14622893 supply_8\NN\13576355 and_9\CC\1740 demand_10\NN\6513366 are_11\VBP\836236 of_12\IN\1740 particular_13\JJ\1740 interest_14\NN\5682570 in_15\IN\13603305 the_16\DT\1740 presence_17\NN\13954253 of_18\IN\1740 obstructive_19\JJ\1740 <e2>coronary_20\JJ\1740 artery_21\NN\5417975 disease</e2>_22\NN\14061805 ,_23\,\1740 but_24\CC\1740 have_25\VBP\2108377 not_26\RB\1740 been_27\VBN\836236 measured_28\VBN\697589 previously_29\RB\1740 in_30\IN\13603305 man_31\NN\9605289 ._32\.\1740
D004071_D003324 NONE the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>digitalis_3\NN\15059939 glycosides</e1>_4\NNS\14727670 on_5\IN\1740 myocardial_6\JJ\1740 oxygen_7\NN\14622893 supply_8\NN\13576355 and_9\CC\1740 demand_10\NN\6513366 are_11\VBP\836236 of_12\IN\1740 particular_13\JJ\1740 interest_14\NN\5682570 in_15\IN\13603305 the_16\DT\1740 presence_17\NN\13954253 of_18\IN\1740 obstructive_19\JJ\1740 <e2>coronary_20\JJ\1740 artery_21\NN\5417975 disease</e2>_22\NN\14061805 ,_23\,\1740 but_24\CC\1740 have_25\VBP\2108377 not_26\RB\1740 been_27\VBN\836236 measured_28\VBN\697589 previously_29\RB\1740 in_30\IN\13603305 man_31\NN\9605289 ._32\.\1740
D010042_D006333 NONE we_0\PRP\1740 assessed_1\VBD\670261 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>ouabain</e1>_5\NN\1740 (_6\-LRB-\1740 0.015_7\CD\1740 mg/kg_8\NN\1740 body_9\NN\19128 weight_10\NN\5009170 )_11\-RRB-\1740 on_12\IN\1740 hemodynamic_13\JJ\1740 ,_14\,\1740 volumetric_15\JJ\1740 ,_16\,\1740 and_17\CC\1740 metabolic_18\JJ\1740 parameters_19\NNS\5858936 in_20\IN\13603305 11_21\CD\13745420 patients_22\NNS\9898892 with_23\IN\1740 severe_24\JJ\1740 chronic_25\JJ\1740 coronary_26\JJ\1740 artery_27\NN\5417975 disease_28\NN\14061805 without_29\IN\1740 clinical_30\JJ\1740 <e2>congestive_31\JJ\1740 heart_32\NN\5919034 failure</e2>_33\NN\66216 ._34\.\1740
D010042_D006333 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 chronic_6\JJ\1740 coronary_7\JJ\1740 artery_8\NN\5417975 disease_9\NN\14061805 who_10\WP\8299493 are_11\VBP\836236 not_12\RB\1740 in_13\IN\13603305 clinical_14\JJ\1740 <e2>congestive_15\JJ\1740 heart_16\NN\5919034 failure</e2>_17\NN\66216 left_18\VBD\120316 ventricular_19\JJ\1740 end-diastolic_20\JJ\1740 volume_21\NN\33615 falls_22\VBZ\1835496 after_23\IN\1740 <e1>ouabain</e1>_24\NN\1740 administration_25\NN\1133281 even_26\RB\1740 when_27\WRB\1740 it_28\PRP\6125041 is_29\VBZ\836236 initially_30\RB\1740 normal_31\JJ\1740 ._32\.\1740
D010042_D002303 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 in_3\IN\13603305 patients_4\NNS\9898892 with_5\IN\1740 chronic_6\JJ\1740 coronary_7\JJ\1740 artery_8\NN\5417975 disease_9\NN\14061805 who_10\WP\8299493 are_11\VBP\836236 not_12\RB\1740 in_13\IN\13603305 clinical_14\JJ\1740 congestive_15\JJ\1740 heart_16\NN\5919034 failure_17\NN\66216 <e2>left_18\VBD\120316 ventricular_19\JJ\1740 end-diastolic_20\JJ\1740 volume_21\NN\33615 falls</e2>_22\VBZ\1835496 after_23\IN\1740 <e1>ouabain</e1>_24\NN\1740 administration_25\NN\1133281 even_26\RB\1740 when_27\WRB\1740 it_28\PRP\6125041 is_29\VBZ\836236 initially_30\RB\1740 normal_31\JJ\1740 ._32\.\1740
2893236
D005680_D012133 NONE <e1>gaba</e1>_0\NN\14601829 involvement_1\NN\1080366 in_2\IN\13603305 naloxone_3\NN\3808977 induced_4\VBN\1627355 reversal_5\NN\199130 of_6\IN\1740 <e2>respiratory_7\JJ\1740 paralysis</e2>_8\NN\14557898 produced_9\VBN\1617192 by_10\IN\1740 thiopental_11\NN\2792049 ._12\.\1740
D005680_D012133 NONE naloxone_0\NN\3808977 (_1\-LRB-\1740 2.5_2\CD\1740 mg/kg_3\NN\1740 ,_4\,\1740 i.v._5\NN\1740 )_6\-RRB-\1740 reversed_7\VBN\109660 <e2>respiratory_8\JJ\1740 paralysis</e2>_9\NN\14557898 ,_10\,\1740 glutamate_11\NN\15010703 and_12\CC\1740 <e1>gaba</e1>_13\NN\14601829 levels_14\NNS\4916342 to_15\TO\1740 control_16\NN\5190804 values_17\NNS\5941423 in_18\IN\13603305 brain_19\NN\5462674 stem_20\NN\6290637 and_21\CC\1740 cortex_22\NN\5462674 with_23\IN\1740 no_24\DT\7204911 changes_25\NNS\7283608 in_26\IN\13603305 caudate_27\NN\5497363 or_28\CC\3541091 cerebellum_29\NN\5462674 ._30\.\1740
D005680_D012133 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 naloxone_3\NN\3808977 reverses_4\VBZ\109660 <e2>respiratory_5\JJ\1740 paralysis</e2>_6\NN\14557898 produced_7\VBN\1617192 by_8\IN\1740 thiopental_9\NN\2792049 and_10\CC\1740 involves_11\VBZ\2676054 <e1>gaba</e1>_12\NN\14601829 in_13\IN\13603305 its_14\PRP$\6125041 action_15\NN\30358 ._16\.\1740
D009270_D012133 NONE gaba_0\NN\14601829 involvement_1\NN\1080366 in_2\IN\13603305 <e1>naloxone</e1>_3\NN\3808977 induced_4\VBN\1627355 reversal_5\NN\199130 of_6\IN\1740 <e2>respiratory_7\JJ\1740 paralysis</e2>_8\NN\14557898 produced_9\VBN\1617192 by_10\IN\1740 thiopental_11\NN\2792049 ._12\.\1740
D009270_D012133 NONE in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 <e1>naloxone</e1>_3\NN\3808977 reversed_4\VBD\109660 <e2>respiratory_5\JJ\1740 paralysis</e2>_6\NN\14557898 induced_7\VBN\1627355 by_8\IN\1740 thiopental_9\NN\2792049 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D009270_D012133 NONE <e1>naloxone</e1>_0\NN\3808977 (_1\-LRB-\1740 2.5_2\CD\1740 mg/kg_3\NN\1740 ,_4\,\1740 i.v._5\NN\1740 )_6\-RRB-\1740 reversed_7\VBN\109660 <e2>respiratory_8\JJ\1740 paralysis</e2>_9\NN\14557898 ,_10\,\1740 glutamate_11\NN\15010703 and_12\CC\1740 gaba_13\NN\14601829 levels_14\NNS\4916342 to_15\TO\1740 control_16\NN\5190804 values_17\NNS\5941423 in_18\IN\13603305 brain_19\NN\5462674 stem_20\NN\6290637 and_21\CC\1740 cortex_22\NN\5462674 with_23\IN\1740 no_24\DT\7204911 changes_25\NNS\7283608 in_26\IN\13603305 caudate_27\NN\5497363 or_28\CC\3541091 cerebellum_29\NN\5462674 ._30\.\1740
D009270_D012133 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 <e1>naloxone</e1>_3\NN\3808977 reverses_4\VBZ\109660 <e2>respiratory_5\JJ\1740 paralysis</e2>_6\NN\14557898 produced_7\VBN\1617192 by_8\IN\1740 thiopental_9\NN\2792049 and_10\CC\1740 involves_11\VBZ\2676054 gaba_12\NN\14601829 in_13\IN\13603305 its_14\PRP$\6125041 action_15\NN\30358 ._16\.\1740
D013874_D012133 CID gaba_0\NN\14601829 involvement_1\NN\1080366 in_2\IN\13603305 naloxone_3\NN\3808977 induced_4\VBN\1627355 reversal_5\NN\199130 of_6\IN\1740 <e2>respiratory_7\JJ\1740 paralysis</e2>_8\NN\14557898 produced_9\VBN\1617192 by_10\IN\1740 <e1>thiopental</e1>_11\NN\2792049 ._12\.\1740
D013874_D012133 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 naloxone_3\NN\3808977 reversed_4\VBD\109660 <e2>respiratory_5\JJ\1740 paralysis</e2>_6\NN\14557898 induced_7\VBN\1627355 by_8\IN\1740 <e1>thiopental</e1>_9\NN\2792049 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D013874_D012133 CID these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 naloxone_3\NN\3808977 reverses_4\VBZ\109660 <e2>respiratory_5\JJ\1740 paralysis</e2>_6\NN\14557898 produced_7\VBN\1617192 by_8\IN\1740 <e1>thiopental</e1>_9\NN\2792049 and_10\CC\1740 involves_11\VBZ\2676054 gaba_12\NN\14601829 in_13\IN\13603305 its_14\PRP$\6125041 action_15\NN\30358 ._16\.\1740
D013874_D012131 NONE 50_0\CD\13745420 mg/kg_1\NN\1740 ,_2\,\1740 i.v._3\NN\1740 <e1>thiopental</e1>_4\NN\2792049 produced_5\VBN\1617192 <e2>respiratory_6\JJ\1740 arrest</e2>_7\NN\88481 with_8\IN\1740 further_9\JJ\1740 increase_10\NN\13576355 in_11\IN\13603305 gaba_12\NN\14601829 and_13\CC\1740 decrease_14\VB\169651 in_15\IN\13603305 glutamate_16\NN\15010703 again_17\RB\1740 in_18\IN\13603305 cortex_19\NN\5462674 and_20\CC\1740 brain_21\NN\5462674 stem_22\NN\6290637 without_23\IN\1740 affecting_24\VBG\126264 any_25\DT\1740 of_26\IN\1740 the_27\DT\1740 amino_28\NN\14621446 acids_29\NNS\14818238 studied_30\VBN\630380 in_31\IN\13603305 four_32\CD\13741022 regions_33\NNS\27167 of_34\IN\1740 rat_35\NN\2329401 brain_36\NN\5462674 ._37\.\1740
D005680_D012131 NONE 50_0\CD\13745420 mg/kg_1\NN\1740 ,_2\,\1740 i.v._3\NN\1740 thiopental_4\NN\2792049 produced_5\VBN\1617192 <e2>respiratory_6\JJ\1740 arrest</e2>_7\NN\88481 with_8\IN\1740 further_9\JJ\1740 increase_10\NN\13576355 in_11\IN\13603305 <e1>gaba</e1>_12\NN\14601829 and_13\CC\1740 decrease_14\VB\169651 in_15\IN\13603305 glutamate_16\NN\15010703 again_17\RB\1740 in_18\IN\13603305 cortex_19\NN\5462674 and_20\CC\1740 brain_21\NN\5462674 stem_22\NN\6290637 without_23\IN\1740 affecting_24\VBG\126264 any_25\DT\1740 of_26\IN\1740 the_27\DT\1740 amino_28\NN\14621446 acids_29\NNS\14818238 studied_30\VBN\630380 in_31\IN\13603305 four_32\CD\13741022 regions_33\NNS\27167 of_34\IN\1740 rat_35\NN\2329401 brain_36\NN\5462674 ._37\.\1740
D018698_D012131 NONE 50_0\CD\13745420 mg/kg_1\NN\1740 ,_2\,\1740 i.v._3\NN\1740 thiopental_4\NN\2792049 produced_5\VBN\1617192 <e2>respiratory_6\JJ\1740 arrest</e2>_7\NN\88481 with_8\IN\1740 further_9\JJ\1740 increase_10\NN\13576355 in_11\IN\13603305 gaba_12\NN\14601829 and_13\CC\1740 decrease_14\VB\169651 in_15\IN\13603305 <e1>glutamate</e1>_16\NN\15010703 again_17\RB\1740 in_18\IN\13603305 cortex_19\NN\5462674 and_20\CC\1740 brain_21\NN\5462674 stem_22\NN\6290637 without_23\IN\1740 affecting_24\VBG\126264 any_25\DT\1740 of_26\IN\1740 the_27\DT\1740 amino_28\NN\14621446 acids_29\NNS\14818238 studied_30\VBN\630380 in_31\IN\13603305 four_32\CD\13741022 regions_33\NNS\27167 of_34\IN\1740 rat_35\NN\2329401 brain_36\NN\5462674 ._37\.\1740
D000596_D012131 NONE 50_0\CD\13745420 mg/kg_1\NN\1740 ,_2\,\1740 i.v._3\NN\1740 thiopental_4\NN\2792049 produced_5\VBN\1617192 <e2>respiratory_6\JJ\1740 arrest</e2>_7\NN\88481 with_8\IN\1740 further_9\JJ\1740 increase_10\NN\13576355 in_11\IN\13603305 gaba_12\NN\14601829 and_13\CC\1740 decrease_14\VB\169651 in_15\IN\13603305 glutamate_16\NN\15010703 again_17\RB\1740 in_18\IN\13603305 cortex_19\NN\5462674 and_20\CC\1740 brain_21\NN\5462674 stem_22\NN\6290637 without_23\IN\1740 affecting_24\VBG\126264 any_25\DT\1740 of_26\IN\1740 the_27\DT\1740 <e1>amino_28\NN\14621446 acids</e1>_29\NNS\14818238 studied_30\VBN\630380 in_31\IN\13603305 four_32\CD\13741022 regions_33\NNS\27167 of_34\IN\1740 rat_35\NN\2329401 brain_36\NN\5462674 ._37\.\1740
D018698_D012133 NONE naloxone_0\NN\3808977 (_1\-LRB-\1740 2.5_2\CD\1740 mg/kg_3\NN\1740 ,_4\,\1740 i.v._5\NN\1740 )_6\-RRB-\1740 reversed_7\VBN\109660 <e2>respiratory_8\JJ\1740 paralysis</e2>_9\NN\14557898 ,_10\,\1740 <e1>glutamate</e1>_11\NN\15010703 and_12\CC\1740 gaba_13\NN\14601829 levels_14\NNS\4916342 to_15\TO\1740 control_16\NN\5190804 values_17\NNS\5941423 in_18\IN\13603305 brain_19\NN\5462674 stem_20\NN\6290637 and_21\CC\1740 cortex_22\NN\5462674 with_23\IN\1740 no_24\DT\7204911 changes_25\NNS\7283608 in_26\IN\13603305 caudate_27\NN\5497363 or_28\CC\3541091 cerebellum_29\NN\5462674 ._30\.\1740
8677458
D015080_D006470 CID continuous_0\JJ\1740 subcutaneous_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 <e1>mesna</e1>_4\NN\1740 to_5\TO\1740 prevent_6\VB\1740 ifosfamide-induced_7\JJ\1740 <e2>hemorrhagic_8\JJ\1740 cystitis</e2>_9\NN\14566129 ._10\.\1740
D015080_D006470 CID <e2>hemorrhagic_0\JJ\1740 cystitis</e2>_1\NN\14566129 is_2\VBZ\836236 a_3\DT\13649268 major_4\JJ\1740 potential_5\JJ\1740 toxicity_6\NN\13576101 of_7\IN\1740 ifosfamide_8\NN\1740 that_9\WDT\1740 can_10\MD\3094503 be_11\VB\836236 prevented_12\VBN\1740 by_13\IN\1740 administering_14\VBG\2436349 <e1>mesna</e1>_15\NN\1740 along_16\IN\1740 with_17\IN\1740 the_18\DT\1740 cytotoxic_19\JJ\1740 agent_20\NN\7347 ._21\.\1740
D015080_D003556 CID continuous_0\JJ\1740 subcutaneous_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 <e1>mesna</e1>_4\NN\1740 to_5\TO\1740 prevent_6\VB\1740 ifosfamide-induced_7\JJ\1740 <e2>hemorrhagic_8\JJ\1740 cystitis</e2>_9\NN\14566129 ._10\.\1740
D015080_D003556 CID <e2>hemorrhagic_0\JJ\1740 cystitis</e2>_1\NN\14566129 is_2\VBZ\836236 a_3\DT\13649268 major_4\JJ\1740 potential_5\JJ\1740 toxicity_6\NN\13576101 of_7\IN\1740 ifosfamide_8\NN\1740 that_9\WDT\1740 can_10\MD\3094503 be_11\VB\836236 prevented_12\VBN\1740 by_13\IN\1740 administering_14\VBG\2436349 <e1>mesna</e1>_15\NN\1740 along_16\IN\1740 with_17\IN\1740 the_18\DT\1740 cytotoxic_19\JJ\1740 agent_20\NN\7347 ._21\.\1740
D007069_D006470 CID continuous_0\JJ\1740 subcutaneous_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 mesna_4\NN\1740 to_5\TO\1740 prevent_6\VB\1740 <e1>ifosfamide-induced</e1>_7\JJ\1740 <e2>hemorrhagic_8\JJ\1740 cystitis</e2>_9\NN\14566129 ._10\.\1740
D007069_D006470 CID <e2>hemorrhagic_0\JJ\1740 cystitis</e2>_1\NN\14566129 is_2\VBZ\836236 a_3\DT\13649268 major_4\JJ\1740 potential_5\JJ\1740 toxicity_6\NN\13576101 of_7\IN\1740 <e1>ifosfamide</e1>_8\NN\1740 that_9\WDT\1740 can_10\MD\3094503 be_11\VB\836236 prevented_12\VBN\1740 by_13\IN\1740 administering_14\VBG\2436349 mesna_15\NN\1740 along_16\IN\1740 with_17\IN\1740 the_18\DT\1740 cytotoxic_19\JJ\1740 agent_20\NN\7347 ._21\.\1740
D007069_D003556 CID continuous_0\JJ\1740 subcutaneous_1\JJ\1740 administration_2\NN\1133281 of_3\IN\1740 mesna_4\NN\1740 to_5\TO\1740 prevent_6\VB\1740 <e1>ifosfamide-induced</e1>_7\JJ\1740 <e2>hemorrhagic_8\JJ\1740 cystitis</e2>_9\NN\14566129 ._10\.\1740
D007069_D003556 CID <e2>hemorrhagic_0\JJ\1740 cystitis</e2>_1\NN\14566129 is_2\VBZ\836236 a_3\DT\13649268 major_4\JJ\1740 potential_5\JJ\1740 toxicity_6\NN\13576101 of_7\IN\1740 <e1>ifosfamide</e1>_8\NN\1740 that_9\WDT\1740 can_10\MD\3094503 be_11\VB\836236 prevented_12\VBN\1740 by_13\IN\1740 administering_14\VBG\2436349 mesna_15\NN\1740 along_16\IN\1740 with_17\IN\1740 the_18\DT\1740 cytotoxic_19\JJ\1740 agent_20\NN\7347 ._21\.\1740
D007069_D064420 NONE hemorrhagic_0\JJ\1740 cystitis_1\NN\14566129 is_2\VBZ\836236 a_3\DT\13649268 major_4\JJ\1740 potential_5\JJ\1740 <e2>toxicity</e2>_6\NN\13576101 of_7\IN\1740 <e1>ifosfamide</e1>_8\NN\1740 that_9\WDT\1740 can_10\MD\3094503 be_11\VB\836236 prevented_12\VBN\1740 by_13\IN\1740 administering_14\VBG\2436349 mesna_15\NN\1740 along_16\IN\1740 with_17\IN\1740 the_18\DT\1740 cytotoxic_19\JJ\1740 agent_20\NN\7347 ._21\.\1740
D015080_D064420 NONE hemorrhagic_0\JJ\1740 cystitis_1\NN\14566129 is_2\VBZ\836236 a_3\DT\13649268 major_4\JJ\1740 potential_5\JJ\1740 <e2>toxicity</e2>_6\NN\13576101 of_7\IN\1740 ifosfamide_8\NN\1740 that_9\WDT\1740 can_10\MD\3094503 be_11\VB\836236 prevented_12\VBN\1740 by_13\IN\1740 administering_14\VBG\2436349 <e1>mesna</e1>_15\NN\1740 along_16\IN\1740 with_17\IN\1740 the_18\DT\1740 cytotoxic_19\JJ\1740 agent_20\NN\7347 ._21\.\1740
D015080_D014839 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 subcutaneous_3\JJ\1740 delivery_4\NN\315986 of_5\IN\1740 the_6\DT\1740 neutralizing_7\VBG\126264 agent_8\NN\7347 will_9\MD\5650329 not_10\RB\1740 be_11\VB\836236 associated_12\VBN\628491 with_13\IN\1740 the_14\DT\1740 risk_15\NN\14541044 of_16\IN\1740 inadequate_17\JJ\1740 urinary_18\JJ\1740 <e1>mesna</e1>_19\NN\1740 concentrations_20\NNS\4916342 ,_21\,\1740 such_22\JJ\1740 as_23\IN\14622893 in_24\IN\13603305 a_25\DT\13649268 patient_26\NN\9898892 taking_27\VBG\2367363 oral_28\JJ\1740 mesna_29\NN\1740 who_30\WP\8299493 experiences_31\VBZ\2108377 severe_32\JJ\1740 ifosfamide-induced_33\JJ\1740 <e2>emesis</e2>_34\NN\116687 and_35\CC\1740 is_36\VBZ\836236 unable_37\JJ\1740 to_38\TO\1740 absorb_39\VB\1540449 the_40\DT\1740 drug_41\NN\14778436 ._42\.\1740
D015080_D014839 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 subcutaneous_3\JJ\1740 delivery_4\NN\315986 of_5\IN\1740 the_6\DT\1740 neutralizing_7\VBG\126264 agent_8\NN\7347 will_9\MD\5650329 not_10\RB\1740 be_11\VB\836236 associated_12\VBN\628491 with_13\IN\1740 the_14\DT\1740 risk_15\NN\14541044 of_16\IN\1740 inadequate_17\JJ\1740 urinary_18\JJ\1740 mesna_19\NN\1740 concentrations_20\NNS\4916342 ,_21\,\1740 such_22\JJ\1740 as_23\IN\14622893 in_24\IN\13603305 a_25\DT\13649268 patient_26\NN\9898892 taking_27\VBG\2367363 oral_28\JJ\1740 <e1>mesna</e1>_29\NN\1740 who_30\WP\8299493 experiences_31\VBZ\2108377 severe_32\JJ\1740 ifosfamide-induced_33\JJ\1740 <e2>emesis</e2>_34\NN\116687 and_35\CC\1740 is_36\VBZ\836236 unable_37\JJ\1740 to_38\TO\1740 absorb_39\VB\1540449 the_40\DT\1740 drug_41\NN\14778436 ._42\.\1740
D007069_D014839 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 subcutaneous_3\JJ\1740 delivery_4\NN\315986 of_5\IN\1740 the_6\DT\1740 neutralizing_7\VBG\126264 agent_8\NN\7347 will_9\MD\5650329 not_10\RB\1740 be_11\VB\836236 associated_12\VBN\628491 with_13\IN\1740 the_14\DT\1740 risk_15\NN\14541044 of_16\IN\1740 inadequate_17\JJ\1740 urinary_18\JJ\1740 mesna_19\NN\1740 concentrations_20\NNS\4916342 ,_21\,\1740 such_22\JJ\1740 as_23\IN\14622893 in_24\IN\13603305 a_25\DT\13649268 patient_26\NN\9898892 taking_27\VBG\2367363 oral_28\JJ\1740 mesna_29\NN\1740 who_30\WP\8299493 experiences_31\VBZ\2108377 severe_32\JJ\1740 <e1>ifosfamide-induced</e1>_33\JJ\1740 <e2>emesis</e2>_34\NN\116687 and_35\CC\1740 is_36\VBZ\836236 unable_37\JJ\1740 to_38\TO\1740 absorb_39\VB\1540449 the_40\DT\1740 drug_41\NN\14778436 ._42\.\1740
3411101
C033457_D056486 CID <e1>quinidine_0\NN\2715941 phenylethylbarbiturate-induced</e1>_1\JJ\1740 fulminant_2\JJ\1740 <e2>hepatitis</e2>_3\NN\14127211 in_4\IN\13603305 a_5\DT\13649268 pregnant_6\JJ\1740 woman_7\NN\9605289 ._8\.\1740
C033457_D056486 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 19-year-old_6\JJ\1740 laotian_7\JJ\1740 patient_8\NN\9898892 affected_9\VBN\126264 by_10\IN\1740 fulminant_11\JJ\1740 <e2>hepatitis</e2>_12\NN\14127211 during_13\IN\1740 the_14\DT\1740 third_15\JJ\1740 trimester_16\NN\15113229 of_17\IN\1740 her_18\PRP$\1740 pregnancy_19\NN\14034177 after_20\IN\1740 a_21\DT\13649268 1-month_22\JJ\1740 administration_23\NN\1133281 of_24\IN\1740 <e1>quinidine_25\NN\2715941 phenylethylbarbiturate</e1>_26\JJ\1740 ._27\.\1740
C033457_D056486 CID quinidine_0\NN\2715941 itself_1\PRP\1740 or_2\CC\3541091 <e1>phenylethylbarbiturate</e1>_3\JJ\1740 may_4\MD\15209706 be_5\VB\836236 responsible_6\JJ\1740 for_7\IN\1740 fulminant_8\JJ\1740 <e2>hepatitis</e2>_9\NN\14127211 in_10\IN\13603305 this_11\DT\1740 patient_12\NN\9898892 ._13\.\1740
D011802_D056486 NONE <e1>quinidine</e1>_0\NN\2715941 itself_1\PRP\1740 or_2\CC\3541091 phenylethylbarbiturate_3\JJ\1740 may_4\MD\15209706 be_5\VB\836236 responsible_6\JJ\1740 for_7\IN\1740 fulminant_8\JJ\1740 <e2>hepatitis</e2>_9\NN\14127211 in_10\IN\13603305 this_11\DT\1740 patient_12\NN\9898892 ._13\.\1740
17943461
D015215_D009202 CID myocardial_0\JJ\1740 fas_1\NN\14304060 ligand_2\NN\20090 expression_3\NN\4679549 increases_4\VBZ\169651 susceptibility_5\NN\13920835 to_6\TO\1740 <e1>azt-induced</e1>_7\JJ\1740 <e2>cardiomyopathy</e2>_8\NN\14103288 ._9\.\1740
D015215_D002311 CID methods_0\NNS\5616786 and_1\CC\1740 results_2\NNS\34213 :_3\:\1740 in_4\IN\13603305 order_5\NN\7168131 to_6\TO\1740 investigate_7\VB\644583 whether_8\IN\1740 the_9\DT\1740 haart_10\NN\3740161 component_11\NN\5867413 <e1>zidovudine</e1>_12\NN\3834836 (_13\-LRB-\1740 3'-azido-2',3'-deoxythymidine_14\NN\1740 ;_15\:\1740 azt_16\NN\3834836 )_17\-RRB-\1740 triggers_18\VBZ\1641914 the_19\DT\1740 fas-dependent_20\JJ\1740 cell-death_21\NN\1740 pathway_22\NN\5483677 and_23\CC\1740 cause_24\VB\1617192 cytoskeletal_25\JJ\1740 disruption_26\NN\1066163 in_27\IN\13603305 a_28\DT\13649268 murine_29\JJ\1740 model_30\NN\5888929 of_31\IN\1740 <e2>dcm</e2>_32\NN\1740 ,_33\,\1740 8-week-old_34\JJ\1740 transgenic_35\JJ\1740 (_36\-LRB-\1740 expressing_37\VBG\928630 fas_38\NN\14304060 ligand_39\NN\20090 in_40\IN\13603305 the_41\DT\1740 myocardium_42\NN\5389939 :_43\:\1740 fasl_44\NN\1740 tg_45\NN\1740 )_46\-RRB-\1740 and_47\CC\1740 non-transgenic_48\JJ\1740 (_49\-LRB-\1740 ntg_50\NN\1740 )_51\-RRB-\1740 mice_52\NNS\2329401 received_53\VBD\2210855 water_54\NN\14618834 ad_55\NN\7247071 libitum_56\NN\1740 containing_57\VBG\2632940 different_58\JJ\1740 concentrations_59\NNS\4916342 of_60\IN\1740 azt_61\NN\3834836 (_62\-LRB-\1740 0_63\CD\13741022 ,_64\,\1740 0.07_65\CD\1740 ,_66\,\1740 0.2_67\CD\1740 ,_68\,\1740 and_69\CC\1740 0.7_70\CD\1740 mg/ml_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D015215_D002311 CID methods_0\NNS\5616786 and_1\CC\1740 results_2\NNS\34213 :_3\:\1740 in_4\IN\13603305 order_5\NN\7168131 to_6\TO\1740 investigate_7\VB\644583 whether_8\IN\1740 the_9\DT\1740 haart_10\NN\3740161 component_11\NN\5867413 zidovudine_12\NN\3834836 (_13\-LRB-\1740 <e1>3'-azido-2',3'-deoxythymidine</e1>_14\NN\1740 ;_15\:\1740 azt_16\NN\3834836 )_17\-RRB-\1740 triggers_18\VBZ\1641914 the_19\DT\1740 fas-dependent_20\JJ\1740 cell-death_21\NN\1740 pathway_22\NN\5483677 and_23\CC\1740 cause_24\VB\1617192 cytoskeletal_25\JJ\1740 disruption_26\NN\1066163 in_27\IN\13603305 a_28\DT\13649268 murine_29\JJ\1740 model_30\NN\5888929 of_31\IN\1740 <e2>dcm</e2>_32\NN\1740 ,_33\,\1740 8-week-old_34\JJ\1740 transgenic_35\JJ\1740 (_36\-LRB-\1740 expressing_37\VBG\928630 fas_38\NN\14304060 ligand_39\NN\20090 in_40\IN\13603305 the_41\DT\1740 myocardium_42\NN\5389939 :_43\:\1740 fasl_44\NN\1740 tg_45\NN\1740 )_46\-RRB-\1740 and_47\CC\1740 non-transgenic_48\JJ\1740 (_49\-LRB-\1740 ntg_50\NN\1740 )_51\-RRB-\1740 mice_52\NNS\2329401 received_53\VBD\2210855 water_54\NN\14618834 ad_55\NN\7247071 libitum_56\NN\1740 containing_57\VBG\2632940 different_58\JJ\1740 concentrations_59\NNS\4916342 of_60\IN\1740 azt_61\NN\3834836 (_62\-LRB-\1740 0_63\CD\13741022 ,_64\,\1740 0.07_65\CD\1740 ,_66\,\1740 0.2_67\CD\1740 ,_68\,\1740 and_69\CC\1740 0.7_70\CD\1740 mg/ml_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D015215_D002311 CID methods_0\NNS\5616786 and_1\CC\1740 results_2\NNS\34213 :_3\:\1740 in_4\IN\13603305 order_5\NN\7168131 to_6\TO\1740 investigate_7\VB\644583 whether_8\IN\1740 the_9\DT\1740 haart_10\NN\3740161 component_11\NN\5867413 zidovudine_12\NN\3834836 (_13\-LRB-\1740 3'-azido-2',3'-deoxythymidine_14\NN\1740 ;_15\:\1740 <e1>azt</e1>_16\NN\3834836 )_17\-RRB-\1740 triggers_18\VBZ\1641914 the_19\DT\1740 fas-dependent_20\JJ\1740 cell-death_21\NN\1740 pathway_22\NN\5483677 and_23\CC\1740 cause_24\VB\1617192 cytoskeletal_25\JJ\1740 disruption_26\NN\1066163 in_27\IN\13603305 a_28\DT\13649268 murine_29\JJ\1740 model_30\NN\5888929 of_31\IN\1740 <e2>dcm</e2>_32\NN\1740 ,_33\,\1740 8-week-old_34\JJ\1740 transgenic_35\JJ\1740 (_36\-LRB-\1740 expressing_37\VBG\928630 fas_38\NN\14304060 ligand_39\NN\20090 in_40\IN\13603305 the_41\DT\1740 myocardium_42\NN\5389939 :_43\:\1740 fasl_44\NN\1740 tg_45\NN\1740 )_46\-RRB-\1740 and_47\CC\1740 non-transgenic_48\JJ\1740 (_49\-LRB-\1740 ntg_50\NN\1740 )_51\-RRB-\1740 mice_52\NNS\2329401 received_53\VBD\2210855 water_54\NN\14618834 ad_55\NN\7247071 libitum_56\NN\1740 containing_57\VBG\2632940 different_58\JJ\1740 concentrations_59\NNS\4916342 of_60\IN\1740 azt_61\NN\3834836 (_62\-LRB-\1740 0_63\CD\13741022 ,_64\,\1740 0.07_65\CD\1740 ,_66\,\1740 0.2_67\CD\1740 ,_68\,\1740 and_69\CC\1740 0.7_70\CD\1740 mg/ml_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D015215_D002311 CID methods_0\NNS\5616786 and_1\CC\1740 results_2\NNS\34213 :_3\:\1740 in_4\IN\13603305 order_5\NN\7168131 to_6\TO\1740 investigate_7\VB\644583 whether_8\IN\1740 the_9\DT\1740 haart_10\NN\3740161 component_11\NN\5867413 zidovudine_12\NN\3834836 (_13\-LRB-\1740 3'-azido-2',3'-deoxythymidine_14\NN\1740 ;_15\:\1740 azt_16\NN\3834836 )_17\-RRB-\1740 triggers_18\VBZ\1641914 the_19\DT\1740 fas-dependent_20\JJ\1740 cell-death_21\NN\1740 pathway_22\NN\5483677 and_23\CC\1740 cause_24\VB\1617192 cytoskeletal_25\JJ\1740 disruption_26\NN\1066163 in_27\IN\13603305 a_28\DT\13649268 murine_29\JJ\1740 model_30\NN\5888929 of_31\IN\1740 <e2>dcm</e2>_32\NN\1740 ,_33\,\1740 8-week-old_34\JJ\1740 transgenic_35\JJ\1740 (_36\-LRB-\1740 expressing_37\VBG\928630 fas_38\NN\14304060 ligand_39\NN\20090 in_40\IN\13603305 the_41\DT\1740 myocardium_42\NN\5389939 :_43\:\1740 fasl_44\NN\1740 tg_45\NN\1740 )_46\-RRB-\1740 and_47\CC\1740 non-transgenic_48\JJ\1740 (_49\-LRB-\1740 ntg_50\NN\1740 )_51\-RRB-\1740 mice_52\NNS\2329401 received_53\VBD\2210855 water_54\NN\14618834 ad_55\NN\7247071 libitum_56\NN\1740 containing_57\VBG\2632940 different_58\JJ\1740 concentrations_59\NNS\4916342 of_60\IN\1740 <e1>azt</e1>_61\NN\3834836 (_62\-LRB-\1740 0_63\CD\13741022 ,_64\,\1740 0.07_65\CD\1740 ,_66\,\1740 0.2_67\CD\1740 ,_68\,\1740 and_69\CC\1740 0.7_70\CD\1740 mg/ml_71\NN\1740 )_72\-RRB-\1740 ._73\.\1740
D015215_D002311 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 <e1>azt-treated</e1>_3\JJ\1740 fasl_4\NN\1740 tg_5\NN\1740 mice_6\NNS\2329401 developed_7\VBD\1753788 <e2>cardiac_8\JJ\1740 dilation</e2>_9\NN\7138085 and_10\CC\1740 depressed_11\JJ\1740 cardiac_12\JJ\1740 function_13\NN\13783581 in_14\IN\13603305 a_15\DT\13649268 dose-dependent_16\JJ\1740 manner_17\NN\4916342 ,_18\,\1740 with_19\IN\1740 concomitant_20\JJ\1740 inflammatory_21\JJ\1740 infiltration_22\NN\975452 of_23\IN\1740 both_24\DT\1740 ventricles_25\NNS\5303402 ._26\.\1740
11027904
D008691_D010146 NONE <e2>pain</e2>_0\NN\14299637 responses_1\NNS\11410625 in_2\IN\13603305 <e1>methadone-maintained</e1>_3\JJ\1740 opioid_4\NN\1740 abusers_5\NNS\9633969 ._6\.\1740
D008691_D010146 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 describe_5\VB\1001294 <e2>pain</e2>_6\NN\14299637 tolerance_7\NN\5032565 and_8\CC\1740 analgesic_9\JJ\1740 response_10\NN\11410625 in_11\IN\13603305 a_12\DT\13649268 sample_13\NN\5820620 of_14\IN\1740 opioid_15\NN\1740 addicts_16\NNS\10059582 stabilized_17\VBD\126264 in_18\IN\13603305 <e1>methadone-maintenance</e1>_19\NN\1740 (_20\-LRB-\1740 mm_21\NN\13649268 )_22\-RRB-\1740 treatment_23\NN\654885 (_24\-LRB-\1740 n_25\NN\14622893 =_26\JJ\1740 60_27\CD\13745420 )_28\-RRB-\1740 in_29\IN\13603305 comparison_30\NN\635850 to_31\TO\1740 matched_32\VBN\2664769 nondependent_33\JJ\1740 control_34\JJ\1740 subjects_35\NNS\6598915 (_36\-LRB-\1740 n_37\NN\14622893 =_38\JJ\1740 60_39\CD\13745420 )_40\-RRB-\1740 ._41\.\1740
D008691_D009293 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 designed_3\VBN\1631534 to_4\TO\1740 describe_5\VB\1001294 pain_6\NN\14299637 tolerance_7\NN\5032565 and_8\CC\1740 analgesic_9\JJ\1740 response_10\NN\11410625 in_11\IN\13603305 a_12\DT\13649268 sample_13\NN\5820620 of_14\IN\1740 <e2>opioid_15\NN\1740 addicts</e2>_16\NNS\10059582 stabilized_17\VBD\126264 in_18\IN\13603305 <e1>methadone-maintenance</e1>_19\NN\1740 (_20\-LRB-\1740 mm_21\NN\13649268 )_22\-RRB-\1740 treatment_23\NN\654885 (_24\-LRB-\1740 n_25\NN\14622893 =_26\JJ\1740 60_27\CD\13745420 )_28\-RRB-\1740 in_29\IN\13603305 comparison_30\NN\635850 to_31\TO\1740 matched_32\VBN\2664769 nondependent_33\JJ\1740 control_34\JJ\1740 subjects_35\NNS\6598915 (_36\-LRB-\1740 n_37\NN\14622893 =_38\JJ\1740 60_39\CD\13745420 )_40\-RRB-\1740 ._41\.\1740
D004091_D010146 NONE by_0\IN\1740 using_1\VBG\1156834 a_2\DT\13649268 placebo-controlled_3\JJ\1740 ,_4\,\1740 two-way_5\JJ\1740 factorial_6\JJ\1740 design_7\NN\927261 ,_8\,\1740 tolerance_9\NN\5032565 to_10\TO\1740 cold-pressor_11\NN\1740 (_12\-LRB-\1740 cp_13\NN\1740 )_14\-RRB-\1740 <e2>pain</e2>_15\NN\14299637 was_16\VBD\836236 examined_17\VBN\789138 ,_18\,\1740 both_19\CC\1740 before_20\IN\1740 and_21\CC\1740 after_22\IN\1740 oral_23\JJ\1740 administration_24\NN\1133281 of_25\IN\1740 therapeutic_26\JJ\1740 doses_27\NNS\3740161 of_28\IN\1740 common_29\JJ\1740 opioid_30\NN\1740 (_31\-LRB-\1740 <e1>hydromorphone</e1>_32\NN\2707683 2_33\CD\13741022 mg_34\NN\13717155 )_35\-RRB-\1740 and_36\CC\1740 nonsteroidal_37\JJ\1740 anti-inflammatory_38\JJ\1740 (_39\-LRB-\1740 ketorolac_40\NN\3828465 10_41\CD\13745420 mg_42\NN\13717155 )_43\-RRB-\1740 analgesic_44\NN\3740161 agents_45\NNS\7347 ._46\.\1740
D020910_D010146 NONE by_0\IN\1740 using_1\VBG\1156834 a_2\DT\13649268 placebo-controlled_3\JJ\1740 ,_4\,\1740 two-way_5\JJ\1740 factorial_6\JJ\1740 design_7\NN\927261 ,_8\,\1740 tolerance_9\NN\5032565 to_10\TO\1740 cold-pressor_11\NN\1740 (_12\-LRB-\1740 cp_13\NN\1740 )_14\-RRB-\1740 <e2>pain</e2>_15\NN\14299637 was_16\VBD\836236 examined_17\VBN\789138 ,_18\,\1740 both_19\CC\1740 before_20\IN\1740 and_21\CC\1740 after_22\IN\1740 oral_23\JJ\1740 administration_24\NN\1133281 of_25\IN\1740 therapeutic_26\JJ\1740 doses_27\NNS\3740161 of_28\IN\1740 common_29\JJ\1740 opioid_30\NN\1740 (_31\-LRB-\1740 hydromorphone_32\NN\2707683 2_33\CD\13741022 mg_34\NN\13717155 )_35\-RRB-\1740 and_36\CC\1740 nonsteroidal_37\JJ\1740 anti-inflammatory_38\JJ\1740 (_39\-LRB-\1740 <e1>ketorolac</e1>_40\NN\3828465 10_41\CD\13745420 mg_42\NN\13717155 )_43\-RRB-\1740 analgesic_44\NN\3740161 agents_45\NNS\7347 ._46\.\1740
11705128
D012254_D000743 CID management_0\NN\1123598 strategies_1\NNS\5902545 for_2\IN\1740 <e1>ribavirin-induced</e1>_3\JJ\1740 <e2>hemolytic_4\JJ\1740 anemia</e2>_5\NN\14189204 in_6\IN\13603305 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 hepatitis_10\NN\14127211 c_11\NN\13714184 :_12\:\1740 clinical_13\JJ\1740 and_14\CC\1740 economic_15\JJ\1740 implications_16\NNS\5774614 ._17\.\1740
D012254_D000743 CID combination_0\NN\7951464 therapy_1\NN\657604 is_2\VBZ\836236 associated_3\VBN\628491 with_4\IN\1740 a_5\DT\13649268 clinically_6\RB\1740 important_7\JJ\1740 adverse_8\JJ\1740 effect_9\NN\34213 :_10\:\1740 <e1>ribavirin-induced</e1>_11\JJ\1740 <e2>hemolytic_12\JJ\1740 anemia</e2>_13\NN\14189204 (_14\-LRB-\1740 riha_15\NN\1740 )_16\-RRB-\1740 ._17\.\1740
D012254_D000743 CID combination_0\NN\7951464 therapy_1\NN\657604 is_2\VBZ\836236 associated_3\VBN\628491 with_4\IN\1740 a_5\DT\13649268 clinically_6\RB\1740 important_7\JJ\1740 adverse_8\JJ\1740 effect_9\NN\34213 :_10\:\1740 <e1>ribavirin-induced</e1>_11\JJ\1740 hemolytic_12\JJ\1740 anemia_13\NN\14189204 (_14\-LRB-\1740 <e2>riha</e2>_15\NN\1740 )_16\-RRB-\1740 ._17\.\1740
D012254_D000743 CID the_0\DT\1740 standard_1\NN\13577171 of_2\IN\1740 care_3\NN\575741 for_4\IN\1740 management_5\NN\1123598 of_6\IN\1740 <e2>riha</e2>_7\NN\1740 is_8\VBZ\836236 reduction_9\NN\351485 or_10\CC\3541091 discontinuation_11\NN\209943 of_12\IN\1740 the_13\DT\1740 <e1>ribavirin</e1>_14\NN\2725367 dosage_15\NN\13576355 ._16\.\1740
D012254_D000743 CID questions_0\NNS\7193184 remain_1\VBP\2604760 about_2\IN\1740 the_3\DT\1740 optimal_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 <e1>ribavirin</e1>_7\NN\2725367 and_8\CC\1740 the_9\DT\1740 incidence_10\NN\13821570 of_11\IN\1740 <e2>riha</e2>_12\NN\1740 in_13\IN\13603305 a_14\DT\13649268 real-world_15\JJ\1740 population_16\NN\7942152 ._17\.\1740
D012254_D006526 NONE management_0\NN\1123598 strategies_1\NNS\5902545 for_2\IN\1740 <e1>ribavirin-induced</e1>_3\JJ\1740 hemolytic_4\JJ\1740 anemia_5\NN\14189204 in_6\IN\13603305 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 <e2>hepatitis_10\NN\14127211 c</e2>_11\NN\13714184 :_12\:\1740 clinical_13\JJ\1740 and_14\CC\1740 economic_15\JJ\1740 implications_16\NNS\5774614 ._17\.\1740
D012254_D019698 NONE objectives_0\NNS\5980875 :_1\:\1740 recently_2\RB\1740 published_3\VBN\1621555 studies_4\NNS\635850 have_5\VBP\2108377 demonstrated_6\VBN\2137132 increased_7\VBN\169651 efficacy_8\NN\5199286 and_9\CC\1740 cost-effectiveness_10\NN\1740 of_11\IN\1740 combination_12\NN\7951464 therapy_13\NN\657604 with_14\IN\1740 interferon_15\NN\2725367 and_16\CC\1740 <e1>alpha-2b/ribavirin</e1>_17\NN\1740 compared_18\VBN\644583 with_19\IN\1740 interferon-alpha_20\NN\1740 monotherapy_21\NN\1740 in_22\IN\13603305 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 <e2>chronic_26\JJ\1740 hepatitis_27\NN\14127211 c</e2>_28\NN\13714184 (_29\-LRB-\1740 chc_30\NN\1740 )_31\-RRB-\1740 ._32\.\1740
D012254_D019698 NONE objectives_0\NNS\5980875 :_1\:\1740 recently_2\RB\1740 published_3\VBN\1621555 studies_4\NNS\635850 have_5\VBP\2108377 demonstrated_6\VBN\2137132 increased_7\VBN\169651 efficacy_8\NN\5199286 and_9\CC\1740 cost-effectiveness_10\NN\1740 of_11\IN\1740 combination_12\NN\7951464 therapy_13\NN\657604 with_14\IN\1740 interferon_15\NN\2725367 and_16\CC\1740 <e1>alpha-2b/ribavirin</e1>_17\NN\1740 compared_18\VBN\644583 with_19\IN\1740 interferon-alpha_20\NN\1740 monotherapy_21\NN\1740 in_22\IN\13603305 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 chronic_26\JJ\1740 hepatitis_27\NN\14127211 c_28\NN\13714184 (_29\-LRB-\1740 <e2>chc</e2>_30\NN\1740 )_31\-RRB-\1740 ._32\.\1740
D016898_D019698 NONE objectives_0\NNS\5980875 :_1\:\1740 recently_2\RB\1740 published_3\VBN\1621555 studies_4\NNS\635850 have_5\VBP\2108377 demonstrated_6\VBN\2137132 increased_7\VBN\169651 efficacy_8\NN\5199286 and_9\CC\1740 cost-effectiveness_10\NN\1740 of_11\IN\1740 combination_12\NN\7951464 therapy_13\NN\657604 with_14\IN\1740 interferon_15\NN\2725367 and_16\CC\1740 alpha-2b/ribavirin_17\NN\1740 compared_18\VBN\644583 with_19\IN\1740 <e1>interferon-alpha</e1>_20\NN\1740 monotherapy_21\NN\1740 in_22\IN\13603305 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 <e2>chronic_26\JJ\1740 hepatitis_27\NN\14127211 c</e2>_28\NN\13714184 (_29\-LRB-\1740 chc_30\NN\1740 )_31\-RRB-\1740 ._32\.\1740
D016898_D019698 NONE objectives_0\NNS\5980875 :_1\:\1740 recently_2\RB\1740 published_3\VBN\1621555 studies_4\NNS\635850 have_5\VBP\2108377 demonstrated_6\VBN\2137132 increased_7\VBN\169651 efficacy_8\NN\5199286 and_9\CC\1740 cost-effectiveness_10\NN\1740 of_11\IN\1740 combination_12\NN\7951464 therapy_13\NN\657604 with_14\IN\1740 interferon_15\NN\2725367 and_16\CC\1740 alpha-2b/ribavirin_17\NN\1740 compared_18\VBN\644583 with_19\IN\1740 <e1>interferon-alpha</e1>_20\NN\1740 monotherapy_21\NN\1740 in_22\IN\13603305 the_23\DT\1740 treatment_24\NN\654885 of_25\IN\1740 chronic_26\JJ\1740 hepatitis_27\NN\14127211 c_28\NN\13714184 (_29\-LRB-\1740 <e2>chc</e2>_30\NN\1740 )_31\-RRB-\1740 ._32\.\1740
17975693
D002939_D001008 CID results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 indicate_4\VBP\952524 that_5\IN\1740 <e1>ciprofloxacin-</e1>_6\NN\1740 and_7\CC\1740 norfloxacin-treated_8\JJ\1740 rats_9\NNS\2329401 showed_10\VBD\2137132 <e2>anxious_11\JJ\1740 behaviour</e2>_12\NN\14006945 in_13\IN\13603305 comparison_14\NN\635850 to_15\TO\1740 control_16\JJ\1740 rats_17\NNS\2329401 in_18\IN\13603305 all_19\PDT\1740 the_20\DT\1740 parameters_21\NNS\5858936 studied_22\VBN\630380 ._23\.\1740
D009643_D001008 CID results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 indicate_4\VBP\952524 that_5\IN\1740 ciprofloxacin-_6\NN\1740 and_7\CC\1740 <e1>norfloxacin-treated</e1>_8\JJ\1740 rats_9\NNS\2329401 showed_10\VBD\2137132 <e2>anxious_11\JJ\1740 behaviour</e2>_12\NN\14006945 in_13\IN\13603305 comparison_14\NN\635850 to_15\TO\1740 control_16\JJ\1740 rats_17\NNS\2329401 in_18\IN\13603305 all_19\PDT\1740 the_20\DT\1740 parameters_21\NNS\5858936 studied_22\VBN\630380 ._23\.\1740
18627295
D004317_D009202 CID <e1>doxorubicin</e1>_0\NN\2716866 <e2>cardiomyopathy-induced</e2>_1\JJ\1740 inflammation_2\NN\14299637 and_3\CC\1740 apoptosis_4\NN\11486178 are_5\VBP\836236 attenuated_6\VBN\224901 by_7\IN\1740 gene_8\NN\8459252 deletion_9\NN\13508333 of_10\IN\1740 the_11\DT\1740 kinin_12\NN\14744841 b1_13\NN\1740 receptor_14\NN\5225602 ._15\.\1740
D004317_D009202 CID to_0\TO\1740 elucidate_1\VB\939277 the_2\DT\1740 possible_3\JJ\1740 role_4\NN\719494 of_5\IN\1740 the_6\DT\1740 kinin_7\NN\14744841 b1_8\NN\1740 receptor_9\NN\5225602 (_10\-LRB-\1740 b1r_11\NN\1740 )_12\-RRB-\1740 during_13\IN\1740 the_14\DT\1740 development_15\NN\248977 of_16\IN\1740 <e1>dox</e1>_17\NN\1740 <e2>cardiomyopathy</e2>_18\IN\14103288 ,_19\,\1740 we_20\PRP\1740 studied_21\VBD\630380 b1r_22\NN\1740 knockout_23\JJ\1740 mice_24\NNS\2329401 (_25\-LRB-\1740 b1r(-/-_26\NN\1740 )_27\-RRB-\1740 )_28\-RRB-\1740 by_29\IN\1740 investigating_30\VBG\644583 cardiac_31\JJ\1740 inflammation_32\NN\14299637 and_33\CC\1740 apoptosis_34\NN\11486178 after_35\IN\1740 induction_36\NN\7450842 of_37\IN\1740 dox-induced_38\JJ\1740 cardiomyopathy_39\JJ\1740 ._40\.\1740
D004317_D009202 CID to_0\TO\1740 elucidate_1\VB\939277 the_2\DT\1740 possible_3\JJ\1740 role_4\NN\719494 of_5\IN\1740 the_6\DT\1740 kinin_7\NN\14744841 b1_8\NN\1740 receptor_9\NN\5225602 (_10\-LRB-\1740 b1r_11\NN\1740 )_12\-RRB-\1740 during_13\IN\1740 the_14\DT\1740 development_15\NN\248977 of_16\IN\1740 <e1>dox</e1>_17\NN\1740 cardiomyopathy_18\IN\14103288 ,_19\,\1740 we_20\PRP\1740 studied_21\VBD\630380 b1r_22\NN\1740 knockout_23\JJ\1740 mice_24\NNS\2329401 (_25\-LRB-\1740 b1r(-/-_26\NN\1740 )_27\-RRB-\1740 )_28\-RRB-\1740 by_29\IN\1740 investigating_30\VBG\644583 cardiac_31\JJ\1740 inflammation_32\NN\14299637 and_33\CC\1740 apoptosis_34\NN\11486178 after_35\IN\1740 induction_36\NN\7450842 of_37\IN\1740 dox-induced_38\JJ\1740 <e2>cardiomyopathy</e2>_39\JJ\1740 ._40\.\1740
D004317_D009202 CID to_0\TO\1740 elucidate_1\VB\939277 the_2\DT\1740 possible_3\JJ\1740 role_4\NN\719494 of_5\IN\1740 the_6\DT\1740 kinin_7\NN\14744841 b1_8\NN\1740 receptor_9\NN\5225602 (_10\-LRB-\1740 b1r_11\NN\1740 )_12\-RRB-\1740 during_13\IN\1740 the_14\DT\1740 development_15\NN\248977 of_16\IN\1740 dox_17\NN\1740 <e2>cardiomyopathy</e2>_18\IN\14103288 ,_19\,\1740 we_20\PRP\1740 studied_21\VBD\630380 b1r_22\NN\1740 knockout_23\JJ\1740 mice_24\NNS\2329401 (_25\-LRB-\1740 b1r(-/-_26\NN\1740 )_27\-RRB-\1740 )_28\-RRB-\1740 by_29\IN\1740 investigating_30\VBG\644583 cardiac_31\JJ\1740 inflammation_32\NN\14299637 and_33\CC\1740 apoptosis_34\NN\11486178 after_35\IN\1740 induction_36\NN\7450842 of_37\IN\1740 <e1>dox-induced</e1>_38\JJ\1740 cardiomyopathy_39\JJ\1740 ._40\.\1740
D004317_D009202 CID to_0\TO\1740 elucidate_1\VB\939277 the_2\DT\1740 possible_3\JJ\1740 role_4\NN\719494 of_5\IN\1740 the_6\DT\1740 kinin_7\NN\14744841 b1_8\NN\1740 receptor_9\NN\5225602 (_10\-LRB-\1740 b1r_11\NN\1740 )_12\-RRB-\1740 during_13\IN\1740 the_14\DT\1740 development_15\NN\248977 of_16\IN\1740 dox_17\NN\1740 cardiomyopathy_18\IN\14103288 ,_19\,\1740 we_20\PRP\1740 studied_21\VBD\630380 b1r_22\NN\1740 knockout_23\JJ\1740 mice_24\NNS\2329401 (_25\-LRB-\1740 b1r(-/-_26\NN\1740 )_27\-RRB-\1740 )_28\-RRB-\1740 by_29\IN\1740 investigating_30\VBG\644583 cardiac_31\JJ\1740 inflammation_32\NN\14299637 and_33\CC\1740 apoptosis_34\NN\11486178 after_35\IN\1740 induction_36\NN\7450842 of_37\IN\1740 <e1>dox-induced</e1>_38\JJ\1740 <e2>cardiomyopathy</e2>_39\JJ\1740 ._40\.\1740
D004317_D009202 CID these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 b1r_4\NN\1740 is_5\VBZ\836236 detrimental_6\JJ\1740 in_7\IN\13603305 <e1>dox</e1>_8\NN\1740 <e2>cardiomyopathy</e2>_9\JJ\1740 in_10\IN\13603305 that_11\IN\1740 it_12\PRP\6125041 mediates_13\VBZ\761713 the_14\DT\1740 inflammatory_15\JJ\1740 response_16\NN\11410625 and_17\CC\1740 apoptosis_18\NN\11486178 ._19\.\1740
D004317_D009202 CID these_0\DT\1740 insights_1\NNS\5710020 might_2\MD\5029706 have_3\VB\2108377 useful_4\JJ\1740 implications_5\NNS\5774614 for_6\IN\1740 future_7\JJ\1740 studies_8\NNS\635850 utilizing_9\VBG\161225 b1r_10\NN\1740 antagonists_11\NNS\7846 for_12\IN\1740 treatment_13\NN\654885 of_14\IN\1740 human_15\JJ\1740 <e1>dox</e1>_16\NN\1740 <e2>cardiomyopathy</e2>_17\JJ\1740 ._18\.\1740
D004317_D007249 NONE <e1>doxorubicin</e1>_0\NN\2716866 cardiomyopathy-induced_1\JJ\1740 <e2>inflammation</e2>_2\NN\14299637 and_3\CC\1740 apoptosis_4\NN\11486178 are_5\VBP\836236 attenuated_6\VBN\224901 by_7\IN\1740 gene_8\NN\8459252 deletion_9\NN\13508333 of_10\IN\1740 the_11\DT\1740 kinin_12\NN\14744841 b1_13\NN\1740 receptor_14\NN\5225602 ._15\.\1740
D004317_D007249 NONE to_0\TO\1740 elucidate_1\VB\939277 the_2\DT\1740 possible_3\JJ\1740 role_4\NN\719494 of_5\IN\1740 the_6\DT\1740 kinin_7\NN\14744841 b1_8\NN\1740 receptor_9\NN\5225602 (_10\-LRB-\1740 b1r_11\NN\1740 )_12\-RRB-\1740 during_13\IN\1740 the_14\DT\1740 development_15\NN\248977 of_16\IN\1740 <e1>dox</e1>_17\NN\1740 cardiomyopathy_18\IN\14103288 ,_19\,\1740 we_20\PRP\1740 studied_21\VBD\630380 b1r_22\NN\1740 knockout_23\JJ\1740 mice_24\NNS\2329401 (_25\-LRB-\1740 b1r(-/-_26\NN\1740 )_27\-RRB-\1740 )_28\-RRB-\1740 by_29\IN\1740 investigating_30\VBG\644583 cardiac_31\JJ\1740 <e2>inflammation</e2>_32\NN\14299637 and_33\CC\1740 apoptosis_34\NN\11486178 after_35\IN\1740 induction_36\NN\7450842 of_37\IN\1740 dox-induced_38\JJ\1740 cardiomyopathy_39\JJ\1740 ._40\.\1740
D004317_D007249 NONE to_0\TO\1740 elucidate_1\VB\939277 the_2\DT\1740 possible_3\JJ\1740 role_4\NN\719494 of_5\IN\1740 the_6\DT\1740 kinin_7\NN\14744841 b1_8\NN\1740 receptor_9\NN\5225602 (_10\-LRB-\1740 b1r_11\NN\1740 )_12\-RRB-\1740 during_13\IN\1740 the_14\DT\1740 development_15\NN\248977 of_16\IN\1740 dox_17\NN\1740 cardiomyopathy_18\IN\14103288 ,_19\,\1740 we_20\PRP\1740 studied_21\VBD\630380 b1r_22\NN\1740 knockout_23\JJ\1740 mice_24\NNS\2329401 (_25\-LRB-\1740 b1r(-/-_26\NN\1740 )_27\-RRB-\1740 )_28\-RRB-\1740 by_29\IN\1740 investigating_30\VBG\644583 cardiac_31\JJ\1740 <e2>inflammation</e2>_32\NN\14299637 and_33\CC\1740 apoptosis_34\NN\11486178 after_35\IN\1740 induction_36\NN\7450842 of_37\IN\1740 <e1>dox-induced</e1>_38\JJ\1740 cardiomyopathy_39\JJ\1740 ._40\.\1740
D018943_D066126 NONE clinical_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 the_3\DT\1740 <e1>anthracycline</e1>_4\NN\1740 doxorubicin_5\NN\2716866 (_6\-LRB-\1740 dox_7\NN\1740 )_8\-RRB-\1740 is_9\VBZ\836236 limited_10\VBN\2510337 by_11\IN\1740 its_12\PRP$\6125041 <e2>cardiotoxic</e2>_13\JJ\1740 effects_14\NNS\13245626 ,_15\,\1740 which_16\WDT\1740 are_17\VBP\836236 attributed_18\VBN\670261 to_19\TO\1740 the_20\DT\1740 induction_21\NN\7450842 of_22\IN\1740 apoptosis_23\NN\11486178 ._24\.\1740
D004317_D066126 NONE clinical_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 the_3\DT\1740 anthracycline_4\NN\1740 <e1>doxorubicin</e1>_5\NN\2716866 (_6\-LRB-\1740 dox_7\NN\1740 )_8\-RRB-\1740 is_9\VBZ\836236 limited_10\VBN\2510337 by_11\IN\1740 its_12\PRP$\6125041 <e2>cardiotoxic</e2>_13\JJ\1740 effects_14\NNS\13245626 ,_15\,\1740 which_16\WDT\1740 are_17\VBP\836236 attributed_18\VBN\670261 to_19\TO\1740 the_20\DT\1740 induction_21\NN\7450842 of_22\IN\1740 apoptosis_23\NN\11486178 ._24\.\1740
D004317_D066126 NONE clinical_0\JJ\1740 use_1\NN\407535 of_2\IN\1740 the_3\DT\1740 anthracycline_4\NN\1740 doxorubicin_5\NN\2716866 (_6\-LRB-\1740 <e1>dox</e1>_7\NN\1740 )_8\-RRB-\1740 is_9\VBZ\836236 limited_10\VBN\2510337 by_11\IN\1740 its_12\PRP$\6125041 <e2>cardiotoxic</e2>_13\JJ\1740 effects_14\NNS\13245626 ,_15\,\1740 which_16\WDT\1740 are_17\VBP\836236 attributed_18\VBN\670261 to_19\TO\1740 the_20\DT\1740 induction_21\NN\7450842 of_22\IN\1740 apoptosis_23\NN\11486178 ._24\.\1740
D004317_D006331 NONE <e1>dox</e1>_0\NN\1740 control_1\NN\5190804 mice_2\NNS\2329401 showed_3\VBD\2137132 <e2>cardiac_4\JJ\1740 dysfunction</e2>_5\NN\14204950 measured_6\VBN\697589 by_7\IN\1740 pressure-volume_8\JJ\1740 loops_9\NNS\3323703 in_10\FW\13603305 vivo_11\FW\1740 ._12\.\1740
D004317_D006331 NONE in_0\IN\13603305 <e1>dox</e1>_1\NN\1740 b1r(-/-_2\NN\1740 )_3\-RRB-\1740 mice_4\NNS\2329401 ,_5\,\1740 <e2>cardiac_6\JJ\1740 dysfunction</e2>_7\NN\14204950 was_8\VBD\836236 improved_9\VBN\126264 compared_10\VBN\644583 to_11\TO\1740 dox_12\NN\1740 control_13\NN\5190804 mice_14\NNS\2329401 ,_15\,\1740 which_16\WDT\1740 was_17\VBD\836236 associated_18\VBN\628491 with_19\IN\1740 normalization_20\NN\1123598 of_21\IN\1740 the_22\DT\1740 bax/bcl-2_23\NN\1740 ratio_24\NN\13815152 and_25\CC\1740 interleukin_26\NN\14943950 6_27\CD\13741022 ,_28\,\1740 as_29\RB\1740 well_30\RB\1740 as_31\IN\14622893 akt_32\NN\1740 activation_33\NN\13561719 state_34\NN\8491826 ._35\.\1740
D004317_D006331 NONE in_0\IN\13603305 dox_1\NN\1740 b1r(-/-_2\NN\1740 )_3\-RRB-\1740 mice_4\NNS\2329401 ,_5\,\1740 <e2>cardiac_6\JJ\1740 dysfunction</e2>_7\NN\14204950 was_8\VBD\836236 improved_9\VBN\126264 compared_10\VBN\644583 to_11\TO\1740 <e1>dox</e1>_12\NN\1740 control_13\NN\5190804 mice_14\NNS\2329401 ,_15\,\1740 which_16\WDT\1740 was_17\VBD\836236 associated_18\VBN\628491 with_19\IN\1740 normalization_20\NN\1123598 of_21\IN\1740 the_22\DT\1740 bax/bcl-2_23\NN\1740 ratio_24\NN\13815152 and_25\CC\1740 interleukin_26\NN\14943950 6_27\CD\13741022 ,_28\,\1740 as_29\RB\1740 well_30\RB\1740 as_31\IN\14622893 akt_32\NN\1740 activation_33\NN\13561719 state_34\NN\8491826 ._35\.\1740
2564649
D005283_D009127 CID involvement_0\NN\1080366 of_1\IN\1740 locus_2\NN\8645963 coeruleus_3\NN\1740 and_4\CC\1740 noradrenergic_5\JJ\1740 neurotransmission_6\NN\1740 in_7\IN\13603305 <e1>fentanyl-induced</e1>_8\JJ\1740 <e2>muscular_9\JJ\1740 rigidity</e2>_10\NN\5023233 in_11\IN\13603305 the_12\DT\1740 rat_13\NN\2329401 ._14\.\1740
D005283_D009127 CID whereas_0\IN\1740 <e2>muscular_1\JJ\1740 rigidity</e2>_2\NN\5023233 is_3\VBZ\836236 a_4\DT\13649268 well-known_5\JJ\1740 side_6\NN\8630039 effect_7\NN\34213 that_8\WDT\1740 is_9\VBZ\836236 associated_10\VBN\628491 with_11\IN\1740 high-dose_12\JJ\1740 <e1>fentanyl</e1>_13\JJ\1740 anesthesia_14\NN\14034177 ,_15\,\1740 a_16\DT\13649268 paucity_17\NN\5116953 of_18\IN\1740 information_19\NN\6598915 exists_20\VBZ\1740 with_21\IN\1740 regard_22\NN\5817845 to_23\IN\1740 its_24\PRP$\6125041 underlying_25\VBG\2604760 mechanism(s_26\NN\1740 )_27\-RRB-\1740 ._28\.\1740
D005283_D009127 CID it_0\PRP\6125041 is_1\VBZ\836236 speculated_2\VBN\719734 that_3\IN\1740 the_4\DT\1740 induction_5\NN\7450842 of_6\IN\1740 <e2>muscular_7\JJ\1740 rigidity</e2>_8\NN\5023233 by_9\IN\1740 <e1>fentanyl</e1>_10\NN\2707683 may_11\MD\15209706 involve_12\VB\2676054 the_13\DT\1740 coerulospinal_14\JJ\1740 noradrenergic_15\JJ\1740 fibers_16\NNS\14580897 to_17\IN\1740 the_18\DT\1740 spinal_19\JJ\1740 motoneurons_20\NNS\5465567 ._21\.\1740
D011224_D009127 NONE such_0\JJ\1740 an_1\DT\6697703 induced_2\VBN\1627355 <e2>muscular_3\JJ\1740 rigidity</e2>_4\NN\5023233 by_5\IN\1740 the_6\DT\1740 narcotic_7\JJ\1740 agent_8\NN\7347 was_9\VBD\836236 significantly_10\RB\1740 antagonized_11\VBN\1787955 or_12\CC\3541091 even_13\RB\1740 reduced_14\VBN\441445 by_15\IN\1740 prior_16\JJ\1740 electrolytic_17\JJ\1740 lesions_18\NNS\14204950 of_19\IN\1740 the_20\DT\1740 locus_21\NN\8645963 coeruleus_22\NN\1740 or_23\CC\3541091 pretreatment_24\NN\1740 with_25\IN\1740 the_26\DT\1740 alpha-adrenoceptor_27\JJ\1740 blocker_28\NN\10101634 ,_29\,\1740 <e1>prazosin</e1>_30\NN\2698769 ._31\.\1740
7542793
D016572_D007674 CID <e2>nephrotoxicity</e2>_0\NN\1740 of_1\IN\1740 <e1>cyclosporin_2\NN\1740 a</e1>_3\NN\13649268 and_4\CC\1740 fk506_5\NN\1740 :_6\:\1740 inhibition_7\NN\1068773 of_8\IN\1740 calcineurin_9\NN\1740 phosphatase_10\NN\14732946 ._11\.\1740
D016572_D007674 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 <e2>nephrotoxic</e2>_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 <e1>csa</e1>_8\NN\1740 and_9\CC\1740 fk506_10\NN\1740 is_11\VBZ\836236 likely_12\RB\1740 mediated_13\VBN\761713 through_14\IN\1740 binding_15\NN\4688246 to_16\TO\1740 renal_17\JJ\1740 immunophilin_18\NN\1740 and_19\CC\1740 inhibiting_20\VBG\2510337 calcineurin_21\NN\1740 phosphatase_22\NN\14732946 ._23\.\1740
D016559_D007674 CID <e2>nephrotoxicity</e2>_0\NN\1740 of_1\IN\1740 cyclosporin_2\NN\1740 a_3\NN\13649268 and_4\CC\1740 <e1>fk506</e1>_5\NN\1740 :_6\:\1740 inhibition_7\NN\1068773 of_8\IN\1740 calcineurin_9\NN\1740 phosphatase_10\NN\14732946 ._11\.\1740
D016559_D007674 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 <e2>nephrotoxic</e2>_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 csa_8\NN\1740 and_9\CC\1740 <e1>fk506</e1>_10\NN\1740 is_11\VBZ\836236 likely_12\RB\1740 mediated_13\VBN\761713 through_14\IN\1740 binding_15\NN\4688246 to_16\TO\1740 renal_17\JJ\1740 immunophilin_18\NN\1740 and_19\CC\1740 inhibiting_20\VBG\2510337 calcineurin_21\NN\1740 phosphatase_22\NN\14732946 ._23\.\1740
D016572_D006984 NONE <e1>cyclosporin_0\NN\1740 a</e1>_1\NN\13649268 (_2\-LRB-\1740 csa_3\NN\1740 ;_4\:\1740 50_5\CD\13745420 mg/kg_6\NN\1740 )_7\-RRB-\1740 and_8\CC\1740 fujimycine_9\NN\1740 (_10\-LRB-\1740 fk506_11\NN\1740 ;_12\:\1740 5_13\CD\13741022 mg/kg_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 the_19\DT\1740 related_20\JJ\1740 macrolide_21\NN\1740 immunosuppressant_22\JJ\1740 rapamycin_23\NN\1740 (_24\-LRB-\1740 5_25\CD\13741022 mg/kg_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 caused_29\VBD\1617192 a_30\DT\13649268 reduction_31\NN\351485 of_32\IN\1740 glomerular_33\JJ\1740 filtration_34\NN\13518963 rate_35\NN\13815152 ,_36\,\1740 degenerative_37\JJ\1740 changes_38\NNS\7283608 of_39\IN\1740 proximal_40\JJ\1740 tubular_41\JJ\1740 epithelium_42\NN\5267548 ,_43\,\1740 and_44\CC\1740 <e2>hypertrophy</e2>_45\NN\14365950 of_46\IN\1740 the_47\DT\1740 juxtaglomerular_48\JJ\1740 apparatus_49\NN\3294048 in_50\IN\13603305 male_51\JJ\1740 wistar_52\NNP\1740 rats_53\NNS\2329401 when_54\WRB\1740 given_55\VBN\2327200 for_56\IN\1740 10_57\CD\13745420 days_58\NNS\15140892 ._59\.\1740
D016572_D006984 NONE cyclosporin_0\NN\1740 a_1\NN\13649268 (_2\-LRB-\1740 <e1>csa</e1>_3\NN\1740 ;_4\:\1740 50_5\CD\13745420 mg/kg_6\NN\1740 )_7\-RRB-\1740 and_8\CC\1740 fujimycine_9\NN\1740 (_10\-LRB-\1740 fk506_11\NN\1740 ;_12\:\1740 5_13\CD\13741022 mg/kg_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 the_19\DT\1740 related_20\JJ\1740 macrolide_21\NN\1740 immunosuppressant_22\JJ\1740 rapamycin_23\NN\1740 (_24\-LRB-\1740 5_25\CD\13741022 mg/kg_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 caused_29\VBD\1617192 a_30\DT\13649268 reduction_31\NN\351485 of_32\IN\1740 glomerular_33\JJ\1740 filtration_34\NN\13518963 rate_35\NN\13815152 ,_36\,\1740 degenerative_37\JJ\1740 changes_38\NNS\7283608 of_39\IN\1740 proximal_40\JJ\1740 tubular_41\JJ\1740 epithelium_42\NN\5267548 ,_43\,\1740 and_44\CC\1740 <e2>hypertrophy</e2>_45\NN\14365950 of_46\IN\1740 the_47\DT\1740 juxtaglomerular_48\JJ\1740 apparatus_49\NN\3294048 in_50\IN\13603305 male_51\JJ\1740 wistar_52\NNP\1740 rats_53\NNS\2329401 when_54\WRB\1740 given_55\VBN\2327200 for_56\IN\1740 10_57\CD\13745420 days_58\NNS\15140892 ._59\.\1740
D016559_D006984 NONE cyclosporin_0\NN\1740 a_1\NN\13649268 (_2\-LRB-\1740 csa_3\NN\1740 ;_4\:\1740 50_5\CD\13745420 mg/kg_6\NN\1740 )_7\-RRB-\1740 and_8\CC\1740 <e1>fujimycine</e1>_9\NN\1740 (_10\-LRB-\1740 fk506_11\NN\1740 ;_12\:\1740 5_13\CD\13741022 mg/kg_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 the_19\DT\1740 related_20\JJ\1740 macrolide_21\NN\1740 immunosuppressant_22\JJ\1740 rapamycin_23\NN\1740 (_24\-LRB-\1740 5_25\CD\13741022 mg/kg_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 caused_29\VBD\1617192 a_30\DT\13649268 reduction_31\NN\351485 of_32\IN\1740 glomerular_33\JJ\1740 filtration_34\NN\13518963 rate_35\NN\13815152 ,_36\,\1740 degenerative_37\JJ\1740 changes_38\NNS\7283608 of_39\IN\1740 proximal_40\JJ\1740 tubular_41\JJ\1740 epithelium_42\NN\5267548 ,_43\,\1740 and_44\CC\1740 <e2>hypertrophy</e2>_45\NN\14365950 of_46\IN\1740 the_47\DT\1740 juxtaglomerular_48\JJ\1740 apparatus_49\NN\3294048 in_50\IN\13603305 male_51\JJ\1740 wistar_52\NNP\1740 rats_53\NNS\2329401 when_54\WRB\1740 given_55\VBN\2327200 for_56\IN\1740 10_57\CD\13745420 days_58\NNS\15140892 ._59\.\1740
D016559_D006984 NONE cyclosporin_0\NN\1740 a_1\NN\13649268 (_2\-LRB-\1740 csa_3\NN\1740 ;_4\:\1740 50_5\CD\13745420 mg/kg_6\NN\1740 )_7\-RRB-\1740 and_8\CC\1740 fujimycine_9\NN\1740 (_10\-LRB-\1740 <e1>fk506</e1>_11\NN\1740 ;_12\:\1740 5_13\CD\13741022 mg/kg_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 the_19\DT\1740 related_20\JJ\1740 macrolide_21\NN\1740 immunosuppressant_22\JJ\1740 rapamycin_23\NN\1740 (_24\-LRB-\1740 5_25\CD\13741022 mg/kg_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 caused_29\VBD\1617192 a_30\DT\13649268 reduction_31\NN\351485 of_32\IN\1740 glomerular_33\JJ\1740 filtration_34\NN\13518963 rate_35\NN\13815152 ,_36\,\1740 degenerative_37\JJ\1740 changes_38\NNS\7283608 of_39\IN\1740 proximal_40\JJ\1740 tubular_41\JJ\1740 epithelium_42\NN\5267548 ,_43\,\1740 and_44\CC\1740 <e2>hypertrophy</e2>_45\NN\14365950 of_46\IN\1740 the_47\DT\1740 juxtaglomerular_48\JJ\1740 apparatus_49\NN\3294048 in_50\IN\13603305 male_51\JJ\1740 wistar_52\NNP\1740 rats_53\NNS\2329401 when_54\WRB\1740 given_55\VBN\2327200 for_56\IN\1740 10_57\CD\13745420 days_58\NNS\15140892 ._59\.\1740
D018942_D006984 NONE cyclosporin_0\NN\1740 a_1\NN\13649268 (_2\-LRB-\1740 csa_3\NN\1740 ;_4\:\1740 50_5\CD\13745420 mg/kg_6\NN\1740 )_7\-RRB-\1740 and_8\CC\1740 fujimycine_9\NN\1740 (_10\-LRB-\1740 fk506_11\NN\1740 ;_12\:\1740 5_13\CD\13741022 mg/kg_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 the_19\DT\1740 related_20\JJ\1740 <e1>macrolide</e1>_21\NN\1740 immunosuppressant_22\JJ\1740 rapamycin_23\NN\1740 (_24\-LRB-\1740 5_25\CD\13741022 mg/kg_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 caused_29\VBD\1617192 a_30\DT\13649268 reduction_31\NN\351485 of_32\IN\1740 glomerular_33\JJ\1740 filtration_34\NN\13518963 rate_35\NN\13815152 ,_36\,\1740 degenerative_37\JJ\1740 changes_38\NNS\7283608 of_39\IN\1740 proximal_40\JJ\1740 tubular_41\JJ\1740 epithelium_42\NN\5267548 ,_43\,\1740 and_44\CC\1740 <e2>hypertrophy</e2>_45\NN\14365950 of_46\IN\1740 the_47\DT\1740 juxtaglomerular_48\JJ\1740 apparatus_49\NN\3294048 in_50\IN\13603305 male_51\JJ\1740 wistar_52\NNP\1740 rats_53\NNS\2329401 when_54\WRB\1740 given_55\VBN\2327200 for_56\IN\1740 10_57\CD\13745420 days_58\NNS\15140892 ._59\.\1740
D020123_D006984 NONE cyclosporin_0\NN\1740 a_1\NN\13649268 (_2\-LRB-\1740 csa_3\NN\1740 ;_4\:\1740 50_5\CD\13745420 mg/kg_6\NN\1740 )_7\-RRB-\1740 and_8\CC\1740 fujimycine_9\NN\1740 (_10\-LRB-\1740 fk506_11\NN\1740 ;_12\:\1740 5_13\CD\13741022 mg/kg_14\NN\1740 )_15\-RRB-\1740 ,_16\,\1740 but_17\CC\1740 not_18\RB\1740 the_19\DT\1740 related_20\JJ\1740 macrolide_21\NN\1740 immunosuppressant_22\JJ\1740 <e1>rapamycin</e1>_23\NN\1740 (_24\-LRB-\1740 5_25\CD\13741022 mg/kg_26\NN\1740 )_27\-RRB-\1740 ,_28\,\1740 caused_29\VBD\1617192 a_30\DT\13649268 reduction_31\NN\351485 of_32\IN\1740 glomerular_33\JJ\1740 filtration_34\NN\13518963 rate_35\NN\13815152 ,_36\,\1740 degenerative_37\JJ\1740 changes_38\NNS\7283608 of_39\IN\1740 proximal_40\JJ\1740 tubular_41\JJ\1740 epithelium_42\NN\5267548 ,_43\,\1740 and_44\CC\1740 <e2>hypertrophy</e2>_45\NN\14365950 of_46\IN\1740 the_47\DT\1740 juxtaglomerular_48\JJ\1740 apparatus_49\NN\3294048 in_50\IN\13603305 male_51\JJ\1740 wistar_52\NNP\1740 rats_53\NNS\2329401 when_54\WRB\1740 given_55\VBN\2327200 for_56\IN\1740 10_57\CD\13745420 days_58\NNS\15140892 ._59\.\1740
D016572_D064420 NONE the_0\DT\1740 molecular_1\JJ\1740 mechanisms_2\NNS\13446390 of_3\IN\1740 <e1>csa</e1>_4\NN\1740 and_5\CC\1740 fk506_6\NN\1740 <e2>toxicity</e2>_7\NN\13576101 were_8\VBD\836236 investigated_9\VBN\644583 ._10\.\1740
D016559_D064420 NONE the_0\DT\1740 molecular_1\JJ\1740 mechanisms_2\NNS\13446390 of_3\IN\1740 csa_4\NN\1740 and_5\CC\1740 <e1>fk506</e1>_6\NN\1740 <e2>toxicity</e2>_7\NN\13576101 were_8\VBD\836236 investigated_9\VBN\644583 ._10\.\1740
1300436
D005665_D007674 NONE potential_0\JJ\1740 deleterious_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 <e1>furosemide</e1>_4\NN\3214670 in_5\IN\13603305 radiocontrast_6\NN\1740 <e2>nephropathy</e2>_7\RB\1740 ._8\.\1740
D005665_D007674 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 determine_7\VB\1645601 the_8\DT\1740 efficacy_9\NN\5199286 of_10\IN\1740 <e1>furosemide</e1>_11\NN\3214670 in_12\IN\13603305 addition_13\NN\3081021 to_14\TO\1740 intravenous_15\JJ\1740 fluids_16\NNS\19613 in_17\IN\13603305 the_18\DT\1740 prevention_19\NN\1073995 of_20\IN\1740 radiocontrast_21\NN\1740 <e2>nephropathy</e2>_22\RB\1740 ._23\.\1740
D005665_D007674 NONE <e1>furosemide</e1>_0\NNP\3214670 may_1\MD\15209706 be_2\VB\836236 deleterious_3\JJ\1740 in_4\IN\13603305 the_5\DT\1740 prevention_6\NN\1073995 of_7\IN\1740 radiocontrast_8\NN\1740 <e2>nephropathy</e2>_9\RB\1740 ._10\.\1740
D005665_D058186 CID radiological_0\JJ\1740 studies_1\NNS\635850 were_2\VBD\836236 mostly_3\RB\1740 angiographies_4\NNS\904623 performed_5\VBN\2367363 with_6\IN\1740 both_7\CC\1740 ionic_8\JJ\1740 and_9\CC\1740 non-ionic_10\JJ\1740 contrast_11\NN\13854649 material_12\NN\19613 ,_13\,\1740 at_14\IN\14622893 an_15\DT\6697703 average_16\JJ\1740 dose_17\NN\3740161 of_18\IN\1740 245_19\CD\1740 ml._20\NN\1740 <e2>renal_21\JJ\1740 function_22\NN\13783581 significantly_23\RB\1740 deteriorated</e2>_24\VBD\208836 in_25\IN\13603305 the_26\DT\1740 group_27\NN\2137 pretreated_28\VBN\1740 with_29\IN\1740 <e1>furosemide</e1>_30\NN\3214670 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 0.005_34\CD\1740 by_35\IN\1740 anova_36\NN\6021247 )_37\-RRB-\1740 ,_38\,\1740 with_39\IN\1740 a_40\DT\13649268 rise_41\NN\7324673 in_42\IN\13603305 serum_43\NN\5397468 creatinine_44\NN\1740 from_45\IN\1740 145_46\CD\1740 +/-_47\CC\1740 13_48\CD\13745420 to_49\TO\1740 182_50\CD\1740 +/-_51\CC\1740 16_52\CD\13745420 mumol/l_53\NN\1740 at_54\IN\14622893 24_55\CD\13745420 h_56\NN\14622893 ,_57\,\1740 while_58\IN\15122231 no_59\DT\7204911 change_60\NN\7283608 occurred_61\VBD\2623529 in_62\IN\13603305 the_63\DT\1740 control_64\NN\5190804 group_65\NN\2137 (_66\-LRB-\1740 from_67\IN\1740 141_68\CD\1740 +/-_69\CC\1740 6_70\CD\13741022 to_71\TO\1740 142_72\CD\1740 +/-_73\CC\1740 7_74\CD\13741022 mumol/l_75\NN\1740 )_76\-RRB-\1740 ._77\.\1740
D003404_D058186 NONE radiological_0\JJ\1740 studies_1\NNS\635850 were_2\VBD\836236 mostly_3\RB\1740 angiographies_4\NNS\904623 performed_5\VBN\2367363 with_6\IN\1740 both_7\CC\1740 ionic_8\JJ\1740 and_9\CC\1740 non-ionic_10\JJ\1740 contrast_11\NN\13854649 material_12\NN\19613 ,_13\,\1740 at_14\IN\14622893 an_15\DT\6697703 average_16\JJ\1740 dose_17\NN\3740161 of_18\IN\1740 245_19\CD\1740 ml._20\NN\1740 <e2>renal_21\JJ\1740 function_22\NN\13783581 significantly_23\RB\1740 deteriorated</e2>_24\VBD\208836 in_25\IN\13603305 the_26\DT\1740 group_27\NN\2137 pretreated_28\VBN\1740 with_29\IN\1740 furosemide_30\NN\3214670 (_31\-LRB-\1740 p_32\NN\14622893 <_33\XX\1740 0.005_34\CD\1740 by_35\IN\1740 anova_36\NN\6021247 )_37\-RRB-\1740 ,_38\,\1740 with_39\IN\1740 a_40\DT\13649268 rise_41\NN\7324673 in_42\IN\13603305 serum_43\NN\5397468 <e1>creatinine</e1>_44\NN\1740 from_45\IN\1740 145_46\CD\1740 +/-_47\CC\1740 13_48\CD\13745420 to_49\TO\1740 182_50\CD\1740 +/-_51\CC\1740 16_52\CD\13745420 mumol/l_53\NN\1740 at_54\IN\14622893 24_55\CD\13745420 h_56\NN\14622893 ,_57\,\1740 while_58\IN\15122231 no_59\DT\7204911 change_60\NN\7283608 occurred_61\VBD\2623529 in_62\IN\13603305 the_63\DT\1740 control_64\NN\5190804 group_65\NN\2137 (_66\-LRB-\1740 from_67\IN\1740 141_68\CD\1740 +/-_69\CC\1740 6_70\CD\13741022 to_71\TO\1740 142_72\CD\1740 +/-_73\CC\1740 7_74\CD\13741022 mumol/l_75\NN\1740 )_76\-RRB-\1740 ._77\.\1740
D005665_D051437 NONE <e2>renal_0\JJ\1740 failure</e2>_1\NN\66216 was_2\VBD\836236 associated_3\VBN\628491 with_4\IN\1740 weight_5\NN\5009170 loss_6\NN\13252973 in_7\IN\13603305 the_8\DT\1740 <e1>furosemide-treated</e1>_9\JJ\1740 group_10\NN\2137 ._11\.\1740
D005665_D015431 NONE renal_0\JJ\1740 failure_1\NN\66216 was_2\VBD\836236 associated_3\VBN\628491 with_4\IN\1740 <e2>weight_5\NN\5009170 loss</e2>_6\NN\13252973 in_7\IN\13603305 the_8\DT\1740 <e1>furosemide-treated</e1>_9\JJ\1740 group_10\NN\2137 ._11\.\1740
12101159
D004110_D006323 CID delayed_0\VBN\439958 <e2>asystolic</e2>_1\JJ\1740 cardiac_2\JJ\1740 arrest_3\NN\88481 after_4\IN\1740 <e1>diltiazem</e1>_5\NN\2938514 overdose_6\NN\1740 ;_7\:\1740 resuscitation_8\NN\1047338 with_9\IN\1740 high_10\JJ\1740 dose_11\NN\3740161 intravenous_12\JJ\1740 calcium_13\NN\14625458 ._14\.\1740
D004110_D006323 CID delayed_0\VBN\439958 asystolic_1\JJ\1740 <e2>cardiac_2\JJ\1740 arrest</e2>_3\NN\88481 after_4\IN\1740 <e1>diltiazem</e1>_5\NN\2938514 overdose_6\NN\1740 ;_7\:\1740 resuscitation_8\NN\1047338 with_9\IN\1740 high_10\JJ\1740 dose_11\NN\3740161 intravenous_12\JJ\1740 calcium_13\NN\14625458 ._14\.\1740
D004110_D006323 CID this_0\DT\1740 case_1\NN\7283608 suggests_2\VBZ\1010118 there_3\EX\27167 is_4\VBZ\836236 a_5\DT\13649268 role_6\NN\719494 for_7\IN\1740 aggressive_8\JJ\1740 high_9\JJ\1740 dose_10\NN\3740161 intravenous_11\JJ\1740 calcium_12\NN\14625458 therapy_13\NN\657604 in_14\IN\13603305 severe_15\JJ\1740 <e1>diltiazem</e1>_16\NN\2938514 overdose_17\NN\1740 ,_18\,\1740 particularly_19\RB\1740 with_20\IN\1740 the_21\DT\1740 onset_22\NN\7325190 of_23\IN\1740 <e2>asystole</e2>_24\NN\14204950 ._25\.\1740
D004110_D006323 CID it_0\PRP\6125041 should_1\MD\1740 be_2\VB\836236 considered_3\VBN\689344 early_4\JJ\1740 in_5\IN\13603305 cases_6\NNS\7283608 of_7\IN\1740 <e2>cardiac_8\JJ\1740 arrest</e2>_9\NN\88481 after_10\IN\1740 <e1>diltiazem</e1>_11\NN\2938514 overdose_12\NN\1740 ._13\.\1740
D004110_D062787 CID delayed_0\VBN\439958 asystolic_1\JJ\1740 cardiac_2\JJ\1740 arrest_3\NN\88481 after_4\IN\1740 <e1>diltiazem</e1>_5\NN\2938514 <e2>overdose</e2>_6\NN\1740 ;_7\:\1740 resuscitation_8\NN\1047338 with_9\IN\1740 high_10\JJ\1740 dose_11\NN\3740161 intravenous_12\JJ\1740 calcium_13\NN\14625458 ._14\.\1740
D004110_D062787 CID a_0\DT\13649268 51_1\CD\1740 year_2\NN\15113229 old_3\JJ\1740 man_4\NN\9605289 took_5\VBD\2367363 a_6\DT\13649268 mixed_7\JJ\1740 <e2>overdose</e2>_8\NN\1740 including_9\VBG\690614 1.8_10\CD\1740 -_11\SYM\1740 3.6_12\CD\1740 g_13\NN\13717155 of_14\IN\1740 <e1>diltiazem</e1>_15\NN\2938514 ,_16\,\1740 paracetamol_17\NN\1740 ,_18\,\1740 aspirin_19\NN\2707683 ,_20\,\1740 isosorbide_21\VBP\1740 nitrate_22\VBP\515154 ,_23\,\1740 and_24\CC\1740 alcohol_25\NN\7881800 ._26\.\1740
D004110_D062787 CID this_0\DT\1740 case_1\NN\7283608 suggests_2\VBZ\1010118 there_3\EX\27167 is_4\VBZ\836236 a_5\DT\13649268 role_6\NN\719494 for_7\IN\1740 aggressive_8\JJ\1740 high_9\JJ\1740 dose_10\NN\3740161 intravenous_11\JJ\1740 calcium_12\NN\14625458 therapy_13\NN\657604 in_14\IN\13603305 severe_15\JJ\1740 <e1>diltiazem</e1>_16\NN\2938514 <e2>overdose</e2>_17\NN\1740 ,_18\,\1740 particularly_19\RB\1740 with_20\IN\1740 the_21\DT\1740 onset_22\NN\7325190 of_23\IN\1740 asystole_24\NN\14204950 ._25\.\1740
D004110_D062787 CID it_0\PRP\6125041 should_1\MD\1740 be_2\VB\836236 considered_3\VBN\689344 early_4\JJ\1740 in_5\IN\13603305 cases_6\NNS\7283608 of_7\IN\1740 cardiac_8\JJ\1740 arrest_9\NN\88481 after_10\IN\1740 <e1>diltiazem</e1>_11\NN\2938514 <e2>overdose</e2>_12\NN\1740 ._13\.\1740
D002118_D006323 NONE delayed_0\VBN\439958 <e2>asystolic</e2>_1\JJ\1740 cardiac_2\JJ\1740 arrest_3\NN\88481 after_4\IN\1740 diltiazem_5\NN\2938514 overdose_6\NN\1740 ;_7\:\1740 resuscitation_8\NN\1047338 with_9\IN\1740 high_10\JJ\1740 dose_11\NN\3740161 intravenous_12\JJ\1740 <e1>calcium</e1>_13\NN\14625458 ._14\.\1740
D002118_D006323 NONE delayed_0\VBN\439958 asystolic_1\JJ\1740 <e2>cardiac_2\JJ\1740 arrest</e2>_3\NN\88481 after_4\IN\1740 diltiazem_5\NN\2938514 overdose_6\NN\1740 ;_7\:\1740 resuscitation_8\NN\1047338 with_9\IN\1740 high_10\JJ\1740 dose_11\NN\3740161 intravenous_12\JJ\1740 <e1>calcium</e1>_13\NN\14625458 ._14\.\1740
D002118_D006323 NONE this_0\DT\1740 case_1\NN\7283608 suggests_2\VBZ\1010118 there_3\EX\27167 is_4\VBZ\836236 a_5\DT\13649268 role_6\NN\719494 for_7\IN\1740 aggressive_8\JJ\1740 high_9\JJ\1740 dose_10\NN\3740161 intravenous_11\JJ\1740 <e1>calcium</e1>_12\NN\14625458 therapy_13\NN\657604 in_14\IN\13603305 severe_15\JJ\1740 diltiazem_16\NN\2938514 overdose_17\NN\1740 ,_18\,\1740 particularly_19\RB\1740 with_20\IN\1740 the_21\DT\1740 onset_22\NN\7325190 of_23\IN\1740 <e2>asystole</e2>_24\NN\14204950 ._25\.\1740
D002118_D062787 NONE delayed_0\VBN\439958 asystolic_1\JJ\1740 cardiac_2\JJ\1740 arrest_3\NN\88481 after_4\IN\1740 diltiazem_5\NN\2938514 <e2>overdose</e2>_6\NN\1740 ;_7\:\1740 resuscitation_8\NN\1047338 with_9\IN\1740 high_10\JJ\1740 dose_11\NN\3740161 intravenous_12\JJ\1740 <e1>calcium</e1>_13\NN\14625458 ._14\.\1740
D002118_D062787 NONE this_0\DT\1740 case_1\NN\7283608 suggests_2\VBZ\1010118 there_3\EX\27167 is_4\VBZ\836236 a_5\DT\13649268 role_6\NN\719494 for_7\IN\1740 aggressive_8\JJ\1740 high_9\JJ\1740 dose_10\NN\3740161 intravenous_11\JJ\1740 <e1>calcium</e1>_12\NN\14625458 therapy_13\NN\657604 in_14\IN\13603305 severe_15\JJ\1740 diltiazem_16\NN\2938514 <e2>overdose</e2>_17\NN\1740 ,_18\,\1740 particularly_19\RB\1740 with_20\IN\1740 the_21\DT\1740 onset_22\NN\7325190 of_23\IN\1740 asystole_24\NN\14204950 ._25\.\1740
D000082_D062787 NONE a_0\DT\13649268 51_1\CD\1740 year_2\NN\15113229 old_3\JJ\1740 man_4\NN\9605289 took_5\VBD\2367363 a_6\DT\13649268 mixed_7\JJ\1740 <e2>overdose</e2>_8\NN\1740 including_9\VBG\690614 1.8_10\CD\1740 -_11\SYM\1740 3.6_12\CD\1740 g_13\NN\13717155 of_14\IN\1740 diltiazem_15\NN\2938514 ,_16\,\1740 <e1>paracetamol</e1>_17\NN\1740 ,_18\,\1740 aspirin_19\NN\2707683 ,_20\,\1740 isosorbide_21\VBP\1740 nitrate_22\VBP\515154 ,_23\,\1740 and_24\CC\1740 alcohol_25\NN\7881800 ._26\.\1740
D001241_D062787 NONE a_0\DT\13649268 51_1\CD\1740 year_2\NN\15113229 old_3\JJ\1740 man_4\NN\9605289 took_5\VBD\2367363 a_6\DT\13649268 mixed_7\JJ\1740 <e2>overdose</e2>_8\NN\1740 including_9\VBG\690614 1.8_10\CD\1740 -_11\SYM\1740 3.6_12\CD\1740 g_13\NN\13717155 of_14\IN\1740 diltiazem_15\NN\2938514 ,_16\,\1740 paracetamol_17\NN\1740 ,_18\,\1740 <e1>aspirin</e1>_19\NN\2707683 ,_20\,\1740 isosorbide_21\VBP\1740 nitrate_22\VBP\515154 ,_23\,\1740 and_24\CC\1740 alcohol_25\NN\7881800 ._26\.\1740
D007547_D062787 NONE a_0\DT\13649268 51_1\CD\1740 year_2\NN\15113229 old_3\JJ\1740 man_4\NN\9605289 took_5\VBD\2367363 a_6\DT\13649268 mixed_7\JJ\1740 <e2>overdose</e2>_8\NN\1740 including_9\VBG\690614 1.8_10\CD\1740 -_11\SYM\1740 3.6_12\CD\1740 g_13\NN\13717155 of_14\IN\1740 diltiazem_15\NN\2938514 ,_16\,\1740 paracetamol_17\NN\1740 ,_18\,\1740 aspirin_19\NN\2707683 ,_20\,\1740 <e1>isosorbide</e1>_21\VBP\1740 nitrate_22\VBP\515154 ,_23\,\1740 and_24\CC\1740 alcohol_25\NN\7881800 ._26\.\1740
D009566_D062787 NONE a_0\DT\13649268 51_1\CD\1740 year_2\NN\15113229 old_3\JJ\1740 man_4\NN\9605289 took_5\VBD\2367363 a_6\DT\13649268 mixed_7\JJ\1740 <e2>overdose</e2>_8\NN\1740 including_9\VBG\690614 1.8_10\CD\1740 -_11\SYM\1740 3.6_12\CD\1740 g_13\NN\13717155 of_14\IN\1740 diltiazem_15\NN\2938514 ,_16\,\1740 paracetamol_17\NN\1740 ,_18\,\1740 aspirin_19\NN\2707683 ,_20\,\1740 isosorbide_21\VBP\1740 <e1>nitrate</e1>_22\VBP\515154 ,_23\,\1740 and_24\CC\1740 alcohol_25\NN\7881800 ._26\.\1740
D000431_D062787 NONE a_0\DT\13649268 51_1\CD\1740 year_2\NN\15113229 old_3\JJ\1740 man_4\NN\9605289 took_5\VBD\2367363 a_6\DT\13649268 mixed_7\JJ\1740 <e2>overdose</e2>_8\NN\1740 including_9\VBG\690614 1.8_10\CD\1740 -_11\SYM\1740 3.6_12\CD\1740 g_13\NN\13717155 of_14\IN\1740 diltiazem_15\NN\2938514 ,_16\,\1740 paracetamol_17\NN\1740 ,_18\,\1740 aspirin_19\NN\2707683 ,_20\,\1740 isosorbide_21\VBP\1740 nitrate_22\VBP\515154 ,_23\,\1740 and_24\CC\1740 <e1>alcohol</e1>_25\NN\7881800 ._26\.\1740
11099450
D007980_D010300 NONE the_0\DT\1740 objective_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 explore_7\VB\789138 the_8\DT\1740 functional_9\JJ\1740 anatomy_10\NN\6078327 of_11\IN\1740 the_12\DT\1740 globus_13\NN\1740 pallidus_14\NN\1740 internus_15\NN\1740 (_16\-LRB-\1740 gpi_17\NNS\1740 )_18\-RRB-\1740 by_19\IN\1740 studying_20\VBG\630380 the_21\DT\1740 effects_22\NNS\13245626 of_23\IN\1740 unilateral_24\JJ\1740 pallidotomy_25\NN\1740 on_26\IN\1740 <e2>parkinsonian</e2>_27\JJ\1740 '_28\``\1740 off_29\NN\1740 '_30\``\1740 signs_31\NNS\6643763 and_32\CC\1740 <e1>levodopa-induced</e1>_33\JJ\1740 dyskinesias_34\NNS\14084880 (_35\-LRB-\1740 lid_36\NN\5313679 )_37\-RRB-\1740 ._38\.\1740
D007980_D010300 NONE the_0\DT\1740 differential_1\JJ\1740 predictive_2\JJ\1740 value_3\NN\5856066 of_4\IN\1740 <e1>levodopa</e1>_5\NN\14604959 responsiveness_6\NN\5652926 for_7\IN\1740 the_8\DT\1740 outcome_9\NN\7291312 of_10\IN\1740 <e2>parkinsonian</e2>_11\NN\1740 '_12\``\1740 off_13\NN\1740 '_14\``\1740 signs_15\NNS\6643763 and_16\CC\1740 lid_17\NN\5313679 and_18\CC\1740 the_19\DT\1740 different_20\JJ\1740 correlations_21\NNS\13841213 of_22\IN\1740 ventral_23\JJ\1740 lesion_24\NN\14204950 volume_25\NN\33615 with_26\IN\1740 dyskinesias_27\NNS\14084880 and_28\CC\1740 parkinsonian_29\JJ\1740 '_30\''\1740 off_31\NN\1740 '_32\``\1740 signs_33\NNS\6643763 indicate_34\VBP\952524 that_35\IN\1740 different_36\JJ\1740 anatomical_37\JJ\1740 or_38\CC\3541091 pathophysiological_39\JJ\1740 substrates_40\NNS\19613 may_41\MD\15209706 be_42\VB\836236 responsible_43\JJ\1740 for_44\IN\1740 the_45\DT\1740 generation_46\NN\7942152 of_47\IN\1740 parkinsonian_48\NN\1740 '_49\''\1740 off_50\NN\1740 '_51\``\1740 signs_52\NNS\6643763 and_53\CC\1740 dyskinesias_54\NNS\14084880 ._55\.\1740
D007980_D010300 NONE the_0\DT\1740 differential_1\JJ\1740 predictive_2\JJ\1740 value_3\NN\5856066 of_4\IN\1740 <e1>levodopa</e1>_5\NN\14604959 responsiveness_6\NN\5652926 for_7\IN\1740 the_8\DT\1740 outcome_9\NN\7291312 of_10\IN\1740 parkinsonian_11\NN\1740 '_12\``\1740 off_13\NN\1740 '_14\``\1740 signs_15\NNS\6643763 and_16\CC\1740 lid_17\NN\5313679 and_18\CC\1740 the_19\DT\1740 different_20\JJ\1740 correlations_21\NNS\13841213 of_22\IN\1740 ventral_23\JJ\1740 lesion_24\NN\14204950 volume_25\NN\33615 with_26\IN\1740 dyskinesias_27\NNS\14084880 and_28\CC\1740 <e2>parkinsonian</e2>_29\JJ\1740 '_30\''\1740 off_31\NN\1740 '_32\``\1740 signs_33\NNS\6643763 indicate_34\VBP\952524 that_35\IN\1740 different_36\JJ\1740 anatomical_37\JJ\1740 or_38\CC\3541091 pathophysiological_39\JJ\1740 substrates_40\NNS\19613 may_41\MD\15209706 be_42\VB\836236 responsible_43\JJ\1740 for_44\IN\1740 the_45\DT\1740 generation_46\NN\7942152 of_47\IN\1740 parkinsonian_48\NN\1740 '_49\''\1740 off_50\NN\1740 '_51\``\1740 signs_52\NNS\6643763 and_53\CC\1740 dyskinesias_54\NNS\14084880 ._55\.\1740
D007980_D010300 NONE the_0\DT\1740 differential_1\JJ\1740 predictive_2\JJ\1740 value_3\NN\5856066 of_4\IN\1740 <e1>levodopa</e1>_5\NN\14604959 responsiveness_6\NN\5652926 for_7\IN\1740 the_8\DT\1740 outcome_9\NN\7291312 of_10\IN\1740 parkinsonian_11\NN\1740 '_12\``\1740 off_13\NN\1740 '_14\``\1740 signs_15\NNS\6643763 and_16\CC\1740 lid_17\NN\5313679 and_18\CC\1740 the_19\DT\1740 different_20\JJ\1740 correlations_21\NNS\13841213 of_22\IN\1740 ventral_23\JJ\1740 lesion_24\NN\14204950 volume_25\NN\33615 with_26\IN\1740 dyskinesias_27\NNS\14084880 and_28\CC\1740 parkinsonian_29\JJ\1740 '_30\''\1740 off_31\NN\1740 '_32\``\1740 signs_33\NNS\6643763 indicate_34\VBP\952524 that_35\IN\1740 different_36\JJ\1740 anatomical_37\JJ\1740 or_38\CC\3541091 pathophysiological_39\JJ\1740 substrates_40\NNS\19613 may_41\MD\15209706 be_42\VB\836236 responsible_43\JJ\1740 for_44\IN\1740 the_45\DT\1740 generation_46\NN\7942152 of_47\IN\1740 <e2>parkinsonian</e2>_48\NN\1740 '_49\''\1740 off_50\NN\1740 '_51\``\1740 signs_52\NNS\6643763 and_53\CC\1740 dyskinesias_54\NNS\14084880 ._55\.\1740
D007980_D004409 CID the_0\DT\1740 objective_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 explore_7\VB\789138 the_8\DT\1740 functional_9\JJ\1740 anatomy_10\NN\6078327 of_11\IN\1740 the_12\DT\1740 globus_13\NN\1740 pallidus_14\NN\1740 internus_15\NN\1740 (_16\-LRB-\1740 gpi_17\NNS\1740 )_18\-RRB-\1740 by_19\IN\1740 studying_20\VBG\630380 the_21\DT\1740 effects_22\NNS\13245626 of_23\IN\1740 unilateral_24\JJ\1740 pallidotomy_25\NN\1740 on_26\IN\1740 parkinsonian_27\JJ\1740 '_28\``\1740 off_29\NN\1740 '_30\``\1740 signs_31\NNS\6643763 and_32\CC\1740 <e1>levodopa-induced</e1>_33\JJ\1740 <e2>dyskinesias</e2>_34\NNS\14084880 (_35\-LRB-\1740 lid_36\NN\5313679 )_37\-RRB-\1740 ._38\.\1740
D007980_D004409 CID the_0\DT\1740 objective_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 explore_7\VB\789138 the_8\DT\1740 functional_9\JJ\1740 anatomy_10\NN\6078327 of_11\IN\1740 the_12\DT\1740 globus_13\NN\1740 pallidus_14\NN\1740 internus_15\NN\1740 (_16\-LRB-\1740 gpi_17\NNS\1740 )_18\-RRB-\1740 by_19\IN\1740 studying_20\VBG\630380 the_21\DT\1740 effects_22\NNS\13245626 of_23\IN\1740 unilateral_24\JJ\1740 pallidotomy_25\NN\1740 on_26\IN\1740 parkinsonian_27\JJ\1740 '_28\``\1740 off_29\NN\1740 '_30\``\1740 signs_31\NNS\6643763 and_32\CC\1740 <e1>levodopa-induced</e1>_33\JJ\1740 dyskinesias_34\NNS\14084880 (_35\-LRB-\1740 <e2>lid</e2>_36\NN\5313679 )_37\-RRB-\1740 ._38\.\1740
D007980_D004409 CID we_0\PRP\1740 found_1\VBD\2426171 significant_2\JJ\1740 positive_3\JJ\1740 correlations_4\NNS\13841213 between_5\IN\1740 the_6\DT\1740 preoperative_7\JJ\1740 <e1>levodopa</e1>_8\NN\14604959 responsiveness_9\NN\5652926 of_10\IN\1740 motor_11\NN\3699975 signs_12\NNS\6643763 and_13\CC\1740 the_14\DT\1740 levodopa_15\NN\14604959 responsiveness_16\NN\5652926 of_17\IN\1740 scores_18\NNS\13757724 in_19\IN\13603305 timed_20\VBN\489837 tests_21\NNS\5798043 (_22\-LRB-\1740 core_23\NN\7996689 assessment_24\NNP\5732756 program_25\NNP\5833840 for_26\IN\1740 intracerebral_27\NNP\1740 transplantations_28\NNPS\671351 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 contralateral_32\JJ\1740 limbs_33\NNS\5559908 and_34\CC\1740 the_35\DT\1740 improvement_36\NN\7359599 in_37\IN\13603305 these_38\DT\1740 scores_39\NNS\13757724 after_40\IN\1740 surgery_41\NN\6045562 ,_42\,\1740 whereas_43\IN\1740 there_44\EX\27167 was_45\VBD\836236 no_46\DT\7204911 correlation_47\NN\13841213 with_48\IN\1740 the_49\DT\1740 improvement_50\NN\7359599 in_51\IN\13603305 <e2>lid</e2>_52\NN\5313679 ._53\.\1740
D007980_D004409 CID we_0\PRP\1740 found_1\VBD\2426171 significant_2\JJ\1740 positive_3\JJ\1740 correlations_4\NNS\13841213 between_5\IN\1740 the_6\DT\1740 preoperative_7\JJ\1740 levodopa_8\NN\14604959 responsiveness_9\NN\5652926 of_10\IN\1740 motor_11\NN\3699975 signs_12\NNS\6643763 and_13\CC\1740 the_14\DT\1740 <e1>levodopa</e1>_15\NN\14604959 responsiveness_16\NN\5652926 of_17\IN\1740 scores_18\NNS\13757724 in_19\IN\13603305 timed_20\VBN\489837 tests_21\NNS\5798043 (_22\-LRB-\1740 core_23\NN\7996689 assessment_24\NNP\5732756 program_25\NNP\5833840 for_26\IN\1740 intracerebral_27\NNP\1740 transplantations_28\NNPS\671351 )_29\-RRB-\1740 in_30\IN\13603305 the_31\DT\1740 contralateral_32\JJ\1740 limbs_33\NNS\5559908 and_34\CC\1740 the_35\DT\1740 improvement_36\NN\7359599 in_37\IN\13603305 these_38\DT\1740 scores_39\NNS\13757724 after_40\IN\1740 surgery_41\NN\6045562 ,_42\,\1740 whereas_43\IN\1740 there_44\EX\27167 was_45\VBD\836236 no_46\DT\7204911 correlation_47\NN\13841213 with_48\IN\1740 the_49\DT\1740 improvement_50\NN\7359599 in_51\IN\13603305 <e2>lid</e2>_52\NN\5313679 ._53\.\1740
D007980_D004409 CID the_0\DT\1740 differential_1\JJ\1740 predictive_2\JJ\1740 value_3\NN\5856066 of_4\IN\1740 <e1>levodopa</e1>_5\NN\14604959 responsiveness_6\NN\5652926 for_7\IN\1740 the_8\DT\1740 outcome_9\NN\7291312 of_10\IN\1740 parkinsonian_11\NN\1740 '_12\``\1740 off_13\NN\1740 '_14\``\1740 signs_15\NNS\6643763 and_16\CC\1740 <e2>lid</e2>_17\NN\5313679 and_18\CC\1740 the_19\DT\1740 different_20\JJ\1740 correlations_21\NNS\13841213 of_22\IN\1740 ventral_23\JJ\1740 lesion_24\NN\14204950 volume_25\NN\33615 with_26\IN\1740 dyskinesias_27\NNS\14084880 and_28\CC\1740 parkinsonian_29\JJ\1740 '_30\''\1740 off_31\NN\1740 '_32\``\1740 signs_33\NNS\6643763 indicate_34\VBP\952524 that_35\IN\1740 different_36\JJ\1740 anatomical_37\JJ\1740 or_38\CC\3541091 pathophysiological_39\JJ\1740 substrates_40\NNS\19613 may_41\MD\15209706 be_42\VB\836236 responsible_43\JJ\1740 for_44\IN\1740 the_45\DT\1740 generation_46\NN\7942152 of_47\IN\1740 parkinsonian_48\NN\1740 '_49\''\1740 off_50\NN\1740 '_51\``\1740 signs_52\NNS\6643763 and_53\CC\1740 dyskinesias_54\NNS\14084880 ._55\.\1740
D007980_D004409 CID the_0\DT\1740 differential_1\JJ\1740 predictive_2\JJ\1740 value_3\NN\5856066 of_4\IN\1740 <e1>levodopa</e1>_5\NN\14604959 responsiveness_6\NN\5652926 for_7\IN\1740 the_8\DT\1740 outcome_9\NN\7291312 of_10\IN\1740 parkinsonian_11\NN\1740 '_12\``\1740 off_13\NN\1740 '_14\``\1740 signs_15\NNS\6643763 and_16\CC\1740 lid_17\NN\5313679 and_18\CC\1740 the_19\DT\1740 different_20\JJ\1740 correlations_21\NNS\13841213 of_22\IN\1740 ventral_23\JJ\1740 lesion_24\NN\14204950 volume_25\NN\33615 with_26\IN\1740 <e2>dyskinesias</e2>_27\NNS\14084880 and_28\CC\1740 parkinsonian_29\JJ\1740 '_30\''\1740 off_31\NN\1740 '_32\``\1740 signs_33\NNS\6643763 indicate_34\VBP\952524 that_35\IN\1740 different_36\JJ\1740 anatomical_37\JJ\1740 or_38\CC\3541091 pathophysiological_39\JJ\1740 substrates_40\NNS\19613 may_41\MD\15209706 be_42\VB\836236 responsible_43\JJ\1740 for_44\IN\1740 the_45\DT\1740 generation_46\NN\7942152 of_47\IN\1740 parkinsonian_48\NN\1740 '_49\''\1740 off_50\NN\1740 '_51\``\1740 signs_52\NNS\6643763 and_53\CC\1740 dyskinesias_54\NNS\14084880 ._55\.\1740
D007980_D004409 CID the_0\DT\1740 differential_1\JJ\1740 predictive_2\JJ\1740 value_3\NN\5856066 of_4\IN\1740 <e1>levodopa</e1>_5\NN\14604959 responsiveness_6\NN\5652926 for_7\IN\1740 the_8\DT\1740 outcome_9\NN\7291312 of_10\IN\1740 parkinsonian_11\NN\1740 '_12\``\1740 off_13\NN\1740 '_14\``\1740 signs_15\NNS\6643763 and_16\CC\1740 lid_17\NN\5313679 and_18\CC\1740 the_19\DT\1740 different_20\JJ\1740 correlations_21\NNS\13841213 of_22\IN\1740 ventral_23\JJ\1740 lesion_24\NN\14204950 volume_25\NN\33615 with_26\IN\1740 dyskinesias_27\NNS\14084880 and_28\CC\1740 parkinsonian_29\JJ\1740 '_30\''\1740 off_31\NN\1740 '_32\``\1740 signs_33\NNS\6643763 indicate_34\VBP\952524 that_35\IN\1740 different_36\JJ\1740 anatomical_37\JJ\1740 or_38\CC\3541091 pathophysiological_39\JJ\1740 substrates_40\NNS\19613 may_41\MD\15209706 be_42\VB\836236 responsible_43\JJ\1740 for_44\IN\1740 the_45\DT\1740 generation_46\NN\7942152 of_47\IN\1740 parkinsonian_48\NN\1740 '_49\''\1740 off_50\NN\1740 '_51\``\1740 signs_52\NNS\6643763 and_53\CC\1740 <e2>dyskinesias</e2>_54\NNS\14084880 ._55\.\1740
1079693
D000305_D014605 NONE even_0\RB\1740 after_1\IN\1740 early_2\JJ\1740 detection_3\NN\5708432 and_4\CC\1740 prompt_5\VB\1645601 treatment_6\NN\654885 ,_7\,\1740 41_8\CD\1740 %_9\NN\1740 of_10\IN\1740 cases_11\NNS\7283608 of_12\IN\1740 <e2>uveitis</e2>_13\NN\14336539 did_14\VBD\1640855 not_15\RB\1740 respond_16\VB\2367363 to_17\IN\1740 more_18\JJR\1740 than_19\IN\1740 six_20\CD\13741022 months_21\NNS\15113229 of_22\IN\1740 intensive_23\JJ\1740 topical_24\JJ\1740 treatment_25\NN\654885 with_26\IN\1740 <e1>corticosteroids</e1>_27\NNS\14745635 and_28\CC\1740 mydriatics_29\NNS\3247620 ._30\.\1740
D002738_D012164 NONE we_0\PRP\1740 used_1\VBD\1156834 <e1>chloroquine</e1>_2\NN\2721948 or_3\CC\3541091 hydroxychloroquine_4\NN\2721538 in_5\IN\13603305 173_6\CD\1740 of_7\IN\1740 210_8\CD\1740 cases_9\NNS\7283608 and_10\CC\1740 found_11\VBD\2426171 only_12\RB\1740 one_13\CD\13741022 case_14\NN\7283608 of_15\IN\1740 <e2>chorioretinopathy</e2>_16\JJ\1740 attributable_17\JJ\1740 to_18\TO\1740 these_19\DT\1740 drugs_20\NNS\14778436 ._21\.\1740
D006886_D012164 CID we_0\PRP\1740 used_1\VBD\1156834 chloroquine_2\NN\2721948 or_3\CC\3541091 <e1>hydroxychloroquine</e1>_4\NN\2721538 in_5\IN\13603305 173_6\CD\1740 of_7\IN\1740 210_8\CD\1740 cases_9\NNS\7283608 and_10\CC\1740 found_11\VBD\2426171 only_12\RB\1740 one_13\CD\13741022 case_14\NN\7283608 of_15\IN\1740 <e2>chorioretinopathy</e2>_16\JJ\1740 attributable_17\JJ\1740 to_18\TO\1740 these_19\DT\1740 drugs_20\NNS\14778436 ._21\.\1740
D000305_D002386 NONE systemically_0\RB\1740 administered_1\VBN\2436349 <e1>corticosteroids</e1>_2\NNS\14745635 were_3\VBD\836236 used_4\VBN\1156834 in_5\IN\13603305 75_6\CD\1740 of_7\IN\1740 210_8\CD\1740 cases_9\NNS\7283608 ;_10\:\1740 a_11\DT\13649268 significant_12\JJ\1740 number_13\NN\5107765 of_14\IN\1740 posterior_15\JJ\1740 subcapsular_16\JJ\1740 <e2>cataracts</e2>_17\NNS\14252864 was_18\VBD\836236 found_19\VBN\2426171 ._20\.\1740
11195262
D014635_D007177 CID contribution_0\NN\786195 of_1\IN\1740 <e1>sodium_2\NN\14625458 valproate</e1>_3\NN\1740 to_4\TO\1740 the_5\DT\1740 <e2>syndrome_6\NN\5870365 of_7\IN\1740 inappropriate_8\JJ\1740 secretion_9\NN\13526110 of_10\IN\1740 antidiuretic_11\JJ\1740 hormone</e2>_12\NN\5404728 ._13\.\1740
D014635_D007177 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 62-year-old_6\JJ\1740 man_7\NN\9605289 who_8\WP\8299493 was_9\VBD\836236 administered_10\VBN\2436349 <e1>sodium_11\NN\14625458 valproate</e1>_12\NN\1740 (_13\-LRB-\1740 vpa_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 who_17\WP\8299493 subsequently_18\RB\1740 developed_19\VBD\1753788 the_20\DT\1740 <e2>syndrome_21\NN\5870365 of_22\IN\1740 inappropriate_23\JJ\1740 secretion_24\NN\13526110 of_25\IN\1740 antidiuretic_26\JJ\1740 hormone</e2>_27\NN\5404728 (_28\-LRB-\1740 siadh_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D014635_D007177 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 62-year-old_6\JJ\1740 man_7\NN\9605289 who_8\WP\8299493 was_9\VBD\836236 administered_10\VBN\2436349 <e1>sodium_11\NN\14625458 valproate</e1>_12\NN\1740 (_13\-LRB-\1740 vpa_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 who_17\WP\8299493 subsequently_18\RB\1740 developed_19\VBD\1753788 the_20\DT\1740 syndrome_21\NN\5870365 of_22\IN\1740 inappropriate_23\JJ\1740 secretion_24\NN\13526110 of_25\IN\1740 antidiuretic_26\JJ\1740 hormone_27\NN\5404728 (_28\-LRB-\1740 <e2>siadh</e2>_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D014635_D007177 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 62-year-old_6\JJ\1740 man_7\NN\9605289 who_8\WP\8299493 was_9\VBD\836236 administered_10\VBN\2436349 sodium_11\NN\14625458 valproate_12\NN\1740 (_13\-LRB-\1740 <e1>vpa</e1>_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 who_17\WP\8299493 subsequently_18\RB\1740 developed_19\VBD\1753788 the_20\DT\1740 <e2>syndrome_21\NN\5870365 of_22\IN\1740 inappropriate_23\JJ\1740 secretion_24\NN\13526110 of_25\IN\1740 antidiuretic_26\JJ\1740 hormone</e2>_27\NN\5404728 (_28\-LRB-\1740 siadh_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D014635_D007177 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 62-year-old_6\JJ\1740 man_7\NN\9605289 who_8\WP\8299493 was_9\VBD\836236 administered_10\VBN\2436349 sodium_11\NN\14625458 valproate_12\NN\1740 (_13\-LRB-\1740 <e1>vpa</e1>_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 who_17\WP\8299493 subsequently_18\RB\1740 developed_19\VBD\1753788 the_20\DT\1740 syndrome_21\NN\5870365 of_22\IN\1740 inappropriate_23\JJ\1740 secretion_24\NN\13526110 of_25\IN\1740 antidiuretic_26\JJ\1740 hormone_27\NN\5404728 (_28\-LRB-\1740 <e2>siadh</e2>_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D014635_D007177 CID we_0\PRP\1740 consider_1\VBP\689344 this_2\DT\1740 episode_3\NN\7283608 of_4\IN\1740 <e2>siadh</e2>_5\NN\1740 to_6\TO\1740 be_7\VB\836236 the_8\DT\1740 result_9\NN\34213 of_10\IN\1740 a_11\DT\13649268 combination_12\NN\7951464 of_13\IN\1740 factors_14\NNS\7326557 including_15\VBG\690614 a_16\DT\13649268 weakness_17\NN\14462666 of_18\IN\1740 the_19\DT\1740 central_20\JJ\1740 nervous_21\JJ\1740 system_22\NN\3575240 and_23\CC\1740 the_24\DT\1740 long-term_25\JJ\1740 administration_26\NN\1133281 of_27\IN\1740 <e1>vpa</e1>_28\NN\1740 ._29\.\1740
D014635_D004830 NONE he_0\PRP\14622893 had_1\VBD\2108377 been_2\VBN\836236 taking_3\VBG\2367363 <e1>vpa</e1>_4\NN\1740 for_5\IN\1740 treatment_6\NN\654885 of_7\IN\1740 idiopathic_8\JJ\1740 generalized_9\VBN\634472 <e2>tonic-clonic_10\JJ\1740 convulsions</e2>_11\NNS\14081375 since_12\IN\1740 he_13\PRP\14622893 was_14\VBD\836236 56_15\CD\1740 years_16\NNS\15144371 old_17\JJ\1740 ._18\.\1740
D014635_D002493 NONE we_0\PRP\1740 consider_1\VBP\689344 this_2\DT\1740 episode_3\NN\7283608 of_4\IN\1740 siadh_5\NN\1740 to_6\TO\1740 be_7\VB\836236 the_8\DT\1740 result_9\NN\34213 of_10\IN\1740 a_11\DT\13649268 combination_12\NN\7951464 of_13\IN\1740 factors_14\NNS\7326557 including_15\VBG\690614 a_16\DT\13649268 <e2>weakness_17\NN\14462666 of_18\IN\1740 the_19\DT\1740 central_20\JJ\1740 nervous_21\JJ\1740 system</e2>_22\NN\3575240 and_23\CC\1740 the_24\DT\1740 long-term_25\JJ\1740 administration_26\NN\1133281 of_27\IN\1740 <e1>vpa</e1>_28\NN\1740 ._29\.\1740
2334179
D010396_D012594 NONE <e1>d-penicillamine</e1>_0\NN\1740 in_1\IN\13603305 the_2\DT\1740 treatment_3\NN\654885 of_4\IN\1740 <e2>localized_5\JJ\1740 scleroderma</e2>_6\NN\14187378 ._7\.\1740
D010396_D012594 NONE case_0\NN\7283608 reports_1\NNS\6470073 of_2\IN\1740 11_3\CD\13745420 patients_4\NNS\9898892 with_5\IN\1740 severe_6\JJ\1740 ,_7\,\1740 extensive_8\JJ\1740 <e2>localized_9\JJ\1740 scleroderma</e2>_10\NN\14187378 who_11\WP\8299493 were_12\VBD\836236 treated_13\VBN\2376958 with_14\IN\1740 <e1>d-penicillamine</e1>_15\NN\1740 are_16\VBP\836236 summarized_17\VBN\958334 in_18\IN\13603305 this_19\DT\1740 article_20\NN\6367571 ._21\.\1740
D010396_D012594 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>d-penicillamine</e1>_4\NN\1740 may_5\MD\15209706 be_6\VB\836236 effective_7\JJ\1740 in_8\IN\13603305 severe_9\JJ\1740 cases_10\NNS\7283608 of_11\IN\1740 <e2>localized_12\JJ\1740 scleroderma</e2>_13\NN\14187378 ._14\.\1740
D010396_D009404 CID <e1>d-penicillamine</e1>_0\NN\1740 caused_1\VBD\1617192 <e2>nephrotic_2\JJ\1740 syndrome</e2>_3\NN\5870365 in_4\IN\13603305 1_5\CD\13741022 patient_6\NN\9898892 and_7\CC\1740 milder_8\NN\1740 reversible_9\JJ\1740 proteinuria_10\NN\14299637 in_11\IN\13603305 3_12\CD\13741022 other_13\JJ\1740 patients_14\NNS\9898892 ;_15\:\1740 none_16\NN\15228378 developed_17\VBD\1753788 renal_18\JJ\1740 insufficiency_19\NN\14462946 ._20\.\1740
D010396_D011507 CID <e1>d-penicillamine</e1>_0\NN\1740 caused_1\VBD\1617192 nephrotic_2\JJ\1740 syndrome_3\NN\5870365 in_4\IN\13603305 1_5\CD\13741022 patient_6\NN\9898892 and_7\CC\1740 milder_8\NN\1740 reversible_9\JJ\1740 <e2>proteinuria</e2>_10\NN\14299637 in_11\IN\13603305 3_12\CD\13741022 other_13\JJ\1740 patients_14\NNS\9898892 ;_15\:\1740 none_16\NN\15228378 developed_17\VBD\1753788 renal_18\JJ\1740 insufficiency_19\NN\14462946 ._20\.\1740
D010396_D051437 NONE <e1>d-penicillamine</e1>_0\NN\1740 caused_1\VBD\1617192 nephrotic_2\JJ\1740 syndrome_3\NN\5870365 in_4\IN\13603305 1_5\CD\13741022 patient_6\NN\9898892 and_7\CC\1740 milder_8\NN\1740 reversible_9\JJ\1740 proteinuria_10\NN\14299637 in_11\IN\13603305 3_12\CD\13741022 other_13\JJ\1740 patients_14\NNS\9898892 ;_15\:\1740 none_16\NN\15228378 developed_17\VBD\1753788 <e2>renal_18\JJ\1740 insufficiency</e2>_19\NN\14462946 ._20\.\1740
18657397
D010406_D004827 NONE detailed_0\JJ\1740 spectral_1\JJ\1740 profile_2\NN\6999802 analysis_3\NN\633864 of_4\IN\1740 <e1>penicillin-induced</e1>_5\JJ\1740 <e2>epileptiform_6\NN\1740 activity</e2>_7\NN\30358 in_8\IN\13603305 anesthetized_9\JJ\1740 rats_10\NNS\2329401 ._11\.\1740
D010406_D004827 NONE <e1>penicillin</e1>_0\NN\2716866 model_1\NN\5888929 is_2\VBZ\836236 a_3\DT\13649268 widely_4\RB\1740 used_5\VBN\1156834 experimental_6\JJ\1740 model_7\NN\5888929 for_8\IN\1740 <e2>epilepsy</e2>_9\NN\14085708 research_10\NN\633864 ._11\.\1740
D010406_D004827 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 we_4\PRP\1740 aimed_5\VBD\1987160 to_6\TO\1740 portray_7\VB\988028 a_8\DT\13649268 detailed_9\VBN\955601 spectral_10\JJ\1740 analysis_11\NN\633864 of_12\IN\1740 <e1>penicillin-induced</e1>_13\JJ\1740 <e2>epileptiform_14\NN\1740 activity</e2>_15\NN\30358 in_16\IN\13603305 comparison_17\NN\635850 with_18\IN\1740 basal_19\JJ\1740 brain_20\NN\5462674 activity_21\NN\30358 in_22\IN\13603305 anesthetized_23\VBN\84738 wistar_24\NNP\1740 rats_25\NNS\2329401 ._26\.\1740
D010406_D004827 NONE basal_0\JJ\1740 activity_1\NN\30358 ,_2\,\1740 latent_3\JJ\1740 period_4\NN\13575869 and_5\CC\1740 the_6\DT\1740 <e1>penicillin-induced</e1>_7\JJ\1740 <e2>epileptiform_8\NN\1740 activity</e2>_9\NN\30358 periods_10\NNS\13575869 were_11\VBD\836236 then_12\RB\1740 analyzed_13\VBN\78760 using_14\VBG\1156834 both_15\CC\1740 conventional_16\JJ\1740 methods_17\NNS\5616786 and_18\CC\1740 spectral_19\JJ\1740 analysis_20\NN\633864 ._21\.\1740
D010400_D004827 CID after_0\IN\1740 a_1\DT\13649268 short_2\JJ\1740 period_3\NN\13575869 of_4\IN\1740 basal_5\JJ\1740 activity_6\NN\30358 recording_7\NN\6791372 ,_8\,\1740 <e2>epileptic</e2>_9\JJ\1740 focus_10\NN\5704266 was_11\VBD\836236 induced_12\VBN\1627355 by_13\IN\1740 injecting_14\VBG\81072 400iu/2_15\CD\1740 microl_16\NN\1740 <e1>penicillin-g_17\NN\1740 potassium</e1>_18\NN\14625458 into_19\IN\1740 the_20\DT\1740 left_21\JJ\1740 lateral_22\JJ\1740 ventricle_23\NN\5303402 while_24\IN\15122231 the_25\DT\1740 cortical_26\JJ\1740 activity_27\NN\30358 was_28\VBD\836236 continuously_29\RB\1740 recorded_30\VBN\2225492 ._31\.\1740
9270571
D004298_D020734 NONE potential_0\JJ\1740 therapeutic_1\JJ\1740 use_2\NN\407535 of_3\IN\1740 the_4\DT\1740 selective_5\JJ\1740 <e1>dopamine</e1>_6\NN\14807737 d1_7\NN\1740 receptor_8\NN\5225602 agonist_9\NN\9613191 ,_10\,\1740 a-86929_11\NN\1740 :_12\:\1740 an_13\DT\6697703 acute_14\JJ\1740 study_15\NN\635850 in_16\IN\13603305 <e2>parkinsonian</e2>_17\JJ\1740 levodopa-primed_18\JJ\1740 monkeys_19\NNS\2469914 ._20\.\1740
C095427_D020734 NONE potential_0\JJ\1740 therapeutic_1\JJ\1740 use_2\NN\407535 of_3\IN\1740 the_4\DT\1740 selective_5\JJ\1740 dopamine_6\NN\14807737 d1_7\NN\1740 receptor_8\NN\5225602 agonist_9\NN\9613191 ,_10\,\1740 <e1>a-86929</e1>_11\NN\1740 :_12\:\1740 an_13\DT\6697703 acute_14\JJ\1740 study_15\NN\635850 in_16\IN\13603305 <e2>parkinsonian</e2>_17\JJ\1740 levodopa-primed_18\JJ\1740 monkeys_19\NNS\2469914 ._20\.\1740
C095427_D020734 NONE acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>a-86929</e1>_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 mptp-induced_9\JJ\1740 <e2>parkinsonism</e2>_10\NN\14085708 as_11\IN\14622893 levodopa_12\NN\14604959 and_13\CC\1740 ly-171555_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 levodopa-induced_23\JJ\1740 dyskinesias_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 ly-171555_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 levodopa_36\NN\14604959 ._37\.\1740
D007980_D020734 NONE potential_0\JJ\1740 therapeutic_1\JJ\1740 use_2\NN\407535 of_3\IN\1740 the_4\DT\1740 selective_5\JJ\1740 dopamine_6\NN\14807737 d1_7\NN\1740 receptor_8\NN\5225602 agonist_9\NN\9613191 ,_10\,\1740 a-86929_11\NN\1740 :_12\:\1740 an_13\DT\6697703 acute_14\JJ\1740 study_15\NN\635850 in_16\IN\13603305 <e2>parkinsonian</e2>_17\JJ\1740 <e1>levodopa-primed</e1>_18\JJ\1740 monkeys_19\NNS\2469914 ._20\.\1740
D007980_D020734 NONE acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a-86929_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 mptp-induced_9\JJ\1740 <e2>parkinsonism</e2>_10\NN\14085708 as_11\IN\14622893 <e1>levodopa</e1>_12\NN\14604959 and_13\CC\1740 ly-171555_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 levodopa-induced_23\JJ\1740 dyskinesias_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 ly-171555_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 levodopa_36\NN\14604959 ._37\.\1740
D007980_D020734 NONE acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a-86929_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 mptp-induced_9\JJ\1740 <e2>parkinsonism</e2>_10\NN\14085708 as_11\IN\14622893 levodopa_12\NN\14604959 and_13\CC\1740 ly-171555_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 <e1>levodopa-induced</e1>_23\JJ\1740 dyskinesias_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 ly-171555_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 levodopa_36\NN\14604959 ._37\.\1740
D007980_D020734 NONE acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a-86929_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 mptp-induced_9\JJ\1740 <e2>parkinsonism</e2>_10\NN\14085708 as_11\IN\14622893 levodopa_12\NN\14604959 and_13\CC\1740 ly-171555_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 levodopa-induced_23\JJ\1740 dyskinesias_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 ly-171555_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 <e1>levodopa</e1>_36\NN\14604959 ._37\.\1740
D004298_D010300 NONE the_0\DT\1740 clinical_1\JJ\1740 utility_2\NN\8186047 of_3\IN\1740 <e1>dopamine</e1>_4\NN\14807737 (_5\-LRB-\1740 da_6\NN\10484858 )_7\-RRB-\1740 d1_8\NN\1740 receptor_9\NN\5225602 agonists_10\NNS\9613191 in_11\IN\13603305 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 <e2>parkinson_15\NN\1740 's_16\POS\1740 disease</e2>_17\NN\14061805 (_18\-LRB-\1740 pd_19\NN\14625458 )_20\-RRB-\1740 is_21\VBZ\836236 still_22\RB\1740 unclear_23\JJ\1740 ._24\.\1740
D004298_D010300 NONE the_0\DT\1740 clinical_1\JJ\1740 utility_2\NN\8186047 of_3\IN\1740 <e1>dopamine</e1>_4\NN\14807737 (_5\-LRB-\1740 da_6\NN\10484858 )_7\-RRB-\1740 d1_8\NN\1740 receptor_9\NN\5225602 agonists_10\NNS\9613191 in_11\IN\13603305 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 parkinson_15\NN\1740 's_16\POS\1740 disease_17\NN\14061805 (_18\-LRB-\1740 <e2>pd</e2>_19\NN\14625458 )_20\-RRB-\1740 is_21\VBZ\836236 still_22\RB\1740 unclear_23\JJ\1740 ._24\.\1740
D004298_D010300 NONE the_0\DT\1740 clinical_1\JJ\1740 utility_2\NN\8186047 of_3\IN\1740 dopamine_4\NN\14807737 (_5\-LRB-\1740 <e1>da</e1>_6\NN\10484858 )_7\-RRB-\1740 d1_8\NN\1740 receptor_9\NN\5225602 agonists_10\NNS\9613191 in_11\IN\13603305 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 <e2>parkinson_15\NN\1740 's_16\POS\1740 disease</e2>_17\NN\14061805 (_18\-LRB-\1740 pd_19\NN\14625458 )_20\-RRB-\1740 is_21\VBZ\836236 still_22\RB\1740 unclear_23\JJ\1740 ._24\.\1740
D004298_D010300 NONE the_0\DT\1740 clinical_1\JJ\1740 utility_2\NN\8186047 of_3\IN\1740 dopamine_4\NN\14807737 (_5\-LRB-\1740 <e1>da</e1>_6\NN\10484858 )_7\-RRB-\1740 d1_8\NN\1740 receptor_9\NN\5225602 agonists_10\NNS\9613191 in_11\IN\13603305 the_12\DT\1740 treatment_13\NN\654885 of_14\IN\1740 parkinson_15\NN\1740 's_16\POS\1740 disease_17\NN\14061805 (_18\-LRB-\1740 <e2>pd</e2>_19\NN\14625458 )_20\-RRB-\1740 is_21\VBZ\836236 still_22\RB\1740 unclear_23\JJ\1740 ._24\.\1740
D004298_D010300 NONE potent_0\JJ\1740 <e1>da</e1>_1\NN\10484858 d1_2\NN\1740 receptor_3\NN\5225602 agents_4\NNS\7347 with_5\IN\1740 an_6\DT\6697703 intermediate_7\JJ\1740 duration_8\NN\15113229 of_9\IN\1740 efficacy_10\NN\5199286 such_11\JJ\1740 as_12\IN\14622893 a-86929_13\NN\1740 (_14\-LRB-\1740 approximately_15\RB\1740 4_16\CD\13741022 hr_17\NN\15154774 at_18\IN\14622893 higher_19\JJR\1740 doses_20\NNS\3740161 tested_21\VBN\670261 )_22\-RRB-\1740 are_23\VBP\836236 potential_24\JJ\1740 therapeutic_25\JJ\1740 tools_26\NNS\3563967 in_27\IN\13603305 <e2>pd</e2>_28\NN\14625458 and_29\CC\1740 merit_30\NN\5138208 further_31\JJ\1740 attention_32\NN\5701944 ._33\.\1740
D015632_D004409 NONE we_0\PRP\1740 therefore_1\RB\1740 conducted_2\VBD\2436349 the_3\DT\1740 present_4\JJ\1740 acute_5\JJ\1740 dose-response_6\JJ\1740 study_7\NN\635850 in_8\IN\13603305 four_9\CD\13741022 <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>_10\CD\1740 (mptp)-exposed_11\VBN\1740 cynomolgus_12\JJ\1740 monkeys_13\NNS\2469914 primed_14\VBN\406243 to_15\TO\1740 exhibit_16\VB\2632167 levodopa-induced_17\JJ\1740 <e2>dyskinesias</e2>_18\NNS\14084880 to_19\TO\1740 evaluate_20\VB\670261 the_21\DT\1740 locomotor_22\NN\1740 and_23\CC\1740 dyskinetic_24\JJ\1740 effects_25\NNS\13245626 on_26\IN\1740 challenge_27\NN\13927383 with_28\IN\1740 four_29\CD\13741022 doses_30\NNS\3740161 (_31\-LRB-\1740 from_32\IN\1740 0.03_33\CD\1740 to_34\TO\1740 1.0_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 a-86929_39\NN\1740 (_40\-LRB-\1740 [-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+_41\NN\1740 +_42\CC\1740 +_43\CC\1740 azacyclopent-1-_44\NN\1740 ena[c]phenathrene-9_45\NN\1740 -_46\HYPH\1740 10-diol_47\NN\1740 )_48\-RRB-\1740 ,_49\,\1740 a_50\DT\13649268 selective_51\JJ\1740 and_52\CC\1740 full_53\JJ\1740 da_54\NN\10484858 d1-like_55\JJ\1740 receptor_56\NN\5225602 agonist_57\NN\9613191 with_58\IN\1740 an_59\DT\6697703 intermediate_60\JJ\1740 duration_61\NN\15113229 of_62\IN\1740 action_63\NN\30358 ._64\.\1740
D015632_D004409 NONE we_0\PRP\1740 therefore_1\RB\1740 conducted_2\VBD\2436349 the_3\DT\1740 present_4\JJ\1740 acute_5\JJ\1740 dose-response_6\JJ\1740 study_7\NN\635850 in_8\IN\13603305 four_9\CD\13741022 <e1>1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</e1>_10\CD\1740 (mptp)-exposed_11\VBN\1740 cynomolgus_12\JJ\1740 monkeys_13\NNS\2469914 primed_14\VBN\406243 to_15\TO\1740 exhibit_16\VB\2632167 levodopa-induced_17\JJ\1740 dyskinesias_18\NNS\14084880 to_19\TO\1740 evaluate_20\VB\670261 the_21\DT\1740 locomotor_22\NN\1740 and_23\CC\1740 <e2>dyskinetic</e2>_24\JJ\1740 effects_25\NNS\13245626 on_26\IN\1740 challenge_27\NN\13927383 with_28\IN\1740 four_29\CD\13741022 doses_30\NNS\3740161 (_31\-LRB-\1740 from_32\IN\1740 0.03_33\CD\1740 to_34\TO\1740 1.0_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 a-86929_39\NN\1740 (_40\-LRB-\1740 [-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+_41\NN\1740 +_42\CC\1740 +_43\CC\1740 azacyclopent-1-_44\NN\1740 ena[c]phenathrene-9_45\NN\1740 -_46\HYPH\1740 10-diol_47\NN\1740 )_48\-RRB-\1740 ,_49\,\1740 a_50\DT\13649268 selective_51\JJ\1740 and_52\CC\1740 full_53\JJ\1740 da_54\NN\10484858 d1-like_55\JJ\1740 receptor_56\NN\5225602 agonist_57\NN\9613191 with_58\IN\1740 an_59\DT\6697703 intermediate_60\JJ\1740 duration_61\NN\15113229 of_62\IN\1740 action_63\NN\30358 ._64\.\1740
D015632_D004409 NONE we_0\PRP\1740 therefore_1\RB\1740 conducted_2\VBD\2436349 the_3\DT\1740 present_4\JJ\1740 acute_5\JJ\1740 dose-response_6\JJ\1740 study_7\NN\635850 in_8\IN\13603305 four_9\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\CD\1740 <e1>(mptp)-exposed</e1>_11\VBN\1740 cynomolgus_12\JJ\1740 monkeys_13\NNS\2469914 primed_14\VBN\406243 to_15\TO\1740 exhibit_16\VB\2632167 levodopa-induced_17\JJ\1740 <e2>dyskinesias</e2>_18\NNS\14084880 to_19\TO\1740 evaluate_20\VB\670261 the_21\DT\1740 locomotor_22\NN\1740 and_23\CC\1740 dyskinetic_24\JJ\1740 effects_25\NNS\13245626 on_26\IN\1740 challenge_27\NN\13927383 with_28\IN\1740 four_29\CD\13741022 doses_30\NNS\3740161 (_31\-LRB-\1740 from_32\IN\1740 0.03_33\CD\1740 to_34\TO\1740 1.0_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 a-86929_39\NN\1740 (_40\-LRB-\1740 [-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+_41\NN\1740 +_42\CC\1740 +_43\CC\1740 azacyclopent-1-_44\NN\1740 ena[c]phenathrene-9_45\NN\1740 -_46\HYPH\1740 10-diol_47\NN\1740 )_48\-RRB-\1740 ,_49\,\1740 a_50\DT\13649268 selective_51\JJ\1740 and_52\CC\1740 full_53\JJ\1740 da_54\NN\10484858 d1-like_55\JJ\1740 receptor_56\NN\5225602 agonist_57\NN\9613191 with_58\IN\1740 an_59\DT\6697703 intermediate_60\JJ\1740 duration_61\NN\15113229 of_62\IN\1740 action_63\NN\30358 ._64\.\1740
D015632_D004409 NONE we_0\PRP\1740 therefore_1\RB\1740 conducted_2\VBD\2436349 the_3\DT\1740 present_4\JJ\1740 acute_5\JJ\1740 dose-response_6\JJ\1740 study_7\NN\635850 in_8\IN\13603305 four_9\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\CD\1740 <e1>(mptp)-exposed</e1>_11\VBN\1740 cynomolgus_12\JJ\1740 monkeys_13\NNS\2469914 primed_14\VBN\406243 to_15\TO\1740 exhibit_16\VB\2632167 levodopa-induced_17\JJ\1740 dyskinesias_18\NNS\14084880 to_19\TO\1740 evaluate_20\VB\670261 the_21\DT\1740 locomotor_22\NN\1740 and_23\CC\1740 <e2>dyskinetic</e2>_24\JJ\1740 effects_25\NNS\13245626 on_26\IN\1740 challenge_27\NN\13927383 with_28\IN\1740 four_29\CD\13741022 doses_30\NNS\3740161 (_31\-LRB-\1740 from_32\IN\1740 0.03_33\CD\1740 to_34\TO\1740 1.0_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 a-86929_39\NN\1740 (_40\-LRB-\1740 [-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+_41\NN\1740 +_42\CC\1740 +_43\CC\1740 azacyclopent-1-_44\NN\1740 ena[c]phenathrene-9_45\NN\1740 -_46\HYPH\1740 10-diol_47\NN\1740 )_48\-RRB-\1740 ,_49\,\1740 a_50\DT\13649268 selective_51\JJ\1740 and_52\CC\1740 full_53\JJ\1740 da_54\NN\10484858 d1-like_55\JJ\1740 receptor_56\NN\5225602 agonist_57\NN\9613191 with_58\IN\1740 an_59\DT\6697703 intermediate_60\JJ\1740 duration_61\NN\15113229 of_62\IN\1740 action_63\NN\30358 ._64\.\1740
D015632_D004409 NONE acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a-86929_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 <e1>mptp-induced</e1>_9\JJ\1740 parkinsonism_10\NN\14085708 as_11\IN\14622893 levodopa_12\NN\14604959 and_13\CC\1740 ly-171555_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 levodopa-induced_23\JJ\1740 <e2>dyskinesias</e2>_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 ly-171555_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 levodopa_36\NN\14604959 ._37\.\1740
D007980_D004409 CID we_0\PRP\1740 therefore_1\RB\1740 conducted_2\VBD\2436349 the_3\DT\1740 present_4\JJ\1740 acute_5\JJ\1740 dose-response_6\JJ\1740 study_7\NN\635850 in_8\IN\13603305 four_9\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\CD\1740 (mptp)-exposed_11\VBN\1740 cynomolgus_12\JJ\1740 monkeys_13\NNS\2469914 primed_14\VBN\406243 to_15\TO\1740 exhibit_16\VB\2632167 <e1>levodopa-induced</e1>_17\JJ\1740 <e2>dyskinesias</e2>_18\NNS\14084880 to_19\TO\1740 evaluate_20\VB\670261 the_21\DT\1740 locomotor_22\NN\1740 and_23\CC\1740 dyskinetic_24\JJ\1740 effects_25\NNS\13245626 on_26\IN\1740 challenge_27\NN\13927383 with_28\IN\1740 four_29\CD\13741022 doses_30\NNS\3740161 (_31\-LRB-\1740 from_32\IN\1740 0.03_33\CD\1740 to_34\TO\1740 1.0_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 a-86929_39\NN\1740 (_40\-LRB-\1740 [-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+_41\NN\1740 +_42\CC\1740 +_43\CC\1740 azacyclopent-1-_44\NN\1740 ena[c]phenathrene-9_45\NN\1740 -_46\HYPH\1740 10-diol_47\NN\1740 )_48\-RRB-\1740 ,_49\,\1740 a_50\DT\13649268 selective_51\JJ\1740 and_52\CC\1740 full_53\JJ\1740 da_54\NN\10484858 d1-like_55\JJ\1740 receptor_56\NN\5225602 agonist_57\NN\9613191 with_58\IN\1740 an_59\DT\6697703 intermediate_60\JJ\1740 duration_61\NN\15113229 of_62\IN\1740 action_63\NN\30358 ._64\.\1740
D007980_D004409 CID we_0\PRP\1740 therefore_1\RB\1740 conducted_2\VBD\2436349 the_3\DT\1740 present_4\JJ\1740 acute_5\JJ\1740 dose-response_6\JJ\1740 study_7\NN\635850 in_8\IN\13603305 four_9\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\CD\1740 (mptp)-exposed_11\VBN\1740 cynomolgus_12\JJ\1740 monkeys_13\NNS\2469914 primed_14\VBN\406243 to_15\TO\1740 exhibit_16\VB\2632167 <e1>levodopa-induced</e1>_17\JJ\1740 dyskinesias_18\NNS\14084880 to_19\TO\1740 evaluate_20\VB\670261 the_21\DT\1740 locomotor_22\NN\1740 and_23\CC\1740 <e2>dyskinetic</e2>_24\JJ\1740 effects_25\NNS\13245626 on_26\IN\1740 challenge_27\NN\13927383 with_28\IN\1740 four_29\CD\13741022 doses_30\NNS\3740161 (_31\-LRB-\1740 from_32\IN\1740 0.03_33\CD\1740 to_34\TO\1740 1.0_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 a-86929_39\NN\1740 (_40\-LRB-\1740 [-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+_41\NN\1740 +_42\CC\1740 +_43\CC\1740 azacyclopent-1-_44\NN\1740 ena[c]phenathrene-9_45\NN\1740 -_46\HYPH\1740 10-diol_47\NN\1740 )_48\-RRB-\1740 ,_49\,\1740 a_50\DT\13649268 selective_51\JJ\1740 and_52\CC\1740 full_53\JJ\1740 da_54\NN\10484858 d1-like_55\JJ\1740 receptor_56\NN\5225602 agonist_57\NN\9613191 with_58\IN\1740 an_59\DT\6697703 intermediate_60\JJ\1740 duration_61\NN\15113229 of_62\IN\1740 action_63\NN\30358 ._64\.\1740
D007980_D004409 CID acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a-86929_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 mptp-induced_9\JJ\1740 parkinsonism_10\NN\14085708 as_11\IN\14622893 <e1>levodopa</e1>_12\NN\14604959 and_13\CC\1740 ly-171555_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 levodopa-induced_23\JJ\1740 <e2>dyskinesias</e2>_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 ly-171555_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 levodopa_36\NN\14604959 ._37\.\1740
D007980_D004409 CID acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a-86929_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 mptp-induced_9\JJ\1740 parkinsonism_10\NN\14085708 as_11\IN\14622893 levodopa_12\NN\14604959 and_13\CC\1740 ly-171555_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 <e1>levodopa-induced</e1>_23\JJ\1740 <e2>dyskinesias</e2>_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 ly-171555_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 levodopa_36\NN\14604959 ._37\.\1740
D007980_D004409 CID acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a-86929_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 mptp-induced_9\JJ\1740 parkinsonism_10\NN\14085708 as_11\IN\14622893 levodopa_12\NN\14604959 and_13\CC\1740 ly-171555_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 levodopa-induced_23\JJ\1740 <e2>dyskinesias</e2>_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 ly-171555_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 <e1>levodopa</e1>_36\NN\14604959 ._37\.\1740
C095427_D004409 NONE we_0\PRP\1740 therefore_1\RB\1740 conducted_2\VBD\2436349 the_3\DT\1740 present_4\JJ\1740 acute_5\JJ\1740 dose-response_6\JJ\1740 study_7\NN\635850 in_8\IN\13603305 four_9\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\CD\1740 (mptp)-exposed_11\VBN\1740 cynomolgus_12\JJ\1740 monkeys_13\NNS\2469914 primed_14\VBN\406243 to_15\TO\1740 exhibit_16\VB\2632167 levodopa-induced_17\JJ\1740 <e2>dyskinesias</e2>_18\NNS\14084880 to_19\TO\1740 evaluate_20\VB\670261 the_21\DT\1740 locomotor_22\NN\1740 and_23\CC\1740 dyskinetic_24\JJ\1740 effects_25\NNS\13245626 on_26\IN\1740 challenge_27\NN\13927383 with_28\IN\1740 four_29\CD\13741022 doses_30\NNS\3740161 (_31\-LRB-\1740 from_32\IN\1740 0.03_33\CD\1740 to_34\TO\1740 1.0_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 <e1>a-86929</e1>_39\NN\1740 (_40\-LRB-\1740 [-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+_41\NN\1740 +_42\CC\1740 +_43\CC\1740 azacyclopent-1-_44\NN\1740 ena[c]phenathrene-9_45\NN\1740 -_46\HYPH\1740 10-diol_47\NN\1740 )_48\-RRB-\1740 ,_49\,\1740 a_50\DT\13649268 selective_51\JJ\1740 and_52\CC\1740 full_53\JJ\1740 da_54\NN\10484858 d1-like_55\JJ\1740 receptor_56\NN\5225602 agonist_57\NN\9613191 with_58\IN\1740 an_59\DT\6697703 intermediate_60\JJ\1740 duration_61\NN\15113229 of_62\IN\1740 action_63\NN\30358 ._64\.\1740
C095427_D004409 NONE we_0\PRP\1740 therefore_1\RB\1740 conducted_2\VBD\2436349 the_3\DT\1740 present_4\JJ\1740 acute_5\JJ\1740 dose-response_6\JJ\1740 study_7\NN\635850 in_8\IN\13603305 four_9\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\CD\1740 (mptp)-exposed_11\VBN\1740 cynomolgus_12\JJ\1740 monkeys_13\NNS\2469914 primed_14\VBN\406243 to_15\TO\1740 exhibit_16\VB\2632167 levodopa-induced_17\JJ\1740 dyskinesias_18\NNS\14084880 to_19\TO\1740 evaluate_20\VB\670261 the_21\DT\1740 locomotor_22\NN\1740 and_23\CC\1740 <e2>dyskinetic</e2>_24\JJ\1740 effects_25\NNS\13245626 on_26\IN\1740 challenge_27\NN\13927383 with_28\IN\1740 four_29\CD\13741022 doses_30\NNS\3740161 (_31\-LRB-\1740 from_32\IN\1740 0.03_33\CD\1740 to_34\TO\1740 1.0_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 <e1>a-86929</e1>_39\NN\1740 (_40\-LRB-\1740 [-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+_41\NN\1740 +_42\CC\1740 +_43\CC\1740 azacyclopent-1-_44\NN\1740 ena[c]phenathrene-9_45\NN\1740 -_46\HYPH\1740 10-diol_47\NN\1740 )_48\-RRB-\1740 ,_49\,\1740 a_50\DT\13649268 selective_51\JJ\1740 and_52\CC\1740 full_53\JJ\1740 da_54\NN\10484858 d1-like_55\JJ\1740 receptor_56\NN\5225602 agonist_57\NN\9613191 with_58\IN\1740 an_59\DT\6697703 intermediate_60\JJ\1740 duration_61\NN\15113229 of_62\IN\1740 action_63\NN\30358 ._64\.\1740
C095427_D004409 NONE we_0\PRP\1740 therefore_1\RB\1740 conducted_2\VBD\2436349 the_3\DT\1740 present_4\JJ\1740 acute_5\JJ\1740 dose-response_6\JJ\1740 study_7\NN\635850 in_8\IN\13603305 four_9\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\CD\1740 (mptp)-exposed_11\VBN\1740 cynomolgus_12\JJ\1740 monkeys_13\NNS\2469914 primed_14\VBN\406243 to_15\TO\1740 exhibit_16\VB\2632167 levodopa-induced_17\JJ\1740 <e2>dyskinesias</e2>_18\NNS\14084880 to_19\TO\1740 evaluate_20\VB\670261 the_21\DT\1740 locomotor_22\NN\1740 and_23\CC\1740 dyskinetic_24\JJ\1740 effects_25\NNS\13245626 on_26\IN\1740 challenge_27\NN\13927383 with_28\IN\1740 four_29\CD\13741022 doses_30\NNS\3740161 (_31\-LRB-\1740 from_32\IN\1740 0.03_33\CD\1740 to_34\TO\1740 1.0_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 a-86929_39\NN\1740 (_40\-LRB-\1740 <e1>[-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+_41\NN\1740 +_42\CC\1740 +_43\CC\1740 azacyclopent-1-_44\NN\1740 ena[c]phenathrene-9_45\NN\1740 -_46\HYPH\1740 10-diol</e1>_47\NN\1740 )_48\-RRB-\1740 ,_49\,\1740 a_50\DT\13649268 selective_51\JJ\1740 and_52\CC\1740 full_53\JJ\1740 da_54\NN\10484858 d1-like_55\JJ\1740 receptor_56\NN\5225602 agonist_57\NN\9613191 with_58\IN\1740 an_59\DT\6697703 intermediate_60\JJ\1740 duration_61\NN\15113229 of_62\IN\1740 action_63\NN\30358 ._64\.\1740
C095427_D004409 NONE we_0\PRP\1740 therefore_1\RB\1740 conducted_2\VBD\2436349 the_3\DT\1740 present_4\JJ\1740 acute_5\JJ\1740 dose-response_6\JJ\1740 study_7\NN\635850 in_8\IN\13603305 four_9\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\CD\1740 (mptp)-exposed_11\VBN\1740 cynomolgus_12\JJ\1740 monkeys_13\NNS\2469914 primed_14\VBN\406243 to_15\TO\1740 exhibit_16\VB\2632167 levodopa-induced_17\JJ\1740 dyskinesias_18\NNS\14084880 to_19\TO\1740 evaluate_20\VB\670261 the_21\DT\1740 locomotor_22\NN\1740 and_23\CC\1740 <e2>dyskinetic</e2>_24\JJ\1740 effects_25\NNS\13245626 on_26\IN\1740 challenge_27\NN\13927383 with_28\IN\1740 four_29\CD\13741022 doses_30\NNS\3740161 (_31\-LRB-\1740 from_32\IN\1740 0.03_33\CD\1740 to_34\TO\1740 1.0_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 a-86929_39\NN\1740 (_40\-LRB-\1740 <e1>[-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+_41\NN\1740 +_42\CC\1740 +_43\CC\1740 azacyclopent-1-_44\NN\1740 ena[c]phenathrene-9_45\NN\1740 -_46\HYPH\1740 10-diol</e1>_47\NN\1740 )_48\-RRB-\1740 ,_49\,\1740 a_50\DT\13649268 selective_51\JJ\1740 and_52\CC\1740 full_53\JJ\1740 da_54\NN\10484858 d1-like_55\JJ\1740 receptor_56\NN\5225602 agonist_57\NN\9613191 with_58\IN\1740 an_59\DT\6697703 intermediate_60\JJ\1740 duration_61\NN\15113229 of_62\IN\1740 action_63\NN\30358 ._64\.\1740
C095427_D004409 NONE acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>a-86929</e1>_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 mptp-induced_9\JJ\1740 parkinsonism_10\NN\14085708 as_11\IN\14622893 levodopa_12\NN\14604959 and_13\CC\1740 ly-171555_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 levodopa-induced_23\JJ\1740 <e2>dyskinesias</e2>_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 ly-171555_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 levodopa_36\NN\14604959 ._37\.\1740
D004298_D004409 NONE we_0\PRP\1740 therefore_1\RB\1740 conducted_2\VBD\2436349 the_3\DT\1740 present_4\JJ\1740 acute_5\JJ\1740 dose-response_6\JJ\1740 study_7\NN\635850 in_8\IN\13603305 four_9\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\CD\1740 (mptp)-exposed_11\VBN\1740 cynomolgus_12\JJ\1740 monkeys_13\NNS\2469914 primed_14\VBN\406243 to_15\TO\1740 exhibit_16\VB\2632167 levodopa-induced_17\JJ\1740 <e2>dyskinesias</e2>_18\NNS\14084880 to_19\TO\1740 evaluate_20\VB\670261 the_21\DT\1740 locomotor_22\NN\1740 and_23\CC\1740 dyskinetic_24\JJ\1740 effects_25\NNS\13245626 on_26\IN\1740 challenge_27\NN\13927383 with_28\IN\1740 four_29\CD\13741022 doses_30\NNS\3740161 (_31\-LRB-\1740 from_32\IN\1740 0.03_33\CD\1740 to_34\TO\1740 1.0_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 a-86929_39\NN\1740 (_40\-LRB-\1740 [-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+_41\NN\1740 +_42\CC\1740 +_43\CC\1740 azacyclopent-1-_44\NN\1740 ena[c]phenathrene-9_45\NN\1740 -_46\HYPH\1740 10-diol_47\NN\1740 )_48\-RRB-\1740 ,_49\,\1740 a_50\DT\13649268 selective_51\JJ\1740 and_52\CC\1740 full_53\JJ\1740 <e1>da</e1>_54\NN\10484858 d1-like_55\JJ\1740 receptor_56\NN\5225602 agonist_57\NN\9613191 with_58\IN\1740 an_59\DT\6697703 intermediate_60\JJ\1740 duration_61\NN\15113229 of_62\IN\1740 action_63\NN\30358 ._64\.\1740
D004298_D004409 NONE we_0\PRP\1740 therefore_1\RB\1740 conducted_2\VBD\2436349 the_3\DT\1740 present_4\JJ\1740 acute_5\JJ\1740 dose-response_6\JJ\1740 study_7\NN\635850 in_8\IN\13603305 four_9\CD\13741022 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_10\CD\1740 (mptp)-exposed_11\VBN\1740 cynomolgus_12\JJ\1740 monkeys_13\NNS\2469914 primed_14\VBN\406243 to_15\TO\1740 exhibit_16\VB\2632167 levodopa-induced_17\JJ\1740 dyskinesias_18\NNS\14084880 to_19\TO\1740 evaluate_20\VB\670261 the_21\DT\1740 locomotor_22\NN\1740 and_23\CC\1740 <e2>dyskinetic</e2>_24\JJ\1740 effects_25\NNS\13245626 on_26\IN\1740 challenge_27\NN\13927383 with_28\IN\1740 four_29\CD\13741022 doses_30\NNS\3740161 (_31\-LRB-\1740 from_32\IN\1740 0.03_33\CD\1740 to_34\TO\1740 1.0_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 of_38\IN\1740 a-86929_39\NN\1740 (_40\-LRB-\1740 [-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+_41\NN\1740 +_42\CC\1740 +_43\CC\1740 azacyclopent-1-_44\NN\1740 ena[c]phenathrene-9_45\NN\1740 -_46\HYPH\1740 10-diol_47\NN\1740 )_48\-RRB-\1740 ,_49\,\1740 a_50\DT\13649268 selective_51\JJ\1740 and_52\CC\1740 full_53\JJ\1740 <e1>da</e1>_54\NN\10484858 d1-like_55\JJ\1740 receptor_56\NN\5225602 agonist_57\NN\9613191 with_58\IN\1740 an_59\DT\6697703 intermediate_60\JJ\1740 duration_61\NN\15113229 of_62\IN\1740 action_63\NN\30358 ._64\.\1740
D015632_D020734 CID acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a-86929_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 <e1>mptp-induced</e1>_9\JJ\1740 <e2>parkinsonism</e2>_10\NN\14085708 as_11\IN\14622893 levodopa_12\NN\14604959 and_13\CC\1740 ly-171555_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 levodopa-induced_23\JJ\1740 dyskinesias_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 ly-171555_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 levodopa_36\NN\14604959 ._37\.\1740
C416545_D020734 NONE acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a-86929_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 mptp-induced_9\JJ\1740 <e2>parkinsonism</e2>_10\NN\14085708 as_11\IN\14622893 levodopa_12\NN\14604959 and_13\CC\1740 <e1>ly-171555</e1>_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 levodopa-induced_23\JJ\1740 dyskinesias_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 ly-171555_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 levodopa_36\NN\14604959 ._37\.\1740
C416545_D020734 NONE acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a-86929_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 mptp-induced_9\JJ\1740 <e2>parkinsonism</e2>_10\NN\14085708 as_11\IN\14622893 levodopa_12\NN\14604959 and_13\CC\1740 ly-171555_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 levodopa-induced_23\JJ\1740 dyskinesias_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 <e1>ly-171555</e1>_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 levodopa_36\NN\14604959 ._37\.\1740
C416545_D004409 NONE acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a-86929_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 mptp-induced_9\JJ\1740 parkinsonism_10\NN\14085708 as_11\IN\14622893 levodopa_12\NN\14604959 and_13\CC\1740 <e1>ly-171555</e1>_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 levodopa-induced_23\JJ\1740 <e2>dyskinesias</e2>_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 ly-171555_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 levodopa_36\NN\14604959 ._37\.\1740
C416545_D004409 NONE acute_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 a-86929_3\NN\1740 was_4\VBD\836236 as_5\IN\14622893 efficacious_6\JJ\1740 in_7\IN\13603305 alleviating_8\VBG\205885 mptp-induced_9\JJ\1740 parkinsonism_10\NN\14085708 as_11\IN\14622893 levodopa_12\NN\14604959 and_13\CC\1740 ly-171555_14\NN\1740 ,_15\,\1740 but_16\CC\1740 was_17\VBD\836236 less_18\RBR\1740 likely_19\JJ\1740 to_20\TO\1740 reproduce_21\VB\1621555 the_22\DT\1740 levodopa-induced_23\JJ\1740 <e2>dyskinesias</e2>_24\NNS\14084880 in_25\IN\13603305 these_26\DT\1740 animals_27\NNS\4475 than_28\IN\1740 with_29\IN\1740 either_30\CC\1740 <e1>ly-171555</e1>_31\NN\1740 or_32\CC\3541091 subsequent_33\JJ\1740 challenge_34\NN\13927383 of_35\IN\1740 levodopa_36\NN\14604959 ._37\.\1740
C095427_D010300 NONE potent_0\JJ\1740 da_1\NN\10484858 d1_2\NN\1740 receptor_3\NN\5225602 agents_4\NNS\7347 with_5\IN\1740 an_6\DT\6697703 intermediate_7\JJ\1740 duration_8\NN\15113229 of_9\IN\1740 efficacy_10\NN\5199286 such_11\JJ\1740 as_12\IN\14622893 <e1>a-86929</e1>_13\NN\1740 (_14\-LRB-\1740 approximately_15\RB\1740 4_16\CD\13741022 hr_17\NN\15154774 at_18\IN\14622893 higher_19\JJR\1740 doses_20\NNS\3740161 tested_21\VBN\670261 )_22\-RRB-\1740 are_23\VBP\836236 potential_24\JJ\1740 therapeutic_25\JJ\1740 tools_26\NNS\3563967 in_27\IN\13603305 <e2>pd</e2>_28\NN\14625458 and_29\CC\1740 merit_30\NN\5138208 further_31\JJ\1740 attention_32\NN\5701944 ._33\.\1740
8305357
D003630_D012514 NONE liposomal_0\JJ\1740 <e1>daunorubicin</e1>_1\NN\1740 in_2\IN\13603305 advanced_3\JJ\1740 <e2>kaposi_4\NN\1740 's_5\POS\1740 sarcoma</e2>_6\NN\14239918 :_7\:\1740 a_8\DT\13649268 phase_9\NN\15113229 ii_10\CD\13741022 study_11\NN\635850 ._12\.\1740
D003630_D012514 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 non-randomized_3\JJ\1740 phase_4\NN\15113229 ii_5\CD\13741022 clinical_6\JJ\1740 trial_7\NN\786195 to_8\TO\1740 assess_9\VB\670261 the_10\DT\1740 efficacy_11\NN\5199286 and_12\CC\1740 safety_13\NN\13920835 of_14\IN\1740 liposomal_15\JJ\1740 <e1>daunorubicin</e1>_16\NN\1740 (_17\-LRB-\1740 daunoxome_18\NN\1740 )_19\-RRB-\1740 in_20\IN\13603305 the_21\DT\1740 treatment_22\NN\654885 of_23\IN\1740 aids_24\NN\13974317 related_25\JJ\1740 <e2>kaposi_26\NN\1740 's_27\POS\1740 sarcoma</e2>_28\NN\14239918 ._29\.\1740
D003630_D012514 NONE in_0\IN\13603305 this_1\DT\1740 small_2\JJ\1740 patient_3\NN\9898892 sample_4\NN\5820620 ,_5\,\1740 liposomal_6\JJ\1740 <e1>daunorubicin</e1>_7\NN\1740 was_8\VBD\836236 an_9\DT\6697703 effective_10\JJ\1740 and_11\CC\1740 well_12\RB\1740 tolerated_13\VBN\802318 agent_14\NN\7347 in_15\IN\13603305 the_16\DT\1740 treatment_17\NN\654885 of_18\IN\1740 <e2>kaposi_19\NN\1740 's_20\POS\1740 sarcoma</e2>_21\NN\14239918 ._22\.\1740
D003630_D000163 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 non-randomized_3\JJ\1740 phase_4\NN\15113229 ii_5\CD\13741022 clinical_6\JJ\1740 trial_7\NN\786195 to_8\TO\1740 assess_9\VB\670261 the_10\DT\1740 efficacy_11\NN\5199286 and_12\CC\1740 safety_13\NN\13920835 of_14\IN\1740 liposomal_15\JJ\1740 <e1>daunorubicin</e1>_16\NN\1740 (_17\-LRB-\1740 daunoxome_18\NN\1740 )_19\-RRB-\1740 in_20\IN\13603305 the_21\DT\1740 treatment_22\NN\654885 of_23\IN\1740 <e2>aids</e2>_24\NN\13974317 related_25\JJ\1740 kaposi_26\NN\1740 's_27\POS\1740 sarcoma_28\NN\14239918 ._29\.\1740
15985056
D017963_D006606 CID possible_0\JJ\1740 <e1>azithromycin-associated</e1>_1\JJ\1740 <e2>hiccups</e2>_2\NNS\863513 ._3\.\1740
D017963_D006606 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 report_3\VB\831651 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 persistent_7\JJ\1740 <e2>hiccups</e2>_8\NNS\863513 associated_9\VBN\628491 by_10\IN\1740 <e1>azithromycin</e1>_11\NN\2716205 therapy_12\NN\657604 ._13\.\1740
D017963_D006606 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 76-year-old_4\JJ\1740 man_5\NN\9605289 presented_6\VBN\2137132 with_7\IN\1740 persistent_8\JJ\1740 <e2>hiccups</e2>_9\NNS\863513 after_10\IN\1740 beginning_11\VBG\941990 <e1>azithromycin</e1>_12\NN\2716205 for_13\IN\1740 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 pharyngitis_17\NN\14171682 ._18\.\1740
D017963_D006606 CID discontinuation_0\NN\209943 of_1\IN\1740 <e1>azithromycin</e1>_2\NN\2716205 and_3\CC\1740 therapy_4\NN\657604 with_5\IN\1740 baclofen_6\NN\1740 finally_7\RB\1740 resolved_8\VBN\352826 <e2>hiccups</e2>_9\NNS\863513 ._10\.\1740
D017963_D006606 CID our_0\PRP$\1740 hypothesis_1\NN\7162194 is_2\VBZ\836236 that_3\IN\1740 a_4\DT\13649268 vagal_5\JJ\1740 mechanism_6\NN\13446390 mediated_7\VBN\761713 by_8\IN\1740 <e1>azithromycin</e1>_9\NN\2716205 could_10\MD\1740 be_11\VB\836236 the_12\DT\1740 pathogenesis_13\NN\13533470 of_14\IN\1740 <e2>hiccups</e2>_15\NNS\863513 in_16\IN\13603305 our_17\PRP$\1740 patient_18\NN\9898892 ._19\.\1740
D017963_D010612 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 76-year-old_4\JJ\1740 man_5\NN\9605289 presented_6\VBN\2137132 with_7\IN\1740 persistent_8\JJ\1740 hiccups_9\NNS\863513 after_10\IN\1740 beginning_11\VBG\941990 <e1>azithromycin</e1>_12\NN\2716205 for_13\IN\1740 the_14\DT\1740 treatment_15\NN\654885 of_16\IN\1740 <e2>pharyngitis</e2>_17\NN\14171682 ._18\.\1740
D001418_D006606 CID discontinuation_0\NN\209943 of_1\IN\1740 azithromycin_2\NN\2716205 and_3\CC\1740 therapy_4\NN\657604 with_5\IN\1740 <e1>baclofen</e1>_6\NN\1740 finally_7\RB\1740 resolved_8\VBN\352826 <e2>hiccups</e2>_9\NNS\863513 ._10\.\1740
D003907_D006606 NONE corticosteroids_0\NNS\14745635 (_1\-LRB-\1740 <e1>dexamethasone</e1>_2\NN\2721538 and_3\CC\1740 methylprednisolone_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 benzodiazepines_7\NNS\3771443 (_8\-LRB-\1740 midazolam_9\NNS\2830852 )_10\-RRB-\1740 and_11\CC\1740 general_12\JJ\1740 anaesthesia_13\NN\14034177 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 specific_17\JJ\1740 agents_18\NNS\7347 mentioned_19\VBN\730052 most_20\RBS\1740 frequently_21\RB\1740 in_22\IN\13603305 the_23\DT\1740 literature_24\NN\6362953 as_25\IN\14622893 being_26\VBG\836236 associated_27\VBN\628491 with_28\IN\1740 the_29\DT\1740 development_30\NN\248977 of_31\IN\1740 <e2>hiccups</e2>_32\NNS\863513 ._33\.\1740
D008775_D006606 NONE corticosteroids_0\NNS\14745635 (_1\-LRB-\1740 dexamethasone_2\NN\2721538 and_3\CC\1740 <e1>methylprednisolone</e1>_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 benzodiazepines_7\NNS\3771443 (_8\-LRB-\1740 midazolam_9\NNS\2830852 )_10\-RRB-\1740 and_11\CC\1740 general_12\JJ\1740 anaesthesia_13\NN\14034177 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 specific_17\JJ\1740 agents_18\NNS\7347 mentioned_19\VBN\730052 most_20\RBS\1740 frequently_21\RB\1740 in_22\IN\13603305 the_23\DT\1740 literature_24\NN\6362953 as_25\IN\14622893 being_26\VBG\836236 associated_27\VBN\628491 with_28\IN\1740 the_29\DT\1740 development_30\NN\248977 of_31\IN\1740 <e2>hiccups</e2>_32\NNS\863513 ._33\.\1740
D001569_D006606 NONE corticosteroids_0\NNS\14745635 (_1\-LRB-\1740 dexamethasone_2\NN\2721538 and_3\CC\1740 methylprednisolone_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 <e1>benzodiazepines</e1>_7\NNS\3771443 (_8\-LRB-\1740 midazolam_9\NNS\2830852 )_10\-RRB-\1740 and_11\CC\1740 general_12\JJ\1740 anaesthesia_13\NN\14034177 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 specific_17\JJ\1740 agents_18\NNS\7347 mentioned_19\VBN\730052 most_20\RBS\1740 frequently_21\RB\1740 in_22\IN\13603305 the_23\DT\1740 literature_24\NN\6362953 as_25\IN\14622893 being_26\VBG\836236 associated_27\VBN\628491 with_28\IN\1740 the_29\DT\1740 development_30\NN\248977 of_31\IN\1740 <e2>hiccups</e2>_32\NNS\863513 ._33\.\1740
D008874_D006606 NONE corticosteroids_0\NNS\14745635 (_1\-LRB-\1740 dexamethasone_2\NN\2721538 and_3\CC\1740 methylprednisolone_4\NN\1740 )_5\-RRB-\1740 ,_6\,\1740 benzodiazepines_7\NNS\3771443 (_8\-LRB-\1740 <e1>midazolam</e1>_9\NNS\2830852 )_10\-RRB-\1740 and_11\CC\1740 general_12\JJ\1740 anaesthesia_13\NN\14034177 have_14\VBP\2108377 been_15\VBN\836236 the_16\DT\1740 specific_17\JJ\1740 agents_18\NNS\7347 mentioned_19\VBN\730052 most_20\RBS\1740 frequently_21\RB\1740 in_22\IN\13603305 the_23\DT\1740 literature_24\NN\6362953 as_25\IN\14622893 being_26\VBG\836236 associated_27\VBN\628491 with_28\IN\1740 the_29\DT\1740 development_30\NN\248977 of_31\IN\1740 <e2>hiccups</e2>_32\NNS\863513 ._33\.\1740
D018942_D006606 NONE few_0\JJ\1740 cases_1\NNS\7283608 of_2\IN\1740 drug-induced_3\JJ\1740 <e2>hiccups</e2>_4\NNS\863513 have_5\VBP\2108377 been_6\VBN\836236 reported_7\VBN\831651 related_8\JJ\1740 to_9\TO\1740 <e1>macrolide</e1>_10\NN\1740 antimicrobials_11\NNS\14778436 ._12\.\1740
D018942_D006606 NONE using_0\VBG\1156834 the_1\DT\1740 naranjo_2\NNP\1740 adverse_3\JJ\1740 effect_4\NN\34213 reaction_5\NN\13446390 probability_6\NN\33615 scale_7\NN\7260623 this_8\DT\1740 event_9\NN\23100 could_10\MD\1740 be_11\VB\836236 classified_12\VBN\657260 as_13\IN\14622893 possible_14\JJ\1740 (_15\-LRB-\1740 score_16\NN\5736149 5_17\CD\13741022 points_18\NNS\5868954 )_19\-RRB-\1740 ,_20\,\1740 mostly_21\RB\1740 because_22\IN\1740 of_23\IN\1740 the_24\DT\1740 close_25\JJ\1740 temporal_26\JJ\1740 sequence_27\NN\8457976 ,_28\,\1740 previous_29\JJ\1740 reports_30\NNS\6470073 on_31\IN\1740 this_32\DT\1740 reaction_33\NN\13446390 with_34\IN\1740 other_35\JJ\1740 <e1>macrolides</e1>_36\NNS\1740 and_37\CC\1740 the_38\DT\1740 absence_39\NN\14449405 of_40\IN\1740 any_41\DT\1740 alternative_42\JJ\1740 explanation_43\NN\6722453 for_44\IN\1740 <e2>hiccups</e2>_45\NNS\863513 ._46\.\1740
D018942_D006606 NONE however_0\RB\1740 ,_1\,\1740 <e1>macrolide</e1>_2\NN\1740 antimicrobials_3\NNS\14778436 have_4\VBP\2108377 been_5\VBN\836236 reported_6\VBN\831651 to_7\TO\1740 be_8\VB\836236 associated_9\VBN\628491 with_10\IN\1740 <e2>hiccups</e2>_11\NNS\863513 and_12\CC\1740 vagal_13\JJ\1740 mechanism_14\NN\13446390 could_15\MD\1740 explain_16\VB\831651 the_17\DT\1740 development_18\NN\248977 of_19\IN\1740 this_20\DT\1740 side-effect_21\NN\1740 ._22\.\1740
6794356
D016651_D014262 NONE <e2>tricuspid_0\NN\1740 valve_1\VBP\1740 regurgitation</e2>_2\NN\7406350 and_3\CC\1740 <e1>lithium_4\NN\14625458 carbonate</e1>_5\NN\15010703 toxicity_6\NN\13576101 in_7\IN\13603305 a_8\DT\13649268 newborn_9\JJ\1740 infant_10\NN\9918248 ._11\.\1740
D016651_D064420 NONE tricuspid_0\NN\1740 valve_1\VBP\1740 regurgitation_2\NN\7406350 and_3\CC\1740 <e1>lithium_4\NN\14625458 carbonate</e1>_5\NN\15010703 <e2>toxicity</e2>_6\NN\13576101 in_7\IN\13603305 a_8\DT\13649268 newborn_9\JJ\1740 infant_10\NN\9918248 ._11\.\1740
D008094_D014262 NONE a_0\DT\13649268 newborn_1\JJ\1740 with_2\IN\1740 massive_3\JJ\1740 <e2>tricuspid_4\NN\1740 regurgitation</e2>_5\NN\7406350 ,_6\,\1740 atrial_7\JJ\1740 flutter_8\NN\331950 ,_9\,\1740 congestive_10\JJ\1740 heart_11\NN\5919034 failure_12\NN\66216 ,_13\,\1740 and_14\CC\1740 a_15\DT\13649268 high_16\JJ\1740 serum_17\NN\5397468 <e1>lithium</e1>_18\NN\14625458 level_19\NN\4916342 is_20\VBZ\836236 described_21\VBN\1001294 ._22\.\1740
D008094_D014262 NONE this_0\DT\1740 is_1\VBZ\836236 the_2\DT\1740 first_3\JJ\1740 patient_4\NN\9898892 to_5\TO\1740 initially_6\RB\1740 manifest_7\VB\1015244 <e2>tricuspid_8\NN\1740 regurgitation</e2>_9\NN\7406350 and_10\CC\1740 atrial_11\JJ\1740 flutter_12\NN\331950 ,_13\,\1740 and_14\CC\1740 the_15\DT\1740 11th_16\NN\1740 described_17\VBN\1001294 patient_18\NN\9898892 with_19\IN\1740 cardiac_20\JJ\1740 disease_21\NN\14061805 among_22\IN\1740 infants_23\NNS\9918248 exposed_24\VBN\2110927 to_25\TO\1740 <e1>lithium</e1>_26\NN\14625458 compounds_27\NNS\5869584 in_28\IN\13603305 the_29\DT\1740 first_30\JJ\1740 trimester_31\NN\15113229 of_32\IN\1740 pregnancy_33\NN\14034177 ._34\.\1740
D008094_D001282 NONE a_0\DT\13649268 newborn_1\JJ\1740 with_2\IN\1740 massive_3\JJ\1740 tricuspid_4\NN\1740 regurgitation_5\NN\7406350 ,_6\,\1740 <e2>atrial_7\JJ\1740 flutter</e2>_8\NN\331950 ,_9\,\1740 congestive_10\JJ\1740 heart_11\NN\5919034 failure_12\NN\66216 ,_13\,\1740 and_14\CC\1740 a_15\DT\13649268 high_16\JJ\1740 serum_17\NN\5397468 <e1>lithium</e1>_18\NN\14625458 level_19\NN\4916342 is_20\VBZ\836236 described_21\VBN\1001294 ._22\.\1740
D008094_D001282 NONE this_0\DT\1740 is_1\VBZ\836236 the_2\DT\1740 first_3\JJ\1740 patient_4\NN\9898892 to_5\TO\1740 initially_6\RB\1740 manifest_7\VB\1015244 tricuspid_8\NN\1740 regurgitation_9\NN\7406350 and_10\CC\1740 <e2>atrial_11\JJ\1740 flutter</e2>_12\NN\331950 ,_13\,\1740 and_14\CC\1740 the_15\DT\1740 11th_16\NN\1740 described_17\VBN\1001294 patient_18\NN\9898892 with_19\IN\1740 cardiac_20\JJ\1740 disease_21\NN\14061805 among_22\IN\1740 infants_23\NNS\9918248 exposed_24\VBN\2110927 to_25\TO\1740 <e1>lithium</e1>_26\NN\14625458 compounds_27\NNS\5869584 in_28\IN\13603305 the_29\DT\1740 first_30\JJ\1740 trimester_31\NN\15113229 of_32\IN\1740 pregnancy_33\NN\14034177 ._34\.\1740
D008094_D006333 NONE a_0\DT\13649268 newborn_1\JJ\1740 with_2\IN\1740 massive_3\JJ\1740 tricuspid_4\NN\1740 regurgitation_5\NN\7406350 ,_6\,\1740 atrial_7\JJ\1740 flutter_8\NN\331950 ,_9\,\1740 <e2>congestive_10\JJ\1740 heart_11\NN\5919034 failure</e2>_12\NN\66216 ,_13\,\1740 and_14\CC\1740 a_15\DT\13649268 high_16\JJ\1740 serum_17\NN\5397468 <e1>lithium</e1>_18\NN\14625458 level_19\NN\4916342 is_20\VBZ\836236 described_21\VBN\1001294 ._22\.\1740
D008094_D006331 NONE this_0\DT\1740 is_1\VBZ\836236 the_2\DT\1740 first_3\JJ\1740 patient_4\NN\9898892 to_5\TO\1740 initially_6\RB\1740 manifest_7\VB\1015244 tricuspid_8\NN\1740 regurgitation_9\NN\7406350 and_10\CC\1740 atrial_11\JJ\1740 flutter_12\NN\331950 ,_13\,\1740 and_14\CC\1740 the_15\DT\1740 11th_16\NN\1740 described_17\VBN\1001294 patient_18\NN\9898892 with_19\IN\1740 <e2>cardiac_20\JJ\1740 disease</e2>_21\NN\14061805 among_22\IN\1740 infants_23\NNS\9918248 exposed_24\VBN\2110927 to_25\TO\1740 <e1>lithium</e1>_26\NN\14625458 compounds_27\NNS\5869584 in_28\IN\13603305 the_29\DT\1740 first_30\JJ\1740 trimester_31\NN\15113229 of_32\IN\1740 pregnancy_33\NN\14034177 ._34\.\1740
D016651_D006331 NONE <e1>lithium_0\NN\14625458 carbonate</e1>_1\NN\15010703 may_2\MD\15209706 be_3\VB\836236 a_4\DT\13649268 factor_5\NN\7326557 in_6\IN\13603305 the_7\DT\1740 increasing_8\VBG\169651 incidence_9\NN\13821570 of_10\IN\1740 <e2>congenital_11\JJ\1740 heart_12\NN\5919034 disease</e2>_13\NN\14061805 when_14\WRB\1740 taken_15\VBN\2367363 during_16\IN\1740 early_17\JJ\1740 pregnancy_18\NN\14034177 ._19\.\1740
11999899
D012110_D009069 NONE <e1>reserpine</e1>_0\NN\2721160 (_1\-LRB-\1740 1_2\CD\13741022 mg/kg_3\NN\1740 )_4\-RRB-\1740 ,_5\,\1740 administered_6\VBN\2436349 once_7\RB\1740 every_8\DT\1740 other_9\JJ\1740 day_10\NN\15154774 for_11\IN\1740 4_12\CD\13741022 days_13\NNS\15140892 ,_14\,\1740 produced_15\VBN\1617192 increases_16\NNS\13576355 in_17\IN\13603305 <e2>orofacial_18\JJ\1740 dyskinesia</e2>_19\NN\14084880 ,_20\,\1740 tongue_21\NN\5301392 protrusion_22\NN\13919685 and_23\CC\1740 vacuous_24\JJ\1740 chewing_25\NN\199130 in_26\IN\13603305 mice_27\NNS\2329401 ,_28\,\1740 which_29\WDT\1740 are_30\VBP\836236 signs_31\NNS\6643763 indicative_32\JJ\1740 of_33\IN\1740 tardive_34\JJ\1740 dyskinesia_35\NN\14084880 ._36\.\1740
D012110_D009069 NONE <e1>reserpine</e1>_0\NN\2721160 (_1\-LRB-\1740 1_2\CD\13741022 mg/kg_3\NN\1740 )_4\-RRB-\1740 ,_5\,\1740 administered_6\VBN\2436349 90_7\CD\13745420 min_8\NN\15154774 before_9\IN\1740 the_10\DT\1740 test_11\NN\5798043 and_12\CC\1740 followed_13\VBN\1835496 by_14\IN\1740 apomophine_15\NN\1740 injection_16\NN\320852 (_17\-LRB-\1740 0.1_18\CD\1740 mg/kg_19\NN\1740 )_20\-RRB-\1740 5_21\CD\13741022 min_22\NN\15154774 before_23\IN\1740 the_24\DT\1740 test_25\NN\5798043 ,_26\,\1740 did_27\VBD\1640855 not_28\RB\1740 produce_29\VB\1617192 <e2>oral_30\JJ\1740 dyskinesia</e2>_31\NN\14084880 in_32\IN\13603305 mice_33\NNS\2329401 ._34\.\1740
D012110_D004409 CID <e1>reserpine</e1>_0\NN\2721160 (_1\-LRB-\1740 1_2\CD\13741022 mg/kg_3\NN\1740 )_4\-RRB-\1740 ,_5\,\1740 administered_6\VBN\2436349 once_7\RB\1740 every_8\DT\1740 other_9\JJ\1740 day_10\NN\15154774 for_11\IN\1740 4_12\CD\13741022 days_13\NNS\15140892 ,_14\,\1740 produced_15\VBN\1617192 increases_16\NNS\13576355 in_17\IN\13603305 orofacial_18\JJ\1740 dyskinesia_19\NN\14084880 ,_20\,\1740 tongue_21\NN\5301392 protrusion_22\NN\13919685 and_23\CC\1740 vacuous_24\JJ\1740 chewing_25\NN\199130 in_26\IN\13603305 mice_27\NNS\2329401 ,_28\,\1740 which_29\WDT\1740 are_30\VBP\836236 signs_31\NNS\6643763 indicative_32\JJ\1740 of_33\IN\1740 <e2>tardive_34\JJ\1740 dyskinesia</e2>_35\NN\14084880 ._36\.\1740
D012110_D004409 CID these_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 that_3\IN\1740 <e1>reserpine</e1>_4\NN\2721160 produces_5\VBZ\1617192 different_6\JJ\1740 and_7\CC\1740 <e2>abnormal_8\JJ\1740 movements</e2>_9\NNS\191142 ,_10\,\1740 which_11\WDT\1740 are_12\VBP\836236 related_13\JJ\1740 to_14\TO\1740 dose_15\NN\3740161 and_16\CC\1740 schedule_17\NN\5898568 employed_18\VBN\1740 and_19\CC\1740 can_20\MD\3094503 be_21\VB\836236 considered_22\VBN\689344 as_23\IN\14622893 parkinsonian-like_24\JJ\1740 and_25\CC\1740 tardive_26\JJ\1740 dsykinesia_27\NN\1740 signs_28\NNS\6643763 ._29\.\1740
D012110_D004409 CID these_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 that_3\IN\1740 <e1>reserpine</e1>_4\NN\2721160 produces_5\VBZ\1617192 different_6\JJ\1740 and_7\CC\1740 abnormal_8\JJ\1740 movements_9\NNS\191142 ,_10\,\1740 which_11\WDT\1740 are_12\VBP\836236 related_13\JJ\1740 to_14\TO\1740 dose_15\NN\3740161 and_16\CC\1740 schedule_17\NN\5898568 employed_18\VBN\1740 and_19\CC\1740 can_20\MD\3094503 be_21\VB\836236 considered_22\VBN\689344 as_23\IN\14622893 parkinsonian-like_24\JJ\1740 and_25\CC\1740 <e2>tardive_26\JJ\1740 dsykinesia</e2>_27\NN\1740 signs_28\NNS\6643763 ._29\.\1740
D012110_D014202 CID <e1>reserpine</e1>_0\NNP\2721160 also_1\RB\1740 produced_2\VBD\1617192 <e2>tremor</e2>_3\NN\345926 and_4\CC\1740 catalepsy_5\NN\14023236 ,_6\,\1740 which_7\WDT\1740 are_8\VBP\836236 signs_9\NNS\6643763 suggestive_10\JJ\1740 of_11\IN\1740 parkinson_12\NNP\1740 's_13\POS\1740 disease_14\NN\14061805 ._15\.\1740
D012110_D014202 CID however_0\RB\1740 ,_1\,\1740 mk-801_2\NN\1740 injection_3\NN\320852 produced_4\VBD\1617192 a_5\DT\13649268 significant_6\JJ\1740 increase_7\NN\13576355 of_8\IN\1740 <e2>tremor</e2>_9\NN\345926 in_10\IN\13603305 <e1>reserpine-treated</e1>_11\JJ\1740 mice_12\NNS\2329401 ._13\.\1740
D012110_D014202 CID on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 <e1>reserpine</e1>_5\NN\2721160 induced_6\VBN\1627355 increases_7\NNS\13576355 in_8\IN\13603305 <e2>tremor</e2>_9\NN\345926 and_10\CC\1740 catalepsy_11\NN\14023236 compared_12\VBN\644583 to_13\TO\1740 control_14\NN\5190804 mice_15\NNS\2329401 ._16\.\1740
D012110_D014202 CID mk-801_0\NN\1740 (_1\-LRB-\1740 0.1_2\CD\1740 mg/kg_3\NN\1740 )_4\-RRB-\1740 administration_5\NN\1133281 attenuated_6\VBD\224901 the_7\DT\1740 catalepsy_8\NN\14023236 and_9\CC\1740 <e2>tremor</e2>_10\NN\345926 induced_11\VBN\1627355 by_12\IN\1740 <e1>reserpine</e1>_13\NN\2721160 ._14\.\1740
D012110_D014202 CID pretreatment_0\NN\1740 with_1\IN\1740 <e1>reserpine</e1>_2\NN\2721160 (_3\-LRB-\1740 1_4\CD\13741022 mg/kg_5\NN\1740 )_6\-RRB-\1740 24_7\CD\13745420 h_8\NN\14622893 before_9\IN\1740 the_10\DT\1740 observation_11\NN\996969 test_12\NN\5798043 produced_13\VBN\1617192 increases_14\NNS\13576355 in_15\IN\13603305 vacuous_16\JJ\1740 chewing_17\NN\199130 movements_18\NNS\191142 and_19\CC\1740 tongue_20\NN\5301392 protrusion_21\NN\13919685 ,_22\,\1740 as_23\RB\1740 well_24\RB\1740 as_25\IN\14622893 increases_26\NNS\13576355 in_27\IN\13603305 <e2>tremor</e2>_28\NN\345926 and_29\CC\1740 catalepsy_30\NN\14023236 ,_31\,\1740 whereas_32\IN\1740 mk-801_33\NN\1740 (_34\-LRB-\1740 0.1_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 injection_38\NN\320852 90_39\CD\13745420 min_40\NN\15154774 before_41\IN\1740 the_42\DT\1740 test_43\NN\5798043 reversed_44\VBD\109660 the_45\DT\1740 effects_46\NNS\13245626 of_47\IN\1740 reserpine_48\NN\2721160 ._49\.\1740
D012110_D014202 CID pretreatment_0\NN\1740 with_1\IN\1740 reserpine_2\NN\2721160 (_3\-LRB-\1740 1_4\CD\13741022 mg/kg_5\NN\1740 )_6\-RRB-\1740 24_7\CD\13745420 h_8\NN\14622893 before_9\IN\1740 the_10\DT\1740 observation_11\NN\996969 test_12\NN\5798043 produced_13\VBN\1617192 increases_14\NNS\13576355 in_15\IN\13603305 vacuous_16\JJ\1740 chewing_17\NN\199130 movements_18\NNS\191142 and_19\CC\1740 tongue_20\NN\5301392 protrusion_21\NN\13919685 ,_22\,\1740 as_23\RB\1740 well_24\RB\1740 as_25\IN\14622893 increases_26\NNS\13576355 in_27\IN\13603305 <e2>tremor</e2>_28\NN\345926 and_29\CC\1740 catalepsy_30\NN\14023236 ,_31\,\1740 whereas_32\IN\1740 mk-801_33\NN\1740 (_34\-LRB-\1740 0.1_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 injection_38\NN\320852 90_39\CD\13745420 min_40\NN\15154774 before_41\IN\1740 the_42\DT\1740 test_43\NN\5798043 reversed_44\VBD\109660 the_45\DT\1740 effects_46\NNS\13245626 of_47\IN\1740 <e1>reserpine</e1>_48\NN\2721160 ._49\.\1740
D012110_D002375 CID <e1>reserpine</e1>_0\NNP\2721160 also_1\RB\1740 produced_2\VBD\1617192 tremor_3\NN\345926 and_4\CC\1740 <e2>catalepsy</e2>_5\NN\14023236 ,_6\,\1740 which_7\WDT\1740 are_8\VBP\836236 signs_9\NNS\6643763 suggestive_10\JJ\1740 of_11\IN\1740 parkinson_12\NNP\1740 's_13\POS\1740 disease_14\NN\14061805 ._15\.\1740
D012110_D002375 CID mk-801_0\NN\1740 (_1\-LRB-\1740 0.1_2\CD\1740 mg/kg_3\NN\1740 )_4\-RRB-\1740 ,_5\,\1740 administered_6\VBD\2436349 30_7\CD\13745420 min_8\NN\15154774 before_9\IN\1740 the_10\DT\1740 observation_11\NN\996969 test_12\NN\5798043 ,_13\,\1740 prevented_14\VBD\1740 the_15\DT\1740 vacuous_16\JJ\1740 chewing_17\NN\199130 movements_18\NNS\191142 ,_19\,\1740 tongue_20\NN\5301392 protrusions_21\NNS\13919685 and_22\CC\1740 <e2>catalepsy</e2>_23\NN\14023236 induced_24\VBN\1627355 by_25\IN\1740 <e1>reserpine</e1>_26\NN\2721160 ._27\.\1740
D012110_D002375 CID on_0\IN\1740 the_1\DT\1740 other_2\JJ\1740 hand_3\NN\5566919 ,_4\,\1740 <e1>reserpine</e1>_5\NN\2721160 induced_6\VBN\1627355 increases_7\NNS\13576355 in_8\IN\13603305 tremor_9\NN\345926 and_10\CC\1740 <e2>catalepsy</e2>_11\NN\14023236 compared_12\VBN\644583 to_13\TO\1740 control_14\NN\5190804 mice_15\NNS\2329401 ._16\.\1740
D012110_D002375 CID mk-801_0\NN\1740 (_1\-LRB-\1740 0.1_2\CD\1740 mg/kg_3\NN\1740 )_4\-RRB-\1740 administration_5\NN\1133281 attenuated_6\VBD\224901 the_7\DT\1740 <e2>catalepsy</e2>_8\NN\14023236 and_9\CC\1740 tremor_10\NN\345926 induced_11\VBN\1627355 by_12\IN\1740 <e1>reserpine</e1>_13\NN\2721160 ._14\.\1740
D012110_D002375 CID pretreatment_0\NN\1740 with_1\IN\1740 <e1>reserpine</e1>_2\NN\2721160 (_3\-LRB-\1740 1_4\CD\13741022 mg/kg_5\NN\1740 )_6\-RRB-\1740 24_7\CD\13745420 h_8\NN\14622893 before_9\IN\1740 the_10\DT\1740 observation_11\NN\996969 test_12\NN\5798043 produced_13\VBN\1617192 increases_14\NNS\13576355 in_15\IN\13603305 vacuous_16\JJ\1740 chewing_17\NN\199130 movements_18\NNS\191142 and_19\CC\1740 tongue_20\NN\5301392 protrusion_21\NN\13919685 ,_22\,\1740 as_23\RB\1740 well_24\RB\1740 as_25\IN\14622893 increases_26\NNS\13576355 in_27\IN\13603305 tremor_28\NN\345926 and_29\CC\1740 <e2>catalepsy</e2>_30\NN\14023236 ,_31\,\1740 whereas_32\IN\1740 mk-801_33\NN\1740 (_34\-LRB-\1740 0.1_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 injection_38\NN\320852 90_39\CD\13745420 min_40\NN\15154774 before_41\IN\1740 the_42\DT\1740 test_43\NN\5798043 reversed_44\VBD\109660 the_45\DT\1740 effects_46\NNS\13245626 of_47\IN\1740 reserpine_48\NN\2721160 ._49\.\1740
D012110_D002375 CID pretreatment_0\NN\1740 with_1\IN\1740 reserpine_2\NN\2721160 (_3\-LRB-\1740 1_4\CD\13741022 mg/kg_5\NN\1740 )_6\-RRB-\1740 24_7\CD\13745420 h_8\NN\14622893 before_9\IN\1740 the_10\DT\1740 observation_11\NN\996969 test_12\NN\5798043 produced_13\VBN\1617192 increases_14\NNS\13576355 in_15\IN\13603305 vacuous_16\JJ\1740 chewing_17\NN\199130 movements_18\NNS\191142 and_19\CC\1740 tongue_20\NN\5301392 protrusion_21\NN\13919685 ,_22\,\1740 as_23\RB\1740 well_24\RB\1740 as_25\IN\14622893 increases_26\NNS\13576355 in_27\IN\13603305 tremor_28\NN\345926 and_29\CC\1740 <e2>catalepsy</e2>_30\NN\14023236 ,_31\,\1740 whereas_32\IN\1740 mk-801_33\NN\1740 (_34\-LRB-\1740 0.1_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 injection_38\NN\320852 90_39\CD\13745420 min_40\NN\15154774 before_41\IN\1740 the_42\DT\1740 test_43\NN\5798043 reversed_44\VBD\109660 the_45\DT\1740 effects_46\NNS\13245626 of_47\IN\1740 <e1>reserpine</e1>_48\NN\2721160 ._49\.\1740
D012110_D010300 NONE <e1>reserpine</e1>_0\NNP\2721160 also_1\RB\1740 produced_2\VBD\1617192 tremor_3\NN\345926 and_4\CC\1740 catalepsy_5\NN\14023236 ,_6\,\1740 which_7\WDT\1740 are_8\VBP\836236 signs_9\NNS\6643763 suggestive_10\JJ\1740 of_11\IN\1740 <e2>parkinson_12\NNP\1740 's_13\POS\1740 disease</e2>_14\NN\14061805 ._15\.\1740
D012110_D010300 NONE these_0\DT\1740 results_1\NNS\34213 show_2\VBP\2137132 that_3\IN\1740 <e1>reserpine</e1>_4\NN\2721160 produces_5\VBZ\1617192 different_6\JJ\1740 and_7\CC\1740 abnormal_8\JJ\1740 movements_9\NNS\191142 ,_10\,\1740 which_11\WDT\1740 are_12\VBP\836236 related_13\JJ\1740 to_14\TO\1740 dose_15\NN\3740161 and_16\CC\1740 schedule_17\NN\5898568 employed_18\VBN\1740 and_19\CC\1740 can_20\MD\3094503 be_21\VB\836236 considered_22\VBN\689344 as_23\IN\14622893 <e2>parkinsonian-like</e2>_24\JJ\1740 and_25\CC\1740 tardive_26\JJ\1740 dsykinesia_27\NN\1740 signs_28\NNS\6643763 ._29\.\1740
D016291_D002375 NONE <e1>mk-801</e1>_0\NN\1740 (_1\-LRB-\1740 0.1_2\CD\1740 mg/kg_3\NN\1740 )_4\-RRB-\1740 ,_5\,\1740 administered_6\VBD\2436349 30_7\CD\13745420 min_8\NN\15154774 before_9\IN\1740 the_10\DT\1740 observation_11\NN\996969 test_12\NN\5798043 ,_13\,\1740 prevented_14\VBD\1740 the_15\DT\1740 vacuous_16\JJ\1740 chewing_17\NN\199130 movements_18\NNS\191142 ,_19\,\1740 tongue_20\NN\5301392 protrusions_21\NNS\13919685 and_22\CC\1740 <e2>catalepsy</e2>_23\NN\14023236 induced_24\VBN\1627355 by_25\IN\1740 reserpine_26\NN\2721160 ._27\.\1740
D016291_D002375 NONE <e1>mk-801</e1>_0\NN\1740 (_1\-LRB-\1740 0.1_2\CD\1740 mg/kg_3\NN\1740 )_4\-RRB-\1740 administration_5\NN\1133281 attenuated_6\VBD\224901 the_7\DT\1740 <e2>catalepsy</e2>_8\NN\14023236 and_9\CC\1740 tremor_10\NN\345926 induced_11\VBN\1627355 by_12\IN\1740 reserpine_13\NN\2721160 ._14\.\1740
D016291_D002375 NONE pretreatment_0\NN\1740 with_1\IN\1740 reserpine_2\NN\2721160 (_3\-LRB-\1740 1_4\CD\13741022 mg/kg_5\NN\1740 )_6\-RRB-\1740 24_7\CD\13745420 h_8\NN\14622893 before_9\IN\1740 the_10\DT\1740 observation_11\NN\996969 test_12\NN\5798043 produced_13\VBN\1617192 increases_14\NNS\13576355 in_15\IN\13603305 vacuous_16\JJ\1740 chewing_17\NN\199130 movements_18\NNS\191142 and_19\CC\1740 tongue_20\NN\5301392 protrusion_21\NN\13919685 ,_22\,\1740 as_23\RB\1740 well_24\RB\1740 as_25\IN\14622893 increases_26\NNS\13576355 in_27\IN\13603305 tremor_28\NN\345926 and_29\CC\1740 <e2>catalepsy</e2>_30\NN\14023236 ,_31\,\1740 whereas_32\IN\1740 <e1>mk-801</e1>_33\NN\1740 (_34\-LRB-\1740 0.1_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 injection_38\NN\320852 90_39\CD\13745420 min_40\NN\15154774 before_41\IN\1740 the_42\DT\1740 test_43\NN\5798043 reversed_44\VBD\109660 the_45\DT\1740 effects_46\NNS\13245626 of_47\IN\1740 reserpine_48\NN\2721160 ._49\.\1740
D016291_D014202 NONE however_0\RB\1740 ,_1\,\1740 <e1>mk-801</e1>_2\NN\1740 injection_3\NN\320852 produced_4\VBD\1617192 a_5\DT\13649268 significant_6\JJ\1740 increase_7\NN\13576355 of_8\IN\1740 <e2>tremor</e2>_9\NN\345926 in_10\IN\13603305 reserpine-treated_11\JJ\1740 mice_12\NNS\2329401 ._13\.\1740
D016291_D014202 NONE <e1>mk-801</e1>_0\NN\1740 (_1\-LRB-\1740 0.1_2\CD\1740 mg/kg_3\NN\1740 )_4\-RRB-\1740 administration_5\NN\1133281 attenuated_6\VBD\224901 the_7\DT\1740 catalepsy_8\NN\14023236 and_9\CC\1740 <e2>tremor</e2>_10\NN\345926 induced_11\VBN\1627355 by_12\IN\1740 reserpine_13\NN\2721160 ._14\.\1740
D016291_D014202 NONE pretreatment_0\NN\1740 with_1\IN\1740 reserpine_2\NN\2721160 (_3\-LRB-\1740 1_4\CD\13741022 mg/kg_5\NN\1740 )_6\-RRB-\1740 24_7\CD\13745420 h_8\NN\14622893 before_9\IN\1740 the_10\DT\1740 observation_11\NN\996969 test_12\NN\5798043 produced_13\VBN\1617192 increases_14\NNS\13576355 in_15\IN\13603305 vacuous_16\JJ\1740 chewing_17\NN\199130 movements_18\NNS\191142 and_19\CC\1740 tongue_20\NN\5301392 protrusion_21\NN\13919685 ,_22\,\1740 as_23\RB\1740 well_24\RB\1740 as_25\IN\14622893 increases_26\NNS\13576355 in_27\IN\13603305 <e2>tremor</e2>_28\NN\345926 and_29\CC\1740 catalepsy_30\NN\14023236 ,_31\,\1740 whereas_32\IN\1740 <e1>mk-801</e1>_33\NN\1740 (_34\-LRB-\1740 0.1_35\CD\1740 mg/kg_36\NN\1740 )_37\-RRB-\1740 injection_38\NN\320852 90_39\CD\13745420 min_40\NN\15154774 before_41\IN\1740 the_42\DT\1740 test_43\NN\5798043 reversed_44\VBD\109660 the_45\DT\1740 effects_46\NNS\13245626 of_47\IN\1740 reserpine_48\NN\2721160 ._49\.\1740
D001058_D009069 NONE reserpine_0\NN\2721160 (_1\-LRB-\1740 1_2\CD\13741022 mg/kg_3\NN\1740 )_4\-RRB-\1740 ,_5\,\1740 administered_6\VBN\2436349 90_7\CD\13745420 min_8\NN\15154774 before_9\IN\1740 the_10\DT\1740 test_11\NN\5798043 and_12\CC\1740 followed_13\VBN\1835496 by_14\IN\1740 <e1>apomophine</e1>_15\NN\1740 injection_16\NN\320852 (_17\-LRB-\1740 0.1_18\CD\1740 mg/kg_19\NN\1740 )_20\-RRB-\1740 5_21\CD\13741022 min_22\NN\15154774 before_23\IN\1740 the_24\DT\1740 test_25\NN\5798043 ,_26\,\1740 did_27\VBD\1640855 not_28\RB\1740 produce_29\VB\1617192 <e2>oral_30\JJ\1740 dyskinesia</e2>_31\NN\14084880 in_32\IN\13603305 mice_33\NNS\2329401 ._34\.\1740
D016202_D002375 NONE the_0\DT\1740 glutamatergic_1\JJ\1740 blockage_2\NN\14034177 produced_3\VBN\1617192 by_4\IN\1740 <e1>nmda</e1>_5\NN\1740 can_6\MD\3094503 restore_7\VB\1631072 these_8\DT\1740 signs_9\NNS\6643763 ,_10\,\1740 such_11\JJ\1740 as_12\IN\14622893 vacuous_13\JJ\1740 chewing_14\NN\199130 movements_15\NNS\191142 ,_16\,\1740 tongue_17\NN\5301392 protrusions_18\NNS\13919685 ,_19\,\1740 <e2>catalepsy</e2>_20\NN\14023236 and_21\CC\1740 tremor_22\NN\345926 according_23\VBG\2657219 to_24\IN\1740 the_25\DT\1740 employed_26\VBN\1740 model_27\NN\5888929 ._28\.\1740
D016202_D014202 NONE the_0\DT\1740 glutamatergic_1\JJ\1740 blockage_2\NN\14034177 produced_3\VBN\1617192 by_4\IN\1740 <e1>nmda</e1>_5\NN\1740 can_6\MD\3094503 restore_7\VB\1631072 these_8\DT\1740 signs_9\NNS\6643763 ,_10\,\1740 such_11\JJ\1740 as_12\IN\14622893 vacuous_13\JJ\1740 chewing_14\NN\199130 movements_15\NNS\191142 ,_16\,\1740 tongue_17\NN\5301392 protrusions_18\NNS\13919685 ,_19\,\1740 catalepsy_20\NN\14023236 and_21\CC\1740 <e2>tremor</e2>_22\NN\345926 according_23\VBG\2657219 to_24\IN\1740 the_25\DT\1740 employed_26\VBN\1740 model_27\NN\5888929 ._28\.\1740
9205462
D013629_C537296 CID <e2>granulosa_0\NN\1740 cell_1\NN\3080309 tumor_2\NN\14234074 of_3\IN\1740 the_4\DT\1740 ovary</e2>_5\NN\11675842 associated_6\VBN\628491 with_7\IN\1740 antecedent_8\JJ\1740 <e1>tamoxifen</e1>_9\NN\2714883 use_10\NN\407535 ._11\.\1740
D013629_D009369 NONE review_0\NN\5733583 of_1\IN\1740 the_2\DT\1740 literature_3\NN\6362953 reveals_4\VBZ\2137132 an_5\DT\6697703 association_6\NN\8008335 between_7\IN\1740 <e1>tamoxifen</e1>_8\NN\2714883 use_9\NN\407535 and_10\CC\1740 gynecologic_11\JJ\1740 <e2>tumors</e2>_12\NNS\14234074 ._13\.\1740
D013629_D001943 NONE case_0\NN\7283608 :_1\:\1740 a_2\DT\13649268 52-year-old_3\JJ\1740 postmenopausal_4\JJ\1740 woman_5\NN\9605289 was_6\VBD\836236 treated_7\VBN\2376958 with_8\IN\1740 <e1>tamoxifen</e1>_9\NN\2714883 for_10\IN\1740 stage_11\NN\15113229 ii_12\CD\13741022 estrogen_13\NN\14745635 receptor-positive_14\JJ\1740 <e2>breast_15\NN\5225090 carcinoma</e2>_16\NN\14239918 ._17\.\1740
D004967_D001943 NONE case_0\NN\7283608 :_1\:\1740 a_2\DT\13649268 52-year-old_3\JJ\1740 postmenopausal_4\JJ\1740 woman_5\NN\9605289 was_6\VBD\836236 treated_7\VBN\2376958 with_8\IN\1740 tamoxifen_9\NN\2714883 for_10\IN\1740 stage_11\NN\15113229 ii_12\CD\13741022 <e1>estrogen</e1>_13\NN\14745635 receptor-positive_14\JJ\1740 <e2>breast_15\NN\5225090 carcinoma</e2>_16\NN\14239918 ._17\.\1740
D013629_D017093 CID conclusion_0\NN\5837957 :_1\:\1740 patients_2\NNS\9898892 with_3\IN\1740 <e1>tamoxifen-induced</e1>_4\JJ\1740 <e2>liver_5\NN\5298729 dysfunction</e2>_6\NN\14204950 may_7\MD\15209706 be_8\VB\836236 at_9\IN\14622893 increased_10\VBN\169651 risk_11\NN\14541044 for_12\IN\1740 granulosa_13\NN\1740 cell_14\NN\3080309 tumors_15\NNS\14234074 because_16\IN\1740 of_17\IN\1740 alterations_18\NNS\7283608 in_19\IN\13603305 tamoxifen_20\NN\2714883 metabolism_21\NN\13526110 ._22\.\1740
D013629_D017093 CID conclusion_0\NN\5837957 :_1\:\1740 patients_2\NNS\9898892 with_3\IN\1740 tamoxifen-induced_4\JJ\1740 <e2>liver_5\NN\5298729 dysfunction</e2>_6\NN\14204950 may_7\MD\15209706 be_8\VB\836236 at_9\IN\14622893 increased_10\VBN\169651 risk_11\NN\14541044 for_12\IN\1740 granulosa_13\NN\1740 cell_14\NN\3080309 tumors_15\NNS\14234074 because_16\IN\1740 of_17\IN\1740 alterations_18\NNS\7283608 in_19\IN\13603305 <e1>tamoxifen</e1>_20\NN\2714883 metabolism_21\NN\13526110 ._22\.\1740
D013629_D006106 NONE conclusion_0\NN\5837957 :_1\:\1740 patients_2\NNS\9898892 with_3\IN\1740 <e1>tamoxifen-induced</e1>_4\JJ\1740 liver_5\NN\5298729 dysfunction_6\NN\14204950 may_7\MD\15209706 be_8\VB\836236 at_9\IN\14622893 increased_10\VBN\169651 risk_11\NN\14541044 for_12\IN\1740 <e2>granulosa_13\NN\1740 cell_14\NN\3080309 tumors</e2>_15\NNS\14234074 because_16\IN\1740 of_17\IN\1740 alterations_18\NNS\7283608 in_19\IN\13603305 tamoxifen_20\NN\2714883 metabolism_21\NN\13526110 ._22\.\1740
D013629_D006106 NONE conclusion_0\NN\5837957 :_1\:\1740 patients_2\NNS\9898892 with_3\IN\1740 tamoxifen-induced_4\JJ\1740 liver_5\NN\5298729 dysfunction_6\NN\14204950 may_7\MD\15209706 be_8\VB\836236 at_9\IN\14622893 increased_10\VBN\169651 risk_11\NN\14541044 for_12\IN\1740 <e2>granulosa_13\NN\1740 cell_14\NN\3080309 tumors</e2>_15\NNS\14234074 because_16\IN\1740 of_17\IN\1740 alterations_18\NNS\7283608 in_19\IN\13603305 <e1>tamoxifen</e1>_20\NN\2714883 metabolism_21\NN\13526110 ._22\.\1740
19105845
D016642_D012640 CID effect_0\NN\34213 of_1\IN\1740 increasing_2\VBG\169651 intraperitoneal_3\JJ\1740 infusion_4\NN\14589223 rates_5\NNS\13308999 on_6\IN\1740 <e1>bupropion_7\NN\1740 hydrochloride-induced</e1>_8\JJ\1740 <e2>seizures</e2>_9\NNS\14081375 in_10\IN\13603305 mice_11\NNS\2329401 ._12\.\1740
D016642_D012640 CID background_0\NN\4921011 :_1\:\1740 it_2\PRP\6125041 is_3\VBZ\836236 not_4\RB\1740 known_5\VBN\2110220 if_6\IN\1740 there_7\EX\27167 is_8\VBZ\836236 a_9\DT\13649268 relationship_10\NN\31921 between_11\IN\1740 input_12\NN\6791372 rate_13\NN\13815152 and_14\CC\1740 incidence_15\NN\13821570 of_16\IN\1740 <e1>bupropion-induced</e1>_17\JJ\1740 <e2>seizures</e2>_18\NNS\14081375 ._19\.\1740
D016642_D012640 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 investigated_3\VBD\644583 the_4\DT\1740 effect_5\NN\34213 of_6\IN\1740 varying_7\VBG\2666239 the_8\DT\1740 intraperitoneal_9\JJ\1740 infusion_10\NN\14589223 rates_11\NNS\13308999 of_12\IN\1740 <e1>bupropion_13\NN\1740 hcl</e1>_14\NN\1740 120_15\CD\13745420 mg/kg_16\NN\1740 ,_17\,\1740 a_18\DT\13649268 known_19\JJ\1740 <e2>convulsive</e2>_20\JJ\1740 dose_21\NN\3740161 50_22\CD\13745420 (_23\-LRB-\1740 cd50_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 on_27\IN\1740 the_28\DT\1740 incidence_29\NN\13821570 and_30\CC\1740 severity_31\NN\5036394 of_32\IN\1740 bupropion-induced_33\JJ\1740 convulsions_34\NNS\14081375 in_35\IN\13603305 the_36\DT\1740 swiss_37\JJ\1740 albino_38\NN\9606527 mice_39\NNS\2329401 ._40\.\1740
D016642_D012640 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 investigated_3\VBD\644583 the_4\DT\1740 effect_5\NN\34213 of_6\IN\1740 varying_7\VBG\2666239 the_8\DT\1740 intraperitoneal_9\JJ\1740 infusion_10\NN\14589223 rates_11\NNS\13308999 of_12\IN\1740 <e1>bupropion_13\NN\1740 hcl</e1>_14\NN\1740 120_15\CD\13745420 mg/kg_16\NN\1740 ,_17\,\1740 a_18\DT\13649268 known_19\JJ\1740 convulsive_20\JJ\1740 dose_21\NN\3740161 50_22\CD\13745420 (_23\-LRB-\1740 cd50_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 on_27\IN\1740 the_28\DT\1740 incidence_29\NN\13821570 and_30\CC\1740 severity_31\NN\5036394 of_32\IN\1740 bupropion-induced_33\JJ\1740 <e2>convulsions</e2>_34\NNS\14081375 in_35\IN\13603305 the_36\DT\1740 swiss_37\JJ\1740 albino_38\NN\9606527 mice_39\NNS\2329401 ._40\.\1740
D016642_D012640 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 investigated_3\VBD\644583 the_4\DT\1740 effect_5\NN\34213 of_6\IN\1740 varying_7\VBG\2666239 the_8\DT\1740 intraperitoneal_9\JJ\1740 infusion_10\NN\14589223 rates_11\NNS\13308999 of_12\IN\1740 bupropion_13\NN\1740 hcl_14\NN\1740 120_15\CD\13745420 mg/kg_16\NN\1740 ,_17\,\1740 a_18\DT\13649268 known_19\JJ\1740 <e2>convulsive</e2>_20\JJ\1740 dose_21\NN\3740161 50_22\CD\13745420 (_23\-LRB-\1740 cd50_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 on_27\IN\1740 the_28\DT\1740 incidence_29\NN\13821570 and_30\CC\1740 severity_31\NN\5036394 of_32\IN\1740 <e1>bupropion-induced</e1>_33\JJ\1740 convulsions_34\NNS\14081375 in_35\IN\13603305 the_36\DT\1740 swiss_37\JJ\1740 albino_38\NN\9606527 mice_39\NNS\2329401 ._40\.\1740
D016642_D012640 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 investigated_3\VBD\644583 the_4\DT\1740 effect_5\NN\34213 of_6\IN\1740 varying_7\VBG\2666239 the_8\DT\1740 intraperitoneal_9\JJ\1740 infusion_10\NN\14589223 rates_11\NNS\13308999 of_12\IN\1740 bupropion_13\NN\1740 hcl_14\NN\1740 120_15\CD\13745420 mg/kg_16\NN\1740 ,_17\,\1740 a_18\DT\13649268 known_19\JJ\1740 convulsive_20\JJ\1740 dose_21\NN\3740161 50_22\CD\13745420 (_23\-LRB-\1740 cd50_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 on_27\IN\1740 the_28\DT\1740 incidence_29\NN\13821570 and_30\CC\1740 severity_31\NN\5036394 of_32\IN\1740 <e1>bupropion-induced</e1>_33\JJ\1740 <e2>convulsions</e2>_34\NNS\14081375 in_35\IN\13603305 the_36\DT\1740 swiss_37\JJ\1740 albino_38\NN\9606527 mice_39\NNS\2329401 ._40\.\1740
D016642_D012640 CID results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 showed_4\VBD\2137132 that_5\IN\1740 ip_6\NN\5999797 administration_7\NN\1133281 of_8\IN\1740 <e1>bupropion_9\NN\1740 hcl</e1>_10\NN\1740 120_11\CD\13745420 mg/kg_12\NN\1740 by_13\IN\1740 bolus_14\NN\13899404 injection_15\NN\320852 induced_16\VBD\1627355 <e2>convulsions</e2>_17\NNS\14081375 in_18\IN\13603305 6_19\CD\13741022 out_20\IN\66636 of_21\IN\1740 10_22\CD\13745420 mice_23\NNS\2329401 (_24\-LRB-\1740 60_25\CD\13745420 %_26\NN\1740 of_27\IN\1740 convulsing_28\NN\1740 mice_29\NNS\2329401 )_30\-RRB-\1740 in_31\IN\13603305 group_32\NN\2137 1_33\CD\13741022 ._34\.\1740
D016642_D012640 CID logistic_0\JJ\1740 regression_1\NN\14501726 analysis_2\NN\633864 revealed_3\VBD\2137132 that_4\IN\1740 infusion_5\NN\14589223 time_6\NN\7308889 was_7\VBD\836236 significant_8\JJ\1740 (_9\-LRB-\1740 p_10\NN\14622893 =_11\JJ\1740 0.0004_12\CD\1740 ;_13\:\1740 odds_14\VBZ\1740 ratio_15\NN\13815152 =_16\JJ\1740 0.974_17\CD\1740 )_18\-RRB-\1740 and_19\CC\1740 increasing_20\VBG\169651 the_21\DT\1740 ip_22\NN\5999797 infusion_23\NN\14589223 time_24\NN\7308889 of_25\IN\1740 <e1>bupropion_26\NN\1740 hcl</e1>_27\NN\1740 120_28\CD\13745420 mg/kg_29\NN\1740 was_30\VBD\836236 associated_31\VBN\628491 with_32\IN\1740 a_33\DT\13649268 91_34\CD\1740 %_35\NN\1740 reduced_36\VBN\441445 odds_37\NNS\4756635 of_38\IN\1740 <e2>convulsions</e2>_39\NNS\14081375 at_40\IN\14622893 infusion_41\NN\14589223 times_42\NNS\15113229 of_43\IN\1740 15_44\CD\13745420 to_45\TO\1740 90_46\CD\13745420 min_47\NN\15154774 compared_48\VBN\644583 to_49\TO\1740 bolus_50\NN\13899404 injection_51\NN\320852 ._52\.\1740
D016642_D012640 CID conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 conclusion_3\NN\5837957 ,_4\,\1740 the_5\DT\1740 demonstration_6\NN\520257 of_7\IN\1740 an_8\DT\6697703 inverse_9\JJ\1740 relationship_10\NN\31921 between_11\IN\1740 infusion_12\NN\14589223 time_13\NN\7308889 of_14\IN\1740 a_15\DT\13649268 fixed_16\VBN\205885 and_17\CC\1740 <e2>convulsive</e2>_18\JJ\1740 dose_19\NN\3740161 of_20\IN\1740 <e1>bupropion</e1>_21\NN\1740 and_22\CC\1740 the_23\DT\1740 risk_24\NN\14541044 of_25\IN\1740 convulsions_26\NNS\14081375 in_27\IN\13603305 a_28\DT\13649268 prospective_29\JJ\1740 study_30\NN\635850 is_31\VBZ\836236 novel_32\JJ\1740 ._33\.\1740
D016642_D012640 CID conclusion_0\NN\5837957 :_1\:\1740 in_2\IN\13603305 conclusion_3\NN\5837957 ,_4\,\1740 the_5\DT\1740 demonstration_6\NN\520257 of_7\IN\1740 an_8\DT\6697703 inverse_9\JJ\1740 relationship_10\NN\31921 between_11\IN\1740 infusion_12\NN\14589223 time_13\NN\7308889 of_14\IN\1740 a_15\DT\13649268 fixed_16\VBN\205885 and_17\CC\1740 convulsive_18\JJ\1740 dose_19\NN\3740161 of_20\IN\1740 <e1>bupropion</e1>_21\NN\1740 and_22\CC\1740 the_23\DT\1740 risk_24\NN\14541044 of_25\IN\1740 <e2>convulsions</e2>_26\NNS\14081375 in_27\IN\13603305 a_28\DT\13649268 prospective_29\JJ\1740 study_30\NN\635850 is_31\VBZ\836236 novel_32\JJ\1740 ._33\.\1740
9067481
C013440_D056486 NONE in_0\IN\13603305 addition_1\NN\3081021 to_2\IN\1740 its_3\PRP$\6125041 use_4\NN\407535 as_5\IN\14622893 a_6\DT\13649268 stabilizer/rigidifier_7\NN\1740 of_8\IN\1740 membranes_9\NNS\4188643 ,_10\,\1740 <e1>cholesteryl_11\NN\1740 hemisuccinate</e1>_12\NN\1740 ,_13\,\1740 tris_14\NN\1740 salt_15\NN\14818238 (_16\-LRB-\1740 cs_17\NN\14625458 )_18\-RRB-\1740 administration_19\NN\1133281 has_20\VBZ\2108377 also_21\RB\1740 been_22\VBN\836236 shown_23\VBN\2137132 to_24\TO\1740 protect_25\VB\1127795 rats_26\NNS\2329401 from_27\IN\1740 the_28\DT\1740 <e2>hepatotoxic</e2>_29\JJ\1740 effects_30\NNS\13245626 of_31\IN\1740 carbon_32\NN\14622893 tetrachloride_33\NN\14818238 (_34\-LRB-\1740 ccl4_35\NN\1740 )_36\-RRB-\1740 ._37\.\1740
-1_D056486 NONE in_0\IN\13603305 addition_1\NN\3081021 to_2\IN\1740 its_3\PRP$\6125041 use_4\NN\407535 as_5\IN\14622893 a_6\DT\13649268 stabilizer/rigidifier_7\NN\1740 of_8\IN\1740 membranes_9\NNS\4188643 ,_10\,\1740 cholesteryl_11\NN\1740 hemisuccinate_12\NN\1740 ,_13\,\1740 <e1>tris_14\NN\1740 salt</e1>_15\NN\14818238 (_16\-LRB-\1740 cs_17\NN\14625458 )_18\-RRB-\1740 administration_19\NN\1133281 has_20\VBZ\2108377 also_21\RB\1740 been_22\VBN\836236 shown_23\VBN\2137132 to_24\TO\1740 protect_25\VB\1127795 rats_26\NNS\2329401 from_27\IN\1740 the_28\DT\1740 <e2>hepatotoxic</e2>_29\JJ\1740 effects_30\NNS\13245626 of_31\IN\1740 carbon_32\NN\14622893 tetrachloride_33\NN\14818238 (_34\-LRB-\1740 ccl4_35\NN\1740 )_36\-RRB-\1740 ._37\.\1740
-1_D056486 NONE in_0\IN\13603305 addition_1\NN\3081021 to_2\IN\1740 its_3\PRP$\6125041 use_4\NN\407535 as_5\IN\14622893 a_6\DT\13649268 stabilizer/rigidifier_7\NN\1740 of_8\IN\1740 membranes_9\NNS\4188643 ,_10\,\1740 cholesteryl_11\NN\1740 hemisuccinate_12\NN\1740 ,_13\,\1740 tris_14\NN\1740 salt_15\NN\14818238 (_16\-LRB-\1740 <e1>cs</e1>_17\NN\14625458 )_18\-RRB-\1740 administration_19\NN\1133281 has_20\VBZ\2108377 also_21\RB\1740 been_22\VBN\836236 shown_23\VBN\2137132 to_24\TO\1740 protect_25\VB\1127795 rats_26\NNS\2329401 from_27\IN\1740 the_28\DT\1740 <e2>hepatotoxic</e2>_29\JJ\1740 effects_30\NNS\13245626 of_31\IN\1740 carbon_32\NN\14622893 tetrachloride_33\NN\14818238 (_34\-LRB-\1740 ccl4_35\NN\1740 )_36\-RRB-\1740 ._37\.\1740
-1_D056486 NONE a_0\DT\13649268 24-h_1\JJ\1740 pretreatment_2\NN\1740 of_3\IN\1740 both_4\DT\1740 rats_5\NNS\2329401 and_6\CC\1740 mice_7\NNS\2329401 with_8\IN\1740 a_9\DT\13649268 single_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 <e1>cs</e1>_13\NN\14625458 (_14\-LRB-\1740 100mg/kg_15\NN\1740 ,_16\,\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 significant_22\JJ\1740 protection_23\NN\407535 against_24\IN\1740 the_25\DT\1740 <e2>hepatotoxic</e2>_26\JJ\1740 effects_27\NNS\13245626 of_28\IN\1740 ccl4_29\NN\1740 ,_30\,\1740 chcl3_31\NN\1740 ,_32\,\1740 acetaminophen_33\NN\2707683 and_34\CC\1740 galactosamine_35\NN\1740 and_36\CC\1740 against_37\IN\1740 the_38\DT\1740 lethal_39\NN\1740 (_40\-LRB-\1740 and_41\CC\1740 presumably_42\RB\1740 cardiotoxic_43\JJ\1740 )_44\-RRB-\1740 effect_45\NN\34213 of_46\IN\1740 adriamycin_47\NN\1740 administration_48\NN\1133281 ._49\.\1740
-1_D056486 NONE the_0\DT\1740 mechanism_1\NN\13446390 of_2\IN\1740 <e1>cs</e1>_3\NN\14625458 protection_4\NN\407535 does_5\VBZ\1640855 not_6\RB\1740 appear_7\VB\2604760 to_8\TO\1740 be_9\VB\836236 dependent_10\JJ\1740 on_11\IN\1740 the_12\DT\1740 inhibition_13\NN\1068773 of_14\IN\1740 chemical_15\JJ\1740 bioactivation_16\NN\1740 to_17\TO\1740 a_18\DT\13649268 toxic_19\JJ\1740 reactive_20\JJ\1740 intermediate_21\NN\14806838 (_22\-LRB-\1740 in_23\IN\13603305 light_24\NN\11421401 of_25\IN\1740 the_26\DT\1740 protection_27\NN\407535 observed_28\VBN\2163746 against_29\IN\1740 galactosamine_30\NN\1740 <e2>hepatotoxicity</e2>_31\NN\1740 )_32\-RRB-\1740 ._33\.\1740
D002251_D056486 CID in_0\IN\13603305 addition_1\NN\3081021 to_2\IN\1740 its_3\PRP$\6125041 use_4\NN\407535 as_5\IN\14622893 a_6\DT\13649268 stabilizer/rigidifier_7\NN\1740 of_8\IN\1740 membranes_9\NNS\4188643 ,_10\,\1740 cholesteryl_11\NN\1740 hemisuccinate_12\NN\1740 ,_13\,\1740 tris_14\NN\1740 salt_15\NN\14818238 (_16\-LRB-\1740 cs_17\NN\14625458 )_18\-RRB-\1740 administration_19\NN\1133281 has_20\VBZ\2108377 also_21\RB\1740 been_22\VBN\836236 shown_23\VBN\2137132 to_24\TO\1740 protect_25\VB\1127795 rats_26\NNS\2329401 from_27\IN\1740 the_28\DT\1740 <e2>hepatotoxic</e2>_29\JJ\1740 effects_30\NNS\13245626 of_31\IN\1740 <e1>carbon_32\NN\14622893 tetrachloride</e1>_33\NN\14818238 (_34\-LRB-\1740 ccl4_35\NN\1740 )_36\-RRB-\1740 ._37\.\1740
D002251_D056486 CID in_0\IN\13603305 addition_1\NN\3081021 to_2\IN\1740 its_3\PRP$\6125041 use_4\NN\407535 as_5\IN\14622893 a_6\DT\13649268 stabilizer/rigidifier_7\NN\1740 of_8\IN\1740 membranes_9\NNS\4188643 ,_10\,\1740 cholesteryl_11\NN\1740 hemisuccinate_12\NN\1740 ,_13\,\1740 tris_14\NN\1740 salt_15\NN\14818238 (_16\-LRB-\1740 cs_17\NN\14625458 )_18\-RRB-\1740 administration_19\NN\1133281 has_20\VBZ\2108377 also_21\RB\1740 been_22\VBN\836236 shown_23\VBN\2137132 to_24\TO\1740 protect_25\VB\1127795 rats_26\NNS\2329401 from_27\IN\1740 the_28\DT\1740 <e2>hepatotoxic</e2>_29\JJ\1740 effects_30\NNS\13245626 of_31\IN\1740 carbon_32\NN\14622893 tetrachloride_33\NN\14818238 (_34\-LRB-\1740 <e1>ccl4</e1>_35\NN\1740 )_36\-RRB-\1740 ._37\.\1740
D002251_D056486 CID a_0\DT\13649268 24-h_1\JJ\1740 pretreatment_2\NN\1740 of_3\IN\1740 both_4\DT\1740 rats_5\NNS\2329401 and_6\CC\1740 mice_7\NNS\2329401 with_8\IN\1740 a_9\DT\13649268 single_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 cs_13\NN\14625458 (_14\-LRB-\1740 100mg/kg_15\NN\1740 ,_16\,\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 significant_22\JJ\1740 protection_23\NN\407535 against_24\IN\1740 the_25\DT\1740 <e2>hepatotoxic</e2>_26\JJ\1740 effects_27\NNS\13245626 of_28\IN\1740 <e1>ccl4</e1>_29\NN\1740 ,_30\,\1740 chcl3_31\NN\1740 ,_32\,\1740 acetaminophen_33\NN\2707683 and_34\CC\1740 galactosamine_35\NN\1740 and_36\CC\1740 against_37\IN\1740 the_38\DT\1740 lethal_39\NN\1740 (_40\-LRB-\1740 and_41\CC\1740 presumably_42\RB\1740 cardiotoxic_43\JJ\1740 )_44\-RRB-\1740 effect_45\NN\34213 of_46\IN\1740 adriamycin_47\NN\1740 administration_48\NN\1133281 ._49\.\1740
-1_D064420 NONE to_0\TO\1740 further_1\RB\1740 our_2\PRP$\1740 understanding_3\NN\5804793 of_4\IN\1740 the_5\DT\1740 mechanism_6\NN\13446390 of_7\IN\1740 <e1>cs</e1>_8\NN\14625458 cytoprotection_9\NN\1740 ,_10\,\1740 we_11\PRP\1740 examined_12\VBD\789138 in_13\IN\13603305 rats_14\NNS\2329401 and_15\CC\1740 mice_16\VBZ\1740 the_17\DT\1740 protective_18\JJ\1740 abilities_19\NNS\4723816 of_20\IN\1740 cs_21\NN\14625458 and_22\CC\1740 the_23\DT\1740 non-hydrolyzable_24\JJ\1740 ether_25\JJ\1740 form_26\NN\6286395 of_27\IN\1740 cs_28\NN\14625458 ,_29\,\1740 gamma-cholesteryloxybutyric_30\JJ\1740 acid_31\NN\14818238 ,_32\,\1740 tris_33\NN\1740 salt_34\NN\14818238 (_35\-LRB-\1740 cse_36\NN\8342039 )_37\-RRB-\1740 against_38\IN\1740 acetaminophen-_39\NN\1740 ,_40\,\1740 adriamycin-_41\UH\1740 ,_42\,\1740 carbon_43\NN\14622893 tetrachloride-_44\NN\1740 ,_45\,\1740 chloroform-_46\NN\1740 and_47\CC\1740 galactosamine-induced_48\JJ\1740 <e2>toxicity</e2>_49\NN\13576101 ._50\.\1740
-1_D064420 NONE to_0\TO\1740 further_1\RB\1740 our_2\PRP$\1740 understanding_3\NN\5804793 of_4\IN\1740 the_5\DT\1740 mechanism_6\NN\13446390 of_7\IN\1740 cs_8\NN\14625458 cytoprotection_9\NN\1740 ,_10\,\1740 we_11\PRP\1740 examined_12\VBD\789138 in_13\IN\13603305 rats_14\NNS\2329401 and_15\CC\1740 mice_16\VBZ\1740 the_17\DT\1740 protective_18\JJ\1740 abilities_19\NNS\4723816 of_20\IN\1740 <e1>cs</e1>_21\NN\14625458 and_22\CC\1740 the_23\DT\1740 non-hydrolyzable_24\JJ\1740 ether_25\JJ\1740 form_26\NN\6286395 of_27\IN\1740 cs_28\NN\14625458 ,_29\,\1740 gamma-cholesteryloxybutyric_30\JJ\1740 acid_31\NN\14818238 ,_32\,\1740 tris_33\NN\1740 salt_34\NN\14818238 (_35\-LRB-\1740 cse_36\NN\8342039 )_37\-RRB-\1740 against_38\IN\1740 acetaminophen-_39\NN\1740 ,_40\,\1740 adriamycin-_41\UH\1740 ,_42\,\1740 carbon_43\NN\14622893 tetrachloride-_44\NN\1740 ,_45\,\1740 chloroform-_46\NN\1740 and_47\CC\1740 galactosamine-induced_48\JJ\1740 <e2>toxicity</e2>_49\NN\13576101 ._50\.\1740
-1_D064420 NONE to_0\TO\1740 further_1\RB\1740 our_2\PRP$\1740 understanding_3\NN\5804793 of_4\IN\1740 the_5\DT\1740 mechanism_6\NN\13446390 of_7\IN\1740 cs_8\NN\14625458 cytoprotection_9\NN\1740 ,_10\,\1740 we_11\PRP\1740 examined_12\VBD\789138 in_13\IN\13603305 rats_14\NNS\2329401 and_15\CC\1740 mice_16\VBZ\1740 the_17\DT\1740 protective_18\JJ\1740 abilities_19\NNS\4723816 of_20\IN\1740 cs_21\NN\14625458 and_22\CC\1740 the_23\DT\1740 non-hydrolyzable_24\JJ\1740 ether_25\JJ\1740 form_26\NN\6286395 of_27\IN\1740 <e1>cs</e1>_28\NN\14625458 ,_29\,\1740 gamma-cholesteryloxybutyric_30\JJ\1740 acid_31\NN\14818238 ,_32\,\1740 tris_33\NN\1740 salt_34\NN\14818238 (_35\-LRB-\1740 cse_36\NN\8342039 )_37\-RRB-\1740 against_38\IN\1740 acetaminophen-_39\NN\1740 ,_40\,\1740 adriamycin-_41\UH\1740 ,_42\,\1740 carbon_43\NN\14622893 tetrachloride-_44\NN\1740 ,_45\,\1740 chloroform-_46\NN\1740 and_47\CC\1740 galactosamine-induced_48\JJ\1740 <e2>toxicity</e2>_49\NN\13576101 ._50\.\1740
-1_D064420 NONE to_0\TO\1740 further_1\RB\1740 our_2\PRP$\1740 understanding_3\NN\5804793 of_4\IN\1740 the_5\DT\1740 mechanism_6\NN\13446390 of_7\IN\1740 cs_8\NN\14625458 cytoprotection_9\NN\1740 ,_10\,\1740 we_11\PRP\1740 examined_12\VBD\789138 in_13\IN\13603305 rats_14\NNS\2329401 and_15\CC\1740 mice_16\VBZ\1740 the_17\DT\1740 protective_18\JJ\1740 abilities_19\NNS\4723816 of_20\IN\1740 cs_21\NN\14625458 and_22\CC\1740 the_23\DT\1740 non-hydrolyzable_24\JJ\1740 ether_25\JJ\1740 form_26\NN\6286395 of_27\IN\1740 cs_28\NN\14625458 ,_29\,\1740 gamma-cholesteryloxybutyric_30\JJ\1740 acid_31\NN\14818238 ,_32\,\1740 <e1>tris_33\NN\1740 salt</e1>_34\NN\14818238 (_35\-LRB-\1740 cse_36\NN\8342039 )_37\-RRB-\1740 against_38\IN\1740 acetaminophen-_39\NN\1740 ,_40\,\1740 adriamycin-_41\UH\1740 ,_42\,\1740 carbon_43\NN\14622893 tetrachloride-_44\NN\1740 ,_45\,\1740 chloroform-_46\NN\1740 and_47\CC\1740 galactosamine-induced_48\JJ\1740 <e2>toxicity</e2>_49\NN\13576101 ._50\.\1740
-1_D064420 NONE to_0\TO\1740 further_1\RB\1740 our_2\PRP$\1740 understanding_3\NN\5804793 of_4\IN\1740 the_5\DT\1740 mechanism_6\NN\13446390 of_7\IN\1740 cs_8\NN\14625458 cytoprotection_9\NN\1740 ,_10\,\1740 we_11\PRP\1740 examined_12\VBD\789138 in_13\IN\13603305 rats_14\NNS\2329401 and_15\CC\1740 mice_16\VBZ\1740 the_17\DT\1740 protective_18\JJ\1740 abilities_19\NNS\4723816 of_20\IN\1740 cs_21\NN\14625458 and_22\CC\1740 the_23\DT\1740 non-hydrolyzable_24\JJ\1740 ether_25\JJ\1740 form_26\NN\6286395 of_27\IN\1740 cs_28\NN\14625458 ,_29\,\1740 gamma-cholesteryloxybutyric_30\JJ\1740 acid_31\NN\14818238 ,_32\,\1740 tris_33\NN\1740 salt_34\NN\14818238 (_35\-LRB-\1740 <e1>cse</e1>_36\NN\8342039 )_37\-RRB-\1740 against_38\IN\1740 acetaminophen-_39\NN\1740 ,_40\,\1740 adriamycin-_41\UH\1740 ,_42\,\1740 carbon_43\NN\14622893 tetrachloride-_44\NN\1740 ,_45\,\1740 chloroform-_46\NN\1740 and_47\CC\1740 galactosamine-induced_48\JJ\1740 <e2>toxicity</e2>_49\NN\13576101 ._50\.\1740
C103872_D064420 NONE to_0\TO\1740 further_1\RB\1740 our_2\PRP$\1740 understanding_3\NN\5804793 of_4\IN\1740 the_5\DT\1740 mechanism_6\NN\13446390 of_7\IN\1740 cs_8\NN\14625458 cytoprotection_9\NN\1740 ,_10\,\1740 we_11\PRP\1740 examined_12\VBD\789138 in_13\IN\13603305 rats_14\NNS\2329401 and_15\CC\1740 mice_16\VBZ\1740 the_17\DT\1740 protective_18\JJ\1740 abilities_19\NNS\4723816 of_20\IN\1740 cs_21\NN\14625458 and_22\CC\1740 the_23\DT\1740 non-hydrolyzable_24\JJ\1740 ether_25\JJ\1740 form_26\NN\6286395 of_27\IN\1740 cs_28\NN\14625458 ,_29\,\1740 <e1>gamma-cholesteryloxybutyric_30\JJ\1740 acid</e1>_31\NN\14818238 ,_32\,\1740 tris_33\NN\1740 salt_34\NN\14818238 (_35\-LRB-\1740 cse_36\NN\8342039 )_37\-RRB-\1740 against_38\IN\1740 acetaminophen-_39\NN\1740 ,_40\,\1740 adriamycin-_41\UH\1740 ,_42\,\1740 carbon_43\NN\14622893 tetrachloride-_44\NN\1740 ,_45\,\1740 chloroform-_46\NN\1740 and_47\CC\1740 galactosamine-induced_48\JJ\1740 <e2>toxicity</e2>_49\NN\13576101 ._50\.\1740
D000082_D064420 NONE to_0\TO\1740 further_1\RB\1740 our_2\PRP$\1740 understanding_3\NN\5804793 of_4\IN\1740 the_5\DT\1740 mechanism_6\NN\13446390 of_7\IN\1740 cs_8\NN\14625458 cytoprotection_9\NN\1740 ,_10\,\1740 we_11\PRP\1740 examined_12\VBD\789138 in_13\IN\13603305 rats_14\NNS\2329401 and_15\CC\1740 mice_16\VBZ\1740 the_17\DT\1740 protective_18\JJ\1740 abilities_19\NNS\4723816 of_20\IN\1740 cs_21\NN\14625458 and_22\CC\1740 the_23\DT\1740 non-hydrolyzable_24\JJ\1740 ether_25\JJ\1740 form_26\NN\6286395 of_27\IN\1740 cs_28\NN\14625458 ,_29\,\1740 gamma-cholesteryloxybutyric_30\JJ\1740 acid_31\NN\14818238 ,_32\,\1740 tris_33\NN\1740 salt_34\NN\14818238 (_35\-LRB-\1740 cse_36\NN\8342039 )_37\-RRB-\1740 against_38\IN\1740 <e1>acetaminophen-</e1>_39\NN\1740 ,_40\,\1740 adriamycin-_41\UH\1740 ,_42\,\1740 carbon_43\NN\14622893 tetrachloride-_44\NN\1740 ,_45\,\1740 chloroform-_46\NN\1740 and_47\CC\1740 galactosamine-induced_48\JJ\1740 <e2>toxicity</e2>_49\NN\13576101 ._50\.\1740
D004317_D064420 NONE to_0\TO\1740 further_1\RB\1740 our_2\PRP$\1740 understanding_3\NN\5804793 of_4\IN\1740 the_5\DT\1740 mechanism_6\NN\13446390 of_7\IN\1740 cs_8\NN\14625458 cytoprotection_9\NN\1740 ,_10\,\1740 we_11\PRP\1740 examined_12\VBD\789138 in_13\IN\13603305 rats_14\NNS\2329401 and_15\CC\1740 mice_16\VBZ\1740 the_17\DT\1740 protective_18\JJ\1740 abilities_19\NNS\4723816 of_20\IN\1740 cs_21\NN\14625458 and_22\CC\1740 the_23\DT\1740 non-hydrolyzable_24\JJ\1740 ether_25\JJ\1740 form_26\NN\6286395 of_27\IN\1740 cs_28\NN\14625458 ,_29\,\1740 gamma-cholesteryloxybutyric_30\JJ\1740 acid_31\NN\14818238 ,_32\,\1740 tris_33\NN\1740 salt_34\NN\14818238 (_35\-LRB-\1740 cse_36\NN\8342039 )_37\-RRB-\1740 against_38\IN\1740 acetaminophen-_39\NN\1740 ,_40\,\1740 <e1>adriamycin-</e1>_41\UH\1740 ,_42\,\1740 carbon_43\NN\14622893 tetrachloride-_44\NN\1740 ,_45\,\1740 chloroform-_46\NN\1740 and_47\CC\1740 galactosamine-induced_48\JJ\1740 <e2>toxicity</e2>_49\NN\13576101 ._50\.\1740
D002251_D064420 NONE to_0\TO\1740 further_1\RB\1740 our_2\PRP$\1740 understanding_3\NN\5804793 of_4\IN\1740 the_5\DT\1740 mechanism_6\NN\13446390 of_7\IN\1740 cs_8\NN\14625458 cytoprotection_9\NN\1740 ,_10\,\1740 we_11\PRP\1740 examined_12\VBD\789138 in_13\IN\13603305 rats_14\NNS\2329401 and_15\CC\1740 mice_16\VBZ\1740 the_17\DT\1740 protective_18\JJ\1740 abilities_19\NNS\4723816 of_20\IN\1740 cs_21\NN\14625458 and_22\CC\1740 the_23\DT\1740 non-hydrolyzable_24\JJ\1740 ether_25\JJ\1740 form_26\NN\6286395 of_27\IN\1740 cs_28\NN\14625458 ,_29\,\1740 gamma-cholesteryloxybutyric_30\JJ\1740 acid_31\NN\14818238 ,_32\,\1740 tris_33\NN\1740 salt_34\NN\14818238 (_35\-LRB-\1740 cse_36\NN\8342039 )_37\-RRB-\1740 against_38\IN\1740 acetaminophen-_39\NN\1740 ,_40\,\1740 adriamycin-_41\UH\1740 ,_42\,\1740 <e1>carbon_43\NN\14622893 tetrachloride-</e1>_44\NN\1740 ,_45\,\1740 chloroform-_46\NN\1740 and_47\CC\1740 galactosamine-induced_48\JJ\1740 <e2>toxicity</e2>_49\NN\13576101 ._50\.\1740
D002725_D064420 NONE to_0\TO\1740 further_1\RB\1740 our_2\PRP$\1740 understanding_3\NN\5804793 of_4\IN\1740 the_5\DT\1740 mechanism_6\NN\13446390 of_7\IN\1740 cs_8\NN\14625458 cytoprotection_9\NN\1740 ,_10\,\1740 we_11\PRP\1740 examined_12\VBD\789138 in_13\IN\13603305 rats_14\NNS\2329401 and_15\CC\1740 mice_16\VBZ\1740 the_17\DT\1740 protective_18\JJ\1740 abilities_19\NNS\4723816 of_20\IN\1740 cs_21\NN\14625458 and_22\CC\1740 the_23\DT\1740 non-hydrolyzable_24\JJ\1740 ether_25\JJ\1740 form_26\NN\6286395 of_27\IN\1740 cs_28\NN\14625458 ,_29\,\1740 gamma-cholesteryloxybutyric_30\JJ\1740 acid_31\NN\14818238 ,_32\,\1740 tris_33\NN\1740 salt_34\NN\14818238 (_35\-LRB-\1740 cse_36\NN\8342039 )_37\-RRB-\1740 against_38\IN\1740 acetaminophen-_39\NN\1740 ,_40\,\1740 adriamycin-_41\UH\1740 ,_42\,\1740 carbon_43\NN\14622893 tetrachloride-_44\NN\1740 ,_45\,\1740 <e1>chloroform-</e1>_46\NN\1740 and_47\CC\1740 galactosamine-induced_48\JJ\1740 <e2>toxicity</e2>_49\NN\13576101 ._50\.\1740
D005688_D064420 NONE to_0\TO\1740 further_1\RB\1740 our_2\PRP$\1740 understanding_3\NN\5804793 of_4\IN\1740 the_5\DT\1740 mechanism_6\NN\13446390 of_7\IN\1740 cs_8\NN\14625458 cytoprotection_9\NN\1740 ,_10\,\1740 we_11\PRP\1740 examined_12\VBD\789138 in_13\IN\13603305 rats_14\NNS\2329401 and_15\CC\1740 mice_16\VBZ\1740 the_17\DT\1740 protective_18\JJ\1740 abilities_19\NNS\4723816 of_20\IN\1740 cs_21\NN\14625458 and_22\CC\1740 the_23\DT\1740 non-hydrolyzable_24\JJ\1740 ether_25\JJ\1740 form_26\NN\6286395 of_27\IN\1740 cs_28\NN\14625458 ,_29\,\1740 gamma-cholesteryloxybutyric_30\JJ\1740 acid_31\NN\14818238 ,_32\,\1740 tris_33\NN\1740 salt_34\NN\14818238 (_35\-LRB-\1740 cse_36\NN\8342039 )_37\-RRB-\1740 against_38\IN\1740 acetaminophen-_39\NN\1740 ,_40\,\1740 adriamycin-_41\UH\1740 ,_42\,\1740 carbon_43\NN\14622893 tetrachloride-_44\NN\1740 ,_45\,\1740 chloroform-_46\NN\1740 and_47\CC\1740 <e1>galactosamine-induced</e1>_48\JJ\1740 <e2>toxicity</e2>_49\NN\13576101 ._50\.\1740
-1_D066126 NONE a_0\DT\13649268 24-h_1\JJ\1740 pretreatment_2\NN\1740 of_3\IN\1740 both_4\DT\1740 rats_5\NNS\2329401 and_6\CC\1740 mice_7\NNS\2329401 with_8\IN\1740 a_9\DT\13649268 single_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 <e1>cs</e1>_13\NN\14625458 (_14\-LRB-\1740 100mg/kg_15\NN\1740 ,_16\,\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 significant_22\JJ\1740 protection_23\NN\407535 against_24\IN\1740 the_25\DT\1740 hepatotoxic_26\JJ\1740 effects_27\NNS\13245626 of_28\IN\1740 ccl4_29\NN\1740 ,_30\,\1740 chcl3_31\NN\1740 ,_32\,\1740 acetaminophen_33\NN\2707683 and_34\CC\1740 galactosamine_35\NN\1740 and_36\CC\1740 against_37\IN\1740 the_38\DT\1740 lethal_39\NN\1740 (_40\-LRB-\1740 and_41\CC\1740 presumably_42\RB\1740 <e2>cardiotoxic</e2>_43\JJ\1740 )_44\-RRB-\1740 effect_45\NN\34213 of_46\IN\1740 adriamycin_47\NN\1740 administration_48\NN\1133281 ._49\.\1740
D002251_D066126 NONE a_0\DT\13649268 24-h_1\JJ\1740 pretreatment_2\NN\1740 of_3\IN\1740 both_4\DT\1740 rats_5\NNS\2329401 and_6\CC\1740 mice_7\NNS\2329401 with_8\IN\1740 a_9\DT\13649268 single_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 cs_13\NN\14625458 (_14\-LRB-\1740 100mg/kg_15\NN\1740 ,_16\,\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 significant_22\JJ\1740 protection_23\NN\407535 against_24\IN\1740 the_25\DT\1740 hepatotoxic_26\JJ\1740 effects_27\NNS\13245626 of_28\IN\1740 <e1>ccl4</e1>_29\NN\1740 ,_30\,\1740 chcl3_31\NN\1740 ,_32\,\1740 acetaminophen_33\NN\2707683 and_34\CC\1740 galactosamine_35\NN\1740 and_36\CC\1740 against_37\IN\1740 the_38\DT\1740 lethal_39\NN\1740 (_40\-LRB-\1740 and_41\CC\1740 presumably_42\RB\1740 <e2>cardiotoxic</e2>_43\JJ\1740 )_44\-RRB-\1740 effect_45\NN\34213 of_46\IN\1740 adriamycin_47\NN\1740 administration_48\NN\1133281 ._49\.\1740
D002725_D056486 CID a_0\DT\13649268 24-h_1\JJ\1740 pretreatment_2\NN\1740 of_3\IN\1740 both_4\DT\1740 rats_5\NNS\2329401 and_6\CC\1740 mice_7\NNS\2329401 with_8\IN\1740 a_9\DT\13649268 single_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 cs_13\NN\14625458 (_14\-LRB-\1740 100mg/kg_15\NN\1740 ,_16\,\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 significant_22\JJ\1740 protection_23\NN\407535 against_24\IN\1740 the_25\DT\1740 <e2>hepatotoxic</e2>_26\JJ\1740 effects_27\NNS\13245626 of_28\IN\1740 ccl4_29\NN\1740 ,_30\,\1740 <e1>chcl3</e1>_31\NN\1740 ,_32\,\1740 acetaminophen_33\NN\2707683 and_34\CC\1740 galactosamine_35\NN\1740 and_36\CC\1740 against_37\IN\1740 the_38\DT\1740 lethal_39\NN\1740 (_40\-LRB-\1740 and_41\CC\1740 presumably_42\RB\1740 cardiotoxic_43\JJ\1740 )_44\-RRB-\1740 effect_45\NN\34213 of_46\IN\1740 adriamycin_47\NN\1740 administration_48\NN\1133281 ._49\.\1740
D002725_D066126 NONE a_0\DT\13649268 24-h_1\JJ\1740 pretreatment_2\NN\1740 of_3\IN\1740 both_4\DT\1740 rats_5\NNS\2329401 and_6\CC\1740 mice_7\NNS\2329401 with_8\IN\1740 a_9\DT\13649268 single_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 cs_13\NN\14625458 (_14\-LRB-\1740 100mg/kg_15\NN\1740 ,_16\,\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 significant_22\JJ\1740 protection_23\NN\407535 against_24\IN\1740 the_25\DT\1740 hepatotoxic_26\JJ\1740 effects_27\NNS\13245626 of_28\IN\1740 ccl4_29\NN\1740 ,_30\,\1740 <e1>chcl3</e1>_31\NN\1740 ,_32\,\1740 acetaminophen_33\NN\2707683 and_34\CC\1740 galactosamine_35\NN\1740 and_36\CC\1740 against_37\IN\1740 the_38\DT\1740 lethal_39\NN\1740 (_40\-LRB-\1740 and_41\CC\1740 presumably_42\RB\1740 <e2>cardiotoxic</e2>_43\JJ\1740 )_44\-RRB-\1740 effect_45\NN\34213 of_46\IN\1740 adriamycin_47\NN\1740 administration_48\NN\1133281 ._49\.\1740
D000082_D056486 CID a_0\DT\13649268 24-h_1\JJ\1740 pretreatment_2\NN\1740 of_3\IN\1740 both_4\DT\1740 rats_5\NNS\2329401 and_6\CC\1740 mice_7\NNS\2329401 with_8\IN\1740 a_9\DT\13649268 single_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 cs_13\NN\14625458 (_14\-LRB-\1740 100mg/kg_15\NN\1740 ,_16\,\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 significant_22\JJ\1740 protection_23\NN\407535 against_24\IN\1740 the_25\DT\1740 <e2>hepatotoxic</e2>_26\JJ\1740 effects_27\NNS\13245626 of_28\IN\1740 ccl4_29\NN\1740 ,_30\,\1740 chcl3_31\NN\1740 ,_32\,\1740 <e1>acetaminophen</e1>_33\NN\2707683 and_34\CC\1740 galactosamine_35\NN\1740 and_36\CC\1740 against_37\IN\1740 the_38\DT\1740 lethal_39\NN\1740 (_40\-LRB-\1740 and_41\CC\1740 presumably_42\RB\1740 cardiotoxic_43\JJ\1740 )_44\-RRB-\1740 effect_45\NN\34213 of_46\IN\1740 adriamycin_47\NN\1740 administration_48\NN\1133281 ._49\.\1740
D000082_D066126 NONE a_0\DT\13649268 24-h_1\JJ\1740 pretreatment_2\NN\1740 of_3\IN\1740 both_4\DT\1740 rats_5\NNS\2329401 and_6\CC\1740 mice_7\NNS\2329401 with_8\IN\1740 a_9\DT\13649268 single_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 cs_13\NN\14625458 (_14\-LRB-\1740 100mg/kg_15\NN\1740 ,_16\,\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 significant_22\JJ\1740 protection_23\NN\407535 against_24\IN\1740 the_25\DT\1740 hepatotoxic_26\JJ\1740 effects_27\NNS\13245626 of_28\IN\1740 ccl4_29\NN\1740 ,_30\,\1740 chcl3_31\NN\1740 ,_32\,\1740 <e1>acetaminophen</e1>_33\NN\2707683 and_34\CC\1740 galactosamine_35\NN\1740 and_36\CC\1740 against_37\IN\1740 the_38\DT\1740 lethal_39\NN\1740 (_40\-LRB-\1740 and_41\CC\1740 presumably_42\RB\1740 <e2>cardiotoxic</e2>_43\JJ\1740 )_44\-RRB-\1740 effect_45\NN\34213 of_46\IN\1740 adriamycin_47\NN\1740 administration_48\NN\1133281 ._49\.\1740
D005688_D056486 CID a_0\DT\13649268 24-h_1\JJ\1740 pretreatment_2\NN\1740 of_3\IN\1740 both_4\DT\1740 rats_5\NNS\2329401 and_6\CC\1740 mice_7\NNS\2329401 with_8\IN\1740 a_9\DT\13649268 single_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 cs_13\NN\14625458 (_14\-LRB-\1740 100mg/kg_15\NN\1740 ,_16\,\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 significant_22\JJ\1740 protection_23\NN\407535 against_24\IN\1740 the_25\DT\1740 <e2>hepatotoxic</e2>_26\JJ\1740 effects_27\NNS\13245626 of_28\IN\1740 ccl4_29\NN\1740 ,_30\,\1740 chcl3_31\NN\1740 ,_32\,\1740 acetaminophen_33\NN\2707683 and_34\CC\1740 <e1>galactosamine</e1>_35\NN\1740 and_36\CC\1740 against_37\IN\1740 the_38\DT\1740 lethal_39\NN\1740 (_40\-LRB-\1740 and_41\CC\1740 presumably_42\RB\1740 cardiotoxic_43\JJ\1740 )_44\-RRB-\1740 effect_45\NN\34213 of_46\IN\1740 adriamycin_47\NN\1740 administration_48\NN\1133281 ._49\.\1740
D005688_D056486 CID the_0\DT\1740 mechanism_1\NN\13446390 of_2\IN\1740 cs_3\NN\14625458 protection_4\NN\407535 does_5\VBZ\1640855 not_6\RB\1740 appear_7\VB\2604760 to_8\TO\1740 be_9\VB\836236 dependent_10\JJ\1740 on_11\IN\1740 the_12\DT\1740 inhibition_13\NN\1068773 of_14\IN\1740 chemical_15\JJ\1740 bioactivation_16\NN\1740 to_17\TO\1740 a_18\DT\13649268 toxic_19\JJ\1740 reactive_20\JJ\1740 intermediate_21\NN\14806838 (_22\-LRB-\1740 in_23\IN\13603305 light_24\NN\11421401 of_25\IN\1740 the_26\DT\1740 protection_27\NN\407535 observed_28\VBN\2163746 against_29\IN\1740 <e1>galactosamine</e1>_30\NN\1740 <e2>hepatotoxicity</e2>_31\NN\1740 )_32\-RRB-\1740 ._33\.\1740
D005688_D066126 NONE a_0\DT\13649268 24-h_1\JJ\1740 pretreatment_2\NN\1740 of_3\IN\1740 both_4\DT\1740 rats_5\NNS\2329401 and_6\CC\1740 mice_7\NNS\2329401 with_8\IN\1740 a_9\DT\13649268 single_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 cs_13\NN\14625458 (_14\-LRB-\1740 100mg/kg_15\NN\1740 ,_16\,\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 significant_22\JJ\1740 protection_23\NN\407535 against_24\IN\1740 the_25\DT\1740 hepatotoxic_26\JJ\1740 effects_27\NNS\13245626 of_28\IN\1740 ccl4_29\NN\1740 ,_30\,\1740 chcl3_31\NN\1740 ,_32\,\1740 acetaminophen_33\NN\2707683 and_34\CC\1740 <e1>galactosamine</e1>_35\NN\1740 and_36\CC\1740 against_37\IN\1740 the_38\DT\1740 lethal_39\NN\1740 (_40\-LRB-\1740 and_41\CC\1740 presumably_42\RB\1740 <e2>cardiotoxic</e2>_43\JJ\1740 )_44\-RRB-\1740 effect_45\NN\34213 of_46\IN\1740 adriamycin_47\NN\1740 administration_48\NN\1133281 ._49\.\1740
D004317_D056486 NONE a_0\DT\13649268 24-h_1\JJ\1740 pretreatment_2\NN\1740 of_3\IN\1740 both_4\DT\1740 rats_5\NNS\2329401 and_6\CC\1740 mice_7\NNS\2329401 with_8\IN\1740 a_9\DT\13649268 single_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 cs_13\NN\14625458 (_14\-LRB-\1740 100mg/kg_15\NN\1740 ,_16\,\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 significant_22\JJ\1740 protection_23\NN\407535 against_24\IN\1740 the_25\DT\1740 <e2>hepatotoxic</e2>_26\JJ\1740 effects_27\NNS\13245626 of_28\IN\1740 ccl4_29\NN\1740 ,_30\,\1740 chcl3_31\NN\1740 ,_32\,\1740 acetaminophen_33\NN\2707683 and_34\CC\1740 galactosamine_35\NN\1740 and_36\CC\1740 against_37\IN\1740 the_38\DT\1740 lethal_39\NN\1740 (_40\-LRB-\1740 and_41\CC\1740 presumably_42\RB\1740 cardiotoxic_43\JJ\1740 )_44\-RRB-\1740 effect_45\NN\34213 of_46\IN\1740 <e1>adriamycin</e1>_47\NN\1740 administration_48\NN\1133281 ._49\.\1740
D004317_D066126 CID a_0\DT\13649268 24-h_1\JJ\1740 pretreatment_2\NN\1740 of_3\IN\1740 both_4\DT\1740 rats_5\NNS\2329401 and_6\CC\1740 mice_7\NNS\2329401 with_8\IN\1740 a_9\DT\13649268 single_10\JJ\1740 dose_11\NN\3740161 of_12\IN\1740 cs_13\NN\14625458 (_14\-LRB-\1740 100mg/kg_15\NN\1740 ,_16\,\1740 i.p._17\RB\1740 )_18\-RRB-\1740 ,_19\,\1740 resulted_20\VBD\2633881 in_21\IN\13603305 significant_22\JJ\1740 protection_23\NN\407535 against_24\IN\1740 the_25\DT\1740 hepatotoxic_26\JJ\1740 effects_27\NNS\13245626 of_28\IN\1740 ccl4_29\NN\1740 ,_30\,\1740 chcl3_31\NN\1740 ,_32\,\1740 acetaminophen_33\NN\2707683 and_34\CC\1740 galactosamine_35\NN\1740 and_36\CC\1740 against_37\IN\1740 the_38\DT\1740 lethal_39\NN\1740 (_40\-LRB-\1740 and_41\CC\1740 presumably_42\RB\1740 <e2>cardiotoxic</e2>_43\JJ\1740 )_44\-RRB-\1740 effect_45\NN\34213 of_46\IN\1740 <e1>adriamycin</e1>_47\NN\1740 administration_48\NN\1133281 ._49\.\1740
2422478
D012701_D007022 NONE midline_0\JJ\1740 b3_1\NN\1740 <e1>serotonin</e1>_2\NN\14807737 nerves_3\NNS\14373582 in_4\IN\13603305 rat_5\NN\2329401 medulla_6\NN\14864360 are_7\VBP\836236 involved_8\VBN\2676054 in_9\IN\13603305 <e2>hypotensive</e2>_10\JJ\1740 effect_11\NN\34213 of_12\IN\1740 methyldopa_13\NN\2721160 ._14\.\1740
D012701_D007022 NONE previous_0\JJ\1740 experiments_1\NNS\641820 in_2\IN\13603305 this_3\DT\1740 laboratory_4\NN\4602044 have_5\VBP\2108377 shown_6\VBN\2137132 that_7\IN\1740 microinjection_8\NN\1740 of_9\IN\1740 methyldopa_10\NN\2721160 onto_11\IN\1740 the_12\DT\1740 ventrolateral_13\JJ\1740 cells_14\NNS\3080309 of_15\IN\1740 the_16\DT\1740 b3_17\NN\1740 <e1>serotonin</e1>_18\NN\14807737 neurons_19\NNS\5430628 in_20\IN\13603305 the_21\DT\1740 medulla_22\NN\14864360 elicits_23\VBZ\1617192 a_24\DT\13649268 <e2>hypotensive</e2>_25\JJ\1740 response_26\NN\11410625 mediated_27\VBN\761713 by_28\IN\1740 a_29\DT\13649268 projection_30\NN\5775081 descending_31\VBG\1835496 into_32\IN\1740 the_33\DT\1740 spinal_34\JJ\1740 cord_35\NN\3670849 ._36\.\1740
D012701_D007022 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 hypertensive_2\JJ\1740 ,_3\,\1740 stroke-prone_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 methyldopa_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 <e1>serotonin</e1>_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 <e2>hypotension</e2>_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 serotonin_49\NN\14807737 neurotoxin_50\NN\15034074 5,7-dihydroxytryptamine_51\NN\1740 (_52\-LRB-\1740 5,7-dht_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D012701_D007022 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 hypertensive_2\JJ\1740 ,_3\,\1740 stroke-prone_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 methyldopa_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 serotonin_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 <e2>hypotension</e2>_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 <e1>serotonin</e1>_49\NN\14807737 neurotoxin_50\NN\15034074 5,7-dihydroxytryptamine_51\NN\1740 (_52\-LRB-\1740 5,7-dht_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D012701_D007022 NONE however_0\RB\1740 ,_1\,\1740 intraspinal_2\JJ\1740 injection_3\NN\320852 of_4\IN\1740 5,7-dht_5\CD\1740 to_6\TO\1740 produce_7\VB\1617192 a_8\DT\13649268 more_9\RBR\1740 selective_10\JJ\1740 lesion_11\NN\14204950 of_12\IN\1740 only_13\RB\1740 descending_14\VBG\1835496 <e1>serotonin</e1>_15\NN\14807737 projections_16\NNS\5775081 in_17\IN\13603305 the_18\DT\1740 spinal_19\JJ\1740 cord_20\NN\3670849 did_21\VBD\1640855 not_22\RB\1740 affect_23\VB\126264 this_24\DT\1740 <e2>hypotension</e2>_25\NN\14057371 ._26\.\1740
D012701_D007022 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 therefore_3\RB\1740 that_4\IN\1740 ,_5\,\1740 unlike_6\IN\1740 the_7\DT\1740 ventrolateral_8\JJ\1740 b3_9\NN\1740 cells_10\NNS\3080309 which_11\WDT\1740 mediate_12\VBP\761713 a_13\DT\13649268 methyldopa-induced_14\JJ\1740 <e2>hypotension</e2>_15\NN\14057371 via_16\IN\1740 descending_17\VBG\1835496 projections_18\NNS\5775081 ,_19\,\1740 the_20\DT\1740 midline_21\NN\13861050 <e1>serotonin</e1>_22\NN\14807737 b3_23\NN\1740 cells_24\NNS\3080309 in_25\IN\13603305 the_26\DT\1740 medulla_27\NN\14864360 contribute_28\VBP\126264 to_29\TO\1740 the_30\DT\1740 hypotensive_31\JJ\1740 action_32\NN\30358 of_33\IN\1740 methyldopa_34\NN\2721160 ,_35\,\1740 either_36\CC\1740 by_37\IN\1740 way_38\NN\4916342 of_39\IN\1740 an_40\DT\6697703 ascending_41\NN\279835 projection_42\NN\5775081 which_43\WDT\1740 does_44\VBZ\1640855 not_45\RB\1740 pass_46\VB\1835496 through_47\IN\1740 the_48\DT\1740 median_49\JJ\1740 forebrain_50\NN\5462674 bundle_51\NN\7951464 ,_52\,\1740 or_53\CC\3541091 through_54\IN\1740 a_55\DT\13649268 projection_56\NN\5775081 restricted_57\JJ\1740 to_58\TO\1740 the_59\DT\1740 caudal_60\JJ\1740 brainstem_61\NN\5462674 ._62\.\1740
D012701_D007022 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 therefore_3\RB\1740 that_4\IN\1740 ,_5\,\1740 unlike_6\IN\1740 the_7\DT\1740 ventrolateral_8\JJ\1740 b3_9\NN\1740 cells_10\NNS\3080309 which_11\WDT\1740 mediate_12\VBP\761713 a_13\DT\13649268 methyldopa-induced_14\JJ\1740 hypotension_15\NN\14057371 via_16\IN\1740 descending_17\VBG\1835496 projections_18\NNS\5775081 ,_19\,\1740 the_20\DT\1740 midline_21\NN\13861050 <e1>serotonin</e1>_22\NN\14807737 b3_23\NN\1740 cells_24\NNS\3080309 in_25\IN\13603305 the_26\DT\1740 medulla_27\NN\14864360 contribute_28\VBP\126264 to_29\TO\1740 the_30\DT\1740 <e2>hypotensive</e2>_31\JJ\1740 action_32\NN\30358 of_33\IN\1740 methyldopa_34\NN\2721160 ,_35\,\1740 either_36\CC\1740 by_37\IN\1740 way_38\NN\4916342 of_39\IN\1740 an_40\DT\6697703 ascending_41\NN\279835 projection_42\NN\5775081 which_43\WDT\1740 does_44\VBZ\1640855 not_45\RB\1740 pass_46\VB\1835496 through_47\IN\1740 the_48\DT\1740 median_49\JJ\1740 forebrain_50\NN\5462674 bundle_51\NN\7951464 ,_52\,\1740 or_53\CC\3541091 through_54\IN\1740 a_55\DT\13649268 projection_56\NN\5775081 restricted_57\JJ\1740 to_58\TO\1740 the_59\DT\1740 caudal_60\JJ\1740 brainstem_61\NN\5462674 ._62\.\1740
D008750_D007022 CID midline_0\JJ\1740 b3_1\NN\1740 serotonin_2\NN\14807737 nerves_3\NNS\14373582 in_4\IN\13603305 rat_5\NN\2329401 medulla_6\NN\14864360 are_7\VBP\836236 involved_8\VBN\2676054 in_9\IN\13603305 <e2>hypotensive</e2>_10\JJ\1740 effect_11\NN\34213 of_12\IN\1740 <e1>methyldopa</e1>_13\NN\2721160 ._14\.\1740
D008750_D007022 CID previous_0\JJ\1740 experiments_1\NNS\641820 in_2\IN\13603305 this_3\DT\1740 laboratory_4\NN\4602044 have_5\VBP\2108377 shown_6\VBN\2137132 that_7\IN\1740 microinjection_8\NN\1740 of_9\IN\1740 <e1>methyldopa</e1>_10\NN\2721160 onto_11\IN\1740 the_12\DT\1740 ventrolateral_13\JJ\1740 cells_14\NNS\3080309 of_15\IN\1740 the_16\DT\1740 b3_17\NN\1740 serotonin_18\NN\14807737 neurons_19\NNS\5430628 in_20\IN\13603305 the_21\DT\1740 medulla_22\NN\14864360 elicits_23\VBZ\1617192 a_24\DT\13649268 <e2>hypotensive</e2>_25\JJ\1740 response_26\NN\11410625 mediated_27\VBN\761713 by_28\IN\1740 a_29\DT\13649268 projection_30\NN\5775081 descending_31\VBG\1835496 into_32\IN\1740 the_33\DT\1740 spinal_34\JJ\1740 cord_35\NN\3670849 ._36\.\1740
D008750_D007022 CID in_0\IN\13603305 spontaneously_1\JJ\1740 hypertensive_2\JJ\1740 ,_3\,\1740 stroke-prone_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 <e1>methyldopa</e1>_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 serotonin_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 <e2>hypotension</e2>_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 serotonin_49\NN\14807737 neurotoxin_50\NN\15034074 5,7-dihydroxytryptamine_51\NN\1740 (_52\-LRB-\1740 5,7-dht_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D008750_D007022 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 therefore_3\RB\1740 that_4\IN\1740 ,_5\,\1740 unlike_6\IN\1740 the_7\DT\1740 ventrolateral_8\JJ\1740 b3_9\NN\1740 cells_10\NNS\3080309 which_11\WDT\1740 mediate_12\VBP\761713 a_13\DT\13649268 <e1>methyldopa-induced</e1>_14\JJ\1740 <e2>hypotension</e2>_15\NN\14057371 via_16\IN\1740 descending_17\VBG\1835496 projections_18\NNS\5775081 ,_19\,\1740 the_20\DT\1740 midline_21\NN\13861050 serotonin_22\NN\14807737 b3_23\NN\1740 cells_24\NNS\3080309 in_25\IN\13603305 the_26\DT\1740 medulla_27\NN\14864360 contribute_28\VBP\126264 to_29\TO\1740 the_30\DT\1740 hypotensive_31\JJ\1740 action_32\NN\30358 of_33\IN\1740 methyldopa_34\NN\2721160 ,_35\,\1740 either_36\CC\1740 by_37\IN\1740 way_38\NN\4916342 of_39\IN\1740 an_40\DT\6697703 ascending_41\NN\279835 projection_42\NN\5775081 which_43\WDT\1740 does_44\VBZ\1640855 not_45\RB\1740 pass_46\VB\1835496 through_47\IN\1740 the_48\DT\1740 median_49\JJ\1740 forebrain_50\NN\5462674 bundle_51\NN\7951464 ,_52\,\1740 or_53\CC\3541091 through_54\IN\1740 a_55\DT\13649268 projection_56\NN\5775081 restricted_57\JJ\1740 to_58\TO\1740 the_59\DT\1740 caudal_60\JJ\1740 brainstem_61\NN\5462674 ._62\.\1740
D008750_D007022 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 therefore_3\RB\1740 that_4\IN\1740 ,_5\,\1740 unlike_6\IN\1740 the_7\DT\1740 ventrolateral_8\JJ\1740 b3_9\NN\1740 cells_10\NNS\3080309 which_11\WDT\1740 mediate_12\VBP\761713 a_13\DT\13649268 <e1>methyldopa-induced</e1>_14\JJ\1740 hypotension_15\NN\14057371 via_16\IN\1740 descending_17\VBG\1835496 projections_18\NNS\5775081 ,_19\,\1740 the_20\DT\1740 midline_21\NN\13861050 serotonin_22\NN\14807737 b3_23\NN\1740 cells_24\NNS\3080309 in_25\IN\13603305 the_26\DT\1740 medulla_27\NN\14864360 contribute_28\VBP\126264 to_29\TO\1740 the_30\DT\1740 <e2>hypotensive</e2>_31\JJ\1740 action_32\NN\30358 of_33\IN\1740 methyldopa_34\NN\2721160 ,_35\,\1740 either_36\CC\1740 by_37\IN\1740 way_38\NN\4916342 of_39\IN\1740 an_40\DT\6697703 ascending_41\NN\279835 projection_42\NN\5775081 which_43\WDT\1740 does_44\VBZ\1640855 not_45\RB\1740 pass_46\VB\1835496 through_47\IN\1740 the_48\DT\1740 median_49\JJ\1740 forebrain_50\NN\5462674 bundle_51\NN\7951464 ,_52\,\1740 or_53\CC\3541091 through_54\IN\1740 a_55\DT\13649268 projection_56\NN\5775081 restricted_57\JJ\1740 to_58\TO\1740 the_59\DT\1740 caudal_60\JJ\1740 brainstem_61\NN\5462674 ._62\.\1740
D008750_D007022 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 therefore_3\RB\1740 that_4\IN\1740 ,_5\,\1740 unlike_6\IN\1740 the_7\DT\1740 ventrolateral_8\JJ\1740 b3_9\NN\1740 cells_10\NNS\3080309 which_11\WDT\1740 mediate_12\VBP\761713 a_13\DT\13649268 methyldopa-induced_14\JJ\1740 <e2>hypotension</e2>_15\NN\14057371 via_16\IN\1740 descending_17\VBG\1835496 projections_18\NNS\5775081 ,_19\,\1740 the_20\DT\1740 midline_21\NN\13861050 serotonin_22\NN\14807737 b3_23\NN\1740 cells_24\NNS\3080309 in_25\IN\13603305 the_26\DT\1740 medulla_27\NN\14864360 contribute_28\VBP\126264 to_29\TO\1740 the_30\DT\1740 hypotensive_31\JJ\1740 action_32\NN\30358 of_33\IN\1740 <e1>methyldopa</e1>_34\NN\2721160 ,_35\,\1740 either_36\CC\1740 by_37\IN\1740 way_38\NN\4916342 of_39\IN\1740 an_40\DT\6697703 ascending_41\NN\279835 projection_42\NN\5775081 which_43\WDT\1740 does_44\VBZ\1640855 not_45\RB\1740 pass_46\VB\1835496 through_47\IN\1740 the_48\DT\1740 median_49\JJ\1740 forebrain_50\NN\5462674 bundle_51\NN\7951464 ,_52\,\1740 or_53\CC\3541091 through_54\IN\1740 a_55\DT\13649268 projection_56\NN\5775081 restricted_57\JJ\1740 to_58\TO\1740 the_59\DT\1740 caudal_60\JJ\1740 brainstem_61\NN\5462674 ._62\.\1740
D008750_D007022 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 therefore_3\RB\1740 that_4\IN\1740 ,_5\,\1740 unlike_6\IN\1740 the_7\DT\1740 ventrolateral_8\JJ\1740 b3_9\NN\1740 cells_10\NNS\3080309 which_11\WDT\1740 mediate_12\VBP\761713 a_13\DT\13649268 methyldopa-induced_14\JJ\1740 hypotension_15\NN\14057371 via_16\IN\1740 descending_17\VBG\1835496 projections_18\NNS\5775081 ,_19\,\1740 the_20\DT\1740 midline_21\NN\13861050 serotonin_22\NN\14807737 b3_23\NN\1740 cells_24\NNS\3080309 in_25\IN\13603305 the_26\DT\1740 medulla_27\NN\14864360 contribute_28\VBP\126264 to_29\TO\1740 the_30\DT\1740 <e2>hypotensive</e2>_31\JJ\1740 action_32\NN\30358 of_33\IN\1740 <e1>methyldopa</e1>_34\NN\2721160 ,_35\,\1740 either_36\CC\1740 by_37\IN\1740 way_38\NN\4916342 of_39\IN\1740 an_40\DT\6697703 ascending_41\NN\279835 projection_42\NN\5775081 which_43\WDT\1740 does_44\VBZ\1640855 not_45\RB\1740 pass_46\VB\1835496 through_47\IN\1740 the_48\DT\1740 median_49\JJ\1740 forebrain_50\NN\5462674 bundle_51\NN\7951464 ,_52\,\1740 or_53\CC\3541091 through_54\IN\1740 a_55\DT\13649268 projection_56\NN\5775081 restricted_57\JJ\1740 to_58\TO\1740 the_59\DT\1740 caudal_60\JJ\1740 brainstem_61\NN\5462674 ._62\.\1740
D008750_D006973 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 <e2>hypertensive</e2>_2\JJ\1740 ,_3\,\1740 stroke-prone_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 <e1>methyldopa</e1>_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 serotonin_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 hypotension_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 serotonin_49\NN\14807737 neurotoxin_50\NN\15034074 5,7-dihydroxytryptamine_51\NN\1740 (_52\-LRB-\1740 5,7-dht_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D008750_D020521 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 hypertensive_2\JJ\1740 ,_3\,\1740 <e2>stroke-prone</e2>_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 <e1>methyldopa</e1>_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 serotonin_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 hypotension_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 serotonin_49\NN\14807737 neurotoxin_50\NN\15034074 5,7-dihydroxytryptamine_51\NN\1740 (_52\-LRB-\1740 5,7-dht_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D012701_D006973 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 <e2>hypertensive</e2>_2\JJ\1740 ,_3\,\1740 stroke-prone_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 methyldopa_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 <e1>serotonin</e1>_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 hypotension_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 serotonin_49\NN\14807737 neurotoxin_50\NN\15034074 5,7-dihydroxytryptamine_51\NN\1740 (_52\-LRB-\1740 5,7-dht_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D012701_D006973 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 <e2>hypertensive</e2>_2\JJ\1740 ,_3\,\1740 stroke-prone_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 methyldopa_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 serotonin_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 hypotension_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 <e1>serotonin</e1>_49\NN\14807737 neurotoxin_50\NN\15034074 5,7-dihydroxytryptamine_51\NN\1740 (_52\-LRB-\1740 5,7-dht_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D012701_D020521 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 hypertensive_2\JJ\1740 ,_3\,\1740 <e2>stroke-prone</e2>_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 methyldopa_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 <e1>serotonin</e1>_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 hypotension_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 serotonin_49\NN\14807737 neurotoxin_50\NN\15034074 5,7-dihydroxytryptamine_51\NN\1740 (_52\-LRB-\1740 5,7-dht_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D012701_D020521 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 hypertensive_2\JJ\1740 ,_3\,\1740 <e2>stroke-prone</e2>_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 methyldopa_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 serotonin_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 hypotension_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 <e1>serotonin</e1>_49\NN\14807737 neurotoxin_50\NN\15034074 5,7-dihydroxytryptamine_51\NN\1740 (_52\-LRB-\1740 5,7-dht_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D015116_D006973 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 <e2>hypertensive</e2>_2\JJ\1740 ,_3\,\1740 stroke-prone_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 methyldopa_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 serotonin_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 hypotension_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 serotonin_49\NN\14807737 neurotoxin_50\NN\15034074 <e1>5,7-dihydroxytryptamine</e1>_51\NN\1740 (_52\-LRB-\1740 5,7-dht_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D015116_D006973 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 <e2>hypertensive</e2>_2\JJ\1740 ,_3\,\1740 stroke-prone_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 methyldopa_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 serotonin_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 hypotension_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 serotonin_49\NN\14807737 neurotoxin_50\NN\15034074 5,7-dihydroxytryptamine_51\NN\1740 (_52\-LRB-\1740 <e1>5,7-dht</e1>_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D015116_D020521 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 hypertensive_2\JJ\1740 ,_3\,\1740 <e2>stroke-prone</e2>_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 methyldopa_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 serotonin_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 hypotension_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 serotonin_49\NN\14807737 neurotoxin_50\NN\15034074 <e1>5,7-dihydroxytryptamine</e1>_51\NN\1740 (_52\-LRB-\1740 5,7-dht_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D015116_D020521 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 hypertensive_2\JJ\1740 ,_3\,\1740 <e2>stroke-prone</e2>_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 methyldopa_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 serotonin_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 hypotension_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 serotonin_49\NN\14807737 neurotoxin_50\NN\15034074 5,7-dihydroxytryptamine_51\NN\1740 (_52\-LRB-\1740 <e1>5,7-dht</e1>_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D015116_D007022 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 hypertensive_2\JJ\1740 ,_3\,\1740 stroke-prone_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 methyldopa_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 serotonin_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 <e2>hypotension</e2>_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 serotonin_49\NN\14807737 neurotoxin_50\NN\15034074 <e1>5,7-dihydroxytryptamine</e1>_51\NN\1740 (_52\-LRB-\1740 5,7-dht_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D015116_D007022 NONE in_0\IN\13603305 spontaneously_1\JJ\1740 hypertensive_2\JJ\1740 ,_3\,\1740 stroke-prone_4\JJ\1740 rats_5\NNS\2329401 ,_6\,\1740 microinjection_7\NN\1740 of_8\IN\1740 methyldopa_9\NN\2721160 into_10\IN\1740 the_11\DT\1740 area_12\NN\8630985 of_13\IN\1740 the_14\DT\1740 midline_15\JJ\1740 b3_16\NN\1740 serotonin_17\NN\14807737 cell_18\NN\3080309 group_19\NN\2137 in_20\IN\13603305 the_21\DT\1740 ventral_22\JJ\1740 medulla_23\NN\14864360 caused_24\VBD\1617192 a_25\DT\13649268 potent_26\JJ\1740 <e2>hypotension</e2>_27\NN\14057371 of_28\IN\1740 30_29\CD\13745420 -_30\SYM\1740 40_31\CD\13745420 mm_32\NN\13649268 hg_33\NNP\14625458 ,_34\,\1740 which_35\WDT\1740 was_36\VBD\836236 maximal_37\JJ\1740 2_38\CD\13741022 -_39\SYM\1740 3_40\CD\13741022 h_41\NN\14622893 after_42\IN\1740 administration_43\NN\1133281 and_44\CC\1740 was_45\VBD\836236 abolished_46\VBN\1740 by_47\IN\1740 the_48\DT\1740 serotonin_49\NN\14807737 neurotoxin_50\NN\15034074 5,7-dihydroxytryptamine_51\NN\1740 (_52\-LRB-\1740 <e1>5,7-dht</e1>_53\CD\1740 )_54\-RRB-\1740 injected_55\VBN\81072 intracerebroventricularly_56\RB\1740 ._57\.\1740
D015116_D007022 NONE however_0\RB\1740 ,_1\,\1740 intraspinal_2\JJ\1740 injection_3\NN\320852 of_4\IN\1740 <e1>5,7-dht</e1>_5\CD\1740 to_6\TO\1740 produce_7\VB\1617192 a_8\DT\13649268 more_9\RBR\1740 selective_10\JJ\1740 lesion_11\NN\14204950 of_12\IN\1740 only_13\RB\1740 descending_14\VBG\1835496 serotonin_15\NN\14807737 projections_16\NNS\5775081 in_17\IN\13603305 the_18\DT\1740 spinal_19\JJ\1740 cord_20\NN\3670849 did_21\VBD\1640855 not_22\RB\1740 affect_23\VB\126264 this_24\DT\1740 <e2>hypotension</e2>_25\NN\14057371 ._26\.\1740
7421734
D004967_D010049 NONE she_0\PRP\1740 had_1\VBD\2108377 <e2>ovarian_2\JJ\1740 failure</e2>_3\NN\66216 after_4\IN\1740 abdominal_5\JJ\1740 irradiation_6\NN\13920835 and_7\CC\1740 chemotherapy_8\NN\661091 for_9\IN\1740 hodgkin_10\NN\1740 disease_11\NN\14061805 ,_12\,\1740 and_13\CC\1740 received_14\VBD\2210855 exogenous_15\JJ\1740 <e1>estrogens</e1>_16\NNS\14745635 ,_17\,\1740 a_18\DT\13649268 treatment_19\NN\654885 implicated_20\VBN\2677097 in_21\IN\13603305 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 endometrial_25\JJ\1740 cancer_26\NN\14239425 in_27\IN\13603305 menopausal_28\JJ\1740 women_29\NNS\9605289 ._30\.\1740
D004967_D010049 NONE young_0\JJ\1740 women_1\NNS\9605289 on_2\IN\1740 replacement_3\NN\196485 <e1>estrogens</e1>_4\NNS\14745635 for_5\IN\1740 <e2>ovarian_6\JJ\1740 failure</e2>_7\NN\66216 after_8\IN\1740 cancer_9\NN\14239425 therapy_10\NN\657604 may_11\MD\15209706 also_12\RB\1740 have_13\VB\2108377 increased_14\VBN\169651 risk_15\NN\14541044 of_16\IN\1740 endometrial_17\JJ\1740 carcinoma_18\NN\14239918 and_19\CC\1740 should_20\MD\1740 be_21\VB\836236 examined_22\VBN\789138 periodically_23\RB\1740 ._24\.\1740
D004967_D006689 NONE she_0\PRP\1740 had_1\VBD\2108377 ovarian_2\JJ\1740 failure_3\NN\66216 after_4\IN\1740 abdominal_5\JJ\1740 irradiation_6\NN\13920835 and_7\CC\1740 chemotherapy_8\NN\661091 for_9\IN\1740 <e2>hodgkin_10\NN\1740 disease</e2>_11\NN\14061805 ,_12\,\1740 and_13\CC\1740 received_14\VBD\2210855 exogenous_15\JJ\1740 <e1>estrogens</e1>_16\NNS\14745635 ,_17\,\1740 a_18\DT\13649268 treatment_19\NN\654885 implicated_20\VBN\2677097 in_21\IN\13603305 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 endometrial_25\JJ\1740 cancer_26\NN\14239425 in_27\IN\13603305 menopausal_28\JJ\1740 women_29\NNS\9605289 ._30\.\1740
D004967_D016889 CID she_0\PRP\1740 had_1\VBD\2108377 ovarian_2\JJ\1740 failure_3\NN\66216 after_4\IN\1740 abdominal_5\JJ\1740 irradiation_6\NN\13920835 and_7\CC\1740 chemotherapy_8\NN\661091 for_9\IN\1740 hodgkin_10\NN\1740 disease_11\NN\14061805 ,_12\,\1740 and_13\CC\1740 received_14\VBD\2210855 exogenous_15\JJ\1740 <e1>estrogens</e1>_16\NNS\14745635 ,_17\,\1740 a_18\DT\13649268 treatment_19\NN\654885 implicated_20\VBN\2677097 in_21\IN\13603305 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 <e2>endometrial_25\JJ\1740 cancer</e2>_26\NN\14239425 in_27\IN\13603305 menopausal_28\JJ\1740 women_29\NNS\9605289 ._30\.\1740
D004967_D016889 CID young_0\JJ\1740 women_1\NNS\9605289 on_2\IN\1740 replacement_3\NN\196485 <e1>estrogens</e1>_4\NNS\14745635 for_5\IN\1740 ovarian_6\JJ\1740 failure_7\NN\66216 after_8\IN\1740 cancer_9\NN\14239425 therapy_10\NN\657604 may_11\MD\15209706 also_12\RB\1740 have_13\VB\2108377 increased_14\VBN\169651 risk_15\NN\14541044 of_16\IN\1740 <e2>endometrial_17\JJ\1740 carcinoma</e2>_18\NN\14239918 and_19\CC\1740 should_20\MD\1740 be_21\VB\836236 examined_22\VBN\789138 periodically_23\RB\1740 ._24\.\1740
D004967_D009369 NONE young_0\JJ\1740 women_1\NNS\9605289 on_2\IN\1740 replacement_3\NN\196485 <e1>estrogens</e1>_4\NNS\14745635 for_5\IN\1740 ovarian_6\JJ\1740 failure_7\NN\66216 after_8\IN\1740 <e2>cancer</e2>_9\NN\14239425 therapy_10\NN\657604 may_11\MD\15209706 also_12\RB\1740 have_13\VB\2108377 increased_14\VBN\169651 risk_15\NN\14541044 of_16\IN\1740 endometrial_17\JJ\1740 carcinoma_18\NN\14239918 and_19\CC\1740 should_20\MD\1740 be_21\VB\836236 examined_22\VBN\789138 periodically_23\RB\1740 ._24\.\1740
7843916
D003907_D009798 CID <e1>dexamethasone-induced</e1>_0\JJ\1740 <e2>ocular_1\JJ\1740 hypertension</e2>_2\NN\14057371 in_3\IN\13603305 perfusion-cultured_4\JJ\1740 human_5\JJ\1740 eyes_6\NNS\5945642 ._7\.\1740
D003907_D009798 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 the_3\DT\1740 <e1>dexamethasone-treated</e1>_4\JJ\1740 <e2>hypertensive_5\JJ\1740 eyes</e2>_6\NNS\5945642 had_7\VBD\2108377 thickened_8\VBN\126264 trabecular_9\JJ\1740 beams_10\NNS\6791372 ,_11\,\1740 decreased_12\VBD\169651 intertrabecular_13\JJ\1740 spaces_14\NNS\24264 ,_15\,\1740 thickened_16\VBN\126264 juxtacanalicular_17\JJ\1740 tissue_18\NN\5220461 ,_19\,\1740 activated_20\VBN\1641914 trabecular_21\JJ\1740 meshwork_22\NN\3309808 cells_23\NNS\3080309 ,_24\,\1740 and_25\CC\1740 increased_26\VBD\169651 amounts_27\NNS\13329641 of_28\IN\1740 amorphogranular_29\JJ\1740 extracellular_30\JJ\1740 material_31\NN\19613 ,_32\,\1740 especially_33\RB\1740 in_34\IN\13603305 the_35\DT\1740 juxtacanalicular_36\JJ\1740 tissue_37\NN\5220461 and_38\CC\1740 beneath_39\IN\1740 the_40\DT\1740 endothelial_41\JJ\1740 lining_42\NN\4014297 of_43\IN\1740 the_44\DT\1740 canal_45\NN\9241247 of_46\IN\1740 schlemm_47\NNP\1740 ._48\.\1740
D003907_D009798 CID conclusion_0\NN\5837957 :_1\:\1740 <e1>dexamethasone</e1>_2\NN\2721538 treatment_3\NN\654885 of_4\IN\1740 isolated_5\VBN\2512305 ,_6\,\1740 perfusion-cultured_7\JJ\1740 human_8\JJ\1740 eyes_9\NNS\5945642 led_10\VBD\1752884 to_11\TO\1740 the_12\DT\1740 generation_13\NN\7942152 of_14\IN\1740 <e2>ocular_15\JJ\1740 hypertension</e2>_16\NN\14057371 in_17\IN\13603305 approximately_18\RB\1740 30_19\CD\13745420 %_20\NN\1740 of_21\IN\1740 the_22\DT\1740 dexamethasone-treated_23\JJ\1740 eyes_24\NNS\5945642 ._25\.\1740
D003907_D009798 CID conclusion_0\NN\5837957 :_1\:\1740 dexamethasone_2\NN\2721538 treatment_3\NN\654885 of_4\IN\1740 isolated_5\VBN\2512305 ,_6\,\1740 perfusion-cultured_7\JJ\1740 human_8\JJ\1740 eyes_9\NNS\5945642 led_10\VBD\1752884 to_11\TO\1740 the_12\DT\1740 generation_13\NN\7942152 of_14\IN\1740 <e2>ocular_15\JJ\1740 hypertension</e2>_16\NN\14057371 in_17\IN\13603305 approximately_18\RB\1740 30_19\CD\13745420 %_20\NN\1740 of_21\IN\1740 the_22\DT\1740 <e1>dexamethasone-treated</e1>_23\JJ\1740 eyes_24\NNS\5945642 ._25\.\1740
D013256_D005901 NONE <e1>steroid</e1>_0\NN\14727670 treatment_1\NN\654885 resulted_2\VBD\2633881 in_3\IN\13603305 morphologic_4\JJ\1740 changes_5\NNS\7283608 in_6\IN\13603305 the_7\DT\1740 trabecular_8\JJ\1740 meshwork_9\NN\3309808 similar_10\JJ\1740 to_11\TO\1740 those_12\DT\1740 reported_13\VBN\831651 for_14\IN\1740 <e2>corticosteroid_15\NN\14745635 glaucoma</e2>_16\NN\14252864 and_17\CC\1740 open_18\JJ\1740 angle_19\NN\13910384 glaucoma_20\NN\14252864 ._21\.\1740
D013256_D005902 NONE <e1>steroid</e1>_0\NN\14727670 treatment_1\NN\654885 resulted_2\VBD\2633881 in_3\IN\13603305 morphologic_4\JJ\1740 changes_5\NNS\7283608 in_6\IN\13603305 the_7\DT\1740 trabecular_8\JJ\1740 meshwork_9\NN\3309808 similar_10\JJ\1740 to_11\TO\1740 those_12\DT\1740 reported_13\VBN\831651 for_14\IN\1740 corticosteroid_15\NN\14745635 glaucoma_16\NN\14252864 and_17\CC\1740 <e2>open_18\JJ\1740 angle_19\NN\13910384 glaucoma</e2>_20\NN\14252864 ._21\.\1740
6415512
D002220_D004831 CID <e2>myoclonic_0\NNP\1740 ,_1\,\1740 atonic_2\JJ\1740 ,_3\,\1740 and_4\CC\1740 absence_5\NN\14449405 seizures</e2>_6\NNS\14081375 following_7\VBG\1835496 institution_8\NN\8008335 of_9\IN\1740 <e1>carbamazepine</e1>_10\NN\1740 therapy_11\NN\657604 in_12\IN\13603305 children_13\NNS\9622049 ._14\.\1740
D002220_D004831 CID five_0\CD\13741022 children_1\NNS\9622049 ,_2\,\1740 aged_3\JJ\1740 3_4\CD\13741022 to_5\TO\1740 11_6\CD\13745420 years_7\NNS\15144371 ,_8\,\1740 treated_9\VBN\2376958 with_10\IN\1740 <e1>carbamazepine</e1>_11\NN\1740 for_12\IN\1740 epilepsy_13\NN\14085708 ,_14\,\1740 had_15\VBD\2108377 an_16\DT\6697703 acute_17\JJ\1740 aberrant_18\JJ\1740 reaction_19\NN\13446390 characterized_20\VBN\609683 by_21\IN\1740 the_22\DT\1740 onset_23\NN\7325190 of_24\IN\1740 <e2>myoclonic_25\NN\1740 ,_26\,\1740 atypical_27\JJ\1740 absence_28\NN\14449405 and/or_29\CC\1740 atonic_30\JJ\1740 (_31\-LRB-\1740 minor_32\JJ\1740 motor_33\NN\3699975 )_34\-RRB-\1740 seizures</e2>_35\NNS\14081375 within_36\IN\1740 a_37\DT\13649268 few_38\JJ\1740 days_39\NNS\15140892 ._40\.\1740
D002220_D004832 CID <e2>myoclonic_0\NNP\1740 ,_1\,\1740 atonic_2\JJ\1740 ,_3\,\1740 and_4\CC\1740 absence_5\NN\14449405 seizures</e2>_6\NNS\14081375 following_7\VBG\1835496 institution_8\NN\8008335 of_9\IN\1740 <e1>carbamazepine</e1>_10\NN\1740 therapy_11\NN\657604 in_12\IN\13603305 children_13\NNS\9622049 ._14\.\1740
D002220_D004832 CID five_0\CD\13741022 children_1\NNS\9622049 ,_2\,\1740 aged_3\JJ\1740 3_4\CD\13741022 to_5\TO\1740 11_6\CD\13745420 years_7\NNS\15144371 ,_8\,\1740 treated_9\VBN\2376958 with_10\IN\1740 <e1>carbamazepine</e1>_11\NN\1740 for_12\IN\1740 epilepsy_13\NN\14085708 ,_14\,\1740 had_15\VBD\2108377 an_16\DT\6697703 acute_17\JJ\1740 aberrant_18\JJ\1740 reaction_19\NN\13446390 characterized_20\VBN\609683 by_21\IN\1740 the_22\DT\1740 onset_23\NN\7325190 of_24\IN\1740 <e2>myoclonic_25\NN\1740 ,_26\,\1740 atypical_27\JJ\1740 absence_28\NN\14449405 and/or_29\CC\1740 atonic_30\JJ\1740 (_31\-LRB-\1740 minor_32\JJ\1740 motor_33\NN\3699975 )_34\-RRB-\1740 seizures</e2>_35\NNS\14081375 within_36\IN\1740 a_37\DT\13649268 few_38\JJ\1740 days_39\NNS\15140892 ._40\.\1740
D002220_D004827 NONE five_0\CD\13741022 children_1\NNS\9622049 ,_2\,\1740 aged_3\JJ\1740 3_4\CD\13741022 to_5\TO\1740 11_6\CD\13745420 years_7\NNS\15144371 ,_8\,\1740 treated_9\VBN\2376958 with_10\IN\1740 <e1>carbamazepine</e1>_11\NN\1740 for_12\IN\1740 <e2>epilepsy</e2>_13\NN\14085708 ,_14\,\1740 had_15\VBD\2108377 an_16\DT\6697703 acute_17\JJ\1740 aberrant_18\JJ\1740 reaction_19\NN\13446390 characterized_20\VBN\609683 by_21\IN\1740 the_22\DT\1740 onset_23\NN\7325190 of_24\IN\1740 myoclonic_25\NN\1740 ,_26\,\1740 atypical_27\JJ\1740 absence_28\NN\14449405 and/or_29\CC\1740 atonic_30\JJ\1740 (_31\-LRB-\1740 minor_32\JJ\1740 motor_33\NN\3699975 )_34\-RRB-\1740 seizures_35\NNS\14081375 within_36\IN\1740 a_37\DT\13649268 few_38\JJ\1740 days_39\NNS\15140892 ._40\.\1740
D002220_D012640 NONE when_0\WRB\1740 the_1\DT\1740 <e1>carbamazepine</e1>_2\NN\1740 was_3\VBD\836236 discontinued_4\VBN\2609764 ,_5\,\1740 two_6\CD\13741022 of_7\IN\1740 the_8\DT\1740 children_9\NNS\9622049 returned_10\VBD\1835496 to_11\IN\1740 their_12\PRP$\1740 former_13\JJ\1740 state_14\NN\8491826 very_15\RB\1740 quickly_16\RB\1740 ,_17\,\1740 two_18\CD\13741022 had_19\VBD\2108377 the_20\DT\1740 minor_21\JJ\1740 motor_22\NN\3699975 <e2>seizures</e2>_23\NNS\14081375 resolve_24\VBP\352826 in_25\IN\13603305 3_26\CD\13741022 and_27\CC\1740 6_28\CD\13741022 months_29\NNS\15113229 ,_30\,\1740 and_31\CC\1740 one_32\NN\13741022 had_33\VBD\2108377 the_34\DT\1740 seizures_35\NNS\14081375 persist_36\VB\118523 ._37\.\1740
D002220_D012640 NONE when_0\WRB\1740 the_1\DT\1740 <e1>carbamazepine</e1>_2\NN\1740 was_3\VBD\836236 discontinued_4\VBN\2609764 ,_5\,\1740 two_6\CD\13741022 of_7\IN\1740 the_8\DT\1740 children_9\NNS\9622049 returned_10\VBD\1835496 to_11\IN\1740 their_12\PRP$\1740 former_13\JJ\1740 state_14\NN\8491826 very_15\RB\1740 quickly_16\RB\1740 ,_17\,\1740 two_18\CD\13741022 had_19\VBD\2108377 the_20\DT\1740 minor_21\JJ\1740 motor_22\NN\3699975 seizures_23\NNS\14081375 resolve_24\VBP\352826 in_25\IN\13603305 3_26\CD\13741022 and_27\CC\1740 6_28\CD\13741022 months_29\NNS\15113229 ,_30\,\1740 and_31\CC\1740 one_32\NN\13741022 had_33\VBD\2108377 the_34\DT\1740 <e2>seizures</e2>_35\NNS\14081375 persist_36\VB\118523 ._37\.\1740
1969772
D018818_D007022 CID preservation_0\NN\817680 of_1\IN\1740 renal_2\JJ\1740 blood_3\NN\5397468 flow_4\NN\7311115 during_5\IN\1740 <e2>hypotension</e2>_6\NN\14057371 induced_7\VBN\1627355 with_8\IN\1740 <e1>fenoldopam</e1>_9\NN\1740 in_10\IN\13603305 dogs_11\NNS\2083346 ._12\.\1740
D018818_D007022 CID the_0\DT\1740 hypothesis_1\NN\7162194 that_2\IN\1740 <e1>fenoldopam</e1>_3\NN\1740 could_4\MD\1740 be_5\VB\836236 used_6\VBN\1156834 to_7\TO\1740 induce_8\VB\1627355 <e2>hypotension</e2>_9\NN\14057371 and_10\CC\1740 preserve_11\VB\2681795 blood_12\NN\5397468 flow_13\NN\7311115 to_14\TO\1740 the_15\DT\1740 kidney_16\NN\5333259 was_17\VBD\836236 tested_18\VBN\670261 ._19\.\1740
D018818_D007022 CID renal_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 (_3\-LRB-\1740 rbf_4\NN\1740 )_5\-RRB-\1740 increased_6\VBD\169651 during_7\IN\1740 <e1>fenoldopam-induced</e1>_8\JJ\1740 <e2>hypotension</e2>_9\NN\14057371 11_10\CD\13745420 +/-_11\CC\1740 7_12\CD\13741022 per_13\NN\1740 cent_14\NN\13662703 and_15\CC\1740 decreased_16\VBD\169651 21_17\CD\13745420 +/-_18\CC\1740 8_19\CD\13741022 per_20\IN\1740 cent_21\NN\13662703 during_22\IN\1740 sodium_23\NN\14625458 nitroprusside-induced_24\JJ\1740 hypotension_25\NN\14057371 (_26\-LRB-\1740 p_27\NN\14622893 less_28\JJR\1740 than_29\IN\1740 0.01_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D018818_D007022 CID renal_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 (_3\-LRB-\1740 rbf_4\NN\1740 )_5\-RRB-\1740 increased_6\VBD\169651 during_7\IN\1740 <e1>fenoldopam-induced</e1>_8\JJ\1740 hypotension_9\NN\14057371 11_10\CD\13745420 +/-_11\CC\1740 7_12\CD\13741022 per_13\NN\1740 cent_14\NN\13662703 and_15\CC\1740 decreased_16\VBD\169651 21_17\CD\13745420 +/-_18\CC\1740 8_19\CD\13741022 per_20\IN\1740 cent_21\NN\13662703 during_22\IN\1740 sodium_23\NN\14625458 nitroprusside-induced_24\JJ\1740 <e2>hypotension</e2>_25\NN\14057371 (_26\-LRB-\1740 p_27\NN\14622893 less_28\JJR\1740 than_29\IN\1740 0.01_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D012964_D007022 NONE renal_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 (_3\-LRB-\1740 rbf_4\NN\1740 )_5\-RRB-\1740 increased_6\VBD\169651 during_7\IN\1740 fenoldopam-induced_8\JJ\1740 <e2>hypotension</e2>_9\NN\14057371 11_10\CD\13745420 +/-_11\CC\1740 7_12\CD\13741022 per_13\NN\1740 cent_14\NN\13662703 and_15\CC\1740 decreased_16\VBD\169651 21_17\CD\13745420 +/-_18\CC\1740 8_19\CD\13741022 per_20\IN\1740 cent_21\NN\13662703 during_22\IN\1740 <e1>sodium</e1>_23\NN\14625458 nitroprusside-induced_24\JJ\1740 hypotension_25\NN\14057371 (_26\-LRB-\1740 p_27\NN\14622893 less_28\JJR\1740 than_29\IN\1740 0.01_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D012964_D007022 NONE renal_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 (_3\-LRB-\1740 rbf_4\NN\1740 )_5\-RRB-\1740 increased_6\VBD\169651 during_7\IN\1740 fenoldopam-induced_8\JJ\1740 hypotension_9\NN\14057371 11_10\CD\13745420 +/-_11\CC\1740 7_12\CD\13741022 per_13\NN\1740 cent_14\NN\13662703 and_15\CC\1740 decreased_16\VBD\169651 21_17\CD\13745420 +/-_18\CC\1740 8_19\CD\13741022 per_20\IN\1740 cent_21\NN\13662703 during_22\IN\1740 <e1>sodium</e1>_23\NN\14625458 nitroprusside-induced_24\JJ\1740 <e2>hypotension</e2>_25\NN\14057371 (_26\-LRB-\1740 p_27\NN\14622893 less_28\JJR\1740 than_29\IN\1740 0.01_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D009599_D007022 CID renal_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 (_3\-LRB-\1740 rbf_4\NN\1740 )_5\-RRB-\1740 increased_6\VBD\169651 during_7\IN\1740 fenoldopam-induced_8\JJ\1740 <e2>hypotension</e2>_9\NN\14057371 11_10\CD\13745420 +/-_11\CC\1740 7_12\CD\13741022 per_13\NN\1740 cent_14\NN\13662703 and_15\CC\1740 decreased_16\VBD\169651 21_17\CD\13745420 +/-_18\CC\1740 8_19\CD\13741022 per_20\IN\1740 cent_21\NN\13662703 during_22\IN\1740 sodium_23\NN\14625458 <e1>nitroprusside-induced</e1>_24\JJ\1740 hypotension_25\NN\14057371 (_26\-LRB-\1740 p_27\NN\14622893 less_28\JJR\1740 than_29\IN\1740 0.01_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D009599_D007022 CID renal_0\JJ\1740 blood_1\NN\5397468 flow_2\NN\7311115 (_3\-LRB-\1740 rbf_4\NN\1740 )_5\-RRB-\1740 increased_6\VBD\169651 during_7\IN\1740 fenoldopam-induced_8\JJ\1740 hypotension_9\NN\14057371 11_10\CD\13745420 +/-_11\CC\1740 7_12\CD\13741022 per_13\NN\1740 cent_14\NN\13662703 and_15\CC\1740 decreased_16\VBD\169651 21_17\CD\13745420 +/-_18\CC\1740 8_19\CD\13741022 per_20\IN\1740 cent_21\NN\13662703 during_22\IN\1740 sodium_23\NN\14625458 <e1>nitroprusside-induced</e1>_24\JJ\1740 <e2>hypotension</e2>_25\NN\14057371 (_26\-LRB-\1740 p_27\NN\14622893 less_28\JJR\1740 than_29\IN\1740 0.01_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D009599_D007022 CID sodium_0\NN\14625458 <e1>nitroprusside</e1>_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 non-selective_4\JJ\1740 arteriolar_5\JJ\1740 and_6\CC\1740 venous_7\JJ\1740 vasodilator_8\NN\3198383 that_9\WDT\1740 can_10\MD\3094503 produce_11\VB\1617192 redistribution_12\NN\1083077 of_13\IN\1740 blood_14\NN\5397468 flow_15\NN\7311115 away_16\RB\1740 from_17\IN\1740 the_18\DT\1740 kidney_19\NN\5333259 during_20\IN\1740 induced_21\VBN\1627355 <e2>hypotension</e2>_22\NN\14057371 ._23\.\1740
D004298_D007022 NONE fenoldopam_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 selective_3\JJ\1740 <e1>dopamine-1</e1>_4\NN\1740 (_5\-LRB-\1740 da1_6\NN\1740 )_7\-RRB-\1740 receptor_8\NN\5225602 agonist_9\NN\9613191 that_10\WDT\1740 causes_11\VBZ\1617192 vasodilatation_12\NN\1740 to_13\TO\1740 the_14\DT\1740 kidney_15\NN\5333259 and_16\CC\1740 other_17\JJ\1740 organs_18\NNS\7649854 with_19\IN\1740 da1_20\NN\1740 receptors_21\NNS\5225602 and_22\CC\1740 preserves_23\VBZ\2681795 blood_24\NN\5397468 flow_25\NN\7311115 to_26\TO\1740 the_27\DT\1740 kidney_28\NN\5333259 during_29\IN\1740 induced_30\VBN\1627355 <e2>hypotension</e2>_31\NN\14057371 ._32\.\1740
3686155
D001971_D011605 CID postpartum_0\JJ\1740 <e2>psychosis</e2>_1\NN\14380140 induced_2\VBN\1627355 by_3\IN\1740 <e1>bromocriptine</e1>_4\NN\1740 ._5\.\1740
D001971_D011605 CID two_0\CD\13741022 multigravida_1\NN\1740 patients_2\NNS\9898892 with_3\IN\1740 no_4\DT\7204911 prior_5\JJ\1740 psychiatric_6\JJ\1740 history_7\NN\15120823 were_8\VBD\836236 seen_9\VBN\2106506 with_10\IN\1740 postpartum_11\NN\1740 <e2>psychosis</e2>_12\NN\14380140 ,_13\,\1740 having_14\VBG\2108377 received_15\VBN\2210855 <e1>bromocriptine</e1>_16\NN\1740 for_17\IN\1740 inhibition_18\NN\1068773 of_19\IN\1740 lactation_20\NN\15113229 ._21\.\1740
D001971_D011605 CID <e1>bromocriptine</e1>_0\NN\1740 given_1\VBN\2327200 in_2\IN\13603305 high_3\JJ\1740 doses_4\NNS\3740161 has_5\VBZ\2108377 been_6\VBN\836236 associated_7\VBN\628491 with_8\IN\1740 <e2>psychosis</e2>_9\NN\14380140 in_10\IN\13603305 patients_11\NNS\9898892 receiving_12\VBG\2210855 the_13\DT\1740 drug_14\NN\14778436 for_15\IN\1740 parkinson_16\NNP\1740 's_17\POS\1740 disease_18\NN\14061805 ._19\.\1740
D001971_D011605 CID these_0\DT\1740 cases_1\NNS\7283608 demonstrate_2\VBP\2137132 that_3\IN\1740 <e1>bromocriptine</e1>_4\NN\1740 may_5\MD\15209706 cause_6\VB\1617192 <e2>psychosis</e2>_7\NN\14380140 even_8\RB\1740 when_9\WRB\1740 given_10\VBN\2327200 in_11\IN\13603305 low_12\JJ\1740 doses_13\NNS\3740161 ._14\.\1740
D001971_D001523 NONE two_0\CD\13741022 multigravida_1\NN\1740 patients_2\NNS\9898892 with_3\IN\1740 no_4\DT\7204911 prior_5\JJ\1740 <e2>psychiatric</e2>_6\JJ\1740 history_7\NN\15120823 were_8\VBD\836236 seen_9\VBN\2106506 with_10\IN\1740 postpartum_11\NN\1740 psychosis_12\NN\14380140 ,_13\,\1740 having_14\VBG\2108377 received_15\VBN\2210855 <e1>bromocriptine</e1>_16\NN\1740 for_17\IN\1740 inhibition_18\NN\1068773 of_19\IN\1740 lactation_20\NN\15113229 ._21\.\1740
D001971_D007775 NONE two_0\CD\13741022 multigravida_1\NN\1740 patients_2\NNS\9898892 with_3\IN\1740 no_4\DT\7204911 prior_5\JJ\1740 psychiatric_6\JJ\1740 history_7\NN\15120823 were_8\VBD\836236 seen_9\VBN\2106506 with_10\IN\1740 postpartum_11\NN\1740 psychosis_12\NN\14380140 ,_13\,\1740 having_14\VBG\2108377 received_15\VBN\2210855 <e1>bromocriptine</e1>_16\NN\1740 for_17\IN\1740 <e2>inhibition_18\NN\1068773 of_19\IN\1740 lactation</e2>_20\NN\15113229 ._21\.\1740
D001971_D010300 NONE <e1>bromocriptine</e1>_0\NN\1740 given_1\VBN\2327200 in_2\IN\13603305 high_3\JJ\1740 doses_4\NNS\3740161 has_5\VBZ\2108377 been_6\VBN\836236 associated_7\VBN\628491 with_8\IN\1740 psychosis_9\NN\14380140 in_10\IN\13603305 patients_11\NNS\9898892 receiving_12\VBG\2210855 the_13\DT\1740 drug_14\NN\14778436 for_15\IN\1740 <e2>parkinson_16\NNP\1740 's_17\POS\1740 disease</e2>_18\NN\14061805 ._19\.\1740
3120485
982002
D012293_D058186 CID <e2>acute_0\JJ\1740 renal_1\JJ\1740 failure</e2>_2\NN\66216 subsequent_3\JJ\1740 to_4\IN\1740 the_5\DT\1740 administration_6\NN\1133281 of_7\IN\1740 <e1>rifampicin</e1>_8\NN\1740 ._9\.\1740
D012293_D051437 NONE the_0\DT\1740 patients_1\NNS\9898892 had_2\VBD\2108377 developed_3\VBN\1753788 transient_4\JJ\1740 <e2>renal_5\JJ\1740 failure</e2>_6\NN\66216 after_7\IN\1740 the_8\DT\1740 intermittent_9\JJ\1740 administration_10\NN\1133281 of_11\IN\1740 <e1>rifampicin</e1>_12\NN\1740 ._13\.\1740
3950060
D000583_D007674 CID factors_0\NNS\7326557 associated_1\VBN\628491 with_2\IN\1740 <e2>nephrotoxicity</e2>_3\NN\1740 and_4\CC\1740 clinical_5\JJ\1740 outcome_6\NN\7291312 in_7\IN\13603305 patients_8\NNS\9898892 receiving_9\VBG\2210855 <e1>amikacin</e1>_10\NN\1740 ._11\.\1740
D000583_D007674 CID data_0\NNS\7951464 from_1\IN\1740 60_2\CD\13745420 patients_3\NNS\9898892 treated_4\VBN\2376958 with_5\IN\1740 <e1>amikacin</e1>_6\NN\1740 were_7\VBD\836236 analyzed_8\VBN\78760 for_9\IN\1740 factors_10\NNS\7326557 associated_11\VBN\628491 with_12\IN\1740 <e2>nephrotoxicity</e2>_13\NN\1740 ._14\.\1740
16574713
D018817_D020258 NONE although_0\IN\1740 <e1>3,4-methylenedioxymethamphetamine</e1>_1\NN\1740 (_2\-LRB-\1740 mdma_3\NN\3054098 or_4\CC\3541091 ecstasy_5\NN\13985818 )_6\-RRB-\1740 has_7\VBZ\2108377 been_8\VBN\836236 shown_9\VBN\2137132 to_10\TO\1740 damage_11\NN\7296428 brain_12\NN\5462674 serotonin_13\NN\14807737 (_14\-LRB-\1740 5-ht_15\NN\1740 )_16\-RRB-\1740 neurons_17\NNS\5430628 in_18\IN\13603305 animals_19\NNS\4475 and_20\CC\1740 possibly_21\RB\1740 humans_22\NNS\31264 ,_23\,\1740 little_24\JJ\1740 is_25\VBZ\836236 known_26\VBN\2110220 about_27\IN\1740 the_28\DT\1740 long-term_29\JJ\1740 consequences_30\NNS\34213 of_31\IN\1740 mdma-induced_32\JJ\1740 5-ht_33\NN\1740 <e2>neurotoxic_34\JJ\1740 lesions</e2>_35\NNS\14204950 on_36\IN\1740 functions_37\NNS\13783581 in_38\IN\13603305 which_39\WDT\1740 5-ht_40\NN\1740 is_41\VBZ\836236 involved_42\VBN\2676054 ,_43\,\1740 such_44\JJ\1740 as_45\IN\14622893 cognitive_46\JJ\1740 function_47\NN\13783581 ._48\.\1740
D018817_D020258 NONE although_0\IN\1740 3,4-methylenedioxymethamphetamine_1\NN\1740 (_2\-LRB-\1740 <e1>mdma</e1>_3\NN\3054098 or_4\CC\3541091 ecstasy_5\NN\13985818 )_6\-RRB-\1740 has_7\VBZ\2108377 been_8\VBN\836236 shown_9\VBN\2137132 to_10\TO\1740 damage_11\NN\7296428 brain_12\NN\5462674 serotonin_13\NN\14807737 (_14\-LRB-\1740 5-ht_15\NN\1740 )_16\-RRB-\1740 neurons_17\NNS\5430628 in_18\IN\13603305 animals_19\NNS\4475 and_20\CC\1740 possibly_21\RB\1740 humans_22\NNS\31264 ,_23\,\1740 little_24\JJ\1740 is_25\VBZ\836236 known_26\VBN\2110220 about_27\IN\1740 the_28\DT\1740 long-term_29\JJ\1740 consequences_30\NNS\34213 of_31\IN\1740 mdma-induced_32\JJ\1740 5-ht_33\NN\1740 <e2>neurotoxic_34\JJ\1740 lesions</e2>_35\NNS\14204950 on_36\IN\1740 functions_37\NNS\13783581 in_38\IN\13603305 which_39\WDT\1740 5-ht_40\NN\1740 is_41\VBZ\836236 involved_42\VBN\2676054 ,_43\,\1740 such_44\JJ\1740 as_45\IN\14622893 cognitive_46\JJ\1740 function_47\NN\13783581 ._48\.\1740
D018817_D020258 NONE although_0\IN\1740 3,4-methylenedioxymethamphetamine_1\NN\1740 (_2\-LRB-\1740 mdma_3\NN\3054098 or_4\CC\3541091 <e1>ecstasy</e1>_5\NN\13985818 )_6\-RRB-\1740 has_7\VBZ\2108377 been_8\VBN\836236 shown_9\VBN\2137132 to_10\TO\1740 damage_11\NN\7296428 brain_12\NN\5462674 serotonin_13\NN\14807737 (_14\-LRB-\1740 5-ht_15\NN\1740 )_16\-RRB-\1740 neurons_17\NNS\5430628 in_18\IN\13603305 animals_19\NNS\4475 and_20\CC\1740 possibly_21\RB\1740 humans_22\NNS\31264 ,_23\,\1740 little_24\JJ\1740 is_25\VBZ\836236 known_26\VBN\2110220 about_27\IN\1740 the_28\DT\1740 long-term_29\JJ\1740 consequences_30\NNS\34213 of_31\IN\1740 mdma-induced_32\JJ\1740 5-ht_33\NN\1740 <e2>neurotoxic_34\JJ\1740 lesions</e2>_35\NNS\14204950 on_36\IN\1740 functions_37\NNS\13783581 in_38\IN\13603305 which_39\WDT\1740 5-ht_40\NN\1740 is_41\VBZ\836236 involved_42\VBN\2676054 ,_43\,\1740 such_44\JJ\1740 as_45\IN\14622893 cognitive_46\JJ\1740 function_47\NN\13783581 ._48\.\1740
D018817_D020258 NONE although_0\IN\1740 3,4-methylenedioxymethamphetamine_1\NN\1740 (_2\-LRB-\1740 mdma_3\NN\3054098 or_4\CC\3541091 ecstasy_5\NN\13985818 )_6\-RRB-\1740 has_7\VBZ\2108377 been_8\VBN\836236 shown_9\VBN\2137132 to_10\TO\1740 damage_11\NN\7296428 brain_12\NN\5462674 serotonin_13\NN\14807737 (_14\-LRB-\1740 5-ht_15\NN\1740 )_16\-RRB-\1740 neurons_17\NNS\5430628 in_18\IN\13603305 animals_19\NNS\4475 and_20\CC\1740 possibly_21\RB\1740 humans_22\NNS\31264 ,_23\,\1740 little_24\JJ\1740 is_25\VBZ\836236 known_26\VBN\2110220 about_27\IN\1740 the_28\DT\1740 long-term_29\JJ\1740 consequences_30\NNS\34213 of_31\IN\1740 <e1>mdma-induced</e1>_32\JJ\1740 5-ht_33\NN\1740 <e2>neurotoxic_34\JJ\1740 lesions</e2>_35\NNS\14204950 on_36\IN\1740 functions_37\NNS\13783581 in_38\IN\13603305 which_39\WDT\1740 5-ht_40\NN\1740 is_41\VBZ\836236 involved_42\VBN\2676054 ,_43\,\1740 such_44\JJ\1740 as_45\IN\14622893 cognitive_46\JJ\1740 function_47\NN\13783581 ._48\.\1740
D012701_D020258 NONE although_0\IN\1740 3,4-methylenedioxymethamphetamine_1\NN\1740 (_2\-LRB-\1740 mdma_3\NN\3054098 or_4\CC\3541091 ecstasy_5\NN\13985818 )_6\-RRB-\1740 has_7\VBZ\2108377 been_8\VBN\836236 shown_9\VBN\2137132 to_10\TO\1740 damage_11\NN\7296428 brain_12\NN\5462674 <e1>serotonin</e1>_13\NN\14807737 (_14\-LRB-\1740 5-ht_15\NN\1740 )_16\-RRB-\1740 neurons_17\NNS\5430628 in_18\IN\13603305 animals_19\NNS\4475 and_20\CC\1740 possibly_21\RB\1740 humans_22\NNS\31264 ,_23\,\1740 little_24\JJ\1740 is_25\VBZ\836236 known_26\VBN\2110220 about_27\IN\1740 the_28\DT\1740 long-term_29\JJ\1740 consequences_30\NNS\34213 of_31\IN\1740 mdma-induced_32\JJ\1740 5-ht_33\NN\1740 <e2>neurotoxic_34\JJ\1740 lesions</e2>_35\NNS\14204950 on_36\IN\1740 functions_37\NNS\13783581 in_38\IN\13603305 which_39\WDT\1740 5-ht_40\NN\1740 is_41\VBZ\836236 involved_42\VBN\2676054 ,_43\,\1740 such_44\JJ\1740 as_45\IN\14622893 cognitive_46\JJ\1740 function_47\NN\13783581 ._48\.\1740
D012701_D020258 NONE although_0\IN\1740 3,4-methylenedioxymethamphetamine_1\NN\1740 (_2\-LRB-\1740 mdma_3\NN\3054098 or_4\CC\3541091 ecstasy_5\NN\13985818 )_6\-RRB-\1740 has_7\VBZ\2108377 been_8\VBN\836236 shown_9\VBN\2137132 to_10\TO\1740 damage_11\NN\7296428 brain_12\NN\5462674 serotonin_13\NN\14807737 (_14\-LRB-\1740 <e1>5-ht</e1>_15\NN\1740 )_16\-RRB-\1740 neurons_17\NNS\5430628 in_18\IN\13603305 animals_19\NNS\4475 and_20\CC\1740 possibly_21\RB\1740 humans_22\NNS\31264 ,_23\,\1740 little_24\JJ\1740 is_25\VBZ\836236 known_26\VBN\2110220 about_27\IN\1740 the_28\DT\1740 long-term_29\JJ\1740 consequences_30\NNS\34213 of_31\IN\1740 mdma-induced_32\JJ\1740 5-ht_33\NN\1740 <e2>neurotoxic_34\JJ\1740 lesions</e2>_35\NNS\14204950 on_36\IN\1740 functions_37\NNS\13783581 in_38\IN\13603305 which_39\WDT\1740 5-ht_40\NN\1740 is_41\VBZ\836236 involved_42\VBN\2676054 ,_43\,\1740 such_44\JJ\1740 as_45\IN\14622893 cognitive_46\JJ\1740 function_47\NN\13783581 ._48\.\1740
D012701_D020258 NONE although_0\IN\1740 3,4-methylenedioxymethamphetamine_1\NN\1740 (_2\-LRB-\1740 mdma_3\NN\3054098 or_4\CC\3541091 ecstasy_5\NN\13985818 )_6\-RRB-\1740 has_7\VBZ\2108377 been_8\VBN\836236 shown_9\VBN\2137132 to_10\TO\1740 damage_11\NN\7296428 brain_12\NN\5462674 serotonin_13\NN\14807737 (_14\-LRB-\1740 5-ht_15\NN\1740 )_16\-RRB-\1740 neurons_17\NNS\5430628 in_18\IN\13603305 animals_19\NNS\4475 and_20\CC\1740 possibly_21\RB\1740 humans_22\NNS\31264 ,_23\,\1740 little_24\JJ\1740 is_25\VBZ\836236 known_26\VBN\2110220 about_27\IN\1740 the_28\DT\1740 long-term_29\JJ\1740 consequences_30\NNS\34213 of_31\IN\1740 mdma-induced_32\JJ\1740 <e1>5-ht</e1>_33\NN\1740 <e2>neurotoxic_34\JJ\1740 lesions</e2>_35\NNS\14204950 on_36\IN\1740 functions_37\NNS\13783581 in_38\IN\13603305 which_39\WDT\1740 5-ht_40\NN\1740 is_41\VBZ\836236 involved_42\VBN\2676054 ,_43\,\1740 such_44\JJ\1740 as_45\IN\14622893 cognitive_46\JJ\1740 function_47\NN\13783581 ._48\.\1740
D012701_D020258 NONE although_0\IN\1740 3,4-methylenedioxymethamphetamine_1\NN\1740 (_2\-LRB-\1740 mdma_3\NN\3054098 or_4\CC\3541091 ecstasy_5\NN\13985818 )_6\-RRB-\1740 has_7\VBZ\2108377 been_8\VBN\836236 shown_9\VBN\2137132 to_10\TO\1740 damage_11\NN\7296428 brain_12\NN\5462674 serotonin_13\NN\14807737 (_14\-LRB-\1740 5-ht_15\NN\1740 )_16\-RRB-\1740 neurons_17\NNS\5430628 in_18\IN\13603305 animals_19\NNS\4475 and_20\CC\1740 possibly_21\RB\1740 humans_22\NNS\31264 ,_23\,\1740 little_24\JJ\1740 is_25\VBZ\836236 known_26\VBN\2110220 about_27\IN\1740 the_28\DT\1740 long-term_29\JJ\1740 consequences_30\NNS\34213 of_31\IN\1740 mdma-induced_32\JJ\1740 5-ht_33\NN\1740 <e2>neurotoxic_34\JJ\1740 lesions</e2>_35\NNS\14204950 on_36\IN\1740 functions_37\NNS\13783581 in_38\IN\13603305 which_39\WDT\1740 <e1>5-ht</e1>_40\NN\1740 is_41\VBZ\836236 involved_42\VBN\2676054 ,_43\,\1740 such_44\JJ\1740 as_45\IN\14622893 cognitive_46\JJ\1740 function_47\NN\13783581 ._48\.\1740
D018817_D008569 CID in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 no_3\DT\7204911 evidence_4\NN\5816287 of_5\IN\1740 <e2>memory_6\NN\5926676 impairment</e2>_7\NN\7296428 was_8\VBD\836236 observed_9\VBN\2163746 in_10\IN\13603305 moderate_11\JJ\1740 <e1>mdma</e1>_12\NN\3054098 users_13\NNS\7846 ._14\.\1740
D018817_D008569 CID while_0\IN\15122231 the_1\DT\1740 use_2\NN\407535 of_3\IN\1740 <e1>mdma</e1>_4\NN\3054098 in_5\IN\13603305 quantities_6\NNS\2137 that_7\WDT\1740 may_8\MD\15209706 be_9\VB\836236 considered_10\VBN\689344 "_11\``\1740 moderate_12\JJ\1740 "_13\''\1740 is_14\VBZ\836236 not_15\RB\1740 associated_16\VBN\628491 with_17\IN\1740 <e2>impaired_18\JJ\1740 memory_19\NN\5926676 functioning</e2>_20\VBG\2669789 ,_21\,\1740 heavy_22\JJ\1740 use_23\NN\407535 of_24\IN\1740 mdma_25\NN\3054098 use_26\NN\407535 may_27\MD\15209706 lead_28\VB\1752884 to_29\TO\1740 long_30\RB\1740 lasting_31\VBG\2704349 memory_32\NN\5926676 impairments_33\NNS\7296428 ._34\.\1740
D018817_D008569 CID while_0\IN\15122231 the_1\DT\1740 use_2\NN\407535 of_3\IN\1740 <e1>mdma</e1>_4\NN\3054098 in_5\IN\13603305 quantities_6\NNS\2137 that_7\WDT\1740 may_8\MD\15209706 be_9\VB\836236 considered_10\VBN\689344 "_11\``\1740 moderate_12\JJ\1740 "_13\''\1740 is_14\VBZ\836236 not_15\RB\1740 associated_16\VBN\628491 with_17\IN\1740 impaired_18\JJ\1740 memory_19\NN\5926676 functioning_20\VBG\2669789 ,_21\,\1740 heavy_22\JJ\1740 use_23\NN\407535 of_24\IN\1740 mdma_25\NN\3054098 use_26\NN\407535 may_27\MD\15209706 lead_28\VB\1752884 to_29\TO\1740 long_30\RB\1740 lasting_31\VBG\2704349 <e2>memory_32\NN\5926676 impairments</e2>_33\NNS\7296428 ._34\.\1740
D018817_D008569 CID while_0\IN\15122231 the_1\DT\1740 use_2\NN\407535 of_3\IN\1740 mdma_4\NN\3054098 in_5\IN\13603305 quantities_6\NNS\2137 that_7\WDT\1740 may_8\MD\15209706 be_9\VB\836236 considered_10\VBN\689344 "_11\``\1740 moderate_12\JJ\1740 "_13\''\1740 is_14\VBZ\836236 not_15\RB\1740 associated_16\VBN\628491 with_17\IN\1740 <e2>impaired_18\JJ\1740 memory_19\NN\5926676 functioning</e2>_20\VBG\2669789 ,_21\,\1740 heavy_22\JJ\1740 use_23\NN\407535 of_24\IN\1740 <e1>mdma</e1>_25\NN\3054098 use_26\NN\407535 may_27\MD\15209706 lead_28\VB\1752884 to_29\TO\1740 long_30\RB\1740 lasting_31\VBG\2704349 memory_32\NN\5926676 impairments_33\NNS\7296428 ._34\.\1740
D018817_D008569 CID while_0\IN\15122231 the_1\DT\1740 use_2\NN\407535 of_3\IN\1740 mdma_4\NN\3054098 in_5\IN\13603305 quantities_6\NNS\2137 that_7\WDT\1740 may_8\MD\15209706 be_9\VB\836236 considered_10\VBN\689344 "_11\``\1740 moderate_12\JJ\1740 "_13\''\1740 is_14\VBZ\836236 not_15\RB\1740 associated_16\VBN\628491 with_17\IN\1740 impaired_18\JJ\1740 memory_19\NN\5926676 functioning_20\VBG\2669789 ,_21\,\1740 heavy_22\JJ\1740 use_23\NN\407535 of_24\IN\1740 <e1>mdma</e1>_25\NN\3054098 use_26\NN\407535 may_27\MD\15209706 lead_28\VB\1752884 to_29\TO\1740 long_30\RB\1740 lasting_31\VBG\2704349 <e2>memory_32\NN\5926676 impairments</e2>_33\NNS\7296428 ._34\.\1740
4038130
D008619_D009135 CID in_0\IN\13603305 addition_1\NN\3081021 to_2\TO\1740 <e2>muscle_3\NN\5289601 damage</e2>_4\NN\7296428 ,_5\,\1740 severe_6\JJ\1740 damage_7\NN\7296428 was_8\VBD\836236 also_9\RB\1740 seen_10\VBN\2106506 in_11\IN\13603305 harderian_12\JJ\1740 glands_13\NNS\5297523 ,_14\,\1740 especially_15\RB\1740 after_16\IN\1740 exposure_17\NN\5042871 to_18\TO\1740 <e1>mepivacaine</e1>_19\NN\1740 and_20\CC\1740 lidocaine_21\NN\3681148 plus_22\CC\4723816 epinephrine_23\NN\14807929 ._24\.\1740
D008012_D009135 CID in_0\IN\13603305 addition_1\NN\3081021 to_2\TO\1740 <e2>muscle_3\NN\5289601 damage</e2>_4\NN\7296428 ,_5\,\1740 severe_6\JJ\1740 damage_7\NN\7296428 was_8\VBD\836236 also_9\RB\1740 seen_10\VBN\2106506 in_11\IN\13603305 harderian_12\JJ\1740 glands_13\NNS\5297523 ,_14\,\1740 especially_15\RB\1740 after_16\IN\1740 exposure_17\NN\5042871 to_18\TO\1740 mepivacaine_19\NN\1740 and_20\CC\1740 <e1>lidocaine</e1>_21\NN\3681148 plus_22\CC\4723816 epinephrine_23\NN\14807929 ._24\.\1740
D004837_D009135 NONE in_0\IN\13603305 addition_1\NN\3081021 to_2\TO\1740 <e2>muscle_3\NN\5289601 damage</e2>_4\NN\7296428 ,_5\,\1740 severe_6\JJ\1740 damage_7\NN\7296428 was_8\VBD\836236 also_9\RB\1740 seen_10\VBN\2106506 in_11\IN\13603305 harderian_12\JJ\1740 glands_13\NNS\5297523 ,_14\,\1740 especially_15\RB\1740 after_16\IN\1740 exposure_17\NN\5042871 to_18\TO\1740 mepivacaine_19\NN\1740 and_20\CC\1740 lidocaine_21\NN\3681148 plus_22\CC\4723816 <e1>epinephrine</e1>_23\NN\14807929 ._24\.\1740
8800187
D002122_D064420 NONE effect_0\NN\34213 of_1\IN\1740 <e1>calcium_2\NN\14625458 chloride</e1>_3\NN\14818238 and_4\CC\1740 4-aminopyridine_5\NN\1740 therapy_6\NN\657604 on_7\IN\1740 desipramine_8\NN\4482543 <e2>toxicity</e2>_9\NN\13576101 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D015761_D064420 NONE effect_0\NN\34213 of_1\IN\1740 calcium_2\NN\14625458 chloride_3\NN\14818238 and_4\CC\1740 <e1>4-aminopyridine</e1>_5\NN\1740 therapy_6\NN\657604 on_7\IN\1740 desipramine_8\NN\4482543 <e2>toxicity</e2>_9\NN\13576101 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D003891_D064420 NONE effect_0\NN\34213 of_1\IN\1740 calcium_2\NN\14625458 chloride_3\NN\14818238 and_4\CC\1740 4-aminopyridine_5\NN\1740 therapy_6\NN\657604 on_7\IN\1740 <e1>desipramine</e1>_8\NN\4482543 <e2>toxicity</e2>_9\NN\13576101 in_10\IN\13603305 rats_11\NNS\2329401 ._12\.\1740
D002118_D007022 NONE this_0\DT\1740 study_1\NN\635850 addressed_2\VBD\740577 the_3\DT\1740 potential_4\JJ\1740 role_5\NN\719494 of_6\IN\1740 <e1>calcium</e1>_7\NN\14625458 channel_8\NN\6251781 blockade_9\NN\952963 in_10\IN\13603305 tricyclic_11\JJ\1740 antidepressant-induced_12\JJ\1740 <e2>hypotension</e2>_13\NN\14057371 ._14\.\1740
D002118_D007022 NONE these_0\DT\1740 findings_1\NNS\7951464 do_2\VBP\1640855 not_3\RB\1740 support_4\VB\2199590 a_5\DT\13649268 role_6\NN\719494 for_7\IN\1740 <e1>calcium</e1>_8\NN\14625458 channel_9\NN\6251781 inhibition_10\NN\1068773 in_11\IN\13603305 the_12\DT\1740 pathogenesis_13\NN\13533470 of_14\IN\1740 tricyclic_15\JJ\1740 antidepressant-induced_16\JJ\1740 <e2>hypotension</e2>_17\NN\14057371 ._18\.\1740
D002118_D062787 NONE methods_0\NNS\5616786 :_1\:\1740 two_2\CD\13741022 interventions_3\NNS\1239064 were_4\VBD\836236 studied_5\VBN\630380 that_6\WDT\1740 have_7\VBP\2108377 been_8\VBN\836236 shown_9\VBN\2137132 previously_10\RB\1740 to_11\TO\1740 improve_12\VB\126264 blood_13\NN\5397468 pressure_14\NN\11419404 with_15\IN\1740 <e1>calcium</e1>_16\NN\14625458 channel_17\NN\6251781 blocker_18\NN\10101634 <e2>overdose</e2>_19\NN\1740 ._20\.\1740
D003891_D007022 CID anesthetized_0\JJ\1740 rats_1\NNS\2329401 received_2\VBD\2210855 the_3\DT\1740 tricyclic_4\JJ\1740 antidepressant_5\JJ\1740 <e1>desipramine</e1>_6\NN\4482543 ip_7\NN\5999797 to_8\TO\1740 produce_9\VB\1617192 <e2>hypotension</e2>_10\NN\14057371 ,_11\,\1740 qrs_12\NN\1740 prolongation_13\NN\1017987 ,_14\,\1740 and_15\CC\1740 bradycardia_16\NN\14110674 ._17\.\1740
D003891_D001919 CID anesthetized_0\JJ\1740 rats_1\NNS\2329401 received_2\VBD\2210855 the_3\DT\1740 tricyclic_4\JJ\1740 antidepressant_5\JJ\1740 <e1>desipramine</e1>_6\NN\4482543 ip_7\NN\5999797 to_8\TO\1740 produce_9\VB\1617192 hypotension_10\NN\14057371 ,_11\,\1740 qrs_12\NN\1740 prolongation_13\NN\1017987 ,_14\,\1740 and_15\CC\1740 <e2>bradycardia</e2>_16\NN\14110674 ._17\.\1740
D017693_D007022 NONE results_0\NNS\34213 :_1\:\1740 <e1>nahco3</e1>_2\NN\1740 briefly_3\NN\1740 (_4\-LRB-\1740 5_5\CD\13741022 min_6\NN\15154774 )_7\-RRB-\1740 reversed_8\VBD\109660 <e2>hypotension</e2>_9\NN\14057371 and_10\CC\1740 qrs_11\NN\1740 prolongation_12\NN\1017987 ._13\.\1740
D002122_D001145 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>ventricular_3\JJ\1740 arrhythmias</e2>_4\NNS\14103288 (_5\-LRB-\1740 p_6\NN\14622893 =_7\JJ\1740 0.004_8\CD\1740 )_9\-RRB-\1740 and_10\CC\1740 seizures_11\NNS\14081375 (_12\-LRB-\1740 p_13\NN\14622893 =_14\JJ\1740 0.03_15\CD\1740 )_16\-RRB-\1740 in_17\IN\13603305 the_18\DT\1740 <e1>cacl2</e1>_19\NN\1740 group_20\NN\2137 was_21\VBD\836236 higher_22\JJR\1740 than_23\IN\1740 the_24\DT\1740 other_25\JJ\1740 groups_26\NNS\2137 ._27\.\1740
D002122_D012640 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 ventricular_3\JJ\1740 arrhythmias_4\NNS\14103288 (_5\-LRB-\1740 p_6\NN\14622893 =_7\JJ\1740 0.004_8\CD\1740 )_9\-RRB-\1740 and_10\CC\1740 <e2>seizures</e2>_11\NNS\14081375 (_12\-LRB-\1740 p_13\NN\14622893 =_14\JJ\1740 0.03_15\CD\1740 )_16\-RRB-\1740 in_17\IN\13603305 the_18\DT\1740 <e1>cacl2</e1>_19\NN\1740 group_20\NN\2137 was_21\VBD\836236 higher_22\JJR\1740 than_23\IN\1740 the_24\DT\1740 other_25\JJ\1740 groups_26\NNS\2137 ._27\.\1740
D002122_D007022 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 administration_3\NN\1133281 of_4\IN\1740 <e1>cacl2</e1>_5\NN\1740 or_6\CC\3541091 4-aminopyridine_7\NN\1740 did_8\VBD\1640855 not_9\RB\1740 reverse_10\VB\109660 tricyclic_11\JJ\1740 antidepressant-induced_12\JJ\1740 <e2>hypotension</e2>_13\NN\14057371 in_14\IN\13603305 rats_15\NNS\2329401 ._16\.\1740
D015761_D007022 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 administration_3\NN\1133281 of_4\IN\1740 cacl2_5\NN\1740 or_6\CC\3541091 <e1>4-aminopyridine</e1>_7\NN\1740 did_8\VBD\1640855 not_9\RB\1740 reverse_10\VB\109660 tricyclic_11\JJ\1740 antidepressant-induced_12\JJ\1740 <e2>hypotension</e2>_13\NN\14057371 in_14\IN\13603305 rats_15\NNS\2329401 ._16\.\1740
D002122_D002318 NONE <e1>cacl2</e1>_0\NN\1740 therapy_1\NN\657604 may_2\MD\15209706 possibly_3\RB\1740 worsen_4\VBN\146138 both_5\CC\1740 <e2>cardiovascular_6\JJ\1740 and_7\CC\1740 central_8\JJ\1740 nervous_9\JJ\1740 system_10\NN\3575240 toxicity</e2>_11\NN\13576101 ._12\.\1740
D002122_D002493 NONE <e1>cacl2</e1>_0\NN\1740 therapy_1\NN\657604 may_2\MD\15209706 possibly_3\RB\1740 worsen_4\VBN\146138 both_5\CC\1740 <e2>cardiovascular_6\JJ\1740 and_7\CC\1740 central_8\JJ\1740 nervous_9\JJ\1740 system_10\NN\3575240 toxicity</e2>_11\NN\13576101 ._12\.\1740
8546130
D017291_D006212 CID <e1>clarithromycin-associated</e1>_0\JJ\1740 <e2>visual_1\JJ\1740 hallucinations</e2>_2\NNS\14376855 in_3\IN\13603305 a_4\DT\13649268 patient_5\NN\9898892 with_6\IN\1740 chronic_7\JJ\1740 renal_8\JJ\1740 failure_9\NN\66216 on_10\IN\1740 continuous_11\JJ\1740 ambulatory_12\JJ\1740 peritoneal_13\NN\1740 dialysis_14\NN\646833 ._15\.\1740
D017291_D006212 CID unreported_0\VBN\1740 in_1\IN\13603305 the_2\DT\1740 literature_3\NN\6362953 is_4\VBZ\836236 <e2>visual_5\JJ\1740 hallucinations</e2>_6\NNS\14376855 occurring_7\VBG\2623529 in_8\IN\13603305 association_9\NN\8008335 with_10\IN\1740 the_11\DT\1740 new_12\JJ\1740 macrolide_13\NN\1740 antibiotic_14\JJ\1740 ,_15\,\1740 <e1>clarithromycin</e1>_16\NN\1740 ._17\.\1740
D017291_D007676 NONE <e1>clarithromycin-associated</e1>_0\JJ\1740 visual_1\JJ\1740 hallucinations_2\NNS\14376855 in_3\IN\13603305 a_4\DT\13649268 patient_5\NN\9898892 with_6\IN\1740 <e2>chronic_7\JJ\1740 renal_8\JJ\1740 failure</e2>_9\NN\66216 on_10\IN\1740 continuous_11\JJ\1740 ambulatory_12\JJ\1740 peritoneal_13\NN\1740 dialysis_14\NN\646833 ._15\.\1740
D017291_D007676 NONE the_0\DT\1740 combination_1\NN\7951464 of_2\IN\1740 a_3\DT\13649268 relatively_4\RB\1740 high_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 <e1>clarithromycin</e1>_8\NN\1740 in_9\IN\13603305 face_10\NN\5225090 of_11\IN\1740 <e2>chronic_12\JJ\1740 renal_13\JJ\1740 failure</e2>_14\NN\66216 in_15\IN\13603305 a_16\DT\13649268 functionally_17\RB\1740 anephric_18\JJ\1740 patient_19\NN\9898892 ,_20\,\1740 with_21\IN\1740 underlying_22\VBG\2604760 aluminum_23\NN\14625458 intoxication_24\NN\14034177 ,_25\,\1740 may_26\MD\15209706 have_27\VB\2108377 facilitated_28\VBN\2547586 the_29\DT\1740 appearance_30\NN\4723816 of_31\IN\1740 this_32\DT\1740 neurotoxic_33\JJ\1740 side_34\NN\8630039 effect_35\NN\34213 ._36\.\1740
D018942_D006212 NONE unreported_0\VBN\1740 in_1\IN\13603305 the_2\DT\1740 literature_3\NN\6362953 is_4\VBZ\836236 <e2>visual_5\JJ\1740 hallucinations</e2>_6\NNS\14376855 occurring_7\VBG\2623529 in_8\IN\13603305 association_9\NN\8008335 with_10\IN\1740 the_11\DT\1740 new_12\JJ\1740 <e1>macrolide</e1>_13\NN\1740 antibiotic_14\JJ\1740 ,_15\,\1740 clarithromycin_16\NN\1740 ._17\.\1740
D017291_D020258 NONE the_0\DT\1740 combination_1\NN\7951464 of_2\IN\1740 a_3\DT\13649268 relatively_4\RB\1740 high_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 <e1>clarithromycin</e1>_8\NN\1740 in_9\IN\13603305 face_10\NN\5225090 of_11\IN\1740 chronic_12\JJ\1740 renal_13\JJ\1740 failure_14\NN\66216 in_15\IN\13603305 a_16\DT\13649268 functionally_17\RB\1740 anephric_18\JJ\1740 patient_19\NN\9898892 ,_20\,\1740 with_21\IN\1740 underlying_22\VBG\2604760 aluminum_23\NN\14625458 intoxication_24\NN\14034177 ,_25\,\1740 may_26\MD\15209706 have_27\VB\2108377 facilitated_28\VBN\2547586 the_29\DT\1740 appearance_30\NN\4723816 of_31\IN\1740 this_32\DT\1740 <e2>neurotoxic</e2>_33\JJ\1740 side_34\NN\8630039 effect_35\NN\34213 ._36\.\1740
D000535_D007676 NONE the_0\DT\1740 combination_1\NN\7951464 of_2\IN\1740 a_3\DT\13649268 relatively_4\RB\1740 high_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 clarithromycin_8\NN\1740 in_9\IN\13603305 face_10\NN\5225090 of_11\IN\1740 <e2>chronic_12\JJ\1740 renal_13\JJ\1740 failure</e2>_14\NN\66216 in_15\IN\13603305 a_16\DT\13649268 functionally_17\RB\1740 anephric_18\JJ\1740 patient_19\NN\9898892 ,_20\,\1740 with_21\IN\1740 underlying_22\VBG\2604760 <e1>aluminum</e1>_23\NN\14625458 intoxication_24\NN\14034177 ,_25\,\1740 may_26\MD\15209706 have_27\VB\2108377 facilitated_28\VBN\2547586 the_29\DT\1740 appearance_30\NN\4723816 of_31\IN\1740 this_32\DT\1740 neurotoxic_33\JJ\1740 side_34\NN\8630039 effect_35\NN\34213 ._36\.\1740
D000535_D020258 NONE the_0\DT\1740 combination_1\NN\7951464 of_2\IN\1740 a_3\DT\13649268 relatively_4\RB\1740 high_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 clarithromycin_8\NN\1740 in_9\IN\13603305 face_10\NN\5225090 of_11\IN\1740 chronic_12\JJ\1740 renal_13\JJ\1740 failure_14\NN\66216 in_15\IN\13603305 a_16\DT\13649268 functionally_17\RB\1740 anephric_18\JJ\1740 patient_19\NN\9898892 ,_20\,\1740 with_21\IN\1740 underlying_22\VBG\2604760 <e1>aluminum</e1>_23\NN\14625458 intoxication_24\NN\14034177 ,_25\,\1740 may_26\MD\15209706 have_27\VB\2108377 facilitated_28\VBN\2547586 the_29\DT\1740 appearance_30\NN\4723816 of_31\IN\1740 this_32\DT\1740 <e2>neurotoxic</e2>_33\JJ\1740 side_34\NN\8630039 effect_35\NN\34213 ._36\.\1740
9121607
D013256_D012640 NONE neuroactive_0\JJ\1740 <e1>steroids</e1>_1\NNS\14727670 protect_2\VBP\1127795 against_3\IN\1740 pilocarpine-_4\NN\1740 and_5\CC\1740 kainic_6\JJ\1740 acid-induced_7\JJ\1740 limbic_8\JJ\1740 <e2>seizures</e2>_9\NNS\14081375 and_10\CC\1740 status_11\NN\24720 epilepticus_12\NN\1740 in_13\IN\13603305 mice_14\NNS\2329401 ._15\.\1740
D013256_D012640 NONE <e1>steroids</e1>_0\NNS\14727670 with_1\IN\1740 the_2\DT\1740 3-hydroxy_3\JJ\1740 group_4\NN\2137 in_5\IN\13603305 the_6\DT\1740 alpha-position_7\NN\1740 and_8\CC\1740 5-h_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 alpha-_12\NN\1740 or_13\CC\3541091 beta-configurations_14\NNS\1740 were_15\VBD\836236 highly_16\RB\1740 effective_17\JJ\1740 in_18\IN\13603305 protecting_19\VBG\1127795 against_20\IN\1740 pilocarpine_21\NN\14712692 (_22\-LRB-\1740 416_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 s.c.)-induced_26\JJ\1740 limbic_27\JJ\1740 motor_28\NN\3699975 <e2>seizures</e2>_29\NNS\14081375 and_30\CC\1740 status_31\NN\24720 epilepticus_32\NN\1740 (_33\-LRB-\1740 ed50_34\NN\1740 values_35\NNS\5941423 ,_36\,\1740 7.0_37\CD\1740 -_38\SYM\1740 18.7_39\CD\1740 mg/kg_40\NN\1740 ,_41\,\1740 i.p._42\RB\1740 )_43\-RRB-\1740 ._44\.\1740
D013256_D012640 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 <e1>steroids</e1>_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 <e2>seizures</e2>_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D013256_D012640 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 <e1>steroids</e1>_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 <e2>seizure</e2>_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D013256_D012640 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 <e2>seizures</e2>_16\NNS\14081375 ,_17\,\1740 <e1>steroids</e1>_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D013256_D012640 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 <e1>steroids</e1>_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 <e2>seizure</e2>_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D013256_D012640 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 <e2>seizures</e2>_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 <e1>steroids</e1>_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D013256_D012640 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 <e2>seizure</e2>_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 <e1>steroids</e1>_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D013256_D012640 NONE <e1>steroids</e1>_0\NNS\14727670 with_1\IN\1740 the_2\DT\1740 5_3\CD\13741022 alpha,3_4\NN\1740 alpha-_5\NN\1740 or_6\CC\3541091 5_7\CD\13741022 beta,3_8\NN\1740 alpha-configurations_9\NNS\1740 also_10\RB\1740 produced_11\VBD\1617192 a_12\DT\13649268 dose-dependent_13\JJ\1740 delay_14\NN\15271008 in_15\IN\13603305 the_16\DT\1740 onset_17\NN\7325190 of_18\IN\1740 limbic_19\JJ\1740 <e2>seizures</e2>_20\NNS\14081375 induced_21\VBN\1627355 by_22\IN\1740 kainic_23\JJ\1740 acid_24\NN\14818238 (_25\-LRB-\1740 32_26\CD\1740 mg/kg_27\NN\1740 ,_28\,\1740 s.c._29\FW\1740 )_30\-RRB-\1740 ,_31\,\1740 but_32\CC\1740 did_33\VBD\1640855 not_34\RB\1740 completely_35\RB\1740 protect_36\VB\1127795 against_37\IN\1740 the_38\DT\1740 seizures_39\NNS\14081375 ._40\.\1740
D013256_D012640 NONE <e1>steroids</e1>_0\NNS\14727670 with_1\IN\1740 the_2\DT\1740 5_3\CD\13741022 alpha,3_4\NN\1740 alpha-_5\NN\1740 or_6\CC\3541091 5_7\CD\13741022 beta,3_8\NN\1740 alpha-configurations_9\NNS\1740 also_10\RB\1740 produced_11\VBD\1617192 a_12\DT\13649268 dose-dependent_13\JJ\1740 delay_14\NN\15271008 in_15\IN\13603305 the_16\DT\1740 onset_17\NN\7325190 of_18\IN\1740 limbic_19\JJ\1740 seizures_20\NNS\14081375 induced_21\VBN\1627355 by_22\IN\1740 kainic_23\JJ\1740 acid_24\NN\14818238 (_25\-LRB-\1740 32_26\CD\1740 mg/kg_27\NN\1740 ,_28\,\1740 s.c._29\FW\1740 )_30\-RRB-\1740 ,_31\,\1740 but_32\CC\1740 did_33\VBD\1640855 not_34\RB\1740 completely_35\RB\1740 protect_36\VB\1127795 against_37\IN\1740 the_38\DT\1740 <e2>seizures</e2>_39\NNS\14081375 ._40\.\1740
D013256_D012640 NONE however_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 a_3\DT\13649268 second_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 the_7\DT\1740 <e1>steroid</e1>_8\NN\14727670 was_9\VBD\836236 administered_10\VBN\2436349 1_11\CD\13741022 hr_12\NN\15154774 after_13\IN\1740 the_14\DT\1740 first_15\JJ\1740 dose_16\NN\3740161 ,_17\,\1740 complete_18\VB\352826 protection_19\NN\407535 from_20\IN\1740 the_21\DT\1740 kainic_22\JJ\1740 acid-induced_23\JJ\1740 limbic_24\JJ\1740 <e2>seizures</e2>_25\NNS\14081375 and_26\CC\1740 status_27\NN\24720 epilepticus_28\NN\1740 was_29\VBD\836236 obtained_30\VBN\2210855 ._31\.\1740
D013256_D012640 NONE the_0\DT\1740 <e1>steroids</e1>_1\NNS\14727670 also_2\RB\1740 caused_3\VBD\1617192 a_4\DT\13649268 dose-dependent_5\JJ\1740 delay_6\NN\15271008 in_7\IN\13603305 nmda_8\NN\1740 (_9\-LRB-\1740 257_10\CD\1740 mg/kg_11\NN\1740 ,_12\,\1740 s.c.)-induced_13\JJ\1740 lethality_14\NN\4790449 ,_15\,\1740 but_16\CC\1740 did_17\VBD\1640855 not_18\RB\1740 completely_19\RB\1740 protect_20\VB\1127795 against_21\IN\1740 nmda_22\NN\1740 <e2>seizures</e2>_23\NNS\14081375 or_24\CC\3541091 lethality_25\NN\4790449 ._26\.\1740
D013256_D012640 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 neuroactive_3\JJ\1740 <e1>steroids</e1>_4\NNS\14727670 are_5\VBP\836236 highly_6\RB\1740 effective_7\JJ\1740 in_8\IN\13603305 protecting_9\VBG\1127795 against_10\RP\1740 pilocarpine-_11\NN\1740 and_12\CC\1740 kainic_13\JJ\1740 acid-induced_14\JJ\1740 <e2>seizures</e2>_15\NNS\14081375 and_16\CC\1740 status_17\NN\24720 epilepticus_18\NN\1740 in_19\IN\13603305 mice_20\NNS\2329401 ,_21\,\1740 and_22\CC\1740 may_23\MD\15209706 be_24\VB\836236 of_25\IN\1740 utility_26\NN\8186047 in_27\IN\13603305 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 some_31\DT\1740 forms_32\NNS\6286395 of_33\IN\1740 status_34\NN\24720 epilepticus_35\NN\1740 in_36\IN\13603305 humans_37\NNS\31264 ._38\.\1740
D013256_D013226 NONE neuroactive_0\JJ\1740 <e1>steroids</e1>_1\NNS\14727670 protect_2\VBP\1127795 against_3\IN\1740 pilocarpine-_4\NN\1740 and_5\CC\1740 kainic_6\JJ\1740 acid-induced_7\JJ\1740 limbic_8\JJ\1740 seizures_9\NNS\14081375 and_10\CC\1740 <e2>status_11\NN\24720 epilepticus</e2>_12\NN\1740 in_13\IN\13603305 mice_14\NNS\2329401 ._15\.\1740
D013256_D013226 NONE <e1>steroids</e1>_0\NNS\14727670 with_1\IN\1740 the_2\DT\1740 3-hydroxy_3\JJ\1740 group_4\NN\2137 in_5\IN\13603305 the_6\DT\1740 alpha-position_7\NN\1740 and_8\CC\1740 5-h_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 alpha-_12\NN\1740 or_13\CC\3541091 beta-configurations_14\NNS\1740 were_15\VBD\836236 highly_16\RB\1740 effective_17\JJ\1740 in_18\IN\13603305 protecting_19\VBG\1127795 against_20\IN\1740 pilocarpine_21\NN\14712692 (_22\-LRB-\1740 416_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 s.c.)-induced_26\JJ\1740 limbic_27\JJ\1740 motor_28\NN\3699975 seizures_29\NNS\14081375 and_30\CC\1740 <e2>status_31\NN\24720 epilepticus</e2>_32\NN\1740 (_33\-LRB-\1740 ed50_34\NN\1740 values_35\NNS\5941423 ,_36\,\1740 7.0_37\CD\1740 -_38\SYM\1740 18.7_39\CD\1740 mg/kg_40\NN\1740 ,_41\,\1740 i.p._42\RB\1740 )_43\-RRB-\1740 ._44\.\1740
D013256_D013226 NONE however_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 a_3\DT\13649268 second_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 the_7\DT\1740 <e1>steroid</e1>_8\NN\14727670 was_9\VBD\836236 administered_10\VBN\2436349 1_11\CD\13741022 hr_12\NN\15154774 after_13\IN\1740 the_14\DT\1740 first_15\JJ\1740 dose_16\NN\3740161 ,_17\,\1740 complete_18\VB\352826 protection_19\NN\407535 from_20\IN\1740 the_21\DT\1740 kainic_22\JJ\1740 acid-induced_23\JJ\1740 limbic_24\JJ\1740 seizures_25\NNS\14081375 and_26\CC\1740 <e2>status_27\NN\24720 epilepticus</e2>_28\NN\1740 was_29\VBD\836236 obtained_30\VBN\2210855 ._31\.\1740
D013256_D013226 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 neuroactive_3\JJ\1740 <e1>steroids</e1>_4\NNS\14727670 are_5\VBP\836236 highly_6\RB\1740 effective_7\JJ\1740 in_8\IN\13603305 protecting_9\VBG\1127795 against_10\RP\1740 pilocarpine-_11\NN\1740 and_12\CC\1740 kainic_13\JJ\1740 acid-induced_14\JJ\1740 seizures_15\NNS\14081375 and_16\CC\1740 <e2>status_17\NN\24720 epilepticus</e2>_18\NN\1740 in_19\IN\13603305 mice_20\NNS\2329401 ,_21\,\1740 and_22\CC\1740 may_23\MD\15209706 be_24\VB\836236 of_25\IN\1740 utility_26\NN\8186047 in_27\IN\13603305 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 some_31\DT\1740 forms_32\NNS\6286395 of_33\IN\1740 status_34\NN\24720 epilepticus_35\NN\1740 in_36\IN\13603305 humans_37\NNS\31264 ._38\.\1740
D013256_D013226 NONE we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 neuroactive_3\JJ\1740 <e1>steroids</e1>_4\NNS\14727670 are_5\VBP\836236 highly_6\RB\1740 effective_7\JJ\1740 in_8\IN\13603305 protecting_9\VBG\1127795 against_10\RP\1740 pilocarpine-_11\NN\1740 and_12\CC\1740 kainic_13\JJ\1740 acid-induced_14\JJ\1740 seizures_15\NNS\14081375 and_16\CC\1740 status_17\NN\24720 epilepticus_18\NN\1740 in_19\IN\13603305 mice_20\NNS\2329401 ,_21\,\1740 and_22\CC\1740 may_23\MD\15209706 be_24\VB\836236 of_25\IN\1740 utility_26\NN\8186047 in_27\IN\13603305 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 some_31\DT\1740 forms_32\NNS\6286395 of_33\IN\1740 <e2>status_34\NN\24720 epilepticus</e2>_35\NN\1740 in_36\IN\13603305 humans_37\NNS\31264 ._38\.\1740
D010862_D012640 CID neuroactive_0\JJ\1740 steroids_1\NNS\14727670 protect_2\VBP\1127795 against_3\IN\1740 <e1>pilocarpine-</e1>_4\NN\1740 and_5\CC\1740 kainic_6\JJ\1740 acid-induced_7\JJ\1740 limbic_8\JJ\1740 <e2>seizures</e2>_9\NNS\14081375 and_10\CC\1740 status_11\NN\24720 epilepticus_12\NN\1740 in_13\IN\13603305 mice_14\NNS\2329401 ._15\.\1740
D010862_D012640 CID several_0\JJ\1740 structurally_1\RB\1740 related_2\JJ\1740 metabolites_3\NNS\20090 of_4\IN\1740 progesterone_5\NN\14747338 (_6\-LRB-\1740 3_7\CD\13741022 alpha-hydroxy_8\JJ\1740 pregnane-20-ones_9\NNS\1740 )_10\-RRB-\1740 and_11\CC\1740 deoxycorticosterone_12\NN\1740 (_13\-LRB-\1740 3_14\CD\13741022 alpha-hydroxy_15\JJ\1740 pregnane-21-diol-20-ones_16\NNS\1740 )_17\-RRB-\1740 and_18\CC\1740 their_19\PRP$\1740 3_20\CD\13741022 beta-epimers_21\NNS\1740 were_22\VBD\836236 evaluated_23\VBN\670261 for_24\IN\1740 protective_25\JJ\1740 activity_26\NN\30358 against_27\IN\1740 <e1>pilocarpine-</e1>_28\NN\1740 ,_29\,\1740 kainic_30\JJ\1740 acid-_31\NN\1740 and_32\CC\1740 n-methyl-d-aspartate_33\NN\1740 (nmda)-induced_34\JJ\1740 <e2>seizures</e2>_35\NNS\14081375 in_36\IN\13603305 mice_37\NNS\2329401 ._38\.\1740
D010862_D012640 CID steroids_0\NNS\14727670 with_1\IN\1740 the_2\DT\1740 3-hydroxy_3\JJ\1740 group_4\NN\2137 in_5\IN\13603305 the_6\DT\1740 alpha-position_7\NN\1740 and_8\CC\1740 5-h_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 alpha-_12\NN\1740 or_13\CC\3541091 beta-configurations_14\NNS\1740 were_15\VBD\836236 highly_16\RB\1740 effective_17\JJ\1740 in_18\IN\13603305 protecting_19\VBG\1127795 against_20\IN\1740 <e1>pilocarpine</e1>_21\NN\14712692 (_22\-LRB-\1740 416_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 s.c.)-induced_26\JJ\1740 limbic_27\JJ\1740 motor_28\NN\3699975 <e2>seizures</e2>_29\NNS\14081375 and_30\CC\1740 status_31\NN\24720 epilepticus_32\NN\1740 (_33\-LRB-\1740 ed50_34\NN\1740 values_35\NNS\5941423 ,_36\,\1740 7.0_37\CD\1740 -_38\SYM\1740 18.7_39\CD\1740 mg/kg_40\NN\1740 ,_41\,\1740 i.p._42\RB\1740 )_43\-RRB-\1740 ._44\.\1740
D010862_D012640 CID although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 <e1>pilocarpine</e1>_15\NN\14712692 <e2>seizures</e2>_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D010862_D012640 CID although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 <e1>pilocarpine</e1>_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 <e2>seizure</e2>_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D010862_D012640 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 neuroactive_3\JJ\1740 steroids_4\NNS\14727670 are_5\VBP\836236 highly_6\RB\1740 effective_7\JJ\1740 in_8\IN\13603305 protecting_9\VBG\1127795 against_10\RP\1740 <e1>pilocarpine-</e1>_11\NN\1740 and_12\CC\1740 kainic_13\JJ\1740 acid-induced_14\JJ\1740 <e2>seizures</e2>_15\NNS\14081375 and_16\CC\1740 status_17\NN\24720 epilepticus_18\NN\1740 in_19\IN\13603305 mice_20\NNS\2329401 ,_21\,\1740 and_22\CC\1740 may_23\MD\15209706 be_24\VB\836236 of_25\IN\1740 utility_26\NN\8186047 in_27\IN\13603305 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 some_31\DT\1740 forms_32\NNS\6286395 of_33\IN\1740 status_34\NN\24720 epilepticus_35\NN\1740 in_36\IN\13603305 humans_37\NNS\31264 ._38\.\1740
D010862_D013226 CID neuroactive_0\JJ\1740 steroids_1\NNS\14727670 protect_2\VBP\1127795 against_3\IN\1740 <e1>pilocarpine-</e1>_4\NN\1740 and_5\CC\1740 kainic_6\JJ\1740 acid-induced_7\JJ\1740 limbic_8\JJ\1740 seizures_9\NNS\14081375 and_10\CC\1740 <e2>status_11\NN\24720 epilepticus</e2>_12\NN\1740 in_13\IN\13603305 mice_14\NNS\2329401 ._15\.\1740
D010862_D013226 CID steroids_0\NNS\14727670 with_1\IN\1740 the_2\DT\1740 3-hydroxy_3\JJ\1740 group_4\NN\2137 in_5\IN\13603305 the_6\DT\1740 alpha-position_7\NN\1740 and_8\CC\1740 5-h_9\NN\1740 in_10\IN\13603305 the_11\DT\1740 alpha-_12\NN\1740 or_13\CC\3541091 beta-configurations_14\NNS\1740 were_15\VBD\836236 highly_16\RB\1740 effective_17\JJ\1740 in_18\IN\13603305 protecting_19\VBG\1127795 against_20\IN\1740 <e1>pilocarpine</e1>_21\NN\14712692 (_22\-LRB-\1740 416_23\CD\1740 mg/kg_24\NN\1740 ,_25\,\1740 s.c.)-induced_26\JJ\1740 limbic_27\JJ\1740 motor_28\NN\3699975 seizures_29\NNS\14081375 and_30\CC\1740 <e2>status_31\NN\24720 epilepticus</e2>_32\NN\1740 (_33\-LRB-\1740 ed50_34\NN\1740 values_35\NNS\5941423 ,_36\,\1740 7.0_37\CD\1740 -_38\SYM\1740 18.7_39\CD\1740 mg/kg_40\NN\1740 ,_41\,\1740 i.p._42\RB\1740 )_43\-RRB-\1740 ._44\.\1740
D010862_D013226 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 neuroactive_3\JJ\1740 steroids_4\NNS\14727670 are_5\VBP\836236 highly_6\RB\1740 effective_7\JJ\1740 in_8\IN\13603305 protecting_9\VBG\1127795 against_10\RP\1740 <e1>pilocarpine-</e1>_11\NN\1740 and_12\CC\1740 kainic_13\JJ\1740 acid-induced_14\JJ\1740 seizures_15\NNS\14081375 and_16\CC\1740 <e2>status_17\NN\24720 epilepticus</e2>_18\NN\1740 in_19\IN\13603305 mice_20\NNS\2329401 ,_21\,\1740 and_22\CC\1740 may_23\MD\15209706 be_24\VB\836236 of_25\IN\1740 utility_26\NN\8186047 in_27\IN\13603305 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 some_31\DT\1740 forms_32\NNS\6286395 of_33\IN\1740 status_34\NN\24720 epilepticus_35\NN\1740 in_36\IN\13603305 humans_37\NNS\31264 ._38\.\1740
D010862_D013226 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 neuroactive_3\JJ\1740 steroids_4\NNS\14727670 are_5\VBP\836236 highly_6\RB\1740 effective_7\JJ\1740 in_8\IN\13603305 protecting_9\VBG\1127795 against_10\RP\1740 <e1>pilocarpine-</e1>_11\NN\1740 and_12\CC\1740 kainic_13\JJ\1740 acid-induced_14\JJ\1740 seizures_15\NNS\14081375 and_16\CC\1740 status_17\NN\24720 epilepticus_18\NN\1740 in_19\IN\13603305 mice_20\NNS\2329401 ,_21\,\1740 and_22\CC\1740 may_23\MD\15209706 be_24\VB\836236 of_25\IN\1740 utility_26\NN\8186047 in_27\IN\13603305 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 some_31\DT\1740 forms_32\NNS\6286395 of_33\IN\1740 <e2>status_34\NN\24720 epilepticus</e2>_35\NN\1740 in_36\IN\13603305 humans_37\NNS\31264 ._38\.\1740
D007608_D012640 CID neuroactive_0\JJ\1740 steroids_1\NNS\14727670 protect_2\VBP\1127795 against_3\IN\1740 pilocarpine-_4\NN\1740 and_5\CC\1740 <e1>kainic_6\JJ\1740 acid-induced</e1>_7\JJ\1740 limbic_8\JJ\1740 <e2>seizures</e2>_9\NNS\14081375 and_10\CC\1740 status_11\NN\24720 epilepticus_12\NN\1740 in_13\IN\13603305 mice_14\NNS\2329401 ._15\.\1740
D007608_D012640 CID several_0\JJ\1740 structurally_1\RB\1740 related_2\JJ\1740 metabolites_3\NNS\20090 of_4\IN\1740 progesterone_5\NN\14747338 (_6\-LRB-\1740 3_7\CD\13741022 alpha-hydroxy_8\JJ\1740 pregnane-20-ones_9\NNS\1740 )_10\-RRB-\1740 and_11\CC\1740 deoxycorticosterone_12\NN\1740 (_13\-LRB-\1740 3_14\CD\13741022 alpha-hydroxy_15\JJ\1740 pregnane-21-diol-20-ones_16\NNS\1740 )_17\-RRB-\1740 and_18\CC\1740 their_19\PRP$\1740 3_20\CD\13741022 beta-epimers_21\NNS\1740 were_22\VBD\836236 evaluated_23\VBN\670261 for_24\IN\1740 protective_25\JJ\1740 activity_26\NN\30358 against_27\IN\1740 pilocarpine-_28\NN\1740 ,_29\,\1740 <e1>kainic_30\JJ\1740 acid-</e1>_31\NN\1740 and_32\CC\1740 n-methyl-d-aspartate_33\NN\1740 (nmda)-induced_34\JJ\1740 <e2>seizures</e2>_35\NNS\14081375 in_36\IN\13603305 mice_37\NNS\2329401 ._38\.\1740
D007608_D012640 CID steroids_0\NNS\14727670 with_1\IN\1740 the_2\DT\1740 5_3\CD\13741022 alpha,3_4\NN\1740 alpha-_5\NN\1740 or_6\CC\3541091 5_7\CD\13741022 beta,3_8\NN\1740 alpha-configurations_9\NNS\1740 also_10\RB\1740 produced_11\VBD\1617192 a_12\DT\13649268 dose-dependent_13\JJ\1740 delay_14\NN\15271008 in_15\IN\13603305 the_16\DT\1740 onset_17\NN\7325190 of_18\IN\1740 limbic_19\JJ\1740 <e2>seizures</e2>_20\NNS\14081375 induced_21\VBN\1627355 by_22\IN\1740 <e1>kainic_23\JJ\1740 acid</e1>_24\NN\14818238 (_25\-LRB-\1740 32_26\CD\1740 mg/kg_27\NN\1740 ,_28\,\1740 s.c._29\FW\1740 )_30\-RRB-\1740 ,_31\,\1740 but_32\CC\1740 did_33\VBD\1640855 not_34\RB\1740 completely_35\RB\1740 protect_36\VB\1127795 against_37\IN\1740 the_38\DT\1740 seizures_39\NNS\14081375 ._40\.\1740
D007608_D012640 CID steroids_0\NNS\14727670 with_1\IN\1740 the_2\DT\1740 5_3\CD\13741022 alpha,3_4\NN\1740 alpha-_5\NN\1740 or_6\CC\3541091 5_7\CD\13741022 beta,3_8\NN\1740 alpha-configurations_9\NNS\1740 also_10\RB\1740 produced_11\VBD\1617192 a_12\DT\13649268 dose-dependent_13\JJ\1740 delay_14\NN\15271008 in_15\IN\13603305 the_16\DT\1740 onset_17\NN\7325190 of_18\IN\1740 limbic_19\JJ\1740 seizures_20\NNS\14081375 induced_21\VBN\1627355 by_22\IN\1740 <e1>kainic_23\JJ\1740 acid</e1>_24\NN\14818238 (_25\-LRB-\1740 32_26\CD\1740 mg/kg_27\NN\1740 ,_28\,\1740 s.c._29\FW\1740 )_30\-RRB-\1740 ,_31\,\1740 but_32\CC\1740 did_33\VBD\1640855 not_34\RB\1740 completely_35\RB\1740 protect_36\VB\1127795 against_37\IN\1740 the_38\DT\1740 <e2>seizures</e2>_39\NNS\14081375 ._40\.\1740
D007608_D012640 CID however_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 a_3\DT\13649268 second_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 the_7\DT\1740 steroid_8\NN\14727670 was_9\VBD\836236 administered_10\VBN\2436349 1_11\CD\13741022 hr_12\NN\15154774 after_13\IN\1740 the_14\DT\1740 first_15\JJ\1740 dose_16\NN\3740161 ,_17\,\1740 complete_18\VB\352826 protection_19\NN\407535 from_20\IN\1740 the_21\DT\1740 <e1>kainic_22\JJ\1740 acid-induced</e1>_23\JJ\1740 limbic_24\JJ\1740 <e2>seizures</e2>_25\NNS\14081375 and_26\CC\1740 status_27\NN\24720 epilepticus_28\NN\1740 was_29\VBD\836236 obtained_30\VBN\2210855 ._31\.\1740
D007608_D012640 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 neuroactive_3\JJ\1740 steroids_4\NNS\14727670 are_5\VBP\836236 highly_6\RB\1740 effective_7\JJ\1740 in_8\IN\13603305 protecting_9\VBG\1127795 against_10\RP\1740 pilocarpine-_11\NN\1740 and_12\CC\1740 <e1>kainic_13\JJ\1740 acid-induced</e1>_14\JJ\1740 <e2>seizures</e2>_15\NNS\14081375 and_16\CC\1740 status_17\NN\24720 epilepticus_18\NN\1740 in_19\IN\13603305 mice_20\NNS\2329401 ,_21\,\1740 and_22\CC\1740 may_23\MD\15209706 be_24\VB\836236 of_25\IN\1740 utility_26\NN\8186047 in_27\IN\13603305 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 some_31\DT\1740 forms_32\NNS\6286395 of_33\IN\1740 status_34\NN\24720 epilepticus_35\NN\1740 in_36\IN\13603305 humans_37\NNS\31264 ._38\.\1740
D007608_D013226 CID neuroactive_0\JJ\1740 steroids_1\NNS\14727670 protect_2\VBP\1127795 against_3\IN\1740 pilocarpine-_4\NN\1740 and_5\CC\1740 <e1>kainic_6\JJ\1740 acid-induced</e1>_7\JJ\1740 limbic_8\JJ\1740 seizures_9\NNS\14081375 and_10\CC\1740 <e2>status_11\NN\24720 epilepticus</e2>_12\NN\1740 in_13\IN\13603305 mice_14\NNS\2329401 ._15\.\1740
D007608_D013226 CID however_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 a_3\DT\13649268 second_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 the_7\DT\1740 steroid_8\NN\14727670 was_9\VBD\836236 administered_10\VBN\2436349 1_11\CD\13741022 hr_12\NN\15154774 after_13\IN\1740 the_14\DT\1740 first_15\JJ\1740 dose_16\NN\3740161 ,_17\,\1740 complete_18\VB\352826 protection_19\NN\407535 from_20\IN\1740 the_21\DT\1740 <e1>kainic_22\JJ\1740 acid-induced</e1>_23\JJ\1740 limbic_24\JJ\1740 seizures_25\NNS\14081375 and_26\CC\1740 <e2>status_27\NN\24720 epilepticus</e2>_28\NN\1740 was_29\VBD\836236 obtained_30\VBN\2210855 ._31\.\1740
D007608_D013226 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 neuroactive_3\JJ\1740 steroids_4\NNS\14727670 are_5\VBP\836236 highly_6\RB\1740 effective_7\JJ\1740 in_8\IN\13603305 protecting_9\VBG\1127795 against_10\RP\1740 pilocarpine-_11\NN\1740 and_12\CC\1740 <e1>kainic_13\JJ\1740 acid-induced</e1>_14\JJ\1740 seizures_15\NNS\14081375 and_16\CC\1740 <e2>status_17\NN\24720 epilepticus</e2>_18\NN\1740 in_19\IN\13603305 mice_20\NNS\2329401 ,_21\,\1740 and_22\CC\1740 may_23\MD\15209706 be_24\VB\836236 of_25\IN\1740 utility_26\NN\8186047 in_27\IN\13603305 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 some_31\DT\1740 forms_32\NNS\6286395 of_33\IN\1740 status_34\NN\24720 epilepticus_35\NN\1740 in_36\IN\13603305 humans_37\NNS\31264 ._38\.\1740
D007608_D013226 CID we_0\PRP\1740 conclude_1\VBP\628491 that_2\IN\1740 neuroactive_3\JJ\1740 steroids_4\NNS\14727670 are_5\VBP\836236 highly_6\RB\1740 effective_7\JJ\1740 in_8\IN\13603305 protecting_9\VBG\1127795 against_10\RP\1740 pilocarpine-_11\NN\1740 and_12\CC\1740 <e1>kainic_13\JJ\1740 acid-induced</e1>_14\JJ\1740 seizures_15\NNS\14081375 and_16\CC\1740 status_17\NN\24720 epilepticus_18\NN\1740 in_19\IN\13603305 mice_20\NNS\2329401 ,_21\,\1740 and_22\CC\1740 may_23\MD\15209706 be_24\VB\836236 of_25\IN\1740 utility_26\NN\8186047 in_27\IN\13603305 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 some_31\DT\1740 forms_32\NNS\6286395 of_33\IN\1740 <e2>status_34\NN\24720 epilepticus</e2>_35\NN\1740 in_36\IN\13603305 humans_37\NNS\31264 ._38\.\1740
D011374_D012640 NONE several_0\JJ\1740 structurally_1\RB\1740 related_2\JJ\1740 metabolites_3\NNS\20090 of_4\IN\1740 <e1>progesterone</e1>_5\NN\14747338 (_6\-LRB-\1740 3_7\CD\13741022 alpha-hydroxy_8\JJ\1740 pregnane-20-ones_9\NNS\1740 )_10\-RRB-\1740 and_11\CC\1740 deoxycorticosterone_12\NN\1740 (_13\-LRB-\1740 3_14\CD\13741022 alpha-hydroxy_15\JJ\1740 pregnane-21-diol-20-ones_16\NNS\1740 )_17\-RRB-\1740 and_18\CC\1740 their_19\PRP$\1740 3_20\CD\13741022 beta-epimers_21\NNS\1740 were_22\VBD\836236 evaluated_23\VBN\670261 for_24\IN\1740 protective_25\JJ\1740 activity_26\NN\30358 against_27\IN\1740 pilocarpine-_28\NN\1740 ,_29\,\1740 kainic_30\JJ\1740 acid-_31\NN\1740 and_32\CC\1740 n-methyl-d-aspartate_33\NN\1740 (nmda)-induced_34\JJ\1740 <e2>seizures</e2>_35\NNS\14081375 in_36\IN\13603305 mice_37\NNS\2329401 ._38\.\1740
D011374_D012640 NONE several_0\JJ\1740 structurally_1\RB\1740 related_2\JJ\1740 metabolites_3\NNS\20090 of_4\IN\1740 progesterone_5\NN\14747338 (_6\-LRB-\1740 <e1>3_7\CD\13741022 alpha-hydroxy_8\JJ\1740 pregnane-20-ones</e1>_9\NNS\1740 )_10\-RRB-\1740 and_11\CC\1740 deoxycorticosterone_12\NN\1740 (_13\-LRB-\1740 3_14\CD\13741022 alpha-hydroxy_15\JJ\1740 pregnane-21-diol-20-ones_16\NNS\1740 )_17\-RRB-\1740 and_18\CC\1740 their_19\PRP$\1740 3_20\CD\13741022 beta-epimers_21\NNS\1740 were_22\VBD\836236 evaluated_23\VBN\670261 for_24\IN\1740 protective_25\JJ\1740 activity_26\NN\30358 against_27\IN\1740 pilocarpine-_28\NN\1740 ,_29\,\1740 kainic_30\JJ\1740 acid-_31\NN\1740 and_32\CC\1740 n-methyl-d-aspartate_33\NN\1740 (nmda)-induced_34\JJ\1740 <e2>seizures</e2>_35\NNS\14081375 in_36\IN\13603305 mice_37\NNS\2329401 ._38\.\1740
D003900_D012640 NONE several_0\JJ\1740 structurally_1\RB\1740 related_2\JJ\1740 metabolites_3\NNS\20090 of_4\IN\1740 progesterone_5\NN\14747338 (_6\-LRB-\1740 3_7\CD\13741022 alpha-hydroxy_8\JJ\1740 pregnane-20-ones_9\NNS\1740 )_10\-RRB-\1740 and_11\CC\1740 <e1>deoxycorticosterone</e1>_12\NN\1740 (_13\-LRB-\1740 3_14\CD\13741022 alpha-hydroxy_15\JJ\1740 pregnane-21-diol-20-ones_16\NNS\1740 )_17\-RRB-\1740 and_18\CC\1740 their_19\PRP$\1740 3_20\CD\13741022 beta-epimers_21\NNS\1740 were_22\VBD\836236 evaluated_23\VBN\670261 for_24\IN\1740 protective_25\JJ\1740 activity_26\NN\30358 against_27\IN\1740 pilocarpine-_28\NN\1740 ,_29\,\1740 kainic_30\JJ\1740 acid-_31\NN\1740 and_32\CC\1740 n-methyl-d-aspartate_33\NN\1740 (nmda)-induced_34\JJ\1740 <e2>seizures</e2>_35\NNS\14081375 in_36\IN\13603305 mice_37\NNS\2329401 ._38\.\1740
D003900_D012640 NONE several_0\JJ\1740 structurally_1\RB\1740 related_2\JJ\1740 metabolites_3\NNS\20090 of_4\IN\1740 progesterone_5\NN\14747338 (_6\-LRB-\1740 3_7\CD\13741022 alpha-hydroxy_8\JJ\1740 pregnane-20-ones_9\NNS\1740 )_10\-RRB-\1740 and_11\CC\1740 deoxycorticosterone_12\NN\1740 (_13\-LRB-\1740 <e1>3_14\CD\13741022 alpha-hydroxy_15\JJ\1740 pregnane-21-diol-20-ones</e1>_16\NNS\1740 )_17\-RRB-\1740 and_18\CC\1740 their_19\PRP$\1740 3_20\CD\13741022 beta-epimers_21\NNS\1740 were_22\VBD\836236 evaluated_23\VBN\670261 for_24\IN\1740 protective_25\JJ\1740 activity_26\NN\30358 against_27\IN\1740 pilocarpine-_28\NN\1740 ,_29\,\1740 kainic_30\JJ\1740 acid-_31\NN\1740 and_32\CC\1740 n-methyl-d-aspartate_33\NN\1740 (nmda)-induced_34\JJ\1740 <e2>seizures</e2>_35\NNS\14081375 in_36\IN\13603305 mice_37\NNS\2329401 ._38\.\1740
D016202_D012640 NONE several_0\JJ\1740 structurally_1\RB\1740 related_2\JJ\1740 metabolites_3\NNS\20090 of_4\IN\1740 progesterone_5\NN\14747338 (_6\-LRB-\1740 3_7\CD\13741022 alpha-hydroxy_8\JJ\1740 pregnane-20-ones_9\NNS\1740 )_10\-RRB-\1740 and_11\CC\1740 deoxycorticosterone_12\NN\1740 (_13\-LRB-\1740 3_14\CD\13741022 alpha-hydroxy_15\JJ\1740 pregnane-21-diol-20-ones_16\NNS\1740 )_17\-RRB-\1740 and_18\CC\1740 their_19\PRP$\1740 3_20\CD\13741022 beta-epimers_21\NNS\1740 were_22\VBD\836236 evaluated_23\VBN\670261 for_24\IN\1740 protective_25\JJ\1740 activity_26\NN\30358 against_27\IN\1740 pilocarpine-_28\NN\1740 ,_29\,\1740 kainic_30\JJ\1740 acid-_31\NN\1740 and_32\CC\1740 <e1>n-methyl-d-aspartate</e1>_33\NN\1740 (nmda)-induced_34\JJ\1740 <e2>seizures</e2>_35\NNS\14081375 in_36\IN\13603305 mice_37\NNS\2329401 ._38\.\1740
D016202_D012640 NONE several_0\JJ\1740 structurally_1\RB\1740 related_2\JJ\1740 metabolites_3\NNS\20090 of_4\IN\1740 progesterone_5\NN\14747338 (_6\-LRB-\1740 3_7\CD\13741022 alpha-hydroxy_8\JJ\1740 pregnane-20-ones_9\NNS\1740 )_10\-RRB-\1740 and_11\CC\1740 deoxycorticosterone_12\NN\1740 (_13\-LRB-\1740 3_14\CD\13741022 alpha-hydroxy_15\JJ\1740 pregnane-21-diol-20-ones_16\NNS\1740 )_17\-RRB-\1740 and_18\CC\1740 their_19\PRP$\1740 3_20\CD\13741022 beta-epimers_21\NNS\1740 were_22\VBD\836236 evaluated_23\VBN\670261 for_24\IN\1740 protective_25\JJ\1740 activity_26\NN\30358 against_27\IN\1740 pilocarpine-_28\NN\1740 ,_29\,\1740 kainic_30\JJ\1740 acid-_31\NN\1740 and_32\CC\1740 n-methyl-d-aspartate_33\NN\1740 <e1>(nmda)-induced</e1>_34\JJ\1740 <e2>seizures</e2>_35\NNS\14081375 in_36\IN\13603305 mice_37\NNS\2329401 ._38\.\1740
D016202_D012640 NONE the_0\DT\1740 steroids_1\NNS\14727670 also_2\RB\1740 caused_3\VBD\1617192 a_4\DT\13649268 dose-dependent_5\JJ\1740 delay_6\NN\15271008 in_7\IN\13603305 <e1>nmda</e1>_8\NN\1740 (_9\-LRB-\1740 257_10\CD\1740 mg/kg_11\NN\1740 ,_12\,\1740 s.c.)-induced_13\JJ\1740 lethality_14\NN\4790449 ,_15\,\1740 but_16\CC\1740 did_17\VBD\1640855 not_18\RB\1740 completely_19\RB\1740 protect_20\VB\1127795 against_21\IN\1740 nmda_22\NN\1740 <e2>seizures</e2>_23\NNS\14081375 or_24\CC\3541091 lethality_25\NN\4790449 ._26\.\1740
D016202_D012640 NONE the_0\DT\1740 steroids_1\NNS\14727670 also_2\RB\1740 caused_3\VBD\1617192 a_4\DT\13649268 dose-dependent_5\JJ\1740 delay_6\NN\15271008 in_7\IN\13603305 nmda_8\NN\1740 (_9\-LRB-\1740 257_10\CD\1740 mg/kg_11\NN\1740 ,_12\,\1740 s.c.)-induced_13\JJ\1740 lethality_14\NN\4790449 ,_15\,\1740 but_16\CC\1740 did_17\VBD\1640855 not_18\RB\1740 completely_19\RB\1740 protect_20\VB\1127795 against_21\IN\1740 <e1>nmda</e1>_22\NN\1740 <e2>seizures</e2>_23\NNS\14081375 or_24\CC\3541091 lethality_25\NN\4790449 ._26\.\1740
D013256_D064420 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 <e1>steroids</e1>_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 <e2>toxicity</e2>_55\NN\13576101 ._56\.\1740
D013256_D064420 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 <e1>steroids</e1>_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 <e2>toxicity</e2>_55\NN\13576101 ._56\.\1740
D013256_D064420 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 <e1>steroids</e1>_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 <e2>toxicity</e2>_55\NN\13576101 ._56\.\1740
D001569_D012640 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 <e1>benzodiazepine</e1>_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 <e2>seizures</e2>_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D001569_D012640 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 <e1>benzodiazepine</e1>_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 <e2>seizure</e2>_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D001569_D064420 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 <e1>benzodiazepine</e1>_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 <e2>toxicity</e2>_55\NN\13576101 ._56\.\1740
D002998_D012640 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 <e1>clonazepam</e1>_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 <e2>seizures</e2>_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D002998_D012640 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 <e1>clonazepam</e1>_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 <e2>seizure</e2>_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D002998_D012640 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 <e2>seizures</e2>_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 <e1>clonazepam</e1>_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D002998_D012640 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 <e2>seizure</e2>_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 <e1>clonazepam</e1>_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 toxicity_55\NN\13576101 ._56\.\1740
D002998_D064420 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 <e1>clonazepam</e1>_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 <e2>toxicity</e2>_55\NN\13576101 ._56\.\1740
D002998_D064420 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 pilocarpine_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 <e1>clonazepam</e1>_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 <e2>toxicity</e2>_55\NN\13576101 ._56\.\1740
D010862_D064420 NONE although_0\IN\1740 the_1\DT\1740 neuroactive_2\JJ\1740 steroids_3\NNS\14727670 were_4\VBD\836236 considerably_5\RB\1740 less_6\RBR\1740 potent_7\JJ\1740 than_8\IN\1740 the_9\DT\1740 benzodiazepine_10\NN\3771443 clonazepam_11\NN\1740 in_12\IN\13603305 protecting_13\VBG\1127795 against_14\IN\1740 <e1>pilocarpine</e1>_15\NN\14712692 seizures_16\NNS\14081375 ,_17\,\1740 steroids_18\NNS\14727670 with_19\IN\1740 the_20\DT\1740 5_21\CD\13741022 alpha,3_22\NN\1740 alpha-configuration_23\NN\1740 had_24\VBD\2108377 comparable_25\JJ\1740 or_26\CC\3541091 higher_27\JJR\1740 protective_28\JJ\1740 index_29\NN\13850304 values_30\NNS\5941423 (_31\-LRB-\1740 td50_32\NN\1740 for_33\IN\1740 motor_34\NN\3699975 impairment_35\NN\7296428 divided_36\VBN\140123 by_37\IN\1740 ed50_38\NN\1740 for_39\IN\1740 seizure_40\JJ\1740 protection_41\NN\407535 )_42\-RRB-\1740 than_43\IN\1740 clonazepam_44\NN\1740 ,_45\,\1740 indicating_46\VBG\952524 that_47\IN\1740 some_48\DT\1740 neuroactive_49\JJ\1740 steroids_50\NNS\14727670 may_51\MD\15209706 have_52\VB\2108377 lower_53\JJR\1740 relative_54\JJ\1740 <e2>toxicity</e2>_55\NN\13576101 ._56\.\1740
9226773
D008094_D018500 CID persistent_0\JJ\1740 <e2>nephrogenic_1\JJ\1740 diabetes_2\NNS\14075199 insipidus</e2>_3\NN\1740 following_4\VBG\1835496 <e1>lithium</e1>_5\NN\14625458 therapy_6\NN\657604 ._7\.\1740
D008094_D018500 CID ten_0\CD\13745420 years_1\NNS\15144371 previously_2\RB\1740 he_3\PRP\14622893 had_4\VBD\2108377 been_5\VBN\836236 diagnosed_6\VBN\644583 to_7\TO\1740 have_8\VB\2108377 <e1>lithium-induced</e1>_9\JJ\1740 <e2>nephrogenic_10\JJ\1740 diabetes_11\NNS\14075199 insipidus</e2>_12\NN\1740 ,_13\,\1740 and_14\CC\1740 lithium_15\NN\14625458 therapy_16\NN\657604 had_17\VBD\2108377 been_18\VBN\836236 discontinued_19\VBN\2609764 ._20\.\1740
D008094_D018500 CID ten_0\CD\13745420 years_1\NNS\15144371 previously_2\RB\1740 he_3\PRP\14622893 had_4\VBD\2108377 been_5\VBN\836236 diagnosed_6\VBN\644583 to_7\TO\1740 have_8\VB\2108377 lithium-induced_9\JJ\1740 <e2>nephrogenic_10\JJ\1740 diabetes_11\NNS\14075199 insipidus</e2>_12\NN\1740 ,_13\,\1740 and_14\CC\1740 <e1>lithium</e1>_15\NN\14625458 therapy_16\NN\657604 had_17\VBD\2108377 been_18\VBN\836236 discontinued_19\VBN\2609764 ._20\.\1740
D008094_D018500 CID he_0\PRP\14622893 remained_1\VBD\2604760 thirsty_2\JJ\1740 and_3\CC\1740 polyuric_4\JJ\1740 despite_5\IN\7501545 cessation_6\NN\7365849 of_7\IN\1740 <e1>lithium</e1>_8\NN\14625458 and_9\CC\1740 investigations_10\NNS\5797597 on_11\IN\1740 admission_12\NN\49003 showed_13\VBD\2137132 him_14\PRP\1740 to_15\TO\1740 have_16\VB\2108377 normal_17\JJ\1740 osmoregulated_18\VBN\1740 thirst_19\NN\14035298 and_20\CC\1740 vasopressin_21\NN\5407119 secretion_22\NN\13526110 ,_23\,\1740 with_24\IN\1740 clear_25\JJ\1740 evidence_26\NN\5816287 of_27\IN\1740 <e2>nephrogenic_28\JJ\1740 diabetes_29\NNS\14075199 insipidus</e2>_30\NN\1740 ._31\.\1740
D008094_D018500 CID <e1>lithium</e1>_0\NN\14625458 induced_1\VBD\1627355 <e2>nephrogenic_2\JJ\1740 diabetes_3\NN\14075199 insipidus</e2>_4\NN\1740 is_5\VBZ\836236 considered_6\VBN\689344 to_7\TO\1740 be_8\VB\836236 reversible_9\JJ\1740 on_10\IN\1740 cessation_11\NN\7365849 of_12\IN\1740 therapy_13\NN\657604 but_14\CC\1740 polyuria_15\NN\14113228 persisted_16\VBD\118523 in_17\IN\13603305 this_18\DT\1740 patient_19\NN\9898892 for_20\IN\1740 ten_21\CD\13745420 years_22\NNS\15144371 after_23\IN\1740 lithium_24\NN\14625458 was_25\VBD\836236 stopped_26\VBN\2452885 ._27\.\1740
D008094_D018500 CID lithium_0\NN\14625458 induced_1\VBD\1627355 <e2>nephrogenic_2\JJ\1740 diabetes_3\NN\14075199 insipidus</e2>_4\NN\1740 is_5\VBZ\836236 considered_6\VBN\689344 to_7\TO\1740 be_8\VB\836236 reversible_9\JJ\1740 on_10\IN\1740 cessation_11\NN\7365849 of_12\IN\1740 therapy_13\NN\657604 but_14\CC\1740 polyuria_15\NN\14113228 persisted_16\VBD\118523 in_17\IN\13603305 this_18\DT\1740 patient_19\NN\9898892 for_20\IN\1740 ten_21\CD\13745420 years_22\NNS\15144371 after_23\IN\1740 <e1>lithium</e1>_24\NN\14625458 was_25\VBD\836236 stopped_26\VBN\2452885 ._27\.\1740
D008094_D018500 CID we_0\PRP\1740 discuss_1\VBP\1033527 the_2\DT\1740 possible_3\JJ\1740 renal_4\JJ\1740 mechanisms_5\NNS\13446390 and_6\CC\1740 the_7\DT\1740 implications_8\NNS\5774614 for_9\IN\1740 management_10\NN\1123598 of_11\IN\1740 patients_12\NNS\9898892 with_13\IN\1740 <e1>lithium-induced</e1>_14\JJ\1740 <e2>nephrogenic_15\JJ\1740 diabetes_16\NNS\14075199 insipidus</e2>_17\NN\1740 ._18\.\1740
D008094_D011141 CID he_0\PRP\14622893 remained_1\VBD\2604760 thirsty_2\JJ\1740 and_3\CC\1740 <e2>polyuric</e2>_4\JJ\1740 despite_5\IN\7501545 cessation_6\NN\7365849 of_7\IN\1740 <e1>lithium</e1>_8\NN\14625458 and_9\CC\1740 investigations_10\NNS\5797597 on_11\IN\1740 admission_12\NN\49003 showed_13\VBD\2137132 him_14\PRP\1740 to_15\TO\1740 have_16\VB\2108377 normal_17\JJ\1740 osmoregulated_18\VBN\1740 thirst_19\NN\14035298 and_20\CC\1740 vasopressin_21\NN\5407119 secretion_22\NN\13526110 ,_23\,\1740 with_24\IN\1740 clear_25\JJ\1740 evidence_26\NN\5816287 of_27\IN\1740 nephrogenic_28\JJ\1740 diabetes_29\NNS\14075199 insipidus_30\NN\1740 ._31\.\1740
D008094_D011141 CID <e1>lithium</e1>_0\NN\14625458 induced_1\VBD\1627355 nephrogenic_2\JJ\1740 diabetes_3\NN\14075199 insipidus_4\NN\1740 is_5\VBZ\836236 considered_6\VBN\689344 to_7\TO\1740 be_8\VB\836236 reversible_9\JJ\1740 on_10\IN\1740 cessation_11\NN\7365849 of_12\IN\1740 therapy_13\NN\657604 but_14\CC\1740 <e2>polyuria</e2>_15\NN\14113228 persisted_16\VBD\118523 in_17\IN\13603305 this_18\DT\1740 patient_19\NN\9898892 for_20\IN\1740 ten_21\CD\13745420 years_22\NNS\15144371 after_23\IN\1740 lithium_24\NN\14625458 was_25\VBD\836236 stopped_26\VBN\2452885 ._27\.\1740
D008094_D011141 CID lithium_0\NN\14625458 induced_1\VBD\1627355 nephrogenic_2\JJ\1740 diabetes_3\NN\14075199 insipidus_4\NN\1740 is_5\VBZ\836236 considered_6\VBN\689344 to_7\TO\1740 be_8\VB\836236 reversible_9\JJ\1740 on_10\IN\1740 cessation_11\NN\7365849 of_12\IN\1740 therapy_13\NN\657604 but_14\CC\1740 <e2>polyuria</e2>_15\NN\14113228 persisted_16\VBD\118523 in_17\IN\13603305 this_18\DT\1740 patient_19\NN\9898892 for_20\IN\1740 ten_21\CD\13745420 years_22\NNS\15144371 after_23\IN\1740 <e1>lithium</e1>_24\NN\14625458 was_25\VBD\836236 stopped_26\VBN\2452885 ._27\.\1740
D014667_D011141 NONE he_0\PRP\14622893 remained_1\VBD\2604760 thirsty_2\JJ\1740 and_3\CC\1740 <e2>polyuric</e2>_4\JJ\1740 despite_5\IN\7501545 cessation_6\NN\7365849 of_7\IN\1740 lithium_8\NN\14625458 and_9\CC\1740 investigations_10\NNS\5797597 on_11\IN\1740 admission_12\NN\49003 showed_13\VBD\2137132 him_14\PRP\1740 to_15\TO\1740 have_16\VB\2108377 normal_17\JJ\1740 osmoregulated_18\VBN\1740 thirst_19\NN\14035298 and_20\CC\1740 <e1>vasopressin</e1>_21\NN\5407119 secretion_22\NN\13526110 ,_23\,\1740 with_24\IN\1740 clear_25\JJ\1740 evidence_26\NN\5816287 of_27\IN\1740 nephrogenic_28\JJ\1740 diabetes_29\NNS\14075199 insipidus_30\NN\1740 ._31\.\1740
D014667_D018500 NONE he_0\PRP\14622893 remained_1\VBD\2604760 thirsty_2\JJ\1740 and_3\CC\1740 polyuric_4\JJ\1740 despite_5\IN\7501545 cessation_6\NN\7365849 of_7\IN\1740 lithium_8\NN\14625458 and_9\CC\1740 investigations_10\NNS\5797597 on_11\IN\1740 admission_12\NN\49003 showed_13\VBD\2137132 him_14\PRP\1740 to_15\TO\1740 have_16\VB\2108377 normal_17\JJ\1740 osmoregulated_18\VBN\1740 thirst_19\NN\14035298 and_20\CC\1740 <e1>vasopressin</e1>_21\NN\5407119 secretion_22\NN\13526110 ,_23\,\1740 with_24\IN\1740 clear_25\JJ\1740 evidence_26\NN\5816287 of_27\IN\1740 <e2>nephrogenic_28\JJ\1740 diabetes_29\NNS\14075199 insipidus</e2>_30\NN\1740 ._31\.\1740
3780697
D005283_D009127 CID post-operative_0\JJ\1740 <e2>rigidity</e2>_1\NN\5023233 after_2\IN\1740 <e1>fentanyl</e1>_3\JJ\1740 administration_4\NN\1133281 ._5\.\1740
D005283_D009127 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 thoraco-abdominal_3\JJ\1740 <e2>rigidity</e2>_4\NN\5023233 leading_5\VBG\1752884 to_6\TO\1740 respiratory_7\JJ\1740 failure_8\NN\66216 is_9\VBZ\836236 described_10\VBN\1001294 in_11\IN\13603305 the_12\DT\1740 post-operative_13\JJ\1740 period_14\NN\13575869 in_15\IN\13603305 an_16\DT\6697703 elderly_17\JJ\1740 patient_18\NN\9898892 who_19\WP\8299493 received_20\VBD\2210855 a_21\DT\13649268 moderate_22\JJ\1740 dose_23\NN\3740161 of_24\IN\1740 <e1>fentanyl</e1>_25\NN\2707683 ._26\.\1740
D005283_D012131 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 thoraco-abdominal_3\JJ\1740 rigidity_4\NN\5023233 leading_5\VBG\1752884 to_6\TO\1740 <e2>respiratory_7\JJ\1740 failure</e2>_8\NN\66216 is_9\VBZ\836236 described_10\VBN\1001294 in_11\IN\13603305 the_12\DT\1740 post-operative_13\JJ\1740 period_14\NN\13575869 in_15\IN\13603305 an_16\DT\6697703 elderly_17\JJ\1740 patient_18\NN\9898892 who_19\WP\8299493 received_20\VBD\2210855 a_21\DT\13649268 moderate_22\JJ\1740 dose_23\NN\3740161 of_24\IN\1740 <e1>fentanyl</e1>_25\NN\2707683 ._26\.\1740
19203554
D012460_D005921 NONE proteinase_0\NN\14732946 3-antineutrophil_1\NN\1740 cytoplasmic_2\JJ\1740 antibody-(pr3-anca_3\NN\1740 )_4\-RRB-\1740 positive_5\JJ\1740 necrotizing_6\NN\1740 <e2>glomerulonephritis</e2>_7\NN\14113798 after_8\IN\1740 restarting_9\VBG\1857717 <e1>sulphasalazine</e1>_10\NN\1740 treatment_11\NN\654885 ._12\.\1740
D012460_D005921 NONE this_0\DT\1740 case_1\NN\7283608 suggests_2\VBZ\1010118 that_3\IN\1740 <e1>sulphasalazine</e1>_4\NN\1740 can_5\MD\3094503 induce_6\VB\1627355 pr3-anca-positive_7\NN\1740 necrotizing_8\NN\1740 <e2>glomerulonephritis</e2>_9\NN\14113798 ._10\.\1740
D012460_D003093 NONE a_0\DT\13649268 59-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 <e2>ulcerative_4\JJ\1740 colitis</e2>_5\NN\14336539 developed_6\VBD\1753788 red_7\JJ\1740 eyes_8\NNS\5945642 ,_9\,\1740 pleural_10\JJ\1740 effusion_11\NN\6880249 ,_12\,\1740 eosinophilia_13\NN\14299637 and_14\CC\1740 urinary_15\JJ\1740 abnormalities_16\NNS\14034177 after_17\IN\1740 restarting_18\NN\1740 of_19\IN\1740 <e1>sulphasalazine</e1>_20\NN\1740 treatment_21\NN\654885 ._22\.\1740
D012460_D005128 NONE a_0\DT\13649268 59-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 ulcerative_4\JJ\1740 colitis_5\NN\14336539 developed_6\VBD\1753788 <e2>red_7\JJ\1740 eyes</e2>_8\NNS\5945642 ,_9\,\1740 pleural_10\JJ\1740 effusion_11\NN\6880249 ,_12\,\1740 eosinophilia_13\NN\14299637 and_14\CC\1740 urinary_15\JJ\1740 abnormalities_16\NNS\14034177 after_17\IN\1740 restarting_18\NN\1740 of_19\IN\1740 <e1>sulphasalazine</e1>_20\NN\1740 treatment_21\NN\654885 ._22\.\1740
D012460_D005128 NONE although_0\IN\1740 cessation_1\NN\7365849 of_2\IN\1740 <e1>sulphasalazine</e1>_3\JJ\1740 treatment_4\NN\654885 resulted_5\VBD\2633881 in_6\IN\13603305 improvements_7\NNS\7359599 in_8\IN\13603305 fever_9\NN\14299637 ,_10\,\1740 <e2>red_11\JJ\1740 eyes</e2>_12\NNS\5945642 ,_13\,\1740 chest_14\VB\1740 pain_15\NN\14299637 ,_16\,\1740 titer_17\NN\5038593 of_18\IN\1740 c-reactive_19\JJ\1740 protein_20\NN\14944888 and_21\CC\1740 volume_22\NN\33615 of_23\IN\1740 the_24\DT\1740 pleural_25\JJ\1740 effusions_26\NNS\6880249 ,_27\,\1740 we_28\PRP\1740 initiated_29\VBD\1617192 steroid_30\NN\14727670 therapy_31\NN\657604 ,_32\,\1740 because_33\IN\1740 pr3-anca_34\NN\1740 titer_35\NN\5038593 rose_36\VBD\1835496 to_37\IN\1740 320_38\CD\1740 eu_39\NNP\14625458 ,_40\,\1740 eosinophil_41\NN\5449959 count_42\NN\13582013 increased_43\VBD\169651 to_44\TO\1740 1,100_45\CD\1740 cells/microl_46\NN\1740 ,_47\,\1740 and_48\CC\1740 the_49\DT\1740 pleural_50\JJ\1740 effusion_51\NN\6880249 remained_52\VBD\2604760 ._53\.\1740
D012460_D010996 CID a_0\DT\13649268 59-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 ulcerative_4\JJ\1740 colitis_5\NN\14336539 developed_6\VBD\1753788 red_7\JJ\1740 eyes_8\NNS\5945642 ,_9\,\1740 <e2>pleural_10\JJ\1740 effusion</e2>_11\NN\6880249 ,_12\,\1740 eosinophilia_13\NN\14299637 and_14\CC\1740 urinary_15\JJ\1740 abnormalities_16\NNS\14034177 after_17\IN\1740 restarting_18\NN\1740 of_19\IN\1740 <e1>sulphasalazine</e1>_20\NN\1740 treatment_21\NN\654885 ._22\.\1740
D012460_D010996 CID although_0\IN\1740 cessation_1\NN\7365849 of_2\IN\1740 <e1>sulphasalazine</e1>_3\JJ\1740 treatment_4\NN\654885 resulted_5\VBD\2633881 in_6\IN\13603305 improvements_7\NNS\7359599 in_8\IN\13603305 fever_9\NN\14299637 ,_10\,\1740 red_11\JJ\1740 eyes_12\NNS\5945642 ,_13\,\1740 chest_14\VB\1740 pain_15\NN\14299637 ,_16\,\1740 titer_17\NN\5038593 of_18\IN\1740 c-reactive_19\JJ\1740 protein_20\NN\14944888 and_21\CC\1740 volume_22\NN\33615 of_23\IN\1740 the_24\DT\1740 <e2>pleural_25\JJ\1740 effusions</e2>_26\NNS\6880249 ,_27\,\1740 we_28\PRP\1740 initiated_29\VBD\1617192 steroid_30\NN\14727670 therapy_31\NN\657604 ,_32\,\1740 because_33\IN\1740 pr3-anca_34\NN\1740 titer_35\NN\5038593 rose_36\VBD\1835496 to_37\IN\1740 320_38\CD\1740 eu_39\NNP\14625458 ,_40\,\1740 eosinophil_41\NN\5449959 count_42\NN\13582013 increased_43\VBD\169651 to_44\TO\1740 1,100_45\CD\1740 cells/microl_46\NN\1740 ,_47\,\1740 and_48\CC\1740 the_49\DT\1740 pleural_50\JJ\1740 effusion_51\NN\6880249 remained_52\VBD\2604760 ._53\.\1740
D012460_D010996 CID although_0\IN\1740 cessation_1\NN\7365849 of_2\IN\1740 <e1>sulphasalazine</e1>_3\JJ\1740 treatment_4\NN\654885 resulted_5\VBD\2633881 in_6\IN\13603305 improvements_7\NNS\7359599 in_8\IN\13603305 fever_9\NN\14299637 ,_10\,\1740 red_11\JJ\1740 eyes_12\NNS\5945642 ,_13\,\1740 chest_14\VB\1740 pain_15\NN\14299637 ,_16\,\1740 titer_17\NN\5038593 of_18\IN\1740 c-reactive_19\JJ\1740 protein_20\NN\14944888 and_21\CC\1740 volume_22\NN\33615 of_23\IN\1740 the_24\DT\1740 pleural_25\JJ\1740 effusions_26\NNS\6880249 ,_27\,\1740 we_28\PRP\1740 initiated_29\VBD\1617192 steroid_30\NN\14727670 therapy_31\NN\657604 ,_32\,\1740 because_33\IN\1740 pr3-anca_34\NN\1740 titer_35\NN\5038593 rose_36\VBD\1835496 to_37\IN\1740 320_38\CD\1740 eu_39\NNP\14625458 ,_40\,\1740 eosinophil_41\NN\5449959 count_42\NN\13582013 increased_43\VBD\169651 to_44\TO\1740 1,100_45\CD\1740 cells/microl_46\NN\1740 ,_47\,\1740 and_48\CC\1740 the_49\DT\1740 <e2>pleural_50\JJ\1740 effusion</e2>_51\NN\6880249 remained_52\VBD\2604760 ._53\.\1740
D012460_D004802 NONE a_0\DT\13649268 59-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 ulcerative_4\JJ\1740 colitis_5\NN\14336539 developed_6\VBD\1753788 red_7\JJ\1740 eyes_8\NNS\5945642 ,_9\,\1740 pleural_10\JJ\1740 effusion_11\NN\6880249 ,_12\,\1740 <e2>eosinophilia</e2>_13\NN\14299637 and_14\CC\1740 urinary_15\JJ\1740 abnormalities_16\NNS\14034177 after_17\IN\1740 restarting_18\NN\1740 of_19\IN\1740 <e1>sulphasalazine</e1>_20\NN\1740 treatment_21\NN\654885 ._22\.\1740
D012460_D001745 NONE a_0\DT\13649268 59-year-old_1\JJ\1740 woman_2\NN\9605289 with_3\IN\1740 ulcerative_4\JJ\1740 colitis_5\NN\14336539 developed_6\VBD\1753788 red_7\JJ\1740 eyes_8\NNS\5945642 ,_9\,\1740 pleural_10\JJ\1740 effusion_11\NN\6880249 ,_12\,\1740 eosinophilia_13\NN\14299637 and_14\CC\1740 <e2>urinary_15\JJ\1740 abnormalities</e2>_16\NNS\14034177 after_17\IN\1740 restarting_18\NN\1740 of_19\IN\1740 <e1>sulphasalazine</e1>_20\NN\1740 treatment_21\NN\654885 ._22\.\1740
D012460_D005334 CID although_0\IN\1740 cessation_1\NN\7365849 of_2\IN\1740 <e1>sulphasalazine</e1>_3\JJ\1740 treatment_4\NN\654885 resulted_5\VBD\2633881 in_6\IN\13603305 improvements_7\NNS\7359599 in_8\IN\13603305 <e2>fever</e2>_9\NN\14299637 ,_10\,\1740 red_11\JJ\1740 eyes_12\NNS\5945642 ,_13\,\1740 chest_14\VB\1740 pain_15\NN\14299637 ,_16\,\1740 titer_17\NN\5038593 of_18\IN\1740 c-reactive_19\JJ\1740 protein_20\NN\14944888 and_21\CC\1740 volume_22\NN\33615 of_23\IN\1740 the_24\DT\1740 pleural_25\JJ\1740 effusions_26\NNS\6880249 ,_27\,\1740 we_28\PRP\1740 initiated_29\VBD\1617192 steroid_30\NN\14727670 therapy_31\NN\657604 ,_32\,\1740 because_33\IN\1740 pr3-anca_34\NN\1740 titer_35\NN\5038593 rose_36\VBD\1835496 to_37\IN\1740 320_38\CD\1740 eu_39\NNP\14625458 ,_40\,\1740 eosinophil_41\NN\5449959 count_42\NN\13582013 increased_43\VBD\169651 to_44\TO\1740 1,100_45\CD\1740 cells/microl_46\NN\1740 ,_47\,\1740 and_48\CC\1740 the_49\DT\1740 pleural_50\JJ\1740 effusion_51\NN\6880249 remained_52\VBD\2604760 ._53\.\1740
D012460_D002637 NONE although_0\IN\1740 cessation_1\NN\7365849 of_2\IN\1740 <e1>sulphasalazine</e1>_3\JJ\1740 treatment_4\NN\654885 resulted_5\VBD\2633881 in_6\IN\13603305 improvements_7\NNS\7359599 in_8\IN\13603305 fever_9\NN\14299637 ,_10\,\1740 red_11\JJ\1740 eyes_12\NNS\5945642 ,_13\,\1740 <e2>chest_14\VB\1740 pain</e2>_15\NN\14299637 ,_16\,\1740 titer_17\NN\5038593 of_18\IN\1740 c-reactive_19\JJ\1740 protein_20\NN\14944888 and_21\CC\1740 volume_22\NN\33615 of_23\IN\1740 the_24\DT\1740 pleural_25\JJ\1740 effusions_26\NNS\6880249 ,_27\,\1740 we_28\PRP\1740 initiated_29\VBD\1617192 steroid_30\NN\14727670 therapy_31\NN\657604 ,_32\,\1740 because_33\IN\1740 pr3-anca_34\NN\1740 titer_35\NN\5038593 rose_36\VBD\1835496 to_37\IN\1740 320_38\CD\1740 eu_39\NNP\14625458 ,_40\,\1740 eosinophil_41\NN\5449959 count_42\NN\13582013 increased_43\VBD\169651 to_44\TO\1740 1,100_45\CD\1740 cells/microl_46\NN\1740 ,_47\,\1740 and_48\CC\1740 the_49\DT\1740 pleural_50\JJ\1740 effusion_51\NN\6880249 remained_52\VBD\2604760 ._53\.\1740
D013256_D005334 NONE although_0\IN\1740 cessation_1\NN\7365849 of_2\IN\1740 sulphasalazine_3\JJ\1740 treatment_4\NN\654885 resulted_5\VBD\2633881 in_6\IN\13603305 improvements_7\NNS\7359599 in_8\IN\13603305 <e2>fever</e2>_9\NN\14299637 ,_10\,\1740 red_11\JJ\1740 eyes_12\NNS\5945642 ,_13\,\1740 chest_14\VB\1740 pain_15\NN\14299637 ,_16\,\1740 titer_17\NN\5038593 of_18\IN\1740 c-reactive_19\JJ\1740 protein_20\NN\14944888 and_21\CC\1740 volume_22\NN\33615 of_23\IN\1740 the_24\DT\1740 pleural_25\JJ\1740 effusions_26\NNS\6880249 ,_27\,\1740 we_28\PRP\1740 initiated_29\VBD\1617192 <e1>steroid</e1>_30\NN\14727670 therapy_31\NN\657604 ,_32\,\1740 because_33\IN\1740 pr3-anca_34\NN\1740 titer_35\NN\5038593 rose_36\VBD\1835496 to_37\IN\1740 320_38\CD\1740 eu_39\NNP\14625458 ,_40\,\1740 eosinophil_41\NN\5449959 count_42\NN\13582013 increased_43\VBD\169651 to_44\TO\1740 1,100_45\CD\1740 cells/microl_46\NN\1740 ,_47\,\1740 and_48\CC\1740 the_49\DT\1740 pleural_50\JJ\1740 effusion_51\NN\6880249 remained_52\VBD\2604760 ._53\.\1740
D013256_D005128 NONE although_0\IN\1740 cessation_1\NN\7365849 of_2\IN\1740 sulphasalazine_3\JJ\1740 treatment_4\NN\654885 resulted_5\VBD\2633881 in_6\IN\13603305 improvements_7\NNS\7359599 in_8\IN\13603305 fever_9\NN\14299637 ,_10\,\1740 <e2>red_11\JJ\1740 eyes</e2>_12\NNS\5945642 ,_13\,\1740 chest_14\VB\1740 pain_15\NN\14299637 ,_16\,\1740 titer_17\NN\5038593 of_18\IN\1740 c-reactive_19\JJ\1740 protein_20\NN\14944888 and_21\CC\1740 volume_22\NN\33615 of_23\IN\1740 the_24\DT\1740 pleural_25\JJ\1740 effusions_26\NNS\6880249 ,_27\,\1740 we_28\PRP\1740 initiated_29\VBD\1617192 <e1>steroid</e1>_30\NN\14727670 therapy_31\NN\657604 ,_32\,\1740 because_33\IN\1740 pr3-anca_34\NN\1740 titer_35\NN\5038593 rose_36\VBD\1835496 to_37\IN\1740 320_38\CD\1740 eu_39\NNP\14625458 ,_40\,\1740 eosinophil_41\NN\5449959 count_42\NN\13582013 increased_43\VBD\169651 to_44\TO\1740 1,100_45\CD\1740 cells/microl_46\NN\1740 ,_47\,\1740 and_48\CC\1740 the_49\DT\1740 pleural_50\JJ\1740 effusion_51\NN\6880249 remained_52\VBD\2604760 ._53\.\1740
D013256_D002637 NONE although_0\IN\1740 cessation_1\NN\7365849 of_2\IN\1740 sulphasalazine_3\JJ\1740 treatment_4\NN\654885 resulted_5\VBD\2633881 in_6\IN\13603305 improvements_7\NNS\7359599 in_8\IN\13603305 fever_9\NN\14299637 ,_10\,\1740 red_11\JJ\1740 eyes_12\NNS\5945642 ,_13\,\1740 <e2>chest_14\VB\1740 pain</e2>_15\NN\14299637 ,_16\,\1740 titer_17\NN\5038593 of_18\IN\1740 c-reactive_19\JJ\1740 protein_20\NN\14944888 and_21\CC\1740 volume_22\NN\33615 of_23\IN\1740 the_24\DT\1740 pleural_25\JJ\1740 effusions_26\NNS\6880249 ,_27\,\1740 we_28\PRP\1740 initiated_29\VBD\1617192 <e1>steroid</e1>_30\NN\14727670 therapy_31\NN\657604 ,_32\,\1740 because_33\IN\1740 pr3-anca_34\NN\1740 titer_35\NN\5038593 rose_36\VBD\1835496 to_37\IN\1740 320_38\CD\1740 eu_39\NNP\14625458 ,_40\,\1740 eosinophil_41\NN\5449959 count_42\NN\13582013 increased_43\VBD\169651 to_44\TO\1740 1,100_45\CD\1740 cells/microl_46\NN\1740 ,_47\,\1740 and_48\CC\1740 the_49\DT\1740 pleural_50\JJ\1740 effusion_51\NN\6880249 remained_52\VBD\2604760 ._53\.\1740
D013256_D010996 NONE although_0\IN\1740 cessation_1\NN\7365849 of_2\IN\1740 sulphasalazine_3\JJ\1740 treatment_4\NN\654885 resulted_5\VBD\2633881 in_6\IN\13603305 improvements_7\NNS\7359599 in_8\IN\13603305 fever_9\NN\14299637 ,_10\,\1740 red_11\JJ\1740 eyes_12\NNS\5945642 ,_13\,\1740 chest_14\VB\1740 pain_15\NN\14299637 ,_16\,\1740 titer_17\NN\5038593 of_18\IN\1740 c-reactive_19\JJ\1740 protein_20\NN\14944888 and_21\CC\1740 volume_22\NN\33615 of_23\IN\1740 the_24\DT\1740 <e2>pleural_25\JJ\1740 effusions</e2>_26\NNS\6880249 ,_27\,\1740 we_28\PRP\1740 initiated_29\VBD\1617192 <e1>steroid</e1>_30\NN\14727670 therapy_31\NN\657604 ,_32\,\1740 because_33\IN\1740 pr3-anca_34\NN\1740 titer_35\NN\5038593 rose_36\VBD\1835496 to_37\IN\1740 320_38\CD\1740 eu_39\NNP\14625458 ,_40\,\1740 eosinophil_41\NN\5449959 count_42\NN\13582013 increased_43\VBD\169651 to_44\TO\1740 1,100_45\CD\1740 cells/microl_46\NN\1740 ,_47\,\1740 and_48\CC\1740 the_49\DT\1740 pleural_50\JJ\1740 effusion_51\NN\6880249 remained_52\VBD\2604760 ._53\.\1740
D013256_D010996 NONE although_0\IN\1740 cessation_1\NN\7365849 of_2\IN\1740 sulphasalazine_3\JJ\1740 treatment_4\NN\654885 resulted_5\VBD\2633881 in_6\IN\13603305 improvements_7\NNS\7359599 in_8\IN\13603305 fever_9\NN\14299637 ,_10\,\1740 red_11\JJ\1740 eyes_12\NNS\5945642 ,_13\,\1740 chest_14\VB\1740 pain_15\NN\14299637 ,_16\,\1740 titer_17\NN\5038593 of_18\IN\1740 c-reactive_19\JJ\1740 protein_20\NN\14944888 and_21\CC\1740 volume_22\NN\33615 of_23\IN\1740 the_24\DT\1740 pleural_25\JJ\1740 effusions_26\NNS\6880249 ,_27\,\1740 we_28\PRP\1740 initiated_29\VBD\1617192 <e1>steroid</e1>_30\NN\14727670 therapy_31\NN\657604 ,_32\,\1740 because_33\IN\1740 pr3-anca_34\NN\1740 titer_35\NN\5038593 rose_36\VBD\1835496 to_37\IN\1740 320_38\CD\1740 eu_39\NNP\14625458 ,_40\,\1740 eosinophil_41\NN\5449959 count_42\NN\13582013 increased_43\VBD\169651 to_44\TO\1740 1,100_45\CD\1740 cells/microl_46\NN\1740 ,_47\,\1740 and_48\CC\1740 the_49\DT\1740 <e2>pleural_50\JJ\1740 effusion</e2>_51\NN\6880249 remained_52\VBD\2604760 ._53\.\1740
D013256_D010996 NONE one_0\CD\13741022 month_1\NN\15113229 after_2\IN\1740 <e1>steroid</e1>_3\NN\14727670 therapy_4\NN\657604 ,_5\,\1740 the_6\DT\1740 <e2>pleural_7\JJ\1740 effusion</e2>_8\NN\6880249 disappeared_9\VBD\2609764 ,_10\,\1740 and_11\CC\1740 pr3-anca_12\NN\1740 titer_13\NN\5038593 normalized_14\VBD\109660 3_15\CD\13741022 months_16\NNS\15113229 later_17\RB\1740 ._18\.\1740
12842176
D001556_D020258 NONE effect_0\NN\34213 of_1\IN\1740 <e1>lindane</e1>_2\NN\14919948 on_3\IN\1740 hepatic_4\JJ\1740 and_5\CC\1740 brain_6\NN\5462674 cytochrome_7\NN\14888884 p450s_8\NN\1740 and_9\CC\1740 influence_10\NN\5190804 of_11\IN\1740 p450_12\NN\1740 modulation_13\NN\7044917 in_14\IN\13603305 lindane_15\NN\14919948 induced_16\VBN\1627355 <e2>neurotoxicity</e2>_17\NN\1740 ._18\.\1740
D001556_D020258 NONE effect_0\NN\34213 of_1\IN\1740 lindane_2\NN\14919948 on_3\IN\1740 hepatic_4\JJ\1740 and_5\CC\1740 brain_6\NN\5462674 cytochrome_7\NN\14888884 p450s_8\NN\1740 and_9\CC\1740 influence_10\NN\5190804 of_11\IN\1740 p450_12\NN\1740 modulation_13\NN\7044917 in_14\IN\13603305 <e1>lindane</e1>_15\NN\14919948 induced_16\VBN\1627355 <e2>neurotoxicity</e2>_17\NN\1740 ._18\.\1740
D008748_D012640 NONE induction_0\NN\7450842 studies_1\NNS\635850 have_2\VBP\2108377 further_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 while_6\IN\15122231 pretreatment_7\NN\1740 of_8\IN\1740 <e1>3-methylcholanthrene</e1>_9\NN\1740 (_10\-LRB-\1740 mc_11\NN\15286249 )_12\-RRB-\1740 ,_13\,\1740 an_14\DT\6697703 inducer_15\NN\14778436 of_16\IN\1740 p4501a1/1a2_17\NN\1740 ,_18\,\1740 did_19\VBD\1640855 not_20\RB\1740 produce_21\VB\1617192 any_22\DT\1740 significant_23\JJ\1740 effect_24\NN\34213 in_25\IN\13603305 the_26\DT\1740 incidence_27\NN\13821570 of_28\IN\1740 lindane_29\NN\14919948 induced_30\JJ\1740 <e2>convulsions</e2>_31\NNS\14081375 ,_32\,\1740 pretreatment_33\NN\1740 with_34\IN\1740 phenobarbital_35\JJ\1740 (_36\-LRB-\1740 pb_37\NN\14625458 )_38\-RRB-\1740 ,_39\,\1740 an_40\DT\6697703 inducer_41\NN\14778436 of_42\IN\1740 p450_43\NN\1740 2b1/2b2_44\CD\1740 or_45\CC\3541091 ethanol_46\NN\14708720 ,_47\,\1740 an_48\DT\6697703 inducer_49\NN\14778436 of_50\IN\1740 p450_51\NN\1740 2e1_52\NN\1740 catalysed_53\JJ\1740 reactions_54\NNS\13446390 ,_55\,\1740 significantly_56\RB\1740 increased_57\VBD\169651 the_58\DT\1740 incidence_59\NN\13821570 of_60\IN\1740 lindane_61\NN\14919948 induced_62\VBN\1627355 convulsions_63\NNS\14081375 ._64\.\1740
D008748_D012640 NONE induction_0\NN\7450842 studies_1\NNS\635850 have_2\VBP\2108377 further_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 while_6\IN\15122231 pretreatment_7\NN\1740 of_8\IN\1740 <e1>3-methylcholanthrene</e1>_9\NN\1740 (_10\-LRB-\1740 mc_11\NN\15286249 )_12\-RRB-\1740 ,_13\,\1740 an_14\DT\6697703 inducer_15\NN\14778436 of_16\IN\1740 p4501a1/1a2_17\NN\1740 ,_18\,\1740 did_19\VBD\1640855 not_20\RB\1740 produce_21\VB\1617192 any_22\DT\1740 significant_23\JJ\1740 effect_24\NN\34213 in_25\IN\13603305 the_26\DT\1740 incidence_27\NN\13821570 of_28\IN\1740 lindane_29\NN\14919948 induced_30\JJ\1740 convulsions_31\NNS\14081375 ,_32\,\1740 pretreatment_33\NN\1740 with_34\IN\1740 phenobarbital_35\JJ\1740 (_36\-LRB-\1740 pb_37\NN\14625458 )_38\-RRB-\1740 ,_39\,\1740 an_40\DT\6697703 inducer_41\NN\14778436 of_42\IN\1740 p450_43\NN\1740 2b1/2b2_44\CD\1740 or_45\CC\3541091 ethanol_46\NN\14708720 ,_47\,\1740 an_48\DT\6697703 inducer_49\NN\14778436 of_50\IN\1740 p450_51\NN\1740 2e1_52\NN\1740 catalysed_53\JJ\1740 reactions_54\NNS\13446390 ,_55\,\1740 significantly_56\RB\1740 increased_57\VBD\169651 the_58\DT\1740 incidence_59\NN\13821570 of_60\IN\1740 lindane_61\NN\14919948 induced_62\VBN\1627355 <e2>convulsions</e2>_63\NNS\14081375 ._64\.\1740
D008748_D012640 NONE induction_0\NN\7450842 studies_1\NNS\635850 have_2\VBP\2108377 further_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 while_6\IN\15122231 pretreatment_7\NN\1740 of_8\IN\1740 3-methylcholanthrene_9\NN\1740 (_10\-LRB-\1740 <e1>mc</e1>_11\NN\15286249 )_12\-RRB-\1740 ,_13\,\1740 an_14\DT\6697703 inducer_15\NN\14778436 of_16\IN\1740 p4501a1/1a2_17\NN\1740 ,_18\,\1740 did_19\VBD\1640855 not_20\RB\1740 produce_21\VB\1617192 any_22\DT\1740 significant_23\JJ\1740 effect_24\NN\34213 in_25\IN\13603305 the_26\DT\1740 incidence_27\NN\13821570 of_28\IN\1740 lindane_29\NN\14919948 induced_30\JJ\1740 <e2>convulsions</e2>_31\NNS\14081375 ,_32\,\1740 pretreatment_33\NN\1740 with_34\IN\1740 phenobarbital_35\JJ\1740 (_36\-LRB-\1740 pb_37\NN\14625458 )_38\-RRB-\1740 ,_39\,\1740 an_40\DT\6697703 inducer_41\NN\14778436 of_42\IN\1740 p450_43\NN\1740 2b1/2b2_44\CD\1740 or_45\CC\3541091 ethanol_46\NN\14708720 ,_47\,\1740 an_48\DT\6697703 inducer_49\NN\14778436 of_50\IN\1740 p450_51\NN\1740 2e1_52\NN\1740 catalysed_53\JJ\1740 reactions_54\NNS\13446390 ,_55\,\1740 significantly_56\RB\1740 increased_57\VBD\169651 the_58\DT\1740 incidence_59\NN\13821570 of_60\IN\1740 lindane_61\NN\14919948 induced_62\VBN\1627355 convulsions_63\NNS\14081375 ._64\.\1740
D008748_D012640 NONE induction_0\NN\7450842 studies_1\NNS\635850 have_2\VBP\2108377 further_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 while_6\IN\15122231 pretreatment_7\NN\1740 of_8\IN\1740 3-methylcholanthrene_9\NN\1740 (_10\-LRB-\1740 <e1>mc</e1>_11\NN\15286249 )_12\-RRB-\1740 ,_13\,\1740 an_14\DT\6697703 inducer_15\NN\14778436 of_16\IN\1740 p4501a1/1a2_17\NN\1740 ,_18\,\1740 did_19\VBD\1640855 not_20\RB\1740 produce_21\VB\1617192 any_22\DT\1740 significant_23\JJ\1740 effect_24\NN\34213 in_25\IN\13603305 the_26\DT\1740 incidence_27\NN\13821570 of_28\IN\1740 lindane_29\NN\14919948 induced_30\JJ\1740 convulsions_31\NNS\14081375 ,_32\,\1740 pretreatment_33\NN\1740 with_34\IN\1740 phenobarbital_35\JJ\1740 (_36\-LRB-\1740 pb_37\NN\14625458 )_38\-RRB-\1740 ,_39\,\1740 an_40\DT\6697703 inducer_41\NN\14778436 of_42\IN\1740 p450_43\NN\1740 2b1/2b2_44\CD\1740 or_45\CC\3541091 ethanol_46\NN\14708720 ,_47\,\1740 an_48\DT\6697703 inducer_49\NN\14778436 of_50\IN\1740 p450_51\NN\1740 2e1_52\NN\1740 catalysed_53\JJ\1740 reactions_54\NNS\13446390 ,_55\,\1740 significantly_56\RB\1740 increased_57\VBD\169651 the_58\DT\1740 incidence_59\NN\13821570 of_60\IN\1740 lindane_61\NN\14919948 induced_62\VBN\1627355 <e2>convulsions</e2>_63\NNS\14081375 ._64\.\1740
D001556_D012640 CID induction_0\NN\7450842 studies_1\NNS\635850 have_2\VBP\2108377 further_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 while_6\IN\15122231 pretreatment_7\NN\1740 of_8\IN\1740 3-methylcholanthrene_9\NN\1740 (_10\-LRB-\1740 mc_11\NN\15286249 )_12\-RRB-\1740 ,_13\,\1740 an_14\DT\6697703 inducer_15\NN\14778436 of_16\IN\1740 p4501a1/1a2_17\NN\1740 ,_18\,\1740 did_19\VBD\1640855 not_20\RB\1740 produce_21\VB\1617192 any_22\DT\1740 significant_23\JJ\1740 effect_24\NN\34213 in_25\IN\13603305 the_26\DT\1740 incidence_27\NN\13821570 of_28\IN\1740 <e1>lindane</e1>_29\NN\14919948 induced_30\JJ\1740 <e2>convulsions</e2>_31\NNS\14081375 ,_32\,\1740 pretreatment_33\NN\1740 with_34\IN\1740 phenobarbital_35\JJ\1740 (_36\-LRB-\1740 pb_37\NN\14625458 )_38\-RRB-\1740 ,_39\,\1740 an_40\DT\6697703 inducer_41\NN\14778436 of_42\IN\1740 p450_43\NN\1740 2b1/2b2_44\CD\1740 or_45\CC\3541091 ethanol_46\NN\14708720 ,_47\,\1740 an_48\DT\6697703 inducer_49\NN\14778436 of_50\IN\1740 p450_51\NN\1740 2e1_52\NN\1740 catalysed_53\JJ\1740 reactions_54\NNS\13446390 ,_55\,\1740 significantly_56\RB\1740 increased_57\VBD\169651 the_58\DT\1740 incidence_59\NN\13821570 of_60\IN\1740 lindane_61\NN\14919948 induced_62\VBN\1627355 convulsions_63\NNS\14081375 ._64\.\1740
D001556_D012640 CID induction_0\NN\7450842 studies_1\NNS\635850 have_2\VBP\2108377 further_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 while_6\IN\15122231 pretreatment_7\NN\1740 of_8\IN\1740 3-methylcholanthrene_9\NN\1740 (_10\-LRB-\1740 mc_11\NN\15286249 )_12\-RRB-\1740 ,_13\,\1740 an_14\DT\6697703 inducer_15\NN\14778436 of_16\IN\1740 p4501a1/1a2_17\NN\1740 ,_18\,\1740 did_19\VBD\1640855 not_20\RB\1740 produce_21\VB\1617192 any_22\DT\1740 significant_23\JJ\1740 effect_24\NN\34213 in_25\IN\13603305 the_26\DT\1740 incidence_27\NN\13821570 of_28\IN\1740 <e1>lindane</e1>_29\NN\14919948 induced_30\JJ\1740 convulsions_31\NNS\14081375 ,_32\,\1740 pretreatment_33\NN\1740 with_34\IN\1740 phenobarbital_35\JJ\1740 (_36\-LRB-\1740 pb_37\NN\14625458 )_38\-RRB-\1740 ,_39\,\1740 an_40\DT\6697703 inducer_41\NN\14778436 of_42\IN\1740 p450_43\NN\1740 2b1/2b2_44\CD\1740 or_45\CC\3541091 ethanol_46\NN\14708720 ,_47\,\1740 an_48\DT\6697703 inducer_49\NN\14778436 of_50\IN\1740 p450_51\NN\1740 2e1_52\NN\1740 catalysed_53\JJ\1740 reactions_54\NNS\13446390 ,_55\,\1740 significantly_56\RB\1740 increased_57\VBD\169651 the_58\DT\1740 incidence_59\NN\13821570 of_60\IN\1740 lindane_61\NN\14919948 induced_62\VBN\1627355 <e2>convulsions</e2>_63\NNS\14081375 ._64\.\1740
D001556_D012640 CID induction_0\NN\7450842 studies_1\NNS\635850 have_2\VBP\2108377 further_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 while_6\IN\15122231 pretreatment_7\NN\1740 of_8\IN\1740 3-methylcholanthrene_9\NN\1740 (_10\-LRB-\1740 mc_11\NN\15286249 )_12\-RRB-\1740 ,_13\,\1740 an_14\DT\6697703 inducer_15\NN\14778436 of_16\IN\1740 p4501a1/1a2_17\NN\1740 ,_18\,\1740 did_19\VBD\1640855 not_20\RB\1740 produce_21\VB\1617192 any_22\DT\1740 significant_23\JJ\1740 effect_24\NN\34213 in_25\IN\13603305 the_26\DT\1740 incidence_27\NN\13821570 of_28\IN\1740 lindane_29\NN\14919948 induced_30\JJ\1740 <e2>convulsions</e2>_31\NNS\14081375 ,_32\,\1740 pretreatment_33\NN\1740 with_34\IN\1740 phenobarbital_35\JJ\1740 (_36\-LRB-\1740 pb_37\NN\14625458 )_38\-RRB-\1740 ,_39\,\1740 an_40\DT\6697703 inducer_41\NN\14778436 of_42\IN\1740 p450_43\NN\1740 2b1/2b2_44\CD\1740 or_45\CC\3541091 ethanol_46\NN\14708720 ,_47\,\1740 an_48\DT\6697703 inducer_49\NN\14778436 of_50\IN\1740 p450_51\NN\1740 2e1_52\NN\1740 catalysed_53\JJ\1740 reactions_54\NNS\13446390 ,_55\,\1740 significantly_56\RB\1740 increased_57\VBD\169651 the_58\DT\1740 incidence_59\NN\13821570 of_60\IN\1740 <e1>lindane</e1>_61\NN\14919948 induced_62\VBN\1627355 convulsions_63\NNS\14081375 ._64\.\1740
D001556_D012640 CID induction_0\NN\7450842 studies_1\NNS\635850 have_2\VBP\2108377 further_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 while_6\IN\15122231 pretreatment_7\NN\1740 of_8\IN\1740 3-methylcholanthrene_9\NN\1740 (_10\-LRB-\1740 mc_11\NN\15286249 )_12\-RRB-\1740 ,_13\,\1740 an_14\DT\6697703 inducer_15\NN\14778436 of_16\IN\1740 p4501a1/1a2_17\NN\1740 ,_18\,\1740 did_19\VBD\1640855 not_20\RB\1740 produce_21\VB\1617192 any_22\DT\1740 significant_23\JJ\1740 effect_24\NN\34213 in_25\IN\13603305 the_26\DT\1740 incidence_27\NN\13821570 of_28\IN\1740 lindane_29\NN\14919948 induced_30\JJ\1740 convulsions_31\NNS\14081375 ,_32\,\1740 pretreatment_33\NN\1740 with_34\IN\1740 phenobarbital_35\JJ\1740 (_36\-LRB-\1740 pb_37\NN\14625458 )_38\-RRB-\1740 ,_39\,\1740 an_40\DT\6697703 inducer_41\NN\14778436 of_42\IN\1740 p450_43\NN\1740 2b1/2b2_44\CD\1740 or_45\CC\3541091 ethanol_46\NN\14708720 ,_47\,\1740 an_48\DT\6697703 inducer_49\NN\14778436 of_50\IN\1740 p450_51\NN\1740 2e1_52\NN\1740 catalysed_53\JJ\1740 reactions_54\NNS\13446390 ,_55\,\1740 significantly_56\RB\1740 increased_57\VBD\169651 the_58\DT\1740 incidence_59\NN\13821570 of_60\IN\1740 <e1>lindane</e1>_61\NN\14919948 induced_62\VBN\1627355 <e2>convulsions</e2>_63\NNS\14081375 ._64\.\1740
D001556_D012640 CID similarly_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 the_3\DT\1740 p450-mediated_4\JJ\1740 metabolism_5\NN\13526110 of_6\IN\1740 <e1>lindane</e1>_7\NN\14919948 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 cobalt_11\NN\14625458 chloride_12\NN\14818238 incidence_13\NN\13821570 of_14\IN\1740 <e2>convulsions</e2>_15\NNS\14081375 was_16\VBD\836236 increased_17\VBN\169651 in_18\IN\13603305 animals_19\NNS\4475 treated_20\VBN\2376958 with_21\IN\1740 lindane_22\NN\14919948 indicating_23\VBG\952524 that_24\IN\1740 lindane_25\NN\14919948 per_26\FW\1740 se_27\FW\14724645 or_28\CC\3541091 its_29\PRP$\6125041 metabolites_30\NNS\20090 formed_31\VBN\1617192 by_32\IN\1740 pb_33\NN\14625458 or_34\CC\3541091 ethanol_35\NN\14708720 inducible_36\JJ\1740 p450_37\NN\1740 isoenzymes_38\NNS\1740 are_39\VBP\836236 involved_40\VBN\2676054 in_41\IN\13603305 its_42\PRP$\6125041 neurobehavioral_43\JJ\1740 toxicity_44\NN\13576101 ._45\.\1740
D001556_D012640 CID similarly_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 the_3\DT\1740 p450-mediated_4\JJ\1740 metabolism_5\NN\13526110 of_6\IN\1740 lindane_7\NN\14919948 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 cobalt_11\NN\14625458 chloride_12\NN\14818238 incidence_13\NN\13821570 of_14\IN\1740 <e2>convulsions</e2>_15\NNS\14081375 was_16\VBD\836236 increased_17\VBN\169651 in_18\IN\13603305 animals_19\NNS\4475 treated_20\VBN\2376958 with_21\IN\1740 <e1>lindane</e1>_22\NN\14919948 indicating_23\VBG\952524 that_24\IN\1740 lindane_25\NN\14919948 per_26\FW\1740 se_27\FW\14724645 or_28\CC\3541091 its_29\PRP$\6125041 metabolites_30\NNS\20090 formed_31\VBN\1617192 by_32\IN\1740 pb_33\NN\14625458 or_34\CC\3541091 ethanol_35\NN\14708720 inducible_36\JJ\1740 p450_37\NN\1740 isoenzymes_38\NNS\1740 are_39\VBP\836236 involved_40\VBN\2676054 in_41\IN\13603305 its_42\PRP$\6125041 neurobehavioral_43\JJ\1740 toxicity_44\NN\13576101 ._45\.\1740
D001556_D012640 CID similarly_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 the_3\DT\1740 p450-mediated_4\JJ\1740 metabolism_5\NN\13526110 of_6\IN\1740 lindane_7\NN\14919948 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 cobalt_11\NN\14625458 chloride_12\NN\14818238 incidence_13\NN\13821570 of_14\IN\1740 <e2>convulsions</e2>_15\NNS\14081375 was_16\VBD\836236 increased_17\VBN\169651 in_18\IN\13603305 animals_19\NNS\4475 treated_20\VBN\2376958 with_21\IN\1740 lindane_22\NN\14919948 indicating_23\VBG\952524 that_24\IN\1740 <e1>lindane</e1>_25\NN\14919948 per_26\FW\1740 se_27\FW\14724645 or_28\CC\3541091 its_29\PRP$\6125041 metabolites_30\NNS\20090 formed_31\VBN\1617192 by_32\IN\1740 pb_33\NN\14625458 or_34\CC\3541091 ethanol_35\NN\14708720 inducible_36\JJ\1740 p450_37\NN\1740 isoenzymes_38\NNS\1740 are_39\VBP\836236 involved_40\VBN\2676054 in_41\IN\13603305 its_42\PRP$\6125041 neurobehavioral_43\JJ\1740 toxicity_44\NN\13576101 ._45\.\1740
D010634_D012640 NONE induction_0\NN\7450842 studies_1\NNS\635850 have_2\VBP\2108377 further_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 while_6\IN\15122231 pretreatment_7\NN\1740 of_8\IN\1740 3-methylcholanthrene_9\NN\1740 (_10\-LRB-\1740 mc_11\NN\15286249 )_12\-RRB-\1740 ,_13\,\1740 an_14\DT\6697703 inducer_15\NN\14778436 of_16\IN\1740 p4501a1/1a2_17\NN\1740 ,_18\,\1740 did_19\VBD\1640855 not_20\RB\1740 produce_21\VB\1617192 any_22\DT\1740 significant_23\JJ\1740 effect_24\NN\34213 in_25\IN\13603305 the_26\DT\1740 incidence_27\NN\13821570 of_28\IN\1740 lindane_29\NN\14919948 induced_30\JJ\1740 <e2>convulsions</e2>_31\NNS\14081375 ,_32\,\1740 pretreatment_33\NN\1740 with_34\IN\1740 <e1>phenobarbital</e1>_35\JJ\1740 (_36\-LRB-\1740 pb_37\NN\14625458 )_38\-RRB-\1740 ,_39\,\1740 an_40\DT\6697703 inducer_41\NN\14778436 of_42\IN\1740 p450_43\NN\1740 2b1/2b2_44\CD\1740 or_45\CC\3541091 ethanol_46\NN\14708720 ,_47\,\1740 an_48\DT\6697703 inducer_49\NN\14778436 of_50\IN\1740 p450_51\NN\1740 2e1_52\NN\1740 catalysed_53\JJ\1740 reactions_54\NNS\13446390 ,_55\,\1740 significantly_56\RB\1740 increased_57\VBD\169651 the_58\DT\1740 incidence_59\NN\13821570 of_60\IN\1740 lindane_61\NN\14919948 induced_62\VBN\1627355 convulsions_63\NNS\14081375 ._64\.\1740
D010634_D012640 NONE induction_0\NN\7450842 studies_1\NNS\635850 have_2\VBP\2108377 further_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 while_6\IN\15122231 pretreatment_7\NN\1740 of_8\IN\1740 3-methylcholanthrene_9\NN\1740 (_10\-LRB-\1740 mc_11\NN\15286249 )_12\-RRB-\1740 ,_13\,\1740 an_14\DT\6697703 inducer_15\NN\14778436 of_16\IN\1740 p4501a1/1a2_17\NN\1740 ,_18\,\1740 did_19\VBD\1640855 not_20\RB\1740 produce_21\VB\1617192 any_22\DT\1740 significant_23\JJ\1740 effect_24\NN\34213 in_25\IN\13603305 the_26\DT\1740 incidence_27\NN\13821570 of_28\IN\1740 lindane_29\NN\14919948 induced_30\JJ\1740 convulsions_31\NNS\14081375 ,_32\,\1740 pretreatment_33\NN\1740 with_34\IN\1740 <e1>phenobarbital</e1>_35\JJ\1740 (_36\-LRB-\1740 pb_37\NN\14625458 )_38\-RRB-\1740 ,_39\,\1740 an_40\DT\6697703 inducer_41\NN\14778436 of_42\IN\1740 p450_43\NN\1740 2b1/2b2_44\CD\1740 or_45\CC\3541091 ethanol_46\NN\14708720 ,_47\,\1740 an_48\DT\6697703 inducer_49\NN\14778436 of_50\IN\1740 p450_51\NN\1740 2e1_52\NN\1740 catalysed_53\JJ\1740 reactions_54\NNS\13446390 ,_55\,\1740 significantly_56\RB\1740 increased_57\VBD\169651 the_58\DT\1740 incidence_59\NN\13821570 of_60\IN\1740 lindane_61\NN\14919948 induced_62\VBN\1627355 <e2>convulsions</e2>_63\NNS\14081375 ._64\.\1740
D000431_D012640 NONE induction_0\NN\7450842 studies_1\NNS\635850 have_2\VBP\2108377 further_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 while_6\IN\15122231 pretreatment_7\NN\1740 of_8\IN\1740 3-methylcholanthrene_9\NN\1740 (_10\-LRB-\1740 mc_11\NN\15286249 )_12\-RRB-\1740 ,_13\,\1740 an_14\DT\6697703 inducer_15\NN\14778436 of_16\IN\1740 p4501a1/1a2_17\NN\1740 ,_18\,\1740 did_19\VBD\1640855 not_20\RB\1740 produce_21\VB\1617192 any_22\DT\1740 significant_23\JJ\1740 effect_24\NN\34213 in_25\IN\13603305 the_26\DT\1740 incidence_27\NN\13821570 of_28\IN\1740 lindane_29\NN\14919948 induced_30\JJ\1740 <e2>convulsions</e2>_31\NNS\14081375 ,_32\,\1740 pretreatment_33\NN\1740 with_34\IN\1740 phenobarbital_35\JJ\1740 (_36\-LRB-\1740 pb_37\NN\14625458 )_38\-RRB-\1740 ,_39\,\1740 an_40\DT\6697703 inducer_41\NN\14778436 of_42\IN\1740 p450_43\NN\1740 2b1/2b2_44\CD\1740 or_45\CC\3541091 <e1>ethanol</e1>_46\NN\14708720 ,_47\,\1740 an_48\DT\6697703 inducer_49\NN\14778436 of_50\IN\1740 p450_51\NN\1740 2e1_52\NN\1740 catalysed_53\JJ\1740 reactions_54\NNS\13446390 ,_55\,\1740 significantly_56\RB\1740 increased_57\VBD\169651 the_58\DT\1740 incidence_59\NN\13821570 of_60\IN\1740 lindane_61\NN\14919948 induced_62\VBN\1627355 convulsions_63\NNS\14081375 ._64\.\1740
D000431_D012640 NONE induction_0\NN\7450842 studies_1\NNS\635850 have_2\VBP\2108377 further_3\RB\1740 shown_4\VBN\2137132 that_5\IN\1740 while_6\IN\15122231 pretreatment_7\NN\1740 of_8\IN\1740 3-methylcholanthrene_9\NN\1740 (_10\-LRB-\1740 mc_11\NN\15286249 )_12\-RRB-\1740 ,_13\,\1740 an_14\DT\6697703 inducer_15\NN\14778436 of_16\IN\1740 p4501a1/1a2_17\NN\1740 ,_18\,\1740 did_19\VBD\1640855 not_20\RB\1740 produce_21\VB\1617192 any_22\DT\1740 significant_23\JJ\1740 effect_24\NN\34213 in_25\IN\13603305 the_26\DT\1740 incidence_27\NN\13821570 of_28\IN\1740 lindane_29\NN\14919948 induced_30\JJ\1740 convulsions_31\NNS\14081375 ,_32\,\1740 pretreatment_33\NN\1740 with_34\IN\1740 phenobarbital_35\JJ\1740 (_36\-LRB-\1740 pb_37\NN\14625458 )_38\-RRB-\1740 ,_39\,\1740 an_40\DT\6697703 inducer_41\NN\14778436 of_42\IN\1740 p450_43\NN\1740 2b1/2b2_44\CD\1740 or_45\CC\3541091 <e1>ethanol</e1>_46\NN\14708720 ,_47\,\1740 an_48\DT\6697703 inducer_49\NN\14778436 of_50\IN\1740 p450_51\NN\1740 2e1_52\NN\1740 catalysed_53\JJ\1740 reactions_54\NNS\13446390 ,_55\,\1740 significantly_56\RB\1740 increased_57\VBD\169651 the_58\DT\1740 incidence_59\NN\13821570 of_60\IN\1740 lindane_61\NN\14919948 induced_62\VBN\1627355 <e2>convulsions</e2>_63\NNS\14081375 ._64\.\1740
D000431_D012640 NONE similarly_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 the_3\DT\1740 p450-mediated_4\JJ\1740 metabolism_5\NN\13526110 of_6\IN\1740 lindane_7\NN\14919948 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 cobalt_11\NN\14625458 chloride_12\NN\14818238 incidence_13\NN\13821570 of_14\IN\1740 <e2>convulsions</e2>_15\NNS\14081375 was_16\VBD\836236 increased_17\VBN\169651 in_18\IN\13603305 animals_19\NNS\4475 treated_20\VBN\2376958 with_21\IN\1740 lindane_22\NN\14919948 indicating_23\VBG\952524 that_24\IN\1740 lindane_25\NN\14919948 per_26\FW\1740 se_27\FW\14724645 or_28\CC\3541091 its_29\PRP$\6125041 metabolites_30\NNS\20090 formed_31\VBN\1617192 by_32\IN\1740 pb_33\NN\14625458 or_34\CC\3541091 <e1>ethanol</e1>_35\NN\14708720 inducible_36\JJ\1740 p450_37\NN\1740 isoenzymes_38\NNS\1740 are_39\VBP\836236 involved_40\VBN\2676054 in_41\IN\13603305 its_42\PRP$\6125041 neurobehavioral_43\JJ\1740 toxicity_44\NN\13576101 ._45\.\1740
D001556_D064420 NONE similarly_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 the_3\DT\1740 p450-mediated_4\JJ\1740 metabolism_5\NN\13526110 of_6\IN\1740 <e1>lindane</e1>_7\NN\14919948 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 cobalt_11\NN\14625458 chloride_12\NN\14818238 incidence_13\NN\13821570 of_14\IN\1740 convulsions_15\NNS\14081375 was_16\VBD\836236 increased_17\VBN\169651 in_18\IN\13603305 animals_19\NNS\4475 treated_20\VBN\2376958 with_21\IN\1740 lindane_22\NN\14919948 indicating_23\VBG\952524 that_24\IN\1740 lindane_25\NN\14919948 per_26\FW\1740 se_27\FW\14724645 or_28\CC\3541091 its_29\PRP$\6125041 metabolites_30\NNS\20090 formed_31\VBN\1617192 by_32\IN\1740 pb_33\NN\14625458 or_34\CC\3541091 ethanol_35\NN\14708720 inducible_36\JJ\1740 p450_37\NN\1740 isoenzymes_38\NNS\1740 are_39\VBP\836236 involved_40\VBN\2676054 in_41\IN\13603305 its_42\PRP$\6125041 neurobehavioral_43\JJ\1740 <e2>toxicity</e2>_44\NN\13576101 ._45\.\1740
D001556_D064420 NONE similarly_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 the_3\DT\1740 p450-mediated_4\JJ\1740 metabolism_5\NN\13526110 of_6\IN\1740 lindane_7\NN\14919948 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 cobalt_11\NN\14625458 chloride_12\NN\14818238 incidence_13\NN\13821570 of_14\IN\1740 convulsions_15\NNS\14081375 was_16\VBD\836236 increased_17\VBN\169651 in_18\IN\13603305 animals_19\NNS\4475 treated_20\VBN\2376958 with_21\IN\1740 <e1>lindane</e1>_22\NN\14919948 indicating_23\VBG\952524 that_24\IN\1740 lindane_25\NN\14919948 per_26\FW\1740 se_27\FW\14724645 or_28\CC\3541091 its_29\PRP$\6125041 metabolites_30\NNS\20090 formed_31\VBN\1617192 by_32\IN\1740 pb_33\NN\14625458 or_34\CC\3541091 ethanol_35\NN\14708720 inducible_36\JJ\1740 p450_37\NN\1740 isoenzymes_38\NNS\1740 are_39\VBP\836236 involved_40\VBN\2676054 in_41\IN\13603305 its_42\PRP$\6125041 neurobehavioral_43\JJ\1740 <e2>toxicity</e2>_44\NN\13576101 ._45\.\1740
D001556_D064420 NONE similarly_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 the_3\DT\1740 p450-mediated_4\JJ\1740 metabolism_5\NN\13526110 of_6\IN\1740 lindane_7\NN\14919948 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 cobalt_11\NN\14625458 chloride_12\NN\14818238 incidence_13\NN\13821570 of_14\IN\1740 convulsions_15\NNS\14081375 was_16\VBD\836236 increased_17\VBN\169651 in_18\IN\13603305 animals_19\NNS\4475 treated_20\VBN\2376958 with_21\IN\1740 lindane_22\NN\14919948 indicating_23\VBG\952524 that_24\IN\1740 <e1>lindane</e1>_25\NN\14919948 per_26\FW\1740 se_27\FW\14724645 or_28\CC\3541091 its_29\PRP$\6125041 metabolites_30\NNS\20090 formed_31\VBN\1617192 by_32\IN\1740 pb_33\NN\14625458 or_34\CC\3541091 ethanol_35\NN\14708720 inducible_36\JJ\1740 p450_37\NN\1740 isoenzymes_38\NNS\1740 are_39\VBP\836236 involved_40\VBN\2676054 in_41\IN\13603305 its_42\PRP$\6125041 neurobehavioral_43\JJ\1740 <e2>toxicity</e2>_44\NN\13576101 ._45\.\1740
C018021_D012640 NONE similarly_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 the_3\DT\1740 p450-mediated_4\JJ\1740 metabolism_5\NN\13526110 of_6\IN\1740 lindane_7\NN\14919948 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 <e1>cobalt_11\NN\14625458 chloride</e1>_12\NN\14818238 incidence_13\NN\13821570 of_14\IN\1740 <e2>convulsions</e2>_15\NNS\14081375 was_16\VBD\836236 increased_17\VBN\169651 in_18\IN\13603305 animals_19\NNS\4475 treated_20\VBN\2376958 with_21\IN\1740 lindane_22\NN\14919948 indicating_23\VBG\952524 that_24\IN\1740 lindane_25\NN\14919948 per_26\FW\1740 se_27\FW\14724645 or_28\CC\3541091 its_29\PRP$\6125041 metabolites_30\NNS\20090 formed_31\VBN\1617192 by_32\IN\1740 pb_33\NN\14625458 or_34\CC\3541091 ethanol_35\NN\14708720 inducible_36\JJ\1740 p450_37\NN\1740 isoenzymes_38\NNS\1740 are_39\VBP\836236 involved_40\VBN\2676054 in_41\IN\13603305 its_42\PRP$\6125041 neurobehavioral_43\JJ\1740 toxicity_44\NN\13576101 ._45\.\1740
C018021_D064420 NONE similarly_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 the_3\DT\1740 p450-mediated_4\JJ\1740 metabolism_5\NN\13526110 of_6\IN\1740 lindane_7\NN\14919948 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 <e1>cobalt_11\NN\14625458 chloride</e1>_12\NN\14818238 incidence_13\NN\13821570 of_14\IN\1740 convulsions_15\NNS\14081375 was_16\VBD\836236 increased_17\VBN\169651 in_18\IN\13603305 animals_19\NNS\4475 treated_20\VBN\2376958 with_21\IN\1740 lindane_22\NN\14919948 indicating_23\VBG\952524 that_24\IN\1740 lindane_25\NN\14919948 per_26\FW\1740 se_27\FW\14724645 or_28\CC\3541091 its_29\PRP$\6125041 metabolites_30\NNS\20090 formed_31\VBN\1617192 by_32\IN\1740 pb_33\NN\14625458 or_34\CC\3541091 ethanol_35\NN\14708720 inducible_36\JJ\1740 p450_37\NN\1740 isoenzymes_38\NNS\1740 are_39\VBP\836236 involved_40\VBN\2676054 in_41\IN\13603305 its_42\PRP$\6125041 neurobehavioral_43\JJ\1740 <e2>toxicity</e2>_44\NN\13576101 ._45\.\1740
D000431_D064420 NONE similarly_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 the_3\DT\1740 p450-mediated_4\JJ\1740 metabolism_5\NN\13526110 of_6\IN\1740 lindane_7\NN\14919948 was_8\VBD\836236 blocked_9\VBN\1476483 by_10\IN\1740 cobalt_11\NN\14625458 chloride_12\NN\14818238 incidence_13\NN\13821570 of_14\IN\1740 convulsions_15\NNS\14081375 was_16\VBD\836236 increased_17\VBN\169651 in_18\IN\13603305 animals_19\NNS\4475 treated_20\VBN\2376958 with_21\IN\1740 lindane_22\NN\14919948 indicating_23\VBG\952524 that_24\IN\1740 lindane_25\NN\14919948 per_26\FW\1740 se_27\FW\14724645 or_28\CC\3541091 its_29\PRP$\6125041 metabolites_30\NNS\20090 formed_31\VBN\1617192 by_32\IN\1740 pb_33\NN\14625458 or_34\CC\3541091 <e1>ethanol</e1>_35\NN\14708720 inducible_36\JJ\1740 p450_37\NN\1740 isoenzymes_38\NNS\1740 are_39\VBP\836236 involved_40\VBN\2676054 in_41\IN\13603305 its_42\PRP$\6125041 neurobehavioral_43\JJ\1740 <e2>toxicity</e2>_44\NN\13576101 ._45\.\1740
6699841
D009288_D007681 CID <e2>renal_0\JJ\1740 papillary_1\NN\1740 necrosis</e2>_2\NN\11444117 due_3\IN\5174653 to_4\IN\1740 <e1>naproxen</e1>_5\NN\3828465 ._6\.\1740
D009288_D007681 CID a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 sulindac_13\NN\3828465 ,_14\,\1740 fenoprofen_15\JJ\1740 calcium_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 salicylates_20\NNS\3828465 and_21\CC\1740 gold_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 <e2>renal_26\JJ\1740 papillary_27\NN\1740 necrosis</e2>_28\NN\11444117 (_29\-LRB-\1740 rpn_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 <e1>naproxen</e1>_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D009288_D007681 CID a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 sulindac_13\NN\3828465 ,_14\,\1740 fenoprofen_15\JJ\1740 calcium_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 salicylates_20\NNS\3828465 and_21\CC\1740 gold_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 renal_26\JJ\1740 papillary_27\NN\1740 necrosis_28\NN\11444117 (_29\-LRB-\1740 <e2>rpn</e2>_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 <e1>naproxen</e1>_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D013467_D001172 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 <e2>rheumatoid_4\JJ\1740 arthritis</e2>_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 <e1>sulindac</e1>_13\NN\3828465 ,_14\,\1740 fenoprofen_15\JJ\1740 calcium_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 salicylates_20\NNS\3828465 and_21\CC\1740 gold_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 renal_26\JJ\1740 papillary_27\NN\1740 necrosis_28\NN\11444117 (_29\-LRB-\1740 rpn_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 naproxen_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D013467_D007681 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 <e1>sulindac</e1>_13\NN\3828465 ,_14\,\1740 fenoprofen_15\JJ\1740 calcium_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 salicylates_20\NNS\3828465 and_21\CC\1740 gold_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 <e2>renal_26\JJ\1740 papillary_27\NN\1740 necrosis</e2>_28\NN\11444117 (_29\-LRB-\1740 rpn_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 naproxen_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D013467_D007681 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 <e1>sulindac</e1>_13\NN\3828465 ,_14\,\1740 fenoprofen_15\JJ\1740 calcium_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 salicylates_20\NNS\3828465 and_21\CC\1740 gold_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 renal_26\JJ\1740 papillary_27\NN\1740 necrosis_28\NN\11444117 (_29\-LRB-\1740 <e2>rpn</e2>_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 naproxen_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D013467_D007681 NONE we_0\PRP\1740 review_1\VBP\644583 previous_2\JJ\1740 reports_3\NNS\6470073 linking_4\VBG\628491 <e2>rpn</e2>_5\NN\1740 to_6\TO\1740 antiinflammatory_7\JJ\1740 drug_8\NN\14778436 use_9\NN\407535 and_10\CC\1740 discuss_11\VB\1033527 possible_12\JJ\1740 advantages_13\NNS\5154517 of_14\IN\1740 <e1>sulindac</e1>_15\NN\3828465 in_16\IN\13603305 patients_17\NNS\9898892 who_18\WP\8299493 have_19\VBP\2108377 experienced_20\VBN\2108377 renal_21\JJ\1740 toxicity_22\NN\13576101 from_23\IN\1740 other_24\JJ\1740 antiinflammatory_25\JJ\1740 agents_26\NNS\7347 ._27\.\1740
D005279_D001172 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 <e2>rheumatoid_4\JJ\1740 arthritis</e2>_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 sulindac_13\NN\3828465 ,_14\,\1740 <e1>fenoprofen_15\JJ\1740 calcium</e1>_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 salicylates_20\NNS\3828465 and_21\CC\1740 gold_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 renal_26\JJ\1740 papillary_27\NN\1740 necrosis_28\NN\11444117 (_29\-LRB-\1740 rpn_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 naproxen_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D005279_D007681 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 sulindac_13\NN\3828465 ,_14\,\1740 <e1>fenoprofen_15\JJ\1740 calcium</e1>_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 salicylates_20\NNS\3828465 and_21\CC\1740 gold_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 <e2>renal_26\JJ\1740 papillary_27\NN\1740 necrosis</e2>_28\NN\11444117 (_29\-LRB-\1740 rpn_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 naproxen_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D005279_D007681 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 sulindac_13\NN\3828465 ,_14\,\1740 <e1>fenoprofen_15\JJ\1740 calcium</e1>_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 salicylates_20\NNS\3828465 and_21\CC\1740 gold_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 renal_26\JJ\1740 papillary_27\NN\1740 necrosis_28\NN\11444117 (_29\-LRB-\1740 <e2>rpn</e2>_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 naproxen_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D012459_D001172 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 <e2>rheumatoid_4\JJ\1740 arthritis</e2>_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 sulindac_13\NN\3828465 ,_14\,\1740 fenoprofen_15\JJ\1740 calcium_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 <e1>salicylates</e1>_20\NNS\3828465 and_21\CC\1740 gold_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 renal_26\JJ\1740 papillary_27\NN\1740 necrosis_28\NN\11444117 (_29\-LRB-\1740 rpn_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 naproxen_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D012459_D007681 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 sulindac_13\NN\3828465 ,_14\,\1740 fenoprofen_15\JJ\1740 calcium_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 <e1>salicylates</e1>_20\NNS\3828465 and_21\CC\1740 gold_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 <e2>renal_26\JJ\1740 papillary_27\NN\1740 necrosis</e2>_28\NN\11444117 (_29\-LRB-\1740 rpn_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 naproxen_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D012459_D007681 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 sulindac_13\NN\3828465 ,_14\,\1740 fenoprofen_15\JJ\1740 calcium_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 <e1>salicylates</e1>_20\NNS\3828465 and_21\CC\1740 gold_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 renal_26\JJ\1740 papillary_27\NN\1740 necrosis_28\NN\11444117 (_29\-LRB-\1740 <e2>rpn</e2>_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 naproxen_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D006046_D001172 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 <e2>rheumatoid_4\JJ\1740 arthritis</e2>_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 sulindac_13\NN\3828465 ,_14\,\1740 fenoprofen_15\JJ\1740 calcium_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 salicylates_20\NNS\3828465 and_21\CC\1740 <e1>gold</e1>_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 renal_26\JJ\1740 papillary_27\NN\1740 necrosis_28\NN\11444117 (_29\-LRB-\1740 rpn_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 naproxen_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D006046_D007681 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 sulindac_13\NN\3828465 ,_14\,\1740 fenoprofen_15\JJ\1740 calcium_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 salicylates_20\NNS\3828465 and_21\CC\1740 <e1>gold</e1>_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 <e2>renal_26\JJ\1740 papillary_27\NN\1740 necrosis</e2>_28\NN\11444117 (_29\-LRB-\1740 rpn_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 naproxen_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D006046_D007681 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 rheumatoid_4\JJ\1740 arthritis_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 sulindac_13\NN\3828465 ,_14\,\1740 fenoprofen_15\JJ\1740 calcium_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 salicylates_20\NNS\3828465 and_21\CC\1740 <e1>gold</e1>_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 renal_26\JJ\1740 papillary_27\NN\1740 necrosis_28\NN\11444117 (_29\-LRB-\1740 <e2>rpn</e2>_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 naproxen_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D009288_D001172 NONE a_0\DT\13649268 31-year-old_1\JJ\1740 man_2\NN\9605289 with_3\IN\1740 <e2>rheumatoid_4\JJ\1740 arthritis</e2>_5\NN\14171682 ,_6\,\1740 who_7\WP\8299493 had_8\VBD\2108377 previously_9\RB\1740 been_10\VBN\836236 treated_11\VBN\2376958 with_12\IN\1740 sulindac_13\NN\3828465 ,_14\,\1740 fenoprofen_15\JJ\1740 calcium_16\NN\14625458 ,_17\,\1740 high_18\JJ\1740 dose_19\NN\3740161 salicylates_20\NNS\3828465 and_21\CC\1740 gold_22\NN\13371489 salts_23\NNS\14818238 ,_24\,\1740 developed_25\VBD\1753788 renal_26\JJ\1740 papillary_27\NN\1740 necrosis_28\NN\11444117 (_29\-LRB-\1740 rpn_30\NN\1740 )_31\-RRB-\1740 4_32\CD\13741022 months_33\NNS\15113229 after_34\IN\1740 institution_35\NN\8008335 of_36\IN\1740 <e1>naproxen</e1>_37\NN\3828465 therapy_38\NN\657604 ._39\.\1740
D013467_D007674 NONE we_0\PRP\1740 review_1\VBP\644583 previous_2\JJ\1740 reports_3\NNS\6470073 linking_4\VBG\628491 rpn_5\NN\1740 to_6\TO\1740 antiinflammatory_7\JJ\1740 drug_8\NN\14778436 use_9\NN\407535 and_10\CC\1740 discuss_11\VB\1033527 possible_12\JJ\1740 advantages_13\NNS\5154517 of_14\IN\1740 <e1>sulindac</e1>_15\NN\3828465 in_16\IN\13603305 patients_17\NNS\9898892 who_18\WP\8299493 have_19\VBP\2108377 experienced_20\VBN\2108377 <e2>renal_21\JJ\1740 toxicity</e2>_22\NN\13576101 from_23\IN\1740 other_24\JJ\1740 antiinflammatory_25\JJ\1740 agents_26\NNS\7347 ._27\.\1740
1545575
D003520_D006470 CID <e2>hemorrhagic_0\JJ\1740 cystitis</e2>_1\NN\14566129 is_2\VBZ\836236 a_3\DT\13649268 potentially_4\RB\1740 serious_5\JJ\1740 complication_6\NN\1073995 of_7\IN\1740 high-dose_8\JJ\1740 <e1>cyclophosphamide</e1>_9\NN\1740 therapy_10\NN\657604 administered_11\VBN\2436349 before_12\IN\1740 bone_13\NN\5286536 marrow_14\NN\5286536 transplantation_15\NN\671351 ._16\.\1740
D003520_D006470 CID in_0\IN\13603305 an_1\DT\6697703 attempt_2\NN\407535 to_3\TO\1740 obviate_4\VB\2452885 the_5\DT\1740 inconvenience_6\NN\14446652 of_7\IN\1740 bladder_8\NN\5515670 irrigation_9\NN\1057200 ,_10\,\1740 we_11\PRP\1740 conducted_12\VBD\2436349 a_13\DT\13649268 feasibility_14\NN\5152150 trial_15\NN\786195 of_16\IN\1740 uroprophylaxis_17\NN\1740 with_18\IN\1740 mesna_19\NN\1740 ,_20\,\1740 which_21\WDT\1740 neutralizes_22\VBZ\126264 the_23\DT\1740 hepatic_24\JJ\1740 metabolite_25\NN\20090 of_26\IN\1740 <e1>cyclophosphamide</e1>_27\NN\1740 that_28\WDT\1740 causes_29\VBZ\1617192 <e2>hemorrhagic_30\JJ\1740 cystitis</e2>_31\NN\14566129 ._32\.\1740
D003520_D003556 CID <e2>hemorrhagic_0\JJ\1740 cystitis</e2>_1\NN\14566129 is_2\VBZ\836236 a_3\DT\13649268 potentially_4\RB\1740 serious_5\JJ\1740 complication_6\NN\1073995 of_7\IN\1740 high-dose_8\JJ\1740 <e1>cyclophosphamide</e1>_9\NN\1740 therapy_10\NN\657604 administered_11\VBN\2436349 before_12\IN\1740 bone_13\NN\5286536 marrow_14\NN\5286536 transplantation_15\NN\671351 ._16\.\1740
D003520_D003556 CID in_0\IN\13603305 an_1\DT\6697703 attempt_2\NN\407535 to_3\TO\1740 obviate_4\VB\2452885 the_5\DT\1740 inconvenience_6\NN\14446652 of_7\IN\1740 bladder_8\NN\5515670 irrigation_9\NN\1057200 ,_10\,\1740 we_11\PRP\1740 conducted_12\VBD\2436349 a_13\DT\13649268 feasibility_14\NN\5152150 trial_15\NN\786195 of_16\IN\1740 uroprophylaxis_17\NN\1740 with_18\IN\1740 mesna_19\NN\1740 ,_20\,\1740 which_21\WDT\1740 neutralizes_22\VBZ\126264 the_23\DT\1740 hepatic_24\JJ\1740 metabolite_25\NN\20090 of_26\IN\1740 <e1>cyclophosphamide</e1>_27\NN\1740 that_28\WDT\1740 causes_29\VBZ\1617192 <e2>hemorrhagic_30\JJ\1740 cystitis</e2>_31\NN\14566129 ._32\.\1740
D015080_D006470 NONE in_0\IN\13603305 an_1\DT\6697703 attempt_2\NN\407535 to_3\TO\1740 obviate_4\VB\2452885 the_5\DT\1740 inconvenience_6\NN\14446652 of_7\IN\1740 bladder_8\NN\5515670 irrigation_9\NN\1057200 ,_10\,\1740 we_11\PRP\1740 conducted_12\VBD\2436349 a_13\DT\13649268 feasibility_14\NN\5152150 trial_15\NN\786195 of_16\IN\1740 uroprophylaxis_17\NN\1740 with_18\IN\1740 <e1>mesna</e1>_19\NN\1740 ,_20\,\1740 which_21\WDT\1740 neutralizes_22\VBZ\126264 the_23\DT\1740 hepatic_24\JJ\1740 metabolite_25\NN\20090 of_26\IN\1740 cyclophosphamide_27\NN\1740 that_28\WDT\1740 causes_29\VBZ\1617192 <e2>hemorrhagic_30\JJ\1740 cystitis</e2>_31\NN\14566129 ._32\.\1740
D015080_D006470 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 two_3\CD\13741022 of_4\IN\1740 four_5\CD\13741022 consecutive_6\JJ\1740 patients_7\NNS\9898892 who_8\WP\8299493 received_9\VBD\2210855 <e1>mesna</e1>_10\NN\1740 uroprophylaxis_11\NN\1740 before_12\IN\1740 allogeneic_13\JJ\1740 bone_14\NN\5286536 marrow_15\NN\5286536 transplantation_16\NN\671351 had_17\VBD\2108377 severe_18\JJ\1740 <e2>hemorrhagic_19\JJ\1740 cystitis</e2>_20\NN\14566129 for_21\IN\1740 at_22\IN\14622893 least_23\JJS\1740 2_24\CD\13741022 weeks_25\NNS\15113229 ._26\.\1740
D015080_D003556 NONE in_0\IN\13603305 an_1\DT\6697703 attempt_2\NN\407535 to_3\TO\1740 obviate_4\VB\2452885 the_5\DT\1740 inconvenience_6\NN\14446652 of_7\IN\1740 bladder_8\NN\5515670 irrigation_9\NN\1057200 ,_10\,\1740 we_11\PRP\1740 conducted_12\VBD\2436349 a_13\DT\13649268 feasibility_14\NN\5152150 trial_15\NN\786195 of_16\IN\1740 uroprophylaxis_17\NN\1740 with_18\IN\1740 <e1>mesna</e1>_19\NN\1740 ,_20\,\1740 which_21\WDT\1740 neutralizes_22\VBZ\126264 the_23\DT\1740 hepatic_24\JJ\1740 metabolite_25\NN\20090 of_26\IN\1740 cyclophosphamide_27\NN\1740 that_28\WDT\1740 causes_29\VBZ\1617192 <e2>hemorrhagic_30\JJ\1740 cystitis</e2>_31\NN\14566129 ._32\.\1740
D015080_D003556 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 two_3\CD\13741022 of_4\IN\1740 four_5\CD\13741022 consecutive_6\JJ\1740 patients_7\NNS\9898892 who_8\WP\8299493 received_9\VBD\2210855 <e1>mesna</e1>_10\NN\1740 uroprophylaxis_11\NN\1740 before_12\IN\1740 allogeneic_13\JJ\1740 bone_14\NN\5286536 marrow_15\NN\5286536 transplantation_16\NN\671351 had_17\VBD\2108377 severe_18\JJ\1740 <e2>hemorrhagic_19\JJ\1740 cystitis</e2>_20\NN\14566129 for_21\IN\1740 at_22\IN\14622893 least_23\JJS\1740 2_24\CD\13741022 weeks_25\NNS\15113229 ._26\.\1740
12452237
D008012_D010149 NONE can_0\MD\3094503 <e1>lidocaine</e1>_1\NN\3681148 reduce_2\VB\441445 succinylcholine_3\NN\3800001 induced_4\VBN\1627355 <e2>postoperative_5\JJ\1740 myalgia</e2>_6\NN\14322699 ?_7\.\1740
D008012_D010149 NONE in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 where_3\WRB\1740 succinylcholine_4\NN\3800001 is_5\VBZ\836236 used_6\VBN\1156834 ,_7\,\1740 <e1>lidocaine</e1>_8\NN\3681148 is_9\VBZ\836236 proven_10\VBN\2604760 to_11\TO\1740 be_12\VB\836236 the_13\DT\1740 useful_14\JJ\1740 pretreatment_15\NN\1740 agent_16\NN\7347 for_17\IN\1740 the_18\DT\1740 reduction_19\NN\351485 of_20\IN\1740 <e2>postoperative_21\JJ\1740 myalgia</e2>_22\NN\14322699 ._23\.\1740
D013390_D010149 CID can_0\MD\3094503 lidocaine_1\NN\3681148 reduce_2\VB\441445 <e1>succinylcholine</e1>_3\NN\3800001 induced_4\VBN\1627355 <e2>postoperative_5\JJ\1740 myalgia</e2>_6\NN\14322699 ?_7\.\1740
D013390_D010149 CID in_0\IN\13603305 conclusion_1\NN\5837957 ,_2\,\1740 where_3\WRB\1740 <e1>succinylcholine</e1>_4\NN\3800001 is_5\VBZ\836236 used_6\VBN\1156834 ,_7\,\1740 lidocaine_8\NN\3681148 is_9\VBZ\836236 proven_10\VBN\2604760 to_11\TO\1740 be_12\VB\836236 the_13\DT\1740 useful_14\JJ\1740 pretreatment_15\NN\1740 agent_16\NN\7347 for_17\IN\1740 the_18\DT\1740 reduction_19\NN\351485 of_20\IN\1740 <e2>postoperative_21\JJ\1740 myalgia</e2>_22\NN\14322699 ._23\.\1740
D008012_D063806 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 undertaken_3\VBN\1641914 to_4\TO\1740 determine_5\VB\1645601 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 <e1>lidocaine</e1>_9\NN\3681148 pretreatment_10\NN\1740 on_11\IN\1740 reduction_12\NN\351485 of_13\IN\1740 succinylcholine-induced_14\JJ\1740 <e2>myalgia</e2>_15\NN\14322699 in_16\IN\13603305 patients_17\NNS\9898892 undergoing_18\VBG\109660 general_19\JJ\1740 anesthesia_20\NN\14034177 for_21\IN\1740 gynecological_22\JJ\1740 surgery_23\NN\6045562 ._24\.\1740
D013390_D063806 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 undertaken_3\VBN\1641914 to_4\TO\1740 determine_5\VB\1645601 the_6\DT\1740 effect_7\NN\34213 of_8\IN\1740 lidocaine_9\NN\3681148 pretreatment_10\NN\1740 on_11\IN\1740 reduction_12\NN\351485 of_13\IN\1740 <e1>succinylcholine-induced</e1>_14\JJ\1740 <e2>myalgia</e2>_15\NN\14322699 in_16\IN\13603305 patients_17\NNS\9898892 undergoing_18\VBG\109660 general_19\JJ\1740 anesthesia_20\NN\14034177 for_21\IN\1740 gynecological_22\JJ\1740 surgery_23\NN\6045562 ._24\.\1740
16826348
D003561_D010523 CID <e2>peripheral_0\JJ\1740 neuropathy</e2>_1\NN\14204950 caused_2\VBN\1617192 by_3\IN\1740 high-dose_4\JJ\1740 <e1>cytosine_5\NN\14999913 arabinoside</e1>_6\NN\1740 treatment_7\NN\654885 in_8\IN\13603305 a_9\DT\13649268 patient_10\NN\9898892 with_11\IN\1740 acute_12\JJ\1740 myeloid_13\JJ\1740 leukemia_14\NN\14239918 ._15\.\1740
D003561_D010523 CID although_0\IN\1740 the_1\DT\1740 mechanisms_2\NNS\13446390 of_3\IN\1740 <e2>peripheral_4\JJ\1740 neuropathy</e2>_5\NN\14204950 are_6\VBP\836236 still_7\RB\1740 unclear_8\JJ\1740 ,_9\,\1740 high-dose_10\JJ\1740 <e1>cytosine_11\NN\14999913 arabinoside</e1>_12\NN\1740 is_13\VBZ\836236 a_14\DT\13649268 therapy_15\NN\657604 that_16\WDT\1740 is_17\VBZ\836236 potentially_18\RB\1740 toxic_19\JJ\1740 to_20\TO\1740 the_21\DT\1740 peripheral_22\JJ\1740 nervous_23\JJ\1740 system_24\NN\3575240 ,_25\,\1740 and_26\CC\1740 auto/alloimmunity_27\NN\1740 may_28\MD\15209706 play_29\VB\1072262 an_30\DT\6697703 important_31\JJ\1740 role_32\NN\719494 in_33\IN\13603305 these_34\DT\1740 mechanisms_35\NNS\13446390 ._36\.\1740
D003561_D015470 NONE peripheral_0\JJ\1740 neuropathy_1\NN\14204950 caused_2\VBN\1617192 by_3\IN\1740 high-dose_4\JJ\1740 <e1>cytosine_5\NN\14999913 arabinoside</e1>_6\NN\1740 treatment_7\NN\654885 in_8\IN\13603305 a_9\DT\13649268 patient_10\NN\9898892 with_11\IN\1740 <e2>acute_12\JJ\1740 myeloid_13\JJ\1740 leukemia</e2>_14\NN\14239918 ._15\.\1740
D003561_D064420 NONE the_0\DT\1740 central_1\JJ\1740 nervous_2\JJ\1740 system_3\NN\3575240 <e2>toxicity</e2>_4\NN\13576101 of_5\IN\1740 high-dose_6\JJ\1740 <e1>cytosine_7\NN\14999913 arabinoside</e1>_8\NN\1740 is_9\VBZ\836236 well_10\RB\1740 recognized_11\VBN\686447 ,_12\,\1740 but_13\CC\1740 the_14\DT\1740 toxicity_15\NN\13576101 of_16\IN\1740 cytosine_17\NN\14999913 arabinoside_18\NN\1740 in_19\IN\13603305 the_20\DT\1740 peripheral_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 has_24\VBZ\2108377 been_25\VBN\836236 infrequently_26\RB\1740 reported_27\VBN\831651 ._28\.\1740
D003561_D064420 NONE the_0\DT\1740 central_1\JJ\1740 nervous_2\JJ\1740 system_3\NN\3575240 toxicity_4\NN\13576101 of_5\IN\1740 high-dose_6\JJ\1740 <e1>cytosine_7\NN\14999913 arabinoside</e1>_8\NN\1740 is_9\VBZ\836236 well_10\RB\1740 recognized_11\VBN\686447 ,_12\,\1740 but_13\CC\1740 the_14\DT\1740 <e2>toxicity</e2>_15\NN\13576101 of_16\IN\1740 cytosine_17\NN\14999913 arabinoside_18\NN\1740 in_19\IN\13603305 the_20\DT\1740 peripheral_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 has_24\VBZ\2108377 been_25\VBN\836236 infrequently_26\RB\1740 reported_27\VBN\831651 ._28\.\1740
D003561_D064420 NONE the_0\DT\1740 central_1\JJ\1740 nervous_2\JJ\1740 system_3\NN\3575240 <e2>toxicity</e2>_4\NN\13576101 of_5\IN\1740 high-dose_6\JJ\1740 cytosine_7\NN\14999913 arabinoside_8\NN\1740 is_9\VBZ\836236 well_10\RB\1740 recognized_11\VBN\686447 ,_12\,\1740 but_13\CC\1740 the_14\DT\1740 toxicity_15\NN\13576101 of_16\IN\1740 <e1>cytosine_17\NN\14999913 arabinoside</e1>_18\NN\1740 in_19\IN\13603305 the_20\DT\1740 peripheral_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 has_24\VBZ\2108377 been_25\VBN\836236 infrequently_26\RB\1740 reported_27\VBN\831651 ._28\.\1740
D003561_D064420 NONE the_0\DT\1740 central_1\JJ\1740 nervous_2\JJ\1740 system_3\NN\3575240 toxicity_4\NN\13576101 of_5\IN\1740 high-dose_6\JJ\1740 cytosine_7\NN\14999913 arabinoside_8\NN\1740 is_9\VBZ\836236 well_10\RB\1740 recognized_11\VBN\686447 ,_12\,\1740 but_13\CC\1740 the_14\DT\1740 <e2>toxicity</e2>_15\NN\13576101 of_16\IN\1740 <e1>cytosine_17\NN\14999913 arabinoside</e1>_18\NN\1740 in_19\IN\13603305 the_20\DT\1740 peripheral_21\JJ\1740 nervous_22\JJ\1740 system_23\NN\3575240 has_24\VBZ\2108377 been_25\VBN\836236 infrequently_26\RB\1740 reported_27\VBN\831651 ._28\.\1740
D003561_D006987 NONE the_0\DT\1740 first_1\JJ\1740 course_2\NN\883297 of_3\IN\1740 high-dose_4\JJ\1740 <e1>cytosine_5\NN\14999913 arabinoside</e1>_6\NN\1740 resulted_7\VBD\2633881 in_8\IN\13603305 no_9\DT\7204911 unusual_10\JJ\1740 symptoms_11\NNS\5823932 ,_12\,\1740 but_13\CC\1740 on_14\IN\1740 day_15\NN\15154774 21_16\CD\13745420 of_17\IN\1740 the_18\DT\1740 second_19\JJ\1740 course_20\NN\883297 of_21\IN\1740 treatment_22\NN\654885 ,_23\,\1740 the_24\DT\1740 patient_25\NN\9898892 complained_26\VBD\843959 of_27\IN\1740 <e2>numbness</e2>_28\NN\14299637 in_29\IN\13603305 his_30\PRP$\1740 right_31\JJ\1740 foot_32\NN\5563034 ._33\.\1740
D008775_D009422 NONE this_0\DT\1740 <e2>neuropathy</e2>_1\NN\14204950 was_2\VBD\836236 gradually_3\RB\1740 resolving_4\VBG\352826 ;_5\:\1740 however_6\RB\1740 ,_7\,\1740 after_8\IN\1740 the_9\DT\1740 patient_10\NN\9898892 received_11\VBD\2210855 allogeneic_12\JJ\1740 bone_13\NN\5286536 marrow_14\NN\5286536 transplantation_15\NN\671351 ,_16\,\1740 the_17\DT\1740 symptoms_18\NNS\5823932 worsened_19\VBD\146138 ,_20\,\1740 with_21\IN\1740 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 graft-versus-host_25\JJ\1740 disease_26\NN\14061805 ,_27\,\1740 and_28\CC\1740 the_29\DT\1740 symptoms_30\NNS\5823932 subsequently_31\RB\1740 responded_32\VBD\2367363 to_33\IN\1740 <e1>methylprednisolone</e1>_34\NN\1740 ._35\.\1740
D008775_D006086 NONE this_0\DT\1740 neuropathy_1\NN\14204950 was_2\VBD\836236 gradually_3\RB\1740 resolving_4\VBG\352826 ;_5\:\1740 however_6\RB\1740 ,_7\,\1740 after_8\IN\1740 the_9\DT\1740 patient_10\NN\9898892 received_11\VBD\2210855 allogeneic_12\JJ\1740 bone_13\NN\5286536 marrow_14\NN\5286536 transplantation_15\NN\671351 ,_16\,\1740 the_17\DT\1740 symptoms_18\NNS\5823932 worsened_19\VBD\146138 ,_20\,\1740 with_21\IN\1740 the_22\DT\1740 development_23\NN\248977 of_24\IN\1740 <e2>graft-versus-host_25\JJ\1740 disease</e2>_26\NN\14061805 ,_27\,\1740 and_28\CC\1740 the_29\DT\1740 symptoms_30\NNS\5823932 subsequently_31\RB\1740 responded_32\VBD\2367363 to_33\IN\1740 <e1>methylprednisolone</e1>_34\NN\1740 ._35\.\1740
3123611
D003276_D002819 CID <e2>chorea</e2>_0\NNP\14253124 associated_1\VBN\628491 with_2\IN\1740 <e1>oral_3\JJ\1740 contraception</e1>_4\NN\851994 ._5\.\1740
D003276_D002819 CID three_0\CD\13741022 patients_1\NNS\9898892 developed_2\VBD\1753788 <e2>chorea</e2>_3\NN\14253124 while_4\IN\15122231 receiving_5\VBG\2210855 <e1>oral_6\JJ\1740 contraceptives</e1>_7\NNS\3183080 ._8\.\1740
D003276_D002819 CID the_0\DT\1740 third_1\JJ\1740 patient_2\NN\9898892 had_3\VBD\2108377 acute_4\JJ\1740 amphetamine-induced_5\JJ\1740 <e2>chorea</e2>_6\NN\14253124 after_7\IN\1740 prolonged_8\JJ\1740 <e1>oral_9\JJ\1740 contraception</e1>_10\NN\851994 ._11\.\1740
D000661_D002819 CID the_0\DT\1740 third_1\JJ\1740 patient_2\NN\9898892 had_3\VBD\2108377 acute_4\JJ\1740 <e1>amphetamine-induced</e1>_5\JJ\1740 <e2>chorea</e2>_6\NN\14253124 after_7\IN\1740 prolonged_8\JJ\1740 oral_9\JJ\1740 contraception_10\NN\851994 ._11\.\1740
10411803
D015313_D000743 CID severe_0\JJ\1740 immune_1\JJ\1740 <e2>hemolytic_2\JJ\1740 anemia</e2>_3\NN\14189204 associated_4\VBN\628491 with_5\IN\1740 prophylactic_6\JJ\1740 use_7\NN\407535 of_8\IN\1740 <e1>cefotetan</e1>_9\NN\1740 in_10\IN\13603305 obstetric_11\JJ\1740 and_12\CC\1740 gynecologic_13\JJ\1740 procedures_14\NNS\407535 ._15\.\1740
D015313_D000743 CID second-_0\NN\1740 and_1\CC\1740 third-generation_2\JJ\1740 cephalosporins_3\NNS\2716866 ,_4\,\1740 especially_5\RB\1740 <e1>cefotetan</e1>_6\JJ\1740 ,_7\,\1740 are_8\VBP\836236 increasingly_9\RB\1740 associated_10\VBN\628491 with_11\IN\1740 severe_12\JJ\1740 ,_13\,\1740 sometimes_14\RB\1740 fatal_15\JJ\1740 immune_16\JJ\1740 <e2>hemolytic_17\JJ\1740 anemia</e2>_18\NN\14189204 ._19\.\1740
D015313_D000743 CID we_0\PRP\1740 noticed_1\VBD\2163746 that_2\IN\1740 10_3\CD\13745420 of_4\IN\1740 our_5\PRP$\1740 35_6\CD\1740 cases_7\NNS\7283608 of_8\IN\1740 <e1>cefotetan-induced</e1>_9\JJ\1740 <e2>hemolytic_10\JJ\1740 anemias</e2>_11\NNS\14189204 were_12\VBD\836236 in_13\IN\13603305 patients_14\NNS\9898892 who_15\WP\8299493 had_16\VBD\2108377 received_17\VBN\2210855 cefotetan_18\JJ\1740 prophylactically_19\RB\1740 for_20\IN\1740 obstetric_21\JJ\1740 and_22\CC\1740 gynecologic_23\JJ\1740 procedures_24\NNS\407535 ._25\.\1740
D015313_D000743 CID we_0\PRP\1740 noticed_1\VBD\2163746 that_2\IN\1740 10_3\CD\13745420 of_4\IN\1740 our_5\PRP$\1740 35_6\CD\1740 cases_7\NNS\7283608 of_8\IN\1740 cefotetan-induced_9\JJ\1740 <e2>hemolytic_10\JJ\1740 anemias</e2>_11\NNS\14189204 were_12\VBD\836236 in_13\IN\13603305 patients_14\NNS\9898892 who_15\WP\8299493 had_16\VBD\2108377 received_17\VBN\2210855 <e1>cefotetan</e1>_18\JJ\1740 prophylactically_19\RB\1740 for_20\IN\1740 obstetric_21\JJ\1740 and_22\CC\1740 gynecologic_23\JJ\1740 procedures_24\NNS\407535 ._25\.\1740
D002511_D000743 NONE second-_0\NN\1740 and_1\CC\1740 third-generation_2\JJ\1740 <e1>cephalosporins</e1>_3\NNS\2716866 ,_4\,\1740 especially_5\RB\1740 cefotetan_6\JJ\1740 ,_7\,\1740 are_8\VBP\836236 increasingly_9\RB\1740 associated_10\VBN\628491 with_11\IN\1740 severe_12\JJ\1740 ,_13\,\1740 sometimes_14\RB\1740 fatal_15\JJ\1740 immune_16\JJ\1740 <e2>hemolytic_17\JJ\1740 anemia</e2>_18\NN\14189204 ._19\.\1740
16596970
D010862_D012640 NONE <e1>pilocarpine</e1>_0\NN\14712692 <e2>seizures</e2>_1\NNS\14081375 cause_2\VBP\1617192 age-dependent_3\JJ\1740 impairment_4\NN\7296428 in_5\IN\13603305 auditory_6\JJ\1740 location_7\NN\2684 discrimination_8\NN\1123598 ._9\.\1740
D010862_D012640 NONE <e1>pilocarpine</e1>_0\NN\14712692 on_1\IN\1740 either_2\DT\1740 day_3\NN\15154774 induced_4\VBN\1627355 status_5\NN\24720 epilepticus_6\NN\1740 ;_7\:\1740 status_8\NN\24720 epilepticus_9\NN\1740 at_10\IN\14622893 p45_11\NN\1740 resulted_12\VBD\2633881 in_13\IN\13603305 ca3_14\NN\1740 cell_15\NN\3080309 loss_16\NN\13252973 and_17\CC\1740 spontaneous_18\JJ\1740 <e2>seizures</e2>_19\NNS\14081375 ,_20\,\1740 whereas_21\IN\1740 p20_22\NN\1740 rats_23\NNS\2329401 had_24\VBD\2108377 no_25\DT\7204911 cell_26\NN\3080309 loss_27\NN\13252973 or_28\CC\3541091 spontaneous_29\JJ\1740 seizures_30\NNS\14081375 ._31\.\1740
D010862_D012640 NONE <e1>pilocarpine</e1>_0\NN\14712692 on_1\IN\1740 either_2\DT\1740 day_3\NN\15154774 induced_4\VBN\1627355 status_5\NN\24720 epilepticus_6\NN\1740 ;_7\:\1740 status_8\NN\24720 epilepticus_9\NN\1740 at_10\IN\14622893 p45_11\NN\1740 resulted_12\VBD\2633881 in_13\IN\13603305 ca3_14\NN\1740 cell_15\NN\3080309 loss_16\NN\13252973 and_17\CC\1740 spontaneous_18\JJ\1740 seizures_19\NNS\14081375 ,_20\,\1740 whereas_21\IN\1740 p20_22\NN\1740 rats_23\NNS\2329401 had_24\VBD\2108377 no_25\DT\7204911 cell_26\NN\3080309 loss_27\NN\13252973 or_28\CC\3541091 spontaneous_29\JJ\1740 <e2>seizures</e2>_30\NNS\14081375 ._31\.\1740
D010862_D001308 CID <e1>pilocarpine</e1>_0\NN\14712692 seizures_1\NNS\14081375 cause_2\VBP\1617192 age-dependent_3\JJ\1740 <e2>impairment_4\NN\7296428 in_5\IN\13603305 auditory_6\JJ\1740 location_7\NN\2684 discrimination</e2>_8\NN\1123598 ._9\.\1740
D010862_D013226 CID <e1>pilocarpine</e1>_0\NN\14712692 on_1\IN\1740 either_2\DT\1740 day_3\NN\15154774 induced_4\VBN\1627355 <e2>status_5\NN\24720 epilepticus</e2>_6\NN\1740 ;_7\:\1740 status_8\NN\24720 epilepticus_9\NN\1740 at_10\IN\14622893 p45_11\NN\1740 resulted_12\VBD\2633881 in_13\IN\13603305 ca3_14\NN\1740 cell_15\NN\3080309 loss_16\NN\13252973 and_17\CC\1740 spontaneous_18\JJ\1740 seizures_19\NNS\14081375 ,_20\,\1740 whereas_21\IN\1740 p20_22\NN\1740 rats_23\NNS\2329401 had_24\VBD\2108377 no_25\DT\7204911 cell_26\NN\3080309 loss_27\NN\13252973 or_28\CC\3541091 spontaneous_29\JJ\1740 seizures_30\NNS\14081375 ._31\.\1740
D010862_D013226 CID <e1>pilocarpine</e1>_0\NN\14712692 on_1\IN\1740 either_2\DT\1740 day_3\NN\15154774 induced_4\VBN\1627355 status_5\NN\24720 epilepticus_6\NN\1740 ;_7\:\1740 <e2>status_8\NN\24720 epilepticus</e2>_9\NN\1740 at_10\IN\14622893 p45_11\NN\1740 resulted_12\VBD\2633881 in_13\IN\13603305 ca3_14\NN\1740 cell_15\NN\3080309 loss_16\NN\13252973 and_17\CC\1740 spontaneous_18\JJ\1740 seizures_19\NNS\14081375 ,_20\,\1740 whereas_21\IN\1740 p20_22\NN\1740 rats_23\NNS\2329401 had_24\VBD\2108377 no_25\DT\7204911 cell_26\NN\3080309 loss_27\NN\13252973 or_28\CC\3541091 spontaneous_29\JJ\1740 seizures_30\NNS\14081375 ._31\.\1740
2576810
D016666_D006948 CID a_0\DT\13649268 repeated_1\JJ\1740 treatment_2\NN\654885 with_3\IN\1740 <e1>fluvoxamine</e1>_4\NN\1740 (_5\-LRB-\1740 twice_6\RB\1740 daily_7\RB\1740 for_8\IN\1740 14_9\CD\13745420 days_10\NNS\15140892 )_11\-RRB-\1740 potentiated_12\VBD\229605 in_13\IN\13603305 mice_14\NNS\2329401 and_15\CC\1740 in_16\IN\13603305 rats_17\NNS\2329401 (_18\-LRB-\1740 weaker_19\JJR\1740 )_20\-RRB-\1740 the_21\DT\1740 amphetamine-induced_22\JJ\1740 <e2>hyperactivity</e2>_23\NN\14052403 ._24\.\1740
D016666_D006948 CID the_0\DT\1740 <e2>hyperactivity</e2>_1\NN\14052403 induced_2\VBN\1627355 by_3\IN\1740 nomifensine_4\NN\1740 in_5\IN\13603305 mice_6\NNS\2329401 remained_7\VBD\2604760 unaffected_8\JJ\1740 by_9\IN\1740 <e1>fluvoxamine</e1>_10\NN\1740 ._11\.\1740
D000661_D006948 CID a_0\DT\13649268 repeated_1\JJ\1740 treatment_2\NN\654885 with_3\IN\1740 fluvoxamine_4\NN\1740 (_5\-LRB-\1740 twice_6\RB\1740 daily_7\RB\1740 for_8\IN\1740 14_9\CD\13745420 days_10\NNS\15140892 )_11\-RRB-\1740 potentiated_12\VBD\229605 in_13\IN\13603305 mice_14\NNS\2329401 and_15\CC\1740 in_16\IN\13603305 rats_17\NNS\2329401 (_18\-LRB-\1740 weaker_19\JJR\1740 )_20\-RRB-\1740 the_21\DT\1740 <e1>amphetamine-induced</e1>_22\JJ\1740 <e2>hyperactivity</e2>_23\NN\14052403 ._24\.\1740
D009627_D006948 CID the_0\DT\1740 <e2>hyperactivity</e2>_1\NN\14052403 induced_2\VBN\1627355 by_3\IN\1740 <e1>nomifensine</e1>_4\NN\1740 in_5\IN\13603305 mice_6\NNS\2329401 remained_7\VBD\2604760 unaffected_8\JJ\1740 by_9\IN\1740 fluvoxamine_10\NN\1740 ._11\.\1740
12091028
D003975_D006212 NONE <e1>diazepam</e1>_0\NNP\2830852 ,_1\,\1740 unless_2\IN\1740 contraindicated_3\VBN\872886 or_4\CC\3541091 risky_5\JJ\1740 ,_6\,\1740 remains_7\VBZ\2604760 the_8\DT\1740 only_9\JJ\1740 necessary_10\JJ\1740 complementary_11\JJ\1740 drug_12\NN\14778436 to_13\TO\1740 ketamine_14\VB\1740 as_15\IN\14622893 it_16\PRP\6125041 buffers_17\VBZ\169806 its_18\PRP$\6125041 cardiovascular_19\JJ\1740 response_20\NN\11410625 and_21\CC\1740 decreases_22\VBZ\169651 the_23\DT\1740 duration_24\NN\15113229 and_25\CC\1740 intensity_26\NN\5090441 of_27\IN\1740 operative_28\JJ\1740 and_29\CC\1740 postoperative_30\JJ\1740 <e2>hallucinations</e2>_31\NNS\14376855 ._32\.\1740
D007649_D006212 CID diazepam_0\NNP\2830852 ,_1\,\1740 unless_2\IN\1740 contraindicated_3\VBN\872886 or_4\CC\3541091 risky_5\JJ\1740 ,_6\,\1740 remains_7\VBZ\2604760 the_8\DT\1740 only_9\JJ\1740 necessary_10\JJ\1740 complementary_11\JJ\1740 drug_12\NN\14778436 to_13\TO\1740 <e1>ketamine</e1>_14\VB\1740 as_15\IN\14622893 it_16\PRP\6125041 buffers_17\VBZ\169806 its_18\PRP$\6125041 cardiovascular_19\JJ\1740 response_20\NN\11410625 and_21\CC\1740 decreases_22\VBZ\169651 the_23\DT\1740 duration_24\NN\15113229 and_25\CC\1740 intensity_26\NN\5090441 of_27\IN\1740 operative_28\JJ\1740 and_29\CC\1740 postoperative_30\JJ\1740 <e2>hallucinations</e2>_31\NNS\14376855 ._32\.\1740
11245434
D003520_D000740 NONE erythropoietin_0\NN\14888310 restores_1\VBZ\1631072 the_2\DT\1740 <e2>anemia-induced</e2>_3\JJ\1740 reduction_4\NN\351485 in_5\IN\13603305 <e1>cyclophosphamide</e1>_6\NN\1740 cytotoxicity_7\NN\13583478 in_8\IN\13603305 rat_9\NN\2329401 tumors_10\NNS\14234074 ._11\.\1740
D003520_D000740 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 impact_9\NN\7339329 of_10\IN\1740 <e2>anemia</e2>_11\NN\14189204 prevention_12\NN\1073995 by_13\IN\1740 recombinant_14\JJ\1740 human_15\JJ\1740 erythropoietin_16\NN\14888310 (_17\-LRB-\1740 rhuepo_18\JJ\1740 )_19\-RRB-\1740 treatment_20\NN\654885 on_21\IN\1740 the_22\DT\1740 cytotoxicity_23\NN\13583478 of_24\IN\1740 <e1>cyclophosphamide</e1>_25\NN\1740 in_26\IN\13603305 solid_27\JJ\1740 experimental_28\JJ\1740 tumors_29\NNS\14234074 ._30\.\1740
D003520_D000740 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chemotherapy-induced_4\JJ\1740 <e2>anemia</e2>_5\NN\14189204 reduces_6\VBZ\441445 cytotoxicity_7\NN\13583478 of_8\IN\1740 <e1>cyclophosphamide</e1>_9\NN\1740 in_10\IN\13603305 tumors_11\NNS\14234074 ,_12\,\1740 whereas_13\IN\1740 correction_14\NN\248977 of_15\IN\1740 anemia_16\NN\14189204 by_17\IN\1740 rhuepo_18\JJ\1740 treatment_19\NN\654885 (_20\-LRB-\1740 epoetin_21\NN\1740 alpha_22\NN\6828818 )_23\-RRB-\1740 increases_24\VBZ\169651 the_25\DT\1740 sensitivity_26\NN\5651971 ,_27\,\1740 probably_28\RB\1740 as_29\IN\14622893 a_30\DT\13649268 result_31\NN\34213 of_32\IN\1740 an_33\DT\6697703 improved_34\VBN\126264 oxygen_35\NN\14622893 supply_36\NN\13576355 to_37\TO\1740 tumor_38\NN\14234074 tissue_39\NN\5220461 ._40\.\1740
D003520_D000740 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chemotherapy-induced_4\JJ\1740 anemia_5\NN\14189204 reduces_6\VBZ\441445 cytotoxicity_7\NN\13583478 of_8\IN\1740 <e1>cyclophosphamide</e1>_9\NN\1740 in_10\IN\13603305 tumors_11\NNS\14234074 ,_12\,\1740 whereas_13\IN\1740 correction_14\NN\248977 of_15\IN\1740 <e2>anemia</e2>_16\NN\14189204 by_17\IN\1740 rhuepo_18\JJ\1740 treatment_19\NN\654885 (_20\-LRB-\1740 epoetin_21\NN\1740 alpha_22\NN\6828818 )_23\-RRB-\1740 increases_24\VBZ\169651 the_25\DT\1740 sensitivity_26\NN\5651971 ,_27\,\1740 probably_28\RB\1740 as_29\IN\14622893 a_30\DT\13649268 result_31\NN\34213 of_32\IN\1740 an_33\DT\6697703 improved_34\VBN\126264 oxygen_35\NN\14622893 supply_36\NN\13576355 to_37\TO\1740 tumor_38\NN\14234074 tissue_39\NN\5220461 ._40\.\1740
D003520_D064420 NONE erythropoietin_0\NN\14888310 restores_1\VBZ\1631072 the_2\DT\1740 anemia-induced_3\JJ\1740 reduction_4\NN\351485 in_5\IN\13603305 <e1>cyclophosphamide</e1>_6\NN\1740 <e2>cytotoxicity</e2>_7\NN\13583478 in_8\IN\13603305 rat_9\NN\2329401 tumors_10\NNS\14234074 ._11\.\1740
D003520_D064420 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 impact_9\NN\7339329 of_10\IN\1740 anemia_11\NN\14189204 prevention_12\NN\1073995 by_13\IN\1740 recombinant_14\JJ\1740 human_15\JJ\1740 erythropoietin_16\NN\14888310 (_17\-LRB-\1740 rhuepo_18\JJ\1740 )_19\-RRB-\1740 treatment_20\NN\654885 on_21\IN\1740 the_22\DT\1740 <e2>cytotoxicity</e2>_23\NN\13583478 of_24\IN\1740 <e1>cyclophosphamide</e1>_25\NN\1740 in_26\IN\13603305 solid_27\JJ\1740 experimental_28\JJ\1740 tumors_29\NNS\14234074 ._30\.\1740
D003520_D064420 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chemotherapy-induced_4\JJ\1740 anemia_5\NN\14189204 reduces_6\VBZ\441445 <e2>cytotoxicity</e2>_7\NN\13583478 of_8\IN\1740 <e1>cyclophosphamide</e1>_9\NN\1740 in_10\IN\13603305 tumors_11\NNS\14234074 ,_12\,\1740 whereas_13\IN\1740 correction_14\NN\248977 of_15\IN\1740 anemia_16\NN\14189204 by_17\IN\1740 rhuepo_18\JJ\1740 treatment_19\NN\654885 (_20\-LRB-\1740 epoetin_21\NN\1740 alpha_22\NN\6828818 )_23\-RRB-\1740 increases_24\VBZ\169651 the_25\DT\1740 sensitivity_26\NN\5651971 ,_27\,\1740 probably_28\RB\1740 as_29\IN\14622893 a_30\DT\13649268 result_31\NN\34213 of_32\IN\1740 an_33\DT\6697703 improved_34\VBN\126264 oxygen_35\NN\14622893 supply_36\NN\13576355 to_37\TO\1740 tumor_38\NN\14234074 tissue_39\NN\5220461 ._40\.\1740
D003520_D009369 NONE erythropoietin_0\NN\14888310 restores_1\VBZ\1631072 the_2\DT\1740 anemia-induced_3\JJ\1740 reduction_4\NN\351485 in_5\IN\13603305 <e1>cyclophosphamide</e1>_6\NN\1740 cytotoxicity_7\NN\13583478 in_8\IN\13603305 rat_9\NN\2329401 <e2>tumors</e2>_10\NNS\14234074 ._11\.\1740
D003520_D009369 NONE the_0\DT\1740 aim_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 examine_7\VB\789138 the_8\DT\1740 impact_9\NN\7339329 of_10\IN\1740 anemia_11\NN\14189204 prevention_12\NN\1073995 by_13\IN\1740 recombinant_14\JJ\1740 human_15\JJ\1740 erythropoietin_16\NN\14888310 (_17\-LRB-\1740 rhuepo_18\JJ\1740 )_19\-RRB-\1740 treatment_20\NN\654885 on_21\IN\1740 the_22\DT\1740 cytotoxicity_23\NN\13583478 of_24\IN\1740 <e1>cyclophosphamide</e1>_25\NN\1740 in_26\IN\13603305 solid_27\JJ\1740 experimental_28\JJ\1740 <e2>tumors</e2>_29\NNS\14234074 ._30\.\1740
D003520_D009369 NONE when_0\WRB\1740 <e2>tumors</e2>_1\NNS\14234074 were_2\VBD\836236 treated_3\VBN\2376958 with_4\IN\1740 a_5\DT\13649268 single_6\JJ\1740 dose_7\NN\3740161 of_8\IN\1740 <e1>cyclophosphamide</e1>_9\NN\1740 (_10\-LRB-\1740 60_11\CD\13745420 mg/kg_12\NN\1740 i.p._13\RB\1740 )_14\-RRB-\1740 5_15\CD\13741022 days_16\NNS\15140892 after_17\IN\1740 implantation_18\NN\13526110 ,_19\,\1740 a_20\DT\13649268 growth_21\NN\13526110 delay_22\NN\15271008 with_23\IN\1740 a_24\DT\13649268 subsequent_25\JJ\1740 regrowth_26\NN\1740 of_27\IN\1740 the_28\DT\1740 tumors_29\NNS\14234074 was_30\VBD\836236 observed_31\VBN\2163746 ._32\.\1740
D003520_D009369 NONE when_0\WRB\1740 tumors_1\NNS\14234074 were_2\VBD\836236 treated_3\VBN\2376958 with_4\IN\1740 a_5\DT\13649268 single_6\JJ\1740 dose_7\NN\3740161 of_8\IN\1740 <e1>cyclophosphamide</e1>_9\NN\1740 (_10\-LRB-\1740 60_11\CD\13745420 mg/kg_12\NN\1740 i.p._13\RB\1740 )_14\-RRB-\1740 5_15\CD\13741022 days_16\NNS\15140892 after_17\IN\1740 implantation_18\NN\13526110 ,_19\,\1740 a_20\DT\13649268 growth_21\NN\13526110 delay_22\NN\15271008 with_23\IN\1740 a_24\DT\13649268 subsequent_25\JJ\1740 regrowth_26\NN\1740 of_27\IN\1740 the_28\DT\1740 <e2>tumors</e2>_29\NNS\14234074 was_30\VBD\836236 observed_31\VBN\2163746 ._32\.\1740
D003520_D009369 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chemotherapy-induced_4\JJ\1740 anemia_5\NN\14189204 reduces_6\VBZ\441445 cytotoxicity_7\NN\13583478 of_8\IN\1740 <e1>cyclophosphamide</e1>_9\NN\1740 in_10\IN\13603305 <e2>tumors</e2>_11\NNS\14234074 ,_12\,\1740 whereas_13\IN\1740 correction_14\NN\248977 of_15\IN\1740 anemia_16\NN\14189204 by_17\IN\1740 rhuepo_18\JJ\1740 treatment_19\NN\654885 (_20\-LRB-\1740 epoetin_21\NN\1740 alpha_22\NN\6828818 )_23\-RRB-\1740 increases_24\VBZ\169651 the_25\DT\1740 sensitivity_26\NN\5651971 ,_27\,\1740 probably_28\RB\1740 as_29\IN\14622893 a_30\DT\13649268 result_31\NN\34213 of_32\IN\1740 an_33\DT\6697703 improved_34\VBN\126264 oxygen_35\NN\14622893 supply_36\NN\13576355 to_37\TO\1740 tumor_38\NN\14234074 tissue_39\NN\5220461 ._40\.\1740
D003520_D009369 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chemotherapy-induced_4\JJ\1740 anemia_5\NN\14189204 reduces_6\VBZ\441445 cytotoxicity_7\NN\13583478 of_8\IN\1740 <e1>cyclophosphamide</e1>_9\NN\1740 in_10\IN\13603305 tumors_11\NNS\14234074 ,_12\,\1740 whereas_13\IN\1740 correction_14\NN\248977 of_15\IN\1740 anemia_16\NN\14189204 by_17\IN\1740 rhuepo_18\JJ\1740 treatment_19\NN\654885 (_20\-LRB-\1740 epoetin_21\NN\1740 alpha_22\NN\6828818 )_23\-RRB-\1740 increases_24\VBZ\169651 the_25\DT\1740 sensitivity_26\NN\5651971 ,_27\,\1740 probably_28\RB\1740 as_29\IN\14622893 a_30\DT\13649268 result_31\NN\34213 of_32\IN\1740 an_33\DT\6697703 improved_34\VBN\126264 oxygen_35\NN\14622893 supply_36\NN\13576355 to_37\TO\1740 <e2>tumor</e2>_38\NN\14234074 tissue_39\NN\5220461 ._40\.\1740
D016190_D000740 CID <e2>anemia</e2>_0\NN\14189204 was_1\VBD\836236 induced_2\VBN\1627355 using_3\VBG\1156834 a_4\DT\13649268 single_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 <e1>carboplatin</e1>_8\NN\1740 (_9\-LRB-\1740 50_10\CD\13745420 mg/kg_11\NN\1740 i.v._12\NN\1740 )_13\-RRB-\1740 resulting_14\VBG\2633881 in_15\IN\13603305 a_16\DT\13649268 long-lasting_17\JJ\1740 reduction_18\NN\351485 (_19\-LRB-\1740 30_20\CD\13745420 %_21\NN\1740 )_22\-RRB-\1740 of_23\IN\1740 the_24\DT\1740 hemoglobin_25\NN\14888884 concentration_26\NN\4916342 ._27\.\1740
D016190_D000740 CID in_0\IN\13603305 a_1\DT\13649268 second_2\JJ\1740 group_3\NN\2137 ,_4\,\1740 the_5\DT\1740 development_6\NN\248977 of_7\IN\1740 <e2>anemia</e2>_8\NN\14189204 was_9\VBD\836236 prevented_10\VBN\1740 by_11\IN\1740 rhuepo_12\NN\1740 (_13\-LRB-\1740 1000_14\CD\13745420 iu/kg_15\NNS\1740 )_16\-RRB-\1740 administered_17\VBD\2436349 s.c._18\NN\1740 three_19\CD\13741022 times/week_20\NN\1740 starting_21\NN\457382 7_22\CD\13741022 days_23\NNS\15140892 before_24\IN\1740 <e1>carboplatin</e1>_25\NN\1740 application_26\NN\947128 ._27\.\1740
D016190_D009369 NONE four_0\CD\13741022 days_1\NNS\15140892 after_2\IN\1740 <e1>carboplatin</e1>_3\NN\1740 treatment_4\NN\654885 ,_5\,\1740 <e2>tumors</e2>_6\NNS\14234074 (_7\-LRB-\1740 ds-sarcoma_8\NN\1740 of_9\IN\1740 the_10\DT\1740 rat_11\NN\2329401 )_12\-RRB-\1740 were_13\VBD\836236 implanted_14\VBN\1421622 s.c._15\NN\1740 onto_16\IN\1740 the_17\DT\1740 hind_18\NN\2568959 food_19\NN\20090 dorsum_20\NN\5220461 ._21\.\1740
D016190_D009369 NONE neither_0\CC\1740 <e1>carboplatin</e1>_1\NN\1740 nor_2\CC\1740 rhuepo_3\JJ\1740 treatment_4\NN\654885 influenced_5\VBD\137313 <e2>tumor</e2>_6\NN\14234074 growth_7\NN\13526110 rate_8\NN\13815152 per_9\IN\1740 se_10\FW\14724645 ._11\.\1740
D016190_D012509 NONE four_0\CD\13741022 days_1\NNS\15140892 after_2\IN\1740 <e1>carboplatin</e1>_3\NN\1740 treatment_4\NN\654885 ,_5\,\1740 tumors_6\NNS\14234074 (_7\-LRB-\1740 <e2>ds-sarcoma</e2>_8\NN\1740 of_9\IN\1740 the_10\DT\1740 rat_11\NN\2329401 )_12\-RRB-\1740 were_13\VBD\836236 implanted_14\VBN\1421622 s.c._15\NN\1740 onto_16\IN\1740 the_17\DT\1740 hind_18\NN\2568959 food_19\NN\20090 dorsum_20\NN\5220461 ._21\.\1740
D010100_D000740 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chemotherapy-induced_4\JJ\1740 <e2>anemia</e2>_5\NN\14189204 reduces_6\VBZ\441445 cytotoxicity_7\NN\13583478 of_8\IN\1740 cyclophosphamide_9\NN\1740 in_10\IN\13603305 tumors_11\NNS\14234074 ,_12\,\1740 whereas_13\IN\1740 correction_14\NN\248977 of_15\IN\1740 anemia_16\NN\14189204 by_17\IN\1740 rhuepo_18\JJ\1740 treatment_19\NN\654885 (_20\-LRB-\1740 epoetin_21\NN\1740 alpha_22\NN\6828818 )_23\-RRB-\1740 increases_24\VBZ\169651 the_25\DT\1740 sensitivity_26\NN\5651971 ,_27\,\1740 probably_28\RB\1740 as_29\IN\14622893 a_30\DT\13649268 result_31\NN\34213 of_32\IN\1740 an_33\DT\6697703 improved_34\VBN\126264 <e1>oxygen</e1>_35\NN\14622893 supply_36\NN\13576355 to_37\TO\1740 tumor_38\NN\14234074 tissue_39\NN\5220461 ._40\.\1740
D010100_D000740 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chemotherapy-induced_4\JJ\1740 anemia_5\NN\14189204 reduces_6\VBZ\441445 cytotoxicity_7\NN\13583478 of_8\IN\1740 cyclophosphamide_9\NN\1740 in_10\IN\13603305 tumors_11\NNS\14234074 ,_12\,\1740 whereas_13\IN\1740 correction_14\NN\248977 of_15\IN\1740 <e2>anemia</e2>_16\NN\14189204 by_17\IN\1740 rhuepo_18\JJ\1740 treatment_19\NN\654885 (_20\-LRB-\1740 epoetin_21\NN\1740 alpha_22\NN\6828818 )_23\-RRB-\1740 increases_24\VBZ\169651 the_25\DT\1740 sensitivity_26\NN\5651971 ,_27\,\1740 probably_28\RB\1740 as_29\IN\14622893 a_30\DT\13649268 result_31\NN\34213 of_32\IN\1740 an_33\DT\6697703 improved_34\VBN\126264 <e1>oxygen</e1>_35\NN\14622893 supply_36\NN\13576355 to_37\TO\1740 tumor_38\NN\14234074 tissue_39\NN\5220461 ._40\.\1740
D010100_D064420 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chemotherapy-induced_4\JJ\1740 anemia_5\NN\14189204 reduces_6\VBZ\441445 <e2>cytotoxicity</e2>_7\NN\13583478 of_8\IN\1740 cyclophosphamide_9\NN\1740 in_10\IN\13603305 tumors_11\NNS\14234074 ,_12\,\1740 whereas_13\IN\1740 correction_14\NN\248977 of_15\IN\1740 anemia_16\NN\14189204 by_17\IN\1740 rhuepo_18\JJ\1740 treatment_19\NN\654885 (_20\-LRB-\1740 epoetin_21\NN\1740 alpha_22\NN\6828818 )_23\-RRB-\1740 increases_24\VBZ\169651 the_25\DT\1740 sensitivity_26\NN\5651971 ,_27\,\1740 probably_28\RB\1740 as_29\IN\14622893 a_30\DT\13649268 result_31\NN\34213 of_32\IN\1740 an_33\DT\6697703 improved_34\VBN\126264 <e1>oxygen</e1>_35\NN\14622893 supply_36\NN\13576355 to_37\TO\1740 tumor_38\NN\14234074 tissue_39\NN\5220461 ._40\.\1740
D010100_D009369 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chemotherapy-induced_4\JJ\1740 anemia_5\NN\14189204 reduces_6\VBZ\441445 cytotoxicity_7\NN\13583478 of_8\IN\1740 cyclophosphamide_9\NN\1740 in_10\IN\13603305 <e2>tumors</e2>_11\NNS\14234074 ,_12\,\1740 whereas_13\IN\1740 correction_14\NN\248977 of_15\IN\1740 anemia_16\NN\14189204 by_17\IN\1740 rhuepo_18\JJ\1740 treatment_19\NN\654885 (_20\-LRB-\1740 epoetin_21\NN\1740 alpha_22\NN\6828818 )_23\-RRB-\1740 increases_24\VBZ\169651 the_25\DT\1740 sensitivity_26\NN\5651971 ,_27\,\1740 probably_28\RB\1740 as_29\IN\14622893 a_30\DT\13649268 result_31\NN\34213 of_32\IN\1740 an_33\DT\6697703 improved_34\VBN\126264 <e1>oxygen</e1>_35\NN\14622893 supply_36\NN\13576355 to_37\TO\1740 tumor_38\NN\14234074 tissue_39\NN\5220461 ._40\.\1740
D010100_D009369 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 chemotherapy-induced_4\JJ\1740 anemia_5\NN\14189204 reduces_6\VBZ\441445 cytotoxicity_7\NN\13583478 of_8\IN\1740 cyclophosphamide_9\NN\1740 in_10\IN\13603305 tumors_11\NNS\14234074 ,_12\,\1740 whereas_13\IN\1740 correction_14\NN\248977 of_15\IN\1740 anemia_16\NN\14189204 by_17\IN\1740 rhuepo_18\JJ\1740 treatment_19\NN\654885 (_20\-LRB-\1740 epoetin_21\NN\1740 alpha_22\NN\6828818 )_23\-RRB-\1740 increases_24\VBZ\169651 the_25\DT\1740 sensitivity_26\NN\5651971 ,_27\,\1740 probably_28\RB\1740 as_29\IN\14622893 a_30\DT\13649268 result_31\NN\34213 of_32\IN\1740 an_33\DT\6697703 improved_34\VBN\126264 <e1>oxygen</e1>_35\NN\14622893 supply_36\NN\13576355 to_37\TO\1740 <e2>tumor</e2>_38\NN\14234074 tissue_39\NN\5220461 ._40\.\1740
6203632
D007545_D006332 CID development_0\NN\248977 of_1\IN\1740 <e1>isoproterenol-induced</e1>_2\JJ\1740 <e2>cardiac_3\JJ\1740 hypertrophy</e2>_4\NN\14365950 ._5\.\1740
D007545_D006332 CID the_0\DT\1740 development_1\NN\248977 of_2\IN\1740 <e2>cardiac_3\JJ\1740 hypertrophy</e2>_4\NN\14365950 was_5\VBD\836236 studied_6\VBN\630380 in_7\IN\13603305 adult_8\JJ\1740 female_9\NN\15388 wistar_10\NNP\1740 rats_11\NNS\2329401 following_12\VBG\1835496 daily_13\RB\1740 subcutaneous_14\JJ\1740 injections_15\NNS\320852 of_16\IN\1740 <e1>isoproterenol</e1>_17\NN\3740161 (_18\-LRB-\1740 iso_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 0.3_22\CD\1740 mg/kg_23\NN\1740 body_24\NN\19128 weight_25\NN\5009170 )_26\-RRB-\1740 ._27\.\1740
D007545_D006332 CID the_0\DT\1740 development_1\NN\248977 of_2\IN\1740 <e2>cardiac_3\JJ\1740 hypertrophy</e2>_4\NN\14365950 was_5\VBD\836236 studied_6\VBN\630380 in_7\IN\13603305 adult_8\JJ\1740 female_9\NN\15388 wistar_10\NNP\1740 rats_11\NNS\2329401 following_12\VBG\1835496 daily_13\RB\1740 subcutaneous_14\JJ\1740 injections_15\NNS\320852 of_16\IN\1740 isoproterenol_17\NN\3740161 (_18\-LRB-\1740 <e1>iso</e1>_19\NN\1740 )_20\-RRB-\1740 (_21\-LRB-\1740 0.3_22\CD\1740 mg/kg_23\NN\1740 body_24\NN\19128 weight_25\NN\5009170 )_26\-RRB-\1740 ._27\.\1740
D007545_D006984 NONE these_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 the_4\DT\1740 adaptive_5\JJ\1740 response_6\NN\11410625 to_7\TO\1740 <e1>iso</e1>_8\NN\1740 shows_9\VBZ\2137132 an_10\DT\6697703 early_11\JJ\1740 <e2>hypertrophic</e2>_12\JJ\1740 phase_13\NN\15113229 (_14\-LRB-\1740 1_15\CD\13741022 -_16\SYM\1740 4_17\CD\13741022 days_18\NNS\15140892 )_19\-RRB-\1740 characterized_20\VBN\609683 by_21\IN\1740 a_22\DT\13649268 substantial_23\JJ\1740 increase_24\NN\13576355 in_25\IN\13603305 rna_26\NN\14994328 content_27\NN\7951464 and_28\CC\1740 cardiac_29\JJ\1740 mass_30\NN\13575869 in_31\IN\13603305 the_32\DT\1740 absence_33\NN\14449405 of_34\IN\1740 changes_35\NNS\7283608 in_36\IN\13603305 dna_37\NN\14994328 ._38\.\1740
8607407
D002110_D006973 CID acute_0\JJ\1740 blood_1\NN\5397468 pressure_2\NN\11419404 elevations_3\NNS\7445480 with_4\IN\1740 <e1>caffeine</e1>_5\NN\14712692 in_6\IN\13603305 men_7\NNS\8208016 with_8\IN\1740 borderline_9\NN\8512259 systemic_10\JJ\1740 <e2>hypertension</e2>_11\NN\14057371 ._12\.\1740
D002110_D006973 CID whether_0\IN\1740 the_1\DT\1740 vasoconstrictive_2\JJ\1740 actions_3\NNS\30358 of_4\IN\1740 <e1>caffeine</e1>_5\NN\14712692 are_6\VBP\836236 enhanced_7\VBN\227165 in_8\IN\13603305 <e2>hypertensive</e2>_9\JJ\1740 persons_10\NNS\7347 has_11\VBZ\2108377 not_12\RB\1740 been_13\VBN\836236 demonstrated_14\VBN\2137132 ._15\.\1740
D002110_D006973 CID consequently_0\RB\1740 ,_1\,\1740 whereas_2\IN\1740 all_3\DT\1740 participants_4\NNS\9816771 exhibited_5\VBD\2632167 normotensive_6\JJ\1740 levels_7\NNS\4916342 during_8\IN\1740 the_9\DT\1740 resting_10\VBG\2604760 predrug_11\NN\1740 baseline_12\NN\7260623 ,_13\,\1740 33_14\CD\1740 %_15\NN\1740 of_16\IN\1740 borderline_17\NN\8512259 subjects_18\NNS\6598915 achieved_19\VBD\2524171 <e2>hypertensive</e2>_20\JJ\1740 bp_21\NN\1740 levels_22\NNS\4916342 after_23\IN\1740 <e1>caffeine</e1>_24\NN\14712692 ingestion_25\NN\13440063 ._26\.\1740
D002110_D006973 CID thus_0\RB\1740 ,_1\,\1740 in_2\IN\13603305 borderline_3\NN\8512259 <e2>hypertensive</e2>_4\NN\10405694 men_5\NNS\8208016 ,_6\,\1740 exaggerated_7\JJ\1740 responses_8\NNS\11410625 to_9\TO\1740 <e1>caffeine</e1>_10\NN\14712692 were_11\VBD\836236 :_12\:\1740 selective_13\JJ\1740 for_14\IN\1740 diastolic_15\JJ\1740 bp_16\NN\1740 ,_17\,\1740 consistent_18\JJ\1740 with_19\IN\1740 greater_20\JJR\1740 vasoconstriction_21\NN\1149911 ,_22\,\1740 replicated_23\VBN\2035919 in_24\IN\13603305 2_25\CD\13741022 protocols_26\NNS\6652242 ,_27\,\1740 and_28\CC\1740 representative_29\NN\10351874 of_30\IN\1740 nearly_31\RB\1740 all_32\DT\1740 borderline_33\NN\8512259 hypertensives_34\NNS\10405694 ._35\.\1740
D002110_D006973 CID thus_0\RB\1740 ,_1\,\1740 in_2\IN\13603305 borderline_3\NN\8512259 hypertensive_4\NN\10405694 men_5\NNS\8208016 ,_6\,\1740 exaggerated_7\JJ\1740 responses_8\NNS\11410625 to_9\TO\1740 <e1>caffeine</e1>_10\NN\14712692 were_11\VBD\836236 :_12\:\1740 selective_13\JJ\1740 for_14\IN\1740 diastolic_15\JJ\1740 bp_16\NN\1740 ,_17\,\1740 consistent_18\JJ\1740 with_19\IN\1740 greater_20\JJR\1740 vasoconstriction_21\NN\1149911 ,_22\,\1740 replicated_23\VBN\2035919 in_24\IN\13603305 2_25\CD\13741022 protocols_26\NNS\6652242 ,_27\,\1740 and_28\CC\1740 representative_29\NN\10351874 of_30\IN\1740 nearly_31\RB\1740 all_32\DT\1740 borderline_33\NN\8512259 <e2>hypertensives</e2>_34\NNS\10405694 ._35\.\1740
8473723
D008728_D012640 CID <e2>seizures</e2>_0\NNP\14081375 induced_1\VBN\1627355 by_2\IN\1740 combined_3\JJ\1740 <e1>levomepromazine-fluvoxamine</e1>_4\JJ\1740 treatment_5\NN\654885 ._6\.\1740
D008728_D012640 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 combined_5\JJ\1740 <e1>levomepromazine-fluvoxamine</e1>_6\JJ\1740 treatment-induced_7\JJ\1740 <e2>seizures</e2>_8\NNS\14081375 ._9\.\1740
D016666_D012640 CID <e2>seizures</e2>_0\NNP\14081375 induced_1\VBN\1627355 by_2\IN\1740 combined_3\JJ\1740 <e1>levomepromazine-fluvoxamine</e1>_4\JJ\1740 treatment_5\NN\654885 ._6\.\1740
D016666_D012640 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 combined_5\JJ\1740 <e1>levomepromazine-fluvoxamine</e1>_6\JJ\1740 treatment-induced_7\JJ\1740 <e2>seizures</e2>_8\NNS\14081375 ._9\.\1740
17194457
-1_D001523 NONE chronic_0\JJ\1740 exposure_1\NN\5042871 to_2\TO\1740 <e1>pcpa</e1>_3\NN\1740 alone_4\RB\1740 significantly_5\RB\1740 decreased_6\VBD\169651 locomotor_7\NN\1740 activity_8\NN\30358 and_9\CC\1740 increased_10\VBN\169651 <e2>irritability</e2>_11\NN\7552087 but_12\CC\1740 had_13\VBD\2108377 no_14\DT\7204911 effect_15\NN\34213 on_16\IN\1740 sexual_17\JJ\1740 behavior_18\NN\407535 ,_19\,\1740 partner_20\NN\10024362 preference_21\NN\7497473 ,_22\,\1740 or_23\CC\3541091 aggression_24\NN\4657876 ._25\.\1740
-1_D001523 NONE chronic_0\JJ\1740 exposure_1\NN\5042871 to_2\TO\1740 <e1>pcpa</e1>_3\NN\1740 alone_4\RB\1740 significantly_5\RB\1740 decreased_6\VBD\169651 locomotor_7\NN\1740 activity_8\NN\30358 and_9\CC\1740 increased_10\VBN\169651 irritability_11\NN\7552087 but_12\CC\1740 had_13\VBD\2108377 no_14\DT\7204911 effect_15\NN\34213 on_16\IN\1740 sexual_17\JJ\1740 behavior_18\NN\407535 ,_19\,\1740 partner_20\NN\10024362 preference_21\NN\7497473 ,_22\,\1740 or_23\CC\3541091 <e2>aggression</e2>_24\NN\4657876 ._25\.\1740
D013739_D001523 CID <e1>t</e1>_0\NN\14999913 alone_1\RB\1740 had_2\VBD\2108377 no_3\DT\7204911 effect_4\NN\34213 on_5\IN\1740 locomotion_6\NN\4773351 ,_7\,\1740 <e2>irritability</e2>_8\NN\7552087 ,_9\,\1740 or_10\CC\3541091 sexual_11\JJ\1740 behavior_12\NN\407535 but_13\CC\1740 increased_14\VBD\169651 partner_15\NN\10024362 preference_16\NN\7497473 and_17\CC\1740 aggression_18\NN\4657876 ._19\.\1740
D013739_D001523 CID <e1>t</e1>_0\NN\14999913 alone_1\RB\1740 had_2\VBD\2108377 no_3\DT\7204911 effect_4\NN\34213 on_5\IN\1740 locomotion_6\NN\4773351 ,_7\,\1740 irritability_8\NN\7552087 ,_9\,\1740 or_10\CC\3541091 sexual_11\JJ\1740 behavior_12\NN\407535 but_13\CC\1740 increased_14\VBD\169651 partner_15\NN\10024362 preference_16\NN\7497473 and_17\CC\1740 <e2>aggression</e2>_18\NN\4657876 ._19\.\1740
D012701_D001523 NONE based_0\VBN\2694933 on_1\IN\1740 these_2\DT\1740 data_3\NNS\7951464 ,_4\,\1740 it_5\PRP\6125041 can_6\MD\3094503 be_7\VB\836236 speculated_8\VBN\719734 that_9\IN\1740 pubertal_10\JJ\1740 aas_11\NN\6697703 users_12\NNS\7846 with_13\IN\1740 low_14\JJ\1740 central_15\JJ\1740 <e1>5-ht</e1>_16\NN\1740 may_17\MD\15209706 be_18\VB\836236 especially_19\RB\1740 prone_20\JJ\1740 to_21\TO\1740 exhibit_22\VB\2632167 <e2>aggressive_23\JJ\1740 behavior</e2>_24\NN\407535 ._25\.\1740
20394767
D015016_D012021 CID furthermore_0\RB\1740 ,_1\,\1740 <e1>yohimbine</e1>_2\NN\1740 increased_3\VBD\169651 baseline_4\NN\7260623 <e2>startle</e2>_5\VBP\1809064 amplitude_6\NN\7444668 in_7\IN\13603305 the_8\DT\1740 les_9\NN\14187378 ,_10\,\1740 while_11\IN\15122231 mcpp_12\NN\1740 suppressed_13\VBD\2510337 baseline_14\NN\7260623 startle_15\VBP\1809064 in_16\IN\13603305 both_17\CC\1740 the_18\DT\1740 les_19\NN\14187378 and_20\CC\1740 fps_21\NN\8338847 and_22\CC\1740 ptz_23\NN\1740 suppressed_24\VBD\2510337 baseline_25\NN\7260623 startle_26\VBP\1809064 in_27\IN\13603305 the_28\DT\1740 fps_29\NN\8338847 ._30\.\1740
D015016_D012021 CID furthermore_0\RB\1740 ,_1\,\1740 <e1>yohimbine</e1>_2\NN\1740 increased_3\VBD\169651 baseline_4\NN\7260623 startle_5\VBP\1809064 amplitude_6\NN\7444668 in_7\IN\13603305 the_8\DT\1740 les_9\NN\14187378 ,_10\,\1740 while_11\IN\15122231 mcpp_12\NN\1740 suppressed_13\VBD\2510337 baseline_14\NN\7260623 <e2>startle</e2>_15\VBP\1809064 in_16\IN\13603305 both_17\CC\1740 the_18\DT\1740 les_19\NN\14187378 and_20\CC\1740 fps_21\NN\8338847 and_22\CC\1740 ptz_23\NN\1740 suppressed_24\VBD\2510337 baseline_25\NN\7260623 startle_26\VBP\1809064 in_27\IN\13603305 the_28\DT\1740 fps_29\NN\8338847 ._30\.\1740
D015016_D012021 CID furthermore_0\RB\1740 ,_1\,\1740 <e1>yohimbine</e1>_2\NN\1740 increased_3\VBD\169651 baseline_4\NN\7260623 startle_5\VBP\1809064 amplitude_6\NN\7444668 in_7\IN\13603305 the_8\DT\1740 les_9\NN\14187378 ,_10\,\1740 while_11\IN\15122231 mcpp_12\NN\1740 suppressed_13\VBD\2510337 baseline_14\NN\7260623 startle_15\VBP\1809064 in_16\IN\13603305 both_17\CC\1740 the_18\DT\1740 les_19\NN\14187378 and_20\CC\1740 fps_21\NN\8338847 and_22\CC\1740 ptz_23\NN\1740 suppressed_24\VBD\2510337 baseline_25\NN\7260623 <e2>startle</e2>_26\VBP\1809064 in_27\IN\13603305 the_28\DT\1740 fps_29\NN\8338847 ._30\.\1740
C015068_D012021 CID furthermore_0\RB\1740 ,_1\,\1740 yohimbine_2\NN\1740 increased_3\VBD\169651 baseline_4\NN\7260623 <e2>startle</e2>_5\VBP\1809064 amplitude_6\NN\7444668 in_7\IN\13603305 the_8\DT\1740 les_9\NN\14187378 ,_10\,\1740 while_11\IN\15122231 <e1>mcpp</e1>_12\NN\1740 suppressed_13\VBD\2510337 baseline_14\NN\7260623 startle_15\VBP\1809064 in_16\IN\13603305 both_17\CC\1740 the_18\DT\1740 les_19\NN\14187378 and_20\CC\1740 fps_21\NN\8338847 and_22\CC\1740 ptz_23\NN\1740 suppressed_24\VBD\2510337 baseline_25\NN\7260623 startle_26\VBP\1809064 in_27\IN\13603305 the_28\DT\1740 fps_29\NN\8338847 ._30\.\1740
C015068_D012021 CID furthermore_0\RB\1740 ,_1\,\1740 yohimbine_2\NN\1740 increased_3\VBD\169651 baseline_4\NN\7260623 startle_5\VBP\1809064 amplitude_6\NN\7444668 in_7\IN\13603305 the_8\DT\1740 les_9\NN\14187378 ,_10\,\1740 while_11\IN\15122231 <e1>mcpp</e1>_12\NN\1740 suppressed_13\VBD\2510337 baseline_14\NN\7260623 <e2>startle</e2>_15\VBP\1809064 in_16\IN\13603305 both_17\CC\1740 the_18\DT\1740 les_19\NN\14187378 and_20\CC\1740 fps_21\NN\8338847 and_22\CC\1740 ptz_23\NN\1740 suppressed_24\VBD\2510337 baseline_25\NN\7260623 startle_26\VBP\1809064 in_27\IN\13603305 the_28\DT\1740 fps_29\NN\8338847 ._30\.\1740
C015068_D012021 CID furthermore_0\RB\1740 ,_1\,\1740 yohimbine_2\NN\1740 increased_3\VBD\169651 baseline_4\NN\7260623 startle_5\VBP\1809064 amplitude_6\NN\7444668 in_7\IN\13603305 the_8\DT\1740 les_9\NN\14187378 ,_10\,\1740 while_11\IN\15122231 <e1>mcpp</e1>_12\NN\1740 suppressed_13\VBD\2510337 baseline_14\NN\7260623 startle_15\VBP\1809064 in_16\IN\13603305 both_17\CC\1740 the_18\DT\1740 les_19\NN\14187378 and_20\CC\1740 fps_21\NN\8338847 and_22\CC\1740 ptz_23\NN\1740 suppressed_24\VBD\2510337 baseline_25\NN\7260623 <e2>startle</e2>_26\VBP\1809064 in_27\IN\13603305 the_28\DT\1740 fps_29\NN\8338847 ._30\.\1740
D010433_D012021 CID furthermore_0\RB\1740 ,_1\,\1740 yohimbine_2\NN\1740 increased_3\VBD\169651 baseline_4\NN\7260623 <e2>startle</e2>_5\VBP\1809064 amplitude_6\NN\7444668 in_7\IN\13603305 the_8\DT\1740 les_9\NN\14187378 ,_10\,\1740 while_11\IN\15122231 mcpp_12\NN\1740 suppressed_13\VBD\2510337 baseline_14\NN\7260623 startle_15\VBP\1809064 in_16\IN\13603305 both_17\CC\1740 the_18\DT\1740 les_19\NN\14187378 and_20\CC\1740 fps_21\NN\8338847 and_22\CC\1740 <e1>ptz</e1>_23\NN\1740 suppressed_24\VBD\2510337 baseline_25\NN\7260623 startle_26\VBP\1809064 in_27\IN\13603305 the_28\DT\1740 fps_29\NN\8338847 ._30\.\1740
D010433_D012021 CID furthermore_0\RB\1740 ,_1\,\1740 yohimbine_2\NN\1740 increased_3\VBD\169651 baseline_4\NN\7260623 startle_5\VBP\1809064 amplitude_6\NN\7444668 in_7\IN\13603305 the_8\DT\1740 les_9\NN\14187378 ,_10\,\1740 while_11\IN\15122231 mcpp_12\NN\1740 suppressed_13\VBD\2510337 baseline_14\NN\7260623 <e2>startle</e2>_15\VBP\1809064 in_16\IN\13603305 both_17\CC\1740 the_18\DT\1740 les_19\NN\14187378 and_20\CC\1740 fps_21\NN\8338847 and_22\CC\1740 <e1>ptz</e1>_23\NN\1740 suppressed_24\VBD\2510337 baseline_25\NN\7260623 startle_26\VBP\1809064 in_27\IN\13603305 the_28\DT\1740 fps_29\NN\8338847 ._30\.\1740
D010433_D012021 CID furthermore_0\RB\1740 ,_1\,\1740 yohimbine_2\NN\1740 increased_3\VBD\169651 baseline_4\NN\7260623 startle_5\VBP\1809064 amplitude_6\NN\7444668 in_7\IN\13603305 the_8\DT\1740 les_9\NN\14187378 ,_10\,\1740 while_11\IN\15122231 mcpp_12\NN\1740 suppressed_13\VBD\2510337 baseline_14\NN\7260623 startle_15\VBP\1809064 in_16\IN\13603305 both_17\CC\1740 the_18\DT\1740 les_19\NN\14187378 and_20\CC\1740 fps_21\NN\8338847 and_22\CC\1740 <e1>ptz</e1>_23\NN\1740 suppressed_24\VBD\2510337 baseline_25\NN\7260623 <e2>startle</e2>_26\VBP\1809064 in_27\IN\13603305 the_28\DT\1740 fps_29\NN\8338847 ._30\.\1740
9228650
C049860_D000647 CID effects_0\NNS\13245626 of_1\IN\1740 <e1>nik-247</e1>_2\NN\1740 on_3\IN\1740 cholinesterase_4\NN\14732946 and_5\CC\1740 scopolamine-induced_6\JJ\1740 <e2>amnesia</e2>_7\NN\5669934 ._8\.\1740
C049860_D000647 CID the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>nik-247</e1>_3\NN\1740 on_4\IN\1740 cholinesterase_5\NN\14732946 ,_6\,\1740 scopolamine-induced_7\JJ\1740 <e2>amnesia</e2>_8\NN\5669934 and_9\CC\1740 spontaneous_10\JJ\1740 movement_11\NN\191142 were_12\VBD\836236 examined_13\VBN\789138 and_14\CC\1740 compared_15\VBN\644583 with_16\IN\1740 those_17\DT\1740 of_18\IN\1740 the_19\DT\1740 well-known_20\JJ\1740 cholinesterase_21\NN\14732946 inhibitors_22\NNS\20090 tacrine_23\VBP\1740 and_24\CC\1740 e-2020_25\NN\1740 ._26\.\1740
C049860_D000647 CID these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>nik-247</e1>_4\NN\1740 at_5\IN\14622893 a_6\DT\13649268 low_7\JJ\1740 dose_8\NN\3740161 (_9\-LRB-\1740 0.1_10\CD\1740 -_11\SYM\1740 1_12\CD\13741022 mg/kg_13\NN\1740 p.o._14\NN\10360747 )_15\-RRB-\1740 improves_16\VBZ\126264 scopolamine-induced_17\JJ\1740 <e2>amnesia</e2>_18\NN\5669934 but_19\CC\1740 does_20\VBZ\1640855 not_21\RB\1740 affect_22\VB\126264 spontaneous_23\JJ\1740 movement_24\NN\191142 ._25\.\1740
D012601_D000647 CID effects_0\NNS\13245626 of_1\IN\1740 nik-247_2\NN\1740 on_3\IN\1740 cholinesterase_4\NN\14732946 and_5\CC\1740 <e1>scopolamine-induced</e1>_6\JJ\1740 <e2>amnesia</e2>_7\NN\5669934 ._8\.\1740
D012601_D000647 CID the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 nik-247_3\NN\1740 on_4\IN\1740 cholinesterase_5\NN\14732946 ,_6\,\1740 <e1>scopolamine-induced</e1>_7\JJ\1740 <e2>amnesia</e2>_8\NN\5669934 and_9\CC\1740 spontaneous_10\JJ\1740 movement_11\NN\191142 were_12\VBD\836236 examined_13\VBN\789138 and_14\CC\1740 compared_15\VBN\644583 with_16\IN\1740 those_17\DT\1740 of_18\IN\1740 the_19\DT\1740 well-known_20\JJ\1740 cholinesterase_21\NN\14732946 inhibitors_22\NNS\20090 tacrine_23\VBP\1740 and_24\CC\1740 e-2020_25\NN\1740 ._26\.\1740
D012601_D000647 CID all_0\DT\1740 compounds_1\NNS\5869584 at_2\IN\14622893 0.1_3\CD\1740 -_4\SYM\1740 1_5\CD\13741022 mg/kg_6\NN\1740 p.o._7\NN\10360747 significantly_8\RB\1740 improved_9\VBD\126264 the_10\DT\1740 <e2>amnesia</e2>_11\NN\5669934 induced_12\VBN\1627355 by_13\IN\1740 <e1>scopolamine</e1>_14\NN\14712692 (_15\-LRB-\1740 0.5_16\CD\1740 mg/kg_17\NN\1740 s.c._18\NN\1740 )_19\-RRB-\1740 in_20\IN\13603305 rats_21\NNS\2329401 performing_22\VBG\2367363 a_23\DT\13649268 passive_24\JJ\1740 avoidance_25\NN\203342 task_26\NN\575741 ._27\.\1740
D012601_D000647 CID these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 nik-247_4\NN\1740 at_5\IN\14622893 a_6\DT\13649268 low_7\JJ\1740 dose_8\NN\3740161 (_9\-LRB-\1740 0.1_10\CD\1740 -_11\SYM\1740 1_12\CD\13741022 mg/kg_13\NN\1740 p.o._14\NN\10360747 )_15\-RRB-\1740 improves_16\VBZ\126264 <e1>scopolamine-induced</e1>_17\JJ\1740 <e2>amnesia</e2>_18\NN\5669934 but_19\CC\1740 does_20\VBZ\1640855 not_21\RB\1740 affect_22\VB\126264 spontaneous_23\JJ\1740 movement_24\NN\191142 ._25\.\1740
D013619_D000647 CID the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 nik-247_3\NN\1740 on_4\IN\1740 cholinesterase_5\NN\14732946 ,_6\,\1740 scopolamine-induced_7\JJ\1740 <e2>amnesia</e2>_8\NN\5669934 and_9\CC\1740 spontaneous_10\JJ\1740 movement_11\NN\191142 were_12\VBD\836236 examined_13\VBN\789138 and_14\CC\1740 compared_15\VBN\644583 with_16\IN\1740 those_17\DT\1740 of_18\IN\1740 the_19\DT\1740 well-known_20\JJ\1740 cholinesterase_21\NN\14732946 inhibitors_22\NNS\20090 <e1>tacrine</e1>_23\VBP\1740 and_24\CC\1740 e-2020_25\NN\1740 ._26\.\1740
C076946_D000647 CID the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 nik-247_3\NN\1740 on_4\IN\1740 cholinesterase_5\NN\14732946 ,_6\,\1740 scopolamine-induced_7\JJ\1740 <e2>amnesia</e2>_8\NN\5669934 and_9\CC\1740 spontaneous_10\JJ\1740 movement_11\NN\191142 were_12\VBD\836236 examined_13\VBN\789138 and_14\CC\1740 compared_15\VBN\644583 with_16\IN\1740 those_17\DT\1740 of_18\IN\1740 the_19\DT\1740 well-known_20\JJ\1740 cholinesterase_21\NN\14732946 inhibitors_22\NNS\20090 tacrine_23\VBP\1740 and_24\CC\1740 <e1>e-2020</e1>_25\NN\1740 ._26\.\1740
C049860_D000544 NONE the_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>nik-247</e1>_4\NN\1740 may_5\MD\15209706 be_6\VB\836236 a_7\DT\13649268 useful_8\JJ\1740 drug_9\NN\14778436 for_10\IN\1740 the_11\DT\1740 treatment_12\NN\654885 of_13\IN\1740 <e2>alzheimer_14\NN\1740 's_15\POS\1740 disease</e2>_16\NN\14061805 ._17\.\1740
17702969
D005473_D005315 CID prenatal_0\JJ\1740 exposure_1\NN\5042871 to_2\TO\1740 <e1>fluoxetine</e1>_3\NN\4169152 induces_4\VBZ\1627355 <e2>fetal_5\JJ\1740 pulmonary_6\JJ\1740 hypertension</e2>_7\NN\14057371 in_8\IN\13603305 the_9\DT\1740 rat_10\NN\2329401 ._11\.\1740
D005473_D005315 CID as_0\IN\14622893 compared_1\VBN\644583 with_2\IN\1740 controls_3\NNS\5190804 ,_4\,\1740 <e1>fluoxetine</e1>_5\NN\4169152 exposure_6\NN\5042871 resulted_7\VBD\2633881 in_8\IN\13603305 <e2>fetal_9\JJ\1740 pulmonary_10\JJ\1740 hypertension</e2>_11\NN\14057371 as_12\IN\14622893 evidenced_13\VBN\1015244 by_14\IN\1740 an_15\DT\6697703 increase_16\NN\13576355 in_17\IN\13603305 the_18\DT\1740 weight_19\NN\5009170 ratio_20\NN\13815152 of_21\IN\1740 the_22\DT\1740 right_23\JJ\1740 ventricle_24\NN\5303402 to_25\TO\1740 the_26\DT\1740 left_27\JJ\1740 ventricle_28\NN\5303402 plus_29\CC\4723816 septum_30\NN\5222790 (_31\-LRB-\1740 p_32\NN\14622893 =_33\JJ\1740 0.02_34\CD\1740 )_35\-RRB-\1740 and_36\CC\1740 by_37\IN\1740 an_38\DT\6697703 increase_39\NN\13576355 in_40\IN\13603305 pulmonary_41\JJ\1740 arterial_42\JJ\1740 medial_43\JJ\1740 thickness_44\NN\5093581 (_45\-LRB-\1740 p_46\NN\14622893 <_47\XX\1740 0.01_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D005473_D006976 CID prenatal_0\JJ\1740 exposure_1\NN\5042871 to_2\TO\1740 <e1>fluoxetine</e1>_3\NN\4169152 induces_4\VBZ\1627355 <e2>fetal_5\JJ\1740 pulmonary_6\JJ\1740 hypertension</e2>_7\NN\14057371 in_8\IN\13603305 the_9\DT\1740 rat_10\NN\2329401 ._11\.\1740
D005473_D006976 CID epidemiological_0\JJ\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>fluoxetine</e1>_4\NN\4169152 exposure_5\NN\5042871 prenatally_6\RB\1740 increases_7\VBZ\169651 the_8\DT\1740 prevalence_9\NN\4764412 of_10\IN\1740 persistent_11\JJ\1740 <e2>pulmonary_12\JJ\1740 hypertension_13\NN\14057371 syndrome</e2>_14\NN\5870365 of_15\IN\1740 the_16\DT\1740 newborn_17\JJ\1740 ._18\.\1740
D005473_D006976 CID the_0\DT\1740 mechanism_1\NN\13446390 responsible_2\JJ\1740 for_3\IN\1740 this_4\DT\1740 effect_5\NN\34213 is_6\VBZ\836236 unclear_7\JJ\1740 and_8\CC\1740 paradoxical_9\JJ\1740 ,_10\,\1740 considering_11\VBG\689344 the_12\DT\1740 current_13\JJ\1740 evidence_14\NN\5816287 of_15\IN\1740 a_16\DT\13649268 <e2>pulmonary_17\JJ\1740 hypertension</e2>_18\NN\14057371 protective_19\JJ\1740 <e1>fluoxetine</e1>_20\NN\4169152 effect_21\NN\34213 in_22\IN\13603305 adult_23\JJ\1740 rodents_24\NNS\1886756 ._25\.\1740
D005473_D006976 CID as_0\IN\14622893 compared_1\VBN\644583 with_2\IN\1740 controls_3\NNS\5190804 ,_4\,\1740 <e1>fluoxetine</e1>_5\NN\4169152 exposure_6\NN\5042871 resulted_7\VBD\2633881 in_8\IN\13603305 <e2>fetal_9\JJ\1740 pulmonary_10\JJ\1740 hypertension</e2>_11\NN\14057371 as_12\IN\14622893 evidenced_13\VBN\1015244 by_14\IN\1740 an_15\DT\6697703 increase_16\NN\13576355 in_17\IN\13603305 the_18\DT\1740 weight_19\NN\5009170 ratio_20\NN\13815152 of_21\IN\1740 the_22\DT\1740 right_23\JJ\1740 ventricle_24\NN\5303402 to_25\TO\1740 the_26\DT\1740 left_27\JJ\1740 ventricle_28\NN\5303402 plus_29\CC\4723816 septum_30\NN\5222790 (_31\-LRB-\1740 p_32\NN\14622893 =_33\JJ\1740 0.02_34\CD\1740 )_35\-RRB-\1740 and_36\CC\1740 by_37\IN\1740 an_38\DT\6697703 increase_39\NN\13576355 in_40\IN\13603305 pulmonary_41\JJ\1740 arterial_42\JJ\1740 medial_43\JJ\1740 thickness_44\NN\5093581 (_45\-LRB-\1740 p_46\NN\14622893 <_47\XX\1740 0.01_48\CD\1740 )_49\-RRB-\1740 ._50\.\1740
D005473_D006976 CID conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 contrast_3\NN\13854649 to_4\TO\1740 the_5\DT\1740 adult_6\NN\7846 ,_7\,\1740 <e1>fluoxetine</e1>_8\NN\4169152 exposure_9\NN\5042871 in_10\IN\13603305 utero_11\NN\1740 induces_12\VBZ\1627355 <e2>pulmonary_13\JJ\1740 hypertension</e2>_14\NN\14057371 in_15\IN\13603305 the_16\DT\1740 fetal_17\JJ\1740 rat_18\NN\2329401 as_19\IN\14622893 a_20\DT\13649268 result_21\NN\34213 of_22\IN\1740 a_23\DT\13649268 developmentally_24\RB\1740 regulated_25\VBN\296178 increase_26\NN\13576355 in_27\IN\13603305 pulmonary_28\JJ\1740 vascular_29\JJ\1740 smooth_30\JJ\1740 muscle_31\NN\5289601 proliferation_32\NN\13489037 ._33\.\1740
17490790
D007505_D009410 CID peripheral_0\JJ\1740 <e1>iron_1\NN\14625458 dextran</e1>_2\NN\1740 induced_3\JJ\1740 <e2>degeneration_4\NN\29677 of_5\IN\1740 dopaminergic_6\JJ\1740 neurons</e2>_7\NNS\5430628 in_8\IN\13603305 rat_9\NN\2329401 substantia_10\RB\1740 nigra_11\JJ\1740 ._12\.\1740
D007505_D009410 CID to_0\TO\1740 demonstrate_1\VB\2137132 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 peripheral_5\JJ\1740 iron_6\NN\14625458 overload_7\NN\3679986 and_8\CC\1740 dopaminergic_9\JJ\1740 neuron_10\NN\5430628 loss_11\NN\13252973 in_12\IN\13603305 rat_13\NN\2329401 substantia_14\RB\1740 nigra_15\JJ\1740 (_16\-LRB-\1740 sn_17\NN\14625458 )_18\-RRB-\1740 ,_19\,\1740 in_20\IN\13603305 the_21\DT\1740 present_22\JJ\1740 study_23\NN\635850 we_24\PRP\1740 used_25\VBD\1156834 fast_26\JJ\1740 cyclic_27\JJ\1740 voltammetry_28\NN\1740 ,_29\,\1740 tyrosine_30\NN\14601829 hydroxylase_31\NN\1740 (_32\-LRB-\1740 th_33\NN\15163157 )_34\-RRB-\1740 immunohistochemistry_35\NN\791527 ,_36\,\1740 perls_37\NNP\1740 '_38\POS\1740 iron_39\NN\14625458 staining_40\NN\275424 ,_41\,\1740 and_42\CC\1740 high_43\JJ\1740 performance_44\NN\6619065 liquid_45\NN\14939900 chromatography-electrochemical_46\JJ\1740 detection_47\NN\5708432 to_48\TO\1740 study_49\VB\630380 the_50\DT\1740 <e2>degeneration_51\NN\29677 of_52\IN\1740 dopaminergic_53\JJ\1740 neurons</e2>_54\NNS\5430628 and_55\CC\1740 increased_56\VBD\169651 iron_57\NN\14625458 content_58\NN\7951464 in_59\IN\13603305 the_60\DT\1740 sn_61\NN\14625458 of_62\IN\1740 <e1>iron_63\NN\14625458 dextran</e1>_64\NN\1740 overloaded_65\VBN\452512 animals_66\NNS\4475 ._67\.\1740
D007505_D009410 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 peripheral_4\JJ\1740 <e1>iron_5\NN\14625458 dextran</e1>_6\NN\1740 can_7\MD\3094503 increase_8\VB\169651 the_9\DT\1740 iron_10\NN\14625458 level_11\NN\4916342 in_12\IN\13603305 the_13\DT\1740 sn_14\NNP\14625458 ,_15\,\1740 where_16\WRB\1740 excessive_17\JJ\1740 iron_18\NN\14625458 causes_19\VBZ\1617192 the_20\DT\1740 <e2>degeneration_21\NN\29677 of_22\IN\1740 dopaminergic_23\JJ\1740 neurons</e2>_24\NNS\5430628 ._25\.\1740
D007501_D010300 NONE <e1>iron</e1>_0\NN\14625458 accumulation_1\NN\13497135 is_2\VBZ\836236 considered_3\VBN\689344 to_4\TO\1740 be_5\VB\836236 involved_6\VBN\2676054 in_7\IN\13603305 the_8\DT\1740 pathogenesis_9\NN\13533470 of_10\IN\1740 <e2>parkinson_11\NN\1740 's_12\POS\1740 disease</e2>_13\NN\14061805 ._14\.\1740
D007501_D009410 NONE to_0\TO\1740 demonstrate_1\VB\2137132 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 peripheral_5\JJ\1740 <e1>iron</e1>_6\NN\14625458 overload_7\NN\3679986 and_8\CC\1740 dopaminergic_9\JJ\1740 neuron_10\NN\5430628 loss_11\NN\13252973 in_12\IN\13603305 rat_13\NN\2329401 substantia_14\RB\1740 nigra_15\JJ\1740 (_16\-LRB-\1740 sn_17\NN\14625458 )_18\-RRB-\1740 ,_19\,\1740 in_20\IN\13603305 the_21\DT\1740 present_22\JJ\1740 study_23\NN\635850 we_24\PRP\1740 used_25\VBD\1156834 fast_26\JJ\1740 cyclic_27\JJ\1740 voltammetry_28\NN\1740 ,_29\,\1740 tyrosine_30\NN\14601829 hydroxylase_31\NN\1740 (_32\-LRB-\1740 th_33\NN\15163157 )_34\-RRB-\1740 immunohistochemistry_35\NN\791527 ,_36\,\1740 perls_37\NNP\1740 '_38\POS\1740 iron_39\NN\14625458 staining_40\NN\275424 ,_41\,\1740 and_42\CC\1740 high_43\JJ\1740 performance_44\NN\6619065 liquid_45\NN\14939900 chromatography-electrochemical_46\JJ\1740 detection_47\NN\5708432 to_48\TO\1740 study_49\VB\630380 the_50\DT\1740 <e2>degeneration_51\NN\29677 of_52\IN\1740 dopaminergic_53\JJ\1740 neurons</e2>_54\NNS\5430628 and_55\CC\1740 increased_56\VBD\169651 iron_57\NN\14625458 content_58\NN\7951464 in_59\IN\13603305 the_60\DT\1740 sn_61\NN\14625458 of_62\IN\1740 iron_63\NN\14625458 dextran_64\NN\1740 overloaded_65\VBN\452512 animals_66\NNS\4475 ._67\.\1740
D007501_D009410 NONE to_0\TO\1740 demonstrate_1\VB\2137132 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 peripheral_5\JJ\1740 iron_6\NN\14625458 overload_7\NN\3679986 and_8\CC\1740 dopaminergic_9\JJ\1740 neuron_10\NN\5430628 loss_11\NN\13252973 in_12\IN\13603305 rat_13\NN\2329401 substantia_14\RB\1740 nigra_15\JJ\1740 (_16\-LRB-\1740 sn_17\NN\14625458 )_18\-RRB-\1740 ,_19\,\1740 in_20\IN\13603305 the_21\DT\1740 present_22\JJ\1740 study_23\NN\635850 we_24\PRP\1740 used_25\VBD\1156834 fast_26\JJ\1740 cyclic_27\JJ\1740 voltammetry_28\NN\1740 ,_29\,\1740 tyrosine_30\NN\14601829 hydroxylase_31\NN\1740 (_32\-LRB-\1740 th_33\NN\15163157 )_34\-RRB-\1740 immunohistochemistry_35\NN\791527 ,_36\,\1740 perls_37\NNP\1740 '_38\POS\1740 <e1>iron</e1>_39\NN\14625458 staining_40\NN\275424 ,_41\,\1740 and_42\CC\1740 high_43\JJ\1740 performance_44\NN\6619065 liquid_45\NN\14939900 chromatography-electrochemical_46\JJ\1740 detection_47\NN\5708432 to_48\TO\1740 study_49\VB\630380 the_50\DT\1740 <e2>degeneration_51\NN\29677 of_52\IN\1740 dopaminergic_53\JJ\1740 neurons</e2>_54\NNS\5430628 and_55\CC\1740 increased_56\VBD\169651 iron_57\NN\14625458 content_58\NN\7951464 in_59\IN\13603305 the_60\DT\1740 sn_61\NN\14625458 of_62\IN\1740 iron_63\NN\14625458 dextran_64\NN\1740 overloaded_65\VBN\452512 animals_66\NNS\4475 ._67\.\1740
D007501_D009410 NONE to_0\TO\1740 demonstrate_1\VB\2137132 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 peripheral_5\JJ\1740 iron_6\NN\14625458 overload_7\NN\3679986 and_8\CC\1740 dopaminergic_9\JJ\1740 neuron_10\NN\5430628 loss_11\NN\13252973 in_12\IN\13603305 rat_13\NN\2329401 substantia_14\RB\1740 nigra_15\JJ\1740 (_16\-LRB-\1740 sn_17\NN\14625458 )_18\-RRB-\1740 ,_19\,\1740 in_20\IN\13603305 the_21\DT\1740 present_22\JJ\1740 study_23\NN\635850 we_24\PRP\1740 used_25\VBD\1156834 fast_26\JJ\1740 cyclic_27\JJ\1740 voltammetry_28\NN\1740 ,_29\,\1740 tyrosine_30\NN\14601829 hydroxylase_31\NN\1740 (_32\-LRB-\1740 th_33\NN\15163157 )_34\-RRB-\1740 immunohistochemistry_35\NN\791527 ,_36\,\1740 perls_37\NNP\1740 '_38\POS\1740 iron_39\NN\14625458 staining_40\NN\275424 ,_41\,\1740 and_42\CC\1740 high_43\JJ\1740 performance_44\NN\6619065 liquid_45\NN\14939900 chromatography-electrochemical_46\JJ\1740 detection_47\NN\5708432 to_48\TO\1740 study_49\VB\630380 the_50\DT\1740 <e2>degeneration_51\NN\29677 of_52\IN\1740 dopaminergic_53\JJ\1740 neurons</e2>_54\NNS\5430628 and_55\CC\1740 increased_56\VBD\169651 <e1>iron</e1>_57\NN\14625458 content_58\NN\7951464 in_59\IN\13603305 the_60\DT\1740 sn_61\NN\14625458 of_62\IN\1740 iron_63\NN\14625458 dextran_64\NN\1740 overloaded_65\VBN\452512 animals_66\NNS\4475 ._67\.\1740
D007501_D009410 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 peripheral_4\JJ\1740 iron_5\NN\14625458 dextran_6\NN\1740 can_7\MD\3094503 increase_8\VB\169651 the_9\DT\1740 <e1>iron</e1>_10\NN\14625458 level_11\NN\4916342 in_12\IN\13603305 the_13\DT\1740 sn_14\NNP\14625458 ,_15\,\1740 where_16\WRB\1740 excessive_17\JJ\1740 iron_18\NN\14625458 causes_19\VBZ\1617192 the_20\DT\1740 <e2>degeneration_21\NN\29677 of_22\IN\1740 dopaminergic_23\JJ\1740 neurons</e2>_24\NNS\5430628 ._25\.\1740
D007501_D009410 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 peripheral_4\JJ\1740 iron_5\NN\14625458 dextran_6\NN\1740 can_7\MD\3094503 increase_8\VB\169651 the_9\DT\1740 iron_10\NN\14625458 level_11\NN\4916342 in_12\IN\13603305 the_13\DT\1740 sn_14\NNP\14625458 ,_15\,\1740 where_16\WRB\1740 excessive_17\JJ\1740 <e1>iron</e1>_18\NN\14625458 causes_19\VBZ\1617192 the_20\DT\1740 <e2>degeneration_21\NN\29677 of_22\IN\1740 dopaminergic_23\JJ\1740 neurons</e2>_24\NNS\5430628 ._25\.\1740
D014443_D009410 NONE to_0\TO\1740 demonstrate_1\VB\2137132 the_2\DT\1740 relationship_3\NN\31921 between_4\IN\1740 peripheral_5\JJ\1740 iron_6\NN\14625458 overload_7\NN\3679986 and_8\CC\1740 dopaminergic_9\JJ\1740 neuron_10\NN\5430628 loss_11\NN\13252973 in_12\IN\13603305 rat_13\NN\2329401 substantia_14\RB\1740 nigra_15\JJ\1740 (_16\-LRB-\1740 sn_17\NN\14625458 )_18\-RRB-\1740 ,_19\,\1740 in_20\IN\13603305 the_21\DT\1740 present_22\JJ\1740 study_23\NN\635850 we_24\PRP\1740 used_25\VBD\1156834 fast_26\JJ\1740 cyclic_27\JJ\1740 voltammetry_28\NN\1740 ,_29\,\1740 <e1>tyrosine</e1>_30\NN\14601829 hydroxylase_31\NN\1740 (_32\-LRB-\1740 th_33\NN\15163157 )_34\-RRB-\1740 immunohistochemistry_35\NN\791527 ,_36\,\1740 perls_37\NNP\1740 '_38\POS\1740 iron_39\NN\14625458 staining_40\NN\275424 ,_41\,\1740 and_42\CC\1740 high_43\JJ\1740 performance_44\NN\6619065 liquid_45\NN\14939900 chromatography-electrochemical_46\JJ\1740 detection_47\NN\5708432 to_48\TO\1740 study_49\VB\630380 the_50\DT\1740 <e2>degeneration_51\NN\29677 of_52\IN\1740 dopaminergic_53\JJ\1740 neurons</e2>_54\NNS\5430628 and_55\CC\1740 increased_56\VBD\169651 iron_57\NN\14625458 content_58\NN\7951464 in_59\IN\13603305 the_60\DT\1740 sn_61\NN\14625458 of_62\IN\1740 iron_63\NN\14625458 dextran_64\NN\1740 overloaded_65\VBN\452512 animals_66\NNS\4475 ._67\.\1740
11752998
D000241_D059787 NONE background_0\NN\4921011 :_1\:\1740 preclinical_2\JJ\1740 studies_3\NNS\635850 of_4\IN\1740 intrathecal_5\JJ\1740 <e1>adenosine</e1>_6\NN\14964367 suggest_7\VBP\1010118 it_8\PRP\6125041 may_9\MD\15209706 be_10\VB\836236 effective_11\JJ\1740 in_12\IN\13603305 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 <e2>acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 pain</e2>_19\NN\14299637 in_20\IN\13603305 humans_21\NNS\31264 ,_22\,\1740 and_23\CC\1740 preliminary_24\JJ\1740 studies_25\NNS\635850 in_26\IN\13603305 volunteers_27\NNS\10582746 and_28\CC\1740 patients_29\NNS\9898892 with_30\IN\1740 a_31\DT\13649268 swedish_32\JJ\1740 formulation_33\NN\14818238 of_34\IN\1740 adenosine_35\NN\14964367 suggests_36\VBZ\1010118 it_37\PRP\6125041 may_38\MD\15209706 be_39\VB\836236 effective_40\JJ\1740 in_41\IN\13603305 hypersensitivity_42\NN\14531772 states_43\NNS\8491826 but_44\CC\1740 not_45\RB\1740 with_46\IN\1740 acute_47\JJ\1740 noxious_48\JJ\1740 stimulation_49\NN\242808 ._50\.\1740
D000241_D059787 NONE background_0\NN\4921011 :_1\:\1740 preclinical_2\JJ\1740 studies_3\NNS\635850 of_4\IN\1740 intrathecal_5\JJ\1740 adenosine_6\NN\14964367 suggest_7\VBP\1010118 it_8\PRP\6125041 may_9\MD\15209706 be_10\VB\836236 effective_11\JJ\1740 in_12\IN\13603305 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 <e2>acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 pain</e2>_19\NN\14299637 in_20\IN\13603305 humans_21\NNS\31264 ,_22\,\1740 and_23\CC\1740 preliminary_24\JJ\1740 studies_25\NNS\635850 in_26\IN\13603305 volunteers_27\NNS\10582746 and_28\CC\1740 patients_29\NNS\9898892 with_30\IN\1740 a_31\DT\13649268 swedish_32\JJ\1740 formulation_33\NN\14818238 of_34\IN\1740 <e1>adenosine</e1>_35\NN\14964367 suggests_36\VBZ\1010118 it_37\PRP\6125041 may_38\MD\15209706 be_39\VB\836236 effective_40\JJ\1740 in_41\IN\13603305 hypersensitivity_42\NN\14531772 states_43\NNS\8491826 but_44\CC\1740 not_45\RB\1740 with_46\IN\1740 acute_47\JJ\1740 noxious_48\JJ\1740 stimulation_49\NN\242808 ._50\.\1740
D000241_D059350 NONE background_0\NN\4921011 :_1\:\1740 preclinical_2\JJ\1740 studies_3\NNS\635850 of_4\IN\1740 intrathecal_5\JJ\1740 <e1>adenosine</e1>_6\NN\14964367 suggest_7\VBP\1010118 it_8\PRP\6125041 may_9\MD\15209706 be_10\VB\836236 effective_11\JJ\1740 in_12\IN\13603305 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 <e2>acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 pain</e2>_19\NN\14299637 in_20\IN\13603305 humans_21\NNS\31264 ,_22\,\1740 and_23\CC\1740 preliminary_24\JJ\1740 studies_25\NNS\635850 in_26\IN\13603305 volunteers_27\NNS\10582746 and_28\CC\1740 patients_29\NNS\9898892 with_30\IN\1740 a_31\DT\13649268 swedish_32\JJ\1740 formulation_33\NN\14818238 of_34\IN\1740 adenosine_35\NN\14964367 suggests_36\VBZ\1010118 it_37\PRP\6125041 may_38\MD\15209706 be_39\VB\836236 effective_40\JJ\1740 in_41\IN\13603305 hypersensitivity_42\NN\14531772 states_43\NNS\8491826 but_44\CC\1740 not_45\RB\1740 with_46\IN\1740 acute_47\JJ\1740 noxious_48\JJ\1740 stimulation_49\NN\242808 ._50\.\1740
D000241_D059350 NONE background_0\NN\4921011 :_1\:\1740 preclinical_2\JJ\1740 studies_3\NNS\635850 of_4\IN\1740 intrathecal_5\JJ\1740 adenosine_6\NN\14964367 suggest_7\VBP\1010118 it_8\PRP\6125041 may_9\MD\15209706 be_10\VB\836236 effective_11\JJ\1740 in_12\IN\13603305 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 <e2>acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 pain</e2>_19\NN\14299637 in_20\IN\13603305 humans_21\NNS\31264 ,_22\,\1740 and_23\CC\1740 preliminary_24\JJ\1740 studies_25\NNS\635850 in_26\IN\13603305 volunteers_27\NNS\10582746 and_28\CC\1740 patients_29\NNS\9898892 with_30\IN\1740 a_31\DT\13649268 swedish_32\JJ\1740 formulation_33\NN\14818238 of_34\IN\1740 <e1>adenosine</e1>_35\NN\14964367 suggests_36\VBZ\1010118 it_37\PRP\6125041 may_38\MD\15209706 be_39\VB\836236 effective_40\JJ\1740 in_41\IN\13603305 hypersensitivity_42\NN\14531772 states_43\NNS\8491826 but_44\CC\1740 not_45\RB\1740 with_46\IN\1740 acute_47\JJ\1740 noxious_48\JJ\1740 stimulation_49\NN\242808 ._50\.\1740
D000241_D004342 NONE background_0\NN\4921011 :_1\:\1740 preclinical_2\JJ\1740 studies_3\NNS\635850 of_4\IN\1740 intrathecal_5\JJ\1740 <e1>adenosine</e1>_6\NN\14964367 suggest_7\VBP\1010118 it_8\PRP\6125041 may_9\MD\15209706 be_10\VB\836236 effective_11\JJ\1740 in_12\IN\13603305 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 pain_19\NN\14299637 in_20\IN\13603305 humans_21\NNS\31264 ,_22\,\1740 and_23\CC\1740 preliminary_24\JJ\1740 studies_25\NNS\635850 in_26\IN\13603305 volunteers_27\NNS\10582746 and_28\CC\1740 patients_29\NNS\9898892 with_30\IN\1740 a_31\DT\13649268 swedish_32\JJ\1740 formulation_33\NN\14818238 of_34\IN\1740 adenosine_35\NN\14964367 suggests_36\VBZ\1010118 it_37\PRP\6125041 may_38\MD\15209706 be_39\VB\836236 effective_40\JJ\1740 in_41\IN\13603305 <e2>hypersensitivity</e2>_42\NN\14531772 states_43\NNS\8491826 but_44\CC\1740 not_45\RB\1740 with_46\IN\1740 acute_47\JJ\1740 noxious_48\JJ\1740 stimulation_49\NN\242808 ._50\.\1740
D000241_D004342 NONE background_0\NN\4921011 :_1\:\1740 preclinical_2\JJ\1740 studies_3\NNS\635850 of_4\IN\1740 intrathecal_5\JJ\1740 adenosine_6\NN\14964367 suggest_7\VBP\1010118 it_8\PRP\6125041 may_9\MD\15209706 be_10\VB\836236 effective_11\JJ\1740 in_12\IN\13603305 the_13\DT\1740 treatment_14\NN\654885 of_15\IN\1740 acute_16\JJ\1740 and_17\CC\1740 chronic_18\JJ\1740 pain_19\NN\14299637 in_20\IN\13603305 humans_21\NNS\31264 ,_22\,\1740 and_23\CC\1740 preliminary_24\JJ\1740 studies_25\NNS\635850 in_26\IN\13603305 volunteers_27\NNS\10582746 and_28\CC\1740 patients_29\NNS\9898892 with_30\IN\1740 a_31\DT\13649268 swedish_32\JJ\1740 formulation_33\NN\14818238 of_34\IN\1740 <e1>adenosine</e1>_35\NN\14964367 suggests_36\VBZ\1010118 it_37\PRP\6125041 may_38\MD\15209706 be_39\VB\836236 effective_40\JJ\1740 in_41\IN\13603305 <e2>hypersensitivity</e2>_42\NN\14531772 states_43\NNS\8491826 but_44\CC\1740 not_45\RB\1740 with_46\IN\1740 acute_47\JJ\1740 noxious_48\JJ\1740 stimulation_49\NN\242808 ._50\.\1740
D000241_D004342 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 screen_7\VB\2533282 for_8\IN\1740 efficacy_9\NN\5199286 of_10\IN\1740 a_11\DT\13649268 different_12\JJ\1740 formulation_13\NN\14818238 of_14\IN\1740 <e1>adenosine</e1>_15\NN\14964367 marketed_16\VBN\2260362 in_17\IN\13603305 the_18\DT\1740 us_19\NNP\14964590 ,_20\,\1740 using_21\VBG\1156834 both_22\CC\1740 acute_23\JJ\1740 noxious_24\JJ\1740 stimulation_25\NN\242808 and_26\CC\1740 capsaicin-evoked_27\JJ\1740 mechanical_28\JJ\1740 <e2>hypersensitivity</e2>_29\NN\14531772 ._30\.\1740
D000241_D004342 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 show_4\VBP\2137132 selective_5\JJ\1740 inhibition_6\NN\1068773 by_7\IN\1740 intrathecal_8\JJ\1740 <e1>adenosine</e1>_9\NN\14964367 of_10\IN\1740 <e2>hypersensitivity</e2>_11\NN\14531772 ,_12\,\1740 presumed_13\VBN\719734 to_14\TO\1740 reflect_15\VB\923793 central_16\JJ\1740 sensitization_17\NN\14531772 in_18\IN\13603305 humans_19\NNS\31264 after_20\IN\1740 peripheral_21\JJ\1740 capsaicin_22\NN\15032661 injection_23\NN\320852 ._24\.\1740
D002211_D004342 NONE the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 study_4\NN\635850 was_5\VBD\836236 to_6\TO\1740 screen_7\VB\2533282 for_8\IN\1740 efficacy_9\NN\5199286 of_10\IN\1740 a_11\DT\13649268 different_12\JJ\1740 formulation_13\NN\14818238 of_14\IN\1740 adenosine_15\NN\14964367 marketed_16\VBN\2260362 in_17\IN\13603305 the_18\DT\1740 us_19\NNP\14964590 ,_20\,\1740 using_21\VBG\1156834 both_22\CC\1740 acute_23\JJ\1740 noxious_24\JJ\1740 stimulation_25\NN\242808 and_26\CC\1740 <e1>capsaicin-evoked</e1>_27\JJ\1740 mechanical_28\JJ\1740 <e2>hypersensitivity</e2>_29\NN\14531772 ._30\.\1740
D002211_D004342 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 show_4\VBP\2137132 selective_5\JJ\1740 inhibition_6\NN\1068773 by_7\IN\1740 intrathecal_8\JJ\1740 adenosine_9\NN\14964367 of_10\IN\1740 <e2>hypersensitivity</e2>_11\NN\14531772 ,_12\,\1740 presumed_13\VBN\719734 to_14\TO\1740 reflect_15\VB\923793 central_16\JJ\1740 sensitization_17\NN\14531772 in_18\IN\13603305 humans_19\NNS\31264 after_20\IN\1740 peripheral_21\JJ\1740 <e1>capsaicin</e1>_22\NN\15032661 injection_23\NN\320852 ._24\.\1740
D000241_D010146 NONE methods_0\NNS\5616786 :_1\:\1740 following_2\VBG\1835496 food_3\NNP\20090 and_4\CC\1740 drug_5\NNP\14778436 administration_6\NNP\1133281 and_7\CC\1740 institutional_8\JJ\1740 review_9\NN\5733583 board_10\NN\8324514 approval_11\NN\1212519 and_12\CC\1740 written_13\VBN\1697816 informed_14\JJ\1740 consent_15\NN\6689297 ,_16\,\1740 65_17\CD\1740 volunteers_18\NNS\10582746 were_19\VBD\836236 studied_20\VBN\630380 in_21\IN\13603305 two_22\CD\13741022 trials_23\NNS\786195 :_24\:\1740 an_25\DT\6697703 open-label_26\JJ\1740 ,_27\,\1740 dose-escalating_28\JJ\1740 trial_29\NN\786195 with_30\IN\1740 intrathecal_31\JJ\1740 <e1>adenosine</e1>_32\NN\14964367 doses_33\NNS\3740161 of_34\IN\1740 0.25_35\CD\1740 -_36\SYM\1740 2.0_37\CD\1740 mg_38\NN\13717155 and_39\CC\1740 a_40\DT\13649268 double-blind_41\JJ\1740 ,_42\,\1740 placebo-controlled_43\JJ\1740 trial_44\NN\786195 of_45\IN\1740 adenosine_46\NN\14964367 ,_47\,\1740 2_48\CD\13741022 mg._49\NN\1740 cerebrospinal_50\JJ\1740 fluid_51\NN\19613 was_52\VBD\836236 obtained_53\VBN\2210855 for_54\IN\1740 pharmacokinetic_55\JJ\1740 analysis_56\NN\633864 ,_57\,\1740 and_58\CC\1740 <e2>pain</e2>_59\NN\14299637 ratings_60\NNS\5733583 in_61\IN\13603305 response_62\NN\11410625 to_63\TO\1740 acute_64\JJ\1740 heat_65\NN\11452218 stimuli_66\NNS\5816287 and_67\CC\1740 areas_68\NNS\8630985 of_69\IN\1740 mechanical_70\JJ\1740 hyperalgesia_71\NN\1740 and_72\CC\1740 allodynia_73\NN\1740 after_74\IN\1740 intradermal_75\JJ\1740 capsaicin_76\NN\15032661 injection_77\NN\320852 were_78\VBD\836236 determined_79\VBN\1645601 ._80\.\1740
D000241_D010146 NONE methods_0\NNS\5616786 :_1\:\1740 following_2\VBG\1835496 food_3\NNP\20090 and_4\CC\1740 drug_5\NNP\14778436 administration_6\NNP\1133281 and_7\CC\1740 institutional_8\JJ\1740 review_9\NN\5733583 board_10\NN\8324514 approval_11\NN\1212519 and_12\CC\1740 written_13\VBN\1697816 informed_14\JJ\1740 consent_15\NN\6689297 ,_16\,\1740 65_17\CD\1740 volunteers_18\NNS\10582746 were_19\VBD\836236 studied_20\VBN\630380 in_21\IN\13603305 two_22\CD\13741022 trials_23\NNS\786195 :_24\:\1740 an_25\DT\6697703 open-label_26\JJ\1740 ,_27\,\1740 dose-escalating_28\JJ\1740 trial_29\NN\786195 with_30\IN\1740 intrathecal_31\JJ\1740 adenosine_32\NN\14964367 doses_33\NNS\3740161 of_34\IN\1740 0.25_35\CD\1740 -_36\SYM\1740 2.0_37\CD\1740 mg_38\NN\13717155 and_39\CC\1740 a_40\DT\13649268 double-blind_41\JJ\1740 ,_42\,\1740 placebo-controlled_43\JJ\1740 trial_44\NN\786195 of_45\IN\1740 <e1>adenosine</e1>_46\NN\14964367 ,_47\,\1740 2_48\CD\13741022 mg._49\NN\1740 cerebrospinal_50\JJ\1740 fluid_51\NN\19613 was_52\VBD\836236 obtained_53\VBN\2210855 for_54\IN\1740 pharmacokinetic_55\JJ\1740 analysis_56\NN\633864 ,_57\,\1740 and_58\CC\1740 <e2>pain</e2>_59\NN\14299637 ratings_60\NNS\5733583 in_61\IN\13603305 response_62\NN\11410625 to_63\TO\1740 acute_64\JJ\1740 heat_65\NN\11452218 stimuli_66\NNS\5816287 and_67\CC\1740 areas_68\NNS\8630985 of_69\IN\1740 mechanical_70\JJ\1740 hyperalgesia_71\NN\1740 and_72\CC\1740 allodynia_73\NN\1740 after_74\IN\1740 intradermal_75\JJ\1740 capsaicin_76\NN\15032661 injection_77\NN\320852 were_78\VBD\836236 determined_79\VBN\1645601 ._80\.\1740
D000241_D010146 NONE results_0\NNS\34213 :_1\:\1740 <e1>adenosine</e1>_2\NN\14964367 produced_3\VBD\1617192 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 <e2>pain</e2>_7\NN\14299637 report_8\NN\6470073 to_9\TO\1740 acute_10\JJ\1740 noxious_11\JJ\1740 thermal_12\JJ\1740 or_13\CC\3541091 chemical_14\JJ\1740 stimulation_15\NN\242808 but_16\CC\1740 reduced_17\VBD\441445 mechanical_18\JJ\1740 hyperalgesia_19\NN\1740 and_20\CC\1740 allodynia_21\NN\1740 from_22\IN\1740 intradermal_23\JJ\1740 capsaicin_24\NN\15032661 injection_25\NN\320852 for_26\IN\1740 at_27\IN\14622893 least_28\JJS\1740 24_29\CD\13745420 h._30\NN\1740 in_31\IN\13603305 contrast_32\NN\13854649 ,_33\,\1740 residence_34\NN\8491027 time_35\NN\7308889 of_36\IN\1740 adenosine_37\NN\14964367 in_38\IN\13603305 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 was_41\VBD\836236 short_42\JJ\1740 (_43\-LRB-\1740 <_44\XX\1740 4_45\CD\13741022 h_46\NN\14622893 )_47\-RRB-\1740 ._48\.\1740
D000241_D010146 NONE results_0\NNS\34213 :_1\:\1740 adenosine_2\NN\14964367 produced_3\VBD\1617192 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 <e2>pain</e2>_7\NN\14299637 report_8\NN\6470073 to_9\TO\1740 acute_10\JJ\1740 noxious_11\JJ\1740 thermal_12\JJ\1740 or_13\CC\3541091 chemical_14\JJ\1740 stimulation_15\NN\242808 but_16\CC\1740 reduced_17\VBD\441445 mechanical_18\JJ\1740 hyperalgesia_19\NN\1740 and_20\CC\1740 allodynia_21\NN\1740 from_22\IN\1740 intradermal_23\JJ\1740 capsaicin_24\NN\15032661 injection_25\NN\320852 for_26\IN\1740 at_27\IN\14622893 least_28\JJS\1740 24_29\CD\13745420 h._30\NN\1740 in_31\IN\13603305 contrast_32\NN\13854649 ,_33\,\1740 residence_34\NN\8491027 time_35\NN\7308889 of_36\IN\1740 <e1>adenosine</e1>_37\NN\14964367 in_38\IN\13603305 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 was_41\VBD\836236 short_42\JJ\1740 (_43\-LRB-\1740 <_44\XX\1740 4_45\CD\13741022 h_46\NN\14622893 )_47\-RRB-\1740 ._48\.\1740
D000241_D006930 NONE methods_0\NNS\5616786 :_1\:\1740 following_2\VBG\1835496 food_3\NNP\20090 and_4\CC\1740 drug_5\NNP\14778436 administration_6\NNP\1133281 and_7\CC\1740 institutional_8\JJ\1740 review_9\NN\5733583 board_10\NN\8324514 approval_11\NN\1212519 and_12\CC\1740 written_13\VBN\1697816 informed_14\JJ\1740 consent_15\NN\6689297 ,_16\,\1740 65_17\CD\1740 volunteers_18\NNS\10582746 were_19\VBD\836236 studied_20\VBN\630380 in_21\IN\13603305 two_22\CD\13741022 trials_23\NNS\786195 :_24\:\1740 an_25\DT\6697703 open-label_26\JJ\1740 ,_27\,\1740 dose-escalating_28\JJ\1740 trial_29\NN\786195 with_30\IN\1740 intrathecal_31\JJ\1740 <e1>adenosine</e1>_32\NN\14964367 doses_33\NNS\3740161 of_34\IN\1740 0.25_35\CD\1740 -_36\SYM\1740 2.0_37\CD\1740 mg_38\NN\13717155 and_39\CC\1740 a_40\DT\13649268 double-blind_41\JJ\1740 ,_42\,\1740 placebo-controlled_43\JJ\1740 trial_44\NN\786195 of_45\IN\1740 adenosine_46\NN\14964367 ,_47\,\1740 2_48\CD\13741022 mg._49\NN\1740 cerebrospinal_50\JJ\1740 fluid_51\NN\19613 was_52\VBD\836236 obtained_53\VBN\2210855 for_54\IN\1740 pharmacokinetic_55\JJ\1740 analysis_56\NN\633864 ,_57\,\1740 and_58\CC\1740 pain_59\NN\14299637 ratings_60\NNS\5733583 in_61\IN\13603305 response_62\NN\11410625 to_63\TO\1740 acute_64\JJ\1740 heat_65\NN\11452218 stimuli_66\NNS\5816287 and_67\CC\1740 areas_68\NNS\8630985 of_69\IN\1740 <e2>mechanical_70\JJ\1740 hyperalgesia</e2>_71\NN\1740 and_72\CC\1740 allodynia_73\NN\1740 after_74\IN\1740 intradermal_75\JJ\1740 capsaicin_76\NN\15032661 injection_77\NN\320852 were_78\VBD\836236 determined_79\VBN\1645601 ._80\.\1740
D000241_D006930 NONE methods_0\NNS\5616786 :_1\:\1740 following_2\VBG\1835496 food_3\NNP\20090 and_4\CC\1740 drug_5\NNP\14778436 administration_6\NNP\1133281 and_7\CC\1740 institutional_8\JJ\1740 review_9\NN\5733583 board_10\NN\8324514 approval_11\NN\1212519 and_12\CC\1740 written_13\VBN\1697816 informed_14\JJ\1740 consent_15\NN\6689297 ,_16\,\1740 65_17\CD\1740 volunteers_18\NNS\10582746 were_19\VBD\836236 studied_20\VBN\630380 in_21\IN\13603305 two_22\CD\13741022 trials_23\NNS\786195 :_24\:\1740 an_25\DT\6697703 open-label_26\JJ\1740 ,_27\,\1740 dose-escalating_28\JJ\1740 trial_29\NN\786195 with_30\IN\1740 intrathecal_31\JJ\1740 <e1>adenosine</e1>_32\NN\14964367 doses_33\NNS\3740161 of_34\IN\1740 0.25_35\CD\1740 -_36\SYM\1740 2.0_37\CD\1740 mg_38\NN\13717155 and_39\CC\1740 a_40\DT\13649268 double-blind_41\JJ\1740 ,_42\,\1740 placebo-controlled_43\JJ\1740 trial_44\NN\786195 of_45\IN\1740 adenosine_46\NN\14964367 ,_47\,\1740 2_48\CD\13741022 mg._49\NN\1740 cerebrospinal_50\JJ\1740 fluid_51\NN\19613 was_52\VBD\836236 obtained_53\VBN\2210855 for_54\IN\1740 pharmacokinetic_55\JJ\1740 analysis_56\NN\633864 ,_57\,\1740 and_58\CC\1740 pain_59\NN\14299637 ratings_60\NNS\5733583 in_61\IN\13603305 response_62\NN\11410625 to_63\TO\1740 acute_64\JJ\1740 heat_65\NN\11452218 stimuli_66\NNS\5816287 and_67\CC\1740 areas_68\NNS\8630985 of_69\IN\1740 mechanical_70\JJ\1740 hyperalgesia_71\NN\1740 and_72\CC\1740 <e2>allodynia</e2>_73\NN\1740 after_74\IN\1740 intradermal_75\JJ\1740 capsaicin_76\NN\15032661 injection_77\NN\320852 were_78\VBD\836236 determined_79\VBN\1645601 ._80\.\1740
D000241_D006930 NONE methods_0\NNS\5616786 :_1\:\1740 following_2\VBG\1835496 food_3\NNP\20090 and_4\CC\1740 drug_5\NNP\14778436 administration_6\NNP\1133281 and_7\CC\1740 institutional_8\JJ\1740 review_9\NN\5733583 board_10\NN\8324514 approval_11\NN\1212519 and_12\CC\1740 written_13\VBN\1697816 informed_14\JJ\1740 consent_15\NN\6689297 ,_16\,\1740 65_17\CD\1740 volunteers_18\NNS\10582746 were_19\VBD\836236 studied_20\VBN\630380 in_21\IN\13603305 two_22\CD\13741022 trials_23\NNS\786195 :_24\:\1740 an_25\DT\6697703 open-label_26\JJ\1740 ,_27\,\1740 dose-escalating_28\JJ\1740 trial_29\NN\786195 with_30\IN\1740 intrathecal_31\JJ\1740 adenosine_32\NN\14964367 doses_33\NNS\3740161 of_34\IN\1740 0.25_35\CD\1740 -_36\SYM\1740 2.0_37\CD\1740 mg_38\NN\13717155 and_39\CC\1740 a_40\DT\13649268 double-blind_41\JJ\1740 ,_42\,\1740 placebo-controlled_43\JJ\1740 trial_44\NN\786195 of_45\IN\1740 <e1>adenosine</e1>_46\NN\14964367 ,_47\,\1740 2_48\CD\13741022 mg._49\NN\1740 cerebrospinal_50\JJ\1740 fluid_51\NN\19613 was_52\VBD\836236 obtained_53\VBN\2210855 for_54\IN\1740 pharmacokinetic_55\JJ\1740 analysis_56\NN\633864 ,_57\,\1740 and_58\CC\1740 pain_59\NN\14299637 ratings_60\NNS\5733583 in_61\IN\13603305 response_62\NN\11410625 to_63\TO\1740 acute_64\JJ\1740 heat_65\NN\11452218 stimuli_66\NNS\5816287 and_67\CC\1740 areas_68\NNS\8630985 of_69\IN\1740 <e2>mechanical_70\JJ\1740 hyperalgesia</e2>_71\NN\1740 and_72\CC\1740 allodynia_73\NN\1740 after_74\IN\1740 intradermal_75\JJ\1740 capsaicin_76\NN\15032661 injection_77\NN\320852 were_78\VBD\836236 determined_79\VBN\1645601 ._80\.\1740
D000241_D006930 NONE methods_0\NNS\5616786 :_1\:\1740 following_2\VBG\1835496 food_3\NNP\20090 and_4\CC\1740 drug_5\NNP\14778436 administration_6\NNP\1133281 and_7\CC\1740 institutional_8\JJ\1740 review_9\NN\5733583 board_10\NN\8324514 approval_11\NN\1212519 and_12\CC\1740 written_13\VBN\1697816 informed_14\JJ\1740 consent_15\NN\6689297 ,_16\,\1740 65_17\CD\1740 volunteers_18\NNS\10582746 were_19\VBD\836236 studied_20\VBN\630380 in_21\IN\13603305 two_22\CD\13741022 trials_23\NNS\786195 :_24\:\1740 an_25\DT\6697703 open-label_26\JJ\1740 ,_27\,\1740 dose-escalating_28\JJ\1740 trial_29\NN\786195 with_30\IN\1740 intrathecal_31\JJ\1740 adenosine_32\NN\14964367 doses_33\NNS\3740161 of_34\IN\1740 0.25_35\CD\1740 -_36\SYM\1740 2.0_37\CD\1740 mg_38\NN\13717155 and_39\CC\1740 a_40\DT\13649268 double-blind_41\JJ\1740 ,_42\,\1740 placebo-controlled_43\JJ\1740 trial_44\NN\786195 of_45\IN\1740 <e1>adenosine</e1>_46\NN\14964367 ,_47\,\1740 2_48\CD\13741022 mg._49\NN\1740 cerebrospinal_50\JJ\1740 fluid_51\NN\19613 was_52\VBD\836236 obtained_53\VBN\2210855 for_54\IN\1740 pharmacokinetic_55\JJ\1740 analysis_56\NN\633864 ,_57\,\1740 and_58\CC\1740 pain_59\NN\14299637 ratings_60\NNS\5733583 in_61\IN\13603305 response_62\NN\11410625 to_63\TO\1740 acute_64\JJ\1740 heat_65\NN\11452218 stimuli_66\NNS\5816287 and_67\CC\1740 areas_68\NNS\8630985 of_69\IN\1740 mechanical_70\JJ\1740 hyperalgesia_71\NN\1740 and_72\CC\1740 <e2>allodynia</e2>_73\NN\1740 after_74\IN\1740 intradermal_75\JJ\1740 capsaicin_76\NN\15032661 injection_77\NN\320852 were_78\VBD\836236 determined_79\VBN\1645601 ._80\.\1740
D000241_D006930 NONE results_0\NNS\34213 :_1\:\1740 <e1>adenosine</e1>_2\NN\14964367 produced_3\VBD\1617192 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 pain_7\NN\14299637 report_8\NN\6470073 to_9\TO\1740 acute_10\JJ\1740 noxious_11\JJ\1740 thermal_12\JJ\1740 or_13\CC\3541091 chemical_14\JJ\1740 stimulation_15\NN\242808 but_16\CC\1740 reduced_17\VBD\441445 <e2>mechanical_18\JJ\1740 hyperalgesia</e2>_19\NN\1740 and_20\CC\1740 allodynia_21\NN\1740 from_22\IN\1740 intradermal_23\JJ\1740 capsaicin_24\NN\15032661 injection_25\NN\320852 for_26\IN\1740 at_27\IN\14622893 least_28\JJS\1740 24_29\CD\13745420 h._30\NN\1740 in_31\IN\13603305 contrast_32\NN\13854649 ,_33\,\1740 residence_34\NN\8491027 time_35\NN\7308889 of_36\IN\1740 adenosine_37\NN\14964367 in_38\IN\13603305 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 was_41\VBD\836236 short_42\JJ\1740 (_43\-LRB-\1740 <_44\XX\1740 4_45\CD\13741022 h_46\NN\14622893 )_47\-RRB-\1740 ._48\.\1740
D000241_D006930 NONE results_0\NNS\34213 :_1\:\1740 <e1>adenosine</e1>_2\NN\14964367 produced_3\VBD\1617192 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 pain_7\NN\14299637 report_8\NN\6470073 to_9\TO\1740 acute_10\JJ\1740 noxious_11\JJ\1740 thermal_12\JJ\1740 or_13\CC\3541091 chemical_14\JJ\1740 stimulation_15\NN\242808 but_16\CC\1740 reduced_17\VBD\441445 mechanical_18\JJ\1740 hyperalgesia_19\NN\1740 and_20\CC\1740 <e2>allodynia</e2>_21\NN\1740 from_22\IN\1740 intradermal_23\JJ\1740 capsaicin_24\NN\15032661 injection_25\NN\320852 for_26\IN\1740 at_27\IN\14622893 least_28\JJS\1740 24_29\CD\13745420 h._30\NN\1740 in_31\IN\13603305 contrast_32\NN\13854649 ,_33\,\1740 residence_34\NN\8491027 time_35\NN\7308889 of_36\IN\1740 adenosine_37\NN\14964367 in_38\IN\13603305 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 was_41\VBD\836236 short_42\JJ\1740 (_43\-LRB-\1740 <_44\XX\1740 4_45\CD\13741022 h_46\NN\14622893 )_47\-RRB-\1740 ._48\.\1740
D000241_D006930 NONE results_0\NNS\34213 :_1\:\1740 adenosine_2\NN\14964367 produced_3\VBD\1617192 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 pain_7\NN\14299637 report_8\NN\6470073 to_9\TO\1740 acute_10\JJ\1740 noxious_11\JJ\1740 thermal_12\JJ\1740 or_13\CC\3541091 chemical_14\JJ\1740 stimulation_15\NN\242808 but_16\CC\1740 reduced_17\VBD\441445 <e2>mechanical_18\JJ\1740 hyperalgesia</e2>_19\NN\1740 and_20\CC\1740 allodynia_21\NN\1740 from_22\IN\1740 intradermal_23\JJ\1740 capsaicin_24\NN\15032661 injection_25\NN\320852 for_26\IN\1740 at_27\IN\14622893 least_28\JJS\1740 24_29\CD\13745420 h._30\NN\1740 in_31\IN\13603305 contrast_32\NN\13854649 ,_33\,\1740 residence_34\NN\8491027 time_35\NN\7308889 of_36\IN\1740 <e1>adenosine</e1>_37\NN\14964367 in_38\IN\13603305 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 was_41\VBD\836236 short_42\JJ\1740 (_43\-LRB-\1740 <_44\XX\1740 4_45\CD\13741022 h_46\NN\14622893 )_47\-RRB-\1740 ._48\.\1740
D000241_D006930 NONE results_0\NNS\34213 :_1\:\1740 adenosine_2\NN\14964367 produced_3\VBD\1617192 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 pain_7\NN\14299637 report_8\NN\6470073 to_9\TO\1740 acute_10\JJ\1740 noxious_11\JJ\1740 thermal_12\JJ\1740 or_13\CC\3541091 chemical_14\JJ\1740 stimulation_15\NN\242808 but_16\CC\1740 reduced_17\VBD\441445 mechanical_18\JJ\1740 hyperalgesia_19\NN\1740 and_20\CC\1740 <e2>allodynia</e2>_21\NN\1740 from_22\IN\1740 intradermal_23\JJ\1740 capsaicin_24\NN\15032661 injection_25\NN\320852 for_26\IN\1740 at_27\IN\14622893 least_28\JJS\1740 24_29\CD\13745420 h._30\NN\1740 in_31\IN\13603305 contrast_32\NN\13854649 ,_33\,\1740 residence_34\NN\8491027 time_35\NN\7308889 of_36\IN\1740 <e1>adenosine</e1>_37\NN\14964367 in_38\IN\13603305 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 was_41\VBD\836236 short_42\JJ\1740 (_43\-LRB-\1740 <_44\XX\1740 4_45\CD\13741022 h_46\NN\14622893 )_47\-RRB-\1740 ._48\.\1740
D002211_D010146 NONE methods_0\NNS\5616786 :_1\:\1740 following_2\VBG\1835496 food_3\NNP\20090 and_4\CC\1740 drug_5\NNP\14778436 administration_6\NNP\1133281 and_7\CC\1740 institutional_8\JJ\1740 review_9\NN\5733583 board_10\NN\8324514 approval_11\NN\1212519 and_12\CC\1740 written_13\VBN\1697816 informed_14\JJ\1740 consent_15\NN\6689297 ,_16\,\1740 65_17\CD\1740 volunteers_18\NNS\10582746 were_19\VBD\836236 studied_20\VBN\630380 in_21\IN\13603305 two_22\CD\13741022 trials_23\NNS\786195 :_24\:\1740 an_25\DT\6697703 open-label_26\JJ\1740 ,_27\,\1740 dose-escalating_28\JJ\1740 trial_29\NN\786195 with_30\IN\1740 intrathecal_31\JJ\1740 adenosine_32\NN\14964367 doses_33\NNS\3740161 of_34\IN\1740 0.25_35\CD\1740 -_36\SYM\1740 2.0_37\CD\1740 mg_38\NN\13717155 and_39\CC\1740 a_40\DT\13649268 double-blind_41\JJ\1740 ,_42\,\1740 placebo-controlled_43\JJ\1740 trial_44\NN\786195 of_45\IN\1740 adenosine_46\NN\14964367 ,_47\,\1740 2_48\CD\13741022 mg._49\NN\1740 cerebrospinal_50\JJ\1740 fluid_51\NN\19613 was_52\VBD\836236 obtained_53\VBN\2210855 for_54\IN\1740 pharmacokinetic_55\JJ\1740 analysis_56\NN\633864 ,_57\,\1740 and_58\CC\1740 <e2>pain</e2>_59\NN\14299637 ratings_60\NNS\5733583 in_61\IN\13603305 response_62\NN\11410625 to_63\TO\1740 acute_64\JJ\1740 heat_65\NN\11452218 stimuli_66\NNS\5816287 and_67\CC\1740 areas_68\NNS\8630985 of_69\IN\1740 mechanical_70\JJ\1740 hyperalgesia_71\NN\1740 and_72\CC\1740 allodynia_73\NN\1740 after_74\IN\1740 intradermal_75\JJ\1740 <e1>capsaicin</e1>_76\NN\15032661 injection_77\NN\320852 were_78\VBD\836236 determined_79\VBN\1645601 ._80\.\1740
D002211_D010146 NONE results_0\NNS\34213 :_1\:\1740 adenosine_2\NN\14964367 produced_3\VBD\1617192 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 <e2>pain</e2>_7\NN\14299637 report_8\NN\6470073 to_9\TO\1740 acute_10\JJ\1740 noxious_11\JJ\1740 thermal_12\JJ\1740 or_13\CC\3541091 chemical_14\JJ\1740 stimulation_15\NN\242808 but_16\CC\1740 reduced_17\VBD\441445 mechanical_18\JJ\1740 hyperalgesia_19\NN\1740 and_20\CC\1740 allodynia_21\NN\1740 from_22\IN\1740 intradermal_23\JJ\1740 <e1>capsaicin</e1>_24\NN\15032661 injection_25\NN\320852 for_26\IN\1740 at_27\IN\14622893 least_28\JJS\1740 24_29\CD\13745420 h._30\NN\1740 in_31\IN\13603305 contrast_32\NN\13854649 ,_33\,\1740 residence_34\NN\8491027 time_35\NN\7308889 of_36\IN\1740 adenosine_37\NN\14964367 in_38\IN\13603305 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 was_41\VBD\836236 short_42\JJ\1740 (_43\-LRB-\1740 <_44\XX\1740 4_45\CD\13741022 h_46\NN\14622893 )_47\-RRB-\1740 ._48\.\1740
D002211_D006930 CID methods_0\NNS\5616786 :_1\:\1740 following_2\VBG\1835496 food_3\NNP\20090 and_4\CC\1740 drug_5\NNP\14778436 administration_6\NNP\1133281 and_7\CC\1740 institutional_8\JJ\1740 review_9\NN\5733583 board_10\NN\8324514 approval_11\NN\1212519 and_12\CC\1740 written_13\VBN\1697816 informed_14\JJ\1740 consent_15\NN\6689297 ,_16\,\1740 65_17\CD\1740 volunteers_18\NNS\10582746 were_19\VBD\836236 studied_20\VBN\630380 in_21\IN\13603305 two_22\CD\13741022 trials_23\NNS\786195 :_24\:\1740 an_25\DT\6697703 open-label_26\JJ\1740 ,_27\,\1740 dose-escalating_28\JJ\1740 trial_29\NN\786195 with_30\IN\1740 intrathecal_31\JJ\1740 adenosine_32\NN\14964367 doses_33\NNS\3740161 of_34\IN\1740 0.25_35\CD\1740 -_36\SYM\1740 2.0_37\CD\1740 mg_38\NN\13717155 and_39\CC\1740 a_40\DT\13649268 double-blind_41\JJ\1740 ,_42\,\1740 placebo-controlled_43\JJ\1740 trial_44\NN\786195 of_45\IN\1740 adenosine_46\NN\14964367 ,_47\,\1740 2_48\CD\13741022 mg._49\NN\1740 cerebrospinal_50\JJ\1740 fluid_51\NN\19613 was_52\VBD\836236 obtained_53\VBN\2210855 for_54\IN\1740 pharmacokinetic_55\JJ\1740 analysis_56\NN\633864 ,_57\,\1740 and_58\CC\1740 pain_59\NN\14299637 ratings_60\NNS\5733583 in_61\IN\13603305 response_62\NN\11410625 to_63\TO\1740 acute_64\JJ\1740 heat_65\NN\11452218 stimuli_66\NNS\5816287 and_67\CC\1740 areas_68\NNS\8630985 of_69\IN\1740 <e2>mechanical_70\JJ\1740 hyperalgesia</e2>_71\NN\1740 and_72\CC\1740 allodynia_73\NN\1740 after_74\IN\1740 intradermal_75\JJ\1740 <e1>capsaicin</e1>_76\NN\15032661 injection_77\NN\320852 were_78\VBD\836236 determined_79\VBN\1645601 ._80\.\1740
D002211_D006930 CID methods_0\NNS\5616786 :_1\:\1740 following_2\VBG\1835496 food_3\NNP\20090 and_4\CC\1740 drug_5\NNP\14778436 administration_6\NNP\1133281 and_7\CC\1740 institutional_8\JJ\1740 review_9\NN\5733583 board_10\NN\8324514 approval_11\NN\1212519 and_12\CC\1740 written_13\VBN\1697816 informed_14\JJ\1740 consent_15\NN\6689297 ,_16\,\1740 65_17\CD\1740 volunteers_18\NNS\10582746 were_19\VBD\836236 studied_20\VBN\630380 in_21\IN\13603305 two_22\CD\13741022 trials_23\NNS\786195 :_24\:\1740 an_25\DT\6697703 open-label_26\JJ\1740 ,_27\,\1740 dose-escalating_28\JJ\1740 trial_29\NN\786195 with_30\IN\1740 intrathecal_31\JJ\1740 adenosine_32\NN\14964367 doses_33\NNS\3740161 of_34\IN\1740 0.25_35\CD\1740 -_36\SYM\1740 2.0_37\CD\1740 mg_38\NN\13717155 and_39\CC\1740 a_40\DT\13649268 double-blind_41\JJ\1740 ,_42\,\1740 placebo-controlled_43\JJ\1740 trial_44\NN\786195 of_45\IN\1740 adenosine_46\NN\14964367 ,_47\,\1740 2_48\CD\13741022 mg._49\NN\1740 cerebrospinal_50\JJ\1740 fluid_51\NN\19613 was_52\VBD\836236 obtained_53\VBN\2210855 for_54\IN\1740 pharmacokinetic_55\JJ\1740 analysis_56\NN\633864 ,_57\,\1740 and_58\CC\1740 pain_59\NN\14299637 ratings_60\NNS\5733583 in_61\IN\13603305 response_62\NN\11410625 to_63\TO\1740 acute_64\JJ\1740 heat_65\NN\11452218 stimuli_66\NNS\5816287 and_67\CC\1740 areas_68\NNS\8630985 of_69\IN\1740 mechanical_70\JJ\1740 hyperalgesia_71\NN\1740 and_72\CC\1740 <e2>allodynia</e2>_73\NN\1740 after_74\IN\1740 intradermal_75\JJ\1740 <e1>capsaicin</e1>_76\NN\15032661 injection_77\NN\320852 were_78\VBD\836236 determined_79\VBN\1645601 ._80\.\1740
D002211_D006930 CID results_0\NNS\34213 :_1\:\1740 adenosine_2\NN\14964367 produced_3\VBD\1617192 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 pain_7\NN\14299637 report_8\NN\6470073 to_9\TO\1740 acute_10\JJ\1740 noxious_11\JJ\1740 thermal_12\JJ\1740 or_13\CC\3541091 chemical_14\JJ\1740 stimulation_15\NN\242808 but_16\CC\1740 reduced_17\VBD\441445 <e2>mechanical_18\JJ\1740 hyperalgesia</e2>_19\NN\1740 and_20\CC\1740 allodynia_21\NN\1740 from_22\IN\1740 intradermal_23\JJ\1740 <e1>capsaicin</e1>_24\NN\15032661 injection_25\NN\320852 for_26\IN\1740 at_27\IN\14622893 least_28\JJS\1740 24_29\CD\13745420 h._30\NN\1740 in_31\IN\13603305 contrast_32\NN\13854649 ,_33\,\1740 residence_34\NN\8491027 time_35\NN\7308889 of_36\IN\1740 adenosine_37\NN\14964367 in_38\IN\13603305 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 was_41\VBD\836236 short_42\JJ\1740 (_43\-LRB-\1740 <_44\XX\1740 4_45\CD\13741022 h_46\NN\14622893 )_47\-RRB-\1740 ._48\.\1740
D002211_D006930 CID results_0\NNS\34213 :_1\:\1740 adenosine_2\NN\14964367 produced_3\VBD\1617192 no_4\DT\7204911 effect_5\NN\34213 on_6\IN\1740 pain_7\NN\14299637 report_8\NN\6470073 to_9\TO\1740 acute_10\JJ\1740 noxious_11\JJ\1740 thermal_12\JJ\1740 or_13\CC\3541091 chemical_14\JJ\1740 stimulation_15\NN\242808 but_16\CC\1740 reduced_17\VBD\441445 mechanical_18\JJ\1740 hyperalgesia_19\NN\1740 and_20\CC\1740 <e2>allodynia</e2>_21\NN\1740 from_22\IN\1740 intradermal_23\JJ\1740 <e1>capsaicin</e1>_24\NN\15032661 injection_25\NN\320852 for_26\IN\1740 at_27\IN\14622893 least_28\JJS\1740 24_29\CD\13745420 h._30\NN\1740 in_31\IN\13603305 contrast_32\NN\13854649 ,_33\,\1740 residence_34\NN\8491027 time_35\NN\7308889 of_36\IN\1740 adenosine_37\NN\14964367 in_38\IN\13603305 cerebrospinal_39\JJ\1740 fluid_40\NN\19613 was_41\VBD\836236 short_42\JJ\1740 (_43\-LRB-\1740 <_44\XX\1740 4_45\CD\13741022 h_46\NN\14622893 )_47\-RRB-\1740 ._48\.\1740
D000241_D009437 NONE the_0\DT\1740 long-lasting_1\JJ\1740 effect_2\NN\34213 is_3\VBZ\836236 consistent_4\JJ\1740 with_5\IN\1740 that_6\DT\1740 observed_7\VBN\2163746 in_8\IN\13603305 preliminary_9\JJ\1740 reports_10\NNS\6470073 of_11\IN\1740 patients_12\NNS\9898892 with_13\IN\1740 chronic_14\JJ\1740 <e2>neuropathic_15\JJ\1740 pain</e2>_16\NN\14299637 and_17\CC\1740 is_18\VBZ\836236 not_19\RB\1740 due_20\JJ\1740 to_21\TO\1740 prolonged_22\JJ\1740 residence_23\NN\8491027 of_24\IN\1740 <e1>adenosine</e1>_25\NN\14964367 in_26\IN\13603305 cerebrospinal_27\JJ\1740 fluid_28\NN\19613 ._29\.\1740
11079278
D008790_D017202 NONE effect_0\NN\34213 of_1\IN\1740 intravenous_2\JJ\1740 <e1>metoprolol</e1>_3\NN\2832168 or_4\CC\3541091 intravenous_5\JJ\1740 metoprolol_6\NN\2832168 plus_7\CC\4723816 glucagon_8\VBD\1740 on_9\IN\1740 dobutamine-induced_10\JJ\1740 <e2>myocardial_11\JJ\1740 ischemia</e2>_12\NN\14195315 ._13\.\1740
D008790_D017202 NONE effect_0\NN\34213 of_1\IN\1740 intravenous_2\JJ\1740 metoprolol_3\NN\2832168 or_4\CC\3541091 intravenous_5\JJ\1740 <e1>metoprolol</e1>_6\NN\2832168 plus_7\CC\4723816 glucagon_8\VBD\1740 on_9\IN\1740 dobutamine-induced_10\JJ\1740 <e2>myocardial_11\JJ\1740 ischemia</e2>_12\NN\14195315 ._13\.\1740
D008790_D017202 NONE conclusion_0\NN\5837957 :_1\:\1740 during_2\IN\1740 dobutamine_3\NN\1740 stress_4\NN\7083732 testing_5\NN\639556 ,_6\,\1740 <e1>metoprolol</e1>_7\NN\2832168 attenuates_8\NNS\1740 or_9\CC\3541091 eliminates_10\VBZ\1619929 evidence_11\NN\5816287 of_12\IN\1740 <e2>myocardial_13\JJ\1740 ischemia</e2>_14\NN\14195315 ._15\.\1740
D004280_D017202 CID effect_0\NN\34213 of_1\IN\1740 intravenous_2\JJ\1740 metoprolol_3\NN\2832168 or_4\CC\3541091 intravenous_5\JJ\1740 metoprolol_6\NN\2832168 plus_7\CC\4723816 glucagon_8\VBD\1740 on_9\IN\1740 <e1>dobutamine-induced</e1>_10\JJ\1740 <e2>myocardial_11\JJ\1740 ischemia</e2>_12\NN\14195315 ._13\.\1740
D004280_D017202 CID conclusion_0\NN\5837957 :_1\:\1740 during_2\IN\1740 <e1>dobutamine</e1>_3\NN\1740 stress_4\NN\7083732 testing_5\NN\639556 ,_6\,\1740 metoprolol_7\NN\2832168 attenuates_8\NNS\1740 or_9\CC\3541091 eliminates_10\VBZ\1619929 evidence_11\NN\5816287 of_12\IN\1740 <e2>myocardial_13\JJ\1740 ischemia</e2>_14\NN\14195315 ._15\.\1740
7416947
D004077_D020018 CID subjective_0\JJ\1740 assessment_1\NN\5732756 of_2\IN\1740 <e2>sexual_3\JJ\1740 dysfunction</e2>_4\NN\14204950 of_5\IN\1740 patients_6\NNS\9898892 on_7\IN\1740 long-term_8\JJ\1740 administration_9\NN\1133281 of_10\IN\1740 <e1>digoxin</e1>_11\NN\15060131 ._12\.\1740
D004077_D012214 NONE the_0\DT\1740 patients_1\NNS\9898892 of_2\IN\1740 the_3\DT\1740 study_4\NN\635850 and_5\CC\1740 control_6\NN\5190804 group_7\NN\2137 (_8\-LRB-\1740 without_9\IN\1740 <e1>digoxin</e1>_10\NN\15060131 )_11\-RRB-\1740 were_12\VBD\836236 of_13\IN\1740 similar_14\JJ\1740 cardiac_15\JJ\1740 functional_16\JJ\1740 capacity_17\NN\5202497 and_18\CC\1740 age_19\NN\4916342 (_20\-LRB-\1740 25_21\CD\13745420 -_22\SYM\1740 40_23\CD\13745420 years_24\NNS\15144371 )_25\-RRB-\1740 and_26\CC\1740 were_27\VBD\836236 randomly_28\RB\1740 selected_29\VBN\697589 from_30\IN\1740 the_31\DT\1740 <e2>rheumatic_32\JJ\1740 heart_33\NN\5919034 disease</e2>_34\NN\14061805 patients_35\NNS\9898892 ._36\.\1740
19761039
D010936_D004409 NONE effect_0\NN\34213 of_1\IN\1740 methanolic_2\JJ\1740 extract_3\NN\14589223 of_4\IN\1740 <e1>hibiscus_5\FW\12170585 rosa_6\VBD\1740 sinensis</e1>_7\NN\1740 (_8\-LRB-\1740 100_9\CD\13745420 -_10\SYM\1740 300_11\CD\1740 mg/kg_12\NN\1740 )_13\-RRB-\1740 was_14\VBD\836236 studied_15\VBN\630380 on_16\IN\1740 reserpine-induced_17\JJ\1740 orofacial_18\JJ\1740 <e2>dyskinesia</e2>_19\NN\14084880 and_20\CC\1740 neurochemical_21\JJ\1740 alterations_22\NNS\7283608 ._23\.\1740
D010936_D004409 NONE the_0\DT\1740 results_1\NNS\34213 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 suggested_6\VBD\1010118 that_7\IN\1740 <e1>hibiscus_8\NN\12170585 rosa_9\VBD\1740 sinensis</e1>_10\NN\1740 had_11\VBD\2108377 a_12\DT\13649268 protective_13\JJ\1740 role_14\NN\719494 against_15\IN\1740 reserpine-induced_16\JJ\1740 orofacial_17\JJ\1740 <e2>dyskinesia</e2>_18\NN\14084880 and_19\CC\1740 oxidative_20\JJ\1740 stress_21\NN\7083732 ._22\.\1740
D012110_D004409 CID effect_0\NN\34213 of_1\IN\1740 methanolic_2\JJ\1740 extract_3\NN\14589223 of_4\IN\1740 hibiscus_5\FW\12170585 rosa_6\VBD\1740 sinensis_7\NN\1740 (_8\-LRB-\1740 100_9\CD\13745420 -_10\SYM\1740 300_11\CD\1740 mg/kg_12\NN\1740 )_13\-RRB-\1740 was_14\VBD\836236 studied_15\VBN\630380 on_16\IN\1740 <e1>reserpine-induced</e1>_17\JJ\1740 orofacial_18\JJ\1740 <e2>dyskinesia</e2>_19\NN\14084880 and_20\CC\1740 neurochemical_21\JJ\1740 alterations_22\NNS\7283608 ._23\.\1740
D012110_D004409 CID the_0\DT\1740 results_1\NNS\34213 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 suggested_6\VBD\1010118 that_7\IN\1740 hibiscus_8\NN\12170585 rosa_9\VBD\1740 sinensis_10\NN\1740 had_11\VBD\2108377 a_12\DT\13649268 protective_13\JJ\1740 role_14\NN\719494 against_15\IN\1740 <e1>reserpine-induced</e1>_16\JJ\1740 orofacial_17\JJ\1740 <e2>dyskinesia</e2>_18\NN\14084880 and_19\CC\1740 oxidative_20\JJ\1740 stress_21\NN\7083732 ._22\.\1740
12852481
D001241_D000014 CID <e1>aspirin</e1>_0\NN\2707683 (_1\-LRB-\1740 acetylsalicylic_2\JJ\1740 acid_3\NN\14818238 [_4\-LRB-\1740 asa_5\NN\1740 ]_6\-RRB-\1740 )_7\-RRB-\1740 ,_8\,\1740 an_9\DT\6697703 irreversible_10\JJ\1740 cyclooxygenase_11\NN\14732946 1_12\CD\13741022 and_13\CC\1740 2_14\CD\13741022 inhibitor_15\NN\20090 ,_16\,\1740 induces_17\VBZ\1627355 <e2>developmental_18\JJ\1740 anomalies</e2>_19\NNS\14501726 when_20\WRB\1740 administered_21\VBN\2436349 to_22\IN\1740 wistar_23\NNP\1740 rats_24\NNS\2329401 on_25\IN\1740 gestational_26\JJ\1740 day_27\NN\15154774 (_28\-LRB-\1740 gd_29\NN\14970136 )_30\-RRB-\1740 9_31\CD\13741022 ,_32\,\1740 10_33\CD\13745420 ,_34\,\1740 or_35\CC\3541091 11_36\CD\13745420 (_37\-LRB-\1740 kimmel_38\NNP\1740 ca_39\NNP\14625458 ,_40\,\1740 wilson_41\NNP\1740 jg_42\NNP\1740 ,_43\,\1740 schumacher_44\NNP\1740 hj_45\NNP\1740 ._46\.\1740
D001241_D000014 CID aspirin_0\NN\2707683 (_1\-LRB-\1740 <e1>acetylsalicylic_2\JJ\1740 acid</e1>_3\NN\14818238 [_4\-LRB-\1740 asa_5\NN\1740 ]_6\-RRB-\1740 )_7\-RRB-\1740 ,_8\,\1740 an_9\DT\6697703 irreversible_10\JJ\1740 cyclooxygenase_11\NN\14732946 1_12\CD\13741022 and_13\CC\1740 2_14\CD\13741022 inhibitor_15\NN\20090 ,_16\,\1740 induces_17\VBZ\1627355 <e2>developmental_18\JJ\1740 anomalies</e2>_19\NNS\14501726 when_20\WRB\1740 administered_21\VBN\2436349 to_22\IN\1740 wistar_23\NNP\1740 rats_24\NNS\2329401 on_25\IN\1740 gestational_26\JJ\1740 day_27\NN\15154774 (_28\-LRB-\1740 gd_29\NN\14970136 )_30\-RRB-\1740 9_31\CD\13741022 ,_32\,\1740 10_33\CD\13745420 ,_34\,\1740 or_35\CC\3541091 11_36\CD\13745420 (_37\-LRB-\1740 kimmel_38\NNP\1740 ca_39\NNP\14625458 ,_40\,\1740 wilson_41\NNP\1740 jg_42\NNP\1740 ,_43\,\1740 schumacher_44\NNP\1740 hj_45\NNP\1740 ._46\.\1740
D001241_D000014 CID aspirin_0\NN\2707683 (_1\-LRB-\1740 acetylsalicylic_2\JJ\1740 acid_3\NN\14818238 [_4\-LRB-\1740 <e1>asa</e1>_5\NN\1740 ]_6\-RRB-\1740 )_7\-RRB-\1740 ,_8\,\1740 an_9\DT\6697703 irreversible_10\JJ\1740 cyclooxygenase_11\NN\14732946 1_12\CD\13741022 and_13\CC\1740 2_14\CD\13741022 inhibitor_15\NN\20090 ,_16\,\1740 induces_17\VBZ\1627355 <e2>developmental_18\JJ\1740 anomalies</e2>_19\NNS\14501726 when_20\WRB\1740 administered_21\VBN\2436349 to_22\IN\1740 wistar_23\NNP\1740 rats_24\NNS\2329401 on_25\IN\1740 gestational_26\JJ\1740 day_27\NN\15154774 (_28\-LRB-\1740 gd_29\NN\14970136 )_30\-RRB-\1740 9_31\CD\13741022 ,_32\,\1740 10_33\CD\13745420 ,_34\,\1740 or_35\CC\3541091 11_36\CD\13745420 (_37\-LRB-\1740 kimmel_38\NNP\1740 ca_39\NNP\14625458 ,_40\,\1740 wilson_41\NNP\1740 jg_42\NNP\1740 ,_43\,\1740 schumacher_44\NNP\1740 hj_45\NNP\1740 ._46\.\1740
D001241_D000014 CID objectives_0\NNS\5980875 of_1\IN\1740 the_2\DT\1740 current_3\JJ\1740 study_4\NN\635850 were_5\VBD\836236 to_6\TO\1740 compare_7\VB\644583 results_8\NNS\34213 between_9\IN\1740 sprague-dawley_10\NN\1740 (_11\-LRB-\1740 sd_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 wistar_15\NNP\1740 strains_16\NNS\7358060 when_17\WRB\1740 <e1>asa</e1>_18\NN\1740 is_19\VBZ\836236 administered_20\VBN\2436349 on_21\IN\1740 gd_22\NN\14970136 9_23\CD\13741022 ,_24\,\1740 10_25\CD\13745420 ,_26\,\1740 or_27\CC\3541091 11_28\CD\13745420 ;_29\:\1740 to_30\TO\1740 compare_31\VB\644583 the_32\DT\1740 malformation_33\NN\14213199 patterns_34\NNS\5726345 following_35\VBG\1835496 single_36\JJ\1740 and_37\CC\1740 multiple_38\JJ\1740 dosings_39\NNS\1740 during_40\IN\1740 organogenesis_41\NN\1740 in_42\IN\13603305 sd_43\NN\1740 rats_44\NNS\2329401 ;_45\:\1740 and_46\CC\1740 to_47\TO\1740 test_48\VB\670261 the_49\DT\1740 hypothesis_50\NN\7162194 that_51\IN\1740 maternal_52\JJ\1740 gastrointestinal_53\JJ\1740 toxicity_54\NN\13576101 confounds_55\VBZ\2604760 the_56\DT\1740 detection_57\NN\5708432 of_58\IN\1740 low_59\JJ\1740 incidence_60\NN\13821570 <e2>malformations</e2>_61\NNS\14213199 with_62\IN\1740 asa_63\NN\1740 when_64\WRB\1740 a_65\DT\13649268 multiple_66\JJ\1740 dosing_67\NN\1740 paradigm_68\NN\13803782 is_69\VBZ\836236 used_70\VBN\1156834 ._71\.\1740
D001241_D000014 CID objectives_0\NNS\5980875 of_1\IN\1740 the_2\DT\1740 current_3\JJ\1740 study_4\NN\635850 were_5\VBD\836236 to_6\TO\1740 compare_7\VB\644583 results_8\NNS\34213 between_9\IN\1740 sprague-dawley_10\NN\1740 (_11\-LRB-\1740 sd_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 wistar_15\NNP\1740 strains_16\NNS\7358060 when_17\WRB\1740 asa_18\NN\1740 is_19\VBZ\836236 administered_20\VBN\2436349 on_21\IN\1740 gd_22\NN\14970136 9_23\CD\13741022 ,_24\,\1740 10_25\CD\13745420 ,_26\,\1740 or_27\CC\3541091 11_28\CD\13745420 ;_29\:\1740 to_30\TO\1740 compare_31\VB\644583 the_32\DT\1740 malformation_33\NN\14213199 patterns_34\NNS\5726345 following_35\VBG\1835496 single_36\JJ\1740 and_37\CC\1740 multiple_38\JJ\1740 dosings_39\NNS\1740 during_40\IN\1740 organogenesis_41\NN\1740 in_42\IN\13603305 sd_43\NN\1740 rats_44\NNS\2329401 ;_45\:\1740 and_46\CC\1740 to_47\TO\1740 test_48\VB\670261 the_49\DT\1740 hypothesis_50\NN\7162194 that_51\IN\1740 maternal_52\JJ\1740 gastrointestinal_53\JJ\1740 toxicity_54\NN\13576101 confounds_55\VBZ\2604760 the_56\DT\1740 detection_57\NN\5708432 of_58\IN\1740 low_59\JJ\1740 incidence_60\NN\13821570 <e2>malformations</e2>_61\NNS\14213199 with_62\IN\1740 <e1>asa</e1>_63\NN\1740 when_64\WRB\1740 a_65\DT\13649268 multiple_66\JJ\1740 dosing_67\NN\1740 paradigm_68\NN\13803782 is_69\VBZ\836236 used_70\VBN\1156834 ._71\.\1740
D001241_D000014 CID results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 literature_3\NN\6362953 evaluation_4\NN\874067 suggested_5\VBD\1010118 that_6\IN\1740 nsaids_7\NNS\2721538 induce_8\VBP\1627355 ventricular_9\NN\1740 septal_10\JJ\1740 defects_11\NNS\14462666 (_12\-LRB-\1740 vsds_13\NNS\1740 )_14\-RRB-\1740 and_15\CC\1740 midline_16\JJ\1740 defects_17\NNS\14462666 (_18\-LRB-\1740 mds_19\NNS\14622893 )_20\-RRB-\1740 in_21\IN\13603305 rats_22\NNS\2329401 and_23\CC\1740 diaphragmatic_24\JJ\1740 hernia_25\NN\14295248 (_26\-LRB-\1740 dh_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 mds_30\NNS\14622893 ,_31\,\1740 and_32\CC\1740 vsds_33\NNS\1740 in_34\IN\13603305 rabbits_35\NNS\2323902 (_36\-LRB-\1740 cook_37\NN\10605985 jc_38\NN\1740 et_39\FW\1740 al._40\FW\1740 ,_41\,\1740 2003_42\CD\1740 )_43\-RRB-\1740 ;_44\:\1740 hence_45\RB\1740 ,_46\,\1740 the_47\DT\1740 present_48\JJ\1740 study_49\NN\635850 focused_50\VBD\628491 on_51\IN\1740 these_52\DT\1740 <e2>malformations</e2>_53\NNS\14213199 ,_54\,\1740 even_55\RB\1740 though_56\IN\1740 <e1>asa</e1>_57\NN\1740 induces_58\VBZ\1627355 several_59\JJ\1740 other_60\JJ\1740 low-incidence_61\JJ\1740 malformations_62\NNS\14213199 ._63\.\1740
D001241_D000014 CID results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 literature_3\NN\6362953 evaluation_4\NN\874067 suggested_5\VBD\1010118 that_6\IN\1740 nsaids_7\NNS\2721538 induce_8\VBP\1627355 ventricular_9\NN\1740 septal_10\JJ\1740 defects_11\NNS\14462666 (_12\-LRB-\1740 vsds_13\NNS\1740 )_14\-RRB-\1740 and_15\CC\1740 midline_16\JJ\1740 defects_17\NNS\14462666 (_18\-LRB-\1740 mds_19\NNS\14622893 )_20\-RRB-\1740 in_21\IN\13603305 rats_22\NNS\2329401 and_23\CC\1740 diaphragmatic_24\JJ\1740 hernia_25\NN\14295248 (_26\-LRB-\1740 dh_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 mds_30\NNS\14622893 ,_31\,\1740 and_32\CC\1740 vsds_33\NNS\1740 in_34\IN\13603305 rabbits_35\NNS\2323902 (_36\-LRB-\1740 cook_37\NN\10605985 jc_38\NN\1740 et_39\FW\1740 al._40\FW\1740 ,_41\,\1740 2003_42\CD\1740 )_43\-RRB-\1740 ;_44\:\1740 hence_45\RB\1740 ,_46\,\1740 the_47\DT\1740 present_48\JJ\1740 study_49\NN\635850 focused_50\VBD\628491 on_51\IN\1740 these_52\DT\1740 malformations_53\NNS\14213199 ,_54\,\1740 even_55\RB\1740 though_56\IN\1740 <e1>asa</e1>_57\NN\1740 induces_58\VBZ\1627355 several_59\JJ\1740 other_60\JJ\1740 low-incidence_61\JJ\1740 <e2>malformations</e2>_62\NNS\14213199 ._63\.\1740
D001241_D000014 CID variations_0\NNS\7296428 and_1\CC\1740 <e2>malformations</e2>_2\NNS\14213199 were_3\VBD\836236 similar_4\JJ\1740 when_5\WRB\1740 <e1>asa</e1>_6\NN\1740 was_7\VBD\836236 administered_8\VBN\2436349 as_9\IN\14622893 a_10\DT\13649268 single_11\JJ\1740 dose_12\NN\3740161 or_13\CC\3541091 during_14\IN\1740 the_15\DT\1740 period_16\NN\13575869 of_17\IN\1740 organogenesis_18\NN\1740 (_19\-LRB-\1740 gds_20\NNS\14970136 6_21\CD\13741022 to_22\TO\1740 17_23\CD\13745420 )_24\-RRB-\1740 ._25\.\1740
D001241_D000014 CID it_0\PRP\6125041 was_1\VBD\836236 also_2\RB\1740 evident_3\JJ\1740 that_4\IN\1740 ,_5\,\1740 by_6\IN\1740 titrating_7\VBG\489837 the_8\DT\1740 dose_9\NN\3740161 to_10\TO\1740 achieve_11\VB\2524171 a_12\DT\13649268 maximum_13\NN\13653902 tolerated_14\VBN\802318 dose_15\NN\3740161 ,_16\,\1740 <e2>malformations</e2>_17\NNS\14213199 that_18\WDT\1740 normally_19\RB\1740 occur_20\VBP\2623529 at_21\IN\14622893 low_22\JJ\1740 incidence_23\NN\13821570 ,_24\,\1740 as_25\IN\14622893 reported_26\VBN\831651 from_27\IN\1740 previous_28\JJ\1740 single_29\JJ\1740 dose_30\NN\3740161 studies_31\NNS\635850 ,_32\,\1740 could_33\MD\1740 also_34\RB\1740 be_35\VB\836236 induced_36\VBN\1627355 with_37\IN\1740 <e1>asa</e1>_38\NN\1740 given_39\VBN\2327200 at_40\IN\14622893 multiple_41\JJ\1740 doses_42\NNS\3740161 ._43\.\1740
D001241_D005767 NONE objectives_0\NNS\5980875 of_1\IN\1740 the_2\DT\1740 current_3\JJ\1740 study_4\NN\635850 were_5\VBD\836236 to_6\TO\1740 compare_7\VB\644583 results_8\NNS\34213 between_9\IN\1740 sprague-dawley_10\NN\1740 (_11\-LRB-\1740 sd_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 wistar_15\NNP\1740 strains_16\NNS\7358060 when_17\WRB\1740 <e1>asa</e1>_18\NN\1740 is_19\VBZ\836236 administered_20\VBN\2436349 on_21\IN\1740 gd_22\NN\14970136 9_23\CD\13741022 ,_24\,\1740 10_25\CD\13745420 ,_26\,\1740 or_27\CC\3541091 11_28\CD\13745420 ;_29\:\1740 to_30\TO\1740 compare_31\VB\644583 the_32\DT\1740 malformation_33\NN\14213199 patterns_34\NNS\5726345 following_35\VBG\1835496 single_36\JJ\1740 and_37\CC\1740 multiple_38\JJ\1740 dosings_39\NNS\1740 during_40\IN\1740 organogenesis_41\NN\1740 in_42\IN\13603305 sd_43\NN\1740 rats_44\NNS\2329401 ;_45\:\1740 and_46\CC\1740 to_47\TO\1740 test_48\VB\670261 the_49\DT\1740 hypothesis_50\NN\7162194 that_51\IN\1740 maternal_52\JJ\1740 <e2>gastrointestinal_53\JJ\1740 toxicity</e2>_54\NN\13576101 confounds_55\VBZ\2604760 the_56\DT\1740 detection_57\NN\5708432 of_58\IN\1740 low_59\JJ\1740 incidence_60\NN\13821570 malformations_61\NNS\14213199 with_62\IN\1740 asa_63\NN\1740 when_64\WRB\1740 a_65\DT\13649268 multiple_66\JJ\1740 dosing_67\NN\1740 paradigm_68\NN\13803782 is_69\VBZ\836236 used_70\VBN\1156834 ._71\.\1740
D001241_D005767 NONE objectives_0\NNS\5980875 of_1\IN\1740 the_2\DT\1740 current_3\JJ\1740 study_4\NN\635850 were_5\VBD\836236 to_6\TO\1740 compare_7\VB\644583 results_8\NNS\34213 between_9\IN\1740 sprague-dawley_10\NN\1740 (_11\-LRB-\1740 sd_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 wistar_15\NNP\1740 strains_16\NNS\7358060 when_17\WRB\1740 asa_18\NN\1740 is_19\VBZ\836236 administered_20\VBN\2436349 on_21\IN\1740 gd_22\NN\14970136 9_23\CD\13741022 ,_24\,\1740 10_25\CD\13745420 ,_26\,\1740 or_27\CC\3541091 11_28\CD\13745420 ;_29\:\1740 to_30\TO\1740 compare_31\VB\644583 the_32\DT\1740 malformation_33\NN\14213199 patterns_34\NNS\5726345 following_35\VBG\1835496 single_36\JJ\1740 and_37\CC\1740 multiple_38\JJ\1740 dosings_39\NNS\1740 during_40\IN\1740 organogenesis_41\NN\1740 in_42\IN\13603305 sd_43\NN\1740 rats_44\NNS\2329401 ;_45\:\1740 and_46\CC\1740 to_47\TO\1740 test_48\VB\670261 the_49\DT\1740 hypothesis_50\NN\7162194 that_51\IN\1740 maternal_52\JJ\1740 <e2>gastrointestinal_53\JJ\1740 toxicity</e2>_54\NN\13576101 confounds_55\VBZ\2604760 the_56\DT\1740 detection_57\NN\5708432 of_58\IN\1740 low_59\JJ\1740 incidence_60\NN\13821570 malformations_61\NNS\14213199 with_62\IN\1740 <e1>asa</e1>_63\NN\1740 when_64\WRB\1740 a_65\DT\13649268 multiple_66\JJ\1740 dosing_67\NN\1740 paradigm_68\NN\13803782 is_69\VBZ\836236 used_70\VBN\1156834 ._71\.\1740
D001241_D006345 CID results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 literature_3\NN\6362953 evaluation_4\NN\874067 suggested_5\VBD\1010118 that_6\IN\1740 nsaids_7\NNS\2721538 induce_8\VBP\1627355 <e2>ventricular_9\NN\1740 septal_10\JJ\1740 defects</e2>_11\NNS\14462666 (_12\-LRB-\1740 vsds_13\NNS\1740 )_14\-RRB-\1740 and_15\CC\1740 midline_16\JJ\1740 defects_17\NNS\14462666 (_18\-LRB-\1740 mds_19\NNS\14622893 )_20\-RRB-\1740 in_21\IN\13603305 rats_22\NNS\2329401 and_23\CC\1740 diaphragmatic_24\JJ\1740 hernia_25\NN\14295248 (_26\-LRB-\1740 dh_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 mds_30\NNS\14622893 ,_31\,\1740 and_32\CC\1740 vsds_33\NNS\1740 in_34\IN\13603305 rabbits_35\NNS\2323902 (_36\-LRB-\1740 cook_37\NN\10605985 jc_38\NN\1740 et_39\FW\1740 al._40\FW\1740 ,_41\,\1740 2003_42\CD\1740 )_43\-RRB-\1740 ;_44\:\1740 hence_45\RB\1740 ,_46\,\1740 the_47\DT\1740 present_48\JJ\1740 study_49\NN\635850 focused_50\VBD\628491 on_51\IN\1740 these_52\DT\1740 malformations_53\NNS\14213199 ,_54\,\1740 even_55\RB\1740 though_56\IN\1740 <e1>asa</e1>_57\NN\1740 induces_58\VBZ\1627355 several_59\JJ\1740 other_60\JJ\1740 low-incidence_61\JJ\1740 malformations_62\NNS\14213199 ._63\.\1740
D001241_D006345 CID results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 literature_3\NN\6362953 evaluation_4\NN\874067 suggested_5\VBD\1010118 that_6\IN\1740 nsaids_7\NNS\2721538 induce_8\VBP\1627355 ventricular_9\NN\1740 septal_10\JJ\1740 defects_11\NNS\14462666 (_12\-LRB-\1740 <e2>vsds</e2>_13\NNS\1740 )_14\-RRB-\1740 and_15\CC\1740 midline_16\JJ\1740 defects_17\NNS\14462666 (_18\-LRB-\1740 mds_19\NNS\14622893 )_20\-RRB-\1740 in_21\IN\13603305 rats_22\NNS\2329401 and_23\CC\1740 diaphragmatic_24\JJ\1740 hernia_25\NN\14295248 (_26\-LRB-\1740 dh_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 mds_30\NNS\14622893 ,_31\,\1740 and_32\CC\1740 vsds_33\NNS\1740 in_34\IN\13603305 rabbits_35\NNS\2323902 (_36\-LRB-\1740 cook_37\NN\10605985 jc_38\NN\1740 et_39\FW\1740 al._40\FW\1740 ,_41\,\1740 2003_42\CD\1740 )_43\-RRB-\1740 ;_44\:\1740 hence_45\RB\1740 ,_46\,\1740 the_47\DT\1740 present_48\JJ\1740 study_49\NN\635850 focused_50\VBD\628491 on_51\IN\1740 these_52\DT\1740 malformations_53\NNS\14213199 ,_54\,\1740 even_55\RB\1740 though_56\IN\1740 <e1>asa</e1>_57\NN\1740 induces_58\VBZ\1627355 several_59\JJ\1740 other_60\JJ\1740 low-incidence_61\JJ\1740 malformations_62\NNS\14213199 ._63\.\1740
D001241_D006345 CID results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 literature_3\NN\6362953 evaluation_4\NN\874067 suggested_5\VBD\1010118 that_6\IN\1740 nsaids_7\NNS\2721538 induce_8\VBP\1627355 ventricular_9\NN\1740 septal_10\JJ\1740 defects_11\NNS\14462666 (_12\-LRB-\1740 vsds_13\NNS\1740 )_14\-RRB-\1740 and_15\CC\1740 midline_16\JJ\1740 defects_17\NNS\14462666 (_18\-LRB-\1740 mds_19\NNS\14622893 )_20\-RRB-\1740 in_21\IN\13603305 rats_22\NNS\2329401 and_23\CC\1740 diaphragmatic_24\JJ\1740 hernia_25\NN\14295248 (_26\-LRB-\1740 dh_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 mds_30\NNS\14622893 ,_31\,\1740 and_32\CC\1740 <e2>vsds</e2>_33\NNS\1740 in_34\IN\13603305 rabbits_35\NNS\2323902 (_36\-LRB-\1740 cook_37\NN\10605985 jc_38\NN\1740 et_39\FW\1740 al._40\FW\1740 ,_41\,\1740 2003_42\CD\1740 )_43\-RRB-\1740 ;_44\:\1740 hence_45\RB\1740 ,_46\,\1740 the_47\DT\1740 present_48\JJ\1740 study_49\NN\635850 focused_50\VBD\628491 on_51\IN\1740 these_52\DT\1740 malformations_53\NNS\14213199 ,_54\,\1740 even_55\RB\1740 though_56\IN\1740 <e1>asa</e1>_57\NN\1740 induces_58\VBZ\1627355 several_59\JJ\1740 other_60\JJ\1740 low-incidence_61\JJ\1740 malformations_62\NNS\14213199 ._63\.\1740
D001241_D009436 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 literature_3\NN\6362953 evaluation_4\NN\874067 suggested_5\VBD\1010118 that_6\IN\1740 nsaids_7\NNS\2721538 induce_8\VBP\1627355 ventricular_9\NN\1740 septal_10\JJ\1740 defects_11\NNS\14462666 (_12\-LRB-\1740 vsds_13\NNS\1740 )_14\-RRB-\1740 and_15\CC\1740 <e2>midline_16\JJ\1740 defects</e2>_17\NNS\14462666 (_18\-LRB-\1740 mds_19\NNS\14622893 )_20\-RRB-\1740 in_21\IN\13603305 rats_22\NNS\2329401 and_23\CC\1740 diaphragmatic_24\JJ\1740 hernia_25\NN\14295248 (_26\-LRB-\1740 dh_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 mds_30\NNS\14622893 ,_31\,\1740 and_32\CC\1740 vsds_33\NNS\1740 in_34\IN\13603305 rabbits_35\NNS\2323902 (_36\-LRB-\1740 cook_37\NN\10605985 jc_38\NN\1740 et_39\FW\1740 al._40\FW\1740 ,_41\,\1740 2003_42\CD\1740 )_43\-RRB-\1740 ;_44\:\1740 hence_45\RB\1740 ,_46\,\1740 the_47\DT\1740 present_48\JJ\1740 study_49\NN\635850 focused_50\VBD\628491 on_51\IN\1740 these_52\DT\1740 malformations_53\NNS\14213199 ,_54\,\1740 even_55\RB\1740 though_56\IN\1740 <e1>asa</e1>_57\NN\1740 induces_58\VBZ\1627355 several_59\JJ\1740 other_60\JJ\1740 low-incidence_61\JJ\1740 malformations_62\NNS\14213199 ._63\.\1740
D001241_D009436 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 literature_3\NN\6362953 evaluation_4\NN\874067 suggested_5\VBD\1010118 that_6\IN\1740 nsaids_7\NNS\2721538 induce_8\VBP\1627355 ventricular_9\NN\1740 septal_10\JJ\1740 defects_11\NNS\14462666 (_12\-LRB-\1740 vsds_13\NNS\1740 )_14\-RRB-\1740 and_15\CC\1740 midline_16\JJ\1740 defects_17\NNS\14462666 (_18\-LRB-\1740 <e2>mds</e2>_19\NNS\14622893 )_20\-RRB-\1740 in_21\IN\13603305 rats_22\NNS\2329401 and_23\CC\1740 diaphragmatic_24\JJ\1740 hernia_25\NN\14295248 (_26\-LRB-\1740 dh_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 mds_30\NNS\14622893 ,_31\,\1740 and_32\CC\1740 vsds_33\NNS\1740 in_34\IN\13603305 rabbits_35\NNS\2323902 (_36\-LRB-\1740 cook_37\NN\10605985 jc_38\NN\1740 et_39\FW\1740 al._40\FW\1740 ,_41\,\1740 2003_42\CD\1740 )_43\-RRB-\1740 ;_44\:\1740 hence_45\RB\1740 ,_46\,\1740 the_47\DT\1740 present_48\JJ\1740 study_49\NN\635850 focused_50\VBD\628491 on_51\IN\1740 these_52\DT\1740 malformations_53\NNS\14213199 ,_54\,\1740 even_55\RB\1740 though_56\IN\1740 <e1>asa</e1>_57\NN\1740 induces_58\VBZ\1627355 several_59\JJ\1740 other_60\JJ\1740 low-incidence_61\JJ\1740 malformations_62\NNS\14213199 ._63\.\1740
D001241_D009436 NONE results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 literature_3\NN\6362953 evaluation_4\NN\874067 suggested_5\VBD\1010118 that_6\IN\1740 nsaids_7\NNS\2721538 induce_8\VBP\1627355 ventricular_9\NN\1740 septal_10\JJ\1740 defects_11\NNS\14462666 (_12\-LRB-\1740 vsds_13\NNS\1740 )_14\-RRB-\1740 and_15\CC\1740 midline_16\JJ\1740 defects_17\NNS\14462666 (_18\-LRB-\1740 mds_19\NNS\14622893 )_20\-RRB-\1740 in_21\IN\13603305 rats_22\NNS\2329401 and_23\CC\1740 diaphragmatic_24\JJ\1740 hernia_25\NN\14295248 (_26\-LRB-\1740 dh_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 <e2>mds</e2>_30\NNS\14622893 ,_31\,\1740 and_32\CC\1740 vsds_33\NNS\1740 in_34\IN\13603305 rabbits_35\NNS\2323902 (_36\-LRB-\1740 cook_37\NN\10605985 jc_38\NN\1740 et_39\FW\1740 al._40\FW\1740 ,_41\,\1740 2003_42\CD\1740 )_43\-RRB-\1740 ;_44\:\1740 hence_45\RB\1740 ,_46\,\1740 the_47\DT\1740 present_48\JJ\1740 study_49\NN\635850 focused_50\VBD\628491 on_51\IN\1740 these_52\DT\1740 malformations_53\NNS\14213199 ,_54\,\1740 even_55\RB\1740 though_56\IN\1740 <e1>asa</e1>_57\NN\1740 induces_58\VBZ\1627355 several_59\JJ\1740 other_60\JJ\1740 low-incidence_61\JJ\1740 malformations_62\NNS\14213199 ._63\.\1740
D001241_D065630 CID results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 literature_3\NN\6362953 evaluation_4\NN\874067 suggested_5\VBD\1010118 that_6\IN\1740 nsaids_7\NNS\2721538 induce_8\VBP\1627355 ventricular_9\NN\1740 septal_10\JJ\1740 defects_11\NNS\14462666 (_12\-LRB-\1740 vsds_13\NNS\1740 )_14\-RRB-\1740 and_15\CC\1740 midline_16\JJ\1740 defects_17\NNS\14462666 (_18\-LRB-\1740 mds_19\NNS\14622893 )_20\-RRB-\1740 in_21\IN\13603305 rats_22\NNS\2329401 and_23\CC\1740 <e2>diaphragmatic_24\JJ\1740 hernia</e2>_25\NN\14295248 (_26\-LRB-\1740 dh_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 mds_30\NNS\14622893 ,_31\,\1740 and_32\CC\1740 vsds_33\NNS\1740 in_34\IN\13603305 rabbits_35\NNS\2323902 (_36\-LRB-\1740 cook_37\NN\10605985 jc_38\NN\1740 et_39\FW\1740 al._40\FW\1740 ,_41\,\1740 2003_42\CD\1740 )_43\-RRB-\1740 ;_44\:\1740 hence_45\RB\1740 ,_46\,\1740 the_47\DT\1740 present_48\JJ\1740 study_49\NN\635850 focused_50\VBD\628491 on_51\IN\1740 these_52\DT\1740 malformations_53\NNS\14213199 ,_54\,\1740 even_55\RB\1740 though_56\IN\1740 <e1>asa</e1>_57\NN\1740 induces_58\VBZ\1627355 several_59\JJ\1740 other_60\JJ\1740 low-incidence_61\JJ\1740 malformations_62\NNS\14213199 ._63\.\1740
D001241_D065630 CID results_0\NNS\34213 :_1\:\1740 the_2\DT\1740 literature_3\NN\6362953 evaluation_4\NN\874067 suggested_5\VBD\1010118 that_6\IN\1740 nsaids_7\NNS\2721538 induce_8\VBP\1627355 ventricular_9\NN\1740 septal_10\JJ\1740 defects_11\NNS\14462666 (_12\-LRB-\1740 vsds_13\NNS\1740 )_14\-RRB-\1740 and_15\CC\1740 midline_16\JJ\1740 defects_17\NNS\14462666 (_18\-LRB-\1740 mds_19\NNS\14622893 )_20\-RRB-\1740 in_21\IN\13603305 rats_22\NNS\2329401 and_23\CC\1740 diaphragmatic_24\JJ\1740 hernia_25\NN\14295248 (_26\-LRB-\1740 <e2>dh</e2>_27\NN\1740 )_28\-RRB-\1740 ,_29\,\1740 mds_30\NNS\14622893 ,_31\,\1740 and_32\CC\1740 vsds_33\NNS\1740 in_34\IN\13603305 rabbits_35\NNS\2323902 (_36\-LRB-\1740 cook_37\NN\10605985 jc_38\NN\1740 et_39\FW\1740 al._40\FW\1740 ,_41\,\1740 2003_42\CD\1740 )_43\-RRB-\1740 ;_44\:\1740 hence_45\RB\1740 ,_46\,\1740 the_47\DT\1740 present_48\JJ\1740 study_49\NN\635850 focused_50\VBD\628491 on_51\IN\1740 these_52\DT\1740 malformations_53\NNS\14213199 ,_54\,\1740 even_55\RB\1740 though_56\IN\1740 <e1>asa</e1>_57\NN\1740 induces_58\VBZ\1627355 several_59\JJ\1740 other_60\JJ\1740 low-incidence_61\JJ\1740 malformations_62\NNS\14213199 ._63\.\1740
19058474
D014859_D010490 NONE fatal_0\JJ\1740 <e2>haemopericardium</e2>_1\NN\1740 and_2\CC\1740 gastrointestinal_3\JJ\1740 haemorrhage_4\NN\14285662 due_5\JJ\1740 to_6\TO\1740 possible_7\JJ\1740 interaction_8\NN\37396 of_9\IN\1740 cranberry_10\NN\13112664 juice_11\NN\7566340 with_12\IN\1740 <e1>warfarin</e1>_13\NN\2718259 ._14\.\1740
D014859_D006471 CID fatal_0\JJ\1740 haemopericardium_1\NN\1740 and_2\CC\1740 <e2>gastrointestinal_3\JJ\1740 haemorrhage</e2>_4\NN\14285662 due_5\JJ\1740 to_6\TO\1740 possible_7\JJ\1740 interaction_8\NN\37396 of_9\IN\1740 cranberry_10\NN\13112664 juice_11\NN\7566340 with_12\IN\1740 <e1>warfarin</e1>_13\NN\2718259 ._14\.\1740
D014859_D006470 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 fatal_5\JJ\1740 internal_6\JJ\1740 <e2>haemorrhage</e2>_7\NN\14285662 in_8\IN\13603305 an_9\DT\6697703 elderly_10\JJ\1740 man_11\NN\9605289 who_12\WP\8299493 consumed_13\VBD\1168468 only_14\RB\1740 cranberry_15\VB\1740 juice_16\NN\7566340 for_17\IN\1740 two_18\CD\13741022 weeks_19\NNS\15113229 while_20\IN\15122231 maintaining_21\VBG\2202928 his_22\PRP$\1740 usual_23\JJ\1740 dosage_24\NN\13576355 of_25\IN\1740 <e1>warfarin</e1>_26\NN\2718259 ._27\.\1740
11009181
D001058_D010300 NONE <e1>apomorphine</e1>_0\NN\3786417 :_1\:\1740 an_2\DT\6697703 underutilized_3\JJ\1740 therapy_4\NN\657604 for_5\IN\1740 <e2>parkinson_6\NN\1740 's_7\POS\1740 disease</e2>_8\NN\14061805 ._9\.\1740
D001058_D010300 NONE <e1>apomorphine</e1>_0\NNP\3786417 was_1\VBD\836236 the_2\DT\1740 first_3\JJ\1740 dopaminergic_4\JJ\1740 drug_5\NN\14778436 ever_6\RB\1740 used_7\VBD\1156834 to_8\TO\1740 treat_9\VB\2376958 symptoms_10\NNS\5823932 of_11\IN\1740 <e2>parkinson_12\NNP\1740 's_13\POS\1740 disease</e2>_14\NN\14061805 ._15\.\1740
D001058_D010300 NONE while_0\IN\15122231 powerful_1\JJ\1740 antiparkinsonian_2\NN\1740 effects_3\NNS\13245626 had_4\VBD\2108377 been_5\VBN\836236 observed_6\VBN\2163746 as_7\RB\1740 early_8\RB\1740 as_9\IN\14622893 1951_10\CD\1740 ,_11\,\1740 the_12\DT\1740 potential_13\NN\14481929 of_14\IN\1740 treating_15\VBG\2376958 fluctuating_16\VBG\1850315 <e2>parkinson_17\NNP\1740 's_18\POS\1740 disease</e2>_19\NN\14061805 by_20\IN\1740 subcutaneous_21\JJ\1740 administration_22\NN\1133281 of_23\IN\1740 <e1>apomorphine</e1>_24\NN\3786417 has_25\VBZ\2108377 only_26\RB\1740 recently_27\RB\1740 become_28\VBN\146138 the_29\DT\1740 subject_30\NN\6598915 of_31\IN\1740 systematic_32\JJ\1740 study_33\NN\635850 ._34\.\1740
D001058_D010300 NONE given_0\VBN\2327200 the_1\DT\1740 marked_2\JJ\1740 degree_3\NN\4916342 of_4\IN\1740 efficacy_5\NN\5199286 of_6\IN\1740 subcutaneous_7\JJ\1740 <e1>apomorphine</e1>_8\NN\3786417 treatment_9\NN\654885 in_10\IN\13603305 fluctuating_11\VBG\1850315 <e2>parkinson_12\NNP\1740 's_13\POS\1740 disease</e2>_14\NN\14061805 ,_15\,\1740 this_16\DT\1740 approach_17\NN\940842 seems_18\VBZ\2604760 to_19\TO\1740 deserve_20\VB\2604760 more_21\RBR\1740 widespread_22\JJ\1740 clinical_23\JJ\1740 use_24\NN\407535 ._25\.\1740
D001058_D004409 NONE in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 there_3\EX\27167 is_4\VBZ\836236 convincing_5\VBG\766418 clinical_6\JJ\1740 evidence_7\NN\5816287 that_8\IN\1740 monotherapy_9\NN\1740 with_10\IN\1740 continuous_11\JJ\1740 subcutaneous_12\JJ\1740 <e1>apomorphine</e1>_13\NN\3786417 infusions_14\NNS\14589223 is_15\VBZ\836236 associated_16\VBN\628491 with_17\IN\1740 marked_18\JJ\1740 reductions_19\NNS\351485 of_20\IN\1740 preexisting_21\VBG\2603699 levodopa-induced_22\JJ\1740 <e2>dyskinesias</e2>_23\NNS\14084880 ._24\.\1740
D007980_D004409 CID in_0\IN\13603305 addition_1\NN\3081021 ,_2\,\1740 there_3\EX\27167 is_4\VBZ\836236 convincing_5\VBG\766418 clinical_6\JJ\1740 evidence_7\NN\5816287 that_8\IN\1740 monotherapy_9\NN\1740 with_10\IN\1740 continuous_11\JJ\1740 subcutaneous_12\JJ\1740 apomorphine_13\NN\3786417 infusions_14\NNS\14589223 is_15\VBZ\836236 associated_16\VBN\628491 with_17\IN\1740 marked_18\JJ\1740 reductions_19\NNS\351485 of_20\IN\1740 preexisting_21\VBG\2603699 <e1>levodopa-induced</e1>_22\JJ\1740 <e2>dyskinesias</e2>_23\NNS\14084880 ._24\.\1740
D001058_D001523 NONE the_0\DT\1740 main_1\JJ\1740 side_2\NN\8630039 effects_3\NNS\13245626 of_4\IN\1740 subcutaneous_5\JJ\1740 <e1>apomorphine</e1>_6\NN\3786417 treatment_7\NN\654885 are_8\VBP\836236 related_9\JJ\1740 to_10\TO\1740 cutaneous_11\JJ\1740 tolerability_12\NN\1740 problems_13\NNS\14408086 ,_14\,\1740 whereas_15\IN\1740 sedation_16\NN\14034177 and_17\CC\1740 <e2>psychiatric</e2>_18\JJ\1740 complications_19\NNS\1073995 play_20\VBP\1072262 a_21\DT\13649268 lesser_22\JJR\1740 role_23\NN\719494 ._24\.\1740
15897593
D064730_D001855 NONE <e1>dexrazoxane</e1>_0\NNP\1740 protects_1\VBZ\1127795 against_2\IN\1740 <e2>myelosuppression</e2>_3\NN\1740 from_4\IN\1740 the_5\DT\1740 dna_6\NN\14994328 cleavage-enhancing_7\JJ\1740 drugs_8\NNS\14778436 etoposide_9\VBP\1740 and_10\CC\1740 daunorubicin_11\NN\1740 but_12\CC\1740 not_13\RB\1740 doxorubicin_14\NN\2716866 ._15\.\1740
D064730_D001855 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 <e1>dexrazoxane</e1>_5\NN\1740 reduced_6\VBD\441445 <e2>myelosuppression</e2>_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D064730_D001855 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 <e1>dexrazoxane</e1>_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 <e2>myelosuppression</e2>_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D064730_D001855 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 <e2>myelosuppression</e2>_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 <e1>dexrazoxane</e1>_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D064730_D001855 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 <e1>dexrazoxane</e1>_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 <e2>myelosuppression</e2>_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D005047_D001855 NONE dexrazoxane_0\NNP\1740 protects_1\VBZ\1127795 against_2\IN\1740 <e2>myelosuppression</e2>_3\NN\1740 from_4\IN\1740 the_5\DT\1740 dna_6\NN\14994328 cleavage-enhancing_7\JJ\1740 drugs_8\NNS\14778436 <e1>etoposide</e1>_9\VBP\1740 and_10\CC\1740 daunorubicin_11\NN\1740 but_12\CC\1740 not_13\RB\1740 doxorubicin_14\NN\2716866 ._15\.\1740
D005047_D001855 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 anthracyclines_3\NNS\1740 daunorubicin_4\NN\1740 and_5\CC\1740 doxorubicin_6\NN\2716866 and_7\CC\1740 the_8\DT\1740 epipodophyllotoxin_9\NN\1740 <e1>etoposide</e1>_10\NN\1740 are_11\VBP\836236 potent_12\JJ\1740 dna_13\NN\14994328 cleavage-enhancing_14\JJ\1740 drugs_15\NNS\14778436 that_16\WDT\1740 are_17\VBP\836236 widely_18\RB\1740 used_19\VBN\1156834 in_20\IN\13603305 clinical_21\JJ\1740 oncology_22\NN\6043075 ;_23\:\1740 however_24\RB\1740 ,_25\,\1740 <e2>myelosuppression</e2>_26\NN\1740 and_27\CC\1740 cardiac_28\JJ\1740 toxicity_29\NN\13576101 limit_30\NN\5123416 their_31\PRP$\1740 use_32\NN\407535 ._33\.\1740
D005047_D001855 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 <e2>myelosuppression</e2>_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 <e1>etoposide</e1>_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D005047_D001855 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 <e1>etoposide</e1>_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 <e2>myelosuppression</e2>_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D003630_D001855 NONE dexrazoxane_0\NNP\1740 protects_1\VBZ\1127795 against_2\IN\1740 <e2>myelosuppression</e2>_3\NN\1740 from_4\IN\1740 the_5\DT\1740 dna_6\NN\14994328 cleavage-enhancing_7\JJ\1740 drugs_8\NNS\14778436 etoposide_9\VBP\1740 and_10\CC\1740 <e1>daunorubicin</e1>_11\NN\1740 but_12\CC\1740 not_13\RB\1740 doxorubicin_14\NN\2716866 ._15\.\1740
D003630_D001855 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 anthracyclines_3\NNS\1740 <e1>daunorubicin</e1>_4\NN\1740 and_5\CC\1740 doxorubicin_6\NN\2716866 and_7\CC\1740 the_8\DT\1740 epipodophyllotoxin_9\NN\1740 etoposide_10\NN\1740 are_11\VBP\836236 potent_12\JJ\1740 dna_13\NN\14994328 cleavage-enhancing_14\JJ\1740 drugs_15\NNS\14778436 that_16\WDT\1740 are_17\VBP\836236 widely_18\RB\1740 used_19\VBN\1156834 in_20\IN\13603305 clinical_21\JJ\1740 oncology_22\NN\6043075 ;_23\:\1740 however_24\RB\1740 ,_25\,\1740 <e2>myelosuppression</e2>_26\NN\1740 and_27\CC\1740 cardiac_28\JJ\1740 toxicity_29\NN\13576101 limit_30\NN\5123416 their_31\PRP$\1740 use_32\NN\407535 ._33\.\1740
D003630_D001855 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 <e2>myelosuppression</e2>_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 <e1>daunorubicin</e1>_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D003630_D001855 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 <e1>daunorubicin</e1>_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 <e2>myelosuppression</e2>_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D004317_D001855 NONE dexrazoxane_0\NNP\1740 protects_1\VBZ\1127795 against_2\IN\1740 <e2>myelosuppression</e2>_3\NN\1740 from_4\IN\1740 the_5\DT\1740 dna_6\NN\14994328 cleavage-enhancing_7\JJ\1740 drugs_8\NNS\14778436 etoposide_9\VBP\1740 and_10\CC\1740 daunorubicin_11\NN\1740 but_12\CC\1740 not_13\RB\1740 <e1>doxorubicin</e1>_14\NN\2716866 ._15\.\1740
D004317_D001855 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 anthracyclines_3\NNS\1740 daunorubicin_4\NN\1740 and_5\CC\1740 <e1>doxorubicin</e1>_6\NN\2716866 and_7\CC\1740 the_8\DT\1740 epipodophyllotoxin_9\NN\1740 etoposide_10\NN\1740 are_11\VBP\836236 potent_12\JJ\1740 dna_13\NN\14994328 cleavage-enhancing_14\JJ\1740 drugs_15\NNS\14778436 that_16\WDT\1740 are_17\VBP\836236 widely_18\RB\1740 used_19\VBN\1156834 in_20\IN\13603305 clinical_21\JJ\1740 oncology_22\NN\6043075 ;_23\:\1740 however_24\RB\1740 ,_25\,\1740 <e2>myelosuppression</e2>_26\NN\1740 and_27\CC\1740 cardiac_28\JJ\1740 toxicity_29\NN\13576101 limit_30\NN\5123416 their_31\PRP$\1740 use_32\NN\407535 ._33\.\1740
D004317_D001855 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 <e2>myelosuppression</e2>_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 <e1>doxorubicin</e1>_43\NN\2716866 ._44\.\1740
D004317_D001855 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 <e2>myelosuppression</e2>_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 <e1>doxorubicin</e1>_43\NN\2716866 ._44\.\1740
D018943_D001855 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 <e1>anthracyclines</e1>_3\NNS\1740 daunorubicin_4\NN\1740 and_5\CC\1740 doxorubicin_6\NN\2716866 and_7\CC\1740 the_8\DT\1740 epipodophyllotoxin_9\NN\1740 etoposide_10\NN\1740 are_11\VBP\836236 potent_12\JJ\1740 dna_13\NN\14994328 cleavage-enhancing_14\JJ\1740 drugs_15\NNS\14778436 that_16\WDT\1740 are_17\VBP\836236 widely_18\RB\1740 used_19\VBN\1156834 in_20\IN\13603305 clinical_21\JJ\1740 oncology_22\NN\6043075 ;_23\:\1740 however_24\RB\1740 ,_25\,\1740 <e2>myelosuppression</e2>_26\NN\1740 and_27\CC\1740 cardiac_28\JJ\1740 toxicity_29\NN\13576101 limit_30\NN\5123416 their_31\PRP$\1740 use_32\NN\407535 ._33\.\1740
D018943_D066126 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 <e1>anthracyclines</e1>_3\NNS\1740 daunorubicin_4\NN\1740 and_5\CC\1740 doxorubicin_6\NN\2716866 and_7\CC\1740 the_8\DT\1740 epipodophyllotoxin_9\NN\1740 etoposide_10\NN\1740 are_11\VBP\836236 potent_12\JJ\1740 dna_13\NN\14994328 cleavage-enhancing_14\JJ\1740 drugs_15\NNS\14778436 that_16\WDT\1740 are_17\VBP\836236 widely_18\RB\1740 used_19\VBN\1156834 in_20\IN\13603305 clinical_21\JJ\1740 oncology_22\NN\6043075 ;_23\:\1740 however_24\RB\1740 ,_25\,\1740 myelosuppression_26\NN\1740 and_27\CC\1740 <e2>cardiac_28\JJ\1740 toxicity</e2>_29\NN\13576101 limit_30\NN\5123416 their_31\PRP$\1740 use_32\NN\407535 ._33\.\1740
D018943_D066126 NONE dexrazoxane_0\NNP\1740 (_1\-LRB-\1740 icrf-187_2\NN\1740 )_3\-RRB-\1740 is_4\VBZ\836236 recommended_5\VBN\875394 for_6\IN\1740 protection_7\NN\407535 against_8\IN\1740 <e1>anthracycline-induced</e1>_9\JJ\1740 <e2>cardiotoxicity</e2>_10\NN\1740 ._11\.\1740
D003630_D066126 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 anthracyclines_3\NNS\1740 <e1>daunorubicin</e1>_4\NN\1740 and_5\CC\1740 doxorubicin_6\NN\2716866 and_7\CC\1740 the_8\DT\1740 epipodophyllotoxin_9\NN\1740 etoposide_10\NN\1740 are_11\VBP\836236 potent_12\JJ\1740 dna_13\NN\14994328 cleavage-enhancing_14\JJ\1740 drugs_15\NNS\14778436 that_16\WDT\1740 are_17\VBP\836236 widely_18\RB\1740 used_19\VBN\1156834 in_20\IN\13603305 clinical_21\JJ\1740 oncology_22\NN\6043075 ;_23\:\1740 however_24\RB\1740 ,_25\,\1740 myelosuppression_26\NN\1740 and_27\CC\1740 <e2>cardiac_28\JJ\1740 toxicity</e2>_29\NN\13576101 limit_30\NN\5123416 their_31\PRP$\1740 use_32\NN\407535 ._33\.\1740
D004317_D066126 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 anthracyclines_3\NNS\1740 daunorubicin_4\NN\1740 and_5\CC\1740 <e1>doxorubicin</e1>_6\NN\2716866 and_7\CC\1740 the_8\DT\1740 epipodophyllotoxin_9\NN\1740 etoposide_10\NN\1740 are_11\VBP\836236 potent_12\JJ\1740 dna_13\NN\14994328 cleavage-enhancing_14\JJ\1740 drugs_15\NNS\14778436 that_16\WDT\1740 are_17\VBP\836236 widely_18\RB\1740 used_19\VBN\1156834 in_20\IN\13603305 clinical_21\JJ\1740 oncology_22\NN\6043075 ;_23\:\1740 however_24\RB\1740 ,_25\,\1740 myelosuppression_26\NN\1740 and_27\CC\1740 <e2>cardiac_28\JJ\1740 toxicity</e2>_29\NN\13576101 limit_30\NN\5123416 their_31\PRP$\1740 use_32\NN\407535 ._33\.\1740
D011034_D001855 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 anthracyclines_3\NNS\1740 daunorubicin_4\NN\1740 and_5\CC\1740 doxorubicin_6\NN\2716866 and_7\CC\1740 the_8\DT\1740 <e1>epipodophyllotoxin</e1>_9\NN\1740 etoposide_10\NN\1740 are_11\VBP\836236 potent_12\JJ\1740 dna_13\NN\14994328 cleavage-enhancing_14\JJ\1740 drugs_15\NNS\14778436 that_16\WDT\1740 are_17\VBP\836236 widely_18\RB\1740 used_19\VBN\1156834 in_20\IN\13603305 clinical_21\JJ\1740 oncology_22\NN\6043075 ;_23\:\1740 however_24\RB\1740 ,_25\,\1740 <e2>myelosuppression</e2>_26\NN\1740 and_27\CC\1740 cardiac_28\JJ\1740 toxicity_29\NN\13576101 limit_30\NN\5123416 their_31\PRP$\1740 use_32\NN\407535 ._33\.\1740
D011034_D066126 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 anthracyclines_3\NNS\1740 daunorubicin_4\NN\1740 and_5\CC\1740 doxorubicin_6\NN\2716866 and_7\CC\1740 the_8\DT\1740 <e1>epipodophyllotoxin</e1>_9\NN\1740 etoposide_10\NN\1740 are_11\VBP\836236 potent_12\JJ\1740 dna_13\NN\14994328 cleavage-enhancing_14\JJ\1740 drugs_15\NNS\14778436 that_16\WDT\1740 are_17\VBP\836236 widely_18\RB\1740 used_19\VBN\1156834 in_20\IN\13603305 clinical_21\JJ\1740 oncology_22\NN\6043075 ;_23\:\1740 however_24\RB\1740 ,_25\,\1740 myelosuppression_26\NN\1740 and_27\CC\1740 <e2>cardiac_28\JJ\1740 toxicity</e2>_29\NN\13576101 limit_30\NN\5123416 their_31\PRP$\1740 use_32\NN\407535 ._33\.\1740
D005047_D066126 NONE purpose_0\NNP\5980875 :_1\:\1740 the_2\DT\1740 anthracyclines_3\NNS\1740 daunorubicin_4\NN\1740 and_5\CC\1740 doxorubicin_6\NN\2716866 and_7\CC\1740 the_8\DT\1740 epipodophyllotoxin_9\NN\1740 <e1>etoposide</e1>_10\NN\1740 are_11\VBP\836236 potent_12\JJ\1740 dna_13\NN\14994328 cleavage-enhancing_14\JJ\1740 drugs_15\NNS\14778436 that_16\WDT\1740 are_17\VBP\836236 widely_18\RB\1740 used_19\VBN\1156834 in_20\IN\13603305 clinical_21\JJ\1740 oncology_22\NN\6043075 ;_23\:\1740 however_24\RB\1740 ,_25\,\1740 myelosuppression_26\NN\1740 and_27\CC\1740 <e2>cardiac_28\JJ\1740 toxicity</e2>_29\NN\13576101 limit_30\NN\5123416 their_31\PRP$\1740 use_32\NN\407535 ._33\.\1740
D064730_D066126 NONE <e1>dexrazoxane</e1>_0\NNP\1740 (_1\-LRB-\1740 icrf-187_2\NN\1740 )_3\-RRB-\1740 is_4\VBZ\836236 recommended_5\VBN\875394 for_6\IN\1740 protection_7\NN\407535 against_8\IN\1740 anthracycline-induced_9\JJ\1740 <e2>cardiotoxicity</e2>_10\NN\1740 ._11\.\1740
D064730_D066126 NONE dexrazoxane_0\NNP\1740 (_1\-LRB-\1740 <e1>icrf-187</e1>_2\NN\1740 )_3\-RRB-\1740 is_4\VBZ\836236 recommended_5\VBN\875394 for_6\IN\1740 protection_7\NN\407535 against_8\IN\1740 anthracycline-induced_9\JJ\1740 <e2>cardiotoxicity</e2>_10\NN\1740 ._11\.\1740
D064730_D006402 NONE experimental_0\NN\1740 design_1\VBD\1631534 :_2\:\1740 because_3\IN\1740 of_4\IN\1740 their_5\PRP$\1740 widespread_6\JJ\1740 use_7\NN\407535 ,_8\,\1740 the_9\DT\1740 <e2>hematologic_10\JJ\1740 toxicity</e2>_11\NN\13576101 following_12\VBG\1835496 coadministration_13\NN\1740 of_14\IN\1740 <e1>dexrazoxane</e1>_15\NN\1740 and_16\CC\1740 these_17\DT\1740 three_18\CD\13741022 structurally_19\RB\1740 different_20\JJ\1740 dna_21\NN\14994328 cleavage_22\NN\24720 enhancers_23\NNS\5853636 was_24\VBD\836236 investigated_25\VBN\644583 :_26\:\1740 sensitivity_27\NN\5651971 of_28\IN\1740 human_29\JJ\1740 and_30\CC\1740 murine_31\JJ\1740 blood_32\NN\5397468 progenitor_33\NN\9792555 cells_34\NNS\3080309 to_35\TO\1740 etoposide_36\VB\1740 ,_37\,\1740 daunorubicin_38\NN\1740 ,_39\,\1740 and_40\CC\1740 doxorubicin_41\NN\2716866 +/-_42\CC\1740 dexrazoxane_43\NN\1740 was_44\VBD\836236 determined_45\VBN\1645601 in_46\IN\13603305 granulocyte-macrophage_47\JJ\1740 colony_48\NN\7965085 forming_49\NN\1740 assays_50\NNS\5733583 ._51\.\1740
D064730_D006402 NONE experimental_0\NN\1740 design_1\VBD\1631534 :_2\:\1740 because_3\IN\1740 of_4\IN\1740 their_5\PRP$\1740 widespread_6\JJ\1740 use_7\NN\407535 ,_8\,\1740 the_9\DT\1740 <e2>hematologic_10\JJ\1740 toxicity</e2>_11\NN\13576101 following_12\VBG\1835496 coadministration_13\NN\1740 of_14\IN\1740 dexrazoxane_15\NN\1740 and_16\CC\1740 these_17\DT\1740 three_18\CD\13741022 structurally_19\RB\1740 different_20\JJ\1740 dna_21\NN\14994328 cleavage_22\NN\24720 enhancers_23\NNS\5853636 was_24\VBD\836236 investigated_25\VBN\644583 :_26\:\1740 sensitivity_27\NN\5651971 of_28\IN\1740 human_29\JJ\1740 and_30\CC\1740 murine_31\JJ\1740 blood_32\NN\5397468 progenitor_33\NN\9792555 cells_34\NNS\3080309 to_35\TO\1740 etoposide_36\VB\1740 ,_37\,\1740 daunorubicin_38\NN\1740 ,_39\,\1740 and_40\CC\1740 doxorubicin_41\NN\2716866 +/-_42\CC\1740 <e1>dexrazoxane</e1>_43\NN\1740 was_44\VBD\836236 determined_45\VBN\1645601 in_46\IN\13603305 granulocyte-macrophage_47\JJ\1740 colony_48\NN\7965085 forming_49\NN\1740 assays_50\NNS\5733583 ._51\.\1740
D064730_D006402 NONE clinical_0\JJ\1740 trials_1\NNS\786195 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 brain_5\NN\5462674 metastases_6\NNS\13533470 combining_7\VBG\2630189 <e1>dexrazoxane</e1>_8\NN\1740 and_9\CC\1740 high_10\JJ\1740 doses_11\NNS\3740161 of_12\IN\1740 etoposide_13\NN\1740 is_14\VBZ\836236 ongoing_15\JJ\1740 with_16\IN\1740 the_17\DT\1740 aim_18\NN\5980875 of_19\IN\1740 improving_20\VBG\126264 efficacy_21\NN\5199286 without_22\IN\1740 aggravating_23\VBG\126264 <e2>hematologic_24\JJ\1740 toxicity</e2>_25\NN\13576101 ._26\.\1740
D005047_D006402 CID experimental_0\NN\1740 design_1\VBD\1631534 :_2\:\1740 because_3\IN\1740 of_4\IN\1740 their_5\PRP$\1740 widespread_6\JJ\1740 use_7\NN\407535 ,_8\,\1740 the_9\DT\1740 <e2>hematologic_10\JJ\1740 toxicity</e2>_11\NN\13576101 following_12\VBG\1835496 coadministration_13\NN\1740 of_14\IN\1740 dexrazoxane_15\NN\1740 and_16\CC\1740 these_17\DT\1740 three_18\CD\13741022 structurally_19\RB\1740 different_20\JJ\1740 dna_21\NN\14994328 cleavage_22\NN\24720 enhancers_23\NNS\5853636 was_24\VBD\836236 investigated_25\VBN\644583 :_26\:\1740 sensitivity_27\NN\5651971 of_28\IN\1740 human_29\JJ\1740 and_30\CC\1740 murine_31\JJ\1740 blood_32\NN\5397468 progenitor_33\NN\9792555 cells_34\NNS\3080309 to_35\TO\1740 <e1>etoposide</e1>_36\VB\1740 ,_37\,\1740 daunorubicin_38\NN\1740 ,_39\,\1740 and_40\CC\1740 doxorubicin_41\NN\2716866 +/-_42\CC\1740 dexrazoxane_43\NN\1740 was_44\VBD\836236 determined_45\VBN\1645601 in_46\IN\13603305 granulocyte-macrophage_47\JJ\1740 colony_48\NN\7965085 forming_49\NN\1740 assays_50\NNS\5733583 ._51\.\1740
D005047_D006402 CID clinical_0\JJ\1740 trials_1\NNS\786195 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 brain_5\NN\5462674 metastases_6\NNS\13533470 combining_7\VBG\2630189 dexrazoxane_8\NN\1740 and_9\CC\1740 high_10\JJ\1740 doses_11\NNS\3740161 of_12\IN\1740 <e1>etoposide</e1>_13\NN\1740 is_14\VBZ\836236 ongoing_15\JJ\1740 with_16\IN\1740 the_17\DT\1740 aim_18\NN\5980875 of_19\IN\1740 improving_20\VBG\126264 efficacy_21\NN\5199286 without_22\IN\1740 aggravating_23\VBG\126264 <e2>hematologic_24\JJ\1740 toxicity</e2>_25\NN\13576101 ._26\.\1740
D003630_D006402 CID experimental_0\NN\1740 design_1\VBD\1631534 :_2\:\1740 because_3\IN\1740 of_4\IN\1740 their_5\PRP$\1740 widespread_6\JJ\1740 use_7\NN\407535 ,_8\,\1740 the_9\DT\1740 <e2>hematologic_10\JJ\1740 toxicity</e2>_11\NN\13576101 following_12\VBG\1835496 coadministration_13\NN\1740 of_14\IN\1740 dexrazoxane_15\NN\1740 and_16\CC\1740 these_17\DT\1740 three_18\CD\13741022 structurally_19\RB\1740 different_20\JJ\1740 dna_21\NN\14994328 cleavage_22\NN\24720 enhancers_23\NNS\5853636 was_24\VBD\836236 investigated_25\VBN\644583 :_26\:\1740 sensitivity_27\NN\5651971 of_28\IN\1740 human_29\JJ\1740 and_30\CC\1740 murine_31\JJ\1740 blood_32\NN\5397468 progenitor_33\NN\9792555 cells_34\NNS\3080309 to_35\TO\1740 etoposide_36\VB\1740 ,_37\,\1740 <e1>daunorubicin</e1>_38\NN\1740 ,_39\,\1740 and_40\CC\1740 doxorubicin_41\NN\2716866 +/-_42\CC\1740 dexrazoxane_43\NN\1740 was_44\VBD\836236 determined_45\VBN\1645601 in_46\IN\13603305 granulocyte-macrophage_47\JJ\1740 colony_48\NN\7965085 forming_49\NN\1740 assays_50\NNS\5733583 ._51\.\1740
D004317_D006402 CID experimental_0\NN\1740 design_1\VBD\1631534 :_2\:\1740 because_3\IN\1740 of_4\IN\1740 their_5\PRP$\1740 widespread_6\JJ\1740 use_7\NN\407535 ,_8\,\1740 the_9\DT\1740 <e2>hematologic_10\JJ\1740 toxicity</e2>_11\NN\13576101 following_12\VBG\1835496 coadministration_13\NN\1740 of_14\IN\1740 dexrazoxane_15\NN\1740 and_16\CC\1740 these_17\DT\1740 three_18\CD\13741022 structurally_19\RB\1740 different_20\JJ\1740 dna_21\NN\14994328 cleavage_22\NN\24720 enhancers_23\NNS\5853636 was_24\VBD\836236 investigated_25\VBN\644583 :_26\:\1740 sensitivity_27\NN\5651971 of_28\IN\1740 human_29\JJ\1740 and_30\CC\1740 murine_31\JJ\1740 blood_32\NN\5397468 progenitor_33\NN\9792555 cells_34\NNS\3080309 to_35\TO\1740 etoposide_36\VB\1740 ,_37\,\1740 daunorubicin_38\NN\1740 ,_39\,\1740 and_40\CC\1740 <e1>doxorubicin</e1>_41\NN\2716866 +/-_42\CC\1740 dexrazoxane_43\NN\1740 was_44\VBD\836236 determined_45\VBN\1645601 in_46\IN\13603305 granulocyte-macrophage_47\JJ\1740 colony_48\NN\7965085 forming_49\NN\1740 assays_50\NNS\5733583 ._51\.\1740
D064730_D015431 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 <e1>dexrazoxane</e1>_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 <e2>weight_9\NN\5009170 loss</e2>_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D064730_D015431 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 <e1>dexrazoxane</e1>_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 <e2>weight_34\NN\5009170 loss</e2>_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D064730_D015431 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 <e2>weight_9\NN\5009170 loss</e2>_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 <e1>dexrazoxane</e1>_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D064730_D015431 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 <e1>dexrazoxane</e1>_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 <e2>weight_34\NN\5009170 loss</e2>_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D064730_D064420 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 <e1>dexrazoxane</e1>_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 <e2>cytotoxicity</e2>_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D064730_D064420 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 <e1>dexrazoxane</e1>_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 <e2>cytotoxicity</e2>_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D003630_D015431 CID results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 <e2>weight_9\NN\5009170 loss</e2>_10\NN\13252973 from_11\IN\1740 <e1>daunorubicin</e1>_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D003630_D015431 CID results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 <e1>daunorubicin</e1>_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 <e2>weight_34\NN\5009170 loss</e2>_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D003630_D064420 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 <e1>daunorubicin</e1>_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 <e2>cytotoxicity</e2>_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D005047_D015431 CID results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 <e2>weight_9\NN\5009170 loss</e2>_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 <e1>etoposide</e1>_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D005047_D015431 CID results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 <e1>etoposide</e1>_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 <e2>weight_34\NN\5009170 loss</e2>_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D005047_D064420 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 <e1>etoposide</e1>_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 <e2>cytotoxicity</e2>_41\NN\13583478 from_42\IN\1740 doxorubicin_43\NN\2716866 ._44\.\1740
D004317_D015431 CID results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 <e2>weight_9\NN\5009170 loss</e2>_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 <e1>doxorubicin</e1>_43\NN\2716866 ._44\.\1740
D004317_D015431 CID results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 <e2>weight_34\NN\5009170 loss</e2>_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 cytotoxicity_41\NN\13583478 from_42\IN\1740 <e1>doxorubicin</e1>_43\NN\2716866 ._44\.\1740
D004317_D064420 NONE results_0\NNS\34213 :_1\:\1740 nontoxic_2\JJ\1740 doses_3\NNS\3740161 of_4\IN\1740 dexrazoxane_5\NN\1740 reduced_6\VBD\441445 myelosuppression_7\NN\1740 and_8\CC\1740 weight_9\NN\5009170 loss_10\NN\13252973 from_11\IN\1740 daunorubicin_12\NN\1740 and_13\CC\1740 etoposide_14\NN\1740 in_15\IN\13603305 mice_16\NNS\2329401 and_17\CC\1740 antagonized_18\VBD\1787955 their_19\PRP$\1740 antiproliferative_20\JJ\1740 effects_21\NNS\13245626 in_22\IN\13603305 the_23\DT\1740 colony_24\NN\7965085 assay_25\NN\5733583 ;_26\:\1740 however_27\RB\1740 ,_28\,\1740 dexrazoxane_29\NN\1740 neither_30\CC\1740 reduced_31\VBD\441445 myelosuppression_32\NN\1740 ,_33\,\1740 weight_34\NN\5009170 loss_35\NN\13252973 ,_36\,\1740 nor_37\CC\1740 the_38\DT\1740 in_39\FW\13603305 vitro_40\FW\1740 <e2>cytotoxicity</e2>_41\NN\13583478 from_42\IN\1740 <e1>doxorubicin</e1>_43\NN\2716866 ._44\.\1740
D064730_D009362 NONE clinical_0\JJ\1740 trials_1\NNS\786195 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 brain_5\NN\5462674 <e2>metastases</e2>_6\NNS\13533470 combining_7\VBG\2630189 <e1>dexrazoxane</e1>_8\NN\1740 and_9\CC\1740 high_10\JJ\1740 doses_11\NNS\3740161 of_12\IN\1740 etoposide_13\NN\1740 is_14\VBZ\836236 ongoing_15\JJ\1740 with_16\IN\1740 the_17\DT\1740 aim_18\NN\5980875 of_19\IN\1740 improving_20\VBG\126264 efficacy_21\NN\5199286 without_22\IN\1740 aggravating_23\VBG\126264 hematologic_24\JJ\1740 toxicity_25\NN\13576101 ._26\.\1740
D005047_D009362 NONE clinical_0\JJ\1740 trials_1\NNS\786195 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 brain_5\NN\5462674 <e2>metastases</e2>_6\NNS\13533470 combining_7\VBG\2630189 dexrazoxane_8\NN\1740 and_9\CC\1740 high_10\JJ\1740 doses_11\NNS\3740161 of_12\IN\1740 <e1>etoposide</e1>_13\NN\1740 is_14\VBZ\836236 ongoing_15\JJ\1740 with_16\IN\1740 the_17\DT\1740 aim_18\NN\5980875 of_19\IN\1740 improving_20\VBG\126264 efficacy_21\NN\5199286 without_22\IN\1740 aggravating_23\VBG\126264 hematologic_24\JJ\1740 toxicity_25\NN\13576101 ._26\.\1740
1595783
D000638_D008171 NONE <e1>amiodarone</e1>_0\NN\2715941 <e2>pulmonary_1\JJ\1740 toxicity</e2>_2\NN\13576101 ._3\.\1740
D000638_D008171 NONE the_0\DT\1740 <e2>pulmonary_1\JJ\1740 toxicity</e2>_2\NN\13576101 of_3\IN\1740 <e1>amiodarone</e1>_4\NN\2715941 is_5\VBZ\836236 thought_6\VBN\670261 to_7\TO\1740 result_8\VB\2633881 from_9\IN\1740 direct_10\JJ\1740 injury_11\NN\14052046 related_12\JJ\1740 to_13\TO\1740 the_14\DT\1740 intracellular_15\JJ\1740 accumulation_16\NN\13497135 of_17\IN\1740 phospholipid_18\NN\14938907 and_19\CC\1740 t_20\NN\14999913 cell-mediated_21\JJ\1740 hypersensitivity_22\NN\14531772 pneumonitis_23\NN\14336539 ._24\.\1740
D000638_D008171 NONE the_0\DT\1740 clinical_1\JJ\1740 and_2\CC\1740 radiographic_3\JJ\1740 features_4\NNS\5849040 of_5\IN\1740 <e1>amiodarone-induced</e1>_6\JJ\1740 <e2>pulmonary_7\JJ\1740 toxicity</e2>_8\NN\13576101 are_9\VBP\836236 characteristic_10\JJ\1740 but_11\CC\1740 nonspecific_12\JJ\1740 ._13\.\1740
D000638_D011014 CID <e1>amiodarone</e1>_0\NN\2715941 is_1\VBZ\836236 an_2\DT\6697703 effective_3\JJ\1740 antiarrhythmic_4\JJ\1740 agent_5\NN\7347 whose_6\WP$\1740 utility_7\NN\8186047 is_8\VBZ\836236 limited_9\VBN\2510337 by_10\IN\1740 many_11\JJ\1740 side-effects_12\NNS\1740 ,_13\,\1740 the_14\DT\1740 most_15\RBS\1740 problematic_16\JJ\1740 being_17\VBG\836236 <e2>pneumonitis</e2>_18\NN\14336539 ._19\.\1740
D000638_D004342 NONE the_0\DT\1740 pulmonary_1\JJ\1740 toxicity_2\NN\13576101 of_3\IN\1740 <e1>amiodarone</e1>_4\NN\2715941 is_5\VBZ\836236 thought_6\VBN\670261 to_7\TO\1740 result_8\VB\2633881 from_9\IN\1740 direct_10\JJ\1740 injury_11\NN\14052046 related_12\JJ\1740 to_13\TO\1740 the_14\DT\1740 intracellular_15\JJ\1740 accumulation_16\NN\13497135 of_17\IN\1740 phospholipid_18\NN\14938907 and_19\CC\1740 t_20\NN\14999913 cell-mediated_21\JJ\1740 <e2>hypersensitivity_22\NN\14531772 pneumonitis</e2>_23\NN\14336539 ._24\.\1740
D000638_D000542 NONE the_0\DT\1740 pulmonary_1\JJ\1740 toxicity_2\NN\13576101 of_3\IN\1740 <e1>amiodarone</e1>_4\NN\2715941 is_5\VBZ\836236 thought_6\VBN\670261 to_7\TO\1740 result_8\VB\2633881 from_9\IN\1740 direct_10\JJ\1740 injury_11\NN\14052046 related_12\JJ\1740 to_13\TO\1740 the_14\DT\1740 intracellular_15\JJ\1740 accumulation_16\NN\13497135 of_17\IN\1740 phospholipid_18\NN\14938907 and_19\CC\1740 t_20\NN\14999913 cell-mediated_21\JJ\1740 <e2>hypersensitivity_22\NN\14531772 pneumonitis</e2>_23\NN\14336539 ._24\.\1740
3952818
D005472_D066126 NONE <e2>cardiac_0\JJ\1740 toxicity</e2>_1\NN\13576101 of_2\IN\1740 <e1>5-fluorouracil</e1>_3\NN\1740 ._4\.\1740
D005472_D066126 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 coronary_4\JJ\1740 spasm_5\NN\14299637 may_6\MD\15209706 be_7\VB\836236 the_8\DT\1740 cause_9\NN\7323922 of_10\IN\1740 <e2>cardiotoxicity</e2>_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 <e1>5-fu</e1>_14\CD\1740 ,_15\,\1740 and_16\CC\1740 that_17\IN\1740 calcium_18\NN\14625458 antagonists_19\NNS\7846 may_20\MD\15209706 probably_21\RB\1740 be_22\VB\836236 used_23\VBN\1156834 in_24\IN\13603305 the_25\DT\1740 prevention_26\NN\1073995 or_27\CC\3541091 treatment_28\NN\654885 of_29\IN\1740 5-fu_30\NN\1740 cardiotoxicity_31\NN\1740 ._32\.\1740
D005472_D066126 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 coronary_4\JJ\1740 spasm_5\NN\14299637 may_6\MD\15209706 be_7\VB\836236 the_8\DT\1740 cause_9\NN\7323922 of_10\IN\1740 cardiotoxicity_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 <e1>5-fu</e1>_14\CD\1740 ,_15\,\1740 and_16\CC\1740 that_17\IN\1740 calcium_18\NN\14625458 antagonists_19\NNS\7846 may_20\MD\15209706 probably_21\RB\1740 be_22\VB\836236 used_23\VBN\1156834 in_24\IN\13603305 the_25\DT\1740 prevention_26\NN\1073995 or_27\CC\3541091 treatment_28\NN\654885 of_29\IN\1740 5-fu_30\NN\1740 <e2>cardiotoxicity</e2>_31\NN\1740 ._32\.\1740
D005472_D066126 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 coronary_4\JJ\1740 spasm_5\NN\14299637 may_6\MD\15209706 be_7\VB\836236 the_8\DT\1740 cause_9\NN\7323922 of_10\IN\1740 <e2>cardiotoxicity</e2>_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 5-fu_14\CD\1740 ,_15\,\1740 and_16\CC\1740 that_17\IN\1740 calcium_18\NN\14625458 antagonists_19\NNS\7846 may_20\MD\15209706 probably_21\RB\1740 be_22\VB\836236 used_23\VBN\1156834 in_24\IN\13603305 the_25\DT\1740 prevention_26\NN\1073995 or_27\CC\3541091 treatment_28\NN\654885 of_29\IN\1740 <e1>5-fu</e1>_30\NN\1740 cardiotoxicity_31\NN\1740 ._32\.\1740
D005472_D066126 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 coronary_4\JJ\1740 spasm_5\NN\14299637 may_6\MD\15209706 be_7\VB\836236 the_8\DT\1740 cause_9\NN\7323922 of_10\IN\1740 cardiotoxicity_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 5-fu_14\CD\1740 ,_15\,\1740 and_16\CC\1740 that_17\IN\1740 calcium_18\NN\14625458 antagonists_19\NNS\7846 may_20\MD\15209706 probably_21\RB\1740 be_22\VB\836236 used_23\VBN\1156834 in_24\IN\13603305 the_25\DT\1740 prevention_26\NN\1073995 or_27\CC\3541091 treatment_28\NN\654885 of_29\IN\1740 <e1>5-fu</e1>_30\NN\1740 <e2>cardiotoxicity</e2>_31\NN\1740 ._32\.\1740
D005472_D003110 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 <e2>colon_8\NN\5535484 carcinoma</e2>_9\NN\14239918 and_10\CC\1740 liver_11\NN\5298729 metastasis_12\NN\13533470 who_13\WP\8299493 presented_14\VBD\2137132 chest_15\JJ\1740 pain_16\NN\14299637 after_17\IN\1740 <e1>5-fluorouracil</e1>_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 administration_22\NN\1133281 ._23\.\1740
D005472_D003110 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 <e2>colon_8\NN\5535484 carcinoma</e2>_9\NN\14239918 and_10\CC\1740 liver_11\NN\5298729 metastasis_12\NN\13533470 who_13\WP\8299493 presented_14\VBD\2137132 chest_15\JJ\1740 pain_16\NN\14299637 after_17\IN\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 <e1>5-fu</e1>_20\NN\1740 )_21\-RRB-\1740 administration_22\NN\1133281 ._23\.\1740
D005472_D009362 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 colon_8\NN\5535484 carcinoma_9\NN\14239918 and_10\CC\1740 liver_11\NN\5298729 <e2>metastasis</e2>_12\NN\13533470 who_13\WP\8299493 presented_14\VBD\2137132 chest_15\JJ\1740 pain_16\NN\14299637 after_17\IN\1740 <e1>5-fluorouracil</e1>_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 administration_22\NN\1133281 ._23\.\1740
D005472_D009362 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 colon_8\NN\5535484 carcinoma_9\NN\14239918 and_10\CC\1740 liver_11\NN\5298729 <e2>metastasis</e2>_12\NN\13533470 who_13\WP\8299493 presented_14\VBD\2137132 chest_15\JJ\1740 pain_16\NN\14299637 after_17\IN\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 <e1>5-fu</e1>_20\NN\1740 )_21\-RRB-\1740 administration_22\NN\1133281 ._23\.\1740
D005472_D002637 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 colon_8\NN\5535484 carcinoma_9\NN\14239918 and_10\CC\1740 liver_11\NN\5298729 metastasis_12\NN\13533470 who_13\WP\8299493 presented_14\VBD\2137132 <e2>chest_15\JJ\1740 pain</e2>_16\NN\14299637 after_17\IN\1740 <e1>5-fluorouracil</e1>_18\NN\1740 (_19\-LRB-\1740 5-fu_20\NN\1740 )_21\-RRB-\1740 administration_22\NN\1133281 ._23\.\1740
D005472_D002637 CID we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 patient_6\NN\9898892 with_7\IN\1740 colon_8\NN\5535484 carcinoma_9\NN\14239918 and_10\CC\1740 liver_11\NN\5298729 metastasis_12\NN\13533470 who_13\WP\8299493 presented_14\VBD\2137132 <e2>chest_15\JJ\1740 pain</e2>_16\NN\14299637 after_17\IN\1740 5-fluorouracil_18\NN\1740 (_19\-LRB-\1740 <e1>5-fu</e1>_20\NN\1740 )_21\-RRB-\1740 administration_22\NN\1133281 ._23\.\1740
D009543_D000788 NONE clinical_0\JJ\1740 electrocardiographic_1\JJ\1740 evolution_2\NN\29677 was_3\VBD\836236 similar_4\JJ\1740 to_5\TO\1740 that_6\DT\1740 observed_7\VBN\2163746 in_8\IN\13603305 <e2>prinzmetal_9\NNP\1740 's_10\POS\1740 angina</e2>_11\NN\14171682 ,_12\,\1740 and_13\CC\1740 chest_14\JJ\1740 pain_15\NN\14299637 promptly_16\RB\1740 resolved_17\VBN\352826 with_18\IN\1740 <e1>nifedipine</e1>_19\NN\2938514 ._20\.\1740
D009543_D002637 NONE clinical_0\JJ\1740 electrocardiographic_1\JJ\1740 evolution_2\NN\29677 was_3\VBD\836236 similar_4\JJ\1740 to_5\TO\1740 that_6\DT\1740 observed_7\VBN\2163746 in_8\IN\13603305 prinzmetal_9\NNP\1740 's_10\POS\1740 angina_11\NN\14171682 ,_12\,\1740 and_13\CC\1740 <e2>chest_14\JJ\1740 pain</e2>_15\NN\14299637 promptly_16\RB\1740 resolved_17\VBN\352826 with_18\IN\1740 <e1>nifedipine</e1>_19\NN\2938514 ._20\.\1740
D005472_D003329 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e2>coronary_4\JJ\1740 spasm</e2>_5\NN\14299637 may_6\MD\15209706 be_7\VB\836236 the_8\DT\1740 cause_9\NN\7323922 of_10\IN\1740 cardiotoxicity_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 <e1>5-fu</e1>_14\CD\1740 ,_15\,\1740 and_16\CC\1740 that_17\IN\1740 calcium_18\NN\14625458 antagonists_19\NNS\7846 may_20\MD\15209706 probably_21\RB\1740 be_22\VB\836236 used_23\VBN\1156834 in_24\IN\13603305 the_25\DT\1740 prevention_26\NN\1073995 or_27\CC\3541091 treatment_28\NN\654885 of_29\IN\1740 5-fu_30\NN\1740 cardiotoxicity_31\NN\1740 ._32\.\1740
D005472_D003329 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e2>coronary_4\JJ\1740 spasm</e2>_5\NN\14299637 may_6\MD\15209706 be_7\VB\836236 the_8\DT\1740 cause_9\NN\7323922 of_10\IN\1740 cardiotoxicity_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 5-fu_14\CD\1740 ,_15\,\1740 and_16\CC\1740 that_17\IN\1740 calcium_18\NN\14625458 antagonists_19\NNS\7846 may_20\MD\15209706 probably_21\RB\1740 be_22\VB\836236 used_23\VBN\1156834 in_24\IN\13603305 the_25\DT\1740 prevention_26\NN\1073995 or_27\CC\3541091 treatment_28\NN\654885 of_29\IN\1740 <e1>5-fu</e1>_30\NN\1740 cardiotoxicity_31\NN\1740 ._32\.\1740
D002118_D003329 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e2>coronary_4\JJ\1740 spasm</e2>_5\NN\14299637 may_6\MD\15209706 be_7\VB\836236 the_8\DT\1740 cause_9\NN\7323922 of_10\IN\1740 cardiotoxicity_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 5-fu_14\CD\1740 ,_15\,\1740 and_16\CC\1740 that_17\IN\1740 <e1>calcium</e1>_18\NN\14625458 antagonists_19\NNS\7846 may_20\MD\15209706 probably_21\RB\1740 be_22\VB\836236 used_23\VBN\1156834 in_24\IN\13603305 the_25\DT\1740 prevention_26\NN\1073995 or_27\CC\3541091 treatment_28\NN\654885 of_29\IN\1740 5-fu_30\NN\1740 cardiotoxicity_31\NN\1740 ._32\.\1740
D002118_D066126 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 coronary_4\JJ\1740 spasm_5\NN\14299637 may_6\MD\15209706 be_7\VB\836236 the_8\DT\1740 cause_9\NN\7323922 of_10\IN\1740 <e2>cardiotoxicity</e2>_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 5-fu_14\CD\1740 ,_15\,\1740 and_16\CC\1740 that_17\IN\1740 <e1>calcium</e1>_18\NN\14625458 antagonists_19\NNS\7846 may_20\MD\15209706 probably_21\RB\1740 be_22\VB\836236 used_23\VBN\1156834 in_24\IN\13603305 the_25\DT\1740 prevention_26\NN\1073995 or_27\CC\3541091 treatment_28\NN\654885 of_29\IN\1740 5-fu_30\NN\1740 cardiotoxicity_31\NN\1740 ._32\.\1740
D002118_D066126 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 coronary_4\JJ\1740 spasm_5\NN\14299637 may_6\MD\15209706 be_7\VB\836236 the_8\DT\1740 cause_9\NN\7323922 of_10\IN\1740 cardiotoxicity_11\NN\1740 due_12\IN\5174653 to_13\TO\1740 5-fu_14\CD\1740 ,_15\,\1740 and_16\CC\1740 that_17\IN\1740 <e1>calcium</e1>_18\NN\14625458 antagonists_19\NNS\7846 may_20\MD\15209706 probably_21\RB\1740 be_22\VB\836236 used_23\VBN\1156834 in_24\IN\13603305 the_25\DT\1740 prevention_26\NN\1073995 or_27\CC\3541091 treatment_28\NN\654885 of_29\IN\1740 5-fu_30\NN\1740 <e2>cardiotoxicity</e2>_31\NN\1740 ._32\.\1740
8475949
D010419_D017180 NONE case_0\NN\7283608 report_1\NN\6470073 :_2\:\1740 <e1>pentamidine</e1>_3\NN\1740 and_4\CC\1740 polymorphic_5\JJ\1740 <e2>ventricular_6\JJ\1740 tachycardia</e2>_7\NN\14110674 revisited_8\VBN\2004874 ._9\.\1740
D010419_D017180 NONE <e1>pentamidine_0\NN\1740 isethionate</e1>_1\NN\1740 has_2\VBZ\2108377 been_3\VBN\836236 associated_4\VBN\628491 with_5\IN\1740 <e2>ventricular_6\JJ\1740 tachyarrhythmias</e2>_7\NNS\1740 ,_8\,\1740 including_9\VBG\690614 torsade_10\NN\1740 de_11\NNP\1740 pointes_12\NNS\1740 ._13\.\1740
D010419_D016171 CID <e1>pentamidine_0\NN\1740 isethionate</e1>_1\NN\1740 has_2\VBZ\2108377 been_3\VBN\836236 associated_4\VBN\628491 with_5\IN\1740 ventricular_6\JJ\1740 tachyarrhythmias_7\NNS\1740 ,_8\,\1740 including_9\VBG\690614 <e2>torsade_10\NN\1740 de_11\NNP\1740 pointes</e2>_12\NNS\1740 ._13\.\1740
D010419_D016171 CID <e1>pentamidine-induced</e1>_0\JJ\1740 <e2>torsade_1\NN\1740 de_2\IN\1740 pointes</e2>_3\NNS\1740 may_4\MD\15209706 be_5\VB\836236 related_6\JJ\1740 to_7\TO\1740 serum_8\NN\5397468 magnesium_9\NN\14625458 levels_10\NNS\4916342 and_11\CC\1740 hypomagnesemia_12\NN\1740 may_13\MD\15209706 synergistically_14\RB\1740 induce_15\VB\1627355 torsade_16\NN\1740 ._17\.\1740
D010419_D016171 CID <e2>torsade_0\NNP\1740 de_1\NNP\1740 pointes</e2>_2\NNS\1740 occurred_3\VBD\2623529 after_4\IN\1740 an_5\DT\6697703 average_6\NN\6021499 of_7\IN\1740 10_8\CD\13745420 days_9\NNS\15140892 of_10\IN\1740 treatment_11\NN\654885 with_12\IN\1740 <e1>pentamidine</e1>_13\NN\1740 ._14\.\1740
D010419_D016171 CID <e2>torsade_0\NNP\1740 de_1\NNP\1740 pointes</e2>_2\NNS\1740 can_3\MD\3094503 be_4\VB\836236 treated_5\VBN\2376958 when_6\WRB\1740 recognized_7\VBN\686447 early_8\RB\1740 ,_9\,\1740 possibly_10\RB\1740 without_11\IN\1740 discontinuation_12\NN\209943 of_13\IN\1740 <e1>pentamidine</e1>_14\NN\1740 ._15\.\1740
D010419_C537153 NONE <e1>pentamidine-induced</e1>_0\JJ\1740 torsade_1\NN\1740 de_2\IN\1740 pointes_3\NNS\1740 may_4\MD\15209706 be_5\VB\836236 related_6\JJ\1740 to_7\TO\1740 serum_8\NN\5397468 magnesium_9\NN\14625458 levels_10\NNS\4916342 and_11\CC\1740 <e2>hypomagnesemia</e2>_12\NN\1740 may_13\MD\15209706 synergistically_14\RB\1740 induce_15\VB\1627355 torsade_16\NN\1740 ._17\.\1740
D008274_D016171 NONE pentamidine-induced_0\JJ\1740 <e2>torsade_1\NN\1740 de_2\IN\1740 pointes</e2>_3\NNS\1740 may_4\MD\15209706 be_5\VB\836236 related_6\JJ\1740 to_7\TO\1740 serum_8\NN\5397468 <e1>magnesium</e1>_9\NN\14625458 levels_10\NNS\4916342 and_11\CC\1740 hypomagnesemia_12\NN\1740 may_13\MD\15209706 synergistically_14\RB\1740 induce_15\VB\1627355 torsade_16\NN\1740 ._17\.\1740
D008274_C537153 NONE pentamidine-induced_0\JJ\1740 torsade_1\NN\1740 de_2\IN\1740 pointes_3\NNS\1740 may_4\MD\15209706 be_5\VB\836236 related_6\JJ\1740 to_7\TO\1740 serum_8\NN\5397468 <e1>magnesium</e1>_9\NN\14625458 levels_10\NNS\4916342 and_11\CC\1740 <e2>hypomagnesemia</e2>_12\NN\1740 may_13\MD\15209706 synergistically_14\RB\1740 induce_15\VB\1627355 torsade_16\NN\1740 ._17\.\1740
D008274_D008133 NONE when_0\WRB\1740 <e2>qtc_1\NN\1740 interval_2\NN\33615 prolongation</e2>_3\NN\1017987 is_4\VBZ\836236 observed_5\VBN\2163746 ,_6\,\1740 early_7\JJ\1740 <e1>magnesium</e1>_8\NN\14625458 supplementation_9\NN\5108947 is_10\VBZ\836236 advocated_11\VBN\875394 ._12\.\1740
11860495
D013256_D000647 NONE <e1>steroid</e1>_0\NN\14727670 structure_1\NN\21939 and_2\CC\1740 pharmacological_3\JJ\1740 properties_4\NNS\32613 determine_5\VBP\1645601 the_6\DT\1740 <e2>anti-amnesic</e2>_7\JJ\1740 effects_8\NNS\13245626 of_9\IN\1740 pregnenolone_10\NN\1740 sulphate_11\NN\15010703 in_12\IN\13603305 the_13\DT\1740 passive_14\JJ\1740 avoidance_15\NN\203342 task_16\NN\575741 in_17\IN\13603305 rats_18\NNS\2329401 ._19\.\1740
C018370_D000647 NONE steroid_0\NN\14727670 structure_1\NN\21939 and_2\CC\1740 pharmacological_3\JJ\1740 properties_4\NNS\32613 determine_5\VBP\1645601 the_6\DT\1740 <e2>anti-amnesic</e2>_7\JJ\1740 effects_8\NNS\13245626 of_9\IN\1740 <e1>pregnenolone_10\NN\1740 sulphate</e1>_11\NN\15010703 in_12\IN\13603305 the_13\DT\1740 passive_14\JJ\1740 avoidance_15\NN\203342 task_16\NN\575741 in_17\IN\13603305 rats_18\NNS\2329401 ._19\.\1740
C018370_D000647 NONE moreover_0\RB\1740 ,_1\,\1740 <e1>pregs</e1>_2\NNS\1740 is_3\VBZ\836236 able_4\JJ\1740 to_5\TO\1740 reverse_6\VB\109660 the_7\DT\1740 <e2>amnesic-like</e2>_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 nmdar_11\NN\1740 and_12\CC\1740 gaba(a)r_13\NN\1740 ligands_14\NNS\20090 ._15\.\1740
C018370_D000647 NONE the_0\DT\1740 memory-enhancing_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 <e1>pregs</e1>_4\NNS\1740 and_5\CC\1740 its_6\PRP$\6125041 analogs_7\NNS\4743605 were_8\VBD\836236 tested_9\VBN\670261 in_10\IN\13603305 the_11\DT\1740 passive_12\JJ\1740 avoidance_13\NN\203342 task_14\NN\575741 using_15\VBG\1156834 the_16\DT\1740 model_17\NN\5888929 of_18\IN\1740 scopolamine-induced_19\JJ\1740 <e2>amnesia</e2>_20\NN\5669934 ._21\.\1740
C018370_D000647 NONE moreover_0\RB\1740 ,_1\,\1740 enantioselectivity_2\NN\1740 was_3\VBD\836236 demonstrated_4\VBN\2137132 by_5\IN\1740 the_6\DT\1740 ability_7\NN\4723816 of_8\IN\1740 natural_9\JJ\1740 <e1>pregs</e1>_10\NNS\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 order_14\NN\7168131 of_15\IN\1740 magnitude_16\NN\4916342 more_17\RBR\1740 effective_18\JJ\1740 than_19\IN\1740 its_20\PRP$\6125041 synthetic_21\JJ\1740 enantiomer_22\NN\14818238 in_23\IN\13603305 reversing_24\VBG\109660 scopolamine-induced_25\JJ\1740 <e2>amnesia</e2>_26\NN\5669934 ._27\.\1740
D005680_D000647 NONE moreover_0\RB\1740 ,_1\,\1740 pregs_2\NNS\1740 is_3\VBZ\836236 able_4\JJ\1740 to_5\TO\1740 reverse_6\VB\109660 the_7\DT\1740 <e2>amnesic-like</e2>_8\JJ\1740 effects_9\NNS\13245626 of_10\IN\1740 nmdar_11\NN\1740 and_12\CC\1740 <e1>gaba(a)r</e1>_13\NN\1740 ligands_14\NNS\20090 ._15\.\1740
D012601_D000647 CID the_0\DT\1740 memory-enhancing_1\JJ\1740 effects_2\NNS\13245626 of_3\IN\1740 pregs_4\NNS\1740 and_5\CC\1740 its_6\PRP$\6125041 analogs_7\NNS\4743605 were_8\VBD\836236 tested_9\VBN\670261 in_10\IN\13603305 the_11\DT\1740 passive_12\JJ\1740 avoidance_13\NN\203342 task_14\NN\575741 using_15\VBG\1156834 the_16\DT\1740 model_17\NN\5888929 of_18\IN\1740 <e1>scopolamine-induced</e1>_19\JJ\1740 <e2>amnesia</e2>_20\NN\5669934 ._21\.\1740
D012601_D000647 CID moreover_0\RB\1740 ,_1\,\1740 enantioselectivity_2\NN\1740 was_3\VBD\836236 demonstrated_4\VBN\2137132 by_5\IN\1740 the_6\DT\1740 ability_7\NN\4723816 of_8\IN\1740 natural_9\JJ\1740 pregs_10\NNS\1740 to_11\TO\1740 be_12\VB\836236 an_13\DT\6697703 order_14\NN\7168131 of_15\IN\1740 magnitude_16\NN\4916342 more_17\RBR\1740 effective_18\JJ\1740 than_19\IN\1740 its_20\PRP$\6125041 synthetic_21\JJ\1740 enantiomer_22\NN\14818238 in_23\IN\13603305 reversing_24\VBG\109660 <e1>scopolamine-induced</e1>_25\JJ\1740 <e2>amnesia</e2>_26\NN\5669934 ._27\.\1740
2257294
C034753_D001855 NONE <e1>benzylacyclouridine</e1>_0\NN\1740 reverses_1\VBZ\109660 azidothymidine-induced_2\JJ\1740 <e2>marrow_3\NN\5286536 suppression</e2>_4\NN\13489037 without_5\IN\1740 impairment_6\NN\7296428 of_7\IN\1740 anti-human_8\JJ\1740 immunodeficiency_9\NN\13973990 virus_10\NN\9312843 activity_11\NN\30358 ._12\.\1740
C034753_D001855 NONE when_0\WRB\1740 coadministered_1\VBN\1740 with_2\IN\1740 azt_3\NN\3834836 from_4\IN\1740 the_5\DT\1740 onset_6\NN\7325190 of_7\IN\1740 drug_8\NN\14778436 administration_9\NN\1133281 ,_10\,\1740 <e1>bau</e1>_11\NN\1740 reduced_12\VBD\441445 azt-induced_13\JJ\1740 <e2>marrow_14\NN\5286536 toxicity</e2>_15\NN\13576101 ._16\.\1740
C034753_D007153 NONE <e1>benzylacyclouridine</e1>_0\NN\1740 reverses_1\VBZ\109660 azidothymidine-induced_2\JJ\1740 marrow_3\NN\5286536 suppression_4\NN\13489037 without_5\IN\1740 impairment_6\NN\7296428 of_7\IN\1740 anti-human_8\JJ\1740 <e2>immunodeficiency</e2>_9\NN\13973990 virus_10\NN\9312843 activity_11\NN\30358 ._12\.\1740
D015215_D001855 CID benzylacyclouridine_0\NN\1740 reverses_1\VBZ\109660 <e1>azidothymidine-induced</e1>_2\JJ\1740 <e2>marrow_3\NN\5286536 suppression</e2>_4\NN\13489037 without_5\IN\1740 impairment_6\NN\7296428 of_7\IN\1740 anti-human_8\JJ\1740 immunodeficiency_9\NN\13973990 virus_10\NN\9312843 activity_11\NN\30358 ._12\.\1740
D015215_D001855 CID when_0\WRB\1740 coadministered_1\VBN\1740 with_2\IN\1740 <e1>azt</e1>_3\NN\3834836 from_4\IN\1740 the_5\DT\1740 onset_6\NN\7325190 of_7\IN\1740 drug_8\NN\14778436 administration_9\NN\1133281 ,_10\,\1740 bau_11\NN\1740 reduced_12\VBD\441445 azt-induced_13\JJ\1740 <e2>marrow_14\NN\5286536 toxicity</e2>_15\NN\13576101 ._16\.\1740
D015215_D001855 CID when_0\WRB\1740 coadministered_1\VBN\1740 with_2\IN\1740 azt_3\NN\3834836 from_4\IN\1740 the_5\DT\1740 onset_6\NN\7325190 of_7\IN\1740 drug_8\NN\14778436 administration_9\NN\1133281 ,_10\,\1740 bau_11\NN\1740 reduced_12\VBD\441445 <e1>azt-induced</e1>_13\JJ\1740 <e2>marrow_14\NN\5286536 toxicity</e2>_15\NN\13576101 ._16\.\1740
D015215_D007153 NONE benzylacyclouridine_0\NN\1740 reverses_1\VBZ\109660 <e1>azidothymidine-induced</e1>_2\JJ\1740 marrow_3\NN\5286536 suppression_4\NN\13489037 without_5\IN\1740 impairment_6\NN\7296428 of_7\IN\1740 anti-human_8\JJ\1740 <e2>immunodeficiency</e2>_9\NN\13973990 virus_10\NN\9312843 activity_11\NN\30358 ._12\.\1740
D015215_D007153 NONE increased_0\VBN\169651 extracellular_1\JJ\1740 concentrations_2\NNS\4916342 of_3\IN\1740 uridine_4\NN\1740 (_5\-LRB-\1740 urd_6\NN\1740 )_7\-RRB-\1740 have_8\VBP\2108377 been_9\VBN\836236 reported_10\VBN\831651 to_11\TO\1740 reduce_12\VB\441445 ,_13\,\1740 in_14\FW\13603305 vitro_15\FW\1740 ,_16\,\1740 <e1>azidothymidine</e1>_17\NN\1740 (azt)-induced_18\JJ\1740 inhibition_19\NN\1068773 of_20\IN\1740 human_21\JJ\1740 granulocyte-macrophage_22\JJ\1740 progenitor_23\NN\9792555 cells_24\NNS\3080309 without_25\IN\1740 impairment_26\NN\7296428 of_27\IN\1740 its_28\PRP$\6125041 antihuman_29\NN\1740 <e2>immunodeficiency</e2>_30\NN\13973990 virus_31\NN\9312843 (_32\-LRB-\1740 hiv_33\NN\14186340 )_34\-RRB-\1740 activity_35\NN\30358 ._36\.\1740
D015215_D007153 NONE increased_0\VBN\169651 extracellular_1\JJ\1740 concentrations_2\NNS\4916342 of_3\IN\1740 uridine_4\NN\1740 (_5\-LRB-\1740 urd_6\NN\1740 )_7\-RRB-\1740 have_8\VBP\2108377 been_9\VBN\836236 reported_10\VBN\831651 to_11\TO\1740 reduce_12\VB\441445 ,_13\,\1740 in_14\FW\13603305 vitro_15\FW\1740 ,_16\,\1740 azidothymidine_17\NN\1740 <e1>(azt)-induced</e1>_18\JJ\1740 inhibition_19\NN\1068773 of_20\IN\1740 human_21\JJ\1740 granulocyte-macrophage_22\JJ\1740 progenitor_23\NN\9792555 cells_24\NNS\3080309 without_25\IN\1740 impairment_26\NN\7296428 of_27\IN\1740 its_28\PRP$\6125041 antihuman_29\NN\1740 <e2>immunodeficiency</e2>_30\NN\13973990 virus_31\NN\9312843 (_32\-LRB-\1740 hiv_33\NN\14186340 )_34\-RRB-\1740 activity_35\NN\30358 ._36\.\1740
D014529_D007153 NONE increased_0\VBN\169651 extracellular_1\JJ\1740 concentrations_2\NNS\4916342 of_3\IN\1740 <e1>uridine</e1>_4\NN\1740 (_5\-LRB-\1740 urd_6\NN\1740 )_7\-RRB-\1740 have_8\VBP\2108377 been_9\VBN\836236 reported_10\VBN\831651 to_11\TO\1740 reduce_12\VB\441445 ,_13\,\1740 in_14\FW\13603305 vitro_15\FW\1740 ,_16\,\1740 azidothymidine_17\NN\1740 (azt)-induced_18\JJ\1740 inhibition_19\NN\1068773 of_20\IN\1740 human_21\JJ\1740 granulocyte-macrophage_22\JJ\1740 progenitor_23\NN\9792555 cells_24\NNS\3080309 without_25\IN\1740 impairment_26\NN\7296428 of_27\IN\1740 its_28\PRP$\6125041 antihuman_29\NN\1740 <e2>immunodeficiency</e2>_30\NN\13973990 virus_31\NN\9312843 (_32\-LRB-\1740 hiv_33\NN\14186340 )_34\-RRB-\1740 activity_35\NN\30358 ._36\.\1740
D014529_D007153 NONE increased_0\VBN\169651 extracellular_1\JJ\1740 concentrations_2\NNS\4916342 of_3\IN\1740 uridine_4\NN\1740 (_5\-LRB-\1740 <e1>urd</e1>_6\NN\1740 )_7\-RRB-\1740 have_8\VBP\2108377 been_9\VBN\836236 reported_10\VBN\831651 to_11\TO\1740 reduce_12\VB\441445 ,_13\,\1740 in_14\FW\13603305 vitro_15\FW\1740 ,_16\,\1740 azidothymidine_17\NN\1740 (azt)-induced_18\JJ\1740 inhibition_19\NN\1068773 of_20\IN\1740 human_21\JJ\1740 granulocyte-macrophage_22\JJ\1740 progenitor_23\NN\9792555 cells_24\NNS\3080309 without_25\IN\1740 impairment_26\NN\7296428 of_27\IN\1740 its_28\PRP$\6125041 antihuman_29\NN\1740 <e2>immunodeficiency</e2>_30\NN\13973990 virus_31\NN\9312843 (_32\-LRB-\1740 hiv_33\NN\14186340 )_34\-RRB-\1740 activity_35\NN\30358 ._36\.\1740
D014529_D064420 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 clinical_3\JJ\1740 <e2>toxicities</e2>_4\NNS\13576101 associated_5\VBN\628491 with_6\IN\1740 chronic_7\JJ\1740 <e1>urd</e1>_8\NNP\1740 administration_9\NN\1133281 ,_10\,\1740 the_11\DT\1740 ability_12\NN\4723816 of_13\IN\1740 benzylacyclouridine_14\NN\1740 (_15\-LRB-\1740 bau_16\NN\1740 )_17\-RRB-\1740 to_18\TO\1740 effect_19\NN\34213 ,_20\,\1740 in_21\FW\13603305 vivo_22\FW\1740 ,_23\,\1740 azt-induced_24\JJ\1740 anemia_25\NN\14189204 and_26\CC\1740 leukopenia_27\NN\14189204 was_28\VBD\836236 assessed_29\VBN\670261 ._30\.\1740
D014529_D064420 NONE this_0\DT\1740 agent_1\NN\7347 inhibits_2\VBZ\2510337 <e1>urd</e1>_3\NNP\1740 catabolism_4\NN\13526110 and_5\CC\1740 ,_6\,\1740 in_7\FW\13603305 vivo_8\FW\1740 ,_9\,\1740 increases_10\VBZ\169651 the_11\DT\1740 plasma_12\NN\5398023 concentration_13\NN\4916342 of_14\IN\1740 urd_15\NNP\1740 in_16\IN\13603305 a_17\DT\13649268 dose-dependent_18\JJ\1740 manner_19\NN\4916342 ,_20\,\1740 without_21\IN\1740 urd-related_22\JJ\1740 <e2>toxicity</e2>_23\NN\13576101 ._24\.\1740
D014529_D064420 NONE this_0\DT\1740 agent_1\NN\7347 inhibits_2\VBZ\2510337 urd_3\NNP\1740 catabolism_4\NN\13526110 and_5\CC\1740 ,_6\,\1740 in_7\FW\13603305 vivo_8\FW\1740 ,_9\,\1740 increases_10\VBZ\169651 the_11\DT\1740 plasma_12\NN\5398023 concentration_13\NN\4916342 of_14\IN\1740 <e1>urd</e1>_15\NNP\1740 in_16\IN\13603305 a_17\DT\13649268 dose-dependent_18\JJ\1740 manner_19\NN\4916342 ,_20\,\1740 without_21\IN\1740 urd-related_22\JJ\1740 <e2>toxicity</e2>_23\NN\13576101 ._24\.\1740
D014529_D064420 NONE this_0\DT\1740 agent_1\NN\7347 inhibits_2\VBZ\2510337 urd_3\NNP\1740 catabolism_4\NN\13526110 and_5\CC\1740 ,_6\,\1740 in_7\FW\13603305 vivo_8\FW\1740 ,_9\,\1740 increases_10\VBZ\169651 the_11\DT\1740 plasma_12\NN\5398023 concentration_13\NN\4916342 of_14\IN\1740 urd_15\NNP\1740 in_16\IN\13603305 a_17\DT\13649268 dose-dependent_18\JJ\1740 manner_19\NN\4916342 ,_20\,\1740 without_21\IN\1740 <e1>urd-related</e1>_22\JJ\1740 <e2>toxicity</e2>_23\NN\13576101 ._24\.\1740
D014529_D000740 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 clinical_3\JJ\1740 toxicities_4\NNS\13576101 associated_5\VBN\628491 with_6\IN\1740 chronic_7\JJ\1740 <e1>urd</e1>_8\NNP\1740 administration_9\NN\1133281 ,_10\,\1740 the_11\DT\1740 ability_12\NN\4723816 of_13\IN\1740 benzylacyclouridine_14\NN\1740 (_15\-LRB-\1740 bau_16\NN\1740 )_17\-RRB-\1740 to_18\TO\1740 effect_19\NN\34213 ,_20\,\1740 in_21\FW\13603305 vivo_22\FW\1740 ,_23\,\1740 azt-induced_24\JJ\1740 <e2>anemia</e2>_25\NN\14189204 and_26\CC\1740 leukopenia_27\NN\14189204 was_28\VBD\836236 assessed_29\VBN\670261 ._30\.\1740
D014529_D007970 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 clinical_3\JJ\1740 toxicities_4\NNS\13576101 associated_5\VBN\628491 with_6\IN\1740 chronic_7\JJ\1740 <e1>urd</e1>_8\NNP\1740 administration_9\NN\1133281 ,_10\,\1740 the_11\DT\1740 ability_12\NN\4723816 of_13\IN\1740 benzylacyclouridine_14\NN\1740 (_15\-LRB-\1740 bau_16\NN\1740 )_17\-RRB-\1740 to_18\TO\1740 effect_19\NN\34213 ,_20\,\1740 in_21\FW\13603305 vivo_22\FW\1740 ,_23\,\1740 azt-induced_24\JJ\1740 anemia_25\NN\14189204 and_26\CC\1740 <e2>leukopenia</e2>_27\NN\14189204 was_28\VBD\836236 assessed_29\VBN\670261 ._30\.\1740
C034753_D064420 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 clinical_3\JJ\1740 <e2>toxicities</e2>_4\NNS\13576101 associated_5\VBN\628491 with_6\IN\1740 chronic_7\JJ\1740 urd_8\NNP\1740 administration_9\NN\1133281 ,_10\,\1740 the_11\DT\1740 ability_12\NN\4723816 of_13\IN\1740 <e1>benzylacyclouridine</e1>_14\NN\1740 (_15\-LRB-\1740 bau_16\NN\1740 )_17\-RRB-\1740 to_18\TO\1740 effect_19\NN\34213 ,_20\,\1740 in_21\FW\13603305 vivo_22\FW\1740 ,_23\,\1740 azt-induced_24\JJ\1740 anemia_25\NN\14189204 and_26\CC\1740 leukopenia_27\NN\14189204 was_28\VBD\836236 assessed_29\VBN\670261 ._30\.\1740
C034753_D064420 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 clinical_3\JJ\1740 <e2>toxicities</e2>_4\NNS\13576101 associated_5\VBN\628491 with_6\IN\1740 chronic_7\JJ\1740 urd_8\NNP\1740 administration_9\NN\1133281 ,_10\,\1740 the_11\DT\1740 ability_12\NN\4723816 of_13\IN\1740 benzylacyclouridine_14\NN\1740 (_15\-LRB-\1740 <e1>bau</e1>_16\NN\1740 )_17\-RRB-\1740 to_18\TO\1740 effect_19\NN\34213 ,_20\,\1740 in_21\FW\13603305 vivo_22\FW\1740 ,_23\,\1740 azt-induced_24\JJ\1740 anemia_25\NN\14189204 and_26\CC\1740 leukopenia_27\NN\14189204 was_28\VBD\836236 assessed_29\VBN\670261 ._30\.\1740
C034753_D000740 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 clinical_3\JJ\1740 toxicities_4\NNS\13576101 associated_5\VBN\628491 with_6\IN\1740 chronic_7\JJ\1740 urd_8\NNP\1740 administration_9\NN\1133281 ,_10\,\1740 the_11\DT\1740 ability_12\NN\4723816 of_13\IN\1740 <e1>benzylacyclouridine</e1>_14\NN\1740 (_15\-LRB-\1740 bau_16\NN\1740 )_17\-RRB-\1740 to_18\TO\1740 effect_19\NN\34213 ,_20\,\1740 in_21\FW\13603305 vivo_22\FW\1740 ,_23\,\1740 azt-induced_24\JJ\1740 <e2>anemia</e2>_25\NN\14189204 and_26\CC\1740 leukopenia_27\NN\14189204 was_28\VBD\836236 assessed_29\VBN\670261 ._30\.\1740
C034753_D000740 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 clinical_3\JJ\1740 toxicities_4\NNS\13576101 associated_5\VBN\628491 with_6\IN\1740 chronic_7\JJ\1740 urd_8\NNP\1740 administration_9\NN\1133281 ,_10\,\1740 the_11\DT\1740 ability_12\NN\4723816 of_13\IN\1740 benzylacyclouridine_14\NN\1740 (_15\-LRB-\1740 <e1>bau</e1>_16\NN\1740 )_17\-RRB-\1740 to_18\TO\1740 effect_19\NN\34213 ,_20\,\1740 in_21\FW\13603305 vivo_22\FW\1740 ,_23\,\1740 azt-induced_24\JJ\1740 <e2>anemia</e2>_25\NN\14189204 and_26\CC\1740 leukopenia_27\NN\14189204 was_28\VBD\836236 assessed_29\VBN\670261 ._30\.\1740
C034753_D000740 NONE in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 <e2>anemic</e2>_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 <e1>bau</e1>_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
C034753_D000740 NONE in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 <e1>bau</e1>_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 <e2>anemia</e2>_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
C034753_D007970 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 clinical_3\JJ\1740 toxicities_4\NNS\13576101 associated_5\VBN\628491 with_6\IN\1740 chronic_7\JJ\1740 urd_8\NNP\1740 administration_9\NN\1133281 ,_10\,\1740 the_11\DT\1740 ability_12\NN\4723816 of_13\IN\1740 <e1>benzylacyclouridine</e1>_14\NN\1740 (_15\-LRB-\1740 bau_16\NN\1740 )_17\-RRB-\1740 to_18\TO\1740 effect_19\NN\34213 ,_20\,\1740 in_21\FW\13603305 vivo_22\FW\1740 ,_23\,\1740 azt-induced_24\JJ\1740 anemia_25\NN\14189204 and_26\CC\1740 <e2>leukopenia</e2>_27\NN\14189204 was_28\VBD\836236 assessed_29\VBN\670261 ._30\.\1740
C034753_D007970 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 clinical_3\JJ\1740 toxicities_4\NNS\13576101 associated_5\VBN\628491 with_6\IN\1740 chronic_7\JJ\1740 urd_8\NNP\1740 administration_9\NN\1133281 ,_10\,\1740 the_11\DT\1740 ability_12\NN\4723816 of_13\IN\1740 benzylacyclouridine_14\NN\1740 (_15\-LRB-\1740 <e1>bau</e1>_16\NN\1740 )_17\-RRB-\1740 to_18\TO\1740 effect_19\NN\34213 ,_20\,\1740 in_21\FW\13603305 vivo_22\FW\1740 ,_23\,\1740 azt-induced_24\JJ\1740 anemia_25\NN\14189204 and_26\CC\1740 <e2>leukopenia</e2>_27\NN\14189204 was_28\VBD\836236 assessed_29\VBN\670261 ._30\.\1740
C034753_D007970 NONE in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 <e2>leukopenic</e2>_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 <e1>bau</e1>_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
C034753_D007970 NONE in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 <e1>bau</e1>_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 <e2>leukopenia</e2>_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_D064420 NONE because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 clinical_3\JJ\1740 <e2>toxicities</e2>_4\NNS\13576101 associated_5\VBN\628491 with_6\IN\1740 chronic_7\JJ\1740 urd_8\NNP\1740 administration_9\NN\1133281 ,_10\,\1740 the_11\DT\1740 ability_12\NN\4723816 of_13\IN\1740 benzylacyclouridine_14\NN\1740 (_15\-LRB-\1740 bau_16\NN\1740 )_17\-RRB-\1740 to_18\TO\1740 effect_19\NN\34213 ,_20\,\1740 in_21\FW\13603305 vivo_22\FW\1740 ,_23\,\1740 <e1>azt-induced</e1>_24\JJ\1740 anemia_25\NN\14189204 and_26\CC\1740 leukopenia_27\NN\14189204 was_28\VBD\836236 assessed_29\VBN\670261 ._30\.\1740
D015215_D000740 CID because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 clinical_3\JJ\1740 toxicities_4\NNS\13576101 associated_5\VBN\628491 with_6\IN\1740 chronic_7\JJ\1740 urd_8\NNP\1740 administration_9\NN\1133281 ,_10\,\1740 the_11\DT\1740 ability_12\NN\4723816 of_13\IN\1740 benzylacyclouridine_14\NN\1740 (_15\-LRB-\1740 bau_16\NN\1740 )_17\-RRB-\1740 to_18\TO\1740 effect_19\NN\34213 ,_20\,\1740 in_21\FW\13603305 vivo_22\FW\1740 ,_23\,\1740 <e1>azt-induced</e1>_24\JJ\1740 <e2>anemia</e2>_25\NN\14189204 and_26\CC\1740 leukopenia_27\NN\14189204 was_28\VBD\836236 assessed_29\VBN\670261 ._30\.\1740
D015215_D000740 CID in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 <e2>anemic</e2>_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 <e1>azt</e1>_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_D000740 CID in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 <e1>azt</e1>_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 <e2>anemia</e2>_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_D000740 CID in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 <e2>anemic</e2>_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 <e1>azt</e1>_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_D000740 CID in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 <e1>azt</e1>_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 <e2>anemia</e2>_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_D000740 CID in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 <e2>anemic</e2>_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 <e1>azt-induced</e1>_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_D000740 CID in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 <e1>azt-induced</e1>_38\JJ\1740 <e2>anemia</e2>_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_D007970 CID because_0\IN\1740 of_1\IN\1740 the_2\DT\1740 clinical_3\JJ\1740 toxicities_4\NNS\13576101 associated_5\VBN\628491 with_6\IN\1740 chronic_7\JJ\1740 urd_8\NNP\1740 administration_9\NN\1133281 ,_10\,\1740 the_11\DT\1740 ability_12\NN\4723816 of_13\IN\1740 benzylacyclouridine_14\NN\1740 (_15\-LRB-\1740 bau_16\NN\1740 )_17\-RRB-\1740 to_18\TO\1740 effect_19\NN\34213 ,_20\,\1740 in_21\FW\13603305 vivo_22\FW\1740 ,_23\,\1740 <e1>azt-induced</e1>_24\JJ\1740 anemia_25\NN\14189204 and_26\CC\1740 <e2>leukopenia</e2>_27\NN\14189204 was_28\VBD\836236 assessed_29\VBN\670261 ._30\.\1740
D015215_D007970 CID in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 <e2>leukopenic</e2>_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 <e1>azt</e1>_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_D007970 CID in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 <e1>azt</e1>_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 <e2>leukopenia</e2>_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_D007970 CID in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 <e2>leukopenic</e2>_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 <e1>azt</e1>_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_D007970 CID in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 <e1>azt</e1>_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 <e2>leukopenia</e2>_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_D007970 CID in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 <e2>leukopenic</e2>_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 <e1>azt-induced</e1>_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_D007970 CID in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 <e1>azt-induced</e1>_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 <e2>leukopenia</e2>_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 megaloblastosis_71\NN\1740 ._72\.\1740
D015215_-1 NONE in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 <e1>azt</e1>_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 <e2>megaloblastosis</e2>_71\NN\1740 ._72\.\1740
D015215_-1 NONE in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 <e1>azt</e1>_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 <e2>megaloblastosis</e2>_71\NN\1740 ._72\.\1740
D015215_-1 NONE in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 bau_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 <e1>azt-induced</e1>_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 <e2>megaloblastosis</e2>_71\NN\1740 ._72\.\1740
C034753_-1 NONE in_0\IN\13603305 mice_1\NNS\2329401 rendered_2\VBN\120316 anemic_3\JJ\1740 and_4\CC\1740 leukopenic_5\JJ\1740 by_6\IN\1740 the_7\DT\1740 administration_8\NN\1133281 of_9\IN\1740 azt_10\NN\3834836 for_11\IN\1740 28_12\CD\13745420 days_13\NNS\15140892 in_14\IN\13603305 drinking_15\NN\838098 water_16\NN\14618834 (_17\-LRB-\1740 1.5_18\CD\1740 mg/ml_19\NN\1740 )_20\-RRB-\1740 ,_21\,\1740 the_22\DT\1740 continued_23\VBN\2367363 administration_24\NN\1133281 of_25\IN\1740 azt_26\NN\3834836 plus_27\CC\4723816 daily_28\JJ\1740 <e1>bau</e1>_29\NN\1740 (_30\-LRB-\1740 300_31\CD\1740 mg/kg_32\NN\1740 ,_33\,\1740 orally_34\RB\1740 )_35\-RRB-\1740 partially_36\RB\1740 reversed_37\VBN\109660 azt-induced_38\JJ\1740 anemia_39\NN\14189204 and_40\CC\1740 leukopenia_41\NN\14189204 (_42\-LRB-\1740 p_43\NN\14622893 less_44\JJR\1740 than_45\IN\1740 .05_46\CD\1740 )_47\-RRB-\1740 ,_48\,\1740 increased_49\VBN\169651 peripheral_50\JJ\1740 reticulocytes_51\NNS\5454070 (_52\-LRB-\1740 to_53\TO\1740 4.9_54\CD\1740 %_55\NN\1740 ,_56\,\1740 p_57\NN\14622893 less_58\JJR\1740 than_59\IN\1740 .01_60\CD\1740 )_61\-RRB-\1740 ,_62\,\1740 increased_63\VBD\169651 cellularity_64\NN\14034177 in_65\IN\13603305 the_66\DT\1740 marrow_67\NN\5286536 ,_68\,\1740 and_69\CC\1740 improved_70\VBD\126264 <e2>megaloblastosis</e2>_71\NN\1740 ._72\.\1740
20103708
D013311_D003928 CID the_0\DT\1740 protective_1\JJ\1740 role_2\NN\719494 of_3\IN\1740 nrf2_4\NN\1740 in_5\IN\13603305 <e1>streptozotocin-induced</e1>_6\JJ\1740 <e2>diabetic_7\JJ\1740 nephropathy</e2>_8\NN\14573196 ._9\.\1740
D013311_D003928 CID research_0\NN\633864 design_1\NN\927261 and_2\CC\1740 methods_3\NNS\5616786 :_4\:\1740 we_5\PRP\1740 explore_6\VBP\789138 the_7\DT\1740 protective_8\JJ\1740 role_9\NN\719494 of_10\IN\1740 nrf2_11\NN\1740 against_12\IN\1740 <e2>diabetic_13\JJ\1740 nephropathy</e2>_14\NN\14573196 using_15\VBG\1156834 human_16\JJ\1740 kidney_17\NN\5333259 biopsy_18\NN\5739043 tissues_19\NNS\5220461 from_20\IN\1740 diabetic_21\JJ\1740 nephropathy_22\JJ\1740 patients_23\NNS\9898892 ,_24\,\1740 a_25\DT\13649268 <e1>streptozotocin-induced</e1>_26\JJ\1740 diabetic_27\JJ\1740 nephropathy_28\JJ\1740 model_29\NN\5888929 in_30\IN\13603305 nrf2(-/-_31\NN\1740 )_32\-RRB-\1740 mice_33\NNS\2329401 ,_34\,\1740 and_35\CC\1740 cultured_36\VBN\245457 human_37\JJ\1740 mesangial_38\JJ\1740 cells_39\NNS\3080309 ._40\.\1740
D013311_D003928 CID research_0\NN\633864 design_1\NN\927261 and_2\CC\1740 methods_3\NNS\5616786 :_4\:\1740 we_5\PRP\1740 explore_6\VBP\789138 the_7\DT\1740 protective_8\JJ\1740 role_9\NN\719494 of_10\IN\1740 nrf2_11\NN\1740 against_12\IN\1740 diabetic_13\JJ\1740 nephropathy_14\NN\14573196 using_15\VBG\1156834 human_16\JJ\1740 kidney_17\NN\5333259 biopsy_18\NN\5739043 tissues_19\NNS\5220461 from_20\IN\1740 <e2>diabetic_21\JJ\1740 nephropathy</e2>_22\JJ\1740 patients_23\NNS\9898892 ,_24\,\1740 a_25\DT\13649268 <e1>streptozotocin-induced</e1>_26\JJ\1740 diabetic_27\JJ\1740 nephropathy_28\JJ\1740 model_29\NN\5888929 in_30\IN\13603305 nrf2(-/-_31\NN\1740 )_32\-RRB-\1740 mice_33\NNS\2329401 ,_34\,\1740 and_35\CC\1740 cultured_36\VBN\245457 human_37\JJ\1740 mesangial_38\JJ\1740 cells_39\NNS\3080309 ._40\.\1740
D013311_D003928 CID research_0\NN\633864 design_1\NN\927261 and_2\CC\1740 methods_3\NNS\5616786 :_4\:\1740 we_5\PRP\1740 explore_6\VBP\789138 the_7\DT\1740 protective_8\JJ\1740 role_9\NN\719494 of_10\IN\1740 nrf2_11\NN\1740 against_12\IN\1740 diabetic_13\JJ\1740 nephropathy_14\NN\14573196 using_15\VBG\1156834 human_16\JJ\1740 kidney_17\NN\5333259 biopsy_18\NN\5739043 tissues_19\NNS\5220461 from_20\IN\1740 diabetic_21\JJ\1740 nephropathy_22\JJ\1740 patients_23\NNS\9898892 ,_24\,\1740 a_25\DT\13649268 <e1>streptozotocin-induced</e1>_26\JJ\1740 <e2>diabetic_27\JJ\1740 nephropathy</e2>_28\JJ\1740 model_29\NN\5888929 in_30\IN\13603305 nrf2(-/-_31\NN\1740 )_32\-RRB-\1740 mice_33\NNS\2329401 ,_34\,\1740 and_35\CC\1740 cultured_36\VBN\245457 human_37\JJ\1740 mesangial_38\JJ\1740 cells_39\NNS\3080309 ._40\.\1740
D010100_D003928 NONE objective_0\NN\5980875 :_1\:\1740 <e2>diabetic_2\JJ\1740 nephropathy</e2>_3\NN\14573196 is_4\VBZ\836236 one_5\CD\13741022 of_6\IN\1740 the_7\DT\1740 major_8\JJ\1740 causes_9\NNS\7323922 of_10\IN\1740 renal_11\JJ\1740 failure_12\NN\66216 ,_13\,\1740 which_14\WDT\1740 is_15\VBZ\836236 accompanied_16\VBN\1835496 by_17\IN\1740 the_18\DT\1740 production_19\NN\30358 of_20\IN\1740 reactive_21\JJ\1740 <e1>oxygen</e1>_22\NN\14622893 species_23\NNS\7992450 (_24\-LRB-\1740 ros_25\NN\6894544 )_26\-RRB-\1740 ._27\.\1740
D010100_D051437 NONE objective_0\NN\5980875 :_1\:\1740 diabetic_2\JJ\1740 nephropathy_3\NN\14573196 is_4\VBZ\836236 one_5\CD\13741022 of_6\IN\1740 the_7\DT\1740 major_8\JJ\1740 causes_9\NNS\7323922 of_10\IN\1740 <e2>renal_11\JJ\1740 failure</e2>_12\NN\66216 ,_13\,\1740 which_14\WDT\1740 is_15\VBZ\836236 accompanied_16\VBN\1835496 by_17\IN\1740 the_18\DT\1740 production_19\NN\30358 of_20\IN\1740 reactive_21\JJ\1740 <e1>oxygen</e1>_22\NN\14622893 species_23\NNS\7992450 (_24\-LRB-\1740 ros_25\NN\6894544 )_26\-RRB-\1740 ._27\.\1740
D013311_D058186 NONE in_0\IN\13603305 the_1\DT\1740 animal_2\NN\4475 study_3\NN\635850 ,_4\,\1740 nrf2_5\NN\1740 was_6\VBD\836236 demonstrated_7\VBN\2137132 to_8\TO\1740 be_9\VB\836236 crucial_10\JJ\1740 in_11\IN\13603305 ameliorating_12\VBG\126264 <e1>streptozotocin-induced</e1>_13\JJ\1740 <e2>renal_14\JJ\1740 damage</e2>_15\NN\7296428 ._16\.\1740
18997632
D002110_D017180 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>ventricular_3\JJ\1740 tachycardia</e2>_4\NN\14110674 related_5\JJ\1740 to_6\TO\1740 <e1>caffeine</e1>_7\NN\14712692 pretreatment_8\NN\1740 ._9\.\1740
D002110_D017180 CID we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 no_5\DT\7204911 previous_6\JJ\1740 history_7\NN\15120823 of_8\IN\1740 cardiac_9\JJ\1740 disease_10\NN\14061805 or_11\CC\3541091 arrhythmia_12\NN\14103288 who_13\WP\8299493 developed_14\VBD\1753788 sustained_15\JJ\1740 bigeminy_16\NN\1740 and_17\CC\1740 2_18\CD\13741022 brief_19\JJ\1740 runs_20\NNS\186634 of_21\IN\1740 <e2>ventricular_22\JJ\1740 tachycardia</e2>_23\NN\14110674 after_24\IN\1740 <e1>caffeine</e1>_25\NN\14712692 administration_26\NN\1133281 ._27\.\1740
D002110_D012640 CID intravenous_0\JJ\1740 <e1>caffeine</e1>_1\NN\14712692 is_2\VBZ\836236 commonly_3\RB\1740 used_4\VBN\1156834 to_5\TO\1740 improve_6\VB\126264 <e2>seizure</e2>_7\JJ\1740 duration_8\NN\15113229 and_9\CC\1740 quality_10\NN\24264 in_11\IN\13603305 such_12\JJ\1740 patients_13\NNS\9898892 and_14\CC\1740 is_15\VBZ\836236 generally_16\RB\1740 well_17\RB\1740 tolerated_18\VBN\802318 aside_19\RB\1740 from_20\IN\1740 occasional_21\JJ\1740 reports_22\NNS\6470073 of_23\IN\1740 relatively_24\RB\1740 benign_25\JJ\1740 ventricular_26\JJ\1740 ectopy_27\NN\1740 ._28\.\1740
D002110_D018879 CID intravenous_0\JJ\1740 <e1>caffeine</e1>_1\NN\14712692 is_2\VBZ\836236 commonly_3\RB\1740 used_4\VBN\1156834 to_5\TO\1740 improve_6\VB\126264 seizure_7\JJ\1740 duration_8\NN\15113229 and_9\CC\1740 quality_10\NN\24264 in_11\IN\13603305 such_12\JJ\1740 patients_13\NNS\9898892 and_14\CC\1740 is_15\VBZ\836236 generally_16\RB\1740 well_17\RB\1740 tolerated_18\VBN\802318 aside_19\RB\1740 from_20\IN\1740 occasional_21\JJ\1740 reports_22\NNS\6470073 of_23\IN\1740 relatively_24\RB\1740 benign_25\JJ\1740 <e2>ventricular_26\JJ\1740 ectopy</e2>_27\NN\1740 ._28\.\1740
D002110_D006331 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 no_5\DT\7204911 previous_6\JJ\1740 history_7\NN\15120823 of_8\IN\1740 <e2>cardiac_9\JJ\1740 disease</e2>_10\NN\14061805 or_11\CC\3541091 arrhythmia_12\NN\14103288 who_13\WP\8299493 developed_14\VBD\1753788 sustained_15\JJ\1740 bigeminy_16\NN\1740 and_17\CC\1740 2_18\CD\13741022 brief_19\JJ\1740 runs_20\NNS\186634 of_21\IN\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 after_24\IN\1740 <e1>caffeine</e1>_25\NN\14712692 administration_26\NN\1133281 ._27\.\1740
D002110_D001145 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 with_4\IN\1740 no_5\DT\7204911 previous_6\JJ\1740 history_7\NN\15120823 of_8\IN\1740 cardiac_9\JJ\1740 disease_10\NN\14061805 or_11\CC\3541091 <e2>arrhythmia</e2>_12\NN\14103288 who_13\WP\8299493 developed_14\VBD\1753788 sustained_15\JJ\1740 bigeminy_16\NN\1740 and_17\CC\1740 2_18\CD\13741022 brief_19\JJ\1740 runs_20\NNS\186634 of_21\IN\1740 ventricular_22\JJ\1740 tachycardia_23\NN\14110674 after_24\IN\1740 <e1>caffeine</e1>_25\NN\14712692 administration_26\NN\1133281 ._27\.\1740
D002110_D001145 NONE although_0\IN\1740 intravenous_1\JJ\1740 <e1>caffeine</e1>_2\NN\14712692 is_3\VBZ\836236 generally_4\RB\1740 well_5\RB\1740 tolerated_6\VBN\802318 ,_7\,\1740 the_8\DT\1740 clinician_9\NN\10462860 should_10\MD\1740 be_11\VB\836236 aware_12\JJ\1740 of_13\IN\1740 the_14\DT\1740 potential_15\NN\14481929 for_16\IN\1740 unpredictable_17\JJ\1740 and_18\CC\1740 serious_19\JJ\1740 <e2>ventricular_20\NN\1740 arrhythmias</e2>_21\NNS\14103288 ._22\.\1740
14633084
D003907_D006470 NONE use_0\NN\407535 of_1\IN\1740 <e1>dexamethasone</e1>_2\NN\2721538 with_3\IN\1740 mesna_4\NN\1740 for_5\IN\1740 the_6\DT\1740 prevention_7\NN\1073995 of_8\IN\1740 ifosfamide-induced_9\JJ\1740 <e2>hemorrhagic_10\JJ\1740 cystitis</e2>_11\NN\14566129 ._12\.\1740
D003907_D006470 NONE in_0\IN\13603305 the_1\DT\1740 study_2\NN\635850 presented_3\VBN\2137132 here_4\RB\1740 ,_5\,\1740 we_6\PRP\1740 investigated_7\VBD\644583 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>dexamethasone</e1>_11\NN\2721538 in_12\IN\13603305 combination_13\NN\7951464 with_14\IN\1740 mesna_15\NN\1740 for_16\IN\1740 the_17\DT\1740 prevention_18\NN\1073995 of_19\IN\1740 ifs-induced_20\JJ\1740 <e2>hc</e2>_21\NN\1740 ._22\.\1740
D003907_D006470 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>dexamethasone</e1>_2\NN\2721538 in_3\IN\13603305 combination_4\NN\7951464 with_5\IN\1740 mesna_6\NN\1740 was_7\VBD\836236 efficient_8\JJ\1740 in_9\IN\13603305 blocking_10\VBG\1476483 ifs-induced_11\JJ\1740 <e2>hc</e2>_12\NN\1740 ._13\.\1740
D003907_D006470 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 replacement_3\NN\196485 of_4\IN\1740 last_5\JJ\1740 two_6\CD\13741022 doses_7\NNS\3740161 of_8\IN\1740 mesna_9\NN\1740 with_10\IN\1740 saline_11\NN\14849367 or_12\CC\3541091 all_13\DT\1740 of_14\IN\1740 the_15\DT\1740 mesna_16\NN\1740 doses_17\NNS\3740161 with_18\IN\1740 <e1>dexamethasone</e1>_19\NN\2721538 did_20\VBD\1640855 not_21\RB\1740 prevent_22\VB\1740 <e2>hc</e2>_23\NN\1740 ._24\.\1740
D003907_D003556 NONE use_0\NN\407535 of_1\IN\1740 <e1>dexamethasone</e1>_2\NN\2721538 with_3\IN\1740 mesna_4\NN\1740 for_5\IN\1740 the_6\DT\1740 prevention_7\NN\1073995 of_8\IN\1740 ifosfamide-induced_9\JJ\1740 <e2>hemorrhagic_10\JJ\1740 cystitis</e2>_11\NN\14566129 ._12\.\1740
D003907_D003556 NONE in_0\IN\13603305 the_1\DT\1740 study_2\NN\635850 presented_3\VBN\2137132 here_4\RB\1740 ,_5\,\1740 we_6\PRP\1740 investigated_7\VBD\644583 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>dexamethasone</e1>_11\NN\2721538 in_12\IN\13603305 combination_13\NN\7951464 with_14\IN\1740 mesna_15\NN\1740 for_16\IN\1740 the_17\DT\1740 prevention_18\NN\1073995 of_19\IN\1740 ifs-induced_20\JJ\1740 <e2>hc</e2>_21\NN\1740 ._22\.\1740
D003907_D003556 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>dexamethasone</e1>_2\NN\2721538 in_3\IN\13603305 combination_4\NN\7951464 with_5\IN\1740 mesna_6\NN\1740 was_7\VBD\836236 efficient_8\JJ\1740 in_9\IN\13603305 blocking_10\VBG\1476483 ifs-induced_11\JJ\1740 <e2>hc</e2>_12\NN\1740 ._13\.\1740
D003907_D003556 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 replacement_3\NN\196485 of_4\IN\1740 last_5\JJ\1740 two_6\CD\13741022 doses_7\NNS\3740161 of_8\IN\1740 mesna_9\NN\1740 with_10\IN\1740 saline_11\NN\14849367 or_12\CC\3541091 all_13\DT\1740 of_14\IN\1740 the_15\DT\1740 mesna_16\NN\1740 doses_17\NNS\3740161 with_18\IN\1740 <e1>dexamethasone</e1>_19\NN\2721538 did_20\VBD\1640855 not_21\RB\1740 prevent_22\VB\1740 <e2>hc</e2>_23\NN\1740 ._24\.\1740
D015080_D006470 NONE use_0\NN\407535 of_1\IN\1740 dexamethasone_2\NN\2721538 with_3\IN\1740 <e1>mesna</e1>_4\NN\1740 for_5\IN\1740 the_6\DT\1740 prevention_7\NN\1073995 of_8\IN\1740 ifosfamide-induced_9\JJ\1740 <e2>hemorrhagic_10\JJ\1740 cystitis</e2>_11\NN\14566129 ._12\.\1740
D015080_D006470 NONE in_0\IN\13603305 the_1\DT\1740 study_2\NN\635850 presented_3\VBN\2137132 here_4\RB\1740 ,_5\,\1740 we_6\PRP\1740 investigated_7\VBD\644583 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 dexamethasone_11\NN\2721538 in_12\IN\13603305 combination_13\NN\7951464 with_14\IN\1740 <e1>mesna</e1>_15\NN\1740 for_16\IN\1740 the_17\DT\1740 prevention_18\NN\1073995 of_19\IN\1740 ifs-induced_20\JJ\1740 <e2>hc</e2>_21\NN\1740 ._22\.\1740
D015080_D006470 NONE conclusion_0\NN\5837957 :_1\:\1740 dexamethasone_2\NN\2721538 in_3\IN\13603305 combination_4\NN\7951464 with_5\IN\1740 <e1>mesna</e1>_6\NN\1740 was_7\VBD\836236 efficient_8\JJ\1740 in_9\IN\13603305 blocking_10\VBG\1476483 ifs-induced_11\JJ\1740 <e2>hc</e2>_12\NN\1740 ._13\.\1740
D015080_D006470 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 replacement_3\NN\196485 of_4\IN\1740 last_5\JJ\1740 two_6\CD\13741022 doses_7\NNS\3740161 of_8\IN\1740 <e1>mesna</e1>_9\NN\1740 with_10\IN\1740 saline_11\NN\14849367 or_12\CC\3541091 all_13\DT\1740 of_14\IN\1740 the_15\DT\1740 mesna_16\NN\1740 doses_17\NNS\3740161 with_18\IN\1740 dexamethasone_19\NN\2721538 did_20\VBD\1640855 not_21\RB\1740 prevent_22\VB\1740 <e2>hc</e2>_23\NN\1740 ._24\.\1740
D015080_D006470 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 replacement_3\NN\196485 of_4\IN\1740 last_5\JJ\1740 two_6\CD\13741022 doses_7\NNS\3740161 of_8\IN\1740 mesna_9\NN\1740 with_10\IN\1740 saline_11\NN\14849367 or_12\CC\3541091 all_13\DT\1740 of_14\IN\1740 the_15\DT\1740 <e1>mesna</e1>_16\NN\1740 doses_17\NNS\3740161 with_18\IN\1740 dexamethasone_19\NN\2721538 did_20\VBD\1640855 not_21\RB\1740 prevent_22\VB\1740 <e2>hc</e2>_23\NN\1740 ._24\.\1740
D015080_D003556 NONE use_0\NN\407535 of_1\IN\1740 dexamethasone_2\NN\2721538 with_3\IN\1740 <e1>mesna</e1>_4\NN\1740 for_5\IN\1740 the_6\DT\1740 prevention_7\NN\1073995 of_8\IN\1740 ifosfamide-induced_9\JJ\1740 <e2>hemorrhagic_10\JJ\1740 cystitis</e2>_11\NN\14566129 ._12\.\1740
D015080_D003556 NONE in_0\IN\13603305 the_1\DT\1740 study_2\NN\635850 presented_3\VBN\2137132 here_4\RB\1740 ,_5\,\1740 we_6\PRP\1740 investigated_7\VBD\644583 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 dexamethasone_11\NN\2721538 in_12\IN\13603305 combination_13\NN\7951464 with_14\IN\1740 <e1>mesna</e1>_15\NN\1740 for_16\IN\1740 the_17\DT\1740 prevention_18\NN\1073995 of_19\IN\1740 ifs-induced_20\JJ\1740 <e2>hc</e2>_21\NN\1740 ._22\.\1740
D015080_D003556 NONE conclusion_0\NN\5837957 :_1\:\1740 dexamethasone_2\NN\2721538 in_3\IN\13603305 combination_4\NN\7951464 with_5\IN\1740 <e1>mesna</e1>_6\NN\1740 was_7\VBD\836236 efficient_8\JJ\1740 in_9\IN\13603305 blocking_10\VBG\1476483 ifs-induced_11\JJ\1740 <e2>hc</e2>_12\NN\1740 ._13\.\1740
D015080_D003556 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 replacement_3\NN\196485 of_4\IN\1740 last_5\JJ\1740 two_6\CD\13741022 doses_7\NNS\3740161 of_8\IN\1740 <e1>mesna</e1>_9\NN\1740 with_10\IN\1740 saline_11\NN\14849367 or_12\CC\3541091 all_13\DT\1740 of_14\IN\1740 the_15\DT\1740 mesna_16\NN\1740 doses_17\NNS\3740161 with_18\IN\1740 dexamethasone_19\NN\2721538 did_20\VBD\1640855 not_21\RB\1740 prevent_22\VB\1740 <e2>hc</e2>_23\NN\1740 ._24\.\1740
D015080_D003556 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 replacement_3\NN\196485 of_4\IN\1740 last_5\JJ\1740 two_6\CD\13741022 doses_7\NNS\3740161 of_8\IN\1740 mesna_9\NN\1740 with_10\IN\1740 saline_11\NN\14849367 or_12\CC\3541091 all_13\DT\1740 of_14\IN\1740 the_15\DT\1740 <e1>mesna</e1>_16\NN\1740 doses_17\NNS\3740161 with_18\IN\1740 dexamethasone_19\NN\2721538 did_20\VBD\1640855 not_21\RB\1740 prevent_22\VB\1740 <e2>hc</e2>_23\NN\1740 ._24\.\1740
D007069_D006470 CID use_0\NN\407535 of_1\IN\1740 dexamethasone_2\NN\2721538 with_3\IN\1740 mesna_4\NN\1740 for_5\IN\1740 the_6\DT\1740 prevention_7\NN\1073995 of_8\IN\1740 <e1>ifosfamide-induced</e1>_9\JJ\1740 <e2>hemorrhagic_10\JJ\1740 cystitis</e2>_11\NN\14566129 ._12\.\1740
D007069_D006470 CID aim_0\NN\5980875 :_1\:\1740 <e2>hemorrhagic_2\JJ\1740 cystitis</e2>_3\NN\14566129 (_4\-LRB-\1740 hc_5\NN\1740 )_6\-RRB-\1740 is_7\VBZ\836236 a_8\DT\13649268 limiting_9\VBG\2510337 side-effect_10\NN\1740 of_11\IN\1740 chemotherapy_12\NN\661091 with_13\IN\1740 <e1>ifosfamide</e1>_14\NN\1740 (_15\-LRB-\1740 ifs_16\NNP\1740 )_17\-RRB-\1740 ._18\.\1740
D007069_D006470 CID aim_0\NN\5980875 :_1\:\1740 hemorrhagic_2\JJ\1740 cystitis_3\NN\14566129 (_4\-LRB-\1740 <e2>hc</e2>_5\NN\1740 )_6\-RRB-\1740 is_7\VBZ\836236 a_8\DT\13649268 limiting_9\VBG\2510337 side-effect_10\NN\1740 of_11\IN\1740 chemotherapy_12\NN\661091 with_13\IN\1740 <e1>ifosfamide</e1>_14\NN\1740 (_15\-LRB-\1740 ifs_16\NNP\1740 )_17\-RRB-\1740 ._18\.\1740
D007069_D006470 CID aim_0\NN\5980875 :_1\:\1740 <e2>hemorrhagic_2\JJ\1740 cystitis</e2>_3\NN\14566129 (_4\-LRB-\1740 hc_5\NN\1740 )_6\-RRB-\1740 is_7\VBZ\836236 a_8\DT\13649268 limiting_9\VBG\2510337 side-effect_10\NN\1740 of_11\IN\1740 chemotherapy_12\NN\661091 with_13\IN\1740 ifosfamide_14\NN\1740 (_15\-LRB-\1740 <e1>ifs</e1>_16\NNP\1740 )_17\-RRB-\1740 ._18\.\1740
D007069_D006470 CID aim_0\NN\5980875 :_1\:\1740 hemorrhagic_2\JJ\1740 cystitis_3\NN\14566129 (_4\-LRB-\1740 <e2>hc</e2>_5\NN\1740 )_6\-RRB-\1740 is_7\VBZ\836236 a_8\DT\13649268 limiting_9\VBG\2510337 side-effect_10\NN\1740 of_11\IN\1740 chemotherapy_12\NN\661091 with_13\IN\1740 ifosfamide_14\NN\1740 (_15\-LRB-\1740 <e1>ifs</e1>_16\NNP\1740 )_17\-RRB-\1740 ._18\.\1740
D007069_D006470 CID in_0\IN\13603305 the_1\DT\1740 study_2\NN\635850 presented_3\VBN\2137132 here_4\RB\1740 ,_5\,\1740 we_6\PRP\1740 investigated_7\VBD\644583 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 dexamethasone_11\NN\2721538 in_12\IN\13603305 combination_13\NN\7951464 with_14\IN\1740 mesna_15\NN\1740 for_16\IN\1740 the_17\DT\1740 prevention_18\NN\1073995 of_19\IN\1740 <e1>ifs-induced</e1>_20\JJ\1740 <e2>hc</e2>_21\NN\1740 ._22\.\1740
D007069_D006470 CID conclusion_0\NN\5837957 :_1\:\1740 dexamethasone_2\NN\2721538 in_3\IN\13603305 combination_4\NN\7951464 with_5\IN\1740 mesna_6\NN\1740 was_7\VBD\836236 efficient_8\JJ\1740 in_9\IN\13603305 blocking_10\VBG\1476483 <e1>ifs-induced</e1>_11\JJ\1740 <e2>hc</e2>_12\NN\1740 ._13\.\1740
D007069_D003556 CID use_0\NN\407535 of_1\IN\1740 dexamethasone_2\NN\2721538 with_3\IN\1740 mesna_4\NN\1740 for_5\IN\1740 the_6\DT\1740 prevention_7\NN\1073995 of_8\IN\1740 <e1>ifosfamide-induced</e1>_9\JJ\1740 <e2>hemorrhagic_10\JJ\1740 cystitis</e2>_11\NN\14566129 ._12\.\1740
D007069_D003556 CID aim_0\NN\5980875 :_1\:\1740 <e2>hemorrhagic_2\JJ\1740 cystitis</e2>_3\NN\14566129 (_4\-LRB-\1740 hc_5\NN\1740 )_6\-RRB-\1740 is_7\VBZ\836236 a_8\DT\13649268 limiting_9\VBG\2510337 side-effect_10\NN\1740 of_11\IN\1740 chemotherapy_12\NN\661091 with_13\IN\1740 <e1>ifosfamide</e1>_14\NN\1740 (_15\-LRB-\1740 ifs_16\NNP\1740 )_17\-RRB-\1740 ._18\.\1740
D007069_D003556 CID aim_0\NN\5980875 :_1\:\1740 hemorrhagic_2\JJ\1740 cystitis_3\NN\14566129 (_4\-LRB-\1740 <e2>hc</e2>_5\NN\1740 )_6\-RRB-\1740 is_7\VBZ\836236 a_8\DT\13649268 limiting_9\VBG\2510337 side-effect_10\NN\1740 of_11\IN\1740 chemotherapy_12\NN\661091 with_13\IN\1740 <e1>ifosfamide</e1>_14\NN\1740 (_15\-LRB-\1740 ifs_16\NNP\1740 )_17\-RRB-\1740 ._18\.\1740
D007069_D003556 CID aim_0\NN\5980875 :_1\:\1740 <e2>hemorrhagic_2\JJ\1740 cystitis</e2>_3\NN\14566129 (_4\-LRB-\1740 hc_5\NN\1740 )_6\-RRB-\1740 is_7\VBZ\836236 a_8\DT\13649268 limiting_9\VBG\2510337 side-effect_10\NN\1740 of_11\IN\1740 chemotherapy_12\NN\661091 with_13\IN\1740 ifosfamide_14\NN\1740 (_15\-LRB-\1740 <e1>ifs</e1>_16\NNP\1740 )_17\-RRB-\1740 ._18\.\1740
D007069_D003556 CID aim_0\NN\5980875 :_1\:\1740 hemorrhagic_2\JJ\1740 cystitis_3\NN\14566129 (_4\-LRB-\1740 <e2>hc</e2>_5\NN\1740 )_6\-RRB-\1740 is_7\VBZ\836236 a_8\DT\13649268 limiting_9\VBG\2510337 side-effect_10\NN\1740 of_11\IN\1740 chemotherapy_12\NN\661091 with_13\IN\1740 ifosfamide_14\NN\1740 (_15\-LRB-\1740 <e1>ifs</e1>_16\NNP\1740 )_17\-RRB-\1740 ._18\.\1740
D007069_D003556 CID in_0\IN\13603305 the_1\DT\1740 study_2\NN\635850 presented_3\VBN\2137132 here_4\RB\1740 ,_5\,\1740 we_6\PRP\1740 investigated_7\VBD\644583 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 dexamethasone_11\NN\2721538 in_12\IN\13603305 combination_13\NN\7951464 with_14\IN\1740 mesna_15\NN\1740 for_16\IN\1740 the_17\DT\1740 prevention_18\NN\1073995 of_19\IN\1740 <e1>ifs-induced</e1>_20\JJ\1740 <e2>hc</e2>_21\NN\1740 ._22\.\1740
D007069_D003556 CID conclusion_0\NN\5837957 :_1\:\1740 dexamethasone_2\NN\2721538 in_3\IN\13603305 combination_4\NN\7951464 with_5\IN\1740 mesna_6\NN\1740 was_7\VBD\836236 efficient_8\JJ\1740 in_9\IN\13603305 blocking_10\VBG\1476483 <e1>ifs-induced</e1>_11\JJ\1740 <e2>hc</e2>_12\NN\1740 ._13\.\1740
19274460
D003520_D009101 NONE dsmm_0\NN\1740 xi_1\NN\13745420 study_2\NN\635850 :_3\:\1740 dose_4\NN\3740161 definition_5\NN\6738281 for_6\IN\1740 intravenous_7\JJ\1740 <e1>cyclophosphamide</e1>_8\NN\1740 in_9\IN\13603305 combination_10\NN\7951464 with_11\IN\1740 bortezomib/dexamethasone_12\NN\1740 for_13\IN\1740 remission_14\NN\7368256 induction_15\NN\7450842 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 newly_19\RB\1740 diagnosed_20\VBN\644583 <e2>myeloma</e2>_21\NN\14239425 ._22\.\1740
D003520_D009101 NONE a_0\DT\13649268 clinical_1\JJ\1740 trial_2\NN\786195 was_3\VBD\836236 initiated_4\VBN\1617192 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 recommended_8\VBN\875394 dose_9\NN\3740161 of_10\IN\1740 <e1>cyclophosphamide</e1>_11\NN\1740 in_12\IN\13603305 combination_13\NN\7951464 with_14\IN\1740 bortezomib_15\NN\1740 and_16\CC\1740 dexamethasone_17\NN\2721538 as_18\IN\14622893 induction_19\NN\7450842 treatment_20\NN\654885 before_21\IN\1740 stem_22\NN\6290637 cell_23\NN\3080309 transplantation_24\NN\671351 for_25\IN\1740 younger_26\JJR\1740 patients_27\NNS\9898892 with_28\IN\1740 newly_29\RB\1740 diagnosed_30\VBN\644583 <e2>multiple_31\JJ\1740 myeloma</e2>_32\NN\14239425 (_33\-LRB-\1740 mm_34\NN\13649268 )_35\-RRB-\1740 ._36\.\1740
D003520_D009101 NONE a_0\DT\13649268 clinical_1\JJ\1740 trial_2\NN\786195 was_3\VBD\836236 initiated_4\VBN\1617192 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 recommended_8\VBN\875394 dose_9\NN\3740161 of_10\IN\1740 <e1>cyclophosphamide</e1>_11\NN\1740 in_12\IN\13603305 combination_13\NN\7951464 with_14\IN\1740 bortezomib_15\NN\1740 and_16\CC\1740 dexamethasone_17\NN\2721538 as_18\IN\14622893 induction_19\NN\7450842 treatment_20\NN\654885 before_21\IN\1740 stem_22\NN\6290637 cell_23\NN\3080309 transplantation_24\NN\671351 for_25\IN\1740 younger_26\JJR\1740 patients_27\NNS\9898892 with_28\IN\1740 newly_29\RB\1740 diagnosed_30\VBN\644583 multiple_31\JJ\1740 myeloma_32\NN\14239425 (_33\-LRB-\1740 <e2>mm</e2>_34\NN\13649268 )_35\-RRB-\1740 ._36\.\1740
D003520_D009101 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 bortezomib_4\NN\1740 in_5\IN\13603305 combination_6\NN\7951464 with_7\IN\1740 <e1>cyclophosphamide</e1>_8\NN\1740 at_9\IN\14622893 900_10\CD\1740 mg/m(2_11\NN\1740 )_12\-RRB-\1740 and_13\CC\1740 dexamethasone_14\NN\2721538 is_15\VBZ\836236 an_16\DT\6697703 effective_17\JJ\1740 induction_18\NN\7450842 treatment_19\NN\654885 for_20\IN\1740 patients_21\NNS\9898892 with_22\IN\1740 newly_23\RB\1740 diagnosed_24\VBN\644583 <e2>mm</e2>_25\NN\13649268 that_26\WDT\1740 warrants_27\VBZ\1012073 further_28\JJ\1740 investigation_29\NN\5797597 ._30\.\1740
C400082_D009101 NONE dsmm_0\NN\1740 xi_1\NN\13745420 study_2\NN\635850 :_3\:\1740 dose_4\NN\3740161 definition_5\NN\6738281 for_6\IN\1740 intravenous_7\JJ\1740 cyclophosphamide_8\NN\1740 in_9\IN\13603305 combination_10\NN\7951464 with_11\IN\1740 <e1>bortezomib/dexamethasone</e1>_12\NN\1740 for_13\IN\1740 remission_14\NN\7368256 induction_15\NN\7450842 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 newly_19\RB\1740 diagnosed_20\VBN\644583 <e2>myeloma</e2>_21\NN\14239425 ._22\.\1740
C400082_D009101 NONE a_0\DT\13649268 clinical_1\JJ\1740 trial_2\NN\786195 was_3\VBD\836236 initiated_4\VBN\1617192 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 recommended_8\VBN\875394 dose_9\NN\3740161 of_10\IN\1740 cyclophosphamide_11\NN\1740 in_12\IN\13603305 combination_13\NN\7951464 with_14\IN\1740 <e1>bortezomib</e1>_15\NN\1740 and_16\CC\1740 dexamethasone_17\NN\2721538 as_18\IN\14622893 induction_19\NN\7450842 treatment_20\NN\654885 before_21\IN\1740 stem_22\NN\6290637 cell_23\NN\3080309 transplantation_24\NN\671351 for_25\IN\1740 younger_26\JJR\1740 patients_27\NNS\9898892 with_28\IN\1740 newly_29\RB\1740 diagnosed_30\VBN\644583 <e2>multiple_31\JJ\1740 myeloma</e2>_32\NN\14239425 (_33\-LRB-\1740 mm_34\NN\13649268 )_35\-RRB-\1740 ._36\.\1740
C400082_D009101 NONE a_0\DT\13649268 clinical_1\JJ\1740 trial_2\NN\786195 was_3\VBD\836236 initiated_4\VBN\1617192 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 recommended_8\VBN\875394 dose_9\NN\3740161 of_10\IN\1740 cyclophosphamide_11\NN\1740 in_12\IN\13603305 combination_13\NN\7951464 with_14\IN\1740 <e1>bortezomib</e1>_15\NN\1740 and_16\CC\1740 dexamethasone_17\NN\2721538 as_18\IN\14622893 induction_19\NN\7450842 treatment_20\NN\654885 before_21\IN\1740 stem_22\NN\6290637 cell_23\NN\3080309 transplantation_24\NN\671351 for_25\IN\1740 younger_26\JJR\1740 patients_27\NNS\9898892 with_28\IN\1740 newly_29\RB\1740 diagnosed_30\VBN\644583 multiple_31\JJ\1740 myeloma_32\NN\14239425 (_33\-LRB-\1740 <e2>mm</e2>_34\NN\13649268 )_35\-RRB-\1740 ._36\.\1740
C400082_D009101 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e1>bortezomib</e1>_4\NN\1740 in_5\IN\13603305 combination_6\NN\7951464 with_7\IN\1740 cyclophosphamide_8\NN\1740 at_9\IN\14622893 900_10\CD\1740 mg/m(2_11\NN\1740 )_12\-RRB-\1740 and_13\CC\1740 dexamethasone_14\NN\2721538 is_15\VBZ\836236 an_16\DT\6697703 effective_17\JJ\1740 induction_18\NN\7450842 treatment_19\NN\654885 for_20\IN\1740 patients_21\NNS\9898892 with_22\IN\1740 newly_23\RB\1740 diagnosed_24\VBN\644583 <e2>mm</e2>_25\NN\13649268 that_26\WDT\1740 warrants_27\VBZ\1012073 further_28\JJ\1740 investigation_29\NN\5797597 ._30\.\1740
D003907_D009101 NONE dsmm_0\NN\1740 xi_1\NN\13745420 study_2\NN\635850 :_3\:\1740 dose_4\NN\3740161 definition_5\NN\6738281 for_6\IN\1740 intravenous_7\JJ\1740 cyclophosphamide_8\NN\1740 in_9\IN\13603305 combination_10\NN\7951464 with_11\IN\1740 <e1>bortezomib/dexamethasone</e1>_12\NN\1740 for_13\IN\1740 remission_14\NN\7368256 induction_15\NN\7450842 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 newly_19\RB\1740 diagnosed_20\VBN\644583 <e2>myeloma</e2>_21\NN\14239425 ._22\.\1740
D003907_D009101 NONE a_0\DT\13649268 clinical_1\JJ\1740 trial_2\NN\786195 was_3\VBD\836236 initiated_4\VBN\1617192 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 recommended_8\VBN\875394 dose_9\NN\3740161 of_10\IN\1740 cyclophosphamide_11\NN\1740 in_12\IN\13603305 combination_13\NN\7951464 with_14\IN\1740 bortezomib_15\NN\1740 and_16\CC\1740 <e1>dexamethasone</e1>_17\NN\2721538 as_18\IN\14622893 induction_19\NN\7450842 treatment_20\NN\654885 before_21\IN\1740 stem_22\NN\6290637 cell_23\NN\3080309 transplantation_24\NN\671351 for_25\IN\1740 younger_26\JJR\1740 patients_27\NNS\9898892 with_28\IN\1740 newly_29\RB\1740 diagnosed_30\VBN\644583 <e2>multiple_31\JJ\1740 myeloma</e2>_32\NN\14239425 (_33\-LRB-\1740 mm_34\NN\13649268 )_35\-RRB-\1740 ._36\.\1740
D003907_D009101 NONE a_0\DT\13649268 clinical_1\JJ\1740 trial_2\NN\786195 was_3\VBD\836236 initiated_4\VBN\1617192 to_5\TO\1740 evaluate_6\VB\670261 the_7\DT\1740 recommended_8\VBN\875394 dose_9\NN\3740161 of_10\IN\1740 cyclophosphamide_11\NN\1740 in_12\IN\13603305 combination_13\NN\7951464 with_14\IN\1740 bortezomib_15\NN\1740 and_16\CC\1740 <e1>dexamethasone</e1>_17\NN\2721538 as_18\IN\14622893 induction_19\NN\7450842 treatment_20\NN\654885 before_21\IN\1740 stem_22\NN\6290637 cell_23\NN\3080309 transplantation_24\NN\671351 for_25\IN\1740 younger_26\JJR\1740 patients_27\NNS\9898892 with_28\IN\1740 newly_29\RB\1740 diagnosed_30\VBN\644583 multiple_31\JJ\1740 myeloma_32\NN\14239425 (_33\-LRB-\1740 <e2>mm</e2>_34\NN\13649268 )_35\-RRB-\1740 ._36\.\1740
D003907_D009101 NONE the_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 bortezomib_4\NN\1740 in_5\IN\13603305 combination_6\NN\7951464 with_7\IN\1740 cyclophosphamide_8\NN\1740 at_9\IN\14622893 900_10\CD\1740 mg/m(2_11\NN\1740 )_12\-RRB-\1740 and_13\CC\1740 <e1>dexamethasone</e1>_14\NN\2721538 is_15\VBZ\836236 an_16\DT\6697703 effective_17\JJ\1740 induction_18\NN\7450842 treatment_19\NN\654885 for_20\IN\1740 patients_21\NNS\9898892 with_22\IN\1740 newly_23\RB\1740 diagnosed_24\VBN\644583 <e2>mm</e2>_25\NN\13649268 that_26\WDT\1740 warrants_27\VBZ\1012073 further_28\JJ\1740 investigation_29\NN\5797597 ._30\.\1740
6769133
D004317_D066126 NONE <e2>cardiotoxic</e2>_0\NNP\1740 and_1\CC\1740 possible_2\JJ\1740 leukemogenic_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>adriamycin</e1>_6\NN\1740 in_7\IN\13603305 nonhuman_8\JJ\1740 primates_9\NNS\1342529 ._10\.\1740
D004317_D006333 CID 8_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 10_3\CD\13745420 monkeys_4\NNS\2469914 developed_5\VBD\1753788 <e2>congestive_6\JJ\1740 heart_7\NN\5919034 failure</e2>_8\NN\66216 at_9\IN\14622893 an_10\DT\6697703 average_11\JJ\1740 cumulative_12\JJ\1740 <e1>adriamycin</e1>_13\NN\1740 dose_14\NN\3740161 (_15\-LRB-\1740 310_16\CD\1740 mg/m2_17\NN\1740 )_18\-RRB-\1740 well_19\RB\1740 below_20\IN\1740 that_21\DT\1740 considered_22\VBD\689344 the_23\DT\1740 safe_24\JJ\1740 upper_25\JJ\1740 limit_26\NN\5123416 (_27\-LRB-\1740 550_28\CD\1740 mg/m2_29\NN\1740 )_30\-RRB-\1740 in_31\IN\13603305 man_32\NN\9605289 ._33\.\1740
D018943_D001768 NONE histologically_0\RB\1740 ,_1\,\1740 the_2\DT\1740 <e2>myocardial_3\JJ\1740 lesions</e2>_4\NNS\14204950 resembled_5\VBD\2657219 those_6\DT\1740 found_7\VBN\2426171 in_8\IN\13603305 human_9\JJ\1740 <e1>anthracycline-induced</e1>_10\JJ\1740 cardiomyopathy_11\NN\14103288 ._12\.\1740
D018943_D009202 NONE histologically_0\RB\1740 ,_1\,\1740 the_2\DT\1740 myocardial_3\JJ\1740 lesions_4\NNS\14204950 resembled_5\VBD\2657219 those_6\DT\1740 found_7\VBN\2426171 in_8\IN\13603305 human_9\JJ\1740 <e1>anthracycline-induced</e1>_10\JJ\1740 <e2>cardiomyopathy</e2>_11\NN\14103288 ._12\.\1740
D004317_D015470 CID 1_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 10_3\CD\13745420 monkeys_4\NNS\2469914 developed_5\VBD\1753788 <e2>acute_6\JJ\1740 myeloblastic_7\JJ\1740 leukemia</e2>_8\NN\14239918 after_9\IN\1740 receiving_10\VBG\2210855 324_11\CD\1740 mg/m2_12\NN\1740 of_13\IN\1740 <e1>adriamycin</e1>_14\NN\1740 ;_15\:\1740 the_16\DT\1740 10th_17\JJ\1740 monkey_18\NN\2469914 is_19\VBZ\836236 alive_20\JJ\1740 and_21\CC\1740 well_22\RB\1740 26_23\CD\13745420 months_24\NNS\15113229 after_25\IN\1740 the_26\DT\1740 last_27\JJ\1740 dose_28\NN\3740161 of_29\IN\1740 drug_30\NN\14778436 ._31\.\1740
D004317_D007938 NONE our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e1>adriamycin</e1>_4\NN\1740 is_5\VBZ\836236 a_6\DT\13649268 more_7\RBR\1740 potent_8\JJ\1740 cardiotoxin_9\NN\1740 in_10\IN\13603305 monkeys_11\NNS\2469914 than_12\IN\1740 in_13\IN\13603305 man_14\NN\9605289 ,_15\,\1740 and_16\CC\1740 that_17\IN\1740 <e2>leukemia</e2>_18\NN\14239918 may_19\MD\15209706 be_20\VB\836236 a_21\DT\13649268 consequence_22\NN\34213 of_23\IN\1740 prolonged_24\JJ\1740 treatment_25\NN\654885 with_26\IN\1740 this_27\DT\1740 drug_28\NN\14778436 ._29\.\1740
3762968
D014042_D014899 CID transketolase_0\NN\1740 abnormality_1\NN\14034177 in_2\IN\13603305 <e1>tolazamide-induced</e1>_3\JJ\1740 <e2>wernicke_4\NNP\1740 's_5\POS\1740 encephalopathy</e2>_6\JJ\1740 ._7\.\1740
D014042_D014899 CID we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 thiamine-dependent_3\JJ\1740 enzyme_4\NN\14723628 ,_5\,\1740 transketolase_6\NN\1740 ,_7\,\1740 from_8\IN\1740 fibroblasts_9\NNS\5447757 of_10\IN\1740 a_11\DT\13649268 diabetic_12\JJ\1740 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 <e2>wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy</e2>_18\JJ\1740 when_19\WRB\1740 treated_20\VBN\2376958 with_21\IN\1740 <e1>tolazamide</e1>_22\RB\1740 ,_23\,\1740 in_24\IN\13603305 order_25\NN\7168131 to_26\TO\1740 delineate_27\VB\2137132 if_28\IN\1740 this_29\DT\1740 patient_30\NN\9898892 also_31\RB\1740 had_32\VBD\2108377 transketolase_33\NN\1740 abnormality_34\NN\14034177 [_35\-LRB-\1740 high_36\JJ\1740 km_37\NN\13649268 for_38\IN\1740 thiamine_39\NN\15090742 pyrophosphate_40\NN\15010703 (_41\-LRB-\1740 tpp_42\NN\1740 )_43\-RRB-\1740 ]_44\-RRB-\1740 ,_45\,\1740 as_46\IN\14622893 previously_47\RB\1740 reported_48\VBN\831651 in_49\IN\13603305 postalcoholic_50\JJ\1740 wernicke-korsakoff_51\JJ\1740 syndrome_52\NN\5870365 ._53\.\1740
D014042_D014899 CID these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 a_3\DT\13649268 similarity_4\NN\4742535 between_5\IN\1740 postalcoholic_6\JJ\1740 wernicke-korsakoff_7\JJ\1740 syndrome_8\NN\5870365 and_9\CC\1740 the_10\DT\1740 patient_11\NN\9898892 with_12\IN\1740 <e1>tolazamide-induced</e1>_13\JJ\1740 <e2>wernicke_14\NNP\1740 's_15\POS\1740 encephalopathy</e2>_16\JJ\1740 from_17\IN\1740 the_18\DT\1740 standpoint_19\NN\6196284 of_20\IN\1740 transketolase_21\NN\1740 abnormality_22\NN\14034177 ._23\.\1740
D013831_D003920 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 <e1>thiamine-dependent</e1>_3\JJ\1740 enzyme_4\NN\14723628 ,_5\,\1740 transketolase_6\NN\1740 ,_7\,\1740 from_8\IN\1740 fibroblasts_9\NNS\5447757 of_10\IN\1740 a_11\DT\13649268 <e2>diabetic</e2>_12\JJ\1740 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy_18\JJ\1740 when_19\WRB\1740 treated_20\VBN\2376958 with_21\IN\1740 tolazamide_22\RB\1740 ,_23\,\1740 in_24\IN\13603305 order_25\NN\7168131 to_26\TO\1740 delineate_27\VB\2137132 if_28\IN\1740 this_29\DT\1740 patient_30\NN\9898892 also_31\RB\1740 had_32\VBD\2108377 transketolase_33\NN\1740 abnormality_34\NN\14034177 [_35\-LRB-\1740 high_36\JJ\1740 km_37\NN\13649268 for_38\IN\1740 thiamine_39\NN\15090742 pyrophosphate_40\NN\15010703 (_41\-LRB-\1740 tpp_42\NN\1740 )_43\-RRB-\1740 ]_44\-RRB-\1740 ,_45\,\1740 as_46\IN\14622893 previously_47\RB\1740 reported_48\VBN\831651 in_49\IN\13603305 postalcoholic_50\JJ\1740 wernicke-korsakoff_51\JJ\1740 syndrome_52\NN\5870365 ._53\.\1740
D013831_D014899 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 <e1>thiamine-dependent</e1>_3\JJ\1740 enzyme_4\NN\14723628 ,_5\,\1740 transketolase_6\NN\1740 ,_7\,\1740 from_8\IN\1740 fibroblasts_9\NNS\5447757 of_10\IN\1740 a_11\DT\13649268 diabetic_12\JJ\1740 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 <e2>wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy</e2>_18\JJ\1740 when_19\WRB\1740 treated_20\VBN\2376958 with_21\IN\1740 tolazamide_22\RB\1740 ,_23\,\1740 in_24\IN\13603305 order_25\NN\7168131 to_26\TO\1740 delineate_27\VB\2137132 if_28\IN\1740 this_29\DT\1740 patient_30\NN\9898892 also_31\RB\1740 had_32\VBD\2108377 transketolase_33\NN\1740 abnormality_34\NN\14034177 [_35\-LRB-\1740 high_36\JJ\1740 km_37\NN\13649268 for_38\IN\1740 thiamine_39\NN\15090742 pyrophosphate_40\NN\15010703 (_41\-LRB-\1740 tpp_42\NN\1740 )_43\-RRB-\1740 ]_44\-RRB-\1740 ,_45\,\1740 as_46\IN\14622893 previously_47\RB\1740 reported_48\VBN\831651 in_49\IN\13603305 postalcoholic_50\JJ\1740 wernicke-korsakoff_51\JJ\1740 syndrome_52\NN\5870365 ._53\.\1740
D013831_D020915 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 <e1>thiamine-dependent</e1>_3\JJ\1740 enzyme_4\NN\14723628 ,_5\,\1740 transketolase_6\NN\1740 ,_7\,\1740 from_8\IN\1740 fibroblasts_9\NNS\5447757 of_10\IN\1740 a_11\DT\13649268 diabetic_12\JJ\1740 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy_18\JJ\1740 when_19\WRB\1740 treated_20\VBN\2376958 with_21\IN\1740 tolazamide_22\RB\1740 ,_23\,\1740 in_24\IN\13603305 order_25\NN\7168131 to_26\TO\1740 delineate_27\VB\2137132 if_28\IN\1740 this_29\DT\1740 patient_30\NN\9898892 also_31\RB\1740 had_32\VBD\2108377 transketolase_33\NN\1740 abnormality_34\NN\14034177 [_35\-LRB-\1740 high_36\JJ\1740 km_37\NN\13649268 for_38\IN\1740 thiamine_39\NN\15090742 pyrophosphate_40\NN\15010703 (_41\-LRB-\1740 tpp_42\NN\1740 )_43\-RRB-\1740 ]_44\-RRB-\1740 ,_45\,\1740 as_46\IN\14622893 previously_47\RB\1740 reported_48\VBN\831651 in_49\IN\13603305 postalcoholic_50\JJ\1740 <e2>wernicke-korsakoff_51\JJ\1740 syndrome</e2>_52\NN\5870365 ._53\.\1740
D014042_D003920 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 thiamine-dependent_3\JJ\1740 enzyme_4\NN\14723628 ,_5\,\1740 transketolase_6\NN\1740 ,_7\,\1740 from_8\IN\1740 fibroblasts_9\NNS\5447757 of_10\IN\1740 a_11\DT\13649268 <e2>diabetic</e2>_12\JJ\1740 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy_18\JJ\1740 when_19\WRB\1740 treated_20\VBN\2376958 with_21\IN\1740 <e1>tolazamide</e1>_22\RB\1740 ,_23\,\1740 in_24\IN\13603305 order_25\NN\7168131 to_26\TO\1740 delineate_27\VB\2137132 if_28\IN\1740 this_29\DT\1740 patient_30\NN\9898892 also_31\RB\1740 had_32\VBD\2108377 transketolase_33\NN\1740 abnormality_34\NN\14034177 [_35\-LRB-\1740 high_36\JJ\1740 km_37\NN\13649268 for_38\IN\1740 thiamine_39\NN\15090742 pyrophosphate_40\NN\15010703 (_41\-LRB-\1740 tpp_42\NN\1740 )_43\-RRB-\1740 ]_44\-RRB-\1740 ,_45\,\1740 as_46\IN\14622893 previously_47\RB\1740 reported_48\VBN\831651 in_49\IN\13603305 postalcoholic_50\JJ\1740 wernicke-korsakoff_51\JJ\1740 syndrome_52\NN\5870365 ._53\.\1740
D014042_D020915 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 thiamine-dependent_3\JJ\1740 enzyme_4\NN\14723628 ,_5\,\1740 transketolase_6\NN\1740 ,_7\,\1740 from_8\IN\1740 fibroblasts_9\NNS\5447757 of_10\IN\1740 a_11\DT\13649268 diabetic_12\JJ\1740 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy_18\JJ\1740 when_19\WRB\1740 treated_20\VBN\2376958 with_21\IN\1740 <e1>tolazamide</e1>_22\RB\1740 ,_23\,\1740 in_24\IN\13603305 order_25\NN\7168131 to_26\TO\1740 delineate_27\VB\2137132 if_28\IN\1740 this_29\DT\1740 patient_30\NN\9898892 also_31\RB\1740 had_32\VBD\2108377 transketolase_33\NN\1740 abnormality_34\NN\14034177 [_35\-LRB-\1740 high_36\JJ\1740 km_37\NN\13649268 for_38\IN\1740 thiamine_39\NN\15090742 pyrophosphate_40\NN\15010703 (_41\-LRB-\1740 tpp_42\NN\1740 )_43\-RRB-\1740 ]_44\-RRB-\1740 ,_45\,\1740 as_46\IN\14622893 previously_47\RB\1740 reported_48\VBN\831651 in_49\IN\13603305 postalcoholic_50\JJ\1740 <e2>wernicke-korsakoff_51\JJ\1740 syndrome</e2>_52\NN\5870365 ._53\.\1740
D014042_D020915 NONE these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 a_3\DT\13649268 similarity_4\NN\4742535 between_5\IN\1740 postalcoholic_6\JJ\1740 <e2>wernicke-korsakoff_7\JJ\1740 syndrome</e2>_8\NN\5870365 and_9\CC\1740 the_10\DT\1740 patient_11\NN\9898892 with_12\IN\1740 <e1>tolazamide-induced</e1>_13\JJ\1740 wernicke_14\NNP\1740 's_15\POS\1740 encephalopathy_16\JJ\1740 from_17\IN\1740 the_18\DT\1740 standpoint_19\NN\6196284 of_20\IN\1740 transketolase_21\NN\1740 abnormality_22\NN\14034177 ._23\.\1740
D013835_D003920 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 thiamine-dependent_3\JJ\1740 enzyme_4\NN\14723628 ,_5\,\1740 transketolase_6\NN\1740 ,_7\,\1740 from_8\IN\1740 fibroblasts_9\NNS\5447757 of_10\IN\1740 a_11\DT\13649268 <e2>diabetic</e2>_12\JJ\1740 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy_18\JJ\1740 when_19\WRB\1740 treated_20\VBN\2376958 with_21\IN\1740 tolazamide_22\RB\1740 ,_23\,\1740 in_24\IN\13603305 order_25\NN\7168131 to_26\TO\1740 delineate_27\VB\2137132 if_28\IN\1740 this_29\DT\1740 patient_30\NN\9898892 also_31\RB\1740 had_32\VBD\2108377 transketolase_33\NN\1740 abnormality_34\NN\14034177 [_35\-LRB-\1740 high_36\JJ\1740 km_37\NN\13649268 for_38\IN\1740 <e1>thiamine_39\NN\15090742 pyrophosphate</e1>_40\NN\15010703 (_41\-LRB-\1740 tpp_42\NN\1740 )_43\-RRB-\1740 ]_44\-RRB-\1740 ,_45\,\1740 as_46\IN\14622893 previously_47\RB\1740 reported_48\VBN\831651 in_49\IN\13603305 postalcoholic_50\JJ\1740 wernicke-korsakoff_51\JJ\1740 syndrome_52\NN\5870365 ._53\.\1740
D013835_D003920 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 thiamine-dependent_3\JJ\1740 enzyme_4\NN\14723628 ,_5\,\1740 transketolase_6\NN\1740 ,_7\,\1740 from_8\IN\1740 fibroblasts_9\NNS\5447757 of_10\IN\1740 a_11\DT\13649268 <e2>diabetic</e2>_12\JJ\1740 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy_18\JJ\1740 when_19\WRB\1740 treated_20\VBN\2376958 with_21\IN\1740 tolazamide_22\RB\1740 ,_23\,\1740 in_24\IN\13603305 order_25\NN\7168131 to_26\TO\1740 delineate_27\VB\2137132 if_28\IN\1740 this_29\DT\1740 patient_30\NN\9898892 also_31\RB\1740 had_32\VBD\2108377 transketolase_33\NN\1740 abnormality_34\NN\14034177 [_35\-LRB-\1740 high_36\JJ\1740 km_37\NN\13649268 for_38\IN\1740 thiamine_39\NN\15090742 pyrophosphate_40\NN\15010703 (_41\-LRB-\1740 <e1>tpp</e1>_42\NN\1740 )_43\-RRB-\1740 ]_44\-RRB-\1740 ,_45\,\1740 as_46\IN\14622893 previously_47\RB\1740 reported_48\VBN\831651 in_49\IN\13603305 postalcoholic_50\JJ\1740 wernicke-korsakoff_51\JJ\1740 syndrome_52\NN\5870365 ._53\.\1740
D013835_D003920 NONE we_0\PRP\1740 found_1\VBD\2426171 that_2\IN\1740 the_3\DT\1740 above-mentioned_4\JJ\1740 patient_5\NN\9898892 and_6\CC\1740 one_7\CD\13741022 of_8\IN\1740 the_9\DT\1740 <e2>diabetic</e2>_10\JJ\1740 kindreds_11\NNS\7950920 with_12\IN\1740 no_13\DT\7204911 history_14\NN\15120823 of_15\IN\1740 wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy_18\JJ\1740 had_19\VBD\2108377 abnormal_20\JJ\1740 transketolase_21\NN\1740 as_22\IN\14622893 determined_23\VBN\1645601 by_24\IN\1740 its_25\PRP$\6125041 km_26\NNP\13649268 for_27\IN\1740 <e1>tpp</e1>_28\NNP\1740 ._29\.\1740
D013835_D014899 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 thiamine-dependent_3\JJ\1740 enzyme_4\NN\14723628 ,_5\,\1740 transketolase_6\NN\1740 ,_7\,\1740 from_8\IN\1740 fibroblasts_9\NNS\5447757 of_10\IN\1740 a_11\DT\13649268 diabetic_12\JJ\1740 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 <e2>wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy</e2>_18\JJ\1740 when_19\WRB\1740 treated_20\VBN\2376958 with_21\IN\1740 tolazamide_22\RB\1740 ,_23\,\1740 in_24\IN\13603305 order_25\NN\7168131 to_26\TO\1740 delineate_27\VB\2137132 if_28\IN\1740 this_29\DT\1740 patient_30\NN\9898892 also_31\RB\1740 had_32\VBD\2108377 transketolase_33\NN\1740 abnormality_34\NN\14034177 [_35\-LRB-\1740 high_36\JJ\1740 km_37\NN\13649268 for_38\IN\1740 <e1>thiamine_39\NN\15090742 pyrophosphate</e1>_40\NN\15010703 (_41\-LRB-\1740 tpp_42\NN\1740 )_43\-RRB-\1740 ]_44\-RRB-\1740 ,_45\,\1740 as_46\IN\14622893 previously_47\RB\1740 reported_48\VBN\831651 in_49\IN\13603305 postalcoholic_50\JJ\1740 wernicke-korsakoff_51\JJ\1740 syndrome_52\NN\5870365 ._53\.\1740
D013835_D014899 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 thiamine-dependent_3\JJ\1740 enzyme_4\NN\14723628 ,_5\,\1740 transketolase_6\NN\1740 ,_7\,\1740 from_8\IN\1740 fibroblasts_9\NNS\5447757 of_10\IN\1740 a_11\DT\13649268 diabetic_12\JJ\1740 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 <e2>wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy</e2>_18\JJ\1740 when_19\WRB\1740 treated_20\VBN\2376958 with_21\IN\1740 tolazamide_22\RB\1740 ,_23\,\1740 in_24\IN\13603305 order_25\NN\7168131 to_26\TO\1740 delineate_27\VB\2137132 if_28\IN\1740 this_29\DT\1740 patient_30\NN\9898892 also_31\RB\1740 had_32\VBD\2108377 transketolase_33\NN\1740 abnormality_34\NN\14034177 [_35\-LRB-\1740 high_36\JJ\1740 km_37\NN\13649268 for_38\IN\1740 thiamine_39\NN\15090742 pyrophosphate_40\NN\15010703 (_41\-LRB-\1740 <e1>tpp</e1>_42\NN\1740 )_43\-RRB-\1740 ]_44\-RRB-\1740 ,_45\,\1740 as_46\IN\14622893 previously_47\RB\1740 reported_48\VBN\831651 in_49\IN\13603305 postalcoholic_50\JJ\1740 wernicke-korsakoff_51\JJ\1740 syndrome_52\NN\5870365 ._53\.\1740
D013835_D014899 NONE we_0\PRP\1740 found_1\VBD\2426171 that_2\IN\1740 the_3\DT\1740 above-mentioned_4\JJ\1740 patient_5\NN\9898892 and_6\CC\1740 one_7\CD\13741022 of_8\IN\1740 the_9\DT\1740 diabetic_10\JJ\1740 kindreds_11\NNS\7950920 with_12\IN\1740 no_13\DT\7204911 history_14\NN\15120823 of_15\IN\1740 <e2>wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy</e2>_18\JJ\1740 had_19\VBD\2108377 abnormal_20\JJ\1740 transketolase_21\NN\1740 as_22\IN\14622893 determined_23\VBN\1645601 by_24\IN\1740 its_25\PRP$\6125041 km_26\NNP\13649268 for_27\IN\1740 <e1>tpp</e1>_28\NNP\1740 ._29\.\1740
D013835_D020915 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 thiamine-dependent_3\JJ\1740 enzyme_4\NN\14723628 ,_5\,\1740 transketolase_6\NN\1740 ,_7\,\1740 from_8\IN\1740 fibroblasts_9\NNS\5447757 of_10\IN\1740 a_11\DT\13649268 diabetic_12\JJ\1740 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy_18\JJ\1740 when_19\WRB\1740 treated_20\VBN\2376958 with_21\IN\1740 tolazamide_22\RB\1740 ,_23\,\1740 in_24\IN\13603305 order_25\NN\7168131 to_26\TO\1740 delineate_27\VB\2137132 if_28\IN\1740 this_29\DT\1740 patient_30\NN\9898892 also_31\RB\1740 had_32\VBD\2108377 transketolase_33\NN\1740 abnormality_34\NN\14034177 [_35\-LRB-\1740 high_36\JJ\1740 km_37\NN\13649268 for_38\IN\1740 <e1>thiamine_39\NN\15090742 pyrophosphate</e1>_40\NN\15010703 (_41\-LRB-\1740 tpp_42\NN\1740 )_43\-RRB-\1740 ]_44\-RRB-\1740 ,_45\,\1740 as_46\IN\14622893 previously_47\RB\1740 reported_48\VBN\831651 in_49\IN\13603305 postalcoholic_50\JJ\1740 <e2>wernicke-korsakoff_51\JJ\1740 syndrome</e2>_52\NN\5870365 ._53\.\1740
D013835_D020915 NONE we_0\PRP\1740 studied_1\VBD\630380 a_2\DT\13649268 thiamine-dependent_3\JJ\1740 enzyme_4\NN\14723628 ,_5\,\1740 transketolase_6\NN\1740 ,_7\,\1740 from_8\IN\1740 fibroblasts_9\NNS\5447757 of_10\IN\1740 a_11\DT\13649268 diabetic_12\JJ\1740 patient_13\NN\9898892 who_14\WP\8299493 developed_15\VBD\1753788 wernicke_16\NNP\1740 's_17\POS\1740 encephalopathy_18\JJ\1740 when_19\WRB\1740 treated_20\VBN\2376958 with_21\IN\1740 tolazamide_22\RB\1740 ,_23\,\1740 in_24\IN\13603305 order_25\NN\7168131 to_26\TO\1740 delineate_27\VB\2137132 if_28\IN\1740 this_29\DT\1740 patient_30\NN\9898892 also_31\RB\1740 had_32\VBD\2108377 transketolase_33\NN\1740 abnormality_34\NN\14034177 [_35\-LRB-\1740 high_36\JJ\1740 km_37\NN\13649268 for_38\IN\1740 thiamine_39\NN\15090742 pyrophosphate_40\NN\15010703 (_41\-LRB-\1740 <e1>tpp</e1>_42\NN\1740 )_43\-RRB-\1740 ]_44\-RRB-\1740 ,_45\,\1740 as_46\IN\14622893 previously_47\RB\1740 reported_48\VBN\831651 in_49\IN\13603305 postalcoholic_50\JJ\1740 <e2>wernicke-korsakoff_51\JJ\1740 syndrome</e2>_52\NN\5870365 ._53\.\1740
3732088
D011188_D001145 NONE diuretics_0\NNS\3247620 ,_1\,\1740 <e1>potassium</e1>_2\NN\14625458 and_3\CC\1740 <e2>arrhythmias</e2>_4\VBZ\1740 in_5\IN\13603305 hypertensive_6\JJ\1740 coronary_7\JJ\1740 disease_8\NN\14061805 ._9\.\1740
D011188_D001145 NONE it_0\PRP\6125041 has_1\VBZ\2108377 been_2\VBN\836236 proposed_3\VBN\1010118 that_4\IN\1740 modest_5\JJ\1740 changes_6\NNS\7283608 in_7\IN\13603305 plasma_8\NN\5398023 <e1>potassium</e1>_9\NN\14625458 can_10\MD\3094503 alter_11\VB\126264 the_12\DT\1740 tendency_13\NN\6193203 towards_14\IN\1740 <e2>cardiac_15\JJ\1740 arrhythmias</e2>_16\NNS\14103288 ._17\.\1740
D011188_D006973 NONE diuretics_0\NNS\3247620 ,_1\,\1740 <e1>potassium</e1>_2\NN\14625458 and_3\CC\1740 arrhythmias_4\VBZ\1740 in_5\IN\13603305 <e2>hypertensive</e2>_6\JJ\1740 coronary_7\JJ\1740 disease_8\NN\14061805 ._9\.\1740
D011188_D006973 NONE thus_0\RB\1740 ,_1\,\1740 myocardial_2\JJ\1740 electrical_3\JJ\1740 excitability_4\NN\5653575 was_5\VBD\836236 measured_6\VBN\697589 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 mild_10\JJ\1740 essential_11\JJ\1740 <e2>hypertension</e2>_12\NN\14057371 and_13\CC\1740 known_14\JJ\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 after_18\IN\1740 8_19\CD\13741022 weeks_20\NNS\15113229 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 a_24\DT\13649268 <e1>potassium-conserving</e1>_25\JJ\1740 diuretic_26\NN\3247620 (_27\-LRB-\1740 amiloride_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 a_31\DT\13649268 similar_32\JJ\1740 period_33\NN\13575869 on_34\IN\1740 a_35\DT\13649268 potassium-losing_36\JJ\1740 diuretic_37\NN\3247620 (_38\-LRB-\1740 chlorthalidone_39\NN\3214670 )_40\-RRB-\1740 in_41\IN\13603305 a_42\DT\13649268 randomised_43\VBN\278117 study_44\NN\635850 ._45\.\1740
D011188_D006973 NONE thus_0\RB\1740 ,_1\,\1740 myocardial_2\JJ\1740 electrical_3\JJ\1740 excitability_4\NN\5653575 was_5\VBD\836236 measured_6\VBN\697589 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 mild_10\JJ\1740 essential_11\JJ\1740 <e2>hypertension</e2>_12\NN\14057371 and_13\CC\1740 known_14\JJ\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 after_18\IN\1740 8_19\CD\13741022 weeks_20\NNS\15113229 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 a_24\DT\13649268 potassium-conserving_25\JJ\1740 diuretic_26\NN\3247620 (_27\-LRB-\1740 amiloride_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 a_31\DT\13649268 similar_32\JJ\1740 period_33\NN\13575869 on_34\IN\1740 a_35\DT\13649268 <e1>potassium-losing</e1>_36\JJ\1740 diuretic_37\NN\3247620 (_38\-LRB-\1740 chlorthalidone_39\NN\3214670 )_40\-RRB-\1740 in_41\IN\13603305 a_42\DT\13649268 randomised_43\VBN\278117 study_44\NN\635850 ._45\.\1740
D011188_D003327 NONE diuretics_0\NNS\3247620 ,_1\,\1740 <e1>potassium</e1>_2\NN\14625458 and_3\CC\1740 arrhythmias_4\VBZ\1740 in_5\IN\13603305 hypertensive_6\JJ\1740 <e2>coronary_7\JJ\1740 disease</e2>_8\NN\14061805 ._9\.\1740
D011188_D003324 NONE thus_0\RB\1740 ,_1\,\1740 myocardial_2\JJ\1740 electrical_3\JJ\1740 excitability_4\NN\5653575 was_5\VBD\836236 measured_6\VBN\697589 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 mild_10\JJ\1740 essential_11\JJ\1740 hypertension_12\NN\14057371 and_13\CC\1740 known_14\JJ\1740 <e2>coronary_15\JJ\1740 artery_16\NN\5417975 disease</e2>_17\NN\14061805 after_18\IN\1740 8_19\CD\13741022 weeks_20\NNS\15113229 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 a_24\DT\13649268 <e1>potassium-conserving</e1>_25\JJ\1740 diuretic_26\NN\3247620 (_27\-LRB-\1740 amiloride_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 a_31\DT\13649268 similar_32\JJ\1740 period_33\NN\13575869 on_34\IN\1740 a_35\DT\13649268 potassium-losing_36\JJ\1740 diuretic_37\NN\3247620 (_38\-LRB-\1740 chlorthalidone_39\NN\3214670 )_40\-RRB-\1740 in_41\IN\13603305 a_42\DT\13649268 randomised_43\VBN\278117 study_44\NN\635850 ._45\.\1740
D011188_D003324 NONE thus_0\RB\1740 ,_1\,\1740 myocardial_2\JJ\1740 electrical_3\JJ\1740 excitability_4\NN\5653575 was_5\VBD\836236 measured_6\VBN\697589 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 mild_10\JJ\1740 essential_11\JJ\1740 hypertension_12\NN\14057371 and_13\CC\1740 known_14\JJ\1740 <e2>coronary_15\JJ\1740 artery_16\NN\5417975 disease</e2>_17\NN\14061805 after_18\IN\1740 8_19\CD\13741022 weeks_20\NNS\15113229 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 a_24\DT\13649268 potassium-conserving_25\JJ\1740 diuretic_26\NN\3247620 (_27\-LRB-\1740 amiloride_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 a_31\DT\13649268 similar_32\JJ\1740 period_33\NN\13575869 on_34\IN\1740 a_35\DT\13649268 <e1>potassium-losing</e1>_36\JJ\1740 diuretic_37\NN\3247620 (_38\-LRB-\1740 chlorthalidone_39\NN\3214670 )_40\-RRB-\1740 in_41\IN\13603305 a_42\DT\13649268 randomised_43\VBN\278117 study_44\NN\635850 ._45\.\1740
D000584_D006973 NONE thus_0\RB\1740 ,_1\,\1740 myocardial_2\JJ\1740 electrical_3\JJ\1740 excitability_4\NN\5653575 was_5\VBD\836236 measured_6\VBN\697589 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 mild_10\JJ\1740 essential_11\JJ\1740 <e2>hypertension</e2>_12\NN\14057371 and_13\CC\1740 known_14\JJ\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 after_18\IN\1740 8_19\CD\13741022 weeks_20\NNS\15113229 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 a_24\DT\13649268 potassium-conserving_25\JJ\1740 diuretic_26\NN\3247620 (_27\-LRB-\1740 <e1>amiloride</e1>_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 a_31\DT\13649268 similar_32\JJ\1740 period_33\NN\13575869 on_34\IN\1740 a_35\DT\13649268 potassium-losing_36\JJ\1740 diuretic_37\NN\3247620 (_38\-LRB-\1740 chlorthalidone_39\NN\3214670 )_40\-RRB-\1740 in_41\IN\13603305 a_42\DT\13649268 randomised_43\VBN\278117 study_44\NN\635850 ._45\.\1740
D000584_D003324 NONE thus_0\RB\1740 ,_1\,\1740 myocardial_2\JJ\1740 electrical_3\JJ\1740 excitability_4\NN\5653575 was_5\VBD\836236 measured_6\VBN\697589 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 mild_10\JJ\1740 essential_11\JJ\1740 hypertension_12\NN\14057371 and_13\CC\1740 known_14\JJ\1740 <e2>coronary_15\JJ\1740 artery_16\NN\5417975 disease</e2>_17\NN\14061805 after_18\IN\1740 8_19\CD\13741022 weeks_20\NNS\15113229 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 a_24\DT\13649268 potassium-conserving_25\JJ\1740 diuretic_26\NN\3247620 (_27\-LRB-\1740 <e1>amiloride</e1>_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 a_31\DT\13649268 similar_32\JJ\1740 period_33\NN\13575869 on_34\IN\1740 a_35\DT\13649268 potassium-losing_36\JJ\1740 diuretic_37\NN\3247620 (_38\-LRB-\1740 chlorthalidone_39\NN\3214670 )_40\-RRB-\1740 in_41\IN\13603305 a_42\DT\13649268 randomised_43\VBN\278117 study_44\NN\635850 ._45\.\1740
D002752_D006973 NONE thus_0\RB\1740 ,_1\,\1740 myocardial_2\JJ\1740 electrical_3\JJ\1740 excitability_4\NN\5653575 was_5\VBD\836236 measured_6\VBN\697589 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 mild_10\JJ\1740 essential_11\JJ\1740 <e2>hypertension</e2>_12\NN\14057371 and_13\CC\1740 known_14\JJ\1740 coronary_15\JJ\1740 artery_16\NN\5417975 disease_17\NN\14061805 after_18\IN\1740 8_19\CD\13741022 weeks_20\NNS\15113229 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 a_24\DT\13649268 potassium-conserving_25\JJ\1740 diuretic_26\NN\3247620 (_27\-LRB-\1740 amiloride_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 a_31\DT\13649268 similar_32\JJ\1740 period_33\NN\13575869 on_34\IN\1740 a_35\DT\13649268 potassium-losing_36\JJ\1740 diuretic_37\NN\3247620 (_38\-LRB-\1740 <e1>chlorthalidone</e1>_39\NN\3214670 )_40\-RRB-\1740 in_41\IN\13603305 a_42\DT\13649268 randomised_43\VBN\278117 study_44\NN\635850 ._45\.\1740
D002752_D003324 NONE thus_0\RB\1740 ,_1\,\1740 myocardial_2\JJ\1740 electrical_3\JJ\1740 excitability_4\NN\5653575 was_5\VBD\836236 measured_6\VBN\697589 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 mild_10\JJ\1740 essential_11\JJ\1740 hypertension_12\NN\14057371 and_13\CC\1740 known_14\JJ\1740 <e2>coronary_15\JJ\1740 artery_16\NN\5417975 disease</e2>_17\NN\14061805 after_18\IN\1740 8_19\CD\13741022 weeks_20\NNS\15113229 of_21\IN\1740 treatment_22\NN\654885 with_23\IN\1740 a_24\DT\13649268 potassium-conserving_25\JJ\1740 diuretic_26\NN\3247620 (_27\-LRB-\1740 amiloride_28\NN\1740 )_29\-RRB-\1740 and_30\CC\1740 a_31\DT\13649268 similar_32\JJ\1740 period_33\NN\13575869 on_34\IN\1740 a_35\DT\13649268 potassium-losing_36\JJ\1740 diuretic_37\NN\3247620 (_38\-LRB-\1740 <e1>chlorthalidone</e1>_39\NN\3214670 )_40\-RRB-\1740 in_41\IN\13603305 a_42\DT\13649268 randomised_43\VBN\278117 study_44\NN\635850 ._45\.\1740
D000584_D018879 NONE compared_0\VBN\644583 to_1\TO\1740 <e1>amiloride</e1>_2\NN\1740 treatment_3\NN\654885 ,_4\,\1740 the_5\DT\1740 chlorthalidone_6\NN\3214670 phase_7\NN\15113229 was_8\VBD\836236 associated_9\VBN\628491 with_10\IN\1740 an_11\DT\6697703 increased_12\VBN\169651 frequency_13\NN\15286249 of_14\IN\1740 <e2>ventricular_15\JJ\1740 ectopic_16\JJ\1740 beats</e2>_17\NNS\8289449 (_18\-LRB-\1740 24-hour_19\JJ\1740 holter_20\NNP\1740 monitoring_21\NN\879759 )_22\-RRB-\1740 and_23\CC\1740 a_24\DT\13649268 higher_25\JJR\1740 lown_26\NNP\1740 grading_27\NN\1009871 ,_28\,\1740 increased_29\VBD\169651 upslope_30\NN\1740 and_31\CC\1740 duration_32\NN\15113229 of_33\IN\1740 the_34\DT\1740 monophasic_35\JJ\1740 action_36\NN\30358 potential_37\NN\14481929 ,_38\,\1740 prolonged_39\JJ\1740 ventricular_40\JJ\1740 effective_41\JJ\1740 refractory_42\JJ\1740 period_43\NN\13575869 ,_44\,\1740 and_45\CC\1740 increased_46\VBN\169651 electrical_47\JJ\1740 instability_48\NN\13972797 during_49\IN\1740 programmed_50\VBN\794981 ventricular_51\NN\1740 stimulation_52\NN\242808 ._53\.\1740
D002752_D018879 CID compared_0\VBN\644583 to_1\TO\1740 amiloride_2\NN\1740 treatment_3\NN\654885 ,_4\,\1740 the_5\DT\1740 <e1>chlorthalidone</e1>_6\NN\3214670 phase_7\NN\15113229 was_8\VBD\836236 associated_9\VBN\628491 with_10\IN\1740 an_11\DT\6697703 increased_12\VBN\169651 frequency_13\NN\15286249 of_14\IN\1740 <e2>ventricular_15\JJ\1740 ectopic_16\JJ\1740 beats</e2>_17\NNS\8289449 (_18\-LRB-\1740 24-hour_19\JJ\1740 holter_20\NNP\1740 monitoring_21\NN\879759 )_22\-RRB-\1740 and_23\CC\1740 a_24\DT\13649268 higher_25\JJR\1740 lown_26\NNP\1740 grading_27\NN\1009871 ,_28\,\1740 increased_29\VBD\169651 upslope_30\NN\1740 and_31\CC\1740 duration_32\NN\15113229 of_33\IN\1740 the_34\DT\1740 monophasic_35\JJ\1740 action_36\NN\30358 potential_37\NN\14481929 ,_38\,\1740 prolonged_39\JJ\1740 ventricular_40\JJ\1740 effective_41\JJ\1740 refractory_42\JJ\1740 period_43\NN\13575869 ,_44\,\1740 and_45\CC\1740 increased_46\VBN\169651 electrical_47\JJ\1740 instability_48\NN\13972797 during_49\IN\1740 programmed_50\VBN\794981 ventricular_51\NN\1740 stimulation_52\NN\242808 ._53\.\1740
D011188_D017202 NONE the_0\DT\1740 above_1\JJ\1740 results_2\NNS\34213 indicate_3\VBP\952524 that_4\IN\1740 because_5\IN\1740 <e1>potassium-losing</e1>_6\JJ\1740 diuretic_7\NN\3247620 therapy_8\NN\657604 can_9\MD\3094503 increase_10\VB\169651 myocardial_11\JJ\1740 electrical_12\JJ\1740 excitability_13\NN\5653575 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 <e2>ischaemic_17\JJ\1740 heart_18\NN\5919034 disease</e2>_19\NN\14061805 ,_20\,\1740 even_21\RB\1740 minor_22\JJ\1740 falls_23\NNS\11692265 in_24\IN\13603305 plasma_25\NN\5398023 potassium_26\NN\14625458 concentrations_27\NNS\4916342 are_28\VBP\836236 probably_29\RB\1740 best_30\RBS\1740 avoided_31\VBN\2452885 in_32\IN\13603305 such_33\JJ\1740 patients_34\NNS\9898892 ._35\.\1740
D011188_D017202 NONE the_0\DT\1740 above_1\JJ\1740 results_2\NNS\34213 indicate_3\VBP\952524 that_4\IN\1740 because_5\IN\1740 potassium-losing_6\JJ\1740 diuretic_7\NN\3247620 therapy_8\NN\657604 can_9\MD\3094503 increase_10\VB\169651 myocardial_11\JJ\1740 electrical_12\JJ\1740 excitability_13\NN\5653575 in_14\IN\13603305 patients_15\NNS\9898892 with_16\IN\1740 <e2>ischaemic_17\JJ\1740 heart_18\NN\5919034 disease</e2>_19\NN\14061805 ,_20\,\1740 even_21\RB\1740 minor_22\JJ\1740 falls_23\NNS\11692265 in_24\IN\13603305 plasma_25\NN\5398023 <e1>potassium</e1>_26\NN\14625458 concentrations_27\NNS\4916342 are_28\VBP\836236 probably_29\RB\1740 best_30\RBS\1740 avoided_31\VBN\2452885 in_32\IN\13603305 such_33\JJ\1740 patients_34\NNS\9898892 ._35\.\1740
3137399
D016685_D066126 NONE a_0\DT\13649268 prospective_1\JJ\1740 study_2\NN\635850 on_3\IN\1740 the_4\DT\1740 dose_5\NN\3740161 dependency_6\NN\24720 of_7\IN\1740 <e2>cardiotoxicity</e2>_8\NN\1740 induced_9\VBN\1627355 by_10\IN\1740 <e1>mitomycin_11\NN\2716866 c.</e1>_12\NN\1740
D016685_D066126 NONE since_0\IN\1740 1975_1\CD\1740 <e1>mitomycin_2\NN\2716866 c</e1>_3\NN\13714184 (_4\-LRB-\1740 mmc_5\NN\1740 )_6\-RRB-\1740 has_7\VBZ\2108377 been_8\VBN\836236 suggested_9\VBN\1010118 to_10\TO\1740 be_11\VB\836236 <e2>cardiotoxic</e2>_12\JJ\1740 ,_13\,\1740 especially_14\RB\1740 when_15\WRB\1740 combined_16\VBN\2630189 with_17\IN\1740 or_18\CC\3541091 given_19\VBN\2327200 following_20\VBG\1835496 doxorubicin_21\NN\2716866 ._22\.\1740
D016685_D066126 NONE since_0\IN\1740 1975_1\CD\1740 mitomycin_2\NN\2716866 c_3\NN\13714184 (_4\-LRB-\1740 <e1>mmc</e1>_5\NN\1740 )_6\-RRB-\1740 has_7\VBZ\2108377 been_8\VBN\836236 suggested_9\VBN\1010118 to_10\TO\1740 be_11\VB\836236 <e2>cardiotoxic</e2>_12\JJ\1740 ,_13\,\1740 especially_14\RB\1740 when_15\WRB\1740 combined_16\VBN\2630189 with_17\IN\1740 or_18\CC\3541091 given_19\VBN\2327200 following_20\VBG\1835496 doxorubicin_21\NN\2716866 ._22\.\1740
D016685_D066126 NONE based_0\VBN\2694933 on_1\IN\1740 the_2\DT\1740 combined_3\JJ\1740 data_4\NNS\7951464 from_5\IN\1740 the_6\DT\1740 present_7\JJ\1740 study_8\NN\635850 and_9\CC\1740 the_10\DT\1740 literature_11\NN\6362953 ,_12\,\1740 we_13\PRP\1740 suggest_14\VBP\1010118 that_15\IN\1740 <e1>mmc-related</e1>_16\JJ\1740 <e2>cardiotoxicity</e2>_17\NN\1740 is_18\VBZ\836236 dose_19\NN\3740161 dependent_20\JJ\1740 ,_21\,\1740 occurring_22\VBG\2623529 at_23\IN\14622893 cumulative_24\JJ\1740 dose_25\NN\3740161 levels_26\NNS\4916342 of_27\IN\1740 30_28\CD\13745420 mg_29\NN\13717155 m-2_30\NN\1740 or_31\CC\3541091 more_32\JJR\1740 ,_33\,\1740 mainly_34\RB\1740 in_35\IN\13603305 patients_36\NNS\9898892 also_37\RB\1740 (_38\-LRB-\1740 previously_39\RB\1740 or_40\CC\3541091 simultaneously_41\RB\1740 )_42\-RRB-\1740 treated_43\VBN\2376958 with_44\IN\1740 doxorubicin_45\NN\2716866 ._46\.\1740
D004317_D066126 NONE since_0\IN\1740 1975_1\CD\1740 mitomycin_2\NN\2716866 c_3\NN\13714184 (_4\-LRB-\1740 mmc_5\NN\1740 )_6\-RRB-\1740 has_7\VBZ\2108377 been_8\VBN\836236 suggested_9\VBN\1010118 to_10\TO\1740 be_11\VB\836236 <e2>cardiotoxic</e2>_12\JJ\1740 ,_13\,\1740 especially_14\RB\1740 when_15\WRB\1740 combined_16\VBN\2630189 with_17\IN\1740 or_18\CC\3541091 given_19\VBN\2327200 following_20\VBG\1835496 <e1>doxorubicin</e1>_21\NN\2716866 ._22\.\1740
D004317_D066126 NONE based_0\VBN\2694933 on_1\IN\1740 the_2\DT\1740 combined_3\JJ\1740 data_4\NNS\7951464 from_5\IN\1740 the_6\DT\1740 present_7\JJ\1740 study_8\NN\635850 and_9\CC\1740 the_10\DT\1740 literature_11\NN\6362953 ,_12\,\1740 we_13\PRP\1740 suggest_14\VBP\1010118 that_15\IN\1740 mmc-related_16\JJ\1740 <e2>cardiotoxicity</e2>_17\NN\1740 is_18\VBZ\836236 dose_19\NN\3740161 dependent_20\JJ\1740 ,_21\,\1740 occurring_22\VBG\2623529 at_23\IN\14622893 cumulative_24\JJ\1740 dose_25\NN\3740161 levels_26\NNS\4916342 of_27\IN\1740 30_28\CD\13745420 mg_29\NN\13717155 m-2_30\NN\1740 or_31\CC\3541091 more_32\JJR\1740 ,_33\,\1740 mainly_34\RB\1740 in_35\IN\13603305 patients_36\NNS\9898892 also_37\RB\1740 (_38\-LRB-\1740 previously_39\RB\1740 or_40\CC\3541091 simultaneously_41\RB\1740 )_42\-RRB-\1740 treated_43\VBN\2376958 with_44\IN\1740 <e1>doxorubicin</e1>_45\NN\2716866 ._46\.\1740
D016685_D006333 CID one_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 patients_3\NNS\9898892 developed_4\VBD\1753788 <e2>cardiac_5\JJ\1740 failure</e2>_6\NN\66216 after_7\IN\1740 30_8\CD\13745420 mg_9\NN\13717155 m-2_10\NN\1740 <e1>mmc</e1>_11\NN\1740 and_12\CC\1740 only_13\RB\1740 150_14\CD\1740 mg_15\NN\13717155 m-2_16\NN\1740 doxorubicin_17\NN\2716866 ._18\.\1740
D004317_D006333 CID one_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 patients_3\NNS\9898892 developed_4\VBD\1753788 <e2>cardiac_5\JJ\1740 failure</e2>_6\NN\66216 after_7\IN\1740 30_8\CD\13745420 mg_9\NN\13717155 m-2_10\NN\1740 mmc_11\NN\1740 and_12\CC\1740 only_13\RB\1740 150_14\CD\1740 mg_15\NN\13717155 m-2_16\NN\1740 <e1>doxorubicin</e1>_17\NN\2716866 ._18\.\1740
761833
D000641_D003128 NONE reversal_0\NN\199130 of_1\IN\1740 <e1>ammonia</e1>_2\JJ\1740 <e2>coma</e2>_3\NN\5678932 in_4\IN\13603305 rats_5\NNS\2329401 by_6\IN\1740 l-dopa_7\NN\14604959 :_8\:\1740 a_9\DT\13649268 peripheral_10\JJ\1740 effect_11\NN\34213 ._12\.\1740
D000641_D003128 NONE <e1>ammonia</e1>_0\JJ\1740 <e2>coma</e2>_1\NN\5678932 was_2\VBD\836236 produced_3\VBN\1617192 in_4\IN\13603305 rats_5\NNS\2329401 within_6\IN\1740 10_7\CD\13745420 to_8\TO\1740 15_9\CD\13745420 minutes_10\NNS\6502378 of_11\IN\1740 an_12\DT\6697703 intraperitonealinjection_13\NN\1740 of_14\IN\1740 1.7_15\CD\1740 mmol_16\NN\1740 nh4cl_17\NN\1740 ._18\.\1740
D000641_D003128 NONE intraventricular_0\JJ\1740 infusion_1\NN\14589223 of_2\IN\1740 dopamine_3\NN\14807737 sufficient_4\JJ\1740 to_5\TO\1740 raise_6\VB\153263 the_7\DT\1740 brain_8\NN\5462674 dopamine_9\NN\14807737 to_10\TO\1740 the_11\DT\1740 same_12\JJ\1740 extent_13\NN\13939892 did_14\VBD\1640855 not_15\RB\1740 prevent_16\VB\1740 the_17\DT\1740 <e1>ammonia</e1>_18\JJ\1740 <e2>coma</e2>_19\NN\5678932 nor_20\CC\1740 affect_21\VBP\126264 the_22\DT\1740 blood_23\NN\5397468 and_24\CC\1740 brain_25\NN\5462674 ammonia_26\NN\14940386 concentrations_27\NNS\4916342 ._28\.\1740
D000641_D003128 NONE intraventricular_0\JJ\1740 infusion_1\NN\14589223 of_2\IN\1740 dopamine_3\NN\14807737 sufficient_4\JJ\1740 to_5\TO\1740 raise_6\VB\153263 the_7\DT\1740 brain_8\NN\5462674 dopamine_9\NN\14807737 to_10\TO\1740 the_11\DT\1740 same_12\JJ\1740 extent_13\NN\13939892 did_14\VBD\1640855 not_15\RB\1740 prevent_16\VB\1740 the_17\DT\1740 ammonia_18\JJ\1740 <e2>coma</e2>_19\NN\5678932 nor_20\CC\1740 affect_21\VBP\126264 the_22\DT\1740 blood_23\NN\5397468 and_24\CC\1740 brain_25\NN\5462674 <e1>ammonia</e1>_26\NN\14940386 concentrations_27\NNS\4916342 ._28\.\1740
D000641_D003128 NONE bilateral_0\JJ\1740 nephrectomy_1\NN\393369 eliminated_2\VBD\1619929 the_3\DT\1740 beneficial_4\JJ\1740 effect_5\NN\34213 of_6\IN\1740 l-dopa_7\NN\14604959 on_8\IN\1740 blood_9\NN\5397468 and_10\CC\1740 brain_11\NN\5462674 <e1>ammonia</e1>_12\NN\14940386 and_13\CC\1740 the_14\DT\1740 ammonia_15\JJ\1740 <e2>coma</e2>_16\NN\5678932 was_17\VBD\836236 not_18\RB\1740 prevented_19\VBN\1740 ._20\.\1740
D000641_D003128 NONE bilateral_0\JJ\1740 nephrectomy_1\NN\393369 eliminated_2\VBD\1619929 the_3\DT\1740 beneficial_4\JJ\1740 effect_5\NN\34213 of_6\IN\1740 l-dopa_7\NN\14604959 on_8\IN\1740 blood_9\NN\5397468 and_10\CC\1740 brain_11\NN\5462674 ammonia_12\NN\14940386 and_13\CC\1740 the_14\DT\1740 <e1>ammonia</e1>_15\JJ\1740 <e2>coma</e2>_16\NN\5678932 was_17\VBD\836236 not_18\RB\1740 prevented_19\VBN\1740 ._20\.\1740
D000641_D003128 NONE thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 reduction_3\NN\351485 in_4\IN\13603305 blood_5\NN\5397468 and_6\CC\1740 brain_7\NN\5462674 <e1>ammonia</e1>_8\NN\14940386 and_9\CC\1740 the_10\DT\1740 prevention_11\NN\1073995 of_12\IN\1740 ammonia_13\JJ\1740 <e2>coma</e2>_14\NN\5678932 after_15\IN\1740 l-dopa_16\JJ\1740 ,_17\,\1740 can_18\MD\3094503 be_19\VB\836236 accounted_20\VBN\2604760 for_21\IN\1740 by_22\IN\1740 the_23\DT\1740 peripheral_24\JJ\1740 effect_25\NN\34213 of_26\IN\1740 dopamine_27\NN\14807737 on_28\IN\1740 renal_29\JJ\1740 function_30\NN\13783581 rather_31\RB\1740 than_32\IN\1740 its_33\PRP$\6125041 central_34\JJ\1740 action_35\NN\30358 ._36\.\1740
D000641_D003128 NONE thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 reduction_3\NN\351485 in_4\IN\13603305 blood_5\NN\5397468 and_6\CC\1740 brain_7\NN\5462674 ammonia_8\NN\14940386 and_9\CC\1740 the_10\DT\1740 prevention_11\NN\1073995 of_12\IN\1740 <e1>ammonia</e1>_13\JJ\1740 <e2>coma</e2>_14\NN\5678932 after_15\IN\1740 l-dopa_16\JJ\1740 ,_17\,\1740 can_18\MD\3094503 be_19\VB\836236 accounted_20\VBN\2604760 for_21\IN\1740 by_22\IN\1740 the_23\DT\1740 peripheral_24\JJ\1740 effect_25\NN\34213 of_26\IN\1740 dopamine_27\NN\14807737 on_28\IN\1740 renal_29\JJ\1740 function_30\NN\13783581 rather_31\RB\1740 than_32\IN\1740 its_33\PRP$\6125041 central_34\JJ\1740 action_35\NN\30358 ._36\.\1740
D007980_D003128 NONE reversal_0\NN\199130 of_1\IN\1740 ammonia_2\JJ\1740 <e2>coma</e2>_3\NN\5678932 in_4\IN\13603305 rats_5\NNS\2329401 by_6\IN\1740 <e1>l-dopa</e1>_7\NN\14604959 :_8\:\1740 a_9\DT\13649268 peripheral_10\JJ\1740 effect_11\NN\34213 ._12\.\1740
D007980_D003128 NONE this_0\DT\1740 <e2>coma</e2>_1\NN\5678932 was_2\VBD\836236 prevented_3\VBN\1740 with_4\IN\1740 1.68_5\CD\1740 mmol_6\NN\1740 <e1>l-dopa</e1>_7\NN\14604959 given_8\VBN\2327200 by_9\IN\1740 gastric_10\JJ\1740 intubation_11\NN\320852 15_12\CD\13745420 minutes_13\NNS\6502378 before_14\IN\1740 the_15\DT\1740 ammonium_16\NN\14743582 salt_17\NN\14818238 injection_18\NN\320852 ._19\.\1740
D007980_D003128 NONE bilateral_0\JJ\1740 nephrectomy_1\NN\393369 eliminated_2\VBD\1619929 the_3\DT\1740 beneficial_4\JJ\1740 effect_5\NN\34213 of_6\IN\1740 <e1>l-dopa</e1>_7\NN\14604959 on_8\IN\1740 blood_9\NN\5397468 and_10\CC\1740 brain_11\NN\5462674 ammonia_12\NN\14940386 and_13\CC\1740 the_14\DT\1740 ammonia_15\JJ\1740 <e2>coma</e2>_16\NN\5678932 was_17\VBD\836236 not_18\RB\1740 prevented_19\VBN\1740 ._20\.\1740
D007980_D003128 NONE thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 reduction_3\NN\351485 in_4\IN\13603305 blood_5\NN\5397468 and_6\CC\1740 brain_7\NN\5462674 ammonia_8\NN\14940386 and_9\CC\1740 the_10\DT\1740 prevention_11\NN\1073995 of_12\IN\1740 ammonia_13\JJ\1740 <e2>coma</e2>_14\NN\5678932 after_15\IN\1740 <e1>l-dopa</e1>_16\JJ\1740 ,_17\,\1740 can_18\MD\3094503 be_19\VB\836236 accounted_20\VBN\2604760 for_21\IN\1740 by_22\IN\1740 the_23\DT\1740 peripheral_24\JJ\1740 effect_25\NN\34213 of_26\IN\1740 dopamine_27\NN\14807737 on_28\IN\1740 renal_29\JJ\1740 function_30\NN\13783581 rather_31\RB\1740 than_32\IN\1740 its_33\PRP$\6125041 central_34\JJ\1740 action_35\NN\30358 ._36\.\1740
D000643_D003128 CID ammonia_0\JJ\1740 <e2>coma</e2>_1\NN\5678932 was_2\VBD\836236 produced_3\VBN\1617192 in_4\IN\13603305 rats_5\NNS\2329401 within_6\IN\1740 10_7\CD\13745420 to_8\TO\1740 15_9\CD\13745420 minutes_10\NNS\6502378 of_11\IN\1740 an_12\DT\6697703 intraperitonealinjection_13\NN\1740 of_14\IN\1740 1.7_15\CD\1740 mmol_16\NN\1740 <e1>nh4cl</e1>_17\NN\1740 ._18\.\1740
D064751_D003128 NONE this_0\DT\1740 <e2>coma</e2>_1\NN\5678932 was_2\VBD\836236 prevented_3\VBN\1740 with_4\IN\1740 1.68_5\CD\1740 mmol_6\NN\1740 l-dopa_7\NN\14604959 given_8\VBN\2327200 by_9\IN\1740 gastric_10\JJ\1740 intubation_11\NN\320852 15_12\CD\13745420 minutes_13\NNS\6502378 before_14\IN\1740 the_15\DT\1740 <e1>ammonium_16\NN\14743582 salt</e1>_17\NN\14818238 injection_18\NN\320852 ._19\.\1740
D004298_D003128 NONE intraventricular_0\JJ\1740 infusion_1\NN\14589223 of_2\IN\1740 <e1>dopamine</e1>_3\NN\14807737 sufficient_4\JJ\1740 to_5\TO\1740 raise_6\VB\153263 the_7\DT\1740 brain_8\NN\5462674 dopamine_9\NN\14807737 to_10\TO\1740 the_11\DT\1740 same_12\JJ\1740 extent_13\NN\13939892 did_14\VBD\1640855 not_15\RB\1740 prevent_16\VB\1740 the_17\DT\1740 ammonia_18\JJ\1740 <e2>coma</e2>_19\NN\5678932 nor_20\CC\1740 affect_21\VBP\126264 the_22\DT\1740 blood_23\NN\5397468 and_24\CC\1740 brain_25\NN\5462674 ammonia_26\NN\14940386 concentrations_27\NNS\4916342 ._28\.\1740
D004298_D003128 NONE intraventricular_0\JJ\1740 infusion_1\NN\14589223 of_2\IN\1740 dopamine_3\NN\14807737 sufficient_4\JJ\1740 to_5\TO\1740 raise_6\VB\153263 the_7\DT\1740 brain_8\NN\5462674 <e1>dopamine</e1>_9\NN\14807737 to_10\TO\1740 the_11\DT\1740 same_12\JJ\1740 extent_13\NN\13939892 did_14\VBD\1640855 not_15\RB\1740 prevent_16\VB\1740 the_17\DT\1740 ammonia_18\JJ\1740 <e2>coma</e2>_19\NN\5678932 nor_20\CC\1740 affect_21\VBP\126264 the_22\DT\1740 blood_23\NN\5397468 and_24\CC\1740 brain_25\NN\5462674 ammonia_26\NN\14940386 concentrations_27\NNS\4916342 ._28\.\1740
D004298_D003128 NONE thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 reduction_3\NN\351485 in_4\IN\13603305 blood_5\NN\5397468 and_6\CC\1740 brain_7\NN\5462674 ammonia_8\NN\14940386 and_9\CC\1740 the_10\DT\1740 prevention_11\NN\1073995 of_12\IN\1740 ammonia_13\JJ\1740 <e2>coma</e2>_14\NN\5678932 after_15\IN\1740 l-dopa_16\JJ\1740 ,_17\,\1740 can_18\MD\3094503 be_19\VB\836236 accounted_20\VBN\2604760 for_21\IN\1740 by_22\IN\1740 the_23\DT\1740 peripheral_24\JJ\1740 effect_25\NN\34213 of_26\IN\1740 <e1>dopamine</e1>_27\NN\14807737 on_28\IN\1740 renal_29\JJ\1740 function_30\NN\13783581 rather_31\RB\1740 than_32\IN\1740 its_33\PRP$\6125041 central_34\JJ\1740 action_35\NN\30358 ._36\.\1740
D007980_D001927 NONE these_0\DT\1740 results_1\NNS\34213 provide_2\VBP\2199590 a_3\DT\13649268 reasonable_4\JJ\1740 explanation_5\NN\6722453 for_6\IN\1740 the_7\DT\1740 beneficial_8\JJ\1740 effects_9\NNS\13245626 observed_10\VBN\2163746 in_11\IN\13603305 some_12\DT\1740 <e2>encephalopathic</e2>_13\JJ\1740 patients_14\NNS\9898892 receiving_15\VBG\2210855 <e1>l-dopa</e1>_16\JJ\1740 ._17\.\1740
8278214
D009020_D006930 CID <e2>hyperalgesia</e2>_0\NN\1740 and_1\CC\1740 myoclonus_2\NN\14360459 in_3\IN\13603305 terminal_4\JJ\1740 cancer_5\NN\14239425 patients_6\NNS\9898892 treated_7\VBN\2376958 with_8\IN\1740 continuous_9\JJ\1740 intravenous_10\JJ\1740 <e1>morphine</e1>_11\NN\2707683 ._12\.\1740
D009020_D006930 CID eight_0\CD\13741022 cancer_1\NN\14239425 patients_2\NNS\9898892 in_3\IN\13603305 the_4\DT\1740 terminal_5\JJ\1740 stages_6\NNS\15113229 of_7\IN\1740 the_8\DT\1740 disease_9\NN\14061805 treated_10\VBN\2376958 with_11\IN\1740 high_12\JJ\1740 doses_13\NNS\3740161 of_14\IN\1740 intravenous_15\JJ\1740 <e1>morphine</e1>_16\NN\2707683 developed_17\VBD\1753788 <e2>hyperalgesia</e2>_18\NN\1740 ._19\.\1740
D009020_D006930 CID although_0\IN\1740 only_1\RB\1740 few_2\JJ\1740 clinical_3\JJ\1740 descriptions_4\NNS\6722453 of_5\IN\1740 the_6\DT\1740 relationship_7\NN\31921 between_8\IN\1740 <e2>hyperalgesia/myoclonus</e2>_9\JJ\1740 and_10\CC\1740 high_11\JJ\1740 doses_12\NNS\3740161 of_13\IN\1740 <e1>morphine</e1>_14\NN\2707683 are_15\VBP\836236 available_16\JJ\1740 ,_17\,\1740 experimental_18\JJ\1740 support_19\NN\407535 from_20\IN\1740 animal_21\JJ\1740 studies_22\NNS\635850 indicates_23\VBZ\952524 that_24\IN\1740 morphine_25\NN\2707683 ,_26\,\1740 or_27\CC\3541091 its_28\PRP$\6125041 metabolites_29\NNS\20090 ,_30\,\1740 plays_31\VBZ\1072262 a_32\DT\13649268 causative_33\JJ\1740 role_34\NN\719494 for_35\IN\1740 the_36\DT\1740 observed_37\VBN\2163746 behavioural_38\JJ\1740 syndrome_39\NN\5870365 ._40\.\1740
D009020_D006930 CID although_0\IN\1740 only_1\RB\1740 few_2\JJ\1740 clinical_3\JJ\1740 descriptions_4\NNS\6722453 of_5\IN\1740 the_6\DT\1740 relationship_7\NN\31921 between_8\IN\1740 <e2>hyperalgesia/myoclonus</e2>_9\JJ\1740 and_10\CC\1740 high_11\JJ\1740 doses_12\NNS\3740161 of_13\IN\1740 morphine_14\NN\2707683 are_15\VBP\836236 available_16\JJ\1740 ,_17\,\1740 experimental_18\JJ\1740 support_19\NN\407535 from_20\IN\1740 animal_21\JJ\1740 studies_22\NNS\635850 indicates_23\VBZ\952524 that_24\IN\1740 <e1>morphine</e1>_25\NN\2707683 ,_26\,\1740 or_27\CC\3541091 its_28\PRP$\6125041 metabolites_29\NNS\20090 ,_30\,\1740 plays_31\VBZ\1072262 a_32\DT\13649268 causative_33\JJ\1740 role_34\NN\719494 for_35\IN\1740 the_36\DT\1740 observed_37\VBN\2163746 behavioural_38\JJ\1740 syndrome_39\NN\5870365 ._40\.\1740
D009020_D009207 CID hyperalgesia_0\NN\1740 and_1\CC\1740 <e2>myoclonus</e2>_2\NN\14360459 in_3\IN\13603305 terminal_4\JJ\1740 cancer_5\NN\14239425 patients_6\NNS\9898892 treated_7\VBN\2376958 with_8\IN\1740 continuous_9\JJ\1740 intravenous_10\JJ\1740 <e1>morphine</e1>_11\NN\2707683 ._12\.\1740
D009020_D009207 CID although_0\IN\1740 only_1\RB\1740 few_2\JJ\1740 clinical_3\JJ\1740 descriptions_4\NNS\6722453 of_5\IN\1740 the_6\DT\1740 relationship_7\NN\31921 between_8\IN\1740 <e2>hyperalgesia/myoclonus</e2>_9\JJ\1740 and_10\CC\1740 high_11\JJ\1740 doses_12\NNS\3740161 of_13\IN\1740 <e1>morphine</e1>_14\NN\2707683 are_15\VBP\836236 available_16\JJ\1740 ,_17\,\1740 experimental_18\JJ\1740 support_19\NN\407535 from_20\IN\1740 animal_21\JJ\1740 studies_22\NNS\635850 indicates_23\VBZ\952524 that_24\IN\1740 morphine_25\NN\2707683 ,_26\,\1740 or_27\CC\3541091 its_28\PRP$\6125041 metabolites_29\NNS\20090 ,_30\,\1740 plays_31\VBZ\1072262 a_32\DT\13649268 causative_33\JJ\1740 role_34\NN\719494 for_35\IN\1740 the_36\DT\1740 observed_37\VBN\2163746 behavioural_38\JJ\1740 syndrome_39\NN\5870365 ._40\.\1740
D009020_D009207 CID although_0\IN\1740 only_1\RB\1740 few_2\JJ\1740 clinical_3\JJ\1740 descriptions_4\NNS\6722453 of_5\IN\1740 the_6\DT\1740 relationship_7\NN\31921 between_8\IN\1740 <e2>hyperalgesia/myoclonus</e2>_9\JJ\1740 and_10\CC\1740 high_11\JJ\1740 doses_12\NNS\3740161 of_13\IN\1740 morphine_14\NN\2707683 are_15\VBP\836236 available_16\JJ\1740 ,_17\,\1740 experimental_18\JJ\1740 support_19\NN\407535 from_20\IN\1740 animal_21\JJ\1740 studies_22\NNS\635850 indicates_23\VBZ\952524 that_24\IN\1740 <e1>morphine</e1>_25\NN\2707683 ,_26\,\1740 or_27\CC\3541091 its_28\PRP$\6125041 metabolites_29\NNS\20090 ,_30\,\1740 plays_31\VBZ\1072262 a_32\DT\13649268 causative_33\JJ\1740 role_34\NN\719494 for_35\IN\1740 the_36\DT\1740 observed_37\VBN\2163746 behavioural_38\JJ\1740 syndrome_39\NN\5870365 ._40\.\1740
D009020_D009369 NONE hyperalgesia_0\NN\1740 and_1\CC\1740 myoclonus_2\NN\14360459 in_3\IN\13603305 terminal_4\JJ\1740 <e2>cancer</e2>_5\NN\14239425 patients_6\NNS\9898892 treated_7\VBN\2376958 with_8\IN\1740 continuous_9\JJ\1740 intravenous_10\JJ\1740 <e1>morphine</e1>_11\NN\2707683 ._12\.\1740
D009020_D009369 NONE eight_0\CD\13741022 <e2>cancer</e2>_1\NN\14239425 patients_2\NNS\9898892 in_3\IN\13603305 the_4\DT\1740 terminal_5\JJ\1740 stages_6\NNS\15113229 of_7\IN\1740 the_8\DT\1740 disease_9\NN\14061805 treated_10\VBN\2376958 with_11\IN\1740 high_12\JJ\1740 doses_13\NNS\3740161 of_14\IN\1740 intravenous_15\JJ\1740 <e1>morphine</e1>_16\NN\2707683 developed_17\VBD\1753788 hyperalgesia_18\NN\1740 ._19\.\1740
10728962
D014667_D007022 CID <e1>vasopressin</e1>_0\NN\5407119 in_1\IN\13603305 the_2\DT\1740 treatment_3\NN\654885 of_4\IN\1740 milrinone-induced_5\JJ\1740 <e2>hypotension</e2>_6\NN\14057371 in_7\IN\13603305 severe_8\JJ\1740 heart_9\NN\5919034 failure_10\NN\66216 ._11\.\1740
D014667_D007022 CID in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 decompensated_3\JJ\1740 heart_4\NN\5919034 failure_5\NN\66216 with_6\IN\1740 <e2>hypotension</e2>_7\NN\14057371 after_8\IN\1740 treatment_9\NN\654885 with_10\IN\1740 milrinone_11\NN\1740 ,_12\,\1740 low_13\JJ\1740 doses_14\NNS\3740161 of_15\IN\1740 <e1>vasopressin</e1>_16\NN\5407119 restored_17\VBN\1631072 blood_18\NN\5397468 pressure_19\NN\11419404 without_20\IN\1740 inhibiting_21\VBG\2510337 the_22\DT\1740 inotropic_23\JJ\1740 effect_24\NN\34213 of_25\IN\1740 milrinone_26\NN\1740 ._27\.\1740
D014667_D006333 NONE <e1>vasopressin</e1>_0\NN\5407119 in_1\IN\13603305 the_2\DT\1740 treatment_3\NN\654885 of_4\IN\1740 milrinone-induced_5\JJ\1740 hypotension_6\NN\14057371 in_7\IN\13603305 severe_8\JJ\1740 <e2>heart_9\NN\5919034 failure</e2>_10\NN\66216 ._11\.\1740
D014667_D006333 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 decompensated_3\JJ\1740 <e2>heart_4\NN\5919034 failure</e2>_5\NN\66216 with_6\IN\1740 hypotension_7\NN\14057371 after_8\IN\1740 treatment_9\NN\654885 with_10\IN\1740 milrinone_11\NN\1740 ,_12\,\1740 low_13\JJ\1740 doses_14\NNS\3740161 of_15\IN\1740 <e1>vasopressin</e1>_16\NN\5407119 restored_17\VBN\1631072 blood_18\NN\5397468 pressure_19\NN\11419404 without_20\IN\1740 inhibiting_21\VBG\2510337 the_22\DT\1740 inotropic_23\JJ\1740 effect_24\NN\34213 of_25\IN\1740 milrinone_26\NN\1740 ._27\.\1740
D020105_D007022 CID vasopressin_0\NN\5407119 in_1\IN\13603305 the_2\DT\1740 treatment_3\NN\654885 of_4\IN\1740 <e1>milrinone-induced</e1>_5\JJ\1740 <e2>hypotension</e2>_6\NN\14057371 in_7\IN\13603305 severe_8\JJ\1740 heart_9\NN\5919034 failure_10\NN\66216 ._11\.\1740
D020105_D007022 CID the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 phosphodiesterase_3\NN\1740 inhibitors_4\NNS\20090 such_5\JJ\1740 as_6\IN\14622893 <e1>milrinone</e1>_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 severe_12\JJ\1740 heart_13\NN\5919034 failure_14\NN\66216 is_15\VBZ\836236 frequently_16\RB\1740 restricted_17\JJ\1740 because_18\IN\1740 they_19\PRP\1740 cause_20\VBP\1617192 vasodilation_21\NN\365995 and_22\CC\1740 <e2>hypotension</e2>_23\NN\14057371 ._24\.\1740
D020105_D007022 CID in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 decompensated_3\JJ\1740 heart_4\NN\5919034 failure_5\NN\66216 with_6\IN\1740 <e2>hypotension</e2>_7\NN\14057371 after_8\IN\1740 treatment_9\NN\654885 with_10\IN\1740 <e1>milrinone</e1>_11\NN\1740 ,_12\,\1740 low_13\JJ\1740 doses_14\NNS\3740161 of_15\IN\1740 vasopressin_16\NN\5407119 restored_17\VBN\1631072 blood_18\NN\5397468 pressure_19\NN\11419404 without_20\IN\1740 inhibiting_21\VBG\2510337 the_22\DT\1740 inotropic_23\JJ\1740 effect_24\NN\34213 of_25\IN\1740 milrinone_26\NN\1740 ._27\.\1740
D020105_D007022 CID in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 decompensated_3\JJ\1740 heart_4\NN\5919034 failure_5\NN\66216 with_6\IN\1740 <e2>hypotension</e2>_7\NN\14057371 after_8\IN\1740 treatment_9\NN\654885 with_10\IN\1740 milrinone_11\NN\1740 ,_12\,\1740 low_13\JJ\1740 doses_14\NNS\3740161 of_15\IN\1740 vasopressin_16\NN\5407119 restored_17\VBN\1631072 blood_18\NN\5397468 pressure_19\NN\11419404 without_20\IN\1740 inhibiting_21\VBG\2510337 the_22\DT\1740 inotropic_23\JJ\1740 effect_24\NN\34213 of_25\IN\1740 <e1>milrinone</e1>_26\NN\1740 ._27\.\1740
D020105_D006333 NONE vasopressin_0\NN\5407119 in_1\IN\13603305 the_2\DT\1740 treatment_3\NN\654885 of_4\IN\1740 <e1>milrinone-induced</e1>_5\JJ\1740 hypotension_6\NN\14057371 in_7\IN\13603305 severe_8\JJ\1740 <e2>heart_9\NN\5919034 failure</e2>_10\NN\66216 ._11\.\1740
D020105_D006333 NONE the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 phosphodiesterase_3\NN\1740 inhibitors_4\NNS\20090 such_5\JJ\1740 as_6\IN\14622893 <e1>milrinone</e1>_7\NN\1740 in_8\IN\13603305 the_9\DT\1740 treatment_10\NN\654885 of_11\IN\1740 severe_12\JJ\1740 <e2>heart_13\NN\5919034 failure</e2>_14\NN\66216 is_15\VBZ\836236 frequently_16\RB\1740 restricted_17\JJ\1740 because_18\IN\1740 they_19\PRP\1740 cause_20\VBP\1617192 vasodilation_21\NN\365995 and_22\CC\1740 hypotension_23\NN\14057371 ._24\.\1740
D020105_D006333 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 decompensated_3\JJ\1740 <e2>heart_4\NN\5919034 failure</e2>_5\NN\66216 with_6\IN\1740 hypotension_7\NN\14057371 after_8\IN\1740 treatment_9\NN\654885 with_10\IN\1740 <e1>milrinone</e1>_11\NN\1740 ,_12\,\1740 low_13\JJ\1740 doses_14\NNS\3740161 of_15\IN\1740 vasopressin_16\NN\5407119 restored_17\VBN\1631072 blood_18\NN\5397468 pressure_19\NN\11419404 without_20\IN\1740 inhibiting_21\VBG\2510337 the_22\DT\1740 inotropic_23\JJ\1740 effect_24\NN\34213 of_25\IN\1740 milrinone_26\NN\1740 ._27\.\1740
D020105_D006333 NONE in_0\IN\13603305 patients_1\NNS\9898892 with_2\IN\1740 decompensated_3\JJ\1740 <e2>heart_4\NN\5919034 failure</e2>_5\NN\66216 with_6\IN\1740 hypotension_7\NN\14057371 after_8\IN\1740 treatment_9\NN\654885 with_10\IN\1740 milrinone_11\NN\1740 ,_12\,\1740 low_13\JJ\1740 doses_14\NNS\3740161 of_15\IN\1740 vasopressin_16\NN\5407119 restored_17\VBN\1631072 blood_18\NN\5397468 pressure_19\NN\11419404 without_20\IN\1740 inhibiting_21\VBG\2510337 the_22\DT\1740 inotropic_23\JJ\1740 effect_24\NN\34213 of_25\IN\1740 <e1>milrinone</e1>_26\NN\1740 ._27\.\1740
343678
D006514_D006509 NONE <e2>hepatitis_0\NN\14127211 b</e2>_1\NN\1355326 immune_2\JJ\1740 globulin_3\NN\14736972 (_4\-LRB-\1740 hbig_5\NN\1740 )_6\-RRB-\1740 and_7\CC\1740 immune_8\JJ\1740 serum_9\NN\5397468 globulin_10\NN\14736972 (_11\-LRB-\1740 isg_12\NN\1740 )_13\-RRB-\1740 were_14\VBD\836236 examined_15\VBN\789138 in_16\IN\13603305 a_17\DT\13649268 randomized_18\JJ\1740 ,_19\,\1740 double-blind_20\JJ\1740 trial_21\NN\786195 to_22\TO\1740 assess_23\VB\670261 their_24\PRP$\1740 relative_25\JJ\1740 efficacies_26\NNS\5199286 in_27\IN\13603305 preventing_28\VBG\1740 type_29\NN\5839024 b_30\NN\1355326 hepatitis_31\NN\14127211 after_32\IN\1740 needle-stick_33\JJ\1740 exposure_34\NN\5042871 to_35\TO\1740 <e1>hepatitis_36\NN\14127211 b_37\NN\1355326 surface_38\NN\21939 antigen</e1>_39\NN\20090 (hbsag)-positive_40\JJ\1740 donors_41\NNS\9608709 ._42\.\1740
D006514_D006509 NONE hepatitis_0\NN\14127211 b_1\NN\1355326 immune_2\JJ\1740 globulin_3\NN\14736972 (_4\-LRB-\1740 hbig_5\NN\1740 )_6\-RRB-\1740 and_7\CC\1740 immune_8\JJ\1740 serum_9\NN\5397468 globulin_10\NN\14736972 (_11\-LRB-\1740 isg_12\NN\1740 )_13\-RRB-\1740 were_14\VBD\836236 examined_15\VBN\789138 in_16\IN\13603305 a_17\DT\13649268 randomized_18\JJ\1740 ,_19\,\1740 double-blind_20\JJ\1740 trial_21\NN\786195 to_22\TO\1740 assess_23\VB\670261 their_24\PRP$\1740 relative_25\JJ\1740 efficacies_26\NNS\5199286 in_27\IN\13603305 preventing_28\VBG\1740 <e2>type_29\NN\5839024 b_30\NN\1355326 hepatitis</e2>_31\NN\14127211 after_32\IN\1740 needle-stick_33\JJ\1740 exposure_34\NN\5042871 to_35\TO\1740 <e1>hepatitis_36\NN\14127211 b_37\NN\1355326 surface_38\NN\21939 antigen</e1>_39\NN\20090 (hbsag)-positive_40\JJ\1740 donors_41\NNS\9608709 ._42\.\1740
D006514_D006509 NONE <e2>hepatitis_0\NN\14127211 b</e2>_1\NN\1355326 immune_2\JJ\1740 globulin_3\NN\14736972 (_4\-LRB-\1740 hbig_5\NN\1740 )_6\-RRB-\1740 and_7\CC\1740 immune_8\JJ\1740 serum_9\NN\5397468 globulin_10\NN\14736972 (_11\-LRB-\1740 isg_12\NN\1740 )_13\-RRB-\1740 were_14\VBD\836236 examined_15\VBN\789138 in_16\IN\13603305 a_17\DT\13649268 randomized_18\JJ\1740 ,_19\,\1740 double-blind_20\JJ\1740 trial_21\NN\786195 to_22\TO\1740 assess_23\VB\670261 their_24\PRP$\1740 relative_25\JJ\1740 efficacies_26\NNS\5199286 in_27\IN\13603305 preventing_28\VBG\1740 type_29\NN\5839024 b_30\NN\1355326 hepatitis_31\NN\14127211 after_32\IN\1740 needle-stick_33\JJ\1740 exposure_34\NN\5042871 to_35\TO\1740 hepatitis_36\NN\14127211 b_37\NN\1355326 surface_38\NN\21939 antigen_39\NN\20090 <e1>(hbsag)-positive</e1>_40\JJ\1740 donors_41\NNS\9608709 ._42\.\1740
D006514_D006509 NONE hepatitis_0\NN\14127211 b_1\NN\1355326 immune_2\JJ\1740 globulin_3\NN\14736972 (_4\-LRB-\1740 hbig_5\NN\1740 )_6\-RRB-\1740 and_7\CC\1740 immune_8\JJ\1740 serum_9\NN\5397468 globulin_10\NN\14736972 (_11\-LRB-\1740 isg_12\NN\1740 )_13\-RRB-\1740 were_14\VBD\836236 examined_15\VBN\789138 in_16\IN\13603305 a_17\DT\13649268 randomized_18\JJ\1740 ,_19\,\1740 double-blind_20\JJ\1740 trial_21\NN\786195 to_22\TO\1740 assess_23\VB\670261 their_24\PRP$\1740 relative_25\JJ\1740 efficacies_26\NNS\5199286 in_27\IN\13603305 preventing_28\VBG\1740 <e2>type_29\NN\5839024 b_30\NN\1355326 hepatitis</e2>_31\NN\14127211 after_32\IN\1740 needle-stick_33\JJ\1740 exposure_34\NN\5042871 to_35\TO\1740 hepatitis_36\NN\14127211 b_37\NN\1355326 surface_38\NN\21939 antigen_39\NN\20090 <e1>(hbsag)-positive</e1>_40\JJ\1740 donors_41\NNS\9608709 ._42\.\1740
430165
D010672_D010291 CID transient_0\JJ\1740 <e2>hemiparesis</e2>_1\NN\1740 :_2\:\1740 a_3\DT\13649268 rare_4\JJ\1740 manifestation_5\NN\7321772 of_6\IN\1740 <e1>diphenylhydantoin</e1>_7\NN\3550533 toxicity_8\NN\13576101 ._9\.\1740
D010672_D010291 CID two_0\CD\13741022 patients_1\NNS\9898892 are_2\VBP\836236 presented_3\VBN\2137132 who_4\WP\8299493 suffered_5\VBD\2110220 progressive_6\JJ\1740 <e2>hemiparesis</e2>_7\NN\1740 due_8\JJ\1740 to_9\TO\1740 <e1>dph</e1>_10\NN\6702458 overdose_11\NN\1740 ._12\.\1740
D010672_D064420 NONE transient_0\JJ\1740 hemiparesis_1\NN\1740 :_2\:\1740 a_3\DT\13649268 rare_4\JJ\1740 manifestation_5\NN\7321772 of_6\IN\1740 <e1>diphenylhydantoin</e1>_7\NN\3550533 <e2>toxicity</e2>_8\NN\13576101 ._9\.\1740
D010672_D064420 NONE it_0\PRP\6125041 is_1\VBZ\836236 assumed_2\VBN\719734 that_3\IN\1740 patients_4\NNS\9898892 with_5\IN\1740 some_6\DT\1740 cerebral_7\JJ\1740 damage_8\NN\7296428 are_9\VBP\836236 liable_10\JJ\1740 to_11\TO\1740 manifest_12\VB\1015244 <e1>dph</e1>_13\NN\6702458 <e2>toxicity</e2>_14\NN\13576101 as_15\IN\14622893 focal_16\JJ\1740 neurological_17\JJ\1740 signs_18\NNS\6643763 ._19\.\1740
D010672_D062787 CID among_0\IN\1740 the_1\DT\1740 common_2\JJ\1740 side_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>diphenylhydantoin</e1>_6\NN\3550533 (_7\-LRB-\1740 dph_8\NN\6702458 )_9\-RRB-\1740 <e2>overdose</e2>_10\RB\1740 ,_11\,\1740 the_12\DT\1740 most_13\RBS\1740 frequently_14\RB\1740 encountered_15\VBN\2604760 neurological_16\JJ\1740 signs_17\NNS\6643763 are_18\VBP\836236 those_19\DT\1740 of_20\IN\1740 cerebellar_21\JJ\1740 dysfunction_22\NN\14204950 ._23\.\1740
D010672_D062787 CID among_0\IN\1740 the_1\DT\1740 common_2\JJ\1740 side_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 diphenylhydantoin_6\NN\3550533 (_7\-LRB-\1740 <e1>dph</e1>_8\NN\6702458 )_9\-RRB-\1740 <e2>overdose</e2>_10\RB\1740 ,_11\,\1740 the_12\DT\1740 most_13\RBS\1740 frequently_14\RB\1740 encountered_15\VBN\2604760 neurological_16\JJ\1740 signs_17\NNS\6643763 are_18\VBP\836236 those_19\DT\1740 of_20\IN\1740 cerebellar_21\JJ\1740 dysfunction_22\NN\14204950 ._23\.\1740
D010672_D062787 CID two_0\CD\13741022 patients_1\NNS\9898892 are_2\VBP\836236 presented_3\VBN\2137132 who_4\WP\8299493 suffered_5\VBD\2110220 progressive_6\JJ\1740 hemiparesis_7\NN\1740 due_8\JJ\1740 to_9\TO\1740 <e1>dph</e1>_10\NN\6702458 <e2>overdose</e2>_11\NN\1740 ._12\.\1740
D010672_D002526 CID among_0\IN\1740 the_1\DT\1740 common_2\JJ\1740 side_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 <e1>diphenylhydantoin</e1>_6\NN\3550533 (_7\-LRB-\1740 dph_8\NN\6702458 )_9\-RRB-\1740 overdose_10\RB\1740 ,_11\,\1740 the_12\DT\1740 most_13\RBS\1740 frequently_14\RB\1740 encountered_15\VBN\2604760 neurological_16\JJ\1740 signs_17\NNS\6643763 are_18\VBP\836236 those_19\DT\1740 of_20\IN\1740 <e2>cerebellar_21\JJ\1740 dysfunction</e2>_22\NN\14204950 ._23\.\1740
D010672_D002526 CID among_0\IN\1740 the_1\DT\1740 common_2\JJ\1740 side_3\JJ\1740 effects_4\NNS\13245626 of_5\IN\1740 diphenylhydantoin_6\NN\3550533 (_7\-LRB-\1740 <e1>dph</e1>_8\NN\6702458 )_9\-RRB-\1740 overdose_10\RB\1740 ,_11\,\1740 the_12\DT\1740 most_13\RBS\1740 frequently_14\RB\1740 encountered_15\VBN\2604760 neurological_16\JJ\1740 signs_17\NNS\6643763 are_18\VBP\836236 those_19\DT\1740 of_20\IN\1740 <e2>cerebellar_21\JJ\1740 dysfunction</e2>_22\NN\14204950 ._23\.\1740
D010672_D001927 NONE it_0\PRP\6125041 is_1\VBZ\836236 assumed_2\VBN\719734 that_3\IN\1740 patients_4\NNS\9898892 with_5\IN\1740 some_6\DT\1740 <e2>cerebral_7\JJ\1740 damage</e2>_8\NN\7296428 are_9\VBP\836236 liable_10\JJ\1740 to_11\TO\1740 manifest_12\VB\1015244 <e1>dph</e1>_13\NN\6702458 toxicity_14\NN\13576101 as_15\IN\14622893 focal_16\JJ\1740 neurological_17\JJ\1740 signs_18\NNS\6643763 ._19\.\1740
1628552
D002738_D006327 NONE <e1>chloroquine</e1>_0\NN\2721948 related_1\JJ\1740 complete_2\JJ\1740 <e2>heart_3\NN\5919034 block</e2>_4\NN\21939 with_5\IN\1740 blindness_6\NN\14552802 :_7\:\1740 case_8\NN\7283608 report_9\NN\6470073 ._10\.\1740
D002738_D006327 NONE ophthalmological_0\JJ\1740 assessment_1\NN\5732756 revealed_2\VBD\2137132 features_3\NNS\5849040 of_4\IN\1740 <e1>chloroquine</e1>_5\NN\2721948 retinopathy_6\NN\14252864 ,_7\,\1740 cardiac_8\JJ\1740 assessment_9\NN\5732756 revealed_10\VBD\2137132 features_11\NNS\5849040 of_12\IN\1740 heart_13\NN\5919034 failure_14\NN\66216 and_15\CC\1740 a_16\DT\13649268 complete_17\JJ\1740 <e2>heart_18\NN\5919034 block</e2>_19\NN\21939 with_20\IN\1740 right_21\JJ\1740 bundle_22\NN\7951464 branch_23\NN\8220714 block_24\NN\21939 pattern_25\NN\5726345 ._26\.\1740
D002738_D006327 NONE the_0\DT\1740 <e2>heart_1\NN\5919034 block</e2>_2\NN\21939 was_3\VBD\836236 treated_4\VBN\2376958 by_5\IN\1740 pacemaker_6\NN\5925366 insertion_7\NN\6598915 and_8\CC\1740 the_9\DT\1740 heart_10\NN\5919034 failure_11\NN\66216 resolved_12\VBD\352826 spontaneously_13\RB\1740 following_14\VBG\1835496 <e1>chloroquine</e1>_15\NN\2721948 discontinuation_16\NN\209943 ._17\.\1740
D002738_D001766 CID <e1>chloroquine</e1>_0\NN\2721948 related_1\JJ\1740 complete_2\JJ\1740 heart_3\NN\5919034 block_4\NN\21939 with_5\IN\1740 <e2>blindness</e2>_6\NN\14552802 :_7\:\1740 case_8\NN\7283608 report_9\NN\6470073 ._10\.\1740
D002738_D015354 NONE a_0\DT\13649268 27-year_1\JJ\1740 old_2\JJ\1740 african_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 history_6\NN\15120823 of_7\IN\1740 regular_8\JJ\1740 <e1>chloroquine</e1>_9\NN\2721948 ingestion_10\NN\13440063 presented_11\VBN\2137132 with_12\IN\1740 progressive_13\JJ\1740 <e2>deterioration_14\NN\14560612 of_15\IN\1740 vision</e2>_16\NN\5767733 ,_17\,\1740 easy_18\JJ\1740 fatiguability_19\NN\1740 ,_20\,\1740 dyspnoea_21\NN\14299637 ,_22\,\1740 dizziness_23\VBP\1740 progressing_24\VBG\252019 to_25\IN\1740 syncopal_26\VB\1740 attacks_27\NNS\955060 ._28\.\1740
D002738_D005221 CID a_0\DT\13649268 27-year_1\JJ\1740 old_2\JJ\1740 african_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 history_6\NN\15120823 of_7\IN\1740 regular_8\JJ\1740 <e1>chloroquine</e1>_9\NN\2721948 ingestion_10\NN\13440063 presented_11\VBN\2137132 with_12\IN\1740 progressive_13\JJ\1740 deterioration_14\NN\14560612 of_15\IN\1740 vision_16\NN\5767733 ,_17\,\1740 easy_18\JJ\1740 <e2>fatiguability</e2>_19\NN\1740 ,_20\,\1740 dyspnoea_21\NN\14299637 ,_22\,\1740 dizziness_23\VBP\1740 progressing_24\VBG\252019 to_25\IN\1740 syncopal_26\VB\1740 attacks_27\NNS\955060 ._28\.\1740
D002738_D004417 CID a_0\DT\13649268 27-year_1\JJ\1740 old_2\JJ\1740 african_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 history_6\NN\15120823 of_7\IN\1740 regular_8\JJ\1740 <e1>chloroquine</e1>_9\NN\2721948 ingestion_10\NN\13440063 presented_11\VBN\2137132 with_12\IN\1740 progressive_13\JJ\1740 deterioration_14\NN\14560612 of_15\IN\1740 vision_16\NN\5767733 ,_17\,\1740 easy_18\JJ\1740 fatiguability_19\NN\1740 ,_20\,\1740 <e2>dyspnoea</e2>_21\NN\14299637 ,_22\,\1740 dizziness_23\VBP\1740 progressing_24\VBG\252019 to_25\IN\1740 syncopal_26\VB\1740 attacks_27\NNS\955060 ._28\.\1740
D002738_D004244 CID a_0\DT\13649268 27-year_1\JJ\1740 old_2\JJ\1740 african_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 history_6\NN\15120823 of_7\IN\1740 regular_8\JJ\1740 <e1>chloroquine</e1>_9\NN\2721948 ingestion_10\NN\13440063 presented_11\VBN\2137132 with_12\IN\1740 progressive_13\JJ\1740 deterioration_14\NN\14560612 of_15\IN\1740 vision_16\NN\5767733 ,_17\,\1740 easy_18\JJ\1740 fatiguability_19\NN\1740 ,_20\,\1740 dyspnoea_21\NN\14299637 ,_22\,\1740 <e2>dizziness</e2>_23\VBP\1740 progressing_24\VBG\252019 to_25\IN\1740 syncopal_26\VB\1740 attacks_27\NNS\955060 ._28\.\1740
D002738_D013575 CID a_0\DT\13649268 27-year_1\JJ\1740 old_2\JJ\1740 african_3\JJ\1740 woman_4\NN\9605289 with_5\IN\1740 history_6\NN\15120823 of_7\IN\1740 regular_8\JJ\1740 <e1>chloroquine</e1>_9\NN\2721948 ingestion_10\NN\13440063 presented_11\VBN\2137132 with_12\IN\1740 progressive_13\JJ\1740 deterioration_14\NN\14560612 of_15\IN\1740 vision_16\NN\5767733 ,_17\,\1740 easy_18\JJ\1740 fatiguability_19\NN\1740 ,_20\,\1740 dyspnoea_21\NN\14299637 ,_22\,\1740 dizziness_23\VBP\1740 progressing_24\VBG\252019 to_25\IN\1740 <e2>syncopal_26\VB\1740 attacks</e2>_27\NNS\955060 ._28\.\1740
D002738_D012164 CID ophthalmological_0\JJ\1740 assessment_1\NN\5732756 revealed_2\VBD\2137132 features_3\NNS\5849040 of_4\IN\1740 <e1>chloroquine</e1>_5\NN\2721948 <e2>retinopathy</e2>_6\NN\14252864 ,_7\,\1740 cardiac_8\JJ\1740 assessment_9\NN\5732756 revealed_10\VBD\2137132 features_11\NNS\5849040 of_12\IN\1740 heart_13\NN\5919034 failure_14\NN\66216 and_15\CC\1740 a_16\DT\13649268 complete_17\JJ\1740 heart_18\NN\5919034 block_19\NN\21939 with_20\IN\1740 right_21\JJ\1740 bundle_22\NN\7951464 branch_23\NN\8220714 block_24\NN\21939 pattern_25\NN\5726345 ._26\.\1740
D002738_D006333 CID ophthalmological_0\JJ\1740 assessment_1\NN\5732756 revealed_2\VBD\2137132 features_3\NNS\5849040 of_4\IN\1740 <e1>chloroquine</e1>_5\NN\2721948 retinopathy_6\NN\14252864 ,_7\,\1740 cardiac_8\JJ\1740 assessment_9\NN\5732756 revealed_10\VBD\2137132 features_11\NNS\5849040 of_12\IN\1740 <e2>heart_13\NN\5919034 failure</e2>_14\NN\66216 and_15\CC\1740 a_16\DT\13649268 complete_17\JJ\1740 heart_18\NN\5919034 block_19\NN\21939 with_20\IN\1740 right_21\JJ\1740 bundle_22\NN\7951464 branch_23\NN\8220714 block_24\NN\21939 pattern_25\NN\5726345 ._26\.\1740
D002738_D006333 CID the_0\DT\1740 heart_1\NN\5919034 block_2\NN\21939 was_3\VBD\836236 treated_4\VBN\2376958 by_5\IN\1740 pacemaker_6\NN\5925366 insertion_7\NN\6598915 and_8\CC\1740 the_9\DT\1740 <e2>heart_10\NN\5919034 failure</e2>_11\NN\66216 resolved_12\VBD\352826 spontaneously_13\RB\1740 following_14\VBG\1835496 <e1>chloroquine</e1>_15\NN\2721948 discontinuation_16\NN\209943 ._17\.\1740
D002738_D002037 CID ophthalmological_0\JJ\1740 assessment_1\NN\5732756 revealed_2\VBD\2137132 features_3\NNS\5849040 of_4\IN\1740 <e1>chloroquine</e1>_5\NN\2721948 retinopathy_6\NN\14252864 ,_7\,\1740 cardiac_8\JJ\1740 assessment_9\NN\5732756 revealed_10\VBD\2137132 features_11\NNS\5849040 of_12\IN\1740 heart_13\NN\5919034 failure_14\NN\66216 and_15\CC\1740 a_16\DT\13649268 complete_17\JJ\1740 heart_18\NN\5919034 block_19\NN\21939 with_20\IN\1740 <e2>right_21\JJ\1740 bundle_22\NN\7951464 branch_23\NN\8220714 block</e2>_24\NN\21939 pattern_25\NN\5726345 ._26\.\1740
1445986
D015313_D000743 CID <e1>cefotetan-induced</e1>_0\JJ\1740 immune_1\JJ\1740 <e2>hemolytic_2\JJ\1740 anemia</e2>_3\NN\14189204 ._4\.\1740
D010406_D000743 NONE immune_0\JJ\1740 <e2>hemolytic_1\JJ\1740 anemia</e2>_2\NN\14189204 due_3\IN\5174653 to_4\TO\1740 a_5\DT\13649268 drug-adsorption_6\JJ\1740 mechanism_7\NN\13446390 has_8\VBZ\2108377 been_9\VBN\836236 described_10\VBN\1001294 primarily_11\RB\1740 in_12\IN\13603305 patients_13\NNS\9898892 receiving_14\VBG\2210855 <e1>penicillins</e1>_15\NNS\2716866 and_16\CC\1740 first-generation_17\NN\1740 cephalosporins_18\NNS\2716866 ._19\.\1740
D002511_D000743 NONE immune_0\JJ\1740 <e2>hemolytic_1\JJ\1740 anemia</e2>_2\NN\14189204 due_3\IN\5174653 to_4\TO\1740 a_5\DT\13649268 drug-adsorption_6\JJ\1740 mechanism_7\NN\13446390 has_8\VBZ\2108377 been_9\VBN\836236 described_10\VBN\1001294 primarily_11\RB\1740 in_12\IN\13603305 patients_13\NNS\9898892 receiving_14\VBG\2210855 penicillins_15\NNS\2716866 and_16\CC\1740 first-generation_17\NN\1740 <e1>cephalosporins</e1>_18\NNS\2716866 ._19\.\1740
D015313_D000740 NONE we_0\PRP\1740 describe_1\VBP\1001294 a_2\DT\13649268 patient_3\NN\9898892 who_4\WP\8299493 developed_5\VBD\1753788 <e2>anemia</e2>_6\NN\14189204 while_7\IN\15122231 receiving_8\VBG\2210855 intravenous_9\JJ\1740 <e1>cefotetan</e1>_10\NN\1740 ._11\.\1740
20042557
D015742_D003693 CID patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 performed_5\VBD\2367363 a_6\DT\13649268 double-blind_7\JJ\1740 ,_8\,\1740 randomized_9\JJ\1740 controlled_10\VBN\2422663 trial_11\NN\786195 at_12\IN\14622893 an_13\DT\6697703 academic_14\JJ\1740 medical_15\JJ\1740 center_16\NN\8497294 of_17\IN\1740 elderly_18\JJ\1740 patients_19\NNS\9898892 (_20\-LRB-\1740 >_21\NNS\1740 or=65_22\NNP\1740 years_23\NNS\15144371 )_24\-RRB-\1740 without_25\IN\1740 preoperative_26\JJ\1740 <e2>delirium</e2>_27\NN\14391660 or_28\CC\3541091 severe_29\JJ\1740 dementia_30\NN\14395018 who_31\WP\8299493 underwent_32\VBD\109660 hip_33\NN\5220461 fracture_34\NN\14285662 repair_35\NN\248977 under_36\IN\1740 spinal_37\JJ\1740 anesthesia_38\NN\14034177 with_39\IN\1740 <e1>propofol</e1>_40\NN\1740 sedation_41\NN\14034177 ._42\.\1740
D015742_D003693 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 use_3\NN\407535 of_4\IN\1740 light_5\JJ\1740 <e1>propofol</e1>_6\NN\1740 sedation_7\NN\14034177 decreased_8\VBD\169651 the_9\DT\1740 prevalence_10\NN\4764412 of_11\IN\1740 <e2>postoperative_12\JJ\1740 delirium</e2>_13\NN\14391660 by_14\IN\1740 50_15\CD\13745420 %_16\NN\1740 compared_17\VBN\644583 with_18\IN\1740 deep_19\JJ\1740 sedation_20\NN\14034177 ._21\.\1740
D015742_D003704 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 performed_5\VBD\2367363 a_6\DT\13649268 double-blind_7\JJ\1740 ,_8\,\1740 randomized_9\JJ\1740 controlled_10\VBN\2422663 trial_11\NN\786195 at_12\IN\14622893 an_13\DT\6697703 academic_14\JJ\1740 medical_15\JJ\1740 center_16\NN\8497294 of_17\IN\1740 elderly_18\JJ\1740 patients_19\NNS\9898892 (_20\-LRB-\1740 >_21\NNS\1740 or=65_22\NNP\1740 years_23\NNS\15144371 )_24\-RRB-\1740 without_25\IN\1740 preoperative_26\JJ\1740 delirium_27\NN\14391660 or_28\CC\3541091 severe_29\JJ\1740 <e2>dementia</e2>_30\NN\14395018 who_31\WP\8299493 underwent_32\VBD\109660 hip_33\NN\5220461 fracture_34\NN\14285662 repair_35\NN\248977 under_36\IN\1740 spinal_37\JJ\1740 anesthesia_38\NN\14034177 with_39\IN\1740 <e1>propofol</e1>_40\NN\1740 sedation_41\NN\14034177 ._42\.\1740
D015742_D006620 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 we_4\PRP\1740 performed_5\VBD\2367363 a_6\DT\13649268 double-blind_7\JJ\1740 ,_8\,\1740 randomized_9\JJ\1740 controlled_10\VBN\2422663 trial_11\NN\786195 at_12\IN\14622893 an_13\DT\6697703 academic_14\JJ\1740 medical_15\JJ\1740 center_16\NN\8497294 of_17\IN\1740 elderly_18\JJ\1740 patients_19\NNS\9898892 (_20\-LRB-\1740 >_21\NNS\1740 or=65_22\NNP\1740 years_23\NNS\15144371 )_24\-RRB-\1740 without_25\IN\1740 preoperative_26\JJ\1740 delirium_27\NN\14391660 or_28\CC\3541091 severe_29\JJ\1740 dementia_30\NN\14395018 who_31\WP\8299493 underwent_32\VBD\109660 <e2>hip_33\NN\5220461 fracture</e2>_34\NN\14285662 repair_35\NN\248977 under_36\IN\1740 spinal_37\JJ\1740 anesthesia_38\NN\14034177 with_39\IN\1740 <e1>propofol</e1>_40\NN\1740 sedation_41\NN\14034177 ._42\.\1740
D015742_D011183 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 use_3\NN\407535 of_4\IN\1740 light_5\JJ\1740 <e1>propofol</e1>_6\NN\1740 sedation_7\NN\14034177 decreased_8\VBD\169651 the_9\DT\1740 prevalence_10\NN\4764412 of_11\IN\1740 <e2>postoperative_12\JJ\1740 delirium</e2>_13\NN\14391660 by_14\IN\1740 50_15\CD\13745420 %_16\NN\1740 compared_17\VBN\644583 with_18\IN\1740 deep_19\JJ\1740 sedation_20\NN\14034177 ._21\.\1740
10840460
D003520_D003556 CID <e1>cyclophosphamide-induced</e1>_0\JJ\1740 <e2>cystitis</e2>_1\NN\14566129 in_2\IN\13603305 freely-moving_3\JJ\1740 conscious_4\JJ\1740 rats_5\NNS\2329401 :_6\:\1740 behavioral_7\JJ\1740 approach_8\NN\940842 to_9\IN\1740 a_10\DT\13649268 new_11\JJ\1740 model_12\NN\5888929 of_13\IN\1740 visceral_14\JJ\1740 pain_15\NN\14299637 ._16\.\1740
D003520_D003556 CID <e1>cyclophosphamide</e1>_0\NN\1740 (_1\-LRB-\1740 cp_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 an_5\DT\6697703 antitumoral_6\JJ\1740 agent_7\NN\7347 known_8\VBN\2110220 to_9\TO\1740 produce_10\VB\1617192 toxic_11\JJ\1740 effects_12\NNS\13245626 on_13\IN\1740 the_14\DT\1740 bladder_15\NN\5515670 wall_16\NN\3894379 through_17\IN\1740 its_18\PRP$\6125041 main_19\JJ\1740 toxic_20\JJ\1740 metabolite_21\NN\20090 acrolein_22\NN\14584765 ,_23\,\1740 was_24\VBD\836236 used_25\VBN\1156834 to_26\TO\1740 induce_27\VB\1627355 <e2>cystitis</e2>_28\NN\14566129 ._29\.\1740
D003520_D003556 CID cyclophosphamide_0\NN\1740 (_1\-LRB-\1740 <e1>cp</e1>_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 an_5\DT\6697703 antitumoral_6\JJ\1740 agent_7\NN\7347 known_8\VBN\2110220 to_9\TO\1740 produce_10\VB\1617192 toxic_11\JJ\1740 effects_12\NNS\13245626 on_13\IN\1740 the_14\DT\1740 bladder_15\NN\5515670 wall_16\NN\3894379 through_17\IN\1740 its_18\PRP$\6125041 main_19\JJ\1740 toxic_20\JJ\1740 metabolite_21\NN\20090 acrolein_22\NN\14584765 ,_23\,\1740 was_24\VBD\836236 used_25\VBN\1156834 to_26\TO\1740 induce_27\VB\1627355 <e2>cystitis</e2>_28\NN\14566129 ._29\.\1740
D003520_D003556 CID conclusions_0\NNS\5837957 :_1\:\1740 overall_2\RB\1740 ,_3\,\1740 these_4\DT\1740 results_5\NNS\34213 indicate_6\VBP\952524 that_7\IN\1740 this_8\DT\1740 experimental_9\JJ\1740 model_10\NN\5888929 of_11\IN\1740 <e1>cp-induced</e1>_12\JJ\1740 <e2>cystitis</e2>_13\NN\14566129 may_14\MD\15209706 be_15\VB\836236 an_16\DT\6697703 interesting_17\JJ\1740 new_18\JJ\1740 behavioral_19\JJ\1740 model_20\NN\5888929 of_21\IN\1740 inflammatory_22\JJ\1740 visceral_23\JJ\1740 pain_24\NN\14299637 ,_25\,\1740 allowing_26\VBG\797697 a_27\DT\13649268 better_28\JJR\1740 understanding_29\NN\5804793 of_30\IN\1740 these_31\DT\1740 painful_32\JJ\1740 syndromes_33\NNS\5870365 and_34\CC\1740 thus_35\RB\1740 a_36\DT\13649268 better_37\RBR\1740 therapeutic_38\JJ\1740 approach_39\NN\940842 to_40\IN\1740 them_41\PRP\1740 ._42\.\1740
D003520_D059265 NONE <e1>cyclophosphamide-induced</e1>_0\JJ\1740 cystitis_1\NN\14566129 in_2\IN\13603305 freely-moving_3\JJ\1740 conscious_4\JJ\1740 rats_5\NNS\2329401 :_6\:\1740 behavioral_7\JJ\1740 approach_8\NN\940842 to_9\IN\1740 a_10\DT\13649268 new_11\JJ\1740 model_12\NN\5888929 of_13\IN\1740 <e2>visceral_14\JJ\1740 pain</e2>_15\NN\14299637 ._16\.\1740
D003520_D059265 NONE conclusions_0\NNS\5837957 :_1\:\1740 overall_2\RB\1740 ,_3\,\1740 these_4\DT\1740 results_5\NNS\34213 indicate_6\VBP\952524 that_7\IN\1740 this_8\DT\1740 experimental_9\JJ\1740 model_10\NN\5888929 of_11\IN\1740 <e1>cp-induced</e1>_12\JJ\1740 cystitis_13\NN\14566129 may_14\MD\15209706 be_15\VB\836236 an_16\DT\6697703 interesting_17\JJ\1740 new_18\JJ\1740 behavioral_19\JJ\1740 model_20\NN\5888929 of_21\IN\1740 inflammatory_22\JJ\1740 <e2>visceral_23\JJ\1740 pain</e2>_24\NN\14299637 ,_25\,\1740 allowing_26\VBG\797697 a_27\DT\13649268 better_28\JJR\1740 understanding_29\NN\5804793 of_30\IN\1740 these_31\DT\1740 painful_32\JJ\1740 syndromes_33\NNS\5870365 and_34\CC\1740 thus_35\RB\1740 a_36\DT\13649268 better_37\RBR\1740 therapeutic_38\JJ\1740 approach_39\NN\940842 to_40\IN\1740 them_41\PRP\1740 ._42\.\1740
D000171_D003556 NONE cyclophosphamide_0\NN\1740 (_1\-LRB-\1740 cp_2\NN\1740 )_3\-RRB-\1740 ,_4\,\1740 an_5\DT\6697703 antitumoral_6\JJ\1740 agent_7\NN\7347 known_8\VBN\2110220 to_9\TO\1740 produce_10\VB\1617192 toxic_11\JJ\1740 effects_12\NNS\13245626 on_13\IN\1740 the_14\DT\1740 bladder_15\NN\5515670 wall_16\NN\3894379 through_17\IN\1740 its_18\PRP$\6125041 main_19\JJ\1740 toxic_20\JJ\1740 metabolite_21\NN\20090 <e1>acrolein</e1>_22\NN\14584765 ,_23\,\1740 was_24\VBD\836236 used_25\VBN\1156834 to_26\TO\1740 induce_27\VB\1627355 <e2>cystitis</e2>_28\NN\14566129 ._29\.\1740
D009020_D001523 NONE <e1>morphine</e1>_0\NN\2707683 dose-dependently_1\RB\1740 reversed_2\VBD\109660 these_3\DT\1740 <e2>behavioral_4\JJ\1740 disorders</e2>_5\NNS\14034177 ._6\.\1740
D009020_D004487 NONE at_0\IN\14622893 the_1\DT\1740 time_2\NN\7308889 of_3\IN\1740 administration_4\NN\1133281 of_5\IN\1740 <e1>morphine</e1>_6\NN\2707683 ,_7\,\1740 histological_8\JJ\1740 modifications_9\NNS\191142 of_10\IN\1740 the_11\DT\1740 bladder_12\NN\5515670 wall_13\NN\3894379 ,_14\,\1740 such_15\JJ\1740 as_16\IN\14622893 chorionic_17\JJ\1740 and_18\CC\1740 muscle_19\NN\5289601 layer_20\NN\21939 <e2>edema</e2>_21\NN\14315192 ,_22\,\1740 were_23\VBD\836236 observed_24\VBN\2163746 ._25\.\1740
D003520_D010146 CID conclusions_0\NNS\5837957 :_1\:\1740 overall_2\RB\1740 ,_3\,\1740 these_4\DT\1740 results_5\NNS\34213 indicate_6\VBP\952524 that_7\IN\1740 this_8\DT\1740 experimental_9\JJ\1740 model_10\NN\5888929 of_11\IN\1740 <e1>cp-induced</e1>_12\JJ\1740 cystitis_13\NN\14566129 may_14\MD\15209706 be_15\VB\836236 an_16\DT\6697703 interesting_17\JJ\1740 new_18\JJ\1740 behavioral_19\JJ\1740 model_20\NN\5888929 of_21\IN\1740 inflammatory_22\JJ\1740 visceral_23\JJ\1740 pain_24\NN\14299637 ,_25\,\1740 allowing_26\VBG\797697 a_27\DT\13649268 better_28\JJR\1740 understanding_29\NN\5804793 of_30\IN\1740 these_31\DT\1740 <e2>painful_32\JJ\1740 syndromes</e2>_33\NNS\5870365 and_34\CC\1740 thus_35\RB\1740 a_36\DT\13649268 better_37\RBR\1740 therapeutic_38\JJ\1740 approach_39\NN\940842 to_40\IN\1740 them_41\PRP\1740 ._42\.\1740
11860278
D004298_D004827 NONE <e1>dopamine</e1>_0\NN\14807737 (_1\-LRB-\1740 da_2\NN\10484858 )_3\-RRB-\1740 ,_4\,\1740 through_5\IN\1740 d1/d2_6\NN\1740 receptor-mediated_7\JJ\1740 signaling_8\NN\33020 ,_9\,\1740 plays_10\VBZ\1072262 a_11\DT\13649268 major_12\JJ\1740 role_13\NN\719494 in_14\IN\13603305 the_15\DT\1740 control_16\NN\5190804 of_17\IN\1740 <e2>epileptic_18\JJ\1740 seizures</e2>_19\NNS\14081375 arising_20\VBG\2623529 in_21\IN\13603305 the_22\DT\1740 limbic_23\JJ\1740 system_24\NN\3575240 ._25\.\1740
D004298_D004827 NONE dopamine_0\NN\14807737 (_1\-LRB-\1740 <e1>da</e1>_2\NN\10484858 )_3\-RRB-\1740 ,_4\,\1740 through_5\IN\1740 d1/d2_6\NN\1740 receptor-mediated_7\JJ\1740 signaling_8\NN\33020 ,_9\,\1740 plays_10\VBZ\1072262 a_11\DT\13649268 major_12\JJ\1740 role_13\NN\719494 in_14\IN\13603305 the_15\DT\1740 control_16\NN\5190804 of_17\IN\1740 <e2>epileptic_18\JJ\1740 seizures</e2>_19\NNS\14081375 arising_20\VBG\2623529 in_21\IN\13603305 the_22\DT\1740 limbic_23\JJ\1740 system_24\NN\3575240 ._25\.\1740
D004298_D004827 NONE in_0\IN\13603305 this_1\DT\1740 respect_2\NN\5817845 ,_3\,\1740 little_4\JJ\1740 is_5\VBZ\836236 known_6\VBN\2110220 about_7\IN\1740 the_8\DT\1740 role_9\NN\719494 of_10\IN\1740 <e1>da</e1>_11\NN\10484858 receptors_12\NNS\5225602 in_13\IN\13603305 the_14\DT\1740 occurrence_15\NN\29378 of_16\IN\1740 <e2>epilepsy-induced</e2>_17\JJ\1740 neuronal_18\JJ\1740 cell_19\NN\3080309 death_20\NN\7296428 ._21\.\1740
D010862_D012640 CID here_0\RB\1740 we_1\PRP\1740 analyze_2\VBP\78760 the_3\DT\1740 occurrence_4\NN\29378 of_5\IN\1740 <e2>seizures</e2>_6\NNS\14081375 and_7\CC\1740 neurotoxicity_8\NN\1740 in_9\IN\13603305 d2r_10\NN\1740 -/-_11\JJ\1740 mice_12\NNS\2329401 treated_13\VBN\2376958 with_14\IN\1740 the_15\DT\1740 cholinergic_16\JJ\1740 agonist_17\NN\9613191 <e1>pilocarpine</e1>_18\NN\14712692 ._19\.\1740
D010862_D012640 CID however_0\RB\1740 ,_1\,\1740 <e1>pilocarpine-induced</e1>_2\JJ\1740 <e2>seizures</e2>_3\NNS\14081375 result_4\VBP\2633881 in_5\IN\13603305 a_6\DT\13649268 more_7\RBR\1740 widespread_8\JJ\1740 neuronal_9\JJ\1740 death_10\NN\7296428 in_11\IN\13603305 both_12\CC\1740 wt_13\NN\1740 and_14\CC\1740 d2r_15\NN\1740 -/-_16\NN\1740 brains_17\NNS\5462674 in_18\IN\13603305 comparison_19\NN\635850 to_20\TO\1740 ka_21\NN\1740 ._22\.\1740
D010862_D020258 NONE here_0\RB\1740 we_1\PRP\1740 analyze_2\VBP\78760 the_3\DT\1740 occurrence_4\NN\29378 of_5\IN\1740 seizures_6\NNS\14081375 and_7\CC\1740 <e2>neurotoxicity</e2>_8\NN\1740 in_9\IN\13603305 d2r_10\NN\1740 -/-_11\JJ\1740 mice_12\NNS\2329401 treated_13\VBN\2376958 with_14\IN\1740 the_15\DT\1740 cholinergic_16\JJ\1740 agonist_17\NN\9613191 <e1>pilocarpine</e1>_18\NN\14712692 ._19\.\1740
D007608_D012640 CID however_0\RB\1740 ,_1\,\1740 pilocarpine-induced_2\JJ\1740 <e2>seizures</e2>_3\NNS\14081375 result_4\VBP\2633881 in_5\IN\13603305 a_6\DT\13649268 more_7\RBR\1740 widespread_8\JJ\1740 neuronal_9\JJ\1740 death_10\NN\7296428 in_11\IN\13603305 both_12\CC\1740 wt_13\NN\1740 and_14\CC\1740 d2r_15\NN\1740 -/-_16\NN\1740 brains_17\NNS\5462674 in_18\IN\13603305 comparison_19\NN\635850 to_20\TO\1740 <e1>ka</e1>_21\NN\1740 ._22\.\1740
D018698_D012640 NONE thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 absence_3\NN\14449405 of_4\IN\1740 d2r_5\NN\1740 lowers_6\VBZ\1850315 the_7\DT\1740 threshold_8\NN\15265518 for_9\IN\1740 <e2>seizures</e2>_10\NNS\14081375 induced_11\VBN\1627355 by_12\IN\1740 both_13\CC\1740 <e1>glutamate</e1>_14\NN\15010703 and_15\CC\1740 acetylcholine_16\NN\14807558 ._17\.\1740
D000109_D012640 NONE thus_0\RB\1740 ,_1\,\1740 the_2\DT\1740 absence_3\NN\14449405 of_4\IN\1740 d2r_5\NN\1740 lowers_6\VBZ\1850315 the_7\DT\1740 threshold_8\NN\15265518 for_9\IN\1740 <e2>seizures</e2>_10\NNS\14081375 induced_11\VBN\1627355 by_12\IN\1740 both_13\CC\1740 glutamate_14\NN\15010703 and_15\CC\1740 <e1>acetylcholine</e1>_16\NN\14807558 ._17\.\1740
2819587
11302406
D015725_D016171 CID <e1>fluconazole-induced</e1>_0\JJ\1740 <e2>torsade_1\NN\1740 de_2\FW\1740 pointes</e2>_3\NNS\1740 ._4\.\1740
D015725_D016171 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 present_3\VB\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e1>fluconazole-associated</e1>_7\JJ\1740 <e2>torsade_8\NN\1740 de_9\IN\1740 pointes</e2>_10\NNS\1740 (_11\-LRB-\1740 tdp_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 discuss_15\VB\1033527 fluconazole_16\NN\1740 's_17\POS\1740 role_18\NN\719494 in_19\IN\13603305 causing_20\VBG\1617192 tdp_21\NN\1740 ._22\.\1740
D015725_D016171 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 present_3\VB\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e1>fluconazole-associated</e1>_7\JJ\1740 torsade_8\NN\1740 de_9\IN\1740 pointes_10\NNS\1740 (_11\-LRB-\1740 <e2>tdp</e2>_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 discuss_15\VB\1033527 fluconazole_16\NN\1740 's_17\POS\1740 role_18\NN\719494 in_19\IN\13603305 causing_20\VBG\1617192 tdp_21\NN\1740 ._22\.\1740
D015725_D016171 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 present_3\VB\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 <e1>fluconazole-associated</e1>_7\JJ\1740 torsade_8\NN\1740 de_9\IN\1740 pointes_10\NNS\1740 (_11\-LRB-\1740 tdp_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 discuss_15\VB\1033527 fluconazole_16\NN\1740 's_17\POS\1740 role_18\NN\719494 in_19\IN\13603305 causing_20\VBG\1617192 <e2>tdp</e2>_21\NN\1740 ._22\.\1740
D015725_D016171 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 present_3\VB\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 fluconazole-associated_7\JJ\1740 <e2>torsade_8\NN\1740 de_9\IN\1740 pointes</e2>_10\NNS\1740 (_11\-LRB-\1740 tdp_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 discuss_15\VB\1033527 <e1>fluconazole</e1>_16\NN\1740 's_17\POS\1740 role_18\NN\719494 in_19\IN\13603305 causing_20\VBG\1617192 tdp_21\NN\1740 ._22\.\1740
D015725_D016171 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 present_3\VB\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 fluconazole-associated_7\JJ\1740 torsade_8\NN\1740 de_9\IN\1740 pointes_10\NNS\1740 (_11\-LRB-\1740 <e2>tdp</e2>_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 discuss_15\VB\1033527 <e1>fluconazole</e1>_16\NN\1740 's_17\POS\1740 role_18\NN\719494 in_19\IN\13603305 causing_20\VBG\1617192 tdp_21\NN\1740 ._22\.\1740
D015725_D016171 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 present_3\VB\2137132 a_4\DT\13649268 case_5\NN\7283608 of_6\IN\1740 fluconazole-associated_7\JJ\1740 torsade_8\NN\1740 de_9\IN\1740 pointes_10\NNS\1740 (_11\-LRB-\1740 tdp_12\NN\1740 )_13\-RRB-\1740 and_14\CC\1740 discuss_15\VB\1033527 <e1>fluconazole</e1>_16\NN\1740 's_17\POS\1740 role_18\NN\719494 in_19\IN\13603305 causing_20\VBG\1617192 <e2>tdp</e2>_21\NN\1740 ._22\.\1740
D015725_D016171 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 68-year-old_4\JJ\1740 white_5\JJ\1740 woman_6\NN\9605289 with_7\IN\1740 candida_8\NN\12992868 glabrata_9\NN\1740 isolated_10\VBN\2512305 from_11\IN\1740 a_12\DT\13649268 presacral_13\JJ\1740 abscess_14\NN\14299637 developed_15\VBD\1753788 <e2>tdp</e2>_16\NN\1740 eight_17\CD\13741022 days_18\NNS\15140892 after_19\IN\1740 commencing_20\VBG\348746 oral_21\JJ\1740 <e1>fluconazole</e1>_22\NN\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 no_26\DT\7204911 other_27\JJ\1740 risk_28\NN\14541044 factors_29\NNS\7326557 for_30\IN\1740 tdp_31\NN\1740 ,_32\,\1740 including_33\VBG\690614 coronary_34\JJ\1740 artery_35\NN\5417975 disease_36\NN\14061805 ,_37\,\1740 cardiomyopathy_38\JJ\1740 ,_39\,\1740 congestive_40\JJ\1740 heart_41\NN\5919034 failure_42\NN\66216 ,_43\,\1740 and_44\CC\1740 electrolyte_45\NN\14589223 abnormalities_46\NNS\14034177 there_47\EX\27167 was_48\VBD\836236 a_49\DT\13649268 temporal_50\JJ\1740 association_51\NN\8008335 between_52\IN\1740 the_53\DT\1740 initiation_54\NN\7450842 of_55\IN\1740 fluconazole_56\NN\1740 and_57\CC\1740 tdp_58\NN\1740 ._59\.\1740
D015725_D016171 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 68-year-old_4\JJ\1740 white_5\JJ\1740 woman_6\NN\9605289 with_7\IN\1740 candida_8\NN\12992868 glabrata_9\NN\1740 isolated_10\VBN\2512305 from_11\IN\1740 a_12\DT\13649268 presacral_13\JJ\1740 abscess_14\NN\14299637 developed_15\VBD\1753788 tdp_16\NN\1740 eight_17\CD\13741022 days_18\NNS\15140892 after_19\IN\1740 commencing_20\VBG\348746 oral_21\JJ\1740 <e1>fluconazole</e1>_22\NN\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 no_26\DT\7204911 other_27\JJ\1740 risk_28\NN\14541044 factors_29\NNS\7326557 for_30\IN\1740 <e2>tdp</e2>_31\NN\1740 ,_32\,\1740 including_33\VBG\690614 coronary_34\JJ\1740 artery_35\NN\5417975 disease_36\NN\14061805 ,_37\,\1740 cardiomyopathy_38\JJ\1740 ,_39\,\1740 congestive_40\JJ\1740 heart_41\NN\5919034 failure_42\NN\66216 ,_43\,\1740 and_44\CC\1740 electrolyte_45\NN\14589223 abnormalities_46\NNS\14034177 there_47\EX\27167 was_48\VBD\836236 a_49\DT\13649268 temporal_50\JJ\1740 association_51\NN\8008335 between_52\IN\1740 the_53\DT\1740 initiation_54\NN\7450842 of_55\IN\1740 fluconazole_56\NN\1740 and_57\CC\1740 tdp_58\NN\1740 ._59\.\1740
D015725_D016171 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 68-year-old_4\JJ\1740 white_5\JJ\1740 woman_6\NN\9605289 with_7\IN\1740 candida_8\NN\12992868 glabrata_9\NN\1740 isolated_10\VBN\2512305 from_11\IN\1740 a_12\DT\13649268 presacral_13\JJ\1740 abscess_14\NN\14299637 developed_15\VBD\1753788 tdp_16\NN\1740 eight_17\CD\13741022 days_18\NNS\15140892 after_19\IN\1740 commencing_20\VBG\348746 oral_21\JJ\1740 <e1>fluconazole</e1>_22\NN\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 no_26\DT\7204911 other_27\JJ\1740 risk_28\NN\14541044 factors_29\NNS\7326557 for_30\IN\1740 tdp_31\NN\1740 ,_32\,\1740 including_33\VBG\690614 coronary_34\JJ\1740 artery_35\NN\5417975 disease_36\NN\14061805 ,_37\,\1740 cardiomyopathy_38\JJ\1740 ,_39\,\1740 congestive_40\JJ\1740 heart_41\NN\5919034 failure_42\NN\66216 ,_43\,\1740 and_44\CC\1740 electrolyte_45\NN\14589223 abnormalities_46\NNS\14034177 there_47\EX\27167 was_48\VBD\836236 a_49\DT\13649268 temporal_50\JJ\1740 association_51\NN\8008335 between_52\IN\1740 the_53\DT\1740 initiation_54\NN\7450842 of_55\IN\1740 fluconazole_56\NN\1740 and_57\CC\1740 <e2>tdp</e2>_58\NN\1740 ._59\.\1740
D015725_D016171 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 68-year-old_4\JJ\1740 white_5\JJ\1740 woman_6\NN\9605289 with_7\IN\1740 candida_8\NN\12992868 glabrata_9\NN\1740 isolated_10\VBN\2512305 from_11\IN\1740 a_12\DT\13649268 presacral_13\JJ\1740 abscess_14\NN\14299637 developed_15\VBD\1753788 <e2>tdp</e2>_16\NN\1740 eight_17\CD\13741022 days_18\NNS\15140892 after_19\IN\1740 commencing_20\VBG\348746 oral_21\JJ\1740 fluconazole_22\NN\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 no_26\DT\7204911 other_27\JJ\1740 risk_28\NN\14541044 factors_29\NNS\7326557 for_30\IN\1740 tdp_31\NN\1740 ,_32\,\1740 including_33\VBG\690614 coronary_34\JJ\1740 artery_35\NN\5417975 disease_36\NN\14061805 ,_37\,\1740 cardiomyopathy_38\JJ\1740 ,_39\,\1740 congestive_40\JJ\1740 heart_41\NN\5919034 failure_42\NN\66216 ,_43\,\1740 and_44\CC\1740 electrolyte_45\NN\14589223 abnormalities_46\NNS\14034177 there_47\EX\27167 was_48\VBD\836236 a_49\DT\13649268 temporal_50\JJ\1740 association_51\NN\8008335 between_52\IN\1740 the_53\DT\1740 initiation_54\NN\7450842 of_55\IN\1740 <e1>fluconazole</e1>_56\NN\1740 and_57\CC\1740 tdp_58\NN\1740 ._59\.\1740
D015725_D016171 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 68-year-old_4\JJ\1740 white_5\JJ\1740 woman_6\NN\9605289 with_7\IN\1740 candida_8\NN\12992868 glabrata_9\NN\1740 isolated_10\VBN\2512305 from_11\IN\1740 a_12\DT\13649268 presacral_13\JJ\1740 abscess_14\NN\14299637 developed_15\VBD\1753788 tdp_16\NN\1740 eight_17\CD\13741022 days_18\NNS\15140892 after_19\IN\1740 commencing_20\VBG\348746 oral_21\JJ\1740 fluconazole_22\NN\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 no_26\DT\7204911 other_27\JJ\1740 risk_28\NN\14541044 factors_29\NNS\7326557 for_30\IN\1740 <e2>tdp</e2>_31\NN\1740 ,_32\,\1740 including_33\VBG\690614 coronary_34\JJ\1740 artery_35\NN\5417975 disease_36\NN\14061805 ,_37\,\1740 cardiomyopathy_38\JJ\1740 ,_39\,\1740 congestive_40\JJ\1740 heart_41\NN\5919034 failure_42\NN\66216 ,_43\,\1740 and_44\CC\1740 electrolyte_45\NN\14589223 abnormalities_46\NNS\14034177 there_47\EX\27167 was_48\VBD\836236 a_49\DT\13649268 temporal_50\JJ\1740 association_51\NN\8008335 between_52\IN\1740 the_53\DT\1740 initiation_54\NN\7450842 of_55\IN\1740 <e1>fluconazole</e1>_56\NN\1740 and_57\CC\1740 tdp_58\NN\1740 ._59\.\1740
D015725_D016171 CID case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 68-year-old_4\JJ\1740 white_5\JJ\1740 woman_6\NN\9605289 with_7\IN\1740 candida_8\NN\12992868 glabrata_9\NN\1740 isolated_10\VBN\2512305 from_11\IN\1740 a_12\DT\13649268 presacral_13\JJ\1740 abscess_14\NN\14299637 developed_15\VBD\1753788 tdp_16\NN\1740 eight_17\CD\13741022 days_18\NNS\15140892 after_19\IN\1740 commencing_20\VBG\348746 oral_21\JJ\1740 fluconazole_22\NN\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 no_26\DT\7204911 other_27\JJ\1740 risk_28\NN\14541044 factors_29\NNS\7326557 for_30\IN\1740 tdp_31\NN\1740 ,_32\,\1740 including_33\VBG\690614 coronary_34\JJ\1740 artery_35\NN\5417975 disease_36\NN\14061805 ,_37\,\1740 cardiomyopathy_38\JJ\1740 ,_39\,\1740 congestive_40\JJ\1740 heart_41\NN\5919034 failure_42\NN\66216 ,_43\,\1740 and_44\CC\1740 electrolyte_45\NN\14589223 abnormalities_46\NNS\14034177 there_47\EX\27167 was_48\VBD\836236 a_49\DT\13649268 temporal_50\JJ\1740 association_51\NN\8008335 between_52\IN\1740 the_53\DT\1740 initiation_54\NN\7450842 of_55\IN\1740 <e1>fluconazole</e1>_56\NN\1740 and_57\CC\1740 <e2>tdp</e2>_58\NN\1740 ._59\.\1740
D015725_D016171 CID the_0\DT\1740 <e2>tdp</e2>_1\NN\1740 resolved_2\VBD\352826 when_3\WRB\1740 <e1>fluconazole</e1>_4\NN\1740 was_5\VBD\836236 discontinued_6\VBN\2609764 ;_7\:\1740 however_8\RB\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 continued_12\VBD\2367363 to_13\TO\1740 have_14\VB\2108377 premature_15\JJ\1740 ventricular_16\JJ\1740 contractions_17\NNS\358931 and_18\CC\1740 nonsustained_19\JJ\1740 ventricular_20\JJ\1740 tachycardia_21\NN\14110674 (_22\-LRB-\1740 nsvt_23\NN\1740 )_24\-RRB-\1740 until_25\IN\1740 six_26\CD\13741022 days_27\NNS\15140892 after_28\IN\1740 drug_29\NN\14778436 cessation_30\NN\7365849 discussion_31\NN\6252138 :_32\:\1740 use_33\NN\407535 of_34\IN\1740 the_35\DT\1740 naranjo_36\NNP\1740 probability_37\NN\33615 scale_38\NN\7260623 indicates_39\VBZ\952524 a_40\DT\13649268 probable_41\JJ\1740 relationship_42\NN\31921 between_43\IN\1740 the_44\DT\1740 use_45\NN\407535 of_46\IN\1740 fluconazole_47\NN\1740 and_48\CC\1740 the_49\DT\1740 development_50\NN\248977 of_51\IN\1740 tdp_52\NN\1740 ._53\.\1740
D015725_D016171 CID the_0\DT\1740 tdp_1\NN\1740 resolved_2\VBD\352826 when_3\WRB\1740 <e1>fluconazole</e1>_4\NN\1740 was_5\VBD\836236 discontinued_6\VBN\2609764 ;_7\:\1740 however_8\RB\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 continued_12\VBD\2367363 to_13\TO\1740 have_14\VB\2108377 premature_15\JJ\1740 ventricular_16\JJ\1740 contractions_17\NNS\358931 and_18\CC\1740 nonsustained_19\JJ\1740 ventricular_20\JJ\1740 tachycardia_21\NN\14110674 (_22\-LRB-\1740 nsvt_23\NN\1740 )_24\-RRB-\1740 until_25\IN\1740 six_26\CD\13741022 days_27\NNS\15140892 after_28\IN\1740 drug_29\NN\14778436 cessation_30\NN\7365849 discussion_31\NN\6252138 :_32\:\1740 use_33\NN\407535 of_34\IN\1740 the_35\DT\1740 naranjo_36\NNP\1740 probability_37\NN\33615 scale_38\NN\7260623 indicates_39\VBZ\952524 a_40\DT\13649268 probable_41\JJ\1740 relationship_42\NN\31921 between_43\IN\1740 the_44\DT\1740 use_45\NN\407535 of_46\IN\1740 fluconazole_47\NN\1740 and_48\CC\1740 the_49\DT\1740 development_50\NN\248977 of_51\IN\1740 <e2>tdp</e2>_52\NN\1740 ._53\.\1740
D015725_D016171 CID the_0\DT\1740 <e2>tdp</e2>_1\NN\1740 resolved_2\VBD\352826 when_3\WRB\1740 fluconazole_4\NN\1740 was_5\VBD\836236 discontinued_6\VBN\2609764 ;_7\:\1740 however_8\RB\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 continued_12\VBD\2367363 to_13\TO\1740 have_14\VB\2108377 premature_15\JJ\1740 ventricular_16\JJ\1740 contractions_17\NNS\358931 and_18\CC\1740 nonsustained_19\JJ\1740 ventricular_20\JJ\1740 tachycardia_21\NN\14110674 (_22\-LRB-\1740 nsvt_23\NN\1740 )_24\-RRB-\1740 until_25\IN\1740 six_26\CD\13741022 days_27\NNS\15140892 after_28\IN\1740 drug_29\NN\14778436 cessation_30\NN\7365849 discussion_31\NN\6252138 :_32\:\1740 use_33\NN\407535 of_34\IN\1740 the_35\DT\1740 naranjo_36\NNP\1740 probability_37\NN\33615 scale_38\NN\7260623 indicates_39\VBZ\952524 a_40\DT\13649268 probable_41\JJ\1740 relationship_42\NN\31921 between_43\IN\1740 the_44\DT\1740 use_45\NN\407535 of_46\IN\1740 <e1>fluconazole</e1>_47\NN\1740 and_48\CC\1740 the_49\DT\1740 development_50\NN\248977 of_51\IN\1740 tdp_52\NN\1740 ._53\.\1740
D015725_D016171 CID the_0\DT\1740 tdp_1\NN\1740 resolved_2\VBD\352826 when_3\WRB\1740 fluconazole_4\NN\1740 was_5\VBD\836236 discontinued_6\VBN\2609764 ;_7\:\1740 however_8\RB\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 continued_12\VBD\2367363 to_13\TO\1740 have_14\VB\2108377 premature_15\JJ\1740 ventricular_16\JJ\1740 contractions_17\NNS\358931 and_18\CC\1740 nonsustained_19\JJ\1740 ventricular_20\JJ\1740 tachycardia_21\NN\14110674 (_22\-LRB-\1740 nsvt_23\NN\1740 )_24\-RRB-\1740 until_25\IN\1740 six_26\CD\13741022 days_27\NNS\15140892 after_28\IN\1740 drug_29\NN\14778436 cessation_30\NN\7365849 discussion_31\NN\6252138 :_32\:\1740 use_33\NN\407535 of_34\IN\1740 the_35\DT\1740 naranjo_36\NNP\1740 probability_37\NN\33615 scale_38\NN\7260623 indicates_39\VBZ\952524 a_40\DT\13649268 probable_41\JJ\1740 relationship_42\NN\31921 between_43\IN\1740 the_44\DT\1740 use_45\NN\407535 of_46\IN\1740 <e1>fluconazole</e1>_47\NN\1740 and_48\CC\1740 the_49\DT\1740 development_50\NN\248977 of_51\IN\1740 <e2>tdp</e2>_52\NN\1740 ._53\.\1740
D015725_D016171 CID in_0\IN\13603305 our_1\PRP$\1740 patient_2\NN\9898892 ,_3\,\1740 there_4\EX\27167 was_5\VBD\836236 no_6\DT\7204911 other_7\JJ\1740 etiology_8\NN\7326557 identified_9\VBD\699815 that_10\WDT\1740 could_11\MD\1740 explain_12\VB\831651 qt_13\NN\1740 prolongation_14\NN\1017987 or_15\CC\3541091 <e2>tdp</e2>_16\NN\1740 the_17\DT\1740 complete_18\JJ\1740 disappearance_19\NN\42757 of_20\IN\1740 nsvt_21\NN\1740 and_22\CC\1740 premature_23\JJ\1740 ventricular_24\JJ\1740 contractions_25\NNS\358931 followed_26\VBN\1835496 by_27\IN\1740 normalization_28\NN\1123598 of_29\IN\1740 qt_30\NN\1740 interval_31\NN\33615 after_32\IN\1740 the_33\DT\1740 drug_34\NN\14778436 was_35\VBD\836236 stopped_36\VBN\2452885 strongly_37\RB\1740 suggests_38\VBZ\1010118 <e1>fluconazole</e1>_39\NN\1740 as_40\IN\14622893 the_41\DT\1740 etiology_42\NN\7326557 ._43\.\1740
D015725_D016171 CID conclusions_0\NNS\5837957 :_1\:\1740 clinicians_2\NNS\10462860 should_3\MD\1740 be_4\VB\836236 aware_5\JJ\1740 that_6\IN\1740 <e1>fluconazole</e1>_7\NN\1740 ,_8\,\1740 even_9\RB\1740 at_10\IN\14622893 low_11\JJ\1740 doses_12\NNS\3740161 ,_13\,\1740 may_14\MD\15209706 cause_15\VB\1617192 prolongation_16\NN\1017987 of_17\IN\1740 the_18\DT\1740 qt_19\NNP\1740 interval_20\NN\33615 ,_21\,\1740 leading_22\VBG\1752884 to_23\TO\1740 <e2>tdp</e2>_24\NN\1740 ._25\.\1740
D015725_D003324 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 68-year-old_4\JJ\1740 white_5\JJ\1740 woman_6\NN\9605289 with_7\IN\1740 candida_8\NN\12992868 glabrata_9\NN\1740 isolated_10\VBN\2512305 from_11\IN\1740 a_12\DT\13649268 presacral_13\JJ\1740 abscess_14\NN\14299637 developed_15\VBD\1753788 tdp_16\NN\1740 eight_17\CD\13741022 days_18\NNS\15140892 after_19\IN\1740 commencing_20\VBG\348746 oral_21\JJ\1740 <e1>fluconazole</e1>_22\NN\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 no_26\DT\7204911 other_27\JJ\1740 risk_28\NN\14541044 factors_29\NNS\7326557 for_30\IN\1740 tdp_31\NN\1740 ,_32\,\1740 including_33\VBG\690614 <e2>coronary_34\JJ\1740 artery_35\NN\5417975 disease</e2>_36\NN\14061805 ,_37\,\1740 cardiomyopathy_38\JJ\1740 ,_39\,\1740 congestive_40\JJ\1740 heart_41\NN\5919034 failure_42\NN\66216 ,_43\,\1740 and_44\CC\1740 electrolyte_45\NN\14589223 abnormalities_46\NNS\14034177 there_47\EX\27167 was_48\VBD\836236 a_49\DT\13649268 temporal_50\JJ\1740 association_51\NN\8008335 between_52\IN\1740 the_53\DT\1740 initiation_54\NN\7450842 of_55\IN\1740 fluconazole_56\NN\1740 and_57\CC\1740 tdp_58\NN\1740 ._59\.\1740
D015725_D003324 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 68-year-old_4\JJ\1740 white_5\JJ\1740 woman_6\NN\9605289 with_7\IN\1740 candida_8\NN\12992868 glabrata_9\NN\1740 isolated_10\VBN\2512305 from_11\IN\1740 a_12\DT\13649268 presacral_13\JJ\1740 abscess_14\NN\14299637 developed_15\VBD\1753788 tdp_16\NN\1740 eight_17\CD\13741022 days_18\NNS\15140892 after_19\IN\1740 commencing_20\VBG\348746 oral_21\JJ\1740 fluconazole_22\NN\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 no_26\DT\7204911 other_27\JJ\1740 risk_28\NN\14541044 factors_29\NNS\7326557 for_30\IN\1740 tdp_31\NN\1740 ,_32\,\1740 including_33\VBG\690614 <e2>coronary_34\JJ\1740 artery_35\NN\5417975 disease</e2>_36\NN\14061805 ,_37\,\1740 cardiomyopathy_38\JJ\1740 ,_39\,\1740 congestive_40\JJ\1740 heart_41\NN\5919034 failure_42\NN\66216 ,_43\,\1740 and_44\CC\1740 electrolyte_45\NN\14589223 abnormalities_46\NNS\14034177 there_47\EX\27167 was_48\VBD\836236 a_49\DT\13649268 temporal_50\JJ\1740 association_51\NN\8008335 between_52\IN\1740 the_53\DT\1740 initiation_54\NN\7450842 of_55\IN\1740 <e1>fluconazole</e1>_56\NN\1740 and_57\CC\1740 tdp_58\NN\1740 ._59\.\1740
D015725_D009202 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 68-year-old_4\JJ\1740 white_5\JJ\1740 woman_6\NN\9605289 with_7\IN\1740 candida_8\NN\12992868 glabrata_9\NN\1740 isolated_10\VBN\2512305 from_11\IN\1740 a_12\DT\13649268 presacral_13\JJ\1740 abscess_14\NN\14299637 developed_15\VBD\1753788 tdp_16\NN\1740 eight_17\CD\13741022 days_18\NNS\15140892 after_19\IN\1740 commencing_20\VBG\348746 oral_21\JJ\1740 <e1>fluconazole</e1>_22\NN\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 no_26\DT\7204911 other_27\JJ\1740 risk_28\NN\14541044 factors_29\NNS\7326557 for_30\IN\1740 tdp_31\NN\1740 ,_32\,\1740 including_33\VBG\690614 coronary_34\JJ\1740 artery_35\NN\5417975 disease_36\NN\14061805 ,_37\,\1740 <e2>cardiomyopathy</e2>_38\JJ\1740 ,_39\,\1740 congestive_40\JJ\1740 heart_41\NN\5919034 failure_42\NN\66216 ,_43\,\1740 and_44\CC\1740 electrolyte_45\NN\14589223 abnormalities_46\NNS\14034177 there_47\EX\27167 was_48\VBD\836236 a_49\DT\13649268 temporal_50\JJ\1740 association_51\NN\8008335 between_52\IN\1740 the_53\DT\1740 initiation_54\NN\7450842 of_55\IN\1740 fluconazole_56\NN\1740 and_57\CC\1740 tdp_58\NN\1740 ._59\.\1740
D015725_D009202 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 68-year-old_4\JJ\1740 white_5\JJ\1740 woman_6\NN\9605289 with_7\IN\1740 candida_8\NN\12992868 glabrata_9\NN\1740 isolated_10\VBN\2512305 from_11\IN\1740 a_12\DT\13649268 presacral_13\JJ\1740 abscess_14\NN\14299637 developed_15\VBD\1753788 tdp_16\NN\1740 eight_17\CD\13741022 days_18\NNS\15140892 after_19\IN\1740 commencing_20\VBG\348746 oral_21\JJ\1740 fluconazole_22\NN\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 no_26\DT\7204911 other_27\JJ\1740 risk_28\NN\14541044 factors_29\NNS\7326557 for_30\IN\1740 tdp_31\NN\1740 ,_32\,\1740 including_33\VBG\690614 coronary_34\JJ\1740 artery_35\NN\5417975 disease_36\NN\14061805 ,_37\,\1740 <e2>cardiomyopathy</e2>_38\JJ\1740 ,_39\,\1740 congestive_40\JJ\1740 heart_41\NN\5919034 failure_42\NN\66216 ,_43\,\1740 and_44\CC\1740 electrolyte_45\NN\14589223 abnormalities_46\NNS\14034177 there_47\EX\27167 was_48\VBD\836236 a_49\DT\13649268 temporal_50\JJ\1740 association_51\NN\8008335 between_52\IN\1740 the_53\DT\1740 initiation_54\NN\7450842 of_55\IN\1740 <e1>fluconazole</e1>_56\NN\1740 and_57\CC\1740 tdp_58\NN\1740 ._59\.\1740
D015725_D006333 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 68-year-old_4\JJ\1740 white_5\JJ\1740 woman_6\NN\9605289 with_7\IN\1740 candida_8\NN\12992868 glabrata_9\NN\1740 isolated_10\VBN\2512305 from_11\IN\1740 a_12\DT\13649268 presacral_13\JJ\1740 abscess_14\NN\14299637 developed_15\VBD\1753788 tdp_16\NN\1740 eight_17\CD\13741022 days_18\NNS\15140892 after_19\IN\1740 commencing_20\VBG\348746 oral_21\JJ\1740 <e1>fluconazole</e1>_22\NN\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 no_26\DT\7204911 other_27\JJ\1740 risk_28\NN\14541044 factors_29\NNS\7326557 for_30\IN\1740 tdp_31\NN\1740 ,_32\,\1740 including_33\VBG\690614 coronary_34\JJ\1740 artery_35\NN\5417975 disease_36\NN\14061805 ,_37\,\1740 cardiomyopathy_38\JJ\1740 ,_39\,\1740 <e2>congestive_40\JJ\1740 heart_41\NN\5919034 failure</e2>_42\NN\66216 ,_43\,\1740 and_44\CC\1740 electrolyte_45\NN\14589223 abnormalities_46\NNS\14034177 there_47\EX\27167 was_48\VBD\836236 a_49\DT\13649268 temporal_50\JJ\1740 association_51\NN\8008335 between_52\IN\1740 the_53\DT\1740 initiation_54\NN\7450842 of_55\IN\1740 fluconazole_56\NN\1740 and_57\CC\1740 tdp_58\NN\1740 ._59\.\1740
D015725_D006333 NONE case_0\NN\7283608 summary_1\NN\6722453 :_2\:\1740 a_3\DT\13649268 68-year-old_4\JJ\1740 white_5\JJ\1740 woman_6\NN\9605289 with_7\IN\1740 candida_8\NN\12992868 glabrata_9\NN\1740 isolated_10\VBN\2512305 from_11\IN\1740 a_12\DT\13649268 presacral_13\JJ\1740 abscess_14\NN\14299637 developed_15\VBD\1753788 tdp_16\NN\1740 eight_17\CD\13741022 days_18\NNS\15140892 after_19\IN\1740 commencing_20\VBG\348746 oral_21\JJ\1740 fluconazole_22\NN\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 no_26\DT\7204911 other_27\JJ\1740 risk_28\NN\14541044 factors_29\NNS\7326557 for_30\IN\1740 tdp_31\NN\1740 ,_32\,\1740 including_33\VBG\690614 coronary_34\JJ\1740 artery_35\NN\5417975 disease_36\NN\14061805 ,_37\,\1740 cardiomyopathy_38\JJ\1740 ,_39\,\1740 <e2>congestive_40\JJ\1740 heart_41\NN\5919034 failure</e2>_42\NN\66216 ,_43\,\1740 and_44\CC\1740 electrolyte_45\NN\14589223 abnormalities_46\NNS\14034177 there_47\EX\27167 was_48\VBD\836236 a_49\DT\13649268 temporal_50\JJ\1740 association_51\NN\8008335 between_52\IN\1740 the_53\DT\1740 initiation_54\NN\7450842 of_55\IN\1740 <e1>fluconazole</e1>_56\NN\1740 and_57\CC\1740 tdp_58\NN\1740 ._59\.\1740
D015725_D018879 NONE the_0\DT\1740 tdp_1\NN\1740 resolved_2\VBD\352826 when_3\WRB\1740 <e1>fluconazole</e1>_4\NN\1740 was_5\VBD\836236 discontinued_6\VBN\2609764 ;_7\:\1740 however_8\RB\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 continued_12\VBD\2367363 to_13\TO\1740 have_14\VB\2108377 <e2>premature_15\JJ\1740 ventricular_16\JJ\1740 contractions</e2>_17\NNS\358931 and_18\CC\1740 nonsustained_19\JJ\1740 ventricular_20\JJ\1740 tachycardia_21\NN\14110674 (_22\-LRB-\1740 nsvt_23\NN\1740 )_24\-RRB-\1740 until_25\IN\1740 six_26\CD\13741022 days_27\NNS\15140892 after_28\IN\1740 drug_29\NN\14778436 cessation_30\NN\7365849 discussion_31\NN\6252138 :_32\:\1740 use_33\NN\407535 of_34\IN\1740 the_35\DT\1740 naranjo_36\NNP\1740 probability_37\NN\33615 scale_38\NN\7260623 indicates_39\VBZ\952524 a_40\DT\13649268 probable_41\JJ\1740 relationship_42\NN\31921 between_43\IN\1740 the_44\DT\1740 use_45\NN\407535 of_46\IN\1740 fluconazole_47\NN\1740 and_48\CC\1740 the_49\DT\1740 development_50\NN\248977 of_51\IN\1740 tdp_52\NN\1740 ._53\.\1740
D015725_D018879 NONE the_0\DT\1740 tdp_1\NN\1740 resolved_2\VBD\352826 when_3\WRB\1740 fluconazole_4\NN\1740 was_5\VBD\836236 discontinued_6\VBN\2609764 ;_7\:\1740 however_8\RB\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 continued_12\VBD\2367363 to_13\TO\1740 have_14\VB\2108377 <e2>premature_15\JJ\1740 ventricular_16\JJ\1740 contractions</e2>_17\NNS\358931 and_18\CC\1740 nonsustained_19\JJ\1740 ventricular_20\JJ\1740 tachycardia_21\NN\14110674 (_22\-LRB-\1740 nsvt_23\NN\1740 )_24\-RRB-\1740 until_25\IN\1740 six_26\CD\13741022 days_27\NNS\15140892 after_28\IN\1740 drug_29\NN\14778436 cessation_30\NN\7365849 discussion_31\NN\6252138 :_32\:\1740 use_33\NN\407535 of_34\IN\1740 the_35\DT\1740 naranjo_36\NNP\1740 probability_37\NN\33615 scale_38\NN\7260623 indicates_39\VBZ\952524 a_40\DT\13649268 probable_41\JJ\1740 relationship_42\NN\31921 between_43\IN\1740 the_44\DT\1740 use_45\NN\407535 of_46\IN\1740 <e1>fluconazole</e1>_47\NN\1740 and_48\CC\1740 the_49\DT\1740 development_50\NN\248977 of_51\IN\1740 tdp_52\NN\1740 ._53\.\1740
D015725_D018879 NONE in_0\IN\13603305 our_1\PRP$\1740 patient_2\NN\9898892 ,_3\,\1740 there_4\EX\27167 was_5\VBD\836236 no_6\DT\7204911 other_7\JJ\1740 etiology_8\NN\7326557 identified_9\VBD\699815 that_10\WDT\1740 could_11\MD\1740 explain_12\VB\831651 qt_13\NN\1740 prolongation_14\NN\1017987 or_15\CC\3541091 tdp_16\NN\1740 the_17\DT\1740 complete_18\JJ\1740 disappearance_19\NN\42757 of_20\IN\1740 nsvt_21\NN\1740 and_22\CC\1740 <e2>premature_23\JJ\1740 ventricular_24\JJ\1740 contractions</e2>_25\NNS\358931 followed_26\VBN\1835496 by_27\IN\1740 normalization_28\NN\1123598 of_29\IN\1740 qt_30\NN\1740 interval_31\NN\33615 after_32\IN\1740 the_33\DT\1740 drug_34\NN\14778436 was_35\VBD\836236 stopped_36\VBN\2452885 strongly_37\RB\1740 suggests_38\VBZ\1010118 <e1>fluconazole</e1>_39\NN\1740 as_40\IN\14622893 the_41\DT\1740 etiology_42\NN\7326557 ._43\.\1740
D015725_D017180 NONE the_0\DT\1740 tdp_1\NN\1740 resolved_2\VBD\352826 when_3\WRB\1740 <e1>fluconazole</e1>_4\NN\1740 was_5\VBD\836236 discontinued_6\VBN\2609764 ;_7\:\1740 however_8\RB\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 continued_12\VBD\2367363 to_13\TO\1740 have_14\VB\2108377 premature_15\JJ\1740 ventricular_16\JJ\1740 contractions_17\NNS\358931 and_18\CC\1740 nonsustained_19\JJ\1740 <e2>ventricular_20\JJ\1740 tachycardia</e2>_21\NN\14110674 (_22\-LRB-\1740 nsvt_23\NN\1740 )_24\-RRB-\1740 until_25\IN\1740 six_26\CD\13741022 days_27\NNS\15140892 after_28\IN\1740 drug_29\NN\14778436 cessation_30\NN\7365849 discussion_31\NN\6252138 :_32\:\1740 use_33\NN\407535 of_34\IN\1740 the_35\DT\1740 naranjo_36\NNP\1740 probability_37\NN\33615 scale_38\NN\7260623 indicates_39\VBZ\952524 a_40\DT\13649268 probable_41\JJ\1740 relationship_42\NN\31921 between_43\IN\1740 the_44\DT\1740 use_45\NN\407535 of_46\IN\1740 fluconazole_47\NN\1740 and_48\CC\1740 the_49\DT\1740 development_50\NN\248977 of_51\IN\1740 tdp_52\NN\1740 ._53\.\1740
D015725_D017180 NONE the_0\DT\1740 tdp_1\NN\1740 resolved_2\VBD\352826 when_3\WRB\1740 <e1>fluconazole</e1>_4\NN\1740 was_5\VBD\836236 discontinued_6\VBN\2609764 ;_7\:\1740 however_8\RB\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 continued_12\VBD\2367363 to_13\TO\1740 have_14\VB\2108377 premature_15\JJ\1740 ventricular_16\JJ\1740 contractions_17\NNS\358931 and_18\CC\1740 nonsustained_19\JJ\1740 ventricular_20\JJ\1740 tachycardia_21\NN\14110674 (_22\-LRB-\1740 <e2>nsvt</e2>_23\NN\1740 )_24\-RRB-\1740 until_25\IN\1740 six_26\CD\13741022 days_27\NNS\15140892 after_28\IN\1740 drug_29\NN\14778436 cessation_30\NN\7365849 discussion_31\NN\6252138 :_32\:\1740 use_33\NN\407535 of_34\IN\1740 the_35\DT\1740 naranjo_36\NNP\1740 probability_37\NN\33615 scale_38\NN\7260623 indicates_39\VBZ\952524 a_40\DT\13649268 probable_41\JJ\1740 relationship_42\NN\31921 between_43\IN\1740 the_44\DT\1740 use_45\NN\407535 of_46\IN\1740 fluconazole_47\NN\1740 and_48\CC\1740 the_49\DT\1740 development_50\NN\248977 of_51\IN\1740 tdp_52\NN\1740 ._53\.\1740
D015725_D017180 NONE the_0\DT\1740 tdp_1\NN\1740 resolved_2\VBD\352826 when_3\WRB\1740 fluconazole_4\NN\1740 was_5\VBD\836236 discontinued_6\VBN\2609764 ;_7\:\1740 however_8\RB\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 continued_12\VBD\2367363 to_13\TO\1740 have_14\VB\2108377 premature_15\JJ\1740 ventricular_16\JJ\1740 contractions_17\NNS\358931 and_18\CC\1740 nonsustained_19\JJ\1740 <e2>ventricular_20\JJ\1740 tachycardia</e2>_21\NN\14110674 (_22\-LRB-\1740 nsvt_23\NN\1740 )_24\-RRB-\1740 until_25\IN\1740 six_26\CD\13741022 days_27\NNS\15140892 after_28\IN\1740 drug_29\NN\14778436 cessation_30\NN\7365849 discussion_31\NN\6252138 :_32\:\1740 use_33\NN\407535 of_34\IN\1740 the_35\DT\1740 naranjo_36\NNP\1740 probability_37\NN\33615 scale_38\NN\7260623 indicates_39\VBZ\952524 a_40\DT\13649268 probable_41\JJ\1740 relationship_42\NN\31921 between_43\IN\1740 the_44\DT\1740 use_45\NN\407535 of_46\IN\1740 <e1>fluconazole</e1>_47\NN\1740 and_48\CC\1740 the_49\DT\1740 development_50\NN\248977 of_51\IN\1740 tdp_52\NN\1740 ._53\.\1740
D015725_D017180 NONE the_0\DT\1740 tdp_1\NN\1740 resolved_2\VBD\352826 when_3\WRB\1740 fluconazole_4\NN\1740 was_5\VBD\836236 discontinued_6\VBN\2609764 ;_7\:\1740 however_8\RB\1740 ,_9\,\1740 the_10\DT\1740 patient_11\NN\9898892 continued_12\VBD\2367363 to_13\TO\1740 have_14\VB\2108377 premature_15\JJ\1740 ventricular_16\JJ\1740 contractions_17\NNS\358931 and_18\CC\1740 nonsustained_19\JJ\1740 ventricular_20\JJ\1740 tachycardia_21\NN\14110674 (_22\-LRB-\1740 <e2>nsvt</e2>_23\NN\1740 )_24\-RRB-\1740 until_25\IN\1740 six_26\CD\13741022 days_27\NNS\15140892 after_28\IN\1740 drug_29\NN\14778436 cessation_30\NN\7365849 discussion_31\NN\6252138 :_32\:\1740 use_33\NN\407535 of_34\IN\1740 the_35\DT\1740 naranjo_36\NNP\1740 probability_37\NN\33615 scale_38\NN\7260623 indicates_39\VBZ\952524 a_40\DT\13649268 probable_41\JJ\1740 relationship_42\NN\31921 between_43\IN\1740 the_44\DT\1740 use_45\NN\407535 of_46\IN\1740 <e1>fluconazole</e1>_47\NN\1740 and_48\CC\1740 the_49\DT\1740 development_50\NN\248977 of_51\IN\1740 tdp_52\NN\1740 ._53\.\1740
D015725_D017180 NONE in_0\IN\13603305 our_1\PRP$\1740 patient_2\NN\9898892 ,_3\,\1740 there_4\EX\27167 was_5\VBD\836236 no_6\DT\7204911 other_7\JJ\1740 etiology_8\NN\7326557 identified_9\VBD\699815 that_10\WDT\1740 could_11\MD\1740 explain_12\VB\831651 qt_13\NN\1740 prolongation_14\NN\1017987 or_15\CC\3541091 tdp_16\NN\1740 the_17\DT\1740 complete_18\JJ\1740 disappearance_19\NN\42757 of_20\IN\1740 <e2>nsvt</e2>_21\NN\1740 and_22\CC\1740 premature_23\JJ\1740 ventricular_24\JJ\1740 contractions_25\NNS\358931 followed_26\VBN\1835496 by_27\IN\1740 normalization_28\NN\1123598 of_29\IN\1740 qt_30\NN\1740 interval_31\NN\33615 after_32\IN\1740 the_33\DT\1740 drug_34\NN\14778436 was_35\VBD\836236 stopped_36\VBN\2452885 strongly_37\RB\1740 suggests_38\VBZ\1010118 <e1>fluconazole</e1>_39\NN\1740 as_40\IN\14622893 the_41\DT\1740 etiology_42\NN\7326557 ._43\.\1740
D011188_D003866 NONE the_0\DT\1740 possible_1\JJ\1740 mechanism_2\NN\13446390 is_3\VBZ\836236 <e2>depression</e2>_4\NN\14373582 of_5\IN\1740 rapidly_6\RB\1740 activating_7\VBG\1641914 delayed_8\VBN\439958 rectifier_9\NN\3269401 <e1>potassium</e1>_10\NN\14625458 currents_11\NNS\11449002 ._12\.\1740
D015725_D008133 NONE in_0\IN\13603305 our_1\PRP$\1740 patient_2\NN\9898892 ,_3\,\1740 there_4\EX\27167 was_5\VBD\836236 no_6\DT\7204911 other_7\JJ\1740 etiology_8\NN\7326557 identified_9\VBD\699815 that_10\WDT\1740 could_11\MD\1740 explain_12\VB\831651 <e2>qt_13\NN\1740 prolongation</e2>_14\NN\1017987 or_15\CC\3541091 tdp_16\NN\1740 the_17\DT\1740 complete_18\JJ\1740 disappearance_19\NN\42757 of_20\IN\1740 nsvt_21\NN\1740 and_22\CC\1740 premature_23\JJ\1740 ventricular_24\JJ\1740 contractions_25\NNS\358931 followed_26\VBN\1835496 by_27\IN\1740 normalization_28\NN\1123598 of_29\IN\1740 qt_30\NN\1740 interval_31\NN\33615 after_32\IN\1740 the_33\DT\1740 drug_34\NN\14778436 was_35\VBD\836236 stopped_36\VBN\2452885 strongly_37\RB\1740 suggests_38\VBZ\1010118 <e1>fluconazole</e1>_39\NN\1740 as_40\IN\14622893 the_41\DT\1740 etiology_42\NN\7326557 ._43\.\1740
D015725_D008133 NONE conclusions_0\NNS\5837957 :_1\:\1740 clinicians_2\NNS\10462860 should_3\MD\1740 be_4\VB\836236 aware_5\JJ\1740 that_6\IN\1740 <e1>fluconazole</e1>_7\NN\1740 ,_8\,\1740 even_9\RB\1740 at_10\IN\14622893 low_11\JJ\1740 doses_12\NNS\3740161 ,_13\,\1740 may_14\MD\15209706 cause_15\VB\1617192 <e2>prolongation_16\NN\1017987 of_17\IN\1740 the_18\DT\1740 qt_19\NNP\1740 interval</e2>_20\NN\33615 ,_21\,\1740 leading_22\VBG\1752884 to_23\TO\1740 tdp_24\NN\1740 ._25\.\1740
D015725_D001145 NONE serial_0\JJ\1740 electrocardiographic_1\JJ\1740 monitoring_2\NN\879759 may_3\MD\15209706 be_4\VB\836236 considered_5\VBN\689344 when_6\WRB\1740 <e1>fluconazole</e1>_7\NN\1740 is_8\VBZ\836236 administered_9\VBN\2436349 in_10\IN\13603305 patients_11\NNS\9898892 who_12\WP\8299493 are_13\VBP\836236 at_14\IN\14622893 risk_15\NN\14541044 for_16\IN\1740 <e2>ventricular_17\JJ\1740 arrhythmias</e2>_18\NNS\14103288 ._19\.\1740
11271907
D003520_D006470 CID fatal_0\JJ\1740 <e2>haemorrhagic_1\JJ\1740 myocarditis</e2>_2\NN\14338942 secondary_3\JJ\1740 to_4\TO\1740 <e1>cyclophosphamide</e1>_5\NN\1740 therapy_6\NN\657604 ._7\.\1740
D003520_D006470 CID <e2>haemorrhagic_0\JJ\1740 myocarditis</e2>_1\NN\14338942 is_2\VBZ\836236 a_3\DT\13649268 rare_4\JJ\1740 but_5\CC\1740 important_6\JJ\1740 complication_7\NN\1073995 of_8\IN\1740 <e1>cyclophosphamide</e1>_9\NN\1740 therapy_10\NN\657604 ._11\.\1740
D003520_D009205 CID fatal_0\JJ\1740 <e2>haemorrhagic_1\JJ\1740 myocarditis</e2>_2\NN\14338942 secondary_3\JJ\1740 to_4\TO\1740 <e1>cyclophosphamide</e1>_5\NN\1740 therapy_6\NN\657604 ._7\.\1740
D003520_D009205 CID <e2>haemorrhagic_0\JJ\1740 myocarditis</e2>_1\NN\14338942 is_2\VBZ\836236 a_3\DT\13649268 rare_4\JJ\1740 but_5\CC\1740 important_6\JJ\1740 complication_7\NN\1073995 of_8\IN\1740 <e1>cyclophosphamide</e1>_9\NN\1740 therapy_10\NN\657604 ._11\.\1740
20304337
D003042_-1 NONE <e2>brainstem_0\NN\5462674 dysgenesis</e2>_1\NN\14045507 in_2\IN\13603305 an_3\DT\6697703 infant_4\NN\9918248 prenatally_5\RB\1740 exposed_6\VBN\2110927 to_7\TO\1740 <e1>cocaine</e1>_8\NN\3492717 ._9\.\1740
1255900
D006493_D013924 NONE the_0\DT\1740 disease_1\NN\14061805 occurred_2\VBD\2623529 subsequent_3\JJ\1740 to_4\IN\1740 the_5\DT\1740 initiation_6\NN\7450842 of_7\IN\1740 <e1>heparin</e1>_8\NN\2718259 therapy_9\NN\657604 for_10\IN\1740 suspected_11\VBN\916909 pelvic_12\JJ\1740 <e2>thrombophlebitis</e2>_13\NN\14352890 and_14\CC\1740 cleared_15\VBD\126264 rapidly_16\RB\1740 subsequent_17\JJ\1740 to_18\IN\1740 its_19\PRP$\6125041 discontinuation_20\NN\209943 ._21\.\1740
18405372
D012460_D056486 CID <e2>hepatotoxicity</e2>_0\NN\1740 associated_1\VBN\628491 with_2\IN\1740 <e1>sulfasalazine</e1>_3\NN\1740 in_4\IN\13603305 inflammatory_5\JJ\1740 arthritis_6\NN\14171682 :_7\:\1740 a_8\DT\13649268 case_9\NN\7283608 series_10\VBZ\1740 from_11\IN\1740 a_12\DT\13649268 local_13\JJ\1740 surveillance_14\NN\635012 of_15\IN\1740 serious_16\JJ\1740 adverse_17\JJ\1740 events_18\NNS\23100 ._19\.\1740
D012460_D056486 CID patients_0\NNS\9898892 '_1\''\1740 ,_2\,\1740 who_3\WP\8299493 had_4\VBD\2108377 <e2>hepatotoxicity</e2>_5\NN\1740 on_6\IN\1740 <e1>sulfasalazine</e1>_7\NN\1740 and_8\CC\1740 met_9\VBD\1182709 a_10\DT\13649268 definition_11\NN\6738281 of_12\IN\1740 a_13\DT\13649268 serious_14\JJ\1740 adr_15\NN\1740 ,_16\,\1740 were_17\VBD\836236 identified_18\VBN\699815 ._19\.\1740
D012460_D056486 CID the_0\DT\1740 likely_1\JJ\1740 frequency_2\NN\15286249 of_3\IN\1740 <e2>hepatotoxicity</e2>_4\NN\1740 with_5\IN\1740 <e1>sulfasalazine</e1>_6\NN\1740 was_7\VBD\836236 estimated_8\VBN\637259 by_9\IN\1740 making_10\VBG\126264 a_11\DT\13649268 series_12\NN\8456993 of_13\IN\1740 conservative_14\JJ\1740 assumptions_15\NNS\6753299 ._16\.\1740
D012460_D056486 CID the_0\DT\1740 likely_1\JJ\1740 frequency_2\NN\15286249 of_3\IN\1740 serious_4\JJ\1740 <e2>hepatotoxicity</e2>_5\NN\1740 with_6\IN\1740 <e1>sulfasalazine</e1>_7\NN\1740 was_8\VBD\836236 estimated_9\VBN\637259 at_10\IN\14622893 0.4_11\CD\1740 %_12\NN\1740 of_13\IN\1740 treated_14\VBN\2376958 patients_15\NNS\9898892 ._16\.\1740
D012460_D056486 CID conclusion_0\NN\5837957 :_1\:\1740 serious_2\JJ\1740 <e2>hepatotoxicity</e2>_3\NN\1740 associated_4\VBN\628491 with_5\IN\1740 <e1>sulfasalazine</e1>_6\NN\1740 appears_7\VBZ\2604760 to_8\TO\1740 be_9\VB\836236 under-appreciated_10\JJ\1740 and_11\CC\1740 intensive_12\JJ\1740 monitoring_13\NN\879759 and_14\CC\1740 vigilance_15\NN\5650579 in_16\IN\13603305 the_17\DT\1740 first_18\JJ\1740 6_19\CD\13741022 weeks_20\NNS\15113229 of_21\IN\1740 treatment_22\NN\654885 is_23\VBZ\836236 especially_24\RB\1740 important_25\JJ\1740 ._26\.\1740
D012460_D001168 NONE hepatotoxicity_0\NN\1740 associated_1\VBN\628491 with_2\IN\1740 <e1>sulfasalazine</e1>_3\NN\1740 in_4\IN\13603305 inflammatory_5\JJ\1740 <e2>arthritis</e2>_6\NN\14171682 :_7\:\1740 a_8\DT\13649268 case_9\NN\7283608 series_10\VBZ\1740 from_11\IN\1740 a_12\DT\13649268 local_13\JJ\1740 surveillance_14\NN\635012 of_15\IN\1740 serious_16\JJ\1740 adverse_17\JJ\1740 events_18\NNS\23100 ._19\.\1740
7565311
D016190_D058186 CID <e2>acute_0\JJ\1740 renal_1\JJ\1740 failure</e2>_2\NN\66216 in_3\IN\13603305 high_4\JJ\1740 dose_5\NN\3740161 <e1>carboplatin</e1>_6\NN\1740 chemotherapy_7\NN\661091 ._8\.\1740
D016190_D058186 CID <e1>carboplatin</e1>_0\NNP\1740 has_1\VBZ\2108377 been_2\VBN\836236 reported_3\VBN\831651 to_4\TO\1740 cause_5\VB\1617192 <e2>acute_6\JJ\1740 renal_7\JJ\1740 failure</e2>_8\NN\66216 when_9\WRB\1740 administered_10\VBN\2436349 in_11\IN\13603305 high_12\JJ\1740 doses_13\NNS\3740161 to_14\TO\1740 adult_15\JJ\1740 patients_16\NNS\9898892 ._17\.\1740
D016190_D018233 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 4_3\CD\13741022 1/2-year-old_4\JJ\1740 girl_5\NN\10787470 who_6\WP\8299493 was_7\VBD\836236 treated_8\VBN\2376958 with_9\IN\1740 high-dose_10\JJ\1740 <e1>carboplatin</e1>_11\NN\1740 for_12\IN\1740 metastatic_13\JJ\1740 parameningeal_14\NN\1740 <e2>embryonal_15\JJ\1740 rhabdomyosarcoma</e2>_16\NN\14246359 ._17\.\1740
6695415
D010665_D002543 CID <e2>cerebral_0\JJ\1740 hemorrhage</e2>_1\NN\14285662 associated_2\VBN\628491 with_3\IN\1740 <e1>phenylpropanolamine</e1>_4\NN\2682038 in_5\IN\13603305 combination_6\NN\7951464 with_7\IN\1740 caffeine_8\NN\14712692 ._9\.\1740
D010665_D002543 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e1>ppa/caffeine</e1>_4\NN\1740 can_5\MD\3094503 lead_6\VB\1752884 to_7\TO\1740 <e2>cerebral_8\JJ\1740 hemorrhage</e2>_9\NN\14285662 in_10\IN\13603305 previously_11\RB\1740 hypertensive_12\JJ\1740 animals_13\NNS\4475 when_14\WRB\1740 administered_15\VBN\2436349 in_16\IN\13603305 greater_17\JJR\1740 than_18\IN\1740 the_19\DT\1740 allowed_20\VBN\797697 dosage_21\NN\13576355 ._22\.\1740
D002110_D002543 CID <e2>cerebral_0\JJ\1740 hemorrhage</e2>_1\NN\14285662 associated_2\VBN\628491 with_3\IN\1740 phenylpropanolamine_4\NN\2682038 in_5\IN\13603305 combination_6\NN\7951464 with_7\IN\1740 <e1>caffeine</e1>_8\NN\14712692 ._9\.\1740
D002110_D002543 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e1>ppa/caffeine</e1>_4\NN\1740 can_5\MD\3094503 lead_6\VB\1752884 to_7\TO\1740 <e2>cerebral_8\JJ\1740 hemorrhage</e2>_9\NN\14285662 in_10\IN\13603305 previously_11\RB\1740 hypertensive_12\JJ\1740 animals_13\NNS\4475 when_14\WRB\1740 administered_15\VBN\2436349 in_16\IN\13603305 greater_17\JJR\1740 than_18\IN\1740 the_19\DT\1740 allowed_20\VBN\797697 dosage_21\NN\13576355 ._22\.\1740
D010665_D020521 CID <e1>phenylpropanolamine</e1>_0\NN\2682038 (_1\-LRB-\1740 ppa_2\NN\1740 )_3\-RRB-\1740 is_4\VBZ\836236 a_5\DT\13649268 drug_6\NN\14778436 that_7\WDT\1740 has_8\VBZ\2108377 been_9\VBN\836236 associated_10\VBN\628491 with_11\IN\1740 serious_12\JJ\1740 side_13\NN\8630039 effects_14\NNS\13245626 including_15\VBG\690614 <e2>stroke</e2>_16\NN\556313 ._17\.\1740
D010665_D020521 CID phenylpropanolamine_0\NN\2682038 (_1\-LRB-\1740 <e1>ppa</e1>_2\NN\1740 )_3\-RRB-\1740 is_4\VBZ\836236 a_5\DT\13649268 drug_6\NN\14778436 that_7\WDT\1740 has_8\VBZ\2108377 been_9\VBN\836236 associated_10\VBN\628491 with_11\IN\1740 serious_12\JJ\1740 side_13\NN\8630039 effects_14\NNS\13245626 including_15\VBG\690614 <e2>stroke</e2>_16\NN\556313 ._17\.\1740
D010665_D020521 CID in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 determine_3\VB\1645601 if_4\IN\1740 <e1>ppa/caffeine</e1>_5\NN\1740 can_6\MD\3094503 lead_7\VB\1752884 to_8\TO\1740 <e2>stroke</e2>_9\VB\1206218 in_10\IN\13603305 normotensive_11\NN\1740 and/or_12\CC\1740 hypertensive_13\JJ\1740 rats_14\NNS\2329401 ,_15\,\1740 we_16\PRP\1740 administered_17\VBD\2436349 the_18\DT\1740 combination_19\NN\7951464 in_20\IN\13603305 six_21\CD\13741022 times_22\NNS\15113229 the_23\DT\1740 allowed_24\VBN\797697 human_25\JJ\1740 dose_26\NN\3740161 calculated_27\VBN\632627 on_28\IN\1740 a_29\DT\13649268 per_30\IN\1740 weight_31\NN\5009170 basis_32\NN\13790712 for_33\IN\1740 the_34\DT\1740 rats_35\NNS\2329401 two_36\CD\13741022 times_37\NNS\15113229 per_38\IN\1740 day_39\NN\15154774 for_40\IN\1740 five_41\CD\13741022 days_42\NNS\15140892 ._43\.\1740
D010665_D006973 CID in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 determine_3\VB\1645601 if_4\IN\1740 <e1>ppa/caffeine</e1>_5\NN\1740 can_6\MD\3094503 lead_7\VB\1752884 to_8\TO\1740 stroke_9\VB\1206218 in_10\IN\13603305 normotensive_11\NN\1740 and/or_12\CC\1740 <e2>hypertensive</e2>_13\JJ\1740 rats_14\NNS\2329401 ,_15\,\1740 we_16\PRP\1740 administered_17\VBD\2436349 the_18\DT\1740 combination_19\NN\7951464 in_20\IN\13603305 six_21\CD\13741022 times_22\NNS\15113229 the_23\DT\1740 allowed_24\VBN\797697 human_25\JJ\1740 dose_26\NN\3740161 calculated_27\VBN\632627 on_28\IN\1740 a_29\DT\13649268 per_30\IN\1740 weight_31\NN\5009170 basis_32\NN\13790712 for_33\IN\1740 the_34\DT\1740 rats_35\NNS\2329401 two_36\CD\13741022 times_37\NNS\15113229 per_38\IN\1740 day_39\NN\15154774 for_40\IN\1740 five_41\CD\13741022 days_42\NNS\15140892 ._43\.\1740
D010665_D006973 CID a_0\DT\13649268 single_1\JJ\1740 <e1>ppa/caffeine</e1>_2\JJ\1740 administration_3\NN\1133281 (_4\-LRB-\1740 same_5\JJ\1740 dose_6\NN\3740161 )_7\-RRB-\1740 lead_8\VBP\1752884 to_9\TO\1740 acute_10\JJ\1740 <e2>hypertension</e2>_11\NN\14057371 in_12\IN\13603305 both_13\CC\1740 the_14\DT\1740 normotensive_15\NN\1740 and_16\CC\1740 hypertensive_17\JJ\1740 animals_18\NNS\4475 ._19\.\1740
D010665_D006973 CID a_0\DT\13649268 single_1\JJ\1740 <e1>ppa/caffeine</e1>_2\JJ\1740 administration_3\NN\1133281 (_4\-LRB-\1740 same_5\JJ\1740 dose_6\NN\3740161 )_7\-RRB-\1740 lead_8\VBP\1752884 to_9\TO\1740 acute_10\JJ\1740 hypertension_11\NN\14057371 in_12\IN\13603305 both_13\CC\1740 the_14\DT\1740 normotensive_15\NN\1740 and_16\CC\1740 <e2>hypertensive</e2>_17\JJ\1740 animals_18\NNS\4475 ._19\.\1740
D010665_D006973 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e1>ppa/caffeine</e1>_4\NN\1740 can_5\MD\3094503 lead_6\VB\1752884 to_7\TO\1740 cerebral_8\JJ\1740 hemorrhage_9\NN\14285662 in_10\IN\13603305 previously_11\RB\1740 <e2>hypertensive</e2>_12\JJ\1740 animals_13\NNS\4475 when_14\WRB\1740 administered_15\VBN\2436349 in_16\IN\13603305 greater_17\JJR\1740 than_18\IN\1740 the_19\DT\1740 allowed_20\VBN\797697 dosage_21\NN\13576355 ._22\.\1740
D002110_D020521 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 determine_3\VB\1645601 if_4\IN\1740 <e1>ppa/caffeine</e1>_5\NN\1740 can_6\MD\3094503 lead_7\VB\1752884 to_8\TO\1740 <e2>stroke</e2>_9\VB\1206218 in_10\IN\13603305 normotensive_11\NN\1740 and/or_12\CC\1740 hypertensive_13\JJ\1740 rats_14\NNS\2329401 ,_15\,\1740 we_16\PRP\1740 administered_17\VBD\2436349 the_18\DT\1740 combination_19\NN\7951464 in_20\IN\13603305 six_21\CD\13741022 times_22\NNS\15113229 the_23\DT\1740 allowed_24\VBN\797697 human_25\JJ\1740 dose_26\NN\3740161 calculated_27\VBN\632627 on_28\IN\1740 a_29\DT\13649268 per_30\IN\1740 weight_31\NN\5009170 basis_32\NN\13790712 for_33\IN\1740 the_34\DT\1740 rats_35\NNS\2329401 two_36\CD\13741022 times_37\NNS\15113229 per_38\IN\1740 day_39\NN\15154774 for_40\IN\1740 five_41\CD\13741022 days_42\NNS\15140892 ._43\.\1740
D002110_D006973 CID in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 determine_3\VB\1645601 if_4\IN\1740 <e1>ppa/caffeine</e1>_5\NN\1740 can_6\MD\3094503 lead_7\VB\1752884 to_8\TO\1740 stroke_9\VB\1206218 in_10\IN\13603305 normotensive_11\NN\1740 and/or_12\CC\1740 <e2>hypertensive</e2>_13\JJ\1740 rats_14\NNS\2329401 ,_15\,\1740 we_16\PRP\1740 administered_17\VBD\2436349 the_18\DT\1740 combination_19\NN\7951464 in_20\IN\13603305 six_21\CD\13741022 times_22\NNS\15113229 the_23\DT\1740 allowed_24\VBN\797697 human_25\JJ\1740 dose_26\NN\3740161 calculated_27\VBN\632627 on_28\IN\1740 a_29\DT\13649268 per_30\IN\1740 weight_31\NN\5009170 basis_32\NN\13790712 for_33\IN\1740 the_34\DT\1740 rats_35\NNS\2329401 two_36\CD\13741022 times_37\NNS\15113229 per_38\IN\1740 day_39\NN\15154774 for_40\IN\1740 five_41\CD\13741022 days_42\NNS\15140892 ._43\.\1740
D002110_D006973 CID a_0\DT\13649268 single_1\JJ\1740 <e1>ppa/caffeine</e1>_2\JJ\1740 administration_3\NN\1133281 (_4\-LRB-\1740 same_5\JJ\1740 dose_6\NN\3740161 )_7\-RRB-\1740 lead_8\VBP\1752884 to_9\TO\1740 acute_10\JJ\1740 <e2>hypertension</e2>_11\NN\14057371 in_12\IN\13603305 both_13\CC\1740 the_14\DT\1740 normotensive_15\NN\1740 and_16\CC\1740 hypertensive_17\JJ\1740 animals_18\NNS\4475 ._19\.\1740
D002110_D006973 CID a_0\DT\13649268 single_1\JJ\1740 <e1>ppa/caffeine</e1>_2\JJ\1740 administration_3\NN\1133281 (_4\-LRB-\1740 same_5\JJ\1740 dose_6\NN\3740161 )_7\-RRB-\1740 lead_8\VBP\1752884 to_9\TO\1740 acute_10\JJ\1740 hypertension_11\NN\14057371 in_12\IN\13603305 both_13\CC\1740 the_14\DT\1740 normotensive_15\NN\1740 and_16\CC\1740 <e2>hypertensive</e2>_17\JJ\1740 animals_18\NNS\4475 ._19\.\1740
D002110_D006973 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e1>ppa/caffeine</e1>_4\NN\1740 can_5\MD\3094503 lead_6\VB\1752884 to_7\TO\1740 cerebral_8\JJ\1740 hemorrhage_9\NN\14285662 in_10\IN\13603305 previously_11\RB\1740 <e2>hypertensive</e2>_12\JJ\1740 animals_13\NNS\4475 when_14\WRB\1740 administered_15\VBN\2436349 in_16\IN\13603305 greater_17\JJR\1740 than_18\IN\1740 the_19\DT\1740 allowed_20\VBN\797697 dosage_21\NN\13576355 ._22\.\1740
7596955
D000242_D001791 NONE at_0\IN\14622893 various_1\JJ\1740 time_2\NN\7308889 intervals_3\NNS\33615 ,_4\,\1740 physical_5\JJ\1740 examination_6\NN\633864 and_7\CC\1740 blood_8\NN\5397468 collection_9\NN\31264 for_10\IN\1740 ex_11\FW\10287213 vivo_12\FW\1740 <e2>platelet_13\NN\5432736 aggregation</e2>_14\NN\31264 and_15\CC\1740 determination_16\NN\43195 of_17\IN\1740 intraplatelet_18\JJ\1740 <e1>camp</e1>_19\NN\3763727 were_20\VBD\836236 performed_21\VBN\2367363 ._22\.\1740
C045645_D006261 CID seven_0\CD\13741022 out_1\IN\66636 of_2\IN\1740 12_3\CD\13745420 subjects_4\NNS\6598915 experienced_5\JJ\1740 <e2>headache</e2>_6\NN\5829480 of_7\IN\1740 a_8\DT\13649268 short_9\JJ\1740 duration_10\NN\15113229 accompanying_11\VBG\1835496 facial_12\JJ\1740 flush_13\NN\15113229 in_14\IN\13603305 one_15\CD\13741022 and_16\CC\1740 nausea_17\NN\14299637 in_18\IN\13603305 one_19\CD\13741022 ,_20\,\1740 especially_21\RB\1740 after_22\IN\1740 ingestion_23\NN\13440063 of_24\IN\1740 <e1>clz</e1>_25\NN\1740 ._26\.\1740
C045645_D005483 CID seven_0\CD\13741022 out_1\IN\66636 of_2\IN\1740 12_3\CD\13745420 subjects_4\NNS\6598915 experienced_5\JJ\1740 headache_6\NN\5829480 of_7\IN\1740 a_8\DT\13649268 short_9\JJ\1740 duration_10\NN\15113229 accompanying_11\VBG\1835496 <e2>facial_12\JJ\1740 flush</e2>_13\NN\15113229 in_14\IN\13603305 one_15\CD\13741022 and_16\CC\1740 nausea_17\NN\14299637 in_18\IN\13603305 one_19\CD\13741022 ,_20\,\1740 especially_21\RB\1740 after_22\IN\1740 ingestion_23\NN\13440063 of_24\IN\1740 <e1>clz</e1>_25\NN\1740 ._26\.\1740
C045645_D009325 CID seven_0\CD\13741022 out_1\IN\66636 of_2\IN\1740 12_3\CD\13745420 subjects_4\NNS\6598915 experienced_5\JJ\1740 headache_6\NN\5829480 of_7\IN\1740 a_8\DT\13649268 short_9\JJ\1740 duration_10\NN\15113229 accompanying_11\VBG\1835496 facial_12\JJ\1740 flush_13\NN\15113229 in_14\IN\13603305 one_15\CD\13741022 and_16\CC\1740 <e2>nausea</e2>_17\NN\14299637 in_18\IN\13603305 one_19\CD\13741022 ,_20\,\1740 especially_21\RB\1740 after_22\IN\1740 ingestion_23\NN\13440063 of_24\IN\1740 <e1>clz</e1>_25\NN\1740 ._26\.\1740
20510337
C024989_D007674 NONE <e1>coenzyme_0\NN\14682133 q10</e1>_1\NN\1740 treatment_2\NN\654885 ameliorates_3\VBZ\126264 acute_4\JJ\1740 cisplatin_5\NN\1740 <e2>nephrotoxicity</e2>_6\NN\1740 in_7\IN\13603305 mice_8\NNS\2329401 ._9\.\1740
C024989_D007674 NONE also_0\RB\1740 ,_1\,\1740 histopathological_2\JJ\1740 <e2>renal_3\JJ\1740 tissue_4\NN\5220461 damage</e2>_5\NN\7296428 mediated_6\VBN\761713 by_7\IN\1740 cisplatin_8\NN\1740 was_9\VBD\836236 ameliorated_10\VBN\126264 by_11\IN\1740 <e1>coenzyme_12\NN\14682133 q10</e1>_13\NN\1740 treatment_14\NN\654885 ._15\.\1740
C024989_D007674 NONE it_0\PRP\6125041 was_1\VBD\836236 concluded_2\VBN\628491 that_3\IN\1740 <e1>coenzyme_4\NN\14682133 q10</e1>_5\NN\1740 represents_6\VBZ\2664769 a_7\DT\13649268 potential_8\JJ\1740 therapeutic_9\JJ\1740 option_10\NN\6480506 to_11\TO\1740 protect_12\VB\1127795 against_13\IN\1740 acute_14\JJ\1740 cisplatin_15\NN\1740 <e2>nephrotoxicity</e2>_16\NN\1740 commonly_17\RB\1740 encountered_18\VBN\2604760 in_19\IN\13603305 clinical_20\JJ\1740 practice_21\NN\407535 ._22\.\1740
D002945_D007674 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 treatment_2\NN\654885 ameliorates_3\VBZ\126264 acute_4\JJ\1740 <e1>cisplatin</e1>_5\NN\1740 <e2>nephrotoxicity</e2>_6\NN\1740 in_7\IN\13603305 mice_8\NNS\2329401 ._9\.\1740
D002945_D007674 NONE also_0\RB\1740 ,_1\,\1740 histopathological_2\JJ\1740 <e2>renal_3\JJ\1740 tissue_4\NN\5220461 damage</e2>_5\NN\7296428 mediated_6\VBN\761713 by_7\IN\1740 <e1>cisplatin</e1>_8\NN\1740 was_9\VBD\836236 ameliorated_10\VBN\126264 by_11\IN\1740 coenzyme_12\NN\14682133 q10_13\NN\1740 treatment_14\NN\654885 ._15\.\1740
D002945_D007674 NONE it_0\PRP\6125041 was_1\VBD\836236 concluded_2\VBN\628491 that_3\IN\1740 coenzyme_4\NN\14682133 q10_5\NN\1740 represents_6\VBZ\2664769 a_7\DT\13649268 potential_8\JJ\1740 therapeutic_9\JJ\1740 option_10\NN\6480506 to_11\TO\1740 protect_12\VB\1127795 against_13\IN\1740 acute_14\JJ\1740 <e1>cisplatin</e1>_15\NN\1740 <e2>nephrotoxicity</e2>_16\NN\1740 commonly_17\RB\1740 encountered_18\VBN\2604760 in_19\IN\13603305 clinical_20\JJ\1740 practice_21\NN\407535 ._22\.\1740
C024989_D058186 NONE the_0\DT\1740 nephroprotective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 <e1>coenzyme_4\NN\14682133 q10</e1>_5\NN\1740 was_6\VBD\836236 investigated_7\VBN\644583 in_8\IN\13603305 mice_9\NNS\2329401 with_10\IN\1740 <e2>acute_11\JJ\1740 renal_12\JJ\1740 injury</e2>_13\NN\14052046 induced_14\VBN\1627355 by_15\IN\1740 a_16\DT\13649268 single_17\JJ\1740 i.p._18\RB\1740 injection_19\NN\320852 of_20\IN\1740 cisplatin_21\NN\1740 (_22\-LRB-\1740 5_23\CD\13741022 mg/kg_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
D002945_D058186 CID the_0\DT\1740 nephroprotective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 coenzyme_4\NN\14682133 q10_5\NN\1740 was_6\VBD\836236 investigated_7\VBN\644583 in_8\IN\13603305 mice_9\NNS\2329401 with_10\IN\1740 <e2>acute_11\JJ\1740 renal_12\JJ\1740 injury</e2>_13\NN\14052046 induced_14\VBN\1627355 by_15\IN\1740 a_16\DT\13649268 single_17\JJ\1740 i.p._18\RB\1740 injection_19\NN\320852 of_20\IN\1740 <e1>cisplatin</e1>_21\NN\1740 (_22\-LRB-\1740 5_23\CD\13741022 mg/kg_24\NN\1740 )_25\-RRB-\1740 ._26\.\1740
C024989_D009369 NONE <e1>coenzyme_0\NN\14682133 q10</e1>_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 <e2>tumor</e2>_28\NN\14234074 necrosis_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
C024989_D009336 NONE <e1>coenzyme_0\NN\14682133 q10</e1>_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 tumor_28\NN\14234074 <e2>necrosis</e2>_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D005978_D009369 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 <e1>reduced_11\VBN\441445 glutathione</e1>_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 <e2>tumor</e2>_28\NN\14234074 necrosis_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D005978_D009336 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 <e1>reduced_11\VBN\441445 glutathione</e1>_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 tumor_28\NN\14234074 <e2>necrosis</e2>_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D013481_D009369 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 <e1>superoxide</e1>_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 <e2>tumor</e2>_28\NN\14234074 necrosis_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D013481_D009336 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 <e1>superoxide</e1>_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 tumor_28\NN\14234074 <e2>necrosis</e2>_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D009569_D009369 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 <e2>tumor</e2>_28\NN\14234074 necrosis_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 <e1>nitric_32\JJ\1740 oxide</e1>_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D009569_D009336 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 tumor_28\NN\14234074 <e2>necrosis</e2>_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 <e1>nitric_32\JJ\1740 oxide</e1>_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D010984_D009369 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 <e2>tumor</e2>_28\NN\14234074 necrosis_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 <e1>platinum</e1>_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D010984_D009336 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 tumor_28\NN\14234074 <e2>necrosis</e2>_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 <e1>platinum</e1>_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D012643_D009369 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 <e2>tumor</e2>_28\NN\14234074 necrosis_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 <e1>selenium</e1>_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D012643_D009336 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 tumor_28\NN\14234074 <e2>necrosis</e2>_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 <e1>selenium</e1>_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D015032_D009369 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 <e2>tumor</e2>_28\NN\14234074 necrosis_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 <e1>zinc</e1>_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D015032_D009336 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 tumor_28\NN\14234074 <e2>necrosis</e2>_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 <e1>zinc</e1>_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 cisplatin_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D002945_D009369 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 <e2>tumor</e2>_28\NN\14234074 necrosis_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 <e1>cisplatin</e1>_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
D002945_D009336 NONE coenzyme_0\NN\14682133 q10_1\NN\1740 significantly_2\RB\1740 compensated_3\VBD\2673134 deficits_4\NNS\5113133 in_5\IN\13603305 the_6\DT\1740 antioxidant_7\JJ\1740 defense_8\NN\952963 mechanisms_9\NNS\13446390 (_10\-LRB-\1740 reduced_11\VBN\441445 glutathione_12\NN\1740 level_13\NN\4916342 and_14\CC\1740 superoxide_15\NN\14971519 dismutase_16\NN\1740 activity_17\NN\30358 )_18\-RRB-\1740 ,_19\,\1740 suppressed_20\VBD\2510337 lipid_21\NN\14944888 peroxidation_22\NN\1740 ,_23\,\1740 decreased_24\VBD\169651 the_25\DT\1740 elevations_26\NNS\7445480 of_27\IN\1740 tumor_28\NN\14234074 <e2>necrosis</e2>_29\NN\11444117 factor-alpha_30\NN\1740 ,_31\,\1740 nitric_32\JJ\1740 oxide_33\NN\14818238 and_34\CC\1740 platinum_35\NN\14627081 ion_36\NN\9386422 concentration_37\NN\4916342 ,_38\,\1740 and_39\CC\1740 attenuated_40\VBD\224901 the_41\DT\1740 reductions_42\NNS\351485 of_43\IN\1740 selenium_44\NN\14724645 and_45\CC\1740 zinc_46\NN\14625458 ions_47\NNS\9386422 in_48\IN\13603305 renal_49\JJ\1740 tissue_50\NN\5220461 resulted_51\VBD\2633881 from_52\IN\1740 <e1>cisplatin</e1>_53\NN\1740 administration_54\NN\1133281 ._55\.\1740
17511042
C417083_D063726 CID an_0\DT\6697703 extremely_1\RB\1740 rare_2\JJ\1740 case_3\NN\7283608 of_4\IN\1740 <e2>delusional_5\JJ\1740 parasitosis</e2>_6\NN\1740 in_7\IN\13603305 a_8\DT\13649268 chronic_9\JJ\1740 hepatitis_10\NN\14127211 c_11\NN\13714184 patient_12\NN\9898892 during_13\IN\1740 <e1>pegylated_14\JJ\1740 interferon_15\NN\2725367 alpha-2b</e1>_16\NN\1740 and_17\CC\1740 ribavirin_18\NN\2725367 treatment_19\NN\654885 ._20\.\1740
C417083_D063726 CID we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 49-year-old_3\JJ\1740 woman_4\NN\9605289 who_5\WP\8299493 developed_6\VBD\1753788 a_7\DT\13649268 <e2>delusional_8\JJ\1740 parasitosis</e2>_9\NN\1740 during_10\IN\1740 treatment_11\NN\654885 with_12\IN\1740 <e1>pegylated_13\JJ\1740 interferon_14\NN\2725367 alpha-2b</e1>_15\NN\1740 weekly_16\NN\6593803 and_17\CC\1740 ribavirin_18\NN\2725367 ._19\.\1740
C417083_D019698 NONE an_0\DT\6697703 extremely_1\RB\1740 rare_2\JJ\1740 case_3\NN\7283608 of_4\IN\1740 delusional_5\JJ\1740 parasitosis_6\NN\1740 in_7\IN\13603305 a_8\DT\13649268 <e2>chronic_9\JJ\1740 hepatitis_10\NN\14127211 c</e2>_11\NN\13714184 patient_12\NN\9898892 during_13\IN\1740 <e1>pegylated_14\JJ\1740 interferon_15\NN\2725367 alpha-2b</e1>_16\NN\1740 and_17\CC\1740 ribavirin_18\NN\2725367 treatment_19\NN\654885 ._20\.\1740
D012254_D063726 CID an_0\DT\6697703 extremely_1\RB\1740 rare_2\JJ\1740 case_3\NN\7283608 of_4\IN\1740 <e2>delusional_5\JJ\1740 parasitosis</e2>_6\NN\1740 in_7\IN\13603305 a_8\DT\13649268 chronic_9\JJ\1740 hepatitis_10\NN\14127211 c_11\NN\13714184 patient_12\NN\9898892 during_13\IN\1740 pegylated_14\JJ\1740 interferon_15\NN\2725367 alpha-2b_16\NN\1740 and_17\CC\1740 <e1>ribavirin</e1>_18\NN\2725367 treatment_19\NN\654885 ._20\.\1740
D012254_D063726 CID we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 49-year-old_3\JJ\1740 woman_4\NN\9605289 who_5\WP\8299493 developed_6\VBD\1753788 a_7\DT\13649268 <e2>delusional_8\JJ\1740 parasitosis</e2>_9\NN\1740 during_10\IN\1740 treatment_11\NN\654885 with_12\IN\1740 pegylated_13\JJ\1740 interferon_14\NN\2725367 alpha-2b_15\NN\1740 weekly_16\NN\6593803 and_17\CC\1740 <e1>ribavirin</e1>_18\NN\2725367 ._19\.\1740
D012254_D019698 NONE an_0\DT\6697703 extremely_1\RB\1740 rare_2\JJ\1740 case_3\NN\7283608 of_4\IN\1740 delusional_5\JJ\1740 parasitosis_6\NN\1740 in_7\IN\13603305 a_8\DT\13649268 <e2>chronic_9\JJ\1740 hepatitis_10\NN\14127211 c</e2>_11\NN\13714184 patient_12\NN\9898892 during_13\IN\1740 pegylated_14\JJ\1740 interferon_15\NN\2725367 alpha-2b_16\NN\1740 and_17\CC\1740 <e1>ribavirin</e1>_18\NN\2725367 treatment_19\NN\654885 ._20\.\1740
D012254_D019698 NONE during_0\IN\1740 treatment_1\NN\654885 of_2\IN\1740 <e2>chronic_3\JJ\1740 hepatitis_4\NN\14127211 c</e2>_5\NN\13714184 patients_6\NNS\9898892 with_7\IN\1740 interferon_8\NN\2725367 and_9\CC\1740 <e1>ribavirin</e1>_10\NN\2725367 ,_11\,\1740 a_12\DT\13649268 lot_13\NN\13757724 of_14\IN\1740 side_15\NN\8630039 effects_16\NNS\13245626 are_17\VBP\836236 described_18\VBN\1001294 ._19\.\1740
1928887
D009270_D007022 NONE <e1>naloxone</e1>_0\NN\3808977 reversal_1\NN\199130 of_2\IN\1740 <e2>hypotension</e2>_3\NN\14057371 due_4\JJ\1740 to_5\TO\1740 captopril_6\NN\2673637 overdose_7\NN\1740 ._8\.\1740
D009270_D007022 NONE the_0\DT\1740 opioid_1\NN\1740 antagonist_2\NN\7846 <e1>naloxone</e1>_3\NN\3808977 has_4\VBZ\2108377 been_5\VBN\836236 shown_6\VBN\2137132 to_7\TO\1740 block_8\VB\1476483 or_9\CC\3541091 reverse_10\VB\109660 the_11\DT\1740 <e2>hypotensive</e2>_12\JJ\1740 actions_13\NNS\30358 of_14\IN\1740 captopril_15\NN\2673637 ._16\.\1740
D009270_D007022 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 intentional_6\JJ\1740 captopril_7\NN\2673637 overdose_8\NN\1740 ,_9\,\1740 manifested_10\VBN\1015244 by_11\IN\1740 marked_12\JJ\1740 <e2>hypotension</e2>_13\NN\14057371 ,_14\,\1740 that_15\WDT\1740 resolved_16\VBD\352826 promptly_17\RB\1740 with_18\IN\1740 the_19\DT\1740 administration_20\NN\1133281 of_21\IN\1740 <e1>naloxone</e1>_22\NN\3808977 ._23\.\1740
D009270_D007022 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 is_5\VBZ\836236 the_6\DT\1740 first_7\JJ\1740 reported_8\VBN\831651 case_9\NN\7283608 of_10\IN\1740 captopril-induced_11\JJ\1740 <e2>hypotension</e2>_12\NN\14057371 treated_13\VBN\2376958 with_14\IN\1740 <e1>naloxone</e1>_15\NN\3808977 ._16\.\1740
D009270_D007022 NONE our_0\PRP$\1740 experience_1\NN\5984287 demonstrates_2\VBZ\2137132 a_3\DT\13649268 possible_4\JJ\1740 role_5\NN\719494 of_6\IN\1740 <e1>naloxone</e1>_7\NN\3808977 in_8\IN\13603305 the_9\DT\1740 reversal_10\NN\199130 of_11\IN\1740 <e2>hypotension</e2>_12\NN\14057371 resulting_13\VBG\2633881 from_14\IN\1740 captopril_15\NN\2673637 ._16\.\1740
D009270_D062787 NONE <e1>naloxone</e1>_0\NN\3808977 reversal_1\NN\199130 of_2\IN\1740 hypotension_3\NN\14057371 due_4\JJ\1740 to_5\TO\1740 captopril_6\NN\2673637 <e2>overdose</e2>_7\NN\1740 ._8\.\1740
D009270_D062787 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 intentional_6\JJ\1740 captopril_7\NN\2673637 <e2>overdose</e2>_8\NN\1740 ,_9\,\1740 manifested_10\VBN\1015244 by_11\IN\1740 marked_12\JJ\1740 hypotension_13\NN\14057371 ,_14\,\1740 that_15\WDT\1740 resolved_16\VBD\352826 promptly_17\RB\1740 with_18\IN\1740 the_19\DT\1740 administration_20\NN\1133281 of_21\IN\1740 <e1>naloxone</e1>_22\NN\3808977 ._23\.\1740
D002216_D007022 NONE naloxone_0\NN\3808977 reversal_1\NN\199130 of_2\IN\1740 <e2>hypotension</e2>_3\NN\14057371 due_4\JJ\1740 to_5\TO\1740 <e1>captopril</e1>_6\NN\2673637 overdose_7\NN\1740 ._8\.\1740
D002216_D007022 NONE the_0\DT\1740 opioid_1\NN\1740 antagonist_2\NN\7846 naloxone_3\NN\3808977 has_4\VBZ\2108377 been_5\VBN\836236 shown_6\VBN\2137132 to_7\TO\1740 block_8\VB\1476483 or_9\CC\3541091 reverse_10\VB\109660 the_11\DT\1740 <e2>hypotensive</e2>_12\JJ\1740 actions_13\NNS\30358 of_14\IN\1740 <e1>captopril</e1>_15\NN\2673637 ._16\.\1740
D002216_D007022 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 intentional_6\JJ\1740 <e1>captopril</e1>_7\NN\2673637 overdose_8\NN\1740 ,_9\,\1740 manifested_10\VBN\1015244 by_11\IN\1740 marked_12\JJ\1740 <e2>hypotension</e2>_13\NN\14057371 ,_14\,\1740 that_15\WDT\1740 resolved_16\VBD\352826 promptly_17\RB\1740 with_18\IN\1740 the_19\DT\1740 administration_20\NN\1133281 of_21\IN\1740 naloxone_22\NN\3808977 ._23\.\1740
D002216_D007022 NONE to_0\IN\1740 our_1\PRP$\1740 knowledge_2\NN\23100 ,_3\,\1740 this_4\DT\1740 is_5\VBZ\836236 the_6\DT\1740 first_7\JJ\1740 reported_8\VBN\831651 case_9\NN\7283608 of_10\IN\1740 <e1>captopril-induced</e1>_11\JJ\1740 <e2>hypotension</e2>_12\NN\14057371 treated_13\VBN\2376958 with_14\IN\1740 naloxone_15\NN\3808977 ._16\.\1740
D002216_D007022 NONE our_0\PRP$\1740 experience_1\NN\5984287 demonstrates_2\VBZ\2137132 a_3\DT\13649268 possible_4\JJ\1740 role_5\NN\719494 of_6\IN\1740 naloxone_7\NN\3808977 in_8\IN\13603305 the_9\DT\1740 reversal_10\NN\199130 of_11\IN\1740 <e2>hypotension</e2>_12\NN\14057371 resulting_13\VBG\2633881 from_14\IN\1740 <e1>captopril</e1>_15\NN\2673637 ._16\.\1740
D002216_D062787 NONE naloxone_0\NN\3808977 reversal_1\NN\199130 of_2\IN\1740 hypotension_3\NN\14057371 due_4\JJ\1740 to_5\TO\1740 <e1>captopril</e1>_6\NN\2673637 <e2>overdose</e2>_7\NN\1740 ._8\.\1740
D002216_D062787 NONE we_0\PRP\1740 report_1\VBP\831651 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 an_5\DT\6697703 intentional_6\JJ\1740 <e1>captopril</e1>_7\NN\2673637 <e2>overdose</e2>_8\NN\1740 ,_9\,\1740 manifested_10\VBN\1015244 by_11\IN\1740 marked_12\JJ\1740 hypotension_13\NN\14057371 ,_14\,\1740 that_15\WDT\1740 resolved_16\VBD\352826 promptly_17\RB\1740 with_18\IN\1740 the_19\DT\1740 administration_20\NN\1133281 of_21\IN\1740 naloxone_22\NN\3808977 ._23\.\1740
10354657
D008094_D013959 NONE these_0\DT\1740 were_1\VBD\836236 evaluated_2\VBN\670261 with_3\IN\1740 respect_4\NN\5817845 to_5\TO\1740 the_6\DT\1740 duration_7\NN\15113229 of_8\IN\1740 <e1>lithium</e1>_9\NN\14625458 therapy_10\NN\657604 ,_11\,\1740 age_12\NN\4916342 ,_13\,\1740 sex_14\NN\13440063 ,_15\,\1740 and_16\CC\1740 family_17\NN\8189659 history_18\NN\15120823 (_19\-LRB-\1740 whether_20\IN\1740 or_21\CC\3541091 not_22\RB\1740 the_23\DT\1740 patient_24\NN\9898892 had_25\VBD\2108377 a_26\DT\13649268 first-degree_27\JJ\1740 relative_28\NN\7846 with_29\IN\1740 <e2>thyroid_30\NN\5329735 disease</e2>_31\NN\14061805 )_32\-RRB-\1740 ._33\.\1740
D008094_D013959 NONE all_0\DT\1740 patients_1\NNS\9898892 having_2\VBG\2108377 first-degree_3\JJ\1740 relatives_4\NNS\7846 affected_5\VBN\126264 by_6\IN\1740 <e2>thyroid_7\NN\5329735 illness</e2>_8\NN\14052046 had_9\VBD\2108377 accelerated_10\VBN\226566 onset_11\NN\7325190 of_12\IN\1740 hypothyroidism_13\NN\14059928 (_14\-LRB-\1740 3.7_15\CD\1740 years_16\NNS\15144371 after_17\IN\1740 onset_18\NN\7325190 of_19\IN\1740 <e1>lithium</e1>_20\NN\14625458 therapy_21\NN\657604 )_22\-RRB-\1740 compared_23\VBN\644583 with_24\IN\1740 patients_25\NNS\9898892 without_26\IN\1740 a_27\DT\13649268 family_28\NN\8189659 history_29\NN\15120823 (_30\-LRB-\1740 8.6_31\CD\1740 years_32\NNS\15144371 after_33\IN\1740 onset_34\NN\7325190 of_35\IN\1740 lithium_36\NN\14625458 therapy_37\NN\657604 )_38\-RRB-\1740 ._39\.\1740
D008094_D013959 NONE all_0\DT\1740 patients_1\NNS\9898892 having_2\VBG\2108377 first-degree_3\JJ\1740 relatives_4\NNS\7846 affected_5\VBN\126264 by_6\IN\1740 <e2>thyroid_7\NN\5329735 illness</e2>_8\NN\14052046 had_9\VBD\2108377 accelerated_10\VBN\226566 onset_11\NN\7325190 of_12\IN\1740 hypothyroidism_13\NN\14059928 (_14\-LRB-\1740 3.7_15\CD\1740 years_16\NNS\15144371 after_17\IN\1740 onset_18\NN\7325190 of_19\IN\1740 lithium_20\NN\14625458 therapy_21\NN\657604 )_22\-RRB-\1740 compared_23\VBN\644583 with_24\IN\1740 patients_25\NNS\9898892 without_26\IN\1740 a_27\DT\13649268 family_28\NN\8189659 history_29\NN\15120823 (_30\-LRB-\1740 8.6_31\CD\1740 years_32\NNS\15144371 after_33\IN\1740 onset_34\NN\7325190 of_35\IN\1740 <e1>lithium</e1>_36\NN\14625458 therapy_37\NN\657604 )_38\-RRB-\1740 ._39\.\1740
D008094_D013959 NONE conclusions_0\NNS\5837957 :_1\:\1740 familial_2\JJ\1740 <e2>thyroid_3\NN\5329735 illness</e2>_4\NN\14052046 is_5\VBZ\836236 a_6\DT\13649268 risk_7\NN\14541044 factor_8\NN\7326557 for_9\IN\1740 hypothyroidism_10\NN\14059928 and_11\CC\1740 hypercalcemia_12\NN\14299637 during_13\IN\1740 <e1>lithium</e1>_14\NN\14625458 therapy_15\NN\657604 ._16\.\1740
D008094_D001714 NONE patients_0\NNS\9898892 :_1\:\1740 one_2\CD\13741022 hundred_3\CD\13745420 and_4\CC\1740 one_5\CD\13741022 patients_6\NNS\9898892 (_7\-LRB-\1740 28_8\CD\13745420 men_9\NNS\8208016 and_10\CC\1740 73_11\CD\1740 women_12\NNS\9605289 )_13\-RRB-\1740 with_14\IN\1740 <e2>bipolar_15\JJ\1740 disorder</e2>_16\NN\14034177 receiving_17\VBG\2210855 <e1>lithium</e1>_18\NN\14625458 maintenance_19\NN\266806 therapy_20\NN\657604 ranging_21\VBG\2604760 from_22\IN\1740 1_23\CD\13741022 year_24\NN\15113229 's_25\POS\1740 to_26\IN\1740 32_27\CD\1740 years_28\NNS\15144371 '_29\POS\1740 duration_30\NN\15113229 ._31\.\1740
D008094_D007037 CID all_0\DT\1740 patients_1\NNS\9898892 having_2\VBG\2108377 first-degree_3\JJ\1740 relatives_4\NNS\7846 affected_5\VBN\126264 by_6\IN\1740 thyroid_7\NN\5329735 illness_8\NN\14052046 had_9\VBD\2108377 accelerated_10\VBN\226566 onset_11\NN\7325190 of_12\IN\1740 <e2>hypothyroidism</e2>_13\NN\14059928 (_14\-LRB-\1740 3.7_15\CD\1740 years_16\NNS\15144371 after_17\IN\1740 onset_18\NN\7325190 of_19\IN\1740 <e1>lithium</e1>_20\NN\14625458 therapy_21\NN\657604 )_22\-RRB-\1740 compared_23\VBN\644583 with_24\IN\1740 patients_25\NNS\9898892 without_26\IN\1740 a_27\DT\13649268 family_28\NN\8189659 history_29\NN\15120823 (_30\-LRB-\1740 8.6_31\CD\1740 years_32\NNS\15144371 after_33\IN\1740 onset_34\NN\7325190 of_35\IN\1740 lithium_36\NN\14625458 therapy_37\NN\657604 )_38\-RRB-\1740 ._39\.\1740
D008094_D007037 CID all_0\DT\1740 patients_1\NNS\9898892 having_2\VBG\2108377 first-degree_3\JJ\1740 relatives_4\NNS\7846 affected_5\VBN\126264 by_6\IN\1740 thyroid_7\NN\5329735 illness_8\NN\14052046 had_9\VBD\2108377 accelerated_10\VBN\226566 onset_11\NN\7325190 of_12\IN\1740 <e2>hypothyroidism</e2>_13\NN\14059928 (_14\-LRB-\1740 3.7_15\CD\1740 years_16\NNS\15144371 after_17\IN\1740 onset_18\NN\7325190 of_19\IN\1740 lithium_20\NN\14625458 therapy_21\NN\657604 )_22\-RRB-\1740 compared_23\VBN\644583 with_24\IN\1740 patients_25\NNS\9898892 without_26\IN\1740 a_27\DT\13649268 family_28\NN\8189659 history_29\NN\15120823 (_30\-LRB-\1740 8.6_31\CD\1740 years_32\NNS\15144371 after_33\IN\1740 onset_34\NN\7325190 of_35\IN\1740 <e1>lithium</e1>_36\NN\14625458 therapy_37\NN\657604 )_38\-RRB-\1740 ._39\.\1740
D008094_D007037 CID conclusions_0\NNS\5837957 :_1\:\1740 familial_2\JJ\1740 thyroid_3\NN\5329735 illness_4\NN\14052046 is_5\VBZ\836236 a_6\DT\13649268 risk_7\NN\14541044 factor_8\NN\7326557 for_9\IN\1740 <e2>hypothyroidism</e2>_10\NN\14059928 and_11\CC\1740 hypercalcemia_12\NN\14299637 during_13\IN\1740 <e1>lithium</e1>_14\NN\14625458 therapy_15\NN\657604 ._16\.\1740
D008094_D006934 NONE conclusions_0\NNS\5837957 :_1\:\1740 familial_2\JJ\1740 thyroid_3\NN\5329735 illness_4\NN\14052046 is_5\VBZ\836236 a_6\DT\13649268 risk_7\NN\14541044 factor_8\NN\7326557 for_9\IN\1740 hypothyroidism_10\NN\14059928 and_11\CC\1740 <e2>hypercalcemia</e2>_12\NN\14299637 during_13\IN\1740 <e1>lithium</e1>_14\NN\14625458 therapy_15\NN\657604 ._16\.\1740
18086064
D020927_D009203 NONE <e1>dexmedetomidine</e1>_0\NNP\1740 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 trend_5\NN\8679972 towards_6\IN\1740 improved_7\VBN\126264 cardiac_8\JJ\1740 outcomes_9\NNS\7291312 ;_10\:\1740 all-cause_11\JJ\1740 mortality_12\NN\5054863 (_13\-LRB-\1740 or_14\NN\3541091 0.27_15\CD\1740 ,_16\,\1740 95_17\CD\1740 %_18\NN\1740 ci_19\NN\13635336 0.01_20\CD\1740 -_21\SYM\1740 7.13_22\CD\1740 ,_23\,\1740 p_24\NN\14622893 =_25\JJ\1740 0.44_26\CD\1740 )_27\-RRB-\1740 ,_28\,\1740 non-fatal_29\JJ\1740 <e2>myocardial_30\JJ\1740 infarction</e2>_31\NN\14204950 (_32\-LRB-\1740 or_33\NN\3541091 0.26_34\CD\1740 ,_35\,\1740 95_36\CD\1740 %_37\NN\1740 ci_38\NN\13635336 0.04_39\CD\1740 -_40\SYM\1740 1.60_41\CD\1740 ,_42\,\1740 p_43\NN\14622893 =_44\JJ\1740 0.14_45\CD\1740 )_46\-RRB-\1740 ,_47\,\1740 and_48\CC\1740 myocardial_49\JJ\1740 ischaemia_50\NN\14195315 (_51\-LRB-\1740 or_52\NN\3541091 0.65_53\CD\1740 ,_54\,\1740 95_55\CD\1740 %_56\NN\1740 ci_57\NN\13635336 0.26_58\CD\1740 -_59\SYM\1740 1.63_60\CD\1740 ,_61\,\1740 p_62\NN\14622893 =_63\JJ\1740 0.36_64\CD\1740 )_65\-RRB-\1740 ._66\.\1740
D020927_D017202 NONE <e1>dexmedetomidine</e1>_0\NNP\1740 was_1\VBD\836236 associated_2\VBN\628491 with_3\IN\1740 a_4\DT\13649268 trend_5\NN\8679972 towards_6\IN\1740 improved_7\VBN\126264 cardiac_8\JJ\1740 outcomes_9\NNS\7291312 ;_10\:\1740 all-cause_11\JJ\1740 mortality_12\NN\5054863 (_13\-LRB-\1740 or_14\NN\3541091 0.27_15\CD\1740 ,_16\,\1740 95_17\CD\1740 %_18\NN\1740 ci_19\NN\13635336 0.01_20\CD\1740 -_21\SYM\1740 7.13_22\CD\1740 ,_23\,\1740 p_24\NN\14622893 =_25\JJ\1740 0.44_26\CD\1740 )_27\-RRB-\1740 ,_28\,\1740 non-fatal_29\JJ\1740 myocardial_30\JJ\1740 infarction_31\NN\14204950 (_32\-LRB-\1740 or_33\NN\3541091 0.26_34\CD\1740 ,_35\,\1740 95_36\CD\1740 %_37\NN\1740 ci_38\NN\13635336 0.04_39\CD\1740 -_40\SYM\1740 1.60_41\CD\1740 ,_42\,\1740 p_43\NN\14622893 =_44\JJ\1740 0.14_45\CD\1740 )_46\-RRB-\1740 ,_47\,\1740 and_48\CC\1740 <e2>myocardial_49\JJ\1740 ischaemia</e2>_50\NN\14195315 (_51\-LRB-\1740 or_52\NN\3541091 0.65_53\CD\1740 ,_54\,\1740 95_55\CD\1740 %_56\NN\1740 ci_57\NN\13635336 0.26_58\CD\1740 -_59\SYM\1740 1.63_60\CD\1740 ,_61\,\1740 p_62\NN\14622893 =_63\JJ\1740 0.36_64\CD\1740 )_65\-RRB-\1740 ._66\.\1740
1899352
D015080_D006417 NONE the_0\DT\1740 frequency_1\NN\15286249 and_2\CC\1740 predictability_3\NN\4753455 of_4\IN\1740 <e2>hematuria</e2>_5\NN\14299637 are_6\VBP\836236 not_7\RB\1740 precise_8\JJ\1740 ,_9\,\1740 and_10\CC\1740 at_11\IN\14622893 least_12\JJS\1740 daily_13\JJ\1740 monitoring_14\NN\879759 by_15\IN\1740 urine_16\NN\14853947 hematest_17\NNP\1740 is_18\VBZ\836236 essential_19\JJ\1740 ,_20\,\1740 adding_21\VBG\156601 <e1>mesna</e1>_22\NN\1740 to_23\IN\1740 the_24\DT\1740 infusate_25\NN\1740 in_26\IN\13603305 patients_27\NNS\9898892 with_28\IN\1740 persistent_29\JJ\1740 hematuria_30\NN\14299637 ._31\.\1740
D015080_D006417 NONE the_0\DT\1740 frequency_1\NN\15286249 and_2\CC\1740 predictability_3\NN\4753455 of_4\IN\1740 hematuria_5\NN\14299637 are_6\VBP\836236 not_7\RB\1740 precise_8\JJ\1740 ,_9\,\1740 and_10\CC\1740 at_11\IN\14622893 least_12\JJS\1740 daily_13\JJ\1740 monitoring_14\NN\879759 by_15\IN\1740 urine_16\NN\14853947 hematest_17\NNP\1740 is_18\VBZ\836236 essential_19\JJ\1740 ,_20\,\1740 adding_21\VBG\156601 <e1>mesna</e1>_22\NN\1740 to_23\IN\1740 the_24\DT\1740 infusate_25\NN\1740 in_26\IN\13603305 patients_27\NNS\9898892 with_28\IN\1740 persistent_29\JJ\1740 <e2>hematuria</e2>_30\NN\14299637 ._31\.\1740
16725121
D009638_D012640 NONE down-regulation_0\NN\1740 of_1\IN\1740 <e1>norepinephrine</e1>_2\NN\14807929 transporter_3\NN\4490091 function_4\NN\13783581 induced_5\VBN\1627355 by_6\IN\1740 chronic_7\JJ\1740 administration_8\NN\1133281 of_9\IN\1740 desipramine_10\NN\4482543 linking_11\VBG\628491 to_12\TO\1740 the_13\DT\1740 alteration_14\NN\7283608 of_15\IN\1740 sensitivity_16\NN\5651971 of_17\IN\1740 local-anesthetics-induced_18\JJ\1740 <e2>convulsions</e2>_19\NNS\14081375 and_20\CC\1740 the_21\DT\1740 counteraction_22\NN\231567 by_23\IN\1740 co-administration_24\NN\1740 with_25\IN\1740 local_26\JJ\1740 anesthetics_27\NNS\3247620 ._28\.\1740
D009638_D012640 NONE alterations_0\NNS\7283608 of_1\IN\1740 <e1>norepinephrine</e1>_2\NN\14807929 transporter_3\NN\4490091 (_4\-LRB-\1740 net_5\NN\3085333 )_6\-RRB-\1740 function_7\NN\13783581 by_8\IN\1740 chronic_9\JJ\1740 inhibition_10\NN\1068773 of_11\IN\1740 net_12\NN\3085333 in_13\IN\13603305 relation_14\NN\2137 to_15\TO\1740 sensitization_16\NN\14531772 to_17\IN\1740 <e2>seizures</e2>_18\NNS\14081375 induce_19\NN\1740 by_20\IN\1740 cocaine_21\NN\3492717 and_22\CC\1740 local_23\JJ\1740 anesthetics_24\NNS\3247620 were_25\VBD\836236 studied_26\VBN\630380 in_27\IN\13603305 mice_28\NNS\2329401 ._29\.\1740
D003891_D012640 NONE down-regulation_0\NN\1740 of_1\IN\1740 norepinephrine_2\NN\14807929 transporter_3\NN\4490091 function_4\NN\13783581 induced_5\VBN\1627355 by_6\IN\1740 chronic_7\JJ\1740 administration_8\NN\1133281 of_9\IN\1740 <e1>desipramine</e1>_10\NN\4482543 linking_11\VBG\628491 to_12\TO\1740 the_13\DT\1740 alteration_14\NN\7283608 of_15\IN\1740 sensitivity_16\NN\5651971 of_17\IN\1740 local-anesthetics-induced_18\JJ\1740 <e2>convulsions</e2>_19\NNS\14081375 and_20\CC\1740 the_21\DT\1740 counteraction_22\NN\231567 by_23\IN\1740 co-administration_24\NN\1740 with_25\IN\1740 local_26\JJ\1740 anesthetics_27\NNS\3247620 ._28\.\1740
D003891_D012640 NONE daily_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>desipramine</e1>_3\NN\4482543 increased_4\VBD\169651 the_5\DT\1740 incidence_6\NN\13821570 of_7\IN\1740 appearance_8\NN\4723816 of_9\IN\1740 lidocaine-induced_10\JJ\1740 <e2>convulsions</e2>_11\NNS\14081375 and_12\CC\1740 decreased_13\VBD\169651 that_14\DT\1740 of_15\IN\1740 cocaine-induced_16\JJ\1740 convulsions_17\NNS\14081375 ._18\.\1740
D003891_D012640 NONE daily_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>desipramine</e1>_3\NN\4482543 increased_4\VBD\169651 the_5\DT\1740 incidence_6\NN\13821570 of_7\IN\1740 appearance_8\NN\4723816 of_9\IN\1740 lidocaine-induced_10\JJ\1740 convulsions_11\NNS\14081375 and_12\CC\1740 decreased_13\VBD\169651 that_14\DT\1740 of_15\IN\1740 cocaine-induced_16\JJ\1740 <e2>convulsions</e2>_17\NNS\14081375 ._18\.\1740
D003891_D012640 NONE co-administration_0\NN\1740 of_1\IN\1740 lidocaine_2\NN\3681148 with_3\IN\1740 <e1>desipramine</e1>_4\NN\4482543 reversed_5\VBD\109660 the_6\DT\1740 changes_7\NNS\7283608 of_8\IN\1740 <e2>convulsive</e2>_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 lidocaine_12\NN\3681148 and_13\CC\1740 cocaine_14\NN\3492717 induced_15\VBN\1627355 by_16\IN\1740 repeated_17\VBN\952524 administration_18\NN\1133281 of_19\IN\1740 desipramine_20\NN\4482543 ._21\.\1740
D003891_D012640 NONE co-administration_0\NN\1740 of_1\IN\1740 lidocaine_2\NN\3681148 with_3\IN\1740 desipramine_4\NN\4482543 reversed_5\VBD\109660 the_6\DT\1740 changes_7\NNS\7283608 of_8\IN\1740 <e2>convulsive</e2>_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 lidocaine_12\NN\3681148 and_13\CC\1740 cocaine_14\NN\3492717 induced_15\VBN\1627355 by_16\IN\1740 repeated_17\VBN\952524 administration_18\NN\1133281 of_19\IN\1740 <e1>desipramine</e1>_20\NN\4482543 ._21\.\1740
D003891_D012640 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 down-regulation_4\NN\1740 of_5\IN\1740 hippocampal_6\NN\1740 net_7\NN\3085333 induced_8\VBN\1627355 by_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 <e1>desipramine</e1>_13\NN\4482543 may_14\MD\15209706 be_15\VB\836236 relevant_16\JJ\1740 to_17\TO\1740 desipramine-induced_18\JJ\1740 sensitization_19\NN\14531772 of_20\IN\1740 lidocaine_21\NN\3681148 <e2>convulsions</e2>_22\NNS\14081375 ._23\.\1740
D003891_D012640 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 down-regulation_4\NN\1740 of_5\IN\1740 hippocampal_6\NN\1740 net_7\NN\3085333 induced_8\VBN\1627355 by_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 desipramine_13\NN\4482543 may_14\MD\15209706 be_15\VB\836236 relevant_16\JJ\1740 to_17\TO\1740 <e1>desipramine-induced</e1>_18\JJ\1740 sensitization_19\NN\14531772 of_20\IN\1740 lidocaine_21\NN\3681148 <e2>convulsions</e2>_22\NNS\14081375 ._23\.\1740
D003891_D012640 NONE <e1>desipramine-induced</e1>_0\JJ\1740 sensitization_1\NN\14531772 of_2\IN\1740 lidocaine_3\NN\3681148 <e2>seizures</e2>_4\NNS\14081375 may_5\MD\15209706 have_6\VB\2108377 a_7\DT\13649268 mechanism_8\NN\13446390 distinct_9\JJ\1740 from_10\IN\1740 kindling_11\NN\15101361 resulting_12\VBG\2633881 from_13\IN\1740 repeated_14\VBN\952524 administration_15\NN\1133281 of_16\IN\1740 cocaine_17\NN\3492717 ._18\.\1740
D003042_D012640 CID alterations_0\NNS\7283608 of_1\IN\1740 norepinephrine_2\NN\14807929 transporter_3\NN\4490091 (_4\-LRB-\1740 net_5\NN\3085333 )_6\-RRB-\1740 function_7\NN\13783581 by_8\IN\1740 chronic_9\JJ\1740 inhibition_10\NN\1068773 of_11\IN\1740 net_12\NN\3085333 in_13\IN\13603305 relation_14\NN\2137 to_15\TO\1740 sensitization_16\NN\14531772 to_17\IN\1740 <e2>seizures</e2>_18\NNS\14081375 induce_19\NN\1740 by_20\IN\1740 <e1>cocaine</e1>_21\NN\3492717 and_22\CC\1740 local_23\JJ\1740 anesthetics_24\NNS\3247620 were_25\VBD\836236 studied_26\VBN\630380 in_27\IN\13603305 mice_28\NNS\2329401 ._29\.\1740
D003042_D012640 CID daily_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 desipramine_3\NN\4482543 increased_4\VBD\169651 the_5\DT\1740 incidence_6\NN\13821570 of_7\IN\1740 appearance_8\NN\4723816 of_9\IN\1740 lidocaine-induced_10\JJ\1740 <e2>convulsions</e2>_11\NNS\14081375 and_12\CC\1740 decreased_13\VBD\169651 that_14\DT\1740 of_15\IN\1740 <e1>cocaine-induced</e1>_16\JJ\1740 convulsions_17\NNS\14081375 ._18\.\1740
D003042_D012640 CID daily_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 desipramine_3\NN\4482543 increased_4\VBD\169651 the_5\DT\1740 incidence_6\NN\13821570 of_7\IN\1740 appearance_8\NN\4723816 of_9\IN\1740 lidocaine-induced_10\JJ\1740 convulsions_11\NNS\14081375 and_12\CC\1740 decreased_13\VBD\169651 that_14\DT\1740 of_15\IN\1740 <e1>cocaine-induced</e1>_16\JJ\1740 <e2>convulsions</e2>_17\NNS\14081375 ._18\.\1740
D003042_D012640 CID co-administration_0\NN\1740 of_1\IN\1740 lidocaine_2\NN\3681148 with_3\IN\1740 desipramine_4\NN\4482543 reversed_5\VBD\109660 the_6\DT\1740 changes_7\NNS\7283608 of_8\IN\1740 <e2>convulsive</e2>_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 lidocaine_12\NN\3681148 and_13\CC\1740 <e1>cocaine</e1>_14\NN\3492717 induced_15\VBN\1627355 by_16\IN\1740 repeated_17\VBN\952524 administration_18\NN\1133281 of_19\IN\1740 desipramine_20\NN\4482543 ._21\.\1740
D003042_D012640 CID desipramine-induced_0\JJ\1740 sensitization_1\NN\14531772 of_2\IN\1740 lidocaine_3\NN\3681148 <e2>seizures</e2>_4\NNS\14081375 may_5\MD\15209706 have_6\VB\2108377 a_7\DT\13649268 mechanism_8\NN\13446390 distinct_9\JJ\1740 from_10\IN\1740 kindling_11\NN\15101361 resulting_12\VBG\2633881 from_13\IN\1740 repeated_14\VBN\952524 administration_15\NN\1133281 of_16\IN\1740 <e1>cocaine</e1>_17\NN\3492717 ._18\.\1740
D008012_D012640 CID daily_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 desipramine_3\NN\4482543 increased_4\VBD\169651 the_5\DT\1740 incidence_6\NN\13821570 of_7\IN\1740 appearance_8\NN\4723816 of_9\IN\1740 <e1>lidocaine-induced</e1>_10\JJ\1740 <e2>convulsions</e2>_11\NNS\14081375 and_12\CC\1740 decreased_13\VBD\169651 that_14\DT\1740 of_15\IN\1740 cocaine-induced_16\JJ\1740 convulsions_17\NNS\14081375 ._18\.\1740
D008012_D012640 CID daily_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 desipramine_3\NN\4482543 increased_4\VBD\169651 the_5\DT\1740 incidence_6\NN\13821570 of_7\IN\1740 appearance_8\NN\4723816 of_9\IN\1740 <e1>lidocaine-induced</e1>_10\JJ\1740 convulsions_11\NNS\14081375 and_12\CC\1740 decreased_13\VBD\169651 that_14\DT\1740 of_15\IN\1740 cocaine-induced_16\JJ\1740 <e2>convulsions</e2>_17\NNS\14081375 ._18\.\1740
D008012_D012640 CID co-administration_0\NN\1740 of_1\IN\1740 <e1>lidocaine</e1>_2\NN\3681148 with_3\IN\1740 desipramine_4\NN\4482543 reversed_5\VBD\109660 the_6\DT\1740 changes_7\NNS\7283608 of_8\IN\1740 <e2>convulsive</e2>_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 lidocaine_12\NN\3681148 and_13\CC\1740 cocaine_14\NN\3492717 induced_15\VBN\1627355 by_16\IN\1740 repeated_17\VBN\952524 administration_18\NN\1133281 of_19\IN\1740 desipramine_20\NN\4482543 ._21\.\1740
D008012_D012640 CID co-administration_0\NN\1740 of_1\IN\1740 lidocaine_2\NN\3681148 with_3\IN\1740 desipramine_4\NN\4482543 reversed_5\VBD\109660 the_6\DT\1740 changes_7\NNS\7283608 of_8\IN\1740 <e2>convulsive</e2>_9\JJ\1740 activity_10\NN\30358 of_11\IN\1740 <e1>lidocaine</e1>_12\NN\3681148 and_13\CC\1740 cocaine_14\NN\3492717 induced_15\VBN\1627355 by_16\IN\1740 repeated_17\VBN\952524 administration_18\NN\1133281 of_19\IN\1740 desipramine_20\NN\4482543 ._21\.\1740
D008012_D012640 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 down-regulation_4\NN\1740 of_5\IN\1740 hippocampal_6\NN\1740 net_7\NN\3085333 induced_8\VBN\1627355 by_9\IN\1740 chronic_10\JJ\1740 administration_11\NN\1133281 of_12\IN\1740 desipramine_13\NN\4482543 may_14\MD\15209706 be_15\VB\836236 relevant_16\JJ\1740 to_17\TO\1740 desipramine-induced_18\JJ\1740 sensitization_19\NN\14531772 of_20\IN\1740 <e1>lidocaine</e1>_21\NN\3681148 <e2>convulsions</e2>_22\NNS\14081375 ._23\.\1740
D008012_D012640 CID desipramine-induced_0\JJ\1740 sensitization_1\NN\14531772 of_2\IN\1740 <e1>lidocaine</e1>_3\NN\3681148 <e2>seizures</e2>_4\NNS\14081375 may_5\MD\15209706 have_6\VB\2108377 a_7\DT\13649268 mechanism_8\NN\13446390 distinct_9\JJ\1740 from_10\IN\1740 kindling_11\NN\15101361 resulting_12\VBG\2633881 from_13\IN\1740 repeated_14\VBN\952524 administration_15\NN\1133281 of_16\IN\1740 cocaine_17\NN\3492717 ._18\.\1740
2917114
D006024_D001919 NONE use_0\NN\407535 of_1\IN\1740 <e1>glycopyrronium</e1>_2\NN\1740 5_3\CD\13741022 micrograms_4\NNS\13717155 kg-1_5\NN\1740 provided_6\VBD\2199590 greater_7\JJR\1740 cardiovascular_8\JJ\1740 stability_9\NN\4777852 and_10\CC\1740 ,_11\,\1740 given_12\VBN\2327200 1_13\CD\13741022 min_14\NN\15154774 before_15\IN\1740 the_16\DT\1740 edrophonium_17\NN\1740 ,_18\,\1740 was_19\VBD\836236 sufficient_20\JJ\1740 to_21\TO\1740 minimize_22\VB\441445 early_23\JJ\1740 ,_24\,\1740 edrophonium-induced_25\JJ\1740 <e2>bradycardias</e2>_26\NNS\14110674 ._27\.\1740
D004491_D001919 CID use_0\NN\407535 of_1\IN\1740 glycopyrronium_2\NN\1740 5_3\CD\13741022 micrograms_4\NNS\13717155 kg-1_5\NN\1740 provided_6\VBD\2199590 greater_7\JJR\1740 cardiovascular_8\JJ\1740 stability_9\NN\4777852 and_10\CC\1740 ,_11\,\1740 given_12\VBN\2327200 1_13\CD\13741022 min_14\NN\15154774 before_15\IN\1740 the_16\DT\1740 <e1>edrophonium</e1>_17\NN\1740 ,_18\,\1740 was_19\VBD\836236 sufficient_20\JJ\1740 to_21\TO\1740 minimize_22\VB\441445 early_23\JJ\1740 ,_24\,\1740 edrophonium-induced_25\JJ\1740 <e2>bradycardias</e2>_26\NNS\14110674 ._27\.\1740
D004491_D001919 CID use_0\NN\407535 of_1\IN\1740 glycopyrronium_2\NN\1740 5_3\CD\13741022 micrograms_4\NNS\13717155 kg-1_5\NN\1740 provided_6\VBD\2199590 greater_7\JJR\1740 cardiovascular_8\JJ\1740 stability_9\NN\4777852 and_10\CC\1740 ,_11\,\1740 given_12\VBN\2327200 1_13\CD\13741022 min_14\NN\15154774 before_15\IN\1740 the_16\DT\1740 edrophonium_17\NN\1740 ,_18\,\1740 was_19\VBD\836236 sufficient_20\JJ\1740 to_21\TO\1740 minimize_22\VB\441445 early_23\JJ\1740 ,_24\,\1740 <e1>edrophonium-induced</e1>_25\JJ\1740 <e2>bradycardias</e2>_26\NNS\14110674 ._27\.\1740
19139001
D000518_D015179 NONE longitudinal_0\JJ\1740 assessment_1\NN\5732756 of_2\IN\1740 air_3\NN\14877585 conduction_4\NN\11419404 audiograms_5\NNS\4076846 in_6\IN\13603305 a_7\DT\13649268 phase_8\NN\15113229 iii_9\CD\13741022 clinical_10\JJ\1740 trial_11\NN\786195 of_12\IN\1740 <e1>difluoromethylornithine</e1>_13\NN\1740 and_14\CC\1740 sulindac_15\NN\3828465 for_16\IN\1740 prevention_17\NN\1073995 of_18\IN\1740 sporadic_19\JJ\1740 <e2>colorectal_20\JJ\1740 adenomas</e2>_21\NNS\14236226 ._22\.\1740
D013467_D015179 NONE longitudinal_0\JJ\1740 assessment_1\NN\5732756 of_2\IN\1740 air_3\NN\14877585 conduction_4\NN\11419404 audiograms_5\NNS\4076846 in_6\IN\13603305 a_7\DT\13649268 phase_8\NN\15113229 iii_9\CD\13741022 clinical_10\JJ\1740 trial_11\NN\786195 of_12\IN\1740 difluoromethylornithine_13\NN\1740 and_14\CC\1740 <e1>sulindac</e1>_15\NN\3828465 for_16\IN\1740 prevention_17\NN\1073995 of_18\IN\1740 sporadic_19\JJ\1740 <e2>colorectal_20\JJ\1740 adenomas</e2>_21\NNS\14236226 ._22\.\1740
D000518_D018256 NONE a_0\DT\13649268 phase_1\NN\15113229 iii_2\CD\13741022 clinical_3\JJ\1740 trial_4\NN\786195 assessed_5\VBD\670261 the_6\DT\1740 recurrence_7\NN\7342049 of_8\IN\1740 <e2>adenomatous_9\JJ\1740 polyps</e2>_10\NNS\14234074 after_11\IN\1740 treatment_12\NN\654885 for_13\IN\1740 36_14\CD\1740 months_15\NNS\15113229 with_16\IN\1740 <e1>difluoromethylornithine</e1>_17\NN\1740 (_18\-LRB-\1740 dfmo_19\NN\1740 )_20\-RRB-\1740 plus_21\CC\4723816 sulindac_22\NN\3828465 or_23\CC\3541091 matched_24\VBN\2664769 placebos_25\NNS\3740161 ._26\.\1740
D000518_D018256 NONE a_0\DT\13649268 phase_1\NN\15113229 iii_2\CD\13741022 clinical_3\JJ\1740 trial_4\NN\786195 assessed_5\VBD\670261 the_6\DT\1740 recurrence_7\NN\7342049 of_8\IN\1740 <e2>adenomatous_9\JJ\1740 polyps</e2>_10\NNS\14234074 after_11\IN\1740 treatment_12\NN\654885 for_13\IN\1740 36_14\CD\1740 months_15\NNS\15113229 with_16\IN\1740 difluoromethylornithine_17\NN\1740 (_18\-LRB-\1740 <e1>dfmo</e1>_19\NN\1740 )_20\-RRB-\1740 plus_21\CC\4723816 sulindac_22\NN\3828465 or_23\CC\3541091 matched_24\VBN\2664769 placebos_25\NNS\3740161 ._26\.\1740
D013467_D018256 NONE a_0\DT\13649268 phase_1\NN\15113229 iii_2\CD\13741022 clinical_3\JJ\1740 trial_4\NN\786195 assessed_5\VBD\670261 the_6\DT\1740 recurrence_7\NN\7342049 of_8\IN\1740 <e2>adenomatous_9\JJ\1740 polyps</e2>_10\NNS\14234074 after_11\IN\1740 treatment_12\NN\654885 for_13\IN\1740 36_14\CD\1740 months_15\NNS\15113229 with_16\IN\1740 difluoromethylornithine_17\NN\1740 (_18\-LRB-\1740 dfmo_19\NN\1740 )_20\-RRB-\1740 plus_21\CC\4723816 <e1>sulindac</e1>_22\NN\3828465 or_23\CC\3541091 matched_24\VBN\2664769 placebos_25\NNS\3740161 ._26\.\1740
D000518_D034381 NONE temporary_0\JJ\1740 <e2>hearing_1\NN\1184814 loss</e2>_2\NN\13252973 is_3\VBZ\836236 a_4\DT\13649268 known_5\JJ\1740 toxicity_6\NN\13576101 of_7\IN\1740 treatment_8\NN\654885 with_9\IN\1740 <e1>dfmo</e1>_10\NN\1740 ,_11\,\1740 thus_12\RB\1740 a_13\DT\13649268 comprehensive_14\JJ\1740 approach_15\NN\940842 was_16\VBD\836236 developed_17\VBN\1753788 to_18\TO\1740 analyze_19\VB\78760 serial_20\JJ\1740 air_21\NN\14877585 conduction_22\NN\11419404 audiograms_23\NNS\4076846 ._24\.\1740
D000518_D034381 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 the_6\DT\1740 proportion_7\NN\13824815 of_8\IN\1740 subjects_9\NNS\6598915 in_10\IN\13603305 the_11\DT\1740 <e1>dfmo</e1>_12\NN\1740 plus_13\CC\4723816 sulindac_14\NN\3828465 group_15\NN\2137 who_16\WP\8299493 experienced_17\VBD\2108377 clinically_18\RB\1740 significant_19\JJ\1740 <e2>hearing_20\NN\1184814 loss</e2>_21\NN\13252973 compared_22\VBN\644583 with_23\IN\1740 the_24\DT\1740 placebo_25\NN\3740161 group_26\NN\2137 ._27\.\1740
D000518_D064420 NONE temporary_0\JJ\1740 hearing_1\NN\1184814 loss_2\NN\13252973 is_3\VBZ\836236 a_4\DT\13649268 known_5\JJ\1740 <e2>toxicity</e2>_6\NN\13576101 of_7\IN\1740 treatment_8\NN\654885 with_9\IN\1740 <e1>dfmo</e1>_10\NN\1740 ,_11\,\1740 thus_12\RB\1740 a_13\DT\13649268 comprehensive_14\JJ\1740 approach_15\NN\940842 was_16\VBD\836236 developed_17\VBN\1753788 to_18\TO\1740 analyze_19\VB\78760 serial_20\JJ\1740 air_21\NN\14877585 conduction_22\NN\11419404 audiograms_23\NNS\4076846 ._24\.\1740
D013467_D034381 CID there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 significant_3\JJ\1740 difference_4\NN\4723816 in_5\IN\13603305 the_6\DT\1740 proportion_7\NN\13824815 of_8\IN\1740 subjects_9\NNS\6598915 in_10\IN\13603305 the_11\DT\1740 dfmo_12\NN\1740 plus_13\CC\4723816 <e1>sulindac</e1>_14\NN\3828465 group_15\NN\2137 who_16\WP\8299493 experienced_17\VBD\2108377 clinically_18\RB\1740 significant_19\JJ\1740 <e2>hearing_20\NN\1184814 loss</e2>_21\NN\13252973 compared_22\VBN\644583 with_23\IN\1740 the_24\DT\1740 placebo_25\NN\3740161 group_26\NN\2137 ._27\.\1740
14745746
C090450_D001943 NONE patients_0\NNS\9898892 participating_1\VBG\2367363 in_2\IN\13603305 a_3\DT\13649268 randomised_4\VBN\278117 trial_5\NN\786195 of_6\IN\1740 <e1>anastrozole</e1>_7\NN\1740 ,_8\,\1740 tamoxifen_9\NN\2714883 alone_10\RB\1740 or_11\CC\3541091 combined_12\JJ\1740 (_13\-LRB-\1740 atac_14\NN\1740 )_15\-RRB-\1740 (_16\-LRB-\1740 n=94_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 a_20\DT\13649268 group_21\NN\2137 of_22\IN\1740 women_23\NNS\9605289 without_24\IN\1740 <e2>breast_25\NN\5225090 cancer</e2>_26\NN\14239425 (_27\-LRB-\1740 n=35_28\NN\1740 )_29\-RRB-\1740 completed_30\VBD\352826 a_31\DT\13649268 battery_32\NN\8389297 of_33\IN\1740 neuropsychological_34\JJ\1740 measures_35\NNS\168237 ._36\.\1740
D013629_D001943 NONE patients_0\NNS\9898892 participating_1\VBG\2367363 in_2\IN\13603305 a_3\DT\13649268 randomised_4\VBN\278117 trial_5\NN\786195 of_6\IN\1740 anastrozole_7\NN\1740 ,_8\,\1740 <e1>tamoxifen</e1>_9\NN\2714883 alone_10\RB\1740 or_11\CC\3541091 combined_12\JJ\1740 (_13\-LRB-\1740 atac_14\NN\1740 )_15\-RRB-\1740 (_16\-LRB-\1740 n=94_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 a_20\DT\13649268 group_21\NN\2137 of_22\IN\1740 women_23\NNS\9605289 without_24\IN\1740 <e2>breast_25\NN\5225090 cancer</e2>_26\NN\14239425 (_27\-LRB-\1740 n=35_28\NN\1740 )_29\-RRB-\1740 completed_30\VBD\352826 a_31\DT\13649268 battery_32\NN\8389297 of_33\IN\1740 neuropsychological_34\JJ\1740 measures_35\NNS\168237 ._36\.\1740
8854309
D003042_D011681 CID a_0\DT\13649268 measure_1\NN\168237 of_2\IN\1740 <e2>pupillary_3\JJ\1740 oscillation</e2>_4\NN\13518963 as_5\IN\14622893 a_6\DT\13649268 marker_7\NN\21939 of_8\IN\1740 <e1>cocaine-induced</e1>_9\JJ\1740 paranoia_10\NN\14398067 ._11\.\1740
D003042_D010259 CID a_0\DT\13649268 measure_1\NN\168237 of_2\IN\1740 pupillary_3\JJ\1740 oscillation_4\NN\13518963 as_5\IN\14622893 a_6\DT\13649268 marker_7\NN\21939 of_8\IN\1740 <e1>cocaine-induced</e1>_9\JJ\1740 <e2>paranoia</e2>_10\NN\14398067 ._11\.\1740
D003042_D010259 CID <e1>cocaine-induced</e1>_0\JJ\1740 <e2>paranoia</e2>_1\NN\14398067 (_2\-LRB-\1740 cip_3\NN\1740 )_4\-RRB-\1740 remains_5\VBZ\2604760 an_6\DT\6697703 important_7\JJ\1740 drug-induced_8\JJ\1740 model_9\NN\5888929 of_10\IN\1740 idiopathic_11\JJ\1740 paranoia_12\NN\14398067 for_13\IN\1740 which_14\WDT\1740 no_15\DT\7204911 psychophysiologic_16\JJ\1740 marker_17\NN\21939 has_18\VBZ\2108377 yet_19\RB\1740 emerged_20\VBN\422090 ._21\.\1740
D003042_D010259 CID <e1>cocaine-induced</e1>_0\JJ\1740 paranoia_1\NN\14398067 (_2\-LRB-\1740 <e2>cip</e2>_3\NN\1740 )_4\-RRB-\1740 remains_5\VBZ\2604760 an_6\DT\6697703 important_7\JJ\1740 drug-induced_8\JJ\1740 model_9\NN\5888929 of_10\IN\1740 idiopathic_11\JJ\1740 paranoia_12\NN\14398067 for_13\IN\1740 which_14\WDT\1740 no_15\DT\7204911 psychophysiologic_16\JJ\1740 marker_17\NN\21939 has_18\VBZ\2108377 yet_19\RB\1740 emerged_20\VBN\422090 ._21\.\1740
D003042_D010259 CID <e1>cocaine-induced</e1>_0\JJ\1740 paranoia_1\NN\14398067 (_2\-LRB-\1740 cip_3\NN\1740 )_4\-RRB-\1740 remains_5\VBZ\2604760 an_6\DT\6697703 important_7\JJ\1740 drug-induced_8\JJ\1740 model_9\NN\5888929 of_10\IN\1740 idiopathic_11\JJ\1740 <e2>paranoia</e2>_12\NN\14398067 for_13\IN\1740 which_14\WDT\1740 no_15\DT\7204911 psychophysiologic_16\JJ\1740 marker_17\NN\21939 has_18\VBZ\2108377 yet_19\RB\1740 emerged_20\VBN\422090 ._21\.\1740
D016578_D011681 NONE measures_0\NNS\168237 of_1\IN\1740 <e2>pupillary_2\JJ\1740 oscillation</e2>_3\NN\13518963 were_4\VBD\836236 able_5\JJ\1740 to_6\TO\1740 significantly_7\RB\1740 distinguish_8\VB\618878 a_9\DT\13649268 group_10\NN\2137 of_11\IN\1740 abstinent_12\JJ\1740 <e1>crack_13\NN\9379111 cocaine</e1>_14\NN\3492717 abusers_15\NNS\9633969 endorsing_16\VBG\806502 past_17\JJ\1740 cip_18\NN\1740 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 32_22\CD\1740 )_23\-RRB-\1740 from_24\IN\1740 another_25\DT\1740 group_26\NN\2137 of_27\IN\1740 crack_28\NN\9379111 addicts_29\NNS\10059582 who_30\WP\8299493 denied_31\VBD\823436 past_32\IN\28270 cip_33\NN\1740 (_34\-LRB-\1740 n_35\NN\14622893 =_36\JJ\1740 29_37\CD\13745420 )_38\-RRB-\1740 ._39\.\1740
D016578_D011681 NONE measures_0\NNS\168237 of_1\IN\1740 <e2>pupillary_2\JJ\1740 oscillation</e2>_3\NN\13518963 were_4\VBD\836236 able_5\JJ\1740 to_6\TO\1740 significantly_7\RB\1740 distinguish_8\VB\618878 a_9\DT\13649268 group_10\NN\2137 of_11\IN\1740 abstinent_12\JJ\1740 crack_13\NN\9379111 cocaine_14\NN\3492717 abusers_15\NNS\9633969 endorsing_16\VBG\806502 past_17\JJ\1740 cip_18\NN\1740 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 32_22\CD\1740 )_23\-RRB-\1740 from_24\IN\1740 another_25\DT\1740 group_26\NN\2137 of_27\IN\1740 <e1>crack</e1>_28\NN\9379111 addicts_29\NNS\10059582 who_30\WP\8299493 denied_31\VBD\823436 past_32\IN\28270 cip_33\NN\1740 (_34\-LRB-\1740 n_35\NN\14622893 =_36\JJ\1740 29_37\CD\13745420 )_38\-RRB-\1740 ._39\.\1740
D016578_D010259 NONE measures_0\NNS\168237 of_1\IN\1740 pupillary_2\JJ\1740 oscillation_3\NN\13518963 were_4\VBD\836236 able_5\JJ\1740 to_6\TO\1740 significantly_7\RB\1740 distinguish_8\VB\618878 a_9\DT\13649268 group_10\NN\2137 of_11\IN\1740 abstinent_12\JJ\1740 <e1>crack_13\NN\9379111 cocaine</e1>_14\NN\3492717 abusers_15\NNS\9633969 endorsing_16\VBG\806502 past_17\JJ\1740 <e2>cip</e2>_18\NN\1740 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 32_22\CD\1740 )_23\-RRB-\1740 from_24\IN\1740 another_25\DT\1740 group_26\NN\2137 of_27\IN\1740 crack_28\NN\9379111 addicts_29\NNS\10059582 who_30\WP\8299493 denied_31\VBD\823436 past_32\IN\28270 cip_33\NN\1740 (_34\-LRB-\1740 n_35\NN\14622893 =_36\JJ\1740 29_37\CD\13745420 )_38\-RRB-\1740 ._39\.\1740
D016578_D010259 NONE measures_0\NNS\168237 of_1\IN\1740 pupillary_2\JJ\1740 oscillation_3\NN\13518963 were_4\VBD\836236 able_5\JJ\1740 to_6\TO\1740 significantly_7\RB\1740 distinguish_8\VB\618878 a_9\DT\13649268 group_10\NN\2137 of_11\IN\1740 abstinent_12\JJ\1740 <e1>crack_13\NN\9379111 cocaine</e1>_14\NN\3492717 abusers_15\NNS\9633969 endorsing_16\VBG\806502 past_17\JJ\1740 cip_18\NN\1740 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 32_22\CD\1740 )_23\-RRB-\1740 from_24\IN\1740 another_25\DT\1740 group_26\NN\2137 of_27\IN\1740 crack_28\NN\9379111 addicts_29\NNS\10059582 who_30\WP\8299493 denied_31\VBD\823436 past_32\IN\28270 <e2>cip</e2>_33\NN\1740 (_34\-LRB-\1740 n_35\NN\14622893 =_36\JJ\1740 29_37\CD\13745420 )_38\-RRB-\1740 ._39\.\1740
D016578_D010259 NONE measures_0\NNS\168237 of_1\IN\1740 pupillary_2\JJ\1740 oscillation_3\NN\13518963 were_4\VBD\836236 able_5\JJ\1740 to_6\TO\1740 significantly_7\RB\1740 distinguish_8\VB\618878 a_9\DT\13649268 group_10\NN\2137 of_11\IN\1740 abstinent_12\JJ\1740 crack_13\NN\9379111 cocaine_14\NN\3492717 abusers_15\NNS\9633969 endorsing_16\VBG\806502 past_17\JJ\1740 <e2>cip</e2>_18\NN\1740 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 32_22\CD\1740 )_23\-RRB-\1740 from_24\IN\1740 another_25\DT\1740 group_26\NN\2137 of_27\IN\1740 <e1>crack</e1>_28\NN\9379111 addicts_29\NNS\10059582 who_30\WP\8299493 denied_31\VBD\823436 past_32\IN\28270 cip_33\NN\1740 (_34\-LRB-\1740 n_35\NN\14622893 =_36\JJ\1740 29_37\CD\13745420 )_38\-RRB-\1740 ._39\.\1740
D016578_D010259 NONE measures_0\NNS\168237 of_1\IN\1740 pupillary_2\JJ\1740 oscillation_3\NN\13518963 were_4\VBD\836236 able_5\JJ\1740 to_6\TO\1740 significantly_7\RB\1740 distinguish_8\VB\618878 a_9\DT\13649268 group_10\NN\2137 of_11\IN\1740 abstinent_12\JJ\1740 crack_13\NN\9379111 cocaine_14\NN\3492717 abusers_15\NNS\9633969 endorsing_16\VBG\806502 past_17\JJ\1740 cip_18\NN\1740 (_19\-LRB-\1740 n_20\NN\14622893 =_21\JJ\1740 32_22\CD\1740 )_23\-RRB-\1740 from_24\IN\1740 another_25\DT\1740 group_26\NN\2137 of_27\IN\1740 <e1>crack</e1>_28\NN\9379111 addicts_29\NNS\10059582 who_30\WP\8299493 denied_31\VBD\823436 past_32\IN\28270 <e2>cip</e2>_33\NN\1740 (_34\-LRB-\1740 n_35\NN\14622893 =_36\JJ\1740 29_37\CD\13745420 )_38\-RRB-\1740 ._39\.\1740
9321531
D007980_D010300 NONE conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 late-stage_3\JJ\1740 <e2>parkinson_4\NNP\1740 's_5\POS\1740 disease</e2>_6\NN\14061805 ,_7\,\1740 pallidotomy_8\NN\1740 significantly_9\RB\1740 reduces_10\VBZ\441445 <e1>levodopa-induced</e1>_11\JJ\1740 dyskinesias_12\NNS\14084880 and_13\CC\1740 off-period_14\JJ\1740 disability_15\NN\14547369 ._16\.\1740
D007980_D004409 CID conclusions_0\NNS\5837957 :_1\:\1740 in_2\IN\13603305 late-stage_3\JJ\1740 parkinson_4\NNP\1740 's_5\POS\1740 disease_6\NN\14061805 ,_7\,\1740 pallidotomy_8\NN\1740 significantly_9\RB\1740 reduces_10\VBZ\441445 <e1>levodopa-induced</e1>_11\JJ\1740 <e2>dyskinesias</e2>_12\NNS\14084880 and_13\CC\1740 off-period_14\JJ\1740 disability_15\NN\14547369 ._16\.\1740
8617710
D020280_D003072 NONE absence_0\NN\14449405 of_1\IN\1740 effect_2\NN\34213 of_3\IN\1740 <e1>sertraline</e1>_4\NN\4169152 on_5\IN\1740 time-based_6\JJ\1740 sensitization_7\NN\14531772 of_8\IN\1740 <e2>cognitive_9\JJ\1740 impairment</e2>_10\NN\7296428 with_11\IN\1740 haloperidol_12\NN\3713736 ._13\.\1740
D020280_D003072 NONE conclusion_0\NN\5837957 :_1\:\1740 haloperidol_2\NNP\3713736 produced_3\VBD\1617192 a_4\DT\13649268 clear_5\JJ\1740 profile_6\NN\6999802 of_7\IN\1740 <e2>cognitive_8\JJ\1740 impairment</e2>_9\NN\7296428 that_10\WDT\1740 was_11\VBD\836236 not_12\RB\1740 worsened_13\VBN\146138 by_14\IN\1740 concomitant_15\JJ\1740 <e1>sertraline</e1>_16\NN\4169152 administration_17\NN\1133281 ._18\.\1740
D006220_D003072 CID absence_0\NN\14449405 of_1\IN\1740 effect_2\NN\34213 of_3\IN\1740 sertraline_4\NN\4169152 on_5\IN\1740 time-based_6\JJ\1740 sensitization_7\NN\14531772 of_8\IN\1740 <e2>cognitive_9\JJ\1740 impairment</e2>_10\NN\7296428 with_11\IN\1740 <e1>haloperidol</e1>_12\NN\3713736 ._13\.\1740
D006220_D003072 CID results_0\NNS\34213 :_1\:\1740 <e2>impairment_2\NN\7296428 of_3\IN\1740 cognitive_4\JJ\1740 function</e2>_5\NN\13783581 was_6\VBD\836236 observed_7\VBN\2163746 6_8\CD\13741022 to_9\TO\1740 8_10\CD\13741022 hours_11\NNS\15118228 after_12\IN\1740 administration_13\NN\1133281 of_14\IN\1740 <e1>haloperidol</e1>_15\NN\3713736 on_16\IN\1740 day_17\NNP\15154774 2_18\CD\13741022 but_19\CC\1740 was_20\VBD\836236 not_21\RB\1740 evident_22\JJ\1740 23_23\CD\13745420 hours_24\NNS\15118228 after_25\IN\1740 dosing_26\NN\1740 ._27\.\1740
D006220_D003072 CID conclusion_0\NN\5837957 :_1\:\1740 <e1>haloperidol</e1>_2\NNP\3713736 produced_3\VBD\1617192 a_4\DT\13649268 clear_5\JJ\1740 profile_6\NN\6999802 of_7\IN\1740 <e2>cognitive_8\JJ\1740 impairment</e2>_9\NN\7296428 that_10\WDT\1740 was_11\VBD\836236 not_12\RB\1740 worsened_13\VBN\146138 by_14\IN\1740 concomitant_15\JJ\1740 sertraline_16\NN\4169152 administration_17\NN\1133281 ._18\.\1740
384871
D004977_D009901 CID <e2>bilateral_0\JJ\1740 optic_1\NN\5299178 neuropathy</e2>_2\NN\14204950 due_3\JJ\1740 to_4\TO\1740 combined_5\JJ\1740 <e1>ethambutol</e1>_6\NN\1740 and_7\CC\1740 isoniazid_8\NN\2716205 treatment_9\NN\654885 ._10\.\1740
D007538_D009901 CID <e2>bilateral_0\JJ\1740 optic_1\NN\5299178 neuropathy</e2>_2\NN\14204950 due_3\JJ\1740 to_4\TO\1740 combined_5\JJ\1740 ethambutol_6\NN\1740 and_7\CC\1740 <e1>isoniazid</e1>_8\NN\2716205 treatment_9\NN\654885 ._10\.\1740
D004977_D064420 NONE the_0\DT\1740 hazards_1\NNS\14541044 of_2\IN\1740 optic_3\JJ\1740 nerve_4\NN\5475681 <e2>toxicity</e2>_5\NN\13576101 due_6\IN\5174653 to_7\TO\1740 <e1>ethambutol</e1>_8\NN\1740 are_9\VBP\836236 known_10\VBN\2110220 ._11\.\1740
16629641
D007372_D006526 NONE the_0\DT\1740 current_1\JJ\1740 best_2\JJS\1740 treatment_3\NN\654885 for_4\IN\1740 <e2>hcv_5\NN\1740 infection</e2>_6\NN\14052046 is_7\VBZ\836236 combination_8\NN\7951464 therapy_9\NN\657604 with_10\IN\1740 pegylated_11\JJ\1740 <e1>interferon</e1>_12\NN\2725367 and_13\CC\1740 ribavirin_14\NN\2725367 ._15\.\1740
D012254_D006526 NONE the_0\DT\1740 current_1\JJ\1740 best_2\JJS\1740 treatment_3\NN\654885 for_4\IN\1740 <e2>hcv_5\NN\1740 infection</e2>_6\NN\14052046 is_7\VBZ\836236 combination_8\NN\7951464 therapy_9\NN\657604 with_10\IN\1740 pegylated_11\JJ\1740 interferon_12\NN\2725367 and_13\CC\1740 <e1>ribavirin</e1>_14\NN\2725367 ._15\.\1740
D012254_D006526 NONE hemoglobin_0\NN\14888884 concentrations_1\NNS\4916342 decrease_2\VBP\169651 mainly_3\RB\1740 as_4\IN\14622893 a_5\DT\13649268 result_6\NN\34213 of_7\IN\1740 <e1>ribavirin-induced</e1>_8\JJ\1740 hemolysis_9\NN\13509528 ,_10\,\1740 and_11\CC\1740 this_12\DT\1740 anemia_13\NN\14189204 can_14\MD\3094503 be_15\VB\836236 problematic_16\JJ\1740 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 <e2>hcv_20\NN\1740 infection</e2>_21\NN\14052046 ,_22\,\1740 especially_23\RB\1740 those_24\DT\1740 who_25\WP\8299493 have_26\VBP\2108377 comorbid_27\VB\1740 renal_28\JJ\1740 or_29\CC\3541091 cardiovascular_30\JJ\1740 disorders_31\NNS\14034177 ._32\.\1740
D012254_D006461 NONE hemoglobin_0\NN\14888884 concentrations_1\NNS\4916342 decrease_2\VBP\169651 mainly_3\RB\1740 as_4\IN\14622893 a_5\DT\13649268 result_6\NN\34213 of_7\IN\1740 <e1>ribavirin-induced</e1>_8\JJ\1740 <e2>hemolysis</e2>_9\NN\13509528 ,_10\,\1740 and_11\CC\1740 this_12\DT\1740 anemia_13\NN\14189204 can_14\MD\3094503 be_15\VB\836236 problematic_16\JJ\1740 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 hcv_20\NN\1740 infection_21\NN\14052046 ,_22\,\1740 especially_23\RB\1740 those_24\DT\1740 who_25\WP\8299493 have_26\VBP\2108377 comorbid_27\VB\1740 renal_28\JJ\1740 or_29\CC\3541091 cardiovascular_30\JJ\1740 disorders_31\NNS\14034177 ._32\.\1740
D012254_D000740 NONE hemoglobin_0\NN\14888884 concentrations_1\NNS\4916342 decrease_2\VBP\169651 mainly_3\RB\1740 as_4\IN\14622893 a_5\DT\13649268 result_6\NN\34213 of_7\IN\1740 <e1>ribavirin-induced</e1>_8\JJ\1740 hemolysis_9\NN\13509528 ,_10\,\1740 and_11\CC\1740 this_12\DT\1740 <e2>anemia</e2>_13\NN\14189204 can_14\MD\3094503 be_15\VB\836236 problematic_16\JJ\1740 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 hcv_20\NN\1740 infection_21\NN\14052046 ,_22\,\1740 especially_23\RB\1740 those_24\DT\1740 who_25\WP\8299493 have_26\VBP\2108377 comorbid_27\VB\1740 renal_28\JJ\1740 or_29\CC\3541091 cardiovascular_30\JJ\1740 disorders_31\NNS\14034177 ._32\.\1740
D012254_D000740 NONE although_0\IN\1740 <e1>ribavirin-associated</e1>_1\JJ\1740 <e2>anemia</e2>_2\NN\14189204 can_3\MD\3094503 be_4\VB\836236 reversed_5\VBN\109660 by_6\IN\1740 dose_7\NN\3740161 reduction_8\NN\351485 or_9\CC\3541091 discontinuation_10\NN\209943 ,_11\,\1740 this_12\DT\1740 approach_13\NN\940842 compromises_14\VBZ\1035530 outcomes_15\NNS\7291312 by_16\IN\1740 significantly_17\RB\1740 decreasing_18\VBG\169651 svr_19\NN\8342039 rates_20\NNS\13308999 ._21\.\1740
D012254_D000740 NONE recombinant_0\JJ\1740 human_1\JJ\1740 erythropoietin_2\NN\14888310 has_3\VBZ\2108377 been_4\VBN\836236 used_5\VBN\1156834 to_6\TO\1740 manage_7\VB\2524171 <e1>ribavirin-associated</e1>_8\JJ\1740 <e2>anemia</e2>_9\NN\14189204 but_10\CC\1740 has_11\VBZ\2108377 other_12\JJ\1740 potential_13\JJ\1740 disadvantages_14\NNS\5161436 ._15\.\1740
D012254_D007674 NONE hemoglobin_0\NN\14888884 concentrations_1\NNS\4916342 decrease_2\VBP\169651 mainly_3\RB\1740 as_4\IN\14622893 a_5\DT\13649268 result_6\NN\34213 of_7\IN\1740 <e1>ribavirin-induced</e1>_8\JJ\1740 hemolysis_9\NN\13509528 ,_10\,\1740 and_11\CC\1740 this_12\DT\1740 anemia_13\NN\14189204 can_14\MD\3094503 be_15\VB\836236 problematic_16\JJ\1740 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 hcv_20\NN\1740 infection_21\NN\14052046 ,_22\,\1740 especially_23\RB\1740 those_24\DT\1740 who_25\WP\8299493 have_26\VBP\2108377 comorbid_27\VB\1740 <e2>renal_28\JJ\1740 or_29\CC\3541091 cardiovascular_30\JJ\1740 disorders</e2>_31\NNS\14034177 ._32\.\1740
D012254_D002318 NONE hemoglobin_0\NN\14888884 concentrations_1\NNS\4916342 decrease_2\VBP\169651 mainly_3\RB\1740 as_4\IN\14622893 a_5\DT\13649268 result_6\NN\34213 of_7\IN\1740 <e1>ribavirin-induced</e1>_8\JJ\1740 hemolysis_9\NN\13509528 ,_10\,\1740 and_11\CC\1740 this_12\DT\1740 anemia_13\NN\14189204 can_14\MD\3094503 be_15\VB\836236 problematic_16\JJ\1740 in_17\IN\13603305 patients_18\NNS\9898892 with_19\IN\1740 hcv_20\NN\1740 infection_21\NN\14052046 ,_22\,\1740 especially_23\RB\1740 those_24\DT\1740 who_25\WP\8299493 have_26\VBP\2108377 comorbid_27\VB\1740 <e2>renal_28\JJ\1740 or_29\CC\3541091 cardiovascular_30\JJ\1740 disorders</e2>_31\NNS\14034177 ._32\.\1740
C026956_D000743 NONE <e1>viramidine</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 liver-targeting_3\JJ\1740 prodrug_4\NN\1740 of_5\IN\1740 ribavirin_6\NN\2725367 ,_7\,\1740 has_8\VBZ\2108377 the_9\DT\1740 potential_10\NN\14481929 to_11\TO\1740 maintain_12\VB\2202928 the_13\DT\1740 virologic_14\JJ\1740 efficacy_15\NN\5199286 of_16\IN\1740 ribavirin_17\NN\2725367 while_18\IN\15122231 decreasing_19\VBG\169651 the_20\DT\1740 risk_21\NN\14541044 of_22\IN\1740 <e2>hemolytic_23\JJ\1740 anemia</e2>_24\NN\14189204 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 chronic_28\JJ\1740 hepatitis_29\NN\14127211 c._30\NN\1740
C026956_D019698 NONE <e1>viramidine</e1>_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 liver-targeting_3\JJ\1740 prodrug_4\NN\1740 of_5\IN\1740 ribavirin_6\NN\2725367 ,_7\,\1740 has_8\VBZ\2108377 the_9\DT\1740 potential_10\NN\14481929 to_11\TO\1740 maintain_12\VB\2202928 the_13\DT\1740 virologic_14\JJ\1740 efficacy_15\NN\5199286 of_16\IN\1740 ribavirin_17\NN\2725367 while_18\IN\15122231 decreasing_19\VBG\169651 the_20\DT\1740 risk_21\NN\14541044 of_22\IN\1740 hemolytic_23\JJ\1740 anemia_24\NN\14189204 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 <e2>chronic_28\JJ\1740 hepatitis_29\NN\14127211 c.</e2>_30\NN\1740
D012254_D000743 CID viramidine_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 liver-targeting_3\JJ\1740 prodrug_4\NN\1740 of_5\IN\1740 <e1>ribavirin</e1>_6\NN\2725367 ,_7\,\1740 has_8\VBZ\2108377 the_9\DT\1740 potential_10\NN\14481929 to_11\TO\1740 maintain_12\VB\2202928 the_13\DT\1740 virologic_14\JJ\1740 efficacy_15\NN\5199286 of_16\IN\1740 ribavirin_17\NN\2725367 while_18\IN\15122231 decreasing_19\VBG\169651 the_20\DT\1740 risk_21\NN\14541044 of_22\IN\1740 <e2>hemolytic_23\JJ\1740 anemia</e2>_24\NN\14189204 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 chronic_28\JJ\1740 hepatitis_29\NN\14127211 c._30\NN\1740
D012254_D000743 CID viramidine_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 liver-targeting_3\JJ\1740 prodrug_4\NN\1740 of_5\IN\1740 ribavirin_6\NN\2725367 ,_7\,\1740 has_8\VBZ\2108377 the_9\DT\1740 potential_10\NN\14481929 to_11\TO\1740 maintain_12\VB\2202928 the_13\DT\1740 virologic_14\JJ\1740 efficacy_15\NN\5199286 of_16\IN\1740 <e1>ribavirin</e1>_17\NN\2725367 while_18\IN\15122231 decreasing_19\VBG\169651 the_20\DT\1740 risk_21\NN\14541044 of_22\IN\1740 <e2>hemolytic_23\JJ\1740 anemia</e2>_24\NN\14189204 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 chronic_28\JJ\1740 hepatitis_29\NN\14127211 c._30\NN\1740
D012254_D019698 NONE viramidine_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 liver-targeting_3\JJ\1740 prodrug_4\NN\1740 of_5\IN\1740 <e1>ribavirin</e1>_6\NN\2725367 ,_7\,\1740 has_8\VBZ\2108377 the_9\DT\1740 potential_10\NN\14481929 to_11\TO\1740 maintain_12\VB\2202928 the_13\DT\1740 virologic_14\JJ\1740 efficacy_15\NN\5199286 of_16\IN\1740 ribavirin_17\NN\2725367 while_18\IN\15122231 decreasing_19\VBG\169651 the_20\DT\1740 risk_21\NN\14541044 of_22\IN\1740 hemolytic_23\JJ\1740 anemia_24\NN\14189204 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 <e2>chronic_28\JJ\1740 hepatitis_29\NN\14127211 c.</e2>_30\NN\1740
D012254_D019698 NONE viramidine_0\NNP\1740 ,_1\,\1740 a_2\DT\13649268 liver-targeting_3\JJ\1740 prodrug_4\NN\1740 of_5\IN\1740 ribavirin_6\NN\2725367 ,_7\,\1740 has_8\VBZ\2108377 the_9\DT\1740 potential_10\NN\14481929 to_11\TO\1740 maintain_12\VB\2202928 the_13\DT\1740 virologic_14\JJ\1740 efficacy_15\NN\5199286 of_16\IN\1740 <e1>ribavirin</e1>_17\NN\2725367 while_18\IN\15122231 decreasing_19\VBG\169651 the_20\DT\1740 risk_21\NN\14541044 of_22\IN\1740 hemolytic_23\JJ\1740 anemia_24\NN\14189204 in_25\IN\13603305 patients_26\NNS\9898892 with_27\IN\1740 <e2>chronic_28\JJ\1740 hepatitis_29\NN\14127211 c.</e2>_30\NN\1740
16132524
D017239_D005909 NONE intracavitary_0\JJ\1740 chemotherapy_1\NN\661091 (_2\-LRB-\1740 <e1>paclitaxel/carboplatin</e1>_3\NN\1740 liquid_4\NN\14939900 crystalline_5\NN\1740 cubic_6\JJ\1740 phases_7\NNS\15113229 )_8\-RRB-\1740 for_9\IN\1740 recurrent_10\JJ\1740 <e2>glioblastoma</e2>_11\NN\14236743 --_12\:\1740 clinical_13\JJ\1740 observations_14\NNS\996969 ._15\.\1740
D017239_D005909 NONE for_0\IN\1740 human_1\JJ\1740 <e2>glioblastoma</e2>_2\NN\14236743 recurrences_3\NNS\7342049 ,_4\,\1740 the_5\DT\1740 feasibility_6\NN\5152150 ,_7\,\1740 safety_8\NN\13920835 ,_9\,\1740 and_10\CC\1740 short-term_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 a_14\DT\13649268 surgical_15\JJ\1740 intracavitary_16\JJ\1740 application_17\NN\947128 of_18\IN\1740 <e1>paclitaxel</e1>_19\NN\1740 and_20\CC\1740 carboplatin_21\NN\1740 encapsulated_22\VBN\1587062 by_23\IN\1740 liquid_24\JJ\1740 crystalline_25\NN\1740 cubic_26\JJ\1740 phases_27\NNS\15113229 are_28\VBP\836236 examined_29\VBN\789138 in_30\IN\13603305 a_31\DT\13649268 pilot_32\NN\9826204 study_33\NN\635850 ._34\.\1740
D017239_D005909 NONE a_0\DT\13649268 total_1\NN\3553 of_2\IN\1740 12_3\CD\13745420 patients_4\NNS\9898892 with_5\IN\1740 a_6\DT\13649268 recurrence_7\NN\7342049 of_8\IN\1740 a_9\DT\13649268 <e2>glioblastoma</e2>_10\NN\14236743 multiforme_11\JJ\1740 underwent_12\VBD\109660 re-resection_13\NN\1740 and_14\CC\1740 received_15\VBD\2210855 an_16\DT\6697703 intracavitary_17\JJ\1740 application_18\NN\947128 of_19\IN\1740 <e1>paclitaxel</e1>_20\NN\1740 and_21\CC\1740 carboplatin_22\NN\1740 cubic_23\JJ\1740 phases_24\NNS\15113229 in_25\IN\13603305 different_26\JJ\1740 dosages_27\NNS\13576355 ._28\.\1740
D016190_D005909 NONE intracavitary_0\JJ\1740 chemotherapy_1\NN\661091 (_2\-LRB-\1740 <e1>paclitaxel/carboplatin</e1>_3\NN\1740 liquid_4\NN\14939900 crystalline_5\NN\1740 cubic_6\JJ\1740 phases_7\NNS\15113229 )_8\-RRB-\1740 for_9\IN\1740 recurrent_10\JJ\1740 <e2>glioblastoma</e2>_11\NN\14236743 --_12\:\1740 clinical_13\JJ\1740 observations_14\NNS\996969 ._15\.\1740
D016190_D005909 NONE for_0\IN\1740 human_1\JJ\1740 <e2>glioblastoma</e2>_2\NN\14236743 recurrences_3\NNS\7342049 ,_4\,\1740 the_5\DT\1740 feasibility_6\NN\5152150 ,_7\,\1740 safety_8\NN\13920835 ,_9\,\1740 and_10\CC\1740 short-term_11\JJ\1740 effects_12\NNS\13245626 of_13\IN\1740 a_14\DT\13649268 surgical_15\JJ\1740 intracavitary_16\JJ\1740 application_17\NN\947128 of_18\IN\1740 paclitaxel_19\NN\1740 and_20\CC\1740 <e1>carboplatin</e1>_21\NN\1740 encapsulated_22\VBN\1587062 by_23\IN\1740 liquid_24\JJ\1740 crystalline_25\NN\1740 cubic_26\JJ\1740 phases_27\NNS\15113229 are_28\VBP\836236 examined_29\VBN\789138 in_30\IN\13603305 a_31\DT\13649268 pilot_32\NN\9826204 study_33\NN\635850 ._34\.\1740
D016190_D005909 NONE a_0\DT\13649268 total_1\NN\3553 of_2\IN\1740 12_3\CD\13745420 patients_4\NNS\9898892 with_5\IN\1740 a_6\DT\13649268 recurrence_7\NN\7342049 of_8\IN\1740 a_9\DT\13649268 <e2>glioblastoma</e2>_10\NN\14236743 multiforme_11\JJ\1740 underwent_12\VBD\109660 re-resection_13\NN\1740 and_14\CC\1740 received_15\VBD\2210855 an_16\DT\6697703 intracavitary_17\JJ\1740 application_18\NN\947128 of_19\IN\1740 paclitaxel_20\NN\1740 and_21\CC\1740 <e1>carboplatin</e1>_22\NN\1740 cubic_23\JJ\1740 phases_24\NNS\15113229 in_25\IN\13603305 different_26\JJ\1740 dosages_27\NNS\13576355 ._28\.\1740
D017239_D001929 CID six_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 patients_3\NNS\9898892 received_4\VBD\2210855 more_5\JJR\1740 than_6\IN\1740 15_7\CD\13745420 mg_8\NN\13717155 <e1>paclitaxel</e1>_9\NN\1740 and_10\CC\1740 suffered_11\VBN\2110220 from_12\IN\1740 moderate_13\JJ\1740 to_14\TO\1740 severe_15\JJ\1740 <e2>brain_16\NN\5462674 edema</e2>_17\NN\14315192 ,_18\,\1740 while_19\IN\15122231 the_20\DT\1740 remaining_21\VBG\2604760 patients_22\NNS\9898892 received_23\VBD\2210855 only_24\RB\1740 a_25\DT\13649268 total_26\NN\3553 of_27\IN\1740 15_28\CD\13745420 mg_29\NN\13717155 paclitaxel_30\NN\1740 ._31\.\1740
D017239_D001929 CID six_0\CD\13741022 of_1\IN\1740 the_2\DT\1740 patients_3\NNS\9898892 received_4\VBD\2210855 more_5\JJR\1740 than_6\IN\1740 15_7\CD\13745420 mg_8\NN\13717155 paclitaxel_9\NN\1740 and_10\CC\1740 suffered_11\VBN\2110220 from_12\IN\1740 moderate_13\JJ\1740 to_14\TO\1740 severe_15\JJ\1740 <e2>brain_16\NN\5462674 edema</e2>_17\NN\14315192 ,_18\,\1740 while_19\IN\15122231 the_20\DT\1740 remaining_21\VBG\2604760 patients_22\NNS\9898892 received_23\VBD\2210855 only_24\RB\1740 a_25\DT\13649268 total_26\NN\3553 of_27\IN\1740 15_28\CD\13745420 mg_29\NN\13717155 <e1>paclitaxel</e1>_30\NN\1740 ._31\.\1740
8841157
C081489_D006973 NONE <e1>valsartan</e1>_0\NNP\2712393 ,_1\,\1740 a_2\DT\13649268 new_3\JJ\1740 angiotensin_4\NN\4522421 ii_5\CD\13741022 antagonist_6\NN\7846 for_7\IN\1740 the_8\DT\1740 treatment_9\NN\654885 of_10\IN\1740 essential_11\JJ\1740 <e2>hypertension</e2>_12\NN\14057371 :_13\:\1740 a_14\DT\13649268 comparative_15\JJ\1740 study_16\NN\635850 of_17\IN\1740 the_18\DT\1740 efficacy_19\NN\5199286 and_20\CC\1740 safety_21\NN\13920835 against_22\IN\1740 amlodipine_23\NN\1740 ._24\.\1740
C081489_D006973 NONE methods_0\NNS\5616786 :_1\:\1740 one_2\CD\13741022 hundred_3\CD\13745420 sixty-eight_4\JJ\1740 adult_5\JJ\1740 outpatients_6\NNS\10405694 with_7\IN\1740 mild_8\NN\1740 to_9\TO\1740 moderate_10\JJ\1740 <e2>hypertension</e2>_11\NN\14057371 were_12\VBD\836236 randomly_13\RB\1740 allocated_14\VBN\2228698 in_15\IN\13603305 double-blind_16\JJ\1740 fashion_17\NN\4916342 and_18\CC\1740 equal_19\JJ\1740 number_20\NN\5107765 to_21\TO\1740 receive_22\VB\2210855 80_23\CD\13745420 mg_24\NN\13717155 <e1>valsartan</e1>_25\NN\2712393 or_26\CC\3541091 5_27\CD\13741022 mg_28\NN\13717155 amlodipine_29\NN\1740 for_30\IN\1740 12_31\CD\13745420 weeks_32\NNS\15113229 ._33\.\1740
C081489_D006973 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 data_3\NNS\7951464 show_4\VBP\2137132 that_5\IN\1740 <e1>valsartan</e1>_6\NN\2712393 is_7\VBZ\836236 at_8\IN\14622893 least_9\JJS\1740 as_10\IN\14622893 effective_11\JJ\1740 as_12\IN\14622893 amlodipine_13\NN\1740 in_14\IN\13603305 the_15\DT\1740 treatment_16\NN\654885 of_17\IN\1740 mild_18\NN\1740 to_19\TO\1740 moderate_20\JJ\1740 <e2>hypertension</e2>_21\NN\14057371 ._22\.\1740
D000804_D006973 NONE valsartan_0\NNP\2712393 ,_1\,\1740 a_2\DT\13649268 new_3\JJ\1740 <e1>angiotensin_4\NN\4522421 ii</e1>_5\CD\13741022 antagonist_6\NN\7846 for_7\IN\1740 the_8\DT\1740 treatment_9\NN\654885 of_10\IN\1740 essential_11\JJ\1740 <e2>hypertension</e2>_12\NN\14057371 :_13\:\1740 a_14\DT\13649268 comparative_15\JJ\1740 study_16\NN\635850 of_17\IN\1740 the_18\DT\1740 efficacy_19\NN\5199286 and_20\CC\1740 safety_21\NN\13920835 against_22\IN\1740 amlodipine_23\NN\1740 ._24\.\1740
D017311_D006973 NONE valsartan_0\NNP\2712393 ,_1\,\1740 a_2\DT\13649268 new_3\JJ\1740 angiotensin_4\NN\4522421 ii_5\CD\13741022 antagonist_6\NN\7846 for_7\IN\1740 the_8\DT\1740 treatment_9\NN\654885 of_10\IN\1740 essential_11\JJ\1740 <e2>hypertension</e2>_12\NN\14057371 :_13\:\1740 a_14\DT\13649268 comparative_15\JJ\1740 study_16\NN\635850 of_17\IN\1740 the_18\DT\1740 efficacy_19\NN\5199286 and_20\CC\1740 safety_21\NN\13920835 against_22\IN\1740 <e1>amlodipine</e1>_23\NN\1740 ._24\.\1740
D017311_D006973 NONE methods_0\NNS\5616786 :_1\:\1740 one_2\CD\13741022 hundred_3\CD\13745420 sixty-eight_4\JJ\1740 adult_5\JJ\1740 outpatients_6\NNS\10405694 with_7\IN\1740 mild_8\NN\1740 to_9\TO\1740 moderate_10\JJ\1740 <e2>hypertension</e2>_11\NN\14057371 were_12\VBD\836236 randomly_13\RB\1740 allocated_14\VBN\2228698 in_15\IN\13603305 double-blind_16\JJ\1740 fashion_17\NN\4916342 and_18\CC\1740 equal_19\JJ\1740 number_20\NN\5107765 to_21\TO\1740 receive_22\VB\2210855 80_23\CD\13745420 mg_24\NN\13717155 valsartan_25\NN\2712393 or_26\CC\3541091 5_27\CD\13741022 mg_28\NN\13717155 <e1>amlodipine</e1>_29\NN\1740 for_30\IN\1740 12_31\CD\13745420 weeks_32\NNS\15113229 ._33\.\1740
D017311_D006973 NONE conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 data_3\NNS\7951464 show_4\VBP\2137132 that_5\IN\1740 valsartan_6\NN\2712393 is_7\VBZ\836236 at_8\IN\14622893 least_9\JJS\1740 as_10\IN\14622893 effective_11\JJ\1740 as_12\IN\14622893 <e1>amlodipine</e1>_13\NN\1740 in_14\IN\13603305 the_15\DT\1740 treatment_16\NN\654885 of_17\IN\1740 mild_18\NN\1740 to_19\TO\1740 moderate_20\JJ\1740 <e2>hypertension</e2>_21\NN\14057371 ._22\.\1740
D017311_D004487 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 drug-related_3\JJ\1740 dependent_4\JJ\1740 <e2>edema</e2>_5\NN\14315192 was_6\VBD\836236 somewhat_7\RB\1740 higher_8\JJR\1740 in_9\IN\13603305 the_10\DT\1740 <e1>amlodipine</e1>_11\NN\1740 group_12\NN\2137 ,_13\,\1740 particularly_14\RB\1740 at_15\IN\14622893 a_16\DT\13649268 dose_17\NN\3740161 of_18\IN\1740 10_19\CD\13745420 mg_20\NN\13717155 per_21\IN\1740 day_22\NN\15154774 (_23\-LRB-\1740 2.4_24\CD\1740 %_25\NN\1740 for_26\IN\1740 80_27\CD\13745420 mg_28\NN\13717155 valsartan_29\NN\2712393 ;_30\:\1740 3.6_31\CD\1740 %_32\NN\1740 for_33\IN\1740 5_34\CD\13741022 mg_35\NN\13717155 amlodipine_36\NN\1740 ;_37\:\1740 0_38\CD\13741022 %_39\NN\1740 for_40\IN\1740 valsartan_41\NN\2712393 plus_42\CC\4723816 5_43\CD\13741022 mg_44\NN\13717155 amlodipine_45\NN\1740 ;_46\:\1740 14.3_47\CD\1740 %_48\NN\1740 for_49\IN\1740 10_50\CD\13745420 mg_51\NN\13717155 amlodipine_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
D017311_D004487 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 drug-related_3\JJ\1740 dependent_4\JJ\1740 <e2>edema</e2>_5\NN\14315192 was_6\VBD\836236 somewhat_7\RB\1740 higher_8\JJR\1740 in_9\IN\13603305 the_10\DT\1740 amlodipine_11\NN\1740 group_12\NN\2137 ,_13\,\1740 particularly_14\RB\1740 at_15\IN\14622893 a_16\DT\13649268 dose_17\NN\3740161 of_18\IN\1740 10_19\CD\13745420 mg_20\NN\13717155 per_21\IN\1740 day_22\NN\15154774 (_23\-LRB-\1740 2.4_24\CD\1740 %_25\NN\1740 for_26\IN\1740 80_27\CD\13745420 mg_28\NN\13717155 valsartan_29\NN\2712393 ;_30\:\1740 3.6_31\CD\1740 %_32\NN\1740 for_33\IN\1740 5_34\CD\13741022 mg_35\NN\13717155 <e1>amlodipine</e1>_36\NN\1740 ;_37\:\1740 0_38\CD\13741022 %_39\NN\1740 for_40\IN\1740 valsartan_41\NN\2712393 plus_42\CC\4723816 5_43\CD\13741022 mg_44\NN\13717155 amlodipine_45\NN\1740 ;_46\:\1740 14.3_47\CD\1740 %_48\NN\1740 for_49\IN\1740 10_50\CD\13745420 mg_51\NN\13717155 amlodipine_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
D017311_D004487 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 drug-related_3\JJ\1740 dependent_4\JJ\1740 <e2>edema</e2>_5\NN\14315192 was_6\VBD\836236 somewhat_7\RB\1740 higher_8\JJR\1740 in_9\IN\13603305 the_10\DT\1740 amlodipine_11\NN\1740 group_12\NN\2137 ,_13\,\1740 particularly_14\RB\1740 at_15\IN\14622893 a_16\DT\13649268 dose_17\NN\3740161 of_18\IN\1740 10_19\CD\13745420 mg_20\NN\13717155 per_21\IN\1740 day_22\NN\15154774 (_23\-LRB-\1740 2.4_24\CD\1740 %_25\NN\1740 for_26\IN\1740 80_27\CD\13745420 mg_28\NN\13717155 valsartan_29\NN\2712393 ;_30\:\1740 3.6_31\CD\1740 %_32\NN\1740 for_33\IN\1740 5_34\CD\13741022 mg_35\NN\13717155 amlodipine_36\NN\1740 ;_37\:\1740 0_38\CD\13741022 %_39\NN\1740 for_40\IN\1740 valsartan_41\NN\2712393 plus_42\CC\4723816 5_43\CD\13741022 mg_44\NN\13717155 <e1>amlodipine</e1>_45\NN\1740 ;_46\:\1740 14.3_47\CD\1740 %_48\NN\1740 for_49\IN\1740 10_50\CD\13745420 mg_51\NN\13717155 amlodipine_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
D017311_D004487 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 drug-related_3\JJ\1740 dependent_4\JJ\1740 <e2>edema</e2>_5\NN\14315192 was_6\VBD\836236 somewhat_7\RB\1740 higher_8\JJR\1740 in_9\IN\13603305 the_10\DT\1740 amlodipine_11\NN\1740 group_12\NN\2137 ,_13\,\1740 particularly_14\RB\1740 at_15\IN\14622893 a_16\DT\13649268 dose_17\NN\3740161 of_18\IN\1740 10_19\CD\13745420 mg_20\NN\13717155 per_21\IN\1740 day_22\NN\15154774 (_23\-LRB-\1740 2.4_24\CD\1740 %_25\NN\1740 for_26\IN\1740 80_27\CD\13745420 mg_28\NN\13717155 valsartan_29\NN\2712393 ;_30\:\1740 3.6_31\CD\1740 %_32\NN\1740 for_33\IN\1740 5_34\CD\13741022 mg_35\NN\13717155 amlodipine_36\NN\1740 ;_37\:\1740 0_38\CD\13741022 %_39\NN\1740 for_40\IN\1740 valsartan_41\NN\2712393 plus_42\CC\4723816 5_43\CD\13741022 mg_44\NN\13717155 amlodipine_45\NN\1740 ;_46\:\1740 14.3_47\CD\1740 %_48\NN\1740 for_49\IN\1740 10_50\CD\13745420 mg_51\NN\13717155 <e1>amlodipine</e1>_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C081489_D004487 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 drug-related_3\JJ\1740 dependent_4\JJ\1740 <e2>edema</e2>_5\NN\14315192 was_6\VBD\836236 somewhat_7\RB\1740 higher_8\JJR\1740 in_9\IN\13603305 the_10\DT\1740 amlodipine_11\NN\1740 group_12\NN\2137 ,_13\,\1740 particularly_14\RB\1740 at_15\IN\14622893 a_16\DT\13649268 dose_17\NN\3740161 of_18\IN\1740 10_19\CD\13745420 mg_20\NN\13717155 per_21\IN\1740 day_22\NN\15154774 (_23\-LRB-\1740 2.4_24\CD\1740 %_25\NN\1740 for_26\IN\1740 80_27\CD\13745420 mg_28\NN\13717155 <e1>valsartan</e1>_29\NN\2712393 ;_30\:\1740 3.6_31\CD\1740 %_32\NN\1740 for_33\IN\1740 5_34\CD\13741022 mg_35\NN\13717155 amlodipine_36\NN\1740 ;_37\:\1740 0_38\CD\13741022 %_39\NN\1740 for_40\IN\1740 valsartan_41\NN\2712393 plus_42\CC\4723816 5_43\CD\13741022 mg_44\NN\13717155 amlodipine_45\NN\1740 ;_46\:\1740 14.3_47\CD\1740 %_48\NN\1740 for_49\IN\1740 10_50\CD\13745420 mg_51\NN\13717155 amlodipine_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
C081489_D004487 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 drug-related_3\JJ\1740 dependent_4\JJ\1740 <e2>edema</e2>_5\NN\14315192 was_6\VBD\836236 somewhat_7\RB\1740 higher_8\JJR\1740 in_9\IN\13603305 the_10\DT\1740 amlodipine_11\NN\1740 group_12\NN\2137 ,_13\,\1740 particularly_14\RB\1740 at_15\IN\14622893 a_16\DT\13649268 dose_17\NN\3740161 of_18\IN\1740 10_19\CD\13745420 mg_20\NN\13717155 per_21\IN\1740 day_22\NN\15154774 (_23\-LRB-\1740 2.4_24\CD\1740 %_25\NN\1740 for_26\IN\1740 80_27\CD\13745420 mg_28\NN\13717155 valsartan_29\NN\2712393 ;_30\:\1740 3.6_31\CD\1740 %_32\NN\1740 for_33\IN\1740 5_34\CD\13741022 mg_35\NN\13717155 amlodipine_36\NN\1740 ;_37\:\1740 0_38\CD\13741022 %_39\NN\1740 for_40\IN\1740 <e1>valsartan</e1>_41\NN\2712393 plus_42\CC\4723816 5_43\CD\13741022 mg_44\NN\13717155 amlodipine_45\NN\1740 ;_46\:\1740 14.3_47\CD\1740 %_48\NN\1740 for_49\IN\1740 10_50\CD\13745420 mg_51\NN\13717155 amlodipine_52\NN\1740 )_53\-RRB-\1740 ._54\.\1740
12180796
D009569_D009369 NONE immunohistochemical_0\JJ\1740 study_1\NN\635850 on_2\IN\1740 inducible_3\JJ\1740 type_4\NN\5839024 of_5\IN\1740 <e1>nitric_6\JJ\1740 oxide</e1>_7\NN\14818238 (_8\-LRB-\1740 inos_9\NN\1740 )_10\-RRB-\1740 ,_11\,\1740 basic_12\JJ\1740 fibroblast_13\NN\5447757 growth_14\NN\13526110 factor_15\NN\7326557 (_16\-LRB-\1740 bfgf_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 <e2>tumor</e2>_20\NN\14234074 growth_21\NN\13526110 factor-beta1_22\NN\1740 (_23\-LRB-\1740 tgf-beta1_24\NN\1740 )_25\-RRB-\1740 in_26\IN\13603305 arteritis_27\NN\14336539 induced_28\VBN\1627355 in_29\IN\13603305 rats_30\NNS\2329401 by_31\IN\1740 fenoldopam_32\NN\1740 and_33\CC\1740 theophylline_34\NN\2905612 ,_35\,\1740 vasodilators_36\NNS\3198383 ._37\.\1740
D009569_D009369 NONE arteritis_0\NN\14336539 induced_1\VBN\1627355 in_2\IN\13603305 rats_3\NNS\2329401 by_4\IN\1740 vasodilators_5\NNS\3198383 ,_6\,\1740 fenoldopam_7\NN\1740 and_8\CC\1740 theophylline_9\NN\2905612 ,_10\,\1740 was_11\VBD\836236 examined_12\VBN\789138 immunohistochemically_13\RB\1740 for_14\IN\1740 expressions_15\NNS\4679549 of_16\IN\1740 inducible_17\JJ\1740 type_18\NN\5839024 of_19\IN\1740 <e1>nitric_20\JJ\1740 oxide</e1>_21\NN\14818238 synthase_22\NN\1740 (_23\-LRB-\1740 inos_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 basic_27\JJ\1740 fibroblast_28\NN\5447757 growth_29\NN\13526110 factor_30\NN\7326557 (_31\-LRB-\1740 bfgf_32\NN\1740 )_33\-RRB-\1740 and_34\CC\1740 <e2>tumor</e2>_35\NN\14234074 growth_36\NN\13526110 factor-beta1_37\NN\1740 (_38\-LRB-\1740 tgf-beta1_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
D009569_D001167 NONE immunohistochemical_0\JJ\1740 study_1\NN\635850 on_2\IN\1740 inducible_3\JJ\1740 type_4\NN\5839024 of_5\IN\1740 <e1>nitric_6\JJ\1740 oxide</e1>_7\NN\14818238 (_8\-LRB-\1740 inos_9\NN\1740 )_10\-RRB-\1740 ,_11\,\1740 basic_12\JJ\1740 fibroblast_13\NN\5447757 growth_14\NN\13526110 factor_15\NN\7326557 (_16\-LRB-\1740 bfgf_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 tumor_20\NN\14234074 growth_21\NN\13526110 factor-beta1_22\NN\1740 (_23\-LRB-\1740 tgf-beta1_24\NN\1740 )_25\-RRB-\1740 in_26\IN\13603305 <e2>arteritis</e2>_27\NN\14336539 induced_28\VBN\1627355 in_29\IN\13603305 rats_30\NNS\2329401 by_31\IN\1740 fenoldopam_32\NN\1740 and_33\CC\1740 theophylline_34\NN\2905612 ,_35\,\1740 vasodilators_36\NNS\3198383 ._37\.\1740
D009569_D001167 NONE <e2>arteritis</e2>_0\NN\14336539 induced_1\VBN\1627355 in_2\IN\13603305 rats_3\NNS\2329401 by_4\IN\1740 vasodilators_5\NNS\3198383 ,_6\,\1740 fenoldopam_7\NN\1740 and_8\CC\1740 theophylline_9\NN\2905612 ,_10\,\1740 was_11\VBD\836236 examined_12\VBN\789138 immunohistochemically_13\RB\1740 for_14\IN\1740 expressions_15\NNS\4679549 of_16\IN\1740 inducible_17\JJ\1740 type_18\NN\5839024 of_19\IN\1740 <e1>nitric_20\JJ\1740 oxide</e1>_21\NN\14818238 synthase_22\NN\1740 (_23\-LRB-\1740 inos_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 basic_27\JJ\1740 fibroblast_28\NN\5447757 growth_29\NN\13526110 factor_30\NN\7326557 (_31\-LRB-\1740 bfgf_32\NN\1740 )_33\-RRB-\1740 and_34\CC\1740 tumor_35\NN\14234074 growth_36\NN\13526110 factor-beta1_37\NN\1740 (_38\-LRB-\1740 tgf-beta1_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
D018818_D009369 NONE immunohistochemical_0\JJ\1740 study_1\NN\635850 on_2\IN\1740 inducible_3\JJ\1740 type_4\NN\5839024 of_5\IN\1740 nitric_6\JJ\1740 oxide_7\NN\14818238 (_8\-LRB-\1740 inos_9\NN\1740 )_10\-RRB-\1740 ,_11\,\1740 basic_12\JJ\1740 fibroblast_13\NN\5447757 growth_14\NN\13526110 factor_15\NN\7326557 (_16\-LRB-\1740 bfgf_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 <e2>tumor</e2>_20\NN\14234074 growth_21\NN\13526110 factor-beta1_22\NN\1740 (_23\-LRB-\1740 tgf-beta1_24\NN\1740 )_25\-RRB-\1740 in_26\IN\13603305 arteritis_27\NN\14336539 induced_28\VBN\1627355 in_29\IN\13603305 rats_30\NNS\2329401 by_31\IN\1740 <e1>fenoldopam</e1>_32\NN\1740 and_33\CC\1740 theophylline_34\NN\2905612 ,_35\,\1740 vasodilators_36\NNS\3198383 ._37\.\1740
D018818_D009369 NONE arteritis_0\NN\14336539 induced_1\VBN\1627355 in_2\IN\13603305 rats_3\NNS\2329401 by_4\IN\1740 vasodilators_5\NNS\3198383 ,_6\,\1740 <e1>fenoldopam</e1>_7\NN\1740 and_8\CC\1740 theophylline_9\NN\2905612 ,_10\,\1740 was_11\VBD\836236 examined_12\VBN\789138 immunohistochemically_13\RB\1740 for_14\IN\1740 expressions_15\NNS\4679549 of_16\IN\1740 inducible_17\JJ\1740 type_18\NN\5839024 of_19\IN\1740 nitric_20\JJ\1740 oxide_21\NN\14818238 synthase_22\NN\1740 (_23\-LRB-\1740 inos_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 basic_27\JJ\1740 fibroblast_28\NN\5447757 growth_29\NN\13526110 factor_30\NN\7326557 (_31\-LRB-\1740 bfgf_32\NN\1740 )_33\-RRB-\1740 and_34\CC\1740 <e2>tumor</e2>_35\NN\14234074 growth_36\NN\13526110 factor-beta1_37\NN\1740 (_38\-LRB-\1740 tgf-beta1_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
D018818_D001167 CID immunohistochemical_0\JJ\1740 study_1\NN\635850 on_2\IN\1740 inducible_3\JJ\1740 type_4\NN\5839024 of_5\IN\1740 nitric_6\JJ\1740 oxide_7\NN\14818238 (_8\-LRB-\1740 inos_9\NN\1740 )_10\-RRB-\1740 ,_11\,\1740 basic_12\JJ\1740 fibroblast_13\NN\5447757 growth_14\NN\13526110 factor_15\NN\7326557 (_16\-LRB-\1740 bfgf_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 tumor_20\NN\14234074 growth_21\NN\13526110 factor-beta1_22\NN\1740 (_23\-LRB-\1740 tgf-beta1_24\NN\1740 )_25\-RRB-\1740 in_26\IN\13603305 <e2>arteritis</e2>_27\NN\14336539 induced_28\VBN\1627355 in_29\IN\13603305 rats_30\NNS\2329401 by_31\IN\1740 <e1>fenoldopam</e1>_32\NN\1740 and_33\CC\1740 theophylline_34\NN\2905612 ,_35\,\1740 vasodilators_36\NNS\3198383 ._37\.\1740
D018818_D001167 CID <e2>arteritis</e2>_0\NN\14336539 induced_1\VBN\1627355 in_2\IN\13603305 rats_3\NNS\2329401 by_4\IN\1740 vasodilators_5\NNS\3198383 ,_6\,\1740 <e1>fenoldopam</e1>_7\NN\1740 and_8\CC\1740 theophylline_9\NN\2905612 ,_10\,\1740 was_11\VBD\836236 examined_12\VBN\789138 immunohistochemically_13\RB\1740 for_14\IN\1740 expressions_15\NNS\4679549 of_16\IN\1740 inducible_17\JJ\1740 type_18\NN\5839024 of_19\IN\1740 nitric_20\JJ\1740 oxide_21\NN\14818238 synthase_22\NN\1740 (_23\-LRB-\1740 inos_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 basic_27\JJ\1740 fibroblast_28\NN\5447757 growth_29\NN\13526110 factor_30\NN\7326557 (_31\-LRB-\1740 bfgf_32\NN\1740 )_33\-RRB-\1740 and_34\CC\1740 tumor_35\NN\14234074 growth_36\NN\13526110 factor-beta1_37\NN\1740 (_38\-LRB-\1740 tgf-beta1_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
D013806_D009369 NONE immunohistochemical_0\JJ\1740 study_1\NN\635850 on_2\IN\1740 inducible_3\JJ\1740 type_4\NN\5839024 of_5\IN\1740 nitric_6\JJ\1740 oxide_7\NN\14818238 (_8\-LRB-\1740 inos_9\NN\1740 )_10\-RRB-\1740 ,_11\,\1740 basic_12\JJ\1740 fibroblast_13\NN\5447757 growth_14\NN\13526110 factor_15\NN\7326557 (_16\-LRB-\1740 bfgf_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 <e2>tumor</e2>_20\NN\14234074 growth_21\NN\13526110 factor-beta1_22\NN\1740 (_23\-LRB-\1740 tgf-beta1_24\NN\1740 )_25\-RRB-\1740 in_26\IN\13603305 arteritis_27\NN\14336539 induced_28\VBN\1627355 in_29\IN\13603305 rats_30\NNS\2329401 by_31\IN\1740 fenoldopam_32\NN\1740 and_33\CC\1740 <e1>theophylline</e1>_34\NN\2905612 ,_35\,\1740 vasodilators_36\NNS\3198383 ._37\.\1740
D013806_D009369 NONE arteritis_0\NN\14336539 induced_1\VBN\1627355 in_2\IN\13603305 rats_3\NNS\2329401 by_4\IN\1740 vasodilators_5\NNS\3198383 ,_6\,\1740 fenoldopam_7\NN\1740 and_8\CC\1740 <e1>theophylline</e1>_9\NN\2905612 ,_10\,\1740 was_11\VBD\836236 examined_12\VBN\789138 immunohistochemically_13\RB\1740 for_14\IN\1740 expressions_15\NNS\4679549 of_16\IN\1740 inducible_17\JJ\1740 type_18\NN\5839024 of_19\IN\1740 nitric_20\JJ\1740 oxide_21\NN\14818238 synthase_22\NN\1740 (_23\-LRB-\1740 inos_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 basic_27\JJ\1740 fibroblast_28\NN\5447757 growth_29\NN\13526110 factor_30\NN\7326557 (_31\-LRB-\1740 bfgf_32\NN\1740 )_33\-RRB-\1740 and_34\CC\1740 <e2>tumor</e2>_35\NN\14234074 growth_36\NN\13526110 factor-beta1_37\NN\1740 (_38\-LRB-\1740 tgf-beta1_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
D013806_D001167 CID immunohistochemical_0\JJ\1740 study_1\NN\635850 on_2\IN\1740 inducible_3\JJ\1740 type_4\NN\5839024 of_5\IN\1740 nitric_6\JJ\1740 oxide_7\NN\14818238 (_8\-LRB-\1740 inos_9\NN\1740 )_10\-RRB-\1740 ,_11\,\1740 basic_12\JJ\1740 fibroblast_13\NN\5447757 growth_14\NN\13526110 factor_15\NN\7326557 (_16\-LRB-\1740 bfgf_17\NN\1740 )_18\-RRB-\1740 and_19\CC\1740 tumor_20\NN\14234074 growth_21\NN\13526110 factor-beta1_22\NN\1740 (_23\-LRB-\1740 tgf-beta1_24\NN\1740 )_25\-RRB-\1740 in_26\IN\13603305 <e2>arteritis</e2>_27\NN\14336539 induced_28\VBN\1627355 in_29\IN\13603305 rats_30\NNS\2329401 by_31\IN\1740 fenoldopam_32\NN\1740 and_33\CC\1740 <e1>theophylline</e1>_34\NN\2905612 ,_35\,\1740 vasodilators_36\NNS\3198383 ._37\.\1740
D013806_D001167 CID <e2>arteritis</e2>_0\NN\14336539 induced_1\VBN\1627355 in_2\IN\13603305 rats_3\NNS\2329401 by_4\IN\1740 vasodilators_5\NNS\3198383 ,_6\,\1740 fenoldopam_7\NN\1740 and_8\CC\1740 <e1>theophylline</e1>_9\NN\2905612 ,_10\,\1740 was_11\VBD\836236 examined_12\VBN\789138 immunohistochemically_13\RB\1740 for_14\IN\1740 expressions_15\NNS\4679549 of_16\IN\1740 inducible_17\JJ\1740 type_18\NN\5839024 of_19\IN\1740 nitric_20\JJ\1740 oxide_21\NN\14818238 synthase_22\NN\1740 (_23\-LRB-\1740 inos_24\NN\1740 )_25\-RRB-\1740 ,_26\,\1740 basic_27\JJ\1740 fibroblast_28\NN\5447757 growth_29\NN\13526110 factor_30\NN\7326557 (_31\-LRB-\1740 bfgf_32\NN\1740 )_33\-RRB-\1740 and_34\CC\1740 tumor_35\NN\14234074 growth_36\NN\13526110 factor-beta1_37\NN\1740 (_38\-LRB-\1740 tgf-beta1_39\NN\1740 )_40\-RRB-\1740 ._41\.\1740
9431903
D005996_D046628 NONE effect_0\NN\34213 of_1\IN\1740 <e1>glyceryl_2\NN\14621446 trinitrate</e1>_3\NN\1740 on_4\IN\1740 the_5\DT\1740 <e2>sphincter_6\NN\5289297 of_7\IN\1740 oddi_8\NN\1740 spasm</e2>_9\NN\14299637 evoked_10\VBN\1617192 by_11\IN\1740 prostigmine-morphine_12\JJ\1740 administration_13\NN\1133281 ._14\.\1740
D005996_D046628 NONE objective_0\NN\5980875 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 <e1>glyceryl_8\NN\14621446 trinitrate</e1>_9\NN\1740 on_10\IN\1740 the_11\DT\1740 prostigmine-morphine-induced_12\JJ\1740 <e2>sphincter_13\NN\5289297 of_14\IN\1740 oddi_15\NN\1740 spasm</e2>_16\NN\14299637 was_17\VBD\836236 evaluated_18\VBN\670261 in_19\IN\13603305 nine_20\CD\13741022 female_21\JJ\1740 patients_22\NNS\9898892 with_23\IN\1740 sphincter_24\NN\5289297 of_25\IN\1740 oddi_26\NNP\1740 dyskinesia_27\NN\14084880 ._28\.\1740
D005996_D046628 NONE objective_0\NN\5980875 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 <e1>glyceryl_8\NN\14621446 trinitrate</e1>_9\NN\1740 on_10\IN\1740 the_11\DT\1740 prostigmine-morphine-induced_12\JJ\1740 sphincter_13\NN\5289297 of_14\IN\1740 oddi_15\NN\1740 spasm_16\NN\14299637 was_17\VBD\836236 evaluated_18\VBN\670261 in_19\IN\13603305 nine_20\CD\13741022 female_21\JJ\1740 patients_22\NNS\9898892 with_23\IN\1740 <e2>sphincter_24\NN\5289297 of_25\IN\1740 oddi_26\NNP\1740 dyskinesia</e2>_27\NN\14084880 ._28\.\1740
D005996_D046628 NONE conclusion_0\NN\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 provide_4\VBP\2199590 the_5\DT\1740 first_6\JJ\1740 evidence_7\NN\5816287 of_8\IN\1740 the_9\DT\1740 effectiveness_10\NN\5190804 of_11\IN\1740 <e1>glyceryl_12\NN\14621446 trinitrate</e1>_13\NN\1740 on_14\IN\1740 the_15\DT\1740 morphine-induced_16\JJ\1740 <e2>sphincter_17\NN\5289297 of_18\IN\1740 oddi_19\NN\1740 spasm</e2>_20\NN\14299637 in_21\IN\13603305 humans_22\NNS\31264 ._23\.\1740
D005996_D046628 NONE since_0\IN\1740 <e1>glyceryl_1\NN\14621446 trinitrate</e1>_2\NN\1740 is_3\VBZ\836236 able_4\JJ\1740 to_5\TO\1740 overcome_6\VB\1101913 even_7\RB\1740 the_8\DT\1740 drastic_9\JJ\1740 effect_10\NN\34213 of_11\IN\1740 morphine_12\NN\2707683 ,_13\,\1740 it_14\PRP\6125041 might_15\MD\5029706 be_16\VB\836236 of_17\IN\1740 relevance_18\NN\13791389 in_19\IN\13603305 the_20\DT\1740 treatment_21\NN\654885 of_22\IN\1740 <e2>sphincter_23\NN\5289297 of_24\IN\1740 oddi_25\NNP\1740 dyskinesia</e2>_26\NN\14084880 ._27\.\1740
D005996_D013035 NONE effect_0\NN\34213 of_1\IN\1740 <e1>glyceryl_2\NN\14621446 trinitrate</e1>_3\NN\1740 on_4\IN\1740 the_5\DT\1740 <e2>sphincter_6\NN\5289297 of_7\IN\1740 oddi_8\NN\1740 spasm</e2>_9\NN\14299637 evoked_10\VBN\1617192 by_11\IN\1740 prostigmine-morphine_12\JJ\1740 administration_13\NN\1133281 ._14\.\1740
D005996_D013035 NONE objective_0\NN\5980875 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 <e1>glyceryl_8\NN\14621446 trinitrate</e1>_9\NN\1740 on_10\IN\1740 the_11\DT\1740 prostigmine-morphine-induced_12\JJ\1740 <e2>sphincter_13\NN\5289297 of_14\IN\1740 oddi_15\NN\1740 spasm</e2>_16\NN\14299637 was_17\VBD\836236 evaluated_18\VBN\670261 in_19\IN\13603305 nine_20\CD\13741022 female_21\JJ\1740 patients_22\NNS\9898892 with_23\IN\1740 sphincter_24\NN\5289297 of_25\IN\1740 oddi_26\NNP\1740 dyskinesia_27\NN\14084880 ._28\.\1740
D005996_D013035 NONE conclusion_0\NN\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 provide_4\VBP\2199590 the_5\DT\1740 first_6\JJ\1740 evidence_7\NN\5816287 of_8\IN\1740 the_9\DT\1740 effectiveness_10\NN\5190804 of_11\IN\1740 <e1>glyceryl_12\NN\14621446 trinitrate</e1>_13\NN\1740 on_14\IN\1740 the_15\DT\1740 morphine-induced_16\JJ\1740 <e2>sphincter_17\NN\5289297 of_18\IN\1740 oddi_19\NN\1740 spasm</e2>_20\NN\14299637 in_21\IN\13603305 humans_22\NNS\31264 ._23\.\1740
D009388_D046628 CID effect_0\NN\34213 of_1\IN\1740 glyceryl_2\NN\14621446 trinitrate_3\NN\1740 on_4\IN\1740 the_5\DT\1740 <e2>sphincter_6\NN\5289297 of_7\IN\1740 oddi_8\NN\1740 spasm</e2>_9\NN\14299637 evoked_10\VBN\1617192 by_11\IN\1740 <e1>prostigmine-morphine</e1>_12\JJ\1740 administration_13\NN\1133281 ._14\.\1740
D009388_D046628 CID objective_0\NN\5980875 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 glyceryl_8\NN\14621446 trinitrate_9\NN\1740 on_10\IN\1740 the_11\DT\1740 <e1>prostigmine-morphine-induced</e1>_12\JJ\1740 <e2>sphincter_13\NN\5289297 of_14\IN\1740 oddi_15\NN\1740 spasm</e2>_16\NN\14299637 was_17\VBD\836236 evaluated_18\VBN\670261 in_19\IN\13603305 nine_20\CD\13741022 female_21\JJ\1740 patients_22\NNS\9898892 with_23\IN\1740 sphincter_24\NN\5289297 of_25\IN\1740 oddi_26\NNP\1740 dyskinesia_27\NN\14084880 ._28\.\1740
D009388_D046628 CID objective_0\NN\5980875 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 glyceryl_8\NN\14621446 trinitrate_9\NN\1740 on_10\IN\1740 the_11\DT\1740 <e1>prostigmine-morphine-induced</e1>_12\JJ\1740 sphincter_13\NN\5289297 of_14\IN\1740 oddi_15\NN\1740 spasm_16\NN\14299637 was_17\VBD\836236 evaluated_18\VBN\670261 in_19\IN\13603305 nine_20\CD\13741022 female_21\JJ\1740 patients_22\NNS\9898892 with_23\IN\1740 <e2>sphincter_24\NN\5289297 of_25\IN\1740 oddi_26\NNP\1740 dyskinesia</e2>_27\NN\14084880 ._28\.\1740
D009388_D046628 CID method_0\NNP\5616786 :_1\:\1740 <e2>sphincter_2\NN\5289297 of_3\IN\1740 oddi_4\NN\1740 spasm</e2>_5\NN\14299637 was_6\VBD\836236 induced_7\VBN\1627355 by_8\IN\1740 <e1>prostigmine-morphine</e1>_9\JJ\1740 administration_10\NN\1133281 (_11\-LRB-\1740 0.5_12\CD\1740 mg_13\NN\13717155 prostigmine_14\NN\1740 intramuscularly_15\RB\1740 and_16\CC\1740 10_17\CD\13745420 mg_18\NN\13717155 morphine_19\NN\2707683 subcutaneously_20\RB\1740 )_21\-RRB-\1740 and_22\CC\1740 visualized_23\VBN\1636397 by_24\IN\1740 quantitative_25\JJ\1740 hepatobiliary_26\JJ\1740 scintigraphy_27\NN\1740 ._28\.\1740
D009388_D046628 CID method_0\NNP\5616786 :_1\:\1740 <e2>sphincter_2\NN\5289297 of_3\IN\1740 oddi_4\NN\1740 spasm</e2>_5\NN\14299637 was_6\VBD\836236 induced_7\VBN\1627355 by_8\IN\1740 prostigmine-morphine_9\JJ\1740 administration_10\NN\1133281 (_11\-LRB-\1740 0.5_12\CD\1740 mg_13\NN\13717155 <e1>prostigmine</e1>_14\NN\1740 intramuscularly_15\RB\1740 and_16\CC\1740 10_17\CD\13745420 mg_18\NN\13717155 morphine_19\NN\2707683 subcutaneously_20\RB\1740 )_21\-RRB-\1740 and_22\CC\1740 visualized_23\VBN\1636397 by_24\IN\1740 quantitative_25\JJ\1740 hepatobiliary_26\JJ\1740 scintigraphy_27\NN\1740 ._28\.\1740
D009388_D013035 CID effect_0\NN\34213 of_1\IN\1740 glyceryl_2\NN\14621446 trinitrate_3\NN\1740 on_4\IN\1740 the_5\DT\1740 <e2>sphincter_6\NN\5289297 of_7\IN\1740 oddi_8\NN\1740 spasm</e2>_9\NN\14299637 evoked_10\VBN\1617192 by_11\IN\1740 <e1>prostigmine-morphine</e1>_12\JJ\1740 administration_13\NN\1133281 ._14\.\1740
D009388_D013035 CID objective_0\NN\5980875 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 glyceryl_8\NN\14621446 trinitrate_9\NN\1740 on_10\IN\1740 the_11\DT\1740 <e1>prostigmine-morphine-induced</e1>_12\JJ\1740 <e2>sphincter_13\NN\5289297 of_14\IN\1740 oddi_15\NN\1740 spasm</e2>_16\NN\14299637 was_17\VBD\836236 evaluated_18\VBN\670261 in_19\IN\13603305 nine_20\CD\13741022 female_21\JJ\1740 patients_22\NNS\9898892 with_23\IN\1740 sphincter_24\NN\5289297 of_25\IN\1740 oddi_26\NNP\1740 dyskinesia_27\NN\14084880 ._28\.\1740
D009388_D013035 CID method_0\NNP\5616786 :_1\:\1740 <e2>sphincter_2\NN\5289297 of_3\IN\1740 oddi_4\NN\1740 spasm</e2>_5\NN\14299637 was_6\VBD\836236 induced_7\VBN\1627355 by_8\IN\1740 <e1>prostigmine-morphine</e1>_9\JJ\1740 administration_10\NN\1133281 (_11\-LRB-\1740 0.5_12\CD\1740 mg_13\NN\13717155 prostigmine_14\NN\1740 intramuscularly_15\RB\1740 and_16\CC\1740 10_17\CD\13745420 mg_18\NN\13717155 morphine_19\NN\2707683 subcutaneously_20\RB\1740 )_21\-RRB-\1740 and_22\CC\1740 visualized_23\VBN\1636397 by_24\IN\1740 quantitative_25\JJ\1740 hepatobiliary_26\JJ\1740 scintigraphy_27\NN\1740 ._28\.\1740
D009388_D013035 CID method_0\NNP\5616786 :_1\:\1740 <e2>sphincter_2\NN\5289297 of_3\IN\1740 oddi_4\NN\1740 spasm</e2>_5\NN\14299637 was_6\VBD\836236 induced_7\VBN\1627355 by_8\IN\1740 prostigmine-morphine_9\JJ\1740 administration_10\NN\1133281 (_11\-LRB-\1740 0.5_12\CD\1740 mg_13\NN\13717155 <e1>prostigmine</e1>_14\NN\1740 intramuscularly_15\RB\1740 and_16\CC\1740 10_17\CD\13745420 mg_18\NN\13717155 morphine_19\NN\2707683 subcutaneously_20\RB\1740 )_21\-RRB-\1740 and_22\CC\1740 visualized_23\VBN\1636397 by_24\IN\1740 quantitative_25\JJ\1740 hepatobiliary_26\JJ\1740 scintigraphy_27\NN\1740 ._28\.\1740
D009388_D013035 CID results_0\NNS\34213 :_1\:\1740 <e1>prostigmine-morphine</e1>_2\JJ\1740 provocation_3\NN\1221611 caused_4\VBD\1617192 significant_5\JJ\1740 increases_6\NNS\13576355 in_7\IN\13603305 the_8\DT\1740 time_9\NN\7308889 to_10\TO\1740 peak_11\VB\2020590 activity_12\NN\30358 (_13\-LRB-\1740 tmax_14\NN\1740 )_15\-RRB-\1740 over_16\IN\5867413 the_17\DT\1740 hepatic_18\JJ\1740 hilum_19\NN\5223370 (_20\-LRB-\1740 hh_21\NN\1740 :_22\:\1740 34.33_23\CD\1740 +/-_24\CC\1740 5.05_25\CD\1740 vs._26\CC\1740 22.77_27\CD\1740 +/-_28\CC\1740 3.26_29\CD\1740 )_30\-RRB-\1740 and_31\CC\1740 the_32\DT\1740 common_33\JJ\1740 bile_34\NN\5405946 duct_35\NN\5248181 (_36\-LRB-\1740 cbd_37\NN\1740 :_38\:\1740 60.44_39\CD\1740 +/-_40\CC\1740 5.99_41\CD\1740 vs._42\CC\1740 40.0_43\CD\1740 +/-_44\CC\1740 2.88_45\CD\1740 )_46\-RRB-\1740 and_47\CC\1740 in_48\IN\13603305 the_49\DT\1740 half-time_50\NN\1740 of_51\IN\1740 excretion_52\NN\13466586 (_53\-LRB-\1740 t1/2_54\NN\1740 )_55\-RRB-\1740 over_56\IN\5867413 the_57\DT\1740 liver_58\NN\5298729 parenchyma_59\NN\5267548 (_60\-LRB-\1740 lp_61\NN\3924069 :_62\:\1740 120.04_63\CD\1740 +/-_64\CC\1740 16.01_65\CD\1740 vs._66\CC\1740 27.37_67\CD\1740 +/-_68\CC\1740 2.19_69\CD\1740 )_70\-RRB-\1740 ,_71\,\1740 hh_72\NN\1740 (_73\-LRB-\1740 117.61_74\CD\1740 +/-_75\CC\1740 14.71_76\CD\1740 vs._77\CC\1740 31.85_78\CD\1740 +/-_79\CC\1740 3.99_80\CD\1740 )_81\-RRB-\1740 and_82\CC\1740 cbd_83\NN\1740 (_84\-LRB-\1740 158.11_85\CD\1740 +/-_86\CC\1740 9.18_87\CD\1740 vs._88\CC\1740 40.1_89\CD\1740 +/-_90\CC\1740 6.24_91\CD\1740 )_92\-RRB-\1740 ,_93\,\1740 indicating_94\VBG\952524 a_95\DT\13649268 complete_96\JJ\1740 <e2>spasm</e2>_97\NN\14299637 at_98\IN\14622893 the_99\DT\1740 level_100\NN\4916342 of_101\IN\1740 the_102\DT\1740 sphincter_103\NN\5289297 of_104\IN\1740 oddi_105\NNP\1740 ._106\.\1740
D009020_D046628 CID effect_0\NN\34213 of_1\IN\1740 glyceryl_2\NN\14621446 trinitrate_3\NN\1740 on_4\IN\1740 the_5\DT\1740 <e2>sphincter_6\NN\5289297 of_7\IN\1740 oddi_8\NN\1740 spasm</e2>_9\NN\14299637 evoked_10\VBN\1617192 by_11\IN\1740 <e1>prostigmine-morphine</e1>_12\JJ\1740 administration_13\NN\1133281 ._14\.\1740
D009020_D046628 CID objective_0\NN\5980875 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 glyceryl_8\NN\14621446 trinitrate_9\NN\1740 on_10\IN\1740 the_11\DT\1740 <e1>prostigmine-morphine-induced</e1>_12\JJ\1740 <e2>sphincter_13\NN\5289297 of_14\IN\1740 oddi_15\NN\1740 spasm</e2>_16\NN\14299637 was_17\VBD\836236 evaluated_18\VBN\670261 in_19\IN\13603305 nine_20\CD\13741022 female_21\JJ\1740 patients_22\NNS\9898892 with_23\IN\1740 sphincter_24\NN\5289297 of_25\IN\1740 oddi_26\NNP\1740 dyskinesia_27\NN\14084880 ._28\.\1740
D009020_D046628 CID objective_0\NN\5980875 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 glyceryl_8\NN\14621446 trinitrate_9\NN\1740 on_10\IN\1740 the_11\DT\1740 <e1>prostigmine-morphine-induced</e1>_12\JJ\1740 sphincter_13\NN\5289297 of_14\IN\1740 oddi_15\NN\1740 spasm_16\NN\14299637 was_17\VBD\836236 evaluated_18\VBN\670261 in_19\IN\13603305 nine_20\CD\13741022 female_21\JJ\1740 patients_22\NNS\9898892 with_23\IN\1740 <e2>sphincter_24\NN\5289297 of_25\IN\1740 oddi_26\NNP\1740 dyskinesia</e2>_27\NN\14084880 ._28\.\1740
D009020_D046628 CID method_0\NNP\5616786 :_1\:\1740 <e2>sphincter_2\NN\5289297 of_3\IN\1740 oddi_4\NN\1740 spasm</e2>_5\NN\14299637 was_6\VBD\836236 induced_7\VBN\1627355 by_8\IN\1740 <e1>prostigmine-morphine</e1>_9\JJ\1740 administration_10\NN\1133281 (_11\-LRB-\1740 0.5_12\CD\1740 mg_13\NN\13717155 prostigmine_14\NN\1740 intramuscularly_15\RB\1740 and_16\CC\1740 10_17\CD\13745420 mg_18\NN\13717155 morphine_19\NN\2707683 subcutaneously_20\RB\1740 )_21\-RRB-\1740 and_22\CC\1740 visualized_23\VBN\1636397 by_24\IN\1740 quantitative_25\JJ\1740 hepatobiliary_26\JJ\1740 scintigraphy_27\NN\1740 ._28\.\1740
D009020_D046628 CID method_0\NNP\5616786 :_1\:\1740 <e2>sphincter_2\NN\5289297 of_3\IN\1740 oddi_4\NN\1740 spasm</e2>_5\NN\14299637 was_6\VBD\836236 induced_7\VBN\1627355 by_8\IN\1740 prostigmine-morphine_9\JJ\1740 administration_10\NN\1133281 (_11\-LRB-\1740 0.5_12\CD\1740 mg_13\NN\13717155 prostigmine_14\NN\1740 intramuscularly_15\RB\1740 and_16\CC\1740 10_17\CD\13745420 mg_18\NN\13717155 <e1>morphine</e1>_19\NN\2707683 subcutaneously_20\RB\1740 )_21\-RRB-\1740 and_22\CC\1740 visualized_23\VBN\1636397 by_24\IN\1740 quantitative_25\JJ\1740 hepatobiliary_26\JJ\1740 scintigraphy_27\NN\1740 ._28\.\1740
D009020_D046628 CID conclusion_0\NN\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 provide_4\VBP\2199590 the_5\DT\1740 first_6\JJ\1740 evidence_7\NN\5816287 of_8\IN\1740 the_9\DT\1740 effectiveness_10\NN\5190804 of_11\IN\1740 glyceryl_12\NN\14621446 trinitrate_13\NN\1740 on_14\IN\1740 the_15\DT\1740 <e1>morphine-induced</e1>_16\JJ\1740 <e2>sphincter_17\NN\5289297 of_18\IN\1740 oddi_19\NN\1740 spasm</e2>_20\NN\14299637 in_21\IN\13603305 humans_22\NNS\31264 ._23\.\1740
D009020_D046628 CID since_0\IN\1740 glyceryl_1\NN\14621446 trinitrate_2\NN\1740 is_3\VBZ\836236 able_4\JJ\1740 to_5\TO\1740 overcome_6\VB\1101913 even_7\RB\1740 the_8\DT\1740 drastic_9\JJ\1740 effect_10\NN\34213 of_11\IN\1740 <e1>morphine</e1>_12\NN\2707683 ,_13\,\1740 it_14\PRP\6125041 might_15\MD\5029706 be_16\VB\836236 of_17\IN\1740 relevance_18\NN\13791389 in_19\IN\13603305 the_20\DT\1740 treatment_21\NN\654885 of_22\IN\1740 <e2>sphincter_23\NN\5289297 of_24\IN\1740 oddi_25\NNP\1740 dyskinesia</e2>_26\NN\14084880 ._27\.\1740
D009020_D013035 CID effect_0\NN\34213 of_1\IN\1740 glyceryl_2\NN\14621446 trinitrate_3\NN\1740 on_4\IN\1740 the_5\DT\1740 <e2>sphincter_6\NN\5289297 of_7\IN\1740 oddi_8\NN\1740 spasm</e2>_9\NN\14299637 evoked_10\VBN\1617192 by_11\IN\1740 <e1>prostigmine-morphine</e1>_12\JJ\1740 administration_13\NN\1133281 ._14\.\1740
D009020_D013035 CID objective_0\NN\5980875 :_1\:\1740 in_2\IN\13603305 this_3\DT\1740 study_4\NN\635850 the_5\DT\1740 effect_6\NN\34213 of_7\IN\1740 glyceryl_8\NN\14621446 trinitrate_9\NN\1740 on_10\IN\1740 the_11\DT\1740 <e1>prostigmine-morphine-induced</e1>_12\JJ\1740 <e2>sphincter_13\NN\5289297 of_14\IN\1740 oddi_15\NN\1740 spasm</e2>_16\NN\14299637 was_17\VBD\836236 evaluated_18\VBN\670261 in_19\IN\13603305 nine_20\CD\13741022 female_21\JJ\1740 patients_22\NNS\9898892 with_23\IN\1740 sphincter_24\NN\5289297 of_25\IN\1740 oddi_26\NNP\1740 dyskinesia_27\NN\14084880 ._28\.\1740
D009020_D013035 CID method_0\NNP\5616786 :_1\:\1740 <e2>sphincter_2\NN\5289297 of_3\IN\1740 oddi_4\NN\1740 spasm</e2>_5\NN\14299637 was_6\VBD\836236 induced_7\VBN\1627355 by_8\IN\1740 <e1>prostigmine-morphine</e1>_9\JJ\1740 administration_10\NN\1133281 (_11\-LRB-\1740 0.5_12\CD\1740 mg_13\NN\13717155 prostigmine_14\NN\1740 intramuscularly_15\RB\1740 and_16\CC\1740 10_17\CD\13745420 mg_18\NN\13717155 morphine_19\NN\2707683 subcutaneously_20\RB\1740 )_21\-RRB-\1740 and_22\CC\1740 visualized_23\VBN\1636397 by_24\IN\1740 quantitative_25\JJ\1740 hepatobiliary_26\JJ\1740 scintigraphy_27\NN\1740 ._28\.\1740
D009020_D013035 CID method_0\NNP\5616786 :_1\:\1740 <e2>sphincter_2\NN\5289297 of_3\IN\1740 oddi_4\NN\1740 spasm</e2>_5\NN\14299637 was_6\VBD\836236 induced_7\VBN\1627355 by_8\IN\1740 prostigmine-morphine_9\JJ\1740 administration_10\NN\1133281 (_11\-LRB-\1740 0.5_12\CD\1740 mg_13\NN\13717155 prostigmine_14\NN\1740 intramuscularly_15\RB\1740 and_16\CC\1740 10_17\CD\13745420 mg_18\NN\13717155 <e1>morphine</e1>_19\NN\2707683 subcutaneously_20\RB\1740 )_21\-RRB-\1740 and_22\CC\1740 visualized_23\VBN\1636397 by_24\IN\1740 quantitative_25\JJ\1740 hepatobiliary_26\JJ\1740 scintigraphy_27\NN\1740 ._28\.\1740
D009020_D013035 CID results_0\NNS\34213 :_1\:\1740 <e1>prostigmine-morphine</e1>_2\JJ\1740 provocation_3\NN\1221611 caused_4\VBD\1617192 significant_5\JJ\1740 increases_6\NNS\13576355 in_7\IN\13603305 the_8\DT\1740 time_9\NN\7308889 to_10\TO\1740 peak_11\VB\2020590 activity_12\NN\30358 (_13\-LRB-\1740 tmax_14\NN\1740 )_15\-RRB-\1740 over_16\IN\5867413 the_17\DT\1740 hepatic_18\JJ\1740 hilum_19\NN\5223370 (_20\-LRB-\1740 hh_21\NN\1740 :_22\:\1740 34.33_23\CD\1740 +/-_24\CC\1740 5.05_25\CD\1740 vs._26\CC\1740 22.77_27\CD\1740 +/-_28\CC\1740 3.26_29\CD\1740 )_30\-RRB-\1740 and_31\CC\1740 the_32\DT\1740 common_33\JJ\1740 bile_34\NN\5405946 duct_35\NN\5248181 (_36\-LRB-\1740 cbd_37\NN\1740 :_38\:\1740 60.44_39\CD\1740 +/-_40\CC\1740 5.99_41\CD\1740 vs._42\CC\1740 40.0_43\CD\1740 +/-_44\CC\1740 2.88_45\CD\1740 )_46\-RRB-\1740 and_47\CC\1740 in_48\IN\13603305 the_49\DT\1740 half-time_50\NN\1740 of_51\IN\1740 excretion_52\NN\13466586 (_53\-LRB-\1740 t1/2_54\NN\1740 )_55\-RRB-\1740 over_56\IN\5867413 the_57\DT\1740 liver_58\NN\5298729 parenchyma_59\NN\5267548 (_60\-LRB-\1740 lp_61\NN\3924069 :_62\:\1740 120.04_63\CD\1740 +/-_64\CC\1740 16.01_65\CD\1740 vs._66\CC\1740 27.37_67\CD\1740 +/-_68\CC\1740 2.19_69\CD\1740 )_70\-RRB-\1740 ,_71\,\1740 hh_72\NN\1740 (_73\-LRB-\1740 117.61_74\CD\1740 +/-_75\CC\1740 14.71_76\CD\1740 vs._77\CC\1740 31.85_78\CD\1740 +/-_79\CC\1740 3.99_80\CD\1740 )_81\-RRB-\1740 and_82\CC\1740 cbd_83\NN\1740 (_84\-LRB-\1740 158.11_85\CD\1740 +/-_86\CC\1740 9.18_87\CD\1740 vs._88\CC\1740 40.1_89\CD\1740 +/-_90\CC\1740 6.24_91\CD\1740 )_92\-RRB-\1740 ,_93\,\1740 indicating_94\VBG\952524 a_95\DT\13649268 complete_96\JJ\1740 <e2>spasm</e2>_97\NN\14299637 at_98\IN\14622893 the_99\DT\1740 level_100\NN\4916342 of_101\IN\1740 the_102\DT\1740 sphincter_103\NN\5289297 of_104\IN\1740 oddi_105\NNP\1740 ._106\.\1740
D009020_D013035 CID conclusion_0\NN\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 provide_4\VBP\2199590 the_5\DT\1740 first_6\JJ\1740 evidence_7\NN\5816287 of_8\IN\1740 the_9\DT\1740 effectiveness_10\NN\5190804 of_11\IN\1740 glyceryl_12\NN\14621446 trinitrate_13\NN\1740 on_14\IN\1740 the_15\DT\1740 <e1>morphine-induced</e1>_16\JJ\1740 <e2>sphincter_17\NN\5289297 of_18\IN\1740 oddi_19\NN\1740 spasm</e2>_20\NN\14299637 in_21\IN\13603305 humans_22\NNS\31264 ._23\.\1740
3015327
D007538_D009422 CID remodelling_0\NN\1740 of_1\IN\1740 nerve_2\NN\5475681 structure_3\NN\21939 in_4\IN\13603305 experimental_5\JJ\1740 <e1>isoniazid</e1>_6\NNS\2716205 <e2>neuropathy</e2>_7\JJ\1740 in_8\IN\13603305 the_9\DT\1740 rat_10\NN\2329401 ._11\.\1740
D007538_D009422 CID the_0\DT\1740 <e2>neuropathy</e2>_1\NN\14204950 caused_2\VBN\1617192 by_3\IN\1740 a_4\DT\13649268 single_5\JJ\1740 dose_6\NN\3740161 of_7\IN\1740 <e1>isoniazid</e1>_8\NNS\2716205 in_9\IN\13603305 rats_10\NNS\2329401 was_11\VBD\836236 studied_12\VBN\630380 with_13\IN\1740 a_14\DT\13649268 computer-assisted_15\JJ\1740 morphometric_16\JJ\1740 method_17\NN\5616786 ._18\.\1740
9201797
D002354_D002375 NONE the_0\DT\1740 attenuating_1\NN\1740 effect_2\NN\34213 of_3\IN\1740 <e1>carteolol_4\NN\1740 hydrochloride</e1>_5\NN\14817592 ,_6\,\1740 a_7\DT\13649268 beta-adrenoceptor_8\NN\5608868 antagonist_9\NN\7846 ,_10\,\1740 on_11\IN\1740 neuroleptic-induced_12\JJ\1740 <e2>catalepsy</e2>_13\NN\14023236 in_14\IN\13603305 rats_15\NNS\2329401 ._16\.\1740
D002354_D002375 NONE therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 <e1>carteolol</e1>_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 beta-adrenoceptor_8\NN\5608868 antagonist_9\NN\7846 ,_10\,\1740 on_11\IN\1740 haloperidol-induced_12\JJ\1740 <e2>catalepsy</e2>_13\NN\14023236 in_14\IN\13603305 rats_15\NNS\2329401 were_16\VBD\836236 behaviorally_17\RB\1740 studied_18\VBN\630380 and_19\CC\1740 compared_20\VBN\644583 with_21\IN\1740 those_22\DT\1740 of_23\IN\1740 propranolol_24\NN\1740 and_25\CC\1740 biperiden_26\JJ\1740 ,_27\,\1740 a_28\DT\13649268 muscarinic_29\JJ\1740 receptor_30\NN\5225602 antagonist_31\NN\7846 ._32\.\1740
D002354_D002375 NONE <e1>carteolol</e1>_0\NNP\1740 ,_1\,\1740 as_2\RB\1740 well_3\RB\1740 as_4\IN\14622893 propranolol_5\NN\1740 and_6\CC\1740 biperiden_7\JJ\1740 ,_8\,\1740 inhibited_9\VBD\2510337 the_10\DT\1740 haloperidol-induced_11\JJ\1740 <e2>catalepsy</e2>_12\NN\14023236 ._13\.\1740
D002354_D002375 NONE these_0\DT\1740 results_1\NNS\34213 strongly_2\RB\1740 suggest_3\VBP\1010118 that_4\IN\1740 <e1>carteolol</e1>_5\NN\1740 improves_6\VBZ\126264 haloperidol-induced_7\JJ\1740 <e2>catalepsy</e2>_8\NN\14023236 via_9\IN\1740 its_10\PRP$\6125041 beta-adrenoceptor_11\NN\5608868 antagonistic_12\JJ\1740 activity_13\NN\30358 and_14\CC\1740 is_15\VBZ\836236 expected_16\VBN\670261 to_17\TO\1740 be_18\VB\836236 effective_19\JJ\1740 in_20\IN\13603305 the_21\DT\1740 treatment_22\NN\654885 of_23\IN\1740 akathisia_24\NN\1740 without_25\IN\1740 attenuating_26\VBG\224901 neuroleptic-induced_27\JJ\1740 antipsychotic_28\JJ\1740 effects_29\NNS\13245626 due_30\JJ\1740 to_31\TO\1740 its_32\PRP$\6125041 postsynaptic_33\JJ\1740 dopamine_34\NN\14807737 receptor_35\NN\5225602 antagonistic_36\JJ\1740 activity_37\NN\30358 ._38\.\1740
D006220_D002375 CID therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 carteolol_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 beta-adrenoceptor_8\NN\5608868 antagonist_9\NN\7846 ,_10\,\1740 on_11\IN\1740 <e1>haloperidol-induced</e1>_12\JJ\1740 <e2>catalepsy</e2>_13\NN\14023236 in_14\IN\13603305 rats_15\NNS\2329401 were_16\VBD\836236 behaviorally_17\RB\1740 studied_18\VBN\630380 and_19\CC\1740 compared_20\VBN\644583 with_21\IN\1740 those_22\DT\1740 of_23\IN\1740 propranolol_24\NN\1740 and_25\CC\1740 biperiden_26\JJ\1740 ,_27\,\1740 a_28\DT\13649268 muscarinic_29\JJ\1740 receptor_30\NN\5225602 antagonist_31\NN\7846 ._32\.\1740
D006220_D002375 CID carteolol_0\NNP\1740 ,_1\,\1740 as_2\RB\1740 well_3\RB\1740 as_4\IN\14622893 propranolol_5\NN\1740 and_6\CC\1740 biperiden_7\JJ\1740 ,_8\,\1740 inhibited_9\VBD\2510337 the_10\DT\1740 <e1>haloperidol-induced</e1>_11\JJ\1740 <e2>catalepsy</e2>_12\NN\14023236 ._13\.\1740
D006220_D002375 CID these_0\DT\1740 results_1\NNS\34213 strongly_2\RB\1740 suggest_3\VBP\1010118 that_4\IN\1740 carteolol_5\NN\1740 improves_6\VBZ\126264 <e1>haloperidol-induced</e1>_7\JJ\1740 <e2>catalepsy</e2>_8\NN\14023236 via_9\IN\1740 its_10\PRP$\6125041 beta-adrenoceptor_11\NN\5608868 antagonistic_12\JJ\1740 activity_13\NN\30358 and_14\CC\1740 is_15\VBZ\836236 expected_16\VBN\670261 to_17\TO\1740 be_18\VB\836236 effective_19\JJ\1740 in_20\IN\13603305 the_21\DT\1740 treatment_22\NN\654885 of_23\IN\1740 akathisia_24\NN\1740 without_25\IN\1740 attenuating_26\VBG\224901 neuroleptic-induced_27\JJ\1740 antipsychotic_28\JJ\1740 effects_29\NNS\13245626 due_30\JJ\1740 to_31\TO\1740 its_32\PRP$\6125041 postsynaptic_33\JJ\1740 dopamine_34\NN\14807737 receptor_35\NN\5225602 antagonistic_36\JJ\1740 activity_37\NN\30358 ._38\.\1740
D011433_D002375 NONE therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 carteolol_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 beta-adrenoceptor_8\NN\5608868 antagonist_9\NN\7846 ,_10\,\1740 on_11\IN\1740 haloperidol-induced_12\JJ\1740 <e2>catalepsy</e2>_13\NN\14023236 in_14\IN\13603305 rats_15\NNS\2329401 were_16\VBD\836236 behaviorally_17\RB\1740 studied_18\VBN\630380 and_19\CC\1740 compared_20\VBN\644583 with_21\IN\1740 those_22\DT\1740 of_23\IN\1740 <e1>propranolol</e1>_24\NN\1740 and_25\CC\1740 biperiden_26\JJ\1740 ,_27\,\1740 a_28\DT\13649268 muscarinic_29\JJ\1740 receptor_30\NN\5225602 antagonist_31\NN\7846 ._32\.\1740
D011433_D002375 NONE carteolol_0\NNP\1740 ,_1\,\1740 as_2\RB\1740 well_3\RB\1740 as_4\IN\14622893 <e1>propranolol</e1>_5\NN\1740 and_6\CC\1740 biperiden_7\JJ\1740 ,_8\,\1740 inhibited_9\VBD\2510337 the_10\DT\1740 haloperidol-induced_11\JJ\1740 <e2>catalepsy</e2>_12\NN\14023236 ._13\.\1740
D001712_D002375 NONE therefore_0\RB\1740 ,_1\,\1740 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 carteolol_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 beta-adrenoceptor_8\NN\5608868 antagonist_9\NN\7846 ,_10\,\1740 on_11\IN\1740 haloperidol-induced_12\JJ\1740 <e2>catalepsy</e2>_13\NN\14023236 in_14\IN\13603305 rats_15\NNS\2329401 were_16\VBD\836236 behaviorally_17\RB\1740 studied_18\VBN\630380 and_19\CC\1740 compared_20\VBN\644583 with_21\IN\1740 those_22\DT\1740 of_23\IN\1740 propranolol_24\NN\1740 and_25\CC\1740 <e1>biperiden</e1>_26\JJ\1740 ,_27\,\1740 a_28\DT\13649268 muscarinic_29\JJ\1740 receptor_30\NN\5225602 antagonist_31\NN\7846 ._32\.\1740
D001712_D002375 NONE carteolol_0\NNP\1740 ,_1\,\1740 as_2\RB\1740 well_3\RB\1740 as_4\IN\14622893 propranolol_5\NN\1740 and_6\CC\1740 <e1>biperiden</e1>_7\JJ\1740 ,_8\,\1740 inhibited_9\VBD\2510337 the_10\DT\1740 haloperidol-induced_11\JJ\1740 <e2>catalepsy</e2>_12\NN\14023236 ._13\.\1740
D002354_D009069 NONE <e1>carteolol</e1>_0\NNP\1740 did_1\VBD\1640855 not_2\RB\1740 evoke_3\VB\1617192 postsynaptic_4\JJ\1740 dopamine_5\NN\14807737 receptor-stimulating_6\JJ\1740 behavioral_7\JJ\1740 signs_8\NNS\6643763 such_9\JJ\1740 as_10\IN\14622893 stereotypy_11\NN\1740 and_12\CC\1740 <e2>hyperlocomotion</e2>_13\NN\1740 in_14\IN\13603305 rats_15\NNS\2329401 ._16\.\1740
D004298_D009069 NONE carteolol_0\NNP\1740 did_1\VBD\1640855 not_2\RB\1740 evoke_3\VB\1617192 postsynaptic_4\JJ\1740 <e1>dopamine</e1>_5\NN\14807737 receptor-stimulating_6\JJ\1740 behavioral_7\JJ\1740 signs_8\NNS\6643763 such_9\JJ\1740 as_10\IN\14622893 stereotypy_11\NN\1740 and_12\CC\1740 <e2>hyperlocomotion</e2>_13\NN\1740 in_14\IN\13603305 rats_15\NNS\2329401 ._16\.\1740
D002354_D017109 NONE these_0\DT\1740 results_1\NNS\34213 strongly_2\RB\1740 suggest_3\VBP\1010118 that_4\IN\1740 <e1>carteolol</e1>_5\NN\1740 improves_6\VBZ\126264 haloperidol-induced_7\JJ\1740 catalepsy_8\NN\14023236 via_9\IN\1740 its_10\PRP$\6125041 beta-adrenoceptor_11\NN\5608868 antagonistic_12\JJ\1740 activity_13\NN\30358 and_14\CC\1740 is_15\VBZ\836236 expected_16\VBN\670261 to_17\TO\1740 be_18\VB\836236 effective_19\JJ\1740 in_20\IN\13603305 the_21\DT\1740 treatment_22\NN\654885 of_23\IN\1740 <e2>akathisia</e2>_24\NN\1740 without_25\IN\1740 attenuating_26\VBG\224901 neuroleptic-induced_27\JJ\1740 antipsychotic_28\JJ\1740 effects_29\NNS\13245626 due_30\JJ\1740 to_31\TO\1740 its_32\PRP$\6125041 postsynaptic_33\JJ\1740 dopamine_34\NN\14807737 receptor_35\NN\5225602 antagonistic_36\JJ\1740 activity_37\NN\30358 ._38\.\1740
D006220_D017109 NONE these_0\DT\1740 results_1\NNS\34213 strongly_2\RB\1740 suggest_3\VBP\1010118 that_4\IN\1740 carteolol_5\NN\1740 improves_6\VBZ\126264 <e1>haloperidol-induced</e1>_7\JJ\1740 catalepsy_8\NN\14023236 via_9\IN\1740 its_10\PRP$\6125041 beta-adrenoceptor_11\NN\5608868 antagonistic_12\JJ\1740 activity_13\NN\30358 and_14\CC\1740 is_15\VBZ\836236 expected_16\VBN\670261 to_17\TO\1740 be_18\VB\836236 effective_19\JJ\1740 in_20\IN\13603305 the_21\DT\1740 treatment_22\NN\654885 of_23\IN\1740 <e2>akathisia</e2>_24\NN\1740 without_25\IN\1740 attenuating_26\VBG\224901 neuroleptic-induced_27\JJ\1740 antipsychotic_28\JJ\1740 effects_29\NNS\13245626 due_30\JJ\1740 to_31\TO\1740 its_32\PRP$\6125041 postsynaptic_33\JJ\1740 dopamine_34\NN\14807737 receptor_35\NN\5225602 antagonistic_36\JJ\1740 activity_37\NN\30358 ._38\.\1740
D004298_D002375 NONE these_0\DT\1740 results_1\NNS\34213 strongly_2\RB\1740 suggest_3\VBP\1010118 that_4\IN\1740 carteolol_5\NN\1740 improves_6\VBZ\126264 haloperidol-induced_7\JJ\1740 <e2>catalepsy</e2>_8\NN\14023236 via_9\IN\1740 its_10\PRP$\6125041 beta-adrenoceptor_11\NN\5608868 antagonistic_12\JJ\1740 activity_13\NN\30358 and_14\CC\1740 is_15\VBZ\836236 expected_16\VBN\670261 to_17\TO\1740 be_18\VB\836236 effective_19\JJ\1740 in_20\IN\13603305 the_21\DT\1740 treatment_22\NN\654885 of_23\IN\1740 akathisia_24\NN\1740 without_25\IN\1740 attenuating_26\VBG\224901 neuroleptic-induced_27\JJ\1740 antipsychotic_28\JJ\1740 effects_29\NNS\13245626 due_30\JJ\1740 to_31\TO\1740 its_32\PRP$\6125041 postsynaptic_33\JJ\1740 <e1>dopamine</e1>_34\NN\14807737 receptor_35\NN\5225602 antagonistic_36\JJ\1740 activity_37\NN\30358 ._38\.\1740
D004298_D017109 NONE these_0\DT\1740 results_1\NNS\34213 strongly_2\RB\1740 suggest_3\VBP\1010118 that_4\IN\1740 carteolol_5\NN\1740 improves_6\VBZ\126264 haloperidol-induced_7\JJ\1740 catalepsy_8\NN\14023236 via_9\IN\1740 its_10\PRP$\6125041 beta-adrenoceptor_11\NN\5608868 antagonistic_12\JJ\1740 activity_13\NN\30358 and_14\CC\1740 is_15\VBZ\836236 expected_16\VBN\670261 to_17\TO\1740 be_18\VB\836236 effective_19\JJ\1740 in_20\IN\13603305 the_21\DT\1740 treatment_22\NN\654885 of_23\IN\1740 <e2>akathisia</e2>_24\NN\1740 without_25\IN\1740 attenuating_26\VBG\224901 neuroleptic-induced_27\JJ\1740 antipsychotic_28\JJ\1740 effects_29\NNS\13245626 due_30\JJ\1740 to_31\TO\1740 its_32\PRP$\6125041 postsynaptic_33\JJ\1740 <e1>dopamine</e1>_34\NN\14807737 receptor_35\NN\5225602 antagonistic_36\JJ\1740 activity_37\NN\30358 ._38\.\1740
15042318
D004317_C535648 NONE the_0\DT\1740 authors_1\NNS\9610660 describe_2\VBP\1001294 the_3\DT\1740 unusual_4\JJ\1740 association_5\NN\8008335 between_6\IN\1740 diffuse_7\JJ\1740 b-cell_8\NN\1740 <e2>gastric_9\JJ\1740 lymphoma</e2>_10\NN\14239918 and_11\CC\1740 myotonic_12\JJ\1740 dystrophy_13\NN\14151139 ,_14\,\1740 the_15\DT\1740 most_16\RBS\1740 common_17\JJ\1740 form_18\NN\6286395 of_19\IN\1740 adult_20\JJ\1740 muscular_21\JJ\1740 dystrophy_22\NN\14151139 ,_23\,\1740 and_24\CC\1740 sudden_25\JJ\1740 atrial_26\JJ\1740 fibrillation_27\NN\14361664 following_28\VBG\1835496 one_29\CD\13741022 cycle_30\NN\15269513 of_31\IN\1740 <e1>doxorubicin-based</e1>_32\JJ\1740 chemotherapy_33\NN\661091 in_34\IN\13603305 the_35\DT\1740 same_36\JJ\1740 patient_37\NN\9898892 ._38\.\1740
D004317_D009223 NONE the_0\DT\1740 authors_1\NNS\9610660 describe_2\VBP\1001294 the_3\DT\1740 unusual_4\JJ\1740 association_5\NN\8008335 between_6\IN\1740 diffuse_7\JJ\1740 b-cell_8\NN\1740 gastric_9\JJ\1740 lymphoma_10\NN\14239918 and_11\CC\1740 <e2>myotonic_12\JJ\1740 dystrophy</e2>_13\NN\14151139 ,_14\,\1740 the_15\DT\1740 most_16\RBS\1740 common_17\JJ\1740 form_18\NN\6286395 of_19\IN\1740 adult_20\JJ\1740 muscular_21\JJ\1740 dystrophy_22\NN\14151139 ,_23\,\1740 and_24\CC\1740 sudden_25\JJ\1740 atrial_26\JJ\1740 fibrillation_27\NN\14361664 following_28\VBG\1835496 one_29\CD\13741022 cycle_30\NN\15269513 of_31\IN\1740 <e1>doxorubicin-based</e1>_32\JJ\1740 chemotherapy_33\NN\661091 in_34\IN\13603305 the_35\DT\1740 same_36\JJ\1740 patient_37\NN\9898892 ._38\.\1740
D004317_D009136 NONE the_0\DT\1740 authors_1\NNS\9610660 describe_2\VBP\1001294 the_3\DT\1740 unusual_4\JJ\1740 association_5\NN\8008335 between_6\IN\1740 diffuse_7\JJ\1740 b-cell_8\NN\1740 gastric_9\JJ\1740 lymphoma_10\NN\14239918 and_11\CC\1740 myotonic_12\JJ\1740 dystrophy_13\NN\14151139 ,_14\,\1740 the_15\DT\1740 most_16\RBS\1740 common_17\JJ\1740 form_18\NN\6286395 of_19\IN\1740 adult_20\JJ\1740 <e2>muscular_21\JJ\1740 dystrophy</e2>_22\NN\14151139 ,_23\,\1740 and_24\CC\1740 sudden_25\JJ\1740 atrial_26\JJ\1740 fibrillation_27\NN\14361664 following_28\VBG\1835496 one_29\CD\13741022 cycle_30\NN\15269513 of_31\IN\1740 <e1>doxorubicin-based</e1>_32\JJ\1740 chemotherapy_33\NN\661091 in_34\IN\13603305 the_35\DT\1740 same_36\JJ\1740 patient_37\NN\9898892 ._38\.\1740
D004317_D001281 CID the_0\DT\1740 authors_1\NNS\9610660 describe_2\VBP\1001294 the_3\DT\1740 unusual_4\JJ\1740 association_5\NN\8008335 between_6\IN\1740 diffuse_7\JJ\1740 b-cell_8\NN\1740 gastric_9\JJ\1740 lymphoma_10\NN\14239918 and_11\CC\1740 myotonic_12\JJ\1740 dystrophy_13\NN\14151139 ,_14\,\1740 the_15\DT\1740 most_16\RBS\1740 common_17\JJ\1740 form_18\NN\6286395 of_19\IN\1740 adult_20\JJ\1740 muscular_21\JJ\1740 dystrophy_22\NN\14151139 ,_23\,\1740 and_24\CC\1740 sudden_25\JJ\1740 <e2>atrial_26\JJ\1740 fibrillation</e2>_27\NN\14361664 following_28\VBG\1835496 one_29\CD\13741022 cycle_30\NN\15269513 of_31\IN\1740 <e1>doxorubicin-based</e1>_32\JJ\1740 chemotherapy_33\NN\661091 in_34\IN\13603305 the_35\DT\1740 same_36\JJ\1740 patient_37\NN\9898892 ._38\.\1740
8492347
D005665_D013746 CID <e2>tetany</e2>_0\NN\14304060 and_1\CC\1740 rhabdomyolysis_2\NN\1740 due_3\IN\5174653 to_4\IN\1740 surreptitious_5\JJ\1740 <e1>furosemide</e1>_6\NN\3214670 --_7\:\1740 importance_8\NN\5138488 of_9\IN\1740 magnesium_10\NN\14625458 supplementation_11\NN\5108947 ._12\.\1740
D005665_D012206 CID tetany_0\NN\14304060 and_1\CC\1740 <e2>rhabdomyolysis</e2>_2\NN\1740 due_3\IN\5174653 to_4\IN\1740 surreptitious_5\JJ\1740 <e1>furosemide</e1>_6\NN\3214670 --_7\:\1740 importance_8\NN\5138488 of_9\IN\1740 magnesium_10\NN\14625458 supplementation_11\NN\5108947 ._12\.\1740
D008274_D013746 NONE <e2>tetany</e2>_0\NN\14304060 and_1\CC\1740 rhabdomyolysis_2\NN\1740 due_3\IN\5174653 to_4\IN\1740 surreptitious_5\JJ\1740 furosemide_6\NN\3214670 --_7\:\1740 importance_8\NN\5138488 of_9\IN\1740 <e1>magnesium</e1>_10\NN\14625458 supplementation_11\NN\5108947 ._12\.\1740
D008274_D012206 NONE tetany_0\NN\14304060 and_1\CC\1740 <e2>rhabdomyolysis</e2>_2\NN\1740 due_3\IN\5174653 to_4\IN\1740 surreptitious_5\JJ\1740 furosemide_6\NN\3214670 --_7\:\1740 importance_8\NN\5138488 of_9\IN\1740 <e1>magnesium</e1>_10\NN\14625458 supplementation_11\NN\5108947 ._12\.\1740
D011188_D007008 NONE while_0\IN\15122231 severe_1\JJ\1740 <e2>hypokalemia</e2>_2\NN\14299637 may_3\MD\15209706 cause_4\VB\1617192 muscle_5\NN\5289601 weakness_6\NN\14462666 ,_7\,\1740 severe_8\JJ\1740 hypomagnesemia_9\NN\1740 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 muscle_13\NN\5289601 spasms_14\NNS\14299637 and_15\CC\1740 tetany_16\NN\14304060 which_17\WDT\1740 can_18\MD\3094503 not_19\RB\1740 be_20\VB\836236 corrected_21\VBN\138508 by_22\IN\1740 <e1>potassium</e1>_23\NN\14625458 and_24\CC\1740 calcium_25\NN\14625458 supplementation_26\NN\5108947 alone_27\RB\1740 (_28\-LRB-\1740 1,2_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D011188_D018908 NONE while_0\IN\15122231 severe_1\JJ\1740 hypokalemia_2\NN\14299637 may_3\MD\15209706 cause_4\VB\1617192 <e2>muscle_5\NN\5289601 weakness</e2>_6\NN\14462666 ,_7\,\1740 severe_8\JJ\1740 hypomagnesemia_9\NN\1740 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 muscle_13\NN\5289601 spasms_14\NNS\14299637 and_15\CC\1740 tetany_16\NN\14304060 which_17\WDT\1740 can_18\MD\3094503 not_19\RB\1740 be_20\VB\836236 corrected_21\VBN\138508 by_22\IN\1740 <e1>potassium</e1>_23\NN\14625458 and_24\CC\1740 calcium_25\NN\14625458 supplementation_26\NN\5108947 alone_27\RB\1740 (_28\-LRB-\1740 1,2_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D011188_C537153 NONE while_0\IN\15122231 severe_1\JJ\1740 hypokalemia_2\NN\14299637 may_3\MD\15209706 cause_4\VB\1617192 muscle_5\NN\5289601 weakness_6\NN\14462666 ,_7\,\1740 severe_8\JJ\1740 <e2>hypomagnesemia</e2>_9\NN\1740 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 muscle_13\NN\5289601 spasms_14\NNS\14299637 and_15\CC\1740 tetany_16\NN\14304060 which_17\WDT\1740 can_18\MD\3094503 not_19\RB\1740 be_20\VB\836236 corrected_21\VBN\138508 by_22\IN\1740 <e1>potassium</e1>_23\NN\14625458 and_24\CC\1740 calcium_25\NN\14625458 supplementation_26\NN\5108947 alone_27\RB\1740 (_28\-LRB-\1740 1,2_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D011188_D013035 NONE while_0\IN\15122231 severe_1\JJ\1740 hypokalemia_2\NN\14299637 may_3\MD\15209706 cause_4\VB\1617192 muscle_5\NN\5289601 weakness_6\NN\14462666 ,_7\,\1740 severe_8\JJ\1740 hypomagnesemia_9\NN\1740 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 <e2>muscle_13\NN\5289601 spasms</e2>_14\NNS\14299637 and_15\CC\1740 tetany_16\NN\14304060 which_17\WDT\1740 can_18\MD\3094503 not_19\RB\1740 be_20\VB\836236 corrected_21\VBN\138508 by_22\IN\1740 <e1>potassium</e1>_23\NN\14625458 and_24\CC\1740 calcium_25\NN\14625458 supplementation_26\NN\5108947 alone_27\RB\1740 (_28\-LRB-\1740 1,2_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D011188_D013746 NONE while_0\IN\15122231 severe_1\JJ\1740 hypokalemia_2\NN\14299637 may_3\MD\15209706 cause_4\VB\1617192 muscle_5\NN\5289601 weakness_6\NN\14462666 ,_7\,\1740 severe_8\JJ\1740 hypomagnesemia_9\NN\1740 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 muscle_13\NN\5289601 spasms_14\NNS\14299637 and_15\CC\1740 <e2>tetany</e2>_16\NN\14304060 which_17\WDT\1740 can_18\MD\3094503 not_19\RB\1740 be_20\VB\836236 corrected_21\VBN\138508 by_22\IN\1740 <e1>potassium</e1>_23\NN\14625458 and_24\CC\1740 calcium_25\NN\14625458 supplementation_26\NN\5108947 alone_27\RB\1740 (_28\-LRB-\1740 1,2_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D002118_D007008 NONE while_0\IN\15122231 severe_1\JJ\1740 <e2>hypokalemia</e2>_2\NN\14299637 may_3\MD\15209706 cause_4\VB\1617192 muscle_5\NN\5289601 weakness_6\NN\14462666 ,_7\,\1740 severe_8\JJ\1740 hypomagnesemia_9\NN\1740 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 muscle_13\NN\5289601 spasms_14\NNS\14299637 and_15\CC\1740 tetany_16\NN\14304060 which_17\WDT\1740 can_18\MD\3094503 not_19\RB\1740 be_20\VB\836236 corrected_21\VBN\138508 by_22\IN\1740 potassium_23\NN\14625458 and_24\CC\1740 <e1>calcium</e1>_25\NN\14625458 supplementation_26\NN\5108947 alone_27\RB\1740 (_28\-LRB-\1740 1,2_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D002118_D018908 NONE while_0\IN\15122231 severe_1\JJ\1740 hypokalemia_2\NN\14299637 may_3\MD\15209706 cause_4\VB\1617192 <e2>muscle_5\NN\5289601 weakness</e2>_6\NN\14462666 ,_7\,\1740 severe_8\JJ\1740 hypomagnesemia_9\NN\1740 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 muscle_13\NN\5289601 spasms_14\NNS\14299637 and_15\CC\1740 tetany_16\NN\14304060 which_17\WDT\1740 can_18\MD\3094503 not_19\RB\1740 be_20\VB\836236 corrected_21\VBN\138508 by_22\IN\1740 potassium_23\NN\14625458 and_24\CC\1740 <e1>calcium</e1>_25\NN\14625458 supplementation_26\NN\5108947 alone_27\RB\1740 (_28\-LRB-\1740 1,2_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D002118_C537153 NONE while_0\IN\15122231 severe_1\JJ\1740 hypokalemia_2\NN\14299637 may_3\MD\15209706 cause_4\VB\1617192 muscle_5\NN\5289601 weakness_6\NN\14462666 ,_7\,\1740 severe_8\JJ\1740 <e2>hypomagnesemia</e2>_9\NN\1740 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 muscle_13\NN\5289601 spasms_14\NNS\14299637 and_15\CC\1740 tetany_16\NN\14304060 which_17\WDT\1740 can_18\MD\3094503 not_19\RB\1740 be_20\VB\836236 corrected_21\VBN\138508 by_22\IN\1740 potassium_23\NN\14625458 and_24\CC\1740 <e1>calcium</e1>_25\NN\14625458 supplementation_26\NN\5108947 alone_27\RB\1740 (_28\-LRB-\1740 1,2_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D002118_D013035 NONE while_0\IN\15122231 severe_1\JJ\1740 hypokalemia_2\NN\14299637 may_3\MD\15209706 cause_4\VB\1617192 muscle_5\NN\5289601 weakness_6\NN\14462666 ,_7\,\1740 severe_8\JJ\1740 hypomagnesemia_9\NN\1740 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 <e2>muscle_13\NN\5289601 spasms</e2>_14\NNS\14299637 and_15\CC\1740 tetany_16\NN\14304060 which_17\WDT\1740 can_18\MD\3094503 not_19\RB\1740 be_20\VB\836236 corrected_21\VBN\138508 by_22\IN\1740 potassium_23\NN\14625458 and_24\CC\1740 <e1>calcium</e1>_25\NN\14625458 supplementation_26\NN\5108947 alone_27\RB\1740 (_28\-LRB-\1740 1,2_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D002118_D013746 NONE while_0\IN\15122231 severe_1\JJ\1740 hypokalemia_2\NN\14299637 may_3\MD\15209706 cause_4\VB\1617192 muscle_5\NN\5289601 weakness_6\NN\14462666 ,_7\,\1740 severe_8\JJ\1740 hypomagnesemia_9\NN\1740 is_10\VBZ\836236 associated_11\VBN\628491 with_12\IN\1740 muscle_13\NN\5289601 spasms_14\NNS\14299637 and_15\CC\1740 <e2>tetany</e2>_16\NN\14304060 which_17\WDT\1740 can_18\MD\3094503 not_19\RB\1740 be_20\VB\836236 corrected_21\VBN\138508 by_22\IN\1740 potassium_23\NN\14625458 and_24\CC\1740 <e1>calcium</e1>_25\NN\14625458 supplementation_26\NN\5108947 alone_27\RB\1740 (_28\-LRB-\1740 1,2_29\CD\1740 )_30\-RRB-\1740 ._31\.\1740
D008274_D007008 NONE symptomatic_0\JJ\1740 <e2>hypokalemia</e2>_1\NN\14299637 has_2\VBZ\2108377 been_3\VBN\836236 reported_4\VBN\831651 in_5\IN\13603305 such_6\JJ\1740 patients_7\NNS\9898892 (_8\-LRB-\1740 3_9\CD\13741022 -_10\SYM\1740 7_11\CD\13741022 )_12\-RRB-\1740 and_13\CC\1740 in_14\IN\13603305 one_15\CD\13741022 case_16\NN\7283608 hypocalcemia_17\NN\14299637 was_18\VBD\836236 observed_19\VBN\2163746 (_20\-LRB-\1740 8)_21\CD\1740 ,_22\,\1740 but_23\CC\1740 the_24\DT\1740 effects_25\NNS\13245626 of_26\IN\1740 <e1>magnesium</e1>_27\NN\14625458 depletion_28\NN\351638 were_29\VBD\836236 not_30\RB\1740 noted_31\VBN\1009240 in_32\IN\13603305 these_33\DT\1740 patients_34\NNS\9898892 ._35\.\1740
D008274_D006996 NONE symptomatic_0\JJ\1740 hypokalemia_1\NN\14299637 has_2\VBZ\2108377 been_3\VBN\836236 reported_4\VBN\831651 in_5\IN\13603305 such_6\JJ\1740 patients_7\NNS\9898892 (_8\-LRB-\1740 3_9\CD\13741022 -_10\SYM\1740 7_11\CD\13741022 )_12\-RRB-\1740 and_13\CC\1740 in_14\IN\13603305 one_15\CD\13741022 case_16\NN\7283608 <e2>hypocalcemia</e2>_17\NN\14299637 was_18\VBD\836236 observed_19\VBN\2163746 (_20\-LRB-\1740 8)_21\CD\1740 ,_22\,\1740 but_23\CC\1740 the_24\DT\1740 effects_25\NNS\13245626 of_26\IN\1740 <e1>magnesium</e1>_27\NN\14625458 depletion_28\NN\351638 were_29\VBD\836236 not_30\RB\1740 noted_31\VBN\1009240 in_32\IN\13603305 these_33\DT\1740 patients_34\NNS\9898892 ._35\.\1740
10414674
D007660_D013345 NONE patients_0\NNS\9898892 with_1\IN\1740 <e2>aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage</e2>_4\NN\14285662 (_5\-LRB-\1740 sah_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 <e1>ketoprofen</e1>_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 ketoprofen_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 acetaminophen_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 acetaminophen_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 aneurysmal_58\JJ\1740 sah_59\NN\1740 ._60\.\1740
D007660_D013345 NONE patients_0\NNS\9898892 with_1\IN\1740 aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage_4\NN\14285662 (_5\-LRB-\1740 <e2>sah</e2>_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 <e1>ketoprofen</e1>_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 ketoprofen_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 acetaminophen_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 acetaminophen_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 aneurysmal_58\JJ\1740 sah_59\NN\1740 ._60\.\1740
D007660_D013345 NONE patients_0\NNS\9898892 with_1\IN\1740 aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage_4\NN\14285662 (_5\-LRB-\1740 sah_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 <e1>ketoprofen</e1>_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 ketoprofen_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 acetaminophen_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 acetaminophen_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 aneurysmal_58\JJ\1740 <e2>sah</e2>_59\NN\1740 ._60\.\1740
D007660_D013345 NONE patients_0\NNS\9898892 with_1\IN\1740 <e2>aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage</e2>_4\NN\14285662 (_5\-LRB-\1740 sah_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 ketoprofen_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 <e1>ketoprofen</e1>_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 acetaminophen_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 acetaminophen_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 aneurysmal_58\JJ\1740 sah_59\NN\1740 ._60\.\1740
D007660_D013345 NONE patients_0\NNS\9898892 with_1\IN\1740 aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage_4\NN\14285662 (_5\-LRB-\1740 <e2>sah</e2>_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 ketoprofen_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 <e1>ketoprofen</e1>_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 acetaminophen_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 acetaminophen_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 aneurysmal_58\JJ\1740 sah_59\NN\1740 ._60\.\1740
D007660_D013345 NONE patients_0\NNS\9898892 with_1\IN\1740 aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage_4\NN\14285662 (_5\-LRB-\1740 sah_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 ketoprofen_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 <e1>ketoprofen</e1>_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 acetaminophen_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 acetaminophen_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 aneurysmal_58\JJ\1740 <e2>sah</e2>_59\NN\1740 ._60\.\1740
D007660_D013345 NONE <e1>ketoprofen</e1>_0\NNP\3828465 but_1\CC\1740 not_2\RB\1740 acetaminophen_3\RB\1740 impaired_4\JJ\1740 platelet_5\NN\5432736 function_6\NN\13783581 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 <e2>sah</e2>_10\NN\1740 ._11\.\1740
D007660_D017542 NONE patients_0\NNS\9898892 with_1\IN\1740 aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage_4\NN\14285662 (_5\-LRB-\1740 sah_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 <e1>ketoprofen</e1>_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 ketoprofen_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 acetaminophen_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 acetaminophen_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 <e2>aneurysmal</e2>_58\JJ\1740 sah_59\NN\1740 ._60\.\1740
D007660_D017542 NONE patients_0\NNS\9898892 with_1\IN\1740 aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage_4\NN\14285662 (_5\-LRB-\1740 sah_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 ketoprofen_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 <e1>ketoprofen</e1>_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 acetaminophen_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 acetaminophen_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 <e2>aneurysmal</e2>_58\JJ\1740 sah_59\NN\1740 ._60\.\1740
D000082_D013345 NONE patients_0\NNS\9898892 with_1\IN\1740 <e2>aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage</e2>_4\NN\14285662 (_5\-LRB-\1740 sah_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 ketoprofen_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 ketoprofen_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 <e1>acetaminophen</e1>_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 acetaminophen_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 aneurysmal_58\JJ\1740 sah_59\NN\1740 ._60\.\1740
D000082_D013345 NONE patients_0\NNS\9898892 with_1\IN\1740 aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage_4\NN\14285662 (_5\-LRB-\1740 <e2>sah</e2>_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 ketoprofen_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 ketoprofen_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 <e1>acetaminophen</e1>_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 acetaminophen_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 aneurysmal_58\JJ\1740 sah_59\NN\1740 ._60\.\1740
D000082_D013345 NONE patients_0\NNS\9898892 with_1\IN\1740 aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage_4\NN\14285662 (_5\-LRB-\1740 sah_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 ketoprofen_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 ketoprofen_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 <e1>acetaminophen</e1>_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 acetaminophen_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 aneurysmal_58\JJ\1740 <e2>sah</e2>_59\NN\1740 ._60\.\1740
D000082_D013345 NONE patients_0\NNS\9898892 with_1\IN\1740 <e2>aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage</e2>_4\NN\14285662 (_5\-LRB-\1740 sah_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 ketoprofen_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 ketoprofen_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 acetaminophen_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 <e1>acetaminophen</e1>_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 aneurysmal_58\JJ\1740 sah_59\NN\1740 ._60\.\1740
D000082_D013345 NONE patients_0\NNS\9898892 with_1\IN\1740 aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage_4\NN\14285662 (_5\-LRB-\1740 <e2>sah</e2>_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 ketoprofen_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 ketoprofen_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 acetaminophen_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 <e1>acetaminophen</e1>_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 aneurysmal_58\JJ\1740 sah_59\NN\1740 ._60\.\1740
D000082_D013345 NONE patients_0\NNS\9898892 with_1\IN\1740 aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage_4\NN\14285662 (_5\-LRB-\1740 sah_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 ketoprofen_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 ketoprofen_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 acetaminophen_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 <e1>acetaminophen</e1>_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 aneurysmal_58\JJ\1740 <e2>sah</e2>_59\NN\1740 ._60\.\1740
D000082_D013345 NONE ketoprofen_0\NNP\3828465 but_1\CC\1740 not_2\RB\1740 <e1>acetaminophen</e1>_3\RB\1740 impaired_4\JJ\1740 platelet_5\NN\5432736 function_6\NN\13783581 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 <e2>sah</e2>_10\NN\1740 ._11\.\1740
D000082_D017542 NONE patients_0\NNS\9898892 with_1\IN\1740 aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage_4\NN\14285662 (_5\-LRB-\1740 sah_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 ketoprofen_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 ketoprofen_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 <e1>acetaminophen</e1>_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 acetaminophen_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 <e2>aneurysmal</e2>_58\JJ\1740 sah_59\NN\1740 ._60\.\1740
D000082_D017542 NONE patients_0\NNS\9898892 with_1\IN\1740 aneurysmal_2\JJ\1740 subarachnoid_3\JJ\1740 hemorrhage_4\NN\14285662 (_5\-LRB-\1740 sah_6\NN\1740 )_7\-RRB-\1740 were_8\VBD\836236 randomized_9\VBN\278117 to_10\TO\1740 receive_11\VB\2210855 either_12\CC\1740 ketoprofen_13\NN\3828465 ,_14\,\1740 100_15\CD\13745420 mg_16\NN\13717155 ,_17\,\1740 three_18\CD\13741022 times_19\NNS\15113229 a_20\DT\13649268 day_21\NN\15154774 (_22\-LRB-\1740 ketoprofen_23\NN\3828465 group_24\NN\2137 ,_25\,\1740 n_26\NN\14622893 =_27\JJ\1740 9_28\CD\13741022 )_29\-RRB-\1740 or_30\CC\3541091 a_31\DT\13649268 weak_32\JJ\1740 nsaid_33\NN\2721538 ,_34\,\1740 acetaminophen_35\RB\1740 ,_36\,\1740 1_37\CD\13741022 g_38\NN\13717155 ,_39\,\1740 three_40\CD\13741022 times_41\NNS\15113229 a_42\DT\13649268 day_43\NN\15154774 (_44\-LRB-\1740 <e1>acetaminophen</e1>_45\JJ\1740 group_46\NN\2137 ,_47\,\1740 n_48\NN\14622893 =_49\JJ\1740 9_50\CD\13741022 )_51\-RRB-\1740 starting_52\VBG\2009433 immediately_53\RB\1740 after_54\IN\1740 the_55\DT\1740 diagnosis_56\NN\152018 of_57\IN\1740 <e2>aneurysmal</e2>_58\JJ\1740 sah_59\NN\1740 ._60\.\1740
D000244_D001791 NONE maximal_0\JJ\1740 <e2>platelet_1\NN\5432736 aggregation</e2>_2\NN\31264 induced_3\VBN\1627355 by_4\IN\1740 6_5\CD\13741022 microm_6\NN\1740 of_7\IN\1740 <e1>adenosine_8\NN\14964367 diphosphate</e1>_9\NN\1740 decreased_10\VBD\169651 after_11\IN\1740 administration_12\NN\1133281 of_13\IN\1740 ketoprofen_14\NN\3828465 ._15\.\1740
D007660_D001791 CID maximal_0\JJ\1740 <e2>platelet_1\NN\5432736 aggregation</e2>_2\NN\31264 induced_3\VBN\1627355 by_4\IN\1740 6_5\CD\13741022 microm_6\NN\1740 of_7\IN\1740 adenosine_8\NN\14964367 diphosphate_9\NN\1740 decreased_10\VBD\169651 after_11\IN\1740 administration_12\NN\1133281 of_13\IN\1740 <e1>ketoprofen</e1>_14\NN\3828465 ._15\.\1740
D000082_D001791 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 maximal_3\JJ\1740 <e2>platelet_4\NN\5432736 aggregation</e2>_5\NN\31264 increased_6\VBD\169651 in_7\IN\13603305 the_8\DT\1740 <e1>acetaminophen</e1>_9\NN\2707683 group_10\NN\2137 on_11\IN\1740 the_12\DT\1740 third_13\JJ\1740 postoperative_14\JJ\1740 day_15\NN\15154774 as_16\IN\14622893 compared_17\VBN\644583 with_18\IN\1740 the_19\DT\1740 pretreatment_20\NN\1740 platelet_21\NN\5432736 aggregation_22\NN\31264 results_23\NNS\34213 (_24\-LRB-\1740 p_25\NN\14622893 <_26\XX\1740 .05_27\CD\1740 )_28\-RRB-\1740 ._29\.\1740
D000082_D001791 NONE in_0\IN\13603305 contrast_1\NN\13854649 ,_2\,\1740 maximal_3\JJ\1740 platelet_4\NN\5432736 aggregation_5\NN\31264 increased_6\VBD\169651 in_7\IN\13603305 the_8\DT\1740 <e1>acetaminophen</e1>_9\NN\2707683 group_10\NN\2137 on_11\IN\1740 the_12\DT\1740 third_13\JJ\1740 postoperative_14\JJ\1740 day_15\NN\15154774 as_16\IN\14622893 compared_17\VBN\644583 with_18\IN\1740 the_19\DT\1740 pretreatment_20\NN\1740 <e2>platelet_21\NN\5432736 aggregation</e2>_22\NN\31264 results_23\NNS\34213 (_24\-LRB-\1740 p_25\NN\14622893 <_26\XX\1740 .05_27\CD\1740 )_28\-RRB-\1740 ._29\.\1740
D007660_D006406 CID one_0\CD\13741022 patient_1\NN\9898892 in_2\IN\13603305 the_3\DT\1740 <e1>ketoprofen</e1>_4\NN\3828465 group_5\NN\2137 developed_6\VBD\1753788 a_7\DT\13649268 postoperative_8\JJ\1740 intracranial_9\JJ\1740 <e2>hematoma</e2>_10\NN\14317720 ._11\.\1740
D007660_D002532 NONE if_0\IN\1740 <e1>ketoprofen</e1>_1\NN\3828465 is_2\VBZ\836236 used_3\VBN\1156834 before_4\IN\1740 surgery_5\NN\6045562 on_6\IN\1740 cerebral_7\JJ\1740 <e2>artery_8\NN\5417975 aneurysms</e2>_9\NNS\14057371 ,_10\,\1740 it_11\PRP\6125041 may_12\MD\15209706 pose_13\VB\2620587 an_14\DT\6697703 additional_15\JJ\1740 risk_16\NN\14541044 factor_17\NN\7326557 for_18\IN\1740 hemorrhage_19\NN\14285662 ._20\.\1740
D007660_D006470 NONE if_0\IN\1740 <e1>ketoprofen</e1>_1\NN\3828465 is_2\VBZ\836236 used_3\VBN\1156834 before_4\IN\1740 surgery_5\NN\6045562 on_6\IN\1740 cerebral_7\JJ\1740 artery_8\NN\5417975 aneurysms_9\NNS\14057371 ,_10\,\1740 it_11\PRP\6125041 may_12\MD\15209706 pose_13\VB\2620587 an_14\DT\6697703 additional_15\JJ\1740 risk_16\NN\14541044 factor_17\NN\7326557 for_18\IN\1740 <e2>hemorrhage</e2>_19\NN\14285662 ._20\.\1740
8643966
D017239_D002289 NONE chemotherapy_0\NN\661091 of_1\IN\1740 advanced_2\JJ\1740 inoperable_3\JJ\1740 <e2>non-small_4\JJ\1740 cell_5\NN\3080309 lung_6\NN\5528060 cancer</e2>_7\NN\14239425 with_8\IN\1740 <e1>paclitaxel</e1>_9\NN\1740 :_10\:\1740 a_11\DT\13649268 phase_12\NN\15113229 ii_13\CD\13741022 trial_14\NN\786195 ._15\.\1740
D017239_D002289 NONE two_0\CD\13741022 phase_1\NN\15113229 ii_2\CD\13741022 trials_3\NNS\786195 of_4\IN\1740 24-hour_5\JJ\1740 <e1>paclitaxel</e1>_6\NN\1740 infusions_7\NNS\14589223 in_8\IN\13603305 chemotherapy-naive_9\JJ\1740 patients_10\NNS\9898892 with_11\IN\1740 stage_12\NN\15113229 iiib_13\NN\1740 or_14\CC\3541091 iv_15\CD\13741022 <e2>non-small_16\JJ\1740 cell_17\NN\3080309 lung_18\NN\5528060 cancer</e2>_19\NN\14239425 (_20\-LRB-\1740 nsclc_21\NN\1740 )_22\-RRB-\1740 reported_23\VBD\831651 response_24\NN\11410625 rates_25\NNS\13308999 of_26\IN\1740 21_27\CD\13745420 %_28\NN\1740 and_29\CC\1740 24_30\CD\13745420 %_31\NN\1740 ._32\.\1740
D017239_D002289 NONE two_0\CD\13741022 phase_1\NN\15113229 ii_2\CD\13741022 trials_3\NNS\786195 of_4\IN\1740 24-hour_5\JJ\1740 <e1>paclitaxel</e1>_6\NN\1740 infusions_7\NNS\14589223 in_8\IN\13603305 chemotherapy-naive_9\JJ\1740 patients_10\NNS\9898892 with_11\IN\1740 stage_12\NN\15113229 iiib_13\NN\1740 or_14\CC\3541091 iv_15\CD\13741022 non-small_16\JJ\1740 cell_17\NN\3080309 lung_18\NN\5528060 cancer_19\NN\14239425 (_20\-LRB-\1740 <e2>nsclc</e2>_21\NN\1740 )_22\-RRB-\1740 reported_23\VBD\831651 response_24\NN\11410625 rates_25\NNS\13308999 of_26\IN\1740 21_27\CD\13745420 %_28\NN\1740 and_29\CC\1740 24_30\CD\13745420 %_31\NN\1740 ._32\.\1740
D017239_D002289 NONE we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 efficacy_3\NN\5199286 and_4\CC\1740 toxicity_5\NN\13576101 of_6\IN\1740 a_7\DT\13649268 3-hour_8\CD\1740 <e1>paclitaxel</e1>_9\NN\1740 infusion_10\NN\14589223 in_11\IN\13603305 a_12\DT\13649268 phase_13\NN\15113229 ii_14\CD\13741022 trial_15\NN\786195 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 inoperable_19\JJ\1740 stage_20\NN\15113229 iiib_21\NN\1740 or_22\CC\3541091 iv_23\CD\13741022 <e2>nsclc</e2>_24\NN\1740 ._25\.\1740
D017239_D002289 NONE further_0\JJ\1740 phase_1\NN\15113229 ii_2\CD\13741022 studies_3\NNS\635850 with_4\IN\1740 <e1>paclitaxel</e1>_5\NN\1740 combined_6\VBN\2630189 with_7\IN\1740 other_8\JJ\1740 drugs_9\NNS\14778436 active_10\JJ\1740 against_11\IN\1740 <e2>nsclc</e2>_12\NN\1740 are_13\VBP\836236 indicated_14\VBN\952524 ,_15\,\1740 and_16\CC\1740 phase_17\NN\15113229 iii_18\CD\13741022 studies_19\NNS\635850 comparing_20\VBG\644583 paclitaxel_21\NN\1740 with_22\IN\1740 standard_23\JJ\1740 chemotherapy_24\NN\661091 remain_25\VBP\2604760 to_26\TO\1740 be_27\VB\836236 completed_28\VBN\352826 ._29\.\1740
D017239_D002289 NONE further_0\JJ\1740 phase_1\NN\15113229 ii_2\CD\13741022 studies_3\NNS\635850 with_4\IN\1740 paclitaxel_5\NN\1740 combined_6\VBN\2630189 with_7\IN\1740 other_8\JJ\1740 drugs_9\NNS\14778436 active_10\JJ\1740 against_11\IN\1740 <e2>nsclc</e2>_12\NN\1740 are_13\VBP\836236 indicated_14\VBN\952524 ,_15\,\1740 and_16\CC\1740 phase_17\NN\15113229 iii_18\CD\13741022 studies_19\NNS\635850 comparing_20\VBG\644583 <e1>paclitaxel</e1>_21\NN\1740 with_22\IN\1740 standard_23\JJ\1740 chemotherapy_24\NN\661091 remain_25\VBP\2604760 to_26\TO\1740 be_27\VB\836236 completed_28\VBN\352826 ._29\.\1740
D017239_D009369 NONE <e1>paclitaxel</e1>_0\NN\1740 (_1\-LRB-\1740 taxol_2\NNP\1740 ;_3\:\1740 bristol-myers_4\NNP\1740 squibb_5\NNP\1740 company_6\NNP\8053576 ,_7\,\1740 princeton_8\NNP\1740 ,_9\,\1740 nj_10\NNP\1740 )_11\-RRB-\1740 has_12\VBZ\2108377 demonstrated_13\VBN\2137132 significant_14\JJ\1740 antineoplastic_15\JJ\1740 activity_16\NN\30358 against_17\IN\1740 different_18\JJ\1740 <e2>tumor</e2>_19\NN\14234074 types_20\NNS\5839024 ,_21\,\1740 notably_22\RB\1740 ovarian_23\JJ\1740 and_24\CC\1740 breast_25\NN\5225090 carcinoma_26\NN\14239918 ._27\.\1740
D017239_D009369 NONE paclitaxel_0\NN\1740 (_1\-LRB-\1740 <e1>taxol</e1>_2\NNP\1740 ;_3\:\1740 bristol-myers_4\NNP\1740 squibb_5\NNP\1740 company_6\NNP\8053576 ,_7\,\1740 princeton_8\NNP\1740 ,_9\,\1740 nj_10\NNP\1740 )_11\-RRB-\1740 has_12\VBZ\2108377 demonstrated_13\VBN\2137132 significant_14\JJ\1740 antineoplastic_15\JJ\1740 activity_16\NN\30358 against_17\IN\1740 different_18\JJ\1740 <e2>tumor</e2>_19\NN\14234074 types_20\NNS\5839024 ,_21\,\1740 notably_22\RB\1740 ovarian_23\JJ\1740 and_24\CC\1740 breast_25\NN\5225090 carcinoma_26\NN\14239918 ._27\.\1740
D017239_D010051 NONE <e1>paclitaxel</e1>_0\NN\1740 (_1\-LRB-\1740 taxol_2\NNP\1740 ;_3\:\1740 bristol-myers_4\NNP\1740 squibb_5\NNP\1740 company_6\NNP\8053576 ,_7\,\1740 princeton_8\NNP\1740 ,_9\,\1740 nj_10\NNP\1740 )_11\-RRB-\1740 has_12\VBZ\2108377 demonstrated_13\VBN\2137132 significant_14\JJ\1740 antineoplastic_15\JJ\1740 activity_16\NN\30358 against_17\IN\1740 different_18\JJ\1740 tumor_19\NN\14234074 types_20\NNS\5839024 ,_21\,\1740 notably_22\RB\1740 <e2>ovarian_23\JJ\1740 and_24\CC\1740 breast_25\NN\5225090 carcinoma</e2>_26\NN\14239918 ._27\.\1740
D017239_D010051 NONE paclitaxel_0\NN\1740 (_1\-LRB-\1740 <e1>taxol</e1>_2\NNP\1740 ;_3\:\1740 bristol-myers_4\NNP\1740 squibb_5\NNP\1740 company_6\NNP\8053576 ,_7\,\1740 princeton_8\NNP\1740 ,_9\,\1740 nj_10\NNP\1740 )_11\-RRB-\1740 has_12\VBZ\2108377 demonstrated_13\VBN\2137132 significant_14\JJ\1740 antineoplastic_15\JJ\1740 activity_16\NN\30358 against_17\IN\1740 different_18\JJ\1740 tumor_19\NN\14234074 types_20\NNS\5839024 ,_21\,\1740 notably_22\RB\1740 <e2>ovarian_23\JJ\1740 and_24\CC\1740 breast_25\NN\5225090 carcinoma</e2>_26\NN\14239918 ._27\.\1740
D017239_D001943 NONE <e1>paclitaxel</e1>_0\NN\1740 (_1\-LRB-\1740 taxol_2\NNP\1740 ;_3\:\1740 bristol-myers_4\NNP\1740 squibb_5\NNP\1740 company_6\NNP\8053576 ,_7\,\1740 princeton_8\NNP\1740 ,_9\,\1740 nj_10\NNP\1740 )_11\-RRB-\1740 has_12\VBZ\2108377 demonstrated_13\VBN\2137132 significant_14\JJ\1740 antineoplastic_15\JJ\1740 activity_16\NN\30358 against_17\IN\1740 different_18\JJ\1740 tumor_19\NN\14234074 types_20\NNS\5839024 ,_21\,\1740 notably_22\RB\1740 <e2>ovarian_23\JJ\1740 and_24\CC\1740 breast_25\NN\5225090 carcinoma</e2>_26\NN\14239918 ._27\.\1740
D017239_D001943 NONE paclitaxel_0\NN\1740 (_1\-LRB-\1740 <e1>taxol</e1>_2\NNP\1740 ;_3\:\1740 bristol-myers_4\NNP\1740 squibb_5\NNP\1740 company_6\NNP\8053576 ,_7\,\1740 princeton_8\NNP\1740 ,_9\,\1740 nj_10\NNP\1740 )_11\-RRB-\1740 has_12\VBZ\2108377 demonstrated_13\VBN\2137132 significant_14\JJ\1740 antineoplastic_15\JJ\1740 activity_16\NN\30358 against_17\IN\1740 different_18\JJ\1740 tumor_19\NN\14234074 types_20\NNS\5839024 ,_21\,\1740 notably_22\RB\1740 <e2>ovarian_23\JJ\1740 and_24\CC\1740 breast_25\NN\5225090 carcinoma</e2>_26\NN\14239918 ._27\.\1740
D017239_D064420 NONE we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 efficacy_3\NN\5199286 and_4\CC\1740 <e2>toxicity</e2>_5\NN\13576101 of_6\IN\1740 a_7\DT\13649268 3-hour_8\CD\1740 <e1>paclitaxel</e1>_9\NN\1740 infusion_10\NN\14589223 in_11\IN\13603305 a_12\DT\13649268 phase_13\NN\15113229 ii_14\CD\13741022 trial_15\NN\786195 in_16\IN\13603305 patients_17\NNS\9898892 with_18\IN\1740 inoperable_19\JJ\1740 stage_20\NN\15113229 iiib_21\NN\1740 or_22\CC\3541091 iv_23\CD\13741022 nsclc_24\NN\1740 ._25\.\1740
D017239_D064420 NONE <e1>paclitaxel</e1>_0\NN\1740 is_1\VBZ\836236 thus_2\RB\1740 an_3\DT\6697703 active_4\JJ\1740 single_5\JJ\1740 agent_6\NN\7347 in_7\IN\13603305 this_8\DT\1740 patient_9\NN\9898892 population_10\NN\7942152 ,_11\,\1740 with_12\IN\1740 a_13\DT\13649268 3-hour_14\NN\1740 infusion_15\NN\14589223 proving_16\VBG\2604760 comparably_17\RB\1740 effective_18\JJ\1740 to_19\TO\1740 a_20\DT\13649268 24-hour_21\JJ\1740 infusion_22\NN\14589223 and_23\CC\1740 superior_24\JJ\1740 in_25\IN\13603305 terms_26\NNS\13945919 of_27\IN\1740 the_28\DT\1740 incidence_29\NN\13821570 of_30\IN\1740 hematologic_31\JJ\1740 and_32\CC\1740 nonhematologic_33\JJ\1740 <e2>toxicity</e2>_34\NN\13576101 ._35\.\1740
9041081
D013256_D009798 NONE during_0\IN\1740 the_1\DT\1740 follow-up_2\NN\4599396 ,_3\,\1740 3_4\CD\13741022 patients_5\NNS\9898892 (_6\-LRB-\1740 12_7\CD\13745420 %_8\NN\1740 )_9\-RRB-\1740 developed_10\VBD\1753788 <e1>steroid-induced</e1>_11\JJ\1740 <e2>elevated_12\JJ\1740 intraocular_13\JJ\1740 pressure</e2>_14\NN\11419404 (_15\-LRB-\1740 iop_16\NNS\11495041 )_17\-RRB-\1740 that_18\WDT\1740 resolved_19\VBN\352826 after_20\IN\1740 corticosteroid_21\NN\14745635 therapy_22\NN\657604 was_23\VBD\836236 discontinued_24\VBN\2609764 ._25\.\1740
D013256_D009798 NONE the_0\DT\1740 transient_1\JJ\1740 <e1>steroid-induced</e1>_2\JJ\1740 <e2>iop_3\NN\11495041 rise</e2>_4\NN\7324673 did_5\VBD\1640855 not_6\RB\1740 seem_7\VB\2604760 to_8\TO\1740 cause_9\VB\1617192 functional_10\JJ\1740 impairment_11\NN\7296428 ._12\.\1740
D000305_D009798 CID during_0\IN\1740 the_1\DT\1740 follow-up_2\NN\4599396 ,_3\,\1740 3_4\CD\13741022 patients_5\NNS\9898892 (_6\-LRB-\1740 12_7\CD\13745420 %_8\NN\1740 )_9\-RRB-\1740 developed_10\VBD\1753788 steroid-induced_11\JJ\1740 <e2>elevated_12\JJ\1740 intraocular_13\JJ\1740 pressure</e2>_14\NN\11419404 (_15\-LRB-\1740 iop_16\NNS\11495041 )_17\-RRB-\1740 that_18\WDT\1740 resolved_19\VBN\352826 after_20\IN\1740 <e1>corticosteroid</e1>_21\NN\14745635 therapy_22\NN\657604 was_23\VBD\836236 discontinued_24\VBN\2609764 ._25\.\1740
16710500
D004977_D009901 CID <e1>ethambutol-associated</e1>_0\JJ\1740 <e2>optic_1\NN\5299178 neuropathy</e2>_2\JJ\1740 ._3\.\1740
D004977_D009901 CID clinical_0\NN\1740 picture_1\NN\4076846 :_2\:\1740 three_3\CD\13741022 patients_4\NNS\9898892 with_5\IN\1740 <e1>ethambutol-associated</e1>_6\JJ\1740 toxic_7\JJ\1740 <e2>optic_8\JJ\1740 neuropathy</e2>_9\NN\14204950 are_10\VBP\836236 described_11\VBN\1001294 ._12\.\1740
D004977_D014376 NONE introduction_0\NNP\235435 :_1\:\1740 <e1>ethambutol</e1>_2\NNP\1740 is_3\VBZ\836236 used_4\VBN\1156834 in_5\IN\13603305 the_6\DT\1740 treatment_7\NN\654885 of_8\IN\1740 <e2>tuberculosis</e2>_9\NN\14127211 ,_10\,\1740 which_11\WDT\1740 is_12\VBZ\836236 still_13\RB\1740 prevalent_14\JJ\1740 in_15\IN\13603305 southeast_16\NNP\13830305 asia_17\NNP\7951464 ,_18\,\1740 and_19\CC\1740 can_20\MD\3094503 be_21\VB\836236 associated_22\VBN\628491 with_23\IN\1740 permanent_24\JJ\1740 visual_25\JJ\1740 loss_26\NN\13252973 ._27\.\1740
D004977_D014786 CID introduction_0\NNP\235435 :_1\:\1740 <e1>ethambutol</e1>_2\NNP\1740 is_3\VBZ\836236 used_4\VBN\1156834 in_5\IN\13603305 the_6\DT\1740 treatment_7\NN\654885 of_8\IN\1740 tuberculosis_9\NN\14127211 ,_10\,\1740 which_11\WDT\1740 is_12\VBZ\836236 still_13\RB\1740 prevalent_14\JJ\1740 in_15\IN\13603305 southeast_16\NNP\13830305 asia_17\NNP\7951464 ,_18\,\1740 and_19\CC\1740 can_20\MD\3094503 be_21\VB\836236 associated_22\VBN\628491 with_23\IN\1740 permanent_24\JJ\1740 <e2>visual_25\JJ\1740 loss</e2>_26\NN\13252973 ._27\.\1740
D004977_D014786 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>ethambutol</e1>_2\JJ\1740 usage_3\NN\407535 is_4\VBZ\836236 associated_5\VBN\628491 with_6\IN\1740 permanent_7\JJ\1740 <e2>visual_8\JJ\1740 loss</e2>_9\NN\13252973 and_10\CC\1740 should_11\MD\1740 be_12\VB\836236 avoided_13\VBN\2452885 if_14\IN\1740 possible_15\JJ\1740 or_16\CC\3541091 used_17\VBN\1156834 with_18\IN\1740 caution_19\NN\4662951 and_20\CC\1740 proper_21\JJ\1740 ophthalmological_22\JJ\1740 follow-up_23\NN\4599396 ._24\.\1740
12093990
D012254_D000257 NONE intravenous_0\JJ\1740 <e1>ribavirin</e1>_1\NN\2725367 treatment_2\NN\654885 for_3\IN\1740 severe_4\JJ\1740 <e2>adenovirus_5\NN\1335659 disease</e2>_6\NN\14061805 in_7\IN\13603305 immunocompromised_8\VBN\1740 children_9\NNS\9622049 ._10\.\1740
D012254_D000257 NONE objective_0\NN\5980875 :_1\:\1740 we_2\PRP\1740 report_3\VBP\831651 our_4\PRP$\1740 experience_5\NN\5984287 with_6\IN\1740 intravenous_7\JJ\1740 <e1>ribavirin</e1>_8\NN\2725367 therapy_9\NN\657604 for_10\IN\1740 severe_11\JJ\1740 <e2>adenovirus_12\NN\1335659 disease</e2>_13\NN\14061805 in_14\IN\13603305 a_15\DT\13649268 series_16\NN\8456993 of_17\IN\1740 immunocompromised_18\VBN\1740 children_19\NNS\9622049 and_20\CC\1740 review_21\VB\644583 the_22\DT\1740 literature_23\NN\6362953 ._24\.\1740
D012254_D000257 NONE design/methods_0\PRP\1740 :_1\:\1740 we_2\PRP\1740 retrospectively_3\RB\1740 reviewed_4\VBD\644583 the_5\DT\1740 medical_6\JJ\1740 records_7\NNS\6643408 of_8\IN\1740 5_9\CD\13741022 children_10\NNS\9622049 treated_11\VBN\2376958 with_12\IN\1740 intravenous_13\JJ\1740 <e1>ribavirin</e1>_14\NN\2725367 for_15\IN\1740 documented_16\VBN\1000214 severe_17\JJ\1740 <e2>adenovirus_18\NN\1335659 disease</e2>_19\NN\14061805 ._20\.\1740
D012254_D000257 NONE although_0\IN\1740 intravenous_1\JJ\1740 <e1>ribavirin</e1>_2\NN\2725367 was_3\VBD\836236 not_4\RB\1740 effective_5\JJ\1740 for_6\IN\1740 all_7\DT\1740 children_8\NNS\9622049 with_9\IN\1740 severe_10\JJ\1740 <e2>adenovirus_11\NN\1335659 disease</e2>_12\NN\14061805 in_13\IN\13603305 this_14\DT\1740 series_15\NN\8456993 or_16\CC\3541091 in_17\IN\13603305 the_18\DT\1740 literature_19\NN\6362953 ,_20\,\1740 therapy_21\NN\657604 is_22\VBZ\836236 unlikely_23\JJ\1740 to_24\TO\1740 be_25\VB\836236 of_26\IN\1740 benefit_27\NN\13278375 if_28\IN\1740 begun_29\VBN\941990 late_30\RB\1740 in_31\IN\13603305 the_32\DT\1740 course_33\NN\883297 of_34\IN\1740 the_35\DT\1740 infection_36\NN\14052046 ._37\.\1740
D012254_D000257 NONE conclusions_0\NNS\5837957 :_1\:\1740 two_2\CD\13741022 of_3\IN\1740 5_4\CD\13741022 children_5\NNS\9622049 with_6\IN\1740 severe_7\JJ\1740 <e2>adenovirus_8\NN\1335659 disease</e2>_9\NN\14061805 treated_10\VBN\2376958 with_11\IN\1740 intravenous_12\JJ\1740 <e1>ribavirin</e1>_13\NN\2725367 recovered_14\VBN\2210855 ._15\.\1740
D012254_D000257 NONE given_0\VBN\2327200 the_1\DT\1740 seriousness_2\JJ\1740 and_3\CC\1740 increasing_4\VBG\169651 prevalence_5\NN\4764412 of_6\IN\1740 <e2>adenovirus_7\NN\1335659 disease</e2>_8\NN\14061805 in_9\IN\13603305 certain_10\JJ\1740 hosts_11\NNS\9605289 ,_12\,\1740 especially_13\RB\1740 children_14\NNS\9622049 ,_15\,\1740 a_16\DT\13649268 large_17\JJ\1740 ,_18\,\1740 multicenter_19\NN\1740 clinical_20\JJ\1740 trial_21\NN\786195 of_22\IN\1740 potentially_23\RB\1740 useful_24\JJ\1740 anti-adenoviral_25\JJ\1740 therapies_26\NNS\657604 ,_27\,\1740 such_28\JJ\1740 as_29\IN\14622893 intravenous_30\JJ\1740 <e1>ribavirin</e1>_31\NN\2725367 ,_32\,\1740 is_33\VBZ\836236 clearly_34\RB\1740 required_35\VBN\754942 to_36\TO\1740 demonstrate_37\VB\2137132 the_38\DT\1740 most_39\RBS\1740 effective_40\JJ\1740 and_41\CC\1740 least_42\JJS\1740 toxic_43\JJ\1740 therapy_44\NN\657604 ._45\.\1740
D012254_D018357 NONE <e1>ribavirin</e1>_0\NN\2725367 is_1\VBZ\836236 licensed_2\VBN\803325 in_3\IN\13603305 aerosol_4\NN\11439690 form_5\NN\6286395 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 <e2>respiratory_10\JJ\1740 syncytial_11\JJ\1740 virus_12\NN\9312843 infection</e2>_13\NN\14052046 ,_14\,\1740 and_15\CC\1740 orally_16\RB\1740 in_17\IN\13603305 combination_18\NN\7951464 with_19\IN\1740 interferon_20\NN\2725367 to_21\TO\1740 treat_22\VB\2376958 hepatitis_23\NN\14127211 c._24\NN\1740 intravenous_25\JJ\1740 ribavirin_26\NN\2725367 is_27\VBZ\836236 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 choice_31\NN\5788149 for_32\IN\1740 infection_33\NN\14052046 with_34\IN\1740 hemorrhagic_35\JJ\1740 fever_36\NN\14299637 viruses_37\NNS\9312843 ._38\.\1740
D012254_D018357 NONE ribavirin_0\NN\2725367 is_1\VBZ\836236 licensed_2\VBN\803325 in_3\IN\13603305 aerosol_4\NN\11439690 form_5\NN\6286395 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 <e2>respiratory_10\JJ\1740 syncytial_11\JJ\1740 virus_12\NN\9312843 infection</e2>_13\NN\14052046 ,_14\,\1740 and_15\CC\1740 orally_16\RB\1740 in_17\IN\13603305 combination_18\NN\7951464 with_19\IN\1740 interferon_20\NN\2725367 to_21\TO\1740 treat_22\VB\2376958 hepatitis_23\NN\14127211 c._24\NN\1740 intravenous_25\JJ\1740 <e1>ribavirin</e1>_26\NN\2725367 is_27\VBZ\836236 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 choice_31\NN\5788149 for_32\IN\1740 infection_33\NN\14052046 with_34\IN\1740 hemorrhagic_35\JJ\1740 fever_36\NN\14299637 viruses_37\NNS\9312843 ._38\.\1740
D012254_D006526 NONE <e1>ribavirin</e1>_0\NN\2725367 is_1\VBZ\836236 licensed_2\VBN\803325 in_3\IN\13603305 aerosol_4\NN\11439690 form_5\NN\6286395 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 respiratory_10\JJ\1740 syncytial_11\JJ\1740 virus_12\NN\9312843 infection_13\NN\14052046 ,_14\,\1740 and_15\CC\1740 orally_16\RB\1740 in_17\IN\13603305 combination_18\NN\7951464 with_19\IN\1740 interferon_20\NN\2725367 to_21\TO\1740 treat_22\VB\2376958 <e2>hepatitis_23\NN\14127211 c.</e2>_24\NN\1740 intravenous_25\JJ\1740 ribavirin_26\NN\2725367 is_27\VBZ\836236 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 choice_31\NN\5788149 for_32\IN\1740 infection_33\NN\14052046 with_34\IN\1740 hemorrhagic_35\JJ\1740 fever_36\NN\14299637 viruses_37\NNS\9312843 ._38\.\1740
D012254_D006526 NONE ribavirin_0\NN\2725367 is_1\VBZ\836236 licensed_2\VBN\803325 in_3\IN\13603305 aerosol_4\NN\11439690 form_5\NN\6286395 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 respiratory_10\JJ\1740 syncytial_11\JJ\1740 virus_12\NN\9312843 infection_13\NN\14052046 ,_14\,\1740 and_15\CC\1740 orally_16\RB\1740 in_17\IN\13603305 combination_18\NN\7951464 with_19\IN\1740 interferon_20\NN\2725367 to_21\TO\1740 treat_22\VB\2376958 <e2>hepatitis_23\NN\14127211 c.</e2>_24\NN\1740 intravenous_25\JJ\1740 <e1>ribavirin</e1>_26\NN\2725367 is_27\VBZ\836236 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 choice_31\NN\5788149 for_32\IN\1740 infection_33\NN\14052046 with_34\IN\1740 hemorrhagic_35\JJ\1740 fever_36\NN\14299637 viruses_37\NNS\9312843 ._38\.\1740
D012254_D006482 NONE <e1>ribavirin</e1>_0\NN\2725367 is_1\VBZ\836236 licensed_2\VBN\803325 in_3\IN\13603305 aerosol_4\NN\11439690 form_5\NN\6286395 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 respiratory_10\JJ\1740 syncytial_11\JJ\1740 virus_12\NN\9312843 infection_13\NN\14052046 ,_14\,\1740 and_15\CC\1740 orally_16\RB\1740 in_17\IN\13603305 combination_18\NN\7951464 with_19\IN\1740 interferon_20\NN\2725367 to_21\TO\1740 treat_22\VB\2376958 hepatitis_23\NN\14127211 c._24\NN\1740 intravenous_25\JJ\1740 ribavirin_26\NN\2725367 is_27\VBZ\836236 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 choice_31\NN\5788149 for_32\IN\1740 <e2>infection_33\NN\14052046 with_34\IN\1740 hemorrhagic_35\JJ\1740 fever_36\NN\14299637 viruses</e2>_37\NNS\9312843 ._38\.\1740
D012254_D006482 NONE ribavirin_0\NN\2725367 is_1\VBZ\836236 licensed_2\VBN\803325 in_3\IN\13603305 aerosol_4\NN\11439690 form_5\NN\6286395 for_6\IN\1740 the_7\DT\1740 treatment_8\NN\654885 of_9\IN\1740 respiratory_10\JJ\1740 syncytial_11\JJ\1740 virus_12\NN\9312843 infection_13\NN\14052046 ,_14\,\1740 and_15\CC\1740 orally_16\RB\1740 in_17\IN\13603305 combination_18\NN\7951464 with_19\IN\1740 interferon_20\NN\2725367 to_21\TO\1740 treat_22\VB\2376958 hepatitis_23\NN\14127211 c._24\NN\1740 intravenous_25\JJ\1740 <e1>ribavirin</e1>_26\NN\2725367 is_27\VBZ\836236 the_28\DT\1740 treatment_29\NN\654885 of_30\IN\1740 choice_31\NN\5788149 for_32\IN\1740 <e2>infection_33\NN\14052046 with_34\IN\1740 hemorrhagic_35\JJ\1740 fever_36\NN\14299637 viruses</e2>_37\NNS\9312843 ._38\.\1740
D012254_D000740 NONE the_0\DT\1740 most_1\RBS\1740 common_2\JJ\1740 adverse_3\JJ\1740 effect_4\NN\34213 of_5\IN\1740 intravenous_6\JJ\1740 <e1>ribavirin</e1>_7\NN\2725367 is_8\VBZ\836236 reversible_9\JJ\1740 mild_10\JJ\1740 <e2>anemia</e2>_11\NN\14189204 ._12\.\1740
C059262_D000257 NONE the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 <e1>cidofovir</e1>_3\NN\1740 in_4\IN\13603305 severe_5\JJ\1740 <e2>adenovirus_6\NN\1335659 infection</e2>_7\NN\14052046 has_8\VBZ\2108377 been_9\VBN\836236 limited_10\VBN\2510337 by_11\IN\1740 adverse_12\JJ\1740 effects_13\NNS\13245626 ,_14\,\1740 the_15\DT\1740 most_16\RBS\1740 significant_17\JJ\1740 of_18\IN\1740 which_19\WDT\1740 is_20\VBZ\836236 nephrotoxicity_21\NN\1740 ._22\.\1740
C059262_D007674 NONE the_0\DT\1740 use_1\NN\407535 of_2\IN\1740 <e1>cidofovir</e1>_3\NN\1740 in_4\IN\13603305 severe_5\JJ\1740 adenovirus_6\NN\1335659 infection_7\NN\14052046 has_8\VBZ\2108377 been_9\VBN\836236 limited_10\VBN\2510337 by_11\IN\1740 adverse_12\JJ\1740 effects_13\NNS\13245626 ,_14\,\1740 the_15\DT\1740 most_16\RBS\1740 significant_17\JJ\1740 of_18\IN\1740 which_19\WDT\1740 is_20\VBZ\836236 <e2>nephrotoxicity</e2>_21\NN\1740 ._22\.\1740
C059262_D058186 CID use_0\NN\407535 of_1\IN\1740 <e1>cidofovir</e1>_2\NN\1740 in_3\IN\13603305 1_4\CD\13741022 child_5\NN\9622049 was_6\VBD\836236 associated_7\VBN\628491 with_8\IN\1740 <e2>progressive_9\JJ\1740 renal_10\JJ\1740 failure</e2>_11\NN\66216 and_12\CC\1740 neutropenia_13\NN\14196405 ._14\.\1740
C059262_D009503 CID use_0\NN\407535 of_1\IN\1740 <e1>cidofovir</e1>_2\NN\1740 in_3\IN\13603305 1_4\CD\13741022 child_5\NN\9622049 was_6\VBD\836236 associated_7\VBN\628491 with_8\IN\1740 progressive_9\JJ\1740 renal_10\JJ\1740 failure_11\NN\66216 and_12\CC\1740 <e2>neutropenia</e2>_13\NN\14196405 ._14\.\1740
D012254_D007239 NONE although_0\IN\1740 intravenous_1\JJ\1740 <e1>ribavirin</e1>_2\NN\2725367 was_3\VBD\836236 not_4\RB\1740 effective_5\JJ\1740 for_6\IN\1740 all_7\DT\1740 children_8\NNS\9622049 with_9\IN\1740 severe_10\JJ\1740 adenovirus_11\NN\1335659 disease_12\NN\14061805 in_13\IN\13603305 this_14\DT\1740 series_15\NN\8456993 or_16\CC\3541091 in_17\IN\13603305 the_18\DT\1740 literature_19\NN\6362953 ,_20\,\1740 therapy_21\NN\657604 is_22\VBZ\836236 unlikely_23\JJ\1740 to_24\TO\1740 be_25\VB\836236 of_26\IN\1740 benefit_27\NN\13278375 if_28\IN\1740 begun_29\VBN\941990 late_30\RB\1740 in_31\IN\13603305 the_32\DT\1740 course_33\NN\883297 of_34\IN\1740 the_35\DT\1740 <e2>infection</e2>_36\NN\14052046 ._37\.\1740
17049862
D010672_D007035 NONE is_0\VBZ\836236 <e1>phenytoin</e1>_1\NN\3550533 administration_2\NN\1133281 safe_3\JJ\1740 in_4\IN\13603305 a_5\DT\13649268 <e2>hypothermic</e2>_6\JJ\1740 child_7\NN\9622049 ?_8\.\1740
D010672_D007035 NONE the_0\DT\1740 cardiac_1\JJ\1740 depressant_2\JJ\1740 actions_3\NNS\30358 of_4\IN\1740 <e1>phenytoin</e1>_5\NN\3550533 and_6\CC\1740 <e2>hypothermia</e2>_7\NN\14034177 can_8\MD\3094503 be_9\VB\836236 additive_10\JJ\1740 ._11\.\1740
D010672_D007035 NONE administration_0\NN\1133281 of_1\IN\1740 <e1>phenytoin</e1>_2\NN\3550533 in_3\IN\13603305 the_4\DT\1740 presence_5\NN\13954253 of_6\IN\1740 <e2>hypothermia</e2>_7\NN\14034177 may_8\MD\15209706 lead_9\VB\1752884 to_10\TO\1740 an_11\DT\6697703 adverse_12\JJ\1740 cardiac_13\JJ\1740 event_14\NN\23100 in_15\IN\13603305 children_16\NNS\9622049 ._17\.\1740
D010672_D012640 NONE intravenous_0\JJ\1740 <e1>phenytoin</e1>_1\NN\3550533 was_2\VBD\836236 administered_3\VBN\2436349 during_4\IN\1740 the_5\DT\1740 later_6\JJ\1740 part_7\NN\31921 of_8\IN\1740 the_9\DT\1740 surgery_10\NN\6045562 for_11\IN\1740 <e2>seizure</e2>_12\JJ\1740 prophylaxis_13\NN\1077350 ._14\.\1740
D010672_D001919 CID following_0\VBG\1835496 <e1>phenytoin</e1>_1\NN\3550533 administration_2\NN\1133281 ,_3\,\1740 the_4\DT\1740 patient_5\NN\9898892 developed_6\VBD\1753788 acute_7\JJ\1740 severe_8\JJ\1740 <e2>bradycardia</e2>_9\NN\14110674 ,_10\,\1740 refractory_11\JJ\1740 to_12\TO\1740 atropine_13\NN\14712692 and_14\CC\1740 adrenaline_15\NN\14807929 ._16\.\1740
D001285_D001919 NONE following_0\VBG\1835496 phenytoin_1\NN\3550533 administration_2\NN\1133281 ,_3\,\1740 the_4\DT\1740 patient_5\NN\9898892 developed_6\VBD\1753788 acute_7\JJ\1740 severe_8\JJ\1740 <e2>bradycardia</e2>_9\NN\14110674 ,_10\,\1740 refractory_11\JJ\1740 to_12\TO\1740 <e1>atropine</e1>_13\NN\14712692 and_14\CC\1740 adrenaline_15\NN\14807929 ._16\.\1740
D004837_D001919 NONE following_0\VBG\1835496 phenytoin_1\NN\3550533 administration_2\NN\1133281 ,_3\,\1740 the_4\DT\1740 patient_5\NN\9898892 developed_6\VBD\1753788 acute_7\JJ\1740 severe_8\JJ\1740 <e2>bradycardia</e2>_9\NN\14110674 ,_10\,\1740 refractory_11\JJ\1740 to_12\TO\1740 atropine_13\NN\14712692 and_14\CC\1740 <e1>adrenaline</e1>_15\NN\14807929 ._16\.\1740
11063349
D020123_D064420 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 is_7\VBZ\836236 to_8\TO\1740 evaluate_9\VB\670261 the_10\DT\1740 effects_11\NNS\13245626 of_12\IN\1740 <e1>rapa</e1>_13\NN\1740 conversion_14\NN\7359599 in_15\IN\13603305 patients_16\NNS\9898892 undergoing_17\VBG\109660 cyclosporine_18\NN\1740 (_19\-LRB-\1740 csa_20\NN\1740 )_21\-RRB-\1740 or_22\CC\3541091 tacrolimus_23\NN\1740 (_24\-LRB-\1740 tac_25\NN\1740 )_26\-RRB-\1740 <e2>toxicity</e2>_27\NN\13576101 ._28\.\1740
D016572_D064420 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 is_7\VBZ\836236 to_8\TO\1740 evaluate_9\VB\670261 the_10\DT\1740 effects_11\NNS\13245626 of_12\IN\1740 rapa_13\NN\1740 conversion_14\NN\7359599 in_15\IN\13603305 patients_16\NNS\9898892 undergoing_17\VBG\109660 <e1>cyclosporine</e1>_18\NN\1740 (_19\-LRB-\1740 csa_20\NN\1740 )_21\-RRB-\1740 or_22\CC\3541091 tacrolimus_23\NN\1740 (_24\-LRB-\1740 tac_25\NN\1740 )_26\-RRB-\1740 <e2>toxicity</e2>_27\NN\13576101 ._28\.\1740
D016572_D064420 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 is_7\VBZ\836236 to_8\TO\1740 evaluate_9\VB\670261 the_10\DT\1740 effects_11\NNS\13245626 of_12\IN\1740 rapa_13\NN\1740 conversion_14\NN\7359599 in_15\IN\13603305 patients_16\NNS\9898892 undergoing_17\VBG\109660 cyclosporine_18\NN\1740 (_19\-LRB-\1740 <e1>csa</e1>_20\NN\1740 )_21\-RRB-\1740 or_22\CC\3541091 tacrolimus_23\NN\1740 (_24\-LRB-\1740 tac_25\NN\1740 )_26\-RRB-\1740 <e2>toxicity</e2>_27\NN\13576101 ._28\.\1740
D016572_D064420 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 <e1>csa</e1>_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 <e2>toxicity</e2>_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016572_D064420 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 <e1>csa</e1>_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 <e2>toxicity</e2>_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016559_D064420 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 is_7\VBZ\836236 to_8\TO\1740 evaluate_9\VB\670261 the_10\DT\1740 effects_11\NNS\13245626 of_12\IN\1740 rapa_13\NN\1740 conversion_14\NN\7359599 in_15\IN\13603305 patients_16\NNS\9898892 undergoing_17\VBG\109660 cyclosporine_18\NN\1740 (_19\-LRB-\1740 csa_20\NN\1740 )_21\-RRB-\1740 or_22\CC\3541091 <e1>tacrolimus</e1>_23\NN\1740 (_24\-LRB-\1740 tac_25\NN\1740 )_26\-RRB-\1740 <e2>toxicity</e2>_27\NN\13576101 ._28\.\1740
D016559_D064420 NONE background_0\NN\4921011 :_1\:\1740 the_2\DT\1740 aim_3\NN\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 is_7\VBZ\836236 to_8\TO\1740 evaluate_9\VB\670261 the_10\DT\1740 effects_11\NNS\13245626 of_12\IN\1740 rapa_13\NN\1740 conversion_14\NN\7359599 in_15\IN\13603305 patients_16\NNS\9898892 undergoing_17\VBG\109660 cyclosporine_18\NN\1740 (_19\-LRB-\1740 csa_20\NN\1740 )_21\-RRB-\1740 or_22\CC\3541091 tacrolimus_23\NN\1740 (_24\-LRB-\1740 <e1>tac</e1>_25\NN\1740 )_26\-RRB-\1740 <e2>toxicity</e2>_27\NN\13576101 ._28\.\1740
D016559_D064420 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 <e1>tac</e1>_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 <e2>toxicity</e2>_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016559_D064420 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 <e1>tac</e1>_17\NN\1740 <e2>toxicity</e2>_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016572_D007674 CID the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 <e1>csa</e1>_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 <e2>nephrotoxicity</e2>_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016572_D007674 CID the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 <e2>nephrotoxicity</e2>_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 <e1>csa</e1>_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016572_-1 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 <e1>csa</e1>_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 <e2>facial_24\JJ\1740 dysmorphism</e2>_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016572_-1 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 <e1>csa</e1>_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 <e2>facial_24\JJ\1740 dysmorphism</e2>_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016572_D008232 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 <e1>csa</e1>_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 <e2>posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder</e2>_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016572_D008232 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 <e1>csa</e1>_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 <e2>ptld</e2>_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016572_D008232 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 <e1>csa</e1>_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 <e2>posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder</e2>_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016572_D008232 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 <e1>csa</e1>_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 <e2>ptld</e2>_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016572_D056486 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 <e1>csa</e1>_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 <e2>hepatotoxicity</e2>_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016572_D056486 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 <e1>csa</e1>_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 <e2>hepatotoxicity</e2>_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016559_D007674 CID the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 <e1>tac</e1>_8\NN\1740 <e2>nephrotoxicity</e2>_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016559_D007674 CID the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 <e2>nephrotoxicity</e2>_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 <e1>tac</e1>_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016559_-1 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 <e1>tac</e1>_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 <e2>facial_24\JJ\1740 dysmorphism</e2>_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016559_-1 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 <e1>tac</e1>_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 <e2>facial_24\JJ\1740 dysmorphism</e2>_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016559_D008232 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 <e1>tac</e1>_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 <e2>posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder</e2>_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016559_D008232 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 <e1>tac</e1>_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 <e2>ptld</e2>_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016559_D008232 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 <e1>tac</e1>_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 <e2>posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder</e2>_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016559_D008232 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 <e1>tac</e1>_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 <e2>ptld</e2>_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 hepatotoxicity_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016559_D056486 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 <e1>tac</e1>_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 tac_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 <e2>hepatotoxicity</e2>_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D016559_D056486 NONE the_0\DT\1740 indications_1\NNS\33020 for_2\IN\1740 switch_3\NN\3096960 were_4\VBD\836236 chronic_5\JJ\1740 csa_6\NN\1740 or_7\CC\3541091 tac_8\NN\1740 nephrotoxicity_9\NN\1740 (_10\-LRB-\1740 12_11\CD\13745420 )_12\-RRB-\1740 ,_13\,\1740 acute_14\JJ\1740 csa_15\NN\1740 or_16\CC\3541091 <e1>tac</e1>_17\NN\1740 toxicity_18\NN\13576101 (_19\-LRB-\1740 3_20\CD\13741022 )_21\-RRB-\1740 ,_22\,\1740 severe_23\JJ\1740 facial_24\JJ\1740 dysmorphism_25\NN\1740 (_26\-LRB-\1740 2_27\CD\13741022 )_28\-RRB-\1740 ,_29\,\1740 posttransplant_30\JJ\1740 lymphoproliferative_31\JJ\1740 disorder_32\NN\14034177 (_33\-LRB-\1740 ptld_34\NN\1740 )_35\-RRB-\1740 in_36\IN\13603305 remission_37\NN\7368256 (_38\-LRB-\1740 2_39\CD\13741022 )_40\-RRB-\1740 ,_41\,\1740 and_42\CC\1740 <e2>hepatotoxicity</e2>_43\NN\1740 in_44\IN\13603305 1_45\CD\13741022 ._46\.\1740
D003404_D007674 NONE results_0\NNS\34213 :_1\:\1740 in_2\IN\13603305 the_3\DT\1740 12_4\CD\13745420 patients_5\NNS\9898892 switched_6\VBD\138508 because_7\IN\1740 of_8\IN\1740 chronic_9\JJ\1740 <e2>nephrotoxicity</e2>_10\NN\1740 there_11\EX\27167 was_12\VBD\836236 a_13\DT\13649268 significant_14\JJ\1740 decrease_15\NN\7296428 in_16\IN\13603305 serum_17\NN\5397468 <e1>creatinine</e1>_18\NN\1740 [_19\-LRB-\1740 233+/-34_20\CD\1740 to_21\TO\1740 210+/-56_22\CD\1740 micromol/liter_23\NN\1740 (_24\-LRB-\1740 p<0.05_25\NN\1740 )_26\-RRB-\1740 at_27\IN\14622893 6_28\CD\13741022 months_29\NNS\15113229 ]_30\-RRB-\1740 ._31\.\1740
D020123_D011014 NONE <e1>rapa</e1>_0\NN\1740 was_1\VBD\836236 discontinued_2\VBN\2609764 in_3\IN\13603305 four_4\CD\13741022 patients_5\NNS\9898892 ,_6\,\1740 because_7\IN\1740 of_8\IN\1740 <e2>pneumonia</e2>_9\NN\14145095 in_10\IN\13603305 two_11\CD\13741022 ,_12\,\1740 ptld_13\NN\1740 in_14\IN\13603305 one_15\CD\13741022 ,_16\,\1740 and_17\CC\1740 oral_18\JJ\1740 aphtous_19\JJ\1740 ulcers_20\NNS\14211294 in_21\IN\13603305 one_22\CD\13741022 ._23\.\1740
D020123_D008232 NONE <e1>rapa</e1>_0\NN\1740 was_1\VBD\836236 discontinued_2\VBN\2609764 in_3\IN\13603305 four_4\CD\13741022 patients_5\NNS\9898892 ,_6\,\1740 because_7\IN\1740 of_8\IN\1740 pneumonia_9\NN\14145095 in_10\IN\13603305 two_11\CD\13741022 ,_12\,\1740 <e2>ptld</e2>_13\NN\1740 in_14\IN\13603305 one_15\CD\13741022 ,_16\,\1740 and_17\CC\1740 oral_18\JJ\1740 aphtous_19\JJ\1740 ulcers_20\NNS\14211294 in_21\IN\13603305 one_22\CD\13741022 ._23\.\1740
D020123_D013281 NONE <e1>rapa</e1>_0\NN\1740 was_1\VBD\836236 discontinued_2\VBN\2609764 in_3\IN\13603305 four_4\CD\13741022 patients_5\NNS\9898892 ,_6\,\1740 because_7\IN\1740 of_8\IN\1740 pneumonia_9\NN\14145095 in_10\IN\13603305 two_11\CD\13741022 ,_12\,\1740 ptld_13\NN\1740 in_14\IN\13603305 one_15\CD\13741022 ,_16\,\1740 and_17\CC\1740 oral_18\JJ\1740 <e2>aphtous_19\JJ\1740 ulcers</e2>_20\NNS\14211294 in_21\IN\13603305 one_22\CD\13741022 ._23\.\1740
D020123_D011020 NONE however_0\RB\1740 ,_1\,\1740 when_2\WRB\1740 converting_3\VBG\126264 patients_4\NNS\9898892 to_5\TO\1740 <e1>rapa</e1>_6\NN\1740 drug_7\NN\14778436 levels_8\NNS\4916342 should_9\MD\1740 be_10\VB\836236 monitored_11\VBN\2169352 to_12\TO\1740 avoid_13\VB\2452885 over-immunosuppression_14\NN\1740 and_15\CC\1740 adequate_16\JJ\1740 antiviral_17\JJ\1740 and_18\CC\1740 <e2>pneumocystis_19\NN\1740 carinii_20\NN\1740 pneumonia</e2>_21\NN\14145095 prophylaxis_22\NN\1077350 should_23\MD\1740 be_24\VB\836236 given_25\VBN\2327200 ._26\.\1740
11900788
D009538_D002375 CID <e1>nicotine</e1>_0\NN\14712692 potentiation_1\NN\13564910 of_2\IN\1740 morphine-induced_3\JJ\1740 <e2>catalepsy</e2>_4\NN\14023236 in_5\IN\13603305 mice_6\NNS\2329401 ._7\.\1740
D009538_D002375 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>nicotine</e1>_7\NN\14712692 on_8\IN\1740 <e2>catalepsy</e2>_9\NN\14023236 induced_10\VBN\1627355 by_11\IN\1740 morphine_12\NN\2707683 in_13\IN\13603305 mice_14\NNS\2329401 have_15\VBP\2108377 been_16\VBN\836236 investigated_17\VBN\644583 ._18\.\1740
D009538_D002375 CID morphine_0\NN\2707683 but_1\CC\1740 not_2\RB\1740 <e1>nicotine</e1>_3\NN\14712692 induced_4\VBD\1627355 a_5\DT\13649268 dose-dependent_6\JJ\1740 <e2>catalepsy</e2>_7\NN\14023236 ._8\.\1740
D009538_D002375 CID intraperitoneal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 atropine_3\NN\14712692 ,_4\,\1740 naloxone_5\NN\3808977 ,_6\,\1740 mecamylamine_7\NN\1740 ,_8\,\1740 and_9\CC\1740 hexamethonium_10\NN\1740 to_11\TO\1740 mice_12\NNS\2329401 reduced_13\VBD\441445 <e2>catalepsy</e2>_14\NN\14023236 induced_15\VBN\1627355 by_16\IN\1740 a_17\DT\13649268 combination_18\NN\7951464 of_19\IN\1740 morphine_20\NN\2707683 with_21\IN\1740 <e1>nicotine</e1>_22\NN\14712692 ._23\.\1740
D009538_D002375 CID intracerebroventricular_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 atropine_3\NN\14712692 ,_4\,\1740 hexamethonium_5\NN\1740 ,_6\,\1740 and_7\CC\1740 naloxone_8\NN\3808977 also_9\RB\1740 decreased_10\VBD\169651 <e2>catalepsy</e2>_11\NN\14023236 induced_12\VBN\1627355 by_13\IN\1740 morphine_14\NN\2707683 plus_15\CC\4723816 <e1>nicotine</e1>_16\NN\14712692 ._17\.\1740
D009538_D002375 CID it_0\PRP\6125041 was_1\VBD\836236 concluded_2\VBN\628491 that_3\IN\1740 morphine_4\NN\2707683 <e2>catalepsy</e2>_5\NN\14023236 can_6\MD\3094503 be_7\VB\836236 elicited_8\VBN\1617192 by_9\IN\1740 opioid_10\NN\1740 and_11\CC\1740 cholinergic_12\JJ\1740 receptors_13\NNS\5225602 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 potentiation_17\NN\13564910 of_18\IN\1740 morphine_19\NN\2707683 induced_20\VBN\1627355 by_21\IN\1740 <e1>nicotine</e1>_22\NN\14712692 may_23\MD\15209706 also_24\RB\1740 be_25\VB\836236 mediated_26\VBN\761713 through_27\IN\1740 cholinergic_28\JJ\1740 receptor_29\NN\5225602 mechanisms_30\NNS\13446390 ._31\.\1740
D009020_D002375 CID nicotine_0\NN\14712692 potentiation_1\NN\13564910 of_2\IN\1740 <e1>morphine-induced</e1>_3\JJ\1740 <e2>catalepsy</e2>_4\NN\14023236 in_5\IN\13603305 mice_6\NNS\2329401 ._7\.\1740
D009020_D002375 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 ,_4\,\1740 effects_5\NNS\13245626 of_6\IN\1740 nicotine_7\NN\14712692 on_8\IN\1740 <e2>catalepsy</e2>_9\NN\14023236 induced_10\VBN\1627355 by_11\IN\1740 <e1>morphine</e1>_12\NN\2707683 in_13\IN\13603305 mice_14\NNS\2329401 have_15\VBP\2108377 been_16\VBN\836236 investigated_17\VBN\644583 ._18\.\1740
D009020_D002375 CID <e1>morphine</e1>_0\NN\2707683 but_1\CC\1740 not_2\RB\1740 nicotine_3\NN\14712692 induced_4\VBD\1627355 a_5\DT\13649268 dose-dependent_6\JJ\1740 <e2>catalepsy</e2>_7\NN\14023236 ._8\.\1740
D009020_D002375 CID intraperitoneal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 atropine_3\NN\14712692 ,_4\,\1740 naloxone_5\NN\3808977 ,_6\,\1740 mecamylamine_7\NN\1740 ,_8\,\1740 and_9\CC\1740 hexamethonium_10\NN\1740 to_11\TO\1740 mice_12\NNS\2329401 reduced_13\VBD\441445 <e2>catalepsy</e2>_14\NN\14023236 induced_15\VBN\1627355 by_16\IN\1740 a_17\DT\13649268 combination_18\NN\7951464 of_19\IN\1740 <e1>morphine</e1>_20\NN\2707683 with_21\IN\1740 nicotine_22\NN\14712692 ._23\.\1740
D009020_D002375 CID intracerebroventricular_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 atropine_3\NN\14712692 ,_4\,\1740 hexamethonium_5\NN\1740 ,_6\,\1740 and_7\CC\1740 naloxone_8\NN\3808977 also_9\RB\1740 decreased_10\VBD\169651 <e2>catalepsy</e2>_11\NN\14023236 induced_12\VBN\1627355 by_13\IN\1740 <e1>morphine</e1>_14\NN\2707683 plus_15\CC\4723816 nicotine_16\NN\14712692 ._17\.\1740
D009020_D002375 CID it_0\PRP\6125041 was_1\VBD\836236 concluded_2\VBN\628491 that_3\IN\1740 <e1>morphine</e1>_4\NN\2707683 <e2>catalepsy</e2>_5\NN\14023236 can_6\MD\3094503 be_7\VB\836236 elicited_8\VBN\1617192 by_9\IN\1740 opioid_10\NN\1740 and_11\CC\1740 cholinergic_12\JJ\1740 receptors_13\NNS\5225602 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 potentiation_17\NN\13564910 of_18\IN\1740 morphine_19\NN\2707683 induced_20\VBN\1627355 by_21\IN\1740 nicotine_22\NN\14712692 may_23\MD\15209706 also_24\RB\1740 be_25\VB\836236 mediated_26\VBN\761713 through_27\IN\1740 cholinergic_28\JJ\1740 receptor_29\NN\5225602 mechanisms_30\NNS\13446390 ._31\.\1740
D009020_D002375 CID it_0\PRP\6125041 was_1\VBD\836236 concluded_2\VBN\628491 that_3\IN\1740 morphine_4\NN\2707683 <e2>catalepsy</e2>_5\NN\14023236 can_6\MD\3094503 be_7\VB\836236 elicited_8\VBN\1617192 by_9\IN\1740 opioid_10\NN\1740 and_11\CC\1740 cholinergic_12\JJ\1740 receptors_13\NNS\5225602 ,_14\,\1740 and_15\CC\1740 the_16\DT\1740 potentiation_17\NN\13564910 of_18\IN\1740 <e1>morphine</e1>_19\NN\2707683 induced_20\VBN\1627355 by_21\IN\1740 nicotine_22\NN\14712692 may_23\MD\15209706 also_24\RB\1740 be_25\VB\836236 mediated_26\VBN\761713 through_27\IN\1740 cholinergic_28\JJ\1740 receptor_29\NN\5225602 mechanisms_30\NNS\13446390 ._31\.\1740
D001285_D002375 NONE intraperitoneal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 <e1>atropine</e1>_3\NN\14712692 ,_4\,\1740 naloxone_5\NN\3808977 ,_6\,\1740 mecamylamine_7\NN\1740 ,_8\,\1740 and_9\CC\1740 hexamethonium_10\NN\1740 to_11\TO\1740 mice_12\NNS\2329401 reduced_13\VBD\441445 <e2>catalepsy</e2>_14\NN\14023236 induced_15\VBN\1627355 by_16\IN\1740 a_17\DT\13649268 combination_18\NN\7951464 of_19\IN\1740 morphine_20\NN\2707683 with_21\IN\1740 nicotine_22\NN\14712692 ._23\.\1740
D001285_D002375 NONE intracerebroventricular_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 <e1>atropine</e1>_3\NN\14712692 ,_4\,\1740 hexamethonium_5\NN\1740 ,_6\,\1740 and_7\CC\1740 naloxone_8\NN\3808977 also_9\RB\1740 decreased_10\VBD\169651 <e2>catalepsy</e2>_11\NN\14023236 induced_12\VBN\1627355 by_13\IN\1740 morphine_14\NN\2707683 plus_15\CC\4723816 nicotine_16\NN\14712692 ._17\.\1740
D009270_D002375 NONE intraperitoneal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 atropine_3\NN\14712692 ,_4\,\1740 <e1>naloxone</e1>_5\NN\3808977 ,_6\,\1740 mecamylamine_7\NN\1740 ,_8\,\1740 and_9\CC\1740 hexamethonium_10\NN\1740 to_11\TO\1740 mice_12\NNS\2329401 reduced_13\VBD\441445 <e2>catalepsy</e2>_14\NN\14023236 induced_15\VBN\1627355 by_16\IN\1740 a_17\DT\13649268 combination_18\NN\7951464 of_19\IN\1740 morphine_20\NN\2707683 with_21\IN\1740 nicotine_22\NN\14712692 ._23\.\1740
D009270_D002375 NONE intracerebroventricular_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 atropine_3\NN\14712692 ,_4\,\1740 hexamethonium_5\NN\1740 ,_6\,\1740 and_7\CC\1740 <e1>naloxone</e1>_8\NN\3808977 also_9\RB\1740 decreased_10\VBD\169651 <e2>catalepsy</e2>_11\NN\14023236 induced_12\VBN\1627355 by_13\IN\1740 morphine_14\NN\2707683 plus_15\CC\4723816 nicotine_16\NN\14712692 ._17\.\1740
D008464_D002375 NONE intraperitoneal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 atropine_3\NN\14712692 ,_4\,\1740 naloxone_5\NN\3808977 ,_6\,\1740 <e1>mecamylamine</e1>_7\NN\1740 ,_8\,\1740 and_9\CC\1740 hexamethonium_10\NN\1740 to_11\TO\1740 mice_12\NNS\2329401 reduced_13\VBD\441445 <e2>catalepsy</e2>_14\NN\14023236 induced_15\VBN\1627355 by_16\IN\1740 a_17\DT\13649268 combination_18\NN\7951464 of_19\IN\1740 morphine_20\NN\2707683 with_21\IN\1740 nicotine_22\NN\14712692 ._23\.\1740
D018738_D002375 NONE intraperitoneal_0\JJ\1740 administration_1\NN\1133281 of_2\IN\1740 atropine_3\NN\14712692 ,_4\,\1740 naloxone_5\NN\3808977 ,_6\,\1740 mecamylamine_7\NN\1740 ,_8\,\1740 and_9\CC\1740 <e1>hexamethonium</e1>_10\NN\1740 to_11\TO\1740 mice_12\NNS\2329401 reduced_13\VBD\441445 <e2>catalepsy</e2>_14\NN\14023236 induced_15\VBN\1627355 by_16\IN\1740 a_17\DT\13649268 combination_18\NN\7951464 of_19\IN\1740 morphine_20\NN\2707683 with_21\IN\1740 nicotine_22\NN\14712692 ._23\.\1740
D018738_D002375 NONE intracerebroventricular_0\JJ\1740 injection_1\NN\320852 of_2\IN\1740 atropine_3\NN\14712692 ,_4\,\1740 <e1>hexamethonium</e1>_5\NN\1740 ,_6\,\1740 and_7\CC\1740 naloxone_8\NN\3808977 also_9\RB\1740 decreased_10\VBD\169651 <e2>catalepsy</e2>_11\NN\14023236 induced_12\VBN\1627355 by_13\IN\1740 morphine_14\NN\2707683 plus_15\CC\4723816 nicotine_16\NN\14712692 ._17\.\1740
11583940
C063008_D007674 NONE two_0\CD\13741022 recently_1\RB\1740 available_2\JJ\1740 immunosuppressive_3\JJ\1740 agents_4\NNS\7347 ,_5\,\1740 <e1>mycophenolate_6\JJ\1740 mofetil</e1>_7\NN\1740 and_8\CC\1740 sirolimus_9\NN\1740 (_10\-LRB-\1740 rapamycin_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 no_15\DT\7204911 <e2>nephrotoxicity</e2>_16\NN\1740 ._17\.\1740
D020123_D007674 NONE two_0\CD\13741022 recently_1\RB\1740 available_2\JJ\1740 immunosuppressive_3\JJ\1740 agents_4\NNS\7347 ,_5\,\1740 mycophenolate_6\JJ\1740 mofetil_7\NN\1740 and_8\CC\1740 <e1>sirolimus</e1>_9\NN\1740 (_10\-LRB-\1740 rapamycin_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 no_15\DT\7204911 <e2>nephrotoxicity</e2>_16\NN\1740 ._17\.\1740
D020123_D007674 NONE two_0\CD\13741022 recently_1\RB\1740 available_2\JJ\1740 immunosuppressive_3\JJ\1740 agents_4\NNS\7347 ,_5\,\1740 mycophenolate_6\JJ\1740 mofetil_7\NN\1740 and_8\CC\1740 sirolimus_9\NN\1740 (_10\-LRB-\1740 <e1>rapamycin</e1>_11\NN\1740 )_12\-RRB-\1740 ,_13\,\1740 have_14\VBP\2108377 no_15\DT\7204911 <e2>nephrotoxicity</e2>_16\NN\1740 ._17\.\1740
1700207
C032151_D001145 NONE antiarrhythmic_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 optical_3\JJ\1740 isomers_4\NNS\14818238 of_5\IN\1740 <e1>cibenzoline</e1>_6\NN\1740 on_7\IN\1740 canine_8\NN\5282746 <e2>ventricular_9\NN\1740 arrhythmias</e2>_10\VBZ\1740 ._11\.\1740
C032151_D001145 NONE antiarrhythmic_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>(+)-cibenzoline</e1>_3\NN\1740 and_4\CC\1740 (-)-cibenzoline_5\NN\1740 were_6\VBD\836236 examined_7\VBN\789138 using_8\VBG\1156834 two_9\CD\13741022 canine_10\NN\5282746 <e2>ventricular_11\NN\1740 arrhythmia</e2>_12\NN\14103288 models_13\NNS\5888929 ._14\.\1740
C032151_D001145 NONE antiarrhythmic_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 (+)-cibenzoline_3\NN\1740 and_4\CC\1740 <e1>(-)-cibenzoline</e1>_5\NN\1740 were_6\VBD\836236 examined_7\VBN\789138 using_8\VBG\1156834 two_9\CD\13741022 canine_10\NN\5282746 <e2>ventricular_11\NN\1740 arrhythmia</e2>_12\NN\14103288 models_13\NNS\5888929 ._14\.\1740
C032151_D001145 NONE ten_0\CD\13745420 and_1\CC\1740 5_2\CD\13741022 mg/kg_3\NN\1740 i.v._4\NN\1740 <e1>(+)-cibenzoline</e1>_5\NN\1740 suppressed_6\VBD\2510337 digitalis-_7\NN\1740 and_8\CC\1740 adrenaline-induced_9\JJ\1740 <e2>arrhythmias</e2>_10\NNS\14103288 ,_11\,\1740 respectively_12\RB\1740 ._13\.\1740
C032151_D001145 NONE the_0\DT\1740 minimum_1\JJ\1740 effective_2\JJ\1740 plasma_3\NN\5398023 concentrations_4\NNS\4916342 of_5\IN\1740 <e1>(+)-cibenzoline</e1>_6\NN\1740 for_7\IN\1740 digitalis-_8\JJ\1740 and_9\CC\1740 adrenaline-induced_10\JJ\1740 <e2>arrhythmias</e2>_11\NNS\14103288 were_12\VBD\836236 1.4_13\CD\1740 +/-_14\CC\1740 0.4_15\CD\1740 and_16\CC\1740 2.0_17\CD\1740 +/-_18\CC\1740 0.6_19\CD\1740 micrograms/ml_20\NNS\1740 ,_21\,\1740 respectively_22\RB\1740 (_23\-LRB-\1740 mean_24\NN\6021761 +/-_25\CC\1740 sd_26\NN\1740 ,_27\,\1740 n_28\NN\14622893 =_29\JJ\1740 6_30\CD\13741022 )_31\-RRB-\1740 ._32\.\1740
C032151_D001145 NONE a_0\DT\13649268 lower_1\JJR\1740 dose_2\NN\3740161 of_3\IN\1740 1_4\CD\13741022 mg/kg_5\NN\1740 i.v._6\NN\1740 of_7\IN\1740 <e1>(-)-cibenzoline</e1>_8\NN\1740 suppressed_9\VBD\2510337 the_10\DT\1740 digitalis-induced_11\JJ\1740 <e2>arrhythmia</e2>_12\NN\14103288 ,_13\,\1740 whereas_14\IN\1740 5_15\CD\13741022 mg/kg_16\NN\1740 i.v._17\NN\1740 was_18\VBD\836236 needed_19\VBN\2604760 to_20\TO\1740 suppress_21\VB\2510337 adrenaline-induced_22\JJ\1740 arrhythmias_23\NNS\14103288 ._24\.\1740
C032151_D001145 NONE a_0\DT\13649268 lower_1\JJR\1740 dose_2\NN\3740161 of_3\IN\1740 1_4\CD\13741022 mg/kg_5\NN\1740 i.v._6\NN\1740 of_7\IN\1740 <e1>(-)-cibenzoline</e1>_8\NN\1740 suppressed_9\VBD\2510337 the_10\DT\1740 digitalis-induced_11\JJ\1740 arrhythmia_12\NN\14103288 ,_13\,\1740 whereas_14\IN\1740 5_15\CD\13741022 mg/kg_16\NN\1740 i.v._17\NN\1740 was_18\VBD\836236 needed_19\VBN\2604760 to_20\TO\1740 suppress_21\VB\2510337 adrenaline-induced_22\JJ\1740 <e2>arrhythmias</e2>_23\NNS\14103288 ._24\.\1740
C032151_D001145 NONE the_0\DT\1740 minimum_1\JJ\1740 effective_2\JJ\1740 plasma_3\NN\5398023 concentrations_4\NNS\4916342 of_5\IN\1740 <e1>(-)-cibenzoline</e1>_6\NN\1740 for_7\IN\1740 digitalis-_8\JJ\1740 and_9\CC\1740 adrenaline-induced_10\JJ\1740 <e2>arrhythmia</e2>_11\NN\14103288 were_12\VBD\836236 0.06_13\CD\1740 +/-_14\CC\1740 0.04_15\CD\1740 and_16\CC\1740 0.7_17\CD\1740 +/-_18\CC\1740 0.1_19\CD\1740 micrograms/ml_20\NNS\1740 ,_21\,\1740 respectively_22\RB\1740 (_23\-LRB-\1740 mean_24\NN\6021761 +/-_25\CC\1740 sd_26\NN\1740 ,_27\,\1740 n_28\NN\14622893 =_29\JJ\1740 6_30\CD\13741022 )_31\-RRB-\1740 ._32\.\1740
D004070_D001145 NONE <e1>digitalis</e1>_0\NN\15059939 <e2>arrhythmia</e2>_1\NN\14103288 ,_2\,\1740 which_3\WDT\1740 is_4\VBZ\836236 suppressed_5\VBN\2510337 by_6\IN\1740 na_7\NN\14625458 channel_8\NN\6251781 blockers_9\NNS\10101634 ,_10\,\1740 was_11\VBD\836236 induced_12\VBN\1627355 by_13\IN\1740 intermittent_14\JJ\1740 intravenous_15\JJ\1740 (_16\-LRB-\1740 i.v._17\NN\1740 )_18\-RRB-\1740 injection_19\NN\320852 of_20\IN\1740 ouabain_21\NN\1740 in_22\IN\13603305 pentobarbital-anesthetized_23\JJ\1740 dogs_24\NNS\2083346 ._25\.\1740
D004070_D001145 NONE ten_0\CD\13745420 and_1\CC\1740 5_2\CD\13741022 mg/kg_3\NN\1740 i.v._4\NN\1740 (+)-cibenzoline_5\NN\1740 suppressed_6\VBD\2510337 <e1>digitalis-</e1>_7\NN\1740 and_8\CC\1740 adrenaline-induced_9\JJ\1740 <e2>arrhythmias</e2>_10\NNS\14103288 ,_11\,\1740 respectively_12\RB\1740 ._13\.\1740
D004070_D001145 NONE the_0\DT\1740 minimum_1\JJ\1740 effective_2\JJ\1740 plasma_3\NN\5398023 concentrations_4\NNS\4916342 of_5\IN\1740 (+)-cibenzoline_6\NN\1740 for_7\IN\1740 <e1>digitalis-</e1>_8\JJ\1740 and_9\CC\1740 adrenaline-induced_10\JJ\1740 <e2>arrhythmias</e2>_11\NNS\14103288 were_12\VBD\836236 1.4_13\CD\1740 +/-_14\CC\1740 0.4_15\CD\1740 and_16\CC\1740 2.0_17\CD\1740 +/-_18\CC\1740 0.6_19\CD\1740 micrograms/ml_20\NNS\1740 ,_21\,\1740 respectively_22\RB\1740 (_23\-LRB-\1740 mean_24\NN\6021761 +/-_25\CC\1740 sd_26\NN\1740 ,_27\,\1740 n_28\NN\14622893 =_29\JJ\1740 6_30\CD\13741022 )_31\-RRB-\1740 ._32\.\1740
D004070_D001145 NONE a_0\DT\13649268 lower_1\JJR\1740 dose_2\NN\3740161 of_3\IN\1740 1_4\CD\13741022 mg/kg_5\NN\1740 i.v._6\NN\1740 of_7\IN\1740 (-)-cibenzoline_8\NN\1740 suppressed_9\VBD\2510337 the_10\DT\1740 <e1>digitalis-induced</e1>_11\JJ\1740 <e2>arrhythmia</e2>_12\NN\14103288 ,_13\,\1740 whereas_14\IN\1740 5_15\CD\13741022 mg/kg_16\NN\1740 i.v._17\NN\1740 was_18\VBD\836236 needed_19\VBN\2604760 to_20\TO\1740 suppress_21\VB\2510337 adrenaline-induced_22\JJ\1740 arrhythmias_23\NNS\14103288 ._24\.\1740
D004070_D001145 NONE a_0\DT\13649268 lower_1\JJR\1740 dose_2\NN\3740161 of_3\IN\1740 1_4\CD\13741022 mg/kg_5\NN\1740 i.v._6\NN\1740 of_7\IN\1740 (-)-cibenzoline_8\NN\1740 suppressed_9\VBD\2510337 the_10\DT\1740 <e1>digitalis-induced</e1>_11\JJ\1740 arrhythmia_12\NN\14103288 ,_13\,\1740 whereas_14\IN\1740 5_15\CD\13741022 mg/kg_16\NN\1740 i.v._17\NN\1740 was_18\VBD\836236 needed_19\VBN\2604760 to_20\TO\1740 suppress_21\VB\2510337 adrenaline-induced_22\JJ\1740 <e2>arrhythmias</e2>_23\NNS\14103288 ._24\.\1740
D004070_D001145 NONE the_0\DT\1740 minimum_1\JJ\1740 effective_2\JJ\1740 plasma_3\NN\5398023 concentrations_4\NNS\4916342 of_5\IN\1740 (-)-cibenzoline_6\NN\1740 for_7\IN\1740 <e1>digitalis-</e1>_8\JJ\1740 and_9\CC\1740 adrenaline-induced_10\JJ\1740 <e2>arrhythmia</e2>_11\NN\14103288 were_12\VBD\836236 0.06_13\CD\1740 +/-_14\CC\1740 0.04_15\CD\1740 and_16\CC\1740 0.7_17\CD\1740 +/-_18\CC\1740 0.1_19\CD\1740 micrograms/ml_20\NNS\1740 ,_21\,\1740 respectively_22\RB\1740 (_23\-LRB-\1740 mean_24\NN\6021761 +/-_25\CC\1740 sd_26\NN\1740 ,_27\,\1740 n_28\NN\14622893 =_29\JJ\1740 6_30\CD\13741022 )_31\-RRB-\1740 ._32\.\1740
D012964_D001145 NONE digitalis_0\NN\15059939 <e2>arrhythmia</e2>_1\NN\14103288 ,_2\,\1740 which_3\WDT\1740 is_4\VBZ\836236 suppressed_5\VBN\2510337 by_6\IN\1740 <e1>na</e1>_7\NN\14625458 channel_8\NN\6251781 blockers_9\NNS\10101634 ,_10\,\1740 was_11\VBD\836236 induced_12\VBN\1627355 by_13\IN\1740 intermittent_14\JJ\1740 intravenous_15\JJ\1740 (_16\-LRB-\1740 i.v._17\NN\1740 )_18\-RRB-\1740 injection_19\NN\320852 of_20\IN\1740 ouabain_21\NN\1740 in_22\IN\13603305 pentobarbital-anesthetized_23\JJ\1740 dogs_24\NNS\2083346 ._25\.\1740
D010042_D001145 CID digitalis_0\NN\15059939 <e2>arrhythmia</e2>_1\NN\14103288 ,_2\,\1740 which_3\WDT\1740 is_4\VBZ\836236 suppressed_5\VBN\2510337 by_6\IN\1740 na_7\NN\14625458 channel_8\NN\6251781 blockers_9\NNS\10101634 ,_10\,\1740 was_11\VBD\836236 induced_12\VBN\1627355 by_13\IN\1740 intermittent_14\JJ\1740 intravenous_15\JJ\1740 (_16\-LRB-\1740 i.v._17\NN\1740 )_18\-RRB-\1740 injection_19\NN\320852 of_20\IN\1740 <e1>ouabain</e1>_21\NN\1740 in_22\IN\13603305 pentobarbital-anesthetized_23\JJ\1740 dogs_24\NNS\2083346 ._25\.\1740
D010424_D001145 NONE digitalis_0\NN\15059939 <e2>arrhythmia</e2>_1\NN\14103288 ,_2\,\1740 which_3\WDT\1740 is_4\VBZ\836236 suppressed_5\VBN\2510337 by_6\IN\1740 na_7\NN\14625458 channel_8\NN\6251781 blockers_9\NNS\10101634 ,_10\,\1740 was_11\VBD\836236 induced_12\VBN\1627355 by_13\IN\1740 intermittent_14\JJ\1740 intravenous_15\JJ\1740 (_16\-LRB-\1740 i.v._17\NN\1740 )_18\-RRB-\1740 injection_19\NN\320852 of_20\IN\1740 ouabain_21\NN\1740 in_22\IN\13603305 <e1>pentobarbital-anesthetized</e1>_23\JJ\1740 dogs_24\NNS\2083346 ._25\.\1740
D002118_D001145 NONE <e2>adrenaline_0\NN\14807929 arrhythmia</e2>_1\NN\14103288 ,_2\,\1740 which_3\WDT\1740 is_4\VBZ\836236 suppressed_5\VBN\2510337 by_6\IN\1740 <e1>ca</e1>_7\NN\14625458 channel_8\NN\6251781 blockers_9\NNS\10101634 ,_10\,\1740 was_11\VBD\836236 induced_12\VBN\1627355 by_13\IN\1740 adrenaline_14\NN\14807929 infusion_15\NN\14589223 in_16\IN\13603305 halothane-anesthetized_17\JJ\1740 dogs_18\NNS\2083346 ._19\.\1740
D004837_D001145 CID <e2>adrenaline_0\NN\14807929 arrhythmia</e2>_1\NN\14103288 ,_2\,\1740 which_3\WDT\1740 is_4\VBZ\836236 suppressed_5\VBN\2510337 by_6\IN\1740 ca_7\NN\14625458 channel_8\NN\6251781 blockers_9\NNS\10101634 ,_10\,\1740 was_11\VBD\836236 induced_12\VBN\1627355 by_13\IN\1740 <e1>adrenaline</e1>_14\NN\14807929 infusion_15\NN\14589223 in_16\IN\13603305 halothane-anesthetized_17\JJ\1740 dogs_18\NNS\2083346 ._19\.\1740
D004837_D001145 CID ten_0\CD\13745420 and_1\CC\1740 5_2\CD\13741022 mg/kg_3\NN\1740 i.v._4\NN\1740 (+)-cibenzoline_5\NN\1740 suppressed_6\VBD\2510337 digitalis-_7\NN\1740 and_8\CC\1740 <e1>adrenaline-induced</e1>_9\JJ\1740 <e2>arrhythmias</e2>_10\NNS\14103288 ,_11\,\1740 respectively_12\RB\1740 ._13\.\1740
D004837_D001145 CID the_0\DT\1740 minimum_1\JJ\1740 effective_2\JJ\1740 plasma_3\NN\5398023 concentrations_4\NNS\4916342 of_5\IN\1740 (+)-cibenzoline_6\NN\1740 for_7\IN\1740 digitalis-_8\JJ\1740 and_9\CC\1740 <e1>adrenaline-induced</e1>_10\JJ\1740 <e2>arrhythmias</e2>_11\NNS\14103288 were_12\VBD\836236 1.4_13\CD\1740 +/-_14\CC\1740 0.4_15\CD\1740 and_16\CC\1740 2.0_17\CD\1740 +/-_18\CC\1740 0.6_19\CD\1740 micrograms/ml_20\NNS\1740 ,_21\,\1740 respectively_22\RB\1740 (_23\-LRB-\1740 mean_24\NN\6021761 +/-_25\CC\1740 sd_26\NN\1740 ,_27\,\1740 n_28\NN\14622893 =_29\JJ\1740 6_30\CD\13741022 )_31\-RRB-\1740 ._32\.\1740
D004837_D001145 CID a_0\DT\13649268 lower_1\JJR\1740 dose_2\NN\3740161 of_3\IN\1740 1_4\CD\13741022 mg/kg_5\NN\1740 i.v._6\NN\1740 of_7\IN\1740 (-)-cibenzoline_8\NN\1740 suppressed_9\VBD\2510337 the_10\DT\1740 digitalis-induced_11\JJ\1740 <e2>arrhythmia</e2>_12\NN\14103288 ,_13\,\1740 whereas_14\IN\1740 5_15\CD\13741022 mg/kg_16\NN\1740 i.v._17\NN\1740 was_18\VBD\836236 needed_19\VBN\2604760 to_20\TO\1740 suppress_21\VB\2510337 <e1>adrenaline-induced</e1>_22\JJ\1740 arrhythmias_23\NNS\14103288 ._24\.\1740
D004837_D001145 CID a_0\DT\13649268 lower_1\JJR\1740 dose_2\NN\3740161 of_3\IN\1740 1_4\CD\13741022 mg/kg_5\NN\1740 i.v._6\NN\1740 of_7\IN\1740 (-)-cibenzoline_8\NN\1740 suppressed_9\VBD\2510337 the_10\DT\1740 digitalis-induced_11\JJ\1740 arrhythmia_12\NN\14103288 ,_13\,\1740 whereas_14\IN\1740 5_15\CD\13741022 mg/kg_16\NN\1740 i.v._17\NN\1740 was_18\VBD\836236 needed_19\VBN\2604760 to_20\TO\1740 suppress_21\VB\2510337 <e1>adrenaline-induced</e1>_22\JJ\1740 <e2>arrhythmias</e2>_23\NNS\14103288 ._24\.\1740
D004837_D001145 CID the_0\DT\1740 minimum_1\JJ\1740 effective_2\JJ\1740 plasma_3\NN\5398023 concentrations_4\NNS\4916342 of_5\IN\1740 (-)-cibenzoline_6\NN\1740 for_7\IN\1740 digitalis-_8\JJ\1740 and_9\CC\1740 <e1>adrenaline-induced</e1>_10\JJ\1740 <e2>arrhythmia</e2>_11\NN\14103288 were_12\VBD\836236 0.06_13\CD\1740 +/-_14\CC\1740 0.04_15\CD\1740 and_16\CC\1740 0.7_17\CD\1740 +/-_18\CC\1740 0.1_19\CD\1740 micrograms/ml_20\NNS\1740 ,_21\,\1740 respectively_22\RB\1740 (_23\-LRB-\1740 mean_24\NN\6021761 +/-_25\CC\1740 sd_26\NN\1740 ,_27\,\1740 n_28\NN\14622893 =_29\JJ\1740 6_30\CD\13741022 )_31\-RRB-\1740 ._32\.\1740
D006221_D001145 NONE <e2>adrenaline_0\NN\14807929 arrhythmia</e2>_1\NN\14103288 ,_2\,\1740 which_3\WDT\1740 is_4\VBZ\836236 suppressed_5\VBN\2510337 by_6\IN\1740 ca_7\NN\14625458 channel_8\NN\6251781 blockers_9\NNS\10101634 ,_10\,\1740 was_11\VBD\836236 induced_12\VBN\1627355 by_13\IN\1740 adrenaline_14\NN\14807929 infusion_15\NN\14589223 in_16\IN\13603305 <e1>halothane-anesthetized</e1>_17\JJ\1740 dogs_18\NNS\2083346 ._19\.\1740
6118280
D001569_D009207 NONE serotonergic_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 <e1>benzodiazepines</e1>_3\NNS\3771443 and_4\CC\1740 baclofen_5\VB\1740 block_6\NN\21939 muscimol-induced_7\JJ\1740 <e2>myoclonic_8\JJ\1740 jerks</e2>_9\NNS\10322238 in_10\IN\13603305 a_11\DT\13649268 strain_12\NN\7358060 of_13\IN\1740 mice_14\NNS\2329401 ._15\.\1740
D001569_D009207 NONE of_0\IN\1740 the_1\DT\1740 <e1>benzodiazepines</e1>_2\NNS\3771443 ,_3\,\1740 clonazepam_4\NN\1740 (_5\-LRB-\1740 0.1_6\CD\1740 -_7\SYM\1740 0.3_8\CD\1740 mg/kg_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 found_12\VBN\2426171 to_13\TO\1740 be_14\VB\836236 several_15\JJ\1740 fold_16\NN\13864763 more_17\RBR\1740 potent_18\JJ\1740 than_19\IN\1740 diazepam_20\NN\2830852 (_21\-LRB-\1740 0.3_22\CD\1740 -_23\SYM\1740 3_24\CD\13741022 mg/kg_25\NN\1740 )_26\-RRB-\1740 in_27\IN\13603305 blocking_28\VBG\1476483 the_29\DT\1740 <e2>myoclonic_30\JJ\1740 jerks</e2>_31\NNS\10322238 ._32\.\1740
D001569_D009207 NONE considering_0\VBG\689344 the_1\DT\1740 fact_2\NN\5816287 that_3\IN\1740 5-htp_4\NN\1740 and_5\CC\1740 the_6\DT\1740 <e1>benzodiazepines</e1>_7\NNS\3771443 have_8\VBP\2108377 been_9\VBN\836236 found_10\VBN\2426171 to_11\TO\1740 be_12\VB\836236 beneficial_13\JJ\1740 in_14\IN\13603305 the_15\DT\1740 management_16\NN\1123598 of_17\IN\1740 clinical_18\JJ\1740 <e2>myoclonus</e2>_19\NN\14360459 ,_20\,\1740 the_21\DT\1740 muscimol-induced_22\JJ\1740 myoclonus_23\NN\14360459 seems_24\VBZ\2604760 to_25\TO\1740 be_26\VB\836236 a_27\DT\13649268 satisfactory_28\JJ\1740 animal_29\NN\4475 model_30\NN\5888929 that_31\WDT\1740 may_32\MD\15209706 prove_33\VB\2604760 useful_34\JJ\1740 for_35\IN\1740 the_36\DT\1740 development_37\NN\248977 of_38\IN\1740 new_39\JJ\1740 drug_40\NN\14778436 treatments_41\NNS\654885 for_42\IN\1740 this_43\DT\1740 condition_44\NN\24720 ._45\.\1740
D001569_D009207 NONE considering_0\VBG\689344 the_1\DT\1740 fact_2\NN\5816287 that_3\IN\1740 5-htp_4\NN\1740 and_5\CC\1740 the_6\DT\1740 <e1>benzodiazepines</e1>_7\NNS\3771443 have_8\VBP\2108377 been_9\VBN\836236 found_10\VBN\2426171 to_11\TO\1740 be_12\VB\836236 beneficial_13\JJ\1740 in_14\IN\13603305 the_15\DT\1740 management_16\NN\1123598 of_17\IN\1740 clinical_18\JJ\1740 myoclonus_19\NN\14360459 ,_20\,\1740 the_21\DT\1740 muscimol-induced_22\JJ\1740 <e2>myoclonus</e2>_23\NN\14360459 seems_24\VBZ\2604760 to_25\TO\1740 be_26\VB\836236 a_27\DT\13649268 satisfactory_28\JJ\1740 animal_29\NN\4475 model_30\NN\5888929 that_31\WDT\1740 may_32\MD\15209706 prove_33\VB\2604760 useful_34\JJ\1740 for_35\IN\1740 the_36\DT\1740 development_37\NN\248977 of_38\IN\1740 new_39\JJ\1740 drug_40\NN\14778436 treatments_41\NNS\654885 for_42\IN\1740 this_43\DT\1740 condition_44\NN\24720 ._45\.\1740
D001418_D009207 NONE serotonergic_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 benzodiazepines_3\NNS\3771443 and_4\CC\1740 <e1>baclofen</e1>_5\VB\1740 block_6\NN\21939 muscimol-induced_7\JJ\1740 <e2>myoclonic_8\JJ\1740 jerks</e2>_9\NNS\10322238 in_10\IN\13603305 a_11\DT\13649268 strain_12\NN\7358060 of_13\IN\1740 mice_14\NNS\2329401 ._15\.\1740
D001418_D009207 NONE our_0\PRP$\1740 present_1\JJ\1740 study_2\NN\635850 indicated_3\VBD\952524 the_4\DT\1740 possible_5\JJ\1740 value_6\NN\5856066 of_7\IN\1740 mk-212_8\NN\1740 and_9\CC\1740 <e1>(-)-baclofen</e1>_10\NN\1740 in_11\IN\13603305 the_12\DT\1740 management_13\NN\1123598 of_14\IN\1740 clinical_15\JJ\1740 <e2>myoclonus</e2>_16\NN\14360459 ._17\.\1740
D009118_D009207 CID serotonergic_0\JJ\1740 drugs_1\NNS\14778436 ,_2\,\1740 benzodiazepines_3\NNS\3771443 and_4\CC\1740 baclofen_5\VB\1740 block_6\NN\21939 <e1>muscimol-induced</e1>_7\JJ\1740 <e2>myoclonic_8\JJ\1740 jerks</e2>_9\NNS\10322238 in_10\IN\13603305 a_11\DT\13649268 strain_12\NN\7358060 of_13\IN\1740 mice_14\NNS\2329401 ._15\.\1740
D009118_D009207 CID in_0\IN\13603305 male_1\JJ\1740 swiss_2\JJ\1740 mice_3\NNS\2329401 ,_4\,\1740 <e1>muscimol</e1>_5\NN\1740 produced_6\VBD\1617192 <e2>myoclonic_7\JJ\1740 jerks</e2>_8\NNS\10322238 ._9\.\1740
D009118_D009207 CID considering_0\VBG\689344 the_1\DT\1740 fact_2\NN\5816287 that_3\IN\1740 5-htp_4\NN\1740 and_5\CC\1740 the_6\DT\1740 benzodiazepines_7\NNS\3771443 have_8\VBP\2108377 been_9\VBN\836236 found_10\VBN\2426171 to_11\TO\1740 be_12\VB\836236 beneficial_13\JJ\1740 in_14\IN\13603305 the_15\DT\1740 management_16\NN\1123598 of_17\IN\1740 clinical_18\JJ\1740 <e2>myoclonus</e2>_19\NN\14360459 ,_20\,\1740 the_21\DT\1740 <e1>muscimol-induced</e1>_22\JJ\1740 myoclonus_23\NN\14360459 seems_24\VBZ\2604760 to_25\TO\1740 be_26\VB\836236 a_27\DT\13649268 satisfactory_28\JJ\1740 animal_29\NN\4475 model_30\NN\5888929 that_31\WDT\1740 may_32\MD\15209706 prove_33\VB\2604760 useful_34\JJ\1740 for_35\IN\1740 the_36\DT\1740 development_37\NN\248977 of_38\IN\1740 new_39\JJ\1740 drug_40\NN\14778436 treatments_41\NNS\654885 for_42\IN\1740 this_43\DT\1740 condition_44\NN\24720 ._45\.\1740
D009118_D009207 CID considering_0\VBG\689344 the_1\DT\1740 fact_2\NN\5816287 that_3\IN\1740 5-htp_4\NN\1740 and_5\CC\1740 the_6\DT\1740 benzodiazepines_7\NNS\3771443 have_8\VBP\2108377 been_9\VBN\836236 found_10\VBN\2426171 to_11\TO\1740 be_12\VB\836236 beneficial_13\JJ\1740 in_14\IN\13603305 the_15\DT\1740 management_16\NN\1123598 of_17\IN\1740 clinical_18\JJ\1740 myoclonus_19\NN\14360459 ,_20\,\1740 the_21\DT\1740 <e1>muscimol-induced</e1>_22\JJ\1740 <e2>myoclonus</e2>_23\NN\14360459 seems_24\VBZ\2604760 to_25\TO\1740 be_26\VB\836236 a_27\DT\13649268 satisfactory_28\JJ\1740 animal_29\NN\4475 model_30\NN\5888929 that_31\WDT\1740 may_32\MD\15209706 prove_33\VB\2604760 useful_34\JJ\1740 for_35\IN\1740 the_36\DT\1740 development_37\NN\248977 of_38\IN\1740 new_39\JJ\1740 drug_40\NN\14778436 treatments_41\NNS\654885 for_42\IN\1740 this_43\DT\1740 condition_44\NN\24720 ._45\.\1740
D002998_D009207 NONE of_0\IN\1740 the_1\DT\1740 benzodiazepines_2\NNS\3771443 ,_3\,\1740 <e1>clonazepam</e1>_4\NN\1740 (_5\-LRB-\1740 0.1_6\CD\1740 -_7\SYM\1740 0.3_8\CD\1740 mg/kg_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 found_12\VBN\2426171 to_13\TO\1740 be_14\VB\836236 several_15\JJ\1740 fold_16\NN\13864763 more_17\RBR\1740 potent_18\JJ\1740 than_19\IN\1740 diazepam_20\NN\2830852 (_21\-LRB-\1740 0.3_22\CD\1740 -_23\SYM\1740 3_24\CD\13741022 mg/kg_25\NN\1740 )_26\-RRB-\1740 in_27\IN\13603305 blocking_28\VBG\1476483 the_29\DT\1740 <e2>myoclonic_30\JJ\1740 jerks</e2>_31\NNS\10322238 ._32\.\1740
D003975_D009207 NONE of_0\IN\1740 the_1\DT\1740 benzodiazepines_2\NNS\3771443 ,_3\,\1740 clonazepam_4\NN\1740 (_5\-LRB-\1740 0.1_6\CD\1740 -_7\SYM\1740 0.3_8\CD\1740 mg/kg_9\NN\1740 )_10\-RRB-\1740 was_11\VBD\836236 found_12\VBN\2426171 to_13\TO\1740 be_14\VB\836236 several_15\JJ\1740 fold_16\NN\13864763 more_17\RBR\1740 potent_18\JJ\1740 than_19\IN\1740 <e1>diazepam</e1>_20\NN\2830852 (_21\-LRB-\1740 0.3_22\CD\1740 -_23\SYM\1740 3_24\CD\13741022 mg/kg_25\NN\1740 )_26\-RRB-\1740 in_27\IN\13603305 blocking_28\VBG\1476483 the_29\DT\1740 <e2>myoclonic_30\JJ\1740 jerks</e2>_31\NNS\10322238 ._32\.\1740
D006916_D009207 NONE considering_0\VBG\689344 the_1\DT\1740 fact_2\NN\5816287 that_3\IN\1740 <e1>5-htp</e1>_4\NN\1740 and_5\CC\1740 the_6\DT\1740 benzodiazepines_7\NNS\3771443 have_8\VBP\2108377 been_9\VBN\836236 found_10\VBN\2426171 to_11\TO\1740 be_12\VB\836236 beneficial_13\JJ\1740 in_14\IN\13603305 the_15\DT\1740 management_16\NN\1123598 of_17\IN\1740 clinical_18\JJ\1740 <e2>myoclonus</e2>_19\NN\14360459 ,_20\,\1740 the_21\DT\1740 muscimol-induced_22\JJ\1740 myoclonus_23\NN\14360459 seems_24\VBZ\2604760 to_25\TO\1740 be_26\VB\836236 a_27\DT\13649268 satisfactory_28\JJ\1740 animal_29\NN\4475 model_30\NN\5888929 that_31\WDT\1740 may_32\MD\15209706 prove_33\VB\2604760 useful_34\JJ\1740 for_35\IN\1740 the_36\DT\1740 development_37\NN\248977 of_38\IN\1740 new_39\JJ\1740 drug_40\NN\14778436 treatments_41\NNS\654885 for_42\IN\1740 this_43\DT\1740 condition_44\NN\24720 ._45\.\1740
D006916_D009207 NONE considering_0\VBG\689344 the_1\DT\1740 fact_2\NN\5816287 that_3\IN\1740 <e1>5-htp</e1>_4\NN\1740 and_5\CC\1740 the_6\DT\1740 benzodiazepines_7\NNS\3771443 have_8\VBP\2108377 been_9\VBN\836236 found_10\VBN\2426171 to_11\TO\1740 be_12\VB\836236 beneficial_13\JJ\1740 in_14\IN\13603305 the_15\DT\1740 management_16\NN\1123598 of_17\IN\1740 clinical_18\JJ\1740 myoclonus_19\NN\14360459 ,_20\,\1740 the_21\DT\1740 muscimol-induced_22\JJ\1740 <e2>myoclonus</e2>_23\NN\14360459 seems_24\VBZ\2604760 to_25\TO\1740 be_26\VB\836236 a_27\DT\13649268 satisfactory_28\JJ\1740 animal_29\NN\4475 model_30\NN\5888929 that_31\WDT\1740 may_32\MD\15209706 prove_33\VB\2604760 useful_34\JJ\1740 for_35\IN\1740 the_36\DT\1740 development_37\NN\248977 of_38\IN\1740 new_39\JJ\1740 drug_40\NN\14778436 treatments_41\NNS\654885 for_42\IN\1740 this_43\DT\1740 condition_44\NN\24720 ._45\.\1740
C014896_D009207 NONE our_0\PRP$\1740 present_1\JJ\1740 study_2\NN\635850 indicated_3\VBD\952524 the_4\DT\1740 possible_5\JJ\1740 value_6\NN\5856066 of_7\IN\1740 <e1>mk-212</e1>_8\NN\1740 and_9\CC\1740 (-)-baclofen_10\NN\1740 in_11\IN\13603305 the_12\DT\1740 management_13\NN\1123598 of_14\IN\1740 clinical_15\JJ\1740 <e2>myoclonus</e2>_16\NN\14360459 ._17\.\1740
20552622
D000420_D013617 CID swallowing-induced_0\JJ\1740 <e2>atrial_1\JJ\1740 tachyarrhythmia</e2>_2\NN\1740 triggered_3\VBN\1641914 by_4\IN\1740 <e1>salbutamol</e1>_5\NN\1740 :_6\:\1740 case_7\NN\7283608 report_8\NN\6470073 and_9\CC\1740 review_10\NN\5733583 of_11\IN\1740 the_12\DT\1740 literature_13\NN\6362953 ._14\.\1740
D000420_D013617 CID conclusion_0\NN\5837957 :_1\:\1740 <e1>salbutamol</e1>_2\NNP\1740 is_3\VBZ\836236 presented_4\VBN\2137132 here_5\RB\1740 as_6\IN\14622893 a_7\DT\13649268 possible_8\JJ\1740 trigger_9\NN\3659292 for_10\IN\1740 <e2>siat</e2>_11\NN\1740 ._12\.\1740
D001262_D001145 NONE the_0\DT\1740 <e2>arrhythmia</e2>_1\NN\14103288 resolved_2\VBN\352826 after_3\IN\1740 therapy_4\NN\657604 with_5\IN\1740 <e1>atenolol</e1>_6\NNS\2832168 ,_7\,\1740 but_8\CC\1740 recurred_9\VBD\339934 a_10\DT\13649268 year_11\NN\15113229 later_12\RB\1740 ._13\.\1740
D001262_D001145 NONE after_0\IN\1740 stopping_1\VBG\2452885 the_2\DT\1740 beta-agonist_3\JJ\1740 ,_4\,\1740 and_5\CC\1740 after_6\IN\1740 a_7\DT\13649268 week_8\NN\15113229 with_9\IN\1740 the_10\DT\1740 <e1>atenolol</e1>_11\NNS\2832168 ,_12\,\1740 the_13\DT\1740 <e2>arrhythmia</e2>_14\NN\14103288 disappeared_15\VBD\2609764 ._16\.\1740
D000420_D013610 NONE although_0\IN\1740 it_1\PRP\6125041 is_2\VBZ\836236 difficult_3\JJ\1740 to_4\TO\1740 define_5\VB\2604760 causality_6\NN\31921 in_7\IN\13603305 a_8\DT\13649268 case_9\NN\7283608 report_10\NN\6470073 ,_11\,\1740 it_12\PRP\6125041 is_13\VBZ\836236 logical_14\JJ\1740 to_15\TO\1740 think_16\VB\670261 that_17\IN\1740 a_18\DT\13649268 beta-agonist_19\JJ\1740 like_20\UH\5839024 <e1>salbutamol</e1>_21\NN\1740 (_22\-LRB-\1740 known_23\VBN\2110220 to_24\TO\1740 induce_25\VB\1627355 <e2>tachycardia</e2>_26\NN\14110674 )_27\-RRB-\1740 may_28\MD\15209706 be_29\VB\836236 the_30\DT\1740 trigger_31\NN\3659292 of_32\IN\1740 adrenergic_33\JJ\1740 reflexes_34\NNS\859001 originating_35\VBG\2623529 in_36\IN\13603305 the_37\DT\1740 esophagus_38\NN\5461816 while_39\IN\15122231 swallowing_40\VBG\1156834 and_41\CC\1740 that_42\IN\1740 a_43\DT\13649268 beta-blocker_44\NN\1740 such_45\JJ\1740 as_46\IN\14622893 atenolol_47\NNS\2832168 (_48\-LRB-\1740 that_49\WDT\1740 blocks_50\VBZ\1476483 the_51\DT\1740 adrenergic_52\JJ\1740 activity_53\NN\30358 )_54\-RRB-\1740 may_55\MD\15209706 relieve_56\VB\205885 it_57\PRP\6125041 ._58\.\1740
D001262_D013610 NONE although_0\IN\1740 it_1\PRP\6125041 is_2\VBZ\836236 difficult_3\JJ\1740 to_4\TO\1740 define_5\VB\2604760 causality_6\NN\31921 in_7\IN\13603305 a_8\DT\13649268 case_9\NN\7283608 report_10\NN\6470073 ,_11\,\1740 it_12\PRP\6125041 is_13\VBZ\836236 logical_14\JJ\1740 to_15\TO\1740 think_16\VB\670261 that_17\IN\1740 a_18\DT\13649268 beta-agonist_19\JJ\1740 like_20\UH\5839024 salbutamol_21\NN\1740 (_22\-LRB-\1740 known_23\VBN\2110220 to_24\TO\1740 induce_25\VB\1627355 <e2>tachycardia</e2>_26\NN\14110674 )_27\-RRB-\1740 may_28\MD\15209706 be_29\VB\836236 the_30\DT\1740 trigger_31\NN\3659292 of_32\IN\1740 adrenergic_33\JJ\1740 reflexes_34\NNS\859001 originating_35\VBG\2623529 in_36\IN\13603305 the_37\DT\1740 esophagus_38\NN\5461816 while_39\IN\15122231 swallowing_40\VBG\1156834 and_41\CC\1740 that_42\IN\1740 a_43\DT\13649268 beta-blocker_44\NN\1740 such_45\JJ\1740 as_46\IN\14622893 <e1>atenolol</e1>_47\NNS\2832168 (_48\-LRB-\1740 that_49\WDT\1740 blocks_50\VBZ\1476483 the_51\DT\1740 adrenergic_52\JJ\1740 activity_53\NN\30358 )_54\-RRB-\1740 may_55\MD\15209706 relieve_56\VB\205885 it_57\PRP\6125041 ._58\.\1740
11282081
D014700_D001281 CID effects_0\NNS\13245626 of_1\IN\1740 <e1>verapamil</e1>_2\NN\2938514 on_3\IN\1740 <e2>atrial_4\JJ\1740 fibrillation</e2>_5\NN\14361664 and_6\CC\1740 its_7\PRP$\6125041 electrophysiological_8\JJ\1740 determinants_9\NNS\5686481 in_10\IN\13603305 dogs_11\NNS\2083346 ._12\.\1740
D014700_D001281 CID methods_0\NNS\5616786 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 potential_5\JJ\1740 mechanisms_6\NNS\13446390 of_7\IN\1740 <e2>af</e2>_8\NN\1740 promotion_9\NN\6598915 by_10\IN\1740 ca(2_11\NN\1740 +_12\CC\1740 )_13\-RRB-\1740 channel_14\NN\6251781 blockers_15\NNS\10101634 ,_16\,\1740 we_17\PRP\1740 administered_18\VBD\2436349 <e1>verapamil</e1>_19\NNS\2938514 to_20\TO\1740 morphine-chloralose_21\RB\1740 anesthetized_22\JJ\1740 dogs_23\NNS\2083346 ._24\.\1740
D014700_D001281 CID results_0\NNS\34213 :_1\:\1740 <e1>verapamil</e1>_2\NNS\2938514 caused_3\VBD\1617192 <e2>af</e2>_4\NN\1740 promotion_5\NN\6598915 in_6\IN\13603305 six_7\CD\13741022 dogs_8\NNS\2083346 ,_9\,\1740 increasing_10\VBG\169651 mean_11\NN\6021761 duration_12\NN\15113229 of_13\IN\1740 af_14\NN\1740 induced_15\VBN\1627355 by_16\IN\1740 burst_17\NN\376063 pacing_18\NN\15122011 ,_19\,\1740 from_20\IN\1740 8+/-4_21\JJ\1740 s_22\NNS\15154774 (_23\-LRB-\1740 mean+/-s.e._24\JJ\1740 )_25\-RRB-\1740 to_26\TO\1740 95+/-39_27\CD\1740 s_28\NNS\15154774 (_29\-LRB-\1740 p<0.01_30\NN\1740 vs._31\NN\1740 control_32\NN\5190804 )_33\-RRB-\1740 at_34\IN\14622893 a_35\DT\13649268 loading_36\NN\4571088 dose_37\NN\3740161 of_38\IN\1740 0.1_39\CD\1740 mg/kg_40\NN\1740 and_41\CC\1740 228+/-101_42\CD\1740 s_43\NNS\15154774 (_44\-LRB-\1740 p<0.0005_45\NN\1740 vs._46\IN\1740 control_47\NN\5190804 )_48\-RRB-\1740 at_49\IN\14622893 a_50\DT\13649268 dose_51\NN\3740161 of_52\IN\1740 0.2_53\CD\1740 mg/kg_54\NN\1740 ._55\.\1740
D014700_D001281 CID results_0\NNS\34213 :_1\:\1740 <e1>verapamil</e1>_2\NNS\2938514 caused_3\VBD\1617192 af_4\NN\1740 promotion_5\NN\6598915 in_6\IN\13603305 six_7\CD\13741022 dogs_8\NNS\2083346 ,_9\,\1740 increasing_10\VBG\169651 mean_11\NN\6021761 duration_12\NN\15113229 of_13\IN\1740 <e2>af</e2>_14\NN\1740 induced_15\VBN\1627355 by_16\IN\1740 burst_17\NN\376063 pacing_18\NN\15122011 ,_19\,\1740 from_20\IN\1740 8+/-4_21\JJ\1740 s_22\NNS\15154774 (_23\-LRB-\1740 mean+/-s.e._24\JJ\1740 )_25\-RRB-\1740 to_26\TO\1740 95+/-39_27\CD\1740 s_28\NNS\15154774 (_29\-LRB-\1740 p<0.01_30\NN\1740 vs._31\NN\1740 control_32\NN\5190804 )_33\-RRB-\1740 at_34\IN\14622893 a_35\DT\13649268 loading_36\NN\4571088 dose_37\NN\3740161 of_38\IN\1740 0.1_39\CD\1740 mg/kg_40\NN\1740 and_41\CC\1740 228+/-101_42\CD\1740 s_43\NNS\15154774 (_44\-LRB-\1740 p<0.0005_45\NN\1740 vs._46\IN\1740 control_47\NN\5190804 )_48\-RRB-\1740 at_49\IN\14622893 a_50\DT\13649268 dose_51\NN\3740161 of_52\IN\1740 0.2_53\CD\1740 mg/kg_54\NN\1740 ._55\.\1740
D014700_D001281 CID in_0\IN\13603305 these_1\DT\1740 experiments_2\NNS\641820 ,_3\,\1740 <e1>verapamil</e1>_4\NN\2938514 shortened_5\VBD\429060 mean_6\NN\6021761 effective_7\JJ\1740 refractory_8\JJ\1740 period_9\NN\13575869 (_10\-LRB-\1740 erp_11\NN\1740 )_12\-RRB-\1740 from_13\IN\1740 122+/-5_14\CD\1740 to_15\TO\1740 114+/-4_16\CD\1740 ms_17\NN\14187378 (_18\-LRB-\1740 p<0.02_19\NN\1740 )_20\-RRB-\1740 at_21\IN\14622893 a_22\DT\13649268 cycle_23\NN\15269513 length_24\NN\5093581 of_25\IN\1740 300_26\CD\1740 ms_27\NN\14187378 ,_28\,\1740 decreased_29\VBD\169651 erp_30\NN\1740 heterogeneity_31\NN\4750940 (_32\-LRB-\1740 from_33\IN\1740 15+/-1_34\CD\1740 to_35\TO\1740 10+/-1_36\CD\1740 %_37\NN\1740 ,_38\,\1740 p<0.05_39\NN\1740 )_40\-RRB-\1740 ,_41\,\1740 heterogeneously_42\RB\1740 accelerated_43\VBD\226566 atrial_44\JJ\1740 conduction_45\NN\11419404 and_46\CC\1740 decreased_47\VBD\169651 the_48\DT\1740 cycle_49\NN\15269513 length_50\NN\5093581 of_51\IN\1740 <e2>af</e2>_52\NN\1740 (_53\-LRB-\1740 94+/-4_54\CD\1740 to_55\TO\1740 84+/-3_56\CD\1740 ms_57\NN\14187378 ,_58\,\1740 p<0.005_59\JJ\1740 )_60\-RRB-\1740 ._61\.\1740
D014700_D001281 CID diltiazem_0\NNP\2938514 did_1\VBD\1640855 not_2\RB\1740 affect_3\VB\126264 erp_4\NN\1740 ,_5\,\1740 <e2>af</e2>_6\NN\1740 cycle_7\NN\15269513 length_8\NN\5093581 or_9\CC\3541091 af_10\NN\1740 duration_11\NN\15113229 ,_12\,\1740 but_13\CC\1740 produced_14\VBD\1617192 conduction_15\NN\11419404 acceleration_16\NN\7296428 similar_17\JJ\1740 to_18\TO\1740 that_19\DT\1740 caused_20\VBN\1617192 by_21\IN\1740 <e1>verapamil</e1>_22\NN\2938514 (_23\-LRB-\1740 n=5_24\JJ\1740 )_25\-RRB-\1740 ._26\.\1740
D014700_D001281 CID diltiazem_0\NNP\2938514 did_1\VBD\1640855 not_2\RB\1740 affect_3\VB\126264 erp_4\NN\1740 ,_5\,\1740 af_6\NN\1740 cycle_7\NN\15269513 length_8\NN\5093581 or_9\CC\3541091 <e2>af</e2>_10\NN\1740 duration_11\NN\15113229 ,_12\,\1740 but_13\CC\1740 produced_14\VBD\1617192 conduction_15\NN\11419404 acceleration_16\NN\7296428 similar_17\JJ\1740 to_18\TO\1740 that_19\DT\1740 caused_20\VBN\1617192 by_21\IN\1740 <e1>verapamil</e1>_22\NN\2938514 (_23\-LRB-\1740 n=5_24\JJ\1740 )_25\-RRB-\1740 ._26\.\1740
D014700_D001281 CID in_0\IN\13603305 the_1\DT\1740 presence_2\NN\13954253 of_3\IN\1740 autonomic_4\JJ\1740 blockade_5\NN\952963 ,_6\,\1740 <e1>verapamil</e1>_7\NN\2938514 failed_8\VBD\1798936 to_9\TO\1740 promote_10\VB\2556126 <e2>af</e2>_11\NN\1740 and_12\CC\1740 increased_13\VBD\169651 ,_14\,\1740 rather_15\RB\1740 than_16\IN\1740 decreasing_17\VBG\169651 ,_18\,\1740 refractoriness_19\VB\1740 ._20\.\1740
D014700_D001281 CID epicardial_0\JJ\1740 mapping_1\NN\13783581 suggested_2\VBD\1010118 that_3\IN\1740 <e1>verapamil</e1>_4\NN\2938514 promoted_5\VBD\2556126 <e2>af</e2>_6\NN\1740 by_7\IN\1740 increasing_8\VBG\169651 the_9\DT\1740 number_10\NN\5107765 of_11\IN\1740 simultaneous_12\JJ\1740 wavefronts_13\NNS\8660339 reflected_14\VBN\923793 by_15\IN\1740 separate_16\JJ\1740 zones_17\NNS\8664443 of_18\IN\1740 reactivation_19\NN\1740 in_20\IN\13603305 each_21\DT\1740 cycle_22\NN\15269513 ._23\.\1740
D014700_D001281 CID conclusions_0\NNS\5837957 :_1\:\1740 <e1>verapamil</e1>_2\NN\2938514 promotes_3\VBZ\2556126 <e2>af</e2>_4\NN\1740 in_5\IN\13603305 normal_6\JJ\1740 dogs_7\NNS\2083346 by_8\IN\1740 promoting_9\VBG\2556126 multiple_10\JJ\1740 circuit_11\NN\3269401 reentry_12\NN\328015 ,_13\,\1740 an_14\DT\6697703 effect_15\NN\34213 dependent_16\JJ\1740 on_17\IN\1740 intact_18\JJ\1740 autonomic_19\JJ\1740 tone_20\NN\7071483 and_21\CC\1740 not_22\RB\1740 shared_23\VBN\2660631 by_24\IN\1740 diltiazem_25\NN\2938514 ._26\.\1740
D002118_D013617 NONE background_0\NN\4921011 :_1\:\1740 <e2>atrial_2\JJ\1740 tachycardia-induced</e2>_3\JJ\1740 remodeling_4\NN\1740 promotes_5\VBZ\2556126 the_6\DT\1740 occurrence_7\NN\29378 and_8\CC\1740 maintenance_9\NN\266806 of_10\IN\1740 atrial_11\JJ\1740 fibrillation_12\NN\14361664 (_13\-LRB-\1740 af_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 decreases_17\VBZ\169651 l-type_18\NN\1740 <e1>ca(2</e1>_19\NN\1740 +_20\CC\1740 )_21\-RRB-\1740 current_22\JJ\1740 ._23\.\1740
D002118_D001281 NONE background_0\NN\4921011 :_1\:\1740 atrial_2\JJ\1740 tachycardia-induced_3\JJ\1740 remodeling_4\NN\1740 promotes_5\VBZ\2556126 the_6\DT\1740 occurrence_7\NN\29378 and_8\CC\1740 maintenance_9\NN\266806 of_10\IN\1740 <e2>atrial_11\JJ\1740 fibrillation</e2>_12\NN\14361664 (_13\-LRB-\1740 af_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 decreases_17\VBZ\169651 l-type_18\NN\1740 <e1>ca(2</e1>_19\NN\1740 +_20\CC\1740 )_21\-RRB-\1740 current_22\JJ\1740 ._23\.\1740
D002118_D001281 NONE background_0\NN\4921011 :_1\:\1740 atrial_2\JJ\1740 tachycardia-induced_3\JJ\1740 remodeling_4\NN\1740 promotes_5\VBZ\2556126 the_6\DT\1740 occurrence_7\NN\29378 and_8\CC\1740 maintenance_9\NN\266806 of_10\IN\1740 atrial_11\JJ\1740 fibrillation_12\NN\14361664 (_13\-LRB-\1740 <e2>af</e2>_14\NN\1740 )_15\-RRB-\1740 and_16\CC\1740 decreases_17\VBZ\169651 l-type_18\NN\1740 <e1>ca(2</e1>_19\NN\1740 +_20\CC\1740 )_21\-RRB-\1740 current_22\JJ\1740 ._23\.\1740
D002118_D001281 NONE there_0\EX\27167 is_1\VBZ\836236 also_2\RB\1740 a_3\DT\13649268 clinical_4\JJ\1740 suggestion_5\NN\5833840 that_6\IN\1740 acute_7\JJ\1740 l-type_8\NN\1740 <e1>ca(2</e1>_9\NN\1740 )_10\-RRB-\1740 channel_11\NN\6251781 blockade_12\NN\952963 can_13\MD\3094503 promote_14\VB\2556126 <e2>af</e2>_15\NN\1740 ,_16\,\1740 consistent_17\JJ\1740 with_18\IN\1740 an_19\DT\6697703 af_20\NN\1740 promoting_21\NN\1740 effect_22\NN\34213 of_23\IN\1740 ca(2_24\NN\1740 +_25\CC\1740 )_26\-RRB-\1740 channel_27\NN\6251781 inhibition_28\NN\1068773 ._29\.\1740
D002118_D001281 NONE there_0\EX\27167 is_1\VBZ\836236 also_2\RB\1740 a_3\DT\13649268 clinical_4\JJ\1740 suggestion_5\NN\5833840 that_6\IN\1740 acute_7\JJ\1740 l-type_8\NN\1740 <e1>ca(2</e1>_9\NN\1740 )_10\-RRB-\1740 channel_11\NN\6251781 blockade_12\NN\952963 can_13\MD\3094503 promote_14\VB\2556126 af_15\NN\1740 ,_16\,\1740 consistent_17\JJ\1740 with_18\IN\1740 an_19\DT\6697703 <e2>af</e2>_20\NN\1740 promoting_21\NN\1740 effect_22\NN\34213 of_23\IN\1740 ca(2_24\NN\1740 +_25\CC\1740 )_26\-RRB-\1740 channel_27\NN\6251781 inhibition_28\NN\1068773 ._29\.\1740
D002118_D001281 NONE there_0\EX\27167 is_1\VBZ\836236 also_2\RB\1740 a_3\DT\13649268 clinical_4\JJ\1740 suggestion_5\NN\5833840 that_6\IN\1740 acute_7\JJ\1740 l-type_8\NN\1740 ca(2_9\NN\1740 )_10\-RRB-\1740 channel_11\NN\6251781 blockade_12\NN\952963 can_13\MD\3094503 promote_14\VB\2556126 <e2>af</e2>_15\NN\1740 ,_16\,\1740 consistent_17\JJ\1740 with_18\IN\1740 an_19\DT\6697703 af_20\NN\1740 promoting_21\NN\1740 effect_22\NN\34213 of_23\IN\1740 <e1>ca(2</e1>_24\NN\1740 +_25\CC\1740 )_26\-RRB-\1740 channel_27\NN\6251781 inhibition_28\NN\1068773 ._29\.\1740
D002118_D001281 NONE there_0\EX\27167 is_1\VBZ\836236 also_2\RB\1740 a_3\DT\13649268 clinical_4\JJ\1740 suggestion_5\NN\5833840 that_6\IN\1740 acute_7\JJ\1740 l-type_8\NN\1740 ca(2_9\NN\1740 )_10\-RRB-\1740 channel_11\NN\6251781 blockade_12\NN\952963 can_13\MD\3094503 promote_14\VB\2556126 af_15\NN\1740 ,_16\,\1740 consistent_17\JJ\1740 with_18\IN\1740 an_19\DT\6697703 <e2>af</e2>_20\NN\1740 promoting_21\NN\1740 effect_22\NN\34213 of_23\IN\1740 <e1>ca(2</e1>_24\NN\1740 +_25\CC\1740 )_26\-RRB-\1740 channel_27\NN\6251781 inhibition_28\NN\1068773 ._29\.\1740
D002118_D001281 NONE methods_0\NNS\5616786 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 potential_5\JJ\1740 mechanisms_6\NNS\13446390 of_7\IN\1740 <e2>af</e2>_8\NN\1740 promotion_9\NN\6598915 by_10\IN\1740 <e1>ca(2</e1>_11\NN\1740 +_12\CC\1740 )_13\-RRB-\1740 channel_14\NN\6251781 blockers_15\NNS\10101634 ,_16\,\1740 we_17\PRP\1740 administered_18\VBD\2436349 verapamil_19\NNS\2938514 to_20\TO\1740 morphine-chloralose_21\RB\1740 anesthetized_22\JJ\1740 dogs_23\NNS\2083346 ._24\.\1740
D009020_D001281 NONE methods_0\NNS\5616786 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 potential_5\JJ\1740 mechanisms_6\NNS\13446390 of_7\IN\1740 <e2>af</e2>_8\NN\1740 promotion_9\NN\6598915 by_10\IN\1740 ca(2_11\NN\1740 +_12\CC\1740 )_13\-RRB-\1740 channel_14\NN\6251781 blockers_15\NNS\10101634 ,_16\,\1740 we_17\PRP\1740 administered_18\VBD\2436349 verapamil_19\NNS\2938514 to_20\TO\1740 <e1>morphine-chloralose</e1>_21\RB\1740 anesthetized_22\JJ\1740 dogs_23\NNS\2083346 ._24\.\1740
D002698_D001281 NONE methods_0\NNS\5616786 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 potential_5\JJ\1740 mechanisms_6\NNS\13446390 of_7\IN\1740 <e2>af</e2>_8\NN\1740 promotion_9\NN\6598915 by_10\IN\1740 ca(2_11\NN\1740 +_12\CC\1740 )_13\-RRB-\1740 channel_14\NN\6251781 blockers_15\NNS\10101634 ,_16\,\1740 we_17\PRP\1740 administered_18\VBD\2436349 verapamil_19\NNS\2938514 to_20\TO\1740 <e1>morphine-chloralose</e1>_21\RB\1740 anesthetized_22\JJ\1740 dogs_23\NNS\2083346 ._24\.\1740
D004110_D001281 NONE <e1>diltiazem</e1>_0\NNP\2938514 did_1\VBD\1640855 not_2\RB\1740 affect_3\VB\126264 erp_4\NN\1740 ,_5\,\1740 <e2>af</e2>_6\NN\1740 cycle_7\NN\15269513 length_8\NN\5093581 or_9\CC\3541091 af_10\NN\1740 duration_11\NN\15113229 ,_12\,\1740 but_13\CC\1740 produced_14\VBD\1617192 conduction_15\NN\11419404 acceleration_16\NN\7296428 similar_17\JJ\1740 to_18\TO\1740 that_19\DT\1740 caused_20\VBN\1617192 by_21\IN\1740 verapamil_22\NN\2938514 (_23\-LRB-\1740 n=5_24\JJ\1740 )_25\-RRB-\1740 ._26\.\1740
D004110_D001281 NONE <e1>diltiazem</e1>_0\NNP\2938514 did_1\VBD\1640855 not_2\RB\1740 affect_3\VB\126264 erp_4\NN\1740 ,_5\,\1740 af_6\NN\1740 cycle_7\NN\15269513 length_8\NN\5093581 or_9\CC\3541091 <e2>af</e2>_10\NN\1740 duration_11\NN\15113229 ,_12\,\1740 but_13\CC\1740 produced_14\VBD\1617192 conduction_15\NN\11419404 acceleration_16\NN\7296428 similar_17\JJ\1740 to_18\TO\1740 that_19\DT\1740 caused_20\VBN\1617192 by_21\IN\1740 verapamil_22\NN\2938514 (_23\-LRB-\1740 n=5_24\JJ\1740 )_25\-RRB-\1740 ._26\.\1740
D004110_D001281 NONE conclusions_0\NNS\5837957 :_1\:\1740 verapamil_2\NN\2938514 promotes_3\VBZ\2556126 <e2>af</e2>_4\NN\1740 in_5\IN\13603305 normal_6\JJ\1740 dogs_7\NNS\2083346 by_8\IN\1740 promoting_9\VBG\2556126 multiple_10\JJ\1740 circuit_11\NN\3269401 reentry_12\NN\328015 ,_13\,\1740 an_14\DT\6697703 effect_15\NN\34213 dependent_16\JJ\1740 on_17\IN\1740 intact_18\JJ\1740 autonomic_19\JJ\1740 tone_20\NN\7071483 and_21\CC\1740 not_22\RB\1740 shared_23\VBN\2660631 by_24\IN\1740 <e1>diltiazem</e1>_25\NN\2938514 ._26\.\1740
7650771
D004456_D064420 NONE cholinergic_0\JJ\1740 <e2>toxicity</e2>_1\NN\13576101 resulting_2\VBG\2633881 from_3\IN\1740 ocular_4\JJ\1740 instillation_5\NN\320852 of_6\IN\1740 <e1>echothiophate_7\JJ\1740 iodide</e1>_8\NN\14904359 eye_9\NN\5299178 drops_10\NNS\13899200 ._11\.\1740
D004456_D018908 CID a_0\DT\13649268 patient_1\NN\9898892 developed_2\VBD\1753788 a_3\DT\13649268 severe_4\JJ\1740 cholinergic_5\JJ\1740 syndrome_6\NN\5870365 from_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>echothiophate_11\JJ\1740 iodide</e1>_12\NN\14904359 ophthalmic_13\JJ\1740 drops_14\NNS\13899200 ,_15\,\1740 presented_16\VBN\2137132 with_17\IN\1740 profound_18\JJ\1740 <e2>muscle_19\NN\5289601 weakness</e2>_20\NN\14462666 and_21\CC\1740 was_22\VBD\836236 initially_23\RB\1740 given_24\VBN\2327200 the_25\DT\1740 diagnosis_26\NN\152018 of_27\IN\1740 myasthenia_28\JJ\1740 gravis_29\NN\1740 ._30\.\1740
D004456_D009157 NONE a_0\DT\13649268 patient_1\NN\9898892 developed_2\VBD\1753788 a_3\DT\13649268 severe_4\JJ\1740 cholinergic_5\JJ\1740 syndrome_6\NN\5870365 from_7\IN\1740 the_8\DT\1740 use_9\NN\407535 of_10\IN\1740 <e1>echothiophate_11\JJ\1740 iodide</e1>_12\NN\14904359 ophthalmic_13\JJ\1740 drops_14\NNS\13899200 ,_15\,\1740 presented_16\VBN\2137132 with_17\IN\1740 profound_18\JJ\1740 muscle_19\NN\5289601 weakness_20\NN\14462666 and_21\CC\1740 was_22\VBD\836236 initially_23\RB\1740 given_24\VBN\2327200 the_25\DT\1740 diagnosis_26\NN\152018 of_27\IN\1740 <e2>myasthenia_28\JJ\1740 gravis</e2>_29\NN\1740 ._30\.\1740
19893084
D005839_D058186 CID in_0\IN\13603305 this_1\DT\1740 study_2\NN\635850 we_3\PRP\1740 postulated_4\VBD\756338 that_5\IN\1740 during_6\IN\1740 <e2>acute_7\JJ\1740 renal_8\JJ\1740 failure</e2>_9\NN\66216 induced_10\VBN\1627355 by_11\IN\1740 <e1>gentamicin</e1>_12\NN\2716866 the_13\DT\1740 transient_14\JJ\1740 or_15\CC\3541091 dynamic_16\JJ\1740 response_17\NN\11410625 of_18\IN\1740 blood_19\NN\5397468 vessels_20\NNS\5246511 could_21\MD\1740 be_22\VB\836236 affected_23\VBN\126264 ,_24\,\1740 and_25\CC\1740 that_26\IN\1740 antioxidants_27\NNS\14724436 can_28\MD\3094503 prevent_29\VB\1740 the_30\DT\1740 changes_31\NNS\7283608 in_32\IN\13603305 dynamic_33\JJ\1740 responses_34\NNS\11410625 of_35\IN\1740 blood_36\NN\5397468 vessels_37\NNS\5246511 ._38\.\1740
7066357
D011692_D009404 CID plasma_0\NN\5398023 and_1\CC\1740 urinary_2\JJ\1740 lipids_3\NNS\14944888 and_4\CC\1740 lipoproteins_5\NNS\14731135 during_6\IN\1740 the_7\DT\1740 development_8\NN\248977 of_9\IN\1740 <e2>nephrotic_10\JJ\1740 syndrome</e2>_11\NN\5870365 induced_12\VBN\1627355 in_13\IN\13603305 the_14\DT\1740 rat_15\NN\2329401 by_16\IN\1740 <e1>puromycin_17\NN\1740 aminonucleoside</e1>_18\NN\1740 ._19\.\1740
D011692_D009404 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 undertaken_3\VBN\1641914 to_4\TO\1740 ascertain_5\VB\664483 whether_6\IN\1740 the_7\DT\1740 alterations_8\NNS\7283608 of_9\IN\1740 plasma_10\NN\5398023 lipoproteins_11\NNS\14731135 found_12\VBN\2426171 in_13\IN\13603305 <e2>nephrotic_14\JJ\1740 syndrome</e2>_15\NN\5870365 induced_16\VBN\1627355 by_17\IN\1740 <e1>puromycin_18\NN\1740 aminonucleoside</e1>_19\NN\1740 were_20\VBD\836236 due_21\JJ\1740 to_22\TO\1740 nephrotic_23\JJ\1740 syndrome_24\NN\5870365 per_25\IN\1740 se_26\FW\14724645 ,_27\,\1740 or_28\CC\3541091 ,_29\,\1740 at_30\IN\14622893 least_31\JJS\1740 in_32\IN\13603305 part_33\NN\31921 ,_34\,\1740 to_35\TO\1740 the_36\DT\1740 aminonucleoside_37\NN\1740 ._38\.\1740
D011692_D009404 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 undertaken_3\VBN\1641914 to_4\TO\1740 ascertain_5\VB\664483 whether_6\IN\1740 the_7\DT\1740 alterations_8\NNS\7283608 of_9\IN\1740 plasma_10\NN\5398023 lipoproteins_11\NNS\14731135 found_12\VBN\2426171 in_13\IN\13603305 nephrotic_14\JJ\1740 syndrome_15\NN\5870365 induced_16\VBN\1627355 by_17\IN\1740 <e1>puromycin_18\NN\1740 aminonucleoside</e1>_19\NN\1740 were_20\VBD\836236 due_21\JJ\1740 to_22\TO\1740 <e2>nephrotic_23\JJ\1740 syndrome</e2>_24\NN\5870365 per_25\IN\1740 se_26\FW\14724645 ,_27\,\1740 or_28\CC\3541091 ,_29\,\1740 at_30\IN\14622893 least_31\JJS\1740 in_32\IN\13603305 part_33\NN\31921 ,_34\,\1740 to_35\TO\1740 the_36\DT\1740 aminonucleoside_37\NN\1740 ._38\.\1740
D011692_D009404 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 undertaken_3\VBN\1641914 to_4\TO\1740 ascertain_5\VB\664483 whether_6\IN\1740 the_7\DT\1740 alterations_8\NNS\7283608 of_9\IN\1740 plasma_10\NN\5398023 lipoproteins_11\NNS\14731135 found_12\VBN\2426171 in_13\IN\13603305 <e2>nephrotic_14\JJ\1740 syndrome</e2>_15\NN\5870365 induced_16\VBN\1627355 by_17\IN\1740 puromycin_18\NN\1740 aminonucleoside_19\NN\1740 were_20\VBD\836236 due_21\JJ\1740 to_22\TO\1740 nephrotic_23\JJ\1740 syndrome_24\NN\5870365 per_25\IN\1740 se_26\FW\14724645 ,_27\,\1740 or_28\CC\3541091 ,_29\,\1740 at_30\IN\14622893 least_31\JJS\1740 in_32\IN\13603305 part_33\NN\31921 ,_34\,\1740 to_35\TO\1740 the_36\DT\1740 <e1>aminonucleoside</e1>_37\NN\1740 ._38\.\1740
D011692_D009404 CID this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 undertaken_3\VBN\1641914 to_4\TO\1740 ascertain_5\VB\664483 whether_6\IN\1740 the_7\DT\1740 alterations_8\NNS\7283608 of_9\IN\1740 plasma_10\NN\5398023 lipoproteins_11\NNS\14731135 found_12\VBN\2426171 in_13\IN\13603305 nephrotic_14\JJ\1740 syndrome_15\NN\5870365 induced_16\VBN\1627355 by_17\IN\1740 puromycin_18\NN\1740 aminonucleoside_19\NN\1740 were_20\VBD\836236 due_21\JJ\1740 to_22\TO\1740 <e2>nephrotic_23\JJ\1740 syndrome</e2>_24\NN\5870365 per_25\IN\1740 se_26\FW\14724645 ,_27\,\1740 or_28\CC\3541091 ,_29\,\1740 at_30\IN\14622893 least_31\JJS\1740 in_32\IN\13603305 part_33\NN\31921 ,_34\,\1740 to_35\TO\1740 the_36\DT\1740 <e1>aminonucleoside</e1>_37\NN\1740 ._38\.\1740
D011692_D009404 CID the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 the_3\DT\1740 present_4\JJ\1740 study_5\NN\635850 was_6\VBD\836236 to_7\TO\1740 investigate_8\VB\644583 the_9\DT\1740 changes_10\NNS\7283608 in_11\IN\13603305 plasma_12\NN\5398023 and_13\CC\1740 urinary_14\JJ\1740 lipoproteins_15\NNS\14731135 during_16\IN\1740 the_17\DT\1740 administration_18\NN\1133281 of_19\IN\1740 <e1>puromycin_20\NN\1740 aminonucleoside</e1>_21\NN\1740 (_22\-LRB-\1740 20_23\CD\13745420 mg/kg_24\NN\1740 for_25\IN\1740 7_26\CD\13741022 days_27\NNS\15140892 )_28\-RRB-\1740 and_29\CC\1740 the_30\DT\1740 subsequent_31\JJ\1740 development_32\NN\248977 of_33\IN\1740 <e2>nephrotic_34\JJ\1740 syndrome</e2>_35\NN\5870365 ._36\.\1740
D005227_D009404 NONE in_0\IN\13603305 <e2>pre-nephrotic</e2>_1\JJ\1740 stage_2\NN\15113229 the_3\DT\1740 plasma_4\NN\5398023 level_5\NN\4916342 of_6\IN\1740 <e1>fatty_7\JJ\1740 acids</e1>_8\NNS\14818238 ,_9\,\1740 triacylglycerol_10\NN\1740 and_11\CC\1740 vldl_12\NN\14939230 decreased_13\VBD\169651 while_14\IN\15122231 that_15\DT\1740 of_16\IN\1740 phospholipid_17\NN\14938907 ,_18\,\1740 cholesteryl_19\NN\1740 esters_20\NNS\14727670 and_21\CC\1740 hdl_22\NN\14939230 remained_23\VBD\2604760 constant_24\JJ\1740 ._25\.\1740
D014280_D009404 NONE in_0\IN\13603305 <e2>pre-nephrotic</e2>_1\JJ\1740 stage_2\NN\15113229 the_3\DT\1740 plasma_4\NN\5398023 level_5\NN\4916342 of_6\IN\1740 fatty_7\JJ\1740 acids_8\NNS\14818238 ,_9\,\1740 <e1>triacylglycerol</e1>_10\NN\1740 and_11\CC\1740 vldl_12\NN\14939230 decreased_13\VBD\169651 while_14\IN\15122231 that_15\DT\1740 of_16\IN\1740 phospholipid_17\NN\14938907 ,_18\,\1740 cholesteryl_19\NN\1740 esters_20\NNS\14727670 and_21\CC\1740 hdl_22\NN\14939230 remained_23\VBD\2604760 constant_24\JJ\1740 ._25\.\1740
D002788_D009404 NONE in_0\IN\13603305 <e2>pre-nephrotic</e2>_1\JJ\1740 stage_2\NN\15113229 the_3\DT\1740 plasma_4\NN\5398023 level_5\NN\4916342 of_6\IN\1740 fatty_7\JJ\1740 acids_8\NNS\14818238 ,_9\,\1740 triacylglycerol_10\NN\1740 and_11\CC\1740 vldl_12\NN\14939230 decreased_13\VBD\169651 while_14\IN\15122231 that_15\DT\1740 of_16\IN\1740 phospholipid_17\NN\14938907 ,_18\,\1740 <e1>cholesteryl_19\NN\1740 esters</e1>_20\NNS\14727670 and_21\CC\1740 hdl_22\NN\14939230 remained_23\VBD\2604760 constant_24\JJ\1740 ._25\.\1740
3962737
D000638_D056486 CID <e2>hepatotoxicity</e2>_0\NN\1740 of_1\IN\1740 <e1>amiodarone</e1>_2\NN\2715941 ._3\.\1740
D000638_D056486 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 <e2>cholestatic_3\JJ\1740 hepatitis</e2>_4\NN\14127211 due_5\JJ\1740 to_6\TO\1740 <e1>amiodarone</e1>_7\NN\2715941 treatment_8\NN\654885 is_9\VBZ\836236 presented_10\VBN\2137132 below_11\IN\1740 and_12\CC\1740 a_13\DT\13649268 review_14\NN\5733583 of_15\IN\1740 the_16\DT\1740 hepatotoxicity_17\NN\1740 of_18\IN\1740 amiodarone_19\NN\2715941 is_20\VBZ\836236 given_21\VBN\2327200 ._22\.\1740
D000638_D056486 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 cholestatic_3\JJ\1740 hepatitis_4\NN\14127211 due_5\JJ\1740 to_6\TO\1740 <e1>amiodarone</e1>_7\NN\2715941 treatment_8\NN\654885 is_9\VBZ\836236 presented_10\VBN\2137132 below_11\IN\1740 and_12\CC\1740 a_13\DT\13649268 review_14\NN\5733583 of_15\IN\1740 the_16\DT\1740 <e2>hepatotoxicity</e2>_17\NN\1740 of_18\IN\1740 amiodarone_19\NN\2715941 is_20\VBZ\836236 given_21\VBN\2327200 ._22\.\1740
D000638_D056486 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 <e2>cholestatic_3\JJ\1740 hepatitis</e2>_4\NN\14127211 due_5\JJ\1740 to_6\TO\1740 amiodarone_7\NN\2715941 treatment_8\NN\654885 is_9\VBZ\836236 presented_10\VBN\2137132 below_11\IN\1740 and_12\CC\1740 a_13\DT\13649268 review_14\NN\5733583 of_15\IN\1740 the_16\DT\1740 hepatotoxicity_17\NN\1740 of_18\IN\1740 <e1>amiodarone</e1>_19\NN\2715941 is_20\VBZ\836236 given_21\VBN\2327200 ._22\.\1740
D000638_D056486 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 cholestatic_3\JJ\1740 hepatitis_4\NN\14127211 due_5\JJ\1740 to_6\TO\1740 amiodarone_7\NN\2715941 treatment_8\NN\654885 is_9\VBZ\836236 presented_10\VBN\2137132 below_11\IN\1740 and_12\CC\1740 a_13\DT\13649268 review_14\NN\5733583 of_15\IN\1740 the_16\DT\1740 <e2>hepatotoxicity</e2>_17\NN\1740 of_18\IN\1740 <e1>amiodarone</e1>_19\NN\2715941 is_20\VBZ\836236 given_21\VBN\2327200 ._22\.\1740
D000638_D056486 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 solid_4\JJ\1740 evidence_5\NN\5816287 exists_6\NNS\1740 of_7\IN\1740 <e2>hepatic_8\JJ\1740 injury</e2>_9\NN\14052046 due_10\IN\5174653 to_11\TO\1740 <e1>amiodarone</e1>_12\JJ\1740 treatment_13\NN\654885 ,_14\,\1740 including_15\VBG\690614 steatosis_16\NN\1740 ,_17\,\1740 alterations_18\NNS\7283608 resembling_19\VBG\2657219 alcoholic_20\JJ\1740 hepatitis_21\NN\14127211 ,_22\,\1740 cholestatic_23\JJ\1740 hepatitis_24\NN\14127211 and_25\CC\1740 micronodular_26\JJ\1740 cirrhosis_27\NN\14116321 of_28\IN\1740 the_29\DT\1740 liver_30\NN\5298729 ._31\.\1740
D000638_D056486 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 solid_4\JJ\1740 evidence_5\NN\5816287 exists_6\NNS\1740 of_7\IN\1740 hepatic_8\JJ\1740 injury_9\NN\14052046 due_10\IN\5174653 to_11\TO\1740 <e1>amiodarone</e1>_12\JJ\1740 treatment_13\NN\654885 ,_14\,\1740 including_15\VBG\690614 steatosis_16\NN\1740 ,_17\,\1740 alterations_18\NNS\7283608 resembling_19\VBG\2657219 alcoholic_20\JJ\1740 hepatitis_21\NN\14127211 ,_22\,\1740 <e2>cholestatic_23\JJ\1740 hepatitis</e2>_24\NN\14127211 and_25\CC\1740 micronodular_26\JJ\1740 cirrhosis_27\NN\14116321 of_28\IN\1740 the_29\DT\1740 liver_30\NN\5298729 ._31\.\1740
D000638_D013610 NONE <e1>amiodarone</e1>_0\NN\2715941 has_1\VBZ\2108377 proved_2\VBN\2604760 very_3\RB\1740 effective_4\JJ\1740 in_5\IN\13603305 the_6\DT\1740 treatment_7\NN\654885 of_8\IN\1740 otherwise_9\RB\1740 resistant_10\JJ\1740 cardiac_11\JJ\1740 <e2>tachyarrhythmias</e2>_12\NNS\1740 ._13\.\1740
D000638_D002779 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 <e2>cholestatic_3\JJ\1740 hepatitis</e2>_4\NN\14127211 due_5\JJ\1740 to_6\TO\1740 <e1>amiodarone</e1>_7\NN\2715941 treatment_8\NN\654885 is_9\VBZ\836236 presented_10\VBN\2137132 below_11\IN\1740 and_12\CC\1740 a_13\DT\13649268 review_14\NN\5733583 of_15\IN\1740 the_16\DT\1740 hepatotoxicity_17\NN\1740 of_18\IN\1740 amiodarone_19\NN\2715941 is_20\VBZ\836236 given_21\VBN\2327200 ._22\.\1740
D000638_D002779 CID a_0\DT\13649268 patient_1\NN\9898892 with_2\IN\1740 <e2>cholestatic_3\JJ\1740 hepatitis</e2>_4\NN\14127211 due_5\JJ\1740 to_6\TO\1740 amiodarone_7\NN\2715941 treatment_8\NN\654885 is_9\VBZ\836236 presented_10\VBN\2137132 below_11\IN\1740 and_12\CC\1740 a_13\DT\13649268 review_14\NN\5733583 of_15\IN\1740 the_16\DT\1740 hepatotoxicity_17\NN\1740 of_18\IN\1740 <e1>amiodarone</e1>_19\NN\2715941 is_20\VBZ\836236 given_21\VBN\2327200 ._22\.\1740
D000638_D002779 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 solid_4\JJ\1740 evidence_5\NN\5816287 exists_6\NNS\1740 of_7\IN\1740 hepatic_8\JJ\1740 injury_9\NN\14052046 due_10\IN\5174653 to_11\TO\1740 <e1>amiodarone</e1>_12\JJ\1740 treatment_13\NN\654885 ,_14\,\1740 including_15\VBG\690614 steatosis_16\NN\1740 ,_17\,\1740 alterations_18\NNS\7283608 resembling_19\VBG\2657219 alcoholic_20\JJ\1740 hepatitis_21\NN\14127211 ,_22\,\1740 <e2>cholestatic_23\JJ\1740 hepatitis</e2>_24\NN\14127211 and_25\CC\1740 micronodular_26\JJ\1740 cirrhosis_27\NN\14116321 of_28\IN\1740 the_29\DT\1740 liver_30\NN\5298729 ._31\.\1740
D000638_D005234 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 solid_4\JJ\1740 evidence_5\NN\5816287 exists_6\NNS\1740 of_7\IN\1740 hepatic_8\JJ\1740 injury_9\NN\14052046 due_10\IN\5174653 to_11\TO\1740 <e1>amiodarone</e1>_12\JJ\1740 treatment_13\NN\654885 ,_14\,\1740 including_15\VBG\690614 <e2>steatosis</e2>_16\NN\1740 ,_17\,\1740 alterations_18\NNS\7283608 resembling_19\VBG\2657219 alcoholic_20\JJ\1740 hepatitis_21\NN\14127211 ,_22\,\1740 cholestatic_23\JJ\1740 hepatitis_24\NN\14127211 and_25\CC\1740 micronodular_26\JJ\1740 cirrhosis_27\NN\14116321 of_28\IN\1740 the_29\DT\1740 liver_30\NN\5298729 ._31\.\1740
D000638_D006519 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 solid_4\JJ\1740 evidence_5\NN\5816287 exists_6\NNS\1740 of_7\IN\1740 hepatic_8\JJ\1740 injury_9\NN\14052046 due_10\IN\5174653 to_11\TO\1740 <e1>amiodarone</e1>_12\JJ\1740 treatment_13\NN\654885 ,_14\,\1740 including_15\VBG\690614 steatosis_16\NN\1740 ,_17\,\1740 alterations_18\NNS\7283608 resembling_19\VBG\2657219 <e2>alcoholic_20\JJ\1740 hepatitis</e2>_21\NN\14127211 ,_22\,\1740 cholestatic_23\JJ\1740 hepatitis_24\NN\14127211 and_25\CC\1740 micronodular_26\JJ\1740 cirrhosis_27\NN\14116321 of_28\IN\1740 the_29\DT\1740 liver_30\NN\5298729 ._31\.\1740
D000638_D008103 CID it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 solid_4\JJ\1740 evidence_5\NN\5816287 exists_6\NNS\1740 of_7\IN\1740 hepatic_8\JJ\1740 injury_9\NN\14052046 due_10\IN\5174653 to_11\TO\1740 <e1>amiodarone</e1>_12\JJ\1740 treatment_13\NN\654885 ,_14\,\1740 including_15\VBG\690614 steatosis_16\NN\1740 ,_17\,\1740 alterations_18\NNS\7283608 resembling_19\VBG\2657219 alcoholic_20\JJ\1740 hepatitis_21\NN\14127211 ,_22\,\1740 cholestatic_23\JJ\1740 hepatitis_24\NN\14127211 and_25\CC\1740 micronodular_26\JJ\1740 <e2>cirrhosis_27\NN\14116321 of_28\IN\1740 the_29\DT\1740 liver</e2>_30\NN\5298729 ._31\.\1740
15096016
D007980_D018476 NONE pallidal_0\JJ\1740 stimulation_1\NN\242808 improves_2\VBZ\126264 <e2>bradykinesia</e2>_3\NN\1740 and_4\CC\1740 rigidity_5\NN\5023233 to_6\IN\1740 a_7\DT\13649268 minor_8\JJ\1740 extent_9\NN\13939892 ;_10\:\1740 however_11\RB\1740 ,_12\,\1740 its_13\PRP$\6125041 strength_14\NN\4916342 seems_15\VBZ\2604760 to_16\TO\1740 be_17\VB\836236 in_18\IN\13603305 improving_19\VBG\126264 <e1>levodopa-induced</e1>_20\JJ\1740 dyskinesias_21\NNS\14084880 ._22\.\1740
D007980_D009127 NONE pallidal_0\JJ\1740 stimulation_1\NN\242808 improves_2\VBZ\126264 bradykinesia_3\NN\1740 and_4\CC\1740 <e2>rigidity</e2>_5\NN\5023233 to_6\IN\1740 a_7\DT\13649268 minor_8\JJ\1740 extent_9\NN\13939892 ;_10\:\1740 however_11\RB\1740 ,_12\,\1740 its_13\PRP$\6125041 strength_14\NN\4916342 seems_15\VBZ\2604760 to_16\TO\1740 be_17\VB\836236 in_18\IN\13603305 improving_19\VBG\126264 <e1>levodopa-induced</e1>_20\JJ\1740 dyskinesias_21\NNS\14084880 ._22\.\1740
D007980_D004409 CID pallidal_0\JJ\1740 stimulation_1\NN\242808 improves_2\VBZ\126264 bradykinesia_3\NN\1740 and_4\CC\1740 rigidity_5\NN\5023233 to_6\IN\1740 a_7\DT\13649268 minor_8\JJ\1740 extent_9\NN\13939892 ;_10\:\1740 however_11\RB\1740 ,_12\,\1740 its_13\PRP$\6125041 strength_14\NN\4916342 seems_15\VBZ\2604760 to_16\TO\1740 be_17\VB\836236 in_18\IN\13603305 improving_19\VBG\126264 <e1>levodopa-induced</e1>_20\JJ\1740 <e2>dyskinesias</e2>_21\NNS\14084880 ._22\.\1740
8586822
D002216_D006973 NONE contribution_0\NN\786195 of_1\IN\1740 the_2\DT\1740 sympathetic_3\JJ\1740 nervous_4\JJ\1740 system_5\NN\3575240 to_6\TO\1740 salt-sensitivity_7\NN\1740 in_8\IN\13603305 lifetime_9\NN\15113229 <e1>captopril-treated</e1>_10\JJ\1740 spontaneously_11\JJ\1740 <e2>hypertensive</e2>_12\JJ\1740 rats_13\NNS\2329401 ._14\.\1740
D002216_D006973 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 test_3\VB\670261 the_4\DT\1740 hypothesis_5\NN\7162194 that_6\IN\1740 ,_7\,\1740 in_8\IN\13603305 lifetime_9\NN\15113229 <e1>captopril-treated</e1>_10\JJ\1740 spontaneously_11\JJ\1740 <e2>hypertensive</e2>_12\JJ\1740 rats_13\NNS\2329401 (_14\-LRB-\1740 shr_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 the_18\DT\1740 sympathetic_19\JJ\1740 nervous_20\JJ\1740 system_21\NN\3575240 contributes_22\VBZ\126264 importantly_23\RB\1740 to_24\TO\1740 the_25\DT\1740 hypertensive_26\JJ\1740 effect_27\NN\34213 of_28\IN\1740 dietary_29\JJ\1740 sodium_30\NN\14625458 chloride_31\NN\14818238 supplementation_32\NN\5108947 ._33\.\1740
D002216_D006973 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 test_3\VB\670261 the_4\DT\1740 hypothesis_5\NN\7162194 that_6\IN\1740 ,_7\,\1740 in_8\IN\13603305 lifetime_9\NN\15113229 <e1>captopril-treated</e1>_10\JJ\1740 spontaneously_11\JJ\1740 hypertensive_12\JJ\1740 rats_13\NNS\2329401 (_14\-LRB-\1740 shr_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 the_18\DT\1740 sympathetic_19\JJ\1740 nervous_20\JJ\1740 system_21\NN\3575240 contributes_22\VBZ\126264 importantly_23\RB\1740 to_24\TO\1740 the_25\DT\1740 <e2>hypertensive</e2>_26\JJ\1740 effect_27\NN\34213 of_28\IN\1740 dietary_29\JJ\1740 sodium_30\NN\14625458 chloride_31\NN\14818238 supplementation_32\NN\5108947 ._33\.\1740
D017673_D006973 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 test_3\VB\670261 the_4\DT\1740 hypothesis_5\NN\7162194 that_6\IN\1740 ,_7\,\1740 in_8\IN\13603305 lifetime_9\NN\15113229 captopril-treated_10\JJ\1740 spontaneously_11\JJ\1740 <e2>hypertensive</e2>_12\JJ\1740 rats_13\NNS\2329401 (_14\-LRB-\1740 shr_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 the_18\DT\1740 sympathetic_19\JJ\1740 nervous_20\JJ\1740 system_21\NN\3575240 contributes_22\VBZ\126264 importantly_23\RB\1740 to_24\TO\1740 the_25\DT\1740 hypertensive_26\JJ\1740 effect_27\NN\34213 of_28\IN\1740 <e1>dietary_29\JJ\1740 sodium_30\NN\14625458 chloride</e1>_31\NN\14818238 supplementation_32\NN\5108947 ._33\.\1740
D017673_D006973 CID objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 test_3\VB\670261 the_4\DT\1740 hypothesis_5\NN\7162194 that_6\IN\1740 ,_7\,\1740 in_8\IN\13603305 lifetime_9\NN\15113229 captopril-treated_10\JJ\1740 spontaneously_11\JJ\1740 hypertensive_12\JJ\1740 rats_13\NNS\2329401 (_14\-LRB-\1740 shr_15\NN\1740 )_16\-RRB-\1740 ,_17\,\1740 the_18\DT\1740 sympathetic_19\JJ\1740 nervous_20\JJ\1740 system_21\NN\3575240 contributes_22\VBZ\126264 importantly_23\RB\1740 to_24\TO\1740 the_25\DT\1740 <e2>hypertensive</e2>_26\JJ\1740 effect_27\NN\34213 of_28\IN\1740 <e1>dietary_29\JJ\1740 sodium_30\NN\14625458 chloride</e1>_31\NN\14818238 supplementation_32\NN\5108947 ._33\.\1740
D017673_D006973 CID intravenous_0\JJ\1740 infusion_1\NN\14589223 of_2\IN\1740 the_3\DT\1740 ganglionic_4\JJ\1740 blocker_5\NN\10101634 hexamethonium_6\NN\1740 resulted_7\VBD\2633881 in_8\IN\13603305 a_9\DT\13649268 rapid_10\JJ\1740 decline_11\NN\13458571 in_12\IN\13603305 map_13\NN\4076846 that_14\WDT\1740 eliminated_15\VBD\1619929 the_16\DT\1740 <e1>dietary_17\JJ\1740 sodium_18\NN\14625458 chloride-induced</e1>_19\JJ\1740 <e2>increase_20\NN\13576355 in_21\IN\13603305 map</e2>_22\NN\4076846 in_23\IN\13603305 both_24\DT\1740 groups_25\NNS\2137 ._26\.\1740
D018738_D006973 NONE intravenous_0\JJ\1740 infusion_1\NN\14589223 of_2\IN\1740 the_3\DT\1740 ganglionic_4\JJ\1740 blocker_5\NN\10101634 <e1>hexamethonium</e1>_6\NN\1740 resulted_7\VBD\2633881 in_8\IN\13603305 a_9\DT\13649268 rapid_10\JJ\1740 decline_11\NN\13458571 in_12\IN\13603305 map_13\NN\4076846 that_14\WDT\1740 eliminated_15\VBD\1619929 the_16\DT\1740 dietary_17\JJ\1740 sodium_18\NN\14625458 chloride-induced_19\JJ\1740 <e2>increase_20\NN\13576355 in_21\IN\13603305 map</e2>_22\NN\4076846 in_23\IN\13603305 both_24\DT\1740 groups_25\NNS\2137 ._26\.\1740
7651879
D005442_D012640 CID <e2>seizure</e2>_0\NN\14081375 after_1\IN\1740 <e1>flumazenil</e1>_2\JJ\1740 administration_3\NN\1133281 in_4\IN\13603305 a_5\DT\13649268 pediatric_6\JJ\1740 patient_7\NN\9898892 ._8\.\1740
D005442_D012640 CID we_0\PRP\1740 report_1\VBP\831651 the_2\DT\1740 occurrence_3\NN\29378 of_4\IN\1740 a_5\DT\13649268 generalized_6\JJ\1740 <e2>tonic-clonic_7\JJ\1740 seizure</e2>_8\NN\14081375 in_9\IN\13603305 a_10\DT\13649268 pediatric_11\JJ\1740 patient_12\NN\9898892 following_13\VBG\1835496 the_14\DT\1740 administration_15\NN\1133281 of_16\IN\1740 <e1>flumazenil</e1>_17\NN\1740 ._18\.\1740
D005442_D012131 NONE <e1>flumazenil</e1>_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 benzodiazepine_3\NN\3771443 receptor_4\NN\5225602 antagonist_5\NN\7846 used_6\VBN\1156834 to_7\TO\1740 reverse_8\VB\109660 sedation_9\NN\14034177 and_10\CC\1740 <e2>respiratory_11\JJ\1740 depression</e2>_12\NN\14373582 induced_13\VBN\1627355 by_14\IN\1740 benzodiazepines_15\NNS\3771443 ._16\.\1740
D001569_D012131 NONE flumazenil_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 <e1>benzodiazepine</e1>_3\NN\3771443 receptor_4\NN\5225602 antagonist_5\NN\7846 used_6\VBN\1156834 to_7\TO\1740 reverse_8\VB\109660 sedation_9\NN\14034177 and_10\CC\1740 <e2>respiratory_11\JJ\1740 depression</e2>_12\NN\14373582 induced_13\VBN\1627355 by_14\IN\1740 benzodiazepines_15\NNS\3771443 ._16\.\1740
D001569_D012131 NONE flumazenil_0\NN\1740 is_1\VBZ\836236 a_2\DT\13649268 benzodiazepine_3\NN\3771443 receptor_4\NN\5225602 antagonist_5\NN\7846 used_6\VBN\1156834 to_7\TO\1740 reverse_8\VB\109660 sedation_9\NN\14034177 and_10\CC\1740 <e2>respiratory_11\JJ\1740 depression</e2>_12\NN\14373582 induced_13\VBN\1627355 by_14\IN\1740 <e1>benzodiazepines</e1>_15\NNS\3771443 ._16\.\1740
6402369
D007069_D001745 CID treatment_0\NN\654885 of_1\IN\1740 <e1>ifosfamide-induced</e1>_2\JJ\1740 <e2>urothelial_3\JJ\1740 toxicity</e2>_4\NN\13576101 by_5\IN\1740 oral_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 sodium_9\NN\14625458 2-mercaptoethane_10\NN\1740 sulphonate_11\JJ\1740 (_12\-LRB-\1740 mesna_13\NN\1740 )_14\-RRB-\1740 to_15\TO\1740 patients_16\NNS\9898892 with_17\IN\1740 inoperable_18\JJ\1740 lung_19\NN\5528060 cancer_20\NN\14239425 ._21\.\1740
D007069_D001745 CID the_0\DT\1740 protective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 oral_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 thiol_8\NN\1740 compound_9\NN\5869584 sodium_10\NN\14625458 2-mercaptoethane_11\NN\1740 sulphonate_12\JJ\1740 (_13\-LRB-\1740 mesna_14\NN\1740 )_15\-RRB-\1740 against_16\IN\1740 <e2>urothelial_17\JJ\1740 toxicity</e2>_18\NN\13576101 induced_19\VBN\1627355 by_20\IN\1740 <e1>ifosfamide</e1>_21\NN\1740 (_22\-LRB-\1740 if_23\NN\1740 )_24\-RRB-\1740 was_25\VBD\836236 tested_26\VBN\670261 in_27\IN\13603305 a_28\DT\13649268 group_29\NN\2137 of_30\IN\1740 45_31\CD\1740 patients_32\NNS\9898892 with_33\IN\1740 inoperable_34\JJ\1740 lung_35\NN\5528060 cancer_36\NN\14239425 under_37\IN\1740 treatment_38\NN\654885 with_39\IN\1740 if_40\NN\1740 (_41\-LRB-\1740 2250_42\CD\1740 mg/m2_43\NN\1740 on_44\IN\1740 days_45\NNS\15140892 2_46\CD\13741022 -_47\SYM\1740 5_48\CD\13741022 )_49\-RRB-\1740 as_50\IN\14622893 part_51\NN\31921 of_52\IN\1740 a_53\DT\13649268 polychemotherapy_54\NN\1740 regimen_55\NN\5898568 repeated_56\VBN\952524 in_57\IN\13603305 a_58\DT\13649268 4-week_59\NN\1740 cycle_60\NN\15269513 ._61\.\1740
D007069_D001745 CID the_0\DT\1740 protective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 oral_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 thiol_8\NN\1740 compound_9\NN\5869584 sodium_10\NN\14625458 2-mercaptoethane_11\NN\1740 sulphonate_12\JJ\1740 (_13\-LRB-\1740 mesna_14\NN\1740 )_15\-RRB-\1740 against_16\IN\1740 <e2>urothelial_17\JJ\1740 toxicity</e2>_18\NN\13576101 induced_19\VBN\1627355 by_20\IN\1740 ifosfamide_21\NN\1740 (_22\-LRB-\1740 <e1>if</e1>_23\NN\1740 )_24\-RRB-\1740 was_25\VBD\836236 tested_26\VBN\670261 in_27\IN\13603305 a_28\DT\13649268 group_29\NN\2137 of_30\IN\1740 45_31\CD\1740 patients_32\NNS\9898892 with_33\IN\1740 inoperable_34\JJ\1740 lung_35\NN\5528060 cancer_36\NN\14239425 under_37\IN\1740 treatment_38\NN\654885 with_39\IN\1740 if_40\NN\1740 (_41\-LRB-\1740 2250_42\CD\1740 mg/m2_43\NN\1740 on_44\IN\1740 days_45\NNS\15140892 2_46\CD\13741022 -_47\SYM\1740 5_48\CD\13741022 )_49\-RRB-\1740 as_50\IN\14622893 part_51\NN\31921 of_52\IN\1740 a_53\DT\13649268 polychemotherapy_54\NN\1740 regimen_55\NN\5898568 repeated_56\VBN\952524 in_57\IN\13603305 a_58\DT\13649268 4-week_59\NN\1740 cycle_60\NN\15269513 ._61\.\1740
D007069_D001745 CID the_0\DT\1740 protective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 oral_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 thiol_8\NN\1740 compound_9\NN\5869584 sodium_10\NN\14625458 2-mercaptoethane_11\NN\1740 sulphonate_12\JJ\1740 (_13\-LRB-\1740 mesna_14\NN\1740 )_15\-RRB-\1740 against_16\IN\1740 <e2>urothelial_17\JJ\1740 toxicity</e2>_18\NN\13576101 induced_19\VBN\1627355 by_20\IN\1740 ifosfamide_21\NN\1740 (_22\-LRB-\1740 if_23\NN\1740 )_24\-RRB-\1740 was_25\VBD\836236 tested_26\VBN\670261 in_27\IN\13603305 a_28\DT\13649268 group_29\NN\2137 of_30\IN\1740 45_31\CD\1740 patients_32\NNS\9898892 with_33\IN\1740 inoperable_34\JJ\1740 lung_35\NN\5528060 cancer_36\NN\14239425 under_37\IN\1740 treatment_38\NN\654885 with_39\IN\1740 <e1>if</e1>_40\NN\1740 (_41\-LRB-\1740 2250_42\CD\1740 mg/m2_43\NN\1740 on_44\IN\1740 days_45\NNS\15140892 2_46\CD\13741022 -_47\SYM\1740 5_48\CD\13741022 )_49\-RRB-\1740 as_50\IN\14622893 part_51\NN\31921 of_52\IN\1740 a_53\DT\13649268 polychemotherapy_54\NN\1740 regimen_55\NN\5898568 repeated_56\VBN\952524 in_57\IN\13603305 a_58\DT\13649268 4-week_59\NN\1740 cycle_60\NN\15269513 ._61\.\1740
D007069_D008175 NONE treatment_0\NN\654885 of_1\IN\1740 <e1>ifosfamide-induced</e1>_2\JJ\1740 urothelial_3\JJ\1740 toxicity_4\NN\13576101 by_5\IN\1740 oral_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 sodium_9\NN\14625458 2-mercaptoethane_10\NN\1740 sulphonate_11\JJ\1740 (_12\-LRB-\1740 mesna_13\NN\1740 )_14\-RRB-\1740 to_15\TO\1740 patients_16\NNS\9898892 with_17\IN\1740 inoperable_18\JJ\1740 <e2>lung_19\NN\5528060 cancer</e2>_20\NN\14239425 ._21\.\1740
D007069_D008175 NONE the_0\DT\1740 protective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 oral_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 thiol_8\NN\1740 compound_9\NN\5869584 sodium_10\NN\14625458 2-mercaptoethane_11\NN\1740 sulphonate_12\JJ\1740 (_13\-LRB-\1740 mesna_14\NN\1740 )_15\-RRB-\1740 against_16\IN\1740 urothelial_17\JJ\1740 toxicity_18\NN\13576101 induced_19\VBN\1627355 by_20\IN\1740 <e1>ifosfamide</e1>_21\NN\1740 (_22\-LRB-\1740 if_23\NN\1740 )_24\-RRB-\1740 was_25\VBD\836236 tested_26\VBN\670261 in_27\IN\13603305 a_28\DT\13649268 group_29\NN\2137 of_30\IN\1740 45_31\CD\1740 patients_32\NNS\9898892 with_33\IN\1740 inoperable_34\JJ\1740 <e2>lung_35\NN\5528060 cancer</e2>_36\NN\14239425 under_37\IN\1740 treatment_38\NN\654885 with_39\IN\1740 if_40\NN\1740 (_41\-LRB-\1740 2250_42\CD\1740 mg/m2_43\NN\1740 on_44\IN\1740 days_45\NNS\15140892 2_46\CD\13741022 -_47\SYM\1740 5_48\CD\13741022 )_49\-RRB-\1740 as_50\IN\14622893 part_51\NN\31921 of_52\IN\1740 a_53\DT\13649268 polychemotherapy_54\NN\1740 regimen_55\NN\5898568 repeated_56\VBN\952524 in_57\IN\13603305 a_58\DT\13649268 4-week_59\NN\1740 cycle_60\NN\15269513 ._61\.\1740
D007069_D008175 NONE the_0\DT\1740 protective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 oral_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 thiol_8\NN\1740 compound_9\NN\5869584 sodium_10\NN\14625458 2-mercaptoethane_11\NN\1740 sulphonate_12\JJ\1740 (_13\-LRB-\1740 mesna_14\NN\1740 )_15\-RRB-\1740 against_16\IN\1740 urothelial_17\JJ\1740 toxicity_18\NN\13576101 induced_19\VBN\1627355 by_20\IN\1740 ifosfamide_21\NN\1740 (_22\-LRB-\1740 <e1>if</e1>_23\NN\1740 )_24\-RRB-\1740 was_25\VBD\836236 tested_26\VBN\670261 in_27\IN\13603305 a_28\DT\13649268 group_29\NN\2137 of_30\IN\1740 45_31\CD\1740 patients_32\NNS\9898892 with_33\IN\1740 inoperable_34\JJ\1740 <e2>lung_35\NN\5528060 cancer</e2>_36\NN\14239425 under_37\IN\1740 treatment_38\NN\654885 with_39\IN\1740 if_40\NN\1740 (_41\-LRB-\1740 2250_42\CD\1740 mg/m2_43\NN\1740 on_44\IN\1740 days_45\NNS\15140892 2_46\CD\13741022 -_47\SYM\1740 5_48\CD\13741022 )_49\-RRB-\1740 as_50\IN\14622893 part_51\NN\31921 of_52\IN\1740 a_53\DT\13649268 polychemotherapy_54\NN\1740 regimen_55\NN\5898568 repeated_56\VBN\952524 in_57\IN\13603305 a_58\DT\13649268 4-week_59\NN\1740 cycle_60\NN\15269513 ._61\.\1740
D007069_D008175 NONE the_0\DT\1740 protective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 oral_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 thiol_8\NN\1740 compound_9\NN\5869584 sodium_10\NN\14625458 2-mercaptoethane_11\NN\1740 sulphonate_12\JJ\1740 (_13\-LRB-\1740 mesna_14\NN\1740 )_15\-RRB-\1740 against_16\IN\1740 urothelial_17\JJ\1740 toxicity_18\NN\13576101 induced_19\VBN\1627355 by_20\IN\1740 ifosfamide_21\NN\1740 (_22\-LRB-\1740 if_23\NN\1740 )_24\-RRB-\1740 was_25\VBD\836236 tested_26\VBN\670261 in_27\IN\13603305 a_28\DT\13649268 group_29\NN\2137 of_30\IN\1740 45_31\CD\1740 patients_32\NNS\9898892 with_33\IN\1740 inoperable_34\JJ\1740 <e2>lung_35\NN\5528060 cancer</e2>_36\NN\14239425 under_37\IN\1740 treatment_38\NN\654885 with_39\IN\1740 <e1>if</e1>_40\NN\1740 (_41\-LRB-\1740 2250_42\CD\1740 mg/m2_43\NN\1740 on_44\IN\1740 days_45\NNS\15140892 2_46\CD\13741022 -_47\SYM\1740 5_48\CD\13741022 )_49\-RRB-\1740 as_50\IN\14622893 part_51\NN\31921 of_52\IN\1740 a_53\DT\13649268 polychemotherapy_54\NN\1740 regimen_55\NN\5898568 repeated_56\VBN\952524 in_57\IN\13603305 a_58\DT\13649268 4-week_59\NN\1740 cycle_60\NN\15269513 ._61\.\1740
D015080_D001745 NONE treatment_0\NN\654885 of_1\IN\1740 ifosfamide-induced_2\JJ\1740 <e2>urothelial_3\JJ\1740 toxicity</e2>_4\NN\13576101 by_5\IN\1740 oral_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 <e1>sodium_9\NN\14625458 2-mercaptoethane_10\NN\1740 sulphonate</e1>_11\JJ\1740 (_12\-LRB-\1740 mesna_13\NN\1740 )_14\-RRB-\1740 to_15\TO\1740 patients_16\NNS\9898892 with_17\IN\1740 inoperable_18\JJ\1740 lung_19\NN\5528060 cancer_20\NN\14239425 ._21\.\1740
D015080_D001745 NONE treatment_0\NN\654885 of_1\IN\1740 ifosfamide-induced_2\JJ\1740 <e2>urothelial_3\JJ\1740 toxicity</e2>_4\NN\13576101 by_5\IN\1740 oral_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 sodium_9\NN\14625458 2-mercaptoethane_10\NN\1740 sulphonate_11\JJ\1740 (_12\-LRB-\1740 <e1>mesna</e1>_13\NN\1740 )_14\-RRB-\1740 to_15\TO\1740 patients_16\NNS\9898892 with_17\IN\1740 inoperable_18\JJ\1740 lung_19\NN\5528060 cancer_20\NN\14239425 ._21\.\1740
D015080_D001745 NONE the_0\DT\1740 protective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 oral_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 thiol_8\NN\1740 compound_9\NN\5869584 <e1>sodium_10\NN\14625458 2-mercaptoethane_11\NN\1740 sulphonate</e1>_12\JJ\1740 (_13\-LRB-\1740 mesna_14\NN\1740 )_15\-RRB-\1740 against_16\IN\1740 <e2>urothelial_17\JJ\1740 toxicity</e2>_18\NN\13576101 induced_19\VBN\1627355 by_20\IN\1740 ifosfamide_21\NN\1740 (_22\-LRB-\1740 if_23\NN\1740 )_24\-RRB-\1740 was_25\VBD\836236 tested_26\VBN\670261 in_27\IN\13603305 a_28\DT\13649268 group_29\NN\2137 of_30\IN\1740 45_31\CD\1740 patients_32\NNS\9898892 with_33\IN\1740 inoperable_34\JJ\1740 lung_35\NN\5528060 cancer_36\NN\14239425 under_37\IN\1740 treatment_38\NN\654885 with_39\IN\1740 if_40\NN\1740 (_41\-LRB-\1740 2250_42\CD\1740 mg/m2_43\NN\1740 on_44\IN\1740 days_45\NNS\15140892 2_46\CD\13741022 -_47\SYM\1740 5_48\CD\13741022 )_49\-RRB-\1740 as_50\IN\14622893 part_51\NN\31921 of_52\IN\1740 a_53\DT\13649268 polychemotherapy_54\NN\1740 regimen_55\NN\5898568 repeated_56\VBN\952524 in_57\IN\13603305 a_58\DT\13649268 4-week_59\NN\1740 cycle_60\NN\15269513 ._61\.\1740
D015080_D001745 NONE the_0\DT\1740 protective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 oral_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 thiol_8\NN\1740 compound_9\NN\5869584 sodium_10\NN\14625458 2-mercaptoethane_11\NN\1740 sulphonate_12\JJ\1740 (_13\-LRB-\1740 <e1>mesna</e1>_14\NN\1740 )_15\-RRB-\1740 against_16\IN\1740 <e2>urothelial_17\JJ\1740 toxicity</e2>_18\NN\13576101 induced_19\VBN\1627355 by_20\IN\1740 ifosfamide_21\NN\1740 (_22\-LRB-\1740 if_23\NN\1740 )_24\-RRB-\1740 was_25\VBD\836236 tested_26\VBN\670261 in_27\IN\13603305 a_28\DT\13649268 group_29\NN\2137 of_30\IN\1740 45_31\CD\1740 patients_32\NNS\9898892 with_33\IN\1740 inoperable_34\JJ\1740 lung_35\NN\5528060 cancer_36\NN\14239425 under_37\IN\1740 treatment_38\NN\654885 with_39\IN\1740 if_40\NN\1740 (_41\-LRB-\1740 2250_42\CD\1740 mg/m2_43\NN\1740 on_44\IN\1740 days_45\NNS\15140892 2_46\CD\13741022 -_47\SYM\1740 5_48\CD\13741022 )_49\-RRB-\1740 as_50\IN\14622893 part_51\NN\31921 of_52\IN\1740 a_53\DT\13649268 polychemotherapy_54\NN\1740 regimen_55\NN\5898568 repeated_56\VBN\952524 in_57\IN\13603305 a_58\DT\13649268 4-week_59\NN\1740 cycle_60\NN\15269513 ._61\.\1740
D015080_D008175 NONE treatment_0\NN\654885 of_1\IN\1740 ifosfamide-induced_2\JJ\1740 urothelial_3\JJ\1740 toxicity_4\NN\13576101 by_5\IN\1740 oral_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 <e1>sodium_9\NN\14625458 2-mercaptoethane_10\NN\1740 sulphonate</e1>_11\JJ\1740 (_12\-LRB-\1740 mesna_13\NN\1740 )_14\-RRB-\1740 to_15\TO\1740 patients_16\NNS\9898892 with_17\IN\1740 inoperable_18\JJ\1740 <e2>lung_19\NN\5528060 cancer</e2>_20\NN\14239425 ._21\.\1740
D015080_D008175 NONE treatment_0\NN\654885 of_1\IN\1740 ifosfamide-induced_2\JJ\1740 urothelial_3\JJ\1740 toxicity_4\NN\13576101 by_5\IN\1740 oral_6\JJ\1740 administration_7\NN\1133281 of_8\IN\1740 sodium_9\NN\14625458 2-mercaptoethane_10\NN\1740 sulphonate_11\JJ\1740 (_12\-LRB-\1740 <e1>mesna</e1>_13\NN\1740 )_14\-RRB-\1740 to_15\TO\1740 patients_16\NNS\9898892 with_17\IN\1740 inoperable_18\JJ\1740 <e2>lung_19\NN\5528060 cancer</e2>_20\NN\14239425 ._21\.\1740
D015080_D008175 NONE the_0\DT\1740 protective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 oral_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 thiol_8\NN\1740 compound_9\NN\5869584 <e1>sodium_10\NN\14625458 2-mercaptoethane_11\NN\1740 sulphonate</e1>_12\JJ\1740 (_13\-LRB-\1740 mesna_14\NN\1740 )_15\-RRB-\1740 against_16\IN\1740 urothelial_17\JJ\1740 toxicity_18\NN\13576101 induced_19\VBN\1627355 by_20\IN\1740 ifosfamide_21\NN\1740 (_22\-LRB-\1740 if_23\NN\1740 )_24\-RRB-\1740 was_25\VBD\836236 tested_26\VBN\670261 in_27\IN\13603305 a_28\DT\13649268 group_29\NN\2137 of_30\IN\1740 45_31\CD\1740 patients_32\NNS\9898892 with_33\IN\1740 inoperable_34\JJ\1740 <e2>lung_35\NN\5528060 cancer</e2>_36\NN\14239425 under_37\IN\1740 treatment_38\NN\654885 with_39\IN\1740 if_40\NN\1740 (_41\-LRB-\1740 2250_42\CD\1740 mg/m2_43\NN\1740 on_44\IN\1740 days_45\NNS\15140892 2_46\CD\13741022 -_47\SYM\1740 5_48\CD\13741022 )_49\-RRB-\1740 as_50\IN\14622893 part_51\NN\31921 of_52\IN\1740 a_53\DT\13649268 polychemotherapy_54\NN\1740 regimen_55\NN\5898568 repeated_56\VBN\952524 in_57\IN\13603305 a_58\DT\13649268 4-week_59\NN\1740 cycle_60\NN\15269513 ._61\.\1740
D015080_D008175 NONE the_0\DT\1740 protective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 oral_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 thiol_8\NN\1740 compound_9\NN\5869584 sodium_10\NN\14625458 2-mercaptoethane_11\NN\1740 sulphonate_12\JJ\1740 (_13\-LRB-\1740 <e1>mesna</e1>_14\NN\1740 )_15\-RRB-\1740 against_16\IN\1740 urothelial_17\JJ\1740 toxicity_18\NN\13576101 induced_19\VBN\1627355 by_20\IN\1740 ifosfamide_21\NN\1740 (_22\-LRB-\1740 if_23\NN\1740 )_24\-RRB-\1740 was_25\VBD\836236 tested_26\VBN\670261 in_27\IN\13603305 a_28\DT\13649268 group_29\NN\2137 of_30\IN\1740 45_31\CD\1740 patients_32\NNS\9898892 with_33\IN\1740 inoperable_34\JJ\1740 <e2>lung_35\NN\5528060 cancer</e2>_36\NN\14239425 under_37\IN\1740 treatment_38\NN\654885 with_39\IN\1740 if_40\NN\1740 (_41\-LRB-\1740 2250_42\CD\1740 mg/m2_43\NN\1740 on_44\IN\1740 days_45\NNS\15140892 2_46\CD\13741022 -_47\SYM\1740 5_48\CD\13741022 )_49\-RRB-\1740 as_50\IN\14622893 part_51\NN\31921 of_52\IN\1740 a_53\DT\13649268 polychemotherapy_54\NN\1740 regimen_55\NN\5898568 repeated_56\VBN\952524 in_57\IN\13603305 a_58\DT\13649268 4-week_59\NN\1740 cycle_60\NN\15269513 ._61\.\1740
D013438_D001745 NONE the_0\DT\1740 protective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 oral_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 <e1>thiol</e1>_8\NN\1740 compound_9\NN\5869584 sodium_10\NN\14625458 2-mercaptoethane_11\NN\1740 sulphonate_12\JJ\1740 (_13\-LRB-\1740 mesna_14\NN\1740 )_15\-RRB-\1740 against_16\IN\1740 <e2>urothelial_17\JJ\1740 toxicity</e2>_18\NN\13576101 induced_19\VBN\1627355 by_20\IN\1740 ifosfamide_21\NN\1740 (_22\-LRB-\1740 if_23\NN\1740 )_24\-RRB-\1740 was_25\VBD\836236 tested_26\VBN\670261 in_27\IN\13603305 a_28\DT\13649268 group_29\NN\2137 of_30\IN\1740 45_31\CD\1740 patients_32\NNS\9898892 with_33\IN\1740 inoperable_34\JJ\1740 lung_35\NN\5528060 cancer_36\NN\14239425 under_37\IN\1740 treatment_38\NN\654885 with_39\IN\1740 if_40\NN\1740 (_41\-LRB-\1740 2250_42\CD\1740 mg/m2_43\NN\1740 on_44\IN\1740 days_45\NNS\15140892 2_46\CD\13741022 -_47\SYM\1740 5_48\CD\13741022 )_49\-RRB-\1740 as_50\IN\14622893 part_51\NN\31921 of_52\IN\1740 a_53\DT\13649268 polychemotherapy_54\NN\1740 regimen_55\NN\5898568 repeated_56\VBN\952524 in_57\IN\13603305 a_58\DT\13649268 4-week_59\NN\1740 cycle_60\NN\15269513 ._61\.\1740
D013438_D008175 NONE the_0\DT\1740 protective_1\JJ\1740 effect_2\NN\34213 of_3\IN\1740 oral_4\JJ\1740 administration_5\NN\1133281 of_6\IN\1740 the_7\DT\1740 <e1>thiol</e1>_8\NN\1740 compound_9\NN\5869584 sodium_10\NN\14625458 2-mercaptoethane_11\NN\1740 sulphonate_12\JJ\1740 (_13\-LRB-\1740 mesna_14\NN\1740 )_15\-RRB-\1740 against_16\IN\1740 urothelial_17\JJ\1740 toxicity_18\NN\13576101 induced_19\VBN\1627355 by_20\IN\1740 ifosfamide_21\NN\1740 (_22\-LRB-\1740 if_23\NN\1740 )_24\-RRB-\1740 was_25\VBD\836236 tested_26\VBN\670261 in_27\IN\13603305 a_28\DT\13649268 group_29\NN\2137 of_30\IN\1740 45_31\CD\1740 patients_32\NNS\9898892 with_33\IN\1740 inoperable_34\JJ\1740 <e2>lung_35\NN\5528060 cancer</e2>_36\NN\14239425 under_37\IN\1740 treatment_38\NN\654885 with_39\IN\1740 if_40\NN\1740 (_41\-LRB-\1740 2250_42\CD\1740 mg/m2_43\NN\1740 on_44\IN\1740 days_45\NNS\15140892 2_46\CD\13741022 -_47\SYM\1740 5_48\CD\13741022 )_49\-RRB-\1740 as_50\IN\14622893 part_51\NN\31921 of_52\IN\1740 a_53\DT\13649268 polychemotherapy_54\NN\1740 regimen_55\NN\5898568 repeated_56\VBN\952524 in_57\IN\13603305 a_58\DT\13649268 4-week_59\NN\1740 cycle_60\NN\15269513 ._61\.\1740
D015080_D064420 NONE there_0\EX\27167 were_1\VBD\836236 no_2\DT\7204911 appreciable_3\JJ\1740 differences_4\NNS\4723816 between_5\IN\1740 the_6\DT\1740 <e1>mesna</e1>_7\NN\1740 series_8\NN\8456993 and_9\CC\1740 the_10\DT\1740 conventional_11\JJ\1740 prophylaxis_12\NN\1077350 series_13\NN\8456993 with_14\IN\1740 respect_15\NN\5817845 to_16\TO\1740 either_17\CC\1740 haematological_18\JJ\1740 or_19\CC\3541091 systemic_20\JJ\1740 <e2>toxicity</e2>_21\NN\13576101 of_22\IN\1740 the_23\DT\1740 cytostatic_24\JJ\1740 treatment_25\NN\654885 ._26\.\1740
8958188
C045894_D009369 NONE extensive_0\JJ\1740 experimental_1\JJ\1740 and_2\CC\1740 limited_3\JJ\1740 clinical_4\JJ\1740 data_5\NNS\7951464 have_6\VBP\2108377 shown_7\VBN\2137132 that_8\IN\1740 <e1>lometrexol</e1>_9\NN\1740 has_10\VBZ\2108377 activity_11\NN\30358 against_12\IN\1740 <e2>tumours</e2>_13\NNS\14234074 which_14\WDT\1740 are_15\VBP\836236 refractory_16\JJ\1740 to_17\TO\1740 other_18\JJ\1740 drugs_19\NNS\14778436 ,_20\,\1740 notably_21\RB\1740 methotrexate_22\VBP\1740 ._23\.\1740
D008727_D009369 NONE extensive_0\JJ\1740 experimental_1\JJ\1740 and_2\CC\1740 limited_3\JJ\1740 clinical_4\JJ\1740 data_5\NNS\7951464 have_6\VBP\2108377 shown_7\VBN\2137132 that_8\IN\1740 lometrexol_9\NN\1740 has_10\VBZ\2108377 activity_11\NN\30358 against_12\IN\1740 <e2>tumours</e2>_13\NNS\14234074 which_14\WDT\1740 are_15\VBP\836236 refractory_16\JJ\1740 to_17\TO\1740 other_18\JJ\1740 drugs_19\NNS\14778436 ,_20\,\1740 notably_21\RB\1740 <e1>methotrexate</e1>_22\VBP\1740 ._23\.\1740
C045894_D064420 NONE however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 initial_3\JJ\1740 clinical_4\JJ\1740 development_5\NN\248977 of_6\IN\1740 <e1>lometrexol</e1>_7\NN\1740 was_8\VBD\836236 curtailed_9\VBN\235368 because_10\IN\1740 of_11\IN\1740 severe_12\JJ\1740 and_13\CC\1740 cumulative_14\JJ\1740 antiproliferative_15\JJ\1740 <e2>toxicities</e2>_16\NNS\13576101 ._17\.\1740
C045894_D064420 NONE preclinical_0\JJ\1740 murine_1\JJ\1740 studies_2\NNS\635850 demonstrated_3\VBD\2137132 that_4\IN\1740 the_5\DT\1740 <e2>toxicity</e2>_6\NN\13576101 of_7\IN\1740 <e1>lometrexol</e1>_8\NN\1740 can_9\MD\3094503 be_10\VB\836236 prevented_11\VBN\1740 by_12\IN\1740 low_13\JJ\1740 dose_14\NN\3740161 folic_15\NN\1740 acid_16\NN\14818238 administration_17\NN\1133281 ,_18\,\1740 i.e._19\FW\1740 for_20\IN\1740 7_21\CD\13741022 days_22\NNS\15140892 prior_23\RB\1740 to_24\IN\1740 and_25\CC\1740 7_26\CD\13741022 days_27\NNS\15140892 following_28\VBG\1835496 a_29\DT\13649268 single_30\JJ\1740 bolus_31\NN\13899404 dose_32\NN\3740161 ._33\.\1740
C045894_D064420 NONE this_0\DT\1740 observation_1\NN\996969 prompted_2\VBD\1645601 a_3\DT\13649268 phase_4\NN\15113229 i_5\CD\14622893 clinical_6\JJ\1740 study_7\NN\635850 of_8\IN\1740 <e1>lometrexol</e1>_9\NN\1740 given_10\VBN\2327200 with_11\IN\1740 folic_12\JJ\1740 acid_13\NN\14818238 supplementation_14\NN\5108947 which_15\WDT\1740 has_16\VBZ\2108377 confirmed_17\VBN\1011725 that_18\IN\1740 the_19\DT\1740 <e2>toxicity</e2>_20\NN\13576101 of_21\IN\1740 lometrexol_22\NN\1740 can_23\MD\3094503 be_24\VB\836236 markedly_25\RB\1740 reduced_26\VBN\441445 by_27\IN\1740 folic_28\JJ\1740 acid_29\NN\14818238 supplementation_30\NN\5108947 ._31\.\1740
C045894_D064420 NONE this_0\DT\1740 observation_1\NN\996969 prompted_2\VBD\1645601 a_3\DT\13649268 phase_4\NN\15113229 i_5\CD\14622893 clinical_6\JJ\1740 study_7\NN\635850 of_8\IN\1740 lometrexol_9\NN\1740 given_10\VBN\2327200 with_11\IN\1740 folic_12\JJ\1740 acid_13\NN\14818238 supplementation_14\NN\5108947 which_15\WDT\1740 has_16\VBZ\2108377 confirmed_17\VBN\1011725 that_18\IN\1740 the_19\DT\1740 <e2>toxicity</e2>_20\NN\13576101 of_21\IN\1740 <e1>lometrexol</e1>_22\NN\1740 can_23\MD\3094503 be_24\VB\836236 markedly_25\RB\1740 reduced_26\VBN\441445 by_27\IN\1740 folic_28\JJ\1740 acid_29\NN\14818238 supplementation_30\NN\5108947 ._31\.\1740
C045894_D064420 NONE associated_0\VBN\628491 studies_1\NNS\635850 demonstrated_2\VBD\2137132 that_3\IN\1740 <e1>lometrexol</e1>_4\NN\1740 plasma_5\NN\5398023 pharmacokinetics_6\NNS\6054892 were_7\VBD\836236 not_8\RB\1740 altered_9\VBN\126264 by_10\IN\1740 folic_11\JJ\1740 acid_12\NN\14818238 administration_13\NN\1133281 indicating_14\VBG\952524 that_15\IN\1740 supplementation_16\NN\5108947 is_17\VBZ\836236 unlikely_18\JJ\1740 to_19\TO\1740 reduce_20\VB\441445 <e2>toxicity</e2>_21\NN\13576101 by_22\IN\1740 enhancing_23\VBG\227165 lometrexol_24\NN\1740 plasma_25\NN\5398023 clearance_26\NN\5089947 ._27\.\1740
C045894_D064420 NONE associated_0\VBN\628491 studies_1\NNS\635850 demonstrated_2\VBD\2137132 that_3\IN\1740 lometrexol_4\NN\1740 plasma_5\NN\5398023 pharmacokinetics_6\NNS\6054892 were_7\VBD\836236 not_8\RB\1740 altered_9\VBN\126264 by_10\IN\1740 folic_11\JJ\1740 acid_12\NN\14818238 administration_13\NN\1133281 indicating_14\VBG\952524 that_15\IN\1740 supplementation_16\NN\5108947 is_17\VBZ\836236 unlikely_18\JJ\1740 to_19\TO\1740 reduce_20\VB\441445 <e2>toxicity</e2>_21\NN\13576101 by_22\IN\1740 enhancing_23\VBG\227165 <e1>lometrexol</e1>_24\NN\1740 plasma_25\NN\5398023 clearance_26\NN\5089947 ._27\.\1740
D005492_D064420 NONE preclinical_0\JJ\1740 murine_1\JJ\1740 studies_2\NNS\635850 demonstrated_3\VBD\2137132 that_4\IN\1740 the_5\DT\1740 <e2>toxicity</e2>_6\NN\13576101 of_7\IN\1740 lometrexol_8\NN\1740 can_9\MD\3094503 be_10\VB\836236 prevented_11\VBN\1740 by_12\IN\1740 low_13\JJ\1740 dose_14\NN\3740161 <e1>folic_15\NN\1740 acid</e1>_16\NN\14818238 administration_17\NN\1133281 ,_18\,\1740 i.e._19\FW\1740 for_20\IN\1740 7_21\CD\13741022 days_22\NNS\15140892 prior_23\RB\1740 to_24\IN\1740 and_25\CC\1740 7_26\CD\13741022 days_27\NNS\15140892 following_28\VBG\1835496 a_29\DT\13649268 single_30\JJ\1740 bolus_31\NN\13899404 dose_32\NN\3740161 ._33\.\1740
D005492_D064420 NONE this_0\DT\1740 observation_1\NN\996969 prompted_2\VBD\1645601 a_3\DT\13649268 phase_4\NN\15113229 i_5\CD\14622893 clinical_6\JJ\1740 study_7\NN\635850 of_8\IN\1740 lometrexol_9\NN\1740 given_10\VBN\2327200 with_11\IN\1740 <e1>folic_12\JJ\1740 acid</e1>_13\NN\14818238 supplementation_14\NN\5108947 which_15\WDT\1740 has_16\VBZ\2108377 confirmed_17\VBN\1011725 that_18\IN\1740 the_19\DT\1740 <e2>toxicity</e2>_20\NN\13576101 of_21\IN\1740 lometrexol_22\NN\1740 can_23\MD\3094503 be_24\VB\836236 markedly_25\RB\1740 reduced_26\VBN\441445 by_27\IN\1740 folic_28\JJ\1740 acid_29\NN\14818238 supplementation_30\NN\5108947 ._31\.\1740
D005492_D064420 NONE this_0\DT\1740 observation_1\NN\996969 prompted_2\VBD\1645601 a_3\DT\13649268 phase_4\NN\15113229 i_5\CD\14622893 clinical_6\JJ\1740 study_7\NN\635850 of_8\IN\1740 lometrexol_9\NN\1740 given_10\VBN\2327200 with_11\IN\1740 folic_12\JJ\1740 acid_13\NN\14818238 supplementation_14\NN\5108947 which_15\WDT\1740 has_16\VBZ\2108377 confirmed_17\VBN\1011725 that_18\IN\1740 the_19\DT\1740 <e2>toxicity</e2>_20\NN\13576101 of_21\IN\1740 lometrexol_22\NN\1740 can_23\MD\3094503 be_24\VB\836236 markedly_25\RB\1740 reduced_26\VBN\441445 by_27\IN\1740 <e1>folic_28\JJ\1740 acid</e1>_29\NN\14818238 supplementation_30\NN\5108947 ._31\.\1740
D005492_D064420 NONE there_0\EX\27167 was_1\VBD\836236 no_2\DT\7204911 clear_3\JJ\1740 relationship_4\NN\31921 between_5\IN\1740 clinical_6\JJ\1740 <e2>toxicity</e2>_7\NN\13576101 and_8\CC\1740 the_9\DT\1740 extent_10\NN\13939892 of_11\IN\1740 plasma_12\NN\5398023 <e1>folate</e1>_13\NN\15090742 elevation_14\NN\7445480 ._15\.\1740
D005492_D064420 NONE associated_0\VBN\628491 studies_1\NNS\635850 demonstrated_2\VBD\2137132 that_3\IN\1740 lometrexol_4\NN\1740 plasma_5\NN\5398023 pharmacokinetics_6\NNS\6054892 were_7\VBD\836236 not_8\RB\1740 altered_9\VBN\126264 by_10\IN\1740 <e1>folic_11\JJ\1740 acid</e1>_12\NN\14818238 administration_13\NN\1133281 indicating_14\VBG\952524 that_15\IN\1740 supplementation_16\NN\5108947 is_17\VBZ\836236 unlikely_18\JJ\1740 to_19\TO\1740 reduce_20\VB\441445 <e2>toxicity</e2>_21\NN\13576101 by_22\IN\1740 enhancing_23\VBG\227165 lometrexol_24\NN\1740 plasma_25\NN\5398023 clearance_26\NN\5089947 ._27\.\1740
10743694
1535072
D015016_D020018 NONE <e1>yohimbine</e1>_0\NN\1740 treatment_1\NN\654885 of_2\IN\1740 <e2>sexual_3\JJ\1740 side_4\NN\8630039 effects</e2>_5\NNS\13245626 induced_6\VBN\1627355 by_7\IN\1740 serotonin_8\NN\14807737 reuptake_9\NN\13571580 blockers_10\NNS\10101634 ._11\.\1740
D015016_D020018 NONE a_0\DT\13649268 single_1\JJ\1740 case_2\NN\7283608 report_3\NN\6470073 suggests_4\VBZ\1010118 that_5\IN\1740 <e1>yohimbine</e1>_6\NN\1740 may_7\MD\15209706 be_8\VB\836236 used_9\VBN\1156834 to_10\TO\1740 treat_11\VB\2376958 the_12\DT\1740 <e2>sexual_13\JJ\1740 side_14\NN\8630039 effects</e2>_15\NNS\13245626 of_16\IN\1740 clomipramine_17\NN\4482543 ._18\.\1740
D015016_D020018 NONE this_0\DT\1740 study_1\NN\635850 evaluated_2\VBD\670261 <e1>yohimbine</e1>_3\NN\1740 as_4\IN\14622893 a_5\DT\13649268 treatment_6\NN\654885 for_7\IN\1740 the_8\DT\1740 <e2>sexual_9\JJ\1740 side_10\NN\8630039 effects</e2>_11\NNS\13245626 caused_12\VBN\1617192 by_13\IN\1740 serotonin_14\NN\14807737 reuptake_15\NN\13571580 blockers_16\NNS\10101634 ._17\.\1740
D015016_D020018 NONE method_0\NN\5616786 :_1\:\1740 six_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 either_5\CC\1740 obsessive_6\JJ\1740 compulsive_7\JJ\1740 disorder_8\NN\14034177 ,_9\,\1740 trichotillomania_10\NN\9181557 ,_11\,\1740 anxiety_12\NN\14373582 ,_13\,\1740 or_14\CC\3541091 affective_15\JJ\1740 disorders_16\NNS\14034177 who_17\WP\8299493 suffered_18\VBD\2110220 <e2>sexual_19\JJ\1740 side_20\NN\8630039 effects</e2>_21\NNS\13245626 after_22\IN\1740 treatment_23\NN\654885 with_24\IN\1740 serotonin_25\NN\14807737 reuptake_26\NN\13571580 blockers_27\NNS\10101634 were_28\VBD\836236 given_29\VBN\2327200 <e1>yohimbine</e1>_30\NN\1740 on_31\IN\1740 a_32\DT\13649268 p.r.n_33\NN\1740 ._34\.\1740
D015016_D020018 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 indicate_7\VBP\952524 that_8\IN\1740 <e1>yohimbine</e1>_9\NN\1740 may_10\MD\15209706 be_11\VB\836236 an_12\DT\6697703 effective_13\JJ\1740 treatment_14\NN\654885 for_15\IN\1740 the_16\DT\1740 <e2>sexual_17\JJ\1740 side_18\NN\8630039 effects</e2>_19\NNS\13245626 caused_20\VBN\1617192 by_21\IN\1740 serotonin_22\NN\14807737 reuptake_23\NN\13571580 blockers_24\NNS\10101634 ._25\.\1740
D012701_D020018 NONE yohimbine_0\NN\1740 treatment_1\NN\654885 of_2\IN\1740 <e2>sexual_3\JJ\1740 side_4\NN\8630039 effects</e2>_5\NNS\13245626 induced_6\VBN\1627355 by_7\IN\1740 <e1>serotonin</e1>_8\NN\14807737 reuptake_9\NN\13571580 blockers_10\NNS\10101634 ._11\.\1740
D012701_D020018 NONE this_0\DT\1740 study_1\NN\635850 evaluated_2\VBD\670261 yohimbine_3\NN\1740 as_4\IN\14622893 a_5\DT\13649268 treatment_6\NN\654885 for_7\IN\1740 the_8\DT\1740 <e2>sexual_9\JJ\1740 side_10\NN\8630039 effects</e2>_11\NNS\13245626 caused_12\VBN\1617192 by_13\IN\1740 <e1>serotonin</e1>_14\NN\14807737 reuptake_15\NN\13571580 blockers_16\NNS\10101634 ._17\.\1740
D012701_D020018 NONE method_0\NN\5616786 :_1\:\1740 six_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 either_5\CC\1740 obsessive_6\JJ\1740 compulsive_7\JJ\1740 disorder_8\NN\14034177 ,_9\,\1740 trichotillomania_10\NN\9181557 ,_11\,\1740 anxiety_12\NN\14373582 ,_13\,\1740 or_14\CC\3541091 affective_15\JJ\1740 disorders_16\NNS\14034177 who_17\WP\8299493 suffered_18\VBD\2110220 <e2>sexual_19\JJ\1740 side_20\NN\8630039 effects</e2>_21\NNS\13245626 after_22\IN\1740 treatment_23\NN\654885 with_24\IN\1740 <e1>serotonin</e1>_25\NN\14807737 reuptake_26\NN\13571580 blockers_27\NNS\10101634 were_28\VBD\836236 given_29\VBN\2327200 yohimbine_30\NN\1740 on_31\IN\1740 a_32\DT\13649268 p.r.n_33\NN\1740 ._34\.\1740
D012701_D020018 NONE conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 results_3\NNS\34213 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 indicate_7\VBP\952524 that_8\IN\1740 yohimbine_9\NN\1740 may_10\MD\15209706 be_11\VB\836236 an_12\DT\6697703 effective_13\JJ\1740 treatment_14\NN\654885 for_15\IN\1740 the_16\DT\1740 <e2>sexual_17\JJ\1740 side_18\NN\8630039 effects</e2>_19\NNS\13245626 caused_20\VBN\1617192 by_21\IN\1740 <e1>serotonin</e1>_22\NN\14807737 reuptake_23\NN\13571580 blockers_24\NNS\10101634 ._25\.\1740
D015016_D007172 NONE background_0\NN\4921011 :_1\:\1740 preclinical_2\JJ\1740 and_3\CC\1740 clinical_4\JJ\1740 studies_5\NNS\635850 suggest_6\VBP\1010118 that_7\IN\1740 <e1>yohimbine</e1>_8\NN\1740 facilitates_9\VBZ\2547586 sexual_10\JJ\1740 behavior_11\NN\407535 and_12\CC\1740 may_13\MD\15209706 be_14\VB\836236 helpful_15\JJ\1740 in_16\IN\13603305 the_17\DT\1740 treatment_18\NN\654885 of_19\IN\1740 <e2>male_20\JJ\1740 impotence</e2>_21\NN\4723816 ._22\.\1740
D002997_D020018 CID a_0\DT\13649268 single_1\JJ\1740 case_2\NN\7283608 report_3\NN\6470073 suggests_4\VBZ\1010118 that_5\IN\1740 yohimbine_6\NN\1740 may_7\MD\15209706 be_8\VB\836236 used_9\VBN\1156834 to_10\TO\1740 treat_11\VB\2376958 the_12\DT\1740 <e2>sexual_13\JJ\1740 side_14\NN\8630039 effects</e2>_15\NNS\13245626 of_16\IN\1740 <e1>clomipramine</e1>_17\NN\4482543 ._18\.\1740
D012701_D009771 NONE method_0\NN\5616786 :_1\:\1740 six_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 either_5\CC\1740 <e2>obsessive_6\JJ\1740 compulsive_7\JJ\1740 disorder</e2>_8\NN\14034177 ,_9\,\1740 trichotillomania_10\NN\9181557 ,_11\,\1740 anxiety_12\NN\14373582 ,_13\,\1740 or_14\CC\3541091 affective_15\JJ\1740 disorders_16\NNS\14034177 who_17\WP\8299493 suffered_18\VBD\2110220 sexual_19\JJ\1740 side_20\NN\8630039 effects_21\NNS\13245626 after_22\IN\1740 treatment_23\NN\654885 with_24\IN\1740 <e1>serotonin</e1>_25\NN\14807737 reuptake_26\NN\13571580 blockers_27\NNS\10101634 were_28\VBD\836236 given_29\VBN\2327200 yohimbine_30\NN\1740 on_31\IN\1740 a_32\DT\13649268 p.r.n_33\NN\1740 ._34\.\1740
D012701_D014256 NONE method_0\NN\5616786 :_1\:\1740 six_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 either_5\CC\1740 obsessive_6\JJ\1740 compulsive_7\JJ\1740 disorder_8\NN\14034177 ,_9\,\1740 <e2>trichotillomania</e2>_10\NN\9181557 ,_11\,\1740 anxiety_12\NN\14373582 ,_13\,\1740 or_14\CC\3541091 affective_15\JJ\1740 disorders_16\NNS\14034177 who_17\WP\8299493 suffered_18\VBD\2110220 sexual_19\JJ\1740 side_20\NN\8630039 effects_21\NNS\13245626 after_22\IN\1740 treatment_23\NN\654885 with_24\IN\1740 <e1>serotonin</e1>_25\NN\14807737 reuptake_26\NN\13571580 blockers_27\NNS\10101634 were_28\VBD\836236 given_29\VBN\2327200 yohimbine_30\NN\1740 on_31\IN\1740 a_32\DT\13649268 p.r.n_33\NN\1740 ._34\.\1740
D012701_D001008 NONE method_0\NN\5616786 :_1\:\1740 six_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 either_5\CC\1740 obsessive_6\JJ\1740 compulsive_7\JJ\1740 disorder_8\NN\14034177 ,_9\,\1740 trichotillomania_10\NN\9181557 ,_11\,\1740 <e2>anxiety</e2>_12\NN\14373582 ,_13\,\1740 or_14\CC\3541091 affective_15\JJ\1740 disorders_16\NNS\14034177 who_17\WP\8299493 suffered_18\VBD\2110220 sexual_19\JJ\1740 side_20\NN\8630039 effects_21\NNS\13245626 after_22\IN\1740 treatment_23\NN\654885 with_24\IN\1740 <e1>serotonin</e1>_25\NN\14807737 reuptake_26\NN\13571580 blockers_27\NNS\10101634 were_28\VBD\836236 given_29\VBN\2327200 yohimbine_30\NN\1740 on_31\IN\1740 a_32\DT\13649268 p.r.n_33\NN\1740 ._34\.\1740
D012701_D019964 NONE method_0\NN\5616786 :_1\:\1740 six_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 either_5\CC\1740 obsessive_6\JJ\1740 compulsive_7\JJ\1740 disorder_8\NN\14034177 ,_9\,\1740 trichotillomania_10\NN\9181557 ,_11\,\1740 anxiety_12\NN\14373582 ,_13\,\1740 or_14\CC\3541091 <e2>affective_15\JJ\1740 disorders</e2>_16\NNS\14034177 who_17\WP\8299493 suffered_18\VBD\2110220 sexual_19\JJ\1740 side_20\NN\8630039 effects_21\NNS\13245626 after_22\IN\1740 treatment_23\NN\654885 with_24\IN\1740 <e1>serotonin</e1>_25\NN\14807737 reuptake_26\NN\13571580 blockers_27\NNS\10101634 were_28\VBD\836236 given_29\VBN\2327200 yohimbine_30\NN\1740 on_31\IN\1740 a_32\DT\13649268 p.r.n_33\NN\1740 ._34\.\1740
D015016_D009771 NONE method_0\NN\5616786 :_1\:\1740 six_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 either_5\CC\1740 <e2>obsessive_6\JJ\1740 compulsive_7\JJ\1740 disorder</e2>_8\NN\14034177 ,_9\,\1740 trichotillomania_10\NN\9181557 ,_11\,\1740 anxiety_12\NN\14373582 ,_13\,\1740 or_14\CC\3541091 affective_15\JJ\1740 disorders_16\NNS\14034177 who_17\WP\8299493 suffered_18\VBD\2110220 sexual_19\JJ\1740 side_20\NN\8630039 effects_21\NNS\13245626 after_22\IN\1740 treatment_23\NN\654885 with_24\IN\1740 serotonin_25\NN\14807737 reuptake_26\NN\13571580 blockers_27\NNS\10101634 were_28\VBD\836236 given_29\VBN\2327200 <e1>yohimbine</e1>_30\NN\1740 on_31\IN\1740 a_32\DT\13649268 p.r.n_33\NN\1740 ._34\.\1740
D015016_D014256 NONE method_0\NN\5616786 :_1\:\1740 six_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 either_5\CC\1740 obsessive_6\JJ\1740 compulsive_7\JJ\1740 disorder_8\NN\14034177 ,_9\,\1740 <e2>trichotillomania</e2>_10\NN\9181557 ,_11\,\1740 anxiety_12\NN\14373582 ,_13\,\1740 or_14\CC\3541091 affective_15\JJ\1740 disorders_16\NNS\14034177 who_17\WP\8299493 suffered_18\VBD\2110220 sexual_19\JJ\1740 side_20\NN\8630039 effects_21\NNS\13245626 after_22\IN\1740 treatment_23\NN\654885 with_24\IN\1740 serotonin_25\NN\14807737 reuptake_26\NN\13571580 blockers_27\NNS\10101634 were_28\VBD\836236 given_29\VBN\2327200 <e1>yohimbine</e1>_30\NN\1740 on_31\IN\1740 a_32\DT\13649268 p.r.n_33\NN\1740 ._34\.\1740
D015016_D001008 NONE method_0\NN\5616786 :_1\:\1740 six_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 either_5\CC\1740 obsessive_6\JJ\1740 compulsive_7\JJ\1740 disorder_8\NN\14034177 ,_9\,\1740 trichotillomania_10\NN\9181557 ,_11\,\1740 <e2>anxiety</e2>_12\NN\14373582 ,_13\,\1740 or_14\CC\3541091 affective_15\JJ\1740 disorders_16\NNS\14034177 who_17\WP\8299493 suffered_18\VBD\2110220 sexual_19\JJ\1740 side_20\NN\8630039 effects_21\NNS\13245626 after_22\IN\1740 treatment_23\NN\654885 with_24\IN\1740 serotonin_25\NN\14807737 reuptake_26\NN\13571580 blockers_27\NNS\10101634 were_28\VBD\836236 given_29\VBN\2327200 <e1>yohimbine</e1>_30\NN\1740 on_31\IN\1740 a_32\DT\13649268 p.r.n_33\NN\1740 ._34\.\1740
D015016_D001008 NONE side_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 <e1>yohimbine</e1>_3\NN\1740 included_4\VBD\690614 excessive_5\JJ\1740 sweating_6\NN\13440063 ,_7\,\1740 increased_8\VBD\169651 <e2>anxiety</e2>_9\NN\14373582 ,_10\,\1740 and_11\CC\1740 a_12\DT\13649268 wound-up_13\JJ\1740 feeling_14\NN\24720 in_15\IN\13603305 some_16\DT\1740 patients_17\NNS\9898892 ._18\.\1740
D015016_D019964 NONE method_0\NN\5616786 :_1\:\1740 six_2\CD\13741022 patients_3\NNS\9898892 with_4\IN\1740 either_5\CC\1740 obsessive_6\JJ\1740 compulsive_7\JJ\1740 disorder_8\NN\14034177 ,_9\,\1740 trichotillomania_10\NN\9181557 ,_11\,\1740 anxiety_12\NN\14373582 ,_13\,\1740 or_14\CC\3541091 <e2>affective_15\JJ\1740 disorders</e2>_16\NNS\14034177 who_17\WP\8299493 suffered_18\VBD\2110220 sexual_19\JJ\1740 side_20\NN\8630039 effects_21\NNS\13245626 after_22\IN\1740 treatment_23\NN\654885 with_24\IN\1740 serotonin_25\NN\14807737 reuptake_26\NN\13571580 blockers_27\NNS\10101634 were_28\VBD\836236 given_29\VBN\2327200 <e1>yohimbine</e1>_30\NN\1740 on_31\IN\1740 a_32\DT\13649268 p.r.n_33\NN\1740 ._34\.\1740
7880714
7053705
D013866_D006504 CID <e2>hepatic_0\JJ\1740 veno-occlusive_1\JJ\1740 disease</e2>_2\NN\14061805 caused_3\VBN\1617192 by_4\IN\1740 <e1>6-thioguanine</e1>_5\NN\1740 ._6\.\1740
D013866_D006504 CID clinically_0\RB\1740 reversible_1\JJ\1740 <e2>veno-occlusive_2\JJ\1740 disease_3\NN\14061805 of_4\IN\1740 the_5\DT\1740 liver</e2>_6\NN\5298729 developed_7\VBD\1753788 in_8\IN\13603305 a_9\DT\13649268 23-year-old_10\JJ\1740 man_11\NN\9605289 with_12\IN\1740 acute_13\JJ\1740 lymphocytic_14\JJ\1740 leukemia_15\NN\14239918 after_16\IN\1740 10_17\CD\13745420 months_18\NNS\15113229 of_19\IN\1740 maintenance_20\NN\266806 therapy_21\NN\657604 with_22\IN\1740 <e1>6-thioguanine</e1>_23\NN\1740 ._24\.\1740
D013866_D006504 CID this_0\DT\1740 case_1\NN\7283608 presented_2\VBD\2137132 a_3\DT\13649268 unique_4\JJ\1740 opportunity_5\NN\14481929 to_6\TO\1740 observe_7\VB\2163746 the_8\DT\1740 histologic_9\JJ\1740 features_10\NNS\5849040 of_11\IN\1740 clinically_12\RB\1740 reversible_13\JJ\1740 <e2>hepatic_14\JJ\1740 veno-occlusive_15\JJ\1740 disease</e2>_16\NN\14061805 over_17\IN\5867413 time_18\NN\7308889 ,_19\,\1740 and_20\CC\1740 may_21\MD\15209706 be_22\VB\836236 the_23\DT\1740 first_24\JJ\1740 case_25\NN\7283608 of_26\IN\1740 veno-occlusive_27\JJ\1740 related_28\JJ\1740 solely_29\RB\1740 to_30\TO\1740 <e1>6-thioguanine</e1>_31\NN\1740 ._32\.\1740
D013866_D054198 NONE clinically_0\RB\1740 reversible_1\JJ\1740 veno-occlusive_2\JJ\1740 disease_3\NN\14061805 of_4\IN\1740 the_5\DT\1740 liver_6\NN\5298729 developed_7\VBD\1753788 in_8\IN\13603305 a_9\DT\13649268 23-year-old_10\JJ\1740 man_11\NN\9605289 with_12\IN\1740 <e2>acute_13\JJ\1740 lymphocytic_14\JJ\1740 leukemia</e2>_15\NN\14239918 after_16\IN\1740 10_17\CD\13745420 months_18\NNS\15113229 of_19\IN\1740 maintenance_20\NN\266806 therapy_21\NN\657604 with_22\IN\1740 <e1>6-thioguanine</e1>_23\NN\1740 ._24\.\1740
8384253
D014750_D008228 NONE forty_0\CD\13745420 patients_1\NNS\9898892 with_2\IN\1740 <e2>non-hodgkin_3\NNP\1740 's_4\POS\1740 lymphoma</e2>_5\NNP\14239918 treated_6\VBN\2376958 with_7\IN\1740 <e1>vincristine</e1>_8\NN\3917455 between_9\IN\1740 1984_10\CD\1740 and_11\CC\1740 1990_12\CD\1740 (_13\-LRB-\1740 cumulative_14\JJ\1740 dose_15\NN\3740161 12_16\CD\13745420 mg_17\NN\13717155 in_18\IN\13603305 18_19\CD\13745420 -_20\SYM\1740 24_21\CD\13745420 weeks_22\NNS\15113229 )_23\-RRB-\1740 were_24\VBD\836236 investigated_25\VBN\644583 in_26\IN\13603305 order_27\NN\7168131 to_28\TO\1740 evaluate_29\VB\670261 the_30\DT\1740 long_31\JJ\1740 term_32\NN\6286395 effects_33\NNS\13245626 of_34\IN\1740 vincristine_35\NN\3917455 on_36\IN\1740 the_37\DT\1740 peripheral_38\JJ\1740 nervous_39\JJ\1740 system_40\NN\3575240 ._41\.\1740
D014750_D008228 NONE forty_0\CD\13745420 patients_1\NNS\9898892 with_2\IN\1740 <e2>non-hodgkin_3\NNP\1740 's_4\POS\1740 lymphoma</e2>_5\NNP\14239918 treated_6\VBN\2376958 with_7\IN\1740 vincristine_8\NN\3917455 between_9\IN\1740 1984_10\CD\1740 and_11\CC\1740 1990_12\CD\1740 (_13\-LRB-\1740 cumulative_14\JJ\1740 dose_15\NN\3740161 12_16\CD\13745420 mg_17\NN\13717155 in_18\IN\13603305 18_19\CD\13745420 -_20\SYM\1740 24_21\CD\13745420 weeks_22\NNS\15113229 )_23\-RRB-\1740 were_24\VBD\836236 investigated_25\VBN\644583 in_26\IN\13603305 order_27\NN\7168131 to_28\TO\1740 evaluate_29\VB\670261 the_30\DT\1740 long_31\JJ\1740 term_32\NN\6286395 effects_33\NNS\13245626 of_34\IN\1740 <e1>vincristine</e1>_35\NN\3917455 on_36\IN\1740 the_37\DT\1740 peripheral_38\JJ\1740 nervous_39\JJ\1740 system_40\NN\3575240 ._41\.\1740
D014750_D009422 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 with_4\IN\1740 the_5\DT\1740 above_6\JJ\1740 mentioned_7\JJ\1740 <e1>vincristine</e1>_8\NN\3917455 dose_9\NN\3740161 schedule_10\NN\5898568 signs_11\NNS\6643763 and_12\CC\1740 symptoms_13\NNS\5823932 of_14\IN\1740 vincristine_15\NN\3917455 <e2>neuropathy</e2>_16\NN\14204950 are_17\VBP\836236 reversible_18\JJ\1740 for_19\IN\1740 a_20\DT\13649268 great_21\JJ\1740 deal_22\NN\1106808 and_23\CC\1740 prognosis_24\NN\6748969 is_25\VBZ\836236 fairly_26\RB\1740 good_27\JJ\1740 ._28\.\1740
D014750_D009422 NONE it_0\PRP\6125041 is_1\VBZ\836236 concluded_2\VBN\628491 that_3\IN\1740 with_4\IN\1740 the_5\DT\1740 above_6\JJ\1740 mentioned_7\JJ\1740 vincristine_8\NN\3917455 dose_9\NN\3740161 schedule_10\NN\5898568 signs_11\NNS\6643763 and_12\CC\1740 symptoms_13\NNS\5823932 of_14\IN\1740 <e1>vincristine</e1>_15\NN\3917455 <e2>neuropathy</e2>_16\NN\14204950 are_17\VBP\836236 reversible_18\JJ\1740 for_19\IN\1740 a_20\DT\13649268 great_21\JJ\1740 deal_22\NN\1106808 and_23\CC\1740 prognosis_24\NN\6748969 is_25\VBZ\836236 fairly_26\RB\1740 good_27\JJ\1740 ._28\.\1740
8111719
D007069_D006212 CID <e2>hallucinations</e2>_0\NNS\14376855 and_1\CC\1740 <e1>ifosfamide-induced</e1>_2\JJ\1740 neurotoxicity_3\NN\1740 ._4\.\1740
D007069_D006212 CID background_0\NN\4921011 :_1\:\1740 <e2>hallucinations</e2>_2\NNP\14376855 as_3\IN\14622893 a_4\DT\13649268 symptom_5\NN\5823932 of_6\IN\1740 central_7\JJ\1740 neurotoxicity_8\NN\1740 are_9\VBP\836236 a_10\DT\13649268 known_11\JJ\1740 but_12\CC\1740 poorly_13\RB\1740 described_14\VBN\1001294 side_15\NN\8630039 effect_16\NN\34213 of_17\IN\1740 <e1>ifosfamide</e1>_18\NN\1740 ._19\.\1740
D007069_D006212 CID most_0\JJS\1740 cases_1\NNS\7283608 of_2\IN\1740 <e1>ifosfamide-induced</e1>_3\JJ\1740 <e2>hallucinations</e2>_4\NNS\14376855 have_5\VBP\2108377 been_6\VBN\836236 reported_7\VBN\831651 with_8\IN\1740 other_9\JJ\1740 mental_10\JJ\1740 status_11\NN\24720 changes_12\NNS\7283608 ._13\.\1740
D007069_D006212 CID methods_0\NNS\5616786 :_1\:\1740 the_2\DT\1740 authors_3\NNS\9610660 interviewed_4\VBD\964694 six_5\CD\13741022 persons_6\NNS\7347 with_7\IN\1740 <e1>ifosfamide-induced</e1>_8\JJ\1740 <e2>hallucinations</e2>_9\NNS\14376855 in_10\IN\13603305 the_11\DT\1740 presence_12\NN\13954253 of_13\IN\1740 a_14\DT\13649268 clear_15\JJ\1740 sensorium_16\NN\5486920 ._17\.\1740
D007069_D006212 CID the_0\DT\1740 clinician_1\NN\10462860 should_2\MD\1740 be_3\VB\836236 alerted_4\VBN\870213 for_5\IN\1740 possible_6\JJ\1740 <e1>ifosfamide-induced</e1>_7\JJ\1740 <e2>hallucinations</e2>_8\NNS\14376855 ,_9\,\1740 which_10\WDT\1740 may_11\MD\15209706 occur_12\VB\2623529 without_13\IN\1740 other_14\JJ\1740 signs_15\NNS\6643763 of_16\IN\1740 neurotoxicity_17\NN\1740 ._18\.\1740
D007069_D020258 NONE hallucinations_0\NNS\14376855 and_1\CC\1740 <e1>ifosfamide-induced</e1>_2\JJ\1740 <e2>neurotoxicity</e2>_3\NN\1740 ._4\.\1740
D007069_D020258 NONE background_0\NN\4921011 :_1\:\1740 hallucinations_2\NNP\14376855 as_3\IN\14622893 a_4\DT\13649268 symptom_5\NN\5823932 of_6\IN\1740 central_7\JJ\1740 <e2>neurotoxicity</e2>_8\NN\1740 are_9\VBP\836236 a_10\DT\13649268 known_11\JJ\1740 but_12\CC\1740 poorly_13\RB\1740 described_14\VBN\1001294 side_15\NN\8630039 effect_16\NN\34213 of_17\IN\1740 <e1>ifosfamide</e1>_18\NN\1740 ._19\.\1740
D007069_D020258 NONE the_0\DT\1740 clinician_1\NN\10462860 should_2\MD\1740 be_3\VB\836236 alerted_4\VBN\870213 for_5\IN\1740 possible_6\JJ\1740 <e1>ifosfamide-induced</e1>_7\JJ\1740 hallucinations_8\NNS\14376855 ,_9\,\1740 which_10\WDT\1740 may_11\MD\15209706 occur_12\VB\2623529 without_13\IN\1740 other_14\JJ\1740 signs_15\NNS\6643763 of_16\IN\1740 <e2>neurotoxicity</e2>_17\NN\1740 ._18\.\1740
D006220_D011595 NONE if_0\IN\1740 <e2>agitation</e2>_1\NN\14373582 becomes_2\VBZ\146138 marked_3\JJ\1740 ,_4\,\1740 high-potency_5\NN\1740 neuroleptics_6\NNS\4470232 (_7\-LRB-\1740 i.e._8\FW\1740 ,_9\,\1740 <e1>haloperidol</e1>_10\JJ\1740 )_11\-RRB-\1740 may_12\MD\15209706 be_13\VB\836236 effective_14\JJ\1740 ._15\.\1740
9579567
D013629_D001943 NONE since_0\IN\1740 <e1>tamoxifen</e1>_1\NN\2714883 is_2\VBZ\836236 widely_3\RB\1740 used_4\VBN\1156834 in_5\IN\13603305 <e2>breast_6\NN\5225090 cancer</e2>_7\NN\14239425 treatment_8\NN\654885 and_9\CC\1740 has_10\VBZ\2108377 been_11\VBN\836236 proposed_12\VBN\1010118 for_13\IN\1740 the_14\DT\1740 prevention_15\NN\1073995 of_16\IN\1740 breast_17\NN\5225090 cancer_18\NN\14239425 ,_19\,\1740 its_20\PRP$\6125041 endometrial_21\JJ\1740 iatrogenic_22\JJ\1740 effects_23\NNS\13245626 must_24\MD\9367203 be_25\VB\836236 carefully_26\RB\1740 examined_27\VBN\789138 ._28\.\1740
D013629_D001943 NONE since_0\IN\1740 <e1>tamoxifen</e1>_1\NN\2714883 is_2\VBZ\836236 widely_3\RB\1740 used_4\VBN\1156834 in_5\IN\13603305 breast_6\NN\5225090 cancer_7\NN\14239425 treatment_8\NN\654885 and_9\CC\1740 has_10\VBZ\2108377 been_11\VBN\836236 proposed_12\VBN\1010118 for_13\IN\1740 the_14\DT\1740 prevention_15\NN\1073995 of_16\IN\1740 <e2>breast_17\NN\5225090 cancer</e2>_18\NN\14239425 ,_19\,\1740 its_20\PRP$\6125041 endometrial_21\JJ\1740 iatrogenic_22\JJ\1740 effects_23\NNS\13245626 must_24\MD\9367203 be_25\VB\836236 carefully_26\RB\1740 examined_27\VBN\789138 ._28\.\1740
D013629_D001943 NONE we_0\PRP\1740 have_1\VBP\2108377 investigated_2\VBN\644583 the_3\DT\1740 association_4\NN\8008335 between_5\IN\1740 endometrial_6\JJ\1740 cancer_7\NN\14239425 and_8\CC\1740 <e1>tamoxifen</e1>_9\NN\2714883 use_10\NN\407535 or_11\CC\3541091 other_12\JJ\1740 treatments_13\NNS\654885 in_14\IN\13603305 women_15\NNS\9605289 treated_16\VBN\2376958 for_17\IN\1740 <e2>breast_18\NN\5225090 cancer</e2>_19\NN\14239425 in_20\IN\13603305 a_21\DT\13649268 case-control_22\JJ\1740 study_23\NN\635850 ._24\.\1740
D013629_D001943 NONE our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 a_3\DT\13649268 causal_4\JJ\1740 role_5\NN\719494 of_6\IN\1740 <e1>tamoxifen</e1>_7\NN\2714883 in_8\IN\13603305 endometrial_9\JJ\1740 cancer_10\NN\14239425 ,_11\,\1740 particularly_12\RB\1740 when_13\WRB\1740 used_14\VBN\1156834 as_15\IN\14622893 currently_16\RB\1740 proposed_17\VBN\1010118 for_18\IN\1740 <e2>breast_19\NN\5225090 cancer</e2>_20\NN\14239425 prevention_21\NN\1073995 ._22\.\1740
D013629_D001943 NONE women_0\NNS\9605289 who_1\WP\8299493 receive_2\VBP\2210855 <e1>tamoxifen</e1>_3\NN\2714883 for_4\IN\1740 <e2>breast_5\NN\5225090 cancer</e2>_6\NN\14239425 should_7\MD\1740 be_8\VB\836236 offered_9\VBN\2327200 gynaecological_10\JJ\1740 surveillance_11\NN\635012 during_12\IN\1740 and_13\CC\1740 after_14\IN\1740 treatment_15\NN\654885 ._16\.\1740
D013629_D001943 NONE a_0\DT\13649268 long-term_1\JJ\1740 evaluation_2\NN\874067 of_3\IN\1740 the_4\DT\1740 risk-benefit_5\JJ\1740 ratio_6\NN\13815152 of_7\IN\1740 <e1>tamoxifen</e1>_8\NN\2714883 as_9\IN\14622893 a_10\DT\13649268 preventive_11\JJ\1740 treatment_12\NN\654885 for_13\IN\1740 <e2>breast_14\NN\5225090 cancer</e2>_15\NN\14239425 is_16\VBZ\836236 clearly_17\RB\1740 warranted_18\VBN\1012073 ._19\.\1740
D013629_D016889 CID we_0\PRP\1740 have_1\VBP\2108377 investigated_2\VBN\644583 the_3\DT\1740 association_4\NN\8008335 between_5\IN\1740 <e2>endometrial_6\JJ\1740 cancer</e2>_7\NN\14239425 and_8\CC\1740 <e1>tamoxifen</e1>_9\NN\2714883 use_10\NN\407535 or_11\CC\3541091 other_12\JJ\1740 treatments_13\NNS\654885 in_14\IN\13603305 women_15\NNS\9605289 treated_16\VBN\2376958 for_17\IN\1740 breast_18\NN\5225090 cancer_19\NN\14239425 in_20\IN\13603305 a_21\DT\13649268 case-control_22\JJ\1740 study_23\NN\635850 ._24\.\1740
D013629_D016889 CID women_0\NNS\9605289 who_1\WP\8299493 had_2\VBD\2108377 received_3\VBN\2210855 <e1>tamoxifen</e1>_4\NN\2714883 were_5\VBD\836236 significantly_6\RB\1740 more_7\RBR\1740 likely_8\JJ\1740 to_9\TO\1740 have_10\VB\2108377 <e2>endometrial_11\JJ\1740 cancer</e2>_12\NN\14239425 diagnosed_13\VBN\644583 than_14\IN\1740 those_15\DT\1740 who_16\WP\8299493 had_17\VBD\2108377 not_18\RB\1740 (_19\-LRB-\1740 crude_20\JJ\1740 relative_21\JJ\1740 risk_22\NN\14541044 =_23\JJ\1740 4.9_24\CD\1740 ,_25\,\1740 p_26\NN\14622893 =_27\JJ\1740 0.0001_28\CD\1740 )_29\-RRB-\1740 ._30\.\1740
D013629_D016889 CID women_0\NNS\9605289 who_1\WP\8299493 had_2\VBD\2108377 <e2>endometrial_3\JJ\1740 cancer</e2>_4\NN\14239425 and_5\CC\1740 had_6\VBD\2108377 received_7\VBN\2210855 <e1>tamoxifen</e1>_8\NN\2714883 had_9\VBD\2108377 more_10\RBR\1740 advanced_11\JJ\1740 disease_12\NN\14061805 and_13\CC\1740 poorer_14\JJR\1740 prognosis_15\NN\6748969 than_16\IN\1740 those_17\DT\1740 with_18\IN\1740 endometrial_19\JJ\1740 cancer_20\NN\14239425 who_21\WP\8299493 had_22\VBD\2108377 not_23\RB\1740 received_24\VBN\2210855 this_25\DT\1740 treatment_26\NN\654885 ._27\.\1740
D013629_D016889 CID women_0\NNS\9605289 who_1\WP\8299493 had_2\VBD\2108377 endometrial_3\JJ\1740 cancer_4\NN\14239425 and_5\CC\1740 had_6\VBD\2108377 received_7\VBN\2210855 <e1>tamoxifen</e1>_8\NN\2714883 had_9\VBD\2108377 more_10\RBR\1740 advanced_11\JJ\1740 disease_12\NN\14061805 and_13\CC\1740 poorer_14\JJR\1740 prognosis_15\NN\6748969 than_16\IN\1740 those_17\DT\1740 with_18\IN\1740 <e2>endometrial_19\JJ\1740 cancer</e2>_20\NN\14239425 who_21\WP\8299493 had_22\VBD\2108377 not_23\RB\1740 received_24\VBN\2210855 this_25\DT\1740 treatment_26\NN\654885 ._27\.\1740
D013629_D016889 CID our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 a_3\DT\13649268 causal_4\JJ\1740 role_5\NN\719494 of_6\IN\1740 <e1>tamoxifen</e1>_7\NN\2714883 in_8\IN\13603305 <e2>endometrial_9\JJ\1740 cancer</e2>_10\NN\14239425 ,_11\,\1740 particularly_12\RB\1740 when_13\WRB\1740 used_14\VBN\1156834 as_15\IN\14622893 currently_16\RB\1740 proposed_17\VBN\1010118 for_18\IN\1740 breast_19\NN\5225090 cancer_20\NN\14239425 prevention_21\NN\1073995 ._22\.\1740
D013629_D016889 CID <e2>endometrial_0\JJ\1740 cancers</e2>_1\NNS\14239425 diagnosed_2\VBN\644583 in_3\IN\13603305 women_4\NNS\9605289 treated_5\VBN\2376958 with_6\IN\1740 <e1>tamoxifen</e1>_7\NN\2714883 have_8\VBP\2108377 poorer_9\JJR\1740 prognosis_10\NN\6748969 ._11\.\1740
D013629_D020178 NONE women_0\NNS\9605289 who_1\WP\8299493 had_2\VBD\2108377 endometrial_3\JJ\1740 cancer_4\NN\14239425 and_5\CC\1740 had_6\VBD\2108377 received_7\VBN\2210855 <e1>tamoxifen</e1>_8\NN\2714883 had_9\VBD\2108377 more_10\RBR\1740 <e2>advanced_11\JJ\1740 disease</e2>_12\NN\14061805 and_13\CC\1740 poorer_14\JJR\1740 prognosis_15\NN\6748969 than_16\IN\1740 those_17\DT\1740 with_18\IN\1740 endometrial_19\JJ\1740 cancer_20\NN\14239425 who_21\WP\8299493 had_22\VBD\2108377 not_23\RB\1740 received_24\VBN\2210855 this_25\DT\1740 treatment_26\NN\654885 ._27\.\1740
9669632
D020117_D043183 NONE effects_0\NNS\13245626 of_1\IN\1740 <e1>cisapride</e1>_2\NN\1740 on_3\IN\1740 symptoms_4\NNS\5823932 and_5\CC\1740 postcibal_6\JJ\1740 small-bowel_7\JJ\1740 motor_8\NN\3699975 function_9\NN\13783581 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 <e2>irritable_13\JJ\1740 bowel_14\NN\5298729 syndrome</e2>_15\NN\5870365 ._16\.\1740
D020117_D043183 NONE our_0\PRP$\1740 aim_1\NN\5980875 was_2\VBD\836236 to_3\TO\1740 assess_4\VB\670261 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 long-term_8\JJ\1740 treatment_9\NN\654885 with_10\IN\1740 a_11\DT\13649268 prokinetic_12\JJ\1740 agent_13\NN\7347 ,_14\,\1740 <e1>cisapride</e1>_15\NN\1740 ,_16\,\1740 on_17\IN\1740 postprandial_18\JJ\1740 jejunal_19\JJ\1740 motility_20\NN\4773351 and_21\CC\1740 symptoms_22\NNS\5823932 in_23\IN\13603305 the_24\DT\1740 <e2>irritable_25\JJ\1740 bowel_26\NN\5298729 syndrome</e2>_27\NN\5870365 (_28\-LRB-\1740 ibs_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D020117_D043183 NONE our_0\PRP$\1740 aim_1\NN\5980875 was_2\VBD\836236 to_3\TO\1740 assess_4\VB\670261 the_5\DT\1740 effects_6\NNS\13245626 of_7\IN\1740 long-term_8\JJ\1740 treatment_9\NN\654885 with_10\IN\1740 a_11\DT\13649268 prokinetic_12\JJ\1740 agent_13\NN\7347 ,_14\,\1740 <e1>cisapride</e1>_15\NN\1740 ,_16\,\1740 on_17\IN\1740 postprandial_18\JJ\1740 jejunal_19\JJ\1740 motility_20\NN\4773351 and_21\CC\1740 symptoms_22\NNS\5823932 in_23\IN\13603305 the_24\DT\1740 irritable_25\JJ\1740 bowel_26\NN\5298729 syndrome_27\NN\5870365 (_28\-LRB-\1740 <e2>ibs</e2>_29\NN\1740 )_30\-RRB-\1740 ._31\.\1740
D020117_D043183 NONE methods_0\NNS\5616786 :_1\:\1740 thirty-eight_2\NN\1740 patients_3\NNS\9898892 with_4\IN\1740 <e2>ibs</e2>_5\NN\1740 (_6\-LRB-\1740 constipation-predominant_7\JJ\1740 ,_8\,\1740 n_9\NN\14622893 =_10\JJ\1740 17_11\CD\13745420 ;_12\:\1740 diarrhoea-predominant_13\JJ\1740 ,_14\,\1740 n_15\NN\14622893 =_16\JJ\1740 21_17\CD\13745420 )_18\-RRB-\1740 underwent_19\VBD\109660 24-h_20\JJ\1740 ambulatory_21\JJ\1740 jejunal_22\JJ\1740 manometry_23\NN\1740 before_24\IN\1740 and_25\CC\1740 after_26\IN\1740 12_27\CD\13745420 week_28\NN\15113229 's_29\POS\1740 treatment_30\NN\654885 [_31\-LRB-\1740 <e1>cisapride</e1>_32\NN\1740 ,_33\,\1740 5_34\CD\13741022 mg_35\NN\13717155 three_36\CD\13741022 times_37\NNS\15113229 daily_38\RB\1740 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 19_42\CD\13745420 )_43\-RRB-\1740 or_44\CC\3541091 placebo_45\NN\3740161 (_46\-LRB-\1740 n_47\NN\14622893 =_48\JJ\1740 19_49\CD\13745420 )_50\-RRB-\1740 ]_51\-RRB-\1740 ._52\.\1740
D020117_D043183 NONE symptom_0\NN\5823932 scores_1\NNS\13757724 relating_2\VBG\628491 to_3\IN\1740 the_4\DT\1740 severity_5\NN\5036394 of_6\IN\1740 constipation_7\NN\14299637 were_8\VBD\836236 lower_9\JJR\1740 in_10\IN\13603305 <e1>cisapride-treated</e1>_11\JJ\1740 constipation-predominant_12\JJ\1740 <e2>ibs</e2>_13\NN\1740 patients_14\NNS\9898892 [_15\-LRB-\1740 score_16\NN\5736149 ,_17\,\1740 54_18\CD\1740 +/-_19\CC\1740 5_20\CD\13741022 versus_21\CC\1740 67_22\CD\1740 +/-_23\CC\1740 14_24\CD\13745420 mm_25\NN\13649268 ,_26\,\1740 cisapride_27\NN\1740 versus_28\CC\1740 placebo_29\NN\3740161 (_30\-LRB-\1740 p_31\NN\14622893 <_32\XX\1740 0.05_33\CD\1740 )_34\-RRB-\1740 ;_35\:\1740 pretreatment_36\NN\1740 ,_37\,\1740 62_38\CD\1740 +/-_39\CC\1740 19_40\CD\13745420 mm_41\NNS\13649268 ]_42\-RRB-\1740 ._43\.\1740
D020117_D043183 NONE symptom_0\NN\5823932 scores_1\NNS\13757724 relating_2\VBG\628491 to_3\IN\1740 the_4\DT\1740 severity_5\NN\5036394 of_6\IN\1740 constipation_7\NN\14299637 were_8\VBD\836236 lower_9\JJR\1740 in_10\IN\13603305 cisapride-treated_11\JJ\1740 constipation-predominant_12\JJ\1740 <e2>ibs</e2>_13\NN\1740 patients_14\NNS\9898892 [_15\-LRB-\1740 score_16\NN\5736149 ,_17\,\1740 54_18\CD\1740 +/-_19\CC\1740 5_20\CD\13741022 versus_21\CC\1740 67_22\CD\1740 +/-_23\CC\1740 14_24\CD\13745420 mm_25\NN\13649268 ,_26\,\1740 <e1>cisapride</e1>_27\NN\1740 versus_28\CC\1740 placebo_29\NN\3740161 (_30\-LRB-\1740 p_31\NN\14622893 <_32\XX\1740 0.05_33\CD\1740 )_34\-RRB-\1740 ;_35\:\1740 pretreatment_36\NN\1740 ,_37\,\1740 62_38\CD\1740 +/-_39\CC\1740 19_40\CD\13745420 mm_41\NNS\13649268 ]_42\-RRB-\1740 ._43\.\1740
D020117_D043183 NONE diarrhoea-predominant_0\JJ\1740 <e2>ibs</e2>_1\NN\1740 patients_2\NNS\9898892 had_3\VBD\2108377 a_4\DT\13649268 higher_5\JJR\1740 pain_6\NN\14299637 score_7\NN\5736149 after_8\IN\1740 <e1>cisapride</e1>_9\NN\1740 therapy_10\NN\657604 [_11\-LRB-\1740 score_12\NN\5736149 ,_13\,\1740 55_14\CD\1740 +/-_15\CC\1740 15_16\CD\13745420 versus_17\CC\1740 34_18\CD\1740 +/-_19\CC\1740 12_20\CD\13745420 mm_21\NN\13649268 ,_22\,\1740 cisapride_23\NN\1740 versus_24\CC\1740 placebo_25\NN\3740161 (_26\-LRB-\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 ;_31\:\1740 pretreatment_32\NN\1740 ,_33\,\1740 67_34\CD\1740 +/-_35\CC\1740 19_36\CD\13745420 mm_37\NNS\13649268 ]_38\-RRB-\1740 ._39\.\1740
D020117_D043183 NONE diarrhoea-predominant_0\JJ\1740 <e2>ibs</e2>_1\NN\1740 patients_2\NNS\9898892 had_3\VBD\2108377 a_4\DT\13649268 higher_5\JJR\1740 pain_6\NN\14299637 score_7\NN\5736149 after_8\IN\1740 cisapride_9\NN\1740 therapy_10\NN\657604 [_11\-LRB-\1740 score_12\NN\5736149 ,_13\,\1740 55_14\CD\1740 +/-_15\CC\1740 15_16\CD\13745420 versus_17\CC\1740 34_18\CD\1740 +/-_19\CC\1740 12_20\CD\13745420 mm_21\NN\13649268 ,_22\,\1740 <e1>cisapride</e1>_23\NN\1740 versus_24\CC\1740 placebo_25\NN\3740161 (_26\-LRB-\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 ;_31\:\1740 pretreatment_32\NN\1740 ,_33\,\1740 67_34\CD\1740 +/-_35\CC\1740 19_36\CD\13745420 mm_37\NNS\13649268 ]_38\-RRB-\1740 ._39\.\1740
D020117_D043183 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>cisapride</e1>_2\NN\1740 affects_3\VBZ\126264 jejunal_4\JJ\1740 contraction_5\NN\358931 characteristics_6\NNS\5849040 and_7\CC\1740 some_8\DT\1740 symptoms_9\NNS\5823932 in_10\IN\13603305 <e2>ibs</e2>_11\NNP\1740 ._12\.\1740
D020117_D003248 NONE methods_0\NNS\5616786 :_1\:\1740 thirty-eight_2\NN\1740 patients_3\NNS\9898892 with_4\IN\1740 ibs_5\NN\1740 (_6\-LRB-\1740 <e2>constipation-predominant</e2>_7\JJ\1740 ,_8\,\1740 n_9\NN\14622893 =_10\JJ\1740 17_11\CD\13745420 ;_12\:\1740 diarrhoea-predominant_13\JJ\1740 ,_14\,\1740 n_15\NN\14622893 =_16\JJ\1740 21_17\CD\13745420 )_18\-RRB-\1740 underwent_19\VBD\109660 24-h_20\JJ\1740 ambulatory_21\JJ\1740 jejunal_22\JJ\1740 manometry_23\NN\1740 before_24\IN\1740 and_25\CC\1740 after_26\IN\1740 12_27\CD\13745420 week_28\NN\15113229 's_29\POS\1740 treatment_30\NN\654885 [_31\-LRB-\1740 <e1>cisapride</e1>_32\NN\1740 ,_33\,\1740 5_34\CD\13741022 mg_35\NN\13717155 three_36\CD\13741022 times_37\NNS\15113229 daily_38\RB\1740 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 19_42\CD\13745420 )_43\-RRB-\1740 or_44\CC\3541091 placebo_45\NN\3740161 (_46\-LRB-\1740 n_47\NN\14622893 =_48\JJ\1740 19_49\CD\13745420 )_50\-RRB-\1740 ]_51\-RRB-\1740 ._52\.\1740
D020117_D003248 NONE symptom_0\NN\5823932 scores_1\NNS\13757724 relating_2\VBG\628491 to_3\IN\1740 the_4\DT\1740 severity_5\NN\5036394 of_6\IN\1740 <e2>constipation</e2>_7\NN\14299637 were_8\VBD\836236 lower_9\JJR\1740 in_10\IN\13603305 <e1>cisapride-treated</e1>_11\JJ\1740 constipation-predominant_12\JJ\1740 ibs_13\NN\1740 patients_14\NNS\9898892 [_15\-LRB-\1740 score_16\NN\5736149 ,_17\,\1740 54_18\CD\1740 +/-_19\CC\1740 5_20\CD\13741022 versus_21\CC\1740 67_22\CD\1740 +/-_23\CC\1740 14_24\CD\13745420 mm_25\NN\13649268 ,_26\,\1740 cisapride_27\NN\1740 versus_28\CC\1740 placebo_29\NN\3740161 (_30\-LRB-\1740 p_31\NN\14622893 <_32\XX\1740 0.05_33\CD\1740 )_34\-RRB-\1740 ;_35\:\1740 pretreatment_36\NN\1740 ,_37\,\1740 62_38\CD\1740 +/-_39\CC\1740 19_40\CD\13745420 mm_41\NNS\13649268 ]_42\-RRB-\1740 ._43\.\1740
D020117_D003248 NONE symptom_0\NN\5823932 scores_1\NNS\13757724 relating_2\VBG\628491 to_3\IN\1740 the_4\DT\1740 severity_5\NN\5036394 of_6\IN\1740 constipation_7\NN\14299637 were_8\VBD\836236 lower_9\JJR\1740 in_10\IN\13603305 <e1>cisapride-treated</e1>_11\JJ\1740 <e2>constipation-predominant</e2>_12\JJ\1740 ibs_13\NN\1740 patients_14\NNS\9898892 [_15\-LRB-\1740 score_16\NN\5736149 ,_17\,\1740 54_18\CD\1740 +/-_19\CC\1740 5_20\CD\13741022 versus_21\CC\1740 67_22\CD\1740 +/-_23\CC\1740 14_24\CD\13745420 mm_25\NN\13649268 ,_26\,\1740 cisapride_27\NN\1740 versus_28\CC\1740 placebo_29\NN\3740161 (_30\-LRB-\1740 p_31\NN\14622893 <_32\XX\1740 0.05_33\CD\1740 )_34\-RRB-\1740 ;_35\:\1740 pretreatment_36\NN\1740 ,_37\,\1740 62_38\CD\1740 +/-_39\CC\1740 19_40\CD\13745420 mm_41\NNS\13649268 ]_42\-RRB-\1740 ._43\.\1740
D020117_D003248 NONE symptom_0\NN\5823932 scores_1\NNS\13757724 relating_2\VBG\628491 to_3\IN\1740 the_4\DT\1740 severity_5\NN\5036394 of_6\IN\1740 <e2>constipation</e2>_7\NN\14299637 were_8\VBD\836236 lower_9\JJR\1740 in_10\IN\13603305 cisapride-treated_11\JJ\1740 constipation-predominant_12\JJ\1740 ibs_13\NN\1740 patients_14\NNS\9898892 [_15\-LRB-\1740 score_16\NN\5736149 ,_17\,\1740 54_18\CD\1740 +/-_19\CC\1740 5_20\CD\13741022 versus_21\CC\1740 67_22\CD\1740 +/-_23\CC\1740 14_24\CD\13745420 mm_25\NN\13649268 ,_26\,\1740 <e1>cisapride</e1>_27\NN\1740 versus_28\CC\1740 placebo_29\NN\3740161 (_30\-LRB-\1740 p_31\NN\14622893 <_32\XX\1740 0.05_33\CD\1740 )_34\-RRB-\1740 ;_35\:\1740 pretreatment_36\NN\1740 ,_37\,\1740 62_38\CD\1740 +/-_39\CC\1740 19_40\CD\13745420 mm_41\NNS\13649268 ]_42\-RRB-\1740 ._43\.\1740
D020117_D003248 NONE symptom_0\NN\5823932 scores_1\NNS\13757724 relating_2\VBG\628491 to_3\IN\1740 the_4\DT\1740 severity_5\NN\5036394 of_6\IN\1740 constipation_7\NN\14299637 were_8\VBD\836236 lower_9\JJR\1740 in_10\IN\13603305 cisapride-treated_11\JJ\1740 <e2>constipation-predominant</e2>_12\JJ\1740 ibs_13\NN\1740 patients_14\NNS\9898892 [_15\-LRB-\1740 score_16\NN\5736149 ,_17\,\1740 54_18\CD\1740 +/-_19\CC\1740 5_20\CD\13741022 versus_21\CC\1740 67_22\CD\1740 +/-_23\CC\1740 14_24\CD\13745420 mm_25\NN\13649268 ,_26\,\1740 <e1>cisapride</e1>_27\NN\1740 versus_28\CC\1740 placebo_29\NN\3740161 (_30\-LRB-\1740 p_31\NN\14622893 <_32\XX\1740 0.05_33\CD\1740 )_34\-RRB-\1740 ;_35\:\1740 pretreatment_36\NN\1740 ,_37\,\1740 62_38\CD\1740 +/-_39\CC\1740 19_40\CD\13745420 mm_41\NNS\13649268 ]_42\-RRB-\1740 ._43\.\1740
D020117_D003967 NONE methods_0\NNS\5616786 :_1\:\1740 thirty-eight_2\NN\1740 patients_3\NNS\9898892 with_4\IN\1740 ibs_5\NN\1740 (_6\-LRB-\1740 constipation-predominant_7\JJ\1740 ,_8\,\1740 n_9\NN\14622893 =_10\JJ\1740 17_11\CD\13745420 ;_12\:\1740 <e2>diarrhoea-predominant</e2>_13\JJ\1740 ,_14\,\1740 n_15\NN\14622893 =_16\JJ\1740 21_17\CD\13745420 )_18\-RRB-\1740 underwent_19\VBD\109660 24-h_20\JJ\1740 ambulatory_21\JJ\1740 jejunal_22\JJ\1740 manometry_23\NN\1740 before_24\IN\1740 and_25\CC\1740 after_26\IN\1740 12_27\CD\13745420 week_28\NN\15113229 's_29\POS\1740 treatment_30\NN\654885 [_31\-LRB-\1740 <e1>cisapride</e1>_32\NN\1740 ,_33\,\1740 5_34\CD\13741022 mg_35\NN\13717155 three_36\CD\13741022 times_37\NNS\15113229 daily_38\RB\1740 (_39\-LRB-\1740 n_40\NN\14622893 =_41\JJ\1740 19_42\CD\13745420 )_43\-RRB-\1740 or_44\CC\3541091 placebo_45\NN\3740161 (_46\-LRB-\1740 n_47\NN\14622893 =_48\JJ\1740 19_49\CD\13745420 )_50\-RRB-\1740 ]_51\-RRB-\1740 ._52\.\1740
D020117_D003967 NONE results_0\NNS\34213 :_1\:\1740 in_2\IN\13603305 <e2>diarrhoea-predominant</e2>_3\JJ\1740 patients_4\NNS\9898892 significant_5\JJ\1740 differences_6\NNS\4723816 in_7\IN\13603305 contraction_8\NN\358931 characteristics_9\NNS\5849040 were_10\VBD\836236 observed_11\VBN\2163746 between_12\IN\1740 the_13\DT\1740 <e1>cisapride</e1>_14\NN\1740 and_15\CC\1740 placebo_16\NN\3740161 groups_17\NNS\2137 ._18\.\1740
D020117_D003967 NONE in_0\IN\13603305 <e1>cisapride-treated</e1>_1\JJ\1740 <e2>diarrhoea-predominant</e2>_2\JJ\1740 patients_3\NNS\9898892 the_4\DT\1740 mean_5\JJ\1740 contraction_6\NN\358931 amplitude_7\NN\7444668 was_8\VBD\836236 higher_9\JJR\1740 (_10\-LRB-\1740 29.3_11\CD\1740 +/-_12\CC\1740 3.2_13\CD\1740 versus_14\CC\1740 24.9_15\CD\1740 +/-_16\CC\1740 2.6_17\CD\1740 mm_18\NN\13649268 hg_19\NNP\14625458 ,_20\,\1740 cisapride_21\NN\1740 versus_22\CC\1740 placebo_23\NN\3740161 (_24\-LRB-\1740 p_25\NN\14622893 <_26\XX\1740 0.001_27\CD\1740 )_28\-RRB-\1740 ;_29\:\1740 pretreatment_30\NN\1740 ,_31\,\1740 25.7_32\CD\1740 +/-_33\CC\1740 6.0_34\CD\1740 mm_35\NN\13649268 hg_36\NN\14625458 )_37\-RRB-\1740 ,_38\,\1740 the_39\DT\1740 mean_40\JJ\1740 contraction_41\NN\358931 duration_42\NN\15113229 longer_43\RBR\1740 (_44\-LRB-\1740 3.4_45\CD\1740 +/-_46\CC\1740 0.2_47\CD\1740 versus_48\CC\1740 3.0_49\CD\1740 +/-_50\CC\1740 0.2_51\CD\1740 sec_52\NN\15154774 ,_53\,\1740 cisapride_54\NN\1740 versus_55\CC\1740 placebo_56\NN\3740161 (_57\-LRB-\1740 p_58\NN\14622893 <_59\XX\1740 0.001_60\CD\1740 )_61\-RRB-\1740 ;_62\:\1740 pretreatment_63\NN\1740 ,_64\,\1740 3.1_65\CD\1740 +/-_66\CC\1740 0.5_67\CD\1740 sec_68\NN\15154774 )_69\-RRB-\1740 ,_70\,\1740 and_71\CC\1740 the_72\DT\1740 mean_73\JJ\1740 contraction_74\NN\358931 frequency_75\NN\15286249 lower_76\JJR\1740 (_77\-LRB-\1740 2.0_78\CD\1740 +/-_79\CC\1740 0.2_80\CD\1740 versus_81\CC\1740 2.5_82\CD\1740 +/-_83\CC\1740 0.4_84\CD\1740 cont./min_85\NN\1740 ,_86\,\1740 cisapride_87\NN\1740 versus_88\CC\1740 placebo_89\NN\3740161 (_90\-LRB-\1740 p_91\NN\14622893 <_92\XX\1740 0.001_93\CD\1740 )_94\-RRB-\1740 ;_95\:\1740 pretreatment_96\NN\1740 ,_97\,\1740 2.5_98\CD\1740 +/-_99\CC\1740 1.1_100\CD\1740 cont./min_101\NN\1740 ]_102\-RRB-\1740 than_103\IN\1740 patients_104\NNS\9898892 treated_105\VBN\2376958 with_106\IN\1740 placebo_107\NN\3740161 ._108\.\1740
D020117_D003967 NONE in_0\IN\13603305 cisapride-treated_1\JJ\1740 <e2>diarrhoea-predominant</e2>_2\JJ\1740 patients_3\NNS\9898892 the_4\DT\1740 mean_5\JJ\1740 contraction_6\NN\358931 amplitude_7\NN\7444668 was_8\VBD\836236 higher_9\JJR\1740 (_10\-LRB-\1740 29.3_11\CD\1740 +/-_12\CC\1740 3.2_13\CD\1740 versus_14\CC\1740 24.9_15\CD\1740 +/-_16\CC\1740 2.6_17\CD\1740 mm_18\NN\13649268 hg_19\NNP\14625458 ,_20\,\1740 <e1>cisapride</e1>_21\NN\1740 versus_22\CC\1740 placebo_23\NN\3740161 (_24\-LRB-\1740 p_25\NN\14622893 <_26\XX\1740 0.001_27\CD\1740 )_28\-RRB-\1740 ;_29\:\1740 pretreatment_30\NN\1740 ,_31\,\1740 25.7_32\CD\1740 +/-_33\CC\1740 6.0_34\CD\1740 mm_35\NN\13649268 hg_36\NN\14625458 )_37\-RRB-\1740 ,_38\,\1740 the_39\DT\1740 mean_40\JJ\1740 contraction_41\NN\358931 duration_42\NN\15113229 longer_43\RBR\1740 (_44\-LRB-\1740 3.4_45\CD\1740 +/-_46\CC\1740 0.2_47\CD\1740 versus_48\CC\1740 3.0_49\CD\1740 +/-_50\CC\1740 0.2_51\CD\1740 sec_52\NN\15154774 ,_53\,\1740 cisapride_54\NN\1740 versus_55\CC\1740 placebo_56\NN\3740161 (_57\-LRB-\1740 p_58\NN\14622893 <_59\XX\1740 0.001_60\CD\1740 )_61\-RRB-\1740 ;_62\:\1740 pretreatment_63\NN\1740 ,_64\,\1740 3.1_65\CD\1740 +/-_66\CC\1740 0.5_67\CD\1740 sec_68\NN\15154774 )_69\-RRB-\1740 ,_70\,\1740 and_71\CC\1740 the_72\DT\1740 mean_73\JJ\1740 contraction_74\NN\358931 frequency_75\NN\15286249 lower_76\JJR\1740 (_77\-LRB-\1740 2.0_78\CD\1740 +/-_79\CC\1740 0.2_80\CD\1740 versus_81\CC\1740 2.5_82\CD\1740 +/-_83\CC\1740 0.4_84\CD\1740 cont./min_85\NN\1740 ,_86\,\1740 cisapride_87\NN\1740 versus_88\CC\1740 placebo_89\NN\3740161 (_90\-LRB-\1740 p_91\NN\14622893 <_92\XX\1740 0.001_93\CD\1740 )_94\-RRB-\1740 ;_95\:\1740 pretreatment_96\NN\1740 ,_97\,\1740 2.5_98\CD\1740 +/-_99\CC\1740 1.1_100\CD\1740 cont./min_101\NN\1740 ]_102\-RRB-\1740 than_103\IN\1740 patients_104\NNS\9898892 treated_105\VBN\2376958 with_106\IN\1740 placebo_107\NN\3740161 ._108\.\1740
D020117_D003967 NONE in_0\IN\13603305 cisapride-treated_1\JJ\1740 <e2>diarrhoea-predominant</e2>_2\JJ\1740 patients_3\NNS\9898892 the_4\DT\1740 mean_5\JJ\1740 contraction_6\NN\358931 amplitude_7\NN\7444668 was_8\VBD\836236 higher_9\JJR\1740 (_10\-LRB-\1740 29.3_11\CD\1740 +/-_12\CC\1740 3.2_13\CD\1740 versus_14\CC\1740 24.9_15\CD\1740 +/-_16\CC\1740 2.6_17\CD\1740 mm_18\NN\13649268 hg_19\NNP\14625458 ,_20\,\1740 cisapride_21\NN\1740 versus_22\CC\1740 placebo_23\NN\3740161 (_24\-LRB-\1740 p_25\NN\14622893 <_26\XX\1740 0.001_27\CD\1740 )_28\-RRB-\1740 ;_29\:\1740 pretreatment_30\NN\1740 ,_31\,\1740 25.7_32\CD\1740 +/-_33\CC\1740 6.0_34\CD\1740 mm_35\NN\13649268 hg_36\NN\14625458 )_37\-RRB-\1740 ,_38\,\1740 the_39\DT\1740 mean_40\JJ\1740 contraction_41\NN\358931 duration_42\NN\15113229 longer_43\RBR\1740 (_44\-LRB-\1740 3.4_45\CD\1740 +/-_46\CC\1740 0.2_47\CD\1740 versus_48\CC\1740 3.0_49\CD\1740 +/-_50\CC\1740 0.2_51\CD\1740 sec_52\NN\15154774 ,_53\,\1740 <e1>cisapride</e1>_54\NN\1740 versus_55\CC\1740 placebo_56\NN\3740161 (_57\-LRB-\1740 p_58\NN\14622893 <_59\XX\1740 0.001_60\CD\1740 )_61\-RRB-\1740 ;_62\:\1740 pretreatment_63\NN\1740 ,_64\,\1740 3.1_65\CD\1740 +/-_66\CC\1740 0.5_67\CD\1740 sec_68\NN\15154774 )_69\-RRB-\1740 ,_70\,\1740 and_71\CC\1740 the_72\DT\1740 mean_73\JJ\1740 contraction_74\NN\358931 frequency_75\NN\15286249 lower_76\JJR\1740 (_77\-LRB-\1740 2.0_78\CD\1740 +/-_79\CC\1740 0.2_80\CD\1740 versus_81\CC\1740 2.5_82\CD\1740 +/-_83\CC\1740 0.4_84\CD\1740 cont./min_85\NN\1740 ,_86\,\1740 cisapride_87\NN\1740 versus_88\CC\1740 placebo_89\NN\3740161 (_90\-LRB-\1740 p_91\NN\14622893 <_92\XX\1740 0.001_93\CD\1740 )_94\-RRB-\1740 ;_95\:\1740 pretreatment_96\NN\1740 ,_97\,\1740 2.5_98\CD\1740 +/-_99\CC\1740 1.1_100\CD\1740 cont./min_101\NN\1740 ]_102\-RRB-\1740 than_103\IN\1740 patients_104\NNS\9898892 treated_105\VBN\2376958 with_106\IN\1740 placebo_107\NN\3740161 ._108\.\1740
D020117_D003967 NONE in_0\IN\13603305 cisapride-treated_1\JJ\1740 <e2>diarrhoea-predominant</e2>_2\JJ\1740 patients_3\NNS\9898892 the_4\DT\1740 mean_5\JJ\1740 contraction_6\NN\358931 amplitude_7\NN\7444668 was_8\VBD\836236 higher_9\JJR\1740 (_10\-LRB-\1740 29.3_11\CD\1740 +/-_12\CC\1740 3.2_13\CD\1740 versus_14\CC\1740 24.9_15\CD\1740 +/-_16\CC\1740 2.6_17\CD\1740 mm_18\NN\13649268 hg_19\NNP\14625458 ,_20\,\1740 cisapride_21\NN\1740 versus_22\CC\1740 placebo_23\NN\3740161 (_24\-LRB-\1740 p_25\NN\14622893 <_26\XX\1740 0.001_27\CD\1740 )_28\-RRB-\1740 ;_29\:\1740 pretreatment_30\NN\1740 ,_31\,\1740 25.7_32\CD\1740 +/-_33\CC\1740 6.0_34\CD\1740 mm_35\NN\13649268 hg_36\NN\14625458 )_37\-RRB-\1740 ,_38\,\1740 the_39\DT\1740 mean_40\JJ\1740 contraction_41\NN\358931 duration_42\NN\15113229 longer_43\RBR\1740 (_44\-LRB-\1740 3.4_45\CD\1740 +/-_46\CC\1740 0.2_47\CD\1740 versus_48\CC\1740 3.0_49\CD\1740 +/-_50\CC\1740 0.2_51\CD\1740 sec_52\NN\15154774 ,_53\,\1740 cisapride_54\NN\1740 versus_55\CC\1740 placebo_56\NN\3740161 (_57\-LRB-\1740 p_58\NN\14622893 <_59\XX\1740 0.001_60\CD\1740 )_61\-RRB-\1740 ;_62\:\1740 pretreatment_63\NN\1740 ,_64\,\1740 3.1_65\CD\1740 +/-_66\CC\1740 0.5_67\CD\1740 sec_68\NN\15154774 )_69\-RRB-\1740 ,_70\,\1740 and_71\CC\1740 the_72\DT\1740 mean_73\JJ\1740 contraction_74\NN\358931 frequency_75\NN\15286249 lower_76\JJR\1740 (_77\-LRB-\1740 2.0_78\CD\1740 +/-_79\CC\1740 0.2_80\CD\1740 versus_81\CC\1740 2.5_82\CD\1740 +/-_83\CC\1740 0.4_84\CD\1740 cont./min_85\NN\1740 ,_86\,\1740 <e1>cisapride</e1>_87\NN\1740 versus_88\CC\1740 placebo_89\NN\3740161 (_90\-LRB-\1740 p_91\NN\14622893 <_92\XX\1740 0.001_93\CD\1740 )_94\-RRB-\1740 ;_95\:\1740 pretreatment_96\NN\1740 ,_97\,\1740 2.5_98\CD\1740 +/-_99\CC\1740 1.1_100\CD\1740 cont./min_101\NN\1740 ]_102\-RRB-\1740 than_103\IN\1740 patients_104\NNS\9898892 treated_105\VBN\2376958 with_106\IN\1740 placebo_107\NN\3740161 ._108\.\1740
D020117_D003967 NONE <e2>diarrhoea-predominant</e2>_0\JJ\1740 ibs_1\NN\1740 patients_2\NNS\9898892 had_3\VBD\2108377 a_4\DT\13649268 higher_5\JJR\1740 pain_6\NN\14299637 score_7\NN\5736149 after_8\IN\1740 <e1>cisapride</e1>_9\NN\1740 therapy_10\NN\657604 [_11\-LRB-\1740 score_12\NN\5736149 ,_13\,\1740 55_14\CD\1740 +/-_15\CC\1740 15_16\CD\13745420 versus_17\CC\1740 34_18\CD\1740 +/-_19\CC\1740 12_20\CD\13745420 mm_21\NN\13649268 ,_22\,\1740 cisapride_23\NN\1740 versus_24\CC\1740 placebo_25\NN\3740161 (_26\-LRB-\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 ;_31\:\1740 pretreatment_32\NN\1740 ,_33\,\1740 67_34\CD\1740 +/-_35\CC\1740 19_36\CD\13745420 mm_37\NNS\13649268 ]_38\-RRB-\1740 ._39\.\1740
D020117_D003967 NONE <e2>diarrhoea-predominant</e2>_0\JJ\1740 ibs_1\NN\1740 patients_2\NNS\9898892 had_3\VBD\2108377 a_4\DT\13649268 higher_5\JJR\1740 pain_6\NN\14299637 score_7\NN\5736149 after_8\IN\1740 cisapride_9\NN\1740 therapy_10\NN\657604 [_11\-LRB-\1740 score_12\NN\5736149 ,_13\,\1740 55_14\CD\1740 +/-_15\CC\1740 15_16\CD\13745420 versus_17\CC\1740 34_18\CD\1740 +/-_19\CC\1740 12_20\CD\13745420 mm_21\NN\13649268 ,_22\,\1740 <e1>cisapride</e1>_23\NN\1740 versus_24\CC\1740 placebo_25\NN\3740161 (_26\-LRB-\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 ;_31\:\1740 pretreatment_32\NN\1740 ,_33\,\1740 67_34\CD\1740 +/-_35\CC\1740 19_36\CD\13745420 mm_37\NNS\13649268 ]_38\-RRB-\1740 ._39\.\1740
D020117_D010146 NONE diarrhoea-predominant_0\JJ\1740 ibs_1\NN\1740 patients_2\NNS\9898892 had_3\VBD\2108377 a_4\DT\13649268 higher_5\JJR\1740 <e2>pain</e2>_6\NN\14299637 score_7\NN\5736149 after_8\IN\1740 <e1>cisapride</e1>_9\NN\1740 therapy_10\NN\657604 [_11\-LRB-\1740 score_12\NN\5736149 ,_13\,\1740 55_14\CD\1740 +/-_15\CC\1740 15_16\CD\13745420 versus_17\CC\1740 34_18\CD\1740 +/-_19\CC\1740 12_20\CD\13745420 mm_21\NN\13649268 ,_22\,\1740 cisapride_23\NN\1740 versus_24\CC\1740 placebo_25\NN\3740161 (_26\-LRB-\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 ;_31\:\1740 pretreatment_32\NN\1740 ,_33\,\1740 67_34\CD\1740 +/-_35\CC\1740 19_36\CD\13745420 mm_37\NNS\13649268 ]_38\-RRB-\1740 ._39\.\1740
D020117_D010146 NONE diarrhoea-predominant_0\JJ\1740 ibs_1\NN\1740 patients_2\NNS\9898892 had_3\VBD\2108377 a_4\DT\13649268 higher_5\JJR\1740 <e2>pain</e2>_6\NN\14299637 score_7\NN\5736149 after_8\IN\1740 cisapride_9\NN\1740 therapy_10\NN\657604 [_11\-LRB-\1740 score_12\NN\5736149 ,_13\,\1740 55_14\CD\1740 +/-_15\CC\1740 15_16\CD\13745420 versus_17\CC\1740 34_18\CD\1740 +/-_19\CC\1740 12_20\CD\13745420 mm_21\NN\13649268 ,_22\,\1740 <e1>cisapride</e1>_23\NN\1740 versus_24\CC\1740 placebo_25\NN\3740161 (_26\-LRB-\1740 p_27\NN\14622893 <_28\XX\1740 0.05_29\CD\1740 )_30\-RRB-\1740 ;_31\:\1740 pretreatment_32\NN\1740 ,_33\,\1740 67_34\CD\1740 +/-_35\CC\1740 19_36\CD\13745420 mm_37\NNS\13649268 ]_38\-RRB-\1740 ._39\.\1740
873132
D003840_D002779 NONE increased_0\VBN\169651 sulfation_1\NN\1740 and_2\CC\1740 decreased_3\VBD\169651 7alpha-hydroxylation_4\NN\1740 of_5\IN\1740 <e1>deoxycholic_6\JJ\1740 acid</e1>_7\NN\14818238 in_8\IN\13603305 ethinyl_9\JJ\1740 estradiol-induced_10\JJ\1740 <e2>cholestasis</e2>_11\NN\14052403 in_12\IN\13603305 rats_13\NNS\2329401 ._14\.\1740
D004997_D002779 CID increased_0\VBN\169651 sulfation_1\NN\1740 and_2\CC\1740 decreased_3\VBD\169651 7alpha-hydroxylation_4\NN\1740 of_5\IN\1740 deoxycholic_6\JJ\1740 acid_7\NN\14818238 in_8\IN\13603305 <e1>ethinyl_9\JJ\1740 estradiol-induced</e1>_10\JJ\1740 <e2>cholestasis</e2>_11\NN\14052403 in_12\IN\13603305 rats_13\NNS\2329401 ._14\.\1740
20973483
D058915_D010300 NONE in_0\FW\13603305 vivo_1\FW\1740 characterization_2\NN\6724763 of_3\IN\1740 a_4\DT\13649268 dual_5\JJ\1740 <e1>adenosine_6\NN\14964367 a2a/a1_7\NN\1740 receptor_8\NN\5225602 antagonist</e1>_9\NN\7846 in_10\IN\13603305 animal_11\JJ\1740 models_12\NNS\5888929 of_13\IN\1740 <e2>parkinson_14\NN\1740 's_15\POS\1740 disease</e2>_16\NN\14061805 ._17\.\1740
D058915_D010300 NONE the_0\DT\1740 in_1\FW\13603305 vivo_2\FW\1740 characterization_3\NN\6724763 of_4\IN\1740 a_5\DT\13649268 dual_6\JJ\1740 <e1>adenosine_7\NN\14964367 a(2a)/a(1_8\NN\1740 )_9\-RRB-\1740 receptor_10\NN\5225602 antagonist</e1>_11\NN\7846 in_12\IN\13603305 several_13\JJ\1740 animal_14\JJ\1740 models_15\NNS\5888929 of_16\IN\1740 <e2>parkinson_17\NN\1740 's_18\POS\1740 disease</e2>_19\NN\14061805 is_20\VBZ\836236 described_21\VBN\1001294 ._22\.\1740
D006220_D010300 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 <e2>parkinson_44\NN\1740 's_45\POS\1740 disease</e2>_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 <e1>haloperidol-induced</e1>_53\JJ\1740 catalepsy_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 reserpine-induced_59\JJ\1740 akinesia_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 6-hydroxydopamine_63\NN\1740 (_64\-LRB-\1740 6-ohda_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 mptp-treated_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D006220_D002375 CID compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 parkinson_44\NN\1740 's_45\POS\1740 disease_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 <e1>haloperidol-induced</e1>_53\JJ\1740 <e2>catalepsy</e2>_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 reserpine-induced_59\JJ\1740 akinesia_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 6-hydroxydopamine_63\NN\1740 (_64\-LRB-\1740 6-ohda_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 mptp-treated_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D006220_D004409 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 parkinson_44\NN\1740 's_45\POS\1740 disease_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 <e1>haloperidol-induced</e1>_53\JJ\1740 catalepsy_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 reserpine-induced_59\JJ\1740 <e2>akinesia</e2>_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 6-hydroxydopamine_63\NN\1740 (_64\-LRB-\1740 6-ohda_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 mptp-treated_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D012110_D010300 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 <e2>parkinson_44\NN\1740 's_45\POS\1740 disease</e2>_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 haloperidol-induced_53\JJ\1740 catalepsy_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 <e1>reserpine-induced</e1>_59\JJ\1740 akinesia_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 6-hydroxydopamine_63\NN\1740 (_64\-LRB-\1740 6-ohda_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 mptp-treated_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D012110_D002375 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 parkinson_44\NN\1740 's_45\POS\1740 disease_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 haloperidol-induced_53\JJ\1740 <e2>catalepsy</e2>_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 <e1>reserpine-induced</e1>_59\JJ\1740 akinesia_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 6-hydroxydopamine_63\NN\1740 (_64\-LRB-\1740 6-ohda_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 mptp-treated_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D012110_D004409 CID compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 parkinson_44\NN\1740 's_45\POS\1740 disease_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 haloperidol-induced_53\JJ\1740 catalepsy_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 <e1>reserpine-induced</e1>_59\JJ\1740 <e2>akinesia</e2>_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 6-hydroxydopamine_63\NN\1740 (_64\-LRB-\1740 6-ohda_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 mptp-treated_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D016627_D010300 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 <e2>parkinson_44\NN\1740 's_45\POS\1740 disease</e2>_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 haloperidol-induced_53\JJ\1740 catalepsy_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 reserpine-induced_59\JJ\1740 akinesia_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 <e1>6-hydroxydopamine</e1>_63\NN\1740 (_64\-LRB-\1740 6-ohda_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 mptp-treated_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D016627_D010300 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 <e2>parkinson_44\NN\1740 's_45\POS\1740 disease</e2>_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 haloperidol-induced_53\JJ\1740 catalepsy_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 reserpine-induced_59\JJ\1740 akinesia_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 6-hydroxydopamine_63\NN\1740 (_64\-LRB-\1740 <e1>6-ohda</e1>_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 mptp-treated_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D016627_D002375 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 parkinson_44\NN\1740 's_45\POS\1740 disease_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 haloperidol-induced_53\JJ\1740 <e2>catalepsy</e2>_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 reserpine-induced_59\JJ\1740 akinesia_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 <e1>6-hydroxydopamine</e1>_63\NN\1740 (_64\-LRB-\1740 6-ohda_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 mptp-treated_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D016627_D002375 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 parkinson_44\NN\1740 's_45\POS\1740 disease_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 haloperidol-induced_53\JJ\1740 <e2>catalepsy</e2>_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 reserpine-induced_59\JJ\1740 akinesia_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 6-hydroxydopamine_63\NN\1740 (_64\-LRB-\1740 <e1>6-ohda</e1>_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 mptp-treated_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D016627_D004409 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 parkinson_44\NN\1740 's_45\POS\1740 disease_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 haloperidol-induced_53\JJ\1740 catalepsy_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 reserpine-induced_59\JJ\1740 <e2>akinesia</e2>_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 <e1>6-hydroxydopamine</e1>_63\NN\1740 (_64\-LRB-\1740 6-ohda_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 mptp-treated_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D016627_D004409 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 parkinson_44\NN\1740 's_45\POS\1740 disease_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 haloperidol-induced_53\JJ\1740 catalepsy_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 reserpine-induced_59\JJ\1740 <e2>akinesia</e2>_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 6-hydroxydopamine_63\NN\1740 (_64\-LRB-\1740 <e1>6-ohda</e1>_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 mptp-treated_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D015632_D010300 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 <e2>parkinson_44\NN\1740 's_45\POS\1740 disease</e2>_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 haloperidol-induced_53\JJ\1740 catalepsy_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 reserpine-induced_59\JJ\1740 akinesia_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 6-hydroxydopamine_63\NN\1740 (_64\-LRB-\1740 6-ohda_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 <e1>mptp-treated</e1>_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D015632_D002375 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 parkinson_44\NN\1740 's_45\POS\1740 disease_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 haloperidol-induced_53\JJ\1740 <e2>catalepsy</e2>_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 reserpine-induced_59\JJ\1740 akinesia_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 6-hydroxydopamine_63\NN\1740 (_64\-LRB-\1740 6-ohda_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 <e1>mptp-treated</e1>_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
D015632_D004409 NONE compound_0\NN\5869584 1_1\CD\13741022 is_2\VBZ\836236 a_3\DT\13649268 potent_4\JJ\1740 a(2a)/a(1_5\NN\1740 )_6\-RRB-\1740 receptor_7\NN\5225602 antagonist_8\NN\7846 in_9\FW\13603305 vitro_10\FW\1740 (_11\-LRB-\1740 a(2a_12\NN\1740 )_13\-RRB-\1740 k(i_14\NN\1740 )_15\-RRB-\1740 =_16\JJ\1740 4.1_17\CD\1740 nm_18\NN\13649268 ;_19\:\1740 a(1_20\LS\1740 )_21\-RRB-\1740 k(i_22\NN\1740 )_23\-RRB-\1740 =_24\JJ\1740 17.0_25\CD\1740 nm_26\NN\13649268 )_27\-RRB-\1740 that_28\WDT\1740 has_29\VBZ\2108377 excellent_30\JJ\1740 activity_31\NN\30358 ,_32\,\1740 after_33\IN\1740 oral_34\JJ\1740 administration_35\NN\1133281 ,_36\,\1740 across_37\IN\1740 a_38\DT\13649268 number_39\NN\5107765 of_40\IN\1740 animal_41\NN\4475 models_42\NNS\5888929 of_43\IN\1740 parkinson_44\NN\1740 's_45\POS\1740 disease_46\NN\14061805 including_47\VBG\690614 mouse_48\NN\2329401 and_49\CC\1740 rat_50\NN\2329401 models_51\NNS\5888929 of_52\IN\1740 haloperidol-induced_53\JJ\1740 catalepsy_54\NN\14023236 ,_55\,\1740 mouse_56\NN\2329401 model_57\NN\5888929 of_58\IN\1740 reserpine-induced_59\JJ\1740 <e2>akinesia</e2>_60\NN\14558226 ,_61\,\1740 rat_62\NN\2329401 6-hydroxydopamine_63\NN\1740 (_64\-LRB-\1740 6-ohda_65\NN\1740 )_66\-RRB-\1740 lesion_67\NN\14204950 model_68\NN\5888929 of_69\IN\1740 drug-induced_70\JJ\1740 rotation_71\NN\331950 ,_72\,\1740 and_73\CC\1740 <e1>mptp-treated</e1>_74\JJ\1740 non-human_75\JJ\1740 primate_76\JJ\1740 model_77\NN\5888929 ._78\.\1740
3183120
C033706_D001927 CID reversible_0\JJ\1740 <e2>cerebral_1\JJ\1740 lesions</e2>_2\NNS\14204950 associated_3\VBN\628491 with_4\IN\1740 <e1>tiazofurin</e1>_5\NN\1740 usage_6\NN\407535 :_7\:\1740 mr_8\NN\6339416 demonstration_9\NN\520257 ._10\.\1740
9549528
D007980_D020734 NONE cortical_0\JJ\1740 motor_1\NN\3699975 overactivation_2\NN\1740 in_3\IN\13603305 <e2>parkinsonian</e2>_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 <e1>l-dopa-induced</e1>_7\JJ\1740 peak-dose_8\JJ\1740 dyskinesia_9\NN\14084880 ._10\.\1740
D007980_D020734 NONE we_0\PRP\1740 have_1\VBP\2108377 studied_2\VBN\630380 the_3\DT\1740 regional_4\JJ\1740 cerebral_5\JJ\1740 blood_6\NN\5397468 flow_7\NN\7311115 (_8\-LRB-\1740 rcbf_9\NN\1740 )_10\-RRB-\1740 changes_11\NNS\7283608 induced_12\VBN\1627355 by_13\IN\1740 the_14\DT\1740 execution_15\NN\1161161 of_16\IN\1740 a_17\DT\13649268 finger-to-thumb_18\JJ\1740 opposition_19\NN\37396 motor_20\NN\3699975 task_21\NN\575741 in_22\IN\13603305 the_23\DT\1740 supplementary_24\NN\1740 and_25\CC\1740 primary_26\JJ\1740 motor_27\NN\3699975 cortex_28\NN\5462674 of_29\IN\1740 two_30\CD\13741022 groups_31\NNS\2137 of_32\IN\1740 <e2>parkinsonian</e2>_33\JJ\1740 patients_34\NNS\9898892 on_35\IN\1740 <e1>l-dopa</e1>_36\JJ\1740 medication_37\NN\3247620 ,_38\,\1740 the_39\DT\1740 first_40\JJ\1740 one_41\CD\13741022 without_42\IN\1740 l-dopa_43\JJ\1740 induced_44\VBD\1627355 dyskinesia_45\NN\14084880 (_46\-LRB-\1740 n_47\NN\14622893 =_48\JJ\1740 23_49\CD\13745420 )_50\-RRB-\1740 and_51\CC\1740 the_52\DT\1740 other_53\JJ\1740 with_54\IN\1740 moderate_55\JJ\1740 peak-dose_56\JJ\1740 dyskinesia_57\NN\14084880 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 15_61\CD\13745420 )_62\-RRB-\1740 ,_63\,\1740 and_64\CC\1740 of_65\IN\1740 a_66\DT\13649268 group_67\NN\2137 of_68\IN\1740 14_69\CD\13745420 normal_70\JJ\1740 subjects_71\NNS\6598915 ._72\.\1740
D007980_D020734 NONE we_0\PRP\1740 have_1\VBP\2108377 studied_2\VBN\630380 the_3\DT\1740 regional_4\JJ\1740 cerebral_5\JJ\1740 blood_6\NN\5397468 flow_7\NN\7311115 (_8\-LRB-\1740 rcbf_9\NN\1740 )_10\-RRB-\1740 changes_11\NNS\7283608 induced_12\VBN\1627355 by_13\IN\1740 the_14\DT\1740 execution_15\NN\1161161 of_16\IN\1740 a_17\DT\13649268 finger-to-thumb_18\JJ\1740 opposition_19\NN\37396 motor_20\NN\3699975 task_21\NN\575741 in_22\IN\13603305 the_23\DT\1740 supplementary_24\NN\1740 and_25\CC\1740 primary_26\JJ\1740 motor_27\NN\3699975 cortex_28\NN\5462674 of_29\IN\1740 two_30\CD\13741022 groups_31\NNS\2137 of_32\IN\1740 <e2>parkinsonian</e2>_33\JJ\1740 patients_34\NNS\9898892 on_35\IN\1740 l-dopa_36\JJ\1740 medication_37\NN\3247620 ,_38\,\1740 the_39\DT\1740 first_40\JJ\1740 one_41\CD\13741022 without_42\IN\1740 <e1>l-dopa</e1>_43\JJ\1740 induced_44\VBD\1627355 dyskinesia_45\NN\14084880 (_46\-LRB-\1740 n_47\NN\14622893 =_48\JJ\1740 23_49\CD\13745420 )_50\-RRB-\1740 and_51\CC\1740 the_52\DT\1740 other_53\JJ\1740 with_54\IN\1740 moderate_55\JJ\1740 peak-dose_56\JJ\1740 dyskinesia_57\NN\14084880 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 15_61\CD\13745420 )_62\-RRB-\1740 ,_63\,\1740 and_64\CC\1740 of_65\IN\1740 a_66\DT\13649268 group_67\NN\2137 of_68\IN\1740 14_69\CD\13745420 normal_70\JJ\1740 subjects_71\NNS\6598915 ._72\.\1740
D007980_D004409 CID cortical_0\JJ\1740 motor_1\NN\3699975 overactivation_2\NN\1740 in_3\IN\13603305 parkinsonian_4\JJ\1740 patients_5\NNS\9898892 with_6\IN\1740 <e1>l-dopa-induced</e1>_7\JJ\1740 peak-dose_8\JJ\1740 <e2>dyskinesia</e2>_9\NN\14084880 ._10\.\1740
D007980_D004409 CID we_0\PRP\1740 have_1\VBP\2108377 studied_2\VBN\630380 the_3\DT\1740 regional_4\JJ\1740 cerebral_5\JJ\1740 blood_6\NN\5397468 flow_7\NN\7311115 (_8\-LRB-\1740 rcbf_9\NN\1740 )_10\-RRB-\1740 changes_11\NNS\7283608 induced_12\VBN\1627355 by_13\IN\1740 the_14\DT\1740 execution_15\NN\1161161 of_16\IN\1740 a_17\DT\13649268 finger-to-thumb_18\JJ\1740 opposition_19\NN\37396 motor_20\NN\3699975 task_21\NN\575741 in_22\IN\13603305 the_23\DT\1740 supplementary_24\NN\1740 and_25\CC\1740 primary_26\JJ\1740 motor_27\NN\3699975 cortex_28\NN\5462674 of_29\IN\1740 two_30\CD\13741022 groups_31\NNS\2137 of_32\IN\1740 parkinsonian_33\JJ\1740 patients_34\NNS\9898892 on_35\IN\1740 <e1>l-dopa</e1>_36\JJ\1740 medication_37\NN\3247620 ,_38\,\1740 the_39\DT\1740 first_40\JJ\1740 one_41\CD\13741022 without_42\IN\1740 l-dopa_43\JJ\1740 induced_44\VBD\1627355 <e2>dyskinesia</e2>_45\NN\14084880 (_46\-LRB-\1740 n_47\NN\14622893 =_48\JJ\1740 23_49\CD\13745420 )_50\-RRB-\1740 and_51\CC\1740 the_52\DT\1740 other_53\JJ\1740 with_54\IN\1740 moderate_55\JJ\1740 peak-dose_56\JJ\1740 dyskinesia_57\NN\14084880 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 15_61\CD\13745420 )_62\-RRB-\1740 ,_63\,\1740 and_64\CC\1740 of_65\IN\1740 a_66\DT\13649268 group_67\NN\2137 of_68\IN\1740 14_69\CD\13745420 normal_70\JJ\1740 subjects_71\NNS\6598915 ._72\.\1740
D007980_D004409 CID we_0\PRP\1740 have_1\VBP\2108377 studied_2\VBN\630380 the_3\DT\1740 regional_4\JJ\1740 cerebral_5\JJ\1740 blood_6\NN\5397468 flow_7\NN\7311115 (_8\-LRB-\1740 rcbf_9\NN\1740 )_10\-RRB-\1740 changes_11\NNS\7283608 induced_12\VBN\1627355 by_13\IN\1740 the_14\DT\1740 execution_15\NN\1161161 of_16\IN\1740 a_17\DT\13649268 finger-to-thumb_18\JJ\1740 opposition_19\NN\37396 motor_20\NN\3699975 task_21\NN\575741 in_22\IN\13603305 the_23\DT\1740 supplementary_24\NN\1740 and_25\CC\1740 primary_26\JJ\1740 motor_27\NN\3699975 cortex_28\NN\5462674 of_29\IN\1740 two_30\CD\13741022 groups_31\NNS\2137 of_32\IN\1740 parkinsonian_33\JJ\1740 patients_34\NNS\9898892 on_35\IN\1740 <e1>l-dopa</e1>_36\JJ\1740 medication_37\NN\3247620 ,_38\,\1740 the_39\DT\1740 first_40\JJ\1740 one_41\CD\13741022 without_42\IN\1740 l-dopa_43\JJ\1740 induced_44\VBD\1627355 dyskinesia_45\NN\14084880 (_46\-LRB-\1740 n_47\NN\14622893 =_48\JJ\1740 23_49\CD\13745420 )_50\-RRB-\1740 and_51\CC\1740 the_52\DT\1740 other_53\JJ\1740 with_54\IN\1740 moderate_55\JJ\1740 peak-dose_56\JJ\1740 <e2>dyskinesia</e2>_57\NN\14084880 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 15_61\CD\13745420 )_62\-RRB-\1740 ,_63\,\1740 and_64\CC\1740 of_65\IN\1740 a_66\DT\13649268 group_67\NN\2137 of_68\IN\1740 14_69\CD\13745420 normal_70\JJ\1740 subjects_71\NNS\6598915 ._72\.\1740
D007980_D004409 CID we_0\PRP\1740 have_1\VBP\2108377 studied_2\VBN\630380 the_3\DT\1740 regional_4\JJ\1740 cerebral_5\JJ\1740 blood_6\NN\5397468 flow_7\NN\7311115 (_8\-LRB-\1740 rcbf_9\NN\1740 )_10\-RRB-\1740 changes_11\NNS\7283608 induced_12\VBN\1627355 by_13\IN\1740 the_14\DT\1740 execution_15\NN\1161161 of_16\IN\1740 a_17\DT\13649268 finger-to-thumb_18\JJ\1740 opposition_19\NN\37396 motor_20\NN\3699975 task_21\NN\575741 in_22\IN\13603305 the_23\DT\1740 supplementary_24\NN\1740 and_25\CC\1740 primary_26\JJ\1740 motor_27\NN\3699975 cortex_28\NN\5462674 of_29\IN\1740 two_30\CD\13741022 groups_31\NNS\2137 of_32\IN\1740 parkinsonian_33\JJ\1740 patients_34\NNS\9898892 on_35\IN\1740 l-dopa_36\JJ\1740 medication_37\NN\3247620 ,_38\,\1740 the_39\DT\1740 first_40\JJ\1740 one_41\CD\13741022 without_42\IN\1740 <e1>l-dopa</e1>_43\JJ\1740 induced_44\VBD\1627355 <e2>dyskinesia</e2>_45\NN\14084880 (_46\-LRB-\1740 n_47\NN\14622893 =_48\JJ\1740 23_49\CD\13745420 )_50\-RRB-\1740 and_51\CC\1740 the_52\DT\1740 other_53\JJ\1740 with_54\IN\1740 moderate_55\JJ\1740 peak-dose_56\JJ\1740 dyskinesia_57\NN\14084880 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 15_61\CD\13745420 )_62\-RRB-\1740 ,_63\,\1740 and_64\CC\1740 of_65\IN\1740 a_66\DT\13649268 group_67\NN\2137 of_68\IN\1740 14_69\CD\13745420 normal_70\JJ\1740 subjects_71\NNS\6598915 ._72\.\1740
D007980_D004409 CID we_0\PRP\1740 have_1\VBP\2108377 studied_2\VBN\630380 the_3\DT\1740 regional_4\JJ\1740 cerebral_5\JJ\1740 blood_6\NN\5397468 flow_7\NN\7311115 (_8\-LRB-\1740 rcbf_9\NN\1740 )_10\-RRB-\1740 changes_11\NNS\7283608 induced_12\VBN\1627355 by_13\IN\1740 the_14\DT\1740 execution_15\NN\1161161 of_16\IN\1740 a_17\DT\13649268 finger-to-thumb_18\JJ\1740 opposition_19\NN\37396 motor_20\NN\3699975 task_21\NN\575741 in_22\IN\13603305 the_23\DT\1740 supplementary_24\NN\1740 and_25\CC\1740 primary_26\JJ\1740 motor_27\NN\3699975 cortex_28\NN\5462674 of_29\IN\1740 two_30\CD\13741022 groups_31\NNS\2137 of_32\IN\1740 parkinsonian_33\JJ\1740 patients_34\NNS\9898892 on_35\IN\1740 l-dopa_36\JJ\1740 medication_37\NN\3247620 ,_38\,\1740 the_39\DT\1740 first_40\JJ\1740 one_41\CD\13741022 without_42\IN\1740 <e1>l-dopa</e1>_43\JJ\1740 induced_44\VBD\1627355 dyskinesia_45\NN\14084880 (_46\-LRB-\1740 n_47\NN\14622893 =_48\JJ\1740 23_49\CD\13745420 )_50\-RRB-\1740 and_51\CC\1740 the_52\DT\1740 other_53\JJ\1740 with_54\IN\1740 moderate_55\JJ\1740 peak-dose_56\JJ\1740 <e2>dyskinesia</e2>_57\NN\14084880 (_58\-LRB-\1740 n_59\NN\14622893 =_60\JJ\1740 15_61\CD\13745420 )_62\-RRB-\1740 ,_63\,\1740 and_64\CC\1740 of_65\IN\1740 a_66\DT\13649268 group_67\NN\2137 of_68\IN\1740 14_69\CD\13745420 normal_70\JJ\1740 subjects_71\NNS\6598915 ._72\.\1740
D007980_D004409 CID these_0\DT\1740 results_1\NNS\34213 are_2\VBP\836236 compatible_3\JJ\1740 with_4\IN\1740 the_5\DT\1740 hypothesis_6\NN\7162194 that_7\IN\1740 an_8\DT\6697703 hyperkinetic_9\JJ\1740 <e2>abnormal_10\JJ\1740 involuntary_11\JJ\1740 movement</e2>_12\NN\191142 ,_13\,\1740 like_14\IN\5839024 <e1>l-dopa-induced</e1>_15\JJ\1740 peak_16\NN\13758296 dose_17\NN\3740161 dyskinesia_18\NN\14084880 ,_19\,\1740 is_20\VBZ\836236 due_21\JJ\1740 to_22\TO\1740 a_23\DT\13649268 disinhibition_24\NN\1740 of_25\IN\1740 the_26\DT\1740 primary_27\JJ\1740 and_28\CC\1740 associated_29\VBN\628491 motor_30\NN\3699975 cortex_31\NN\5462674 secondary_32\JJ\1740 to_33\TO\1740 an_34\DT\6697703 excessive_35\JJ\1740 outflow_36\NN\7407777 of_37\IN\1740 the_38\DT\1740 pallidothalamocortical_39\JJ\1740 motor_40\NN\3699975 loop_41\NN\3323703 ._42\.\1740
D007980_D004409 CID these_0\DT\1740 results_1\NNS\34213 are_2\VBP\836236 compatible_3\JJ\1740 with_4\IN\1740 the_5\DT\1740 hypothesis_6\NN\7162194 that_7\IN\1740 an_8\DT\6697703 hyperkinetic_9\JJ\1740 abnormal_10\JJ\1740 involuntary_11\JJ\1740 movement_12\NN\191142 ,_13\,\1740 like_14\IN\5839024 <e1>l-dopa-induced</e1>_15\JJ\1740 peak_16\NN\13758296 dose_17\NN\3740161 <e2>dyskinesia</e2>_18\NN\14084880 ,_19\,\1740 is_20\VBZ\836236 due_21\JJ\1740 to_22\TO\1740 a_23\DT\13649268 disinhibition_24\NN\1740 of_25\IN\1740 the_26\DT\1740 primary_27\JJ\1740 and_28\CC\1740 associated_29\VBN\628491 motor_30\NN\3699975 cortex_31\NN\5462674 secondary_32\JJ\1740 to_33\TO\1740 an_34\DT\6697703 excessive_35\JJ\1740 outflow_36\NN\7407777 of_37\IN\1740 the_38\DT\1740 pallidothalamocortical_39\JJ\1740 motor_40\NN\3699975 loop_41\NN\3323703 ._42\.\1740
D007980_D006948 NONE these_0\DT\1740 results_1\NNS\34213 are_2\VBP\836236 compatible_3\JJ\1740 with_4\IN\1740 the_5\DT\1740 hypothesis_6\NN\7162194 that_7\IN\1740 an_8\DT\6697703 <e2>hyperkinetic</e2>_9\JJ\1740 abnormal_10\JJ\1740 involuntary_11\JJ\1740 movement_12\NN\191142 ,_13\,\1740 like_14\IN\5839024 <e1>l-dopa-induced</e1>_15\JJ\1740 peak_16\NN\13758296 dose_17\NN\3740161 dyskinesia_18\NN\14084880 ,_19\,\1740 is_20\VBZ\836236 due_21\JJ\1740 to_22\TO\1740 a_23\DT\13649268 disinhibition_24\NN\1740 of_25\IN\1740 the_26\DT\1740 primary_27\JJ\1740 and_28\CC\1740 associated_29\VBN\628491 motor_30\NN\3699975 cortex_31\NN\5462674 secondary_32\JJ\1740 to_33\TO\1740 an_34\DT\6697703 excessive_35\JJ\1740 outflow_36\NN\7407777 of_37\IN\1740 the_38\DT\1740 pallidothalamocortical_39\JJ\1740 motor_40\NN\3699975 loop_41\NN\3323703 ._42\.\1740
18239197
D014282_D003072 CID increased_0\VBN\169651 <e2>mental_1\JJ\1740 slowing</e2>_2\NN\7296428 associated_3\VBN\628491 with_4\IN\1740 the_5\DT\1740 apoe_6\NN\1740 epsilon4_7\NN\1740 allele_8\NN\5436752 after_9\IN\1740 <e1>trihexyphenidyl</e1>_10\JJ\1740 oral_11\JJ\1740 anticholinergic_12\JJ\1740 challenge_13\NN\13927383 in_14\IN\13603305 healthy_15\JJ\1740 elderly_16\JJ\1740 ._17\.\1740
D014282_D003072 CID results_0\NNS\34213 :_1\:\1740 a_2\DT\13649268 2.0-mg_3\JJ\1740 oral_4\JJ\1740 dose_5\NN\3740161 of_6\IN\1740 <e1>trihexyphenidyl</e1>_7\NN\1740 resulted_8\VBD\2633881 in_9\IN\13603305 increased_10\VBN\169651 subjective_11\JJ\1740 ratings_12\NNS\5733583 of_13\IN\1740 <e2>mental_14\JJ\1740 slowness</e2>_15\NN\5648247 in_16\IN\13603305 carriers_17\NNS\9629752 of_18\IN\1740 the_19\DT\1740 apoe_20\NN\1740 epsilon4_21\NN\1740 allele_22\NN\5436752 only_23\RB\1740 ._24\.\1740
D014282_D003072 CID drug_0\NN\14778436 effects_1\NNS\13245626 as_2\IN\14622893 determined_3\VBN\1645601 by_4\IN\1740 difference_5\NN\4723816 scores_6\NNS\13757724 between_7\IN\1740 2.0_8\CD\1740 mg_9\NN\13717155 <e1>trihexyphenidyl</e1>_10\NN\1740 and_11\CC\1740 placebo_12\VB\1740 on_13\IN\1740 ratings_14\NNS\5733583 of_15\IN\1740 <e2>mental_16\JJ\1740 slowness</e2>_17\NN\5648247 significantly_18\RB\1740 correlated_19\VBN\2657219 with_20\IN\1740 total_21\JJ\1740 and_22\CC\1740 delayed_23\VBD\439958 recall_24\NN\7185325 on_25\IN\1740 the_26\DT\1740 buschke_27\NNP\1740 selective_28\NNP\1740 reminding_29\NNP\1740 test_30\NNP\5798043 in_31\IN\13603305 carriers_32\NNS\9629752 of_33\IN\1740 the_34\DT\1740 apoe_35\NN\1740 epsilon4_36\NN\1740 allele_37\NN\5436752 only_38\RB\1740 ._39\.\1740
D014282_D003072 CID conclusion_0\NN\5837957 :_1\:\1740 the_2\DT\1740 epsilon4_3\NN\1740 allele_4\NN\5436752 in_5\IN\13603305 healthy_6\JJ\1740 elderly_7\JJ\1740 was_8\VBD\836236 associated_9\VBN\628491 with_10\IN\1740 increased_11\VBN\169651 subjective_12\JJ\1740 <e2>mental_13\JJ\1740 slowing</e2>_14\NN\7296428 after_15\IN\1740 <e1>trihexyphenidyl</e1>_16\JJ\1740 anticholinergic_17\JJ\1740 challenge_18\NN\13927383 ._19\.\1740
D014282_D003221 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 objectives_3\NNS\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 were_7\VBD\836236 to_8\TO\1740 examine_9\VB\789138 the_10\DT\1740 relationship_11\NN\31921 between_12\IN\1740 apoe_13\NN\1740 epsilon4_14\NN\1740 and_15\CC\1740 subjective_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 <e1>trihexyphenidyl</e1>_19\NN\1740 on_20\IN\1740 measures_21\NNS\168237 reflecting_22\VBG\923793 sedation_23\NN\14034177 and_24\CC\1740 <e2>confusion</e2>_25\NN\13972797 and_26\CC\1740 to_27\TO\1740 investigate_28\VB\644583 the_29\DT\1740 relationship_30\NN\31921 between_31\IN\1740 trihexyphenidyl-induced_32\JJ\1740 subjective_33\JJ\1740 effects_34\NNS\13245626 and_35\CC\1740 objective_36\JJ\1740 memory_37\NN\5926676 performance_38\NN\6619065 ._39\.\1740
D014282_D003221 NONE objectives_0\NNS\5980875 :_1\:\1740 the_2\DT\1740 objectives_3\NNS\5980875 of_4\IN\1740 this_5\DT\1740 study_6\NN\635850 were_7\VBD\836236 to_8\TO\1740 examine_9\VB\789138 the_10\DT\1740 relationship_11\NN\31921 between_12\IN\1740 apoe_13\NN\1740 epsilon4_14\NN\1740 and_15\CC\1740 subjective_16\JJ\1740 effects_17\NNS\13245626 of_18\IN\1740 trihexyphenidyl_19\NN\1740 on_20\IN\1740 measures_21\NNS\168237 reflecting_22\VBG\923793 sedation_23\NN\14034177 and_24\CC\1740 <e2>confusion</e2>_25\NN\13972797 and_26\CC\1740 to_27\TO\1740 investigate_28\VB\644583 the_29\DT\1740 relationship_30\NN\31921 between_31\IN\1740 <e1>trihexyphenidyl-induced</e1>_32\JJ\1740 subjective_33\JJ\1740 effects_34\NNS\13245626 and_35\CC\1740 objective_36\JJ\1740 memory_37\NN\5926676 performance_38\NN\6619065 ._39\.\1740
17241657
D003042_D012640 CID earlier_0\JJR\1740 studies_1\NNS\635850 have_2\VBP\2108377 demonstrated_3\VBN\2137132 that_4\IN\1740 antagonism_5\NN\24720 of_6\IN\1740 sigma1_7\NN\1740 receptors_8\NNS\5225602 attenuates_9\VBZ\224901 the_10\DT\1740 <e2>convulsive</e2>_11\JJ\1740 ,_12\,\1740 lethal_13\JJ\1740 ,_14\,\1740 locomotor_15\NN\1740 stimulatory_16\NN\1740 and_17\CC\1740 rewarding_18\VBG\2546467 actions_19\NNS\30358 of_20\IN\1740 <e1>cocaine</e1>_21\NN\3492717 in_22\IN\13603305 mice_23\NNS\2329401 ._24\.\1740
D003042_D012640 CID in_0\IN\13603305 behavioral_1\JJ\1740 studies_2\NNS\635850 ,_3\,\1740 pretreatment_4\NN\1740 of_5\IN\1740 swiss_6\NNP\8166552 webster_7\NNP\1740 mice_8\NNS\2329401 with_9\IN\1740 umb24_10\NN\1740 or_11\CC\3541091 (+/-)-sm_12\NN\1740 21_13\CD\13745420 significantly_14\RB\1740 attenuated_15\VBD\224901 <e1>cocaine-induced</e1>_16\JJ\1740 <e2>convulsions</e2>_17\NNS\14081375 and_18\CC\1740 locomotor_19\NN\1740 activity_20\NN\30358 ,_21\,\1740 but_22\CC\1740 not_23\RB\1740 lethality_24\NN\4790449 ._25\.\1740
C519696_D012640 NONE in_0\IN\13603305 behavioral_1\JJ\1740 studies_2\NNS\635850 ,_3\,\1740 pretreatment_4\NN\1740 of_5\IN\1740 swiss_6\NNP\8166552 webster_7\NNP\1740 mice_8\NNS\2329401 with_9\IN\1740 <e1>umb24</e1>_10\NN\1740 or_11\CC\3541091 (+/-)-sm_12\NN\1740 21_13\CD\13745420 significantly_14\RB\1740 attenuated_15\VBD\224901 cocaine-induced_16\JJ\1740 <e2>convulsions</e2>_17\NNS\14081375 and_18\CC\1740 locomotor_19\NN\1740 activity_20\NN\30358 ,_21\,\1740 but_22\CC\1740 not_23\RB\1740 lethality_24\NN\4790449 ._25\.\1740
C107044_D012640 NONE in_0\IN\13603305 behavioral_1\JJ\1740 studies_2\NNS\635850 ,_3\,\1740 pretreatment_4\NN\1740 of_5\IN\1740 swiss_6\NNP\8166552 webster_7\NNP\1740 mice_8\NNS\2329401 with_9\IN\1740 umb24_10\NN\1740 or_11\CC\3541091 <e1>(+/-)-sm_12\NN\1740 21</e1>_13\CD\13745420 significantly_14\RB\1740 attenuated_15\VBD\224901 cocaine-induced_16\JJ\1740 <e2>convulsions</e2>_17\NNS\14081375 and_18\CC\1740 locomotor_19\NN\1740 activity_20\NN\30358 ,_21\,\1740 but_22\CC\1740 not_23\RB\1740 lethality_24\NN\4790449 ._25\.\1740
20558148
D016202_D002375 NONE glutamatergic_0\JJ\1740 neurotransmission_1\NN\1740 mediated_2\VBN\761713 by_3\IN\1740 <e1>nmda</e1>_4\NN\1740 receptors_5\NNS\5225602 in_6\IN\13603305 the_7\DT\1740 inferior_8\JJ\1740 colliculus_9\NN\1740 can_10\MD\3094503 modulate_11\VB\1724459 haloperidol-induced_12\JJ\1740 <e2>catalepsy</e2>_13\NN\14023236 ._14\.\1740
D016202_D002375 NONE haloperidol-induced_0\JJ\1740 <e2>catalepsy</e2>_1\NN\14023236 was_2\VBD\836236 challenged_3\VBN\869596 with_4\IN\1740 prior_5\JJ\1740 intracollicular_6\JJ\1740 microinjections_7\NNS\1740 of_8\IN\1740 glutamate_9\JJ\1740 <e1>nmda</e1>_10\NN\1740 receptor_11\NN\5225602 antagonists_12\NNS\7846 ,_13\,\1740 mk-801_14\NN\1740 (_15\-LRB-\1740 15_16\CD\13745420 or_17\CC\3541091 30_18\CD\13745420 mmol/0.5_19\CD\1740 microl_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 ap7_23\NN\1740 (_24\-LRB-\1740 10_25\CD\13745420 or_26\CC\3541091 20_27\CD\13745420 nmol/0.5_28\CD\1740 microl_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 or_32\CC\3541091 of_33\IN\1740 the_34\DT\1740 nmda_35\NN\1740 receptor_36\NN\5225602 agonist_37\NN\9613191 n-methyl-d-aspartate_38\NN\1740 (_39\-LRB-\1740 nmda_40\NN\1740 ,_41\,\1740 20_42\CD\13745420 or_43\CC\3541091
D016202_D002375 NONE haloperidol-induced_0\JJ\1740 <e2>catalepsy</e2>_1\NN\14023236 was_2\VBD\836236 challenged_3\VBN\869596 with_4\IN\1740 prior_5\JJ\1740 intracollicular_6\JJ\1740 microinjections_7\NNS\1740 of_8\IN\1740 glutamate_9\JJ\1740 nmda_10\NN\1740 receptor_11\NN\5225602 antagonists_12\NNS\7846 ,_13\,\1740 mk-801_14\NN\1740 (_15\-LRB-\1740 15_16\CD\13745420 or_17\CC\3541091 30_18\CD\13745420 mmol/0.5_19\CD\1740 microl_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 ap7_23\NN\1740 (_24\-LRB-\1740 10_25\CD\13745420 or_26\CC\3541091 20_27\CD\13745420 nmol/0.5_28\CD\1740 microl_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 or_32\CC\3541091 of_33\IN\1740 the_34\DT\1740 <e1>nmda</e1>_35\NN\1740 receptor_36\NN\5225602 agonist_37\NN\9613191 n-methyl-d-aspartate_38\NN\1740 (_39\-LRB-\1740 nmda_40\NN\1740 ,_41\,\1740 20_42\CD\13745420 or_43\CC\3541091
D016202_D002375 NONE haloperidol-induced_0\JJ\1740 <e2>catalepsy</e2>_1\NN\14023236 was_2\VBD\836236 challenged_3\VBN\869596 with_4\IN\1740 prior_5\JJ\1740 intracollicular_6\JJ\1740 microinjections_7\NNS\1740 of_8\IN\1740 glutamate_9\JJ\1740 nmda_10\NN\1740 receptor_11\NN\5225602 antagonists_12\NNS\7846 ,_13\,\1740 mk-801_14\NN\1740 (_15\-LRB-\1740 15_16\CD\13745420 or_17\CC\3541091 30_18\CD\13745420 mmol/0.5_19\CD\1740 microl_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 ap7_23\NN\1740 (_24\-LRB-\1740 10_25\CD\13745420 or_26\CC\3541091 20_27\CD\13745420 nmol/0.5_28\CD\1740 microl_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 or_32\CC\3541091 of_33\IN\1740 the_34\DT\1740 nmda_35\NN\1740 receptor_36\NN\5225602 agonist_37\NN\9613191 <e1>n-methyl-d-aspartate</e1>_38\NN\1740 (_39\-LRB-\1740 nmda_40\NN\1740 ,_41\,\1740 20_42\CD\13745420 or_43\CC\3541091
D016202_D002375 NONE haloperidol-induced_0\JJ\1740 <e2>catalepsy</e2>_1\NN\14023236 was_2\VBD\836236 challenged_3\VBN\869596 with_4\IN\1740 prior_5\JJ\1740 intracollicular_6\JJ\1740 microinjections_7\NNS\1740 of_8\IN\1740 glutamate_9\JJ\1740 nmda_10\NN\1740 receptor_11\NN\5225602 antagonists_12\NNS\7846 ,_13\,\1740 mk-801_14\NN\1740 (_15\-LRB-\1740 15_16\CD\13745420 or_17\CC\3541091 30_18\CD\13745420 mmol/0.5_19\CD\1740 microl_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 ap7_23\NN\1740 (_24\-LRB-\1740 10_25\CD\13745420 or_26\CC\3541091 20_27\CD\13745420 nmol/0.5_28\CD\1740 microl_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 or_32\CC\3541091 of_33\IN\1740 the_34\DT\1740 nmda_35\NN\1740 receptor_36\NN\5225602 agonist_37\NN\9613191 n-methyl-d-aspartate_38\NN\1740 (_39\-LRB-\1740 <e1>nmda</e1>_40\NN\1740 ,_41\,\1740 20_42\CD\13745420 or_43\CC\3541091
D006220_D002375 CID glutamatergic_0\JJ\1740 neurotransmission_1\NN\1740 mediated_2\VBN\761713 by_3\IN\1740 nmda_4\NN\1740 receptors_5\NNS\5225602 in_6\IN\13603305 the_7\DT\1740 inferior_8\JJ\1740 colliculus_9\NN\1740 can_10\MD\3094503 modulate_11\VB\1724459 <e1>haloperidol-induced</e1>_12\JJ\1740 <e2>catalepsy</e2>_13\NN\14023236 ._14\.\1740
D006220_D002375 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 examined_3\VBD\789138 the_4\DT\1740 influence_5\NN\5190804 of_6\IN\1740 excitatory_7\NN\1740 amino_8\NN\14621446 acid-mediated_9\JJ\1740 mechanisms_10\NNS\13446390 in_11\IN\13603305 the_12\DT\1740 ic_13\NN\8339454 on_14\IN\1740 the_15\DT\1740 <e2>catalepsy</e2>_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 the_19\DT\1740 dopamine_20\NN\14807737 receptor_21\NN\5225602 blocker_22\NN\10101634 <e1>haloperidol</e1>_23\NN\3713736 administered_24\VBN\2436349 systemically_25\RB\1740 (_26\-LRB-\1740 1_27\CD\13741022 or_28\CC\3541091 0.5_29\CD\1740 mg/kg_30\NN\1740 )_31\-RRB-\1740 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
D006220_D002375 CID <e1>haloperidol-induced</e1>_0\JJ\1740 <e2>catalepsy</e2>_1\NN\14023236 was_2\VBD\836236 challenged_3\VBN\869596 with_4\IN\1740 prior_5\JJ\1740 intracollicular_6\JJ\1740 microinjections_7\NNS\1740 of_8\IN\1740 glutamate_9\JJ\1740 nmda_10\NN\1740 receptor_11\NN\5225602 antagonists_12\NNS\7846 ,_13\,\1740 mk-801_14\NN\1740 (_15\-LRB-\1740 15_16\CD\13745420 or_17\CC\3541091 30_18\CD\13745420 mmol/0.5_19\CD\1740 microl_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 ap7_23\NN\1740 (_24\-LRB-\1740 10_25\CD\13745420 or_26\CC\3541091 20_27\CD\13745420 nmol/0.5_28\CD\1740 microl_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 or_32\CC\3541091 of_33\IN\1740 the_34\DT\1740 nmda_35\NN\1740 receptor_36\NN\5225602 agonist_37\NN\9613191 n-methyl-d-aspartate_38\NN\1740 (_39\-LRB-\1740 nmda_40\NN\1740 ,_41\,\1740 20_42\CD\13745420 or_43\CC\3541091
D006220_D002375 CID the_0\DT\1740 results_1\NNS\34213 showed_2\VBD\2137132 that_3\IN\1740 intracollicular_4\JJ\1740 microinjection_5\NN\1740 of_6\IN\1740 mk-801_7\NN\1740 and_8\CC\1740 ap7_9\NN\1740 previous_10\JJ\1740 to_11\TO\1740 systemic_12\JJ\1740 injections_13\NNS\320852 of_14\IN\1740 <e1>haloperidol</e1>_15\NN\3713736 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 <e2>catalepsy</e2>_19\NN\14023236 ,_20\,\1740 as_21\IN\14622893 indicated_22\VBN\952524 by_23\IN\1740 a_24\DT\13649268 reduced_25\VBN\441445 latency_26\NN\15269513 to_27\TO\1740 step_28\VB\1835496 down_29\RP\1740 from_30\IN\1740 a_31\DT\13649268 horizontal_32\JJ\1740 bar_33\NN\4105893 ._34\.\1740
D006220_D002375 CID these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 glutamate-mediated_4\JJ\1740 mechanisms_5\NNS\13446390 in_6\IN\13603305 the_7\DT\1740 neural_8\JJ\1740 circuits_9\NNS\3269401 at_10\IN\14622893 the_11\DT\1740 ic_12\NN\8339454 level_13\NN\4916342 influence_14\NN\5190804 <e1>haloperidol-induced</e1>_15\JJ\1740 <e2>catalepsy</e2>_16\NN\14023236 and_17\CC\1740 participate_18\VB\2367363 in_19\IN\13603305 the_20\DT\1740 regulation_21\NN\6652242 of_22\IN\1740 motor_23\NN\3699975 activity_24\NN\30358 ._25\.\1740
D000596_D002375 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 examined_3\VBD\789138 the_4\DT\1740 influence_5\NN\5190804 of_6\IN\1740 excitatory_7\NN\1740 <e1>amino_8\NN\14621446 acid-mediated</e1>_9\JJ\1740 mechanisms_10\NNS\13446390 in_11\IN\13603305 the_12\DT\1740 ic_13\NN\8339454 on_14\IN\1740 the_15\DT\1740 <e2>catalepsy</e2>_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 the_19\DT\1740 dopamine_20\NN\14807737 receptor_21\NN\5225602 blocker_22\NN\10101634 haloperidol_23\NN\3713736 administered_24\VBN\2436349 systemically_25\RB\1740 (_26\-LRB-\1740 1_27\CD\13741022 or_28\CC\3541091 0.5_29\CD\1740 mg/kg_30\NN\1740 )_31\-RRB-\1740 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
D004298_D002375 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 examined_3\VBD\789138 the_4\DT\1740 influence_5\NN\5190804 of_6\IN\1740 excitatory_7\NN\1740 amino_8\NN\14621446 acid-mediated_9\JJ\1740 mechanisms_10\NNS\13446390 in_11\IN\13603305 the_12\DT\1740 ic_13\NN\8339454 on_14\IN\1740 the_15\DT\1740 <e2>catalepsy</e2>_16\NN\14023236 induced_17\VBN\1627355 by_18\IN\1740 the_19\DT\1740 <e1>dopamine</e1>_20\NN\14807737 receptor_21\NN\5225602 blocker_22\NN\10101634 haloperidol_23\NN\3713736 administered_24\VBN\2436349 systemically_25\RB\1740 (_26\-LRB-\1740 1_27\CD\13741022 or_28\CC\3541091 0.5_29\CD\1740 mg/kg_30\NN\1740 )_31\-RRB-\1740 in_32\IN\13603305 rats_33\NNS\2329401 ._34\.\1740
D018698_D002375 NONE haloperidol-induced_0\JJ\1740 <e2>catalepsy</e2>_1\NN\14023236 was_2\VBD\836236 challenged_3\VBN\869596 with_4\IN\1740 prior_5\JJ\1740 intracollicular_6\JJ\1740 microinjections_7\NNS\1740 of_8\IN\1740 <e1>glutamate</e1>_9\JJ\1740 nmda_10\NN\1740 receptor_11\NN\5225602 antagonists_12\NNS\7846 ,_13\,\1740 mk-801_14\NN\1740 (_15\-LRB-\1740 15_16\CD\13745420 or_17\CC\3541091 30_18\CD\13745420 mmol/0.5_19\CD\1740 microl_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 ap7_23\NN\1740 (_24\-LRB-\1740 10_25\CD\13745420 or_26\CC\3541091 20_27\CD\13745420 nmol/0.5_28\CD\1740 microl_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 or_32\CC\3541091 of_33\IN\1740 the_34\DT\1740 nmda_35\NN\1740 receptor_36\NN\5225602 agonist_37\NN\9613191 n-methyl-d-aspartate_38\NN\1740 (_39\-LRB-\1740 nmda_40\NN\1740 ,_41\,\1740 20_42\CD\13745420 or_43\CC\3541091
D018698_D002375 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 <e1>glutamate-mediated</e1>_4\JJ\1740 mechanisms_5\NNS\13446390 in_6\IN\13603305 the_7\DT\1740 neural_8\JJ\1740 circuits_9\NNS\3269401 at_10\IN\14622893 the_11\DT\1740 ic_12\NN\8339454 level_13\NN\4916342 influence_14\NN\5190804 haloperidol-induced_15\JJ\1740 <e2>catalepsy</e2>_16\NN\14023236 and_17\CC\1740 participate_18\VB\2367363 in_19\IN\13603305 the_20\DT\1740 regulation_21\NN\6652242 of_22\IN\1740 motor_23\NN\3699975 activity_24\NN\30358 ._25\.\1740
D016291_D002375 NONE haloperidol-induced_0\JJ\1740 <e2>catalepsy</e2>_1\NN\14023236 was_2\VBD\836236 challenged_3\VBN\869596 with_4\IN\1740 prior_5\JJ\1740 intracollicular_6\JJ\1740 microinjections_7\NNS\1740 of_8\IN\1740 glutamate_9\JJ\1740 nmda_10\NN\1740 receptor_11\NN\5225602 antagonists_12\NNS\7846 ,_13\,\1740 <e1>mk-801</e1>_14\NN\1740 (_15\-LRB-\1740 15_16\CD\13745420 or_17\CC\3541091 30_18\CD\13745420 mmol/0.5_19\CD\1740 microl_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 ap7_23\NN\1740 (_24\-LRB-\1740 10_25\CD\13745420 or_26\CC\3541091 20_27\CD\13745420 nmol/0.5_28\CD\1740 microl_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 or_32\CC\3541091 of_33\IN\1740 the_34\DT\1740 nmda_35\NN\1740 receptor_36\NN\5225602 agonist_37\NN\9613191 n-methyl-d-aspartate_38\NN\1740 (_39\-LRB-\1740 nmda_40\NN\1740 ,_41\,\1740 20_42\CD\13745420 or_43\CC\3541091
D016291_D002375 NONE the_0\DT\1740 results_1\NNS\34213 showed_2\VBD\2137132 that_3\IN\1740 intracollicular_4\JJ\1740 microinjection_5\NN\1740 of_6\IN\1740 <e1>mk-801</e1>_7\NN\1740 and_8\CC\1740 ap7_9\NN\1740 previous_10\JJ\1740 to_11\TO\1740 systemic_12\JJ\1740 injections_13\NNS\320852 of_14\IN\1740 haloperidol_15\NN\3713736 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 <e2>catalepsy</e2>_19\NN\14023236 ,_20\,\1740 as_21\IN\14622893 indicated_22\VBN\952524 by_23\IN\1740 a_24\DT\13649268 reduced_25\VBN\441445 latency_26\NN\15269513 to_27\TO\1740 step_28\VB\1835496 down_29\RP\1740 from_30\IN\1740 a_31\DT\13649268 horizontal_32\JJ\1740 bar_33\NN\4105893 ._34\.\1740
C031231_D002375 NONE haloperidol-induced_0\JJ\1740 <e2>catalepsy</e2>_1\NN\14023236 was_2\VBD\836236 challenged_3\VBN\869596 with_4\IN\1740 prior_5\JJ\1740 intracollicular_6\JJ\1740 microinjections_7\NNS\1740 of_8\IN\1740 glutamate_9\JJ\1740 nmda_10\NN\1740 receptor_11\NN\5225602 antagonists_12\NNS\7846 ,_13\,\1740 mk-801_14\NN\1740 (_15\-LRB-\1740 15_16\CD\13745420 or_17\CC\3541091 30_18\CD\13745420 mmol/0.5_19\CD\1740 microl_20\NN\1740 )_21\-RRB-\1740 and_22\CC\1740 <e1>ap7</e1>_23\NN\1740 (_24\-LRB-\1740 10_25\CD\13745420 or_26\CC\3541091 20_27\CD\13745420 nmol/0.5_28\CD\1740 microl_29\NN\1740 )_30\-RRB-\1740 ,_31\,\1740 or_32\CC\3541091 of_33\IN\1740 the_34\DT\1740 nmda_35\NN\1740 receptor_36\NN\5225602 agonist_37\NN\9613191 n-methyl-d-aspartate_38\NN\1740 (_39\-LRB-\1740 nmda_40\NN\1740 ,_41\,\1740 20_42\CD\13745420 or_43\CC\3541091
C031231_D002375 NONE the_0\DT\1740 results_1\NNS\34213 showed_2\VBD\2137132 that_3\IN\1740 intracollicular_4\JJ\1740 microinjection_5\NN\1740 of_6\IN\1740 mk-801_7\NN\1740 and_8\CC\1740 <e1>ap7</e1>_9\NN\1740 previous_10\JJ\1740 to_11\TO\1740 systemic_12\JJ\1740 injections_13\NNS\320852 of_14\IN\1740 haloperidol_15\NN\3713736 significantly_16\RB\1740 attenuated_17\VBD\224901 the_18\DT\1740 <e2>catalepsy</e2>_19\NN\14023236 ,_20\,\1740 as_21\IN\14622893 indicated_22\VBN\952524 by_23\IN\1740 a_24\DT\13649268 reduced_25\VBN\441445 latency_26\NN\15269513 to_27\TO\1740 step_28\VB\1835496 down_29\RP\1740 from_30\IN\1740 a_31\DT\13649268 horizontal_32\JJ\1740 bar_33\NN\4105893 ._34\.\1740
10027919
C051883_D006962 NONE <e1>22-oxacalcitriol</e1>_0\NN\1740 suppresses_1\VBZ\2510337 <e2>secondary_2\JJ\1740 hyperparathyroidism</e2>_3\NN\14059928 without_4\IN\1740 inducing_5\VBG\1627355 low_6\JJ\1740 bone_7\NN\5286536 turnover_8\NN\13819207 in_9\IN\13603305 dogs_10\NNS\2083346 with_11\IN\1740 renal_12\JJ\1740 failure_13\NN\66216 ._14\.\1740
C051883_D006962 NONE in_0\IN\13603305 long-standing_1\JJ\1740 <e2>secondary_2\JJ\1740 hyperparathyroidism</e2>_3\NN\14059928 ,_4\,\1740 <e1>oct</e1>_5\NN\15209706 (_6\-LRB-\1740 0.03_7\CD\1740 microg/kg_8\NNS\1740 )_9\-RRB-\1740 stabilized_10\VBD\126264 serum_11\NN\5397468 pth_12\NN\1740 levels_13\NNS\4916342 during_14\IN\1740 the_15\DT\1740 first_16\JJ\1740 months_17\NNS\15113229 ._18\.\1740
C051883_D006962 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 indicate_4\VBP\952524 that_5\IN\1740 even_6\RB\1740 though_7\IN\1740 <e1>oct</e1>_8\NN\15209706 does_9\VBZ\1640855 not_10\RB\1740 completely_11\RB\1740 prevent_12\VB\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 hypercalcemia_16\NN\14299637 in_17\IN\13603305 experimental_18\JJ\1740 dogs_19\NNS\2083346 with_20\IN\1740 renal_21\JJ\1740 insufficiency_22\NN\14462946 ,_23\,\1740 it_24\PRP\6125041 may_25\MD\15209706 be_26\VB\836236 of_27\IN\1740 use_28\NN\407535 in_29\IN\13603305 the_30\DT\1740 management_31\NN\1123598 of_32\IN\1740 <e2>secondary_33\JJ\1740 hyperparathyroidism</e2>_34\NN\14059928 because_35\IN\1740 it_36\PRP\6125041 does_37\VBZ\1640855 not_38\RB\1740 induce_39\VB\1627355 low_40\JJ\1740 bone_41\NN\5286536 turnover_42\NN\13819207 and_43\CC\1740 ,_44\,\1740 therefore_45\RB\1740 ,_46\,\1740 does_47\VBZ\1640855 not_48\RB\1740 increase_49\VB\169651 the_50\DT\1740 risk_51\NN\14541044 of_52\IN\1740 adynamic_53\JJ\1740 bone_54\NN\5286536 disease_55\NN\14061805 ._56\.\1740
C051883_D001851 NONE <e1>22-oxacalcitriol</e1>_0\NN\1740 suppresses_1\VBZ\2510337 secondary_2\JJ\1740 hyperparathyroidism_3\NN\14059928 without_4\IN\1740 inducing_5\VBG\1627355 <e2>low_6\JJ\1740 bone_7\NN\5286536 turnover</e2>_8\NN\13819207 in_9\IN\13603305 dogs_10\NNS\2083346 with_11\IN\1740 renal_12\JJ\1740 failure_13\NN\66216 ._14\.\1740
C051883_D001851 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 indicate_4\VBP\952524 that_5\IN\1740 even_6\RB\1740 though_7\IN\1740 <e1>oct</e1>_8\NN\15209706 does_9\VBZ\1640855 not_10\RB\1740 completely_11\RB\1740 prevent_12\VB\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 hypercalcemia_16\NN\14299637 in_17\IN\13603305 experimental_18\JJ\1740 dogs_19\NNS\2083346 with_20\IN\1740 renal_21\JJ\1740 insufficiency_22\NN\14462946 ,_23\,\1740 it_24\PRP\6125041 may_25\MD\15209706 be_26\VB\836236 of_27\IN\1740 use_28\NN\407535 in_29\IN\13603305 the_30\DT\1740 management_31\NN\1123598 of_32\IN\1740 secondary_33\JJ\1740 hyperparathyroidism_34\NN\14059928 because_35\IN\1740 it_36\PRP\6125041 does_37\VBZ\1640855 not_38\RB\1740 induce_39\VB\1627355 <e2>low_40\JJ\1740 bone_41\NN\5286536 turnover</e2>_42\NN\13819207 and_43\CC\1740 ,_44\,\1740 therefore_45\RB\1740 ,_46\,\1740 does_47\VBZ\1640855 not_48\RB\1740 increase_49\VB\169651 the_50\DT\1740 risk_51\NN\14541044 of_52\IN\1740 adynamic_53\JJ\1740 bone_54\NN\5286536 disease_55\NN\14061805 ._56\.\1740
C051883_D001851 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 indicate_4\VBP\952524 that_5\IN\1740 even_6\RB\1740 though_7\IN\1740 <e1>oct</e1>_8\NN\15209706 does_9\VBZ\1640855 not_10\RB\1740 completely_11\RB\1740 prevent_12\VB\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 hypercalcemia_16\NN\14299637 in_17\IN\13603305 experimental_18\JJ\1740 dogs_19\NNS\2083346 with_20\IN\1740 renal_21\JJ\1740 insufficiency_22\NN\14462946 ,_23\,\1740 it_24\PRP\6125041 may_25\MD\15209706 be_26\VB\836236 of_27\IN\1740 use_28\NN\407535 in_29\IN\13603305 the_30\DT\1740 management_31\NN\1123598 of_32\IN\1740 secondary_33\JJ\1740 hyperparathyroidism_34\NN\14059928 because_35\IN\1740 it_36\PRP\6125041 does_37\VBZ\1640855 not_38\RB\1740 induce_39\VB\1627355 low_40\JJ\1740 bone_41\NN\5286536 turnover_42\NN\13819207 and_43\CC\1740 ,_44\,\1740 therefore_45\RB\1740 ,_46\,\1740 does_47\VBZ\1640855 not_48\RB\1740 increase_49\VB\169651 the_50\DT\1740 risk_51\NN\14541044 of_52\IN\1740 <e2>adynamic_53\JJ\1740 bone_54\NN\5286536 disease</e2>_55\NN\14061805 ._56\.\1740
C051883_D051437 NONE <e1>22-oxacalcitriol</e1>_0\NN\1740 suppresses_1\VBZ\2510337 secondary_2\JJ\1740 hyperparathyroidism_3\NN\14059928 without_4\IN\1740 inducing_5\VBG\1627355 low_6\JJ\1740 bone_7\NN\5286536 turnover_8\NN\13819207 in_9\IN\13603305 dogs_10\NNS\2083346 with_11\IN\1740 <e2>renal_12\JJ\1740 failure</e2>_13\NN\66216 ._14\.\1740
C051883_D051437 NONE results_0\NNS\34213 :_1\:\1740 in_2\IN\13603305 nx_3\NNP\1740 dogs_4\NNS\2083346 ,_5\,\1740 <e1>oct</e1>_6\NN\15209706 significantly_7\RB\1740 decreased_8\VBD\169651 serum_9\NN\5397468 pth_10\NN\1740 levels_11\NNS\4916342 soon_12\RB\1740 after_13\IN\1740 the_14\DT\1740 induction_15\NN\7450842 of_16\IN\1740 <e2>renal_17\JJ\1740 insufficiency</e2>_18\NN\14462946 ._19\.\1740
C051883_D051437 NONE conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 indicate_4\VBP\952524 that_5\IN\1740 even_6\RB\1740 though_7\IN\1740 <e1>oct</e1>_8\NN\15209706 does_9\VBZ\1640855 not_10\RB\1740 completely_11\RB\1740 prevent_12\VB\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 hypercalcemia_16\NN\14299637 in_17\IN\13603305 experimental_18\JJ\1740 dogs_19\NNS\2083346 with_20\IN\1740 <e2>renal_21\JJ\1740 insufficiency</e2>_22\NN\14462946 ,_23\,\1740 it_24\PRP\6125041 may_25\MD\15209706 be_26\VB\836236 of_27\IN\1740 use_28\NN\407535 in_29\IN\13603305 the_30\DT\1740 management_31\NN\1123598 of_32\IN\1740 secondary_33\JJ\1740 hyperparathyroidism_34\NN\14059928 because_35\IN\1740 it_36\PRP\6125041 does_37\VBZ\1640855 not_38\RB\1740 induce_39\VB\1627355 low_40\JJ\1740 bone_41\NN\5286536 turnover_42\NN\13819207 and_43\CC\1740 ,_44\,\1740 therefore_45\RB\1740 ,_46\,\1740 does_47\VBZ\1640855 not_48\RB\1740 increase_49\VB\169651 the_50\DT\1740 risk_51\NN\14541044 of_52\IN\1740 adynamic_53\JJ\1740 bone_54\NN\5286536 disease_55\NN\14061805 ._56\.\1740
D002117_D051437 NONE background_0\NN\4921011 :_1\:\1740 <e1>calcitriol</e1>_2\NN\1740 therapy_3\NN\657604 suppresses_4\VBZ\2510337 serum_5\NN\5397468 levels_6\NNS\4916342 of_7\IN\1740 parathyroid_8\JJ\1740 hormone_9\NN\5404728 (_10\-LRB-\1740 pth_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 <e2>renal_16\JJ\1740 failure</e2>_17\NN\66216 but_18\CC\1740 has_19\VBZ\2108377 several_20\JJ\1740 drawbacks_21\NNS\5161614 ,_22\,\1740 including_23\VBG\690614 hypercalcemia_24\NN\14299637 and/or_25\CC\1740 marked_26\JJ\1740 suppression_27\NN\13489037 of_28\IN\1740 bone_29\NN\5286536 turnover_30\NN\13819207 ,_31\,\1740 which_32\WDT\1740 may_33\MD\15209706 lead_34\VB\1752884 to_35\TO\1740 adynamic_36\JJ\1740 bone_37\NN\5286536 disease_38\NN\14061805 ._39\.\1740
D002117_D006934 CID background_0\NN\4921011 :_1\:\1740 <e1>calcitriol</e1>_2\NN\1740 therapy_3\NN\657604 suppresses_4\VBZ\2510337 serum_5\NN\5397468 levels_6\NNS\4916342 of_7\IN\1740 parathyroid_8\JJ\1740 hormone_9\NN\5404728 (_10\-LRB-\1740 pth_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 renal_16\JJ\1740 failure_17\NN\66216 but_18\CC\1740 has_19\VBZ\2108377 several_20\JJ\1740 drawbacks_21\NNS\5161614 ,_22\,\1740 including_23\VBG\690614 <e2>hypercalcemia</e2>_24\NN\14299637 and/or_25\CC\1740 marked_26\JJ\1740 suppression_27\NN\13489037 of_28\IN\1740 bone_29\NN\5286536 turnover_30\NN\13819207 ,_31\,\1740 which_32\WDT\1740 may_33\MD\15209706 lead_34\VB\1752884 to_35\TO\1740 adynamic_36\JJ\1740 bone_37\NN\5286536 disease_38\NN\14061805 ._39\.\1740
D002117_D001851 CID background_0\NN\4921011 :_1\:\1740 <e1>calcitriol</e1>_2\NN\1740 therapy_3\NN\657604 suppresses_4\VBZ\2510337 serum_5\NN\5397468 levels_6\NNS\4916342 of_7\IN\1740 parathyroid_8\JJ\1740 hormone_9\NN\5404728 (_10\-LRB-\1740 pth_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 renal_16\JJ\1740 failure_17\NN\66216 but_18\CC\1740 has_19\VBZ\2108377 several_20\JJ\1740 drawbacks_21\NNS\5161614 ,_22\,\1740 including_23\VBG\690614 hypercalcemia_24\NN\14299637 and/or_25\CC\1740 marked_26\JJ\1740 <e2>suppression_27\NN\13489037 of_28\IN\1740 bone_29\NN\5286536 turnover</e2>_30\NN\13819207 ,_31\,\1740 which_32\WDT\1740 may_33\MD\15209706 lead_34\VB\1752884 to_35\TO\1740 adynamic_36\JJ\1740 bone_37\NN\5286536 disease_38\NN\14061805 ._39\.\1740
D002117_D001851 CID background_0\NN\4921011 :_1\:\1740 <e1>calcitriol</e1>_2\NN\1740 therapy_3\NN\657604 suppresses_4\VBZ\2510337 serum_5\NN\5397468 levels_6\NNS\4916342 of_7\IN\1740 parathyroid_8\JJ\1740 hormone_9\NN\5404728 (_10\-LRB-\1740 pth_11\NN\1740 )_12\-RRB-\1740 in_13\IN\13603305 patients_14\NNS\9898892 with_15\IN\1740 renal_16\JJ\1740 failure_17\NN\66216 but_18\CC\1740 has_19\VBZ\2108377 several_20\JJ\1740 drawbacks_21\NNS\5161614 ,_22\,\1740 including_23\VBG\690614 hypercalcemia_24\NN\14299637 and/or_25\CC\1740 marked_26\JJ\1740 suppression_27\NN\13489037 of_28\IN\1740 bone_29\NN\5286536 turnover_30\NN\13819207 ,_31\,\1740 which_32\WDT\1740 may_33\MD\15209706 lead_34\VB\1752884 to_35\TO\1740 <e2>adynamic_36\JJ\1740 bone_37\NN\5286536 disease</e2>_38\NN\14061805 ._39\.\1740
C051883_D007674 NONE this_0\DT\1740 study_1\NN\635850 was_2\VBD\836236 undertaken_3\VBN\1641914 to_4\TO\1740 determine_5\VB\1645601 the_6\DT\1740 effects_7\NNS\13245626 of_8\IN\1740 <e1>oct</e1>_9\NN\15209706 on_10\IN\1740 serum_11\NN\5397468 pth_12\NN\1740 levels_13\NNS\4916342 and_14\CC\1740 bone_15\NN\5286536 turnover_16\NN\13819207 in_17\IN\13603305 states_18\NNS\8491826 of_19\IN\1740 normal_20\JJ\1740 or_21\CC\3541091 <e2>impaired_22\JJ\1740 renal_23\JJ\1740 function</e2>_24\NN\13783581 ._25\.\1740
C051883_-1 NONE in_0\IN\13603305 nx_1\NNP\1740 dogs_2\NNS\2083346 ,_3\,\1740 <e1>oct</e1>_4\NN\15209706 reversed_5\VBD\109660 abnormal_6\JJ\1740 bone_7\NN\5286536 formation_8\NN\7938773 ,_9\,\1740 such_10\JJ\1740 as_11\IN\14622893 <e2>woven_12\JJ\1740 osteoid</e2>_13\NN\1740 and_14\CC\1740 fibrosis_15\NN\14204950 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 not_19\RB\1740 significantly_20\RB\1740 alter_21\VB\126264 the_22\DT\1740 level_23\NN\4916342 of_24\IN\1740 bone_25\NN\5286536 turnover_26\NN\13819207 ._27\.\1740
C051883_D005355 NONE in_0\IN\13603305 nx_1\NNP\1740 dogs_2\NNS\2083346 ,_3\,\1740 <e1>oct</e1>_4\NN\15209706 reversed_5\VBD\109660 abnormal_6\JJ\1740 bone_7\NN\5286536 formation_8\NN\7938773 ,_9\,\1740 such_10\JJ\1740 as_11\IN\14622893 woven_12\JJ\1740 osteoid_13\NN\1740 and_14\CC\1740 <e2>fibrosis</e2>_15\NN\14204950 ,_16\,\1740 but_17\CC\1740 did_18\VBD\1640855 not_19\RB\1740 significantly_20\RB\1740 alter_21\VB\126264 the_22\DT\1740 level_23\NN\4916342 of_24\IN\1740 bone_25\NN\5286536 turnover_26\NN\13819207 ._27\.\1740
C051883_D006934 CID conclusions_0\NNS\5837957 :_1\:\1740 these_2\DT\1740 results_3\NNS\34213 indicate_4\VBP\952524 that_5\IN\1740 even_6\RB\1740 though_7\IN\1740 <e1>oct</e1>_8\NN\15209706 does_9\VBZ\1640855 not_10\RB\1740 completely_11\RB\1740 prevent_12\VB\1740 the_13\DT\1740 occurrence_14\NN\29378 of_15\IN\1740 <e2>hypercalcemia</e2>_16\NN\14299637 in_17\IN\13603305 experimental_18\JJ\1740 dogs_19\NNS\2083346 with_20\IN\1740 renal_21\JJ\1740 insufficiency_22\NN\14462946 ,_23\,\1740 it_24\PRP\6125041 may_25\MD\15209706 be_26\VB\836236 of_27\IN\1740 use_28\NN\407535 in_29\IN\13603305 the_30\DT\1740 management_31\NN\1123598 of_32\IN\1740 secondary_33\JJ\1740 hyperparathyroidism_34\NN\14059928 because_35\IN\1740 it_36\PRP\6125041 does_37\VBZ\1640855 not_38\RB\1740 induce_39\VB\1627355 low_40\JJ\1740 bone_41\NN\5286536 turnover_42\NN\13819207 and_43\CC\1740 ,_44\,\1740 therefore_45\RB\1740 ,_46\,\1740 does_47\VBZ\1640855 not_48\RB\1740 increase_49\VB\169651 the_50\DT\1740 risk_51\NN\14541044 of_52\IN\1740 adynamic_53\JJ\1740 bone_54\NN\5286536 disease_55\NN\14061805 ._56\.\1740
7189975
D002045_D012640 CID a_0\DT\13649268 cd50_1\NN\1740 dose_2\NN\3740161 of_3\IN\1740 local_4\JJ\1740 anesthetic_5\JJ\1740 (_6\-LRB-\1740 causing_7\VBG\1617192 <e2>convulsions</e2>_8\NNS\14081375 in_9\IN\13603305 50_10\CD\13745420 %_11\NN\1740 of_12\IN\1740 mice_13\NNS\2329401 )_14\-RRB-\1740 was_15\VBD\836236 fatal_16\JJ\1740 in_17\IN\13603305 90_18\CD\13745420 %_19\NN\1740 of_20\IN\1740 <e1>bupivacaine-induced</e1>_21\JJ\1740 seizures_22\NNS\14081375 ,_23\,\1740 in_24\IN\13603305 57_25\CD\1740 %_26\NN\1740 of_27\IN\1740 the_28\DT\1740 chloroprocaine_29\NN\1740 group_30\NN\2137 ,_31\,\1740 and_32\CC\1740 in_33\IN\13603305 6_34\CD\13741022 %_35\NN\1740 of_36\IN\1740 the_37\DT\1740 lidocaine_38\NN\3681148 group_39\NN\2137 ._40\.\1740
D002045_D012640 CID a_0\DT\13649268 cd50_1\NN\1740 dose_2\NN\3740161 of_3\IN\1740 local_4\JJ\1740 anesthetic_5\JJ\1740 (_6\-LRB-\1740 causing_7\VBG\1617192 convulsions_8\NNS\14081375 in_9\IN\13603305 50_10\CD\13745420 %_11\NN\1740 of_12\IN\1740 mice_13\NNS\2329401 )_14\-RRB-\1740 was_15\VBD\836236 fatal_16\JJ\1740 in_17\IN\13603305 90_18\CD\13745420 %_19\NN\1740 of_20\IN\1740 <e1>bupivacaine-induced</e1>_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 ,_23\,\1740 in_24\IN\13603305 57_25\CD\1740 %_26\NN\1740 of_27\IN\1740 the_28\DT\1740 chloroprocaine_29\NN\1740 group_30\NN\2137 ,_31\,\1740 and_32\CC\1740 in_33\IN\13603305 6_34\CD\13741022 %_35\NN\1740 of_36\IN\1740 the_37\DT\1740 lidocaine_38\NN\3681148 group_39\NN\2137 ._40\.\1740
C004616_D012640 CID a_0\DT\13649268 cd50_1\NN\1740 dose_2\NN\3740161 of_3\IN\1740 local_4\JJ\1740 anesthetic_5\JJ\1740 (_6\-LRB-\1740 causing_7\VBG\1617192 <e2>convulsions</e2>_8\NNS\14081375 in_9\IN\13603305 50_10\CD\13745420 %_11\NN\1740 of_12\IN\1740 mice_13\NNS\2329401 )_14\-RRB-\1740 was_15\VBD\836236 fatal_16\JJ\1740 in_17\IN\13603305 90_18\CD\13745420 %_19\NN\1740 of_20\IN\1740 bupivacaine-induced_21\JJ\1740 seizures_22\NNS\14081375 ,_23\,\1740 in_24\IN\13603305 57_25\CD\1740 %_26\NN\1740 of_27\IN\1740 the_28\DT\1740 <e1>chloroprocaine</e1>_29\NN\1740 group_30\NN\2137 ,_31\,\1740 and_32\CC\1740 in_33\IN\13603305 6_34\CD\13741022 %_35\NN\1740 of_36\IN\1740 the_37\DT\1740 lidocaine_38\NN\3681148 group_39\NN\2137 ._40\.\1740
C004616_D012640 CID a_0\DT\13649268 cd50_1\NN\1740 dose_2\NN\3740161 of_3\IN\1740 local_4\JJ\1740 anesthetic_5\JJ\1740 (_6\-LRB-\1740 causing_7\VBG\1617192 convulsions_8\NNS\14081375 in_9\IN\13603305 50_10\CD\13745420 %_11\NN\1740 of_12\IN\1740 mice_13\NNS\2329401 )_14\-RRB-\1740 was_15\VBD\836236 fatal_16\JJ\1740 in_17\IN\13603305 90_18\CD\13745420 %_19\NN\1740 of_20\IN\1740 bupivacaine-induced_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 ,_23\,\1740 in_24\IN\13603305 57_25\CD\1740 %_26\NN\1740 of_27\IN\1740 the_28\DT\1740 <e1>chloroprocaine</e1>_29\NN\1740 group_30\NN\2137 ,_31\,\1740 and_32\CC\1740 in_33\IN\13603305 6_34\CD\13741022 %_35\NN\1740 of_36\IN\1740 the_37\DT\1740 lidocaine_38\NN\3681148 group_39\NN\2137 ._40\.\1740
D008012_D012640 CID a_0\DT\13649268 cd50_1\NN\1740 dose_2\NN\3740161 of_3\IN\1740 local_4\JJ\1740 anesthetic_5\JJ\1740 (_6\-LRB-\1740 causing_7\VBG\1617192 <e2>convulsions</e2>_8\NNS\14081375 in_9\IN\13603305 50_10\CD\13745420 %_11\NN\1740 of_12\IN\1740 mice_13\NNS\2329401 )_14\-RRB-\1740 was_15\VBD\836236 fatal_16\JJ\1740 in_17\IN\13603305 90_18\CD\13745420 %_19\NN\1740 of_20\IN\1740 bupivacaine-induced_21\JJ\1740 seizures_22\NNS\14081375 ,_23\,\1740 in_24\IN\13603305 57_25\CD\1740 %_26\NN\1740 of_27\IN\1740 the_28\DT\1740 chloroprocaine_29\NN\1740 group_30\NN\2137 ,_31\,\1740 and_32\CC\1740 in_33\IN\13603305 6_34\CD\13741022 %_35\NN\1740 of_36\IN\1740 the_37\DT\1740 <e1>lidocaine</e1>_38\NN\3681148 group_39\NN\2137 ._40\.\1740
D008012_D012640 CID a_0\DT\13649268 cd50_1\NN\1740 dose_2\NN\3740161 of_3\IN\1740 local_4\JJ\1740 anesthetic_5\JJ\1740 (_6\-LRB-\1740 causing_7\VBG\1617192 convulsions_8\NNS\14081375 in_9\IN\13603305 50_10\CD\13745420 %_11\NN\1740 of_12\IN\1740 mice_13\NNS\2329401 )_14\-RRB-\1740 was_15\VBD\836236 fatal_16\JJ\1740 in_17\IN\13603305 90_18\CD\13745420 %_19\NN\1740 of_20\IN\1740 bupivacaine-induced_21\JJ\1740 <e2>seizures</e2>_22\NNS\14081375 ,_23\,\1740 in_24\IN\13603305 57_25\CD\1740 %_26\NN\1740 of_27\IN\1740 the_28\DT\1740 chloroprocaine_29\NN\1740 group_30\NN\2137 ,_31\,\1740 and_32\CC\1740 in_33\IN\13603305 6_34\CD\13741022 %_35\NN\1740 of_36\IN\1740 the_37\DT\1740 <e1>lidocaine</e1>_38\NN\3681148 group_39\NN\2137 ._40\.\1740
7724492
D004317_D007674 NONE acute_0\JJ\1740 <e2>renal_1\JJ\1740 toxicity</e2>_2\NN\13576101 of_3\IN\1740 <e1>doxorubicin</e1>_4\NN\2716866 (adriamycin)-loaded_5\IN\1740 cyanoacrylate_6\JJ\1740 nanoparticles_7\NNS\1740 ._8\.\1740
D004317_D007674 NONE acute_0\JJ\1740 <e2>renal_1\JJ\1740 toxicity</e2>_2\NN\13576101 of_3\IN\1740 doxorubicin_4\NN\2716866 <e1>(adriamycin)-loaded</e1>_5\IN\1740 cyanoacrylate_6\JJ\1740 nanoparticles_7\NNS\1740 ._8\.\1740
D004317_D007674 NONE acute_0\JJ\1740 <e1>doxorubicin-loaded</e1>_1\JJ\1740 nanoparticle_2\NN\1740 (_3\-LRB-\1740 dxnp_4\NNP\1740 )_5\-RRB-\1740 <e2>renal_6\JJ\1740 toxicity</e2>_7\NN\13576101 was_8\VBD\836236 explored_9\VBN\789138 in_10\IN\13603305 both_11\CC\1740 normal_12\JJ\1740 rats_13\NNS\2329401 and_14\CC\1740 rats_15\NNS\2329401 with_16\IN\1740 experimental_17\JJ\1740 glomerulonephritis_18\NN\14113798 ._19\.\1740
D004317_D007674 NONE these_0\DT\1740 results_1\NNS\34213 demonstrate_2\VBP\2137132 that_3\IN\1740 ,_4\,\1740 in_5\IN\13603305 these_6\DT\1740 experimental_7\JJ\1740 conditions_8\NNS\14512817 ,_9\,\1740 dxnp_10\NNP\1740 killed_11\VBD\2473431 less_12\JJR\1740 animals_13\NNS\4475 than_14\IN\1740 free_15\JJ\1740 <e1>dx</e1>_16\NN\1740 ,_17\,\1740 despite_18\IN\7501545 of_19\IN\1740 an_20\DT\6697703 enhanced_21\VBN\227165 <e2>renal_22\JJ\1740 toxicity</e2>_23\NN\13576101 of_24\IN\1740 the_25\DT\1740 former_26\JJ\1740 ._27\.\1740
D003487_D007674 NONE acute_0\JJ\1740 <e2>renal_1\JJ\1740 toxicity</e2>_2\NN\13576101 of_3\IN\1740 doxorubicin_4\NN\2716866 (adriamycin)-loaded_5\IN\1740 <e1>cyanoacrylate</e1>_6\JJ\1740 nanoparticles_7\NNS\1740 ._8\.\1740
D004317_D005921 NONE acute_0\JJ\1740 <e1>doxorubicin-loaded</e1>_1\JJ\1740 nanoparticle_2\NN\1740 (_3\-LRB-\1740 dxnp_4\NNP\1740 )_5\-RRB-\1740 renal_6\JJ\1740 toxicity_7\NN\13576101 was_8\VBD\836236 explored_9\VBN\789138 in_10\IN\13603305 both_11\CC\1740 normal_12\JJ\1740 rats_13\NNS\2329401 and_14\CC\1740 rats_15\NNS\2329401 with_16\IN\1740 experimental_17\JJ\1740 <e2>glomerulonephritis</e2>_18\NN\14113798 ._19\.\1740
D004317_D005921 NONE in_0\IN\13603305 rats_1\NNS\2329401 with_2\IN\1740 immune_3\JJ\1740 experimental_4\JJ\1740 <e2>glomerulonephritis</e2>_5\NN\14113798 ,_6\,\1740 5/6_7\CD\1740 rats_8\NNS\2329401 given_9\VBN\2327200 <e1>dx</e1>_10\NN\1740 died_11\VBD\146138 within_12\IN\1740 7_13\CD\13741022 days_14\NNS\15140892 ,_15\,\1740 in_16\IN\13603305 contrast_17\NN\13854649 to_18\TO\1740 animals_19\NNS\4475 treated_20\VBN\2376958 by_21\IN\1740 dxnp_22\NNP\1740 ,_23\,\1740 np_24\NNP\14625458 ,_25\,\1740 or_26\CC\3541091 untreated_27\JJ\1740 ,_28\,\1740 which_29\WDT\1740 all_30\DT\1740 survived_31\VBD\1108148 ._32\.\1740
D004317_D011507 CID a_0\DT\13649268 3_1\CD\13741022 times_2\NNS\15113229 higher_3\JJR\1740 <e2>proteinuria</e2>_4\NN\14299637 appeared_5\VBD\2604760 in_6\IN\13603305 animals_7\NNS\4475 treated_8\VBN\2376958 with_9\IN\1740 dxnp_10\NNP\1740 than_11\IN\1740 in_12\IN\13603305 those_13\DT\1740 treated_14\VBN\2376958 with_15\IN\1740 <e1>dx</e1>_16\NN\1740 ._17\.\1740
D004317_D011507 CID <e2>proteinuria</e2>_0\NNP\14299637 appeared_1\VBD\2604760 in_2\IN\13603305 all_3\DT\1740 series_4\NN\8456993 ,_5\,\1740 but_6\CC\1740 was_7\VBD\836236 2_8\CD\13741022 -_9\SYM\1740 5_10\CD\13741022 times_11\NNS\15113229 more_12\RBR\1740 intense_13\JJ\1740 (_14\-LRB-\1740 p_15\NN\14622893 >_16\NN\1740 0.001_17\CD\1740 )_18\-RRB-\1740 and_19\CC\1740 prolonged_20\VBN\317700 after_21\IN\1740 <e1>doxorubicin</e1>_22\NN\2716866 treatment_23\NN\654885 (_24\-LRB-\1740 400_25\CD\1740 -_26\SYM\1740 700_27\CD\1740 mg/day_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 without_31\IN\1740 significant_32\JJ\1740 difference_33\NN\4723816 between_34\IN\1740 dxnp_35\NNP\1740 and_36\CC\1740 dx_37\NN\1740 ._38\.\1740
D004317_D011507 CID <e2>proteinuria</e2>_0\NNP\14299637 appeared_1\VBD\2604760 in_2\IN\13603305 all_3\DT\1740 series_4\NN\8456993 ,_5\,\1740 but_6\CC\1740 was_7\VBD\836236 2_8\CD\13741022 -_9\SYM\1740 5_10\CD\13741022 times_11\NNS\15113229 more_12\RBR\1740 intense_13\JJ\1740 (_14\-LRB-\1740 p_15\NN\14622893 >_16\NN\1740 0.001_17\CD\1740 )_18\-RRB-\1740 and_19\CC\1740 prolonged_20\VBN\317700 after_21\IN\1740 doxorubicin_22\NN\2716866 treatment_23\NN\654885 (_24\-LRB-\1740 400_25\CD\1740 -_26\SYM\1740 700_27\CD\1740 mg/day_28\NN\1740 )_29\-RRB-\1740 ,_30\,\1740 without_31\IN\1740 significant_32\JJ\1740 difference_33\NN\4723816 between_34\IN\1740 dxnp_35\NNP\1740 and_36\CC\1740 <e1>dx</e1>_37\NN\1740 ._38\.\1740
15565293
D004977_D009901 CID optical_0\JJ\1740 coherence_1\NN\14419164 tomography_2\NN\900375 can_3\MD\3094503 measure_4\VB\697589 axonal_5\JJ\1740 loss_6\NN\13252973 in_7\IN\13603305 patients_8\NNS\9898892 with_9\IN\1740 <e1>ethambutol-induced</e1>_10\JJ\1740 <e2>optic_11\NN\5299178 neuropathy</e2>_12\JJ\1740 ._13\.\1740
D004977_D009901 CID purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 map_3\VB\1686132 and_4\CC\1740 identify_5\VB\699815 the_6\DT\1740 pattern_7\NN\5726345 ,_8\,\1740 in_9\FW\13603305 vivo_10\FW\1740 ,_11\,\1740 of_12\IN\1740 axonal_13\JJ\1740 degeneration_14\NN\29677 in_15\IN\13603305 <e1>ethambutol-induced</e1>_16\JJ\1740 <e2>optic_17\JJ\1740 neuropathy</e2>_18\JJ\1740 using_19\VBG\1156834 optical_20\JJ\1740 coherence_21\NN\14419164 tomography_22\NN\900375 (_23\-LRB-\1740 oct_24\NN\15209706 )_25\-RRB-\1740 ._26\.\1740
D004977_D009901 CID a_0\DT\13649268 serious_1\JJ\1740 complication_2\NN\1073995 of_3\IN\1740 <e1>ethambutol</e1>_4\NN\1740 is_5\VBZ\836236 an_6\DT\6697703 <e2>optic_7\JJ\1740 neuropathy</e2>_8\JJ\1740 that_9\WDT\1740 impairs_10\VBZ\258857 visual_11\JJ\1740 acuity_12\NN\5654362 ,_13\,\1740 contrast_14\NN\13854649 sensitivity_15\NN\5651971 ,_16\,\1740 and_17\CC\1740 color_18\NN\4950126 vision_19\NN\5767733 ._20\.\1740
D004977_D009901 CID methods_0\NNS\5616786 :_1\:\1740 three_2\CD\13741022 subjects_3\NNS\6598915 with_4\IN\1740 a_5\DT\13649268 history_6\NN\15120823 of_7\IN\1740 <e1>ethambutol</e1>_8\JJ\1740 (emb)-induced_9\JJ\1740 <e2>optic_10\JJ\1740 neuropathy</e2>_11\NN\14204950 of_12\IN\1740 short-_13\NN\1740 ,_14\,\1740 intermediate-_15\NN\1740 ,_16\,\1740 and_17\CC\1740 long-term_18\JJ\1740 visual_19\JJ\1740 deficits_20\NNS\5113133 were_21\VBD\836236 administered_22\VBN\2436349 a_23\DT\13649268 full_24\JJ\1740 neuro-ophthalmologic_25\JJ\1740 examination_26\NN\633864 including_27\VBG\690614 visual_28\JJ\1740 acuity_29\NN\5654362 ,_30\,\1740 color_31\NN\4950126 vision_32\NN\5767733 ,_33\,\1740 contrast_34\VBP\650353 sensitivity_35\NN\5651971 ,_36\,\1740 and_37\CC\1740 fundus_38\JJ\1740 examination_39\NN\633864 ._40\.\1740
D004977_D009901 CID methods_0\NNS\5616786 :_1\:\1740 three_2\CD\13741022 subjects_3\NNS\6598915 with_4\IN\1740 a_5\DT\13649268 history_6\NN\15120823 of_7\IN\1740 ethambutol_8\JJ\1740 <e1>(emb)-induced</e1>_9\JJ\1740 <e2>optic_10\JJ\1740 neuropathy</e2>_11\NN\14204950 of_12\IN\1740 short-_13\NN\1740 ,_14\,\1740 intermediate-_15\NN\1740 ,_16\,\1740 and_17\CC\1740 long-term_18\JJ\1740 visual_19\JJ\1740 deficits_20\NNS\5113133 were_21\VBD\836236 administered_22\VBN\2436349 a_23\DT\13649268 full_24\JJ\1740 neuro-ophthalmologic_25\JJ\1740 examination_26\NN\633864 including_27\VBG\690614 visual_28\JJ\1740 acuity_29\NN\5654362 ,_30\,\1740 color_31\NN\4950126 vision_32\NN\5767733 ,_33\,\1740 contrast_34\VBP\650353 sensitivity_35\NN\5651971 ,_36\,\1740 and_37\CC\1740 fundus_38\JJ\1740 examination_39\NN\633864 ._40\.\1740
D004977_D009901 CID in_0\IN\13603305 all_1\DT\1740 subjects_2\NNS\6598915 with_3\IN\1740 history_4\NN\15120823 of_5\IN\1740 <e1>emb-induced</e1>_6\JJ\1740 <e2>optic_7\NN\5299178 neuropathy</e2>_8\JJ\1740 ,_9\,\1740 there_10\EX\27167 was_11\VBD\836236 a_12\DT\13649268 mean_13\JJ\1740 loss_14\NN\13252973 of_15\IN\1740 72_16\CD\1740 %_17\NN\1740 nerve_18\NN\5475681 fiber_19\NN\14580897 layer_20\NN\21939 thickness_21\NN\5093581 in_22\IN\13603305 the_23\DT\1740 temporal_24\JJ\1740 quadrant_25\NN\8593262 (_26\-LRB-\1740 patient_27\NN\9898892 a_28\NN\13649268 ,_29\,\1740 with_30\IN\1740 eventual_31\JJ\1740 recovery_32\NN\7357388 of_33\IN\1740 visual_34\JJ\1740 acuity_35\NN\5654362 and_36\CC\1740 fields_37\NNS\8673395 ,_38\,\1740 58_39\CD\1740 %_40\NN\1740 loss_41\NN\13252973 ;_42\:\1740 patient_43\NN\9898892 b_44\NN\1355326 ,_45\,\1740 with_46\IN\1740 intermediate_47\JJ\1740 visual_48\JJ\1740 deficits_49\NNS\5113133 ,_50\,\1740 68_51\CD\1740 %_52\NN\1740 loss_53\NN\13252973 ;_54\:\1740 patient_55\NN\9898892 c_56\NN\13714184 ,_57\,\1740 with_58\IN\1740 chronic_59\JJ\1740 visual_60\JJ\1740 deficits_61\NNS\5113133 ,_62\,\1740 90_63\CD\13745420 %_64\NN\1740 loss_65\NN\13252973 )_66\-RRB-\1740 ,_67\,\1740 with_68\IN\1740 an_69\DT\6697703 average_70\JJ\1740 mean_71\NN\6021761 optic_72\JJ\1740 nerve_73\NN\5475681 thickness_74\NN\5093581 of_75\IN\1740 26+/-16_76\CD\1740 microm_77\RB\1740 ._78\.\1740
D004977_D009901 CID conclusions_0\NNS\5837957 :_1\:\1740 the_2\DT\1740 oct_3\NN\15209706 results_4\VBZ\2633881 in_5\IN\13603305 these_6\DT\1740 patients_7\NNS\9898892 with_8\IN\1740 <e1>emb-induced</e1>_9\JJ\1740 <e2>optic_10\JJ\1740 neuropathy</e2>_11\JJ\1740 show_12\VBP\2137132 considerable_13\JJ\1740 loss_14\NN\13252973 especially_15\RB\1740 of_16\IN\1740 the_17\DT\1740 temporal_18\JJ\1740 fibers_19\NNS\14580897 ._20\.\1740
D004977_D009901 CID additionally_0\RB\1740 ,_1\,\1740 in_2\IN\13603305 terms_3\NNS\13945919 of_4\IN\1740 management_5\NN\1123598 of_6\IN\1740 <e1>emb-induced</e1>_7\JJ\1740 <e2>optic_8\NN\5299178 neuropathy</e2>_9\RB\1740 ,_10\,\1740 it_11\PRP\6125041 is_12\VBZ\836236 important_13\JJ\1740 to_14\TO\1740 properly_15\RB\1740 manage_16\VB\2524171 ethambutol_17\NN\1740 dosing_18\NN\1740 in_19\IN\13603305 patients_20\NNS\9898892 with_21\IN\1740 renal_22\JJ\1740 impairment_23\NN\7296428 and_24\CC\1740 to_25\TO\1740 achieve_26\VB\2524171 proper_27\JJ\1740 transition_28\NN\199130 to_29\TO\1740 a_30\DT\13649268 maintenance_31\NN\266806 dose_32\NN\3740161 once_33\IN\1740 an_34\DT\6697703 appropriate_35\JJ\1740 loading_36\NN\4571088 dose_37\NN\3740161 has_38\VBZ\2108377 been_39\VBN\836236 reached_40\VBN\2005948 ._41\.\1740
D004977_D009901 CID additionally_0\RB\1740 ,_1\,\1740 in_2\IN\13603305 terms_3\NNS\13945919 of_4\IN\1740 management_5\NN\1123598 of_6\IN\1740 emb-induced_7\JJ\1740 <e2>optic_8\NN\5299178 neuropathy</e2>_9\RB\1740 ,_10\,\1740 it_11\PRP\6125041 is_12\VBZ\836236 important_13\JJ\1740 to_14\TO\1740 properly_15\RB\1740 manage_16\VB\2524171 <e1>ethambutol</e1>_17\NN\1740 dosing_18\NN\1740 in_19\IN\13603305 patients_20\NNS\9898892 with_21\IN\1740 renal_22\JJ\1740 impairment_23\NN\7296428 and_24\CC\1740 to_25\TO\1740 achieve_26\VB\2524171 proper_27\JJ\1740 transition_28\NN\199130 to_29\TO\1740 a_30\DT\13649268 maintenance_31\NN\266806 dose_32\NN\3740161 once_33\IN\1740 an_34\DT\6697703 appropriate_35\JJ\1740 loading_36\NN\4571088 dose_37\NN\3740161 has_38\VBZ\2108377 been_39\VBN\836236 reached_40\VBN\2005948 ._41\.\1740
D004977_D009410 NONE purpose_0\NNP\5980875 :_1\:\1740 to_2\TO\1740 map_3\VB\1686132 and_4\CC\1740 identify_5\VB\699815 the_6\DT\1740 pattern_7\NN\5726345 ,_8\,\1740 in_9\FW\13603305 vivo_10\FW\1740 ,_11\,\1740 of_12\IN\1740 <e2>axonal_13\JJ\1740 degeneration</e2>_14\NN\29677 in_15\IN\13603305 <e1>ethambutol-induced</e1>_16\JJ\1740 optic_17\JJ\1740 neuropathy_18\JJ\1740 using_19\VBG\1156834 optical_20\JJ\1740 coherence_21\NN\14419164 tomography_22\NN\900375 (_23\-LRB-\1740 oct_24\NN\15209706 )_25\-RRB-\1740 ._26\.\1740
D004977_D014376 NONE <e1>ethambutol</e1>_0\NNP\1740 is_1\VBZ\836236 an_2\DT\6697703 antimycobacterial_3\JJ\1740 agent_4\NN\7347 often_5\RB\1740 used_6\VBD\1156834 to_7\TO\1740 treat_8\VB\2376958 <e2>tuberculosis</e2>_9\NN\14127211 ._10\.\1740
D004977_D014786 CID methods_0\NNS\5616786 :_1\:\1740 three_2\CD\13741022 subjects_3\NNS\6598915 with_4\IN\1740 a_5\DT\13649268 history_6\NN\15120823 of_7\IN\1740 <e1>ethambutol</e1>_8\JJ\1740 (emb)-induced_9\JJ\1740 optic_10\JJ\1740 neuropathy_11\NN\14204950 of_12\IN\1740 short-_13\NN\1740 ,_14\,\1740 intermediate-_15\NN\1740 ,_16\,\1740 and_17\CC\1740 long-term_18\JJ\1740 <e2>visual_19\JJ\1740 deficits</e2>_20\NNS\5113133 were_21\VBD\836236 administered_22\VBN\2436349 a_23\DT\13649268 full_24\JJ\1740 neuro-ophthalmologic_25\JJ\1740 examination_26\NN\633864 including_27\VBG\690614 visual_28\JJ\1740 acuity_29\NN\5654362 ,_30\,\1740 color_31\NN\4950126 vision_32\NN\5767733 ,_33\,\1740 contrast_34\VBP\650353 sensitivity_35\NN\5651971 ,_36\,\1740 and_37\CC\1740 fundus_38\JJ\1740 examination_39\NN\633864 ._40\.\1740
D004977_D014786 CID methods_0\NNS\5616786 :_1\:\1740 three_2\CD\13741022 subjects_3\NNS\6598915 with_4\IN\1740 a_5\DT\13649268 history_6\NN\15120823 of_7\IN\1740 ethambutol_8\JJ\1740 <e1>(emb)-induced</e1>_9\JJ\1740 optic_10\JJ\1740 neuropathy_11\NN\14204950 of_12\IN\1740 short-_13\NN\1740 ,_14\,\1740 intermediate-_15\NN\1740 ,_16\,\1740 and_17\CC\1740 long-term_18\JJ\1740 <e2>visual_19\JJ\1740 deficits</e2>_20\NNS\5113133 were_21\VBD\836236 administered_22\VBN\2436349 a_23\DT\13649268 full_24\JJ\1740 neuro-ophthalmologic_25\JJ\1740 examination_26\NN\633864 including_27\VBG\690614 visual_28\JJ\1740 acuity_29\NN\5654362 ,_30\,\1740 color_31\NN\4950126 vision_32\NN\5767733 ,_33\,\1740 contrast_34\VBP\650353 sensitivity_35\NN\5651971 ,_36\,\1740 and_37\CC\1740 fundus_38\JJ\1740 examination_39\NN\633864 ._40\.\1740
D004977_D014786 CID in_0\IN\13603305 all_1\DT\1740 subjects_2\NNS\6598915 with_3\IN\1740 history_4\NN\15120823 of_5\IN\1740 <e1>emb-induced</e1>_6\JJ\1740 optic_7\NN\5299178 neuropathy_8\JJ\1740 ,_9\,\1740 there_10\EX\27167 was_11\VBD\836236 a_12\DT\13649268 mean_13\JJ\1740 loss_14\NN\13252973 of_15\IN\1740 72_16\CD\1740 %_17\NN\1740 nerve_18\NN\5475681 fiber_19\NN\14580897 layer_20\NN\21939 thickness_21\NN\5093581 in_22\IN\13603305 the_23\DT\1740 temporal_24\JJ\1740 quadrant_25\NN\8593262 (_26\-LRB-\1740 patient_27\NN\9898892 a_28\NN\13649268 ,_29\,\1740 with_30\IN\1740 eventual_31\JJ\1740 recovery_32\NN\7357388 of_33\IN\1740 visual_34\JJ\1740 acuity_35\NN\5654362 and_36\CC\1740 fields_37\NNS\8673395 ,_38\,\1740 58_39\CD\1740 %_40\NN\1740 loss_41\NN\13252973 ;_42\:\1740 patient_43\NN\9898892 b_44\NN\1355326 ,_45\,\1740 with_46\IN\1740 intermediate_47\JJ\1740 <e2>visual_48\JJ\1740 deficits</e2>_49\NNS\5113133 ,_50\,\1740 68_51\CD\1740 %_52\NN\1740 loss_53\NN\13252973 ;_54\:\1740 patient_55\NN\9898892 c_56\NN\13714184 ,_57\,\1740 with_58\IN\1740 chronic_59\JJ\1740 visual_60\JJ\1740 deficits_61\NNS\5113133 ,_62\,\1740 90_63\CD\13745420 %_64\NN\1740 loss_65\NN\13252973 )_66\-RRB-\1740 ,_67\,\1740 with_68\IN\1740 an_69\DT\6697703 average_70\JJ\1740 mean_71\NN\6021761 optic_72\JJ\1740 nerve_73\NN\5475681 thickness_74\NN\5093581 of_75\IN\1740 26+/-16_76\CD\1740 microm_77\RB\1740 ._78\.\1740
D004977_D014786 CID in_0\IN\13603305 all_1\DT\1740 subjects_2\NNS\6598915 with_3\IN\1740 history_4\NN\15120823 of_5\IN\1740 <e1>emb-induced</e1>_6\JJ\1740 optic_7\NN\5299178 neuropathy_8\JJ\1740 ,_9\,\1740 there_10\EX\27167 was_11\VBD\836236 a_12\DT\13649268 mean_13\JJ\1740 loss_14\NN\13252973 of_15\IN\1740 72_16\CD\1740 %_17\NN\1740 nerve_18\NN\5475681 fiber_19\NN\14580897 layer_20\NN\21939 thickness_21\NN\5093581 in_22\IN\13603305 the_23\DT\1740 temporal_24\JJ\1740 quadrant_25\NN\8593262 (_26\-LRB-\1740 patient_27\NN\9898892 a_28\NN\13649268 ,_29\,\1740 with_30\IN\1740 eventual_31\JJ\1740 recovery_32\NN\7357388 of_33\IN\1740 visual_34\JJ\1740 acuity_35\NN\5654362 and_36\CC\1740 fields_37\NNS\8673395 ,_38\,\1740 58_39\CD\1740 %_40\NN\1740 loss_41\NN\13252973 ;_42\:\1740 patient_43\NN\9898892 b_44\NN\1355326 ,_45\,\1740 with_46\IN\1740 intermediate_47\JJ\1740 visual_48\JJ\1740 deficits_49\NNS\5113133 ,_50\,\1740 68_51\CD\1740 %_52\NN\1740 loss_53\NN\13252973 ;_54\:\1740 patient_55\NN\9898892 c_56\NN\13714184 ,_57\,\1740 with_58\IN\1740 chronic_59\JJ\1740 <e2>visual_60\JJ\1740 deficits</e2>_61\NNS\5113133 ,_62\,\1740 90_63\CD\13745420 %_64\NN\1740 loss_65\NN\13252973 )_66\-RRB-\1740 ,_67\,\1740 with_68\IN\1740 an_69\DT\6697703 average_70\JJ\1740 mean_71\NN\6021761 optic_72\JJ\1740 nerve_73\NN\5475681 thickness_74\NN\5093581 of_75\IN\1740 26+/-16_76\CD\1740 microm_77\RB\1740 ._78\.\1740
D004977_D051437 NONE additionally_0\RB\1740 ,_1\,\1740 in_2\IN\13603305 terms_3\NNS\13945919 of_4\IN\1740 management_5\NN\1123598 of_6\IN\1740 <e1>emb-induced</e1>_7\JJ\1740 optic_8\NN\5299178 neuropathy_9\RB\1740 ,_10\,\1740 it_11\PRP\6125041 is_12\VBZ\836236 important_13\JJ\1740 to_14\TO\1740 properly_15\RB\1740 manage_16\VB\2524171 ethambutol_17\NN\1740 dosing_18\NN\1740 in_19\IN\13603305 patients_20\NNS\9898892 with_21\IN\1740 <e2>renal_22\JJ\1740 impairment</e2>_23\NN\7296428 and_24\CC\1740 to_25\TO\1740 achieve_26\VB\2524171 proper_27\JJ\1740 transition_28\NN\199130 to_29\TO\1740 a_30\DT\13649268 maintenance_31\NN\266806 dose_32\NN\3740161 once_33\IN\1740 an_34\DT\6697703 appropriate_35\JJ\1740 loading_36\NN\4571088 dose_37\NN\3740161 has_38\VBZ\2108377 been_39\VBN\836236 reached_40\VBN\2005948 ._41\.\1740
D004977_D051437 NONE additionally_0\RB\1740 ,_1\,\1740 in_2\IN\13603305 terms_3\NNS\13945919 of_4\IN\1740 management_5\NN\1123598 of_6\IN\1740 emb-induced_7\JJ\1740 optic_8\NN\5299178 neuropathy_9\RB\1740 ,_10\,\1740 it_11\PRP\6125041 is_12\VBZ\836236 important_13\JJ\1740 to_14\TO\1740 properly_15\RB\1740 manage_16\VB\2524171 <e1>ethambutol</e1>_17\NN\1740 dosing_18\NN\1740 in_19\IN\13603305 patients_20\NNS\9898892 with_21\IN\1740 <e2>renal_22\JJ\1740 impairment</e2>_23\NN\7296428 and_24\CC\1740 to_25\TO\1740 achieve_26\VB\2524171 proper_27\JJ\1740 transition_28\NN\199130 to_29\TO\1740 a_30\DT\13649268 maintenance_31\NN\266806 dose_32\NN\3740161 once_33\IN\1740 an_34\DT\6697703 appropriate_35\JJ\1740 loading_36\NN\4571088 dose_37\NN\3740161 has_38\VBZ\2108377 been_39\VBN\836236 reached_40\VBN\2005948 ._41\.\1740
17074608
D014635_D002819 CID <e1>valproate-induced</e1>_0\JJ\1740 <e2>chorea</e2>_1\NN\14253124 and_2\CC\1740 encephalopathy_3\JJ\1740 in_4\IN\13603305 atypical_5\JJ\1740 nonketotic_6\JJ\1740 hyperglycinemia_7\NN\1740 ._8\.\1740
D014635_D002819 CID this_0\DT\1740 report_1\NN\6470073 describes_2\VBZ\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 mild_6\JJ\1740 language_7\NN\33020 delay_8\NN\15271008 and_9\CC\1740 mental_10\JJ\1740 retardation_11\NN\7296428 ,_12\,\1740 who_13\WP\8299493 was_14\VBD\836236 found_15\VBN\2426171 to_16\TO\1740 have_17\VB\2108377 nonketotic_18\JJ\1740 hyperglycinemia_19\NN\1740 following_20\VBG\1835496 her_21\PRP$\1740 presentation_22\NN\1027379 with_23\IN\1740 acute_24\JJ\1740 encephalopathy_25\JJ\1740 and_26\CC\1740 <e2>chorea</e2>_27\NN\14253124 shortly_28\RB\1740 after_29\IN\1740 initiation_30\NN\7450842 of_31\IN\1740 <e1>valproate</e1>_32\NN\1740 therapy_33\NN\657604 ._34\.\1740
D014635_D001927 CID <e1>valproate-induced</e1>_0\JJ\1740 chorea_1\NN\14253124 and_2\CC\1740 <e2>encephalopathy</e2>_3\JJ\1740 in_4\IN\13603305 atypical_5\JJ\1740 nonketotic_6\JJ\1740 hyperglycinemia_7\NN\1740 ._8\.\1740
D014635_D001927 CID this_0\DT\1740 report_1\NN\6470073 describes_2\VBZ\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 mild_6\JJ\1740 language_7\NN\33020 delay_8\NN\15271008 and_9\CC\1740 mental_10\JJ\1740 retardation_11\NN\7296428 ,_12\,\1740 who_13\WP\8299493 was_14\VBD\836236 found_15\VBN\2426171 to_16\TO\1740 have_17\VB\2108377 nonketotic_18\JJ\1740 hyperglycinemia_19\NN\1740 following_20\VBG\1835496 her_21\PRP$\1740 presentation_22\NN\1027379 with_23\IN\1740 acute_24\JJ\1740 <e2>encephalopathy</e2>_25\JJ\1740 and_26\CC\1740 chorea_27\NN\14253124 shortly_28\RB\1740 after_29\IN\1740 initiation_30\NN\7450842 of_31\IN\1740 <e1>valproate</e1>_32\NN\1740 therapy_33\NN\657604 ._34\.\1740
D014635_D020158 NONE <e1>valproate-induced</e1>_0\JJ\1740 chorea_1\NN\14253124 and_2\CC\1740 encephalopathy_3\JJ\1740 in_4\IN\13603305 atypical_5\JJ\1740 <e2>nonketotic_6\JJ\1740 hyperglycinemia</e2>_7\NN\1740 ._8\.\1740
D014635_D020158 NONE this_0\DT\1740 report_1\NN\6470073 describes_2\VBZ\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 mild_6\JJ\1740 language_7\NN\33020 delay_8\NN\15271008 and_9\CC\1740 mental_10\JJ\1740 retardation_11\NN\7296428 ,_12\,\1740 who_13\WP\8299493 was_14\VBD\836236 found_15\VBN\2426171 to_16\TO\1740 have_17\VB\2108377 <e2>nonketotic_18\JJ\1740 hyperglycinemia</e2>_19\NN\1740 following_20\VBG\1835496 her_21\PRP$\1740 presentation_22\NN\1027379 with_23\IN\1740 acute_24\JJ\1740 encephalopathy_25\JJ\1740 and_26\CC\1740 chorea_27\NN\14253124 shortly_28\RB\1740 after_29\IN\1740 initiation_30\NN\7450842 of_31\IN\1740 <e1>valproate</e1>_32\NN\1740 therapy_33\NN\657604 ._34\.\1740
D005998_D020158 NONE <e2>nonketotic_0\JJ\1740 hyperglycinemia</e2>_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 disorder_4\NN\14034177 of_5\IN\1740 amino_6\NN\14621446 acid_7\NN\14818238 metabolism_8\NN\13526110 in_9\IN\13603305 which_10\WDT\1740 a_11\DT\13649268 defect_12\NN\14462666 in_13\IN\13603305 the_14\DT\1740 <e1>glycine</e1>_15\NN\14601829 cleavage_16\NN\24720 system_17\NN\3575240 leads_18\VBZ\1752884 to_19\TO\1740 an_20\DT\6697703 accumulation_21\NN\13497135 of_22\IN\1740 glycine_23\NN\14601829 in_24\IN\13603305 the_25\DT\1740 brain_26\NN\5462674 and_27\CC\1740 other_28\JJ\1740 body_29\NN\19128 compartments_30\NNS\13910384 ._31\.\1740
D005998_D020158 NONE <e2>nonketotic_0\JJ\1740 hyperglycinemia</e2>_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 disorder_4\NN\14034177 of_5\IN\1740 amino_6\NN\14621446 acid_7\NN\14818238 metabolism_8\NN\13526110 in_9\IN\13603305 which_10\WDT\1740 a_11\DT\13649268 defect_12\NN\14462666 in_13\IN\13603305 the_14\DT\1740 glycine_15\NN\14601829 cleavage_16\NN\24720 system_17\NN\3575240 leads_18\VBZ\1752884 to_19\TO\1740 an_20\DT\6697703 accumulation_21\NN\13497135 of_22\IN\1740 <e1>glycine</e1>_23\NN\14601829 in_24\IN\13603305 the_25\DT\1740 brain_26\NN\5462674 and_27\CC\1740 other_28\JJ\1740 body_29\NN\19128 compartments_30\NNS\13910384 ._31\.\1740
D005998_D000592 NONE nonketotic_0\JJ\1740 hyperglycinemia_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 <e2>disorder_4\NN\14034177 of_5\IN\1740 amino_6\NN\14621446 acid_7\NN\14818238 metabolism</e2>_8\NN\13526110 in_9\IN\13603305 which_10\WDT\1740 a_11\DT\13649268 defect_12\NN\14462666 in_13\IN\13603305 the_14\DT\1740 <e1>glycine</e1>_15\NN\14601829 cleavage_16\NN\24720 system_17\NN\3575240 leads_18\VBZ\1752884 to_19\TO\1740 an_20\DT\6697703 accumulation_21\NN\13497135 of_22\IN\1740 glycine_23\NN\14601829 in_24\IN\13603305 the_25\DT\1740 brain_26\NN\5462674 and_27\CC\1740 other_28\JJ\1740 body_29\NN\19128 compartments_30\NNS\13910384 ._31\.\1740
D005998_D000592 NONE nonketotic_0\JJ\1740 hyperglycinemia_1\NN\1740 is_2\VBZ\836236 a_3\DT\13649268 <e2>disorder_4\NN\14034177 of_5\IN\1740 amino_6\NN\14621446 acid_7\NN\14818238 metabolism</e2>_8\NN\13526110 in_9\IN\13603305 which_10\WDT\1740 a_11\DT\13649268 defect_12\NN\14462666 in_13\IN\13603305 the_14\DT\1740 glycine_15\NN\14601829 cleavage_16\NN\24720 system_17\NN\3575240 leads_18\VBZ\1752884 to_19\TO\1740 an_20\DT\6697703 accumulation_21\NN\13497135 of_22\IN\1740 <e1>glycine</e1>_23\NN\14601829 in_24\IN\13603305 the_25\DT\1740 brain_26\NN\5462674 and_27\CC\1740 other_28\JJ\1740 body_29\NN\19128 compartments_30\NNS\13910384 ._31\.\1740
D014635_D007805 NONE this_0\DT\1740 report_1\NN\6470073 describes_2\VBZ\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 mild_6\JJ\1740 <e2>language_7\NN\33020 delay</e2>_8\NN\15271008 and_9\CC\1740 mental_10\JJ\1740 retardation_11\NN\7296428 ,_12\,\1740 who_13\WP\8299493 was_14\VBD\836236 found_15\VBN\2426171 to_16\TO\1740 have_17\VB\2108377 nonketotic_18\JJ\1740 hyperglycinemia_19\NN\1740 following_20\VBG\1835496 her_21\PRP$\1740 presentation_22\NN\1027379 with_23\IN\1740 acute_24\JJ\1740 encephalopathy_25\JJ\1740 and_26\CC\1740 chorea_27\NN\14253124 shortly_28\RB\1740 after_29\IN\1740 initiation_30\NN\7450842 of_31\IN\1740 <e1>valproate</e1>_32\NN\1740 therapy_33\NN\657604 ._34\.\1740
D014635_D008607 NONE this_0\DT\1740 report_1\NN\6470073 describes_2\VBZ\1001294 a_3\DT\13649268 patient_4\NN\9898892 with_5\IN\1740 mild_6\JJ\1740 language_7\NN\33020 delay_8\NN\15271008 and_9\CC\1740 <e2>mental_10\JJ\1740 retardation</e2>_11\NN\7296428 ,_12\,\1740 who_13\WP\8299493 was_14\VBD\836236 found_15\VBN\2426171 to_16\TO\1740 have_17\VB\2108377 nonketotic_18\JJ\1740 hyperglycinemia_19\NN\1740 following_20\VBG\1835496 her_21\PRP$\1740 presentation_22\NN\1027379 with_23\IN\1740 acute_24\JJ\1740 encephalopathy_25\JJ\1740 and_26\CC\1740 chorea_27\NN\14253124 shortly_28\RB\1740 after_29\IN\1740 initiation_30\NN\7450842 of_31\IN\1740 <e1>valproate</e1>_32\NN\1740 therapy_33\NN\657604 ._34\.\1740
15580403
D012254_D006461 NONE adequate_0\JJ\1740 timing_1\NN\5044673 of_2\IN\1740 <e1>ribavirin</e1>_3\NN\2725367 reduction_4\NN\351485 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 <e2>hemolysis</e2>_8\NN\13509528 during_9\IN\1740 combination_10\NN\7951464 therapy_11\NN\657604 of_12\IN\1740 interferon_13\NN\2725367 and_14\CC\1740 ribavirin_15\NN\2725367 for_16\IN\1740 chronic_17\JJ\1740 hepatitis_18\NN\14127211 c._19\NN\1740
D012254_D006461 NONE adequate_0\JJ\1740 timing_1\NN\5044673 of_2\IN\1740 ribavirin_3\NN\2725367 reduction_4\NN\351485 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 <e2>hemolysis</e2>_8\NN\13509528 during_9\IN\1740 combination_10\NN\7951464 therapy_11\NN\657604 of_12\IN\1740 interferon_13\NN\2725367 and_14\CC\1740 <e1>ribavirin</e1>_15\NN\2725367 for_16\IN\1740 chronic_17\JJ\1740 hepatitis_18\NN\14127211 c._19\NN\1740
D012254_D006461 NONE in_0\IN\13603305 this_1\DT\1740 clinical_2\JJ\1740 retrospective_3\JJ\1740 cohort_4\NN\8184861 study_5\NN\635850 we_6\PRP\1740 have_7\VBP\2108377 examined_8\VBN\789138 the_9\DT\1740 suitable_10\JJ\1740 timing_11\NN\5044673 of_12\IN\1740 <e1>ribavirin</e1>_13\NN\2725367 reduction_14\NN\351485 in_15\IN\13603305 patients_16\NNS\9898892 with_17\IN\1740 <e2>hemolysis</e2>_18\NN\13509528 during_19\IN\1740 combination_20\NN\7951464 therapy_21\NN\657604 ._22\.\1740
D012254_D019698 NONE adequate_0\JJ\1740 timing_1\NN\5044673 of_2\IN\1740 <e1>ribavirin</e1>_3\NN\2725367 reduction_4\NN\351485 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 hemolysis_8\NN\13509528 during_9\IN\1740 combination_10\NN\7951464 therapy_11\NN\657604 of_12\IN\1740 interferon_13\NN\2725367 and_14\CC\1740 ribavirin_15\NN\2725367 for_16\IN\1740 <e2>chronic_17\JJ\1740 hepatitis_18\NN\14127211 c.</e2>_19\NN\1740
D012254_D019698 NONE adequate_0\JJ\1740 timing_1\NN\5044673 of_2\IN\1740 ribavirin_3\NN\2725367 reduction_4\NN\351485 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 hemolysis_8\NN\13509528 during_9\IN\1740 combination_10\NN\7951464 therapy_11\NN\657604 of_12\IN\1740 interferon_13\NN\2725367 and_14\CC\1740 <e1>ribavirin</e1>_15\NN\2725367 for_16\IN\1740 <e2>chronic_17\JJ\1740 hepatitis_18\NN\14127211 c.</e2>_19\NN\1740
D007372_D006461 NONE adequate_0\JJ\1740 timing_1\NN\5044673 of_2\IN\1740 ribavirin_3\NN\2725367 reduction_4\NN\351485 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 <e2>hemolysis</e2>_8\NN\13509528 during_9\IN\1740 combination_10\NN\7951464 therapy_11\NN\657604 of_12\IN\1740 <e1>interferon</e1>_13\NN\2725367 and_14\CC\1740 ribavirin_15\NN\2725367 for_16\IN\1740 chronic_17\JJ\1740 hepatitis_18\NN\14127211 c._19\NN\1740
D007372_D019698 NONE adequate_0\JJ\1740 timing_1\NN\5044673 of_2\IN\1740 ribavirin_3\NN\2725367 reduction_4\NN\351485 in_5\IN\13603305 patients_6\NNS\9898892 with_7\IN\1740 hemolysis_8\NN\13509528 during_9\IN\1740 combination_10\NN\7951464 therapy_11\NN\657604 of_12\IN\1740 <e1>interferon</e1>_13\NN\2725367 and_14\CC\1740 ribavirin_15\NN\2725367 for_16\IN\1740 <e2>chronic_17\JJ\1740 hepatitis_18\NN\14127211 c.</e2>_19\NN\1740
D007372_D000743 CID background_0\NN\4921011 :_1\:\1740 <e2>hemolytic_2\JJ\1740 anemia</e2>_3\NN\14189204 is_4\VBZ\836236 one_5\CD\13741022 of_6\IN\1740 the_7\DT\1740 major_8\JJ\1740 adverse_9\JJ\1740 events_10\NNS\23100 of_11\IN\1740 the_12\DT\1740 combination_13\NN\7951464 therapy_14\NN\657604 of_15\IN\1740 <e1>interferon</e1>_16\NN\2725367 and_17\CC\1740 ribavirin_18\NN\2725367 ._19\.\1740
D012254_D000743 CID background_0\NN\4921011 :_1\:\1740 <e2>hemolytic_2\JJ\1740 anemia</e2>_3\NN\14189204 is_4\VBZ\836236 one_5\CD\13741022 of_6\IN\1740 the_7\DT\1740 major_8\JJ\1740 adverse_9\JJ\1740 events_10\NNS\23100 of_11\IN\1740 the_12\DT\1740 combination_13\NN\7951464 therapy_14\NN\657604 of_15\IN\1740 interferon_16\NN\2725367 and_17\CC\1740 <e1>ribavirin</e1>_18\NN\2725367 ._19\.\1740
D012254_D000743 CID because_0\IN\1740 of_1\IN\1740 <e1>ribavirin-related</e1>_2\JJ\1740 <e2>hemolytic_3\JJ\1740 anemia</e2>_4\NN\14189204 ,_5\,\1740 dose_6\NN\3740161 reduction_7\NN\351485 is_8\VBZ\836236 a_9\DT\13649268 common_10\JJ\1740 event_11\NN\23100 in_12\IN\13603305 this_13\DT\1740 therapy_14\NN\657604 ._15\.\1740
D012254_D000740 NONE however_0\RB\1740 ,_1\,\1740 10_2\CD\13745420 of_3\IN\1740 37_4\CD\1740 patients_5\NNS\9898892 with_6\IN\1740 reduction_7\NN\351485 of_8\IN\1740 <e1>ribavirin</e1>_9\NN\2725367 could_10\MD\1740 not_11\RB\1740 continue_12\VB\2367363 combination_13\NN\7951464 therapy_14\NN\657604 because_15\IN\1740 their_16\PRP$\1740 <_17\XX\1740 8.5_18\CD\1740 g/dl_19\NN\1740 hemoglobin_20\NN\14888884 values_21\NNS\5941423 decreased_22\VBD\169651 to_23\TO\1740 or_24\CC\3541091 <e2>anemia-related</e2>_25\JJ\1740 severe_26\JJ\1740 side_27\NN\8630039 effects_28\NNS\13245626 occurred_29\VBD\2623529 (_30\-LRB-\1740 group_31\NN\2137 b_32\NN\1355326 )_33\-RRB-\1740 ._34\.\1740
12600698
C005435_D015837 NONE protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 <e1>edaravone</e1>_3\NN\1740 against_4\IN\1740 streptomycin-induced_5\JJ\1740 <e2>vestibulotoxicity</e2>_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 guinea_9\NN\13388245 pig_10\NN\2395003 ._11\.\1740
C005435_D015837 NONE this_0\DT\1740 study_1\NN\635850 investigated_2\VBD\644583 alleviation_3\NN\7492516 of_4\IN\1740 streptomycin-induced_5\JJ\1740 <e2>vestibulotoxicity</e2>_6\NN\1740 by_7\IN\1740 <e1>edaravone</e1>_8\NN\1740 in_9\IN\13603305 guinea_10\NN\13388245 pigs_11\NNS\2395003 ._12\.\1740
C005435_D015837 NONE these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 <e1>edaravone</e1>_4\NN\1740 suppresses_5\VBZ\2510337 streptomycin-induced_6\JJ\1740 <e2>vestibulotoxicity</e2>_7\NN\1740 ._8\.\1740
D013307_D015837 CID protective_0\JJ\1740 effect_1\NN\34213 of_2\IN\1740 edaravone_3\NN\1740 against_4\IN\1740 <e1>streptomycin-induced</e1>_5\JJ\1740 <e2>vestibulotoxicity</e2>_6\NN\1740 in_7\IN\13603305 the_8\DT\1740 guinea_9\NN\13388245 pig_10\NN\2395003 ._11\.\1740
D013307_D015837 CID this_0\DT\1740 study_1\NN\635850 investigated_2\VBD\644583 alleviation_3\NN\7492516 of_4\IN\1740 <e1>streptomycin-induced</e1>_5\JJ\1740 <e2>vestibulotoxicity</e2>_6\NN\1740 by_7\IN\1740 edaravone_8\NN\1740 in_9\IN\13603305 guinea_10\NN\13388245 pigs_11\NNS\2395003 ._12\.\1740
D013307_D015837 CID these_0\DT\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 edaravone_4\NN\1740 suppresses_5\VBZ\2510337 <e1>streptomycin-induced</e1>_6\JJ\1740 <e2>vestibulotoxicity</e2>_7\NN\1740 ._8\.\1740
C005435_D002544 NONE <e1>edaravone</e1>_0\NN\1740 ,_1\,\1740 a_2\DT\13649268 free_3\JJ\1740 radical_4\NN\9465459 scavenger_5\NN\14779550 ,_6\,\1740 has_7\VBZ\2108377 potent_8\JJ\1740 free_9\JJ\1740 radical_10\JJ\1740 quenching_11\NN\209943 action_12\NN\30358 and_13\CC\1740 is_14\VBZ\836236 used_15\VBN\1156834 in_16\IN\13603305 clinical_17\JJ\1740 practice_18\NN\407535 to_19\TO\1740 treat_20\VB\2376958 <e2>cerebral_21\JJ\1740 infarction</e2>_22\NN\14204950 ._23\.\1740
18541230
D011692_D009401 CID protective_0\JJ\1740 effects_1\NNS\13245626 of_2\IN\1740 antithrombin_3\NN\1740 on_4\IN\1740 <e1>puromycin_5\NN\1740 aminonucleoside</e1>_6\NN\1740 <e2>nephrosis</e2>_7\NN\14304060 in_8\IN\13603305 rats_9\NNS\2329401 ._10\.\1740
D011692_D009401 CID we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 antithrombin_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 plasma_8\NN\5398023 inhibitor_9\NN\20090 of_10\IN\1740 coagulation_11\NN\13518963 factors_12\NNS\7326557 ,_13\,\1740 in_14\IN\13603305 rats_15\NNS\2329401 with_16\IN\1740 <e1>puromycin_17\NN\1740 aminonucleoside-induced</e1>_18\JJ\1740 <e2>nephrosis</e2>_19\NN\14304060 ,_20\,\1740 which_21\WDT\1740 is_22\VBZ\836236 an_23\DT\6697703 experimental_24\JJ\1740 model_25\NN\5888929 of_26\IN\1740 human_27\JJ\1740 nephrotic_28\JJ\1740 syndrome_29\NN\5870365 ._30\.\1740
D011692_D009404 NONE we_0\PRP\1740 investigated_1\VBD\644583 the_2\DT\1740 effects_3\NNS\13245626 of_4\IN\1740 antithrombin_5\NN\1740 ,_6\,\1740 a_7\DT\13649268 plasma_8\NN\5398023 inhibitor_9\NN\20090 of_10\IN\1740 coagulation_11\NN\13518963 factors_12\NNS\7326557 ,_13\,\1740 in_14\IN\13603305 rats_15\NNS\2329401 with_16\IN\1740 <e1>puromycin_17\NN\1740 aminonucleoside-induced</e1>_18\JJ\1740 nephrosis_19\NN\14304060 ,_20\,\1740 which_21\WDT\1740 is_22\VBZ\836236 an_23\DT\6697703 experimental_24\JJ\1740 model_25\NN\5888929 of_26\IN\1740 human_27\JJ\1740 <e2>nephrotic_28\JJ\1740 syndrome</e2>_29\NN\5870365 ._30\.\1740
D011692_D009404 NONE these_0\DT\1740 findings_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 thrombin_4\NN\14735953 plays_5\VBZ\1072262 an_6\DT\6697703 important_7\JJ\1740 role_8\NN\719494 in_9\IN\13603305 the_10\DT\1740 pathogenesis_11\NN\13533470 of_12\IN\1740 <e1>puromycin_13\NN\1740 aminonucleoside-induced</e1>_14\JJ\1740 <e2>nephrotic_15\JJ\1740 syndrome</e2>_16\NN\5870365 ._17\.\1740
D011692_D006402 NONE treatment_0\NN\654885 with_1\IN\1740 antithrombin_2\NN\1740 attenuated_3\VBD\224901 the_4\DT\1740 <e1>puromycin_5\NN\1740 aminonucleoside-induced</e1>_6\JJ\1740 <e2>hematological_7\JJ\1740 abnormalities</e2>_8\NNS\14034177 ._9\.\1740
D011692_D007674 NONE <e1>puromycin_0\NN\1740 aminonucleoside-induced</e1>_1\JJ\1740 <e2>renal_2\JJ\1740 dysfunction</e2>_3\NN\14204950 and_4\CC\1740 hyperlipidemia_5\NN\14299637 were_6\VBD\836236 also_7\RB\1740 suppressed_8\VBN\2510337 ._9\.\1740
D011692_D006949 NONE <e1>puromycin_0\NN\1740 aminonucleoside-induced</e1>_1\JJ\1740 renal_2\JJ\1740 dysfunction_3\NN\14204950 and_4\CC\1740 <e2>hyperlipidemia</e2>_5\NN\14299637 were_6\VBD\836236 also_7\RB\1740 suppressed_8\VBN\2510337 ._9\.\1740
48362
D011802_D056486 CID <e1>quinidine</e1>_0\NN\2715941 <e2>hepatitis</e2>_1\NN\14127211 ._2\.\1740
D011802_D056486 CID we_0\PRP\1740 concluded_1\VBD\628491 that_2\IN\1740 this_3\DT\1740 patient_4\NN\9898892 had_5\VBD\2108377 <e1>quinidine</e1>_6\NN\2715941 <e2>hepatotoxicity</e2>_7\NN\1740 and_8\CC\1740 believe_9\VBP\686447 that_10\IN\1740 this_11\DT\1740 is_12\VBZ\836236 the_13\DT\1740 first_14\JJ\1740 case_15\NN\7283608 reported_16\VBN\831651 with_17\IN\1740 liver_18\NN\5298729 biopsy_19\NN\5739043 documentation_20\NN\6650070 ._21\.\1740
17263743
C009250_D006323 NONE <e2>cardiac_0\JJ\1740 arrest</e2>_1\NN\88481 in_2\IN\13603305 a_3\DT\13649268 child_4\NN\9622049 with_5\IN\1740 cerebral_6\JJ\1740 palsy_7\NN\14557898 undergoing_8\VBG\109660 <e1>sevoflurane</e1>_9\NN\1740 induction_10\NN\7450842 of_11\IN\1740 anesthesia_12\NN\14034177 after_13\IN\1740 preoperative_14\JJ\1740 clonidine_15\NN\2721160 ._16\.\1740
C009250_D002547 NONE cardiac_0\JJ\1740 arrest_1\NN\88481 in_2\IN\13603305 a_3\DT\13649268 child_4\NN\9622049 with_5\IN\1740 <e2>cerebral_6\JJ\1740 palsy</e2>_7\NN\14557898 undergoing_8\VBG\109660 <e1>sevoflurane</e1>_9\NN\1740 induction_10\NN\7450842 of_11\IN\1740 anesthesia_12\NN\14034177 after_13\IN\1740 preoperative_14\JJ\1740 clonidine_15\NN\2721160 ._16\.\1740
D003000_D006323 CID <e2>cardiac_0\JJ\1740 arrest</e2>_1\NN\88481 in_2\IN\13603305 a_3\DT\13649268 child_4\NN\9622049 with_5\IN\1740 cerebral_6\JJ\1740 palsy_7\NN\14557898 undergoing_8\VBG\109660 sevoflurane_9\NN\1740 induction_10\NN\7450842 of_11\IN\1740 anesthesia_12\NN\14034177 after_13\IN\1740 preoperative_14\JJ\1740 <e1>clonidine</e1>_15\NN\2721160 ._16\.\1740
D003000_D006323 CID there_0\EX\27167 are_1\VBP\836236 no_2\DT\7204911 previous_3\JJ\1740 reports_4\NNS\6470073 of_5\IN\1740 <e1>clonidine-associated</e1>_6\JJ\1740 <e2>cardiac_7\JJ\1740 arrest</e2>_8\NN\88481 in_9\IN\13603305 a_10\DT\13649268 child_11\NN\9622049 undergoing_12\VBG\109660 induction_13\NN\7450842 of_14\IN\1740 anesthesia_15\NN\14034177 ._16\.\1740
D003000_D002547 NONE cardiac_0\JJ\1740 arrest_1\NN\88481 in_2\IN\13603305 a_3\DT\13649268 child_4\NN\9622049 with_5\IN\1740 <e2>cerebral_6\JJ\1740 palsy</e2>_7\NN\14557898 undergoing_8\VBG\109660 sevoflurane_9\NN\1740 induction_10\NN\7450842 of_11\IN\1740 anesthesia_12\NN\14034177 after_13\IN\1740 preoperative_14\JJ\1740 <e1>clonidine</e1>_15\NN\2721160 ._16\.\1740
D003000_D002547 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 5-year-old_6\JJ\1740 child_7\NN\9622049 with_8\IN\1740 <e2>cerebral_9\JJ\1740 palsy</e2>_10\NN\14557898 and_11\CC\1740 seizure_12\VB\1740 disorder_13\NN\14034177 ,_14\,\1740 receiving_15\VBG\2210855 <e1>clonidine</e1>_16\NN\2721160 for_17\IN\1740 restlessness_18\NN\4773351 ,_19\,\1740 who_20\WP\8299493 presented_21\VBD\2137132 for_22\IN\1740 placement_23\NN\5074774 of_24\IN\1740 a_25\DT\13649268 baclofen_26\NN\1740 pump_27\NN\3736970 ._28\.\1740
D003000_D004827 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 5-year-old_6\JJ\1740 child_7\NN\9622049 with_8\IN\1740 cerebral_9\JJ\1740 palsy_10\NN\14557898 and_11\CC\1740 <e2>seizure_12\VB\1740 disorder</e2>_13\NN\14034177 ,_14\,\1740 receiving_15\VBG\2210855 <e1>clonidine</e1>_16\NN\2721160 for_17\IN\1740 restlessness_18\NN\4773351 ,_19\,\1740 who_20\WP\8299493 presented_21\VBD\2137132 for_22\IN\1740 placement_23\NN\5074774 of_24\IN\1740 a_25\DT\13649268 baclofen_26\NN\1740 pump_27\NN\3736970 ._28\.\1740
D003000_D011595 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 5-year-old_6\JJ\1740 child_7\NN\9622049 with_8\IN\1740 cerebral_9\JJ\1740 palsy_10\NN\14557898 and_11\CC\1740 seizure_12\VB\1740 disorder_13\NN\14034177 ,_14\,\1740 receiving_15\VBG\2210855 <e1>clonidine</e1>_16\NN\2721160 for_17\IN\1740 <e2>restlessness</e2>_18\NN\4773351 ,_19\,\1740 who_20\WP\8299493 presented_21\VBD\2137132 for_22\IN\1740 placement_23\NN\5074774 of_24\IN\1740 a_25\DT\13649268 baclofen_26\NN\1740 pump_27\NN\3736970 ._28\.\1740
D001418_D002547 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 5-year-old_6\JJ\1740 child_7\NN\9622049 with_8\IN\1740 <e2>cerebral_9\JJ\1740 palsy</e2>_10\NN\14557898 and_11\CC\1740 seizure_12\VB\1740 disorder_13\NN\14034177 ,_14\,\1740 receiving_15\VBG\2210855 clonidine_16\NN\2721160 for_17\IN\1740 restlessness_18\NN\4773351 ,_19\,\1740 who_20\WP\8299493 presented_21\VBD\2137132 for_22\IN\1740 placement_23\NN\5074774 of_24\IN\1740 a_25\DT\13649268 <e1>baclofen</e1>_26\NN\1740 pump_27\NN\3736970 ._28\.\1740
D001418_D004827 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 5-year-old_6\JJ\1740 child_7\NN\9622049 with_8\IN\1740 cerebral_9\JJ\1740 palsy_10\NN\14557898 and_11\CC\1740 <e2>seizure_12\VB\1740 disorder</e2>_13\NN\14034177 ,_14\,\1740 receiving_15\VBG\2210855 clonidine_16\NN\2721160 for_17\IN\1740 restlessness_18\NN\4773351 ,_19\,\1740 who_20\WP\8299493 presented_21\VBD\2137132 for_22\IN\1740 placement_23\NN\5074774 of_24\IN\1740 a_25\DT\13649268 <e1>baclofen</e1>_26\NN\1740 pump_27\NN\3736970 ._28\.\1740
D001418_D011595 NONE we_0\PRP\1740 present_1\VBP\2137132 a_2\DT\13649268 case_3\NN\7283608 of_4\IN\1740 a_5\DT\13649268 5-year-old_6\JJ\1740 child_7\NN\9622049 with_8\IN\1740 cerebral_9\JJ\1740 palsy_10\NN\14557898 and_11\CC\1740 seizure_12\VB\1740 disorder_13\NN\14034177 ,_14\,\1740 receiving_15\VBG\2210855 clonidine_16\NN\2721160 for_17\IN\1740 <e2>restlessness</e2>_18\NN\4773351 ,_19\,\1740 who_20\WP\8299493 presented_21\VBD\2137132 for_22\IN\1740 placement_23\NN\5074774 of_24\IN\1740 a_25\DT\13649268 <e1>baclofen</e1>_26\NN\1740 pump_27\NN\3736970 ._28\.\1740
D003000_D001008 NONE without_0\IN\1740 the_1\DT\1740 knowledge_2\NN\23100 of_3\IN\1740 the_4\DT\1740 medical_5\JJ\1740 personnel_6\NNS\8008335 ,_7\,\1740 the_8\DT\1740 patient_9\NN\9898892 's_10\POS\1740 mother_11\NN\10399491 administered_12\VBD\2436349 three_13\CD\13741022 doses_14\NNS\3740161 of_15\IN\1740 <e1>clonidine</e1>_16\NN\2721160 during_17\IN\1740 the_18\DT\1740 evening_19\NN\15164957 before_20\IN\1740 and_21\CC\1740 morning_22\NN\15113229 of_23\IN\1740 surgery_24\NN\6045562 to_25\TO\1740 reduce_26\VB\441445 <e2>anxiety</e2>_27\NN\14373582 ._28\.\1740
10910842
D011239_D018908 CID <e1>prednisolone-induced</e1>_0\JJ\1740 <e2>muscle_1\NN\5289601 dysfunction</e2>_2\NN\14204950 is_3\VBZ\836236 caused_4\VBN\1617192 more_5\RBR\1740 by_6\IN\1740 atrophy_7\NN\14299637 than_8\IN\1740 by_9\IN\1740 altered_10\JJ\1740 acetylcholine_11\NN\14807558 receptor_12\NN\5225602 expression_13\NN\4679549 ._14\.\1740
D011239_D001284 NONE <e1>prednisolone-induced</e1>_0\JJ\1740 muscle_1\NN\5289601 dysfunction_2\NN\14204950 is_3\VBZ\836236 caused_4\VBN\1617192 more_5\RBR\1740 by_6\IN\1740 <e2>atrophy</e2>_7\NN\14299637 than_8\IN\1740 by_9\IN\1740 altered_10\JJ\1740 acetylcholine_11\NN\14807558 receptor_12\NN\5225602 expression_13\NN\4679549 ._14\.\1740
D000109_D018908 NONE prednisolone-induced_0\JJ\1740 <e2>muscle_1\NN\5289601 dysfunction</e2>_2\NN\14204950 is_3\VBZ\836236 caused_4\VBN\1617192 more_5\RBR\1740 by_6\IN\1740 atrophy_7\NN\14299637 than_8\IN\1740 by_9\IN\1740 altered_10\JJ\1740 <e1>acetylcholine</e1>_11\NN\14807558 receptor_12\NN\5225602 expression_13\NN\4679549 ._14\.\1740
D000109_D001284 NONE prednisolone-induced_0\JJ\1740 muscle_1\NN\5289601 dysfunction_2\NN\14204950 is_3\VBZ\836236 caused_4\VBN\1617192 more_5\RBR\1740 by_6\IN\1740 <e2>atrophy</e2>_7\NN\14299637 than_8\IN\1740 by_9\IN\1740 altered_10\JJ\1740 <e1>acetylcholine</e1>_11\NN\14807558 receptor_12\NN\5225602 expression_13\NN\4679549 ._14\.\1740
D014403_D013746 NONE on_0\IN\1740 day_1\NNP\15154774 8_2\CD\13741022 ,_3\,\1740 the_4\DT\1740 nerve-evoked_5\JJ\1740 peak_6\NN\13758296 twitch_7\NN\14360459 tensions_8\NNS\14375890 ,_9\,\1740 <e2>tetanic</e2>_10\JJ\1740 tensions_11\NNS\14375890 ,_12\,\1740 and_13\CC\1740 fatigability_14\NN\5040275 ,_15\,\1740 and_16\CC\1740 the_17\DT\1740 dose-response_18\JJ\1740 curves_19\NNS\13863771 of_20\IN\1740 <e1>d-tubocurarine</e1>_21\NN\1740 in_22\IN\13603305 the_23\DT\1740 tibialis_24\NN\5289861 cranialis_25\NN\1740 muscle_26\NN\5289601 were_27\VBD\836236 measured_28\VBN\697589 in_29\FW\13603305 vivo_30\FW\1740 and_31\CC\1740 related_32\JJ\1740 to_33\TO\1740 muscle_34\NN\5289601 mass_35\NN\13575869 or_36\CC\3541091 expression_37\NN\4679549 of_38\IN\1740 achrs_39\NN\1740 ._40\.\1740
D011239_D009468 NONE our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 <e2>neuromuscular_5\JJ\1740 dysfunction</e2>_6\NN\14204950 after_7\IN\1740 <e1>prednisolone</e1>_8\NN\2721538 is_9\VBZ\836236 dose-dependent_10\JJ\1740 ,_11\,\1740 and_12\CC\1740 derives_13\VBZ\634472 primarily_14\RB\1740 from_15\IN\1740 muscle_16\NN\5289601 atrophy_17\NN\14299637 and_18\CC\1740 derives_19\VBZ\634472 less_20\RBR\1740 so_21\RB\1740 from_22\IN\1740 changes_23\NNS\7283608 in_24\IN\13603305 achr_25\NN\1740 expression_26\NN\4679549 ._27\.\1740
D011239_D009133 CID our_0\PRP$\1740 results_1\NNS\34213 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 neuromuscular_5\JJ\1740 dysfunction_6\NN\14204950 after_7\IN\1740 <e1>prednisolone</e1>_8\NN\2721538 is_9\VBZ\836236 dose-dependent_10\JJ\1740 ,_11\,\1740 and_12\CC\1740 derives_13\VBZ\634472 primarily_14\RB\1740 from_15\IN\1740 <e2>muscle_16\NN\5289601 atrophy</e2>_17\NN\14299637 and_18\CC\1740 derives_19\VBZ\634472 less_20\RBR\1740 so_21\RB\1740 from_22\IN\1740 changes_23\NNS\7283608 in_24\IN\13603305 achr_25\NN\1740 expression_26\NN\4679549 ._27\.\1740
D000109_D009133 NONE we_0\PRP\1740 suggest_1\VBP\1010118 that_2\IN\1740 the_3\DT\1740 observed_4\VBN\2163746 effects_5\NNS\13245626 are_6\VBP\836236 dose-dependent_7\JJ\1740 and_8\CC\1740 derive_9\JJ\1740 primarily_10\RB\1740 from_11\IN\1740 <e2>muscle_12\NN\5289601 atrophy</e2>_13\NN\14299637 and_14\CC\1740 derive_15\VBP\634472 less_16\JJR\1740 from_17\IN\1740 changes_18\NNS\7283608 in_19\IN\13603305 <e1>acetylcholine</e1>_20\NN\14807558 receptor_21\NN\5225602 expression_22\NN\4679549 ._23\.\1740
2750819
D008278_D020879 CID <e2>neuromuscular_0\JJ\1740 blockade</e2>_1\NN\952963 with_2\IN\1740 <e1>magnesium_3\NN\14625458 sulfate</e1>_4\NN\15010703 and_5\CC\1740 nifedipine_6\NN\2938514 ._7\.\1740
D008278_D020879 CID a_0\DT\13649268 patient_1\NN\9898892 who_2\WP\8299493 received_3\VBD\2210855 tocolysis_4\NN\1740 with_5\IN\1740 nifedipine_6\NN\2938514 developed_7\VBD\1753788 <e2>neuromuscular_8\JJ\1740 blockade</e2>_9\NN\952963 after_10\IN\1740 500_11\CD\13745420 mg_12\NN\13717155 of_13\IN\1740 <e1>magnesium_14\NN\14625458 sulfate</e1>_15\NN\15010703 was_16\VBD\836236 administered_17\VBN\2436349 ._18\.\1740
D009543_D020879 CID <e2>neuromuscular_0\JJ\1740 blockade</e2>_1\NN\952963 with_2\IN\1740 magnesium_3\NN\14625458 sulfate_4\NN\15010703 and_5\CC\1740 <e1>nifedipine</e1>_6\NN\2938514 ._7\.\1740
D009543_D020879 CID a_0\DT\13649268 patient_1\NN\9898892 who_2\WP\8299493 received_3\VBD\2210855 tocolysis_4\NN\1740 with_5\IN\1740 <e1>nifedipine</e1>_6\NN\2938514 developed_7\VBD\1753788 <e2>neuromuscular_8\JJ\1740 blockade</e2>_9\NN\952963 after_10\IN\1740 500_11\CD\13745420 mg_12\NN\13717155 of_13\IN\1740 magnesium_14\NN\14625458 sulfate_15\NN\15010703 was_16\VBD\836236 administered_17\VBN\2436349 ._18\.\1740
D009543_D064420 NONE this_0\DT\1740 reaction_1\NN\13446390 demonstrates_2\VBZ\2137132 that_3\IN\1740 <e1>nifedipine</e1>_4\NN\2938514 can_5\MD\3094503 seriously_6\RB\1740 potentiate_7\VB\229605 the_8\DT\1740 <e2>toxicity</e2>_9\NN\13576101 of_10\IN\1740 magnesium_11\NN\14625458 ._12\.\1740
D008274_D064420 NONE this_0\DT\1740 reaction_1\NN\13446390 demonstrates_2\VBZ\2137132 that_3\IN\1740 nifedipine_4\NN\2938514 can_5\MD\3094503 seriously_6\RB\1740 potentiate_7\VB\229605 the_8\DT\1740 <e2>toxicity</e2>_9\NN\13576101 of_10\IN\1740 <e1>magnesium</e1>_11\NN\14625458 ._12\.\1740
8494478
D002939_D007674 NONE <e1>ciprofloxacin-induced</e1>_0\JJ\1740 <e2>nephrotoxicity</e2>_1\NN\1740 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 cancer_5\NN\14239425 ._6\.\1740
D002939_D007674 NONE <e2>nephrotoxicity</e2>_0\NN\1740 associated_1\VBN\628491 with_2\IN\1740 <e1>ciprofloxacin</e1>_3\NN\2716866 is_4\VBZ\836236 uncommon_5\JJ\1740 ._6\.\1740
D002939_D009369 NONE <e1>ciprofloxacin-induced</e1>_0\JJ\1740 nephrotoxicity_1\NN\1740 in_2\IN\13603305 patients_3\NNS\9898892 with_4\IN\1740 <e2>cancer</e2>_5\NN\14239425 ._6\.\1740
D002939_D009369 NONE five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 <e2>cancer</e2>_3\NN\14239425 who_4\WP\8299493 developed_5\VBD\1753788 acute_6\JJ\1740 renal_7\JJ\1740 failure_8\NN\66216 that_9\WDT\1740 followed_10\VBD\1835496 treatment_11\NN\654885 with_12\IN\1740 <e1>ciprofloxacin</e1>_13\NN\2716866 are_14\VBP\836236 described_15\VBN\1001294 and_16\CC\1740 an_17\DT\6697703 additional_18\JJ\1740 15_19\CD\13745420 cases_20\NNS\7283608 reported_21\VBN\831651 in_22\IN\13603305 the_23\DT\1740 literature_24\NN\6362953 are_25\VBP\836236 reviewed_26\VBN\644583 ._27\.\1740
D002939_D058186 CID five_0\CD\13741022 patients_1\NNS\9898892 with_2\IN\1740 cancer_3\NN\14239425 who_4\WP\8299493 developed_5\VBD\1753788 <e2>acute_6\JJ\1740 renal_7\JJ\1740 failure</e2>_8\NN\66216 that_9\WDT\1740 followed_10\VBD\1835496 treatment_11\NN\654885 with_12\IN\1740 <e1>ciprofloxacin</e1>_13\NN\2716866 are_14\VBP\836236 described_15\VBN\1001294 and_16\CC\1740 an_17\DT\6697703 additional_18\JJ\1740 15_19\CD\13745420 cases_20\NNS\7283608 reported_21\VBN\831651 in_22\IN\13603305 the_23\DT\1740 literature_24\NN\6362953 are_25\VBP\836236 reviewed_26\VBN\644583 ._27\.\1740
D002939_D058186 CID an_0\DT\6697703 improvement_1\NN\7359599 in_2\IN\13603305 renal_3\JJ\1740 function_4\NN\13783581 that_5\WDT\1740 followed_6\VBD\1835496 the_7\DT\1740 discontinuation_8\NN\209943 of_9\IN\1740 the_10\DT\1740 offending_11\NN\1740 antibiotic_12\JJ\1740 supports_13\VBZ\2199590 the_14\DT\1740 presumptive_15\JJ\1740 diagnosis_16\NN\152018 of_17\IN\1740 <e1>ciprofloxacin-induced</e1>_18\JJ\1740 <e2>acute_19\JJ\1740 renal_20\JJ\1740 failure</e2>_21\NN\66216 ._22\.\1740
10524660
D005996_D020326 CID <e1>glyceryl_0\NN\14621446 trinitrate</e1>_1\NN\1740 induces_2\VBZ\1627355 attacks_3\NNS\955060 of_4\IN\1740 <e2>migraine_5\NN\14326607 without_6\IN\1740 aura</e2>_7\NN\14299637 in_8\IN\13603305 sufferers_9\NNS\9630641 of_10\IN\1740 migraine_11\NN\14326607 with_12\IN\1740 aura_13\NN\14299637 ._14\.\1740
D005996_D020325 NONE <e1>glyceryl_0\NN\14621446 trinitrate</e1>_1\NN\1740 induces_2\VBZ\1627355 attacks_3\NNS\955060 of_4\IN\1740 migraine_5\NN\14326607 without_6\IN\1740 aura_7\NN\14299637 in_8\IN\13603305 sufferers_9\NNS\9630641 of_10\IN\1740 <e2>migraine_11\NN\14326607 with_12\IN\1740 aura</e2>_13\NN\14299637 ._14\.\1740
D005996_D020325 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 clarify_3\VB\939277 whether_4\IN\1740 the_5\DT\1740 same_6\JJ\1740 is_7\VBZ\836236 true_8\JJ\1740 for_9\IN\1740 <e2>migraine_10\NN\14326607 with_11\IN\1740 aura</e2>_12\NN\14299637 ,_13\,\1740 in_14\IN\13603305 the_15\DT\1740 present_16\JJ\1740 study_17\NN\635850 we_18\PRP\1740 examined_19\VBD\789138 the_20\DT\1740 headache_21\NN\5829480 response_22\NN\11410625 to_23\TO\1740 intravenous_24\JJ\1740 infusion_25\NN\14589223 of_26\IN\1740 <e1>glyceryl_27\NN\14621446 trinitrate</e1>_28\NN\1740 (_29\-LRB-\1740 gtn_30\NN\1740 )_31\-RRB-\1740 (_32\-LRB-\1740 0.5_33\CD\1740 microg/kg/min_34\NN\1740 for_35\IN\1740 20_36\CD\13745420 min_37\NN\15154774 )_38\-RRB-\1740 in_39\IN\13603305 12_40\CD\13745420 sufferers_41\NNS\9630641 of_42\IN\1740 migraine_43\NN\14326607 with_44\IN\1740 aura_45\NN\14299637 ._46\.\1740
D005996_D020325 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 clarify_3\VB\939277 whether_4\IN\1740 the_5\DT\1740 same_6\JJ\1740 is_7\VBZ\836236 true_8\JJ\1740 for_9\IN\1740 migraine_10\NN\14326607 with_11\IN\1740 aura_12\NN\14299637 ,_13\,\1740 in_14\IN\13603305 the_15\DT\1740 present_16\JJ\1740 study_17\NN\635850 we_18\PRP\1740 examined_19\VBD\789138 the_20\DT\1740 headache_21\NN\5829480 response_22\NN\11410625 to_23\TO\1740 intravenous_24\JJ\1740 infusion_25\NN\14589223 of_26\IN\1740 <e1>glyceryl_27\NN\14621446 trinitrate</e1>_28\NN\1740 (_29\-LRB-\1740 gtn_30\NN\1740 )_31\-RRB-\1740 (_32\-LRB-\1740 0.5_33\CD\1740 microg/kg/min_34\NN\1740 for_35\IN\1740 20_36\CD\13745420 min_37\NN\15154774 )_38\-RRB-\1740 in_39\IN\13603305 12_40\CD\13745420 sufferers_41\NNS\9630641 of_42\IN\1740 <e2>migraine_43\NN\14326607 with_44\IN\1740 aura</e2>_45\NN\14299637 ._46\.\1740
D005996_D020325 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 clarify_3\VB\939277 whether_4\IN\1740 the_5\DT\1740 same_6\JJ\1740 is_7\VBZ\836236 true_8\JJ\1740 for_9\IN\1740 <e2>migraine_10\NN\14326607 with_11\IN\1740 aura</e2>_12\NN\14299637 ,_13\,\1740 in_14\IN\13603305 the_15\DT\1740 present_16\JJ\1740 study_17\NN\635850 we_18\PRP\1740 examined_19\VBD\789138 the_20\DT\1740 headache_21\NN\5829480 response_22\NN\11410625 to_23\TO\1740 intravenous_24\JJ\1740 infusion_25\NN\14589223 of_26\IN\1740 glyceryl_27\NN\14621446 trinitrate_28\NN\1740 (_29\-LRB-\1740 <e1>gtn</e1>_30\NN\1740 )_31\-RRB-\1740 (_32\-LRB-\1740 0.5_33\CD\1740 microg/kg/min_34\NN\1740 for_35\IN\1740 20_36\CD\13745420 min_37\NN\15154774 )_38\-RRB-\1740 in_39\IN\13603305 12_40\CD\13745420 sufferers_41\NNS\9630641 of_42\IN\1740 migraine_43\NN\14326607 with_44\IN\1740 aura_45\NN\14299637 ._46\.\1740
D005996_D020325 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 clarify_3\VB\939277 whether_4\IN\1740 the_5\DT\1740 same_6\JJ\1740 is_7\VBZ\836236 true_8\JJ\1740 for_9\IN\1740 migraine_10\NN\14326607 with_11\IN\1740 aura_12\NN\14299637 ,_13\,\1740 in_14\IN\13603305 the_15\DT\1740 present_16\JJ\1740 study_17\NN\635850 we_18\PRP\1740 examined_19\VBD\789138 the_20\DT\1740 headache_21\NN\5829480 response_22\NN\11410625 to_23\TO\1740 intravenous_24\JJ\1740 infusion_25\NN\14589223 of_26\IN\1740 glyceryl_27\NN\14621446 trinitrate_28\NN\1740 (_29\-LRB-\1740 <e1>gtn</e1>_30\NN\1740 )_31\-RRB-\1740 (_32\-LRB-\1740 0.5_33\CD\1740 microg/kg/min_34\NN\1740 for_35\IN\1740 20_36\CD\13745420 min_37\NN\15154774 )_38\-RRB-\1740 in_39\IN\13603305 12_40\CD\13745420 sufferers_41\NNS\9630641 of_42\IN\1740 <e2>migraine_43\NN\14326607 with_44\IN\1740 aura</e2>_45\NN\14299637 ._46\.\1740
D009569_D010146 NONE in_0\IN\13603305 recent_1\JJ\1740 years_2\NNS\15144371 ,_3\,\1740 increasing_4\VBG\169651 evidence_5\NN\5816287 has_6\VBZ\2108377 suggested_7\VBN\1010118 that_8\IN\1740 the_9\DT\1740 messenger_10\NN\9629752 molecule_11\NN\9465459 <e1>nitric_12\JJ\1740 oxide</e1>_13\NN\14818238 (_14\-LRB-\1740 no_15\NN\7204911 )_16\-RRB-\1740 is_17\VBZ\836236 involved_18\VBN\2676054 in_19\IN\13603305 <e2>pain</e2>_20\NN\14299637 mechanisms_21\NNS\13446390 of_22\IN\1740 migraine_23\NN\14326607 without_24\IN\1740 aura_25\NN\14299637 ._26\.\1740
D009569_D010146 NONE in_0\IN\13603305 recent_1\JJ\1740 years_2\NNS\15144371 ,_3\,\1740 increasing_4\VBG\169651 evidence_5\NN\5816287 has_6\VBZ\2108377 suggested_7\VBN\1010118 that_8\IN\1740 the_9\DT\1740 messenger_10\NN\9629752 molecule_11\NN\9465459 nitric_12\JJ\1740 oxide_13\NN\14818238 (_14\-LRB-\1740 <e1>no</e1>_15\NN\7204911 )_16\-RRB-\1740 is_17\VBZ\836236 involved_18\VBN\2676054 in_19\IN\13603305 <e2>pain</e2>_20\NN\14299637 mechanisms_21\NNS\13446390 of_22\IN\1740 migraine_23\NN\14326607 without_24\IN\1740 aura_25\NN\14299637 ._26\.\1740
D009569_D010146 NONE the_0\DT\1740 results_1\NNS\34213 therefore_2\RB\1740 suggest_3\VBP\1010118 that_4\IN\1740 <e1>no</e1>_5\NN\7204911 is_6\VBZ\836236 involved_7\VBN\2676054 in_8\IN\13603305 the_9\DT\1740 <e2>pain</e2>_10\NN\14299637 mechanisms_11\NNS\13446390 of_12\IN\1740 migraine_13\NN\14326607 with_14\IN\1740 aura_15\NN\14299637 ._16\.\1740
D009569_D020326 CID in_0\IN\13603305 recent_1\JJ\1740 years_2\NNS\15144371 ,_3\,\1740 increasing_4\VBG\169651 evidence_5\NN\5816287 has_6\VBZ\2108377 suggested_7\VBN\1010118 that_8\IN\1740 the_9\DT\1740 messenger_10\NN\9629752 molecule_11\NN\9465459 <e1>nitric_12\JJ\1740 oxide</e1>_13\NN\14818238 (_14\-LRB-\1740 no_15\NN\7204911 )_16\-RRB-\1740 is_17\VBZ\836236 involved_18\VBN\2676054 in_19\IN\13603305 pain_20\NN\14299637 mechanisms_21\NNS\13446390 of_22\IN\1740 <e2>migraine_23\NN\14326607 without_24\IN\1740 aura</e2>_25\NN\14299637 ._26\.\1740
D009569_D020326 CID in_0\IN\13603305 recent_1\JJ\1740 years_2\NNS\15144371 ,_3\,\1740 increasing_4\VBG\169651 evidence_5\NN\5816287 has_6\VBZ\2108377 suggested_7\VBN\1010118 that_8\IN\1740 the_9\DT\1740 messenger_10\NN\9629752 molecule_11\NN\9465459 nitric_12\JJ\1740 oxide_13\NN\14818238 (_14\-LRB-\1740 <e1>no</e1>_15\NN\7204911 )_16\-RRB-\1740 is_17\VBZ\836236 involved_18\VBN\2676054 in_19\IN\13603305 pain_20\NN\14299637 mechanisms_21\NNS\13446390 of_22\IN\1740 <e2>migraine_23\NN\14326607 without_24\IN\1740 aura</e2>_25\NN\14299637 ._26\.\1740
D005996_D006261 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 clarify_3\VB\939277 whether_4\IN\1740 the_5\DT\1740 same_6\JJ\1740 is_7\VBZ\836236 true_8\JJ\1740 for_9\IN\1740 migraine_10\NN\14326607 with_11\IN\1740 aura_12\NN\14299637 ,_13\,\1740 in_14\IN\13603305 the_15\DT\1740 present_16\JJ\1740 study_17\NN\635850 we_18\PRP\1740 examined_19\VBD\789138 the_20\DT\1740 <e2>headache</e2>_21\NN\5829480 response_22\NN\11410625 to_23\TO\1740 intravenous_24\JJ\1740 infusion_25\NN\14589223 of_26\IN\1740 <e1>glyceryl_27\NN\14621446 trinitrate</e1>_28\NN\1740 (_29\-LRB-\1740 gtn_30\NN\1740 )_31\-RRB-\1740 (_32\-LRB-\1740 0.5_33\CD\1740 microg/kg/min_34\NN\1740 for_35\IN\1740 20_36\CD\13745420 min_37\NN\15154774 )_38\-RRB-\1740 in_39\IN\13603305 12_40\CD\13745420 sufferers_41\NNS\9630641 of_42\IN\1740 migraine_43\NN\14326607 with_44\IN\1740 aura_45\NN\14299637 ._46\.\1740
D005996_D006261 NONE in_0\IN\13603305 order_1\NN\7168131 to_2\TO\1740 clarify_3\VB\939277 whether_4\IN\1740 the_5\DT\1740 same_6\JJ\1740 is_7\VBZ\836236 true_8\JJ\1740 for_9\IN\1740 migraine_10\NN\14326607 with_11\IN\1740 aura_12\NN\14299637 ,_13\,\1740 in_14\IN\13603305 the_15\DT\1740 present_16\JJ\1740 study_17\NN\635850 we_18\PRP\1740 examined_19\VBD\789138 the_20\DT\1740 <e2>headache</e2>_21\NN\5829480 response_22\NN\11410625 to_23\TO\1740 intravenous_24\JJ\1740 infusion_25\NN\14589223 of_26\IN\1740 glyceryl_27\NN\14621446 trinitrate_28\NN\1740 (_29\-LRB-\1740 <e1>gtn</e1>_30\NN\1740 )_31\-RRB-\1740 (_32\-LRB-\1740 0.5_33\CD\1740 microg/kg/min_34\NN\1740 for_35\IN\1740 20_36\CD\13745420 min_37\NN\15154774 )_38\-RRB-\1740 in_39\IN\13603305 12_40\CD\13745420 sufferers_41\NNS\9630641 of_42\IN\1740 migraine_43\NN\14326607 with_44\IN\1740 aura_45\NN\14299637 ._46\.\1740
D005996_D006261 NONE <e2>headache</e2>_0\NNP\5829480 was_1\VBD\836236 more_2\RBR\1740 severe_3\JJ\1740 in_4\IN\13603305 migraineurs_5\NNS\1740 than_6\IN\1740 in_7\IN\13603305 the_8\DT\1740 controls_9\NNS\5190804 during_10\IN\1740 and_11\CC\1740 immediately_12\RB\1740 after_13\IN\1740 <e1>gtn</e1>_14\NN\1740 infusion_15\NN\14589223 (_16\-LRB-\1740 p=0.037_17\NN\1740 )_18\-RRB-\1740 as_19\RB\1740 well_20\RB\1740 as_21\IN\14622893 during_22\IN\1740 the_23\DT\1740 following_24\VBG\1835496 11_25\CD\13745420 h_26\NN\14622893 (_27\-LRB-\1740 p_28\NN\14622893 =_29\JJ\1740 0.008_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D005996_D006261 NONE in_0\IN\13603305 the_1\DT\1740 controls_2\NNS\5190804 ,_3\,\1740 the_4\DT\1740 <e1>gtn-induced</e1>_5\JJ\1740 <e2>headache</e2>_6\NN\5829480 gradually_7\RB\1740 disappeared_8\VBD\2609764 ,_9\,\1740 whereas_10\IN\1740 in_11\IN\13603305 migraineurs_12\NNS\1740 peak_13\NN\13758296 headache_14\NN\5829480 intensity_15\NN\5090441 occurred_16\VBD\2623529 at_17\IN\14622893 a_18\DT\13649268 mean_19\NN\6021761 time_20\NN\7308889 of_21\IN\1740 240_22\CD\1740 min_23\NN\15154774 post-infusion_24\NN\1740 ._25\.\1740
D005996_D006261 NONE in_0\IN\13603305 the_1\DT\1740 controls_2\NNS\5190804 ,_3\,\1740 the_4\DT\1740 <e1>gtn-induced</e1>_5\JJ\1740 headache_6\NN\5829480 gradually_7\RB\1740 disappeared_8\VBD\2609764 ,_9\,\1740 whereas_10\IN\1740 in_11\IN\13603305 migraineurs_12\NNS\1740 peak_13\NN\13758296 <e2>headache</e2>_14\NN\5829480 intensity_15\NN\5090441 occurred_16\VBD\2623529 at_17\IN\14622893 a_18\DT\13649268 mean_19\NN\6021761 time_20\NN\7308889 of_21\IN\1740 240_22\CD\1740 min_23\NN\15154774 post-infusion_24\NN\1740 ._25\.\1740
D005996_D008881 NONE headache_0\NNP\5829480 was_1\VBD\836236 more_2\RBR\1740 severe_3\JJ\1740 in_4\IN\13603305 <e2>migraineurs</e2>_5\NNS\1740 than_6\IN\1740 in_7\IN\13603305 the_8\DT\1740 controls_9\NNS\5190804 during_10\IN\1740 and_11\CC\1740 immediately_12\RB\1740 after_13\IN\1740 <e1>gtn</e1>_14\NN\1740 infusion_15\NN\14589223 (_16\-LRB-\1740 p=0.037_17\NN\1740 )_18\-RRB-\1740 as_19\RB\1740 well_20\RB\1740 as_21\IN\14622893 during_22\IN\1740 the_23\DT\1740 following_24\VBG\1835496 11_25\CD\13745420 h_26\NN\14622893 (_27\-LRB-\1740 p_28\NN\14622893 =_29\JJ\1740 0.008_30\CD\1740 )_31\-RRB-\1740 ._32\.\1740
D005996_D008881 NONE in_0\IN\13603305 the_1\DT\1740 controls_2\NNS\5190804 ,_3\,\1740 the_4\DT\1740 <e1>gtn-induced</e1>_5\JJ\1740 headache_6\NN\5829480 gradually_7\RB\1740 disappeared_8\VBD\2609764 ,_9\,\1740 whereas_10\IN\1740 in_11\IN\13603305 <e2>migraineurs</e2>_12\NNS\1740 peak_13\NN\13758296 headache_14\NN\5829480 intensity_15\NN\5090441 occurred_16\VBD\2623529 at_17\IN\14622893 a_18\DT\13649268 mean_19\NN\6021761 time_20\NN\7308889 of_21\IN\1740 240_22\CD\1740 min_23\NN\15154774 post-infusion_24\NN\1740 ._25\.\1740
D009569_D020325 NONE the_0\DT\1740 results_1\NNS\34213 therefore_2\RB\1740 suggest_3\VBP\1010118 that_4\IN\1740 <e1>no</e1>_5\NN\7204911 is_6\VBZ\836236 involved_7\VBN\2676054 in_8\IN\13603305 the_9\DT\1740 pain_10\NN\14299637 mechanisms_11\NNS\13446390 of_12\IN\1740 <e2>migraine_13\NN\14326607 with_14\IN\1740 aura</e2>_15\NN\14299637 ._16\.\1740
D009569_D020325 NONE since_0\IN\1740 cortical_1\JJ\1740 spreading_2\NN\7311115 depression_3\NN\14373582 has_4\VBZ\2108377 been_5\VBN\836236 shown_6\VBN\2137132 to_7\TO\1740 liberate_8\VB\146138 <e1>no</e1>_9\NN\7204911 in_10\IN\13603305 animals_11\NNS\4475 ,_12\,\1740 this_13\DT\1740 finding_14\NN\43195 may_15\MD\15209706 help_16\VB\2556126 our_17\PRP$\1740 understanding_18\NN\5804793 of_19\IN\1740 the_20\DT\1740 coupling_21\NN\3091374 between_22\IN\1740 cortical_23\JJ\1740 spreading_24\NN\7311115 depression_25\NN\14373582 and_26\CC\1740 headache_27\NN\5829480 in_28\IN\13603305 <e2>migraine_29\NN\14326607 with_30\IN\1740 aura</e2>_31\NN\14299637 ._32\.\1740
D009569_D003866 NONE since_0\IN\1740 cortical_1\JJ\1740 spreading_2\NN\7311115 <e2>depression</e2>_3\NN\14373582 has_4\VBZ\2108377 been_5\VBN\836236 shown_6\VBN\2137132 to_7\TO\1740 liberate_8\VB\146138 <e1>no</e1>_9\NN\7204911 in_10\IN\13603305 animals_11\NNS\4475 ,_12\,\1740 this_13\DT\1740 finding_14\NN\43195 may_15\MD\15209706 help_16\VB\2556126 our_17\PRP$\1740 understanding_18\NN\5804793 of_19\IN\1740 the_20\DT\1740 coupling_21\NN\3091374 between_22\IN\1740 cortical_23\JJ\1740 spreading_24\NN\7311115 depression_25\NN\14373582 and_26\CC\1740 headache_27\NN\5829480 in_28\IN\13603305 migraine_29\NN\14326607 with_30\IN\1740 aura_31\NN\14299637 ._32\.\1740
D009569_D003866 NONE since_0\IN\1740 cortical_1\JJ\1740 spreading_2\NN\7311115 depression_3\NN\14373582 has_4\VBZ\2108377 been_5\VBN\836236 shown_6\VBN\2137132 to_7\TO\1740 liberate_8\VB\146138 <e1>no</e1>_9\NN\7204911 in_10\IN\13603305 animals_11\NNS\4475 ,_12\,\1740 this_13\DT\1740 finding_14\NN\43195 may_15\MD\15209706 help_16\VB\2556126 our_17\PRP$\1740 understanding_18\NN\5804793 of_19\IN\1740 the_20\DT\1740 coupling_21\NN\3091374 between_22\IN\1740 cortical_23\JJ\1740 spreading_24\NN\7311115 <e2>depression</e2>_25\NN\14373582 and_26\CC\1740 headache_27\NN\5829480 in_28\IN\13603305 migraine_29\NN\14326607 with_30\IN\1740 aura_31\NN\14299637 ._32\.\1740
D009569_D006261 NONE since_0\IN\1740 cortical_1\JJ\1740 spreading_2\NN\7311115 depression_3\NN\14373582 has_4\VBZ\2108377 been_5\VBN\836236 shown_6\VBN\2137132 to_7\TO\1740 liberate_8\VB\146138 <e1>no</e1>_9\NN\7204911 in_10\IN\13603305 animals_11\NNS\4475 ,_12\,\1740 this_13\DT\1740 finding_14\NN\43195 may_15\MD\15209706 help_16\VB\2556126 our_17\PRP$\1740 understanding_18\NN\5804793 of_19\IN\1740 the_20\DT\1740 coupling_21\NN\3091374 between_22\IN\1740 cortical_23\JJ\1740 spreading_24\NN\7311115 depression_25\NN\14373582 and_26\CC\1740 <e2>headache</e2>_27\NN\5829480 in_28\IN\13603305 migraine_29\NN\14326607 with_30\IN\1740 aura_31\NN\14299637 ._32\.\1740
9154656
D000809_D009404 NONE plasma_0\NN\5398023 concentration_1\NN\4916342 and_2\CC\1740 urine_3\NN\14853947 excretion_4\NN\13466586 of_5\IN\1740 the_6\DT\1740 <e1>renin-angiotensin</e1>_7\JJ\1740 system_8\NN\3575240 proteins_9\NNS\14944888 are_10\VBP\836236 altered_11\VBN\126264 in_12\IN\13603305 rats_13\NNS\2329401 with_14\IN\1740 <e2>nephrotic_15\JJ\1740 syndrome</e2>_16\NN\5870365 (_17\-LRB-\1740 ns_18\NN\14622893 )_19\-RRB-\1740 ._20\.\1740
D000809_D009404 NONE plasma_0\NN\5398023 concentration_1\NN\4916342 and_2\CC\1740 urine_3\NN\14853947 excretion_4\NN\13466586 of_5\IN\1740 the_6\DT\1740 <e1>renin-angiotensin</e1>_7\JJ\1740 system_8\NN\3575240 proteins_9\NNS\14944888 are_10\VBP\836236 altered_11\VBN\126264 in_12\IN\13603305 rats_13\NNS\2329401 with_14\IN\1740 nephrotic_15\JJ\1740 syndrome_16\NN\5870365 (_17\-LRB-\1740 <e2>ns</e2>_18\NN\14622893 )_19\-RRB-\1740 ._20\.\1740
D011692_D009404 CID <e2>ns</e2>_0\NN\14622893 was_1\VBD\836236 induced_2\VBN\1627355 by_3\IN\1740 a_4\DT\13649268 single_5\JJ\1740 injection_6\NN\320852 of_7\IN\1740 <e1>puromycin_8\NN\1740 amino-nucleoside</e1>_9\NN\1740 (_10\-LRB-\1740 pan_11\NN\3101986 )_12\-RRB-\1740 ._13\.\1740
D011692_D009404 CID <e2>ns</e2>_0\NN\14622893 was_1\VBD\836236 induced_2\VBN\1627355 by_3\IN\1740 a_4\DT\13649268 single_5\JJ\1740 injection_6\NN\320852 of_7\IN\1740 puromycin_8\NN\1740 amino-nucleoside_9\NN\1740 (_10\-LRB-\1740 <e1>pan</e1>_11\NN\3101986 )_12\-RRB-\1740 ._13\.\1740
D011692_D009404 CID although_0\IN\1740 a_1\DT\13649268 great_2\JJ\1740 urinary_3\JJ\1740 excretion_4\NN\13466586 and_5\CC\1740 half-normal_6\JJ\1740 plasma_7\NN\5398023 levels_8\NNS\4916342 of_9\IN\1740 ao_10\NN\1740 were_11\VBD\836236 observed_12\VBN\2163746 on_13\IN\1740 day_14\NN\15154774 6_15\CD\13741022 after_16\IN\1740 <e1>pan</e1>_17\NN\3101986 injection_18\NN\320852 ,_19\,\1740 when_20\WRB\1740 <e2>ns</e2>_21\NN\14622893 was_22\VBD\836236 clearly_23\RB\1740 established_24\VBN\2426171 ,_25\,\1740 hepatic_26\JJ\1740 ao_27\NN\1740 mrna_28\NN\14832193 levels_29\NNS\4916342 did_30\VBD\1640855 not_31\RB\1740 change_32\VB\46534 ._33\.\1740
D011692_D009404 CID these_0\DT\1740 data_1\NNS\7951464 suggest_2\VBP\1010118 that_3\IN\1740 the_4\DT\1740 hepatic_5\JJ\1740 and_6\CC\1740 extrahepatic_7\JJ\1740 ao_8\NN\1740 mrna_9\NN\14832193 levels_10\NNS\4916342 are_11\VBP\836236 unaltered_12\JJ\1740 during_13\IN\1740 the_14\DT\1740 development_15\NN\248977 of_16\IN\1740 the_17\DT\1740 acute_18\JJ\1740 <e2>ns</e2>_19\NN\14622893 induced_20\VBN\1627355 by_21\IN\1740 <e1>pan</e1>_22\NN\3101986 ._23\.\1740
7619765
D005047_D009203 CID <e1>etoposide-related</e1>_0\JJ\1740 <e2>myocardial_1\JJ\1740 infarction</e2>_2\NN\14204950 ._3\.\1740
D005047_D009203 CID the_0\DT\1740 occurrence_1\NN\29378 of_2\IN\1740 a_3\DT\13649268 <e2>myocardial_4\JJ\1740 infarction</e2>_5\NN\14204950 is_6\VBZ\836236 reported_7\VBN\831651 after_8\IN\1740 chemotherapy_9\NN\661091 containing_10\VBG\2632940 <e1>etoposide</e1>_11\NN\1740 ,_12\,\1740 in_13\IN\13603305 a_14\DT\13649268 man_15\NN\9605289 with_16\IN\1740 no_17\DT\7204911 risk_18\NN\14541044 factors_19\NNS\7326557 for_20\IN\1740 coronary_21\JJ\1740 heart_22\NN\5919034 disease_23\NN\14061805 ._24\.\1740
D005047_D003327 NONE the_0\DT\1740 occurrence_1\NN\29378 of_2\IN\1740 a_3\DT\13649268 myocardial_4\JJ\1740 infarction_5\NN\14204950 is_6\VBZ\836236 reported_7\VBN\831651 after_8\IN\1740 chemotherapy_9\NN\661091 containing_10\VBG\2632940 <e1>etoposide</e1>_11\NN\1740 ,_12\,\1740 in_13\IN\13603305 a_14\DT\13649268 man_15\NN\9605289 with_16\IN\1740 no_17\DT\7204911 risk_18\NN\14541044 factors_19\NNS\7326557 for_20\IN\1740 <e2>coronary_21\JJ\1740 heart_22\NN\5919034 disease</e2>_23\NN\14061805 ._24\.\1740
12571256
C044834_D007674 NONE methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 conducted_3\VBD\2436349 a_4\DT\13649268 randomized_5\JJ\1740 ,_6\,\1740 double-blind_7\JJ\1740 ,_8\,\1740 prospective_9\JJ\1740 ,_10\,\1740 multicenter_11\NN\1740 study_12\NN\635850 comparing_13\VBG\644583 the_14\DT\1740 <e2>nephrotoxic</e2>_15\JJ\1740 effects_16\NNS\13245626 of_17\IN\1740 an_18\DT\6697703 iso-osmolar_19\JJ\1740 ,_20\,\1740 dimeric_21\JJ\1740 ,_22\,\1740 nonionic_23\JJ\1740 contrast_24\NN\13854649 medium_25\NN\3575240 ,_26\,\1740 <e1>iodixanol</e1>_27\NN\1740 ,_28\,\1740 with_29\IN\1740 those_30\DT\1740 of_31\IN\1740 a_32\DT\13649268 low-osmolar_33\JJ\1740 ,_34\,\1740 nonionic_35\JJ\1740 ,_36\,\1740 monomeric_37\JJ\1740 contrast_38\NN\13854649 medium_39\NN\3575240 ,_40\,\1740 iohexol_41\NN\1740 ._42\.\1740
C044834_D007674 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e2>nephropathy</e2>_2\NNP\14573196 induced_3\VBN\1627355 by_4\IN\1740 contrast_5\NN\13854649 medium_6\NN\3575240 may_7\MD\15209706 be_8\VB\836236 less_9\RBR\1740 likely_10\JJ\1740 to_11\TO\1740 develop_12\VB\1753788 in_13\IN\13603305 high-risk_14\JJ\1740 patients_15\NNS\9898892 when_16\WRB\1740 <e1>iodixanol</e1>_17\NN\1740 is_18\VBZ\836236 used_19\VBN\1156834 rather_20\RB\1740 than_21\IN\1740 a_22\DT\13649268 low-osmolar_23\JJ\1740 ,_24\,\1740 nonionic_25\JJ\1740 contrast_26\NN\13854649 medium_27\NN\3575240 ._28\.\1740
D007472_D007674 CID methods_0\NNS\5616786 :_1\:\1740 we_2\PRP\1740 conducted_3\VBD\2436349 a_4\DT\13649268 randomized_5\JJ\1740 ,_6\,\1740 double-blind_7\JJ\1740 ,_8\,\1740 prospective_9\JJ\1740 ,_10\,\1740 multicenter_11\NN\1740 study_12\NN\635850 comparing_13\VBG\644583 the_14\DT\1740 <e2>nephrotoxic</e2>_15\JJ\1740 effects_16\NNS\13245626 of_17\IN\1740 an_18\DT\6697703 iso-osmolar_19\JJ\1740 ,_20\,\1740 dimeric_21\JJ\1740 ,_22\,\1740 nonionic_23\JJ\1740 contrast_24\NN\13854649 medium_25\NN\3575240 ,_26\,\1740 iodixanol_27\NN\1740 ,_28\,\1740 with_29\IN\1740 those_30\DT\1740 of_31\IN\1740 a_32\DT\13649268 low-osmolar_33\JJ\1740 ,_34\,\1740 nonionic_35\JJ\1740 ,_36\,\1740 monomeric_37\JJ\1740 contrast_38\NN\13854649 medium_39\NN\3575240 ,_40\,\1740 <e1>iohexol</e1>_41\NN\1740 ._42\.\1740
D003404_D003920 NONE the_0\DT\1740 study_1\NN\635850 involved_2\VBD\2676054 129_3\CD\1740 patients_4\NNS\9898892 with_5\IN\1740 <e2>diabetes</e2>_6\NNS\14075199 with_7\IN\1740 serum_8\NN\5397468 <e1>creatinine</e1>_9\NN\1740 concentrations_10\NNS\4916342 of_11\IN\1740 1.5_12\CD\1740 to_13\TO\1740 3.5_14\CD\1740 mg_15\NN\13717155 per_16\IN\1740 deciliter_17\NN\13616054 who_18\WP\8299493 underwent_19\VBD\109660 coronary_20\JJ\1740 or_21\CC\3541091 aortofemoral_22\JJ\1740 angiography_23\NN\904623 ._24\.\1740
1848636
D008790_D007008 NONE the_0\DT\1740 drug_1\NN\14778436 effect_2\NN\34213 studied_3\VBN\630380 was_4\VBD\836236 the_5\DT\1740 antagonism_6\NN\24720 by_7\IN\1740 <e1>metoprolol</e1>_8\NN\2832168 of_9\IN\1740 terbutaline-induced_10\JJ\1740 <e2>hypokalemia</e2>_11\NN\14299637 ._12\.\1740
D013726_D007008 CID the_0\DT\1740 drug_1\NN\14778436 effect_2\NN\34213 studied_3\VBN\630380 was_4\VBD\836236 the_5\DT\1740 antagonism_6\NN\24720 by_7\IN\1740 metoprolol_8\NN\2832168 of_9\IN\1740 <e1>terbutaline-induced</e1>_10\JJ\1740 <e2>hypokalemia</e2>_11\NN\14299637 ._12\.\1740
10225068
D008012_D011128 CID <e2>cauda_0\JJ\1740 equina_1\NN\1740 syndrome</e2>_2\NN\5870365 after_3\IN\1740 spinal_4\JJ\1740 anaesthesia_5\NN\14034177 with_6\IN\1740 hyperbaric_7\JJ\1740 5_8\CD\13741022 %_9\NN\1740 <e1>lignocaine</e1>_10\NN\1740 :_11\:\1740 a_12\DT\13649268 review_13\NN\5733583 of_14\IN\1740 six_15\CD\13741022 cases_16\NNS\7283608 of_17\IN\1740 cauda_18\JJ\1740 equina_19\NN\1740 syndrome_20\NN\5870365 reported_21\VBN\831651 to_22\IN\1740 the_23\DT\1740 swedish_24\NNP\6953731 pharmaceutical_25\NNP\3740161 insurance_26\NNP\13344071 1993_27\CD\1740 -_28\SYM\1740 1997_29\CD\1740 ._30\.\1740
D008012_D011128 CID cauda_0\JJ\1740 equina_1\NN\1740 syndrome_2\NN\5870365 after_3\IN\1740 spinal_4\JJ\1740 anaesthesia_5\NN\14034177 with_6\IN\1740 hyperbaric_7\JJ\1740 5_8\CD\13741022 %_9\NN\1740 <e1>lignocaine</e1>_10\NN\1740 :_11\:\1740 a_12\DT\13649268 review_13\NN\5733583 of_14\IN\1740 six_15\CD\13741022 cases_16\NNS\7283608 of_17\IN\1740 <e2>cauda_18\JJ\1740 equina_19\NN\1740 syndrome</e2>_20\NN\5870365 reported_21\VBN\831651 to_22\IN\1740 the_23\DT\1740 swedish_24\NNP\6953731 pharmaceutical_25\NNP\3740161 insurance_26\NNP\13344071 1993_27\CD\1740 -_28\SYM\1740 1997_29\CD\1740 ._30\.\1740
D008012_D020258 NONE the_0\DT\1740 dose_1\NN\3740161 of_2\IN\1740 hyperbaric_3\NN\1740 5_4\CD\13741022 %_5\NN\1740 <e1>lignocaine</e1>_6\NN\1740 administered_7\VBN\2436349 ranged_8\VBD\2604760 from_9\IN\1740 60_10\CD\13745420 to_11\TO\1740 120_12\CD\13745420 mg._13\NN\1740 three_14\CD\13741022 of_15\IN\1740 the_16\DT\1740 cases_17\NNS\7283608 were_18\VBD\836236 most_19\RBS\1740 likely_20\RB\1740 caused_21\VBN\1617192 by_22\IN\1740 direct_23\JJ\1740 <e2>neurotoxicity</e2>_24\NN\1740 of_25\IN\1740 hyperbaric_26\JJ\1740 5_27\CD\13741022 %_28\NN\1740 lignocaine_29\NN\1740 ._30\.\1740
D008012_D020258 NONE the_0\DT\1740 dose_1\NN\3740161 of_2\IN\1740 hyperbaric_3\NN\1740 5_4\CD\13741022 %_5\NN\1740 lignocaine_6\NN\1740 administered_7\VBN\2436349 ranged_8\VBD\2604760 from_9\IN\1740 60_10\CD\13745420 to_11\TO\1740 120_12\CD\13745420 mg._13\NN\1740 three_14\CD\13741022 of_15\IN\1740 the_16\DT\1740 cases_17\NNS\7283608 were_18\VBD\836236 most_19\RBS\1740 likely_20\RB\1740 caused_21\VBN\1617192 by_22\IN\1740 direct_23\JJ\1740 <e2>neurotoxicity</e2>_24\NN\1740 of_25\IN\1740 hyperbaric_26\JJ\1740 5_27\CD\13741022 %_28\NN\1740 <e1>lignocaine</e1>_29\NN\1740 ._30\.\1740
11284996
D009569_D006261 CID calcitonin_0\NN\5413241 gene-related_1\JJ\1740 peptide_2\NN\14724264 levels_3\NNS\4916342 during_4\IN\1740 <e1>nitric_5\JJ\1740 oxide-induced</e1>_6\JJ\1740 <e2>headache</e2>_7\NN\5829480 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 chronic_11\JJ\1740 tension-type_12\NN\1740 headache_13\NN\5829480 ._14\.\1740
D009569_D006261 CID it_0\PRP\6125041 has_1\VBZ\2108377 been_2\VBN\836236 proposed_3\VBN\1010118 that_4\IN\1740 <e1>nitric_5\JJ\1740 oxide</e1>_6\NN\14818238 (_7\-LRB-\1740 no_8\NN\7204911 )_9\-RRB-\1740 induced_10\JJ\1740 <e2>headache</e2>_11\NN\5829480 in_12\IN\13603305 primary_13\JJ\1740 headaches_14\NNS\5829480 may_15\MD\15209706 be_16\VB\836236 associated_17\VBN\628491 with_18\IN\1740 release_19\NN\3748886 of_20\IN\1740 calcitonin_21\NN\5413241 gene-related_22\JJ\1740 peptide_23\NN\14724264 (_24\-LRB-\1740 cgrp_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D009569_D006261 CID it_0\PRP\6125041 has_1\VBZ\2108377 been_2\VBN\836236 proposed_3\VBN\1010118 that_4\IN\1740 nitric_5\JJ\1740 oxide_6\NN\14818238 (_7\-LRB-\1740 <e1>no</e1>_8\NN\7204911 )_9\-RRB-\1740 induced_10\JJ\1740 <e2>headache</e2>_11\NN\5829480 in_12\IN\13603305 primary_13\JJ\1740 headaches_14\NNS\5829480 may_15\MD\15209706 be_16\VB\836236 associated_17\VBN\628491 with_18\IN\1740 release_19\NN\3748886 of_20\IN\1740 calcitonin_21\NN\5413241 gene-related_22\JJ\1740 peptide_23\NN\14724264 (_24\-LRB-\1740 cgrp_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D009569_D006261 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 we_4\PRP\1740 aimed_5\VBD\1987160 to_6\TO\1740 investigate_7\VB\644583 plasma_8\NN\5398023 levels_9\NNS\4916342 of_10\IN\1740 cgrp_11\NN\1740 during_12\IN\1740 <e2>headache</e2>_13\NN\5829480 induced_14\VBN\1627355 by_15\IN\1740 the_16\DT\1740 <e1>no</e1>_17\NN\7204911 donor_18\NN\9608709 glyceryl_19\NN\14621446 trinitrate_20\NN\1740 (_21\-LRB-\1740 gtn_22\NN\1740 )_23\-RRB-\1740 in_24\IN\13603305 16_25\CD\13745420 patients_26\NNS\9898892 with_27\IN\1740 chronic_28\JJ\1740 tension-type_29\JJ\1740 headache_30\NN\5829480 and_31\CC\1740 16_32\CD\13745420 healthy_33\JJ\1740 controls_34\NNS\5190804 ._35\.\1740
D009569_D006261 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 indicates_3\VBZ\952524 that_4\IN\1740 <e1>no-induced</e1>_5\JJ\1740 immediate_6\JJ\1740 <e2>headache</e2>_7\NN\5829480 is_8\VBZ\836236 not_9\RB\1740 associated_10\VBN\628491 with_11\IN\1740 release_12\NN\3748886 of_13\IN\1740 cgrp_14\NN\1740 ._15\.\1740
D009569_D018781 NONE calcitonin_0\NN\5413241 gene-related_1\JJ\1740 peptide_2\NN\14724264 levels_3\NNS\4916342 during_4\IN\1740 <e1>nitric_5\JJ\1740 oxide-induced</e1>_6\JJ\1740 headache_7\NN\5829480 in_8\IN\13603305 patients_9\NNS\9898892 with_10\IN\1740 chronic_11\JJ\1740 <e2>tension-type_12\NN\1740 headache</e2>_13\NN\5829480 ._14\.\1740
D009569_D018781 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 we_4\PRP\1740 aimed_5\VBD\1987160 to_6\TO\1740 investigate_7\VB\644583 plasma_8\NN\5398023 levels_9\NNS\4916342 of_10\IN\1740 cgrp_11\NN\1740 during_12\IN\1740 headache_13\NN\5829480 induced_14\VBN\1627355 by_15\IN\1740 the_16\DT\1740 <e1>no</e1>_17\NN\7204911 donor_18\NN\9608709 glyceryl_19\NN\14621446 trinitrate_20\NN\1740 (_21\-LRB-\1740 gtn_22\NN\1740 )_23\-RRB-\1740 in_24\IN\13603305 16_25\CD\13745420 patients_26\NNS\9898892 with_27\IN\1740 chronic_28\JJ\1740 <e2>tension-type_29\JJ\1740 headache</e2>_30\NN\5829480 and_31\CC\1740 16_32\CD\13745420 healthy_33\JJ\1740 controls_34\NNS\5190804 ._35\.\1740
D009569_D051270 NONE it_0\PRP\6125041 has_1\VBZ\2108377 been_2\VBN\836236 proposed_3\VBN\1010118 that_4\IN\1740 <e1>nitric_5\JJ\1740 oxide</e1>_6\NN\14818238 (_7\-LRB-\1740 no_8\NN\7204911 )_9\-RRB-\1740 induced_10\JJ\1740 headache_11\NN\5829480 in_12\IN\13603305 <e2>primary_13\JJ\1740 headaches</e2>_14\NNS\5829480 may_15\MD\15209706 be_16\VB\836236 associated_17\VBN\628491 with_18\IN\1740 release_19\NN\3748886 of_20\IN\1740 calcitonin_21\NN\5413241 gene-related_22\JJ\1740 peptide_23\NN\14724264 (_24\-LRB-\1740 cgrp_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D009569_D051270 NONE it_0\PRP\6125041 has_1\VBZ\2108377 been_2\VBN\836236 proposed_3\VBN\1010118 that_4\IN\1740 nitric_5\JJ\1740 oxide_6\NN\14818238 (_7\-LRB-\1740 <e1>no</e1>_8\NN\7204911 )_9\-RRB-\1740 induced_10\JJ\1740 headache_11\NN\5829480 in_12\IN\13603305 <e2>primary_13\JJ\1740 headaches</e2>_14\NNS\5829480 may_15\MD\15209706 be_16\VB\836236 associated_17\VBN\628491 with_18\IN\1740 release_19\NN\3748886 of_20\IN\1740 calcitonin_21\NN\5413241 gene-related_22\JJ\1740 peptide_23\NN\14724264 (_24\-LRB-\1740 cgrp_25\NN\1740 )_26\-RRB-\1740 ._27\.\1740
D005996_D006261 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 we_4\PRP\1740 aimed_5\VBD\1987160 to_6\TO\1740 investigate_7\VB\644583 plasma_8\NN\5398023 levels_9\NNS\4916342 of_10\IN\1740 cgrp_11\NN\1740 during_12\IN\1740 <e2>headache</e2>_13\NN\5829480 induced_14\VBN\1627355 by_15\IN\1740 the_16\DT\1740 no_17\NN\7204911 donor_18\NN\9608709 <e1>glyceryl_19\NN\14621446 trinitrate</e1>_20\NN\1740 (_21\-LRB-\1740 gtn_22\NN\1740 )_23\-RRB-\1740 in_24\IN\13603305 16_25\CD\13745420 patients_26\NNS\9898892 with_27\IN\1740 chronic_28\JJ\1740 tension-type_29\JJ\1740 headache_30\NN\5829480 and_31\CC\1740 16_32\CD\13745420 healthy_33\JJ\1740 controls_34\NNS\5190804 ._35\.\1740
D005996_D006261 CID in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 we_4\PRP\1740 aimed_5\VBD\1987160 to_6\TO\1740 investigate_7\VB\644583 plasma_8\NN\5398023 levels_9\NNS\4916342 of_10\IN\1740 cgrp_11\NN\1740 during_12\IN\1740 <e2>headache</e2>_13\NN\5829480 induced_14\VBN\1627355 by_15\IN\1740 the_16\DT\1740 no_17\NN\7204911 donor_18\NN\9608709 glyceryl_19\NN\14621446 trinitrate_20\NN\1740 (_21\-LRB-\1740 <e1>gtn</e1>_22\NN\1740 )_23\-RRB-\1740 in_24\IN\13603305 16_25\CD\13745420 patients_26\NNS\9898892 with_27\IN\1740 chronic_28\JJ\1740 tension-type_29\JJ\1740 headache_30\NN\5829480 and_31\CC\1740 16_32\CD\13745420 healthy_33\JJ\1740 controls_34\NNS\5190804 ._35\.\1740
D005996_D006261 CID the_0\DT\1740 subjects_1\NNS\6598915 were_2\VBD\836236 randomly_3\RB\1740 allocated_4\VBN\2228698 to_5\TO\1740 receive_6\VB\2210855 0.5_7\CD\1740 microg/kg/min_8\NN\1740 <e1>gtn</e1>_9\NN\1740 or_10\CC\3541091 placebo_11\VB\1740 over_12\IN\5867413 20_13\CD\13745420 min_14\NN\15154774 on_15\IN\1740 two_16\CD\13741022 <e2>headache-free</e2>_17\JJ\1740 days_18\NNS\15140892 ._19\.\1740
D005996_D006261 CID both_0\DT\1740 patients_1\NNS\9898892 and_2\CC\1740 controls_3\NNS\5190804 developed_4\VBD\1753788 significantly_5\RB\1740 stronger_6\JJR\1740 immediate_7\JJ\1740 <e2>headache</e2>_8\NN\5829480 on_9\IN\1740 the_10\DT\1740 <e1>gtn</e1>_11\NN\1740 day_12\NN\15154774 than_13\IN\1740 on_14\IN\1740 the_15\DT\1740 placebo_16\NN\3740161 day_17\NN\15154774 and_18\CC\1740 the_19\DT\1740 headache_20\NN\5829480 was_21\VBD\836236 significantly_22\RB\1740 more_23\RBR\1740 pronounced_24\JJ\1740 in_25\IN\13603305 patients_26\NNS\9898892 than_27\IN\1740 in_28\IN\13603305 controls_29\NNS\5190804 ._30\.\1740
D005996_D006261 CID both_0\DT\1740 patients_1\NNS\9898892 and_2\CC\1740 controls_3\NNS\5190804 developed_4\VBD\1753788 significantly_5\RB\1740 stronger_6\JJR\1740 immediate_7\JJ\1740 headache_8\NN\5829480 on_9\IN\1740 the_10\DT\1740 <e1>gtn</e1>_11\NN\1740 day_12\NN\15154774 than_13\IN\1740 on_14\IN\1740 the_15\DT\1740 placebo_16\NN\3740161 day_17\NN\15154774 and_18\CC\1740 the_19\DT\1740 <e2>headache</e2>_20\NN\5829480 was_21\VBD\836236 significantly_22\RB\1740 more_23\RBR\1740 pronounced_24\JJ\1740 in_25\IN\13603305 patients_26\NNS\9898892 than_27\IN\1740 in_28\IN\13603305 controls_29\NNS\5190804 ._30\.\1740
D005996_D018781 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 we_4\PRP\1740 aimed_5\VBD\1987160 to_6\TO\1740 investigate_7\VB\644583 plasma_8\NN\5398023 levels_9\NNS\4916342 of_10\IN\1740 cgrp_11\NN\1740 during_12\IN\1740 headache_13\NN\5829480 induced_14\VBN\1627355 by_15\IN\1740 the_16\DT\1740 no_17\NN\7204911 donor_18\NN\9608709 <e1>glyceryl_19\NN\14621446 trinitrate</e1>_20\NN\1740 (_21\-LRB-\1740 gtn_22\NN\1740 )_23\-RRB-\1740 in_24\IN\13603305 16_25\CD\13745420 patients_26\NNS\9898892 with_27\IN\1740 chronic_28\JJ\1740 <e2>tension-type_29\JJ\1740 headache</e2>_30\NN\5829480 and_31\CC\1740 16_32\CD\13745420 healthy_33\JJ\1740 controls_34\NNS\5190804 ._35\.\1740
D005996_D018781 NONE in_0\IN\13603305 the_1\DT\1740 present_2\JJ\1740 study_3\NN\635850 we_4\PRP\1740 aimed_5\VBD\1987160 to_6\TO\1740 investigate_7\VB\644583 plasma_8\NN\5398023 levels_9\NNS\4916342 of_10\IN\1740 cgrp_11\NN\1740 during_12\IN\1740 headache_13\NN\5829480 induced_14\VBN\1627355 by_15\IN\1740 the_16\DT\1740 no_17\NN\7204911 donor_18\NN\9608709 glyceryl_19\NN\14621446 trinitrate_20\NN\1740 (_21\-LRB-\1740 <e1>gtn</e1>_22\NN\1740 )_23\-RRB-\1740 in_24\IN\13603305 16_25\CD\13745420 patients_26\NNS\9898892 with_27\IN\1740 chronic_28\JJ\1740 <e2>tension-type_29\JJ\1740 headache</e2>_30\NN\5829480 and_31\CC\1740 16_32\CD\13745420 healthy_33\JJ\1740 controls_34\NNS\5190804 ._35\.\1740
921394
D007649_D003866 NONE injections_0\NNS\320852 of_1\IN\1740 <e1>ketamine</e1>_2\NN\3054098 in_3\IN\13603305 doses_4\NNS\3740161 from_5\IN\1740 100_6\CD\13745420 microgram_7\NN\13717155 to_8\IN\1740 3_9\CD\13741022 mg_10\NN\13717155 into_11\IN\1740 the_12\DT\1740 artery_13\NN\5417975 produced_14\VBD\1617192 a_15\DT\13649268 <e2>depression</e2>_16\NN\14373582 of_17\IN\1740 the_18\DT\1740 sa_19\NNP\8390511 nodal_20\NN\1740 activity_21\NN\30358 by_22\IN\1740 a_23\DT\13649268 direct_24\JJ\1740 action_25\NN\30358 ._26\.\1740
D007649_D013610 CID bilateral_0\JJ\1740 vagotomy_1\NN\1740 and_2\CC\1740 sympathectomy_3\NN\393369 or_4\CC\3541091 prior_5\JJ\1740 administration_6\NN\1133281 of_7\IN\1740 a_8\DT\13649268 ganglion_9\NN\5462674 blocker_10\NN\10101634 failed_11\VBD\1798936 to_12\TO\1740 inhibit_13\VB\2510337 the_14\DT\1740 occurrence_15\NN\29378 of_16\IN\1740 the_17\DT\1740 <e1>ketamine-induced</e1>_18\JJ\1740 <e2>tachycardia</e2>_19\NN\14110674 ,_20\,\1740 while_21\IN\15122231 it_22\PRP\6125041 was_23\VBD\836236 completely_24\RB\1740 abolished_25\VBN\1740 in_26\IN\13603305 the_27\DT\1740 reserpinized_28\VBN\1740 dogs_29\NNS\2083346 or_30\CC\3541091 by_31\IN\1740 a_32\DT\13649268 prior_33\JJ\1740 injection_34\NN\320852 of_35\IN\1740 a_36\DT\13649268 beta-blocking_37\JJ\1740 agent_38\NN\7347 into_39\IN\1740 the_40\DT\1740 sa_41\NN\8390511 node_42\NN\13870805 artery_43\NN\5417975 ._44\.\1740
6817363
C036466_D007859 NONE effects_0\NNS\13245626 of_1\IN\1740 the_2\DT\1740 novel_3\JJ\1740 compound_4\NN\5869584 <e1>aniracetam</e1>_5\NN\1740 (_6\-LRB-\1740 ro_7\NN\6894544 13_8\CD\13745420 -_9\SYM\1740 5057_10\CD\1740 )_11\-RRB-\1740 upon_12\IN\1740 <e2>impaired_13\JJ\1740 learning_14\NN\5701944 and_15\CC\1740 memory</e2>_16\NN\5926676 in_17\IN\13603305 rodents_18\NNS\1886756 ._19\.\1740
C036466_D007859 NONE effects_0\NNS\13245626 of_1\IN\1740 the_2\DT\1740 novel_3\JJ\1740 compound_4\NN\5869584 aniracetam_5\NN\1740 (_6\-LRB-\1740 <e1>ro_7\NN\6894544 13_8\CD\13745420 -_9\SYM\1740 5057</e1>_10\CD\1740 )_11\-RRB-\1740 upon_12\IN\1740 <e2>impaired_13\JJ\1740 learning_14\NN\5701944 and_15\CC\1740 memory</e2>_16\NN\5926676 in_17\IN\13603305 rodents_18\NNS\1886756 ._19\.\1740
C036466_D008569 NONE effects_0\NNS\13245626 of_1\IN\1740 the_2\DT\1740 novel_3\JJ\1740 compound_4\NN\5869584 <e1>aniracetam</e1>_5\NN\1740 (_6\-LRB-\1740 ro_7\NN\6894544 13_8\CD\13745420 -_9\SYM\1740 5057_10\CD\1740 )_11\-RRB-\1740 upon_12\IN\1740 <e2>impaired_13\JJ\1740 learning_14\NN\5701944 and_15\CC\1740 memory</e2>_16\NN\5926676 in_17\IN\13603305 rodents_18\NNS\1886756 ._19\.\1740
C036466_D008569 NONE effects_0\NNS\13245626 of_1\IN\1740 the_2\DT\1740 novel_3\JJ\1740 compound_4\NN\5869584 aniracetam_5\NN\1740 (_6\-LRB-\1740 <e1>ro_7\NN\6894544 13_8\CD\13745420 -_9\SYM\1740 5057</e1>_10\CD\1740 )_11\-RRB-\1740 upon_12\IN\1740 <e2>impaired_13\JJ\1740 learning_14\NN\5701944 and_15\CC\1740 memory</e2>_16\NN\5926676 in_17\IN\13603305 rodents_18\NNS\1886756 ._19\.\1740
C036466_D003072 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>aniracetam</e1>_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 <e2>impaired_19\JJ\1740 cognitive_20\JJ\1740 functions</e2>_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D003072 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 <e1>ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057</e1>_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 <e2>impaired_19\JJ\1740 cognitive_20\JJ\1740 functions</e2>_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D003072 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 <e1>1-anisoyl-2-pyrrolidinone</e1>_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 <e2>impaired_19\JJ\1740 cognitive_20\JJ\1740 functions</e2>_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D003072 NONE these_0\DT\1740 improvements_1\NNS\7359599 or_2\CC\3541091 normalizations_3\NNS\1123598 of_4\IN\1740 <e2>impaired_5\JJ\1740 cognitive_6\JJ\1740 functions</e2>_7\NNS\13783581 were_8\VBD\836236 seen_9\VBN\2106506 at_10\IN\14622893 oral_11\JJ\1740 <e1>aniracetam</e1>_12\NN\1740 doses_13\NNS\3740161 of_14\IN\1740 10_15\CD\13745420 -_16\SYM\1740 100_17\CD\13745420 mg/kg_18\NN\1740 ._19\.\1740
C036466_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>aniracetam</e1>_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 <e2>hypercapnia</e2>_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>aniracetam</e1>_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 <e2>hypercapnia</e2>_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 <e1>ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057</e1>_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 <e2>hypercapnia</e2>_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 <e1>ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057</e1>_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 <e2>hypercapnia</e2>_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 <e1>1-anisoyl-2-pyrrolidinone</e1>_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 <e2>hypercapnia</e2>_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 <e1>1-anisoyl-2-pyrrolidinone</e1>_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 <e2>hypercapnia</e2>_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>aniracetam</e1>_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 <e2>amnesia</e2>_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 <e1>aniracetam</e1>_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 <e2>amnesia</e2>_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 <e1>ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057</e1>_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 <e2>amnesia</e2>_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 <e1>ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057</e1>_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 <e2>amnesia</e2>_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 <e1>1-anisoyl-2-pyrrolidinone</e1>_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 <e2>amnesia</e2>_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
C036466_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 <e1>1-anisoyl-2-pyrrolidinone</e1>_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 <e2>amnesia</e2>_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D012601_D003072 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 <e2>impaired_19\JJ\1740 cognitive_20\JJ\1740 functions</e2>_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 <e1>scopolamine-induced</e1>_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D012601_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 <e2>hypercapnia</e2>_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 <e1>scopolamine-induced</e1>_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D012601_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 <e1>scopolamine-induced</e1>_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 <e2>hypercapnia</e2>_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D012601_D000647 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 <e1>scopolamine-induced</e1>_77\JJ\1740 short-term_78\JJ\1740 <e2>amnesia</e2>_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D012601_D000647 CID the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 <e1>scopolamine-induced</e1>_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 <e2>amnesia</e2>_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D002701_D003072 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 <e2>impaired_19\JJ\1740 cognitive_20\JJ\1740 functions</e2>_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 <e1>chloramphenicol</e1>_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D002701_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 <e2>hypercapnia</e2>_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 <e1>chloramphenicol</e1>_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D002701_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 <e1>chloramphenicol</e1>_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 <e2>hypercapnia</e2>_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D002701_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 <e2>amnesia</e2>_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 <e1>chloramphenicol</e1>_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D002701_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 <e2>amnesia</e2>_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 <e1>chloramphenicol</e1>_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D003513_D003072 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 <e2>impaired_19\JJ\1740 cognitive_20\JJ\1740 functions</e2>_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 <e1>cycloheximide</e1>_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D003513_D003072 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 <e2>impaired_19\JJ\1740 cognitive_20\JJ\1740 functions</e2>_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 <e1>cycloheximide</e1>_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D003513_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 <e2>hypercapnia</e2>_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 <e1>cycloheximide</e1>_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D003513_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 <e1>cycloheximide</e1>_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 <e2>hypercapnia</e2>_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D003513_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 <e2>hypercapnia</e2>_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 <e1>cycloheximide</e1>_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D003513_D006935 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 <e1>cycloheximide</e1>_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 <e2>hypercapnia</e2>_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D003513_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 <e2>amnesia</e2>_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 <e1>cycloheximide</e1>_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D003513_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 <e2>amnesia</e2>_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 <e1>cycloheximide</e1>_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 cycloheximide_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D003513_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 <e2>amnesia</e2>_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 amnesia_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 <e1>cycloheximide</e1>_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
D003513_D000647 NONE the_0\DT\1740 effect_1\NN\34213 of_2\IN\1740 aniracetam_3\NN\1740 (_4\-LRB-\1740 ro_5\NN\6894544 13_6\CD\13745420 -_7\SYM\1740 5057_8\CD\1740 ,_9\,\1740 1-anisoyl-2-pyrrolidinone_10\JJ\1740 )_11\-RRB-\1740 was_12\VBD\836236 studied_13\VBN\630380 on_14\IN\1740 various_15\JJ\1740 forms_16\NNS\6286395 of_17\IN\1740 experimentally_18\RB\1740 impaired_19\JJ\1740 cognitive_20\JJ\1740 functions_21\NNS\13783581 (_22\-LRB-\1740 learning_23\NN\5701944 and_24\CC\1740 memory_25\NN\5926676 )_26\-RRB-\1740 in_27\IN\13603305 rodents_28\NNS\1886756 and_29\CC\1740 produced_30\VBD\1617192 the_31\DT\1740 following_32\VBG\1835496 effects_33\NNS\13245626 :_34\:\1740 (_35\-LRB-\1740 1_36\LS\13741022 )_37\-RRB-\1740 almost_38\RB\1740 complete_39\VBP\352826 prevention_40\NN\1073995 of_41\IN\1740 the_42\DT\1740 incapacity_43\NN\5644922 to_44\TO\1740 learn_45\VB\607114 a_46\DT\13649268 discrete_47\JJ\1740 escape_48\NN\46177 response_49\NN\11410625 in_50\IN\13603305 rats_51\NNS\2329401 exposed_52\VBN\2110927 to_53\TO\1740 sublethal_54\JJ\1740 hypercapnia_55\NN\14034177 immediately_56\RB\1740 before_57\IN\1740 the_58\DT\1740 acquisition_59\NN\41899 session_60\NN\7142566 ;_61\:\1740 (_62\-LRB-\1740 2_63\LS\13741022 )_64\-RRB-\1740 partial_65\JJ\1740 (_66\-LRB-\1740 rats_67\NNS\2329401 )_68\-RRB-\1740 or_69\CC\3541091 complete_70\JJ\1740 (_71\-LRB-\1740 mice_72\NNS\2329401 )_73\-RRB-\1740 prevention_74\NN\1073995 of_75\IN\1740 the_76\DT\1740 scopolamine-induced_77\JJ\1740 short-term_78\JJ\1740 amnesia_79\NN\5669934 for_80\IN\1740 a_81\DT\13649268 passive_82\JJ\1740 avoidance_83\NN\203342 task_84\NN\575741 ;_85\:\1740 (_86\-LRB-\1740 3_87\LS\13741022 )_88\-RRB-\1740 complete_89\VBP\352826 protection_90\NN\407535 against_91\IN\1740 <e2>amnesia</e2>_92\NN\5669934 for_93\IN\1740 a_94\DT\13649268 passive_95\JJ\1740 avoidance_96\NN\203342 task_97\NN\575741 in_98\IN\13603305 rats_99\NNS\2329401 submitted_100\VBN\1952898 to_101\TO\1740 electroconvulsive_102\JJ\1740 shock_103\NN\7510495 immediately_104\RB\1740 after_105\IN\1740 avoidance_106\NN\203342 acquisition_107\NN\41899 ;_108\:\1740 (_109\-LRB-\1740 4_110\LS\13741022 )_111\-RRB-\1740 prevention_112\NN\1073995 of_113\IN\1740 the_114\DT\1740 long-term_115\JJ\1740 retention-_116\NN\1740 or_117\CC\3541091 retrieval-deficit_118\NN\1740 for_119\IN\1740 a_120\DT\13649268 passive_121\JJ\1740 avoidance_122\NN\203342 task_123\NN\575741 induced_124\VBN\1627355 in_125\IN\13603305 rats_126\NNS\2329401 and_127\CC\1740 mice_128\NNS\2329401 by_129\IN\1740 chloramphenicol_130\NN\2716866 or_131\CC\3541091 cycloheximide_132\NN\1740 administered_133\VBN\2436349 immediately_134\RB\1740 after_135\IN\1740 acquisition_136\NN\41899 ;_137\:\1740 (_138\-LRB-\1740 5_139\LS\13741022 )_140\-RRB-\1740 reversal_141\JJ\1740 ,_142\,\1740 when_143\WRB\1740 administered_144\VBN\2436349 as_145\RB\1740 late_146\JJ\1740 as_147\IN\14622893 1_148\CD\13741022 h_149\NN\14622893 before_150\IN\1740 the_151\DT\1740 retention_152\NN\809465 test_153\NN\5798043 ,_154\,\1740 of_155\IN\1740 the_156\DT\1740 deficit_157\NN\5113133 in_158\IN\13603305 retention_159\NN\809465 or_160\CC\3541091 retrieval_161\NN\13450862 of_162\IN\1740 a_163\DT\13649268 passive_164\JJ\1740 avoidance_165\NN\203342 task_166\NN\575741 induced_167\VBN\1627355 by_168\IN\1740 <e1>cycloheximide</e1>_169\NN\1740 injected_170\VBD\81072 2_171\CD\13741022 days_172\NNS\15140892 previously_173\RB\1740 ;_174\:\1740 (_175\-LRB-\1740 6_176\LS\13741022 )_177\-RRB-\1740 prevention_178\NN\1073995 of_179\IN\1740 the_180\DT\1740 deficit_181\NN\5113133 in_182\IN\13603305 the_183\DT\1740 retrieval_184\NN\13450862 of_185\IN\1740 an_186\DT\6697703 active_187\JJ\1740 avoidance_188\NN\203342 task_189\NN\575741 induced_190\VBN\1627355 in_191\IN\13603305 mice_192\NNS\2329401 by_193\IN\1740 subconvulsant_194\JJ\1740 electroshock_195\NN\662681 or_196\CC\3541091 hypercapnia_197\NN\14034177 applied_198\VBD\2676054 immediately_199\RB\1740 before_200\IN\1740 retrieval_201\NN\13450862 testing_202\NN\639556 (_203\-LRB-\1740 24_204\CD\13745420 h_205\NN\14622893 after_206\IN\1740 acquisition_207\NN\41899 )_208\-RRB-\1740 ._209\.\1740
8742498
D009243_D056486 NONE influence_0\NN\5190804 of_1\IN\1740 diet_2\JJ\1740 free_3\JJ\1740 of_4\IN\1740 <e1>nad-precursors</e1>_5\NNS\1740 on_6\IN\1740 acetaminophen_7\JJ\1740 <e2>hepatotoxicity</e2>_8\NN\1740 in_9\IN\13603305 mice_10\NNS\2329401 ._11\.\1740
D009243_D056486 NONE the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 investigates_3\VBZ\644583 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 a_7\DT\13649268 diet_8\NN\7560652 free_9\JJ\1740 of_10\IN\1740 precursors_11\NNS\14580897 of_12\IN\1740 <e1>nad</e1>_13\NN\14800277 ,_14\,\1740 the_15\DT\1740 substrate_16\NN\19613 on_17\IN\1740 which_18\WDT\1740 parp_19\NN\1740 acts_20\VBZ\1619354 ,_21\,\1740 in_22\IN\13603305 female_23\JJ\1740 nmri_24\NN\1740 mice_25\NNS\2329401 with_26\IN\1740 aap_27\NN\1740 <e2>hepatitis</e2>_28\NN\14127211 and_29\CC\1740 evaluates_30\VBZ\670261 the_31\DT\1740 influence_32\NN\5190804 of_33\IN\1740 simultaneous_34\JJ\1740 ethanol_35\NN\14708720 consumption_36\NN\13440063 in_37\IN\13603305 these_38\DT\1740 animals_39\NNS\4475 ._40\.\1740
D009243_D056486 NONE our_0\PRP$\1740 results_1\NNS\34213 provide_2\VBP\2199590 evidence_3\NN\5816287 that_4\IN\1740 the_5\DT\1740 aap-induced_6\JJ\1740 <e2>hepatitis</e2>_7\NN\14127211 and_8\CC\1740 its_9\PRP$\6125041 exacerbation_10\NN\374224 by_11\IN\1740 ethanol_12\NN\14708720 can_13\MD\3094503 either_14\RB\1740 be_15\VB\836236 reduced_16\VBN\441445 by_17\IN\1740 end-product_18\JJ\1740 inhibition_19\NN\1068773 of_20\IN\1740 parp_21\NN\1740 by_22\IN\1740 naa_23\NN\1740 or_24\CC\3541091 by_25\IN\1740 dietary_26\JJ\1740 depletion_27\NN\351638 of_28\IN\1740 the_29\DT\1740 enzyme_30\NN\14723628 's_31\POS\1740 substrate_32\JJ\1740 <e1>nad</e1>_33\NN\14800277 ._34\.\1740
D000082_D056486 CID influence_0\NN\5190804 of_1\IN\1740 diet_2\JJ\1740 free_3\JJ\1740 of_4\IN\1740 nad-precursors_5\NNS\1740 on_6\IN\1740 <e1>acetaminophen</e1>_7\JJ\1740 <e2>hepatotoxicity</e2>_8\NN\1740 in_9\IN\13603305 mice_10\NNS\2329401 ._11\.\1740
D000082_D056486 CID recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 demonstrated_3\VBD\2137132 the_4\DT\1740 hepatoprotective_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 nicotinic_8\JJ\1740 acid_9\NN\14818238 amide_10\NN\14727670 ,_11\,\1740 a_12\DT\13649268 selective_13\JJ\1740 inhibitor_14\NN\20090 of_15\IN\1740 poly(adp-ribose_16\NN\1740 )_17\-RRB-\1740 polymerase_18\NN\14732946 (_19\-LRB-\1740 parp_20\NN\1740 ;_21\:\1740 ec_22\NN\8294696 2.4.2.30_23\NN\1740 )_24\-RRB-\1740 on_25\IN\1740 mice_26\NNS\2329401 suffering_27\VBG\2110220 from_28\IN\1740 <e1>acetaminophen</e1>_29\JJ\1740 <e2>(aap)-hepatitis</e2>_30\NN\1740 ,_31\,\1740 suggesting_32\VBG\1010118 that_33\IN\1740 the_34\DT\1740 aap-induced_35\JJ\1740 liver_36\NN\5298729 injury_37\NN\14052046 involves_38\VBZ\2676054 a_39\DT\13649268 step_40\NN\168237 which_41\WDT\1740 depends_42\VBZ\2604760 on_43\IN\1740 adenoribosylation_44\NN\1740 ._45\.\1740
D000082_D056486 CID recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 demonstrated_3\VBD\2137132 the_4\DT\1740 hepatoprotective_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 nicotinic_8\JJ\1740 acid_9\NN\14818238 amide_10\NN\14727670 ,_11\,\1740 a_12\DT\13649268 selective_13\JJ\1740 inhibitor_14\NN\20090 of_15\IN\1740 poly(adp-ribose_16\NN\1740 )_17\-RRB-\1740 polymerase_18\NN\14732946 (_19\-LRB-\1740 parp_20\NN\1740 ;_21\:\1740 ec_22\NN\8294696 2.4.2.30_23\NN\1740 )_24\-RRB-\1740 on_25\IN\1740 mice_26\NNS\2329401 suffering_27\VBG\2110220 from_28\IN\1740 <e1>acetaminophen</e1>_29\JJ\1740 (aap)-hepatitis_30\NN\1740 ,_31\,\1740 suggesting_32\VBG\1010118 that_33\IN\1740 the_34\DT\1740 aap-induced_35\JJ\1740 <e2>liver_36\NN\5298729 injury</e2>_37\NN\14052046 involves_38\VBZ\2676054 a_39\DT\13649268 step_40\NN\168237 which_41\WDT\1740 depends_42\VBZ\2604760 on_43\IN\1740 adenoribosylation_44\NN\1740 ._45\.\1740
D000082_D056486 CID recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 demonstrated_3\VBD\2137132 the_4\DT\1740 hepatoprotective_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 nicotinic_8\JJ\1740 acid_9\NN\14818238 amide_10\NN\14727670 ,_11\,\1740 a_12\DT\13649268 selective_13\JJ\1740 inhibitor_14\NN\20090 of_15\IN\1740 poly(adp-ribose_16\NN\1740 )_17\-RRB-\1740 polymerase_18\NN\14732946 (_19\-LRB-\1740 parp_20\NN\1740 ;_21\:\1740 ec_22\NN\8294696 2.4.2.30_23\NN\1740 )_24\-RRB-\1740 on_25\IN\1740 mice_26\NNS\2329401 suffering_27\VBG\2110220 from_28\IN\1740 acetaminophen_29\JJ\1740 <e2><e1>(aap)-hepatitis</e1></e2>_30\NN\1740 ,_31\,\1740 suggesting_32\VBG\1010118 that_33\IN\1740 the_34\DT\1740 aap-induced_35\JJ\1740 liver_36\NN\5298729 injury_37\NN\14052046 involves_38\VBZ\2676054 a_39\DT\13649268 step_40\NN\168237 which_41\WDT\1740 depends_42\VBZ\2604760 on_43\IN\1740 adenoribosylation_44\NN\1740 ._45\.\1740
D000082_D056486 CID recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 demonstrated_3\VBD\2137132 the_4\DT\1740 hepatoprotective_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 nicotinic_8\JJ\1740 acid_9\NN\14818238 amide_10\NN\14727670 ,_11\,\1740 a_12\DT\13649268 selective_13\JJ\1740 inhibitor_14\NN\20090 of_15\IN\1740 poly(adp-ribose_16\NN\1740 )_17\-RRB-\1740 polymerase_18\NN\14732946 (_19\-LRB-\1740 parp_20\NN\1740 ;_21\:\1740 ec_22\NN\8294696 2.4.2.30_23\NN\1740 )_24\-RRB-\1740 on_25\IN\1740 mice_26\NNS\2329401 suffering_27\VBG\2110220 from_28\IN\1740 acetaminophen_29\JJ\1740 <e1>(aap)-hepatitis</e1>_30\NN\1740 ,_31\,\1740 suggesting_32\VBG\1010118 that_33\IN\1740 the_34\DT\1740 aap-induced_35\JJ\1740 <e2>liver_36\NN\5298729 injury</e2>_37\NN\14052046 involves_38\VBZ\2676054 a_39\DT\13649268 step_40\NN\168237 which_41\WDT\1740 depends_42\VBZ\2604760 on_43\IN\1740 adenoribosylation_44\NN\1740 ._45\.\1740
D000082_D056486 CID recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 demonstrated_3\VBD\2137132 the_4\DT\1740 hepatoprotective_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 nicotinic_8\JJ\1740 acid_9\NN\14818238 amide_10\NN\14727670 ,_11\,\1740 a_12\DT\13649268 selective_13\JJ\1740 inhibitor_14\NN\20090 of_15\IN\1740 poly(adp-ribose_16\NN\1740 )_17\-RRB-\1740 polymerase_18\NN\14732946 (_19\-LRB-\1740 parp_20\NN\1740 ;_21\:\1740 ec_22\NN\8294696 2.4.2.30_23\NN\1740 )_24\-RRB-\1740 on_25\IN\1740 mice_26\NNS\2329401 suffering_27\VBG\2110220 from_28\IN\1740 acetaminophen_29\JJ\1740 <e2>(aap)-hepatitis</e2>_30\NN\1740 ,_31\,\1740 suggesting_32\VBG\1010118 that_33\IN\1740 the_34\DT\1740 <e1>aap-induced</e1>_35\JJ\1740 liver_36\NN\5298729 injury_37\NN\14052046 involves_38\VBZ\2676054 a_39\DT\13649268 step_40\NN\168237 which_41\WDT\1740 depends_42\VBZ\2604760 on_43\IN\1740 adenoribosylation_44\NN\1740 ._45\.\1740
D000082_D056486 CID recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 demonstrated_3\VBD\2137132 the_4\DT\1740 hepatoprotective_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 nicotinic_8\JJ\1740 acid_9\NN\14818238 amide_10\NN\14727670 ,_11\,\1740 a_12\DT\13649268 selective_13\JJ\1740 inhibitor_14\NN\20090 of_15\IN\1740 poly(adp-ribose_16\NN\1740 )_17\-RRB-\1740 polymerase_18\NN\14732946 (_19\-LRB-\1740 parp_20\NN\1740 ;_21\:\1740 ec_22\NN\8294696 2.4.2.30_23\NN\1740 )_24\-RRB-\1740 on_25\IN\1740 mice_26\NNS\2329401 suffering_27\VBG\2110220 from_28\IN\1740 acetaminophen_29\JJ\1740 (aap)-hepatitis_30\NN\1740 ,_31\,\1740 suggesting_32\VBG\1010118 that_33\IN\1740 the_34\DT\1740 <e1>aap-induced</e1>_35\JJ\1740 <e2>liver_36\NN\5298729 injury</e2>_37\NN\14052046 involves_38\VBZ\2676054 a_39\DT\13649268 step_40\NN\168237 which_41\WDT\1740 depends_42\VBZ\2604760 on_43\IN\1740 adenoribosylation_44\NN\1740 ._45\.\1740
D000082_D056486 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 investigates_3\VBZ\644583 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 a_7\DT\13649268 diet_8\NN\7560652 free_9\JJ\1740 of_10\IN\1740 precursors_11\NNS\14580897 of_12\IN\1740 nad_13\NN\14800277 ,_14\,\1740 the_15\DT\1740 substrate_16\NN\19613 on_17\IN\1740 which_18\WDT\1740 parp_19\NN\1740 acts_20\VBZ\1619354 ,_21\,\1740 in_22\IN\13603305 female_23\JJ\1740 nmri_24\NN\1740 mice_25\NNS\2329401 with_26\IN\1740 <e1>aap</e1>_27\NN\1740 <e2>hepatitis</e2>_28\NN\14127211 and_29\CC\1740 evaluates_30\VBZ\670261 the_31\DT\1740 influence_32\NN\5190804 of_33\IN\1740 simultaneous_34\JJ\1740 ethanol_35\NN\14708720 consumption_36\NN\13440063 in_37\IN\13603305 these_38\DT\1740 animals_39\NNS\4475 ._40\.\1740
D000082_D056486 CID in_0\IN\13603305 these_1\DT\1740 animals_2\NNS\4475 ,_3\,\1740 only_4\RB\1740 minor_5\JJ\1740 increases_6\NNS\13576355 of_7\IN\1740 serum_8\NN\5397468 transaminase_9\NN\15077571 activities_10\NNS\30358 were_11\VBD\836236 measured_12\VBN\697589 in_13\IN\13603305 the_14\DT\1740 presence_15\NN\13954253 of_16\IN\1740 <e1>aap</e1>_17\NNS\1740 ,_18\,\1740 and_19\CC\1740 unlike_20\IN\1740 the_21\DT\1740 exacerbation_22\NN\374224 caused_23\VBN\1617192 by_24\IN\1740 ethanol_25\NN\14708720 in_26\IN\13603305 mice_27\NNS\2329401 on_28\IN\1740 a_29\DT\13649268 standard_30\JJ\1740 diet_31\NN\7560652 ,_32\,\1740 the_33\DT\1740 <e2>liver_34\NN\5298729 damage</e2>_35\NN\7296428 was_36\VBD\836236 inhibited_37\VBN\2510337 by_38\IN\1740 50_39\CD\13745420 %_40\NN\1740 by_41\IN\1740 ethanol_42\NN\14708720 ._43\.\1740
D000082_D056486 CID a_0\DT\13649268 further_1\JJ\1740 64_2\CD\1740 %_3\NN\1740 reduction_4\NN\351485 of_5\IN\1740 <e2>hepatitis</e2>_6\NN\14127211 was_7\VBD\836236 observed_8\VBN\2163746 ,_9\,\1740 when_10\WRB\1740 naa_11\NNP\1740 was_12\VBD\836236 given_13\VBN\2327200 to_14\IN\1740 <e1>ethanol/aap-mice</e1>_15\NN\1740 ._16\.\1740
D000082_D056486 CID our_0\PRP$\1740 results_1\NNS\34213 provide_2\VBP\2199590 evidence_3\NN\5816287 that_4\IN\1740 the_5\DT\1740 <e1>aap-induced</e1>_6\JJ\1740 <e2>hepatitis</e2>_7\NN\14127211 and_8\CC\1740 its_9\PRP$\6125041 exacerbation_10\NN\374224 by_11\IN\1740 ethanol_12\NN\14708720 can_13\MD\3094503 either_14\RB\1740 be_15\VB\836236 reduced_16\VBN\441445 by_17\IN\1740 end-product_18\JJ\1740 inhibition_19\NN\1068773 of_20\IN\1740 parp_21\NN\1740 by_22\IN\1740 naa_23\NN\1740 or_24\CC\3541091 by_25\IN\1740 dietary_26\JJ\1740 depletion_27\NN\351638 of_28\IN\1740 the_29\DT\1740 enzyme_30\NN\14723628 's_31\POS\1740 substrate_32\JJ\1740 nad_33\NN\14800277 ._34\.\1740
D000082_D056486 CID we_0\PRP\1740 see_1\VBP\2106506 the_2\DT\1740 main_3\JJ\1740 application_4\NN\947128 of_5\IN\1740 naa_6\NNP\1740 as_7\IN\14622893 for_8\IN\1740 the_9\DT\1740 combinational_10\JJ\1740 use_11\NN\407535 in_12\IN\13603305 pharmaceutical_13\JJ\1740 preparations_14\NNS\407535 of_15\IN\1740 <e1>acetaminophen</e1>_16\NN\2707683 in_17\IN\13603305 order_18\NN\7168131 to_19\TO\1740 avoid_20\VB\2452885 <e2>hepatic_21\JJ\1740 damage</e2>_22\NN\7296428 in_23\IN\13603305 patients_24\NNS\9898892 treated_25\VBN\2376958 with_26\IN\1740 this_27\DT\1740 widely_28\RB\1740 used_29\VBD\1156834 analgesic_30\NN\3740161 ._31\.\1740
D009536_D056486 NONE recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 demonstrated_3\VBD\2137132 the_4\DT\1740 hepatoprotective_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 <e1>nicotinic_8\JJ\1740 acid_9\NN\14818238 amide</e1>_10\NN\14727670 ,_11\,\1740 a_12\DT\13649268 selective_13\JJ\1740 inhibitor_14\NN\20090 of_15\IN\1740 poly(adp-ribose_16\NN\1740 )_17\-RRB-\1740 polymerase_18\NN\14732946 (_19\-LRB-\1740 parp_20\NN\1740 ;_21\:\1740 ec_22\NN\8294696 2.4.2.30_23\NN\1740 )_24\-RRB-\1740 on_25\IN\1740 mice_26\NNS\2329401 suffering_27\VBG\2110220 from_28\IN\1740 acetaminophen_29\JJ\1740 <e2>(aap)-hepatitis</e2>_30\NN\1740 ,_31\,\1740 suggesting_32\VBG\1010118 that_33\IN\1740 the_34\DT\1740 aap-induced_35\JJ\1740 liver_36\NN\5298729 injury_37\NN\14052046 involves_38\VBZ\2676054 a_39\DT\13649268 step_40\NN\168237 which_41\WDT\1740 depends_42\VBZ\2604760 on_43\IN\1740 adenoribosylation_44\NN\1740 ._45\.\1740
D009536_D056486 NONE recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 demonstrated_3\VBD\2137132 the_4\DT\1740 hepatoprotective_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 <e1>nicotinic_8\JJ\1740 acid_9\NN\14818238 amide</e1>_10\NN\14727670 ,_11\,\1740 a_12\DT\13649268 selective_13\JJ\1740 inhibitor_14\NN\20090 of_15\IN\1740 poly(adp-ribose_16\NN\1740 )_17\-RRB-\1740 polymerase_18\NN\14732946 (_19\-LRB-\1740 parp_20\NN\1740 ;_21\:\1740 ec_22\NN\8294696 2.4.2.30_23\NN\1740 )_24\-RRB-\1740 on_25\IN\1740 mice_26\NNS\2329401 suffering_27\VBG\2110220 from_28\IN\1740 acetaminophen_29\JJ\1740 (aap)-hepatitis_30\NN\1740 ,_31\,\1740 suggesting_32\VBG\1010118 that_33\IN\1740 the_34\DT\1740 aap-induced_35\JJ\1740 <e2>liver_36\NN\5298729 injury</e2>_37\NN\14052046 involves_38\VBZ\2676054 a_39\DT\13649268 step_40\NN\168237 which_41\WDT\1740 depends_42\VBZ\2604760 on_43\IN\1740 adenoribosylation_44\NN\1740 ._45\.\1740
D009536_D056486 NONE a_0\DT\13649268 further_1\JJ\1740 64_2\CD\1740 %_3\NN\1740 reduction_4\NN\351485 of_5\IN\1740 <e2>hepatitis</e2>_6\NN\14127211 was_7\VBD\836236 observed_8\VBN\2163746 ,_9\,\1740 when_10\WRB\1740 <e1>naa</e1>_11\NNP\1740 was_12\VBD\836236 given_13\VBN\2327200 to_14\IN\1740 ethanol/aap-mice_15\NN\1740 ._16\.\1740
D009536_D056486 NONE our_0\PRP$\1740 results_1\NNS\34213 provide_2\VBP\2199590 evidence_3\NN\5816287 that_4\IN\1740 the_5\DT\1740 aap-induced_6\JJ\1740 <e2>hepatitis</e2>_7\NN\14127211 and_8\CC\1740 its_9\PRP$\6125041 exacerbation_10\NN\374224 by_11\IN\1740 ethanol_12\NN\14708720 can_13\MD\3094503 either_14\RB\1740 be_15\VB\836236 reduced_16\VBN\441445 by_17\IN\1740 end-product_18\JJ\1740 inhibition_19\NN\1068773 of_20\IN\1740 parp_21\NN\1740 by_22\IN\1740 <e1>naa</e1>_23\NN\1740 or_24\CC\3541091 by_25\IN\1740 dietary_26\JJ\1740 depletion_27\NN\351638 of_28\IN\1740 the_29\DT\1740 enzyme_30\NN\14723628 's_31\POS\1740 substrate_32\JJ\1740 nad_33\NN\14800277 ._34\.\1740
D009536_D056486 NONE we_0\PRP\1740 see_1\VBP\2106506 the_2\DT\1740 main_3\JJ\1740 application_4\NN\947128 of_5\IN\1740 <e1>naa</e1>_6\NNP\1740 as_7\IN\14622893 for_8\IN\1740 the_9\DT\1740 combinational_10\JJ\1740 use_11\NN\407535 in_12\IN\13603305 pharmaceutical_13\JJ\1740 preparations_14\NNS\407535 of_15\IN\1740 acetaminophen_16\NN\2707683 in_17\IN\13603305 order_18\NN\7168131 to_19\TO\1740 avoid_20\VB\2452885 <e2>hepatic_21\JJ\1740 damage</e2>_22\NN\7296428 in_23\IN\13603305 patients_24\NNS\9898892 treated_25\VBN\2376958 with_26\IN\1740 this_27\DT\1740 widely_28\RB\1740 used_29\VBD\1156834 analgesic_30\NN\3740161 ._31\.\1740
D011064_D056486 NONE recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 demonstrated_3\VBD\2137132 the_4\DT\1740 hepatoprotective_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 nicotinic_8\JJ\1740 acid_9\NN\14818238 amide_10\NN\14727670 ,_11\,\1740 a_12\DT\13649268 selective_13\JJ\1740 inhibitor_14\NN\20090 of_15\IN\1740 <e1>poly(adp-ribose_16\NN\1740 )</e1>_17\-RRB-\1740 polymerase_18\NN\14732946 (_19\-LRB-\1740 parp_20\NN\1740 ;_21\:\1740 ec_22\NN\8294696 2.4.2.30_23\NN\1740 )_24\-RRB-\1740 on_25\IN\1740 mice_26\NNS\2329401 suffering_27\VBG\2110220 from_28\IN\1740 acetaminophen_29\JJ\1740 <e2>(aap)-hepatitis</e2>_30\NN\1740 ,_31\,\1740 suggesting_32\VBG\1010118 that_33\IN\1740 the_34\DT\1740 aap-induced_35\JJ\1740 liver_36\NN\5298729 injury_37\NN\14052046 involves_38\VBZ\2676054 a_39\DT\13649268 step_40\NN\168237 which_41\WDT\1740 depends_42\VBZ\2604760 on_43\IN\1740 adenoribosylation_44\NN\1740 ._45\.\1740
D011064_D056486 NONE recently_0\RB\1740 ,_1\,\1740 we_2\PRP\1740 demonstrated_3\VBD\2137132 the_4\DT\1740 hepatoprotective_5\JJ\1740 effects_6\NNS\13245626 of_7\IN\1740 nicotinic_8\JJ\1740 acid_9\NN\14818238 amide_10\NN\14727670 ,_11\,\1740 a_12\DT\13649268 selective_13\JJ\1740 inhibitor_14\NN\20090 of_15\IN\1740 <e1>poly(adp-ribose_16\NN\1740 )</e1>_17\-RRB-\1740 polymerase_18\NN\14732946 (_19\-LRB-\1740 parp_20\NN\1740 ;_21\:\1740 ec_22\NN\8294696 2.4.2.30_23\NN\1740 )_24\-RRB-\1740 on_25\IN\1740 mice_26\NNS\2329401 suffering_27\VBG\2110220 from_28\IN\1740 acetaminophen_29\JJ\1740 (aap)-hepatitis_30\NN\1740 ,_31\,\1740 suggesting_32\VBG\1010118 that_33\IN\1740 the_34\DT\1740 aap-induced_35\JJ\1740 <e2>liver_36\NN\5298729 injury</e2>_37\NN\14052046 involves_38\VBZ\2676054 a_39\DT\13649268 step_40\NN\168237 which_41\WDT\1740 depends_42\VBZ\2604760 on_43\IN\1740 adenoribosylation_44\NN\1740 ._45\.\1740
D000431_D056486 CID the_0\DT\1740 present_1\JJ\1740 study_2\NN\635850 investigates_3\VBZ\644583 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 a_7\DT\13649268 diet_8\NN\7560652 free_9\JJ\1740 of_10\IN\1740 precursors_11\NNS\14580897 of_12\IN\1740 nad_13\NN\14800277 ,_14\,\1740 the_15\DT\1740 substrate_16\NN\19613 on_17\IN\1740 which_18\WDT\1740 parp_19\NN\1740 acts_20\VBZ\1619354 ,_21\,\1740 in_22\IN\13603305 female_23\JJ\1740 nmri_24\NN\1740 mice_25\NNS\2329401 with_26\IN\1740 aap_27\NN\1740 <e2>hepatitis</e2>_28\NN\14127211 and_29\CC\1740 evaluates_30\VBZ\670261 the_31\DT\1740 influence_32\NN\5190804 of_33\IN\1740 simultaneous_34\JJ\1740 <e1>ethanol</e1>_35\NN\14708720 consumption_36\NN\13440063 in_37\IN\13603305 these_38\DT\1740 animals_39\NNS\4475 ._40\.\1740
D000431_D056486 CID in_0\IN\13603305 these_1\DT\1740 animals_2\NNS\4475 ,_3\,\1740 only_4\RB\1740 minor_5\JJ\1740 increases_6\NNS\13576355 of_7\IN\1740 serum_8\NN\5397468 transaminase_9\NN\15077571 activities_10\NNS\30358 were_11\VBD\836236 measured_12\VBN\697589 in_13\IN\13603305 the_14\DT\1740 presence_15\NN\13954253 of_16\IN\1740 aap_17\NNS\1740 ,_18\,\1740 and_19\CC\1740 unlike_20\IN\1740 the_21\DT\1740 exacerbation_22\NN\374224 caused_23\VBN\1617192 by_24\IN\1740 <e1>ethanol</e1>_25\NN\14708720 in_26\IN\13603305 mice_27\NNS\2329401 on_28\IN\1740 a_29\DT\13649268 standard_30\JJ\1740 diet_31\NN\7560652 ,_32\,\1740 the_33\DT\1740 <e2>liver_34\NN\5298729 damage</e2>_35\NN\7296428 was_36\VBD\836236 inhibited_37\VBN\2510337 by_38\IN\1740 50_39\CD\13745420 %_40\NN\1740 by_41\IN\1740 ethanol_42\NN\14708720 ._43\.\1740
D000431_D056486 CID in_0\IN\13603305 these_1\DT\1740 animals_2\NNS\4475 ,_3\,\1740 only_4\RB\1740 minor_5\JJ\1740 increases_6\NNS\13576355 of_7\IN\1740 serum_8\NN\5397468 transaminase_9\NN\15077571 activities_10\NNS\30358 were_11\VBD\836236 measured_12\VBN\697589 in_13\IN\13603305 the_14\DT\1740 presence_15\NN\13954253 of_16\IN\1740 aap_17\NNS\1740 ,_18\,\1740 and_19\CC\1740 unlike_20\IN\1740 the_21\DT\1740 exacerbation_22\NN\374224 caused_23\VBN\1617192 by_24\IN\1740 ethanol_25\NN\14708720 in_26\IN\13603305 mice_27\NNS\2329401 on_28\IN\1740 a_29\DT\13649268 standard_30\JJ\1740 diet_31\NN\7560652 ,_32\,\1740 the_33\DT\1740 <e2>liver_34\NN\5298729 damage</e2>_35\NN\7296428 was_36\VBD\836236 inhibited_37\VBN\2510337 by_38\IN\1740 50_39\CD\13745420 %_40\NN\1740 by_41\IN\1740 <e1>ethanol</e1>_42\NN\14708720 ._43\.\1740
D000431_D056486 CID a_0\DT\13649268 further_1\JJ\1740 64_2\CD\1740 %_3\NN\1740 reduction_4\NN\351485 of_5\IN\1740 <e2>hepatitis</e2>_6\NN\14127211 was_7\VBD\836236 observed_8\VBN\2163746 ,_9\,\1740 when_10\WRB\1740 naa_11\NNP\1740 was_12\VBD\836236 given_13\VBN\2327200 to_14\IN\1740 <e1>ethanol/aap-mice</e1>_15\NN\1740 ._16\.\1740
D000431_D056486 CID our_0\PRP$\1740 results_1\NNS\34213 provide_2\VBP\2199590 evidence_3\NN\5816287 that_4\IN\1740 the_5\DT\1740 aap-induced_6\JJ\1740 <e2>hepatitis</e2>_7\NN\14127211 and_8\CC\1740 its_9\PRP$\6125041 exacerbation_10\NN\374224 by_11\IN\1740 <e1>ethanol</e1>_12\NN\14708720 can_13\MD\3094503 either_14\RB\1740 be_15\VB\836236 reduced_16\VBN\441445 by_17\IN\1740 end-product_18\JJ\1740 inhibition_19\NN\1068773 of_20\IN\1740 parp_21\NN\1740 by_22\IN\1740 naa_23\NN\1740 or_24\CC\3541091 by_25\IN\1740 dietary_26\JJ\1740 depletion_27\NN\351638 of_28\IN\1740 the_29\DT\1740 enzyme_30\NN\14723628 's_31\POS\1740 substrate_32\JJ\1740 nad_33\NN\14800277 ._34\.\1740
D018698_D056486 NONE <e2>liver_0\NN\5298729 injuries</e2>_1\NNS\14052046 were_2\VBD\836236 quantified_3\VBN\947077 as_4\IN\14622893 serum_5\NN\5397468 activities_6\NNS\30358 of_7\IN\1740 <e1>glutamate-oxaloacetate</e1>_8\JJ\1740 transaminase_9\NN\15077571 (_10\-LRB-\1740 got_11\NN\1740 )_12\-RRB-\1740 and_13\CC\1740 glutamate-pyruvate_14\JJ\1740 transaminase_15\NN\15077571 (_16\-LRB-\1740 gpt_17\NN\1740 )_18\-RRB-\1740 ._19\.\1740
D018698_D056486 NONE <e2>liver_0\NN\5298729 injuries</e2>_1\NNS\14052046 were_2\VBD\836236 quantified_3\VBN\947077 as_4\IN\14622893 serum_5\NN\5397468 activities_6\NNS\30358 of_7\IN\1740 glutamate-oxaloacetate_8\JJ\1740 transaminase_9\NN\15077571 (_10\-LRB-\1740 got_11\NN\1740 )_12\-RRB-\1740 and_13\CC\1740 <e1>glutamate-pyruvate</e1>_14\JJ\1740 transaminase_15\NN\15077571 (_16\-LRB-\1740 gpt_17\NN\1740 )_18\-RRB-\1740 ._19\.\1740
D062907_D056486 NONE <e2>liver_0\NN\5298729 injuries</e2>_1\NNS\14052046 were_2\VBD\836236 quantified_3\VBN\947077 as_4\IN\14622893 serum_5\NN\5397468 activities_6\NNS\30358 of_7\IN\1740 <e1>glutamate-oxaloacetate</e1>_8\JJ\1740 transaminase_9\NN\15077571 (_10\-LRB-\1740 got_11\NN\1740 )_12\-RRB-\1740 and_13\CC\1740 glutamate-pyruvate_14\JJ\1740 transaminase_15\NN\15077571 (_16\-LRB-\1740 gpt_17\NN\1740 )_18\-RRB-\1740 ._19\.\1740
D019289_D056486 NONE <e2>liver_0\NN\5298729 injuries</e2>_1\NNS\14052046 were_2\VBD\836236 quantified_3\VBN\947077 as_4\IN\14622893 serum_5\NN\5397468 activities_6\NNS\30358 of_7\IN\1740 glutamate-oxaloacetate_8\JJ\1740 transaminase_9\NN\15077571 (_10\-LRB-\1740 got_11\NN\1740 )_12\-RRB-\1740 and_13\CC\1740 <e1>glutamate-pyruvate</e1>_14\JJ\1740 transaminase_15\NN\15077571 (_16\-LRB-\1740 gpt_17\NN\1740 )_18\-RRB-\1740 ._19\.\1740
1415380
D011803_D006463 CID <e2>hemolytic-uremic_0\JJ\1740 syndrome</e2>_1\NN\5870365 associated_2\VBN\628491 with_3\IN\1740 ingestion_4\NN\13440063 of_5\IN\1740 <e1>quinine</e1>_6\NN\2721948 ._7\.\1740
D011803_D006463 CID <e2>hemolytic-uremic_0\JJ\1740 syndrome</e2>_1\NN\5870365 following_2\VBG\1835496 <e1>quinine</e1>_3\NN\2721948 ingestion_4\NN\13440063 is_5\VBZ\836236 a_6\DT\13649268 newly_7\RB\1740 described_8\VBN\1001294 phenomenon_9\NN\29677 ,_10\,\1740 with_11\IN\1740 just_12\RB\1740 two_13\CD\13741022 previous_14\JJ\1740 descriptions_15\NNS\6722453 of_16\IN\1740 4_17\CD\13741022 cases_18\NNS\7283608 in_19\IN\13603305 the_20\DT\1740 literature_21\NN\6362953 ._22\.\1740
D011803_D006463 CID <e1>quinine-associated</e1>_0\JJ\1740 <e2>hemolytic-uremic_1\JJ\1740 syndrome</e2>_2\NN\5870365 probably_3\RB\1740 occurs_4\VBZ\2623529 more_5\RBR\1740 often_6\RB\1740 than_7\IN\1740 is_8\VBZ\836236 recognized_9\VBN\686447 ._10\.\1740
8480959
D008148_D006937 NONE efficacy_0\NNP\5199286 and_1\CC\1740 tolerability_2\NN\1740 of_3\IN\1740 <e1>lovastatin</e1>_4\NN\3676175 in_5\IN\13603305 3390_6\CD\1740 women_7\NNS\9605289 with_8\IN\1740 moderate_9\JJ\1740 <e2>hypercholesterolemia</e2>_10\NN\14299637 ._11\.\1740
D008148_D006937 NONE objective_0\NN\5980875 :_1\:\1740 to_2\TO\1740 evaluate_3\VB\670261 the_4\DT\1740 efficacy_5\NN\5199286 and_6\CC\1740 safety_7\NN\13920835 of_8\IN\1740 <e1>lovastatin</e1>_9\NN\3676175 in_10\IN\13603305 women_11\NNS\9605289 with_12\IN\1740 moderate_13\JJ\1740 <e2>hypercholesterolemia</e2>_14\NN\14299637 ._15\.\1740
D008148_D006937 NONE conclusion_0\NN\5837957 :_1\:\1740 <e1>lovastatin</e1>_2\NNP\3676175 is_3\VBZ\836236 highly_4\RB\1740 effective_5\JJ\1740 and_6\CC\1740 generally_7\RB\1740 well_8\RB\1740 tolerated_9\VBN\802318 as_10\IN\14622893 therapy_11\NN\657604 for_12\IN\1740 primary_13\JJ\1740 <e2>hypercholesterolemia</e2>_14\NN\14299637 in_15\IN\13603305 women_16\NNS\9605289 ._17\.\1740
D003401_D009135 NONE <e2>myopathy</e2>_0\NNP\14204950 ,_1\,\1740 defined_2\VBN\2604760 as_3\IN\14622893 muscle_4\NN\5289601 symptoms_5\NNS\5823932 with_6\IN\1740 <e1>creatine</e1>_7\NN\14601829 kinase_8\NN\14732946 elevations_9\NNS\7445480 greater_10\JJR\1740 than_11\IN\1740 10_12\CD\13745420 times_13\NNS\15113229 the_14\DT\1740 upper_15\JJ\1740 limit_16\NN\5123416 of_17\IN\1740 normal_18\JJ\1740 ,_19\,\1740 was_20\VBD\836236 rare_21\JJ\1740 and_22\CC\1740 associated_23\VBN\628491 with_24\IN\1740 the_25\DT\1740 highest_26\JJS\1740 recommended_27\VBN\875394 daily_28\JJ\1740 dose_29\NN\3740161 of_30\IN\1740 lovastatin_31\NN\3676175 (_32\-LRB-\1740 80_33\CD\13745420 mg_34\NN\13717155 )_35\-RRB-\1740 ._36\.\1740
D008148_D009135 CID <e2>myopathy</e2>_0\NNP\14204950 ,_1\,\1740 defined_2\VBN\2604760 as_3\IN\14622893 muscle_4\NN\5289601 symptoms_5\NNS\5823932 with_6\IN\1740 creatine_7\NN\14601829 kinase_8\NN\14732946 elevations_9\NNS\7445480 greater_10\JJR\1740 than_11\IN\1740 10_12\CD\13745420 times_13\NNS\15113229 the_14\DT\1740 upper_15\JJ\1740 limit_16\NN\5123416 of_17\IN\1740 normal_18\JJ\1740 ,_19\,\1740 was_20\VBD\836236 rare_21\JJ\1740 and_22\CC\1740 associated_23\VBN\628491 with_24\IN\1740 the_25\DT\1740 highest_26\JJS\1740 recommended_27\VBN\875394 daily_28\JJ\1740 dose_29\NN\3740161 of_30\IN\1740 <e1>lovastatin</e1>_31\NN\3676175 (_32\-LRB-\1740 80_33\CD\13745420 mg_34\NN\13717155 )_35\-RRB-\1740 ._36\.\1740
17965424
C422649_D001172 NONE gastrointestinal_0\JJ\1740 tolerability_1\NN\1740 of_2\IN\1740 <e1>etoricoxib</e1>_3\NN\1740 in_4\IN\13603305 <e2>rheumatoid_5\JJ\1740 arthritis</e2>_6\NN\14171682 patients_7\NNS\9898892 :_8\:\1740 results_9\NNS\34213 of_10\IN\1740 the_11\DT\1740 etoricoxib_12\NN\1740 vs_13\RB\1740 diclofenac_14\VB\1740 sodium_15\NN\14625458 gastrointestinal_16\NN\1740 tolerability_17\NN\1740 and_18\CC\1740 effectiveness_19\NN\5190804 trial_20\NN\786195 (_21\-LRB-\1740 edge-ii_22\NN\1740 )_23\-RRB-\1740 ._24\.\1740
C422649_D001172 NONE gastrointestinal_0\JJ\1740 tolerability_1\NN\1740 of_2\IN\1740 etoricoxib_3\NN\1740 in_4\IN\13603305 <e2>rheumatoid_5\JJ\1740 arthritis</e2>_6\NN\14171682 patients_7\NNS\9898892 :_8\:\1740 results_9\NNS\34213 of_10\IN\1740 the_11\DT\1740 <e1>etoricoxib</e1>_12\NN\1740 vs_13\RB\1740 diclofenac_14\VB\1740 sodium_15\NN\14625458 gastrointestinal_16\NN\1740 tolerability_17\NN\1740 and_18\CC\1740 effectiveness_19\NN\5190804 trial_20\NN\786195 (_21\-LRB-\1740 edge-ii_22\NN\1740 )_23\-RRB-\1740 ._24\.\1740
C422649_D001172 NONE objective_0\NN\5980875 :_1\:\1740 a_2\DT\13649268 randomised_3\VBN\278117 ,_4\,\1740 double-blind_5\NN\1740 study_6\NN\635850 to_7\TO\1740 compare_8\VB\644583 the_9\DT\1740 gastrointestinal_10\NN\1740 (_11\-LRB-\1740 gi_12\NN\13634615 )_13\-RRB-\1740 tolerability_14\NN\1740 ,_15\,\1740 safety_16\NN\13920835 and_17\CC\1740 efficacy_18\NN\5199286 of_19\IN\1740 <e1>etoricoxib</e1>_20\NN\1740 and_21\CC\1740 diclofenac_22\VB\1740 in_23\IN\13603305 patients_24\NNS\9898892 with_25\IN\1740 <e2>rheumatoid_26\JJ\1740 arthritis</e2>_27\NN\14171682 (_28\-LRB-\1740 ra_29\NN\14625458 )_30\-RRB-\1740 ._31\.\1740
C422649_D001172 NONE objective_0\NN\5980875 :_1\:\1740 a_2\DT\13649268 randomised_3\VBN\278117 ,_4\,\1740 double-blind_5\NN\1740 study_6\NN\635850 to_7\TO\1740 compare_8\VB\644583 the_9\DT\1740 gastrointestinal_10\NN\1740 (_11\-LRB-\1740 gi_12\NN\13634615 )_13\-RRB-\1740 tolerability_14\NN\1740 ,_15\,\1740 safety_16\NN\13920835 and_17\CC\1740 efficacy_18\NN\5199286 of_19\IN\1740 <e1>etoricoxib</e1>_20\NN\1740 and_21\CC\1740 diclofenac_22\VB\1740 in_23\IN\13603305 patients_24\NNS\9898892 with_25\IN\1740 rheumatoid_26\JJ\1740 arthritis_27\NN\14171682 (_28\-LRB-\1740 <e2>ra</e2>_29\NN\14625458 )_30\-RRB-\1740 ._31\.\1740
C422649_D001172 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 a_4\DT\13649268 total_5\NN\3553 of_6\IN\1740 4086_7\CD\1740 patients_8\NNS\9898892 (_9\-LRB-\1740 mean_10\NN\6021761 age_11\NN\4916342 60.8_12\CD\1740 years_13\NNS\15144371 )_14\-RRB-\1740 diagnosed_15\VBN\644583 with_16\IN\1740 <e2>ra</e2>_17\NN\14625458 were_18\VBD\836236 enrolled_19\VBN\2471690 and_20\CC\1740 received_21\VBN\2210855 <e1>etoricoxib</e1>_22\NN\1740 90_23\CD\13745420 mg_24\NN\13717155 daily_25\RB\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 2032_29\CD\1740 )_30\-RRB-\1740 or_31\CC\3541091 diclofenac_32\JJ\1740 75_33\CD\1740 mg_34\NN\13717155 twice_35\RB\1740 daily_36\RB\1740 (_37\-LRB-\1740 n_38\NN\14622893 =_39\JJ\1740 2054_40\CD\1740 )_41\-RRB-\1740 ._42\.\1740
D004008_D001172 NONE gastrointestinal_0\JJ\1740 tolerability_1\NN\1740 of_2\IN\1740 etoricoxib_3\NN\1740 in_4\IN\13603305 <e2>rheumatoid_5\JJ\1740 arthritis</e2>_6\NN\14171682 patients_7\NNS\9898892 :_8\:\1740 results_9\NNS\34213 of_10\IN\1740 the_11\DT\1740 etoricoxib_12\NN\1740 vs_13\RB\1740 <e1>diclofenac_14\VB\1740 sodium</e1>_15\NN\14625458 gastrointestinal_16\NN\1740 tolerability_17\NN\1740 and_18\CC\1740 effectiveness_19\NN\5190804 trial_20\NN\786195 (_21\-LRB-\1740 edge-ii_22\NN\1740 )_23\-RRB-\1740 ._24\.\1740
D004008_D001172 NONE objective_0\NN\5980875 :_1\:\1740 a_2\DT\13649268 randomised_3\VBN\278117 ,_4\,\1740 double-blind_5\NN\1740 study_6\NN\635850 to_7\TO\1740 compare_8\VB\644583 the_9\DT\1740 gastrointestinal_10\NN\1740 (_11\-LRB-\1740 gi_12\NN\13634615 )_13\-RRB-\1740 tolerability_14\NN\1740 ,_15\,\1740 safety_16\NN\13920835 and_17\CC\1740 efficacy_18\NN\5199286 of_19\IN\1740 etoricoxib_20\NN\1740 and_21\CC\1740 <e1>diclofenac</e1>_22\VB\1740 in_23\IN\13603305 patients_24\NNS\9898892 with_25\IN\1740 <e2>rheumatoid_26\JJ\1740 arthritis</e2>_27\NN\14171682 (_28\-LRB-\1740 ra_29\NN\14625458 )_30\-RRB-\1740 ._31\.\1740
D004008_D001172 NONE objective_0\NN\5980875 :_1\:\1740 a_2\DT\13649268 randomised_3\VBN\278117 ,_4\,\1740 double-blind_5\NN\1740 study_6\NN\635850 to_7\TO\1740 compare_8\VB\644583 the_9\DT\1740 gastrointestinal_10\NN\1740 (_11\-LRB-\1740 gi_12\NN\13634615 )_13\-RRB-\1740 tolerability_14\NN\1740 ,_15\,\1740 safety_16\NN\13920835 and_17\CC\1740 efficacy_18\NN\5199286 of_19\IN\1740 etoricoxib_20\NN\1740 and_21\CC\1740 <e1>diclofenac</e1>_22\VB\1740 in_23\IN\13603305 patients_24\NNS\9898892 with_25\IN\1740 rheumatoid_26\JJ\1740 arthritis_27\NN\14171682 (_28\-LRB-\1740 <e2>ra</e2>_29\NN\14625458 )_30\-RRB-\1740 ._31\.\1740
D004008_D001172 NONE patients_0\NNS\9898892 and_1\CC\1740 methods_2\NNS\5616786 :_3\:\1740 a_4\DT\13649268 total_5\NN\3553 of_6\IN\1740 4086_7\CD\1740 patients_8\NNS\9898892 (_9\-LRB-\1740 mean_10\NN\6021761 age_11\NN\4916342 60.8_12\CD\1740 years_13\NNS\15144371 )_14\-RRB-\1740 diagnosed_15\VBN\644583 with_16\IN\1740 <e2>ra</e2>_17\NN\14625458 were_18\VBD\836236 enrolled_19\VBN\2471690 and_20\CC\1740 received_21\VBN\2210855 etoricoxib_22\NN\1740 90_23\CD\13745420 mg_24\NN\13717155 daily_25\RB\1740 (_26\-LRB-\1740 n_27\NN\14622893 =_28\JJ\1740 2032_29\CD\1740 )_30\-RRB-\1740 or_31\CC\3541091 <e1>diclofenac</e1>_32\JJ\1740 75_33\CD\1740 mg_34\NN\13717155 twice_35\RB\1740 daily_36\RB\1740 (_37\-LRB-\1740 n_38\NN\14622893 =_39\JJ\1740 2054_40\CD\1740 )_41\-RRB-\1740 ._42\.\1740
C422649_D005767 NONE the_0\DT\1740 cumulative_1\JJ\1740 discontinuation_2\NN\209943 rate_3\NN\13815152 due_4\IN\5174653 to_5\TO\1740 <e2>gi_6\NN\13634615 aes</e2>_7\NNS\1740 was_8\VBD\836236 significantly_9\RB\1740 lower_10\JJR\1740 with_11\IN\1740 <e1>etoricoxib</e1>_12\NN\1740 than_13\IN\1740 diclofenac_14\JJ\1740 (_15\-LRB-\1740 5.2_16\CD\1740 vs_17\CC\13634784 8.5_18\CD\1740 events_19\NNS\23100 per_20\IN\1740 100_21\CD\13745420 patient-years_22\NNS\1740 ,_23\,\1740 respectively_24\RB\1740 ;_25\:\1740 hazard_26\NN\14541044 ratio_27\NN\13815152 0.62_28\CD\1740 (_29\-LRB-\1740 95_30\CD\1740 %_31\NN\1740 ci_32\NN\13635336 :_33\:\1740 0.47_34\CD\1740 ,_35\,\1740 0.81_36\CD\1740 ;_37\:\1740 p_38\NN\14622893 <_39\XX\1740 or=0.001_40\NN\1740 )_41\-RRB-\1740 )_42\-RRB-\1740 ._43\.\1740
C422649_D005767 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>etoricoxib</e1>_2\NN\1740 90_3\CD\13745420 mg_4\NN\13717155 demonstrated_5\VBD\2137132 a_6\DT\13649268 significantly_7\RB\1740 lower_8\JJR\1740 risk_9\NN\14541044 for_10\IN\1740 discontinuing_11\VBG\2609764 treatment_12\NN\654885 due_13\JJ\1740 to_14\TO\1740 <e2>gi_15\NN\13634615 aes</e2>_16\NNS\1740 compared_17\VBN\644583 with_18\IN\1740 diclofenac_19\JJ\1740 150_20\CD\1740 mg._21\NN\1740 discontinuations_22\NNS\209943 from_23\IN\1740 renovascular_24\JJ\1740 aes_25\NNS\1740 ,_26\,\1740 although_27\IN\1740 less_28\RBR\1740 common_29\JJ\1740 than_30\IN\1740 discontinuations_31\NNS\209943 from_32\IN\1740 gi_33\NN\13634615 aes_34\NNS\1740 ,_35\,\1740 were_36\VBD\836236 significantly_37\RB\1740 higher_38\JJR\1740 with_39\IN\1740 etoricoxib_40\NN\1740 ._41\.\1740
C422649_D005767 NONE conclusions_0\NNS\5837957 :_1\:\1740 <e1>etoricoxib</e1>_2\NN\1740 90_3\CD\13745420 mg_4\NN\13717155 demonstrated_5\VBD\2137132 a_6\DT\13649268 significantly_7\RB\1740 lower_8\JJR\1740 risk_9\NN\14541044 for_10\IN\1740 discontinuing_11\VBG\2609764 treatment_12\NN\654885 due_13\JJ\1740 to_14\TO\1740 gi_15\NN\13634615 aes_16\NNS\1740 compared_17\VBN\644583 with_18\IN\1740 diclofenac_19\JJ\1740 150_20\CD\1740 mg._21\NN\1740 discontinuations_22\NNS\209943 from_23\IN\1740 renovascular_24\JJ\1740 aes_25\NNS\1740 ,_26\,\1740 although_27\IN\1740 less_28\RBR\1740 common_29\JJ\1740 than_30\IN\1740 discontinuations_31\NNS\209943 from_32\IN\1740 <e2>gi_33\NN\13634615 aes</e2>_34\NNS\1740 ,_35\,\1740 were_36\VBD\836236 significantly_37\RB\1740 higher_38\JJR\1740 with_39\IN\1740 etoricoxib_40\NN\1740 ._41\.\1740
C422649_D005767 NONE conclusions_0\NNS\5837957 :_1\:\1740 etoricoxib_2\NN\1740 90_3\CD\13745420 mg_4\NN\13717155 demonstrated_5\VBD\2137132 a_6\DT\13649268 significantly_7\RB\1740 lower_8\JJR\1740 risk_9\NN\14541044 for_10\IN\1740 discontinuing_11\VBG\2609764 treatment_12\NN\654885 due_13\JJ\1740 to_14\TO\1740 <e2>gi_15\NN\13634615 aes</e2>_16\NNS\1740 compared_17\VBN\644583 with_18\IN\1740 diclofenac_19\JJ\1740 150_20\CD\1740 mg._21\NN\1740 discontinuations_22\NNS\209943 from_23\IN\1740 renovascular_24\JJ\1740 aes_25\NNS\1740 ,_26\,\1740 although_27\IN\1740 less_28\RBR\1740 common_29\JJ\1740 than_30\IN\1740 discontinuations_31\NNS\209943 from_32\IN\1740 gi_33\NN\13634615 aes_34\NNS\1740 ,_35\,\1740 were_36\VBD\836236 significantly_37\RB\1740 higher_38\JJR\1740 with_39\IN\1740 <e1>etoricoxib</e1>_40\NN\1740 ._41\.\1740
C422649_D005767 NONE conclusions_0\NNS\5837957 :_1\:\1740 etoricoxib_2\NN\1740 90_3\CD\13745420 mg_4\NN\13717155 demonstrated_5\VBD\2137132 a_6\DT\13649268 significantly_7\RB\1740 lower_8\JJR\1740 risk_9\NN\14541044 for_10\IN\1740 discontinuing_11\VBG\2609764 treatment_12\NN\654885 due_13\JJ\1740 to_14\TO\1740 gi_15\NN\13634615 aes_16\NNS\1740 compared_17\VBN\644583 with_18\IN\1740 diclofenac_19\JJ\1740 150_20\CD\1740 mg._21\NN\1740 discontinuations_22\NNS\209943 from_23\IN\1740 renovascular_24\JJ\1740 aes_25\NNS\1740 ,_26\,\1740 although_27\IN\1740 less_28\RBR\1740 common_29\JJ\1740 than_30\IN\1740 discontinuations_31\NNS\209943 from_32\IN\1740 <e2>gi_33\NN\13634615 aes</e2>_34\NNS\1740 ,_35\,\1740 were_36\VBD\836236 significantly_37\RB\1740 higher_38\JJR\1740 with_39\IN\1740 <e1>etoricoxib</e1>_40\NN\1740 ._41\.\1740
D004008_D005767 CID the_0\DT\1740 cumulative_1\JJ\1740 discontinuation_2\NN\209943 rate_3\NN\13815152 due_4\IN\5174653 to_5\TO\1740 <e2>gi_6\NN\13634615 aes</e2>_7\NNS\1740 was_8\VBD\836236 significantly_9\RB\1740 lower_10\JJR\1740 with_11\IN\1740 etoricoxib_12\NN\1740 than_13\IN\1740 <e1>diclofenac</e1>_14\JJ\1740 (_15\-LRB-\1740 5.2_16\CD\1740 vs_17\CC\13634784 8.5_18\CD\1740 events_19\NNS\23100 per_20\IN\1740 100_21\CD\13745420 patient-years_22\NNS\1740 ,_23\,\1740 respectively_24\RB\1740 ;_25\:\1740 hazard_26\NN\14541044 ratio_27\NN\13815152 0.62_28\CD\1740 (_29\-LRB-\1740 95_30\CD\1740 %_31\NN\1740 ci_32\NN\13635336 :_33\:\1740 0.47_34\CD\1740 ,_35\,\1740 0.81_36\CD\1740 ;_37\:\1740 p_38\NN\14622893 <_39\XX\1740 or=0.001_40\NN\1740 )_41\-RRB-\1740 )_42\-RRB-\1740 ._43\.\1740
D004008_D005767 CID conclusions_0\NNS\5837957 :_1\:\1740 etoricoxib_2\NN\1740 90_3\CD\13745420 mg_4\NN\13717155 demonstrated_5\VBD\2137132 a_6\DT\13649268 significantly_7\RB\1740 lower_8\JJR\1740 risk_9\NN\14541044 for_10\IN\1740 discontinuing_11\VBG\2609764 treatment_12\NN\654885 due_13\JJ\1740 to_14\TO\1740 <e2>gi_15\NN\13634615 aes</e2>_16\NNS\1740 compared_17\VBN\644583 with_18\IN\1740 <e1>diclofenac</e1>_19\JJ\1740 150_20\CD\1740 mg._21\NN\1740 discontinuations_22\NNS\209943 from_23\IN\1740 renovascular_24\JJ\1740 aes_25\NNS\1740 ,_26\,\1740 although_27\IN\1740 less_28\RBR\1740 common_29\JJ\1740 than_30\IN\1740 discontinuations_31\NNS\209943 from_32\IN\1740 gi_33\NN\13634615 aes_34\NNS\1740 ,_35\,\1740 were_36\VBD\836236 significantly_37\RB\1740 higher_38\JJR\1740 with_39\IN\1740 etoricoxib_40\NN\1740 ._41\.\1740
D004008_D005767 CID conclusions_0\NNS\5837957 :_1\:\1740 etoricoxib_2\NN\1740 90_3\CD\13745420 mg_4\NN\13717155 demonstrated_5\VBD\2137132 a_6\DT\13649268 significantly_7\RB\1740 lower_8\JJR\1740 risk_9\NN\14541044 for_10\IN\1740 discontinuing_11\VBG\2609764 treatment_12\NN\654885 due_13\JJ\1740 to_14\TO\1740 gi_15\NN\13634615 aes_16\NNS\1740 compared_17\VBN\644583 with_18\IN\1740 <e1>diclofenac</e1>_19\JJ\1740 150_20\CD\1740 mg._21\NN\1740 discontinuations_22\NNS\209943 from_23\IN\1740 renovascular_24\JJ\1740 aes_25\NNS\1740 ,_26\,\1740 although_27\IN\1740 less_28\RBR\1740 common_29\JJ\1740 than_30\IN\1740 discontinuations_31\NNS\209943 from_32\IN\1740 <e2>gi_33\NN\13634615 aes</e2>_34\NNS\1740 ,_35\,\1740 were_36\VBD\836236 significantly_37\RB\1740 higher_38\JJR\1740 with_39\IN\1740 etoricoxib_40\NN\1740 ._41\.\1740
C422649_D006973 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 discontinuations_3\NNS\209943 for_4\IN\1740 <e2>hypertension-related</e2>_5\JJ\1740 and_6\CC\1740 oedema-related_7\JJ\1740 aes_8\NNS\1740 were_9\VBD\836236 significantly_10\RB\1740 higher_11\JJR\1740 with_12\IN\1740 <e1>etoricoxib</e1>_13\NN\1740 (_14\-LRB-\1740 2.5_15\CD\1740 %_16\NN\1740 and_17\CC\1740 1.1_18\CD\1740 %_19\NN\1740 respectively_20\RB\1740 )_21\-RRB-\1740 compared_22\VBN\644583 with_23\IN\1740 diclofenac_24\NN\1740 (_25\-LRB-\1740 1.5_26\CD\1740 %_27\NN\1740 and_28\CC\1740 0.4_29\CD\1740 %_30\NN\1740 respectively_31\RB\1740 ;_32\:\1740 p<0.001_33\NN\1740 for_34\IN\1740 hypertension_35\NN\14057371 and_36\CC\1740 p<0.01_37\NN\1740 for_38\IN\1740 oedema_39\NN\14315192 )_40\-RRB-\1740 ._41\.\1740
C422649_D006973 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 discontinuations_3\NNS\209943 for_4\IN\1740 hypertension-related_5\JJ\1740 and_6\CC\1740 oedema-related_7\JJ\1740 aes_8\NNS\1740 were_9\VBD\836236 significantly_10\RB\1740 higher_11\JJR\1740 with_12\IN\1740 <e1>etoricoxib</e1>_13\NN\1740 (_14\-LRB-\1740 2.5_15\CD\1740 %_16\NN\1740 and_17\CC\1740 1.1_18\CD\1740 %_19\NN\1740 respectively_20\RB\1740 )_21\-RRB-\1740 compared_22\VBN\644583 with_23\IN\1740 diclofenac_24\NN\1740 (_25\-LRB-\1740 1.5_26\CD\1740 %_27\NN\1740 and_28\CC\1740 0.4_29\CD\1740 %_30\NN\1740 respectively_31\RB\1740 ;_32\:\1740 p<0.001_33\NN\1740 for_34\IN\1740 <e2>hypertension</e2>_35\NN\14057371 and_36\CC\1740 p<0.01_37\NN\1740 for_38\IN\1740 oedema_39\NN\14315192 )_40\-RRB-\1740 ._41\.\1740
C422649_D004487 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 discontinuations_3\NNS\209943 for_4\IN\1740 hypertension-related_5\JJ\1740 and_6\CC\1740 <e2>oedema-related</e2>_7\JJ\1740 aes_8\NNS\1740 were_9\VBD\836236 significantly_10\RB\1740 higher_11\JJR\1740 with_12\IN\1740 <e1>etoricoxib</e1>_13\NN\1740 (_14\-LRB-\1740 2.5_15\CD\1740 %_16\NN\1740 and_17\CC\1740 1.1_18\CD\1740 %_19\NN\1740 respectively_20\RB\1740 )_21\-RRB-\1740 compared_22\VBN\644583 with_23\IN\1740 diclofenac_24\NN\1740 (_25\-LRB-\1740 1.5_26\CD\1740 %_27\NN\1740 and_28\CC\1740 0.4_29\CD\1740 %_30\NN\1740 respectively_31\RB\1740 ;_32\:\1740 p<0.001_33\NN\1740 for_34\IN\1740 hypertension_35\NN\14057371 and_36\CC\1740 p<0.01_37\NN\1740 for_38\IN\1740 oedema_39\NN\14315192 )_40\-RRB-\1740 ._41\.\1740
C422649_D004487 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 discontinuations_3\NNS\209943 for_4\IN\1740 hypertension-related_5\JJ\1740 and_6\CC\1740 oedema-related_7\JJ\1740 aes_8\NNS\1740 were_9\VBD\836236 significantly_10\RB\1740 higher_11\JJR\1740 with_12\IN\1740 <e1>etoricoxib</e1>_13\NN\1740 (_14\-LRB-\1740 2.5_15\CD\1740 %_16\NN\1740 and_17\CC\1740 1.1_18\CD\1740 %_19\NN\1740 respectively_20\RB\1740 )_21\-RRB-\1740 compared_22\VBN\644583 with_23\IN\1740 diclofenac_24\NN\1740 (_25\-LRB-\1740 1.5_26\CD\1740 %_27\NN\1740 and_28\CC\1740 0.4_29\CD\1740 %_30\NN\1740 respectively_31\RB\1740 ;_32\:\1740 p<0.001_33\NN\1740 for_34\IN\1740 hypertension_35\NN\14057371 and_36\CC\1740 p<0.01_37\NN\1740 for_38\IN\1740 <e2>oedema</e2>_39\NN\14315192 )_40\-RRB-\1740 ._41\.\1740
D004008_D006973 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 discontinuations_3\NNS\209943 for_4\IN\1740 <e2>hypertension-related</e2>_5\JJ\1740 and_6\CC\1740 oedema-related_7\JJ\1740 aes_8\NNS\1740 were_9\VBD\836236 significantly_10\RB\1740 higher_11\JJR\1740 with_12\IN\1740 etoricoxib_13\NN\1740 (_14\-LRB-\1740 2.5_15\CD\1740 %_16\NN\1740 and_17\CC\1740 1.1_18\CD\1740 %_19\NN\1740 respectively_20\RB\1740 )_21\-RRB-\1740 compared_22\VBN\644583 with_23\IN\1740 <e1>diclofenac</e1>_24\NN\1740 (_25\-LRB-\1740 1.5_26\CD\1740 %_27\NN\1740 and_28\CC\1740 0.4_29\CD\1740 %_30\NN\1740 respectively_31\RB\1740 ;_32\:\1740 p<0.001_33\NN\1740 for_34\IN\1740 hypertension_35\NN\14057371 and_36\CC\1740 p<0.01_37\NN\1740 for_38\IN\1740 oedema_39\NN\14315192 )_40\-RRB-\1740 ._41\.\1740
D004008_D006973 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 discontinuations_3\NNS\209943 for_4\IN\1740 hypertension-related_5\JJ\1740 and_6\CC\1740 oedema-related_7\JJ\1740 aes_8\NNS\1740 were_9\VBD\836236 significantly_10\RB\1740 higher_11\JJR\1740 with_12\IN\1740 etoricoxib_13\NN\1740 (_14\-LRB-\1740 2.5_15\CD\1740 %_16\NN\1740 and_17\CC\1740 1.1_18\CD\1740 %_19\NN\1740 respectively_20\RB\1740 )_21\-RRB-\1740 compared_22\VBN\644583 with_23\IN\1740 <e1>diclofenac</e1>_24\NN\1740 (_25\-LRB-\1740 1.5_26\CD\1740 %_27\NN\1740 and_28\CC\1740 0.4_29\CD\1740 %_30\NN\1740 respectively_31\RB\1740 ;_32\:\1740 p<0.001_33\NN\1740 for_34\IN\1740 <e2>hypertension</e2>_35\NN\14057371 and_36\CC\1740 p<0.01_37\NN\1740 for_38\IN\1740 oedema_39\NN\14315192 )_40\-RRB-\1740 ._41\.\1740
D004008_D004487 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 discontinuations_3\NNS\209943 for_4\IN\1740 hypertension-related_5\JJ\1740 and_6\CC\1740 <e2>oedema-related</e2>_7\JJ\1740 aes_8\NNS\1740 were_9\VBD\836236 significantly_10\RB\1740 higher_11\JJR\1740 with_12\IN\1740 etoricoxib_13\NN\1740 (_14\-LRB-\1740 2.5_15\CD\1740 %_16\NN\1740 and_17\CC\1740 1.1_18\CD\1740 %_19\NN\1740 respectively_20\RB\1740 )_21\-RRB-\1740 compared_22\VBN\644583 with_23\IN\1740 <e1>diclofenac</e1>_24\NN\1740 (_25\-LRB-\1740 1.5_26\CD\1740 %_27\NN\1740 and_28\CC\1740 0.4_29\CD\1740 %_30\NN\1740 respectively_31\RB\1740 ;_32\:\1740 p<0.001_33\NN\1740 for_34\IN\1740 hypertension_35\NN\14057371 and_36\CC\1740 p<0.01_37\NN\1740 for_38\IN\1740 oedema_39\NN\14315192 )_40\-RRB-\1740 ._41\.\1740
D004008_D004487 NONE the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 discontinuations_3\NNS\209943 for_4\IN\1740 hypertension-related_5\JJ\1740 and_6\CC\1740 oedema-related_7\JJ\1740 aes_8\NNS\1740 were_9\VBD\836236 significantly_10\RB\1740 higher_11\JJR\1740 with_12\IN\1740 etoricoxib_13\NN\1740 (_14\-LRB-\1740 2.5_15\CD\1740 %_16\NN\1740 and_17\CC\1740 1.1_18\CD\1740 %_19\NN\1740 respectively_20\RB\1740 )_21\-RRB-\1740 compared_22\VBN\644583 with_23\IN\1740 <e1>diclofenac</e1>_24\NN\1740 (_25\-LRB-\1740 1.5_26\CD\1740 %_27\NN\1740 and_28\CC\1740 0.4_29\CD\1740 %_30\NN\1740 respectively_31\RB\1740 ;_32\:\1740 p<0.001_33\NN\1740 for_34\IN\1740 hypertension_35\NN\14057371 and_36\CC\1740 p<0.01_37\NN\1740 for_38\IN\1740 <e2>oedema</e2>_39\NN\14315192 )_40\-RRB-\1740 ._41\.\1740
6381653
D007980_D004409 CID <e1>levodopa-induced</e1>_0\JJ\1740 <e2>dyskinesia</e2>_1\NN\14084880 and_2\CC\1740 thalamotomy_3\NN\1740 ._4\.\1740
D007980_D004409 CID <e1>levodopa-induced</e1>_0\JJ\1740 <e2>dyskinesia</e2>_1\NN\14084880 of_2\IN\1740 the_3\DT\1740 limbs_4\NNS\5559908 in_5\IN\13603305 thirteen_6\CD\13745420 cases_7\NNS\7283608 of_8\IN\1740 parkinsonism_9\NNP\14085708 ,_10\,\1740 which_11\WDT\1740 was_12\VBD\836236 choreic_13\JJ\1740 ,_14\,\1740 ballistic_15\JJ\1740 or_16\CC\3541091 dystonic_17\JJ\1740 in_18\IN\13603305 type_19\NN\5839024 ,_20\,\1740 was_21\VBD\836236 alleviated_22\VBN\205885 almost_23\RB\1740 completely_24\RB\1740 by_25\IN\1740 stereotaxic_26\JJ\1740 surgery_27\NN\6045562 using_28\VBG\1156834 a_29\DT\13649268 microelectrode_30\JJ\1740 technique_31\NN\5660268 for_32\IN\1740 the_33\DT\1740 ventralis_34\NN\1740 oralis_35\NN\1740 anterior_36\JJ\1740 and_37\CC\1740 posterior_38\JJ\1740 nuclei_39\NNS\5445668 of_40\IN\1740 the_41\DT\1740 thalamus_42\NN\5462674 ,_43\,\1740 but_44\CC\1740 much_45\RB\1740 less_46\JJR\1740 by_47\IN\1740 the_48\DT\1740 ventralis_49\NN\1740 intermedius_50\NN\1740 nucleus_51\NN\5445668 ._52\.\1740
D007980_D004409 CID control_0\NN\5190804 of_1\IN\1740 <e1>levodopa-induced</e1>_2\JJ\1740 <e2>dyskinesias</e2>_3\NNS\14084880 by_4\IN\1740 thalamic_5\NN\1740 lesions_6\NNS\14204950 in_7\IN\13603305 the_8\DT\1740 course_9\NN\883297 of_10\IN\1740 routine_11\JJ\1740 treatment_12\NN\654885 of_13\IN\1740 parkinsonism_14\NN\14085708 is_15\VBZ\836236 discussed_16\VBN\1033527 ._17\.\1740
D007980_D010302 NONE <e1>levodopa-induced</e1>_0\JJ\1740 dyskinesia_1\NN\14084880 of_2\IN\1740 the_3\DT\1740 limbs_4\NNS\5559908 in_5\IN\13603305 thirteen_6\CD\13745420 cases_7\NNS\7283608 of_8\IN\1740 <e2>parkinsonism</e2>_9\NNP\14085708 ,_10\,\1740 which_11\WDT\1740 was_12\VBD\836236 choreic_13\JJ\1740 ,_14\,\1740 ballistic_15\JJ\1740 or_16\CC\3541091 dystonic_17\JJ\1740 in_18\IN\13603305 type_19\NN\5839024 ,_20\,\1740 was_21\VBD\836236 alleviated_22\VBN\205885 almost_23\RB\1740 completely_24\RB\1740 by_25\IN\1740 stereotaxic_26\JJ\1740 surgery_27\NN\6045562 using_28\VBG\1156834 a_29\DT\13649268 microelectrode_30\JJ\1740 technique_31\NN\5660268 for_32\IN\1740 the_33\DT\1740 ventralis_34\NN\1740 oralis_35\NN\1740 anterior_36\JJ\1740 and_37\CC\1740 posterior_38\JJ\1740 nuclei_39\NNS\5445668 of_40\IN\1740 the_41\DT\1740 thalamus_42\NN\5462674 ,_43\,\1740 but_44\CC\1740 much_45\RB\1740 less_46\JJR\1740 by_47\IN\1740 the_48\DT\1740 ventralis_49\NN\1740 intermedius_50\NN\1740 nucleus_51\NN\5445668 ._52\.\1740
D007980_D010302 NONE control_0\NN\5190804 of_1\IN\1740 <e1>levodopa-induced</e1>_2\JJ\1740 dyskinesias_3\NNS\14084880 by_4\IN\1740 thalamic_5\NN\1740 lesions_6\NNS\14204950 in_7\IN\13603305 the_8\DT\1740 course_9\NN\883297 of_10\IN\1740 routine_11\JJ\1740 treatment_12\NN\654885 of_13\IN\1740 <e2>parkinsonism</e2>_14\NN\14085708 is_15\VBZ\836236 discussed_16\VBN\1033527 ._17\.\1740
D007980_D020821 NONE <e1>levodopa-induced</e1>_0\JJ\1740 dyskinesia_1\NN\14084880 of_2\IN\1740 the_3\DT\1740 limbs_4\NNS\5559908 in_5\IN\13603305 thirteen_6\CD\13745420 cases_7\NNS\7283608 of_8\IN\1740 parkinsonism_9\NNP\14085708 ,_10\,\1740 which_11\WDT\1740 was_12\VBD\836236 choreic_13\JJ\1740 ,_14\,\1740 ballistic_15\JJ\1740 or_16\CC\3541091 <e2>dystonic</e2>_17\JJ\1740 in_18\IN\13603305 type_19\NN\5839024 ,_20\,\1740 was_21\VBD\836236 alleviated_22\VBN\205885 almost_23\RB\1740 completely_24\RB\1740 by_25\IN\1740 stereotaxic_26\JJ\1740 surgery_27\NN\6045562 using_28\VBG\1156834 a_29\DT\13649268 microelectrode_30\JJ\1740 technique_31\NN\5660268 for_32\IN\1740 the_33\DT\1740 ventralis_34\NN\1740 oralis_35\NN\1740 anterior_36\JJ\1740 and_37\CC\1740 posterior_38\JJ\1740 nuclei_39\NNS\5445668 of_40\IN\1740 the_41\DT\1740 thalamus_42\NN\5462674 ,_43\,\1740 but_44\CC\1740 much_45\RB\1740 less_46\JJR\1740 by_47\IN\1740 the_48\DT\1740 ventralis_49\NN\1740 intermedius_50\NN\1740 nucleus_51\NN\5445668 ._52\.\1740
D007980_D013786 NONE control_0\NN\5190804 of_1\IN\1740 <e1>levodopa-induced</e1>_2\JJ\1740 dyskinesias_3\NNS\14084880 by_4\IN\1740 <e2>thalamic_5\NN\1740 lesions</e2>_6\NNS\14204950 in_7\IN\13603305 the_8\DT\1740 course_9\NN\883297 of_10\IN\1740 routine_11\JJ\1740 treatment_12\NN\654885 of_13\IN\1740 parkinsonism_14\NN\14085708 is_15\VBZ\836236 discussed_16\VBN\1033527 ._17\.\1740
12691807
D007980_D004421 CID <e1>levodopa-induced</e1>_0\JJ\1740 oromandibular_1\JJ\1740 <e2>dystonia</e2>_2\NN\1740 in_3\IN\13603305 progressive_4\JJ\1740 supranuclear_5\NN\1740 palsy_6\NN\14557898 ._7\.\1740
D007980_D013494 NONE <e1>levodopa-induced</e1>_0\JJ\1740 oromandibular_1\JJ\1740 dystonia_2\NN\1740 in_3\IN\13603305 <e2>progressive_4\JJ\1740 supranuclear_5\NN\1740 palsy</e2>_6\NN\14557898 ._7\.\1740
D007980_D013494 NONE in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 we_3\PRP\1740 describe_4\VBP\1001294 an_5\DT\6697703 unusual_6\JJ\1740 case_7\NN\7283608 of_8\IN\1740 reversible_9\JJ\1740 <e1>levodopa-induced</e1>_10\JJ\1740 oromandibular_11\JJ\1740 dystonia_12\NN\1740 (_13\-LRB-\1740 omd_14\NN\1740 )_15\-RRB-\1740 in_16\IN\13603305 a_17\DT\13649268 <e2>psp</e2>_18\NN\1740 patient_19\NN\9898892 to_20\TO\1740 highlight_21\VB\514463 the_22\DT\1740 importance_23\NN\5138488 of_24\IN\1740 recognizing_25\VBG\686447 this_26\DT\1740 drug_27\NN\14778436 related_28\JJ\1740 complication_29\NN\1073995 in_30\IN\13603305 the_31\DT\1740 management_32\NN\1123598 of_33\IN\1740 psp_34\NNP\1740 ,_35\,\1740 and_36\CC\1740 discuss_37\VBP\1033527 the_38\DT\1740 possible_39\JJ\1740 underlying_40\JJ\1740 pathophysiology_41\NN\1740 ._42\.\1740
D007980_D013494 NONE in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 we_3\PRP\1740 describe_4\VBP\1001294 an_5\DT\6697703 unusual_6\JJ\1740 case_7\NN\7283608 of_8\IN\1740 reversible_9\JJ\1740 <e1>levodopa-induced</e1>_10\JJ\1740 oromandibular_11\JJ\1740 dystonia_12\NN\1740 (_13\-LRB-\1740 omd_14\NN\1740 )_15\-RRB-\1740 in_16\IN\13603305 a_17\DT\13649268 psp_18\NN\1740 patient_19\NN\9898892 to_20\TO\1740 highlight_21\VB\514463 the_22\DT\1740 importance_23\NN\5138488 of_24\IN\1740 recognizing_25\VBG\686447 this_26\DT\1740 drug_27\NN\14778436 related_28\JJ\1740 complication_29\NN\1073995 in_30\IN\13603305 the_31\DT\1740 management_32\NN\1123598 of_33\IN\1740 <e2>psp</e2>_34\NNP\1740 ,_35\,\1740 and_36\CC\1740 discuss_37\VBP\1033527 the_38\DT\1740 possible_39\JJ\1740 underlying_40\JJ\1740 pathophysiology_41\NN\1740 ._42\.\1740
D007980_D004409 NONE <e1>levodopa-induced</e1>_0\JJ\1740 <e2>dyskinesias</e2>_1\NNS\14084880 have_2\VBP\2108377 been_3\VBN\836236 reported_4\VBN\831651 in_5\IN\13603305 parkinson_6\NNP\1740 's_7\POS\1740 disease_8\NN\14061805 and_9\CC\1740 multiple_10\JJ\1740 system_11\NN\3575240 atrophy_12\NN\14299637 ._13\.\1740
D007980_D010300 NONE <e1>levodopa-induced</e1>_0\JJ\1740 dyskinesias_1\NNS\14084880 have_2\VBP\2108377 been_3\VBN\836236 reported_4\VBN\831651 in_5\IN\13603305 <e2>parkinson_6\NNP\1740 's_7\POS\1740 disease</e2>_8\NN\14061805 and_9\CC\1740 multiple_10\JJ\1740 system_11\NN\3575240 atrophy_12\NN\14299637 ._13\.\1740
D007980_D019578 NONE <e1>levodopa-induced</e1>_0\JJ\1740 dyskinesias_1\NNS\14084880 have_2\VBP\2108377 been_3\VBN\836236 reported_4\VBN\831651 in_5\IN\13603305 parkinson_6\NNP\1740 's_7\POS\1740 disease_8\NN\14061805 and_9\CC\1740 <e2>multiple_10\JJ\1740 system_11\NN\3575240 atrophy</e2>_12\NN\14299637 ._13\.\1740
D007980_D008538 NONE in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 we_3\PRP\1740 describe_4\VBP\1001294 an_5\DT\6697703 unusual_6\JJ\1740 case_7\NN\7283608 of_8\IN\1740 reversible_9\JJ\1740 <e1>levodopa-induced</e1>_10\JJ\1740 <e2>oromandibular_11\JJ\1740 dystonia</e2>_12\NN\1740 (_13\-LRB-\1740 omd_14\NN\1740 )_15\-RRB-\1740 in_16\IN\13603305 a_17\DT\13649268 psp_18\NN\1740 patient_19\NN\9898892 to_20\TO\1740 highlight_21\VB\514463 the_22\DT\1740 importance_23\NN\5138488 of_24\IN\1740 recognizing_25\VBG\686447 this_26\DT\1740 drug_27\NN\14778436 related_28\JJ\1740 complication_29\NN\1073995 in_30\IN\13603305 the_31\DT\1740 management_32\NN\1123598 of_33\IN\1740 psp_34\NNP\1740 ,_35\,\1740 and_36\CC\1740 discuss_37\VBP\1033527 the_38\DT\1740 possible_39\JJ\1740 underlying_40\JJ\1740 pathophysiology_41\NN\1740 ._42\.\1740
D007980_D008538 NONE in_0\IN\13603305 this_1\DT\1740 report_2\NN\6470073 we_3\PRP\1740 describe_4\VBP\1001294 an_5\DT\6697703 unusual_6\JJ\1740 case_7\NN\7283608 of_8\IN\1740 reversible_9\JJ\1740 <e1>levodopa-induced</e1>_10\JJ\1740 oromandibular_11\JJ\1740 dystonia_12\NN\1740 (_13\-LRB-\1740 <e2>omd</e2>_14\NN\1740 )_15\-RRB-\1740 in_16\IN\13603305 a_17\DT\13649268 psp_18\NN\1740 patient_19\NN\9898892 to_20\TO\1740 highlight_21\VB\514463 the_22\DT\1740 importance_23\NN\5138488 of_24\IN\1740 recognizing_25\VBG\686447 this_26\DT\1740 drug_27\NN\14778436 related_28\JJ\1740 complication_29\NN\1073995 in_30\IN\13603305 the_31\DT\1740 management_32\NN\1123598 of_33\IN\1740 psp_34\NNP\1740 ,_35\,\1740 and_36\CC\1740 discuss_37\VBP\1033527 the_38\DT\1740 possible_39\JJ\1740 underlying_40\JJ\1740 pathophysiology_41\NN\1740 ._42\.\1740
2055425
D013311_D003920 CID the_0\DT\1740 ability_1\NN\4723816 of_2\IN\1740 insulin_3\NN\5407119 treatment_4\NN\654885 to_5\TO\1740 reverse_6\VB\109660 or_7\CC\3541091 prevent_8\VB\1740 the_9\DT\1740 changes_10\NNS\7283608 in_11\IN\13603305 urinary_12\JJ\1740 bladder_13\NN\5515670 function_14\NN\13783581 caused_15\VBN\1617192 by_16\IN\1740 <e1>streptozotocin-induced</e1>_17\JJ\1740 <e2>diabetes_18\NN\14075199 mellitus</e2>_19\NN\1740 ._20\.\1740
D013311_D003920 CID the_0\DT\1740 effects_1\NNS\13245626 of_2\IN\1740 insulin_3\NN\5407119 treatment_4\NN\654885 on_5\IN\1740 in_6\FW\13603305 vivo_7\FW\1740 and_8\CC\1740 in_9\FW\13603305 vitro_10\FW\1740 urinary_11\JJ\1740 bladder_12\NN\5515670 function_13\NN\13783581 in_14\IN\13603305 <e2><e1>streptozotocin-diabetic</e1></e2>_15\JJ\1740 rats_16\NNS\2329401 were_17\VBD\836236 investigated_18\VBN\644583 ._19\.\1740
D013311_D003920 CID the_0\DT\1740 data_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 the_4\DT\1740 effects_5\NNS\13245626 of_6\IN\1740 <e1>streptozotocin-induced</e1>_7\JJ\1740 <e2>diabetes</e2>_8\NNS\14075199 on_9\IN\1740 urinary_10\JJ\1740 bladder_11\NN\5515670 function_12\NN\13783581 are_13\VBP\836236 both_14\CC\1740 prevented_15\VBN\1740 and_16\CC\1740 reversed_17\VBN\109660 by_18\IN\1740 insulin_19\NN\5407119 treatment_20\NN\654885 ._21\.\1740
D000255_D003920 NONE insulin_0\NN\5407119 treatment_1\NN\654885 also_2\RB\1740 prevented_3\VBD\1740 the_4\DT\1740 increases_5\NNS\13576355 in_6\IN\13603305 contractile_7\JJ\1740 responses_8\NNS\11410625 of_9\IN\1740 bladder_10\NN\5515670 body_11\NN\19128 strips_12\VBZ\2205272 from_13\IN\1740 <e2>diabetic</e2>_14\JJ\1740 rats_15\NNS\2329401 to_16\TO\1740 nerve_17\NN\5475681 stimulation_18\NN\242808 ,_19\,\1740 <e1>atp</e1>_20\NN\14964590 ,_21\,\1740 and_22\CC\1740 bethanechol_23\NN\1740 ._24\.\1740
D000255_D003920 NONE insulin_0\NN\5407119 treatment_1\NN\654885 reversed_2\VBD\109660 the_3\DT\1740 increases_4\NNS\13576355 in_5\IN\13603305 contractile_6\JJ\1740 responses_7\NNS\11410625 of_8\IN\1740 bladder_9\NN\5515670 body_10\NN\19128 strips_11\VBZ\2205272 from_12\IN\1740 <e2>diabetic</e2>_13\JJ\1740 rats_14\NNS\2329401 to_15\TO\1740 nerve_16\NN\5475681 stimulation_17\NN\242808 ,_18\,\1740 <e1>atp</e1>_19\NN\14964590 ,_20\,\1740 and_21\CC\1740 bethanechol_22\NN\1740 ._23\.\1740
D018723_D003920 NONE insulin_0\NN\5407119 treatment_1\NN\654885 also_2\RB\1740 prevented_3\VBD\1740 the_4\DT\1740 increases_5\NNS\13576355 in_6\IN\13603305 contractile_7\JJ\1740 responses_8\NNS\11410625 of_9\IN\1740 bladder_10\NN\5515670 body_11\NN\19128 strips_12\VBZ\2205272 from_13\IN\1740 <e2>diabetic</e2>_14\JJ\1740 rats_15\NNS\2329401 to_16\TO\1740 nerve_17\NN\5475681 stimulation_18\NN\242808 ,_19\,\1740 atp_20\NN\14964590 ,_21\,\1740 and_22\CC\1740 <e1>bethanechol</e1>_23\NN\1740 ._24\.\1740
D018723_D003920 NONE insulin_0\NN\5407119 treatment_1\NN\654885 reversed_2\VBD\109660 the_3\DT\1740 increases_4\NNS\13576355 in_5\IN\13603305 contractile_6\JJ\1740 responses_7\NNS\11410625 of_8\IN\1740 bladder_9\NN\5515670 body_10\NN\19128 strips_11\VBZ\2205272 from_12\IN\1740 <e2>diabetic</e2>_13\JJ\1740 rats_14\NNS\2329401 to_15\TO\1740 nerve_16\NN\5475681 stimulation_17\NN\242808 ,_18\,\1740 atp_19\NN\14964590 ,_20\,\1740 and_21\CC\1740 <e1>bethanechol</e1>_22\NN\1740 ._23\.\1740
3769769
D014282_D001919 CID <e2>bradycardia</e2>_0\NNP\14110674 due_1\IN\5174653 to_2\TO\1740 <e1>trihexyphenidyl_3\VB\1740 hydrochloride</e1>_4\NN\14817592 ._5\.\1740
D014282_D012559 NONE a_0\DT\13649268 chronic_1\JJ\1740 <e2>schizophrenic</e2>_2\JJ\1740 patient_3\NN\9898892 was_4\VBD\836236 treated_5\VBN\2376958 with_6\IN\1740 an_7\DT\6697703 anticholinergic_8\JJ\1740 drug_9\NN\14778436 ,_10\,\1740 <e1>trihexyphenidyl_11\NN\1740 hydrochloride</e1>_12\NN\14817592 ._13\.\1740
6674249
D015119_D009135 CID why_0\WRB\9178999 may_1\MD\15209706 <e1>epsilon-aminocaproic_2\JJ\1740 acid</e1>_3\NN\14818238 (_4\-LRB-\1740 eaca_5\NN\1740 )_6\-RRB-\1740 induce_7\VBP\1627355 <e2>myopathy</e2>_8\NN\14204950 in_9\IN\13603305 man_10\NN\9605289 ?_11\.\1740
D015119_D009135 CID why_0\WRB\9178999 may_1\MD\15209706 epsilon-aminocaproic_2\JJ\1740 acid_3\NN\14818238 (_4\-LRB-\1740 <e1>eaca</e1>_5\NN\1740 )_6\-RRB-\1740 induce_7\VBP\1627355 <e2>myopathy</e2>_8\NN\14204950 in_9\IN\13603305 man_10\NN\9605289 ?_11\.\1740
D015119_D009135 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>necrotizing_3\VBG\1740 myopathy</e2>_4\NN\14204950 due_5\JJ\1740 to_6\TO\1740 a_7\DT\13649268 short_8\JJ\1740 <e1>epsilon-aminocaproic_9\JJ\1740 acid</e1>_10\NN\14818238 (_11\-LRB-\1740 eaca_12\NN\1740 )_13\-RRB-\1740 treatment_14\NN\654885 in_15\IN\13603305 a_16\DT\13649268 72_17\CD\1740 year-old_18\NN\1740 patient_19\NN\9898892 with_20\IN\1740 subarachnoid_21\JJ\1740 haemorrhage_22\NN\14285662 (_23\-LRB-\1740 sah_24\NN\1740 )_25\-RRB-\1740 is_26\VBZ\836236 described_27\VBN\1001294 ._28\.\1740
D015119_D009135 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>necrotizing_3\VBG\1740 myopathy</e2>_4\NN\14204950 due_5\JJ\1740 to_6\TO\1740 a_7\DT\13649268 short_8\JJ\1740 epsilon-aminocaproic_9\JJ\1740 acid_10\NN\14818238 (_11\-LRB-\1740 <e1>eaca</e1>_12\NN\1740 )_13\-RRB-\1740 treatment_14\NN\654885 in_15\IN\13603305 a_16\DT\13649268 72_17\CD\1740 year-old_18\NN\1740 patient_19\NN\9898892 with_20\IN\1740 subarachnoid_21\JJ\1740 haemorrhage_22\NN\14285662 (_23\-LRB-\1740 sah_24\NN\1740 )_25\-RRB-\1740 is_26\VBZ\836236 described_27\VBN\1001294 ._28\.\1740
D015119_D009336 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>necrotizing_3\VBG\1740 myopathy</e2>_4\NN\14204950 due_5\JJ\1740 to_6\TO\1740 a_7\DT\13649268 short_8\JJ\1740 <e1>epsilon-aminocaproic_9\JJ\1740 acid</e1>_10\NN\14818238 (_11\-LRB-\1740 eaca_12\NN\1740 )_13\-RRB-\1740 treatment_14\NN\654885 in_15\IN\13603305 a_16\DT\13649268 72_17\CD\1740 year-old_18\NN\1740 patient_19\NN\9898892 with_20\IN\1740 subarachnoid_21\JJ\1740 haemorrhage_22\NN\14285662 (_23\-LRB-\1740 sah_24\NN\1740 )_25\-RRB-\1740 is_26\VBZ\836236 described_27\VBN\1001294 ._28\.\1740
D015119_D009336 CID a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 <e2>necrotizing_3\VBG\1740 myopathy</e2>_4\NN\14204950 due_5\JJ\1740 to_6\TO\1740 a_7\DT\13649268 short_8\JJ\1740 epsilon-aminocaproic_9\JJ\1740 acid_10\NN\14818238 (_11\-LRB-\1740 <e1>eaca</e1>_12\NN\1740 )_13\-RRB-\1740 treatment_14\NN\654885 in_15\IN\13603305 a_16\DT\13649268 72_17\CD\1740 year-old_18\NN\1740 patient_19\NN\9898892 with_20\IN\1740 subarachnoid_21\JJ\1740 haemorrhage_22\NN\14285662 (_23\-LRB-\1740 sah_24\NN\1740 )_25\-RRB-\1740 is_26\VBZ\836236 described_27\VBN\1001294 ._28\.\1740
D015119_D013345 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 necrotizing_3\VBG\1740 myopathy_4\NN\14204950 due_5\JJ\1740 to_6\TO\1740 a_7\DT\13649268 short_8\JJ\1740 <e1>epsilon-aminocaproic_9\JJ\1740 acid</e1>_10\NN\14818238 (_11\-LRB-\1740 eaca_12\NN\1740 )_13\-RRB-\1740 treatment_14\NN\654885 in_15\IN\13603305 a_16\DT\13649268 72_17\CD\1740 year-old_18\NN\1740 patient_19\NN\9898892 with_20\IN\1740 <e2>subarachnoid_21\JJ\1740 haemorrhage</e2>_22\NN\14285662 (_23\-LRB-\1740 sah_24\NN\1740 )_25\-RRB-\1740 is_26\VBZ\836236 described_27\VBN\1001294 ._28\.\1740
D015119_D013345 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 necrotizing_3\VBG\1740 myopathy_4\NN\14204950 due_5\JJ\1740 to_6\TO\1740 a_7\DT\13649268 short_8\JJ\1740 <e1>epsilon-aminocaproic_9\JJ\1740 acid</e1>_10\NN\14818238 (_11\-LRB-\1740 eaca_12\NN\1740 )_13\-RRB-\1740 treatment_14\NN\654885 in_15\IN\13603305 a_16\DT\13649268 72_17\CD\1740 year-old_18\NN\1740 patient_19\NN\9898892 with_20\IN\1740 subarachnoid_21\JJ\1740 haemorrhage_22\NN\14285662 (_23\-LRB-\1740 <e2>sah</e2>_24\NN\1740 )_25\-RRB-\1740 is_26\VBZ\836236 described_27\VBN\1001294 ._28\.\1740
D015119_D013345 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 necrotizing_3\VBG\1740 myopathy_4\NN\14204950 due_5\JJ\1740 to_6\TO\1740 a_7\DT\13649268 short_8\JJ\1740 epsilon-aminocaproic_9\JJ\1740 acid_10\NN\14818238 (_11\-LRB-\1740 <e1>eaca</e1>_12\NN\1740 )_13\-RRB-\1740 treatment_14\NN\654885 in_15\IN\13603305 a_16\DT\13649268 72_17\CD\1740 year-old_18\NN\1740 patient_19\NN\9898892 with_20\IN\1740 <e2>subarachnoid_21\JJ\1740 haemorrhage</e2>_22\NN\14285662 (_23\-LRB-\1740 sah_24\NN\1740 )_25\-RRB-\1740 is_26\VBZ\836236 described_27\VBN\1001294 ._28\.\1740
D015119_D013345 NONE a_0\DT\13649268 case_1\NN\7283608 of_2\IN\1740 necrotizing_3\VBG\1740 myopathy_4\NN\14204950 due_5\JJ\1740 to_6\TO\1740 a_7\DT\13649268 short_8\JJ\1740 epsilon-aminocaproic_9\JJ\1740 acid_10\NN\14818238 (_11\-LRB-\1740 <e1>eaca</e1>_12\NN\1740 )_13\-RRB-\1740 treatment_14\NN\654885 in_15\IN\13603305 a_16\DT\13649268 72_17\CD\1740 year-old_18\NN\1740 patient_19\NN\9898892 with_20\IN\1740 subarachnoid_21\JJ\1740 haemorrhage_22\NN\14285662 (_23\-LRB-\1740 <e2>sah</e2>_24\NN\1740 )_25\-RRB-\1740 is_26\VBZ\836236 described_27\VBN\1001294 ._28\.\1740
15686794
D000638_D017116 CID acute_0\JJ\1740 <e2>low_1\JJ\1740 back_2\JJ\1740 pain</e2>_3\NN\14299637 during_4\IN\1740 intravenous_5\JJ\1740 administration_6\NN\1133281 of_7\IN\1740 <e1>amiodarone</e1>_8\NN\2715941 :_9\:\1740 a_10\DT\13649268 report_11\NN\6470073 of_12\IN\1740 two_13\CD\13741022 cases_14\NNS\7283608 ._15\.\1740
D000638_D017116 CID we_0\PRP\1740 briefly_1\RB\1740 describe_2\VBP\1001294 two_3\CD\13741022 patients_4\NNS\9898892 suffering_5\VBG\2110220 from_6\IN\1740 recent-onset_7\JJ\1740 atrial_8\JJ\1740 fibrillation_9\NN\14361664 ,_10\,\1740 who_11\WP\8299493 experienced_12\VBD\2108377 an_13\DT\6697703 acute_14\JJ\1740 devastating_15\VBG\1564144 <e2>low_16\JJ\1740 back_17\RB\1740 pain</e2>_18\NN\14299637 a_19\DT\13649268 few_20\JJ\1740 minutes_21\NNS\6502378 after_22\IN\1740 initiation_23\NN\7450842 of_24\IN\1740 intravenous_25\JJ\1740 <e1>amiodarone</e1>_26\NN\2715941 loading_27\NN\4571088 ._28\.\1740
D000638_D001281 NONE <e1>amiodarone</e1>_0\NN\2715941 represents_1\VBZ\2664769 an_2\DT\6697703 effective_3\JJ\1740 antiarrhythmic_4\JJ\1740 drug_5\NN\14778436 for_6\IN\1740 cardioversion_7\NN\1740 of_8\IN\1740 recent-onset_9\JJ\1740 <e2>atrial_10\JJ\1740 fibrillation</e2>_11\NN\14361664 (_12\-LRB-\1740 af_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 maintenance_16\NN\266806 of_17\IN\1740 sinus_18\NN\5248181 rhythm_19\NN\15122011 ._20\.\1740
D000638_D001281 NONE <e1>amiodarone</e1>_0\NN\2715941 represents_1\VBZ\2664769 an_2\DT\6697703 effective_3\JJ\1740 antiarrhythmic_4\JJ\1740 drug_5\NN\14778436 for_6\IN\1740 cardioversion_7\NN\1740 of_8\IN\1740 recent-onset_9\JJ\1740 atrial_10\JJ\1740 fibrillation_11\NN\14361664 (_12\-LRB-\1740 <e2>af</e2>_13\NN\1740 )_14\-RRB-\1740 and_15\CC\1740 maintenance_16\NN\266806 of_17\IN\1740 sinus_18\NN\5248181 rhythm_19\NN\15122011 ._20\.\1740
D000638_D001281 NONE we_0\PRP\1740 briefly_1\RB\1740 describe_2\VBP\1001294 two_3\CD\13741022 patients_4\NNS\9898892 suffering_5\VBG\2110220 from_6\IN\1740 recent-onset_7\JJ\1740 <e2>atrial_8\JJ\1740 fibrillation</e2>_9\NN\14361664 ,_10\,\1740 who_11\WP\8299493 experienced_12\VBD\2108377 an_13\DT\6697703 acute_14\JJ\1740 devastating_15\VBG\1564144 low_16\JJ\1740 back_17\RB\1740 pain_18\NN\14299637 a_19\DT\13649268 few_20\JJ\1740 minutes_21\NNS\6502378 after_22\IN\1740 initiation_23\NN\7450842 of_24\IN\1740 intravenous_25\JJ\1740 <e1>amiodarone</e1>_26\NN\2715941 loading_27\NN\4571088 ._28\.\1740
3413271
D004837_D017202 CID mechanisms_0\NNS\13446390 of_1\IN\1740 <e2>myocardial_2\JJ\1740 ischemia</e2>_3\NN\14195315 induced_4\VBN\1627355 by_5\IN\1740 <e1>epinephrine</e1>_6\NN\14807929 :_7\:\1740 comparison_8\NN\635850 with_9\IN\1740 exercise-induced_10\JJ\1740 ischemia_11\NN\14195315 ._12\.\1740
D004837_D017202 CID the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 <e1>epinephrine</e1>_3\NN\14807929 in_4\IN\13603305 eliciting_5\VBG\1617192 <e2>myocardial_6\JJ\1740 ischemia</e2>_7\NN\14195315 was_8\VBD\836236 examined_9\VBN\789138 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 coronary_13\JJ\1740 artery_14\NN\5417975 disease_15\NN\14061805 ._16\.\1740
D004837_D017202 CID both_0\CC\1740 <e1>epinephrine</e1>_1\NN\14807929 and_2\CC\1740 exercise_3\NN\621627 produced_4\JJ\1740 <e2>myocardial_5\JJ\1740 ischemia</e2>_6\NN\14195315 as_7\IN\14622893 evidenced_8\VBN\1015244 by_9\IN\1740 st_10\JJ\1740 segment_11\NN\3892891 depression_12\NN\14373582 and_13\CC\1740 angina_14\NN\14171682 ._15\.\1740
D004837_D017202 CID however_0\RB\1740 ,_1\,\1740 the_2\DT\1740 mechanisms_3\NNS\13446390 of_4\IN\1740 <e2>myocardial_5\JJ\1740 ischemia</e2>_6\NN\14195315 induced_7\VBN\1627355 by_8\IN\1740 <e1>epinephrine</e1>_9\NN\14807929 were_10\VBD\836236 significantly_11\RB\1740 different_12\JJ\1740 from_13\IN\1740 those_14\DT\1740 of_15\IN\1740 exercise_16\NN\621627 ._17\.\1740
D004837_D017202 CID exercise-induced_0\JJ\1740 <e2>myocardial_1\JJ\1740 ischemia</e2>_2\NN\14195315 was_3\VBD\836236 marked_4\VBN\1296462 predominantly_5\RB\1740 by_6\IN\1740 increased_7\VBN\169651 heart_8\NN\5919034 rate_9\NN\13815152 and_10\CC\1740 rate-pressure_11\JJ\1740 product_12\NN\3076708 with_13\IN\1740 a_14\DT\13649268 minor_15\JJ\1740 contribution_16\NN\786195 of_17\IN\1740 end-diastolic_18\JJ\1740 volume_19\NN\33615 ,_20\,\1740 while_21\IN\15122231 <e1>epinephrine-induced</e1>_22\JJ\1740 ischemia_23\NN\14195315 was_24\VBD\836236 characterized_25\VBN\609683 by_26\IN\1740 a_27\DT\13649268 marked_28\JJ\1740 increase_29\NN\13576355 in_30\IN\13603305 contractility_31\NN\5200169 and_32\CC\1740 a_33\DT\13649268 less_34\RBR\1740 pronounced_35\JJ\1740 increase_36\NN\13576355 in_37\IN\13603305 heart_38\NN\5919034 rate_39\NN\13815152 and_40\CC\1740 rate-pressure_41\JJ\1740 product_42\NN\3076708 ._43\.\1740
D004837_D007511 NONE mechanisms_0\NNS\13446390 of_1\IN\1740 myocardial_2\JJ\1740 ischemia_3\NN\14195315 induced_4\VBN\1627355 by_5\IN\1740 <e1>epinephrine</e1>_6\NN\14807929 :_7\:\1740 comparison_8\NN\635850 with_9\IN\1740 exercise-induced_10\JJ\1740 <e2>ischemia</e2>_11\NN\14195315 ._12\.\1740
D004837_D007511 NONE objective_0\JJ\1740 signs_1\NNS\6643763 of_2\IN\1740 <e2>ischemia</e2>_3\NN\14195315 and_4\CC\1740 factors_5\NNS\7326557 increasing_6\VBG\169651 myocardial_7\JJ\1740 oxygen_8\NN\14622893 consumption_9\NN\13440063 were_10\VBD\836236 compared_11\VBN\644583 during_12\IN\1740 <e1>epinephrine</e1>_13\NN\14807929 infusion_14\NN\14589223 and_15\CC\1740 supine_16\JJ\1740 bicycle_17\NN\4576211 exercise_18\NN\621627 ._19\.\1740
D004837_D007511 NONE exercise-induced_0\JJ\1740 myocardial_1\JJ\1740 ischemia_2\NN\14195315 was_3\VBD\836236 marked_4\VBN\1296462 predominantly_5\RB\1740 by_6\IN\1740 increased_7\VBN\169651 heart_8\NN\5919034 rate_9\NN\13815152 and_10\CC\1740 rate-pressure_11\JJ\1740 product_12\NN\3076708 with_13\IN\1740 a_14\DT\13649268 minor_15\JJ\1740 contribution_16\NN\786195 of_17\IN\1740 end-diastolic_18\JJ\1740 volume_19\NN\33615 ,_20\,\1740 while_21\IN\15122231 <e1>epinephrine-induced</e1>_22\JJ\1740 <e2>ischemia</e2>_23\NN\14195315 was_24\VBD\836236 characterized_25\VBN\609683 by_26\IN\1740 a_27\DT\13649268 marked_28\JJ\1740 increase_29\NN\13576355 in_30\IN\13603305 contractility_31\NN\5200169 and_32\CC\1740 a_33\DT\13649268 less_34\RBR\1740 pronounced_35\JJ\1740 increase_36\NN\13576355 in_37\IN\13603305 heart_38\NN\5919034 rate_39\NN\13815152 and_40\CC\1740 rate-pressure_41\JJ\1740 product_42\NN\3076708 ._43\.\1740
D004837_D007511 NONE these_0\DT\1740 findings_1\NNS\7951464 indicate_2\VBP\952524 that_3\IN\1740 <e2>ischemia</e2>_4\NN\14195315 produced_5\VBN\1617192 by_6\IN\1740 <e1>epinephrine</e1>_7\NN\14807929 ,_8\,\1740 as_9\IN\14622893 may_10\MD\15209706 occur_11\VB\2623529 during_12\IN\1740 states_13\NNS\8491826 of_14\IN\1740 emotional_15\JJ\1740 distress_16\NN\7494363 ,_17\,\1740 has_18\VBZ\2108377 a_19\DT\13649268 mechanism_20\NN\13446390 distinct_21\JJ\1740 from_22\IN\1740 that_23\DT\1740 due_24\IN\5174653 to_25\IN\1740 physical_26\JJ\1740 exertion_27\NN\620752 ._28\.\1740
D004837_D003324 NONE the_0\DT\1740 role_1\NN\719494 of_2\IN\1740 <e1>epinephrine</e1>_3\NN\14807929 in_4\IN\13603305 eliciting_5\VBG\1617192 myocardial_6\JJ\1740 ischemia_7\NN\14195315 was_8\VBD\836236 examined_9\VBN\789138 in_10\IN\13603305 patients_11\NNS\9898892 with_12\IN\1740 <e2>coronary_13\JJ\1740 artery_14\NN\5417975 disease</e2>_15\NN\14061805 ._16\.\1740
D010100_D007511 NONE objective_0\JJ\1740 signs_1\NNS\6643763 of_2\IN\1740 <e2>ischemia</e2>_3\NN\14195315 and_4\CC\1740 factors_5\NNS\7326557 increasing_6\VBG\169651 myocardial_7\JJ\1740 <e1>oxygen</e1>_8\NN\14622893 consumption_9\NN\13440063 were_10\VBD\836236 compared_11\VBN\644583 during_12\IN\1740 epinephrine_13\NN\14807929 infusion_14\NN\14589223 and_15\CC\1740 supine_16\JJ\1740 bicycle_17\NN\4576211 exercise_18\NN\621627 ._19\.\1740
D004837_D003866 NONE both_0\CC\1740 <e1>epinephrine</e1>_1\NN\14807929 and_2\CC\1740 exercise_3\NN\621627 produced_4\JJ\1740 myocardial_5\JJ\1740 ischemia_6\NN\14195315 as_7\IN\14622893 evidenced_8\VBN\1015244 by_9\IN\1740 st_10\JJ\1740 segment_11\NN\3892891 <e2>depression</e2>_12\NN\14373582 and_13\CC\1740 angina_14\NN\14171682 ._15\.\1740
D004837_D000787 NONE both_0\CC\1740 <e1>epinephrine</e1>_1\NN\14807929 and_2\CC\1740 exercise_3\NN\621627 produced_4\JJ\1740 myocardial_5\JJ\1740 ischemia_6\NN\14195315 as_7\IN\14622893 evidenced_8\VBN\1015244 by_9\IN\1740 st_10\JJ\1740 segment_11\NN\3892891 depression_12\NN\14373582 and_13\CC\1740 <e2>angina</e2>_14\NN\14171682 ._15\.\1740
7161250
D006220_D010302 CID the_0\DT\1740 incidence_1\NN\13821570 of_2\IN\1740 <e2>parkinsonism</e2>_3\NN\14085708 was_4\VBD\836236 higher_5\JJR\1740 at_6\IN\14622893 higher_7\JJR\1740 doses_8\NNS\3740161 of_9\IN\1740 <e1>haloperidol</e1>_10\NN\3713736 and_11\CC\1740 in_12\IN\13603305 younger_13\JJR\1740 patients_14\NNS\9898892 ._15\.\1740
D001569_D017109 NONE <e2>akathisia</e2>_0\NNP\1740 was_1\VBD\836236 controlled_2\VBN\2422663 by_3\IN\1740 the_4\DT\1740 <e1>benzodiazepine</e1>_5\NN\3771443 lorazepam_6\NN\2830852 in_7\IN\13603305 14_8\CD\13745420 out_9\IN\66636 of_10\IN\1740 16_11\CD\13745420 patients_12\NNS\9898892 ,_13\,\1740 while_14\IN\15122231 prophylactic_15\JJ\1740 antiparkinsonians_16\NNS\1740 were_17\VBD\836236 ineffective_18\JJ\1740 ._19\.\1740
D008140_D017109 NONE <e2>akathisia</e2>_0\NNP\1740 was_1\VBD\836236 controlled_2\VBN\2422663 by_3\IN\1740 the_4\DT\1740 benzodiazepine_5\NN\3771443 <e1>lorazepam</e1>_6\NN\2830852 in_7\IN\13603305 14_8\CD\13745420 out_9\IN\66636 of_10\IN\1740 16_11\CD\13745420 patients_12\NNS\9898892 ,_13\,\1740 while_14\IN\15122231 prophylactic_15\JJ\1740 antiparkinsonians_16\NNS\1740 were_17\VBD\836236 ineffective_18\JJ\1740 ._19\.\1740
19996135
D014148_D012640 CID high-dose_0\JJ\1740 <e1>tranexamic_1\NN\1740 acid</e1>_2\NNP\14818238 is_3\VBZ\836236 associated_4\VBN\628491 with_5\IN\1740 nonischemic_6\JJ\1740 clinical_7\JJ\1740 <e2>seizures</e2>_8\NNS\14081375 in_9\IN\13603305 cardiac_10\JJ\1740 surgical_11\JJ\1740 patients_12\NNS\9898892 ._13\.\1740
D014148_D012640 CID the_0\DT\1740 purpose_1\NN\5980875 of_2\IN\1740 this_3\DT\1740 review_4\NN\5733583 was_5\VBD\836236 to_6\TO\1740 perform_7\VB\2367363 a_8\DT\13649268 retrospective_9\JJ\1740 analysis_10\NN\633864 to_11\TO\1740 examine_12\VB\789138 whether_13\IN\1740 there_14\EX\27167 was_15\VBD\836236 a_16\DT\13649268 relation_17\NN\2137 between_18\IN\1740 <e1>txa</e1>_19\NN\1740 usage_20\NN\407535 and_21\CC\1740 <e2>seizures</e2>_22\NNS\14081375 after_23\IN\1740 cardiac_24\JJ\1740 surgery_25\NN\6045562 ._26\.\1740
D014148_D012640 CID all_0\DT\1740 24_1\CD\13745420 patients_2\NNS\9898892 with_3\IN\1740 <e2>seizures</e2>_4\NNS\14081375 received_5\VBD\2210855 high_6\JJ\1740 doses_7\NNS\3740161 of_8\IN\1740 <e1>txa</e1>_9\NN\1740 intraoperatively_10\RB\1740 ranging_11\VBG\2604760 from_12\IN\1740 61_13\CD\1740 to_14\TO\1740 259_15\CD\1740 mg/kg_16\NN\1740 ,_17\,\1740 had_18\VBD\2108377 a_19\DT\13649268 mean_20\NN\6021761 age_21\NN\4916342 of_22\IN\1740 69.9_23\CD\1740 years_24\NNS\15144371 ,_25\,\1740 and_26\CC\1740 21_27\CD\13745420 of_28\IN\1740 24_29\CD\13745420 had_30\VBD\2108377 undergone_31\VBN\109660 open_32\JJ\1740 chamber_33\NN\3285912 rather_34\RB\1740 than_35\IN\1740 coronary_36\JJ\1740 bypass_37\NN\3519981 procedures_38\NNS\407535 ._39\.\1740
D014148_D012640 CID conclusion_0\NN\5837957 :_1\:\1740 our_2\PRP$\1740 results_3\NNS\34213 suggest_4\VBP\1010118 that_5\IN\1740 use_6\NN\407535 of_7\IN\1740 high-dose_8\JJ\1740 <e1>txa</e1>_9\NN\1740 in_10\IN\13603305 older_11\JJR\1740 patients_12\NNS\9898892 in_13\IN\13603305 conjunction_14\NN\5048123 with_15\IN\1740 cardiopulmonary_16\JJ\1740 bypass_17\NN\3519981 and_18\CC\1740 open-chamber_19\NN\1740 cardiac_20\JJ\1740 surgery_21\NN\6045562 is_22\VBZ\836236 associated_23\VBN\628491 with_24\IN\1740 clinical_25\JJ\1740 <e2>seizures</e2>_26\NNS\14081375 in_27\IN\13603305 susceptible_28\JJ\1740 patients_29\NNS\9898892 ._30\.\1740
